,1,2
0,T2,Procedure 10 24	pathologically
1,T3,Value 25 34	confirmed
2,R2,Has_value Arg1:T2 Arg2:T3
3,T4,Condition 35 58	invasive adenocarcinoma
4,T5,Condition 62 86	ductal carcinoma in situ
5,*,OR T5 T4
6,R1,AND Arg1:T4 Arg2:T2
7,R3,AND Arg1:T5 Arg2:T2
8,T1,Procedure 132 152	segmental mastectomy
9,T6,Procedure 160 170	lumpectomy
10,R4,Subsumes Arg1:T1 Arg2:T6
11,T7,Procedure 212 229	radiation therapy
12,T8,Negation 188 191	not
13,R5,Has_negation Arg1:T7 Arg2:T8
14,T9,Qualifier 87 100	of the breast
15,R6,Has_qualifier Arg1:T4 Arg2:T9
16,R7,Has_qualifier Arg1:T5 Arg2:T9
17,T10,Condition 276 298	local-regional disease
18,T11,Undefined_semantics 276 298	local-regional disease
19,T12,Temporal 269 275	active
20,R8,Has_temporal Arg1:T10 Arg2:T12
21,T13,Negation 260 263	not
22,R9,Has_negation Arg1:T10 Arg2:T13
23,T14,Pregnancy_considerations 323 677	Patients must not be pregnant because of the potential for fetal harm as a result of radiation treatment. Women of child-bearing age will be given a serum pregnancy test prior to study entry to ensure they are not pregnant. They will also be counseled on the importance of avoiding pregnancy and hormonal contraception while undergoing radiation therapy.
24,T15,Post-eligibility 679 804	Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment.
25,T16,Post-eligibility 806 970	All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines.
0,T1,Condition 26 41	liver cirrhosis
1,T2,Mood 14 22	evidence
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Condition 55 58	HCC
4,T4,Mood 43 51	Evidence
5,R2,Has_mood Arg1:T3 Arg2:T4
6,T5,Condition 78 95	hepatitis B virus
7,T6,Condition 97 100	HIV
8,*,OR T6 T5
0,T1,Condition 0 12	primigravida
1,T2,Condition 14 33	singleton pregnancy
2,T3,Person 35 47	maternal age
3,T4,Value 48 59	18-35 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,T6,Measurement 65 83	pregnancy duration
6,T7,Value 84 95	16-20 weeks
7,R2,Has_value Arg1:T6 Arg2:T7
8,T5,Temporal 96 126	at the time of study inclusion
9,R3,Has_temporal Arg1:T6 Arg2:T5
0,T1,Condition 0 4	T1DM
1,T2,Temporal 5 27	for at least 12 months
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Measurement 40 52	HbA1c levels
4,T4,Multiplier 29 39	persistent
5,R2,Has_multiplier Arg1:T3 Arg2:T4
6,T5,Value 53 59	= 7.5%
7,T6,Value 61 72	58 mmol/mol
8,R3,Subsumes Arg1:T5 Arg2:T6
9,R4,Has_value Arg1:T3 Arg2:T5
10,T7,Procedure 82 109	optimized education therapy
11,R5,AND Arg1:T3 Arg2:T7
12,T8,Multiplier 112 121	recurrent
13,T9,Qualifier 122 128	severe
14,T10,Condition 129 150	hypoglycemic episodes
15,T11,Condition 154 178	high glucose variability
16,*,OR T10 T11
17,T12,Scope 129 178	hypoglycemic episodes or high glucose variability
18,R6,Has_qualifier Arg1:T12 Arg2:T9
19,R7,Has_multiplier Arg1:T12 Arg2:T8
20,T13,Mood 180 191	willingness
21,T14,Procedure 195 216	wear the insulin pump
22,T15,Device 204 216	insulin pump
23,R8,multi Arg1:T14 Arg2:T15
24,R9,Has_mood Arg1:T14 Arg2:T13
0,T1,Condition 11 24	recurrent UTI
1,T2,Multiplier 37 42	three
2,T3,Measurement 43 50	culture
3,R1,Has_multiplier Arg1:T3 Arg2:T2
4,T4,Temporal 63 84	within last 12 months
5,R2,Has_temporal Arg1:T1 Arg2:T4
6,R3,AND Arg1:T1 Arg2:T3
7,T5,Condition 96 117	neuromuscular disease
8,T6,Procedure 182 198	prolapse surgery
9,T7,Procedure 209 229	incontinence surgery
10,T8,Drug 246 272	anticholinergic medication
11,T9,Temporal 280 292	last 2 month
12,R4,Has_temporal Arg1:T8 Arg2:T9
13,T10,Qualifier 304 321	bladder injection
14,T11,Drug 327 345	onabotulinumtoxinA
15,R5,Has_qualifier Arg1:T11 Arg2:T10
16,T12,Person 347 355	Prisoner
17,T13,Condition 364 373	Pregnancy
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 240 242	2.
2,T3,Parsing_Error 356 358	3.
3,T4,Parsing_Error 544 546	4.
4,T5,Person 3 6	Age
5,T6,Value 8 30	12 to 36 months of age
6,T7,"Not_a_criteria 31 237	(The diagnosis of CP is often uncertain under the age of 12 months. The cutoff at 36 months is to have a population of young children when the brain is most ""plastic"" and most susceptible to reorganization)"
7,T8,Condition 267 277	spastic CP
8,T9,Non-query-able 359 542	Etiology: The insult to the central nervous system that caused the motor dysfunction must have occurred during gestation or within one year after birth independent of gestational age.
9,T10,Temporal 490 510	one year after birth
10,T11,Measurement 571 621	Gross Motor Function Classification System (GMFCS)
11,T12,"Value 622 642	levels I, II and III"
12,R1,Has_value Arg1:T11 Arg2:T12
0,T1,Condition 12 34	Chronic Kidney Disease
1,T2,Measurement 0 5	Stage
2,T3,Value 6 11	3 - 5
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
0,T1,Condition 8 22	skin pathology
1,T2,Condition 34 42	freckles
2,T3,Qualifier 24 33	excessive
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 47 61	skin blemishes
5,*,OR T2 T4 T1
6,T5,Condition 92 104	skin disease
7,T6,Condition 108 124	hypersensitivity
8,T7,Condition 138 155	contact allergies
9,T8,Condition 158 165	Sarcoma
10,T9,Condition 169 182	squamous cell
11,T10,Procedure 183 192	histology
12,*,OR T9 T8
13,T11,Scope 158 182	Sarcoma or squamous cell
14,R2,Has_scope Arg1:T10 Arg2:T11
15,T12,Condition 195 213	Metastatic disease
16,T13,Qualifier 214 227	to the breast
17,R3,Has_qualifier Arg1:T12 Arg2:T13
18,T14,Observation 238 249	tobacco use
19,T15,Temporal 230 237	Current
20,R4,Has_temporal Arg1:T14 Arg2:T15
0,T1,Procedure 11 37	mid-urethral sling surgery
1,T2,Condition 72 100	urgency urinary incontinence
2,T3,Condition 61 67;80 100	stress urinary incontinence
3,*,OR T2 T3
4,T4,"Post-eligibility 102 199	Able to consent, fill out study documents, and complete all study procedures and follow-up visits"
5,T5,Person 222 225	age
6,T6,Value 201 218	At least 18 years
7,R1,Has_value Arg1:T5 Arg2:T6
8,T7,Non-query-able 227 243	English speaking
9,T8,Non-query-able 245 323	Be able and willing to learn clean intermittent self catheterization technique
0,T1,Device 16 28	insulin pump
1,T2,Condition 30 39	pregnancy
2,T3,Mood 43 61	planning to become
3,T4,Condition 62 70	pregnant
4,R1,Has_mood Arg1:T4 Arg2:T3
5,T5,Temporal 71 90	in the next 2 years
6,R2,Has_temporal Arg1:T3 Arg2:T5
7,*,OR T2 T4
8,T6,Negation 93 100	lack of
9,T7,Observation 101 133	ability to use the study devices
10,R3,Has_negation Arg1:T7 Arg2:T6
11,T8,Device 120 133	study devices
12,R4,multi Arg1:T7 Arg2:T8
13,T9,Qualifier 146 152	severe
14,T10,Condition 153 169	chronic diseases
15,R5,Has_qualifier Arg1:T10 Arg2:T9
16,T11,Observation 135 142	history
17,R6,Has_temporal Arg1:T10 Arg2:T11
18,T12,Temporal 171 177	recent
19,T13,Temporal 181 192	concomitant
20,T14,Drug 200 215	corticosteroids
21,*,OR T13 T12
22,T15,Scope 171 192	recent or concomitant
23,R7,Has_scope Arg1:T14 Arg2:T15
24,T16,Drug 217 221;233 238	drug abuse
25,T17,Drug 225 238	alcohol abuse
26,*,OR T17 T16
27,T18,Condition 240 262	psychiatric complaints
28,T19,Observation 287 313	correct use of the devices
29,T20,Mood 268 282	interfere with
30,R8,Has_mood Arg1:T19 Arg2:T20
31,R9,Has_context Arg1:T18 Arg2:T19
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 64 66	2.
2,T3,Parsing_Error 364 366	3.
3,T4,Condition 27 61	CP secondary to neuronal migration
4,T5,"Undefined_semantics 67 361	Co-morbidities: Medical conditions that may prevent the administration of rehabilitation therapies at the intensity required by the study, or that may compromise the study ability to maintain blindness, or that have a co-morbidity not typically associated with CP (i.e. cancer, cystic fibrosis)"
5,T6,Post-eligibility 367 508	Co-interventions: Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study.
6,T7,Undefined_semantics 367 508	Co-interventions: Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study.
0,T1,Condition 35 38	HCV
1,T2,Qualifier 39 49	Genotype 1
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Temporal 9 20	chronically
4,T4,Multiplier 9 20	chronically
5,R2,multi Arg1:T3 Arg2:T4
6,R3,Has_temporal Arg1:T1 Arg2:T3
7,T5,Measurement 51 69	HCV RNA viral load
8,T6,Value 73 86	≥ 10*5* IU/mL
9,T7,"Value 88 101	100,000 IU/mL"
10,R4,Subsumes Arg1:T6 Arg2:T7
11,R5,Has_value Arg1:T5 Arg2:T6
12,T8,Temporal 103 115	at screening
13,T9,Reference_point 106 115	screening
14,R6,multi Arg1:T8 Arg2:T9
15,R7,Has_temporal Arg1:T5 Arg2:T8
0,T1,Person 0 5	Women
1,T2,Condition 11 32	multi-fetal pregnancy
2,T3,Condition 34 51	diabetes mellitus
3,T4,Condition 53 73	chronic hypertension
4,T5,Condition 78 99	chronic renal disease
5,*,OR T4 T5 T3 T2
0,T1,Condition 11 33	cardiovascular disease
1,T2,Observation 0 7	History
2,T3,Temporal 36 43	Current
3,T4,Condition 44 53	pregnancy
4,R1,Has_temporal Arg1:T4 Arg2:T3
5,T5,Condition 69 81	hypertension
6,T6,Qualifier 56 68	Uncontrolled
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Qualifier 84 96	Uncontrolled
9,T8,Condition 97 111	hyperlipidemia
10,R3,Has_qualifier Arg1:T8 Arg2:T7
11,T9,Procedure 122 149	hormone replacement therapy
12,T10,Temporal 114 121	Current
13,R4,Has_temporal Arg1:T9 Arg2:T10
14,T11,Observation 160 183	use of tobacco products
15,T12,Temporal 152 159	Current
16,R5,Has_temporal Arg1:T11 Arg2:T12
17,T13,Condition 186 208	Elevated liver enzymes
18,T14,Condition 219 237	autoimmune disease
19,T15,Temporal 211 218	Current
20,R6,Has_temporal Arg1:T14 Arg2:T15
21,T16,Multiplier 240 249	Daily use
22,T17,Drug 256 268	antioxidants
23,T18,Multiplier 269 275	>300mg
24,R7,Has_multiplier Arg1:T17 Arg2:T18
25,R8,Has_multiplier Arg1:T17 Arg2:T16
0,T1,Mood 9 22	scheduled for
1,T2,Procedure 23 36	thyroidectomy
2,T3,Procedure 42 60	general anesthesia
3,R1,AND Arg1:T2 Arg2:T3
4,R2,Has_mood Arg1:T2 Arg2:T1
5,T4,Visit 68 104	University of Chile Clinical Hospita
6,R3,AND Arg1:T2 Arg2:T4
0,T1,Person 23 28	years
1,T2,Value 9 22	older than 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 30 47	Ischemic symptoms
4,T4,Mood 51 59	evidence
5,T5,Condition 63 82	myocardial ischemia
6,T6,Qualifier 84 93	inducible
7,T7,Qualifier 97 108	spontaneous
8,*,OR T6 T7
9,T8,Scope 84 108	inducible or spontaneous
10,R2,Has_scope Arg1:T5 Arg2:T8
11,R3,Has_mood Arg1:T5 Arg2:T4
12,T9,Value 129 133	>50%
13,T10,Qualifier 134 141	de novo
14,T11,Measurement 142 150	stenosis
15,R4,Has_value Arg1:T11 Arg2:T9
16,R5,Has_qualifier Arg1:T11 Arg2:T10
17,T12,Condition 142 150	stenosis
18,R6,AND Arg1:T12 Arg2:T11
19,R7,multi Arg1:T12 Arg2:T11
20,T13,Qualifier 162 185	native coronary vessels
21,R8,Has_qualifier Arg1:T12 Arg2:T13
22,*,OR T3 T5
23,R9,AND Arg1:T5 Arg2:T12
0,T1,Qualifier 6 14	elective
1,T2,Procedure 15 31;68 75	gastrointestinal surgery
2,T3,Procedure 60 75	bladder surgery
3,T4,Procedure 48 56;68 75	prostate surgery
4,T5,Procedure 33 46;68 75	gynecological surgery
5,*,OR T2 T4 T3 T5
6,T6,"Scope 15 75	gastrointestinal, gynecological, prostate or bladder surgery"
7,R1,Has_qualifier Arg1:T6 Arg2:T1
8,T7,Value 93 107	= 60 years old
9,T8,Person 104 107	old
10,R2,Has_value Arg1:T8 Arg2:T7
11,T9,Procedure 125 145	laparoscopic surgery
12,T10,Measurement 165 169	last
13,T11,Value 174 182	= 2 hour
14,R3,Has_value Arg1:T10 Arg2:T11
15,T12,Mood 153 161	expected
16,R4,Has_mood Arg1:T10 Arg2:T12
17,T13,Qualifier 184 208	under general anesthesia
18,R5,Has_qualifier Arg1:T10 Arg2:T13
19,T14,Mood 225 229	will
20,T15,Procedure 230 246	stay in hospital
21,T16,Value 251 280	at least 7 days after surgery
22,R6,Has_mood Arg1:T15 Arg2:T14
23,R7,Has_value Arg1:T15 Arg2:T16
24,T17,Negation 283 290	lack of
25,T18,Condition 311 328	vision impairment
26,T19,Condition 299 306;318 328	hearing impairment
27,*,OR T18 T19
28,T20,Scope 299 328	hearing and vision impairment
29,R8,Has_negation Arg1:T20 Arg2:T17
30,T21,Condition 336 348	able to read
31,T22,Procedure 357 378	neurobehavioral tests
32,T23,Mood 379 395	can be performed
33,R9,Has_mood Arg1:T22 Arg2:T23
0,T1,Observation 17 42	secondary school students
1,T2,Qualifier 46 54	years 10
2,T3,Qualifier 46 51;56 58	years 11
3,T4,Qualifier 46 51;64 66	years 12
4,*,OR T3 T4 T2
5,T5,Temporal 67 74	in 2017
6,T6,"Scope 46 66	years 10, 11, and 12"
7,R1,Has_scope Arg1:T1 Arg2:T6
8,R2,Has_temporal Arg1:T1 Arg2:T5
9,T7,Visit 0 16	South Australian
10,T8,Informed_consent 76 130	Written parental consent for those under the age of 18
11,T9,Informed_consent 132 246	Written student consent assent for those under the age of 18 (or if 18 years old and older consent for themselves)
12,T10,Multiplier 285 290	first
13,T11,Procedure 291 306	pharyngeal swab
14,T12,Mood 311 321	willing to
15,T13,Observation 322 350	comply with study procedures
16,R3,Has_mood Arg1:T13 Arg2:T12
17,R4,Has_multiplier Arg1:T11 Arg2:T10
0,T1,Condition 0 24	Type 2 diabetes mellitus
1,T2,Measurement 30 35	HbA1c
2,T3,Value 36 43	> 7.5 %
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 45 60	Body mass index
5,T5,Value 61 80	> 35 and < 50 kg/m2
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Procedure 96 111	Gastric By-Pass
8,T7,Mood 82 91	Candidate
9,R3,Has_mood Arg1:T6 Arg2:T7
10,T8,Drug 128 165	GLP1 (glucagon-like peptide) analogue
11,T9,Drug 169 176	insulin
12,T10,Procedure 113 122	Treatment
13,*,OR T8 T9
14,T11,Scope 128 176	GLP1 (glucagon-like peptide) analogue or insulin
15,R4,Has_scope Arg1:T10 Arg2:T11
0,T1,Visit 29 97	Gynecological emergency Unit at Hospital de Clínicas de Porto Alegre
1,T2,Procedure 112 130	uterine evacuation
2,T3,Condition 149 158	gestation
3,T4,Multiplier 136 145	<12 weeks
4,R1,Has_multiplier Arg1:T3 Arg2:T4
5,R2,AND Arg1:T2 Arg2:T3
0,T1,Procedure 12 42	combined organ transplantation
1,T2,Qualifier 51 68	extra-renal organ
2,T3,Procedure 76 97	islet cell transplant
3,*,OR T3 T2
4,T4,Scope 51 97	extra-renal organ and/or islet cell transplant
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Procedure 126 147;166 181	non-renal solid organ transplantation
7,T6,Procedure 155 181	islet cell transplantation
8,*,OR T6 T5
9,T7,Temporal 117 125	previous
10,T8,Scope 126 181	non-renal solid organ and/or islet cell transplantation
11,R2,Has_temporal Arg1:T8 Arg2:T7
12,T9,Condition 187 205	Infection with HIV
13,T10,Non-query-able 211 298	Inability or unwillingness of a participant and/or guardian to provide informed consent
14,T11,Post-eligibility 211 298	Inability or unwillingness of a participant and/or guardian to provide informed consent
0,T1,Qualifier 20 28	elective
1,T2,Procedure 29 46	abdominal surgery
2,T3,Measurement 55 74	expected blood loss
3,T4,Value 78 86	= 500 ml
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T2 Arg2:T1
6,R3,AND Arg1:T2 Arg2:T3
7,T5,Measurement 88 107	ASA Physical Status
8,T6,Value 108 116	II - III
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Informed_consent 118 154	Signed written informed consent form
11,T8,Measurement 156 167	Body weight
12,T9,Value 168 176	= 140 kg
13,R5,Has_value Arg1:T8 Arg2:T9
14,T10,Condition 178 184	Sepsis
15,T11,Condition 186 191	Burns
16,T12,Condition 193 209	Renal impairment
17,T13,Measurement 211 221	AKIN stage
18,T14,Value 222 225	= 1
19,R6,Has_value Arg1:T13 Arg2:T14
20,R7,Subsumes Arg1:T12 Arg2:T13
21,T15,Qualifier 230 235	acute
22,T16,Qualifier 243 250	chronic
23,T17,Procedure 251 276	renal replacement therapy
24,*,OR T16 T15
25,T18,Scope 230 250	acute and/or chronic
26,R8,Has_scope Arg1:T17 Arg2:T18
27,*,OR T12 T17
28,T19,Condition 294 314	cerebral haemorrhage
29,T20,Condition 278 290;303 314	Intracranial haemorrhage
30,*,OR T19 T20
31,T21,Condition 316 330	Critically ill
32,T22,Visit 367 386	intensive care unit
33,T23,Mood 341 350	typically
34,T24,Procedure 351 359	admitted
35,R10,Has_mood Arg1:T24 Arg2:T23
36,R9,AND Arg1:T24 Arg2:T22
37,R11,AND Arg1:T21 Arg2:T24
38,T25,Condition 389 403	Hyperhydration
39,T26,Condition 405 421	Pulmonary oedema
40,T27,Condition 423 434	Dehydration
41,T28,Condition 436 449	Hyperkalaemia
42,T29,Condition 458 472	hypernatraemia
43,T30,Qualifier 451 457	Severe
44,R12,Has_qualifier Arg1:T29 Arg2:T30
45,T31,Condition 481 496	hyperchloraemia
46,T32,Qualifier 474 480	Severe
47,R13,Has_qualifier Arg1:T31 Arg2:T32
48,T33,Condition 507 532	impaired hepatic function
49,T34,Qualifier 498 506	Severely
50,R14,Has_qualifier Arg1:T33 Arg2:T34
51,T35,Condition 534 558	Congestive heart failure
52,T36,Condition 567 579	coagulopathy
53,T37,Qualifier 560 566	Severe
54,R15,Has_qualifier Arg1:T36 Arg2:T37
55,T38,Procedure 581 597	Organ transplant
56,T39,Condition 608 627	Metabolic alkalosis
57,T40,Competing_trial 629 731	Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
0,T1,Condition 0 13	Target lesion
1,T2,Qualifier 29 43	left main stem
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 45 50	STEMI
4,T4,Condition 52 62	Restenosis
5,T5,Condition 64 81	Cardiogenic shock
6,T6,Condition 83 95	Malignancies
7,T7,Condition 105 124	comorbid conditions
8,T8,Qualifier 99 104	other
9,R2,Has_qualifier Arg1:T7 Arg2:T8
10,T9,Observation 130 145	life expectancy
11,T10,Value 146 165	less than 12 months
12,T11,Observation 188 210	protocol noncompliance
13,T12,Mood 174 177	may
14,R3,Has_mood Arg1:T11 Arg2:T12
15,R4,Has_value Arg1:T9 Arg2:T10
16,*,OR T9 T11
17,T13,Scope 130 210	life expectancy less than 12 months or that may result in protocol noncompliance
18,*,OR T6 T7
19,T14,Scope 83 124	Malignancies or other comorbid conditions
20,R5,Has_scope Arg1:T14 Arg2:T13
21,T15,Condition 218 225	allergy
22,T16,Drug 233 250	study medications
23,T17,Drug 252 260	probucol
24,T18,Drug 262 271	sirolimus
25,T19,Drug 273 284	zotarolimus
26,*,OR T17 T18 T19
27,T20,"Scope 252 284	probucol, sirolimus, zotarolimus"
28,R6,Subsumes Arg1:T16 Arg2:T20
29,R7,AND Arg1:T15 Arg2:T16
30,T21,Condition 287 296	Pregnancy
31,T22,Temporal 298 305	present
32,T23,Mood 307 316	suspected
33,T24,Mood 321 328	planned
34,*,OR T23 T24 T22
35,T25,"Scope 298 328	present, suspected, or planned"
36,R8,Has_scope Arg1:T21 Arg2:T25
0,T1,Measurement 9 12	ASA
1,T2,Value 13 21	III y IV
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 23 35	Chronic pain
4,T4,Condition 45 49;62 67	Drug abuse
5,T5,Condition 54 67	alcohol abuse
6,*,OR T4 T5
7,T6,Drug 84 90	opioid
8,T7,Drug 95 104	sedatives
9,*,OR T6 T7
10,T8,Multiplier 69 80	Chronic use
11,T9,Scope 84 104	opioid and sedatives
12,R2,Has_multiplier Arg1:T9 Arg2:T8
13,T10,Condition 106 130	Neuropsychiatric illness
14,T11,Drug 132 137	NSAID
15,T12,Qualifier 142 147	other
16,T13,Drug 148 158	analgesics
17,R3,Has_qualifier Arg1:T13 Arg2:T12
18,*,OR T13 T11
19,T14,Temporal 168 200	48 hours previous to the surgery
20,T15,Reference_point 189 200	the surgery
21,R4,Has_index Arg1:T14 Arg2:T15
22,T16,Scope 132 158	NSAID and other analgesics
23,R5,Has_temporal Arg1:T16 Arg2:T14
24,T17,Measurement 202 205	CMI
25,T18,Value 206 209	> 3
26,R6,Has_value Arg1:T17 Arg2:T18
0,T1,Condition 9 20	anaphylaxis
1,T2,Temporal 0 8	Previous
2,T3,Drug 48 63	Bexsero vaccine
3,R1,AND Arg1:T1 Arg2:T3
4,R2,Has_temporal Arg1:T1 Arg2:T2
5,T4,Temporal 65 73	Previous
6,T5,Drug 85 108	meningococcal B vaccine
7,T6,Drug 110 117	Bexsero
8,R3,Subsumes Arg1:T5 Arg2:T6
9,R4,Has_temporal Arg1:T5 Arg2:T4
10,T7,Condition 126 135	pregnancy
0,T1,Observation 17 37	expected to be alive
1,T2,Negation 13 16	not
2,T3,Value 42 62	longer than 3 months
3,R1,Has_value Arg1:T1 Arg2:T3
4,R2,Has_negation Arg1:T1 Arg2:T2
5,T4,Measurement 65 101	Mini-mental State Examination (MMSE)
6,T5,Value 113 117	= 23
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Condition 131 139	dementia
9,T7,Condition 141 160	psychiatric illness
10,T8,Condition 168 202	diseases of central nervous system
11,T9,Drug 220 229	sedatives
12,T10,Temporal 205 212	current
13,T11,Drug 233 247	antidepressant
14,*,OR T11 T9
15,T12,Scope 220 247	sedatives or antidepressant
16,R4,Has_temporal Arg1:T12 Arg2:T10
17,T13,Condition 250 260	alcoholism
18,T14,Condition 265 280	drug dependence
19,*,OR T14 T13
20,T15,Non-query-able 283 405	patients previously included in this study (for patients who have second intra-abdominal surgery during the study period).
21,T16,Non-query-able 407 463	difficult to follow up or patients with poor compliance.
22,T17,Condition 465 490	uncontrolled hypertension
23,T18,Value 492 506	> 180/100 mmHg
24,R5,Has_value Arg1:T17 Arg2:T18
0,T1,Procedure 20 37	bariatric surgery
1,T2,Condition 0 16	Contraindication
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Condition 39 48	Pregnancy
4,T4,Observation 50 86	Affiliation of health care assurance
5,T5,Condition 88 109	Psychiatric disorders
0,T1,Person 3 7	Male
1,T2,Person 12 18	female
2,T3,Value 44 53	≥18 years
3,T4,Person 57 60	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,*,OR T2 T1
6,T5,Multiplier 86 93	primary
7,T6,Multiplier 97 107	subsequent
8,T7,Procedure 126 161	living donor kidney transplantation
9,T8,Procedure 108 122;139 161	deceased-donor kidney transplantation
10,*,OR T8 T7
11,*,OR T6 T5
12,T9,Scope 108 161	deceased-donor or living donor kidney transplantation
13,T10,Scope 86 107	primary or subsequent
14,R2,Has_scope Arg1:T9 Arg2:T10
15,T11,Non-query-able 167 232	Subject and/or guardian must be able to provide informed consent.
16,T12,Post-eligibility 167 232	Subject and/or guardian must be able to provide informed consent.
17,T13,Non-query-able 237 308	Subject and/or guardian must be able to comply with the study protocol.
18,T14,Post-eligibility 237 308	Subject and/or guardian must be able to comply with the study protocol.
0,T1,Post-eligibility 0 54	patients who do not wish to participate in the project
1,T2,Condition 71 88	ectopic pregnancy
2,T3,Condition 105 118	comorbidities
3,T4,Condition 120 144	heart failure congestive
4,T5,Condition 146 183	chronic obstructive pulmonary disease
5,*,OR T4 T5
6,T6,"Scope 120 183	heart failure congestive, chronic obstructive pulmonary disease"
7,R1,Subsumes Arg1:T3 Arg2:T6
8,T7,Condition 201 218	hypovolemic shock
9,T8,Condition 235 256	cervical incompetence
10,T9,Qualifier 273 281	infected
11,T10,Condition 294 302	abortion
12,T11,Condition 282 293	miscarriage
13,*,OR T11 T10
14,T12,Scope 282 302	miscarriage/abortion
15,R2,Has_qualifier Arg1:T12 Arg2:T9
16,T13,Condition 316 321	fever
17,T14,Condition 323 342	pus from the cervix
18,T15,Measurement 344 356	leukocytosis
19,T16,Temporal 358 365	> 14000
20,R3,Has_temporal Arg1:T15 Arg2:T16
21,*,OR T13 T14 T15
22,T17,"Scope 316 366	fever, pus from the cervix, leukocytosis [> 14000]"
23,R4,Has_scope Arg1:T12 Arg2:T17
24,T18,Qualifier 384 388	twin
25,T19,Condition 389 398	pregnancy
26,R5,Has_qualifier Arg1:T19 Arg2:T18
27,T20,Condition 415 430	Marfan syndrome
28,T21,Condition 442 450	allergic
29,T22,Drug 454 465	misoprostol
30,R6,AND Arg1:T21 Arg2:T22
31,T23,Condition 482 494	coagulopathy
32,T24,Observation 511 542	opening of cervical internal os
33,T25,Value 544 562	4 mm of dilatation
34,R7,Has_value Arg1:T24 Arg2:T25
35,T26,Procedure 617 624	surgery
36,T27,Qualifier 632 638	cervix
37,R8,Has_qualifier Arg1:T26 Arg2:T27
38,T28,Procedure 640 650	conization
39,R9,Subsumes Arg1:T26 Arg2:T28
40,T29,Drug 687 691	IUDs
0,T1,Person 0 3	Age
1,T2,Value 4 17	over 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 33 46	rectal cancer
4,T4,Qualifier 47 52	stage
5,T5,Measurement 54 56	cT
6,T6,Measurement 63 65	cN
7,T7,Measurement 70 72	cM
8,T8,Value 56 61	1-2-3
9,T9,Value 65 68	0-1
10,T10,Value 72 73	0
11,R2,Has_value Arg1:T7 Arg2:T10
12,R3,Has_value Arg1:T6 Arg2:T9
13,R4,Has_value Arg1:T5 Arg2:T8
14,*,OR T5 T6 T7
15,T11,"Scope 54 73	cT1-2-3, cN0-1, cM0"
16,R5,Has_scope Arg1:T4 Arg2:T11
17,R6,Has_qualifier Arg1:T3 Arg2:T4
18,T12,Qualifier 82 122	equal or below 10 cm from the anal verge
19,T13,Mood 124 134	candidates
20,T14,Procedure 144 166	low anterior resection
21,T15,Procedure 144 156;171 182	low anterior anastomosis
22,*,OR T15 T14
23,T16,Scope 144 182	low anterior resection and anastomosis
24,R7,Has_mood Arg1:T16 Arg2:T13
25,T17,Temporal 200 212	preoperative
26,T18,Procedure 213 231	chemo-radiotherapy
27,A1,Optional T18
28,R8,Has_temporal Arg1:T18 Arg2:T17
29,T19,Condition 76 81	Tumor
30,R9,Has_qualifier Arg1:T19 Arg2:T12
31,T20,Condition 234 248	Adenocarcinoma
32,T21,Qualifier 252 283	low or moderate differentiation
33,R10,Has_qualifier Arg1:T20 Arg2:T21
34,T22,Measurement 285 288	ASA
35,T23,"Value 289 299	I, II, III"
36,R11,Has_value Arg1:T22 Arg2:T23
0,T1,Value 11 19	65 years
1,T2,Person 20 23	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Informed_consent 31 75	able and willing to give an informed consent
4,T4,Procedure 106 124	trans-femoral TAVI
5,T5,Temporal 87 97	undergoing
6,T6,Qualifier 98 105	planned
7,R2,Has_qualifier Arg1:T4 Arg2:T6
8,R3,Has_temporal Arg1:T4 Arg2:T5
9,T7,Measurement 127 142	Calculated eGFR
10,T8,Value 143 164	below 60ml/min/1.73m2
11,R4,Has_value Arg1:T7 Arg2:T8
0,T1,Condition 49 64	Liver cirrhosis
1,T2,Observation 0 28	Do not sign informed consent
2,T3,Condition 30 38	Pregnant
3,T4,Condition 83 97	adenocarcinoma
4,T5,Qualifier 66 82	Undifferentiated
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,T6,Condition 100 103	cT4
7,T7,Condition 105 128	Metastatic disease (M1)
8,T8,Condition 130 151	chronic renal failure
9,T9,Procedure 155 163	dialysis
10,T10,Measurement 165 168	ASA
11,T11,Value 169 171	IV
12,R2,Has_value Arg1:T10 Arg2:T11
13,T12,Measurement 173 176	BMI
14,T13,Value 177 196	<18 and> 35 kg / m2
15,R3,Has_value Arg1:T12 Arg2:T13
0,T1,Condition 11 34	acute coronary syndrome
1,T2,Temporal 35 54	in the past 30 days
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 68 92	congesting heart failure
4,T4,Measurement 98 132	left ventricular ejection fraction
5,T5,Value 133 137	<30%
6,T6,Condition 141 153	exacerbation
7,T7,Temporal 154 173	in the past 30 days
8,R2,Has_value Arg1:T4 Arg2:T5
9,R3,Has_temporal Arg1:T6 Arg2:T7
10,*,OR T4 T6
11,T8,Scope 98 173	left ventricular ejection fraction <30% or exacerbation in the past 30 days
12,R4,Has_scope Arg1:T3 Arg2:T8
13,T9,Procedure 184 202	dialysis treatment
14,T10,Temporal 176 183	Current
15,R5,Has_temporal Arg1:T9 Arg2:T10
16,T11,Drug 211 221	furosemide
17,T12,Condition 222 238	hypersensitivity
18,R6,AND Arg1:T12 Arg2:T11
19,T13,Condition 241 258	Contraindications
20,T14,Procedure 262 291	placement of a Foley catheter
21,T15,Qualifier 299 306	bladder
22,R7,Has_qualifier Arg1:T14 Arg2:T15
23,R8,AND Arg1:T13 Arg2:T14
0,T1,Condition 12 26	Osteoarthritis
1,T2,Measurement 28 45	Kellgren-Lawrence
2,T3,Value 46 49	> 3
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 52 71	Minimum joint space
5,T5,Value 72 78	> 2 mm
6,T6,Procedure 94 107	AP radiograph
7,R2,Has_value Arg1:T4 Arg2:T5
8,T7,Condition 109 122	Hip dysplasia
9,T8,Measurement 124 141	center edge angle
10,T9,Value 142 147	< 20°
11,T10,Procedure 151 164	AP radiograph
12,R3,Has_value Arg1:T8 Arg2:T9
13,T11,Condition 204 218;246 253	cardiovascular disease
14,T12,Condition 220 225;246 253	renal disease
15,T13,Condition 227 234;246 253	hepatic disease
16,T14,Condition 236 253	endocrine disease
17,T15,Condition 255 261	cancer
18,T16,Condition 265 273	diabetes
19,T17,Qualifier 192 203	significant
20,T18,"Scope 204 273	cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes"
21,R4,Has_qualifier Arg1:T18 Arg2:T17
22,*,OR T11 T12 T13 T14 T15 T16
23,T19,Condition 297 306	infection
24,T20,Qualifier 289 296	ongoing
25,R5,Has_qualifier Arg1:T19 Arg2:T20
26,T21,Condition 317 320	HIV
27,T22,Condition 325 334	Hepatitis
28,T23,Parsing_Error 321 324	and
29,*,OR T21 T22
30,T24,Scope 317 334	HIV and Hepatitis
31,R6,Subsumes Arg1:T19 Arg2:T24
32,T25,Condition 374 390	septic arthritis
33,T26,Condition 360 373	osteomyelitis
34,*,OR T26 T25
35,T27,Parsing_Error 373 374	/
36,T28,Procedure 392 415	Anticoagulation therapy
37,T29,Pregnancy_considerations 417 460	Patients who are pregnant or breast feeding
38,T30,Condition 535 552	chondrocalcinosis
39,T31,Condition 554 569	hemochromatosis
40,T32,Condition 571 593	inflammatory arthritis
41,T33,Condition 595 618	arthropathy of the knee
42,T34,Condition 651 666	Paget's disease
43,T35,Condition 690 712	hemophilic arthropathy
44,T36,Condition 714 734	infectious arthritis
45,T37,Condition 736 756	Charcot's knee joint
46,T38,Condition 758 780	villonodular synovitis
47,T39,Condition 786 809	synovial chondromatosis
48,T40,Parsing_Error 782 785	and
49,T41,Qualifier 674 679	femur
50,T42,Qualifier 683 688	tibia
51,T43,Qualifier 635 650	juxta-articular
52,*,OR T41 T42
53,T44,Qualifier 527 531	knee
54,T45,Condition 499 519	inflammatory disease
55,T46,Condition 486 495;512 519	rheumatic disease
56,T47,Condition 476 484;512 519	systemic disease
57,*,OR T45 T47 T46
58,T48,"Scope 476 519	systemic, rheumatic or inflammatory disease"
59,R7,Has_qualifier Arg1:T48 Arg2:T44
60,*,OR T48 T30 T31 T32 T50 T35 T36 T37 T38 T39
61,T49,Scope 674 688	femur or tibia
62,R8,Has_qualifier Arg1:T34 Arg2:T43
63,R9,Has_scope Arg1:T34 Arg2:T49
64,T50,Scope 595 688	arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia
65,T51,Procedure 827 855	immunosuppressant medication
66,T52,Measurement 894 913	serum chemistry lab
67,T53,Measurement 880 890;910 913	hematology lab
68,*,OR T52 T53
69,T54,Value 871 879	abnormal
70,T55,Scope 880 913	hematology or serum chemistry lab
71,R10,Has_value Arg1:T55 Arg2:T54
72,T56,Procedure 942 951	injection
73,T57,Qualifier 965 969	knee
74,T58,Temporal 970 1005	within 2 months of study enrollment
75,T59,Reference_point 989 1005	study enrollment
76,R11,Has_index Arg1:T58 Arg2:T59
77,R12,Has_qualifier Arg1:T56 Arg2:T57
78,T60,Measurement 1007 1010	BMI
79,T61,Value 1011 1026	greater than 35
80,T62,Value 1030 1042	less than 20
81,*,OR T61 T62
82,T63,Scope 1011 1042	greater than 35 or less than 20
83,R13,Has_scope Arg1:T60 Arg2:T63
0,T1,Person 0 7	Females
1,T2,Condition 16 24	pregnant
2,T3,Condition 28 35	nursing
3,*,OR T2 T3
4,T4,Negation 47 50	not
5,T5,Mood 51 60	scheduled
6,T6,Procedure 65 91	trans-jugular liver biopsy
7,R1,Has_mood Arg1:T6 Arg2:T5
8,R2,Has_negation Arg1:T5 Arg2:T4
9,T7,"Non-query-able 93 237	Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 h afterwards,."
10,T8,Condition 306 344	transient right-to-left cardiac shunts
11,T9,Condition 287 301;330 344	bi-directional cardiac shunts
12,T10,Condition 272 285;330 344	right-to-left cardiac shunts
13,*,OR T8 T10 T9
14,T11,Mood 262 271	suspected
15,T12,Mood 253 258	known
16,*,OR T11 T12
17,T13,Scope 253 271	known or suspected
18,T14,"Scope 272 344	right-to-left, bi-directional, or transient right-to-left cardiac shunts"
19,R3,Has_scope Arg1:T14 Arg2:T13
20,T15,Condition 360 382	pulmonary hypertension
21,T16,Condition 386 421	unstable cardiopulmonary conditions
22,*,OR T15 T16
23,T17,Procedure 445 457	chemotherapy
24,T18,Temporal 432 441	currently
25,T19,Procedure 510 541	hepatic loco-regional treatment
26,T20,Procedure 498 506;518 541	systemic loco-regional treatment
27,*,OR T19 T20
28,T21,Condition 472 487	primary cancers
29,T22,Qualifier 466 471	other
30,R4,Has_qualifier Arg1:T21 Arg2:T22
31,T23,Scope 498 541	systemic or hepatic loco-regional treatment
32,R5,Has_scope Arg1:T21 Arg2:T23
33,*,OR T21 T17
34,T24,Scope 445 541	chemotherapy or with other primary cancers requiring systemic or hepatic loco-regional treatment
35,R6,Has_temporal Arg1:T24 Arg2:T18
36,T25,Condition 561 579	medically unstable
37,T26,Condition 598 607;622 625	seriously ill
38,T27,Condition 611 625	terminally ill
39,*,OR T26 T27 T28 T25
40,T28,Condition 646 678	clinical course is unpredictable
41,T29,Procedure 706 718	life support
42,T30,Visit 727 745	critical care unit
43,R7,AND Arg1:T29 Arg2:T30
44,T31,Condition 762 788	unstable occlusive disease
45,T32,Scope 796 812	crescendo angina
46,R8,Subsumes Arg1:T31 Arg2:T32
47,T33,Qualifier 829 848	clinically unstable
48,T34,Condition 849 868	cardiac arrhythmias
49,T35,Condition 888 911	ventricular tachycardia
50,T36,Multiplier 878 887	recurrent
51,R9,Has_multiplier Arg1:T35 Arg2:T36
52,R10,Has_qualifier Arg1:T34 Arg2:T33
53,T37,Scope 829 868	clinically unstable cardiac arrhythmias
54,R11,AND Arg1:T37 Arg2:T35
55,T38,Qualifier 928 940	uncontrolled
56,T39,Condition 941 965	congestive heart failure
57,T40,Measurement 967 971	NYHA
58,T41,Value 972 980	Class IV
59,R12,Has_value Arg1:T40 Arg2:T41
60,R13,Has_qualifier Arg1:T39 Arg2:T38
61,T42,Scope 928 965	uncontrolled congestive heart failure
62,R14,Subsumes Arg1:T42 Arg2:T40
63,T43,Temporal 997 1003	recent
64,T44,Condition 1004 1023	cerebral hemorrhage
65,R15,Has_temporal Arg1:T44 Arg2:T43
66,T45,Procedure 1054 1061	surgery
67,T46,Temporal 1062 1120	within 24 hours prior to the study sonographic examination
68,T47,Reference_point 1087 1120	the study sonographic examination
69,T48,Procedure 1097 1120	sonographic examination
70,R16,Has_index Arg1:T46 Arg2:T47
71,R17,AND Arg1:T47 Arg2:T48
72,R18,Has_temporal Arg1:T45 Arg2:T46
73,T49,Condition 1150 1170	anaphylactic allergy
74,T50,Drug 1174 1178	eggs
75,T51,Drug 1182 1194	egg products
76,*,OR T50 T51
77,T52,Scope 1174 1194	eggs or egg products
78,R19,Has_scope Arg1:T49 Arg2:T52
79,T53,Condition 1249 1270	generalized urticaria
80,T54,Condition 1272 1295	difficulty in breathing
81,T55,Condition 1297 1318	swelling of the mouth
82,T56,Condition 1297 1312;1323 1329	swelling of the throat
83,T57,Condition 1331 1342	hypotension
84,T58,Condition 1347 1352	shock
85,*,OR T58 T57 T56 T55 T54 T53
86,T59,"Scope 1249 1352	generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock"
87,T60,Scope 1150 1194	anaphylactic allergy to eggs or egg products
88,R20,Subsumes Arg1:T60 Arg2:T59
89,T61,Condition 1545 1569	congenital heart defects
90,T62,Qualifier 1586 1592	severe
91,T63,Condition 1593 1602	emphysema
92,T64,Condition 1604 1624	pulmonary vasculitis
93,T65,Condition 1642 1658	pulmonary emboli
94,*,OR T65 T64 T63
95,R21,Has_qualifier Arg1:T63 Arg2:T62
96,T66,Condition 1675 1704	respiratory distress syndrome
97,T67,Condition 1720 1730	thrombosis
98,T68,Qualifier 1762 1778	mesenteric veins
99,T69,Qualifier 1751 1757;1773 1778	portal veins
100,T70,Qualifier 1742 1749;1773 1778	hepatic veins
101,*,OR T69 T70 T68
102,T71,"Scope 1742 1778	hepatic, portal, or mesenteric veins"
103,R22,Has_scope Arg1:T67 Arg2:T71
0,T1,Condition 11 34	ischaemic heart disease
1,T2,Condition 36 51	cardiac failure
2,T3,Condition 53 76	cerebrovascular disease
3,T4,Condition 78 94	liver impairment
4,T5,Measurement 96 99	ALT
5,T6,Measurement 100 103	AST
6,*,OR T6 T5
7,T7,Value 103 110	>50IU/L
8,R1,Has_value Arg1:T6 Arg2:T7
9,R2,Has_value Arg1:T5 Arg2:T7
10,T8,Measurement 115 120	stage
11,T9,Value 121 124	3-5
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Condition 125 147	chronic kidney disease
14,R4,AND Arg1:T10 Arg2:T8
15,T11,Scope 96 110	ALT/AST>50IU/L
16,R5,Subsumes Arg1:T4 Arg2:T11
17,*,OR T1 T2 T3 T4 T8
18,T12,Condition 161 169	overdose
19,T13,Condition 173 190	suicidal ideation
20,*,OR T13 T12
21,T14,Measurement 201 209	weighing
22,T15,Value 210 216	<55kgs
23,R6,Has_value Arg1:T14 Arg2:T15
24,T16,Condition 233 245	chronic pain
25,T17,Qualifier 246 265	requiring treatment
26,R7,Has_qualifier Arg1:T16 Arg2:T17
27,T18,Condition 274 287	known allergy
28,T19,Drug 291 302	paracetamol
29,R8,AND Arg1:T18 Arg2:T19
30,T20,Drug 326 359	non-steroidal anti-inflammatories
31,T21,Temporal 307 318	concomitant
32,T22,Drug 362 381	oral anticoagulants
33,T23,Drug 385 400	corticosteroids
34,*,OR T23 T22 T20
35,T24,"Scope 326 400	non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids"
36,R9,Has_temporal Arg1:T24 Arg2:T21
37,*,OR T18 T24
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,T3,Person 24 27	age
3,T4,Value 28 45	18 years or older
4,T5,Condition 75 80	sALCL
5,T6,Qualifier 64 74	refractory
6,T7,Qualifier 52 60	relapsed
7,*,OR T6 T7
8,T8,Multiplier 110 120	at least 1
9,T9,Procedure 132 144	chemotherapy
10,R1,Has_multiplier Arg1:T9 Arg2:T8
11,T10,Scope 52 74	relapsed or refractory
12,R2,Has_scope Arg1:T5 Arg2:T10
13,R3,Has_value Arg1:T3 Arg2:T4
14,*,OR T2 T1
15,R4,AND Arg1:T5 Arg2:T9
16,T11,Non-query-able 146 178	Bidimensional measurable disease
17,T12,Measurement 183 217;225 243	Eastern Cooperative Oncology Group performance status
18,T13,Measurement 219 223	ECOG
19,T14,Value 247 253	0 or 1
20,R5,Subsumes Arg1:T12 Arg2:T13
21,R6,Has_value Arg1:T12 Arg2:T14
22,T15,"Pregnancy_considerations 255 577	Female patients who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence"
23,T16,Pregnancy_considerations 579 775	Male patients who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence
24,T17,Non-query-able 777 838	Clinical laboratory values as specified in the study protocol
0,T1,Condition 26 29	FAI
1,T2,Qualifier 14 25	symptomatic
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 69 72	FAI
4,T4,Qualifier 44 65	radiographic evidence
5,T5,Qualifier 31 39;57 65	Clinical evidence
6,T6,Scope 31 65	Clinical and radiographic evidence
7,R2,Has_scope Arg1:T3 Arg2:T6
8,T7,Post-eligibility 74 129	Patients able to provide consent to study participation
9,T8,Procedure 156 180	physical therapy program
10,T9,Temporal 145 152	6 weeks
11,R3,Has_temporal Arg1:T8 Arg2:T9
0,T1,Procedure 17 43	trans-jugular liver biopsy
1,T2,Temporal 44 79	the day of the ultrasound procedure
2,T3,Reference_point 59 79	ultrasound procedure
3,T4,Procedure 59 79	ultrasound procedure
4,R1,AND Arg1:T3 Arg2:T4
5,R2,Has_index Arg1:T2 Arg2:T3
6,R3,Has_temporal Arg1:T1 Arg2:T2
7,T5,Value 85 102	at least 21 years
8,T6,Person 106 109	age
9,R4,Has_value Arg1:T6 Arg2:T5
10,T7,Condition 115 131	medically stable
11,T8,Person 139 145	female
12,T9,Condition 149 172	child-bearing potential
13,T10,Condition 186 194	negative
14,T11,Measurement 195 209	pregnancy test
15,R5,AND Arg1:T11 Arg2:T10
16,T12,Scope 139 172	female of child-bearing potential
17,A1,Optional T12
18,R6,AND Arg1:T12 Arg2:T11
19,T13,Non-query-able 212 266	Be conscious and able to comply with study procedures.
20,T14,Post-eligibility 268 359	Have read and signed the IRB-approved Informed Consent form for participating in the study.
0,T1,Drug 24 35	brentuximab
1,T2,Procedure 69 90	allogeneic transplant
2,T3,Condition 128 150	primary cutaneous ALCL
3,T4,Condition 191 196	sALCL
4,*,OR T3 T4
5,T5,Condition 228 245	meningeal disease
6,T6,Condition 219 227;238 245	cerebral disease
7,T7,Condition 277 319	progressive multifocal leukoencephalopathy
8,T8,Condition 321 324	PML
9,R1,Subsumes Arg1:T7 Arg2:T8
10,*,OR T5 T6
11,T9,Scope 219 245	cerebral/meningeal disease
12,R2,Subsumes Arg1:T9 Arg2:T7
13,T10,Pregnancy_considerations 327 390	Female patients who are lactating and breastfeeding or pregnant
14,T11,Measurement 398 426	human immunodeficiency virus
15,T12,Measurement 428 431	HIV
16,R3,Subsumes Arg1:T11 Arg2:T12
17,T13,Value 433 441	positive
18,R4,Has_value Arg1:T11 Arg2:T13
19,T14,Measurement 449 476	hepatitis B surface antigen
20,T15,Value 477 485	positive
21,T16,Condition 516 537	hepatitis C infection
22,T17,Qualifier 509 515	active
23,R5,Has_qualifier Arg1:T16 Arg2:T17
24,R6,Has_value Arg1:T14 Arg2:T15
25,*,OR T14 T16
0,T1,Value 0 3	=18
1,T2,Person 4 13	years old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Person 15 18	men
4,T4,Condition 22 37	post-menopausal
5,T5,Person 38 43	women
6,A1,Optional T3
7,A2,Optional T5
8,R2,AND Arg1:T5 Arg2:T4
9,*,OR T3 T5
10,T6,Condition 56 66	no periods
11,T7,Temporal 67 88	for 12 months or more
12,T8,Procedure 114 122	surgical
13,T9,Condition 123 132	menopause
14,R3,AND Arg1:T9 Arg2:T8
15,R4,Has_temporal Arg1:T6 Arg2:T7
16,*,OR T6 T9
17,T10,"Scope 56 132	no periods for 12 months or more, or those who have had a surgical menopause"
18,R5,Subsumes Arg1:T4 Arg2:T10
19,T11,Condition 143 155	hypertensive
20,T12,Qualifier 135 142	Treated
21,R6,Has_qualifier Arg1:T11 Arg2:T12
22,T13,Measurement 173 233	average daytime ambulatory blood pressure measurement (ABPM)
23,T14,Value 234 245	<150/95mmHg
24,R7,Has_value Arg1:T13 Arg2:T14
25,T15,Qualifier 249 261	stable doses
26,T16,Drug 277 304	antihypertensive medication
27,T17,Multiplier 265 276	one or more
28,R8,Has_multiplier Arg1:T16 Arg2:T17
29,R9,Has_qualifier Arg1:T16 Arg2:T15
30,T18,Drug 342 355	ACE inhibitor
31,T19,Drug 357 385	angiotensin receptor blocker
32,T20,Drug 389 397	diuretic
33,*,OR T18 T19 T20
34,T21,Multiplier 306 318	at least one
35,T22,"Scope 342 397	ACE inhibitor, angiotensin receptor blocker or diuretic"
36,R10,Has_multiplier Arg1:T22 Arg2:T21
37,R11,Subsumes Arg1:T16 Arg2:T22
38,T23,Temporal 399 411	for 3 months
39,R12,Has_temporal Arg1:T15 Arg2:T23
40,T24,Qualifier 416 425	untreated
41,T25,Condition 426 447	hypertensive patients
42,T26,Measurement 456 476	average daytime ABPM
43,T27,Value 477 496	=135/85 but <150/95
44,R13,Has_value Arg1:T26 Arg2:T27
45,T28,Scope 135 155	Treated hypertensive
46,A3,Optional T28
47,T29,Scope 416 447	untreated hypertensive patients
48,A4,Optional T29
49,R14,Has_qualifier Arg1:T25 Arg2:T24
50,R15,AND Arg1:T29 Arg2:T26
51,T30,"Scope 173 411	average daytime ambulatory blood pressure measurement (ABPM) <150/95mmHg on stable doses of one or more antihypertensive medication (at least one of which should be; an ACE inhibitor, angiotensin receptor blocker or diuretic) for 3 months"
52,R16,Has_scope Arg1:T28 Arg2:T30
53,*,OR T28 T29
0,T1,Person 0 7	Infants
1,T2,Procedure 34 69	postnatal vitamin D supplementation
2,T3,Drug 44 53	vitamin D
3,R1,multi Arg1:T2 Arg2:T3
4,T4,Condition 71 82	prematurity
5,T5,Condition 95 110	low birthweight
6,*,OR T4 T5
7,T6,Measurement 99 110	birthweight
8,T7,Value 111 118	<2500 g
9,R2,Has_value Arg1:T6 Arg2:T7
10,R3,multi Arg1:T5 Arg2:T6
11,T8,Condition 120 131	poor health
12,T9,Temporal 141 148	current
13,T10,Temporal 152 156	past
14,*,OR T9 T10
15,T11,Condition 157 182	significant disease state
16,T12,Condition 186 208	congenital abnormality
17,*,OR T11 T12
18,T13,Scope 141 156	current or past
19,R4,Has_scope Arg1:T11 Arg2:T13
0,T1,Condition 0 7	Healthy
1,T2,Condition 9 13	term
2,T3,Observation 15 28	breastfeeding
3,T4,Person 29 36	infants
4,T5,Observation 49 72	predominately breastfed
5,T6,Multiplier 73 94	for at least 6-months
6,R1,Has_multiplier Arg1:T5 Arg2:T6
7,T7,Non-representable 96 228	This will be determined by answering yes/no to question 'do you intend to breastfeed until your infant is at least 6 months of age.'
0,T1,Person 0 3	Age
1,T2,Value 4 14	≥ 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 16 19	Age
4,T4,Value 20 30	≥ 12 years
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 49 62	bone sarcomas
7,A1,Optional T5
8,R3,AND Arg1:T5 Arg2:T3
9,*,OR T1 T5
10,T6,Procedure 66 80	Histologically
11,T7,Value 81 90	confirmed
12,R4,Has_value Arg1:T6 Arg2:T7
13,T8,Condition 158 169;178 185	soft-tissue sarcoma
14,T9,Qualifier 147 157	high grade
15,T10,Qualifier 136 146	metastatic
16,T11,Temporal 118 127	recurrent
17,T12,Qualifier 104 116	unresectable
18,*,OR T9 T10 T11 T12
19,T13,Condition 173 185	bone sarcoma
20,T14,Scope 158 185	soft-tissue or bone sarcoma
21,*,OR T8 T13
22,T15,"Scope 104 157	unresectable, recurrent, and/or metastatic high grade"
23,R5,Has_scope Arg1:T14 Arg2:T15
24,T16,Condition 220 240	soft tissue sarcomas
25,T17,Condition 242 256	leiomyosarcoma
26,T18,Condition 298 309	liposarcoma
27,T19,Qualifier 258 279	poorly differentiated
28,T20,Qualifier 280 297	de-differentiated
29,*,OR T20 T19
30,T21,Scope 258 297	poorly differentiated/de-differentiated
31,R6,Has_scope Arg1:T18 Arg2:T21
32,T22,Condition 351 358	sarcoma
33,T23,Qualifier 334 350	undifferentiated
34,T24,Qualifier 322 333	pleomorphic
35,T25,Qualifier 311 321	high grade
36,T26,Condition 359 362	MFH
37,T27,Condition 367 383	synovial sarcoma
38,*,OR T26 T22
39,T28,Scope 351 383	sarcoma/MFH and synovial sarcoma
40,T29,Scope 311 350	high grade pleomorphic undifferentiated
41,R7,Has_scope Arg1:T28 Arg2:T29
42,T30,Condition 390 403	bone sarcomas
43,T31,Condition 405 418	Ewing sarcoma
44,T32,Condition 420 432	osteosarcoma
45,T33,Condition 438 452	chondrosarcoma
46,T34,Qualifier 454 471	de-differentiated
47,T35,Qualifier 475 486	mesenchymal
48,*,OR T35 T34
49,T36,Scope 454 486	de-differentiated or mesenchymal
50,R8,Has_scope Arg1:T33 Arg2:T36
51,T37,"Scope 404 488	(Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal])"
52,*,OR T31 T32 T33
53,R9,Subsumes Arg1:T30 Arg2:T37
54,T38,"Scope 242 383	leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma"
55,R10,Subsumes Arg1:T16 Arg2:T38
56,*,OR T16 T30
57,T39,Grammar_Error 386 389	and
58,T40,"Scope 220 488	soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal])"
59,R11,Subsumes Arg1:T14 Arg2:T40
60,R12,AND Arg1:T14 Arg2:T6
61,T41,Measurement 491 514	ECOG Performance Status
62,T42,Value 518 524	0 or 1
63,R13,Has_value Arg1:T41 Arg2:T42
64,T43,Condition 548 566	measurable disease
65,T44,Procedure 570 572;577 582	CT scans
66,T45,Procedure 573 582	MRI scans
67,*,OR T44 T45
68,T46,Scope 570 582	CT/MRI scans
69,R14,AND Arg1:T46 Arg2:T43
70,T47,Procedure 618 625	imaging
71,T48,Temporal 609 617	Baseline
72,R15,Has_temporal Arg1:T47 Arg2:T48
73,T49,Temporal 644 668	within 30 days of dosing
74,T50,Reference_point 662 668	dosing
75,R16,Has_index Arg1:T49 Arg2:T50
76,R17,Has_temporal Arg1:T47 Arg2:T49
77,T51,Non-query-able 671 811	At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts.
78,T52,Multiplier 840 843	1-3
79,T53,Temporal 844 849	prior
80,T54,Procedure 850 868	systemic therapies
81,T55,Qualifier 876 894	metastatic setting
82,R18,Has_qualifier Arg1:T54 Arg2:T55
83,R19,Has_temporal Arg1:T54 Arg2:T53
84,R20,Has_multiplier Arg1:T54 Arg2:T52
85,T56,Condition 897 920	Adequate organ function
86,T57,Temporal 921 945	within 14 days of dosing
87,T58,Reference_point 939 945	dosing
88,R21,Has_index Arg1:T57 Arg2:T58
89,R22,Has_temporal Arg1:T56 Arg2:T57
90,T59,Non-query-able 947 1027	Must be willing to provide and have available archival tissue for PD-L1 testing.
91,T60,"Post-eligibility 1029 1065	Written, voluntary informed consent."
92,T61,"Non-query-able 1029 1065	Written, voluntary informed consent."
93,T62,Person 1083 1088	women
94,T63,Person 1075 1078	men
95,*,OR T62 T63
96,T64,Condition 1092 1114	childbearing potential
97,T65,Procedure 1156 1169	birth control
98,T66,Temporal 1170 1199	from providing signed consent
99,T67,Reference_point 1175 1199	providing signed consent
100,R23,Has_index Arg1:T66 Arg2:T67
101,T68,Temporal 1204 1253	for 120 days after last study drug administration
102,T69,Reference_point 1223 1253	last study drug administration
103,R24,Has_index Arg1:T68 Arg2:T69
104,R25,Has_temporal Arg1:T65 Arg2:T66
105,R26,Has_temporal Arg1:T65 Arg2:T68
106,T70,Scope 1075 1114	men and women of childbearing potential
107,A2,Optional T70
108,R27,AND Arg1:T70 Arg2:T65
109,T71,Non-query-able 1067 1254	Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration.
110,T72,Non-query-able 1255 1377	Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause.
111,T73,Person 1255 1260	Women
112,T74,Condition 1264 1286	childbearing potential
113,T75,Condition 1295 1309	pre-menopausal
114,T76,Person 1310 1315	women
115,T77,Person 1320 1325	women
116,T78,Temporal 1326 1376	within the first 2 years of the onset of menopause
117,T79,Reference_point 1354 1376	the onset of menopause
118,R28,Has_index Arg1:T78 Arg2:T79
119,T80,Condition 1387 1409	childbearing potential
120,T81,Person 1378 1383	Women
121,T82,Measurement 1431 1445	pregnancy test
122,T83,Value 1422 1430	negative
123,R29,Has_value Arg1:T82 Arg2:T83
124,T84,Temporal 1446 1471	≤ 72 hours prior to Day 1
125,T85,Reference_point 1466 1471	Day 1
126,R30,Has_index Arg1:T84 Arg2:T85
127,R31,Has_temporal Arg1:T82 Arg2:T84
128,T86,Scope 1378 1409	Women of childbearing potential
129,A3,Optional T86
130,R32,AND Arg1:T86 Arg2:T82
131,T87,Procedure 1504 1517	birth control
132,T88,Condition 1527 1545	surgically sterile
133,T89,Device 1547 1561	barrier device
134,T90,Device 1563 1569	condom
135,T91,Device 1571 1580	diaphragm
136,T92,"Scope 1563 1580	condom, diaphragm"
137,*,OR T91 T90
138,R33,Has_scope Arg1:T89 Arg2:T92
139,T93,Device 1583 1601	contraceptive coil
140,T94,Device 1603 1628	intrauterine device (IUD)
141,T95,Procedure 1634 1644	abstinence
142,*,OR T88 T89 T93 T94 T95
143,T96,Grammar_Error 1630 1633	and
144,T97,"Scope 1527 1644	surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence"
145,R34,Subsumes Arg1:T87 Arg2:T97
146,T98,Observation 1647 1662	Life expectancy
147,T99,Value 1666 1675	>12 weeks
148,R35,Has_value Arg1:T98 Arg2:T99
149,T100,Condition 1692 1722	central nervous system disease
150,T101,Procedure 1779 1791	radiotherapy
151,T102,Procedure 1795 1802	surgery
152,T103,Condition 1815 1837	CNS metastatic disease
153,R36,AND Arg1:T102 Arg2:T103
154,R37,AND Arg1:T101 Arg2:T103
155,*,OR T101 T102
156,T104,Condition 1866 1886	clinical progression
157,T105,Negation 1846 1853	without
158,R38,Has_negation Arg1:T104 Arg2:T105
159,T106,Temporal 1887 1926	for at least 4 weeks prior to screening
160,T107,Reference_point 1917 1926	screening
161,R39,Has_index Arg1:T106 Arg2:T107
162,R40,Has_temporal Arg1:T104 Arg2:T106
163,T108,Condition 1965 1981	brain metastases
164,T109,Qualifier 1955 1964	enlarging
165,T110,Qualifier 1948 1951	new
166,*,OR T109 T110
167,T111,Scope 1948 1964	new or enlarging
168,R41,Has_scope Arg1:T108 Arg2:T111
169,T112,Negation 1933 1935	no
170,R42,Has_negation Arg1:T108 Arg2:T112
171,T113,Drug 1995 2003	steroids
172,T114,Negation 1991 1994	off
173,R43,Has_negation Arg1:T113 Arg2:T114
174,T115,Temporal 2004 2058	for at least 7 days before first dose of pembrolizumab
175,T116,Reference_point 2031 2058	first dose of pembrolizumab
176,T117,Drug 2045 2058	pembrolizumab
177,R44,AND Arg1:T116 Arg2:T117
178,R45,Has_index Arg1:T115 Arg2:T116
179,R46,Has_temporal Arg1:T113 Arg2:T115
180,A4,Optional T100
181,T118,"Scope 1779 2058	radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab"
182,R47,Has_scope Arg1:T100 Arg2:T118
0,T1,Condition 0 12	Partial mole
1,T2,Condition 39 54	molar pregnancy
2,T3,Procedure 25 34	treatment
3,R1,AND Arg1:T3 Arg2:T2
4,T4,Procedure 66 76	evacuation
5,T5,Procedure 80 92	chemotherapy
6,*,OR T4 T5
7,T6,Scope 66 92	evacuation or chemotherapy
8,R2,Subsumes Arg1:T3 Arg2:T6
9,T7,Person 94 99	Women
10,T8,Procedure 110 122	hysterectomy
11,T9,Condition 140 146	H Mole
12,R3,AND Arg1:T8 Arg2:T9
0,T1,Multiplier 6 11	daily
1,T2,Drug 12 22	medication
2,T3,Condition 27 44	chronic condition
3,R1,Has_multiplier Arg1:T2 Arg2:T1
4,R2,AND Arg1:T2 Arg2:T3
5,T4,Qualifier 46 51	acute
6,T5,Condition 52 73	narrow angle glaucoma
7,R3,Has_qualifier Arg1:T5 Arg2:T4
8,T6,Temporal 75 83	previous
9,T7,Condition 84 102	adverse experience
10,T8,Drug 108 119	study drugs
11,R4,AND Arg1:T7 Arg2:T8
12,R5,Has_temporal Arg1:T7 Arg2:T6
13,T9,Condition 133 148	motion sickness
14,T10,Measurement 183 186	BMI
15,T11,Value 187 191	> 30
16,R6,Has_value Arg1:T10 Arg2:T11
17,T12,Person 193 198	women
18,T13,Condition 207 215	pregnant
19,T14,Condition 217 226	lactating
20,T15,Mood 231 251	planning on becoming
21,T16,Condition 252 260	pregnant
22,R7,Has_mood Arg1:T16 Arg2:T15
23,*,OR T13 T14 T16
24,T17,Multiplier 262 269	regular
25,T18,Observation 270 293	use of tobacco products
26,R8,Has_multiplier Arg1:T18 Arg2:T17
27,T19,Temporal 295 302	current
28,T20,Condition 303 325	substance use disorder
29,R9,Has_temporal Arg1:T20 Arg2:T19
30,T21,Qualifier 327 349	clinically significant
31,T22,Procedure 350 353	ECG
32,R10,Has_qualifier Arg1:T22 Arg2:T21
33,T23,Temporal 355 362	current
34,T24,Temporal 363 370	ongoing
35,T25,Condition 371 391	psychiatric disorder
36,R11,Has_temporal Arg1:T25 Arg2:T24
37,R12,Has_temporal Arg1:T25 Arg2:T23
0,T1,Non-query-able 0 47	Provide signed and dated informed consent form.
1,T2,Post-eligibility 49 140	Willing to comply with all study procedures and be available for the duration of the study.
2,T3,Person 142 146	Male
3,T4,Person 150 156	female
4,*,OR T4 T3
5,T5,Person 158 162	aged
6,T6,Value 163 181	= 18 to = 60 years
7,R1,Has_value Arg1:T5 Arg2:T6
8,T7,Temporal 182 201	on day of inclusion
9,R2,Has_temporal Arg1:T6 Arg2:T7
10,T8,Condition 207 226	good general health
11,T9,Observation 236 251	medical history
12,T10,Procedure 256 269	physical exam
13,R3,Has_temporal Arg1:T8 Arg2:T9
14,R4,AND Arg1:T8 Arg2:T10
0,T1,Value 0 18	Less than 18 years
1,T2,Person 22 25	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 28 37	Pregnancy
4,T4,Drug 55 76	vitamin K antagonists
5,T5,Multiplier 40 47	Chronic
6,T6,Drug 80 106	direct thrombin inhibitors
7,T7,Drug 111 137	oral Xa-factor antagonists
8,*,OR T7 T6 T4
9,T8,"Scope 55 137	vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists"
10,R2,Has_multiplier Arg1:T8 Arg2:T5
11,T9,Condition 140 156	Hypersensitivity
12,T10,Drug 160 172;194 199	antiplatelet drugs
13,T11,Drug 180 199	anticoagulant drugs
14,*,OR T11 T10
15,T12,Scope 160 199	antiplatelet and/or anticoagulant drugs
16,R3,Has_scope Arg1:T9 Arg2:T12
17,T13,Condition 221 239	high bleeding risk
18,T14,Condition 209 217	bleeding
19,T15,Qualifier 202 208	Active
20,R4,Has_qualifier Arg1:T14 Arg2:T15
21,T16,Condition 248 261	liver failure
22,T17,Qualifier 241 247	severe
23,R5,Has_qualifier Arg1:T16 Arg2:T17
24,T18,Qualifier 263 269	active
25,T19,Condition 270 282	peptic ulcer
26,R6,Has_qualifier Arg1:T19 Arg2:T18
27,T20,Measurement 284 304	creatinine clearance
28,T21,Value 305 316	< 30 mL/min
29,R7,Has_value Arg1:T20 Arg2:T21
30,T22,Measurement 318 333	platelets count
31,T23,Value 334 347	< 100.000 mm3
32,R8,Has_value Arg1:T22 Arg2:T23
33,*,OR T22 T20 T19 T16 T14 T13
34,T24,Qualifier 351 363	Uncontrolled
35,T25,Condition 364 385	systemic hypertension
36,R9,Has_qualifier Arg1:T25 Arg2:T24
37,T26,Condition 388 405	Cardiogenic shock
38,T27,Procedure 417 453	myocardial revascularization surgery
39,T28,Temporal 408 416	Previous
40,R10,Has_temporal Arg1:T27 Arg2:T28
41,T29,Device 463 479;497 502	internal mammary graft
42,T30,Device 483 502	radial artery graft
43,*,OR T29 T30
44,T31,Multiplier 459 462	= 1
45,T32,Scope 463 502	internal mammary or radial artery graft
46,R11,Has_multiplier Arg1:T32 Arg2:T31
47,R12,Has_scope Arg1:T27 Arg2:T32
48,T33,Qualifier 516 523	chronic
49,T34,Condition 524 551	peripheral arterial disease
50,T35,Procedure 578 595	femoral technique
51,T36,Negation 552 562	preventing
52,R13,Has_negation Arg1:T35 Arg2:T36
53,R14,AND Arg1:T34 Arg2:T35
54,R15,Has_qualifier Arg1:T34 Arg2:T33
55,T37,Qualifier 598 604	Severe
56,T38,Temporal 605 616	concomitant
57,T39,Condition 617 624	disease
58,T40,Observation 630 645	life expectancy
59,T41,Value 646 661	below 12 months
60,R16,Has_value Arg1:T40 Arg2:T41
61,R17,Has_temporal Arg1:T39 Arg2:T38
62,R18,Has_qualifier Arg1:T39 Arg2:T37
63,R19,Has_context Arg1:T39 Arg2:T40
64,T42,Non-query-able 664 747	Participation in drug or devices investigative clinical trials in the last 30 days;
65,T43,"Post-eligibility 749 893	Medical, geographic or social conditions impairing the participation in the study or inability to understand and sign the informed consent term."
0,T1,Procedure 6 49	systemic therapy targeting PD-1: PD-L1 axis
1,T2,Procedure 80 121	conventional multidisciplinary management
2,T3,Qualifier 69 76	curable
3,R1,AND Arg1:T3 Arg2:T2
4,T4,Context_Error 69 76	curable
5,T5,Condition 176 191	medical disease
6,T6,Undefined_semantics 176 191	medical disease
7,T7,Temporal 165 175	concurrent
8,T8,Qualifier 152 164	uncontrolled
9,T9,Qualifier 138 144	severe
10,*,OR T8 T9
11,T10,Scope 138 164	severe and/or uncontrolled
12,R2,Has_temporal Arg1:T5 Arg2:T7
13,R3,Has_scope Arg1:T5 Arg2:T10
14,T11,Subjective_judgement 197 231	in the opinion of the investigator
15,T12,Non-query-able 124 313	Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol.
16,T13,Procedure 342 365	wide field radiotherapy
17,T14,Temporal 366 375	≤ 4 weeks
18,T15,Procedure 379 417	limited field radiation for palliation
19,T16,Temporal 418 446	< 2 weeks prior to screening
20,T17,Reference_point 437 446	screening
21,R4,Has_index Arg1:T16 Arg2:T17
22,R5,Has_temporal Arg1:T15 Arg2:T16
23,R6,Has_temporal Arg1:T13 Arg2:T14
24,*,OR T13 T15 T18
25,T18,Condition 463 472	recovered
26,T19,Qualifier 473 483	adequately
27,T20,Negation 459 462	not
28,R7,Has_negation Arg1:T18 Arg2:T20
29,R8,Has_qualifier Arg1:T18 Arg2:T19
30,T21,Condition 489 517	side effects of such therapy
31,T22,Undefined_semantics 489 517	side effects of such therapy
32,T23,Procedure 505 517	such therapy
33,R9,AND Arg1:T21 Arg2:T23
34,R10,AND Arg1:T18 Arg2:T21
35,T24,Condition 545 555	infections
36,T25,Procedure 566 573	therapy
37,T26,Qualifier 556 573	requiring therapy
38,R11,AND Arg1:T26 Arg2:T25
39,R12,Has_qualifier Arg1:T24 Arg2:T26
40,T27,Measurement 619 653	Human Immunodeficiency Virus (HIV)
41,T28,Value 606 614	positive
42,T29,Qualifier 655 673	HIV 1/2 antibodies
43,R13,Has_qualifier Arg1:T27 Arg2:T29
44,R14,Has_value Arg1:T27 Arg2:T28
45,T30,Condition 676 694	active Hepatitis B
46,T31,Measurement 696 701	HBsAg
47,T32,Value 702 710	reactive
48,R15,Has_value Arg1:T31 Arg2:T32
49,R16,Subsumes Arg1:T30 Arg2:T31
50,T33,Condition 716 727	Hepatitis C
51,T34,Measurement 729 750	HCV RNA [qualitative]
52,T35,Value 754 762	detected
53,R17,Has_value Arg1:T34 Arg2:T35
54,R18,AND Arg1:T33 Arg2:T34
55,*,OR T30 T33 T27
56,T36,Measurement 788 808	Hepatitis C antibody
57,T37,Value 779 787	negative
58,R19,Has_value Arg1:T36 Arg2:T37
59,T38,Non-query-able 765 841	patients with negative Hepatitis C antibody testing may not need RNA testing
60,T39,Not_a_criteria 765 841	patients with negative Hepatitis C antibody testing may not need RNA testing
61,T40,Condition 871 882;902 910	psychiatric disorder
62,T41,Condition 886 910	substance abuse disorder
63,*,OR T40 T41
64,T42,Subjective_judgement 844 984	Patients that have a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.
65,T43,Procedure 1008 1038	systemic anti-cancer treatment
66,T44,Temporal 1039 1076	prior to the first dose of study drug
67,T45,Reference_point 1048 1076	the first dose of study drug
68,R20,Has_index Arg1:T44 Arg2:T45
69,R21,Has_temporal Arg1:T43 Arg2:T44
70,T46,Parsing_Error 986 1110	Patients who received systemic anti-cancer treatment prior to the first dose of study drug within the following time frames:
71,T47,Condition 1133 1151	autoimmune disease
72,T48,Temporal 1126 1132	active
73,R22,Has_temporal Arg1:T47 Arg2:T48
74,T49,Condition 1179 1197	autoimmune disease
75,T50,Observation 1168 1175	history
76,R23,Has_temporal Arg1:T49 Arg2:T50
77,T51,Condition 1201 1241	syndrome that requires systemic steroids
78,T52,Drug 1224 1241	systemic steroids
79,R24,AND Arg1:T51 Arg2:T52
80,T53,Undefined_semantics 1201 1241	syndrome that requires systemic steroids
81,T54,Drug 1245 1269	immunosuppressive agents
82,T55,Condition 1201 1223;1245 1269	syndrome that requires immunosuppressive agents
83,R25,AND Arg1:T55 Arg2:T54
84,*,OR T55 T51 T49 T47
85,T56,Condition 1306 1322	childhood asthma
86,T57,Qualifier 1297 1305	resolved
87,R26,Has_qualifier Arg1:T56 Arg2:T57
88,T58,Condition 1285 1293	vitiligo
89,*,OR T56 T58 T59
90,T59,Condition 1323 1328	atopy
91,T61,Not_a_criteria 1271 1361	Patients with vitiligo or resolved childhood asthma/atopy would be exception to this rule.
92,T62,Not_a_criteria 1362 1466	Patients that require inhaled steroids or local steroid injections would not be excluded from the study.
93,T63,Condition 1481 1495	hypothyroidism
94,T64,Condition 1505 1523	autoimmune disease
95,T65,Negation 1496 1499	not
96,R27,Has_negation Arg1:T64 Arg2:T65
97,R28,AND Arg1:T63 Arg2:T64
98,T66,Qualifier 1532 1561	stable on hormone replacement
99,T67,Procedure 1542 1561	hormone replacement
100,R29,AND Arg1:T66 Arg2:T67
101,R30,Has_qualifier Arg1:T63 Arg2:T66
102,T68,Grammar_Error 1562 1597	will not be excluded from the study
103,T69,Not_a_criteria 1467 1598	Patients with hypothyroidism not from autoimmune disease that is stable on hormone replacement will not be excluded from the study.
104,T70,Person 1600 1605	Women
105,T71,Condition 1614 1622	pregnant
106,T72,Condition 1626 1633	nursing
107,T73,Observation 1634 1647	breastfeeding
108,*,OR T73 T72 T71
109,T74,Condition 1656 1689	hypersensitivity to pembrolizumab
110,T75,Drug 1676 1689	pembrolizumab
111,R31,AND Arg1:T74 Arg2:T75
112,T76,Condition 1656 1675;1701 1704	hypersensitivity to mAb
113,T77,Drug 1701 1704	mAb
114,R32,AND Arg1:T76 Arg2:T77
115,*,OR T76 T74
116,T78,Drug 1767 1775	steroids
117,T79,Condition 1787 1798	pneumonitis
118,T80,Temporal 1779 1786	current
119,R33,Has_temporal Arg1:T79 Arg2:T80
120,T81,Condition 1741 1752	pneumonitis
121,T82,Observation 1713 1720	history
122,R34,Has_temporal Arg1:T81 Arg2:T82
123,T83,Qualifier 1758 1775	required steroids
124,R35,AND Arg1:T83 Arg2:T78
125,R36,Has_qualifier Arg1:T81 Arg2:T83
126,*,OR T81 T79
127,T84,Condition 1825 1855	central nervous system disease
128,T85,Undefined_semantics 1825 1855	central nervous system disease
129,T86,Qualifier 1815 1824	untreated
130,R37,Has_qualifier Arg1:T84 Arg2:T86
131,T87,Condition 1890 1901	CNS lesions
132,T88,Procedure 1921 1928	surgery
133,T89,Procedure 1932 1957	stereotactic radiosurgery
134,T90,Temporal 1969 1980	for 4 weeks
135,T91,Qualifier 1962 1968	stable
136,R38,Has_temporal Arg1:T91 Arg2:T90
137,*,OR T89 T88
138,T92,Scope 1921 1957	surgery or stereotactic radiosurgery
139,R39,Has_scope Arg1:T87 Arg2:T92
140,R40,Has_qualifier Arg1:T87 Arg2:T91
141,T93,Qualifier 1871 1881	controlled
142,T94,Qualifier 1882 1889	treated
143,R41,Has_qualifier Arg1:T87 Arg2:T94
144,R42,Has_qualifier Arg1:T87 Arg2:T93
145,T95,Condition 1996 2050	Inability to comply with protocol required procedures.
146,T96,Undefined_semantics 1996 2050	Inability to comply with protocol required procedures.
147,T97,Non-query-able 1996 2050	Inability to comply with protocol required procedures.
148,T98,Post-eligibility 1996 2050	Inability to comply with protocol required procedures.
149,T99,Condition 2066 2084	medical conditions
150,T100,Procedure 2106 2137	systemic corticosteroid therapy
151,T101,Temporal 2098 2105	chronic
152,R43,Has_temporal Arg1:T100 Arg2:T101
153,T102,Drug 2167 2195	immunosuppressive medication
154,T103,Undefined_semantics 2167 2195	immunosuppressive medication
155,T104,Qualifier 2090 2137	require chronic systemic corticosteroid therapy
156,T105,Qualifier 2141 2148;2167 2195	require immunosuppressive medication
157,R44,AND Arg1:T105 Arg2:T102
158,R45,AND Arg1:T104 Arg2:T100
159,*,OR T104 T105
160,T106,Scope 2090 2195	require chronic systemic corticosteroid therapy or require any other form of immunosuppressive medication
161,R46,Has_scope Arg1:T99 Arg2:T106
162,T107,Multiplier 2221 2250	physiologic replacement doses
163,T108,Drug 2254 2268	hydrocortisone
164,R47,Has_multiplier Arg1:T108 Arg2:T107
165,T109,Drug 2345 2359	hydrocortisone
166,T110,Multiplier 2333 2344	up to 20 mg
167,R48,Has_multiplier Arg1:T109 Arg2:T110
168,T111,Drug 2372 2382	prednisone
169,T112,Multiplier 2364 2368	5 mg
170,R49,Has_multiplier Arg1:T111 Arg2:T112
171,T113,Drug 2409 2423	hydrocortisone
172,T114,Multiplier 2403 2408	10 mg
173,R50,Has_multiplier Arg1:T113 Arg2:T114
174,T115,Drug 2435 2445	prednisone
175,T116,Multiplier 2428 2434	2.5 mg
176,R51,Has_multiplier Arg1:T115 Arg2:T116
177,*,OR T115 T113
178,*,OR T111 T109
179,T117,Multiplier 2384 2398	in the morning
180,T118,Multiplier 2447 2461	in the evening
181,R52,Has_multiplier Arg1:T113 Arg2:T118
182,R53,Has_multiplier Arg1:T109 Arg2:T117
183,T119,Scope 2333 2461	up to 20 mg hydrocortisone (or 5 mg of prednisone) in the morning and 10 mg hydrocortisone (or 2.5 mg prednisone) in the evening
184,T120,Scope 2221 2268	physiologic replacement doses of hydrocortisone
185,R54,Subsumes Arg1:T120 Arg2:T119
186,T121,Condition 2499 2516	bowel obstruction
187,T122,Condition 2520 2537	bowel perforation
188,T123,Condition 2482 2516	risk factors for bowel obstruction
189,T124,Condition 2482 2498;2520 2537	risk factors for bowel perforation
190,R55,AND Arg1:T123 Arg2:T121
191,R56,AND Arg1:T124 Arg2:T122
192,*,OR T123 T124
193,T125,Observation 2577 2584	history
194,T126,Condition 2588 2608	acute diverticulitis
195,T127,Condition 2610 2633	intra-abdominal abscess
196,T128,Condition 2635 2659	abdominal carcinomatosis
197,*,OR T126 T127 T128
198,T129,"Scope 2588 2659	acute diverticulitis, intra-abdominal abscess, abdominal carcinomatosis"
199,R57,Has_temporal Arg1:T129 Arg2:T125
200,T130,Scope 2482 2537	risk factors for bowel obstruction or bowel perforation
201,R58,Subsumes Arg1:T130 Arg2:T129
202,T131,Drug 2692 2704	live vaccine
203,T132,Temporal 2705 2762	within 30 days prior to the first dose of trial treatment
204,T133,Reference_point 2729 2762	the first dose of trial treatment
205,R59,Has_index Arg1:T132 Arg2:T133
206,R60,Has_temporal Arg1:T131 Arg2:T132
0,T1,Procedure 0 10	Ultrasound
1,T2,Condition 21 34	complete mole
2,R1,AND Arg1:T1 Arg2:T2
0,T1,Observation 0 22	valid driver's license
1,T2,Observation 24 40	english-speaking
2,T3,Observation 45 53	literate
0,T1,Qualifier 0 20	ST-segment elevation
1,T2,Condition 21 48	acute myocardial infarction
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Temporal 58 100	during the first 12 hours of sympton onset
4,R2,Has_temporal Arg1:T2 Arg2:T3
5,T4,Condition 132 166	percutaneous coronary intervention
6,T5,Mood 103 123	Intention to perform
7,R3,Has_mood Arg1:T4 Arg2:T5
8,T6,Qualifier 124 131	primary
9,R4,Has_qualifier Arg1:T4 Arg2:T6
10,T7,Non-query-able 169 193	Signed informed consent;
11,T8,Qualifier 216 227	transradial
12,T9,Qualifier 232 244	transfemoral
13,T10,Qualifier 245 252	primary
14,T11,Procedure 253 287	percutaneous coronary intervention
15,R5,Has_qualifier Arg1:T11 Arg2:T10
16,*,OR T9 T8
17,T12,Scope 216 244	transradial and transfemoral
18,R6,Has_scope Arg1:T11 Arg2:T12
19,T13,Mood 203 215	eligible for
20,R7,Has_mood Arg1:T11 Arg2:T13
21,T14,"Non-representable 289 508	being pre-requisites: (a) familiarity of the operator with the radial and femoral techniques using vascular closure devices, (b) agreement of the operator to use the access route determined by the randomization process."
0,T1,"Pregnancy_considerations 0 354	Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination."
1,T2,"Non-query-able 356 576	Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure."
2,T3,Drug 612 626	rabies vaccine
3,T4,Drug 659 681	rabies immune globulin
4,T5,Observation 578 594	Previous history
5,T6,Observation 629 645	Previous history
6,R1,Has_temporal Arg1:T3 Arg2:T5
7,R2,Has_temporal Arg1:T4 Arg2:T6
8,T7,Condition 688 714	major psychiatric disorder
9,T8,Qualifier 724 730	severe
10,T9,Condition 731 741	depression
11,R3,Has_qualifier Arg1:T9 Arg2:T8
12,T10,Qualifier 743 749	severe
13,T11,Condition 750 766	anxiety disorder
14,R4,Has_qualifier Arg1:T11 Arg2:T10
15,T12,Condition 768 777	psychosis
16,T13,Condition 779 792	schizophrenia
17,T14,Condition 800 827	major psychiatric disorders
18,T15,Qualifier 794 799	other
19,R5,Has_qualifier Arg1:T14 Arg2:T15
20,T16,Condition 832 840	seizures
21,T17,Qualifier 853 857	mild
22,T18,Condition 858 868	depression
23,T19,Condition 872 888	anxiety disorder
24,T20,Negation 918 921	not
25,T21,Qualifier 898 913	well controlled
26,*,OR T18 T19
27,T22,Scope 858 888	depression or anxiety disorder
28,R6,Has_qualifier Arg1:T22 Arg2:T17
29,R7,Has_qualifier Arg1:T22 Arg2:T21
30,R8,Has_negation Arg1:T22 Arg2:T20
31,*,OR T16 T14 T13 T12 T11 T9
32,T23,"Scope 724 840	severe depression, severe anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures"
33,R9,Subsumes Arg1:T7 Arg2:T23
34,T24,Drug 954 976	immunosuppressive drug
35,T25,Temporal 977 1001	at the time of the study
36,T26,Temporal 1005 1023	30 days previously
37,*,OR T25 T26
38,T27,Scope 977 1023	at the time of the study or 30 days previously
39,R10,Has_scope Arg1:T24 Arg2:T27
40,T28,Drug 1025 1041	Topical steroids
41,T29,Negation 1047 1050	not
42,R11,Has_negation Arg1:T28 Arg2:T29
43,R12,AND Arg1:T24 Arg2:T28
44,T30,Condition 1156 1182	immunosuppressive disorder
45,T31,Condition 1192 1205	HIV infection
46,T32,Condition 1207 1239	common variable immunodeficiency
47,T33,Temporal 1241 1247	active
48,T34,Condition 1248 1255	cancers
49,T35,Procedure 1259 1271	chemotherapy
50,*,OR T35 T34
51,T36,Scope 1248 1271	cancers or chemotherapy
52,R13,Has_temporal Arg1:T36 Arg2:T33
53,*,OR T32 T36 T31
54,T37,"Scope 1192 1271	HIV infection, common variable immunodeficiency, active cancers or chemotherapy"
55,R14,Subsumes Arg1:T30 Arg2:T37
56,T38,Condition 1285 1304	renal insufficiency
57,T39,Observation 1274 1281	History
58,T40,Procedure 1318 1326	dialysis
59,T41,Mood 1308 1317	requiring
60,R15,Has_mood Arg1:T40 Arg2:T41
61,*,OR T38 T40
62,T42,Scope 1285 1326	renal insufficiency or requiring dialysis
63,R16,Has_temporal Arg1:T42 Arg2:T39
64,T43,"Post-eligibility 1329 1523	Have any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol."
65,T44,"Post-eligibility 1525 1843	Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator."
66,T45,Condition 1854 1870	adverse reaction
67,T46,Temporal 1845 1853	Previous
68,T47,Drug 1885 1903	antimalarial drugs
69,T48,Qualifier 1904 1922	used in this study
70,R17,Has_qualifier Arg1:T47 Arg2:T48
71,R18,Has_temporal Arg1:T45 Arg2:T46
72,R19,AND Arg1:T45 Arg2:T47
0,T1,Condition 0 20	Autoimmune hepatitis
1,T2,Condition 22 52	Primary sclerosing cholangitis
0,T1,Person 0 5	Adult
1,T2,Person 7 10	age
2,T3,Value 11 29	18 years and older
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 46 69	end-stage renal disease
5,T5,Condition 70 74	ESRD
6,T6,Condition 76 98	chronic kidney disease
7,T7,Condition 99 102	CKD
8,T8,Qualifier 103 110	stage 5
9,R2,Subsumes Arg1:T4 Arg2:T5
10,R3,Subsumes Arg1:T6 Arg2:T7
11,R4,Has_qualifier Arg1:T6 Arg2:T8
12,R5,Subsumes Arg1:T4 Arg2:T6
0,T1,Drug 11 24	ascorbic acid
1,T2,Condition 0 7	Allergy
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Condition 26 32	Asthma
4,T4,Condition 34 38	COPD
5,T5,Condition 40 47	Allergy
6,T6,Drug 51 58	opioids
7,R2,AND Arg1:T5 Arg2:T6
8,T7,Condition 80 99	chemical dependence
9,T8,Observation 69 76	history
10,T9,Temporal 60 68	Previous
11,R3,Has_temporal Arg1:T7 Arg2:T8
12,R4,Has_temporal Arg1:T7 Arg2:T9
13,T10,Procedure 107 122	cardiac surgery
14,T11,Temporal 101 106	Prior
15,R5,Has_temporal Arg1:T10 Arg2:T11
16,T12,Condition 130 143	hyperoxaluria
17,T13,Condition 156 169	renal calculi
18,T14,Observation 145 152	History
19,R6,Has_temporal Arg1:T13 Arg2:T14
20,T15,Condition 182 190	allergic
21,T16,Condition 194 210	hypersensitivity
22,T17,Drug 223 236	ascorbic acid
23,*,OR T15 T16
24,T18,Scope 182 210	allergic or hypersensitivity
25,R7,AND Arg1:T18 Arg2:T17
26,T19,Multiplier 264 275	1 g or more
27,T20,Drug 279 292	ascorbic acid
28,R8,Has_multiplier Arg1:T20 Arg2:T19
0,T1,Person 3 8	Women
1,T2,Value 9 23	18 to 40 years
2,T3,Person 27 30	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Observation 45 78	can give written informed consent
5,T5,Post-eligibility 45 78	can give written informed consent
6,T6,Post-eligibility 83 168	Available for all visits and consent to follow all procedures scheduled for the study
7,T7,Post-eligibility 173 267	Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method
8,T8,Drug 203 206	gel
9,T9,Multiplier 182 187	daily
10,R2,Has_multiplier Arg1:T8 Arg2:T9
11,T10,Procedure 211 221	monitoring
12,R3,Has_multiplier Arg1:T10 Arg2:T9
13,T11,Condition 272 279	Healthy
14,T12,Condition 298 313	sexually active
15,T13,Observation 284 297	self-reported
16,T14,Qualifier 284 297	self-reported
17,R4,multi Arg1:T14 Arg2:T13
18,R5,Has_qualifier Arg1:T12 Arg2:T14
19,T15,Condition 318 330	HIV-negative
20,T16,Measurement 318 321	HIV
21,T17,Value 322 330	negative
22,R6,Has_value Arg1:T16 Arg2:T17
23,R7,multi Arg1:T15 Arg2:T16
24,T18,Measurement 350 364	HIV rapid test
25,T19,Temporal 365 386	at time of enrollment
26,T20,Reference_point 368 386	time of enrollment
27,R8,Has_temporal Arg1:T18 Arg2:T19
28,R9,AND Arg1:T15 Arg2:T18
29,T21,"Pregnancy_considerations 391 568	On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment"
30,T22,Drug 602 619	exogenous hormone
31,T23,Negation 580 587	absence
32,R10,Has_negation Arg1:T22 Arg2:T23
33,T24,Scope 580 619	absence of the use of exogenous hormone
34,A1,Optional T24
35,T25,Value 645 652	regular
36,T26,Measurement 653 668	menstrual cycle
37,T27,Condition 645 668	regular menstrual cycle
38,R11,multi Arg1:T27 Arg2:T26
39,R12,Has_value Arg1:T26 Arg2:T25
40,T28,Value 689 707	minimum of 21 days
41,T29,Value 714 732	maximum of 36 days
42,T30,Scope 689 732	minimum of 21 days and a maximum of 36 days
43,R13,Subsumes Arg1:T25 Arg2:T30
44,R14,AND Arg1:T24 Arg2:T27
45,T31,Procedure 764 784	speculum examination
46,T32,Procedure 757 763;773 784	pelvic examination
47,T33,Procedure 789 799	colposcopy
48,T34,Temporal 800 825	at the time of enrollment
49,T35,Scope 757 799	pelvic/speculum examination and colposcopy
50,R15,Has_temporal Arg1:T35 Arg2:T34
51,*,OR T33 T32 T31
52,T36,Observation 842 848	vagina
53,T37,Observation 831 837	cervix
54,T38,Value 856 862	normal
55,T39,Qualifier 856 862	normal
56,T40,Subjective_judgement 863 896	as determined by the investigator
57,R16,Has_qualifier Arg1:T36 Arg2:T39
58,R17,Has_qualifier Arg1:T37 Arg2:T39
59,T41,Scope 831 862	cervix and vagina appear normal
60,R18,Has_scope Arg1:T35 Arg2:T41
61,T42,Condition 918 936	genital infections
62,T43,Mood 901 913	Asymptomatic
63,R19,Has_mood Arg1:T42 Arg2:T43
64,T44,Temporal 937 962	at the time of enrollment
65,R20,Has_temporal Arg1:T42 Arg2:T44
66,T45,Mood 968 975	Willing
67,T46,Drug 999 1015	vaginal products
68,T47,Drug 1019 1026;999 1006	objects vaginal
69,T48,Temporal 1027 1061	within 14 days prior to enrollment
70,T49,Temporal 1066 1095	for the duration of the study
71,T50,Reference_point 1051 1061	enrollment
72,T51,Reference_point 1086 1095	the study
73,R21,multi Arg1:T49 Arg2:T51
74,R22,multi Arg1:T48 Arg2:T50
75,T52,Scope 999 1026	vaginal products or objects
76,*,OR T47 T46
77,R23,Has_mood Arg1:T52 Arg2:T45
78,R24,Has_temporal Arg1:T52 Arg2:T48
79,R25,Has_temporal Arg1:T52 Arg2:T49
80,T53,Observation 1137 1161	adherence questionnaires
81,T54,Observation 1119 1132;1147 1161	acceptability questionnaires
82,T55,Temporal 1162 1182	throughout the study
83,T56,Negation 979 986	refrain
84,R26,Has_negation Arg1:T52 Arg2:T56
85,T57,Mood 1101 1108	Willing
86,T58,Scope 1119 1161	acceptability and adherence questionnaires
87,R27,Has_mood Arg1:T58 Arg2:T57
88,R28,Has_temporal Arg1:T58 Arg2:T55
89,T59,Post-eligibility 1188 1284	Willing to refrain from participation in any other research study for the duration of this study
90,T60,Post-eligibility 1101 1182	Willing to answer acceptability and adherence questionnaires throughout the study
91,T61,Post-eligibility 1290 1413	Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures
92,T62,Non-query-able 1290 1413	Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures
93,T63,Non-query-able 1188 1284	Willing to refrain from participation in any other research study for the duration of this study
94,T64,Non-query-able 1101 1182	Willing to answer acceptability and adherence questionnaires throughout the study
0,T1,Device 0 24	Elective Cardiac surgery
1,T2,Measurement 26 79	American Society of Anesthesiologists physical status
2,T3,Value 80 91	class I-III
3,R1,Has_value Arg1:T2 Arg2:T3
0,T1,Condition 13 21	pregnant
1,T2,Condition 30 47	pregnancy outcome
2,T3,Temporal 48 82	within 3 months prior to enrolment
3,T4,Reference_point 73 82	enrolment
4,R1,multi Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T6,Qualifier 25 29	last
7,T7,Temporal 25 29	last
8,R3,Has_qualifier Arg1:T2 Arg2:T6
9,R4,multi Arg1:T6 Arg2:T7
10,T8,Condition 97 111	breast-feeding
11,T9,Temporal 87 96	Currently
12,T10,Temporal 3 12	Currently
13,R2,Has_temporal Arg1:T2 Arg2:T3
14,R5,Has_temporal Arg1:T1 Arg2:T10
15,R6,Has_temporal Arg1:T8 Arg2:T9
16,T5,Context_Error 116 190	Participated in any other research study within 60 days prior to screening
17,T11,Context_Error 195 243	Previously participated in any HIV vaccine study
18,T12,Condition 258 279	urogenital infections
19,T13,Qualifier 248 257	Untreated
20,R7,Has_qualifier Arg1:T12 Arg2:T13
21,T14,Condition 288 299	symptomatic
22,T15,Condition 303 315	asymptomatic
23,*,OR T15 T14
24,T16,Scope 288 315	symptomatic or asymptomatic
25,R8,Has_scope Arg1:T12 Arg2:T16
26,T17,Temporal 317 351	within 2 weeks prior to enrollment
27,T18,Reference_point 341 351	enrollment
28,R9,Has_index Arg1:T17 Arg2:T18
29,R10,Has_temporal Arg1:T12 Arg2:T17
30,T19,Condition 368 406	abnormal physical finding on the vulva
31,T20,Condition 368 400;408 421	abnormal physical finding on the vaginal walls
32,T21,Condition 368 400;425 431	abnormal physical finding on the cervix
33,*,OR T21 T20 T19
34,T22,Procedure 446 466	speculum examination
35,T23,Procedure 439 445;455 466	pelvic examination
36,*,OR T23 T22 T24
37,T24,Procedure 474 484	colposcopy
38,T25,Scope 439 484	pelvic/speculum examination and/or colposcopy
39,T26,"Scope 368 431	abnormal physical finding on the vulva, vaginal walls or cervix"
40,R11,causal Arg1:T26 Arg2:T25
41,T27,Condition 512 522;534 542	urogenital prolapse
42,T28,Condition 526 542	uterine prolapse
43,T29,Condition 556 572	vaginal bleeding
44,T30,Qualifier 544 555	undiagnosed
45,R12,Has_qualifier Arg1:T29 Arg2:T30
46,T31,Condition 574 594	urethral obstruction
47,*,OR T27 T28
48,T32,Qualifier 500 511	significant
49,T33,Observation 489 496	History
50,T34,Scope 512 542	urogenital or uterine prolapse
51,T35,Subjective_judgement 500 511	significant
52,R13,Has_qualifier Arg1:T34 Arg2:T32
53,R14,Has_temporal Arg1:T34 Arg2:T33
54,*,OR T34 T29 T31
55,T36,Measurement 599 608	Pap smear
56,T37,Temporal 616 628	at screening
57,T38,Value 634 654	requires cryotherapy
58,T39,Value 634 642;656 662	requires biopsy
59,T40,Value 634 642;664 673	requires treatment
60,T41,Procedure 643 654	cryotherapy
61,T42,Procedure 656 662	biopsy
62,T43,Procedure 664 673	treatment
63,T44,Value 634 642;705 723	requires further evaluation
64,T45,Procedure 705 723	further evaluation
65,*,OR T38 T39 T40 T44
66,T46,"Scope 634 673;702 723	requires cryotherapy, biopsy, treatment or further evaluation"
67,R15,Has_scope Arg1:T36 Arg2:T46
68,R16,Has_temporal Arg1:T36 Arg2:T37
69,R17,multi Arg1:T38 Arg2:T41
70,R18,multi Arg1:T39 Arg2:T42
71,R19,multi Arg1:T40 Arg2:T43
72,R20,multi Arg1:T44 Arg2:T45
73,T47,Condition 794 816	laboratory abnormality
74,T48,Condition 783 793;805 816	urinalysis abnormality
75,T49,Condition 770 779;805 816	chemistry abnormality
76,T50,Condition 757 768;805 816	haematology abnormality
77,T51,"Value 732 747	Grade 2, 3 or 4"
78,T52,Temporal 748 756	baseline
79,T53,Measurement 834 877	DAIDS Table for Grading Adverse Experiences
80,*,OR T48 T49 T50
81,R21,Has_temporal Arg1:T53 Arg2:T52
82,R22,Has_value Arg1:T53 Arg2:T51
83,T54,Procedure 757 768	haematology
84,T55,Procedure 770 779	chemistry
85,T56,Procedure 783 793	urinalysis
86,T57,Procedure 794 804	laboratory
87,R23,multi Arg1:T50 Arg2:T54
88,R24,multi Arg1:T49 Arg2:T55
89,R25,multi Arg1:T48 Arg2:T56
90,R26,multi Arg1:T47 Arg2:T57
91,T58,Condition 917 936	bleeding per vagina
92,T59,Qualifier 896 907	undiagnosed
93,T60,Qualifier 883 894	Unexplained
94,T61,Qualifier 908 916	abnormal
95,T62,Condition 938 957	bleeding per vagina
96,T63,Temporal 958 964;978 997	during vaginal intercourse
97,T64,Temporal 968 997	following vaginal intercourse
98,*,OR T64 T63
99,T65,Procedure 1002 1022	gynaecologic surgery
100,T66,Temporal 1023 1057	within 90 days prior to enrollment
101,T67,Reference_point 1047 1057	enrollment
102,R27,Has_index Arg1:T66 Arg2:T67
103,R28,Has_temporal Arg1:T65 Arg2:T66
104,T68,Scope 958 997	during or following vaginal intercourse
105,*,OR T58 T62 T65
106,R29,Has_scope Arg1:T62 Arg2:T68
107,T69,"Scope 917 957	bleeding per vagina, bleeding per vagina"
108,T70,"Scope 883 916	Unexplained, undiagnosed abnormal"
109,R30,Has_scope Arg1:T69 Arg2:T70
110,T71,Condition 1078 1089	anaphylaxis
111,T72,Observation 1067 1074	history
112,T73,Condition 1100 1107	allergy
113,T74,Qualifier 1093 1099	severe
114,R31,Has_qualifier Arg1:T73 Arg2:T74
115,T75,Condition 1121 1131	angioedema
116,T76,Observation 1138 1145	history
117,T77,Condition 1149 1160;1169 1177	sensitivity to latex
118,T78,Condition 1161 1177	allergy to latex
119,*,OR T78 T77
120,T79,Scope 1149 1177	sensitivity/allergy to latex
121,R32,Has_temporal Arg1:T79 Arg2:T76
122,*,OR T71 T73
123,T80,Scope 1078 1107	anaphylaxis or severe allergy
124,R33,causal Arg1:T75 Arg2:T80
125,R34,Has_temporal Arg1:T80 Arg2:T72
126,T81,Condition 1225 1232	disease
127,T82,Qualifier 1213 1224	progressive
128,T83,Multiplier 1202 1209	chronic
129,T84,Temporal 1195 1200	acute
130,T85,Qualifier 1187 1194	serious
131,*,OR T82 T83 T84 T85
132,T86,"Scope 1187 1224	serious acute, chronic or progressive"
133,R35,Has_scope Arg1:T81 Arg2:T86
134,T87,"Post-eligibility 1238 1387	Any condition(s) that, in the opinion of the investigator, might interfere with adherence to study requirements or evaluation of the study objectives"
135,T88,"Subjective_judgement 1183 1232	Any serious acute, chronic or progressive disease"
136,T89,"Post-eligibility 1183 1232	Any serious acute, chronic or progressive disease"
0,T1,Condition 24 51	primary biliary cholangitis
1,T2,Drug 66 86	Ursodeoxycholic Acid
2,T3,Visit 90 109	West China Hospital
3,T4,Temporal 110 130	for at least 6 month
4,T5,Condition 135 154	suboptimal response
5,T6,Drug 158 178	Ursodeoxycholic Acid
6,R1,AND Arg1:T5 Arg2:T6
7,R2,Has_temporal Arg1:T2 Arg2:T4
8,R3,AND Arg1:T2 Arg2:T3
0,T1,Condition 0 17	Diabetes Mellitus
1,T2,Condition 19 42	Acute coronary syndrome
2,T3,Temporal 43 63	in the past 6 months
3,T4,Condition 65 83	Cardiac arrhythmia
4,T5,Condition 94 116	3rd degree heart block
5,T6,Condition 86 89;98 116	2nd degree heart block
6,T7,Condition 120 151	premature ventricular complexes
7,T8,Qualifier 155 169	Lown classes 4
8,T9,Qualifier 155 167;173 174	Lown classes 5
9,*,OR T9 T8
10,T10,Scope 155 174	Lown classes 4 or 5
11,R1,Has_scope Arg1:T7 Arg2:T10
12,*,OR T5 T6
13,T11,Scope 85 175	(2nd and 3rd degree heart block or premature ventricular complexes in Lown classes 4 or 5)
14,R2,Subsumes Arg1:T4 Arg2:T11
15,T12,Condition 200 211;223 234	obstructive sleep apnea
16,T13,Condition 215 234	central sleep apnea
17,T14,Measurement 260 284	Epworth sleepiness scale
18,T15,Value 243 256	score of > 10
19,R3,Has_value Arg1:T14 Arg2:T15
20,*,OR T13 T12
21,T17,Scope 200 234	obstructive or central sleep apnea
22,R5,AND Arg1:T17 Arg2:T14
23,T16,Drug 303 312	Clonidine
24,T18,Measurement 314 329	Body mass index
25,T19,Measurement 331 334	BMI
26,R4,Subsumes Arg1:T18 Arg2:T19
27,T20,Value 336 340	> 34
28,R6,Has_value Arg1:T18 Arg2:T20
29,T21,Informed_consent 342 373	Patients unable to give consent
30,T22,Pregnancy_considerations 375 389	Pregnant women
31,T23,Condition 405 415	leg injury
32,T24,Condition 426 438	nerve damage
33,R7,AND Arg1:T23 Arg2:T24
34,T25,Drug 456 469	anticoagulant
35,T26,Condition 508 525	bleeding disorder
36,T27,Condition 529 543	liver disorder
37,T28,Qualifier 496 507	significant
38,R8,Has_qualifier Arg1:T26 Arg2:T28
39,*,OR T26 T27
40,T29,Measurement 545 555	Hemoglobin
41,T30,Value 556 566	<1.05 g/dl
42,T31,Temporal 567 603	at the time of initiation of therapy
43,T32,Reference_point 582 603	initiation of therapy
44,R9,Has_index Arg1:T31 Arg2:T32
45,R10,Has_value Arg1:T29 Arg2:T30
46,R11,Has_temporal Arg1:T29 Arg2:T31
47,T33,Procedure 643 654	nephrectomy
48,T34,Qualifier 633 642	bilateral
49,T35,Qualifier 619 629	unilateral
50,*,OR T35 T34
51,T36,Scope 619 642	unilateral or bilateral
52,R12,Has_scope Arg1:T33 Arg2:T36
53,T37,Condition 664 681	kidney transplant
54,T38,Qualifier 656 663	Planned
55,T39,Temporal 682 702	in the next 4 months
56,R13,Has_qualifier Arg1:T37 Arg2:T38
57,R14,Has_temporal Arg1:T37 Arg2:T39
58,T40,Observation 704 719	Life expectancy
59,T41,Value 720 734	under 6 months
60,R15,Has_value Arg1:T40 Arg2:T41
61,T42,Condition 736 744	Oliguria
62,T43,Measurement 746 758	urine output
63,T44,Value 759 783	less than 400 ml per day
64,R16,Has_value Arg1:T43 Arg2:T44
65,R17,AND Arg1:T42 Arg2:T43
0,T1,Person 0 3	Age
1,T2,Value 4 34	equal or greater than 70 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Observation 36 53	Onset of symptoms
4,T4,Temporal 54 86	< 3 hours prior to randomisation
5,T5,Reference_point 73 86	randomisation
6,R2,Has_index Arg1:T4 Arg2:T5
7,R3,Has_temporal Arg1:T3 Arg2:T4
8,T6,"Non-query-able 228 345	= 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined total of = 4 mm ST-elevation"
9,T7,Non-query-able 88 223	= 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for a minimum combined total of = 4 mm ST-elevation
10,T8,Informed_consent 347 372	Informed consent received
0,T1,Informed_consent 0 35	Has given written informed consent.
1,T2,Person 37 41	Male
2,T3,Person 45 51	female
3,*,OR T2 T3
4,T4,Visit 52 63	outpatients
5,T5,Value 69 113	at least 18 years and not more than 45 years
6,T6,Person 64 68	aged
7,R1,Has_value Arg1:T6 Arg2:T5
8,T7,Condition 135 160	major depressive disorder
9,T8,"Qualifier 164 251	Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria"
10,R2,Has_qualifier Arg1:T7 Arg2:T8
11,T9,Measurement 262 269	HAMD-17
12,T10,Temporal 254 261	Current
13,T11,Value 270 280	score = 20
14,R3,Has_value Arg1:T9 Arg2:T11
15,R4,Has_temporal Arg1:T9 Arg2:T10
16,T12,Condition 305 318	index episode
17,T13,Temporal 322 357	greater than or equal to four weeks
18,R5,Has_temporal Arg1:T12 Arg2:T13
0,T1,Condition 3 23	Cognitive impairment
1,T3,Qualifier 29 45	mild to moderate
2,T2,Measurement 66 107	Clinical Deterioration Rating (CDR) score
3,T4,Value 108 133	range between 0.5 and 2.0
4,R1,Has_value Arg1:T2 Arg2:T4
5,R2,Has_qualifier Arg1:T1 Arg2:T3
6,T5,Procedure 151 160	brain MRI
7,T6,Observation 164 193	white matter hyperintensities
8,T7,Condition 195 208	leukoaraiosis
9,T8,Value 212 237	moderate or severe degree
10,T9,Measurement 255 284	modified Fazekas visual scale
11,R3,Has_value Arg1:T9 Arg2:T8
12,R4,AND Arg1:T7 Arg2:T9
13,R5,Has_context Arg1:T5 Arg2:T6
14,T10,Condition 304 320	lacunar infarcts
15,*,OR T9 T10
16,T11,Scope 195 320	leukoaraiosis of moderate or severe degree according to the modified Fazekas visual scale and/or presence of lacunar infarcts
17,R6,Subsumes Arg1:T6 Arg2:T11
18,T12,Parsing_Error 0 2	1.
19,T13,Parsing_Error 136 138	2.
20,T14,Parsing_Error 324 326	3.
21,T15,Non-query-able 327 365	Consent to participation in the study.
0,T1,Drug 0 9	Methadone
1,T2,Condition 21 38	cocaine-dependent
2,T3,Multiplier 60 74	1g to 2g a day
3,T4,Multiplier 76 95	1 to 3 times a week
4,T5,Qualifier 0 20	Methadone-maintained
5,R3,multi Arg1:T5 Arg2:T1
6,R4,Has_qualifier Arg1:T2 Arg2:T5
7,T6,Scope 60 95	1g to 2g a day; 1 to 3 times a week
8,R1,Has_scope Arg1:T1 Arg2:T6
0,T1,Person 0 4	Male
1,T2,Person 21 27	female
2,T3,Qualifier 12 20	pregnant
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Negation 8 11	non
5,R2,Has_negation Arg1:T3 Arg2:T4
6,T5,Person 40 44	ages
7,T6,Value 48 53	18-65
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Informed_consent 55 109	Patients willing and able to sign the informed consent
10,T8,Post-eligibility 112 189	atients able to comply with follow-up requirements including self-evaluations
11,T9,Procedure 212 242	primary total knee replacement
12,T10,Condition 273 287	osteoarthritis
13,T11,Condition 289 308	traumatic arthritis
14,T12,Condition 313 331	avascular necrosis
15,*,OR T12 T11 T10
0,T1,Person 0 3	Age
1,T2,Value 4 14	< 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 16 26	Creatinine
4,T4,Value 27 38	> 1.5 mg/dL
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 58 65	allergy
7,T6,Procedure 69 91	Iodine contrast agents
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Condition 93 102	Pregnancy
10,T8,Condition 111 130	atrial fibrillation
11,T9,Condition 132 162;173 185	Multiple premature ventricular contractions
12,T10,Condition 132 150;166 185	Multiple premature atrial contractions
13,*,OR T10 T9
14,T11,Measurement 187 204	Ejection fraction
15,T12,Value 205 209	<35%
16,R4,Has_value Arg1:T11 Arg2:T12
17,T13,Condition 221 245	congestive heart failure
18,T14,Qualifier 211 220	Class III
19,R5,Has_qualifier Arg1:T13 Arg2:T14
0,T1,Person 45 50	Women
1,T2,Person 0 5	Women
2,T3,Condition 34 43	pregnancy
3,T4,Qualifier 11 20	confirmed
4,T5,Qualifier 24 33	suspected
5,*,OR T4 T5
6,T6,Scope 11 33	confirmed or suspected
7,R1,Has_scope Arg1:T3 Arg2:T6
8,T7,Condition 57 66	lactation
9,T8,Condition 74 84	puerperium
10,*,OR T7 T8
11,T9,Condition 86 102	Hypersensibility
12,T10,Drug 106 133	ingredients of intervention
13,R2,AND Arg1:T9 Arg2:T10
14,T11,Non-representable 135 176	Physical impossibility for apply the drug
15,T12,Condition 221 236	thyroid disease
16,T13,Condition 212 217;229 236	heart disease
17,T14,Condition 203 210;229 236	hepatic disease
18,T15,Condition 196 201;229 236	renal disease
19,T16,Condition 184 194;229 236	pancreatic disease
20,*,OR T13 T14 T16 T12 T15
21,T17,Condition 239 251	Hypertension
22,T18,Procedure 272 293	treatment for glucose
23,T19,Temporal 263 271	Previous
24,R3,Has_temporal Arg1:T18 Arg2:T19
25,T20,Measurement 295 310	Body Mass Index
26,T21,Value 311 322	=39.9 kg/m2
27,R4,Has_value Arg1:T20 Arg2:T21
28,T22,Measurement 324 337	Triglycerides
29,T23,Value 338 348	=500 mg/dL
30,R5,Has_value Arg1:T22 Arg2:T23
31,T24,Measurement 350 367	Total cholesterol
32,T25,Value 368 378	=300 mg/dL
33,R6,Has_value Arg1:T24 Arg2:T25
34,T26,Person 389 411	rotating shift workers
35,T27,Person 380 385;398 411	Night shift workers
36,*,OR T27 T26
37,T28,Measurement 413 427	Blood Pressure
38,T29,Value 428 440	=140/90 mmHg
39,R7,Has_value Arg1:T28 Arg2:T29
0,T1,"Competing_trial 0 140	Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug."
1,T2,Condition 165 186	psychiatric diagnosis
2,T3,Qualifier 157 164	primary
3,T4,Qualifier 150 156	Axis I
4,R1,Has_qualifier Arg1:T2 Arg2:T3
5,R2,Has_qualifier Arg1:T2 Arg2:T4
6,T5,Negation 187 197	other than
7,T6,Condition 198 223	major depressive disorder
8,R3,Has_negation Arg1:T6 Arg2:T5
9,R4,AND Arg1:T2 Arg2:T6
10,T7,Condition 226 248	Organic mental disease
11,T8,Condition 260 278	mental retardation
12,R5,Subsumes Arg1:T7 Arg2:T8
13,T9,Qualifier 292 314	clinically significant
14,T10,Condition 315 322	disease
15,R6,Has_qualifier Arg1:T10 Arg2:T9
16,T11,Condition 338 352;426 433	cardiovascular disease
17,T12,Condition 396 410;426 433	endocrinologic disease
18,T13,Condition 383 394;426 433	hematologic disease
19,T14,Condition 370 381;426 433	respiratory disease
20,T15,Condition 363 368;426 433	renal disease
21,T16,Condition 354 361;426 433	hepatic disease
22,T17,Condition 415 433	neurologic disease
23,*,OR T13 T14 T15 T11 T12 T16 T19 T10
24,T18,Qualifier 438 460	clinically significant
25,T19,Condition 461 483	laboratory abnormality
26,T20,Negation 492 495	not
27,T21,Qualifier 496 506	stabilized
28,R7,Has_negation Arg1:T21 Arg2:T20
29,T22,Mood 513 535	anticipated to require
30,T23,Procedure 536 545	treatment
31,T24,Temporal 546 562	during the study
32,R8,Has_temporal Arg1:T23 Arg2:T24
33,R9,Has_mood Arg1:T23 Arg2:T22
34,*,OR T21 T23
35,T25,Scope 492 562	not stabilized or is anticipated to require treatment during the study
36,R10,Has_qualifier Arg1:T19 Arg2:T18
37,R11,Has_scope Arg1:T19 Arg2:T25
38,T26,Competing_trial 565 730	Subjects receiving an investigational agent (including different formulation and generic agents of investigational drug) in the previous 3 months prior to screening.
39,T27,"Pregnancy_considerations 732 845	Women in pregnancy or lactation, or female of child bearing potential without appropriate birth control measures."
40,T28,Drug 854 868	antipsychotics
41,T29,Drug 872 888	mood stabilizers
42,T30,Temporal 889 921	within 5 days prior to screening
43,*,OR T28 T29
44,T31,Scope 854 888	antipsychotics or mood stabilizers
45,R12,Has_temporal Arg1:T31 Arg2:T30
46,T32,Drug 937 967	depot antipsychotic medication
47,T33,Temporal 968 1003	within one cycle prior to screening
48,R13,Has_temporal Arg1:T32 Arg2:T33
49,T34,Condition 1012 1019	allergy
50,T35,Condition 1023 1039	lack of response
51,T36,Drug 1043 1054	mirtazapine
52,*,OR T35 T34
53,T37,Scope 1012 1039	allergy or lack of response
54,R14,AND Arg1:T37 Arg2:T36
55,T38,Temporal 1082 1116	within 3 months prior to screening
56,T39,Reference_point 994 1003	screening
57,T40,Reference_point 912 921	screening
58,R15,Has_index Arg1:T30 Arg2:T40
59,R16,Has_index Arg1:T33 Arg2:T39
60,T41,Reference_point 1107 1116	screening
61,R17,Has_index Arg1:T38 Arg2:T41
62,T42,Procedure 1070 1073	ECT
63,T43,Procedure 1077 1081	MECT
64,*,OR T42 T43
65,T44,Scope 1070 1081	ECT or MECT
66,R18,Has_temporal Arg1:T44 Arg2:T38
67,T45,Drug 1130 1150	anticholinergic drug
68,T46,Condition 1151 1158	allergy
69,T47,Condition 1177 1194	allergic reaction
70,T48,Condition 1196 1205	skin rash
71,T49,Condition 1207 1216	urticaria
72,T50,Condition 1227 1245	allergic reactions
73,T51,Drug 1262 1267	drugs
74,T52,Qualifier 1221 1226	other
75,R19,Has_qualifier Arg1:T50 Arg2:T52
76,*,OR T47 T48 T49 T50
77,T53,"Scope 1177 1245	allergic reaction, skin rash, urticaria and other allergic reactions"
78,R20,AND Arg1:T53 Arg2:T51
79,T54,"Scope 1177 1267	allergic reaction, skin rash, urticaria and other allergic reactions which caused by drugs"
80,R21,AND Arg1:T46 Arg2:T45
81,T55,Scope 1130 1158	anticholinergic drug allergy
82,R22,Subsumes Arg1:T55 Arg2:T54
83,T56,Observation 1271 1278	Smokers
84,T57,Mood 1293 1300	risk of
85,T58,Observation 1301 1309;1327 1336	suicidal behaviors
86,T59,Observation 1317 1336	self-harm behaviors
87,*,OR T59 T58
88,T60,Scope 1301 1336	suicidal and/or self-harm behaviors
89,R23,Has_mood Arg1:T60 Arg2:T57
0,T1,Device 27 30	PCI
1,T2,Temporal 31 58	< 60 minutes from diagnosis
2,T3,Reference_point 49 58	diagnosis
3,R1,Has_index Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T1 Arg2:T2
5,T4,Non-query-able 79 147	inability to arrive at the catheterisation laboratory within 3 hours
6,T5,Procedure 158 162	CABG
7,T6,Condition 164 188	Left bundle branch block
8,T7,Condition 192 210	ventricular pacing
9,*,OR T6 T7
10,T8,Condition 226 243	cardiogenic shock
11,T9,Measurement 246 258	Killip Class
12,T10,Value 259 260	4
13,R3,Has_value Arg1:T9 Arg2:T10
14,R4,AND Arg1:T8 Arg2:T9
15,T11,Measurement 278 289	body weight
16,T12,Value 290 297	< 55 kg
17,R5,Has_value Arg1:T11 Arg2:T12
18,T13,Condition 333 345	hypertension
19,T14,Qualifier 320 332	Uncontrolled
20,R6,Has_qualifier Arg1:T13 Arg2:T14
21,T15,Measurement 368 382	blood pressure
22,T16,Value 383 398	= 180/110 mm Hg
23,T17,Measurement 400 411	systolic BP
24,T18,Value 412 423	= 180 mm Hg
25,T19,Measurement 431 443	diastolic BP
26,T20,Value 444 455	= 110 mm Hg
27,R7,Has_value Arg1:T17 Arg2:T18
28,R8,Has_value Arg1:T19 Arg2:T20
29,T21,Scope 400 455	systolic BP = 180 mm Hg and/or diastolic BP = 110 mm Hg
30,*,OR T17 T19
31,R9,Has_value Arg1:T15 Arg2:T16
32,R10,Subsumes Arg1:T15 Arg2:T21
33,R11,AND Arg1:T13 Arg2:T15
34,T22,Condition 493 499	stroke
35,T23,Condition 503 506	TIA
36,*,OR T23 T22
37,T24,Drug 550 565	anticoagulation
38,T25,Temporal 566 581	within 12 hours
39,R12,Has_temporal Arg1:T24 Arg2:T25
40,T26,Drug 593 615	unfractionated heparin
41,T27,Drug 617 627	enoxaparin
42,T28,Drug 636 647	bivalirudin
43,T29,Drug 666 686	oral anticoagulation
44,T30,Drug 693 701	warfarin
45,T31,Drug 707 712	NOACs
46,T32,"Scope 593 713	unfractionated heparin, enoxaparin, and/or bivalirudin or current use of oral anticoagulation (i.e. warfarin or a NOACs)"
47,T33,Scope 693 712	warfarin or a NOACs
48,*,OR T31 T30
49,R13,Subsumes Arg1:T29 Arg2:T33
50,*,OR T29 T28 T27 T26
51,R14,Subsumes Arg1:T24 Arg2:T32
52,T34,Condition 715 730	Active bleeding
53,T35,Condition 740 757	bleeding disorder
54,T36,Condition 758 767	diathesis
55,*,OR T35 T36 T34
56,T37,Condition 786 815	central nervous system damage
57,T38,Condition 822 830	neoplasm
58,T39,Condition 832 840	aneurysm
59,T40,Procedure 842 854;865 872	intracranial surgery
60,T41,Procedure 858 872	spinal surgery
61,*,OR T38 T39 T40 T41
62,T42,"Scope 822 872	neoplasm, aneurysm, intracranial or spinal surgery"
63,R15,Subsumes Arg1:T37 Arg2:T42
64,T43,Condition 884 890	trauma
65,T44,Qualifier 898 902	head
66,T45,Qualifier 906 913	cranium
67,*,OR T45 T44
68,T46,Temporal 920 930	< 3 months
69,T47,Scope 898 913	head or cranium
70,R16,Has_scope Arg1:T43 Arg2:T47
71,R17,Has_temporal Arg1:T43 Arg2:T46
72,T48,Procedure 933 946	Major surgery
73,T49,Procedure 948 954	biopsy
74,T50,Qualifier 960 977	parenchymal organ
75,T51,Condition 994 1000	trauma
76,T52,Qualifier 982 993	significant
77,R18,Has_qualifier Arg1:T51 Arg2:T52
78,T53,Temporal 1012 1025	past 2 months
79,*,OR T48 T49 T51
80,R19,Has_qualifier Arg1:T49 Arg2:T50
81,T54,"Scope 933 1000	Major surgery, biopsy of a parenchymal organ, or significant trauma"
82,R20,Has_temporal Arg1:T54 Arg2:T53
83,T55,Condition 1080 1101	myocardial infarction
84,R21,Subsumes Arg1:T51 Arg2:T55
85,T56,Observation 1149 1165	risk of bleeding
86,T57,Qualifier 1139 1148	increased
87,R22,Has_qualifier Arg1:T56 Arg2:T57
88,T58,Condition 1189 1206	peptic ulceration
89,T59,Qualifier 1182 1188	active
90,R23,Has_qualifier Arg1:T58 Arg2:T59
91,T60,Condition 1214 1222	neoplasm
92,*,OR T58 T60
93,T61,Scope 1182 1222	active peptic ulceration and/or neoplasm
94,R24,Subsumes Arg1:T56 Arg2:T61
95,T62,Condition 1263 1292	cardiopulmonary resuscitation
96,T63,Qualifier 1253 1262	Prolonged
97,R25,Has_qualifier Arg1:T62 Arg2:T63
98,T64,Temporal 1318 1330	past 2 weeks
99,R26,Has_temporal Arg1:T62 Arg2:T64
100,T65,Condition 1338 1356	acute pericarditis
101,T66,Condition 1364 1395	subacute bacterial endocarditis
102,*,OR T65 T66
103,T67,Condition 1403 1421	acute pancreatitis
104,T68,Condition 1438 1457	hepatic dysfunction
105,T69,Qualifier 1431 1437	severe
106,T70,Condition 1469 1484	hepatic failure
107,T71,Condition 1486 1495	cirrhosis
108,T72,Condition 1497 1516	portal hypertension
109,T73,Condition 1543 1559	active hepatitis
110,T74,Condition 1518 1537	oesophageal varices
111,R27,Has_qualifier Arg1:T68 Arg2:T69
112,*,OR T67 T68
113,T75,"Scope 1469 1559	hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis"
114,*,OR T70 T71 T72 T73
115,R28,Subsumes Arg1:T72 Arg2:T74
116,R29,Subsumes Arg1:T68 Arg2:T75
117,T76,Condition 1561 1569	Dementia
118,T77,Condition 1584 1603	renal insufficiency
119,T78,Qualifier 1577 1583	severe
120,R30,Has_qualifier Arg1:T77 Arg2:T78
121,T79,Competing_trial 1605 1737	Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days
122,T80,Condition 1745 1763	allergic reactions
123,T81,Drug 1767 1779	tenecteplase
124,T82,Drug 1781 1792	clopidogrel
125,T83,Drug 1794 1804	enoxaparin
126,T84,Drug 1809 1816	aspirin
127,*,OR T84 T83 T82 T81
128,T85,"Scope 1767 1816	tenecteplase, clopidogrel, enoxaparin and aspirin"
129,R31,Has_scope Arg1:T80 Arg2:T85
130,T86,Post-eligibility 1818 2023	Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 119 121	2.
2,T3,Parsing_Error 226 228	3.
3,T4,Parsing_Error 280 282	4.
4,T5,Parsing_Error 389 391	5.
5,T6,Parsing_Error 882 884	6.
6,T7,Parsing_Error 1120 1122	7.
7,T8,Parsing_Error 1267 1269	8.
8,T9,Parsing_Error 1327 1329	9.
9,T10,Parsing_Error 1446 1449	10.
10,T11,Parsing_Error 1499 1502	11.
11,T12,Parsing_Error 1556 1559	12.
12,T13,Parsing_Error 1635 1638	13.
13,T14,Parsing_Error 1687 1690	14.
14,T15,Parsing_Error 1729 1732	15.
15,T16,Parsing_Error 1784 1787	16.
16,T17,Parsing_Error 1819 1822	17.
17,T18,Parsing_Error 1857 1860	18.
18,T19,Parsing_Error 1870 1873	19.
19,T20,Parsing_Error 1909 1912	20.
20,T21,Subjective_judgement 14 27	objectionable
21,T22,Condition 28 48	cognitive impairment
22,T23,Qualifier 14 27	objectionable
23,R1,Has_qualifier Arg1:T22 Arg2:T23
24,T24,Negation 3 10	Absence
25,T25,Condition 64 72	dementia
26,T26,Qualifier 76 89	severe degree
27,T27,Measurement 101 110	CDR score
28,T28,Value 111 116	> 2.0
29,R2,Has_value Arg1:T27 Arg2:T28
30,R3,AND Arg1:T25 Arg2:T27
31,R4,Subsumes Arg1:T27 Arg2:T26
32,*,OR T22 T25
33,T29,Scope 14 116	objectionable cognitive impairment or presence of dementia of severe degree defined by CDR score > 2.0
34,R5,Has_negation Arg1:T29 Arg2:T24
35,T30,Procedure 140 149	brain MRI
36,T31,Negation 122 136	Unavailability
37,T32,Observation 122 136	Unavailability
38,T33,Non-query-able 122 136	Unavailability
39,R6,Has_negation Arg1:T30 Arg2:T31
40,T34,Procedure 201 211	cranial CT
41,T35,Condition 162 188	absolute contraindications
42,T36,Undefined_semantics 162 188	absolute contraindications
43,A1,Optional T35
44,R7,AND Arg1:T35 Arg2:T34
45,*,OR T34 T30
46,T37,Non-query-able 229 278	Expected poor compliance with the study protocol.
47,T38,Condition 301 317	major depression
48,T39,Condition 319 332	schizophrenia
49,T40,Condition 334 356	major anxiety syndrome
50,T41,Condition 361 386	manic- depressive illness
51,T42,Observation 283 297	Past diagnosis
52,*,OR T40 T41 T39 T38
53,T43,"Scope 301 386	major depression, schizophrenia, major anxiety syndrome, or manic- depressive illness"
54,R8,Has_scope Arg1:T42 Arg2:T43
55,T44,Condition 405 438	degenerative cognitive impairment
56,T45,Undefined_semantics 405 438	degenerative cognitive impairment
57,T46,Condition 448 490	clinical and/or neuroradiological findings
58,T47,Undefined_semantics 448 490	clinical and/or neuroradiological findings
59,T48,Condition 523 540	memory impairment
60,T49,Condition 550 573	medial temporal atrophy
61,T50,Procedure 577 586	brain MRI
62,T51,Negation 590 597	absence
63,T52,Condition 609 631	vascular abnormalities
64,T53,Subjective_judgement 601 608	evident
65,T54,Condition 639 656	Alzheimer disease
66,T55,Measurement 678 814	National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria
67,T56,Condition 816 833	Parkinson disease
68,T57,Condition 835 853	Huntington disease
69,T58,Condition 855 878	frontotemporal dementia
70,R9,AND Arg1:T49 Arg2:T50
71,R11,Has_negation Arg1:T52 Arg2:T51
72,R12,AND Arg1:T52 Arg2:T53
73,*,OR T57 T56 T58 T54
74,R13,AND Arg1:T54 Arg2:T55
75,*,OR T49 T48
76,T59,"Scope 523 586	memory impairment, or with medial temporal atrophy on brain MRI"
77,R10,AND Arg1:T59 Arg2:T52
78,T60,"Scope 523 631	memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities"
79,T61,"Scope 639 878	Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia"
80,R14,Has_scope Arg1:T60 Arg2:T61
81,T62,"Scope 523 878	memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities; i.e., Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia"
82,R15,AND Arg1:T44 Arg2:T46
83,R16,Subsumes Arg1:T46 Arg2:T62
84,T63,Condition 898 918	cognitive impairment
85,T64,Qualifier 924 936	other causes
86,T65,Condition 944 956;972 982	vitamine B12 deficiency
87,T66,Condition 961 982	folic acid deficiency
88,T67,Condition 984 1001	thyroid disorders
89,T68,Condition 1003 1021	metabolic diseases
90,T69,Condition 1023 1034	head trauma
91,T70,Condition 1036 1041;1056 1085	tumor of the central nervous system
92,T71,Condition 1045 1085	infections of the central nervous system
93,*,OR T70 T71 T72 T66 T65 T67 T68 T69
94,T72,Condition 1087 1116	normal pressure hydrocephalus
95,T73,"Scope 944 1116	vitamine B12 and folic acid deficiency, thyroid disorders, metabolic diseases, head trauma, tumor or infections of the central nervous system, normal pressure hydrocephalus"
96,R17,Subsumes Arg1:T64 Arg2:T73
97,R18,Has_qualifier Arg1:T63 Arg2:T64
98,T74,Undefined_semantics 924 936	other causes
99,T75,"Undefined_semantics 1123 1265	Medical conditions expected to progress, recur, or change to such a degree to interfere with the assessment of the clinical and mental status."
100,T76,"Subjective_judgement 1123 1265	Medical conditions expected to progress, recur, or change to such a degree to interfere with the assessment of the clinical and mental status."
101,T77,"Non-query-able 1123 1265	Medical conditions expected to progress, recur, or change to such a degree to interfere with the assessment of the clinical and mental status."
102,T78,Condition 1290 1297;1311 1324	cardiac insufficiency
103,T79,Condition 1301 1324	pulmonary insufficiency
104,*,OR T79 T78
105,T80,Qualifier 1270 1289	Clinically relevant
106,T81,Scope 1290 1324	cardiac or pulmonary insufficiency
107,R19,Has_qualifier Arg1:T81 Arg2:T80
108,T82,Condition 1358 1371	abnormalities
109,T83,Procedure 1339 1357	electrocardiograph
110,R20,AND Arg1:T83 Arg2:T82
111,T84,Condition 1373 1384	bradycardia
112,T85,Measurement 1386 1392	50 bpm
113,T86,Condition 1397 1408	tachycardia
114,T87,Measurement 1410 1417	120 bpm
115,R21,Subsumes Arg1:T84 Arg2:T85
116,R22,Subsumes Arg1:T86 Arg2:T87
117,*,OR T84 T86
118,T88,Qualifier 1419 1443	under resting conditions
119,T89,Scope 1373 1418	bradycardia (50 bpm) or tachycardia (120 bpm)
120,R23,Has_qualifier Arg1:T89 Arg2:T88
121,T90,Scope 1373 1443	bradycardia (50 bpm) or tachycardia (120 bpm) under resting conditions
122,R24,Has_scope Arg1:T82 Arg2:T90
123,T91,Qualifier 1330 1338	Relevant
124,R25,Has_qualifier Arg1:T82 Arg2:T91
125,T92,Undefined_semantics 1330 1338	Relevant
126,T93,Condition 1450 1471	Myocardial infarction
127,T94,Temporal 1472 1496	within the past 6 months
128,R26,Has_temporal Arg1:T93 Arg2:T94
129,T95,Procedure 1526 1553	neurological rehabilitation
130,T96,Condition 1503 1509	Stroke
131,T97,Non-query-able 1516 1525	requiring
132,T98,Subjective_judgement 1516 1525	requiring
133,T99,Qualifier 1516 1525	requiring
134,R27,Has_qualifier Arg1:T95 Arg2:T99
135,T100,Context_Error 1577 1591	blood pressure
136,T101,Measurement 1593 1601	systolic
137,T102,Measurement 1613 1622	diastolic
138,T103,Value 1602 1611	180 mm Hg
139,T104,Value 1623 1631	95 mm Hg
140,R28,Has_value Arg1:T101 Arg2:T103
141,R29,Has_value Arg1:T102 Arg2:T104
142,T105,"Scope 1593 1631	systolic 180 mm Hg, diastolic 95 mm Hg"
143,T106,Measurement 1577 1591	blood pressure
144,T107,Qualifier 1560 1566	Severe
145,T108,Qualifier 1567 1576	untreated
146,*,OR T108 T107
147,T109,Scope 1560 1576	Severe/untreated
148,R30,Has_scope Arg1:T106 Arg2:T109
149,R31,Subsumes Arg1:T109 Arg2:T105
150,T110,Condition 1659 1684	liver function impairment
151,T111,Subjective_judgement 1639 1658	Clinically relevant
152,T112,Undefined_semantics 1639 1658	Clinically relevant
153,T113,Qualifier 1639 1658	Clinically relevant
154,R32,Has_qualifier Arg1:T110 Arg2:T113
155,T114,Condition 1691 1726	Insulin-dependent diabetes mellitus
156,T115,Condition 1733 1752	Idiopathic epilepsy
157,T116,Condition 1757 1781	anti-epileptic treatment
158,T117,Condition 1795 1801	anemia
159,T118,Qualifier 1788 1794	Severe
160,T119,Measurement 1803 1805	Hb
161,T120,Value 1806 1815	<10 mg/dL
162,R33,Has_value Arg1:T119 Arg2:T120
163,R34,Has_qualifier Arg1:T117 Arg2:T118
164,R35,Subsumes Arg1:T118 Arg2:T119
165,T121,Condition 1830 1854	gastrointestinal disease
166,T122,Qualifier 1823 1829	Severe
167,R36,Has_qualifier Arg1:T121 Arg2:T122
168,T123,Undefined_semantics 1823 1829	Severe
169,T124,Subjective_judgement 1823 1829	Severe
170,T125,Condition 1861 1867	Cancer
171,T126,Condition 1880 1891	intolerance
172,T127,Drug 1895 1906	study drugs
173,R37,AND Arg1:T126 Arg2:T127
174,T128,Context_Error 1880 1906	intolerance to study drugs
175,T129,Undefined_semantics 1913 1998	Coexistent serious illnesses that would imply a drop-out before the end of the trial.
0,T1,Multiplier 4 22	more than 2g a day
1,T2,Multiplier 24 50	5 times a week to everyday
2,R1,Has_multiplier Arg1:T1 Arg2:T2
3,T3,Condition 97 114	psychotic illness
4,T4,Measurement 128 134	DSM-IV
5,T5,Qualifier 136 142	Axis 1
6,R3,Subsumes Arg1:T3 Arg2:T4
7,R2,Has_qualifier Arg1:T4 Arg2:T5
8,T6,Observation 157 164	history
9,T7,Condition 168 179	CNS disease
10,R4,AND Arg1:T6 Arg2:T7
11,T8,Observation 183 190	history
12,T9,Condition 194 203	infection
13,T10,Qualifier 215 225	affect CNS
14,R5,Has_qualifier Arg1:T9 Arg2:T10
15,T11,Condition 227 230	HIV
16,T12,Condition 232 240	syphilis
17,T13,Condition 242 257	cytomegalovirus
18,T14,Condition 259 265	herpes
19,*,OR T11 T12 T13 T14
20,T15,"Scope 227 265	HIV, syphilis, cytomegalovirus, herpes"
21,R6,Subsumes Arg1:T9 Arg2:T15
22,T16,Observation 273 280	history
23,T17,Condition 284 295	head injury
24,T18,Condition 301 322	loss of consciousness
25,T19,Condition 323 331	pregnant
26,R7,AND Arg1:T16 Arg2:T17
27,R8,AND Arg1:T17 Arg2:T18
28,R9,AND Arg1:T8 Arg2:T9
29,*,OR T6 T8 T16 T19 T3
0,T1,Condition 0 23	Acute Coronary Syndrome
1,T2,Non-query-able 0 299	Acute Coronary Syndrome group: 40 patients with type 1 myocardial infarction within 21 days prior to the imaging visit and invasive coronary angiography with angiographic evidence of at least a 50% stenosis in one or more coronary arteries. Only patients undergoing PCI will be included in the study
2,T3,"Non-query-able 302 562	Stable Ischemic Heart Disease group: 40 patients who have undergone invasive coronary angiography within 21 days prior to the imaging visit, with history of typical angina prior to the angiogram, but no prior myocardial infarction or coronary revascularization"
3,T4,Negation 570 572	no
4,T5,Condition 579 582	CAD
5,R1,Has_negation Arg1:T5 Arg2:T4
6,T6,Condition 610 631	myocardial infarction
7,T7,Condition 633 656	acute coronary syndrome
8,T8,Procedure 658 676	coronary angiogram
9,T9,Procedure 681 684	PCI
10,*,OR T6 T7 T8 T9
11,T10,"Scope 610 684	myocardial infarction, acute coronary syndrome, coronary angiogram, or PCI"
12,R2,Subsumes Arg1:T5 Arg2:T10
13,T11,Measurement 693 696	CAC
14,T12,Value 697 716	between 10 to <1000
15,R3,Has_value Arg1:T11 Arg2:T12
16,T13,"Non-query-able 723 864	match to patients in the ACS group by gender, age by decile, and CAC category (using CAC categories of 10 to <100, 100 to <400, 400 to <1000)"
0,T1,Person 9 19	both sexes
1,T2,Person 21 24	Age
2,T3,Measurement 25 48	between 31 and 60 years
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 63 71	diabetes
5,T5,Qualifier 82 94	ADA criteria
6,R2,Has_qualifier Arg1:T4 Arg2:T5
0,T1,Procedure 0 32	Revision total knee arthroplasty
1,T2,Procedure 34 67	Bilateral total knee arthroplasty
2,T3,Condition 83 105	inflammatory arthritis
3,T4,Measurement 123 138	body mass index
4,T5,Measurement 140 143	BMI
5,R1,Subsumes Arg1:T4 Arg2:T5
6,T6,Value 145 149	> 40
7,R2,Has_value Arg1:T4 Arg2:T6
8,T7,Condition 151 158	Allergy
9,T8,Drug 162 173	ropivacaine
10,T9,Drug 175 186	bupivacaine
11,T10,Drug 197 220	local anesthetic agents
12,*,OR T8 T9 T10
13,T11,"Scope 162 220	ropivacaine, bupivacaine, or other local anesthetic agents"
14,R3,Has_scope Arg1:T7 Arg2:T11
15,T12,Drug 237 243	opioid
16,T13,Qualifier 326 340	affected joint
17,T14,Procedure 304 318	reconstruction
18,T15,Qualifier 287 303	unicompartmental
19,T16,Qualifier 278 283	total
20,*,OR T15 T16
21,T17,Scope 278 303	total or unicompartmental
22,R4,Has_scope Arg1:T14 Arg2:T17
23,R5,Has_qualifier Arg1:T14 Arg2:T13
24,T18,Procedure 367 388	high tibial osteotomy
25,T19,Procedure 392 409	femoral osteotomy
26,*,OR T18 T19
27,T20,Condition 425 438;455 465	neuromuscular deficiency
28,T21,Condition 442 465	neurosensory deficiency
29,*,OR T21 T20
30,T22,Condition 548 566	metabolic disorder
31,T23,Condition 536 544;558 566	systemic disorder
32,T24,Condition 590 608	bone deterioration
33,T25,Qualifier 578 589	progressive
34,R6,Has_qualifier Arg1:T24 Arg2:T25
35,*,OR T22 T23
36,T26,Scope 536 566	systemic or metabolic disorder
37,R7,Has_scope Arg1:T24 Arg2:T26
38,T27,Condition 628 655	immunologically compromised
39,T28,Drug 678 686	steroids
40,T29,Qualifier 670 677	chronic
41,R8,Has_qualifier Arg1:T28 Arg2:T29
42,T30,Temporal 688 696	>30 days
43,R9,Has_temporal Arg1:T28 Arg2:T30
44,T31,Negation 699 708	excluding
45,T32,Drug 709 717	inhalers
46,R10,Has_negation Arg1:T32 Arg2:T31
47,*,OR T27 T28
48,T33,"Non-query-able 719 851	Patients' bone stock is compromised by disease or infection, which cannot provide adequate support and/or fixation to the prosthesis"
49,T34,Procedure 867 878	knee fusion
50,T35,Condition 946 955	infection
51,T36,Qualifier 972 982	knee joint
52,R11,Has_qualifier Arg1:T35 Arg2:T36
53,T37,Person 1002 1011	prisoners
0,T1,Condition 19 40	pre-existing diseases
1,T2,Qualifier 0 18	Incompletely cured
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Subjective_judgement 54 68	can be assumed
4,T4,"Non-query-able 0 176	Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal"
5,T5,Condition 197 211	liver diseases
6,T6,Qualifier 187 196	suspected
7,T7,Qualifier 178 183	Known
8,*,OR T6 T7
9,T8,Scope 178 196	Known or suspected
10,R2,Has_scope Arg1:T5 Arg2:T8
11,T9,Subjective_judgement 187 196	suspected
12,T10,Undefined_semantics 187 196	suspected
13,T11,Measurement 247 261	blood pressure
14,T12,Procedure 263 285	electrocardiogram(ECG)
15,T13,Procedure 300 325	gynecological examination
16,T14,Procedure 287 295;314 325	physical examination
17,T15,Procedure 327 349	laboratory examination
18,*,OR T15 T14 T13 T12 T11
19,T16,"Scope 247 349	blood pressure, electrocardiogram(ECG); physical and gynecological examination, laboratory examination"
20,T17,Qualifier 213 232	Clinically relevant
21,T18,Condition 233 241	findings
22,T19,Subjective_judgement 213 232	Clinically relevant
23,T20,Undefined_semantics 213 232	Clinically relevant
24,R3,Has_qualifier Arg1:T18 Arg2:T17
25,R4,Subsumes Arg1:T18 Arg2:T16
0,T1,Person 0 3	Age
1,T2,Value 11 23	20 to 90 y/o
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 26 31	HBsAg
4,T4,Value 32 40	positive
5,T5,Temporal 45 63	more than 6 months
6,T6,Measurement 68 75	HBV DNA
7,T7,Value 76 88	< 2000 IU/ml
8,T8,Measurement 104 109	HBsAg
9,T9,Value 110 118	negative
10,T10,Measurement 123 131	anti-HBc
11,T11,Value 132 140	positive
12,T12,Measurement 146 153	HBV DNA
13,T13,Value 154 166	< 2000 IU/ml
14,R2,Has_value Arg1:T3 Arg2:T4
15,R3,Has_temporal Arg1:T3 Arg2:T5
16,R4,Has_value Arg1:T6 Arg2:T7
17,R5,Has_value Arg1:T8 Arg2:T9
18,R6,Has_value Arg1:T10 Arg2:T11
19,R7,Has_value Arg1:T12 Arg2:T13
20,T14,Scope 26 88	HBsAg-positive for more than 6 months and HBV DNA < 2000 IU/ml
21,T15,Scope 0 25;26 166	Age : from 20 to 90 y/o.
22,HBsAg-positive,for more than 6 months and HBV DNA < 2000 IU/ml (Subgroup 1)or HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml
23,T16,Scope 104 166	HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml
24,*,OR T16 T14
25,T17,Condition 182 204	Inflammatory arthritis
26,T18,Procedure 237 254	biological agents
27,T19,Drug 266 272	Humira
28,T20,Drug 276 282	Enbrel
29,T21,Drug 286 293	Simponi
30,T22,Drug 297 304	Orencia
31,T23,Drug 308 316	Mabthera
32,T24,Drug 320 327	Actemra
33,*,OR T19 T20 T21 T22 T23 T24
34,T25,Scope 266 327	Humira or Enbrel or Simponi or Orencia or Mabthera or Actemra
35,R8,AND Arg1:T17 Arg2:T18
36,R9,Has_scope Arg1:T18 Arg2:T25
0,T1,Condition 13 27	ankle fracture
1,T2,Condition 31 47	ligament rupture
2,*,OR T1 T2
3,T3,Observation 61 99	release from the Canadian Armed Forces
4,T4,Temporal 100 115	within one year
5,R1,Has_temporal Arg1:T3 Arg2:T4
6,T5,Observation 129 160	restrictions on military duties
7,T6,Drug 218 231	acetaminophen
8,T7,Drug 235 243	naproxen
9,T8,Drug 247 256	celecoxib
10,*,OR T7 T8 T6
11,T9,Condition 198 214	adverse reaction
12,T10,Scope 218 256	acetaminophen or naproxen or celecoxib
13,T11,Condition 172 183	intolerance
14,*,OR T11 T9
15,T12,Scope 172 214	intolerance or documented adverse reaction
16,R2,Has_scope Arg1:T12 Arg2:T10
17,T13,Condition 289 304	kidney problems
18,T14,Condition 280 285;296 304	liver problems
19,*,OR T13 T14
20,T15,Observation 269 276	history
21,T16,Scope 280 304	liver or kidney problems
22,R3,Has_temporal Arg1:T16 Arg2:T15
23,T17,Condition 306 314	pregnant
24,T18,Observation 318 331	breastfeeding
25,*,OR T17 T18
0,T1,Visit 0 11	outpatients
1,T2,Person 12 16	aged
2,T3,Value 17 28	18-70 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 53 72	H. pylori infection
5,T5,Measurement 115 135	13C-urea breath test
6,T6,Measurement 137 146	histology
7,T7,Measurement 148 165	rapid urease test
8,T8,Measurement 169 186	bacterial culture
9,*,OR T5 T6 T7 T8
10,T9,"Scope 115 186	13C-urea breath test, histology, rapid urease test or bacterial culture"
11,R2,AND Arg1:T9 Arg2:T4
12,T10,Informed_consent 188 267	an intention of H. pylori eradication treatment and have written inform consent
13,T11,Post-eligibility 269 319	ability to read short messages on the mobile phone
0,T1,Condition 14 35	chronic heart failure
1,T2,Measurement 39 65	New York Heart Association
2,T3,Value 66 81	Class II or III
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Measurement 85 119	left ventricular ejection fraction
6,T5,Value 123 128	= 40%
7,T6,Measurement 145 149	NYHA
8,T7,Value 150 158	class II
9,R4,Has_value Arg1:T6 Arg2:T7
10,T8,Measurement 184 188	NYHA
11,T9,Value 189 198	class III
12,R5,Has_value Arg1:T8 Arg2:T9
13,T10,Value 162 167	= 45%
14,T11,Scope 184 198	NYHA class III
15,T12,Scope 145 158	NYHA class II
16,R3,Has_value Arg1:T11 Arg2:T10
17,A1,Optional T11
18,A2,Optional T12
19,R6,Has_value Arg1:T12 Arg2:T5
20,T13,Scope 123 198	= 40% for patients in NYHA class II or = 45% for patients in NYHA class III
21,*,OR T11 T12
22,R7,Has_scope Arg1:T4 Arg2:T13
23,T14,Measurement 202 218	hemoglobin level
24,T15,Temporal 219 241	at the screening visit
25,T16,Reference_point 222 241	the screening visit
26,R8,Has_index Arg1:T15 Arg2:T16
27,T17,Value 242 263	between 9.5-13.5 g/dl
28,R9,Has_value Arg1:T14 Arg2:T17
29,R10,Has_temporal Arg1:T14 Arg2:T15
30,T18,Condition 269 284	iron deficiency
31,T19,Measurement 306 326	serum ferritin level
32,T20,Value 327 336	< 100µg/l
33,T21,Value 340 364	between 100 and 299 µg/l
34,*,OR T20 T21
35,T22,Scope 327 364	< 100µg/l or between 100 and 299 µg/l
36,R11,Has_scope Arg1:T19 Arg2:T22
37,T23,Measurement 371 394	transferring saturation
38,T24,Value 398 403	< 20%
39,R12,Has_value Arg1:T23 Arg2:T24
40,T25,"Scope 306 403	serum ferritin level < 100µg/l or between 100 and 299 µg/l, when transferring saturation is < 20%"
41,R13,Subsumes Arg1:T18 Arg2:T25
42,T26,Person 406 409	Age
43,T27,Value 410 419	=18 years
44,R14,Has_value Arg1:T26 Arg2:T27
45,T28,Post-eligibility 421 446	Obtained informed consent
46,T29,Procedure 455 478	pharmacological therapy
47,T30,Qualifier 448 454	Stable
48,R15,Has_qualifier Arg1:T29 Arg2:T30
49,T31,Temporal 479 502	during the last 4 weeks
50,T32,Reference_point 490 502	last 4 weeks
51,R16,Has_index Arg1:T31 Arg2:T32
52,T33,Drug 526 535	diuretics
53,T34,Negation 504 525	with the exception of
54,R17,Has_negation Arg1:T33 Arg2:T34
55,R18,AND Arg1:T29 Arg2:T33
56,R19,Has_temporal Arg1:T29 Arg2:T31
0,T1,Condition 0 3;17 28	HCV coinfection
1,T2,Condition 17 28;5 8	coinfection HIV
2,T3,Condition 13 16;17 28	HDV coinfection
3,T4,Condition 31 34	HCC
4,*,OR T3 T2 T1
5,T5,Condition 44 54	malignancy
6,T6,Temporal 55 69	within 3 years
7,*,OR T4 T5
8,T7,Scope 31 54	HCC or other malignancy
9,R1,Has_temporal Arg1:T7 Arg2:T6
10,T8,Condition 72 101	Decompensated liver cirrhosis
11,T9,Measurement 103 112	CTP score
12,T10,Value 113 116	= 7
13,R2,Has_value Arg1:T9 Arg2:T10
14,R3,AND Arg1:T8 Arg2:T9
15,T11,Condition 120 126	Uremia
16,T12,Procedure 142 154	hemodialysis
17,T13,Condition 158 199	continuous ambulatory peritoneal dialysis
18,T14,Measurement 217 220	Ccr
19,T15,Value 221 232	< 50 mL/min
20,*,OR T13 T12
21,T16,Scope 142 199	hemodialysis or continuous ambulatory peritoneal dialysis
22,R4,Has_value Arg1:T14 Arg2:T15
23,*,OR T16 T14
24,T17,Scope 142 232	hemodialysis or continuous ambulatory peritoneal dialysis or patients with Ccr < 50 mL/min
25,R5,Has_scope Arg1:T11 Arg2:T17
26,T18,Pregnancy_considerations 234 265	Pregnant or breastfeeding women
27,T19,Pregnancy_considerations 268 477	Women of child-bearing potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of study drug
0,T1,Measurement 0 21	Body mass index (BMI)
1,T2,Value 23 42	18 ≤ BMI ≤ 32 kg/m²
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 44 64	Postmenopausal state
4,T4,Parsing_Error 44 77	Postmenopausal state revealed by:
5,T5,Condition 111 128	natural menopause
6,T6,Temporal 129 188	at least 12 months prior to first study drug administration
7,T7,Reference_point 157 188	first study drug administration
8,R2,Has_index Arg1:T6 Arg2:T7
9,T8,Condition 193 211	surgical menopause
10,T9,Procedure 215 236	bilateral ovariectomy
11,R3,AND Arg1:T8 Arg2:T9
12,T10,Temporal 237 295	at least 3 months prior to first study drug administration
13,T11,Reference_point 264 295	first study drug administration
14,R4,Has_index Arg1:T10 Arg2:T11
15,R5,Has_temporal Arg1:T8 Arg2:T10
16,R6,Has_temporal Arg1:T5 Arg2:T6
17,*,OR T5 T8 T17
18,T12,Value 320 330	< 65 years
19,T13,Person 325 334	years old
20,R7,Has_value Arg1:T13 Arg2:T12
21,T14,Measurement 336 370	follicle stimulating hormone (FSH)
22,T15,Value 371 380	> 40 IU/L
23,R8,Has_value Arg1:T14 Arg2:T15
24,T16,Person 314 319	women
25,T17,Scope 314 334	women < 65 years old
26,A1,Optional T17
27,R9,AND Arg1:T17 Arg2:T14
0,T1,Non-query-able 1 113	dvanced chronic disease that would not allow the patient to complete the treatment or follow-up or attend visits
1,T2,Non-representable 115 161	allergy to any of the drugs used in this study
2,T3,Procedure 172 213	Helicobacter Pylori eradication treatment
3,T4,Pregnancy_considerations 215 375	pregnancy or breastfeeding (female participants with childbearing potential were required to use medically accepted contraception for the duration of the study)
4,T5,Drug 384 395	antibiotics
5,T6,Drug 399 403	PPIs
6,T7,Drug 407 420	bismuth salts
7,T8,Temporal 421 438	within four weeks
8,*,OR T7 T6 T5
9,T9,Scope 384 420	antibiotics or PPIs or bismuth salts
10,R1,Has_temporal Arg1:T9 Arg2:T8
11,T10,Procedure 449 473	gastrointestinal surgery
0,T1,Condition 9 27	acute ankle injury
1,T2,Qualifier 0 8	Acquired
2,T3,Temporal 37 59	less than 48 hours ago
3,R1,Has_temporal Arg1:T1 Arg2:T3
4,R2,Has_qualifier Arg1:T1 Arg2:T2
5,T4,Qualifier 87 94	Grade I
6,T5,Qualifier 87 92;98 100	Grade II
7,T6,Condition 101 113	ankle sprain
8,*,OR T5 T4
9,T7,Scope 87 100	Grade I or II
10,R3,Has_scope Arg1:T6 Arg2:T7
11,T8,Non-query-able 115 187	Is eligible to receive comprehensive medical care from Garrison Petawawa
0,T1,Condition 0 15	Hemochromatosis
1,T2,Condition 17 30	iron overload
2,T3,Measurement 43 47	TSAT
3,T4,Value 48 53	> 45%
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Subsumes Arg1:T1 Arg2:T2
6,R3,Subsumes Arg1:T2 Arg2:T3
7,T5,Condition 61 77	hypersensitivity
8,T6,Drug 81 91	Ferinject®
9,R4,AND Arg1:T5 Arg2:T6
10,T7,Measurement 118 121	CRP
11,T8,Value 121 129	>20 mg/L
12,R5,Has_value Arg1:T7 Arg2:T8
13,T9,Condition 100 116	active infection
14,T10,Qualifier 131 153	clinically significant
15,T11,Condition 154 162	bleeding
16,T12,Qualifier 164 170	active
17,T13,Condition 171 181	malignancy
18,R6,Has_qualifier Arg1:T13 Arg2:T12
19,R7,Has_qualifier Arg1:T11 Arg2:T10
20,R8,AND Arg1:T9 Arg2:T7
21,*,OR T9 T11 T13
22,T14,Condition 184 205	Chronic liver disease
23,T15,Measurement 223 249	alanine transaminase (ALT)
24,T16,Measurement 253 281	aspartate transaminase (AST)
25,T17,Value 282 335	above three times the upper limit of the normal range
26,*,OR T16 T15
27,T18,Scope 223 281	alanine transaminase (ALT) or aspartate transaminase (AST)
28,R9,Has_value Arg1:T18 Arg2:T17
29,*,OR T14 T18
30,T19,Procedure 338 363	Immunosuppressive therapy
31,T20,Condition 367 381	renal dialysis
32,T21,Mood 383 390	current
33,T22,Mood 394 401	planned
34,T23,Temporal 402 426	within the next 6 months
35,T24,Reference_point 409 426	the next 6 months
36,R10,Has_index Arg1:T23 Arg2:T24
37,*,OR T22 T21
38,T25,Scope 383 401	current or planned
39,*,OR T20 T19
40,T26,Scope 338 381	Immunosuppressive therapy or renal dialysis
41,R11,Has_scope Arg1:T26 Arg2:T25
42,R12,Has_temporal Arg1:T26 Arg2:T23
43,T27,Drug 441 455	erythropoietin
44,T28,Procedure 466 483	oral iron therapy
45,T29,Procedure 489 506	blood transfusion
46,T30,Temporal 507 527	in previous 12 weeks
47,T31,Mood 548 555	planned
48,T32,Temporal 556 580	within the next 6 months
49,T33,Reference_point 563 580	the next 6 months
50,R13,Has_mood Arg1:T32 Arg2:T31
51,T34,Procedure 457 462;471 483	i. v. iron therapy
52,*,OR T34 T28 T27 T29
53,*,OR T32 T30
54,T35,"Scope 441 506	erythropoietin, i. v. or oral iron therapy, and blood transfusion"
55,T36,Scope 507 580	in previous 12 weeks and/or such therapy planned within the next 6 months
56,R14,Has_scope Arg1:T35 Arg2:T36
57,T37,Condition 583 607	Unstable angina pectoris
58,T38,Qualifier 639 661	clinically significant
59,T39,Condition 674 690	valvular disease
60,T40,Condition 694 730	left ventricular outflow obstruction
61,T41,Condition 732 758	obstructive cardiomyopathy
62,T42,Qualifier 760 777	poorly controlled
63,T43,Condition 778 802	fast atrial fibrillation
64,T44,Condition 778 789;806 813	fast atrial flutter
65,T45,Qualifier 815 832	poorly controlled
66,T46,Qualifier 833 844	symptomatic
67,T47,Condition 855 871	tachyarrhythmias
68,T48,Condition 845 851	brady-
69,*,OR T48 T47
70,T49,Scope 845 871	brady- or tachyarrhythmias
71,R15,Has_qualifier Arg1:T49 Arg2:T46
72,R16,Has_qualifier Arg1:T49 Arg2:T45
73,*,OR T44 T43
74,T50,Scope 778 813	fast atrial fibrillation or flutter
75,R17,Has_qualifier Arg1:T50 Arg2:T42
76,*,OR T40 T39 T50 T49 T41
77,T51,Condition 874 901	Acute myocardial infarction
78,T52,Condition 905 928	acute coronary syndrome
79,T53,Condition 930 955	transient ischemic attack
80,T54,Condition 959 965	stroke
81,T55,Temporal 966 990	within the last 3 months
82,T56,Reference_point 973 990	the last 3 months
83,R18,Has_index Arg1:T55 Arg2:T56
84,*,OR T54 T53 T52 T51
85,T57,"Scope 874 965	Acute myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke"
86,R19,Has_temporal Arg1:T57 Arg2:T55
87,T58,Procedure 993 1021	Coronary-artery bypass graft
88,T59,Procedure 1023 1048	percutaneous intervention
89,T60,Procedure 1126 1139	major surgery
90,T61,Procedure 1164 1179	cardiac surgery
91,T62,Procedure 1151 1159;1172 1179	thoracic surgery
92,T63,Temporal 1181 1205	within the last 3 months
93,T64,Reference_point 1188 1205	the last 3 months
94,R20,Has_index Arg1:T63 Arg2:T64
95,*,OR T62 T61
96,*,OR T58 T59 T60
97,T65,Scope 1151 1179	thoracic and cardiac surgery
98,R21,Has_temporal Arg1:T65 Arg2:T63
99,R22,Subsumes Arg1:T60 Arg2:T65
100,T66,Non-query-able 1208 1248	Participation in a CHF training program.
101,T67,Condition 1250 1259	Known HIV
102,T68,Condition 1260 1264	AIDS
103,T69,Post-eligibility 1267 1358	Inability to fully comprehend and/or perform study procedures in the investigator's opinion
104,T70,Condition 1361 1372;1393 1403	Vitamin B12 deficiency
105,T71,Condition 1380 1403	serum folate deficiency
106,*,OR T71 T70
107,T72,Condition 1501 1510	lactation
108,T73,Condition 1488 1497	Pregnancy
109,*,OR T72 T73
110,T74,Procedure 1647 1662	Anticoagulation
111,T75,Post-eligibility 1513 1645	Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study.
0,T1,Qualifier 0 12	Asymptomatic
1,T2,Person 13 18	women
2,T3,Value 19 30	45-68 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Visit 49 64	Piedmont Region
5,T5,Procedure 80 120	regional breast cancer screening program
0,T1,Person 0 3	Age
1,T2,"Value 4 27	>= 65 years, < 90 years"
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Mood 30 39	Scheduled
4,T4,Procedure 51 58	surgery
5,T5,Qualifier 63 70	primary
6,T6,Condition 71 89	solid organ cancer
7,R2,Has_qualifier Arg1:T6 Arg2:T5
8,T7,Procedure 96 114	general anesthesia
9,R3,AND Arg1:T4 Arg2:T6
10,R4,AND Arg1:T4 Arg2:T7
11,T8,Non-representable 116 163	with an expected duration of surgery >=2 hours;
12,R5,Has_mood Arg1:T4 Arg2:T3
13,T9,Qualifier 180 198	patient-controlled
14,T10,Procedure 199 220	intravenous analgesia
15,T11,Temporal 221 234	after surgery
16,R6,Has_qualifier Arg1:T10 Arg2:T9
17,R7,Has_temporal Arg1:T10 Arg2:T11
18,T12,Procedure 227 234	surgery
19,T13,Reference_point 227 234	surgery
20,R8,Has_index Arg1:T11 Arg2:T13
21,R9,multi Arg1:T13 Arg2:T12
22,T14,Post-eligibility 237 269	Provide written informed consent
0,T1,Condition 20 33	breast cancer
1,T2,Observation 0 16	Personal history
2,T3,Condition 37 53	terminal illness
3,T4,Observation 72 103	unable to give informed consent
4,T5,Device 105 120	Breast implants
0,T1,Condition 24 37	schizophrenia
1,T2,Condition 39 47	epilepsy
2,T3,Condition 49 61	parkinsonism
3,T4,Condition 65 82	myasthenia gravis
4,T5,Observation 13 20	history
5,T6,Temporal 0 12	Preoperative
6,R1,Has_temporal Arg1:T5 Arg2:T6
7,*,OR T1 T2 T3 T4
8,T7,"Scope 24 82	schizophrenia, epilepsy, parkinsonism or myasthenia gravis"
9,R2,Has_temporal Arg1:T7 Arg2:T5
10,T8,Procedure 108 120	chemotherapy
11,T9,Procedure 113 120;98 103	therapy radio
12,*,OR T9 T8
13,T10,Temporal 85 97	Preoperative
14,T11,Scope 98 120	radio- or chemotherapy
15,R3,Has_temporal Arg1:T11 Arg2:T10
16,T12,Condition 186 190	coma
17,T13,Condition 201 209	dementia
18,T14,Qualifier 192 200	profound
19,T15,Observation 213 229	language barrier
20,T16,Temporal 155 174	preoperative period
21,T17,Condition 123 147	Inability to communicate
22,R4,Has_temporal Arg1:T17 Arg2:T16
23,R5,Has_qualifier Arg1:T13 Arg2:T14
24,*,OR T12 T13 T15
25,T18,"Scope 186 229	coma, profound dementia or language barrier"
26,R6,Has_scope Arg1:T17 Arg2:T18
27,T19,Condition 245 268	obstructive sleep apnea
28,T20,Temporal 232 244	Preoperative
29,R7,Has_temporal Arg1:T19 Arg2:T20
30,T21,Condition 294 317	obstructive sleep apnea
31,T22,Measurement 324 339	STOP-Bang score
32,T23,Value 340 344	>= 3
33,R8,Has_value Arg1:T22 Arg2:T23
34,*,OR T21 T22
35,T24,"Scope 294 344	obstructive sleep apnea, or a STOP-Bang score >= 3"
36,T25,Scope 232 268	Preoperative obstructive sleep apnea
37,R9,Subsumes Arg1:T25 Arg2:T24
38,T26,Condition 348 360	Brain trauma
39,T27,Procedure 364 376	neurosurgery
40,*,OR T27 T26
41,T28,Measurement 392 426	left ventricular ejection fraction
42,T29,Value 427 432	< 30%
43,R10,Has_value Arg1:T28 Arg2:T29
44,T30,Temporal 379 391	Preoperative
45,R11,Has_temporal Arg1:T28 Arg2:T30
46,T31,Condition 434 453	sick sinus syndrome
47,T32,Qualifier 455 461	severe
48,T33,Condition 462 479	sinus bradycardia
49,T34,Value 481 502	< 50 beats per minute
50,R12,Has_value Arg1:T33 Arg2:T34
51,R13,Has_qualifier Arg1:T33 Arg2:T32
52,*,OR T31 T28 T33 T35
53,T35,Condition 531 553	atrioventricular block
54,T36,Negation 554 561	without
55,T37,Device 562 571	pacemaker
56,R14,Has_negation Arg1:T37 Arg2:T36
57,R15,AND Arg1:T35 Arg2:T37
58,T38,Qualifier 508 530	second-degree or above
59,R16,Has_qualifier Arg1:T35 Arg2:T38
60,T39,Qualifier 574 580	Severe
61,T40,Condition 581 600	hepatic dysfunction
62,T41,Measurement 602 612	Child-Pugh
63,T42,Value 613 620	class C
64,R17,Has_value Arg1:T41 Arg2:T42
65,R18,Has_qualifier Arg1:T40 Arg2:T39
66,T43,Scope 574 600	Severe hepatic dysfunction
67,T44,Scope 602 620	Child-Pugh class C
68,R19,Subsumes Arg1:T43 Arg2:T44
69,T45,Qualifier 625 631	severe
70,T46,Condition 632 649	renal dysfunction
71,R20,Has_qualifier Arg1:T46 Arg2:T45
72,T47,Procedure 666 691	renal replacement therapy
73,T48,Temporal 692 706	before surgery
74,T49,Reference_point 699 706	surgery
75,T50,Procedure 699 706	surgery
76,R21,Has_index Arg1:T48 Arg2:T49
77,R22,multi Arg1:T49 Arg2:T50
78,R23,Has_temporal Arg1:T47 Arg2:T48
79,T51,Scope 625 649	severe renal dysfunction
80,T52,Scope 666 706	renal replacement therapy before surgery
81,R24,Subsumes Arg1:T51 Arg2:T52
82,T53,Measurement 710 728	ASA classification
83,T54,Value 729 734	>= IV
84,R25,Has_value Arg1:T53 Arg2:T54
0,T1,Qualifier 42 47	other
1,T2,Condition 48 55	disease
2,T3,Condition 24 38;48 55	cardiovascular disease
3,R1,Has_qualifier Arg1:T2 Arg2:T1
4,T4,Condition 11 22;48 55	respiratory disease
5,*,OR T3 T4 T2
6,T5,Qualifier 4 10	active
7,T6,Mood 56 65	requiring
8,T7,Procedure 74 83	treatment
9,R2,Has_mood Arg1:T7 Arg2:T6
10,T8,Mood 103 111;87 92	relevant being
11,T9,Condition 116 125	tolerance
12,T10,Condition 129 136	hypoxia
13,T11,Condition 140 157	altitude exposure
14,*,OR T10 T11
15,T12,Scope 129 157	hypoxia or altitude exposure
16,R3,Has_mood Arg1:T9 Arg2:T8
17,R4,Has_scope Arg1:T9 Arg2:T12
18,T13,"Scope 11 55	respiratory, cardiovascular or other disease"
19,R5,Has_qualifier Arg1:T13 Arg2:T5
20,R6,AND Arg1:T13 Arg2:T7
21,R7,Has_scope Arg1:T13 Arg2:T12
22,T14,Condition 236 249	heavy smoking
23,T15,Measurement 255 273	cigarettes per day
24,T16,Measurement 281 291	pack-years
25,T17,Condition 297 311	active smoking
26,T18,Temporal 312 336	during the last 10 years
27,T19,Value 251 254	>20
28,T20,Value 277 280	>20
29,R8,Has_value Arg1:T15 Arg2:T19
30,R9,Has_value Arg1:T16 Arg2:T20
31,R10,Has_temporal Arg1:T17 Arg2:T18
32,T21,Scope 251 336	>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years
33,R11,Subsumes Arg1:T14 Arg2:T21
34,T22,Condition 339 361	regular use of alcohol
35,*,OR T14 T22
36,T23,Condition 364 371	Allergy
37,T24,Drug 375 388	acetazolamide
38,T25,Drug 399 411	sulfonamides
39,T26,Qualifier 393 398	other
40,R12,Has_qualifier Arg1:T25 Arg2:T26
41,*,OR T24 T25
42,T27,Scope 375 411	acetazolamide and other sulfonamides
43,R13,Has_scope Arg1:T23 Arg2:T27
0,T1,Qualifier 7 12	acute
1,T2,Condition 13 35	deep venous thrombosis
2,T3,Qualifier 0 6	proven
3,R1,Has_qualifier Arg1:T2 Arg2:T1
4,R2,Has_qualifier Arg1:T2 Arg2:T3
5,T4,Multiplier 37 54	less than 21 days
6,R3,Has_multiplier Arg1:T2 Arg2:T4
7,T5,Visit 84 119	interventional radiology department
8,T6,Mood 68 79	referred to
9,R4,Has_mood Arg1:T5 Arg2:T6
0,T1,Condition 0 9	Psoriasis
1,T3,Condition 13 34	psoriasis arthropathy
2,*,OR T1 T3
3,T2,Condition 36 62	Inflammatory bowel disease
4,T4,Informed_consent 64 139	Unwillingness to participate in the study with additional imaging protocols
5,T5,Observation 141 159	Expected life-span
6,T6,Value 160 177	less than <1 year
7,R1,Has_value Arg1:T5 Arg2:T6
8,T7,Condition 179 187	Diabetes
9,T8,Procedure 204 223	PET imaging quality
10,T9,Qualifier 226 234	Probable
11,T10,Condition 235 248	noncompliance
12,R2,Has_qualifier Arg1:T10 Arg2:T9
13,T11,Condition 250 259	Pregnancy
14,T12,Person 261 264	Age
15,T13,Value 265 274	<18 years
16,T14,Value 278 287	>75 years
17,*,OR T13 T14
18,T15,Scope 265 287	<18 years or >75 years
19,R3,Has_scope Arg1:T12 Arg2:T15
20,T16,Condition 289 305	Contraindication
21,T17,Drug 310 320	adalimumab
22,R4,AND Arg1:T16 Arg2:T17
23,T18,Drug 322 334	Methotrexate
24,T19,Temporal 340 368	within the previous 6 months
25,R5,Has_temporal Arg1:T18 Arg2:T19
26,T20,Drug 372 389	biologic medicine
27,T21,Temporal 395 423	within the previous 6 months
28,R6,Has_temporal Arg1:T20 Arg2:T21
0,T1,Undefined_semantics 18 40	clinically significant
1,T2,Qualifier 18 40	clinically significant
2,T3,Condition 41 70	abnormal physical examination
3,T4,Undefined_semantics 41 70	abnormal physical examination
4,T5,Condition 41 49;72 83	abnormal vital signs
5,T6,Condition 41 49;87 98	abnormal 12 lead ECG
6,*,OR T5 T6 T3
7,T7,Measurement 110 113	QTc
8,T8,Value 114 138	greater than (>) 450msec
9,R2,Has_value Arg1:T7 Arg2:T8
10,T9,Condition 140 164	Left Bundle Branch Block
11,T10,Device 166 185	permanent pacemaker
12,T11,Condition 189 227	implantable cardioverter defibrillator
13,*,OR T11 T10 T9 T7
14,T12,"Scope 110 227	QTc greater than (>) 450msec, Left Bundle Branch Block, permanent pacemaker or implantable cardioverter defibrillator"
15,R3,Subsumes Arg1:T6 Arg2:T12
16,T13,Temporal 229 254	at Screening or admission
17,T14,Reference_point 232 241	Screening
18,T15,Reference_point 245 254	admission
19,*,OR T14 T15
20,T16,Scope 232 254	Screening or admission
21,R4,Has_scope Arg1:T13 Arg2:T16
22,T17,"Scope 41 98	abnormal physical examination, vital signs or 12 lead ECG"
23,R1,Has_qualifier Arg1:T17 Arg2:T2
24,R5,Has_temporal Arg1:T17 Arg2:T13
25,T18,Condition 305 324	renal insufficiency
26,T19,Condition 296 301;311 324	liver insufficiency
27,*,OR T18 T19 T31
28,T20,Observation 274 281	history
29,T21,Condition 453 475	metabolic disturbances
30,T22,Condition 437 448;463 475	psychiatric disturbances
31,T23,Condition 422 435;463 475	rheumatologic disturbances
32,T24,Condition 409 420;463 475	hematologic disturbances
33,T25,Condition 397 407;463 475	neurologic disturbances
34,T26,Condition 386 395;463 475	endocrine disturbances
35,T27,Condition 368 384;463 475	gastrointestinal disturbances
36,T28,Condition 357 366;463 475	pulmonary disturbances
37,T29,Condition 347 355;463 475	vascular disturbances
38,T30,Condition 338 345;463 475	cardiac disturbances
39,T31,"Scope 338 475	cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances"
40,T32,Qualifier 326 337	significant
41,T33,Subjective_judgement 326 337	significant
42,T34,Undefined_semantics 326 337	significant
43,R6,Has_qualifier Arg1:T31 Arg2:T32
44,*,OR T28 T26 T24 T27 T29 T23 T30 T25 T22 T21
45,T35,"Scope 296 475	liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances"
46,R7,Has_temporal Arg1:T35 Arg2:T20
47,T36,Drug 484 500	any prescription
48,T37,Undefined_semantics 484 500	any prescription
49,T38,Drug 504 531	over-the-counter medication
50,T39,Undefined_semantics 504 531	over-the-counter medication
51,T40,Drug 533 550	herbal medication
52,T41,Drug 552 560	vitamins
53,T42,Drug 565 584	mineral supplements
54,T43,Temporal 585 634	within 14 days prior to study drug administration
55,T44,Reference_point 609 634	study drug administration
56,R8,Has_index Arg1:T43 Arg2:T44
57,T45,Drug 650 661	paracetamol
58,T46,Negation 636 639	not
59,R9,Has_negation Arg1:T45 Arg2:T46
60,*,OR T41 T42 T40 T38 T36
61,T47,"Scope 484 584	any prescription or over-the-counter medication, herbal medication, vitamins, or mineral supplements"
62,R10,AND Arg1:T47 Arg2:T45
63,R11,Has_temporal Arg1:T47 Arg2:T43
64,T48,Drug 664 674	Medication
65,T49,Condition 694 713	age related disease
66,T50,Undefined_semantics 694 713	age related disease
67,T51,Multiplier 679 690	chronic use
68,R12,Has_multiplier Arg1:T48 Arg2:T51
69,R13,AND Arg1:T48 Arg2:T49
70,T52,Undefined_semantics 664 674	Medication
71,T53,Grammar_Error 714 729	will be allowed
72,T54,Subjective_judgement 736 788	approval by both the investigator and to the sponsor
73,T55,"Not_a_criteria 790 913	No change in dose or regimen will be permitted during the study that is, from the Screening visit until the follow-up visit"
74,T56,Condition 977 985	bleeding
75,T57,Qualifier 989 1003	unclear origin
76,T58,Qualifier 970 976	severe
77,T59,Qualifier 957 966	prolonged
78,T60,Qualifier 944 955	spontaneous
79,T61,Observation 933 940	history
80,R14,Has_qualifier Arg1:T56 Arg2:T57
81,*,OR T58 T59 T60
82,T62,"Scope 944 976	spontaneous, prolonged or severe"
83,R15,Has_scope Arg1:T56 Arg2:T62
84,T63,Undefined_semantics 977 985	bleeding
85,R16,Has_temporal Arg1:T56 Arg2:T61
86,T64,Condition 1034 1042	epilepsy
87,T65,Condition 1046 1050	fits
88,T66,Condition 1066 1076	black-outs
89,T67,Qualifier 1054 1065	unexplained
90,R17,Has_qualifier Arg1:T66 Arg2:T67
91,T68,Condition 1088 1106	vasovagal collapse
92,T69,Negation 1077 1087	other than
93,R18,Has_negation Arg1:T68 Arg2:T69
94,R19,AND Arg1:T66 Arg2:T68
95,*,OR T66 T65 T64
96,T70,Observation 1023 1030	history
97,T71,Scope 1034 1106	epilepsy or fits or unexplained black-outs other than vasovagal collapse
98,R20,Has_temporal Arg1:T71 Arg2:T70
0,T1,Condition 0 8	tinnitus
1,T2,Condition 12 24	hearing loss
2,T3,Condition 44 51	vertigo
3,*,OR T1 T2
4,T4,Condition 73 85	peptic ulcer
5,T5,Condition 64 72	bleeding
6,R1,AND Arg1:T5 Arg2:T4
7,T6,Condition 87 95	glaucoma
8,T7,Pregnancy_considerations 97 182	pregnancy or non-acceptance to use anticonception measures during 13 days after debut
9,T8,Measurement 189 203;209 217	blood pressure systolic
10,T9,Measurement 189 203;224 233	blood pressure diastolic
11,T10,Value 204 208	>180
12,T11,Value 219 222	105
13,R2,Has_value Arg1:T9 Arg2:T11
14,R3,Has_value Arg1:T8 Arg2:T10
15,T12,Condition 235 247	ketoacidosis
16,T13,Measurement 255 266	Base Excess
17,T14,Value 267 270	>=2
18,R4,AND Arg1:T12 Arg2:T13
19,R5,Has_value Arg1:T13 Arg2:T14
20,T15,Condition 272 288	psychic disorder
21,T16,Negation 290 293	not
22,T17,Condition 304 319	mild depression
23,R6,Has_negation Arg1:T17 Arg2:T16
24,T18,Condition 330 339	infection
25,T19,Qualifier 322 329	serious
26,R7,Has_qualifier Arg1:T18 Arg2:T19
27,T20,Condition 341 352	neutropenia
28,T21,Condition 354 366	tuberculosis
29,*,OR T20 T21
30,T22,"Scope 341 367	neutropenia, tuberculosis)"
31,R8,Subsumes Arg1:T18 Arg2:T22
32,T23,Condition 369 383	chronic otitis
33,T24,Condition 396 415	vertiginous disease
34,T25,Condition 417 424	Ménière
35,T26,Condition 426 446	Vertiginous migraine
36,T27,Condition 448 461	atypical BPPV
37,*,OR T24 T25 T26 T27
0,T1,Qualifier 12 20	subacute
1,T2,Qualifier 24 31	chronic
2,T3,Condition 32 35	DVT
3,*,OR T2 T1
4,T4,Scope 12 31	subacute or chronic
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Multiplier 36 65	more than 21 days in duration
7,R2,Has_multiplier Arg1:T3 Arg2:T5
8,T6,Condition 67 105	inability to lie in the prone position
9,T7,Non-representable 106 131	required for intervention
10,T8,Condition 133 158	terminal systemic disease
11,T9,Procedure 169 189	palliative treatment
12,T10,Mood 159 168	requiring
13,R3,Has_mood Arg1:T9 Arg2:T10
14,R4,AND Arg1:T8 Arg2:T9
15,T11,Qualifier 191 197	active
16,T12,Condition 198 206	bleeding
17,R5,Has_qualifier Arg1:T12 Arg2:T11
18,T13,Condition 223 237	duodenal ulcer
19,T14,Condition 215 222;232 237	gastric ulcer
20,T15,Qualifier 245 267	cerebrovascular system
21,*,OR T13 T14 T15
22,T16,Scope 215 267	gastric/duodenal ulcer or the cerebrovascular system
23,R6,Has_scope Arg1:T12 Arg2:T16
24,T17,Condition 272 291	haemorrhagic stroke
25,T18,Temporal 292 316	within the previous year
26,T19,Condition 321 355	impaired bleeding-clotting profile
27,T20,Condition 365 385	haemophilic disorder
28,T21,Condition 390 399	pregnancy
29,*,OR T20 T21 T19 T17 T12 T8 T6 T3
30,R7,Has_temporal Arg1:T17 Arg2:T18
0,T1,Observation 0 7	Healthy
1,T2,Person 8 11	men
2,T3,Person 16 21	women
3,T4,Person 23 26	age
4,T5,Value 27 36	40-75 yrs
5,R1,Has_value Arg1:T4 Arg2:T5
6,T6,Negation 38 45	without
7,T7,Condition 46 57	any disease
8,T8,Mood 62 69	need of
9,T9,Drug 70 80	medication
10,R2,Has_mood Arg1:T9 Arg2:T8
11,*,OR T7 T9
12,T10,Scope 46 80	any disease and need of medication
13,R3,Has_negation Arg1:T10 Arg2:T6
14,*,OR T2 T3
15,T11,Observation 110 132	living at low altitude
16,T12,Observation 110 119;134 139	living at <800m
17,R4,Subsumes Arg1:T11 Arg2:T12
18,T13,Informed_consent 143 168	Written informed consent.
19,T14,Person 170 186	Kyrgyz ethnicity
0,T1,Condition 0 23	Axial spondyloarthritis
1,T2,Qualifier 25 38	ASAS criteria
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Procedure 44 54	radiologic
4,T4,Condition 55 67	sacroiliitis
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Procedure 90 93	MRI
7,T6,Procedure 97 102	X-ray
8,*,OR T5 T6
9,T7,Scope 90 102	MRI or X-ray
10,R3,Has_scope Arg1:T4 Arg2:T7
0,T1,Measurement 0 15	Body mass index
1,T2,Value 75 99	between 18 and 30 kg/m^2
2,T3,Measurement 17 20	BMI
3,T4,Measurement 22 73	weight [kilogram(kg)]/height^2 [meter square (m^2)]
4,R1,Subsumes Arg1:T1 Arg2:T3
5,R2,Subsumes Arg1:T1 Arg2:T4
6,R3,Has_value Arg1:T1 Arg2:T2
7,T5,Not_a_criteria 17 73	BMI; weight [kilogram(kg)]/height^2 [meter square (m^2)]
8,T6,Procedure 188 208	physical examination
9,T7,Observation 210 225	medical history
10,T8,Measurement 227 238	vital signs
11,T9,Scope 244 275	12-lead electrocardiogram (ECG)
12,T10,Temporal 276 311	performed at Screening or admission
13,T11,Reference_point 289 298	Screening
14,T12,Reference_point 302 311	admission
15,*,OR T12 T11
16,T13,Scope 289 311	Screening or admission
17,R4,Has_scope Arg1:T10 Arg2:T13
18,T14,"Scope 188 275	physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG)"
19,R5,Has_scope Arg1:T14 Arg2:T13
20,T15,Condition 319 336	deviations in ECG
21,T16,Procedure 333 336	ECG
22,T17,Subjective_judgement 338 413	which are not considered to be of clinical significance to the investigator
23,T18,Grammar_Error 415 429	are acceptable
24,T19,Qualifier 338 413	which are not considered to be of clinical significance to the investigator
25,R6,Has_qualifier Arg1:T15 Arg2:T19
26,R7,AND Arg1:T15 Arg2:T16
27,T20,Procedure 458 483	clinical laboratory tests
28,T21,Temporal 484 506	performed at Screening
29,T22,Reference_point 494 506	at Screening
30,R8,Has_index Arg1:T21 Arg2:T22
31,R9,Has_temporal Arg1:T20 Arg2:T21
32,T23,Undefined_semantics 458 483	clinical laboratory tests
33,T24,Condition 434 441	healthy
34,R10,AND Arg1:T24 Arg2:T20
35,T25,Measurement 530 551	serum chemistry panel
36,T26,Measurement 563 576	liver enzymes
37,T27,Measurement 579 589	hematology
38,T28,Procedure 594 604	urinalysis
39,T29,Value 609 643	outside the normal reference range
40,*,OR T28 T27 T26 T25
41,T30,"Scope 530 604	serum chemistry panel [including liver enzymes], hematology, or urinalysis"
42,R11,Has_value Arg1:T30 Arg2:T29
43,T31,Subjective_judgement 686 709	the investigator judges
44,T32,Subjective_judgement 760 786	not clinically significant
45,T33,Not_a_criteria 788 895	This determination must be recorded in the participants' source documents and initialed by the investigator
46,T34,"Non-query-able 897 1353	Men who are sexually active with a woman of childbearing potential and have not had a vasectomy must agree to use a barrier method of birth control for example, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug."
47,T35,"Parsing_Error 1354 1474	In addition, their female partners should also use an appropriate method of birth control for at least the same duration"
48,T36,"Non-query-able 1354 1474	In addition, their female partners should also use an appropriate method of birth control for at least the same duration"
49,T37,Post-eligibility 1476 1664	Participants' must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
50,T38,Non-query-able 1476 1664	Participants' must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
0,T1,Condition 20 34	vestibulopathy
1,T2,Qualifier 9 19	unilateral
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Negation 36 38	no
4,T4,Condition 52 57	HINTS
5,T5,Qualifier 39 51	pathological
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,R3,Has_negation Arg1:T4 Arg2:T3
8,T6,Condition 83 108	acute vestibular syndrome
9,T7,Post-eligibility 111 148	capable of making their own decisions
0,T1,Drug 11 50	anti-vascular endothelial growth factor
1,T2,Temporal 61 82	in the past 12 months
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 88 110	diabetic macular edema
4,T4,Procedure 111 120	treatment
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Temporal 121 141	in the past 4 months
7,R3,Has_temporal Arg1:T4 Arg2:T5
8,T6,Condition 143 155	Heart attack
9,T7,Condition 157 163	stroke
10,T8,Condition 165 190	transient ischemic attack
11,T9,Condition 194 224	acute congestive heart failure
12,T10,Temporal 225 240	within 4 months
13,R4,Has_temporal Arg1:T9 Arg2:T10
14,*,OR T8 T9 T7 T6
0,T1,Post-eligibility 0 132	Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance).
1,T2,Person 134 137	Age
2,T3,Value 138 142	= 17
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 145 152	Allergy
5,T5,Drug 156 171	povidone iodine
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Procedure 198 209	antibiotics
8,T7,Temporal 210 247	14 days prior to arriving for surgery
9,T8,Reference_point 227 247	arriving for surgery
10,T9,Procedure 240 247	surgery
11,R3,multi Arg1:T8 Arg2:T9
12,R4,Has_index Arg1:T7 Arg2:T8
13,R5,Has_temporal Arg1:T6 Arg2:T7
14,T10,Condition 272 289	immunosuppression
15,T11,Qualifier 264 271	chronic
16,R6,Has_qualifier Arg1:T10 Arg2:T11
17,T12,Condition 299 307	HIV/AIDS
18,R7,Subsumes Arg1:T10 Arg2:T12
19,T13,Post-eligibility 311 364	Unable to adhere to follow up schedule and treatment.
20,T14,Procedure 396 428	revision total knee arthroplasty
21,T15,Condition 433 451	infectious reasons
22,R8,AND Arg1:T14 Arg2:T15
0,T1,Person 0 3	Age
1,T2,Value 4 21	19 years of older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 23 31	Moderate
4,T4,Qualifier 35 41	severe
5,T5,Condition 42 54	claudication
6,*,OR T4 T3
7,T6,Measurement 56 75	Rutherford category
8,T7,Value 76 82	2 or 3
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Scope 23 41	Moderate or severe
11,R3,Subsumes Arg1:T8 Arg2:T6
12,R4,Has_scope Arg1:T5 Arg2:T8
13,T9,Qualifier 85 93	Critical
14,T10,Condition 94 107	limb ischemia
15,R5,Has_qualifier Arg1:T10 Arg2:T9
16,T11,Measurement 109 128	Rutherford category
17,T12,Value 129 135	4 or 5
18,R6,Has_value Arg1:T11 Arg2:T12
19,R7,Subsumes Arg1:T9 Arg2:T11
20,T13,Non-query-able 138 175	Patients with signed informed consent
21,T14,Condition 177 190	Target lesion
22,T15,Measurement 191 197	length
23,T16,Value 198 205	=150 mm
24,T17,Procedure 209 221	angiographic
25,R8,Has_value Arg1:T15 Arg2:T16
26,R9,AND Arg1:T16 Arg2:T17
27,R10,AND Arg1:T14 Arg2:T15
28,T18,Condition 234 242	Stenosis
29,T19,Value 246 259	more than 50%
30,T20,Qualifier 263 285	femoropopliteal artery
31,R11,Has_value Arg1:T18 Arg2:T19
32,R12,Has_qualifier Arg1:T18 Arg2:T20
33,T21,Multiplier 287 299	At least one
34,T22,Condition 300 306;339 366	patent tibioperoneal runoff vessel
35,R13,Has_multiplier Arg1:T22 Arg2:T21
0,T1,Condition 13 30	diabetes mellitus
1,T2,Measurement 32 60	Best corrected visual acuity
2,T3,Value 61 75	20/32 - 20/320
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 77 99	Diabetic macular edema
5,T5,Qualifier 114 134	center of the macula
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Measurement 136 191	Optical coherence tomography central subfield thickness
8,T7,Value 195 215	at least 250 microns
9,R3,Has_value Arg1:T6 Arg2:T7
0,T1,Temporal 0 5	Acute
1,T2,Qualifier 6 14	critical
2,T3,Condition 15 28	limb ischemia
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,R2,Has_temporal Arg1:T3 Arg2:T1
5,T4,Qualifier 30 36	Severe
6,T5,Qualifier 37 45	critical
7,T6,Condition 46 59	limb ischemia
8,T7,Measurement 61 80	Rutherford category
9,T8,Value 81 82	6
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Scope 30 45	Severe critical
12,R4,Has_scope Arg1:T6 Arg2:T9
13,R5,Subsumes Arg1:T9 Arg2:T7
14,T10,Condition 85 107	Major bleeding history
15,T11,Temporal 108 129	within prior 2 months
16,R6,Has_temporal Arg1:T10 Arg2:T11
17,T12,Condition 137 153	hypersensitivity
18,T13,Condition 157 173	contraindication
19,*,OR T13 T12
20,T14,Drug 211 218	heparin
21,T15,Drug 220 227	aspirin
22,T16,Drug 229 240	clopidogrel
23,T17,Drug 244 259	contrast agents
24,*,OR T17 T16 T15 T14
25,T18,"Scope 211 259	heparin, aspirin, clopidogrel or contrast agents"
26,T19,Scope 137 173	hypersensitivity or contraindication
27,R7,Subsumes Arg1:T19 Arg2:T18
28,T20,Person 261 264	Age
29,T21,Value 265 275	> 85 years
30,R8,Has_value Arg1:T20 Arg2:T21
31,T22,Qualifier 277 283	Severe
32,T23,Condition 284 303	hepatic dysfunction
33,R9,Has_qualifier Arg1:T23 Arg2:T22
34,T24,Non-representable 304 339	(> 3 times normal reference values)
35,T25,Qualifier 341 352	Significant
36,T26,Condition 353 370	renal dysfunction
37,R10,Has_qualifier Arg1:T26 Arg2:T25
38,T27,Measurement 372 388	Serum creatinine
39,T28,Value 389 400	> 2.0 mg/dl
40,R11,Has_value Arg1:T27 Arg2:T28
41,R12,Subsumes Arg1:T25 Arg2:T27
42,T29,Condition 414 424	leucopenia
43,T30,Condition 426 437	neutropenia
44,T31,Condition 439 455	thrombocytopenia
45,T32,Condition 457 463	anemia
46,T33,Condition 474 492	bleeding diathesis
47,T34,Qualifier 402 413	Significant
48,*,OR T29 T30 T31 T32 T33
49,T35,"Scope 414 492	leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis"
50,R13,Has_qualifier Arg1:T35 Arg2:T34
51,T36,Measurement 494 498	LVEF
52,T37,Value 499 503	<40%
53,R14,Has_value Arg1:T36 Arg2:T37
54,T38,Qualifier 507 523	clinically overt
55,T39,Condition 524 548	congestive heart failure
56,R15,Has_qualifier Arg1:T39 Arg2:T38
57,*,OR T39 T36
58,T40,Condition 550 558	Pregnant
59,T41,Person 568 573	women
60,T42,Person 559 564	women
61,T43,Condition 579 601	potential childbearing
62,*,OR T40 T43
63,*,OR T41 T42
64,T44,Observation 603 618	Life expectancy
65,T45,Value 619 626	<1 year
66,R16,Has_value Arg1:T44 Arg2:T45
67,T46,Condition 634 645	comorbidity
68,R17,AND Arg1:T44 Arg2:T46
69,T47,Procedure 656 670	bypass surgery
70,T48,Temporal 647 655	Previous
71,T49,Device 674 716	stenting of the superficial femoral artery
72,*,OR T47 T49
73,R18,Has_temporal Arg1:T47 Arg2:T48
74,R19,Has_temporal Arg1:T49 Arg2:T48
75,T50,Qualifier 718 727	Untreated
76,T51,Condition 728 742	inflow disease
77,T52,Qualifier 750 777	ipsilateral pelvic arteries
78,R20,Has_qualifier Arg1:T51 Arg2:T50
79,R21,Has_qualifier Arg1:T51 Arg2:T52
80,T53,Value 779 792	more than 50%
81,T54,Condition 792 800	stenosis
82,T55,Value 807 816	occlusion
83,*,OR T55 T53
84,T56,Scope 779 792;804 816	more than 50% or occlusion
85,R22,Has_scope Arg1:T54 Arg2:T56
86,R23,AND Arg1:T51 Arg2:T54
87,T57,Condition 818 843	Popliteal artery stenosis
88,T58,Value 844 848	>50%
89,T59,Qualifier 852 868	P2 or P3 segment
90,R24,Has_value Arg1:T57 Arg2:T58
91,R25,Has_qualifier Arg1:T57 Arg2:T59
0,T1,Procedure 21 53	revision total knee arthroplasty
0,T1,Mood 0 8	Need for
1,T2,Procedure 9 39	long-term oral anticoagulation
2,R1,Has_mood Arg1:T2 Arg2:T1
3,T3,Device 42 60	Drug-eluting stent
4,T4,Procedure 61 73	implantation
5,T5,Temporal 74 113	within 3 months prior to TAVI procedure
6,T6,Reference_point 99 113	TAVI procedure
7,T7,Procedure 99 113	TAVI procedure
8,R2,multi Arg1:T6 Arg2:T7
9,R4,AND Arg1:T4 Arg2:T3
10,R5,Has_temporal Arg1:T4 Arg2:T5
11,T8,Device 116 132	Bare-metal stent
12,T9,Procedure 133 145	implantation
13,T10,Temporal 146 184	within 1 month prior to TAVI procedure
14,T11,Procedure 170 184	TAVI procedure
15,T12,Reference_point 170 184	TAVI procedure
16,R6,multi Arg1:T11 Arg2:T12
17,R7,AND Arg1:T10 Arg2:T11
18,R8,AND Arg1:T9 Arg2:T8
19,R9,Has_temporal Arg1:T9 Arg2:T10
20,T13,Condition 187 194	Allergy
21,T14,Condition 198 209	intolerance
22,T15,Drug 213 220	aspirin
23,T16,Drug 224 235	clopidogrel
24,*,OR T15 T16
25,*,OR T13 T14
26,T17,Scope 187 209	Allergy or intolerance
27,T18,Scope 213 235	aspirin or clopidogrel
28,R10,Has_scope Arg1:T17 Arg2:T18
29,T19,Device 238 256	Drug-eluting stent
30,T20,Procedure 257 269	implantation
31,T21,Temporal 270 309	within 3 months prior to TAVI procedure
32,T22,Reference_point 295 309	TAVI procedure
33,T23,Procedure 295 309	TAVI procedure
34,R11,multi Arg1:T22 Arg2:T23
35,R12,Has_index Arg1:T21 Arg2:T22
36,R13,AND Arg1:T20 Arg2:T19
37,R14,Has_temporal Arg1:T20 Arg2:T21
38,T24,Device 312 328	Bare-metal stent
39,T25,Procedure 329 341	implantation
40,T26,Temporal 342 380	within 1 month prior to TAVI procedure
41,T27,Reference_point 366 380	TAVI procedure
42,T28,Procedure 366 380	TAVI procedure
43,R15,Has_index Arg1:T26 Arg2:T27
44,R16,AND Arg1:T25 Arg2:T24
45,R17,Has_temporal Arg1:T25 Arg2:T26
46,T29,Condition 383 390	Allergy
47,T30,Condition 394 405	intolerance
48,T31,Drug 409 415	(N)OAC
49,T32,Drug 419 430	clopidogrel
50,*,OR T32 T31
51,*,OR T29 T30
52,T33,Scope 383 405	Allergy or intolerance
53,T34,Scope 409 430	(N)OAC or clopidogrel
54,R18,Has_scope Arg1:T33 Arg2:T34
55,R3,Has_index Arg1:T5 Arg2:T6
56,R19,multi Arg1:T27 Arg2:T28
0,T1,Condition 0 12	Osteoporosis
0,T1,Informed_consent 0 34	Inability to give informed consent
1,T2,Condition 45 54	pregnancy
2,T3,Mood 36 44	Possible
3,R1,Has_mood Arg1:T2 Arg2:T3
4,T4,Procedure 69 79	urine test
5,T5,Value 56 65	confirmed
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,AND Arg1:T2 Arg2:T4
8,T6,Person 82 87	Women
9,T7,Observation 96 109	breastfeeding
10,T8,Qualifier 111 117	Severe
11,T9,Condition 118 132	claustrophobia
12,R4,Has_qualifier Arg1:T9 Arg2:T8
13,T10,Condition 134 155	Inability to lie flat
14,T11,Qualifier 160 173	20-30 minutes
15,R5,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Qualifier 191 235	amount of time to complete the MRI procedure
17,R6,Subsumes Arg1:T11 Arg2:T12
18,T13,Device 255 272	cochlear implants
19,T14,Device 310 324	aneurysm clips
20,T15,Qualifier 295 309	MRI compatible
21,T16,Negation 291 294	non
22,R7,Has_negation Arg1:T15 Arg2:T16
23,R8,Has_qualifier Arg1:T14 Arg2:T15
24,T17,Non-representable 326 380	Potential contraindications to regadenoson use due to:
25,T18,Drug 420 464	Gadolinium (Gd) based contrast agents (GBCA)
26,T19,Condition 382 398	Contraindication
27,R9,AND Arg1:T19 Arg2:T18
0,T1,Person 13 16	age
1,T2,Value 0 9	20-70 yrs
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 18 21;61 82	ASA physical status class
4,T4,Measurement 22 59	American Society of Anesthesiologists
5,T5,Value 83 90	I or II
6,R2,Subsumes Arg1:T3 Arg2:T4
7,R3,Has_value Arg1:T3 Arg2:T5
8,T6,Qualifier 106 119	gynecological
9,T7,Procedure 120 140	laparoscopic surgery
10,T8,Mood 92 101	Scheduled
11,R4,Has_mood Arg1:T7 Arg2:T8
12,R5,Has_qualifier Arg1:T7 Arg2:T6
0,T1,Mood 0 8	Need for
1,T2,Procedure 9 39	long-term oral anticoagulation
2,R1,Has_mood Arg1:T2 Arg2:T1
3,T3,Informed_consent 42 87	Patient has provided written informed consent
0,T1,Qualifier 0 6	Kidney
1,T2,Qualifier 8 19	parathyroid
2,T3,Qualifier 21 31	congenital
3,T4,Qualifier 32 36	bone
4,T5,Qualifier 37 46	metabolic
5,T6,Condition 47 54	disease
6,*,OR T1 T2 T3 T4 T5
7,T7,"Scope 0 46	Kidney, parathyroid, congenital bone metabolic"
8,R1,Has_scope Arg1:T6 Arg2:T7
0,T1,Person 0 4	Aged
1,T2,Value 5 22	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 38 67	invasive coronary angiography
4,T4,Mood 24 33	Scheduled
5,R2,Has_mood Arg1:T3 Arg2:T4
0,T1,Condition 0 8	Allergic
1,T2,Drug 12 23	study drugs
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Drug 25 36	Antiemetics
4,T4,Drug 40 52	steroids use
5,T5,Temporal 53 83	within 24 hrs prior to surgery
6,T6,Reference_point 76 83	surgery
7,T7,Procedure 76 83	surgery
8,R2,multi Arg1:T6 Arg2:T7
9,R3,Has_index Arg1:T5 Arg2:T6
10,*,OR T3 T4
11,T8,Scope 25 52	Antiemetics or steroids use
12,R4,Has_temporal Arg1:T8 Arg2:T5
13,T9,Condition 85 108	Dependence upon opioids
14,T10,Qualifier 110 127	Insulin dependent
15,T11,Drug 110 117	Insulin
16,R5,multi Arg1:T10 Arg2:T11
17,T12,Condition 128 145	Diabetes Mellitus
18,R6,Has_qualifier Arg1:T12 Arg2:T10
19,T13,Condition 147 161;175 182	Cardiovascular disease
20,T14,Condition 165 182	pulmonary disease
21,*,OR T14 T13
22,T15,Condition 184 189;201 214	Renal insufficiency
23,T16,Condition 193 214	hepatic insufficiency
24,*,OR T16 T15
25,T17,Measurement 216 219	BMI
26,T18,Value 219 228	>=35kg/m2
27,R7,Has_value Arg1:T17 Arg2:T18
28,T19,Observation 230 237	History
29,T20,Condition 241 256	motion sickness
30,T21,Condition 260 264	PONV
31,*,OR T20 T21
32,T22,Scope 241 264	motion sickness or PONV
33,R8,Has_temporal Arg1:T22 Arg2:T19
34,T23,Observation 266 282	Cigarette smoker
35,T24,Observation 284 294	Conversion
36,T25,Procedure 298 313	open laparotomy
37,T26,Procedure 319 339	laparoscopic surgery
38,R9,Has_context Arg1:T25 Arg2:T24
39,R10,AND Arg1:T24 Arg2:T26
40,T27,Condition 341 350	Pregnants
0,T1,Value 0 7	Healthy
1,T2,Person 9 13	Male
2,T3,Value 15 17	>7
3,T4,Measurement 18 39	Metabolic Equivalents
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Condition 90 100	Drug abuse
6,T6,Condition 102 115	Alcohol abuse
7,T7,Condition 67 88	Chronic pain syndrome
8,T8,Informed_consent 41 65	Written informed consent
9,T9,Mood 117 126	Suspicion
10,T10,Condition 130 152	neurologic dysfunction
11,T11,Qualifier 156 168	tested sites
12,R2,Has_qualifier Arg1:T10 Arg2:T11
13,R3,Has_mood Arg1:T10 Arg2:T9
14,T12,Temporal 170 177	Ongoing
15,T13,Procedure 178 187	treatment
16,T14,Drug 193 208	antidepressants
17,R4,AND Arg1:T13 Arg2:T14
18,R5,Has_temporal Arg1:T13 Arg2:T12
19,T15,Temporal 210 217	Ongoing
20,T16,Procedure 218 227	treatment
21,T17,Drug 233 243	analgesics
22,R6,AND Arg1:T16 Arg2:T17
23,R7,Has_temporal Arg1:T16 Arg2:T15
24,T18,Procedure 245 257	Pretreatment
25,T19,Drug 267 281	CYP3A inducers
26,T20,Drug 267 272;285 295	CYP3A inhibitors
27,*,OR T19 T20
28,T21,Scope 267 295	CYP3A inducers or inhibitors
29,R8,Has_scope Arg1:T18 Arg2:T21
30,T22,Condition 303 310	allergy
31,T23,Condition 351 371	Obstructive uropathy
32,T24,Drug 314 326	tested drugs
33,R9,AND Arg1:T22 Arg2:T24
34,T25,Condition 328 349	Elevated eye pressure
35,T26,Condition 373 386	Heart disease
36,T27,Condition 388 405	Pulmonary disease
37,T28,Condition 407 427	Neurological disease
38,T29,Condition 429 448	Psychiatric illness
0,T1,Procedure 26 39	deep sedation
1,T2,Visit 43 51	ambulant
2,T3,Procedure 67 78	colonoscopy
3,R1,AND Arg1:T1 Arg2:T2
4,T4,Measurement 80 83	ASA
5,T5,Value 84 87	1-3
6,R2,Has_value Arg1:T4 Arg2:T5
0,T1,Measurement 0 3	mRS
1,T2,Value 3 5	=2
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 19 25	stroke
4,T4,Value 26 41	within 3 months
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 55 78	intracranial hemorrhage
7,T6,Condition 91 114	subarachnoid hemorrhage
8,T7,Condition 117 136	Intracranial tumour
9,T8,Condition 138 159	vascular malformation
10,T9,Condition 163 180	arterial aneurysm
11,*,OR T8 T9 T7
12,T10,Procedure 183 196	Major surgery
13,T11,Value 197 211	within 1 month
14,R3,Has_value Arg1:T10 Arg2:T11
15,T12,Measurement 214 231	Systolic pressure
16,T13,Value 232 241	=180 mmHg
17,T14,Measurement 245 263	diastolic pressure
18,T15,Value 264 273	=110 mmHg
19,R4,Has_value Arg1:T14 Arg2:T15
20,R5,Has_value Arg1:T12 Arg2:T13
21,*,OR T12 T14
22,T16,Measurement 276 290	Platelet count
23,T17,Value 291 300	< 105/mm3
24,R6,Has_value Arg1:T16 Arg2:T17
25,T18,Drug 303 310	Heparin
26,T19,Procedure 311 318	therapy
27,R7,AND Arg1:T19 Arg2:T18
28,T20,Procedure 322 350	oral anticoagulation therapy
29,T21,Temporal 351 366	within 48 hours
30,*,OR T19 T20
31,T22,Scope 303 350	Heparin therapy or oral anticoagulation therapy
32,R8,Has_temporal Arg1:T22 Arg2:T21
33,T23,Value 369 377	Abnormal
34,T24,Measurement 378 382	APTT
35,R9,Has_value Arg1:T24 Arg2:T23
36,T25,Drug 385 393	Thrombin
37,T26,Drug 397 416	Xa factor inhibitor
38,*,OR T26 T25
39,T27,Observation 441 456	life expectancy
40,T28,Value 460 478	less than 3 months
41,R10,Has_value Arg1:T27 Arg2:T28
42,T29,Condition 426 433	disease
43,T30,Qualifier 419 425	Severe
44,R11,Has_qualifier Arg1:T29 Arg2:T30
45,R12,Has_context Arg1:T29 Arg2:T27
46,T31,Measurement 481 494	Blood glucose
47,T32,Value 495 505	< 50 mg/dL
48,T33,Value 507 516	2.7mmol/L
49,R13,Subsumes Arg1:T32 Arg2:T33
50,R14,Has_value Arg1:T31 Arg2:T32
51,T34,Competing_trial 520 604	Patients who have received any other investigational drug or device within 3 months;
52,T35,Condition 606 615	Pregnancy
53,T36,Non-query-able 618 693	Researchers consider patients inappropriate to participate in the registry.
0,T1,Procedure 20 31	fistulotomy
1,T2,Procedure 33 45	fistulectomy
2,T3,Procedure 47 51	LIFT
3,T4,Procedure 53 66	cutting seton
4,T5,Procedure 70 96	advancement flap procedure
5,T6,Condition 98 105	Fistula
6,T7,Qualifier 111 126	multiple tracts
7,R1,Has_qualifier Arg1:T6 Arg2:T7
8,T8,Condition 128 149	Recto-vaginal fistula
9,T9,Condition 175 187	anal fistula
10,T10,Condition 158 187	infection in the anal fistula
11,T11,Non-query-able 189 250	Physical allergies or cultural objections to porcine products
12,T12,Subjective_judgement 252 346	Patient is not medically fit to undergo the LIFT procedure as judged by the treating physician
13,T13,Post-eligibility 252 346	Patient is not medically fit to undergo the LIFT procedure as judged by the treating physician
14,T14,Condition 370 387	collagen disorder
15,T15,Condition 400 415	Crohn's Disease
16,T16,Condition 417 441	Irritable Bowel Syndrome
17,T17,Procedure 443 460	radiation therapy
18,T18,Qualifier 468 484	rectoanal region
19,R2,Has_qualifier Arg1:T17 Arg2:T18
20,*,OR T15 T16 T17
21,T19,Observation 389 396	History
22,T20,"Scope 400 484	Crohn's Disease, Irritable Bowel Syndrome, radiation therapy in the rectoanal region"
23,R3,Has_temporal Arg1:T20 Arg2:T19
0,T1,Measurement 18 35;44 67	1987 ACR criteria with 1996 modifications
1,T2,Condition 40 43	SLE
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Measurement 69 75	SLEDAI
4,T4,Value 76 81	>/= 6
5,T5,Temporal 82 100	at screening visit
6,T6,Reference_point 85 100	screening visit
7,R2,Has_index Arg1:T5 Arg2:T6
8,R3,Has_value Arg1:T3 Arg2:T4
9,R4,Has_temporal Arg1:T3 Arg2:T5
10,T7,Measurement 111 114	ANA
11,T8,Value 102 110	Positive
12,T9,Measurement 118 128	anti-dsDNA
13,T10,Temporal 129 157	within one year of screening
14,T11,Reference_point 148 157	screening
15,R5,Has_index Arg1:T10 Arg2:T11
16,R6,Has_value Arg1:T7 Arg2:T8
17,R7,Has_value Arg1:T9 Arg2:T8
18,*,OR T9 T7
19,R8,Has_temporal Arg1:T9 Arg2:T10
20,R9,Has_temporal Arg1:T7 Arg2:T10
21,T12,Subjective_judgement 159 329	In the opinion of the investigator there is intent to treat with a biologic (e.g. patient failed standard of care treatment) however there is no organ threatening disease
0,T1,Person 12 15	old
1,T2,Value 0 15	18-80 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 31 68	posterior circulation ischemic stroke
4,T4,Observation 71 99	Time from onset to treatment
5,T5,Value 100 108	=6 hours
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 111 116	NIHSS
8,T7,Value 118 122	4-25
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Informed_consent 125 203	Signed informed consent by patient self or legally authorized representatives.
0,T1,Condition 0 8	Dementia
1,T2,Procedure 11 22	Gastroscopy
2,T3,Mood 23 30	planned
3,T4,Temporal 31 47	at the same time
4,R1,Has_mood Arg1:T2 Arg2:T3
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,T5,Condition 50 59	Allergies
7,T6,Drug 63 71	propofol
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Non-representable 73 135	All cases were a 'full stomach' is suspected (gastric banding)
10,T8,Condition 137 146	Pregnancy
0,T1,Parsing_Error 0 2	NA
0,T1,Condition 32 62	trans-sphincteric anal fistula
1,T2,Multiplier 22 31	recurrent
2,T3,Multiplier 11 18	primary
3,*,OR T2 T3
4,T4,Scope 11 31	primary or recurrent
5,R1,Has_scope Arg1:T1 Arg2:T4
0,T1,Condition 0 15	Type 2 Diabetes
1,T2,Condition 17 29	Hypertension
2,T3,Measurement 31 74	Estimated glomerular filtration rate (eGFR)
3,T4,Value 75 86	> 30 ml/min
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Drug 95 102	Ace Inh
6,T6,Drug 107 110	ARB
7,T7,Procedure 115 140	control of blood pressure
8,*,OR T5 T6
9,T8,Scope 95 110	Ace Inh and ARB
10,R2,AND Arg1:T8 Arg2:T7
11,T9,Informed_consent 149 239	willing to be placed on alternate drug(s) in the washout period for blood pressure control
0,T1,Measurement 0 13	Estimated GFR
1,T2,Measurement 15 19	eGFR
2,T3,Value 21 40	< 60 mL/min/1.73 m2
3,T4,Measurement 45 58	blood glucose
4,T5,Value 59 70	> 135 mg/dl
5,T6,Condition 99 118	acute renal failure
6,T7,Procedure 120 134	renal dialysis
7,T8,Condition 136 153	diabetes mellitus
8,R1,Subsumes Arg1:T1 Arg2:T2
9,R2,Has_value Arg1:T1 Arg2:T3
10,R3,Has_value Arg1:T4 Arg2:T5
11,*,OR T1 T4 T6 T7 T8
12,T9,Person 156 161	Women
13,T10,Procedure 175 192	metallic fixation
14,T11,Device 194 215	coronary artery stent
15,T12,Temporal 219 234	recent 3 months
16,T13,Person 239 244	women
17,T14,Device 258 286	mechanical valve replacement
18,T15,Person 329 334	women
19,T16,Device 340 356	aneurysmal clips
20,T17,Device 358 368	pacemakers
21,*,OR T16 T17
22,T18,"Scope 340 368	aneurysmal clips, pacemakers"
23,R4,Has_scope Arg1:T15 Arg2:T18
24,R5,AND Arg1:T13 Arg2:T14
25,*,OR T15 T13 T9
26,*,OR T10 T11
27,T19,"Scope 175 215	metallic fixation, coronary artery stent"
28,R6,Has_temporal Arg1:T19 Arg2:T12
29,R7,Has_scope Arg1:T9 Arg2:T19
30,T20,Condition 387 401	claustrophobia
31,T21,"Pregnancy_considerations 404 552	Women who are pregnant or who are planning to be pregnant, or who are lactating (though the possibility in our target population should be very low)"
32,T22,Condition 570 583	breast cancer
33,T23,Temporal 591 650	recent 5 years before the currently diagnosed breast cancer
34,R8,Has_temporal Arg1:T22 Arg2:T23
35,T24,Reference_point 617 651	currently diagnosed breast cancer.
36,R9,Has_index Arg1:T23 Arg2:T24
37,T25,Procedure 672 684	chemotherapy
38,T26,Temporal 713 726	recent 1 year
39,R10,Has_temporal Arg1:T25 Arg2:T26
40,T27,Post-eligibility 729 777	Women who cannot cooperate with the examinations
0,T1,Condition 0 9	Pregnancy
1,T2,Condition 25 47	chronic kidney disease
2,T3,Measurement 59 63	eGFR
3,T4,Value 64 75	< 30 ml/min
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Condition 77 80	CKD
6,T6,Qualifier 81 89	stage IV
7,T7,Qualifier 81 86;94 95	stage V
8,*,OR T7 T6
9,T8,Scope 81 95	stage IV and V
10,R2,Has_scope Arg1:T5 Arg2:T8
11,R3,AND Arg1:T2 Arg2:T3
12,T9,Qualifier 98 113	Nephrotic range
13,T10,Condition 114 125	proteinuria
14,T11,Measurement 127 142	urinary protein
15,T12,Value 143 155	> 3.5 gm/day
16,R4,Has_value Arg1:T11 Arg2:T12
17,R5,Has_qualifier Arg1:T10 Arg2:T9
18,R6,AND Arg1:T10 Arg2:T11
19,T13,Measurement 169 190	renal transplantation
20,T14,Condition 203 219	multiple myeloma
21,T15,Observation 158 165	History
22,T16,Observation 192 199	History
23,R7,Has_temporal Arg1:T13 Arg2:T15
24,R8,Has_temporal Arg1:T14 Arg2:T16
25,T17,Condition 238 263	hypersensitivity reaction
26,T18,Condition 267 281	intolerability
27,T19,Drug 285 292	Ace Inh
28,T20,Drug 296 299	ARB
29,*,OR T19 T20
30,T21,Scope 285 299	Ace Inh or ARB
31,*,OR T17 T18
32,T22,Scope 238 281	hypersensitivity reaction or intolerability
33,R9,Has_scope Arg1:T22 Arg2:T21
34,T23,Observation 227 234	history
35,R10,Has_temporal Arg1:T22 Arg2:T23
0,T1,Person 0 5	Women
1,T2,Person 6 10	aged
2,T3,Value 11 26	25-75 years old
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Person 29 34	Women
5,T5,Condition 59 72	breast cancer
6,T6,Procedure 94 97	NAC
7,T7,Qualifier 101 120	reduce tumor burden
8,T8,Temporal 121 135	before surgery
9,T9,Reference_point 128 135	surgery
10,R2,Has_index Arg1:T8 Arg2:T9
11,R3,Has_qualifier Arg1:T6 Arg2:T7
12,R4,AND Arg1:T5 Arg2:T6
13,R5,Has_temporal Arg1:T6 Arg2:T8
0,T1,Qualifier 14 20	severe
1,T2,Condition 21 47	left ventricle dysfunction
2,T3,Measurement 56 78	ejection fraction (EF)
3,T4,Value 78 82	=40%
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Observation 84 103	being scheduled for
6,T6,Procedure 104 121	revascularization
7,R2,AND Arg1:T5 Arg2:T6
8,R3,Has_qualifier Arg1:T2 Arg2:T1
0,T1,Person 0 5	Women
1,T2,Condition 9 32	child-bearing potential
2,T3,Negation 38 44	do not
3,T4,Procedure 54 76	adequate contraception
4,R1,Has_negation Arg1:T4 Arg2:T3
5,R2,AND Arg1:T2 Arg2:T4
6,T5,Condition 79 87	Pregnant
7,T6,Condition 91 100	lactating
8,*,OR T5 T6
9,T7,Drug 126 154	primary chemotherapy regimen
10,T8,Multiplier 112 125	more than one
11,R3,Has_multiplier Arg1:T7 Arg2:T8
12,T9,Condition 181 193	malignancies
13,T10,Qualifier 172 180	previous
14,T11,Qualifier 157 168	Concomitant
15,*,OR T11 T10
16,T12,Scope 157 180	Concomitant or previous
17,R4,Has_scope Arg1:T9 Arg2:T12
18,T13,Condition 235 245;263 274	basal cell skin cancer
19,T14,Condition 249 274	squamous cell skin cancer
20,*,OR T14 T13 T15 T16 T17
21,T15,Condition 276 299	in situ cervical cancer
22,T16,Condition 301 321	incidental carcinoid
23,T17,Condition 326 338	other cancer
24,T18,Negation 199 215	the exception of
25,T19,Qualifier 216 234	adequately treated
26,T20,"Scope 235 338	basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer"
27,R5,Has_qualifier Arg1:T20 Arg2:T19
28,R6,Has_negation Arg1:T20 Arg2:T18
29,T21,Temporal 384 395	for 5 years
30,T22,Qualifier 362 383	has been disease free
31,R7,Has_temporal Arg1:T22 Arg2:T21
32,R8,Has_qualifier Arg1:T20 Arg2:T22
33,T23,Condition 418 427	infection
34,T24,Qualifier 398 417	Active uncontrolled
35,R9,Has_qualifier Arg1:T23 Arg2:T24
36,T25,Drug 438 449	antibiotics
37,R10,AND Arg1:T23 Arg2:T25
38,T27,Procedure 575 584	radiation
39,T28,Value 588 601	more than 10%
40,T29,Qualifier 605 609	bone
41,R11,AND Arg1:T29 Arg2:T27
42,R12,Has_value Arg1:T29 Arg2:T28
43,T30,Drug 633 642	topotecan
44,T31,Drug 646 657	gemcitabine
45,*,OR T30 T31
46,T32,Observation 618 627	treatment
47,T33,Scope 633 657	topotecan or gemcitabine
48,R13,Has_scope Arg1:T32 Arg2:T33
49,T34,Condition 660 676	Hypersensitivity
50,T35,Drug 680 692	camptothecin
51,T36,Drug 696 716	nucleoside analogues
52,T37,Scope 680 716	camptothecin or nucleoside analogues
53,R14,Has_scope Arg1:T34 Arg2:T37
54,T38,Drug 729 750	investigational agent
55,T39,Temporal 751 765	within 30 days
56,R15,Has_temporal Arg1:T38 Arg2:T39
57,T40,Temporal 612 617	Prior
58,R16,Has_temporal Arg1:T32 Arg2:T40
59,T26,Temporal 452 462	Concurrent
60,T41,Qualifier 463 469	severe
61,T42,Condition 470 486	medical problems
62,R17,Has_qualifier Arg1:T42 Arg2:T41
63,R18,Has_temporal Arg1:T42 Arg2:T26
64,T43,Qualifier 527 563	limit full compliance with the study
65,R19,Has_qualifier Arg1:T42 Arg2:T43
66,T44,Qualifier 487 514	unrelated to the malignancy
67,T45,Condition 504 514	malignancy
68,R20,multi Arg1:T44 Arg2:T45
69,R21,Has_qualifier Arg1:T42 Arg2:T44
70,*,OR T35 T36
0,T1,Observation 19 27	Patients
1,A1,Optional T1
2,T2,Observation 387 395	controls
3,A2,Optional T2
4,T3,Condition 67 80	schizophrenia
5,T4,Condition 84 108	schizoaffective disorder
6,*,OR T3 T4
7,T5,Qualifier 122 182	ICD-10 (International Classification of Diseases version 10)
8,T6,Qualifier 186 243	DSM-IV/V (Diagnostic and Statistical Manual version 4 /5)
9,*,OR T5 T6
10,T7,Scope 122 243	ICD-10 (International Classification of Diseases version 10) or DSM-IV/V (Diagnostic and Statistical Manual version 4 /5)
11,T8,Scope 67 108	schizophrenia or schizoaffective disorder
12,R1,Has_scope Arg1:T8 Arg2:T7
13,T9,Person 245 248	Age
14,T10,Value 249 260	18-45 years
15,R2,Has_value Arg1:T9 Arg2:T10
16,T11,Negation 262 267	Never
17,T12,Drug 281 304	antipsychotic compounds
18,T13,Drug 308 347	central nervous system (CNS) stimulants
19,T14,Observation 349 366	Legally competent
20,R3,Has_negation Arg1:T12 Arg2:T11
21,R4,Has_negation Arg1:T13 Arg2:T11
22,T15,"Scope 67 366	schizophrenia or schizoaffective disorder according to ICD-10 (International Classification of Diseases version 10) or DSM-IV/V (Diagnostic and Statistical Manual version 4 /5), Age 18-45 years, Never treated with antipsychotic compounds or central nervous system (CNS) stimulants, Legally competent"
23,R5,Has_scope Arg1:T1 Arg2:T15
24,T16,"Non-representable 397 474	Matching patients on age (+/- 2 years), sex and parental socioeconomic status"
25,T17,Person 476 479	Age
26,T18,Value 480 491	18-45 years
27,T19,Negation 493 495	No
28,T20,Condition 496 507;520 527	psychiatric disease
29,T21,Condition 511 527	physical disease
30,*,OR T21 T20
31,R6,Has_negation Arg1:T20 Arg2:T19
32,R7,Has_negation Arg1:T21 Arg2:T19
33,R8,Has_value Arg1:T17 Arg2:T18
34,T22,"Scope 397 527	Matching patients on age (+/- 2 years), sex and parental socioeconomic status, Age 18-45 years, No psychiatric or physical disease"
35,R9,Has_scope Arg1:T2 Arg2:T22
0,T1,Drug 19 54	platinum-based chemotherapy regimen
1,T2,Condition 76 91	primary disease
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Temporal 13 18	prior
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Temporal 94 150	At least 4 weeks since last surgery or radiation therapy
6,T5,Reference_point 117 129	last surgery
7,R3,Has_index Arg1:T4 Arg2:T5
8,T6,Reference_point 133 150	radiation therapy
9,R4,Has_index Arg1:T4 Arg2:T6
10,*,OR T5 T6
11,T7,Condition 167 192	a treatment-free interval
12,T8,Temporal 196 248	greater than 6 months following response to platinum
13,T9,Reference_point 228 248	response to platinum
14,T10,Drug 240 248	platinum
15,R5,Has_index Arg1:T8 Arg2:T9
16,R6,multi Arg1:T9 Arg2:T10
17,R7,Has_temporal Arg1:T7 Arg2:T8
18,T11,Measurement 251 274	ECOG performance status
19,T12,Value 278 279	0
20,T13,"Value 278 281	0,1"
21,T14,Value 287 288	.
22,*,OR T12 T13 T14
23,T15,"Scope 278 287	0,1, or 2"
24,R8,Has_scope Arg1:T11 Arg2:T15
0,T1,Observation 19 27	patients
1,A1,Optional T1
2,T2,Condition 29 44	Substance abuse
3,T3,Multiplier 50 61	daily basis
4,T4,Multiplier 62 85	during the last 3 month
5,T5,Qualifier 156 171	ICD-10/DSM-IV/V
6,R1,Has_multiplier Arg1:T2 Arg2:T3
7,R2,Has_multiplier Arg1:T2 Arg2:T4
8,T6,Condition 133 148	substance abuse
9,T7,Temporal 125 132	ongoing
10,R3,Has_temporal Arg1:T6 Arg2:T7
11,R4,Has_qualifier Arg1:T6 Arg2:T5
12,T8,Drug 188 202	antidepressant
13,T9,Temporal 203 226	during the last 30 days
14,R5,Has_temporal Arg1:T8 Arg2:T9
15,T10,Condition 228 239	Head injury
16,T11,Multiplier 245 264	more than 5 minutes
17,T12,Condition 268 283	unconsciousness
18,R6,Has_multiplier Arg1:T12 Arg2:T11
19,R7,AND Arg1:T10 Arg2:T12
20,T13,Observation 294 316	involuntarily admitted
21,T14,Observation 294 307;320 327	involuntarily treated
22,T15,Device 329 348	Components of metal
23,T16,Device 373 382	Pacemaker
24,T17,Condition 384 393	Pregnancy
25,T18,Condition 395 418	Severe physical illness
26,*,OR T17 T18 T16 T15 T13 T14 T10 T8 T2 T6
27,T19,"Scope 29 418	Substance abuse on a daily basis during the last 3 month or patients fulfilling the criteria of ongoing substance abuse due to ICD-10/DSM-IV/V, Treatment with antidepressant during the last 30 days, Head injury with more than 5 minutes of unconsciousness, Patients involuntarily admitted or treated, Components of metal implanted by operation, Pacemaker, Pregnancy, Severe physical illness"
28,R8,Has_scope Arg1:T1 Arg2:T19
29,T20,Observation 439 447	controls
30,A2,Optional T20
31,T21,Observation 449 471	First degree relatives
32,T22,Condition 477 496	psychiatric disease
33,R9,Has_context Arg1:T22 Arg2:T21
34,T23,Condition 498 513	Substance abuse
35,T24,Temporal 514 537	during the last 3 month
36,R10,Has_temporal Arg1:T23 Arg2:T24
37,T25,Value 541 549	positive
38,T26,Procedure 550 568	screening of drugs
39,T27,Qualifier 572 584	urine-sample
40,R11,Has_qualifier Arg1:T26 Arg2:T27
41,R12,Has_value Arg1:T26 Arg2:T25
42,T28,Condition 586 597	Head injury
43,T29,Multiplier 603 622	more than 5 minutes
44,T30,Condition 626 641	unconsciousness
45,R13,Has_multiplier Arg1:T30 Arg2:T29
46,R14,AND Arg1:T28 Arg2:T30
47,T31,Device 643 662	Components of metal
48,T32,Device 687 696	Pacemaker
49,T33,Condition 698 707	Pregnancy
50,T34,Condition 709 732	Severe physical illness
51,*,OR T33 T34 T32 T31 T28 T26 T23 T22
52,T35,"Scope 449 732	First degree relatives with psychiatric disease, Substance abuse during the last 3 month or positive screening of drugs in urine-sample, Head injury with more than 5 minutes of unconsciousness, Components of metal implanted by operation, Pacemaker, Pregnancy, Severe physical illness"
53,R15,Has_scope Arg1:T20 Arg2:T35
0,T1,Condition 0 21	myocardial infarction
1,T2,Temporal 22 50	within the preceding 4 weeks
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Reference_point 29 50	the preceding 4 weeks
4,R2,Has_index Arg1:T2 Arg2:T3
5,T4,Qualifier 52 58	severe
6,T5,Condition 59 72	valve disease
7,T6,Qualifier 73 100	requiring valve replacement
8,T7,Procedure 83 100	valve replacement
9,R3,multi Arg1:T6 Arg2:T7
10,R4,Has_qualifier Arg1:T5 Arg2:T4
11,R5,Has_qualifier Arg1:T5 Arg2:T6
12,T8,Procedure 102 122	cardiac reoperations
0,T1,Condition 22 36	Morton neuroma
1,T2,Procedure 50 65	ultrasound scan
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Mood 0 18	Clinical suspicion
4,R2,Has_mood Arg1:T1 Arg2:T3
5,T4,Temporal 84 104	more than six months
6,T5,Condition 67 75	Symptoms
7,R3,Has_temporal Arg1:T5 Arg2:T4
8,T6,Measurement 110 132;155 168	thickness of the nerve in short axis
9,T7,Value 141 154	at least 2 mm
10,T9,Value 173 186	at least 5 mm
11,T8,Measurement 110 132;187 211	thickness of the nerve in the longitudinal axis
12,R4,Has_value Arg1:T6 Arg2:T7
13,R5,Has_value Arg1:T8 Arg2:T9
0,T1,Non-query-able 0 7	Refusal
1,T2,Condition 9 25	Contraindication
2,T3,Procedure 29 38	neuraxial
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 40 52	coagulopathy
5,T5,Drug 54 67	anticoagulant
6,T6,Condition 73 88	local infection
7,T7,Condition 90 96	sepsis
8,*,OR T6 T7 T5 T4
9,T8,Condition 103 123	Rupture of membranes
10,T9,"Scope 41 96	oagulopathy, anticoagulant use, local infection, sepsis"
11,T10,Scope 9 38	Contraindication to neuraxial
12,R2,Has_scope Arg1:T10 Arg2:T9
13,*,OR T10 T8
14,T11,Non-query-able 126 307	Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion.
0,T1,Observation 8 36	cooperate with the treatment
1,T2,Negation 4 7	not
2,R1,Has_negation Arg1:T1 Arg2:T2
3,T3,Negation 42 45	not
4,T4,Observation 57 81	child's parental consent
5,R2,Has_negation Arg1:T4 Arg2:T3
6,T5,Informed_consent 38 81	Can not obtain the child's parental consent
0,T1,Drug 32 47	corticosteroids
1,T2,Drug 51 68	local anesthetics
2,T3,Condition 0 16	Contraindication
3,*,OR T1 T2
4,T4,Scope 32 68	corticosteroids or local anesthetics
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Condition 82 106	inflammatory arthropathy
7,T6,Condition 110 120;82 94	neuropathy inflammatory
8,*,OR T6 T5
9,T7,Condition 122 134	Skin lesions
10,T8,Condition 148 165	diabetes mellitus
11,T9,Procedure 183 199	previous surgery
12,T10,Condition 167 179	Infiltration
13,*,OR T10 T9
14,T11,Post-eligibility 213 247	Refusal to participate in the stud
0,T1,Condition 0 17	generally healthy
1,T2,Observation 18 34	grade 1-2 school
2,T3,Person 35 43	children
3,T4,Informed_consent 45 74	with written parental consent
4,T5,Multiplier 81 91	at least 1
5,T6,Qualifier 92 97	sound
6,T7,Qualifier 102 115	fully erupted
7,T8,Condition 116 137	permanent first molar
8,R1,Has_qualifier Arg1:T8 Arg2:T7
9,R2,Has_qualifier Arg1:T8 Arg2:T6
10,R3,Has_multiplier Arg1:T8 Arg2:T5
0,T1,Condition 0 7	Healthy
1,T2,Person 17 20	age
2,T3,Value 21 33	18 and older
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Observation 35 54	Breech presentation
5,T5,Condition 56 75	Singleton gestation
6,T6,Procedure 91 94	ECV
7,T7,Procedure 104 107	CSE
8,T8,Mood 95 103	desiring
9,R2,Has_mood Arg1:T7 Arg2:T8
10,R3,AND Arg1:T6 Arg2:T7
11,T9,Mood 77 90	scheduled for
12,R4,Has_mood Arg1:T6 Arg2:T9
0,T1,Condition 0 17	colorectal cancer
1,T2,Qualifier 18 52	above to 12 cm from the anal verge
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Qualifier 54 66	unresectable
4,T4,Qualifier 67 78	synchronous
5,T5,Condition 79 89	metastases
6,R2,Has_qualifier Arg1:T5 Arg2:T4
7,R3,Has_qualifier Arg1:T5 Arg2:T3
8,T6,Procedure 116 128	chemotherapy
9,T7,Condition 94 111	contraindications
10,T8,Negation 91 93	no
11,R4,Has_negation Arg1:T7 Arg2:T8
12,R5,AND Arg1:T7 Arg2:T6
13,T9,Condition 141 166	peritoneal carcinomatosis
14,T10,Negation 130 137	absence
15,T11,Condition 168 190;198 208	central nervous system metastasis
16,T12,Condition 193 208	bone metastasis
17,*,OR T11 T12 T9
18,T13,"Scope 141 208	peritoneal carcinomatosis, central nervous system o bone metastasis"
19,R6,Has_negation Arg1:T13 Arg2:T10
20,T14,Measurement 230 234	ECOG
21,T15,Value 235 238	= 2
22,T16,Measurement 211 229	performance status
23,*,OR T14 T16
24,T17,Measurement 240 274	Eastern Cooperative Oncology Group
25,R7,Subsumes Arg1:T14 Arg2:T17
26,T18,Scope 211 234;240 274	performance status ECOG Eastern Cooperative Oncology Group
27,R8,Has_value Arg1:T14 Arg2:T15
28,T19,Qualifier 277 289	uncontrolled
29,T20,Temporal 290 301	concomitant
30,T21,Condition 302 356	medical conditions that may compromise to chemotherapy
31,R9,Has_temporal Arg1:T21 Arg2:T20
32,R10,Has_qualifier Arg1:T21 Arg2:T19
33,T22,Qualifier 370 381	symptomatic
34,T23,Condition 382 397	cardiac disease
35,T24,Qualifier 358 369	significant
36,R11,Has_qualifier Arg1:T23 Arg2:T24
37,R12,Has_qualifier Arg1:T23 Arg2:T22
38,T25,Condition 403 412	pregnancy
39,T26,Observation 416 429	breastfeeding
40,*,OR T26 T25
41,T27,Negation 399 402	not
42,T28,Scope 403 429	pregnancy or breastfeeding
43,R13,Has_negation Arg1:T28 Arg2:T27
0,T1,Condition 9 23	rectal tumours
1,T2,Qualifier 24 50	below 12cm from anal verge
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 55 79	locally advanced tumours
4,T4,Condition 80 102	invading blood vessels
5,T5,Condition 104 110;80 88	nerves invading
6,T6,Condition 114 118;80 88	bone invading
7,*,OR T5 T6 T4
8,T7,"Scope 80 118	invading blood vessels, nerves or bone"
9,R2,Has_scope Arg1:T3 Arg2:T7
10,*,OR T1 T3
11,T8,Condition 121 145	Multiple bone metastasis
12,T9,Condition 149 182	central nervous system metastasis
13,*,OR T8 T9
14,T10,Condition 190 208	neoplastic disease
15,T11,Qualifier 184 189	Other
16,R3,Has_qualifier Arg1:T10 Arg2:T11
17,T12,Temporal 209 232	in the 5 previous years
18,T13,Condition 253 278	basal cell skin carcinoma
19,T14,Condition 241 249;259 278	squamous cell skin carcinoma
20,T15,"Condition 282 310	cervical ""in situ"" carcinoma"
21,*,OR T13 T14 T15
22,R4,Has_temporal Arg1:T10 Arg2:T12
23,T16,Negation 234 240	except
24,T17,"Scope 241 310	squamous or basal cell skin carcinoma or cervical ""in situ"" carcinoma"
25,R5,Has_negation Arg1:T17 Arg2:T16
26,R6,Has_scope Arg1:T10 Arg2:T17
27,T18,Condition 324 337	heart disease
28,T19,Qualifier 312 323	Significant
29,R7,Has_qualifier Arg1:T18 Arg2:T19
30,T20,Condition 339 371	chronic congestive heart failure
31,T21,Condition 373 401	symptomatic coronary disease
32,*,OR T20 T21
33,T22,"Scope 339 401	chronic congestive heart failure, symptomatic coronary disease"
34,T23,Scope 312 337	Significant heart disease
35,R8,Subsumes Arg1:T23 Arg2:T22
36,T24,Condition 406 427	myocardial infarction
37,T25,Temporal 428 452	in the previous 6 months
38,R9,Has_temporal Arg1:T24 Arg2:T25
39,*,OR T23 T24
40,T26,Condition 454 475	Peripheral neuropathy
41,T27,Non-query-able 477 518	Patients who do not give informed consent
0,T1,Temporal 0 12	simultaneous
1,T2,Qualifier 13 23	both sided
2,T3,Procedure 55 71	molar extraction
3,T4,Qualifier 38 54	only upper third
4,*,OR T2 T4
5,T5,Scope 13 54	both sided extraction or only upper third
6,R1,Has_scope Arg1:T3 Arg2:T5
7,R2,Has_temporal Arg1:T3 Arg2:T1
8,T6,Procedure 73 91	general anesthesia
9,T7,Condition 111 138	abnormal coagulation status
10,T8,Qualifier 102 110	presumed
11,T9,Qualifier 93 98	known
12,*,OR T9 T8
13,T10,Scope 93 110	known or presumed
14,R3,Has_scope Arg1:T7 Arg2:T10
15,T11,Qualifier 140 145	known
16,T12,Qualifier 149 157	presumed
17,*,OR T11 T12
18,T13,Scope 140 157	known or presumed
19,T14,Condition 167 184	renal dysfunction
20,T15,Condition 158 163;173 184	liver dysfunction
21,*,OR T14 T15
22,T16,Scope 158 184	liver or renal dysfunction
23,R4,Has_scope Arg1:T16 Arg2:T13
24,T17,Condition 186 202	contraindication
25,T18,Drug 211 221	metamizole
26,R5,AND Arg1:T17 Arg2:T18
27,T19,Qualifier 222 227	known
28,T20,Qualifier 231 240	suspected
29,*,OR T19 T20
30,T21,Scope 222 240	known or suspected
31,T22,Qualifier 242 247	known
32,T23,Qualifier 251 260	suspected
33,T24,Condition 261 268	allergy
34,T25,Drug 277 285	novalgin
35,T26,Drug 295 306	pyrazolones
36,T27,Qualifier 289 294	other
37,R6,Has_qualifier Arg1:T26 Arg2:T27
38,T28,Condition 308 329	anaphylactic reaction
39,T29,Drug 338 344	NSAIDS
40,T30,Measurement 356 376	bone marrow function
41,T31,Value 346 355	decreased
42,T32,Measurement 380 392	hematopoesis
43,*,OR T32 T30
44,T33,Scope 356 392	bone marrow function or hematopoesis
45,R7,Has_value Arg1:T33 Arg2:T31
46,T34,Condition 394 411	hepatic porphyria
47,T35,Condition 413 457	glucose-6-phosphate dehydrogenase deficiency
48,T36,Condition 463 472	pregnancy
49,T37,Observation 473 486	breastfeeding
50,*,OR T36 T37 T35 T34 T33
51,R8,AND Arg1:T28 Arg2:T29
52,*,OR T25 T26
53,T38,Scope 277 306	novalgin or other pyrazolones
54,R9,Has_scope Arg1:T24 Arg2:T38
55,*,OR T23 T22
56,T39,Scope 242 260	known or suspected
57,R10,Has_scope Arg1:T24 Arg2:T39
58,*,OR T24 T28
59,T40,"Scope 242 486	known or suspected allergy against novalgin or other pyrazolones, anaphylactic reaction against NSAIDS, decreased bone marrow function or hematopoesis, hepatic porphyria, glucose-6-phosphate dehydrogenase deficiency, and pregnancy/breastfeeding"
60,R11,Has_scope Arg1:T17 Arg2:T21
61,T41,Scope 186 240	contraindication against metamizole known or suspected
62,R12,Subsumes Arg1:T41 Arg2:T40
63,T42,Condition 489 505	contraindication
64,T43,Drug 514 523	ibuprofen
65,R13,AND Arg1:T42 Arg2:T43
66,T44,Qualifier 525 530	known
67,T45,Qualifier 534 543	suspected
68,*,OR T44 T45
69,T46,Condition 544 551	allergy
70,T47,Drug 560 569	ibuprofen
71,T48,Scope 525 543	known or suspected
72,R14,Has_scope Arg1:T46 Arg2:T48
73,R15,AND Arg1:T46 Arg2:T47
74,T49,Condition 571 592	anaphylactic reaction
75,T50,Drug 601 645	Nonsteroidal anti-inflammatory drugs (NSAID)
76,R16,AND Arg1:T49 Arg2:T50
77,T51,Temporal 647 653	active
78,T52,Qualifier 657 666	recurrent
79,T53,Qualifier 667 674	stomach
80,T54,Condition 697 705	bleeding
81,T55,Qualifier 678 686	duodenal
82,T56,Condition 687 693	ulcera
83,*,OR T56 T54
84,*,OR T55 T53
85,T57,Scope 687 705	ulcera or bleeding
86,T58,Scope 667 686	stomach or duodenal
87,*,OR T52 T51
88,T59,Scope 647 666	active or recurrent
89,R17,Has_scope Arg1:T57 Arg2:T58
90,R18,Has_scope Arg1:T57 Arg2:T59
91,T60,Condition 707 719;729 742	severe liver insufficiency
92,T61,Condition 707 713;723 742	severe renal insufficiency
93,T62,Condition 744 771	inflammatory bowel syndrome
94,T63,Condition 777 786	pregnancy
95,T64,Observation 787 800	breastfeeding
96,*,OR T63 T64 T61 T60 T49 T46 T57 T62
97,T65,"Scope 525 800	known or suspected allergy against ibuprofen, anaphylactic reaction against Nonsteroidal anti-inflammatory drugs (NSAID), active or recurrent stomach or duodenal ulcera or bleeding, severe liver or renal insufficiency, inflammatory bowel syndrome, and pregnancy/breastfeeding"
98,T66,Scope 489 523	contraindication against ibuprofen
99,R19,Subsumes Arg1:T66 Arg2:T65
100,T67,Condition 803 812	pregnancy
101,T68,Observation 817 831	breast feeding
102,*,OR T67 T68
0,T1,Person 0 6	Female
1,T2,Person 16 20	aged
2,T3,Value 21 33	=/> 18 years
3,T4,Condition 41 57	reproductive age
4,R1,Has_value Arg1:T2 Arg2:T3
5,T5,"Non-query-able 60 201	Capacity to give consent for study participation, after being adequately informed of the aims, benefits, risks, time and motion of the study."
0,T1,Person 9 13	aged
1,T2,Value 14 35	greater than 18 years
2,T3,Person 39 42	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,R2,Has_value Arg1:T1 Arg2:T2
5,*,OR T1 T3
6,T4,Non-query-able 44 115	Ability to understand and willingness to comply with the study protocol
7,T5,Post-eligibility 44 115	Ability to understand and willingness to comply with the study protocol
8,T6,Post-eligibility 117 141	Written informed consent
9,T7,Non-query-able 117 141	Written informed consent
10,T8,Measurement 164 226	Rotterdam PCOS workshop criteria for polycystic ovary syndrome
11,T9,Value 152 159	meeting
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Condition 239 253	oligomenorrhea
14,T11,Condition 257 267	amenorrhea
15,*,OR T11 T10
16,T12,Multiplier 272 284	at least one
17,T13,Condition 349 365	hyperandrogenism
18,T14,Condition 391 401;412 419	polycystic ovaries
19,T15,Procedure 369 379	ultrasound
20,R4,AND Arg1:T15 Arg2:T14
21,*,OR T13 T15
0,T1,Condition 0 10	Menopausal
1,T2,Person 11 16	women
2,T3,Condition 22 35	breast cancer
3,T4,Procedure 36 43	treated
4,T5,Drug 54 63	tamoxifen
5,T6,Drug 67 86	aromatase inhibitor
6,*,OR T5 T6
7,T7,Scope 54 86	tamoxifen or aromatase inhibitor
8,R1,Has_scope Arg1:T4 Arg2:T7
9,T8,Condition 94 105	hot flashes
10,T9,Observation 118 144	without active sexual life
11,T10,Observation 110 114;126 144	with active sexual life
12,*,OR T9 T10
0,T1,Condition 0 23	abnormal renal function
1,T2,Temporal 25 34	currently
2,T3,Condition 35 43	pregnant
3,T4,Mood 48 64	trying to become
4,T5,Condition 65 73	pregnant
5,R1,Has_mood Arg1:T5 Arg2:T4
6,R2,Has_temporal Arg1:T3 Arg2:T2
7,*,OR T3 T5
8,T6,Drug 96 108	beta-blocker
9,T7,Procedure 81 88	treated
10,R3,AND Arg1:T7 Arg2:T6
11,T8,Drug 117 130	illicit drugs
0,T1,Mood 0 7	planned
1,T2,Qualifier 8 18	sequential
2,T3,Qualifier 19 29	both-sided
3,T4,Procedure 30 58	lower third molar extraction
4,T5,Qualifier 60 71	split-mouth
5,R1,Has_qualifier Arg1:T4 Arg2:T3
6,R2,Has_qualifier Arg1:T4 Arg2:T2
7,R3,Has_qualifier Arg1:T4 Arg2:T5
8,T6,Procedure 78 87	osteotomy
9,R4,AND Arg1:T4 Arg2:T6
10,T7,Procedure 105 127	upper molar extraction
11,T8,Procedure 131 147	local anesthesia
12,R5,AND Arg1:T7 Arg2:T8
13,T9,Scope 105 147	upper molar extraction in local anesthesia
14,A1,Optional T9
15,R6,Has_scope Arg1:T4 Arg2:T9
16,R7,Has_mood Arg1:T4 Arg2:T1
17,T10,Observation 150 178	able to understand the study
18,T11,Non-representable 179 196	and the NRS scale
0,T1,Non-query-able 0 40	Participation in another clinical trial.
1,T2,Mood 51 60	suspected
2,T3,Mood 42 47	Known
3,*,OR T2 T3
4,T4,Condition 77 87	malignancy
5,T5,Condition 91 106	chronic illness
6,*,OR T5 T4
7,T6,Scope 77 106	malignancy or chronic illness
8,T7,Observation 65 75	history of
9,T8,Scope 42 76	Known or suspected (or history of)
10,R1,Has_scope Arg1:T6 Arg2:T8
11,T9,Condition 128 142	mental disease
12,T10,Condition 117 124;135 142	organic disease
13,*,OR T9 T10
14,T11,Qualifier 143 170	diagnosed by a psychiatrist
15,T12,Scope 117 142	organic or mental disease
16,R2,Has_qualifier Arg1:T12 Arg2:T11
17,T13,Condition 178 194	major depression
18,T14,Procedure 205 212	treated
19,T15,Temporal 195 204	currently
20,R3,Has_temporal Arg1:T14 Arg2:T15
21,T16,Drug 218 243	antidepressant medication
22,R4,AND Arg1:T14 Arg2:T16
23,R5,AND Arg1:T13 Arg2:T14
24,T17,Scope 117 170	organic or mental disease diagnosed by a psychiatrist
25,R6,Subsumes Arg1:T17 Arg2:T13
26,T18,Mood 245 254	suspected
27,T19,Observation 275 290	medical history
28,T20,Procedure 298 318	clinical examination
29,*,OR T20 T19
30,T21,Scope 275 318	medical history and/or clinical examination
31,R7,Has_scope Arg1:T18 Arg2:T21
32,R8,Has_mood Arg1:T13 Arg2:T18
33,T22,Post-eligibility 321 376	Conditions that may affect the compliance to the study.
34,T23,Post-eligibility 378 518	Contraindications to therapy with the study drug or hypersensitivity to the study drug (active ingredient or excipients of the formulation).
0,T1,Condition 8 17	pregnancy
1,T2,Condition 21 30	lactation
2,*,OR T2 T1
3,T3,Condition 32 45	Liver disease
4,T4,Condition 49 71	elevated liver enzymes
5,T5,Condition 98 115	diabetes mellitus
6,T6,Value 117 125	Abnormal
7,T7,Measurement 58 71	liver enzymes
8,T8,Value 49 57	elevated
9,R1,Has_value Arg1:T7 Arg2:T8
10,T9,Measurement 126 146	serum glucose levels
11,R2,Has_value Arg1:T9 Arg2:T6
12,T10,Condition 117 146	Abnormal serum glucose levels
13,T11,Temporal 154 164	at fasting
14,T12,Temporal 168 210	after the 2-hr oral glucose tolerance test
15,T13,Reference_point 174 210	the 2-hr oral glucose tolerance test
16,T14,Procedure 178 210	2-hr oral glucose tolerance test
17,*,OR T11 T12
18,T15,Scope 154 210	at fasting or after the 2-hr oral glucose tolerance test
19,R3,Has_scope Arg1:T10 Arg2:T15
20,T16,Reference_point 157 164	fasting
21,T17,Measurement 219 313	criteria for the diagnosis of diabetes mellitus according to the American Diabetes Association
22,T18,Value 211 218	meeting
23,R4,Has_value Arg1:T17 Arg2:T18
24,T19,Qualifier 211 313	meeting criteria for the diagnosis of diabetes mellitus according to the American Diabetes Association
25,R5,Has_qualifier Arg1:T10 Arg2:T19
26,T20,Condition 249 266	diabetes mellitus
27,T21,Procedure 316 345	Insulin sensitizing treatment
28,T22,Temporal 346 370;385 408	within 3 months prior to eight week study period
29,T23,Temporal 374 408	during the eight week study period
30,*,OR T23 T22
31,T24,Scope 346 408	within 3 months prior to or during the eight week study period
32,R6,Has_scope Arg1:T21 Arg2:T24
33,T25,Drug 440 448	estrogen
34,T26,Drug 452 464	progesterone
35,T27,Temporal 465 482;493 509	3 months prior to the study period
36,T28,Temporal 486 509	during the study period
37,*,OR T28 T27
38,T29,Drug 533 560	medroxyprogesterone acetate
39,T30,Condition 565 584	withdrawal bleeding
40,T31,Negation 520 529	exception
41,R7,AND Arg1:T29 Arg2:T30
42,R8,Has_negation Arg1:T29 Arg2:T31
43,T32,Drug 599 622	inhaled corticosteroids
44,T33,Drug 587 595;607 622	Systemic corticosteroids
45,T34,Qualifier 587 595	Systemic
46,T35,Qualifier 599 606	inhaled
47,R9,Has_qualifier Arg1:T33 Arg2:T34
48,R10,Has_qualifier Arg1:T32 Arg2:T35
49,T36,Condition 631 666	hypersensitive reaction to cinnamon
50,T37,Observation 658 666	cinnamon
51,T38,Condition 683 700	seizure disorders
52,T39,Condition 708 730	cardiovascular disease
53,T40,Condition 735 758	cerebrovascular disease
54,*,OR T40 T39 T38
55,T41,Measurement 761 782	Body mass index (BMI)
56,T42,Value 782 793	range 20-50
57,R11,Has_value Arg1:T41 Arg2:T42
58,T43,Parsing_Error 794 844	(excluding all women with BMI under 20 or over 50)
0,T1,Negation 10 13	not
1,T2,Condition 19 32	breast cancer
2,R1,Has_negation Arg1:T2 Arg2:T1
3,T3,Drug 45 54	tamoxifen
4,T4,Drug 58 77	aromatase inhibitor
5,T5,Negation 37 40	not
6,*,OR T3 T4
7,T6,Scope 45 77	tamoxifen or aromatase inhibitor
8,R2,Has_negation Arg1:T6 Arg2:T5
9,T7,Negation 79 82	not
10,T8,Condition 86 95	menopause
11,T9,Negation 100 103	not
12,T10,Condition 109 120	hot flashes
13,R3,Has_negation Arg1:T10 Arg2:T9
14,R4,Has_negation Arg1:T8 Arg2:T7
15,*,OR T8 T10
0,T1,Measurement 0 23	systolic blood pressure
1,T2,Value 24 44	between 140-160 mmHG
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Value 46 65	between 18-80 years
4,T4,Person 66 69	old
5,R2,Has_value Arg1:T4 Arg2:T3
0,T1,Condition 4 21	medical condition
1,T2,Condition 33 47	contraindicate
2,T3,Drug 55 75	stimulant medication
3,R1,AND Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Temporal 81 86	prior
6,T5,Condition 87 103	adverse response
7,T6,Drug 107 134	lisdexamfetamine dimesylate
8,T7,Qualifier 138 143	other
9,T8,Drug 144 164	stimulant medication
10,R3,Has_qualifier Arg1:T8 Arg2:T7
11,*,OR T6 T8
12,T9,Scope 107 164	lisdexamfetamine dimesylate or other stimulant medication
13,R4,Has_scope Arg1:T5 Arg2:T9
14,R5,Has_temporal Arg1:T5 Arg2:T4
15,T10,Temporal 173 183	concurrent
16,T11,Drug 184 221	non-stimulant psychoactive medication
17,R6,Has_temporal Arg1:T11 Arg2:T10
18,T12,Condition 236 249	schizophrenia
19,T13,Condition 265 281	thought disorder
20,T14,Mood 282 290	symptoms
21,R7,Has_mood Arg1:T13 Arg2:T14
22,*,OR T12 T13
23,T15,Condition 292 316	autism spectrum disorder
0,T1,"Not_a_criteria 0 134	100 orphans/vulnerable youth aged 15 to 25 will be recruited through their participation at the day care center, on a voluntary basis."
0,T1,Non-query-able 0 50	Fluent in reading and writing in English language.
1,T2,Person 66 69	age
2,T3,Value 52 62	= 21 years
3,T4,Temporal 70 98	at the time of participation
4,T5,Reference_point 85 98	participation
5,R1,Has_index Arg1:T4 Arg2:T5
6,R2,Has_value Arg1:T2 Arg2:T3
7,R3,Has_temporal Arg1:T2 Arg2:T4
0,T1,Condition 11 24	renal failure
1,T2,Condition 37 44	allergy
2,T3,Drug 48 54	iodine
3,T4,Drug 58 67	shellfish
4,*,OR T3 T4
5,T5,Scope 48 67	iodine or shellfish
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Procedure 78 98	spine fusion surgery
8,T7,Temporal 69 77	previous
9,R2,Has_temporal Arg1:T6 Arg2:T7
10,T8,Qualifier 111 119	elective
11,T9,Qualifier 120 135	posterior spine
12,T10,Procedure 136 172	single-level instrumentation surgery
13,R3,Has_qualifier Arg1:T10 Arg2:T9
14,R4,Has_qualifier Arg1:T10 Arg2:T8
15,T11,Qualifier 185 199	anterior spine
16,T12,Procedure 200 235	multi-level instrumentation surgery
17,R5,Has_qualifier Arg1:T12 Arg2:T11
18,T13,Temporal 100 110	undergoing
19,T14,Temporal 174 184	undergoing
20,R6,Has_temporal Arg1:T10 Arg2:T13
21,R7,Has_temporal Arg1:T12 Arg2:T14
22,T15,Drug 245 259	antibiotic use
23,T16,Temporal 237 244	current
24,R8,Has_temporal Arg1:T15 Arg2:T16
0,T1,"Informed_consent 0 119	Subject or legal representative has voluntarily signed the informed consent approved by the Institutional Review Board,"
1,T2,Procedure 121 141	Hip fracture surgery
2,T3,Procedure 158 176	general anesthesia
3,T4,Value 189 206	65 years or older
4,T5,Temporal 207 228	on the day of surgery
5,T6,Reference_point 210 228	the day of surgery
6,T7,Procedure 221 228	surgery
7,R1,multi Arg1:T6 Arg2:T7
8,R2,Has_index Arg1:T5 Arg2:T6
9,T8,Person 201 206	older
10,R3,Has_value Arg1:T8 Arg2:T4
11,R4,Has_temporal Arg1:T4 Arg2:T5
0,T1,Non-query-able 0 2	NA
0,T1,Person 0 3	Age
1,T2,Value 4 16	less than 15
2,T3,Value 20 35	greater than 25
3,*,OR T2 T3
4,T4,Scope 4 35	less than 15 or greater than 25
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Observation 44 80	participating in the day care center
7,T6,Negation 40 43	not
8,R2,Has_negation Arg1:T5 Arg2:T6
0,T1,Condition 13 17	ADHD
1,T2,Informed_consent 19 80	parental permission and/or teen consent/assent as appropriate
2,T3,Value 90 101	16-25 years
3,T4,Person 105 108	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Measurement 110 112	IQ
6,T6,Value 113 140	greater than or equal to 70
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Observation 152 168	license to drive
9,T8,Observation 142 148;160 168	permit to drive
10,*,OR T8 T7
11,T9,Observation 170 185;201 208	ability to read English
12,T10,Observation 170 180;190 208	ability to understand English
13,*,OR T9 T10
0,T1,Observation 0 30	Inability to follow directions
1,T2,Observation 0 12;34 65	Inability to comprehend the English language
2,*,OR T2 T1
3,T3,Qualifier 67 73	Severe
4,T4,Qualifier 74 85	uncorrected
5,T5,Condition 96 114	auditory handicaps
6,T6,Condition 105 114;86 92	handicaps visual
7,*,OR T6 T5
8,T7,Scope 86 114	visual or auditory handicaps
9,R1,Has_qualifier Arg1:T7 Arg2:T4
10,R2,Has_qualifier Arg1:T7 Arg2:T3
11,T8,Temporal 125 137	at screening
12,T9,Temporal 125 127;141 149	at baseline
13,T10,Condition 116 124	Delirium
14,*,OR T8 T9
15,T11,Scope 125 149	at screening or baseline
16,R3,Has_scope Arg1:T10 Arg2:T11
17,T12,Procedure 151 168	Emergency surgery
0,T1,Person 0 3	Age
1,T2,Value 4 17	3 to 18 years
2,T3,Temporal 18 35	on day of surgery
3,R1,Has_value Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Condition 50 66	spinal deformity
6,T5,Temporal 68 78	undergoing
7,T6,Qualifier 79 87	elective
8,T7,Qualifier 88 103	posterior spine
9,T8,Procedure 104 139	multi-level instrumentation surgery
10,R3,Has_qualifier Arg1:T8 Arg2:T7
11,R4,Has_qualifier Arg1:T8 Arg2:T6
12,R5,Has_temporal Arg1:T8 Arg2:T5
0,T1,Condition 29 62	central nervous system metastases
1,T2,Qualifier 76 83	another
2,T3,Condition 84 94	malignancy
3,T4,Condition 103 113	Malignancy
4,T5,Procedure 114 142	treated with curative intent
5,T6,Negation 152 154	no
6,T7,Condition 161 175	active disease
7,R1,Has_negation Arg1:T7 Arg2:T6
8,T8,Temporal 184 216	for >=5 years prior to enrolment
9,T9,Reference_point 207 216	enrolment
10,R2,Has_index Arg1:T8 Arg2:T9
11,T10,Mood 221 243	felt to be at low risk
12,T11,Condition 248 258	recurrence
13,R3,Has_mood Arg1:T11 Arg2:T10
14,T12,Qualifier 286 296	Adequately
15,T13,Condition 305 333	non-melanomatous skin cancer
16,T14,Procedure 297 304	treated
17,R4,Has_qualifier Arg1:T14 Arg2:T12
18,T15,Condition 337 352	lentigo maligna
19,*,OR T13 T15
20,T16,Condition 361 380	evidence of disease
21,T17,Negation 353 360	without
22,R5,Has_negation Arg1:T16 Arg2:T17
23,T18,Qualifier 382 392	Adequately
24,T19,Procedure 393 400	treated
25,R6,Has_qualifier Arg1:T19 Arg2:T18
26,T20,Condition 401 427	cervical carcinoma in situ
27,T21,Negation 428 435	without
28,T22,Condition 448 455	disease
29,R7,Has_negation Arg1:T22 Arg2:T21
30,T23,Scope 305 352	non-melanomatous skin cancer or lentigo maligna
31,R8,AND Arg1:T23 Arg2:T14
32,R9,AND Arg1:T23 Arg2:T16
33,R10,AND Arg1:T20 Arg2:T19
34,R11,AND Arg1:T20 Arg2:T22
35,T24,Condition 457 492	Prostatic intraepithelial neoplasia
36,T25,Condition 513 528	prostate cancer
37,T26,Negation 493 500	without
38,T27,Mood 436 447	evidence of
39,R12,Has_mood Arg1:T22 Arg2:T27
40,T28,Mood 501 512	evidence of
41,R13,Has_mood Arg1:T25 Arg2:T28
42,R14,Has_negation Arg1:T25 Arg2:T26
43,R15,AND Arg1:T24 Arg2:T25
44,*,OR T20 T24 T23
45,R16,AND Arg1:T4 Arg2:T5
46,R17,AND Arg1:T4 Arg2:T7
47,R18,Has_temporal Arg1:T7 Arg2:T8
48,*,OR T4 T14
49,R19,Has_qualifier Arg1:T3 Arg2:T2
50,T29,Negation 95 101	except
51,T30,Scope 103 528	Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer
52,R20,Has_negation Arg1:T30 Arg2:T29
53,R21,Has_scope Arg1:T3 Arg2:T30
54,T31,Condition 550 583	delayed hypersensitivity reaction
55,T32,Condition 537 546;558 583	immediate hypersensitivity reaction
56,*,OR T31 T32 T36
57,T33,Condition 587 599	idiosyncrasy
58,T34,Drug 603 642	drugs chemically related to panitumumab
59,T35,Drug 603 642;646 656	drugs chemically related to panitumumab excipients
60,*,OR T34 T35
61,T36,Scope 603 656	drugs chemically related to panitumumab or excipients
62,R22,AND Arg1:T36 Arg2:T33
63,T37,Procedure 706 743;751 767	anti-epidermal growth factor receptor antibody therapy
64,T38,Drug 775 786	panitumumab
65,T39,Drug 790 799	cetuximab
66,*,OR T39 T38
67,T40,Scope 775 799	panitumumab or cetuximab
68,R23,Subsumes Arg1:T37 Arg2:T40
69,T41,Procedure 745 749	EGFr
70,R24,Subsumes Arg1:T37 Arg2:T41
71,T42,Procedure 804 849	treatment with small molecule EGFr inhibitors
72,T43,Drug 857 866	gefitinib
73,T44,Drug 868 877	erlotinib
74,T45,Drug 879 888	lapatinib
75,*,OR T45 T44 T43
76,T46,"Scope 857 888	gefitinib, erlotinib, lapatinib"
77,R25,Subsumes Arg1:T42 Arg2:T46
78,*,OR T42 T37
79,T47,Procedure 892 909	Antitumor therapy
80,T48,Procedure 917 929	chemotherapy
81,T49,Procedure 931 947	hormonal therapy
82,T50,Procedure 949 962	immunotherapy
83,T51,Procedure 964 980	antibody therapy
84,T52,Procedure 982 994	radiotherapy
85,*,OR T52 T51 T50 T49 T48
86,T53,"Scope 917 994	chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy"
87,R26,Subsumes Arg1:T47 Arg2:T53
88,T54,Drug 1000 1021	investigational agent
89,T55,Procedure 1025 1032	therapy
90,T56,Temporal 1033 1079	<=30 days before first dose of study treatment
91,T57,Condition 1083 1120	not recovered from any acute toxicity
92,T58,Reference_point 1050 1079	first dose of study treatment
93,R27,Has_index Arg1:T56 Arg2:T58
94,*,OR T54 T55 T47
95,T59,"Scope 892 1032	Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy"
96,R28,Has_temporal Arg1:T59 Arg2:T56
97,*,OR T59 T57
98,T60,Temporal 1155 1183	<=30 days before study entry
99,T61,Qualifier 1123 1128	Other
100,T62,Procedure 1129 1154	investigational procedure
101,R29,Has_qualifier Arg1:T62 Arg2:T61
102,R30,Has_temporal Arg1:T62 Arg2:T60
103,T63,Condition 1197 1222	interstitial lung disease
104,T64,Condition 1224 1227	ILD
105,R31,Subsumes Arg1:T63 Arg2:T64
106,T65,Condition 1235 1259	interstitial pneumonitis
107,T66,Condition 1261 1279	pulmonary fibrosis
108,T67,Mood 1283 1294	evidence of
109,T68,Condition 1295 1298	ILD
110,T69,Temporal 1302 1310	baseline
111,T70,Procedure 1311 1336	chest computer tomography
112,R32,Has_temporal Arg1:T70 Arg2:T69
113,R33,Has_mood Arg1:T68 Arg2:T67
114,R34,AND Arg1:T70 Arg2:T68
115,*,OR T66 T70 T65
116,T71,"Scope 1235 1336	interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography"
117,T72,Scope 1197 1228	interstitial lung disease (ILD)
118,R35,Subsumes Arg1:T72 Arg2:T71
119,T73,Non-query-able 1339 1381	Subject previously enrolled to this study.
120,T74,Condition 1394 1403	keratitis
121,T75,Condition 1405 1425	ulcerative keratitis
122,T76,Qualifier 1429 1435	severe
123,T77,Condition 1436 1443	dry eye
124,R36,Has_qualifier Arg1:T77 Arg2:T76
125,*,OR T77 T75 T74
126,T78,Procedure 1446 1459	Major surgery
127,T79,Procedure 1477 1495	general anesthesia
128,T80,Temporal 1497 1543	<=30 days before first dose of study treatment
129,T81,Reference_point 1514 1543	first dose of study treatment
130,R37,Has_index Arg1:T80 Arg2:T81
131,R38,AND Arg1:T78 Arg2:T79
132,R39,Has_temporal Arg1:T78 Arg2:T80
133,T82,Non-query-able 1545 1610	Subjects must have recovered from any surgery related toxicities.
134,T83,Procedure 1612 1636	Minor surgical procedure
135,T84,Procedure 1644 1655	open biopsy
136,R40,Subsumes Arg1:T83 Arg2:T84
137,T85,Temporal 1657 1702	<=7 days before first dose of study treatment
138,T86,Reference_point 1673 1702	first dose of study treatment
139,R41,Has_index Arg1:T85 Arg2:T86
140,R42,Has_temporal Arg1:T83 Arg2:T85
141,T87,Negation 1707 1714	not yet
142,T88,Condition 1715 1724	recovered
143,T89,Temporal 1730 1735	prior
144,T90,Procedure 1736 1749	minor surgery
145,R43,Has_temporal Arg1:T90 Arg2:T89
146,R44,Has_negation Arg1:T88 Arg2:T87
147,R45,AND Arg1:T88 Arg2:T90
148,*,OR T83 T88
149,T91,Qualifier 1927 1949	Clinically significant
150,T92,Condition 1950 1972	cardiovascular disease
151,T93,Condition 1984 2005	myocardial infarction
152,T94,Condition 2007 2022	unstable angina
153,T95,Condition 2036 2060	congestive heart failure
154,T96,Qualifier 2024 2035	symptomatic
155,R46,Has_qualifier Arg1:T95 Arg2:T96
156,T97,Qualifier 2062 2069	serious
157,T98,Qualifier 2070 2082	uncontrolled
158,T99,Condition 2083 2101	cardiac arrhythmia
159,R47,Has_qualifier Arg1:T99 Arg2:T98
160,R48,Has_qualifier Arg1:T99 Arg2:T97
161,T100,Temporal 2103 2132	<=6 months prior to enrolment
162,T101,Reference_point 2123 2132	enrolment
163,R49,Has_index Arg1:T100 Arg2:T101
164,*,OR T93 T94 T95 T99
165,T102,"Scope 1984 2101	myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia"
166,*,OR T92 T91
167,T103,Scope 1927 1972	Clinically significant cardiovascular disease
168,R50,Subsumes Arg1:T103 Arg2:T102
169,R51,Has_temporal Arg1:T103 Arg2:T100
170,T104,"Post-eligibility 2135 2447	History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with the study participation or investigational product administration, compliance with the study procedures or may interfere with the interpretation of the results."
171,T105,Qualifier 2449 2457	Unstable
172,T106,Condition 2458 2476	pulmonary embolism
173,R52,Has_qualifier Arg1:T106 Arg2:T105
174,T107,Condition 2478 2498	deep vein thrombosis
175,T108,Qualifier 2503 2508	other
176,T109,Qualifier 2509 2520	significant
177,T110,Condition 2521 2529;2537 2557	arterial thromboembolic event
178,T111,Condition 2530 2557	venous thromboembolic event
179,T112,Temporal 2558 2604	<=30 days before first dose of study treatment
180,T113,Reference_point 2575 2604	first dose of study treatment
181,R53,Has_index Arg1:T112 Arg2:T113
182,*,OR T110 T111
183,T114,Scope 2521 2557	arterial/venous thromboembolic event
184,R54,Has_qualifier Arg1:T114 Arg2:T109
185,R55,Has_qualifier Arg1:T114 Arg2:T108
186,*,OR T106 T107 T114
187,T115,"Scope 2449 2557	Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event"
188,R56,Has_temporal Arg1:T115 Arg2:T112
189,T116,Procedure 2612 2627	anticoagulation
190,A1,Optional T116
191,T117,Qualifier 2648 2654	stable
192,T118,Multiplier 2655 2671	therapeutic dose
193,R57,Has_qualifier Arg1:T118 Arg2:T117
194,T119,Temporal 2672 2710	prior to first dose of study treatment
195,T120,Reference_point 2681 2710	first dose of study treatment
196,*,OR T119 T120
197,R58,Has_multiplier Arg1:T116 Arg2:T118
198,R59,Has_temporal Arg1:T116 Arg2:T119
199,T121,Condition 2728 2736	pregnant
200,T122,Observation 2740 2754	breast feeding
201,T123,Observation 2771 2786	become pregnant
202,T124,Temporal 2787 2803	during treatment
203,T125,Temporal 2808 2868	within 2 months after the discontinuation of study treatment
204,T126,Reference_point 2830 2868	the discontinuation of study treatment
205,R60,Has_index Arg1:T125 Arg2:T126
206,T127,Reference_point 2794 2803	treatment
207,R61,Has_index Arg1:T124 Arg2:T127
208,T128,Scope 2787 2868	during treatment and within 2 months after the discontinuation of study treatment
209,*,OR T123 T122 T121
210,T129,"Scope 2728 2786	pregnant or breast feeding, or planning to become pregnant"
211,R62,Has_scope Arg1:T129 Arg2:T128
212,T130,Measurement 2886 2936	test(s) for human immunodeficiency virus infection
213,T131,Value 2877 2885	positive
214,R63,Has_value Arg1:T130 Arg2:T131
215,T132,Condition 3009 3018	infection
216,T133,Temporal 3002 3008	Active
217,R64,Has_temporal Arg1:T132 Arg2:T133
218,T134,Procedure 3029 3047	systemic treatment
219,T135,Condition 3055 3077	uncontrolled infection
220,T136,Temporal 3078 3126	<=14 days prior to first dose of study treatment
221,T137,Reference_point 3097 3126	first dose of study treatment
222,R65,Has_index Arg1:T136 Arg2:T137
223,R66,AND Arg1:T132 Arg2:T134
224,*,OR T132 T135
225,T138,Qualifier 3051 3054	any
226,R67,Has_qualifier Arg1:T135 Arg2:T138
227,T139,Scope 3002 3077	Active infection requiring systemic treatment or any uncontrolled infection
228,R68,Has_temporal Arg1:T139 Arg2:T136
229,T140,Condition 3164 3187	urinary tract infection
230,T141,Qualifier 3150 3163	uncomplicated
231,R69,Has_qualifier Arg1:T140 Arg2:T141
232,T142,Negation 3128 3149	with the exception of
233,T143,Condition 3191 3224	upper respiratory tract infection
234,R70,Has_qualifier Arg1:T143 Arg2:T141
235,*,OR T140 T143
236,T144,Scope 3150 3224	uncomplicated urinary tract infection or upper respiratory tract infection
237,R71,Has_negation Arg1:T144 Arg2:T142
238,R72,Has_scope Arg1:T139 Arg2:T144
239,T145,Post-eligibility 3228 3437	Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures or is unwilling or unable to comply with study requirements.
240,T146,Mood 2759 2770	planning to
241,R73,Has_mood Arg1:T123 Arg2:T146
0,T1,Condition 11 32	serious complications
1,T2,Condition 34 55	cardiovascular events
2,T3,Condition 101 108;79 84	disease liver
3,T4,Condition 101 108;86 92	disease kidney
4,T5,Condition 96 108	lung disease
5,T6,Temporal 109 124	within 3 months
6,*,OR T4 T5 T3
7,T7,Qualifier 67 78	significant
8,T8,"Scope 79 108	liver, kidney or lung disease"
9,R1,Has_qualifier Arg1:T8 Arg2:T7
10,T9,"Scope 34 108	cardiovascular events and recent significant liver, kidney or lung disease"
11,*,OR T2 T8
12,R2,Has_temporal Arg1:T9 Arg2:T6
13,T10,"Scope 34 124	cardiovascular events and recent significant liver, kidney or lung disease within 3 months"
14,R3,Subsumes Arg1:T1 Arg2:T10
15,T11,Condition 127 146	high blood pressure
16,T12,Value 148 160	>160/100mmHg
17,T13,Measurement 132 146	blood pressure
18,R4,Has_value Arg1:T13 Arg2:T12
19,R5,Subsumes Arg1:T11 Arg2:T13
20,R6,multi Arg1:T11 Arg2:T13
21,T14,Condition 163 179	active infection
22,T15,Qualifier 181 190	secondary
23,T16,Condition 191 199	diabetes
24,R7,Has_qualifier Arg1:T16 Arg2:T15
25,T17,Condition 201 210	pregnancy
26,T18,Condition 212 225	alcohol abuse
27,T19,Condition 227 235	allergic
28,T20,Drug 239 261	GLP-1 receptor agonist
29,R8,AND Arg1:T19 Arg2:T20
0,T1,Measurement 0 19	ASA physical status
1,T2,Value 20 24	I-II
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 26 29	age
4,T4,Value 30 49	between 18-80 years
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Drug 55 75	dNMB with rocuronium
7,T6,Procedure 83 116	ear nose and throat (ENT) surgery
8,R3,AND Arg1:T6 Arg2:T5
0,T1,Person 0 3	Age
1,T2,Value 4 17	over 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 20 41	General Condition WHO
4,T4,Value 42 43	0
5,T5,Value 45 46	1
6,T6,Value 50 51	2
7,*,OR T4 T5 T6
8,T7,"Scope 42 51	0, 1 or 2"
9,R2,Has_scope Arg1:T3 Arg2:T7
10,T8,Measurement 54 63	ASA Class
11,T9,Value 64 65	I
12,T10,Value 70 72	II
13,*,OR T9 T10
14,T11,Scope 64 72	I and II
15,R3,Has_scope Arg1:T8 Arg2:T11
16,T12,Mood 74 86	eligible for
17,T13,Procedure 110 119;87 97	treatment endoscopic
18,T14,Procedure 101 119	surgical treatment
19,*,OR T14 T13
20,T15,Qualifier 120 140	with curative intent
21,T16,Scope 87 119	endoscopic or surgical treatment
22,R4,Has_qualifier Arg1:T16 Arg2:T15
23,R5,Has_mood Arg1:T16 Arg2:T12
24,R6,AND Arg1:T16 Arg2:T8
25,T17,Procedure 143 165	Histological diagnosis
26,T18,Condition 180 210	glandular epithelial neoplasia
27,T19,Measurement 212 218	Vienna
28,T20,Value 219 230	4-1 to 4-46
29,R7,Has_value Arg1:T19 Arg2:T20
30,T21,Qualifier 169 179	high grade
31,R8,Subsumes Arg1:T21 Arg2:T19
32,R9,Has_qualifier Arg1:T18 Arg2:T21
33,R10,AND Arg1:T18 Arg2:T17
34,T22,Qualifier 242 252	multifocal
35,T23,Measurement 256 261	stage
36,T24,Value 262 263	0
37,R11,Has_value Arg1:T23 Arg2:T24
38,T25,Measurement 265 266	T
39,T26,Measurement 270 271	N
40,T27,Measurement 274 275	M
41,T28,Value 275 276	0
42,T29,Value 271 272	0
43,T30,Value 266 268	is
44,R12,Has_value Arg1:T25 Arg2:T30
45,R13,Has_value Arg1:T26 Arg2:T29
46,R14,Has_value Arg1:T27 Arg2:T28
47,T31,"Scope 265 276	Tis, N0, M0"
48,T32,Scope 256 263	stage 0
49,R15,Subsumes Arg1:T32 Arg2:T31
50,R16,Has_qualifier Arg1:T18 Arg2:T22
51,R17,AND Arg1:T18 Arg2:T23
52,T33,Qualifier 295 317	histological confirmed
53,T34,Qualifier 280 290;308 317	Endoscopic confirmed
54,T35,Condition 331 352	intestinal metaplasia
55,T36,Procedure 295 307	histological
56,T37,Procedure 280 290	Endoscopic
57,R18,multi Arg1:T33 Arg2:T36
58,R19,multi Arg1:T34 Arg2:T37
59,*,OR T34 T33
60,T38,Scope 280 317	Endoscopic and histological confirmed
61,R20,Has_scope Arg1:T35 Arg2:T38
62,T39,Qualifier 355 367	Histological
63,T40,Procedure 355 367	Histological
64,R21,multi Arg1:T39 Arg2:T40
65,T41,Multiplier 391 394	two
66,T42,Procedure 395 406	endoscopies
67,R22,Has_multiplier Arg1:T42 Arg2:T41
68,R23,AND Arg1:T39 Arg2:T42
69,T43,Procedure 412 420	biopsies
70,R24,AND Arg1:T42 Arg2:T43
71,T44,Multiplier 425 428	two
72,T45,Procedure 429 450	pathological readings
73,R25,Has_multiplier Arg1:T45 Arg2:T44
74,R26,AND Arg1:T39 Arg2:T45
75,T46,Condition 368 377	diagnosis
76,R27,Has_qualifier Arg1:T46 Arg2:T39
77,T47,Non-representable 452 599	biopsies should be carried out according to the protocol of the SFED (four-quadrant biopsies every cm) with at least once acetic acid for staining.
78,T48,Non-representable 600 671	Operators describe Barrett's esophagus using he SFED planimetric model.
79,T49,"Non-representable 672 808	The final exam will be no more than two months before the date of treatment and should have been achieved in investigator establishment,"
80,T50,"Non-representable 810 823	Minimum 1 cm,"
81,T51,Non-representable 825 839	Maximum 12 cm.
82,T52,Condition 845 860	resected lesion
83,T53,Qualifier 876 895	well differentiated
84,T54,Qualifier 900 922	confined to the mucosa
85,T55,Qualifier 924 934	m2 maximum
86,T56,Procedure 939 960	histological analysis
87,R28,AND Arg1:T56 Arg2:T52
88,R29,Has_qualifier Arg1:T52 Arg2:T53
89,R30,Subsumes Arg1:T54 Arg2:T55
90,R31,Has_qualifier Arg1:T52 Arg2:T54
91,T57,Condition 963 972	resection
92,T58,Temporal 983 1003	more than two months
93,R32,Has_temporal Arg1:T57 Arg2:T58
94,T59,Condition 1006 1015	resection
95,T60,Qualifier 1031 1065	macroscopically complete laterally
96,R33,Has_qualifier Arg1:T59 Arg2:T60
97,T61,Condition 1068 1077	resection
98,T62,Procedure 1093 1107	histologically
99,T63,Qualifier 1108 1125	complete in depth
100,R34,Has_qualifier Arg1:T61 Arg2:T63
101,R35,AND Arg1:T62 Arg2:T61
102,T64,Condition 1128 1137	resection
103,T65,Procedure 1153 1167	histologically
104,T66,Qualifier 1168 1186	complete laterally
105,R36,Has_qualifier Arg1:T64 Arg2:T66
106,T67,"Non-representable 1228 1367	that is to say with a clear margin of safety (margin may be high-grade dysplasia provided that the latter has not macroscopic translation),"
107,T68,Condition 1206 1226	microinvasive cancer
108,R37,AND Arg1:T66 Arg2:T68
109,T69,"Non-representable 1369 1551	At least one endoscopic and histologic follow-up should be conducted with dye in a period of less than two months before the date of treatment, and at the investigator establishment."
110,T70,Non-representable 1553 1641	Patient may take an inhibitor of proton pump equivalent to 2 times 40 mg of esomeprazole
111,T71,Qualifier 1683 1693	metastatic
112,T72,Qualifier 1662 1668	celiac
113,T73,Qualifier 1647 1658	mediastinal
114,T74,"Scope 1647 1693	mediastinal or celiac, or suspected metastatic"
115,T75,Condition 1694 1705	lymph nodes
116,T76,Procedure 1709 1712	EUS
117,T77,Negation 1644 1646	No
118,R38,Has_negation Arg1:T75 Arg2:T77
119,R39,Has_scope Arg1:T75 Arg2:T74
120,R40,AND Arg1:T76 Arg2:T75
121,T78,Observation 1715 1754	Affiliation to a social security system
122,T79,Negation 1768 1775	Lack of
123,T80,Observation 1776 1792;1801 1815	participation in clinical study
124,T81,Qualifier 1793 1800	another
125,R41,Has_qualifier Arg1:T80 Arg2:T81
126,R42,Has_negation Arg1:T80 Arg2:T79
127,T82,Observation 1818 1841	Informed consent signed
0,T1,Post-eligibility 0 85	Subject or subject's legally acceptable representative has provided informed consent.
1,T2,Person 87 91	Male
2,T3,Person 95 101	female
3,T4,Value 102 112	>=18 years
4,T5,Person 116 119	age
5,R1,Has_value Arg1:T5 Arg2:T4
6,*,OR T3 T2
7,T6,Procedure 122 136	Histologically
8,T7,Procedure 140 153	cytologically
9,T8,Value 154 163	confirmed
10,T9,Condition 177 191	adenocarcinoma
11,T10,Qualifier 199 204	colon
12,T11,Qualifier 208 214	rectum
13,*,OR T10 T11
14,T12,Scope 199 214	colon or rectum
15,R2,Has_scope Arg1:T9 Arg2:T12
16,*,OR T7 T6
17,T13,Scope 122 153	Histologically or cytologically
18,R3,Has_value Arg1:T13 Arg2:T8
19,R4,Has_scope Arg1:T9 Arg2:T13
20,T14,"Non-query-able 217 480	Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status."
21,T15,Measurement 482 542	Eastern Cooperative Oncology Group (ECOG) performance status
22,T16,"Value 546 555	0, 1 or 2"
23,R5,Has_value Arg1:T15 Arg2:T16
24,T17,Condition 572 594	non-measurable disease
25,T18,Condition 558 568;587 594	Measurable disease
26,*,OR T17 T18
27,T19,Procedure 599 617	RECIST Version 1.1
28,T20,Scope 558 594	Measurable or non-measurable disease
29,R6,AND Arg1:T20 Arg2:T19
30,T21,Qualifier 630 636	failed
31,T22,Procedure 643 660;691 714	fluoropyrimidine- containing chemotherapy
32,T23,Procedure 662 674;691 714	oxaliplatin- containing chemotherapy
33,T24,Procedure 680 714	irinotecan-containing chemotherapy
34,T25,Condition 728 746	metastatic disease
35,*,OR T24 T23 T22
36,T26,"Scope 643 714	fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy"
37,R7,AND Arg1:T26 Arg2:T25
38,R8,Has_qualifier Arg1:T26 Arg2:T21
39,T27,Condition 777 796	disease progression
40,T28,Condition 827 838	intolerance
41,T29,Procedure 842 853	the regimen
42,R9,AND Arg1:T28 Arg2:T29
43,T30,Condition 855 873	Metastatic relapse
44,T31,Temporal 874 928	within 6 months after completing adjuvant chemotherapy
45,T32,Reference_point 890 928	after completing adjuvant chemotherapy
46,T33,Procedure 945 955;971 989	irinotecan containing regimen
47,T34,Procedure 959 989	oxaliplatin containing regimen
48,*,OR T34 T33
49,T35,Scope 945 989	irinotecan or oxaliplatin containing regimen
50,R10,Has_temporal Arg1:T30 Arg2:T31
51,R11,Has_scope Arg1:T30 Arg2:T35
52,T36,Condition 1091 1123	Adequate baseline organ function
53,T37,Temporal 1136 1183	<=7 days prior to first dose of study treatment
54,T38,Reference_point 1154 1183	first dose of study treatment
55,R12,Has_index Arg1:T37 Arg2:T38
56,R13,Has_temporal Arg1:T36 Arg2:T37
57,*,OR T27 T28 T30
58,T39,Scope 748 1078	Failure is defined as either disease progression (clinical or radiological) or intolerance to the regimen. Metastatic relapse within 6 months after completing adjuvant chemotherapy (with either an irinotecan or oxaliplatin containing regimen) will also be considered as treatment failure of a prior regimen for metastatic disease.
59,R14,Subsumes Arg1:T21 Arg2:T39
60,T40,Measurement 1221 1252	Absolute neutrophil count (ANC)
61,T41,Value 1253 1275	>=1.5 x 10^9/Liter (L)
62,R15,Has_value Arg1:T40 Arg2:T41
63,T42,Measurement 1277 1291	Platelet count
64,T43,Value 1292 1305	>=75 x 10^9/L
65,R16,Has_value Arg1:T42 Arg2:T43
66,T44,Measurement 1307 1317	Hemoglobin
67,T45,Value 1318 1345	>=8.0 gram/deciliter (g/dL)
68,R17,Has_value Arg1:T44 Arg2:T45
69,*,OR T40 T42 T44
70,T46,Measurement 1376 1386	Creatinine
71,T47,Value 1387 1422	<=1.5 x upper limit of normal (ULN)
72,R18,Has_value Arg1:T46 Arg2:T47
73,T48,Measurement 1456 1487	spartate aminotransferase (AST)
74,T49,Value 1488 1497	<=3 x ULN
75,R19,Has_value Arg1:T48 Arg2:T49
76,T50,Measurement 1499 1529	Alanine aminotransferase (ALT)
77,T51,Value 1530 1539	<=3 x ULN
78,R20,Has_value Arg1:T50 Arg2:T51
79,T52,Measurement 1541 1556	Total Bilirubin
80,T53,Value 1557 1568	<=1.5 x ULN
81,R21,Has_value Arg1:T52 Arg2:T53
82,T54,Measurement 1603 1618	Serum Magnesium
83,T55,Value 1619 1639	within normal limits
84,R22,Has_value Arg1:T54 Arg2:T55
85,T56,Measurement 1641 1654	Serum Calcium
86,T57,Value 1655 1675	within normal limits
87,R23,Has_value Arg1:T56 Arg2:T57
88,T58,Measurement 1677 1692	Serum Potassium
89,T59,Value 1693 1713	within normal limits
90,R24,Has_value Arg1:T58 Arg2:T59
91,T60,"Pregnancy_considerations 1861 2324	Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use adequate contraception, during the study and for 2 months following the last dose of study treatment. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use adequate contraception, from time of signing informed consent until 5 months after the last dose of study treatment."
92,T61,Non-query-able 1716 1859	All prior treatment related toxicities common terminology criteria for adverse events (CTCAE) version 4.03 <=Grade 1 at the time of enrollment.
0,T1,Condition 33 46	renal disease
1,T2,Condition 22 29;39 46	hepatic disease
2,*,OR T1 T2
3,T3,Qualifier 0 18	Clinical diagnosis
4,T4,Qualifier 48 66	Clinical diagnosis
5,T5,Qualifier 81 86	acute
6,T6,Qualifier 70 77	chronic
7,T7,Condition 87 97	alcoholism
8,*,OR T6 T5
9,T8,Scope 70 86	chronic or acute
10,R1,Has_scope Arg1:T7 Arg2:T8
11,R2,Has_qualifier Arg1:T7 Arg2:T4
12,T9,Condition 110 117	allergy
13,T10,Condition 121 137	hypersensitivity
14,T11,Drug 141 151	Sugammadex
15,T12,Drug 159 167	atropine
16,T13,Drug 171 182	Neostigmine
17,*,OR T12 T13 T11
18,T14,Scope 141 182	Sugammadex and/or atropine or Neostigmine
19,*,OR T9 T10
20,T15,Scope 110 137	allergy or hypersensitivity
21,R3,Has_scope Arg1:T15 Arg2:T14
22,T16,Condition 209 220	CNS effects
23,T17,Drug 192 203	medications
24,R4,AND Arg1:T17 Arg2:T16
25,T18,Condition 233 251	neurologic disease
26,T19,Observation 222 229	History
27,R5,Has_temporal Arg1:T18 Arg2:T19
28,T20,Condition 253 272	Diaphragmatic palsy
29,T21,Condition 274 283	Pregnancy
30,T22,Condition 287 294	nursing
31,*,OR T21 T22
32,T23,Observation 296 303	History
33,T24,Condition 307 328	malignant arrhythmias
34,R6,Has_temporal Arg1:T24 Arg2:T23
35,T25,Scope 22 46	hepatic or renal disease
36,R7,Has_qualifier Arg1:T25 Arg2:T3
37,T26,Observation 99 106	History
38,R8,Has_temporal Arg1:T15 Arg2:T26
0,T1,Condition 0 10	Overweight
1,T2,Condition 15 20	obese
2,T3,Condition 21 25	PCOS
3,*,OR T2 T1
4,T4,Temporal 40 55	newly diagnosed
5,T5,Condition 56 59	IGR
6,R1,Has_temporal Arg1:T5 Arg2:T4
7,T6,Condition 62 66	PCOS
8,T7,Qualifier 86 109	2003 Rotterdam criteria
9,R2,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Condition 111 121	Overweight
11,T9,Condition 124 131	obesity
12,T10,Qualifier 165 172	WHO-WPR
13,*,OR T9 T8
14,T11,Scope 111 131	Overweight / obesity
15,R3,Has_qualifier Arg1:T11 Arg2:T10
16,T12,Condition 174 201	Impaired glucose regulation
17,T13,Qualifier 235 263	1998 WHO diagnostic criteria
18,R4,Has_qualifier Arg1:T12 Arg2:T13
0,T1,Person 0 4	Aged
1,T2,Value 5 13	under 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Negation 16 23	Lack of
4,T4,Observation 24 47	informed consent signed
5,R2,Has_negation Arg1:T4 Arg2:T3
6,T5,Procedure 50 74	Radiofrequency treatment
7,T6,Observation 75 82	history
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Temporal 85 93	on going
10,T8,Condition 94 104	neoplastic
11,T9,Observation 105 112	history
12,R4,Has_temporal Arg1:T8 Arg2:T9
13,R5,Has_temporal Arg1:T8 Arg2:T7
14,T10,Value 120 125	short
15,T11,Measurement 126 135	prognosis
16,R6,Has_value Arg1:T11 Arg2:T10
17,R7,AND Arg1:T8 Arg2:T11
18,T12,Observation 150 189	participation in another clinical study
19,T13,Temporal 138 149	Concomitant
20,R8,Has_temporal Arg1:T12 Arg2:T13
21,T14,Condition 191 207	Contraindication
22,T15,Procedure 211 229	general anesthesia
23,R9,AND Arg1:T14 Arg2:T15
24,T16,Qualifier 248 267	esophageal location
25,T17,Condition 271 282	scleroderma
26,R10,Has_qualifier Arg1:T17 Arg2:T16
27,T18,Device 298 315	cardiac pacemaker
28,T19,Device 298 305;319 329	cardiac stimulator
29,*,OR T18 T19
30,T20,Observation 331 339	Pregnant
31,T21,Person 340 345	women
32,T22,Mood 349 361	likely to be
33,T23,Observation 331 339	Pregnant
34,R11,Has_mood Arg1:T20 Arg2:T22
35,*,OR T23 T20
36,T24,Qualifier 362 403	in the absence of effective contraception
37,R12,Has_qualifier Arg1:T20 Arg2:T24
38,T25,Condition 406 425	Esophageal stenosis
39,T26,Mood 426 440	preventing the
40,T27,Device 455 464	endoscope
41,T28,Procedure 441 464	passage of an endoscope
42,R13,multi Arg1:T28 Arg2:T27
43,R14,Has_mood Arg1:T28 Arg2:T26
44,R15,AND Arg1:T25 Arg2:T28
45,T29,Procedure 467 476	Histology
46,T30,Condition 488 507	glandular neoplasia
47,T31,Qualifier 477 487	other than
48,R16,Has_qualifier Arg1:T30 Arg2:T31
49,R17,AND Arg1:T29 Arg2:T30
50,T32,Observation 510 517	History
51,T33,Temporal 524 531	current
52,T34,Condition 543 560	esophageal cancer
53,T35,Qualifier 561 607	invading the submucosal layer of the esophagus
54,R18,Has_qualifier Arg1:T34 Arg2:T35
55,*,OR T33 T32
56,T36,Scope 510 531	History of or current
57,R19,Has_scope Arg1:T34 Arg2:T36
58,T37,Procedure 618 636	Surgical treatment
59,T38,Observation 637 644	history
60,R20,Has_temporal Arg1:T37 Arg2:T38
61,T39,Procedure 653 674	anti-reflux treatment
62,T40,Negation 646 652	except
63,R21,Has_negation Arg1:T39 Arg2:T40
64,T41,Procedure 679 702	esophageal radiotherapy
65,R22,AND Arg1:T37 Arg2:T39
66,*,OR T37 T41
67,T42,Temporal 705 713	previous
68,T43,Procedure 714 734	esophageal treatment
69,T44,Qualifier 738 752	another method
70,T45,Procedure 753 761	ablation
71,R24,Has_qualifier Arg1:T45 Arg2:T44
72,R25,Has_temporal Arg1:T43 Arg2:T42
73,T46,Procedure 763 783	photodynamic therapy
74,T47,Procedure 785 809	argon plasma coagulation
75,T48,Procedure 811 816	laser
76,*,OR T46 T47 T48
77,T49,"Scope 763 816	photodynamic therapy, argon plasma coagulation, laser"
78,T50,Scope 738 761	another method ablation
79,R23,Subsumes Arg1:T50 Arg2:T49
80,R26,Has_scope Arg1:T43 Arg2:T50
81,T51,Condition 824 842	Esophageal varices
82,T52,Procedure 855 864	endoscopy
83,R27,AND Arg1:T52 Arg2:T51
84,T53,Condition 867 879	Coagulopathy
85,T54,Drug 890 904	anticoagulants
86,T55,Measurement 920 923	INR
87,T56,Value 923 928	> 1.3
88,R28,Has_value Arg1:T55 Arg2:T56
89,T57,Measurement 934 948	platelet count
90,T58,"Value 949 967	<75,000 per microL"
91,R29,Has_value Arg1:T57 Arg2:T58
92,*,OR T57 T55
93,*,OR T53 T54
94,T59,Non-representable 905 919	responsible an
95,T60,Measurement 970 985	Life expectancy
96,T61,Value 989 1006	less than 3 years
97,*,OR T60 T61
98,T62,Condition 1015 1035	intercurrent disease
99,T63,Condition 1048 1058	neoplastic
100,T64,"Scope 1015 1058	intercurrent disease, especially neoplastic"
101,R30,AND Arg1:T64 Arg2:T60
102,T65,Non-representable 1008 1014	due to
103,T66,Condition 1061 1076	Liver cirrhosis
104,T67,Measurement 1078 1088	Child-Pugh
105,T68,Value 1089 1099	all stages
106,R31,Has_value Arg1:T67 Arg2:T68
107,R32,AND Arg1:T66 Arg2:T67
108,T69,Condition 1102 1121	Respiratory failure
109,T70,Condition 1124 1137	Renal failure
110,T71,Measurement 1139 1144	Cl Cr
111,T72,"Value 1145 1164	< 60 mL /min /1,73m"
112,R33,Has_value Arg1:T71 Arg2:T72
113,R34,AND Arg1:T70 Arg2:T71
114,T73,Condition 1168 1180	Heart attack
115,T74,Temporal 1181 1207	within the last six months
116,T75,Condition 1211 1246	progressive coronary artery disease
117,R35,Has_temporal Arg1:T73 Arg2:T74
118,T76,Reference_point 1188 1207	the last six months
119,R36,Has_index Arg1:T74 Arg2:T76
120,*,OR T73 T75
121,T77,Qualifier 1249 1255	Severe
122,T78,Condition 1256 1276	distal arteriopathie
123,T79,Measurement 1279 1284;1288 1311	stage of Leriche and Fontaine
124,T80,Value 1277 1278;1285 1287	> II
125,R37,Has_value Arg1:T79 Arg2:T80
126,R38,Has_qualifier Arg1:T78 Arg2:T77
127,R39,AND Arg1:T78 Arg2:T79
0,T1,Person 0 3	Men
1,T2,Person 20 25	women
2,T3,Qualifier 7 19	non-pregnant
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Person 63 66	age
5,T5,Value 70 89	18 and 45 years old
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Person 108 119	non-smokers
8,*,OR T2 T1
9,T7,Informed_consent 369 443	Provide written informed consent before initiation of any study procedures
10,T8,Post-eligibility 445 506	Available for follow-up for the planned duration of the study
11,T9,Non-query-able 508 555	Able to communicate well with the investigators
12,T10,"Post-eligibility 557 647	Able to adhere to the study protocol schedule, study restrictions and examination schedule"
13,T11,Measurement 698 701	BMI
14,T12,Value 702 727	between >17 and =28 kg/m2
15,R3,Has_value Arg1:T11 Arg2:T12
16,T13,"Non-query-able 730 895	Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication histor"
17,T14,Condition 971 975	pain
18,T15,Qualifier 949 954	acute
19,T16,Qualifier 958 970	intermittent
20,T17,Scope 949 970	acute or intermittent
21,R4,Has_scope Arg1:T14 Arg2:T17
22,T18,Condition 991 995	pain
23,T19,Qualifier 977 990	postoperative
24,R5,Has_qualifier Arg1:T18 Arg2:T19
25,T20,Condition 997 1019	respiratory compromise
26,T21,Condition 1037 1043	asthma
27,T22,Qualifier 1021 1026	acute
28,T23,Qualifier 1030 1036	severe
29,T24,Negation 912 914	no
30,*,OR T23 T22
31,T25,Scope 1021 1036	acute or severe
32,R6,Has_scope Arg1:T21 Arg2:T25
33,T26,Condition 1048 1060	constipation
34,T27,"Scope 949 1060	acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation"
35,R7,Has_negation Arg1:T27 Arg2:T24
36,T28,Measurement 1113 1138	urine drug screening test
37,T29,Value 1104 1112	Negative
38,R8,Has_value Arg1:T28 Arg2:T29
39,T30,Value 1170 1176	normal
40,T31,Measurement 1204 1221	white blood cells
41,T32,Measurement 1223 1226	WBC
42,T33,Measurement 1229 1239	hemoglobin
43,T34,Measurement 1241 1244	Hgb
44,T35,Measurement 1247 1256	platelets
45,T36,Measurement 1258 1264	sodium
46,T37,Measurement 1266 1275	potassium
47,T38,Measurement 1277 1285	chloride
48,T39,Measurement 1287 1298	bicarbonate
49,T40,Measurement 1300 1319	blood urea nitrogen
50,T41,Measurement 1321 1324	BUN
51,T42,Measurement 1327 1337	creatinine
52,T43,Measurement 1339 1342	ALT
53,T44,Measurement 1361 1364	AST
54,T45,Measurement 1386 1395	bilirubin
55,R9,Subsumes Arg1:T31 Arg2:T32
56,R10,Subsumes Arg1:T33 Arg2:T34
57,R11,Subsumes Arg1:T40 Arg2:T41
58,T46,"Scope 1204 1395	white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin"
59,R12,Has_value Arg1:T46 Arg2:T30
60,T47,Value 1402 1408	normal
61,T48,Measurement 1436 1449	urine protein
62,T49,Measurement 1454 1467	urine glucose
63,T50,Scope 1436 1467	urine protein and urine glucose
64,R13,Has_value Arg1:T50 Arg2:T47
65,*,OR T16 T15
66,T51,"Pregnancy_considerations 1469 2016	Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parte"
67,T52,Competing_trial 2019 2199	Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session
68,T53,Non-query-able 2202 2328	grees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day
69,T54,Measurement 2344 2347	ECG
70,T55,Value 2337 2343	normal
71,R14,Has_value Arg1:T54 Arg2:T55
72,T56,Negation 2354 2357	not
73,T57,Observation 2395 2426	pathologic Q wave abnormalities
74,T58,Observation 2440 2457	ST-T wave changes
75,T59,Condition 2459 2487	left ventricular hypertrophy
76,T60,Condition 2489 2514	right bundle branch block
77,T61,Condition 2516 2540	left bundle branch block
78,T62,"Scope 2395 2541	pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block."
79,R15,Has_negation Arg1:T62 Arg2:T56
80,T63,Measurement 2593 2604	Temperature
81,T64,Value 2605 2614	35-37.9°C
82,T65,Value 2616 2626	95-100.3°F
83,R16,Subsumes Arg1:T64 Arg2:T65
84,R17,Has_value Arg1:T63 Arg2:T64
85,T66,Measurement 2629 2652	Systolic blood pressure
86,T67,Value 2653 2664	90-140 mmHg
87,R18,Has_value Arg1:T66 Arg2:T67
88,T68,Measurement 2666 2690	Diastolic blood pressure
89,T69,Value 2691 2701	60-90 mmHg
90,R19,Has_value Arg1:T68 Arg2:T69
91,T70,Measurement 2703 2713	Heart rate
92,T71,Value 2714 2737	55-100 beats per minute
93,R20,Has_value Arg1:T70 Arg2:T71
94,T72,Measurement 2739 2755	Respiration rate
95,T73,Value 2756 2780	12-18 breaths per minute
96,R21,Has_value Arg1:T72 Arg2:T73
0,T1,Qualifier 31 40	high-risk
1,T2,Qualifier 57 60	cT3
2,T3,Qualifier 10 27	intermediate-risk
3,T4,Condition 41 56	prostate cancer
4,*,OR T3 T1
5,T5,Scope 10 40	intermediate-risk or high-risk
6,R1,Has_scope Arg1:T4 Arg2:T5
7,R2,Has_qualifier Arg1:T4 Arg2:T2
8,T6,Measurement 62 75	Gleason score
9,T7,Value 76 79	= 7
10,T8,Value 81 84	3+4
11,T9,Value 92 95	4+3
12,*,OR T8 T9
13,T10,Scope 81 95	3+4 and/or 4+3
14,R3,Subsumes Arg1:T7 Arg2:T10
15,R4,Has_scope Arg1:T6 Arg2:T10
16,T11,Measurement 105 108	PSA
17,T12,Value 109 119	= 20 ng/ml
18,R5,Has_value Arg1:T11 Arg2:T12
19,T13,Condition 121 127;141 158	intact erectile function
20,T14,Temporal 128 140	preoperative
21,R6,Has_temporal Arg1:T13 Arg2:T14
22,T15,Measurement 167 171	IIEF
23,T16,Value 172 176	= 21
24,T17,Observation 178 184	IIEF-6
25,R7,Has_value Arg1:T15 Arg2:T16
26,T18,Scope 167 176	IIEF = 21
27,R8,Subsumes Arg1:T18 Arg2:T17
28,R9,Has_scope Arg1:T13 Arg2:T18
0,T1,Measurement 0 3	ASA
1,T2,Value 44 55	class 1 & 2
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 78 94	knee arthroscopy
0,T1,Condition 14 35	medical comorbidities
1,T2,Procedure 57 84	definitive surgical therapy
2,T3,Mood 36 56	preventing them from
3,R1,Has_mood Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Qualifier 101 111	persistent
6,T5,Observation 112 124	stone burden
7,T6,Temporal 125 162	following definitive surgical therapy
8,T7,Reference_point 135 162	definitive surgical therapy
9,T8,Procedure 135 162	definitive surgical therapy
10,R3,multi Arg1:T7 Arg2:T8
11,R4,AND Arg1:T6 Arg2:T8
12,R5,Has_qualifier Arg1:T5 Arg2:T4
13,R6,Has_temporal Arg1:T5 Arg2:T6
0,T1,Measurement 0 12	uterine size
1,T2,Value 13 22	<12 weeks
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 37 49	benign cause
4,T4,Procedure 58 70	hysterectomy
5,T5,Condition 76 90	fibroid uterus
6,T6,Condition 92 114	perimenopausal beeding
7,T7,Negation 115 118	not
8,T8,Qualifier 119 150	responding to medical treatment
9,T9,Procedure 133 150	medical treatment
10,R2,multi Arg1:T8 Arg2:T9
11,T10,Condition 154 185	complex endometrial hyperplasia
12,T11,Negation 186 193	without
13,T12,Condition 194 200	atypia
14,R3,Has_negation Arg1:T12 Arg2:T11
15,R4,AND Arg1:T10 Arg2:T12
16,R5,AND Arg1:T3 Arg2:T4
17,T13,Scope 37 70	benign cause for the hysterectomy
18,*,OR T5 T6 T10
19,R6,Has_qualifier Arg1:T6 Arg2:T8
20,R7,Has_negation Arg1:T8 Arg2:T7
21,T14,"Scope 76 200	fibroid uterus, perimenopausal beeding not responding to medical treatment or complex endometrial hyperplasia without atypia"
22,R8,Subsumes Arg1:T13 Arg2:T14
23,T15,Negation 203 210	Absence
24,T16,Condition 214 234	significant scarring
25,T17,Qualifier 242 248	pelvis
26,T18,Qualifier 249 272	from previous surgeries
27,T19,Temporal 254 262	previous
28,T20,Procedure 263 272	surgeries
29,R9,Has_temporal Arg1:T20 Arg2:T19
30,R10,multi Arg1:T18 Arg2:T20
31,R11,Has_qualifier Arg1:T16 Arg2:T17
32,R12,Has_qualifier Arg1:T16 Arg2:T18
33,R13,Has_negation Arg1:T16 Arg2:T15
0,T1,Condition 0 11	micturition
1,T2,Observation 23 43	neurological history
2,T3,Procedure 57 80	lower abdominal surgery
3,T4,Condition 98 109	micturition
4,T5,Qualifier 89 97	abnormal
5,R1,Has_qualifier Arg1:T4 Arg2:T5
0,T1,"Pregnancy_considerations 0 191	Women who are pregnant, lactating or breast feeding or have a positive serum pregnancy test at enrollment or positive urine pregnancy test on the morning of the first day of any study session"
1,T2,Person 193 200	Smokers
2,T3,Competing_trial 391 481	Participation in any ongoing investigational drug trial/study or clinical drug trial/study
3,T4,Condition 494 531	chronic obstructive pulmonary disease
4,T5,"Condition 535 549	cor pulmonale,"
5,T6,Condition 567 596	decreased respiratory reserve
6,T7,Condition 598 605	hypoxia
7,T8,Condition 607 618	hypercapnia
8,T9,Condition 635 657	respiratory depression
9,*,OR T4 T5 T6 T7 T8 T9
10,T10,Measurement 694 708	HIV serologies
11,T11,Measurement 675 686;698 708	Hepatitis B serologies
12,T12,Measurement 675 684;688 689;698 708	Hepatitis C serologies
13,*,OR T10 T11 T12
14,T13,"Scope 675 708	Hepatitis B, C and HIV serologies"
15,T14,Value 666 674	positive
16,R1,Has_value Arg1:T13 Arg2:T14
17,T15,Measurement 719 744	urine drug screening test
18,T16,Value 710 718	Positive
19,R2,Has_value Arg1:T15 Arg2:T16
20,T17,"Non-query-able 746 1020	Use of any prescription medication during the session 0 to 30 days or over-the counter medication e.g. antihistamines or topical corticosteroids (vitamin, herbal supplements and birth control medications not included) during the session 0 to 3 days before entry to the study"
21,T18,"Non-query-able 1022 1536	Use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product or agents deemed to be immunosuppressive as determined by physician investigator with 72 hours prior to dosing (e.g. antihistamines, systemic or topical corticosteroids (within 3 weeks prior to dosing), cyclosporine, tacrolimus, cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin (BCG), monoclonal antibodies, radiation therapy"
22,T19,Drug 1546 1574	monoamine oxidase inhibitors
23,T20,Temporal 1575 1597	21 days prior to study
24,T21,Reference_point 1592 1597	study
25,R3,Has_temporal Arg1:T19 Arg2:T20
26,R4,Has_index Arg1:T20 Arg2:T21
27,T22,Drug 1648 1659	pentazocine
28,T23,Drug 1661 1671	nalbuphine
29,T24,Drug 1675 1686	butorphanol
30,T25,Drug 1709 1722	buprenorphine
31,*,OR T22 T23 T24 T25
32,T26,Drug 1751 1767	anticholinergics
33,T27,"Non-query-able 1820 1983	Consumption of beverages containing alcohol, grapefruit juice, Seville oranges, or quinine (e.g. tonic water) or foods containing poppy seeds in the last 72 hours."
34,T28,Non-query-able 1985 2072	Donation or loss of greater than one pint of blood within 60 days of entry to the study
35,T29,Condition 2112 2128	hypersensitivity
36,T30,Drug 2132 2140	fentanyl
37,T31,Drug 2142 2150	morphine
38,T32,Drug 2152 2159	codeine
39,T33,Drug 2161 2172	hydrocodone
40,T34,Drug 2174 2187	hydromorphone
41,T35,Drug 2189 2198	oxycodone
42,T36,Drug 2200 2211	oxymorphone
43,T37,Drug 2213 2223	naltrexone
44,T38,Drug 2227 2235	naloxone
45,T39,Device 2278 2282	TDDS
46,*,OR T30 T31 T32 T33 T34 T35 T36 T37 T38 T39
47,T40,Device 2284 2313	polyester/ethyl vinyl acetate
48,T41,Device 2315 2336	polyacrylate adhesive
49,T42,Device 2338 2355	silicone adhesive
50,T43,Device 2357 2371	dimethicone NF
51,T44,Device 2376 2386	polyolefin
52,*,OR T40 T41 T42 T43 T44
53,T45,"Scope 2132 2386	fentanyl, morphine, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, naltrexone or naloxone or any of the inactive ingredients in the TDDS (polyester/ethyl vinyl acetate, polyacrylate adhesive, silicone adhesive, dimethicone NF, or polyolefin"
54,T46,"Scope 2284 2386	polyester/ethyl vinyl acetate, polyacrylate adhesive, silicone adhesive, dimethicone NF, or polyolefin"
55,R5,Subsumes Arg1:T39 Arg2:T46
56,R6,Has_scope Arg1:T29 Arg2:T45
57,T47,Condition 2409 2422	schizophrenia
58,T48,Condition 2432 2459	major psychiatric diagnosis
59,T49,Condition 2463 2477	mental illness
60,T50,Condition 2484 2500	major depression
61,*,OR T47 T48 T49
62,R7,Subsumes Arg1:T49 Arg2:T50
63,T51,Condition 2547 2556	addiction
64,T52,Condition 2560 2565	abuse
65,T53,Qualifier 2539 2546	alcohol
66,T54,Qualifier 2531 2535	drug
67,*,OR T53 T54
68,T55,Scope 2531 2546	drug or alcohol
69,T56,Scope 2547 2565	addiction or abuse
70,R8,Has_scope Arg1:T56 Arg2:T55
71,*,OR T51 T52
72,T57,"Non-query-able 2567 2741	Any condition that would, in the opinion of the MAI, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol"
73,T58,Post-eligibility 2743 2803	Inability to communicate or cooperate with the investigators
74,T59,"Non-query-able 2805 3125	Subject has an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at the application site (upper arm), sunburn, raised moles and scars, open sore, scar tissue, tattoo, or coloration that would interfere with placement of test articles, skin assessment, or reactions to drug"
75,T60,"Non-query-able 3127 3461	Failure to pass opioid dependence challenge test on the first day study day of any study session (i.e., before taking the first dose of naltrexone hydrochloride). Each subject will be injected subcutaneously with naloxone hydrochloride (0.8 mg injection) and will be observed for 45 minutes for signs and symptoms of opioid withdrawal"
76,T61,"Non-query-able 3464 3755	Within 4 weeks prior to dosing, use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product or agents deemed to be immunosuppressive as determined by physician investigator"
0,T1,Measurement 0 4	IIEF
1,T2,Value 5 9	< 21
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Temporal 22 42	in the past 6 months
4,T4,Procedure 11 21	Operations
5,R2,Has_temporal Arg1:T4 Arg2:T3
6,T5,Condition 55 82	limit the erectile function
7,R3,AND Arg1:T4 Arg2:T5
8,T6,Condition 84 104	Erectile dysfunction
9,T7,Observation 112 119	history
10,R4,Has_temporal Arg1:T6 Arg2:T7
11,T8,Drug 131 141	medication
12,T9,Temporal 123 130	current
13,T10,Condition 146 166	erectile dysfunction
14,R5,Has_temporal Arg1:T8 Arg2:T9
15,R6,AND Arg1:T8 Arg2:T10
16,*,OR T6 T8
17,T11,Competing_trial 168 216	Current involvement in another comparable study.
0,T1,Person 0 4	Male
1,T2,Person 8 14	Female
2,*,OR T1 T2
3,T3,Qualifier 56 73	infection related
4,T4,Condition 74 79	stone
5,R1,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Mood 82 99	Medically fit for
7,T6,Procedure 100 130	definitive surgical management
8,T7,Condition 134 139	stone
9,R2,AND Arg1:T6 Arg2:T7
10,R3,Has_mood Arg1:T6 Arg2:T5
11,T8,Observation 142 157	Life expectancy
12,T9,Value 158 179	greater than one year
13,R4,Has_value Arg1:T8 Arg2:T9
14,T10,Condition 182 187	Stone
15,T11,Negation 188 192	free
16,R5,Has_negation Arg1:T10 Arg2:T11
17,T12,Temporal 193 226	after definitive surgical therapy
18,T13,Reference_point 199 226	definitive surgical therapy
19,T14,Procedure 199 226	definitive surgical therapy
20,R6,Has_index Arg1:T12 Arg2:T13
21,R7,multi Arg1:T13 Arg2:T14
22,T15,Scope 182 192	Stone free
23,R8,Has_temporal Arg1:T15 Arg2:T12
24,T16,Qualifier 238 261	fragments less than 3mm
25,R9,Subsumes Arg1:T15 Arg2:T16
0,T1,Condition 19 43	gynecological malignancy
1,T2,Mood 0 9	Suspected
2,T3,Mood 13 18	known
3,*,OR T2 T3
4,T4,Scope 0 18	Suspected or known
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Measurement 46 58	uterine size
7,T6,Value 59 68	>12 weeks
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 71 84	Endometriosis
10,T8,Condition 98 110	adnexal mass
11,T9,Condition 113 143	cervix flushed with the vagina
12,T10,Condition 158 178	significant scarring
13,T11,Qualifier 186 197	pelvic area
14,T12,Procedure 212 219	surgery
15,T13,Qualifier 198 219	from previous surgery
16,R3,multi Arg1:T13 Arg2:T12
17,R4,Has_qualifier Arg1:T10 Arg2:T11
18,R5,Has_qualifier Arg1:T10 Arg2:T13
19,T14,Temporal 203 211	previous
20,R6,Has_temporal Arg1:T12 Arg2:T14
0,T1,Procedure 11 27	cardiac ablation
1,T2,Condition 32 34	AF
2,T3,Qualifier 0 10	Successful
3,R1,Has_qualifier Arg1:T1 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Negation 47 54	freedom
6,T5,Condition 60 73	AF recurrence
7,R3,Has_negation Arg1:T5 Arg2:T4
8,T6,Condition 103 125	arrhythmic recurrences
9,T7,Value 134 156	longer than 30 seconds
10,R4,Has_value Arg1:T6 Arg2:T7
11,R5,AND Arg1:T5 Arg2:T6
12,T8,Temporal 158 200	3 months after successful cardiac ablation
13,T9,Reference_point 184 200	cardiac ablation
14,R6,Has_index Arg1:T8 Arg2:T9
15,T10,Non-query-able 202 258	AF recurrence during 3-month blanking period is excluded
16,R7,Has_temporal Arg1:T5 Arg2:T8
17,T11,Drug 312 335	anticoagulation therapy
18,T12,Temporal 340 386	at least two (2) months prior to randomization
19,T13,Reference_point 373 386	randomization
20,R8,Has_index Arg1:T12 Arg2:T13
21,R9,Has_temporal Arg1:T11 Arg2:T12
22,T14,Measurement 406 418	CHADS2 score
23,T15,Value 419 422	= 2
24,T16,Measurement 426 444	CHA2DS2-VASc score
25,T17,Value 446 448	=3
26,*,OR T14 T16
27,R10,Has_value Arg1:T14 Arg2:T15
28,R11,Has_value Arg1:T16 Arg2:T17
29,T18,Measurement 451 485	Left ventricular ejection fraction
30,T19,Value 486 491	> 25%
31,R12,Has_value Arg1:T18 Arg2:T19
32,T20,Measurement 493 500	LA size
33,T21,Value 501 505	< 65
34,R13,Has_value Arg1:T20 Arg2:T21
35,T22,Observation 512 542	risk for thromboembolic events
36,T23,Value 507 511	High
37,R14,Has_value Arg1:T22 Arg2:T23
38,T24,Measurement 550 562	CHADS2 score
39,T25,Value 563 566	= 2
40,T26,Measurement 570 588	CHA2DS2-VASc score
41,T27,Value 589 592	= 3
42,T28,Drug 606 609	OAT
43,T29,Temporal 610 644	before undergoing cardiac ablation
44,T30,Reference_point 628 644	cardiac ablation
45,R15,Has_index Arg1:T29 Arg2:T30
46,R16,Has_temporal Arg1:T28 Arg2:T29
47,R17,Has_value Arg1:T24 Arg2:T25
48,R18,Has_value Arg1:T26 Arg2:T27
49,*,OR T24 T26
50,T31,Scope 550 592	CHADS2 score = 2 or CHA2DS2-VASc score = 3
51,R19,Subsumes Arg1:T22 Arg2:T31
52,T32,Post-eligibility 647 725	ble and willing to comply with all pre- and follow-up testing and requirements
53,T33,Informed_consent 727 755	Signed informed consent form
54,T34,Person 757 760	Age
55,T35,Value 761 778	18 years or older
56,R20,Has_value Arg1:T34 Arg2:T35
0,T1,Temporal 0 12	Preoperative
1,T2,Condition 13 26	renal failure
2,R1,Has_temporal Arg1:T2 Arg2:T1
3,T3,Measurement 41 57	serum creatinine
4,T4,Value 58 69	> 2.0 mg/dL
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Scope 41 69	serum creatinine > 2.0 mg/dL
7,R3,Subsumes Arg1:T2 Arg2:T5
8,T6,Measurement 73 126	American Society of Anesthesiologists Physical Status
9,T7,Value 127 134	IV or V
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Condition 136 153	Pulmonary disease
12,T9,Procedure 168 187	home oxygen therapy
13,T10,Drug 200 209	methadone
14,T11,Drug 211 224	hydromorphone
15,T12,Drug 229 237	ketamine
16,T13,Temporal 239 251	Preoperative
17,T14,Temporal 252 258	recent
18,T15,Observation 259 266	history
19,T16,Condition 280 293	alcohol abuse
20,T17,Condition 270 276;288 293	opioid abuse
21,*,OR T16 T17
22,T18,Scope 270 293	opioid or alcohol abuse
23,R5,Has_temporal Arg1:T18 Arg2:T15
24,R6,Has_temporal Arg1:T18 Arg2:T14
25,R7,Has_temporal Arg1:T18 Arg2:T13
26,T19,Qualifier 295 306	Significant
27,T20,Condition 307 320	liver disease
28,R8,Has_qualifier Arg1:T20 Arg2:T19
29,T21,Device 341 351	PCA device
30,T22,Observation 322 338	Inability to use
31,T23,Observation 322 334;355 381	Inability to speak the English language
32,*,OR T23 T22
33,R9,AND Arg1:T22 Arg2:T21
0,T1,Visit 23 38	Cachexia Clinic
1,T2,Condition 44 67	involuntary weight loss
2,T3,Value 71 100	>5% of their premorbid weight
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Temporal 101 129	within the previous 6 months
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,T5,Person 148 154	of age
7,T6,Value 139 147;155 163	18 years or older
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 175 202	Karnofsky performance score
10,T8,Value 206 218	60 or higher
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Non-query-able 224 270	Can maintain oral food intake during the study
13,T10,Non-query-able 275 348	Can understand the study procedures and can sign an informed consent form
14,T12,Drug 379 388	melatonin
15,T13,Temporal 362 371	currently
16,T14,Negation 358 361	not
17,R5,Has_temporal Arg1:T12 Arg2:T13
18,R6,Has_negation Arg1:T12 Arg2:T14
19,T15,Drug 405 422	megestrol acetate
20,T16,Observation 439 450	lose weight
21,T17,Temporal 427 435	continue
22,R7,Has_temporal Arg1:T16 Arg2:T17
23,T18,Temporal 459 475	at least 2 weeks
24,T19,Procedure 479 486	therapy
25,R8,Has_temporal Arg1:T19 Arg2:T18
26,R9,AND Arg1:T16 Arg2:T19
27,T20,Temporal 394 404	Are taking
28,R10,Has_temporal Arg1:T15 Arg2:T20
29,T21,Measurement 499 530	calculated creatinine clearance
30,T22,Value 534 547	>/= 60 cc/min
31,R11,Has_value Arg1:T21 Arg2:T22
0,T1,Condition 0 8	Pregnant
1,T2,Measurement 10 67	American Society of Anesthesiologists risk classification
2,T3,Value 68 76	I and II
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Person 78 81	Age
5,T5,Value 82 92	> 18 years
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Value 94 106	Non-laboring
8,T7,Qualifier 122 130	elective
9,T8,Procedure 131 148	cesarean sections
10,R3,Has_qualifier Arg1:T8 Arg2:T7
0,T1,Value 18 32	50 to 85 years
1,T2,Person 33 36	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Measurement 56 84	Mini Mental Status (MMS) tes
4,T4,Value 86 112	between 16 to 26 inclusive
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 114 149	Clinical Dementia Rating (CDR) test
7,T6,Value 150 172	inferior or equal to 1
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 174 323	National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test
10,T8,Value 324 332	positive
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,"Measurement 361 441	Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test"
13,T10,Value 442 450	positive
14,R5,Has_value Arg1:T9 Arg2:T10
0,T1,Drug 0 3	OAT
1,T2,Negation 25 28	not
2,T3,Qualifier 40 42	AF
3,R1,Has_qualifier Arg1:T1 Arg2:T3
4,R2,Has_negation Arg1:T3 Arg2:T2
5,T4,Device 50 66	prosthetic valve
6,T5,Condition 68 79	PV stenosis
7,T6,Condition 90 108	pulmonary embolism
8,T7,Measurement 157 170	standard echo
9,T8,Temporal 184 202	3-months follow-up
10,T9,Reference_point 193 202	follow-up
11,R3,Has_index Arg1:T8 Arg2:T9
12,T10,Value 122 147	spontaneous echo contrast
13,T11,Value 149 152	SEC
14,R4,Has_temporal Arg1:T7 Arg2:T8
15,R5,Has_value Arg1:T7 Arg2:T10
16,R6,Subsumes Arg1:T10 Arg2:T11
17,*,OR T4 T5 T6 T7
18,T12,"Scope 50 202	prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up"
19,R7,Has_scope Arg1:T1 Arg2:T12
20,T13,Procedure 210 225	cardiac surgery
21,T14,Temporal 226 249	within the past 60 days
22,T15,Temporal 251 259	2 months
23,T16,Procedure 264 289	valvular cardiac surgical
24,T17,Procedure 319 333	ventriculotomy
25,T18,Procedure 335 344	atriotomy
26,T19,Procedure 350 362	valve repair
27,T20,Procedure 350 355;366 377	valve replacement
28,T21,Device 396 413	prosthetic valve)
29,*,OR T17 T18 T20 T19 T21
30,T22,"Scope 319 412	ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve"
31,R8,Subsumes Arg1:T16 Arg2:T22
32,R9,Subsumes Arg1:T14 Arg2:T15
33,R10,Has_temporal Arg1:T13 Arg2:T14
34,*,OR T13 T16
35,T23,Condition 424 445	myocardial infarction
36,T24,Condition 447 449	MI
37,T25,Procedure 456 490	percutaneous coronary intervention
38,T26,Procedure 491 494	PCI
39,T27,Temporal 495 519	within the past 3 months
40,R11,Subsumes Arg1:T23 Arg2:T24
41,*,OR T23 T25
42,R12,Subsumes Arg1:T25 Arg2:T26
43,T28,Scope 424 494	myocardial infarction (MI) or a percutaneous coronary intervention PCI
44,R13,Subsumes Arg1:T28 Arg2:T27
45,T29,Procedure 530 553	cardiac transplantation
46,T30,Mood 521 529	Awaiting
47,T31,Procedure 563 578	cardiac surgery
48,*,OR T29 T31
49,T32,Temporal 579 603	within the next 365 days
50,T33,Temporal 579 585;605 614	within 12 months
51,R14,Subsumes Arg1:T32 Arg2:T33
52,T34,Scope 530 578	cardiac transplantation or other cardiac surgery
53,R15,Has_mood Arg1:T34 Arg2:T30
54,R16,Has_temporal Arg1:T34 Arg2:T32
55,T35,Condition 628 648	left atrial thrombus
56,T36,Condition 662 679	pulmonary disease
57,T37,Qualifier 650 661	Significant
58,T38,Condition 688 717	restrictive pulmonary disease
59,T39,Condition 735 739	COPD
60,T40,Non-query-able 744 842	any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
61,*,OR T38 T39
62,R17,Has_qualifier Arg1:T36 Arg2:T37
63,T41,"Scope 688 740	restrictive pulmonary disease, constrictive or COPD)"
64,R18,Subsumes Arg1:T36 Arg2:T41
65,T42,Non-query-able 845 951	ignificant medical problem that in the opinion of the investigator would preclude enrollment in this study
66,T43,Pregnancy_considerations 953 1026	Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)
67,T44,Condition 1052 1070	systemic infection
68,T45,Condition 1074 1080	sepsis
69,*,OR T44 T45
70,T46,Non-query-able 1028 1041	Acute illness
71,T47,Condition 1082 1097	Unstable angina
72,T48,Condition 1099 1115	Contraindication
73,T49,Drug 1119 1134	anticoagulation
74,R19,AND Arg1:T48 Arg2:T49
75,T50,Drug 1142 1149	heparin
76,T51,Drug 1151 1159	warfarin
77,T52,Non-query-able 1164 1220	nother commercially available anticoagulation medication
78,*,OR T50 T51
79,T53,"Scope 1142 1159	heparin, warfarin"
80,R20,Subsumes Arg1:T49 Arg2:T53
81,T54,Condition 1252 1274	bleeding abnormalities
82,T55,Condition 1234 1248;1261 1274	blood clotting abnormalities
83,*,OR T54 T55
84,T56,Observation 1276 1291	Life expectancy
85,T57,Value 1292 1310	less than 360 days
86,T58,Value 1292 1301;1312 1321	less than 12 months
87,R21,Subsumes Arg1:T57 Arg2:T58
88,R22,Has_value Arg1:T56 Arg2:T57
89,T59,Condition 1337 1350	Heart Failure
90,T60,Qualifier 1324 1336	Uncontrolled
91,R23,Has_qualifier Arg1:T59 Arg2:T60
92,T61,Condition 1375 1388	heart failure
93,T62,Qualifier 1354 1368	NYHA Class III
94,T63,Qualifier 1354 1364;1372 1374	NYHA Class IV
95,*,OR T62 T63
96,T64,Scope 1354 1374	NYHA Class III or IV
97,R24,Has_scope Arg1:T61 Arg2:T64
98,*,OR T59 T61
99,T65,"Competing_trial 1390 1480	Enrollment in a clinical study evaluating another device or drug, within the past 6 months"
100,T66,Post-eligibility 1482 1538	Unable or unwilling to comply with protocol requirements
0,T1,Condition 8 16	dementia
1,T2,Condition 20 28	delirium
2,*,OR T1 T2
3,T3,Temporal 79 93	at study entry
4,T4,Scope 8 28	dementia or delirium
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Condition 103 111	pregnant
7,T6,Drug 133 148	corticosteroids
8,T7,Temporal 153 173	longer than 48 hours
9,T8,Condition 184 199	pulmonary edema
10,T9,Condition 201 208	ascites
11,T10,Condition 212 225	pitting edema
12,T11,Condition 259 273	unable to walk
13,T12,Observation 286 293	history
14,T13,Condition 305 336	adverse gastrointestinal events
15,T14,Qualifier 297 304	serious
16,R3,Has_qualifier Arg1:T13 Arg2:T14
17,T15,Condition 344 352	bleeding
18,T16,Condition 356 367	perforation
19,*,OR T15 T16
20,T17,Scope 344 367	bleeding or perforation
21,R5,Subsumes Arg1:T13 Arg2:T17
22,T18,Condition 382 394	coagulopathy
23,T19,Observation 369 376	history
24,R4,Has_temporal Arg1:T13 Arg2:T12
25,R6,Has_temporal Arg1:T18 Arg2:T19
26,T20,Drug 406 420	anti-coagulant
27,T21,Temporal 398 405	current
28,R7,Has_temporal Arg1:T20 Arg2:T21
29,*,OR T18 T20 T13
30,T22,Measurement 438 445	ALT/AST
31,T23,Value 445 470	>3x upper limit of normal
32,R8,Has_value Arg1:T22 Arg2:T23
33,T24,Drug 488 500	methotrexate
34,T25,Drug 522 549	melatonin receptor agonists
35,T26,Drug 559 566	Rozerem
36,T27,Drug 569 578	ramelteon
37,R9,Subsumes Arg1:T26 Arg2:T27
38,R10,Subsumes Arg1:T25 Arg2:T26
39,R2,Has_temporal Arg1:T6 Arg2:T7
40,*,OR T8 T9 T10
0,T1,Procedure 33 64	posterior spinal fusion surgery
1,T2,Qualifier 24 32	elective
2,T3,Qualifier 66 80	lower thoracic
3,T4,Qualifier 82 88	lumbar
4,T5,Qualifier 90 96	sacral
5,*,OR T3 T4 T5
6,T6,"Scope 66 96	lower thoracic, lumbar, sacral"
7,R1,Has_qualifier Arg1:T1 Arg2:T2
8,R2,Has_scope Arg1:T1 Arg2:T6
9,T7,Person 99 103	Ages
10,T8,Value 104 109	18-80
11,R3,Has_value Arg1:T7 Arg2:T8
0,T1,Observation 0 21	Non- English speakers
1,T2,Measurement 23 29	Height
2,T3,"Value 30 38	< 4' 11"""
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Observation 40 43	BMI
5,T5,Value 44 54	>40 Kg/ mm
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Drug 56 71	Antiemetic drug
8,T7,Temporal 76 118	in the 24 hours prior to cesarean delivery
9,T8,Reference_point 101 118	cesarean delivery
10,T9,Procedure 101 118	cesarean delivery
11,R3,Has_index Arg1:T7 Arg2:T8
12,R4,multi Arg1:T8 Arg2:T9
13,R5,Has_temporal Arg1:T6 Arg2:T7
14,T10,Condition 121 155	Hypertensive diseases of pregnancy
15,T11,Condition 157 177	Chronic hypertension
16,T12,Procedure 188 214	antihypertensive treatment
17,R6,AND Arg1:T11 Arg2:T12
18,T13,Post-eligibility 216 330	Any other physical or psychiatric condition that may impair their ability to cooperate with study data collection.
0,T1,Context_Error 0 73	patient already treated by medicines which could interfere with the study
1,T2,Measurement 79 99	level of vitamin B12
2,T3,Value 75 78	low
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 104 110;79 87	folate level of
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Condition 193 210	pulmonary illness
7,T6,Condition 212 234	cardiovascular illness
8,T7,Condition 236 252	evolutive cancer
9,T8,Condition 254 274	neurological illness
10,T9,Condition 276 289	blood illness
11,*,OR T8 T9 T7 T6 T5
12,T10,"Context_Error 156 292	clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness….)"
0,T1,Condition 26 39	heart failure
1,T2,Person 41 44	men
2,T3,Person 49 54	women
3,*,OR T2 T3
4,T4,Person 56 60	aged
5,T5,Value 61 70	>18 years
6,R1,Has_value Arg1:T4 Arg2:T5
7,T7,Condition 0 11	Symptomatic
8,T6,Measurement 111 144	New York Heart Association (NYHA)
9,T8,"Value 73 103	Functional class II, III or IV"
10,R2,Has_value Arg1:T6 Arg2:T8
11,T9,Measurement 146 180	Left ventricular ejection fraction
12,T10,Value 181 185	<35%
13,R3,Has_value Arg1:T9 Arg2:T10
14,T11,Condition 187 195;212 220	Ischemic etiology
15,T12,Condition 200 220	nonischemic etiology
16,*,OR T12 T11
17,T13,Measurement 222 254	Type B natriuretic peptide (BNP)
18,T14,Value 255 265	>150 pg/ml
19,T15,Measurement 270 297	pro-BNP [N-terminal-proBNP]
20,T16,Value 298 311	= 600 pg / ml
21,R4,Has_value Arg1:T15 Arg2:T16
22,R5,Has_value Arg1:T13 Arg2:T14
23,*,OR T13 T15
24,T17,Procedure 335 347	hospitalized
25,T18,Condition 352 374	cardiac decompensation
26,T19,Temporal 375 405	within the preceding 12 months
27,R6,AND Arg1:T17 Arg2:T18
28,R7,Has_temporal Arg1:T17 Arg2:T19
29,T20,Scope 335 405	hospitalized for cardiac decompensation within the preceding 12 months
30,A1,Optional T20
31,T21,Measurement 407 410	BNP
32,T22,Value 411 421	>100 pg/ml
33,R8,Has_value Arg1:T21 Arg2:T22
34,T23,Measurement 426 443	N-terminal-proBNP
35,T24,Value 444 457	= 400 pg / ml
36,R9,Has_value Arg1:T23 Arg2:T24
37,*,OR T21 T23
38,T25,Scope 407 458	BNP >100 pg/ml (or N-terminal-proBNP = 400 pg / ml)
39,R10,Has_scope Arg1:T20 Arg2:T25
40,T26,Scope 222 312	Type B natriuretic peptide (BNP) >150 pg/ml (or pro-BNP [N-terminal-proBNP] = 600 pg / ml)
41,*,OR T26 T20
0,T1,Person 15 18	age
1,T2,Value 0 11	25-50 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Observation 36 44;55 62	physical assault
4,T4,Observation 48 62	sexual assault
5,*,OR T4 T3
6,T5,Condition 20 24	PTSD
7,T6,Scope 36 62	physical or sexual assault
8,R2,Has_scope Arg1:T5 Arg2:T6
9,T7,Observation 64 81	Medically healthy
10,T8,Observation 83 99	English speaking
0,T1,Condition 0 7	Allergy
1,T2,Condition 9 20	sensitivity
2,T3,Condition 34 51	contraindications
3,T4,Drug 66 77	medications
4,T5,Qualifier 94 99	study
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,*,OR T3 T2 T1
7,T6,"Scope 0 51	Allergy, sensitivity, or absolute contraindications"
8,R2,AND Arg1:T6 Arg2:T4
9,T7,Condition 113 127	CNS depression
10,T8,Drug 149 159	medication
11,T9,Condition 171 185	CNS depression
12,R3,AND Arg1:T9 Arg2:T8
13,*,OR T9 T7
14,T10,Condition 199 217	cognitive deficits
15,T11,Condition 219 227	dementia
16,T12,Condition 232 240	delirium
17,*,OR T12 T11 T10
18,T13,Condition 249 274	respiratory comorbidities
19,T14,Qualifier 242 248	severe
20,R4,Has_qualifier Arg1:T13 Arg2:T14
21,T15,Condition 281 318	chronic obstructive pulmonary disease
22,T16,Condition 320 329	pneumonia
23,T17,Condition 331 350	respiratory failure
24,*,OR T17 T16 T15
25,T18,"Scope 281 350	chronic obstructive pulmonary disease, pneumonia, respiratory failure"
26,R5,Subsumes Arg1:T13 Arg2:T18
27,T19,Condition 353 379	sleep disordered breathing
28,T20,Condition 391 394	OSA
29,T21,Condition 396 428	obesity hypoventilation syndrome
30,*,OR T20 T21
31,T22,"Scope 391 428	OSA, obesity hypoventilation syndrome"
32,R6,Subsumes Arg1:T19 Arg2:T22
33,T23,Pregnancy_considerations 431 459	pregnancy and breast feeding
34,T24,Condition 472 484	chronic pain
35,T25,Drug 518 524	opioid
36,T26,Multiplier 497 516	at least once daily
37,R7,Has_multiplier Arg1:T25 Arg2:T26
38,T27,Qualifier 529 543	preoperatively
39,R8,Has_qualifier Arg1:T25 Arg2:T27
40,*,OR T24 T25
41,T28,Condition 545 561	renal impairment
42,T29,Measurement 564 568	CrCl
43,T30,Value 569 582	=60 mL/minute
44,R9,AND Arg1:T28 Arg2:T29
45,R10,Has_value Arg1:T29 Arg2:T30
46,T31,"Post-eligibility 584 691	not fluent in English to be able to participate in the study process, including consent and phone interview"
47,T32,Measurement 693 708	Body Mass Index
48,T33,Value 709 712	>35
49,R11,Has_value Arg1:T32 Arg2:T33
50,T34,Mood 714 723	inability
51,T35,Drug 732 747	oral medication
52,R12,Has_mood Arg1:T35 Arg2:T34
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 158 160	2.
2,T3,Parsing_Error 266 268	3.
3,T4,Parsing_Error 298 300	4.
4,T5,Parsing_Error 329 331	5.
5,T6,Parsing_Error 347 349	6.
6,T7,Parsing_Error 487 489	7.
7,T8,Parsing_Error 727 729	8.
8,T9,Parsing_Error 816 818	9.
9,T10,Parsing_Error 852 855	10.
10,T11,Condition 55 72	colorectal cancer
11,T12,Qualifier 89 101	unresectable
12,T13,Condition 118 125	disease
13,T14,Undefined_semantics 118 125	disease
14,T15,Qualifier 102 117	stage IV (UICC)
15,T16,Value 108 110	IV
16,R2,Subsumes Arg1:T13 Arg2:T11
17,R1,Has_qualifier Arg1:T13 Arg2:T15
18,R3,Has_qualifier Arg1:T13 Arg2:T12
19,T17,Procedure 17 31	histologically
20,T18,Value 32 41	confirmed
21,*,OR T17 T18
22,R4,AND Arg1:T11 Arg2:T17
23,T19,Drug 206 212	FOLFOX
24,T20,Non-query-able 178 186	feasible
25,T21,Procedure 232 252	palliative treatment
26,T22,Procedure 220 228;243 252	adjuvant treatment
27,*,OR T21 T22
28,T23,Non-query-able 253 263	is allowed
29,T24,Measurement 269 292	ECOG Performance status
30,T25,Value 293 296	≤ 1
31,T26,Observation 301 316	Life expectancy
32,T27,Value 317 327	> 3 months
33,R5,Has_value Arg1:T26 Arg2:T27
34,T28,Person 332 335	Age
35,T29,Value 336 345	≥18 years
36,R6,Has_value Arg1:T28 Arg2:T29
37,T30,Parsing_Error 350 406	Haematologic function as follows (5% deviation allowed):
38,T31,Measurement 408 411	ANC
39,T32,Value 412 425	≥ 1.5 x 109/L
40,T33,Measurement 427 436	platelets
41,T34,Value 437 449	≥ 100 x109/L
42,T35,Measurement 451 461	hemoglobin
43,T36,Value 462 470	≥ 9 g/dl
44,T37,Value 462 463;474 485	≥ 5.59 mmol/l
45,*,OR T37 T36
46,T38,Scope 462 485	≥ 9 g/dl or 5.59 mmol/l
47,R7,Has_scope Arg1:T35 Arg2:T38
48,T39,Measurement 499 513	liver function
49,T40,Value 490 498	Adequate
50,R8,Has_value Arg1:T39 Arg2:T40
51,T41,Parsing_Error 490 548	Adequate liver function as follows (10% deviation allowed)
52,T42,Measurement 550 582	serum alanine transaminase (ALT)
53,T43,Value 583 594	≤ 2.5 x ULN
54,R9,Has_value Arg1:T42 Arg2:T43
55,T44,Condition 607 623	liver metastases
56,A1,Optional T44
57,T45,Value 624 633	< 5 x ULN
58,R10,Subsumes Arg1:T43 Arg2:T44
59,R11,Has_value Arg1:T44 Arg2:T45
60,T46,Measurement 636 651	total bilirubin
61,T47,Value 652 663	≤ 1.5 x ULN
62,T48,Condition 679 697	Gilbert's syndrome
63,A2,Optional T48
64,T49,Measurement 698 713	total bilirubin
65,T50,Value 714 724	≤2.5 x ULN
66,R12,Has_value Arg1:T46 Arg2:T47
67,*,OR T46 T48
68,T51,Measurement 739 753	renal function
69,T52,Value 730 738	Adequate
70,R13,Has_value Arg1:T51 Arg2:T52
71,T53,Parsing_Error 730 788	Adequate renal function as follows (10% deviation allowed)
72,T54,Measurement 792 802	creatinine
73,T55,Value 803 814	≤ 1.5 x ULN
74,R14,Has_value Arg1:T54 Arg2:T55
75,T56,Post-eligibility 819 850	Signed written informed consent
76,T57,Condition 865 888	child-bearing potential
77,T58,Person 856 861	Women
78,T59,Measurement 910 924	pregnancy test
79,T60,Value 901 909	negative
80,T61,Scope 856 888	Women of child-bearing potential
81,A3,Optional T61
82,R15,AND Arg1:T61 Arg2:T59
83,R16,Has_value Arg1:T59 Arg2:T60
0,T1,Condition 11 27	hypersensitivity
1,T2,Condition 31 38	allergy
2,T3,Drug 53 64	study drugs
3,T4,Non-representable 67 99	rugs of similar chemical classes
4,T5,Drug 101 123	ACE inhibitors (ACEIs)
5,T6,Drug 125 164	angiotensin II receptor blockers (ARBs)
6,T7,Drug 169 190	neprilysin inhibitors
7,T8,Condition 222 239	contraindications
8,T9,Mood 203 208	known
9,T10,Mood 212 221	suspected
10,*,OR T10 T9
11,T11,Scope 203 221	known or suspected
12,R1,Has_scope Arg1:T8 Arg2:T11
13,T12,Drug 247 258	study drugs
14,*,OR T7 T6 T5 T3
15,T13,"Scope 53 190	study drugs, drugs of similar chemical classes, ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or neprilysin inhibitors"
16,*,OR T2 T1
17,R2,AND Arg1:T8 Arg2:T12
18,T14,Scope 11 38	hypersensitivity or allergy
19,R3,Has_scope Arg1:T14 Arg2:T13
20,*,OR T14 T8
21,T15,Drug 324 329	ACEIs
22,T16,Drug 333 337	ARBs
23,T17,Condition 281 292	intolerance
24,T18,Observation 270 277	history
25,T19,Temporal 261 269	Previous
26,R4,Has_temporal Arg1:T17 Arg2:T18
27,R5,Has_temporal Arg1:T17 Arg2:T19
28,*,OR T15 T16
29,T20,Scope 324 337	ACEIs or ARBs
30,R6,Has_scope Arg1:T17 Arg2:T20
31,T21,Condition 357 367	angioedema
32,T22,Drug 406 411	ACEIs
33,T23,Drug 416 420	ARBs
34,T24,Procedure 386 395	treatment
35,T25,Mood 370 385	Requirement for
36,R7,Has_mood Arg1:T24 Arg2:T25
37,*,OR T22 T23
38,T26,Scope 406 420	ACEIs and ARBs
39,R8,Has_scope Arg1:T24 Arg2:T26
40,T27,Observation 346 353	history
41,R9,Has_temporal Arg1:T21 Arg2:T27
42,T28,Qualifier 431 436	acute
43,T29,Qualifier 437 450	decompensated
44,T30,Condition 451 464	heart failure
45,R10,Has_qualifier Arg1:T30 Arg2:T29
46,R11,Has_qualifier Arg1:T30 Arg2:T28
47,T31,Condition 466 478	exacerbation
48,T32,Condition 482 503	chronic heart failure
49,R12,AND Arg1:T31 Arg2:T32
50,T33,Procedure 554 573	intravenous therapy
51,T34,Condition 518 523	signs
52,T35,Condition 528 536	symptoms
53,T36,Scope 518 536	signs and symptoms
54,T37,Scope 466 503	exacerbation of chronic heart failure
55,R13,Has_scope Arg1:T37 Arg2:T36
56,R14,AND Arg1:T36 Arg2:T33
57,T38,Qualifier 577 588	Symptomatic
58,T39,Condition 589 600	hypotension
59,R15,Has_qualifier Arg1:T39 Arg2:T38
60,T40,Measurement 603 646	Estimated glomerular filtration rate (eGFR)
61,T41,Value 647 651	<30%
62,T42,Measurement 654 669	Serum potassium
63,T43,Value 670 681	>5.4 mmol/L
64,R16,Has_value Arg1:T42 Arg2:T43
65,T44,Condition 684 707	Acute coronary syndrome
66,T45,Condition 709 715	stroke
67,T46,Condition 717 743	transient ischaemic attack
68,T47,Condition 745 752	cardiac
69,T48,Condition 754 761	carotid
70,T49,Procedure 772 800	major cardiovascular surgery
71,T50,Procedure 802 836	percutaneous coronary intervention
72,T51,Procedure 841 860	carotid angioplasty
73,T52,Temporal 861 880	within the 3 months
74,*,OR T49 T50 T51
75,T53,"Scope 772 860	major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty"
76,R17,Has_temporal Arg1:T53 Arg2:T52
77,*,OR T48 T47 T46 T45 T44 T53
78,T54,Condition 895 917	carotid artery disease
79,T55,Condition 883 891;903 917	Coronary artery disease
80,T56,Procedure 936 944;961 973	surgical intervention
81,T57,Mood 918 924	likely
82,T58,Procedure 948 973	percutaneous intervention
83,T59,Temporal 974 993	within the 6 months
84,*,OR T58 T56
85,T60,Scope 936 973	surgical or percutaneous intervention
86,R18,Has_mood Arg1:T60 Arg2:T57
87,R19,Has_temporal Arg1:T60 Arg2:T59
88,*,OR T55 T54
89,T61,Scope 883 917	Coronary or carotid artery disease
90,R20,Has_scope Arg1:T61 Arg2:T60
91,T62,Device 1014 1060	cardiac resynchronization therapy (CRT) device
92,T63,Procedure 996 1008	Implantation
93,R21,AND Arg1:T63 Arg2:T62
94,T64,Temporal 1061 1076	within 3 months
95,T65,Mood 1080 1086	intent
96,T66,Procedure 1090 1097	implant
97,T67,Device 1100 1103	CRT
98,R22,AND Arg1:T66 Arg2:T67
99,R23,Has_mood Arg1:T66 Arg2:T65
100,R24,Has_temporal Arg1:T63 Arg2:T64
101,*,OR T63 T66
102,T68,Procedure 1117 1133	heart transplant
103,T69,Observation 1106 1113	History
104,T70,Observation 1137 1157	on a transplant list
105,T71,Device 1166 1205	left ventricular (LV) assistance device
106,R25,Has_temporal Arg1:T68 Arg2:T69
107,*,OR T68 T70 T71
108,T72,Observation 1208 1215	History
109,T73,Condition 1219 1243	severe pulmonary disease
110,R26,Has_temporal Arg1:T73 Arg2:T72
111,T74,Condition 1295 1309	cardiomyopathy
112,T75,Procedure 1274 1286	chemotherapy
113,T76,Qualifier 1274 1294	chemotherapy-induced
114,T77,Condition 1259 1269	peripartum
115,T78,Qualifier 1259 1270;1287 1294	peripartum- induced
116,*,OR T78 T76
117,T79,Scope 1259 1294	peripartum- or chemotherapy-induced
118,R27,Has_scope Arg1:T74 Arg2:T79
119,T80,Temporal 1310 1330	within the 12 months
120,R28,Has_temporal Arg1:T74 Arg2:T80
121,T81,Condition 1354 1376	ventricular arrhythmia
122,T82,Qualifier 1344 1353	untreated
123,R29,Has_qualifier Arg1:T81 Arg2:T82
124,T83,Condition 1382 1399	syncopal episodes
125,T84,Temporal 1400 1419	within the 3 months
126,R30,AND Arg1:T81 Arg2:T83
127,R31,Has_temporal Arg1:T83 Arg2:T84
128,T85,Condition 1434 1445	bradycardia
129,T86,Condition 1473 1495	atrioventricular block
130,T87,Qualifier 1460 1472	third-degree
131,T88,Qualifier 1449 1456;1466 1472	second- degree
132,T89,Negation 1496 1503	without
133,T90,Device 1506 1515	pacemaker
134,R32,Has_negation Arg1:T90 Arg2:T89
135,*,OR T88 T87
136,T91,Scope 1449 1472	second- or third-degree
137,R33,Has_scope Arg1:T86 Arg2:T91
138,R34,AND Arg1:T86 Arg2:T90
139,*,OR T85 T86
140,T92,Qualifier 1530 1558	haemodynamically significant
141,T93,Condition 1573 1593	aortic valve disease
142,T94,Condition 1559 1565;1580 1593	mitral valve disease
143,*,OR T94 T93
144,T95,Scope 1559 1593	mitral and/or aortic valve disease
145,R35,Has_qualifier Arg1:T95 Arg2:T92
146,T96,Condition 1602 1622	mitral regurgitation
147,T97,Qualifier 1623 1649	secondary to LV dilatation
148,T98,Condition 1636 1649	LV dilatation
149,R36,multi Arg1:T97 Arg2:T98
150,R37,multi Arg1:T76 Arg2:T75
151,R38,multi Arg1:T78 Arg2:T77
152,R39,Has_qualifier Arg1:T96 Arg2:T97
153,T99,Negation 1595 1601	except
154,R40,Has_negation Arg1:T96 Arg2:T99
155,R41,AND Arg1:T95 Arg2:T96
156,T100,Qualifier 1670 1698	haemodynamically significant
157,T101,Condition 1699 1718	obstructive lesions
158,T102,Qualifier 1726 1742	LV outflow tract
159,R42,Has_qualifier Arg1:T101 Arg2:T102
160,T103,Condition 1765 1783	subaortic stenosis
161,T104,Condition 1754 1760;1775 1783	aortic stenosis
162,*,OR T104 T103
163,*,OR T101 T100
164,T105,Scope 1670 1742	haemodynamically significant obstructive lesions of the LV outflow tract
165,T106,Scope 1754 1783	aortic and subaortic stenosis
166,R43,Subsumes Arg1:T105 Arg2:T106
167,T107,Condition 1790 1798;1810 1819	surgical condition
168,T108,Condition 1802 1819	medical condition
169,T109,"Condition 1846 1906	alter the absorption, distribution, metabolism, or excretion"
170,T110,Drug 1910 1921	study drugs
171,R44,AND Arg1:T109 Arg2:T110
172,T111,Condition 1994 2020	inflammatory bowel disease
173,*,OR T107 T108
174,T112,Scope 1790 1819	surgical or medical condition
175,R45,AND Arg1:T112 Arg2:T109
176,T113,"Scope 1790 1921	surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs"
177,T114,Temporal 2021 2041	during the 12 months
178,T115,Qualifier 1987 1993	active
179,R46,Has_qualifier Arg1:T111 Arg2:T115
180,R47,Has_temporal Arg1:T111 Arg2:T114
181,T116,Qualifier 2043 2049	Active
182,T117,Condition 2050 2058;2070 2076	duodenal ulcers
183,T118,Condition 2062 2076	gastric ulcers
184,*,OR T118 T117
185,T119,Scope 2050 2076	duodenal or gastric ulcers
186,R48,Has_qualifier Arg1:T119 Arg2:T116
187,T120,Temporal 2077 2096	during the 3 months
188,R49,Has_temporal Arg1:T119 Arg2:T120
189,T121,Condition 2110 2125	hepatic disease
190,T122,Measurement 2169 2195	aspartate aminotransferase
191,T123,Measurement 2199 2223	alanine aminotransferase
192,*,OR T123 T122
193,T124,Value 2231 2265	exceeding 2x upper limit of normal
194,T125,Scope 2169 2223	aspartate aminotransferase or alanine aminotransferase
195,R50,Has_value Arg1:T125 Arg2:T124
196,T126,Condition 2278 2300	hepatic encephalopathy
197,T127,Observation 2267 2274	history
198,R51,Has_temporal Arg1:T126 Arg2:T127
199,T128,Condition 2313 2332	oesophageal varices
200,T129,Observation 2302 2309	history
201,R52,Has_temporal Arg1:T128 Arg2:T129
202,T130,Observation 2337 2344	history
203,T131,Condition 2348 2365	porto-caval shunt
204,R53,Has_temporal Arg1:T131 Arg2:T130
205,*,OR T131 T128 T126 T125
206,T132,Procedure 2375 2384	treatment
207,T133,Temporal 2367 2374	Current
208,T134,Drug 2390 2404;2419 2425	cholestyramine resins
209,T135,Drug 2408 2425	colestipol resins
210,*,OR T134 T135
211,R54,Has_temporal Arg1:T132 Arg2:T133
212,T136,Scope 2390 2425	cholestyramine or colestipol resins
213,R55,Has_scope Arg1:T132 Arg2:T136
214,T137,Mood 2098 2106	Evidence
215,R56,Has_mood Arg1:T121 Arg2:T137
216,T138,Scope 2098 2125	Evidence of hepatic disease
217,T139,"Scope 2169 2425	aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins"
218,R57,Subsumes Arg1:T138 Arg2:T139
219,*,OR T111 T119 T138
220,T140,"Scope 1987 2425	active inflammatory bowel disease during the 12 months. Active duodenal or gastric ulcers during the 3 months. Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins"
221,R58,Subsumes Arg1:T113 Arg2:T140
222,T141,Observation 2465 2480	life expectancy
223,T142,Value 2484 2492	<5 years
224,R59,Has_value Arg1:T141 Arg2:T142
225,T143,Condition 2450 2457	disease
226,T144,Qualifier 2440 2449	any other
227,R60,Has_qualifier Arg1:T143 Arg2:T144
228,R61,Has_context Arg1:T143 Arg2:T141
0,T1,Condition 0 14	Claustrophobia
1,T2,Observation 23 65	inability to lie still in a confined space
2,T3,Condition 73 90	medical disorders
3,T4,Qualifier 67 72	Major
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Condition 98 101	HIV
6,T6,Condition 103 109	cancer
7,*,OR T5 T6
8,T7,"Scope 98 109	HIV, cancer"
9,R2,Subsumes Arg1:T3 Arg2:T7
10,T8,Device 112 138	Magnetic metallic implants
11,T9,Device 148 154	screws
12,T10,Device 156 160	pins
13,T11,Device 162 179	shrapnel remnants
14,T12,Device 181 195	aneurysm clips
15,T13,Device 197 220	artificial heart valves
16,T14,Device 222 231;243 251	inner ear implants
17,T15,Device 233 241;243 251	cochlear implants
18,R3,Subsumes Arg1:T14 Arg2:T15
19,T16,Device 253 270	artificial joints
20,T17,Device 276 291	vascular stents
21,T18,"Scope 148 291	screws, pins, shrapnel remnants, aneurysm clips, artificial heart valves, inner ear (cochlear) implants, artificial joints, and vascular stents"
22,R4,Subsumes Arg1:T8 Arg2:T18
23,*,OR T9 T10 T11 T12 T13 T14 T16 T17
24,T19,Device 308 325	magnetic implants
25,T20,Device 294 304;317 325	Electronic implants
26,*,OR T19 T20
27,T21,Device 335 345	pacemakers
28,T22,Scope 294 325	Electronic or magnetic implants
29,R5,Subsumes Arg1:T22 Arg2:T21
30,T23,Observation 347 363	Permanent makeup
31,T24,Observation 367 374	tattoos
32,*,OR T23 T24
33,T25,Device 380 393	metallic dyes
34,R6,AND Arg1:T24 Arg2:T25
35,R7,AND Arg1:T23 Arg2:T25
36,T26,Condition 405 413	pregnant
37,T27,Observation 431 463	history of loss of consciousness
38,T28,Value 465 488	greater than 10 minutes
39,R8,Has_value Arg1:T27 Arg2:T28
40,T29,Qualifier 417 430	self-reported
41,R9,Has_qualifier Arg1:T27 Arg2:T29
42,T30,Subjective_judgement 491 543	Physical disabilities that prohibit task performance
43,T31,Condition 553 562	blindness
44,T32,Condition 566 574	deafness
45,*,OR T31 T32
46,T33,Condition 577 596	Psychotic disorders
47,T34,Condition 604 617	schizophrenia
48,R10,Subsumes Arg1:T33 Arg2:T34
49,T35,Post-eligibility 620 704	Any other condition that the investigator believes might put the participant at risk
0,T1,Subjective_judgement 0 117	adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy; 2.
1,T2,Non-query-able 0 117	adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy; 2.
2,T3,Procedure 137 164	systemic anticancer therapy
3,T4,Temporal 165 191	≤ 3 weeks prior to cycle 1
4,T5,Reference_point 184 191	cycle 1
5,R1,Has_index Arg1:T4 Arg2:T5
6,R2,Has_temporal Arg1:T3 Arg2:T4
7,T6,Condition 232 243;250 259	Hepatitis B infection
8,T7,Condition 232 241;248 259	Hepatitis C infection
9,T8,Negation 264 267	NOT
10,R3,Has_negation Arg1:T6 Arg2:T8
11,R4,Has_negation Arg1:T7 Arg2:T8
12,T9,Condition 221 230	infection
13,T10,Temporal 214 220	active
14,T11,Qualifier 201 213	Uncontrolled
15,R5,Has_qualifier Arg1:T9 Arg2:T11
16,R6,Has_temporal Arg1:T9 Arg2:T10
17,T12,Scope 232 286	Hepatitis B and C infection are NOT exclusion criteria
18,R7,Has_scope Arg1:T9 Arg2:T12
19,T13,Condition 301 314	HIV infection
20,T14,Condition 319 332	Renal failure
21,T15,Procedure 343 356	haemodialysis
22,T16,Procedure 360 379	peritoneal dialysis
23,*,OR T15 T16
24,T17,Scope 343 379	haemodialysis or peritoneal dialysis
25,R8,Has_scope Arg1:T14 Arg2:T17
26,T18,Condition 401 409	pregnant
27,T19,Condition 413 427	breast-feeding
28,*,OR T18 T19
29,T20,Parsing_Error 429 431	6.
30,T21,Parsing_Error 381 383	5.
31,T22,Condition 472 505	obstructed gastrointestinal tract
32,T23,Condition 460 468;483 505	diseased gastrointestinal tract
33,T24,Undefined_semantics 460 468;483 505	diseased gastrointestinal tract
34,*,OR T22 T23
35,T25,Qualifier 446 459	significantly
36,T26,Subjective_judgement 446 459	significantly
37,T27,Non-query-able 446 459	significantly
38,T28,Condition 507 520	malabsorption
39,T29,Condition 535 543	vomiting
40,T30,Qualifier 522 534	uncontrolled
41,R9,Has_qualifier Arg1:T29 Arg2:T30
42,T31,Condition 547 555	diarrhea
43,T32,Condition 569 606	inability to swallow oral medications
44,T33,Parsing_Error 608 610	7.
45,*,OR T29 T31 T28
46,T34,Condition 635 649	CNS metastasis
47,T35,Parsing_Error 650 652	8.
48,T36,Qualifier 623 634	symptomatic
49,R10,Has_qualifier Arg1:T34 Arg2:T36
50,T37,Procedure 687 706	anti-cancer therapy
51,T38,Temporal 678 686	previous
52,R11,Has_temporal Arg1:T37 Arg2:T38
53,T39,Procedure 735 742	surgery
54,T40,Condition 710 729	incomplete recovery
55,T41,Drug 758 769	oxaliplatin
56,T42,Qualifier 758 777	oxaliplatin-induced
57,T43,Condition 778 799	peripheral neuropathy
58,R12,Has_qualifier Arg1:T43 Arg2:T42
59,R13,AND Arg1:T40 Arg2:T39
60,R14,Subsumes Arg1:T40 Arg2:T43
61,T44,Condition 653 672	Unresolved toxicity
62,R15,AND Arg1:T44 Arg2:T37
63,*,OR T44 T40
64,T45,Parsing_Error 812 814	9.
65,T46,Temporal 836 891	within the 12 months prior to study drug administration
66,T47,Reference_point 866 891	study drug administration
67,*,OR T46 T47
68,T48,Condition 893 914	myocardial infarction
69,T49,Condition 923 938	unstable angina
70,T50,Condition 916 922;932 938	severe angina
71,T51,Condition 940 948;960 979	coronary artery bypass graft
72,T52,Condition 949 979	peripheral artery bypass graft
73,T53,Condition 981 1017	symptomatic congestive heart failure
74,T54,Condition 1019 1043	cerebrovascular accident
75,T55,Condition 1047 1072	transient ischemic attack
76,T56,Condition 1074 1092	pulmonary embolism
77,T57,Condition 1094 1114	deep vein thrombosis
78,T58,Condition 1119 1145	other thromboembolic event
79,*,OR T58 T57 T56 T55 T54 T53 T51 T52 T50 T49 T48
80,T59,"Scope 893 1145	myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event"
81,R16,Has_temporal Arg1:T59 Arg2:T46
0,T1,Person 0 3	Age
1,T2,Value 4 9	18-65
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 88 107	rotator cuff repair
4,T4,Procedure 112 125	acromioplasty
5,T5,Qualifier 64 75	day surgery
6,T6,Procedure 32 35	ISB
7,T7,Procedure 40 58	general anesthesia
8,T8,Scope 0 10;11 58	Age 18-65
9,scheduled,to receive ISB and general anesthesia
10,T9,Scope 88 125	rotator cuff repair and acromioplasty
11,R2,Has_qualifier Arg1:T9 Arg2:T5
12,T10,Scope 32 58	ISB and general anesthesia
13,R3,Has_scope Arg1:T9 Arg2:T10
0,T1,Parsing_Error 0 2	NA
0,T1,Person 6 15	years old
1,T2,Value 0 5	18-65
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 17 21	Male
4,T4,Person 25 31	female
5,*,OR T3 T4
6,T5,Condition 48 51	GAD
7,T6,Measurement 65 71	DSM-IV
8,R2,AND Arg1:T5 Arg2:T6
9,T7,Measurement 73 83	HAMA score
10,T8,Value 83 86	=17
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Post-eligibility 88 125	Provide with written informed consent
13,T10,Procedure 177 181	SSRI
14,T11,Procedure 183 187	SNRI
15,T12,Procedure 191 195	NASA
16,T13,Temporal 150 163	for two weeks
17,T14,Procedure 139 149	washed-out
18,R4,Has_temporal Arg1:T14 Arg2:T13
19,*,OR T10 T11 T12
0,T1,Post-eligibility 0 144	Provision of written informed consent (by patient or appropriate designee according to local regulations) prior to any study specific procedures
1,T2,Person 147 151	Aged
2,T3,Value 152 169	18 years or older
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Person 171 175	male
5,T5,Person 179 185	female
6,*,OR T4 T5
7,T6,Condition 199 221	stable angina pectoris
8,T7,Qualifier 227 248	angiographic evidence
9,T8,Condition 252 255	CAD
10,R2,Has_qualifier Arg1:T8 Arg2:T7
11,T9,Observation 257 274	diameter stenosis
12,T10,Multiplier 275 280	= 50%
13,R3,Has_multiplier Arg1:T9 Arg2:T10
14,T11,Qualifier 356 379	right coronary arteries
15,T12,Qualifier 335 350;362 379	left circumflex coronary arteries
16,T13,Qualifier 309 333;362 379	left anterior descending coronary arteries
17,T14,Qualifier 298 307;362 379	left main coronary arteries
18,T15,Non-query-able 352 355	and
19,*,OR T11 T14 T13 T12
20,T16,"Scope 298 379	left main, left anterior descending, left circumflex, and right coronary arteries"
21,T17,Qualifier 285 290;362 379	major coronary arteries
22,R4,Subsumes Arg1:T17 Arg2:T16
23,R5,Has_context Arg1:T8 Arg2:T9
24,R6,Has_qualifier Arg1:T8 Arg2:T17
25,T18,Condition 402 423	myocardial infarction
26,T19,Condition 425 427	MI
27,R7,Subsumes Arg1:T18 Arg2:T19
28,T20,Procedure 441 467	coronary revascularization
29,T21,Procedure 475 509	percutaneous coronary intervention
30,T22,Procedure 511 514	PCI
31,T23,Procedure 519 547	coronary artery bypass graft
32,T24,Procedure 549 553	CABG
33,T25,Negation 556 559	not
34,T26,Procedure 583 586	PCI
35,T27,Qualifier 574 582	elective
36,T28,Temporal 587 619	during the index hospitalization
37,T29,Reference_point 598 619	index hospitalization
38,R8,Has_index Arg1:T28 Arg2:T29
39,R9,Has_qualifier Arg1:T26 Arg2:T27
40,R10,Has_negation Arg1:T26 Arg2:T25
41,R11,Subsumes Arg1:T23 Arg2:T24
42,R12,Subsumes Arg1:T21 Arg2:T22
43,T30,"Scope 475 585	percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), not including the elective PC"
44,R13,Subsumes Arg1:T20 Arg2:T30
45,*,OR T21 T23
46,R14,Has_temporal Arg1:T20 Arg2:T28
47,T31,Condition 643 667	type 2 diabetes mellitus
48,T32,Observation 670 712	Post-procedural residual diameter stenosis
49,T33,Condition 728 735	lesions
50,T34,Qualifier 720 727	treated
51,R15,Has_qualifier Arg1:T33 Arg2:T34
52,R16,Has_context Arg1:T33 Arg2:T32
53,T35,Value 736 741	< 20%
54,R17,Has_value Arg1:T32 Arg2:T35
55,T36,Procedure 759 777	stent implantation
56,T37,Procedure 801 820	balloon angioplasty
57,T38,Value 781 786	< 50%
58,R18,AND Arg1:T33 Arg2:T36
59,T39,Condition 728 735	lesions
60,R19,Has_qualifier Arg1:T39 Arg2:T34
61,T40,Observation 670 712	Post-procedural residual diameter stenosis
62,R20,Has_context Arg1:T39 Arg2:T40
63,R21,Has_value Arg1:T40 Arg2:T38
64,R22,AND Arg1:T39 Arg2:T37
65,*,OR T33 T39
66,T41,Condition 822 850	Post-procedural thrombolysis
67,T42,Condition 854 875	myocardial infarction
68,T43,Measurement 854 875;883 888	myocardial infarction grade
69,T44,Value 889 890	3
70,T45,Qualifier 899 914	treated vessels
71,R24,Has_value Arg1:T43 Arg2:T44
72,T47,Measurement 925 946	cardiac troponin test
73,T48,Value 916 924	Negative
74,T49,Temporal 947 977	before the index elective PCI.
75,T50,Reference_point 958 976	index elective PCI
76,T51,Procedure 973 976	PCI
77,R27,Has_index Arg1:T49 Arg2:T50
78,R28,multi Arg1:T50 Arg2:T51
79,T46,Measurement 877 881	TIMI
80,R23,Subsumes Arg1:T43 Arg2:T46
81,R25,multi Arg1:T43 Arg2:T42
82,R26,Has_qualifier Arg1:T41 Arg2:T45
83,R29,Has_temporal Arg1:T47 Arg2:T49
84,R30,Has_value Arg1:T47 Arg2:T48
85,T52,Drug 986 997	Clopidogrel
86,T53,Multiplier 998 1003	75 mg
87,T54,Multiplier 1004 1009	daily
88,T55,Temporal 1015 1034	for at least 7 days
89,T56,Drug 1045 1056	Clopidogrel
90,T57,Multiplier 1057 1062	75 mg
91,T58,Multiplier 1063 1068	daily
92,T59,Temporal 1074 1094	for less than 7 days
93,T60,Drug 1118 1129	Clopidogrel
94,T61,Multiplier 1104 1117	300 to 600 mg
95,T62,Temporal 1143 1153	before PCI
96,T63,Reference_point 1150 1153	PCI
97,T64,Procedure 1150 1153	PCI
98,R31,multi Arg1:T63 Arg2:T64
99,R32,Has_index Arg1:T62 Arg2:T63
100,R33,Has_multiplier Arg1:T60 Arg2:T61
101,R34,Has_temporal Arg1:T60 Arg2:T62
102,R35,Has_multiplier Arg1:T56 Arg2:T57
103,R36,Has_multiplier Arg1:T56 Arg2:T58
104,R37,Has_temporal Arg1:T56 Arg2:T59
105,T65,Scope 1045 1154	Clopidogrel 75 mg daily dose for less than 7 days but with 300 to 600 mg Clopidogrel loading dose before PCI.
106,R38,Has_multiplier Arg1:T52 Arg2:T53
107,R39,Has_multiplier Arg1:T52 Arg2:T54
108,R40,Has_temporal Arg1:T52 Arg2:T55
109,*,OR T52 T65
110,T66,Drug 1163 1183	acetylsalicylic acid
111,T67,Drug 1185 1188	ASA
112,R41,Subsumes Arg1:T66 Arg2:T67
113,T68,Multiplier 1190 1196	100 mg
114,T69,Multiplier 1197 1202	daily
115,T70,Temporal 1213 1232	for at least 7 days
116,T71,Drug 1243 1246	ASA
117,T72,Multiplier 1247 1253	100 mg
118,T73,Multiplier 1254 1259	daily
119,T74,Temporal 1265 1285	for less than 7 days
120,T75,Drug 1302 1305	ASA
121,T76,Multiplier 1295 1301	300 mg
122,T77,Temporal 1319 1329	before PCI
123,T78,Reference_point 1326 1329	PCI
124,T79,Procedure 1326 1329	PCI
125,R42,multi Arg1:T78 Arg2:T79
126,R43,Has_index Arg1:T77 Arg2:T78
127,R44,Has_multiplier Arg1:T75 Arg2:T76
128,R45,Has_temporal Arg1:T75 Arg2:T77
129,R46,Has_multiplier Arg1:T71 Arg2:T72
130,R47,Has_multiplier Arg1:T71 Arg2:T73
131,R48,Has_temporal Arg1:T71 Arg2:T74
132,T80,Scope 1243 1329	ASA 100 mg daily dose for less than 7 days but with 300 mg ASA loading dose before PCI
133,R49,Has_multiplier Arg1:T66 Arg2:T68
134,R50,Has_multiplier Arg1:T66 Arg2:T69
135,R51,Has_temporal Arg1:T66 Arg2:T70
136,*,OR T66 T80
137,T81,Pregnancy_considerations 1332 1418	have a negative urine or blood pregnancy test at enrolment and prior to randomization;
138,T82,"Pregnancy_considerations 1420 1663	currently be using a hormonal contraceptive and agree to continue its use in addition to using double-barrier local contraception (i.e., intra-uterine device plus spermicidal and condom for male partner) from screening through study completion"
0,T1,Condition 8 25	suicidal tendency
1,T2,Measurement 31 62	score of the sixth item of HAMA
2,T3,Value 63 65	=3
3,T4,Measurement 71 84	score of HAMD
4,T5,Value 85 88	=21
5,R1,Has_value Arg1:T2 Arg2:T3
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 90 98	Pregnant
8,T7,Condition 102 111	lactating
9,T8,Person 112 117	women
10,*,OR T6 T7
11,T9,Condition 142 158	hypersensitivity
12,T10,Drug 162 174	tandospirone
13,T11,Condition 130 138	allergic
14,T12,Qualifier 162 174	tandospirone
15,R3,multi Arg1:T12 Arg2:T10
16,*,OR T11 T9
17,T13,Scope 130 158	allergic or hypersensitivity
18,R4,Has_qualifier Arg1:T13 Arg2:T12
19,T14,Condition 196 203;265 272	cardiac disease
20,T15,Condition 205 210;265 272	renal disease
21,T16,Condition 212 222;265 272	neurologic disease
22,T17,Condition 224 239;265 272	cerebrovascular disease
23,T18,Condition 241 250;265 272	metabolic disease
24,T19,Condition 255 272	pulmonary disease
25,*,OR T19 T18 T17 T16 T14 T15
26,T20,"Scope 196 272	cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease"
27,T21,Qualifier 187 195	unstable
28,T22,Qualifier 176 183	Serious
29,T23,Scope 176 195	Serious or unstable
30,R5,Has_scope Arg1:T20 Arg2:T23
31,T24,Condition 274 301	Secondary anxiety disorders
32,T25,Condition 311 329	alcohol dependence
33,T26,Condition 303 307;319 329	Drug dependence
34,*,OR T25 T26
35,T27,Scope 303 329	Drug or alcohol dependence
36,T28,Temporal 330 343	within 1 year
37,R6,Has_temporal Arg1:T27 Arg2:T28
38,T29,Procedure 371 391	benzodiazepine drugs
39,T31,Temporal 354 363	currently
40,T32,Person 393 400	Drivers
41,T33,Person 405 432	dangerous machine operators
42,*,OR T32 T33
43,T34,Grammar_Error 401 404	and
44,T35,Observation 434 472	Participated in other clinical studies
45,T36,Temporal 476 492	the last 30 days
46,R9,Has_temporal Arg1:T35 Arg2:T36
47,T37,Condition 538 562	laboratory abnormalities
48,T38,Condition 531 534;549 562	ECG abnormalities
49,T39,Procedure 538 548	laboratory
50,T40,Procedure 531 534	ECG
51,R10,multi Arg1:T37 Arg2:T39
52,R11,multi Arg1:T38 Arg2:T40
53,T41,Scope 531 562	ECG or laboratory abnormalities
54,T42,Qualifier 508 530	clinically significant
55,R12,Has_qualifier Arg1:T41 Arg2:T42
56,T43,Condition 591 599	epilepsy
57,T44,Measurement 624 627	TSH
58,T45,Value 615 623	abnormal
59,R13,Has_value Arg1:T44 Arg2:T45
60,R7,Has_temporal Arg1:T29 Arg2:T31
0,T1,Condition 24 33	pregnancy
1,T2,Multiplier 17 23	single
2,T3,Qualifier 0 6	normal
3,T4,Qualifier 7 16	full term
4,R1,Has_multiplier Arg1:T1 Arg2:T2
5,R2,Has_qualifier Arg1:T1 Arg2:T4
6,R3,Has_qualifier Arg1:T1 Arg2:T3
7,T5,Person 35 38	age
8,T6,Value 39 55	18 years or more
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Measurement 57 60	BMI
11,T8,Value 61 74	20 - 35 kg/m2
12,R5,Has_value Arg1:T7 Arg2:T8
13,T9,Post-eligibility 76 109	written informed consent obtained
0,T1,"Pregnancy_considerations 0 128	Currently pregnant or using a reliable contraception (e.g. injectables, intrauterine devices, implant, oral contraceptive pills)"
1,T2,Pregnancy_considerations 130 165	Desiring pregnancy in the next year
2,T3,Procedure 178 192	tubal ligation
3,T4,Procedure 196 208	hysterectomy
4,*,OR T3 T4
5,T6,Non-query-able 210 226	Contraindication
6,T7,Post-eligibility 261 354	Unable to comprehend consent material because of language barrier or psychological difficulty
7,T5,Procedure 245 259	contraceptives
8,T8,Drug 230 239	progestin
9,T9,Qualifier 240 244	only
10,R1,AND Arg1:T5 Arg2:T8
11,R2,Has_qualifier Arg1:T8 Arg2:T9
0,T1,Person 0 3	age
1,T2,Value 4 13	<18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 16 25	Pregnancy
4,T4,Informed_consent 27 70	inability to give informed written consent;
5,T5,Procedure 81 97	thoracic surgery
6,T6,Procedure 101 121	thrombolytic therapy
7,T7,Condition 126 143	pleural infection
8,*,OR T5 T6
9,T8,Scope 81 121	thoracic surgery or thrombolytic therapy
10,T9,Temporal 72 80	previous
11,R2,Has_temporal Arg1:T8 Arg2:T9
12,R3,AND Arg1:T8 Arg2:T7
13,T10,Procedure 146 166	medical thoracoscopy
14,T11,Mood 167 186	cannot be performed
15,T12,Temporal 187 202	within 48 hours
16,R4,Has_temporal Arg1:T10 Arg2:T12
17,R5,Has_mood Arg1:T10 Arg2:T11
18,T13,Negation 167 173	cannot
19,R6,multi Arg1:T11 Arg2:T13
20,T14,Condition 205 226	inability to tolerate
21,T15,Procedure 227 236	procedure
22,R7,AND Arg1:T14 Arg2:T15
23,T16,Condition 244 267	hemodynamic instability
24,T17,Condition 278 287	hypoxemia
25,*,OR T16 T17
26,T18,Qualifier 271 277	severe
27,R8,Has_qualifier Arg1:T17 Arg2:T18
28,T19,Scope 244 287	hemodynamic instability or severe hypoxemia
29,T20,Scope 205 236	inability to tolerate procedure
30,R9,Has_scope Arg1:T20 Arg2:T19
31,T21,Condition 311 323	coagulopathy
32,T22,Procedure 303 310	correct
33,R10,AND Arg1:T22 Arg2:T21
34,T23,Mood 290 302	inability to
35,R11,Has_mood Arg1:T22 Arg2:T23
36,T24,Condition 340 372	homogeneously echogenic effusion
37,T25,Procedure 376 386	pleural US
38,R12,AND Arg1:T24 Arg2:T25
0,T1,Post-eligibility 43 88	Capable of providing written informed consent
1,T2,Measurement 29 32	HIV
2,T3,Value 33 41	negative
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 0 2	BV
5,T5,Value 3 11	positive
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 15 27	Nugent score
8,R3,AND Arg1:T4 Arg2:T6
0,T1,Person 0 3	age
1,T2,Value 4 22	less than 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 24 31	allergy
4,T4,Drug 35 46	study drugs
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Condition 48 64	substance misuse
7,T6,Condition 71 87	contraindication
8,T7,Drug 96 107	study drugs
9,R3,AND Arg1:T6 Arg2:T7
10,*,OR T5 T6
0,T1,Condition 28 53	septated pleural effusion
1,T2,Procedure 57 80	pleural ultrasonography
2,T3,Procedure 88 101	chest CT scan
3,*,OR T2 T3
4,T4,Condition 0 4	CPPE
5,T5,Scope 0 53	CPPE along with evidence of septated pleural effusion
6,T6,Mood 16 27	evidence of
7,R1,Has_mood Arg1:T1 Arg2:T6
8,T7,Scope 57 101	pleural ultrasonography and/or chest CT scan
9,R2,Has_scope Arg1:T5 Arg2:T7
10,T8,Condition 103 110	empyema
0,T1,Measurement 11 32	13 C-urea breath test
1,T2,Value 2 10	positive
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 41 59	H.pylori treatment
4,T4,Multiplier 60 79	more than two times
5,R2,Has_multiplier Arg1:T3 Arg2:T4
6,T5,Person 81 84	Age
7,T6,Value 85 94	>18 years
8,R3,Has_value Arg1:T5 Arg2:T6
0,T1,Drug 0 17	Bismuth compounds
1,T2,Drug 19 33	acid inhibitor
2,T3,Drug 38 49	antibiotics
3,T4,Temporal 50 95	during 4 weeks before the patient is enrolled
4,T5,Reference_point 72 95	the patient is enrolled
5,R1,Has_index Arg1:T4 Arg2:T5
6,*,OR T2 T3 T1
7,T6,"Scope 0 49	Bismuth compounds, acid inhibitor, or antibiotics"
8,R2,Has_temporal Arg1:T6 Arg2:T4
9,T7,Condition 97 105	Allergic
10,T8,Drug 113 124	medications
11,R3,AND Arg1:T7 Arg2:T8
12,T9,Procedure 126 156	Upper gastrointestinal surgery
13,T10,Observation 157 164	history
14,R4,Has_temporal Arg1:T9 Arg2:T10
15,T11,Qualifier 166 173	Serious
16,T12,Condition 174 193	heart insufficiency
17,R5,Has_qualifier Arg1:T12 Arg2:T11
18,T13,Condition 195 214	liver insufficiency
19,T14,Condition 216 235	renal insufficiency
20,T15,Qualifier 240 245	other
21,T16,Condition 246 270	serious medical problems
22,R6,Has_qualifier Arg1:T16 Arg2:T15
23,*,OR T14 T13 T12 T16
24,T17,Condition 284 299	blood dyscrasia
25,T18,Mood 272 280	Evidence
26,R7,Has_mood Arg1:T17 Arg2:T18
27,T19,Condition 301 309	Pregnant
28,T20,Condition 314 323	lactating
29,T21,Person 324 329	women
30,*,OR T20 T19
31,T22,Non-query-able 331 407	Can't express his complain correctly and can't cooperate with the researcher
0,T1,Person 0 5	Adult
1,T2,Value 16 26	> 18 years
2,T3,Person 21 26	years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Scope 16 26	> 18 years
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Procedure 42 72	cardiopulmonary bypass surgery
7,T6,Measurement 78 110	Glomerular Filtration Rate (GFR)
8,T7,Value 111 138	greater than or equal to 60
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Measurement 143 177	left ventricular ejection fraction
11,T9,Value 178 206	greater than or equal to 40%
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Mood 28 41	scheduled for
14,R5,Has_mood Arg1:T5 Arg2:T10
0,T1,Non-query-able 0 175	Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study medication
1,T2,Drug 190 199	sorafenib
2,T3,Drug 203 214	oxaliplatin
3,T4,Procedure 221 233	chemotherapy
4,T5,Qualifier 190 220	sorafenib or oxaliplatin-based
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,T6,Temporal 234 248	within 14 days
7,T7,Reference_point 252 282	first dose of study medication
8,R2,Has_index Arg1:T6 Arg2:T7
9,R3,Has_temporal Arg1:T4 Arg2:T6
10,T8,Condition 292 302;314 331	esophageal variceal bleeding
11,T9,Condition 306 331	gastric variceal bleeding
12,*,OR T8 T9
13,T10,Temporal 332 356	within the last 6 months
14,T11,Scope 292 331	esophageal or gastric variceal bleeding
15,R4,Has_temporal Arg1:T11 Arg2:T10
16,T12,Condition 382 389	ascites
17,T13,Condition 419 439	portal vein invasion
18,T14,Qualifier 447 471	main portal branch (Vp4)
19,T15,Qualifier 473 491	inferior vena cava
20,T16,Condition 496 515	cardiac involvement
21,T17,Condition 519 522	HCC
22,T18,Procedure 532 539	imaging
23,T19,"Scope 447 491	main portal branch (Vp4), inferior vena cava"
24,*,OR T14 T15
25,R5,Has_scope Arg1:T13 Arg2:T19
26,*,OR T13 T16
27,T20,"Scope 419 515	portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement"
28,R6,AND Arg1:T20 Arg2:T18
29,R7,AND Arg1:T20 Arg2:T17
30,T21,Condition 570 592	hepatic encephalopathy
31,T22,Temporal 593 613	in the last 6 months
32,R8,Has_temporal Arg1:T21 Arg2:T22
33,T23,Procedure 640 662	hematologic transplant
34,T24,Procedure 625 636;652 662	solid organ transplant
35,*,OR T24 T23
36,T25,Procedure 678 694	systemic therapy
37,T26,Condition 699 702	HCC
38,R9,AND Arg1:T25 Arg2:T26
39,T27,Drug 750 759	sorafenib
40,T28,Drug 763 774	oxaliplatin
41,T29,Procedure 781 793	chemotherapy
42,T30,Qualifier 750 780	sorafenib or oxaliplatin-based
43,R10,Has_qualifier Arg1:T29 Arg2:T30
44,T31,Temporal 795 800	prior
45,T32,Reference_point 804 829	start of study medication
46,R11,Has_index Arg1:T31 Arg2:T32
47,T33,Scope 678 793	systemic therapy for HCC in the advanced (incurable) setting other than sorafenib or oxaliplatin-based chemotherapy
48,R13,Has_temporal Arg1:T33 Arg2:T31
49,T34,Temporal 838 844	active
50,T35,Condition 845 863	autoimmune disease
51,R14,Has_temporal Arg1:T35 Arg2:T34
52,T36,Procedure 882 900	systemic treatment
53,T37,Temporal 901 920	in the past 2 years
54,R15,AND Arg1:T35 Arg2:T36
55,R16,Has_temporal Arg1:T35 Arg2:T37
56,T38,Not_a_criteria 922 989	Replacement therapy is not considered a form of systemic treatment.
57,T39,Condition 1010 1026	immunodeficiency
58,T40,Procedure 1043 1067	systemic steroid therapy
59,T41,Procedure 1089 1114	immunosuppressive therapy
60,T42,Temporal 1115 1134	within 7 days prior
61,T43,Reference_point 1138 1172	the first dose of study medication
62,R17,Has_index Arg1:T42 Arg2:T43
63,*,OR T40 T41
64,T44,Scope 1043 1114	systemic steroid therapy or any other form of immunosuppressive therapy
65,R18,Has_temporal Arg1:T44 Arg2:T42
66,*,OR T39 T44
67,T45,Procedure 1187 1207	locoregional therapy
68,T46,Procedure 1218 1256	transcatheter chemoembolization [TACE]
69,T47,Procedure 1258 1290	transcatheter embolization [TAE]
70,T48,Procedure 1292 1323	hepatic arterial infusion [HAI]
71,T49,Procedure 1325 1334	radiation
72,T50,Procedure 1336 1353	radioembolization
73,T51,Procedure 1358 1366	ablation
74,T52,Temporal 1382 1402	within 4 weeks prior
75,T53,Reference_point 1410 1440	first dose of study medication
76,R19,Has_index Arg1:T52 Arg2:T53
77,T54,Qualifier 1211 1216	liver
78,T55,Qualifier 1371 1381	other site
79,*,OR T55 T54
80,R20,Has_qualifier Arg1:T45 Arg2:T54
81,T56,"Scope 1218 1366	transcatheter chemoembolization [TACE], transcatheter embolization [TAE], hepatic arterial infusion [HAI], radiation, radioembolization, or ablation"
82,R21,Subsumes Arg1:T45 Arg2:T56
83,R22,Has_temporal Arg1:T45 Arg2:T52
84,T57,Procedure 1450 1463	major surgery
85,T58,Qualifier 1467 1472	liver
86,T59,Qualifier 1476 1486	other site
87,*,OR T58 T59
88,R23,Has_qualifier Arg1:T57 Arg2:T58
89,T60,Temporal 1487 1507	within 4 weeks prior
90,T61,Reference_point 1515 1545	first dose of study medication
91,R24,Has_index Arg1:T60 Arg2:T61
92,R25,Has_temporal Arg1:T57 Arg2:T60
93,T62,Procedure 1557 1570	minor surgery
94,T63,Temporal 1571 1584	≤7 days prior
95,T64,Reference_point 1592 1622	first dose of study medication
96,R26,Has_index Arg1:T63 Arg2:T64
97,R27,Has_temporal Arg1:T62 Arg2:T63
98,T65,"Undefined_semantics 1624 1763	Has not recovered adequately (i.e., Grade ≤1 or baseline) from the toxicity and/or complications from any intervention prior to study start"
99,T66,"Context_Error 1624 1763	Has not recovered adequately (i.e., Grade ≤1 or baseline) from the toxicity and/or complications from any intervention prior to study start"
100,T67,Subjective_judgement 1632 1652	recovered adequately
101,T68,Condition 1792 1802	malignancy
102,T69,Qualifier 1781 1791	additional
103,R28,Has_qualifier Arg1:T68 Arg2:T69
104,T70,Temporal 1803 1857	within 3 years prior to first dose of study medication
105,T71,Reference_point 1827 1857	first dose of study medication
106,T72,Procedure 1891 1898	treated
107,T73,Qualifier 1880 1890	curatively
108,R29,Has_qualifier Arg1:T72 Arg2:T73
109,T74,Undefined_semantics 1880 1898	curatively treated
110,T75,Condition 1899 1931	basal cell carcinoma of the skin
111,T76,Condition 1933 1968	squamous cell carcinoma of the skin
112,*,OR T75 T76 T77
113,T77,Condition 1996 2011	in situ cancers
114,T78,Procedure 1987 1995	resected
115,T79,Qualifier 1976 1986	curatively
116,R30,Has_qualifier Arg1:T78 Arg2:T79
117,T80,Qualifier 1880 1898	curatively treated
118,R31,Has_qualifier Arg1:T75 Arg2:T80
119,T81,Qualifier 1976 1995	curatively resected
120,R32,Has_qualifier Arg1:T77 Arg2:T81
121,T82,"Scope 1880 2011	curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers"
122,R34,Has_index Arg1:T70 Arg2:T71
123,R35,Has_temporal Arg1:T68 Arg2:T70
124,T83,Observation 2025 2032	history
125,T84,Observation 2044 2052	evidence
126,T85,Condition 2057 2096	central nervous system (CNS) metastases
127,T86,Condition 2104 2128	carcinomatous meningitis
128,*,OR T86 T85
129,T87,Scope 2057 2128	central nervous system (CNS) metastases and/or carcinomatous meningitis
130,R36,Has_context Arg1:T87 Arg2:T84
131,R37,Has_temporal Arg1:T87 Arg2:T83
132,T89,Drug 2190 2198	steroids
133,T90,Drug 2210 2221	pneumonitis
134,T91,Temporal 2202 2209	current
135,T92,Observation 2136 2143	history
136,T93,Condition 2148 2175	non-infectious) pneumonitis
137,R38,AND Arg1:T93 Arg2:T89
138,*,OR T89 T90
139,R39,Has_temporal Arg1:T90 Arg2:T91
140,R40,Has_temporal Arg1:T93 Arg2:T92
141,T88,Procedure 2257 2273	systemic therapy
142,T94,Temporal 2230 2236	active
143,T95,Condition 2237 2246	infection
144,T96,Qualifier 2247 2273	requiring systemic therapy
145,R41,Has_qualifier Arg1:T95 Arg2:T96
146,R42,Has_temporal Arg1:T95 Arg2:T94
147,T99,Procedure 2502 2515	immunotherapy
148,T100,Drug 2524 2568	anti-Programmed Cell Death Receptor 1 (PD-1)
149,T101,Drug 2570 2622	Programmed Cell Death Receptor Ligand 1 (anti-PD-L1)
150,T102,Drug 2627 2680	anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)
151,T103,Non-query-able 2699 2750	participated in clinical studies with pembrolizumab
152,T104,Drug 2737 2750	pembrolizumab
153,*,OR T100 T101 T102
154,T105,"Scope 2524 2680	anti-Programmed Cell Death Receptor 1 (PD-1), Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)"
155,R43,Has_scope Arg1:T99 Arg2:T105
156,T106,Observation 2699 2750	participated in clinical studies with pembrolizumab
157,*,OR T99 T106
158,T107,Condition 2775 2809	human immunodeficiency virus (HIV)
159,T108,Observation 2764 2771	history
160,R44,Has_temporal Arg1:T107 Arg2:T108
161,T109,Condition 2832 2843	Hepatitis B
162,T110,Qualifier 2815 2824	untreated
163,T111,Qualifier 2825 2831	active
164,R45,Has_qualifier Arg1:T109 Arg2:T111
165,R46,Has_qualifier Arg1:T109 Arg2:T110
166,T112,Condition 2849 2860	hepatitis C
167,T113,Procedure 2892 2907	therapy for HCV
168,T114,Temporal 2908 2922	<4 weeks prior
169,T115,Drug 2936 2949	pembrolizumab
170,T116,Reference_point 2926 2949	receiving pembrolizumab
171,R47,Has_index Arg1:T114 Arg2:T116
172,R48,Has_temporal Arg1:T113 Arg2:T114
173,R49,AND Arg1:T112 Arg2:T113
174,T117,Condition 2966 2978	live vaccine
175,T118,Temporal 2986 2999	30 days prior
176,T119,Reference_point 3007 3034	first dose of study therapy
177,R50,Has_index Arg1:T118 Arg2:T119
178,R51,Has_temporal Arg1:T117 Arg2:T118
179,T120,Negation 1858 1879	with the exception of
180,R33,Has_negation Arg1:T82 Arg2:T120
181,R52,Has_scope Arg1:T68 Arg2:T82
182,T97,Condition 2278 2286	pregnant
183,T98,Observation 2290 2304	breast feeding
184,*,OR T97 T98 T121 T122
185,T121,Observation 2308 2329	expecting to conceive
186,T122,Observation 2308 2320;2333 2339	expecting to father
187,T123,Temporal 2340 2388	starting from the first dose of study medication
188,T124,Reference_point 2354 2388	the first dose of study medication
189,R53,Has_index Arg1:T123 Arg2:T124
190,T125,Temporal 2390 2417	throughout the study period
191,T126,Reference_point 2401 2417	the study period
192,R55,Has_index Arg1:T125 Arg2:T126
193,T127,Temporal 2423 2481	for up to 120 days after the last dose of study medication
194,T128,Reference_point 2448 2481	the last dose of study medication
195,R56,Has_index Arg1:T127 Arg2:T128
196,T129,"Scope 2340 2481	starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication"
197,R54,Has_scope Arg1:T122 Arg2:T129
198,T130,Negation 739 749	other than
199,R12,Has_negation Arg1:T29 Arg2:T130
200,R57,AND Arg1:T25 Arg2:T29
0,T1,Person 0 3	Age
1,T3,Procedure 20 35	Hospitalization
2,T4,Condition 41 69	acute undifferentiated fever
3,T5,Measurement 71 82	temperature
4,T6,Value 83 91	> 37.5 C
5,T7,Condition 93 101	tympanic
6,R2,Has_value Arg1:T5 Arg2:T6
7,T8,"Scope 71 101	temperature > 37.5 C, tympanic"
8,R3,Has_scope Arg1:T4 Arg2:T8
9,R4,AND Arg1:T3 Arg2:T4
10,T9,Multiplier 103 111	=14 days
11,R5,Has_multiplier Arg1:T3 Arg2:T9
12,T10,Observation 152 159	history
13,T11,Condition 163 168	fever
14,T12,Multiplier 169 178	= 14 days
15,R6,Has_multiplier Arg1:T11 Arg2:T12
16,R7,Has_temporal Arg1:T11 Arg2:T10
17,T13,Condition 204 209	fever
18,T14,Temporal 210 238	within 24 hours of admission
19,T15,Procedure 124 144	admitted to hospital
20,R8,Has_temporal Arg1:T13 Arg2:T14
21,T16,Reference_point 229 238	admission
22,R9,Has_index Arg1:T14 Arg2:T16
23,T2,Value 4 18	= 15 years old
24,R1,Has_value Arg1:T1 Arg2:T2
25,T17,Scope 152 238	history of fever = 14 days who subsequently develop fever within 24 hours of admission
26,R10,Has_scope Arg1:T15 Arg2:T17
27,T18,Condition 261 273	scrub typhus
28,T19,Condition 286 314	acute undifferentiated fever
29,T20,Condition 329 347	focus of infection
30,T21,Negation 320 328	no clear
31,R11,Has_negation Arg1:T20 Arg2:T21
32,T22,Value 352 360	negative
33,T23,Measurement 361 380	malaria blood smear
34,R12,Has_value Arg1:T23 Arg2:T22
35,T24,Value 388 396	negative
36,T25,Measurement 397 408	malaria RDT
37,R13,Has_value Arg1:T25 Arg2:T24
38,*,OR T23 T25
39,T26,Multiplier 428 431	one
40,T27,Multiplier 433 437	none
41,T28,Multiplier 442 458	a combination of
42,*,OR T26 T27 T28
43,T29,"Scope 428 458	one, none, or a combination of"
44,T30,Condition 491 497	eschar
45,T31,Condition 499 503	rash
46,T32,Condition 505 520	lymphadenopathy
47,T33,Condition 522 530	headache
48,T34,Condition 532 539	myalgia
49,T35,Condition 541 546	cough
50,T36,Condition 548 554	nausea
51,T37,Condition 559 579	abdominal discomfort
52,*,OR T30 T31 T32 T33 T34 T35 T36 T37
53,T38,"Scope 491 579	eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort"
54,R14,Has_scope Arg1:T38 Arg2:T29
55,T39,"Scope 428 579	one, none, or a combination of other clinical findings such as eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort"
56,A1,Optional T39
57,T40,Scope 286 408	acute undifferentiated fever with no clear focus of infection and negative malaria blood smear and/or negative malaria RDT
58,R15,Subsumes Arg1:T18 Arg2:T40
59,T41,Measurement 593 609	scrub typhus RDT
60,T42,Value 584 592	positive
61,R16,Has_value Arg1:T41 Arg2:T42
62,T43,Procedure 611 631	Scrub Typhus IgM RDT
63,R17,Subsumes Arg1:T41 Arg2:T43
64,T44,Value 680 688	positive
65,T45,Procedure 689 692	PCR
66,T46,Qualifier 712 732	O. tsutsugamushi DNA
67,R18,Has_qualifier Arg1:T45 Arg2:T46
68,T47,Qualifier 742 764	admission blood sample
69,R19,Has_qualifier Arg1:T45 Arg2:T47
70,R20,Has_value Arg1:T45 Arg2:T44
71,*,OR T41 T45
72,T48,Observation 766 790	Written informed consent
73,T49,Observation 799 822	written informed assent
74,*,OR T49 T48
75,T50,Observation 836 864	Able to take oral medication
76,T51,Drug 849 864	oral medication
77,R21,multi Arg1:T50 Arg2:T51
0,T1,Condition 0 18	Purulent infection
1,T2,Non-query-able 20 42	Refusal to participate
2,T3,Post-eligibility 20 42	Refusal to participate
3,T4,Condition 44 51	Allergy
4,T5,Drug 55 70	tested material
5,T6,Reference_point 55 70	tested material
6,R1,AND Arg1:T4 Arg2:T5
7,T7,Context_Error 55 70	tested material
0,T1,Person 0 5	Women
1,T2,Person 16 19	age
2,T3,Value 23 25;6 11	18 under
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 48 62	axillary nodes
5,T5,Qualifier 39 47	positive
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Procedure 64 83	Neoadjuvant therapy
8,T7,Condition 96 109	breast cancer
9,R3,AND Arg1:T6 Arg2:T7
10,T8,Person 121 126	Women
11,T9,Procedure 141 146	SLNBx
12,T10,Procedure 150 174	axillary node dissection
13,*,OR T9 T10
14,T11,Qualifier 132 140	previous
15,T12,Scope 141 174	SLNBx or axillary node dissection
16,R4,Has_qualifier Arg1:T12 Arg2:T11
17,T13,Pregnancy_considerations 176 190	Pregnant women
18,T14,Procedure 212 221	radiation
19,T15,Qualifier 222 241	above the diaphragm
20,R5,Has_qualifier Arg1:T14 Arg2:T15
21,T16,Qualifier 247 261	below the neck
22,R6,Has_qualifier Arg1:T14 Arg2:T16
23,T17,Qualifier 203 211	previous
24,R7,Has_qualifier Arg1:T14 Arg2:T17
25,T18,Person 192 197	Women
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 106 108	2.
2,T3,Parsing_Error 177 179	3.
3,T4,Parsing_Error 234 236	4.
4,T5,Parsing_Error 255 257	5.
5,T6,Parsing_Error 313 315	6.
6,T7,Parsing_Error 361 363	7.
7,T8,Value 12 22	≥ 18 years
8,T9,Person 17 26	years-old
9,R1,Has_value Arg1:T9 Arg2:T8
10,T10,Visit 33 59	Instituto Teletón Santiago
11,T11,Visit 66 102	Hospital Clínico Mutual de seguridad
12,*,OR T10 T11
13,T12,Grammar_Error 61 64	and
14,T13,Condition 119 137	spinal cord injury
15,T14,Qualifier 109 118	C5 to T12
16,R2,Has_qualifier Arg1:T13 Arg2:T14
17,T15,Measurement 153 160	ISNCSCI
18,T16,Value 161 175	grades C and D
19,R3,Has_value Arg1:T15 Arg2:T16
20,R4,AND Arg1:T13 Arg2:T15
21,T17,Qualifier 194 207	non-traumatic
22,T18,Condition 225 232	lesions
23,T19,Qualifier 180 189	Traumatic
24,T20,Qualifier 209 224	non-progressive
25,R5,Has_qualifier Arg1:T18 Arg2:T20
26,R6,Has_qualifier Arg1:T18 Arg2:T17
27,R7,Has_qualifier Arg1:T18 Arg2:T19
28,T21,Temporal 237 253	Onset > 6 months
29,T22,Condition 258 282;294 311	Ability to ambulate with assistive devices
30,T23,Condition 258 277;286 311	Ability to ambulate without assistive devices
31,*,OR T22 T23
32,T24,Condition 316 340;351 359	Ability to follow verbal commands
33,T25,Condition 316 333;344 359	Ability to follow visual commands
34,*,OR T25 T24
35,T26,Post-eligibility 364 387	Signed informed consent
36,T27,Non-query-able 364 387	Signed informed consent
0,T1,Drug 11 22	Doxycycline
1,T2,Drug 26 44	Methylprednisolone
2,*,OR T1 T2
3,T3,Condition 0 7	allergy
4,T4,Scope 11 44	Doxycycline or Methylprednisolone
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Condition 47 56	pregnancy
7,T6,Condition 59 68	diagnosis
8,T7,Condition 71 93	Inflammatory arthritis
9,T8,Condition 97 105	diabetes
10,*,OR T7 T8
11,T9,Qualifier 108 117	secondary
12,T10,Condition 118 137	adhesive capsulitis
13,T11,Observation 139 146	history
14,T12,Qualifier 150 161	significant
15,T13,Condition 162 168	trauma
16,R2,Has_qualifier Arg1:T13 Arg2:T12
17,T14,Condition 170 194	rotator cuff tear injury
18,T15,Condition 196 202	stroke
19,*,OR T15 T14 T13
20,T16,"Scope 150 202	significant trauma, rotator cuff tear injury, stroke"
21,R3,Has_temporal Arg1:T16 Arg2:T11
22,R4,Has_qualifier Arg1:T10 Arg2:T9
23,T17,"Scope 139 202	history of significant trauma, rotator cuff tear injury, stroke"
24,R5,Subsumes Arg1:T10 Arg2:T17
25,T18,Mood 205 216	evidence of
26,T19,Condition 217 226	arthritis
27,T20,Procedure 230 235	x-ray
28,R6,AND Arg1:T20 Arg2:T19
29,R7,Has_mood Arg1:T19 Arg2:T18
30,T21,Temporal 238 245	current
31,T22,Condition 246 264	infectious disease
32,R8,Has_temporal Arg1:T22 Arg2:T21
33,T23,Qualifier 271 274	any
34,T24,Temporal 275 283	previous
35,T25,Procedure 284 293	treatment
36,T26,Condition 306 325	adhesive capsulitis
37,R9,Has_temporal Arg1:T25 Arg2:T24
38,R10,Has_qualifier Arg1:T25 Arg2:T23
39,R11,AND Arg1:T25 Arg2:T26
40,T27,Qualifier 333 350	affected shoulder
41,R12,Has_qualifier Arg1:T26 Arg2:T27
0,T1,Condition 2 10	Diabetes
1,T2,Temporal 20 29	>12 years
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Multiplier 48 63	more than three
4,T4,Procedure 64 90	glucose lowering therapies
5,R2,Has_multiplier Arg1:T4 Arg2:T3
6,T5,Observation 92 103	Weight-loss
7,T6,Value 107 111	>5kg
8,T7,Temporal 119 137	preceding 6 months
9,R3,Has_value Arg1:T5 Arg2:T6
10,R4,Has_temporal Arg1:T5 Arg2:T7
11,T8,Condition 152 174	chronic kidney disease
12,T9,Qualifier 139 151	Stage 4 or 5
13,R5,Has_qualifier Arg1:T8 Arg2:T9
14,T10,Measurement 176 180	eGFR
15,T11,Value 180 197	< 30ml/min/1.73m2
16,R6,Has_value Arg1:T10 Arg2:T11
17,R7,Subsumes Arg1:T8 Arg2:T10
18,T12,Drug 222 229	Insulin
19,T13,Drug 231 249	thiazolidinediones
20,T14,Drug 251 259	steroids
21,T15,Drug 263 296	atypical antipsychotic medication
22,*,OR T12 T13 T14 T15
23,T16,Condition 308 323	thyroid disease
24,T17,Qualifier 298 307	Untreated
25,R8,Has_qualifier Arg1:T16 Arg2:T17
26,T18,Condition 331 352	macrovascular disease
27,T19,Condition 363 386	coronary artery disease
28,T20,Condition 388 394	stroke
29,T21,Condition 395 398	TIA
30,T22,Condition 402 429	peripheral vascular disease
31,*,OR T19 T20 T21 T22
32,T23,"Scope 363 429	coronary artery disease, stroke/TIA or peripheral vascular disease"
33,R9,Subsumes Arg1:T18 Arg2:T23
34,T24,Condition 443 453	arrhythmia
35,T25,Condition 465 484	atrial fibrillation
36,T26,Condition 486 500	atrial flutter
37,T27,Condition 512 545	3rd degree atrioventricular block
38,T28,Condition 505 508;516 545	2nd degree atrioventricular block
39,*,OR T25 T26 T28 T27
40,T29,"Scope 465 545	atrial fibrillation, atrial flutter, or 2nd or 3rd degree atrioventricular block"
41,R10,Subsumes Arg1:T24 Arg2:T29
42,T30,Condition 554 567	heart failure
43,T31,Condition 595 608	heart disease
44,T32,Observation 623 631	exercise
45,T33,Procedure 647 650	MRP
46,T34,Negation 610 619	Inability
47,*,OR T32 T33
48,T35,Scope 623 650	exercise or undertake a MRP
49,R11,Has_negation Arg1:T35 Arg2:T34
50,T36,Condition 661 677	contraindication
51,T37,Procedure 681 684	CMR
52,R12,AND Arg1:T36 Arg2:T37
53,T38,Condition 686 709	Cardiovascular symptoms
54,T39,Condition 711 717	angina
55,Inflammatory,condition e.g. Connective tissue disorder
56,T40,Condition 728 736	dyspnoea
57,*,OR T39 T40
58,T41,"Scope 711 736	angina, limiting dyspnoea"
59,R13,Has_scope Arg1:T38 Arg2:T41
60,T42,Condition 771 783	Inflammatory
61,T43,"Condition 799 826	Connective tissue disorder,"
62,T44,Condition 827 847	Rheumatoid arthritis
63,*,OR T43 T44
64,T45,"Scope 799 847	Connective tissue disorder, Rheumatoid arthritis"
65,R14,Subsumes Arg1:T42 Arg2:T45
0,T1,Negation 16 19	not
1,T2,Observation 20 47	meet the inclusion criteria
2,R1,Has_negation Arg1:T2 Arg2:T1
3,T3,Observation 69 76	history
4,T4,Condition 80 88	allergic
5,T5,Drug 102 115	human albumin
6,R2,AND Arg1:T4 Arg2:T5
7,R3,Has_temporal Arg1:T4 Arg2:T3
8,T6,Drug 152 170	iodinated contrast
9,T7,Temporal 171 205	during the 7 days prior to surgery
10,T8,Reference_point 198 205	surgery
11,R4,Has_index Arg1:T7 Arg2:T8
12,T9,Procedure 198 205	surgery
13,R5,multi Arg1:T8 Arg2:T9
14,T10,Condition 210 218	pregnant
15,T11,Person 219 224	women
16,R6,Has_temporal Arg1:T6 Arg2:T7
0,T1,Condition 6 22	hypersensitivity
1,T2,Drug 26 38	tetracycline
2,T3,Drug 40 51	doxycycline
3,T4,Drug 55 67	azithromycin
4,*,OR T3 T4 T2
5,T5,"Scope 26 67	tetracycline, doxycycline or azithromycin"
6,R1,Has_scope Arg1:T1 Arg2:T5
7,T6,Drug 87 98	doxycycline
8,T7,Drug 100 112	azithromycin
9,T8,Drug 114 129	chloramphenicol
10,T9,Drug 131 141	rifampicin
11,T10,Drug 146 158	tetracycline
12,T11,Temporal 159 186	during the preceding 7 days
13,*,OR T10 T9 T8 T7 T6
14,T12,"Scope 87 158	doxycycline, azithromycin, chloramphenicol, rifampicin, or tetracycline"
15,R2,Has_temporal Arg1:T12 Arg2:T11
16,T13,Condition 188 197	Pregnancy
17,T14,Observation 201 215	breast-feeding
18,*,OR T13 T14
19,T15,Condition 231 248	myasthenia gravis
20,T16,Condition 252 280	systemic lupus erythematosus
21,*,OR T15 T16
22,T17,Condition 311 320	infection
23,T18,Procedure 322 337	diagnostic test
24,R3,AND Arg1:T17 Arg2:T18
25,T19,Condition 353 366	acute malaria
26,T20,Condition 368 374	dengue
27,T21,Condition 376 389	leptospirosis
28,T22,Condition 391 398	typhoid
29,T23,Condition 400 421	Japanese encephalitis
30,*,OR T23 T22 T21 T20 T19
31,T24,"Scope 353 421	acute malaria, dengue, leptospirosis, typhoid, Japanese encephalitis"
32,R4,Subsumes Arg1:T17 Arg2:T24
33,T25,Condition 436 438	TB
34,T26,Procedure 442 454	TB treatment
35,T27,Temporal 455 468	in = 6 months
36,*,OR T25 T26
37,R5,Has_temporal Arg1:T26 Arg2:T27
38,T28,Procedure 529 534	HAART
39,T29,Condition 543 546	HIV
40,R6,AND Arg1:T28 Arg2:T29
41,T30,Multiplier 548 561	long term use
42,T31,Drug 565 583	immunosuppressants
43,R7,Has_multiplier Arg1:T31 Arg2:T30
44,T32,Drug 590 598	steroids
45,T33,Drug 600 612	chemotherapy
46,T34,Drug 614 628	TNF-inhibitors
47,*,OR T34 T33 T32
48,T35,"Scope 590 628	steroids, chemotherapy, TNF-inhibitors"
49,R8,Subsumes Arg1:T31 Arg2:T35
50,*,OR T28 T31
51,T36,Non-representable 650 900	Patients with severe disease whom the clinical team feel their condition necessitates the need for additional scrub typhus treatment beyond the allocated antibiotic treatment assigned at randomization (e.g. IV chloramphenicol and/or PO/NG rifampicin)
0,T1,Condition 6 9	HCC
1,T2,Procedure 33 42	radiology
2,T3,Procedure 44 53	histology
3,T4,Procedure 58 66	cytology
4,*,OR T3 T4 T2
5,T5,"Scope 33 66	radiology, histology, or cytology"
6,R1,Has_scope Arg1:T1 Arg2:T5
7,T6,Condition 127 134;68 81	subtype fibrolamellar
8,T7,Condition 87 134	mixed hepatocellular/cholangiocarcinoma subtype
9,T8,Negation 140 152	not eligible
10,R2,Has_negation Arg1:T7 Arg2:T8
11,R3,Has_negation Arg1:T6 Arg2:T8
12,T9,"Scope 68 152	fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible"
13,R4,Has_scope Arg1:T1 Arg2:T9
14,T10,Measurement 159 195	Barcelona Clinic Liver Cancer (BCLC)
15,T11,Value 196 203	Stage C
16,R5,Has_value Arg1:T10 Arg2:T11
17,T12,Condition 204 211	disease
18,T13,Context_Error 204 211	disease
19,T14,Measurement 215 219	BCLC
20,T15,Value 220 227	Stage B
21,R6,Has_value Arg1:T14 Arg2:T15
22,T16,Qualifier 240 272	amenable to locoregional therapy
23,T17,Qualifier 276 310	refractory to locoregional therapy
24,T18,Qualifier 319 360	amenable to a curative treatment approach
25,T19,Negation 236 239	not
26,T20,Negation 315 318	not
27,T21,Scope 240 310	amenable to locoregional therapy or refractory to locoregional therapy
28,*,OR T21 T19
29,*,OR T16 T17
30,R7,Has_negation Arg1:T18 Arg2:T20
31,R8,AND Arg1:T12 Arg2:T10
32,T22,Condition 228 235	disease
33,T23,Context_Error 228 235	disease
34,R9,AND Arg1:T22 Arg2:T14
35,*,OR T22 T12
36,R10,Has_scope Arg1:T22 Arg2:T21
37,R11,Has_qualifier Arg1:T22 Arg2:T18
38,T24,Measurement 368 378;381 392	Child-Pugh liver score
39,T25,Value 379 380	A
40,R12,Has_value Arg1:T24 Arg2:T25
41,T26,Temporal 393 412	within 7 days prior
42,T27,Reference_point 416 446	first dose of study medication
43,R13,Has_index Arg1:T26 Arg2:T27
44,R14,Has_temporal Arg1:T24 Arg2:T26
45,T28,Observation 454 469	life expectancy
46,T29,Value 473 482	>3 months
47,R15,Has_value Arg1:T28 Arg2:T29
48,T30,Multiplier 488 500	at least one
49,T32,Condition 512 518	lesion
50,T31,Measurement 528 546	RECIST version 1.1
51,T33,Value 501 511	measurable
52,R16,Has_value Arg1:T31 Arg2:T33
53,R17,AND Arg1:T32 Arg2:T31
54,R18,Has_multiplier Arg1:T32 Arg2:T30
55,T34,Measurement 582 642	Eastern Cooperative Oncology Group (ECOG) performance status
56,T35,Value 646 652	0 or 1
57,R19,Has_value Arg1:T34 Arg2:T35
58,T36,Temporal 663 682	within 7 days prior
59,T37,Reference_point 686 730	receiving the first dose of study medication
60,R20,Has_index Arg1:T36 Arg2:T37
61,R21,Has_temporal Arg1:T34 Arg2:T36
62,T38,Procedure 757 769	radiographic
63,T39,Observation 747 756;770 781	objective progression
64,R22,Has_context Arg1:T38 Arg2:T39
65,T40,Temporal 782 797	during or after
66,T41,Reference_point 798 856	treatment with sorafenib or oxaliplatin-based chemotherapy
67,T42,Drug 813 822	sorafenib
68,T43,Drug 826 837	oxaliplatin
69,T44,Qualifier 813 843	sorafenib or oxaliplatin-based
70,T45,Procedure 844 856	chemotherapy
71,R23,Has_qualifier Arg1:T45 Arg2:T44
72,T46,Condition 866 877	intolerance
73,T47,Drug 881 890	sorafenib
74,T48,Drug 894 905	oxaliplatin
75,T49,Qualifier 881 911	sorafenib or oxaliplatin-based
76,T50,Procedure 912 924	chemotherapy
77,R24,Has_qualifier Arg1:T50 Arg2:T49
78,R25,AND Arg1:T46 Arg2:T50
79,R26,Has_index Arg1:T40 Arg2:T41
80,R27,Has_temporal Arg1:T38 Arg2:T40
81,*,OR T38 T46
82,T51,Person 926 932	Female
83,T52,Condition 949 971	childbearing potential
84,T53,Scope 926 971	Female participants of childbearing potential
85,A1,Optional T53
86,T54,Measurement 1008 1022;993 998	pregnancy test urine
87,T55,Measurement 1002 1022	serum pregnancy test
88,T56,Temporal 1023 1044	within 72 hours prior
89,*,OR T55 T54
90,T57,Scope 993 1022	urine or serum pregnancy test
91,R28,Has_temporal Arg1:T57 Arg2:T56
92,T58,Value 984 992	negative
93,R29,Has_value Arg1:T57 Arg2:T58
94,R30,Has_scope Arg1:T53 Arg2:T57
95,T59,Reference_point 1048 1089	receiving the first dose of study therapy
96,R31,Has_index Arg1:T56 Arg2:T59
97,T60,Procedure 1164 1186	adequate contraception
98,T61,Person 1102 1106	male
99,T62,Person 1091 1097	Female
100,*,OR T61 T62
101,T63,Grammar_Error 1098 1101	and
102,T64,Condition 1123 1145	reproductive potential
103,T65,Scope 1091 1145	Female and male participants of reproductive potential
104,A2,Optional T65
105,R32,AND Arg1:T65 Arg2:T60
106,T66,"Non-query-able 1091 1328	Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication"
107,T67,Post-eligibility 926 1089	Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy
108,T68,"Post-eligibility 1091 1328	Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication"
0,T1,Person 0 5	Women
1,T2,Value 6 20	above 18 years
2,T3,Person 24 27	age
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 72 85	breast cancer
5,T5,Qualifier 59 66	stage 1
6,T6,Qualifier 59 64;70 71	stage 2
7,*,OR T5 T6
8,T7,Procedure 33 39	biopsy
9,T8,Scope 59 71	stage 1 or 2
10,R2,Has_scope Arg1:T4 Arg2:T8
11,R3,AND Arg1:T7 Arg2:T4
12,T9,Procedure 109 127	partial mastectomy
13,T10,Procedure 133 138	SLNBx
14,T11,Visit 139 157	at Memorial Health
15,R4,AND Arg1:T9 Arg2:T10
16,T12,Mood 90 108	will be undergoing
17,R5,Has_mood Arg1:T9 Arg2:T12
18,R6,AND Arg1:T4 Arg2:T9
0,T1,Procedure 15 31	throat surgeries
1,T2,Procedure 33 46	tonsillectomy
2,T3,Procedure 48 66	adenotonsillectomy
3,T4,Procedure 68 85	uvulopalatoplasty
4,T5,Procedure 87 112	uvulopalatopharyngoplasty
5,T6,"Scope 33 112	tonsillectomy, adenotonsillectomy, uvulopalatoplasty, uvulopalatopharyngoplasty"
6,R1,Subsumes Arg1:T1 Arg2:T6
7,T7,Condition 128 149	acute throat diseases
8,T8,Undefined_semantics 128 149	acute throat diseases
9,T9,Condition 151 162	pharyngitis
10,T10,Condition 164 175	tonsillitis
11,T11,Condition 177 196	pharyngotonsillitis
12,*,OR T11 T10 T9
13,T12,"Scope 151 196	pharyngitis, tonsillitis, pharyngotonsillitis"
14,R2,Subsumes Arg1:T7 Arg2:T12
0,T1,Informed_consent 0 72	Capacity to provide informed consent before any trial-related activities
1,T2,Condition 86 90	T2DM
2,T3,Temporal 92 100	=3months
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,T4,Measurement 103 108	HbA1c
5,T5,Measurement 0 110	Capacity to provide informed consent before any trial-related activities
6,Established,T2DM (=3months)
7,HbA1c,=
8,T6,Value 109 113	= 9%
9,T7,Value 138 143	= 10%
10,*,OR T6 T7
11,T8,Scope 109 143	= 9% if on triple therapy or = 10%
12,R2,Has_scope Arg1:T4 Arg2:T8
13,T9,Procedure 203 227	glucose lowering therapy
14,T10,Drug 278 287	metformin
15,T11,Drug 289 302	sulphonylurea
16,T12,"Drug 304 321	DPP-IV inhibitor,"
17,T13,Drug 322 335	GLP-1 therapy
18,T14,Drug 342 347	SGLT2
19,T15,Observation 352 356	diet
20,T16,Observation 361 369	exercise
21,*,OR T10 T11 T12 T13 T14 T15 T16
22,T17,"Scope 278 369	metformin, sulphonylurea, DPP-IV inhibitor, GLP-1 therapy or an SGLT2 +/- diet and exercise"
23,R3,Subsumes Arg1:T9 Arg2:T17
24,T18,Condition 402 410	diabetes
25,T19,Measurement 417 422	HbA1c
26,T20,Value 423 429	> 6.5%
27,R4,Has_value Arg1:T19 Arg2:T20
28,R5,Subsumes Arg1:T18 Arg2:T19
29,T21,Negation 432 435	not
30,T22,Procedure 457 481	glucose lowering therapy
31,R6,Has_negation Arg1:T22 Arg2:T21
32,T23,Measurement 513 528	Body mass index
33,T24,Value 529 538	> 30Kg/m2
34,T25,Value 542 554	> 27.5 Kg/m2
35,*,OR T24 T25
36,T26,Scope 529 554	> 30Kg/m2 or > 27.5 Kg/m2
37,R7,Has_scope Arg1:T23 Arg2:T26
38,T27,Condition 584 588	T2DM
39,T28,Person 600 603	age
40,T29,Value 589 595;607 622	before 60 years of age
41,R8,Has_value Arg1:T28 Arg2:T29
42,T30,Person 624 627	Age
43,T31,Value 628 646	=18 and = 65 years
44,R9,Has_value Arg1:T30 Arg2:T31
0,T1,Value 0 8;16 25	18 years and older
1,T2,Person 12 15	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Qualifier 41 49	stage II
4,T4,Condition 50 69	adhesive capsulitis
5,R2,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Qualifier 70 107	as determined by clinical examination
7,T6,Procedure 87 107	clinical examination
8,R3,multi Arg1:T5 Arg2:T6
9,R4,Has_qualifier Arg1:T4 Arg2:T5
10,T7,Negation 140 150	absence of
11,T8,Condition 151 168	abnormal findings
12,T9,Procedure 172 177	X-ray
13,R5,AND Arg1:T9 Arg2:T8
14,R6,Has_negation Arg1:T8 Arg2:T7
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 42 44	2.
2,T3,Parsing_Error 99 101	3.
3,T4,Parsing_Error 144 146	4.
4,T5,Parsing_Error 167 169	5.
5,T6,Parsing_Error 196 198	6.
6,T7,Condition 3 22	Orthopedic injuries
7,T8,Qualifier 32 40	unstable
8,R1,Has_qualifier Arg1:T7 Arg2:T8
9,T9,Condition 45 57	Osteoporosis
10,T10,Qualifier 63 97	high risk of pathological fracture
11,R2,Has_qualifier Arg1:T9 Arg2:T10
12,T11,Subjective_judgement 63 97	high risk of pathological fracture
13,T12,Undefined_semantics 63 97	high risk of pathological fracture
14,T13,Non-query-able 63 97	high risk of pathological fracture
15,T14,Condition 102 119	Cutaneous lesions
16,T15,Condition 127 142	pressure ulcers
17,*,OR T15 T14
18,T16,Condition 147 165	Joint contractures
19,T17,Condition 170 194	Cardiopulmonary diseases
20,T18,Measurement 199 210	Body weight
21,T19,Value 211 227	exceeding 150 Kg
22,R3,Has_value Arg1:T18 Arg2:T19
0,T1,Qualifier 0 9	singleton
1,T2,Qualifier 11 15	term
2,T3,Condition 16 25	pregnancy
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,R2,Has_qualifier Arg1:T3 Arg2:T1
5,T4,Drug 40 53	buprenorphine
6,T5,Procedure 40 73	buprenorphine maintenance therapy
7,R3,multi Arg1:T5 Arg2:T4
8,T6,Temporal 27 36	currently
9,R4,Has_temporal Arg1:T5 Arg2:T6
10,T7,Mood 75 88	scheduled for
11,T8,Qualifier 89 97	elective
12,T9,Procedure 98 100	CD
13,T10,Procedure 107 124	spinal anesthesia
14,R5,AND Arg1:T9 Arg2:T10
15,R6,Has_qualifier Arg1:T9 Arg2:T8
16,R7,Has_mood Arg1:T9 Arg2:T7
0,T1,"Non-query-able 0 77	Earlier operations in the foot and leg, that is judged to complicate training"
1,T2,Condition 85 94	arthritis
2,T3,Condition 103 111	diabetes
3,T4,Condition 113 128	Leg ulcerations
4,T5,Condition 132 154	infections in the foot
5,*,OR T4 T5
6,T6,Post-eligibility 157 208	Judged unable to comply with the training protocol.
7,T7,Drug 223 235	pain killers
8,T8,Multiplier 210 215	Daily
9,R1,Has_multiplier Arg1:T7 Arg2:T8
10,T9,Drug 237 256	Glucocorticosteroid
11,T10,Procedure 257 266	injection
12,R2,AND Arg1:T10 Arg2:T9
13,T11,Condition 274 298	diseased achilles tendon
14,T12,Temporal 299 323	within the last 6 months
15,R3,AND Arg1:T10 Arg2:T11
16,R4,Has_temporal Arg1:T10 Arg2:T12
17,T13,Condition 334 352	allergic reactions
18,T14,Drug 356 375	glucocorticosteroid
19,T15,Drug 379 395	local anesthetic
20,*,OR T15 T14
21,T16,Scope 356 395	glucocorticosteroid or local anesthetic
22,T17,Temporal 326 333	Earlier
23,R5,Has_temporal Arg1:T13 Arg2:T17
24,R6,Subsumes Arg1:T13 Arg2:T16
25,T18,Condition 398 407	Pregnancy
26,T19,Mood 411 429	planning to become
27,T20,Condition 430 438	pregnant
28,R7,Has_mood Arg1:T20 Arg2:T19
29,*,OR T18 T20
30,T21,Measurement 440 443	BMI
31,T22,Value 444 452	above 30
32,R8,Has_value Arg1:T21 Arg2:T22
0,T1,Drug 4 17	illicit drugs
1,T2,Condition 21 28	relapse
2,T3,Temporal 29 67	during the last trimester of pregnancy
3,T4,Reference_point 36 67	the last trimester of pregnancy
4,R1,Has_index Arg1:T3 Arg2:T4
5,T5,Condition 58 67	pregnancy
6,T6,Qualifier 40 54	last trimester
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,R3,multi Arg1:T4 Arg2:T5
9,*,OR T2 T1
10,T7,Scope 4 28	illicit drugs or relapse
11,R4,Has_temporal Arg1:T7 Arg2:T3
12,T8,Measurement 78 89	drug screen
13,T9,Value 69 77	positive
14,T10,Temporal 90 113	at the time of delivery
15,T11,Reference_point 93 113	the time of delivery
16,R5,Has_index Arg1:T10 Arg2:T11
17,T12,Procedure 105 113	delivery
18,R6,multi Arg1:T11 Arg2:T12
19,R7,Has_value Arg1:T8 Arg2:T9
20,R8,Has_temporal Arg1:T8 Arg2:T10
21,T13,Condition 115 124	allergies
22,T14,Drug 132 161	medications used in the study
23,R9,AND Arg1:T13 Arg2:T14
24,T15,Drug 181 191	gabapentin
25,T16,Qualifier 170 180	prescribed
26,R10,Has_qualifier Arg1:T15 Arg2:T16
27,T17,Temporal 192 223	at the time of admission for CD
28,T18,Reference_point 207 223	admission for CD
29,T19,Procedure 207 216	admission
30,T20,Procedure 221 223	CD
31,R11,AND Arg1:T19 Arg2:T20
32,R12,multi Arg1:T18 Arg2:T19
33,R13,Has_index Arg1:T17 Arg2:T18
34,R14,Has_temporal Arg1:T15 Arg2:T17
35,T21,Condition 225 242	contraindications
36,T22,Procedure 246 266	neuraxial anesthesia
37,T23,Mood 270 277	require
38,T24,Procedure 278 296	general anesthesia
39,T25,Procedure 301 303	CD
40,R15,AND Arg1:T24 Arg2:T25
41,R16,Has_mood Arg1:T24 Arg2:T23
42,R17,AND Arg1:T21 Arg2:T22
43,*,OR T21 T24
44,T26,Measurement 316 335	ASA physical status
45,T27,Value 336 346	4 or above
46,R18,Has_value Arg1:T26 Arg2:T27
0,T1,Condition 0 17	Midsubstance pain
1,T2,Qualifier 25 40	achilles tendon
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 42 50	Symptoms
4,T4,Temporal 51 72	for at least 3 months
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Procedure 74 93	Ultrasound scanning
7,T6,Temporal 94 112	at the first visit
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Condition 119 151	thickness of the achilles tendon
10,T8,Qualifier 152 162	above 7 mm
11,T9,Qualifier 166 200	20% thicker than the contralateral
12,*,OR T8 T9
13,T10,Scope 152 200	above 7 mm or 20% thicker than the contralateral
14,R4,Has_scope Arg1:T7 Arg2:T10
15,R5,AND Arg1:T5 Arg2:T7
16,T11,Non-query-able 203 241	Patient can read and understand danish
0,T1,Observation 0 26	Informed consent of parent
1,T2,Observation 0 19;33 47	Informed consent of legal guardian
2,*,OR T1 T2 T4 T3
3,T3,Observation 49 65;76 86	informed consent of subject
4,T4,Observation 49 57;69 86	informed assent of subject
5,T5,Person 103 107	Male
6,T6,Person 111 117	female
7,*,OR T5 T6
8,T7,Person 118 126	children
9,T8,Value 127 134;147 162	between 10 and 35 years
10,T9,Person 139 143	ages
11,R1,Has_value Arg1:T9 Arg2:T8
12,T10,Condition 168 192	congenital heart disease
13,T11,Procedure 224 242	Fontan circulation
14,R2,AND Arg1:T10 Arg2:T11
15,T12,Observation 245 263	Ability of perform
16,T13,Procedure 266 287	maximal exercise test
17,R3,AND Arg1:T12 Arg2:T13
18,T14,Measurement 304 336	respiratory exchange ratio (RER)
19,T15,Value 337 353	greater than 1.0
20,R4,Has_value Arg1:T14 Arg2:T15
21,T16,Qualifier 354 385	at the time of maximal exercise
22,R5,Has_qualifier Arg1:T14 Arg2:T16
23,T17,Scope 245 287	Ability of perform a maximal exercise test
24,T18,Scope 304 385	respiratory exchange ratio (RER) greater than 1.0 at the time of maximal exercise
25,R6,Subsumes Arg1:T17 Arg2:T18
0,T1,Drug 11 24	beta blockers
1,T2,Temporal 25 57	within 2 months of randomization
2,T3,Reference_point 44 57	randomization
3,R1,Has_index Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T1 Arg2:T2
5,T4,Observation 77 103	listed for transplantation
6,T5,Procedure 88 103	transplantation
7,R3,multi Arg1:T4 Arg2:T5
8,T6,Temporal 104 135	at time of entry into the study
9,T7,Reference_point 115 135	entry into the study
10,R4,Has_index Arg1:T6 Arg2:T7
11,R5,Has_temporal Arg1:T4 Arg2:T6
12,T8,Mood 139 161	anticipated to undergo
13,T9,Procedure 162 183	heart transplantation
14,T10,Procedure 185 215	interventional catheterization
15,T11,Procedure 220 246	corrective cardiac surgery
16,T12,Temporal 247 297	during the 7 months following entry into the study
17,T13,Reference_point 277 297	entry into the study
18,R6,Has_index Arg1:T12 Arg2:T13
19,*,OR T9 T10 T11
20,T14,"Scope 162 246	heart transplantation, interventional catheterization, or corrective cardiac surgery"
21,R7,Has_mood Arg1:T14 Arg2:T8
22,R8,Has_temporal Arg1:T14 Arg2:T12
23,*,OR T4 T14
24,T15,Qualifier 312 323	symptomatic
25,T16,Qualifier 299 308	Sustained
26,T17,Condition 324 348	ventricular dysrhythmias
27,T18,Qualifier 349 377	uncontrolled by drug therapy
28,T19,Procedure 365 377	drug therapy
29,T20,Drug 365 369	drug
30,R9,multi Arg1:T19 Arg2:T20
31,R10,multi Arg1:T18 Arg2:T19
32,*,OR T16 T15
33,T21,Scope 299 323	Sustained or symptomatic
34,R11,Has_scope Arg1:T17 Arg2:T21
35,T22,Device 395 420	implantable defibrillator
36,T23,Qualifier 349 364;381 420	uncontrolled by the use of an implantable defibrillator
37,R12,multi Arg1:T23 Arg2:T22
38,*,OR T23 T18
39,T24,Scope 349 420	uncontrolled by drug therapy or the use of an implantable defibrillator
40,R13,Has_scope Arg1:T17 Arg2:T24
41,T25,Qualifier 429 440	significant
42,T26,Condition 441 467	cardiac conduction defects
43,R14,Has_qualifier Arg1:T26 Arg2:T25
44,T27,Condition 475 485;500 508	2nd degree AV block
45,T28,Condition 489 508	3rd degree AV block
46,*,OR T28 T27 T29
47,T29,Condition 513 532	sick sinus syndrome
48,T30,Scope 429 467	significant cardiac conduction defects
49,T31,"Scope 475 532	2nd degree or 3rd degree AV block, or sick sinus syndrome"
50,T32,Negation 534 540	unless
51,T33,Qualifier 543 554	functioning
52,T34,Device 555 564	pacemaker
53,R15,Has_qualifier Arg1:T34 Arg2:T33
54,R16,Has_negation Arg1:T34 Arg2:T32
55,R17,AND Arg1:T31 Arg2:T34
56,R18,Has_scope Arg1:T30 Arg2:T31
57,*,OR T17 T30
58,T35,Qualifier 578 589	Uncorrected
59,T36,Condition 590 601;624 637	obstructive valve disease
60,T37,Qualifier 605 611	severe
61,T38,Condition 612 637	regurgitant valve disease
62,R19,Has_qualifier Arg1:T36 Arg2:T35
63,R20,Has_qualifier Arg1:T38 Arg2:T37
64,T39,Condition 639 664	nondilated cardiomyopathy
65,T40,Qualifier 669 680	significant
66,T41,Condition 681 721	systemic ventricular outflow obstruction
67,R21,Has_qualifier Arg1:T41 Arg2:T40
68,*,OR T39 T41 T38 T36
69,T42,Condition 729 754	renovascular hypertension
70,T43,Condition 770 792	pulmonary hypertension
71,T44,Mood 758 769	evidence of
72,R22,Has_mood Arg1:T43 Arg2:T44
73,T45,Measurement 794 823	pulmonary vascular resistance
74,T46,Value 824 838	> 6 Wood units
75,R23,Has_value Arg1:T45 Arg2:T46
76,T47,Scope 794 838	pulmonary vascular resistance > 6 Wood units
77,T48,Scope 758 792	evidence of pulmonary hypertension
78,R24,Subsumes Arg1:T48 Arg2:T47
79,*,OR T42 T48
80,T49,Qualifier 840 874	unresponsive to vasodilator agents
81,T50,Drug 856 874	vasodilator agents
82,R25,multi Arg1:T49 Arg2:T50
83,T51,Drug 883 889	oxygen
84,T52,Drug 891 904	nitroprusside
85,T53,Drug 909 921	nitric oxide
86,*,OR T52 T53 T51
87,T54,"Scope 883 921	oxygen, nitroprusside, or nitric oxide"
88,R26,Subsumes Arg1:T50 Arg2:T54
89,T55,Scope 729 839	renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance > 6 Wood units)
90,R27,Has_qualifier Arg1:T55 Arg2:T49
91,T56,Observation 923 930	History
92,T57,Temporal 934 941	current
93,T58,Mood 942 962	clinical evidence of
94,*,OR T56 T57
95,T59,Qualifier 963 981	moderate-to-severe
96,T60,Qualifier 982 987	fixed
97,T61,Condition 988 1017	obstructive pulmonary disease
98,T62,Qualifier 1021 1027	severe
99,T63,Condition 1028 1052	reactive airway diseases
100,R28,Has_qualifier Arg1:T61 Arg2:T60
101,R29,Has_qualifier Arg1:T61 Arg2:T59
102,T64,Condition 1060 1066	asthma
103,R30,Subsumes Arg1:T63 Arg2:T64
104,T65,"Scope 1028 1067	reactive airway diseases (e.g., asthma)"
105,R31,Has_qualifier Arg1:T65 Arg2:T62
106,*,OR T61 T65
107,T66,"Scope 963 1067	moderate-to-severe fixed obstructive pulmonary disease or severe reactive airway diseases (e.g., asthma)"
108,R32,Has_mood Arg1:T66 Arg2:T58
109,T67,Scope 923 941	History or current
110,R33,Has_scope Arg1:T66 Arg2:T67
111,T68,Procedure 1078 1093	hospitalization
112,T69,Mood 1068 1077	requiring
113,R34,Has_mood Arg1:T68 Arg2:T69
114,T70,Temporal 1094 1117	within the past 2 years
115,T71,Temporal 1129 1138	currently
116,T72,Drug 1145 1178	long-term inhaled bronchodilators
117,R35,Has_temporal Arg1:T72 Arg2:T71
118,R36,Has_temporal Arg1:T68 Arg2:T70
119,T73,Reference_point 1101 1117	the past 2 years
120,R37,Has_index Arg1:T70 Arg2:T73
121,*,OR T68 T72
122,T74,Scope 1068 1178	requiring hospitalization within the past 2 years or patient currently using long-term inhaled bronchodilators
123,R38,Has_scope Arg1:T66 Arg2:T74
124,T75,Qualifier 1180 1185	Renal
125,T76,Qualifier 1187 1194	hepatic
126,T77,Qualifier 1196 1212	gastrointestinal
127,T78,Qualifier 1217 1224	biliary
128,T79,Condition 1225 1233	disorder
129,*,OR T78 T77 T76 T75
130,T80,"Scope 1180 1224	Renal, hepatic, gastrointestinal, or biliary"
131,R39,Has_scope Arg1:T79 Arg2:T80
132,T81,Condition 1245 1262	impair absorption
133,T82,Condition 1245 1251;1264 1274	impair metabolism
134,T83,Condition 1245 1251;1278 1287	impair excretion
135,T84,Drug 1291 1321	orally administered medication
136,T85,"Scope 1245 1287	impair absorption, metabolism or excretion"
137,R40,AND Arg1:T85 Arg2:T84
138,R41,Has_scope Arg1:T79 Arg2:T85
139,T86,Temporal 1323 1333	Concurrent
140,T87,Condition 1334 1350	terminal illness
141,T88,Condition 1360 1374	severe disease
142,T89,Qualifier 1354 1359	other
143,R42,Has_qualifier Arg1:T88 Arg2:T89
144,T90,Qualifier 1382 1388	active
145,T91,Condition 1389 1397	neoplasm
146,R43,Has_qualifier Arg1:T91 Arg2:T90
147,T92,Scope 1382 1397	active neoplasm
148,*,OR T87 T88 T95
149,R44,Subsumes Arg1:T88 Arg2:T92
150,T94,Procedure 1420 1430	laboratory
151,T95,Condition 1408 1439	significant laboratory value(s)
152,T93,"Non-representable 1440 1523	which, in the opinion of the investigator, could preclude participation or survival"
153,T96,Measurement 1420 1430	laboratory
154,R45,multi Arg1:T95 Arg2:T94
155,R46,multi Arg1:T94 Arg2:T96
156,T97,"Scope 1334 1439	terminal illness or other severe disease (e.g., active neoplasm) or other significant laboratory value(s)"
157,R47,Has_temporal Arg1:T97 Arg2:T86
158,T98,Condition 1525 1544	Endocrine disorders
159,T99,Condition 1553 1574	primary aldosteronism
160,T100,Condition 1576 1592	pheochromocytoma
161,T101,Condition 1604 1618	hypothyroidism
162,T102,Condition 1594 1599;1608 1618	hyper thyroidism
163,*,OR T99 T100 T102 T101 T104
164,T103,Qualifier 1620 1637	insulin-dependent
165,T104,Condition 1638 1655	diabetes mellitus
166,R48,Has_qualifier Arg1:T104 Arg2:T103
167,T105,"Scope 1553 1655	primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism, insulin-dependent diabetes mellitus"
168,R49,Subsumes Arg1:T98 Arg2:T105
169,T106,Observation 1657 1670;1684 1696	Unwillingness to cooperate
170,T107,Observation 1674 1696	inability to cooperate
171,*,OR T107 T106 T108 T110 T111 T109
172,T108,Observation 1657 1670;1701 1716;1730 1745	Unwillingness for the parents to give consent
173,T109,Observation 1674 1683;1701 1716;1730 1745	inability for the parents to give consent
174,T110,Observation 1657 1670;1701 1708;1720 1745	Unwillingness for the guardians to give consent
175,T111,Observation 1674 1683;1701 1708;1720 1745	inability for the guardians to give consent
176,T112,Condition 1856 1865	Pregnancy
177,T113,Mood 1869 1877	possible
178,T114,Condition 1878 1887	pregnancy
179,R50,Has_mood Arg1:T114 Arg2:T113
180,*,OR T112 T114 T120 T131
181,T115,Temporal 1888 1912	at time of randomization
182,R51,Has_temporal Arg1:T114 Arg2:T115
183,T116,Reference_point 1891 1912	time of randomization
184,R52,Has_index Arg1:T115 Arg2:T116
185,T117,Person 1917 1923	female
186,T118,Observation 1927 1950	child bearing potential
187,T119,Observation 1959 1968	lactating
188,T120,Scope 1917 1968	female of child bearing potential who are lactating
189,T121,Observation 1973 1988	sexually active
190,T122,Negation 1993 1996	not
191,T123,Qualifier 2004 2012	adequate
192,T124,Observation 2013 2038	contraceptive precautions
193,R53,Has_qualifier Arg1:T124 Arg2:T123
194,R54,Has_negation Arg1:T124 Arg2:T122
195,T125,Device 2046 2065	intrauterine device
196,T126,Drug 2069 2088	oral contraceptives
197,T127,Temporal 2089 2131	for 3 months prior to entry into the study
198,T128,Reference_point 2111 2131	entry into the study
199,R55,Has_index Arg1:T127 Arg2:T128
200,*,OR T126 T125
201,R56,Has_temporal Arg1:T126 Arg2:T127
202,T129,Scope 2046 2131	intrauterine device or oral contraceptives for 3 months prior to entry into the study
203,T130,Scope 1993 2038	not taking adequate contraceptive precautions
204,R57,Subsumes Arg1:T130 Arg2:T129
205,T131,"Scope 1973 2132	sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study)"
206,T132,Drug 2144 2164	investigational drug
207,T133,Temporal 2165 2196	within 30 days of randomization
208,T134,Reference_point 2183 2196	randomization
209,R58,Has_index Arg1:T133 Arg2:T134
210,T135,Temporal 2201 2248	within 5 half-lives of the investigational drug
211,T136,Drug 2228 2248	investigational drug
212,R60,multi Arg1:T135 Arg2:T136
213,*,OR T133 T135
214,T137,"Scope 2165 2248	within 30 days of randomization, or within 5 half-lives of the investigational drug"
215,R59,Has_scope Arg1:T132 Arg2:T137
216,T138,Observation 2281 2288	History
217,T139,Condition 2292 2308	drug sensitivity
218,T140,Condition 2312 2329	allergic reaction
219,T141,Drug 2333 2347	alpha-blockers
220,T142,Drug 2351 2364	beta-blockers
221,*,OR T141 T142
222,T143,Scope 2333 2364	alpha-blockers or beta-blockers
223,*,OR T139 T140
224,T144,Scope 2292 2329	drug sensitivity or allergic reaction
225,R61,Has_scope Arg1:T144 Arg2:T143
226,R62,Has_temporal Arg1:T144 Arg2:T138
227,T146,Temporal 2406 2439	within two weeks of randomization
228,T145,Drug 2441 2455	MAO inhibitors
229,T147,Drug 2457 2481	Calcium channel blockers
230,T148,Drug 2483 2497	alpha blockers
231,T149,Drug 2499 2512	beta blockers
232,T150,Drug 2514 2526	disopyramide
233,T151,Drug 2528 2538	flecainide
234,T152,Drug 2540 2549	encainide
235,T153,Drug 2551 2561	moricizine
236,T154,Drug 2563 2574	propafenone
237,T155,Drug 2576 2583	sotalol
238,T156,Drug 2588 2612	beta adrenergic agonists
239,*,OR T156 T155 T154 T153 T152 T151 T150 T149 T148 T147 T145
240,T157,"Scope 2441 2612	MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists"
241,R63,Has_temporal Arg1:T157 Arg2:T146
242,T158,Procedure 2614 2632	Hospital admission
243,T159,Condition 2637 2663	protein losing enteropathy
244,T160,Condition 2667 2685	plastic bronchitis
245,T161,Temporal 2686 2718	within 3 months of randomization
246,*,OR T159 T160
247,T162,Scope 2637 2685	protein losing enteropathy or plastic bronchitis
248,R64,Has_scope Arg1:T158 Arg2:T162
249,R65,Has_temporal Arg1:T158 Arg2:T161
250,T163,Reference_point 2705 2718	randomization
251,R66,Has_index Arg1:T161 Arg2:T163
252,T164,Qualifier 2720 2726	Active
253,T165,Qualifier 2734 2741	chronic
254,T166,Condition 2742 2768	protein losing enteropathy
255,T167,Condition 2772 2790	plastic bronchitis
256,T168,Drug 2795 2813	inhaled medication
257,R68,AND Arg1:T167 Arg2:T168
258,*,OR T164 T165
259,*,OR T166 T167
260,T169,Scope 2742 2848	protein losing enteropathy or plastic bronchitis (on inhaled medication to control the plastic bronchitis)
261,T170,Scope 2720 2741	Active and/or chronic
262,R67,Has_scope Arg1:T169 Arg2:T170
263,T171,Condition 2851 2866	Hypoalbuminemia
264,T172,Measurement 2878 2891	serum albumin
265,T173,Value 2892 2900	<2.0g/dL
266,R69,Has_value Arg1:T172 Arg2:T173
267,R70,Subsumes Arg1:T171 Arg2:T172
268,T174,Condition 2902 2919	Renal dysfunction
269,T175,Measurement 2931 2947	serum creatinine
270,T176,Value 2948 2957	>2.0mg/dL
271,R71,AND Arg1:T174 Arg2:T175
272,R72,Has_value Arg1:T175 Arg2:T176
273,T177,Condition 2959 2978	Hepatic dysfunction
274,T178,Measurement 2990 2999	serum AST
275,T179,Measurement 2990 2995;3007 3010	serum ALT
276,*,OR T178 T179
277,T180,Value 3010 3041	> 3 times upper limit of normal
278,T181,Scope 2990 3010	serum AST and/or ALT
279,R73,Has_value Arg1:T181 Arg2:T180
280,T182,Value 3043 3065	approximately 120 IU/L
281,T183,Non-representable 3075 3101	will vary depending on age
282,R74,Subsumes Arg1:T180 Arg2:T182
283,T184,"Scope 2990 3102	serum AST and/or ALT> 3 times upper limit of normal (approximately 120 IU/L however, will vary depending on age)"
284,R75,Subsumes Arg1:T177 Arg2:T184
285,T185,Qualifier 3105 3116	Significant
286,T186,Condition 3117 3123	anemia
287,T187,Condition 3127 3139	polycythemia
288,T188,Measurement 3151 3161	hemoglobin
289,T189,Value 3162 3170	>18gm/dL
290,T190,Measurement 3174 3184	hemoglobin
291,T191,Value 3185 3192	<7gm/dL
292,R77,Has_value Arg1:T190 Arg2:T191
293,R78,Has_value Arg1:T188 Arg2:T189
294,*,OR T188 T190
295,T192,Scope 3151 3192	hemoglobin >18gm/dL or hemoglobin <7gm/dL
296,*,OR T187 T186
297,T193,Scope 3105 3139	Significant anemia or polycythemia
298,R76,Subsumes Arg1:T193 Arg2:T192
299,T194,Scope 3117 3139	anemia or polycythemia
300,R79,Has_qualifier Arg1:T194 Arg2:T185
301,T195,Value 3194 3211	Severely elevated
302,T196,Measurement 3212 3221	serum BNP
303,R80,Has_value Arg1:T196 Arg2:T195
304,T197,Measurement 3233 3236	BNP
305,T198,Value 3236 3245	>300pg/ml
306,R81,Has_value Arg1:T197 Arg2:T198
307,T199,Scope 3194 3221	Severely elevated serum BNP
308,T200,Scope 3233 3245	BNP>300pg/ml
309,R82,Subsumes Arg1:T199 Arg2:T200
0,T1,Pregnancy_considerations 0 100	Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study
1,T2,Person 111 115	aged
2,T3,Value 116 132	<18 years of age
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,"Non-query-able 134 176	Patients who cannot give informed consent,"
5,T5,Pregnancy_considerations 178 252	Pregnant patients or those who are breastfeeding will be deemed ineligible
6,T6,Drug 280 294	anti-TNF agent
7,T7,Procedure 261 270	treatment
8,T8,Temporal 255 260	Prior
9,R2,Has_temporal Arg1:T7 Arg2:T8
10,R3,AND Arg1:T7 Arg2:T6
11,T9,Condition 296 313	Contra-indication
12,T10,Drug 324 327	GLM
13,T11,Condition 329 345	Hypersensitivity
14,T12,Drug 353 369	active substance
15,T13,Drug 387 397	excipients
16,*,OR T12 T13
17,T14,Scope 353 397	active substance or to any of the excipients
18,R4,Has_scope Arg1:T11 Arg2:T14
19,T15,Condition 406 423	tuberculosis (TB)
20,T16,Temporal 399 405	Active
21,R5,Has_temporal Arg1:T15 Arg2:T16
22,T17,Qualifier 425 430	acute
23,T18,Qualifier 434 441	chronic
24,T19,Condition 442 463	Hepatitis B infection
25,*,OR T17 T18
26,T20,Scope 425 441	acute or chronic
27,R6,Has_scope Arg1:T19 Arg2:T20
28,T21,Condition 473 490	severe infections
29,T22,Condition 499 505	sepsis
30,T23,Condition 513 537	opportunistic infections
31,T24,Condition 548 561	HIV infection
32,R7,Subsumes Arg1:T23 Arg2:T24
33,R8,Subsumes Arg1:T21 Arg2:T22
34,*,OR T21 T23 T19 T15 T11 T27
35,T25,Qualifier 563 571	Moderate
36,T26,Qualifier 575 581	severe
37,*,OR T26 T25
38,T27,Condition 582 595	heart failure
39,T28,Measurement 597 601	NYHA
40,T29,Value 602 614	class III/IV
41,R9,Has_value Arg1:T28 Arg2:T29
42,T30,Scope 563 581	Moderate or severe
43,R10,Subsumes Arg1:T30 Arg2:T28
44,R11,Has_scope Arg1:T27 Arg2:T30
45,T31,"Scope 329 614	Hypersensitivity to the active substance or to any of the excipients; Active tuberculosis (TB), acute or chronic Hepatitis B infection or other severe infections such as sepsis and/or opportunistic infections including HIV infection; Moderate or severe heart failure (NYHA class III/IV"
46,R12,AND Arg1:T9 Arg2:T10
47,T32,Scope 296 327	Contra-indication to use of GLM
48,R13,Subsumes Arg1:T32 Arg2:T31
49,T33,Qualifier 672 678	latent
50,T34,Qualifier 662 668	active
51,T35,Temporal 654 661	current
52,*,OR T33 T34
53,R14,Has_temporal Arg1:T34 Arg2:T35
54,T36,Condition 679 681	TB
55,T37,Scope 654 677	current active or laten
56,R15,Has_scope Arg1:T36 Arg2:T37
57,T38,Observation 687 702	medical history
58,T39,Procedure 704 724	physical examination
59,T40,Procedure 732 748	chest radiograph
60,T41,Measurement 762 843	Mycobacterium tuberculosis antigen-specific interferon-gamma release assay (IGRA)
61,T42,Value 753 761	positive
62,R16,Has_value Arg1:T41 Arg2:T42
63,*,OR T40 T39 T38
64,T43,"Scope 687 748	medical history, physical examination and/or chest radiograph"
65,R17,AND Arg1:T43 Arg2:T36
66,*,OR T43 T41
67,T44,Procedure 922 946	gastrointestinal surgery
68,T45,Temporal 947 979	within 2 months before screening
69,R18,Has_temporal Arg1:T44 Arg2:T45
70,T46,Procedure 898 907	colectomy
71,T47,Mood 879 896	imminent risk for
72,T48,Observation 861 871	history of
73,*,OR T47 T48
74,T49,"Scope 861 896	history of, or at imminent risk for"
75,R19,Has_scope Arg1:T46 Arg2:T49
76,T50,Condition 993 1018	colonic mucosal dysplasia
77,T51,Condition 1022 1048	adenomatous colonic polyps
78,T52,Procedure 1063 1070	removed
79,T53,Negation 1059 1062	not
80,R20,Has_negation Arg1:T52 Arg2:T53
81,*,OR T51 T50
82,R21,AND Arg1:T51 Arg2:T52
83,T54,Procedure 1082 1093	stool study
84,T55,Value 1094 1102	positive
85,T56,Qualifier 1107 1124	enteric pathogens
86,T57,Qualifier 1128 1155	Clostridium difficile toxin
87,*,OR T56 T57
88,T58,Scope 1107 1155	enteric pathogens or Clostridium difficile toxin
89,R22,Has_scope Arg1:T55 Arg2:T58
90,R23,Has_value Arg1:T54 Arg2:T55
91,T59,Drug 1158 1178	Oral corticosteroids
92,T60,Multiplier 1189 1206;1225 1232	>40 mg prednisone per day
93,R24,Has_multiplier Arg1:T59 Arg2:T60
94,T61,Drug 1245 1257	cyclosporine
95,T62,Drug 1259 1269	tacrolimus
96,T63,Drug 1271 1280	sirolimus
97,T64,Drug 1285 1306	mycophenolate mofetil
98,T65,Temporal 1307 1360	within 8 weeks before the first study agent injection
99,*,OR T64 T63 T62 T61
100,T66,"Scope 1245 1306	cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil"
101,R25,Has_temporal Arg1:T66 Arg2:T65
102,T67,Drug 1375 1396	investigational agent
103,T68,Temporal 1397 1416	within 5 half-lives
104,R26,Has_temporal Arg1:T67 Arg2:T68
105,T69,Temporal 1431 1469	before the first study agent injection
106,R27,Has_temporal Arg1:T67 Arg2:T69
107,*,OR T67 T66 T59
108,T70,Drug 1502 1519	live vaccinations
109,T71,Temporal 1520 1553	within 4 weeks prior to enrolment
110,R28,Has_temporal Arg1:T70 Arg2:T71
0,T1,Observation 44 47	die
1,T2,Temporal 48 83	within 3 days of hospital admission
2,T3,Reference_point 65 83	hospital admission
3,R1,Has_index Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T1 Arg2:T2
0,T1,Person 0 4	Male
1,T2,Value 6 14	18 years
2,T3,Person 18 21	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Condition 39 45	hernia
5,T5,Mood 46 55	requiring
6,T6,Procedure 56 77	surgical intervention
7,R2,Has_mood Arg1:T6 Arg2:T5
8,R3,AND Arg1:T4 Arg2:T6
0,T1,Value 9 19	= 18 years
1,T2,Person 23 26	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Non-query-able 28 153	Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
4,T4,Condition 180 182	UC
5,T5,Qualifier 187 205	moderate-to-severe
6,T6,Measurement 237 247	Mayo score
7,T7,Value 251 255	6-12
8,T8,Measurement 265 284	endoscopic subscore
9,T9,Value 285 287	=2
10,R2,Has_value Arg1:T6 Arg2:T7
11,R3,AND Arg1:T6 Arg2:T8
12,R4,Has_value Arg1:T8 Arg2:T9
13,R5,Subsumes Arg1:T5 Arg2:T6
14,R6,Has_qualifier Arg1:T4 Arg2:T5
15,T10,Condition 306 325	inadequate response
16,T11,Condition 337 355	failed to tolerate
17,*,OR T10 T11
18,T12,Multiplier 357 366	1 or more
19,T13,Drug 408 431	oral 5-aminosalicylates
20,T14,Drug 433 453	oral corticosteroids
21,T15,Drug 455 473	azathioprine (AZA)
22,T16,Drug 482 504	6-mercaptopurine (6MP)
23,*,OR T15 T16 T14 T13
24,T17,Drug 509 523	corticosteroid
25,T18,Condition 524 533	dependent
26,R7,AND Arg1:T18 Arg2:T17
27,T19,"Non-representable 534 611	(ie, an inability to taper corticosteroids without recurrence of UC symptoms)"
28,T20,"Scope 408 504	oral 5-aminosalicylates, oral corticosteroids, azathioprine (AZA), and/or 6-mercaptopurine (6MP)"
29,R8,Has_multiplier Arg1:T20 Arg2:T12
30,T21,"Scope 306 355	inadequate response to, or had failed to tolerate"
31,R9,Has_scope Arg1:T21 Arg2:T20
32,*,OR T21 T18
33,T22,Drug 649 672	oral 5-aminosalicylates
34,T24,Drug 676 691	corticosteroids
35,T25,Qualifier 710 721	stable dose
36,T26,Temporal 722 758	for at least 2 weeks before baseline
37,R10,Has_temporal Arg1:T25 Arg2:T26
38,*,OR T22 T24
39,T27,Scope 649 691	oral 5-aminosalicylates or corticosteroids
40,T28,Drug 783 786	AZA
41,T29,Drug 794 797	6MP
42,*,OR T28 T29
43,T23,Qualifier 816 827	stable dose
44,T30,Temporal 828 864	for at least 4 weeks before baseline
45,R11,Has_temporal Arg1:T23 Arg2:T30
46,T31,Scope 783 797	AZA and/or 6MP
47,R12,Has_qualifier Arg1:T31 Arg2:T23
48,T32,Procedure 636 643	treated
49,R13,Has_qualifier Arg1:T27 Arg2:T25
50,*,OR T31 T27
51,T33,"Scope 649 864	oral 5-aminosalicylates or corticosteroids were to receive a stable dose for at least 2 weeks before baseline, and patients receiving AZA and/or 6MP were to receive a stable dose for at least 4 weeks before baseline"
52,R14,Has_scope Arg1:T32 Arg2:T33
53,T34,Non-representable 866 967	Patients were required to maintain stable doses of their concomitant UC medications during the study.
54,T35,Pregnancy_considerations 969 1140	Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR
55,T36,"Pregnancy_considerations 1142 1272	Surgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR"
56,T37,Pregnancy_considerations 1274 1385	Postmenopausal women with postmenopausal defined as permanent cessation >1 year of previously occurring menses.
57,T38,Pregnancy_considerations 1387 1532	Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.
58,T39,Non-representable 1534 1607	Subjects have following investigations within 1 month prior to enrolment.
59,T40,Procedure 1609 1623	Routine bloods
60,T41,Procedure 1634 1637	U&E
61,T42,Procedure 1639 1642	FBC
62,T43,Procedure 1644 1648	LFTs
63,T44,Procedure 1650 1676	inflammatory markers (CRP)
64,T45,Procedure 1681 1688	albumin
65,*,OR T45 T44 T43 T42 T41
66,T46,"Scope 1634 1688	U&E, FBC, LFTs, inflammatory markers (CRP) and albumin"
67,R15,Subsumes Arg1:T40 Arg2:T46
68,T47,"Non-representable 1708 1748	Medical history, concomitant medications"
69,T48,Procedure 1750 1800	Intradermal reaction to Tuberculin (PPD skin test)
70,T49,Procedure 1804 1884	Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA)
71,*,OR T49 T48
72,T50,Temporal 1573 1606	within 1 month prior to enrolment
73,T51,Procedure 1900 1911	chest X-Ray
74,T52,Procedure 1886 1898	TB screening
75,R16,Subsumes Arg1:T52 Arg2:T51
76,T53,Procedure 1951 1968	Stool examination
77,T54,Qualifier 1969 2022	for enteric pathogens including Clostridium difficile
78,R17,Has_qualifier Arg1:T53 Arg2:T54
79,T55,Non-query-able 2054 2070	Informed consent
80,T56,Non-representable 2024 2052	Inclusion/exclusion criteria
81,T57,Procedure 2072 2082	Mayo score
82,T58,Procedure 2094 2107	sigmoidoscopy
83,R18,Subsumes Arg1:T57 Arg2:T58
84,T59,Procedure 2180 2203	abdominal circumference
85,T60,Procedure 2169 2175	height
86,T61,Procedure 2158 2164	weight
0,T1,Condition 0 14	Intolerability
1,T2,Drug 18 28	tamsulosin
2,T3,Drug 32 45	related drugs
3,*,OR T2 T3
4,T4,Scope 18 45	tamsulosin or related drugs
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Non-query-able 47 70	Investigator discretion
7,T6,Informed_consent 72 149	Unwillingness or inability to comply with protocol procedures and assessments
0,T1,Person 4 9	adult
1,T2,Value 19 27;35 43	18 years or older
2,T3,Person 31 34	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Visit 60 80	intensive care units
5,T5,Visit 84 113	St. Boniface General Hospital
6,T6,Procedure 44 52	admitted
7,T7,Scope 60 113	intensive care units of St. Boniface General Hospital
8,R2,Has_scope Arg1:T6 Arg2:T7
9,T8,Condition 134 163	acute pulmonary blastomycosis
10,T9,Procedure 174 196	mechanical ventilation
11,R3,AND Arg1:T8 Arg2:T9
0,T1,Condition 0 10	Malignancy
1,T2,Condition 33 51	medical conditions
2,T3,Qualifier 21 32	significant
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Value 107 125	less than 18 years
5,T5,Person 129 132	age
6,R2,Has_value Arg1:T5 Arg2:T4
7,T6,Condition 147 172	interstitial lung disease
8,T7,Condition 174 185	sarcoidosis
9,T8,Condition 205 217	lung disease
10,T9,Temporal 135 146	Concomitant
11,*,OR T7 T6 T8
12,T10,"Scope 147 217	interstitial lung disease, sarcoidosis, other significant lung disease"
13,R3,Has_temporal Arg1:T10 Arg2:T9
14,T11,Procedure 241 251	transplant
15,T12,Non-representable 254 283	Significant travel with work.
16,T13,Post-eligibility 285 354	Unable to make appointments (every three to six months over 2 years).
17,T14,Non-representable 356 433	Those residing in another country or planned absence for more than one month.
18,*,OR T1 T2
0,T1,Person 0 3	Men
1,T2,Value 4 27	between 45 and 80 years
2,T3,Person 28 31	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Measurement 55 88	serum testosterone concentrations
5,T5,Value 51 54	low
6,T6,Value 90 101	< 300 ng/dL
7,R2,Subsumes Arg1:T5 Arg2:T6
8,R3,Has_value Arg1:T4 Arg2:T5
9,T7,Multiplier 115 127	at least one
10,T8,Condition 128 132	sign
11,T9,Condition 136 143	symptom
12,T10,Condition 147 159	hypogonadism
13,*,OR T9 T8
14,T11,Scope 128 143	sign or symptom
15,R4,Has_multiplier Arg1:T11 Arg2:T7
16,R5,AND Arg1:T11 Arg2:T10
17,T12,Mood 169 180	evidence of
18,T13,Condition 181 208	cardiovascular (CV) disease
19,T14,Mood 222 236	increased risk
20,T15,Condition 241 251	CV disease
21,R6,Has_mood Arg1:T13 Arg2:T12
22,R7,Has_mood Arg1:T15 Arg2:T14
23,*,OR T13 T15
0,T1,Condition 0 13	Renal disease
1,T2,Negation 14 23	unrelated
2,T3,Condition 27 30	SLE
3,R1,Has_negation Arg1:T3 Arg2:T2
4,R2,AND Arg1:T1 Arg2:T3
5,T4,Condition 37 54	diabetes mellitus
6,T5,Condition 76 102	tubulointerstitial disease
7,T6,Condition 62 72;95 102	glomerular disease
8,T7,Condition 104 124	renovascular disease
9,*,OR T4 T6 T5 T7
10,T8,"Scope 37 124	diabetes mellitus, other glomerular or tubulointerstitial disease, renovascular disease"
11,T9,Procedure 130 149	transplanted kidney
12,*,OR T1 T9
13,R3,Subsumes Arg1:T1 Arg2:T8
14,T10,Measurement 152 188	Estimated glomerular filtration rate
15,T11,Measurement 190 194	eGFR
16,T12,Value 204 226	=20 mL/min per 1.73 m2
17,T13,Measurement 230 246	serum creatinine
18,T14,Value 247 262	>300 micromol/L
19,T15,Value 264 274	3.39 mg/dL
20,R4,Subsumes Arg1:T14 Arg2:T15
21,R5,Has_value Arg1:T13 Arg2:T14
22,R6,Subsumes Arg1:T10 Arg2:T11
23,R7,Has_value Arg1:T10 Arg2:T12
24,*,OR T10 T13
25,T16,Procedure 291 303	Renal biopsy
26,T17,Condition 324 346	fibrocellular crescent
27,T18,Condition 312 320;338 346	cellular crescent
28,*,OR T17 T18
29,T19,Multiplier 350 376	more than 25% of glomeruli
30,T20,Scope 313 346	ellular or fibrocellular crescent
31,R8,Has_multiplier Arg1:T20 Arg2:T19
32,R9,Has_scope Arg1:T16 Arg2:T20
33,T21,Qualifier 379 382	CNS
34,T22,Condition 422 427	lupus
35,T23,Qualifier 399 418	organ manifestation
36,T24,Procedure 456 481	immunosuppressive therapy
37,R10,AND Arg1:T22 Arg2:T24
38,*,OR T23 T21
39,T25,Scope 379 418	CNS or other severe organ manifestation
40,R11,Has_scope Arg1:T22 Arg2:T25
41,T26,Drug 523 545	corticosteroid therapy
42,T27,Condition 552 558	asthma
43,T28,Condition 560 586	inflammatory bowel disease
44,T29,Condition 495 509	Co-morbidities
45,R12,AND Arg1:T29 Arg2:T26
46,*,OR T27 T28
47,T30,"Scope 552 586	asthma, inflammatory bowel disease"
48,R13,Subsumes Arg1:T29 Arg2:T30
49,T31,Drug 605 617	prednisolone
50,T32,Drug 622 632	prednisone
51,T33,Drug 622 632;637 647	prednisone equivalent
52,*,OR T32 T33 T31
53,T34,Multiplier 652 677	>20 mg/D for over 4 weeks
54,T35,Temporal 689 702	past 3 months
55,T36,"Scope 605 648	prednisolone (or prednisone, or equivalent)"
56,R14,Has_multiplier Arg1:T36 Arg2:T34
57,R15,Has_temporal Arg1:T36 Arg2:T35
58,T37,Drug 720 723	MMF
59,T38,Multiplier 727 752	>1.5 g/D for over 4 weeks
60,R16,Has_multiplier Arg1:T37 Arg2:T38
61,T39,Temporal 764 777	past 3 months
62,R17,Has_temporal Arg1:T37 Arg2:T39
63,T40,Condition 786 802	hypersensitivity
64,T41,Condition 806 820	intolerability
65,T42,Drug 824 836	prednisolone
66,T43,Drug 841 851	prednisone
67,T44,Drug 841 851;856 866	prednisone equivalent
68,T45,Drug 869 872	TAC
69,T46,Drug 877 880	MMF
70,T47,Multiplier 894 917	1.25 g or below per day
71,R18,Has_multiplier Arg1:T46 Arg2:T47
72,*,OR T40 T41
73,T48,Scope 786 820	hypersensitivity or intolerability
74,*,OR T42 T43 T44 T45 T46
75,T49,"Scope 824 917	prednisolone (or prednisone, or equivalent), TAC, or MMF at a dose of 1.25 g or below per day"
76,R19,Has_scope Arg1:T48 Arg2:T49
77,T50,Drug 963 966	TAC
78,T51,Drug 968 980	cyclosporine
79,T52,Drug 994 1015	calcineurin inhibitor
80,T53,Multiplier 1020 1032	over 4 weeks
81,T54,Temporal 1044 1059	past 12 months.
82,*,OR T50 T51 T52
83,T55,"Scope 963 1015	TAC, cyclosporine or any other calcineurin inhibitor"
84,R20,Has_multiplier Arg1:T55 Arg2:T53
85,R21,Has_temporal Arg1:T55 Arg2:T54
86,T56,Drug 1076 1092	cyclophosphamide
87,T57,Drug 1094 1105	leflunomide
88,T58,Drug 1110 1122	methotrexate
89,T59,Multiplier 1132 1139	2 weeks
90,*,OR T56 T57 T58
91,T60,Procedure 1151 1167	biological agent
92,T61,Temporal 1206 1219	past 6 months
93,T62,"Scope 1076 1122	cyclophosphamide, leflunomide, or methotrexate"
94,R22,Has_multiplier Arg1:T62 Arg2:T59
95,*,OR T62 T60
96,T63,"Scope 1076 1170	cyclophosphamide, leflunomide, or methotrexate for over 2 weeks, or use of biological agent(s)"
97,R23,Has_temporal Arg1:T63 Arg2:T61
98,T64,Negation 1316 1323	allowed
99,T65,Drug 1240 1252	azathioprine
100,T66,Drug 1254 1264	mizoribine
101,T67,Drug 1278 1293	immunoglobulins
102,T68,Drug 1298 1312	anti-malarials
103,*,OR T68 T67 T66 T65
104,T69,"Scope 1240 1312	azathioprine, mizoribine, intravenous immunoglobulins and anti-malarials"
105,R24,Has_negation Arg1:T69 Arg2:T64
106,T70,Condition 1340 1352	hypertension
107,T71,Qualifier 1327 1339	Uncontrolled
108,R25,Has_qualifier Arg1:T70 Arg2:T71
109,T72,Measurement 1358 1369	systolic BP
110,T73,Measurement 1383 1395	diastolic BP
111,T74,Value 1370 1379	>160 mmHg
112,T75,Value 1396 1404	>95 mmHg
113,*,OR T72 T73
114,R26,Has_value Arg1:T72 Arg2:T74
115,R27,Has_value Arg1:T73 Arg2:T75
116,T76,Scope 1358 1404	systolic BP >160 mmHg or diastolic BP >95 mmHg
117,R28,Subsumes Arg1:T70 Arg2:T76
118,T77,Pregnancy_considerations 1407 1446	Women who are pregnant or breastfeeding
119,T78,"Pregnancy_considerations 1449 1558	Women with childbearing potential or their male partners, who refuse to use an effective birth control method"
0,T1,Condition 60 73;84 91	Hailey Hailey disease
1,T2,Condition 77 91	Darier disease
2,*,OR T1 T2
3,T3,Procedure 34 46	histological
4,T4,Scope 60 92	Hailey Hailey or Darier diseases
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 119 126	lesions
7,T6,Context_Error 119 126	lesions
8,T7,Qualifier 107 118	very severe
9,T8,Subjective_judgement 107 118	very severe
10,T9,Undefined_semantics 107 118	very severe
11,R2,Has_qualifier Arg1:T5 Arg2:T7
12,T10,Person 159 163	aged
13,T11,Value 164 178	18 ans or more
14,R3,Has_value Arg1:T10 Arg2:T11
15,T12,Observation 193 208	health coverage
16,T13,Context_Error 193 208	health coverage
17,T14,Post-eligibility 210 250	Patient who have signed the consent form
18,T15,Context_Error 210 250	Patient who have signed the consent form
19,T16,Post-eligibility 252 307	Patient proficient into filling out the questionnaires.
20,T17,Non-query-able 252 307	Patient proficient into filling out the questionnaires.
21,T18,Non-query-able 210 250	Patient who have signed the consent form
0,T1,Procedure 60 72	brow lifting
1,T2,Drug 78 93	botulinum toxin
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Person 15 21	female
4,T4,Multiplier 12 14	30
5,R2,Has_multiplier Arg1:T3 Arg2:T4
6,R3,AND Arg1:T3 Arg2:T1
0,T1,Value 8 20	18 and older
1,T2,Person 0 6	Adults
2,T3,Person 8 20	18 and older
3,R1,Has_value Arg1:T3 Arg2:T1
4,R2,multi Arg1:T3 Arg2:T1
5,R3,Subsumes Arg1:T2 Arg2:T3
6,T4,Condition 53 55	SA
7,T5,Condition 73 79	asthma
8,T6,Qualifier 59 63	mild
9,T7,Qualifier 64 72	moderate
10,*,OR T7 T6
11,T8,Scope 59 72	mild-moderate
12,R4,Has_scope Arg1:T5 Arg2:T8
13,T9,Observation 84 116	followed by an asthma specialist
14,T10,Temporal 117 138	for at least 6 months
15,R5,Has_temporal Arg1:T9 Arg2:T10
16,T11,"Post-eligibility 141 242	Must agree to have regular clinic visits (minimum 3-4 per year for SA, 1-2 for mild-moderate asthma)."
17,T12,Condition 254 269	good compliance
18,T13,Drug 275 286	medications
19,T14,Condition 301 307	asthma
20,T15,Condition 312 316	COPD
21,*,OR T15 T14
22,R6,AND Arg1:T12 Arg2:T13
0,T1,Condition 32 53	acquired hypogonadism
1,T2,Condition 18 28;41 53	congenital hypogonadism
2,T3,Non-representable 54 128	for whom long-term therapy with placebo would not be medically appropriate
3,*,OR T2 T1
4,T4,Measurement 148 179	prostate specific antigen (PSA)
5,T5,Value 180 191	> 3.0 ng/mL
6,T6,Drug 206 234	5-alpha reductase inhibitors
7,T7,Value 196 199	1.5
8,A1,Optional T6
9,R1,Has_value Arg1:T6 Arg2:T7
10,*,OR T5 T6
11,T8,Scope 180 235	> 3.0 ng/mL (or 1.5 if on 5-alpha reductase inhibitors)
12,R2,Has_scope Arg1:T4 Arg2:T8
13,T9,Drug 277 289	testosterone
14,T10,Temporal 290 310	in the past 6 months
15,R3,Has_temporal Arg1:T9 Arg2:T10
16,T11,Condition 348 363	contraindicated
17,T12,Procedure 324 344	testosterone therapy
18,R4,AND Arg1:T11 Arg2:T12
19,T13,Drug 324 336	testosterone
20,R5,multi Arg1:T12 Arg2:T13
21,T14,Measurement 365 387	Confirmed testosterone
22,T15,Value 388 399	< 100 ng/dL
23,R6,Has_value Arg1:T14 Arg2:T15
24,T16,Measurement 401 422	Body Mass Index (BMI)
25,T17,Value 423 427	> 50
26,R7,Has_value Arg1:T16 Arg2:T17
27,T18,Measurement 429 451	Hemoglobin A1c (HbA1C)
28,T19,Value 452 457	> 11%
29,R8,Has_value Arg1:T18 Arg2:T19
30,T20,Measurement 459 475	Hematocrit (Hct)
31,T21,Value 476 481	> 50%
32,R9,Has_value Arg1:T20 Arg2:T21
33,T22,Measurement 483 526	Estimated Glomerular Filtration Rate (eGFR)
34,T23,Value 527 538	< 30 ml/min
35,R10,Has_value Arg1:T22 Arg2:T23
36,T24,Condition 551 571	deep vein thrombosis
37,T25,Condition 575 593	pulmonary embolism
38,T26,Condition 597 612	prostate cancer
39,T27,Condition 616 629	heart failure
40,T28,Qualifier 631 640	Class III
41,T29,Qualifier 631 636;645 647	Class IV
42,*,OR T29 T28
43,T30,Scope 631 647	Class III and IV
44,R11,Has_scope Arg1:T27 Arg2:T30
45,*,OR T26 T27 T25 T24
0,T1,Condition 0 16	Hypersensibility
1,T2,Drug 20 25	toxin
2,T3,Drug 29 39	excipients
3,*,OR T2 T3
4,T4,Scope 20 39	toxin or excipients
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T6,Condition 41 50	Myastheny
7,T7,Condition 52 74	Deglutition's problems
8,T8,Condition 100 109	dysphagia
9,T9,Observation 76 96	Past medical history
10,T10,Condition 113 133	aspiration pneumonia
11,*,OR T10 T8
12,T11,Scope 100 133	dysphagia or aspiration pneumonia
13,R2,Has_temporal Arg1:T11 Arg2:T9
14,T12,Condition 135 144	Pregnancy
15,T13,Measurement 155 165	B-HCG test
16,T14,Value 146 154	positive
17,R3,Has_value Arg1:T13 Arg2:T14
18,T15,Observation 200 213	breastfeeding
19,*,OR T12 T15
20,R4,AND Arg1:T12 Arg2:T13
21,T16,Temporal 176 195	a maxima 72h before
22,R5,Has_temporal Arg1:T13 Arg2:T16
23,T19,Non-query-able 275 296	Guardianship patients
24,T20,Condition 298 313	Skin infections
25,T21,Temporal 314 336	at the inclusion visit
26,T22,Visit 321 336	inclusion visit
27,R6,AND Arg1:T21 Arg2:T22
28,R7,Has_temporal Arg1:T20 Arg2:T21
29,T23,Temporal 350 368	in the last 7 days
30,T24,Procedure 338 349;394 413	Application of local treatments
31,T25,Drug 421 431	emollients
32,T26,Drug 435 446	antiseptics
33,T27,Negation 415 420	apart
34,*,OR T25 T26
35,T28,Scope 421 446	emollients or antiseptics
36,R8,Has_negation Arg1:T28 Arg2:T27
37,R9,Has_scope Arg1:T24 Arg2:T28
38,R10,Has_temporal Arg1:T24 Arg2:T23
39,T29,Drug 465 479	botulism toxin
40,T30,Procedure 451 461	injections
41,R11,AND Arg1:T30 Arg2:T29
42,T31,Procedure 483 503	dynamic phototherapy
43,T32,Procedure 507 512	laser
44,T33,Temporal 513 533	in the last 6 months
45,*,OR T30 T31 T32
46,T34,Scope 451 512	injections of botulism toxin or dynamic phototherapy or laser
47,R12,Has_temporal Arg1:T34 Arg2:T33
48,T35,Procedure 536 554	Systemic treatment
49,T36,Drug 560 570	aminosides
50,R13,AND Arg1:T35 Arg2:T36
51,T37,Temporal 571 590	in the last 15 days
52,R14,Has_temporal Arg1:T35 Arg2:T37
53,T38,Context_Error 592 618	Inclusion in another study
54,T39,Non-query-able 592 618	Inclusion in another study
55,T40,Post-eligibility 592 618	Inclusion in another study
56,T41,Temporal 619 639	in the last 2 months
57,T42,Procedure 592 618	Inclusion in another study
58,R15,Has_temporal Arg1:T42 Arg2:T41
59,T5,Condition 224 243	physical incapacity
60,T17,Condition 215 221;233 243	Mental incapacity
61,T18,Procedure 247 273	fill in the questionnaires
62,T43,"Scope 215 243	Mental , physical incapacity"
63,*,OR T5 T17
64,R16,AND Arg1:T43 Arg2:T18
0,T1,Condition 14 16	LN
1,T2,Qualifier 17 31	Class III/IV±V
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Procedure 53 59	biopsy
4,T4,Temporal 70 85	within 12 weeks
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,R3,AND Arg1:T1 Arg2:T3
7,T5,Measurement 114 124	anti-dsDNA
8,T6,Value 105 113	Positive
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Condition 134 136	LN
11,T8,Condition 142 153	proteinuria
12,T9,Measurement 155 185	urine protein/creatinine ratio
13,T10,Value 186 190	>1.0
14,T11,Measurement 194 213	24-hr urine protein
15,T12,Value 214 220	>1.0 g
16,R5,Has_value Arg1:T9 Arg2:T10
17,R6,Has_value Arg1:T11 Arg2:T12
18,*,OR T9 T11
19,T13,Scope 155 220	urine protein/creatinine ratio >1.0 or 24-hr urine protein >1.0 g
20,R7,Subsumes Arg1:T8 Arg2:T13
21,R8,AND Arg1:T7 Arg2:T8
22,T14,Qualifier 127 133	Active
23,R9,Has_qualifier Arg1:T7 Arg2:T14
24,T15,Condition 251 260	hematuria
25,A1,Optional T15
26,T16,Non-query-able 263 335	Both 'incident' (i.e. new) patients and 'flare' patients can be included
0,T1,Procedure 35 51	forehead surgery
1,T2,Procedure 23 34;44 51	periorbital surgery
2,*,OR T2 T1
3,T3,Condition 66 98	plucked the upper eyebrow margin
4,T4,Observation 114 128	eyebrow tatoos
5,T5,Procedure 155 180	botulinum toxin injection
6,T6,Qualifier 144 154	upper face
7,R1,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Temporal 181 202	in the past 12 months
9,R2,Has_temporal Arg1:T5 Arg2:T7
10,T8,Temporal 258 279	in the past 12 months
11,T9,Procedure 218 228;240 257	resorbable fillers injection
12,T10,Qualifier 229 239	upper face
13,R3,Has_qualifier Arg1:T9 Arg2:T10
14,R4,Has_temporal Arg1:T9 Arg2:T8
15,T11,Procedure 304 313;325 342	permanent fillers injection
16,T12,Qualifier 314 324	upper face
17,R5,Has_qualifier Arg1:T11 Arg2:T12
18,T13,Condition 344 352	Pregnant
19,T14,Condition 363 372	Lactating
20,T15,Condition 409 433	neuromuscular conditions
21,T16,Condition 435 452	myasthenia gravis
22,T17,Condition 454 476	Eaton Lambert syndrome
23,*,OR T17 T16
24,T18,"Scope 435 476	myasthenia gravis, Eaton Lambert syndrome"
25,R6,Subsumes Arg1:T15 Arg2:T18
26,T19,Drug 541 550	botulinum
27,T20,Condition 516 537	potentiate the effect
28,T21,Drug 494 504	medication
29,R7,AND Arg1:T21 Arg2:T20
30,R8,AND Arg1:T20 Arg2:T19
31,T22,Drug 556 582	aminoglycoside antibiotics
32,T23,Scope 494 550	medication that could potentiate the effect of botulinum
33,R9,Subsumes Arg1:T23 Arg2:T22
34,T24,Drug 614 629	botulinum toxin
35,T25,Drug 633 646	human albumin
36,T26,Condition 599 610	sensitivity
37,*,OR T24 T25
38,T27,Scope 614 646	botulinum toxin or human albumin
39,R10,Has_scope Arg1:T26 Arg2:T27
0,T1,Condition 21 34	complications
1,T2,Qualifier 14 20	severe
2,T3,Qualifier 38 44	severe
3,T4,Condition 45 54	infection
4,R1,Has_qualifier Arg1:T1 Arg2:T2
5,*,OR T1 T4
6,R2,Has_qualifier Arg1:T4 Arg2:T3
7,T5,Condition 57 65	Invasion
8,T6,Qualifier 69 91	central nervous system
9,R3,Has_qualifier Arg1:T5 Arg2:T6
10,T7,Condition 115 128	heart disease
11,T8,Qualifier 108 114	severe
12,R4,Has_qualifier Arg1:T7 Arg2:T8
13,T9,Condition 148 171	ventricular tachycardia
14,T10,Condition 173 175	VT
15,R5,Subsumes Arg1:T9 Arg2:T10
16,T11,Condition 178 197	atrial fibrillation
17,T12,Condition 199 201	AF
18,R6,Subsumes Arg1:T11 Arg2:T12
19,T13,Condition 204 215	heart block
20,T14,Condition 217 238	myocardial infarction
21,T15,Condition 240 242	MI
22,T16,Condition 245 269	congestive heart failure
23,T17,Condition 271 274	CHF
24,R7,Subsumes Arg1:T14 Arg2:T15
25,R8,Subsumes Arg1:T16 Arg2:T17
26,T18,Condition 277 299	coronary heart disease
27,*,OR T9 T11 T13 T14 T16 T18
28,T19,"Scope 148 299	ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease"
29,R9,Subsumes Arg1:T7 Arg2:T19
30,T20,Condition 347 355	allergic
31,T21,Qualifier 340 346	severe
32,R10,Has_qualifier Arg1:T20 Arg2:T21
33,T22,Condition 387 395	allergic
34,T23,Condition 402 412	intolerant
35,*,OR T22 T23
36,T24,Procedure 436 457	chemotherapy regimens
37,T25,Scope 387 412	allergic to or intolerant
38,R11,AND Arg1:T25 Arg2:T24
39,T26,Qualifier 464 469	other
40,T27,Condition 470 486	malignant tumors
41,T28,Temporal 494 506	past 5 years
42,R12,Has_qualifier Arg1:T27 Arg2:T26
43,R13,Has_temporal Arg1:T27 Arg2:T28
44,*,OR T20 T25 T27
45,T29,Drug 527 538	doxorubicin
46,T30,Drug 573 583	adriamycin
47,T31,Multiplier 588 607	more than 300 mg/m2
48,T32,Qualifier 548 569	total cumulative dose
49,R14,Has_qualifier Arg1:T30 Arg2:T32
50,R15,Has_multiplier Arg1:T30 Arg2:T31
51,T33,Drug 0 8	Patients
52,T34,Drug 634 644	epirubicin
53,T35,Qualifier 609 630	total cumulative dose
54,T36,Multiplier 649 668	more than 450 mg/m2
55,R16,Has_qualifier Arg1:T34 Arg2:T35
56,R17,Has_multiplier Arg1:T34 Arg2:T36
57,*,OR T29 T30 T34
58,T37,Competing_trial 671 717	Patients participate in other clinical studies
59,T38,Non-query-able 720 769	Other patients who are not suitable for the study
0,T1,Drug 7 26	basal-bolus insulin
1,T2,Measurement 28 45	onset of diabetes
2,T3,Value 46 58	after age 30
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 60 63	BMI
5,T5,Value 64 76	less than 35
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 78 82	eGFR
8,T7,Value 83 100	at least 60 ml/mn
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Measurement 102 108	Hb A1c
11,T9,Value 109 118	7.0-10.0%
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Non-query-able 120 166	willingness to perform home glucose monitoring
14,T11,Non-query-able 168 233	willingness to transmit glucose and medication information weekly
0,T1,Condition 0 7	Healthy
1,T2,Person 8 12	male
2,T3,"Value 25 39;46 57	18 to 45 years , inclusive"
3,T4,Person 43 46	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Negation 88 95	absence
6,T6,Observation 99 140	evidence of any active or chronic disease
7,R2,Has_negation Arg1:T6 Arg2:T5
8,T7,Observation 162 169;183 190	medical history
9,T8,Observation 174 190	surgical history
10,*,OR T7 T8
11,T9,Procedure 203 223	physical examination
12,T10,Procedure 234 245	vital signs
13,T11,Procedure 247 258	12-lead ECG
14,T12,Procedure 260 270	hematology
15,T13,Procedure 272 287	blood chemistry
16,T14,Procedure 289 297	serology
17,T15,Procedure 302 312	urinalysis
18,T16,"Scope 88 312	absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology and urinalysis"
19,R3,Subsumes Arg1:T1 Arg2:T16
20,T17,Measurement 314 335	Body mass index (BMI)
21,T18,Value 336 360	18 to 30 kg/m2 inclusive
22,R4,Has_value Arg1:T17 Arg2:T18
23,T19,Person 362 366	Male
24,T20,Condition 385 406	surgically sterilized
25,T21,Condition 385 406	surgically sterilized
26,T22,Negation 410 413	not
27,R5,Has_negation Arg1:T20 Arg2:T22
28,*,OR T21 T20
29,T23,Person 420 426	female
30,T24,Condition 439 462	child-bearing potential
31,R6,AND Arg1:T19 Arg2:T23
32,R7,AND Arg1:T23 Arg2:T24
33,T25,Multiplier 472 475	two
34,T26,Device 476 498	forms of contraception
35,T27,Undefined_semantics 476 498	forms of contraception
36,R8,Has_multiplier Arg1:T26 Arg2:T25
37,T28,Device 523 537	barrier method
38,R9,Subsumes Arg1:T26 Arg2:T28
39,T29,Temporal 539 568	for the duration of the study
40,T30,Temporal 573 604	for 77 days after the last dose
41,T31,Reference_point 591 604	the last dose
42,T32,Reference_point 559 568	the study
43,R10,Has_index Arg1:T29 Arg2:T32
44,R11,Has_index Arg1:T30 Arg2:T31
45,R12,Has_temporal Arg1:T26 Arg2:T29
46,R13,Has_temporal Arg1:T26 Arg2:T30
0,T1,Condition 0 13	Primary B-NHL
1,T2,Condition 15 19	PTCL
2,*,OR T1 T2 T5
3,T3,Condition 21 101	ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma
4,T4,Negation 107 115	excluded
5,R1,Has_negation Arg1:T3 Arg2:T4
6,T5,Condition 120 122	HL
7,T6,Person 162 166	Ages
8,T7,"Value 167 196	=18 years old, < 80 years old"
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Multiplier 252 264	At least one
11,T9,Condition 276 282	lesion
12,R3,Has_multiplier Arg1:T9 Arg2:T8
13,T10,Observation 285 308	Expected survival time=
14,T11,Value 308 316	3 months
15,R4,Has_value Arg1:T10 Arg2:T11
16,T12,Measurement 335 347	transaminase
17,T13,Value 347 380	=2.5× upper limit of normal value
18,T14,Measurement 381 390	bilirubin
19,T15,Value 390 422	=1.5×upper limit of normal value
20,R5,Has_value Arg1:T12 Arg2:T13
21,R6,Has_value Arg1:T14 Arg2:T15
22,T16,Measurement 441 457	serum creatinine
23,T17,Value 461 474	44-133 mmol/L
24,R7,Has_value Arg1:T16 Arg2:T17
25,T18,Measurement 491 499	test:WBC
26,T19,Value 499 509	=3.0×109/L
27,T20,Measurement 510 521	Neutrophils
28,T21,Value 521 531	=1.5×109/L
29,T22,Measurement 532 534	Hb
30,T23,Value 534 541	=100g/L
31,T24,Measurement 542 550	Platelet
32,T25,Value 550 559	=80×109/L
33,T26,Measurement 561 565	LVEF
34,T27,Value 565 569	=50%
35,R8,Has_value Arg1:T18 Arg2:T19
36,R9,Has_value Arg1:T20 Arg2:T21
37,R10,Has_value Arg1:T22 Arg2:T23
38,R11,Has_value Arg1:T24 Arg2:T25
39,R12,Has_value Arg1:T26 Arg2:T27
40,T28,Measurement 572 598;606 635	New York Heart Association heart function classification
41,T29,Value 639 649	I-II grade
42,R13,Has_value Arg1:T28 Arg2:T29
43,T30,Measurement 600 604	NYHA
44,R14,Subsumes Arg1:T28 Arg2:T30
45,T31,Informed_consent 651 674	signed informed consent
46,T32,Measurement 199 245	ECOG (Eastern Cooperative Oncology Group)score
47,T33,Value 247 250	0-2
48,R15,Has_value Arg1:T32 Arg2:T33
0,T1,Qualifier 27 49	clinically significant
1,T2,Condition 27 57	clinically significant disease
2,T3,Condition 27 49;61 69	clinically significant disorder
3,*,OR T3 T2
4,R1,Has_qualifier Arg1:T3 Arg2:T1
5,R2,Has_qualifier Arg1:T2 Arg2:T1
6,T4,Undefined_semantics 27 69	clinically significant disease or disorder
7,T5,Subjective_judgement 27 69	clinically significant disease or disorder
8,T6,Observation 0 7	History
9,R3,Has_temporal Arg1:T3 Arg2:T6
10,R4,Has_temporal Arg1:T2 Arg2:T6
11,T7,"Subjective_judgement 71 285	Any condition or disease that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator"
12,T8,"Post-eligibility 71 285	Any condition or disease that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator"
13,T9,Qualifier 298 320	clinically significant
14,T10,Subjective_judgement 298 320	clinically significant
15,T11,Condition 321 337	hypersensitivity
16,T12,Condition 341 364	allergic drug reactions
17,*,OR T11 T12
18,R5,Has_qualifier Arg1:T11 Arg2:T9
19,R6,AND Arg1:T12 Arg2:T10
20,T13,Condition 394 407	alcohol abuse
21,T14,Observation 370 379	suspicion
22,T15,Observation 383 390	history
23,*,OR T15 T14
24,T16,Scope 370 390	suspicion or history
25,T17,Condition 415 450	consumption of other drugs of abuse
26,*,OR T17 T13
27,T18,Scope 394 450	alcohol abuse and/or consumption of other drugs of abuse
28,R7,Has_scope Arg1:T18 Arg2:T16
29,T19,Condition 452 466	Regular smoker
30,T20,Multiplier 468 471	> 5
31,T21,Observation 472 482	cigarettes
32,T23,Multiplier 499 502;509 516	> 1 per day
33,T24,Observation 503 508	cigar
34,T22,Multiplier 484 487	> 1
35,T25,Observation 488 495	pipeful
36,R8,Has_multiplier Arg1:T25 Arg2:T22
37,R9,Has_multiplier Arg1:T21 Arg2:T20
38,R10,Has_multiplier Arg1:T24 Arg2:T23
39,*,OR T24 T25 T21
40,T26,"Scope 468 516	> 5 cigarettes, > 1 pipeful or > 1 cigar per day"
41,R11,Subsumes Arg1:T19 Arg2:T26
42,T27,Measurement 532 543	hepatitis B
43,T28,Value 519 527	Positive
44,T29,Measurement 545 556	hepatitis C
45,T30,Condition 560 573	HIV infection
46,R12,Has_value Arg1:T27 Arg2:T28
47,R13,Has_value Arg1:T29 Arg2:T28
48,*,OR T30 T29 T27
49,T31,Condition 575 595	Dietary restrictions
50,T32,Qualifier 601 653	would prohibit the consumption of standardized meals
51,T33,Undefined_semantics 601 653	would prohibit the consumption of standardized meals
52,T34,Subjective_judgement 601 653	would prohibit the consumption of standardized meals
53,R14,Has_qualifier Arg1:T31 Arg2:T32
54,T35,"Context_Error 655 803	Participation in an investigational drug or device study within 90 days prior to screening, as calculated from the follow-up from the previous study"
0,T1,Condition 0 15	Type 1 diabetes
1,T2,Condition 23 48	peripheral artery disease
2,T3,Measurement 50 63	Liver enzymes
3,T4,Value 64 118	equal or more than 1.5 times the upper limit of normal
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Measurement 142 146	NYHA
6,T6,Value 147 162	class III or IV
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Condition 120 141	Chronic heart failure
9,R3,AND Arg1:T7 Arg2:T5
10,T8,Procedure 172 185	haemodialysis
11,T9,Procedure 189 208	peritoneal dialysis
12,*,OR T9 T8
13,T10,Temporal 164 171	Current
14,T11,Scope 172 208	haemodialysis or peritoneal dialysis
15,R4,Has_temporal Arg1:T11 Arg2:T10
16,T12,Condition 210 233	End stage liver disease
17,T13,Condition 255 276	chronic liver disease
18,T14,Condition 246 251;263 276	acute liver disease
19,*,OR T14 T13
20,T15,Temporal 281 287	recent
21,T16,Condition 321 328	ascites
22,T17,Condition 330 344	encephalopathy
23,T18,Condition 346 363	variceal bleeding
24,T19,Measurement 365 374	bilirubin
25,T20,Value 375 406	equal or greater than 2.0 mg/dL
26,R5,Has_value Arg1:T19 Arg2:T20
27,T21,Measurement 408 415	albumin
28,T22,Value 416 444	equal or less than 3.5 g/ dL
29,R6,Has_value Arg1:T21 Arg2:T22
30,T23,Measurement 446 462	prothrombin time
31,T24,Value 463 492	greater or equal to 4 seconds
32,R7,Has_value Arg1:T23 Arg2:T24
33,T25,Measurement 494 497	INR
34,T26,Value 498 526	greater than or equal to 1.7
35,R8,Has_value Arg1:T25 Arg2:T26
36,T27,Temporal 530 535	prior
37,T28,Procedure 536 552	liver transplant
38,R9,Has_temporal Arg1:T28 Arg2:T27
39,*,OR T25 T23 T28 T21 T19 T18 T17 T16
40,T29,"Scope 321 552	ascites, encephalopathy, variceal bleeding, bilirubin equal or greater than 2.0 mg/dL, albumin equal or less than 3.5 g/ dL, prothrombin time greater or equal to 4 seconds, INR greater than or equal to 1.7 or prior liver transplant"
41,R10,Has_temporal Arg1:T29 Arg2:T15
42,T30,"Scope 246 552	acute or chronic liver disease and recent history of one of the following: ascites, encephalopathy, variceal bleeding, bilirubin equal or greater than 2.0 mg/dL, albumin equal or less than 3.5 g/ dL, prothrombin time greater or equal to 4 seconds, INR greater than or equal to 1.7 or prior liver transplant"
43,R11,Subsumes Arg1:T12 Arg2:T30
44,T31,Condition 573 589	hypersensitivity
45,T32,Drug 593 607	trial products
46,T33,Drug 611 627	related products
47,*,OR T33 T32
48,T34,Scope 593 627	trial products or related products
49,T35,Mood 563 572	suspected
50,T36,Mood 554 559	Known
51,*,OR T35 T36
52,T37,Scope 554 572	Known or suspected
53,R12,Has_scope Arg1:T31 Arg2:T37
54,R13,Has_scope Arg1:T31 Arg2:T34
55,T38,"Pregnancy_considerations 629 809	Female of child-bearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods as required by law or local practice."
56,T39,Non-query-able 811 915	Expected simultaneous participation in any other clinical trial of an investigational medicinal product.
57,T40,Non-query-able 917 1001	Receipt of any investigational medicinal product within 30 days before randomization
58,T41,Condition 1045 1064	malignant neoplasms
59,T42,Temporal 1003 1010	Current
60,T43,Temporal 1014 1018	past
61,T44,Temporal 1020 1043	within the last 5 years
62,R14,Subsumes Arg1:T43 Arg2:T44
63,*,OR T43 T42
64,T45,Scope 1003 1044	Current or past (within the last 5 years)
65,R15,Has_scope Arg1:T41 Arg2:T45
66,T46,Condition 1073 1083;1107 1116	basal cell carcinoma
67,T47,Condition 1088 1116	squamous cell skin carcinoma
68,*,OR T46 T47
69,T48,Negation 1066 1072	except
70,T49,Scope 1073 1116	basal cell and squamous cell skin carcinoma
71,R16,Has_negation Arg1:T49 Arg2:T48
72,R17,Has_scope Arg1:T41 Arg2:T49
73,T50,Post-eligibility 1119 1250	Any condition that in the investigator's opinion would make the subject unable to adhere to the trial visit schedule and procedures
74,T51,Non-query-able 1252 1296	Known history of non-compliance to treatment
0,T1,Value 0 16	18-year or older
1,T2,Person 11 14	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Visit 35 47	hospitalized
4,T4,Visit 51 70	neuro-critical care
5,T5,Condition 77 97	Arachnoid hemorrhage
6,T6,Qualifier 99 119	Intra parenchymatous
7,T7,Condition 120 128	hematoma
8,R2,Has_qualifier Arg1:T7 Arg2:T6
9,T8,Condition 130 136	stroke
10,T9,Condition 138 163	Acute brain Severe injury
11,T10,Condition 165 192	Post-operative complication
12,T11,Procedure 206 218	neurosurgery
13,T12,Qualifier 193 218	of an act of neurosurgery
14,T13,Procedure 233 247	neuroradiology
15,T14,Qualifier 193 205;222 247	of an act of programmed neuroradiology
16,R3,multi Arg1:T12 Arg2:T11
17,R4,multi Arg1:T14 Arg2:T13
18,*,OR T12 T14
19,T15,Scope 193 247	of an act of neurosurgery or programmed neuroradiology
20,R5,Has_scope Arg1:T10 Arg2:T15
21,T16,Procedure 262 284	mechanical ventilation
22,T17,Procedure 249 257	Sedation
23,T18,Temporal 293 301	> 2 days
24,T19,Mood 285 292	planned
25,R6,Has_mood Arg1:T18 Arg2:T19
26,T20,Scope 249 284	Sedation and mechanical ventilation
27,R7,Has_temporal Arg1:T20 Arg2:T18
28,T21,Measurement 317 341	intracranial temperature
29,T22,Measurement 317 329;346 354	intracranial pressure
30,*,OR T22 T21
31,T23,Device 358 381	intraparenchymal sensor
32,T24,Device 383 391	Sophysa®
33,R8,Subsumes Arg1:T23 Arg2:T24
34,T25,Scope 358 392	intraparenchymal sensor (Sophysa®)
35,T26,Scope 317 354	intracranial temperature and pressure
36,R9,Has_scope Arg1:T26 Arg2:T25
37,T27,Measurement 394 411	Brain temperature
38,T28,Value 412 420	> 38.5°C
39,T29,Temporal 421 445	for more than 30 minutes
40,R10,Has_value Arg1:T27 Arg2:T28
41,R11,Has_temporal Arg1:T27 Arg2:T29
0,T1,Visit 27 56	participating research centre
1,T2,Mood 62 74	suspicion of
2,T3,Qualifier 78 87	confirmed
3,*,OR T2 T3
4,T4,Condition 88 106	endometrial cancer
5,T5,Scope 62 87	suspicion of or confirmed
6,R1,Has_scope Arg1:T4 Arg2:T5
7,T6,Condition 138 163	epithelial ovarian cancer
8,T7,Condition 123 134;149 163	endometrial ovarian cancer
9,*,OR T7 T6
10,T8,Multiplier 218 224	weekly
11,T9,Drug 225 231	taxane
12,T10,Drug 233 243	paclitaxel
13,T11,Procedure 245 254	treatment
14,R2,Subsumes Arg1:T9 Arg2:T10
15,R3,Has_multiplier Arg1:T9 Arg2:T8
16,R4,AND Arg1:T11 Arg2:T9
17,T12,"Non-representable 256 345	This will often be a third or fourth line treatment, i.e. patients with advanced disease."
18,T13,Procedure 385 398	tissue biopsy
19,T14,Mood 347 378	Technical possibility to obtain
20,R5,Has_mood Arg1:T13 Arg2:T14
21,T15,Condition 434 451	tumour recurrence
0,T1,Condition 0 8	Pregnant
1,T2,Person 9 14	woman
2,T3,Observation 18 31	breastfeeding
3,*,OR T3 T1
4,T4,Condition 33 50	immunosuppression
5,T5,Condition 61 65	AIDS
6,T6,Drug 67 82	corticosteroids
7,T7,Multiplier 83 96	over 60mg/day
8,R1,Has_multiplier Arg1:T6 Arg2:T7
9,*,OR T5 T6
10,T8,"Scope 61 96	AIDS, corticosteroids over 60mg/day"
11,R2,Subsumes Arg1:T4 Arg2:T8
12,T9,Procedure 117 126	treatment
13,T10,Drug 106 116	antibiotic
14,R3,AND Arg1:T9 Arg2:T10
15,T11,Temporal 127 150	at the day of inclusion
16,R4,Has_temporal Arg1:T9 Arg2:T11
17,T12,Observation 178 197	signed consent form
18,T14,Condition 152 175	impossibility to obtain
19,T13,Reference_point 134 150	day of inclusion
20,R5,Has_index Arg1:T11 Arg2:T13
21,R6,Has_context Arg1:T14 Arg2:T12
0,T1,Condition 6 39	upper gastrointestinal malignancy
1,T2,Condition 41 49	Bleeding
2,T3,Condition 55 70	gastric varices
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 88 106	esophageal varices
5,A1,Optional T4
6,R2,AND Arg1:T2 Arg2:T4
7,T5,Negation 115 124	any other
8,T6,Procedure 125 142	endoscopic method
9,T7,Condition 151 162	GI bleeding
10,T8,Procedure 170 194	endoscopic band ligation
11,R3,Has_negation Arg1:T8 Arg2:T5
12,R4,AND Arg1:T6 Arg2:T8
13,R5,AND Arg1:T6 Arg2:T7
14,T9,Condition 196 213	Variceal bleeding
15,T10,Temporal 214 233	in the last 90 days
16,R6,Has_temporal Arg1:T9 Arg2:T10
17,T11,"Procedure 246 300	transjugular, intrahepatic, portosystemic shunt (TIPS)"
18,T12,Procedure 304 334	vascular decompression surgery
19,*,OR T11 T12
20,T13,Observation 235 242	History
21,T14,"Scope 246 334	transjugular, intrahepatic, portosystemic shunt (TIPS) or vascular decompression surgery"
22,R7,Has_temporal Arg1:T14 Arg2:T13
23,T15,Person 345 352	females
24,T16,Condition 336 344	Pregnant
25,T17,Person 354 378	Incarcerated individuals
26,T18,Condition 380 398	Myocardial infarct
27,T19,Condition 400 424	cerebrovascular accident
28,T20,Condition 426 432	sepsis
29,T21,Condition 434 453	respiratory failure
30,T22,Qualifier 458 464	severe
31,T23,Condition 465 485	intercurrent illness
32,R8,Has_qualifier Arg1:T23 Arg2:T22
33,T24,Temporal 486 513	within the previous 6 weeks
34,*,OR T20 T21 T23 T19 T18
35,T25,"Scope 380 485	Myocardial infarct, cerebrovascular accident, sepsis, respiratory failure, or severe intercurrent illness"
36,R9,Has_temporal Arg1:T25 Arg2:T24
37,T26,Condition 515 548	Non-cirrhotic portal hypertension
38,T27,Condition 557 575	esophageal varices
39,R10,AND Arg1:T26 Arg2:T27
40,T28,Condition 596 603	allergy
41,T29,Mood 586 595	suspected
42,T30,Mood 577 582	Known
43,*,OR T29 T30
44,T31,Scope 577 595	Known or suspected
45,R11,Has_scope Arg1:T28 Arg2:T31
46,T32,Drug 607 617	octreotide
47,R12,AND Arg1:T28 Arg2:T32
0,T1,Device 28 48	Avaira sphere lenses
1,T2,Device 56 71	CL prescription
2,T3,Context_Error 72 137	outside the range of the available parameters of the study lenses
3,T4,Non-query-able 72 137	outside the range of the available parameters of the study lenses
4,T5,Qualifier 72 137	outside the range of the available parameters of the study lenses
5,R1,Has_qualifier Arg1:T2 Arg2:T5
6,T6,Device 146 164	spectacle cylinder
7,T7,Value 165 171	≥1.00D
8,R2,Has_value Arg1:T6 Arg2:T7
9,T8,Observation 206 213	history
10,T9,Condition 231 250	comfortable CL wear
11,T10,Negation 217 220	not
12,R3,Has_negation Arg1:T9 Arg2:T10
13,R4,Has_temporal Arg1:T9 Arg2:T8
14,T11,Temporal 252 267	5 days per week
15,T12,Temporal 269 282	> 8 hours/day
16,T13,Measurement 289 332	contact lens best corrected distance vision
17,T14,Value 333 349;364 377	worse than 20/25 in either eye
18,T15,Value 333 343;351 362;364 377	worse than 0.10 logMAR in either eye
19,R5,Subsumes Arg1:T14 Arg2:T15
20,T16,Scope 333 377	worse than 20/25 (0.10 logMAR) in either eye
21,R6,Has_scope Arg1:T13 Arg2:T16
22,T17,Qualifier 392 414	clinically significant
23,T18,Subjective_judgement 392 414	clinically significant
24,T19,Qualifier 416 425	grade 2-4
25,T20,Value 422 425	2-4
26,R7,Has_value Arg1:T19 Arg2:T20
27,R8,Subsumes Arg1:T17 Arg2:T19
28,T21,Condition 427 457	anterior segment abnormalities
29,T22,Context_Error 427 457	anterior segment abnormalities
30,R9,Has_qualifier Arg1:T21 Arg2:T17
31,T23,Condition 481 497	systemic disease
32,T24,Condition 471 477;490 497	ocular disease
33,T25,Condition 501 520	need of medications
34,T26,Undefined_semantics 501 520	need of medications
35,T27,Subjective_judgement 501 520	need of medications
36,T28,Undefined_semantics 471 497	ocular or systemic disease
37,T29,Qualifier 527 565	might interfere with contact lens wear
38,T30,Subjective_judgement 527 565	might interfere with contact lens wear
39,*,OR T23 T24 T25
40,T31,Scope 471 520	ocular or systemic disease or need of medications
41,R10,Has_qualifier Arg1:T31 Arg2:T29
42,T32,Procedure 568 577	Slit lamp
43,T33,Value 578 586	findings
44,T34,Undefined_semantics 578 586	findings
45,R11,Has_value Arg1:T32 Arg2:T33
46,T35,Condition 598 625	contraindicate contact lens
47,T36,Undefined_semantics 598 625	contraindicate contact lens
48,R12,AND Arg1:T32 Arg2:T35
49,T37,Parsing_Error 568 639	Slit lamp findings that would contraindicate contact lens wear such as:
50,T38,Condition 641 661	Pathological dry eye
51,T39,Condition 665 684	associated findings
52,R13,AND Arg1:T39 Arg2:T38
53,*,OR T39 T38
54,T40,Condition 686 695	Pterygium
55,T41,Condition 697 707	pinguecula
56,T42,Condition 712 725	corneal scars
57,T43,Qualifier 726 748	within the visual axis
58,R14,Has_qualifier Arg1:T42 Arg2:T43
59,*,OR T42 T41 T40
60,T44,Condition 750 768	Neovascularization
61,T45,Value 769 800	> 0.75 mm in from of the limbus
62,R15,Has_value Arg1:T44 Arg2:T45
63,T46,Condition 802 838	Giant papillary conjunctivitis (GCP)
64,T47,Qualifier 839 857	worse than grade 1
65,R16,Has_qualifier Arg1:T46 Arg2:T47
66,T48,Condition 859 875	Anterior uveitis
67,T49,Condition 879 885	iritis
68,*,OR T48 T49
69,T50,Temporal 887 891	past
70,T51,Temporal 895 902	present
71,*,OR T51 T50
72,T52,Scope 887 902	past or present
73,T53,Scope 859 885	Anterior uveitis or iritis
74,R17,Has_scope Arg1:T53 Arg2:T52
75,T54,Condition 905 922	Seborrheic eczema
76,T55,Condition 924 949	Seborrheic conjunctivitis
77,T56,Condition 962 976	corneal ulcers
78,T57,Condition 980 997	fungal infections
79,T58,Observation 951 958	History
80,R18,Has_temporal Arg1:T57 Arg2:T58
81,R19,Has_temporal Arg1:T56 Arg2:T58
82,T59,Condition 999 1020	Poor personal hygiene
83,T60,Condition 1045 1065	corneal hypoesthesia
84,T61,Condition 1067 1094	reduced corneal sensitivity
85,R20,Subsumes Arg1:T60 Arg2:T61
86,T62,Observation 1034 1041	history
87,T63,Condition 1101 1108	aphakia
88,T64,Condition 1110 1121	keratoconus
89,T65,Condition 1127 1150	highly irregular cornea
90,*,OR T65 T64 T63
91,R21,Has_temporal Arg1:T60 Arg2:T62
92,T66,Condition 1157 1167	Presbyopia
93,T67,Condition 1175 1213	dependence on spectacles for near work
94,*,OR T66 T67
95,T68,Procedure 1254 1280	corneal refractive surgery
96,T69,Non-query-able 1283 1359	Is participating in any other type of eye related clinical or research study
0,T1,Condition 27 39	CRE bacteria
1,T2,Condition 20 23;31 39	GRE bacteria
2,*,OR T1 T2
3,T3,Multiplier 106 116	at least 3
4,T4,Value 117 126	positives
5,T5,Procedure 127 132	swabs
6,T6,Temporal 133 149	in the last mont
7,R1,Has_temporal Arg1:T5 Arg2:T6
8,R2,Has_multiplier Arg1:T5 Arg2:T3
9,R3,Has_value Arg1:T5 Arg2:T4
10,T7,Condition 41 53	Colonization
11,T8,Qualifier 54 94	confirmed by our microbiology department
12,R4,Has_qualifier Arg1:T7 Arg2:T8
13,R5,AND Arg1:T7 Arg2:T5
0,T1,Condition 6 22	hypersensitivity
1,T2,Drug 26 37	paracetamol
2,T3,Drug 41 49	mannitol
3,*,OR T2 T3
4,T4,Non-representable 50 79	(excipient with known effect)
5,T5,Scope 26 49	paracetamol or mannitol
6,R1,Has_scope Arg1:T1 Arg2:T5
7,T6,Condition 88 116	hepatocellular insufficiency
8,T7,Measurement 118 122	ASAT
9,T8,Measurement 126 130	ALAT
10,T9,Value 131 135	> 5N
11,*,OR T7 T8 T11
12,T11,Measurement 140 149	bilirubin
13,T12,Value 150 154	> 2N
14,R2,Has_value Arg1:T11 Arg2:T12
15,R3,Has_value Arg1:T8 Arg2:T9
16,R4,Has_value Arg1:T7 Arg2:T9
17,T10,"Scope 118 154	ASAT or ALAT > 5N, or bilirubin > 2N"
18,R5,Subsumes Arg1:T6 Arg2:T10
19,T13,Procedure 157 185	Pharmacological intervention
20,T14,Drug 157 172	Pharmacological
21,R6,multi Arg1:T13 Arg2:T14
22,T15,Drug 205 220	corticosteroids
23,T16,Drug 222 228	NSAIDs
24,T17,Drug 232 243	paracetamol
25,*,OR T16 T17 T15
26,T18,"Scope 205 243	corticosteroids, NSAIDs or paracetamol"
27,T19,Procedure 248 269	physical intervention
28,T20,Procedure 271 297	external cooling technique
29,T21,Qualifier 299 329	that may influence temperature
30,T22,Temporal 330 349	in the last 6 hours
31,R7,Subsumes Arg1:T19 Arg2:T20
32,R8,Has_scope Arg1:T13 Arg2:T18
33,*,OR T13 T19
34,T23,"Scope 157 298	Pharmacological intervention (administration of corticosteroids, NSAIDs or paracetamol) or physical intervention (external cooling technique)"
35,R9,Has_qualifier Arg1:T23 Arg2:T21
36,R10,Has_temporal Arg1:T23 Arg2:T22
37,T24,Measurement 318 329	temperature
38,R11,multi Arg1:T21 Arg2:T24
39,T25,Condition 352 360	Pregnant
40,T26,Observation 364 377	breastfeeding
41,*,OR T26 T25
42,T27,Person 378 383	women
43,T28,Competing_trial 385 421	Previous participation in this study
0,T1,Negation 18 21	not
1,T2,Procedure 26 44	surgical treatment
2,T3,Condition 55 73	endometrial cancer
3,R1,AND Arg1:T3 Arg2:T2
4,R2,Has_negation Arg1:T2 Arg2:T1
5,T4,Condition 118 143	epithelial ovarian cancer
6,T5,Condition 103 114;129 143	endometrial ovarian cancer
7,*,OR T5 T4
8,T6,Negation 84 87	not
9,T7,Scope 103 143	endometrial or epithelial ovarian cancer
10,R3,Has_negation Arg1:T7 Arg2:T6
11,T8,Negation 161 164	not
12,T9,Observation 165 196	agree to the proposed treatment
13,R4,Has_negation Arg1:T9 Arg2:T8
14,T10,Visit 242 266	non-participating centre
15,T11,Procedure 227 236	treatment
16,R5,AND Arg1:T11 Arg2:T10
17,T12,Observation 306 327	give informed consent
18,T13,Negation 281 287	cannot
19,T14,Negation 291 305	do not want to
20,*,OR T13 T14
21,T15,Scope 281 305	cannot or do not want to
22,R6,Has_scope Arg1:T12 Arg2:T15
23,T16,Observation 339 356	language barriers
24,*,OR T12 T16
0,T1,Value 3 26;34 45	between 18 and 40 years (inclusive)
1,T2,Person 30 33	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 57 82	self-reported visual exam
4,T4,Temporal 83 104	in the last two years
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Device 120 146	Avaira sphere contact lens
7,T6,Temporal 155 187	at least 1 week in Avaira sphere
8,T7,Reference_point 174 187	Avaira sphere
9,T8,Device 174 187	Avaira sphere
10,R3,Has_index Arg1:T6 Arg2:T7
11,R4,Has_temporal Arg1:T5 Arg2:T6
12,T9,Device 196 208	contact lens
13,T10,Value 240 268	+ 2.25 to - 8.00 (inclusive)
14,T11,Qualifier 209 218	spherical
15,R5,Has_qualifier Arg1:T9 Arg2:T11
16,R6,Has_value Arg1:T9 Arg2:T10
17,T12,Device 276 294	spectacle cylinder
18,T13,Value 295 306	up to 0.75D
19,R7,Has_value Arg1:T12 Arg2:T13
20,T14,Measurement 333 380	best corrected spectacle distance visual acuity
21,T15,Value 384 389;404 413	20/25 or better
22,T16,Value 391 402;404 413	0.10 logMAR or better
23,R8,Subsumes Arg1:T15 Arg2:T16
24,R9,Has_value Arg1:T14 Arg2:T15
25,T17,Measurement 442 464	distance visual acuity
26,T18,Value 468 473;488 497	20/30 or better
27,T19,Value 475 486;488 497	0.18 logMAR or better
28,R10,Has_value Arg1:T17 Arg2:T18
29,T20,Device 519 539	study contact lenses
30,R11,AND Arg1:T17 Arg2:T20
31,R12,Has_value Arg1:T17 Arg2:T19
32,T21,Condition 546 559	clear corneas
33,T22,Condition 574 588	ocular disease
34,T23,Negation 564 566	no
35,T24,Temporal 567 573	active
36,R13,Has_temporal Arg1:T22 Arg2:T24
37,R14,Has_negation Arg1:T22 Arg2:T23
38,T25,"Post-eligibility 590 653	Has read, understood and signed the information consent letter."
39,T26,"Non-query-able 590 653	Has read, understood and signed the information consent letter."
40,T27,Non-query-able 655 750	Patient contact lens refraction should fit within the available parameters of the study lenses.
41,T28,Context_Error 655 750	Patient contact lens refraction should fit within the available parameters of the study lenses.
42,T29,"Non-query-able 752 891	Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so)."
43,T30,Non-query-able 893 937	Is willing to comply with the visit schedule
44,T31,Post-eligibility 893 937	Is willing to comply with the visit schedule
45,T32,"Post-eligibility 752 891	Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so)."
0,T1,Person 0 5	Adult
1,T2,Person 6 11	males
2,T3,Person 16 23	females
3,T4,Value 32 56	18 years of age or older
4,*,OR T2 T3
5,T5,Mood 71 80	suspicion
6,T6,Mood 59 67	Evidence
7,*,OR T5 T6
8,T7,Condition 84 118	upper gastrointestinal bleed (GIB)
9,T8,Scope 59 80	Evidence or suspicion
10,R1,Has_scope Arg1:T7 Arg2:T8
11,T9,Mood 142 151	suspected
12,T10,Mood 133 138	known
13,*,OR T10 T9
14,T11,Condition 152 161	cirrhosis
15,T12,Scope 133 151	known or suspected
16,R2,Has_scope Arg1:T11 Arg2:T12
17,T13,Condition 163 172	Upper GIB
18,T14,Qualifier 173 182	secondary
19,T15,Qualifier 186 194	bleeding
20,T16,Condition 195 213	esophageal varices
21,R3,AND Arg1:T14 Arg2:T16
22,R4,Has_qualifier Arg1:T13 Arg2:T14
23,R5,Has_qualifier Arg1:T16 Arg2:T15
24,T17,Procedure 225 245	esophageal endoscopy
25,R6,AND Arg1:T16 Arg2:T17
26,T18,Mood 247 256	requiring
27,T19,Procedure 257 287	endoscopic band ligation (EBL)
28,R7,Has_mood Arg1:T19 Arg2:T18
29,R8,AND Arg1:T16 Arg2:T19
30,T20,Temporal 288 303	at presentation
31,R9,Has_temporal Arg1:T19 Arg2:T20
32,T21,"Informed_consent 305 460	Willing and able to provide informed consent for study, or have a Legally authorized representative (LAR) provide consent if the patient is unable to do so"
0,T1,Person 0 3	age
1,T2,Value 3 12	>18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 23 36	limb ischemia
4,T4,Measurement 38 54	Rutherford class
5,T5,Value 55 58	4-6
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Qualifier 14 22	critical
8,R3,Has_qualifier Arg1:T3 Arg2:T6
9,T7,Scope 38 58	Rutherford class 4-6
10,R4,Subsumes Arg1:T6 Arg2:T7
11,T8,Measurement 61 82	angiographic stenosis
12,T9,Value 82 86	>50%
13,T10,Condition 90 99	occlusion
14,T11,Multiplier 103 115	at least one
15,T12,Qualifier 116 129	tibial vessel
16,T13,Qualifier 133 146	at least 40mm
17,T14,Procedure 160 184	interventional treatment
18,T15,Mood 188 197	scheduled
19,R5,Has_mood Arg1:T14 Arg2:T15
20,R6,Has_qualifier Arg1:T12 Arg2:T13
21,R7,Has_multiplier Arg1:T12 Arg2:T11
22,R8,Has_qualifier Arg1:T10 Arg2:T12
23,R9,Has_value Arg1:T8 Arg2:T9
24,R10,AND Arg1:T10 Arg2:T14
0,T1,Person 0 3	Age
1,T2,Value 4 19	greater than 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 21 31	NOSE score
4,T4,Value 32 47	greater than 55
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 49 71	Nasal septal deviation
0,T1,Qualifier 14 23	bilateral
1,T2,Mood 0 13	Scheduled for
2,T3,Procedure 24 50	varus rotational osteotomy
3,T4,Procedure 52 55	VRO
4,R1,Subsumes Arg1:T3 Arg2:T4
5,T5,Procedure 100 118	osseous procedures
6,T6,Procedure 108 118;84 95	procedures soft tissue
7,T7,Scope 84 118	soft tissue and osseous procedures
8,A1,Optional T7
9,R2,Has_scope Arg1:T3 Arg2:T7
10,R3,Has_qualifier Arg1:T3 Arg2:T1
11,R4,Has_mood Arg1:T3 Arg2:T2
0,T1,Qualifier 0 8	Atypical
1,T2,Condition 9 31	Parkinsonian Syndromes
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 33 52	Parkinson's disease
4,T4,Condition 58 72	hallucinations
5,T5,Condition 74 93	Parkinson's disease
6,T6,Condition 99 129	impulse Control disorder (ICD)
7,R3,AND Arg1:T5 Arg2:T6
8,T7,Condition 131 150	Parkinson's disease
9,T8,Drug 172 183	APOMORPHINE
10,T9,Non-representable 192 249	justifying the use of the pump continuously day and night
11,R4,AND Arg1:T7 Arg2:T8
12,T10,Condition 267 281	severe disease
13,T11,Condition 293 301	insomnia
14,R5,AND Arg1:T10 Arg2:T11
15,T12,"Non-representable 303 415	Exclusion for monitoring difficulties (mutation, insufficient motivation, priority associated pathology in care)"
16,T13,Mood 425 444	unwilling to accept
17,T14,Negation 425 434	unwilling
18,T15,Device 447 451	pump
19,R6,Has_mood Arg1:T15 Arg2:T13
20,T16,Procedure 475 490	polysomnography
21,T17,Mood 461 474	not accepting
22,T18,Negation 461 464	not
23,T19,Procedure 495 522	multiple sleep latency test
24,R7,Has_mood Arg1:T16 Arg2:T17
25,R8,Has_mood Arg1:T19 Arg2:T17
26,T20,Condition 537 552	health problems
27,T21,Condition 558 570	skin disease
28,T22,Negation 571 581	precluding
29,T23,Procedure 582 614	continuous subcutaneous infusion
30,R9,Has_negation Arg1:T23 Arg2:T22
31,*,OR T20 T21
32,T24,Scope 537 570	health problems or a skin disease
33,R10,AND Arg1:T24 Arg2:T23
34,T25,Person 616 622	Female
35,T26,Condition 623 633	parturient
36,T27,Condition 637 644	nursing
37,*,OR T27 T26
38,T28,Condition 646 665	Cardiac dysrhythmia
39,T29,Drug 692 703	domperidone
40,T30,Drug 707 718	apomorphine
41,*,OR T29 T30
42,T31,Negation 666 676	precluding
43,T32,Scope 692 718	domperidone or apomorphine
44,R11,Has_negation Arg1:T32 Arg2:T31
45,T33,Scope 666 718	precluding treatment with domperidone or apomorphine
46,R12,Has_scope Arg1:T28 Arg2:T33
47,T34,Measurement 730 733	QTc
48,T36,Value 734 742	= 440 ms
49,T37,Measurement 751 754	QTc
50,T38,Value 755 763	= 450 ms
51,T39,Person 767 772	women
52,T40,Person 746 749	men
53,R13,Has_value Arg1:T34 Arg2:T36
54,R14,Has_value Arg1:T37 Arg2:T38
55,A1,Optional T40
56,A2,Optional T39
57,R15,AND Arg1:T40 Arg2:T34
58,R16,AND Arg1:T39 Arg2:T37
59,*,OR T40 T39
60,T35,"Scope 730 772	QTc = 440 ms in men, QTc = 450 ms in women"
61,R17,Subsumes Arg1:T28 Arg2:T35
62,T41,Drug 775 798	antiemetic neuroleptics
63,T42,Drug 800 813	Tetrabenazine
64,T43,Condition 815 844	Excessive alcohol consumption
65,T44,Condition 846 862	Hypersensitivity
66,T45,Drug 866 877	apomorphine
67,T46,Drug 892 902	excipients
68,*,OR T45 T46
69,T47,Scope 866 902	apomorphine or one of the excipients
70,R18,Has_scope Arg1:T44 Arg2:T47
71,T48,Condition 904 926	Respiratory Depression
72,T49,Condition 928 946	Hepatic impairment
73,T50,Condition 948 971	Intellectual Disability
74,T51,Condition 973 981	Dementia
75,R2,AND Arg1:T3 Arg2:T4
0,T1,Procedure 15 40	dual antiplatelet therapy
1,T2,Negation 41 51	other than
2,T3,Condition 52 71	atrial fibrillation
3,T4,Condition 0 11	indications
4,R1,AND Arg1:T4 Arg2:T1
5,T5,Condition 75 106	left atrial appendage occlusion
6,*,OR T3 T5
7,T6,Temporal 107 132	at the time of enrollment
8,T7,Mood 136 156	predicted appearance
9,T8,Temporal 177 209	within the duration of the trial
10,T9,Condition 215 238	coronary artery disease
11,T10,Scope 136 209	predicted appearance of such indications within the duration of the trial
12,*,OR T6 T10
13,T11,Scope 52 106	atrial fibrillation or left atrial appendage occlusion
14,R2,Has_negation Arg1:T11 Arg2:T2
15,R3,Has_scope Arg1:T4 Arg2:T11
16,T12,Scope 107 239	at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. coronary artery disease)
17,R4,Has_scope Arg1:T4 Arg2:T12
18,R5,Subsumes Arg1:T10 Arg2:T9
19,T13,Condition 241 252	indications
20,T14,Procedure 256 271	anticoagulation
21,T15,Temporal 272 297	at the time of enrollment
22,T16,Mood 301 321	predicted appearance
23,T17,Temporal 342 374	within the duration of the trial
24,T18,Scope 301 374	predicted appearance of such indications within the duration of the trial
25,*,OR T15 T18
26,T19,Condition 380 398	pulmonary embolism
27,R6,Subsumes Arg1:T18 Arg2:T19
28,R7,AND Arg1:T13 Arg2:T14
29,T20,Scope 272 399	at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. pulmonary embolism)
30,R8,Has_scope Arg1:T13 Arg2:T20
31,T21,Drug 418 429	clopidogrel
32,T22,Drug 433 453	acetylsalicylic acid
33,T23,Condition 407 414	allergy
34,*,OR T21 T22
35,T24,Non-representable 454 483	precluding its administration
36,T25,Scope 418 453	clopidogrel or acetylsalicylic acid
37,R9,Has_scope Arg1:T23 Arg2:T25
38,T26,Condition 543 564	coagulation disorders
39,T27,Condition 566 580	poor tolerance
40,T28,Observation 587 609	technical difficulties
41,T29,Procedure 626 658	transesophageal echocardiography
42,*,OR T27 T28
43,T30,Scope 566 609	poor tolerance of or technical difficulties
44,R10,AND Arg1:T30 Arg2:T29
45,T31,Measurement 660 675	peridevice leak
46,T32,Value 676 680	>5mm
47,T33,Procedure 684 722	transesophageal echocardiography study
48,R11,Has_value Arg1:T31 Arg2:T32
49,R12,AND Arg1:T33 Arg2:T31
50,T34,Condition 745 765	left atrial thrombus
51,T35,Procedure 769 801	transesophageal echocardiography
52,T36,Procedure 835 864	left atrial appendage closure
53,T37,Temporal 818 864	after successful left atrial appendage closure
54,T38,Reference_point 824 864	successful left atrial appendage closure
55,T39,Qualifier 824 834	successful
56,R13,Has_qualifier Arg1:T36 Arg2:T39
57,R14,multi Arg1:T37 Arg2:T36
58,R15,Has_index Arg1:T37 Arg2:T38
59,T40,Temporal 869 886	before enrollment
60,T41,Reference_point 876 886	enrollment
61,R16,AND Arg1:T35 Arg2:T34
62,T42,Scope 818 886	after successful left atrial appendage closure but before enrollment
63,R17,Has_scope Arg1:T35 Arg2:T42
64,T43,Observation 888 903	life expectancy
65,T44,Value 907 925	less than 18months
66,R18,Has_value Arg1:T43 Arg2:T44
67,T45,Competing_trial 927 1043	participation in other clinical studies with experimental therapies at the time of enrollment and preceding 3 months
68,T46,Condition 1045 1067	chronic kidney disease
69,T47,Qualifier 1068 1076	stage IV
70,T48,Qualifier 1068 1073;1081 1082	stage V
71,*,OR T48 T47
72,T49,Scope 1068 1082	stage IV and V
73,R19,Has_scope Arg1:T46 Arg2:T49
74,T50,Person 1084 1089	women
75,T51,Condition 1098 1106	pregnant
76,T52,Observation 1110 1124	breast feeding
77,T53,Pregnancy_considerations 1084 1277	women who are pregnant or breast feeding; women of childbearing potential who do not consent to apply at least to methods of contraception. This criterion does not apply to postmenopausal women
78,*,OR T51 T52
0,T1,Procedure 0 22	Intranasal steroid use
1,T2,Temporal 23 51	within the last three months
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Temporal 53 60	Current
4,T4,Procedure 61 81	systemic steroid use
5,R2,Has_temporal Arg1:T4 Arg2:T3
6,T5,Qualifier 61 69	systemic
7,T6,Drug 70 77	steroid
8,T7,Qualifier 0 10	Intranasal
9,T8,Drug 11 18	steroid
10,R3,Has_qualifier Arg1:T8 Arg2:T7
11,R4,multi Arg1:T1 Arg2:T8
12,R5,Has_qualifier Arg1:T6 Arg2:T5
13,R6,multi Arg1:T4 Arg2:T6
14,T9,Temporal 83 88	Prior
15,T10,Procedure 89 103	septal surgery
16,R7,Has_temporal Arg1:T10 Arg2:T9
17,T11,Condition 125 133	pregnant
18,T12,Temporal 137 145	actively
19,T13,Observation 146 159	breastfeeding
20,R8,Has_temporal Arg1:T13 Arg2:T12
21,*,OR T11 T13
0,T1,Condition 9 25	major amputation
1,T2,Non-representable 26 51	known before intervention
2,T3,Drug 64 74	Paclitaxel
3,T4,Condition 53 60	allergy
4,R1,AND Arg1:T4 Arg2:T3
5,T5,Condition 76 92	contraindication
6,T6,Procedure 97 128	combined antiplatelet treatment
7,R2,AND Arg1:T5 Arg2:T6
8,T7,Observation 130 145	life expectancy
9,T8,Value 146 153	<1 year
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Condition 155 171	hypersensitivity
12,T10,Condition 175 191	contraindication
13,T11,Multiplier 195 201	one of
14,T12,Drug 206 217	study drugs
15,R4,Has_multiplier Arg1:T12 Arg2:T11
16,*,OR T9 T10
17,T13,Scope 155 191	hypersensitivity or contraindication
18,R5,AND Arg1:T13 Arg2:T12
19,T14,Informed_consent 219 234	lack of consent
0,T1,Condition 11 30	Parkinson's disease
1,T2,Qualifier 0 10	Idiopathic
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 71 89	motor fluctuations
4,T4,Condition 91 116	Chronic Insomnia disorder
5,T5,Qualifier 143 161	criteria of DMS- V
6,T6,Measurement 208 231	insomnia severity index
7,T7,Value 232 236	> 15
8,R2,Has_value Arg1:T6 Arg2:T7
9,R3,Has_qualifier Arg1:T4 Arg2:T5
10,R4,AND Arg1:T4 Arg2:T6
11,T8,Drug 301 312	apomorphine
12,T9,Device 268 274	device
13,R5,AND Arg1:T8 Arg2:T9
14,T10,"Non-query-able 314 448	Collection of written informed consent (legal obligation for any project under the public health law , bioethics laws and / or CNIL) ."
15,T11,Person 450 478	Affiliate to social security
16,T12,Person 463 478;482 493	social security beneficiary
17,*,OR T12 T11
0,T1,Procedure 11 42	left atrial appendage occlusion
1,T2,Qualifier 0 10	successful
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Device 48 61	Amulet device
4,T4,Temporal 62 99	within 37 days prior to randomization
5,R2,AND Arg1:T1 Arg2:T3
6,R3,Has_temporal Arg1:T1 Arg2:T4
7,T5,Procedure 117 142	dual antiplatelet therapy
8,T6,Drug 144 155	clopidogrel
9,T7,Drug 160 180	acetylsalicylic acid
10,T8,Scope 144 180	clopidogrel and acetylsalicylic acid
11,R4,Has_scope Arg1:T5 Arg2:T8
12,T9,Procedure 190 219	left atrial appendage closure
13,T10,Temporal 182 237	between left atrial appendage closure and randomization
14,T11,Reference_point 224 237	randomization
15,T12,Reference_point 190 219	left atrial appendage closure
16,R5,multi Arg1:T12 Arg2:T9
17,T13,Scope 190 237	left atrial appendage closure and randomization
18,R6,Has_scope Arg1:T10 Arg2:T13
19,T14,Person 253 256	age
20,T15,Value 257 274	18 years or older
21,T16,Temporal 275 323	at the time of signing the informed consent form
22,T17,Reference_point 290 323	signing the informed consent form
23,R7,Has_index Arg1:T16 Arg2:T17
24,R8,Has_value Arg1:T14 Arg2:T15
25,R9,Has_temporal Arg1:T14 Arg2:T16
26,T18,Post-eligibility 325 507	participant is willing to follow all study procedures; especially randomized antiplatelet treatment regimen and follow-up visits with transesophageal echocardiography when applicable
27,T19,Informed_consent 509 571	participant is willing to sign the study informed consent form
0,T1,Temporal 0 12	Preoperative
1,T2,Drug 23 36	anticoagulant
2,R1,Has_temporal Arg1:T2 Arg2:T1
3,T3,Drug 38 44	Plavix
4,T4,Drug 46 54	warfarin
5,T5,Drug 56 63	lovenox
6,*,OR T5 T4 T3
7,T6,"Scope 38 63	Plavix, warfarin, lovenox"
8,R2,Subsumes Arg1:T2 Arg2:T6
9,T7,Condition 83 99	hypersensitivity
10,T8,Drug 103 107	EACA
11,R3,AND Arg1:T7 Arg2:T8
12,T9,Condition 120 140	thromboembolic event
13,T10,Condition 171 190	renal insufficiency
14,T11,Condition 148 150	PE
15,T12,Condition 154 157	DVT
16,*,OR T11 T12
17,T13,Scope 148 157	PE or DVT
18,R4,Subsumes Arg1:T9 Arg2:T13
19,T14,Condition 171 176;194 201	renal failure
20,*,OR T14 T10
21,T15,Qualifier 203 213	Congenital
22,T16,Qualifier 217 225	acquired
23,T17,Condition 226 238	coagulopathy
24,*,OR T16 T15
25,T18,Scope 203 225	Congenital or acquired
26,R5,Has_scope Arg1:T17 Arg2:T18
27,T19,Measurement 254 257	INR
28,T20,Value 258 262;276 288	>1.4 times normal
29,T21,Measurement 266 269	PTT
30,T22,Value 270 288	> 1.4 times normal
31,R6,Has_value Arg1:T21 Arg2:T22
32,R7,Has_value Arg1:T19 Arg2:T20
33,*,OR T21 T19
34,T23,Scope 254 288	INR >1.4 or PTT > 1.4 times normal
35,R8,Has_scope Arg1:T17 Arg2:T23
36,T24,Measurement 293 302	Platelets
37,T25,"Value 303 315	<150,000/mm3"
38,R9,Has_value Arg1:T24 Arg2:T25
39,T26,Procedure 319 350	preoperative laboratory testing
40,R10,AND Arg1:T26 Arg2:T24
41,*,OR T17 T24
42,T27,Procedure 359 386	hormone replacement therapy
43,T28,Drug 390 419	hormonal contraceptive agents
44,T29,Temporal 420 448	within days prior to surgery
45,T30,Reference_point 441 448	surgery
46,R11,Has_index Arg1:T29 Arg2:T30
47,*,OR T28 T27
48,T31,Scope 359 419	hormone replacement therapy or hormonal contraceptive agents
49,R12,Has_temporal Arg1:T31 Arg2:T29
50,T32,Drug 457 477	acetylsalicylic acid
51,T33,Drug 479 482	ASA
52,R13,Subsumes Arg1:T32 Arg2:T33
53,T34,Drug 485 504	antiplatelet agents
54,T35,Temporal 505 535	within 7 days prior to surgery
55,T36,Reference_point 528 535	surgery
56,R14,Has_index Arg1:T35 Arg2:T36
57,*,OR T34 T32
58,T37,"Scope 457 504	acetylsalicylic acid (ASA), antiplatelet agents"
59,R15,Has_temporal Arg1:T37 Arg2:T35
60,T38,Condition 537 545	Pregnant
61,T39,Observation 547 560	Breastfeeding
62,T40,Procedure 575 595	neuraxial anesthesia
63,T41,Negation 562 574	Not received
64,R16,Has_negation Arg1:T40 Arg2:T41
0,T1,Negation 5 8	not
1,T2,Procedure 18 39	influenza vaccination
2,R1,Has_negation Arg1:T2 Arg2:T1
3,T3,Procedure 241 258	influenza vaccine
4,T4,Temporal 259 275	within <6 months
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Condition 288 311	Guillain-Barré syndrome
7,T6,Condition 313 340	Immunosuppressive disorders
8,T7,Drug 313 330;344 355	Immunosuppressive medications
9,*,OR T6 T7
10,T8,Drug 367 382	oral prednisone
11,T9,Multiplier 383 395	>10 mg daily
12,R3,Has_multiplier Arg1:T8 Arg2:T9
13,T10,Procedure 404 416	chemotherapy
14,*,OR T8 T10
15,T11,"Scope 367 426	oral prednisone >10 mg daily, recent chemotherapy treatment"
16,R4,Subsumes Arg1:T7 Arg2:T11
17,T12,Non-query-able 429 491	Emergency cases as determined by the investigator or physician
0,T1,"Post-eligibility 0 173	Subjects who the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, and able to converse with study personnel"
1,T2,Person 176 179	Age
2,T3,Value 180 197	18 years or older
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Procedure 210 231	major cardiac surgery
5,T5,Procedure 238 260	cardiopulmonary bypass
6,R2,AND Arg1:T4 Arg2:T5
0,T1,Person 0 4	Aged
1,T2,Value 5 22	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Multiplier 41 52	one or more
4,T4,Drug 53 60	statins
5,R2,Has_multiplier Arg1:T4 Arg2:T3
6,T5,Non-query-able 62 118	Withdrawn from statins because of perceived side effects
7,T6,Condition 130 142	side effects
8,T7,Temporal 143 171	within 2 weeks of initiation
9,T8,Reference_point 161 171	initiation
10,R3,Has_index Arg1:T7 Arg2:T8
11,R4,Has_temporal Arg1:T6 Arg2:T7
12,T9,Condition 182 192	indication
13,T10,Drug 197 204	statins
14,R5,AND Arg1:T9 Arg2:T10
15,T11,Observation 230 266	prevention of cardiovascular disease
16,T12,Qualifier 220 229	secondary
17,T13,Qualifier 209 216	primary
18,*,OR T13 T12
19,T14,Condition 270 283	dyslipidaemia
20,T15,Scope 209 229	primary or secondary
21,R6,Has_scope Arg1:T11 Arg2:T15
22,T16,Scope 209 283	primary or secondary prevention of cardiovascular disease or dyslipidaemia
23,*,OR T11 T14
24,R7,Subsumes Arg1:T9 Arg2:T16
0,T1,Person 0 3	Age
1,T2,Value 4 41	greater than or equal to 18 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Drug 59 75	vasoactive drugs
4,T4,Device 82 105	central venous catheter
5,T5,Condition 127 132	shock
6,R2,AND Arg1:T3 Arg2:T5
7,T6,Measurement 159 181	mean arterial pressure
8,T7,Value 182 199	less than 70 mmHg
9,T8,Measurement 203 226	systolic blood pressure
10,T9,Value 227 245	less than 100 mmHg
11,T10,"Non-query-able 134 642	Shock will be defined as mean arterial pressure less than 70 mmHg or systolic blood pressure less than 100 mmHg despite administration of at least 1000 mL of crystalloid or 500 mL of colloid, unless there is an elevation in the central venous pressure to > 12 mmHg or in the pulmonary artery occlusion pressure to > 14 mmHg coupled with signs of tissue hypoperfusion (e.g. altered mental state, mottled skin, urine output < 0.5 mL/kg body weight for one hour, or a serum lactate level of > 2 mmol per liter)."
12,R3,AND Arg1:T3 Arg2:T4
0,T1,Mood 9 18	scheduled
1,T2,Procedure 23 46	laser laryngeal surgery
2,T3,Procedure 53 71	general anesthesia
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Drug 84 92	Propofol
5,T5,Drug 96 106	desflurane
6,*,OR T4 T5
7,T6,Scope 84 106	Propofol or desflurane
8,R2,Has_scope Arg1:T3 Arg2:T6
9,R3,Has_mood Arg1:T2 Arg2:T1
0,T1,Procedure 11 25	abdominoplasty
1,T2,Procedure 29 60	TRAM flap breast reconstruction
2,*,OR T1 T2
0,T1,Person 9 13	aged
1,T2,Value 14 31	at least 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 47 68	chronic heart failure
4,T4,Temporal 77 99	for at least 12 months
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Drug 123 127	iron
7,T6,Condition 123 138	iron deficiency
8,R3,multi Arg1:T6 Arg2:T5
9,T7,Measurement 140 157	Serum haemoglobin
10,T8,Value 161 177	9.5 to 14.0 g/dL
11,R4,Has_value Arg1:T7 Arg2:T8
0,T1,Post-eligibility 0 135	Baseline cognitive deficits sufficient to make objective pain self-assessments unreliable in the estimation of the Study Investigators.
1,T2,Condition 137 154	Immunocompromised
2,T3,Condition 164 176	Coagulopathy
3,T4,Condition 185 190;201 212	liver dysfunction
4,T5,Condition 195 212	renal dysfunction
5,*,OR T5 T4
6,T6,Qualifier 178 184	Severe
7,T7,Scope 185 212	liver and renal dysfunction
8,R1,Has_qualifier Arg1:T7 Arg2:T6
9,T8,Condition 227 248	neurological deficits
10,T9,Qualifier 214 226	Preoperative
11,R2,Has_qualifier Arg1:T8 Arg2:T9
12,T10,Observation 254 265	dura damage
13,T11,Procedure 273 280	surgery
14,R3,Has_context Arg1:T11 Arg2:T10
15,T12,Post-eligibility 282 347	Inability to follow directions or comprehend the English language
16,T13,Pregnancy_considerations 350 447	Females who are pregnant as determined by positive pregnancy test on or before the day of surgery
17,T14,Person 450 459	Prisoners
18,T15,Post-eligibility 462 505	Patient refusal to provide informed consent
19,T16,Condition 508 515	Allergy
20,T17,Drug 519 542	amide local anesthetics
21,T18,Drug 544 553	lidocaine
22,T19,Drug 555 566	bupivacaine
23,T20,Drug 568 579	ropivacaine
24,T21,Drug 584 590	opioid
25,T22,Drug 592 600	fentanyl
26,*,OR T18 T19 T20
27,T23,"Scope 544 579	lidocaine, bupivacaine, ropivacaine"
28,R4,Subsumes Arg1:T17 Arg2:T23
29,R5,Subsumes Arg1:T21 Arg2:T22
30,*,OR T17 T21
31,T24,"Scope 519 602	amide local anesthetics (lidocaine, bupivacaine, ropivacaine) or opioid (fentanyl)."
32,R6,Has_scope Arg1:T16 Arg2:T24
0,T1,Condition 0 21	Anaphylactic reaction
1,T2,Temporal 27 35	previous
2,T3,Drug 44 61	influenza vaccine
3,T4,Drug 75 89	its components
4,*,OR T3 T4
5,T5,Scope 44 89	influenza vaccine or to any of its components
6,R1,Has_temporal Arg1:T5 Arg2:T2
7,R2,Has_scope Arg1:T1 Arg2:T5
8,T6,Condition 97 145	Immunoglobulin E (IgE)-mediated hypersensitivity
9,T7,Drug 149 153	eggs
10,T8,Condition 168 173	hives
11,T9,Condition 175 196	swelling of the mouth
12,T10,Condition 175 190;201 207	swelling of the throat
13,T11,Condition 209 232	difficulty in breathing
14,T12,Condition 234 245	hypotension
15,T13,Condition 250 255	shock
16,*,OR T13 T12 T11 T10 T9 T8
17,T14,"Scope 168 255	hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock"
18,R3,AND Arg1:T6 Arg2:T7
19,R4,Has_scope Arg1:T6 Arg2:T14
20,T15,Condition 257 281	Guillain- Barré syndrome
21,T16,Temporal 282 332	within eight weeks of a previous influenza vaccine
22,T17,Reference_point 304 332	a previous influenza vaccine
23,T18,Temporal 306 314	previous
24,T19,Drug 315 332	influenza vaccine
25,R5,Has_temporal Arg1:T19 Arg2:T18
26,R6,multi Arg1:T17 Arg2:T19
27,R7,Has_index Arg1:T16 Arg2:T17
28,R8,Has_temporal Arg1:T15 Arg2:T16
29,T20,Drug 341 348	aspirin
30,T21,Drug 352 383	salicylate- containing products
31,T22,Temporal 384 416	within 30 days before enrollment
32,*,OR T20 T21
33,T23,Scope 341 383	aspirin or salicylate- containing products
34,R9,Has_temporal Arg1:T23 Arg2:T22
35,T24,Person 418 435	Household members
36,T25,Person 439 447	children
37,T26,Person 451 458	Group A
38,T27,Scope 439 458	children in Group A
39,R10,Has_scope Arg1:T24 Arg2:T27
0,T1,Condition 0 22	Cardiopulmonary arrest
1,T2,Condition 24 33	Pregnancy
2,T3,Condition 42 61	right heart failure
3,T4,Qualifier 35 41	Severe
4,R1,Has_qualifier Arg1:T3 Arg2:T4
0,T1,Condition 11 21	neuropathy
1,T2,Drug 51 60	analgesia
2,T3,Qualifier 23 32	Regularly
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 75 87	chronic pain
5,T5,Condition 117 131	mental illness
6,T6,Qualifier 110 116	severe
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Drug 205 213	fibrates
9,T8,Condition 388 399	anaphylaxis
10,T9,"Condition 401 417	facial swelling,"
11,T10,Condition 418 429	severe rash
12,T11,Condition 431 442	muscle ache
13,T12,Measurement 456 477	serum creatine kinase
14,T13,Value 448 452	rise
15,R3,AND Arg1:T11 Arg2:T12
16,R4,Has_value Arg1:T12 Arg2:T13
17,T14,Condition 479 500	inflammatory myopathy
18,T15,Condition 502 516	rhabdomyolysis
19,T16,Condition 520 548	liver function abnormalities
20,T17,Measurement 550 572	aspartate transaminase
21,T18,Measurement 574 577	AST
22,T19,Measurement 582 602	alanine transaminase
23,T20,Measurement 604 607	ALT
24,T21,Value 609 651	greater than 3 times upper limit or normal
25,R5,Subsumes Arg1:T17 Arg2:T18
26,R6,Subsumes Arg1:T19 Arg2:T20
27,*,OR T19 T17
28,T22,Scope 550 608	aspartate transaminase (AST) or alanine transaminase (ALT)
29,R7,Has_value Arg1:T22 Arg2:T21
30,R8,Subsumes Arg1:T16 Arg2:T22
31,*,OR T16 T15 T14 T11 T10 T9 T8
32,T23,"Non-query-able 655 865	Side-effects taking longer than 2 weeks to develop (because in such participants much longer blocks of treatment would be required, if the present study is positive such studies will be planned for the future)*"
33,T24,Condition 886 897	intolerance
34,T25,Drug 879 885	statin
35,R9,AND Arg1:T24 Arg2:T25
36,T26,Drug 923 943	antiretroviral drugs
37,T27,Condition 964 975	intolerance
38,T28,Drug 957 963	statin
39,R10,AND Arg1:T27 Arg2:T28
40,T29,Pregnancy_considerations 996 1022	Pregnant or breast feeding
41,T30,"Non-query-able 1078 1151	In clinical judgement of study doctor, participant should not participate"
42,T31,Non-query-able 1025 1075	Side effects taking longer than 2 weeks to present
0,T1,Non-query-able 0 65	A medical condition that could interfere with study participation
1,T2,Measurement 67 78	Body weight
2,T3,Value 79 94	less than 50 kg
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Competing_trial 96 166	Participating in another study involving an investigational medication
0,T1,Condition 46 63	renal dysfunction
1,T2,Condition 34 41;52 63	hepatic dysfunction
2,T3,Condition 23 32;52 63	pulmonary dysfunction
3,T4,Condition 14 21;52 63	cardiac dysfunction
4,T5,Condition 65 73	epilepsy
5,T6,Qualifier 78 90	uncontrolled
6,T7,Condition 91 103	hypertension
7,R1,Has_qualifier Arg1:T7 Arg2:T6
8,T8,Drug 121 174	medications that influence the central nervous system
9,T9,Condition 231 258	alteration of mental status
10,T10,Observation 263 284	refuse to participate
11,T11,Informed_consent 263 284	refuse to participate
12,R2,multi Arg1:T10 Arg2:T11
13,*,OR T9 T10 T1 T4 T3 T2 T5 T7 T8
0,T1,Person 0 5	Adult
1,T2,Person 15 19	aged
2,T3,Value 20 37	18 years or older
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Procedure 62 100	posterior lumbar spinal fusion surgery
6,T5,Qualifier 53 61	elective
7,T6,Mood 39 52	Scheduled for
8,R3,Has_qualifier Arg1:T4 Arg2:T5
9,R4,Has_mood Arg1:T4 Arg2:T6
10,T7,Qualifier 101 123	between 1 and 3 levels
11,R5,Has_qualifier Arg1:T4 Arg2:T7
0,T1,Condition 0 16	Hypersensitivity
1,T2,Drug 24 40	active substance
2,T3,Drug 45 48	FCM
3,T4,Drug 63 73	excipients
4,*,OR T3 T4 T2
5,T5,"Scope 24 73	active substance, to FCM or any of its excipients"
6,R1,Has_scope Arg1:T1 Arg2:T5
7,T6,Condition 89 105	hypersensitivity
8,T7,Drug 115 139	parenteral iron products
9,R2,AND Arg1:T6 Arg2:T7
10,T8,Qualifier 81 88	serious
11,R3,Has_qualifier Arg1:T6 Arg2:T8
12,T9,Condition 141 148	Anaemia
13,T10,Negation 149 152	not
14,T11,Drug 167 182	iron deficiency
15,T12,Mood 153 166	attributed to
16,R4,Has_mood Arg1:T11 Arg2:T12
17,T13,Qualifier 189 194	other
18,T14,Condition 195 213	microcytic anaemia
19,R5,Has_qualifier Arg1:T14 Arg2:T13
20,R6,Has_negation Arg1:T11 Arg2:T10
21,R7,AND Arg1:T9 Arg2:T11
22,T15,Scope 141 182	Anaemia not attributed to iron deficiency
23,T16,Scope 189 213	other microcytic anaemia
24,R8,Subsumes Arg1:T15 Arg2:T16
25,T17,Condition 227 240	iron overload
26,T18,Condition 244 283	disturbances in the utilisation of iron
27,*,OR T17 T18
28,T19,Drug 227 231	iron
29,T20,Drug 279 283	iron
30,R9,multi Arg1:T17 Arg2:T19
31,R10,multi Arg1:T18 Arg2:T20
0,T1,Condition 0 7	Healthy
1,T2,Person 8 16	children
2,T3,Person 17 21	aged
3,T4,Value 22 43	6 months to 72 months
4,R1,Has_value Arg1:T3 Arg2:T4
0,T1,"Competing_trial 0 166	Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial"
0,T1,Condition 0 15	Type 2 diabetes
1,T2,Person 17 20	Age
2,T3,Value 21 34	18 - 75 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 36 55;65 94	Anti-GAD antibodies (Glutamic Acid Decarboxylase)
5,T5,Value 56 64	negative
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 96 112	C-peptide levels
8,T7,Value 113 124	= 1.5 ng/mL
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Measurement 126 147	Fasting blood glucose
11,T9,Value 148 159	> 126 mg/dl
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Measurement 161 166	HbA1c
14,T11,Value 167 179	8.0 - 10.5 %
15,R5,Has_value Arg1:T10 Arg2:T11
16,T12,Measurement 181 184	BMI
17,T13,Temporal 204 212	Previous
18,T14,Procedure 213 220	therapy
19,T15,Drug 226 230	BBIT
20,T16,Drug 232 283	basal insulin and at least once daily bolus insulin
21,R6,Subsumes Arg1:T15 Arg2:T16
22,R7,AND Arg1:T14 Arg2:T15
23,R8,Has_temporal Arg1:T14 Arg2:T13
24,T17,Value 185 202	25.0 - 45.0 kg/m2
25,R9,Has_value Arg1:T12 Arg2:T17
0,T1,Non-representable 0 38	Not applicable to this follow up study
0,T1,Procedure 11 38	oral antidiabetic treatment
1,T2,Drug 11 28	oral antidiabetic
2,R1,multi Arg1:T1 Arg2:T2
3,T3,Negation 39 49	except for
4,T4,Drug 50 59	metformin
5,R2,Has_negation Arg1:T4 Arg2:T3
6,R3,AND Arg1:T1 Arg2:T4
7,T5,Drug 67 81	sulphonylureas
8,T6,Drug 83 100	DPP-IV inhibitors
9,T7,Drug 102 120	thiazolidinediones
10,T8,Drug 122 139	SGLT-2 inhibitors
11,T9,Drug 182 197	GLP-1 analogues
12,T10,Temporal 223 270	within the last three months prior to Screening
13,T11,Reference_point 261 270	Screening
14,R4,Has_index Arg1:T10 Arg2:T11
15,*,OR T6 T5 T7 T8 T9
16,T12,"Scope 67 222	sulphonylureas, DPP-IV inhibitors, thiazolidinediones, SGLT-2 inhibitors (Sodium dependent glucose transporter) or GLP-1 analogues (glucagone like peptide)"
17,T13,Scope 11 59	oral antidiabetic treatment except for metformin
18,R5,Subsumes Arg1:T13 Arg2:T12
19,R6,Has_temporal Arg1:T13 Arg2:T10
20,T14,Multiplier 272 280	Repeated
21,T15,Condition 293 313	severe hypoglycaemia
22,T16,Temporal 314 359	within the last six months prior to Screening
23,T17,Reference_point 350 359	Screening
24,R7,Has_index Arg1:T16 Arg2:T17
25,R8,Has_temporal Arg1:T15 Arg2:T16
26,R9,Has_multiplier Arg1:T15 Arg2:T14
27,T18,Condition 372 393	diabetic ketoacidosis
28,T19,Observation 361 368	History
29,T20,Condition 395 412	precoma diabetica
30,T21,Condition 417 430	diabetic coma
31,*,OR T20 T21 T18
32,T22,"Scope 372 430	diabetic ketoacidosis, precoma diabetica, or diabetic coma"
33,R10,Has_temporal Arg1:T22 Arg2:T19
34,T23,Drug 457 477	investigational drug
35,T24,Procedure 432 441	Treatment
36,R11,AND Arg1:T24 Arg2:T23
37,T25,Temporal 478 523	within the last three months before Screening
38,T26,Reference_point 514 523	Screening
39,R12,Has_index Arg1:T25 Arg2:T26
40,R13,Has_temporal Arg1:T24 Arg2:T25
41,T27,Condition 525 541	Acute infections
42,T28,Temporal 542 587	within the last four weeks prior to Screening
43,T29,Reference_point 578 587	Screening
44,R14,Has_index Arg1:T28 Arg2:T29
45,R15,Has_temporal Arg1:T27 Arg2:T28
46,T30,Multiplier 589 598	Recurrent
47,T31,Condition 599 620	urogenital infections
48,R16,Has_multiplier Arg1:T31 Arg2:T30
49,T32,Observation 622 629	History
50,T33,Condition 633 645	pancreatitis
51,R17,Has_temporal Arg1:T33 Arg2:T32
52,T34,Observation 647 665	Anamnestic history
53,T35,Condition 669 685	hypersensitivity
54,T36,Drug 693 704	study drugs
55,T37,Drug 711 749	drugs with similar chemical structures
56,*,OR T36 T37
57,T38,Scope 693 749	study drugs or to drugs with similar chemical structures
58,R18,Has_scope Arg1:T35 Arg2:T38
59,R19,Has_temporal Arg1:T35 Arg2:T34
60,T39,Condition 781 790	allergies
61,T40,Qualifier 762 768	severe
62,T41,Qualifier 772 780	multiple
63,*,OR T40 T41
64,T42,Scope 762 780	severe or multiple
65,R20,Has_scope Arg1:T39 Arg2:T42
66,T43,Observation 751 758	History
67,R21,Has_temporal Arg1:T39 Arg2:T43
68,T44,Temporal 792 803	Concomitant
69,T45,Observation 804 842	participation in other clinical trials
70,R22,Has_temporal Arg1:T45 Arg2:T44
71,T46,Condition 844 859	Type 1 diabetes
72,T47,Condition 861 883	Cardiovascular disease
73,T48,Qualifier 884 903	Clinically relevant
74,T49,Condition 904 927	ventricular tachycardia
75,T50,Condition 931 955	ventricular fibrillation
76,T51,Condition 957 976	3rd degree AV block
77,T52,Condition 980 999	Torsades de Pointes
78,T53,Procedure 1003 1012	treatment
79,T54,Drug 1018 1038	antiarrhythmic drugs
80,R23,AND Arg1:T53 Arg2:T54
81,*,OR T52 T51 T49 T50 T53
82,T55,Procedure 1040 1074	Percutaneous coronary intervention
83,T56,Temporal 1075 1099	within the past 6 months
84,R24,Has_temporal Arg1:T55 Arg2:T56
85,T57,"Scope 904 1038	ventricular tachycardia or ventricular fibrillation, 3rd degree AV block or Torsades de Pointes or treatment with antiarrhythmic drugs"
86,R25,Has_qualifier Arg1:T57 Arg2:T48
87,*,OR T57 T55 T63
88,T58,Temporal 1122 1146	within the past 6 months
89,T59,Condition 1148 1174	myocardial infarction (MI)
90,T60,Procedure 1176 1206	coronary artery bypass surgery
91,T61,Condition 1208 1223	unstable angina
92,T62,Condition 1228 1234	stroke
93,*,OR T61 T62 T59 T60
94,T63,"Scope 1148 1234	myocardial infarction (MI), coronary artery bypass surgery; unstable angina; or stroke"
95,R26,Has_temporal Arg1:T63 Arg2:T58
96,T64,"Scope 884 1234	Clinically relevant ventricular tachycardia or ventricular fibrillation, 3rd degree AV block or Torsades de Pointes or treatment with antiarrhythmic drugs. Percutaneous coronary intervention within the past 6 months. Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery; unstable angina; or stroke"
97,R27,Subsumes Arg1:T47 Arg2:T64
98,T65,Condition 1237 1247	Malignancy
99,T66,Condition 1258 1266	leukemia
100,T67,Condition 1271 1279	lymphoma
101,T68,Temporal 1280 1298	within the last 5y
102,*,OR T66 T67
103,T69,Scope 1258 1279	leukemia and lymphoma
104,R28,Subsumes Arg1:T65 Arg2:T69
105,R29,Has_temporal Arg1:T65 Arg2:T68
106,T70,Condition 1301 1314	Liver disease
107,T71,Condition 1323 1332	cirrhosis
108,T72,Condition 1336 1360	chronic active hepatitis
109,*,OR T71 T72
110,T73,Scope 1323 1360	cirrhosis or chronic active hepatitis
111,R30,Subsumes Arg1:T70 Arg2:T73
112,T74,Qualifier 1363 1374	Significant
113,T75,Condition 1375 1392	renal dysfunction
114,R31,Has_qualifier Arg1:T75 Arg2:T74
115,T76,Non-representable 1393 1447	(see also exclusion criteria laboratory abnormalities)
116,T77,Condition 1450 1484	State after kidney transplantation
117,T78,Procedure 1462 1484	kidney transplantation
118,R32,multi Arg1:T78 Arg2:T77
119,T79,Condition 1486 1503	Endocrine disease
120,T80,Measurement 1506 1529	Systolic blood pressure
121,T81,Value 1530 1563	outside the range of 100-160 mmHg
122,R33,Has_value Arg1:T80 Arg2:T81
123,T82,Measurement 1567 1591	diastolic blood pressure
124,T83,Value 1592 1605	above 95 mmHg
125,R34,Has_value Arg1:T82 Arg2:T83
126,T84,Temporal 1606 1618	at Screening
127,*,OR T80 T82
128,T85,Scope 1506 1605	Systolic blood pressure outside the range of 100-160 mmHg or diastolic blood pressure above 95 mmHg
129,R35,Has_temporal Arg1:T85 Arg2:T84
130,T86,Non-representable 1486 1504	Endocrine disease:
131,T87,Observation 1620 1627	History
132,T88,Qualifier 1631 1637	active
133,T89,Condition 1638 1653	substance abuse
134,R36,Has_qualifier Arg1:T89 Arg2:T88
135,R37,Has_temporal Arg1:T89 Arg2:T87
136,T90,Measurement 1665 1672	alcohol
137,T91,Value 1673 1682	> 40g/day
138,R38,Has_value Arg1:T90 Arg2:T91
139,T92,Scope 1665 1682	alcohol > 40g/day
140,R39,Subsumes Arg1:T89 Arg2:T92
141,T93,Temporal 1684 1707	within the past 2 years
142,R40,Has_temporal Arg1:T89 Arg2:T93
143,T94,Condition 1710 1719	Pregnancy
144,T95,Observation 1723 1745	childbearing potential
145,T96,Negation 1746 1753	without
146,T97,Qualifier 1754 1762	adequate
147,T98,Procedure 1763 1776	contraception
148,R41,Has_qualifier Arg1:T98 Arg2:T97
149,R42,Has_negation Arg1:T98 Arg2:T96
150,*,OR T94 T95
151,T99,Procedure 1786 1793	therapy
152,T100,Temporal 1778 1785	Present
153,T101,Drug 1799 1816	systemic steroids
154,R43,Has_temporal Arg1:T99 Arg2:T100
155,R44,AND Arg1:T99 Arg2:T101
156,T102,Condition 1830 1850	psychiatric disorder
157,T103,Drug 1864 1879;1898 1904	anti-depressive agents
158,T104,Drug 1883 1904	anti-psychotic agents
159,T105,Negation 1905 1926	with the exception of
160,T106,Drug 1927 1942	benzodiazepines
161,T107,Drug 1947 1952	SSRIs
162,T108,Drug 1953 1959	SNRI's
163,*,OR T108 T107 T106
164,T109,Scope 1927 1959	benzodiazepines and SSRIs/SNRI's
165,R45,Has_negation Arg1:T109 Arg2:T105
166,*,OR T104 T103
167,T110,Scope 1864 1904	anti-depressive or anti-psychotic agents
168,R46,Has_scope Arg1:T110 Arg2:T109
169,T111,Scope 1864 1959	anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI's
170,R47,Has_scope Arg1:T102 Arg2:T111
171,T112,Observation 2014 2033	unreliable subjects
172,T113,Non-representable 2002 2013	Potentially
173,T114,Observation 2078 2102	unsuitable for the study
174,T115,Non-representable 2045 2071	judged by the investigator
175,*,OR T112 T114
176,T116,Condition 2105 2122	Contraindications
177,T117,Procedure 2127 2159	Magnetic resonance (MR) scanning
178,R48,AND Arg1:T116 Arg2:T117
179,T118,Device 2181 2198	cardiac pacemaker
180,T119,Device 2203 2224	implants out of metal
181,T120,Condition 2228 2242	claustrophobia
182,*,OR T118 T119 T120
183,T121,Scope 2105 2159	Contraindications for Magnetic resonance (MR) scanning
184,T122,Scope 2181 2242	cardiac pacemaker and implants out of metal or claustrophobia
185,R49,Subsumes Arg1:T121 Arg2:T122
0,T1,Person 0 3	Age
1,T2,Value 4 21	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 23 45	Mechanical ventilation
4,T4,Measurement 47 50	IAP
5,T5,Value 51 73	between 12 and 20 mmHg
6,T6,Multiplier 77 114	at least two consecutive measurements
7,T7,Temporal 115 128	within 1-12 h
8,R2,Has_temporal Arg1:T6 Arg2:T7
9,R3,Has_value Arg1:T4 Arg2:T5
10,R4,Has_multiplier Arg1:T4 Arg2:T6
11,T8,Measurement 130 160	Spontaneous breathing activity
12,T9,Procedure 234 242	sedation
13,T10,Qualifier 220 233	Physician-led
14,R5,Has_qualifier Arg1:T9 Arg2:T10
15,T11,Measurement 191 201	RASS score
16,T12,Value 202 218	between 0 and -4
17,T13,Value 164 189	at least 6 breaths/minute
18,R6,Has_value Arg1:T8 Arg2:T13
19,T14,Negation 256 269	as opposed to
20,T15,Qualifier 270 288	nurse-led protocol
21,R7,Has_qualifier Arg1:T10 Arg2:T15
22,R8,Has_negation Arg1:T15 Arg2:T14
0,T1,Parsing_Error 46 48	1.
1,T2,Parsing_Error 87 89	2.
2,T3,Parsing_Error 128 130	3.
3,T4,Parsing_Error 286 288	4.
4,T5,Parsing_Error 353 355	5.
5,T6,Parsing_Error 516 518	6.
6,T7,Parsing_Error 578 580	7.
7,T8,Parsing_Error 613 615	1.
8,T9,Parsing_Error 669 671	2.
9,T10,Parsing_Error 749 751	3.
10,T11,Parsing_Error 802 804	4.
11,T12,Parsing_Error 845 847	8.
12,T13,Parsing_Error 913 915	9.
13,T14,Parsing_Error 1041 1044	10.
14,T15,Parsing_Error 1166 1169	11.
15,T16,Parsing_Error 1291 1294	12.
16,T17,Parsing_Error 1396 1399	13.
17,T18,Parsing_Error 1437 1440	14.
18,T19,Parsing_Error 1478 1481	15.
19,T20,Parsing_Error 1622 1625	16.
20,T21,Parsing_Error 1692 1695	17.
21,T22,Parsing_Error 1725 1728	18.
22,T23,Parsing_Error 1862 1865	19.
23,T24,Parsing_Error 2030 2033	20.
24,T25,Parsing_Error 2076 2079	21.
25,T26,Parsing_Error 2215 2218	22.
26,T27,Parsing_Error 2257 2260	23.
27,T28,Parsing_Error 2309 2312	24.
28,T29,Parsing_Error 0 44	Exclusions Related to Cardiovascular Disease
29,T30,Parsing_Error 475 514	Exclusions Related to Pulmonary Disease
30,T31,Parsing_Error 995 1039	Exclusions Based on Other Medical Conditions
31,T32,Parsing_Error 1814 1860	Exclusions Based on Concomitant Medication Use
32,T33,Parsing_Error 1991 2028	Exclusions Based on Laboratory Values
33,T34,Condition 73 85	hypertension
34,T35,Qualifier 60 72	uncontrolled
35,R1,Has_qualifier Arg1:T34 Arg2:T35
36,T36,Observation 49 56	History
37,R2,Has_temporal Arg1:T34 Arg2:T36
38,T37,Condition 90 112	Persistent hypotension
39,T38,Temporal 113 125	at Screening
40,T39,Reference_point 116 125	Screening
41,R3,Has_index Arg1:T38 Arg2:T39
42,R4,Has_temporal Arg1:T37 Arg2:T38
43,T40,Observation 143 150	history
44,T41,Condition 154 178	left-sided heart disease
45,T42,Condition 209 224	cardiac disease
46,T43,Qualifier 186 208	clinically significant
47,T44,Undefined_semantics 186 208	clinically significant
48,T45,Subjective_judgement 186 208	clinically significant
49,T46,Condition 234 256	pulmonary hypertension
50,T47,Measurement 272 281	WHO Group
51,T48,Value 282 283	2
52,R5,Has_value Arg1:T47 Arg2:T48
53,*,OR T41 T42 T46
54,R6,Has_qualifier Arg1:T42 Arg2:T43
55,R7,AND Arg1:T46 Arg2:T47
56,T49,Scope 154 283	left-sided heart disease and/or clinically significant cardiac disease in which pulmonary hypertension is more likely WHO Group 2
57,R8,Has_temporal Arg1:T49 Arg2:T40
58,T50,Condition 309 322	heart failure
59,T51,Qualifier 295 308	decompensated
60,T52,Qualifier 289 294	Acute
61,R9,Has_qualifier Arg1:T50 Arg2:T51
62,R10,Has_qualifier Arg1:T50 Arg2:T52
63,T53,Temporal 323 350	within 1 month of Screening
64,T54,Reference_point 341 350	Screening
65,R11,Has_index Arg1:T53 Arg2:T54
66,R12,Has_temporal Arg1:T50 Arg2:T53
67,T55,Temporal 375 398	<8 weeks from Screening
68,T56,Temporal 356 362	Recent
69,T57,Reference_point 389 398	Screening
70,R13,Has_index Arg1:T55 Arg2:T57
71,R14,Subsumes Arg1:T56 Arg2:T55
72,T58,Qualifier 403 410	planned
73,T59,Non-query-able 403 410	planned
74,T60,Procedure 425 472	cardiopulmonary rehabilitation exercise program
75,*,OR T58 T56
76,T61,Scope 356 410	Recent initiation (<8 weeks from Screening) or planned
77,R15,Has_scope Arg1:T60 Arg2:T61
78,T62,Condition 540 543	PAH
79,T63,Procedure 555 575	PAH-specific therapy
80,T64,Negation 548 551	not
81,*,OR T63 T64
82,T65,Temporal 519 534	Newly diagnosed
83,R16,Has_temporal Arg1:T62 Arg2:T65
84,T66,Parsing_Error 581 611	Pulmonary hypertension due to:
85,T67,Condition 628 666	congenital systemic-to-pulmonary shunt
86,T68,Qualifier 616 627	Uncorrected
87,R17,Has_qualifier Arg1:T67 Arg2:T68
88,T69,Condition 672 704	Pulmonary veno-occlusive disease
89,T70,Undefined_semantics 672 704	Pulmonary veno-occlusive disease
90,T71,Condition 712 747	pulmonary capillary hemangiomatosis
91,*,OR T71 T69
92,T72,Condition 763 800	pulmonary hypertension of the newborn
93,T73,Qualifier 752 762	Persistent
94,R18,Has_qualifier Arg1:T72 Arg2:T73
95,T74,Measurement 805 832	WHO clinical classification
96,T75,Value 833 843	Groups 2-5
97,R19,Has_value Arg1:T74 Arg2:T75
98,T76,Condition 872 878;903 910	airway disease
99,T77,Condition 886 910	parenchymal lung disease
100,*,OR T76 T77
101,T78,Qualifier 860 871	significant
102,T79,Scope 872 910	airway and/or parenchymal lung disease
103,R20,Has_qualifier Arg1:T79 Arg2:T78
104,T80,Subjective_judgement 860 871	significant
105,T81,Undefined_semantics 860 871	significant
106,T82,Condition 945 957	tuberculosis
107,T83,Condition 961 967;985 992	fungal disease
108,T84,Condition 971 992	mycobacterial disease
109,*,OR T84 T83 T82
110,T85,Multiplier 916 923	Chronic
111,T86,Condition 924 933	infection
112,R21,Has_multiplier Arg1:T86 Arg2:T85
113,T87,Scope 945 992	tuberculosis or fungal or mycobacterial disease
114,T88,Observation 934 944	related to
115,R22,Has_context Arg1:T87 Arg2:T88
116,R23,Has_scope Arg1:T86 Arg2:T87
117,T89,Condition 1094 1111	tuberculosis (TB)
118,T90,Condition 1113 1136	hepatitis B virus (HBV)
119,T91,Condition 1140 1163	hepatitis C virus (HCV)
120,*,OR T90 T91 T89
121,T92,Condition 1053 1063	infections
122,T93,Multiplier 1045 1052	Chronic
123,R24,Has_multiplier Arg1:T92 Arg2:T93
124,T94,"Scope 1094 1163	tuberculosis (TB), hepatitis B virus (HBV) or hepatitis C virus (HCV)"
125,R25,Subsumes Arg1:T92 Arg2:T94
126,T95,Condition 1181 1200	portal hypertension
127,T96,Condition 1204 1225	chronic liver disease
128,T97,Measurement 1246 1277	serology for infection with HCV
129,T98,Measurement 1246 1268;1285 1288	serology for infection HBV
130,T99,Value 1237 1245	positive
131,R26,Has_value Arg1:T98 Arg2:T99
132,R27,Has_value Arg1:T97 Arg2:T99
133,*,OR T98 T97
134,*,OR T95 T96
135,T100,Scope 1237 1288	positive serology for infection with HCV and/or HBV
136,R28,Subsumes Arg1:T96 Arg2:T100
137,T101,Condition 1314 1333;1354 1365	infection requiring antibiotics
138,T102,Undefined_semantics 1314 1333;1354 1365	infection requiring antibiotics
139,T103,Subjective_judgement 1314 1333;1354 1365	infection requiring antibiotics
140,T104,Temporal 1366 1393	within 4 weeks of Screening
141,T105,Reference_point 1384 1393	Screening
142,R29,Has_index Arg1:T104 Arg2:T105
143,R30,Has_temporal Arg1:T101 Arg2:T104
144,T106,Measurement 1400 1415	Body mass index
145,T107,Value 1416 1421	≥35.0
146,R31,Has_value Arg1:T106 Arg2:T107
147,T108,Temporal 1422 1434	at Screening
148,T109,Reference_point 1425 1434	Screening
149,R32,Has_index Arg1:T108 Arg2:T109
150,R33,Has_temporal Arg1:T106 Arg2:T108
151,T110,Condition 1452 1475	obstructive sleep apnea
152,T111,Observation 1441 1448	History
153,R34,Has_temporal Arg1:T110 Arg2:T111
154,T112,Condition 1493 1503	malignancy
155,T113,Undefined_semantics 1493 1503	malignancy
156,T114,Temporal 1504 1527	within the last 5 years
157,R35,Has_temporal Arg1:T112 Arg2:T114
158,T115,Observation 1482 1489	History
159,R36,Has_temporal Arg1:T112 Arg2:T115
160,T116,Condition 1536 1559	nonmelanoma skin cancer
161,T117,Negation 1529 1535	except
162,T118,Condition 1564 1590	cervical carcinoma in situ
163,T119,Procedure 1591 1598	treated
164,T120,Qualifier 1604 1619	curative intent
165,R37,Has_qualifier Arg1:T119 Arg2:T120
166,R38,AND Arg1:T118 Arg2:T119
167,R39,Has_negation Arg1:T118 Arg2:T117
168,R40,Has_negation Arg1:T116 Arg2:T117
169,T121,Condition 1626 1652	Neuropsychiatric disorders
170,T122,Undefined_semantics 1626 1652	Neuropsychiatric disorders
171,T123,Condition 1665 1689	psychological conditions
172,T124,Condition 1626 1642;1653 1661	Neuropsychiatric symptoms
173,T125,Undefined_semantics 1626 1642;1653 1661	Neuropsychiatric symptoms
174,T126,Undefined_semantics 1665 1689	psychological conditions
175,*,OR T124 T121 T123
176,T127,Condition 1696 1705	Pregnancy
177,T128,Condition 1709 1723	breast-feeding
178,*,OR T127 T128
179,T129,Drug 1750 1756;1770 1787	B cell -depleting agents
180,T130,Drug 1760 1787	lymphocyte-depleting agents
181,T131,Drug 1793 1802	rituximab
182,T132,Drug 1804 1811	Campath
183,*,OR T131 T132
184,T133,"Scope 1793 1811	rituximab, Campath"
185,T134,Scope 1750 1787	B cell or lymphocyte-depleting agents
186,*,OR T129 T130
187,R41,Subsumes Arg1:T134 Arg2:T133
188,T135,Temporal 1729 1734	Prior
189,R42,Has_temporal Arg1:T134 Arg2:T135
190,T136,Drug 1900 1929	leukotriene pathway inhibitor
191,T137,Qualifier 1892 1899	another
192,T138,Context_Error 1892 1899	another
193,R43,Has_qualifier Arg1:T136 Arg2:T137
194,T139,Multiplier 1877 1888	regular use
195,R44,Has_multiplier Arg1:T136 Arg2:T139
196,T140,Undefined_semantics 1941 1988	over-the-counter medications or herbal remedies
197,T141,Temporal 1866 1876	Concurrent
198,R45,Has_temporal Arg1:T136 Arg2:T141
199,T142,Condition 2046 2073	chronic renal insufficiency
200,T143,Qualifier 2034 2045	Significant
201,T144,Subjective_judgement 2034 2045	Significant
202,R46,Has_qualifier Arg1:T142 Arg2:T143
203,T145,Measurement 2095 2115	alanine transaminase
204,T146,Measurement 2117 2139	aspartate transaminase
205,T147,Value 2148 2180	>3 × upper limit of normal (ULN)
206,T148,Measurement 2080 2093;2141 2147	Transaminases levels
207,T149,"Scope 2095 2139	alanine transaminase, aspartate transaminase"
208,R47,Subsumes Arg1:T148 Arg2:T149
209,R48,Has_value Arg1:T148 Arg2:T147
210,T150,Measurement 2188 2203	bilirubin level
211,T151,Value 2204 2212	>2 × ULN
212,R49,Has_value Arg1:T150 Arg2:T151
213,T152,Measurement 2219 2244	Absolute neutrophil count
214,T153,Value 2245 2254	<1500 mm3
215,R50,Has_value Arg1:T152 Arg2:T153
216,T154,Measurement 2261 2285	Hemoglobin concentration
217,T155,Value 2286 2293	<9 g/dL
218,R51,Has_value Arg1:T154 Arg2:T155
219,T156,Temporal 2294 2306	at Screening
220,T157,Reference_point 2297 2306	Screening
221,R52,Has_index Arg1:T156 Arg2:T157
222,R53,Has_temporal Arg1:T154 Arg2:T156
223,T158,Condition 2313 2332	Hepatic dysfunction
224,T159,Measurement 2347 2357	Child-Pugh
225,T160,Value 2358 2370	Class B or C
226,R54,Has_value Arg1:T159 Arg2:T160
227,R55,AND Arg1:T158 Arg2:T159
0,T1,Condition 26 40	CNS metastases
1,T2,Condition 44 70	leptomeningeal involvement
2,*,OR T1 T2
3,T5,Procedure 144 151	treated
4,T6,Qualifier 164 179	been stable for
5,T7,Temporal 180 220	at least six months prior to study start
6,R1,Has_temporal Arg1:T6 Arg2:T7
7,*,OR T5 T6
8,T4,Condition 92 108	brain metastases
9,T8,Observation 238 248	history of
10,T9,Condition 249 265	brain metastases
11,R3,AND Arg1:T8 Arg2:T9
12,T10,Procedure 278 299	head CT with contrast
13,T11,Scope 238 265	history of brain metastases
14,A1,Optional T11
15,R4,AND Arg1:T11 Arg2:T10
16,T12,Condition 359 374	bone metastases
17,T13,Procedure 432 464	hepatic artery chemoembolization
18,T14,Temporal 465 489	within the last 6 months
19,T15,Temporal 491 500	one month
20,T16,Observation 514 547	other sites of measurable disease
21,R5,Has_context Arg1:T15 Arg2:T16
22,*,OR T14 T15
23,T17,Scope 465 547	within the last 6 months (one month if there are other sites of measurable disease
24,R6,Has_scope Arg1:T13 Arg2:T17
25,T18,Procedure 597 627	radioactive directed therapies
26,T19,Drug 676 686	epothilone
27,T20,Condition 706 727	peripheral neuropathy
28,T21,Condition 731 750	unresolved diarrhea
29,T22,Measurement 764 769	Grade
30,T23,Value 751 763;770 771	greater than 1
31,R7,AND Arg1:T21 Arg2:T22
32,R8,Has_value Arg1:T22 Arg2:T23
33,*,OR T20 T21
34,T24,Condition 787 815	severe cardiac insufficiency
35,T25,Drug 832 840	Coumadin
36,T26,Drug 850 876	warfarin-containing agents
37,*,OR T25 T26
38,R9,AND Arg1:T24 Arg2:T25
39,T27,Qualifier 899 907	low dose
40,T28,Drug 908 916	warfarin
41,T29,Multiplier 918 930	1 mg or less
42,*,OR T29 T27
43,R10,Has_qualifier Arg1:T28 Arg2:T27
44,T30,Device 955 972	in-dwelling lines
45,T31,Device 955 966;976 981	in-dwelling ports
46,*,OR T30 T31
47,T32,Scope 787 931	severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less)
48,R11,AND Arg1:T32 Arg2:T30
49,T34,Condition 1037 1055	another malignancy
50,T35,Temporal 1056 1091	within 5 years prior to study entry
51,T36,Scope 832 876	Coumadin or other warfarin-containing agents
52,R13,Has_temporal Arg1:T34 Arg2:T35
53,T37,Condition 1118 1142	non-melanoma skin cancer
54,T38,Qualifier 1099 1117	curatively treated
55,T39,Condition 1144 1159	prostate cancer
56,T40,Condition 1164 1187	cervical cancer in situ
57,*,OR T37 T39 T40
58,T41,"Scope 1118 1187	non-melanoma skin cancer, prostate cancer, or cervical cancer in situ"
59,R14,Has_qualifier Arg1:T41 Arg2:T38
60,T42,Observation 1026 1036	history of
61,R16,Has_temporal Arg1:T34 Arg2:T42
62,T43,Condition 1240 1262	uncontrolled infection
63,T44,Condition 1273 1281	abcesses
64,T45,Condition 1285 1293	fistulae
65,T46,Scope 1273 1293	abcesses or fistulae
66,*,OR T44 T45
67,R17,Subsumes Arg1:T43 Arg2:T46
68,T47,Qualifier 1203 1209	active
69,T48,Qualifier 1213 1222	suspected
70,*,OR T47 T48
71,T49,Qualifier 1223 1228	acute
72,T50,Qualifier 1232 1239	chronic
73,*,OR T49 T50
74,T51,Scope 1203 1239	active or suspected acute or chronic
75,R18,Has_scope Arg1:T43 Arg2:T51
76,T52,Condition 1322 1341	psychiatric illness
77,T53,Condition 1311 1318;1334 1341	medical illness
78,*,OR T53 T52
79,T54,Observation 1353 1367	preclude study
80,T55,Observation 1371 1387	informed consent
81,T56,Observation 1406 1439	noncompliance to medical regimens
82,T57,Observation 1443 1452;1470 1504	inability to return for all scheduled visits
83,T58,Observation 1456 1503	unwillingness to return for all scheduled visit
84,*,OR T57 T58 T56 T54 T55
85,T59,Scope 1347 1504	would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits
86,R19,Has_scope Arg1:T53 Arg2:T59
87,R2,AND Arg1:T4 Arg2:T5
88,T60,Condition 1506 1510	HIV+
89,T61,Measurement 1506 1509	HIV
90,T62,Value 1509 1510	+
91,R20,Has_value Arg1:T61 Arg2:T62
92,T63,Condition 1521 1529	Pregnant
93,T64,Condition 1533 1542	lactating
94,R21,multi Arg1:T60 Arg2:T61
95,*,OR T64 T63
96,T65,Qualifier 14 25	symptomatic
97,R22,Has_qualifier Arg1:T1 Arg2:T65
98,R23,Has_qualifier Arg1:T2 Arg2:T65
99,T3,Negation 877 898	with the exception of
100,R12,Has_negation Arg1:T28 Arg2:T3
101,R24,AND Arg1:T36 Arg2:T28
102,T66,Negation 1092 1098	except
103,T33,Non-representable 983 1025	Patients taking any experimental therapies
104,R15,Has_negation Arg1:T41 Arg2:T66
105,R25,Has_scope Arg1:T34 Arg2:T41
106,T67,Temporal 652 662	previously
107,R26,Has_temporal Arg1:T19 Arg2:T67
108,T68,Temporal 573 583	previously
109,R27,Has_temporal Arg1:T18 Arg2:T68
110,T69,Multiplier 382 416	only site(s) of measurable disease
111,R28,AND Arg1:T69 Arg2:T12
112,T70,Negation 110 116	unless
113,R29,Has_negation Arg1:T5 Arg2:T70
0,T1,Measurement 0 25	planned surgical duration
1,T2,Value 26 43	more than 3 hours
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 45 61	contraindication
4,T4,Procedure 65 83	spinal anaesthesia
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Qualifier 85 91	severe
7,T6,Condition 92 111	respiratory disease
8,R3,Has_qualifier Arg1:T6 Arg2:T5
9,T7,Condition 143 163	sleep apnea syndrome
10,T8,Procedure 131 138	treated
11,R4,AND Arg1:T8 Arg2:T7
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,T3,Value 28 42	20 to 80 years
3,T4,Person 46 49	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Temporal 50 62	at screening
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,*,OR T2 T1
8,T6,Mood 65 74	Scheduled
9,T7,Procedure 97 112	open-laparotomy
10,T8,Mood 78 88	electively
11,R3,Has_mood Arg1:T7 Arg2:T8
12,R4,Has_mood Arg1:T7 Arg2:T6
13,T9,Measurement 115 164	American Society of Anesthesiology Physical Class
14,T10,Value 165 168	1-3
15,R5,Has_value Arg1:T9 Arg2:T10
16,T11,Informed_consent 171 222	Ability and willingness to provide informed consent
0,T1,Condition 0 16	Contraindication
1,T2,Drug 21 29	propofol
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 46 62	Contraindication
4,T4,Procedure 67 82	IAP measurement
5,T5,Qualifier 86 101	supine position
6,T6,Qualifier 107 124	head-of-bed at 0°
7,R2,Has_qualifier Arg1:T4 Arg2:T5
8,R3,Has_qualifier Arg1:T4 Arg2:T6
9,R4,AND Arg1:T3 Arg2:T4
10,T7,Qualifier 126 131	Other
11,T8,Procedure 132 165	intervention for reduction of IAP
12,T9,Mood 166 173	planned
13,R5,Has_mood Arg1:T8 Arg2:T9
14,R6,Has_qualifier Arg1:T8 Arg2:T7
15,T10,Temporal 175 183	Previous
16,T11,Measurement 184 206	propofol infusion rate
17,T12,Value 207 217	>4 mg/kg/h
18,R7,Has_value Arg1:T11 Arg2:T12
19,R8,Has_temporal Arg1:T11 Arg2:T10
0,T1,Condition 28 55	metastatic carcinoid tumors
1,T2,Value 21 27	proven
2,T3,Procedure 14 20	biopsy
3,R1,Has_value Arg1:T3 Arg2:T2
4,R2,AND Arg1:T1 Arg2:T3
5,T4,Condition 59 86	other neuroendocrine tumors
6,T5,Condition 88 98	Islet cell
7,T6,Condition 100 111	Gastrinomas
8,T7,Condition 116 123	VIPomas
9,T8,"Scope 88 123	Islet cell, Gastrinomas and VIPomas"
10,*,OR T5 T6 T7
11,R3,Subsumes Arg1:T4 Arg2:T8
12,*,OR T1 T4
13,T9,Condition 143 160	measurable lesion
14,T10,Qualifier 173 177	bone
15,T11,"Scope 14 124	biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas)"
16,T12,Procedure 215 225	irradiated
17,T13,Procedure 243 253	irradiated
18,T14,Observation 271 282	progression
19,T15,Procedure 293 310	radiation therapy
20,T16,Temporal 283 310	since the radiation therapy
21,R6,Has_temporal Arg1:T14 Arg2:T16
22,T18,Negation 195 203	not been
23,R5,Has_negation Arg1:T12 Arg2:T18
24,R7,Has_context Arg1:T13 Arg2:T14
25,*,OR T12 T13
26,R9,AND Arg1:T11 Arg2:T9
27,T17,Scope 195 310	not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy
28,R8,Has_scope Arg1:T9 Arg2:T17
29,T19,Condition 331 356;368 376	major impairment of renal function
30,T20,Condition 331 350;360 376	major impairment of hepatic function
31,T21,Negation 328 330	no
32,T22,Scope 331 376	major impairment of renal or hepatic function
33,R10,Has_negation Arg1:T22 Arg2:T21
34,T23,Measurement 429 444	total bilirubin
35,T24,Value 445 455	<1.5 X ULN
36,T25,Measurement 457 460	AST
37,T26,Measurement 462 465	ALT
38,T27,Value 465 474	<2.5X ULN
39,T28,Condition 488 504	liver metastases
40,T29,Value 476 484	<5 X ULN
41,R11,AND Arg1:T29 Arg2:T28
42,*,OR T27 T29
43,R12,Has_value Arg1:T26 Arg2:T27
44,R13,Has_value Arg1:T25 Arg2:T27
45,R14,Has_value Arg1:T23 Arg2:T24
46,T30,"Scope 457 517	AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)"
47,*,OR T23 T30
48,T31,"Scope 429 517	total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)"
49,R15,Subsumes Arg1:T22 Arg2:T31
50,T32,Drug 531 546	Sandostatin Lar
51,T33,Drug 548 581	long acting somatostatin analogue
52,R16,Subsumes Arg1:T32 Arg2:T33
53,T34,Qualifier 596 607	stable dose
54,T35,Temporal 608 640	for 30 days prior to study entry
55,T36,Drug 645 680	short acting somatostatin analogues
56,T37,Qualifier 707 729	clinically stable dose
57,T38,Temporal 750 770	prior to study entry
58,R17,Has_temporal Arg1:T37 Arg2:T38
59,R18,Has_qualifier Arg1:T32 Arg2:T34
60,R19,Has_temporal Arg1:T34 Arg2:T35
61,A1,Optional T32
62,A2,Optional T36
63,R20,Has_qualifier Arg1:T36 Arg2:T37
64,T39,Observation 784 799	life expectancy
65,T40,Value 803 832	greater than three (3) months
66,R21,Has_value Arg1:T39 Arg2:T40
67,T41,Measurement 834 862	Karnofsky Performance Status
68,T42,Value 863 867	> 60
69,R22,Has_value Arg1:T41 Arg2:T42
70,T43,Person 869 875	Female
71,T44,Measurement 906 926	serum pregnancy test
72,T45,Value 897 905	negative
73,R23,Has_value Arg1:T44 Arg2:T45
74,T46,Temporal 927 939	at screening
75,R24,Has_temporal Arg1:T44 Arg2:T46
76,A3,Optional T43
77,R25,AND Arg1:T43 Arg2:T44
78,T47,Procedure 974 996	bilateral oophorectomy
79,T48,Procedure 1004 1016	hysterectomy
80,T49,Condition 1046 1060	postmenopausal
81,*,OR T47 T48 T49
82,T51,Scope 974 1060	bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal
83,T50,Scope 974 1060	bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal
84,T52,Scope 897 939	negative serum pregnancy test at screening
85,*,OR T52 T50
86,T53,Reference_point 293 310	radiation therapy
87,R26,multi Arg1:T53 Arg2:T15
88,R27,Has_index Arg1:T16 Arg2:T53
89,T54,Negation 162 172	other than
90,R4,Has_negation Arg1:T10 Arg2:T54
91,R28,Has_qualifier Arg1:T9 Arg2:T10
92,*,OR T19 T20
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 37 39	2.
2,T3,Parsing_Error 77 79	3.
3,T4,Parsing_Error 155 157	1.
4,T5,Parsing_Error 215 217	2.
5,T6,Parsing_Error 470 472	3.
6,T7,Parsing_Error 543 545	4.
7,T8,Parsing_Error 577 579	5.
8,T9,Parsing_Error 856 858	6.
9,T10,Parsing_Error 919 921	7.
10,T11,Person 3 7	Male
11,T12,Person 11 17	female
12,*,OR T12 T11
13,T13,Value 19 30	18-75 years
14,T14,Person 25 34	years old
15,R1,Has_value Arg1:T14 Arg2:T13
16,T15,Measurement 59 68	WHO Group
17,T16,Value 69 70	1
18,R2,Has_value Arg1:T15 Arg2:T16
19,T17,Condition 71 74	PAH
20,R3,AND Arg1:T17 Arg2:T15
21,T18,Procedure 80 107	Right heart catheterization
22,T19,Parsing_Error 80 153	Right heart catheterization performed at Screening with results that are:
23,T20,Temporal 108 130	performed at Screening
24,T21,Reference_point 121 130	Screening
25,R4,Has_index Arg1:T20 Arg2:T21
26,R5,Has_temporal Arg1:T18 Arg2:T20
27,T22,Measurement 158 190	Mean pulmonary arterial pressure
28,T23,Value 191 199	≥25 mmHg
29,R6,Has_value Arg1:T22 Arg2:T23
30,T24,Qualifier 201 208	at rest
31,R7,Has_qualifier Arg1:T22 Arg2:T24
32,T25,Condition 218 247	Pulmonary venous hypertension
33,T26,Measurement 261 302	pulmonary capillary wedge pressure (PCWP)
34,T27,Value 303 311	≤15 mmHg
35,R8,Has_value Arg1:T26 Arg2:T27
36,R9,AND Arg1:T25 Arg2:T26
37,T28,Condition 344 369	mean left atrial pressure
38,T29,Condition 373 412	left ventricular end-diastolic pressure
39,T30,Value 413 421	≤15 mmHg
40,R10,Has_value Arg1:T29 Arg2:T30
41,R11,Has_value Arg1:T28 Arg2:T30
42,*,OR T29 T28
43,T31,Negation 429 436	absence
44,T32,Condition 440 463	left atrial obstruction
45,R12,Has_negation Arg1:T32 Arg2:T31
46,T33,Condition 473 508	Pulmonary vascular resistance (PVR)
47,T34,Value 509 523	≥300 dyn•s/cm5
48,T35,Value 525 540	3.75 Wood units
49,R13,Subsumes Arg1:T34 Arg2:T35
50,R14,Has_value Arg1:T33 Arg2:T34
51,T36,Measurement 550 561	WHO/NYHA-FC
52,T37,Value 565 567	II
53,T38,Value 571 574	III
54,*,OR T38 T37
55,T39,Scope 565 574	II or III
56,R15,Has_scope Arg1:T36 Arg2:T39
57,T40,Qualifier 586 597	stable dose
58,T41,Multiplier 601 613	at least one
59,T42,Procedure 631 653	PAH-specific therapies
60,T43,Drug 655 685	endothelin receptor antagonist
61,T44,Drug 690 730	agent acting on the nitric oxide pathway
62,T45,Drug 732 766	phosphodiesterase type 5 inhibitor
63,T46,Drug 770 806	soluble guanylate cyclase stimulator
64,*,OR T46 T45
65,T47,Scope 732 806	phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator
66,R16,Subsumes Arg1:T44 Arg2:T47
67,T48,Drug 818 830;847 853	prostacyclin analog
68,T49,Drug 834 853	prostacyclin analog
69,*,OR T43 T44 T49 T48
70,T50,"Scope 655 853	endothelin receptor antagonist, an agent acting on the nitric oxide pathway (phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator), and/or a prostacyclin or prostacyclin analog"
71,R17,Subsumes Arg1:T42 Arg2:T50
72,R18,Has_multiplier Arg1:T42 Arg2:T41
73,R19,Has_qualifier Arg1:T42 Arg2:T40
74,T51,Measurement 865 887	6-minute walk distance
75,T52,Value 896 916	≥150 and ≤500 meters
76,R20,Has_value Arg1:T51 Arg2:T52
77,T53,Procedure 929 955	ventilation-perfusion scan
78,T54,Condition 971 993	thromboembolic disease
79,T56,Negation 961 970	rules out
80,R21,Has_negation Arg1:T54 Arg2:T56
81,R22,AND Arg1:T54 Arg2:T53
0,T1,Measurement 0 15	physical status
1,T2,Value 16 23	I - III
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 55 71	hip arthroplasty
4,T4,Mood 34 54	scheduled to undergo
5,R2,Has_mood Arg1:T3 Arg2:T4
0,T1,Measurement 0 15	Body mass index
1,T2,Value 16 34	less than 18 kg/m2
2,T3,Value 38 59	greater than 30 kg/m2
3,*,OR T2 T3
4,T4,Scope 16 59	less than 18 kg/m2 or greater than 30 kg/m2
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Procedure 82 97	open-laparotomy
7,T6,Temporal 73 81	previous
8,R2,Has_temporal Arg1:T5 Arg2:T6
9,T7,Observation 62 69	History
10,R3,Has_temporal Arg1:T5 Arg2:T7
11,T8,Condition 113 131	major complication
12,T9,Procedure 100 107	Surgery
13,T10,Mood 136 140	need
14,T11,Condition 141 158	blood transfusion
15,R4,Has_mood Arg1:T11 Arg2:T10
16,*,OR T8 T11
17,T12,"Scope 113 158	major complication, or need blood transfusion"
18,R5,Has_scope Arg1:T9 Arg2:T12
19,T13,Condition 172 188	hypersensitivity
20,T14,Condition 192 208	adverse reaction
21,T15,Drug 212 229	local anesthetics
22,T16,Drug 231 237	opioid
23,T17,Drug 246 302	ingredient of the medications administered in this study
24,*,OR T16 T15 T17
25,T18,"Scope 212 302	local anesthetics, opioid, or any ingredient of the medications administered in this study"
26,*,OR T14 T13
27,T19,Scope 172 208	hypersensitivity or adverse reaction
28,R6,Has_scope Arg1:T19 Arg2:T18
29,T20,Condition 312 323	comorbidity
30,T21,Qualifier 305 311	Severe
31,R7,Has_qualifier Arg1:T20 Arg2:T21
32,T22,Qualifier 326 333	Chronic
33,T23,Temporal 334 346	preoperative
34,T24,Drug 347 353	opioid
35,R8,Has_temporal Arg1:T24 Arg2:T23
36,R9,Has_qualifier Arg1:T24 Arg2:T22
37,T25,Condition 368 376	Pregnant
38,T26,Observation 380 393	breastfeeding
39,T27,Condition 396 405	Inability
40,T28,Procedure 409 420	use the PCA
41,R10,AND Arg1:T27 Arg2:T28
42,*,OR T25 T26
0,T1,Negation 29 41	discontinued
1,T2,Multiplier 17 28	permanently
2,R1,Has_multiplier Arg1:T1 Arg2:T2
3,T3,Drug 47 56	nilotinib
4,T4,Procedure 57 66	treatment
5,R2,AND Arg1:T4 Arg2:T3
6,R3,Has_negation Arg1:T4 Arg2:T1
7,T5,Condition 94 115	unacceptable toxicity
8,T6,Observation 117 131	non-compliance
9,T7,Procedure 135 151	study procedures
10,R4,AND Arg1:T6 Arg2:T7
11,T8,Negation 153 163	withdrawal
12,T9,Observation 167 174	consent
13,R5,Has_negation Arg1:T9 Arg2:T8
14,T10,Observation 178 194	any other reason
15,*,OR T9 T10 T5 T6
16,T11,"Scope 94 194	unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason"
17,R6,Has_scope Arg1:T4 Arg2:T11
18,T12,Qualifier 225 243	Novartis sponsored
19,T13,Observation 207 224;244 261	participated in a combination trial
20,T14,Non-representable 195 387	Patient has participated in a Novartis sponsored combination trial where nilotinib was dispensed in combination with another study medication and patient is still receiving combination therapy
21,T15,Procedure 425 434	treatment
22,T16,Temporal 405 414	currently
23,R7,Has_temporal Arg1:T15 Arg2:T16
24,T17,Drug 440 455	any medications
25,T18,Qualifier 461 506	have the potential to prolong the QT interval
26,T19,Qualifier 510 537	inducing Torsade de Pointes
27,*,OR T18 T19
28,T20,Scope 461 537	have the potential to prolong the QT interval or inducing Torsade de Pointes
29,R8,Has_scope Arg1:T17 Arg2:T20
30,R9,AND Arg1:T15 Arg2:T17
31,T21,Non-representable 542 749	the treatment cannot be either safely discontinued at least one week prior to nilotinib treatment or switched to a different medication prior to start of nilotinib treatment and for the duration of the study
32,T22,Observation 750 758	Pregnant
33,T23,Observation 762 769	nursing
34,T24,Person 782 787	women
35,*,OR T23 T22
36,T25,Observation 771 780	lactating
37,R10,Subsumes Arg1:T23 Arg2:T25
38,T26,Observation 922 941	hcG laboratory test
39,T27,Value 913 921	positive
40,R11,Has_value Arg1:T26 Arg2:T27
41,R12,Has_context Arg1:T22 Arg2:T26
42,T28,Person 943 948	Women
43,T29,Observation 952 975	child-bearing potential
44,T30,Observation 998 1042	physiologically capable of becoming pregnant
45,T31,Person 992 997	women
46,T32,Negation 1044 1050	unless
47,T33,Qualifier 1066 1090	highly effective methods
48,T34,Observation 1094 1107	contraception
49,T35,Temporal 1108 1124	during the study
50,T36,Temporal 1129 1174	for 30 days after the final dose of nilotinib
51,T37,Reference_point 1147 1174	the final dose of nilotinib
52,R13,Has_index Arg1:T36 Arg2:T37
53,T38,Scope 1108 1174	during the study and for 30 days after the final dose of nilotinib
54,R14,Has_scope Arg1:T34 Arg2:T38
55,R15,Has_qualifier Arg1:T34 Arg2:T33
56,R16,Has_negation Arg1:T34 Arg2:T32
57,T39,"Scope 992 1174	women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 30 days after the final dose of nilotinib"
58,T40,Scope 943 975	Women of child-bearing potential
59,R17,Subsumes Arg1:T40 Arg2:T39
0,T1,Condition 0 30	Paroxysmal atrial fibrillation
1,T2,Condition 71 90	atrial fibrillation
2,T3,Qualifier 47 57	persistent
3,T4,Qualifier 61 70	permanent
4,*,OR T4 T3
5,T5,Scope 47 70	persistent or permanent
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Device 102 124	pacemaker implantation
8,T7,Procedure 136 151	atrial ablation
9,T8,Mood 165 179	unable to take
10,T9,Drug 180 188	warfarin
11,T10,Drug 198 228	oral anti-coagulant medication
12,*,OR T9 T10
13,T11,Scope 180 228	warfarin or other oral anti-coagulant medication
14,R2,Has_mood Arg1:T11 Arg2:T8
15,T12,Condition 257 272	unstable angina
16,T13,Temporal 276 289	last one week
17,R3,Has_temporal Arg1:T12 Arg2:T13
18,T14,Condition 310 331	myocardial infarction
19,T15,Temporal 339 354	last two months
20,R4,Has_temporal Arg1:T14 Arg2:T15
21,T16,Procedure 389 410	major cardiac surgery
22,T17,Temporal 418 433	last two months
23,R5,Has_temporal Arg1:T16 Arg2:T17
24,T18,Competing_trial 436 483	Patient is participating in a conflicting study
25,T19,Post-eligibility 486 531	Patient is unable to perform exercise testing
26,T20,Post-eligibility 534 611	Patient is mentally incapacitated and cannot consent or comply with follow-up
27,T21,Measurement 626 652	New York Heart Association
28,T22,Measurement 654 658	NYHA
29,T23,Value 660 672	class III/IV
30,R6,Subsumes Arg1:T21 Arg2:T22
31,R7,Has_value Arg1:T21 Arg2:T23
32,T24,Condition 673 686	heart failure
33,R8,AND Arg1:T24 Arg2:T21
34,T25,Measurement 701 735	left ventricular ejection fraction
35,T26,Measurement 737 741	LVEF
36,R9,Subsumes Arg1:T25 Arg2:T26
37,T27,Value 743 756	less than 35%
38,R10,Has_value Arg1:T25 Arg2:T27
39,T28,Mood 757 773	not secondary to
40,T29,Condition 774 785	tachycardia
41,R11,Has_mood Arg1:T29 Arg2:T28
42,T30,Condition 788 797	Pregnancy
43,T31,Condition 827 851	cardiac rhythm disorders
44,T32,Qualifier 821 826	other
45,R12,Has_qualifier Arg1:T31 Arg2:T32
46,T33,Procedure 861 889	coronary artery intervention
0,T1,Condition 37 56	atrial fibrillation
1,T2,Qualifier 26 36	persistent
2,T3,Qualifier 14 25	symptomatic
3,R1,Has_qualifier Arg1:T1 Arg2:T3
4,R2,Has_qualifier Arg1:T1 Arg2:T2
5,T4,Temporal 60 76	less than 1-year
6,R3,Has_temporal Arg1:T1 Arg2:T4
7,T5,Person 119 122	old
8,T6,Value 105 118	over 65 years
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Informed_consent 125 192	Patients give informed consent prior to participating in this study
0,T1,Temporal 11 20	currently
1,T3,Qualifier 35 53	Novartis-sponsored
2,T4,Observation 21 34;55 108	enrolled in a Oncology Clinical Development & Medical Affairs study
3,R1,Has_qualifier Arg1:T4 Arg2:T3
4,R2,Has_temporal Arg1:T4 Arg2:T1
5,T2,Drug 119 128	nilotinib
6,T5,Non-representable 133 189	has fulfilled all their requirements in the parent study
7,T6,Procedure 232 241	treatment
8,T7,Drug 247 256	nilotinib
9,R3,AND Arg1:T6 Arg2:T7
10,T8,Non-representable 258 291	as determined by the investigator
11,T9,Temporal 202 211	currently
12,R4,Has_temporal Arg1:T6 Arg2:T9
13,T10,Observation 318 328;363 406	compliance with the parent study protocol requirements
14,T11,Non-representable 330 361	as assessed by the investigator
15,T12,Observation 408 419;432 463	Willingness to comply with scheduled visits
16,T13,Observation 424 463	ability to comply with scheduled visits
17,T14,Observation 408 419;432 446;465 480	Willingness to comply with treatment plans
18,T15,Observation 513 537	Written informed consent
19,T16,Temporal 547 584	prior to enrolling in roll-over study
20,T17,Reference_point 556 584	enrolling in roll-over study
21,R5,Has_index Arg1:T16 Arg2:T17
22,R6,Has_temporal Arg1:T15 Arg2:T16
0,T1,Pregnancy_considerations 0 145	Pregnancy (a negative serum or urine pregnancy test should be available for women of child-bearing potential before study inclusion) or lactation
1,T2,Pregnancy_considerations 147 288	Women of childbearing potential who do not practice a medically accepted highly effective contraception during the trial and one month beyond
2,T3,Non-query-able 290 501	History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
3,T4,Competing_trial 503 608	Participation in another clinical trial during the present clinical trial or within the last three months
4,T5,Informed_consent 610 721	Medical or psychological condition that would not permit completion of the trial or signing of informed consent
5,T6,Drug 732 750	fibrinolytic agent
6,T7,"Procedure 752 774	surgical thrombectomy,"
7,T8,Procedure 810 829	thrombus aspiration
8,T9,Procedure 810 818;833 838	thrombus lysis
9,T10,Procedure 852 863	cava filter
10,T11,Condition 894 896	PE
11,T12,"Scope 732 863	fibrinolytic agent, surgical thrombectomy, interventional (catheter-directed) thrombus aspiration or lysis, or use of a cava filter"
12,*,OR T6 T7 T8 T9 T10
13,R1,AND Arg1:T12 Arg2:T11
14,T13,Drug 939 952	anticoagulant
15,T14,Qualifier 917 932	therapeutically
16,R2,Has_qualifier Arg1:T13 Arg2:T14
17,T15,Temporal 957 994	more than 48 hours prior to enrolment
18,T16,Reference_point 985 994	enrolment
19,R3,Has_index Arg1:T15 Arg2:T16
20,R4,Has_temporal Arg1:T13 Arg2:T15
21,T17,Qualifier 1005 1014	long-term
22,T18,Drug 1032 1060	low molecular weight heparin
23,T19,Drug 1062 1083	vitamin K antagonists
24,T20,Drug 1087 1091	NOAC
25,T21,Condition 1132 1142	PE episode
26,T22,Drug 1151 1170	antiplatelet agents
27,T23,Negation 1171 1177	except
28,T24,Negation 1111 1116	other
29,T25,Qualifier 1126 1131	index
30,R5,Has_qualifier Arg1:T21 Arg2:T25
31,R6,Has_negation Arg1:T21 Arg2:T24
32,*,OR T18 T19 T20
33,T26,"Scope 1033 1091	ow molecular weight heparin, vitamin K antagonists or NOAC"
34,R8,AND Arg1:T26 Arg2:T21
35,T27,Drug 1178 1198	acetylsalicylic acid
36,T28,Multiplier 1211 1223	=100 mg/day;
37,R10,Has_negation Arg1:T27 Arg2:T23
38,R9,Has_multiplier Arg1:T22 Arg2:T28
39,T29,Scope 1151 1222	antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day
40,T30,"Scope 1032 1223	low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage =100 mg/day;"
41,R7,Has_qualifier Arg1:T30 Arg2:T17
42,*,OR T26 T29
43,T31,Condition 1225 1240	Active bleeding
44,T32,Observation 1262 1275	bleeding risk
45,T33,Qualifier 1250 1261	significant
46,R11,Has_qualifier Arg1:T32 Arg2:T33
47,*,OR T31 T32
48,T34,Condition 1283 1305	gastrointestinal ulcer
49,T35,Condition 1307 1326	malignant neoplasms
50,T36,Condition 1328 1336	injuries
51,T37,Procedure 1347 1356	surgeries
52,T38,Qualifier 1364 1369	brain
53,T39,Qualifier 1371 1382	spinal cord
54,T40,Qualifier 1386 1390	eyes
55,*,OR T38 T39 T40
56,T41,"Scope 1364 1390	brain, spinal cord or eyes"
57,T42,Condition 1399 1421	intracranial bleedings
58,T43,Condition 1442 1459	esophagus varices
59,T44,Condition 1461 1470	aneurysms
60,T45,Condition 1502 1525	vascular abnormalities)
61,T46,Qualifier 1489 1501	intracranial
62,T47,Qualifier 1474 1485	intraspinal
63,*,OR T47 T46
64,T48,Scope 1474 1501	intraspinal or intracranial
65,R12,Has_scope Arg1:T45 Arg2:T48
66,*,OR T45 T44 T43 T42 T37 T36 T35 T34
67,R13,Has_scope Arg1:T37 Arg2:T41
68,T49,"Scope 1283 1524	gastrointestinal ulcer, malignant neoplasms, injuries or recent surgeries of the brain, spinal cord or eyes, recent intracranial bleedings, known or suspected esophagus varices, aneurysms or intraspinal or intracranial vascular abnormalities"
69,R14,Subsumes Arg1:T32 Arg2:T49
70,T50,Device 1527 1550	Artificial heart valves
71,T51,Drug 1579 1592	anticoagulant
72,R15,AND Arg1:T50 Arg2:T51
73,T52,Condition 1594 1613	Renal insufficiency
74,T53,Measurement 1619 1649	estimated creatinine clearance
75,T54,Value 1650 1667	<30 ml/min/1.73m2
76,R16,Has_value Arg1:T53 Arg2:T54
77,R17,AND Arg1:T52 Arg2:T53
78,T55,Condition 1669 1690	Chronic liver disease
79,T56,Measurement 1696 1712	aminotransferase
80,T57,Value 1720 1781	two times or more above the local upper limit of normal range
81,R18,Has_value Arg1:T56 Arg2:T57
82,R19,AND Arg1:T55 Arg2:T56
83,T58,Drug 1820 1848	inhibitors of P-glycoprotein
84,T60,Drug 1854 1866	ketoconazole
85,T61,Drug 1868 1879	cyclosporin
86,T62,Drug 1881 1893	itraconazole
87,T63,Drug 1897 1908	dronedarone
88,*,OR T60 T61 T62 T63
89,T59,"Scope 1854 1908	ketoconazole, cyclosporin, itraconazole or dronedarone"
90,R20,Subsumes Arg1:T58 Arg2:T59
91,T64,Post-eligibility 1910 1986	Unwillingness or inability to adhere to treatment or to the follow-up visits
92,T65,Observation 1988 2003	Life expectancy
93,T66,Value 2004 2022	less than 6 months
94,R21,Has_value Arg1:T65 Arg2:T66
0,T1,Condition 11 23	hypertension
1,T2,Qualifier 0 10	Controlled
2,T3,Measurement 25 36	systolic BP
3,T4,Value 37 42	< 150
4,T5,Measurement 47 59	diastolic BP
5,T6,Value 60 69	< 90 mmHg
6,T7,Person 81 85	aged
7,T8,Value 86 103	60 years or older
8,T9,Measurement 105 116	systolic BP
9,T10,Value 117 122	< 140
10,T11,Measurement 127 139	diastolic BP
11,T12,Value 140 149	< 90 mmHg
12,T13,Person 175 180	years
13,T14,Value 161 174	40 through 59
14,T15,Qualifier 198 215	JNC 8th guideline
15,R1,Has_qualifier Arg1:T1 Arg2:T2
16,T16,"Scope 25 180	systolic BP < 150 and diastolic BP < 90 mmHg in persons aged 60 years or older, systolic BP < 140 and diastolic BP < 90 mmHg in persons 40 through 59 years"
17,R2,Has_qualifier Arg1:T1 Arg2:T15
18,R3,Has_value Arg1:T3 Arg2:T4
19,R4,Has_value Arg1:T5 Arg2:T6
20,R5,Has_value Arg1:T7 Arg2:T8
21,R6,Has_value Arg1:T9 Arg2:T10
22,R7,Has_value Arg1:T11 Arg2:T12
23,R8,AND Arg1:T14 Arg2:T13
24,R9,Has_scope Arg1:T1 Arg2:T16
25,T17,Scope 25 69	systolic BP < 150 and diastolic BP < 90 mmHg
26,T18,Scope 105 149	systolic BP < 140 and diastolic BP < 90 mmHg
27,R10,AND Arg1:T17 Arg2:T7
28,R11,AND Arg1:T18 Arg2:T13
29,*,OR T17 T18
30,T19,Condition 229 250	diastolic dysfunction
31,T20,Measurement 259 263	E/E'
32,T21,Value 264 268	> 10
33,R12,Has_value Arg1:T20 Arg2:T21
34,R13,AND Arg1:T19 Arg2:T20
35,T22,"Post-eligibility 270 520	The patient agrees to the study protocol and the schedule of clinical and echocardiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site"
0,T1,Qualifier 0 20	Clinically diagnosed
1,T2,Condition 21 44	autoimmune encephalitis
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Qualifier 46 57	Ineffective
4,T4,Procedure 58 76	1st line treatment
5,T5,Drug 83 93	steroid IV
6,T6,Drug 95 99	IVIg
7,T7,Procedure 105 123	2nd line treatment
8,T8,Drug 130 139	Rituximab
9,T9,Drug 143 159	cyclophosphamide
10,*,OR T8 T9
11,T10,Scope 130 159	Rituximab or cyclophosphamide
12,R2,Subsumes Arg1:T7 Arg2:T10
13,*,OR T5 T6
14,T11,"Scope 83 99	steroid IV, IVIg"
15,R3,Subsumes Arg1:T4 Arg2:T11
16,R4,Has_qualifier Arg1:T4 Arg2:T3
17,R5,Has_qualifier Arg1:T7 Arg2:T3
0,T1,Person 0 3	Age
1,T2,Value 4 13	=18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 50 55	acute
4,T4,Condition 56 58	PE
5,T5,Procedure 76 90	CT angiography
6,T6,Procedure 92 123	ventilation/perfusion lung scan
7,T7,"Procedure 138 169	invasive pulmonary angiography,"
8,T8,Condition 244 264	deep vein thrombosis
9,R2,Has_qualifier Arg1:T4 Arg2:T3
10,*,OR T5 T6 T7
11,A1,Optional T8
12,T9,"Scope 76 168	CT angiography, ventilation/perfusion lung scan, or selective invasive pulmonary angiography"
13,R3,AND Arg1:T9 Arg2:T4
14,T10,Condition 277 297	hemodynamic collapse
15,T11,Negation 266 273	Absence
16,T12,Condition 277 288;302 316	hemodynamic decompensation
17,*,OR T10 T12
18,T13,"Scope 277 316	hemodynamic collapse, or decompensation"
19,R4,Has_negation Arg1:T13 Arg2:T11
20,T14,Multiplier 375 387	At least one
21,T15,Condition 388 416	sign of RV pressure overload
22,T16,Condition 388 407;417 428	sign of RV pressure dysfunction
23,*,OR T15 T16
24,T17,Procedure 432 446	CT angiography
25,T18,Procedure 450 466	echocardiography
26,*,OR T17 T18
27,T19,Scope 432 466	CT angiography or echocardiography
28,T20,Scope 388 428	sign of RV pressure overload/dysfunction
29,R5,Has_multiplier Arg1:T20 Arg2:T14
30,R6,Has_scope Arg1:T19 Arg2:T20
31,T21,Measurement 520 535	troponin levels
32,T22,Value 511 519	elevated
33,R7,Has_value Arg1:T21 Arg2:T22
34,T23,Condition 477 494	myocardial injury
35,R8,AND Arg1:T23 Arg2:T21
36,T24,Condition 547 558	RV) failure
37,T25,Measurement 575 591	NT-proBNP levels
38,T26,Value 592 602	>600 pg/ml
39,R9,Has_value Arg1:T25 Arg2:T26
40,R10,AND Arg1:T24 Arg2:T25
41,T27,Post-eligibility 617 827	Ability of the subject to understand the character and individual consequences of the clinical trial; signed and dated informed consent of the subject available before the start of any specific trial procedures
0,T1,Post-eligibility 0 83	Unwillingness or inability to comply with the procedures described in this protocol
1,T2,Temporal 146 169	within the study period
2,T3,Procedure 138 145	surgery
3,T4,Qualifier 130 137	cardiac
4,T5,Negation 126 129	non
5,R1,Has_negation Arg1:T4 Arg2:T5
6,R2,Has_qualifier Arg1:T3 Arg2:T4
7,T6,Qualifier 120 125	major
8,R3,Has_qualifier Arg1:T3 Arg2:T6
9,T7,Mood 112 119	planned
10,R4,Has_mood Arg1:T3 Arg2:T7
11,T8,Procedure 93 108	cardiac surgery
12,T9,Mood 85 92	Planned
13,R5,Has_mood Arg1:T8 Arg2:T9
14,*,OR T8 T3
15,T10,Scope 85 145	Planned cardiac surgery or planned major non-cardiac surgery
16,R6,Has_temporal Arg1:T7 Arg2:T2
17,T11,Reference_point 157 169	study period
18,R7,Has_index Arg1:T2 Arg2:T11
19,T12,Procedure 182 208	coronary revascularization
20,T13,Procedure 172 178;191 208	Stroke revascularization
21,*,OR T12 T13
22,T14,Temporal 209 229	in the past 6 months
23,T15,Scope 172 208	Stroke or coronary revascularization
24,R8,Has_temporal Arg1:T15 Arg2:T14
25,T16,Condition 255 272	pulmonary disease
26,T17,Qualifier 232 242;243 254	Clinically significant
27,R9,Has_qualifier Arg1:T16 Arg2:T17
28,T18,Condition 285 300	hyperthyroidism
29,T19,Condition 305 319	hypothyroidism
30,*,OR T18 T19
31,T20,Qualifier 275 284	Untreated
32,T21,"Scope 285 319	hyperthyroidism, or hypothyroidism"
33,R10,Has_qualifier Arg1:T21 Arg2:T20
34,T22,Condition 337 343	cancer
35,T23,Negation 345 355	other than
36,T24,Condition 356 376;391 402	superficial squamous skin cancer
37,T25,Condition 380 402	basal cell skin cancer
38,*,OR T25 T24
39,T26,Scope 356 402	superficial squamous or basal cell skin cancer
40,R11,Has_negation Arg1:T26 Arg2:T23
41,T27,Temporal 404 423	in the past 3 years
42,T28,Procedure 435 444	treatment
43,T29,Condition 460 466	cancer
44,T30,Qualifier 453 459	active
45,R12,Has_qualifier Arg1:T29 Arg2:T30
46,R13,AND Arg1:T28 Arg2:T29
47,T31,Scope 337 403	cancer (other than superficial squamous or basal cell skin cancer)
48,R14,Has_temporal Arg1:T31 Arg2:T27
49,*,OR T31 T28
50,T32,Pregnancy_considerations 469 585	Female of child-bearing potential who do not use adequate contraception and women who are pregnant or breast-feeding
51,T33,"Subjective_judgement 587 809	Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study"
52,T34,Measurement 812 832	LV ejection fraction
53,T35,Value 833 838	< 50%
54,R15,Has_value Arg1:T34 Arg2:T35
55,T36,Condition 853 866	renal disease
56,T37,Qualifier 841 852	Significant
57,R16,Has_qualifier Arg1:T36 Arg2:T37
58,T38,Measurement 881 897	serum creatinine
59,T39,Value 898 909	> 2.5 mg/dL
60,R17,Has_value Arg1:T38 Arg2:T39
61,R18,AND Arg1:T36 Arg2:T38
62,T40,Condition 911 926	Hepatic disease
63,T41,Condition 930 955	biliary tract obstruction
64,T42,Condition 972 996	hepatic enzyme elevation
65,T43,Qualifier 960 971	significant
66,R19,Has_qualifier Arg1:T42 Arg2:T43
67,T44,Measurement 998 1001	ALT
68,T45,Measurement 1005 1008	AST
69,T46,Value 1009 1040	> 3 times upper limit of normal
70,*,OR T44 T45
71,T47,Scope 998 1008	ALT or AST
72,R20,Has_value Arg1:T47 Arg2:T46
73,R21,Has_scope Arg1:T42 Arg2:T47
74,*,OR T40 T41 T42
75,T48,Condition 1055 1066	intolerance
76,T49,Drug 1070 1073	ARB
77,T50,Drug 1077 1087	amlodipine
78,*,OR T49 T50
79,T51,Scope 1070 1087	ARB or amlodipine
80,R22,Has_scope Arg1:T48 Arg2:T51
81,T52,Condition 1106 1132	restrictive cardiomyopathy
82,T53,Condition 1090 1102;1118 1132	Hypertrophic cardiomyopathy
83,T54,Condition 1154 1170	valvular disease
84,T55,Qualifier 1147 1153	severe
85,T56,Qualifier 1135 1143	Moderate
86,*,OR T56 T55
87,T57,Scope 1135 1153	Moderate or severe
88,R23,Has_scope Arg1:T54 Arg2:T57
89,T58,Condition 1173 1198	Constrictive pericarditis
90,T59,Condition 1200 1219	Atrial fibrillation
91,T60,Measurement 1227 1237	heart rate
92,T61,Value 1238 1247	> 120/min
93,R24,Has_value Arg1:T60 Arg2:T61
94,R25,AND Arg1:T59 Arg2:T60
95,T62,Condition 1258 1269	systolic BP
96,T63,Qualifier 1250 1257	Sitting
97,R26,Has_qualifier Arg1:T62 Arg2:T63
98,T64,Value 1270 1280	< 100 mmHg
99,R27,Has_value Arg1:T62 Arg2:T64
0,T1,Measurement 0 10	Hemoglobin
1,T2,Value 11 19	> 12g/dL
2,T3,Measurement 21 32	Hematochrit
3,T4,Value 33 37	>36%
4,T5,Measurement 39 53	Thrombocytosis
5,T6,Value 54 60	> 750K
6,R1,Has_value Arg1:T1 Arg2:T2
7,R2,Has_value Arg1:T3 Arg2:T4
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 62 65	AST
10,T8,Measurement 69 72	ALT
11,*,OR T7 T8
12,T9,Value 73 78	> 120
13,T10,Scope 62 72	AST or ALT
14,R4,Has_value Arg1:T10 Arg2:T9
15,T11,Condition 80 87	HIV (+)
16,T12,Condition 89 97	Allergic
17,T13,Drug 112 126	erythropoietin
18,R5,AND Arg1:T12 Arg2:T13
19,T14,Condition 128 153	Uncontrolled hypertension
20,T15,Condition 170 193	autoimmune encephalitis
21,T16,Temporal 159 193	before the autoimmune encephalitis
22,T17,Reference_point 166 193	the autoimmune encephalitis
23,R6,Has_index Arg1:T16 Arg2:T17
24,R7,multi Arg1:T17 Arg2:T15
25,T18,Measurement 155 158	mRS
26,T19,Value 194 197	> 3
27,R8,Has_value Arg1:T18 Arg2:T19
28,R9,Has_temporal Arg1:T18 Arg2:T16
29,T20,Condition 217 226	pregnancy
30,T21,Observation 199 213	Breast feeding
31,T22,Condition 239 254	ischemic stroke
32,T23,Condition 258 278	pulmonary thrombosis
33,T24,Observation 228 235	History
34,*,OR T22 T23
35,T25,Scope 239 278	ischemic stroke or pulmonary thrombosis
36,R10,Has_temporal Arg1:T25 Arg2:T24
37,T26,Observation 280 301	Refuse to be enrolled
38,*,OR T21 T20
0,T1,Drug 18 21	HES
1,T2,Drug 23 41	dextrane solutions
2,T3,Multiplier 45 53	> 500 ml
3,T4,Drug 57 74	Gelatin solutions
4,T5,Temporal 75 113	within the 24 h prior to randomization
5,*,OR T1 T2 T4
6,R1,Has_multiplier Arg1:T4 Arg2:T3
7,T6,"Scope 18 74	HES, dextrane solutions or > 500 ml of Gelatin solutions"
8,R2,Has_temporal Arg1:T6 Arg2:T5
9,T7,Observation 115 129	Death expected
10,T8,Temporal 130 150	within the next 48 h
11,R3,Has_temporal Arg1:T7 Arg2:T8
12,T9,Condition 152 160	moribund
13,T10,Measurement 184 187	ASA
14,T11,Value 188 197	= class V
15,R4,Has_value Arg1:T10 Arg2:T11
16,R5,Subsumes Arg1:T9 Arg2:T10
17,R6,Subsumes Arg1:T7 Arg2:T9
18,T12,Non-query-able 200 264	Patients whose medical condition does preclude the PLR manoeuvre
19,T13,Non-representable 266 327	Patients for whom the need of pressure infusions are expected
20,T14,Condition 345 358	renal support
21,T15,Mood 329 344	Requirement for
22,R7,Has_mood Arg1:T14 Arg2:T15
23,T16,Drug 517 524	heparin
24,T17,Condition 543 570	chronic coagulation disease
25,T18,Drug 573 599	anticoagulation medication
26,T19,Measurement 606 633	partial thromboplastin time
27,T20,Value 634 642	> 60 sec
28,R9,Has_value Arg1:T19 Arg2:T20
29,*,OR T17 T18
30,T21,Scope 543 599	chronic coagulation disease / anticoagulation medication
31,R8,Has_scope Arg1:T16 Arg2:T21
32,T22,Condition 645 659	Acutely burned
33,T23,Non-representable 670 781	Contraindications according to summary of product characteristics of investigational test and reference product
34,T24,Non-query-able 783 885	Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
0,T1,Person 0 3	Age
1,T2,Value 4 40	between 1 month and 24 months of age
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 97 105	epilepsy
4,T4,Condition 143 151	seizures
5,T5,Multiplier 118 142;151 156	At least an average of 4 /week
6,R2,Has_multiplier Arg1:T4 Arg2:T5
7,T6,Drug 219 239	anti-epileptic drugs
8,T7,Multiplier 215 218	two
9,R3,Has_multiplier Arg1:T6 Arg2:T7
10,T8,Condition 185 193	response
11,T9,Qualifier 178 184	Failed
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,R5,AND Arg1:T8 Arg2:T6
14,T10,Drug 303 318	corticosteroids
15,R6,AND Arg1:T6 Arg2:T10
16,T11,Informed_consent 321 380	Children with written informed consent from parent/guardian
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,T3,Value 24 43	= 18 and = 85 years
3,T4,Person 47 50	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,*,OR T2 T1
6,T5,Person 52 57	Women
7,T6,Condition 61 84	child bearing potential
8,T7,Measurement 107 130	standard pregnancy test
9,T8,Value 95 103	negative
10,T9,Measurement 132 137	urine
11,T10,Measurement 141 146	serum
12,*,OR T10 T9
13,T11,Scope 132 146	urine or serum
14,R2,Subsumes Arg1:T7 Arg2:T11
15,R3,Has_value Arg1:T7 Arg2:T8
16,T12,Scope 52 84	Women of child bearing potential
17,A1,Optional T12
18,R4,AND Arg1:T12 Arg2:T7
19,T13,Measurement 163 174	body weight
20,T14,Value 175 195	= 55 kg and = 140 kg
21,R5,Has_value Arg1:T13 Arg2:T14
22,T15,Measurement 200 221	body mass index (BMI)
23,T16,Value 222 232	= 18 kg/m2
24,R6,Has_value Arg1:T15 Arg2:T16
25,T17,Condition 253 266	severe sepsis
26,T18,Condition 269 281	septic shock
27,*,OR T18 T17
28,T19,Temporal 282 317	at admission on Intensive Care Unit
29,R7,Has_temporal Arg1:T18 Arg2:T19
30,R8,Has_temporal Arg1:T17 Arg2:T19
31,T20,Reference_point 285 317	admission on Intensive Care Unit
32,R9,Has_index Arg1:T19 Arg2:T20
33,T21,Non-representable 326 367	be enrolled within 90 min after admission
34,T22,Drug 517 535	antibiotic therapy
35,T23,Temporal 562 584	prior to randomization
36,T24,Reference_point 571 584	randomization
37,R10,Has_index Arg1:T23 Arg2:T24
38,R11,Has_temporal Arg1:T22 Arg2:T23
39,T25,Condition 603 619	fluid responsive
40,T26,Measurement 677 705	mean arterial pressure (MAP)
41,T27,Qualifier 706 737	after passive leg raising (PLR)
42,R12,Has_qualifier Arg1:T26 Arg2:T27
43,T28,Value 668 673	> 10%
44,R13,Has_value Arg1:T26 Arg2:T28
45,R14,Subsumes Arg1:T25 Arg2:T26
46,T29,"Post-eligibility 739 836	Signed informed consent by patient, legal representative or authorized person or deferred consent"
0,T1,Person 0 3	Age
1,T2,Value 4 29	<1m or > 24 months of age
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Negation 31 33	No
4,T4,Condition 54 62	epilepsy
5,R2,Has_negation Arg1:T4 Arg2:T3
6,T5,Condition 68 76	seizures
7,T6,Multiplier 64 67;76 81	< 4 /week
8,R3,Has_multiplier Arg1:T5 Arg2:T6
9,T7,Drug 126 130	AEDs
10,T8,Multiplier 122 125	< 2
11,R4,Has_multiplier Arg1:T7 Arg2:T8
12,T9,Drug 145 160	corticosteroids
13,T10,Temporal 164 204	previous 3 months prior to randomisation
14,T11,Reference_point 191 204	randomisation
15,R5,Has_index Arg1:T10 Arg2:T11
16,R6,Has_temporal Arg1:T9 Arg2:T10
17,T12,Condition 206 223	Metabolic disease
18,T13,Condition 224 240	contraindicating
19,T14,Procedure 252 266	ketogenic diet
20,T15,"Condition 272 304	pyruvate carboxylase deficiency,"
21,T16,Condition 305 309	MCAD
22,*,OR T15 T16
23,R7,AND Arg1:T12 Arg2:T13
24,R8,AND Arg1:T13 Arg2:T14
25,T17,"Scope 272 309	pyruvate carboxylase deficiency, MCAD"
26,R9,Has_scope Arg1:T12 Arg2:T17
27,T18,Condition 386 406	neurological disease
28,T19,Qualifier 374 385	Progressive
29,R10,Has_qualifier Arg1:T18 Arg2:T19
30,T20,Condition 415 438	gastroesophageal reflux
31,T21,Qualifier 408 414	Severe
32,R11,Has_qualifier Arg1:T20 Arg2:T21
33,T22,Procedure 468 482	ketogenic diet
34,T23,Qualifier 440 448	Previous
35,R12,Has_qualifier Arg1:T22 Arg2:T23
36,T24,Competing_trial 484 574	Concurrent participation in another clinical trial of an investigational medicinal product
37,T25,Non-query-able 577 638	Patients who are prescribed AEDs not listed in the trial IMPs
0,T1,Person 18 21	age
1,T2,Value 25 33;9 13	18 years over
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-query-able 38 60	agree informed consent
4,T4,Post-eligibility 38 60	agree informed consent
5,T5,Multiplier 74 86	at least one
6,T6,Condition 87 92	polyp
7,T7,Qualifier 96 109	eligible size
8,T8,Context_Error 96 109	eligible size
9,T9,Value 111 117	6-10mm
10,R2,Has_qualifier Arg1:T6 Arg2:T7
11,R3,Subsumes Arg1:T7 Arg2:T9
12,R4,Has_multiplier Arg1:T6 Arg2:T5
0,T1,Procedure 11 39	Interleukin-2 (IL-2) therapy
1,T2,Temporal 40 69	within 8 weeks of study entry
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 111 162;88 95	illness that may interfere with study participation medical
4,T4,Condition 99 162	psychiatric illness that may interfere with study participation
5,*,OR T3 T4
6,T5,Condition 164 172	Pregnant
0,T1,Observation 24 31	survive
1,T2,Negation 8 11	not
2,T3,Value 32 48	more than 4 days
3,R1,Has_value Arg1:T1 Arg2:T3
4,R2,Has_negation Arg1:T3 Arg2:T2
5,T4,Condition 58 66	allergic
6,T5,Drug 72 82	penicillin
7,T6,Drug 88 98	carbapenem
8,*,OR T5 T6
9,T7,Scope 72 98	penicillin or a carbapenem
10,R3,Has_scope Arg1:T4 Arg2:T7
11,T8,Condition 139 150	bacteraemia
12,T9,Qualifier 125 138	polymicrobial
13,R4,Has_qualifier Arg1:T8 Arg2:T9
14,T10,"Non-query-able 283 380	Treatment is not with the intent to cure the infection (that is, palliative care is an exclusion)"
15,T11,Pregnancy_considerations 383 410	Pregnancy or breast-feeding
16,T12,Drug 432 446	antimicrobials
17,T13,Qualifier 420 431	concomitant
18,R5,Has_qualifier Arg1:T12 Arg2:T13
19,T14,Temporal 454 482	first 4 days after enrolment
20,R6,Has_temporal Arg1:T12 Arg2:T14
21,T15,Reference_point 473 482	enrolment
22,R7,Has_index Arg1:T14 Arg2:T15
23,T16,Observation 511 532	Gram-negative bacilli
24,R8,Has_context Arg1:T12 Arg2:T16
25,T17,Negation 534 540	except
26,T18,Drug 542 571	rimethoprim/sulphamethoxazole
27,R9,Has_negation Arg1:T18 Arg2:T17
28,T19,Measurement 655 677	Pitt bacteraemia score
29,T20,Value 681 683	>4
30,R10,Has_value Arg1:T19 Arg2:T20
31,T21,Condition 794 807	brain abscess
32,T22,Condition 823 833	meningitis
33,T23,Qualifier 809 822	post-surgical
34,R11,Has_qualifier Arg1:T22 Arg2:T23
35,T24,Condition 835 850	shunt infection
36,*,OR T21 T22 T24
0,T1,Qualifier 29 34	other
1,T2,Condition 35 63	Axis I psychiatric disorders
2,T3,Negation 65 75	except for
3,T4,Condition 76 110	generalized anxiety disorder (GAD)
4,T5,Temporal 130 157	during a depressive episode
5,T6,Reference_point 139 157	depressive episode
6,T7,Condition 139 157	depressive episode
7,R1,Has_index Arg1:T5 Arg2:T6
8,R2,AND Arg1:T6 Arg2:T7
9,R3,Has_negation Arg1:T4 Arg2:T3
10,R4,Has_temporal Arg1:T4 Arg2:T5
11,R5,Has_qualifier Arg1:T2 Arg2:T1
12,R6,AND Arg1:T2 Arg2:T4
13,T8,Condition 181 196	drug dependence
14,T9,Condition 170 177;186 196	alcohol dependence
15,T10,Condition 181 185;200 205	drug abuse
16,T11,Condition 170 177;200 205	alcohol abuse
17,*,OR T10 T9 T8 T11
18,T12,Temporal 206 229	in the last three years
19,T13,Scope 170 205	alcohol or drug dependence or abuse
20,R7,Has_temporal Arg1:T13 Arg2:T12
21,T14,Condition 242 264	developmental disorder
22,T15,Measurement 268 276	IQ score
23,T16,Value 277 281	< 70
24,R8,Has_value Arg1:T15 Arg2:T16
25,*,OR T14 T15
26,T17,Condition 295 312	acute suicidality
27,T18,Condition 314 325	Acute grief
28,T19,Temporal 327 336	< 1 month
29,R9,Has_temporal Arg1:T18 Arg2:T19
30,T20,Condition 355 364	psychosis
31,T21,Temporal 350 354	past
32,T22,Temporal 339 346	Current
33,*,OR T21 T22
34,T23,Scope 339 354	Current or past
35,R10,Has_scope Arg1:T20 Arg2:T23
36,T24,Condition 366 395	Primary neurological disorder
37,T25,Condition 426 434	dementia
38,T26,Condition 436 442	stroke
39,T27,Condition 444 456	brain tumors
40,T28,Condition 458 466	epilepsy
41,T29,Condition 468 487	Parkinson's disease
42,T30,Condition 492 514	demyelinating diseases
43,*,OR T30 T29 T28 T27 T26 T25
44,T31,"Scope 426 514	dementia, stroke, brain tumors, epilepsy, Parkinson's disease, or demyelinating diseases"
45,R11,Subsumes Arg1:T24 Arg2:T31
46,T32,Procedure 516 519	MRI
47,T33,Condition 520 537	contraindications
48,R12,AND Arg1:T33 Arg2:T32
49,T34,Condition 555 578	intellectual disability
50,T35,Condition 543 551;568 578	physical disability
51,*,OR T34 T35
52,T36,Procedure 632 657	Electroconvulsive therapy
53,T37,Temporal 658 674	in last 6 months
54,R13,Has_temporal Arg1:T36 Arg2:T37
55,T38,Drug 683 709	antidepressant medications
56,T39,Qualifier 713 718	other
57,T40,Drug 719 743	psychotropic medications
58,R14,Has_qualifier Arg1:T40 Arg2:T39
59,*,OR T40 T38
60,T41,Temporal 744 763	in the last 4 weeks
61,T42,Temporal 744 746;768 784	in the last 6 weeks
62,T43,Drug 789 799	fluoxetine
63,R15,AND Arg1:T42 Arg2:T43
64,*,OR T41 T42
65,T44,Scope 744 800	in the last 4 weeks (or the last 6 weeks for fluoxetine)
66,T45,Scope 683 743	antidepressant medications or other psychotropic medications
67,R16,Has_scope Arg1:T45 Arg2:T44
68,T46,Multiplier 802 816	Occasional use
69,T47,Drug 820 835;858 867	benzodiazepines sedatives
70,T48,Drug 839 867	non-benzodiazepine sedatives
71,T49,Drug 877 885	zolpidem
72,T50,Drug 887 898	eszopiclone
73,T51,Drug 903 911	zaleplon
74,*,OR T51 T50 T49
75,T52,"Scope 877 911	zolpidem, eszopiclone, or zaleplon"
76,T53,Negation 932 944	is allowable
77,*,OR T47 T48
78,T54,Scope 820 867	benzodiazepines or non-benzodiazepine sedatives
79,R17,Subsumes Arg1:T54 Arg2:T52
80,R18,Has_negation Arg1:T54 Arg2:T53
81,R19,Has_multiplier Arg1:T54 Arg2:T46
82,T55,Drug 977 989	escitalopram
83,T56,Procedure 956 973	therapeutic trial
84,T57,Qualifier 949 955	failed
85,R20,Has_qualifier Arg1:T56 Arg2:T57
86,R21,AND Arg1:T56 Arg2:T55
87,T58,Temporal 990 1023	in the current depressive episode
88,T59,Reference_point 1005 1023	depressive episode
89,T60,Condition 1005 1023	depressive episode
90,R22,multi Arg1:T59 Arg2:T60
91,R23,AND Arg1:T58 Arg2:T60
92,T61,Temporal 1036 1065	at least 6 weeks of treatment
93,T62,Multiplier 1071 1099	daily dose of 10mg or higher
94,T63,Scope 1036 1099	at least 6 weeks of treatment at a daily dose of 10mg or higher
95,R24,Subsumes Arg1:T58 Arg2:T63
96,R25,Has_temporal Arg1:T55 Arg2:T58
97,T64,Condition 1108 1115	allergy
98,T65,Condition 1119 1135	hypersensitivity
99,T66,Drug 1139 1151	escitalopram
100,T67,Drug 1155 1164	bupropion
101,*,OR T66 T67
102,*,OR T65 T64
103,T68,Scope 1108 1135	allergy or hypersensitivity
104,T69,Scope 1139 1164	escitalopram or bupropion
105,R26,Subsumes Arg1:T68 Arg2:T69
106,T70,Mood 1177 1184	planned
107,T71,Temporal 1166 1173	Current
108,*,OR T70 T71
109,T72,Procedure 1185 1198	psychotherapy
110,T73,Scope 1166 1184	Current or planned
111,R27,Has_scope Arg1:T72 Arg2:T73
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 28 30	2.
2,T3,Parsing_Error 94 96	3.
3,T4,Parsing_Error 122 124	4.
4,T5,Parsing_Error 268 270	5.
5,T6,Parsing_Error 340 342	6.
6,T7,Parsing_Error 400 402	7.
7,T8,Post-eligibility 3 26	Signed informed consent
8,T9,Non-query-able 3 26	Signed informed consent
9,T10,Person 48 52	aged
10,T11,Value 53 92	between 18 years and 45 years inclusive
11,R1,Has_value Arg1:T10 Arg2:T11
12,T12,Condition 31 38	Healthy
13,T13,Measurement 97 105	Weighing
14,T14,Value 106 120	at least 50 kg
15,R2,Has_value Arg1:T13 Arg2:T14
16,T15,"Not_a_criteria 125 266	Volunteers must be hospitalized on Days 1-4, 7-9, and 17-20 for pharmacokinetic assessments for each biomarker and TPV/r (Days 7-9 and 17-20)"
17,T16,"Post-eligibility 125 266	Volunteers must be hospitalized on Days 1-4, 7-9, and 17-20 for pharmacokinetic assessments for each biomarker and TPV/r (Days 7-9 and 17-20)"
18,T17,Post-eligibility 271 338	Volunteers must be willing to complete all study-related activities
19,T18,Post-eligibility 343 398	Each volunteer must have a valid social security number
20,T19,Non-query-able 343 398	Each volunteer must have a valid social security number
21,T20,Non-query-able 271 338	Volunteers must be willing to complete all study-related activities
22,T21,Observation 439 454	medical history
23,T22,Procedure 456 476	physical examination
24,T23,Measurement 481 496	laboratory test
25,T24,"Undefined_semantics 439 496	medical history, physical examination and laboratory test"
26,T25,"Post-eligibility 403 496	Each volunteer must have acceptable medical history, physical examination and laboratory test"
0,T1,Measurement 0 6	Weight
1,T2,Value 7 14	< 800 g
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 17 33	Airway anomalies
4,T4,Condition 36 55	Pulmonary air leaks
5,T5,Condition 74 102	cardiothoracic malformations
6,T6,Condition 58 70;89 102	Craniofacial malformations
7,*,OR T5 T6
0,T1,Condition 14 23	allergies
1,T2,Condition 27 44	contraindications
2,T3,Drug 48 65	study medications
3,*,OR T1 T2
4,T4,Scope 14 44	allergies or contraindications
5,R1,AND Arg1:T4 Arg2:T3
0,T1,Person 0 3	Age
1,T2,Value 4 21	60 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 45 70	major depressive disorder
4,T4,Procedure 72 81	DSM-IV-TR
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Multiplier 84 98	single episode
7,T6,Multiplier 100 109	recurrent
8,T7,Multiplier 113 120	chronic
9,*,OR T6 T7 T5
10,T8,"Scope 84 120	single episode, recurrent or chronic"
11,T9,Negation 122 129	without
12,T10,Condition 130 148	psychotic features
13,R3,Has_negation Arg1:T10 Arg2:T9
14,T11,Procedure 165 169	MINI
15,T12,Procedure 174 187	clinical exam
16,T13,Scope 165 187	MINI and clinical exam
17,R4,Has_scope Arg1:T3 Arg2:T8
18,R5,AND Arg1:T3 Arg2:T10
19,R6,Has_scope Arg1:T3 Arg2:T13
20,T14,Measurement 198 209	MADRS score
21,T15,Value 190 197;210 214	Minimum = 15
22,R7,Has_value Arg1:T14 Arg2:T15
23,T16,Measurement 217 239	Mini-Mental State Exam
24,T17,Value 240 244	= 24
25,R8,Has_value Arg1:T16 Arg2:T17
26,T18,Non-query-able 247 265	Fluent in English.
0,T1,Condition 0 21	Bloodstream infection
1,T2,Qualifier 27 44	Enterobacter spp.
2,T3,Qualifier 46 65	Serratia marcescens
3,T4,Qualifier 67 83	Providencia spp.
4,T5,Qualifier 85 104	Morganella morganii
5,T6,Qualifier 108 128	Citrobacter freundii
6,T7,"Scope 28 128	nterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii"
7,*,OR T2 T3 T4 T5 T6
8,R1,Has_scope Arg1:T1 Arg2:T7
9,T8,Drug 180 211	3rd generation cephalosporins (
10,T9,Drug 216 227	ceftriaxone
11,T10,Drug 229 239	cefotaxime
12,T11,Drug 243 254	ceftazidime
13,*,OR T9 T10 T11
14,T12,"Scope 216 254	ceftriaxone, cefotaxime or ceftazidime"
15,R2,Subsumes Arg1:T8 Arg2:T12
16,T13,Drug 257 266	meropenem
17,T14,Drug 271 294	piperacillin-tazobactam
18,T15,Multiplier 300 312	at least one
19,T16,Measurement 313 326	blood culture
20,R3,Has_multiplier Arg1:T16 Arg2:T15
21,R4,AND Arg1:T16 Arg2:T1
22,R5,AND Arg1:T1 Arg2:T8
23,T17,Person 588 592	aged
24,T18,Value 593 610	18 years and over
25,T19,Temporal 491 512;525 574	No more than 72 hours since the first positive blood culture collection
26,T20,Reference_point 531 574	the first positive blood culture collection
27,T21,Value 541 549	positive
28,T22,Measurement 550 574	blood culture collection
29,R7,Has_value Arg1:T22 Arg2:T21
30,R8,multi Arg1:T20 Arg2:T22
31,T23,Value 612 617	>=21y
32,T24,Person 621 630	Singapore
33,A1,Optional T24
34,R9,Has_value Arg1:T24 Arg2:T23
35,*,OR T18 T24
36,T25,Scope 593 631	18 years and over (>=21y in Singapore)
37,R6,Has_scope Arg1:T17 Arg2:T25
0,T1,Drug 0 13	Anticoagulant
1,T2,Temporal 22 44	during the past 1 week
2,T3,Procedure 52 61	procedure
3,T4,Reference_point 52 61	procedure
4,R1,Has_index Arg1:T2 Arg2:T4
5,R2,Has_temporal Arg1:T1 Arg2:T2
6,T5,Condition 69 81	coagulopathy
7,T6,Condition 94 109	liver cirrhosis
8,T7,Condition 111 133	chronic kidney disease
9,T8,Condition 135 145	malignancy
10,T9,Condition 147 173	inflammatory bowel disease
11,T10,Condition 175 205	significant infectious disease
12,T11,Condition 207 225	polyposis syndrome
13,*,OR T6 T7 T8 T9 T10 T11
14,T12,Observation 83 90	History
15,T13,"Scope 94 225	liver cirrhosis, chronic kidney disease, malignancy, inflammatory bowel disease, significant infectious disease, polyposis syndrome"
16,R3,Has_temporal Arg1:T13 Arg2:T12
0,T1,Condition 79 102	high risk blood disease
1,T2,Condition 106 112	cancer
2,*,OR T1 T2
3,T3,Measurement 140 165	Estimated life expectancy
4,T4,Value 169 207	at least 6 weeks following study entry
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 209 263	Cancer and Leukemia Group B (CALGB) performance status
7,T8,Value 264 287	less than or equal to 2
8,T9,Measurement 289 311	White blood cell count
9,T10,Measurement 313 321	platelet
10,T11,Measurement 323 333	hematocrit
11,T12,Measurement 335 347	tuberculosis
12,T13,Measurement 349 381	aspartate aminotransferase (AST)
13,R2,Has_value Arg1:T5 Arg2:T8
14,T6,Measurement 383 413	alanine aminotransferase (ALT)
15,T7,Measurement 415 435	alkaline phosphatase
16,T14,Measurement 437 447	creatinine
17,T15,Measurement 453 469	HIV test results
18,T16,Qualifier 470 499	reviewed by transplant center
19,T17,"Scope 289 469	White blood cell count, platelet, hematocrit, tuberculosis, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, and HIV test results"
20,R3,Has_qualifier Arg1:T17 Arg2:T16
21,T18,Procedure 501 534	Multiple gated acquisition (MUGA)
22,T19,Procedure 536 550	echocardiogram
23,T20,Procedure 552 563	cardiac MRI
24,T21,Procedure 572 602	pulmonary function tests (PFT)
25,*,OR T18 T19 T20 T21
26,T22,Qualifier 617 646	reviewed by transplant center
27,T23,"Scope 501 602	Multiple gated acquisition (MUGA), echocardiogram, cardiac MRI, and/or pulmonary function tests (PFT)"
28,R4,Has_qualifier Arg1:T23 Arg2:T22
29,T24,Person 970 976	female
30,A1,Optional T24
31,T25,Procedure 993 1006	contraception
32,R5,AND Arg1:T24 Arg2:T25
33,T26,Temporal 1007 1027	throughout the study
34,R6,Has_temporal Arg1:T25 Arg2:T26
35,T27,Measurement 909 945	umbilical cord blood units available
36,T28,Value 888 905	Sufficient number
37,R7,Has_value Arg1:T27 Arg2:T28
38,T29,Qualifier 946 965	for transplantation
39,T30,Procedure 950 965	transplantation
40,R8,multi Arg1:T29 Arg2:T30
41,R9,Has_qualifier Arg1:T27 Arg2:T29
0,T1,Measurement 0 3	ASA
1,T2,Value 4 5	I
2,T3,Value 7 9	II
3,T4,Value 11 14	III
4,*,OR T4 T3 T2
5,T5,"Scope 4 14	I, II, III"
6,R1,Has_scope Arg1:T1 Arg2:T5
7,T6,Procedure 30 48	ambulatory surgery
8,T7,Procedure 71 89	general anesthesia
9,T8,Qualifier 65 89	under general anesthesia
10,R2,multi Arg1:T8 Arg2:T7
11,R3,Has_qualifier Arg1:T6 Arg2:T8
0,T1,Value 0 16	Mild-to-moderate
1,T2,Measurement 17 20	RDS
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Measurement 23 36	Postnatal age
4,T4,Value 37 50	2 to 48 hours
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 53 68	Gestational age
7,T6,Value 69 91	27 0/7 to 36 6/7 weeks
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 107 117	nasal CPAP
10,T8,Value 129 139	= 5 cm H2O
11,T9,Measurement 144 148	FiO2
12,T10,Value 149 170	between 0.30 and 0.60
13,T11,Temporal 171 191	for at least 2 hours
14,T12,Measurement 204 208	SpO2
15,T13,Value 209 215	90-95%
16,R4,Has_value Arg1:T12 Arg2:T13
17,R5,Has_value Arg1:T7 Arg2:T8
18,R6,AND Arg1:T7 Arg2:T9
19,R7,Has_value Arg1:T9 Arg2:T10
20,R8,Has_temporal Arg1:T7 Arg2:T11
21,R9,AND Arg1:T7 Arg2:T12
22,T14,Informed_consent 218 234	Informed consent
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 224 226	2.
2,T3,Parsing_Error 2789 2792	25.
3,T4,Parsing_Error 2771 2774	24.
4,T5,Parsing_Error 2697 2700	23.
5,T6,Parsing_Error 2623 2626	22.
6,T7,Parsing_Error 2587 2590	21.
7,T8,Parsing_Error 2557 2560	20.
8,T9,Parsing_Error 2499 2502	19.
9,T10,Parsing_Error 2400 2403	18.
10,T11,Parsing_Error 2238 2241	17.
11,T12,Parsing_Error 2100 2103	16.
12,T13,Parsing_Error 1867 1870	15.
13,T14,Parsing_Error 1739 1742	14.
14,T15,Parsing_Error 1678 1681	13.
15,T16,Parsing_Error 1539 1542	12.
16,T17,Parsing_Error 1431 1434	11.
17,T18,Parsing_Error 1399 1402	10.
18,T19,Parsing_Error 1320 1322	9.
19,T20,Parsing_Error 1214 1216	8.
20,T21,Parsing_Error 1157 1159	7.
21,T22,Parsing_Error 990 992	6.
22,T23,Parsing_Error 734 736	5.
23,T24,Parsing_Error 632 634	4.
24,T25,Parsing_Error 376 378	3.
25,T26,Measurement 2793 2814	Body Mass Index (BMI)
26,T27,Value 2815 2825	> 30 kg/m²
27,R1,Has_value Arg1:T26 Arg2:T27
28,T28,Measurement 2775 2778	HIV
29,T29,Value 2779 2787	positive
30,R2,Has_value Arg1:T28 Arg2:T29
31,T30,Drug 2708 2735	investigational medications
32,T31,Undefined_semantics 2708 2735	investigational medications
33,T32,Temporal 2736 2769	within 30 days before study entry
34,T33,Reference_point 2758 2769	study entry
35,R3,Has_index Arg1:T32 Arg2:T33
36,R4,Has_temporal Arg1:T30 Arg2:T32
37,T34,Condition 2627 2657	Clinically unacceptable result
38,T35,Temporal 2658 2695	at the screening physical examination
39,T36,Reference_point 2661 2695	the screening physical examination
40,T37,Procedure 2675 2695	physical examination
41,R5,Has_index Arg1:T35 Arg2:T36
42,R6,AND Arg1:T36 Arg2:T37
43,T38,Qualifier 2627 2650	Clinically unacceptable
44,R7,Has_qualifier Arg1:T34 Arg2:T38
45,T39,Subjective_judgement 2627 2650	Clinically unacceptable
46,T40,Undefined_semantics 2627 2657	Clinically unacceptable result
47,T41,Condition 2600 2621	hepatic insufficiency
48,T42,Condition 2591 2596;2608 2621	Renal insufficiency
49,*,OR T41 T42
50,T43,Device 2572 2585	venous access
51,T44,Qualifier 2561 2571	Inadequate
52,R8,Has_qualifier Arg1:T43 Arg2:T44
53,T45,Drug 2537 2555	herbal medications
54,T46,Temporal 2503 2514	Concomitant
55,R9,Has_temporal Arg1:T45 Arg2:T46
56,T47,Drug 2434 2453	oral contraceptives
57,T48,Temporal 2404 2415	Concomitant
58,R10,Has_temporal Arg1:T47 Arg2:T48
59,T49,Not_a_criteria 2454 2497	(may be included with 7-day washout period)
60,T50,Drug 2276 2307	drug that could affect bleeding
61,T51,Undefined_semantics 2276 2307	drug that could affect bleeding
62,T52,Drug 2315 2322	aspirin
63,T53,Drug 2324 2335	clopidogrel
64,T54,Drug 2337 2348	ticlopidine
65,T55,Drug 2350 2358	warfarin
66,T56,Drug 2360 2367	heparin
67,T57,Drug 2369 2397	low-molecular weight heparin
68,*,OR T57 T56 T55 T54 T53 T52
69,T58,"Scope 2315 2397	aspirin, clopidogrel, ticlopidine, warfarin, heparin, low-molecular weight heparin"
70,R11,Subsumes Arg1:T50 Arg2:T58
71,T59,Temporal 2104 2115	Concomitant
72,T60,Drug 2138 2177;2186 2194	food product known to alter P450 enzyme activity
73,T61,Drug 2138 2165;2181 2194	food product known to alter P-gp activity
74,*,OR T60 T61
75,T62,Drug 2203 2219	grapefruit juice
76,T63,Drug 2221 2236	Seville oranges
77,*,OR T62 T63
78,T64,"Scope 2203 2236	grapefruit juice, Seville oranges"
79,T65,Scope 2138 2194	food product known to alter P450 enzyme or P-gp activity
80,R12,Subsumes Arg1:T65 Arg2:T64
81,R13,Has_temporal Arg1:T65 Arg2:T59
82,T66,Temporal 1871 1882	Concomitant
83,T67,Drug 1938 1986;1995 2008	medications known to be highly dependent on P450 for clearance
84,T68,Drug 1938 1981;1990 2008	medications known to be highly dependent on P-gp for clearance
85,*,OR T68 T67
86,T69,Measurement 2028 2049	plasma concentrations
87,T70,Value 2019 2027	elevated
88,R14,Has_value Arg1:T69 Arg2:T70
89,T71,Condition 2090 2098	toxicity
90,T72,Scope 1938 2008	medications known to be highly dependent on P450 or P-gp for clearance
91,R15,Has_temporal Arg1:T72 Arg2:T66
92,T73,Qualifier 2082 2089	serious
93,R17,Has_qualifier Arg1:T71 Arg2:T73
94,T74,Scope 2019 2049	elevated plasma concentrations
95,R16,Has_scope Arg1:T72 Arg2:T74
96,R18,AND Arg1:T74 Arg2:T71
97,T75,Drug 1810 1848;1857 1865	medications known to alter P450 enzyme activity
98,T76,Drug 1810 1836;1852 1865	medications known to alter P-gp activity
99,*,OR T75 T76
100,T77,Undefined_semantics 1938 2008	medications known to be highly dependent on P450 or P-gp for clearance
101,T78,Undefined_semantics 2138 2194	food product known to alter P450 enzyme or P-gp activity
102,T80,Temporal 1743 1754	Concomitant
103,T81,Scope 1810 1865	medications known to alter P450 enzyme or P-gp activity
104,R19,Has_temporal Arg1:T81 Arg2:T80
105,T82,Temporal 1682 1693	Concomitant
106,T83,Drug 1715 1737	experimental compounds
107,R20,Has_temporal Arg1:T83 Arg2:T82
108,T84,Drug 1563 1571	caffeine
109,T85,Drug 1573 1581	warfarin
110,T86,Drug 1583 1592	vitamin K
111,T87,Drug 1594 1604	omeprazole
112,T88,Drug 1606 1622	dextromethorphan
113,T89,Drug 1624 1633	midazolam
114,T90,Drug 1635 1645	tipranavir
115,T91,Drug 1647 1656	ritonavir
116,T92,Condition 1543 1559	Hypersensitivity
117,T93,"Scope 1563 1656	caffeine, warfarin, vitamin K, omeprazole, dextromethorphan, midazolam, tipranavir, ritonavir"
118,*,OR T91 T90 T89 T88 T87 T86 T85 T84
119,R21,Has_scope Arg1:T92 Arg2:T93
120,T94,Person 1451 1456	women
121,T95,Condition 1435 1450	Sexually active
122,T96,Value 1460 1472	childbearing
123,T97,Person 1473 1476	age
124,R22,Has_value Arg1:T97 Arg2:T96
125,T98,Device 1506 1537	barrier method of birth control
126,T99,Qualifier 1495 1505	acceptable
127,T100,Negation 1484 1487	not
128,R23,Has_negation Arg1:T98 Arg2:T100
129,R24,Has_qualifier Arg1:T98 Arg2:T99
130,T101,Condition 1403 1411	Pregnant
131,T102,Observation 1415 1429	breast feeding
132,T103,Drug 1330 1346	tobacco products
133,T105,Observation 1365 1372	smoking
134,T106,Temporal 1373 1397	within the past 2 months
135,T104,Observation 1354 1361	history
136,R25,Has_temporal Arg1:T105 Arg2:T104
137,R26,Has_temporal Arg1:T105 Arg2:T106
138,*,OR T103 T105
139,T107,Non-query-able 1217 1318	Unable to abstain from more than one beer or alcohol equivalent per day for the duration of the study
140,T108,Condition 1171 1184	alcohol abuse
141,T109,Condition 1188 1194;1199 1212	use of illicit drugs
142,*,OR T108 T109
143,T110,Condition 1139 1155	collagen disease
144,T111,Condition 1127 1135;1148 1155	vascular disease
145,T112,Condition 1112 1125;1148 1155	hematological disease
146,T113,Condition 1094 1110;1148 1155	gastrointestinal disease
147,T114,Condition 1079 1092;1148 1155	immunological disease
148,T115,Condition 1068 1077;1148 1155	endocrine disease
149,T116,Condition 1057 1066;1148 1155	pulmonary disease
150,T117,Condition 1048 1055;1148 1155	cardiac disease
151,T118,Condition 1039 1046;1148 1155	hepatic disease
152,T119,Subjective_judgement 1016 1038	clinically significant
153,*,OR T110 T111 T112 T113 T114 T115 T116 T117 T118
154,T120,"Scope 1039 1155	hepatic, cardiac, pulmonary, endocrine, immunological, gastrointestinal, hematological, vascular or collagen disease"
155,T121,Qualifier 1016 1038	clinically significant
156,R27,Has_qualifier Arg1:T120 Arg2:T121
157,T122,Observation 993 1000	History
158,R28,Has_temporal Arg1:T120 Arg2:T122
159,T123,Qualifier 737 756	Clinically relevant
160,T124,Undefined_semantics 737 756	Clinically relevant
161,T125,Condition 757 781	laboratory abnormalities
162,T126,Measurement 788 791	Hgb
163,T127,Value 791 798	<11g/dL
164,R29,Has_value Arg1:T126 Arg2:T127
165,T128,Measurement 800 803	Hct
166,T129,Measurement 812 829	total cholesterol
167,T130,Measurement 841 854	triglycerides
168,T131,Measurement 866 881	fasting glucose
169,T132,Measurement 893 913	liver function tests
170,T133,Value 914 941	>2.5x upper limit of normal
171,T134,Measurement 952 982	international normalized ratio
172,T135,Value 983 987	>1.2
173,R30,Has_value Arg1:T134 Arg2:T135
174,T136,Temporal 943 951	baseline
175,R31,Has_temporal Arg1:T134 Arg2:T136
176,R32,Has_value Arg1:T132 Arg2:T133
177,T137,Value 882 891	>130mg/dL
178,R33,Has_value Arg1:T131 Arg2:T137
179,T138,Value 855 864	>500mg/dL
180,R34,Has_value Arg1:T130 Arg2:T138
181,T139,Value 830 839	>240mg/dL
182,R35,Has_value Arg1:T129 Arg2:T139
183,T140,Value 803 810	<30g/dL
184,R36,Has_value Arg1:T128 Arg2:T140
185,*,OR T126 T128 T129 T130 T131 T132 T134
186,T141,"Scope 788 987	Hgb<11g/dL, Hct<30g/dL, total cholesterol >240mg/dL, triglycerides >500mg/dL, fasting glucose >130mg/dL, liver function tests >2.5x upper limit of normal, baseline international normalized ratio >1.2"
187,T142,Scope 737 781	Clinically relevant laboratory abnormalities
188,R37,Has_qualifier Arg1:T125 Arg2:T123
189,R38,Subsumes Arg1:T142 Arg2:T141
190,T143,Measurement 650 663	liver enzymes
191,T144,Value 641 649	elevated
192,R39,Has_value Arg1:T143 Arg2:T144
193,T145,Context_Error 635 732	Known elevated liver enzymes in past clinical trials with any compound (experimental or marketed)
194,T146,Non-query-able 635 732	Known elevated liver enzymes in past clinical trials with any compound (experimental or marketed)
195,T147,Condition 419 437	medical conditions
196,T148,Undefined_semantics 757 781	laboratory abnormalities
197,T149,Subjective_judgement 737 756	Clinically relevant
198,T150,Condition 612 630	hormonal disorders
199,T151,Condition 597 608;621 630	oncological disorders
200,T152,Condition 583 595;621 630	neurological disorders
201,T153,Condition 570 581;621 630	psychiatric disorders
202,T154,Condition 555 568;621 630	hematological disorders
203,T155,Condition 542 553;621 630	immunologic disorders
204,T156,Condition 531 540;621 630	metabolic disorders
205,T157,Condition 515 529;621 630	cardiovascular disorders
206,T158,Condition 502 513;621 630	respiratory disorders
207,T159,Condition 495 500;621 630	renal disorders
208,T160,Condition 486 493;621 630	hepatic disorders
209,T161,Condition 468 484;621 630	gastrointestinal disorders
210,*,OR T155 T156 T154 T153 T150 T151 T152 T157 T158 T159 T160 T161
211,T162,"Scope 468 630	gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematological, psychiatric, neurological, oncological or hormonal disorders"
212,R40,Subsumes Arg1:T147 Arg2:T162
213,T163,Qualifier 407 418	significant
214,R41,Has_qualifier Arg1:T147 Arg2:T163
215,T164,Subjective_judgement 407 418	significant
216,T165,"Subjective_judgement 227 374	Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance"
217,T166,"Post-eligibility 227 374	Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance"
218,T167,Condition 26 33	allergy
219,T168,Drug 41 52	study drugs
220,T169,Context_Error 41 52	study drugs
221,R42,AND Arg1:T167 Arg2:T168
222,T170,"Subjective_judgement 3 222	History or presence of allergy to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation"
223,T171,"Non-query-able 3 222	History or presence of allergy to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation"
224,*,OR T101 T102
0,T1,Drug 11 29	sedative hypnotics
1,T2,Drug 31 44	tranquilizers
2,T3,Drug 46 61	anticonvulsants
3,T4,Drug 63 77	antihistamines
4,T5,Qualifier 86 98	non-sedating
5,T6,Negation 79 85	except
6,R1,Has_negation Arg1:T5 Arg2:T6
7,R2,Has_qualifier Arg1:T4 Arg2:T5
8,T7,Drug 101 116	benzodiazepines
9,T8,Drug 118 127	clonidine
10,T9,Drug 135 170	medication known to affect dopamine
11,T10,Temporal 171 198	at start of baseline period
12,*,OR T8 T9 T7 T4 T3 T2 T1
13,T11,"Scope 11 170	sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine"
14,R3,Has_temporal Arg1:T11 Arg2:T10
15,T12,Qualifier 200 211	significant
16,T13,Qualifier 224 236	uncontrolled
17,T14,Qualifier 212 220	unstable
18,*,OR T13 T14
19,T15,Scope 212 236	unstable or uncontrolled
20,T16,Condition 245 264	psychiatric disease
21,T17,Condition 237 244;257 264	medical disease
22,*,OR T16 T17
23,T18,Scope 237 264	medical/psychiatric disease
24,R4,Has_scope Arg1:T18 Arg2:T15
25,R5,Has_qualifier Arg1:T18 Arg2:T12
26,T19,Condition 289 300	head trauma
27,T20,Procedure 289 293;301 308	head surgery
28,T21,Condition 312 328	seizure disorder
29,*,OR T20 T19 T21
30,T22,Observation 278 285	history
31,T23,Scope 289 328	head trauma/surgery or seizure disorder
32,T24,Qualifier 266 277	significant
33,R6,Has_temporal Arg1:T23 Arg2:T22
34,R7,Has_qualifier Arg1:T22 Arg2:T24
35,T25,Condition 330 348	radiation exposure
36,T26,Value 349 364	exceeding 20mSv
37,R8,Has_value Arg1:T25 Arg2:T26
38,T27,Temporal 365 382	in last 12 months
39,R9,Has_temporal Arg1:T25 Arg2:T27
40,T28,Condition 384 393	pregnancy
41,T29,Condition 395 410	substance abuse
42,T30,Condition 395 404;411 421	substance dependence
43,T31,Drug 433 440	alcohol
44,*,OR T30 T29
45,T32,Scope 395 421	substance abuse/dependence
46,R10,Subsumes Arg1:T32 Arg2:T31
47,T33,Condition 448 459	sleep apnea
48,T34,Person 468 481	shift workers
49,*,OR T33 T34
50,T35,Procedure 488 510	sodium-restricted diet
51,T36,Drug 527 532	Xyrem
52,T37,Drug 535 549	sodium oxybate
53,T38,Drug 552 555	GHB
54,*,OR T37 T38 T36
55,T39,Temporal 516 520	ever
56,T40,Scope 527 555	Xyrem / sodium oxybate / GHB
57,R11,Has_temporal Arg1:T40 Arg2:T39
58,T41,Condition 569 583	claustrophobia
59,T42,Device 585 599	metal implants
60,T43,Device 585 590;602 609	metal objects
61,T44,Mood 627 645	may interfere with
62,T45,Procedure 646 649	MRI
63,R12,Has_mood Arg1:T45 Arg2:T44
64,*,OR T43 T42
65,T46,Scope 585 609	metal implants / objects
66,R13,AND Arg1:T46 Arg2:T45
67,T47,Condition 651 697	succinic semialdehyde dehydrogenase deficiency
0,T1,Person 0 4	Male
1,T2,Person 9 15	female
2,*,OR T1 T2
3,T3,Person 16 31	Active-duty SMs
4,T4,Person 35 43	Veterans
5,*,OR T3 T4
6,T5,Value 49 60	18 or older
7,T6,Person 44 48	aged
8,R1,Has_value Arg1:T6 Arg2:T5
9,T7,Condition 72 91	good general health
10,T8,Observation 105 110	blast
11,T9,Observation 94 104	History of
12,T10,Condition 118 136	impact head trauma
13,R2,Has_context Arg1:T10 Arg2:T8
14,R3,Has_temporal Arg1:T10 Arg2:T9
15,T11,Measurement 150 212	Defense and Veterans Brain Injury Center (DVBIC) mTBI criteria
16,T12,Value 142 149	meeting
17,R4,Has_value Arg1:T11 Arg2:T12
18,R5,AND Arg1:T10 Arg2:T11
19,T13,Condition 296 323	alteration in consciousness
20,T14,Temporal 325 360	for up to 24 hours after the injury
21,T15,Reference_point 350 360	the injury
22,R6,Has_index Arg1:T14 Arg2:T15
23,T16,Condition 363 384	loss of consciousness
24,T17,Temporal 385 397	0-30 minutes
25,R7,Has_temporal Arg1:T16 Arg2:T17
26,R8,Has_temporal Arg1:T13 Arg2:T14
27,T18,Condition 406 428	post-traumatic amnesia
28,T19,Temporal 429 452	up to 1 day post-injury
29,R9,Has_temporal Arg1:T18 Arg2:T19
30,*,OR T18 T16 T13
31,T20,Measurement 472 490	Glasgow Coma Scale
32,T21,Value 505 510	13-15
33,T22,Procedure 516 528	head imaging
34,T23,Condition 529 537	findings
35,T24,Negation 573 581	negative
36,R10,Has_negation Arg1:T23 Arg2:T24
37,R11,AND Arg1:T22 Arg2:T23
38,A1,Optional T22
39,A2,Optional T20
40,R12,Has_value Arg1:T20 Arg2:T21
41,T25,"Scope 296 452	alteration in consciousness (for up to 24 hours after the injury), loss of consciousness 0-30 minutes, and/or post-traumatic amnesia up to 1 day post-injury"
42,R13,Subsumes Arg1:T11 Arg2:T25
43,T26,Condition 593 596	HAs
44,T27,Qualifier 584 592	Frequent
45,R14,Has_qualifier Arg1:T26 Arg2:T27
46,T28,Temporal 610 644	within 3months after a head injury
47,T29,Reference_point 631 644	a head injury
48,R15,Has_index Arg1:T28 Arg2:T29
49,R16,Has_temporal Arg1:T26 Arg2:T28
50,T30,Condition 650 653	HAs
51,T31,Multiplier 669 695	last 4 or more hours a day
52,T32,Qualifier 708 736	moderate to severe intensity
53,T33,Drug 839 846	triptan
54,T34,Drug 850 860	ergotamine
55,T35,Multiplier 923 956	at least 8 days per 4-week period
56,T36,Temporal 967 999	within 30 days after head injury
57,T37,Temporal 1033 1087	at least 3 months prior to the Initial Screening Visit
58,T38,Reference_point 1060 1087	the Initial Screening Visit
59,R17,Has_index Arg1:T37 Arg2:T38
60,T39,Scope 669 736	last 4 or more hours a day and reach a moderate to severe intensity
61,T40,Scope 839 860	triptan or ergotamine
62,*,OR T33 T34
63,*,OR T39 T40
64,T41,"Scope 669 860	last 4 or more hours a day and reach a moderate to severe intensity at any point during the headache, or 2) may be of any severity or duration if the participant takes a triptan or ergotamine"
65,R18,Has_scope Arg1:T30 Arg2:T41
66,R19,Has_multiplier Arg1:T30 Arg2:T35
67,R20,Has_temporal Arg1:T30 Arg2:T36
68,R21,Has_temporal Arg1:T30 Arg2:T37
69,T42,Pregnancy_considerations 1191 1479	Women of childbearing potential must agree to abstain from sexual relations that could result in pregnancy or use an effective method of birth control acceptable to both participant and the clinician prescriber during the study. Men are not required to use contraception during the study.
70,T43,Non-query-able 1482 1557	articipants must have English fluency sufficient to complete study measures
0,T1,Condition 0 8	Glaucoma
1,T2,Condition 11 25	Ocular allergy
2,T3,Condition 27 45	Autoimmune disease
3,T4,Observation 47 64	Contact lens-wear
4,T5,Temporal 65 77	during study
5,R1,Has_temporal Arg1:T4 Arg2:T5
6,T6,Temporal 79 86	Current
7,T7,Condition 87 103	punctal plugging
8,R2,Has_temporal Arg1:T7 Arg2:T6
9,T8,Condition 105 113	Pregnant
10,T9,Condition 114 123	lactating
11,*,OR T8 T9
12,T10,Mood 125 138	Candidate for
13,T11,Drug 139 164	topical anti-inflammatory
14,R3,Has_mood Arg1:T11 Arg2:T10
15,T12,Qualifier 166 177	Cicatricial
16,T13,Condition 178 205	meibomian gland dysfunction
17,R4,Has_qualifier Arg1:T13 Arg2:T12
0,T1,Condition 0 18	Multiple pregnancy
1,T2,Temporal 20 25	Prior
2,T3,Condition 26 51	spontaneous preterm birth
3,T4,Condition 72 78	losses
4,T5,Qualifier 79 108	between 16(0) and 36(6) weeks
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,T6,Qualifier 55 71	second trimester
7,R2,Has_qualifier Arg1:T4 Arg2:T6
8,*,OR T3 T4
9,T7,Scope 26 108	spontaneous preterm birth or second trimester losses between 16(0) and 36(6) weeks
10,R3,Has_temporal Arg1:T7 Arg2:T2
11,T8,Condition 110 126	Cerclage in situ
12,T9,Condition 128 163	Painful regular uterine contraction
13,T10,Condition 171 184	preterm labor
14,*,OR T9 T10
15,T11,Condition 186 204	Ruptured membranes
16,T12,Condition 206 225	Major fetal defects
17,T13,Condition 227 250	Active vaginal bleeding
18,T14,Condition 252 267	Placenda previa
19,T15,Condition 275 282	accreta
20,*,OR T14 T15
21,T16,Measurement 284 301	Cervical dilation
22,T17,Value 302 309	>1.5 cm
23,R4,Has_value Arg1:T16 Arg2:T17
24,T18,Condition 317 334	visible membranes
25,T19,Procedure 338 349	pelvic exam
26,R5,AND Arg1:T19 Arg2:T18
27,*,OR T16 T19
28,T20,Mood 351 363	Suspicion of
29,T21,Condition 364 380	chorioamnionitis
30,R6,Has_mood Arg1:T21 Arg2:T20
0,T1,Qualifier 11 18	healthy
1,T2,Person 19 25	adults
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Person 26 29	age
4,T4,Value 30 35	18-55
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 64 72	insomnia
7,T6,Qualifier 45 50	DSM-5
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Condition 125 129	PTSD
10,T8,Qualifier 77 88	Criterion A
11,R4,Has_qualifier Arg1:T7 Arg2:T8
12,T9,Condition 141 147	trauma
13,T10,Qualifier 135 140	index
14,R5,Has_qualifier Arg1:T9 Arg2:T10
15,T11,Temporal 174 212	the past 5 years and at least 3 months
16,R6,Has_temporal Arg1:T9 Arg2:T11
17,T12,Non-query-able 231 321	and insomnia symptoms must have started or worsened after the exposure to the index trauma
0,T1,Condition 21 31	narcolepsy
1,T2,Condition 37 46	cataplexy
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 50 57	healthy
4,*,OR T1 T3
0,T1,Condition 0 27	Meibomian Gland Dysfunction
1,T2,Mood 29 41	Eligible for
2,T3,Procedure 42 56	heat treatment
3,R1,Has_mood Arg1:T3 Arg2:T2
4,T4,Measurement 58 86	Ocular Surface Disease Index
5,T5,Measurement 88 92	OSDI
6,R2,Subsumes Arg1:T4 Arg2:T5
7,T6,Value 94 97	>12
8,R3,Has_value Arg1:T4 Arg2:T6
9,T7,Measurement 125 130;99 106	score Quality
10,T8,Measurement 110 130	expressibility score
11,T9,Non-representable 99 169	Quality or expressibility score =20 years old: >1 or >20 years old: =1
12,T10,Measurement 171 216	Non-invasive tear film break-up time (NITBUT)
13,T11,Value 217 222	<10 s
14,R4,Has_value Arg1:T10 Arg2:T11
15,T13,Multiplier 226 238	at least one
16,T14,Qualifier 239 242	eye
17,R5,Has_multiplier Arg1:T14 Arg2:T13
18,R6,Has_qualifier Arg1:T10 Arg2:T14
19,T12,Measurement 244 259	Schirmer-1 test
20,T15,Value 260 265	>5 mm
21,T16,Temporal 266 277	after 5 min
22,R7,Has_value Arg1:T12 Arg2:T15
23,R8,Has_temporal Arg1:T12 Arg2:T16
0,T1,Non-query-able 0 47	Participation in other interventional research.
1,T2,Condition 60 83	penetrating head injury
2,T3,Condition 96 99	TBI
3,T4,Value 100 121	more severe than mild
4,T5,Measurement 125 139	DVBIC criteria
5,R1,Has_value Arg1:T5 Arg2:T4
6,R2,AND Arg1:T3 Arg2:T5
7,T6,Qualifier 156 163	primary
8,T7,Qualifier 167 176	secondary
9,T8,Condition 177 188	HA disorder
10,T9,Condition 200 204	PTHA
11,T10,Negation 189 199	other than
12,R3,Has_negation Arg1:T9 Arg2:T10
13,R4,AND Arg1:T8 Arg2:T9
14,*,OR T7 T6
15,T11,Scope 156 176	primary or secondary
16,R5,Has_scope Arg1:T8 Arg2:T11
17,T12,Observation 206 222	Lifetime history
18,T13,Multiplier 226 235	5 or more
19,T14,Condition 236 244	migraine
20,T15,Qualifier 248 256	probable
21,T16,Condition 257 265	migraine
22,R6,Has_qualifier Arg1:T16 Arg2:T15
23,*,OR T16 T14
24,T17,Temporal 276 291	pre-dating mTBI
25,T18,Procedure 287 291	mTBI
26,T19,Reference_point 287 291	mTBI
27,R7,Has_index Arg1:T17 Arg2:T19
28,R8,multi Arg1:T19 Arg2:T18
29,T20,Scope 236 265	migraine or probable migraine
30,R9,Has_multiplier Arg1:T20 Arg2:T13
31,R10,Has_temporal Arg1:T20 Arg2:T12
32,R11,Has_temporal Arg1:T20 Arg2:T17
33,T21,Condition 293 296	HAs
34,T22,Qualifier 312 340	moderate or severe intensity
35,T23,Multiplier 347 384	average of more than 2 days per month
36,T24,Temporal 385 416	preceding the concussive trauma
37,R12,Has_multiplier Arg1:T21 Arg2:T23
38,R13,Has_temporal Arg1:T21 Arg2:T24
39,R14,Has_qualifier Arg1:T21 Arg2:T22
40,T25,Condition 429 432	HAs
41,T26,Qualifier 418 428	Continuous
42,R15,Has_qualifier Arg1:T25 Arg2:T26
43,T27,Qualifier 452 462	persistent
44,T28,Multiplier 463 468	daily
45,T29,Measurement 481 495;514 529	HA-free period between attacks
46,T30,Value 496 513	less than 8 hours
47,R16,Has_value Arg1:T29 Arg2:T30
48,T31,Negation 478 480	no
49,R17,Has_negation Arg1:T29 Arg2:T31
50,T32,Condition 469 472	HAs
51,R18,Has_multiplier Arg1:T32 Arg2:T28
52,R19,Has_qualifier Arg1:T32 Arg2:T27
53,R20,AND Arg1:T32 Arg2:T29
54,R21,Subsumes Arg1:T25 Arg2:T32
55,T33,Qualifier 532 537	Acute
56,T34,Qualifier 541 548	serious
57,T35,Condition 549 564	medical illness
58,T36,Qualifier 568 576	unstable
59,T37,Condition 577 600	chronic medical illness
60,T38,Condition 608 623	unstable angina
61,T39,Condition 625 646	myocardial infarction
62,T40,Temporal 647 662	within 6 months
63,R22,Has_temporal Arg1:T39 Arg2:T40
64,T41,Condition 664 688	congestive heart failure
65,T42,Qualifier 690 712	clinically significant
66,T43,Qualifier 716 726	concerning
67,T44,Condition 727 746	cardiac arrhythmias
68,*,OR T42 T43
69,T45,Temporal 748 759	preexisting
70,T46,Condition 760 771	hypotension
71,T47,Measurement 773 796	systolic blood pressure
72,T48,Value 796 800	<110
73,T49,Condition 805 828	orthostatic hypotension
74,T50,Measurement 830 843	systolic drop
75,T51,Value 844 853	>20 mm Hg
76,T52,Temporal 854 874	after 2 min standing
77,T53,Condition 890 905	lightheadedness
78,T54,Condition 908 921;933 940	chronic renal failure
79,T55,Condition 925 940	hepatic failure
80,T56,Condition 942 960	acute pancreatitis
81,T57,Condition 962 979	Meniere's disease
82,T58,Condition 1008 1019	sleep apnea
83,T59,Qualifier 998 1007	untreated
84,T60,"Non-representable 1022 1220	The eligibility of potential participants having acute serious and/or chronic medical illnesses other than those listed will be evaluated on a case-by-case basis by a study physician, PA-C, or ARNP."
85,*,OR T34 T33
86,T61,Scope 532 548	Acute or serious
87,R23,Has_scope Arg1:T35 Arg2:T61
88,R24,Has_qualifier Arg1:T37 Arg2:T36
89,T62,Scope 690 726	clinically significant or concerning
90,R25,Has_scope Arg1:T44 Arg2:T62
91,R26,Has_temporal Arg1:T46 Arg2:T45
92,R27,Has_value Arg1:T47 Arg2:T48
93,R28,Has_value Arg1:T50 Arg2:T51
94,R29,Has_temporal Arg1:T50 Arg2:T52
95,T63,Scope 830 905	systolic drop >20 mm Hg after 2 min standing accompanied by lightheadedness
96,R30,Subsumes Arg1:T49 Arg2:T63
97,R31,Has_qualifier Arg1:T58 Arg2:T59
98,R32,Subsumes Arg1:T46 Arg2:T47
99,*,OR T46 T49 T54 T55 T56 T57 T58 T39 T38 T41 T44
100,T64,"Scope 608 1019	unstable angina, myocardial infarction within 6 months, congestive heart failure, clinically significant or concerning cardiac arrhythmias; preexisting hypotension [systolic blood pressure<110] or orthostatic hypotension [systolic drop >20 mm Hg after 2 min standing accompanied by lightheadedness], chronic renal or hepatic failure, acute pancreatitis, Meniere's disease, or diagnosed but untreated sleep apnea"
101,*,OR T35 T37
102,T65,Scope 532 600	Acute or serious medical illness or unstable chronic medical illness
103,R33,Subsumes Arg1:T65 Arg2:T64
104,T66,Drug 1229 1237	prazosin
105,T67,Qualifier 1241 1246	other
106,T68,Drug 1247 1265	alpha-1 antagonist
107,T69,Drug 1296 1305	alfuzosin
108,T70,Drug 1307 1316	doxazosin
109,T71,Drug 1318 1327	silodosin
110,T72,Drug 1329 1339	tamsulosin
111,T73,Drug 1341 1350	terazosin
112,T74,Temporal 1368 1417	in the 2 weeks prior to initial screen (P1) visit
113,T75,Reference_point 1392 1417	initial screen (P1) visit
114,R34,Has_index Arg1:T74 Arg2:T75
115,R35,Has_qualifier Arg1:T68 Arg2:T67
116,*,OR T66 T68
117,T76,Scope 1229 1265	prazosin or other alpha-1 antagonist
118,*,OR T69 T70 T71 T72 T73
119,T77,"Scope 1296 1350	alfuzosin, doxazosin, silodosin, tamsulosin, terazosin"
120,R36,Subsumes Arg1:T76 Arg2:T77
121,R37,Has_temporal Arg1:T76 Arg2:T74
122,T78,Condition 1455 1462	Allergy
123,T79,Condition 1475 1491	adverse reaction
124,T80,Temporal 1466 1474	previous
125,R38,Has_temporal Arg1:T79 Arg2:T80
126,T81,Drug 1495 1503	prazosin
127,T82,Drug 1513 1531	alpha-1 antagonist
128,T83,Qualifier 1507 1512	other
129,R39,Has_qualifier Arg1:T82 Arg2:T83
130,*,OR T81 T82
131,T84,Scope 1495 1531	prazosin or other alpha-1 antagonist
132,*,OR T78 T79
133,T85,Scope 1455 1491	Allergy or previous adverse reaction
134,R40,Has_scope Arg1:T85 Arg2:T84
135,T86,Condition 1553 1571	psychotic disorder
136,T87,Condition 1540 1549	psychosis
137,T88,Qualifier 1533 1539	Active
138,T89,Condition 1573 1590	severe depression
139,T90,Condition 1649 1672	psychiatric instability
140,T91,Qualifier 1642 1648	severe
141,R41,Has_qualifier Arg1:T90 Arg2:T91
142,T92,Condition 1683 1706	situational life crisis
143,T93,Qualifier 1676 1682	severe
144,R42,Has_qualifier Arg1:T92 Arg2:T93
145,T94,Condition 1745 1753	suicidal
146,T95,Condition 1757 1766	homicidal
147,*,OR T94 T95
148,*,OR T87 T86 T89 T90 T92
149,T96,Scope 1745 1766	suicidal or homicidal
150,R43,Subsumes Arg1:T92 Arg2:T96
151,R44,Has_qualifier Arg1:T87 Arg2:T88
152,T97,Condition 1868 1890	Substance Use Disorder
153,T98,Condition 1898 1924	caffeine-related disorders
154,T99,Negation 1891 1897	except
155,T100,Condition 1929 1954	tobacco-related disorders
156,*,OR T98 T100
157,T101,"Scope 1898 1954	caffeine-related disorders, or tobacco-related disorders"
158,R45,Has_negation Arg1:T101 Arg2:T99
159,R46,Has_scope Arg1:T97 Arg2:T101
160,T102,"Measurement 1776 1859	Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria"
161,T103,Value 1770 1775	Meets
162,R47,Has_value Arg1:T102 Arg2:T103
163,R48,AND Arg1:T97 Arg2:T102
164,T104,Condition 1968 1976	delirium
165,T105,Temporal 1977 2002	within the prior 3 months
166,R49,Has_temporal Arg1:T104 Arg2:T105
167,T106,Condition 2004 2012	epilepsy
168,T107,Condition 2014 2020	stroke
169,T108,Condition 2022 2030	dementia
170,T109,Condition 2032 2050	psychotic disorder
171,T110,Condition 2055 2071	bipolar disorder
172,*,OR T109 T110 T108 T107 T106 T104
173,T111,Condition 2073 2103	Structural brain abnormalities
174,T112,Procedure 2117 2124	imaging
175,T113,Temporal 2111 2116	prior
176,T114,Qualifier 2107 2110	any
177,R50,Has_qualifier Arg1:T112 Arg2:T114
178,R51,Has_temporal Arg1:T112 Arg2:T113
179,R52,AND Arg1:T111 Arg2:T112
180,T115,Qualifier 2141 2159	clinically evident
181,T116,Condition 2160 2174	manifestations
182,R53,Has_qualifier Arg1:T116 Arg2:T115
183,R54,AND Arg1:T111 Arg2:T116
184,T117,Procedure 2201 2242	transcranial magnetic stimulation studies
185,T118,Temporal 2176 2183	Current
186,R55,Has_temporal Arg1:T117 Arg2:T118
187,T119,Condition 2253 2275	childbearing potential
188,T120,Person 2244 2249	Women
189,T121,Negation 2281 2287	not be
190,T122,Condition 2288 2296	pregnant
191,T123,Mood 2298 2316	planning to become
192,T124,Condition 2317 2325	pregnant
193,T125,Temporal 2326 2349	during the study period
194,T126,Condition 2354 2361	nursing
195,R56,Has_temporal Arg1:T126 Arg2:T125
196,R57,Has_mood Arg1:T124 Arg2:T123
197,*,OR T124 T126 T122
198,T127,"Scope 2288 2361	pregnant, planning to become pregnant during the study period, or nursing"
199,R58,Has_negation Arg1:T127 Arg2:T121
200,T128,Scope 2244 2275	Women of childbearing potential
201,R59,Has_scope Arg1:T128 Arg2:T127
202,T129,Procedure 2364 2399	Participation in a HA support group
203,T130,Procedure 2426 2436	meditation
204,T131,Procedure 2440 2444	yoga
205,T132,Non-representable 2364 2611	Participation in a HA support group or other activity such as meditation or yoga intended to mitigate HA or other chronic pain must be stable at least 4 weeks prior to beginning the initial screen (P1) visit and may not be started during the study
206,T133,Observation 2613 2638	Failure to record HA data
207,T134,Multiplier 2639 2663	for at least 80% of days
208,T135,Temporal 2664 2691	during the Screening Period
209,R60,Has_multiplier Arg1:T133 Arg2:T134
210,R61,Has_temporal Arg1:T133 Arg2:T135
211,T136,Non-query-able 2693 2740	Not suitable for study per clinician judgement.
212,T137,"Non-representable 2742 3336	The use of HA rescue or symptom-relieving medications will be allowed during the study. This includes triptans, ergotamines, opioids, simple analgesics (e.g. acetaminophen, aspirin, or non-steroidal anti-inflammatories [NSAIDS], and combination analgesics. Their use will be recorded on the concurrent medication CRF during the Preliminary Screening Period (P1) and throughout the remainder of the study. Randomization of participants will be stratified based on whether their use of HA medications meets ICHD-3 beta criteria for overuse of these medications, as described in section 5.5 below."
213,T138,"Non-representable 3338 3835	Opioid Medications: Use of opioids for treatment of HA or non-HA-related pain or for any other purpose is allowed during the study. Any opioid use would ideally be excluded due to potential confounding effects on interpretation of response to treatment. However, in this population, particularly in Veterans with chronic pain or undergoing minor orthopedic or dental procedures, opioid use is common. Use of opioids, including frequency and dose, will be recorded on the concurrent medication CRF."
214,T139,Drug 3890 3901	medications
215,T140,Multiplier 3902 3920	on a routine basis
216,T141,Qualifier 3934 3945	stable dose
217,T142,Temporal 3946 4013	for at least 4 weeks prior to the Preliminary Screening Period (P1)
218,R62,Has_temporal Arg1:T141 Arg2:T142
219,T143,Qualifier 3884 3889	other
220,R63,Has_qualifier Arg1:T139 Arg2:T143
221,R64,Has_multiplier Arg1:T139 Arg2:T140
222,T144,Scope 3884 3920	other medications on a routine basis
223,A1,Optional T144
224,R65,Has_qualifier Arg1:T144 Arg2:T141
225,T145,Non-representable 4177 4220	The following medications are not excluded:
226,T146,"Non-representable 4222 4326	Psychoactive drugs (for example, anticonvulsants, benzodiazepines, antidepressants, sedative/hypnotics),"
227,T147,"Non-representable 4328 4492	Antihypertensive medications (including beta-blockers, calcium channel blockers, angiotensin converting enzyme [ACE] inhibitors, and angiotensin receptor blockers),"
228,T148,"Non-representable 4494 4734	The use of magnesium in any dose that is prescribed for the purpose of HA prevention or treatment must be stable for at least 4 weeks. The incidental use of magnesium in multi-vitamins, laxatives, etc. is permissible but must be documented."
229,T149,"Non-representable 4736 4812	Hormones (for example, testosterone, estrogen, or progesterone) in any form."
230,T150,"Non-representable 4814 4988	The ""as-needed"" (prn) use of psychoactive and other drugs such as antibiotics is not excluded; however, such use must be discussed with a clinician prescriber and documented."
231,T151,Drug 5001 5011	butalbital
232,T152,Temporal 5024 5089	within 4 weeks of beginning the Preliminary Screening Period (P1)
233,R66,Has_temporal Arg1:T151 Arg2:T152
234,T153,Non-representable 5163 5534	Participants who have been taking trazodone will undergo a 2-week washout period before the Preliminary Screening Period (P1 visit). Combining prazosin and trazodone may increase the risk of priapism. We have decided to begin the washout period before the Preliminary Screening Period in order to remove any confounding variables while on the headache log and actigraphy.
235,T154,Drug 5536 5546	Sildenafil
236,T155,Drug 5548 5554	Viagra
237,T156,Drug 5557 5566	tadalafil
238,T157,Drug 5568 5574	Cialis
239,T158,Drug 5577 5587	vardenafil
240,T159,Drug 5589 5596	Levitra
241,T160,Drug 5603 5611	avanafil
242,T161,Drug 5613 5620	Stendra
243,R67,Subsumes Arg1:T154 Arg2:T155
244,R68,Subsumes Arg1:T156 Arg2:T157
245,R69,Subsumes Arg1:T158 Arg2:T159
246,R70,Subsumes Arg1:T160 Arg2:T161
247,T162,Temporal 5644 5687	during the study drug dose Titration Period
248,*,OR T154 T156 T158 T160
249,T163,"Scope 5536 5621	Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra)"
250,R71,Has_temporal Arg1:T163 Arg2:T162
251,T164,Drug 5930 5938	nitrates
252,T165,Drug 5966 5976	stimulants
253,T166,Drug 5986 5993	ephedra
254,R72,Subsumes Arg1:T165 Arg2:T166
255,*,OR T164 T165
256,T167,Temporal 6012 6063	in the two weeks prior to initial screen (P1) visit
257,T168,Scope 5930 5994	nitrates and supplements containing stimulants (such as ephedra)
258,R73,Has_temporal Arg1:T168 Arg2:T167
259,T169,Drug 6263 6284	prescribed stimulants
260,T170,Drug 6294 6305	amphetamine
261,T171,Drug 6309 6326	dextroamphetamine
262,*,OR T170 T171
263,T172,Scope 6294 6326	amphetamine or dextroamphetamine
264,R74,Subsumes Arg1:T169 Arg2:T172
265,T173,Temporal 6367 6420	in the 2 weeks prior to the initial screen (P1) visit
266,R75,Has_temporal Arg1:T169 Arg2:T173
0,T1,Condition 0 21	Psychiatric disorders
1,T2,Negation 22 27	other
2,T3,Condition 33 41	insomnia
3,T4,Condition 43 47	PTSD
4,T5,Condition 61 68	phobias
5,T6,Condition 80 87	bipolar
6,T7,Condition 92 111	psychotic disorders
7,T8,Temporal 193 202	past year
8,T9,Qualifier 137 142	DSM-5
9,T10,Qualifier 143 151	moderate
10,T11,Condition 163 181	drug use disorders
11,T12,Condition 152 159;168 181	alcohol use disorders
12,*,OR T6 T7
13,T13,Scope 80 111	bipolar and psychotic disorders
14,R1,Subsumes Arg1:T1 Arg2:T13
15,*,OR T3 T4 T5
16,T14,"Scope 33 68	insomnia, PTSD and specific phobias"
17,R2,Has_negation Arg1:T14 Arg2:T2
18,*,OR T11 T12
19,T15,Scope 152 181	alcohol or drug use disorders
20,R3,Has_qualifier Arg1:T15 Arg2:T10
21,R4,Has_qualifier Arg1:T15 Arg2:T9
22,R5,Has_temporal Arg1:T15 Arg2:T8
23,T16,Condition 220 234	sleep disorder
24,T17,Negation 235 240	other
25,T18,Condition 246 254	insomnia
26,T19,Condition 281 286	apnea
27,T20,Condition 287 295	hypopnea
28,T21,Measurement 299 329	periodic limb movement indices
29,T22,Value 330 339	> 10/hour
30,R6,Has_value Arg1:T21 Arg2:T22
31,*,OR T19 T20
32,T23,Measurement 265 268	PSG
33,T24,Scope 281 295	apnea/hypopnea
34,R7,Has_scope Arg1:T23 Arg2:T24
35,*,OR T23 T21
36,T25,Scope 265 339	PSG findings of apnea/hypopnea or periodic limb movement indices > 10/hour
37,R8,Subsumes Arg1:T16 Arg2:T25
38,R9,Has_negation Arg1:T18 Arg2:T17
39,T26,Non-query-able 342 422	Medical conditions that require consistent use of medication or compromise sleep
40,T27,Condition 455 477	traumatic brain injury
41,T28,Qualifier 436 444	moderate
42,T29,Qualifier 448 454	severe
43,T30,Condition 486 508	traumatic brain injury
44,T31,Qualifier 481 485	mild
45,T32,Condition 522 546	post-concussive symptoms
46,R10,Has_qualifier Arg1:T30 Arg2:T31
47,R11,AND Arg1:T30 Arg2:T32
48,*,OR T29 T28
49,T33,Scope 436 454	moderate to severe
50,R12,Has_scope Arg1:T27 Arg2:T33
51,*,OR T27 T30
52,T34,Condition 549 566	Suicidal ideation
53,T35,Temporal 626 639	past 6 months
54,R13,Has_temporal Arg1:T34 Arg2:T35
55,T36,Measurement 668 706	Columbia Suicide Severity Rating Scale
56,T37,Value 641 645;650 660	Type 5 ideation
57,T38,Value 641 647;652 660	Type 4 ideation
58,*,OR T37 T38
59,T39,Scope 641 660	Type 4 - 5 ideation
60,R14,Has_scope Arg1:T36 Arg2:T39
61,T40,Condition 741 759	suicidal behavior.
62,T41,Drug 761 769	Caffeine
63,T42,Non-query-able 761 826	Caffeine use exceeding 5 cups of coffee per day or its equivalent
64,T43,"Non-query-able 829 923	Habitual bedtimes after 3 AM, habitual rise times after 10 AM, or habitual napping > 1hour/day"
65,T44,"Pregnancy_considerations 926 993	Pregnancy or breastfeeding, or expecting to conceive while in study"
66,T45,Measurement 1005 1021	urine toxicology
67,T46,Value 996 1004	Positive
68,R15,Has_value Arg1:T45 Arg2:T46
0,T1,Person 6 10	ages
1,T2,Value 0 5	18-50
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 33 48	Cervical length
4,T4,Value 49 55	<=25mm
5,T5,Qualifier 56 85	between 18(0) and 23(6) weeks
6,R2,Has_qualifier Arg1:T3 Arg2:T5
7,R3,Has_value Arg1:T3 Arg2:T4
8,T6,Condition 12 31	Singleton pregnancy
0,T1,Person 0 5	Adult
1,T2,Person 6 9	men
2,T3,Person 14 19	women
3,T4,Value 19 33	> 18 years old
4,T5,Person 30 33	old
5,R1,Has_value Arg1:T5 Arg2:T4
6,*,OR T2 T3
7,T6,Qualifier 47 56	sustained
8,T7,Condition 57 80	ventricular tachycardia
9,T8,Measurement 86 88	HR
10,T9,Value 88 97	> 120 bpm
11,R2,Has_value Arg1:T8 Arg2:T9
12,R3,Has_qualifier Arg1:T7 Arg2:T6
13,R4,AND Arg1:T7 Arg2:T8
14,T10,Measurement 99 122	Systolic blood pressure
15,T11,Value 122 131	> 90 mmHg
16,R5,Has_value Arg1:T10 Arg2:T11
17,T12,Negation 133 135	No
18,T13,Mood 136 144	signs of
19,T14,Condition 145 170	poor peripheral perfusion
20,R6,Has_mood Arg1:T14 Arg2:T13
21,R7,Has_negation Arg1:T14 Arg2:T12
22,T15,Condition 183 190	dyspnea
23,T16,Negation 172 182	Absence of
24,R8,Has_negation Arg1:T15 Arg2:T16
25,T17,Negation 192 202	Absence of
26,T18,Condition 210 216	angina
27,T19,Qualifier 203 209	severe
28,R9,Has_qualifier Arg1:T18 Arg2:T19
29,R10,Has_negation Arg1:T18 Arg2:T17
30,T20,Informed_consent 218 237	Signed consent form
0,T1,Temporal 0 8	Previous
1,T2,Drug 21 26	drugs
2,T3,Drug 35 45	fingolimod
3,T4,Drug 47 58	natalizumab
4,T5,Drug 60 71	alemtuzumab
5,T6,Drug 73 85	mitoxantrone
6,T7,Drug 90 101	ocrelizumab
7,*,OR T7 T6 T5 T4 T3
8,T8,"Scope 35 101	fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab"
9,R1,Subsumes Arg1:T2 Arg2:T8
10,R2,Has_temporal Arg1:T2 Arg2:T1
11,T9,Value 104 112	Positive
12,T10,Measurement 113 124;140 160	hepatitis C surface antigen test
13,T11,Measurement 128 160	hepatitis B surface antigen test
14,T12,Measurement 168 197	hepatits B core antibody test
15,T13,Qualifier 202 224	immunoglobulin G (IgG)
16,T14,Qualifier 232 254	immunoglobulin M (IgM)
17,*,OR T13 T14
18,T15,Scope 202 254	immunoglobulin G (IgG) and/or immunoglobulin M (IgM)
19,R3,Has_scope Arg1:T12 Arg2:T15
20,*,OR T10 T11 T12
21,T16,Scope 113 254	hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM)
22,R4,Has_value Arg1:T16 Arg2:T9
23,T17,Temporal 257 264	Current
24,T18,Temporal 268 284	previous history
25,T20,Condition 288 315	immune deficiency disorders
26,T21,Measurement 337 371	human immunodeficiency virus (HIV)
27,T22,Value 328 336	positive
28,R5,Has_value Arg1:T21 Arg2:T22
29,R6,Subsumes Arg1:T20 Arg2:T21
30,*,OR T18 T17
31,T19,Scope 257 284	Current or previous history
32,R7,Has_scope Arg1:T20 Arg2:T19
33,T23,Procedure 401 418;439 446	immunosuppressive therapy
34,T24,Procedure 422 446	myelosuppressive therapy
35,*,OR T24 T23
36,T25,Temporal 381 390	Currently
37,T26,Drug 466 487	monoclonal antibodies
38,T27,Drug 489 501	methotrexate
39,T28,Drug 503 519	cyclophosphamide
40,T29,Drug 521 533	cyclosporine
41,T30,Drug 537 549	azathioprine
42,T31,Drug 569 584	corticosteroids
43,T32,Multiplier 554 565	chronic use
44,R8,Has_multiplier Arg1:T31 Arg2:T32
45,*,OR T30 T31 T29 T28 T27 T26
46,T33,"Scope 466 584	monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids"
47,T34,Scope 401 446	immunosuppressive or myelosuppressive therapy
48,R9,Subsumes Arg1:T34 Arg2:T33
49,R10,Has_temporal Arg1:T34 Arg2:T25
50,T35,Procedure 598 610	tuberculosis
51,T36,Procedure 632 644	tuberculosis
52,T37,Procedure 656 668	tuberculosis
53,T38,Qualifier 649 655	latent
54,T39,Qualifier 625 631	active
55,R11,Has_qualifier Arg1:T36 Arg2:T39
56,R12,Has_qualifier Arg1:T37 Arg2:T38
57,T40,Observation 587 594	History
58,R13,Has_temporal Arg1:T35 Arg2:T40
59,*,OR T35 T36 T37
60,T41,Condition 693 741	Progressive Multifocal Leukoencephalopathy (PML)
61,T42,Procedure 745 777	Magnetic Resonance Imaging (MRI)
62,R14,AND Arg1:T42 Arg2:T41
63,T43,Mood 670 678	Evidence
64,T44,Mood 682 689	suspect
65,*,OR T44 T43
66,T45,Scope 670 689	Evidence or suspect
67,R15,Has_scope Arg1:T41 Arg2:T45
68,T46,Observation 801 808	history
69,T47,Condition 812 822	malignancy
70,T48,Condition 787 797	malignancy
71,T49,Qualifier 780 786	Active
72,R16,Has_temporal Arg1:T47 Arg2:T46
73,R17,Has_qualifier Arg1:T48 Arg2:T49
74,*,OR T48 T47
75,T50,Non-representable 825 879	Other protocol defined exclusion criteria could apply.
0,T1,Condition 0 25	Non-ST segement elevation
1,T2,Condition 26 49	acute coronary syndrome
0,T1,Qualifier 0 13	Highly active
1,T2,Condition 14 17	RMS
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Non-representable 18 32	as defined by:
4,T4,Multiplier 34 37	One
5,T5,Condition 38 45	relapse
6,T6,Temporal 46 66	in the previous year
7,R2,Has_temporal Arg1:T5 Arg2:T6
8,R3,Has_multiplier Arg1:T5 Arg2:T4
9,T7,Multiplier 71 81	at least 1
10,T8,Condition 102 108	lesion
11,T9,Qualifier 82 101	T1 Gadolinium (Gd)+
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Multiplier 112 121	9 or more
14,T11,Condition 122 132	T2 lesions
15,T12,Temporal 134 150	while on therapy
16,T13,Reference_point 143 150	therapy
17,T14,Procedure 143 150	therapy
18,R5,Has_index Arg1:T12 Arg2:T13
19,R6,multi Arg1:T13 Arg2:T14
20,R7,Has_multiplier Arg1:T11 Arg2:T10
21,R8,Has_multiplier Arg1:T8 Arg2:T7
22,*,OR T8 T11
23,T15,Drug 162 192	disease modifying drugs (DMDs)
24,T16,Qualifier 156 161	other
25,R9,Has_qualifier Arg1:T15 Arg2:T16
26,T17,Scope 34 132	One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions
27,R10,Has_temporal Arg1:T17 Arg2:T12
28,R11,AND Arg1:T14 Arg2:T15
29,T18,Multiplier 194 205	Two or more
30,T19,Condition 206 214	relapses
31,T20,Temporal 215 235	in the previous year
32,R12,Has_temporal Arg1:T19 Arg2:T20
33,R13,Has_multiplier Arg1:T19 Arg2:T18
34,T21,Measurement 271 316	Expanded Disability Status Scale (EDSS) score
35,T22,Value 317 345	less than equals to (<=) 5.0
36,R14,Has_value Arg1:T21 Arg2:T22
37,T23,Post-eligibility 348 402	Other protocol defined inclusion criteria could apply.
0,T1,Condition 0 9	Pregnancy
1,T2,Condition 11 34	Hemodynamic instability
2,T3,Measurement 36 51	Body mass index
3,T4,Value 52 75	greater than 40 kg / m2
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Qualifier 84 95	intravenous
6,T6,Drug 96 106	amiodarone
7,T7,Drug 110 119	lidocaine
8,T8,Temporal 120 140	in the last 24 hours
9,*,OR T7 T6
10,T9,Scope 96 119	amiodarone or lidocaine
11,R2,Has_temporal Arg1:T9 Arg2:T8
12,R3,Has_qualifier Arg1:T9 Arg2:T5
13,T10,Condition 142 165	Acute coronary syndrome
14,T11,Condition 179 190	tachycardia
15,T12,Condition 196 205;226 228	irregular RR
16,T13,Condition 209 228	supraventricular RR
17,*,OR T12 T13
18,T14,Condition 230 247	Contraindications
19,T15,Drug 251 262	study drugs
20,R4,AND Arg1:T14 Arg2:T15
0,T1,Condition 0 17	Left main disease
1,T2,Condition 25 41	hypersensitivity
2,T3,Condition 45 61	contraindication
3,*,OR T2 T3
4,T4,Drug 99 106	Heparin
5,T5,Drug 108 115	aspirin
6,T6,Drug 117 128	clopidogrel
7,T7,Drug 130 139	sirolimus
8,T8,Drug 141 153	siptagliptin
9,T9,Drug 158 164	statin
10,*,OR T9 T8 T7 T6 T5 T4
11,T10,"Scope 99 164	Heparin, aspirin, clopidogrel, sirolimus, siptagliptin and statin"
12,T11,Scope 25 61	hypersensitivity or contraindication
13,R1,Has_scope Arg1:T11 Arg2:T10
14,T12,Condition 166 190	Congestive heart failure
15,T13,Measurement 206 210	LVEF
16,T14,Value 211 215	<30%
17,T15,Condition 219 236	cardiogenic shock
18,R2,Has_value Arg1:T13 Arg2:T14
19,*,OR T13 T15
20,T16,Scope 207 236	VEF <30% or cardiogenic shock
21,R3,Subsumes Arg1:T12 Arg2:T16
22,T17,Condition 252 271	myocardial ischemia
23,T18,Qualifier 239 251	Uncontrolled
24,R4,Has_qualifier Arg1:T17 Arg2:T18
25,T19,Condition 282 292	chest pain
26,T20,Qualifier 273 281	repeated
27,T21,Condition 296 303	dyspnea
28,T22,Temporal 304 327	after revascularization
29,T23,Reference_point 310 327	revascularization
30,T24,Procedure 310 327	revascularization
31,R5,Has_index Arg1:T22 Arg2:T23
32,R6,multi Arg1:T23 Arg2:T24
33,*,OR T21 T19
34,T25,Scope 282 303	chest pain or dyspnea
35,R7,Has_qualifier Arg1:T25 Arg2:T20
36,R8,Has_temporal Arg1:T25 Arg2:T22
37,R9,Subsumes Arg1:T17 Arg2:T25
38,T26,Condition 343 365	ventricular arrhythmia
39,T27,Qualifier 330 342	Uncontrolled
40,R10,Has_qualifier Arg1:T26 Arg2:T27
41,T28,Condition 378 388	malignancy
42,T29,Procedure 394 406	chemotherapy
43,R11,AND Arg1:T28 Arg2:T29
44,T30,Condition 416 435	hematologic disease
45,T31,Qualifier 408 415	Serious
46,R12,Has_qualifier Arg1:T30 Arg2:T31
47,T32,Condition 442 445	CML
48,T33,Condition 447 450	MDS
49,*,OR T32 T33
50,T34,"Scope 442 450	CML, MDS"
51,R13,Subsumes Arg1:T30 Arg2:T34
52,T35,Condition 461 479	infectious disease
53,T36,Drug 486 497	antibiotics
54,R14,AND Arg1:T35 Arg2:T36
55,T37,Measurement 507 523	Creatinine level
56,T38,Value 524 534	>1.5 mg/dL
57,T39,Procedure 552 560	dialysis
58,R15,Has_value Arg1:T37 Arg2:T38
59,*,OR T37 T39
60,T40,Condition 600 616	active infection
61,T41,Condition 618 628	malignancy
62,*,OR T40 T41
63,T42,Condition 586 593	illness
64,T43,Qualifier 575 585	concurrent
65,T44,Qualifier 568 574	severe
66,R16,Has_qualifier Arg1:T42 Arg2:T43
67,R17,Has_qualifier Arg1:T42 Arg2:T44
68,T45,"Scope 600 628	active infection, malignancy"
69,R18,Subsumes Arg1:T42 Arg2:T45
70,T46,Observation 633 647	ife expectancy
71,T47,Value 651 669	less than one year
72,R19,Has_value Arg1:T46 Arg2:T47
73,T48,Pregnancy_considerations 671 717	Pregnancy or women with potential childbearing
74,T49,Condition 719 728	Type I DM
75,T50,Drug 745 752	insulin
76,T51,Condition 765 777	pancreatitis
77,T52,"Informed_consent 779 849	Who cannot read the informed consent form (e.g. illiteracy, foreigner)"
0,T1,Condition 0 19	Unilateral leg pain
1,T2,Condition 33 49	lateral stenosis
2,T3,Condition 51 66	disc protrusion
3,T4,Condition 70 84	herniated disc
4,*,OR T4 T3 T2
5,T5,"Scope 33 84	lateral stenosis, disc protrusion or herniated disc"
6,R1,AND Arg1:T5 Arg2:T1
7,T6,Person 87 90	Age
8,T7,Value 91 114	between 18 and 80 years
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Condition 136 140	pain
11,T9,Measurement 142 145	NVS
12,T10,Value 145 148	>4)
13,R3,Has_value Arg1:T9 Arg2:T10
14,R4,AND Arg1:T8 Arg2:T9
15,T11,Qualifier 129 135	severe
16,T12,Qualifier 117 125	Moderate
17,*,OR T11 T12
18,T13,Scope 117 135	Moderate to severe
19,R5,Has_scope Arg1:T8 Arg2:T13
20,T14,Post-eligibility 151 193	Right proficient oral and written language
0,T1,Condition 24 49	chronic myeloid leukaemia
1,T2,Procedure 109 145	allogeneic stem cell transplantation
2,T3,Temporal 146 179	between 01/01/2010 and 30/09/2013
3,T4,Drug 218 227	Nilotinib
4,T5,Drug 231 240	Dasatinib
5,*,OR T4 T5
6,T6,Temporal 194 204	previously
7,T7,Scope 218 240	Nilotinib or Dasatinib
8,R1,Has_temporal Arg1:T7 Arg2:T6
9,R2,Has_temporal Arg1:T2 Arg2:T3
10,T8,Qualifier 64 71	chronic
11,T9,Qualifier 73 84	accelerated
12,T10,Qualifier 88 95	blastic
13,T11,Qualifier 53 62	any phase
14,R3,Has_qualifier Arg1:T1 Arg2:T11
15,T12,"Scope 64 95	chronic, accelerated or blastic"
16,*,OR T8 T9 T10
17,R4,Subsumes Arg1:T11 Arg2:T12
18,T13,Person 4 9	adult
0,T1,Condition 5 22	singleton infants
1,T2,Condition 0 4;15 22	Term infants
2,T3,Value 24 33	>37 weeks
3,T4,Measurement 34 49	gestational age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Scope 0 22	Term singleton infants
6,*,OR T1 T2
7,T6,Scope 24 49	>37 weeks gestational age
8,R2,Has_scope Arg1:T5 Arg2:T6
9,T7,Measurement 52 64	Birth weight
10,T8,Value 65 72	> 2500g
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Condition 74 81	Healthy
13,T10,Temporal 82 94	at inclusion
14,R4,Has_temporal Arg1:T9 Arg2:T10
15,T11,Condition 96 105	Breastfed
16,T12,Qualifier 106 117	exclusively
17,T13,Qualifier 121 134	predominantly
18,*,OR T12 T13
19,T14,Multiplier 136 146	>50% meals
20,T15,Temporal 148 160	at inclusion
21,T16,Scope 106 134	exclusively or predominantly
22,R5,Subsumes Arg1:T16 Arg2:T14
23,R6,Has_scope Arg1:T11 Arg2:T16
24,R7,Has_temporal Arg1:T11 Arg2:T15
25,T17,Negation 162 164	No
26,T18,Temporal 165 173	previous
27,T19,Procedure 174 194	iron supplementation
28,R8,Has_temporal Arg1:T19 Arg2:T18
29,R9,Has_negation Arg1:T19 Arg2:T17
30,T20,Negation 196 198	No
31,T21,Temporal 199 207	previous
32,T22,Procedure 208 225	blood transfusion
33,R10,Has_temporal Arg1:T22 Arg2:T21
34,R11,Has_negation Arg1:T22 Arg2:T20
35,T23,Informed_consent 227 249	Informed consent given
0,T1,Condition 0 19	Pulseless extremity
1,T2,Condition 21 50	Compromised neurologic status
2,T3,Qualifier 113 118;87 93	nerve radial
3,T4,Qualifier 113 118;95 100	nerve ulnar
4,T5,Qualifier 106 118	median nerve
5,*,OR T3 T4 T5
6,T6,"Scope 87 118	radial, ulnar, and median nerve"
7,R1,Has_scope Arg1:T2 Arg2:T6
8,T7,Condition 127 134	allergy
9,T8,Drug 138 155	local anesthetics
10,R2,AND Arg1:T7 Arg2:T8
11,T9,Negation 160 163	Not
12,T10,Mood 164 177	scheduled for
13,T11,Procedure 178 220	closed reduction with percutaneous pinning
14,T12,Procedure 227 245	general anesthesia
15,R3,AND Arg1:T11 Arg2:T12
16,R4,Has_mood Arg1:T11 Arg2:T10
17,R5,Has_negation Arg1:T10 Arg2:T9
18,T13,Condition 247 265	Bleeding diathesis
19,T14,Measurement 267 316	American Society of Anesthesiologist (ASA) status
20,T15,Value 317 328	4 or higher
21,R6,Has_value Arg1:T14 Arg2:T15
22,T16,Condition 331 342	Sleep apnea
23,T17,Procedure 346 361	polysomnography
24,R7,AND Arg1:T17 Arg2:T16
0,T1,Value 15 22;39 49	between 6-12 weeks
1,T2,Value 15 22;51 64	between 42 to 90 days
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Person 66 72	of age
4,R2,Has_value Arg1:T3 Arg2:T1
5,T4,Temporal 73 109	at the time of the first vaccination
6,R3,Has_temporal Arg1:T3 Arg2:T4
7,T5,Condition 339 354	health problems
8,T6,Qualifier 331 338	obvious
9,R4,Has_qualifier Arg1:T5 Arg2:T6
10,T7,Negation 323 327	Free
11,R5,Has_negation Arg1:T5 Arg2:T7
12,T8,Value 477 500	between 36 and 42 weeks
13,T9,Measurement 460 476	gestation period
14,R6,Has_value Arg1:T9 Arg2:T8
15,T10,Condition 447 451	Born
16,R7,AND Arg1:T10 Arg2:T9
17,T11,Non-query-able 112 242	Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol
18,T12,Observation 244 268	Written informed consent
19,T13,Qualifier 287 293	parent
20,T14,Qualifier 297 305	guardian
21,*,OR T13 T14
22,T15,Scope 287 305	parent or guardian
23,R8,Has_scope Arg1:T12 Arg2:T15
0,T1,Measurement 19 40	intracranial pressure
1,T2,Value 14 18	high
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 57 75	Multiple Sclerosis
4,T4,Condition 92 129	Guillain-Barré syndrome radiculopathy
5,T5,Qualifier 133 141	vascular
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Procedure 174 189	lumbar surgery.
8,T7,Pregnancy_considerations 191 221	Patients pregnant or lactating
9,T8,Condition 238 245	allergy
10,T9,Condition 249 260	intolerance
11,*,OR T8 T9
12,T10,Drug 275 280	drugs
13,T11,Scope 238 260	allergy or intolerance
14,R3,AND Arg1:T11 Arg2:T10
15,T12,Condition 309 329	cognitive impairment
16,T13,Qualifier 302 308	severe
17,R4,Has_qualifier Arg1:T12 Arg2:T13
18,T14,Procedure 346 379	intrathecal injectio radiculalgia
19,T15,Condition 420 441	psychiatric pathology
20,T16,Qualifier 414 419	major
21,T17,Qualifier 396 413	poorly controlled
22,R5,Has_qualifier Arg1:T15 Arg2:T16
23,R6,Has_qualifier Arg1:T15 Arg2:T17
24,T18,Condition 458 473	type I diabetes
25,T19,Condition 495 511	type II diabetes
26,T20,Qualifier 477 494	poorly controlled
27,T21,Measurement 513 518	Hb1Ac
28,T22,Value 518 522	>8.5
29,R7,Has_value Arg1:T21 Arg2:T22
30,R8,Has_qualifier Arg1:T19 Arg2:T20
31,*,OR T18 T19
32,R9,AND Arg1:T19 Arg2:T21
33,T23,Condition 540 548	glaucoma
34,T24,Condition 565 587	caudal equine syndrome
35,T25,Procedure 623 641	steroid injections
36,T26,Procedure 645 662	local anesthetics
37,*,OR T25 T26
38,T27,Condition 679 701	central canal stenosis
39,T28,Drug 741 761	oral corticosteroids
0,T1,Condition 0 22	Supracondylar fracture
1,T2,Person 24 27	Age
2,T3,Value 28 38	2-17 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 40 84	American Society of Anesthesiologists Status
5,T5,Value 85 89	1 -3
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Procedure 105 147	closed reduction with percutaneous pinning
8,T7,Procedure 154 172	general anesthesia
9,R3,AND Arg1:T6 Arg2:T7
10,T8,Mood 91 104	Scheduled for
11,R4,Has_mood Arg1:T6 Arg2:T8
0,T1,Condition 0 16	preterm delivery
1,T2,Value 18 27	<37 weeks
2,T3,Measurement 31 40	gestation
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Scope 18 40	<37 weeks of gestation
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Measurement 43 55	birth weight
7,T6,Value 56 64	< 2500 g
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 66 84	multiple pregnancy
10,T8,Condition 86 99	major illness
11,T9,Condition 103 121	congenital anomaly
12,*,OR T8 T9
13,T10,Multiplier 129 133	<50%
14,T11,Observation 134 143	breastfed
15,R4,Has_multiplier Arg1:T11 Arg2:T10
16,T12,Temporal 144 168	at the time of inclusion
17,R5,Subsumes Arg1:T11 Arg2:T12
18,T13,Condition 170 182	food allergy
19,T14,Condition 184 191	anaemia
20,T15,Measurement 193 195	Hb
21,T16,Value 196 204	<105 g/L
22,T17,Value 206 215	10.5 g/dL
23,R6,Subsumes Arg1:T16 Arg2:T17
24,R7,Has_value Arg1:T15 Arg2:T16
25,T18,Scope 193 216	Hb <105 g/L [10.5 g/dL]
26,R8,Subsumes Arg1:T14 Arg2:T18
27,T19,Temporal 218 230	at inclusion
28,R9,Has_temporal Arg1:T14 Arg2:T19
29,T20,Informed_consent 232 256	lack of informed consent
0,T1,Drug 45 52;7 26;71 102	product any investigational other than the study vaccine(s)
1,T2,Drug 30 52;7 10;71 102	non-registered product any other than the study vaccine(s)
2,*,OR T1 T2
3,T3,Drug 54 58	drug
4,T4,Drug 62 69	vaccine
5,*,OR T3 T4
6,T5,Scope 54 69	drug or vaccine
7,T6,Scope 7 52;71 102	any investigational or non-registered product other than the study vaccine(s)
8,R1,Subsumes Arg1:T6 Arg2:T5
9,T7,Temporal 103 117	within 30 days
10,T8,Observation 164 175	planned use
11,T9,Temporal 176 199	during the study period
12,R2,Has_temporal Arg1:T8 Arg2:T9
13,R3,Has_temporal Arg1:T6 Arg2:T7
14,*,OR T6 T8
15,R4,Has_scope Arg1:T8 Arg2:T5
16,T10,Drug 258 276	immunosuppressants
17,T11,Drug 280 308	other immune-modifying drugs
18,*,OR T10 T11
19,T12,Temporal 309 326	within six months
20,T13,Temporal 201 208	Chronic
21,T14,Temporal 236 253	more than 14 days
22,R5,Subsumes Arg1:T13 Arg2:T14
23,T15,Scope 258 308	immunosuppressants or other immune-modifying drugs
24,R6,Has_temporal Arg1:T15 Arg2:T13
25,R7,Has_temporal Arg1:T15 Arg2:T12
26,T16,Observation 361 368	Planned
27,T17,Drug 405 412	vaccine
28,T18,Qualifier 413 447	not foreseen by the study protocol
29,R8,Has_qualifier Arg1:T17 Arg2:T18
30,T19,Temporal 459 515	period starting one month before each dose of vaccine(s)
31,T20,Temporal 561 581	1 month after dose 3
32,T21,Temporal 520 557	ending 7 days after dose 1 and dose 2
33,T22,Drug 540 546	dose 1
34,T23,Drug 551 557	dose 2
35,T24,Drug 575 581	dose 3
36,*,OR T22 T23
37,T25,Scope 540 557	dose 1 and dose 2
38,T26,Scope 459 581	period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3
39,R10,Has_scope Arg1:T17 Arg2:T26
40,R11,AND Arg1:T16 Arg2:T17
41,T27,Drug 593 604	vaccination
42,T28,Condition 613 623	diphtheria
43,T29,Condition 625 632	tetanus
44,T30,Condition 634 643	pertussis
45,T31,Condition 645 650	polio
46,T32,Condition 652 663	hepatitis B
47,T33,Condition 665 694	Haemophilus influenzae type b
48,T34,Condition 703 716	S. pneumoniae
49,T35,Temporal 782 816	within the first two weeks of life
50,T36,Qualifier 758 781	first dose can be given
51,R12,Has_temporal Arg1:T36 Arg2:T35
52,*,OR T28 T29 T30 T31 T32 T33 T34
53,T37,"Scope 613 716	diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae"
54,R13,Has_scope Arg1:T27 Arg2:T37
55,T38,"Scope 593 716	vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae"
56,T39,Drug 739 747	vaccines
57,R14,Has_qualifier Arg1:T39 Arg2:T36
58,T40,Observation 860 867	History
59,T41,Condition 887 897	diphtheria
60,T42,Condition 899 906	tetanus
61,T43,Condition 908 917	pertussis
62,T44,Condition 919 930	hepatitis B
63,T45,Condition 932 937	polio
64,T46,Condition 943 972	Haemophilus influenzae type b
65,*,OR T45 T46 T44 T43 T42 T41
66,T47,"Scope 887 972	diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b"
67,R16,Has_scope Arg1:T40 Arg2:T47
68,T48,Condition 995 1011	allergic disease
69,T49,Observation 984 991	History
70,T50,Condition 1015 1024;995 1003	reactions allergic
71,T51,Scope 995 1024	allergic disease or reactions
72,*,OR T50 T48
73,R17,Has_scope Arg1:T49 Arg2:T51
74,T52,Qualifier 1038 1049	exacerbated
75,R18,Has_qualifier Arg1:T51 Arg2:T52
76,T53,Condition 1096 1104	seizures
77,T54,Observation 1085 1092	History
78,T55,Condition 1185 1203	febrile convulsion
79,T56,Qualifier 1171 1184	uncomplicated
80,T57,Multiplier 1163 1169	single
81,T59,Condition 1220 1240	neurological disease
82,T60,Condition 1243 1256	Acute disease
83,T61,Temporal 1257 1281	at the time of enrolment
84,R22,Has_temporal Arg1:T60 Arg2:T61
85,T62,Condition 1310 1327;1347 1356	immunosuppressive condition
86,T63,Condition 1331 1356	immunodeficient condition
87,*,OR T62 T63
88,T64,Observation 1398 1412	family history
89,T65,Condition 1416 1426;1441 1457	congenital immunodeficiency
90,T66,Condition 1430 1457	hereditary immunodeficiency
91,T67,Scope 1416 1457	congenital or hereditary immunodeficiency
92,R23,Has_scope Arg1:T64 Arg2:T67
93,T68,Condition 1460 1484	Major congenital defects
94,T69,Condition 1488 1511	serious chronic illness
95,*,OR T68 T69
96,T70,Drug 1532 1547	immunoglobulins
97,T71,Drug 1555 1573	any blood products
98,*,OR T70 T71
99,T72,Temporal 1574 1585	since birth
100,T73,Scope 1532 1573	immunoglobulins and/or any blood products
101,T74,Observation 1589 1596	planned
102,T75,Temporal 1612 1648	during the active phase of the study
103,R25,Has_temporal Arg1:T74 Arg2:T75
104,*,OR T72 T74
105,T76,Scope 1574 1648	since birth or planned administration during the active phase of the study
106,R24,Has_scope Arg1:T73 Arg2:T76
107,T77,Negation 717 738	with the exception of
108,R15,Has_negation Arg1:T39 Arg2:T77
109,R26,AND Arg1:T38 Arg2:T39
110,T78,Reference_point 789 816	the first two weeks of life
111,R27,Has_index Arg1:T35 Arg2:T78
112,R19,Has_qualifier Arg1:T55 Arg2:T56
113,R20,Has_multiplier Arg1:T55 Arg2:T57
114,T58,Negation 1121 1135	does not apply
115,R21,Has_negation Arg1:T55 Arg2:T58
116,R28,AND Arg1:T53 Arg2:T55
117,*,OR T53 T59
118,T79,"Scope 1096 1240	seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease"
119,R29,Has_temporal Arg1:T79 Arg2:T54
120,T80,Reference_point 1272 1281	enrolment
121,R30,Has_index Arg1:T61 Arg2:T80
122,T81,Reference_point 1623 1648	active phase of the study
123,R31,Has_index Arg1:T75 Arg2:T81
124,T82,Reference_point 1580 1585	birth
125,R32,Has_index Arg1:T72 Arg2:T82
126,T83,Reference_point 492 515	each dose of vaccine(s)
127,R33,Has_index Arg1:T19 Arg2:T83
128,T84,Reference_point 540 557	dose 1 and dose 2
129,R34,Has_index Arg1:T21 Arg2:T84
130,T85,Reference_point 575 581	dose 3
131,R35,Has_index Arg1:T20 Arg2:T85
132,R9,multi Arg1:T85 Arg2:T24
133,R36,multi Arg1:T84 Arg2:T25
134,*,OR T21 T20
0,T1,Person 0 11	Patient age
1,T2,Value 12 23	>= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 25 50	Zubrod performance status
4,T4,Value 54 57	0-3
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 59 60	T
7,T6,Value 60 63	1-3
8,T7,Measurement 64 65	N
9,T8,Measurement 67 68	M
10,T9,Value 65 66	0
11,T10,Value 68 69	0
12,R3,Has_value Arg1:T7 Arg2:T9
13,R4,Has_value Arg1:T8 Arg2:T10
14,R5,Has_value Arg1:T5 Arg2:T6
15,T11,Scope 59 69	T1-3 N0 M0
16,T12,Condition 70 84	adenocarcinoma
17,T13,Qualifier 92 100	prostate
18,R6,Has_qualifier Arg1:T12 Arg2:T13
19,R7,Has_scope Arg1:T12 Arg2:T11
20,T14,Measurement 102 117	Prostate volume
21,T15,Value 118 126	= 100 cc
22,R8,Has_value Arg1:T14 Arg2:T15
23,T16,Informed_consent 128 162	Signed study-specific consent form
24,T17,Condition 164 188	Extension of local tumor
25,T18,Qualifier 200 215	adjacent organs
26,T19,Negation 216 226	other than
27,T20,Qualifier 227 243	seminal vesicles
28,R9,Has_negation Arg1:T20 Arg2:T19
29,T21,Scope 200 243	adjacent organs other than seminal vesicles
30,R10,Has_scope Arg1:T17 Arg2:T21
31,T22,Measurement 250 265	Prostate volume
32,T23,Value 266 274	> 100 cc
33,R11,Has_value Arg1:T22 Arg2:T23
34,T24,Condition 276 293	Nodal involvement
35,T25,Condition 295 313	Metastatic disease
36,T26,Temporal 315 320	Prior
37,T27,Qualifier 321 327	pelvic
38,T28,Procedure 328 340	radiotherapy
39,R12,Has_qualifier Arg1:T28 Arg2:T27
40,R13,Has_temporal Arg1:T28 Arg2:T26
41,T29,Negation 341 347	except
42,T30,Procedure 359 378	combination therapy
43,T31,Condition 383 399	prostate cancer
44,R14,AND Arg1:T30 Arg2:T31
45,T32,Condition 383 398	prostate cancer
46,R15,AND Arg1:T30 Arg2:T32
47,R16,Has_negation Arg1:T30 Arg2:T29
48,R17,AND Arg1:T28 Arg2:T30
49,T33,Observation 400 407	History
50,T34,Condition 411 422	scleroderma
51,R18,Has_temporal Arg1:T34 Arg2:T33
52,T35,Condition 438 449;463 471	psychiatric disorder
53,T36,Condition 453 471	addictive disorder
54,*,OR T35 T36
0,T1,Condition 6 14	cataract
1,T2,Procedure 42 72	clear corneal cataract surgery
2,T3,Qualifier 73 97	with phacoemulsification
3,T4,Qualifier 102 154	implantation of a posterior chamber intraocular lens
4,R1,Has_qualifier Arg1:T2 Arg2:T3
5,R2,Has_qualifier Arg1:T2 Arg2:T4
6,T5,Measurement 187 215	pinhole corrected Snellen VA
7,T6,Value 219 244	at least 20/200 or better
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Qualifier 248 257	both eyes
10,R4,Has_qualifier Arg1:T6 Arg2:T7
0,T1,Person 0 3	Age
1,T2,Value 4 8	>=19
2,T3,Condition 36 45	dizziness
3,T4,Condition 47 70	Orthostatic hypotension
4,T5,Qualifier 71 94	after 3-minute standing
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,T6,Measurement 96 124	systolic blood pressure drop
7,T7,Measurement 133 162	diastolic blood pressure drop
8,T8,Value 163 167	>=10
9,T9,Value 125 129	>=20
10,R2,Has_value Arg1:T6 Arg2:T9
11,*,OR T6 T7
12,R3,Has_value Arg1:T7 Arg2:T8
13,T10,Scope 96 167	systolic blood pressure drop >=20 or diastolic blood pressure drop >=10
14,R4,Subsumes Arg1:T4 Arg2:T10
15,R5,Has_value Arg1:T1 Arg2:T2
0,T1,Observation 26 39	suicidal risk
1,T2,Observation 47 55	violence
2,*,OR T1 T2
3,T3,Condition 88 96	Delirium
4,T4,Condition 98 106	Dementia
5,T5,Condition 127 145	cognitive disorder
6,T6,Condition 108 116;137 145	Amnestic disorder
7,*,OR T5 T6
8,T7,Condition 175 189	hypothyroidism
9,T8,Negation 190 196	unless
10,T9,Drug 221 239	thyroid medication
11,R1,Has_negation Arg1:T9 Arg2:T8
12,R2,AND Arg1:T7 Arg2:T9
13,T10,Condition 350 365	substance abuse
14,T11,Measurement 303 312	DSM-IV-TR
15,R3,AND Arg1:T11 Arg2:T10
16,T12,Condition 368 389	hepatic insufficiency
17,T13,Measurement 439 465	aspartate aminotransferase
18,T14,Measurement 467 470	AST
19,T15,Measurement 479 503	alanine aminotransferase
20,T16,Measurement 505 508	ALT
21,R4,Subsumes Arg1:T13 Arg2:T14
22,R5,Subsumes Arg1:T15 Arg2:T16
23,*,OR T13 T15
24,T17,Value 391 428	three times the upper limit of normal
25,T18,Scope 439 509	aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)
26,R6,Has_value Arg1:T18 Arg2:T17
27,R7,Subsumes Arg1:T12 Arg2:T18
28,T19,Procedure 512 528	liver transplant
29,T20,Condition 540 562	cirrhosis of the liver
30,*,OR T12 T19 T20
31,T21,Condition 565 575	malignancy
32,T22,Negation 577 583	except
33,T23,Condition 584 604	basal cell carcinoma
34,R8,Has_negation Arg1:T23 Arg2:T22
35,T24,Procedure 613 625	chemotherapy
36,T25,Temporal 626 658	within 1 year prior to screening
37,T26,Reference_point 649 658	screening
38,R9,Has_index Arg1:T25 Arg2:T26
39,R10,Has_temporal Arg1:T24 Arg2:T25
40,*,OR T21 T24 T27
41,T27,Condition 660 670	malignancy
42,T28,Temporal 671 687	more than 1 year
43,T29,Qualifier 722 727	local
44,T30,Negation 732 739	without
45,T31,Condition 740 750	metastasis
46,T32,Condition 758 768	recurrence
47,*,OR T31 T32
48,T33,Scope 740 768	metastasis and/or recurrence
49,R11,Has_negation Arg1:T33 Arg2:T30
50,R12,Has_qualifier Arg1:T27 Arg2:T29
51,R13,Has_temporal Arg1:T27 Arg2:T28
52,R14,Has_scope Arg1:T27 Arg2:T33
53,T34,Condition 864 881	medical condition
54,T35,Qualifier 855 863	unstable
55,R15,Has_qualifier Arg1:T34 Arg2:T35
56,T36,Condition 885 909	life threatening disease
57,T37,Observation 915 935	anticipated survival
58,T38,Value 939 957	less than 6 months
59,R16,Has_value Arg1:T37 Arg2:T38
60,*,OR T36 T34
61,T39,Scope 855 909	unstable medical condition or life threatening disease
62,R17,Has_context Arg1:T39 Arg2:T37
63,T40,Non-query-able 960 1040	need for therapies that may obscure the results of treatment and/or of the study
64,T41,Competing_trial 1042 1119	Participation in another clinical trial within 30 days of the screening visit
65,T42,Post-eligibility 1122 1176	Anticipated inability to attend scheduled study visits
66,T43,Non-query-able 1179 1318	Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol
67,T44,Competing_trial 1321 1377	Patients with a history of prior pharmacogenomic testing
68,T45,Procedure 1394 1417	psychotropic medication
69,T46,Pregnancy_considerations 1480 1530	Patients who are known to be pregnant or lactating
70,T47,Procedure 1560 1582	gastric bypass surgery
0,T1,Qualifier 0 12	Drug-induced
1,T2,Condition 13 24	hypotension
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,"Non-representable 26 109	if necessary, evaluate patient after discontinuing the causative drug for one month"
4,T4,Condition 111 124	Heart failure
5,T5,Condition 128 149	Chronic renal failure
6,*,OR T4 T5
7,T6,Condition 158 177	supine hypertension
8,T7,Qualifier 151 157	Severe
9,R2,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Measurement 179 202	Systolic Blood Pressure
11,T9,Measurement 211 235	Diastolic Blood Pressure
12,T10,Value 203 207	>180
13,T11,Value 235 243	>110mmHg
14,R3,Has_value Arg1:T9 Arg2:T11
15,R4,Has_value Arg1:T8 Arg2:T10
16,*,OR T8 T9
17,T12,Scope 179 243	Systolic Blood Pressure >180 or Diastolic Blood Pressure>110mmHg
18,T13,Scope 151 177	Severe supine hypertension
19,R5,Subsumes Arg1:T13 Arg2:T12
20,T14,Condition 246 254	Pregnant
21,T15,Person 255 260	women
22,T16,Condition 262 276	breast-feeding
23,*,OR T16 T14
24,T17,Observation 278 309	Unable to perform questionnaire
0,T1,Value 4 28	intraocular inflammation
1,T2,Temporal 54 96	during the screening slit lamp examination
2,T3,Reference_point 61 96	the screening slit lamp examination
3,R1,Has_index Arg1:T2 Arg2:T3
4,T4,Procedure 75 96	slit lamp examination
5,R2,Has_value Arg1:T4 Arg2:T1
6,R3,Has_temporal Arg1:T4 Arg2:T2
7,T5,Condition 4 28	intraocular inflammation
8,T6,Measurement 128 150	Ocular Pain Assessment
9,T7,"Value 104 120	greater than ""0"""
10,T8,Temporal 168 180	at Screening
11,R4,Has_value Arg1:T6 Arg2:T7
12,R5,Has_temporal Arg1:T6 Arg2:T8
13,T9,Condition 186 210	intraocular inflammation
14,T10,Temporal 236 278	during the screening slit lamp examination
15,T11,Reference_point 243 278	the screening slit lamp examination
16,T12,Procedure 257 278	slit lamp examination
17,T13,Value 186 210	intraocular inflammation
18,R6,Has_value Arg1:T12 Arg2:T13
19,R7,Has_temporal Arg1:T12 Arg2:T10
0,T1,Person 12 15	age
1,T2,Value 0 8;16 24	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 39 52	schizophrenia
4,T4,Condition 53 77	schizoaffective disorder
5,*,OR T3 T4
6,T5,"Measurement 86 170	Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision"
7,T6,Measurement 172 181	DSM-IV-TR
8,R2,Subsumes Arg1:T5 Arg2:T6
9,T7,Measurement 229 259	Brief Psychiatric Rating Scale
10,T8,Measurement 261 265	BPRS
11,R3,Subsumes Arg1:T7 Arg2:T8
12,T9,Value 267 271	= 45
13,R4,Has_value Arg1:T7 Arg2:T9
14,T10,Informed_consent 274 361	Be capable and willing to provide written informed consent to participate in this study
15,T11,"Post-eligibility 364 502	Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests"
0,T1,Condition 68 73	NSCLC
1,T2,Qualifier 34 54	cytologically proven
2,T3,Qualifier 16 30;48 54	histologically proven
3,*,OR T2 T3
4,T4,Scope 16 54	histologically or cytologically proven
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 107 112;121 133	stage IIIb disease
7,T6,Condition 107 117;126 133	stage IIIa disease
8,*,OR T5 T6
9,T7,Qualifier 75 87	Unresectable
10,T8,Qualifier 89 105	locally advanced
11,R2,Subsumes Arg1:T7 Arg2:T8
12,T9,Scope 107 133	stage IIIa or IIIb disease
13,R3,Has_qualifier Arg1:T9 Arg2:T7
14,T10,Qualifier 224 233	esophagus
15,T11,Multiplier 188 200;213 215	greater than 30
16,T12,Multiplier 204 216	equal to 30%
17,*,OR T12 T11
18,T13,Scope 188 216	greater than or equal to 30%
19,R4,Has_scope Arg1:T10 Arg2:T13
20,T14,Measurement 143 155	radiotherapy
21,T15,Qualifier 135 142	Initial
22,R5,Has_qualifier Arg1:T14 Arg2:T15
23,R6,Has_qualifier Arg1:T14 Arg2:T10
24,T16,Observation 235 250	Life expectancy
25,T17,Value 267 284	equal to 6 months
26,T18,Value 251 263;276 284	greater than 6 months
27,*,OR T17 T18
28,T19,Scope 251 284	greater than or equal to 6 months
29,R7,Has_scope Arg1:T16 Arg2:T19
30,T20,Condition 378 396	Measurable disease
31,T21,Temporal 341 376	3 months before study randomization
32,T22,Reference_point 357 376	study randomization
33,R8,Has_index Arg1:T21 Arg2:T22
34,T23,Measurement 286 307	Estimated weight loss
35,T24,Value 321 333	equal to 10%
36,T25,Value 308 317;330 333	less than 10%
37,*,OR T24 T25
38,T26,Scope 308 333	less than or equal to 10%
39,R9,Has_scope Arg1:T23 Arg2:T26
40,R10,Has_temporal Arg1:T23 Arg2:T21
41,T28,Measurement 424 458;466 484	Eastern Cooperative Oncology Group performance status
42,T29,Measurement 460 464	ECOG
43,R11,Subsumes Arg1:T28 Arg2:T29
44,T30,Value 488 493	0 - 2
45,R12,Has_value Arg1:T28 Arg2:T30
46,T31,Measurement 495 505	Hemoglobin
47,T32,Measurement 507 510	hgb
48,R13,Subsumes Arg1:T31 Arg2:T32
49,T33,Value 528 544	equal to 10 g/dL
50,T34,Value 512 524;537 544	greater than 10 g/dL
51,*,OR T33 T34
52,T35,Scope 512 544	greater than or equal to 10 g/dL
53,T36,Temporal 596 637	in the 4 weeks before study randomization
54,T37,Reference_point 618 637	study randomization
55,R14,Has_index Arg1:T36 Arg2:T37
56,T38,Negation 545 552	without
57,T39,Observation 553 574	transfusional support
58,T40,Observation 578 595	growth factor use
59,*,OR T39 T40
60,T41,Scope 553 595	transfusional support or growth factor use
61,R15,Has_negation Arg1:T41 Arg2:T38
62,R16,Has_scope Arg1:T31 Arg2:T35
63,R17,Has_temporal Arg1:T31 Arg2:T36
64,R18,Has_temporal Arg1:T41 Arg2:T36
65,T42,Measurement 639 664	Absolute neutrophil count
66,T43,Measurement 666 669	ANC
67,R19,Subsumes Arg1:T42 Arg2:T43
68,T44,Value 687 708	equal to 1.5 x 10^9/L
69,T45,Value 671 683;696 708	greater than 1.5 x 10^9/L
70,*,OR T45 T44
71,T46,Scope 671 708	greater than or equal to 1.5 x 10^9/L
72,T47,Negation 709 716	without
73,T48,Observation 717 734	growth factor use
74,R20,Has_negation Arg1:T48 Arg2:T47
75,T49,Temporal 735 776	in the 2 weeks before study randomization
76,T50,Reference_point 757 776	study randomization
77,R21,Has_index Arg1:T49 Arg2:T50
78,R22,Has_scope Arg1:T42 Arg2:T46
79,R23,Has_temporal Arg1:T42 Arg2:T49
80,R24,Has_temporal Arg1:T48 Arg2:T49
81,T51,Measurement 778 792	Platelet count
82,T52,Value 793 805;818 830	greater than 100 x 10^9/L
83,T53,Value 809 830	equal to 100 x 10^9/L
84,*,OR T53 T52
85,T54,Scope 793 830	greater than or equal to 100 x 10^9/L
86,R25,Has_scope Arg1:T51 Arg2:T54
87,T55,Measurement 832 847	Serum bilirubin
88,T56,Value 861 917	equal to 1.5 x institutional upper limit of normal (ULN)
89,T57,Value 848 857;870 917	less than 1.5 x institutional upper limit of normal (ULN)
90,*,OR T56 T57
91,T58,Scope 848 917	less than or equal to 1.5 x institutional upper limit of normal (ULN)
92,R26,Has_scope Arg1:T55 Arg2:T58
93,T59,Measurement 919 935	Serum creatinine
94,T60,Value 949 967	equal to 2.0 mg/dL
95,T61,Value 936 945	less than
96,T62,Value 958 967	2.0 mg/dL
97,*,OR T60 T62
98,T63,Scope 937 967	ess than or equal to 2.0 mg/dL
99,R27,Has_scope Arg1:T59 Arg2:T63
100,T64,Measurement 991 1007	serum creatinine
101,T65,Value 1024 1036;1067 1072	equal to 1.4 mg/dL
102,T66,Value 1008 1020;1033 1036;1067 1072	greater than 1.4 mg/dL
103,*,OR T65 T66
104,T67,Value 1041 1050;1063 1072	less than 2.0 mg/dL
105,T68,Value 1054 1072	equal to 2.0 mg/dL
106,*,OR T68 T67
107,T69,Scope 1008 1072	greater than or equal to 1.4 and less than or equal to 2.0 mg/dL
108,R28,Has_scope Arg1:T64 Arg2:T69
109,T70,Measurement 1092 1128	24-hour urinary creatinine clearance
110,T71,Value 1145 1163	equal to 50 mL/min
111,T72,Value 1129 1141;1154 1163	greater than 50 mL/min
112,*,OR T71 T72
113,T73,Scope 1129 1163	greater than or equal to 50 mL/min
114,R29,Has_scope Arg1:T70 Arg2:T73
115,T74,Scope 919 967	Serum creatinine less than or equal to 2.0 mg/dL
116,T75,Scope 991 1163	serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min
117,*,OR T74 T75
118,T76,Person 1166 1173	Females
119,T77,Condition 1177 1199	childbearing potential
120,R30,AND Arg1:T76 Arg2:T77
121,T78,Measurement 1219 1239	urine pregnancy test
122,T79,Measurement 1210 1215;1225 1239	serum pregnancy test
123,*,OR T78 T79
124,T80,Scope 1210 1239	serum or urine pregnancy test
125,T81,Value 1201 1209	negative
126,R31,Has_value Arg1:T80 Arg2:T81
127,T82,Observation 1267 1283	informed consent
128,T84,"Temporal 1284 1389	before participating in any study-specific procedure, randomization, or receiving investigational product"
129,T85,"Reference_point 1291 1389	participating in any study-specific procedure, randomization, or receiving investigational product"
130,T86,Qualifier 1312 1326	study-specific
131,T87,Procedure 1327 1336	procedure
132,T88,Procedure 1338 1351	randomization
133,T89,Drug 1366 1389	investigational product
134,*,OR T88 T89 T87 T86
135,T90,"Scope 1312 1389	study-specific procedure, randomization, or receiving investigational product"
136,R32,multi Arg1:T85 Arg2:T90
137,R33,Has_temporal Arg1:T82 Arg2:T84
138,T83,Qualifier 1453 1461	adequate
139,T91,Procedure 1462 1483	contraception methods
140,R34,Has_qualifier Arg1:T91 Arg2:T83
141,T92,Condition 1406 1429	reproductive capability
142,A1,Optional T92
143,R35,AND Arg1:T92 Arg2:T91
144,T27,Value 398 406;414 422	18 years or older
145,T93,Person 410 413	age
146,R36,Has_value Arg1:T93 Arg2:T27
0,T1,Person 8 11	men
1,T2,Person 16 21	women
2,T3,Person 23 26	age
3,T4,Value 27 35	40-75 yr
4,T5,Qualifier 0 7	Healthy
5,T6,Negation 38 45	without
6,T7,Condition 50 57	disease
7,T8,Qualifier 46 49	any
8,T9,Procedure 70 80	medication
9,R1,Has_qualifier Arg1:T7 Arg2:T8
10,R2,Has_negation Arg1:T7 Arg2:T6
11,R3,Has_value Arg1:T3 Arg2:T4
12,*,OR T2 T1
13,R4,Has_value Arg1:T3 Arg2:T4
14,T10,"Scope 8 22	men and women,"
15,R5,Has_qualifier Arg1:T10 Arg2:T5
16,R6,Has_negation Arg1:T9 Arg2:T6
17,T11,"Non-query-able 83 140	Born, raised and currently living at low altitude (<800m)"
18,T12,Post-eligibility 143 167	Written informed consent
19,T13,Non-query-able 170 186	Kyrgyz ethnicity
0,T1,Observation 0 19	Legally incompetent
1,T2,Condition 23 40	mentally impaired
2,T3,Person 48 54	minors
3,T4,Condition 56 67	Alzheimer's
4,T5,Condition 78 86	dementia
5,*,OR T4 T5 T3
6,*,OR T2 T1
7,T6,"Scope 48 86	minors, Alzheimer's subjects, dementia"
8,T7,Scope 0 40	Legally incompetent or mentally impaired
9,R1,Subsumes Arg1:T7 Arg2:T6
10,T8,Value 95 116	Younger than 18 years
11,T9,Person 120 123	age
12,R2,Has_value Arg1:T9 Arg2:T8
13,T10,Observation 150 168	vulnerable subject
14,T11,Condition 175 183;196 204	bleeding disorder
15,T12,Condition 187 204	clotting disorder
16,*,OR T12 T11
17,T13,Temporal 206 218	Preoperative
18,T14,Procedure 219 242	anticoagulation therapy
19,R3,Has_temporal Arg1:T14 Arg2:T13
20,T15,Drug 219 234	anticoagulation
21,R4,multi Arg1:T14 Arg2:T15
22,T16,Value 244 252	Abnormal
23,T17,Measurement 253 272	coagulation profile
24,R5,Has_value Arg1:T17 Arg2:T16
25,T18,Condition 244 272	Abnormal coagulation profile
26,R6,multi Arg1:T17 Arg2:T18
27,T19,Condition 274 288	Renal disorder
28,T20,Condition 274 279;292 305	Renal insufficiency
29,*,OR T20 T19
30,T21,Condition 307 326	Sickle cell disease
0,T1,Condition 0 14	Non-compliance
1,T2,Procedure 20 27	DOTPlus
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Non-query-able 29 202	Alternatively DOT can be done by telephoning patient on a daily basis 5 times a week and having patient annotate taking drug in a log which would be reviewed by clinic staff
4,T4,Procedure 221 228	treated
5,T5,Condition 233 245	tuberculosis
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Temporal 246 266	in the prior 2 years
8,T7,Procedure 298 309	PCR testing
9,T8,Condition 319 330	sensitivity
10,T9,Drug 334 343	rifamycin
11,R3,AND Arg1:T8 Arg2:T9
12,R4,AND Arg1:T7 Arg2:T8
13,T10,Condition 283 286	DST
14,R5,Has_temporal Arg1:T4 Arg2:T6
15,*,OR T4 T10
16,R6,Subsumes Arg1:T10 Arg2:T7
17,T11,Condition 352 368	hypersensitivity
18,T12,Drug 372 380	rifampin
19,T13,Drug 384 393	rifabutin
20,*,OR T12 T13
21,T14,Scope 372 393	rifampin or rifabutin
22,R7,Has_scope Arg1:T11 Arg2:T14
23,T15,Measurement 396 409	Liver enzymes
24,T16,Value 410 434	greater than 2 times ULN
25,R8,Has_value Arg1:T15 Arg2:T16
26,T17,Measurement 437 446	Bilirubin
27,T18,Value 447 471	greater than 2 times ULN
28,T19,Measurement 474 490	Serum creatinine
29,T20,Value 491 515	greater than 3 times ULN
30,R9,Has_value Arg1:T19 Arg2:T20
31,R10,Has_value Arg1:T17 Arg2:T18
32,T21,Measurement 518 528	Hemoglobin
33,T22,Value 529 546	less than 7.0 gms
34,T23,Qualifier 547 579	even if receiving erythropoietin
35,R11,Has_value Arg1:T21 Arg2:T22
36,T24,Measurement 582 607	Absolute neutrophil count
37,T25,Value 608 631	less than 750 cells/mm3
38,R12,Has_value Arg1:T24 Arg2:T25
39,T26,Qualifier 632 655	even if receiving G-CSF
40,R13,Has_qualifier Arg1:T22 Arg2:T23
41,R14,Has_qualifier Arg1:T25 Arg2:T26
42,T27,Measurement 658 679	Fasting triglycerides
43,T28,Value 680 702	greater than 400 mg/dL
44,R15,Has_value Arg1:T27 Arg2:T28
45,T29,Measurement 705 724	Fasting cholesterol
46,T30,Value 725 753	> 1.6 upper limits of normal
47,R16,Has_value Arg1:T29 Arg2:T30
48,T31,Condition 756 770	GI intolerance
49,T32,Drug 774 798	tuberculosis medications
50,T33,Drug 828 852	tuberculosis medications
51,T34,Procedure 809 824	discontinuation
52,R17,AND Arg1:T31 Arg2:T32
53,R18,AND Arg1:T31 Arg2:T34
54,R19,AND Arg1:T34 Arg2:T33
55,T35,Measurement 855 870	Fasting glucose
56,T36,Value 871 888	greater 150 mg/dL
57,R20,Has_value Arg1:T35 Arg2:T36
58,T37,Condition 891 899	Pregnant
59,T38,Person 900 905	women
60,T39,Post-eligibility 908 948	Use of one of the prohibited medications
61,T40,Post-eligibility 950 1043	Any condition that the investigators feel could compromise the use of the current medication.
62,T41,Measurement 1052 1066	CD4 cell count
63,T42,Value 1070 1089	50 cells/mm3or less
64,R21,Has_value Arg1:T41 Arg2:T42
65,T43,Condition 1091 1102	Hepatitis B
66,T44,Condition 1091 1100;1106 1107	Hepatitis C
67,*,OR T44 T43
68,T45,Observation 1119 1126;1143 1146	Alcohol use
69,T46,Observation 1130 1146	illicit drug use
70,*,OR T45 T46
0,T1,Person 17 20	old
1,T2,Value 21 29;8 16	and more 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 36 54	multiple sclerosis
4,T4,Measurement 72 99	criteria of Mac Donald 2010
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Qualifier 102 121	relapsing-remitting
7,T6,Qualifier 123 125	RR
8,T7,Qualifier 128 149	secondary-progressive
9,T8,Qualifier 151 153	SP
10,T9,Qualifier 158 177	primary-progressive
11,T10,Qualifier 179 181	PP
12,R3,Subsumes Arg1:T5 Arg2:T6
13,R4,Subsumes Arg1:T7 Arg2:T8
14,R5,Subsumes Arg1:T9 Arg2:T10
15,*,OR T9 T7 T5
16,T11,"Scope 102 182	relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP)"
17,R6,Has_scope Arg1:T3 Arg2:T11
18,T12,Drug 209 226	dimethyl-fumarate
19,T13,Visit 264 313	Rothschild Foundation in the Neurology Department
20,T14,Informed_consent 315 373	having given written consent to participation in the study
0,T1,Non-query-able 0 2	NA
0,T1,Condition 0 18;32 37	Metastatic disease NSCLC
1,T2,Condition 19 31	(M1)/stage 4
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Condition 39 46;62 70	Pleural effusion
4,T4,Condition 50 70	pericardial effusion
5,*,OR T4 T3
6,T5,Value 71 100	greater than 100 ml in volume
7,T6,Measurement 139 167	positron emission tomography
8,T7,Measurement 175 194;200 204	computed tomography scan
9,T8,Measurement 169 172	PET
10,R2,Subsumes Arg1:T6 Arg2:T8
11,T9,Measurement 196 198	CT
12,R3,Subsumes Arg1:T7 Arg2:T9
13,T10,Measurement 208 218	ultrasound
14,*,OR T6 T7 T10
15,T11,"Scope 139 218	positron emission tomography [PET], computed tomography [CT] scan or ultrasound"
16,R4,Has_scope Arg1:T4 Arg2:T11
17,R5,Has_value Arg1:T11 Arg2:T5
18,T12,"Non-query-able 39 744	Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography [PET], computed tomography [CT] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ NSCLC, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized."
19,T13,Temporal 782 838	before completing the protocol chemo/radiotherapy course
20,T14,Observation 746 781	Plan to remove the tumor surgically
21,R6,Has_temporal Arg1:T14 Arg2:T13
22,T15,Qualifier 869 878	esophagus
23,T16,Multiplier 853 864	any part of
24,R7,Has_multiplier Arg1:T15 Arg2:T16
25,T17,Procedure 886 898	radiotherapy
26,T18,Procedure 840 849	Shielding
27,R8,Has_qualifier Arg1:T18 Arg2:T15
28,T19,Procedure 910 941	posterior spinal cord shielding
29,R9,Subsumes Arg1:T18 Arg2:T19
30,T20,Drug 950 962	chemotherapy
31,T21,Procedure 964 976	radiotherapy
32,T22,Procedure 981 988	surgery
33,T23,Condition 993 998	NSCLC
34,T24,Temporal 944 949	Prior
35,*,OR T20 T21 T22
36,T25,"Scope 950 988	chemotherapy, radiotherapy, or surgery"
37,R10,Has_scope Arg1:T23 Arg2:T25
38,R11,Has_temporal Arg1:T25 Arg2:T24
39,T26,Condition 1015 1025	malignancy
40,T27,Qualifier 1006 1014	invasive
41,T29,Temporal 1026 1049	during the past 3 years
42,T28,Negation 1050 1060	other than
43,T30,Condition 1061 1089	non-melanomatous skin cancer
44,R12,Has_negation Arg1:T30 Arg2:T28
45,R13,Has_qualifier Arg1:T26 Arg2:T27
46,R14,Has_temporal Arg1:T26 Arg2:T29
47,T31,Negation 1232 1239	are not
48,T32,Condition 1117 1146	surgically-cured malignancies
49,R15,Has_negation Arg1:T32 Arg2:T31
50,T33,Non-query-able 1259 1321	sponsor approval must be obtained before patient is randomized
51,T34,Condition 1347 1356	dysphagia
52,T35,Condition 1360 1396	conditions predisposing to dysphagia
53,T36,Condition 1415 1446	gastroesophageal reflux disease
54,T37,Qualifier 1402 1414	uncontrolled
55,R16,Has_qualifier Arg1:T36 Arg2:T37
56,T38,Condition 1448 1452	GERD
57,T39,Condition 1455 1464	dyspepsia
58,*,OR T36 T39
59,T40,"Scope 1402 1464	uncontrolled gastroesophageal reflux disease [GERD], dyspepsia"
60,*,OR T34 T35
61,T41,Scope 1347 1396	dysphagia or conditions predisposing to dysphagia
62,R17,Subsumes Arg1:T36 Arg2:T38
63,R18,Subsumes Arg1:T41 Arg2:T40
64,T42,Condition 1483 1495	pancreatitis
65,T43,Observation 1472 1482	History of
66,R19,Has_temporal Arg1:T42 Arg2:T43
67,T44,Temporal 1497 1545	Four weeks or less since completion of treatment
68,T45,Reference_point 1522 1545	completion of treatment
69,T46,Procedure 1536 1545	treatment
70,R20,AND Arg1:T45 Arg2:T46
71,R21,Has_index Arg1:T44 Arg2:T45
72,T47,Drug 1555 1578	investigational product
73,T48,Device 1555 1570;1579 1585	investigational device
74,*,OR T48 T47
75,T49,Qualifier 1631 1641	unresolved
76,T50,Condition 1642 1650	toxicity
77,R22,Has_qualifier Arg1:T50 Arg2:T49
78,T51,Competing_trial 1589 1611	another clinical study
79,T52,Temporal 1656 1664	previous
80,T53,Procedure 1665 1674	treatment
81,R23,Has_temporal Arg1:T53 Arg2:T52
82,R24,AND Arg1:T50 Arg2:T53
83,T54,Scope 1555 1585	investigational product/device
84,R25,Has_temporal Arg1:T54 Arg2:T44
85,R26,AND Arg1:T54 Arg2:T51
86,*,OR T54 T50
87,T55,Observation 1336 1346	history of
88,A1,Optional T55
89,R27,Has_temporal Arg1:T41 Arg2:T55
90,T56,Temporal 1000 1005	Prior
91,R28,Has_temporal Arg1:T26 Arg2:T56
92,T57,Temporal 1676 1684	Previous
93,T58,Procedure 1685 1694	treatment
94,T59,Drug 1719 1743	fibroblast growth factor
95,R29,Has_temporal Arg1:T58 Arg2:T57
96,R30,AND Arg1:T58 Arg2:T59
97,T60,Value 1757 1770	sero-positive
98,T61,Measurement 1775 1809	human immunodeficiency virus (HIV)
99,R31,Has_value Arg1:T61 Arg2:T60
100,T62,Condition 1757 1809	sero-positive for human immunodeficiency virus (HIV)
101,R32,multi Arg1:T62 Arg2:T61
102,T63,Condition 1757 1774;1811 1834	sero-positive for hepatitis C virus (HCV)
103,T64,Condition 1757 1774;1839 1862	sero-positive for hepatitis B virus (HBV)
104,T65,Measurement 1811 1834	hepatitis C virus (HCV)
105,T66,Measurement 1839 1862	hepatitis B virus (HBV)
106,R33,Has_value Arg1:T65 Arg2:T60
107,R34,Has_value Arg1:T66 Arg2:T60
108,R35,multi Arg1:T63 Arg2:T65
109,R36,multi Arg1:T64 Arg2:T66
110,*,OR T62 T63 T64
111,T67,Condition 1864 1872	Pregnant
112,T68,Condition 1876 1889	breastfeeding
113,T69,Person 1890 1895	women
114,*,OR T68 T67
115,T70,Condition 1903 1914	sensitivity
116,T71,Qualifier 1918 1933	E. coli derived
117,T72,Drug 1934 1942	products
118,R37,Has_qualifier Arg1:T72 Arg2:T71
119,R38,AND Arg1:T70 Arg2:T72
120,T73,Condition 1944 1963	Compromised ability
121,T74,Informed_consent 1982 2011	give written informed consent
122,T75,Non-representable 2022 2050	comply with study procedures
123,*,OR T74 T75
124,T76,Scope 1982 2050	give written informed consent and/or to comply with study procedures
125,R39,Has_scope Arg1:T73 Arg2:T76
126,T77,Informed_consent 2063 2092	sign an informed consent form
127,T78,Observation 2052 2062	Refusal to
128,R40,Has_context Arg1:T77 Arg2:T78
129,T79,Non-representable 2186 2267	Unwilling or unable to complete the patient reported outcome (PRO) questionnaires
130,T80,"Non-query-able 2269 2362	Psychological, social, familial, or geographical reasons that would prevent regular follow-up"
131,T81,Informed_consent 2127 2169	sign the hospital information release form
132,R41,Has_context Arg1:T81 Arg2:T78
133,*,OR T77 T81
0,T1,Condition 11 22;48 55	respiratory disease
1,T2,Condition 24 38;48 55	cardiovascular disease
2,T3,Condition 48 55	disease
3,T4,Qualifier 42 47	other
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Qualifier 4 10	active
6,T6,"Scope 11 55	respiratory, cardiovascular or other disease"
7,R2,Has_qualifier Arg1:T6 Arg2:T5
8,*,OR T3 T2 T1
9,T7,Procedure 74 83	treatment
10,T8,Qualifier 66 73	regular
11,R3,Has_qualifier Arg1:T7 Arg2:T8
12,T9,Condition 116 125	tolerance
13,T10,Condition 129 136	hypoxia
14,T11,Mood 103 115	relevant for
15,T12,Observation 140 157	altitude exposure
16,*,OR T10 T12
17,T13,Scope 129 157	hypoxia or altitude exposure
18,R4,Has_scope Arg1:T9 Arg2:T13
19,R5,Has_mood Arg1:T9 Arg2:T11
20,R6,AND Arg1:T6 Arg2:T7
21,*,OR T6 T9
22,T14,"Non-query-able 160 361	Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol"
23,T15,Condition 364 371	Allergy
24,T16,Drug 375 388	acetazolamide
25,T17,Drug 399 411	sulfonamides
26,T18,Scope 375 411	acetazolamide and other sulfonamides
27,*,OR T16 T17
28,R7,Has_scope Arg1:T15 Arg2:T18
0,T1,Condition 15 20	naive
1,T2,Drug 0 14	Antiretroviral
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Drug 29 36	Kaletra
4,T4,Measurement 72 82	viral load
5,T5,Value 61 71	suppressed
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Drug 95 100	NNRTI
8,T7,Drug 104 113	integrase
9,T8,Negation 133 140	without
10,T9,Temporal 141 146	prior
11,T10,Drug 165 167	PI
12,T11,Value 168 189	for more than 2 weeks
13,R3,Has_value Arg1:T10 Arg2:T11
14,R4,Has_temporal Arg1:T10 Arg2:T9
15,R5,Has_negation Arg1:T10 Arg2:T8
16,*,OR T6 T7
17,T12,Procedure 48 55	regimen
18,R6,AND Arg1:T12 Arg2:T3
19,T13,Procedure 125 132	regimen
20,T14,Scope 95 113	NNRTI or integrase
21,R7,Has_scope Arg1:T13 Arg2:T14
22,T15,Drug 201 206	NNRTI
23,T16,Drug 210 219	integrase
24,T17,Procedure 231 238	regimen
25,*,OR T16 T15
26,T18,Scope 201 219	NNRTI or integrase
27,R8,Has_scope Arg1:T17 Arg2:T18
28,T19,Drug 262 264	PI
29,T20,Temporal 244 249	prior
30,R9,Has_temporal Arg1:T19 Arg2:T20
31,T21,Temporal 265 285	greater than 2 weeks
32,R10,Has_temporal Arg1:T19 Arg2:T21
33,T22,Drug 407 409	PI
34,T23,Procedure 421 429	regimens
35,R11,AND Arg1:T23 Arg2:T22
36,T24,Measurement 446 456	viral load
37,T25,Value 435 445	suppressed
38,R12,Has_value Arg1:T24 Arg2:T25
39,T26,Value 755 772	at least 18 years
40,T27,Person 776 779	age
41,R13,Has_value Arg1:T27 Arg2:T26
42,T28,Non-query-able 784 813	able to give informed consent
43,T29,Post-eligibility 784 813	able to give informed consent
44,T30,Condition 831 833	TB
45,T31,Qualifier 837 878	criteria per Brazilian Ministry of Health
46,R14,Has_qualifier Arg1:T30 Arg2:T31
47,T32,Condition 887 909	good clinical response
48,T33,Condition 913 915	TB
49,R15,AND Arg1:T32 Arg2:T33
50,T34,Condition 929 941	tuberculosis
51,T35,Procedure 929 949	tuberculosis therapy
52,T36,Drug 961 969	rifampin
53,T37,Temporal 970 1004	for the 2 weeks prior to screening
54,T38,Reference_point 995 1004	screening
55,R16,Has_index Arg1:T37 Arg2:T38
56,R17,AND Arg1:T35 Arg2:T36
57,R18,Has_temporal Arg1:T35 Arg2:T37
58,T39,Drug 1031 1050	protease inhibitors
59,T40,Negation 1005 1011	except
60,T41,Temporal 1051 1077	at time of diagnosis of TB
61,T42,Reference_point 1054 1077	time of diagnosis of TB
62,R19,Has_index Arg1:T41 Arg2:T42
63,R20,Has_temporal Arg1:T39 Arg2:T41
64,R21,Has_negation Arg1:T39 Arg2:T40
65,R22,AND Arg1:T35 Arg2:T39
66,T43,Measurement 1196 1199	HIV
67,T44,Value 1200 1208	positive
68,R23,Has_value Arg1:T43 Arg2:T44
69,T45,Condition 1196 1208	HIV positive
70,T46,Measurement 1264 1278	CD4 cell count
71,T47,Value 1279 1304	greater than 50 cells/mm3
72,T48,Procedure 1318 1321	ART
73,T49,Negation 1307 1310	not
74,R24,Has_negation Arg1:T48 Arg2:T49
75,R25,Has_value Arg1:T46 Arg2:T47
76,T50,Scope 1307 1321	not taking ART
77,A1,Optional T50
78,R26,AND Arg1:T50 Arg2:T46
0,T1,Procedure 22 49	high tibial osteotomy (HTO)
1,T2,Temporal 9 19	undergoing
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Temporal 60 70	undergoing
4,T4,Procedure 71 102	tibial tubercle osteotomy (TTO)
5,R2,Has_temporal Arg1:T4 Arg2:T3
6,T5,Procedure 119 172	medial patello-femoral ligament (MPFL) reconstruction
7,A1,Optional T5
8,R3,AND Arg1:T4 Arg2:T5
0,T1,Condition 20 31	HF symptoms
1,T2,Condition 20 22;36 41	HF signs
2,T3,Qualifier 12 19	typical
3,T4,Scope 20 41	HF symptoms and signs
4,R1,Has_qualifier Arg1:T4 Arg2:T3
5,T5,Measurement 43 63	LV ejection fraction
6,T6,Value 64 68	= 50
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Measurement 89 98	NT-proBNP
9,T8,Qualifier 70 78	elevated
10,R3,Has_qualifier Arg1:T7 Arg2:T8
11,T9,Value 100 119	at least >125 pg/ml
12,R4,Has_value Arg1:T7 Arg2:T9
13,T10,Measurement 122 150	echocardiographic structural
14,T11,Measurement 154 177	left atrial volume inde
15,T12,Value 179 189	> 34 mL/m2
16,T13,Measurement 195 222	left ventricular mass index
17,T14,Value 223 232	=115 g/m2
18,T15,Person 237 242	males
19,T16,Person 260 267	females
20,T17,Measurement 195 222	left ventricular mass index
21,T18,Value 247 255	=95 g/m2
22,R5,Has_value Arg1:T17 Arg2:T14
23,R6,AND Arg1:T17 Arg2:T15
24,R7,Has_value Arg1:T13 Arg2:T18
25,R8,AND Arg1:T13 Arg2:T16
26,T19,Measurement 272 294	functional alterations
27,T20,Measurement 296 300	E/e'
28,T21,Value 300 303	=13
29,T22,Measurement 310 341	mean e' septal and lateral wall
30,T23,Value 342 350	< 9 cm/s
31,R9,Has_value Arg1:T20 Arg2:T21
32,R10,Has_value Arg1:T22 Arg2:T23
33,T24,Scope 296 351	E/e'=13 and a mean e' septal and lateral wall < 9 cm/s)
34,R11,Subsumes Arg1:T19 Arg2:T24
35,R12,Has_value Arg1:T11 Arg2:T12
36,*,OR T11 T13 T17
37,T25,Scope 154 267	left atrial volume index > 34 mL/m2 or a left ventricular mass index =115 g/m2 for males and =95 g/m2 for females
38,R13,Subsumes Arg1:T10 Arg2:T25
0,T1,Pregnancy_considerations 0 31	pregnant or breastfeeding woman
1,T2,Post-eligibility 33 75	patient with a measure of legal protection
2,T3,Non-query-able 77 107	subject unaffiliated insurance
0,T1,Condition 0 11	Molar teeth
1,T2,Measurement 13 20	Milller
2,T3,Value 21 28	Class 4
3,T4,Condition 29 46	recession defects
4,R1,Has_value Arg1:T2 Arg2:T3
5,R2,AND Arg1:T4 Arg2:T2
6,T5,Condition 48 57	Pregnancy
7,T6,Non-query-able 59 72	Self-reported
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Condition 75 82	Smoking
10,T8,Condition 115 123;97 102	diseases local
11,T9,Condition 106 123	systemic diseases
12,*,OR T9 T8
13,T10,Qualifier 84 96	Uncontrolled
14,T11,Scope 97 123	local or systemic diseases
15,R4,Has_qualifier Arg1:T11 Arg2:T10
16,T12,Qualifier 124 150	that affects wound healing
17,R5,Has_qualifier Arg1:T11 Arg2:T12
18,T13,Condition 152 160	diabetes
19,T14,Condition 162 172;189 198	autoimmune disorders
20,T15,Condition 176 198	inflammatory disorders
21,*,OR T15 T14 T13
22,T16,"Scope 152 198	diabetes, autoimmune or inflammatory disorders"
23,T17,Scope 84 150	Uncontrolled local or systemic diseases that affects wound healing
24,R6,Subsumes Arg1:T17 Arg2:T16
25,T18,Observation 201 213	Past history
26,T19,Drug 217 233	systemic steroid
27,T20,Temporal 238 250	over 2 weeks
28,T21,Temporal 251 274	within the last 2 years
29,R7,Has_temporal Arg1:T19 Arg2:T18
30,R8,Has_temporal Arg1:T19 Arg2:T20
31,R9,Has_temporal Arg1:T19 Arg2:T21
32,T22,Condition 276 293	Poor oral hygiene
33,T23,Observation 299 312	non-compliant
34,T24,Non-query-able 299 312	non-compliant
35,T25,Drug 325 334	Ibuprofen
36,T26,Condition 335 342	Allergy
37,T27,Condition 343 355	interlerance
38,R10,AND Arg1:T26 Arg2:T25
39,R11,AND Arg1:T27 Arg2:T25
40,*,OR T27 T26
41,T28,Procedure 357 378	Anticoagulant therapy
42,T29,Drug 385 393	Warfarin
43,T30,Drug 395 401	Plavix
44,*,OR T30 T29
45,T31,"Scope 385 401	Warfarin, Plavix"
46,R12,Subsumes Arg1:T28 Arg2:T31
47,T32,Grammar_Error 410 441	will not be automatic exclusion
48,T33,Measurement 480 488	INR test
49,T34,Value 515 531	between 2.0 to 3
50,R13,Has_value Arg1:T33 Arg2:T34
51,R14,AND Arg1:T28 Arg2:T33
52,T35,Procedure 595 616	anticoagulant therapy
53,T36,Not_a_criteria 533 665	Physician consultation will be requested to determine whether anticoagulant therapy can be discontinued for 3 days prior to surgery.
54,T37,Non-query-able 533 665	Physician consultation will be requested to determine whether anticoagulant therapy can be discontinued for 3 days prior to surgery.
55,T38,Non-query-able 667 723	Objection to blood draw or application of blood products
56,T39,Non-query-able 725 816	Students and staff from USC Ostrow school of Dentistry will not be recruited for this study
0,T1,Condition 0 7	Healthy
1,T2,Person 9 14	women
2,T3,Person 15 19	ages
3,T4,Value 20 30	18 to 39yo
4,T5,Measurement 36 39	BMI
5,T6,Value 40 43	<30
6,R1,Has_value Arg1:T3 Arg2:T4
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Condition 45 69	Regular menstrual cycles
9,T8,Value 84 102	between 24-35 days
10,T9,Measurement 75 83	duration
11,R3,AND Arg1:T7 Arg2:T9
12,R4,Has_value Arg1:T9 Arg2:T8
13,T11,Measurement 187 205	progesterone level
14,T10,Value 215 232	5ng/mL or greater
15,R5,Has_value Arg1:T11 Arg2:T10
16,T12,Pregnancy_considerations 235 280	Not seeking pregnancy during the study period
17,T13,Procedure 291 325	non-hormonal form of contraception
18,T14,Procedure 336 349	sterilization
19,T15,Procedure 351 365	tubal ligation
20,T16,Procedure 367 373	Essure
21,*,OR T15 T16
22,T17,"Scope 351 373	tubal ligation, Essure"
23,R6,Subsumes Arg1:T14 Arg2:T17
24,T18,Procedure 376 386	copper IUD
25,T19,Procedure 388 407	intrauterine device
26,R7,Subsumes Arg1:T18 Arg2:T19
27,T20,Procedure 410 425	barrier methods
28,T21,Observation 429 439	abstinence
29,*,OR T14 T18 T20 T21
30,T22,"Scope 336 439	sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence"
31,R8,Subsumes Arg1:T13 Arg2:T22
32,T23,Non-query-able 441 470	Must speak English or Spanish
0,T1,Procedure 31 61	full resection of the pancreas
1,T2,Procedure 20 27;36 61	partial resection of the pancreas
2,T3,Condition 81 96	malignant tumor
3,T4,Condition 71 77;91 96	benign tumor
4,*,OR T3 T4
5,T5,Scope 71 96	benign or malignant tumor
6,T6,Scope 20 61	partial or full resection of the pancreas
7,R1,Has_scope Arg1:T6 Arg2:T5
0,T1,Person 36 40	ages
1,T2,Value 28 35;44 62	between 18 to 70 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 84 110	gingival recession defects
4,T4,Multiplier 64 72	Multiple
5,R2,Has_multiplier Arg1:T3 Arg2:T4
6,T5,Multiplier 116 130	minimum of two
7,R3,Has_multiplier Arg1:T3 Arg2:T5
8,T6,Value 158 169	3mm or more
9,T7,Measurement 170 179	recession
10,R4,Has_value Arg1:T7 Arg2:T6
11,T8,Multiplier 183 195	at least one
12,R5,Has_multiplier Arg1:T7 Arg2:T8
13,R6,AND Arg1:T3 Arg2:T7
14,T9,Procedure 221 239	surgical treatment
15,T10,Negation 212 214	No
16,R7,Has_negation Arg1:T9 Arg2:T10
17,T11,Non-query-able 212 272	No prior surgical treatment in the sites planned for therapy
18,T12,Value 274 289	Minimum of 2 mm
19,T13,Measurement 293 312	keratinized gingiva
20,R8,Has_value Arg1:T13 Arg2:T12
21,T14,Observation 325 367	cervical restorations extending to the CEJ
22,T15,Negation 314 321	Absence
23,R9,Has_negation Arg1:T14 Arg2:T15
24,T16,Measurement 369 375	Miller
25,T17,Condition 393 410	recession defects
26,T18,"Value 376 392	class 1, 2 and 3"
27,*,OR T16 T18
28,R10,AND Arg1:T17 Arg2:T16
29,T19,Non-query-able 429 532	Availability to undergo treatment and return for follow up visits at specified post-operative intervals
0,T1,Condition 10 18	pregnant
1,T2,Temporal 0 9	Currently
2,T3,Observation 22 35	breastfeeding
3,T4,Qualifier 37 43	Severe
4,T5,Condition 44 65	pelvic organ prolapse
5,T6,Condition 69 77	prolapse
6,T8,Qualifier 97 154	may prevent retention of the vaginal ring after insertion
7,*,OR T5 T6
8,T9,Scope 44 77	pelvic organ prolapse or prolapse
9,R1,Has_qualifier Arg1:T9 Arg2:T4
10,R2,Has_qualifier Arg1:T9 Arg2:T8
11,T7,Drug 163 187	oral contraceptive pills
12,T10,Device 189 196	patches
13,T11,Device 198 206	implants
14,T12,Procedure 210 245	hormonal intrauterine contraception
15,T13,Temporal 246 277	in the month prior to screening
16,T14,Reference_point 268 277	screening
17,R3,Has_index Arg1:T13 Arg2:T14
18,*,OR T10 T11 T7 T12
19,T15,"Scope 163 245	oral contraceptive pills, patches, implants or hormonal intrauterine contraception"
20,R4,Has_temporal Arg1:T15 Arg2:T13
21,T16,Drug 286 310	depo medroxyprogesterone
22,T17,Temporal 311 339	within 6 months of screening
23,R5,Has_temporal Arg1:T16 Arg2:T17
24,T18,Drug 348 359	medications
25,T19,Observation 365 378	interact with
26,T20,Drug 379 409	contraceptive steroid hormones
27,R6,Has_context Arg1:T18 Arg2:T19
28,R7,AND Arg1:T19 Arg2:T20
29,T21,Drug 411 437	anti-epileptic medications
30,T22,Drug 439 447	rifampin
31,T23,Drug 449 458	rifabutin
32,T24,Drug 460 473	fosamprenavir
33,*,OR T24 T23 T22 T21
34,T25,"Scope 411 473	anti-epileptic medications, rifampin, rifabutin, fosamprenavir"
35,T26,Scope 348 409	medications that interact with contraceptive steroid hormones
36,R8,Subsumes Arg1:T26 Arg2:T25
37,T27,Temporal 663 670	current
38,T28,Temporal 674 678	past
39,T29,Observation 679 686	history
40,T30,Condition 690 703	breast cancer
41,*,OR T28 T27
42,T31,Scope 663 678	current or past
43,R9,Has_temporal Arg1:T30 Arg2:T29
44,R10,Has_scope Arg1:T29 Arg2:T31
45,T32,Qualifier 705 711	severe
46,T33,Qualifier 712 725	decompensated
47,T34,Condition 726 735	cirrhosis
48,R11,Has_qualifier Arg1:T34 Arg2:T33
49,R12,Has_qualifier Arg1:T34 Arg2:T32
50,T35,Observation 737 744	history
51,T36,Condition 748 768	deep vein thrombosis
52,T37,Condition 772 789	pulmonary embolus
53,T38,Condition 791 799	diabetes
54,T39,Condition 805 816	nephropathy
55,T40,Condition 817 828	retinopathy
56,T41,Condition 829 839	neuropathy
57,T42,Qualifier 843 848	other
58,T43,Condition 849 865	vascular disease
59,T44,Temporal 876 898	more than 20 years ago
60,*,OR T43 T42 T41 T40 T39
61,T45,Scope 805 865	nephropathy/retinopathy/neuropathy or other vascular disease
62,R13,Has_temporal Arg1:T45 Arg2:T44
63,R14,Has_scope Arg1:T38 Arg2:T45
64,T46,Temporal 900 907	current
65,T47,Qualifier 908 919	symptomatic
66,T48,Condition 920 939	gallbladder disease
67,T49,Condition 941 953	hypertension
68,T50,Condition 955 977	ischemic heart disease
69,T51,Condition 985 1007	thrombogenic mutations
70,T52,Condition 1009 1031	hepatocellular adenoma
71,T53,Condition 1033 1051	malignant hepatoma
72,T54,Drug 552 583	combined hormonal contraceptive
73,T55,Multiplier 1053 1061	multiple
74,T56,Mood 1062 1074	risk factors
75,T57,Condition 1079 1117	atherosclerotic cardiovascular disease
76,T58,Condition 1119 1137	multiple sclerosis
77,R15,Has_mood Arg1:T57 Arg2:T56
78,R16,Has_multiplier Arg1:T56 Arg2:T55
79,T59,Condition 1143 1163	prolonged immobility
80,R17,AND Arg1:T58 Arg2:T59
81,T60,Observation 1165 1172	history
82,T61,Condition 1176 1201	peripartum cardiomyopathy
83,T62,Observation 1203 1220	cigarette smoking
84,T63,Value 1225 1230	=35yo
85,T64,Person 1228 1230	yo
86,R18,Has_value Arg1:T64 Arg2:T63
87,R19,Has_temporal Arg1:T61 Arg2:T60
88,T65,Scope 1203 1230	cigarette smoking and =35yo
89,T66,Procedure 1243 1277	complicated solid organ transplant
90,T67,Observation 1232 1239	history
91,T68,Observation 1279 1286	history
92,T69,Condition 1290 1296	stroke
93,T70,Observation 1298 1305	history
94,T71,Condition 1309 1338	superficial venous thrombosis
95,T72,Qualifier 1339 1353	not associated
96,T73,Device 1359 1367	catheter
97,T74,Condition 1369 1397	systemic lupus erythematosus
98,T75,Value 1403 1411	positive
99,T76,Measurement 1412 1439	antiphospholipid antibodies
100,R20,Has_value Arg1:T76 Arg2:T75
101,T77,Condition 1441 1463	valvular heart disease
102,T78,Condition 1479 1501	pulmonary hypertension
103,T79,Condition 1505 1524	atrial fibrillation
104,T80,Condition 1528 1550	bacterial endocarditis
105,T81,Condition 1556 1577	acute viral hepatitis
106,*,OR T80 T79 T78
107,R21,AND Arg1:T74 Arg2:T76
108,R22,Has_qualifier Arg1:T71 Arg2:T72
109,R23,AND Arg1:T72 Arg2:T73
110,R24,Has_temporal Arg1:T71 Arg2:T70
111,R25,Has_temporal Arg1:T69 Arg2:T68
112,R26,Has_temporal Arg1:T66 Arg2:T67
113,T82,Scope 1441 1550	valvular heart disease complicated by pulmonary hypertension or atrial fibrillation or bacterial endocarditis
114,*,OR T50 T49 T48
115,T83,"Scope 920 977	gallbladder disease, hypertension, ischemic heart disease"
116,R27,Has_qualifier Arg1:T83 Arg2:T47
117,R28,Has_temporal Arg1:T83 Arg2:T46
118,*,OR T83 T51 T52 T53 T82 T81 T74 T71 T69 T66 T57 T58 T61 T65 T45
119,T84,Condition 480 497	Medical condition
120,T86,Value 532 538	3 or 4
121,T87,Measurement 606 661	Center for Disease Control Medical Eligibility Criteria
122,T85,Measurement 503 509;523 531	safety category
123,R29,Subsumes Arg1:T85 Arg2:T87
124,R30,Has_value Arg1:T85 Arg2:T86
125,R31,AND Arg1:T85 Arg2:T54
126,R32,AND Arg1:T84 Arg2:T85
127,T88,"Scope 663 1577	current or past history of breast cancer, severe decompensated cirrhosis, history of deep vein thrombosis or pulmonary embolus, diabetes with nephropathy/retinopathy/neuropathy or other vascular disease diagnosed more than 20 years ago, current symptomatic gallbladder disease, hypertension, ischemic heart disease, known thrombogenic mutations, hepatocellular adenoma, malignant hepatoma, multiple risk factors for atherosclerotic cardiovascular disease, multiple sclerosis with prolonged immobility, history of peripartum cardiomyopathy, cigarette smoking and =35yo, history of complicated solid organ transplant, history of stroke, history of superficial venous thrombosis not associated with catheter, systemic lupus erythematosus with positive antiphospholipid antibodies, valvular heart disease complicated by pulmonary hypertension or atrial fibrillation or bacterial endocarditis, and acute viral hepatitis"
128,T89,"Scope 480 661	Medical condition with safety deemed to be category 3 or 4 when using a combined hormonal contraceptive, as determined by the Center for Disease Control Medical Eligibility Criteria"
129,R33,Subsumes Arg1:T89 Arg2:T88
130,*,OR T1 T3
131,T90,Scope 10 35	pregnant or breastfeeding
132,R34,Has_temporal Arg1:T90 Arg2:T2
0,T1,Procedure 0 21	adjuvant radiotherapy
1,T2,Condition 31 59	intra-abdominal inflammation
2,T3,Procedure 74 81	imaging
3,T4,Procedure 89 99	laboratory
4,T5,Condition 122 129	abscess
5,T6,Condition 133 146	cholecystitis
6,*,OR T5 T6
7,*,OR T3 T4
8,T7,Scope 74 99	imaging and/or laboratory
9,R1,Has_scope Arg1:T2 Arg2:T7
10,T8,Scope 31 59;61 99	intra-abdominal inflammation diagnosed by imaging and/or laboratory
11,T9,Scope 122 146	abscess or cholecystitis
12,R2,Subsumes Arg1:T8 Arg2:T9
13,T10,Condition 149 170	chronic pancreatitis
14,T11,Multiplier 149 156	chronic
15,T12,Condition 157 169	pancreatitis
16,R3,Has_multiplier Arg1:T12 Arg2:T11
17,T13,Condition 171 219	pancreatic polypeptide producing endocrine tumor
18,T14,Measurement 221 305	American Society of Anesthesiologists physical-health status classification (ASA-PS)
19,T15,Value 305 307	>3
20,R4,Has_value Arg1:T14 Arg2:T15
21,T16,Qualifier 309 325	Poorly regulated
22,T17,Condition 326 334	diabetes
23,T18,Qualifier 336 359	>200 mg/dl (=11 mmol/l)
24,R5,Subsumes Arg1:T16 Arg2:T18
25,R6,Has_qualifier Arg1:T17 Arg2:T16
0,T1,Measurement 0 4	eGFR
1,T2,Value 5 15	<45 ml/min
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 43 67	urogenital abnormalities
4,T4,Qualifier 17 27	structural
5,T5,Qualifier 32 42	functional
6,T6,Parsing_Error 28 31	and
7,*,OR T4 T5
8,T7,Scope 17 42	structural and functional
9,R2,Has_scope Arg1:T3 Arg2:T7
10,T8,Observation 74 110	predispose for urogenital infections
11,T9,Condition 89 110	urogenital infections
12,R3,multi Arg1:T8 Arg2:T9
13,T10,Procedure 112 139	Investigational product use
14,T11,Temporal 140 160	in the last 6 months
15,T12,Drug 162 177	SGLT2 inhibitor
16,T13,Drug 179 182	TZD
17,T14,Drug 184 198	DPP4 inhibitor
18,T15,Drug 203 210	GLP1 RA
19,T16,Temporal 215 239	within the past 6 months
20,R4,Has_temporal Arg1:T10 Arg2:T11
21,*,OR T12 T13 T14 T15
22,T17,"Scope 162 210	SGLT2 inhibitor, TZD, DPP4 inhibitor and GLP1 RA"
23,R5,Has_temporal Arg1:T17 Arg2:T16
24,T18,Condition 241 244	DKA
25,T19,Condition 245 266	Diabetic Ketoacidosis
26,T20,Condition 271 274	HHS
27,T21,Condition 275 312	Hyperosmoloar Hyperglycaemic Syndrome
28,R6,Subsumes Arg1:T18 Arg2:T19
29,R7,Subsumes Arg1:T20 Arg2:T21
30,*,OR T18 T20
31,T22,Temporal 314 338	within the last 6 months
32,T23,Scope 241 313	DKA(Diabetic Ketoacidosis) or HHS(Hyperosmoloar Hyperglycaemic Syndrome)
33,R8,Has_temporal Arg1:T23 Arg2:T22
34,T24,Pregnancy_considerations 340 349	Pregnancy
35,T25,Procedure 390 416	magnetic resonance imaging
36,T26,Observation 363 386	major contraindications
37,R9,AND Arg1:T26 Arg2:T25
38,T27,Device 418 436	cardiac pacemakers
39,T28,Condition 438 452	claustrophobia
40,T29,Observation 454 468	foreign bodies
41,T30,Device 473 498	implanted medical devices
42,T31,Qualifier 504 528	ferromagnetic properties
43,R10,Has_qualifier Arg1:T30 Arg2:T31
44,T32,Condition 532 547	Liver cirrhosis
45,T33,Condition 549 564	Type 1 diabetes
46,T34,Condition 585 606	insulin insufficiency
47,T35,Qualifier 573 584	uncorrected
48,T36,Qualifier 566 572	Severe
49,T37,Scope 566 584	Severe uncorrected
50,R11,Has_scope Arg1:T34 Arg2:T37
51,T38,Observation 620 634	alcohol intake
52,T39,Qualifier 608 619	Significant
53,R12,Has_qualifier Arg1:T38 Arg2:T39
54,T40,Condition 636 649	HIV infection
55,T41,Procedure 658 688	Traditional Chinese Medication
56,T42,Procedure 692 713	alternative therapies
57,*,OR T41 T42
58,T43,Condition 736 757	chronic liver disease
59,T44,Condition 760 783;784 785	chronic viral hepatitis B
60,T45,Condition 760 783;788 789	chronic viral hepatitis C
61,*,OR T44 T45 T47 T48 T49
62,T46,Parsing_Error 786 787	&
63,T47,Condition 792 816	autoimmune liver disease
64,T48,Condition 818 833	hemochromatosis
65,T49,Condition 835 843	Wilson's
66,T50,"Scope 760 843	chronic viral hepatitis(B & C), autoimmune liver disease, hemochromatosis, Wilson's"
67,R13,Subsumes Arg1:T43 Arg2:T50
68,T51,Drug 857 868	medications
69,T52,Condition 885 894	steatosis
70,R14,AND Arg1:T51 Arg2:T52
71,T53,Drug 899 911	Methotrexate
72,T54,Drug 913 928	anticonvulsants
73,T55,Drug 930 952	antiretroviral therapy
74,*,OR T53 T54 T55
75,T56,"Scope 899 952	Methotrexate, anticonvulsants, antiretroviral therapy"
76,R15,Subsumes Arg1:T51 Arg2:T56
77,T57,Condition 963 969	stroke
78,T58,Drug 971 986	Steroid therapy
79,T59,Condition 999 1008	Cushing's
80,T60,Qualifier 988 998	Endogenous
81,R16,Has_qualifier Arg1:T59 Arg2:T60
82,T61,Condition 1010 1038	Familial hypertriglyceridemi
0,T1,Condition 32 53	irriversible pulpitis
1,T2,Condition 57 70	pulp necrosis
2,T3,Condition 74 96	acute dental infection
3,T4,Qualifier 0 5	Teeth
4,R1,Has_qualifier Arg1:T1 Arg2:T4
5,R2,Has_qualifier Arg1:T2 Arg2:T4
6,*,OR T2 T3 T1
7,T5,Condition 112 128	systemic illness
8,T6,Condition 134 149	contraindicated
9,T7,Procedure 150 170	vital pulp treatment
10,T8,Condition 178 197	sickle cell disease
11,R3,AND Arg1:T6 Arg2:T7
12,R4,AND Arg1:T5 Arg2:T6
13,T9,Scope 112 170	systemic illness that contraindicated vital pulp treatment
14,R5,Subsumes Arg1:T9 Arg2:T8
15,T10,Observation 199 228	Teeth that are not restorable
0,T1,Condition 0 6	Smoker
1,T2,Condition 10 23	former smoker
2,*,OR T2 T1
3,T3,Device 38 55	dental prostheses
4,T4,Device 70 89	orthodontic devices
5,T5,Drug 92 102	Antibiotic
6,T6,Multiplier 116 127	routine use
7,T7,Drug 131 147	oral antiseptics
8,T8,Temporal 148 172	in the previous 3 months
9,R1,Has_temporal Arg1:T7 Arg2:T8
10,R2,Has_multiplier Arg1:T7 Arg2:T6
11,T9,Condition 191 207	systemic disease
12,T10,Qualifier 213 264	could alter the production or composition of saliva
13,R3,Has_qualifier Arg1:T9 Arg2:T10
0,T1,Condition 14 18	NASH
1,T2,Procedure 0 6	biopsy
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Condition 20 29	Type 2 DM
4,T4,Measurement 31 36	HbA1c
5,T5,Value 38 43	>6.5%
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 45 48	BMI
8,T7,Value 49 58	< 45kg/m2
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Drug 64 83	anti-diabetic agent
11,T9,Negation 84 90	except
12,T10,Drug 91 107	SGLT2 inhibitors
13,T11,Drug 109 113	TZDs
14,T12,Drug 114 132	thiazolidinediones
15,T13,Drug 135 139;163 173	DPP4 inhibitors
16,T14,Drug 140 161;163 173	Dipeptidyl peptidase4 inhibitors
17,T15,Drug 178 186	GLP1 RAs
18,T16,Drug 187 228	Glucagon-like Peptide 1-Receptor Agonists
19,R4,Subsumes Arg1:T15 Arg2:T16
20,R5,Subsumes Arg1:T13 Arg2:T14
21,R6,Subsumes Arg1:T11 Arg2:T12
22,T17,"Scope 91 228	SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists"
23,R7,Has_negation Arg1:T17 Arg2:T9
24,*,OR T10 T11 T13 T15
0,T1,Person 0 9	Pediatric
1,T2,Condition 24 41	deep dental decay
2,T3,Qualifier 45 59	primary molars
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Qualifier 61 66	Teeth
5,T5,Condition 94 113	reversible pulpitis
6,R2,Has_qualifier Arg1:T5 Arg2:T4
0,T1,Qualifier 0 12	Systemically
1,T2,Condition 13 20	healthy
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Person 21 27	adults
4,T4,Multiplier 30 43	Minimum of 24
5,T5,Observation 44 59	permanent teeth
6,R2,Has_multiplier Arg1:T5 Arg2:T4
7,T6,Negation 62 64	No
8,T7,Condition 65 75	gingivitis
9,T8,Measurement 77 110	Community Periodontal Index score
10,T9,Value 111 114	= 0
11,R3,Has_value Arg1:T8 Arg2:T9
12,R4,Has_negation Arg1:T7 Arg2:T6
13,T10,Scope 62 75	No gingivitis
14,T11,Scope 77 114	Community Periodontal Index score = 0
15,R5,Subsumes Arg1:T10 Arg2:T11
16,T12,Negation 118 120	No
17,T13,Condition 121 134	periodontitis
18,R6,Has_negation Arg1:T13 Arg2:T12
19,T14,Measurement 136 169	Community Periodontal Index score
20,T15,Value 170 173	= 0
21,R7,Has_value Arg1:T14 Arg2:T15
22,T16,Scope 136 173	Community Periodontal Index score = 0
23,T17,Scope 118 134	No periodontitis
24,R8,Subsumes Arg1:T17 Arg2:T16
25,T18,Qualifier 188 197	untreated
26,T19,Condition 198 204	caries
27,T20,Negation 177 184	Absence
28,R9,Has_qualifier Arg1:T19 Arg2:T18
29,R10,Has_negation Arg1:T19 Arg2:T20
0,T1,Person 0 3	age
1,T2,Value 4 22	less than 13 years
2,T3,Temporal 23 43	at time of procedure
3,R1,Has_value Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Drug 52 67	pain medication
6,T5,Temporal 68 86	prior to procedure
7,R3,Has_temporal Arg1:T4 Arg2:T5
8,T6,Condition 88 104	pectus carinatum
9,T7,Condition 106 123	Poland's syndrome
10,T8,Condition 132 150	chest wall anomaly
11,T9,Negation 151 161	other than
12,T10,Condition 162 178	pectus excavatum
13,R4,Has_negation Arg1:T10 Arg2:T9
14,R5,AND Arg1:T8 Arg2:T10
15,*,OR T8 T7 T6
16,T11,Procedure 189 215	repair of pectus excavatum
17,T12,Temporal 180 188	previous
18,R6,Has_temporal Arg1:T11 Arg2:T12
19,T13,Temporal 234 242	previous
20,T14,Procedure 243 259	thoracic surgery
21,R7,Has_temporal Arg1:T14 Arg2:T13
22,T15,Condition 261 285	congenital heart disease
23,T16,Condition 287 305	bleeding dyscrasia
24,T17,Condition 313 336	anesthetic risk factors
25,T18,Qualifier 307 312	major
26,R8,Has_qualifier Arg1:T17 Arg2:T18
27,T19,Condition 360 383	problem with anesthesia
28,T20,Temporal 351 359	previous
29,R9,Has_temporal Arg1:T19 Arg2:T20
30,*,OR T17 T19
31,T21,Condition 385 394	pregnancy
32,T22,Condition 396 431	inability to communicate in English
0,T1,Person 0 9	Caucasian
1,T2,Condition 46 68	essential hypertension
2,T3,Qualifier 31 44	uncomplicated
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Drug 123 128	ACE-I
5,T5,Drug 132 136	ARBs
6,T6,Drug 141 150	diuretics
7,*,OR T5 T4
8,T7,Multiplier 158 172	maximum dosage
9,R2,Has_multiplier Arg1:T6 Arg2:T7
10,R3,Has_multiplier Arg1:T4 Arg2:T7
11,R4,Has_multiplier Arg1:T5 Arg2:T7
12,T8,Qualifier 70 89	not well controlled
13,R5,Has_qualifier Arg1:T2 Arg2:T8
14,T9,Scope 123 172	ACE-I or ARBs and diuretics at the maximum dosage
15,R6,Has_scope Arg1:T8 Arg2:T9
0,T1,Procedure 14 28	Nuss procedure
1,T2,Mood 0 9	scheduled
2,T3,Condition 33 49	pectus excavatum
3,R1,AND Arg1:T1 Arg2:T3
4,R2,Has_mood Arg1:T1 Arg2:T2
5,T4,Value 62 79	at least 13 years
6,T5,Person 80 83	old
7,R3,Has_value Arg1:T5 Arg2:T4
8,T6,Temporal 84 112	at the time of the procedure
9,R4,Has_temporal Arg1:T5 Arg2:T6
0,T1,Condition 0 17	diabetes mellitus
1,T2,Condition 19 41	secondary hypertension
2,T3,Condition 43 52	pregnancy
0,T1,Person 0 3	Age
1,T2,Value 5 16	60-85 years
2,T3,Observation 18 30	right-handed
3,R1,Has_value Arg1:T1 Arg2:T2
4,T4,Condition 44 60	Major depression
5,T5,Qualifier 62 70	unipolar
6,T6,Measurement 148 150;75 142	IV Structured Clinical Interview for Diagnostic and Statistical Manual
7,T7,Measurement 164 180	DSM-IV criteria)
8,R2,Has_qualifier Arg1:T4 Arg2:T5
9,T8,Measurement 144 147	DSM
10,T9,Measurement 152 156	SCID
11,*,OR T8 T9
12,R4,Subsumes Arg1:T6 Arg2:T8
13,T10,Scope 75 179	Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria
14,R3,AND Arg1:T10 Arg2:T4
15,T11,Condition 190 212	onset of first episode
16,T12,Person 183 186	Age
17,T13,Value 213 223	= 50 years
18,R5,Has_value Arg1:T12 Arg2:T13
19,R6,AND Arg1:T11 Arg2:T12
20,T14,Multiplier 235 240	three
21,T15,Condition 241 260	depressive episodes
22,R7,Has_multiplier Arg1:T15 Arg2:T14
23,T16,Condition 275 285	depression
24,T17,Measurement 289 329	24-Item Hamilton Depression Rating Scale
25,T18,Measurement 331 335	HDRS
26,T19,Value 337 341	= 20
27,R8,Has_value Arg1:T17 Arg2:T19
28,R9,Subsumes Arg1:T17 Arg2:T18
29,R10,AND Arg1:T16 Arg2:T17
0,T1,Measurement 0 17	Total lesion area
1,T2,Value 21 27	>12 DA
2,T3,Value 31 40	>30.5 mm2
3,*,OR T2 T3
4,T4,Scope 21 40	>12 DA or >30.5 mm2
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Measurement 59 85	subretinal hemorrhage area
7,T6,Value 99 124	=50% of total lesion area
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 143 147;160 164	scar area
10,T8,Measurement 151 164	fibrosis area
11,*,OR T8 T7
12,T9,Scope 143 164	scar or fibrosis area
13,T10,Value 178 203	=50% of total lesion area
14,R3,Has_value Arg1:T9 Arg2:T10
15,T11,Condition 222 230	RPE tear
16,T12,Temporal 232 237	Prior
17,T13,Procedure 238 247	treatment
18,T14,Procedure 272 290	vitrectomy surgery
19,T15,Procedure 292 310	submacular surgery
20,T16,Procedure 321 342	surgical intervention
21,T17,Qualifier 315 320	other
22,T18,Condition 347 350	AMD
23,R4,Has_qualifier Arg1:T16 Arg2:T17
24,*,OR T15 T16 T14
25,T19,"Scope 272 342	vitrectomy surgery, submacular surgery, or other surgical intervention"
26,R5,AND Arg1:T19 Arg2:T18
27,T20,Condition 356 364	pregnant
28,T21,Condition 368 377	lactating
29,*,OR T21 T20
30,T22,Person 378 383	woman
0,T1,Observation 10 77	ability to lay in a supine position with their hands at their sides
1,T2,Temporal 78 101	during CVP measurements
2,T3,Procedure 85 101	CVP measurements
3,T4,Reference_point 85 101	CVP measurements
4,R1,Has_index Arg1:T2 Arg2:T4
5,R2,Has_temporal Arg1:T1 Arg2:T2
6,T5,Post-eligibility 103 167	A consent form signed by the patient or patient's representative
7,T6,Person 187 190	age
8,T7,Value 191 196	18-90
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Device 220 235	indwelling CICC
11,T9,Observation 244 267	transitioning to a PICC
12,T10,Device 263 267	PICC
13,T11,Device 293 304	CICC placed
14,T12,Qualifier 305 333;353 361	in the internal jugular vein position
15,T13,Qualifier 305 311;337 361	in the subclavian vein position
16,*,OR T13 T12
17,T14,Scope 305 361	in the internal jugular vein or subclavian vein position
18,R4,Has_scope Arg1:T11 Arg2:T14
0,T1,Person 0 8	Children
1,T2,Procedure 20 31	ENT surgery
2,T3,Temporal 9 19	undergoing
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,T4,Procedure 38 57	general anaesthesia
5,R2,AND Arg1:T2 Arg2:T4
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 46 48	2.
2,T3,Parsing_Error 94 96	3.
3,T4,Parsing_Error 112 114	4.
4,T5,Parsing_Error 180 182	5.
5,T6,Parsing_Error 229 231	6.
6,T7,Parsing_Error 289 291	7.
7,T8,Parsing_Error 356 358	8.
8,T9,Parsing_Error 405 407	9.
9,T10,Parsing_Error 493 496	10.
10,T11,Condition 3 20	Left main disease
11,T12,Value 38 43	> 50%
12,T13,Context_Error 21 44	(angiographically> 50%)
13,T14,Condition 49 66	Cardiogenic shock
14,T15,Condition 69 92	hemodynamic instability
15,T16,Condition 106 110	CABG
16,T17,Temporal 97 105	Previous
17,R1,Has_temporal Arg1:T16 Arg2:T17
18,T18,Condition 133 144	bradycardia
19,T19,Subjective_judgement 148 178	investigator clinical judgment
20,T20,Non-query-able 115 129	Increased risk
21,T21,Subjective_judgement 115 129	Increased risk
22,T22,Qualifier 115 129	Increased risk
23,R2,Has_qualifier Arg1:T18 Arg2:T22
24,T23,Condition 190 227	chronic obstructive pulmonary disease
25,T24,Qualifier 183 189	Severe
26,R3,Has_qualifier Arg1:T23 Arg2:T24
27,T25,Condition 232 247;254 264	Coronary vessel tortuosity
28,T26,Condition 232 247;268 287	Coronary vessel extremely calcified
29,*,OR T26 T25
30,T27,Condition 299 327	left ventricular hypertrophy
31,T28,Qualifier 292 298	Severe
32,R4,Has_qualifier Arg1:T27 Arg2:T28
33,T29,Condition 338 354	valvular disease
34,T30,Qualifier 331 337	severe
35,*,OR T29 T30 T27
36,T31,Condition 359 364	STEMI
37,T32,Condition 368 377	non-STEMI
38,T33,Temporal 378 403	within the past five days
39,*,OR T32 T31
40,R5,Has_temporal Arg1:T32 Arg2:T33
41,R6,Has_temporal Arg1:T31 Arg2:T33
42,T34,Condition 417 438	myocardial infarction
43,T35,Temporal 408 416	Previous
44,R7,Has_temporal Arg1:T34 Arg2:T35
45,T36,Qualifier 439 479	in the distribution of the target vessel
46,R8,Has_qualifier Arg1:T34 Arg2:T36
47,T37,Condition 497 530	Acute decompensated heart failure
0,T1,Condition 42 67	major depressive disorder
1,T2,Qualifier 85 90	DSM-V
2,T3,"Procedure 142 237	Structured Clinical Interview for DSM-V Axis I Disorders, Research Version, Non-patient Edition"
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,R2,AND Arg1:T1 Arg2:T3
5,T4,Condition 294 311	suicidal ideation
6,T5,Condition 294 302;316 325	suicidal behaviour
7,T6,Condition 337 346	self-harm
8,T7,Condition 354 368	harm to others
9,*,OR T5 T4 T6 T7
10,T8,Condition 384 399	substance abuse
11,T9,Condition 384 393;407 417	substance dependence
12,*,OR T8 T9
13,T10,Procedure 431 460	drug screen for illicit drugs
14,T11,Value 422 430	positive
15,R3,Has_value Arg1:T10 Arg2:T11
16,T12,Condition 462 485	Substantial alcohol use
17,T13,Drug 502 538	Monoamine Oxidase Inhibitors (MAOIs)
18,T14,Drug 554 574	antibiotic linezolid
19,T15,Drug 583 595	thiazine dye
20,T16,Drug 596 621	methylthioninium chloride
21,R4,Subsumes Arg1:T15 Arg2:T16
22,T17,Drug 623 637	methylene blue
23,R5,Subsumes Arg1:T16 Arg2:T17
24,*,OR T14 T15
25,T18,Scope 554 638	antibiotic linezolid and the thiazine dye methylthioninium chloride (methylene blue)
26,R6,Subsumes Arg1:T13 Arg2:T18
27,T19,Drug 655 675	serotonin-precursors
28,T20,Drug 685 697	L-tryptophan
29,T21,Drug 699 709	oxitriptan
30,*,OR T21 T20
31,T22,"Scope 685 709	L-tryptophan, oxitriptan"
32,R7,Subsumes Arg1:T19 Arg2:T22
33,T23,Drug 727 745	serotonergic drugs
34,T24,Drug 747 755	triptans
35,T25,Drug 765 789	tricyclic antidepressant
36,T26,Drug 792 799	lithium
37,T27,Drug 801 809	tramadol
38,T28,Drug 811 826	St. John's Wort
39,*,OR T28 T27 T26 T25 T24
40,T29,"Scope 747 826	triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort"
41,R8,Subsumes Arg1:T23 Arg2:T29
42,T30,Drug 848 854	NSAIDS
43,T31,Drug 856 859	ASA
44,T32,Drug 871 885	anticoagulants
45,T33,Qualifier 865 870	other
46,R9,Has_qualifier Arg1:T32 Arg2:T33
47,*,OR T31 T32 T30
48,T34,Drug 903 915	Thioridazine
49,T35,Temporal 829 840	Concomitant
50,T36,"Scope 848 885	NSAIDS, ASA, and other anticoagulants"
51,R10,Has_temporal Arg1:T36 Arg2:T35
52,T37,Drug 932 949	CYP1A2 Inhibitors
53,T38,Drug 966 974	Triptans
54,T39,Drug 976 989	5HT1 Agonists
55,R11,Subsumes Arg1:T38 Arg2:T39
56,T40,Measurement 992 1006	Blood pressure
57,T41,Value 1007 1026	greater than 140/90
58,T42,Measurement 1036 1046	pulse rate
59,T43,Value 1047 1066	greater than 90 bpm
60,R12,Has_value Arg1:T42 Arg2:T43
61,R13,Has_value Arg1:T40 Arg2:T41
62,T44,Temporal 1068 1074	Recent
63,T45,Observation 1075 1082	history
64,T46,Condition 1086 1107	myocardial infarction
65,R14,Has_temporal Arg1:T45 Arg2:T44
66,T47,Condition 1109 1133	cerebrovascular accident
67,T48,Condition 1135 1154	cardiac arrhythmias
68,T49,Condition 1159 1181	unstable heart disease
69,*,OR T49 T48 T47 T46
70,T50,"Scope 1086 1181	myocardial infarction, cerebrovascular accident, cardiac arrhythmias, or unstable heart disease"
71,R15,Has_temporal Arg1:T50 Arg2:T45
72,T51,Condition 1208 1224	physical illness
73,T52,Condition 1225 1241	contraindicating
74,T53,Drug 1253 1268	levomilnacipran
75,T54,Drug 1273 1283	duloxetine
76,*,OR T53 T54
77,T55,Procedure 1297 1310	physical exam
78,T56,Procedure 1321 1331	laboratory
79,T57,Temporal 1346 1380	during the first week of the study
80,*,OR T55 T56
81,T58,Scope 1297 1331	physical exam or in the laboratory
82,T59,Scope 1253 1283	levomilnacipran and duloxetine
83,R16,AND Arg1:T51 Arg2:T52
84,R17,Has_scope Arg1:T52 Arg2:T59
85,R18,Has_scope Arg1:T51 Arg2:T58
86,R19,Has_temporal Arg1:T58 Arg2:T57
87,T60,Drug 1397 1407	medication
88,T61,Drug 1437 1453	anticholinergics
89,T62,Temporal 1382 1389	Current
90,R20,Has_temporal Arg1:T60 Arg2:T62
91,T63,Condition 1417 1431	affect voiding
92,R21,Subsumes Arg1:T60 Arg2:T61
93,R22,AND Arg1:T60 Arg2:T63
94,T64,Condition 1467 1496	obstructive urinary disorders
95,T65,Condition 1501 1508	dysuria
96,T66,Condition 1510 1531	prostatic hypertrophy
97,T67,Condition 1533 1544	prostatitis
98,T68,Condition 1556 1597	lower urinary tract obstructive disorders
99,T69,Qualifier 1550 1555	other
100,R23,Has_qualifier Arg1:T68 Arg2:T69
101,*,OR T67 T68 T66 T65 T64
102,T70,Observation 1456 1463	History
103,T71,"Scope 1467 1597	obstructive urinary disorders and dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders"
104,R24,Has_temporal Arg1:T71 Arg2:T70
105,T72,Condition 1611 1635	Stevens-Johnson Syndrome
106,T73,Condition 1640 1659	Erythema multiforme
107,*,OR T73 T72
108,T74,Condition 1662 1677	Diabetes Type I
109,T75,Condition 1662 1675;1682 1684	Diabetes Type II
110,*,OR T75 T74
111,T76,Condition 1686 1706	Fructose intolerance
112,T77,Condition 1708 1739	glucose-galactose malabsorption
113,T78,Condition 1743 1775	sucrose-isomaltase insufficiency
114,*,OR T78 T77 T76
115,T79,Condition 1778 1796	Hepatic Impairment
116,T80,Condition 1811 1832	narrow-angle glaucoma
117,T81,Qualifier 1798 1810	Uncontrolled
118,R25,Has_qualifier Arg1:T80 Arg2:T81
119,T82,Condition 1841 1857	renal impairment
120,T83,Qualifier 1834 1840	Severe
121,R26,Has_qualifier Arg1:T82 Arg2:T83
122,T84,Condition 1870 1886	seizure disorder
123,T85,Observation 1859 1866	History
124,R27,Has_temporal Arg1:T84 Arg2:T85
125,T86,Condition 1888 1921	Anatomically narrow ocular angles
126,T87,Condition 1924 1936	Osteoporosis
127,T88,Mood 1940 1950	major risk
128,T89,Condition 1955 1969	bone fractures
129,R28,Has_mood Arg1:T89 Arg2:T88
130,*,OR T87 T89
0,T1,Qualifier 0 22	Clinically significant
1,T2,Qualifier 23 26	new
2,T3,Condition 27 34	illness
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,R2,Has_qualifier Arg1:T3 Arg2:T1
5,T4,Temporal 35 70	within 1 month before randomization
6,T5,Reference_point 57 70	randomization
7,R3,Has_index Arg1:T4 Arg2:T5
8,R4,Has_temporal Arg1:T3 Arg2:T4
9,T6,Observation 76 146	may affect the participant's ability to fulfill the study requirements
10,T7,Observation 150 188;76 79	significantly confound the assessments may
11,*,OR T6 T7
12,T8,Scope 76 188	may affect the participant's ability to fulfill the study requirements or significantly confound the assessments
13,R5,Has_scope Arg1:T3 Arg2:T8
14,T9,Observation 207 221	cannot swallow
15,T10,Drug 222 246	investigational products
16,R6,AND Arg1:T9 Arg2:T10
17,T11,Condition 266 270	T2DM
18,T12,Condition 280 304	hypoglycemia unawareness
19,T13,Condition 306 326	Aortic regurgitation
20,T14,Qualifier 327 342	mild or greater
21,R7,Has_qualifier Arg1:T13 Arg2:T14
22,T15,Condition 344 364	Mitral regurgitation
23,T16,Qualifier 365 384	moderate or greater
24,R8,Has_qualifier Arg1:T15 Arg2:T16
25,T17,Condition 386 392;403 417	Mitral valve stenosis
26,T18,Condition 396 417	aortic valve stenosis
27,T19,Qualifier 418 435	greater than mild
28,*,OR T18 T17
29,T20,Scope 386 417	Mitral or aortic valve stenosis
30,R9,Has_qualifier Arg1:T20 Arg2:T19
31,T21,Condition 441 456	aortic stenosis
32,A1,Optional T21
33,T22,Measurement 458 461	jet
34,T23,Value 462 490	>3.0 meters per second [m/s]
35,T24,Measurement 492 505	mean gradient
36,T25,Value 506 539	>25 millimeters of mercury [mmHg]
37,T26,Measurement 545 562	aortic valve area
38,T27,Value 563 594	<1.5 centimeters squared [cm^2]
39,R10,Has_value Arg1:T22 Arg2:T23
40,R11,Has_value Arg1:T24 Arg2:T25
41,R12,Has_value Arg1:T26 Arg2:T27
42,T28,Condition 596 611	mitral stenosis
43,T29,Measurement 613 626	mean gradient
44,T30,Value 627 634	>5 mmHg
45,R13,Has_value Arg1:T29 Arg2:T30
46,T31,Measurement 639 656	mitral valve area
47,T32,Value 657 666	<1.5 cm^2
48,R14,Has_value Arg1:T31 Arg2:T32
49,A2,Optional T28
50,T33,"Scope 458 594	jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]"
51,R15,Has_scope Arg1:T21 Arg2:T33
52,T34,Scope 613 666	mean gradient >5 mmHg and mitral valve area <1.5 cm^2
53,R16,Has_scope Arg1:T28 Arg2:T34
54,T35,"Scope 441 666	aortic stenosis: jet >3.0 meters per second [m/s], mean gradient >25 millimeters of mercury [mmHg], and aortic valve area <1.5 centimeters squared [cm^2]; mitral stenosis: mean gradient >5 mmHg and mitral valve area <1.5 cm^2"
55,T36,Scope 386 435	Mitral or aortic valve stenosis greater than mild
56,R17,Has_scope Arg1:T36 Arg2:T35
57,T37,Measurement 669 710	Systolic pulmonary artery pressure (SPAP)
58,T38,Value 711 719	>40 mmHg
59,R18,Has_value Arg1:T37 Arg2:T38
60,T39,Measurement 728 769	tricuspid regurgitation [TR] jet velocity
61,T40,Value 770 778	>2.9 m/s
62,R19,Has_value Arg1:T39 Arg2:T40
63,*,OR T37 T39 T42
64,T42,Measurement 1016 1022	RVOTAT
65,T43,Value 1023 1047	=100 milliseconds (msec)
66,R20,Has_value Arg1:T42 Arg2:T43
67,T41,"Non-representable 780 995	In cases where an actual SPAP value is not measurable due to lack of adequate TR jet, the pulmonary flow acceleration time measured at the right ventricular outflow tract (RVOTAT) will be used to assess eligibility."
68,T44,Measurement 1283 1317	Left ventricular ejection fraction
69,T45,Value 1318 1322	<45%
70,R21,Has_value Arg1:T44 Arg2:T45
71,T46,Condition 1324 1341	Intracardiac mass
72,T47,Condition 1343 1348	tumor
73,T48,Condition 1353 1361	thrombus
74,*,OR T48 T47 T46
75,T49,"Non-representable 1066 1281	suggesting an elevated mean SPAP; eligibility for the those participants with RVOTAT between 100 and 120 msec will be determined based on combined assessment of the TR jet, septal motion, and right ventricular size."
76,T50,Condition 1375 1399	congenital heart disease
77,T51,Mood 1363 1374	Evidence of
78,R22,Has_mood Arg1:T50 Arg2:T51
79,T52,Qualifier 1401 1423	Clinically significant
80,T53,Condition 1424 1444	pericardial effusion
81,R23,Has_qualifier Arg1:T53 Arg2:T52
82,T54,Qualifier 1450 1468	moderate or larger
83,T55,Condition 1477 1499	hemodynamic compromise
84,T56,Scope 1450 1499	moderate or larger or with hemodynamic compromise
85,*,OR T54 T55
86,R24,Subsumes Arg1:T52 Arg2:T56
87,T57,Qualifier 1502 1513	Significant
88,T58,Condition 1523 1538	hepatic disease
89,T59,Condition 1514 1519;1531 1538	renal disease
90,*,OR T58 T59
91,T60,Scope 1514 1538	renal or hepatic disease
92,R25,Has_qualifier Arg1:T60 Arg2:T57
93,T61,Measurement 1557 1573	serum creatinine
94,T62,Value 1574 1619	greater than 1.5× upper limit of normal (ULN)
95,R26,Has_value Arg1:T61 Arg2:T62
96,T63,Measurement 1621 1640	serum transaminases
97,T64,Value 1641 1660	greater than 3× ULN
98,R27,Has_value Arg1:T63 Arg2:T64
99,T65,Measurement 1665 1680	total bilirubin
100,T66,Value 1681 1702	greater than 1.5× ULN
101,T67,Negation 1706 1716	absence of
102,T68,Condition 1717 1735	Gilbert's syndrome
103,R28,Has_negation Arg1:T68 Arg2:T67
104,R29,Has_value Arg1:T65 Arg2:T66
105,R30,AND Arg1:T65 Arg2:T68
106,*,OR T63 T65 T61
107,T69,"Scope 1557 1735	serum creatinine greater than 1.5× upper limit of normal (ULN), serum transaminases greater than 3× ULN, or total bilirubin greater than 1.5× ULN in absence of Gilbert's syndrome"
108,R31,Has_scope Arg1:T60 Arg2:T69
109,T70,Condition 1741 1758	suicidal ideation
110,T71,Qualifier 1759 1770	with intent
111,T72,Qualifier 1779 1793	without a plan
112,T73,Qualifier 1771 1775;1787 1793	with a plan
113,*,OR T72 T73
114,R32,Has_qualifier Arg1:T70 Arg2:T71
115,T74,Scope 1771 1793	with or without a plan
116,R33,Has_scope Arg1:T70 Arg2:T74
117,T75,Temporal 1795 1809;1832 1841	at the time of Screening
118,T76,Temporal 1813 1841	within 6 months of Screening
119,*,OR T76 T75
120,T77,Scope 1795 1841	at the time of or within 6 months of Screening
121,R34,Has_scope Arg1:T70 Arg2:T77
122,T78,Procedure 1902 1982	Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS)
123,T79,Measurement 1878 1889	questions 4
124,T80,Measurement 1878 1887;1893 1894	questions 5
125,*,OR T79 T80
126,T81,Value 1870 1873	Yes
127,T82,Scope 1878 1894	questions 4 or 5
128,R35,Has_value Arg1:T82 Arg2:T81
129,R36,Has_scope Arg1:T78 Arg2:T82
130,R37,AND Arg1:T70 Arg2:T78
131,T83,Condition 1988 2005	suicidal behavior
132,T84,Temporal 2006 2017	in the past
133,T85,Procedure 2031 2037	C-SSRS
134,R38,Has_temporal Arg1:T83 Arg2:T84
135,R39,AND Arg1:T85 Arg2:T83
136,T86,Observation 2043 2050	history
137,T87,Condition 2054 2062	anorexia
138,T88,Condition 2066 2073	bulimia
139,T89,Temporal 2074 2105	within 2 years before Screening
140,T90,Reference_point 2096 2105	Screening
141,R40,Has_index Arg1:T89 Arg2:T90
142,*,OR T88 T87
143,T91,Scope 2054 2073	anorexia or bulimia
144,R41,Has_temporal Arg1:T91 Arg2:T89
145,R42,Has_temporal Arg1:T91 Arg2:T86
146,T92,Condition 2107 2147	Attention Deficit Hyperactivity Disorder
147,T93,"Qualifier 2153 2219	Diagnostic and Statistical Manual of Mental Disorders, 5th Edition"
148,T94,Condition 2220 2239	depressive disorder
149,T95,Condition 2241 2257	bipolar disorder
150,T96,Condition 2262 2275	schizophrenia
151,*,OR T95 T96 T94
152,T97,"Scope 2220 2275	depressive disorder, bipolar disorder, or schizophrenia"
153,R43,Has_qualifier Arg1:T97 Arg2:T93
154,*,OR T91 T92 T97
155,T98,Condition 2283 2299;2335 2346	secondary causes for obesity
156,T99,Qualifier 2301 2308	genetic
157,T100,Qualifier 2310 2319	endocrine
158,T101,Qualifier 2324 2333	metabolic
159,*,OR T99 T100 T101
160,T102,"Scope 2301 2333	genetic, endocrine, or metabolic"
161,R44,Has_scope Arg1:T98 Arg2:T102
162,T103,Condition 2352 2373	Prader-Willi syndrome
163,T104,Condition 2375 2396	Bardet Biedl syndrome
164,T105,Condition 2398 2413	Down's Syndrome
165,T106,Condition 2415 2439	untreated hypothyroidism
166,T107,Condition 2441 2459	Cushing's syndrome
167,T108,Multiplier 2461 2466	daily
168,T109,Drug 2467 2490	systemic corticosteroid
169,T110,Temporal 2500 2523	for longer than 30 days
170,R45,Has_multiplier Arg1:T109 Arg2:T108
171,R46,Has_temporal Arg1:T109 Arg2:T110
172,T111,Observation 2525 2532	history
173,T112,Qualifier 2536 2556	significant exposure
174,T113,Drug 2560 2575	corticosteroids
175,T114,Condition 2580 2595	chronic illness
176,T115,Temporal 2596 2616	during the past year
177,T116,Non-representable 2618 2650	inhaled steroids will be allowed
178,R47,AND Arg1:T113 Arg2:T114
179,R48,Has_temporal Arg1:T113 Arg2:T115
180,R49,Has_qualifier Arg1:T113 Arg2:T112
181,R50,Has_temporal Arg1:T113 Arg2:T111
182,*,OR T109 T113 T107 T106 T105 T104 T103
183,T117,"Scope 2352 2650	Prader-Willi syndrome, Bardet Biedl syndrome, Down's Syndrome, untreated hypothyroidism, Cushing's syndrome, daily systemic corticosteroid exposure for longer than 30 days, history of significant exposure to corticosteroids for chronic illness during the past year; inhaled steroids will be allowed"
184,T118,"Scope 2283 2346	secondary causes (genetic, endocrine, or metabolic) for obesity"
185,R51,Subsumes Arg1:T118 Arg2:T117
186,T119,Drug 2666 2699	products intended for weight loss
187,T120,Qualifier 2710 2722	prescription
188,T121,Qualifier 2730 2752	over-the-counter (OTC)
189,T122,Qualifier 2764 2770	herbal
190,T123,Temporal 2784 2815	within 1 month before Screening
191,T124,Reference_point 2806 2815	Screening
192,R52,Has_index Arg1:T123 Arg2:T124
193,*,OR T120 T121 T122
194,T125,"Scope 2710 2770	prescription drugs, over-the-counter (OTC) drugs, and herbal"
195,R54,Has_scope Arg1:T119 Arg2:T125
196,R53,Has_temporal Arg1:T119 Arg2:T123
197,T126,Drug 2817 2856	selective serotonin reuptake inhibitors
198,T127,Drug 2858 2902	serotonin norepinephrine reuptake inhibitors
199,T128,Drug 2904 2929	tricyclic antidepressants
200,T129,Drug 2931 2940	bupropion
201,T130,Drug 2942 2950	triptans
202,T131,Drug 2952 2967	St. John's Wort
203,T132,Drug 2969 2979	tryptophan
204,T133,Drug 2981 2990	linezolid
205,T134,Drug 2992 3008	dextromethorphan
206,T135,Qualifier 3012 3020	any form
207,R55,Has_qualifier Arg1:T134 Arg2:T135
208,T136,Drug 3047 3054	lithium
209,T137,Drug 3056 3064	tramadol
210,T138,Drug 3066 3080	antipsychotics
211,T139,Drug 3090 3110	dopamine antagonists
212,*,OR T138 T139
213,T140,Drug 3113 3136	antiseizure medications
214,T141,Drug 3147 3160	valproic acid
215,T142,Drug 3162 3172	zonisamide
216,T143,Drug 3174 3184	topiramate
217,T144,Drug 3190 3201	lamotrigine
218,*,OR T143 T144 T142 T141
219,T145,"Scope 3147 3201	valproic acid, zonisamide, topiramate, and lamotrigine"
220,R56,Subsumes Arg1:T140 Arg2:T145
221,T146,Drug 3203 3216	oral steroids
222,T147,Drug 3230 3246	inhaled steroids
223,T148,Drug 3218 3225;3238 3246	topical steroids
224,T149,Negation 3251 3261	acceptable
225,A3,Optional T146
226,T150,Scope 3218 3246	topical and inhaled steroids
227,R57,Has_negation Arg1:T150 Arg2:T149
228,R58,Has_scope Arg1:T146 Arg2:T150
229,T151,Drug 3264 3285	stimulant medications
230,T152,Drug 3291 3298	Ritalin
231,T153,Drug 3300 3308	Concerta
232,T154,Drug 3310 3321	Biphetamine
233,T155,Drug 3327 3336	Dexedrine
234,*,OR T152 T153 T154 T155
235,T156,"Scope 3291 3336	Ritalin, Concerta, Biphetamine, and Dexedrine"
236,R59,Has_scope Arg1:T151 Arg2:T156
237,T157,Drug 3339 3354	benzodiazepines
238,T158,Drug 3363 3368	drugs
239,T159,Condition 3400 3420	cardiac valvulopathy
240,T160,Temporal 3421 3453	within 6 months before Screening
241,T161,Drug 3484 3493	pergolide
242,T162,Drug 3495 3505	ergotamine
243,T163,Drug 3507 3519	methysergide
244,T164,Drug 3525 3536	cabergoline
245,*,OR T163 T164 T162 T161
246,T165,"Scope 3484 3536	pergolide, ergotamine, methysergide, and cabergoline"
247,T166,Qualifier 3369 3420	known to increase the risk for cardiac valvulopathy
248,R61,multi Arg1:T166 Arg2:T159
249,R62,Has_qualifier Arg1:T158 Arg2:T166
250,T167,Scope 3363 3420	drugs known to increase the risk for cardiac valvulopathy
251,R60,Subsumes Arg1:T167 Arg2:T165
252,R63,Has_temporal Arg1:T167 Arg2:T160
253,T168,Observation 3538 3545	History
254,T169,Qualifier 3561 3583	clinically significant
255,T170,Condition 3584 3591	disease
256,T171,Condition 3597 3607	malignancy
257,T172,Qualifier 3609 3616	cardiac
258,T173,Qualifier 3618 3629	respiratory
259,T174,Qualifier 3631 3647	gastrointestinal
260,T175,Qualifier 3649 3654	renal
261,T176,Qualifier 3659 3670	psychiatric
262,T177,Condition 3671 3678	disease
263,*,OR T175 T176 T174 T173 T172
264,T178,"Scope 3609 3670	cardiac, respiratory, gastrointestinal, renal, or psychiatric"
265,R64,Has_scope Arg1:T177 Arg2:T178
266,T179,"Scope 3609 3678	cardiac, respiratory, gastrointestinal, renal, or psychiatric disease"
267,R65,Subsumes Arg1:T171 Arg2:T179
268,*,OR T168 T169
269,T180,Scope 3538 3583	History or evidence of clinically significant
270,R66,Has_scope Arg1:T170 Arg2:T180
271,T181,Scope 3538 3591	History or evidence of clinically significant disease
272,T182,"Scope 3597 3678	malignancy; cardiac, respiratory, gastrointestinal, renal, or psychiatric disease"
273,R67,Has_scope Arg1:T182 Arg2:T181
274,T183,Negation 3680 3690	other than
275,T184,Condition 3691 3702	prediabetes
276,R68,Has_negation Arg1:T184 Arg2:T183
277,T185,Value 3704 3712	impaired
278,T186,Measurement 3713 3728	fasting glucose
279,T187,Condition 3732 3758	impaired glucose tolerance
280,R69,Has_value Arg1:T186 Arg2:T185
281,T188,Condition 3704 3728	impaired fasting glucose
282,*,OR T188 T187
283,T189,Condition 3761 3776	type 2 diabetes
284,T190,Drug 3790 3815	oral anti-diabetic agents
285,T191,Drug 3827 3839	sulfonylurea
286,T192,Negation 3817 3826	excluding
287,R70,Has_negation Arg1:T191 Arg2:T192
288,T193,Scope 3817 3839	excluding sulfonylurea
289,T194,Qualifier 3844 3855	non-insulin
290,T195,Qualifier 3856 3866	injectable
291,T196,Drug 3867 3886	antidiabetic agents
292,R71,Has_qualifier Arg1:T196 Arg2:T195
293,R72,Has_qualifier Arg1:T196 Arg2:T194
294,R73,Subsumes Arg1:T190 Arg2:T193
295,T197,Condition 3888 3911	obstructive sleep apnea
296,T198,Condition 3913 3925	dyslipidemia
297,T199,Condition 3931 3963	nonalcoholic fatty liver disease
298,*,OR T198 T199 T197 T200
299,*,OR T190 T196
300,T200,Scope 3790 3886	oral anti-diabetic agents (excluding sulfonylurea) or non-insulin injectable antidiabetic agents
301,R74,Has_scope Arg1:T189 Arg2:T200
302,T201,Scope 3704 3759	impaired fasting glucose or impaired glucose tolerance)
303,R75,Subsumes Arg1:T184 Arg2:T201
304,R76,AND Arg1:T181 Arg2:T184
305,*,OR T181 T189
306,T202,Drug 3972 3981	Belviq XR
307,T203,Temporal 3982 4014	within 6 months before Screening
308,T204,Reference_point 4005 4014	Screening
309,R77,Has_index Arg1:T203 Arg2:T204
310,T205,Condition 4018 4034	hypersensitivity
311,T206,Drug 4038 4047	Belviq XR
312,T207,Qualifier 4048 4072	or any of the excipients
313,R78,Has_qualifier Arg1:T206 Arg2:T207
314,R79,AND Arg1:T205 Arg2:T206
315,R80,Has_temporal Arg1:T202 Arg2:T203
316,*,OR T202 T205
317,T208,Observation 4086 4100	change in diet
318,T209,Qualifier 4074 4085	Significant
319,T210,Observation 4086 4095;4104 4130	change in level of physical activity
320,T211,Temporal 4131 4159	within 1 month before dosing
321,T212,Reference_point 4153 4159	dosing
322,R82,Has_index Arg1:T211 Arg2:T212
323,T213,Scope 4086 4130	change in diet or level of physical activity
324,R81,Has_qualifier Arg1:T213 Arg2:T209
325,R83,Has_temporal Arg1:T213 Arg2:T211
326,T214,Observation 4163 4179	change in weight
327,T215,Value 4183 4197	more than 5 kg
328,R84,Has_value Arg1:T214 Arg2:T215
329,T216,Temporal 4198 4230	within 3 months before Screening
330,T217,Reference_point 4221 4230	Screening
331,R85,Has_index Arg1:T216 Arg2:T217
332,R86,Has_temporal Arg1:T214 Arg2:T216
333,*,OR T213 T214
334,T218,Observation 4245 4261;4283 4299	very-low-calorie weight loss diet
335,T219,Value 4263 4281	<1000 calories/day
336,R87,Has_value Arg1:T218 Arg2:T219
337,T220,Temporal 4300 4332	within 6 months before Screening
338,T221,Reference_point 4323 4332	Screening
339,R88,Has_index Arg1:T220 Arg2:T221
340,R89,Has_temporal Arg1:T218 Arg2:T220
341,T222,Observation 4334 4341	History
342,T223,Condition 4345 4352;4375 4380	alcohol abuse
343,T224,Condition 4356 4371	drug dependence
344,T225,Condition 4356 4360;4375 4380	drug abuse
345,T226,Condition 4345 4352;4361 4371	alcohol dependence
346,*,OR T223 T226 T224 T225
347,T227,Scope 4345 4380	alcohol or drug dependence or abuse
348,R90,Has_temporal Arg1:T227 Arg2:T222
349,T228,Observation 4382 4403	Recreational drug use
350,T229,Temporal 4404 4435	within 2 years before Screening
351,R91,Has_temporal Arg1:T228 Arg2:T229
352,T230,Reference_point 4426 4435	Screening
353,R92,Has_index Arg1:T229 Arg2:T230
354,T231,Condition 4449 4486	human immunodeficiency virus positive
355,T232,Measurement 4449 4477	human immunodeficiency virus
356,T233,Value 4478 4486	positive
357,R93,Has_value Arg1:T232 Arg2:T233
358,R94,multi Arg1:T231 Arg2:T232
359,T234,Condition 4509 4524	viral hepatitis
360,T235,Qualifier 4502 4508	active
361,R95,Has_qualifier Arg1:T234 Arg2:T235
362,T236,Qualifier 4526 4527	B
363,T237,Qualifier 4531 4532	C
364,*,OR T236 T237
365,T238,Scope 4526 4532	B or C
366,R96,Has_scope Arg1:T234 Arg2:T238
367,T239,Condition 4535 4545	Malignancy
368,T240,Temporal 4546 4577	within 5 years before Screening
369,T241,Reference_point 4568 4577	Screening
370,R97,Has_index Arg1:T240 Arg2:T241
371,R98,Has_temporal Arg1:T239 Arg2:T240
372,T242,Observation 4579 4612	Unable to attend scheduled visits
373,T243,Observation 4618 4640	lack of transportation
374,R99,Subsumes Arg1:T242 Arg2:T243
375,T244,Observation 4645 4664	lack of a caregiver
376,T245,Observation 4645 4652;4668 4676	lack of guardian
377,*,OR T245 T244 T242
378,T246,Observation 4711 4724	Special needs
379,T247,Observation 4746 4766;4781 4793	unable to comprehend instructions
380,T248,Qualifier 4767 4780	study-related
381,R100,Has_qualifier Arg1:T247 Arg2:T248
382,T249,Qualifier 4799 4815	mild to profound
383,T250,Condition 4816 4834	mental retardation
384,R101,Has_qualifier Arg1:T250 Arg2:T249
385,T251,Measurement 4836 4857	intelligence quotient
386,T252,Value 4858 4861	<70
387,R102,Has_value Arg1:T251 Arg2:T252
388,T253,Qualifier 4864 4882	moderate to severe
389,T254,Condition 4883 4912	cognitive developmental delay
390,R103,Has_qualifier Arg1:T254 Arg2:T253
391,T255,Condition 4914 4945	pervasive development disorders
392,T256,Condition 4947 4953	autism
393,T257,Scope 4836 4861	intelligence quotient <70
394,T258,Scope 4799 4834	mild to profound mental retardation
395,R104,Subsumes Arg1:T258 Arg2:T257
396,*,OR T258 T254 T255 T256
397,T259,"Scope 4799 4953	mild to profound mental retardation [intelligence quotient <70], moderate to severe cognitive developmental delay, pervasive development disorders, autism"
398,T260,Scope 4746 4793	unable to comprehend study-related instructions
399,R105,Subsumes Arg1:T260 Arg2:T259
400,T261,Temporal 4956 4963	Ongoing
401,T262,Condition 4964 4972	epilepsy
402,R106,Has_temporal Arg1:T262 Arg2:T261
403,T263,Qualifier 4956 4963	Ongoing
404,R107,multi Arg1:T261 Arg2:T263
405,T264,Condition 4982 4998	seizure disorder
406,T265,Qualifier 4976 4981	other
407,R108,Has_qualifier Arg1:T264 Arg2:T265
408,T266,Drug 5010 5021	medications
409,T267,Condition 5028 5044	seizure disorder
410,T268,Temporal 5045 5073	within 6 months of screening
411,T269,Reference_point 5064 5073	screening
412,R110,Has_index Arg1:T268 Arg2:T269
413,R111,AND Arg1:T267 Arg2:T266
414,T270,Temporal 5077 5121	any time between screening and randomization
415,T271,Reference_point 5094 5103	screening
416,T272,Reference_point 5108 5121	randomization
417,R112,Has_index Arg1:T270 Arg2:T271
418,R113,Has_index Arg1:T270 Arg2:T272
419,T273,Scope 5045 5121	within 6 months of screening or any time between screening and randomization
420,R109,Has_scope Arg1:T267 Arg2:T273
421,*,OR T264 T267 T262
422,T274,Measurement 5143 5157	blood pressure
423,T275,Value 5165 5191	95th percentile or greater
424,R114,Has_value Arg1:T274 Arg2:T275
425,T276,Qualifier 5192 5199	for age
426,T277,Qualifier 5192 5195;5201 5204	for sex
427,T278,Qualifier 5192 5195;5210 5216	for height
428,R115,Has_qualifier Arg1:T274 Arg2:T276
429,R116,Has_qualifier Arg1:T274 Arg2:T278
430,R117,Has_qualifier Arg1:T274 Arg2:T277
431,T279,Multiplier 5220 5239	2 separate readings
432,R118,Has_multiplier Arg1:T274 Arg2:T279
433,T280,Qualifier 5252 5267	2 separate days
434,R119,Has_qualifier Arg1:T279 Arg2:T280
435,T281,Non-representable 5269 5437	Those participants who had uncontrolled hypertension at Screening can be rescreened more than 1 month after initiation or adjustment of antihypertensive therapy 1 time.
436,T282,Observation 5449 5460;5469 5483	enrolled in clinical study
437,T283,Qualifier 5461 5468	another
438,R120,Has_qualifier Arg1:T282 Arg2:T283
439,T284,Temporal 5439 5448	Currently
440,R121,Has_temporal Arg1:T282 Arg2:T284
441,T285,Drug 5500 5520	investigational drug
442,T286,Temporal 5531 5579	within 30 days before providing informed consent
443,T287,Device 5524 5530	device
444,*,OR T287 T285
445,T288,Scope 5500 5530	investigational drug or device
446,R122,Has_temporal Arg1:T288 Arg2:T286
447,*,OR T282 T288
448,T289,Mood 5581 5588	Planned
449,T290,Procedure 5589 5606	bariatric surgery
450,T291,Temporal 5607 5623	during the study
451,R123,Has_mood Arg1:T290 Arg2:T289
452,R124,Has_temporal Arg1:T290 Arg2:T291
453,T292,Reference_point 5614 5623	the study
454,R125,Has_index Arg1:T291 Arg2:T292
455,T293,Temporal 5627 5632	prior
456,T294,Procedure 5633 5662	bariatric surgical procedures
457,R126,AND Arg1:T293 Arg2:T294
458,*,OR T290 T294
459,T295,"Non-query-able 5664 5862	Not suitable to participate in the study in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol"
460,T296,Person 5864 5870	Female
461,T297,Observation 5892 5905	breastfeeding
462,T298,Condition 5909 5917	pregnant
463,T299,Temporal 5918 5930	at Screening
464,T300,Temporal 5918 5920;5934 5942	at Baseline
465,*,OR T299 T300
466,*,OR T297 T298
467,T301,Scope 5892 5917	breastfeeding or pregnant
468,T302,Scope 5918 5942	at Screening or Baseline
469,R127,Has_scope Arg1:T301 Arg2:T302
470,T303,Measurement 5972 6010	beta-human chorionic gonadotropin test
471,T304,Value 5963 5971	positive
472,R128,Has_value Arg1:T303 Arg2:T304
473,T305,Value 6061 6069	negative
474,T306,Measurement 6070 6094	screening pregnancy test
475,R129,Has_value Arg1:T306 Arg2:T305
476,T307,Qualifier 6015 6023	separate
477,T308,Procedure 6024 6043	Baseline assessment
478,R130,Has_qualifier Arg1:T308 Arg2:T307
479,T309,Temporal 6108 6162	more than 72 hours before the first dose of study drug
480,T310,Reference_point 6134 6162	the first dose of study drug
481,R131,Has_index Arg1:T309 Arg2:T310
482,R132,Has_temporal Arg1:T306 Arg2:T309
483,T311,Scope 6061 6162	negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug
484,A4,Optional T311
485,R133,AND Arg1:T311 Arg2:T308
486,T312,Scope 5963 6010	positive beta-human chorionic gonadotropin test
487,T313,Scope 6015 6162	separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug
488,R134,Has_scope Arg1:T312 Arg2:T313
489,T314,Condition 6169 6199	unprotected sexual intercourse
490,T315,Temporal 6200 6233	within 30 days before study entry
491,T316,Reference_point 6222 6233	study entry
492,R135,Has_index Arg1:T315 Arg2:T316
493,R136,Has_temporal Arg1:T314 Arg2:T315
494,T317,Observation 6242 6254	do not agree
495,T318,Qualifier 6264 6280	highly effective
496,T319,Observation 6281 6304	method of contraception
497,R137,Has_qualifier Arg1:T319 Arg2:T318
498,T320,Measurement 6316 6326	abstinence
499,T321,Value 6310 6315	total
500,R139,Has_value Arg1:T320 Arg2:T321
501,T322,Device 6331 6350	intrauterine device
502,T323,Observation 6354 6375	double-barrier method
503,T324,Device 6385 6391	condom
504,T325,Device 6397 6422	diaphragm with spermicide
505,T326,Scope 6385 6422	condom plus diaphragm with spermicide
506,T327,Device 6427 6448	contraceptive implant
507,T328,Drug 6453 6471	oral contraceptive
508,T329,Procedure 6483 6495	vasectomized
509,T330,Person 6496 6503	partner
510,R141,AND Arg1:T330 Arg2:T329
511,T331,Condition 6519 6530	azoospermia
512,R142,AND Arg1:T330 Arg2:T331
513,*,OR T326 T327 T328 T330
514,T332,"Scope 6385 6530	condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia"
515,R140,Subsumes Arg1:T323 Arg2:T332
516,*,OR T320 T322 T323
517,T333,Temporal 6532 6566	throughout the entire study period
518,T334,Temporal 6571 6615	for 28 days after study drug discontinuation
519,T335,Reference_point 6543 6566	the entire study period
520,R143,Has_index Arg1:T333 Arg2:T335
521,T336,Reference_point 6589 6615	study drug discontinuation
522,R144,Has_index Arg1:T334 Arg2:T336
523,T337,Drug 6589 6599	study drug
524,R145,multi Arg1:T336 Arg2:T337
525,T338,"Scope 6310 6530	total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia"
526,T339,Scope 6264 6304	highly effective method of contraception
527,R138,Subsumes Arg1:T339 Arg2:T338
528,R146,Has_context Arg1:T339 Arg2:T317
529,R147,Has_temporal Arg1:T339 Arg2:T333
530,R148,Has_temporal Arg1:T339 Arg2:T334
531,T340,Condition 6631 6640	abstinent
532,T341,Temporal 6621 6630	currently
533,R149,Has_temporal Arg1:T340 Arg2:T341
534,T342,Observation 6667 6688	double-barrier method
535,T343,Observation 6645 6657	do not agree
536,T344,Observation 6726 6741	sexual activity
537,T345,Negation 6713 6720	refrain
538,R150,Has_negation Arg1:T344 Arg2:T345
539,T346,Temporal 6742 6765	during the study period
540,T347,Temporal 6770 6814	for 28 days after study drug discontinuation
541,T348,Reference_point 6749 6765	the study period
542,R151,Has_index Arg1:T346 Arg2:T348
543,T349,Reference_point 6788 6814	study drug discontinuation
544,R153,Has_index Arg1:T347 Arg2:T349
545,T350,Drug 6788 6798	study drug
546,R154,multi Arg1:T349 Arg2:T350
547,*,OR T342 T344
548,T351,Scope 6742 6814	during the study period and for 28 days after study drug discontinuation
549,T352,Scope 6667 6741	double-barrier method (as described above) or refrain from sexual activity
550,R152,Has_scope Arg1:T352 Arg2:T351
551,R155,Has_context Arg1:T352 Arg2:T343
552,T353,Drug 6826 6849	hormonal contraceptives
553,T354,Negation 6859 6862	not
554,T355,Qualifier 6868 6879	stable dose
555,T356,Drug 6892 6914	hormonal contraceptive
556,T357,Temporal 6923 6957	for at least 4 weeks before dosing
557,R156,Has_temporal Arg1:T356 Arg2:T357
558,R157,Has_qualifier Arg1:T356 Arg2:T355
559,R158,Has_negation Arg1:T355 Arg2:T354
560,T358,Drug 6995 7008	contraceptive
561,T359,Temporal 7009 7025	during the study
562,T360,Temporal 7030 7074	for 28 days after study drug discontinuation
563,T361,Reference_point 7048 7074	study drug discontinuation
564,R159,Has_index Arg1:T360 Arg2:T361
565,T362,Observation 6966 6978	do not agree
566,T363,Qualifier 6986 6994	the same
567,T364,Qualifier 6883 6891	the same
568,R160,Has_qualifier Arg1:T356 Arg2:T364
569,R161,Has_qualifier Arg1:T358 Arg2:T363
570,R162,Has_temporal Arg1:T358 Arg2:T359
571,R163,Has_temporal Arg1:T358 Arg2:T360
572,R164,Has_context Arg1:T358 Arg2:T362
573,T365,"Non-representable 7075 7328	(Note: All female participants will be considered to be of childbearing potential unless they have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing])"
0,T1,Informed_consent 0 28	Signed informed consent form
1,T2,Person 30 34	Male
2,T3,Person 38 44	female
3,*,OR T3 T2
4,T4,Person 48 52	aged
5,T5,Value 53 70	50 years or older
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 88 100	PCV patients
8,T7,Condition 80 83	AMD
9,T8,Condition 102 106	BCVA
10,T9,Qualifier 110 128	24 letters or over
11,R2,Has_qualifier Arg1:T8 Arg2:T9
12,*,OR T7 T6
0,T1,Condition 0 20	Psychotic depression
1,T2,Qualifier 24 30	DSM-IV
2,T3,Condition 50 59	delusions
3,T4,Measurement 67 79	SCID-R score
4,T5,Value 80 93	higher than 2
5,R1,Has_value Arg1:T4 Arg2:T5
6,R2,Has_qualifier Arg1:T1 Arg2:T2
7,R3,AND Arg1:T1 Arg2:T3
8,R4,AND Arg1:T1 Arg2:T4
9,T6,Observation 101 113	suicide risk
10,T7,Qualifier 96 100	High
11,R5,Has_qualifier Arg1:T6 Arg2:T7
12,T8,Mood 120 126	intent
13,T9,Mood 130 137	plan to
14,*,OR T8 T9
15,T10,Observation 138 153	attempt suicide
16,T11,Temporal 154 168	in near future
17,T12,Scope 120 137	intent or plan to
18,R6,Has_scope Arg1:T10 Arg2:T12
19,R7,Has_temporal Arg1:T10 Arg2:T11
20,R8,Subsumes Arg1:T6 Arg2:T10
21,T13,Condition 194 214	psychiatric disorder
22,T14,Qualifier 187 193	Axis I
23,R9,Has_qualifier Arg1:T13 Arg2:T14
24,T15,Negation 216 226	other than
25,T16,Condition 227 252	unipolar major depression
26,R10,Has_negation Arg1:T16 Arg2:T15
27,T17,Condition 257 272	substance abuse
28,T18,Scope 187 252	Axis I psychiatric disorder (other than unipolar major depression
29,*,OR T18 T17
30,T19,Condition 286 307	psychiatric disorders
31,T20,Negation 308 318	other than
32,T21,Condition 319 344	unipolar major depression
33,T22,Condition 348 376	generalized anxiety disorder
34,T23,Condition 378 394	bipolar disorder
35,T24,Condition 396 405	hypomania
36,T25,Condition 411 420	dysthymia
37,*,OR T21 T22
38,T27,Scope 319 376	unipolar major depression or generalized anxiety disorder
39,R11,Has_negation Arg1:T27 Arg2:T20
40,*,OR T23 T24 T25
41,T26,"Scope 378 420	bipolar disorder, hypomania, and dysthymia"
42,R12,Subsumes Arg1:T19 Arg2:T26
43,T28,Condition 447 455	Dementia
44,T29,Qualifier 482 488	DSM-IV
45,R13,Has_qualifier Arg1:T28 Arg2:T29
46,T30,Condition 491 516	Mild Cognitive Impairment
47,T31,Condition 518 521	MCI
48,R14,Subsumes Arg1:T30 Arg2:T31
49,T32,Condition 541 556	medical illness
50,T33,Qualifier 525 530	Acute
51,T34,Qualifier 534 540	severe
52,T35,Condition 564 572	delirium
53,T36,Condition 574 591	metastatic cancer
54,T37,Qualifier 593 606	decompensated
55,T38,Condition 607 614;632 639	cardiac failure
56,T39,Condition 616 621;632 639	liver failure
57,T40,Condition 625 639	kidney failure
58,T41,Procedure 641 654	major surgery
59,T42,Condition 656 662	stroke
60,T43,Condition 666 687	myocardial infarction
61,T44,Temporal 699 726	three months prior to entry
62,T45,Reference_point 721 726	entry
63,T46,Drug 738 743	drugs
64,T47,Condition 759 769	depression
65,T48,Drug 777 786	reserpine
66,T49,Drug 788 805	alpha-methyl-dopa
67,T50,Drug 807 815	steroids
68,T51,Condition 817 844	sympathomimetics withdrawal
69,*,OR T33 T34
70,T52,Scope 525 540	Acute or severe
71,R15,Has_scope Arg1:T32 Arg2:T52
72,T53,"Scope 564 687	delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction"
73,R16,Subsumes Arg1:T32 Arg2:T53
74,*,OR T35 T36 T54 T41 T42 T43
75,T54,"Scope 607 639	cardiac, liver or kidney failure"
76,R17,Has_qualifier Arg1:T54 Arg2:T37
77,*,OR T40 T39 T38
78,R18,Has_temporal Arg1:T32 Arg2:T44
79,R19,AND Arg1:T46 Arg2:T47
80,*,OR T48 T49 T50 T51
81,*,OR T32 T46
82,T55,"Scope 777 844	reserpine, alpha-methyl-dopa, steroids, sympathomimetics withdrawal"
83,R20,Subsumes Arg1:T46 Arg2:T55
84,T56,Condition 860 873	brain disease
85,T57,Qualifier 847 859	Neurological
86,T58,Procedure 892 917	electroconvulsive therapy
87,R21,Has_qualifier Arg1:T56 Arg2:T57
88,*,OR T56 T58
89,T59,Drug 942 952	citalopram
90,T60,Drug 956 968	escitalopram
91,T61,Qualifier 980 987	current
92,T62,Condition 988 995	episode
93,*,OR T59 T60
94,R22,Has_qualifier Arg1:T62 Arg2:T61
95,T63,Scope 942 968	citalopram or escitalopram
96,R23,AND Arg1:T63 Arg2:T62
97,T64,Drug 1008 1013	drugs
98,T65,Drug 1043 1049	agents
99,R24,AND Arg1:T64 Arg2:T65
100,T66,"Non-query-able 999 1105	need for drugs that may interact with these agents, i.e. drug metabolized by the 2D6 P450 isoenzyme system"
101,T67,Procedure 1131 1144	psychotherapy
102,T68,Condition 1147 1164	Contraindications
103,T69,Procedure 1168 1171	MRI
104,R25,AND Arg1:T68 Arg2:T69
105,T70,Device 1191 1208	cardiac pacemaker
106,T71,Device 1210 1226	metallic objects
107,T72,Device 1231 1248	metallic implants
108,T73,Device 1271 1284	cardiac stent
109,T74,Condition 1286 1300	claustrophobia
110,*,OR T70 T71 T72 T73 T74
111,T75,"Scope 1191 1300	cardiac pacemaker, metallic objects and metallic implants contraindicating MRI, cardiac stent, claustrophobia"
112,R26,Subsumes Arg1:T68 Arg2:T75
113,T76,Post-eligibility 1303 1329	Inability to speak English
114,T77,Measurement 1342 1355	visual acuity
115,T78,Qualifier 1332 1341	Corrected
116,R27,Has_qualifier Arg1:T77 Arg2:T78
117,T79,Value 1356 1364	< 20/70;
118,R28,Has_value Arg1:T77 Arg2:T79
119,T80,Condition 1365 1380	Color blindness
120,*,OR T77 T80
0,T1,Post-eligibility 0 27	Inability to obtain consent
1,T2,Value 38 52	under 18 years
2,T3,Person 56 59	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Non-query-able 61 90	Non-English speaking subjects
5,T5,Condition 110 128	unable to lay flat
6,T6,Condition 136 159	pulmonary complications
7,T7,Qualifier 129 159	due to pulmonary complications
8,R2,AND Arg1:T7 Arg2:T6
9,T8,Condition 161 198	increased intracranial pressure (ICP)
10,T9,Condition 212 232	spinal cord injuries
11,T10,Qualifier 203 211	unstable
12,R3,Has_qualifier Arg1:T9 Arg2:T10
13,*,OR T9 T8 T5
14,R4,Has_qualifier Arg1:T5 Arg2:T7
15,T11,Condition 254 275	cardiac abnormalities
16,T12,Condition 277 298	atrial septal defects
17,T13,Condition 302 328	ventricular septal defects
18,T14,Condition 337 360	tricuspid valve disease
19,T15,Qualifier 330 336	severe
20,R5,Has_qualifier Arg1:T14 Arg2:T15
21,*,OR T12 T13 T14 T16 T18
22,T16,Condition 369 391	pulmonary hypertension
23,T17,Qualifier 362 368	severe
24,R6,Has_qualifier Arg1:T16 Arg2:T17
25,T18,Measurement 393 410	Ejection fraction
26,T19,Value 411 416	< 15%
27,R7,Has_value Arg1:T18 Arg2:T19
28,T20,"Scope 277 416	atrial septal defects or ventricular septal defects, severe tricuspid valve disease, severe pulmonary hypertension, Ejection fraction < 15%"
29,R8,Subsumes Arg1:T11 Arg2:T20
30,T21,Person 419 428	Prisoners
31,T22,Non-query-able 419 428	Prisoners
32,T23,Condition 450 486	upper extremity deep vein thromboses
33,T24,Qualifier 488 498	subclavian
34,T25,Qualifier 502 508	distal
35,*,OR T25 T24
36,T26,Scope 488 508	subclavian or distal
37,R9,Has_scope Arg1:T23 Arg2:T26
38,T27,Device 540 544;553 565	CICC distal ports
39,T28,Device 548 565	PICC distal ports
40,*,OR T28 T27
41,T29,Qualifier 525 539	non-functional
42,T30,Scope 540 565	CICC or PICC distal ports
43,R10,Has_qualifier Arg1:T30 Arg2:T29
44,T31,Device 581 594	femoral CICCs
45,T32,Person 605 610	women
46,T33,Condition 596 604	Pregnant
0,T1,Person 0 4	Male
1,T2,Value 18 41	between 18 and 40 years
2,T3,Person 42 45	old
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Informed_consent 47 97	Written informed consent signed by the participant
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 20 22	2.
2,T3,Parsing_Error 273 275	3.
3,T4,Person 3 6	Age
4,T5,Value 7 18	18-80 years
5,R1,Has_value Arg1:T4 Arg2:T5
6,T6,Multiplier 37 47	at least 1
7,T7,Value 48 52	≥50%
8,T8,Measurement 53 82	stenosis in a coronary vessel
9,R2,Has_value Arg1:T8 Arg2:T7
10,R3,Has_multiplier Arg1:T8 Arg2:T6
11,T9,Procedure 97 111	FFR assessment
12,T10,Measurement 138 151	Pd / Pa ratio
13,T11,Value 152 158	≥ 0.05
14,R4,Has_value Arg1:T10 Arg2:T11
15,T12,Measurement 179 188	max Pd/Pa
16,T13,Measurement 195 204	min Pd/Pa
17,T14,Condition 226 236	hyperaemia
18,T15,Qualifier 213 225	steady state
19,R5,Has_qualifier Arg1:T14 Arg2:T15
20,T16,Procedure 252 269	visual assessment
21,R6,AND Arg1:T14 Arg2:T16
22,T17,Scope 159 205	(e.g. difference of max Pd/Pa minus min Pd/Pa)
23,T18,Condition 125 151	variation in Pd / Pa ratio
24,R7,Has_scope Arg1:T18 Arg2:T17
0,T1,Observation 0 15	Parents refusal
1,T2,Condition 17 37	Cognitive impairment
2,T3,Condition 39 66	Difficulty in communication
3,T4,Condition 74 89	language issues
4,R1,AND Arg1:T3 Arg2:T4
5,T5,Condition 91 111	Psychiatric disorder
6,T6,Condition 113 139	Severe systematic disorder
7,T7,Condition 141 154	Known allergy
8,T8,Drug 158 171	any drug used
9,R2,AND Arg1:T7 Arg2:T8
0,T1,Condition 0 7	Healthy
1,T2,Person 8 12	male
2,T3,Person 16 22	female
3,T4,Person 23 34	adolescents
4,*,OR T2 T3
5,T5,Person 36 39	age
6,T6,Value 40 54	12 to 17 years
7,T7,Temporal 67 79	at Screening
8,R1,Has_value Arg1:T5 Arg2:T6
9,R2,Has_temporal Arg1:T5 Arg2:T7
10,T8,Measurement 88 109	body mass index (BMI)
11,T9,Value 118 197	greater than or equal to the United States-weighted mean of the 95th percentile
12,T10,Qualifier 198 210	based on age
13,T11,Qualifier 198 206;215 218	based on sex
14,T12,Measurement 226 237	body weight
15,T13,Value 238 268	greater than 60 kilograms (kg)
16,T14,Value 118 142;178 197	greater than or equal to the 95th percentile
17,R3,multi Arg1:T9 Arg2:T14
18,R4,Has_value Arg1:T8 Arg2:T9
19,T15,Scope 198 218	based on age and sex
20,R5,Has_scope Arg1:T8 Arg2:T15
21,R6,Has_value Arg1:T12 Arg2:T13
22,T16,Non-representable 270 369	Participants with Type 2 diabetes mellitus (T2DM) may have a pre-existing or new diagnosis of T2DM.
23,T17,Measurement 371 376	HbA1c
24,T18,Value 377 382	=6.5%
25,R7,Has_value Arg1:T17 Arg2:T18
26,T19,Measurement 384 412	fasting plasma glucose (FPG)
27,T20,Value 413 423	=126 mg/dL
28,T21,Value 425 435	7.0 mmol/L
29,R8,Subsumes Arg1:T20 Arg2:T21
30,R9,Has_value Arg1:T19 Arg2:T20
31,T22,Negation 470 473	not
32,T23,Observation 474 495	planning to move away
33,T24,Temporal 510 539	for the duration of the study
34,T25,Reference_point 530 539	the study
35,R10,Has_index Arg1:T24 Arg2:T25
36,R11,Has_negation Arg1:T23 Arg2:T22
37,R12,Has_temporal Arg1:T23 Arg2:T24
38,T26,Observation 563 580	willing to comply
39,T27,Observation 554 558;571 580	able to comply
40,T28,Observation 638 658	reduced calorie diet
41,T29,Qualifier 624 636	standardized
42,R13,Has_qualifier Arg1:T28 Arg2:T29
43,T30,Observation 683 718	increased physical activity program
44,T31,"Scope 624 718	standardized, reduced calorie diet and an age appropriate, increased physical activity program"
45,T32,Qualifier 666 681	age appropriate
46,R14,Has_qualifier Arg1:T30 Arg2:T32
47,T33,Scope 554 580	able and willing to comply
48,R15,Has_scope Arg1:T33 Arg2:T31
49,T34,Observation 747 760	stable health
50,T35,Non-query-able 761 795	in the opinion of the investigator
51,T36,"Non-representable 797 1016	Able and willing to support and supervise study participation in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol"
52,T37,Observation 1027 1055	willing to personally comply
53,T38,Observation 1018 1022;1035 1055	Able to personally comply
54,T39,Person 1119 1129	caregivers
55,T40,Person 1133 1142	guardians
56,*,OR T40 T39
57,T41,Scope 1119 1142	caregivers or guardians
58,T42,Scope 1018 1055	Able and willing to personally comply
59,R16,Has_scope Arg1:T42 Arg2:T41
0,T1,Condition 0 21	Immunosuppresant host
1,T2,Condition 46 63	pulmonary disease
2,T3,Condition 31 45;56 63	cardiovascular disease
3,*,OR T2 T3
4,T4,Temporal 23 30	Chronic
5,T5,Scope 31 63	cardiovascular/pulmonary disease
6,R1,Has_temporal Arg1:T5 Arg2:T4
7,T6,Condition 65 92	Hospital acquired infection
0,T1,Procedure 20 62	venous malformation embolization operation
1,T2,Procedure 71 89	general anesthesia
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Person 92 96	aged
4,T4,Value 97 112	18-65 years old
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 115 129	operating time
7,T6,Value 137 141	1-4h
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Procedure 146 156	extubation
10,T8,Temporal 157 176	after the operation
11,T9,Reference_point 163 176	the operation
12,T10,Procedure 167 176	operation
13,R4,multi Arg1:T9 Arg2:T10
14,R5,Has_index Arg1:T8 Arg2:T9
15,R6,AND Arg1:T5 Arg2:T7
16,R7,Has_temporal Arg1:T7 Arg2:T8
0,T1,Condition 12 43	Mycoplasma pneumoniae infection
1,T2,Condition 45 60	Lobar pneumonia
2,T3,Condition 64 74	pneumoniae
3,T4,Condition 80 96	pleural effusion
4,R1,AND Arg1:T3 Arg2:T4
5,*,OR T3 T2
0,T1,Multiplier 0 13	long-term use
1,T2,Drug 17 27	analgesics
2,T3,Drug 28 37	sedatives
3,T4,Drug 41 78	non steroidal anti-inflammatory drugs
4,T5,Observation 79 86	history
5,R1,Has_temporal Arg1:T4 Arg2:T5
6,*,OR T2 T3
7,T6,"Scope 17 37	analgesics,sedatives"
8,R2,Has_multiplier Arg1:T6 Arg2:T1
9,*,OR T6 T4
10,T7,Drug 99 114	dexmedetomidine
11,T8,Qualifier 118 123	other
12,T9,Drug 124 129	drugs
13,T10,Condition 130 137	allergy
14,R3,Has_qualifier Arg1:T9 Arg2:T8
15,*,OR T7 T9
16,T11,Scope 99 129	dexmedetomidine or other drugs
17,R4,Has_scope Arg1:T10 Arg2:T11
18,T12,Observation 154 172	cannot communicate
19,T13,Measurement 175 211	preoperative systolic blood pressure
20,T14,Value 212 220	<90 mmHg
21,T15,Measurement 229 239	heart rate
22,T16,Value 240 247	<50/min
23,R5,Has_value Arg1:T13 Arg2:T14
24,*,OR T13 T15
25,R6,Has_value Arg1:T15 Arg2:T16
0,T1,Condition 22 24	MS
1,T2,Qualifier 26 45	relapsing remitting
2,T3,Qualifier 47 66	primary progressive
3,T4,Qualifier 68 89	secondary progressive
4,T5,Qualifier 10 18	any form
5,R1,Has_qualifier Arg1:T1 Arg2:T5
6,*,OR T2 T3 T4
7,T6,"Scope 26 89	relapsing remitting, primary progressive, secondary progressive"
8,R2,Subsumes Arg1:T5 Arg2:T6
9,T7,Value 92 95	any
10,T8,Measurement 135 140;96 100	score EDSS
11,T9,Measurement 102 133	expanded stability status scale
12,R3,Subsumes Arg1:T8 Arg2:T9
13,R4,Has_value Arg1:T8 Arg2:T7
0,T1,Condition 20 37	vaginal infection
1,T2,Qualifier 12 19	another
2,T3,Condition 41 44	STD
3,*,OR T1 T3
4,T4,Scope 20 44	vaginal infection or STD
5,R1,Has_qualifier Arg1:T4 Arg2:T2
6,T5,Condition 46 53	Allergy
7,T6,Drug 57 70	metronidazole
8,R2,AND Arg1:T5 Arg2:T6
9,T7,Condition 72 80	Pregnant
10,T8,Condition 84 91	nursing
11,*,OR T7 T8
12,T9,Drug 108 132	intravaginal antibiotics
13,T10,Drug 100 104;121 132	oral antibiotics
14,*,OR T9 T10
15,T11,Temporal 133 156	within the past 2 weeks
16,T12,Scope 100 132	oral or intravaginal antibiotics
17,R3,Has_temporal Arg1:T12 Arg2:T11
18,T13,Condition 158 161	HIV
19,T14,Qualifier 165 170	other
20,T15,Condition 171 186	chronic disease
21,R4,Has_qualifier Arg1:T15 Arg2:T14
22,*,OR T15 T13
23,T16,Observation 188 225	Inability to keep return appointments
24,T17,Condition 227 244	Contraindications
25,T18,Drug 249 284	Lactobacillus Vaginal Suppositories
26,T19,Negation 291 298	without
27,T20,Observation 299 313	sexual history
28,R5,Has_negation Arg1:T20 Arg2:T19
29,T21,Scope 291 313	without sexual history
30,A1,Optional T21
31,R6,AND Arg1:T17 Arg2:T18
32,T22,Scope 227 284	Contraindications for Lactobacillus Vaginal Suppositories
33,R7,Subsumes Arg1:T22 Arg2:T21
0,T1,Condition 0 19	Singleton pregnancy
1,T2,Condition 33 42	gestation
2,T3,Multiplier 22 32	8-22 weeks
3,R1,Has_multiplier Arg1:T2 Arg2:T3
4,T4,Condition 78 98	gestational diabetes
5,T5,Condition 53 62	pregnancy
6,R2,AND Arg1:T5 Arg2:T4
0,T1,Temporal 0 5	prior
1,T2,Condition 6 23	allergic reaction
2,T3,Drug 27 46	interferon products
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 48 72	congestive heart failure
5,R2,Has_temporal Arg1:T2 Arg2:T1
6,T5,Condition 74 96	elevated liver enzymes
7,*,OR T4 T5 T2
0,T1,Person 0 5	Women
1,T2,Value 9 26	at least 18 years
2,T3,Person 30 33	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Mood 40 51	symptoms of
5,T5,Condition 52 64	vaginal odor
6,T6,Condition 52 59;72 81	vaginal discharge
7,*,OR T6 T5
8,T7,Scope 52 81	vaginal odor and or/discharge
9,R2,Has_mood Arg1:T7 Arg2:T4
10,T8,Condition 122 124	BV
11,T9,Qualifier 109 117;92 100	criteria clinical
12,T10,Qualifier 102 107;109 117	Amsel criteria
13,R3,Subsumes Arg1:T9 Arg2:T10
14,T11,Scope 92 117	clinical (Amsel) criteria
15,R4,Has_scope Arg1:T8 Arg2:T11
16,T12,Observation 137 160	participate in research
17,T13,Mood 126 136	Willing to
18,R5,Has_mood Arg1:T12 Arg2:T13
0,T1,Condition 25 33	diabetes
1,T2,Measurement 80 102	fasting plasma glucose
2,T3,Value 103 114	= 7.0mmol/L
3,T4,Measurement 123 128	HbA1c
4,T5,Value 129 142	= 48mmol/mol)
5,T6,Condition 144 161	Contraindications
6,T7,Drug 165 174	metformin
7,T8,Measurement 184 194	creatinine
8,T9,Value 195 207	= 130µmol/L/
9,T10,Measurement 208 228	alanine transaminase
10,T11,Value 229 255	= 2.0 x upper limit normal
11,T12,Condition 266 277	intolerance
12,T13,Drug 281 290	metformin
13,R1,Has_value Arg1:T2 Arg2:T3
14,R2,Has_value Arg1:T4 Arg2:T5
15,*,OR T2 T4
16,T14,Scope 80 141	fasting plasma glucose = 7.0mmol/L and/ or HbA1c = 48mmol/mol
17,R3,Has_scope Arg1:T1 Arg2:T14
18,R4,AND Arg1:T6 Arg2:T7
19,R5,Has_value Arg1:T8 Arg2:T9
20,R6,Has_value Arg1:T10 Arg2:T11
21,R7,AND Arg1:T12 Arg2:T13
22,*,OR T8 T10 T12
23,T15,Scope 184 290	creatinine = 130µmol/L/ alanine transaminase = 2.0 x upper limit normal/ previous intolerance to metformin
24,R8,Has_scope Arg1:T6 Arg2:T15
25,#1,AnnotatorNotes R8
26,T16,Competing_trial 293 367	Planned continued antenatal care/ delivery at centre not included in trial
27,T17,Non-query-able 369 426	Planned fast for cultural/ religious reasons e.g. Ramadan
0,T1,Person 0 4	male
1,T2,Person 9 15	female
2,T3,Value 25 29;41 49	over 18 years
3,T4,Person 34 37	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,*,OR T2 T1
6,T5,Non-query-able 52 76	written informed consent
7,T6,Condition 241 263	carotid artery disease
8,T7,Qualifier 234 240	severe
9,T8,Qualifier 226 230	mild
10,*,OR T7 T8
11,T9,Scope 226 240	mild to severe
12,R2,Has_scope Arg1:T6 Arg2:T9
0,T1,Condition 10 24;42 49	advanced heart failure
1,T2,Condition 26 32;42 49	kidney failure
2,T3,Condition 36 41;42 49	liver failure
3,*,OR T1 T2 T3
4,T4,Condition 51 79	benign prostatic hyperplasia
5,T5,Condition 81 100	prostatic carcinoma
6,T6,Multiplier 102 110	frequent
7,T7,Condition 111 135	urinary tract infections
8,R1,Has_multiplier Arg1:T7 Arg2:T6
9,T8,Condition 137 165	non-type 1 diabetes mellitus
0,T1,Person 21 25	ages
1,T2,Value 29 33	4-18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 0 8	Children
4,T4,Condition 62 82	spinal cord injuries
5,T5,Measurement 50 54	ASIA
6,T6,Value 55 61	C or D
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Qualifier 39 49	incomplete
9,R3,AND Arg1:T4 Arg2:T5
10,R4,Has_qualifier Arg1:T4 Arg2:T7
11,T8,Temporal 83 124	at least 12 months before study enrolment
12,T9,Reference_point 109 124	study enrolment
13,R5,multi Arg1:T8 Arg2:T9
14,R6,Has_temporal Arg1:T4 Arg2:T8
15,T10,Observation 126 140	Non-ambulatory
16,T11,Observation 144 170	'exercise only' ambulators
17,T12,Device 187 204	assistive devices
18,A1,Optional T12
19,*,OR T10 T11
20,T13,Measurement 223 244	cognitive development
21,T14,Value 206 212	Normal
22,T15,Measurement 213 218;233 244	motor development
23,T16,Temporal 245 265	up to time of injury
24,T17,Reference_point 251 265	time of injury
25,R7,multi Arg1:T16 Arg2:T17
26,T18,Scope 213 244	motor and cognitive development
27,R8,Has_value Arg1:T18 Arg2:T14
28,R9,Has_temporal Arg1:T18 Arg2:T16
29,T19,Condition 267 284	Medical Stability
0,T1,Value 0 9	≥18 years
1,T2,Person 13 16	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 28 46	open-heart surgery
4,T4,Temporal 17 27	undergoing
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Procedure 48 58	sternotomy
7,T6,Procedure 70 101	minimally-invasive sternotomies
8,R3,Subsumes Arg1:T5 Arg2:T6
9,T7,"Scope 48 101	sternotomy, including minimally-invasive sternotomies"
10,R4,Subsumes Arg1:T3 Arg2:T5
0,T1,Undefined_semantics 0 103	any condition that would contra-indicate Magnetic Resonance Imaging or administration of contrast agent
0,T1,Condition 0 24	diabetes mellitus type 1
0,T1,Condition 6 27	neuromuscular disease
1,T2,Observation 49 84	weight bearing on lower extremities
2,T3,Condition 29 45	Contraindication
3,R1,Has_context Arg1:T3 Arg2:T2
4,T4,Condition 86 100	Pressure sores
5,T5,Device 107 114	harness
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 148 159	hypotension
8,T7,Qualifier 133 147	Uncontrollable
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Qualifier 160 172	when upright
11,R4,Has_qualifier Arg1:T6 Arg2:T8
12,T9,Condition 174 197	Lower limb contractures
13,T10,Mood 198 206	impeding
14,T11,Observation 207 247	range of motion necessary for ambulation
15,R5,Has_mood Arg1:T11 Arg2:T10
16,R6,Has_context Arg1:T9 Arg2:T11
17,T12,Non-representable 249 283	Prior enrolment in a BWATT program
18,T13,Post-eligibility 285 342	Unable to commit to intervention for duration of protocol
0,T1,Drug 3 23	systemic antibiotics
1,T2,Condition 42 61	bacterial infection
2,T3,Qualifier 35 41	active
3,T4,Temporal 62 84	at the time of surgery
4,T5,Reference_point 65 84	the time of surgery
5,T6,Procedure 77 84	surgery
6,R1,multi Arg1:T5 Arg2:T6
7,R2,Has_index Arg1:T4 Arg2:T5
8,R3,Has_temporal Arg1:T2 Arg2:T4
9,R4,Has_qualifier Arg1:T2 Arg2:T3
10,*,OR T1 T2
11,T7,Observation 95 128	previously enrolled in this trial
12,T8,Qualifier 166 204	Methicillin-resistant S. aureus (MRSA)
13,T9,Condition 151 160	colonized
14,R5,Has_qualifier Arg1:T9 Arg2:T8
15,T10,Non-representable 204 247	(unethical not to administer glycopeptides)
16,T11,Drug 249 260	beta-lactam
17,T12,Drug 264 274	vancomycin
18,T13,Condition 275 282	allergy
19,T14,"Scope 249 274;305 356	beta-lactam or vancomycin cefazolin or vancomycin, respectively, or to silver"
20,T15,Drug 305 314	cefazolin
21,T16,Drug 318 328	vancomycin
22,*,OR T15 T16 T17 T12 T11
23,T17,Drug 350 356	silver
24,R6,Has_scope Arg1:T13 Arg2:T14
25,T18,Competing_trial 388 453	Participation in other studies that may interfere with this trial
0,T1,Condition 0 7	Allergy
1,T2,Condition 11 27	hypersensitivity
2,T3,Drug 31 42	bupivacaine
3,*,OR T1 T2
4,T4,Scope 0 27	Allergy or hypersensitivity
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 44 53	Pregnancy
7,T6,Person 55 68	Incarceration
8,T7,Person 70 73	Age
9,T8,Value 74 84	< 18 years
10,R2,Has_value Arg1:T7 Arg2:T8
11,T9,Procedure 108 135	thoracic epidural analgesia
12,T10,Qualifier 97 107	continuous
13,T11,Qualifier 86 96	Indwelling
14,R3,Has_qualifier Arg1:T9 Arg2:T10
15,R4,Has_qualifier Arg1:T9 Arg2:T11
0,T1,Drug 20 31	sitagliptin
1,T2,Drug 35 44	metformin
2,T3,Drug 48 65	thiazolidinedione
3,*,OR T2 T3 T1
4,T4,Condition 0 16	Contraindication
5,T5,Scope 20 65	sitagliptin or metformin or thiazolidinedione
6,R1,Has_scope Arg1:T4 Arg2:T5
7,T6,Condition 67 75	Pregnant
8,T7,Condition 79 85	breast
9,*,OR T7 T6
10,T8,Condition 101 116	Type 1 diabetes
11,T9,Condition 118 138	gestational diabetes
12,T10,Condition 143 170	secondary forms of diabetes
13,*,OR T9 T10 T8
14,T11,Negation 172 175	Not
15,T12,Observation 176 187	appropriate
16,T13,Drug 192 215	oral antidiabetic agent
17,R2,AND Arg1:T12 Arg2:T13
18,R3,Has_negation Arg1:T12 Arg2:T11
19,T14,Drug 217 227	Medication
20,T15,Observation 234 257	affect glycemic control
21,R4,AND Arg1:T15 Arg2:T14
22,T16,Drug 259 266	Disease
23,T17,Qualifier 273 288	affect efficacy
24,T18,Qualifier 293 308	safety of drugs
25,*,OR T17 T18
26,T19,Scope 273 308	affect efficacy and safety of drugs
27,R5,Has_scope Arg1:T16 Arg2:T19
28,T20,Condition 314 327	major illness
29,T21,Condition 329 342	Liver disease
30,T22,Condition 344 357	Renal failure
31,T23,Condition 359 372	Heart disease
32,T24,Condition 374 380	Cancer
33,*,OR T24 T23 T22 T21
34,T25,"Scope 329 380	Liver disease, Renal failure, Heart disease, Cancer"
35,R6,Subsumes Arg1:T20 Arg2:T25
0,T1,Condition 0 18	H pylori infection
1,T2,Procedure 45 66	eradication therapies
2,T3,Multiplier 32 44	at least two
3,R1,Has_multiplier Arg1:T2 Arg2:T3
4,T4,Qualifier 19 25	failed
5,R2,Has_qualifier Arg1:T2 Arg2:T4
6,R3,AND Arg1:T1 Arg2:T2
7,T5,Person 68 72	aged
8,T6,Value 73 92	20 years or greater
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Mood 94 105	willingness
11,T8,Procedure 117 131	rescue therapy
12,R5,Has_mood Arg1:T8 Arg2:T7
0,T1,Observation 10 15	smoke
1,T2,Multiplier 16 45	at least ten cigarettes a day
2,R1,Has_multiplier Arg1:T1 Arg2:T2
3,T3,Observation 57 64	smoking
4,T4,Temporal 69 86	at least one year
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Condition 106 119	schizophrenia
7,T6,Condition 121 145	schizoaffective disorder
8,T7,Condition 158 176	psychotic disorder
9,T8,Non-query-able 217 266	Can speak and write fluent conversational English
10,T9,Person 299 302	age
11,T10,Value 272 295	between 18 and 70 years
12,R3,Has_value Arg1:T9 Arg2:T10
13,T11,Post-eligibility 304 351	Are willing to make a smoking cessation attempt
14,T12,Measurement 379 408	Montreal Cognitive Assessment
15,T13,Value 359 371	26 or higher
16,R4,Has_value Arg1:T12 Arg2:T13
0,T1,Measurement 0 5	HbA1c
1,T2,Value 6 14	> 13.0 %
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Negation 16 18	No
4,T4,Procedure 19 28	treatment
5,T5,Drug 34 41	insulin
6,T6,Drug 45 56	oral agents
7,T7,Temporal 57 69	for 6 months
8,*,OR T5 T6
9,T8,Scope 34 56	insulin or oral agents
10,R2,Has_scope Arg1:T4 Arg2:T8
11,R3,Has_temporal Arg1:T8 Arg2:T7
12,R4,Has_negation Arg1:T4 Arg2:T3
13,T9,Value 71 75	20 =
14,T10,Person 76 79	Age
15,T11,Value 80 90	< 80 years
16,*,OR T9 T11
17,R5,Has_value Arg1:T10 Arg2:T9
0,T1,Procedure 20 24	SSRF
1,T2,Visit 28 56	Denver Health Medical Center
2,R1,AND Arg1:T1 Arg2:T2
0,T1,Person 0 4	aged
1,T2,Value 5 23	less than 20 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 36 61	gastric resection surgery
4,T4,Condition 74 81	allergy
5,T5,Drug 85 96	study drugs
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 98 107	pregnancy
8,T7,Condition 111 120	lactating
9,T8,Person 121 126	women
10,*,OR T7 T6
11,T9,Condition 128 153	severe underlying illness
12,T10,Condition 163 186	end stage renal disease
13,T11,Condition 202 217	liver cirrhosis
14,T12,Qualifier 188 201	decompensated
15,R3,Has_qualifier Arg1:T11 Arg2:T12
16,T13,Condition 235 245	malignancy
17,T14,Qualifier 222 234	non-curative
18,R4,Has_qualifier Arg1:T13 Arg2:T14
19,*,OR T10 T11 T13
20,T15,"Scope 163 245	end stage renal disease, decompensated liver cirrhosis, or non-curative malignancy"
21,R5,Subsumes Arg1:T9 Arg2:T15
0,T1,Condition 18 41	myocardial infarction i
1,T2,Temporal 47 60	past 6 months
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 69 85	contraindication
4,T4,Procedure 89 92	NRT
5,R2,AND Arg1:T3 Arg2:T4
6,T5,"Post-eligibility 170 272	Use and unwillingness to stop use of other forms of nicotine such as cigars, pipes, or chewing tobacco"
7,T6,Condition 278 286	pregnant
8,T7,Condition 316 329	manic episode
9,T8,Competing_trial 370 427	Are currently enrolled in another smoking cessation trial
10,T9,Person 443 453	imprisoned
11,T10,Observation 460 487	psychiatric hospitalization
0,T1,Non-query-able 0 2	NA
0,T1,Condition 0 37	Neurological Congenital malformations
1,T2,Condition 60 86	impair intestinal motility
2,*,OR T1 T2
3,T3,Condition 110 140	gastrointestinal abnormalities
4,T4,Qualifier 88 98	Additional
5,R1,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Procedure 151 172	surgical intervention
7,T6,Mood 141 150	requiring
8,R2,Has_mood Arg1:T5 Arg2:T6
9,R3,AND Arg1:T3 Arg2:T5
10,T7,Qualifier 174 184	Congenital
11,T8,Condition 185 207	Cyanotic heart disease
12,T9,Qualifier 99 109	congenital
13,R4,Has_qualifier Arg1:T3 Arg2:T9
14,R5,Has_qualifier Arg1:T8 Arg2:T7
15,T10,Procedure 209 225	Surgical Closure
16,T11,Condition 229 250	abdominal wall defect
17,R6,AND Arg1:T10 Arg2:T11
18,T12,Device 256 275	prosthetic material
19,T13,Device 282 292;311 315	prosthetic mesh
20,T14,Device 296 315	bio-prosthetic mesh
21,*,OR T14 T13
22,T15,Scope 282 315	prosthetic or bio-prosthetic mesh
23,R7,Subsumes Arg1:T12 Arg2:T15
24,R8,AND Arg1:T10 Arg2:T12
0,T1,Person 0 5	Adult
1,T2,Person 15 18	age
2,T3,Value 19 34	18-80 years old
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 41 58	ruptured aneurysm
5,T5,Condition 77 95	cerebral vasospasm
6,T6,Temporal 96 129	post operatively within 3-21 days
7,T7,Reference_point 96 112	post operatively
8,R2,Has_index Arg1:T6 Arg2:T7
9,R3,AND Arg1:T4 Arg2:T5
10,R4,Has_temporal Arg1:T5 Arg2:T6
0,T1,Qualifier 0 11	Symptomatic
1,T2,Condition 12 25	paroxysmal AF
2,T3,Multiplier 34 46	at least one
3,T4,Condition 47 57	AF episode
4,T5,Procedure 58 82	electrocardiographically
5,T6,Qualifier 58 93	electrocardiographically documented
6,T7,Temporal 94 133	within one (1) year prior to enrollment
7,T8,Reference_point 123 133	enrollment
8,R1,Has_index Arg1:T7 Arg2:T8
9,R2,Has_qualifier Arg1:T4 Arg2:T6
10,R3,Subsumes Arg1:T6 Arg2:T5
11,R4,Has_temporal Arg1:T4 Arg2:T7
12,R5,Has_multiplier Arg1:T4 Arg2:T3
13,R6,Has_qualifier Arg1:T2 Arg2:T1
14,T9,Procedure 161 184	electrocardiogram (ECG)
15,T10,Procedure 186 218	Transtelephonic monitoring (TTM)
16,T11,Procedure 220 234	Holter monitor
17,T12,Procedure 238 253	telemetry strip
18,*,OR T12 T11 T10 T9 T5
19,T13,Multiplier 262 274	at least one
20,T14,Drug 275 300	antiarrhythmic drug (AAD)
21,T15,Drug 313 337	III antiarrhythmic drugs
22,T16,Drug 302 309;317 337	Class I antiarrhythmic drugs
23,*,OR T15 T16
24,T17,Scope 302 337	Class I or III antiarrhythmic drugs
25,R7,Subsumes Arg1:T14 Arg2:T17
26,R8,Has_multiplier Arg1:T14 Arg2:T13
27,T18,Condition 355 379	recurrent symptomatic AF
28,T19,Condition 384 395	intolerable
29,T20,Condition 403 406	AAD
30,R9,AND Arg1:T19 Arg2:T20
31,*,OR T18 T19
32,T21,Person 408 411	Age
33,T22,Value 412 429	18 years or older
34,R10,Has_value Arg1:T21 Arg2:T22
35,T23,Informed_consent 431 473	Signed Patient Informed Consent Form (ICF)
36,T24,"Non-query-able 475 562	Able and willing to comply with all pre-, post-, and follow-up testing and requirements"
0,T1,Person 37 40	age
1,T2,Value 16 33	at least 30 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,"Post-eligibility 43 314	Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the Vitamin C+E or Statin or Dual, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure"
4,T4,Condition 335 343	symptoms
5,T5,Condition 369 387	vasospastic angina
6,T6,Mood 393 400	planned
7,T7,Procedure 401 421	Coronary angiography
8,T8,Procedure 426 442	Provocation test
9,T9,Scope 401 442	Coronary angiography and Provocation test
10,R2,Has_mood Arg1:T9 Arg2:T6
11,R3,Has_scope Arg1:T5 Arg2:T9
12,R4,AND Arg1:T5 Arg2:T4
0,T1,Qualifier 13 26	uncomplicated
1,T2,Condition 27 40	gastroschisis
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Measurement 42 57	Gestational age
4,T4,Value 58 67	>33 weeks
5,T5,Temporal 68 87	at time of delivery
6,R2,Has_value Arg1:T3 Arg2:T4
7,R3,Has_temporal Arg1:T3 Arg2:T5
8,T6,Measurement 89 95	Weight
9,T7,Value 96 102	>1900g
10,T8,Temporal 103 122	at time of delivery
11,R4,Has_value Arg1:T6 Arg2:T7
12,R5,Has_temporal Arg1:T6 Arg2:T8
13,T9,Visit 147 174	Riley Hospital for Children
14,T10,Temporal 175 205	prior to any abdominal surgery
15,T11,Procedure 188 205	abdominal surgery
16,T12,Reference_point 184 205	any abdominal surgery
17,R6,Has_index Arg1:T10 Arg2:T12
18,R7,multi Arg1:T12 Arg2:T11
19,T13,Procedure 124 132	Transfer
20,R8,AND Arg1:T13 Arg2:T9
21,R9,Has_temporal Arg1:T13 Arg2:T10
0,T1,Procedure 21 38	catheter ablation
1,T2,Procedure 30 38;9 17	ablation surgical
2,*,OR T1 T2
3,T3,Condition 43 62	atrial fibrillation
4,T4,Scope 9 38	surgical or catheter ablation
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Procedure 73 88	cardiac surgery
7,T6,Temporal 0 8	Previous
8,T7,Temporal 64 72	Previous
9,R2,Has_temporal Arg1:T4 Arg2:T6
10,R3,Has_temporal Arg1:T5 Arg2:T7
11,T8,Procedure 100 104	CABG
12,T9,Temporal 106 141	within the past 6 months (180 days)
13,R4,Subsumes Arg1:T5 Arg2:T8
14,R5,Has_temporal Arg1:T5 Arg2:T9
15,T10,Procedure 143 159;169 191	Valvular cardiac percutaneous procedure
16,T11,Procedure 143 168;182 191	Valvular cardiac surgical procedure
17,*,OR T10 T11
18,T12,Procedure 199 213	ventriculotomy
19,T13,Procedure 215 224	atriotomy
20,T14,Procedure 230 242	valve repair
21,T15,Procedure 230 235;246 257	valve replacement
22,T16,Device 276 292	prosthetic valve
23,*,OR T12 T13 T15 T14 T16
24,T17,"Scope 199 292	ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve"
25,T18,Scope 143 191	Valvular cardiac surgical/percutaneous procedure
26,R6,Subsumes Arg1:T18 Arg2:T17
27,T19,Device 299 315	carotid stenting
28,T20,Procedure 319 333	endarterectomy
29,*,OR T19 T20
30,T21,Condition 346 357	LA thrombus
31,T22,Procedure 361 368	imaging
32,R7,AND Arg1:T22 Arg2:T21
33,T23,Measurement 370 377	LA size
34,T24,Value 378 385	> 50 mm
35,T25,Qualifier 387 413	parasternal long axis view
36,R8,Has_qualifier Arg1:T23 Arg2:T25
37,R9,Has_value Arg1:T23 Arg2:T24
38,T26,Measurement 416 420	LVEF
39,T27,Value 421 426	< 40%
40,R10,Has_value Arg1:T26 Arg2:T27
41,T28,Condition 428 444	Contraindication
42,T29,Drug 448 463	anticoagulation
43,R11,AND Arg1:T28 Arg2:T29
44,T30,Drug 465 472	heparin
45,T31,Drug 476 484	warfarin
46,*,OR T30 T31
47,T32,Scope 465 484	heparin or warfarin
48,T33,Scope 428 463	Contraindication to anticoagulation
49,R12,Subsumes Arg1:T33 Arg2:T32
50,T34,Observation 487 494	History
51,T35,Condition 498 512	blood clotting
52,T36,Condition 516 538	bleeding abnormalities
53,*,OR T35 T36
54,T37,Scope 498 538	blood clotting or bleeding abnormalities
55,R13,Has_temporal Arg1:T37 Arg2:T34
56,T38,Condition 544 546	MI
57,T39,Procedure 540 543	PCI
58,T40,Temporal 547 571	within the past 2 months
59,T41,Temporal 547 562;573 580	within the past 60 days
60,*,OR T41 T40
61,T42,Scope 547 581	within the past 2 months (60 days)
62,T43,Scope 540 546	PCI/MI
63,R14,Subsumes Arg1:T43 Arg2:T42
64,T44,Condition 594 614	thromboembolic event
65,T45,Condition 626 629	TIA
66,R15,Subsumes Arg1:T44 Arg2:T45
67,T46,Temporal 631 656	within the past 12 months
68,T47,Temporal 631 646;658 666	within the past 365 days
69,*,OR T46 T47
70,T48,Scope 631 667	within the past 12 months (365 days)
71,T49,Scope 594 630	thromboembolic event (including TIA)
72,R16,Has_scope Arg1:T49 Arg2:T48
73,T50,Condition 669 692	Rheumatic Heart Disease
74,T51,Qualifier 694 706	Uncontrolled
75,T52,Condition 707 720	heart failure
76,T53,Measurement 724 743	NYHA function class
77,T54,Value 744 747	III
78,T55,Value 751 753	IV
79,*,OR T54 T55
80,T56,Scope 744 753	III or IV
81,R17,Has_scope Arg1:T53 Arg2:T56
82,R18,Has_qualifier Arg1:T52 Arg2:T51
83,T57,Scope 724 753	NYHA function class III or IV
84,R19,Has_scope Arg1:T52 Arg2:T57
85,T58,Condition 762 782	mitral regurgitation
86,T59,Qualifier 755 761	Severe
87,R20,Has_qualifier Arg1:T58 Arg2:T59
88,T62,Measurement 784 802	Regurgitant volume
89,T63,Value 803 815	= 60 mL/beat
90,R21,Has_value Arg1:T62 Arg2:T63
91,T60,Measurement 817 837	Regurgitant fraction
92,T61,Value 838 843	= 50%
93,R22,Has_value Arg1:T60 Arg2:T61
94,T64,Measurement 852 886	Effective regurgitant orifice area
95,T65,Value 887 896	= 0.40cm2
96,R23,Has_value Arg1:T64 Arg2:T65
97,*,OR T60 T64 T62
98,T66,"Scope 784 896	Regurgitant volume = 60 mL/beat, Regurgitant fraction = 50%, and/or Effective regurgitant orifice area = 0.40cm2"
99,T67,Scope 755 782	Severe mitral regurgitation
100,R24,Has_scope Arg1:T67 Arg2:T66
101,T68,Procedure 908 931	cardiac transplantation
102,T69,Procedure 941 956	cardiac surgery
103,T70,Temporal 957 982	within the next 12 months
104,T71,Temporal 957 972;984 992	within the next 365 days
105,R25,Subsumes Arg1:T70 Arg2:T71
106,*,OR T68 T69
107,T72,Scope 908 956	cardiac transplantation or other cardiac surgery
108,R26,Has_temporal Arg1:T72 Arg2:T70
109,T73,Condition 995 1010	Unstable angina
110,T74,Condition 1012 1025	Acute illness
111,T75,Condition 1036 1054	systemic infection
112,T76,Qualifier 1029 1035	active
113,T77,Condition 1058 1064	sepsis
114,T78,Condition 1066 1068	AF
115,T79,Condition 1082 1103	electrolyte imbalance
116,T80,Qualifier 1069 1078	secondary
117,R27,AND Arg1:T80 Arg2:T79
118,R28,Has_qualifier Arg1:T78 Arg2:T80
119,T81,Condition 1105 1120	thyroid disease
120,T82,Condition 1139 1156	non-cardiac cause
121,T83,Qualifier 1125 1135	reversible
122,R29,Has_qualifier Arg1:T82 Arg2:T83
123,*,OR T78 T81 T82
124,T84,Device 1171 1190	implanted ICD/CRT-D
125,T85,Condition 1205 1222	pulmonary disease
126,T86,Qualifier 1193 1204	Significant
127,R30,Has_qualifier Arg1:T85 Arg2:T86
128,T87,Condition 1231 1260	restrictive pulmonary disease
129,T88,Condition 1278 1315	chronic obstructive pulmonary disease
130,T89,Condition 1262 1274;1298 1315	constrictive pulmonary disease
131,*,OR T88 T89 T87
132,T90,"Scope 1231 1315	restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease"
133,T91,Scope 1193 1222	Significant pulmonary disease
134,R31,Subsumes Arg1:T91 Arg2:T90
135,T92,Qualifier 1320 1329	any other
136,T93,Condition 1330 1337;1353 1365	disease of the lungs
137,T94,Condition 1341 1365	malfunction of the lungs
138,*,OR T93 T94 T96
139,T95,Scope 1330 1387	disease or malfunction of the lungs or respiratory system
140,R32,Has_qualifier Arg1:T95 Arg2:T92
141,T96,Condition 1330 1337;1353 1359;1369 1387	disease of the respiratory system
142,T97,Condition 1402 1418	chronic symptoms
143,R33,AND Arg1:T95 Arg2:T97
144,*,OR T91 T95
145,T98,Condition 1421 1452	Gastroesophageal Reflux Disease
146,T99,Condition 1454 1458	GERD
147,T100,Procedure 1477 1501	significant intervention
148,T101,Drug 1516 1530	OTC medication
149,T102,Negation 1502 1505	not
150,R34,Has_negation Arg1:T101 Arg2:T102
151,R35,AND Arg1:T100 Arg2:T101
152,R36,Subsumes Arg1:T98 Arg2:T99
153,T103,Condition 1545 1563	congenital anomaly
154,T104,Qualifier 1533 1544	Significant
155,T105,Condition 1567 1582	medical problem
156,T106,Non-representable 1533 1662	Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study
157,T107,Person 1665 1670	Women
158,T108,Condition 1679 1687	pregnant
159,T109,Procedure 1705 1719	pregnancy test
160,T110,Condition 1723 1737	pre-menopausal
161,A1,Optional T110
162,R37,AND Arg1:T110 Arg2:T109
163,R38,AND Arg1:T108 Arg2:T110
164,T111,"Competing_trial 1740 1835	Concurrent enrollment in an investigational study evaluating another device, biologic, or drug."
165,T112,Condition 1849 1870	intracardiac thrombus
166,T113,Condition 1872 1878	myxoma
167,T114,Condition 1880 1885	tumor
168,T115,Condition 1887 1905	interatrial baffle
169,T116,Device 1909 1914	patch
170,T117,Qualifier 1918 1923	other
171,T118,Condition 1924 1935	abnormality
172,R39,Has_qualifier Arg1:T118 Arg2:T117
173,T119,Procedure 1951 1966	vascular access
174,T120,Procedure 1971 1999	manipulation of the catheter
175,T121,Condition 1941 1950	precludes
176,*,OR T119 T120
177,T122,"Scope 1951 1999	vascular access, or manipulation of the catheter"
178,R40,Has_scope Arg1:T121 Arg2:T122
179,R41,AND Arg1:T118 Arg2:T121
180,*,OR T112 T113 T114 T115 T116 T118
181,T123,Observation 2002 2017	Life expectancy
182,T124,Value 2018 2037	less than 12 months
183,R42,Has_value Arg1:T123 Arg2:T124
0,T1,Informed_consent 0 56	Inability to obtain consent from patient or patients kin
1,T2,Pregnancy_considerations 58 72	Pregnant women
2,T3,Person 96 99	age
3,T4,Value 74 92	less than 18 years
4,T5,Person 125 128	age
5,T6,Value 103 121	more than 80 years
6,R1,Has_value Arg1:T3 Arg2:T4
7,R2,Has_value Arg1:T5 Arg2:T6
8,*,OR T5 T3
9,T7,Measurement 130 145	Hunt Hess Grade
10,T8,Value 146 147	5
11,T9,Condition 148 151	SAH
12,R3,Has_value Arg1:T7 Arg2:T8
13,R4,AND Arg1:T9 Arg2:T7
0,T1,Qualifier 21 33	mono-lateral
1,T2,Qualifier 34 45	symptomatic
2,T3,Condition 46 83	knee articular degenerative pathology
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,R2,Has_qualifier Arg1:T3 Arg2:T1
5,T4,Condition 132 136	pain
6,T5,Condition 140 148	swelling
7,T6,Temporal 100 107	chronic
8,T7,Temporal 109 130	for at least 4 months
9,R3,Subsumes Arg1:T6 Arg2:T7
10,*,OR T4 T5
11,T8,Scope 132 148	pain or swelling
12,R4,Has_temporal Arg1:T8 Arg2:T6
13,T9,Procedure 151 158	imaging
14,T10,Condition 171 191	degenerative changes
15,T11,Condition 206 220	osteoarthritis
16,T12,Condition 224 236	chondropathy
17,T13,Measurement 242 265	Kellgren Lawrence Score
18,T14,Value 266 277	from 0 to 3
19,T15,Procedure 281 286	X-ray
20,R5,Has_value Arg1:T13 Arg2:T14
21,R6,AND Arg1:T15 Arg2:T13
22,*,OR T11 T12
23,T16,Scope 206 236	osteoarthritis or chondropathy
24,T17,Scope 206 286	osteoarthritis or chondropathy with Kellgren Lawrence Score from 0 to 3 at X-ray
25,R7,Subsumes Arg1:T10 Arg2:T17
26,R8,AND Arg1:T9 Arg2:T10
0,T1,Observation 21 77	have a valid Ontario Health Insurance Plan (OHIP) number
1,T2,Negation 17 20	not
2,R1,Has_negation Arg1:T1 Arg2:T2
3,T3,Temporal 78 106	at time of first transfusion
4,T4,Reference_point 89 106	first transfusion
5,R2,Has_index Arg1:T3 Arg2:T4
6,T5,Procedure 95 106	transfusion
7,T6,Multiplier 89 94	first
8,R3,Has_multiplier Arg1:T5 Arg2:T6
9,R4,multi Arg1:T4 Arg2:T5
10,R5,Has_temporal Arg1:T1 Arg2:T3
11,T7,Procedure 152 167	RBC transfusion
12,T8,Procedure 180 203	emergency randomization
13,T9,Qualifier 130 146	emergent release
14,T10,Mood 122 129	require
15,R6,Has_qualifier Arg1:T7 Arg2:T9
16,R7,Has_mood Arg1:T7 Arg2:T10
17,T11,Negation 204 226	could not be completed
18,R8,Has_negation Arg1:T8 Arg2:T11
19,T12,Condition 242 266	complex antibody profile
20,T13,Observation 282 311	impossible to match RBC units
0,T1,Parsing_Error 0 79	Eligible patients must meet the following criteria to be enrolled in the study:
1,T2,Mood 84 99	Newly diagnosed
2,T3,Temporal 84 89	Newly
3,R1,multi Arg1:T2 Arg2:T3
4,T4,Qualifier 101 109	stage IV
5,T5,Measurement 101 106	stage
6,T6,Value 107 109	IV
7,R2,Has_value Arg1:T5 Arg2:T6
8,R3,multi Arg1:T4 Arg2:T5
9,T7,Condition 110 135	squamous cell lung cancer
10,R4,Has_qualifier Arg1:T7 Arg2:T4
11,T8,Condition 190 200	metastases
12,T9,Qualifier 177 189	disseminated
13,R5,Has_qualifier Arg1:T8 Arg2:T9
14,T10,Condition 240 260	pericardial effusion
15,T11,Condition 229 236;252 260	pleural effusion
16,T12,Qualifier 219 228	malignant
17,*,OR T11 T10
18,T13,Scope 229 260	pleural or pericardial effusion
19,R6,Has_qualifier Arg1:T13 Arg2:T12
20,T15,Measurement 295 317	6th TNM staging system
21,T16,Value 277 287	stage IIIB
22,R7,Has_value Arg1:T15 Arg2:T16
23,T17,Scope 277 317	stage IIIB in the 6th TNM staging system
24,R8,Subsumes Arg1:T12 Arg2:T15
25,T14,Procedure 357 373	adjuvant therapy
26,T18,Condition 378 401	early-stage lung cancer
27,R9,causal Arg1:T18 Arg2:T14
28,T19,Temporal 418 469	at least 12 months have elapsed from that treatment
29,T20,Reference_point 455 469	that treatment
30,R10,multi Arg1:T19 Arg2:T20
31,T21,Procedure 460 469	treatment
32,R11,multi Arg1:T20 Arg2:T21
33,T22,Scope 357 401	adjuvant therapy for early-stage lung cancer
34,A1,Optional T22
35,R12,AND Arg1:T22 Arg2:T21
36,T23,Condition 500 536	squamous cell bronchogenic carcinoma
37,T25,Procedure 475 489	Histologically
38,T26,Value 490 499	confirmed
39,R13,Has_value Arg1:T25 Arg2:T26
40,R14,AND Arg1:T23 Arg2:T25
41,T24,Condition 568 600	mixed non-small cell histologies
42,T27,Condition 626 644	squamous carcinoma
43,T28,Qualifier 652 673	predominant histology
44,A2,Optional T24
45,R15,Has_qualifier Arg1:T27 Arg2:T28
46,R16,AND Arg1:T24 Arg2:T27
47,T29,Observation 693 723	small cell anaplastic elements
48,T30,Negation 728 731	not
49,T31,Condition 675 687	Mixed tumors
50,T32,Qualifier 693 723	small cell anaplastic elements
51,R17,Has_qualifier Arg1:T31 Arg2:T32
52,R18,multi Arg1:T32 Arg2:T29
53,R19,Has_negation Arg1:T32 Arg2:T30
54,T33,Procedure 881 893	radiotherapy
55,T34,Temporal 872 880	previous
56,R20,Has_temporal Arg1:T33 Arg2:T34
57,T35,Qualifier 920 936	locally advanced
58,T36,Condition 937 963	non-small cell lung cancer
59,R21,Has_qualifier Arg1:T36 Arg2:T35
60,R22,AND Arg1:T33 Arg2:T36
61,T37,Non-representable 989 1050	the recurrence is outside the original radiation therapy port
62,T38,Procedure 1052 1069	Radiation therapy
63,T39,Temporal 1095 1146	>4 weeks prior to the initiation of study treatment
64,T40,Reference_point 1113 1146	the initiation of study treatment
65,R23,multi Arg1:T39 Arg2:T40
66,R24,Has_temporal Arg1:T38 Arg2:T39
67,T41,Qualifier 1195 1211	locally advanced
68,T42,Condition 1212 1217	NSCLC
69,R25,Has_qualifier Arg1:T42 Arg2:T41
70,T43,Procedure 1175 1180	chemo
71,T44,Procedure 1181 1190	radiation
72,*,OR T44 T43
73,T45,Scope 1175 1190	chemo/radiation
74,R26,AND Arg1:T45 Arg2:T42
75,T46,Negation 1222 1225	not
76,R27,Has_negation Arg1:T45 Arg2:T46
77,T47,Procedure 1263 1291	palliative radiation therapy
78,T48,Condition 1296 1318	symptomatic metastases
79,T49,Qualifier 1296 1307	symptomatic
80,R28,multi Arg1:T48 Arg2:T49
81,R29,AND Arg1:T47 Arg2:T48
82,T50,Temporal 1349 1401	>14 days prior the initiation of the study treatment
83,T51,Reference_point 1364 1401	the initiation of the study treatment
84,R30,multi Arg1:T50 Arg2:T51
85,T52,Non-representable 1407 1469	Presence of evaluable (measureable or non-measurable) disease.
86,T53,Measurement 1474 1497	ECOG Performance Status
87,T54,Value 1501 1507	0 or 1
88,R31,Has_value Arg1:T53 Arg2:T54
89,T55,Measurement 1544 1575	Absolute neutrophil count (ANC)
90,T56,"Value 1576 1589	>1,500/microL"
91,T57,Measurement 1594 1603	platelets
92,T58,"Value 1604 1619	>100,000/microL"
93,T59,Temporal 1621 1657	≤72 hours prior to initial treatment
94,T60,Reference_point 1640 1657	initial treatment
95,R32,multi Arg1:T59 Arg2:T60
96,R33,Has_value Arg1:T57 Arg2:T58
97,R34,Has_value Arg1:T55 Arg2:T56
98,T61,"Scope 1544 1619	Absolute neutrophil count (ANC) >1,500/microL and platelets >100,000/microL"
99,R35,Has_temporal Arg1:T61 Arg2:T59
100,T62,Measurement 1661 1671	Hemoglobin
101,T63,Value 1672 1679	>9 g/dL
102,R36,Has_value Arg1:T62 Arg2:T63
103,T64,Non-representable 1680 1773	(Note: Patients may be transfused or receive erythropoietin to maintain or exceed this level)
104,T65,Measurement 1776 1785	Bilirubin
105,T66,Value 1786 1791	< ULN
106,R37,Has_value Arg1:T65 Arg2:T66
107,T67,Measurement 1794 1824	Alanine aminotransferase (ALT)
108,T68,Measurement 1829 1861	aspartate aminotransferase (AST)
109,T69,Value 1862 1898	≤2.5 times the upper limit of normal
110,T70,Condition 1905 1922	liver involvement
111,T71,Negation 1902 1904	no
112,T72,Context_Error 1905 1922	liver involvement
113,R40,Has_negation Arg1:T70 Arg2:T71
114,T73,Scope 1902 1922	no liver involvement
115,A3,Optional T73
116,T74,Value 1926 1960	≤5 times the upper limit of normal
117,T75,Condition 1966 1984	liver involvement.
118,A4,Optional T75
119,R41,Has_value Arg1:T75 Arg2:T74
120,R38,Has_value Arg1:T73 Arg2:T69
121,*,OR T75 T70
122,T76,Scope 1862 1983	≤2.5 times the upper limit of normal if no liver involvement or ≤5 times the upper limit of normal with liver involvement
123,R39,Has_scope Arg1:T68 Arg2:T76
124,R42,Has_scope Arg1:T67 Arg2:T76
125,T77,Measurement 1986 1996	Creatinine
126,T78,Value 1997 2007	<2.0 mg/dL
127,T79,Measurement 2012 2032	creatinine clearance
128,T80,Value 2033 2043	>40 mL/min
129,R43,Has_value Arg1:T79 Arg2:T80
130,R44,Has_value Arg1:T77 Arg2:T78
131,*,OR T77 T79
132,T81,Qualifier 2066 2088	Cockcroft-Gault method
133,R45,Has_qualifier Arg1:T79 Arg2:T81
134,R46,Has_qualifier Arg1:T77 Arg2:T81
135,T82,"Pregnancy_considerations 2091 2842	8. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and at least 6 months after the last dose of the study treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Sexually active men must agree to use a medically acceptable form of birth control during treatment and at least 6 months after the last dose. If a female partner becomes pregnant during the course of the study the treating physician should be informed immediately."
136,T83,Value 2847 2856	>18 years
137,T84,Person 2860 2863	age
138,R47,Has_value Arg1:T84 Arg2:T83
139,T85,"Post-eligibility 2870 2984	Ability to understand the nature of this study, give written informed consent, and comply with study requirements."
140,T86,"Post-eligibility 2990 3480	Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. An exception to this is when the national/local regulations prohibits some of the key activities of this research like the export of samples to third countries, storage of coded samples or global gene expression profiling without a pre-specified list of target genes. If tissue is not available, a patient will still be eligible for enrollment into the study"
0,T1,Procedure 19 23	ICSI
1,T2,Person 0 5	Women
2,T3,Procedure 32 73	controlled ovarian hyperstimulation (COH)
3,T4,Procedure 79 112	pituitary downregulation by GnRHa
4,T5,Scope 32 112	controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRHa
5,R1,Subsumes Arg1:T1 Arg2:T5
0,T1,Person 24 32	neonates
1,T2,Negation 14 23	excluding
2,R1,Has_negation Arg1:T1 Arg2:T2
3,T3,Multiplier 44 55	one or more
4,T4,Procedure 67 83	RBC transfusions
5,T5,Qualifier 56 66	allogeneic
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Condition 105 111	anemia
8,T7,Procedure 92 101	treatment
9,R3,AND Arg1:T7 Arg2:T6
10,R4,AND Arg1:T4 Arg2:T7
11,R5,Has_multiplier Arg1:T4 Arg2:T3
12,T8,Mood 34 43	requiring
13,R6,Has_mood Arg1:T4 Arg2:T8
0,T1,Person 0 3	age
1,T2,Value 4 14	> 80 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 17 40	Kellgren-Lawrence score
4,T4,Procedure 44 60	X-ray evaluation
5,T5,Value 61 64	> 3
6,R2,AND Arg1:T4 Arg2:T3
7,R3,Has_value Arg1:T3 Arg2:T5
8,T6,Condition 67 88	major axial deviation
9,T7,Measurement 90 95	varus
10,T8,Measurement 102 108	valgus
11,T9,Value 96 99	>5°
12,T10,Value 109 113	> 5°
13,R4,Has_value Arg1:T8 Arg2:T10
14,R5,Has_value Arg1:T7 Arg2:T9
15,T11,"Scope 90 113	varus >5° , valgus > 5°"
16,*,OR T8 T7
17,R6,Subsumes Arg1:T6 Arg2:T11
18,T12,Condition 117 135	systemic disorders
19,T13,Condition 144 152	diabetes
20,T14,Condition 154 174	rheumatoid arthritis
21,T15,Condition 176 199	haematological diseases
22,T16,Condition 201 213	coagulopathy
23,T17,Qualifier 216 222	severe
24,T18,Condition 223 246	cardiovascular diseases
25,T19,Condition 248 258	infections
26,T20,Condition 260 276	immunodepression
27,R7,Has_qualifier Arg1:T18 Arg2:T17
28,R8,Subsumes Arg1:T15 Arg2:T16
29,*,OR T15 T18 T20 T19 T14 T13
30,T21,"Scope 144 276	diabetes, rheumatoid arthritis, haematological diseases (coagulopathy), severe cardiovascular diseases, infections, immunodepression"
31,R9,Subsumes Arg1:T12 Arg2:T21
32,T22,Drug 304 318	anticoagulants
33,T23,Drug 322 336	antiaggregants
34,T24,Procedure 291 298	therapy
35,*,OR T22 T23
36,T25,Scope 304 336	anticoagulants or antiaggregants
37,R10,Has_scope Arg1:T24 Arg2:T25
38,T26,Drug 346 352	NSAIDs
39,T27,Temporal 353 388	in the 5 days before blood donation
40,R11,Has_temporal Arg1:T26 Arg2:T27
41,T28,Measurement 405 407	Hb
42,T29,Value 415 424	< 11 g/dl
43,R12,Has_value Arg1:T28 Arg2:T29
44,T30,Measurement 429 437	platelet
45,T31,"Value 445 458	< 150,000/mmc"
46,R13,Has_value Arg1:T30 Arg2:T31
47,*,OR T30 T28
0,T1,Drug 24 35	gemcitabine
1,T2,Drug 37 48	carboplatin
2,T3,Drug 86 94	Iniparib
3,T4,Temporal 3 8	Prior
4,*,OR T1 T2 T3
5,T5,"Scope 24 94	gemcitabine, carboplatin (except in the adjuvant setting), or Iniparib"
6,R1,Has_temporal Arg1:T5 Arg2:T4
7,T6,Condition 127 135	neoplasm
8,T7,Condition 198 222	non-melanoma skin cancer
9,T8,Procedure 190 197	treated
10,T9,Qualifier 190 197	treated
11,R2,multi Arg1:T9 Arg2:T8
12,R3,Has_qualifier Arg1:T7 Arg2:T9
13,T10,Condition 226 243	carcinoma in-situ
14,T11,Condition 277 284	cancers
15,T12,Qualifier 268 276	invasive
16,R4,Has_qualifier Arg1:T11 Arg2:T12
17,T13,Qualifier 285 305	treated definitively
18,T14,Procedure 285 292	treated
19,R5,multi Arg1:T13 Arg2:T14
20,R6,Has_qualifier Arg1:T11 Arg2:T13
21,*,OR T7 T10 T11
22,T15,Negation 168 189	with the exception of
23,T16,Temporal 329 348	>5 years previously
24,T17,Observation 356 379	evidence of recurrences
25,T18,Negation 353 355	no
26,R7,Has_negation Arg1:T17 Arg2:T18
27,T19,Observation 116 123	history
28,T20,Temporal 108 115	current
29,T21,Temporal 100 104	Past
30,*,OR T20 T21
31,T22,Scope 100 115	Past or current
32,R8,Has_temporal Arg1:T6 Arg2:T19
33,T23,Qualifier 136 166	other than the entry diagnosis
34,T24,Condition 151 166	entry diagnosis
35,R9,multi Arg1:T23 Arg2:T24
36,R10,Has_qualifier Arg1:T6 Arg2:T23
37,T25,"Scope 190 379	treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences"
38,R11,Has_temporal Arg1:T14 Arg2:T16
39,R12,Has_negation Arg1:T25 Arg2:T15
40,T26,Condition 398 413	cardiac disease
41,T27,Observation 387 394	history
42,R13,Has_temporal Arg1:T26 Arg2:T27
43,T28,Parsing_Error 415 428	as defined by
44,T29,Condition 431 453	Malignant hypertension
45,T30,Condition 455 470	Unstable angina
46,T31,Condition 472 496	Congestive heart failure
47,T32,Condition 498 519	Myocardial infarction
48,T33,Temporal 520 548	within the previous 6 months
49,R14,Has_temporal Arg1:T32 Arg2:T33
50,T34,Condition 589 608	cardiac arrhythmias
51,T35,Qualifier 575 587	uncontrolled
52,T36,Qualifier 563 571	unstable
53,T37,Qualifier 550 561	Symptomatic
54,*,OR T35 T36 T37
55,T38,"Scope 550 587	Symptomatic, unstable or uncontrolled"
56,R15,Has_scope Arg1:T34 Arg2:T38
57,T39,Condition 652 671	atrial fibrillation
58,T40,Grammar_Error 672 684	are eligible
59,T41,Negation 672 684	are eligible
60,R16,Has_negation Arg1:T39 Arg2:T41
61,T42,Qualifier 636 651	rate-controlled
62,T43,Qualifier 628 634	stable
63,R17,Has_qualifier Arg1:T39 Arg2:T42
64,R18,Has_qualifier Arg1:T39 Arg2:T43
65,T44,Condition 718 734	brain metastases
66,T45,Temporal 711 717	Active
67,R19,Has_temporal Arg1:T44 Arg2:T45
68,T46,Condition 758 774	brain metastases
69,T47,Procedure 750 757	treated
70,T48,Qualifier 750 757	treated
71,R20,multi Arg1:T48 Arg2:T47
72,R21,Has_qualifier Arg1:T46 Arg2:T48
73,T49,Negation 775 787	are eligible
74,T50,Grammar_Error 775 787	are eligible
75,T51,Procedure 796 813	radiation therapy
76,T52,Temporal 828 865	at least 2 weeks prior to study entry
77,T53,Reference_point 854 865	study entry
78,R23,Has_index Arg1:T52 Arg2:T53
79,T54,Condition 895 914	disease progression
80,T55,Procedure 871 885	follow-up scan
81,T56,Negation 892 894	no
82,R24,Has_negation Arg1:T54 Arg2:T56
83,R25,AND Arg1:T55 Arg2:T54
84,T57,Drug 949 957	steroids
85,T58,Negation 937 940	not
86,T59,Mood 941 948	require
87,R26,Has_mood Arg1:T57 Arg2:T59
88,R27,Has_negation Arg1:T57 Arg2:T58
89,R28,Has_temporal Arg1:T51 Arg2:T52
90,T60,Scope 796 957	radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids
91,T61,Scope 750 774	treated brain metastases
92,A1,Optional T61
93,R22,Has_scope Arg1:T61 Arg2:T60
94,T62,"Scope 750 957	treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids"
95,R29,Has_negation Arg1:T62 Arg2:T49
96,T63,Condition 977 985	pregnant
97,T64,Person 963 968	Women
98,T65,Condition 989 998	lactating
99,*,OR T65 T63
100,T66,Pregnancy_considerations 963 998	Women who are pregnant or lactating
101,T67,Condition 1024 1033	infection
102,T68,Value 1035 1044	> Grade 2
103,T69,Qualifier 1035 1044	> Grade 2
104,R30,multi Arg1:T69 Arg2:T68
105,R31,Has_qualifier Arg1:T67 Arg2:T69
106,T70,Qualifier 1008 1015	serious
107,T71,Temporal 1017 1023	active
108,R32,Has_temporal Arg1:T67 Arg2:T71
109,R33,Has_qualifier Arg1:T67 Arg2:T70
110,T72,Condition 1097 1114	medical condition
111,T73,Qualifier 1078 1085	serious
112,T74,Subjective_judgement 1008 1015	serious
113,T75,Subjective_judgement 1078 1085	serious
114,R34,Has_qualifier Arg1:T72 Arg2:T73
115,T76,Post-eligibility 1076 1190	A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
116,T77,Condition 1126 1189	impair the ability of the patient to receive protocol treatment
117,T78,Mood 1120 1125	would
118,R35,Has_mood Arg1:T77 Arg2:T78
119,R36,AND Arg1:T72 Arg2:T77
120,T79,Procedure 1203 1221	surgical procedure
121,T80,Qualifier 1197 1202	major
122,T81,Subjective_judgement 1197 1202	major
123,R37,Has_qualifier Arg1:T79 Arg2:T80
124,T82,Qualifier 1226 1237	significant
125,T83,Subjective_judgement 1226 1237	significant
126,T84,Condition 1238 1254	traumatic injury
127,T85,Temporal 1255 1286	≤28 days of beginning treatment
128,T86,Reference_point 1267 1286	beginning treatment
129,R38,multi Arg1:T85 Arg2:T86
130,R39,Has_qualifier Arg1:T84 Arg2:T82
131,R40,Has_temporal Arg1:T84 Arg2:T85
132,T87,Procedure 1320 1333	major surgery
133,T88,Mood 1311 1319	need for
134,R41,Has_mood Arg1:T87 Arg2:T88
135,T89,Temporal 1334 1364	during the course of the study
136,T90,Reference_point 1341 1364	the course of the study
137,R42,multi Arg1:T89 Arg2:T90
138,R43,Has_temporal Arg1:T87 Arg2:T89
139,*,OR T87 T84 T79
140,T91,Qualifier 1370 1382	Uncontrolled
141,T92,Temporal 1386 1398	intercurrent
142,T93,Condition 1399 1406	illness
143,T94,Qualifier 1423 1480	in the opinion of the investigator may increase the risks
144,T95,Subjective_judgement 1423 1480	in the opinion of the investigator may increase the risks
145,R44,Has_qualifier Arg1:T93 Arg2:T94
146,*,OR T92 T91
147,T96,Scope 1370 1398	Uncontrolled or intercurrent
148,R45,Has_scope Arg1:T93 Arg2:T96
149,T97,"Post-eligibility 1367 1629	9. Uncontrolled or intercurrent illness including, that in the opinion of the investigator may increase the risks associated with study participation or administration of the investigational products, or that may interfere with the interpretation of the results."
150,T98,Condition 1661 1682	psychiatric condition
151,T99,Condition 1686 1708	laboratory abnormality
152,T100,Procedure 1686 1696	laboratory
153,R46,multi Arg1:T99 Arg2:T100
154,*,OR T99 T98
155,T101,"Post-eligibility 1635 1926	History of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results."
156,T102,Condition 1959 1975	hypersensitivity
157,T103,Condition 1951 1958	allergy
158,*,OR T102 T103
159,T104,Mood 1932 1937	Known
160,T105,Mood 1941 1950	suspected
161,*,OR T105 T104
162,T106,Scope 1932 1950	Known or suspected
163,T107,Drug 1983 2022	agent given in the course of this trial
164,T108,Scope 1951 1975	allergy/hypersensitivity
165,R47,AND Arg1:T108 Arg2:T107
166,R48,Has_scope Arg1:T108 Arg2:T106
167,T109,Post-eligibility 1932 2022	Known or suspected allergy/hypersensitivity to any agent given in the course of this trial
168,T110,Not_a_criteria 2025 2161	The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
0,T1,Qualifier 0 8	Moderate
1,T2,Qualifier 12 18	severe
2,*,OR T1 T2
3,T3,Condition 19 32	endometriosis
4,T4,Scope 0 18	Moderate or severe
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Condition 35 47	Hydrosalpinx
7,T6,Condition 50 71	Uterine abnormalities
8,T7,Condition 74 79	Myoma
9,T8,Temporal 82 90	Previous
10,T9,Procedure 91 106	uterine surgery
0,T1,Non-query-able 0 87	Having significant medical illnesses that would interfere with the conduct of the study
1,T2,Non-query-able 89 139	Clinically significant abnormal laboratory finding
2,T3,Condition 157 179	psychiatric conditions
3,T4,Qualifier 148 156	comorbid
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Qualifier 223 229	DSM-IV
6,R2,Has_qualifier Arg1:T3 Arg2:T5
7,T6,Condition 317 329	OCD symptoms
8,T7,Qualifier 338 344	severe
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Observation 430 446	risk for suicide
11,T9,Pregnancy_considerations 448 529	Being pregnant or having the intention to be pregnant before the end of the study
12,T10,Drug 583 588	SSRIs
13,T11,Drug 592 595	CBT
14,*,OR T10 T11
15,T12,Condition 562 570	response
16,T13,Scope 583 595	SSRIs or CBT
17,R4,Has_scope Arg1:T12 Arg2:T13
18,T14,Qualifier 551 561	inadequate
19,R5,Has_qualifier Arg1:T12 Arg2:T14
20,T15,Mood 624 633	unable to
21,T16,Procedure 646 649	MRI
22,R6,Has_mood Arg1:T16 Arg2:T15
0,T1,Condition 66 75	pregnancy
1,T2,Condition 86 103	contraindications
2,T3,Procedure 108 126	Ventavis treatment
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Qualifier 153 223	Ventavis Summary of Product Characteristics and patient package insert
5,R2,Subsumes Arg1:T2 Arg2:T4
6,*,OR T1 T2
0,T1,Condition 27 38	primary OCD
1,T2,Measurement 112 118	DSM-IV
2,T3,Measurement 57 110	Diagnostic and Statistical Manual of Mental Disorders
3,R1,Subsumes Arg1:T3 Arg2:T2
4,R2,AND Arg1:T3 Arg2:T1
5,T4,Measurement 176 213	Yale-Brown Obsessive-Compulsive Scale
6,T5,Measurement 215 221	Y-BOCS
7,R3,Subsumes Arg1:T4 Arg2:T5
8,T6,Value 223 236	score of = 16
9,T7,Negation 238 243	Never
10,T8,Procedure 263 272	treatment
11,T9,Qualifier 254 262	adequate
12,T10,Negation 276 280	stop
13,T11,Procedure 291 300	treatment
14,T12,Temporal 301 321	for at least 8 weeks
15,R4,Has_negation Arg1:T8 Arg2:T7
16,R5,Has_qualifier Arg1:T8 Arg2:T9
17,R6,Has_negation Arg1:T11 Arg2:T10
18,R7,Has_temporal Arg1:T11 Arg2:T12
19,*,OR T8 T11
20,T13,Person 343 364	degree of high school
21,T14,Post-eligibility 376 412	ccepting to participate in the study
0,T1,Drug 34 42	Ventavis
1,T2,Condition 107 137	primary pulmonary hypertension
2,T3,Condition 144 186	Idiopathic Pulmonary Arterial Hypertension
3,T4,Condition 190 230	Familial Pulmonary Arterial Hypertension
4,*,OR T3 T4
5,T5,Scope 144 230	Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension
6,R1,Subsumes Arg1:T2 Arg2:T5
7,T6,Measurement 250 271	NYHA functional class
8,T7,Value 272 275	III
9,R2,Has_value Arg1:T6 Arg2:T7
10,R3,AND Arg1:T2 Arg2:T6
11,T8,Procedure 322 345	treatment with Ventavis
12,T9,Condition 377 407	primary pulmonary hypertension
13,T10,Procedure 362 372	treatments
14,T11,Qualifier 373 407	for primary pulmonary hypertension
15,R4,AND Arg1:T11 Arg2:T9
16,R5,Has_qualifier Arg1:T10 Arg2:T11
17,*,OR T8 T10
18,T12,Temporal 408 449	within 6 weeks of date of study inclusion
19,T13,Negation 313 315	No
20,T14,Scope 322 407	treatment with Ventavis or other active treatments for primary pulmonary hypertension
21,R6,Has_negation Arg1:T14 Arg2:T13
22,R7,Has_temporal Arg1:T14 Arg2:T12
23,T15,Multiplier 57 66	long-term
24,R8,Has_multiplier Arg1:T1 Arg2:T15
0,T1,Condition 0 14	Morbidly obese
1,T2,Measurement 25 28	BMI
2,T3,Value 29 38	>47 kg/m2
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 44 54	overweight
5,T5,Condition 55 59	lean
6,T6,Measurement 70 73	BMI
7,T7,Value 74 83	<27 kg/m2
8,R2,Has_value Arg1:T6 Arg2:T7
9,T8,Scope 25 38	BMI >47 kg/m2
10,R3,Subsumes Arg1:T1 Arg2:T8
11,T9,Scope 70 83	BMI <27 kg/m2
12,*,OR T4 T5
13,T10,Scope 44 59	overweight/lean
14,R4,Subsumes Arg1:T10 Arg2:T9
15,T11,Scope 44 84	overweight/lean patients (BMI <27 kg/m2)
16,*,OR T1 T10
17,T12,Condition 98 113	type 1 diabetes
18,T13,Condition 118 127	diabetics
19,T14,Qualifier 128 153	requiring insulin therapy
20,T15,Procedure 138 153	insulin therapy
21,T16,Drug 138 145	insulin
22,R5,multi Arg1:T15 Arg2:T16
23,R6,multi Arg1:T14 Arg2:T15
24,R7,Has_qualifier Arg1:T13 Arg2:T14
25,*,OR T12 T13
26,T17,Negation 174 177	not
27,T18,Observation 183 196	weight stable
28,T19,Value 198 203	>2 kg
29,T20,Measurement 204 217	weight change
30,R9,Has_value Arg1:T20 Arg2:T19
31,T21,Temporal 218 234	in past 3 months
32,R10,Has_temporal Arg1:T20 Arg2:T21
33,T22,Scope 198 234	>2 kg weight change in past 3 months
34,R8,Has_negation Arg1:T18 Arg2:T17
35,T23,Scope 174 196	not been weight stable
36,R11,Subsumes Arg1:T23 Arg2:T22
37,T24,Temporal 260 268	recently
38,T25,Condition 269 275	active
39,T26,Value 277 284	>30 min
40,T27,Measurement 288 320	moderate/high intensity exercise
41,R12,Has_value Arg1:T27 Arg2:T26
42,T28,Multiplier 322 334	2 times/week
43,R13,Has_multiplier Arg1:T27 Arg2:T28
44,T29,"Scope 277 334	>30 min of moderate/high intensity exercise, 2 times/week"
45,R14,Subsumes Arg1:T25 Arg2:T29
46,T30,"Scope 269 335	active (>30 min of moderate/high intensity exercise, 2 times/week)"
47,R15,Has_temporal Arg1:T30 Arg2:T24
48,T31,Observation 355 362	smokers
49,T32,Observation 375 387	quit smoking
50,T33,Temporal 388 400	<5 years ago
51,R16,Has_temporal Arg1:T32 Arg2:T33
52,*,OR T31 T32
53,T34,Drug 422 431	metformin
54,T35,Drug 446 455	metformin
55,T36,Temporal 456 469	within 1 year
56,R17,Has_temporal Arg1:T35 Arg2:T36
57,*,OR T34 T35
58,T37,Value 486 494	abnormal
59,T38,Measurement 495 538	estimated glomerular filtration rate (eGFR)
60,R18,Has_value Arg1:T38 Arg2:T37
61,T39,Condition 541 561	Hypertriglyceridemic
62,T40,Value 563 573	>400 mg/dl
63,T41,Measurement 541 561	Hypertriglyceridemic
64,R19,Has_value Arg1:T41 Arg2:T40
65,R20,multi Arg1:T39 Arg2:T41
66,T42,Condition 579 599	hypercholesterolemic
67,T43,Measurement 584 595	cholesterol
68,T44,Value 601 611	>260 mg/dl
69,R21,Has_value Arg1:T43 Arg2:T44
70,R22,multi Arg1:T42 Arg2:T43
71,*,OR T39 T42
72,T45,Condition 623 635	Hypertensive
73,T46,Value 637 650	>160/100 mmHg
74,T47,Measurement 623 635	Hypertensive
75,R23,Has_value Arg1:T47 Arg2:T46
76,R24,multi Arg1:T45 Arg2:T47
77,T48,Drug 679 690	medications
78,T49,Qualifier 691 713	that affect heart rate
79,T50,Qualifier 691 708;718 724	that affect heart rhythm
80,R25,Has_qualifier Arg1:T48 Arg2:T50
81,R26,Has_qualifier Arg1:T48 Arg2:T49
82,T51,Drug 731 752	Ca++ channel blockers
83,T52,Drug 754 762	nitrates
84,T53,Drug 764 770;779 787	alpha- blockers
85,T54,Drug 774 787	beta-blockers
86,*,OR T53 T54 T52 T51
87,T55,"Scope 731 787	Ca++ channel blockers, nitrates, alpha- or beta-blockers"
88,T56,Scope 679 724	medications that affect heart rate and rhythm
89,R27,Subsumes Arg1:T56 Arg2:T55
90,T57,Observation 807 814	history
91,T58,Qualifier 818 829	significant
92,T59,Qualifier 830 839	metabolic
93,T60,Qualifier 841 848	cardiac
94,T61,Condition 850 874	congestive heart failure
95,T62,Qualifier 876 891	cerebrovascular
96,T63,Qualifier 893 906	hematological
97,T64,Qualifier 908 917	pulmonary
98,T65,Qualifier 919 935	gastrointestinal
99,T66,Qualifier 937 942	liver
100,T67,Qualifier 944 949	renal
101,T68,Qualifier 954 963	endocrine
102,T69,Condition 964 971	disease
103,*,OR T59 T60 T62 T63 T64 T65 T66 T67 T68
104,T70,"Scope 830 963	metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine"
105,T71,Condition 975 981	cancer
106,*,OR T69 T71 T73
107,T72,"Non-query-able 982 1094	that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety."
108,T73,Scope 850 874;964 981	congestive heart failure disease or cancer
109,R28,Has_scope Arg1:T73 Arg2:T70
110,R29,Has_qualifier Arg1:T73 Arg2:T58
111,R30,Has_temporal Arg1:T73 Arg2:T57
112,T74,Condition 1096 1104	Pregnant
113,T75,Measurement 1131 1145	pregnancy test
114,T76,Value 1122 1130	positive
115,T77,Observation 1150 1157	nursing
116,R31,Has_value Arg1:T75 Arg2:T76
117,*,OR T74 T77
118,T78,Person 1158 1163	women
119,R32,Subsumes Arg1:T74 Arg2:T75
120,T79,Condition 1179 1196	contraindications
121,T80,Observation 1200 1245	participation in an exercise training program
122,R33,Has_context Arg1:T79 Arg2:T80
123,T81,Drug 1264 1300	active weight suppression medication
124,T82,Drug 1307 1318	phentermine
125,T83,Drug 1319 1327	orlistat
126,T84,Drug 1329 1339	lorcaserin
127,T85,Drug 1341 1376	naltrexone-bupropion in combination
128,T86,Drug 1378 1389	liraglutide
129,T87,Drug 1391 1405	benzephetamine
130,T88,Drug 1407 1421	diethylpropion
131,T89,Drug 1423 1438	phendimetrazine
132,*,OR T83 T82 T84 T85 T86 T87 T88 T89
133,T90,"Scope 1307 1438	phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine, diethylpropion, phendimetrazine"
134,R34,Subsumes Arg1:T81 Arg2:T90
135,T91,Condition 1447 1463	hypersensitivity
136,T92,Drug 1467 1477	perflutren
137,T93,Drug 1492 1500	Definity
138,R35,Subsumes Arg1:T92 Arg2:T93
139,R36,AND Arg1:T91 Arg2:T92
0,T1,Measurement 0 3	ASA
1,T2,Value 4 9	I-III
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 11 22	Colonoscopy
4,T4,Informed_consent 24 75	Written informed consent from participating subject
0,T1,Person 0 3	Age
1,T2,Value 4 30	between 18 and 78 year-old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 42 63	liver transplantation
4,T4,Temporal 33 41	Previous
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Temporal 64 81	more than 6 month
7,R3,Subsumes Arg1:T4 Arg2:T5
8,T6,Measurement 85 93	Genotype
9,T7,Value 94 101	1 and 4
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Condition 102 111	infection
12,R5,AND Arg1:T8 Arg2:T6
13,T9,Condition 114 125	Hepatitis C
14,T10,Multiplier 126 136	recurrence
15,R6,Has_multiplier Arg1:T9 Arg2:T10
16,T11,Measurement 173 192	liver function test
17,T12,Value 164 172	abnormal
18,T13,Measurement 203 210	HCV-RNA
19,T14,Value 194 202	positive
20,R7,Has_value Arg1:T13 Arg2:T14
21,R8,Has_value Arg1:T11 Arg2:T12
22,T15,Procedure 212 224	histological
23,T16,Condition 234 245	hepatitis C
24,T17,Multiplier 246 256	recurrence
25,R9,Has_multiplier Arg1:T16 Arg2:T17
26,T18,Condition 212 256	histological signs of hepatitis C recurrence
27,T19,"Scope 164 256	abnormal liver function test, positive HCV-RNA, histological signs of hepatitis C recurrence"
28,T20,Scope 114 136	Hepatitis C recurrence
29,R10,Subsumes Arg1:T20 Arg2:T19
30,T21,Measurement 259 269	Viral load
31,T22,Value 270 281	≥10000UI/mL
32,R11,Has_value Arg1:T21 Arg2:T22
33,T23,Procedure 284 301	Immunosuppression
34,T24,Drug 307 317	tacrolimus
35,T25,Drug 325 338	mycophenolate
36,T26,Drug 340 350	Prednisone
37,T27,Multiplier 369 377	low dose
38,T28,Value 379 387	≤10 mg/d
39,R14,Subsumes Arg1:T27 Arg2:T28
40,R15,Has_multiplier Arg1:T26 Arg2:T27
41,T29,"Scope 307 388	tacrolimus and/or mycophenolate (Prednisone use is allowed at low dose, ≤10 mg/d)"
42,R12,Has_scope Arg1:T23 Arg2:T29
43,*,OR T24 T25 T26
44,T30,Condition 391 406	Treatment naïve
45,T31,Condition 410 431	treatment experienced
46,*,OR T30 T31
47,T32,Procedure 433 440	Peg-RBV
48,T33,Procedure 444 458	triple therapy
49,*,OR T32 T33
50,T34,Scope 433 458	Peg-RBV or triple therapy
51,T35,Scope 391 431	Treatment naïve or treatment experienced
52,R13,Has_scope Arg1:T35 Arg2:T34
0,T1,Procedure 35 57	solid organ transplant
1,T2,Condition 0 10	Dual organ
2,T3,Condition 0 4;14 20	Dual kidney
3,*,OR T3 T2
4,T4,Scope 0 20	Dual organ or kidney
5,R1,AND Arg1:T4 Arg2:T1
6,T5,Condition 97 109	GI condition
7,T6,Temporal 73 84	preexisting
8,T7,Qualifier 85 96	significant
9,R2,Has_qualifier Arg1:T5 Arg2:T7
10,R3,Has_temporal Arg1:T5 Arg2:T6
11,T8,Condition 186 197	GI disorder
12,T9,Qualifier 198 221	induced by an infection
13,T10,Condition 212 221	infection
14,R4,multi Arg1:T9 Arg2:T10
15,R5,Has_qualifier Arg1:T8 Arg2:T9
16,T11,Condition 223 251	underlying medical condition
17,T12,Drug 268 278	medication
18,T13,Drug 290 293	MPA
19,T14,Negation 279 289	other than
20,R6,Has_negation Arg1:T13 Arg2:T14
21,R7,AND Arg1:T12 Arg2:T13
22,*,OR T8 T11 T12
23,T15,Measurement 295 299	eGFR
24,T16,Value 299 309	<40 ml/min
25,T17,Temporal 310 340	at time of possible conversion
26,R8,Has_value Arg1:T15 Arg2:T16
27,R9,Has_temporal Arg1:T15 Arg2:T17
28,T18,Measurement 342 353	Proteinuria
29,T19,Value 354 365	>1 gram/day
30,T20,Temporal 366 396	at time of possible conversion
31,R10,Has_value Arg1:T18 Arg2:T19
32,R11,Has_temporal Arg1:T18 Arg2:T20
33,T21,Measurement 398 408	Hemoglobin
34,T22,Value 409 417	<10 g/dL
35,R12,Has_value Arg1:T21 Arg2:T22
36,T23,Measurement 419 422	WBC
37,T24,Value 423 432	<3 K/cumm
38,R13,Has_value Arg1:T23 Arg2:T24
39,T25,Measurement 434 443	Platelets
40,T26,Value 444 455	<100 K/cumm
41,R14,Has_value Arg1:T25 Arg2:T26
42,T27,Condition 457 477	Wound healing issues
43,T28,Temporal 478 508	at time of possible conversion
44,R15,Has_temporal Arg1:T27 Arg2:T28
45,T29,Condition 514 530	wound dehiscence
46,T30,Condition 532 547	wound infection
47,T31,Condition 549 566	incisional hernia
48,T32,Condition 568 578	lymphocele
49,T33,Condition 580 586	seroma
50,*,OR T29 T30 T31 T32 T33
51,T34,"Scope 514 586	wound dehiscence, wound infection, incisional hernia, lymphocele, seroma"
52,R16,Has_scope Arg1:T27 Arg2:T34
53,T35,Measurement 598 615	total cholesterol
54,T36,Value 589 597	Elevated
55,T37,Value 617 627	>350 mg/dL
56,R17,Has_value Arg1:T35 Arg2:T36
57,R18,Subsumes Arg1:T36 Arg2:T37
58,T38,Measurement 636 649	triglycerides
59,T39,Value 651 661	>500 ng/dL
60,R19,Has_value Arg1:T38 Arg2:T39
61,T40,Temporal 663 693	at time of possible conversion
62,R20,Has_temporal Arg1:T38 Arg2:T40
63,T41,Condition 695 711	Hypersensitivity
64,T42,Drug 715 725	everolimus
65,T43,Drug 727 736	sirolimus
66,T44,Drug 747 756	rapamycin
67,*,OR T43 T44 T42
0,T1,Condition 11 22	intolerance
1,T2,Drug 26 31	LMWHs
2,T3,Procedure 39 41	HD
3,T4,Temporal 32 41	during HD
4,R1,multi Arg1:T4 Arg2:T3
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,R3,AND Arg1:T1 Arg2:T2
7,T5,Drug 53 61	warfarin
8,T6,Condition 71 89	oral anticoagulant
9,T7,Qualifier 65 70	other
10,R4,Has_qualifier Arg1:T6 Arg2:T7
11,*,OR T5 T6
12,T8,Condition 91 99	Pregnant
0,T1,Person 0 3	Age
1,T2,Value 5 20	> or = 16 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 22 28	Weight
4,T4,Value 30 45	more than 40 Kg
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 47 74	Autoimmune Hemolytic anemia
7,T6,Mood 93 113	biochemical evidence
8,T7,Mood 105 113;80 88	evidence clinical
9,T8,Condition 117 126	hemolysis
10,T9,Qualifier 127 150	refractory to treatment
11,T10,Procedure 141 150	treatment
12,R3,multi Arg1:T9 Arg2:T10
13,T11,Qualifier 166 184	steroids dependant
14,T12,Qualifier 152 162	in relapse
15,T13,Drug 166 174	steroids
16,R4,multi Arg1:T11 Arg2:T13
17,*,OR T12 T11
18,T14,Scope 152 184	in relapse or steroids dependant
19,R5,Has_qualifier Arg1:T8 Arg2:T9
20,R6,Has_scope Arg1:T8 Arg2:T14
21,R7,Has_mood Arg1:T8 Arg2:T7
22,R8,Has_mood Arg1:T8 Arg2:T6
23,T15,Condition 186 221	Idiopathic thrombocytopenic purpura
24,T16,Measurement 227 242	platelet counts
25,T17,"Value 243 251	< 50,000"
26,R9,Has_value Arg1:T16 Arg2:T17
27,T18,Qualifier 253 276	refractory to treatment
28,T19,Drug 267 276	treatment
29,T20,Qualifier 278 288	in relapse
30,T21,Qualifier 292 310	steroids dependant
31,T22,Drug 292 300	steroids
32,R10,multi Arg1:T21 Arg2:T22
33,*,OR T21 T20 T18
34,R11,multi Arg1:T18 Arg2:T19
35,T23,"Scope 253 310	refractory to treatment, in relapse or steroids dependant"
36,R12,Has_scope Arg1:T15 Arg2:T23
0,T1,Observation 2 18	previous history
1,T2,Condition 22 33	intolerance
2,T3,Drug 41 51	study drug
3,T4,Drug 55 72	related compounds
4,*,OR T3 T4
5,T5,Scope 41 72	study drug or related compounds
6,R1,Has_scope Arg1:T2 Arg2:T5
7,R2,Has_temporal Arg1:T2 Arg2:T1
8,T6,Condition 99 109	alcoholism
9,T7,Condition 111 121	drug abuse
10,T8,Condition 123 134;169 177	psychiatric problems
11,T9,Condition 136 149;169 177	psychological problems
12,T10,Condition 159 177	emotional problems
13,*,OR T8 T9 T10
14,T11,Condition 226 238	Sleep apnoea
15,T12,Condition 240 277	Chronic obstructive pulmonary disease
16,T13,Measurement 279 282	BMI
17,T14,Value 283 287	= 35
18,T15,Measurement 291 297	weight
19,T16,Value 298 305	< 50 kg
20,R3,Has_value Arg1:T13 Arg2:T14
21,R4,Has_value Arg1:T15 Arg2:T16
22,*,OR T13 T15
23,T17,Measurement 307 311	SpO2
24,T18,Value 312 318	< 90 %
25,R5,Has_value Arg1:T17 Arg2:T18
26,T19,Measurement 332 344	drug therapy
27,T20,Temporal 320 331	Concomitant
28,T21,Observation 372 388;403 413	enzyme induction of CYP 3A4
29,T22,Observation 372 378;392 413	enzyme inhibition of CYP 3A4
30,*,OR T21 T22
31,R6,Has_temporal Arg1:T19 Arg2:T20
32,T23,Scope 372 413	enzyme induction or inhibition of CYP 3A4
33,R7,Has_scope Arg1:T19 Arg2:T23
34,T24,Condition 416 425	Pregnancy
35,T25,Condition 429 436	nursing
36,*,OR T24 T25
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,T3,Value 15 32	>40 and <70 years
3,T4,Person 33 36	old
4,*,OR T2 T1
5,R1,Has_value Arg1:T4 Arg2:T3
6,T5,Measurement 45 60	body mass index
7,T6,Value 61 78	>27 and <47 kg/m2
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Negation 81 84	Not
10,T8,Condition 100 115	Type 2 diabetes
11,R3,Has_negation Arg1:T8 Arg2:T7
12,T9,Negation 118 121	Not
13,T10,Observation 132 142;158 166	engaged in exercise
14,T11,Temporal 122 131	currently
15,R4,Has_temporal Arg1:T10 Arg2:T11
16,T12,Value 143 154	> 60 min/wk
17,R5,Has_value Arg1:T10 Arg2:T12
18,R6,Has_negation Arg1:T10 Arg2:T9
19,T13,Value 173 188	at least 3 of 5
20,T14,Measurement 189 245	National Cholesterol Education Adult Treatment Panel III
21,R7,Has_value Arg1:T14 Arg2:T13
22,T15,Measurement 257 276	waist circumference
23,T16,Value 247 256	Increased
24,R8,Has_value Arg1:T15 Arg2:T16
25,T17,Value 278 285	=102 cm
26,T18,Value 294 300	=88 cm
27,T19,Person 304 309	women
28,T20,Person 289 292	men
29,A1,Optional T20
30,A2,Optional T19
31,R9,Has_value Arg1:T19 Arg2:T18
32,R10,Has_value Arg1:T20 Arg2:T17
33,*,OR T19 T20
34,T21,Scope 278 309	=102 cm in men; =88 cm in women
35,R11,Subsumes Arg1:T16 Arg2:T21
36,T22,Measurement 321 334	triglycerides
37,T23,Value 312 320	Elevated
38,R12,Has_value Arg1:T22 Arg2:T23
39,T24,Value 336 346	=150 mg/dl
40,R13,Subsumes Arg1:T23 Arg2:T24
41,T25,Drug 355 378	medication for treating
42,T26,Qualifier 321 334	triglycerides
43,R14,Has_qualifier Arg1:T25 Arg2:T26
44,T27,Value 394 401	Reduced
45,T28,Measurement 402 417	HDL-cholesterol
46,R15,Has_value Arg1:T28 Arg2:T27
47,T29,Value 419 427	<40mg/dl
48,T30,Value 436 445	<50 mg/dl
49,T31,Person 449 454	women
50,T32,Person 431 434	men
51,R16,Has_value Arg1:T31 Arg2:T30
52,R17,Has_value Arg1:T32 Arg2:T29
53,A3,Optional T32
54,A4,Optional T31
55,*,OR T32 T31
56,T33,"Scope 419 454	<40mg/dl in men, <50 mg/dl in women"
57,R18,Has_scope Arg1:T27 Arg2:T33
58,T34,Drug 463 486	medication for treating
59,T35,Qualifier 402 417	HDL-cholesterol
60,R19,Has_qualifier Arg1:T34 Arg2:T35
61,T36,Value 502 506	High
62,T37,Measurement 507 521	blood pressure
63,T38,Condition 502 521	High blood pressure
64,R20,Subsumes Arg1:T38 Arg2:T37
65,T39,Value 523 541	=130 mmHg systolic
66,T40,Value 545 562	=85mmHg diastolic
67,*,OR T39 T40
68,T41,Scope 523 562	=130 mmHg systolic or =85mmHg diastolic
69,R21,Subsumes Arg1:T36 Arg2:T41
70,T42,Drug 571 594	medication for treating
71,R22,AND Arg1:T42 Arg2:T38
72,T43,Value 610 618	Elevated
73,T44,Measurement 619 634	fasting glucose
74,T45,Value 636 646	=100 mg/dl
75,R23,Has_value Arg1:T44 Arg2:T43
76,R24,Subsumes Arg1:T43 Arg2:T45
77,T46,Condition 610 634	Elevated fasting glucose
78,R25,multi Arg1:T44 Arg2:T46
79,R26,multi Arg1:T37 Arg2:T38
80,T47,Drug 655 678	medication for treating
81,R27,AND Arg1:T47 Arg2:T46
0,T1,Measurement 0 8	Genotype
1,T2,"Value 9 21	2, 3, 5 or 6"
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 22 31	infection
4,R2,AND Arg1:T3 Arg2:T1
5,T4,Parsing_Error 964 966	1.
6,T5,Parsing_Error 1046 1048	2.
7,T6,Parsing_Error 1104 1106	3.
8,T7,Parsing_Error 1138 1140	4.
9,T8,Parsing_Error 1199 1201	5.
10,T9,Parsing_Error 1212 1214	6.
11,T10,Parsing_Error 1226 1228	7.
12,T11,Parsing_Error 1245 1247	8.
13,T12,Parsing_Error 1304 1306	9.
14,T13,Parsing_Error 1350 1353	10.
15,T14,Parsing_Error 1390 1393	11.
16,T15,Parsing_Error 1407 1410	12.
17,T16,Parsing_Error 1422 1425	13.
18,T17,Parsing_Error 1527 1530	14.
19,T18,Condition 48 57	cirrhosis
20,T19,Qualifier 34 47	Decompensated
21,R3,Has_qualifier Arg1:T18 Arg2:T19
22,T20,Condition 115 138	clinical decompensation
23,T21,Undefined_semantics 115 138	clinical decompensation
24,T22,Condition 149 156	ascites
25,T23,Condition 158 180	hepatic encephalopathy
26,T24,Condition 182 199	variceal bleeding
27,T25,Condition 203 236	spontaneous bacterial peritonitis
28,T26,Measurement 243 253	Child-Pugh
29,T27,Value 254 260	B or C
30,R4,Has_value Arg1:T26 Arg2:T27
31,*,OR T22 T23 T24 T25 T26
32,T28,"Scope 149 260	ascites, hepatic encephalopathy, variceal bleeding or spontaneous bacterial peritonitis, or a Child-Pugh B or C"
33,R5,Subsumes Arg1:T20 Arg2:T28
34,R6,AND Arg1:T19 Arg2:T20
35,T29,Temporal 85 91	actual
36,T30,Temporal 95 103	previous
37,*,OR T29 T30
38,T31,Scope 85 103	actual or previous
39,R7,Has_scope Arg1:T20 Arg2:T31
40,T32,Condition 263 287	Hepatocellular carcinoma
41,T33,Procedure 294 315	liver transplantation
42,T35,Reference_point 294 315	liver transplantation
43,T36,Temporal 288 315	after liver transplantation
44,R8,Has_index Arg1:T36 Arg2:T35
45,R9,Has_temporal Arg1:T32 Arg2:T36
46,T37,Measurement 318 333	Total bilirubin
47,T38,Value 334 343	> 3 mg/dL
48,R10,Has_value Arg1:T37 Arg2:T38
49,T39,Procedure 346 363	Immunosuppression
50,T40,Drug 369 381	cyclosporine
51,T41,Drug 388 402	mTOR inhibitor
52,T42,Drug 404 414	everolimus
53,T43,Drug 418 427	sirolimus
54,*,OR T43 T42
55,T44,Scope 404 427	everolimus or sirolimus
56,R11,Subsumes Arg1:T41 Arg2:T44
57,*,OR T40 T41
58,T45,Scope 369 428	cyclosporine or an mTOR inhibitor (everolimus or sirolimus)
59,R12,Has_scope Arg1:T39 Arg2:T45
60,T46,Condition 438 459	extrahepatic diseases
61,T47,Undefined_semantics 438 459	extrahepatic diseases
62,T48,Qualifier 431 437	Severe
63,T49,Undefined_semantics 431 437	Severe
64,T50,Subjective_judgement 431 437	Severe
65,R13,Has_qualifier Arg1:T46 Arg2:T48
66,T51,Condition 461 475	cardiovascular
67,T52,Condition 477 488	respiratory
68,T53,Condition 490 505	cerebrovascular
69,T54,Condition 528 536	diabetes
70,T55,Qualifier 510 527	poorly controlled
71,R14,Has_qualifier Arg1:T54 Arg2:T55
72,*,OR T51 T52 T53 T54
73,T56,Grammar_Error 506 509	and
74,T57,"Scope 461 536	cardiovascular, respiratory, cerebrovascular and poorly controlled diabetes"
75,R15,Subsumes Arg1:T46 Arg2:T57
76,T58,Measurement 539 548	Platelets
77,T59,Value 549 567	< 75 x 109 cells/L
78,R16,Has_value Arg1:T58 Arg2:T59
79,T60,Measurement 570 586	Neutrophil count
80,T61,Value 587 606	< 0.5 x 109 cells/L
81,R17,Has_value Arg1:T60 Arg2:T61
82,T62,Measurement 609 619	Hemoglobin
83,T63,Value 620 628	< 9 g/dL
84,R18,Has_value Arg1:T62 Arg2:T63
85,T64,Measurement 631 638	Albumin
86,T65,Value 639 646	< 3g/dL
87,R19,Has_value Arg1:T64 Arg2:T65
88,T66,Condition 649 662	HIV infection
89,T67,Condition 665 686	Hepatitis B infection
90,T68,Condition 723 730	alcohol
91,T69,Multiplier 706 719	toxic amounts
92,T70,Undefined_semantics 706 719	toxic amounts
93,T71,Condition 734 752	recreational drugs
94,R20,Has_multiplier Arg1:T68 Arg2:T69
95,*,OR T68 T71
96,T72,Temporal 689 702	Active intake
97,R21,Has_temporal Arg1:T68 Arg2:T72
98,R22,Has_temporal Arg1:T71 Arg2:T72
99,T73,Condition 771 779	pregnant
100,T74,Person 755 762	Females
101,T75,Observation 781 787	become
102,T76,Condition 794 802	pregnant
103,T77,Observation 806 819	breastfeeding
104,R23,Has_context Arg1:T76 Arg2:T75
105,T79,"Non-query-able 835 896	partners are pregnant, become to be pregnant or breastfeeding"
106,T80,Person 823 828	males
107,T81,"Scope 823 896	males whose partners are pregnant, become to be pregnant or breastfeeding"
108,T82,"Scope 755 819	Females who are pregnant, become to be pregnant or breastfeeding"
109,*,OR T82 T81
110,T83,Drug 909 931	disallowed medications
111,T85,Parsing_Error 899 962	Intake of disallowed medications including(but not limited to):
112,T86,Drug 980 994	clarithromycin
113,T87,Drug 996 1008	erythromycin
114,T88,Drug 1010 1023	telithromycin
115,T89,Drug 1025 1034	nafcillin
116,T90,Drug 1036 1044	rifampin
117,*,OR T86 T87 T88 T89 T90
118,T91,Drug 1062 1074	itraconazole
119,T92,Drug 1076 1088	ketoconazole
120,T93,Drug 1090 1102	voriconazole
121,T94,Drug 1126 1136	nifedipine
122,*,OR T91 T92 T93
123,T95,Drug 1158 1171	carbamazepine
124,T96,Drug 1173 1182	phenytoin
125,T97,Drug 1184 1197	phenobarbital
126,T98,Drug 1202 1210	Bosentan
127,T99,Drug 1215 1224	Modafinil
128,T100,Drug 1229 1243	St.Jonh's Wort
129,T101,Drug 1268 1279	cyclosporin
130,T102,Drug 1281 1291	everolimus
131,T103,Drug 1293 1302	sirolimus
132,*,OR T102 T103 T101
133,T104,Drug 1324 1337	glibenclamide
134,T105,Drug 1339 1348	glyburide
135,*,OR T104 T105
136,T106,Drug 1377 1388	gemfibrozil
137,T107,Drug 1394 1405	Eltrombopag
138,T108,Drug 1411 1420	Lapatinib
139,T109,Multiplier 1626 1652	doses greater than 10 mg/d
140,T110,Drug 1502 1525	HIV protease inhibitors
141,T111,Drug 1470 1479	ritonavir
142,A1,Optional T111
143,T112,Drug 1454 1464	etravirine
144,T113,Qualifier 1470 1479;1492 1501	ritonavir unboosted
145,T114,Qualifier 1470 1487	ritonavir boosted
146,*,OR T113 T114
147,T115,Grammar_Error 1488 1491	and
148,T116,Scope 1470 1501	ritonavir boosted and unboosted
149,R24,Has_scope Arg1:T110 Arg2:T116
150,T117,Drug 1443 1452	efavirenz
151,*,OR T117 T112 T110
152,T118,Drug 1540 1551	simvastatin
153,T119,Drug 1553 1564	fluvastatin
154,T120,Drug 1566 1578	rosuvastatin
155,T121,Drug 1610 1622	atorvastatin
156,R25,Has_multiplier Arg1:T121 Arg2:T109
157,T122,Multiplier 1582 1608	doses greater than 10 mg/d
158,R26,Has_multiplier Arg1:T120 Arg2:T122
159,*,OR T118 T119 T120 T121
0,T1,Procedure 0 17	Kidney transplant
1,T2,Visit 32 76	Washington University/Barnes-Jewish Hospital
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Procedure 91 102	GI toxicity
4,T4,Drug 108 111	MPA
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Procedure 195 221	standard immunosuppression
7,T6,Drug 227 237	tacrolimus
8,T7,Drug 242 251	prednison
9,*,OR T6 T7
10,T8,Scope 227 251	tacrolimus and prednison
11,R3,Has_scope Arg1:T5 Arg2:T8
0,T1,Condition 17 36	bacterial infection
1,T2,Condition 27 36;8 13	infection viral
2,*,OR T1 T2
3,T3,Temporal 0 7	Current
4,T4,Scope 8 36	viral or bacterial infection
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Measurement 48 64	serology for HIV
7,T6,Measurement 48 60;66 69	serology for HCV
8,T7,Measurement 48 60;71 74	serology for HBV
9,T8,Value 39 47	Positive
10,T9,"Scope 48 74	serology for HIV, HCV, HBV"
11,*,OR T6 T7 T5
12,R2,Has_value Arg1:T9 Arg2:T8
0,T1,Condition 10 14	NHHD
1,T2,Temporal 42 49	>1 year
2,T3,Procedure 50 58	dialysis
3,T4,Drug 64 86	unfractionated heparin
4,T5,Drug 90 103	anticoagulant
5,R1,Subsumes Arg1:T4 Arg2:T5
6,R2,AND Arg1:T3 Arg2:T4
7,R3,Has_temporal Arg1:T3 Arg2:T2
8,T6,Person 105 108	Age
9,T7,Value 109 114	>= 18
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Non-query-able 116 142	Informed consent available
0,T1,Condition 3 22	Atrial fibrillation
1,T2,Procedure 46 73	cardiac pacemaker treatment
2,T3,Device 46 63	cardiac pacemaker
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Procedure 97 118	metal graft treatment
5,T5,Device 97 108	metal graft
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 124 138	Claustrophobia
8,T7,Condition 144 171	Acute myocardial infarction
9,T8,Condition 173 189	cardiac ischemia
10,T9,Procedure 203 221	6-minute walk test
11,T10,Condition 223 250	hypertrophic cardiomyopathy
12,T11,Condition 252 277	constrictive pericarditis
13,T12,Condition 291 304	valve disease
14,T13,Qualifier 279 290	significant
15,R3,Has_qualifier Arg1:T12 Arg2:T13
16,T14,Condition 308 332	congenital heart disease
17,T15,Condition 334 363	severe pulmonary hypertension
18,T16,Qualifier 334 340	severe
19,R4,Has_qualifier Arg1:T15 Arg2:T16
20,T17,Qualifier 308 318	congenital
21,R5,Has_qualifier Arg1:T14 Arg2:T17
22,*,OR T9 T10 T11 T12 T14 T15
23,*,OR T8 T7
24,T18,"Scope 203 363	6-minute walk test, hypertrophic cardiomyopathy, constrictive pericarditis, significant valve disease or congenital heart disease, severe pulmonary hypertension"
25,T19,"Scope 144 189	Acute myocardial infarction, cardiac ischemia"
26,R6,Subsumes Arg1:T19 Arg2:T18
27,T20,Condition 369 391	Ischemic heart failure
28,T21,Procedure 404 421	revascularization
29,T22,Negation 392 399	without
30,R7,Has_negation Arg1:T21 Arg2:T22
31,T23,Procedure 439 456	revascularization
32,T24,Temporal 457 477	within last 6 months
33,R8,Has_temporal Arg1:T23 Arg2:T24
34,*,OR T21 T23
35,T25,Scope 392 477	without the revascularization or undergone the revascularization within last 6 months
36,R9,Subsumes Arg1:T20 Arg2:T25
37,T26,Procedure 501 516	cardiac surgery
38,T27,Condition 520 542	cerebrovascular events
39,T28,Temporal 543 573	within the previous six months
40,*,OR T27 T26
41,T29,Scope 501 542	cardiac surgery or cerebrovascular events
42,R10,Has_temporal Arg1:T29 Arg2:T28
43,T30,Procedure 605 628	cardiac transplantation
44,T31,Observation 592 596	plan
45,R11,Has_mood Arg1:T30 Arg2:T31
46,T32,Condition 653 672	renal insufficiency
47,T33,Condition 641 648;659 672	hepatic insufficiency
48,T34,Measurement 674 690	serum creatinine
49,T35,Value 690 701	>2.0 mg /dl
50,R12,Has_value Arg1:T34 Arg2:T35
51,T36,Measurement 703 706	AST
52,T37,Measurement 710 713	ALT
53,T38,Value 717 771	five times higher than the upper limit of normal range
54,*,OR T36 T37
55,T39,Scope 703 713	AST or ALT
56,R13,Has_value Arg1:T39 Arg2:T38
57,*,OR T34 T39
58,*,OR T33 T32
59,T40,Scope 641 672	hepatic and renal insufficiency
60,T41,Procedure 793 815	mechanical ventilation
61,T42,Measurement 831 845	blood pressure
62,T43,Value 846 854	< 90mmHg
63,T44,Value 859 868	> 160mmHg
64,*,OR T44 T43
65,T45,"Scope 846 868	< 90mmHg, or > 160mmHg"
66,T46,Condition 875 896	Chronic heart failure
67,T47,Condition 914 943	acute hemodynamic disturbance
68,T48,Condition 947 967	acute decompensation
69,T49,Temporal 968 987	within last 1 month
70,*,OR T48 T47
71,T50,Scope 914 967	acute hemodynamic disturbance or acute decompensation
72,R14,Has_scope Arg1:T46 Arg2:T50
73,R15,Has_temporal Arg1:T46 Arg2:T49
74,T51,Measurement 994 1000	Mobitz
75,T52,Value 1001 1015	Type II or III
76,T53,Condition 1017 1041	atrial ventricular block
77,R16,Has_value Arg1:T51 Arg2:T52
78,R17,AND Arg1:T53 Arg2:T51
79,T54,Qualifier 1042 1048	severe
80,T55,Condition 1049 1071	ventricular arrhythmia
81,R18,Has_qualifier Arg1:T55 Arg2:T54
82,T56,Observation 1098 1125	premature ventricular beats
83,T57,Condition 1150 1173	ventricular tachycardia
84,T58,Qualifier 1136 1149	non-sustained
85,T59,Multiplier 1127 1135	frequent
86,T60,Measurement 1181 1196	Serum potassium
87,T61,Value 1196 1206	<3.2mmol/L
88,T62,Value 1210 1220	>5.5mmol/L
89,*,OR T61 T62
90,T63,"Scope 1196 1220	<3.2mmol/L, or>5.5mmol/L"
91,R19,Has_scope Arg1:T60 Arg2:T63
92,R21,Has_qualifier Arg1:T57 Arg2:T58
93,R20,Has_multiplier Arg1:T57 Arg2:T59
94,T64,Multiplier 1089 1097	frequent
95,T65,Qualifier 1073 1084	polymorphic
96,R22,Has_multiplier Arg1:T56 Arg2:T64
97,R23,Has_qualifier Arg1:T56 Arg2:T65
98,T66,"Scope 1073 1173	polymorphic and frequent premature ventricular beats, frequent non-sustained ventricular tachycardia"
99,R24,Subsumes Arg1:T55 Arg2:T66
100,*,OR T55 T53
101,T67,Person 1227 1233	Female
102,T68,Condition 1245 1253	pregnant
103,T69,Observation 1257 1261	plan
104,T70,Condition 1272 1280	pregnant
105,R25,Has_mood Arg1:T70 Arg2:T69
106,*,OR T68 T70
107,T71,Person 1304 1310	female
108,T72,Observation 1326 1335	unmarried
109,T73,Observation 1348 1358	bear child
110,T74,Negation 1344 1347	not
111,R26,Has_negation Arg1:T73 Arg2:T74
112,T75,Value 1394 1412	less than 6 months
113,T76,Observation 1378 1393	life expectancy
114,R27,Has_value Arg1:T76 Arg2:T75
115,T77,Context_Error 1448 1530	Subject participated in any other clinical trial within the previous three months;
116,T78,Condition 1569 1574	tumor
117,T79,Observation 1549 1565	previous history
118,R28,Has_temporal Arg1:T78 Arg2:T79
119,T80,Condition 1587 1592	tumor
120,T81,Temporal 1579 1586	current
121,R29,Has_temporal Arg1:T80 Arg2:T81
122,T82,Condition 1618 1639	pre-cancerous disease
123,T83,Procedure 1654 1678	pathological examination
124,T84,Condition 1688 1712	ductal carcinoma in situ
125,T85,Condition 1716 1745	cervical epithelial dysplasia
126,*,OR T85 T84
127,R30,AND Arg1:T82 Arg2:T83
128,T86,Scope 1688 1745	ductal carcinoma in situ or cervical epithelial dysplasia
129,R31,Subsumes Arg1:T82 Arg2:T86
130,*,OR T80 T82 T78
131,T87,Procedure 1766 1786	physical examination
132,T88,Procedure 1788 1805	X-ray examination
133,T89,Procedure 1807 1834	type-B ultrasonic detection
134,T90,Procedure 1838 1851	other methods
135,*,OR T90 T89 T88 T87
136,T91,"Scope 1766 1851	physical examination, X-ray examination, type-B ultrasonic detection or other methods"
137,T92,Procedure 1752 1764	Examinations
138,T93,Undefined_semantics 1752 1764	Examinations
139,R32,Subsumes Arg1:T92 Arg2:T91
140,T94,Condition 1881 1895	malignant mass
141,T95,Condition 1897 1914	gland hyperplasia
142,T96,Condition 1918 1925	adenoma
143,T97,Condition 1931 1949	endocrine activity
144,T98,Qualifier 1926 1949	with endocrine activity
145,R33,AND Arg1:T98 Arg2:T97
146,R34,Has_qualifier Arg1:T96 Arg2:T98
147,*,OR T96 T95 T94 T97 T103
148,T99,Condition 2002 2018	pheochromocytoma
149,T100,Condition 2020 2039	thyroid enlargement
150,*,OR T99 T100
151,T101,Condition 1954 1963;1974 1992	impact on endocrine function
152,T102,Condition 1954 1969	impact on heart
153,*,OR T101 T102
154,T103,"Scope 1954 1992	impact on heart, or endocrine function"
155,T104,"Scope 2002 2039	pheochromocytoma, thyroid enlargement"
156,R35,Subsumes Arg1:T103 Arg2:T104
157,T105,"Scope 1881 2040	malignant mass, gland hyperplasia or adenoma with endocrine activity, or impact on heart, or endocrine function (such as pheochromocytoma, thyroid enlargement)"
158,R36,Has_scope Arg1:T92 Arg2:T105
159,T106,Post-eligibility 2047 2224	The Investigator deemed for whatever reason that the subject is not likely to complete the study or comply with the study procedures (due to administration or any other reason).
0,T1,Procedure 0 23	Anticoagulation therapy
1,T2,Temporal 25 30	Prior
2,T3,Procedure 31 35	CABG
3,R1,Has_temporal Arg1:T3 Arg2:T2
4,T4,Qualifier 38 44	Active
5,T5,Condition 45 53	bleeding
6,T6,Qualifier 57 69	at high risk
7,T7,Condition 73 81	bleeding
8,R2,Has_qualifier Arg1:T7 Arg2:T6
9,R3,Has_qualifier Arg1:T5 Arg2:T4
10,*,OR T5 T7
11,T8,Condition 99 112	renal disease
12,T9,Condition 105 112;90 95	disease liver
13,T10,Qualifier 83 89	Severe
14,*,OR T9 T8
15,T11,Scope 90 112	liver or renal disease
16,R4,Has_qualifier Arg1:T11 Arg2:T10
17,T12,Condition 115 131	Hypersensitivity
18,T13,Drug 135 145	ticagrelor
19,R5,AND Arg1:T12 Arg2:T13
20,T14,Observation 147 154	History
21,T15,Condition 158 181	intracranial hemorrhage
22,R6,Has_temporal Arg1:T15 Arg2:T14
0,T1,Measurement 21 41	SIGAM mobility grade
1,T2,Value 6 13	level D
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Multiplier 60 69	1 or more
4,T4,Observation 70 75	falls
5,R2,Has_multiplier Arg1:T4 Arg2:T3
6,T5,Temporal 76 110	in the last month before the study
7,T6,Reference_point 83 110	last month before the study
8,R3,Has_index Arg1:T5 Arg2:T6
9,R4,Has_temporal Arg1:T4 Arg2:T5
10,T7,Measurement 119 139	residual limb length
11,T8,Value 146 209	does not allow for seven inches clearance of bracket attachment
12,R5,Has_value Arg1:T7 Arg2:T8
13,T9,Negation 146 154	does not
14,T10,Non-query-able 229 366	the residual limb must be stable in volume (no change in socket or socket padding in last 6 months) and without pain that limits function
15,T11,Condition 431 459	impediments that affect gait
16,T12,Condition 431 454;461 476	impediments that affect range of motion
17,T13,Condition 431 454;481 501	impediments that affect limb muscle activity
18,*,OR T13 T12 T11
19,T14,Observation 399 414	lower extremity
20,T15,"Scope 431 501	impediments that affect gait, range of motion, or limb muscle activity"
21,T16,Negation 423 427	free
22,R6,Has_negation Arg1:T15 Arg2:T16
23,R7,Has_context Arg1:T15 Arg2:T14
24,T17,Condition 517 531;577 587	cardiovascular conditions
25,T18,Condition 533 542;577 587	pulmonary conditions
26,T19,Condition 544 556;577 587	neurological conditions
27,T20,Condition 566 587	orthopedic conditions
28,*,OR T17 T18 T19 T20
29,T21,"Scope 517 587	cardiovascular, pulmonary, neurological, and/ or orthopedic conditions"
30,T22,Qualifier 599 635	interfere with subject participation
31,R8,Has_qualifier Arg1:T21 Arg2:T22
32,T23,Undefined_semantics 599 635	interfere with subject participation
33,T24,Subjective_judgement 599 635	interfere with subject participation
0,T1,Procedure 0 14	Blood donation
1,T2,Qualifier 15 33	of more than 450ml
2,T3,Value 18 33	more than 450ml
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,Has_qualifier Arg1:T1 Arg2:T2
5,T4,Temporal 34 62	in the previous three months
6,R3,Has_temporal Arg1:T1 Arg2:T4
7,T5,Condition 81 99	abnormal karyotype
8,T6,Condition 112 127	Turner syndrome
9,R4,Subsumes Arg1:T5 Arg2:T6
10,T7,Condition 140 168	premutation of the FMR1 gene
11,T8,Condition 174 188	syndromic form
12,T9,Undefined_semantics 174 188	syndromic form
13,*,OR T7 T8 T5
14,T10,Post-eligibility 190 265	Subject exclusion period in another study without direct individual benefit
15,T11,Context_Error 190 265	Subject exclusion period in another study without direct individual benefit
16,T12,Post-eligibility 267 308	Subject refusing to sign the consent form
17,T13,Non-query-able 190 265	Subject exclusion period in another study without direct individual benefit
18,T14,Non-query-able 267 308	Subject refusing to sign the consent form
0,T1,Person 0 3	Age
1,T2,Value 3 26	=18 years and =80 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 43 77	non-cystic fibrosis bronchiectasis
4,T4,Procedure 91 109	high-resolution CT
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Condition 116 125	sensitive
7,T6,Drug 129 137	amikacin
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Condition 140 176	Acute exacerbation of bronchiectasis
10,T8,"Post-eligibility 179 269	Capable of the completion of bronchoscopy, alveolar lavage, pulmonary function testing etc"
11,T9,Informed_consent 272 325	Willing to join in and sign the informed consent form
0,T1,Value 8 19	18-75 years
1,T2,Person 3 6	Age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Measurement 54 95	Left ventricular ejection fraction (LVEF)
4,T4,Value 96 101	≤ 40%
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Procedure 103 107	ECHO
7,R3,AND Arg1:T3 Arg2:T5
8,T6,Condition 128 149	chronic heart failure
9,T7,Measurement 151 155	NYHA
10,T8,Value 156 171	class II or III
11,R4,Has_value Arg1:T7 Arg2:T8
12,R5,AND Arg1:T6 Arg2:T7
13,T9,Temporal 178 199	In the past one month
14,T10,Observation 235 242	history
15,T11,Condition 244 261	clinical symptoms
16,T12,Condition 244 252;266 271	clinical signs
17,T13,Qualifier 277 294	relatively stable
18,T14,"Scope 235 271	history, clinical symptoms and signs"
19,R6,Has_qualifier Arg1:T14 Arg2:T13
20,R7,Has_temporal Arg1:T14 Arg2:T9
21,T15,Condition 334 355	chronic heart failure
22,T16,Procedure 321 355	treatment of chronic heart failure
23,R8,AND Arg1:T16 Arg2:T15
24,T17,Observation 378 400	maximum tolerance dose
25,T18,Observation 363 374	target dose
26,T19,Temporal 401 417	for over 1 month
27,T20,Temporal 437 452	in last 1 month
28,T21,Observation 422 436	unchanged dose
29,*,OR T18 T17
30,T22,Scope 363 400	target dose or maximum tolerance dose
31,R9,Has_temporal Arg1:T22 Arg2:T19
32,*,OR T22 T21
33,T23,"Scope 363 452	target dose or maximum tolerance dose for over 1 month ,or unchanged dose in last 1 month"
34,R10,Has_scope Arg1:T16 Arg2:T23
35,T24,Post-eligibility 458 504	Understand and sign the informed consent form;
36,T25,Non-query-able 458 504	Understand and sign the informed consent form;
0,T1,Measurement 0 5	weigh
1,T2,Value 6 23	more than 200 lbs
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 29 50	high level ambulators
4,T4,Measurement 89 154	Special Interest Group of Amputee Medicine (SIGAM) mobility grade
5,T5,Value 68 81	levels E to F
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,AND Arg1:T3 Arg2:T4
8,T6,Condition 165 202	ability to follow multi-step commands
0,T1,Procedure 13 25	CABG surgery
1,T2,Mood 0 12	Accepted for
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Drug 42 52	Ticagrelor
4,T4,Temporal 53 68	within 48 hours
5,T5,Procedure 27 36	Treatment
6,R2,AND Arg1:T5 Arg2:T3
7,R3,Has_temporal Arg1:T5 Arg2:T4
0,T1,Parsing_Error 0 35	Patients of familial cases of POF :
1,T2,Person 37 43	Female
2,T3,Value 53 76	between 16 and 40 years
3,T4,Value 86 105	older than 40 years
4,T5,Person 71 76	years
5,R1,Has_value Arg1:T5 Arg2:T3
6,T6,Person 80 85	women
7,A1,Optional T6
8,T7,Reference_point 86 91	older
9,R2,Has_index Arg1:T4 Arg2:T7
10,A2,Optional T2
11,R3,AND Arg1:T2 Arg2:T5
12,R4,Has_value Arg1:T6 Arg2:T4
13,T8,Condition 113 142	cessation of ovarian function
14,T9,Value 143 169	before the age of 40 years
15,T10,Person 154 157	age
16,R5,Has_value Arg1:T10 Arg2:T9
17,T11,Value 175 184	increased
18,T12,Measurement 185 198	levels of FSH
19,R6,Has_value Arg1:T12 Arg2:T11
20,T13,Condition 221 231	amenorrhea
21,T14,Qualifier 211 220	secondary
22,T15,Qualifier 200 207	Primary
23,*,OR T14 T15
24,T16,Scope 200 220	Primary or secondary
25,R7,Has_scope Arg1:T13 Arg2:T16
26,T17,Temporal 232 258	for more than three months
27,T18,Measurement 264 266	LH
28,T19,Measurement 271 274	FSH
29,T20,Value 274 284	> 30mUI/ml
30,T21,Scope 264 274	LH and FSH
31,R8,Has_value Arg1:T21 Arg2:T20
32,R9,Has_temporal Arg1:T16 Arg2:T17
33,R10,AND Arg1:T8 Arg2:T10
34,*,OR T2 T6
35,R11,AND Arg1:T6 Arg2:T8
36,R12,AND Arg1:T8 Arg2:T12
37,T22,Condition 298 316	fragile X syndrome
38,T23,Observation 317 330	in the family
39,T24,Condition 334 359	blepharophimosis syndrome
40,T25,Negation 286 288	No
41,R13,Has_context Arg1:T22 Arg2:T23
42,*,OR T24 T22
43,T26,Scope 298 359	fragile X syndrome in the family or blepharophimosis syndrome
44,R14,Has_negation Arg1:T26 Arg2:T25
45,T27,Multiplier 361 373	At least two
46,T28,Undefined_semantics 374 393	cases in the family
47,T29,Parsing_Error 374 393	cases in the family
48,T30,Condition 402 411	Caucasian
49,T31,Post-eligibility 413 475	Patient signing the consent form for at least the blood sample
50,T32,Non-query-able 477 505	Patient with Social Security
51,T33,Parsing_Error 507 540	Population Index related topics :
52,T34,Condition 546 564	presence of cycles
53,T35,Value 565 590	until the age of 40 years
54,T36,Person 575 578	age
55,R15,Has_value Arg1:T36 Arg2:T35
56,R16,AND Arg1:T34 Arg2:T36
57,T37,"Pregnancy_considerations 542 632	The presence of cycles until the age of 40 years with proven fertility, at least one child"
58,T38,Condition 634 644	Amenorrhea
59,T39,Measurement 649 652	FSH
60,T40,Value 652 662	> 30mUI/ml
61,R17,Has_value Arg1:T39 Arg2:T40
62,T41,Not_a_criteria 711 742	Men of the family of index case
63,T42,Condition 775 791	Caucasian origin
64,T43,Person 766 771	Women
65,T44,Person 793 798	Women
66,T45,Condition 807 821	regular cycles
67,T46,Not_a_criteria 744 764	Population control :
68,T47,Parsing_Error 744 764	Population control :
69,T48,Value 822 843	until at least age 40
70,T49,Person 837 840	age
71,T50,Condition 799 843	who had regular cycles until at least age 40
72,R18,AND Arg1:T50 Arg2:T45
73,R19,AND Arg1:T45 Arg2:T49
74,R20,Has_value Arg1:T49 Arg2:T48
75,T51,Condition 881 891	autoimmune
76,T52,Condition 907 922	thyroid disease
77,T53,Condition 926 941	diabetes type 1
78,*,OR T52 T53
79,T54,Negation 893 895	no
80,T55,Observation 896 903	history
81,T56,Scope 907 941	thyroid disease or diabetes type 1
82,R21,Has_temporal Arg1:T56 Arg2:T55
83,R22,Has_negation Arg1:T56 Arg2:T54
84,T57,Grammar_Error 868 880	Lack of land
85,R23,Subsumes Arg1:T51 Arg2:T56
86,T58,Post-eligibility 944 1004	Woman signing the consent form for at least the blood sample
0,T1,Condition 7 15	bleeding
1,T2,Qualifier 0 6	Active
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Procedure 53 67	facial surgery
4,T4,Procedure 44 49;60 67	nasal surgery
5,*,OR T3 T4
6,T5,Condition 91 119	cardio-pulmonary dysfunction
7,T6,Qualifier 84 90	severe
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Condition 129 147	left heart failure
10,T8,Condition 158 168	arrhythmia
11,T9,Qualifier 149 157	unstable
12,R3,Has_qualifier Arg1:T8 Arg2:T9
13,T10,"Scope 129 168	left heart failure, unstable arrhythmia"
14,*,OR T7 T8
15,R4,Subsumes Arg1:T5 Arg2:T10
16,T11,Condition 187 207	respiratory diseases
17,T12,Condition 224 246	pulmonary tuberculosis
18,T13,Qualifier 217 223	active
19,T14,Condition 248 277;284 301	non-tuberculosis mycobacteria pulmonary disease
20,T15,Condition 279 282	NTM
21,R5,Subsumes Arg1:T14 Arg2:T15
22,T16,Condition 303 326	pulmonary aspergillosis
23,*,OR T12 T14 T16
24,R6,Has_qualifier Arg1:T12 Arg2:T13
25,T17,"Scope 217 326	active pulmonary tuberculosis, non-tuberculosis mycobacteria (NTM) pulmonary disease, pulmonary aspergillosis"
26,R7,Subsumes Arg1:T11 Arg2:T17
27,T18,Condition 337 345	allergic
28,T19,Drug 349 357	amikacin
29,R8,AND Arg1:T18 Arg2:T19
0,T1,Condition 11 16	falls
1,T2,Condition 20 29	dizziness
2,T3,Temporal 30 61	at exit from bed in the morning
3,T4,Multiplier 63 75	at least two
4,T5,Condition 76 85	incidents
5,T6,Temporal 86 102	in the past year
6,R1,Has_temporal Arg1:T5 Arg2:T6
7,R2,Has_multiplier Arg1:T5 Arg2:T4
8,*,OR T2 T1
9,T7,Scope 11 29	falls or dizziness
10,R3,Has_temporal Arg1:T7 Arg2:T3
11,T8,Value 105 120	At least 20/200
12,T9,Measurement 121 144	corrected visual acuity
13,R4,Has_value Arg1:T9 Arg2:T8
14,T10,Condition 146 159	Stable health
15,T11,Condition 161 175	Normal hearing
0,T1,Person 0 3	Age
1,T2,Value 4 8	< 20
2,T3,Value 12 22	> 35 years
3,*,OR T2 T3
4,T4,Scope 4 22	< 20 or > 35 years
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Measurement 25 40	Body mass index
7,T6,Measurement 42 45	BMI
8,R2,Subsumes Arg1:T5 Arg2:T6
9,T7,Value 47 59	< 18.5 kg/m2
10,T8,Value 63 73	> 25 kg/m2
11,*,OR T7 T8
12,T9,Scope 47 73	< 18.5 kg/m2 or > 25 kg/m2
13,R3,Has_scope Arg1:T5 Arg2:T9
14,T10,Condition 92 110	infertility factor
15,T11,Negation 111 121	other than
16,T12,Condition 122 133	anovulation
17,T13,Condition 134 148	oligoovulation
18,*,OR T12 T13
19,T14,Scope 122 148	anovulation/oligoovulation
20,R4,Has_negation Arg1:T14 Arg2:T11
21,T15,Procedure 171 186	ovarian surgery
22,T16,Procedure 190 206	surgical removal
23,T17,Qualifier 214 219	ovary
24,T18,Multiplier 210 213	one
25,R5,Has_multiplier Arg1:T17 Arg2:T18
26,R6,Has_qualifier Arg1:T16 Arg2:T17
27,*,OR T15 T16
28,T20,Drug 243 258	cytotoxic drugs
29,T21,Procedure 262 280	pelvic irradiation
30,T19,Condition 296 318	hormonal abnormalities
31,T22,Condition 283 292;305 318	Metabolic abnormalities
32,*,OR T19 T22
0,T1,Condition 0 47	Active proliferative diabetic retinopathy (PDR)
1,T2,Qualifier 48 64	in the study eye
2,T3,Condition 73 76	NVE
3,T4,Condition 78 81	NVD
4,T5,Condition 83 102	vitreous hemorrhage
5,T6,Condition 107 127	neovascular glaucoma
6,*,OR T3 T4 T5 T6
7,T7,"Scope 73 127	NVE, NVD, vitreous hemorrhage, or neovascular glaucoma"
8,R1,Has_qualifier Arg1:T1 Arg2:T2
9,R2,Subsumes Arg1:T1 Arg2:T7
10,T8,Condition 129 154	Uncontrolled hypertension
11,T9,Measurement 166 174	systolic
12,T10,Value 175 184	>180 mmHg
13,T11,Value 188 198	> 160 mmHg
14,T12,Multiplier 199 228	on 2 consecutive measurements
15,R3,Has_multiplier Arg1:T11 Arg2:T12
16,*,OR T10 T11
17,T13,Scope 175 228	>180 mmHg or > 160 mmHg on 2 consecutive measurements
18,R4,Has_scope Arg1:T9 Arg2:T13
19,T14,Measurement 232 241	diastolic
20,T15,Value 242 252	> 100 mmHg
21,T16,Procedure 256 279	optimal medical regimen
22,T17,Qualifier 253 279	on optimal medical regimen
23,R5,multi Arg1:T17 Arg2:T16
24,R6,Has_value Arg1:T14 Arg2:T15
25,R7,Has_qualifier Arg1:T14 Arg2:T17
26,*,OR T9 T14
27,T18,Scope 166 279	systolic >180 mmHg or > 160 mmHg on 2 consecutive measurements or diastolic > 100 mmHg on optimal medical regimen
28,R8,Has_scope Arg1:T8 Arg2:T18
29,T19,Temporal 280 289	Screening
30,T20,Measurement 290 306	HgA1c blood test
31,T21,Value 307 313	> 10.0
32,R9,Has_value Arg1:T20 Arg2:T21
33,R10,Has_temporal Arg1:T20 Arg2:T19
34,T22,Procedure 314 342	Focal laser photocoagulation
35,T23,Drug 346 378	intravitreal/periocular steroids
36,T24,Qualifier 391 407	in the study eye
37,T25,Temporal 408 457	within the last 90 days prior to study enrollment
38,T26,Reference_point 441 457	study enrollment
39,R11,Has_index Arg1:T25 Arg2:T26
40,*,OR T22 T23
41,T27,Scope 314 378	Focal laser photocoagulation or intravitreal/periocular steroids
42,R12,Has_qualifier Arg1:T27 Arg2:T24
43,R13,Has_temporal Arg1:T27 Arg2:T25
44,T28,Observation 461 471	history of
45,T29,Qualifier 472 484	intravitreal
46,T30,Procedure 485 504	anti-VEGF injection
47,T31,Qualifier 517 533	in the study eye
48,R14,Has_qualifier Arg1:T30 Arg2:T29
49,R15,Has_temporal Arg1:T30 Arg2:T28
50,R16,Has_qualifier Arg1:T30 Arg2:T31
51,T32,Temporal 534 583	within the last 45 days prior to study enrollment
52,T33,Reference_point 567 583	study enrollment
53,R17,Has_index Arg1:T32 Arg2:T33
54,R18,Has_temporal Arg1:T30 Arg2:T32
55,T34,Condition 596 629	rhegmatogenous retinal detachment
56,T35,Observation 585 595	History of
57,T36,Condition 631 646	retinal tear(s)
58,T37,Condition 651 679	traction retinal detachments
59,T38,Qualifier 680 696	in the study eye
60,*,OR T36 T37 T34
61,T39,"Scope 596 679	rhegmatogenous retinal detachment, retinal tear(s), or traction retinal detachments"
62,R19,Has_temporal Arg1:T39 Arg2:T35
63,R20,Has_qualifier Arg1:T39 Arg2:T38
64,T40,Condition 698 717;739 747	Epiretinal membrane traction
65,T41,Condition 725 747	vitreomacular traction
66,*,OR T41 T40
67,T42,Qualifier 748 764	in the study eye
68,T43,Non-representable 765 808	as determined by the central reading center
69,T44,Scope 698 747	Epiretinal membrane and/or vitreomacular traction
70,R21,Has_qualifier Arg1:T44 Arg2:T42
71,T45,Temporal 810 818	Previous
72,T46,Procedure 819 840	pars plana vitrectomy
73,T47,Qualifier 841 857	in the study eye
74,R22,Has_qualifier Arg1:T46 Arg2:T47
75,R23,Has_temporal Arg1:T46 Arg2:T45
76,T48,Procedure 862 881	intraocular surgery
77,T49,Qualifier 882 898	in the study eye
78,T50,Temporal 899 948	within the last 90 days prior to study enrollment
79,R24,Has_qualifier Arg1:T48 Arg2:T49
80,R25,Has_temporal Arg1:T48 Arg2:T50
81,T51,Reference_point 932 948	study enrollment
82,R26,Has_index Arg1:T50 Arg2:T51
83,T52,Procedure 950 969	YAG laser treatment
84,T53,Qualifier 970 986	in the study eye
85,R27,Has_qualifier Arg1:T52 Arg2:T53
86,T54,Temporal 987 1028	in last 30 days prior to study enrollment
87,T55,Reference_point 1012 1028	study enrollment
88,R28,Has_index Arg1:T54 Arg2:T55
89,R29,Has_temporal Arg1:T52 Arg2:T54
90,T56,Condition 1030 1041	High myopia
91,T57,Qualifier 1042 1058	in the study eye
92,R30,Has_qualifier Arg1:T56 Arg2:T57
93,T58,Measurement 1067 1087	spherical equivalent
94,T59,Value 1091 1097	>8.00D
95,R31,Has_value Arg1:T58 Arg2:T59
96,T60,Temporal 1098 1110	at screening
97,R32,AND Arg1:T56 Arg2:T58
98,R33,Has_temporal Arg1:T56 Arg2:T60
99,T61,Qualifier 1111 1116	Other
100,T62,Condition 1117 1135	ocular pathologies
101,T63,Observation 1171 1229	would interfere with the subject's vision in the study eye
102,R34,Has_context Arg1:T62 Arg2:T63
103,R35,Has_qualifier Arg1:T62 Arg2:T61
104,T64,Non-query-able 1141 1170	in the investigator's opinion
105,T65,Multiplier 1231 1238	Chronic
106,T66,Multiplier 1242 1251	recurrent
107,T67,Condition 1252 1259	uveitis
108,*,OR T65 T66
109,T68,Scope 1231 1251	Chronic or recurrent
110,R36,Has_scope Arg1:T67 Arg2:T68
111,T69,Temporal 1261 1268	Ongoing
112,T70,Condition 1269 1285	ocular infection
113,T71,Condition 1269 1275;1289 1301	ocular inflammation
114,T72,Qualifier 1302 1315	in either eye
115,*,OR T71 T70
116,T73,Scope 1269 1301	ocular infection or inflammation
117,T74,Observation 1319 1329	history of
118,T75,Procedure 1330 1346	cataract surgery
119,T76,Condition 1330 1360	cataract surgery complications
120,R37,multi Arg1:T76 Arg2:T75
121,T77,Condition 1361 1374	vitreous loss
122,T78,Qualifier 1375 1391	in the study eye
123,*,OR T76 T77
124,T79,Scope 1330 1374	cataract surgery complications/vitreous loss
125,R38,Has_temporal Arg1:T79 Arg2:T74
126,R39,Has_qualifier Arg1:T79 Arg2:T78
127,T80,Condition 1393 1421	Congenital eye malformations
128,T81,Qualifier 1422 1438	in the study eye
129,R40,Has_qualifier Arg1:T80 Arg2:T81
130,T82,Observation 1442 1452	history of
131,T83,Condition 1453 1478	penetrating ocular trauma
132,T84,Qualifier 1479 1495	in the study eye
133,R41,Has_qualifier Arg1:T83 Arg2:T84
134,R42,Has_temporal Arg1:T83 Arg2:T82
135,T85,Condition 1497 1517	Mentally handicapped
136,T86,Condition 1519 1527	Pregnant
137,T87,Person 1528 1534	female
138,T88,Person 1554 1559	women
139,T89,Value 1560 1578	less than 60 years
140,T90,Person 1579 1582	old
141,R43,Has_value Arg1:T90 Arg2:T89
142,T91,Value 1588 1596	positive
143,T92,Measurement 1597 1617	urine pregnancy test
144,T93,Temporal 1618 1645	during the screening window
145,R44,Has_temporal Arg1:T92 Arg2:T93
146,R45,Has_value Arg1:T92 Arg2:T91
147,T94,Observation 1647 1654	Nursing
148,T95,Person 1655 1661	female
149,T96,Competing_trial 1663 1724	Currently participating in any other clinical research study.
150,T97,Condition 1725 1741	Contraindication
151,T98,Drug 1749 1765	study medication
152,R46,AND Arg1:T97 Arg2:T98
0,T1,Person 0 8	children
1,T2,Person 13 22	teenagers
2,*,OR T2 T1
3,T3,Person 23 27	aged
4,T4,Value 28 46	less than 20 years
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Observation 49 56	history
7,T6,Procedure 60 71	gastrectomy
8,R2,Has_temporal Arg1:T6 Arg2:T5
9,T7,Condition 74 92	gastric malignancy
10,T8,Condition 104 118	adenocarcinoma
11,T9,Condition 123 131	lymphoma
12,*,OR T8 T9
13,T10,Scope 104 131	adenocarcinoma and lymphoma
14,R3,Subsumes Arg1:T7 Arg2:T10
15,T11,Drug 177 184	bismuth
16,T12,Drug 186 197	amoxicillin
17,T13,Drug 199 212	metronidazole
18,T14,Drug 214 228	clarithromycin
19,T15,Drug 230 242	tetracycline
20,T16,Drug 248 251	PPI
21,T17,Drug 253 265	esomeprazole
22,R4,Subsumes Arg1:T16 Arg2:T17
23,*,OR T15 T14 T13 T12 T11
24,T18,Drug 164 175	antibiotics
25,T19,"Scope 177 242	bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline"
26,R5,Subsumes Arg1:T18 Arg2:T19
27,T20,Temporal 134 142	previous
28,T21,Condition 143 160	allergic reaction
29,*,OR T18 T16
30,T22,"Scope 164 266	antibiotics (bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline) and PPI (esomeprazole)"
31,R6,Has_scope Arg1:T21 Arg2:T22
32,R7,Has_temporal Arg1:T21 Arg2:T20
33,T23,Condition 269 285	contraindication
34,T24,Drug 289 304	treatment drugs
35,R8,AND Arg1:T23 Arg2:T24
36,T25,Condition 307 315	pregnant
37,T26,Condition 319 328	lactating
38,T27,Person 329 334	women
39,*,OR T26 T25
40,T28,Qualifier 337 343	severe
41,T29,Temporal 344 354	concurrent
42,T30,Condition 355 362	disease
43,R9,Has_temporal Arg1:T30 Arg2:T29
44,R10,Has_qualifier Arg1:T30 Arg2:T28
45,T31,Temporal 365 376	concomitant
46,T32,Drug 384 395	clopidogrel
47,T33,Informed_consent 404 453	Unwilling to accept random assignment of subjects
48,R11,Has_temporal Arg1:T32 Arg2:T31
0,T1,Observation 0 24	Regular cigarette smoker
1,T2,Observation 26 39	Alcohol abuse
2,T3,Observation 41 51	Drug abuse
0,T1,Person 10 15	women
1,T2,Condition 0 9	Infertile
2,T3,Condition 37 48	anovulation
3,T4,Condition 49 63	oligoovulation
4,T5,Qualifier 21 36	eugonadotrophic
5,*,OR T3 T4
6,T6,Scope 37 63	anovulation/oligoovulation
7,R1,Has_qualifier Arg1:T6 Arg2:T5
8,R2,Has_scope Arg1:T2 Arg2:T6
9,T7,Qualifier 66 77	Unexplained
10,T8,Condition 78 89	infertility
11,R3,Has_qualifier Arg1:T8 Arg2:T7
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,*,OR T1 T2
3,T3,Value 16 24;32 40	18 years or older
4,T4,Person 28 31	age
5,R1,Has_value Arg1:T4 Arg2:T3
6,T5,Condition 80 108	diabetic macular edema (DME)
7,T6,Qualifier 57 79	clinically significant
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Measurement 114 140	central subfield thickness
10,T8,Value 141 148	≥ 350µm
11,T9,Procedure 152 171	spectral domain OCT
12,R3,AND Arg1:T9 Arg2:T7
13,R4,Has_value Arg1:T7 Arg2:T8
14,R5,AND Arg1:T5 Arg2:T9
15,T10,Measurement 172 207	Best corrected visual acuity (BCVA)
16,T11,Value 211 243	20/50 to 20/320 ETDRS equivalent
17,T12,Value 245 269	65 letters to 23 letters
18,R6,Subsumes Arg1:T11 Arg2:T12
19,T13,Qualifier 271 287	in the study eye
20,R7,Has_qualifier Arg1:T10 Arg2:T13
21,R8,Has_value Arg1:T10 Arg2:T11
22,T14,Non-representable 289 338	with BCVA decrement primarily attributable to DME
23,T15,Observation 340 355	Treatment naïve
24,T16,Negation 363 365	no
25,T17,Temporal 366 374	previous
26,T18,Procedure 375 394	anti-VEGF treatment
27,T19,Qualifier 395 411	in the study eye
28,R9,Has_qualifier Arg1:T18 Arg2:T19
29,R10,Has_temporal Arg1:T18 Arg2:T17
30,R11,Has_negation Arg1:T18 Arg2:T16
31,T20,Negation 415 417	no
32,T21,Procedure 418 437	anti-VEGF treatment
33,T22,Temporal 438 478	in the 45 days prior to study enrollment
34,T23,Reference_point 462 478	study enrollment
35,R12,Has_index Arg1:T22 Arg2:T23
36,R13,Has_temporal Arg1:T21 Arg2:T22
37,R14,Has_negation Arg1:T21 Arg2:T20
38,*,OR T21 T18
39,T24,Scope 363 478	no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment
40,R15,Subsumes Arg1:T15 Arg2:T24
41,T25,Non-query-able 480 509	In the investigator's opinion
42,T26,Qualifier 533 544	significant
43,T27,Condition 545 563	intraretinal fluid
44,T28,Qualifier 564 589	with room for improvement
45,T29,Non-representable 564 589	with room for improvement
46,T30,Condition 598 611	macular edema
47,T31,Condition 616 620	BCVA
48,T32,Scope 598 620	macular edema and BCVA
49,R17,Has_qualifier Arg1:T27 Arg2:T26
50,R16,Has_scope Arg1:T28 Arg2:T32
51,R18,Has_qualifier Arg1:T27 Arg2:T28
52,R19,multi Arg1:T28 Arg2:T29
53,T33,Measurement 622 649	Intra-Ocular Pressure (IOP)
54,T34,Value 653 666	under control
55,T35,Measurement 674 677	IOP
56,T36,Value 678 685	≤ 25 mm
57,T37,Qualifier 686 702	in the study eye
58,R20,Has_value Arg1:T35 Arg2:T36
59,R21,Has_qualifier Arg1:T35 Arg2:T37
60,R22,Has_value Arg1:T33 Arg2:T34
61,T38,Drug 739 757	IOP lowering drops
62,T39,Negation 721 724	not
63,R23,Has_negation Arg1:T38 Arg2:T39
64,T40,Qualifier 708 717	study eye
65,R24,Has_qualifier Arg1:T38 Arg2:T40
66,T41,Scope 674 702	IOP ≤ 25 mm in the study eye
67,T42,Scope 622 666	Intra-Ocular Pressure (IOP) is under control
68,R25,Has_scope Arg1:T42 Arg2:T41
69,T43,Post-eligibility 759 807	Willing and able to return for all study visits.
70,T44,Post-eligibility 808 862	Able to meet the extensive post-op evaluation regimen.
71,T45,Informed_consent 863 911	Understands and signs the informed consent form.
0,T1,Person 0 5	Males
1,T2,Person 9 16	females
2,T3,Value 17 36	above the age of 18
3,T4,Person 27 30	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,*,OR T1 T2
6,T5,Qualifier 58 70	laparoscopic
7,T6,Qualifier 74 81	robotic
8,T7,Procedure 82 103	colorectal resections
9,*,OR T6 T5
10,T8,Scope 58 81	laparoscopic or robotic
11,R2,Has_scope Arg1:T7 Arg2:T8
0,T1,Condition 0 17	Horner's Syndrome
1,T2,Drug 40 53	alpha blocker
2,T3,Drug 55 65	tamsulosin
3,T4,Drug 67 76	terazosin
4,T5,Drug 77 86	doxazosin
5,T6,Drug 87 96	alfuzosin
6,T7,Drug 97 106	silodosin
7,T8,Scope 55 106	tamsulosin/ terazosin/doxazosin/alfuzosin/silodosin
8,*,OR T3 T4 T5 T6 T7
9,R1,Subsumes Arg1:T2 Arg2:T8
0,T1,Non-query-able 0 2	NA
0,T1,Condition 11 23	constipation
1,T2,Drug 45 54	narcotics
2,T3,Drug 58 65	opioids
3,T4,Temporal 25 37	Pre-existing
4,*,OR T2 T3
5,T5,Scope 45 65	narcotics or opioids
6,R1,Has_temporal Arg1:T5 Arg2:T4
7,T6,Condition 89 104	hepatic failure
8,T7,Temporal 67 79	Pre-existing
9,T8,Condition 80 85;97 104	renal failure
10,*,OR T6 T8
11,T9,Scope 80 104	renal or hepatic failure
12,R2,Has_temporal Arg1:T9 Arg2:T7
13,T10,Condition 106 120	Mental illness
14,T11,Condition 122 140	mental retardation
15,T12,Condition 145 189	inability to participate in informed consent
16,*,OR T11 T12 T10
17,T13,Condition 197 210	mental status
18,R3,AND Arg1:T12 Arg2:T13
19,T14,Condition 225 233	dementia
20,T15,Temporal 212 224	Pre-existing
21,R4,Has_temporal Arg1:T14 Arg2:T15
22,T16,Condition 235 242	Allergy
23,T17,Procedure 281 290	operation
24,T18,Qualifier 271 280	Emergency
25,R5,Has_qualifier Arg1:T17 Arg2:T18
26,T19,Non-representable 292 343	Subjects who are incarcerated or wards of the state
27,T20,Person 345 351	Minors
28,T21,Condition 367 393	inflammatory bowel disease
29,T22,Condition 402 409	colitis
30,T23,Temporal 395 401	active
31,R6,Has_temporal Arg1:T22 Arg2:T23
32,T24,Condition 427 455	intra-abdominal inflammation
33,T25,Temporal 414 426	pre-existing
34,R7,Has_temporal Arg1:T24 Arg2:T25
35,*,OR T24 T22 T21
36,T26,Condition 457 471	Diverticulitis
37,T27,Temporal 480 486	active
38,T28,Condition 487 496	infection
39,T29,Condition 497 509	inflammation
40,T30,Negation 515 530	not be excluded
41,*,OR T28 T29
42,T31,Scope 487 509	infection/inflammation
43,R8,Has_temporal Arg1:T31 Arg2:T27
44,R9,Has_scope Arg1:T26 Arg2:T31
45,T32,Negation 472 479	without
46,R10,Has_negation Arg1:T31 Arg2:T32
47,R11,Has_negation Arg1:T26 Arg2:T30
0,T1,Procedure 20 55	small bowel video capsule endoscopy
0,T1,Person 0 3	Age
1,T2,Value 4 14	= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Observation 16 68	American Society of Anesthesiologists Classification
4,T4,Value 69 74	I-III
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Value 76 82	Normal
7,T6,Measurement 83 101	cognitive function
8,R3,Has_value Arg1:T6 Arg2:T5
9,T7,Observation 179 210	Agreement to the trial protocol
10,T8,Observation 179 191;222 243	Agreement to the randomized manner
11,*,OR T7 T8
0,T1,Condition 41 51	malignancy
1,T2,Qualifier 52 82	suitable for radiation therapy
2,T3,Procedure 65 82	radiation therapy
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Procedure 19 29	histologic
5,T5,Value 30 35	proof
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,AND Arg1:T1 Arg2:T4
8,R4,Has_qualifier Arg1:T1 Arg2:T2
9,T6,Subjective_judgement 52 82	suitable for radiation therapy
10,T7,Procedure 119 150	external beam radiation therapy
11,T8,Temporal 113 118	prior
12,T9,Procedure 178 195	HDR brachytherapy
13,T10,"Not_a_criteria 207 373	evaluation of doses previously delivered to spinal cord/cauda equine, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration."
14,R5,Has_temporal Arg1:T7 Arg2:T8
15,T11,Qualifier 151 205	to the region proposed for HDR brachytherapy treatment
16,R6,AND Arg1:T11 Arg2:T9
17,R7,Has_qualifier Arg1:T7 Arg2:T11
18,T12,Procedure 378 396	repeat irradiation
19,T13,Value 403 438	exceed any normal tissue constraint
20,T14,Measurement 446 506	MSKCC Radiation Oncology Department dose constraint criteria
21,R8,Has_value Arg1:T14 Arg2:T13
22,R9,AND Arg1:T12 Arg2:T14
23,T15,"Context_Error 551 964	If the total prior radiation dose to the cord or pelvis exceeds 100 Gy BED equivalent, the patient will be potentially eligible, where a total of 100 BED Gy equivalent is determined by the biological equivalent dose (BED) calculation; BED = nd(1 + d/α/β), where n = number of fractions and d = dose per fraction; α/β is the constant for spinal cord late effect and equals 2. [Rades 2005, Nieder 2005, Sahgal 2012]"
24,T16,Measurement 966 969	KPS
25,T17,Value 970 974	≥ 60
26,T18,Person 976 979	Age
27,T19,Value 980 994	≥ 18 years old
28,R10,Has_value Arg1:T18 Arg2:T19
0,T1,Procedure 14 20	labour
1,T2,Person 0 10	parturient
2,T3,Negation 21 28	without
3,T4,Procedure 29 46	cervical dilation
4,T5,Condition 51 79	regular uterine contractions
5,*,OR T4 T5
6,T6,Scope 29 79	cervical dilation and regular uterine contractions
7,R1,Has_negation Arg1:T6 Arg2:T3
0,T1,Condition 0 7	Allergy
1,T2,Drug 11 13	LA
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Qualifier 31 50	near insertion site
4,T4,Qualifier 25 27;36 50	in insertion site
5,*,OR T4 T3
6,T5,Device 58 83	peripheral nerve catheter
7,T6,Scope 25 50	in or near insertion site
8,R2,Has_scope Arg1:T5 Arg2:T6
9,T7,Condition 85 109	Anatomical abnormalities
10,T8,Qualifier 121 131	successful
11,T9,Mood 110 120	preventing
12,T10,Device 132 151	peripheral catheter
13,T11,Procedure 152 161	insertion
14,R3,AND Arg1:T11 Arg2:T10
15,R4,Has_qualifier Arg1:T11 Arg2:T8
16,R5,Has_mood Arg1:T11 Arg2:T9
17,T12,Negation 110 120	preventing
18,R6,multi Arg1:T9 Arg2:T12
19,R7,AND Arg1:T7 Arg2:T11
20,T13,Drug 179 186	opioids
21,T14,Multiplier 163 175	Habitual use
22,R8,Has_multiplier Arg1:T13 Arg2:T14
23,T15,Condition 188 197	Pregnancy
24,T16,Observation 201 214	breastfeeding
25,*,OR T15 T16
26,T17,Value 231 239	negative
27,T18,Procedure 240 254	pregnancy test
28,R9,Has_value Arg1:T18 Arg2:T17
29,T19,Temporal 255 277	before trial inclusion
30,T20,Reference_point 262 277	trial inclusion
31,R10,Has_index Arg1:T19 Arg2:T20
32,R11,Has_temporal Arg1:T18 Arg2:T19
33,T21,Negation 216 228	disproved by
34,R12,Has_negation Arg1:T18 Arg2:T21
0,T1,Condition 16 32	contraindication
1,T2,Procedure 36 39	VCE
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 41 63	small bowel strictures
4,T4,Condition 65 88	oropharyngeal dysphagia
5,T5,Condition 90 99	pregnancy
6,T6,Negation 118 121	not
7,T7,Observation 122 141	surgical candidates
8,R2,Has_negation Arg1:T7 Arg2:T6
9,*,OR T5 T4 T3 T7
10,T8,"Scope 41 141	small bowel strictures, oropharyngeal dysphagia, pregnancy, patients who are not surgical candidates"
11,R3,Subsumes Arg1:T1 Arg2:T8
12,T9,Procedure 144 164	Endoscopic insertion
13,T10,Device 168 191	video capsule endoscope
14,R4,AND Arg1:T9 Arg2:T10
15,T11,Procedure 193 213	Inpatient procedures
16,T12,Condition 225 236	GI bleeding
17,R5,AND Arg1:T11 Arg2:T12
18,T13,Qualifier 218 224	active
19,R6,Has_qualifier Arg1:T12 Arg2:T13
20,T14,Observation 252 269	fluid restriction
21,T15,Observation 281 296	unable to drink
22,T16,Temporal 337 353	prior to the VCE
23,T17,Procedure 350 353	VCE
24,T18,Reference_point 346 353	the VCE
25,R7,multi Arg1:T18 Arg2:T17
26,R8,Has_index Arg1:T16 Arg2:T18
27,*,OR T14 T15
28,T19,Scope 252 296	fluid restriction or who are unable to drink
29,R9,Has_temporal Arg1:T19 Arg2:T16
0,T1,Informed_consent 0 10	no consent
1,T2,Condition 18 25	allergy
2,T3,Drug 42 48	opioid
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 50 67	contraindications
5,T5,Procedure 71 89	epidural analgesia
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 91 105	coagulopathies
8,T7,Measurement 116 130	platelet count
9,T8,"Value 134 151	less than 100,000"
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,"Scope 116 151	platelet count of less than 100,000"
12,R4,Has_scope Arg1:T6 Arg2:T9
13,T10,Procedure 153 166	spine surgery
14,T11,Temporal 167 174	in past
15,R5,Has_temporal Arg1:T10 Arg2:T11
0,T1,Measurement 129 189	MSKCC Radiation Oncology Department dose constraint criteria
1,T2,Condition 13 112	may receive therapeutically effective doses via an external beam approach to the lesion of interest
2,T3,Qualifier 25 50	therapeutically effective
3,T4,Procedure 51 56	doses
4,T5,Procedure 64 77	external beam
5,T6,Context_Error 0 189	Patients who may receive therapeutically effective doses via an external beam approach to the lesion of interest as specified by MSKCC Radiation Oncology Department dose constraint criteria
6,T7,Device 206 224	kyphoplasty cement
7,T8,Device 206 217;228 236	kyphoplasty hardware
8,T9,Qualifier 248 285	preclude effective catheter placement
9,*,OR T8 T7
10,T10,Scope 206 236	kyphoplasty cement or hardware
11,R1,Has_qualifier Arg1:T10 Arg2:T9
12,T11,Condition 302 333	paraspinal extension of disease
13,T12,Condition 339 359	visceral involvement
14,R2,AND Arg1:T11 Arg2:T12
15,T13,Measurement 371 391	complete blood count
16,T14,Value 362 370	Abnormal
17,R3,Has_value Arg1:T13 Arg2:T14
18,T15,Condition 362 391	Abnormal complete blood count
19,T16,Undefined_semantics 362 391	Abnormal complete blood count
20,T17,Parsing_Error 393 414	Any of the following:
21,T18,Measurement 416 430	Platelet count
22,T19,"Value 431 442	< 75,000/ml"
23,T20,Measurement 444 452	Hb level
24,T21,Value 453 461	< 9gm/dl
25,T22,Measurement 463 466	WBC
26,T23,Value 467 475	< 3.5/ml
27,R4,Has_value Arg1:T22 Arg2:T23
28,R5,Has_value Arg1:T18 Arg2:T19
29,R6,Has_value Arg1:T20 Arg2:T21
30,T24,Measurement 486 505	coagulation profile
31,T25,Value 477 485	Abnormal
32,R7,Has_value Arg1:T24 Arg2:T25
33,T26,Condition 477 505	Abnormal coagulation profile
34,T27,Measurement 507 510	INR
35,T28,Value 511 516	> 2.5
36,R8,Has_value Arg1:T27 Arg2:T28
37,T29,Measurement 524 527	PTT
38,T30,Value 528 532	> 80
39,R9,Has_value Arg1:T29 Arg2:T30
40,*,OR T27 T29
41,T31,Scope 507 532	INR > 2.5 and/or PTT > 80
42,R10,Subsumes Arg1:T26 Arg2:T31
43,T32,Drug 554 580	anticoagulation medication
44,T33,Undefined_semantics 554 580	anticoagulation medication
45,T34,Qualifier 586 626	may not be safely held for the procedure
46,T35,Subjective_judgement 586 626	may not be safely held for the procedure
47,R11,AND Arg1:T32 Arg2:T35
48,T36,Multiplier 628 636	≥ 5 days
49,T37,Drug 641 660	antiplatelet agents
50,T38,Drug 665 673	warfarin
51,T39,Multiplier 675 685	≥ 24 hours
52,T40,Drug 690 718	low-molecular weight heparin
53,R12,Has_multiplier Arg1:T40 Arg2:T39
54,A1,Optional T40
55,R13,Has_multiplier Arg1:T37 Arg2:T36
56,A2,Optional T37
57,R14,Has_multiplier Arg1:T38 Arg2:T36
58,A3,Optional T38
59,T41,Scope 628 673	≥ 5 days for antiplatelet agents and warfarin
60,T42,Scope 675 718	≥ 24 hours for low-molecular weight heparin
61,*,OR T41 T42
62,T43,Scope 628 718	≥ 5 days for antiplatelet agents and warfarin; ≥ 24 hours for low-molecular weight heparin
63,T44,Scope 554 626	anticoagulation medication that may not be safely held for the procedure
64,R15,Subsumes Arg1:T44 Arg2:T43
65,T45,Condition 752 791	Contraindications to general anesthesia
66,T46,Procedure 773 791	general anesthesia
67,R16,AND Arg1:T45 Arg2:T46
0,T1,Qualifier 0 6	severe
1,T2,Condition 7 30	coronary artery disease
2,T3,Condition 32 45	heart failure
3,T4,Condition 47 61	kidney failure
4,*,OR T2 T3 T4
5,T5,"Scope 7 61	coronary artery disease, heart failure, kidney failure"
6,R1,Has_qualifier Arg1:T5 Arg2:T1
7,T6,Condition 63 83	insulin-dependent DM
8,T7,Condition 85 102	diabetes mellitus
9,T8,Qualifier 105 122	poorly controlled
10,T9,Condition 123 133	type II DM
11,R2,Has_qualifier Arg1:T9 Arg2:T8
12,R3,Subsumes Arg1:T6 Arg2:T7
13,T10,Condition 135 142;152 157	gastric ulcer
14,T11,Condition 143 157	duodenal ulcer
15,*,OR T11 T10
16,T12,Condition 159 166	allergy
17,T13,Condition 167 184	contra-indication
18,T14,Drug 193 215	drug used in the study
19,*,OR T13 T12
20,T15,Scope 159 184	allergy/contra-indication
21,R4,AND Arg1:T15 Arg2:T14
22,T16,Drug 217 231	corticosteroid
23,T17,Temporal 236 256	during last 3 months
24,R5,Has_temporal Arg1:T16 Arg2:T17
25,T18,Temporal 258 270	preoperative
26,T19,Drug 278 290	opioid drugs
27,T20,Negation 292 297	excl.
28,T21,Drug 298 305	codeine
29,T22,Drug 307 315	tramadol
30,*,OR T21 T22
31,T23,"Scope 298 315	codeine, tramadol"
32,R6,Has_negation Arg1:T23 Arg2:T20
33,R7,Has_scope Arg1:T19 Arg2:T23
34,R8,Has_temporal Arg1:T19 Arg2:T18
35,T24,Condition 318 328	neuropathy
36,T25,Condition 329 347	sensory impairment
37,T26,Qualifier 351 362	lower limbs
38,*,OR T24 T25
39,T27,Scope 318 347	neuropathy/sensory impairment
40,R9,Has_qualifier Arg1:T27 Arg2:T26
41,T28,Observation 364 384	lack of co-operation
42,T29,Condition 391 407	inability to use
43,T30,Device 410 413;444 451	PCA -device
44,R10,AND Arg1:T29 Arg2:T30
45,R11,Subsumes Arg1:T28 Arg2:T29
0,T1,Person 0 5	women
1,T2,Procedure 17 34	caesarean section
2,T3,Temporal 6 16	undergoing
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,T4,Value 38 56	less than 37 weeks
5,T5,Measurement 60 69	gestation
6,R2,Has_value Arg1:T5 Arg2:T4
7,R3,AND Arg1:T2 Arg2:T5
8,T6,Condition 72 84	Hypertension
9,T7,Condition 90 99	pregnancy
10,R4,AND Arg1:T6 Arg2:T7
11,T8,Condition 114 131	coronary diseases
12,T9,Condition 102 109;123 131	Cardiac diseases
13,T10,Condition 137 146	pregnancy
14,*,OR T9 T8
0,T1,Condition 0 9	Pregnancy
1,T2,Condition 14 23	lactation
2,T3,Grammar_Error 10 13	and
3,*,OR T2 T1
4,T4,Condition 39 47	diabetes
5,T5,Condition 49 77	Ischemic heart disease (IHD)
6,T6,Condition 79 85	stroke
7,T7,Condition 87 97	malignancy
8,T8,Condition 102 122	psychiatric diseases
9,T9,Grammar_Error 98 101	and
10,*,OR T8 T7 T6 T5 T4
11,T10,Drug 172 191	vitamin supplements
12,T11,Condition 203 241	clinical evidence for an acute illness
13,T12,Condition 228 241	acute illness
14,T13,Undefined_semantics 203 241	clinical evidence for an acute illness
15,R1,AND Arg1:T11 Arg2:T12
16,T14,Condition 243 260	renal dysfunction
17,T15,Condition 262 281	thyroid dysfunction
18,T16,Condition 283 312	chronic inflammatory diseases
19,T17,Condition 314 343;365 375	inborn errors of homocysteine metabolism
20,T18,Condition 314 330;358 375	inborn errors of folate metabolism
21,T19,Condition 314 330;345 354;365 375	inborn errors of cobalamin metabolism
22,T20,Condition 390 447	condition known to interfere with homocysteine metabolism
23,T21,Undefined_semantics 390 447	condition known to interfere with homocysteine metabolism
24,*,OR T10 T11 T14 T15 T16
25,*,OR T17 T19 T18 T20
26,T22,Non-query-able 466 519	Patients who are already involved in any other trial.
27,T23,Post-eligibility 521 600	Patients not willing to fill consent/ assent form are also excluded from study.
28,T24,Non-query-able 521 600	Patients not willing to fill consent/ assent form are also excluded from study.
0,T1,Condition 0 16	Hypersensitivity
1,T2,Drug 20 30	Colchicine
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 49 71	intra-cardiac thrombus
4,T4,Procedure 75 108	trans-esophageal echocardiography
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Condition 110 119	Pregnancy
0,T1,Procedure 8 38	total knee replacement surgery
1,T2,Qualifier 0 7	primary
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Measurement 40 43;84 89	ASA class
4,T4,Value 90 93	1-3
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 45 82	american society of anesthesiologists
7,R3,Subsumes Arg1:T3 Arg2:T5
0,T1,Condition 13 32	singleton pregnancy
1,T2,Procedure 44 60	cesarean section
2,T3,Value 61 75	after 37 weeks
3,T4,Measurement 79 88	gestation
4,R1,Has_value Arg1:T4 Arg2:T3
5,R2,AND Arg1:T2 Arg2:T4
0,T1,Procedure 19 37	pericardiocentesis
1,T2,Temporal 38 49	during RFCA
2,T3,Reference_point 45 49	RFCA
3,T4,Procedure 45 49	RFCA
4,R1,multi Arg1:T3 Arg2:T4
5,R2,Has_index Arg1:T2 Arg2:T3
6,T5,Qualifier 54 64	paroxysmal
7,T6,Qualifier 68 78	persistent
8,T7,Condition 79 98	atrial fibrillation
9,*,OR T5 T6
10,T8,Scope 54 78	paroxysmal or persistent
11,R3,Has_scope Arg1:T7 Arg2:T8
12,R4,Has_temporal Arg1:T1 Arg2:T2
13,R5,AND Arg1:T1 Arg2:T7
0,T1,Condition 10 19	epileptic
1,T2,Person 48 51	age
2,T3,Value 52 69	between 10-19 yrs
3,T4,Value 71 77	<19yrs
4,R1,Subsumes Arg1:T3 Arg2:T4
5,T5,Visit 103 114;127 138	Out Patient Departments
6,T6,Visit 116 138	In Patient Departments
7,T7,Procedure 154 165	AED therapy
8,T8,Temporal 166 188	for more than 6 months
9,R2,Has_temporal Arg1:T7 Arg2:T8
10,R3,Has_value Arg1:T2 Arg2:T3
11,T9,Measurement 212 231	homocysteine levels
12,T10,Value 207 211	high
13,T11,Value 237 250	> 10.9 µmol/L
14,R4,Has_value Arg1:T9 Arg2:T10
15,R5,Subsumes Arg1:T10 Arg2:T11
16,T12,Not_a_criteria 251 528	(Normal homocysteine levels are 4.3-9.9 µmol/L for male and 3.3-7.2 µmol/L for female adolescent and a high homocysteine concentration is deaned as at least 11.4 µmol/L for male and at least 10.4 µmol/L for female. Gender mean of high homocysteine concentration is 10.9 µmol/L)
17,T13,Parsing_Error 529 532	[5]
0,T1,Condition 13 19	asthma
0,T1,Person 0 4	Aged
1,T2,Value 5 24	between 18-70 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 36 108	Diagnostic and Statistical Manual (DSM) IV and DSM-V diagnostic criteria
4,T4,Scope 26 31	Meets
5,R2,Has_scope Arg1:T3 Arg2:T4
6,T5,Condition 113 141	generalised anxiety disorder
7,T6,Condition 143 146	GAD
8,R3,Subsumes Arg1:T5 Arg2:T6
9,T7,Procedure 157 177	structured interview
10,T8,Procedure 179 245	Mini International Neuropsychiatric Interview-Plus 6 [MINI-Plus 6]
11,R4,Subsumes Arg1:T7 Arg2:T8
12,R5,AND Arg1:T7 Arg2:T3
13,R6,AND Arg1:T5 Arg2:T7
14,T9,Condition 362 369	anxiety
15,T10,Measurement 371 400	Hamilton Anxiety Rating Scale
16,T11,Value 401 405	= 18
17,R7,Has_value Arg1:T10 Arg2:T11
18,R8,AND Arg1:T9 Arg2:T10
19,T12,Temporal 407 433	at the time of study entry
20,T13,Reference_point 414 433	time of study entry
21,R9,Has_index Arg1:T12 Arg2:T13
22,R10,Has_temporal Arg1:T9 Arg2:T12
23,T14,Non-query-able 435 471	Fluent in written and spoken English
24,T15,Non-query-able 473 515	Provides a signed copy of the consent form
25,T16,Condition 546 549	GAD
26,T17,Condition 517 534	Primary diagnosis
27,T18,Negation 535 545	other than
28,R11,Has_negation Arg1:T16 Arg2:T18
29,R12,AND Arg1:T17 Arg2:T16
30,T19,Qualifier 567 585	moderate to severe
31,T20,Condition 586 605	depressive symptoms
32,R13,Has_qualifier Arg1:T20 Arg2:T19
33,T21,Scope 567 605	moderate to severe depressive symptoms
34,T22,Measurement 607 637	Montgomery-Asberg Rating Scale
35,T23,Measurement 639 644	MADRS
36,T24,Value 645 649	= 18
37,R14,Subsumes Arg1:T22 Arg2:T23
38,T25,Temporal 650 672	at time of study entry
39,T26,Value 676 680	= 24
40,T27,Temporal 681 705	at any time during study
41,T28,Scope 645 705	= 18 at time of study entry or = 24 at any time during study
42,R15,Has_temporal Arg1:T24 Arg2:T25
43,*,OR T24 T26
44,R16,Has_temporal Arg1:T26 Arg2:T27
45,T29,Scope 607 644	Montgomery-Asberg Rating Scale: MADRS
46,R17,Has_scope Arg1:T29 Arg2:T28
47,T30,Scope 607 705	Montgomery-Asberg Rating Scale: MADRS = 18 at time of study entry or = 24 at any time during study
48,R18,Subsumes Arg1:T21 Arg2:T30
49,T31,Condition 724 741	suicidal ideation
50,T32,Value 743 746	= 3
51,T33,Measurement 750 780	MADRS suicidal thoughts domain
52,T34,Temporal 781 803	at time of study entry
53,T35,Temporal 807 831	at any time during study
54,*,OR T34 T35
55,T36,Scope 781 831	at time of study entry or at any time during study
56,R19,Has_scope Arg1:T33 Arg2:T36
57,R20,Has_value Arg1:T33 Arg2:T32
58,T37,Scope 743 831	= 3 on MADRS suicidal thoughts domain at time of study entry or at any time during study
59,R21,Has_scope Arg1:T31 Arg2:T37
60,T38,Condition 855 871	bipolar disorder
61,T39,Condition 875 888	schizophrenia
62,T40,Measurement 892 912	structured interview
63,T41,Measurement 914 923	MINI Plus
64,R22,Subsumes Arg1:T40 Arg2:T41
65,*,OR T39 T38
66,T42,Scope 855 888	bipolar disorder or schizophrenia
67,R23,Has_scope Arg1:T40 Arg2:T42
68,T43,Condition 944 964	alcohol use disorder
69,T44,Condition 934 943;952 964	substance use disorder
70,T45,Measurement 968 988	structured interview
71,T46,Measurement 990 999	MINI Plus
72,R24,Subsumes Arg1:T45 Arg2:T46
73,*,OR T44 T43
74,T47,Scope 934 964	substance/alcohol use disorder
75,R25,Has_scope Arg1:T45 Arg2:T47
76,T48,Drug 1061 1075	antidepressant
77,T49,Condition 1051 1057	taking
78,T50,Temporal 1041 1050	Currently
79,R27,Has_temporal Arg1:T49 Arg2:T50
80,T51,Drug 1077 1092	mood stabiliser
81,T52,Drug 1094 1107	antipsychotic
82,T53,Drug 1109 1123	anticonvulsant
83,T54,Drug 1125 1133	warfarin
84,T55,Drug 1137 1145	thyroxin
85,T56,Drug 1203 1217	benzodiazepine
86,T57,Drug 1221 1243	opioid-based analgesic
87,*,OR T56 T57
88,T58,Multiplier 1171 1196	more than 2 days per week
89,T59,Multiplier 1158 1165	regular
90,T60,Temporal 1150 1157	current
91,T61,Scope 1203 1243	benzodiazepine or opioid-based analgesic
92,R29,Subsumes Arg1:T59 Arg2:T58
93,*,OR T55 T54 T53 T52 T51 T48
94,T62,"Scope 1061 1145	antidepressant, mood stabiliser, antipsychotic, anticonvulsant, warfarin or thyroxin"
95,R26,Has_scope Arg1:T49 Arg2:T62
96,T63,Procedure 1166 1169	use
97,R31,Has_multiplier Arg1:T63 Arg2:T59
98,R28,Has_temporal Arg1:T63 Arg2:T60
99,R30,Has_scope Arg1:T63 Arg2:T61
100,*,OR T63 T49
101,T64,Drug 1262 1288	psychotropic nutraceutical
102,T65,Condition 1295 1309	St John's wort
103,T66,Temporal 1245 1252	Current
104,T67,Procedure 1253 1256	use
105,R32,AND Arg1:T67 Arg2:T64
106,R33,Has_temporal Arg1:T67 Arg2:T66
107,R34,Subsumes Arg1:T64 Arg2:T65
108,T68,Condition 1321 1332	intolerance
109,T69,Drug 1336 1340	kava
110,R35,AND Arg1:T68 Arg2:T69
111,T70,Temporal 1312 1320	Previous
112,R36,Has_temporal Arg1:T68 Arg2:T70
113,T71,Multiplier 1342 1355	Three or more
114,T72,Procedure 1363 1388	trials of pharmacotherapy
115,T73,Qualifier 1356 1362	failed
116,T74,Condition 1405 1416	GAD episode
117,T75,Temporal 1397 1404	current
118,R37,Has_qualifier Arg1:T72 Arg2:T73
119,R38,Has_multiplier Arg1:T72 Arg2:T71
120,R39,AND Arg1:T72 Arg2:T74
121,R40,Has_temporal Arg1:T74 Arg2:T75
122,T76,Procedure 1437 1450	psychotherapy
123,T77,Temporal 1452 1484	within four weeks of study entry
124,T78,Temporal 1418 1426	Recently
125,R41,Subsumes Arg1:T78 Arg2:T77
126,R42,Has_temporal Arg1:T76 Arg2:T78
127,T79,Qualifier 1506 1525	clinically unstable
128,T80,Qualifier 1526 1534	systemic
129,T81,Condition 1535 1551	medical disorder
130,R43,Has_qualifier Arg1:T81 Arg2:T80
131,R44,Has_qualifier Arg1:T81 Arg2:T79
132,T82,Mood 1496 1505	suspected
133,T83,Mood 1487 1492	Known
134,*,OR T82 T83
135,T84,Scope 1487 1505	Known or suspected
136,R45,Has_scope Arg1:T81 Arg2:T84
137,T85,Condition 1563 1585	hepato-biliary disease
138,T86,Condition 1563 1577;1586 1598	hepato-biliary inflammation
139,*,OR T85 T86
140,T87,Value 1600 1608	Elevated
141,T88,Measurement 1609 1622	liver enzymes
142,T89,Temporal 1626 1634	baseline
143,T90,Procedure 1635 1645	blood test
144,R46,Has_temporal Arg1:T90 Arg2:T89
145,R47,Has_value Arg1:T88 Arg2:T87
146,R48,AND Arg1:T88 Arg2:T90
147,T91,Condition 1647 1656	Pregnancy
148,T92,Observation 1660 1673	breastfeeding
149,*,OR T92 T91 T93
150,T93,Condition 1678 1696	trying to conceive
151,T94,Negation 1698 1701	Not
152,T96,Qualifier 1708 1726	medically approved
153,T97,Procedure 1727 1740	contraception
154,R49,Has_qualifier Arg1:T97 Arg2:T96
155,T98,Procedure 1752 1762	abstinence
156,R50,Subsumes Arg1:T97 Arg2:T98
157,T99,Person 1767 1773	female
158,T100,Person 1781 1797	childbearing age
159,T101,Observation 1794 1797	age
160,T102,Value 1781 1793	childbearing
161,R51,Has_value Arg1:T101 Arg2:T102
162,T103,Scope 1781 1797	childbearing age
163,R52,multi Arg1:T100 Arg2:T103
164,T104,Scope 1767 1797	female and of childbearing age
165,A1,Optional T104
166,R53,Has_negation Arg1:T97 Arg2:T94
167,T105,Scope 1698 1763	Not using medically approved contraception (including abstinence)
168,R54,Has_scope Arg1:T104 Arg2:T105
169,T95,Observation 1799 1820	Unable to participate
170,T106,Visit 1828 1844	scheduled visits
171,T107,Observation 1846 1860	treatment plan
172,T108,Procedure 1871 1887	trial procedures
173,*,OR T106 T107 T108
174,T109,Negation 1915 1925	except for
175,T110,Observation 1939 1956	genetic component
176,R55,Has_negation Arg1:T110 Arg2:T109
177,T111,"Scope 1828 1887	scheduled visits, treatment plan, or other trial procedures"
178,R56,Has_context Arg1:T111 Arg2:T110
179,R57,Has_context Arg1:T111 Arg2:T95
0,T1,Observation 0 28	Research exemption requested
1,T2,Observation 30 37	History
2,T3,Procedure 41 59	PCV-13 vaccination
3,T4,Observation 61 68	History
4,T5,Device 72 88	cochlear implant
5,R1,Has_temporal Arg1:T3 Arg2:T2
6,R2,Has_temporal Arg1:T5 Arg2:T4
7,T6,Condition 90 120	Cerebrospinal Fluid (CSF) leak
8,T7,Condition 122 152	Congestive Heart Failure (CHF)
9,T8,Condition 154 176	Diabetes Mellitus (DM)
10,T9,Condition 178 206	Chronic Kidney Disease (CKD)
11,T10,Condition 208 242	Human Immunodeficiency Virus (HIV)
12,T11,Condition 244 284	Common Variable Immune Deficiency (CVID)
13,T12,Drug 317 331	PPSV23 vaccine
14,T13,Temporal 332 351	in the last 5 years
15,R3,Has_temporal Arg1:T12 Arg2:T13
16,T14,Person 353 358	Women
17,T15,Condition 367 375	pregnant
18,T16,Procedure 429 464	point of care urine pregnancy tests
19,T17,Multiplier 427 428	2
20,R4,Has_multiplier Arg1:T16 Arg2:T17
21,T18,Temporal 467 488	prior to vaccinations
22,T19,Procedure 476 488	vaccinations
23,T20,Reference_point 476 488	vaccinations
24,R5,Has_index Arg1:T18 Arg2:T20
25,R6,multi Arg1:T20 Arg2:T19
26,R7,Has_temporal Arg1:T16 Arg2:T18
0,T1,Person 9 13	aged
1,T2,Value 14 31	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Temporal 33 76	at the time of signing the informed consent
4,T4,Reference_point 48 76	signing the informed consent
5,R2,Has_index Arg1:T3 Arg2:T4
6,R3,Has_temporal Arg1:T1 Arg2:T3
7,T5,Condition 127 133	asthma
8,T7,Qualifier 143 170	primary respiratory disease
9,R4,Has_qualifier Arg1:T5 Arg2:T7
10,T6,Measurement 173 182	ACT score
11,T8,Value 183 186	<20
12,R5,Has_value Arg1:T6 Arg2:T8
13,T9,Temporal 187 205	at screening visit
14,T10,Observation 208 219	Non-smokers
15,T11,Observation 221 233	never smoked
16,T12,Observation 237 248	not smoking
17,T13,Temporal 249 262	for >6 months
18,R6,Has_temporal Arg1:T12 Arg2:T13
19,T14,Value 268 271	<10
20,T15,Measurement 272 282	pack years
21,R7,Has_value Arg1:T15 Arg2:T14
22,*,OR T11 T12
23,T16,Non-representable 292 372	Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked
24,T17,Scope 221 372	never smoked or not smoking for >6 months with <10 pack years history (Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked
25,R8,Subsumes Arg1:T10 Arg2:T17
26,T18,Person 376 380	Male
27,T19,Person 384 390	female
28,*,OR T18 T19
29,T20,"Pregnancy_considerations 418 763	A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: (i) Not a woman of childbearing potential (WOCBP). (ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 5 days] after the last dose of study treatment."
30,T21,Informed_consent 765 912	Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and protocol.
31,T22,"Non-query-able 914 1016	Subject understands and is willing, able, and likely to comply with study procedures and restrictions."
32,T23,Non-query-able 1018 1110	Subject must be able to read in a language supported by the smart phone app in their region.
33,T24,Procedure 1138 1157	maintenance therapy
34,T25,Multiplier 1159 1169	Fixed dose
35,T26,Drug 1170 1190	combination ICS/LABA
36,R9,Has_multiplier Arg1:T26 Arg2:T25
37,R10,Subsumes Arg1:T24 Arg2:T26
38,T27,Temporal 1192 1204	for 3 months
39,R11,Has_temporal Arg1:T24 Arg2:T27
40,T28,Negation 1206 1212	cannot
41,T29,Multiplier 1218 1230	changed dose
42,R12,Has_negation Arg1:T29 Arg2:T28
43,T30,Temporal 1231 1262	in the month prior to screening
44,T31,Reference_point 1234 1262	the month prior to screening
45,R13,Has_index Arg1:T30 Arg2:T31
46,R14,Has_multiplier Arg1:T24 Arg2:T29
47,R15,Has_temporal Arg1:T29 Arg2:T30
48,T32,Non-representable 1263 1517	and be able to change to an equivalent dose of RELVAR/BREO for the duration of the study. Other background asthma medication such as anti-leukotrienes and oral corticosteroids are permitted provided the dose has been stable for 1 month prior to screening
49,T33,Mood 1536 1543	able to
50,T34,Procedure 1544 1550	change
51,T35,Drug 1554 1564	Salbutamol
52,T36,Drug 1565 1574	Albuterol
53,T37,Procedure 1575 1585	MDI rescue
54,R16,AND Arg1:T37 Arg2:T36
55,R17,AND Arg1:T37 Arg2:T35
56,R18,AND Arg1:T34 Arg2:T37
57,R19,Has_mood Arg1:T34 Arg2:T33
58,T38,Temporal 1586 1615	for the duration of the study
59,T39,Reference_point 1590 1615	the duration of the study
60,R20,multi Arg1:T38 Arg2:T39
61,T40,Condition 1627 1649	capable of withholding
62,T41,Drug 1650 1659	albuterol
63,T42,Drug 1660 1670	salbutamol
64,T43,Multiplier 1671 1691	for at least 6 hours
65,T44,Temporal 1692 1713	prior to study visits
66,T45,Scope 1650 1670	albuterol/salbutamol
67,R21,Has_scope Arg1:T40 Arg2:T45
68,R22,Has_multiplier Arg1:T40 Arg2:T43
69,R23,Has_temporal Arg1:T40 Arg2:T44
70,R24,Has_temporal Arg1:T34 Arg2:T38
71,T46,Non-query-able 1716 2047	Subject must have their own Android or iPhone operating system (IOS) smart phone and a data package suitable for the installation and running of the app and sending and receiving data. Data used by the CIS is approximately 1 megabyte (MB) per month as a maximum; this is less data than a 1 minute video streamed from YouTube (2MB).
72,T47,Non-query-able 2049 2418	Subjects must be willing and able to download the app on their personal smart phone and keep it turned on for the duration of the study. This will also require Bluetooth to be turned on for duration of the study. Subjects will also have to turn on mobile data for the app for the duration of study; unless travelling and when extra data roaming costs could be incurred.
73,T48,Measurement 2420 2429	ACT score
74,T49,Value 2430 2433	<20
75,T50,Temporal 2434 2456	at randomization visit
76,R25,Has_value Arg1:T48 Arg2:T49
77,R26,Has_temporal Arg1:T48 Arg2:T50
0,T1,Person 0 3	Men
1,T2,Person 7 12	women
2,T3,Person 13 17	aged
3,T4,Value 18 35	18 years or older
4,R1,Has_value Arg1:T3 Arg2:T4
5,T6,Condition 96 123	hypertrophic cardiomyopathy
6,T7,Measurement 133 164	left ventricular wall thickness
7,T8,Value 168 183	at least =15 mm
8,T9,Negation 191 198	absence
9,T10,Condition 223 252	systemic cause of hypertrophy
10,T11,Condition 212 219;232 252	cardiac cause of hypertrophy
11,*,OR T10 T11
12,T12,Scope 212 252	cardiac or systemic cause of hypertrophy
13,R2,Has_negation Arg1:T12 Arg2:T9
14,R3,Has_value Arg1:T7 Arg2:T8
15,R4,Has_scope Arg1:T6 Arg2:T12
16,R5,AND Arg1:T6 Arg2:T7
17,T5,Condition 313 346	idiopathic dilated cardiomyopathy
18,T13,Measurement 358 392	left ventricular ejection fraction
19,T14,Value 393 397	=40%
20,R6,Has_value Arg1:T13 Arg2:T14
21,T15,Measurement 399 424	LV end-diastolic diameter
22,T16,Value 425 431	=55 mm
23,T17,Measurement 435 473	left ventricular end-systolic diameter
24,T18,Value 474 480	=45 mm
25,T19,Negation 490 497	absence
26,T20,Condition 501 518	coronary stenoses
27,T21,Procedure 522 533	angiography
28,R7,Has_negation Arg1:T20 Arg2:T19
29,R8,AND Arg1:T21 Arg2:T20
30,R9,Has_value Arg1:T17 Arg2:T18
31,R10,Has_value Arg1:T15 Arg2:T16
32,*,OR T15 T17 T13
33,R11,AND Arg1:T5 Arg2:T21
34,T22,"Scope 358 480	left ventricular ejection fraction =40%, LV end-diastolic diameter =55 mm or left ventricular end-systolic diameter =45 mm"
35,R12,Has_scope Arg1:T5 Arg2:T22
36,T23,Condition 578 588	chest pain
37,T24,Negation 593 600	without
38,T25,Condition 613 648	obstructive coronary artery disease
39,T26,Procedure 659 679	coronary angiography
40,T27,Procedure 683 697	stress testing
41,*,OR T26 T27
42,T28,Scope 659 697	coronary angiography or stress testing
43,R13,Has_scope Arg1:T25 Arg2:T28
44,R14,Has_negation Arg1:T25 Arg2:T24
45,R15,AND Arg1:T23 Arg2:T25
0,T1,Person 0 8	Children
1,T2,Person 9 13	aged
2,T3,Value 14 18	3-16
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 88 95	allergy
5,T5,Drug 101 122	penicillin antibiotic
6,T6,Temporal 172 222	at least six months prior to the current PED visit
7,R2,AND Arg1:T4 Arg2:T5
8,T7,Condition 145 162	allergic reaction
9,R3,Has_temporal Arg1:T7 Arg2:T6
10,R4,AND Arg1:T4 Arg2:T7
11,T8,Condition 239 275	well enough to be discharged to home
12,T9,Temporal 276 310	at the conclusion of the PED visit
13,T10,Reference_point 279 310	the conclusion of the PED visit
14,T11,Visit 301 304	PED
15,R5,multi Arg1:T10 Arg2:T11
16,R6,Has_index Arg1:T9 Arg2:T10
17,R7,Has_temporal Arg1:T8 Arg2:T9
0,T1,Observation 11 33	enrolled in this study
1,T2,Temporal 0 10	Previously
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Procedure 86 104	surgical procedure
4,T4,Temporal 74 85	Concomitant
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Procedure 116 120	CABG
7,T6,Qualifier 105 115	other than
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,R4,AND Arg1:T3 Arg2:T5
10,T7,Procedure 122 145	Anticoagulant treatment
11,T8,Temporal 146 165	after the operation
12,T9,Reference_point 152 165	the operation
13,T10,Procedure 156 165	operation
14,R5,multi Arg1:T9 Arg2:T10
15,R6,Has_index Arg1:T8 Arg2:T9
16,R7,Has_temporal Arg1:T7 Arg2:T8
17,T11,Drug 172 180	warfarin
18,T12,Drug 182 208	direct thrombin inhibitors
19,T13,Drug 210 220	dabigatran
20,R8,Subsumes Arg1:T12 Arg2:T13
21,T14,Drug 223 237	FXa inhibitors
22,T15,Drug 239 250	rivaroxaban
23,T16,Drug 252 260	apixaban
24,T17,Drug 262 269	heparin
25,T18,Drug 271 299	low-molecular weight heparin
26,T19,Drug 301 313	fondaparinux
27,*,OR T15 T16 T17 T18 T19
28,T20,"Scope 239 313	rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux"
29,R9,Subsumes Arg1:T14 Arg2:T20
30,*,OR T11 T12 T14
31,T21,"Scope 172 313	warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux"
32,R10,Subsumes Arg1:T7 Arg2:T21
33,T22,Observation 316 325	Discharge
34,T23,Visit 335 353	operating hospital
35,T24,Visit 360 363	ICU
36,T25,Qualifier 367 374	another
37,T26,Visit 375 383	hospital
38,R11,Has_qualifier Arg1:T26 Arg2:T25
39,T27,Scope 360 383	ICU at another hospital
40,R12,AND Arg1:T22 Arg2:T23
41,R13,Has_scope Arg1:T22 Arg2:T27
42,T28,Condition 385 394	Pregnancy
43,T29,Condition 398 407	lactation
44,T30,Condition 430 446	contraindication
45,T31,Condition 415 426	intolerance
46,T32,Drug 450 460	ticagrelor
47,T33,Drug 464 467	ASA
48,*,OR T32 T33
49,*,OR T31 T30
50,T34,Scope 415 446	intolerance or contraindication
51,T35,Scope 450 467	ticagrelor or ASA
52,R14,Has_scope Arg1:T34 Arg2:T35
53,T36,Condition 473 481	disorder
54,T37,Qualifier 487 521	may interfere with drug absorption
55,R15,Has_qualifier Arg1:T36 Arg2:T37
56,T38,Condition 548 571	coronary artery disease
57,T39,Negation 537 547	other than
58,R16,Has_negation Arg1:T38 Arg2:T39
59,T40,Condition 527 536	condition
60,R17,AND Arg1:T40 Arg2:T38
61,T41,Observation 579 594	life expectancy
62,T42,Value 595 605	<12 months
63,R18,Has_value Arg1:T41 Arg2:T42
64,R19,Has_context Arg1:T40 Arg2:T41
65,T43,Condition 613 634	chronic liver disease
66,T44,Condition 636 649	renal disease
67,T45,Procedure 660 668	dialysis
68,T46,Condition 672 689	bleeding disorder
69,T47,Mood 650 659	requiring
70,R20,Has_mood Arg1:T45 Arg2:T47
71,*,OR T44 T43 T46
72,R21,AND Arg1:T44 Arg2:T45
73,T48,Condition 691 716	Atrioventricular block II
74,T49,Condition 691 713;721 724	Atrioventricular block III
75,T50,Negation 737 744	without
76,T51,Device 745 754	pacemaker
77,R22,Has_negation Arg1:T51 Arg2:T50
78,*,OR T49 T48
79,T52,Condition 781 806	dual antiplatelet therapy
80,T53,Procedure 820 838	stent implantation
81,T54,Temporal 813 819	recent
82,R23,Has_temporal Arg1:T53 Arg2:T54
83,T55,Condition 766 776	indication
84,R24,AND Arg1:T55 Arg2:T52
85,T56,Scope 766 806	indication for dual antiplatelet therapy
86,T57,Scope 813 838	recent stent implantation
87,T58,Temporal 860 891	within 90 days before inclusion
88,T59,Condition 853 859	stroke
89,T60,Condition 840 852	Debilitating
90,R25,Has_temporal Arg1:T59 Arg2:T58
91,R26,AND Arg1:T59 Arg2:T60
92,T61,Temporal 893 901	Previous
93,T62,Procedure 902 923	intracranial bleeding
94,R27,Has_temporal Arg1:T62 Arg2:T61
95,T63,Drug 940 958	immunosuppressants
96,T64,Drug 965 977	cyclosporine
97,T65,Drug 982 992	tacrolimus
98,*,OR T64 T65
99,T66,Scope 965 992	cyclosporine and tacrolimus
100,R28,Subsumes Arg1:T63 Arg2:T66
101,T67,Drug 1010 1034	strong CYP3A4-inhibitors
102,T68,Drug 1041 1053	ketoconazole
103,T69,Drug 1055 1069	clarithromycin
104,T70,Drug 1071 1081	nefazodone
105,T71,Drug 1083 1092	ritonavir
106,T72,Drug 1096 1106	atazanavir
107,*,OR T71 T72 T70 T69 T68
108,T73,"Scope 1041 1106	ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir"
109,R29,Subsumes Arg1:T67 Arg2:T73
110,T74,Non-query-able 1109 1209	Any condition that in the opinion of the investigator may interfere with adherence to trial protocol
0,T1,Person 0 8	Newborns
1,T2,Measurement 9 17	weighing
2,T3,Value 18 31	1.5kg or more
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Temporal 32 40	at birth
5,R2,Has_temporal Arg1:T2 Arg2:T4
0,T1,Condition 0 10	Overweight
1,T2,Condition 11 16	Obese
2,T3,Person 17 22	Adult
3,T4,Person 33 36	age
4,T5,Value 37 49	19 years -65
5,R1,Has_value Arg1:T4 Arg2:T5
6,*,OR T1 T2
7,R2,Subsumes Arg1:T3 Arg2:T4
8,T6,Procedure 70 89	WALI screening tool
9,T7,Value 52 60	eligible
10,R3,Has_value Arg1:T6 Arg2:T7
0,T1,Condition 14 50	Non-androgenetic causes of hair loss
1,T2,Person 53 59	Female
2,T3,Condition 74 95	androgenetic alopecia
3,T4,Procedure 120 144	anti-hair loss treatment
4,T5,Temporal 145 171	within the past six months
5,R1,Has_temporal Arg1:T4 Arg2:T5
6,T6,Condition 199 217	bleeding disorders
7,T7,Procedure 224 245	anticoagulant therapy
8,T8,Condition 273 294	chronic liver disease
9,T9,Condition 296 302	cancer
10,T10,Condition 306 333	connective tissue disorders
11,*,OR T9 T10 T8
12,T11,Temporal 350 357	current
13,T12,Condition 358 373	scalp infection
14,R2,Has_temporal Arg1:T12 Arg2:T11
15,T13,Observation 188 195	history
16,T14,Observation 262 269	history
17,*,OR T6 T7
18,T15,Scope 199 245	bleeding disorders or on anticoagulant therapy
19,R3,Has_temporal Arg1:T15 Arg2:T13
20,T16,"Scope 273 333	chronic liver disease, cancer or connective tissue disorders"
21,R4,Has_temporal Arg1:T16 Arg2:T14
0,T1,Person 12 15	age
1,T2,Value 0 11;16 24	18 years of or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Informed_consent 26 63	capable of providing informed consent
0,T1,Intoxication_considerations 0 179	Subjects with a known or suspected alcohol or drug abuse which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement.
1,T2,Qualifier 192 208	life threatening
2,T3,Condition 209 215	asthma
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,T4,Condition 231 245	asthma episode
5,T5,Qualifier 251 270	required intubation
6,T6,Procedure 260 270	intubation
7,R2,multi Arg1:T5 Arg2:T6
8,R3,Has_qualifier Arg1:T4 Arg2:T5
9,T7,Condition 298 309	hypercapnea
10,T8,Condition 311 329	respiratory arrest
11,T9,Condition 333 349	hypoxic seizures
12,T10,Temporal 350 374	within the last 6 months
13,*,OR T7 T8 T9
14,T11,"Scope 298 349	hypercapnea, respiratory arrest or hypoxic seizures"
15,R4,Has_temporal Arg1:T11 Arg2:T10
16,R5,Has_scope Arg1:T4 Arg2:T11
17,T12,"Scope 231 374	asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months"
18,R6,Subsumes Arg1:T3 Arg2:T12
19,T13,Condition 379 412	lower respiratory tract infection
20,T14,Temporal 413 449	within 7 days of the screening visit
21,R7,Has_temporal Arg1:T13 Arg2:T14
22,T15,Reference_point 434 449	screening visit
23,R8,multi Arg1:T14 Arg2:T15
24,T16,Condition 476 520	chronic obstructive pulmonary disease (COPD)
25,T17,Qualifier 524 529	other
26,T18,Condition 530 551	respiratory disorders
27,T19,Qualifier 562 568	active
28,T20,Condition 569 581	tuberculosis
29,T21,Condition 583 594	lung cancer
30,T22,Condition 596 610	bronchiectasis
31,T23,Condition 612 623	sarcoidosis
32,T24,Condition 625 638	lung fibrosis
33,T25,Condition 640 662	pulmonary hypertension
34,T26,Condition 664 690	interstitial lung diseases
35,T27,Qualifier 694 699	other
36,T28,Qualifier 700 706	active
37,T29,Condition 707 725	pulmonary diseases
38,R9,Has_qualifier Arg1:T29 Arg2:T28
39,R10,Has_qualifier Arg1:T29 Arg2:T27
40,*,OR T26 T29 T25 T24 T23 T22
41,R11,Has_qualifier Arg1:T20 Arg2:T19
42,R12,Has_qualifier Arg1:T18 Arg2:T17
43,*,OR T16 T18
44,T30,Scope 476 551	chronic obstructive pulmonary disease (COPD) or other respiratory disorders
45,T31,"Scope 562 725	active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases"
46,R13,Subsumes Arg1:T30 Arg2:T31
47,T32,Condition 739 755	hypersensitivity
48,T33,Condition 756 767	intolerance
49,T34,Drug 818 825	lactose
50,T35,Drug 827 845	magnesium stearate
51,*,OR T34 T35
52,T36,Drug 775 807	components of the study inhalers
53,T37,"Scope 818 845	lactose, magnesium stearate"
54,R14,Subsumes Arg1:T36 Arg2:T37
55,*,OR T33 T32
56,T38,Scope 739 767	hypersensitivity/intolerance
57,R15,AND Arg1:T38 Arg2:T36
58,T39,Observation 877 884	history
59,T40,Qualifier 888 894	severe
60,T41,Drug 895 907	milk protein
61,T42,Condition 908 915	allergy
62,R16,AND Arg1:T42 Arg2:T41
63,R17,Has_qualifier Arg1:T42 Arg2:T40
64,R18,Has_temporal Arg1:T42 Arg2:T39
65,T43,Non-query-able 922 959	in the opinion of the study physician
66,T44,Condition 961 990	contraindicates participation
67,R19,AND Arg1:T42 Arg2:T44
68,*,OR T38 T42
69,T45,Condition 1264 1291	hematological abnormalities
70,T46,Qualifier 1049 1071	clinically significant
71,T47,Qualifier 1075 1094	rapidly progressing
72,T48,Condition 1107 1121;1278 1291	cardiovascular abnormalities
73,T49,Qualifier 1098 1106	unstable
74,*,OR T46 T47 T49
75,T50,Scope 1049 1106	clinically significant or rapidly progressing or unstable
76,T51,Condition 1123 1135;1278 1291	neurological abnormalities
77,T52,Condition 1137 1151;1278 1291	cardiovascular abnormalities
78,T53,Condition 1153 1165;1278 1291	neurological abnormalities
79,T54,Condition 1167 1172;1278 1291	renal abnormalities
80,T55,Condition 1174 1181;1278 1291	hepatic abnormalities
81,T56,Condition 1183 1196;1278 1291	immunological abnormalities
82,T57,Condition 1198 1207;1278 1291	endocrine abnormalities
83,T58,Qualifier 1219 1231	uncontrolled
84,T59,Condition 1232 1240	diabetes
85,T60,Condition 1244 1259	thyroid disease
86,*,OR T59 T60
87,T61,Scope 1232 1259	diabetes or thyroid disease
88,R20,Has_qualifier Arg1:T61 Arg2:T58
89,R21,Subsumes Arg1:T57 Arg2:T61
90,*,OR T48 T51 T52 T53 T54 T55 T56 T57 T45
91,T62,Qualifier 1301 1313	uncontrolled
92,T63,"Scope 1107 1291	cardiovascular, neurological, cardiovascular, neurological, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities"
93,R22,Has_scope Arg1:T63 Arg2:T50
94,R23,Has_qualifier Arg1:T63 Arg2:T62
95,T64,Observation 1015 1025	Historical
96,T65,Temporal 1029 1036	current
97,*,OR T64 T65
98,T66,Scope 1015 1036	Historical or current
99,R24,Has_scope Arg1:T63 Arg2:T66
100,T67,"Non-representable 1315 1551	Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the analysis if the disease/condition exacerbated during the study."
101,T68,Procedure 1585 1594	treatment
102,T69,Drug 1634 1644	omalizumab
103,T70,Drug 1646 1657	mepolizumab
104,T71,Drug 1663 1669	asthma
105,*,OR T69 T70 T71
106,T72,"Scope 1634 1669	omalizumab, mepolizumab, for asthma"
107,R25,Has_scope Arg1:T68 Arg2:T72
108,T73,"Competing_trial 1672 1878	Subjects who have received an investigational drug and/or medical device within 30 days of entry into this study (Screening), or within five drug half-lives of the investigational drug, whichever is longer."
109,T74,"Non-query-able 1880 2134	A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, employee of the participating investigator, or any family member of a Propeller Health employee."
0,T1,Informed_consent 0 24	Written informed consent
1,T2,Person 26 29	Age
2,T3,Value 30 39	=18 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Procedure 66 79	isolated CABG
5,T5,Condition 101 124	acute coronary syndrome
6,T6,Condition 126 131	STEMI
7,T7,Condition 133 139	NSTEMI
8,T8,Condition 141 156	unstable angina
9,*,OR T6 T7 T8
10,T9,Temporal 158 187	within 6 weeks before surgery
11,T10,Reference_point 180 187	surgery
12,R2,Has_index Arg1:T9 Arg2:T10
13,T11,"Scope 126 156	STEMI, NSTEMI, unstable angina"
14,R3,Subsumes Arg1:T5 Arg2:T11
15,R4,AND Arg1:T4 Arg2:T5
16,T12,Multiplier 55 65	first time
17,R5,Has_multiplier Arg1:T4 Arg2:T12
0,T1,Person 0 8	Children
1,T2,Condition 52 71	developmental delay
2,T3,Condition 75 111	inability to communicate the effects
3,T4,Condition 118 135	allergic reaction
4,R1,AND Arg1:T3 Arg2:T4
5,T5,Qualifier 137 147	non-verbal
6,R2,Has_qualifier Arg1:T3 Arg2:T5
7,*,OR T2 T3
8,T6,Condition 155 171	contraindication
9,T7,Procedure 175 190	allergy testing
10,R3,AND Arg1:T6 Arg2:T7
11,T8,Condition 241 265	severe allergic reaction
12,T9,Procedure 269 279	skin tests
13,R4,AND Arg1:T8 Arg2:T9
14,T10,Observation 228 235	history
15,R5,Has_temporal Arg1:T8 Arg2:T10
16,T11,Condition 283 294	anaphylaxis
17,T12,Temporal 295 316	in the past six weeks
18,R6,Has_temporal Arg1:T11 Arg2:T12
19,T13,Condition 319 328	pregnancy
20,T14,Drug 346 359	antihistamine
21,T15,Temporal 360 382	in the past three days
22,T16,Drug 394 409	diphenhydramine
23,T17,Drug 411 419	Benadryl
24,T18,Drug 423 433	cetirizine
25,T19,Drug 435 441	Zyrtec
26,T20,Drug 445 455	loratadine
27,T21,Drug 457 465	Claritin
28,T22,Drug 469 481	fexofenadine
29,T23,Drug 483 490	Allegra
30,T24,Drug 494 508	levocetirizine
31,T25,Drug 510 515	Xyzal
32,T26,Drug 523 536	desloratadine
33,T27,Drug 538 546	Clarinex
34,R7,Subsumes Arg1:T16 Arg2:T17
35,R8,Subsumes Arg1:T18 Arg2:T19
36,R9,Subsumes Arg1:T20 Arg2:T21
37,R10,Subsumes Arg1:T22 Arg2:T23
38,R11,Subsumes Arg1:T24 Arg2:T25
39,R12,Subsumes Arg1:T26 Arg2:T27
40,*,OR T16 T18 T20 T22 T24 T26
41,T28,"Scope 394 548	diphenhydramine (Benadryl®), cetirizine (Zyrtec®), loratadine (Claritin®), fexofenadine (Allegra®), levocetirizine (Xyzal®), and desloratadine (Clarinex®)"
42,R13,Has_temporal Arg1:T14 Arg2:T15
43,R14,Subsumes Arg1:T14 Arg2:T28
44,T29,Drug 605 626	beta blocker medicine
45,T30,Condition 631 649	cardiac conditions
46,T31,Condition 651 670	high blood pressure
47,T32,Condition 672 690	migraine headaches
48,T33,Condition 709 717	glaucoma
49,T34,Drug 695 704	eye drops
50,T35,Drug 724 735	propranolol
51,T36,Drug 737 747	metoprolol
52,T37,Drug 749 757	atenolol
53,T38,Drug 762 770	Timoptic
54,T39,Drug 776 784	Betoptic
55,T40,Drug 786 795	eye drops
56,R15,Subsumes Arg1:T40 Arg2:T39
57,R16,AND Arg1:T33 Arg2:T34
58,*,OR T30 T31 T32
59,T41,"Scope 631 690	cardiac conditions, high blood pressure, migraine headaches"
60,R17,AND Arg1:T41 Arg2:T29
61,*,OR T35 T36 T37 T38 T40
62,T42,"Scope 724 795	propranolol, metoprolol, atenolol and Timoptic®, or Betoptic® eye drops"
63,R18,Subsumes Arg1:T34 Arg2:T42
64,*,OR T41 T33
65,T43,Person 799 807	Children
66,T44,Visit 827 830	PED
67,T45,Condition 838 842	rash
68,T46,Condition 844 852	vomiting
69,T47,Condition 864 879	asthma symptoms
70,T48,Condition 890 898	coughing
71,T49,Condition 900 908	wheezing
72,T50,Condition 912 930	breathing problems
73,*,OR T49 T50 T48
74,T51,"Scope 890 930	coughing, wheezing or breathing problems"
75,R19,Subsumes Arg1:T47 Arg2:T51
76,*,OR T46 T47 T45
77,T52,Temporal 856 863	current
78,R20,Has_temporal Arg1:T47 Arg2:T52
79,T53,Non-query-able 1014 1211	Patients being admitted to the hospital or those who are deemed too acutely ill for participation (triage level 1 or 2 or as determined by the ED patient care team) will be excluded from the study.
80,T54,Observation 1254 1274	non-English speaking
81,T55,"Non-representable 1285 1368	However, in subsequent studies we will include the non-English speaking population."
82,T56,Observation 1387 1405	wards of the state
83,T57,Observation 1410 1421	foster care
84,T58,Observation 1425 1439	police custody
85,T59,Observation 1443 1452	detention
86,*,OR T56 T57 T58 T59
87,T60,Condition 1490 1505	basal condition
88,T61,Condition 1507 1513	trauma
89,T62,Condition 1515 1524	infection
90,T63,Condition 1526 1541	minor accidents
91,*,OR T61 T62 T63
92,T64,"Scope 1507 1541	trauma, infection, minor accidents"
93,R21,Subsumes Arg1:T60 Arg2:T64
0,T1,Person 0 8	Newborns
1,T2,Condition 14 41	severe congenital anomalies
2,T3,Person 43 51	Newborns
3,T4,Condition 57 88	infection of the umbilical cord
4,T5,Temporal 89 97	at birth
5,R2,Has_temporal Arg1:T4 Arg2:T5
0,T1,Qualifier 0 13	Decompensated
1,T2,Condition 14 27	heart failure
2,T3,Condition 31 54	hemodynamic instability
3,*,OR T3 T2
4,R1,Has_qualifier Arg1:T2 Arg2:T1
5,T4,Temporal 56 61	Prior
6,T5,Condition 62 88	coronary revascularization
7,T6,Procedure 90 93	PCI
8,T7,Procedure 97 101	CABG
9,*,OR T7 T6
10,T8,Condition 106 127	myocardial infarction
11,T9,Measurement 165 171;184 190	CPK-MB levels
12,T10,Measurement 175 190	troponin levels
13,*,OR T10 T9
14,T11,Scope 165 190	CPK-MB or troponin levels
15,T12,Value 156 164	elevated
16,T13,Temporal 145 155	previously
17,R2,Has_temporal Arg1:T11 Arg2:T13
18,R3,Has_value Arg1:T11 Arg2:T12
19,T14,Scope 145 190	previously elevated CPK-MB or troponin levels
20,R4,Subsumes Arg1:T8 Arg2:T14
21,T15,Scope 90 101	PCI or CABG
22,R5,Subsumes Arg1:T5 Arg2:T15
23,*,OR T5 T8
24,R6,Has_temporal Arg1:T5 Arg2:T4
25,R7,Has_temporal Arg1:T8 Arg2:T4
26,T16,Condition 193 212	Accelerating angina
27,T17,Condition 216 231	unstable angina
28,*,OR T16 T17
29,T18,Condition 233 265	Inability to physically tolerate
30,T19,Procedure 266 269	MRI
31,T20,Device 273 290	implanted objects
32,T21,Qualifier 300 316	MRI incompatible
33,R8,Has_qualifier Arg1:T20 Arg2:T21
34,*,OR T19 T20
35,T22,Scope 266 316	MRI or implanted objects that are MRI incompatible
36,R9,Has_scope Arg1:T18 Arg2:T22
37,T23,Informed_consent 318 401	Inability to provide written informed consent obtained at time of study enrollment.
38,T24,Qualifier 403 409	Severe
39,T25,Condition 410 424	claustrophobia
40,R10,Has_qualifier Arg1:T25 Arg2:T24
41,T26,Condition 450 472	sinus node dysfunction
42,T27,Condition 435 446	heart block
43,T28,Qualifier 426 434	Advanced
44,*,OR T27 T26
45,T29,Scope 435 472	heart block or sinus node dysfunction
46,R11,Has_qualifier Arg1:T29 Arg2:T28
47,T30,Condition 474 490	Hypersensitivity
48,T31,Condition 494 502	allergic
49,*,OR T31 T30
50,T32,Drug 515 526	regadenoson
51,T33,Drug 530 539	adenosine
52,*,OR T32 T33
53,T34,Scope 515 539	regadenoson or adenosine
54,T35,Scope 474 502	Hypersensitivity or allergic
55,R12,Has_scope Arg1:T35 Arg2:T34
56,T36,Condition 541 552	Hypotension
57,T37,Qualifier 554 560	Active
58,T38,Condition 561 573	bronchospasm
59,T39,Observation 577 584	history
60,T40,Procedure 588 603	hospitalization
61,T41,Condition 611 623	bronchospasm
62,R13,AND Arg1:T40 Arg2:T41
63,R14,Has_temporal Arg1:T40 Arg2:T39
64,R15,Has_qualifier Arg1:T38 Arg2:T37
65,*,OR T38 T40
66,T42,Observation 625 632	History
67,T43,Condition 636 644	seizures
68,R16,Has_temporal Arg1:T43 Arg2:T42
69,T44,Temporal 646 652	Recent
70,T45,Condition 653 677	cerebrovascular accident
71,R17,Has_temporal Arg1:T45 Arg2:T44
72,T46,Drug 686 698	dipyridamole
73,T47,Temporal 699 721	within the last 5 days
74,R18,Has_temporal Arg1:T46 Arg2:T47
75,T48,Condition 723 739	Contraindication
76,T49,Drug 743 756	aminophylline
77,R19,AND Arg1:T48 Arg2:T49
78,T50,Qualifier 758 764	Severe
79,T51,Condition 765 784	renal insufficiency
80,T52,Measurement 790 826	estimated glomerular filtration rate
81,T53,Value 827 846	<30 ml/min/ 1.73 m2
82,R20,Has_value Arg1:T52 Arg2:T53
83,R21,Has_qualifier Arg1:T51 Arg2:T50
84,R22,AND Arg1:T51 Arg2:T52
85,T54,Condition 848 856	Pregnant
86,T55,Condition 860 867	nursing
87,*,OR T54 T55
0,T1,Condition 0 18	contra-indications
1,T2,Procedure 23 47	regular dental treatment
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Observation 49 64	medical history
4,T4,Condition 70 85	contraindicates
5,T5,Drug 97 108	epinephrine
6,R2,AND Arg1:T4 Arg2:T5
7,R3,Has_temporal Arg1:T4 Arg2:T3
8,T6,Drug 131 137	opioid
9,T7,Drug 144 165	opioid like analgesic
10,T8,Temporal 166 181	within 24 hours
11,*,OR T6 T7
12,T9,Scope 131 165	opioid or an opioid like analgesic
13,R4,Has_temporal Arg1:T9 Arg2:T8
14,T10,Condition 183 191	pregnant
0,T1,Person 0 4	male
1,T2,Condition 19 40	androgenetic alopecia
2,T3,Value 41 70	between 18 years and 60 years
3,T4,Person 65 70	years
4,R1,Has_value Arg1:T4 Arg2:T3
0,T1,Observation 0 40	Inability to understand and read English
1,T2,Person 43 48	Women
2,T3,Condition 49 57	pregnant
3,T4,Condition 61 70	lactating
4,*,OR T3 T4
5,T5,Condition 86 102	terminal illness
0,T1,Person 0 5	Women
1,T2,Procedure 19 23	ICSI
2,T3,Procedure 43 67	ovarian hyperstimulation
3,T4,Procedure 69 72	COH
4,T5,Procedure 79 103	pituitary downregulation
5,T6,Procedure 107 122	GnRH antagonist
6,R1,Subsumes Arg1:T3 Arg2:T4
7,T7,Scope 43 103	ovarian hyperstimulation (COH) with pituitary downregulation
8,R2,AND Arg1:T2 Arg2:T6
9,R3,Has_scope Arg1:T6 Arg2:T7
0,T1,Qualifier 0 6	Severe
1,T2,Condition 7 16	deformity
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 18 23	varus
4,T4,Measurement 27 54	values from mechanical axis
5,T5,Value 55 74	more than 5 degrees
6,R2,Has_value Arg1:T4 Arg2:T5
7,*,OR T3 T4
8,T6,Scope 18 74	varus or values from mechanical axis more than 5 degrees
9,R3,Subsumes Arg1:T2 Arg2:T6
10,T7,Condition 76 83	Allergy
11,T8,Drug 87 102	hyaluronic acid
12,R4,AND Arg1:T7 Arg2:T8
13,T9,Condition 104 108	Pain
14,T10,Qualifier 112 115	hip
15,T11,Qualifier 119 124	ankle
16,*,OR T10 T11
17,T12,Scope 112 124	hip or ankle
18,R5,Has_scope Arg1:T9 Arg2:T12
19,T13,Temporal 126 140;157 175	Post-traumatic of lower extremity
20,T14,Temporal 144 175	post surgery of lower extremity
21,*,OR T13 T14
22,T15,Condition 182 199	infection of knee
23,T16,Temporal 177 181	Post
24,R6,Has_temporal Arg1:T15 Arg2:T16
25,T17,Drug 210 225	hyaluronic acid
26,T18,Procedure 210 235	hyaluronic acid injection
27,R7,multi Arg1:T18 Arg2:T17
28,T19,Temporal 236 251	within 6 months
29,R8,Has_temporal Arg1:T18 Arg2:T19
30,T20,Temporal 201 209	Previous
31,R9,Has_temporal Arg1:T18 Arg2:T20
32,T21,Condition 253 262	Pregnancy
33,T22,Condition 266 275	lactation
34,*,OR T21 T22
35,T23,Condition 288 308	Rheumatoid arthritis
36,T24,Condition 310 316	stroke
37,T25,Condition 318 328	malignancy
38,T26,Condition 330 346	venous occlusion
39,*,OR T26 T25 T24 T23
40,T27,"Scope 288 346	Rheumatoid arthritis, stroke, malignancy, venous occlusion"
41,T28,Qualifier 277 287	Underlying
42,R10,Has_qualifier Arg1:T27 Arg2:T28
0,T1,Person 0 6	Female
1,T2,Value 12 21	≥18 years
2,T3,Person 8 11	Age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Condition 39 45	lesion
5,T5,Value 46 54	> 0.5 cm
6,T6,Measurement 58 79	largest diameter size
7,R2,Has_value Arg1:T6 Arg2:T5
8,T7,Measurement 98 106	BI-RADS®
9,T8,"Value 107 122	3, 4a, 4b or 4c"
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Procedure 126 143	B-mode ultrasound
12,R4,AND Arg1:T9 Arg2:T7
13,R5,AND Arg1:T4 Arg2:T6
14,R6,AND Arg1:T4 Arg2:T9
15,T10,Procedure 168 192	histological examination
16,T11,Procedure 194 215	core cut biopsy (CCB)
17,T12,Procedure 217 245	vacuum-assisted biopsy (VAB)
18,T13,Procedure 247 275	fine needle aspiration (FNA)
19,T14,Procedure 279 286	surgery
20,*,OR T14 T13 T12 T11
21,T15,"Scope 194 286	core cut biopsy (CCB), vacuum-assisted biopsy (VAB), fine needle aspiration (FNA) or surgery"
22,R7,Subsumes Arg1:T10 Arg2:T15
23,T16,Post-eligibility 145 161	Informed consent
24,T17,Post-eligibility 346 392	Signed informed consent of study participation
0,T1,Condition 12 31	low ovarian reserve
1,T3,Measurement 66 69	AMH
2,T2,"Value 70 81	= 1,5 ng/mL"
3,T4,Measurement 89 103	basal CD 3 FSH
4,T5,Value 104 115	= 10 mIU/mL
5,T6,Measurement 123 143	basal CD 3 Estradiol
6,T7,Value 144 154	= 60 ng/mL
7,T8,Measurement 171 191	egg collection yield
8,T9,Value 192 203	= 3 oocytes
9,R1,Has_value Arg1:T3 Arg2:T2
10,R2,Has_value Arg1:T4 Arg2:T5
11,R3,Has_value Arg1:T6 Arg2:T7
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,"Scope 66 203	AMH = 1,5 ng/mL and/or basal CD 3 FSH = 10 mIU/mL and/or basal CD 3 Estradiol = 60 ng/mL and/or previous egg collection yield = 3 oocytes"
14,*,OR T3 T4 T6 T8
15,R5,Subsumes Arg1:T1 Arg2:T10
16,T11,Condition 237 252	thyroid disease
17,T12,Condition 254 271	diabetes mellitus
18,T13,Condition 273 285	hypertension
19,T14,Condition 287 307	pulmonary conditions
20,T15,Condition 309 326	cardiac condition
21,*,OR T11 T12 T13 T14 T15
22,T16,Condition 338 361	male factor infertility
23,T17,Qualifier 331 337	Severe
24,R6,Has_qualifier Arg1:T16 Arg2:T17
25,T18,Measurement 363 387	Total motile sperm count
26,T19,Value 388 402	< 5 million/ml
27,T20,Measurement 410 431	normal WHO morphology
28,T21,Value 432 436	<20%
29,R7,Has_value Arg1:T18 Arg2:T19
30,R8,Has_value Arg1:T20 Arg2:T21
31,*,OR T18 T20
32,T22,Scope 363 436	Total motile sperm count < 5 million/ml and/or normal WHO morphology <20%
33,R9,Subsumes Arg1:T16 Arg2:T22
34,T23,Condition 440 456	Hypersensitivity
35,T24,Drug 460 467	Heparin
36,R10,AND Arg1:T23 Arg2:T24
37,T25,Condition 498 511	thrombophilia
38,T26,Qualifier 489 497	Acquired
39,R11,Has_qualifier Arg1:T25 Arg2:T26
40,T27,Condition 514 531	Active hemorrhage
41,T28,Observation 545 561	risk of bleeding
42,T29,Qualifier 535 544	increased
43,R12,Has_qualifier Arg1:T28 Arg2:T29
44,T30,Condition 569 594	impairment of homeostasis
45,R13,AND Arg1:T28 Arg2:T30
46,*,OR T27 T28
47,T31,Condition 604 623	impairment of liver
48,T32,Condition 604 617;627 646	impairment of pancreatic function
49,*,OR T31 T32
50,T33,Scope 604 646	impairment of liver or pancreatic function
51,T34,Qualifier 597 603	Severe
52,R14,Has_qualifier Arg1:T33 Arg2:T34
53,T35,Qualifier 649 655	Severe
54,T36,Condition 656 675	renal insufficiency
55,R15,Has_qualifier Arg1:T36 Arg2:T35
56,T37,Measurement 677 697	Creatinine Clearance
57,T38,Value 698 709	< 30 ml/min
58,R16,Has_value Arg1:T37 Arg2:T38
59,R17,Subsumes Arg1:T36 Arg2:T37
60,T39,Procedure 728 738	operations
61,T40,Condition 713 721	Injuries
62,T41,Qualifier 746 768	central nervous system
63,T42,Qualifier 770 774	eyes
64,T43,Qualifier 779 783	ears
65,T44,Temporal 795 808	last 2 months
66,*,OR T43 T42 T41
67,T45,"Scope 746 783	central nervous system, eyes and ears"
68,*,OR T39 T40
69,T46,Scope 713 738	Injuries to or operations
70,R18,Has_scope Arg1:T46 Arg2:T45
71,R19,Has_temporal Arg1:T46 Arg2:T44
72,T47,Condition 811 849	Disseminated Intravascular Coagulation
73,T48,Condition 851 854	DIC
74,R20,Subsumes Arg1:T47 Arg2:T48
75,T49,Condition 872 904	heparin-induced thrombocytopenia
76,R21,AND Arg1:T47 Arg2:T49
77,T50,Condition 940 958	endocarditis lenta
78,T51,Condition 907 935	Acute bacterial endocarditis
79,*,OR T50 T51
80,T52,Condition 965 979	organic lesion
81,T53,Observation 990 1006	risk of bleeding
82,T54,Qualifier 985 989	high
83,R22,Has_qualifier Arg1:T53 Arg2:T54
84,R23,Has_context Arg1:T52 Arg2:T53
85,T55,Condition 1014 1033	active peptic ulcer
86,T56,Condition 1035 1053	hemorrhagic stroke
87,T57,Condition 1055 1072	cerebral aneurysm
88,T58,Condition 1076 1094	cerebral neoplasms
89,*,OR T55 T56 T57 T58
90,T59,"Scope 1014 1094	active peptic ulcer, hemorrhagic stroke, cerebral aneurysm or cerebral neoplasms"
91,R24,Subsumes Arg1:T53 Arg2:T59
0,T2,Person 21 24	age
1,T1,Value 7 17	= 18 years
2,T3,Person 0 6	Adults
3,R1,Has_value Arg1:T2 Arg2:T1
4,T4,Visit 42 45	ICU
5,T5,Procedure 69 91	mechanical ventilation
6,T6,Qualifier 60 68	invasive
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Temporal 120 129	=72 hours
9,T8,Procedure 105 116	ventilation
10,T9,Mood 93 104	Anticipated
11,R3,Has_mood Arg1:T8 Arg2:T9
12,R4,Has_temporal Arg1:T8 Arg2:T7
0,T1,Person 0 5	Adult
1,T2,Measurement 51 54	MDS
2,T3,Value 31 50	intermediate-1 risk
3,T4,Value 24 27;46 50	low risk
4,*,OR T3 T4
5,T5,Scope 24 50	low or intermediate-1 risk
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Drug 83 111	hematopoietic growth factors
8,T7,Temporal 112 146	within 3 months prior to screening
9,T8,Reference_point 137 146	screening
10,R2,Has_index Arg1:T7 Arg2:T8
11,R3,Has_temporal Arg1:T6 Arg2:T7
12,T9,Condition 160 166	anemia
13,T10,Qualifier 148 159	Symptomatic
14,R4,Has_qualifier Arg1:T9 Arg2:T10
15,T11,Measurement 168 178	hemoglobin
16,T12,Value 179 187	<10 g/dL
17,R5,Has_value Arg1:T11 Arg2:T12
18,R6,AND Arg1:T9 Arg2:T11
19,T13,Measurement 220 240	Serum erythropoietin
20,T14,Value 241 267	<500 milliunits/milliliter
21,T15,Temporal 276 333	within 14 days prior to the first dose of study treatment
22,R7,Has_value Arg1:T13 Arg2:T14
23,R8,Has_temporal Arg1:T13 Arg2:T15
24,T16,Procedure 346 372	red blood cell transfusion
25,T17,Negation 343 345	no
26,T18,Multiplier 389 397	<4 units
27,T19,Temporal 398 431	within 8 weeks prior to screening
28,R9,Has_multiplier Arg1:T16 Arg2:T18
29,R10,Has_negation Arg1:T16 Arg2:T17
30,R11,Has_temporal Arg1:T16 Arg2:T19
31,T20,Condition 444 450	stable
32,T21,Temporal 451 501	for at least 1 month prior to entry into the study
33,R12,Has_temporal Arg1:T20 Arg2:T21
34,T22,Reference_point 481 501	entry into the study
35,R13,Has_index Arg1:T21 Arg2:T22
36,T23,"Pregnancy_considerations 503 707	For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception"
0,T1,Condition 0 17	COPD exacerbation
1,T2,Condition 31 35	COPD
2,T3,Qualifier 19 30	very severe
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 41 50	hypoxemia
5,T5,Qualifier 54 66	low altitude
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Measurement 68 76	FEV1/FVC
8,T7,Value 77 81	<0.7
9,T8,Measurement 83 87	FEV1
10,T9,Value 88 102	<40% predicted
11,T10,Measurement 104 121	oxygen saturation
12,T11,Qualifier 125 133	room air
13,R3,Has_qualifier Arg1:T10 Arg2:T11
14,T12,Value 134 147	<92% at 750 m
15,R4,Has_value Arg1:T10 Arg2:T12
16,R5,Has_value Arg1:T8 Arg2:T9
17,R6,Has_value Arg1:T6 Arg2:T7
18,*,OR T6 T8 T10
19,T13,"Scope 68 147	FEV1/FVC <0.7, FEV1 <40% predicted, oxygen saturation on room air <92% at 750 m"
20,R7,Has_scope Arg1:T4 Arg2:T13
21,R8,AND Arg1:T2 Arg2:T4
22,R9,AND Arg1:T1 Arg2:T2
23,T14,Condition 151 164	Comorbidities
24,T15,Condition 186 208	cardiovascular disease
25,T16,Qualifier 173 185	uncontrolled
26,R10,Has_qualifier Arg1:T15 Arg2:T16
27,T17,Condition 225 255	systemic arterial hypertension
28,T18,Qualifier 216 224	unstable
29,T19,Condition 257 280	coronary artery disease
30,T20,Condition 291 297	stroke
31,T21,Qualifier 282 290	previous
32,R11,Has_qualifier Arg1:T20 Arg2:T21
33,T22,Condition 299 302	OSA
34,T23,Condition 304 316	pneumothorax
35,T24,Temporal 317 337	in the last 2 months
36,R12,Has_qualifier Arg1:T17 Arg2:T18
37,T25,"Scope 216 280	unstable systemic arterial hypertension, coronary artery disease"
38,*,OR T17 T19
39,R13,Has_scope Arg1:T15 Arg2:T25
40,*,OR T15 T20 T22 T23
41,R14,Has_temporal Arg1:T23 Arg2:T24
42,T26,"Scope 173 337	uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months"
43,R15,Subsumes Arg1:T14 Arg2:T26
44,T27,Condition 379 398	psychiatric disease
45,T28,Condition 362 375;391 398	rheumatologic disease
46,T29,Condition 350 360;391 398	neurologic disease
47,T30,Condition 340 348;391 398	Internal disease
48,T31,Observation 417 430	heavy smoking
49,T32,Multiplier 432 454	>20 cigarettes per day
50,R16,Has_multiplier Arg1:T31 Arg2:T32
51,*,OR T27 T30 T29 T28 T31
52,T33,Condition 463 476	renal failure
53,T34,Condition 480 487	allergy
54,T35,Drug 491 504	acetazolamide
55,T36,Drug 515 527	sulfonamides
56,*,OR T35 T36
57,T37,Scope 491 527	acetazolamide and other sulfonamides
58,R17,Has_scope Arg1:T34 Arg2:T37
59,*,OR T33 T34
0,T1,Qualifier 0 11	Symptomatic
1,T2,Qualifier 12 19	primary
2,T3,Qualifier 20 24	knee
3,T4,Condition 25 39	osteoarthritis
4,R1,Has_qualifier Arg1:T4 Arg2:T3
5,R2,Has_qualifier Arg1:T4 Arg2:T2
6,R3,Has_qualifier Arg1:T4 Arg2:T1
7,T5,Procedure 52 74	conservative treatment
8,T6,Qualifier 45 51	failed
9,R4,Has_qualifier Arg1:T5 Arg2:T6
10,T7,Temporal 75 92	at least 3 months
11,R5,Has_temporal Arg1:T5 Arg2:T7
12,T8,Measurement 94 117	Kellgren-Lawrence grade
13,T9,Value 118 123	I-III
14,R6,Has_value Arg1:T8 Arg2:T9
15,T10,Informed_consent 125 146	Gave informed consent
16,T11,Observation 148 169	Can do questionnaires
0,T1,Condition 0 8	Pregnant
1,T2,Condition 12 21	lactating
2,T3,Person 22 27	women
3,*,OR T2 T1
4,T4,Person 29 34	Women
5,T5,Device 40 55	breast implants
6,T6,Qualifier 63 86	same side as the lesion
7,T7,Reference_point 76 86	the lesion
8,R1,Has_index Arg1:T6 Arg2:T7
9,R2,Has_qualifier Arg1:T5 Arg2:T6
10,T8,Procedure 109 124	local radiation
11,T9,Procedure 128 140	chemotherapy
12,T10,Temporal 141 166	within the last 12 months
13,*,OR T9 T8
14,R3,Has_temporal Arg1:T9 Arg2:T10
15,R4,Has_temporal Arg1:T8 Arg2:T10
16,T11,Person 88 93	Women
17,T12,Person 168 173	Women
18,T13,Condition 190 203	breast cancer
19,T14,Condition 207 221	breast surgery
20,T15,Qualifier 229 242	same quadrant
21,R5,Has_qualifier Arg1:T14 Arg2:T15
22,R6,Has_qualifier Arg1:T13 Arg2:T15
23,*,OR T14 T13
24,T16,Condition 244 251	Lesions
25,T17,Qualifier 252 278	in or close to scar tissue
26,T18,Value 280 285	< 1cm
27,R7,Has_value Arg1:T17 Arg2:T18
28,R8,Has_qualifier Arg1:T16 Arg2:T17
29,T19,Condition 288 300	Skin lesions
30,T20,Condition 304 311	lesions
31,*,OR T20 T19
32,T21,Procedure 327 335	biopsied
33,T22,Temporal 336 346	previously
34,R9,Has_temporal Arg1:T21 Arg2:T22
35,T23,Condition 348 354	Lesion
36,T24,Value 355 371	larger than 4 cm
37,T25,Measurement 379 396	longest dimension
38,R10,AND Arg1:T23 Arg2:T25
39,R11,Has_value Arg1:T25 Arg2:T24
40,T26,Condition 401 407	lesion
41,T27,Multiplier 432 459	more than 50% of the lesion
42,T28,Value 463 485	further down than 4 cm
43,T29,Measurement 486 508	beneath the skin level
44,R12,Has_value Arg1:T29 Arg2:T28
45,R13,Has_multiplier Arg1:T26 Arg2:T27
46,R14,AND Arg1:T26 Arg2:T29
0,T1,Condition 19 32	endometriosis
1,T2,Qualifier 12 18	severe
2,T3,Qualifier 0 8	Moderate
3,*,OR T3 T2
4,T4,Scope 0 18	Moderate or severe
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 35 47	Hydrosalpinx
7,T6,Condition 50 71	Uterine abnormalities
8,T7,Condition 74 79	Myoma
9,T8,Procedure 91 106	uterine surgery
0,T1,Person 0 4	Male
1,T2,Person 9 15	female
2,T3,Person 26 29	age
3,T4,Value 30 39	18-75 yrs
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T5,Condition 42 46	COPD
7,T6,Measurement 70 74	GOLD
8,T7,Measurement 76 80	FEV1
9,T8,Value 81 97	40-80% predicted
10,T9,Measurement 99 103	SpO2
11,T10,Value 104 117	=92% at 750 m
12,R2,Has_value Arg1:T7 Arg2:T8
13,R3,Has_value Arg1:T9 Arg2:T10
14,T11,"Scope 76 117	FEV1 40-80% predicted, SpO2 =92% at 750 m"
15,R4,Has_scope Arg1:T6 Arg2:T11
16,R5,AND Arg1:T6 Arg2:T5
17,T12,"Non-query-able 120 177	Born, raised and currently living at low altitude (<800m)"
18,T13,Post-eligibility 180 204	Written informed consent
0,T1,Condition 0 17	Contraindications
1,T2,Condition 31 47	hypersensitivity
2,T3,Procedure 104 126	epoetin beta treatment
3,*,OR T1 T2
4,T4,Scope 0 47	Contraindications and/or known hypersensitivity
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 146 158	hypertension
7,T6,Qualifier 128 145	Poorly controlled
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Condition 203 225	Acute Myeloid Leukemia
10,T8,Condition 227 230	AML
11,T9,Observation 240 252	risk for AML
12,T10,Qualifier 235 239	high
13,R3,Subsumes Arg1:T7 Arg2:T8
14,*,OR T7 T9
15,R4,Has_qualifier Arg1:T9 Arg2:T10
16,T11,Competing_trial 254 367	Administration of another investigational drug within 1 month before screening or planned during the study period
17,T12,Condition 403 424	Pure Red Cell Aplasia
18,T13,Condition 426 430	PRCA
19,R5,Subsumes Arg1:T12 Arg2:T13
0,T1,Procedure 11 34	mechanically ventilated
1,T2,Temporal 35 44	>72 hours
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Observation 104 142	risk of iatrogenic probiotic infection
4,T4,Condition 205 222	immunocompromised
5,T5,Condition 236 239	HIV
6,T6,Measurement 245 248	CD4
7,T7,Value 240 244;249 257	<200 cells/µL
8,R2,Has_value Arg1:T6 Arg2:T7
9,R3,AND Arg1:T5 Arg2:T6
10,T8,Procedure 283 312	immunosuppressive medications
11,T9,Qualifier 275 282	chronic
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Drug 320 332	azathioprine
14,T11,Drug 334 346	cyclosporine
15,T12,Drug 348 364	cyclophosphamide
16,T13,Drug 366 376	tacrolimus
17,T14,Drug 378 390	methotrexate
18,T15,Drug 392 404	mycofenolate
19,T16,Drug 406 414	Anti-IL2
20,*,OR T10 T11 T12 T13 T14 T15 T16
21,T17,"Scope 320 414	azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate, Anti-IL2"
22,R5,Subsumes Arg1:T8 Arg2:T17
23,T18,Procedure 426 441	transplantation
24,T19,Procedure 498 510	chemotherapy
25,T20,Temporal 518 531	last 3 months
26,R6,Has_temporal Arg1:T19 Arg2:T20
27,T21,Condition 533 544	neutropenia
28,T22,Measurement 546 571	absolute neutrophil count
29,T23,Value 572 578	< 500]
30,R7,Has_value Arg1:T22 Arg2:T23
31,R8,AND Arg1:T21 Arg2:T22
32,T24,"Scope 205 579	immunocompromised populations (HIV <200 CD4 cells/µL, those receiving chronic immunosuppressive medications (e.g., azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate, Anti-IL2), previous transplantation (including stem cell) at any time, malignancy requiring chemotherapy in the last 3 months, neutropenia [absolute neutrophil count < 500])"
33,R9,Subsumes Arg1:T3 Arg2:T24
34,R10,Subsumes Arg1:T4 Arg2:T5
35,*,OR T4 T8 T18 T19 T21
36,T25,Observation 720 751	risk for endovascular infection
37,T26,Condition 775 798	rheumatic heart disease
38,T27,Condition 800 824	congenital valve disease
39,T28,Condition 846 870	congenital heart disease
40,T29,Qualifier 826 845	surgically repaired
41,R11,Has_qualifier Arg1:T28 Arg2:T29
42,T30,Condition 883 916	cyanotic congenital heart disease
43,T31,Qualifier 872 882	unrepaired
44,R12,Has_qualifier Arg1:T30 Arg2:T31
45,T32,Procedure 922 941	intracardiac repair
46,T33,Device 947 966	prosthetic material
47,R13,AND Arg1:T32 Arg2:T33
48,T34,Device 982 1012	bio-prosthetic cardiac valves]
49,T35,Device 968 978;997 1011	mechanical cardiac valves
50,*,OR T34 T35
51,T36,Scope 968 1011	mechanical or bio-prosthetic cardiac valves
52,R14,Subsumes Arg1:T33 Arg2:T36
53,T37,Condition 1034 1046	endocarditis
54,T38,Device 1058 1078	endovascular devices
55,T39,Qualifier 1048 1057	permanent
56,R15,Has_qualifier Arg1:T38 Arg2:T39
57,T40,Device 1086 1105	endovascular grafts
58,T41,Procedure 1113 1135	aortic aneurysm repair
59,T42,Device 1137 1143	stents
60,T43,Qualifier 1154 1168	large arteries
61,R16,Has_qualifier Arg1:T42 Arg2:T43
62,T44,Device 1208 1234	inferior vena cava filters
63,T45,Device 1236 1260	dialysis vascular grafts
64,T46,Device 1290 1312	hemodialysis catheters
65,T47,Device 1314 1324	pacemakers
66,T48,Device 1368 1392	central venous catheters
67,T49,Device 1394 1427	central venous dialysis catheters
68,T50,Device 1431 1470	peripherally inserted central catheters
69,T51,Negation 1483 1486	not
70,T52,Negation 1602 1605	not
71,T53,Device 1514 1536	coronary artery stents
72,T54,Device 1538 1567	coronary artery bypass grafts
73,T55,Device 1578 1597	neurovascular coils
74,T56,Negation 1681 1684	not
75,T57,Condition 1630 1651	mitral valve prolapse
76,T58,Condition 1655 1676	bicuspid aortic valve
77,*,OR T57 T58
78,T59,Scope 1630 1676	mitral valve prolapse or bicuspid aortic valve
79,R17,Has_negation Arg1:T59 Arg2:T56
80,*,OR T55 T54 T53
81,T60,"Scope 1514 1597	coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils"
82,R18,Has_negation Arg1:T60 Arg2:T52
83,*,OR T48 T49 T50
84,T61,Device 1472 1477	PICCs
85,R19,Subsumes Arg1:T50 Arg2:T61
86,T62,"Scope 1368 1478	central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs)"
87,R20,Has_negation Arg1:T62 Arg2:T51
88,*,OR T62 T60 T59
89,*,OR T47 T46 T38 T33 T30 T28 T27 T26
90,T63,"Scope 1086 1260	endovascular grafts [e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids], inferior vena cava filters, dialysis vascular grafts"
91,R21,Subsumes Arg1:T38 Arg2:T63
92,*,OR T41 T42
93,*,OR T40 T44 T45
94,T64,"Scope 753 1741	previously documented rheumatic heart disease, congenital valve disease, surgically repaired congenital heart disease, unrepaired cyanotic congenital heart disease, any intracardiac repair with prosthetic material [mechanical or bio-prosthetic cardiac valves], previous or current endocarditis, permanent endovascular devices (e.g., endovascular grafts [e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids], inferior vena cava filters, dialysis vascular grafts), tunnelled (not short-term) hemodialysis catheters, pacemakers or defibrillators. Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria"
95,R22,Subsumes Arg1:T25 Arg2:T64
96,T65,Condition 1788 1806	acute pancreatitis
97,T66,Qualifier 1781 1787	severe
98,R23,Has_qualifier Arg1:T65 Arg2:T66
99,T67,Negation 1808 1815	without
100,T68,Measurement 1831 1843	Ranson score
101,R24,Has_negation Arg1:T68 Arg2:T67
102,R25,AND Arg1:T65 Arg2:T68
103,T69,Negation 1917 1920	not
104,T70,Condition 1900 1912	pancreatitis
105,T71,Qualifier 1883 1887	mild
106,T72,Qualifier 1891 1899	moderate
107,*,OR T71 T72
108,T73,Scope 1883 1899	mild or moderate
109,R26,Has_scope Arg1:T70 Arg2:T73
110,R27,Has_negation Arg1:T70 Arg2:T69
111,T74,Device 1970 1991	jejunal feeding tubes
112,T75,Device 1959 1966;1978 1991	gastric feeding tubes
113,T76,Condition 2047 2063	contraindication
114,T77,Procedure 2088 2107	enteral medications
115,R28,AND Arg1:T76 Arg2:T77
116,T78,Non-query-able 2110 2175	Intent to withdraw advanced life support as per the ICU physician
117,T79,Competing_trial 2178 2259	Previous enrolment in this or current enrolment in a potentially confounding tria
0,T1,Multiplier 11 24	three or more
1,T2,Qualifier 25 38;39 45	consecutively failed
2,T3,Procedure 46 68	In Vitro Fertilization
3,T4,Procedure 70 73	IVF
4,R1,Subsumes Arg1:T3 Arg2:T4
5,T5,Temporal 82 103	after embryo transfer
6,T6,Reference_point 88 103	embryo transfer
7,R2,Has_index Arg1:T5 Arg2:T6
8,R3,Has_qualifier Arg1:T3 Arg2:T2
9,R4,Has_multiplier Arg1:T3 Arg2:T1
10,R5,Has_temporal Arg1:T3 Arg2:T5
11,T7,Observation 113 127	uterine cavity
12,T8,Value 106 112	Normal
13,R6,Has_value Arg1:T7 Arg2:T8
14,T9,Procedure 144 156	hysteroscopy
15,T10,Procedure 160 163	HSG
16,*,OR T9 T10
17,T11,Scope 144 163	hysteroscopy or HSG
18,R7,Has_context Arg1:T11 Arg2:T7
19,T12,Procedure 174 197	hormonal investigation:
20,T13,Value 167 173	Normal
21,T14,Measurement 198 201	TSH
22,T15,Measurement 203 206	PRL
23,T16,Measurement 208 211	FBS
24,T17,"Scope 198 211	TSH, PRL, FBS"
25,R8,Subsumes Arg1:T12 Arg2:T17
26,R9,Has_value Arg1:T12 Arg2:T13
27,T18,Measurement 240 261	thrombophilia profile
28,T19,Value 214 220	Normal
29,R10,Has_value Arg1:T18 Arg2:T19
30,T20,Measurement 263 266	LAC
31,T21,Measurement 268 275	ACA IgG
32,T22,Measurement 281 287	Prot S
33,T23,Measurement 289 305	Antithrombin III
34,T24,Measurement 268 271;276 279	ACA IgM
35,T25,Measurement 307 326	beta-2 glycoprotein
36,T26,Measurement 328 337	Factors V
37,T27,Measurement 328 335;339 341	Factors II
38,T28,Measurement 343 348	MTHFR
39,T29,"Scope 263 348	LAC, ACA IgG/IgM, Prot S, Antithrombin III, beta-2 glycoprotein, Factors V, II, MTHFR"
40,R11,Subsumes Arg1:T18 Arg2:T29
41,T30,Measurement 358 372	semen analysis
42,T31,Condition 391 402	male factor
43,T32,Qualifier 382 390	moderate
44,T33,Qualifier 377 381	mild
45,*,OR T32 T33
46,T34,Scope 377 390	mild/moderate
47,R12,Has_scope Arg1:T31 Arg2:T34
48,T35,Measurement 404 428	Total motile sperm count
49,T36,Value 429 443	> 5 million/ml
50,T37,Measurement 451 472	normal WHO morphology
51,T38,Value 473 477	>20%
52,R13,Has_value Arg1:T35 Arg2:T36
53,R14,Has_value Arg1:T37 Arg2:T38
54,T39,Scope 404 477	Total motile sperm count > 5 million/ml and/or normal WHO morphology >20%
55,*,OR T35 T37
56,R15,Subsumes Arg1:T31 Arg2:T39
57,T40,Informed_consent 480 521	Patient provides written informed consent
0,T1,Condition 6 15	trombosis
1,T2,Temporal 0 5	Prior
2,T3,Condition 19 40	myocardial infarction
3,T4,Condition 42 73	congenital coagulation disorder
4,T5,Drug 82 97	anti-coagulants
5,T6,Temporal 98 114	prior to surgery
6,T7,Temporal 116 121	prior
7,T8,Procedure 122 138	thoracic surgery
8,T9,Condition 140 149	pregnancy
9,T10,Temporal 151 164	pre-operative
10,T11,Measurement 165 189	fibrinogen concentration
11,T12,Value 190 195	<1g/L
12,R1,Has_value Arg1:T11 Arg2:T12
13,R2,Has_temporal Arg1:T11 Arg2:T10
14,R3,Has_temporal Arg1:T8 Arg2:T7
15,R4,Has_temporal Arg1:T5 Arg2:T6
16,*,OR T4 T3 T8 T9 T11 T5 T1
17,R5,Has_temporal Arg1:T1 Arg2:T2
0,T1,Condition 4 6	MS
1,T2,Condition 7 14	relapse
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Temporal 15 37	in the last five years
4,R2,Has_temporal Arg1:T2 Arg2:T3
5,T4,Condition 116 131	T2/FLAIR lesion
6,T5,Drug 139 149	gadolinium
7,T6,Qualifier 139 159	gadolinium-enhancing
8,T7,Condition 160 166	lesion
9,R3,Has_qualifier Arg1:T7 Arg2:T6
10,T8,Temporal 167 194	within the past three years
11,T9,Multiplier 196 208	at least two
12,T10,Procedure 209 214	scans
13,T11,Temporal 215 248	separated by at least three years
14,R4,Has_multiplier Arg1:T10 Arg2:T9
15,R5,Has_temporal Arg1:T10 Arg2:T11
16,T12,Procedure 279 293	spine MRI scan
17,T13,Procedure 270 275;285 293	brain MRI scan
18,*,OR T12 T13
19,T14,Qualifier 311 324	3mm or larger
20,T15,Condition 295 302	Lesions
21,R6,Has_qualifier Arg1:T15 Arg2:T14
22,*,OR T7 T4
23,T16,Scope 116 166	T2/FLAIR lesion or new gadolinium-enhancing lesion
24,R9,Has_temporal Arg1:T16 Arg2:T8
25,R10,AND Arg1:T16 Arg2:T10
26,R7,Subsumes Arg1:T16 Arg2:T15
27,R8,Has_qualifier Arg1:T16 Arg2:T14
28,T17,Qualifier 346 357	Significant
29,T18,Condition 381 392	intolerance
30,T19,Temporal 396 410	presently-used
31,T20,Drug 411 414	DMT
32,R11,Has_temporal Arg1:T20 Arg2:T19
33,R12,AND Arg1:T18 Arg2:T20
34,R13,Has_qualifier Arg1:T18 Arg2:T17
35,T21,Drug 423 430;442 450	inhaled steroids
36,T22,Drug 434 450	topical steroids
37,T23,Negation 455 458	not
38,T24,Scope 423 450	inhaled or topical steroids
39,*,OR T21 T22
40,R14,Has_scope Arg1:T23 Arg2:T24
41,T25,Non-representable 416 481	Use of inhaled or topical steroids are not an exclusion criteria.
42,T26,Drug 490 503	oral steroids
43,T27,Temporal 508 531	no greater than 14 days
44,T28,Condition 544 560	non-MS condition
45,T29,Negation 564 567	not
46,R15,Has_temporal Arg1:T26 Arg2:T27
47,R16,AND Arg1:T26 Arg2:T28
48,R17,Has_negation Arg1:T26 Arg2:T29
49,T30,Non-representable 483 581	Use of oral steroids for no greater than 14 days given for a non-MS condition is not exclusionary.
50,T31,Drug 583 594	alemtuzumab
51,T32,Drug 597 609	mitoxantrone
52,T33,Drug 612 628	cyclophosphamide
53,T34,Drug 631 643	methotrexate
54,T35,Drug 646 658	cyclosporine
55,T36,Drug 664 673	rituximab
56,T37,Non-query-able 675 754	Prior use of any experimental agent used as a DMT for MS in the last five years
57,T38,Condition 769 781	hypertension
58,T39,Condition 797 805	diabetes
59,T40,Condition 821 827	asthma
60,T41,Condition 846 856	depression
61,T42,Qualifier 756 768	uncontrolled
62,T43,Qualifier 784 796	uncontrolled
63,T44,Qualifier 808 820	uncontrolled
64,T45,Qualifier 833 845	uncontrolled
65,R18,Has_qualifier Arg1:T38 Arg2:T42
66,R19,Has_qualifier Arg1:T39 Arg2:T43
67,R20,Has_qualifier Arg1:T40 Arg2:T44
68,R21,Has_qualifier Arg1:T41 Arg2:T45
69,T46,Condition 858 865	Cancers
70,T47,Negation 866 876	other than
71,T48,Condition 877 900	basal cell skin cancers
72,T49,Temporal 901 924	within the last 5 years
73,R22,Has_temporal Arg1:T48 Arg2:T49
74,R23,Has_negation Arg1:T48 Arg2:T47
75,R24,AND Arg1:T46 Arg2:T48
76,T50,Non-query-able 926 980	Unable to give informed consent or follow the protocol
77,T51,Procedure 1000 1009	brain MRI
78,T52,Mood 982 999	Unable to undergo
79,R25,Has_mood Arg1:T51 Arg2:T52
80,T53,Post-eligibility 1011 1055	Unwilling to be randomized per this protocol
81,T54,Condition 1074 1104	chronic neurological illnesses
82,T55,Observation 1057 1067	History of
83,T56,Qualifier 1116 1124	mimic MS
84,R26,Has_qualifier Arg1:T54 Arg2:T56
85,T57,Condition 1169 1172	ALS
86,T58,Condition 1174 1191	myasthenia gravis
87,T59,Condition 1193 1211	chronic neuropathy
88,*,OR T57 T58 T59
89,T60,"Scope 1169 1211	ALS, myasthenia gravis, chronic neuropathy"
90,T61,Scope 1074 1124	chronic neurological illnesses that might mimic MS
91,R27,Subsumes Arg1:T61 Arg2:T60
92,R28,Has_temporal Arg1:T61 Arg2:T55
0,T1,Visit 48 58	in-patient
1,T2,Procedure 59 82	spinal fusion procedure
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Value 88 105	18 years or older
4,T4,Person 91 96	years
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Temporal 116 130	post-operative
7,T6,Procedure 131 148	pain control plan
8,T7,Drug 158 164	opioid
9,R3,AND Arg1:T6 Arg2:T7
10,R4,Has_temporal Arg1:T6 Arg2:T5
0,T1,Qualifier 14 23	any other
1,T2,Negation 61 75	in addition to
2,T3,Condition 76 105	Obsessive Compulsive Disorder
3,T4,Condition 39 60	psychiatric diagnosis
4,T5,Qualifier 24 31	primary
5,T6,Qualifier 32 38	DSM-IV
6,R1,Has_negation Arg1:T3 Arg2:T2
7,R2,AND Arg1:T4 Arg2:T3
8,T7,Scope 14 38	any other primary DSM-IV
9,R3,Has_scope Arg1:T4 Arg2:T7
10,T8,Condition 158 173	eating disorder
11,T9,Condition 175 199	body dysmorphic disorder
12,T10,Condition 220 235	substance abuse
13,T11,Condition 209 216;230 235	alcohol abuse
14,T12,Condition 271 287	bipolar disorder
15,T13,Condition 316 329	Schizophrenia
16,T14,Condition 340 359	psychotic disorders
17,T15,Qualifier 334 339	other
18,T16,Condition 361 369	Delirium
19,T17,Condition 371 379	Dementia
20,T18,Condition 385 393	Amnestic
21,T19,Condition 404 423	cognitive disorders
22,T20,Qualifier 398 403	other
23,T21,Qualifier 151 157	DSM-IV
24,*,OR T8 T9 T11 T10
25,T22,"Scope 158 235	eating disorder, body dysmorphic disorder, current alcohol or substance abuse"
26,R4,Has_qualifier Arg1:T22 Arg2:T21
27,*,OR T22 T12 T13 T14 T16 T17 T18 T19
28,R5,Has_qualifier Arg1:T14 Arg2:T15
29,R6,Has_qualifier Arg1:T19 Arg2:T20
30,T23,Condition 471 491	Personality Disorder
31,T24,Qualifier 453 470	Axis II Cluster A
32,R7,Has_qualifier Arg1:T23 Arg2:T24
33,T25,Condition 507 538	Antisocial Personality Disorder
34,T26,Condition 493 503;518 538	Borderline Personality Disorder
35,*,OR T25 T26
36,T27,Procedure 574 599	mental status examination
37,T28,Observation 619 645	risk of committing suicide
38,T29,Qualifier 607 618	significant
39,T30,Non-query-able 647 676	in the investigator's opinion
40,R8,Has_qualifier Arg1:T28 Arg2:T29
41,T31,Competing_trial 679 750	Subjects with a history of more than three adequate trials with an SSRI
42,T32,Competing_trial 753 806	Subjects who have had an adequate trial of pregabalin
43,T33,Procedure 837 850	psychotherapy
44,T34,Temporal 851 896	in the last 4 months prior to the first visit
45,T35,Reference_point 885 896	first visit
46,R9,Has_index Arg1:T34 Arg2:T35
47,R10,Has_temporal Arg1:T33 Arg2:T34
48,T36,"Non-query-able 899 1017	Subjects who, during the course of the study, would be likely to require treatment with prohibited concomitant therapy"
49,T37,Condition 1045 1052	allergy
50,T38,Condition 1056 1072	hypersensitivity
51,T39,Drug 1076 1086	pregabalin
52,*,OR T37 T38
53,T40,Scope 1045 1072	allergy or hypersensitivity
54,R11,AND Arg1:T40 Arg2:T39
55,T41,"Competing_trial 1089 1293	Subjects who have participated in any clinical trial within 30 days prior to entering the study, or in a clinical trial involving a psychotropic medication within the 6 months prior to entering the study."
56,T42,"Non-query-able 1295 1848	Any subject who has been taking benzodiazepines before entering the study who: 1) cannot tolerate being free of benzodiazepines for 4 weeks, or 2) has signs or symptoms of benzodiazepine withdrawal or rebound at the end of those 4 weeks. Should a patient entering the study, who is currently on benzodiazepines develop discontinuation symptoms with discontinuation of their benzodiazepine, we will treat these symptoms with a more gradual benzodiazepine taper. Study will be delayed until the patient is able to tolerate the discontinuation for 4 weeks."
57,T43,Condition 1874 1890	seizure disorder
58,T44,Condition 1892 1914	organic brain disorder
59,T45,Condition 1920 1948	history of seizure disorders
60,T46,Negation 1950 1956	except
61,T47,Condition 1961 1977	febrile seizures
62,T48,Qualifier 1981 1990	childhood
63,R12,Has_qualifier Arg1:T47 Arg2:T48
64,R13,Has_negation Arg1:T47 Arg2:T46
65,R14,AND Arg1:T45 Arg2:T47
66,*,OR T43 T44 T45
67,T49,Condition 2008 2025	thyroid pathology
68,T50,Temporal 2078 2099	at least three months
69,T51,Negation 2054 2057	not
70,T52,Qualifier 2063 2073	stabilized
71,T53,Procedure 2031 2040	treatment
72,R15,AND Arg1:T49 Arg2:T53
73,R16,Has_qualifier Arg1:T53 Arg2:T52
74,R17,Has_negation Arg1:T52 Arg2:T51
75,R18,Has_temporal Arg1:T53 Arg2:T50
76,T54,Drug 2114 2131	neuroleptic drugs
77,T55,Temporal 2132 2170	in the two months prior to study entry
78,T56,Reference_point 2159 2170	study entry
79,R19,Has_index Arg1:T55 Arg2:T56
80,R20,Has_temporal Arg1:T54 Arg2:T55
81,T57,Procedure 2174 2203	cognitive behavioural therapy
82,T58,Condition 2216 2219	OCD
83,T59,Temporal 2220 2252	within four weeks of study entry
84,T60,Reference_point 2241 2252	study entry
85,R21,Has_index Arg1:T59 Arg2:T60
86,R22,AND Arg1:T57 Arg2:T58
87,R23,Has_temporal Arg1:T57 Arg2:T59
88,*,OR T54 T57
89,T61,"Pregnancy_considerations 2254 2381	Pregnant or lactating females, or if sexually active and of childbearing potential, not using adequate methods of birth control"
90,T62,Non-query-able 2384 2587	Patients with a history or evidence of a medical condition that would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the trial
91,T63,Drug 2609 2622	psychotropics
92,T64,Drug 2646 2658	betablockers
93,T65,Drug 2669 2684	anticonvulsants
94,T66,Scope 2646 2684	betablockers and other anticonvulsants
95,*,OR T64 T65
96,R24,Subsumes Arg1:T63 Arg2:T66
97,T67,Drug 2686 2702	Sleep medication
98,T68,Negation 2749 2759	acceptable
99,T69,Drug 2735 2744	zopiclone
100,T70,Drug 2716 2731	chloral-hydrate
101,T71,Qualifier 2711 2715	oral
102,R25,Has_qualifier Arg1:T70 Arg2:T71
103,T72,Scope 2711 2744	oral chloral-hydrate or zopiclone
104,*,OR T70 T69
105,R26,Subsumes Arg1:T67 Arg2:T72
106,R27,Has_negation Arg1:T67 Arg2:T68
107,T73,Procedure 2781 2811	herbal psychoactive treatments
108,T74,Drug 2818 2832	St John's Wort
109,T75,Drug 2834 2842	Valerian
110,T76,Drug 2844 2853	Kava Kava
111,T77,Drug 2855 2867	L-tryptophan
112,*,OR T74 T75 T76 T77
113,T78,"Scope 2818 2867	St John's Wort, Valerian, Kava Kava, L-tryptophan"
114,R28,Subsumes Arg1:T73 Arg2:T78
115,T79,"Non-query-able 2870 3032	Patients with any condition or on any therapy that, in the investigator's opinion, or as indicated in the pregabalin product label, may pose a risk to the subject"
116,T80,"Non-query-able 3035 3183	Patients who have had a major life event in the past three months, which in the judgement of the investigator is influencing their current condition"
117,T81,Measurement 3234 3244;3253 3261	laboratory findings
118,T82,Measurement 3249 3261	ECG findings
119,*,OR T82 T81
120,T83,Value 3213 3233	significant abnormal
121,T84,"Scope 3234 3261	laboratory, or ECG findings"
122,R29,Has_value Arg1:T84 Arg2:T83
123,T85,Non-query-able 3262 3298	not resolved by further examinations
0,T1,Qualifier 20 37	H. pylori related
1,T2,Condition 38 55	chronic gastritis
2,T3,Condition 69 82	peptic ulcers
3,A1,Optional T3
4,T4,Person 91 95	aged
5,T5,Value 96 121	greater than 20 years old
6,T6,Mood 130 149	willing to received
7,T7,Procedure 150 169	eradication therapy
8,R1,Has_mood Arg1:T7 Arg2:T6
9,R2,Has_value Arg1:T4 Arg2:T5
10,R3,Has_qualifier Arg1:T2 Arg2:T1
0,T1,Procedure 0 16	Elective surgery
1,T2,Condition 21 38	thoracic aneurysm
2,R1,AND Arg1:T1 Arg2:T2
0,T1,Condition 21 50	Relapsing-remitting MS (RRMS)
1,T2,Condition 52 83	Secondary progressive MS (SPMS)
2,T3,Condition 88 117	Primary progressive MS (PPMS)
3,*,OR T2 T1 T3
4,T4,Non-representable 146 216	Patients defined by subtype based on 2013 updated phenotypic criteria.
5,T5,Condition 240 251	EDSS change
6,T6,Value 255 274	at least 1.0 points
7,T7,Temporal 275 298	over the last two years
8,R1,Has_value Arg1:T5 Arg2:T6
9,R2,Has_temporal Arg1:T5 Arg2:T7
10,T8,Qualifier 330 341	significant
11,T9,Condition 342 366	change in motor function
12,R3,Has_qualifier Arg1:T9 Arg2:T8
13,T10,Temporal 367 389	over at least one year
14,T11,Qualifier 391 411	unrelated to relapse
15,R4,Has_qualifier Arg1:T9 Arg2:T11
16,R5,Has_temporal Arg1:T9 Arg2:T10
17,T12,Value 414 422;430 438	55 years or older
18,T13,Person 426 429	age
19,R6,Has_value Arg1:T13 Arg2:T12
20,T14,Temporal 439 463	at time of randomization
21,R7,Has_temporal Arg1:T13 Arg2:T14
22,T15,Condition 492 512	inflammatory disease
23,T16,Measurement 539 554	Lublin criteria
24,T17,Value 523 531	inactive
25,R8,Has_value Arg1:T16 Arg2:T17
26,R9,AND Arg1:T15 Arg2:T16
27,T18,Qualifier 488 491	new
28,T19,Negation 466 468	No
29,R10,Has_qualifier Arg1:T15 Arg2:T18
30,R11,Has_negation Arg1:T15 Arg2:T19
31,T20,Condition 570 577	relapse
32,T21,Qualifier 566 569	new
33,T22,Negation 563 565	no
34,R12,Has_qualifier Arg1:T20 Arg2:T21
35,R13,Has_negation Arg1:T20 Arg2:T22
36,T23,Temporal 578 601	for at least five years
37,T24,Condition 617 623	lesion
38,T25,Procedure 613 616	MRI
39,T26,Temporal 624 648	for at least three years
40,R14,Has_temporal Arg1:T24 Arg2:T26
41,R15,AND Arg1:T25 Arg2:T24
42,R16,Has_temporal Arg1:T20 Arg2:T23
43,T27,Negation 606 608	no
44,T28,Qualifier 609 612	new
45,R17,Has_qualifier Arg1:T24 Arg2:T28
46,R18,Has_negation Arg1:T24 Arg2:T27
47,T29,Drug 650 665	interferon ß-1a
48,T30,Drug 668 683	interferon ß-1b
49,T31,Drug 686 704	glatiramer acetate
50,T32,Drug 707 718	natalizumab
51,T33,Drug 721 731	fingolimod
52,T34,Drug 734 751	dimethyl fumarate
53,T35,Drug 757 770	teriflunomide
54,T36,Temporal 785 809	for no less than 5 years
55,T37,Multiplier 772 784	continuously
56,R19,Has_multiplier Arg1:T35 Arg2:T37
57,R20,Has_temporal Arg1:T35 Arg2:T36
58,T38,Drug 831 834	DMT
59,T39,Multiplier 835 847	continuously
60,T40,Temporal 849 875	for no less than two years
61,R21,Has_temporal Arg1:T38 Arg2:T40
62,R22,Has_multiplier Arg1:T38 Arg2:T39
63,T41,Post-eligibility 878 1058	Willing to be randomized per this protocol; each patient will be questioned as to their willingness to stay in the trial regardless of the group to which group they are randomized.
64,T42,Post-eligibility 1060 1090	Willing to follow the protocol
65,T43,"Non-representable 1092 1300	Continuously will be defined as no less than 75% of all prescribed doses, with no time of greater than four weeks from last intended dose to have missed a dose (8 weeks for natalizumab, i.e. one missed dose)."
0,T1,Condition 0 8	pregnant
1,T2,Condition 12 19	nursing
2,T3,Person 20 25	woman
3,*,OR T2 T1
4,T4,Qualifier 27 34	serious
5,T5,Temporal 35 46	concomitant
6,T6,Condition 47 54	illness
7,T7,Condition 59 74	malignant tumor
8,T8,Qualifier 78 86	any kind
9,R1,Has_qualifier Arg1:T7 Arg2:T8
10,R2,Has_temporal Arg1:T6 Arg2:T5
11,R3,Has_qualifier Arg1:T6 Arg2:T4
12,T9,Observation 88 95	history
13,T10,Condition 99 115	hypersensitivity
14,T11,Drug 119 129	test drugs
15,R4,AND Arg1:T10 Arg2:T11
16,R5,Has_temporal Arg1:T10 Arg2:T9
17,T12,Qualifier 131 138	serious
18,T13,Condition 139 147	bleeding
19,T14,Temporal 148 178	during the course of the ulcer
20,T15,Reference_point 169 178	the ulcer
21,T16,Condition 173 178	ulcer
22,R6,multi Arg1:T15 Arg2:T16
23,R7,Has_index Arg1:T14 Arg2:T15
24,R8,Has_qualifier Arg1:T13 Arg2:T12
25,R9,Has_temporal Arg1:T13 Arg2:T14
26,T17,Temporal 180 188	previous
27,T18,Procedure 189 204	gastric surgery
28,R10,Has_temporal Arg1:T18 Arg2:T17
29,T19,Drug 216 229	bismuth salts
30,T20,Drug 231 235	PPIs
31,T21,Drug 240 251	antibiotics
32,T22,Temporal 252 273	in the previous month
33,*,OR T20 T21 T19
34,T23,"Scope 216 251	bismuth salts, PPIs, or antibiotics"
35,R11,Has_temporal Arg1:T23 Arg2:T22
0,T1,Condition 0 9	Pregnancy
1,T2,Person 11 14	age
2,T3,Value 15 19	< 18
3,T4,Condition 21 28	nursing
4,T5,Condition 44 51	allergy
5,T6,Drug 55 63	naloxone
6,R1,AND Arg1:T5 Arg2:T6
7,R2,Has_value Arg1:T2 Arg2:T3
8,*,OR T1 T2 T4 T5
0,T1,Condition 44 73	Obsessive-Compulsive Disorder
1,T2,Qualifier 29 36	primary
2,T3,Qualifier 37 43	DSM-IV
3,T4,Scope 29 43	primary DSM-IV
4,R1,Has_scope Arg1:T1 Arg2:T4
5,T5,Visit 11 21	outpatient
6,R2,AND Arg1:T5 Arg2:T1
7,T6,Measurement 128 165	Yale-Brown Obsessive Compulsive Scale
8,T7,Value 96 120	score of greater than 20
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Measurement 167 173	Y-BOCS
11,R4,Subsumes Arg1:T6 Arg2:T8
12,T9,Condition 229 253	major depressive episode
13,T10,Qualifier 222 228	DSM-IV
14,T11,Qualifier 213 221	comorbid
15,T12,Scope 213 228	comorbid DSM-IV
16,R5,Has_scope Arg1:T9 Arg2:T12
17,T13,Condition 327 330	OCD
18,R6,AND Arg1:T9 Arg2:T13
19,T14,Measurement 353 387	Montgomery Depression Rating Scale
20,T15,Qualifier 344 352	baseline
21,R7,Has_qualifier Arg1:T14 Arg2:T15
22,T16,Measurement 389 394	MADRS
23,R8,Subsumes Arg1:T14 Arg2:T16
24,T17,Value 396 429	score of less than or equal to 19
25,R9,Has_value Arg1:T14 Arg2:T17
26,T18,Condition 439 451	onset of OCD
27,T19,Temporal 452 529	predates the onset of the current episode of depression by five or more years
28,T20,Reference_point 465 507	onset of the current episode of depression
29,R10,Has_index Arg1:T19 Arg2:T20
30,T21,Post-eligibility 532 595	The ability to comprehend and comply with protocol requirements
31,T22,Informed_consent 598 652	Written consent must be provided prior to study entry.
32,T24,"Pregnancy_considerations 765 999	All female subjects of childbearing potential (WOCBP), including those who are practicing a medically acceptable method of birth control, must have a negative serum pregnancy test within 72 hours prior to the start of study medication"
33,T23,Person 658 663	women
34,T25,Condition 667 689	childbearing potential
35,T26,Condition 691 696	WOCBP
36,T27,Scope 658 689	women of childbearing potential
37,R11,Subsumes Arg1:T26 Arg2:T27
38,T28,Qualifier 719 739	medically acceptable
39,T29,Procedure 750 763	birth control
40,R12,Has_qualifier Arg1:T29 Arg2:T28
41,R13,AND Arg1:T26 Arg2:T29
42,A1,Optional T26
0,T1,Condition 18 27	psoriasis
1,T2,Negation 28 38	other than
2,T3,Condition 39 63	chronic plaque psoriasis
3,T4,Qualifier 70 77	guttate
4,T5,Qualifier 79 92	erythrodermic
5,T6,Qualifier 94 102	pustular
6,R1,Has_negation Arg1:T3 Arg2:T2
7,T7,Scope 28 63	other than chronic plaque psoriasis
8,*,OR T4 T5 T6
9,T8,"Scope 70 102	guttate, erythrodermic, pustular"
10,R2,Subsumes Arg1:T7 Arg2:T8
11,R3,Has_scope Arg1:T1 Arg2:T7
12,T9,Qualifier 124 130	active
13,T10,Temporal 132 139	ongoing
14,T11,Condition 140 153	skin diseases
15,T12,Condition 157 172	skin infections
16,T13,Non-representable 182 229	interfere with examination of psoriasis lesions
17,*,OR T11 T12
18,T14,Scope 140 172	skin diseases or skin infections
19,R4,Has_temporal Arg1:T14 Arg2:T10
20,R5,Has_qualifier Arg1:T14 Arg2:T9
21,T15,Procedure 262 271	treatment
22,T16,Condition 252 261	psoriasis
23,R6,AND Arg1:T15 Arg2:T16
24,T17,Drug 301 308;321 336	topical corticosteroids
25,T18,Drug 312 336	systemic corticosteroids
26,T19,Drug 344 363	topical medications
27,T20,Drug 370 378	coal tar
28,T21,Drug 381 385;398 409	oral medications
29,T22,Drug 389 409	biologic medications
30,T24,Procedure 446 456	UV therapy
31,R7,Subsumes Arg1:T19 Arg2:T20
32,*,OR T19 T21 T22 T18 T17 T24
33,T23,Non-representable 458 642	The following washout periods will be required: 2 weeks for topical therapy; 2 weeks for phototherapy; 12 weeks for biologic or targeted therapies; 4 weeks for other systemic therapies
34,T25,Temporal 231 238	Ongoing
35,R8,Has_temporal Arg1:T15 Arg2:T25
36,T26,"Scope 301 456	topical or systemic corticosteroids, other topical medications (i.e. coal tar), oral or biologic medications for the treatment of psoriasis, and UV therapy"
37,R9,Subsumes Arg1:T15 Arg2:T26
38,T27,Procedure 651 672	oral estrogen therapy
39,T28,Drug 684 708	oral contraceptive pills
40,T29,Negation 674 683	excluding
41,R10,Has_negation Arg1:T28 Arg2:T29
42,R11,AND Arg1:T27 Arg2:T28
43,T30,"Pregnancy_considerations 710 837	Women who are pregnant, nursing, or of child-bearing potential who are unwilling to use appropriate method(s) of contraception."
44,T31,Mood 848 857	unwilling
45,T32,Procedure 861 887	limit exposure to UV light
46,R12,Has_mood Arg1:T32 Arg2:T31
47,T33,"Non-query-able 889 1012	Current significant medical problems that, in the discretion of the investigator, would put the patient at significant risk"
48,T34,Condition 1028 1059	disorders of calcium metabolism
49,T35,Condition 1067 1080	hypercalcemia
50,*,OR T34 T35
51,T36,"Competing_trial 1082 1233	Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)"
52,T37,Condition 1246 1253	allergy
53,T38,Drug 1257 1280	any component of the IP
54,R13,AND Arg1:T37 Arg2:T38
0,T1,"Informed_consent 0 100	Provide written, signed and dated informed consent prior to initiating any study-related activities."
1,T2,Person 102 106	Male
2,T3,Person 110 116	female
3,T4,Value 117 133	>18 years of age
4,T5,Person 130 133	age
5,R1,Has_value Arg1:T5 Arg2:T4
6,T6,Temporal 134 158	at the time of screening
7,T7,Reference_point 137 158	the time of screening
8,R2,Has_index Arg1:T6 Arg2:T7
9,*,OR T3 T2
10,R3,Has_temporal Arg1:T4 Arg2:T6
11,T8,Measurement 160 186	Fitzpatrick Skin phototype
12,T9,Value 187 192	IV-VI
13,R4,Has_value Arg1:T8 Arg2:T9
14,T10,Person 194 218	non-white race/ethnicity
15,T11,Person 253 270	African Americans
16,T12,Person 272 278	Asians
17,T13,Person 280 297	Pacific Islanders
18,T14,Person 302 311	Hispanics
19,*,OR T13 T14 T12 T11
20,T15,"Scope 253 311	African Americans, Asians, Pacific Islanders and Hispanics"
21,R5,Subsumes Arg1:T10 Arg2:T15
22,T16,Qualifier 344 355	plaque-type
23,T17,Qualifier 336 343	chronic
24,T18,Condition 356 377	psoriasis of the body
25,R6,Has_qualifier Arg1:T18 Arg2:T16
26,R7,Has_qualifier Arg1:T18 Arg2:T17
27,T19,Condition 379 395	Plaque psoriasis
28,T20,Value 401 428	=2% Body Surface Area (BSA)
29,T21,Measurement 429 440	involvement
30,R8,Has_value Arg1:T21 Arg2:T20
31,T22,Measurement 474 484	PASI Score
32,T23,Value 485 488	= 2
33,T24,Measurement 490 508	IGA mod 2011 score
34,T25,Value 512 524	2 or greater
35,T26,Qualifier 535 547	scale of 0-4
36,R9,Has_value Arg1:T24 Arg2:T25
37,R10,Has_value Arg1:T22 Arg2:T23
38,*,OR T22 T24
39,T27,"Scope 401 548	=2% Body Surface Area (BSA) involvement (may include scalp involvement), PASI Score = 2, IGA mod 2011 score of 2 or greater (based on scale of 0-4)"
40,R11,Has_scope Arg1:T19 Arg2:T27
41,T28,"Pregnancy_considerations 550 878	Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d"
42,T29,"Non-query-able 880 991	Must be in general good health as judged by the Investigator, based on medical history and physical examination"
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 32 34	2.
2,T3,Condition 21 30	neoplasia
3,T4,Person 35 38	Man
4,T5,Qualifier 15 20	other
5,R1,Has_qualifier Arg1:T3 Arg2:T5
0,T1,Condition 0 8	Pregnant
1,T2,Person 9 14	women
2,T3,Condition 20 38	abdomen discumfort
3,T4,Procedure 43 53	ultrasound
4,T5,Condition 67 81	polyhydramnios
5,T6,Measurement 83 86	AFI
6,T7,Value 86 91	>25cm
7,R1,Has_value Arg1:T6 Arg2:T7
8,T8,Value 54 63	diagnosis
9,R3,Has_value Arg1:T4 Arg2:T8
10,R2,AND Arg1:T5 Arg2:T4
11,R4,Subsumes Arg1:T4 Arg2:T6
12,T9,Condition 109 120	pregnancies
13,T10,Value 94 100	Single
14,T11,Value 104 108	twin
15,*,OR T10 T11
16,T12,Scope 94 108	Single or twin
17,R5,AND Arg1:T12 Arg2:T9
0,T1,Condition 13 26	heart failure
1,T2,Qualifier 40 59	Framingham criteria
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Informed_consent 61 77	Informed consent
4,T4,Person 79 82	Age
5,T5,Value 83 100	18 years or above
6,R2,Has_value Arg1:T4 Arg2:T5
0,T1,Condition 30 50	urgency incontinence
1,T2,Condition 12 26;38 50	stress urinary incontinence
2,*,OR T1 T2
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 19 21	2.
2,T3,Parsing_Error 105 107	3.
3,T4,Parsing_Error 271 273	4.
4,T5,Person 3 6	Age
5,T6,Value 7 17	≥ 18 years
6,R1,Has_value Arg1:T5 Arg2:T6
7,T7,Condition 35 48	breast cancer
8,T8,Procedure 50 64	histologically
9,T9,Value 65 71	proven
10,R2,Has_value Arg1:T8 Arg2:T9
11,T10,Qualifier 73 83	metastatic
12,T11,Qualifier 87 103	locally advanced
13,*,OR T10 T11 T8
14,T12,"Scope 50 103	histologically proven, metastatic or locally advanced"
15,R3,Has_scope Arg1:T7 Arg2:T12
16,T13,Drug 127 135	Eribulin
17,T14,Temporal 136 168	between January and October 2014
18,T15,Temporal 201 241	between November 2014 and September 2015
19,*,OR T15 T14
20,T16,Scope 136 268	between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part)
21,R4,Has_scope Arg1:T13 Arg2:T16
22,T17,Drug 329 337	Eribulin
23,T18,Procedure 299 325	assessment of the response
24,T19,Non-query-able 274 337	Patient with at least an assessment of the response to Eribulin
0,T1,Qualifier 30 39	untreated
1,T2,Condition 40 50	malignancy
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 59 77	local skin cancers
4,T4,Negation 52 58	except
5,R2,Has_negation Arg1:T3 Arg2:T4
6,R3,AND Arg1:T2 Arg2:T3
7,T5,Condition 80 95	Ischemic stroke
8,T6,Qualifier 118 172	Questionnaire for Verifying Stroke-Free Status (QVSFS)
9,R4,Has_qualifier Arg1:T5 Arg2:T6
10,T7,Procedure 186 200	renal dialysis
11,T8,Condition 209 238	end-stage hepatic dysfunction
12,*,OR T7 T8
13,T9,Qualifier 240 245	Acute
14,T10,Condition 246 255	infection
15,T11,Condition 256 268	inflammation
16,*,OR T10 T11
17,T12,Scope 246 268	infection/inflammation
18,R5,Has_qualifier Arg1:T12 Arg2:T9
19,T13,Measurement 270 281	Temperature
20,T14,Measurement 300 303	WBC
21,T15,Value 282 291	> 101.5 F
22,T16,"Value 303 312	> 15, 000"
23,R6,Has_value Arg1:T13 Arg2:T15
24,R7,Has_value Arg1:T14 Arg2:T16
25,*,OR T13 T14
26,T17,Informed_consent 315 379	Inability to obtain informed consent from patient or next of kin
27,T18,Drug 381 394	Anticoagulant
28,T19,Drug 400 408	warfarin
29,T20,Drug 412 419	heparin
30,*,OR T19 T20
31,T21,Scope 400 419	warfarin or heparin
32,R8,Subsumes Arg1:T18 Arg2:T21
0,T1,Condition 0 18	Multiple pregnancy
1,T2,Value 20 31	more than 3
2,T3,Measurement 32 39	fetuses
3,R2,Has_value Arg1:T3 Arg2:T2
4,T4,Condition 62 80	placental abruptio
5,T5,Observation 42 61	Maternal history of
6,R3,AND Arg1:T5 Arg2:T4
7,T7,Condition 93 97	IUGR
8,T6,Condition 82 87	Fetus
9,R4,AND Arg1:T6 Arg2:T7
10,T8,Condition 99 108	Pregnancy
11,T9,Condition 126 139	pre-eclampsia
12,T10,Observation 154 175	give informed consent
13,T11,Negation 141 153	Unability to
14,R5,Has_negation Arg1:T10 Arg2:T11
15,T12,Scope 20 39	more than 3 fetuses
16,R1,Subsumes Arg1:T1 Arg2:T12
0,T1,Condition 0 21	neurological diseases
1,T2,Procedure 32 48	pelvic surgeries
2,T3,Temporal 23 31	previous
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,T4,Condition 50 58	diabetes
5,T5,Condition 60 82	cognitive difficulties
6,T6,Condition 96 113	urinary infection
7,T7,Grammar_Error 92 95	and
8,T8,Condition 104 113;84 91	infection vaginal
9,*,OR T6 T8
0,T1,Condition 20 28	pregnant
1,T2,Condition 32 41	lactating
2,T3,Person 42 48	female
3,*,OR T2 T1
4,T4,Condition 93 112	supine hypertension
5,T5,Value 113 142	greater than 180mmHg systolic
6,T6,Value 147 164	110mmHg diastolic
7,T7,Measurement 165 167	BP
8,R1,Has_value Arg1:T7 Arg2:T6
9,R2,Has_value Arg1:T7 Arg2:T5
10,T8,Temporal 194 216	at the Screening Visit
11,T9,Reference_point 201 216	Screening Visit
12,R3,Has_index Arg1:T8 Arg2:T9
13,T10,Temporal 70 82	pre-existing
14,R4,Has_temporal Arg1:T4 Arg2:T10
15,R5,AND Arg1:T4 Arg2:T7
16,T11,Temporal 83 92	sustained
17,*,OR T11 T8
18,T12,Scope 168 170;194 216;83 92	or at the Screening Visit sustained
19,R6,Has_scope Arg1:T4 Arg2:T12
20,T13,Temporal 242 254	persistently
21,T14,Value 255 262	greater
22,T15,Multiplier 266 276;290 314	2 separate at least 5 minutes apart
23,T16,Measurement 277 289	measurements
24,R7,Has_multiplier Arg1:T16 Arg2:T15
25,T17,Drug 402 425	medications of interest
26,T18,Temporal 390 401	concomitant
27,R8,Has_temporal Arg1:T17 Arg2:T18
28,T19,Subjective_judgement 775 902	The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be clinically significant
29,T20,Post-eligibility 907 1068	The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406).
30,T21,"Undefined_semantics 1073 1383	Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures."
31,T22,"Subjective_judgement 1073 1383	Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures."
32,T23,Condition 1417 1424;1434 1441	chronic illness
33,T24,Condition 1428 1441	acute illness
34,T25,Condition 1443 1453	disability
35,T26,Condition 1458 1473	other condition
36,*,OR T24 T23 T25 T26
37,T27,"Undefined_semantics 1388 1702	The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject."
38,T28,Procedure 1522 1545	electrocardiogram [ECG]
39,T29,Condition 1508 1518;1546 1554	laboratory findings
40,T30,Condition 1522 1554	electrocardiogram [ECG] findings
41,T31,"Undefined_semantics 1707 1853	Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients."
42,T32,Condition 1864 1882	enrollment failure
43,T33,Non-query-able 1858 1914	Prior enrollment failure or randomization in this study.
44,T34,Condition 1931 1944	alcohol abuse
45,T35,Condition 1954 1969	substance abuse
46,T36,Temporal 1970 1990	within the last year
47,T37,Scope 1931 1969	alcohol abuse or other substance abuse
48,*,OR T34 T35
49,R9,Has_temporal Arg1:T37 Arg2:T36
0,T1,Person 3 8	Women
1,T2,Person 13 16	men
2,T3,Person 17 21	ages
3,T4,Value 22 39	18 years and over
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T2 T1
6,T5,Grammar_Error 9 12	and
7,T6,Post-eligibility 118 156	Willingness to follow recommendations.
8,T7,Post-eligibility 45 113	Interest in participating in a novel nutritional supplement program.
0,T1,"Post-eligibility 0 72	Patient does not meet inclusion criteria, discovered after randomization"
1,T2,Post-eligibility 74 108	Inability to give informed consent
2,T3,Condition 116 133	clotting disorder
3,T4,Drug 144 158	anticoagulants
4,R1,AND Arg1:T3 Arg2:T4
5,T5,Condition 202 224	cardiovascular disease
6,T6,Observation 166 178;202 224	risk factors cardiovascular disease
7,*,OR T5 T6
8,T7,Non-query-able 226 242	Language barrier
0,T1,Condition 0 9	Rest pain
1,T2,Condition 13 24	tissue loss
2,T3,Condition 32 35	PAD
3,T4,Measurement 37 51	Fontaine stage
4,T5,Value 52 55	III
5,T6,Value 60 62	IV
6,*,OR T5 T6
7,T7,Scope 52 62	III and IV
8,R1,Has_scope Arg1:T4 Arg2:T7
9,*,OR T1 T2
10,T8,Scope 0 24	Rest pain or tissue loss
11,R2,AND Arg1:T8 Arg2:T3
12,R3,AND Arg1:T8 Arg2:T4
13,T9,Qualifier 66 71	acute
14,T10,Qualifier 72 87	lower extremity
15,T11,Condition 88 102	ischemic event
16,R4,Has_qualifier Arg1:T11 Arg2:T10
17,R5,Has_qualifier Arg1:T11 Arg2:T9
18,T12,Qualifier 103 138	secondary to thromboembolic disease
19,T13,Qualifier 103 115;142 154	secondary to acute trauma
20,T14,Condition 116 138	thromboembolic disease
21,T15,Condition 142 154	acute trauma
22,R6,multi Arg1:T13 Arg2:T15
23,R7,multi Arg1:T12 Arg2:T14
24,*,OR T13 T12
25,T16,Scope 103 154	secondary to thromboembolic disease or acute trauma
26,R8,Has_scope Arg1:T11 Arg2:T16
27,T17,Measurement 157 173	Walking capacity
28,T18,Value 174 195	significantly limited
29,R9,Has_value Arg1:T17 Arg2:T18
30,T19,Condition 221 233	claudication
31,T20,Negation 210 220	other than
32,R10,Has_negation Arg1:T19 Arg2:T20
33,T21,Condition 244 247;319 328	leg pathology
34,T22,Condition 288 296;319 328	systemic pathology
35,*,OR T21 T22
36,T23,Qualifier 249 254	joint
37,T24,Qualifier 255 270	musculoskeletal
38,T25,Qualifier 272 282	neurologic
39,*,OR T23 T24 T25
40,T26,"Scope 249 282	joint/musculoskeletal, neurologic"
41,R11,Has_scope Arg1:T21 Arg2:T26
42,T27,Condition 298 303;310 317	heart disease
43,T28,Condition 305 317	lung disease
44,*,OR T27 T28
45,T29,"Scope 298 317	heart, lung disease"
46,R12,Subsumes Arg1:T22 Arg2:T29
47,T30,"Scope 244 328	leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology"
48,T31,Condition 199 233	conditions other than claudication
49,T32,Qualifier 210 233	other than claudication
50,R13,multi Arg1:T31 Arg2:T32
51,R14,multi Arg1:T32 Arg2:T19
52,R15,AND Arg1:T31 Arg2:T17
53,R16,Has_scope Arg1:T31 Arg2:T30
54,T34,Drug 353 367	ACE inhibitors
55,T33,Temporal 331 342	Current use
56,T35,Drug 371 403	angiotensin II receptor blockers
57,*,OR T34 T35
58,T36,Scope 353 403	ACE inhibitors or angiotensin II receptor blockers
59,R17,Has_temporal Arg1:T36 Arg2:T33
60,T37,Condition 406 428	Chronic kidney disease
61,T38,Measurement 434 470	estimated Glomerular Filtration Rate
62,T39,Value 471 490	< 30 ml/min/1.73 m2
63,R18,Has_value Arg1:T38 Arg2:T39
64,R19,AND Arg1:T37 Arg2:T38
65,T40,Observation 493 500	History
66,T41,Qualifier 504 513	bilateral
67,T42,Qualifier 514 520	severe
68,T43,Condition 521 542	renal artery stenosis
69,R20,Has_qualifier Arg1:T43 Arg2:T42
70,R21,Has_qualifier Arg1:T43 Arg2:T41
71,T44,Observation 550 557	History
72,T45,Condition 561 571	angioedema
73,T46,Temporal 583 591	previous
74,T47,Procedure 592 615	ACE-inhibitor treatment
75,T48,Drug 592 605	ACE-inhibitor
76,R22,multi Arg1:T47 Arg2:T48
77,T49,Qualifier 619 624	known
78,T50,Condition 625 641	hypersensitivity
79,T51,Drug 645 653	ramipril
80,T52,Drug 663 677	ACE inhibitors
81,*,OR T51 T52
82,T53,Scope 645 677	ramipril or other ACE inhibitors
83,R23,Has_scope Arg1:T50 Arg2:T53
84,R24,Has_qualifier Arg1:T50 Arg2:T49
85,R25,Has_temporal Arg1:T47 Arg2:T46
86,*,OR T50 T47
87,T54,Scope 583 677	previous ACE-inhibitor treatment or known hypersensitivity to ramipril or other ACE inhibitors
88,R26,Has_scope Arg1:T45 Arg2:T54
89,R27,Has_temporal Arg1:T45 Arg2:T44
90,*,OR T43 T45
91,R28,Has_temporal Arg1:T43 Arg2:T40
0,T1,Post-eligibility 0 15	Lack of consent
0,T1,Condition 3 15	Menstruating
1,T2,Person 16 23	females
2,T3,Value 24 35	10-19 years
3,T4,Person 39 42	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Condition 47 57	Non-smoker
6,T6,Drug 108 115	Lysteda
7,T7,Non-query-able 62 115	Physician and patient have agreed to initiate Lysteda
8,T8,Condition 133 136	HMB
9,T9,Non-query-able 137 204	based on the medical judgment of the principal or site investigator
10,T10,Subjective_judgement 137 204	based on the medical judgment of the principal or site investigator
11,T11,Condition 230 247	menstrual periods
12,T12,Temporal 258 304	within 21-60 days from the start of one period
13,T13,Reference_point 281 304	the start of one period
14,R2,Has_temporal Arg1:T11 Arg2:T12
15,T14,Measurement 360 374	pregnancy test
16,T15,Value 351 359	Negative
17,R3,Has_value Arg1:T14 Arg2:T15
18,T16,Post-eligibility 379 415	Informed consent obtained and signed
19,T17,Non-query-able 379 415	Informed consent obtained and signed
20,T18,Post-eligibility 420 455	Informed assent obtained and signed
21,T19,Non-query-able 420 455	Informed assent obtained and signed
22,T20,Non-query-able 460 493	Understanding of study procedures
23,T21,Post-eligibility 460 493	Understanding of study procedures
24,T22,Non-query-able 499 573	Ability to comply with study procedures for the entire length of the study
25,T23,Post-eligibility 499 573	Ability to comply with study procedures for the entire length of the study
26,T24,Condition 605 622	sexually inactive
27,T25,Condition 605 613;624 633	sexually abstinent
28,R4,Subsumes Arg1:T24 Arg2:T25
29,T26,Device 653 683	barrier method with spermicide
30,*,OR T24 T26
31,T27,Observation 638 650	agree to use
32,R5,Has_context Arg1:T26 Arg2:T27
0,T1,Person 3 7	Male
1,T2,Person 12 18	female
2,T3,Value 36 44;52 60	18 years or older
3,T4,Person 48 51	age
4,T5,Visit 65 75	ambulatory
5,R1,Has_value Arg1:T4 Arg2:T3
6,*,OR T2 T1
7,T6,Person 81 88	Females
8,T7,Condition 92 115	child-bearing potential
9,T8,Measurement 144 204	serum beta human chorionic gonadotropin (HCG) pregnancy test
10,T9,Value 135 143	negative
11,R2,Has_value Arg1:T8 Arg2:T9
12,T10,Scope 81 115	Females of child-bearing potential
13,A1,Optional T10
14,R3,AND Arg1:T10 Arg2:T8
15,T11,Condition 241 282	Symptomatic Orthostatic Hypotension (SOH)
16,T12,Qualifier 234 240	severe
17,T13,Drug 360 373	midodrine HCl
18,T14,Qualifier 394 405	stable dose
19,T15,Temporal 406 427	for at least 3 months
20,R4,Has_temporal Arg1:T14 Arg2:T15
21,R5,Has_qualifier Arg1:T11 Arg2:T12
22,T16,Multiplier 460 470	at least 1
23,T17,Condition 610 619	dizziness
24,T18,Condition 621 636	lightheadedness
25,T19,Condition 638 651	feeling faint
26,T20,Condition 656 689	feeling like they might black out
27,T21,Condition 580 608	orthostatic hypotension (OH)
28,T22,Procedure 568 575	treated
29,R6,AND Arg1:T22 Arg2:T21
30,T23,Negation 564 567	not
31,R7,Has_negation Arg1:T22 Arg2:T23
32,T24,Multiplier 540 541	1
33,A2,Optional T22
34,T25,"Scope 610 689	dizziness, lightheadedness, feeling faint, or feeling like they might black out"
35,R8,Has_multiplier Arg1:T25 Arg2:T24
36,R9,Has_scope Arg1:T22 Arg2:T25
0,T1,Subjective_judgement 3 152	Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning.
1,T2,Post-eligibility 3 152	Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning.
2,T3,Post-eligibility 157 188	Unable to consent to the study.
3,T4,Non-query-able 157 188	Unable to consent to the study.
4,T5,Person 193 198	Women
5,T6,Condition 207 215	pregnant
6,T7,Condition 299 319	spontaneous abortion
7,T8,Temporal 289 298	recurrent
8,R1,Has_temporal Arg1:T7 Arg2:T8
9,T9,Condition 423 435	heart attack
10,T10,Temporal 416 422	recent
11,R2,Has_temporal Arg1:T9 Arg2:T10
12,T11,Condition 439 445	stroke
13,T12,Condition 449 471	chronic kidney disease
14,*,OR T12 T11 T9
15,T13,Drug 494 521	immunomodulatory medication
16,T14,Undefined_semantics 494 521	immunomodulatory medication
17,T15,Drug 528 538	interferon
18,R3,Subsumes Arg1:T13 Arg2:T15
19,T16,Drug 641 664	chemotherapeutic agents
20,T17,Undefined_semantics 641 664	chemotherapeutic agents
21,T18,Condition 676 691	allergy to rice
22,T19,Drug 687 691	rice
23,R4,AND Arg1:T18 Arg2:T19
24,T20,Condition 676 686;693 702	allergy to rice bran
25,T21,Drug 693 702	rice bran
26,R5,AND Arg1:T20 Arg2:T21
27,T22,Undefined_semantics 707 728	related food products
28,T23,Condition 740 760	allergy to mushrooms
29,T24,Condition 802 814	malignancies
30,T25,Observation 791 798	History
31,T26,Qualifier 815 842	related to the NK cell line
32,T27,Condition 855 872	NK cell leukemias
33,T28,Condition 877 919	T-cell large granular lymphocyte leukemias
34,T29,Grammar_Error 873 876	and
35,T30,Condition 921 980	NK-cell lymphoproliferative disease of granular lymphocytes
36,T31,Condition 986 1003	NK cell lymphomas
37,T32,Condition 1021 1051	nasal-like NK/T-cell lymphomas
38,T33,Condition 1011 1016;1032 1051	nasal NK/T-cell lymphomas
39,T34,Grammar_Error 1017 1020	and
40,*,OR T33 T32 T31 T30 T28 T27
41,T35,Grammar_Error 982 985	and
42,T36,"Scope 855 1051	NK cell leukemias and T-cell large granular lymphocyte leukemias, NK-cell lymphoproliferative disease of granular lymphocytes, and NK cell lymphomas, e.g., nasal and nasal-like NK/T-cell lymphomas"
43,*,OR T24 T26
44,T37,Scope 802 842	malignancies related to the NK cell line
45,R6,Subsumes Arg1:T37 Arg2:T36
46,R7,Has_temporal Arg1:T37 Arg2:T25
47,T38,Qualifier 325 330	Other
48,T39,Condition 331 352	medical complications
49,R8,Has_qualifier Arg1:T39 Arg2:T38
50,T40,Negation 364 372	preclude
51,T41,Informed_consent 382 408	participating in the study
52,R9,Has_negation Arg1:T41 Arg2:T40
53,R10,AND Arg1:T39 Arg2:T41
54,T42,Scope 325 408	Other medical complications that might preclude one from participating in the study
55,T43,Scope 416 471	recent heart attack or stroke or chronic kidney disease
56,R11,Has_scope Arg1:T42 Arg2:T43
57,T44,Temporal 544 553	Currently
58,T45,Qualifier 561 566	other
59,T46,Drug 567 578	medications
60,T47,Qualifier 598 633	impact on immune system functioning
61,R12,Has_qualifier Arg1:T46 Arg2:T45
62,R13,Has_qualifier Arg1:T46 Arg2:T47
63,T48,Scope 561 633	other medications thought to have an impact on immune system functioning
64,R14,Subsumes Arg1:T46 Arg2:T16
65,R15,Has_temporal Arg1:T48 Arg2:T44
66,T49,Condition 740 750;772 785	allergy to food products
67,*,OR T49 T23
68,T50,Temporal 1058 1065	Current
69,T51,Observation 1066 1072	smoker
70,R16,Has_temporal Arg1:T51 Arg2:T50
0,T1,Measurement 2 19	crown-rump length
1,T2,Value 20 25	= 6mm
2,T3,Negation 30 32	no
3,T4,Observation 33 49	cardiac activity
4,R1,Has_negation Arg1:T4 Arg2:T3
5,R2,Has_value Arg1:T1 Arg2:T2
6,T5,Measurement 56 73	crown-rump length
7,T6,Value 74 78	<6mm
8,T7,Negation 83 85	no
9,T8,Observation 86 98	fetal growth
10,R3,Has_negation Arg1:T8 Arg2:T7
11,R4,Has_value Arg1:T5 Arg2:T6
12,T9,Temporal 99 122	at least one week later
13,T10,Scope 56 98	crown-rump length <6mm and no fetal growth
14,T11,Temporal 127 160	At least one week after diagnosis
15,T12,Reference_point 151 160	diagnosis
16,R5,Has_index Arg1:T11 Arg2:T12
17,*,OR T9 T11
18,T13,Condition 166 177	discrepancy
19,T14,Temporal 181 253	at least one week between crown-rump length and calendar gestational age
20,R6,Has_temporal Arg1:T13 Arg2:T14
21,T15,Reference_point 207 224	crown-rump length
22,T16,Reference_point 229 253	calendar gestational age
23,R7,Has_index Arg1:T14 Arg2:T15
24,R8,Has_index Arg1:T14 Arg2:T16
25,T17,Scope 99 126;127 160	at least one week later OR
26,At,least one week after diagnosis
27,R9,Has_temporal Arg1:T10 Arg2:T9
28,R10,Has_temporal Arg1:T10 Arg2:T11
29,*,OR T10 T13
30,T18,Condition 255 278	Intra-uterine pregnancy
31,T19,Person 280 285	Women
32,T20,Person 286 290	aged
33,T21,Value 291 305	above 16 years
34,R11,Has_value Arg1:T20 Arg2:T21
35,T22,Condition 307 325	Hemodynamic stable
36,T23,Negation 335 337	No
37,T24,Negation 358 360	No
38,T25,Negation 391 393	No
39,T26,Condition 338 356	signs of infection
40,T27,Condition 361 389	signs of incomplete abortion
41,R12,Has_negation Arg1:T26 Arg2:T23
42,R13,Has_negation Arg1:T27 Arg2:T24
43,T28,Drug 416 428	mifepristone
44,T29,Drug 432 443	misoprostol
45,*,OR T29 T28
46,T30,Mood 394 415	contraindications for
47,T31,Scope 416 443	mifepristone or misoprostol
48,R14,Has_mood Arg1:T31 Arg2:T30
49,R15,Has_negation Arg1:T30 Arg2:T25
0,T1,Observation 2 18	positive history
1,T2,Condition 22 42	chronic claudication
2,R1,Has_temporal Arg1:T2 Arg2:T1
3,T3,Condition 45 75	Exercise-limiting claudication
4,T4,Observation 91 98	history
5,T5,Procedure 103 121	direct observation
6,T6,Procedure 131 153	screening walking test
7,T7,Scope 91 153	history and direct observation during a screening walking test
8,R2,Has_scope Arg1:T3 Arg2:T7
9,T8,Condition 204 230	Arterial occlusive disease
10,T9,Procedure 235 268	ankle Brachial index measurements
11,T10,Procedure 282 300	imaging modalities
12,*,OR T9 T10
13,T11,Scope 235 300	ankle Brachial index measurements and/or other imaging modalities
14,R3,AND Arg1:T11 Arg2:T8
15,T12,Qualifier 303 309	Stable
16,T13,Procedure 310 332	blood pressure regimen
17,R4,Has_qualifier Arg1:T13 Arg2:T12
18,T14,Qualifier 334 340	stable
19,T15,Procedure 341 354	lipid regimen
20,R5,Has_qualifier Arg1:T15 Arg2:T14
21,T16,Qualifier 356 362	stable
22,T17,Procedure 363 379	diabetes regimen
23,R6,Has_qualifier Arg1:T17 Arg2:T16
24,T18,Procedure 384 403	risk factor control
25,T19,Multiplier 404 415	for 6 weeks
26,T20,"Scope 303 403	Stable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control"
27,R7,Has_multiplier Arg1:T20 Arg2:T19
0,T1,Value 4 26	from birth to 21 years
1,T2,Person 0 3	Age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Visit 90 117	Seattle Children's Hospital
4,T4,Procedure 32 54	solid organ transplant
5,R2,AND Arg1:T4 Arg2:T3
6,T5,"Post-eligibility 119 174	Signed consent, and when age appropriate, signed assent"
0,T1,Condition 10 32	thromboembolic disease
1,T2,Condition 45 67	thromboembolic disease
2,T3,Observation 34 41	history
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,T4,Temporal 3 9	Active
5,R2,Has_temporal Arg1:T1 Arg2:T4
6,T5,Condition 79 91	retinal vein
7,T6,Condition 95 111	artery occlusion
8,*,OR T6 T5
9,T7,Scope 79 111	retinal vein or artery occlusion
10,R3,Subsumes Arg1:T2 Arg2:T7
11,T8,Condition 120 143	inherited thrombophilia
12,T9,Observation 148 162	family history
13,T10,Condition 166 176	thrombosis
14,T11,Observation 177 203	in a first degree relative
15,R4,Has_context Arg1:T10 Arg2:T9
16,R5,Has_context Arg1:T9 Arg2:T11
17,*,OR T8 T10 T2 T1
18,T12,Condition 240 259	psychiatric illness
19,T13,Condition 229 236;252 259	medical illness
20,T14,Qualifier 222 228	severe
21,T15,Scope 229 259	medical or psychiatric illness
22,R6,Has_qualifier Arg1:T15 Arg2:T14
23,T16,Undefined_semantics 222 228	severe
24,T17,"Qualifier 266 343	in the opinion of the Investigator, would affect subject safety or compliance"
25,T18,"Non-query-able 266 343	in the opinion of the Investigator, would affect subject safety or compliance"
26,R7,Has_qualifier Arg1:T15 Arg2:T17
27,T19,Condition 376 393	bleeding disorder
28,T20,Condition 414 432	bleeding disorders
29,T21,Condition 441 470	type 1 von Willebrand disease
30,T22,Condition 472 502	mild platelet function defects
31,T23,Condition 511 532;544 551	platelet storage pool defects
32,T24,Condition 511 519;536 551	platelet release defects
33,*,OR T23 T24
34,T25,Scope 511 551	platelet storage pool or release defects
35,R8,Subsumes Arg1:T22 Arg2:T25
36,T26,Condition 587 609	Ehlers Danlos syndrome
37,T27,Grammar_Error 610 626	WILL be eligible
38,T28,Condition 571 579	bleeding
39,R9,AND Arg1:T28 Arg2:T26
40,T29,Qualifier 369 375	severe
41,R10,Has_qualifier Arg1:T19 Arg2:T29
42,T30,Undefined_semantics 369 375	severe
43,T31,Qualifier 409 413	mild
44,T32,Undefined_semantics 409 413	mild
45,R11,Has_qualifier Arg1:T20 Arg2:T31
46,T33,"Scope 441 551	type 1 von Willebrand disease, mild platelet function defects such as platelet storage pool or release defects"
47,*,OR T22 T21
48,T34,Scope 409 432	mild bleeding disorders
49,R12,Subsumes Arg1:T34 Arg2:T33
50,*,OR T34 T19
51,T35,Condition 660 669	Pregnancy
52,T36,Temporal 670 694	within the past 6 months
53,T37,Condition 702 716	breast-feeding
54,R13,Has_temporal Arg1:T35 Arg2:T36
55,R14,Has_temporal Arg1:T37 Arg2:T36
56,*,OR T37 T35
57,T38,Procedure 728 750	hormonal contraception
58,T39,Drug 752 760	estrogen
59,T40,Drug 765 774	progestin
60,T41,Scope 752 774	estrogen and progestin
61,R15,Subsumes Arg1:T38 Arg2:T41
62,T42,Temporal 776 806	within 3 months of study entry
63,T43,Reference_point 795 806	study entry
64,R16,Has_index Arg1:T42 Arg2:T43
65,T44,Observation 811 827	anticipated need
66,T45,Procedure 840 882	estrogen-containing hormonal contraception
67,T46,Drug 840 848	estrogen
68,T47,Qualifier 840 859	estrogen-containing
69,R17,Has_qualifier Arg1:T45 Arg2:T47
70,R18,AND Arg1:T47 Arg2:T46
71,T48,Temporal 883 906	during the study period
72,T49,Reference_point 890 906	the study period
73,R19,Has_index Arg1:T48 Arg2:T49
74,R20,Has_context Arg1:T45 Arg2:T44
75,R21,Has_temporal Arg1:T45 Arg2:T48
76,T50,Drug 918 935	systemic steroids
77,T51,Temporal 936 965	within 1 month of study entry
78,T52,Reference_point 954 965	study entry
79,R22,Has_index Arg1:T51 Arg2:T52
80,R23,Has_temporal Arg1:T50 Arg2:T51
81,T53,Condition 981 1004	subarachnoid hemorrhage
82,T54,Observation 970 977	History
83,R24,Has_temporal Arg1:T53 Arg2:T54
84,T55,Condition 1020 1031	Hepatitis B
85,T56,Condition 1020 1029;1033 1034	Hepatitis C
86,T57,Condition 1039 1042	HIV
87,T58,Observation 1009 1016	History
88,T59,"Scope 1020 1042	Hepatitis B, C, or HIV"
89,*,OR T56 T57 T55
90,R25,Has_temporal Arg1:T59 Arg2:T58
91,T60,Measurement 1056 1066	creatinine
92,T61,Temporal 1047 1055	Baseline
93,T62,Value 1067 1111	>20% above the upper limit of normal for age
94,T63,Person 1108 1111	age
95,R26,Has_value Arg1:T60 Arg2:T62
96,R27,Has_temporal Arg1:T60 Arg2:T61
97,T64,Condition 1124 1130	anemia
98,T65,Qualifier 1117 1123	Severe
99,T66,Measurement 1132 1142	hemoglobin
100,T67,Value 1143 1150	<8 g/dL
101,R28,Has_value Arg1:T66 Arg2:T67
102,R29,Subsumes Arg1:T65 Arg2:T66
103,R30,Has_qualifier Arg1:T64 Arg2:T65
104,T68,Measurement 1157 1180	Systolic blood pressure
105,T69,Value 1181 1184	<85
106,T70,Measurement 1188 1212	diastolic blood pressure
107,T71,Value 1213 1216	<55
108,R31,Has_value Arg1:T70 Arg2:T71
109,R32,Has_value Arg1:T68 Arg2:T69
110,*,OR T70 T68
111,T72,Measurement 1222 1232	Heart rate
112,T73,Value 1233 1236	<50
113,T74,Temporal 1237 1257	at time of screening
114,T75,Reference_point 1240 1257	time of screening
115,R33,Has_value Arg1:T72 Arg2:T73
116,R34,Has_temporal Arg1:T72 Arg2:T74
117,T76,Device 1270 1286	intranasal DDAVP
118,T77,Temporal 1287 1300	during menses
119,T78,Reference_point 1294 1300	menses
120,R35,Has_index Arg1:T74 Arg2:T75
121,R36,Has_index Arg1:T77 Arg2:T78
122,R37,Has_temporal Arg1:T76 Arg2:T77
123,T79,Grammar_Error 1301 1318	will be permitted
124,T80,"Grammar_Error 1263 1726	Use of intranasal DDAVP during menses will be permitted, but only if the patient has a history of using DDAVP consistently for ≥3 menstrual cycles prior to study enrollment, so that change in menstrual blood loss due to addition of Lysteda can be assessed. Use of one-time DDAVP during a DDAVP/Stimate challenge is also permitted during the study period, as is use of DDAVP in the event of severe epistaxis, trauma, or surgical procedures during the study period."
125,T81,"Not_a_criteria 1263 1725	Use of intranasal DDAVP during menses will be permitted, but only if the patient has a history of using DDAVP consistently for ≥3 menstrual cycles prior to study enrollment, so that change in menstrual blood loss due to addition of Lysteda can be assessed. Use of one-time DDAVP during a DDAVP/Stimate challenge is also permitted during the study period, as is use of DDAVP in the event of severe epistaxis, trauma, or surgical procedures during the study period"
0,T1,Condition 2 9	disease
1,T2,Qualifier 21 35;45 53	affect hepatic function
2,T3,Qualifier 21 27;39 53	affect renal function
3,*,OR T2 T3
4,T4,Condition 55 72	contraindications
5,T5,Drug 76 93	opioid analgesics
6,R1,AND Arg1:T4 Arg2:T5
7,T6,Condition 95 119	fetal growth retardation
8,T7,Condition 130 144	fetal asphyxia
9,T8,Mood 121 129	signs of
10,T9,Procedure 148 164	cardiotocography
11,R2,Has_mood Arg1:T7 Arg2:T8
12,R3,AND Arg1:T7 Arg2:T9
13,T10,Condition 166 197	meconium stained amniotic fluid
14,T11,Condition 201 224	placental insufficiency
15,*,OR T10 T11 T7 T6 T4 T1
16,T12,Scope 21 53	affect hepatic or renal function
17,R4,Has_scope Arg1:T1 Arg2:T12
18,T13,Drug 264 272	fentanyl
19,T14,Negation 246 249	not
20,T15,Temporal 273 300	during the previous 14 days
21,R5,Has_temporal Arg1:T13 Arg2:T15
22,R6,Has_negation Arg1:T13 Arg2:T14
0,T1,Temporal 0 10	Undergoing
1,T2,Procedure 11 40	right upper extremity surgery
2,T3,Procedure 46 67	supraclavicular block
3,T4,Qualifier 75 93	primary anesthetic
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,R2,AND Arg1:T2 Arg2:T3
6,R3,Has_temporal Arg1:T2 Arg2:T1
7,T5,Person 95 98	Age
8,T6,Value 99 132	greater than or equal to 18 years
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Measurement 141 200	American Society of Anesthesiologists (ASA) physical status
11,T8,Value 201 207	1 to 3
12,T9,Observation 209 238	Able to give informed consent
0,T1,Procedure 37 53	knee replacement
1,T2,Procedure 30 33;42 53	hip replacement
2,*,OR T1 T2
3,T3,Scope 30 53	hip or knee replacement
4,T4,Qualifier 20 29	bilateral
5,R1,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Procedure 76 81;89 105	total knee replacement
7,T6,Procedure 76 85;94 105	total hip replacement
8,*,OR T5 T6
9,T7,Competing_trial 57 179	atients undergoing total hip or knee replacement who have been enrolled in this study for a prior hip or knee replacement;
10,T8,"Competing_trial 181 367	Patients who are concurrently enrolled in another active interventional clinical trial testing a drug or intervention known or believed to interact with aspirin, warfarin, or rivaroxaban"
11,T9,Condition 390 406	contraindication
12,T10,Non-representable 370 461	Patients who have a contraindication to two or more of the three study prophylaxis regimens
13,T11,"Pregnancy_considerations 464 617	Women who are pregnant or breastfeeding, as well as those of reproductive potential unless there is a negative urine pregnancy test on the day of surgery"
14,T12,Drug 673 688	anticoagulation
15,T13,Negation 689 699	other than
16,T14,Drug 705 717	antiplatelet
17,R2,Has_negation Arg1:T14 Arg2:T13
18,T15,Temporal 641 671	longer than the prior 6 months
19,R3,Has_temporal Arg1:T12 Arg2:T15
20,T16,Condition 757 773;794 804	gastrointestinal hemorrhage
21,T17,Condition 775 783;794 804	cerebral hemorrhage
22,T18,Condition 794 804	hemorrhage
23,*,OR T18 T17 T16
24,T19,Temporal 805 837	within 3 months of the operation
25,T20,Reference_point 828 837	operation
26,R4,Has_index Arg1:T19 Arg2:T20
27,T21,"Scope 757 804	gastrointestinal, cerebral, or other hemorrhage"
28,R5,Has_temporal Arg1:T21 Arg2:T19
29,T22,Condition 885 895	hemostasis
30,T23,Qualifier 875 884	defective
31,R6,Has_qualifier Arg1:T22 Arg2:T23
32,T24,Condition 925 933	bleeding
33,T25,Procedure 944 955	transfusion
34,T26,Procedure 960 969	treatment
35,T27,Scope 944 969	transfusion and treatment
36,R7,Has_scope Arg1:T24 Arg2:T27
37,T28,Procedure 997 1016	operative procedure
38,T29,Qualifier 1031 1034	eye
39,T30,Qualifier 1036 1039	ear
40,T31,Qualifier 1044 1066	central nervous system
41,T32,Temporal 1067 1083	within one month
42,*,OR T29 T30 T31
43,T33,"Scope 1031 1066	eye, ear, or central nervous system"
44,R8,Has_scope Arg1:T28 Arg2:T33
45,R9,Has_temporal Arg1:T28 Arg2:T32
46,T34,Condition 1120 1132	hypertension
47,T35,Qualifier 1107 1119	uncontrolled
48,T36,Qualifier 1100 1106	severe
49,T37,Measurement 1138 1149	systolic BP
50,T38,Value 1150 1159	> 220mmHg
51,T39,Measurement 1163 1175	diastolic BP
52,T40,Value 1176 1185	> 120mmHg
53,R10,Has_value Arg1:T37 Arg2:T38
54,R11,Has_value Arg1:T39 Arg2:T40
55,*,OR T39 T37
56,T41,Scope 1138 1185	systolic BP > 220mmHg or diastolic BP > 120mmHg
57,R12,Has_qualifier Arg1:T34 Arg2:T35
58,R13,Has_qualifier Arg1:T34 Arg2:T36
59,R14,Has_scope Arg1:T34 Arg2:T41
60,T42,Measurement 1214 1225	body weight
61,T44,Value 1229 1251	less than 41 kilograms
62,T45,Value 1253 1261	90.4 lbs
63,R16,Subsumes Arg1:T44 Arg2:T45
64,R17,Has_value Arg1:T42 Arg2:T44
65,T43,Person 1324 1333	prisoners
66,T46,Visit 1338 1355	institutionalized
67,*,OR T43 T46
0,T1,Observation 0 15	Patient refusal
1,T2,Procedure 20 41	supraclavicular block
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Observation 43 77	Inability to give informed consent
4,T4,Condition 79 86	Allergy
5,T5,Drug 90 107	local anesthetics
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 109 138	Hemidiaphragmatic dysfunction
8,T7,Condition 159 162	PNP
9,T8,Qualifier 153 158	known
10,T9,Qualifier 140 149	suspected
11,*,OR T9 T8
12,T10,Scope 140 158	suspected or known
13,R3,Has_scope Arg1:T7 Arg2:T10
14,*,OR T7 T6
15,T11,Condition 164 185	Neuromuscular disease
16,T12,Condition 202 231	restrictive pulmonary disease
17,T13,Condition 187 198;214 231	Obstructive pulmonary disease
18,*,OR T13 T12
19,T14,Qualifier 244 252	anatomic
20,T15,Qualifier 233 240	Medical
21,T16,Condition 253 269	contraindication
22,T17,Procedure 273 297	supraclavicular blockade
23,*,OR T14 T15
24,T18,Scope 233 252	Medical or anatomic
25,R4,Has_scope Arg1:T16 Arg2:T18
26,R5,AND Arg1:T16 Arg2:T17
27,T19,Non-representable 298 320	as judged by clinician
28,T20,Condition 322 331	Pregnancy
0,T1,Condition 0 7	healthy
1,T2,Person 8 19	parturients
2,T3,Qualifier 25 38	uncomplicated
3,T4,Qualifier 40 56	single gestation
4,T5,Condition 57 68	pregnancies
5,R1,Has_qualifier Arg1:T5 Arg2:T4
6,R2,Has_qualifier Arg1:T5 Arg2:T3
7,T6,Qualifier 70 79	full term
8,T7,Condition 107 116	pregnancy
9,T8,Value 81 86	38-42
10,T9,Measurement 87 105	weeks of gestation
11,R3,Has_value Arg1:T9 Arg2:T8
12,T10,Scope 81 105	38-42 weeks of gestation
13,R4,Subsumes Arg1:T6 Arg2:T10
14,T11,Informed_consent 118 139	agreed to participate
15,R5,Has_qualifier Arg1:T7 Arg2:T6
0,T1,Person 0 5	Males
1,T2,Person 10 17	females
2,*,OR T1 T2
3,T3,Person 30 33	age
4,T4,Value 18 26;34 42	21 years or older
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Procedure 142 163	total hip replacement
7,T6,Qualifier 56 64	elective
8,T7,Qualifier 65 72	primary
9,T8,Qualifier 100 108	revision
10,T9,Qualifier 113 141	second stage re-implantation
11,T10,Qualifier 74 98	resurfacing arthroplasty
12,T11,"Scope 65 141	primary, resurfacing arthroplasty, revision, or second stage re-implantation"
13,*,OR T9 T8 T10 T7
14,R2,Has_scope Arg1:T5 Arg2:T11
15,R3,Has_qualifier Arg1:T5 Arg2:T6
16,T12,Procedure 264 280	knee replacement
17,T13,Qualifier 246 263	uni compartmental
18,T14,Qualifier 208 242	second stage re-implantation total
19,T15,Qualifier 195 203	revision
20,T16,Qualifier 186 193	primary
21,T17,Qualifier 177 185	elective
22,T18,"Scope 186 263	primary, revision, or second stage re-implantation total or uni compartmental"
23,*,OR T16 T15 T14 T13
24,R4,Has_scope Arg1:T12 Arg2:T18
25,R5,Has_qualifier Arg1:T12 Arg2:T17
26,T19,Post-eligibility 283 390	Patient has necessary mental capacity to participate and is able to comply with study protocol requirements
27,T20,Informed_consent 393 445	Patient is willing and able to give informed consent
28,T21,Post-eligibility 452 503	Patient is willing to be randomized and participate
0,T1,Measurement 14 24	FEV1 / FVC
1,T2,Value 25 29	<70%
2,R1,Has_value Arg1:T1 Arg2:T2
0,T1,Condition 12 15	SCI
1,T2,Temporal 16 23	=1 year
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Measurement 26 38	Level of SCI
4,T4,Value 39 44	C3-T1
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 46 49	AIS
7,T6,Value 50 55	A & B
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Person 58 61	Age
10,T8,Value 62 85	between 18 and 65 years
11,R4,Has_value Arg1:T7 Arg2:T8
0,T1,Condition 14 21	healthy
1,T2,Person 22 28	adults
2,T3,Person 41 45	ages
3,T4,Value 29 36;49 54	between 18-60
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Observation 63 80	fluent in English
6,T6,Qualifier 0 13	self-reported
7,R2,Has_qualifier Arg1:T1 Arg2:T6
0,T1,Condition 44 68	Left Bundle Branch Block
1,T2,Procedure 70 90	Thrombolytic therapy
2,T3,Temporal 91 127	within 24 hours before randomization
3,T4,Procedure 129 149	Oral anticoagulation
4,T5,Measurement 155 191	International Normalized Ratio (INR)
5,T6,Value 192 195	> 2
6,R1,Has_value Arg1:T5 Arg2:T6
7,T7,Measurement 203 212	platelets
8,T8,Value 213 225	< 100.000/µl
9,*,OR T7 T8 T9
10,T9,Condition 235 256	hemorrhagic diathesis
11,T10,Condition 268 299	Transient Ischemic Attack (TIA)
12,T11,Condition 258 264	Stroke
13,*,OR T11 T10
14,T12,Scope 258 299	Stroke or Transient Ischemic Attack (TIA)
15,T13,Temporal 300 324	within the past 6 months
16,T14,Condition 342 370	residual neurological defect
17,R2,Has_temporal Arg1:T12 Arg2:T13
18,*,OR T12 T14
19,T15,Condition 394 410;425 433	gastrointestinal bleeding
20,T16,Condition 414 433	urogenital bleeding
21,T17,Temporal 387 393	active
22,*,OR T15 T16
23,T18,Scope 394 433	gastrointestinal or urogenital bleeding
24,R3,Has_temporal Arg1:T18 Arg2:T17
25,T19,Temporal 449 463	within 6 weeks
26,T20,Procedure 435 448	Major surgery
27,R4,Has_temporal Arg1:T20 Arg2:T19
28,T21,Condition 476 493	allergic reaction
29,T22,Observation 465 472	History
30,T23,Drug 497 506	abciximab
31,T24,Drug 510 522	eptifibatide
32,T25,Drug 530 557	component used in the study
33,T26,Drug 569 583	contrast media
34,R5,Subsumes Arg1:T25 Arg2:T26
35,T27,Scope 497 584	abciximab or eptifibatide or any component used in the study (including contrast media)
36,*,OR T23 T24 T25 T26
37,R6,AND Arg1:T22 Arg2:T21
38,R7,Has_scope Arg1:T21 Arg2:T27
39,T28,Measurement 606 626	creatinine clearance
40,T29,Value 627 636	<30ml/min
41,R8,Has_value Arg1:T28 Arg2:T29
42,T30,Condition 641 662	hepatic insufficiency
43,T31,Measurement 674 700	Alanine transaminase (ALT)
44,T32,Measurement 701 729	aspartate transaminase (AST)
45,T33,Value 730 740	elevations
46,T34,Value 743 769	3xUpper limit normal (ULN)
47,R9,Subsumes Arg1:T33 Arg2:T34
48,R10,Has_value Arg1:T31 Arg2:T33
49,R11,Has_value Arg1:T32 Arg2:T33
50,T35,Condition 599 604;649 662	renal insufficiency
51,*,OR T35 T30 T37
52,T36,Scope 606 636	creatinine clearance <30ml/min
53,R12,Subsumes Arg1:T35 Arg2:T36
54,T37,Scope 674 769	Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN)
55,T38,Condition 860 866;879 886	Severe disease
56,T39,Measurement 892 908	life expectation
57,T40,Value 909 917	< 1 year
58,*,OR T39 T40
59,R13,AND Arg1:T38 Arg2:T39
60,T41,Qualifier 592 598	severe
61,R14,Has_qualifier Arg1:T35 Arg2:T41
62,R15,Has_qualifier Arg1:T30 Arg2:T41
63,T42,Temporal 867 878	concomitant
64,R16,Has_temporal Arg1:T38 Arg2:T42
65,T43,Observation 931 956	participated in any study
66,T44,Drug 966 986	investigational drug
67,T45,Device 990 996	device
68,*,OR T44 T45
69,T46,Scope 966 996	investigational drug or device
70,R17,Has_scope Arg1:T43 Arg2:T46
71,T47,Temporal 1035 1062;997 1011	of the investigational drug within 30 days
72,T48,Temporal 1015 1062	within 5 half-lives of the investigational drug
73,*,OR T47 T48
74,T49,Reference_point 1035 1062	of the investigational drug
75,T50,Scope 997 1062	within 30 days or within 5 half-lives of the investigational drug
76,R18,Has_scope Arg1:T43 Arg2:T50
77,R19,Has_index Arg1:T50 Arg2:T49
78,T51,Observation 1133 1145	inaccessible
79,T52,Temporal 1182 1211	during treatment or follow-up
80,T53,Reference_point 1189 1198	treatment
81,T54,Reference_point 1202 1211	follow-up
82,T55,"Non-representable 1213 1309	In France, a subject is neither affiliated with nor a beneficiary of a social security category."
83,R20,Has_temporal Arg1:T2 Arg2:T3
84,R21,Has_temporal Arg1:T51 Arg2:T52
85,T56,Negation 9 12	not
86,T57,Informed_consent 21 42	give informed consent
87,T58,Mood 13 20	able to
88,R22,Has_mood Arg1:T57 Arg2:T58
89,R23,Has_negation Arg1:T57 Arg2:T56
90,T59,Reference_point 114 127	randomization
91,R24,Has_index Arg1:T3 Arg2:T59
0,T1,Observation 12 33	sympathetic integrity
1,T2,Qualifier 34 56	below the lesion level
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Measurement 104 108;64 95	test skin axon-reflex vasodilatation
4,T4,Measurement 97 102	SkARV
5,R2,Subsumes Arg1:T3 Arg2:T4
6,R3,Has_context Arg1:T3 Arg2:T1
7,T5,Condition 117 126	allergies
8,T6,Drug 130 153	midodrine hydrochloride
9,R4,AND Arg1:T5 Arg2:T6
10,T7,Condition 242 259	diabetes mellitus
11,T8,Condition 212 237	cerebral vascular disease
12,T9,"Condition 188 208;230 237	peripheral vascular, disease"
13,T10,Condition 180 186;230 237	kidney disease
14,T11,Condition 173 178;230 237	heart disease
15,*,OR T8 T11 T10 T9 T7
16,T12,Condition 262 274	Hypertension
17,T13,Measurement 276 278	BP
18,T14,Value 278 290	>140/90 mmHg
19,R5,Has_value Arg1:T13 Arg2:T14
20,R6,AND Arg1:T12 Arg2:T13
21,T15,Condition 304 319	thyroid disease
22,T16,Qualifier 294 303	Untreated
23,R7,Has_qualifier Arg1:T15 Arg2:T16
24,T17,Condition 339 348	infection
25,T18,Condition 328 335	illness
26,T19,Qualifier 322 327	Acute
27,*,OR T18 T17
28,T20,Scope 328 348	illness or infection
29,R8,Has_qualifier Arg1:T20 Arg2:T19
30,T21,Person 359 365	smoker
31,T22,Condition 368 377	Pregnancy
0,T1,Drug 0 12	beta blocker
1,T2,Condition 14 46	supraventricular rhythm disorder
2,T3,Temporal 48 64	previous history
3,T4,Condition 68 87	respiratory disease
4,T5,Negation 88 98	other than
5,T6,Condition 99 103	COPD
6,R1,Has_negation Arg1:T6 Arg2:T5
7,R2,AND Arg1:T4 Arg2:T6
8,R3,Has_temporal Arg1:T4 Arg2:T3
9,T7,Condition 105 113	diabetes
10,T8,Condition 115 136	autonomic dysfunction
11,T9,Condition 138 150	dysautonomia
12,T10,Condition 152 165	renal failure
13,T11,Procedure 167 191	long-term oxygen therapy
14,T12,Observation 193 200	history
15,T13,Condition 204 223	psychiatric illness
16,R4,Has_temporal Arg1:T13 Arg2:T12
0,T1,Person 0 6	adults
1,T2,Value 20 29;7 15	and above 61 years
2,T3,Person 16 19	old
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Observation 31 38	smokers
5,T5,Person 49 54	women
6,T6,Condition 40 48	pregnant
7,T7,Drug 67 79;86 104	prescription insulin medication
8,T8,Drug 67 84;94 104	prescription pain medication
9,*,OR T8 T7
10,T9,Observation 112 119	history
11,T10,Condition 132 142	smell loss
12,T11,Condition 123 128;138 142	taste loss
13,*,OR T10 T11 T15
14,T12,Qualifier 146 151	other
15,T13,Condition 152 166	oral disorders
16,T14,Condition 174 196	burning mouth syndrome
17,R2,Has_qualifier Arg1:T13 Arg2:T12
18,T15,Scope 146 166	other oral disorders
19,R3,Subsumes Arg1:T15 Arg2:T14
20,T16,"Scope 123 197	taste or smell loss or other oral disorders (e.g., burning mouth syndrome)"
21,R4,Has_temporal Arg1:T16 Arg2:T9
22,T17,Temporal 203 210	current
23,T18,Condition 211 223	oral lesions
24,T19,Condition 225 237	canker sores
25,T20,Device 242 251	piercings
26,*,OR T18 T19 T20
27,T21,"Scope 211 251	oral lesions, canker sores, or piercings"
28,R5,Has_temporal Arg1:T21 Arg2:T17
29,T22,Observation 259 266	history
30,T23,Condition 270 282	food allergy
31,R6,Has_temporal Arg1:T23 Arg2:T22
0,T1,Condition 14 28	postmenopausal
1,T2,Person 0 5	Women
2,A1,Optional T2
3,R1,AND Arg1:T2 Arg2:T1
4,T3,Temporal 34 43	12 months
5,T4,Condition 52 68	menstrual period
6,T5,Negation 44 51	without
7,R2,Has_negation Arg1:T4 Arg2:T5
8,R3,Has_temporal Arg1:T4 Arg2:T3
9,T6,Scope 34 68	12 months without menstrual period
10,R4,Subsumes Arg1:T1 Arg2:T6
11,T7,Condition 74 92	surgically sterile
12,T8,Person 99 104	women
13,T9,Condition 108 131	child bearing potential
14,T10,Scope 99 131	women of child bearing potential
15,A2,Optional T10
16,T11,Negation 136 139	not
17,R5,Has_negation Arg1:T10 Arg2:T11
18,T12,Condition 199 213	pregnancy test
19,T13,Qualifier 191 196	doubt
20,A3,Optional T13
21,R6,AND Arg1:T13 Arg2:T12
22,T14,Condition 320 347	Acute myocardial infarction
23,T15,Temporal 348 354	< 12 h
24,T16,Condition 371 377	Angina
25,T17,Condition 371 377;392 400	Angina symptoms
26,T18,Temporal 401 409	> 20 min
27,*,OR T16 T17
28,T19,Scope 371 400	Angina or equivalent symptoms
29,R7,Has_temporal Arg1:T19 Arg2:T18
30,T20,Condition 418 430	ST elevation
31,T21,Measurement 465 480	precordial lead
32,T22,Measurement 489 498	limb lead
33,T23,Value 484 488	1 mm
34,T24,Value 460 464	2 mm
35,R8,Has_value Arg1:T21 Arg2:T24
36,R9,Has_value Arg1:T22 Arg2:T23
37,T25,"Scope 460 498	2 mm precordial lead, = 1 mm limb lead"
38,T26,Measurement 436 456	contiguous ECG leads
39,T27,Value 434 435	2
40,R11,Has_value Arg1:T26 Arg2:T27
41,T28,Scope 434 456	2 contiguous ECG leads
42,R12,Subsumes Arg1:T28 Arg2:T25
43,R10,Has_scope Arg1:T20 Arg2:T28
44,T29,Observation 557 564	Planned
45,T30,Procedure 565 607	primary percutaneous coronary intervention
46,R13,AND Arg1:T29 Arg2:T30
47,T31,Observation 625 647;655 662	given written informed consent
48,R14,Has_temporal Arg1:T14 Arg2:T15
0,T1,Condition 46 70	Hepatocellular Carcinoma
1,T2,Negation 31 34	non
2,T3,Qualifier 35 45	metastatic
3,R1,Has_negation Arg1:T3 Arg2:T2
4,R2,Has_qualifier Arg1:T1 Arg2:T3
5,T4,Qualifier 21 29	advanced
6,T5,Qualifier 7 19	intermediate
7,T6,Qualifier 0 5	Early
8,*,OR T4 T5 T6
9,T7,"Scope 0 29	Early, intermediate, advanced"
10,R3,Has_scope Arg1:T1 Arg2:T7
11,T8,Procedure 87 104	radioembolization
12,T9,Observation 72 82	Indication
13,T10,Subjective_judgement 72 82	Indication
14,R4,Has_context Arg1:T8 Arg2:T9
15,T11,Non-query-able 105 156	validated after pluridisciplinary committee meeting
16,T12,Context_Error 159 238	Isolated target on initial imagery (invasive hepatocellular carcinoma excluded)
17,T13,Measurement 240 290	WHO (World Health organization) Performance status
18,T14,"Value 292 301	0, 1 or 2"
19,R5,Has_value Arg1:T13 Arg2:T14
20,T15,Condition 306 315	cirrhosis
21,T16,Measurement 317 322;325 330	Child score
22,T17,Value 323 324	A
23,R6,Has_value Arg1:T16 Arg2:T17
24,T18,Measurement 336 351	total bilirubin
25,T19,Value 352 385	less than 30 micromoles per liter
26,R7,Has_value Arg1:T18 Arg2:T19
27,A1,Optional T15
28,T20,Scope 317 385	Child A score with total bilirubin less than 30 micromoles per liter
29,R8,Has_scope Arg1:T15 Arg2:T20
30,T21,Measurement 387 407	Creatinine clearance
31,T22,Value 408 434	more or equal to 30 mL/min
32,R9,Has_value Arg1:T21 Arg2:T22
33,T23,Post-eligibility 436 483	Patient informed and consent signature obtained
0,T1,Condition 9 33	hepatocellular carcinoma
1,T2,Qualifier 0 8	Invasive
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 46 60	isolated tumor
4,T4,Negation 34 41	without
5,R2,Has_negation Arg1:T3 Arg2:T4
6,T5,Context_Error 62 105	Disease needing 2 injections of Therasphere
7,T6,Condition 107 117	Thrombosis
8,T7,Qualifier 118 142	extending into the porta
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Condition 143 153	thrombosis
11,T9,Qualifier 164 168;178 184	left branch
12,T10,Qualifier 172 184	right branch
13,*,OR T9 T10
14,T11,Scope 164 184	left or right branch
15,R4,Has_scope Arg1:T8 Arg2:T11
16,T12,Grammar_Error 185 195	authorized
17,T13,Negation 185 195	authorized
18,R5,Has_negation Arg1:T8 Arg2:T13
19,*,OR T6 T8
20,T14,Condition 198 222	extra hepatic metastasis
21,T15,Procedure 246 263	chemoembolization
22,T16,Procedure 265 279	radiofrequency
23,T17,Temporal 280 323	less than 3 months before radioembolization
24,T18,Reference_point 306 323	radioembolization
25,R6,Has_index Arg1:T17 Arg2:T18
26,*,OR T16 T15
27,T19,"Scope 246 279	chemoembolization, radiofrequency"
28,R7,Has_temporal Arg1:T19 Arg2:T17
29,T20,Temporal 366 380;399 416	15 days before radioembolization
30,T21,Temporal 385 416	15 days after radioembolization
31,T22,Negation 325 327	No
32,T23,Procedure 328 342;355 364	antiangiogenic treatment
33,R8,Has_negation Arg1:T23 Arg2:T22
34,R9,Has_temporal Arg1:T23 Arg2:T20
35,R10,Has_temporal Arg1:T23 Arg2:T21
36,T24,Drug 428 437	Sorafenib
37,R11,Subsumes Arg1:T23 Arg2:T24
38,T25,Condition 439 457	Associated disease
39,T26,Qualifier 464 510	could prevent patient from receiving treatment
40,T27,Undefined_semantics 439 510	Associated disease which could prevent patient from receiving treatment
41,R12,Has_qualifier Arg1:T25 Arg2:T26
42,T28,Procedure 512 515	RMI
43,T29,Condition 512 533	RMI contre-indication
44,T30,Undefined_semantics 512 533	RMI contre-indication
45,T31,Context_Error 640 725	Patient already participating in an other therapeutic trial with an experimental drug
46,T32,Condition 727 735	Pregnant
47,T33,Condition 739 761	childbearing potential
48,T34,Person 762 767	women
49,T35,Observation 771 784	breastfeeding
50,T36,Person 785 790	women
51,*,OR T33 T32 T35
52,T37,"Non-query-able 792 997	minors, persons deprived of liberty or protected adults (maintenance of justice, guardianship or supervision) Unable to comply with trial medical follow-up for geographical, social or psychological reasons"
53,T38,Person 792 798	minors
54,T39,Post-eligibility 999 1033	Unable to sign an informed consent
0,T1,Condition 0 8	Pregnant
1,T2,Condition 16 23	nursing
2,*,OR T1 T2
3,T3,Condition 34 41	Allergy
4,T4,Drug 45 56	bupivacaine
5,R1,AND Arg1:T3 Arg2:T4
6,T5,Condition 70 88	drug/alcohol abuse
7,T6,Observation 59 66	History
8,R2,Has_temporal Arg1:T5 Arg2:T6
9,T7,Condition 129 136;98 112	disease cardiovascular
10,T8,Condition 114 121;129 136	hepatic disease
11,T9,Condition 123 136	renal disease
12,T10,Condition 140 163	neurological impairment
13,*,OR T9 T8 T7 T10
0,T1,Person 18 21	old
1,T2,Value 0 17	>18 to < 90 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 23 33	Both sexes
4,T4,Qualifier 43 51	moderate
5,T5,Qualifier 35 39	Mild
6,*,OR T4 T5
7,T6,Condition 52 73	tear film dysfunction
8,T7,Scope 35 51	Mild to moderate
9,R2,Has_scope Arg1:T6 Arg2:T7
10,T8,Measurement 93 97	TBUT
11,T9,Value 98 119	> 5 sec. and < 10 sec
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Measurement 122 130	Schirmer
14,T11,Value 132 150	> 4 mm and < 14 mm
15,R4,Has_value Arg1:T10 Arg2:T11
16,T12,Measurement 152 156	OSDI
17,T13,Value 157 168	< 30 points
18,R5,Has_value Arg1:T12 Arg2:T13
19,T14,Condition 170 186	Corneal staining
20,T15,Qualifier 187 198	< grade III
21,T16,Qualifier 206 219	Oxford scale
22,R6,Has_qualifier Arg1:T15 Arg2:T16
23,R7,Has_qualifier Arg1:T14 Arg2:T15
24,T17,Qualifier 206 218	Oxford scale
25,R8,Has_qualifier Arg1:T15 Arg2:T17
26,T18,Post-eligibility 220 271	Availability to go to each revision when indicated.
0,T1,Drug 16 37	influenza vaccination
1,T2,Condition 4 12	allergic
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Drug 53 74	influenza vaccination
4,T4,Temporal 75 99	within the past 6 months
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Drug 109 119	prednisone
7,T6,Drug 121 133	methotrexate
8,T7,Drug 144 173	immunosuppressing medications
9,T8,Qualifier 138 143	other
10,R3,Has_qualifier Arg1:T7 Arg2:T8
11,*,OR T5 T6 T7
12,T9,Condition 180 193	HIV infection
13,T10,Procedure 228 250	bone marrow transplant
14,T11,Procedure 213 224;240 250	solid organ transplant
15,T12,Qualifier 202 209	history
16,*,OR T10 T11
17,T13,Scope 213 251	solid organ or bone marrow transplant
18,R4,Has_qualifier Arg1:T13 Arg2:T12
19,T14,Procedure 260 285	combination immunotherapy
20,T15,Mood 252 259	require
21,R5,Has_mood Arg1:T14 Arg2:T15
22,T16,Competing_trial 287 409	are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study
0,T1,Procedure 20 36	urologic surgery
0,T1,Drug 29 48	systemic medication
1,T2,Drug 14 21;38 48	topical medication
2,*,OR T1 T2 T3
3,T3,Device 52 70	mechanical devices
4,T4,Drug 136 160	topical immunomodulators
5,T5,Device 162 175	punctal plugs
6,T6,Drug 177 192	corticosteroids
7,T7,Drug 194 223	preservative artificial tears
8,T8,Device 225 239	contact lenses
9,*,OR T4 T5 T8 T7 T6
10,T9,"Scope 136 239	topical immunomodulators, punctal plugs, corticosteroids, preservative artificial tears, contact lenses"
11,T10,Scope 14 70	topical and/or systemic medication or mechanical devices
12,R1,Subsumes Arg1:T10 Arg2:T9
13,T11,Person 253 260	females
14,T12,Observation 267 285	active sexual life
15,T13,Negation 294 297	not
16,T14,Procedure 304 324	contraceptive method
17,R2,Has_negation Arg1:T14 Arg2:T13
18,T15,Person 327 333	Female
19,T16,Condition 351 359	pregnant
20,T17,Condition 363 372	lactating
21,*,OR T16 T17
22,T18,Person 374 380	Female
23,T19,Value 397 405	positive
24,T20,Measurement 406 426	urine pregnancy test
25,R3,Has_value Arg1:T20 Arg2:T19
26,T21,Condition 428 452	Positive drug addictions
27,T22,Procedure 455 475	verbal interrogatory
28,R4,AND Arg1:T21 Arg2:T22
29,T23,Competing_trial 478 566	Subjects who have participated on any other research clinical trials on the last 40 days
30,T24,Condition 586 603	mentally disabled
31,T25,Condition 577 582;595 603	legal disabled
32,*,OR T24 T25
33,T26,Informed_consent 568 663	Subjects legal or mentally disabled to give an informed consent for participating on this study
34,T27,Non-query-able 665 748	Subjects who can't comply with the appointments or with every protocol requirement.
35,T28,Condition 750 788	Serious tear film dysfunction syndrome
36,T29,Measurement 789 793	TBUT
37,T30,Line 750 788	Serious tear film dysfunction syndrome
38,T31,Value 794 799	< 5 s
39,R5,Has_value Arg1:T29 Arg2:T31
40,T32,Measurement 800 808	Schirmer
41,T33,Value 810 816	< 4 mm
42,R6,Has_value Arg1:T32 Arg2:T33
43,T34,Measurement 817 821	OSDI
44,T35,Value 822 832	> 30 pints
45,T36,Measurement 833 849	Corneal staining
46,T37,Value 850 861	> grade III
47,T38,Qualifier 869 881	Oxford scale
48,R7,Has_qualifier Arg1:T36 Arg2:T38
49,R8,Has_value Arg1:T36 Arg2:T37
50,R9,Has_value Arg1:T34 Arg2:T35
51,T39,Line 789 799	TBUT < 5 s
52,T40,Line 800 816	Schirmer: < 4 mm
53,T41,Line 817 832	OSDI > 30 pints
54,T42,Line 833 881	Corneal staining > grade III on the Oxford scale
55,T43,Qualifier 883 897	Non perforated
56,T44,Condition 898 911	corneal ulcer
57,R10,Has_qualifier Arg1:T44 Arg2:T43
58,T45,Condition 924 937	corneal ulcer
59,T46,Qualifier 913 923	Perforated
60,R11,Has_qualifier Arg1:T45 Arg2:T46
61,T47,Condition 950 963	corneal ulcer
62,T48,Qualifier 939 949	Autoimmune
63,R12,Has_qualifier Arg1:T47 Arg2:T48
64,T49,Condition 965 997	Ocular surface scarring diseases
65,T50,Condition 1037 1044;999 1013	lesions Ocular surface
66,T51,Condition 1017 1044;999 1005	annexes metaplastic lesions Ocular
67,*,OR T50 T51
68,T52,Condition 1046 1082	Fibro vascular proliferation lesions
69,T53,Qualifier 1110 1125	corneal surface
70,T54,Qualifier 1090 1102	conjunctival
71,*,OR T53 T54
72,T55,Qualifier 1133 1142	pterygium
73,T56,Scope 1090 1125	conjunctival and/or corneal surface
74,R13,Subsumes Arg1:T56 Arg2:T55
75,R14,Has_scope Arg1:T52 Arg2:T56
76,T57,Temporal 1145 1156	Concomitant
77,T58,Condition 1157 1186	chronic inflammatory diseases
78,T59,Qualifier 1194 1210	ocular structure
79,R15,Has_qualifier Arg1:T58 Arg2:T59
80,R16,Has_temporal Arg1:T58 Arg2:T57
81,T60,Condition 1232 1252	inflammatory disease
82,T61,Qualifier 1212 1217	Acute
83,T62,Qualifier 1221 1231	infectious
84,*,OR T62 T61
85,T63,Scope 1212 1231	Acute or infectious
86,R17,Has_scope Arg1:T60 Arg2:T63
87,T64,Condition 1254 1269	Corneal disease
88,T65,Procedure 1294 1303	treatment
89,T66,Mood 1270 1291	potentially requiring
90,R18,Has_mood Arg1:T65 Arg2:T66
91,T67,Temporal 1304 1333	during the following 3 months
92,R19,AND Arg1:T64 Arg2:T65
93,R20,Has_temporal Arg1:T65 Arg2:T67
94,T68,Non-representable 1335 1399	Use of topical or systemic drug products classified as forbidden
95,T69,Procedure 1401 1427	Ocular surgical procedures
96,T70,Temporal 1428 1467	3 months before the protocol inclusion
97,T71,Reference_point 1448 1466	protocol inclusion
98,T72,Temporal 1428 1466	3 months before the protocol inclusion
99,R21,Has_index Arg1:T72 Arg2:T71
100,R22,Has_temporal Arg1:T69 Arg2:T72
101,T73,Procedure 1468 1478	Treatments
102,T74,Procedure 1482 1492	procedures
103,T75,Procedure 1510 1541	tear film dysfunction treatment
104,T76,Device 1546 1568	punctal silicone plugs
105,*,OR T74 T73
106,T77,Scope 1468 1492	Treatments or procedures
107,R23,Has_scope Arg1:T75 Arg2:T77
108,R24,AND Arg1:T75 Arg2:T76
109,T78,Condition 1571 1597	Posterior segment diseases
110,T79,Procedure 1610 1619	treatment
111,T80,Condition 1623 1655	threatening the visual prognosis
112,*,OR T79 T80
113,T81,Mood 1598 1607	requiring
114,R25,Has_mood Arg1:T79 Arg2:T81
115,T82,Scope 1598 1655	requiring a treatment or threatening the visual prognosis
116,R26,Has_scope Arg1:T78 Arg2:T82
117,T83,Device 1783 1802	hard contact lenses
118,T84,Procedure 1748 1772	penetrating keratoplasty
119,T85,Temporal 1706 1735	during the following 3 months
120,T86,Procedure 1696 1705	treatment
121,T87,Mood 1686 1695	requiring
122,R27,Has_mood Arg1:T86 Arg2:T87
123,R28,Has_temporal Arg1:T86 Arg2:T85
124,T88,Condition 1657 1673	Retinal diseases
125,R29,AND Arg1:T88 Arg2:T86
126,T89,Observation 1737 1744	History
127,R30,Has_temporal Arg1:T84 Arg2:T89
128,T90,Device 1775 1779;1788 1802	Soft contact lenses
129,*,OR T83 T90
130,T91,Temporal 1807 1847	during the last month from inclusion day
131,T92,Reference_point 1834 1847	inclusion day
132,R31,Has_index Arg1:T91 Arg2:T92
133,T93,Scope 1775 1802	Soft or hard contact lenses
134,R32,Has_temporal Arg1:T93 Arg2:T91
0,T1,Person 0 6	adults
1,T2,Informed_consent 7 35	capable of providing consent
2,T3,Condition 88 96	melanoma
3,T4,Qualifier 77 87	metastatic
4,T5,Qualifier 57 73	locally advanced
5,*,OR T5 T4
6,T6,Scope 57 87	locally advanced or metastatic
7,R1,Has_scope Arg1:T3 Arg2:T6
0,T1,Condition 0 24	impaired decision making
1,T2,Condition 26 43	neurofibromatosis
2,T3,Mood 45 50	signs
3,T4,Condition 55 74	central dysfunction
4,R1,Has_mood Arg1:T4 Arg2:T3
5,T5,Condition 76 105	remaining vestibular function
6,T6,Non-representable 107 171	Patients are advised not to participate in the gentamicin arm if
7,T7,Measurement 173 180	hearing
8,T8,Value 184 211	better than 30 deciBel (dB)
9,T9,Qualifier 215 232	pure tone average
10,T10,"Qualifier 234 260	500, 1000, 2000, 3-4000 Hz"
11,R2,Subsumes Arg1:T9 Arg2:T10
12,R3,Has_qualifier Arg1:T7 Arg2:T9
13,R4,Has_value Arg1:T7 Arg2:T8
14,T11,Measurement 266 287	speech discrimination
15,T12,Value 288 303	better than 70%
16,R5,Has_value Arg1:T11 Arg2:T12
17,T13,Non-representable 305 416	the neurosurgeon aim at hearing preservation surgery and do not want to risk gentamicin associated hearing loss
0,T1,Non-representable 0 44	Conversion from laparoscopic to open surgery
1,T2,Observation 46 53	History
2,T3,Condition 57 69	Chronic pain
3,T4,Condition 95 107	chronic pain
4,T5,Temporal 73 80	ongoing
5,T6,Procedure 81 90	treatment
6,R1,Has_temporal Arg1:T6 Arg2:T5
7,R2,AND Arg1:T6 Arg2:T4
8,R3,Has_temporal Arg1:T3 Arg2:T2
9,R4,AND Arg1:T3 Arg2:T6
10,T7,Person 109 112	Age
11,T8,Value 113 129	less than 18 yrs
12,R5,Has_value Arg1:T7 Arg2:T8
13,T9,Condition 131 138	Allergy
14,T10,Drug 142 159	local anesthetics
15,R6,AND Arg1:T9 Arg2:T10
0,T1,Qualifier 14 21	de novo
1,T2,Condition 22 38	stenotic lesions
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Mood 47 55	suitable
4,T4,Procedure 60 77	coronary stenting
5,T5,Device 83 101	drug-eluting stent
6,R2,AND Arg1:T4 Arg2:T5
7,R3,Has_mood Arg1:T4 Arg2:T3
0,T1,Person 0 3	Age
1,T2,Value 4 31	1 day to less than 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Visit 50 79	pediatric intensive care unit
4,T4,Visit 83 120	pediatric cardiac intensive care unit
5,*,OR T3 T4
6,T5,Procedure 146 163	venoarterial ECMO
7,T6,Procedure 132 142;159 163	venovenous ECMO
8,*,OR T5 T6
0,T1,Measurement 0 43	estimated glomerular filtration rate (eGFR)
1,T2,Value 44 55	> 60 ml/min
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 67 101	left ventricular ejection fraction
4,T4,Value 57 66	preserved
5,T5,Value 103 109	>= 50%
6,R2,Subsumes Arg1:T4 Arg2:T5
7,R3,Has_value Arg1:T3 Arg2:T4
8,T6,Procedure 114 130	echocardiography
9,R4,AND Arg1:T6 Arg2:T3
10,T7,Condition 132 139	HEALTHY
11,T8,Value 141 165	normal cardiac structure
12,T9,Value 141 155;170 178	normal cardiac function
13,T10,Procedure 182 198	echocardiography
14,*,OR T8 T9
15,T11,Scope 141 178	normal cardiac structure and function
16,R5,Has_scope Arg1:T10 Arg2:T11
17,T12,Measurement 200 202	BP
18,T13,Value 203 211	< 140/90
19,R6,Has_value Arg1:T12 Arg2:T13
20,A1,Optional T7
21,T14,"Scope 141 211	normal cardiac structure and function on echocardiography, BP < 140/90"
22,R7,Has_scope Arg1:T7 Arg2:T14
23,T15,Condition 213 225	HYPERTENSIVE
24,A2,Optional T15
25,T16,Condition 353 358	HFpEF
26,A3,Optional T16
27,T17,Measurement 238 240	BP
28,T18,Value 241 248	>140/90
29,R8,Has_value Arg1:T17 Arg2:T18
30,T19,Observation 227 234	history
31,T20,Multiplier 250 259	1 or more
32,T21,Drug 260 288	antihypertensive medications
33,R9,Has_multiplier Arg1:T21 Arg2:T20
34,T22,Measurement 290 317	LV ejection fraction (LVEF)
35,T23,Value 318 330	at least 50%
36,R10,Has_value Arg1:T22 Arg2:T23
37,T24,Temporal 332 339	current
38,T25,Measurement 340 342	BP
39,T26,Value 343 351	< 160/90
40,R11,Has_value Arg1:T25 Arg2:T26
41,R12,Has_temporal Arg1:T25 Arg2:T24
42,T27,"Scope 227 351	history of BP >140/90, 1 or more antihypertensive medications, LV ejection fraction (LVEF) at least 50%, current BP < 160/90"
43,R13,Has_scope Arg1:T15 Arg2:T27
44,T28,Qualifier 360 379	physician-confirmed
45,T29,Condition 393 395	HF
46,T30,Qualifier 397 408	symptomatic
47,T31,Condition 409 411	HF
48,R14,Has_qualifier Arg1:T31 Arg2:T30
49,R15,Has_qualifier Arg1:T29 Arg2:T28
50,T32,Measurement 413 417	LVEF
51,T33,Value 418 430	at least 50%
52,R16,Has_value Arg1:T32 Arg2:T33
53,T34,Value 432 440	elevated
54,T35,Measurement 441 460	LV filling pressure
55,R17,Has_value Arg1:T35 Arg2:T34
56,T36,Procedure 464 479	catheterization
57,R18,AND Arg1:T36 Arg2:T35
58,T37,Non-representable 481 507	echocardiographic criteria
59,T38,Measurement 511 537	B-type-natriuretic peptide
60,T39,Value 538 543	> 100
61,R19,Has_value Arg1:T38 Arg2:T39
62,T40,Measurement 545 555	current BP
63,T41,Value 556 564	< 160/90
64,R20,Has_value Arg1:T40 Arg2:T41
65,T42,"Scope 360 564	physician-confirmed diagnosis of HF, symptomatic HF, LVEF at least 50%, elevated LV filling pressure by catheterization, echocardiographic criteria or B-type-natriuretic peptide > 100, current BP < 160/90"
66,R21,Has_scope Arg1:T16 Arg2:T42
0,T1,Non-query-able 0 72	Patients unable to understand the objectives of the dietary intervention
1,T2,Context_Error 74 100	Patients in paliative care
2,T3,Undefined_semantics 102 137	Patients receiving supplement diets
0,T1,Line 0 368	1. High risk profiles for ischemic adverse events such as A. ST-segment elevation myocardial infarction (STEMI) B. Patients with cardiogenic shock or concomitant severe decompensated heart failure C. Myocardial infarction or stent thrombosis in spite of the maintenance of antiplatelet therapy D. Restenosis in stented segments or previous sites of balloon angioplasty
1,T2,Line 369 506	2. Patients who cannot follow allocated DAPT schedule due to the planned surgery or elective procedure within 3 months after the stenting
2,T3,Line 507 622	3. Recent history of major surgery or evident events of gastrointestinal bleeding within 1 month from the procedure
3,T4,Line 623 699	4. Patients on anticoagulation therapy with warfarin or other anticoagulants
4,T5,Line 700 793	5. Life expectancy less than 1 year (such as malignancies or other chronic systemic diseases)
5,T6,Line 794 811	6. Pregnant women
6,T7,"Line 812 964	7. Past history of allergy or other contraindications for the following medications/materials: aspirin, clopidogrel, heparin, cobalt chromium, sirolimus"
7,T8,Condition 26 49	ischemic adverse events
8,T9,Condition 3 21	High risk profiles
9,R1,AND Arg1:T9 Arg2:T8
10,T10,Condition 61 111	ST-segment elevation myocardial infarction (STEMI)
11,T11,Condition 129 146	cardiogenic shock
12,T12,Condition 183 196	heart failure
13,T13,Qualifier 162 168	severe
14,T14,Qualifier 169 182	decompensated
15,R2,Has_qualifier Arg1:T12 Arg2:T14
16,R3,Has_qualifier Arg1:T12 Arg2:T13
17,T15,Scope 58 368	A. ST-segment elevation myocardial infarction (STEMI) B. Patients with cardiogenic shock or concomitant severe decompensated heart failure C. Myocardial infarction or stent thrombosis in spite of the maintenance of antiplatelet therapy D. Restenosis in stented segments or previous sites of balloon angioplasty
18,T16,Scope 3 49	High risk profiles for ischemic adverse events
19,R4,Subsumes Arg1:T16 Arg2:T15
20,T17,Condition 200 221	Myocardial infarction
21,T18,Condition 225 241	stent thrombosis
22,T19,Drug 273 293	antiplatelet therapy
23,*,OR T18 T17
24,T20,Scope 200 241	Myocardial infarction or stent thrombosis
25,R5,AND Arg1:T20 Arg2:T19
26,T21,Scope 197 293	C. Myocardial infarction or stent thrombosis in spite of the maintenance of antiplatelet therapy
27,T22,Condition 297 307	Restenosis
28,*,OR T20 T22 T12 T11 T10
29,T23,Mood 434 441	planned
30,T24,Procedure 442 449	surgery
31,T25,Qualifier 453 461	elective
32,T26,Procedure 462 471	procedure
33,R6,Has_qualifier Arg1:T26 Arg2:T25
34,*,OR T26 T24
35,T27,Scope 442 471	surgery or elective procedure
36,R7,Has_mood Arg1:T27 Arg2:T23
37,T28,Temporal 472 506	within 3 months after the stenting
38,R8,Has_temporal Arg1:T27 Arg2:T28
39,T29,Condition 385 422	cannot follow allocated DAPT schedule
40,R9,Has_scope Arg1:T29 Arg2:T27
41,T30,Procedure 528 541	major surgery
42,T31,Condition 553 588	events of gastrointestinal bleeding
43,T32,Temporal 589 622	within 1 month from the procedure
44,*,OR T31 T30
45,T33,Scope 528 588	major surgery or evident events of gastrointestinal bleeding
46,R10,Has_temporal Arg1:T33 Arg2:T32
47,T34,Procedure 638 661	anticoagulation therapy
48,T35,Drug 667 675	warfarin
49,T36,Qualifier 679 684	other
50,T37,Drug 685 699	anticoagulants
51,R11,Has_qualifier Arg1:T37 Arg2:T36
52,*,OR T35 T37
53,T38,Scope 667 699	warfarin or other anticoagulants
54,R12,Has_scope Arg1:T34 Arg2:T38
55,T39,Observation 703 718	Life expectancy
56,T40,Value 719 735	less than 1 year
57,R13,Has_value Arg1:T39 Arg2:T40
58,T41,Condition 745 757	malignancies
59,T42,Condition 767 792	chronic systemic diseases
60,T43,Qualifier 761 766	other
61,R14,Has_qualifier Arg1:T42 Arg2:T43
62,*,OR T42 T41
63,T44,Scope 745 792	malignancies or other chronic systemic diseases
64,T45,Scope 703 735	Life expectancy less than 1 year
65,R15,Subsumes Arg1:T45 Arg2:T44
66,T46,Condition 797 805	Pregnant
67,T47,Person 806 811	women
68,A1,Optional T47
69,R16,AND Arg1:T47 Arg2:T46
70,T48,Condition 831 838	allergy
71,T49,Condition 848 865	contraindications
72,T50,Qualifier 842 847	other
73,R17,Has_qualifier Arg1:T49 Arg2:T50
74,R18,AND Arg1:T49 Arg2:T48
75,T51,Drug 907 914	aspirin
76,T52,Drug 916 927	clopidogrel
77,T53,Drug 929 936	heparin
78,T54,Drug 938 953	cobalt chromium
79,T55,Drug 955 964	sirolimus
80,*,OR T55 T54 T53 T52 T51
81,T56,"Scope 907 964	aspirin, clopidogrel, heparin, cobalt chromium, sirolimus"
82,T57,Scope 831 865	allergy or other contraindications
83,R19,Has_scope Arg1:T57 Arg2:T56
0,T1,Condition 0 21	Vestibular schwannoma
1,T2,Mood 22 29	advised
2,T5,Procedure 33 51	surgical treatment
3,R1,Has_mood Arg1:T5 Arg2:T2
4,R2,AND Arg1:T1 Arg2:T5
5,T4,Negation 53 55	No
6,T6,Measurement 67 96	remaining vestibular function
7,R3,Has_negation Arg1:T6 Arg2:T4
0,T1,Person 0 3	Age
1,T2,Value 4 15	18 or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 21 31	unilateral
4,T4,Qualifier 35 44	bilateral
5,T5,Condition 45 59	inguinal herna
6,*,OR T4 T3
7,T7,Scope 21 44	unilateral or bilateral
8,R2,Has_scope Arg1:T5 Arg2:T7
9,T8,Measurement 85 131	American Society of Anesthesiology (ASA) Class
10,T9,Value 132 140	I and II
11,R3,Has_value Arg1:T8 Arg2:T9
12,T6,Qualifier 60 83	for laparoscopic repair
13,R4,Has_qualifier Arg1:T5 Arg2:T6
14,T10,Procedure 64 83	laparoscopic repair
15,R5,multi Arg1:T6 Arg2:T10
0,T1,Person 31 34	old
1,T2,Value 17 30	over 65 years
2,T3,Person 0 7	Elderly
3,R1,Has_value Arg1:T1 Arg2:T2
4,R2,Subsumes Arg1:T3 Arg2:T1
5,T4,Undefined_semantics 46 88	clinical indices of cardiovascular disease
6,T5,Person 90 94	Male
7,T6,Person 98 104	female
8,*,OR T6 T5
9,T7,Visit 144 193	Geriatric Unit of the Emile Roux Hospital (AP-HP)
10,T8,Measurement 195 231	MMSE (Mini Mental State Examination)
11,T9,Value 231 246	score > or = 15
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Non-query-able 248 290	Supervision available for study medication
14,T11,Condition 292 316	Able to ingest oral diet
15,T12,Non-query-able 292 316	Able to ingest oral diet
0,T1,Drug 33 40	heparin
1,T2,Condition 49 65	thrombocytopenia
2,T3,Temporal 66 82	prior to consent
3,T4,Reference_point 75 82	consent
4,R1,Has_index Arg1:T3 Arg2:T4
5,R2,Has_temporal Arg1:T2 Arg2:T3
6,T5,Qualifier 33 48	heparin induced
7,R3,multi Arg1:T5 Arg2:T1
8,R4,Has_qualifier Arg1:T2 Arg2:T5
9,T6,Mood 23 32	suspected
10,T7,Mood 14 19	known
11,*,OR T7 T6
12,T8,Scope 14 32	known or suspected
13,R5,Has_scope Arg1:T2 Arg2:T8
14,T9,Condition 98 113	hepatic failure
15,T10,Condition 125 137	coagulopathy
16,T11,Measurement 152 165	transaminases
17,T12,Value 143 151;166 201	elevated more than three times normal values
18,R6,Has_value Arg1:T11 Arg2:T12
19,R7,Subsumes Arg1:T9 Arg2:T10
20,R8,AND Arg1:T10 Arg2:T11
21,T13,Temporal 247 262	within 48 hours
22,T14,Procedure 225 246	decannulate from ECMO
23,R9,Has_temporal Arg1:T14 Arg2:T13
24,T15,Condition 283 291	pregnant
25,T16,Person 292 297	women
26,T17,Mood 273 282	suspected
27,T18,Mood 264 269	Known
28,*,OR T18 T17
29,T19,Scope 264 282	Known or suspected
30,R10,Has_scope Arg1:T15 Arg2:T19
31,T20,Competing_trial 299 332	Previous enrollment in this study
32,T21,Non-query-able 334 388	Primary language spoken that is not English or Spanish
0,T1,Condition 20 43	coronary artery disease
1,T2,Condition 45 62	diabetes mellitus
2,T3,Condition 64 81	contraindications
3,T4,Procedure 85 125	cardiac magnetic resonance imaging (CMR)
4,R1,AND Arg1:T3 Arg2:T4
5,T5,Measurement 127 133	weight
6,T6,Value 134 142	>350 lbs
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Observation 144 177	inability to lie flat for imaging
9,T8,Condition 179 185	anemia
10,T9,Condition 187 204	contraindications
11,T10,Drug 208 219	regadenoson
12,T11,Drug 223 236	aminophylline
13,*,OR T10 T11
14,T12,Scope 208 236	regadenoson or aminophylline
15,R3,Has_scope Arg1:T9 Arg2:T12
16,*,OR T1 T2 T3 T5 T7 T8 T9
17,T13,Condition 238 245	HEALTHY
18,A1,Optional T13
19,T14,Condition 253 275	cardiovascular disease
20,T15,Condition 277 297	cardiac risk factors
21,T16,Drug 308 327	cardiac medications
22,*,OR T15 T16 T14
23,T17,"Scope 253 327	cardiovascular disease, cardiac risk factors or use of cardiac medications"
24,R4,Has_scope Arg1:T13 Arg2:T17
25,T18,Condition 329 341	HYPERTENSIVE
26,A2,Optional T18
27,T19,Condition 349 371	cardiovascular disease
28,T20,Condition 349 363;375 387	cardiovascular risk factors
29,*,OR T20 T19
30,T21,Condition 349 363;375 387;394 411	cardiovascular risk factors from hypertension
31,T22,Negation 388 398	aside from
32,R5,Has_negation Arg1:T21 Arg2:T22
33,T23,Drug 422 441	cardiac medications
34,T24,Scope 349 411	cardiovascular disease or risk factors aside from hypertension
35,*,OR T24 T23
36,T25,Scope 349 441	cardiovascular disease or risk factors aside from hypertension or use of cardiac medications
37,R6,Has_scope Arg1:T18 Arg2:T25
38,T26,Condition 443 448	HFpEF
39,A3,Optional T26
40,T27,Observation 450 466	prior history of
41,T28,Measurement 467 471	LVEF
42,T29,Value 472 481	below 50%
43,R7,Has_value Arg1:T28 Arg2:T29
44,R8,Has_temporal Arg1:T28 Arg2:T27
45,T30,Qualifier 483 488	acute
46,T31,Condition 489 505	decompensated HF
47,R9,Has_qualifier Arg1:T31 Arg2:T30
48,T32,Qualifier 507 515	moderate
49,T33,Qualifier 519 526	greater
50,*,OR T32 T33
51,T34,Condition 527 543	valvular disease
52,T35,Scope 507 526	moderate or greater
53,R10,Has_scope Arg1:T34 Arg2:T35
54,T36,Qualifier 545 556	significant
55,T37,Condition 557 576	cardiac arrhythmias
56,R11,Has_qualifier Arg1:T37 Arg2:T36
57,T38,Condition 578 597	pericardial disease
58,T39,Condition 599 623	congenital heart disease
59,T40,Condition 625 655	primary pulmonary hypertension
60,*,OR T40 T39 T38 T37 T34 T31 T28
61,T41,"Scope 450 655	prior history of LVEF below 50%, acute decompensated HF, moderate or greater valvular disease, significant cardiac arrhythmias, pericardial disease, congenital heart disease, primary pulmonary hypertension"
62,R12,Has_scope Arg1:T26 Arg2:T41
0,T1,Post-eligibility 0 175	Patient has been fully informed and has signed an IRB approved informed consent form within 7 days (Day 7-13) prior to POD 15 and is willing and able to follow study procedure
1,T2,Condition 190 214	primary liver transplant
2,T3,Person 215 224	recipient
3,R1,AND Arg1:T3 Arg2:T2
4,T4,Person 255 258	age
5,T5,Value 237 251	20 to 70 years
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,"Post-eligibility 260 346	Patient should be clearly conscious, fully understand and able to answer questionnaire"
0,T1,Procedure 51 67	organ transplant
1,T2,Negation 68 78	other than
2,T3,Qualifier 81 86	liver
3,R1,Has_negation Arg1:T3 Arg2:T2
4,R2,Has_qualifier Arg1:T1 Arg2:T3
5,T4,Procedure 116 124	dialysis
6,T5,Measurement 177 205	human immunodeficiency virus
7,T6,Value 160 172	seropositive
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 207 210	HIV
10,R4,Subsumes Arg1:T5 Arg2:T7
11,T8,Person 126 135	Recipient
12,T9,Person 139 144	donor
13,*,OR T8 T9
14,T10,Scope 126 144	Recipient or donor
15,R5,AND Arg1:T10 Arg2:T5
16,T11,Procedure 236 252	liver transplant
17,T12,Person 278 283	donor
18,T13,Qualifier 264 277	heart beating
19,T14,Negation 260 263	non
20,R6,Has_negation Arg1:T13 Arg2:T14
21,R7,Has_qualifier Arg1:T12 Arg2:T13
22,T15,Measurement 300 303	HCV
23,T16,Value 304 312	negative
24,R8,Has_value Arg1:T15 Arg2:T16
25,T17,Qualifier 381 386	liver
26,T18,Measurement 329 332	HCV
27,T19,Value 333 341	positive
28,R9,Has_value Arg1:T18 Arg2:T19
29,T20,Person 375 380	donor
30,R10,AND Arg1:T20 Arg2:T18
31,T21,Measurement 343 350	HCV RNA
32,T22,Measurement 361 373	HCV antibody
33,T23,Measurement 354 357	PCR
34,R11,AND Arg1:T21 Arg2:T23
35,*,OR T21 T22
36,T24,Scope 343 373	HCV RNA by PCR or HCV antibody
37,R12,Subsumes Arg1:T18 Arg2:T24
38,R13,Has_qualifier Arg1:T20 Arg2:T17
39,T25,Measurement 403 408	HbsAg
40,T26,Value 409 417	negative
41,R14,Has_value Arg1:T25 Arg2:T26
42,T27,Measurement 434 439	HbsAg
43,T28,Value 440 448	positive
44,T29,Measurement 461 464	PCR
45,T30,Measurement 450 457	HBV DNA
46,T31,Measurement 468 480	HBV antibody
47,R15,AND Arg1:T29 Arg2:T30
48,*,OR T29 T31
49,T32,Scope 450 480	HBV DNA by PCR or HBV antibody
50,T33,Person 482 487	donor
51,T34,Qualifier 488 493	liver
52,R16,Has_qualifier Arg1:T33 Arg2:T34
53,R17,Has_value Arg1:T27 Arg2:T28
54,R18,Subsumes Arg1:T27 Arg2:T32
55,T35,Procedure 518 534	liver transplant
56,T36,Person 551 556	donor
57,T37,Value 557 567	> 70 years
58,T38,Person 571 574	age
59,R19,Has_value Arg1:T38 Arg2:T37
60,T39,Condition 598 608	malignancy
61,T40,Condition 614 635	history of malignancy
62,T41,Temporal 637 660	within the past 5 years
63,R20,Has_temporal Arg1:T40 Arg2:T41
64,T42,Condition 670 694	hepatocellular carcinoma
65,T43,Negation 663 669	except
66,T44,Measurement 702 715	UCSF Criteria
67,T45,Condition 720 725;753 775	basal cell carcinoma of skin
68,T46,Condition 744 775	squamous cell carcinoma of skin
69,T47,Qualifier 729 743	non-metastatic
70,R22,Has_qualifier Arg1:T46 Arg2:T47
71,*,OR T45 T46
72,R23,AND Arg1:T44 Arg2:T42
73,T48,Mood 790 810	treated successfully
74,T49,Scope 670 775	hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin
75,R21,Has_mood Arg1:T49 Arg2:T48
76,R24,Has_negation Arg1:T49 Arg2:T43
77,*,OR T39 T40
78,T50,Condition 824 848	hemodynamically unstable
79,T51,Measurement 852 858	POD 15
80,R25,AND Arg1:T51 Arg2:T50
0,T1,Person 0 3	Age
1,T2,Value 4 14	= 65 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Multiplier 20 34	one additional
4,T4,Condition 42 53	risk factor
5,T5,Condition 35 41	stroke
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 55 67	hypertension
8,T7,Condition 69 77	diabetes
9,T8,Condition 79 92	heart failure
10,T9,Measurement 107 141	left ventricular ejection fraction
11,T10,Value 142 147	<0.40
12,R3,Has_value Arg1:T9 Arg2:T10
13,*,OR T6 T7 T8 T9
14,T11,Observation 93 100	history
15,R4,Has_temporal Arg1:T9 Arg2:T11
16,T12,Temporal 150 158	previous
17,T13,Condition 159 165	stroke
18,T14,Condition 169 194	transient ischemic attack
19,*,OR T13 T14
20,T15,Scope 159 194	stroke or transient ischemic attack
21,R5,Has_temporal Arg1:T15 Arg2:T12
22,T16,"Scope 55 194	hypertension, diabetes, heart failure history of or left ventricular ejection fraction <0.40), previous stroke or transient ischemic attack"
23,T17,Scope 35 53	stroke risk factor
24,R6,Subsumes Arg1:T17 Arg2:T16
25,R7,Has_multiplier Arg1:T17 Arg2:T3
26,T18,Condition 198 217	Atrial fibrillation
27,T19,Measurement 222 225	not
28,T20,Procedure 229 263	oral anticoagulation (OAC) therapy
29,T21,Non-representable 264 276	but eligible
30,R8,AND Arg1:T20 Arg2:T19
31,T22,Condition 278 297	Atrial fibrillation
32,T23,Procedure 313 316	OAC
33,T24,Qualifier 301 312	sub-optimal
34,R9,Has_qualifier Arg1:T23 Arg2:T24
0,T1,Condition 0 9	pregnancy
1,T2,Person 27 40	legal custody
2,T3,Negation 52 59	without
3,T4,Person 60 76	health insurance
4,R1,Has_negation Arg1:T4 Arg2:T3
5,T5,Competing_trial 79 211	patients included in another interventional clinical study involving infections or antibiotics and having the same primary parameter
6,T6,Condition 214 222	moribund
7,T7,Measurement 257 284	procalcitonin concentration
8,T8,Qualifier 294 303	increased
9,R2,Has_qualifier Arg1:T7 Arg2:T8
10,T9,Condition 350 366	poly-traumatised
11,T10,Procedure 378 400	surgical interventions
12,T11,Temporal 412 423	last 4 days
13,R3,Has_temporal Arg1:T10 Arg2:T11
14,T12,Condition 426 450	cardiorespiratory arrest
15,T13,Drug 471 494	anti-thymocyte globulin
16,T14,Condition 497 512	immunodepressed
17,T15,Procedure 523 545	bone marrow transplant
18,T16,Condition 570 588	severe neutropenia
19,*,OR T15 T16
20,T17,"Scope 523 588	bone marrow transplant patients, patients with severe neutropenia"
21,R4,Subsumes Arg1:T14 Arg2:T17
22,T18,Visit 680 683	ICU
23,T19,Drug 651 662	antibiotics
24,T20,Condition 695 705	meningitis
25,T21,Condition 707 716	pneumonia
26,T22,Condition 618 628	indication
27,R5,AND Arg1:T22 Arg2:T19
28,*,OR T20 T21
29,T23,"Scope 695 716	meningitis, pneumonia"
30,R6,Subsumes Arg1:T22 Arg2:T23
31,T24,Condition 723 740	chronic infection
32,T25,Qualifier 751 760	long-term
33,T26,Procedure 761 781	antibiotic treatment
34,R7,Has_qualifier Arg1:T26 Arg2:T25
35,R8,AND Arg1:T26 Arg2:T24
36,T27,Condition 796 808	endocarditis
37,T28,Condition 810 836	osteo-articular infections
38,T29,Condition 838 851	mediastinitis
39,T30,Condition 853 867	deep abscesses
40,T31,Condition 869 891	pneumocystis infection
41,T32,Condition 893 906	toxoplasmosis
42,T33,Condition 908 920	tuberculosis
43,T34,"Scope 795 920	(endocarditis, osteo-articular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis, tuberculosis"
44,R9,Subsumes Arg1:T24 Arg2:T34
45,T35,Condition 965 971	septic
46,T36,Condition 937 961	haemodynamic instability
47,R10,AND Arg1:T36 Arg2:T35
48,T37,Condition 985 1009	espiratory insufficiency
49,T38,Measurement 1030 1039	Pa02/Fi02
50,T39,Value 1040 1050	= 200 mmHg
51,T40,Measurement 1055 1058	PEP
52,T41,Value 1059 1068	= 5 cmH2O
53,R11,Has_value Arg1:T38 Arg2:T39
54,R12,Has_value Arg1:T40 Arg2:T41
55,T42,Scope 1030 1068	Pa02/Fi02 = 200 mmHg and PEP = 5 cmH2O
56,R13,Has_scope Arg1:T37 Arg2:T42
57,*,OR T36 T37
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,T3,Person 29 32	age
3,T4,Temporal 33 44	at Visit 1.
4,T5,Reference_point 36 43	Visit 1
5,R1,Has_index Arg1:T4 Arg2:T5
6,T6,Value 15 25	= 18 years
7,R2,Has_value Arg1:T3 Arg2:T6
8,*,OR T1 T2
9,R3,Has_temporal Arg1:T3 Arg2:T4
10,T7,Measurement 46 60	Sweat chloride
11,T8,Value 61 91	equal or greater than 60 mEq/L
12,T9,Measurement 95 138	quantitative pilocarpine iontophoresis test
13,R4,Has_value Arg1:T7 Arg2:T8
14,R5,AND Arg1:T7 Arg2:T9
15,T10,Multiplier 141 144	Two
16,T11,Condition 164 173	mutations
17,T12,Condition 181 232;240 244	cystic fibrosis transmembrane conductance regulator gene
18,T13,Condition 234 238	CFTR
19,R6,Subsumes Arg1:T12 Arg2:T13
20,R7,Has_multiplier Arg1:T11 Arg2:T10
21,T14,Measurement 255 281	nasal potential difference
22,T15,Measurement 283 286	NPD
23,R8,AND Arg1:T14 Arg2:T15
24,T16,Value 246 254	Abnormal
25,R9,Has_value Arg1:T14 Arg2:T16
26,T17,Value 379 394	less than -5 mV
27,T18,Non-query-able 288 378	as measured by a change in NPD in response to a low chloride solution and isoproterenol of
28,R10,Has_value Arg1:T14 Arg2:T17
29,*,OR T17 T16
30,T19,Condition 433 461	acute pulmonary exacerbation
31,T20,Measurement 472 496	CF Foundation guidelines
32,T21,Non-query-able 498 561	as diagnosed by a faculty member of the Denver Adult CF Program
33,R11,AND Arg1:T19 Arg2:T20
34,T22,Measurement 564 586	Respiratory culture(s)
35,T23,Value 613 635	Pseudomonas aeruginosa
36,T24,Value 639 660	Achromobacter species
37,*,OR T23 T24
38,T25,Scope 613 660	Pseudomonas aeruginosa or Achromobacter species
39,R12,Has_scope Arg1:T22 Arg2:T25
40,T26,Condition 661 677	airway infection
41,T27,"Post-eligibility 680 763	Subject is able to produce sputum, undergo phlebotomy, and provide written consent."
42,T28,"Post-eligibility 765 1290	The subject's treating physician has determined that they should receive either tobramycin or colistin intravenously as one of the designated agents for their APE treatment. Subjects who are able to receive either tobramycin or colistin as part of their antibiotic regimen will be randomized into one of three arms. If a treating physician deems that a subject cannot receive tobramycin due to vestibular toxicity, ototoxicity or bacterial resistance, the subject will be randomized to either standard or PK-adjusted colistin"
0,T1,Non-query-able 0 2	NA
0,T1,Person 0 4	aged
1,T2,Value 5 16	18 or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 34 57	oro-tracheal intubation
4,T4,Condition 64 68	coma
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Measurement 70 88	Glasgow Coma Score
7,T6,Value 89 109	below or equal to 8)
8,R3,Has_value Arg1:T5 Arg2:T6
9,R4,AND Arg1:T4 Arg2:T5
10,T7,Procedure 117 139	mechanical ventilation
11,T8,Temporal 157 200	first 48 hours following hospital admission
12,T9,Reference_point 182 200	hospital admission
13,R5,Has_temporal Arg1:T7 Arg2:T8
14,R6,Has_index Arg1:T8 Arg2:T9
0,T1,Condition 13 25	hypertension
1,T2,Qualifier 0 12	Uncontrolled
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Measurement 38 49	average SBP
4,T4,Value 50 60	= 160 mmHg
5,T5,Multiplier 62 72	2 readings
6,T6,Temporal 79 99	at time of screening
7,T7,Reference_point 90 99	screening
8,R2,Has_index Arg1:T6 Arg2:T7
9,R3,Has_value Arg1:T3 Arg2:T4
10,R4,Has_multiplier Arg1:T3 Arg2:T5
11,R5,Has_temporal Arg1:T3 Arg2:T6
12,T8,Scope 38 100	average SBP = 160 mmHg [2 readings taken at time of screening]
13,T9,Scope 0 25	Uncontrolled hypertension
14,R6,Subsumes Arg1:T9 Arg2:T8
15,T10,Condition 104 127	End stage renal disease
16,T11,Measurement 129 133	CrCl
17,T12,Value 134 145	< 15 ml/min
18,R7,Has_value Arg1:T11 Arg2:T12
19,T13,Scope 129 145	CrCl < 15 ml/min
20,R8,Subsumes Arg1:T10 Arg2:T13
21,T14,Condition 148 170	Valvular Heart Disease
22,T15,Device 192 208	prosthetic valve
23,T16,Condition 210 225	mitral stenosis
24,T17,Qualifier 227 235	moderate
25,T18,Qualifier 239 245	severe
26,T19,Procedure 250 262	valve repair
27,*,OR T17 T18
28,T20,Scope 227 245	moderate to severe
29,R9,Subsumes Arg1:T16 Arg2:T20
30,*,OR T16 T19 T15 T14
31,T21,Measurement 272 286	alcohol intake
32,T22,Person 288 293	males
33,T23,Value 295 310	= 28 units/week
34,T24,Value 265 271	Excess
35,R10,Has_value Arg1:T21 Arg2:T24
36,T25,Person 312 319	females
37,T26,Value 321 336	= 21 units/week
38,T27,"Non-representable 338 400	One unit of alcohol = 8 oz beer, 1 oz hard liquor or 4 oz wine"
39,R11,Has_value Arg1:T22 Arg2:T23
40,*,OR T22 T25
41,R12,Has_value Arg1:T25 Arg2:T26
42,A1,Optional T22
43,A2,Optional T25
44,T28,"Scope 288 336	males: = 28 units/week, females: = 21 units/week"
45,R13,Subsumes Arg1:T24 Arg2:T28
46,T29,Condition 404 422	Intracranial bleed
47,T30,Temporal 423 435	at any point
48,R14,Has_temporal Arg1:T29 Arg2:T30
49,T31,Condition 450 464	Major Bleeding
50,T32,Temporal 466 478	at any point
51,R15,Has_temporal Arg1:T31 Arg2:T32
52,T33,Observation 438 445	History
53,R16,Has_temporal Arg1:T31 Arg2:T33
54,T34,Condition 491 505	overt bleeding
55,T35,Qualifier 511 524	critical site
56,R17,Has_qualifier Arg1:T34 Arg2:T35
57,T36,Qualifier 535 547	intracranial
58,T37,Qualifier 549 560	intraspinal
59,T38,Qualifier 562 573	intraocular
60,T39,Qualifier 575 586	pericardial
61,T40,Qualifier 591 606	retroperitoneal
62,*,OR T40 T39 T38 T37 T36
63,T41,Condition 611 616	bleed
64,T42,Procedure 627 642	hospitalization
65,R18,AND Arg1:T41 Arg2:T42
66,T43,"Scope 535 606	intracranial, intraspinal, intraocular, pericardial, or retroperitoneal"
67,R19,Subsumes Arg1:T35 Arg2:T43
68,*,OR T34 T41
69,T44,"Scope 491 642	overt bleeding at a critical site including intracranial, intraspinal, intraocular, pericardial, or retroperitoneal; or bleed requiring hospitalization"
70,R20,Subsumes Arg1:T31 Arg2:T44
71,T45,Observation 660 675	life-expectancy
72,T46,Value 646 659	Foreshortened
73,R21,Has_value Arg1:T45 Arg2:T46
74,T47,Condition 679 699	severe comorbidities
75,*,OR T47 T45
76,T48,Non-query-able 735 768	Unable to read/understand English
77,T49,Qualifier 770 776	Severe
78,T50,Condition 777 797	cognitive impairment
79,R22,Has_qualifier Arg1:T50 Arg2:T49
80,T51,Measurement 827 869	Short Portable Mental Status Questionnaire
81,T52,Value 816 819	= 5
82,R23,Has_value Arg1:T51 Arg2:T52
83,T53,Scope 770 797	Severe cognitive impairment
84,T54,Scope 816 869	= 5 on the Short Portable Mental Status Questionnaire
85,R24,Subsumes Arg1:T53 Arg2:T54
0,T1,Parsing_Error 0 2	NA
0,T1,Non-query-able 0 2	NA
0,T1,Condition 14 22	pregnant
1,T2,Observation 26 39	breastfeeding
2,T3,Person 0 5	Women
3,*,OR T1 T2
4,T4,Measurement 161 189	human chorionic gonadotropin
5,T5,Procedure 161 205	human chorionic gonadotropin laboratory test
6,T6,Value 152 160	positive
7,T7,Value 207 216	> 5mIU/mL
8,R1,Subsumes Arg1:T6 Arg2:T7
9,R2,Has_value Arg1:T4 Arg2:T6
10,R3,multi Arg1:T5 Arg2:T4
11,R4,AND Arg1:T1 Arg2:T5
12,T9,Condition 394 413	Tromboembolic event
13,T10,Condition 415 418	CVA
14,T11,Condition 422 447	transient ischemic attack
15,T12,Condition 449 452	AMI
16,*,OR T11 T12 T10
17,T13,"Scope 415 452	CVA or transient ischemic attack, AMI"
18,R5,Subsumes Arg1:T9 Arg2:T13
19,T14,Temporal 454 523	less than 3 months prior to the intravitreal injection of bevacizumab
20,T15,Procedure 486 508	intravitreal injection
21,T16,Drug 512 523	bevacizumab
22,R6,AND Arg1:T15 Arg2:T16
23,T17,Reference_point 482 523	the intravitreal injection of bevacizumab
24,R7,Has_index Arg1:T14 Arg2:T17
25,R8,multi Arg1:T17 Arg2:T15
26,R9,Has_temporal Arg1:T9 Arg2:T14
27,T18,Condition 536 552	hypersensitivity
28,T19,Drug 557 568	bevacizumab
29,T20,Observation 525 532	History
30,R10,AND Arg1:T18 Arg2:T19
31,R11,Has_temporal Arg1:T18 Arg2:T20
32,T8,Person 219 224	Women
33,T21,Condition 228 251	child bearing potential
34,T22,Qualifier 271 280	effective
35,T23,Procedure 281 294	contraception
36,R12,Has_qualifier Arg1:T23 Arg2:T22
37,T24,Scope 219 251	Women of child bearing potential
38,A1,Optional T24
39,R13,AND Arg1:T24 Arg2:T23
40,T25,Temporal 307 323	during the trial
41,T26,Temporal 328 392	for at least 28 days following the last dose of study medication
42,T27,Multiplier 363 372	last dose
43,T28,Drug 376 392	study medication
44,R14,Has_multiplier Arg1:T28 Arg2:T27
45,T29,Reference_point 359 392	the last dose of study medication
46,R15,multi Arg1:T29 Arg2:T28
47,R16,Has_index Arg1:T26 Arg2:T29
48,R17,Has_temporal Arg1:T23 Arg2:T25
49,R18,Has_temporal Arg1:T23 Arg2:T26
0,T1,Person 10 13	age
1,T2,Value 17 41	between =12 and 16 years
2,T3,Context_Error 25 26	=
3,T4,Grammar_Error 43 52	inclusive
4,R1,Has_value Arg1:T1 Arg2:T2
5,T5,Procedure 81 90	procedure
6,T6,Observation 65 90	scheduled for a procedure
7,R2,multi Arg1:T6 Arg2:T5
8,T7,Procedure 116 136	neuraxial anesthesia
9,T8,Procedure 105 112;130 131	general t
10,*,OR T7 T8
11,T9,Scope 105 136	general or neuraxial anesthesia
12,R3,Has_scope Arg1:T5 Arg2:T9
13,T10,Procedure 189 202	physical exam
14,T11,Value 167 188	clinically acceptable
15,T12,Value 157 163	normal
16,*,OR T12 T11
17,T13,Scope 157 188	normal or clinically acceptable
18,R4,Has_scope Arg1:T10 Arg2:T13
19,T14,Condition 229 237	diabetes
20,T15,Qualifier 218 228	controlled
21,T16,Temporal 238 252	prior to entry
22,T17,Reference_point 247 252	entry
23,R5,Has_index Arg1:T16 Arg2:T17
24,T18,Condition 265 269;279 288;296 310	mean diastolic blood pressure
25,T19,Condition 265 269;270 278;296 310	mean systolic blood pressure
26,T20,Value 316 323	78 mmHg
27,T21,Value 312 315;319 323	128 mmHg
28,R6,Has_value Arg1:T18 Arg2:T20
29,R7,Has_value Arg1:T19 Arg2:T21
30,T22,Qualifier 325 332	sitting
31,T23,Temporal 334 357	after 5 minutes of rest
32,T24,Reference_point 353 357	rest
33,R8,Has_index Arg1:T23 Arg2:T24
34,T25,Scope 265 332	mean systolic/diastolic office blood pressure =128/78 mmHg (sitting
35,R9,Has_qualifier Arg1:T25 Arg2:T22
36,R10,Has_temporal Arg1:T25 Arg2:T23
37,R11,Has_qualifier Arg1:T14 Arg2:T15
38,R12,Has_temporal Arg1:T14 Arg2:T16
39,T26,Measurement 389 409	serum pregnancy test
40,T27,Measurement 380 385;395 409	urine pregnancy test
41,*,OR T26 T27
42,T28,Measurement 411 439	Human Chorionic Gonadotropin
43,T29,Value 449 457	negative
44,T30,Temporal 458 470	at Screening
45,T31,Temporal 475 480	Day 1
46,T32,Scope 380 440	urine or serum pregnancy test (Human Chorionic Gonadotropin)
47,R13,Has_value Arg1:T32 Arg2:T29
48,T33,Scope 458 480	at Screening and Day 1
49,R14,Has_scope Arg1:T32 Arg2:T33
50,T34,Post-eligibility 482 565	Subject's parent or legal guardian gives informed consent and subject gives assent.
0,T1,Procedure 13 20	vaccine
1,T2,Temporal 21 58	within a month prior to study vaccine
2,T3,Reference_point 45 58	study vaccine
3,R1,Has_temporal Arg1:T1 Arg2:T2
4,R2,Has_index Arg1:T2 Arg2:T3
5,T4,Measurement 69 83	serum antibody
6,T5,Qualifier 92 112	Hep B surface antige
7,T6,Qualifier 121 144	core Hep B core antigen
8,*,OR T5 T6
9,T7,Scope 92 144	Hep B surface antigen and/or core Hep B core antigen
10,T8,Value 60 68	Positive
11,R3,Has_value Arg1:T4 Arg2:T8
12,R4,Has_scope Arg1:T4 Arg2:T7
13,T9,Measurement 146 149	HIV
14,T10,Value 150 158	positive
15,R5,Has_value Arg1:T9 Arg2:T10
16,T11,Measurement 164 167	HCV
17,T12,Value 168 176	negative
18,R6,Has_value Arg1:T11 Arg2:T12
19,T13,Observation 198 222	History of HCV infection
20,T14,"Competing_trial 254 405	Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study"
21,T15,"Post-eligibility 407 502	In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol"
22,T16,Condition 607 623	immunodeficiency
23,T17,Condition 627 645	autoimmune disease
24,*,OR T16 T17
25,T18,Negation 647 661	in addition to
26,T19,Condition 662 675	HCV infection
27,R7,Has_negation Arg1:T19 Arg2:T18
28,T20,Drug 710 727	systemic steroids
29,T21,Procedure 737 765	immunomodulatory medications
30,*,OR T21 T20
31,T22,Procedure 776 798	anticancer medications
32,T23,Procedure 803 824	antiviral medications
33,*,OR T22 T23
34,T24,Scope 776 824	anticancer medications and antiviral medications
35,R8,Subsumes Arg1:T21 Arg2:T24
36,T25,Condition 937 945	diabetes
37,T26,Condition 947 970	coronary artery disease
38,T27,Condition 972 993	rheumatologic illness
39,T28,Condition 995 1005	malignancy
40,T29,Condition 1007 1022	substance abuse
41,*,OR T25 T26 T27 T28 T29
42,T30,Post-eligibility 1096 1142	Unable to continue participation for 156 weeks
43,T31,Procedure 1164 1187	Hepatitis B vaccination
44,T32,Person 1192 1196	Male
45,T33,Person 1200 1206	female
46,*,OR T32 T33
47,T34,Value 1207 1226	< 18 and > 62 years
48,T35,Person 1230 1233	age
49,R9,Has_value Arg1:T35 Arg2:T34
50,T36,Pregnancy_considerations 1235 1259	Is pregnant or lactating
51,T37,Condition 1272 1293	Hepatitis B infection
52,T38,Condition 1339 1348	cirrhosis
0,T1,Condition 21 35	progressive MS
1,T2,Qualifier 13 20	primary
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Procedure 62 65	MRI
4,T4,Mood 37 58	Inability to complete
5,R2,Has_mood Arg1:T3 Arg2:T4
6,T5,Condition 67 84	contraindications
7,T6,Procedure 89 92	MRI
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Measurement 127 133	weight
10,T8,Value 134 141	=140 kg
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Device 143 152	pacemaker
13,T10,Device 154 171	cochlear implants
14,T11,Device 185 214	foreign substances in the eye
15,T12,Device 216 243	intracranial vascular clips
16,T13,Procedure 245 252	surgery
17,T14,Temporal 253 291	within 6 weeks of entry into the study
18,T15,Reference_point 271 291	entry into the study
19,R5,Has_index Arg1:T14 Arg2:T15
20,T16,Device 293 307	coronary stent
21,T17,Procedure 308 317	implanted
22,T18,Temporal 318 370	within 8 weeks prior to the time of the intended MRI
23,T19,Reference_point 342 370	the time of the intended MRI
24,T20,Procedure 367 370	MRI
25,T21,Mood 358 366	intended
26,R6,Has_mood Arg1:T20 Arg2:T21
27,R7,multi Arg1:T19 Arg2:T20
28,R8,Has_index Arg1:T18 Arg2:T19
29,R9,Has_temporal Arg1:T17 Arg2:T18
30,R10,AND Arg1:T17 Arg2:T16
31,R11,Has_temporal Arg1:T13 Arg2:T14
32,*,OR T10 T9 T13 T17 T12 T11 T7
33,T22,"Scope 127 370	weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI"
34,T23,Scope 67 92	contraindications for MRI
35,R12,Subsumes Arg1:T23 Arg2:T22
36,T24,"Scope 67 370	contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI"
37,T25,Scope 37 65	Inability to complete an MRI
38,R13,Subsumes Arg1:T25 Arg2:T22
39,T26,Condition 390 401	intolerance
40,T27,Drug 379 389	Gadolinium
41,R14,AND Arg1:T26 Arg2:T27
42,T28,Condition 414 448	ischemic cerebrovascular disorders
43,T29,Condition 456 462	stroke
44,T30,Condition 464 489	transient ischemic attack
45,*,OR T29 T30
46,T31,Condition 494 521	ischemia of the spinal cord
47,T32,"Scope 456 489	stroke, transient ischemic attack"
48,R15,Subsumes Arg1:T28 Arg2:T32
49,*,OR T28 T31
50,T33,Condition 552 580;596 601	central nervous system (CNS) tumor
51,T34,Condition 584 601	spinal cord tumor
52,T35,Condition 609 619	meningioma
53,T36,Condition 621 627	glioma
54,*,OR T35 T36
55,*,OR T34 T33
56,T37,"Scope 609 627	meningioma, glioma"
57,T38,Scope 552 600	central nervous system (CNS) or spinal cord tumo
58,R16,Subsumes Arg1:T38 Arg2:T37
59,T39,Condition 689 699	myelopathy
60,T40,Condition 669 685	metabolic causes
61,T41,Condition 717 739	vitamin B12 deficiency
62,T42,Qualifier 707 716	untreated
63,R18,Has_qualifier Arg1:T41 Arg2:T42
64,R17,AND Arg1:T40 Arg2:T39
65,T43,Scope 669 699	metabolic causes of myelopathy
66,T44,Scope 707 739	untreated vitamin B12 deficiency
67,R19,Subsumes Arg1:T43 Arg2:T44
68,T45,Condition 771 788	infectious causes
69,T46,Condition 792 802	myelopathy
70,R20,AND Arg1:T45 Arg2:T46
71,T47,Condition 810 818	syphilis
72,T48,Condition 820 832	Lyme disease
73,T49,Condition 834 871	human T-lymphotropic virus 1 (HTLV-1)
74,T50,Condition 873 897	herpes zoster myelopathy
75,*,OR T47 T48 T49 T50
76,T51,"Scope 810 897	syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy"
77,T52,Scope 771 802	infectious causes of myelopathy
78,R21,Subsumes Arg1:T52 Arg2:T51
79,T53,Condition 933 970	progressive CNS degenerative disorder
80,T54,Qualifier 911 932	genetically inherited
81,R22,Has_qualifier Arg1:T53 Arg2:T54
82,T55,Condition 978 1000	hereditary paraparesis
83,T56,Condition 1009 1031	mitochondrial myopathy
84,T57,Condition 1033 1047	encephalopathy
85,T58,Condition 1049 1064	lactic acidosis
86,T59,Condition 1066 1072	stroke
87,T60,Condition 1002 1007;1074 1082	MELAS syndrome
88,T61,"Scope 1009 1072	mitochondrial myopathy, encephalopathy, lactic acidosis, stroke"
89,R23,Subsumes Arg1:T60 Arg2:T61
90,*,OR T55 T60
91,T62,"Scope 978 1082	hereditary paraparesis; MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, stroke] syndrome"
92,T63,Scope 911 970	genetically inherited progressive CNS degenerative disorder
93,R24,Subsumes Arg1:T63 Arg2:T62
94,T64,Condition 1085 1105	Neuromyelitis optica
95,T65,Observation 1107 1114	History
96,T66,Condition 1136 1165	systemic autoimmune disorders
97,T67,Condition 1186 1216	progressive neurologic disease
98,T68,Mood 1166 1185	potentially causing
99,R25,Has_mood Arg1:T67 Arg2:T68
100,R26,AND Arg1:T66 Arg2:T67
101,T69,Condition 1224 1229	lupus
102,T70,Condition 1231 1266	anti-phospholipid antibody syndrome
103,T71,Condition 1268 1286	Sjogren's syndrome
104,T72,Condition 1288 1304	Behçet's disease
105,T73,Condition 1306 1317	sarcoidosis
106,*,OR T70 T69 T72 T73 T71
107,T74,"Scope 1224 1317	lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, Behçet's disease, sarcoidosis"
108,T75,Scope 1136 1216	systemic autoimmune disorders potentially causing progressive neurologic disease
109,R27,Subsumes Arg1:T75 Arg2:T74
110,R28,Has_temporal Arg1:T75 Arg2:T65
111,T76,Qualifier 1331 1337	severe
112,T77,Qualifier 1339 1361	clinically significant
113,T78,Condition 1371 1389	spinal cord trauma
114,T79,Condition 1362 1367;1383 1389	brain trauma
115,*,OR T78 T79
116,T80,Scope 1362 1389	brain or spinal cord trauma
117,R29,Has_qualifier Arg1:T80 Arg2:T77
118,R30,Has_qualifier Arg1:T80 Arg2:T76
119,T81,Condition 1397 1415	cerebral contusion
120,T82,Condition 1417 1440	spinal cord compression
121,*,OR T81 T82
122,T83,"Scope 1397 1440	cerebral contusion, spinal cord compression"
123,T84,"Scope 1331 1389	severe, clinically significant brain or spinal cord trauma"
124,R31,Subsumes Arg1:T84 Arg2:T83
125,T85,Observation 1443 1462	Vulnerable patients
126,T86,Qualifier 1487 1567	Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code
127,R32,Has_qualifier Arg1:T85 Arg2:T86
0,T1,Measurement 0 5	HbA1c
1,T2,Value 6 30	greater than 75 mmol/mol
2,T3,Value 32 36	9.0%
3,R1,Subsumes Arg1:T2 Arg2:T3
4,R2,Has_value Arg1:T1 Arg2:T2
5,T4,Post-eligibility 39 106	Child unwilling to agree to second insulin injection at a meal-time
6,T5,Condition 118 133	coeliac disease
7,T6,Qualifier 108 117	Untreated
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Condition 194 208	Food allergies
10,T8,Negation 210 215	other
11,T9,Condition 232 247	Coeliac Disease
12,R4,Has_negation Arg1:T9 Arg2:T8
13,T10,Person 250 261	Vegetarians
14,T11,Procedure 379 408	glucose-containing medication
0,T1,Non-query-able 0 2	NA
0,T1,Person 0 3	Age
1,T2,Value 4 14	= 18 years
2,T3,Person 18 31	either gender
3,R1,Has_value Arg1:T1 Arg2:T2
4,T4,Informed_consent 33 136	Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed
5,T5,Condition 138 155	Visual impairment
6,T6,Condition 177 205	abnormal new vessel ingrowth
7,T7,Condition 213 226	macular edema
8,*,OR T6 T7
9,T8,Qualifier 251 263	intraretinal
10,T9,Qualifier 265 275	subretinal
11,T10,Qualifier 279 286	sub-RPE
12,*,OR T10 T9 T8
13,T11,Procedure 318 345	ocular coherence tomography
14,T12,Condition 244 249	fluid
15,T13,"Scope 251 286	intraretinal, subretinal or sub-RPE"
16,R2,Subsumes Arg1:T12 Arg2:T13
17,R3,AND Arg1:T11 Arg2:T12
18,T14,Scope 177 226	abnormal new vessel ingrowth and/or macular edema
19,R4,Has_scope Arg1:T5 Arg2:T14
0,T1,Post-eligibility 0 69	Willing to receive three doses of an FDA-approved Hepatitis B vaccine
1,T2,Condition 107 110;93 101	HCV infected
2,T3,Qualifier 81 92	chronically
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Person 187 196	volunteer
5,T5,Qualifier 179 186	Healthy
6,R2,Has_qualifier Arg1:T4 Arg2:T5
0,T1,Condition 13 28	Type 1 diabetes
1,T2,Temporal 34 49	at least a year
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Drug 70 77	insulin
4,T4,Qualifier 64 69	daily
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Drug 118 125	insulin
7,T6,Drug 143 150	insulin
8,T7,Qualifier 130 142	rapid-acting
9,T8,Qualifier 100 117	basal long-acting
10,R3,Has_qualifier Arg1:T5 Arg2:T8
11,R4,Has_qualifier Arg1:T6 Arg2:T7
12,T9,Scope 100 150	basal long-acting insulin and rapid-acting insulin
13,R5,Subsumes Arg1:T3 Arg2:T9
14,T10,Measurement 170 175	HbA1c
15,T11,Value 176 189	< 75 mmol/mol
16,T12,Value 191 195	9.0%
17,R6,Has_value Arg1:T10 Arg2:T11
18,R7,Subsumes Arg1:T11 Arg2:T12
19,T13,Informed_consent 198 311	Participant and/or parent/legal guardian willing and able to give informed consent for participation in the study
20,T14,Non-query-able 314 375	Family have a freezer in which to safely store the test meals
21,T15,"Post-eligibility 378 466	In the Investigator's opinion, is able and willing to comply with all trial requirements"
0,T1,Person 0 3	Age
1,T2,Value 4 15	>/=18 years
2,T3,Temporal 16 28	at screening
3,R1,Has_value Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Qualifier 44 59	relapsing forms
6,T5,Condition 63 87	multiple sclerosis (RMS)
7,R3,Has_qualifier Arg1:T5 Arg2:T4
8,T6,Qualifier 93 107	active disease
9,R4,Has_qualifier Arg1:T5 Arg2:T6
10,T7,Observation 131 147	imaging features
11,T8,Observation 119 127;139 147	clinical features
12,*,OR T8 T7
13,T9,Scope 119 147	clinical or imaging features
14,R5,Has_scope Arg1:T5 Arg2:T9
15,T10,Multiplier 153 165;183 204	at least one over a 6-month period
16,T11,Condition 166 182	clinical relapse
17,R7,Has_multiplier Arg1:T11 Arg2:T10
18,T12,Temporal 205 223	prior to screening
19,R6,Has_temporal Arg1:T11 Arg2:T12
20,T13,Multiplier 237 249;379 401	at least one over a 3 months period
21,T14,Temporal 402 420	prior to screening
22,T15,Condition 250 280	T1 gadolinium-enhancing lesion
23,T16,Condition 305 314	T2 lesion
24,T17,Procedure 330 368	brain Magnetic Resonance Imaging (MRI)
25,T18,Qualifier 295 304	enlarging
26,T19,Temporal 284 287	new
27,*,OR T18 T19
28,T20,Scope 284 304	new and/or enlarging
29,R8,Has_scope Arg1:T16 Arg2:T20
30,*,OR T15 T16
31,T21,Scope 250 368	T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI)
32,R9,Has_multiplier Arg1:T21 Arg2:T13
33,T22,Scope 250 314	T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion
34,R10,AND Arg1:T22 Arg2:T17
35,R11,Has_temporal Arg1:T21 Arg2:T14
36,T23,Negation 426 428	no
37,T24,Multiplier 429 438	change of
38,T25,Procedure 439 475	Disease-Modifying Treatment(s) (DMT)
39,R12,Has_multiplier Arg1:T25 Arg2:T24
40,R13,Has_negation Arg1:T24 Arg2:T23
41,R14,AND Arg1:T21 Arg2:T25
42,T26,Non-representable 476 546	compared to a previous MRI performed within 24 months before screening
43,T27,Scope 153 546	at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s) (DMT) compared to a previous MRI performed within 24 months before screening
44,R15,Has_scope Arg1:T5 Arg2:T27
45,T28,Pregnancy_considerations 548 726	For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 12 months after the last dose of ocrelizumab
46,T29,Observation 751 785	beneficiary of healthcare coverage
0,T1,Person 61 67	adults
1,T2,Person 68 72	aged
2,T3,Value 73 90	at least 19 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 101 114	atraumatic CA
5,T5,Visit 115 126	outpatients
6,T6,Visit 143 145	ER
7,T7,Procedure 159 162	CPR
0,T1,Condition 0 27	Cardio-vascular pathologies
1,T2,Qualifier 43 55	uncontrolled
2,T3,Qualifier 29 38	evoluting
3,*,OR T3 T2
4,T4,Scope 29 55	evoluting and uncontrolled
5,T5,Condition 65 68	HTA
6,T6,Qualifier 58 64	severe
7,T7,Condition 71 89	cardiac deficiency
8,T8,Condition 98 103	angor
9,T9,Condition 112 122	arrhythmia
10,T10,Qualifier 105 111	severe
11,T11,Qualifier 91 97	severe
12,R1,Has_qualifier Arg1:T9 Arg2:T10
13,R2,Has_qualifier Arg1:T8 Arg2:T11
14,R3,Has_qualifier Arg1:T5 Arg2:T6
15,*,OR T4 T5 T7 T8 T9 T1
16,T12,Condition 125 147	Infectious pathologies
17,T13,Qualifier 148 157	evoluting
18,T14,Qualifier 162 186	requiring antibiotherapy
19,T15,Drug 172 186	antibiotherapy
20,R4,multi Arg1:T14 Arg2:T15
21,T16,Scope 148 186	evoluting and requiring antibiotherapy
22,*,OR T13 T14
23,R5,Has_scope Arg1:T12 Arg2:T16
24,T17,Measurement 198 201	HIV
25,T18,Value 201 202	+
26,T19,Condition 198 202	HIV+
27,R6,Has_value Arg1:T17 Arg2:T18
28,R7,Subsumes Arg1:T19 Arg2:T17
29,T20,Procedure 205 217	Transplanted
30,T21,Condition 254 280	severe auto-immune disease
31,*,OR T20 T21
32,T22,Condition 283 303	Psychiatric troubles
33,T24,Qualifier 309 344	do not allow the protocol follow-up
34,R8,Has_qualifier Arg1:T22 Arg2:T24
35,T25,Condition 347 355	Pregnant
36,T26,Condition 359 373	breast-feeding
37,T27,Person 374 379	women
38,*,OR T26 T25
39,T28,Procedure 385 398	contraception
40,T29,Negation 382 384	No
41,R9,Has_negation Arg1:T28 Arg2:T29
0,T1,Negation 0 2	No
1,T2,Observation 9 16	history
2,R1,Has_negation Arg1:T2 Arg2:T1
3,T3,Condition 20 36	seizure activity
4,R2,Has_temporal Arg1:T3 Arg2:T2
5,T4,Condition 39 47	Pregnant
6,T5,Observation 51 64	breastfeeding
7,*,OR T4 T5
8,T6,Condition 67 84	Renal dysfunction
9,T7,Measurement 86 90	CrCl
10,T8,Value 91 101	< 30ml/min
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Scope 86 101	CrCl < 30ml/min
13,R4,Subsumes Arg1:T6 Arg2:T9
14,T10,Measurement 105 138	Beck's Depression Inventory (BDI)
15,T11,Value 139 142	=14
16,R5,Has_value Arg1:T10 Arg2:T11
17,T12,Condition 144 151	Allergy
18,T13,Drug 155 168	levetiracetam
19,R6,AND Arg1:T12 Arg2:T13
0,T1,Condition 0 8	Epilepsy
1,T2,Condition 9 24	partial seizure
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Drug 60 79	antiepileptic drugs
4,T4,Multiplier 53 59	1 to 3
5,R2,Has_multiplier Arg1:T3 Arg2:T4
0,T1,Person 0 5	adult
1,T2,Measurement 16 25	ASA class
2,T3,Value 26 32	1 to 3
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Qualifier 66 74	elective
5,T5,Procedure 82 92	mastectomy
6,T6,Procedure 75 81;96 110	breast quadrantectomy
7,*,OR T5 T6
8,T7,Scope 75 110	breast mastectomy or quadrantectomy
9,R2,Has_qualifier Arg1:T7 Arg2:T4
0,T1,Person 9 14	women
1,T2,Person 19 33	young children
2,T3,Person 34 38	aged
3,T4,Value 39 48	<18 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Condition 138 153	terminal cancer
6,T6,Condition 65 83	underlying disease
7,T7,Qualifier 90 130	without the possibility of resuscitation
8,R2,Has_qualifier Arg1:T6 Arg2:T7
9,T8,Observation 171 202	do-not-resuscitate (DNR) status
10,T10,Condition 205 232	Death by excessive bleeding
11,T9,Condition 250 269	main artery rupture
12,T11,Qualifier 240 249	abdominal
13,R3,Has_qualifier Arg1:T9 Arg2:T11
14,T12,Scope 240 269	abdominal main artery rupture
15,R4,Subsumes Arg1:T10 Arg2:T12
16,T13,Condition 315 317	CA
17,T14,Visit 306 314	hospital
18,T15,Qualifier 303 314	in-hospital
19,R5,Has_qualifier Arg1:T13 Arg2:T15
20,T16,Drug 362 382	anti-cancer medicine
21,T17,Drug 353 360	steroid
22,T18,Procedure 387 414	immunosuppression treatment
23,T19,Temporal 415 424	before CA
24,T20,Condition 422 424	CA
25,T21,Competing_trial 427 482	Patients already been registered with other studies; or
26,R6,Has_temporal Arg1:T18 Arg2:T19
27,T22,Temporal 329 339	previously
28,T23,Procedure 340 347	treated
29,R7,Has_temporal Arg1:T23 Arg2:T22
30,*,OR T17 T16
31,T24,"Scope 353 382	steroid, anti-cancer medicine"
32,R8,Has_scope Arg1:T23 Arg2:T24
33,*,OR T23 T18
34,T25,Informed_consent 484 538	Patients from whom informed consent cannot be obtained
0,T1,Post-eligibility 0 17	patients' refusal
1,T2,Condition 19 35	contraindication
2,T3,Procedure 39 61	regional anaesthesia (
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 61 75	coagulopathies
5,T5,Drug 88 109	anticoagulant therapy
6,T6,Condition 111 118	allergy
7,T7,Procedure 122 140	local anaesthetics
8,T8,Condition 142 151	infection
9,T9,Qualifier 155 168	puncture site
10,R2,Has_qualifier Arg1:T8 Arg2:T9
11,R3,AND Arg1:T6 Arg2:T7
12,*,OR T8 T6 T5 T4
13,T10,"Scope 61 168	coagulopathies, concurrent anticoagulant therapy, allergy to local anaesthetics, infection at puncture site"
14,R4,Subsumes Arg1:T2 Arg2:T10
0,T1,Condition 13 25	eye diseases
1,T2,Qualifier 0 12	Pre-existing
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 27 35	glaucoma
4,R2,Subsumes Arg1:T1 Arg2:T3
5,T4,Drug 64 74	pregabalin
6,T5,Condition 95 110	partial seizure
7,T6,Drug 144 154	pregabalin
8,T7,Observation 39 60	Insufficient response
9,R3,AND Arg1:T7 Arg2:T4
10,R4,AND Arg1:T4 Arg2:T5
11,*,OR T7 T6
0,T1,Person 0 5	Adult
1,T2,Value 24 33;7 16	and older >18 years
2,T3,Person 20 23	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Scope 7 33	>18 years of age and older
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Mood 56 75	will have undergone
7,T6,Procedure 76 94	surgical resection
8,T7,Procedure 98 104	biopsy
9,*,OR T6 T7
10,T8,Condition 110 136	supratentorial brain tumor
11,T9,Informed_consent 141 175	are able to consent for themselves
12,T10,Scope 76 104	surgical resection or biopsy
13,R3,Has_mood Arg1:T10 Arg2:T5
14,R4,AND Arg1:T10 Arg2:T8
15,T11,Non-representable 178 241	Able to be randomized prior to or up to 48 hours after surgery.
0,T1,Condition 7 15	melanoma
1,T2,Qualifier 0 6	HLA-A2
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 40 53;68 78	loco-regional metastasis
4,T4,Condition 57 78	lymph node metastasis
5,T5,Condition 80 95	transit nodules
6,T6,Qualifier 100 121	surgically resectable
7,T7,Negation 96 99	not
8,R2,Has_negation Arg1:T6 Arg2:T7
9,R3,Has_qualifier Arg1:T5 Arg2:T6
10,T8,Procedure 100 110	surgically
11,R4,multi Arg1:T6 Arg2:T8
12,T9,Condition 147 166	visceral metastasis
13,T10,Condition 134 143;156 166	cutaneous metastasis
14,*,OR T9 T10
15,T11,Qualifier 123 133	measurable
16,T12,Scope 134 166	cutaneous or visceral metastasis
17,R5,Has_qualifier Arg1:T12 Arg2:T11
18,T13,Observation 200 214	MART-1 antigen
19,T14,Observation 192 199;207 214	Melan-A antigen
20,T15,Procedure 220 232	chemotherapy
21,T16,Negation 217 219	No
22,T17,Drug 255 263	Deticene
23,T18,Negation 244 254	except for
24,R7,Has_negation Arg1:T17 Arg2:T18
25,T19,Temporal 269 308	before the first T cell clones infusion
26,T20,Reference_point 276 308	the first T cell clones infusion
27,R8,Has_index Arg1:T19 Arg2:T20
28,R9,Has_temporal Arg1:T17 Arg2:T19
29,R10,AND Arg1:T15 Arg2:T17
30,T21,Procedure 313 325	radiotherapy
31,T22,Procedure 329 342	immunotherapy
32,*,OR T21 T22 T15
33,T23,Temporal 343 378	in the last 4 weeks before infusion
34,T24,Reference_point 370 378	infusion
35,R11,Has_index Arg1:T23 Arg2:T24
36,T25,Condition 390 398	melanoma
37,T26,Temporal 409 428	during the protocol
38,T27,Procedure 399 408	treatment
39,R12,causal Arg1:T27 Arg2:T25
40,R13,Has_temporal Arg1:T27 Arg2:T26
41,T28,Observation 431 446	Life expectancy
42,T29,Value 457 478	greater than 6 months
43,R14,Has_value Arg1:T28 Arg2:T29
44,T30,Measurement 500 509	Karnowsky
45,T31,Value 510 525	greater than 80
46,R15,Has_value Arg1:T30 Arg2:T31
47,T32,Measurement 527 531	ECOG
48,T33,"Value 534 543	0, 1 or 2"
49,R16,Has_value Arg1:T32 Arg2:T33
50,T34,Measurement 577 580	HIV
51,T35,Value 564 572	negative
52,T36,Measurement 591 602	C hepatitis
53,T37,Measurement 585 586;593 602	B hepatitis
54,T38,Scope 577 602	HIV and B and C hepatitis
55,R17,Has_value Arg1:T38 Arg2:T35
56,T39,Measurement 658 668	leucocytes
57,T40,Value 669 692	³ 2000 elements per mm3
58,R18,Has_value Arg1:T39 Arg2:T40
59,T41,Measurement 694 704	hemoglobin
60,T42,Value 705 715	³ 10.5g/dl
61,T43,Measurement 717 726	platelets
62,T44,Value 727 744	³ 100 000 per mm3
63,R19,Has_value Arg1:T43 Arg2:T44
64,T45,Measurement 746 782	phosphatases alcalines transaminases
65,T46,Value 783 818	£ 1 time 1/2 compared to the normal
66,R20,Has_value Arg1:T45 Arg2:T46
67,T47,Observation 821 844	Signed informed consent
68,T48,Scope 220 342	chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy
69,R6,Has_temporal Arg1:T48 Arg2:T23
70,R21,Has_negation Arg1:T48 Arg2:T16
71,*,OR T3 T4
72,T49,Temporal 627 656	at the beginning of the study
73,T50,Reference_point 630 656	the beginning of the study
74,R22,Has_index Arg1:T49 Arg2:T50
75,T51,"Scope 658 818	leucocytes ³ 2000 elements per mm3, hemoglobin ³ 10.5g/dl, platelets ³ 100 000 per mm3, phosphatases alcalines transaminases £ 1 time 1/2 compared to the normal"
76,R23,Has_temporal Arg1:T51 Arg2:T49
0,T1,Qualifier 0 24	Endoscopically confirmed
1,T2,Procedure 0 14	Endoscopically
2,R1,multi Arg1:T1 Arg2:T2
3,T3,Qualifier 67 91	Endoscopically confirmed
4,T4,Procedure 67 81	Endoscopically
5,R2,multi Arg1:T3 Arg2:T4
6,T5,Condition 99 132	upper gastrointestinal hemorrhage
7,T6,Temporal 92 98	active
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Temporal 133 141	on Day 1
10,T8,Reference_point 136 141	Day 1
11,R4,multi Arg1:T7 Arg2:T8
12,T9,Condition 25 32	gastric
13,T10,Condition 40 55	duodenal ulcers
14,T11,Temporal 56 64	on Day 1
15,T12,Reference_point 59 64	Day 1
16,R5,multi Arg1:T11 Arg2:T12
17,*,OR T10 T9
18,T13,Scope 25 55	gastric and/or duodenal ulcers
19,R6,Has_qualifier Arg1:T13 Arg2:T1
20,R7,Has_temporal Arg1:T13 Arg2:T11
21,R8,Has_qualifier Arg1:T5 Arg2:T3
22,R9,Has_temporal Arg1:T5 Arg2:T7
23,T14,Qualifier 171 186	aspirin-induced
24,T15,Drug 171 178	aspirin
25,R10,multi Arg1:T14 Arg2:T15
26,T16,Condition 187 193	asthma
27,R11,Has_qualifier Arg1:T16 Arg2:T14
28,T17,Condition 197 223	hypersensitivity to NSAIDs
29,T18,Drug 217 223	NSAIDs
30,R12,multi Arg1:T17 Arg2:T18
31,*,OR T16 T17
32,T19,Observation 155 167	past history
33,T20,Temporal 144 151	Current
34,*,OR T19 T20
35,T21,Scope 144 167	Current or past history
36,T22,Scope 187 223	asthma or hypersensitivity to NSAIDs
37,R13,Has_scope Arg1:T22 Arg2:T21
38,T23,Qualifier 250 282	affecting gastric acid secretion
39,T24,Procedure 242 249	surgery
40,T25,Mood 234 241	planned
41,T26,Temporal 226 230	Past
42,R14,Has_qualifier Arg1:T24 Arg2:T23
43,T27,Scope 226 241	Past or planned
44,R15,Has_scope Arg1:T24 Arg2:T27
45,T28,Condition 319 333	renal disorder
46,T29,Condition 308 315;325 333	hepatic disorder
47,*,OR T28 T29
48,T30,Qualifier 285 307	Clinically significant
49,T31,Subjective_judgement 285 307	Clinically significant
50,T32,Scope 308 333	hepatic or renal disorder
51,R16,Has_qualifier Arg1:T32 Arg2:T30
52,T33,Condition 344 363	cardiac dysfunction
53,T34,Condition 365 377	hypertension
54,T35,Condition 382 404	hematological disorder
55,*,OR T35 T34 T33
56,T36,Qualifier 336 343	Serious
57,T37,Subjective_judgement 336 343	Serious
58,T38,"Scope 344 404	cardiac dysfunction, hypertension, or hematological disorder"
59,R17,Has_qualifier Arg1:T38 Arg2:T36
0,T1,Condition 0 16	Contraindication
1,T2,Drug 20 32	azithromycin
2,T3,Qualifier 41 46	other
3,T4,Drug 47 74	prophylactic antibiotic use
4,R1,Has_qualifier Arg1:T4 Arg2:T3
5,R2,AND Arg1:T1 Arg2:T2
6,R3,AND Arg1:T1 Arg2:T4
0,T1,Drug 19 60	nonsteroid anti-inflammatory drug (NSAID)
1,T2,Temporal 71 107	on the day when consent was obtained
2,T3,Reference_point 74 107	the day when consent was obtained
3,R1,Has_index Arg1:T2 Arg2:T3
4,T4,Condition 268 281	gastric ulcer
5,T5,Condition 285 299	duodenal ulcer
6,*,OR T4 T5
7,T6,Observation 257 264	history
8,T7,Scope 268 299	gastric ulcer or duodenal ulcer
9,R2,Has_temporal Arg1:T7 Arg2:T6
10,R3,Has_temporal Arg1:T1 Arg2:T2
11,T8,Observation 87 94	consent
12,R4,multi Arg1:T3 Arg2:T8
0,T1,Person 0 3	Age
1,T2,Value 4 15	1-59 months
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Temporal 47 68	greater than 6 months
4,T4,Observation 26 46	remain in study area
5,T5,Mood 18 22	Plan
6,R2,Has_mood Arg1:T4 Arg2:T5
7,R3,Has_temporal Arg1:T4 Arg2:T3
8,T6,Procedure 70 94	Discharged from hospital
9,T7,Procedure 105 133	non-trauma related admission
10,R4,AND Arg1:T6 Arg2:T7
11,T8,Visit 86 94	hospital
12,R5,multi Arg1:T6 Arg2:T8
0,T1,Person 0 10	3-17 years
1,T2,Value 0 10	3-17 years
2,T3,Measurement 12 18	weight
3,T4,Value 19 28	</= 100kg
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Procedure 56 76	orthopedic procedure
6,T6,Procedure 44 52;67 76	urologic procedure
7,T7,Drug 103 111	morphine
8,T8,Qualifier 91 102	intrathecal
9,R2,Has_qualifier Arg1:T7 Arg2:T8
10,*,OR T6 T5
11,T9,Scope 44 76	urologic or orthopedic procedure
12,R3,AND Arg1:T9 Arg2:T7
13,T10,Condition 113 120	ability
14,T11,Procedure 138 184	pictorial pain assessment tools and techniques
15,T12,Procedure 128 134;148 184	verbal pain assessment tools and techniques
16,*,OR T12 T11
17,T13,Scope 128 184	verbal or pictorial pain assessment tools and techniques
18,R4,Has_scope Arg1:T10 Arg2:T13
19,T14,Informed_consent 186 229	informed consent and (if applicable) assent
0,T1,Temporal 22 36	within 28 days
1,T2,Context_Error 0 63	Recent participation (within 28 days) in other research studies
2,T3,Post-eligibility 0 63	Recent participation (within 28 days) in other research studies
3,T4,Procedure 84 98	blood donation
4,T5,Procedure 102 117	plasma donation
5,*,OR T5 T4
6,T6,Qualifier 72 83	significant
7,T8,Temporal 65 71	Recent
8,T9,Scope 84 117	blood donation or plasma donation
9,R1,Has_qualifier Arg1:T9 Arg2:T6
10,R2,Has_temporal Arg1:T9 Arg2:T8
11,T10,Undefined_semantics 72 83	significant
12,T7,Condition 119 127	Pregnant
13,T11,Condition 131 140	lactating
14,*,OR T11 T7
15,T13,Value 147 155	positive
16,T14,Temporal 156 168	at screening
17,T15,Measurement 173 207	human immunodeficiency virus (HIV)
18,T16,Measurement 249 272	hepatitis C virus (HCV)
19,T17,Measurement 209 244	hepatitis B surface antigen (HbsAg)
20,*,OR T15 T17 T16
21,T12,"Scope 173 272	human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)"
22,R3,Has_value Arg1:T12 Arg2:T13
23,R4,Has_temporal Arg1:T12 Arg2:T14
24,T18,Condition 313 323	alcoholism
25,T19,Condition 327 337	drug abuse
26,T20,Observation 290 297	history
27,T21,Mood 301 309	evidence
28,*,OR T21 T20
29,T22,Temporal 274 280	Recent
30,T23,Temporal 282 288	2-year
31,R5,Subsumes Arg1:T22 Arg2:T23
32,*,OR T18 T19
33,T24,Scope 313 337	alcoholism or drug abuse
34,T25,Scope 290 309	history or evidence
35,R6,Has_scope Arg1:T24 Arg2:T25
36,R7,Has_temporal Arg1:T24 Arg2:T22
37,T26,"Post-eligibility 339 550	History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease"
38,T27,Drug 579 584;599 615;626 655	drugs known to inhibit cytochrome (CYP) P450 enzymes
39,T28,Drug 579 584;599 607;619 655	drugs known to induce cytochrome (CYP) P450 enzymes
40,*,OR T28 T27
41,T29,Drug 579 584;599 615;663 684	drugs known to inhibit P-glycoprotein (P-gp)
42,T30,Drug 579 584;599 607;619 625;663 684	drugs known to induce P-glycoprotein (P-gp)
43,T31,Temporal 685 723	within 28 days prior to the first dose
44,T32,Temporal 728 748	throughout the study
45,T33,Scope 579 684	drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp)
46,R8,Has_temporal Arg1:T33 Arg2:T31
47,R9,Has_temporal Arg1:T33 Arg2:T32
48,T34,Condition 755 764	allergies
49,T36,Drug 768 783	quinine sulfate
50,T37,Drug 787 800	rosiglitazone
51,T35,Scope 768 800	quinine sulfate or rosiglitazone
52,*,OR T37 T36
53,R10,Has_scope Arg1:T34 Arg2:T35
0,T1,Procedure 20 46	lipid modification therapy
1,T2,Drug 77 84	statins
2,T3,Drug 86 94	fibrates
3,T4,Drug 99 121	bile acid sequestrants
4,*,OR T2 T3 T4
5,T5,"Scope 77 121	statins, fibrates and bile acid sequestrants"
6,R1,Subsumes Arg1:T1 Arg2:T5
7,T6,Grammar_Error 95 98	and
8,T7,Drug 140 148	fish oil
9,T8,"Subjective_judgement 124 240	Subjects taking fish oil or any other supplements, which in the investigator s opinion may interfere with the study."
10,T9,"Post-eligibility 124 240	Subjects taking fish oil or any other supplements, which in the investigator s opinion may interfere with the study."
11,T10,Condition 256 275	acute liver disease
12,T11,Condition 286 306	peptic ulcer disease
13,T12,Temporal 279 285	active
14,R2,Has_temporal Arg1:T11 Arg2:T12
15,R3,AND Arg1:T11 Arg2:T10
16,T13,Measurement 332 348	uric acid levels
17,T14,Value 323 331	elevated
18,T15,Value 349 370	greater than 10 mg/dL
19,R4,Subsumes Arg1:T14 Arg2:T15
20,R5,Has_value Arg1:T13 Arg2:T14
21,T16,Condition 374 378	gout
22,*,OR T13 T16
23,T17,Condition 380 389	Pregnancy
24,T18,Person 393 398	women
25,T19,Observation 409 422	breastfeeding
26,*,OR T17 T19
27,T20,Person 425 431	Female
28,T21,Drug 448 471	hormonal contraceptives
29,T22,Procedure 475 502	hormone replacement therapy
30,T23,Qualifier 561 572	stable dose
31,T24,Temporal 573 594	for at least 3 months
32,R6,Has_temporal Arg1:T23 Arg2:T24
33,*,OR T22 T21
34,T25,Scope 448 502	hormonal contraceptives or hormone replacement therapy
35,R7,Has_qualifier Arg1:T25 Arg2:T23
36,T26,Grammar_Error 503 518	may be included
37,T27,Measurement 597 600	BMI
38,T28,Value 601 615	less than 18.5
39,R8,Has_value Arg1:T27 Arg2:T28
40,T29,Measurement 631 637	weight
41,T30,Qualifier 643 666	varies greater than 20%
42,T31,Temporal 667 689	over the past 3 months
43,R9,Has_temporal Arg1:T30 Arg2:T31
44,R10,Has_qualifier Arg1:T29 Arg2:T30
45,T32,Temporal 734 756	for at least six weeks
46,T33,Drug 812 815	BAS
47,T34,Drug 817 828	antibiotics
48,T35,Drug 830 844	anticoagulants
49,T36,Drug 846 861	anticonvulsants
50,T37,Drug 863 877	antiarrhythmic
51,T38,Drug 879 891	Cyclosporine
52,T39,Drug 893 906	Mycophenolate
53,T40,Drug 911 920	Synthroid
54,T41,Grammar_Error 907 910	and
55,*,OR T40 T39 T38 T37 T36 T35 T34 T33
56,T42,"Scope 812 920	BAS, antibiotics, anticoagulants, anticonvulsants, antiarrhythmic, Cyclosporine, Mycophenolate and Synthroid"
57,R11,Has_temporal Arg1:T42 Arg2:T32
58,T43,Condition 936 952	chronic diarrhea
59,T44,Procedure 954 968	gastric bypass
60,T45,Procedure 972 991	lap band procedures
61,T46,Procedure 993 1001	ostomies
62,T47,Condition 1003 1026	bowel motility problems
63,T48,Condition 1037 1091	conditions that could affect intestinal fat absorption
64,T49,Undefined_semantics 1037 1091	conditions that could affect intestinal fat absorption
65,*,OR T47 T48 T46 T45 T44 T43
66,T50,Non-query-able 1094 1187	Subjects initiating new medications or patients on multiple medications may also be excluded.
67,T51,Condition 1189 1218	Inability to swallow capsules
68,T52,Condition 1257 1273	type II diabetes
69,T53,Condition 1247 1253;1265 1273	type I diabetes
70,*,OR T52 T53 T54
71,T54,Measurement 1277 1282	HbA1c
72,T55,Value 1283 1300	greater than 6.5%
73,R12,Has_value Arg1:T54 Arg2:T55
74,T56,Observation 1236 1243	history
75,T57,Scope 1247 1300	type I or type II diabetes or HbA1c greater than 6.5%
76,R13,Has_temporal Arg1:T57 Arg2:T56
77,T58,"Non-query-able 1303 1507	Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer."
78,T59,"Subjective_judgement 1303 1507	Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer."
79,T60,"Post-eligibility 1303 1507	Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer."
0,T1,Value 18 31	over 40 years
1,T2,Person 26 31	years
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Non-query-able 80 103	Informed consent signed
4,T4,Procedure 105 124	Medical examination
5,T5,Temporal 135 169	prior to participation in research
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Condition 199 216	inner ear disease
8,T7,Observation 188 195	history
9,T8,Negation 180 187	without
10,R3,Has_negation Arg1:T6 Arg2:T8
11,R4,Has_temporal Arg1:T6 Arg2:T7
12,T9,Non-query-able 218 262	Recipient of a French social security scheme
0,T1,Value 12 36	over the age of 85 years
1,T2,Person 21 24	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Subjective_judgement 44 81	at the discretion of the Investigator
4,T4,Post-eligibility 3 116	Patients over the age of 85 years except at the discretion of the Investigator and with agreement of the Sponsor.
5,T5,Condition 134 162	acute promyelocytic leukemia
6,T6,Condition 180 214	chronic myelogenous leukemia (CML)
7,T7,Condition 218 230	blast crisis
8,T8,Condition 235 238	AML
9,T9,Qualifier 239 249	in relapse
10,T10,Qualifier 253 263	refractory
11,*,OR T10 T9
12,T11,Temporal 264 310	after 3 or more previous lines of chemotherapy
13,T12,Multiplier 270 279	3 or more
14,T13,Temporal 280 288	previous
15,T14,Procedure 289 310	lines of chemotherapy
16,R2,Has_temporal Arg1:T14 Arg2:T13
17,R3,Has_multiplier Arg1:T14 Arg2:T12
18,R4,multi Arg1:T11 Arg2:T14
19,T15,Scope 239 263	in relapse or refractory
20,R5,Has_temporal Arg1:T15 Arg2:T11
21,R6,Has_scope Arg1:T8 Arg2:T15
22,T16,Condition 339 342	AML
23,T17,Condition 357 360	MDS
24,T18,Temporal 346 356	antecedent
25,T20,Temporal 374 379	prior
26,T21,Condition 380 392	chemotherapy
27,R7,Has_temporal Arg1:T21 Arg2:T20
28,R8,Has_temporal Arg1:T17 Arg2:T18
29,*,OR T17 T16
30,T19,Scope 339 360	AML or antecedent MDS
31,R9,causal Arg1:T19 Arg2:T21
32,T22,Condition 449 457	toxicity
33,T23,Qualifier 431 448	non-hematological
34,R10,Has_qualifier Arg1:T22 Arg2:T23
35,T24,Qualifier 408 430	clinically significant
36,T25,Subjective_judgement 408 430	clinically significant
37,R11,Has_qualifier Arg1:T22 Arg2:T24
38,T26,Value 466 474	Grade >1
39,T27,Measurement 478 490	NCI CTCAE v4
40,R12,Has_value Arg1:T27 Arg2:T26
41,T28,Qualifier 466 490	Grade >1 by NCI CTCAE v4
42,R13,Has_qualifier Arg1:T22 Arg2:T28
43,T29,Procedure 502 514	chemotherapy
44,T30,Temporal 496 501	prior
45,R14,Has_temporal Arg1:T29 Arg2:T30
46,R15,causal Arg1:T22 Arg2:T29
47,R16,multi Arg1:T28 Arg2:T27
48,T31,Temporal 554 583	within 100 days of transplant
49,T32,Condition 541 545	HSCT
50,T33,Temporal 532 540	have had
51,R17,Has_temporal Arg1:T32 Arg2:T33
52,T34,Procedure 573 583	transplant
53,T35,Reference_point 573 583	transplant
54,R18,multi Arg1:T31 Arg2:T35
55,R19,multi Arg1:T35 Arg2:T34
56,T36,Drug 608 631	immunosuppressive drugs
57,T37,Qualifier 644 666	clinically significant
58,T38,Subjective_judgement 644 666	clinically significant
59,T39,Condition 667 692	graft-versus-host disease
60,T40,Procedure 703 712	treatment
61,T41,Mood 693 702	requiring
62,R20,Has_mood Arg1:T40 Arg2:T41
63,R21,AND Arg1:T39 Arg2:T40
64,R22,Has_qualifier Arg1:T39 Arg2:T37
65,T42,Qualifier 725 733	>Grade 1
66,T43,Qualifier 745 762	non hematological
67,T44,Qualifier 734 744	persistent
68,T45,Multiplier 734 744	persistent
69,R23,multi Arg1:T44 Arg2:T45
70,T46,Condition 763 771	toxicity
71,R24,Has_qualifier Arg1:T46 Arg2:T43
72,R25,Has_qualifier Arg1:T46 Arg2:T44
73,T47,Procedure 787 797	transplant
74,R26,causal Arg1:T46 Arg2:T47
75,R27,Has_qualifier Arg1:T46 Arg2:T42
76,T48,Temporal 595 600	still
77,R28,Has_temporal Arg1:T36 Arg2:T48
78,R29,causal Arg1:T34 Arg2:T32
79,R30,causal Arg1:T36 Arg2:T32
80,R31,causal Arg1:T39 Arg2:T34
81,*,OR T34 T36 T39 T46
82,T49,Condition 820 857	central nervous system (CNS) leukemia
83,T50,"Non-representable 859 1093	Patients with CNS leukemia, which is controlled, but who are still receiving IT therapy at study entry may be considered eligible and continue receive IT therapy at the discretion of the Investigator and with agreement of the Sponsor."
84,T51,Drug 1136 1141	AC220
85,T52,Condition 1147 1191	Disseminated intravascular coagulation (DIC)
86,T53,Procedure 1246 1259	Major surgery
87,T54,Temporal 1260 1294	within 4 weeks prior to enrollment
88,T55,Reference_point 1284 1294	enrollment
89,R32,multi Arg1:T54 Arg2:T55
90,R33,Has_temporal Arg1:T53 Arg2:T54
91,T56,Procedure 1313 1330	Radiation therapy
92,T57,Temporal 1331 1354;1375 1380	within 4 weeks prior to study
93,T58,Temporal 1359 1380	concurrent with study
94,T59,Reference_point 1375 1380	study
95,R34,multi Arg1:T57 Arg2:T59
96,R35,multi Arg1:T58 Arg2:T59
97,T60,"Scope 1331 1380	within 4 weeks prior to, or concurrent with study"
98,R36,Has_scope Arg1:T56 Arg2:T60
99,T61,Condition 1416 1439	prolong QT/QTc interval
100,T62,Drug 1405 1439	drugs that prolong QT/QTc interval
101,T63,Drug 1451 1468	CYP3A4 inhibitors
102,T64,Drug 1506 1517	antibiotics
103,T65,Drug 1519 1530	antifungals
104,T66,Drug 1542 1556	antimicrobials
105,*,OR T66 T65 T64
106,*,OR T63 T62
107,T67,Qualifier 1411 1439	that prolong QT/QTc interval
108,R37,multi Arg1:T62 Arg2:T67
109,R38,multi Arg1:T67 Arg2:T61
110,T68,Negation 1484 1505	with the exception of
111,T69,"Scope 1506 1556	antibiotics, antifungals, and other antimicrobials"
112,R39,Has_negation Arg1:T69 Arg2:T68
113,T70,Scope 1405 1468	drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors
114,R40,Has_scope Arg1:T70 Arg2:T69
115,T71,Condition 1746 1768	cardiovascular disease
116,T72,Qualifier 1718 1730	Uncontrolled
117,T73,Qualifier 1734 1745	significant
118,*,OR T73 T72
119,T74,Scope 1718 1745	Uncontrolled or significant
120,R41,Has_scope Arg1:T71 Arg2:T74
121,T75,Condition 1788 1796	pregnant
122,T76,Condition 1798 1807	lactating
123,T77,Mood 1812 1821	unwilling
124,T78,Condition 1849 1871	childbearing potential
125,T79,Condition 1829 1842	contraception
126,R42,Has_mood Arg1:T79 Arg2:T77
127,A1,Optional T78
128,R43,AND Arg1:T78 Arg2:T79
129,*,OR T76 T75 T78
130,T80,Person 1877 1880	Men
131,T81,Mood 1889 1898	unwilling
132,T82,Drug 1906 1919	contraception
133,R44,Has_mood Arg1:T82 Arg2:T81
134,T83,Observation 1923 1967	their partners are of childbearing potential
135,T84,Non-representable 1923 1967	their partners are of childbearing potential
136,A2,Optional T83
137,R45,AND Arg1:T83 Arg2:T82
138,T85,Condition 1994 2003	infection
139,T86,Qualifier 1981 1993	uncontrolled
140,T87,Temporal 1973 1979	Active
141,R46,Has_qualifier Arg1:T85 Arg2:T86
142,R47,Has_temporal Arg1:T85 Arg2:T87
143,T88,Condition 2009 2037	Human immunodeficiency virus
144,T89,Measurement 2009 2037	Human immunodeficiency virus
145,T90,Value 2038 2048	positivity
146,R48,Has_value Arg1:T89 Arg2:T90
147,R49,multi Arg1:T88 Arg2:T89
148,T91,Condition 2061 2072	hepatitis B
149,T92,Condition 2061 2070;2076 2077	hepatitis C
150,*,OR T92 T91
151,T93,Temporal 2054 2060	Active
152,T94,Condition 2094 2107	liver disease
153,T95,Temporal 2087 2093	active
154,R50,Has_temporal Arg1:T94 Arg2:T95
155,T96,Scope 2061 2077	hepatitis B or C
156,R51,Has_temporal Arg1:T96 Arg2:T93
157,*,OR T96 T94
158,T97,Condition 2124 2130	cancer
159,T98,Observation 2113 2120	History
160,R52,Has_temporal Arg1:T97 Arg2:T98
161,T99,Condition 2170 2181	skin cancer
162,T100,Qualifier 2157 2169	nonmelanotic
163,T101,Qualifier 2139 2153	Stage 1 cervix
164,T102,Negation 2132 2138	except
165,R53,Has_qualifier Arg1:T99 Arg2:T100
166,R54,Has_qualifier Arg1:T99 Arg2:T101
167,R55,Has_negation Arg1:T99 Arg2:T102
168,R56,AND Arg1:T97 Arg2:T99
0,T1,Measurement 0 5	HBsAg
1,T2,Value 6 14	positive
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Temporal 19 37	more than 6 months
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Measurement 39 44	HBeAg
6,T5,Value 45 53	positive
7,T6,Measurement 57 62	HBeAg
8,T7,Value 63 71	negative
9,R3,Has_value Arg1:T4 Arg2:T5
10,R4,Has_value Arg1:T6 Arg2:T7
11,*,OR T4 T6
12,T8,Scope 39 71	HBeAg-positive or HBeAg-negative
13,T9,Person 75 78	Age
14,T10,Value 79 87	> 20 y/o
15,R6,Has_value Arg1:T9 Arg2:T10
16,T11,Drug 96 106	lamivudine
17,T12,Drug 107 115	adefovir
18,T13,Temporal 130 146	more than 1 year
19,T14,Observation 163 184	lamivudine resistance
20,T15,Observation 186 191	LAM-R
21,T16,Measurement 202 209	HBV DNA
22,T17,Value 213 225	undetectable
23,T18,Value 227 237	< 20 IU/ml
24,T19,Temporal 239 256	during enrollment
25,T20,Reference_point 246 256	enrollment
26,R5,Has_index Arg1:T19 Arg2:T20
27,R7,Has_value Arg1:T16 Arg2:T17
28,R8,Subsumes Arg1:T17 Arg2:T18
29,R9,Subsumes Arg1:T14 Arg2:T15
30,T21,Scope 96 115	lamivudine/adefovir
31,R10,Has_temporal Arg1:T21 Arg2:T13
32,R11,Has_context Arg1:T21 Arg2:T14
0,T1,Informed_consent 0 31	Patients with informed consents
1,T2,Condition 41 69	basal disorders of neurology
2,T3,Condition 41 59;74 86	basal disorders of psychiatrics
3,T4,Negation 33 40	Without
4,*,OR T3 T2
5,T5,Scope 41 86	basal disorders of neurology and psychiatrics
6,R1,Has_negation Arg1:T5 Arg2:T4
0,T1,Value 15 33	18-45 years of age
1,T2,Condition 0 7	Healthy
2,T3,Person 8 14	adults
3,T4,Person 27 33	of age
4,R1,Has_value Arg1:T4 Arg2:T1
5,T5,Condition 39 46	smoking
6,T6,Negation 35 38	Non
7,R2,Has_negation Arg1:T5 Arg2:T6
8,T7,Condition 52 60	pregnant
9,T8,Negation 48 51	Non
10,R3,Has_negation Arg1:T7 Arg2:T8
11,T9,Condition 79 97	surgically sterile
12,T10,Procedure 79 89	surgically
13,R4,multi Arg1:T9 Arg2:T10
14,T11,Condition 62 77	post-menopausal
15,T12,Procedure 117 139	contraceptive measures
16,T13,Qualifier 107 116	effective
17,T14,Undefined_semantics 107 116	effective
18,R5,Has_qualifier Arg1:T12 Arg2:T13
19,*,OR T9 T12 T11
20,T15,"Scope 62 139	post-menopausal, surgically sterile or using effective contraceptive measures"
21,T16,Scope 48 60	Non-pregnant
22,R6,Subsumes Arg1:T16 Arg2:T15
23,T17,Measurement 142 163	Body mass index (BMI)
24,T18,Value 164 188	less than or equal to 32
25,R7,Has_value Arg1:T17 Arg2:T18
26,T19,Observation 224 239	medical history
27,T20,Procedure 244 264	physical examination
28,T21,Condition 190 207	Medically healthy
29,T22,Scope 224 264	medical history and physical examination
30,R8,Has_scope Arg1:T21 Arg2:T22
31,T23,Measurement 266 276	Hemoglobin
32,T24,Value 277 295	> or = to 11.5g/dL
33,R9,Has_value Arg1:T23 Arg2:T24
34,T25,Temporal 333 363	within 28 days prior to dosing
35,T26,Reference_point 357 363	dosing
36,R10,Has_index Arg1:T25 Arg2:T26
37,T27,Procedure 315 332	screening process
38,R11,Has_temporal Arg1:T27 Arg2:T25
39,T28,Post-eligibility 365 412	Provision of voluntary written informed consent
0,T1,Person 0 5	Males
1,T2,Person 10 17	females
2,T3,Value 26 43	at least 18 years
3,T4,Person 47 50	age
4,T5,Temporal 51 72	at time of enrollment
5,T6,Reference_point 54 72	time of enrollment
6,R1,Has_index Arg1:T5 Arg2:T6
7,T7,"Post-eligibility 75 174	Subject understands the investigational nature of the study and provides written, informed consent."
0,T1,Procedure 27 56	pictorial pain scoring scales
1,T2,Procedure 17 23;37 56	verbal pain scoring scales
2,*,OR T2 T1
3,T3,Condition 0 9	Inability
4,T4,Scope 17 56	verbal or pictorial pain scoring scales
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Condition 58 74	hypersensitivity
7,T6,Drug 78 113	selective 5-HT receptor antagonists
8,R2,AND Arg1:T5 Arg2:T6
9,T8,Condition 125 152	congenital long QT syndrome
10,T7,Condition 161 179	hepatic impairment
11,T9,Qualifier 154 160	severe
12,R3,Has_qualifier Arg1:T7 Arg2:T9
13,T10,Condition 181 190	pregnancy
14,T11,Condition 194 201	nursing
15,*,OR T10 T11
0,T1,Person 3 8	Males
1,T2,Person 13 20	females
2,T3,Person 21 24	age
3,T4,Value 25 34	≥18 years
4,T5,Condition 45 52	relapse
5,T6,Condition 56 66	refractory
6,*,OR T6 T5
7,T7,Scope 45 66	relapse or refractory
8,T8,Multiplier 38 44	second
9,R1,Has_multiplier Arg1:T7 Arg2:T8
10,R2,Has_value Arg1:T3 Arg2:T4
11,*,OR T1 T2
12,T9,Person 72 77	Males
13,T10,Person 82 89	females
14,T11,Person 90 93	age
15,T12,Value 94 103	≥60 years
16,R3,Has_value Arg1:T11 Arg2:T12
17,T13,Multiplier 107 112	first
18,T14,Condition 113 120	relapse
19,T15,Condition 124 134	refractory
20,*,OR T15 T14
21,T16,Scope 113 134	relapse or refractory
22,R4,Has_multiplier Arg1:T16 Arg2:T13
23,T17,Procedure 159 177	bone marrow sample
24,T18,Temporal 150 158	baseline
25,R5,Has_temporal Arg1:T17 Arg2:T18
26,T19,Qualifier 189 215	Morphologically documented
27,T20,Qualifier 216 223	primary
28,T21,Condition 224 227	AML
29,T22,Condition 231 234	AML
30,*,OR T22 T21
31,R6,Has_qualifier Arg1:T21 Arg2:T20
32,R7,Has_qualifier Arg1:T22 Arg2:T20
33,T23,Condition 248 272	myelodysplastic syndrome
34,R8,causal Arg1:T23 Arg2:T21
35,R9,causal Arg1:T23 Arg2:T22
36,R10,Has_qualifier Arg1:T21 Arg2:T19
37,R11,Has_qualifier Arg1:T22 Arg2:T19
38,T24,Condition 274 277	MDS
39,T25,Value 283 287	≥20%
40,T26,Measurement 288 299	bone marrow
41,T27,Measurement 303 320	peripheral blasts
42,*,OR T27 T26
43,T28,Scope 288 320	bone marrow or peripheral blasts
44,R12,Has_value Arg1:T28 Arg2:T25
45,R13,Has_scope Arg1:T24 Arg2:T28
46,R14,Subsumes Arg1:T23 Arg2:T24
47,T29,Procedure 341 381	World Health Organization (WHO) criteria
48,T30,Procedure 396 412	pathology review
49,R15,AND Arg1:T23 Arg2:T29
50,R16,AND Arg1:T23 Arg2:T30
51,T31,Non-representable 442 480	Able to swallow the liquid study drug.
52,T32,Post-eligibility 442 480	Able to swallow the liquid study drug.
53,T33,Measurement 485 508	ECOG performance status
54,T34,Value 512 518	0 to 2
55,R17,Has_value Arg1:T33 Arg2:T34
56,T35,"Non-representable 520 972	7. In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. The use of chemotherapeutic or antileukemic agents other than hydroxyurea is not permitted during the study with the possible exception of intrathecal (IT) therapy at the discretion of the Investigator and with the agreement of the Sponsor."
57,T36,Condition 1037 1047	toxicities
58,T37,Qualifier 1019 1036	non-hematological
59,T38,Qualifier 996 1018	clinically significant
60,T39,Temporal 1053 1058	prior
61,T40,Qualifier 1077 1085	≤Grade 1
62,T41,Value 1077 1085	≤Grade 1
63,R18,multi Arg1:T40 Arg2:T41
64,R19,Has_qualifier Arg1:T36 Arg2:T40
65,R20,Has_qualifier Arg1:T36 Arg2:T37
66,R21,Has_qualifier Arg1:T36 Arg2:T38
67,T42,Qualifier 1048 1068	from prior treatment
68,T43,Procedure 1059 1068	treatment
69,R22,Has_temporal Arg1:T43 Arg2:T39
70,R23,multi Arg1:T42 Arg2:T43
71,R24,Has_qualifier Arg1:T36 Arg2:T42
72,T44,Drug 1110 1125	FLT3 inhibitors
73,T45,Mood 1129 1138	permitted
74,T46,Procedure 1097 1104	therapy
75,R25,AND Arg1:T46 Arg2:T44
76,R26,Has_mood Arg1:T46 Arg2:T45
77,T47,Procedure 1156 1165	treatment
78,T48,Drug 1171 1176	AC220
79,R27,AND Arg1:T47 Arg2:T48
80,T49,Negation 1140 1146	except
81,R28,Has_negation Arg1:T47 Arg2:T49
82,R29,AND Arg1:T46 Arg2:T47
83,T50,Measurement 1183 1199	Serum creatinine
84,T51,Value 1200 1210	≤1.5 × ULN
85,T52,Measurement 1215 1247	glomerular filtration rate (GFR)
86,T53,Value 1248 1259	> 30 mL/min
87,R30,Has_value Arg1:T52 Arg2:T53
88,R31,Has_value Arg1:T50 Arg2:T51
89,T54,Measurement 1265 1280	Serum potassium
90,T55,Measurement 1265 1270;1282 1291	Serum magnesium
91,T56,Measurement 1265 1270;1297 1304	Serum calcium
92,T57,Value 1322 1365	at least within institutional normal limits
93,T58,"Scope 1265 1304	Serum potassium, magnesium, and calcium"
94,R32,Has_value Arg1:T58 Arg2:T57
95,T59,Measurement 1372 1393	Total serum bilirubin
96,T60,Value 1394 1404	≤1.5 × ULN
97,R33,Has_value Arg1:T59 Arg2:T60
98,T61,Measurement 1410 1444	Serum aspartate transaminase (AST)
99,T62,Measurement 1452 1478	alanine transaminase (ALT)
100,*,OR T62 T61
101,T63,Value 1479 1489	≤2.5 × ULN
102,R34,Has_value Arg1:T62 Arg2:T63
103,R35,Has_value Arg1:T61 Arg2:T63
104,T64,Measurement 1550 1564	pregnancy test
105,T65,Value 1541 1549	negative
106,T66,Procedure 1566 1577	urine β-hCG
107,R36,Subsumes Arg1:T64 Arg2:T66
108,R37,Has_value Arg1:T64 Arg2:T65
109,T67,Person 1495 1502	Females
110,T68,Condition 1506 1528	childbearing potential
111,T69,Scope 1495 1528	Females of childbearing potential
112,A1,Optional T69
113,R38,AND Arg1:T69 Arg2:T64
114,T70,Pregnancy_considerations 1585 1729	Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.
115,T71,Pregnancy_considerations 1495 1579	Females of childbearing potential must have a negative pregnancy test (urine β-hCG).
116,T72,Post-eligibility 1735 1777	Written informed consent must be provided.
0,T1,Person 9 15	minors
1,T2,Person 31 72	legal protection regime type guardianship
2,T3,Condition 74 97	Respiratory pathologies
3,T4,Condition 99 113	cardiovascular
4,T5,Condition 115 120	renal
5,T6,Condition 122 130	diabetes
6,*,OR T3 T4 T5 T6
7,T7,Condition 132 146	Claustrophobia
8,T8,Condition 148 165	Contraindications
9,T9,Device 183 197	magnetic field
10,R1,AND Arg1:T8 Arg2:T9
11,T10,Condition 199 216	Contraindications
12,T11,Drug 230 237	Dotarem
13,R2,AND Arg1:T10 Arg2:T11
0,T1,Condition 20 39	cognitive disorders
1,T3,Condition 46 76	chronic neurological disorders
2,T4,Observation 78 96	Cannot communicate
3,T2,Observation 117 129	Cannot stand
4,T5,Procedure 130 148	general anesthesia
5,R1,AND Arg1:T2 Arg2:T5
0,T1,Condition 0 3;14 25	HCV coinfection
1,T2,Condition 14 25;5 8	coinfection HIV
2,T3,Condition 10 25	HDV coinfection
3,*,OR T3 T2 T1
4,T4,Condition 41 44	HCC
5,T5,Condition 46 56	malignancy
6,T6,Condition 74 89	liver cirrhosis
7,T7,Qualifier 60 73	decompensated
8,R1,Has_qualifier Arg1:T6 Arg2:T7
9,T8,Qualifier 28 40	Uncontrolled
10,R2,Has_qualifier Arg1:T4 Arg2:T8
11,*,OR T4 T5 T6
12,T9,Measurement 91 100	CTP score
13,T10,Value 101 104	= 7
14,R3,Has_value Arg1:T9 Arg2:T10
15,T11,Condition 108 114	Uremia
16,T12,Measurement 127 137	Creatinine
17,T13,Value 138 147	= 2 mg/dl
18,R4,Has_value Arg1:T12 Arg2:T13
19,*,OR T11 T12
0,T1,Non-query-able 0 69	Provision of informed consent prior to any study specific procedures;
1,T2,Person 71 74	Men
2,T3,Person 79 84	women
3,T4,Value 85 103	18 years and older
4,T5,Person 88 93	years
5,R1,Has_value Arg1:T5 Arg2:T4
6,*,OR T3 T2
7,T6,Qualifier 106 113	Group I
8,T7,Condition 114 117	PAH
9,R2,Has_qualifier Arg1:T7 Arg2:T6
10,T8,Measurement 132 136	mPAP
11,T9,Value 136 143	=25mmHg
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Measurement 145 149	PCWP
14,T11,Value 149 156	<15mmHg
15,R4,Has_value Arg1:T10 Arg2:T11
16,T12,Measurement 161 164	PVR
17,T13,Measurement 174 188	(mPAP-PCWP)/CO
18,T14,Value 189 204	>3.0 Woods unit
19,R5,Subsumes Arg1:T12 Arg2:T13
20,T15,Scope 161 189	PVR[The PVR =(mPAP-PCWP)/CO]
21,R6,Has_value Arg1:T15 Arg2:T14
22,T16,"Scope 132 204	mPAP=25mmHg, PCWP<15mmHg and PVR[The PVR =(mPAP-PCWP)/CO]>3.0 Woods unit"
23,T17,Scope 106 117	Group I PAH
24,R7,Subsumes Arg1:T17 Arg2:T16
0,T1,Condition 0 8	allergic
1,T2,Observation 9 16	history
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Drug 20 35	dexmedetomidine
4,R2,AND Arg1:T1 Arg2:T3
5,T4,Qualifier 37 47	refractory
6,T5,Condition 48 59	bradycardia
7,T6,Value 60 68	< 60 bpm
8,R3,Has_value Arg1:T5 Arg2:T6
9,R4,Has_qualifier Arg1:T5 Arg2:T4
10,T7,Qualifier 69 86	despite treatment
11,T8,Procedure 77 86	treatment
12,R5,multi Arg1:T7 Arg2:T8
13,R6,Has_qualifier Arg1:T5 Arg2:T7
14,T9,Qualifier 88 94	severe
15,T10,Condition 95 117	atrioventricular block
16,T11,Qualifier 119 122;131 137	2nd degree
17,T12,Qualifier 127 137	3rd degree
18,*,OR T11 T12
19,T13,Scope 119 137	2nd and 3rd degree
20,R7,Subsumes Arg1:T9 Arg2:T13
21,R8,Has_qualifier Arg1:T10 Arg2:T9
22,T14,Temporal 140 148	previous
23,T15,Procedure 149 168	operation of tongue
24,R9,Has_temporal Arg1:T15 Arg2:T14
0,T1,Visit 15 42	newborn intensive care unit
1,T2,Person 0 7	Infants
2,T3,Condition 44 59	TPN cholestasis
3,T4,Multiplier 63 81	at least 2.5 mg/dl
4,R1,Has_multiplier Arg1:T3 Arg2:T4
5,T5,Procedure 95 108	TPN treatment
6,T6,Multiplier 109 131	for at least one month
7,T7,Informed_consent 133 156	signed informed consent
0,T1,Multiplier 0 5	First
1,T2,Multiplier 6 12	single
2,T3,Condition 13 19	stroke
3,T4,Qualifier 20 29	ischaemic
4,T5,Qualifier 33 45	haemorrhagic
5,*,OR T4 T5
6,T6,Condition 64 74	hemiplegia
7,T7,Scope 20 45	ischaemic or haemorrhagic
8,R1,Has_scope Arg1:T3 Arg2:T7
9,R2,Has_multiplier Arg1:T3 Arg2:T2
10,R3,Has_multiplier Arg1:T3 Arg2:T1
11,R4,AND Arg1:T3 Arg2:T6
12,T8,Condition 76 81	Stoke
13,T9,Temporal 82 105	since less than 2 month
14,R5,Has_temporal Arg1:T8 Arg2:T9
15,T10,Non-representable 107 130	A sufficient understood
16,T11,Condition 134 144	spasticity
17,T12,Measurement 149 162	Tardieu score
18,T13,Value 163 182	upper or equal to 2
19,R6,Has_value Arg1:T12 Arg2:T13
20,T14,Multiplier 186 198	at least one
21,T15,Qualifier 216 236	muscle-triceps surae
22,T16,Qualifier 238 256	flexors of fingers
23,T17,Qualifier 261 266	wrist
24,T18,Qualifier 274 279	elbow
25,*,OR T15 T16 T17 T18
26,T19,"Scope 216 279	muscle-triceps surae, flexors of fingers, of wrist and of elbow"
27,R7,Has_multiplier Arg1:T19 Arg2:T14
28,R8,AND Arg1:T11 Arg2:T12
29,R9,Has_scope Arg1:T12 Arg2:T19
30,T20,Informed_consent 281 295	A free consent
0,T1,Measurement 0 52	American Society of Anesthesiologists Classification
1,T2,Value 53 58	I-III
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,"Post-eligibility 61 160	ormal cognitive function in order to sign written, informed consent and to understand trial protoco"
4,T4,"Post-eligibility 163 227	Agreement to the trial protocol, including the randomized manner"
0,T1,Competing_trial 0 45	The patient is participating in another study
1,T2,Non-query-able 47 115	The patient is in an exclusion period determined by a previous study
2,T3,Informed_consent 117 182	The patient or his/her representative refuses to sign the consent
3,T4,Post-eligibility 184 258	It is impossible to correctly inform the patient or his/her representative
4,T5,Pregnancy_considerations 260 300	The patient is pregnant or breastfeeding
5,T6,Condition 320 336	contraindication
6,T7,Non-representable 302 409	The patient has a contraindication (or an incompatible drug association) for a treatment used in this study
7,T8,Device 429 443	coronary stent
8,T9,Temporal 448 467	less than 12 months
9,R1,Has_temporal Arg1:T8 Arg2:T9
10,T10,Drug 583 590	aspirin
11,T11,Condition 591 598	allergy
12,R2,AND Arg1:T11 Arg2:T10
13,T12,Observation 605 618	bleeding risk
14,T13,Qualifier 600 604	High
15,R3,Has_qualifier Arg1:T12 Arg2:T13
16,T14,Measurement 628 637	platelets
17,T15,"Value 638 651	<50,000 / mm3"
18,T16,Measurement 670 672	Hb
19,T17,Value 673 684	<8.5 g / dL
20,T18,Condition 697 720	intracranial hemorrhage
21,T19,Condition 724 741	subdural hematoma
22,T20,"Procedure 743 757	major surgery,"
23,T21,Procedure 758 782	parenchymal organ biopsy
24,T22,Condition 793 799	trauma
25,T23,Qualifier 786 792	severe
26,R4,Has_qualifier Arg1:T22 Arg2:T23
27,T24,Temporal 800 814	within 30 days
28,T25,Qualifier 833 839	active
29,T26,Condition 840 862	gastrointestinal ulcer
30,R5,Has_qualifier Arg1:T26 Arg2:T25
31,T27,Temporal 870 883	last 3 months
32,R6,Has_value Arg1:T14 Arg2:T15
33,R7,Has_value Arg1:T16 Arg2:T17
34,T28,"Scope 697 799	intracranial hemorrhage or subdural hematoma, major surgery, parenchymal organ biopsy or severe trauma"
35,*,OR T18 T19 T20 T21 T22
36,R8,Has_temporal Arg1:T28 Arg2:T24
37,*,OR T14 T16 T28 T26
38,R9,Has_temporal Arg1:T26 Arg2:T27
39,T30,"Scope 628 883	platelets <50,000 / mm3 during screening, Hb <8.5 g / dL, history of intracranial hemorrhage or subdural hematoma, major surgery, parenchymal organ biopsy or severe trauma within 30 days before inclusion, active gastrointestinal ulcer in the last 3 months"
40,R10,Subsumes Arg1:T12 Arg2:T30
41,T29,Negation 486 489	not
42,T31,Mood 490 497	require
43,T32,Procedure 498 507	treatment
44,T33,Drug 513 520	aspirin
45,T34,Drug 534 552	antiplatelet agent
46,T35,Qualifier 528 533	other
47,R11,Has_qualifier Arg1:T34 Arg2:T35
48,*,OR T33 T34
49,T36,Scope 513 552	aspirin or any other antiplatelet agent
50,R12,Has_scope Arg1:T32 Arg2:T36
51,R13,Has_mood Arg1:T32 Arg2:T31
52,R14,Has_negation Arg1:T31 Arg2:T29
53,T37,Observation 572 582	history of
54,R15,Has_temporal Arg1:T11 Arg2:T37
55,T38,Observation 886 896	History of
56,T39,Condition 897 903	Stroke
57,T40,Temporal 904 924	in the last 3 months
58,R16,Has_temporal Arg1:T39 Arg2:T40
59,R17,Has_temporal Arg1:T39 Arg2:T38
60,T41,Qualifier 927 935	Moderate
61,T42,Qualifier 939 945	severe
62,T43,Condition 946 961	liver affection
63,T44,Qualifier 962 990	associated with coagulopathy
64,T45,Condition 978 990	coagulopathy
65,R18,multi Arg1:T44 Arg2:T45
66,R19,Has_qualifier Arg1:T43 Arg2:T44
67,*,OR T42 T41
68,T46,Scope 927 945	Moderate or severe
69,R20,Has_scope Arg1:T43 Arg2:T46
70,T47,Qualifier 992 998	Active
71,T48,Condition 999 1022	infectious endocarditis
72,R21,Has_qualifier Arg1:T48 Arg2:T47
73,T49,Temporal 992 998	Active
74,R22,multi Arg1:T47 Arg2:T49
75,T50,Qualifier 1024 1030	Active
76,T51,Temporal 1024 1030	Active
77,R23,multi Arg1:T50 Arg2:T51
78,T52,Condition 1031 1036	tumor
79,T53,Procedure 1037 1044	treated
80,T54,Temporal 1045 1069	at the time of inclusion
81,R24,Has_temporal Arg1:T53 Arg2:T54
82,R25,Has_qualifier Arg1:T52 Arg2:T50
83,R26,AND Arg1:T53 Arg2:T52
84,T55,Measurement 1086 1103	expected survival
85,T56,Value 1104 1122	less than one year
86,R27,Has_value Arg1:T55 Arg2:T56
87,R28,AND Arg1:T52 Arg2:T55
0,T1,Competing_trial 0 27	Enrollment in another trial
1,T2,Informed_consent 29 44	Lack of consent
0,T1,Procedure 0 17	kidney transplant
0,T1,Condition 0 9	Pregnancy
1,T2,Observation 14 28	breast feeding
2,*,OR T2 T1
3,T3,Observation 38 63	Estimated life expectancy
4,T4,Value 64 74	<12 months
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Mood 77 86	Scheduled
7,T6,Procedure 87 100	major surgery
8,T7,Temporal 101 121	in the next 6 months
9,R2,Has_temporal Arg1:T6 Arg2:T7
10,R3,Has_mood Arg1:T6 Arg2:T5
11,T10,Measurement 424 427	WHO
12,T11,"Value 428 448	group II, III, IV, V"
13,T12,Condition 449 451	PH
14,R4,Has_value Arg1:T10 Arg2:T11
15,R5,AND Arg1:T12 Arg2:T10
16,T13,Condition 460 477	Renal dysfunction
17,T14,Qualifier 453 459	Severe
18,R6,Has_qualifier Arg1:T13 Arg2:T14
19,T15,Measurement 479 482	Ccr
20,T16,Value 482 492	<30 ml/min
21,T17,Scope 453 477	Severe Renal dysfunction
22,R7,Subsumes Arg1:T17 Arg2:T15
23,R8,Has_value Arg1:T15 Arg2:T16
24,T18,Measurement 495 515	Blood platelet count
25,T19,"Value 515 525	<100,000/L"
26,R9,Has_value Arg1:T18 Arg2:T19
27,T20,Observation 527 545	Expected life span
28,T21,Value 545 553	<6-month
29,R10,Has_value Arg1:T20 Arg2:T21
30,T22,Condition 555 580	Systematical inflammation
31,T23,Condition 582 598	Malignant cancer
32,T24,Condition 603 627	Tricuspid valve stenosis
33,T25,Condition 629 659	Supra-pulmonary valve stenosis
34,*,OR T24 T25
35,T26,Condition 661 669	Allergic
36,T27,Drug 673 686	studied drugs
37,T28,Drug 673 680;690 705	studied metal materials
38,*,OR T27 T28
39,T29,Scope 673 705	studied drugs or metal materials
40,R11,Has_scope Arg1:T26 Arg2:T29
41,T9,Temporal 288 296	Previous
42,T30,Procedure 324 362	treatment with an investigational drug
43,T31,Drug 342 362	investigational drug
44,R12,multi Arg1:T30 Arg2:T31
45,R13,Has_temporal Arg1:T30 Arg2:T9
46,T32,Observation 297 320	enrolment in this study
47,*,OR T30 T32 T33
48,R14,Has_temporal Arg1:T32 Arg2:T9
49,T33,Device 366 372	device
50,R15,Has_temporal Arg1:T33 Arg2:T9
51,T8,Observation 124 156	Inability to follow the protocol
52,T34,Observation 124 136;161 195	Inability to comply with follow-up requirements
53,*,OR T34 T8
0,T1,Drug 9 26	antispastic drugs
1,T2,Condition 28 44	Contraindication
2,T3,Drug 49 57	baclofen
3,T4,Drug 61 66	toxin
4,*,OR T3 T4
5,T5,Scope 49 66	baclofen or toxin
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Condition 82 99	epileptic seizure
8,T7,Temporal 68 78	Antecedent
9,R2,Has_temporal Arg1:T6 Arg2:T7
10,T8,Condition 101 112	Psychiatric
11,T9,Temporal 113 123	antecedent
12,R3,Has_temporal Arg1:T8 Arg2:T9
13,T10,Temporal 0 8	Previous
14,R4,Has_temporal Arg1:T1 Arg2:T10
0,T1,Non-query-able 0 2	NA
0,T1,Informed_consent 0 102	The patient or his/her representative must have given free and informed consent and signed the consent
1,T2,Non-query-able 104 173	The patient must be insured or beneficiary of a health insurance plan
2,T3,Post-eligibility 175 226	The patient is available for 12 months of follow-up
3,T4,Procedure 263 295	transcutaneous implant procedure
4,T5,Device 303 315	aortic valve
5,R1,AND Arg1:T4 Arg2:T5
6,T6,Temporal 327 340	past 24 hours
7,R2,Has_temporal Arg1:T4 Arg2:T6
8,T7,Drug 368 382	anti-vitamin K
9,T8,Drug 384 387	AVK
10,T9,Temporal 399 451	before percutaneous implantation of the aortic valve
11,T10,Reference_point 406 451	percutaneous implantation of the aortic valve
12,R3,Has_index Arg1:T9 Arg2:T10
13,R4,Subsumes Arg1:T7 Arg2:T8
14,R5,Has_temporal Arg1:T7 Arg2:T9
0,T1,Condition 12 30	motor complication
1,T2,Qualifier 0 11	Significant
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Drug 59 64	Drugs
4,T4,Qualifier 65 99	related to acetylcholine metabolis
5,T5,Drug 76 89	acetylcholine
6,R2,Has_qualifier Arg1:T3 Arg2:T4
0,T1,Value 9 28	under the age of 21
1,T2,Person 19 22	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 45 69	excessively thin corneas
4,T4,Condition 86 106	topographic evidence
5,T5,Condition 110 121	keratoconus
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 138 159	ectatic eye disorders
8,T7,Condition 176 195	autoimmune diseases
9,T8,Condition 215 223	pregnant
10,T9,Condition 227 234	nursing
11,*,OR T9 T8
0,T1,Qualifier 19 32	gram-negative
1,T2,Condition 33 43	infections
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 55 65	infections
4,T4,Qualifier 45 54	anaerobic
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 70 78	fungemia
7,*,OR T5 T3 T2
8,T6,Condition 99 109	infections
9,T7,Qualifier 119 125	severe
10,R3,Has_qualifier Arg1:T6 Arg2:T7
11,T8,Qualifier 127 143	life threatening
12,R4,Has_qualifier Arg1:T6 Arg2:T8
13,T9,Person 233 243	drug users
14,T10,Condition 251 256	fever
15,T11,Condition 265 286	neurological disorder
16,T12,Qualifier 258 264	Severe
17,R5,Has_qualifier Arg1:T11 Arg2:T12
18,T13,Observation 298 308	immobility
19,T14,Device 326 336	wheelchair
20,*,OR T13 T14
21,T15,Scope 298 336	immobility or confined to a wheelchair
22,R6,AND Arg1:T15 Arg2:T11
23,T16,Condition 393 402	infection
24,T17,Qualifier 338 363	Bilateral Lower extremity
25,R7,Has_qualifier Arg1:T16 Arg2:T17
0,T1,Procedure 19 66	Intra-Cytoplasmic Sperm Injection (ICSI) cycles
1,T2,Temporal 8 18	undergoing
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Person 0 7	Females
4,T4,Person 68 71	Age
5,T5,Value 72 95	between 20 and 40 years
6,R2,Has_value Arg1:T4 Arg2:T5
0,T1,Value 13 25	21 and older
1,T2,Person 9 12	age
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 41 53	healthy eyes
4,T4,Procedure 94 107	LASIK surgery
5,T5,Temporal 73 83	previously
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Condition 123 148	residual refractive error
0,T1,Condition 0 17	Parkinson disease
1,T2,Measurement 31 93	United Kingdom Parkinson's disease Society Brain Bank Criteria
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 95 115	Postural instability
4,T4,Condition 120 136	gait disturbance
5,*,OR T3 T4
6,T5,Measurement 148 162	Hoehn and Yahr
7,T6,Value 163 172	stage = 3
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 174 204	Mini-Mental status examination
10,T8,Value 205 208	= 2
11,R3,Has_value Arg1:T7 Arg2:T8
0,T1,Visit 16 41	Emergency Department (ED)
1,T2,Measurement 80 130	Acute Bacterial Skin and Skin Structure Infections
2,T3,Measurement 132 138	ABSSSI
3,R1,Subsumes Arg1:T2 Arg2:T3
4,T4,Qualifier 160 173	gram-positive
5,T5,Condition 174 183	infection
6,R2,Has_qualifier Arg1:T5 Arg2:T4
0,T1,Condition 17 30	high response
1,T2,Person 0 7	Females
2,T3,Measurement 32 41	estradiol
3,T4,Temporal 42 70	at time of ovulation trigger
4,T5,Reference_point 53 70	ovulation trigger
5,R1,Has_index Arg1:T4 Arg2:T5
6,T6,Value 74 86	> 5000 pg/ml
7,R2,Has_value Arg1:T3 Arg2:T6
8,R3,Has_temporal Arg1:T3 Arg2:T4
9,T7,Value 90 102	more than 15
10,T8,Measurement 103 110;115 124	oocytes retrieved
11,R4,Has_value Arg1:T8 Arg2:T7
12,*,OR T3 T8
13,T9,Scope 32 124	estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved
14,R5,Subsumes Arg1:T1 Arg2:T9
0,T1,Informed_consent 0 10	no consent
1,T2,Condition 12 40	periprocedural complications
2,T3,Drug 67 74	heparin
3,T4,Drug 96 113	protamine sulfate
4,*,OR T3 T4
5,T5,Mood 41 50	requiring
6,T6,Scope 67 113	heparin or administration of protamine sulfate
7,R1,Has_mood Arg1:T6 Arg2:T5
8,R2,Has_scope Arg1:T2 Arg2:T6
9,T7,Condition 115 121	alergy
10,T8,Drug 125 129	fish
11,T9,Drug 131 140	protamine
12,T10,Drug 142 161	protamine derivates
13,T11,Drug 174 183	Humulin N
14,T12,Drug 185 194	Novolin N
15,T13,Drug 196 207	Novolin NPH
16,T14,Drug 209 219	Gensulin N
17,T15,Drug 221 229	SciLin N
18,T16,Drug 231 244	NPH Iletin II
19,T17,Drug 249 265	isophane insulin
20,*,OR T16 T17 T15 T14 T13 T12 T11
21,T18,"Scope 174 265	Humulin N, Novolin N, Novolin NPH, Gensulin N, SciLin N, NPH Iletin II and isophane insulin"
22,*,OR T8 T9 T10
23,T19,Observation 163 170	history
24,R3,Has_temporal Arg1:T18 Arg2:T19
25,T20,"Scope 125 161	fish, protamine, protamine derivates"
26,R4,Has_scope Arg1:T7 Arg2:T20
27,*,OR T7 T19
0,T1,Condition 27 44	hypercoagulopathy
1,T2,Condition 46 66	deep vein thrombosis
2,T3,Condition 68 71	DVT
3,R1,Subsumes Arg1:T2 Arg2:T3
4,T4,Condition 74 92	pulmonary embolism
5,*,OR T1 T2 T4
6,T5,Observation 16 23	history
7,T6,Condition 94 110	Renal impairment
8,T7,Condition 132 148	hypersensitivity
9,T8,Drug 152 167	tranexamic acid
10,R2,AND Arg1:T7 Arg2:T8
11,T9,Condition 181 200	fibrinolytic states
12,T10,Condition 204 216	coagulopathy
13,T11,Observation 218 225	History
14,T12,Condition 229 240	convulsions
15,R3,Has_temporal Arg1:T12 Arg2:T11
0,T1,Person 0 4	Aged
1,T2,Value 5 12	over 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 33 43	chest pain
4,T4,Qualifier 14 29	Primary symptom
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Procedure 68 71	CTA
7,T6,Condition 48 64	contraindication
8,T7,Negation 45 47	No
9,R3,AND Arg1:T6 Arg2:T5
10,R4,Has_negation Arg1:T6 Arg2:T7
11,T8,Informed_consent 73 125	Willing and able to provide written informed consent
0,T1,Qualifier 0 8	elective
1,T2,Qualifier 9 16	primary
2,T3,Procedure 17 40	total knee arthroplasty
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,R2,Has_qualifier Arg1:T3 Arg2:T1
5,T4,Measurement 42 45	ASA
6,T5,Value 46 51	I-III
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Informed_consent 53 68	written consent
0,T1,Person 10 13	old
1,T2,Value 0 9	<18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 27 40	decompensated
4,T4,Condition 41 54	liver disease
5,R2,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Measurement 56 63	HOMA IR
7,T6,Value 63 68	< 2.0
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 70 73	HIV
10,T8,Value 74 88	seropositivity
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Condition 106 115;90 101	infection Chronic HBV
13,T10,Condition 102 115;90 97	HIV infection Chronic
14,*,OR T10 T9
15,T11,Drug 124 154	immune suppressing medications
16,T12,Condition 163 173	malignancy
17,T13,Qualifier 156 162	Active
18,R5,Has_qualifier Arg1:T12 Arg2:T13
0,T1,Condition 0 30	Irritable Bowel Syndrome (IBS)
1,T2,Qualifier 32 49	ROME III criteria
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 65 73	diarrhea
4,T4,Qualifier 77 87	mixed form
5,*,OR T3 T4
6,T5,Scope 65 87	diarrhea or mixed form
7,R2,Has_scope Arg1:T1 Arg2:T5
8,T6,Person 89 92	age
9,T7,Value 93 104	18-65 years
10,R3,Has_value Arg1:T6 Arg2:T7
0,T1,Condition 0 19	Atrial fibrillation
1,T2,Temporal 23 32	new onset
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 41 72	rate control has been difficult
4,*,OR T1 T3
5,T4,Condition 80 88	bigemini
6,T5,Condition 89 98	trigeminy
7,*,OR T5 T4
8,T6,Temporal 100 105	Prior
9,T7,Procedure 106 118	CABG surgery
10,R2,Has_temporal Arg1:T7 Arg2:T6
11,T8,Condition 120 128	Allergic
12,T9,Drug 132 140	contrast
13,R3,AND Arg1:T8 Arg2:T9
14,T10,Condition 142 167	Advanced renal impairment
15,T11,Condition 181 194	valve disease
16,T12,Qualifier 196 202	severe
17,T13,Condition 203 218	aortic stenosis
18,T14,Condition 222 235	regurgitation
19,*,OR T13 T14
20,T15,Scope 203 235	aortic stenosis or regurgitation
21,R4,Has_qualifier Arg1:T15 Arg2:T12
22,T16,Condition 244 264	mitral regurgitation
23,T17,Qualifier 237 243	severe
24,R5,Has_qualifier Arg1:T16 Arg2:T17
25,*,OR T15 T16
26,T18,Observation 267 282	Life expectancy
27,T19,Value 283 293	<12 months
28,R6,Has_value Arg1:T18 Arg2:T19
29,T20,Competing_trial 295 353	Inclusion in another trial without prior agreement with CI
0,T1,Procedure 20 41	burn excision surgery
1,T2,Temporal 9 19	undergoing
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Person 73 77	Male
4,T4,Person 81 87	female
5,*,OR T3 T4
6,T5,Value 88 99	>= 18 years
7,T6,Person 103 106	age
8,R2,Has_value Arg1:T6 Arg2:T5
9,T7,Informed_consent 108 217	Subject or subject's medical decision maker agrees to participate in this study and provides informed consent
0,T1,Procedure 34 38	TAVI
1,T2,Qualifier 23 33	successful
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Device 58 69	TAVI device
4,T4,Procedure 75 94	transfemoral access
5,T5,Device 128 152	vascular closure devices
6,T6,Informed_consent 154 187	provided written informed consent
0,T1,Measurement 0 7	HCV RNA
1,T2,Condition 20 33	HCV infection
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 57 68;73 82	chronic HCV infection
4,T4,Qualifier 88 98	Genotype 1
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Informed_consent 100 132	Able to provide informed consent
7,T6,Post-eligibility 134 177	Available for ongoing follow-up if required
0,T1,Procedure 0 14	rearthroplasty
1,T2,Measurement 16 19	ASA
2,T3,Value 20 24	IV-V
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Observation 26 51	inadequate spoken finnish
5,T5,Procedure 56 80	reliable pain assessment
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 82 90	Dementia
8,T7,Condition 104 122	impaired cognition
9,*,OR T6 T7
10,T8,Condition 124 140	contraindication
11,T9,Drug 149 159;173 196	medication used in survey protocol
12,T10,Drug 163 196	substance used in survey protocol
13,*,OR T9 T10
14,T11,Scope 149 196	medication or substance used in survey protocol
15,R3,Has_scope Arg1:T8 Arg2:T11
16,T12,Measurement 198 204	weight
17,T13,Value 205 210	<50kg
18,T14,Measurement 214 217	BMI
19,T15,Value 218 227	=35 kg/m2
20,R4,Has_value Arg1:T14 Arg2:T15
21,R5,Has_value Arg1:T12 Arg2:T13
22,*,OR T12 T14
23,T16,Temporal 229 241	preoperative
24,T17,Measurement 242 246	SpO2
25,T18,Value 247 260	less than 93%
26,R6,Has_value Arg1:T17 Arg2:T18
27,R7,Has_temporal Arg1:T17 Arg2:T16
28,T19,Mood 262 280	clinical suspicion
29,T20,Observation 286 320	subject can not use PCA adequately
30,R8,Has_mood Arg1:T20 Arg2:T19
31,T21,Observation 322 329	history
32,T22,Condition 333 348	substance abuse
33,T23,Temporal 352 359	current
34,T24,Condition 360 384	excessive use of alcohol
35,R9,Has_temporal Arg1:T24 Arg2:T23
36,R10,Has_temporal Arg1:T22 Arg2:T21
37,*,OR T22 T24
38,T25,Temporal 386 398	preoperative
39,T26,Drug 413 423	pregabalin
40,T27,Drug 425 435	gabapentin
41,T28,Drug 439 453	strong opiates
42,*,OR T28 T27 T26
43,T29,"Scope 413 453	pregabalin, gabapentin or strong opiates"
44,R11,Has_temporal Arg1:T29 Arg2:T25
0,T1,Condition 0 11	IBS subtype
1,T2,Condition 17 29	constipation
2,T3,Drug 43 58	antidepressants
3,T4,Drug 62 85	H1-receptor antagonists
4,*,OR T3 T4
5,T5,Condition 87 96	pregnancy
6,T6,Observation 98 112	breast feeding
7,*,OR T5 T6
8,T7,Condition 135 141;156 163	kidney disease
9,T8,Condition 150 163	liver disease
10,T9,Qualifier 128 134	severe
11,*,OR T7 T8 T10
12,T10,Condition 173 198	gastrointestinal diseases
13,T11,Scope 135 198	kidney- and/or liver disease or other gastrointestinal diseases
14,R1,Has_qualifier Arg1:T11 Arg2:T9
0,T1,Person 0 3	Age
1,T2,Value 4 14	> 50 years
2,T3,Measurement 16 31	Smoking history
3,T4,Value 32 47	> 10 packs/year
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Measurement 49 53	FEV1
6,T6,Value 54 75	30 - 79% of predicted
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Measurement 80 88	FEV1/FVC
9,T8,Value 89 94	< 70%
10,T9,Measurement 96 100	GOLD
11,T10,Value 101 104	2-3
12,R3,Has_value Arg1:T9 Arg2:T10
13,R4,Has_value Arg1:T7 Arg2:T8
14,T11,Scope 96 104	GOLD 2-3
15,T12,Scope 80 94	FEV1/FVC < 70%
16,R5,Subsumes Arg1:T12 Arg2:T11
17,T13,Measurement 107 110	FRC
18,T14,Value 111 128	> 120 % predicted
19,R6,Has_value Arg1:T13 Arg2:T14
20,T15,Measurement 130 148	Borg dyspnea score
21,T16,Value 149 152	> 3
22,T17,Temporal 164 204	3-min constant rate shuttle walking test
23,T18,Qualifier 208 210	V3
24,R7,Has_qualifier Arg1:T17 Arg2:T18
25,R8,Has_value Arg1:T15 Arg2:T16
26,R9,Has_temporal Arg1:T15 Arg2:T17
0,T1,Person 0 3	Men
1,T2,Person 7 12	women
2,T3,Person 13 17	aged
3,T4,Value 18 29	18-60 years
4,*,OR T1 T2
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Qualifier 32 39	Primary
7,T6,Condition 65 90	Major Depressive Disorder
8,T7,Negation 92 99	without
9,T8,Condition 0 31;32 119	Men or women aged 18-60 years.
10,Primary,"psychiatric diagnosis of Major Depressive Disorder, without psychotic features,"
11,T9,Condition 100 118	psychotic features
12,R2,Has_qualifier Arg1:T6 Arg2:T5
13,R3,Has_negation Arg1:T9 Arg2:T7
14,R4,AND Arg1:T6 Arg2:T9
15,T10,Measurement 176 218	Screening Hamilton Depression Rating Scale
16,T11,Measurement 220 224	HAMD
17,R5,Subsumes Arg1:T10 Arg2:T11
18,T12,Value 226 230	= 18
19,T13,Measurement 245 249	HAMD
20,T14,Qualifier 236 244	Baseline
21,T15,Value 250 254	= 15
22,R6,Has_value Arg1:T13 Arg2:T15
23,R7,Has_qualifier Arg1:T13 Arg2:T14
24,R8,Has_value Arg1:T10 Arg2:T12
25,T16,"Pregnancy_considerations 257 404	If the patient is a woman of child-bearing potential, she must agree to use an acceptable form of birth control for duration of study participation"
26,T17,Informed_consent 407 472	Able to understand and provide informed consent for participation
0,T1,Negation 6 13	without
1,T2,Condition 14 18	PCOS
2,T3,Qualifier 37 55	Rotterdam criteria
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,R2,Has_negation Arg1:T2 Arg2:T1
5,T4,Multiplier 70 80	at least 2
6,T5,Qualifier 81 94	cryopreserved
7,T6,Qualifier 95 107	good quality
8,T7,Observation 108 129	cleavage-stage embryo
9,R3,Has_qualifier Arg1:T7 Arg2:T6
10,R4,Has_qualifier Arg1:T7 Arg2:T5
11,R5,Has_multiplier Arg1:T7 Arg2:T4
12,T8,Qualifier 131 143	good quality
13,T9,Observation 144 166	cleavage-stage embryos
14,R6,Has_qualifier Arg1:T9 Arg2:T8
15,T10,Qualifier 175 203	stage-specific cell division
16,T11,Qualifier 205 242	have blastomeres of fairly equal size
17,T12,Qualifier 248 279	few to no cytoplasmic fragments
18,T13,"Scope 175 279	stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments"
19,R7,Has_scope Arg1:T9 Arg2:T13
20,T14,"Scope 131 279	good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments"
21,T15,Scope 95 129	good quality cleavage-stage embryo
22,R8,Subsumes Arg1:T15 Arg2:T14
0,T1,Post-eligibility 0 31	Non-English speaking/illiterate
1,T2,Condition 60 85	cervical spine conditions
2,T3,Condition 33 40	Painful
3,R1,AND Arg1:T3 Arg2:T2
4,T4,Drug 95 131	non-steroidal anti-inflammatory drug
5,T5,Drug 133 138	NSAID
6,R2,Subsumes Arg1:T4 Arg2:T5
7,T6,Drug 163 171	coumadin
8,T7,Drug 183 196	anticoagulant
9,T8,Condition 211 223	coagulopathy
10,T9,Condition 225 243	bleeding dyscrasia
11,T10,Measurement 248 262	platelet count
12,T11,"Value 263 281	< 150,000/cubic mm"
13,R3,Has_value Arg1:T10 Arg2:T11
14,*,OR T8 T9 T10
15,*,OR T6 T7
16,T12,Condition 283 300	Allergic reaction
17,T13,Observation 324 344	viscosupplementation
18,T14,Observation 304 311	poultry
19,*,OR T14 T13
20,T15,Scope 304 344	poultry or previous viscosupplementation
21,R4,Has_scope Arg1:T12 Arg2:T15
22,T16,Non-query-able 346 428	Involved in workers' compensation or active litigation involving affected shoulder
23,T17,Drug 456 461	NSAID
24,T18,Temporal 470 513	5 days prior to and 6 weeks after injection
25,R5,Has_temporal Arg1:T17 Arg2:T18
26,T19,Reference_point 504 513	injection
27,R6,Has_index Arg1:T18 Arg2:T19
28,T20,Procedure 526 550	corticosteroid injection
29,T21,Temporal 583 596	last 3 months
30,R7,Has_temporal Arg1:T20 Arg2:T21
31,T22,Qualifier 563 571	shoulder
32,R8,Has_qualifier Arg1:T20 Arg2:T22
33,T23,Procedure 609 629	viscosupplementation
34,T24,Drug 633 653	platelet-rich plasma
35,T25,Qualifier 666 674	shoulder
36,*,OR T23 T24
37,T26,Scope 609 653	viscosupplementation or platelet-rich plasma
38,R9,Has_qualifier Arg1:T26 Arg2:T25
39,T27,Temporal 686 699	last 6 months
40,R10,Has_temporal Arg1:T26 Arg2:T27
41,T28,Condition 719 727	fracture
42,T29,Qualifier 713 718	acute
43,R11,Has_qualifier Arg1:T28 Arg2:T29
44,T30,Condition 775 791	systemic illness
45,T31,Qualifier 762 774	uncontrolled
46,R12,Has_qualifier Arg1:T30 Arg2:T31
47,T32,Qualifier 793 805	uncontrolled
48,T33,Condition 806 814	diabetes
49,R13,Has_qualifier Arg1:T33 Arg2:T32
50,T34,Condition 816 844	human immunodeficiency virus
51,T35,Condition 846 856	vasculitis
52,T36,Condition 858 868	autoimmune
53,T37,Condition 869 889	inflammatory disease
54,*,OR T33 T34 T35 T36 T37
55,T38,"Scope 793 889	uncontrolled diabetes, human immunodeficiency virus, vasculitis, autoimmune/inflammatory disease"
56,R14,Subsumes Arg1:T30 Arg2:T38
57,T39,Condition 892 903;919 928	Psychiatric disorders
58,T40,Condition 908 928	somatoform disorders
59,*,OR T40 T39
60,T41,Observation 729 739	History of
61,T42,Condition 740 754	shoulder tumor
62,R15,Has_temporal Arg1:T42 Arg2:T41
63,T43,Mood 430 455	Inability to refrain from
64,R16,Has_mood Arg1:T17 Arg2:T43
65,T44,Observation 515 525	History of
66,T45,Observation 598 608	History of
67,R17,Has_temporal Arg1:T20 Arg2:T44
68,R18,Has_temporal Arg1:T26 Arg2:T45
0,T1,Condition 34 54	autoimmune hepatitis
1,T2,Measurement 72 127	International Autoimmune Hepatitis Study Group criteria
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Measurement 200 215	EASL guidelines
4,T4,Procedure 165 174	treatment
5,T5,Condition 151 154	AIH
6,R2,AND Arg1:T5 Arg2:T4
7,T6,Person 217 220	Age
8,T7,Value 221 231	= 18 years
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Informed_consent 233 306	Must provide informed consent and agree to comply with the trial protocol
0,T1,Procedure 25 45	coronary angiography
1,T2,Qualifier 9 24	diagnostic-only
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Drug 50 60	colchicine
4,T4,Multiplier 61 72	chronically
5,R2,Has_multiplier Arg1:T3 Arg2:T4
6,T5,Condition 85 96	intolerance
7,T6,Drug 100 110	colchicine
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Measurement 112 138	Glomerular filtration rate
10,T8,Value 139 151	<30mL/minute
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Procedure 158 166	dialysis
13,*,OR T7 T9
14,T10,Condition 175 185	malignancy
15,T11,Qualifier 168 174	Active
16,R5,Has_qualifier Arg1:T10 Arg2:T11
17,T12,Condition 189 198	infection
18,*,OR T10 T12
19,T13,Condition 211 225	myelodysplasia
20,T14,Drug 227 243	High-dose statin
21,T15,Temporal 249 277	<24 hours prior to procedure
22,T16,Reference_point 268 277	procedure
23,R6,Has_index Arg1:T15 Arg2:T16
24,R7,Has_temporal Arg1:T14 Arg2:T15
25,T17,Drug 286 299	oral steroids
26,T18,Drug 303 341	non-steroidal anti-inflammatory agents
27,T19,Drug 353 360	aspirin
28,T20,Negation 342 352	other than
29,R8,Has_negation Arg1:T19 Arg2:T20
30,R9,AND Arg1:T18 Arg2:T19
31,T21,Temporal 361 376	within 72 hours
32,T22,Temporal 361 367;380 409	within 3 times the agent's half-life
33,T23,Reference_point 380 409	3 times the agent's half-life
34,T24,Reference_point 368 376	72 hours
35,R10,Has_index Arg1:T21 Arg2:T24
36,R11,Has_index Arg1:T22 Arg2:T23
37,*,OR T22 T21
38,*,OR T17 T18
39,T25,Scope 286 360	oral steroids or non-steroidal anti-inflammatory agents other than aspirin
40,T26,Scope 361 409	within 72 hours or 3 times the agent's half-life
41,R12,Has_scope Arg1:T25 Arg2:T26
42,T27,Drug 440 479	strong CYP3A4/P-glycoprotein inhibitors
43,T28,Drug 494 503	ritonavir
44,T29,Drug 505 517	ketoconazole
45,T30,Drug 519 533	clarithromycin
46,T31,Drug 535 547	cyclosporine
47,T32,Drug 549 558	diltiazem
48,T33,Drug 563 572	verapamil
49,*,OR T28 T29 T30 T31 T32 T33
50,T34,"Scope 494 572	ritonavir, ketoconazole, clarithromycin, cyclosporine, diltiazem and verapamil"
51,R13,Subsumes Arg1:T27 Arg2:T34
52,T35,Non-query-able 575 592	Unable to consent
53,T36,Non-query-able 594 628	Participating in a competing study
0,T1,Condition 0 24	Respiratory exacerbation
1,T2,Temporal 25 64	within the 2 months preceding the study
2,T3,Reference_point 55 64	the study
3,R1,Has_index Arg1:T2 Arg2:T3
4,T4,Temporal 66 73	Current
5,T5,Condition 74 94	diagnostic of asthma
6,R2,Has_temporal Arg1:T5 Arg2:T4
7,T6,Qualifier 96 107	Significant
8,T7,Condition 108 123	O2 desaturation
9,T8,Measurement 125 129	SpO2
10,T9,Value 130 135	< 85%
11,R3,Has_value Arg1:T8 Arg2:T9
12,R4,Has_qualifier Arg1:T7 Arg2:T6
13,T10,Scope 125 135	SpO2 < 85%
14,R5,Subsumes Arg1:T6 Arg2:T10
15,T11,Qualifier 137 144	at rest
16,T12,Qualifier 148 163	during exercise
17,*,OR T11 T12
18,T13,Scope 137 163	at rest or during exercise
19,R6,Has_scope Arg1:T7 Arg2:T13
20,T14,Qualifier 177 184	another
21,T15,Condition 185 194	pathology
22,T16,Qualifier 206 234	influence exercise tolerance
23,R7,Has_qualifier Arg1:T15 Arg2:T16
24,R8,Has_qualifier Arg1:T15 Arg2:T14
25,T17,Procedure 243 254	home oxygen
0,T1,Post-eligibility 0 25	English speaking/literate
1,T2,Person 27 30	Age
2,T3,Value 31 43	18-100 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 45 69	Visual analog score pain
5,T5,Value 70 74	>= 5
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 113 117	pain
8,T7,Temporal 76 109	Greater than or equal to 3 months
9,R3,Has_temporal Arg1:T6 Arg2:T7
10,T8,Temporal 118 141	after onset of symptoms
11,T9,Reference_point 124 141	onset of symptoms
12,R4,Has_index Arg1:T8 Arg2:T9
13,R5,Has_temporal Arg1:T6 Arg2:T8
14,T10,Mood 151 157	failed
15,T11,Procedure 158 181	conservative treatments
16,R6,Has_mood Arg1:T11 Arg2:T10
17,R7,AND Arg1:T6 Arg2:T11
18,T12,Condition 199 214	glenohumeral OA
19,T13,Procedure 219 226	imaging
20,R8,AND Arg1:T13 Arg2:T12
21,T14,Procedure 274 299	intra-articular injection
22,T15,Qualifier 309 327	glenohumeral joint
23,R9,Has_qualifier Arg1:T14 Arg2:T15
24,T16,Condition 238 256	relief of symptoms
25,T17,Qualifier 228 237	Transient
26,R10,Has_qualifier Arg1:T16 Arg2:T17
27,R11,AND Arg1:T16 Arg2:T14
0,T1,Value 17 35	more than 18 years
1,T2,Person 39 42	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 60 80	coronary angiography
4,T4,Mood 47 59	referred for
5,R2,Has_mood Arg1:T3 Arg2:T4
0,T1,Condition 0 16	Overlap syndrome
1,T2,Condition 22 52	Primary Sclerosing Cholangitis
2,T3,Condition 54 57	PSC
3,T4,Condition 62 89	Primary Biliary Cholangitis
4,T5,Condition 91 94	PBC
5,T6,"Measurement 97 112	Paris criteria,"
6,T7,Measurement 129 158	Anti-Mitochondrial Antibodies
7,T8,Value 113 128	strong positive
8,T9,Measurement 160 163	AMA
9,T10,Procedure 171 183	liver biopsy
10,T11,Procedure 187 212	cholangiographic findings
11,T12,Condition 229 232	PBC
12,T13,Condition 236 239	PSC
13,R1,Subsumes Arg1:T2 Arg2:T3
14,R2,Subsumes Arg1:T4 Arg2:T5
15,*,OR T4 T2
16,T14,Scope 22 95	Primary Sclerosing Cholangitis (PSC) or Primary Biliary Cholangitis (PBC)
17,R3,Has_scope Arg1:T1 Arg2:T14
18,R4,Subsumes Arg1:T7 Arg2:T9
19,R5,Has_value Arg1:T7 Arg2:T8
20,*,OR T10 T11
21,T15,Scope 171 212	liver biopsy or cholangiographic findings
22,T16,Scope 229 239	PBC or PSC
23,R6,Has_scope Arg1:T15 Arg2:T16
24,T17,Condition 261 280	acute liver failure
25,T18,Condition 305 327	hepatic encephalopathy
26,T19,Condition 332 344	coagulopathy
27,T20,Measurement 346 349	INR
28,T21,Value 350 355	> 1.5
29,R7,Has_value Arg1:T20 Arg2:T21
30,R8,AND Arg1:T19 Arg2:T20
31,T22,Scope 305 356	hepatic encephalopathy and coagulopathy (INR > 1.5)
32,R9,Has_scope Arg1:T17 Arg2:T22
33,T23,Drug 381 391	prednisone
34,T24,Drug 392 404	prednisolone
35,T25,Drug 412 440	immunosuppressive medication
36,T26,Condition 470 490	autoimmune hepatitis
37,T27,Negation 459 464	other
38,R10,Has_negation Arg1:T26 Arg2:T27
39,*,OR T23 T24 T25
40,T28,Condition 448 458	indication
41,T29,Scope 381 440	prednisone/prednisolone and/or immunosuppressive medication
42,R11,AND Arg1:T29 Arg2:T28
43,T30,Condition 500 518	systemic infection
44,T31,Non-query-able 520 603	Other clinically significant medical conditions that could interfere with the trial
45,T32,"Pregnancy_considerations 606 710	f female of childbearing potential: known pregnancy, or unwilling to practice anticontraceptive measures"
46,T33,"Post-eligibility 713 845	History of noncompliance with medical regimens, or patients who are considered to be potentially unreliable or unable to participate"
47,T34,"Post-eligibility 847 967	Mental instability or incompetence, such that the validity of informed consent or compliance with the trial is uncertain"
0,T1,Condition 20 36	Bipolar Disorder
1,T2,Condition 38 46	Dementia
2,T3,Condition 48 72	Autism Spectrum Disorder
3,T4,Condition 74 87	Schizophrenia
4,T5,Condition 102 120	Psychotic Disorder
5,*,OR T1 T2 T3 T4 T5
6,T6,Condition 123 141	Psychotic symptoms
7,T7,Condition 183 207	major depressive episode
8,T8,Condition 248 262	Panic disorder
9,T9,Condition 264 293	Obsessive Compulsive Disorder
10,T10,Condition 295 324	Posttraumatic Stress Disorder
11,T11,Condition 326 342	Anorexia Nervosa
12,T12,Condition 347 362	Bulimia Nervosa
13,*,OR T8 T9 T10 T11 T12
14,T13,Condition 376 391	Drug Dependence
15,T14,Condition 365 372;381 391	Alcohol Dependence
16,T15,Temporal 219 233	past 12 months
17,T16,"Scope 248 362	Panic disorder, Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, Anorexia Nervosa, or Bulimia Nervosa"
18,R2,Has_temporal Arg1:T16 Arg2:T15
19,T17,Temporal 392 408	within 12 months
20,T18,Condition 365 372;412 417	Alcohol Abuse
21,T19,Condition 376 380;412 417	Drug Abuse
22,*,OR T19 T18
23,*,OR T14 T13
24,T20,Temporal 418 433	within 3 months
25,R3,Has_temporal Arg1:T13 Arg2:T17
26,R4,Has_temporal Arg1:T14 Arg2:T17
27,R5,Has_temporal Arg1:T19 Arg2:T20
28,R6,Has_temporal Arg1:T18 Arg2:T20
29,T21,Drug 445 453	nicotine
30,T22,Drug 458 466	caffeine
31,T23,Measurement 514 531	urine drug screen
32,T24,Scope 445 466	nicotine and caffeine
33,*,OR T21 T22
34,R7,Subsumes Arg1:T19 Arg2:T24
35,T25,Qualifier 557 563	severe
36,T26,Condition 564 584	Personality Disorder
37,R8,Has_qualifier Arg1:T26 Arg2:T25
38,T27,Condition 738 749	head injury
39,T28,Qualifier 730 737	serious
40,T29,Condition 693 715	neurological disorders
41,R9,Has_qualifier Arg1:T27 Arg2:T28
42,*,OR T29 T27
43,T30,Condition 773 790	medical illnesses
44,T31,Qualifier 752 759	Serious
45,T32,Qualifier 764 772	unstable
46,T33,Scope 752 772	Serious and unstable
47,R10,Has_scope Arg1:T30 Arg2:T33
48,T34,Condition 801 823	cardiovascular disease
49,T35,Condition 828 834	cancer
50,*,OR T34 T35
51,T36,Scope 801 834	cardiovascular disease and cancer
52,R11,Has_scope Arg1:T30 Arg2:T36
53,T37,Non-query-able 837 886	Active medical conditions with known mood changes
54,T38,Condition 888 897;910 919	endocrine disorders
55,T39,Condition 899 919	autoimmune disorders
56,*,OR T39 T38
57,T40,Condition 931 948	diabetes mellitus
58,T41,"Pregnancy_considerations 951 1042	For women, pregnancy, lactation, or unwillingness to comply with birth control requirements"
59,T42,Procedure 1073 1083	treatments
60,T43,Procedure 1097 1116	alternative therapy
61,*,OR T42 T43
62,T44,Temporal 1117 1161	within 2 weeks of the pre-treatment PET scan
63,T45,Reference_point 1139 1161	pre-treatment PET scan
64,R12,Has_index Arg1:T44 Arg2:T45
65,T46,Scope 1073 1116	treatments or any other alternative therapy
66,R13,Has_temporal Arg1:T46 Arg2:T44
67,T47,Condition 1198 1202	mood
68,R14,AND Arg1:T46 Arg2:T47
69,T48,Drug 1214 1228	St John's Wort
70,T49,Drug 1230 1251	S-adenosyl methionine
71,T50,Drug 1253 1257	SAMe
72,T51,Drug 1260 1275	n-3 fatty acids
73,T52,Procedure 1280 1293	light therapy
74,*,OR T48 T49 T51 T52
75,R15,Subsumes Arg1:T49 Arg2:T50
76,T53,"Scope 1214 1293	St John's Wort, S-adenosyl methionine (SAMe), n-3 fatty acids, or light therapy"
77,R16,Subsumes Arg1:T46 Arg2:T53
78,T54,Drug 1303 1328	antidepressant medication
79,T55,Temporal 1329 1373	within 1 month of the pre-treatment PET scan
80,T56,Reference_point 1351 1373	pre-treatment PET scan
81,R17,Has_index Arg1:T55 Arg2:T56
82,R18,Has_temporal Arg1:T54 Arg2:T55
83,T57,Temporal 1375 1422	within 5 weeks for fluoxetine and protryptyline
84,T58,Reference_point 1394 1422	fluoxetine and protryptyline
85,R19,Has_index Arg1:T57 Arg2:T58
86,R20,Has_temporal Arg1:T54 Arg2:T57
87,T59,Non-query-able 1426 1726	Failure to achieve a much improved status (i.e. equivalent to >50% symptom reduction) with any lifetime treatment course of CBT (defined as a minimum of 4 sessions of a specified manual-driven therapy by a CBT-trained therapist) or escitalopram (defined as a minimum of 6 weeks of at least 10 mg/day)
88,T60,Condition 1759 1776	suicidal ideation
89,T61,Condition 1780 1803	self-injurious behavior
90,T62,Procedure 1828 1837	treatment
91,T63,Qualifier 1818 1827	immediate
92,*,OR T60 T61
93,R21,Has_qualifier Arg1:T62 Arg2:T63
94,T64,Scope 1752 1803	active suicidal ideation or self-injurious behavior
95,R22,AND Arg1:T64 Arg2:T62
96,T65,"Non-query-able 1974 2054	Currently responding to medication treatment, without clinical reasons to change"
97,T66,Procedure 2107 2120	psychotherapy
98,T67,Qualifier 2101 2106	group
99,T68,Qualifier 2087 2097	individual
100,*,OR T68 T67
101,T69,Scope 2087 2106	individual or group
102,T70,Multiplier 2080 2086	weekly
103,R23,Has_scope Arg1:T66 Arg2:T69
104,R24,Has_multiplier Arg1:T66 Arg2:T70
105,T71,Condition 2145 2164	depressive symptoms
106,R25,AND Arg1:T66 Arg2:T71
107,T72,Measurement 2167 2170	QTc
108,T73,Value 2171 2188	>500 milliseconds
109,R26,Has_value Arg1:T72 Arg2:T73
110,T74,Temporal 2196 2208	at screening
111,T75,Reference_point 2199 2208	screening
112,R27,Has_index Arg1:T74 Arg2:T75
113,T76,Procedure 2192 2195	EKG
114,R28,AND Arg1:T76 Arg2:T72
115,T77,Condition 2211 2228	Contraindications
116,T78,Procedure 2233 2236	MRI
117,T79,Negation 2253 2256	not
118,T80,Device 2268 2277	pacemaker
119,T81,Device 2279 2293	aneurysm clips
120,T82,Device 2295 2311	neurostimulators
121,T83,Device 2313 2330	cochlear implants
122,T84,Device 2332 2337	metal
123,T85,Qualifier 2341 2345	eyes
124,T86,Device 2347 2359	steel worker
125,T87,Device 2361 2382	intra-uterine devices
126,*,OR T80 T81 T82 T83 T84 T86 T87
127,R29,Has_qualifier Arg1:T84 Arg2:T85
128,T88,"Scope 2268 2382	pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, intra-uterine devices"
129,R30,Has_negation Arg1:T88 Arg2:T79
130,R31,AND Arg1:T77 Arg2:T78
131,T89,Non-query-able 2403 2468	Maintenance or prophylactic therapy for stable medical conditions
132,T90,Drug 2471 2490	Hypnotic medication
133,T91,Condition 2573 2581	insomnia
134,R32,AND Arg1:T90 Arg2:T91
135,T92,Temporal 2598 2649	the night before a PET/MRI or clinic ratings visit.
136,T93,Reference_point 2617 2624	PET/MRI
137,T94,Reference_point 2628 2649	clinic ratings visit.
138,*,OR T93 T94
139,T95,Scope 2617 2649	PET/MRI or clinic ratings visit.
140,R33,Has_scope Arg1:T92 Arg2:T95
141,R34,Has_temporal Arg1:T90 Arg2:T92
142,T96,Negation 2594 2597	not
143,R35,Has_negation Arg1:T90 Arg2:T96
144,T97,Drug 2650 2675	Antipsychotic medications
145,T98,Temporal 152 207	at any time during the current major depressive episode
146,T99,Reference_point 171 207	the current major depressive episode
147,R1,AND Arg1:T99 Arg2:T7
148,T100,Temporal 175 182	current
149,R36,Has_temporal Arg1:T7 Arg2:T100
150,R37,Has_index Arg1:T98 Arg2:T99
151,R38,Has_temporal Arg1:T6 Arg2:T98
152,T101,Procedure 1884 1909	electroconvulsive therapy
153,T102,Temporal 1910 1930	in the past 6 months
154,T103,Temporal 1934 1971	during the current depressive episode
155,T104,Reference_point 1941 1971	the current depressive episode
156,T105,Temporal 1945 1952	current
157,T106,Condition 1953 1971	depressive episode
158,R39,Has_temporal Arg1:T106 Arg2:T105
159,T107,Procedure 1365 1373	PET scan
160,R40,multi Arg1:T56 Arg2:T107
161,T108,Drug 1394 1404	fluoxetine
162,T109,Drug 1409 1422	protryptyline
163,R41,multi Arg1:T58 Arg2:T108
164,R42,multi Arg1:T58 Arg2:T109
165,T110,Temporal 1351 1364	pre-treatment
166,R43,Has_temporal Arg1:T107 Arg2:T110
167,*,OR T102 T103
168,T111,Scope 1910 1971	in the past 6 months or during the current depressive episode
169,R44,Has_scope Arg1:T101 Arg2:T111
170,T112,Qualifier 1752 1758	active
171,R45,Has_qualifier Arg1:T60 Arg2:T112
0,T1,Condition 0 4	PCOS
1,T2,Condition 8 24	polycystic ovary
2,T3,Procedure 28 43	ultrasound scan
3,*,OR T1 T2
4,T4,Scope 0 24	PCOS or polycystic ovary
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Qualifier 46 54	Moderate
7,T6,Qualifier 58 64	severe
8,T7,Condition 65 78	endometriosis
9,*,OR T5 T6
10,T8,Scope 46 64	Moderate or severe
11,R2,Has_scope Arg1:T7 Arg2:T8
12,T9,Condition 81 93	Hydrosalpinx
13,T10,Condition 96 117	Uterine abnormalities
14,T11,Condition 121 126	myoma
15,*,OR T10 T11
16,T12,Procedure 138 153	uterine surgery
17,T13,Temporal 129 137	Previous
18,R3,Has_temporal Arg1:T12 Arg2:T13
0,T1,Measurement 0 19	ASA physical status
1,T2,Value 20 21	1
2,T3,Value 25 26	2
3,*,OR T2 T3
4,T4,Scope 20 26	1 or 2
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Informed_consent 28 52	Written informed consent
7,T6,Condition 54 76	Cardiovascular disease
8,T7,Condition 78 95	Pulmonary disease
9,T8,Condition 97 110	Liver disease
10,T9,Condition 112 123	CNS disease
11,T10,Condition 125 132;141 146	Alcohol abuse
12,T11,Condition 136 146	drug abuse
13,T12,Multiplier 148 162	Chronic intake
14,T13,Drug 166 182	CNS active drugs
15,R2,Has_multiplier Arg1:T13 Arg2:T12
16,T14,Measurement 184 199	Body mass index
17,T15,Value 200 204	> 35
18,R3,Has_value Arg1:T14 Arg2:T15
19,T16,Condition 206 223	Diabetes mellitus
20,T17,Condition 225 241	Hypersensitivity
21,T18,Condition 245 252	allergy
22,*,OR T17 T18
23,T19,Drug 267 278	study drugs
24,T20,Scope 225 252	Hypersensitivity or allergy
25,R4,AND Arg1:T20 Arg2:T19
0,T1,Condition 11 32	organic brain disease
1,T2,Observation 0 10	History of
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Qualifier 34 40	DSM-IV
4,T4,Condition 54 61;75 85	Alcohol Dependence
5,T5,Condition 65 85	Substance Dependence
6,*,OR T5 T4
7,T6,Scope 54 85	Alcohol or Substance Dependence
8,R2,Has_qualifier Arg1:T6 Arg2:T3
9,T7,Temporal 86 112	within the last six months
10,R3,Has_temporal Arg1:T6 Arg2:T7
11,T8,Drug 121 129	nicotine
12,T9,Negation 114 120	except
13,R4,Has_negation Arg1:T8 Arg2:T9
14,R5,AND Arg1:T6 Arg2:T8
15,T10,Qualifier 134 139	DSM-5
16,T11,Condition 153 175	Substance Use Disorder
17,R6,Has_qualifier Arg1:T11 Arg2:T10
18,T12,Temporal 176 198	in the last six months
19,T13,Drug 207 215	nicotine
20,T14,Negation 200 206	except
21,R7,Has_negation Arg1:T13 Arg2:T14
22,R8,Has_temporal Arg1:T11 Arg2:T12
23,R9,Has_negation Arg1:T11 Arg2:T14
24,T15,Qualifier 218 224	DSM-IV
25,T16,Condition 238 245;259 264	Alcohol Abuse
26,T17,Condition 249 264	Substance Abuse
27,*,OR T17 T16
28,T18,Scope 238 264	Alcohol or Substance Abuse
29,R10,Has_qualifier Arg1:T18 Arg2:T15
30,T19,Temporal 265 290	within the last one month
31,T20,Drug 299 307	nicotine
32,T21,Negation 292 298	except
33,R11,Has_negation Arg1:T20 Arg2:T21
34,R12,Has_temporal Arg1:T18 Arg2:T19
35,R13,AND Arg1:T18 Arg2:T20
36,T22,Qualifier 312 317	DSM-5
37,T23,Condition 331 353	Substance Use Disorder
38,T24,Temporal 354 376	in the last six months
39,R14,Has_temporal Arg1:T23 Arg2:T24
40,R15,Has_qualifier Arg1:T23 Arg2:T22
41,T25,Drug 385 393	nicotine
42,T26,Negation 378 384	except
43,R16,Has_negation Arg1:T25 Arg2:T26
44,R17,AND Arg1:T23 Arg2:T25
45,T27,Scope 312 394	DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)
46,*,OR T18 T27
47,T28,Condition 396 405	Pregnancy
48,T29,Condition 409 418	lactation
49,*,OR T28 T29
50,T30,Condition 427 444	liver dysfunction
51,T31,Qualifier 420 426	Severe
52,R18,Has_qualifier Arg1:T30 Arg2:T31
53,T32,Measurement 446 449	LFT
54,T33,Value 450 474	3X upper limit of normal
55,R19,Has_value Arg1:T32 Arg2:T33
56,T34,Scope 446 474	LFT 3X upper limit of normal
57,R20,Has_scope Arg1:T30 Arg2:T34
58,T35,Condition 492 508	hypersensitivity
59,T36,Drug 512 525	tetracyclines
60,R21,AND Arg1:T35 Arg2:T36
61,T37,Temporal 477 485	Previous
62,R22,Has_temporal Arg1:T35 Arg2:T37
63,T38,Temporal 527 534	Current
64,T39,Procedure 535 544	treatment
65,T40,Drug 550 562	tetracycline
66,T41,Drug 550 562;566 576	tetracycline derivative
67,*,OR T40 T41
68,R23,Has_temporal Arg1:T39 Arg2:T38
69,T42,Scope 550 576	tetracycline or derivative
70,R24,Has_scope Arg1:T39 Arg2:T42
71,T43,Drug 593 612	oral contraceptives
72,T44,Procedure 578 587	Treatment
73,R25,AND Arg1:T44 Arg2:T43
74,T45,Observation 638 651	birth control
75,T46,Qualifier 623 634	second form
76,R26,Has_qualifier Arg1:T45 Arg2:T46
77,T47,Negation 614 620	unless
78,R27,Has_negation Arg1:T45 Arg2:T47
79,R28,Has_context Arg1:T44 Arg2:T45
80,T48,Drug 692 706	cholestyramine
81,T49,Drug 710 720	colestipol
82,*,OR T48 T49
83,T50,Procedure 677 686	Treatment
84,T51,Scope 692 720	cholestyramine or colestipol
85,R29,Has_scope Arg1:T50 Arg2:T51
86,T52,Procedure 722 731	Treatment
87,T53,Drug 737 757	Urinary alkalinizers
88,T54,Drug 765 779	sodium lactate
89,T55,Drug 781 798	potassium citrate
90,*,OR T54 T55
91,T56,"Scope 765 798	sodium lactate, potassium citrate"
92,R30,Subsumes Arg1:T53 Arg2:T56
93,R31,AND Arg1:T52 Arg2:T53
94,T57,Drug 816 824	warfarin
95,T58,Procedure 801 810	Treatment
96,R32,AND Arg1:T58 Arg2:T57
97,T59,Drug 841 850	bupropion
98,T60,Drug 852 863	varenicline
99,T61,Drug 868 897	nicotine replacement products
100,*,OR T60 T61 T59
101,T62,"Scope 841 897	bupropion, varenicline, or nicotine replacement products"
102,T63,Temporal 898 935	in the month prior to study inclusion
103,T64,Reference_point 920 935	study inclusion
104,R33,Has_index Arg1:T63 Arg2:T64
105,T65,Procedure 826 835	Treatment
106,R34,Has_scope Arg1:T65 Arg2:T62
107,R35,Has_temporal Arg1:T62 Arg2:T63
108,T66,Multiplier 937 957	Less than two months
109,T67,Procedure 958 967	treatment
110,T68,Drug 971 993	adjunctive medications
111,T69,Multiplier 998 1017	less than one month
112,T70,Multiplier 1021 1030	same dose
113,T71,Drug 1032 1045	beta blockers
114,T72,Drug 1047 1062	antidepressants
115,T73,Drug 1064 1080	mood stabilizers
116,R36,AND Arg1:T67 Arg2:T68
117,R37,Has_multiplier Arg1:T67 Arg2:T66
118,R38,Has_multiplier Arg1:T70 Arg2:T69
119,R39,Has_multiplier Arg1:T67 Arg2:T70
120,*,OR T71 T72 T73 T74
121,T74,Drug 1082 1105	antianxiety medications
122,T75,"Scope 1032 1105	beta blockers, antidepressants, mood stabilizers, antianxiety medications"
123,R40,Subsumes Arg1:T68 Arg2:T75
124,T76,Condition 1108 1125	Medical condition
125,T77,Qualifier 1155 1230	would significantly increase the risk associated with the proposed protocol
126,R41,Has_qualifier Arg1:T76 Arg2:T77
127,T78,Condition 1244 1255	head injury
128,T79,Condition 1257 1265	seizures
129,T80,Condition 1270 1276	stroke
130,*,OR T80 T79 T78
131,T81,Observation 1233 1240	History
132,T82,"Scope 1244 1276	head injury, seizures, or stroke"
133,R42,Has_temporal Arg1:T82 Arg2:T81
134,T83,Measurement 1287 1310	urine toxicology screen
135,T84,Qualifier 1315 1348	substances of non-therapeutic use
136,T85,Value 1278 1286	Positive
137,R43,Has_qualifier Arg1:T83 Arg2:T84
138,R44,Has_value Arg1:T83 Arg2:T85
139,T86,Temporal 1349 1377	prior to craving assessments
140,T87,Reference_point 1358 1377	craving assessments
141,R45,Has_index Arg1:T86 Arg2:T87
142,R46,Has_temporal Arg1:T83 Arg2:T86
0,T1,Condition 25 73	ST-elevation acute myocardial infarction (STEMI)
1,T2,Temporal 74 112	within 12 hours of their symptom onset
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T4,Reference_point 93 112	their symptom onset
4,R2,Has_index Arg1:T2 Arg2:T4
5,T3,Observation 121 148	TIMI-3 flow was established
6,T5,Qualifier 152 180	infarct related artery (IRA)
7,R3,Has_qualifier Arg1:T3 Arg2:T5
8,T6,Temporal 181 222	after balloon angioplasty or thrombectomy
9,T7,Procedure 187 206	balloon angioplasty
10,T8,Procedure 210 222	thrombectomy
11,*,OR T7 T8
12,T9,Reference_point 187 222	balloon angioplasty or thrombectomy
13,R4,Has_index Arg1:T6 Arg2:T9
14,T10,Scope 187 222	balloon angioplasty or thrombectomy
15,R5,multi Arg1:T9 Arg2:T10
16,R6,Has_temporal Arg1:T3 Arg2:T6
0,T1,Qualifier 0 6	DSM-IV
1,T2,Qualifier 10 15	DSM-5
2,*,OR T1 T2
3,T3,Condition 29 42	schizophrenia
4,T4,Condition 46 70	schizoaffective disorder
5,*,OR T3 T4
6,T5,Scope 29 70	schizophrenia or schizoaffective disorder
7,T6,Scope 0 15	DSM-IV or DSM-5
8,R1,Has_scope Arg1:T5 Arg2:T6
9,T7,Person 72 76	Male
10,T8,Person 80 86	Female
11,*,OR T7 T8
12,T9,Person 88 91	Age
13,T10,Value 93 107	18 to 65 years
14,R2,Has_value Arg1:T9 Arg2:T10
15,T11,Person 109 118	Caucasian
16,T12,Person 122 135	Non-Caucasian
17,*,OR T11 T12
18,T13,Observation 137 142	Smoke
19,T14,Value 143 171	at least 10 cigarettes daily
20,R3,Has_value Arg1:T13 Arg2:T14
21,T15,Measurement 173 193	Urine cotinine level
22,T16,Value 194 205	? 100 ng/ml
23,R4,Has_value Arg1:T15 Arg2:T16
24,T17,Measurement 207 218	NicAlert(r)
25,T18,Value 227 230	? 3
26,R5,Has_value Arg1:T17 Arg2:T18
27,T19,Scope 207 230	NicAlert(r) reading ? 3
28,T20,Scope 173 205	Urine cotinine level ? 100 ng/ml
29,R6,Subsumes Arg1:T20 Arg2:T19
30,T21,Observation 233 247	Agrees to wear
31,T22,Device 250 276	head mounted display (HMD)
32,R7,AND Arg1:T21 Arg2:T22
33,T23,Temporal 277 297	for up to 45 minutes
34,R8,Has_temporal Arg1:T21 Arg2:T23
35,T24,Observation 299 315	Able to complete
36,T25,Procedure 320 352	Evaluation to Sign Consent (ESC)
37,T26,Value 358 378	minimum score of 80%
38,R9,Has_value Arg1:T25 Arg2:T26
39,R10,Has_context Arg1:T25 Arg2:T24
0,T1,Procedure 0 11	Recanalized
1,T4,Condition 30 33	IRA
2,T5,Procedure 37 57	coronary angiography
3,T2,Qualifier 13 28	TIMI I-III flow
4,R1,Has_qualifier Arg1:T1 Arg2:T2
5,R2,AND Arg1:T1 Arg2:T4
6,T3,"Non-representable 60 177	Patients in whom TIMI-3 flow was not able to be established after wire crossing, balloon angioplasty or thrombectomy."
7,T6,Condition 179 184	STEMI
8,T7,Device 192 204	bypass-graft
9,T8,Condition 205 214	occlusion
10,R3,AND Arg1:T8 Arg2:T7
11,R4,AND Arg1:T6 Arg2:T8
12,T9,Qualifier 216 222	Severe
13,T10,Condition 223 236	heart failure
14,T11,Condition 240 257	cardiogenic shock
15,*,OR T10 T11
16,T12,Scope 223 257	heart failure or cardiogenic shock
17,R5,Has_qualifier Arg1:T12 Arg2:T9
0,T1,Condition 17 33	systemic illness
1,T2,Qualifier 11 16	major
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 58 70	hypertension
4,T4,Qualifier 45 57	uncontrolled
5,T5,Condition 72 80	diabetes
6,T6,"Condition 82 110	chronic renal insufficiency,"
7,T7,Condition 111 130	autoimmune diseases
8,T8,Condition 134 146	malignancies
9,*,OR T8 T7 T6 T5 T3
10,R2,Has_qualifier Arg1:T3 Arg2:T4
11,T9,"Scope 45 146	uncontrolled hypertension, diabetes, chronic renal insufficiency, autoimmune diseases or malignancies"
12,R3,Subsumes Arg1:T1 Arg2:T9
13,T10,Condition 159 181	neurological disorders
14,T11,Condition 228 234	stroke
15,T12,Condition 238 259	peripheral neuropathy
16,T13,Condition 194 210	affect sensation
17,R4,AND Arg1:T10 Arg2:T13
18,*,OR T11 T12
19,T14,Scope 228 259	stroke or peripheral neuropathy
20,R5,Subsumes Arg1:T10 Arg2:T14
21,T15,Condition 272 287	substance abuse
22,T16,Negation 289 295	except
23,T17,Drug 296 307	painkillers
24,R6,Has_negation Arg1:T17 Arg2:T16
25,T18,Qualifier 310 315	heavy
26,T19,Person 316 323	smokers
27,R7,Has_qualifier Arg1:T19 Arg2:T18
28,T20,Observation 354 364	cigarettes
29,T21,Multiplier 332 353	daily consumption >20
30,R8,Has_multiplier Arg1:T20 Arg2:T21
31,T22,Pregnancy_considerations 367 389	pregnancy or lactation
32,T23,Condition 395 411	contraindication
33,T24,Procedure 416 442	magnetic resonance imaging
34,T25,Procedure 444 447	MRI
35,R9,Subsumes Arg1:T24 Arg2:T25
36,R10,AND Arg1:T23 Arg2:T24
37,T26,Condition 466 475	infection
38,T27,Condition 479 491	inflammation
39,*,OR T27 T26
40,T28,Temporal 509 542	at least 1 month before the study
41,T29,Reference_point 537 542	study
42,R11,Has_index Arg1:T28 Arg2:T29
43,T30,Scope 466 491	infection or inflammation
44,R12,Has_temporal Arg1:T30 Arg2:T28
45,T31,Qualifier 458 465	obvious
46,R13,Has_qualifier Arg1:T30 Arg2:T31
0,T1,Procedure 13 20	surgery
1,T2,Procedure 25 61	open reduction and internal fixation
2,T3,Condition 66 80	ankle fracture
3,R1,AND Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
0,T1,Person 0 33	Inmate of a correctional facility
1,T2,Person 40 49	prisoners
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Condition 53 62	Pregnancy
4,T4,Condition 118 140	malignant hyperthermia
5,T5,Observation 107 114;88 94	history family
6,T6,Observation 98 114	personal history
7,*,OR T5 T6
8,T7,Drug 176 184	propofol
9,T8,Drug 188 198	isoflurane
10,T9,Condition 206 213	allergy
11,T10,Condition 151 168	unable to receive
12,*,OR T7 T8
13,T11,Scope 176 198	propofol or isoflurane
14,R2,Has_scope Arg1:T10 Arg2:T11
15,R3,AND Arg1:T10 Arg2:T9
0,T1,Post-eligibility 0 17	Unable to consent
1,T2,Condition 27 45	opioid consumption
2,T3,Qualifier 19 26	Chronic
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 47 54	Allergy
5,T5,Drug 58 74	study medication
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Procedure 76 94	Lower limb surgery
8,T7,Non-query-able 111 146	Unable to complete baseline testing
9,T8,Condition 161 181	neurological deficit
10,T9,Qualifier 148 160	pre-existing
11,R3,Has_qualifier Arg1:T8 Arg2:T9
12,T10,Condition 183 199	Contraindication
13,T11,Procedure 203 221	spinal anaesthesia
14,R4,AND Arg1:T10 Arg2:T11
0,T1,Informed_consent 0 24	Written informed consent
1,T2,Person 26 31	Adult
2,T3,Value 42 61	older than 18 years
3,T4,Person 65 68	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Person 71 75	male
6,T6,Person 80 86	female
7,*,OR T5 T6
8,T7,Scope 42 68	older than 18 years of age
9,R2,Subsumes Arg1:T2 Arg2:T7
10,T8,Qualifier 93 100	chronic
11,T9,Qualifier 101 111	non-cancer
12,T10,Qualifier 116 122	cancer
13,*,OR T9 T10
14,T11,Condition 123 127	pain
15,T12,Scope 101 122	non-cancer and cancer
16,R3,Has_scope Arg1:T11 Arg2:T12
17,R4,Has_qualifier Arg1:T11 Arg2:T8
18,T13,Multiplier 129 158	at least 3 months in duration
19,R5,Subsumes Arg1:T8 Arg2:T13
20,T14,Measurement 186 221;237 255	average weekly pain intensity score on a 11 points NRS
21,T15,Value 222 236	greater than 4
22,R6,Has_value Arg1:T14 Arg2:T15
23,T16,Informed_consent 257 294	Subject agreed to follow the protocol
24,T17,Qualifier 325 332	chronic
25,T18,Qualifier 333 343	non-cancer
26,T19,Qualifier 348 354	cancer
27,T20,Condition 355 359	pain
28,*,OR T19 T18
29,T21,Scope 333 354	non-cancer and cancer
30,R7,Has_scope Arg1:T20 Arg2:T21
31,R8,Has_qualifier Arg1:T20 Arg2:T17
32,T22,Measurement 361 364	not
33,T23,Drug 370 378	cannabis
34,T24,Temporal 399 419	in the last 12 weeks
35,R9,Has_temporal Arg1:T23 Arg2:T24
36,R10,AND Arg1:T23 Arg2:T22
37,T25,Condition 296 310	Naïve cannabis
38,T26,Scope 361 419	not used cannabis in any presentation in the last 12 weeks
39,R11,Subsumes Arg1:T25 Arg2:T26
40,T27,Drug 441 448	opioids
41,T28,Drug 471 487	pain medications
42,T29,Qualifier 453 458	other
43,*,OR T28 T27
44,R12,Has_qualifier Arg1:T28 Arg2:T29
45,T30,Qualifier 502 513	stable dose
46,T31,Temporal 514 534	for the last 15 days
47,R13,Has_temporal Arg1:T30 Arg2:T31
48,T32,Scope 441 487	opioids and other concomitant pain medications
49,A1,Optional T32
50,R14,Has_qualifier Arg1:T32 Arg2:T30
51,T33,Procedure 574 581	MiniCog
52,T34,Condition 537 560	Normal cognitive status
53,R15,AND Arg1:T33 Arg2:T34
54,T35,Condition 583 604	Normal liver function
55,T36,Measurement 617 643	aspartate aminotransferase
56,T37,Value 644 653	10-40 U/L
57,T38,Measurement 658 682	alanine aminotransferase
58,T39,Value 683 691	7-56 U/L
59,R16,Has_value Arg1:T38 Arg2:T39
60,R17,Has_value Arg1:T36 Arg2:T37
61,T40,Scope 617 691	aspartate aminotransferase 10-40 U/L and alanine aminotransferase 7-56 U/L
62,R18,Subsumes Arg1:T35 Arg2:T40
63,T41,Condition 694 715	Normal renal function
64,T42,Measurement 728 750	serum creatinine level
65,T43,Value 751 762	<133 µmol/L
66,T44,Measurement 767 810	Estimated Glomerular Filtration Rate (eGFR)
67,T45,Value 811 838	greater than or equal to 60
68,R19,Has_value Arg1:T44 Arg2:T45
69,R20,Has_value Arg1:T42 Arg2:T43
70,T46,Scope 728 838	serum creatinine level <133 µmol/L and Estimated Glomerular Filtration Rate (eGFR) greater than or equal to 60
71,R21,Subsumes Arg1:T41 Arg2:T46
72,T47,Value 841 849	Negative
73,T48,Measurement 860 904	ßhuman chorionic gonadotropin pregnancy test
74,T49,Non-representable 906 919	if applicable
75,T50,Non-query-able 922 984	Ability to read and respond to questions in French or English.
76,T51,"Pregnancy_considerations 986 1258	A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration."
0,T1,Condition 0 17	COPD exacerbation
1,T2,Qualifier 19 30	very severe
2,T3,Condition 31 35	COPD
3,T4,Condition 41 50	hypoxemia
4,T5,Qualifier 54 66	low altitude
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,R2,AND Arg1:T3 Arg2:T4
7,R3,Has_qualifier Arg1:T3 Arg2:T2
8,*,OR T1 T3
9,T6,Measurement 68 76	FEV1/FVC
10,T7,Value 77 81	<0.7
11,T8,Measurement 83 87	FEV1
12,T9,Value 88 102	<40% predicted
13,R4,Has_value Arg1:T8 Arg2:T9
14,T10,Measurement 104 121	oxygen saturation
15,T11,Qualifier 125 133	room air
16,T12,Value 134 138	<92%
17,T13,Qualifier 142 147	750 m
18,R5,Has_qualifier Arg1:T10 Arg2:T11
19,R6,Has_qualifier Arg1:T10 Arg2:T13
20,R7,Has_value Arg1:T10 Arg2:T12
21,T14,Condition 186 208	cardiovascular disease
22,T15,Qualifier 173 185	uncontrolled
23,T16,Condition 151 164	Comorbidities
24,T17,Qualifier 216 224	unstable
25,T18,Condition 225 255	systemic arterial hypertension
26,T19,Condition 257 280	coronary artery disease
27,R8,Has_qualifier Arg1:T18 Arg2:T17
28,T20,Temporal 282 290	previous
29,T21,Condition 291 297	stroke
30,T22,Condition 299 302	OSA
31,T23,Condition 304 316	pneumothorax
32,T24,Temporal 317 337	in the last 2 months
33,R9,Has_temporal Arg1:T23 Arg2:T24
34,R10,Has_qualifier Arg1:T14 Arg2:T15
35,*,OR T14 T18 T19 T21 T22 T23
36,R11,Has_temporal Arg1:T21 Arg2:T20
37,T25,"Scope 173 337	uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months"
38,R12,Subsumes Arg1:T16 Arg2:T25
39,T26,Qualifier 340 348	Internal
40,T27,Qualifier 350 360	neurologic
41,T28,Qualifier 362 375	rheumatologic
42,T29,Qualifier 379 390	psychiatric
43,T30,Condition 391 398	disease
44,T31,Temporal 409 416	current
45,T32,Observation 423 430	smoking
46,T33,Qualifier 417 422	heavy
47,T34,Value 432 435	>20
48,T35,Measurement 436 454	cigarettes per day
49,R13,Has_value Arg1:T35 Arg2:T34
50,T36,Scope 432 454	>20 cigarettes per day
51,R14,Has_qualifier Arg1:T32 Arg2:T33
52,T37,Scope 417 430	heavy smoking
53,R15,Subsumes Arg1:T37 Arg2:T36
54,T38,Scope 417 455	heavy smoking (>20 cigarettes per day)
55,R16,Has_temporal Arg1:T38 Arg2:T31
56,*,OR T29 T28 T27 T26
57,T39,"Scope 340 390	Internal, neurologic, rheumatologic or psychiatric"
58,R17,Has_scope Arg1:T30 Arg2:T39
59,R18,Has_scope Arg1:T39 Arg2:T37
60,T40,Condition 463 476	renal failure
61,T41,Condition 480 487	allergy
62,T42,Drug 491 504	acetazolamide
63,T43,Drug 515 527	sulfonamides
64,T44,Qualifier 509 514	other
65,*,OR T43 T44 T42
66,T45,Scope 491 527	acetazolamide and other sulfonamides
67,R19,Has_scope Arg1:T41 Arg2:T45
68,*,OR T40 T41
0,T1,Negation 9 15	devoid
1,T2,Condition 35 56	neurological diseases
2,T3,Condition 23 31;48 56	systemic diseases
3,*,OR T2 T3
4,T4,Scope 23 56	systemic or neurological diseases
5,R1,Has_negation Arg1:T4 Arg2:T1
6,T5,Condition 58 74	Chronic migraine
7,T6,Qualifier 79 87	ICHD-III
8,T7,Qualifier 89 138	International Classification of Headache Disorder
9,R2,Subsumes Arg1:T6 Arg2:T7
10,R3,Has_qualifier Arg1:T5 Arg2:T6
11,T8,Condition 150 162	Fibromyalgia
12,T9,Qualifier 172 204	American College of Rheumatology
13,T10,Qualifier 167 170;206 219	ACR 2010 criteria
14,R4,Subsumes Arg1:T10 Arg2:T9
15,R5,AND Arg1:T10 Arg2:T8
0,T1,Value 18 26;34 42	60 years or older
1,T2,Person 30 33	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 44 51	Surgery
4,T5,Qualifier 52 86	scheduled to last at least 2 hours
5,R2,Has_qualifier Arg1:T3 Arg2:T5
6,T4,"Non-representable 88 132	including time for anesthesia induction, etc"
7,T6,Observation 135 159	English speaking ability
8,T7,Observation 162 194	Ability to give informed consent
0,T1,Post-eligibility 0 42	Unable to give informed consent in English
1,T2,Post-eligibility 44 81	Unable to complete surveys in English
2,T3,Post-eligibility 83 142	Unable to understand instructions for using pump in English
3,T4,Post-eligibility 144 168	Unavailable for followup
4,T5,Condition 170 180	Polytrauma
5,T6,Procedure 193 208	other surgeries
6,T7,Condition 219 244	other orthopedic injuries
7,T8,Condition 287 301	ankle fracture
8,R1,AND Arg1:T7 Arg2:T8
9,*,OR T6 T7
10,T9,Condition 303 312	Infection
11,T10,Condition 314 341	Peripheral vascular disease
12,T11,Condition 343 351	Diabetes
13,T12,Procedure 374 386	chemotherapy
14,T13,Condition 388 397	Pregnancy
15,T14,Pregnancy_considerations 399 418	Currently lactating
16,T15,Condition 420 433	Heart disease
17,T16,Condition 437 458	heart rhythm disorder
18,T17,Drug 469 490	anti-arrhythmic drugs
19,*,OR T15 T16 T17
20,T18,Condition 492 515	Severe renal impairment
21,T19,Parsing_Error 517 548	Class 3 or worse kidney disease
22,T20,Condition 551 564	Liver disease
23,T21,Condition 579 592	liver failure
24,T22,Condition 566 575	cirrhosis
25,*,OR T22 T21
26,T23,Scope 566 592	cirrhosis or liver failure
27,R2,Subsumes Arg1:T20 Arg2:T23
28,T24,Condition 601 618	allergic reaction
29,T25,Drug 634 650	local anesthetic
30,R3,AND Arg1:T24 Arg2:T25
31,T26,Drug 680 695	anti-coagulants
32,T27,Drug 699 720	anti-platelet therapy
33,*,OR T26 T27
34,T28,Qualifier 659 670	therapeutic
35,T29,Scope 680 720	anti-coagulants or anti-platelet therapy
36,R4,Has_qualifier Arg1:T29 Arg2:T28
37,T30,Qualifier 722 734	prophylactic
38,T31,Negation 783 786	not
39,*,NOT T30 T31
40,R5,Has_qualifier Arg1:T29 Arg2:T30
41,T32,Drug 819 834	antidepressants
42,T33,Drug 844 867	psychiatric medications
43,*,OR T32 T33
44,T34,Multiplier 869 880	Single shot
45,T35,Procedure 881 898	local nerve block
46,R6,Has_multiplier Arg1:T35 Arg2:T34
47,T36,Temporal 899 915	prior to surgery
48,T37,Reference_point 908 915	surgery
49,R7,Has_index Arg1:T36 Arg2:T37
50,R8,Has_temporal Arg1:T35 Arg2:T36
51,T38,Procedure 946 966	neuraxial anesthesia
52,T39,Procedure 979 997	general anesthesia
53,T40,Negation 967 978	rather than
54,T41,Procedure 1006 1028	open reduction surgery
55,*,NOT T39 T40
56,T42,Scope 946 997	neuraxial anesthesia rather than general anesthesia
57,R9,AND Arg1:T42 Arg2:T41
58,T43,Procedure 1056 1073	analgesic therapy
59,T44,Qualifier 1048 1055	chronic
60,R10,Has_qualifier Arg1:T43 Arg2:T44
61,T45,Condition 1089 1101	chronic pain
62,T46,Qualifier 1080 1088	separate
63,R11,Has_qualifier Arg1:T45 Arg2:T46
64,R12,AND Arg1:T43 Arg2:T45
0,T1,Procedure 20 43	total knee arthroplasty
1,T2,Procedure 50 68	spinal anaesthesia
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Value 70 72;74 82	45 or older
4,T4,Person 72 73	y
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Measurement 84 87	ASA
7,T6,Value 88 91	1-3
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 93 96	BMI
10,T8,Value 97 102	18-35
11,R4,Has_value Arg1:T7 Arg2:T8
0,T1,Condition 6 10	pain
1,T2,Measurement 34 42	duration
2,T3,Value 12 30	less than 3 months
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Qualifier 0 5	Acute
5,T5,Scope 12 42	less than 3 months in duration
6,R2,Subsumes Arg1:T4 Arg2:T5
7,R3,Has_qualifier Arg1:T1 Arg2:T4
8,T6,Condition 79 95	hypersensitivity
9,T7,Drug 99 107	cannabis
10,T8,Drug 111 123	cannabinoids
11,*,OR T7 T8
12,T9,Scope 99 123	cannabis or cannabinoids
13,R4,Has_scope Arg1:T6 Arg2:T9
14,T10,Condition 62 75	adverse event
15,T11,Qualifier 54 61	serious
16,R5,Has_qualifier Arg1:T10 Arg2:T11
17,*,OR T10 T6
18,T12,Non-query-able 125 194	Inability to understand and comply with the instructions of the study
19,T13,Condition 220 235	cardiac disease
20,T14,Qualifier 208 219	significant
21,R6,Has_qualifier Arg1:T13 Arg2:T14
22,T15,Condition 248 279	unstable ischemic heart disease
23,T16,Condition 281 294	heart failure
24,T17,Qualifier 296 302	severe
25,T18,Qualifier 307 319	uncontrolled
26,T19,Condition 320 332	hypertension
27,R7,Has_qualifier Arg1:T19 Arg2:T18
28,R8,Has_qualifier Arg1:T19 Arg2:T17
29,*,OR T15 T16 T19
30,T20,Observation 237 244	history
31,T21,"Scope 248 332	unstable ischemic heart disease, heart failure, severe and uncontrolled hypertension"
32,R9,Has_temporal Arg1:T21 Arg2:T20
33,T22,Qualifier 411 433	clinically significant
34,T23,Condition 434 444	arrhythmia
35,T24,Condition 448 469	myocardial infarction
36,*,OR T23 T24
37,T25,Scope 434 469	arrhythmia or myocardial infarction
38,R10,Has_qualifier Arg1:T25 Arg2:T22
39,T26,Mood 398 408	at risk of
40,R11,Has_mood Arg1:T25 Arg2:T26
41,T27,Scope 208 235	significant cardiac disease
42,R12,Subsumes Arg1:T27 Arg2:T21
43,T28,Condition 479 501	substance use disorder
44,T29,Qualifier 519 594	Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5)
45,R13,Has_qualifier Arg1:T28 Arg2:T29
46,T30,Condition 617 639	dependence on cannabis
47,T31,Condition 656 683	cannabis use disorder (CUD)
48,T32,Qualifier 701 706	DSM 5
49,*,OR T30 T31
50,R14,Has_qualifier Arg1:T31 Arg2:T32
51,T33,Qualifier 729 734	DSM 5
52,T34,Condition 735 748	schizophrenia
53,T35,Condition 750 766	bipolar disorder
54,T36,Condition 780 789	psychosis
55,T37,Condition 798 809	intolerance
56,T38,Drug 813 825	cannabinoids
57,R15,AND Arg1:T37 Arg2:T38
58,R16,Has_qualifier Arg1:T34 Arg2:T33
59,*,OR T34 T35 T36 T37
60,T39,Condition 849 866	suicidal ideation
61,T40,Temporal 827 834	Current
62,T41,Observation 838 845	history
63,*,OR T41 T40
64,T42,Scope 827 845	Current or history
65,R17,Has_scope Arg1:T39 Arg2:T42
66,T43,"Pregnancy_considerations 868 1081	Pregnant, breast-feeding or female patients of child-bearing potential and male patients whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception"
67,T44,Condition 1083 1101	Hepatic impairment
68,T45,Measurement 1226 1269	Estimated Glomerular Filtration Rate (eGFR)
69,T46,Value 1270 1273	<60
70,R18,Has_value Arg1:T45 Arg2:T46
71,T47,Measurement 1103 1129	aspartate aminotransferase
72,T48,Value 1130 1158	more than three times normal
73,R19,Has_value Arg1:T47 Arg2:T48
74,T49,Condition 1163 1188	renal function impairment
75,T50,Measurement 1190 1212	serum creatinine level
76,T51,Value 1213 1224	>133 µmol/L
77,R20,Has_value Arg1:T50 Arg2:T51
78,*,OR T50 T45
79,T52,"Scope 1190 1273	serum creatinine level >133 µmol/L, Estimated Glomerular Filtration Rate (eGFR) <60"
80,R21,Subsumes Arg1:T49 Arg2:T52
81,R22,Subsumes Arg1:T44 Arg2:T47
82,*,OR T44 T49
83,T53,Condition 1276 1296	Cognitive impairment
84,T54,Procedure 1310 1317	MiniCog
85,R23,AND Arg1:T54 Arg2:T53
86,T55,Drug 1362 1391	cannabinoid based medications
87,T56,Temporal 1392 1421	within 90 days of study entry
88,R24,Has_temporal Arg1:T55 Arg2:T56
89,T57,Measurement 1490 1507	urine drug screen
90,T58,Value 1481 1489	Positive
91,R25,Has_value Arg1:T57 Arg2:T58
92,T59,Drug 1512 1524	cannabinoids
93,T60,Drug 1568 1575	alcohol
94,T61,Drug 1577 1584	cocaine
95,T62,Drug 1586 1598	amphetamines
96,T63,Drug 1603 1619	methamphetamines
97,T64,Drug 1634 1641	opioids
98,T65,Qualifier 1621 1633	unprescribed
99,R26,Has_qualifier Arg1:T64 Arg2:T65
100,*,OR T60 T61 T62 T63 T64 T59
101,T66,"Scope 1512 1642	cannabinoids and other potential abuse substances (e.g. alcohol, cocaine, amphetamines and methamphetamines, unprescribed opioids)"
102,R27,Has_scope Arg1:T58 Arg2:T66
103,T67,Competing_trial 1644 1724	Participation in another clinical trial within 30 days of enrolment in our trial
0,T1,Person 0 4	Male
1,T2,Person 9 15	female
2,T3,Person 26 29	age
3,T4,Value 30 39	18-75 yrs
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T2 T1
6,T5,Condition 42 46	COPD
7,T6,Qualifier 70 74	GOLD
8,T7,Measurement 76 80	FEV1
9,T8,Value 81 97	40-80% predicted
10,R2,Has_value Arg1:T7 Arg2:T8
11,T9,Measurement 99 103	SpO2
12,T10,Value 104 108	=92%
13,T11,Qualifier 112 117	750 m
14,R3,Has_qualifier Arg1:T9 Arg2:T11
15,R4,Has_value Arg1:T9 Arg2:T10
16,R5,Has_qualifier Arg1:T5 Arg2:T6
17,T12,Observation 147 169	living at low altitude
18,T13,Value 171 176	<800m
19,R6,Has_value Arg1:T12 Arg2:T13
20,T14,Informed_consent 180 205	Written informed consent.
0,T1,Procedure 0 10	Histologic
1,T2,Procedure 14 23	cytologic
2,T3,Condition 51 56	NSCLC
3,T4,Qualifier 37 50	stage IIIB/IV
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,R2,AND Arg1:T3 Arg2:T2
6,R3,AND Arg1:T3 Arg2:T1
7,T5,Measurement 58 65	ECOG PS
8,T6,"Value 67 70	0,1"
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Undefined_semantics 105 123	measurable disease
11,T8,Qualifier 105 115	measurable
12,T9,Subjective_judgement 105 115	measurable
13,T10,Non-query-able 72 123	Unidimensional or bi-dimensional measurable disease
14,T11,Procedure 139 148	treatment
15,T12,Procedure 170 197	platinum-based chemotherapy
16,T13,Procedure 208 232	second-line chemotherapy
17,T14,Drug 237 257	1 EGF/EGFR inhibitor
18,T15,Qualifier 199 207	standard
19,R5,Has_qualifier Arg1:T13 Arg2:T15
20,*,OR T12 T13 T14
21,T16,"Scope 170 257	platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor"
22,R6,Subsumes Arg1:T11 Arg2:T16
23,T17,Condition 271 290	disease progression
24,T18,Observation 259 267	Evidence
25,T19,Subjective_judgement 259 290	Evidence of disease progression
26,T20,Undefined_semantics 259 290	Evidence of disease progression
27,T21,Observation 292 307	Life expectancy
28,T22,Value 308 317	>12 weeks
29,R7,Has_value Arg1:T21 Arg2:T22
30,T23,Measurement 319 330	Neutrophils
31,T24,Value 331 342	> 1.5 109/l
32,T25,Measurement 344 353	Platelets
33,T26,Value 354 365	> 100 109/l
34,T27,Measurement 367 377	Hemoglobin
35,T28,Value 378 385	> 9g/dl
36,T29,Measurement 387 402	Total bilirubin
37,T30,Value 403 412	< 1.5 UNL
38,T31,Measurement 429 439	ALT (SGPT)
39,T32,Value 440 449	< 2.5 UNL
40,T33,Measurement 414 424	AST (SGOT)
41,R8,Has_value Arg1:T31 Arg2:T32
42,R9,Has_value Arg1:T33 Arg2:T32
43,T34,Measurement 451 472	Alkaline phosphatases
44,T35,Value 473 480	< 5 UNL
45,T36,Measurement 482 492	Creatinine
46,T37,Value 493 500	< 1 UNL
47,R10,Has_value Arg1:T36 Arg2:T37
48,R11,Has_value Arg1:T34 Arg2:T35
49,R12,Has_value Arg1:T29 Arg2:T30
50,R13,Has_value Arg1:T27 Arg2:T28
51,R14,Has_value Arg1:T25 Arg2:T26
52,R15,Has_value Arg1:T23 Arg2:T24
0,T1,Person 16 21	women
1,T2,Person 12 15	old
2,T3,Value 1 11	18-40 year
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 30 44	Amsel criteria
5,T5,Measurement 49 61	Nugent score
6,T6,Value 23 26	BV+
7,T7,Condition 76 78	BV
8,T8,Condition 23 25	BV
9,R3,multi Arg1:T6 Arg2:T8
10,T9,Temporal 79 100	in the prior 6 months
11,R4,Has_temporal Arg1:T7 Arg2:T9
12,T10,Scope 23 61	BV+ by Amsel criteria and Nugent score
13,*,OR T10 T7
14,T12,Pregnancy_considerations 143 215	Not intending or wishing to become pregnant over the course of the study
15,T14,Scope 30 61	Amsel criteria and Nugent score
16,R2,Has_value Arg1:T14 Arg2:T6
17,T11,Observation 102 116	Willing to use
18,T15,Drug 121 129	NuvaRing
19,R5,AND Arg1:T11 Arg2:T15
20,T13,Observation 238 262	written informed consent
21,T16,Observation 217 262	Capable of providing written informed consent
22,*,OR T16 T13
0,T1,Condition 13 23	hemoptysis
1,T2,Qualifier 29 37	severity
2,T3,Value 38 47	> grade 3
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 51 69	NCI CTCAE criteria
5,R2,AND Arg1:T2 Arg2:T4
6,T5,Temporal 70 105	within 4 weeks prior to study entry
7,T6,Reference_point 94 105	study entry
8,R3,Has_index Arg1:T5 Arg2:T6
9,T7,Condition 120 132	hypertension
10,T8,Qualifier 107 119	Uncontrolled
11,R4,Has_qualifier Arg1:T7 Arg2:T8
12,T9,Condition 134 137	CHF
13,T10,Condition 139 145	angina
14,T11,Condition 149 160	arrhythmias
15,*,OR T11 T10 T9
16,T12,Measurement 162 166	LVEF
17,T13,Value 167 174	< 1 UNL
18,R5,Has_value Arg1:T12 Arg2:T13
19,T14,Condition 187 204	second malignancy
20,T15,Temporal 205 219	within 5 years
21,T16,Undefined_semantics 187 204	second malignancy
22,R6,Has_temporal Arg1:T14 Arg2:T15
23,T17,Condition 235 238	HIV
0,T1,Condition 8 17	pregnancy
1,T2,Observation 19 51	Desire/intent to become pregnant
2,T3,Condition 43 51	pregnant
3,R1,multi Arg1:T2 Arg2:T3
4,T4,Temporal 52 80	over the course of the study
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,T5,Person 82 87	Women
7,T6,Temporal 96 124	less than 6 weeks postpartum
8,T7,Reference_point 114 124	postpartum
9,R3,Has_index Arg1:T6 Arg2:T7
10,R4,Has_temporal Arg1:T5 Arg2:T6
11,T8,Procedure 147 169	hormonal contraceptive
12,T9,Observation 126 169	Contraindications to hormonal contraceptive
13,R5,multi Arg1:T9 Arg2:T8
14,T10,Condition 215 235	deep vein thrombosis
15,T11,Person 248 253	women
16,T12,Observation 237 244	smoking
17,R6,Has_context Arg1:T11 Arg2:T12
18,T13,Value 254 273	older than 35 years
19,R7,Has_value Arg1:T11 Arg2:T13
20,*,OR T10 T11
21,T14,"Scope 215 273	deep vein thrombosis, smoking in women older than 35 years"
22,R8,Subsumes Arg1:T9 Arg2:T14
23,T15,Procedure 283 286	IUD
24,T16,Subjective_judgement 288 381	Unable to comprehend consent material because of language barrier or psychological difficulty
0,T1,Person 0 4	aged
1,T2,Value 5 15	= 6 months
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Informed_consent 17 47	sign the informed consent form
4,T4,Post-eligibility 49 160	the legal guardians participate in all the planned follow-up and be able to comply with all research procedures
5,T6,Multiplier 216 217	2
6,T7,Drug 218 256	needle recombinant hepatitis B vaccine
7,T8,Negation 267 269	no
8,T9,Drug 293 305	EV71 vaccine
9,T10,Negation 311 313	no
10,T11,Observation 314 321	history
11,R2,Has_negation Arg1:T11 Arg2:T10
12,T12,Condition 325 339	EV71 infection
13,T13,Procedure 270 281	inoculation
14,T14,Observation 282 289	history
15,R3,Has_negation Arg1:T13 Arg2:T8
16,R4,Has_temporal Arg1:T13 Arg2:T14
17,R5,AND Arg1:T9 Arg2:T13
18,R6,Has_multiplier Arg1:T7 Arg2:T6
19,R7,Has_temporal Arg1:T12 Arg2:T11
20,*,OR T13 T12 T7
21,T5,Observation 345 371	last vaccination intervals
22,T15,Value 372 381	= 14 days
23,R8,Has_value Arg1:T5 Arg2:T15
24,T16,Measurement 383 394	temperature
25,T17,Value 395 407	= 37<U+2103>
26,R9,Has_value Arg1:T16 Arg2:T17
27,T18,Person 409 413	aged
28,T19,Value 414 424	= 6 months
29,R10,Has_value Arg1:T18 Arg2:T19
30,T20,Informed_consent 426 456	sign the informed consent form
31,T21,Post-eligibility 458 569	the legal guardians participate in all the planned follow-up and be able to comply with all research procedures
32,T22,Negation 580 582	no
33,T23,Procedure 583 594	inoculation
34,T24,Observation 595 602	history
35,T25,Drug 606 618	EV71 vaccine
36,R11,Has_negation Arg1:T23 Arg2:T22
37,R12,AND Arg1:T23 Arg2:T25
38,T26,Negation 633 635	no
39,T27,Observation 636 643	history
40,T28,Condition 647 661	EV71 infection
41,R13,Has_negation Arg1:T28 Arg2:T26
42,R14,Has_temporal Arg1:T28 Arg2:T27
43,T29,Observation 667 693	last vaccination intervals
44,T30,Value 694 703	= 14 days
45,R15,Has_value Arg1:T29 Arg2:T30
46,T31,Measurement 705 716	temperature
47,T32,Value 717 729	= 37<U+2103>
48,R16,Has_value Arg1:T31 Arg2:T32
49,T33,Person 731 735	aged
50,T34,Value 736 746	= 8 months
51,R17,Has_value Arg1:T33 Arg2:T34
52,T35,Informed_consent 748 778	sign the informed consent form
53,T36,Informed_consent 1124 1154	sign the informed consent form
54,T37,Measurement 1081 1092	temperature
55,T38,Measurement 1460 1471	temperature
56,T39,Value 1093 1105	= 37<U+2103>
57,T40,Value 1472 1484	= 37<U+2103>
58,R18,Has_value Arg1:T37 Arg2:T39
59,R19,Has_value Arg1:T38 Arg2:T40
60,T41,Person 1107 1111	aged
61,T42,Value 1112 1122	= 8 months
62,R20,Has_value Arg1:T41 Arg2:T42
63,T43,Post-eligibility 780 891	the legal guardians participate in all the planned follow-up and be able to comply with all research procedures
64,T44,Post-eligibility 1156 1267	the legal guardians participate in all the planned follow-up and be able to comply with all research procedures
65,T45,Negation 902 904	no
66,T46,Negation 1278 1280	no
67,T47,Procedure 905 916	inoculation
68,T48,Procedure 1281 1292	inoculation
69,T49,Observation 917 924	history
70,T50,Observation 1293 1300	history
71,T51,Drug 928 940	EV71 vaccine
72,T52,Drug 1304 1316	EV71 vaccine
73,T53,Negation 955 957	no
74,T54,Negation 1331 1333	no
75,T55,Observation 958 965	history
76,T56,Observation 1334 1341	history
77,T57,Condition 969 983	EV71 infection
78,T58,Condition 1345 1359	EV71 infection
79,R21,Has_negation Arg1:T57 Arg2:T53
80,R22,Has_negation Arg1:T58 Arg2:T54
81,R23,Has_temporal Arg1:T57 Arg2:T55
82,R24,Has_temporal Arg1:T58 Arg2:T56
83,R25,Has_negation Arg1:T47 Arg2:T45
84,R26,AND Arg1:T47 Arg2:T51
85,R27,Has_temporal Arg1:T47 Arg2:T49
86,R28,Has_temporal Arg1:T23 Arg2:T24
87,R29,Has_negation Arg1:T48 Arg2:T46
88,R30,AND Arg1:T48 Arg2:T52
89,R31,Has_temporal Arg1:T48 Arg2:T50
90,T59,Observation 989 1015	last vaccination intervals
91,T60,Value 1016 1025	= 14 days
92,R32,Has_value Arg1:T59 Arg2:T60
93,T61,Observation 1034 1072	last attenuated live vaccine intervals
94,T62,Value 1072 1079	=28days
95,R33,Has_value Arg1:T61 Arg2:T62
96,T63,Value 1449 1458	= 28 days
97,T64,Observation 1410 1448	last attenuated live vaccine intervals
98,R34,Has_value Arg1:T64 Arg2:T63
99,T65,Observation 1365 1391	last vaccination intervals
100,T66,Value 1392 1401	= 14 days
101,R35,Has_value Arg1:T65 Arg2:T66
0,T1,Observation 4 11	history
1,T2,Observation 15 29	family history
2,T3,Condition 33 44	anaphylaxis
3,T4,Condition 46 56	convulsion
4,T5,Condition 58 66	epilepsy
5,T6,Condition 68 82	encephalopathy
6,T7,Condition 87 96	psychosis
7,*,OR T6 T7 T5 T4 T3
8,T8,"Scope 33 96	anaphylaxis, convulsion, epilepsy, encephalopathy and psychosis"
9,*,OR T1 T2
10,T9,Scope 4 29	history or family history
11,R1,Has_scope Arg1:T8 Arg2:T9
12,T10,Condition 120 141	inoculation allergies
13,T11,Qualifier 113 119	severe
14,T12,Observation 102 109	history
15,R2,Has_qualifier Arg1:T10 Arg2:T11
16,R3,Has_temporal Arg1:T10 Arg2:T12
17,T13,Condition 178 194	malignant tumors
18,T14,Condition 157 173	immunodeficiency
19,T15,Temporal 195 222	during the treatment period
20,T16,Procedure 234 259	immunosuppressive therapy
21,T17,Drug 261 273	oral steroid
22,T18,Condition 278 281	HIV
23,R4,Subsumes Arg1:T16 Arg2:T17
24,T20,Condition 326 351	congenital immune disease
25,*,OR T14 T13
26,T21,Scope 157 194	immunodeficiency and malignant tumors
27,R5,Has_temporal Arg1:T21 Arg2:T15
28,*,OR T16 T18 T20
29,T19,Observation 306 320	family members
30,R6,Has_context Arg1:T20 Arg2:T19
31,T22,Drug 353 379	Nonspecific immunoglobulin
32,T23,Temporal 393 409	within one month
33,R7,Has_temporal Arg1:T22 Arg2:T23
34,T24,Measurement 411 422	temperature
35,T25,Value 422 435	=37.1<U+2103>
36,T26,Condition 440 459	infectious diseases
37,R8,Has_value Arg1:T24 Arg2:T25
38,*,OR T26 T24
39,T27,Condition 476 492	thrombocytopenia
40,T28,Observation 465 472	history
41,T29,Qualifier 496 501	other
42,T30,Condition 502 518	thrombocytopenia
43,R9,Has_qualifier Arg1:T30 Arg2:T29
44,R10,Has_temporal Arg1:T27 Arg2:T28
45,*,OR T27 T30
46,T31,Condition 546 565	respiratory disease
47,T32,Condition 567 582	acute infection
48,T33,Condition 586 617	chronic disease activity period
49,*,OR T32 T33 T31
50,T34,Qualifier 619 625	severe
51,T35,Condition 626 648	cardiovascular disease
52,R11,Has_qualifier Arg1:T35 Arg2:T34
53,T36,Condition 660 674	kidney disease
54,T37,Condition 650 655;667 674	liver disease
55,*,OR T36 T37 T38 T35
56,T38,Condition 680 693	complications
57,T39,Condition 697 705	diabetes
58,R12,AND Arg1:T38 Arg2:T39
59,T40,Condition 707 717;744 754	infectious dermatosis
60,T41,Condition 719 730;744 754	suppurative dermatosis
61,T42,Condition 735 754	allergic dermatosis
62,*,OR T42 T41 T40
63,T43,Non-query-able 756 816	other conditions that may affect the evaluation of the trail
64,T44,Qualifier 822 829	serious
65,T45,Condition 830 844	adverse events
66,T46,Procedure 886 930	inoculation of the upper dose of the vaccine
67,R13,Has_qualifier Arg1:T45 Arg2:T44
68,R14,AND Arg1:T45 Arg2:T46
69,T47,"Non-representable 932 1051	the abnormality of 4 levels (local, systemic adverse reactions and vital signs) was judged to be related to vaccination"
70,T48,Non-query-able 1053 1111	other new standards of exclusion criteria for first needle
71,T49,Non-query-able 1113 1173	other conditions that may affect the evaluation of the trail
0,T1,Measurement 0 6	Weight
1,T2,Qualifier 7 13	stable
2,T3,Value 15 34	<3 kg weight change
3,T4,Temporal 35 55	within last 3 months
4,R1,Subsumes Arg1:T2 Arg2:T3
5,R2,Has_qualifier Arg1:T1 Arg2:T2
6,R3,Has_temporal Arg1:T1 Arg2:T4
7,T5,Condition 58 93	Constant habitual activity patterns
8,T6,Observation 95 154	no deviation > 1x/wk at 30 min/session within last 3 months
9,R4,Subsumes Arg1:T5 Arg2:T6
10,T7,Condition 157 188	Constant habitual diet patterns
11,T8,Temporal 189 209	within last 3 months
12,R5,Has_temporal Arg1:T7 Arg2:T8
13,T9,Observation 211 256	Willingness to eat a chocolate-flavored snack
14,T10,Temporal 257 273	at test sessions
15,T11,Temporal 257 259;278 302	at two week training period
16,R6,Has_temporal Arg1:T9 Arg2:T11
17,R7,Has_temporal Arg1:T9 Arg2:T10
18,T12,Condition 307 316	allergies
19,T13,Negation 304 306	No
20,R8,Has_negation Arg1:T12 Arg2:T13
21,T14,Observation 324 334	test foods
22,R9,Has_context Arg1:T12 Arg2:T14
23,T15,Observation 340 358	planning to change
24,T16,Drug 366 405	medications known to influence appetite
25,T17,Drug 366 396;409 419	medications known to influence metabolism
26,*,OR T16 T17
27,T18,Scope 366 419	medications known to influence appetite or metabolism
28,R10,Has_mood Arg1:T18 Arg2:T15
29,T19,Negation 336 339	Not
30,T20,Condition 425 433	diabetic
31,T21,Negation 421 424	Not
32,R12,Has_negation Arg1:T20 Arg2:T21
33,T22,Condition 449 461	GI pathology
34,T23,Observation 438 445	history
35,T24,Negation 435 437	No
36,R13,Has_temporal Arg1:T22 Arg2:T23
37,R14,Has_negation Arg1:T22 Arg2:T24
38,R11,Has_negation Arg1:T18 Arg2:T19
39,T25,Condition 467 473	smoker
40,T26,Negation 463 466	Non
41,R15,Has_negation Arg1:T25 Arg2:T26
42,T27,Temporal 474 494	for one year or more
43,R16,Has_temporal Arg1:T25 Arg2:T27
0,T1,Condition 6 15	pregnancy
1,T2,Condition 19 33	breast-feeding
2,*,OR T2 T1
3,T3,Condition 36 74	Medical illness unrelated to the tumor
4,T4,Undefined_semantics 36 74	Medical illness unrelated to the tumor
5,T5,Subjective_judgement 75 191	which in the opinion of the attending physician and principal investigator will preclude administration of the agent
6,T6,Undefined_semantics 75 191	which in the opinion of the attending physician and principal investigator will preclude administration of the agent
7,T7,Post-eligibility 75 191	which in the opinion of the attending physician and principal investigator will preclude administration of the agent
8,T8,Condition 221 243	uncontrolled infection
9,T9,Undefined_semantics 221 243	uncontrolled infection
10,T10,Condition 245 272	chronic renal insufficiency
11,T11,Condition 274 295	myocardial infarction
12,T12,Temporal 296 320	within the past 6 months
13,T13,Condition 322 337	unstable angina
14,T14,Condition 339 358	cardiac arrhythmias
15,T15,Condition 370 397	chronic atrial fibrillation
16,T16,Negation 359 369	other than
17,R1,Has_negation Arg1:T15 Arg2:T16
18,R2,AND Arg1:T14 Arg2:T15
19,*,OR T13 T14 T11 T10 T8
20,R3,Has_temporal Arg1:T11 Arg2:T12
21,T18,Condition 420 440	persistent hepatitis
22,T17,Measurement 445 471	New York Heart Association
23,T19,Value 472 496	Classification III or IV
24,R4,Has_value Arg1:T17 Arg2:T19
25,T20,Condition 497 510	heart disease
26,T21,Undefined_semantics 497 510	heart disease
27,R5,AND Arg1:T20 Arg2:T17
28,*,OR T20 T18 T22 T15
29,T22,Condition 402 416;431 440	chronic active hepatitis
30,T23,Grammar_Error 398 401	and
0,T1,Person 0 5	Women
1,T2,Person 148 153	women
2,T3,Procedure 17 33	cesarean section
3,T4,Qualifier 39 57	general anesthesia
4,T5,Non-representable 76 145	because carbetocin is licensed for use with regional anaesthesia only
5,T6,Procedure 165 181	cesarean section
6,T7,Temporal 185 203	less than 37 weeks
7,T8,Measurement 207 216	gestation
8,R1,Has_temporal Arg1:T8 Arg2:T7
9,R2,AND Arg1:T6 Arg2:T8
0,T1,Visit 8 41	University of New Mexico Hospital
1,T2,Person 0 4	Born
2,T3,Condition 65 74	gestation
3,T4,Value 43 64	Greater than 34 weeks
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Qualifier 84 92	in-utero
6,T6,Observation 93 106	drug exposure
7,R2,Has_qualifier Arg1:T6 Arg2:T5
8,T7,Drug 111 118	opioids
9,R3,AND Arg1:T6 Arg2:T7
10,T8,Negation 119 124	other
11,T9,Drug 130 143	buprenorphine
12,R4,Has_negation Arg1:T9 Arg2:T8
13,T10,Qualifier 145 153	Maternal
14,T11,Qualifier 157 163	infant
15,T12,Measurement 164 181	urine drug screen
16,*,OR T11 T10
17,T13,Scope 145 163	Maternal or infant
18,R5,Has_scope Arg1:T12 Arg2:T13
19,T14,Value 182 190	positive
20,R6,Has_value Arg1:T12 Arg2:T14
21,T15,Qualifier 195 204	methadone
22,T16,Qualifier 212 219	opioids
23,*,OR T15 T16
24,T17,Scope 195 219	methadone and/or opioids
25,R7,Has_scope Arg1:T12 Arg2:T17
0,T1,Person 12 15	age
1,T2,Value 0 8;16 24	18 years or older
2,T3,Condition 64 72	melanoma
3,T4,Procedure 26 40	Histologically
4,T5,Value 41 50	confirmed
5,R1,Has_value Arg1:T4 Arg2:T5
6,R2,AND Arg1:T3 Arg2:T4
7,T6,Condition 74 87	breast cancer
8,T7,Condition 91 109	gynecologic cancer
9,T8,Visit 113 118	MSKCC
10,R3,AND Arg1:T6 Arg2:T4
11,R4,AND Arg1:T7 Arg2:T4
12,*,OR T3 T6 T7
13,T9,Parsing_Error 120 164	Have one of the following disease histories:
14,T10,Condition 225 243	malignant melanoma
15,T11,Condition 247 260	breast cancer
16,*,OR T10 T11
17,T12,Qualifier 196 201	local
18,T13,Qualifier 203 211	regional
19,T14,Qualifier 213 223	metastatic
20,*,OR T14 T13 T12
21,T15,"Scope 196 223	local, regional, metastatic"
22,T16,Temporal 166 181	Newly-diagnosed
23,T17,Multiplier 185 194	recurrent
24,*,OR T17 T16
25,T18,Scope 225 260	malignant melanoma or breast cancer
26,T19,Scope 166 194	Newly-diagnosed or recurrent
27,R5,Has_scope Arg1:T18 Arg2:T19
28,R6,Has_scope Arg1:T18 Arg2:T15
29,T20,Condition 352 357	tumor
30,T21,Procedure 327 343	radiographically
31,T22,Qualifier 304 312	Residual
32,T23,Value 344 351	evident
33,R7,Has_value Arg1:T21 Arg2:T23
34,T24,Procedure 313 323	clinically
35,R8,Has_qualifier Arg1:T24 Arg2:T22
36,*,OR T21 T24
37,T25,Scope 304 351	Residual clinically or radiographically evident
38,R9,Has_scope Arg1:T20 Arg2:T25
39,T26,Condition 369 386	primary cutaneous
40,T27,Condition 391 408	mucosal melanomas
41,T28,Scope 369 408	primary cutaneous and mucosal melanomas
42,*,OR T27 T26
43,R10,Subsumes Arg1:T25 Arg2:T28
44,T29,Procedure 416 433	radiation therapy
45,T30,Procedure 435 447	chemotherapy
46,T31,Procedure 452 459	surgery
47,T32,Procedure 482 501	flap reconstruction
48,T33,Condition 472 501	requiring flap reconstruction
49,R11,AND Arg1:T33 Arg2:T32
50,T34,Qualifier 509 529	head and neck region
51,R12,Has_qualifier Arg1:T32 Arg2:T34
52,*,OR T31 T30 T29
53,T35,Temporal 410 415	Prior
54,T36,Procedure 571 588	excisional biopsy
55,T37,Temporal 562 570	previous
56,R13,Has_temporal Arg1:T36 Arg2:T37
57,T38,Condition 610 628	gynecologic cancer
58,T39,Procedure 646 657	SLN mapping
59,T40,Procedure 662 679	surgical excision
60,T41,Condition 662 692	surgical excision is indicated
61,T42,Condition 646 657;680 692	SLN mapping is indicated
62,R14,AND Arg1:T42 Arg2:T39
63,R15,AND Arg1:T41 Arg2:T40
64,T43,Measurement 713 729	cardiac function
65,T44,Value 697 703	Normal
66,T45,Measurement 704 712	baseline
67,R16,Has_value Arg1:T43 Arg2:T44
68,R17,AND Arg1:T43 Arg2:T45
69,T46,Procedure 741 765	pre-operative evaluation
70,R18,AND Arg1:T43 Arg2:T46
71,T47,Temporal 741 754	pre-operative
72,R19,Has_temporal Arg1:T46 Arg2:T47
73,T48,Subjective_judgement 767 809	At the discretion of the operating surgeon
74,T49,Measurement 811 814	ANC
75,T50,Value 814 823	>1000/mcl
76,R20,Has_value Arg1:T49 Arg2:T50
77,T51,Measurement 828 837	platelets
78,T52,"Value 837 849	>100,000/mcl"
79,R21,Has_value Arg1:T51 Arg2:T52
80,T53,Subjective_judgement 852 894	At the discretion of the operating surgeon
81,T54,Measurement 896 911	Bilirubin level
82,T55,Value 915 926	< 2.0 mg/dl
83,R22,Has_value Arg1:T54 Arg2:T55
84,T56,Condition 958 975	Gilbert's disease
85,T57,Negation 927 944	in the absence of
86,R23,Has_negation Arg1:T56 Arg2:T57
87,T58,Observation 947 954	history
88,R24,Has_temporal Arg1:T56 Arg2:T58
89,T59,Condition 1021 1029	melanoma
90,T60,Condition 1070 1080	malignancy
91,T61,Condition 1092 1100	melanoma
92,T62,Negation 1081 1091	other than
93,R25,Has_negation Arg1:T61 Arg2:T62
94,T63,Condition 1112 1124	skin cancers
95,T64,Temporal 1125 1147	in the past five years
96,T65,Subjective_judgement 1168 1205	up to the discretion of the physician
97,R26,Has_temporal Arg1:T63 Arg2:T64
98,R27,AND Arg1:T60 Arg2:T61
99,*,OR T63 T60
100,T66,Grammar_Error 1102 1105	and
101,T67,Observation 1059 1066	history
102,R28,Has_temporal Arg1:T60 Arg2:T67
103,R29,Has_temporal Arg1:T63 Arg2:T67
104,T68,Post-eligibility 1208 1309	All patients of childbearing and child-creating age must be using an acceptable form of birth control
105,T69,Person 1311 1316	Women
106,T70,Condition 1325 1339	pre-menopausal
107,T71,Scope 1311 1339	Women who are pre-menopausal
108,A1,Optional T71
109,T72,Measurement 1361 1381	serum pregnancy test
110,T73,Value 1352 1360	negative
111,R30,Has_value Arg1:T72 Arg2:T73
112,R31,AND Arg1:T71 Arg2:T72
0,T1,Person 0 5	Women
1,T2,Condition 13 32	singleton pregnancy
2,T3,Procedure 44 60	cesarean section
3,T4,Value 61 75	after 37 weeks
4,T5,Measurement 79 88	gestation
5,R1,Has_value Arg1:T5 Arg2:T4
6,R2,AND Arg1:T3 Arg2:T5
0,T1,Person 0 4	Born
1,T2,Value 5 22	prior to 34 weeks
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Visit 24 52	Neonatal intensive care unit
4,T4,Condition 72 93	medical comorbidities
5,T5,Qualifier 64 71	Serious
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Observation 103 121	substance exposure
8,T7,Qualifier 122 130	in-utero
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Qualifier 135 148	buprenorphine
11,R4,Has_qualifier Arg1:T6 Arg2:T8
12,T9,Negation 157 160	not
13,T10,Drug 161 168	opioids
14,R5,Has_negation Arg1:T10 Arg2:T9
0,T1,Person 0 3	Age
1,T2,Value 4 15	18-65 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 28 38	snake bite
4,T4,Condition 56 74	local envenomation
5,T5,Mood 44 55	features of
6,R2,Has_mood Arg1:T4 Arg2:T5
7,T6,Condition 88 105	systemic features
8,A1,Optional T6
9,R3,AND Arg1:T4 Arg2:T6
10,R4,AND Arg1:T3 Arg2:T4
11,T7,Temporal 107 136	Less than 24 hours since bite
12,T8,Reference_point 132 136	bite
13,T9,Condition 132 136	bite
14,R5,multi Arg1:T8 Arg2:T9
15,R6,Has_index Arg1:T7 Arg2:T8
16,T10,Negation 143 145	No
17,T11,Temporal 146 151	prior
18,T12,Procedure 152 172	antibiotic treatment
19,R7,Has_temporal Arg1:T12 Arg2:T11
20,R8,Has_negation Arg1:T12 Arg2:T10
0,T1,Temporal 0 16	Newly dignosised
1,T2,Condition 17 32	type 2 diabetes
2,T3,Qualifier 46 58	WHO criteria
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T2 Arg2:T1
5,T4,Measurement 59 86	glycated hemoglobin (HbA1c)
6,T5,Value 91 104	more than 10%
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Negation 107 119	Seronegative
9,T7,Condition 124 134	antibodies
10,T8,Qualifier 143 150	insulin
11,T9,Qualifier 152 163	islet cells
12,T10,Qualifier 168 201	glutamic acid decarboxylase (GAD)
13,*,OR T9 T10 T8
14,T11,"Scope 143 201	insulin, islet cells and glutamic acid decarboxylase (GAD)"
15,R4,Has_scope Arg1:T7 Arg2:T11
16,R5,Has_negation Arg1:T7 Arg2:T6
0,T1,Condition 0 20	cognitive impairment
1,T2,Measurement 22 58	Mini-Mental Status Examination score
2,T3,Observation 60 70	illiterate
3,T4,Value 71 80	13 points
4,T5,Observation 82 92	elementary
5,T6,Observation 97 110	middle school
6,T7,Value 111 120	18 points
7,T8,Observation 126 137	high-school
8,T9,Value 138 147	26 points
9,*,OR T6 T5
10,T10,Scope 82 110	elementary and middle school
11,A1,Optional T10
12,A2,Optional T8
13,A3,Optional T3
14,R1,Has_value Arg1:T10 Arg2:T7
15,R2,Has_value Arg1:T3 Arg2:T4
16,R3,Has_value Arg1:T8 Arg2:T9
17,*,OR T10 T3 T8 T11
18,T11,Condition 152 190	inability to respond to verbal command
19,T12,Scope 60 190	illiterate 13 points; elementary and middle school 18 points; and high-school 26 points; or inability to respond to verbal command
20,R4,Has_scope Arg1:T2 Arg2:T12
21,T13,Scope 22 190	Mini-Mental Status Examination score: illiterate 13 points; elementary and middle school 18 points; and high-school 26 points; or inability to respond to verbal command
22,R5,Subsumes Arg1:T1 Arg2:T13
23,T14,Condition 194 225	inability to walk independently
24,T15,Qualifier 230 249	at least 10 minutes
25,R6,Has_qualifier Arg1:T14 Arg2:T15
26,T16,Device 267 282	walking devices
27,A4,Optional T16
28,R7,AND Arg1:T14 Arg2:T16
29,T17,Condition 285 289	pain
30,T18,Condition 293 308	other disorders
31,*,OR T17 T18
32,T19,Qualifier 309 339	precluding their participation
33,T20,Scope 285 308	pain or other disorders
34,R8,Has_qualifier Arg1:T20 Arg2:T19
35,T21,Post-eligibility 285 339	pain or other disorders precluding their participation
0,T1,Visit 26 37	out-patient
1,T2,Procedure 38 48	cystoscopy
2,T3,Condition 54 78	papillary bladder tumour
3,R1,AND Arg1:T2 Arg2:T1
0,T1,Parsing_Error 0 2	NA
0,T1,Condition 13 25	hypertension
1,T2,Condition 29 46	metabolic disease
2,T3,Qualifier 0 12	Uncontrolled
3,*,OR T1 T2
4,T4,Scope 13 46	hypertension or metabolic disease
5,R1,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Condition 48 75	Neurodegenerative disorders
7,T6,Condition 82 99	Parkinson disease
8,T7,Condition 101 104	LBD
9,T8,Condition 109 112	FTD
10,*,OR T7 T8 T6
11,T9,"Scope 82 112	Parkinson disease. LBD, or FTD"
12,R2,Subsumes Arg1:T5 Arg2:T9
13,T10,Condition 116 124	Dementia
14,T11,Condition 128 153	Mild cognitive impairment
15,T12,Measurement 133 153	cognitive impairment
16,T13,Value 128 132	Mild
17,R3,Has_value Arg1:T12 Arg2:T13
18,R4,multi Arg1:T11 Arg2:T12
19,T14,Temporal 154 165	at baseline
20,*,OR T10 T11
21,T15,Scope 116 153	Dementia or Mild cognitive impairment
22,R5,Has_temporal Arg1:T15 Arg2:T14
23,T16,Condition 167 193	Long life major depression
24,T17,Measurement 195 210	Baseline scores
25,T18,Value 211 214	=16
26,T19,Measurement 222 255	17-item Hamilton Depression Scale
27,T20,Temporal 256 267	at baseline
28,T21,Reference_point 259 267	baseline
29,R6,Has_index Arg1:T20 Arg2:T21
30,R7,Has_temporal Arg1:T19 Arg2:T20
31,R8,Has_value Arg1:T19 Arg2:T18
32,R9,Subsumes Arg1:T19 Arg2:T17
33,R10,AND Arg1:T16 Arg2:T19
34,T22,Condition 270 303	Long-life DSM-IV axis 1 disorders
35,T23,Condition 306 324	Mental retardation
36,T24,Condition 327 342	Substance abuse
37,T25,Temporal 345 355	Concurrent
38,T26,Drug 356 366	medication
39,T27,Qualifier 367 412	limiting validity of neuropsychological tests
40,T28,Qualifier 367 387;416 423	limiting validity of imaging
41,*,OR T28 T27
42,R11,AND Arg1:T25 Arg2:T26
43,T29,Scope 367 423	limiting validity of neuropsychological tests or imaging
44,R12,Has_scope Arg1:T25 Arg2:T29
45,T30,Drug 426 442	Anti-depressants
46,T31,Qualifier 448 475	anti-cholinergic properties
47,R13,Has_qualifier Arg1:T30 Arg2:T31
48,T32,Drug 448 464	anti-cholinergic
49,R14,multi Arg1:T31 Arg2:T32
50,T33,Drug 477 512	Monoamine oxidase inhibitors (MAOi)
51,T34,Drug 529 548	narcotic analgesics
52,T35,Multiplier 550 567	>2 doses per week
53,T36,Multiplier 514 525	Regular use
54,R15,Subsumes Arg1:T36 Arg2:T35
55,R16,Has_multiplier Arg1:T34 Arg2:T36
56,T37,Drug 578 590	neuroleptics
57,T38,Drug 599 624	anti-dementia medications
58,T39,Drug 626 633	Aricept
59,T40,Drug 635 641	Exelon
60,T41,Drug 643 651	Razadyne
61,*,OR T41 T40 T39
62,T42,"Scope 626 651	Aricept, Exelon, Razadyne"
63,R17,Subsumes Arg1:T38 Arg2:T42
64,T43,Drug 657 666	memantine
65,T44,Drug 668 675	Namenda
66,R18,Subsumes Arg1:T43 Arg2:T44
67,*,OR T38 T43 T45
68,T45,Drug 681 710	anti-Parkinsonian medications
69,T46,Drug 712 719	Sinemet
70,T47,Drug 721 731	amantadine
71,T48,Drug 733 746	bromocriptine
72,T49,Drug 748 757	pergolide
73,T50,Drug 759 769	selegeline
74,*,OR T50 T49 T48 T47 T46
75,T51,"Scope 712 769	Sinemet, amantadine, bromocriptine, pergolide, selegeline"
76,R19,Subsumes Arg1:T45 Arg2:T51
77,T52,Drug 792 825;840 851	over the counter memory enhancing medications
78,T53,Drug 792 815;829 851	over the counter memory protecting medications
79,T54,Drug 858 871	ginkgo biloba
80,T55,Drug 873 881	vitamins
81,*,OR T54 T55
82,T56,"Scope 858 881	ginkgo biloba, vitamins"
83,T57,Scope 792 851	over the counter memory enhancing or protecting medications
84,R20,Subsumes Arg1:T57 Arg2:T56
85,T58,"Non-representable 773 900	Individuals taking over the counter memory enhancing or protecting medications (e.g. ginkgo biloba, vitamins) are not excluded."
86,T59,Device 912 927	medical devices
87,T60,Procedure 955 966	MRI imaging
88,T61,Qualifier 937 966	incompatible with MRI imaging
89,R21,multi Arg1:T61 Arg2:T60
90,R22,Has_qualifier Arg1:T59 Arg2:T61
91,T62,Measurement 969 988	Radiation exposures
92,T63,Value 989 1023	exceeding annual Rad Worker limits
93,R23,Has_value Arg1:T62 Arg2:T63
94,T64,Condition 1026 1039	Heart failure
95,T65,Measurement 1040 1045	stage
96,T66,Value 1046 1047	D
97,R24,Has_value Arg1:T65 Arg2:T66
98,T68,Qualifier 1062 1088	American Heart Association
99,T69,Condition 1095 1117	Chronic kidney disease
100,T70,Measurement 1121 1127	stages
101,T71,Value 1128 1131	= 4
102,T72,Qualifier 1148 1174	National Kidney Foundation
103,R25,Has_qualifier Arg1:T65 Arg2:T68
104,R26,AND Arg1:T64 Arg2:T65
105,R27,Has_value Arg1:T70 Arg2:T71
106,R28,AND Arg1:T69 Arg2:T70
107,R29,Has_qualifier Arg1:T70 Arg2:T72
108,T67,Condition 1181 1192	Brain tumor
109,T73,Condition 1203 1223	neoplastic disorders
110,T74,Qualifier 1224 1241	outside the brain
111,R30,Has_qualifier Arg1:T73 Arg2:T74
112,T75,Qualifier 1309 1341	likely to affect brain structure
113,T76,Qualifier 1309 1331;1345 1353	likely to affect brain function
114,*,OR T76 T75
115,T77,Procedure 1281 1290	radiation
116,T78,Procedure 1292 1304	chemotherapy
117,*,OR T67 T73 T77 T78
118,T79,"Scope 1181 1305	Brain tumor and other neoplastic disorders outside the brain where disease itself or its treatment (radiation, chemotherapy)"
119,T80,Scope 1310 1353	ikely to affect brain structure or function
120,R31,Subsumes Arg1:T79 Arg2:T80
121,T81,Condition 1356 1362	Stroke
122,T82,Condition 1435 1454	circulation infarct
123,T83,Qualifier 1425 1434	posterior
124,T84,Qualifier 1389 1403	total anterior
125,T85,Qualifier 1405 1421	partial anterior
126,*,OR T83 T85 T84
127,T86,"Scope 1389 1434	total anterior, partial anterior or posterior"
128,R32,Has_scope Arg1:T82 Arg2:T86
129,T87,Measurement 1472 1518	Oxford Community Stroke Project classification
130,R33,AND Arg1:T87 Arg2:T82
131,R34,AND Arg1:T81 Arg2:T87
132,T88,Non-representable 1520 1623	Patients with clinically silent of lacunar strokes and transient ischemic attacks will not be excluded.
133,T89,Qualifier 1625 1636	Significant
134,T90,Condition 1637 1648	head trauma
135,R35,Has_qualifier Arg1:T90 Arg2:T89
136,T91,Condition 1651 1664	Hydrocephalus
137,T92,Observation 1680 1700	refusal to cooperate
138,T93,Observation 1667 1676	Hostility
139,*,OR T93 T92
0,T1,Person 0 6	Female
1,T2,Person 7 10	age
2,T3,Value 11 20	20-50 y/o
3,T4,Mood 25 40	plan to undergo
4,T5,Procedure 41 61	abdominal myomectomy
5,T6,Qualifier 66 77	symptomatic
6,T7,Condition 78 94	myomatous uterus
7,R1,Has_qualifier Arg1:T7 Arg2:T6
8,R2,AND Arg1:T5 Arg2:T7
9,R3,Has_mood Arg1:T5 Arg2:T4
10,R4,Has_value Arg1:T2 Arg2:T3
0,T1,Observation 0 34	Lack of understanding of the study
1,T2,Condition 36 53	contra-indication
2,T3,Procedure 57 85	nicotine replacement therapy
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Observation 101 144	incompatible with detention in police cells
5,T5,Condition 146 169	serious mental disorder
6,T6,Qualifier 196 221	outside Seine-Saint-Denis
7,T7,Observation 177 195	place of residence
8,A1,Optional T7
9,R2,Has_qualifier Arg1:T7 Arg2:T6
0,T1,Condition 0 24	Type 1 diabetes mellitus
1,T2,Condition 37 56	autoimmune diabetes
2,T3,Condition 70 80	antibodies
3,T4,Qualifier 84 91	insulin
4,T5,Qualifier 93 104	islet cells
5,T6,Qualifier 110 113	GAD
6,*,OR T4 T5 T6
7,T7,"Scope 84 113	insulin, islet cells, and GAD"
8,R1,Has_scope Arg1:T3 Arg2:T7
9,R2,AND Arg1:T2 Arg2:T3
10,T8,Condition 116 136	Gestational diabetes
11,T9,Condition 170 195	renal function impairment
12,T10,Condition 160 165;176 195	liver function impairment
13,T11,Condition 153 158;176 195	heart function impairment
14,*,OR T10 T11 T9 T15
15,T12,Qualifier 208 214	severe
16,T13,Condition 215 225	infections
17,T14,Condition 229 252	cerebrovascular disease
18,*,OR T13 T14
19,T15,Scope 215 252	infections or cerebrovascular disease
20,R3,Has_qualifier Arg1:T15 Arg2:T12
0,T1,Qualifier 0 10	Upper limb
1,T2,Condition 11 16	bites
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Multiplier 18 26	Multiple
4,T4,Multiplier 28 31	> 1
5,T5,Condition 33 38	bites
6,R2,Subsumes Arg1:T3 Arg2:T4
7,R3,Has_multiplier Arg1:T5 Arg2:T3
8,T6,Observation 40 58	Wound manipulation
9,T7,Condition 60 84	Extensive local necrosis
10,T8,Condition 60 75;88 93	Extensive local blebs
11,*,OR T8 T7
12,T9,Condition 95 108	Seriously-ill
13,T10,Condition 123 134	hypotension
14,T11,Condition 135 149	capillary leak
15,T12,Qualifier 150 166	life threatening
16,T13,Condition 167 175	bleeding
17,R4,Has_qualifier Arg1:T13 Arg2:T12
18,*,OR T10 T11 T13
19,T14,Condition 188 198	cobra bite
20,T15,Mood 178 187	Suspected
21,R5,Has_mood Arg1:T14 Arg2:T15
22,T16,Condition 204 212	Pregnant
23,T17,Condition 213 227	breast-feeding
24,T18,Person 228 233	women
25,*,OR T17 T16
0,T1,Condition 0 28	Non papillary gross features
1,T2,Condition 36 41	tumor
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Qualifier 43 61	Anteriorly located
4,T4,Condition 62 67	tumor
5,R2,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Non-representable 69 86	Patients criteria
7,T6,Observation 93 111	performance status
8,T7,Value 88 92	Poor
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Condition 124 127	BCG
11,T9,Condition 128 134	sepsis
12,R4,AND Arg1:T9 Arg2:T8
13,T10,Condition 147 166	bladder irradiation
14,T11,Observation 113 120	History
15,T12,Observation 136 143	History
16,R5,Has_temporal Arg1:T9 Arg2:T11
17,R6,Has_temporal Arg1:T10 Arg2:T12
18,T13,Condition 168 186	Contracted bladder
0,T1,Condition 0 24	Intrauterine fetal death
1,T2,Condition 41 66	absence of cardiac motion
2,T3,Procedure 70 80	ultrasound
3,T4,Temporal 104 144	at the time of admission to the hospital
4,T5,Reference_point 119 144	admission to the hospital
5,R1,Has_index Arg1:T4 Arg2:T5
6,R2,AND Arg1:T3 Arg2:T2
7,R3,Has_temporal Arg1:T3 Arg2:T4
8,T6,Measurement 147 172	Estimated gestational age
9,T7,Value 173 194	greater than 20 weeks
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Condition 196 218	Hemodynamically stable
12,T9,Procedure 239 257	induction of labor
13,R5,AND Arg1:T8 Arg2:T9
14,T10,Person 304 309	Women
15,T11,Multiplier 315 318	one
16,T12,Procedure 325 357	low transverse cesarean delivery
17,R6,Has_multiplier Arg1:T12 Arg2:T11
0,T1,Person 13 16	age
1,T2,Value 0 9	= 20years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 32 38	stroke
4,T4,Temporal 40 48	>6months
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Observation 52 61	sedentary
7,T6,Observation 65 86	insufficiently active
8,*,OR T5 T6
9,T7,Non-query-able 89 161	have a writing medical permission to participate in the training program
0,T1,Person 0 4	Male
1,T2,Person 9 15	female
2,T3,Value 25 44	between 40-85 years
3,T4,Person 45 48	old
4,R1,Has_value Arg1:T4 Arg2:T3
5,*,OR T2 T1
6,T5,Non-representable 67 149	Younger subjects are not included as the risk for brain amyloid lesions is too low
7,T6,Observation 169 182	speak English
8,T7,Qualifier 192 206	first language
9,R2,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Observation 222 244	proficiency in English
11,*,OR T6 T8
12,T9,Measurement 296 316	WAIS vocabulary test
13,T10,Value 284 288	> 11
14,R3,Has_value Arg1:T9 Arg2:T10
15,T11,Scope 284 316	> 11 on the WAIS vocabulary test
16,R4,Subsumes Arg1:T8 Arg2:T11
17,T12,Condition 343 359	normal cognition
18,T13,Temporal 360 371	at baseline
19,R5,Has_temporal Arg1:T12 Arg2:T13
20,T14,Measurement 375 403	Clinical Dementia Rating CDR
21,T15,Value 403 405	=0
22,R6,Has_value Arg1:T14 Arg2:T15
23,T16,Measurement 407 437	Global Deterioration Scale GDS
24,T17,Value 437 439	<2
25,R7,Has_value Arg1:T16 Arg2:T17
26,R8,AND Arg1:T12 Arg2:T14
27,R9,AND Arg1:T12 Arg2:T16
28,T18,Condition 466 485	good general health
29,T19,Observation 490 509	able to participate
30,T20,Procedure 524 537	imaging exams
31,T21,Procedure 517 519	LP
32,T22,Scope 517 537	LP and imaging exams
33,R10,Has_scope Arg1:T19 Arg2:T22
34,T23,Non-representable 539 644	This determination is made by the study neurologist and reviewed at a consensus meeting for each subject.
0,T1,Drug 33 44	misoprostol
1,T2,Drug 48 59	vasopressin
2,*,OR T1 T2
3,T3,Condition 13 29	contraindication
4,T4,Scope 33 59	misoprostol or vasopressin
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Observation 61 77	personal history
7,T6,Condition 102 109;81 88	disease cardiac
8,T7,Condition 92 109	pulmonary disease
9,*,OR T7 T6
10,T8,Observation 111 118	history
11,T9,Temporal 122 127	prior
12,T10,Procedure 128 138	myomectomy
13,R2,Has_temporal Arg1:T10 Arg2:T9
14,R3,Has_temporal Arg1:T10 Arg2:T8
15,T11,Scope 81 109	cardiac or pulmonary disease
16,R4,Has_temporal Arg1:T11 Arg2:T5
17,*,OR T8 T5 T3
0,T1,Person 0 9	Arrestees
1,T2,Temporal 34 66	during detention in police cells
2,T3,Reference_point 41 66	detention in police cells
3,R1,Has_index Arg1:T2 Arg2:T3
4,T4,Procedure 10 33	examined by a physician
5,R2,Has_temporal Arg1:T4 Arg2:T2
6,T5,Value 73 84	18 or older
7,T6,Person 68 72	aged
8,R3,Has_value Arg1:T6 Arg2:T5
9,T7,Observation 86 93	smoking
10,T8,Multiplier 94 124	at least 10 cigarettes per day
11,R4,Has_multiplier Arg1:T7 Arg2:T8
12,T9,Informed_consent 126 176	giving written consent to participate in the study
13,T10,Value 192 233	compatible with detention in police cells
14,T11,Measurement 178 191	health status
15,R5,Has_value Arg1:T11 Arg2:T10
0,T1,Condition 0 24	Non diabetic nephropathy
1,T2,Qualifier 26 45	confirmed by biopsy
2,T3,Procedure 39 45	biopsy
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,R2,multi Arg1:T2 Arg2:T3
5,T4,Procedure 49 57	Dialysis
6,T5,Condition 62 81	acute renal failure
7,T6,Temporal 82 110	within the 6 previous months
8,R3,AND Arg1:T4 Arg2:T5
9,R4,Has_temporal Arg1:T4 Arg2:T6
10,T7,Qualifier 147 155	relevant
11,T8,Qualifier 156 165	bilateral
12,T9,Condition 166 190	stenosis of renal artery
13,T10,Value 192 197	> 75%
14,R5,Subsumes Arg1:T7 Arg2:T10
15,R6,Has_qualifier Arg1:T9 Arg2:T8
16,R7,Has_qualifier Arg1:T9 Arg2:T7
17,T11,Measurement 200 232	Urinary albumin/creatinine ratio
18,T12,Value 233 254	higher than 3000 mg/g
19,R8,Has_value Arg1:T11 Arg2:T12
20,T13,Temporal 256 277	at the baseline visit
21,R9,Has_temporal Arg1:T11 Arg2:T13
22,T14,Measurement 280 303	Systolic blood pressure
23,T15,Value 304 314	= 180 mmHg
24,R10,Has_value Arg1:T14 Arg2:T15
25,T16,Measurement 318 342	diastolic blood pressure
26,T17,Value 343 354	= 110 mm Hg
27,T18,Temporal 355 376	at the baseline visit
28,R11,Has_value Arg1:T16 Arg2:T17
29,*,OR T14 T16
30,T19,Scope 280 354	Systolic blood pressure = 180 mmHg or diastolic blood pressure = 110 mm Hg
31,R12,Has_temporal Arg1:T19 Arg2:T18
32,T20,Condition 379 385	Stroke
33,T21,Condition 387 412	transient ischemic attack
34,T22,Condition 414 437	acute coronary syndrome
35,T23,Procedure 442 457	hospitalization
36,T24,Condition 462 475	heart failure
37,T25,Qualifier 476 485	worsening
38,R13,Has_qualifier Arg1:T24 Arg2:T25
39,R14,AND Arg1:T23 Arg2:T24
40,T26,Temporal 487 514	within the previous 30 days
41,*,OR T22 T23 T21 T20
42,T27,"Scope 379 485	Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening"
43,R15,Has_temporal Arg1:T27 Arg2:T26
44,T28,Person 517 537	Professional drivers
45,T29,Person 539 554	risk profession
46,T30,Condition 558 577	respiratory failure
47,*,OR T29 T30 T28
48,T31,Qualifier 580 586	Severe
49,T32,Condition 587 605	daytime sleepiness
50,R16,Has_qualifier Arg1:T32 Arg2:T31
51,T33,Measurement 607 631	Epworth sleepiness scale
52,T34,Value 632 635	>18
53,R17,Has_value Arg1:T33 Arg2:T34
54,T35,Scope 580 605	Severe daytime sleepiness
55,T36,Scope 607 635	Epworth sleepiness scale >18
56,R18,Subsumes Arg1:T35 Arg2:T36
57,T37,Temporal 638 649	Concomitant
58,T38,Procedure 650 659	treatment
59,T39,Multiplier 665 675	high doses
60,T40,Drug 679 699	acetylsalicylic acid
61,T41,Multiplier 701 713	> 500 mg/day
62,R19,Subsumes Arg1:T39 Arg2:T41
63,R20,Has_multiplier Arg1:T40 Arg2:T39
64,R21,AND Arg1:T38 Arg2:T40
65,R22,Has_temporal Arg1:T38 Arg2:T37
66,T42,Temporal 718 728	continuous
67,T43,Procedure 729 738	treatment
68,T44,Drug 744 781	non-steroidal anti-inflammatory drugs
69,R23,AND Arg1:T43 Arg2:T44
70,R24,Has_temporal Arg1:T43 Arg2:T42
71,*,OR T38 T43
72,T45,Temporal 783 791	Previous
73,T46,Procedure 792 801	treatment
74,T47,Device 807 811	CPAP
75,R25,AND Arg1:T46 Arg2:T47
76,R26,Has_temporal Arg1:T46 Arg2:T45
77,T48,Non-query-able 813 895	Participation in another clinical trial within the 30 days prior to randomization.
0,T1,Procedure 6 23	kidney transplant
1,T2,Person 0 5	Adult
2,T3,Person 40 44	y.o.
3,T4,Value 35 39	> 18
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Condition 103 128	cytomegalovirus infection
6,T6,Drug 148 173	immunosuppressive regimen
7,T7,Drug 175 187	azathioprine
8,T8,Drug 191 204	mycophenolate
9,T9,Drug 206 216	tacrolimus
10,T10,Drug 221 231	prednisone
11,R2,AND Arg1:T5 Arg2:T6
12,*,OR T7 T8 T9 T10
13,T11,"Scope 175 231	azathioprine or mycophenolate, tacrolimus and prednisone"
14,R3,Subsumes Arg1:T6 Arg2:T11
0,T1,Value 14 32	18 to 80 years old
1,T2,Person 9 13	aged
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 48 55	obesity
4,T4,Measurement 57 60	BMI
5,T5,Value 61 70	=25 kg/m2
6,T6,Condition 34 44	Overweight
7,*,OR T3 T6
8,T7,Scope 34 55	Overweight or obesity
9,R2,Has_value Arg1:T4 Arg2:T5
10,R3,Subsumes Arg1:T7 Arg2:T4
11,T8,Condition 95 110	type 2 diabetes
12,T9,Multiplier 123 135	at least one
13,T10,Temporal 73 81	Previous
14,T11,Temporal 166 173	current
15,T12,Drug 189 212	oral antidiabetic drugs
16,T13,Drug 220 227	insulin
17,*,OR T12 T13
18,T14,Scope 189 227	oral antidiabetic drugs and/or insulin
19,R4,Has_temporal Arg1:T14 Arg2:T11
20,T15,Measurement 234 249	fasting glucose
21,T16,Value 256 271	above 126 mg/dl
22,R5,Has_value Arg1:T15 Arg2:T16
23,T17,Multiplier 272 295	on at least 2 occasions
24,R6,Has_multiplier Arg1:T15 Arg2:T17
25,T18,Measurement 300 319	blood glucose level
26,T19,Value 371 402	equal to or more than 200 mg/dl
27,T20,Temporal 320 367	at 2 hours after an oral glucose tolerance test
28,T21,Reference_point 337 367	an oral glucose tolerance test
29,T22,Procedure 340 367	oral glucose tolerance test
30,R7,multi Arg1:T21 Arg2:T22
31,R8,Has_index Arg1:T20 Arg2:T21
32,R9,Has_temporal Arg1:T18 Arg2:T20
33,R10,Has_value Arg1:T18 Arg2:T19
34,T23,Measurement 412 445	glycated hemoglobin (HbA1c) level
35,T24,Value 446 453	> 6.5 %
36,R11,Has_value Arg1:T23 Arg2:T24
37,*,OR T23 T18 T15 T14
38,R12,Has_temporal Arg1:T8 Arg2:T10
39,T25,Scope 166 453	current treatment with oral antidiabetic drugs and/or insulin; 2) a fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or 4) a glycated hemoglobin (HbA1c) level > 6.5 %
40,R13,Has_multiplier Arg1:T25 Arg2:T9
41,R14,Has_scope Arg1:T8 Arg2:T25
42,T26,Condition 477 497	diabetic nephropathy
43,T27,Measurement 506 538	urinary albumin/creatinine ratio
44,T28,Value 539 547	>30 mg/g
45,R15,Has_value Arg1:T27 Arg2:T28
46,T29,Measurement 555 591	estimated glomerular filtration rate
47,T30,Value 592 623	more than 20 ml/min per 1.73 m2
48,R16,Has_value Arg1:T29 Arg2:T30
49,T31,Drug 657 697	angiotensin-converting enzyme inhibitors
50,T32,Multiplier 641 653	stable doses
51,T33,Drug 699 731	angiotensin II receptor blockers
52,T34,Drug 735 758	anti-aldosterone agents
53,T35,Temporal 759 781	in the last four weeks
54,*,OR T31 T33 T34
55,T36,"Scope 657 758	angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or anti-aldosterone agents"
56,R17,Has_multiplier Arg1:T36 Arg2:T32
57,R18,Has_temporal Arg1:T36 Arg2:T35
0,T1,Procedure 0 13	Re-transplant
1,T2,Measurement 34 57	panel reactive antibody
2,T3,Measurement 59 62	PRA
3,T4,Value 64 85	equal to or above 50%
4,R1,Subsumes Arg1:T2 Arg2:T3
5,T5,Value 87 94	class I
6,T6,Value 98 106	class II
7,*,OR T6 T5 T4
8,T7,"Scope 64 106	equal to or above 50%, class I or class II"
9,R2,Has_scope Arg1:T2 Arg2:T7
10,T8,Condition 109 132	Acute rejection episode
11,T9,Temporal 140 152	last 30 days
12,T10,Measurement 177 191	Banff criteria
13,T11,Value 165 169	> 2A
14,R3,Has_value Arg1:T10 Arg2:T11
15,R4,Has_temporal Arg1:T8 Arg2:T9
16,*,OR T8 T10
17,T12,Measurement 194 197	GFR
18,T14,Value 205 216	< 40 ml/min
19,R5,Has_value Arg1:T12 Arg2:T14
20,T13,Condition 219 230	Proteinuria
21,T15,"Multiplier 231 240	> 0,5 g/l"
22,R6,Has_multiplier Arg1:T13 Arg2:T15
23,T16,Measurement 243 253	Hemoglobin
24,T17,Value 254 262	< 10 g/l
25,T18,Measurement 270 280	leucocytes
26,T19,Value 281 296	< 4000 cels/mm3
27,T20,Measurement 304 313	platelets
28,T21,Value 314 332	< 150.000 cels/mm3
29,R7,Has_value Arg1:T16 Arg2:T17
30,R8,Has_value Arg1:T18 Arg2:T19
31,R9,Has_value Arg1:T20 Arg2:T21
32,*,OR T16 T18 T20
33,T22,Measurement 335 348	Triglycerides
34,T23,Value 349 360	> 500 mg/dl
35,R10,Has_value Arg1:T22 Arg2:T23
36,T24,Drug 384 391	fibrate
37,A1,Optional T24
38,T25,Measurement 394 411	Cholesterol total
39,T26,Value 412 423	> 300 mg/dl
40,R11,Has_value Arg1:T25 Arg2:T26
41,T27,Drug 447 453	statin
42,A2,Optional T27
43,T28,Condition 456 477	Hepatic abnormalities
44,T29,Condition 492 507	periphery edema
45,T30,Qualifier 480 491	Significant
46,R12,Has_qualifier Arg1:T29 Arg2:T30
47,T31,Condition 510 533	Pulmonary abnormalities
48,T32,Procedure 537 549	breast x-ray
49,T33,Value 550 563	abnormalities
50,R13,Has_value Arg1:T32 Arg2:T33
51,T34,Condition 566 583	Hyper sensibility
52,T35,Drug 587 596	sirolimus
53,R14,AND Arg1:T34 Arg2:T35
0,T1,Condition 29 41	skin disease
1,T2,Qualifier 17 28	significant
2,T3,Observation 0 7	History
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,T4,Condition 69 85	allergic illness
5,T5,Condition 95 117	dermatologic condition
6,*,OR T4 T5
7,T6,Condition 46 65	skin manifestations
8,T7,Scope 69 117	allergic illness or other dermatologic condition
9,R3,Has_scope Arg1:T6 Arg2:T7
10,T8,Condition 153 170	atopic dermatitis
11,T9,Qualifier 146 152	severe
12,T10,Qualifier 126 142	chronic moderate
13,*,OR T9 T10
14,T11,Scope 126 152	chronic moderate or severe
15,R4,Has_scope Arg1:T8 Arg2:T11
16,T12,Subjective_judgement 177 299	would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator
17,T13,Negation 119 125	except
18,R2,Has_negation Arg1:T8 Arg2:T13
19,R5,AND Arg1:T6 Arg2:T8
20,*,OR T1 T6
21,T14,Condition 327 340	skin diseases
22,T15,Condition 349 374	chronic atopic dermatitis
23,T16,Negation 342 348	except
24,R6,Has_negation Arg1:T15 Arg2:T16
25,T17,Qualifier 381 442	could disturb the study assessment and evaluation of the skin
26,T18,Undefined_semantics 381 442	could disturb the study assessment and evaluation of the skin
27,R7,Has_qualifier Arg1:T14 Arg2:T17
28,T19,Condition 494 519	chronic atopic dermatitis
29,T20,Temporal 520 536	within one month
30,R8,Has_temporal Arg1:T19 Arg2:T20
31,T21,Drug 470 489	systemic medication
32,T22,Temporal 463 469	active
33,R9,Has_temporal Arg1:T21 Arg2:T22
34,R10,AND Arg1:T21 Arg2:T19
35,T23,Condition 619 644	chronic atopic dermatitis
36,T24,Temporal 645 661	within two weeks
37,R11,Has_temporal Arg1:T23 Arg2:T24
38,T25,Drug 560 578	topical medication
39,T26,Temporal 553 559	active
40,R12,Has_temporal Arg1:T25 Arg2:T26
41,R13,AND Arg1:T25 Arg2:T23
42,T27,Observation 676 689	sunny holiday
43,T28,Procedure 691 707	UV-light therapy
44,T29,Observation 711 723	solarium use
45,T30,Temporal 724 777	within one month before beginning of study treatments
46,T31,Reference_point 748 777	beginning of study treatments
47,T32,Observation 782 790	planning
48,T33,Temporal 796 812	during the study
49,T34,Temporal 816 845	within 7 days after the study
50,*,OR T34 T33
51,T35,Scope 796 845	during the study or within 7 days after the study
52,*,OR T27 T28 T29
53,T36,"Scope 676 723	sunny holiday, UV-light therapy or solarium use"
54,R14,Has_temporal Arg1:T36 Arg2:T30
55,R15,Has_mood Arg1:T36 Arg2:T32
56,A1,Optional T32
57,R16,Has_scope Arg1:T32 Arg2:T35
58,T37,Condition 847 854	Allergy
59,T38,Drug 940 958	Protopic® ointment
60,T39,Drug 858 865	cis-UCA
61,T40,Drug 894 916	placebo emulsion cream
62,*,OR T40 T38 T39
63,T41,"Scope 858 958	cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment"
64,R17,Has_scope Arg1:T37 Arg2:T41
65,T42,Condition 975 994	skin-related cancer
66,T43,Observation 960 967	History
67,T44,Condition 1010 1035	acquired immunodeficiency
68,T45,Condition 1019 1035;996 1006	immunodeficiency Congenital
69,T46,Procedure 1047 1083	therapy that cause immunosuppression
70,T47,Qualifier 1055 1083	that cause immunosuppression
71,T48,Condition 1066 1083	immunosuppression
72,R18,AND Arg1:T47 Arg2:T48
73,R19,Has_qualifier Arg1:T46 Arg2:T47
74,T49,Temporal 1039 1046	ongoing
75,*,OR T45 T44 T46
76,R20,Has_temporal Arg1:T46 Arg2:T49
77,T50,Non-query-able 1085 1149	Earlier participation in a clinical study performed with cis-UCA
78,T51,Qualifier 1155 1177	clinically significant
79,T52,Procedure 1178 1193	laboratory test
80,R21,Has_qualifier Arg1:T52 Arg2:T51
81,T53,Undefined_semantics 1151 1200	Any clinically significant laboratory test result
82,T54,Subjective_judgement 1151 1200	Any clinically significant laboratory test result
83,T55,Condition 1228 1241	alcohol abuse
84,T56,Condition 1220 1224;1236 1241	drug abuse
85,*,OR T56 T55
86,T57,Observation 1202 1211	Suspected
87,T58,Temporal 1212 1219	current
88,T59,Scope 1220 1241	drug or alcohol abuse
89,R22,Has_context Arg1:T59 Arg2:T57
90,R23,Has_temporal Arg1:T59 Arg2:T58
91,T60,Temporal 1274 1331	during the 4 weeks prior to the first dose administration
92,T61,Reference_point 1302 1331	the first dose administration
93,R24,Has_index Arg1:T60 Arg2:T61
94,T62,Condition 1266 1273	illness
95,T63,Qualifier 1243 1265	Clinically significant
96,R25,Has_qualifier Arg1:T62 Arg2:T63
97,R26,Has_temporal Arg1:T62 Arg2:T60
98,T64,Subjective_judgement 1243 1331	Clinically significant illness during the 4 weeks prior to the first dose administration
99,T65,Post-eligibility 1333 1495	Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient
100,T66,Post-eligibility 1497 1559	Unwillingness or doubtful capacity to comply with the protocol
101,T67,Post-eligibility 1561 1604	Doubtful availability to complete the study
0,T1,Measurement 16 30	calculated PRA
1,T2,Value 31 61	higher than 0% per solid phase
2,T3,Procedure 131 150	single antigen test
3,T4,Value 71 87	anti-HLA class I
4,T5,Value 71 79;97 105	anti-HLA class II
5,*,OR T5 T4
6,T6,Scope 71 104	anti-HLA class I and / or class I
7,R1,Has_scope Arg1:T3 Arg2:T6
8,T7,Procedure 152 159	Luminex
9,R2,Subsumes Arg1:T3 Arg2:T7
10,T8,Procedure 220 246	graft from a cadaver donor
11,T9,Condition 249 262	Identical HLA
12,T10,Procedure 183 194	Cross Match
13,T11,Value 164 172	Positive
14,R3,Has_value Arg1:T10 Arg2:T11
15,T12,Procedure 312 334	solid organ transplant
16,T13,Temporal 303 311	previous
17,T14,Procedure 346 363	kidney transplant
18,R4,Subsumes Arg1:T12 Arg2:T14
19,T15,Qualifier 393 400	another
20,T16,Procedure 401 423	solid organ transplant
21,T17,Temporal 424 437	concomitantly
22,R5,Has_qualifier Arg1:T16 Arg2:T15
23,R6,Has_temporal Arg1:T16 Arg2:T17
24,R7,Has_temporal Arg1:T12 Arg2:T13
25,T18,Condition 440 464;479 488	Glomerular primary focal sclerosis
26,T19,Condition 440 450;469 488	Glomerular segmental sclerosis
27,*,OR T18 T19
28,T20,Condition 490 531	Atypical hemolytic uremic syndrome (aHUS)
29,T21,Condition 534 578	thrombotic thrombocytopenic purpura syndrome
30,*,OR T20 T21
31,T22,Condition 618 641	Hepatitis B virus (HBV)
32,T23,Condition 673 690	Hepatitis C virus
33,T24,Procedure 701 711	PCR result
34,T25,Value 692 700	positive
35,R8,Has_value Arg1:T24 Arg2:T25
36,T26,Qualifier 595 602	chronic
37,T27,Qualifier 651 657	active
38,R9,Has_qualifier Arg1:T22 Arg2:T26
39,R10,Has_qualifier Arg1:T23 Arg2:T27
40,T28,Scope 692 711	positive PCR result
41,*,OR T23 T22
42,T29,Scope 595 690	chronic infection with Hepatitis B virus (HBV) and / or active infection with Hepatitis C virus
43,R11,Subsumes Arg1:T29 Arg2:T28
44,T30,Temporal 713 738	at the time of transplant
45,R12,Has_temporal Arg1:T29 Arg2:T30
46,T31,Condition 780 814	Human Immunodeficiency Virus (HIV)
47,T32,Condition 838 856	systemic infection
48,T33,Qualifier 831 837	active
49,R13,Has_qualifier Arg1:T32 Arg2:T33
50,T34,Drug 903 914	antibiotics
51,R14,AND Arg1:T32 Arg2:T34
52,T35,Multiplier 875 899	continued administration
53,R15,Has_multiplier Arg1:T34 Arg2:T35
54,T36,Condition 935 943	neoplasm
55,T37,Negation 944 950	except
56,T38,Condition 951 972	localized skin cancer
57,R16,Has_negation Arg1:T38 Arg2:T37
58,R17,AND Arg1:T36 Arg2:T38
59,T39,Qualifier 1029 1035	severe
60,T40,Condition 1036 1042	anemia
61,R18,Has_qualifier Arg1:T40 Arg2:T39
62,T41,Measurement 1044 1054	hemoglobin
63,T42,Value 1055 1063	<6g / dl
64,R19,Has_value Arg1:T41 Arg2:T42
65,T43,Condition 1066 1076	leukopenia
66,T44,Measurement 1078 1081	WBC
67,T45,Value 1082 1093	<2500 / mm3
68,R20,Has_value Arg1:T44 Arg2:T45
69,T46,Scope 1044 1063	hemoglobin <6g / dl
70,T47,Scope 1078 1093	WBC <2500 / mm3
71,R21,Subsumes Arg1:T43 Arg2:T47
72,T48,Scope 1029 1042	severe anemia
73,R22,Subsumes Arg1:T48 Arg2:T46
74,T49,Condition 1104 1120	thrombocytopenia
75,T50,Measurement 1122 1131	platelets
76,T51,"Value 1132 1145	<80,000 / mm3"
77,R23,Has_value Arg1:T50 Arg2:T51
78,T52,"Scope 1122 1145	platelets <80,000 / mm3"
79,R24,Subsumes Arg1:T49 Arg2:T52
80,*,OR T43 T49 T48
81,T53,Condition 1166 1190	hemodynamically unstable
82,T54,Measurement 1209 1226	hemoglobin levels
83,T55,Value 1226 1235	> 6g / dL
84,R25,Has_value Arg1:T54 Arg2:T55
85,T56,Condition 1252 1272	intestinal pathology
86,T57,Condition 1276 1291	severe diarrhea
87,T58,Observation 1297 1320	may decrease absorption
88,*,OR T56 T57
89,T59,Scope 1252 1291	intestinal pathology or severe diarrhea
90,R26,Has_context Arg1:T59 Arg2:T58
91,T60,Condition 1373 1389	hypersensitivity
92,T61,Drug 1404 1428	drugs used in this study
93,R27,AND Arg1:T60 Arg2:T61
94,T62,Competing_trial 1431 1537	Patients who have received any investigational drug in the 30 days prior to their inclusion in this study.
95,T63,"Pregnancy_considerations 1539 1756	Potentially fertile women who do not agree to use reliable contraceptive measures during the trial, who are pregnant, breastfeeding or who present a positive pregnancy test at the time of their inclusion in the study."
96,T64,Observation 1775 1791	legally detained
97,T65,Visit 1798 1818	official institution
98,R28,AND Arg1:T64 Arg2:T65
0,T1,Person 65 68	age
1,T2,Value 51 61	≥ 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-query-able 0 38	Subject has provided informed consent.
4,T4,Non-query-able 70 162	Subject is willing and able to comply with all aspects of treatment and evaluation schedule.
5,T5,Condition 231 246	mucosal disease
6,T6,Observation 267 277;307 315	radiologic evidence
7,T7,Observation 279 289;307 315	endoscopic evidence
8,T8,Observation 294 315	histological evidence
9,*,OR T6 T7 T8
10,T9,"Scope 248 315	diagnosis based on radiologic, endoscopic, or histological evidence"
11,R2,Has_scope Arg1:T5 Arg2:T9
12,T10,Temporal 207 226	within last 2 years
13,T11,Temporal 191 205	recent history
14,R3,Has_temporal Arg1:T5 Arg2:T11
15,R4,Has_temporal Arg1:T11 Arg2:T10
16,T12,Undefined_semantics 182 184	CD
0,T1,Observation 0 14	Unable to read
1,T2,Observation 0 9;19 49	Unable to understand the Danish language
2,T3,Observation 0 9;56 77	Unable to give informed consent
3,*,OR T2 T3 T1
4,T4,Measurement 79 98	Cervical dilatation
5,T5,Value 99 105	> 4 cm
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 107 132	Non-cephalic presentation
8,T7,Condition 134 152	Multiple gestation
9,T8,Condition 154 191	Pathological fetal heart rate pattern
10,T9,Procedure 193 207	cardiotocogram
11,T10,Procedure 209 212	CTG
12,*,OR T9 T10
13,T11,Temporal 214 243	before Syntocinon® initiation
14,T12,Drug 221 232	Syntocinon®
15,T13,Reference_point 221 243	Syntocinon® initiation
16,R2,Has_index Arg1:T11 Arg2:T13
17,R3,AND Arg1:T13 Arg2:T12
18,T14,"Scope 193 212	cardiotocogram, CTG"
19,R4,Has_scope Arg1:T8 Arg2:T14
20,R5,Has_temporal Arg1:T8 Arg2:T11
21,T15,Measurement 245 268	Fetal weight estimation
22,T16,Value 269 277	> 4500 g
23,T17,Qualifier 279 287	clinical
24,T18,Procedure 291 301	ultrasonic
25,*,OR T17 T18
26,T19,Scope 279 301	clinical or ultrasonic
27,R6,Has_scope Arg1:T15 Arg2:T19
28,R7,Has_value Arg1:T15 Arg2:T16
29,T20,Informed_consent 304 334	Subject declines participation
30,T21,Measurement 336 351	Gestational age
31,T22,Value 352 380	less than 37 completed weeks
32,R8,Has_value Arg1:T21 Arg2:T22
0,T1,Non-query-able 0 35	Failure to provide informed consent
1,T2,Condition 37 103	Inability to complete 400 m walk within 15 minutes without sitting
2,T3,Condition 107 131;37 95	interpersonal assistance Inability to complete 400 m walk within 15 minutes without
3,*,OR T3 T2
4,T4,Drug 254 267	ACE inhibitor
5,T5,Condition 231 271	Primary indication for ACE inhibitor use
6,T6,Condition 278 302	Congestive Heart Failure
7,T7,Condition 304 307	CAD
8,T8,Condition 309 317	diabetes
9,*,OR T8 T7 T6
10,T9,"Scope 278 317	Congestive Heart Failure, CAD, diabetes"
11,R1,Subsumes Arg1:T5 Arg2:T9
12,T10,Condition 325 359	hypersensitivity to ACE inhibitors
13,T11,Drug 345 359	ACE inhibitors
14,T12,Condition 371 383	hypertension
15,T13,Qualifier 361 370	Resistant
16,T14,Measurement 396 398	BP
17,T15,Value 399 407	> 140/90
18,R2,Has_value Arg1:T14 Arg2:T15
19,R3,Subsumes Arg1:T13 Arg2:T14
20,R4,Has_qualifier Arg1:T12 Arg2:T13
21,T16,Qualifier 409 465	despite the use of three or more anti-hypertensive drugs
22,T17,Drug 442 465	anti-hypertensive drugs
23,T18,Multiplier 428 441	three or more
24,R5,Has_multiplier Arg1:T17 Arg2:T18
25,R6,Has_qualifier Arg1:T13 Arg2:T16
26,T19,Measurement 490 493	SBP
27,T20,Value 494 505	> 180 mm Hg
28,T21,Measurement 509 512	DBP
29,T22,Value 513 524	> 110 mm Hg
30,R7,Has_value Arg1:T21 Arg2:T22
31,R8,Has_value Arg1:T19 Arg2:T20
32,*,OR T19 T21
33,T23,Condition 581 602	Primary renal disease
34,T24,Measurement 604 620	Serum creatinine
35,T25,Value 621 631	>2.5 mg/dL
36,T26,Person 635 638	men
37,T27,Value 643 653	>2.0 mg/dL
38,T28,Person 657 662	women
39,A1,Optional T28
40,A2,Optional T26
41,R9,Has_value Arg1:T28 Arg2:T27
42,R10,Has_value Arg1:T26 Arg2:T25
43,*,OR T26 T28
44,T29,"Scope 621 662	>2.5 mg/dL in men, or >2.0 mg/dL in women"
45,R11,Has_scope Arg1:T24 Arg2:T29
46,T30,Measurement 664 679	Serum potassium
47,T31,Value 680 703	>5.0 molar equivalent/L
48,R12,Has_value Arg1:T30 Arg2:T31
49,T32,Measurement 705 720;725 736	Urinary protein on dipstick
50,T33,Value 721 724	> 1
51,R13,Has_value Arg1:T32 Arg2:T33
52,T34,Measurement 747 760	liver enzymes
53,T35,Measurement 762 790	Aspartate transaminase (AST)
54,T36,Measurement 792 818	Alanine transaminase (ALT)
55,T37,Measurement 823 843	alkaline phosphatase
56,T38,Value 844 881	> 2.5 times the upper limit of normal
57,*,OR T37 T36 T35
58,T39,"Scope 762 843	Aspartate transaminase (AST), Alanine transaminase (ALT), or alkaline phosphatase"
59,R14,Has_value Arg1:T39 Arg2:T38
60,T40,Value 738 746	Abnormal
61,R15,Has_value Arg1:T34 Arg2:T40
62,T41,Scope 738 760	Abnormal liver enzymes
63,R16,Subsumes Arg1:T41 Arg2:T39
64,T42,Condition 891 906	cardiac disease
65,T43,Qualifier 884 890	Severe
66,R17,Has_qualifier Arg1:T42 Arg2:T43
67,T44,Measurement 918 944	New York Heart Association
68,T45,Value 945 960	Class III or IV
69,R18,Has_value Arg1:T44 Arg2:T45
70,T46,Condition 961 985	congestive heart failure
71,T47,Qualifier 987 1009	clinically significant
72,T48,Condition 1010 1025	aortic stenosis
73,T49,Observation 1027 1034	history
74,T50,Condition 1038 1052	cardiac arrest
75,T51,Device 1063 1084	cardiac defibrillator
76,T52,Condition 1089 1108	uncontrolled angina
77,R19,Has_qualifier Arg1:T48 Arg2:T47
78,T53,Qualifier 918 960	New York Heart Association Class III or IV
79,R20,Has_qualifier Arg1:T46 Arg2:T53
80,R21,Has_temporal Arg1:T50 Arg2:T49
81,*,OR T52 T51 T50 T48 T46 T42
82,T54,Condition 1110 1137	Acute myocardial infarction
83,T55,Procedure 1152 1155	ECG
84,T56,Observation 1157 1180	Lives in a nursing home
85,T57,Condition 1267 1287	cognitive impairment
86,T58,Qualifier 1255 1266	Significant
87,R22,Has_qualifier Arg1:T57 Arg2:T58
88,T59,Condition 1321 1329	dementia
89,T60,Measurement 1335 1364	Mini-Mental State Examination
90,T61,Value 1370 1380	score < 24
91,R23,Has_value Arg1:T60 Arg2:T61
92,*,OR T59 T60 T57
93,T62,Condition 1382 1403	Unable to communicate
94,T63,Condition 1415 1434	severe hearing loss
95,T64,Condition 1438 1453	speech disorder
96,*,OR T64 T63
97,T65,Scope 1415 1453	severe hearing loss or speech disorder
98,R24,Subsumes Arg1:T65 Arg2:T62
99,T66,Condition 1462 1479	visual impairment
100,T67,Qualifier 1455 1461	Severe
101,R25,Has_qualifier Arg1:T66 Arg2:T67
102,T68,Condition 1571 1588	co-morbid disease
103,T69,Qualifier 1559 1570	significant
104,R26,Has_qualifier Arg1:T68 Arg2:T69
105,T70,Qualifier 1589 1633	that would prevent participation in exercise
106,T71,Undefined_semantics 1589 1633	that would prevent participation in exercise
107,T72,Subjective_judgement 1589 1633	that would prevent participation in exercise
108,R27,Has_qualifier Arg1:T68 Arg2:T70
109,T73,Non-query-able 1635 1695	Planning to move out of the area during the study time frame
110,T74,Context_Error 1635 1695	Planning to move out of the area during the study time frame
111,T75,Context_Error 1697 1753	Simultaneous participation in another intervention trial
112,T76,Non-query-able 1697 1753	Simultaneous participation in another intervention trial
0,T1,Multiplier 3 10	initial
1,T2,Multiplier 68 75	initial
2,T3,Multiplier 134 141	initial
3,T4,Measurement 11 38	plasma sodium concentration
4,T5,Measurement 76 103	plasma sodium concentration
5,T6,Measurement 142 172	plasma potassium concentration
6,T7,Value 42 63	lower than 130 mmol/L
7,T8,Value 107 129	higher than 150 mmol/L
8,T9,Value 176 197	lower than 3.0 mmol/L
9,R1,Has_value Arg1:T4 Arg2:T7
10,R2,Has_value Arg1:T5 Arg2:T8
11,R3,Has_value Arg1:T6 Arg2:T9
12,R4,Has_multiplier Arg1:T4 Arg2:T1
13,R5,Has_multiplier Arg1:T5 Arg2:T2
14,R6,Has_multiplier Arg1:T6 Arg2:T3
15,T10,Mood 199 207	Need for
16,T11,Drug 208 228	10% glucose solution
17,R7,Has_mood Arg1:T11 Arg2:T10
18,T12,Condition 230 238	Diabetes
19,T13,Condition 240 258	Diabetes insipidus
20,T14,Condition 260 281	Diabetic ketoacidosis
21,T15,Condition 283 296	Renal disease
22,T16,Mood 302 307	needs
23,T17,Procedure 308 316	dialysis
24,R8,Has_mood Arg1:T17 Arg2:T16
25,R9,AND Arg1:T15 Arg2:T17
26,T18,Qualifier 318 337	Protocol-determined
27,T19,Procedure 338 360	chemotherapy hydration
28,R10,Has_qualifier Arg1:T19 Arg2:T18
29,T20,Qualifier 362 368	Severe
30,T21,Condition 369 382	liver disease
31,R11,Has_qualifier Arg1:T21 Arg2:T20
32,T22,Condition 384 411	Inborn errors of metabolism
33,T23,Mood 417 421	need
34,T24,Qualifier 422 441	protocol-determined
35,T25,Procedure 442 455	fluid therapy
36,R12,Has_qualifier Arg1:T25 Arg2:T24
37,R13,Has_mood Arg1:T25 Arg2:T23
38,R14,AND Arg1:T22 Arg2:T25
0,T1,Person 6 9	men
1,T2,Person 0 5	Adult
2,T3,Person 14 19	women
3,T4,Value 21 30	=18 years
4,T5,Person 25 30	years
5,R1,Has_value Arg1:T5 Arg2:T4
6,R2,Subsumes Arg1:T2 Arg2:T5
7,*,OR T1 T3
8,T6,Procedure 49 72	first kidney transplant
9,T7,Qualifier 81 97	incompatible HLA
10,R3,Has_qualifier Arg1:T6 Arg2:T7
11,T8,Qualifier 98 110	living donor
12,R4,Has_qualifier Arg1:T6 Arg2:T8
13,T9,Multiplier 112 122	at least 1
14,T10,Observation 123 135	mismatch HLA
15,R5,Has_multiplier Arg1:T10 Arg2:T9
16,R6,Has_context Arg1:T6 Arg2:T10
17,T11,Qualifier 162 176	AB0 compatible
18,T12,Procedure 177 187	transplant
19,R7,Has_qualifier Arg1:T12 Arg2:T11
20,T13,Measurement 206 220	calculated PRA
21,T14,Value 224 226	0%
22,T15,Qualifier 230 251	solid phase technique
23,R8,Has_value Arg1:T13 Arg2:T14
24,R9,Has_qualifier Arg1:T13 Arg2:T15
25,T16,Procedure 311 341	single antigen test (Luminex®)
26,T17,Observation 256 283	absence of anti-HLA class I
27,T18,Observation 256 266;288 296	absence of class II
28,T19,Scope 256 296	absence of anti-HLA class I and class II
29,R10,Has_scope Arg1:T16 Arg2:T19
30,T20,Informed_consent 344 446	Patients who agree to participate in the Trial by signing the Specific Informed Consent of this study.
31,T21,"Pregnancy_considerations 448 1228	Potentially fertile women should use high reliability contraceptive methods (Pearl-Index <1) in order to avoid pregnancy during the entire duration of the study and up to 6 weeks after the end of their treatment with Mycophenolate Mofetil (MMF). Potentially Fertile Women include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or who is not post-menopausal (defined as amenorrhea = 12 consecutive months, or women who are receiving hormone replacement therapy with a documented level of follicle stimulating hormone (FSH)> 35 mlU / ml). Potentially fertile women must have a pregnancy test with a negative result in the 72 hours prior to the start of the trial."
32,T22,"Pregnancy_considerations 1230 1573	Sexually active males (including vasectomized males) who are being treated with MMF must accept the use of barrier contraceptive methods during MMF treatment and for 90 days thereafter. Potentially fertile partners of these patients should use a reliable contraceptive method during the same period, in order to minimize the risk of pregnancy."
33,T23,Non-query-able 1575 1771	Patients must agree not to donate blood during treatment with MMF and during the 6 subsequent weeks. Males should not make a sperm donation during MMF treatment and up to 90 days after completion.
0,T1,Post-eligibility 0 58	Informed consent obtained prior to any screening procedure
1,T2,Person 60 69	Caucasian
2,T3,Person 70 74	male
3,T4,Person 78 84	female
4,*,OR T4 T3
5,T5,Value 94 111	At least 18 years
6,T6,Person 115 118	age
7,R1,Has_value Arg1:T6 Arg2:T5
8,T7,Measurement 120 126	Weight
9,T8,Value 127 141	at least 45 kg
10,R2,Has_value Arg1:T7 Arg2:T8
11,T9,Condition 175 200	chronic atopic dermatitis
12,T10,Qualifier 168 174	severe
13,T11,Qualifier 156 164	moderate
14,*,OR T10 T11
15,T12,Scope 156 174	moderate or severe
16,R3,Has_scope Arg1:T9 Arg2:T12
17,T13,Condition 202 221	Good general health
18,T14,Observation 237 252	medical history
19,T15,Procedure 254 274	physical examination
20,T16,Procedure 279 304	laboratory determinations
21,T17,Negation 314 316	no
22,T18,Observation 317 357	signs of clinically significant findings
23,T19,Qualifier 326 348	clinically significant
24,R4,Has_qualifier Arg1:T18 Arg2:T19
25,T20,Subjective_judgement 326 348	clinically significant
26,T21,Condition 366 391	chronic atopic dermatitis
27,T22,Negation 359 365	except
28,R5,Has_negation Arg1:T18 Arg2:T17
29,R6,Has_negation Arg1:T21 Arg2:T22
30,R7,AND Arg1:T17 Arg2:T21
31,T23,"Qualifier 222 304	ascertained by medical history, physical examination and laboratory determinations"
32,R8,Has_qualifier Arg1:T13 Arg2:T23
33,T24,Measurement 402 416	pregnancy test
34,T25,Value 393 401	Negative
35,R9,Has_value Arg1:T24 Arg2:T25
36,T26,Condition 418 431	premenopausal
37,T27,Person 432 438	female
38,T28,Scope 418 438	premenopausal female
39,A1,Optional T28
40,R10,AND Arg1:T28 Arg2:T24
41,T29,Post-eligibility 393 596	Negative pregnancy test (premenopausal female patient) at screening and use of adequate contraceptive measures (both male and female patients) throughout the study and 30 days after the last cis-UCA dose
0,T1,Condition 61 68	colitis
1,T2,Observation 39 60	antibiotic-associated
2,T3,Observation 27 37	ulcerative
3,T4,Observation 12 25	indeterminate
4,R1,Has_context Arg1:T1 Arg2:T2
5,R2,Has_context Arg1:T1 Arg2:T3
6,R3,Has_context Arg1:T1 Arg2:T4
7,T5,Measurement 83 88	stool
8,T6,Value 89 105	positive for ova
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Value 110 118;89 101	parasite positive for
11,R5,Has_value Arg1:T5 Arg2:T7
12,T8,Value 127 155;89 101	Clostridium difficule toxins positive for
13,R6,Has_value Arg1:T5 Arg2:T8
14,T9,Temporal 156 177	within 3 months prior
15,T10,Reference_point 181 191	enrollment
16,R7,Has_index Arg1:T9 Arg2:T10
17,R8,Has_temporal Arg1:T5 Arg2:T9
18,T11,Context_Error 207 257	other known infectious cause of abdominal symptoms
19,T12,Condition 294 307	renal disease
20,T13,Temporal 308 330	with the past 6 months
21,R9,Has_temporal Arg1:T12 Arg2:T13
22,T14,Measurement 343 385	estimated glomerular filtration rate (GFR)
23,T15,Value 386 393	outside
24,T16,Reference_point 398 420	normal reference range
25,R10,Has_index Arg1:T15 Arg2:T16
26,R11,Has_value Arg1:T14 Arg2:T15
27,T17,Condition 453 475	intestinal obstruction
28,T18,Observation 442 449	history
29,R12,Has_temporal Arg1:T17 Arg2:T18
30,T19,Condition 487 507	obstructive symptoms
31,T20,Temporal 479 486	current
32,R13,Has_temporal Arg1:T19 Arg2:T20
33,*,OR T17 T19
34,T21,Condition 517 538	severe abdominal pain
35,T22,Condition 557 563	nausea
36,T23,Condition 567 575	vomiting
37,*,OR T22 T23
38,R14,Subsumes Arg1:T19 Arg2:T21
39,R15,Subsumes Arg1:T19 Arg2:T22
40,R16,Subsumes Arg1:T19 Arg2:T23
41,T24,Condition 638 651	gastroparesis
42,T25,Condition 655 666	small bowel
43,T26,Condition 670 693	large bowel dysmotility
44,*,OR T25 T26 T24
45,T27,Condition 723 734;746 755	small bowel resection
46,T28,Condition 738 755	colonic resection
47,*,OR T28 T27
48,T29,Observation 712 719	history
49,T30,Undefined_semantics 783 848	condition believed to have an increased risk of capsule retention
50,T31,Drug 936 973	non-steroidal anti-inflammatory drugs
51,T32,Drug 984 991	aspirin
52,T33,Multiplier 993 1011	two times per week
53,T34,Temporal 1013 1041	during the 4 weeks preceding
54,T35,Reference_point 1042 1052	enrollment
55,R17,Has_index Arg1:T34 Arg2:T35
56,R19,Subsumes Arg1:T31 Arg2:T32
57,R18,Has_multiplier Arg1:T31 Arg2:T33
58,R20,Has_temporal Arg1:T31 Arg2:T34
59,T36,Drug 1063 1070	aspirin
60,T37,Multiplier 1081 1095	< 100 mg daily
61,T38,Qualifier 1054 1062	Low dose
62,R21,Has_qualifier Arg1:T36 Arg2:T38
63,R22,Has_multiplier Arg1:T38 Arg2:T37
64,T39,Grammar_Error 1116 1132	not exclusionary
65,T40,Condition 1160 1169	condition
66,T41,Condition 1179 1198	swallowing problems
67,R23,Subsumes Arg1:T40 Arg2:T41
68,T42,Negation 1205 1214	precludes
69,T43,Informed_consent 1215 1236	compliance with study
70,T44,Informed_consent 1215 1230;1244 1263	compliance with device instructions
71,*,OR T44 T43
72,T45,Scope 1215 1263	compliance with study and/or device instructions
73,R24,Has_negation Arg1:T45 Arg2:T42
74,T46,"Scope 1160 1198	condition, such as swallowing problems"
75,R25,Subsumes Arg1:T46 Arg2:T45
76,T47,Device 1279 1296	cardiac pacemaker
77,T48,Device 1306 1337	implanted electromedical device
78,*,OR T47 T48
79,T49,Condition 1355 1362	allergy
80,T50,Condition 1378 1394	contraindication
81,T51,Drug 1402 1431	medications used in the study
82,*,OR T49 T50
83,T52,Scope 1355 1394	allergy or other known contraindication
84,R26,AND Arg1:T52 Arg2:T51
85,T53,Condition 1445 1453	pregnant
86,T54,Value 1471 1479	positive
87,T55,Measurement 1480 1494	pregnancy test
88,R27,Has_value Arg1:T55 Arg2:T54
89,T56,Qualifier 1502 1510	actively
90,T57,Temporal 1502 1510	actively
91,T58,Observation 1511 1525	breast-feeding
92,R28,Has_qualifier Arg1:T58 Arg2:T56
93,R29,multi Arg1:T56 Arg2:T57
94,R30,AND Arg1:T53 Arg2:T55
95,*,OR T53 T58
96,T59,Person 1558 1589	part of a vulnerable population
97,T60,Person 1595 1604	prisoners
98,T61,Condition 1614 1648	without sufficient mental capacity
99,*,OR T60 T61
100,T62,Scope 1595 1648	prisoners or those without sufficient mental capacity
101,R31,Subsumes Arg1:T59 Arg2:T62
102,T63,Condition 1672 1688	contraindication
103,T64,Procedure 1692 1695	MRE
104,T65,Procedure 1699 1701	IC
105,*,OR T64 T65
106,T66,Scope 1692 1701	MRE or IC
107,R32,Has_scope Arg1:T63 Arg2:T66
108,T67,Competing_trial 1704 1877	Subject has participated in a drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in the study.
109,T68,"Non-representable 1879 1993	Subject has any medical condition that would make it unsafe for them to participate, per Investigator's descretion"
0,T1,Person 0 3	Age
1,T2,Value 4 22	65 years and older
2,T3,Condition 24 36	Hypertension
3,T4,Qualifier 39 48	untreated
4,T5,Measurement 50 79	Systolic Blood Pressure (SBP)
5,T6,Value 80 91	≥ 140 mm Hg
6,T7,Measurement 95 125	Diastolic Blood Pressure (DBP)
7,T8,Value 126 136	≥ 90 mm Hg
8,*,OR T5 T7
9,R1,Has_value Arg1:T5 Arg2:T6
10,R2,Has_value Arg1:T7 Arg2:T8
11,T9,Scope 50 136	Systolic Blood Pressure (SBP) ≥ 140 mm Hg or Diastolic Blood Pressure (DBP) ≥ 90 mm Hg
12,R3,Subsumes Arg1:T3 Arg2:T9
13,R4,Has_qualifier Arg1:T3 Arg2:T4
14,T10,Qualifier 141 148	treated
15,*,OR T4 T10
16,T11,Parsing_Error 150 191	Physical limitations evidenced by either:
17,T12,Measurement 211 245	Short Physical Performance Battery
18,T13,Value 193 203	Score ≤ 10
19,R5,Has_value Arg1:T12 Arg2:T13
20,T14,Measurement 249 262	Walking speed
21,T15,Value 263 274	< 1.2 m/sec
22,T16,Procedure 282 304	400 m usual-paced test
23,R6,Has_value Arg1:T14 Arg2:T15
24,R7,AND Arg1:T14 Arg2:T16
25,*,OR T14 T12
26,T17,Condition 306 325	Sedentary lifestyle
27,T18,Value 338 349	<150 min/wk
28,T19,Measurement 353 379	moderate physical activity
29,T20,Procedure 395 415	CHAMPS questionnaire
30,R8,Has_value Arg1:T19 Arg2:T18
31,R9,AND Arg1:T19 Arg2:T20
32,*,OR T17 T19
33,T21,Non-query-able 417 467	Willingness to participate in all study procedures
0,T1,Person 0 5	Women
1,T2,Drug 22 33	Syntocinon®
2,T3,Procedure 22 42	Syntocinon® infusion
3,R1,multi Arg1:T3 Arg2:T2
4,T4,Procedure 47 66	induction of labour
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Procedure 84 100	cervical priming
7,T6,Drug 104 117	prostaglandin
8,R3,AND Arg1:T5 Arg2:T6
9,A1,Optional T5
10,R4,AND Arg1:T3 Arg2:T5
0,T1,Condition 0 11	Acutely ill
1,T2,Observation 12 24	hospitalised
2,T3,Person 25 33	children
3,T4,Mood 35 43	Need for
4,T5,Procedure 44 69	intravenous fluid therapy
5,R1,Has_mood Arg1:T5 Arg2:T4
0,T1,Condition 13 30	diabetes mellitus
1,T2,Qualifier 44 78	World Health Organization criteria
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Drug 96 103	insulin
4,T4,Procedure 81 90	treatment
5,T5,Drug 110 133	oral hypoglycemic agent
6,T6,Multiplier 135 140	twice
7,T7,Measurement 141 168	random glucose measurements
8,T8,Value 169 189	major than 200 mg/dl
9,T9,Measurement 196 211	fasting glucose
10,T10,Value 212 232	major than 140 mg/dl
11,R2,Has_value Arg1:T9 Arg2:T10
12,R3,Has_multiplier Arg1:T7 Arg2:T6
13,R4,Has_value Arg1:T7 Arg2:T8
14,*,OR T7 T9 T4
15,*,OR T3 T5
16,T11,Scope 96 133	insulin or an oral hypoglycemic agent
17,R5,Has_scope Arg1:T4 Arg2:T11
18,T12,"Scope 81 232	treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl"
19,T13,Scope 13 78	diabetes mellitus according to World Health Organization criteria
20,R6,Subsumes Arg1:T13 Arg2:T12
21,T14,Condition 235 240	Ulcer
22,T15,Qualifier 256 260	legs
23,T16,Qualifier 264 268	feet
24,T17,Measurement 270 275	stage
25,T18,Value 276 285	III or IV
26,R7,Has_value Arg1:T17 Arg2:T18
27,T19,Qualifier 287 315	Wagner Classification System
28,R8,Has_qualifier Arg1:T17 Arg2:T19
29,*,OR T15 T16
30,T20,Scope 256 268	legs or feet
31,R9,Has_scope Arg1:T14 Arg2:T20
32,*,OR T14 T17
33,T21,Informed_consent 318 416	The subject agrees to comply with study protocol requirements and all follow up visit requirements
0,T1,Person 0 3	Age
1,T2,Value 4 22	18 to 75 years old
2,T3,Person 24 28	male
3,T4,Person 32 38	female
4,*,OR T3 T4
5,R1,Has_value Arg1:T1 Arg2:T2
6,T5,Scope 24 38	male or female
7,R2,Has_scope Arg1:T1 Arg2:T5
8,T6,Qualifier 69 83	posterolateral
9,T7,Qualifier 56 65	posterior
10,*,OR T7 T6
11,T8,Condition 84 100	disc herniations
12,T9,Qualifier 104 131	one level between L1 and S1
13,T10,Procedure 137 149	radiographic
14,T11,Qualifier 137 162	radiographic confirmation
15,T12,Condition 166 184	neural compression
16,T13,Procedure 191 193	CT
17,T14,Procedure 201 204	MRI
18,*,OR T13 T14
19,T15,Scope 191 204	CT and/or MRI
20,R3,Has_scope Arg1:T12 Arg2:T15
21,R4,Has_qualifier Arg1:T8 Arg2:T9
22,R5,Has_qualifier Arg1:T8 Arg2:T11
23,T16,Scope 56 83	posterior or posterolateral
24,R6,Has_scope Arg1:T8 Arg2:T16
25,R7,AND Arg1:T11 Arg2:T12
26,T17,Multiplier 207 229	At least six (6) weeks
27,T18,Qualifier 233 239	failed
28,T19,Qualifier 241 253	conservative
29,T20,Procedure 254 263	treatment
30,T21,Temporal 264 280	prior to surgery
31,R8,Has_temporal Arg1:T20 Arg2:T21
32,R9,Has_multiplier Arg1:T20 Arg2:T17
33,R10,Has_qualifier Arg1:T20 Arg2:T19
34,R11,Has_qualifier Arg1:T20 Arg2:T18
35,T22,Procedure 304 311	surgery
36,T23,Condition 323 343	permanent disability
37,T24,Mood 315 322	prevent
38,R12,Has_mood Arg1:T23 Arg2:T24
39,R13,AND Arg1:T22 Arg2:T23
40,*,OR T20 T22
41,T25,Qualifier 294 303	immediate
42,R14,Has_qualifier Arg1:T22 Arg2:T25
43,T26,Measurement 354 375	posterior disc height
44,T27,Value 346 353;376 382	Minimum of 5mm
45,T28,Qualifier 390 404	index level(s)
46,R15,Has_qualifier Arg1:T26 Arg2:T28
47,R16,Has_value Arg1:T26 Arg2:T27
48,T29,Condition 407 422	Lower back pain
49,T30,Condition 430 438	sciatica
50,T31,Condition 455 474	spinal claudication
51,A1,Optional T31
52,*,OR T29 T30
53,T32,Scope 407 438	Lower back pain and/or sciatica
54,R17,AND Arg1:T32 Arg2:T31
55,T33,Measurement 477 505	Oswestry Questionnaire score
56,T34,Value 509 524	at least 40/100
57,T35,Temporal 525 536	at baseline
58,R18,Has_value Arg1:T33 Arg2:T34
59,R19,Has_temporal Arg1:T33 Arg2:T35
60,T36,Measurement 539 551	VAS leg pain
61,T37,Value 555 570	at least 40/100
62,T38,Temporal 571 582	at baseline
63,R20,Has_value Arg1:T36 Arg2:T37
64,R21,Has_temporal Arg1:T36 Arg2:T38
65,T39,"Post-eligibility 585 734	Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements."
0,T1,Measurement 0 42	American Society of Anesthesiologist (ASA)
1,T2,Value 43 54	status I-II
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 55 60	adult
4,T4,Qualifier 81 89	elective
5,T5,Procedure 90 118	laparoscopic cholecystectomy
6,R2,Has_qualifier Arg1:T5 Arg2:T4
0,T1,Condition 0 17	Spondylolisthesis
1,T2,Measurement 18 23	Grade
2,T3,Value 24 36	II or higher
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Qualifier 63 72	bilateral
6,T5,Procedure 73 84	facetectomy
7,T6,Qualifier 56 59	uni
8,*,OR T6 T4
9,T7,Condition 98 107	back pain
10,T8,Condition 103 107;94 97	pain leg
11,*,OR T8 T7
12,T9,Scope 56 72	uni or bilateral
13,R3,Has_scope Arg1:T5 Arg2:T9
14,T10,Scope 94 107	leg/back pain
15,R4,Has_scope Arg1:T5 Arg2:T10
16,T11,Condition 130 152	non-radicular leg pain
17,T12,Condition 122 126;148 152	back pain
18,T13,Qualifier 156 172	unknown etiology
19,*,OR T12 T11
20,T14,Scope 122 152	back or non-radicular leg pain
21,R5,Has_qualifier Arg1:T14 Arg2:T13
22,T15,Procedure 181 188	surgery
23,T16,Qualifier 196 214	index lumbar level
24,T17,Temporal 175 180	Prior
25,R6,Has_temporal Arg1:T15 Arg2:T17
26,R7,Has_qualifier Arg1:T15 Arg2:T16
27,T18,Procedure 237 247	spine DEXA
28,T19,Measurement 269 274	SCORE
29,T20,Value 278 281	= 6
30,R8,Has_value Arg1:T19 Arg2:T20
31,T21,Measurement 290 297	T Score
32,T22,Value 298 312	less than -2.0
33,T23,Qualifier 320 331	index level
34,R9,Has_value Arg1:T21 Arg2:T22
35,R10,Subsumes Arg1:T18 Arg2:T19
36,T24,Mood 225 234	requiring
37,R11,Has_mood Arg1:T18 Arg2:T24
38,R12,Has_qualifier Arg1:T21 Arg2:T23
39,T25,Condition 353 363	herniation
40,T26,Qualifier 367 372	L5/S1
41,R13,Has_qualifier Arg1:T25 Arg2:T26
42,T27,Measurement 378 393	average T score
43,T28,Qualifier 397 402	L1-L4
44,R14,Has_qualifier Arg1:T27 Arg2:T28
45,T29,Non-representable 403 416	shall be used
46,R15,AND Arg1:T27 Arg2:T29
47,T30,Scope 353 372	herniation at L5/S1
48,A1,Optional T30
49,R16,AND Arg1:T30 Arg2:T27
50,R17,AND Arg1:T18 Arg2:T21
51,T31,Condition 431 470	clinically compromised vertebral bodies
52,T32,Qualifier 478 492	index level(s)
53,T33,Condition 541 561	infectious pathology
54,T34,Condition 527 536;552 561	metabolic pathology
55,T35,Condition 515 525;552 561	neoplastic pathology
56,T36,Condition 504 513;552 561	traumatic pathology
57,*,OR T34 T35 T33 T36
58,T37,"Scope 504 561	traumatic, neoplastic, metabolic, or infectious pathology"
59,R18,Has_qualifier Arg1:T31 Arg2:T32
60,R19,Has_scope Arg1:T31 Arg2:T37
61,T38,Condition 597 622	fractures of the vertebra
62,T39,Multiplier 626 634	multiple
63,T40,Condition 635 660	fractures of the vertebra
64,T41,Condition 635 651;664 667	fractures of the hip
65,*,OR T41 T40
66,T42,Scope 635 667	fractures of the vertebra or hip
67,R20,Has_multiplier Arg1:T42 Arg2:T39
68,T43,Qualifier 586 596	pathologic
69,R21,Has_qualifier Arg1:T38 Arg2:T43
70,*,OR T38 T42
71,T44,Condition 682 691	scoliosis
72,T45,Qualifier 695 724	greater than ten (10) degrees
73,R22,Has_qualifier Arg1:T44 Arg2:T45
74,T46,Qualifier 731 738	angular
75,T47,Qualifier 743 753	rotational
76,*,OR T46 T47
77,T48,Scope 731 753	angular and rotational
78,R23,Has_scope Arg1:T44 Arg2:T48
79,T49,Condition 761 778	metabolic disease
80,T50,Observation 805 820	been stabilized
81,T51,Temporal 821 846	for at least three months
82,T52,Condition 854 869	Paget's disease
83,T53,Condition 871 883	osteomalacia
84,T54,Condition 885 908	osteogenesis imperfecta
85,T55,Condition 910 917	thyroid
86,T56,Condition 925 951	parathyroid gland disorder
87,*,OR T55 T56 T52 T53 T54
88,T57,"Scope 854 951	Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder"
89,T58,Negation 801 804	not
90,R24,Has_negation Arg1:T50 Arg2:T58
91,T59,Condition 779 791	bone disease
92,*,OR T49 T59
93,T60,Scope 761 791	metabolic disease bone disease
94,R25,Has_context Arg1:T60 Arg2:T50
95,R26,Has_temporal Arg1:T50 Arg2:T51
96,R27,Subsumes Arg1:T60 Arg2:T57
97,T61,Condition 983 992	infection
98,T62,Qualifier 976 982	active
99,T63,Qualifier 1000 1008	systemic
100,T64,Qualifier 1012 1017	local
101,*,OR T63 T64
102,T65,Scope 1000 1017	systemic or local
103,R28,Has_scope Arg1:T61 Arg2:T65
104,R29,Has_qualifier Arg1:T61 Arg2:T62
105,T66,Condition 1032 1053	cauda equina syndrome
106,T67,Condition 1057 1073;1082 1093	neurogenic bowel dysfunction
107,T68,Condition 1057 1067;1074 1093	neurogenic bladder dysfunction
108,*,OR T67 T68 T66
109,T69,Qualifier 1108 1114	severe
110,T70,Condition 1115 1137	arterial insufficiency
111,T71,Qualifier 1145 1149	legs
112,R30,Has_qualifier Arg1:T70 Arg2:T71
113,R31,Has_qualifier Arg1:T70 Arg2:T69
114,T72,Condition 1200 1239	diminution or absence of dorsalis pedis
115,T73,Condition 1200 1224;1243 1268	diminution or absence of posterior tibialis pulses
116,*,OR T73 T72
117,T74,Procedure 1316 1335	arterial ultrasound
118,T75,Procedure 1353 1377	vascular plethysmography
119,R32,Subsumes Arg1:T74 Arg2:T75
120,T76,Measurement 1386 1412	absolute arterial pressure
121,T77,Value 1416 1432	below 50mm of Hg
122,T78,Qualifier 1440 1444;1454 1459	calf level
123,T79,Qualifier 1448 1459	ankle level
124,*,OR T79 T78
125,T80,Scope 1440 1459	calf or ankle level
126,R33,Has_value Arg1:T76 Arg2:T77
127,R34,Has_scope Arg1:T76 Arg2:T80
128,T81,Procedure 1297 1306	palpation
129,T82,Observation 1273 1283	diminished
130,T83,Observation 1287 1293	absent
131,*,OR T83 T82
132,T84,Scope 1273 1293	diminished or absent
133,R35,Has_scope Arg1:T81 Arg2:T84
134,T85,Condition 1506 1533	peripheral vascular disease
135,T86,Scope 1273 1306	diminished or absent by palpation
136,A2,Optional T86
137,R36,AND Arg1:T86 Arg2:T74
138,T87,Procedure 1151 1184	Screening on physical examination
139,T88,Scope 1200 1268	diminution or absence of dorsalis pedis or posterior tibialis pulses
140,A3,Optional T88
141,R37,AND Arg1:T88 Arg2:T87
142,R38,Has_scope Arg1:T87 Arg2:T86
143,T89,Negation 1487 1495	excluded
144,T90,Scope 1386 1459	absolute arterial pressure is below 50mm of Hg at the calf or ankle level
145,A4,Optional T90
146,R39,Has_negation Arg1:T90 Arg2:T89
147,*,OR T86 T90 T85
148,T91,Qualifier 1549 1560	significant
149,T92,Condition 1561 1582	peripheral neuropathy
150,R40,Has_qualifier Arg1:T92 Arg2:T91
151,T93,Qualifier 1628 1635	Type II
152,T94,Qualifier 1618 1624	Type I
153,T95,Condition 1636 1644	diabetes
154,*,OR T94 T93
155,T96,Scope 1618 1635	Type I or Type II
156,R41,Has_scope Arg1:T95 Arg2:T96
157,T97,Condition 1656 1684	systemic metabolic condition
158,T98,Qualifier 1648 1655	similar
159,R42,Has_qualifier Arg1:T97 Arg2:T98
160,*,OR T95 T97
161,T99,Condition 1693 1712	decreased sensation
162,T100,Qualifier 1718 1731;1768 1780	stocking-like distribution
163,T101,Qualifier 1735 1748;1768 1780	non-radicular distribution
164,T102,Qualifier 1753 1780	non-dermatomal distribution
165,*,OR T100 T101 T102
166,T103,Qualifier 1788 1805	lower extremities
167,T104,Scope 1718 1780	stocking-like or non-radicular and non-dermatomal distribution
168,R43,Has_scope Arg1:T99 Arg2:T104
169,R44,Has_qualifier Arg1:T99 Arg2:T103
170,T105,Qualifier 1820 1837	insulin-dependent
171,T106,Condition 1838 1855	diabetes mellitus
172,R45,Has_qualifier Arg1:T106 Arg2:T105
173,T107,Condition 1869 1883	morbidly obese
174,T108,Measurement 1898 1913	body mass index
175,T109,Value 1914 1917	>40
176,R46,Has_value Arg1:T108 Arg2:T109
177,T110,Measurement 1922 1928	weighs
178,T111,Value 1929 1969	more than 100 lbs over ideal body weight
179,R47,Has_value Arg1:T110 Arg2:T111
180,*,OR T108 T110
181,T112,"Scope 1898 1969	body mass index >40, or weighs more than 100 lbs over ideal body weight"
182,R48,Subsumes Arg1:T107 Arg2:T112
183,T113,Condition 2012 2021	hepatitis
184,T114,Condition 2023 2027	AIDS
185,T115,Condition 2032 2035	HIV
186,*,OR T114 T115 T113
187,T116,"Scope 2012 2035	hepatitis, AIDS, or HIV"
188,T117,Qualifier 2005 2011	active
189,R49,Has_qualifier Arg1:T116 Arg2:T117
190,T118,Condition 2070 2090	rheumatoid arthritis
191,T119,Qualifier 2094 2099	other
192,T120,Condition 2100 2118	autoimmune disease
193,R50,Has_qualifier Arg1:T120 Arg2:T119
194,*,OR T118 T120
195,T121,Drug 2152 2160	titanium
196,T122,Drug 2162 2174	polyethylene
197,T123,Drug 2178 2187	polyester
198,*,OR T122 T123 T121
199,T124,Condition 2141 2148	allergy
200,T125,"Scope 2152 2187	titanium, polyethylene or polyester"
201,R51,Has_scope Arg1:T124 Arg2:T125
202,T126,Condition 2211 2219	pregnant
203,T127,Mood 2223 2245	interested in becoming
204,T128,Condition 2246 2254	pregnant
205,R52,Has_mood Arg1:T128 Arg2:T127
206,*,OR T126 T128
207,T129,Temporal 2255 2280	in the next two (2) years
208,T130,Scope 2211 2254	pregnant or interested in becoming pregnant
209,R53,Has_temporal Arg1:T130 Arg2:T129
210,T131,Condition 2302 2314	tuberculosis
211,T132,Condition 2326 2338	tuberculosis
212,T133,Temporal 2339 2366	in the past three (3) years
213,*,OR T132 T133 T131
214,T134,Condition 2454 2464	malignancy
215,T135,Condition 2473 2497	non-melanoma skin cancer
216,T136,Qualifier 2445 2453	invasive
217,R54,Has_qualifier Arg1:T134 Arg2:T136
218,T137,Condition 2523 2551	treated with curative intent
219,T138,Negation 2572 2574	no
220,T139,Condition 2575 2610	signs or symptoms of the malignancy
221,T140,Temporal 2611 2637	for at least two (2) years
222,R55,Has_temporal Arg1:T139 Arg2:T140
223,R56,Has_negation Arg1:T139 Arg2:T138
224,T141,Scope 2523 2637	treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years
225,T142,Negation 2466 2472	except
226,R57,Has_negation Arg1:T135 Arg2:T142
227,R58,AND Arg1:T134 Arg2:T135
228,*,OR T134 T141
229,T143,Condition 2394 2411	active malignancy
230,T144,Observation 2383 2390	history
231,R59,Has_temporal Arg1:T143 Arg2:T144
232,T145,"Scope 2445 2637	invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years"
233,T146,Scope 2383 2411	history of active malignancy
234,R60,Subsumes Arg1:T146 Arg2:T141
235,T147,Condition 2651 2677	immunologically suppressed
236,T148,Drug 2688 2696	steroids
237,T149,Multiplier 2697 2705	>1 month
238,T150,Temporal 2706 2724	over the past year
239,R61,Has_multiplier Arg1:T148 Arg2:T149
240,R62,Has_temporal Arg1:T148 Arg2:T150
241,*,OR T147 T148
242,T151,Drug 2744 2758	anticoagulants
243,T152,Drug 2771 2778	aspirin
244,T153,Negation 2760 2770	other than
245,R63,Has_negation Arg1:T152 Arg2:T153
246,R64,AND Arg1:T151 Arg2:T152
247,T154,Non-representable 2780 2845	unless the patient can be taken off the anticoagulant for surgery
248,T155,Condition 2879 2897	alcohol dependency
249,T156,Condition 2870 2878;2887 2897	chemical dependency
250,T157,Condition 2913 2937	psychosocial disturbance
251,T158,Qualifier 2901 2912	significant
252,R65,Has_qualifier Arg1:T157 Arg2:T158
253,*,OR T156 T155 T157
254,T159,Observation 2954 2969	life expectancy
255,T160,Value 2973 2998	less than three (3) years
256,R66,Has_value Arg1:T159 Arg2:T160
257,T161,Competing_trial 3001 3065	Subject is currently involved in another investigational study.
258,T162,Competing_trial 3001 3064	Subject is currently involved in another investigational study.
259,T163,Observation 3077 3089	incarcerated
0,T1,Qualifier 0 12	Uncontrolled
1,T2,Condition 13 21	diabetes
2,T4,Condition 23 38	Ulcer infection
3,T3,Qualifier 40 52	Non-diabetic
4,T5,Condition 53 59	ulcers
5,R1,Has_qualifier Arg1:T5 Arg2:T3
6,T6,Condition 60 70;88 109	Orthopedic pathologic conditions
7,T7,Condition 74 109	neuromuscular pathologic conditions
8,*,OR T6 T7
9,T8,Line 60 109	Orthopedic or neuromuscular pathologic conditions
10,T9,Line 40 59	Non-diabetic ulcers
0,T1,Procedure 0 12	Open surgery
1,T2,Condition 24 32	allergic
2,T3,Drug 36 45	lidocaine
3,T4,Drug 55 72	local anesthetics
4,T5,Qualifier 49 54	other
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,*,OR T3 T4
7,T6,Scope 36 72	lidocaine or other local anesthetics
8,R2,Has_scope Arg1:T2 Arg2:T6
9,T7,Condition 75 86	Drug abuser
0,T1,Person 0 5	Adult
1,T2,Value 16 36	18years old or older
2,T3,Person 18 23	years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Scope 16 36	18years old or older
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Procedure 49 61;80 101	living-donor liver transplantation
7,T6,Procedure 65 101	deceased-donor liver transplantation
8,*,OR T5 T6
0,T1,Condition 0 9	full term
1,T2,Qualifier 11 20	singleton
2,T3,Condition 21 29	pregnant
3,T4,Person 30 35	women
4,T5,Qualifier 51 59	elective
5,T6,Procedure 60 77	cesarean delivery
6,T7,Mood 37 50	scheduled for
7,R1,Has_mood Arg1:T6 Arg2:T7
8,R2,Has_qualifier Arg1:T6 Arg2:T5
0,T1,Condition 13 39	sleep disordered breathing
1,T2,Condition 43 66	obstructive sleep apnea
2,*,OR T1 T2
3,T3,Person 68 76	Children
4,T4,Qualifier 88 96	elective
5,T5,Procedure 97 110	tonsillectomy
6,T6,Procedure 114 132	adenotonsillectomy
7,*,OR T5 T6
8,T7,Scope 97 132	tonsillectomy or adenotonsillectomy
9,T8,Visit 136 177	Children's Healthcare of Atlanta Egleston
10,R1,AND Arg1:T7 Arg2:T8
11,R2,Has_qualifier Arg1:T7 Arg2:T4
12,T9,"Informed_consent 188 298	Parent or legal guardian willing to participate, and able to understand and sign the provided informed consent"
0,T1,Condition 19 38	atrial fibrillation
1,T2,Value 40 54	above 18 years
2,T3,Person 49 54	years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Measurement 65 68	TTR
5,T5,Value 69 73	<50%
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Qualifier 74 111	based on the last three values of INR
8,R3,Has_qualifier Arg1:T4 Arg2:T6
0,T1,Person 0 7	Females
1,T2,Value 8 19	18-65 years
2,T3,Person 20 23	old
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Procedure 39 66	colposcopic directed biopsy
5,T5,Temporal 28 38	undergoing
6,R2,Has_temporal Arg1:T4 Arg2:T5
0,T1,Condition 0 19	Cardiac morbidities
1,T2,Condition 21 56	hypertensive disorders of pregnancy
2,T3,Condition 58 77	peripartum bleeding
3,T4,Temporal 79 87	baseline
4,T5,Measurement 88 111	systolic blood pressure
5,T6,Measurement 113 116	SBP
6,R1,Subsumes Arg1:T5 Arg2:T6
7,T7,Value 118 128	< 100 mmHg
8,R2,Has_value Arg1:T5 Arg2:T7
9,R3,Has_temporal Arg1:T5 Arg2:T4
10,T8,Measurement 130 145	body mass index
11,T9,Value 146 150	> 35
12,R4,Has_value Arg1:T8 Arg2:T9
0,T1,"Non-query-able 0 86	Children born outside the cluster, and returning more than 72 hours after the delivery"
1,T2,Non-query-able 88 154	Children that the nurse evaluates to die within the next 24 hours.
0,T1,Person 0 9	Pediatric
1,T2,Value 20 34	under 18 years
2,T3,Person 29 34	years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Scope 20 34	under 18 years
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,"Line 46 169	Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine"
7,T6,Line 0 35	Pediatric patients (under 18 years)
8,T7,Condition 36 45	Pregnancy
9,T8,Line 36 45	Pregnancy
10,T9,Observation 63 75	unresponsive
11,T10,Temporal 76 87	at baseline
12,T11,Condition 98 117	neurologic deficits
13,T12,Temporal 118 129	at baseline
14,T13,Condition 142 150	allergic
15,T14,Drug 154 169	dexmedetomidine
16,R3,AND Arg1:T13 Arg2:T14
17,R4,Has_temporal Arg1:T11 Arg2:T12
18,R5,Has_temporal Arg1:T9 Arg2:T10
19,*,OR T9 T11 T13
0,T1,Condition 6 24	coagulation defect
1,T2,Procedure 51 64	NSAID therapy
2,T3,Temporal 38 50	longstanding
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,T4,Condition 72 88	renal impairment
5,T5,Non-query-able 90 157	Patients may also be excluded at the discretion of the investigator
0,T1,Condition 8 15	allergy
1,T2,Drug 19 28	Celecoxib
2,T3,Drug 30 37	aspirin
3,T4,Drug 49 54	NSAID
4,T5,Qualifier 41 48	another
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,*,OR T2 T3 T4
7,T6,"Scope 19 54	Celecoxib, aspirin or another NSAID"
8,R2,Has_scope Arg1:T1 Arg2:T6
9,T7,Temporal 57 63	Active
10,T8,Condition 64 81	peptic ulceration
11,T9,Condition 85 110	gastrointestinal bleeding
12,*,OR T8 T9
13,T10,Scope 64 110	peptic ulceration or gastrointestinal bleeding
14,R3,Has_temporal Arg1:T10 Arg2:T7
15,T11,Condition 113 139	Inflammatory bowel disease
16,T12,Condition 142 166	Congestive heart failure
17,T13,Measurement 168 172	NYHA
18,T14,Value 173 178	II-IV
19,R4,Has_value Arg1:T13 Arg2:T14
20,T15,Scope 168 178	NYHA II-IV
21,R5,Has_scope Arg1:T12 Arg2:T15
22,T16,Condition 194 216	ischemic heart disease
23,T17,Condition 218 245	peripheral arterial disease
24,T18,Condition 253 276	cerebrovascular disease
25,*,OR T17 T18 T16
26,T19,Condition 290 308	neurologic deficit
27,T20,Observation 279 286	History
28,R6,Has_temporal Arg1:T19 Arg2:T20
29,T21,Condition 328 344	renal impairment
30,T22,Condition 317 324;334 344	hepatic impairment
31,*,OR T21 T22
32,T23,Condition 347 356	Pregnancy
33,T24,Observation 359 373	Breast-feeding
34,T25,Procedure 381 393	hysterectomy
35,T26,Temporal 376 380	Post
36,R7,Has_temporal Arg1:T25 Arg2:T26
37,T27,Condition 396 414	Bleeding disorders
38,T28,Condition 417 427	Drug abuse
39,T29,Condition 430 438;451 460	Cervical infection
40,T30,Condition 443 460	vaginal infection
41,*,OR T30 T29
0,T1,Multiplier 53 64	stable dose
1,T2,Drug 68 76	warfarin
2,R1,Has_multiplier Arg1:T2 Arg2:T1
3,T3,Condition 78 95	liver dysfunction
4,T4,Condition 97 107	alcoholism
5,T5,Qualifier 116 123	another
6,T6,Drug 124 137	anticoagulant
7,T7,Procedure 146 158	chemotherapy
8,T8,Post-eligibility 163 205	if they do not meet the inclusion criteria
9,R2,Has_qualifier Arg1:T6 Arg2:T5
10,*,OR T4 T3 T2 T6 T7
0,T1,Qualifier 0 9	DSM-IV-TR
1,T2,Condition 10 37	substance-related disorders
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Drug 46 54	nicotine
4,T4,Negation 39 45	except
5,R2,Has_negation Arg1:T3 Arg2:T4
6,R3,AND Arg1:T2 Arg2:T3
7,T5,Post-eligibility 57 103	significant medical or neurological conditions
8,T6,Condition 105 123	mental retardation
9,T7,Condition 127 147	organic brain damage
10,*,OR T6 T7
0,T1,Person 0 5	Women
1,T2,Procedure 14 33	medication abortion
2,T3,Temporal 34 59	through 70 days gestation
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,T4,Drug 74 85	Mifeprex(r)
5,T5,Mood 61 73	Eligible for
6,T6,Visit 91 110	study clinical site
7,R2,Has_mood Arg1:T4 Arg2:T5
8,R3,AND Arg1:T4 Arg2:T6
9,T7,Observation 112 119;131 139	English speaking
10,T8,Observation 123 139	Spanish speaking
11,*,OR T7 T8
12,T9,Observation 141 185	Willing and able to participate in the study
13,T10,Observation 197 232	willing to go to the study pharmacy
14,T11,Drug 243 255	mifepristone
15,R4,AND Arg1:T10 Arg2:T11
16,T12,Mood 233 242	to obtain
17,R5,Has_mood Arg1:T11 Arg2:T12
0,T1,Procedure 0 17	bariatric surgery
1,T2,Procedure 41 65	roux-en-y gastric bypass
2,T3,Qualifier 28 40	laparoscopic
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Device 74 97	EEA stapler anastomosis
0,T1,Observation 0 14	Revision cases
1,T2,Qualifier 16 28	Uncontrolled
2,T3,Condition 29 46	bleeding tendency
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,T4,Measurement 48 59	prothrombin
5,T5,Value 66 79	Less than 70%
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 93 115	deep venous thrombosis
8,T7,Observation 82 89	History
9,R3,Has_temporal Arg1:T6 Arg2:T7
10,T8,Qualifier 117 122	Sever
11,T9,Condition 123 139	liver impairment
12,T10,Condition 141 154	liver failure
13,R4,Subsumes Arg1:T9 Arg2:T10
14,R5,Has_qualifier Arg1:T9 Arg2:T8
15,T11,Qualifier 157 162	Sever
16,T12,Condition 163 179	renal impairment
17,T13,Measurement 184 194	creatinine
18,T14,Value 195 206	more than 3
19,R6,Has_value Arg1:T13 Arg2:T14
20,R7,Has_qualifier Arg1:T12 Arg2:T11
21,T15,Scope 184 206	creatinine more than 3
22,T16,Scope 157 179	Sever renal impairment
23,R8,Subsumes Arg1:T16 Arg2:T15
0,T1,Condition 30 51	arterial hypertension
1,T2,Qualifier 14 29	poor-controlled
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Measurement 53 76	systolic blood pressure
4,T4,Value 76 86	> 140 mmHg
5,T5,Measurement 91 115	diastolic blood pressure
6,T6,Value 116 126	> 90 mm Hg
7,R2,Has_value Arg1:T3 Arg2:T4
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Scope 53 126	systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg
10,R4,Has_scope Arg1:T1 Arg2:T7
11,T8,Condition 165 187	Coronary heart disease
12,T9,Qualifier 188 208	greater than ClassII
13,R5,Has_qualifier Arg1:T8 Arg2:T9
14,T10,Condition 219 229	arrhythmia
15,T11,Qualifier 210 218	II-level
16,R6,Has_qualifier Arg1:T10 Arg2:T11
17,T12,Qualifier 0 8	Subjects
18,T13,Condition 241 265	QT interval prolongation
19,T14,Condition 328 347	cardiac dysfunction
20,T15,Qualifier 319 327	Class II
21,R7,Has_qualifier Arg1:T14 Arg2:T15
22,R8,Subsumes Arg1:T10 Arg2:T13
23,*,OR T1 T8 T16
24,T16,"Scope 210 347	II-level arrhythmia (including QT interval prolongation, for man = 450 ms, for woman = 470 ms) together with Class II cardiac dysfunction"
25,T17,Condition 412 432	inability to swallow
26,T18,Condition 434 450	chronic diarrhea
27,T19,Condition 455 477	intestinal obstruction
28,*,OR T17 T18 T19
29,T20,Observation 500 530	gastrointestinal bleeding risk
30,T21,Qualifier 495 499	high
31,R9,Has_qualifier Arg1:T20 Arg2:T21
32,T22,Condition 581 594	ulcer lesions
33,T23,Qualifier 574 580	active
34,R10,Has_qualifier Arg1:T22 Arg2:T23
35,T24,Measurement 609 632	fecal occult blood test
36,T25,Value 600 608	positive
37,T26,Value 634 636	++
38,R11,Has_value Arg1:T24 Arg2:T25
39,T27,Condition 650 661	black stool
40,T28,Condition 666 680	vomiting blood
41,T29,Temporal 688 701	past 3 months
42,*,OR T27 T28
43,T30,"Scope 650 680	black stool, or vomiting blood"
44,R13,Has_temporal Arg1:T30 Arg2:T29
45,T31,Condition 713 727	primary lesion
46,T32,Qualifier 731 738	stomach
47,R14,Has_qualifier Arg1:T31 Arg2:T32
48,T33,Measurement 753 776	fecal occult blood test
49,T34,Value 744 752	positive
50,T35,Value 778 779	+
51,R12,Subsumes Arg1:T25 Arg2:T26
52,R15,Subsumes Arg1:T34 Arg2:T35
53,R16,Has_value Arg1:T33 Arg2:T34
54,T36,Condition 782 809	ulcerated gastric carcinoma
55,T37,Qualifier 823 839	alimentary tract
56,T38,Qualifier 815 822	massive
57,T39,Observation 840 853	bleeding risk
58,R17,Has_qualifier Arg1:T39 Arg2:T37
59,R18,Has_qualifier Arg1:T39 Arg2:T38
60,R19,Has_context Arg1:T36 Arg2:T39
61,*,OR T36 T31 T30 T22
62,R20,AND Arg1:T31 Arg2:T33
63,R21,AND Arg1:T22 Arg2:T24
64,T40,"Scope 568 901	local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 3 months;unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy result"
65,R22,Subsumes Arg1:T20 Arg2:T40
66,T41,Condition 904 924	Abnormal Coagulation
67,T42,Measurement 926 929	INR
68,T43,Value 929 933	>1.5
69,R23,Has_value Arg1:T42 Arg2:T43
70,T44,Measurement 941 945	APTT
71,T45,Value 945 953	>1.5 UNL
72,R24,Has_value Arg1:T44 Arg2:T45
73,*,OR T42 T44
74,T46,Condition 961 978	tendency of bleed
75,T47,Scope 926 953	INR>1.5<U+3001>APTT>1.5 UNL
76,R25,Has_scope Arg1:T41 Arg2:T47
77,R26,AND Arg1:T41 Arg2:T46
78,T48,Condition 1026 1036;997 1000	metastases CNS
79,T49,Pregnancy_considerations 1039 1066	Pregnant or lactating women
80,T50,Non-query-able 1069 1125	Other conditions regimented at investigators' discretion
0,T1,Condition 4 12	pregnant
1,T2,Procedure 26 45	medication abortion
2,T3,Person 57 60	age
3,T4,Value 47 52;64 66	Under 15
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Condition 68 85	Contraindications
6,T6,Procedure 90 109	medication abortion
7,R2,AND Arg1:T5 Arg2:T6
0,T1,Qualifier 0 9	DSM-IV-TR
1,T2,Condition 10 35	major depressive disorder
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Person 37 41	aged
4,T4,Value 42 59	between 20 and 80
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Drug 61 65	durg
7,T6,Negation 66 71	naive
8,T7,Drug 75 79	drug
9,T8,Negation 80 84	free
10,R3,Has_negation Arg1:T7 Arg2:T8
11,R4,Has_negation Arg1:T5 Arg2:T6
12,*,OR T5 T7
0,T1,Qualifier 0 7	Primary
1,T2,Condition 8 30	total hip arthroplasty
2,T3,Condition 32 35	THA
3,R1,Subsumes Arg1:T2 Arg2:T3
4,R2,Has_qualifier Arg1:T2 Arg2:T1
0,T1,Person 0 3	age
1,T2,Value 4 13	<18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Observation 24 31	history
4,T4,Procedure 35 59	roux-en-y gastric bypass
5,R2,Has_temporal Arg1:T4 Arg2:T3
6,T5,Temporal 15 23	previous
7,R3,Has_temporal Arg1:T4 Arg2:T5
8,T6,Procedure 87 107	bariatric procedures
9,T7,Qualifier 81 86	other
10,R4,Has_qualifier Arg1:T6 Arg2:T7
11,T8,Temporal 70 80	undergoing
12,R5,Has_temporal Arg1:T6 Arg2:T8
13,T9,Temporal 109 122	pre-operative
14,T10,Drug 123 140	opioid analgesics
15,R6,Has_temporal Arg1:T10 Arg2:T9
0,T1,Person 0 3	Age
1,T2,Value 5 22	18 to75 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 55 78	advanced gastric cancer
4,T4,Condition 90 104	adenocarcinoma
5,T5,Qualifier 112 137	gastroesophageal junction
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,R3,Subsumes Arg1:T3 Arg2:T4
8,T6,Condition 155 165	metastases
9,T7,Negation 166 173	outside
10,T8,Qualifier 178 185	stomach
11,R4,Has_qualifier Arg1:T6 Arg2:T8
12,R5,Has_negation Arg1:T8 Arg2:T7
13,*,OR T3 T6
14,T9,Multiplier 347 359	at least two
15,T10,Procedure 366 378	chemotherapy
16,R6,Has_multiplier Arg1:T10 Arg2:T9
17,T11,Qualifier 264 271	Failure
18,R7,Has_qualifier Arg1:T10 Arg2:T11
19,T12,Measurement 390 397	ECOG PS
20,T13,Value 401 404	0-2
21,R8,Has_value Arg1:T12 Arg2:T13
22,T14,Measurement 407 409	HB
23,T15,Value 410 419	= 90g / L
24,R9,Has_value Arg1:T14 Arg2:T15
25,T16,Measurement 421 424	ANC
26,T17,Value 425 440	= 1.5 × 109 / L
27,R10,Has_value Arg1:T16 Arg2:T17
28,T18,Measurement 442 445	PLT
29,T19,Value 446 460	= 80 × 109 / L
30,R11,Has_value Arg1:T18 Arg2:T19
31,T20,Measurement 462 471	Bilirubin
32,T21,Value 472 509	<1.25 times the upper limit of normal
33,R12,Has_value Arg1:T20 Arg2:T21
34,T22,Measurement 517 520	ALT
35,T23,Measurement 525 528	AST
36,T24,Value 529 539	<2.5 × ULN
37,R13,Has_value Arg1:T23 Arg2:T24
38,R14,Has_value Arg1:T22 Arg2:T24
39,T25,Condition 541 557	liver metastases
40,T26,Measurement 571 574	ALT
41,T27,Measurement 579 582	AST
42,T28,Value 582 590	<5 × ULN
43,T29,Scope 571 582	ALT and AST
44,R15,Has_value Arg1:T29 Arg2:T28
45,R16,Has_scope Arg1:T25 Arg2:T29
46,T30,Measurement 592 600	Serum Cr
47,T31,Value 601 610	= 1 × ULN
48,R17,Has_value Arg1:T30 Arg2:T31
49,T32,Measurement 611 642	endogenous creatinine clearance
50,T33,Value 642 651	>50ml/min
51,R18,Has_value Arg1:T32 Arg2:T33
52,*,OR T30 T32
53,T34,Observation 682 699	expected survival
54,T35,Value 703 713	= 3 months
55,R19,Has_value Arg1:T34 Arg2:T35
56,T36,Drug 733 741	apatinib
57,T37,Informed_consent 791 882	Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
58,T38,"Pregnancy_considerations 884 1357	Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug"
0,T1,Post-eligibility 0 85	Ability to understand and the willingness to sign a written informed consent document
1,T2,Person 87 90	Age
2,T3,Value 90 108	= 18 and= 75 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 190 213	Squamous-cell carcinoma
5,T5,Qualifier 179 189	Oropharynx
6,T6,Qualifier 174 178	Oral
7,*,OR T5 T6
8,T7,Scope 174 189	Oral/Oropharynx
9,R2,Has_scope Arg1:T4 Arg2:T7
10,T8,Qualifier 215 221	Tongue
11,T9,Qualifier 223 236	buccal mucosa
12,T10,Qualifier 238 249	mouth floor
13,T11,Qualifier 251 262	hard palate
14,T12,Qualifier 264 274	Molar area
15,*,OR T8 T9 T10 T11 T12
16,T13,"Scope 215 274	Tongue, buccal mucosa, mouth floor, hard palate, Molar area"
17,R3,Subsumes Arg1:T7 Arg2:T13
18,T14,Measurement 281 298	depth of invasion
19,T15,Value 299 304	> 4mm
20,R4,Has_value Arg1:T14 Arg2:T15
21,T16,Procedure 308 331	preoperative assessment
22,R5,AND Arg1:T16 Arg2:T14
23,R6,AND Arg1:T4 Arg2:T16
24,T17,Procedure 110 118;155 166	Clinical examination
25,T18,Procedure 120 132;155 166	Histological examination
26,T19,Procedure 134 145;155 166	cytological examination
27,T20,Procedure 147 166	Imaging examination
28,*,OR T17 T18 T20 T19
29,T21,Scope 110 166	Clinical/ Histological/ cytological/ Imaging examination
30,R7,Has_scope Arg1:T4 Arg2:T21
31,T22,Procedure 412 430	surgical resection
32,T23,Condition 346 362	clinical stage I
33,T24,Condition 346 360;365 367	clinical stage II
34,T25,Measurement 375 376	T
35,T26,Value 376 379	1-2
36,T27,Measurement 380 381	N
37,T28,Value 381 382	0
38,T29,Measurement 383 384	M
39,T30,Value 384 385	0
40,R8,Has_value Arg1:T25 Arg2:T26
41,R9,Has_value Arg1:T27 Arg2:T28
42,R10,Has_value Arg1:T29 Arg2:T30
43,T31,Scope 375 385	T1-2 N0 M0
44,*,OR T24 T23
45,T32,Scope 346 367	clinical stage I / II
46,R11,Subsumes Arg1:T32 Arg2:T31
47,T33,Measurement 432 435	KPS
48,T34,Value 435 439	= 70
49,R12,Has_value Arg1:T33 Arg2:T34
50,T35,Measurement 448 476	bone marrow reserve function
51,T36,Value 441 447	Normal
52,R13,Has_value Arg1:T35 Arg2:T36
53,T37,Measurement 495 510	kidney function
54,T38,Measurement 488 493;502 510	liver function
55,*,OR T38 T37
56,T39,Value 481 487	normal
57,R14,Has_value Arg1:T38 Arg2:T39
58,R15,Has_value Arg1:T37 Arg2:T39
59,T40,Observation 512 536	Expected survival period
60,T41,Value 536 545	= 6 month
61,R16,Has_value Arg1:T40 Arg2:T41
0,T1,Person 0 8	Newborns
1,T2,Person 30 37	mothers
2,T3,Condition 12 29	substance abusing
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Person 40 48	Newborns
5,T5,Condition 58 75	contraindications
6,T6,Procedure 87 99	circumcision
7,R2,AND Arg1:T5 Arg2:T6
0,T1,Person 0 5	Adult
1,T2,Person 16 19	age
2,T3,Value 20 24	= 18
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Scope 16 24	age = 18
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Temporal 40 52	preoperative
7,T6,Procedure 53 71	imaging modalities
8,R3,Has_temporal Arg1:T6 Arg2:T5
9,T7,Condition 82 93	brain tumor
10,R4,AND Arg1:T7 Arg2:T6
11,T8,Condition 105 128	metastatic brain tumors
12,R5,Subsumes Arg1:T7 Arg2:T8
13,T9,Condition 133 149	vascular lesions
14,T10,Condition 151 159	aneurysm
15,T11,Condition 161 187	arteriovenous malformation
16,T12,Condition 191 212	arteriovenous fistula
17,T13,Procedure 224 245	surgical intervention
18,T14,Condition 318 323	tumor
19,T15,Condition 327 342	vascular lesion
20,T16,Qualifier 348 373	would take up fluorescein
21,T17,Drug 362 373	fluorescein
22,R6,multi Arg1:T16 Arg2:T17
23,*,OR T14 T15
24,T18,Scope 318 342	tumor or vascular lesion
25,R7,Has_qualifier Arg1:T18 Arg2:T16
26,T19,Informed_consent 375 477	Patient or legally authorized representative provides written informed consent to enroll in this study
0,T1,Condition 6 19	fetal anomaly
1,T2,Condition 27 37	indication
2,T3,Drug 42 65	intrapartum antibiotics
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 67 91	endocarditis prophylaxis
5,T5,Condition 105 123	maternal infection
6,*,OR T4 T5
7,T6,Scope 27 65	indication for intrapartum antibiotics
8,T7,"Scope 67 123	endocarditis prophylaxis, other known maternal infection"
9,R2,Subsumes Arg1:T6 Arg2:T7
0,T1,Non-query-able 0 40	Inability to provide an informed consent
1,T2,Qualifier 59 66	distant
2,T3,Qualifier 54 58	oral
3,T4,Condition 67 77	metastasis
4,T5,Qualifier 81 86	other
5,T6,Condition 87 99	malignancies
6,R1,Has_qualifier Arg1:T6 Arg2:T5
7,*,OR T6 T4
8,R2,Has_qualifier Arg1:T4 Arg2:T2
9,R3,Has_qualifier Arg1:T4 Arg2:T3
10,T7,Temporal 126 131	prior
11,T8,Procedure 132 139	surgery
12,T9,Qualifier 144 151	primary
13,T10,Condition 152 157	tumor
14,T11,Condition 161 171	lymph node
15,R4,Has_temporal Arg1:T8 Arg2:T7
16,*,OR T10 T11
17,T12,Scope 152 171	tumor or lymph node
18,R5,Has_qualifier Arg1:T12 Arg2:T9
19,R6,Has_scope Arg1:T8 Arg2:T12
20,T13,Procedure 185 191	biopsy
21,T14,Negation 174 184	except for
22,R7,Has_negation Arg1:T13 Arg2:T14
23,T15,Scope 174 191	except for biopsy
24,R8,Subsumes Arg1:T8 Arg2:T15
25,T16,Procedure 201 213	radiotherapy
26,T17,Temporal 195 200	Prior
27,T18,Qualifier 218 225	primary
28,T19,Condition 226 231	tumor
29,R9,Has_qualifier Arg1:T19 Arg2:T18
30,R10,Has_temporal Arg1:T16 Arg2:T17
31,R11,AND Arg1:T16 Arg2:T19
32,T20,Procedure 269 307	anti-tumor biological targeted therapy
33,T21,Temporal 249 259	previously
34,R12,Has_temporal Arg1:T20 Arg2:T21
35,T22,Procedure 334 346	chemotherapy
36,T23,Procedure 350 363	immunotherapy
37,T24,Condition 368 382	primary tumors
38,*,OR T22 T23
39,T25,Scope 334 363	chemotherapy or immunotherapy
40,R13,AND Arg1:T25 Arg2:T24
41,T26,Condition 390 400	malignancy
42,T27,Temporal 384 389	Prior
43,R14,Has_temporal Arg1:T26 Arg2:T27
44,T28,Temporal 401 428	within the previous 5 years
45,T29,Condition 441 472	cured skin basal cell carcinoma
46,T30,Condition 476 502	cervical carcinoma in situ
47,*,OR T29 T30
48,R15,Has_temporal Arg1:T26 Arg2:T28
49,T31,Negation 430 440	except for
50,T32,Scope 441 502	cured skin basal cell carcinoma or cervical carcinoma in situ
51,R16,Has_negation Arg1:T32 Arg2:T31
52,R17,Has_scope Arg1:T26 Arg2:T32
53,T33,Qualifier 510 518	3-4 grad
54,T34,Condition 519 526	Allergy
55,T35,Drug 534 538	drug
56,T36,Qualifier 530 533	any
57,R18,Has_qualifier Arg1:T35 Arg2:T36
58,R19,AND Arg1:T34 Arg2:T35
59,R20,Has_qualifier Arg1:T34 Arg2:T33
60,T37,Condition 557 578	Peripheral neuropathy
61,T38,Qualifier 578 587	> 1 grade
62,R21,Has_qualifier Arg1:T37 Arg2:T38
63,T39,Condition 602 620	systematic disease
64,T40,Qualifier 593 601	unstable
65,R22,Has_qualifier Arg1:T39 Arg2:T40
66,T41,Condition 639 648	infection
67,T42,Condition 663 682	high blood pressure
68,T43,Qualifier 650 662	uncontrolled
69,T44,Condition 684 699	unstable angina
70,T45,Temporal 717 741	within the last 3 months
71,T46,Measurement 701 706	onset
72,R23,Has_temporal Arg1:T46 Arg2:T45
73,T47,Condition 710 716	angina
74,R24,AND Arg1:T47 Arg2:T46
75,R25,Has_qualifier Arg1:T42 Arg2:T43
76,T48,Condition 743 767	congestive heart failure
77,T49,Condition 769 790	myocardial infarction
78,T50,Temporal 791 820	within the previous 12 months
79,T51,Qualifier 822 828	severe
80,T52,Condition 829 839	arrhythmia
81,T53,Drug 848 852	drug
82,T54,Procedure 853 862	treatment
83,R26,AND Arg1:T54 Arg2:T53
84,R27,AND Arg1:T52 Arg2:T54
85,R28,Has_qualifier Arg1:T52 Arg2:T51
86,T55,Condition 881 898	metabolic disease
87,T56,Condition 871 877;891 898	kidney disease
88,T57,Condition 864 869;891 898	liver disease
89,*,OR T56 T57 T55 T52 T49 T48 T44 T47 T42 T41
90,R29,Has_temporal Arg1:T49 Arg2:T50
91,T58,"Scope 639 898	infection, uncontrolled high blood pressure, unstable angina, onset of angina within the last 3 months, congestive heart failure, myocardial infarction within the previous 12 months, severe arrhythmia needing drug treatment, liver, kidney or metabolic disease"
92,T59,Scope 593 620	unstable systematic disease
93,R30,Subsumes Arg1:T59 Arg2:T58
94,T60,Condition 901 913	HIV positive
95,T61,Condition 915 931	Chronic diseases
96,T62,Drug 942 955	immune agents
97,T63,Procedure 959 974	hormone therapy
98,*,OR T62 T63
99,T64,Scope 942 974	immune agents or hormone therapy
100,R31,Has_scope Arg1:T61 Arg2:T64
101,T65,Condition 976 984	Pregnant
102,T66,Condition 988 997	lactating
103,*,OR T66 T65
104,T67,Person 998 1003	women
105,T68,"Intoxication_considerations 1005 1102	Drug/alcohol abuse, psychological or spiritual illness that may interfere compliance to the study"
106,T69,Condition 1118 1126	epilepsy
107,T70,Drug 1137 1148	medications
108,T71,Drug 1158 1166	steroids
109,T72,Drug 1170 1189	antiepileptic drugs
110,*,OR T71 T72
111,R32,AND Arg1:T69 Arg2:T70
112,T73,Scope 1158 1189	steroids or antiepileptic drugs
113,R33,Subsumes Arg1:T70 Arg2:T73
114,T74,Non-query-able 1192 1273	The patient has participated in other experimental therapy studies within 30 days
115,T75,Non-query-able 1275 1357	Researchers believe that the situation is unsuitable for participation in the grou
0,T1,Measurement 0 11	Apgar score
1,T2,Value 25 27	>7
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Temporal 12 24	at 5 minutes
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Measurement 29 40	birthweight
6,T5,Value 41 60	greater than 2.4 kg
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Person 62 65	Age
9,T7,Value 69 86	at least 10 hours
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Multiplier 88 100	At least one
12,T9,Observation 101 105	void
13,R5,Has_multiplier Arg1:T9 Arg2:T8
0,T1,Condition 0 8	Pregnant
1,T2,Person 9 14	women
2,T3,Value 15 34	between 34-42 weeks
3,T4,Measurement 35 44	gestation
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Condition 46 61	Singleton fetus
6,T6,Procedure 76 92	labor management
7,T7,Mood 63 75	Admitted for
8,R2,Has_mood Arg1:T6 Arg2:T7
9,T8,Measurement 106 111	fever
10,T9,Value 115 133	100.4 F or greater
11,R3,Has_value Arg1:T8 Arg2:T9
0,T1,Condition 0 8	Pregnant
1,T2,Condition 10 25	Meningeal signs
2,T3,Condition 39 67	Acute angle closure glaucoma
3,T4,Mood 71 80	suspected
4,R1,Has_mood Arg1:T3 Arg2:T4
5,T5,Condition 82 93	Head trauma
6,T6,Temporal 94 123	within the previous two weeks
7,R2,Has_temporal Arg1:T5 Arg2:T6
8,T7,Procedure 125 140	Lumbar puncture
9,T8,Temporal 141 170	within the previous two weeks
10,R3,Has_temporal Arg1:T7 Arg2:T8
11,T9,Condition 172 189	Thunderclap onset
12,T10,Condition 197 205	headache
13,R4,AND Arg1:T10 Arg2:T9
14,T11,Condition 213 220	allergy
15,T12,Drug 235 246	study drugs
16,R5,AND Arg1:T11 Arg2:T12
17,T13,Observation 248 255	History
18,T14,Condition 259 284	intracranial hypertension
19,R6,Has_temporal Arg1:T14 Arg2:T13
20,T15,Person 291 299	prisoner
21,T17,Qualifier 445 451	Severe
22,T18,Condition 452 463	Dehydration
23,R7,Has_qualifier Arg1:T18 Arg2:T17
24,T19,Non-query-able 336 406	Non-English speaking patient or parent/guardian for pediatric patients
25,T16,Negation 309 317	declined
26,T20,Competing_trial 318 334	informed consent
27,T21,Non-representable 408 443	Attending provider excludes patient
0,T1,Condition 0 4	LVAD
1,T2,Drug 8 16	warfarin
2,T3,Non-representable 17 83	requiring temporary interruption of anticoagulation for procedures
3,R1,AND Arg1:T1 Arg2:T2
4,T4,Qualifier 17 83	requiring temporary interruption of anticoagulation for procedures
5,R2,Has_qualifier Arg1:T2 Arg2:T4
0,T1,Measurement 11 25	DSM-V criteria
1,T2,Value 0 10	satisfying
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 30 32	ED
4,R2,AND Arg1:T3 Arg2:T1
5,T4,Parsing_Error 33 73	and for half of the patients in addition
6,T5,Condition 93 109	childhood trauma
7,T6,Observation 82 89	history
8,R3,Has_temporal Arg1:T5 Arg2:T6
0,T1,Drug 11 21	Glitazones
1,T2,Condition 0 7	Allergy
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Condition 23 44	Myocardial infarction
4,T4,Condition 46 59	Heart failure
5,T5,Condition 61 67	Angina
6,T6,Condition 80 93	kidney stones
7,T7,Observation 69 76	History
8,R2,Has_temporal Arg1:T6 Arg2:T7
9,T8,Condition 95 108	Liver disease
10,T9,Measurement 119 132	liver enzymes
11,T10,Value 110 118	abnormal
12,R3,Has_value Arg1:T9 Arg2:T10
13,T11,Scope 110 132	abnormal liver enzymes
14,R4,Subsumes Arg1:T8 Arg2:T11
15,T12,Condition 135 141	Anemia
16,T13,Measurement 143 153	hemoglobin
17,T14,Value 154 161	<8 g/dl
18,R5,Has_value Arg1:T13 Arg2:T14
19,T15,Scope 143 161	hemoglobin <8 g/dl
20,R6,Subsumes Arg1:T12 Arg2:T15
21,T16,Condition 164 170	Cancer
22,T17,Procedure 184 193	treatment
23,T18,Temporal 176 183	current
24,R7,Has_temporal Arg1:T17 Arg2:T18
25,R8,AND Arg1:T16 Arg2:T17
26,T19,Temporal 195 203	Previous
27,T20,Procedure 204 225	organ transplantation
28,R9,Has_temporal Arg1:T20 Arg2:T19
29,T21,Procedure 227 252	Immunosuppressant therapy
30,T22,Condition 254 292	Human immunodeficiency virus infection
31,T23,Condition 294 303	Pregnancy
32,T24,Condition 307 316	lactating
33,*,OR T23 T24
34,T25,Observation 326 337	tobacco use
35,T26,Temporal 318 325	Current
36,R10,Has_temporal Arg1:T25 Arg2:T26
37,T27,Drug 339 347	Dilantin
38,T28,Drug 352 370	oral contraceptive
39,T29,Condition 394 410	drug interaction
40,T30,Drug 416 426	glitazones
41,T31,Mood 384 393	potential
42,R11,Has_mood Arg1:T29 Arg2:T31
43,T32,Scope 339 370	Dilantin and oral contraceptive
44,*,OR T27 T28
45,R12,AND Arg1:T32 Arg2:T29
46,R13,AND Arg1:T29 Arg2:T30
47,T33,Condition 455 467	hypoglycemia
48,T34,Observation 444 451	history
49,R14,Has_temporal Arg1:T33 Arg2:T34
50,T35,Qualifier 428 443	Self-identified
51,R15,Has_qualifier Arg1:T33 Arg2:T35
0,T1,Temporal 24 29	prior
1,T2,Procedure 30 50	abdominal myomectomy
2,R1,Has_temporal Arg1:T2 Arg2:T1
3,T3,Observation 52 67	Post-menopausal
4,T4,Person 68 73	women
5,T5,Condition 104 122	clotting disorders
6,T6,Condition 113 122;95 103	disorders bleeding
7,*,OR T6 T5
8,T7,Condition 151 173	gynecologic malignancy
9,T8,Observation 140 147	history
10,R2,Has_temporal Arg1:T7 Arg2:T8
11,T9,Observation 175 182	History
12,T10,Condition 186 204	allergic reactions
13,T11,Drug 219 287	compounds of similar chemical or biologic composition to misoprostol
14,T12,Drug 276 287	misoprostol
15,R3,multi Arg1:T11 Arg2:T12
16,R4,AND Arg1:T10 Arg2:T11
17,R5,Has_temporal Arg1:T10 Arg2:T9
18,T13,Procedure 312 334	abdominal hysterectomy
19,T14,Mood 299 311	converted to
20,R6,Has_mood Arg1:T13 Arg2:T14
21,T15,Qualifier 355 363	elective
22,T16,Procedure 364 383	surgical procedures
23,T17,Temporal 394 425	at time of abdominal myomectomy
24,T18,Reference_point 405 425	abdominal myomectomy
25,T19,Procedure 405 425	abdominal myomectomy
26,R7,Has_index Arg1:T17 Arg2:T18
27,R8,multi Arg1:T18 Arg2:T19
28,R9,Has_qualifier Arg1:T16 Arg2:T15
29,R10,Has_temporal Arg1:T16 Arg2:T17
30,*,OR T13 T16
31,T20,Qualifier 344 354	additional
32,R11,Has_qualifier Arg1:T16 Arg2:T20
33,T21,Qualifier 338 343	other
34,R12,Has_qualifier Arg1:T16 Arg2:T21
35,T22,Qualifier 463 475	Uncontrolled
36,T23,Condition 476 496	intercurrent illness
37,T24,Qualifier 539 545	active
38,T25,Temporal 528 535	ongoing
39,T26,Condition 546 555	infection
40,*,OR T25 T24
41,T27,Scope 528 545	ongoing or active
42,R13,Has_scope Arg1:T26 Arg2:T27
43,T28,Qualifier 557 568	symptomatic
44,T29,Condition 569 593	congestive heart failure
45,R14,Has_qualifier Arg1:T29 Arg2:T28
46,T30,Condition 595 619	unstable angina pectoris
47,T31,Condition 621 639	cardiac arrhythmia
48,T32,Condition 644 663	psychiatric illness
49,T33,Observation 664 733	social situations that would limit compliance with study requirements
50,*,OR T32 T33 T31 T30 T29 T26
51,R15,Has_qualifier Arg1:T23 Arg2:T22
52,T34,"Scope 528 733	ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
53,T35,Scope 463 496	Uncontrolled intercurrent illness
54,R16,Subsumes Arg1:T35 Arg2:T34
0,T1,Condition 0 13	HIV infection
1,T2,Competing_trial 28 86	participation in previous or concurrent HIV vaccine trials
2,T3,"Pregnancy_considerations 89 129	actating, pregnant or planning pregnancy"
3,T4,Condition 131 156	renal function impairment
4,T5,Measurement 158 174	serum creatinine
5,T6,Value 175 185	>1.5 mg/dl
6,R1,Subsumes Arg1:T4 Arg2:T5
7,T7,Condition 188 204	Fanconi syndrome
8,R2,Subsumes Arg1:T5 Arg2:T6
9,R3,Has_value Arg1:T5 Arg2:T6
10,T8,Measurement 215 235	liver function tests
11,T9,Value 206 214	abnormal
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Measurement 237 240	AST
14,T11,Measurement 241 244	ALT
15,T12,Value 245 253	> 43 U/L
16,*,OR T11 T10
17,T13,Scope 237 244	AST/ALT
18,R5,Subsumes Arg1:T8 Arg2:T13
19,R6,Has_value Arg1:T13 Arg2:T12
20,T14,Condition 256 269	liver disease
21,T15,Condition 271 286	viral hepatitis
22,T16,Condition 288 321	hepatitis B virus (HBV) infection
23,*,OR T14 T15 T16 T8
24,T17,Measurement 323 339	serum phosphorus
25,T18,Value 340 349	<2.2mg/dl
26,T19,Condition 351 363	osteoporosis
27,R7,Has_value Arg1:T17 Arg2:T18
28,T20,Condition 371 382	sensitivity
29,T21,Drug 404 411	Truvada
30,R8,AND Arg1:T20 Arg2:T21
31,T22,Procedure 430 457	immunosuppressive treatment
32,T23,Drug 467 491	systemic corticosteroids
33,R9,Subsumes Arg1:T22 Arg2:T23
34,T24,Non-query-able 493 545	assumption of medication that interacts with Truvada
35,T25,Post-eligibility 548 610	high likelihood of poor adherence to PREP and clinic attendanc
36,T26,Non-query-able 613 771	any condition that in the opinion of the attending physician could endanger the health of the participant or render her unsuitable to participate in the trial
0,T1,Temporal 0 6	recent
1,T2,Condition 7 23	thrombotic event
2,R1,Has_temporal Arg1:T2 Arg2:T1
0,T1,Person 0 3	Age
1,T2,Value 4 18	10 to 65 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 20 31	Temperature
4,T4,Value 32 49	less than 100.4 F
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Procedure 58 73	neurologic exam
7,T6,Value 51 57	Normal
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Value 78 84	normal
10,T8,Measurement 85 98	mental status
11,*,OR T8 T7
0,T1,Procedure 24 44	abdominal myomectomy
1,T2,Condition 61 77	uterine fibroids
2,T3,Procedure 81 95	pelvic imaging
3,T4,Procedure 97 114	pelvic ultrasound
4,T5,Procedure 118 121;97 103	MRI pelvic
5,*,OR T5 T4
6,T6,Scope 97 121	pelvic ultrasound or MRI
7,R1,Subsumes Arg1:T3 Arg2:T6
8,T7,Scope 81 122	pelvic imaging (pelvic ultrasound or MRI)
9,R2,AND Arg1:T7 Arg2:T2
10,T8,Temporal 123 147	within in last 12 months
11,R3,Has_temporal Arg1:T7 Arg2:T8
12,R4,Has_scope Arg1:T1 Arg2:T7
13,T9,Person 149 152	Age
14,T10,Value 153 178	= 18 years and = 50 years
15,R5,Has_value Arg1:T9 Arg2:T10
16,T11,Temporal 180 193	Pre-operative
17,T12,Reference_point 184 193	operative
18,T13,Procedure 184 193	operative
19,R6,multi Arg1:T12 Arg2:T13
20,R7,AND Arg1:T11 Arg2:T13
21,T14,Measurement 194 204	hemoglobin
22,T15,Value 205 212	>8 g/dl
23,R8,Has_value Arg1:T14 Arg2:T15
24,R9,Has_temporal Arg1:T14 Arg2:T11
25,T16,Procedure 230 251	buccal administration
26,T17,Drug 255 266	misoprostol
27,T18,Qualifier 230 251	buccal administration
28,R10,multi Arg1:T16 Arg2:T18
29,T19,Drug 272 279	placebo
30,T20,Temporal 280 311	at least one hour pre-procedure
31,T21,Mood 214 229	Willing to have
32,*,OR T17 T19
33,T22,Scope 255 279	misoprostol or a placebo
34,R11,Has_scope Arg1:T16 Arg2:T22
35,R12,Has_mood Arg1:T16 Arg2:T21
36,R13,Has_temporal Arg1:T16 Arg2:T20
37,T25,Observation 314 335;364 390	Ability to understand a written informed consent
38,T23,Observation 344 390	willingness to sign a written informed consent
39,*,OR T23 T25
40,T24,Observation 412 428	surgical history
41,T26,Observation 404 411;421 428	medical history
42,T27,Qualifier 393 403	Admissible
43,R14,Has_qualifier Arg1:T26 Arg2:T27
44,R15,Has_qualifier Arg1:T24 Arg2:T27
45,T28,Drug 461 472	Depo-Lupron
46,T29,Drug 474 486	Depo-Provera
47,T30,Drug 491 515	Oral Contraceptive pills
48,*,OR T30 T29 T28
49,T31,Procedure 448 455	treated
50,T32,Temporal 437 447	previously
51,R16,Has_temporal Arg1:T31 Arg2:T32
52,T33,"Scope 461 515	Depo-Lupron, Depo-Provera, or Oral Contraceptive pills"
53,R17,Has_scope Arg1:T31 Arg2:T33
54,A1,Optional T31
55,T34,Non-representable 517 588	Intraoperative use of vasopressin and uterine tourniquet is permissible
56,T35,Non-representable 590 626	Can have had prior Cesarean delivery
0,T1,Condition 8 21	suicidal risk
1,T2,Temporal 0 7	current
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 31 40	psychosis
4,T4,Temporal 23 30	current
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Condition 50 56	trauma
7,T6,Temporal 42 49	ongoing
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Condition 71 109	involvement in an abusive relationship
10,T8,Temporal 63 70	current
11,R4,Has_temporal Arg1:T7 Arg2:T8
12,R5,Subsumes Arg1:T5 Arg2:T7
0,T1,Condition 0 3	CKD
1,T2,Value 27 34	Stage 3
2,T3,Value 27 32;39 40	Stage 4
3,*,OR T3 T2
4,T4,Scope 27 40	Stage 3 and 4
5,T5,Measurement 44 85	National Kidney Foundation Classification
6,R1,Has_scope Arg1:T5 Arg2:T4
7,R2,AND Arg1:T1 Arg2:T5
8,T6,Measurement 91 133	estimated glomerular filtration rate (GFR)
9,T7,Value 134 166	between 15 and 59 mL/min/1.73 m2
10,R3,Has_value Arg1:T6 Arg2:T7
11,T8,Qualifier 184 236	Modification of Diet in Renal Disease (MDRD) formula
12,R4,Has_qualifier Arg1:T6 Arg2:T8
13,T9,Person 288 291	Men
14,T10,Person 296 301	women
15,T11,Value 302 316	35 to 70 years
16,T12,Person 320 323	age
17,R5,Has_value Arg1:T12 Arg2:T11
18,*,OR T9 T10
0,T1,Person 0 3	age
1,T2,Value 4 7	=18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-query-able 22 102	not intending to move away from the clinic's catchment area for the next 2 years
4,T4,Measurement 104 118	HIV-1 antibody
5,T5,Value 119 127	negative
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Observation 137 156	commercial sex work
8,T7,Post-eligibility 158 189	contact information is provided
9,T8,Informed_consent 191 215	written informed consent
0,T1,Person 0 3	Age
1,T2,Value 4 14	= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 29 44	cholecystectomy
4,T4,Qualifier 16 28	Laparoscopic
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Qualifier 46 54	Emergent
7,T6,Qualifier 55 63	elective
8,*,OR T5 T6
9,T7,Multiplier 65 67	=2
10,T8,Condition 68 80	risk factors
11,R3,Has_multiplier Arg1:T8 Arg2:T7
12,T9,Condition 82 99	diabetes mellitus
13,T10,Person 101 104	age
14,T11,Value 105 114	=70 years
15,R4,Has_value Arg1:T10 Arg2:T11
16,T12,Measurement 116 119	BMI
17,T13,Value 120 123	=30
18,R5,Has_value Arg1:T12 Arg2:T13
19,T14,Condition 125 144	fascial enlargement
20,*,OR T10 T9 T12 T14
21,T15,"Scope 82 144	diabetes mellitus, age =70 years, BMI =30, fascial enlargement"
22,R6,Subsumes Arg1:T8 Arg2:T15
0,T1,Procedure 15 27	chemotherapy
1,T2,Condition 32 35	MBC
2,R1,causal Arg1:T1 Arg2:T2
3,T3,Observation 0 7	History
4,T4,Value 53 63	< 6 months
5,T5,Procedure 87 109	cytotoxic chemotherapy
6,T6,Qualifier 117 129;142 149	neo-adjuvant setting
7,T7,Qualifier 133 149	adjuvant setting
8,T8,Condition 168 188	metastatic diagnosis
9,T9,Drug 191 202	Trastuzumab
10,T10,Temporal 203 235	≤ 21 days prior to randomization
11,T11,Reference_point 222 235	randomization
12,R2,multi Arg1:T10 Arg2:T11
13,R3,Has_temporal Arg1:T9 Arg2:T10
14,T12,Procedure 238 253	Hormone therapy
15,T13,Temporal 254 285	< 7 days prior to randomization
16,T14,Reference_point 272 285	randomization
17,R4,Has_index Arg1:T13 Arg2:T14
18,T15,Condition 296 317	peripheral neuropathy
19,T16,Qualifier 321 330	Grade ≥ 3
20,T17,Measurement 321 326	Grade
21,T18,Value 327 330	≥ 3
22,R5,Has_value Arg1:T17 Arg2:T18
23,R6,multi Arg1:T16 Arg2:T17
24,R7,Has_qualifier Arg1:T15 Arg2:T16
25,T19,Temporal 288 295	Current
26,R8,Has_temporal Arg1:T15 Arg2:T19
27,T20,Temporal 361 384	within the last 5 years
28,T21,Condition 419 450	carcinoma in situ of the cervix
29,T22,Qualifier 397 418	appropriately treated
30,T23,Procedure 411 418	treated
31,R9,multi Arg1:T22 Arg2:T23
32,R10,Has_qualifier Arg1:T21 Arg2:T22
33,T24,Condition 452 479	non-melanoma skin carcinoma
34,T25,Condition 489 503	uterine cancer
35,T26,Measurement 481 486	Stage
36,T27,Value 487 488	I
37,R11,Has_value Arg1:T26 Arg2:T27
38,R12,AND Arg1:T25 Arg2:T26
39,T28,Condition 350 360	malignancy
40,T29,Qualifier 344 349	other
41,R13,Has_qualifier Arg1:T28 Arg2:T29
42,R14,Has_temporal Arg1:T28 Arg2:T20
43,T30,Negation 386 396	except for
44,*,OR T21 T24 T25
45,T31,Non-representable 505 574	or other cancers with a similar outcome as those previously mentioned
46,T32,"Scope 397 503	appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer"
47,R15,Has_negation Arg1:T32 Arg2:T30
48,T33,Procedure 586 598	radiotherapy
49,T34,Temporal 577 585	Previous
50,R16,Has_temporal Arg1:T33 Arg2:T34
51,T35,Condition 665 678	breast cancer
52,T36,Qualifier 654 664	metastatic
53,T37,Qualifier 634 650	locally advanced
54,T38,Qualifier 620 632	unresectable
55,*,OR T36 T37 T38
56,T39,"Scope 620 664	unresectable, locally advanced or metastatic"
57,R17,Has_scope Arg1:T35 Arg2:T39
58,T40,Value 697 710	more than 25%
59,T41,Measurement 714 733;743 753	marrow-bearing bone irradiated
60,R18,Has_value Arg1:T41 Arg2:T40
61,T42,"Non-representable 577 865	Previous radiotherapy for the treatment of unresectable, locally advanced or metastatic breast cancer is not allowed if more than 25% of marrow-bearing bone has been irradiated or the last fraction of radiotherapy has been administered within approximately 3 weeks prior to randomization."
62,T43,Condition 867 883	Brain metastases
63,T44,Qualifier 893 902	untreated
64,T45,Qualifier 904 915	symptomatic
65,T46,Qualifier 920 935	require therapy
66,T47,Procedure 963 972	radiation
67,T48,Procedure 974 981	surgery
68,T49,Procedure 986 1019	other therapy to control symptoms
69,*,OR T49 T48 T47
70,T50,Condition 1025 1041	brain metastases
71,T51,Temporal 1042 1080	within 2 months prior to randomization
72,T52,Reference_point 1067 1080	randomization
73,R19,multi Arg1:T51 Arg2:T52
74,R20,Has_temporal Arg1:T50 Arg2:T51
75,T53,"Scope 963 1019	radiation, surgery, or other therapy to control symptoms"
76,R21,causal Arg1:T53 Arg2:T50
77,*,OR T45 T46 T44
78,T54,"Scope 893 935	untreated, symptomatic, or require therapy"
79,R22,Has_scope Arg1:T43 Arg2:T54
80,*,OR T43 T53
81,T55,Drug 1140 1154	anthracyclines
82,T56,Drug 1156 1167	Doxorubicin
83,T57,Drug 1171 1192	liposomal doxorubicin
84,T58,Multiplier 1193 1205	> 500 mg/m^2
85,T59,Drug 1207 1217	epirubicin
86,T60,Multiplier 1218 1230	> 900 mg/m^2
87,T61,Drug 1232 1244	mitoxantrone
88,T62,Multiplier 1245 1256	> 120mg/m^2
89,T63,Drug 1261 1271	idarubicin
90,T64,Multiplier 1272 1283	> 90 mg/m^2
91,R23,Has_multiplier Arg1:T63 Arg2:T64
92,R24,Has_multiplier Arg1:T61 Arg2:T62
93,R25,Has_multiplier Arg1:T59 Arg2:T60
94,*,OR T56 T57
95,T65,Scope 1156 1192	Doxorubicin or liposomal doxorubicin
96,R26,Has_multiplier Arg1:T65 Arg2:T58
97,T66,Scope 1156 1283	Doxorubicin or liposomal doxorubicin > 500 mg/m^2; epirubicin > 900 mg/m^2; mitoxantrone > 120mg/m^2 and idarubicin > 90 mg/m^2
98,T67,Scope 1094 1154	exposure to the following cumulative doses of anthracyclines
99,R27,Subsumes Arg1:T67 Arg2:T66
100,T68,Condition 1294 1309	unstable angina
101,T69,Temporal 1286 1293	Current
102,R28,Has_temporal Arg1:T68 Arg2:T69
103,T70,Condition 1335 1359	congestive heart failure
104,T71,Qualifier 1323 1334	symptomatic
105,R29,Has_qualifier Arg1:T70 Arg2:T71
106,T72,Condition 1364 1386	ventricular arrhythmia
107,T73,Qualifier 1387 1406	requiring treatment
108,T74,Procedure 1397 1406	treatment
109,R30,multi Arg1:T73 Arg2:T74
110,R31,Has_qualifier Arg1:T72 Arg2:T73
111,*,OR T72 T70
112,T75,Condition 1420 1441	myocardial infarction
113,T76,Temporal 1442 1480	within 6 months prior to randomization
114,T77,Reference_point 1467 1480	randomization
115,R32,Has_index Arg1:T76 Arg2:T77
116,R33,Has_temporal Arg1:T75 Arg2:T76
117,T78,Measurement 1483 1524	Left ventricular ejection fraction (LVEF)
118,T79,Value 1525 1534	below 50%
119,R34,Has_value Arg1:T78 Arg2:T79
120,T80,Temporal 1535 1586	within approximately 28 days prior to randomization
121,T81,Reference_point 1573 1586	randomization
122,R35,Has_index Arg1:T80 Arg2:T81
123,R36,Has_temporal Arg1:T78 Arg2:T80
124,T82,Condition 1630 1660	congestive heart failure (CHF)
125,T83,Qualifier 1618 1629	symptomatic
126,R37,Has_qualifier Arg1:T82 Arg2:T83
127,T84,Measurement 1610 1614	LVEF
128,T85,Value 1600 1609	decreased
129,R38,Has_value Arg1:T84 Arg2:T85
130,T86,Drug 1684 1695	trastuzumab
131,T87,Qualifier 1675 1683	adjuvant
132,T88,Temporal 1666 1674	previous
133,R39,Has_qualifier Arg1:T86 Arg2:T87
134,R40,Has_temporal Arg1:T86 Arg2:T88
135,T89,Scope 1618 1705	symptomatic congestive heart failure (CHF) with previous adjuvant trastuzumab treatment
136,*,OR T84 T89
137,T90,Observation 1589 1596	History
138,R41,Has_temporal Arg1:T84 Arg2:T90
139,R42,Has_temporal Arg1:T89 Arg2:T90
140,T91,Measurement 1708 1726	Cardiac troponin I
141,T92,Value 1727 1738	≥ 0.2 ng/mL
142,R43,Has_value Arg1:T91 Arg2:T92
143,T93,Temporal 1739 1770	within 28 days of randomization
144,T94,Reference_point 1757 1770	randomization
145,R44,Has_index Arg1:T93 Arg2:T94
146,R45,Has_temporal Arg1:T91 Arg2:T93
147,T95,Condition 1780 1787	dyspnea
148,T96,Qualifier 1773 1779	Severe
149,R46,Has_qualifier Arg1:T95 Arg2:T96
150,T97,Condition 1824 1843	advanced malignancy
151,T98,Procedure 1865 1890	continuous oxygen therapy
152,T99,Temporal 1857 1864	current
153,R47,Has_temporal Arg1:T98 Arg2:T99
154,T100,Condition 1807 1820	complications
155,R48,causal Arg1:T100 Arg2:T97
156,T101,Qualifier 1847 1890	requiring current continuous oxygen therapy
157,R49,multi Arg1:T101 Arg2:T98
158,*,OR T100 T101
159,T102,Scope 1807 1890	complications of advanced malignancy or requiring current continuous oxygen therapy
160,R50,causal Arg1:T95 Arg2:T102
161,T107,Condition 2285 2294	lactation
162,T108,Condition 2272 2281	pregnancy
163,T109,Temporal 2264 2271	Current
164,*,OR T107 T108
165,T110,Scope 2272 2294	pregnancy or lactation
166,R51,Has_temporal Arg1:T110 Arg2:T109
167,T113,Condition 2431 2465	human immunodeficiency virus (HIV)
168,T114,Temporal 2402 2409	Current
169,R52,Has_temporal Arg1:T113 Arg2:T114
170,T115,Condition 2474 2485;2505 2510	hepatitis B virus
171,T116,Condition 2493 2510	hepatitis C virus
172,*,OR T115 T116 T113
173,T117,Condition 2524 2535	intolerance
174,T118,Condition 2557 2574	infusion reaction
175,T119,Measurement 2547 2552	Grade
176,T120,Value 2553 2556	3-4
177,R53,Has_value Arg1:T119 Arg2:T120
178,R54,AND Arg1:T118 Arg2:T119
179,T121,Condition 2579 2595	hypersensitivity
180,T122,Drug 2599 2610	trastuzumab
181,T123,Drug 2612 2627	murine proteins
182,T124,Drug 2632 2641	docetaxel
183,*,OR T123 T124 T122
184,T125,"Scope 2599 2641	trastuzumab, murine proteins, or docetaxel"
185,R55,Has_scope Arg1:T121 Arg2:T125
186,T103,Qualifier 1901 1907	severe
187,T104,Qualifier 1909 1921	uncontrolled
188,T105,Condition 1922 1938	systemic disease
189,T106,Qualifier 1944 1966	clinically significant
190,T129,Condition 1983 1992;2007 2014	pulmonary disease
191,T130,Condition 1997 2014	metabolic disease
192,T128,Condition 1967 1981;2007 2014	cardiovascular disease
193,T131,Condition 2016 2039	wound healing disorders
194,T132,Condition 2041 2047	ulcers
195,T133,Condition 2052 2066	bone fractures
196,*,OR T132 T133 T131 T134
197,*,OR T129 T128 T130
198,T134,"Scope 1967 2014	cardiovascular, pulmonary, or metabolic disease"
199,R56,Has_qualifier Arg1:T134 Arg2:T106
200,T135,"Scope 1944 2066	clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures"
201,R57,Has_qualifier Arg1:T105 Arg2:T104
202,R58,Has_qualifier Arg1:T105 Arg2:T103
203,R59,AND Arg1:T135 Arg2:T105
204,T111,Procedure 2322 2347	investigational treatment
205,T112,Temporal 2348 2399	within approximately 28 days prior to randomization
206,R60,Has_temporal Arg1:T111 Arg2:T112
207,T136,Reference_point 2386 2399	randomization
208,R61,Has_index Arg1:T112 Arg2:T136
209,T126,Condition 2650 2666	hypersensitivity
210,T137,Drug 2681 2692	study drugs
211,T138,Drug 2727 2761	drugs formulated in polysorbate 80
212,*,OR T137 T138
213,T139,"Scope 2681 2761	study drugs, including the excipients, or any drugs formulated in polysorbate 80"
214,R62,Has_scope Arg1:T126 Arg2:T139
215,T127,Observation 2809 2866	unwilling to comply with the requirements of the protocol
216,T140,Observation 2799 2805;2819 2866	unable to comply with the requirements of the protocol
217,*,OR T140 T127
218,T141,Qualifier 2070 2075	Major
219,T142,Procedure 2076 2094	surgical procedure
220,T143,Qualifier 2098 2109	significant
221,T144,Condition 2110 2126	traumatic injury
222,R63,Has_qualifier Arg1:T144 Arg2:T143
223,R64,Has_qualifier Arg1:T142 Arg2:T141
224,*,OR T144 T142
225,T145,Temporal 2127 2178	within approximately 28 days prior to randomization
226,T146,Reference_point 2165 2178	randomization
227,R65,Has_index Arg1:T145 Arg2:T146
228,T147,Scope 2070 2126	Major surgical procedure or significant traumatic injury
229,R66,Has_temporal Arg1:T147 Arg2:T145
230,T148,Mood 2182 2206	anticipation of the need
231,T149,Procedure 2211 2224	major surgery
232,R67,Has_mood Arg1:T149 Arg2:T148
233,T150,Temporal 2225 2261	during the course of study treatment
234,T151,Reference_point 2246 2261	study treatment
235,R68,Has_index Arg1:T150 Arg2:T151
236,T152,Procedure 2252 2261	treatment
237,R69,multi Arg1:T151 Arg2:T152
238,R70,Has_temporal Arg1:T149 Arg2:T150
239,*,OR T149 T147
240,T153,Observation 2297 2307	History of
241,R71,Has_temporal Arg1:T111 Arg2:T153
242,T154,Observation 2513 2523	History of
243,T155,Scope 2547 2574	Grade 3-4 infusion reaction
244,R73,Subsumes Arg1:T117 Arg2:T155
245,*,OR T117 T121
246,T156,"Scope 2524 2641	intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab, murine proteins, or docetaxel"
247,R72,Has_temporal Arg1:T156 Arg2:T154
0,T1,Measurement 0 19	ASA physical status
1,T2,Value 20 25	I-III
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,"Value 28 39;46 57	18-85 years , inclusive"
4,T4,Person 43 46	age
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Measurement 60 67	surgery
7,T6,Temporal 68 85	less than 3 hours
8,R3,Has_temporal Arg1:T5 Arg2:T6
0,T1,Observation 0 13	Conversion to
1,T2,Procedure 14 24	laparotomy
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Procedure 35 50	re intervention
4,T4,Qualifier 26 34	Emergent
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 52 69	Immunosuppression
7,T6,Condition 71 87	Umbilical hernia
0,T1,Procedure 15 33	catheter insertion
1,T2,Mood 0 10	indication
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Condition 36 53	contraindications
4,T4,Procedure 57 78	brachial plexus block
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Condition 86 93	allergy
7,T6,Drug 97 115	local anaesthetics
8,T7,Condition 117 127	malignancy
9,T8,Condition 131 140	infection
10,*,OR T7 T8 T5
11,R3,AND Arg1:T5 Arg2:T6
12,T9,Qualifier 141 152	in the area
13,R4,Has_qualifier Arg1:T8 Arg2:T9
14,R5,Has_qualifier Arg1:T7 Arg2:T9
15,T10,"Scope 86 152	allergy to local anaesthetics, malignancy or infection in the area"
16,T11,Scope 36 78	contraindications to brachial plexus block
17,R6,Subsumes Arg1:T11 Arg2:T10
18,T12,Condition 165 185	neurological deficit
19,T13,Temporal 156 164	existing
20,T14,Qualifier 193 211	area to be blocked
21,R7,Has_qualifier Arg1:T12 Arg2:T14
22,R8,Has_temporal Arg1:T12 Arg2:T13
23,T15,Condition 214 223	pregnancy
24,T16,Temporal 226 233	history
25,T17,Procedure 237 249	neck surgery
26,T18,Procedure 253 265	radiotherapy
27,*,OR T18 T17
28,T19,Scope 237 265	neck surgery or radiotherapy
29,R9,Has_temporal Arg1:T19 Arg2:T16
30,T20,Qualifier 268 274	severe
31,T21,Condition 275 294	respiratory disease
32,R10,Has_qualifier Arg1:T21 Arg2:T20
33,T22,Condition 297 312	chest deformity
34,T23,Informed_consent 315 385	inability to understand the informed consent and demands of the study;
35,T24,Informed_consent 387 402	patient refusal
0,T1,Qualifier 18 41	cytologically confirmed
1,T2,Qualifier 0 14;32 41	Histologically confirmed
2,T3,Condition 42 70	adenocarcinoma of the breast
3,T4,Condition 96 114	metastatic disease
4,T5,Condition 107 114;76 92	disease locally advanced
5,T6,Condition 122 148	candidate for chemotherapy
6,T7,Procedure 136 148	chemotherapy
7,R1,multi Arg1:T6 Arg2:T7
8,R2,AND Arg1:T3 Arg2:T5
9,R3,AND Arg1:T3 Arg2:T4
10,*,OR T1 T2
11,T8,Scope 0 41	Histologically or cytologically confirmed
12,T9,Scope 42 114	adenocarcinoma of the breast with locally advanced or metastatic disease
13,R4,Has_scope Arg1:T9 Arg2:T8
14,R5,AND Arg1:T9 Arg2:T6
15,T10,Measurement 151 198	Human epidermal growth factor receptor 2 (HER2)
16,T11,Value 199 207	positive
17,R6,Has_value Arg1:T10 Arg2:T11
18,T12,Procedure 219 231	chemotherapy
19,T13,Temporal 213 218	prior
20,T14,Negation 210 212	No
21,R7,Has_temporal Arg1:T12 Arg2:T13
22,R8,Has_negation Arg1:T12 Arg2:T14
23,T15,Person 296 299	Age
24,T16,Value 300 310	≥ 18 years
25,R9,Has_value Arg1:T15 Arg2:T16
26,T17,Condition 275 293	Measurable disease
27,T18,Condition 242 272	metastatic breast cancer (MBC)
28,R10,AND Arg1:T12 Arg2:T18
29,T19,Person 317 322	women
30,T20,Condition 326 348	childbearing potential
31,T21,Person 353 356	men
32,T22,Observation 357 396	with partners of childbearing potential
33,T23,Scope 317 348	women of childbearing potential
34,T24,Scope 353 396	men with partners of childbearing potential
35,T25,Scope 317 396	women of childbearing potential and men with partners of childbearing potential
36,A1,Optional T25
37,*,OR T23 T24
38,T26,Qualifier 417 433	highly effective
39,T27,Qualifier 435 447	non-hormonal
40,T28,Procedure 456 469	contraception
41,R11,Has_qualifier Arg1:T28 Arg2:T27
42,R12,Has_qualifier Arg1:T28 Arg2:T26
43,T29,Multiplier 473 474	2
44,T30,Procedure 494 520	non-hormonal contraception
45,R13,Has_multiplier Arg1:T30 Arg2:T29
46,*,OR T28 T30
47,T31,Procedure 552 565	Contraception
48,T32,Temporal 575 619	continue for the duration of study treatment
49,T33,Reference_point 604 619	study treatment
50,R14,Has_index Arg1:T32 Arg2:T33
51,T34,Temporal 624 684	for at least 6 months after the last dose of study treatment
52,T35,Reference_point 652 684	the last dose of study treatment
53,R15,Has_index Arg1:T34 Arg2:T35
54,R16,Has_temporal Arg1:T31 Arg2:T32
55,R17,Has_temporal Arg1:T31 Arg2:T34
56,T36,Person 686 690	Male
57,T37,Observation 706 727	partners are pregnant
58,T38,Device 739 746	condoms
59,T39,Temporal 747 776	for the duration of the study
60,R18,Has_temporal Arg1:T38 Arg2:T39
61,T40,Scope 686 727	Male patients whose partners are pregnant
62,A2,Optional T40
63,R19,AND Arg1:T40 Arg2:T38
0,T1,Parsing_Error 0 2	NA
0,T1,Condition 22 45	calculous cholecystitis
1,T2,Qualifier 0 18	Clinical diagnosis
2,R1,Has_qualifier Arg1:T1 Arg2:T2
0,T1,Measurement 0 21	Body Mass Index (BMI)
1,T2,Value 22 32	= 35 kg/m2
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 34 39	HbA1c
4,T4,Value 40 46	= 5.7%
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Observation 48 64;80 87	Ability to speak English
7,T6,Observation 48 58;69 87	Ability to understand English
8,*,OR T5 T6
0,T1,Person 12 15	old
1,T2,Value 0 11	>= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 38 47	Pregnancy
4,T4,Measurement 58 64	HBs Ag
5,T5,Value 49 57	Positive
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Informed_consent 66 247	Informed consent obtained with information sheet given and explained and the consent form signed by the participant of the project investigator at the latest the day of the inclusio
0,T1,Measurement 0 18	Gallbladder's wall
1,T2,Value 19 23	>3mm
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 25 46	atrophied gallbladder
4,T4,Condition 47 65	gallstone obstruct
5,T5,Qualifier 70 86	Hartmann's pouch
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,*,OR T3 T4 T1
8,T6,Procedure 89 109	Abdominal ultrasound
9,T7,Measurement 122 152	contractibility of gallbladder
10,T8,Value 156 160	poor
11,R3,Has_value Arg1:T7 Arg2:T8
12,R4,AND Arg1:T6 Arg2:T7
13,T9,Person 167 171	aged
14,T10,Condition 186 195;205 213	bad heart function
15,T11,Condition 186 189;200 213	bad lung function
16,*,OR T10 T11
17,A1,Optional T9
18,T12,Scope 186 213	bad heart and lung function
19,R5,Has_scope Arg1:T9 Arg2:T12
20,T13,Condition 233 252	acute cholecystitis
21,T14,Condition 253 265	pancreatitis
22,T15,Condition 266 293	pancreaticobiliary diseases
23,T16,Condition 306 325	choledocholithiasis
24,*,OR T13 T14 T15 T16
25,T17,Condition 328 336	Pregnant
26,T18,Condition 340 351	lactational
27,T19,Person 352 357	women
28,*,OR T17 T18
0,T1,Person 21 24	age
1,T2,Value 0 17	At least 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Post-eligibility 26 49	Signed informed consent
4,T4,Person 68 72	race
5,T5,Value 51 67	African American
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Procedure 96 112	renal transplant
8,T7,Qualifier 87 95	solitary
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Drug 121 131	tacrolimus
11,T9,Temporal 137 180	for at least 2 weeks prior to randomization
12,T10,Reference_point 167 180	randomization
13,R4,Has_index Arg1:T9 Arg2:T10
14,R5,Has_temporal Arg1:T8 Arg2:T9
15,T11,Qualifier 114 120;132 136	Stable dose
16,R6,Has_qualifier Arg1:T8 Arg2:T11
0,T1,Condition 0 20	Rheumatoid arthritis
1,T2,Condition 22 30	Diabetes
2,T3,Observation 34 58	immediate family history
3,T4,Condition 62 70	diabetes
4,R1,Has_context Arg1:T4 Arg2:T3
5,*,OR T2 T4
6,T5,Condition 72 95	Coronary artery disease
7,T6,Condition 97 121	Congestive heart failure
8,T7,Condition 123 142	Pulmonary disorders
9,T8,Condition 154 158	COPD
10,T9,Condition 163 169	asthma
11,*,OR T8 T9
12,T10,Scope 154 169	COPD and asthma
13,R2,Subsumes Arg1:T7 Arg2:T10
14,T11,Condition 171 195	Malabsorptive GI disease
15,T12,Condition 205 219	celiac disease
16,T13,Procedure 224 238	gastric bypass
17,*,OR T12 T13
18,T14,"Scope 205 238	celiac disease, or gastric bypass"
19,R3,Subsumes Arg1:T11 Arg2:T14
20,T15,Qualifier 240 251	Significant
21,T16,Condition 252 267	hepatic disease
22,R4,Has_qualifier Arg1:T16 Arg2:T15
23,T17,Condition 269 288	Renal insufficiency
24,T18,Measurement 290 294	eGFR
25,T19,Value 295 309	< 60 mL/kg/min
26,R5,Has_value Arg1:T18 Arg2:T19
27,T20,Scope 290 309	eGFR < 60 mL/kg/min
28,R6,Subsumes Arg1:T17 Arg2:T20
29,T21,Condition 312 318	Anemia
30,T22,Measurement 320 330	hematocrit
31,T23,Value 331 336	< 34%
32,R7,Has_value Arg1:T22 Arg2:T23
33,T24,Visit 353 368	screening visit
34,T25,Scope 320 336	hematocrit < 34%
35,R8,Subsumes Arg1:T21 Arg2:T25
36,R9,AND Arg1:T21 Arg2:T24
37,T26,Condition 370 378	Pregnant
38,T27,Person 379 386	females
39,T28,Multiplier 403 408	daily
40,T29,Drug 409 420	medications
41,R10,Has_multiplier Arg1:T29 Arg2:T28
42,T30,Qualifier 421 465	that alter glucose metabolism of GI function
43,R11,Has_qualifier Arg1:T29 Arg2:T30
44,T31,Drug 467 482	glucocorticoids
45,T32,Drug 484 497	psychotropics
46,T33,Drug 510 524	metoclopramide
47,T34,Drug 499 508	narcotics
48,*,OR T34 T33 T32 T31
49,T35,"Scope 467 524	glucocorticoids, psychotropics, narcotics, metoclopramide"
50,R12,Subsumes Arg1:T29 Arg2:T35
51,T36,Drug 555 562	insulin
52,T37,Procedure 542 551	injection
53,T38,Drug 555 562	insulin
54,R13,AND Arg1:T37 Arg2:T38
55,*,OR T36 T38
56,T39,Condition 573 584	sensitivity
57,T40,Drug 599 613	study peptides
58,T41,Procedure 635 644	skin test
59,R14,AND Arg1:T39 Arg2:T40
60,R15,AND Arg1:T41 Arg2:T39
61,T42,Condition 663 667	PTSD
62,T43,Condition 669 679	depression
63,T44,Condition 681 694	substance use
64,T45,Condition 696 718	mental health problems
65,T46,Condition 720 735	sleep disorders
66,T47,Condition 737 751	HPA disruption
67,T48,Condition 759 762	TBI
68,*,OR T48 T47 T46 T45 T44 T43 T42
0,T1,Measurement 15 26	HBs Ag test
1,T2,Negation 6 14	refusing
2,R1,Has_negation Arg1:T1 Arg2:T2
3,T3,Condition 32 44	co-infection
4,T4,Condition 50 62	co-infection
5,T5,Qualifier 28 31	HIV
6,R2,Has_qualifier Arg1:T3 Arg2:T5
7,T6,Qualifier 46 49	HCV
8,R3,Has_qualifier Arg1:T4 Arg2:T6
9,T7,Procedure 64 77	HBV treatment
10,T8,Measurement 111 131	Creatinine clearance
11,T9,Value 132 143	< 30 mL/min
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Condition 152 168	gravidic disease
14,T11,Qualifier 145 151	Severe
15,R5,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Qualifier 200 216	life threatening
17,R6,Has_qualifier Arg1:T10 Arg2:T12
18,T13,Condition 274 289	fetal anomalies
19,T14,Condition 326 348	Imminent child's birth
20,T15,Measurement 360 377	cervix dilatation
21,T16,Value 384 397	7 centimeters
22,R7,Has_value Arg1:T15 Arg2:T16
23,R8,AND Arg1:T14 Arg2:T15
24,T17,Post-eligibility 399 458	Intention to deliver in a maternity not linked to the study
25,T18,"Post-eligibility 460 591	Any concomitant medical condition that, according to the clinical site investigator would contraindicate participation in the study"
26,T19,Competing_trial 594 695	Concurrent participation in any other clinical trial without written agreement of the two study teams
0,T1,Value 14 17	>14
1,T2,Measurement 18 27	follicles
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Temporal 28 45	on day of trigger
4,T4,Reference_point 31 45	day of trigger
5,R2,Has_index Arg1:T3 Arg2:T4
6,R3,Has_temporal Arg1:T2 Arg2:T3
7,T5,Condition 56 69	hyperresponse
8,T6,Observation 75 92	OHSS development
9,R4,Has_context Arg1:T5 Arg2:T6
10,T7,Condition 102 114	low response
11,T8,Temporal 47 55	Previous
12,T9,Temporal 93 101	Previous
13,R5,Has_temporal Arg1:T5 Arg2:T8
14,R6,Has_temporal Arg1:T7 Arg2:T9
15,T10,Measurement 128 135	oocytes
16,T11,Value 116 127	less than 3
17,R7,Has_value Arg1:T10 Arg2:T11
18,T12,Procedure 141 169	high dose of FSH stimulation
19,T13,Scope 116 169	less than 3 oocytes on a high dose of FSH stimulation
20,R8,Subsumes Arg1:T7 Arg2:T13
21,T14,Condition 172 191	Endocrine disorders
0,T1,Observation 9 38	refuse to follow the research
1,T2,Temporal 56 64	previous
2,T3,Procedure 65 84	eradication therapy
3,T4,Condition 88 117	Helicobacter pylori infection
4,R1,AND Arg1:T3 Arg2:T4
5,R2,Has_temporal Arg1:T3 Arg2:T2
6,T5,Condition 135 143	pregnant
7,T6,Observation 147 160	breastfeeding
8,*,OR T5 T6
9,T7,Observation 178 185	history
10,T8,Condition 189 196	allergy
11,T9,Drug 204 239	component of triple therapy regimen
12,R3,AND Arg1:T8 Arg2:T9
13,R4,Has_temporal Arg1:T8 Arg2:T7
14,T10,Drug 241 262	proton pump inhibitor
15,T11,Drug 264 274	penicillin
16,T12,Drug 285 294	macrolide
17,*,OR T12 T11 T10
18,T13,"Scope 241 295	proton pump inhibitor, penicillin, and / or macrolide)"
19,R5,Subsumes Arg1:T9 Arg2:T13
20,T14,Value 332 340	impaired
21,T15,Measurement 341 355	liver function
22,R6,Has_value Arg1:T15 Arg2:T14
23,T16,Measurement 370 380	ALT values
24,T17,Value 381 401	within normal limits
25,R7,Has_value Arg1:T16 Arg2:T17
26,T18,Negation 407 409	no
27,T19,Temporal 410 418	previous
28,T20,Condition 419 432	liver disease
29,R8,Has_temporal Arg1:T20 Arg2:T19
30,R9,Has_negation Arg1:T20 Arg2:T18
31,T21,Condition 463 474	arrhythmias
32,T22,Condition 487 505	QT wave elongation
33,T23,Procedure 509 529	electrocardiographic
34,R10,AND Arg1:T23 Arg2:T22
35,*,OR T21 T23
0,T1,Informed_consent 0 110	Patients are able to provide signed and dated written informed consent prior to any study specific procedures.
1,T2,Person 112 117	Women
2,T3,Condition 122 137	post-menopausal
3,T4,Condition 371 375	T2DM
4,T5,Temporal 147 190	as at least 1 year post cessation of menses
5,T6,Reference_point 171 190	cessation of menses
6,T7,Person 196 200	aged
7,T8,Value 201 220	= 45 and = 70 years
8,R1,Has_value Arg1:T7 Arg2:T8
9,T9,Person 222 227	Males
10,T10,Person 232 236	aged
11,T11,Value 237 262	= 40 years and = 70 years
12,R2,Has_value Arg1:T10 Arg2:T11
13,T12,Non-representable 264 341	Patients should have suitable veins for cannulation or repeated venipuncture.
14,A1,Optional T9
15,A2,Optional T2
16,T13,Scope 122 220	post-menopausal (defined as at least 1 year post cessation of menses) and aged = 45 and = 70 years
17,T14,Scope 232 262	aged = 40 years and = 70 years
18,R3,Has_scope Arg1:T9 Arg2:T14
19,R4,Has_scope Arg1:T2 Arg2:T13
20,*,OR T2 T9
21,T15,Temporal 376 406	for at least the last 6 months
22,R5,Has_temporal Arg1:T4 Arg2:T15
23,T16,Procedure 434 462	anti-diabetic drug treatment
24,T17,Negation 425 427	no
25,T18,Qualifier 428 433	other
26,R6,Has_qualifier Arg1:T16 Arg2:T18
27,R7,Has_negation Arg1:T16 Arg2:T17
28,T19,Qualifier 470 476	stable
29,T20,Multiplier 477 503	maximum 3000 mg daily dose
30,T21,Drug 504 513	metformin
31,T22,Qualifier 534 545	stable dose
32,T23,Drug 551 566	DPPIV inhibitor
33,T24,Temporal 577 607	for at least the last 3 months
34,T25,Measurement 610 622	HbA1c levels
35,T26,Value 623 628	=6.0%
36,T27,Value 630 642	=42 mmol/mol
37,T28,Value 648 653	=9.0%
38,T29,Value 655 666	75 mmol/mol
39,R8,Subsumes Arg1:T28 Arg2:T29
40,R9,Subsumes Arg1:T26 Arg2:T27
41,R10,Has_multiplier Arg1:T21 Arg2:T20
42,R11,Has_qualifier Arg1:T20 Arg2:T19
43,R12,Has_qualifier Arg1:T23 Arg2:T22
44,R13,Has_temporal Arg1:T23 Arg2:T24
45,T30,Scope 623 667	=6.0% (=42 mmol/mol) and =9.0% (75 mmol/mol)
46,R14,Has_scope Arg1:T25 Arg2:T30
47,*,OR T16 T21 T23
48,T31,Measurement 677 698	body mass index (BMI)
49,T32,Value 699 709	= 35 kg/m2
50,R15,Has_value Arg1:T31 Arg2:T32
0,T1,Person 0 3	Age
1,T2,Value 4 21	between 20 and 40
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 23 46	Normal menstrual cycles
4,T4,Value 48 58	25-34 days
5,R2,Subsumes Arg1:T3 Arg2:T4
6,T5,Condition 75 85	amenorrhea
7,T6,Condition 60 74	Oligomenorrhea
8,*,OR T5 T6 T7
9,T7,Condition 89 108	polycystic syndrome
10,T8,Qualifier 135 158	Rotterdam criteria 2004
11,R3,Has_qualifier Arg1:T7 Arg2:T8
12,T9,Measurement 161 164	BMI
13,T10,Value 165 182	>18 and <35 kg/m2
14,R4,Has_value Arg1:T9 Arg2:T10
0,T1,Non-query-able 0 153	Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites).
1,T2,Competing_trial 155 328	Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator.
2,T3,Qualifier 360 382	clinically significant
3,T4,Condition 383 390	disease
4,T5,Condition 394 402	disorder
5,T6,Temporal 415 421	recent
6,T7,Temporal 423 433	< 3 months
7,R1,Subsumes Arg1:T6 Arg2:T7
8,T8,Condition 435 455	cardiovascular event
9,T9,"Post-eligibility 330 649	History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study"
10,T10,Condition 674 689	Type 1 diabetes
11,T11,Condition 691 727	maturity onset diabetes of the young
12,T12,Condition 729 747	secondary diabetes
13,T13,Condition 751 769	diabetes insipidus
14,*,OR T12 T13 T11 T10
15,T14,Qualifier 781 800	rapidly progressing
16,T15,Qualifier 772 780	Unstable
17,T16,Condition 801 814	renal disease
18,T17,Measurement 818 854	estimated Glomerular Filtration Rate
19,T18,Value 855 866	< 60 mL/min
20,R2,Has_value Arg1:T17 Arg2:T18
21,T19,Qualifier 868 891	Cockcroft-Gault formula
22,R3,Has_qualifier Arg1:T17 Arg2:T19
23,*,OR T14 T15
24,T20,Scope 772 800	Unstable/rapidly progressing
25,R4,Has_scope Arg1:T16 Arg2:T20
26,*,OR T16 T17
27,T21,Qualifier 895 917	Clinically significant
28,T22,Value 918 937	out of range values
29,T23,Measurement 964 994	alanine aminotransferase (ALT)
30,T24,Measurement 996 1028	aspartate aminotransferase (AST)
31,T25,Measurement 1032 1058	alkaline phosphatase (ALP)
32,*,OR T23 T24 T25
33,T26,"Scope 964 1058	alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)"
34,R5,Has_value Arg1:T26 Arg2:T22
35,R6,Has_qualifier Arg1:T22 Arg2:T21
36,T27,Drug 1112 1125	dapagliflozin
37,T28,Condition 1091 1108	Contraindications
38,R7,AND Arg1:T28 Arg2:T27
39,T29,Drug 1164 1182	antidiabetic drugs
40,T30,Drug 1194 1203	metformin
41,T31,Negation 1183 1193	other than
42,R8,Has_negation Arg1:T30 Arg2:T31
43,R9,AND Arg1:T29 Arg2:T30
44,T32,Temporal 1204 1238	within 3 months prior to screening
45,R10,Has_temporal Arg1:T29 Arg2:T32
46,T33,Measurement 1241 1252	Weight gain
47,T34,Measurement 1241 1247;1256 1260	Weight loss
48,*,OR T34 T33
49,T35,Value 1261 1267	> 5 kg
50,T36,Temporal 1268 1288	in the last 3 months
51,T37,Observation 1298 1314	weight-loss diet
52,T38,Temporal 1290 1297	ongoing
53,R11,Has_temporal Arg1:T37 Arg2:T38
54,T39,Observation 1316 1332	hypocaloric diet
55,R12,Subsumes Arg1:T37 Arg2:T39
56,T40,Drug 1344 1362	weight loss agents
57,T41,Scope 1241 1260	Weight gain or loss
58,R13,Has_value Arg1:T41 Arg2:T35
59,R14,Has_temporal Arg1:T41 Arg2:T36
60,*,OR T37 T40 T41
61,T42,Observation 1390 1403	alcohol abuse
62,T43,Observation 1376 1386	drug abuse
63,T44,Temporal 1404 1425	in the past 12 months
64,*,OR T42 T43
65,T45,Scope 1376 1403	drug abuse or alcohol abuse
66,R15,Has_temporal Arg1:T45 Arg2:T44
67,T46,Observation 1365 1372	History
68,R16,Has_temporal Arg1:T45 Arg2:T46
69,T47,"Post-eligibility 1428 1763	Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk."
70,T48,Procedure 1765 1780	Plasma donation
71,T49,Temporal 1781 1810	within one month of screening
72,R17,Has_temporal Arg1:T48 Arg2:T49
73,T50,Reference_point 1801 1810	screening
74,R18,Has_index Arg1:T49 Arg2:T50
75,T51,Procedure 1818 1832	blood donation
76,T52,Measurement 1833 1843	blood loss
77,T53,Value 1844 1852	> 500 mL
78,R19,Has_value Arg1:T52 Arg2:T53
79,*,OR T51 T52
80,T54,Scope 1818 1852	blood donation/blood loss > 500 mL
81,T55,Temporal 1853 1887	within 3 months prior to screening
82,T56,Temporal 1891 1907	during the study
83,*,OR T55 T56
84,T57,Scope 1853 1907	within 3 months prior to screening or during the study
85,R20,Has_scope Arg1:T54 Arg2:T57
86,*,OR T48 T54
87,T58,Condition 1910 1916	Anemia
88,T59,Measurement 1928 1943	Hemoglobin (Hb)
89,T60,Value 1944 1953	< 115 g/L
90,T61,Value 1955 1961	7.1 mM
91,R21,Subsumes Arg1:T60 Arg2:T61
92,T62,Person 1966 1971	women
93,T63,Value 1976 1985	< 120 g/L
94,T64,Value 1987 1993	7.5 mM
95,T65,Person 1998 2001	men
96,R23,Subsumes Arg1:T63 Arg2:T64
97,A1,Optional T65
98,A2,Optional T62
99,R24,Has_value Arg1:T65 Arg2:T63
100,R22,Has_value Arg1:T62 Arg2:T60
101,*,OR T62 T65
102,T66,Scope 1944 2001	< 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men
103,R25,AND Arg1:T66 Arg2:T59
104,T67,Scope 1928 2001	Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men
105,R26,Subsumes Arg1:T58 Arg2:T67
106,T68,Procedure 2011 2035	anti-coagulant treatment
107,T69,Drug 2044 2051	heparin
108,T70,Drug 2053 2061	warfarin
109,T71,Drug 2063 2082	platelet inhibitors
110,T72,Drug 2084 2092	thrombin
111,T73,Drug 2097 2116	factor X inhibitors
112,*,OR T73 T72 T71 T70 T69
113,T74,"Scope 2044 2115	heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitor"
114,R27,Subsumes Arg1:T68 Arg2:T74
115,T75,Drug 2145 2165	oral glucocorticoids
116,T76,Drug 2167 2181	anti-estrogens
117,T77,Drug 2191 2202	medications
118,T78,Qualifier 2185 2190	other
119,R28,Has_qualifier Arg1:T77 Arg2:T78
120,T79,Qualifier 2221 2259	markedly influence insulin sensitivity
121,*,OR T75 T76 T77
122,T80,"Scope 2145 2202	oral glucocorticoids, anti-estrogens or other medications"
123,R29,Has_qualifier Arg1:T80 Arg2:T79
124,T81,Drug 2269 2283	loop diuretics
125,T82,Observation 2294 2301	smoking
126,T83,Multiplier 2286 2293	Regular
127,R30,Has_multiplier Arg1:T82 Arg2:T83
128,T84,Drug 2320 2328	nicotine
129,T85,Multiplier 2312 2319	regular
130,R31,Has_multiplier Arg1:T84 Arg2:T85
131,*,OR T82 T84
132,T86,Device 2335 2371	Central nervous system aneurysm clip
133,T87,Device 2373 2400	Implanted neural stimulator
134,T88,Device 2412 2429	cardiac pacemaker
135,T89,Device 2433 2446	defibrillator
136,*,OR T88 T89
137,T90,Device 2448 2464	Cochlear implant
138,T91,Device 2483 2508	corpora aliena in the eye
139,T92,Device 2483 2504;2512 2517	corpora aliena in the brain
140,*,OR T92 T91
141,T93,Qualifier 2466 2482	Metal containing
142,R32,Has_qualifier Arg1:T92 Arg2:T93
143,R33,Has_qualifier Arg1:T91 Arg2:T93
144,T94,"Non-query-able 2520 2705	Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study."
0,T1,Value 0 17	18 years or older
1,T2,Condition 48 79	infected by Helicobacter pylori
2,T3,Value 89 97	positive
3,T4,Measurement 101 117	Urea Breath Test
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Value 121 129	positive
6,T6,Procedure 133 170	histopathologic examination of biopsy
7,R2,Has_value Arg1:T6 Arg2:T5
8,T7,Qualifier 174 180;192 201	antrum of gaster
9,T8,Qualifier 185 201	corpus of gaster
10,T9,Procedure 210 230	esophagoduodenoscopy
11,R3,Has_qualifier Arg1:T6 Arg2:T7
12,R4,Has_qualifier Arg1:T6 Arg2:T8
13,R5,AND Arg1:T9 Arg2:T6
14,*,OR T9 T4
15,T10,Person 12 15	old
16,R6,Has_value Arg1:T10 Arg2:T1
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,*,OR T1 T2
3,T3,Person 16 19	Age
4,T4,Value 20 34	18 to 65 years
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 51 69	spinal cord injury
7,T6,Temporal 70 96	between 3 days and 4 weeks
8,R2,Has_temporal Arg1:T5 Arg2:T6
9,T7,Measurement 98 149	American Spinal Injury Association Impairment Scale
10,T8,Value 150 156	A or B
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Informed_consent 158 218	Informed consent for inclusion into the database is obtained
0,T1,Value 0 17	At least 18 years
1,T2,Person 21 24	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Value 26 44	No more than 20 wk
4,T4,Measurement 48 57	gestation
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Condition 48 57	gestation
7,R3,multi Arg1:T5 Arg2:T4
8,T6,Non-representable 59 109	Given Ante-natal Cards of the Ghana Health Service
9,T7,Condition 133 163	routine ante-natal examination
10,T8,Visit 171 178	clinics
11,R4,AND Arg1:T7 Arg2:T8
12,T9,Condition 180 183	HIV
13,T10,Negation 184 192	negative
14,T11,Qualifier 196 210	status unknown
15,*,OR T10 T11
16,T12,Scope 184 210	negative or status unknown
17,R5,Has_scope Arg1:T9 Arg2:T12
18,T13,Condition 252 267	chronic disease
19,T14,Condition 273 283	malignancy
20,T15,Visit 368 379;394 402	Manya Krobo district
21,T16,Visit 383 402	Yilo Krobo district
22,*,OR T15 T16
23,T17,Observation 352 360	Residing
24,T18,Scope 368 402	Manya Krobo or Yilo Krobo district
25,R6,Has_scope Arg1:T17 Arg2:T18
26,T19,Post-eligibility 404 440	Prepared to sign an informed consent
27,T20,Observation 442 460	Living in the area
28,T21,Temporal 461 497	throughout the duration of the study
29,T22,Reference_point 488 497	the study
30,R7,multi Arg1:T21 Arg2:T22
31,R8,Has_temporal Arg1:T20 Arg2:T21
32,T23,Post-eligibility 499 526	Acceptance of home visitors
33,R9,Subsumes Arg1:T13 Arg2:T14
0,T1,Condition 0 23	Non-affective psychosis
1,T2,Measurement 25 37	Premorbid IQ
2,T3,Value 41 48	over 70
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Non-query-able 50 98	A service user of the early intervention service
5,T5,Value 105 115	18 or over
6,T6,Person 100 104	Aged
7,R2,Has_value Arg1:T6 Arg2:T5
8,T7,Value 117 136	up to the age of 35
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Condition 193 215	Psychiatrically stable
11,T9,Procedure 251 267	hospitalisations
12,T10,Negation 248 250	no
13,T11,Observation 271 289	medication changes
14,*,OR T9 T11
15,T12,Temporal 290 305	in last 4 weeks
16,T13,Scope 251 289	hospitalisations or medication changes
17,R4,Has_temporal Arg1:T13 Arg2:T12
18,R5,Has_negation Arg1:T13 Arg2:T10
19,R6,Subsumes Arg1:T8 Arg2:T13
0,T1,Measurement 4 32	difference in blood pressure
1,T2,Qualifier 45 81	selected arm versus non-selected arm
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Value 85 94	= 20 mmHg
4,T4,Value 109 118	= 10 mmHg
5,T5,Measurement 123 128	siDBP
6,T6,Measurement 99 104	siSBP
7,R2,Has_value Arg1:T6 Arg2:T3
8,R3,Has_value Arg1:T5 Arg2:T4
9,T7,Temporal 129 139	at Visit 1
10,R4,AND Arg1:T1 Arg2:T6
11,R5,AND Arg1:T1 Arg2:T5
12,R6,Has_temporal Arg1:T1 Arg2:T7
13,T8,Measurement 154 168	Blood pressure
14,T9,Temporal 175 187	at screening
15,T10,Temporal 175 177;192 205	at randomization
16,T11,Value 209 219	= 180 mmHg
17,T12,Value 233 243	= 110 mmHg
18,T13,Measurement 248 253	siDBP
19,T14,Measurement 224 229	siSBP
20,R7,Has_value Arg1:T14 Arg2:T11
21,R8,Has_value Arg1:T13 Arg2:T12
22,*,OR T14 T13
23,T15,Scope 209 253	= 180 mmHg for siSBP or = 110 mmHg for siDBP
24,R9,Has_scope Arg1:T8 Arg2:T15
25,R10,Has_temporal Arg1:T8 Arg2:T10
26,R11,Has_temporal Arg1:T8 Arg2:T9
27,T16,Condition 281 293	hypertension
28,T17,Qualifier 271 280	secondary
29,R12,Has_qualifier Arg1:T16 Arg2:T17
30,T18,Mood 297 306	suspected
31,T19,Qualifier 310 319	secondary
32,T20,Condition 320 332	hypertension
33,R13,Has_qualifier Arg1:T20 Arg2:T19
34,R14,Has_mood Arg1:T20 Arg2:T18
35,T21,Condition 340 360	renovascular disease
36,T22,Condition 362 379;393 406	adrenal medullary hyperfunction
37,T23,Condition 384 406	cortical hyperfunction
38,T24,Condition 408 432	coarctation of the aorta
39,T25,Condition 434 452	hyperaldosteronism
40,T26,Qualifier 454 464	unilateral
41,T27,Qualifier 468 477	bilateral
42,*,OR T27 T26
43,T28,Condition 478 499	renal artery stenosis
44,T29,Scope 454 477	unilateral or bilateral
45,R15,Has_scope Arg1:T28 Arg2:T29
46,T30,Condition 501 519	Cushing's syndrome
47,T31,Condition 521 537	pheochromocytoma
48,T32,Condition 539 564	polycystic kidney disease
49,*,OR T22 T23 T32 T31 T30 T28 T25 T24 T21
50,T33,"Scope 340 564	renovascular disease, adrenal medullary and cortical hyperfunction, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease"
51,*,OR T16 T20
52,T34,Scope 271 332	secondary hypertension or suspected of secondary hypertension
53,R16,Subsumes Arg1:T34 Arg2:T33
54,T35,Condition 599 623	orthostatic hypertension
55,T36,Qualifier 587 598	symptomatic
56,R17,Has_qualifier Arg1:T35 Arg2:T36
57,T37,Measurement 629 662	difference in the blood pressures
58,T38,Qualifier 671 732	measured at supine position and measured at standing position
59,T39,Value 736 745	= 20 mmHg
60,T40,Value 760 769	= 10 mmHg
61,T41,Measurement 774 779	siDBP
62,T42,Measurement 750 755	siSBP
63,R18,Has_value Arg1:T42 Arg2:T39
64,R19,Has_value Arg1:T41 Arg2:T40
65,R20,Has_qualifier Arg1:T37 Arg2:T38
66,R21,AND Arg1:T37 Arg2:T42
67,R22,AND Arg1:T37 Arg2:T41
68,T43,Scope 629 779	difference in the blood pressures between measured at supine position and measured at standing position is = 20 mmHg for siSBP and = 10 mmHg for siDBP
69,T44,Scope 587 623	symptomatic orthostatic hypertension
70,R23,Subsumes Arg1:T44 Arg2:T43
71,T45,Condition 795 824	type 1 diabetes mellitus (DM)
72,T46,Qualifier 828 840	uncontrolled
73,T47,Condition 841 843	DM
74,R24,Has_qualifier Arg1:T47 Arg2:T46
75,*,OR T47 T45
76,T48,Procedure 857 872	insulin therapy
77,T49,Measurement 881 886	HbA1c
78,T50,Value 887 891	> 9%
79,R25,Has_value Arg1:T49 Arg2:T50
80,*,OR T48 T49
81,T51,Scope 857 891	insulin therapy or with HbA1c > 9%
82,T52,Scope 795 843	type 1 diabetes mellitus (DM) or uncontrolled DM
83,R26,Subsumes Arg1:T52 Arg2:T51
84,T53,Qualifier 908 914	severe
85,T54,Condition 915 933	cardiac conditions
86,R27,Has_qualifier Arg1:T54 Arg2:T53
87,T55,Condition 935 948	heart failure
88,T56,Measurement 950 954	NYHA
89,T57,Value 955 967	Class 3 or 4
90,R28,Has_value Arg1:T56 Arg2:T57
91,T58,Observation 970 977	history
92,T59,Condition 981 1005	ischemic cardiac disease
93,R29,Has_temporal Arg1:T59 Arg2:T58
94,T60,Condition 1007 1022	unstable angina
95,T61,Condition 1024 1045	myocardial infarction
96,T62,Condition 1048 1076	peripheral vascular diseases
97,T63,Procedure 1078 1115	percutaneous transluminal angioplasty
98,T64,Procedure 1119 1147	coronary artery bypass graft
99,T65,Temporal 1148 1170	within recent 6 months
100,*,OR T64 T63
101,T66,Scope 1078 1147	percutaneous transluminal angioplasty or coronary artery bypass graft
102,R30,Has_temporal Arg1:T66 Arg2:T65
103,*,OR T66 T62 T60 T61
104,T67,"Scope 1007 1170	unstable angina, myocardial infarction), peripheral vascular diseases, percutaneous transluminal angioplasty or coronary artery bypass graft within recent 6 months"
105,R31,Subsumes Arg1:T59 Arg2:T66
106,R32,AND Arg1:T55 Arg2:T56
107,*,OR T55 T59
108,T68,"Scope 935 1170	heart failure (NYHA Class 3 or 4), history of ischemic cardiac disease (unstable angina, myocardial infarction), peripheral vascular diseases, percutaneous transluminal angioplasty or coronary artery bypass graft within recent 6 months"
109,R33,Subsumes Arg1:T54 Arg2:T68
110,T69,Qualifier 1187 1209	clinically significant
111,T70,Condition 1210 1233	ventricular tachycardia
112,T71,Condition 1235 1254	atrial fibrillation
113,T72,Condition 1256 1270	atrial flutter
114,T73,Qualifier 1280 1302	clinically significant
115,T74,Condition 1303 1313	arrhythmia
116,R34,Has_qualifier Arg1:T74 Arg2:T73
117,*,OR T71 T70 T72
118,T75,"Scope 1210 1270	ventricular tachycardia, atrial fibrillation, atrial flutter"
119,R35,Has_qualifier Arg1:T75 Arg2:T69
120,*,OR T75 T74
121,T76,Condition 1367 1404	hypertrophic occlusive myocardiopathy
122,T77,Qualifier 1406 1412	severe
123,T78,Condition 1413 1446	occlusive coronary artery disease
124,R36,Has_qualifier Arg1:T78 Arg2:T77
125,T79,Condition 1448 1463	aortic stenosis
126,T80,Qualifier 1465 1492	hemodynamically significant
127,T85,Condition 1509 1530	mitral valve stenosis
128,T87,Condition 1543 1560	cardiogenic shock
129,T88,Observation 1532 1539	History
130,T82,Qualifier 1574 1580	severe
131,T81,Condition 1493 1505;1522 1530	aortic valve stenosis
132,*,OR T81 T85
133,T83,Scope 1493 1530	aortic valve or mitral valve stenosis
134,R37,Has_qualifier Arg1:T83 Arg2:T80
135,*,OR T76 T78 T79 T83
136,R38,Has_temporal Arg1:T87 Arg2:T88
137,T84,Condition 1581 1606	cerebrovascular disorders
138,R39,Has_qualifier Arg1:T84 Arg2:T82
139,T86,Condition 1621 1627	stroke
140,T89,Condition 1629 1648	cerebral infarction
141,T90,Condition 1652 1671	cerebral hemorrhage
142,T91,Temporal 1672 1694	within recent 6 months
143,*,OR T86 T89 T90
144,T92,"Scope 1621 1671	stroke, cerebral infarction or cerebral hemorrhage"
145,R40,Has_temporal Arg1:T92 Arg2:T91
146,T93,Scope 1574 1606	severe cerebrovascular disorders
147,R41,Subsumes Arg1:T93 Arg2:T92
148,T94,Observation 1697 1704	History
149,T95,Temporal 1708 1715	current
150,T96,Observation 1728 1735	wasting
151,T97,Condition 1737 1747;1833 1841	autoimmune diseases
152,T98,Condition 1757 1777	rheumatoid arthritis
153,T99,Condition 1782 1810	systemic lupus erythematosus
154,*,OR T98 T99
155,T100,Condition 1815 1841	connective tissue diseases
156,T102,Scope 1757 1810	rheumatoid arthritis and systemic lupus erythematosus
157,R42,Subsumes Arg1:T97 Arg2:T102
158,*,OR T97 T100 T96
159,*,OR T95 T94
160,T101,Scope 1697 1715	History or current
161,T103,"Scope 1728 1841	wasting, autoimmune (such as rheumatoid arthritis and systemic lupus erythematosus) or connective tissue diseases"
162,R43,Subsumes Arg1:T103 Arg2:T101
163,T104,Qualifier 1874 1883	malignant
164,T105,Qualifier 1862 1870	moderate
165,T106,Condition 1884 1895	retinopathy
166,T107,Condition 1907 1925	retinal hemorrhage
167,T108,Condition 1927 1945	visual disturbance
168,T109,Condition 1950 1971	retinal microaneurysm
169,T110,Temporal 1972 1987	within 6 months
170,*,OR T108 T109 T107
171,*,OR T104 T105
172,T111,Scope 1862 1883	moderate or malignant
173,R44,Has_scope Arg1:T106 Arg2:T111
174,T112,"Scope 1907 1971	retinal hemorrhage, visual disturbance and retinal microaneurysm"
175,R45,Has_temporal Arg1:T112 Arg2:T110
176,R46,Subsumes Arg1:T106 Arg2:T112
177,T113,Condition 2024 2043	intestinal diseases
178,T114,Qualifier 2004 2012	surgical
179,T115,Qualifier 2016 2023	medical
180,*,OR T114 T115
181,T116,Scope 2004 2023	surgical or medical
182,R47,Has_scope Arg1:T113 Arg2:T116
183,T117,Procedure 2063 2072	surgeries
184,T118,Qualifier 2078 2127	could interfere with drug absorption distribution
185,T119,Qualifier 2078 2103;2129 2139	could interfere with drug metabolism
186,T120,Qualifier 2078 2103;2144 2155	could interfere with drug elimination
187,*,OR T119 T120 T118
188,T121,"Scope 2078 2155	could interfere with drug absorption distribution, metabolism and elimination"
189,*,OR T113 T117
190,T122,Scope 2004 2072	surgical or medical intestinal diseases or having received surgeries
191,R48,Has_scope Arg1:T122 Arg2:T121
192,T123,Condition 2168 2178	malignancy
193,T124,Observation 2157 2167	History of
194,R49,Has_temporal Arg1:T123 Arg2:T124
195,T125,Condition 2189 2197	leukemia
196,T126,Condition 2202 2210	lymphoma
197,T127,Temporal 2211 2232	within recent 5 years
198,T128,Condition 2244 2286	localized basal cell carcinoma of the skin
199,T129,Negation 2233 2243	except for
200,R50,Has_negation Arg1:T128 Arg2:T129
201,*,OR T125 T126
202,T130,Scope 2189 2210	leukemia and lymphoma
203,R51,Subsumes Arg1:T123 Arg2:T130
204,R52,AND Arg1:T123 Arg2:T128
205,R53,Has_temporal Arg1:T123 Arg2:T127
206,T131,Condition 2307 2328	inflammatory diseases
207,T132,Qualifier 2339 2346	chronic
208,T133,Procedure 2347 2372	anti-inflammatory therapy
209,T134,Drug 2347 2372	anti-inflammatory therapy
210,R54,multi Arg1:T133 Arg2:T134
211,R55,Has_qualifier Arg1:T133 Arg2:T132
212,R56,AND Arg1:T131 Arg2:T133
213,T135,Condition 2374 2387	Renal failure
214,T136,Procedure 2391 2399	dialysis
215,R57,AND Arg1:T135 Arg2:T136
216,T137,Measurement 2401 2404	AST
217,T138,Measurement 2408 2411	ALT
218,*,OR T137 T138
219,T139,Value 2412 2444	>2 x upper limit of normal (ULN)
220,T140,Scope 2401 2411	AST or ALT
221,R58,Has_value Arg1:T140 Arg2:T139
222,T141,Measurement 2446 2462	Serum creatinine
223,T142,Value 2463 2474	> 1.5 x ULN
224,R59,Has_value Arg1:T141 Arg2:T142
225,T143,Measurement 2476 2491	Serum potassium
226,T144,Value 2492 2504	< 3.5 mmol/L
227,T145,Value 2508 2519	>5.5 mmol/L
228,*,OR T144 T145
229,T146,Scope 2492 2519	< 3.5 mmol/L or >5.5 mmol/L
230,R60,Has_scope Arg1:T143 Arg2:T146
231,T147,Temporal 2531 2548;2617 2633	co-administration during the study
232,T148,Qualifier 2552 2561	non-study
233,T149,Drug 2562 2585	antihypertensive agents
234,T150,Drug 2589 2616	contraindicated medications
235,*,OR T149 T150
236,R61,Has_qualifier Arg1:T149 Arg2:T148
237,R62,Has_temporal Arg1:T149 Arg2:T147
238,R63,Has_temporal Arg1:T150 Arg2:T147
239,T151,Condition 2646 2662	hypersensitivity
240,T152,Drug 2666 2670	ARBs
241,T153,Drug 2674 2690	dihydropyridines
242,*,OR T152 T153
243,T154,Scope 2666 2690	ARBs or dihydropyridines
244,R64,Has_scope Arg1:T151 Arg2:T154
245,T155,Condition 2703 2713	angioedema
246,T156,Procedure 2717 2726	treatment
247,T157,Drug 2732 2746	ACE inhibitors
248,T158,Drug 2750 2754	ARBs
249,*,OR T157 T158
250,T159,Scope 2732 2754	ACE inhibitors or ARBs
251,R65,Has_scope Arg1:T156 Arg2:T159
252,R66,AND Arg1:T155 Arg2:T156
253,T160,Observation 2692 2702	History of
254,R67,Has_temporal Arg1:T155 Arg2:T160
255,T161,Observation 2635 2645	History of
256,R68,Has_temporal Arg1:T151 Arg2:T161
257,T162,Condition 2756 2764	Pregnant
258,T163,Condition 2768 2777	lactating
259,T164,Person 2778 2783	women
260,T165,Person 2788 2794	female
261,T166,Observation 2809 2831	childbearing potential
262,*,OR T163 T162
263,*,OR T164 T165
264,T167,Scope 2756 2831	Pregnant or lactating women and female volunteers of childbearing potential
265,T168,Negation 2886 2889	not
266,T169,Mood 2890 2900	willing to
267,T170,Procedure 2908 2940	adequate method of contraception
268,R69,Has_negation Arg1:T169 Arg2:T168
269,R70,Has_mood Arg1:T170 Arg2:T169
270,T171,"Pregnancy_considerations 2941 3546	(oral contraceptives, intrauterine device, condom, etc.) during the study. Women of childbearing potential who are not surgically sterile will be allowed to participate in the study only if they have negative pregnancy test at Visit 1 (screening) and should continue to use medically acceptable method of contraception (basic body temperature method and rhythm method will not be allowed). Women with no menses for = 12 months will be considered as postmenopausal state and method of contraception using hormonal contraception such as oral contraceptive should be initiated from or prior to the screening."
271,R71,AND Arg1:T167 Arg2:T170
272,T172,Observation 3548 3555	History
273,T173,Condition 3559 3563;3575 3580	drug abuse
274,T174,Condition 3567 3580	alcohol abuse
275,T175,Temporal 3581 3601	within recent 1 year
276,*,OR T173 T174
277,T176,Scope 3559 3580	drug or alcohol abuse
278,R72,Has_temporal Arg1:T176 Arg2:T175
279,R73,Has_temporal Arg1:T176 Arg2:T172
280,T177,Drug 3632 3661	other investigational product
281,T178,Temporal 3662 3684	within recent 12 weeks
282,R74,Has_temporal Arg1:T177 Arg2:T178
283,T179,Non-representable 3686 3782	Conditions which render a subject ineligible for the study at the discretion of the investigator
0,T1,Condition 15 21	injury
1,T2,Qualifier 0 14	Non survivable
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 44 50	trauma
4,T4,Qualifier 23 31	Multiple
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Qualifier 32 43	significant
7,R3,Has_qualifier Arg1:T3 Arg2:T5
8,T6,Condition 86 107	extracranial injuries
9,T7,Condition 69 81;99 107	intracranial injuries
10,T8,Condition 118 132	limb fractures
11,T9,Scope 69 132	intracranial and extracranial injuries including limb fractures
12,R4,Subsumes Arg1:T3 Arg2:T9
13,T10,Condition 272 280	dementia
14,T11,Condition 282 303	demyelinating disease
15,T12,Condition 305 323	autoimmune disease
16,*,OR T10 T11 T12
17,T13,Condition 355 371	contraindication
18,T14,Procedure 375 383	NeuroAiD
19,R5,AND Arg1:T13 Arg2:T14
0,T1,Condition 6 15	asthmatic
1,T2,Observation 19 26	history
2,T3,Condition 30 37	allergy
3,T4,Drug 46 52	peanut
4,T5,Drug 56 69	milk products
5,*,OR T4 T5
6,T6,Scope 46 69	peanut or milk products
7,R1,causal Arg1:T3 Arg2:T6
8,R2,Has_temporal Arg1:T3 Arg2:T2
9,*,OR T3 T1
10,T8,Condition 130 137	illness
11,T9,Qualifier 123 129	Severe
12,R3,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Procedure 149 166	hospital referral
14,T11,Mood 138 148	warranting
15,R4,Has_mood Arg1:T10 Arg2:T11
16,R5,causal Arg1:T10 Arg2:T8
17,T7,Observation 82 121	participation in another clinical trial
0,T1,Person 6 10	male
1,T2,Person 15 21	female
2,T3,Person 22 26	aged
3,T4,Value 27 41	19 to 75 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,"Informed_consent 43 214	Voluntarily consented to participate in the study and signed the informed consent form after receiving the explanation of the objectives, methods and effects of the study."
0,T1,Condition 7 27	substance dependency
1,T2,Condition 40 58	severe head injury
2,T3,Observation 29 36	History
3,R1,Has_temporal Arg1:T2 Arg2:T3
0,T1,Procedure 5 27	mechanical ventilation
1,T2,Mood 0 4	need
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Multiplier 28 48	for more than 2 days
4,R2,Has_multiplier Arg1:T1 Arg2:T3
5,T4,Measurement 50 69	mean blood pressure
6,T5,Value 70 86	more than 60mmHg
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Observation 88 106	predicted ICU stay
9,T7,Value 107 123	more than 7 days
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Visit 98 101	ICU
12,R5,multi Arg1:T6 Arg2:T8
13,T9,Condition 125 134	tolerance
14,T10,Procedure 138 148;160 169	parenteral nutrition
15,T11,Procedure 152 169	enteral nutrition
16,*,OR T10 T11
17,T12,Scope 138 169	parenteral or enteral nutrition
18,R6,Has_scope Arg1:T9 Arg2:T12
0,T1,Qualifier 0 19	irreversible status
1,T2,Condition 23 38	primary disease
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 55 67	malnutrition
4,T4,Temporal 68 85	before enrollment
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Drug 98 114	steroid cortisol
7,T6,Qualifier 131 137	severe
8,T7,Condition 138 155	liver dysfunction
9,R3,Has_qualifier Arg1:T7 Arg2:T6
10,T8,Measurement 157 173	Child-Pugh Score
11,T9,Value 174 175	C
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Scope 157 175	Child-Pugh Score C
14,R5,Subsumes Arg1:T6 Arg2:T10
15,T11,Condition 178 187	pregnancy
16,T12,Informed_consent 189 209	refuse to enrollment
17,T13,Procedure 211 223	re-admission
18,T14,Visit 227 230	ICU
19,R6,AND Arg1:T13 Arg2:T14
20,T15,Non-representable 235 283	has been enrolled during former admission to ICU
0,T1,Condition 0 7	Healthy
1,T2,Person 8 14	adults
2,T3,Value 15 31	30- 65 years old
3,T4,Person 28 31	old
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Measurement 34 37	BMI
6,T6,Value 38 49	25-35 kg/m2
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Condition 52 63	nondiabetic
9,T8,Measurement 78 100	fasting plasma glucose
10,T9,Value 101 111	<126 mg/dL
11,R3,Has_value Arg1:T8 Arg2:T9
12,T11,Measurement 139 142	LDL
13,T10,Value 143 149	=/>130
14,T12,Measurement 154 167	Triglycerides
15,T13,Value 168 179	< 150 mg/dL
16,R4,Has_value Arg1:T11 Arg2:T10
17,R5,Has_value Arg1:T12 Arg2:T13
18,T14,Non-representable 180 279	The 2nd group will have and LDL=/>130 mg/dL and Triglycerides =/>150 mg/dL but less than 400 mg/dL.
19,T15,Non-representable 121 135	one group with
0,T1,Condition 4 23	chronic hepatitis B
1,T2,Measurement 37 69	hepatitis B surface antigen test
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 74 92	active hepatitis C
4,T4,Measurement 106 137	hepatitis C virus [HCV] Ab test
5,T5,Value 142 150	positive
6,T6,Measurement 152 187	HCV ribonucleic acid [RNA] PCR test
7,A1,Optional T5
8,R2,AND Arg1:T5 Arg2:T6
9,R3,Has_value Arg1:T4 Arg2:T5
10,R4,AND Arg1:T3 Arg2:T4
11,T7,Qualifier 247 253	active
12,T8,Condition 254 272	syphilis infection
13,R5,Has_qualifier Arg1:T8 Arg2:T7
14,T9,Condition 274 283	chlamydia
15,T10,Condition 285 294	gonorrhea
16,T11,Condition 299 310	trichomonas
17,*,OR T1 T3 T8 T9 T10 T11 T13
18,T12,Qualifier 313 319	Active
19,T13,Condition 320 328	syphilis
20,R6,Has_qualifier Arg1:T13 Arg2:T12
21,T14,Measurement 343 351	serology
22,R7,AND Arg1:T13 Arg2:T14
23,T15,Measurement 368 376	serology
24,T16,Value 359 367	positive
25,T19,Condition 392 409	treated infection
26,R8,Has_value Arg1:T15 Arg2:T16
27,R9,AND Arg1:T16 Arg2:T19
28,*,OR T14 T15
29,T20,Negation 352 358	unless
30,T21,Procedure 421 434	thyroidectomy
31,T22,Condition 445 460	thyroid disease
32,T23,Qualifier 438 444	active
33,R10,Has_qualifier Arg1:T22 Arg2:T23
34,*,OR T21 T22
35,T24,Drug 471 481	medication
36,T26,Temporal 482 507	during the last 12 months
37,T27,Drug 532 555	thyroid supplementation
38,T28,Qualifier 525 531	stable
39,R11,Has_qualifier Arg1:T27 Arg2:T28
40,R12,AND Arg1:T22 Arg2:T24
41,R13,Has_temporal Arg1:T24 Arg2:T26
42,T29,Condition 572 591	psychiatric illness
43,T30,Qualifier 566 571	major
44,T31,Undefined_semantics 566 571	major
45,T32,Condition 599 614	substance abuse
46,T33,Temporal 624 649	during the past 12 months
47,R16,Has_qualifier Arg1:T29 Arg2:T30
48,T34,Procedure 661 676	hospitalization
49,T35,Condition 691 706	work disability
50,*,OR T34 T35
51,T36,Scope 661 706	hospitalization or periods of work disability
52,T37,Scope 566 614	major psychiatric illness and/or substance abuse
53,R17,Subsumes Arg1:T37 Arg2:T36
54,R15,Has_temporal Arg1:T37 Arg2:T33
55,T38,Subjective_judgement 713 747	in the opinion of the investigator
56,T39,Context_Error 754 776	preclude participation
57,T40,Drug 805 821	licensed vaccine
58,T41,Temporal 822 842	within 14 days prior
59,T42,Reference_point 846 885	the first dose of study vaccine/placebo
60,R18,Has_index Arg1:T41 Arg2:T42
61,T43,Temporal 904 924	within 14 days after
62,T44,Reference_point 929 952	first study vaccination
63,T45,Drug 864 877	study vaccine
64,T46,Drug 878 885	placebo
65,T47,Procedure 935 952	study vaccination
66,T48,Non-query-able 957 965	plans to
67,T49,Temporal 974 1004	within 14 days before or after
68,T50,"Reference_point 1009 1044	second, third or fourth vaccination"
69,T51,Drug 1033 1044	vaccination
70,R20,Has_index Arg1:T49 Arg2:T50
71,T52,Non-query-able 887 895	plans to
72,T53,"Scope 822 1044	within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination"
73,R19,Has_scope Arg1:T40 Arg2:T53
74,*,OR T41 T43 T49
75,T54,Drug 1094 1115	HIV vaccine candidate
76,T55,Temporal 1116 1127	at any time
77,T56,Drug 1147 1176	other experimental vaccine(s)
78,T57,Context_Error 1147 1176	other experimental vaccine(s)
79,T58,Temporal 1177 1202	within the last 12 months
80,T59,Qualifier 1082 1093	therapeutic
81,T60,Qualifier 1066 1078	prophylactic
82,*,OR T60 T59
83,T61,Scope 1066 1093	prophylactic or therapeutic
84,R21,Has_scope Arg1:T54 Arg2:T61
85,R22,Has_temporal Arg1:T54 Arg2:T55
86,*,OR T54 T56
87,R23,Has_temporal Arg1:T56 Arg2:T58
88,T62,Drug 1237 1257	experimental vaccine
89,T63,Drug 1266 1277	HIV vaccine
90,T64,Negation 1259 1265	except
91,R24,Has_negation Arg1:T63 Arg2:T64
92,R25,AND Arg1:T62 Arg2:T63
93,T65,Temporal 1279 1302	more than 12 months ago
94,T67,Context_Error 1237 1257	experimental vaccine
95,T68,Undefined_semantics 1237 1257	experimental vaccine
96,T69,Subjective_judgement 1431 1449	case-by-case basis
97,R26,Has_temporal Arg1:T62 Arg2:T65
98,R27,Has_negation Arg1:T15 Arg2:T20
99,T17,Negation 509 521	not excluded
100,R14,Has_negation Arg1:T27 Arg2:T17
101,R28,AND Arg1:T22 Arg2:T27
0,T1,Person 0 3	Age
1,T2,Value 4 27	between 20 and 80 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 49 83	percutaneous coronary intervention
4,T4,Procedure 101 126	dual antiplatelet therapy
5,T5,Qualifier 127 139	continuously
6,T6,Temporal 140 156	at least 12weeks
7,R2,Has_qualifier Arg1:T4 Arg2:T5
8,R3,Has_temporal Arg1:T4 Arg2:T6
9,*,OR T3 T4
10,T7,Measurement 158 184	Modified Lanza Score grade
11,T8,Value 185 188	0-1
12,R4,Has_value Arg1:T7 Arg2:T8
13,T9,Procedure 201 233	upper gastrointestinal endoscopy
14,R5,AND Arg1:T9 Arg2:T7
15,T10,Condition 240 264	gastrointestinal symptom
16,T11,Qualifier 235 239	mild
17,R6,Has_qualifier Arg1:T10 Arg2:T11
18,T12,Measurement 266 275	Creatinen
19,T13,Value 285 293	= 3mg/dl
20,R7,Has_value Arg1:T12 Arg2:T13
21,T14,Measurement 295 298	BUN
22,T15,Value 299 308	= 50mg/dl
23,R8,Has_value Arg1:T14 Arg2:T15
24,T16,Measurement 310 319	Birilubin
25,T17,Value 320 328	= 3mg/dl
26,R9,Has_value Arg1:T16 Arg2:T17
27,T18,Measurement 330 333	AST
28,T19,Measurement 338 341	ALT
29,T20,Scope 330 341	AST and ALT
30,T21,Value 342 349	= 80U/L
31,R10,Has_value Arg1:T20 Arg2:T21
0,T1,Measurement 16 25	supine BP
1,T2,Value 26 45	>140 mm Hg systolic
2,T3,Value 49 68	>90 mm Hg diastolic
3,*,OR T3 T2 T4 T5
4,T4,Value 72 91	<100 mm Hg systolic
5,T5,Value 95 114	<60 mm Hg diastolic
6,T6,Scope 26 114	>140 mm Hg systolic or >90 mm Hg diastolic or <100 mm Hg systolic or <60 mm Hg diastolic
7,R1,Has_scope Arg1:T1 Arg2:T6
8,T7,Measurement 155 170	Serum potassium
9,T8,Value 171 183	>=5.1 mmol/L
10,T9,Value 187 198	<3.5 mmol/L
11,T10,Temporal 199 211	at screening
12,*,OR T9 T8
13,T11,Scope 171 198	>=5.1 mmol/L or <3.5 mmol/L
14,R2,Has_scope Arg1:T7 Arg2:T11
15,R3,Has_temporal Arg1:T7 Arg2:T10
16,T12,Measurement 264 277	Estimated GFR
17,T13,Value 278 296	<60 mL/min/1.73 m2
18,T14,Observation 307 330	Cockcroft-Gault formula
19,R4,Has_value Arg1:T12 Arg2:T13
20,R5,Has_context Arg1:T12 Arg2:T14
0,T1,Measurement 9 24	gestational age
1,T2,Value 25 36	>= 28 weeks
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 38 61	Systolic blood pressure
4,T4,Value 62 73	>=160 mm Hg
5,T5,Measurement 79 103	diastolic blood pressure
6,T6,Value 107 118	>=110 mm Hg
7,R2,Has_value Arg1:T3 Arg2:T4
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Non-query-able 119 160	measured twice more than 15 minutes apart
10,*,OR T3 T5
11,T8,Post-eligibility 162 183	Able to swallow pills
12,T9,Person 191 196	years
13,T10,Value 185 190	>= 18
14,R4,Has_value Arg1:T9 Arg2:T10
0,T1,Person 0 3	Age
1,T2,Value 4 15	18 or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 42 52	acromegaly
4,T4,Condition 58 88	GH-secreting pituitary adenoma
5,T5,Procedure 92 102	sellar MRI
6,R2,AND Arg1:T5 Arg2:T4
7,R3,AND Arg1:T3 Arg2:T5
8,T6,Qualifier 116 151	biochemical criteria outlined above
9,R4,Has_qualifier Arg1:T3 Arg2:T6
10,T7,Condition 207 227	acromegalic features
11,T8,Qualifier 199 206	typical
12,R5,Has_qualifier Arg1:T7 Arg2:T8
13,T9,Drug 246 268	somatostatin analogues
14,T10,Negation 230 232	No
15,T11,Temporal 233 238	prior
16,R6,Has_temporal Arg1:T9 Arg2:T11
17,R7,Has_negation Arg1:T9 Arg2:T10
18,T12,Condition 271 279;292 306	Adequate renal function
19,T13,Condition 271 287;298 306	Adequate hepatic function
20,T14,Informed_consent 308 354	Provision of a signed written informed consent
0,T1,Condition 17 51	human immunodeficiency virus (HIV)
1,T2,Negation 4 12	negative
2,R1,Has_negation Arg1:T1 Arg2:T2
3,T3,Temporal 62 74	at screening
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Condition 79 86	healthy
6,T5,Procedure 142 165	electrocardiogram (ECG)
7,T6,Observation 125 140	medical history
8,T7,Procedure 103 123	physical examination
9,T8,Procedure 171 194	vital signs measurement
10,T9,Temporal 205 217	at screening
11,T10,"Scope 103 194	physical examination, medical history, electrocardiogram (ECG), and vital signs measurement"
12,R3,Has_scope Arg1:T4 Arg2:T10
13,R4,Has_temporal Arg1:T10 Arg2:T9
14,T11,Post-eligibility 219 329	Are willing/able to adhere to the prohibitions and restrictions specified in the protocol and study procedures
15,T12,Non-query-able 219 329	Are willing/able to adhere to the prohibitions and restrictions specified in the protocol and study procedures
16,T13,Person 331 337	Female
17,T14,Condition 354 376	childbearing potential
18,T15,Measurement 398 418	serum pregnancy test
19,T16,Value 389 397	negative
20,T17,Measurement 420 464	beta human chorionic gonadotropin [beta hCG]
21,R5,Subsumes Arg1:T15 Arg2:T17
22,T18,Scope 398 465	serum pregnancy test (beta human chorionic gonadotropin [beta hCG])
23,R6,Has_value Arg1:T18 Arg2:T16
24,R7,Has_scope Arg1:T14 Arg2:T18
25,A1,Optional T13
26,R8,AND Arg1:T13 Arg2:T14
27,T19,Temporal 466 488	at the Screening visit
28,T20,Reference_point 473 488	Screening visit
29,R9,Has_index Arg1:T19 Arg2:T20
30,T21,Measurement 505 525	urine pregnancy test
31,T22,Value 496 504	negative
32,R10,Has_value Arg1:T21 Arg2:T22
33,T23,Temporal 526 543	pre-dose on Day 1
34,T24,Reference_point 538 543	Day 1
35,R11,Has_index Arg1:T23 Arg2:T24
36,T25,Grammar_Error 526 534	pre-dose
37,R12,Has_temporal Arg1:T21 Arg2:T23
38,R13,Has_temporal Arg1:T18 Arg2:T19
39,R14,AND Arg1:T13 Arg2:T21
40,T26,Condition 590 598	low risk
41,T27,Condition 603 616	HIV infection
42,R15,AND Arg1:T27 Arg2:T26
43,T28,Subjective_judgement 590 598	low risk
44,T29,Undefined_semantics 590 598	low risk
0,T1,Value 0 16	Less than 30 yrs
1,T2,Person 20 23	age
2,T3,Value 27 35	> 65 yrs
3,T4,Person 39 42	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,R2,Has_value Arg1:T2 Arg2:T1
6,T5,Qualifier 48 59	significant
7,T6,Condition 60 74	co-morbidities
8,R3,Has_qualifier Arg1:T6 Arg2:T5
9,T7,Qualifier 84 90	active
10,T8,Condition 115 123;91 96	diseases heart
11,T9,Condition 115 123;98 104	diseases kidney
12,T10,Condition 109 123	liver diseases
13,T11,"Scope 91 123	heart, kidney, or liver diseases"
14,R4,Has_qualifier Arg1:T11 Arg2:T7
15,T12,Qualifier 140 149	malignant
16,T13,Qualifier 125 136	accelerated
17,*,OR T13 T12
18,T14,Condition 150 162	hypertension
19,T15,Scope 125 149	accelerated or malignant
20,R5,Has_scope Arg1:T14 Arg2:T15
21,T16,Condition 164 177	heart failure
22,T17,Condition 179 192	severe anemia
23,*,OR T8 T9 T10 T14 T16 T17
24,T18,"Scope 84 192	active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia"
25,T19,Scope 48 74	significant co-morbidities
26,R6,Subsumes Arg1:T19 Arg2:T18
0,T1,Person 0 4	Male
1,T2,Person 12 18	female
2,T3,Condition 19 26	healthy
3,T4,Person 39 42	age
4,T5,Value 43 57	18 to 55 years
5,R1,Has_value Arg1:T4 Arg2:T5
6,*,OR T2 T1
7,T6,Person 59 66	Females
8,T7,Condition 82 104	childbearing potential
9,T8,Negation 78 81	non
10,R2,Has_negation Arg1:T7 Arg2:T8
11,T9,Measurement 107 128	Body Mass Index (BMI)
12,T10,Value 132 150	17.5 to 30.5 kg/m2
13,R3,Has_value Arg1:T9 Arg2:T10
14,T11,Measurement 158 175	total body weight
15,T12,Value 176 192	>50 kg (110 lbs)
16,R4,Has_value Arg1:T11 Arg2:T12
17,T13,"Post-eligibility 195 341	Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, diet restrictions and other trial procedures."
0,T1,Pregnancy_considerations 0 26	Pregnant or breast feeding
1,T2,Procedure 50 67	esophagus surgery
2,T3,Procedure 39 46;60 67	Stomach surgery
3,*,OR T2 T3
4,T4,Condition 85 103	reflux esophagitis
5,T5,Condition 69 81	Peptic ulcer
6,*,OR T5 T4
7,T6,Condition 105 131	Zollinger-Ellison syndrome
8,T7,Condition 135 172	primary esophageal motility disorders
9,*,OR T6 T7
10,T8,Condition 174 189	Malignant tumor
11,T9,Condition 191 208	Bleeding tendency
12,T10,Condition 212 224	coagulopathy
13,*,OR T9 T10
14,T11,Condition 226 242	Contraindication
15,T12,Drug 246 251	ALBIS
16,R1,AND Arg1:T11 Arg2:T12
17,T13,Qualifier 253 262	Long term
18,T14,Drug 270 277	aspirin
19,T15,Drug 281 306	P2Y12 receptor antagonist
20,*,OR T15 T14
21,T16,Temporal 307 320	within 1month
22,T17,Scope 270 306	aspirin or P2Y12 receptor antagonist
23,R2,Has_qualifier Arg1:T17 Arg2:T13
24,R3,Has_temporal Arg1:T17 Arg2:T16
25,T18,Drug 357 360	PPI
26,T19,Drug 362 365	APA
27,T20,Drug 366 375	H2blocker
28,T21,Drug 377 406	Muscarine receptor antagonist
29,T22,Drug 408 425	anti-gastic agent
30,T23,Drug 427 434	antacid
31,T24,Drug 436 449	anticaogulant
32,T25,Drug 451 472	Bisphosphonate agents
33,T26,Drug 474 488	Cytotoxic drug
34,T27,Drug 490 495	NSAID
35,T28,Drug 497 526	adrenal cortex hormone agents
36,T29,Procedure 528 545	topical treatment
37,T30,Negation 549 556	allowed
38,R4,Has_negation Arg1:T29 Arg2:T30
39,*,OR T18 T19 T20 T21 T22 T23 T24 T25 T26 T27 T28
40,T31,Person 568 575	patient
41,T32,Qualifier 559 567	Terminal
42,R5,Has_qualifier Arg1:T31 Arg2:T32
0,T1,Condition 0 10	Indication
1,T2,Procedure 15 32	emergent cesarean
2,T3,Condition 42 55	fetal anomaly
3,R1,AND Arg1:T1 Arg2:T2
4,*,OR T1 T3
5,T4,Procedure 57 82	Anti-hypertensive therapy
6,T5,Temporal 99 112	past 12 hours
7,R2,Has_temporal Arg1:T4 Arg2:T5
8,T6,Condition 125 134	eclampsia
9,T7,Condition 152 168	CNS complication
10,T8,Condition 176 182	stroke
11,T9,Condition 186 190	PRES
12,*,OR T8 T9
13,T10,Scope 176 190	stroke or PRES
14,R3,Has_scope Arg1:T7 Arg2:T10
15,*,OR T6 T7
16,T11,Temporal 192 209	in this pregnancy
17,T12,"Scope 125 190	eclampsia or other adverse CNS complication (e.g., stroke or PRES"
18,R4,Has_temporal Arg1:T12 Arg2:T11
19,T13,Temporal 229 250	at time of enrollment
20,T14,Reference_point 240 250	enrollment
21,T15,Condition 265 285	asthma complications
22,T16,Condition 220 228	wheezing
23,R5,Has_temporal Arg1:T16 Arg2:T13
24,*,OR T16 T15
25,T17,Condition 293 316	coronary artery disease
26,T18,Condition 320 329	type I DM
27,T19,Condition 335 362	microvascular complications
28,T20,Condition 375 388	heart failure
29,T21,Condition 401 424	dissection of the aorta
30,*,OR T17 T18 T20 T21
31,R6,AND Arg1:T18 Arg2:T19
0,T1,Condition 7 24	co-morbid illness
1,T2,Qualifier 0 6	Severe
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Qualifier 33 44	untreatable
4,T4,Qualifier 45 50	other
5,T5,Condition 51 61	malignancy
6,T6,Qualifier 69 75	active
7,T7,Condition 76 86	infections
8,R2,Has_qualifier Arg1:T7 Arg2:T6
9,R3,Has_qualifier Arg1:T5 Arg2:T4
10,R4,Has_qualifier Arg1:T5 Arg2:T3
11,*,OR T5 T7
12,T8,Scope 33 86	untreatable other malignancy and/or active infections
13,T9,Scope 0 24	Severe co-morbid illness
14,R5,Subsumes Arg1:T9 Arg2:T8
15,T10,Condition 89 97	Pregnant
16,T11,Condition 101 110	lactating
17,T12,Person 111 116	women
18,*,OR T11 T10
19,T13,Condition 118 134	Hypersensitivity
20,T14,Drug 138 149	Sandostatin
21,T15,Drug 157 185	component of the formulation
22,*,OR T14 T15
23,T16,Scope 138 185	Sandostatin or any component of the formulation
24,R6,Has_scope Arg1:T13 Arg2:T16
0,T1,"Context_Error 0 240	Exposure/treatment to an investigational (new chemical entity) or marketed drug or biologic within 30 days preceding the first dose administration, or five half-lives of that investigational drug or biologic, if known (whichever is longer)."
1,T2,"Non-query-able 0 240	Exposure/treatment to an investigational (new chemical entity) or marketed drug or biologic within 30 days preceding the first dose administration, or five half-lives of that investigational drug or biologic, if known (whichever is longer)."
2,T3,Procedure 242 256	Donation blood
3,T4,Grammar_Error 242 256	Donation blood
4,T5,Procedure 242 250;260 265	Donation serum
5,T6,Grammar_Error 242 250;260 265	Donation serum
6,*,OR T5 T3
7,T7,Temporal 266 287	within 8 weeks before
8,T8,Reference_point 292 317	first dose administration
9,R1,Has_index Arg1:T7 Arg2:T8
10,R2,Has_temporal Arg1:T5 Arg2:T7
11,R3,Has_temporal Arg1:T3 Arg2:T7
12,T9,Condition 372 379;388 393	alcohol abuse
13,T10,Condition 383 393	drug abuse
14,*,OR T9 T10
15,T11,Observation 361 368	History
16,T12,Procedure 413 439	current version of the DSM
17,R6,AND Arg1:T10 Arg2:T12
18,R7,AND Arg1:T9 Arg2:T12
19,T13,Temporal 441 462	within 2 years before
20,T14,Reference_point 463 492	the first dose administration
21,R8,Has_index Arg1:T13 Arg2:T14
22,T15,Measurement 506 513;522 528	alcohol screen
23,T16,Measurement 517 528	drug screen
24,*,OR T16 T15 T18
25,T17,Value 497 505	positive
26,R9,Has_value Arg1:T15 Arg2:T17
27,R10,Has_value Arg1:T16 Arg2:T17
28,T18,Scope 372 393	alcohol or drug abuse
29,R4,Has_temporal Arg1:T18 Arg2:T11
30,R5,Has_temporal Arg1:T18 Arg2:T13
31,T19,Procedure 531 542	Vaccination
32,T20,Temporal 543 563	within 30 days prior
33,T21,Reference_point 567 596	the first dose administration
34,T22,Observation 604 609	plans
35,T23,Non-query-able 604 609	plans
36,T24,Procedure 623 634	vaccination
37,T25,Temporal 635 652	during the course
38,T26,Reference_point 660 665	study
39,R11,Has_index Arg1:T25 Arg2:T26
40,R12,Has_index Arg1:T20 Arg2:T21
41,R13,Has_temporal Arg1:T19 Arg2:T20
42,R14,Has_mood Arg1:T24 Arg2:T22
43,R15,Has_temporal Arg1:T24 Arg2:T25
44,*,OR T24 T19
0,T1,Measurement 0 24	Hemoglobin concentration
1,T2,Value 25 41	under 6.5 mmol/l
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 53 58	HBA1c
4,T4,Value 59 79	more than 108 mmol/l
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 81 94	Non-compliant
7,T6,Procedure 100 113	blood-letting
8,T7,Non-query-able 81 94	Non-compliant
9,R3,AND Arg1:T5 Arg2:T6
10,T8,Condition 126 140	infected ulcer
11,T9,Procedure 175 202	revascularization procedure
12,T10,Reference_point 210 222	affected leg
13,T11,Temporal 223 246	within the last 8 weeks
14,R4,Has_temporal Arg1:T9 Arg2:T11
15,R5,Has_index Arg1:T9 Arg2:T10
16,T12,Observation 150 157	planned
17,T13,Observation 165 172	has had
18,*,OR T12 T13
19,T14,Scope 150 172	planned for or has had
20,R6,Has_scope Arg1:T9 Arg2:T14
21,T15,Condition 252 257	ulcer
22,T16,Procedure 268 275	treated
23,T17,Drug 281 295	growth factors
24,T18,Temporal 296 315	in the last 8 weeks
25,R7,Has_temporal Arg1:T16 Arg2:T18
26,R8,AND Arg1:T15 Arg2:T16
27,R9,AND Arg1:T16 Arg2:T17
28,T19,Condition 328 353	deep venous insufficiency
29,T20,Condition 355 379	chronic venous leg ulcer
30,T21,Condition 383 400	stasis dermatitis
31,*,OR T20 T21 T19
32,T22,"Scope 328 400	deep venous insufficiency, chronic venous leg ulcer or stasis dermatitis"
33,T23,Observation 317 324	History
34,R10,Has_temporal Arg1:T22 Arg2:T23
35,T24,Condition 402 416	Breast-feeding
36,T25,Person 417 422	women
37,T26,Condition 426 433	fertile
38,T27,Person 434 439	women
39,T28,Observation 444 496	agreeing to use an effective method of contraception
40,T29,Negation 440 443	not
41,R11,Has_negation Arg1:T28 Arg2:T29
42,R12,AND Arg1:T25 Arg2:T24
43,R13,AND Arg1:T27 Arg2:T26
44,*,OR T25 T27
45,R14,Has_context Arg1:T27 Arg2:T28
46,T30,Non-query-able 498 575	Participation in another clinical ulcer-healing study within the last 4 weeks
47,T31,Non-query-able 577 629	Patient has previously been randomized in this study
48,T32,Subjective_judgement 631 717	Judgement by the investigator that the patient is not able to participate in the study
49,T33,Non-query-able 631 717	Judgement by the investigator that the patient is not able to participate in the study
0,T1,Condition 0 17	Diabetes mellitus
1,T2,Condition 19 29	Foot ulcer
2,T3,Qualifier 37 50	malleoli area
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,"Value 51 79	between 0,25 cm² and 5,0 cm²"
5,R2,Has_value Arg1:T2 Arg2:T4
6,T5,Condition 81 91	Foot ulcer
7,T6,Temporal 101 118	more than 6 weeks
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Measurement 120 140	Ankle-brachial index
10,T8,"Value 141 151	above 0,40"
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Condition 167 182	palpable pulses
13,T10,Reference_point 186 208	arteria dorsalis pedes
14,T11,Reference_point 216 242	arteria tibialis posterior
15,*,OR T10 T11
16,T12,Scope 186 242	arteria dorsalis pedes and/or arteria tibialis posterior
17,R5,Has_scope Arg1:T9 Arg2:T12
18,*,OR T7 T9
19,T13,Non-query-able 244 260	informed consent
20,T14,Post-eligibility 244 260	informed consent
0,T1,Person 8 12	male
1,T2,Condition 0 7	Healthy
2,T3,Person 20 26	female
3,*,OR T1 T3
4,T4,Person 48 52	ages
5,T5,Value 36 43;56 71	between 18 and 55 years
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 79 100	body mass index (BMI)
8,T7,Value 104 123	≥ 18 and ≤ 33 kg/m2
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Measurement 129 140	body weight
11,T9,Value 141 157	≥ 50 and ≤ 90 kg
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Temporal 158 170	at screening
14,T11,Reference_point 161 170	screening
15,R4,Has_index Arg1:T10 Arg2:T11
16,T12,Scope 79 157	body mass index (BMI) of ≥ 18 and ≤ 33 kg/m2 with body weight ≥ 50 and ≤ 90 kg
17,R5,Has_temporal Arg1:T12 Arg2:T10
18,T13,Person 173 180	Females
19,A1,Optional T13
20,T14,Condition 196 217	surgically sterilized
21,T15,Procedure 219 231	hysterectomy
22,T16,Procedure 233 255	bilateral oophorectomy
23,T17,Procedure 260 291	bilateral salpingo-oophorectomy
24,T18,Temporal 324 348	at least 6 months before
25,T19,Reference_point 349 358	screening
26,R6,Has_index Arg1:T18 Arg2:T19
27,*,OR T16 T17 T15
28,T20,"Scope 219 291	hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy"
29,R7,Subsumes Arg1:T14 Arg2:T20
30,R8,Has_temporal Arg1:T14 Arg2:T18
31,T21,Condition 366 380	postmenopausal
32,*,OR T14 T21
33,T22,Temporal 393 414	24 consecutive months
34,T23,Condition 423 429	menses
35,T24,Negation 415 422	without
36,R9,Has_negation Arg1:T23 Arg2:T24
37,R10,Has_temporal Arg1:T23 Arg2:T22
38,T25,Temporal 430 446	before screening
39,T26,Reference_point 437 446	screening
40,R11,Has_index Arg1:T25 Arg2:T26
41,T27,Measurement 455 489	follicle-stimulating hormone [FSH]
42,T28,Value 499 508	> 40 IU/L
43,T29,Temporal 509 521	at screening
44,T30,Reference_point 512 521	screening
45,R12,Has_index Arg1:T29 Arg2:T30
46,R13,Has_temporal Arg1:T27 Arg2:T29
47,R14,Has_value Arg1:T27 Arg2:T28
48,R15,Has_temporal Arg1:T23 Arg2:T25
49,T31,"Scope 393 521	24 consecutive months without menses before screening, with a follicle-stimulating hormone [FSH] level of > 40 IU/L at screening"
50,R16,Subsumes Arg1:T21 Arg2:T31
51,T32,"Scope 196 522	surgically sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy; proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 consecutive months without menses before screening, with a follicle-stimulating hormone [FSH] level of > 40 IU/L at screening)"
52,R17,Has_scope Arg1:T13 Arg2:T32
0,T1,Observation 8 15	history
1,T2,Condition 19 46	chronic psychiatric disease
2,R1,Has_temporal Arg1:T2 Arg2:T1
3,T3,Condition 83 108	female sexual dysfunction
4,T4,Condition 48 66	Medical conditions
5,T5,Qualifier 67 108	associated with female sexual dysfunction
6,R2,multi Arg1:T5 Arg2:T3
7,R3,Has_qualifier Arg1:T4 Arg2:T5
8,T6,Condition 110 132	cardiovascular disease
9,T7,Qualifier 134 146	uncontrolled
10,T8,Qualifier 147 154	chronic
11,T9,Condition 155 157	HT
12,T10,Condition 159 171	hypertension
13,R4,Subsumes Arg1:T9 Arg2:T10
14,T11,Condition 174 176	DM
15,T12,Condition 178 195	diabetes mellitus
16,R5,Subsumes Arg1:T11 Arg2:T12
17,T13,Procedure 209 228	gynecologic surgery
18,T14,Condition 230 257	female gynecological cancer
19,T15,Condition 260 266	breast
20,T16,Condition 268 275	ovarian
21,T17,Condition 277 284	uterine
22,T18,Condition 286 294	cervical
23,*,OR T15 T16 T17 T18
24,T19,"Scope 260 294	breast, ovarian, uterine, cervical"
25,R6,Subsumes Arg1:T14 Arg2:T19
26,R7,Has_qualifier Arg1:T9 Arg2:T8
27,R8,Has_qualifier Arg1:T9 Arg2:T7
28,*,OR T9 T11 T13 T14 T6
29,T20,Observation 198 205	History
30,R9,Has_temporal Arg1:T13 Arg2:T20
31,T21,Condition 325 350	female sexual dysfunction
32,T22,Drug 297 308	Medications
33,T23,Qualifier 309 350	associated with female sexual dysfunction
34,T24,"Scope 110 295	cardiovascular disease, uncontrolled chronic HT (hypertension) ,DM (diabetes mellitus), History of gynecologic surgery, female gynecological cancer ( breast, ovarian, uterine, cervical)"
35,T25,Scope 48 108	Medical conditions associated with female sexual dysfunction
36,R10,Subsumes Arg1:T25 Arg2:T24
37,R11,Has_qualifier Arg1:T22 Arg2:T23
38,T26,Drug 352 367	Antidepressants
39,T27,Drug 368 375	opiates
40,T28,Drug 377 390	beta blockers
41,T29,Drug 392 406	Antiepileptics
42,*,OR T26 T27 T28 T29 T33
43,T30,Drug 409 419	gabapentin
44,T31,Drug 421 431	topiramate
45,T32,Drug 432 441	phenytoin
46,T33,Drug 443 458	benzodiazepines
47,*,OR T30 T31 T32
48,T34,"Scope 409 441	gabapentin, topiramate,phenytoin"
49,R12,Subsumes Arg1:T29 Arg2:T34
50,T35,"Scope 352 458	Antidepressants opiates, beta blockers, Antiepileptics ( gabapentin, topiramate,phenytoin) benzodiazepines"
51,T36,Scope 297 350	Medications associated with female sexual dysfunction
52,R13,Subsumes Arg1:T36 Arg2:T35
0,T1,Condition 0 19	Chronic hepatitis B
1,T2,Measurement 21 26	HBsAg
2,T3,Value 27 35	positive
3,T4,Temporal 36 46	> 6 months
4,R1,Has_value Arg1:T2 Arg2:T3
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,R3,AND Arg1:T1 Arg2:T2
7,T5,Measurement 49 54	HBeAg
8,T6,Value 55 63	negative
9,T7,Temporal 64 126	within six months prior to initiation of peginterferon alfa-2a
10,T9,Reference_point 91 126	initiation of peginterferon alfa-2a
11,T10,Drug 105 126	peginterferon alfa-2a
12,R4,multi Arg1:T9 Arg2:T10
13,R5,Has_index Arg1:T7 Arg2:T9
14,R6,Has_value Arg1:T5 Arg2:T6
15,R7,Has_temporal Arg1:T5 Arg2:T7
16,T8,Measurement 128 135	HBV DNA
17,T11,Value 136 147	< 200 IU/ml
18,T12,Temporal 209 270	within one month prior to initiation of peginterferon alfa-2a
19,T13,Reference_point 235 270	initiation of peginterferon alfa-2a
20,T14,Drug 249 270	peginterferon alfa-2a
21,R8,Has_index Arg1:T12 Arg2:T13
22,R9,AND Arg1:T13 Arg2:T14
23,T15,Drug 155 177	nucleos(t)ide analogue
24,T16,Drug 186 197	Telbivudine
25,T17,Negation 179 185	except
26,R10,Has_negation Arg1:T16 Arg2:T17
27,R11,Has_value Arg1:T8 Arg2:T11
28,T18,Temporal 148 208	during nucleos(t)ide analogue (except Telbivudine) treatment
29,T19,Reference_point 155 208	nucleos(t)ide analogue (except Telbivudine) treatment
30,R12,Has_index Arg1:T18 Arg2:T19
31,R13,Has_temporal Arg1:T8 Arg2:T18
32,R14,Has_temporal Arg1:T8 Arg2:T12
33,T20,Condition 284 297	liver disease
34,T21,Qualifier 272 283	Compensated
35,R15,Has_qualifier Arg1:T20 Arg2:T21
36,T22,Person 299 302	Age
37,T23,Value 303 313	> 18 years
38,T24,Informed_consent 315 339	Written informed consent
0,T1,Person 0 3	Age
1,T2,Value 4 19	18-80 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 22 25	IFG
4,T4,Value 27 36	5.6mmol/L
5,T5,Measurement 48 51	FPG
6,T6,Value 38 46	100mg/dl
7,R2,Subsumes Arg1:T4 Arg2:T6
8,T7,Value 51 61	<7.0mmol/L
9,T8,Value 63 71	126mg/dl
10,R3,Subsumes Arg1:T7 Arg2:T8
11,R4,Has_value Arg1:T5 Arg2:T4
12,R5,Has_value Arg1:T5 Arg2:T7
13,T9,Condition 77 80	IGT
14,T10,Value 82 91	7.8mmol/L
15,T11,Value 93 101	140mg/dl
16,T12,Measurement 103 114	OGTT 2-h PG
17,T13,Measurement 141 146	HbA1C
18,T14,Value 147 155	5.7-6.4%
19,T15,Value 157 170	39-47mmol/mol
20,R6,Subsumes Arg1:T14 Arg2:T15
21,R7,Has_value Arg1:T13 Arg2:T14
22,T16,Value 114 125	<11.1mmol/L
23,T17,Value 127 135	200mg/dl
24,R8,Subsumes Arg1:T16 Arg2:T17
25,R9,Subsumes Arg1:T10 Arg2:T11
26,R10,Has_value Arg1:T12 Arg2:T10
27,R11,Has_value Arg1:T12 Arg2:T16
28,R12,Subsumes Arg1:T3 Arg2:T5
29,R13,Subsumes Arg1:T9 Arg2:T12
30,*,OR T9 T3 T13
31,T18,Value 174 183	2.6mmol/L
32,T19,Value 185 193	100mg/dl
33,T20,Measurement 195 200	LDL-C
34,T21,Value 201 210	5.2mmol/L
35,T22,Value 212 220	200mg/dl
36,R14,Subsumes Arg1:T21 Arg2:T22
37,R15,Subsumes Arg1:T18 Arg2:T19
38,T23,Measurement 227 229	TG
39,T24,Value 229 239	<5.7mmol/L
40,T25,Value 241 249	500mg/dl
41,R16,Subsumes Arg1:T24 Arg2:T25
42,R17,Has_value Arg1:T23 Arg2:T24
43,R18,Has_value Arg1:T20 Arg2:T18
44,R19,Has_value Arg1:T20 Arg2:T21
45,T26,Value 253 260	130mmHg
46,T27,Measurement 261 264	SBP
47,T28,Value 264 272	<180mmHg
48,R20,Has_value Arg1:T27 Arg2:T26
49,R21,Has_value Arg1:T27 Arg2:T28
50,T29,Value 277 284	80mmHg=
51,T30,Measurement 284 287	DBP
52,T31,Value 287 295	<110mmHg
53,R22,Has_value Arg1:T30 Arg2:T29
54,R23,Has_value Arg1:T30 Arg2:T31
55,T32,Temporal 299 306	ongoing
56,T33,Procedure 307 332	anti-hypertensive therapy
57,R24,Has_temporal Arg1:T33 Arg2:T32
58,*,OR T27 T30 T33
59,T34,Informed_consent 335 398	Patients volunteered for the study and signed informed consent.
0,T1,Competing_trial 0 80	Treatment with any investigational drug within 30 days of entry to this protocol
1,T2,Drug 105 116	Telbivudine
2,T3,Condition 125 134	hepatitis
3,T4,Qualifier 118 124	Severe
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Measurement 161 164	ALT
6,T6,Value 164 173	>10 x ULN
7,R2,Has_value Arg1:T5 Arg2:T6
8,R3,AND Arg1:T3 Arg2:T5
9,T7,Condition 200 209	cirrhosis
10,T8,Qualifier 186 199	decompensated
11,R4,Has_qualifier Arg1:T7 Arg2:T8
12,T9,Condition 222 230	jaundice
13,T10,Condition 250 259	cirrhosis
14,T11,Condition 261 268	ascites
15,T12,Condition 270 286	bleeding gastric
16,T13,Condition 290 308	esophageal varices
17,T14,Condition 312 326	encephalopathy
18,*,OR T12 T13 T14
19,T15,"Scope 211 326	defined as jaundice in the presence of cirrhosis, ascites, bleeding gastric or esophageal varices or encephalopathy"
20,R5,Subsumes Arg1:T7 Arg2:T15
21,T16,Condition 342 353	neutropenia
22,T17,Qualifier 329 341	Pre-existent
23,R6,Has_qualifier Arg1:T16 Arg2:T17
24,T18,Measurement 355 366	neutrophils
25,T19,"Value 367 377	<1,500/mm3"
26,R7,Has_value Arg1:T18 Arg2:T19
27,T20,Condition 382 398	thrombocytopenia
28,T21,Measurement 400 409	platelets
29,T22,"Value 410 422	< 90,000/mm3"
30,R8,Has_value Arg1:T21 Arg2:T22
31,R9,AND Arg1:T20 Arg2:T21
32,R10,AND Arg1:T16 Arg2:T18
33,*,OR T16 T20
34,T23,Qualifier 443 460	hepatitis C virus
35,T24,Qualifier 462 479	hepatitis D virus
36,T25,Qualifier 483 511	human immunodeficiency virus
37,T26,Qualifier 513 516	HIV
38,T27,Condition 425 437	Co-infection
39,*,OR T23 T24 T25
40,R11,Subsumes Arg1:T25 Arg2:T26
41,T28,"Scope 443 516	hepatitis C virus, hepatitis D virus or human immunodeficiency virus (HIV"
42,R12,Has_scope Arg1:T27 Arg2:T28
43,T29,Condition 557 570	liver disease
44,T30,Qualifier 537 546	inherited
45,T31,Qualifier 525 533	acquired
46,*,OR T30 T31
47,T32,Scope 525 546	acquired or inherited
48,R13,Has_scope Arg1:T29 Arg2:T32
49,T33,Condition 572 595	alcoholic liver disease
50,T34,Condition 597 626	obesity induced liver disease
51,T35,Condition 628 654	drug related liver disease
52,T36,Condition 656 677	auto-immune hepatitis
53,T37,Condition 679 694	hemochromatosis
54,T38,Condition 696 712	Wilson's disease
55,T39,Condition 716 746	alpha-1 antitrypsin deficiency
56,*,OR T33 T34 T35 T36 T37 T38 T39
57,T40,"Scope 572 745	alcoholic liver disease, obesity induced liver disease, drug related liver disease, auto-immune hepatitis, hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficienc"
58,R14,Subsumes Arg1:T29 Arg2:T40
59,T41,Measurement 748 765	Alpha fetoprotein
60,T42,Value 766 776	> 50 ng/ml
61,R15,Has_value Arg1:T41 Arg2:T42
62,T43,Condition 788 802	hypothyroidism
63,T44,Condition 778 783;792 802	Hyper thyroidism
64,*,OR T43 T44
65,T45,Drug 823 833	medication
66,T46,Non-query-able 804 939	subjects requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met
67,T47,Procedure 942 970	Immune suppressive treatment
68,T48,Temporal 971 999	within the previous 6 months
69,R16,Has_temporal Arg1:T47 Arg2:T48
70,T49,Condition 1001 1019	Contra-indications
71,T50,Drug 1024 1047	alfa-interferon therapy
72,T51,Condition 1063 1079	hypersensitivity
73,T52,Drug 1083 1093	interferon
74,T53,Drug 1097 1110	Peginterferon
75,T54,Non-query-able 1114 1239	any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study
76,*,OR T52 T53
77,T55,Scope 1083 1110	interferon or Peginterferon
78,R17,Has_scope Arg1:T51 Arg2:T55
79,R18,AND Arg1:T49 Arg2:T50
80,R19,Subsumes Arg1:T49 Arg2:T51
81,T56,"Pregnancy_considerations 1242 1267	Pregnancy, breast-feeding"
82,T57,Qualifier 1275 1286	significant
83,T58,Condition 1287 1302	medical illness
84,R20,Has_qualifier Arg1:T58 Arg2:T57
85,T59,Qualifier 1341 1352	significant
86,T60,Condition 1353 1374	pulmonary dysfunction
87,T61,Temporal 1375 1399	in the previous 6 months
88,T62,Condition 1401 1411	malignancy
89,T63,Negation 1412 1422	other than
90,T64,Condition 1423 1450	skin basocellular carcinoma
91,T65,Temporal 1451 1470	in previous 5 years
92,T66,Condition 1472 1498	immunodeficiency syndromes
93,T67,Condition 1505 1519	HIV positivity
94,T68,Condition 1521 1541	auto-immune diseases
95,T69,Procedure 1543 1560	organ transplants
96,T70,Negation 1561 1571	other than
97,T71,Procedure 1572 1578;1588 1598	cornea transplant
98,T72,Procedure 1583 1598	hair transplant
99,*,OR T72 T71
100,T73,Scope 1572 1598	cornea and hair transplant
101,R21,Has_negation Arg1:T73 Arg2:T70
102,T74,Scope 1543 1598	organ transplants other than cornea and hair transplant
103,*,OR T68 T67 T74
104,T75,"Scope 1505 1598	HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant"
105,R22,Subsumes Arg1:T66 Arg2:T75
106,R23,Has_negation Arg1:T64 Arg2:T63
107,T76,Scope 1401 1470	malignancy other than skin basocellular carcinoma in previous 5 years
108,R24,Has_temporal Arg1:T76 Arg2:T65
109,R25,Has_qualifier Arg1:T60 Arg2:T59
110,R26,Has_temporal Arg1:T60 Arg2:T61
111,*,OR T60 T76 T66
112,T77,"Scope 1341 1598	significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant"
113,R27,Subsumes Arg1:T58 Arg2:T77
114,T78,Drug 1663 1671;1690 1698	systemic steroids
115,T79,Qualifier 1655 1662	chronic
116,R28,Has_qualifier Arg1:T78 Arg2:T79
117,T80,Temporal 1700 1730	during the course of the study
118,R29,Has_temporal Arg1:T78 Arg2:T80
119,T81,Reference_point 1711 1730	course of the study
120,R30,Has_index Arg1:T80 Arg2:T81
121,T82,Condition 1732 1747	Substance abuse
122,T83,Qualifier 1757 1764	alcohol
123,T84,Qualifier 1778 1788	I.V. drugs
124,T85,Qualifier 1793 1806	inhaled drugs
125,T86,Temporal 1807 1827	in the past 2 years.
126,*,OR T83 T84 T85
127,T87,Multiplier 1766 1775	>80 g/day
128,R31,Has_multiplier Arg1:T83 Arg2:T87
129,T88,"Scope 1757 1806	alcohol (>80 g/day), I.V. drugs and inhaled drugs"
130,R32,Has_scope Arg1:T82 Arg2:T88
131,R33,Has_temporal Arg1:T82 Arg2:T86
132,T89,"Non-query-able 1829 2017	Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study"
0,T1,Condition 0 10	Menopausal
1,T2,Observation 19 34	Sexually active
0,T1,Condition 16 32	hypersensitivity
1,T2,Drug 40 50	study drug
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 63 71	diabetes
4,T4,Condition 81 94	liver disease
5,T5,Qualifier 74 80	Severe
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Measurement 113 116	AST
8,T7,Measurement 106 109	ALT
9,T8,Value 116 148	=2.5-fold the normal upper limit
10,T9,Condition 151 170	biliary obstruction
11,*,OR T7 T6
12,T10,Scope 106 116	ALT or AST
13,R3,Has_value Arg1:T10 Arg2:T8
14,T11,Scope 74 94	Severe liver disease
15,R4,Subsumes Arg1:T11 Arg2:T10
16,R5,AND Arg1:T11 Arg2:T9
17,T12,Drug 196 208	cyclosporine
18,T13,Procedure 181 190	treatment
19,T14,Temporal 173 180	Ongoing
20,R6,Has_temporal Arg1:T13 Arg2:T14
21,R7,AND Arg1:T13 Arg2:T12
22,T15,Temporal 209 223	within 2 weeks
23,R8,Has_temporal Arg1:T13 Arg2:T15
24,T16,Condition 226 243	Renal dysfunction
25,T17,Measurement 255 286	endogenous creatinine clearance
26,T18,Person 287 291	male
27,A1,Optional T18
28,T19,Person 303 309	female
29,A2,Optional T19
30,T20,Value 309 319	<105ml/min
31,T21,Value 291 301	<120ml/min
32,R9,Has_value Arg1:T18 Arg2:T21
33,R10,Has_value Arg1:T19 Arg2:T20
34,*,OR T18 T19
35,T22,Measurement 321 337	serum creatinine
36,T23,Value 337 344	=2mg/dl
37,T24,Value 346 355	186umol/L
38,R11,Subsumes Arg1:T23 Arg2:T24
39,R12,Has_value Arg1:T22 Arg2:T23
40,T25,Measurement 358 372	Renal function
41,T26,Value 373 392	progressive decline
42,R13,Has_value Arg1:T25 Arg2:T26
43,T27,Measurement 394 397	GFR
44,T28,Value 397 416	<30ml•min-1•1.73m-2
45,R14,Has_value Arg1:T27 Arg2:T28
46,T29,"Scope 287 319	male<120ml/min, female<105ml/min"
47,R15,Has_scope Arg1:T17 Arg2:T29
48,*,OR T17 T22 T25 T27
49,T30,"Scope 255 416	endogenous creatinine clearance male<120ml/min, female<105ml/min, serum creatinine=2mg/dl (186umol/L), Renal function progressive decline, GFR<30ml•min-1•1.73m-2"
50,R16,Subsumes Arg1:T16 Arg2:T30
51,T31,Condition 448 453	ASCVD
52,T32,Condition 465 468	ACS
53,T33,Condition 470 474	SCAD
54,T34,Procedure 476 493	revascularization
55,T35,Condition 495 498	ICM
56,T36,Condition 500 515	ischemic stroke
57,T37,Condition 517 520	TIA
58,T38,Condition 522 526	PASD
59,*,OR T38 T37 T36 T35 T34 T33 T32
60,T39,"Scope 465 526	ACS, SCAD, revascularization, ICM, ischemic stroke, TIA, PASD"
61,R17,Subsumes Arg1:T31 Arg2:T39
62,T40,Measurement 534 537	SBP
63,T41,Measurement 550 553	DBP
64,T42,Value 537 545	=180mmHg
65,T43,Value 553 561	=110mmHg
66,R18,Has_value Arg1:T40 Arg2:T42
67,R19,Has_value Arg1:T41 Arg2:T43
68,*,OR T41 T40
69,T44,Drug 587 600	Beta blockers
70,T45,Temporal 564 571	Ongoing
71,T46,Procedure 572 581	treatment
72,T47,Drug 602 610	Diuretic
73,*,OR T47 T44
74,T48,"Scope 587 610	Beta blockers, Diuretic"
75,R20,Has_temporal Arg1:T46 Arg2:T45
76,R21,Has_scope Arg1:T46 Arg2:T48
77,T49,Condition 613 635	Secondary hypertension
78,T50,Condition 647 650	SAS
79,T51,Condition 652 654	PA
80,T52,Condition 656 659	RAS
81,T53,Condition 661 677	pheochromocytoma
82,T54,Condition 679 697	Cushing's syndrome
83,T55,Condition 699 713	aorta diseases
84,T56,Condition 728 740	hypertension
85,T57,Qualifier 715 727	drug induced
86,R22,Has_qualifier Arg1:T56 Arg2:T57
87,*,OR T55 T54 T56 T53 T52 T51 T50
88,T58,"Scope 647 740	SAS, PA, RAS, pheochromocytoma, Cushing's syndrome, aorta diseases, drug induced hypertension"
89,R23,Subsumes Arg1:T49 Arg2:T58
90,T59,Drug 766 773	statins
91,T60,Drug 775 783	fibrates
92,T61,Temporal 743 750	Ongoing
93,T62,Procedure 751 760	treatment
94,T63,Drug 792 814	cation exchange resins
95,T64,Temporal 815 829	within 2 weeks
96,*,OR T60 T63 T59
97,T65,"Scope 766 814	statins, fibrates, and/or cation exchange resins"
98,R24,Has_temporal Arg1:T62 Arg2:T61
99,R25,Has_scope Arg1:T62 Arg2:T65
100,R26,Has_temporal Arg1:T62 Arg2:T64
101,T66,Condition 832 850	Pancreatic disease
102,T67,Procedure 864 875	gastrectomy
103,T68,Condition 877 897	short bowel syndrome
104,T69,Observation 853 860	History
105,*,OR T68 T67
106,T70,"Scope 864 897	gastrectomy, short bowel syndrome"
107,R27,Has_temporal Arg1:T70 Arg2:T69
108,T71,Temporal 900 907	Ongoing
109,T72,Procedure 908 935	hormone replacement therapy
110,R28,Has_temporal Arg1:T72 Arg2:T71
111,T73,Condition 961 976	malignant tumor
112,T74,Mood 951 960	suspected
113,T75,Mood 938 947	Diagnosed
114,*,OR T74 T75
115,T76,Scope 938 960	Diagnosed or suspected
116,R29,Has_scope Arg1:T73 Arg2:T76
117,T77,Condition 979 1008	Familial hypercholesterolemia
118,T78,Non-query-able 1011 1069	Any diseases may limit the efficacy or safety of the study
119,T79,"Pregnancy_considerations 1072 1198	Pregnant or possibly pregnant woman, or breastfeeding woman, or woman who wishes to become pregnant during study participation"
120,T80,"Non-representable 1201 1870	IFG impaired fast glucose, FPG fasting plasma glucose, IGT impaired glucose tolerance, OGTT oral glucose tolerance test, PG plasma glucose, HbA1C hemoglobin A1C, LDL-C low-density lipoprotein cholesterol, TG triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, GFR glomerular filtration rate, ASCVD arteriosclerotic cardiovascular disease, ACS acute coronary syndrome, SCAD stable coronary artery disease, ICM ischemic cardiomyopathy, TIA transient ischemic attack, PASD peripheral atherosclerotic disease, SAS sleep apnea syndrome, PA primary aldosteronism, RAS renal arterial stenosis"
0,T1,Drug 19 29	prednisone
1,T2,Value 30 40	= 1mg/kg/d
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 62 72	acute GVHD
4,T4,Qualifier 76 80	mild
5,T5,Qualifier 82 88	severe
6,T6,Qualifier 89 96	chronic
7,T7,Condition 97 101	GVHD
8,R2,Has_qualifier Arg1:T7 Arg2:T6
9,*,OR T5 T4
10,T8,"Scope 76 88	mild, severe"
11,R3,Has_scope Arg1:T7 Arg2:T8
12,*,OR T3 T7
13,T9,"Scope 62 101	acute GVHD or mild, severe chronic GVHD"
14,T10,Value 114 123	< 14years
15,T11,Person 127 130	age
16,R4,Has_value Arg1:T11 Arg2:T10
17,T12,Condition 141 157;158 161	sero-positive in HBV
18,T13,Condition 141 157;162 165	sero-positive in HCV
19,T14,Condition 141 157;166 169	sero-positive in HIV
20,T15,Condition 141 157;173 176	sero-positive in RPR
21,*,OR T14 T13 T15 T12
0,T1,Value 33 44	30-80 years
1,T3,Condition 72 87	Type 2 diabetes
2,T4,Condition 131 151	diabetic nephropathy
3,T7,Value 196 209	≤ 2000 mg/day
4,T2,Person 45 51	of age
5,R1,Has_value Arg1:T2 Arg2:T1
6,T5,Value 179 191	≥ 100 mg/day
7,T6,Measurement 153 178	urinary albumin excretion
8,R2,Has_value Arg1:T6 Arg2:T5
9,T8,Scope 153 209	urinary albumin excretion ≥ 100 mg/day but ≤ 2000 mg/day
10,R4,Subsumes Arg1:T4 Arg2:T8
11,T9,Measurement 213 245	Glomerular filtration rate (GFR)
12,T10,Value 246 257	≥ 40 ml/min
13,R5,Has_value Arg1:T9 Arg2:T10
14,T11,Qualifier 275 327	Modification of Diet in Renal Disease (MDRD) formula
15,R6,Has_qualifier Arg1:T9 Arg2:T11
16,T12,Temporal 329 349	in the last 4 months
17,R7,Has_temporal Arg1:T9 Arg2:T12
18,T13,Person 352 358	Female
19,A1,Optional T13
20,T14,Condition 376 390	postmenopausal
21,T15,Procedure 410 432	bilateral oophorectomy
22,T16,Procedure 451 472	surgically sterilized
23,T17,Procedure 476 491	hysterectomized
24,R9,OR Arg1:T16 Arg2:T17
25,T18,Temporal 492 528	at least 6 months prior to screening
26,T19,Scope 451 491	surgically sterilized or hysterectomized
27,R10,Has_temporal Arg1:T19 Arg2:T18
28,R11,OR Arg1:T15 Arg2:T19
29,R8,OR Arg1:T14 Arg2:T15
30,T20,Scope 376 528	postmenopausal or must have had a bilateral oophorectomy or must have been surgically sterilized or hysterectomized at least 6 months prior to screening
31,R12,Has_scope Arg1:T13 Arg2:T20
32,T21,Procedure 612 632	hypertensive therapy
33,A2,Optional T21
34,T22,Measurement 645 659	blood pressure
35,T23,Value 660 674	≥ 135/85 mm Hg
36,T24,Value 679 703	lower than 170/105 mm Hg
37,T25,Scope 660 703	≥ 135/85 mm Hg but lower than 170/105 mm Hg
38,R14,AND Arg1:T21 Arg2:T22
39,R15,Has_scope Arg1:T22 Arg2:T25
40,T26,Drug 756 784	antihypertensive medications
41,T27,Qualifier 749 755	stable
42,R16,Has_qualifier Arg1:T26 Arg2:T27
43,T28,Temporal 789 823	at least 8 weeks prior to baseline
44,R17,Has_temporal Arg1:T26 Arg2:T28
45,T29,Qualifier 835 850	Newly diagnosed
46,T30,Condition 851 872	hypertensive patients
47,T31,Measurement 885 899	blood pressure
48,T32,Value 900 914	≥ 135/85 mm Hg
49,T33,Value 919 943	lower than 170/105 mm Hg
50,T34,Scope 900 943	≥ 135/85 mm Hg but lower than 170/105 mm Hg
51,R19,Has_scope Arg1:T31 Arg2:T34
52,R20,Has_qualifier Arg1:T30 Arg2:T29
53,A3,Optional T29
54,A4,Optional T30
55,T35,Drug 994 1018	hypoglycemic medications
56,T36,Temporal 1023 1056	at least 8 weeks prior to Visit 2
57,R21,Has_temporal Arg1:T35 Arg2:T36
58,T37,Qualifier 987 993	stable
59,R22,Has_qualifier Arg1:T35 Arg2:T37
60,T38,"Non-query-able 1069 1321	Patients must be willing and medically able to discontinue all Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study."
61,T39,Measurement 1323 1344	Oral body temperature
62,T40,Value 1362 1374	35.0-37.5 °C
63,R23,Has_value Arg1:T39 Arg2:T40
64,R3,Has_value Arg1:T6 Arg2:T7
65,T43,Scope 835 872	Newly diagnosed hypertensive patients
66,R13,AND Arg1:T43 Arg2:T31
67,T44,Temporal 944 964	at baseline (Day -1)
68,T45,Reference_point 947 964	baseline (Day -1)
69,R18,Has_index Arg1:T44 Arg2:T45
70,R24,Has_temporal Arg1:T31 Arg2:T44
71,T46,Reference_point 815 823	baseline
72,R25,Has_index Arg1:T28 Arg2:T46
73,T47,Reference_point 1049 1056	Visit 2
74,R26,Has_index Arg1:T36 Arg2:T47
75,T41,Observation 1392 1416	written informed consent
76,T48,Temporal 1417 1445	prior to study participation
77,T49,Reference_point 1426 1445	study participation
78,R27,Has_index Arg1:T48 Arg2:T49
79,R28,Has_temporal Arg1:T41 Arg2:T48
80,T42,Observation 1450 1474	Able to communicate well
81,T50,Observation 1501 1542	comply with the requirements of the study
0,T1,Condition 0 9	pregnancy
1,T2,Condition 17 26	allergies
2,T3,Drug 31 46	tranexamic acid
3,T4,Drug 73 79	Exacyl
4,*,OR T3 T4
5,T5,Scope 31 79	tranexamic acid or any other substance in Exacyl
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Condition 81 101	deep vein thrombosis
8,T7,Procedure 103 130	Hormone Replacement Therapy
9,T8,Drug 134 152	oral contraceptive
10,*,OR T8 T7
11,T9,Drug 160 174	anticoagulants
12,T10,Condition 182 189	obesity
13,T11,Measurement 192 195	BMI
14,T12,Measurement 197 212	body mass index
15,T13,Value 214 223	>30 kg/m2
16,R2,Subsumes Arg1:T11 Arg2:T12
17,R3,Has_value Arg1:T11 Arg2:T13
18,T14,Scope 192 223	BMI (body mass index) >30 kg/m2
19,R4,Subsumes Arg1:T10 Arg2:T14
20,T15,Condition 225 238	renal disease
21,T16,Measurement 243 269	glomerular filtration rate
22,T17,Measurement 271 274	GFR
23,R5,Subsumes Arg1:T16 Arg2:T17
24,T18,"Value 276 295	<60 ml/min/1,73 m*m"
25,R6,Has_value Arg1:T16 Arg2:T18
26,T19,Value 297 305	seizures
27,T20,Value 309 317	epilepsy
28,T21,Temporal 318 329	in the past
29,*,OR T19 T20
30,T22,Scope 297 317	seizures or epilepsy
31,R7,Has_temporal Arg1:T22 Arg2:T21
0,T1,Procedure 4 35	allogeneic stem cell transplant
1,T2,Value 46 56	= 14 years
2,T3,Person 60 63	age
3,T4,Value 68 78	= 60 years
4,T5,Person 82 85	age
5,R1,Has_value Arg1:T5 Arg2:T4
6,R2,Has_value Arg1:T3 Arg2:T2
7,T6,Measurement 87 96	Bilirubin
8,T7,Measurement 98 102	SGOT
9,T8,Measurement 103 107	SGPT
10,T9,Value 108 133	< 5 × upper normal limits
11,R3,Has_value Arg1:T8 Arg2:T9
12,R4,Has_value Arg1:T7 Arg2:T9
13,R5,Has_value Arg1:T6 Arg2:T9
14,T10,Measurement 136 146	Creatinine
15,T11,Value 147 172	< 2 × upper normal limits
16,R6,Has_value Arg1:T10 Arg2:T11
17,T12,Measurement 175 192	Ejection fraction
18,T13,Value 193 198	= 50%
19,T14,Negation 200 202	no
20,T15,Qualifier 203 209	severe
21,T16,Condition 210 220	arrhythmia
22,R7,Has_qualifier Arg1:T16 Arg2:T15
23,R8,Has_negation Arg1:T16 Arg2:T14
24,R9,Has_value Arg1:T12 Arg2:T13
25,*,OR T12 T16
26,T17,Observation 223 248	Estimated life expectancy
27,T18,Value 249 259	= 6 months
28,R10,Has_value Arg1:T17 Arg2:T18
29,T19,Measurement 272 279	CMV-DNA
30,T20,Value 280 291	= 1000cp/ml
31,T21,Person 295 310	treatment group
32,T22,Person 333 351	prophylactic group
33,T23,Value 321 329	negative
34,A1,Optional T21
35,A2,Optional T22
36,R11,Has_value Arg1:T22 Arg2:T23
37,R12,Has_value Arg1:T21 Arg2:T20
38,*,OR T21 T22
39,T24,Scope 280 351	= 1000cp/ml in treatment group and being negative in prophylactic group
40,R13,Has_scope Arg1:T19 Arg2:T24
0,T1,Condition 0 19	Severe Hypertension
1,T2,Measurement 20 25;28 46	Grade WHO classification
2,T3,Value 26 27	3
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 48 93	Mean Sitting Diastolic Blood Pressure (MSDBP)
5,T5,Value 94 102	110 mmHg
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 110 152	Mean Sitting Systolic Blood Pressure MSSBP
8,T7,Value 153 161	180 mmHg
9,R3,Has_value Arg1:T6 Arg2:T7
10,*,OR T4 T6
11,T8,Scope 48 161	Mean Sitting Diastolic Blood Pressure (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg
12,R4,AND Arg1:T1 Arg2:T2
13,R5,Subsumes Arg1:T3 Arg2:T8
14,T9,Procedure 164 201	Acetylsalicyclic acid (ASA) treatment
15,T10,Value 202 209	>1g/day
16,T11,Drug 228 273	Non steroidal anti-inflammatory drug (NSAIDs)
17,R6,Has_value Arg1:T9 Arg2:T10
18,*,OR T9 T11
19,T12,Condition 275 289	Kidney disease
20,T13,Condition 304 312	diabetes
21,T14,Condition 316 328	hypertension
22,*,OR T13 T14 T12
23,T15,Measurement 330 345	Serum potassium
24,T16,Value 346 351	< 3.5
25,T17,Value 355 366	> 5.1 mEq/L
26,*,OR T16 T17
27,R7,Has_value Arg1:T15 Arg2:T16
28,T18,Measurement 368 371	GFR
29,T19,Value 372 390	< 40 ml/min/1.73m2
30,T20,Qualifier 410 422	MDRD formula
31,R8,Has_qualifier Arg1:T19 Arg2:T20
32,T21,Measurement 424 437	Serum albumin
33,T22,Value 438 448	< 2.0mg/dL
34,R9,Has_value Arg1:T21 Arg2:T22
35,T23,Condition 461 488	hypertensive encephalopathy
36,T24,Condition 492 516	cerebrovascular accident
37,*,OR T23 T24
38,T25,Observation 450 457	History
39,T26,Temporal 520 534	any time prior
40,T27,Scope 461 516	hypertensive encephalopathy or cerebrovascular accident
41,R10,Has_scope Arg1:T25 Arg2:T27
42,R11,Has_temporal Arg1:T27 Arg2:T26
43,T28,Condition 568 581	heart failure
44,T29,Measurement 583 622	New York Heart Association (NYHA) Class
45,T30,Value 623 628	II-IV
46,R12,Has_value Arg1:T29 Arg2:T30
47,T31,Scope 583 628	New York Heart Association (NYHA) Class II-IV
48,R13,Has_scope Arg1:T28 Arg2:T31
49,T32,Condition 642 663	myocardial infarction
50,T33,Condition 665 689	unstable angina pectoris
51,T34,Condition 691 714	coronary bypass surgery
52,*,OR T32 T33 T34 T35
53,T35,Condition 723 763	percutaneous coronary intervention (PCI)
54,T36,Temporal 764 789	during the 6 months prior
55,T37,Observation 631 638	History
56,T38,"Scope 642 763	myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI)"
57,R14,Has_scope Arg1:T37 Arg2:T38
58,R15,Has_temporal Arg1:T38 Arg2:T36
59,T39,Condition 812 836	third degree heart block
60,T40,Condition 802 808;818 836	Second degree heart block
61,T41,Device 847 856	pacemaker
62,T42,Negation 837 844	without
63,R16,Has_negation Arg1:T41 Arg2:T42
64,*,OR T40 T39
65,T43,Scope 802 836	Second or third degree heart block
66,R17,AND Arg1:T43 Arg2:T41
67,T44,Condition 898 908	arrhythmia
68,T45,Qualifier 869 897	potentially life threatening
69,R18,Has_qualifier Arg1:T44 Arg2:T45
70,T46,Condition 924 934	arrhythmia
71,T47,Qualifier 912 923	symptomatic
72,R19,Has_qualifier Arg1:T46 Arg2:T47
73,*,OR T46 T44
74,T48,Condition 959 981	valvular heart disease
75,T49,Condition 983 1007	Type 1 diabetes mellitus
76,T50,Condition 1022 1047	Type II diabetes mellitus
77,T51,Measurement 1049 1079	Hemaglobin subtype A1C (HbA1C)
78,T52,Value 1080 1085	>11 %
79,R20,Has_value Arg1:T51 Arg2:T52
80,T53,Qualifier 1009 1021	Uncontrolled
81,R21,Subsumes Arg1:T53 Arg2:T51
82,R22,Has_qualifier Arg1:T50 Arg2:T53
83,T54,Condition 1099 1109	malignancy
84,T55,Condition 1120 1128	leukemia
85,T56,Condition 1133 1141	lymphoma
86,T57,Condition 1151 1176	basal cell skin carcinoma
87,*,OR T55 T56
88,T58,Scope 1120 1141	leukemia and lymphoma
89,R24,Subsumes Arg1:T54 Arg2:T58
90,R23,Subsumes Arg1:T54 Arg2:T57
91,T59,Temporal 1178 1204	within the past five years
92,R25,Has_temporal Arg1:T54 Arg2:T59
93,T60,Temporal 1250 1280	within 4 weeks prior to dosing
94,T61,Value 1345 1359	400 mL or more
95,T62,Temporal 1369 1389	within 8 weeks prior
96,T63,Procedure 1325 1333;1360 1368	Donation of blood
97,T64,Condition 1337 1341;1360 1368	loss of blood
98,*,OR T64 T63
99,R26,Has_value Arg1:T63 Arg2:T61
100,R27,Has_value Arg1:T64 Arg2:T61
101,R28,Has_temporal Arg1:T63 Arg2:T62
102,R29,Has_temporal Arg1:T64 Arg2:T62
103,T65,Condition 1402 1421	Significant illness
104,T66,Temporal 1422 1448	within the two weeks prior
105,R30,Has_temporal Arg1:T65 Arg2:T66
106,T67,Condition 1465 1473;1485 1494	surgical condition
107,T68,Condition 1477 1494	medical condition
108,*,OR T67 T68
109,T69,Scope 1465 1494	surgical or medical condition
110,T70,"Qualifier 1521 1596	alter the absorption, distribution, metabolism, or excretion of study drugs"
111,R31,Has_qualifier Arg1:T69 Arg2:T70
112,T71,Observation 1651 1658	History
113,T72,Condition 1662 1698	major gastrointestinal tract surgery
114,T73,Procedure 1707 1718	gastrectomy
115,T74,Procedure 1720 1737	gastroenterostomy
116,T75,Procedure 1742 1757	bowel resection
117,*,OR T73 T74 T75
118,T76,"Scope 1707 1757	gastrectomy, gastroenterostomy, or bowel resection"
119,R32,Subsumes Arg1:T72 Arg2:T76
120,R33,AND Arg1:T71 Arg2:T72
121,T77,Condition 1798 1824	inflammatory bowel disease
122,T78,Temporal 1825 1851	during the 12 months prior
123,R34,Has_temporal Arg1:T77 Arg2:T78
124,T79,Temporal 1863 1879	Currently active
125,T80,Temporal 1760 1776	Currently active
126,T81,Temporal 1780 1797	previously active
127,*,OR T80 T81
128,R35,Has_temporal Arg1:T77 Arg2:T80
129,T82,Condition 1880 1889	gastritis
130,T83,Condition 1891 1899	duodenal
131,T84,Condition 1903 1917	gastric ulcers
132,T85,Condition 1922 1938;1946 1954	gastrointestinal bleeding
133,T86,Condition 1939 1954	rectal bleeding
134,*,OR T85 T86
135,T87,Temporal 1955 1980	during the 3 months prior
136,T88,"Scope 1880 1954	gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding"
137,R36,Has_temporal Arg1:T88 Arg2:T79
138,R37,Has_temporal Arg1:T88 Arg2:T87
139,T89,Condition 2009 2026	pancreatic injury
140,T90,Observation 1998 2005	history
141,T91,Condition 2028 2040	pancreatitis
142,T92,Measurement 2065 2084	pancreatic function
143,T93,Value 2056 2064	impaired
144,R38,Has_value Arg1:T92 Arg2:T93
145,T94,Condition 2065 2075;2085 2091	pancreatic injury
146,T95,Measurement 2117 2123	lipase
147,T96,Value 2108 2116	abnormal
148,R39,Has_value Arg1:T95 Arg2:T96
149,T97,Measurement 2127 2134	amylase
150,R40,Has_value Arg1:T97 Arg2:T96
151,*,OR T95 T97
152,T98,Scope 2108 2134	abnormal lipase or amylase
153,R41,Subsumes Arg1:T93 Arg2:T98
154,T99,Condition 2147 2162	hepatic disease
155,T100,Observation 2166 2173	history
156,T101,Condition 2177 2199	hepatic encephalopathy
157,T102,Condition 2214 2232	esophageal varices
158,T103,Condition 2250 2266	portocaval shunt
159,T104,Observation 2239 2246	history
160,T105,Observation 2203 2210	history
161,T106,"Scope 2009 2134	pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase"
162,R42,Has_scope Arg1:T90 Arg2:T106
163,*,OR T89 T91 T94 T92
164,*,OR T90 T99 T100 T105 T104
165,R43,AND Arg1:T100 Arg2:T101
166,R44,AND Arg1:T105 Arg2:T102
167,R45,AND Arg1:T104 Arg2:T103
168,T107,Drug 2291 2305	cholestyramine
169,T108,Drug 2309 2327	cholestipol resins
170,*,OR T107 T108
171,T109,Temporal 2268 2275	Current
172,R46,Has_temporal Arg1:T107 Arg2:T109
173,R47,Has_temporal Arg1:T108 Arg2:T109
174,T110,Condition 2340 2356	immunocompromise
175,T111,Observation 2329 2336	History
176,T112,Measurement 2379 2387	HIV test
177,T113,Value 2370 2378	positive
178,R48,Has_value Arg1:T112 Arg2:T113
179,R49,AND Arg1:T111 Arg2:T110
180,*,OR T110 T112
181,T114,Observation 2397 2404	History
182,T115,Measurement 2419 2454;2470 2474	Hepatitis B surface antigen (HBsAg) test
183,T116,Measurement 2458 2474	Hepatitis C test
184,T117,Value 2410 2418	positive
185,R51,Has_value Arg1:T116 Arg2:T117
186,R52,Has_value Arg1:T115 Arg2:T117
187,*,OR T115 T116
188,T118,Scope 2410 2474	positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test
189,R50,Has_scope Arg1:T114 Arg2:T118
190,T119,Observation 2484 2491	History
191,T120,Condition 2495 2499;2511 2516	drug abuse
192,T121,Condition 2503 2516	alcohol abuse
193,*,OR T121 T120
194,T122,Temporal 2517 2543	within the 12 months prior
195,T123,Scope 2495 2516	drug or alcohol abuse
196,R53,Has_scope Arg1:T119 Arg2:T123
197,R54,Has_temporal Arg1:T123 Arg2:T122
198,T124,Condition 2940 2947	allergy
199,T125,Drug 2951 2997	Angiotensin converting enzyme (ACE) inhibitors
200,R55,AND Arg1:T124 Arg2:T125
201,T126,Drug 3008 3026	thiazide diuretics
202,*,OR T125 T126 T127
203,T127,Drug 3036 3060	sulfonamide derived drug
204,T128,Condition 2875 2892	contraindications
205,T129,Drug 2900 2917	study medications
206,R56,AND Arg1:T128 Arg2:T129
207,R57,Subsumes Arg1:T128 Arg2:T124
208,T130,Drug 3476 3485	Aliskiren
209,T131,Condition 3494 3502	Pregnant
210,T132,Condition 3506 3513	nursing
211,T133,Person 3514 3519	woman
212,*,OR T131 T132
213,T134,Competing_trial 1223 1249	any clinical investigation
214,R58,Has_temporal Arg1:T134 Arg2:T60
215,T135,Reference_point 1274 1280	dosing
216,R59,Has_index Arg1:T60 Arg2:T135
217,T136,Non-query-able 2556 2616	Persons directly involved in the execution of this protocol.
218,T137,Condition 2622 2631	condition
219,T138,Non-representable 2637 2671	in the opinion of the investigator
220,T139,Non-representable 2637 2654;2675 2703	in the opinion of the Novartis medical monitor
221,T140,Qualifier 2632 2636;2704 2747	that would jeopardize the evaluation of efficacy
222,T141,Qualifier 2632 2636;2704 2720;2751 2757	that would jeopardize safety
223,*,OR T141 T140
224,T142,Scope 2632 2636;2704 2747;2751 2757	that would jeopardize the evaluation of efficacy safety
225,*,OR T139 T138
226,T143,Scope 2637 2703	in the opinion of the investigator or the Novartis medical monitor
227,R60,Has_scope Arg1:T137 Arg2:T142
228,R61,Has_scope Arg1:T142 Arg2:T143
229,T144,Observation 2759 2769	History of
230,T145,Observation 2770 2803	noncompliance to medical regimens
231,R62,Has_temporal Arg1:T145 Arg2:T144
232,T146,Mood 2807 2823	unwillingness to
233,T147,Informed_consent 2824 2854	comply with the study protocol
234,R63,Has_mood Arg1:T147 Arg2:T146
235,*,OR T145 T147
236,T148,Observation 2929 2939	history of
237,R64,Has_temporal Arg1:T124 Arg2:T148
238,T149,Qualifier 3030 3035	other
239,R65,Has_qualifier Arg1:T127 Arg2:T149
240,T150,Condition 3078 3095	medical condition
241,T151,Condition 3066 3074;3086 3095	surgical condition
242,*,OR T150 T151
243,T152,Non-query-able 3103 3137	in the opinion of the investigator
244,T153,Scope 3066 3095	surgical or medical condition
245,R66,AND Arg1:T153 Arg2:T152
246,T154,Drug 3339 3356	prescription drug
247,T155,Drug 3360 3393	over-the-counter (OTC) medication
248,T156,Qualifier 3403 3429	prohibited by the protocol
249,*,OR T154 T155
250,T157,Scope 3339 3393	prescription drug or over-the-counter (OTC) medication
251,R67,Has_qualifier Arg1:T157 Arg2:T156
252,T158,Qualifier 3143 3215	place the patient at higher risk from his/her participation in the study
253,R68,Has_qualifier Arg1:T153 Arg2:T158
254,T159,Mood 3223 3257	likely to prevent the patient from
255,T160,Informed_consent 3258 3302	complying with the requirements of the study
256,R69,Has_mood Arg1:T160 Arg2:T159
257,R70,AND Arg1:T153 Arg2:T160
258,T161,Negation 3233 3240	prevent
259,R71,multi Arg1:T159 Arg2:T161
260,T162,Temporal 3445 3455	previously
261,T163,Competing_trial 3476 3491	Aliskiren study
262,R72,multi Arg1:T163 Arg2:T130
263,R73,Has_temporal Arg1:T163 Arg2:T162
264,T164,Qualifier 3522 3527	Other
265,T165,Qualifier 3528 3544	protocol-defined
266,T166,Non-representable 3522 3583	Other protocol-defined inclusion/exclusion criteria may apply
267,R74,multi Arg1:T166 Arg2:T164
268,R75,multi Arg1:T166 Arg2:T165
0,T1,Person 0 3	age
1,T2,Value 4 12	> 18 y.o
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 15 83	American Society of Anesthesiologists Physical Status Classification
4,T4,Measurement 85 88	ASA
5,R2,Subsumes Arg1:T3 Arg2:T4
6,T5,Value 90 93	1-2
7,R3,Has_value Arg1:T3 Arg2:T5
8,T6,Informed_consent 95 211	signed informed consent form after reading the information about the study and talking with one of the investigators
0,T1,Measurement 14 37	systolic blood pressure
1,T2,Value 38 47	<100 mmHg
2,T3,Measurement 57 67	heart rate
3,T4,Qualifier 51 56	basal
4,T5,Value 68 75	<60/min
5,R1,Has_value Arg1:T1 Arg2:T2
6,R2,Has_qualifier Arg1:T3 Arg2:T4
7,R3,Has_value Arg1:T3 Arg2:T5
8,T6,Condition 77 99	Portal vein thrombosis
9,T7,Condition 114 121	ascites
10,T8,Condition 125 147	hepatic encephalopathy
11,T9,Qualifier 101 113	Uncontrolled
12,R4,Has_qualifier Arg1:T7 Arg2:T9
13,*,OR T7 T8
14,T10,Condition 156 176	coagulation disorder
15,T11,Qualifier 149 155	Severe
16,T12,Measurement 178 194	prothrombin time
17,T13,Value 195 199	<40%
18,T14,Measurement 204 207	INR
19,T15,Value 208 212	>1.7
20,T16,Measurement 217 231	platelet count
21,T17,"Value 232 243	<30,000/mm3"
22,R5,Has_value Arg1:T14 Arg2:T15
23,R6,Has_value Arg1:T16 Arg2:T17
24,*,OR T14 T16 T12
25,R7,Subsumes Arg1:T12 Arg2:T14
26,T18,"Scope 178 243	prothrombin time <40% (or INR >1.7) or platelet count <30,000/mm3"
27,R8,Has_qualifier Arg1:T10 Arg2:T11
28,R9,Has_scope Arg1:T10 Arg2:T18
29,T19,Condition 278 294	duodenal varices
30,T20,Condition 267 274;291 292	gastric c
31,*,OR T19 T20
32,T21,Qualifier 255 260	large
33,T22,Qualifier 245 251	Medium
34,*,OR T21 T22
35,T23,Scope 267 294	gastric or duodenal varices
36,T24,Scope 245 260	Medium or large
37,R10,Has_scope Arg1:T23 Arg2:T24
38,T25,Condition 307 317	malignancy
39,T26,Qualifier 296 306	Coexisting
40,R11,Has_qualifier Arg1:T25 Arg2:T26
41,T27,Condition 326 349	cardiovascular disorder
42,T28,Qualifier 319 325	Severe
43,T29,Condition 351 364	renal failure
44,T30,Condition 366 377	peritonitis
45,T31,Condition 379 385	sepsis
46,*,OR T31 T30 T29 T27
47,R12,Has_qualifier Arg1:T27 Arg2:T28
48,T32,Condition 394 413	erosive esophagitis
49,T33,Condition 422 442	esophageal stricture
50,T34,Condition 462 476	duodenal ulcer
51,T35,Condition 451 458;471 476	gastric ulcer
52,T36,Qualifier 444 450	active
53,T37,Qualifier 415 421	severe
54,T38,Qualifier 387 393	Severe
55,R13,Has_qualifier Arg1:T32 Arg2:T38
56,R14,Has_qualifier Arg1:T33 Arg2:T37
57,*,OR T34 T35
58,T39,Scope 451 476	gastric or duodenal ulcer
59,R15,Has_qualifier Arg1:T39 Arg2:T36
60,*,OR T32 T33 T39
61,T40,Condition 478 494	Contraindication
62,T41,Drug 498 510	beta-blocker
63,R16,AND Arg1:T40 Arg2:T41
64,T42,Condition 512 521	Pregnancy
65,T43,Informed_consent 523 574	Refusal to give consent to participate in the trial
66,*,OR T1 T3
67,R17,Has_value Arg1:T12 Arg2:T13
0,T1,Procedure 28 42	histologically
1,T2,Value 43 52	confirmed
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 57 60	NHL
4,T4,Condition 64 66	HL
5,T5,Scope 57 66	NHL or HL
6,T8,Qualifier 53 56	R/R
7,R2,Has_qualifier Arg1:T5 Arg2:T8
8,T9,Measurement 79 91	WHO criteria
9,R3,AND Arg1:T8 Arg2:T9
10,R4,Subsumes Arg1:T2 Arg2:T9
11,T10,Scope 53 66	R/R NHL or HL
12,T11,Procedure 108 142	chronic lymphocytic leukemia (CLL)
13,T12,Procedure 147 179	small lymphocytic lymphoma (SLL)
14,T13,Grammar_Error 143 146	and
15,*,OR T11 T12
16,T14,Condition 221 224	NHL
17,T15,Condition 236 274	diffuse large B cell lymphomas (DLBCL)
18,T16,Multiplier 294 304	at least 2
19,T17,Negation 225 235	other than
20,R6,Has_negation Arg1:T15 Arg2:T17
21,T18,Scope 221 274	NHL other than diffuse large B cell lymphomas (DLBCL)
22,A1,Optional T18
23,T19,Procedure 311 320	therapies
24,T20,Temporal 305 310	prior
25,T21,Context_Error 311 320	therapies
26,R8,Has_temporal Arg1:T19 Arg2:T20
27,R9,Has_multiplier Arg1:T19 Arg2:T16
28,R7,AND Arg1:T18 Arg2:T19
29,T22,Condition 336 341	DLBCL
30,T23,Condition 346 348	HL
31,T24,Grammar_Error 342 345	and
32,*,OR T22 T23
33,T25,Procedure 391 407	standard therapy
34,T26,Undefined_semantics 391 407	standard therapy
35,T27,Negation 378 380	no
36,R10,Has_negation Arg1:T25 Arg2:T27
37,T28,Scope 336 348	DLBCL and HL
38,A2,Optional T28
39,R11,AND Arg1:T28 Arg2:T25
40,T29,Measurement 439 453	histologically
41,T30,Qualifier 464 467	R/R
42,*,OR T4 T3
43,R5,AND Arg1:T5 Arg2:T1
44,T6,Condition 468 471	NHL
45,R12,Has_qualifier Arg1:T6 Arg2:T30
46,T7,Measurement 487 499	WHO criteria
47,T31,Value 454 463	confirmed
48,R13,Has_value Arg1:T29 Arg2:T31
49,R14,Subsumes Arg1:T31 Arg2:T7
50,T32,Condition 516 519	NHL
51,T33,Condition 531 569	diffuse large B cell lymphomas (DLBCL)
52,T34,Negation 520 530	other than
53,R15,Has_negation Arg1:T33 Arg2:T34
54,R16,AND Arg1:T32 Arg2:T33
55,T35,Multiplier 589 599	at least 2
56,T36,Temporal 600 605	prior
57,T37,Procedure 606 615	therapies
58,T38,Undefined_semantics 606 615	therapies
59,T39,Context_Error 311 320	therapies
60,T40,Context_Error 606 615	therapies
61,R17,Has_temporal Arg1:T37 Arg2:T36
62,R18,Has_multiplier Arg1:T37 Arg2:T35
63,T41,Scope 516 569	NHL other than diffuse large B cell lymphomas (DLBCL)
64,A3,Optional T41
65,R19,AND Arg1:T41 Arg2:T37
66,T42,Condition 631 636	DLBCL
67,T43,Procedure 679 695	standard therapy
68,T44,Undefined_semantics 679 695	standard therapy
69,T45,Negation 666 668	no
70,R20,Has_negation Arg1:T43 Arg2:T45
71,A4,Optional T42
72,R21,AND Arg1:T42 Arg2:T43
73,T46,Procedure 728 740	chemotherapy
74,T47,Qualifier 717 727	front line
75,R22,Has_qualifier Arg1:T46 Arg2:T47
76,T48,Not_a_criteria 742 790	No upper limit for the number of prior therapies
77,T49,Condition 802 809	Disease
78,T50,Qualifier 792 801	Evaluable
79,T51,Temporal 810 824	in the Phase I
80,A5,Optional T51
81,T52,Temporal 849 864	in the Phase II
82,A6,Optional T52
83,T53,Qualifier 830 840	measurable
84,R23,Has_qualifier Arg1:T51 Arg2:T50
85,R25,Has_qualifier Arg1:T52 Arg2:T53
86,*,OR T53 T50
87,R24,Has_qualifier Arg1:T49 Arg2:T53
88,T54,Person 866 869	Age
89,T55,Value 870 880	> 18 years
90,R26,Has_value Arg1:T54 Arg2:T55
91,T56,Measurement 882 905	ECOG performance status
92,T57,Value 906 909	< 2
93,R27,Has_value Arg1:T56 Arg2:T57
94,T58,Measurement 939 944;956 964	organ function
95,T59,Measurement 949 964	marrow function
96,T60,Value 930 938	adequate
97,T61,Subjective_judgement 930 938	adequate
98,T62,Undefined_semantics 930 938	adequate
99,R28,Has_value Arg1:T58 Arg2:T60
100,R29,Has_value Arg1:T59 Arg2:T60
101,T63,Procedure 975 988	Contraception
102,T64,Qualifier 966 974	Adequate
103,T65,Undefined_semantics 966 974	Adequate
104,T66,Subjective_judgement 966 974	Adequate
105,R30,Has_qualifier Arg1:T63 Arg2:T64
106,T67,Post-eligibility 990 1075	Ability to understand and the willingness to sign a written informed consent document
107,T68,Non-query-able 990 1075	Ability to understand and the willingness to sign a written informed consent document
0,T1,Condition 0 9	Infertile
1,T2,Person 15 20	women
2,T3,Condition 26 30	PCOS
3,T4,Qualifier 49 67	Rotterdam criteria
4,R1,Has_qualifier Arg1:T1 Arg2:T4
5,R2,AND Arg1:T1 Arg2:T3
6,T5,Condition 73 83	resistance
7,T6,Drug 70 72	CC
8,R3,AND Arg1:T5 Arg2:T6
9,T7,"Non-query-able 85 217	defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles"
0,T1,Condition 0 15	Type 2 diabetic
1,T2,Visit 16 25	inpatient
2,T3,Measurement 27 42	Fasting glucose
3,T4,Value 43 53	>140 mg/dl
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Measurement 57 71	random glucose
6,T6,Value 72 82	>180 mg/dl
7,R2,Has_value Arg1:T5 Arg2:T6
8,*,OR T3 T5
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 394 396	2.
2,T3,Parsing_Error 455 457	3.
3,T4,Parsing_Error 494 496	4.
4,T5,Parsing_Error 513 515	5.
5,T6,Parsing_Error 531 533	6.
6,T7,Parsing_Error 587 589	7.
7,T8,Parsing_Error 655 657	8.
8,T10,Temporal 3 8	Prior
9,T11,Procedure 29 41	chemotherapy
10,T9,Procedure 45 57	radiotherapy
11,T12,Temporal 58 78	within 2 weeks prior
12,T13,Reference_point 82 100	entering the study
13,R2,Has_index Arg1:T12 Arg2:T13
14,*,OR T11 T9
15,T14,Scope 29 57	chemotherapy or radiotherapy
16,R1,Has_temporal Arg1:T14 Arg2:T10
17,R3,Has_temporal Arg1:T14 Arg2:T12
18,T15,Condition 123 132	recovered
19,T16,Negation 119 122	not
20,R4,Has_negation Arg1:T15 Arg2:T16
21,T17,Condition 138 152	adverse events
22,R5,AND Arg1:T17 Arg2:T15
23,T18,c-Requires_causality 153 159	due to
24,T19,Drug 160 166	agents
25,T20,Temporal 180 205	more than 2 weeks earlier
26,R6,Has_temporal Arg1:T19 Arg2:T20
27,R7,AND Arg1:T17 Arg2:T19
28,*,OR T17 T14
29,T21,Drug 207 224	Systemic steroids
30,T22,Qualifier 244 254	stabilized
31,T23,Negation 235 238	not
32,R8,Has_negation Arg1:T22 Arg2:T23
33,T24,Temporal 256 264	≥ 5 days
34,R9,Has_temporal Arg1:T22 Arg2:T24
35,R10,Has_qualifier Arg1:T21 Arg2:T22
36,T25,Multiplier 287 297	≤10 mg/day
37,T26,Drug 298 308	prednisone
38,R11,Has_multiplier Arg1:T26 Arg2:T25
39,R12,AND Arg1:T22 Arg2:T26
40,T27,Temporal 309 317	prior to
41,T28,Reference_point 322 346	start of the study drugs
42,R13,Has_index Arg1:T27 Arg2:T28
43,R14,Has_temporal Arg1:T22 Arg2:T27
44,T29,Drug 351 379	other investigational agents
45,T30,Grammar_Error 348 391	No other investigational agents are allowed
46,T31,Context_Error 351 379	other investigational agents
47,T32,Condition 408 426	allergic reactions
48,T33,Drug 430 438	TGR-1202
49,T34,Drug 442 453	carfilzomib
50,*,OR T34 T33
51,T35,Scope 430 453	TGR-1202 or carfilzomib
52,R15,Has_scope Arg1:T32 Arg2:T35
53,T36,Observation 397 404	History
54,R16,Has_temporal Arg1:T32 Arg2:T36
55,T37,Condition 471 492	inter-current illness
56,T38,Qualifier 458 470	Uncontrolled
57,T39,Undefined_semantics 458 492	Uncontrolled inter-current illness
58,T40,Temporal 471 484	inter-current
59,T41,Person 506 511	women
60,T42,Condition 497 505	Pregnant
61,A1,Optional T41
62,R17,AND Arg1:T41 Arg2:T42
63,T43,Person 524 529	women
64,A2,Optional T43
65,T44,Condition 516 523	Nursing
66,R18,AND Arg1:T43 Arg2:T44
67,T45,Condition 542 552	malignancy
68,T46,Temporal 534 541	Current
69,T47,Condition 575 585	malignancy
70,T48,Observation 556 574	history of a prior
71,R19,Has_temporal Arg1:T47 Arg2:T48
72,R20,Has_temporal Arg1:T45 Arg2:T46
73,*,OR T47 T45
74,T49,Measurement 610 644	Human Immunodeficiency Virus (HIV)
75,T50,Value 645 653	positive
76,R21,Has_value Arg1:T49 Arg2:T50
77,T51,Condition 665 676	Hepatitis A
78,T52,Condition 678 689	Hepatitis B
79,T53,Condition 694 705	Hepatitis C
80,*,OR T53 T52 T51
0,T1,Person 0 3	Age
1,T2,Value 4 22	< 20 or > 35 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 25 40	Body mass index
4,T4,Measurement 42 45	BMI
5,T5,Value 47 73	< 18.5 kg/m2 or > 25 kg/m2
6,R2,Subsumes Arg1:T3 Arg2:T4
7,R3,Has_value Arg1:T3 Arg2:T5
8,T6,Condition 92 110	infertility factor
9,T7,Negation 111 121	other than
10,T8,Condition 122 138	anovulatory PCOS
11,R4,Has_negation Arg1:T8 Arg2:T7
12,T9,Procedure 161 176	ovarian surgery
13,T10,Procedure 180 196	surgical removal
14,T11,Qualifier 204 209	ovary
15,T12,Multiplier 200 203	one
16,*,OR T9 T10
17,R5,Has_qualifier Arg1:T10 Arg2:T11
18,R6,Has_multiplier Arg1:T11 Arg2:T12
19,T13,Condition 221 229	exposure
20,T14,Drug 233 248	cytotoxic drugs
21,T15,Procedure 252 270	pelvic irradiation
22,*,OR T14 T15
23,T16,Scope 233 270	cytotoxic drugs or pelvic irradiation
24,R7,Has_scope Arg1:T13 Arg2:T16
25,T17,Procedure 294 310	hormonal therapy
26,T18,Procedure 278 290;303 310	hypoglycemic therapy
27,T19,Qualifier 273 277	Oral
28,*,OR T17 T18
29,T20,Scope 278 310	hypoglycemic or hormonal therapy
30,R8,Has_qualifier Arg1:T20 Arg2:T19
31,T21,Temporal 338 356	preceding 3 months
32,R9,Has_temporal Arg1:T20 Arg2:T21
33,T22,Condition 372 394	hormonal abnormalities
34,T23,Condition 359 368;381 394	Metabolic abnormalities
35,*,OR T22 T23
0,T1,Condition 0 15	Liver cirrhosis
1,T2,Person 17 20	Age
2,T3,Value 21 44	between 18 and 70 years
3,T4,Condition 46 64	Esophageal varices
4,T5,Observation 70 88	high bleeding risk
5,R1,Has_context Arg1:T4 Arg2:T5
6,T6,Measurement 100 102	F2
7,T7,Multiplier 90 99	more than
8,T8,Condition 107 121	red color sign
9,R2,Has_multiplier Arg1:T6 Arg2:T7
10,T9,Scope 90 121	more than F2 and red color sign
11,R3,Has_scope Arg1:T5 Arg2:T9
12,T10,Negation 123 125	No
13,T11,Condition 146 177	upper gastrointestinal bleeding
14,T12,Negation 179 181	No
15,T13,Condition 250 257	varices
16,T14,Condition 261 268	ascites
17,T15,Procedure 229 245	surgical therapy
18,T16,Procedure 214 224;238 245	radiologic therapy
19,T17,Procedure 202 212;238 245	endoscopic therapy
20,*,OR T15 T17 T16
21,T18,"Scope 202 245	endoscopic, radiologic, or surgical therapy"
22,T19,Negation 270 276	Do not
23,T20,Drug 282 294	beta-blocker
24,T21,Drug 296 309	ACE inhibitor
25,T22,Drug 314 321	nitrate
26,*,OR T20 T21 T22
27,T23,"Scope 282 321	beta-blocker, ACE inhibitor, or nitrate"
28,R4,Has_negation Arg1:T23 Arg2:T19
29,T24,Measurement 323 339	Child-Pugh score
30,T25,Value 340 343	<12
31,R5,Has_value Arg1:T24 Arg2:T25
32,*,OR T13 T14
33,T26,Scope 250 268	varices or ascites
34,R6,Has_scope Arg1:T18 Arg2:T26
35,R7,Has_negation Arg1:T18 Arg2:T12
36,R8,Has_negation Arg1:T11 Arg2:T10
0,T1,Procedure 18 33	glucose monitor
1,T2,Condition 0 13	incooperative
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Drug 46 53	insulin
4,T4,Condition 35 42	refusal
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Condition 55 64	pregnancy
0,T1,Drug 0 5;20 37	amide local anaesthetic
1,T2,Drug 13 37	esther local anaesthetic
2,*,OR T1 T2
3,T4,Condition 38 45	allergy
4,T3,Scope 0 37	amide and/or esther local anaesthetic
5,R1,Has_scope Arg1:T4 Arg2:T3
6,T5,Condition 55 62	allergy
7,T6,Drug 47 54	paraben
8,R2,AND Arg1:T5 Arg2:T6
9,T7,Measurement 64 80	Child-Pugh grade
10,T8,Value 81 82	B
11,T9,Value 83 84	C
12,*,OR T8 T9
13,T10,Scope 81 84	B/C
14,R3,Has_scope Arg1:T7 Arg2:T10
15,T11,Condition 85 98	liver failure
16,R4,AND Arg1:T11 Arg2:T7
17,T12,Condition 100 119	renal insufficiency
18,T13,Measurement 121 158	calculated glomerular filtration rate
19,T14,Value 159 182	under 60 ml/min/1.73 m2
20,R5,Has_value Arg1:T13 Arg2:T14
21,T15,Qualifier 196 217	Cockcroft-Gault scale
22,R6,Has_qualifier Arg1:T13 Arg2:T15
23,T16,Condition 221 229	dementia
24,T17,Condition 253 271	swallowing problem
25,T18,Condition 329 338	pregnancy
26,T19,Condition 273 295	chronic pain condition
27,T20,Multiplier 297 308	chronic use
28,T21,Drug 312 327	pain medication
29,R7,Has_multiplier Arg1:T21 Arg2:T20
30,T22,Condition 340 349	lactation
0,T1,Multiplier 31 39	multiple
1,T2,Procedure 40 51;73 84	solid organ transplants
2,T3,Procedure 55 84	islet cell tissue transplants
3,*,OR T3 T2
4,T4,Scope 40 84	solid organ or islet cell tissue transplants
5,R1,Has_multiplier Arg1:T4 Arg2:T1
6,T5,Temporal 94 104	previously
7,T6,Procedure 117 122;133 143	organ transplant
8,T7,Procedure 126 143	tissue transplant
9,*,OR T7 T6
10,T8,Scope 117 143	organ or tissue transplant
11,R2,Has_temporal Arg1:T8 Arg2:T5
12,T9,Procedure 165 197	combined liver-kidney transplant
13,*,OR T4 T8 T9
14,T10,Observation 200 207	History
15,T11,Condition 211 221	malignancy
16,T12,Qualifier 225 241	any organ system
17,R3,Has_qualifier Arg1:T11 Arg2:T12
18,R4,Has_temporal Arg1:T11 Arg2:T10
19,T13,Negation 243 253	other than
20,T14,Condition 254 296	localized basal cell carcinoma of the skin
21,R5,Has_negation Arg1:T14 Arg2:T13
22,T15,Scope 243 296	other than localized basal cell carcinoma of the skin
23,R6,Has_scope Arg1:T11 Arg2:T15
24,T16,Qualifier 299 306	treated
25,T17,Qualifier 310 319	untreated
26,*,OR T16 T17
27,T18,Temporal 321 344	within the past 5 years
28,T19,Non-representable 346 419	regardless of whether there is evidence of local recurrence or metastases
29,T20,Scope 299 319	treated or untreated
30,R7,Has_scope Arg1:T11 Arg2:T20
31,R8,Has_temporal Arg1:T11 Arg2:T18
32,T21,Condition 439 447;467 477	surgical conditions
33,T22,Condition 449 456;467 477	medical conditions
34,T23,Condition 460 477	mental conditions
35,*,OR T21 T22 T23
36,T24,Negation 479 489	other than
37,T25,Temporal 494 501	current
38,T26,Procedure 502 517	transplantation
39,R9,Has_temporal Arg1:T26 Arg2:T25
40,R10,Has_negation Arg1:T26 Arg2:T24
41,T27,"Scope 439 477	surgical, medical or mental conditions"
42,R11,AND Arg1:T27 Arg2:T26
43,T28,Qualifier 562 610	might interfere with the objectives of the study
44,R12,Has_qualifier Arg1:T27 Arg2:T28
45,T29,Condition 613 621	Pregnant
46,T30,Observation 625 632	nursing
47,T31,Observation 634 643	lactating
48,T32,Person 645 650	women
49,R13,Subsumes Arg1:T30 Arg2:T31
0,T1,Procedure 0 18	elective procedure
1,T2,Measurement 20 26	weight
2,T3,Value 27 37	over 40 kg
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 39 79	American Society of Anesthesiology class
5,T5,Value 80 85	I-III
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Multiplier 87 92	first
8,T7,Qualifier 93 101	upper GI
9,T8,Procedure 102 121	endoscopy procedure
10,R3,Has_qualifier Arg1:T8 Arg2:T7
11,R4,Has_multiplier Arg1:T8 Arg2:T6
12,T9,Observation 123 130;146 154	finnish speaking
13,T10,Observation 138 154	swedish speaking
14,*,OR T9 T10
0,T1,Person 0 27	Liver Transplant Recipients
1,T2,Procedure 42 64	liver transplantations
2,T3,Temporal 65 108	for at least 6+1 months prior to enrollment
3,T4,Reference_point 98 108	enrollment
4,R1,Has_index Arg1:T3 Arg2:T4
5,R2,Has_temporal Arg1:T2 Arg2:T3
6,T5,Person 110 137	Liver Transplant Recipients
7,T6,Negation 143 145	no
8,T7,Qualifier 146 151	acute
9,T8,Condition 152 170	rejection episodes
10,R3,Has_qualifier Arg1:T8 Arg2:T7
11,R4,Has_negation Arg1:T8 Arg2:T6
12,T9,Temporal 171 210	within 3 months prior to the enrollment
13,T10,Reference_point 196 210	the enrollment
14,R5,Has_index Arg1:T9 Arg2:T10
15,T11,Condition 219 236	clinically stable
16,R6,Has_temporal Arg1:T8 Arg2:T9
17,T12,Person 238 265	Liver Transplant Recipients
18,T14,Multiplier 289 300	twice-daily
19,T15,Drug 312 327	tacrolimus(TAC)
20,T16,Drug 333 348	everolimus(EVR)
21,T17,Measurement 353 356;365 378	TAC trough levels
22,T18,Measurement 361 378	EVR trough levels
23,T19,Scope 312 348	tacrolimus(TAC) plus everolimus(EVR)
24,R7,Has_multiplier Arg1:T19 Arg2:T14
25,T13,Value 391 413	within targeted ranges
26,T20,Temporal 414 454	for at least 6 weeks prior to enrollment
27,T21,Reference_point 444 454	enrollment
28,R8,Has_index Arg1:T20 Arg2:T21
29,T22,Scope 353 378	TAC and EVR trough levels
30,R9,Has_value Arg1:T22 Arg2:T13
31,R10,Has_temporal Arg1:T22 Arg2:T20
32,T23,Observation 464 488	written informed consent
33,T24,Temporal 489 507	prior to inclusion
34,T25,Reference_point 498 507	inclusion
35,R11,Has_index Arg1:T24 Arg2:T25
36,R12,Has_temporal Arg1:T23 Arg2:T24
37,T26,Person 510 537	Liver transplant recipients
38,T27,Person 561 564	age
39,T28,Value 546 557	18-65 years
40,R13,Has_value Arg1:T27 Arg2:T28
41,T29,Procedure 570 594	primary liver transplant
42,T30,Measurement 596 617	Allograft functioning
43,T31,Value 624 640	acceptable level
44,T32,Measurement 659 662	AST
45,T33,Measurement 664 667	ALT
46,T34,Measurement 669 684	Total Bilirubin
47,T35,Value 692 704	=3 times ULN
48,T36,Temporal 705 724	prior to enrollment
49,T37,"Scope 659 684	AST, ALT, Total Bilirubin"
50,R14,Has_value Arg1:T37 Arg2:T35
51,R16,Has_value Arg1:T30 Arg2:T31
52,T38,Scope 596 640	Allograft functioning at an acceptable level
53,T39,"Scope 659 704	AST, ALT, Total Bilirubin levels =3 times ULN"
54,R15,Subsumes Arg1:T38 Arg2:T37
55,R17,Has_temporal Arg1:T38 Arg2:T36
56,T40,Measurement 739 748	MDRD eGFR
57,T41,Value 749 767	= 30 mL/min/1.73m2
58,R18,Has_value Arg1:T40 Arg2:T41
0,T1,Person 0 4	Aged
1,T2,Value 5 34	5 years to less than 12 years
2,T3,Temporal 35 45	at Visit 1
3,T4,Reference_point 38 45	Visit 1
4,R1,Has_index Arg1:T3 Arg2:T4
5,R2,Has_value Arg1:T1 Arg2:T2
6,R3,Has_temporal Arg1:T2 Arg2:T3
7,T6,Person 142 146	Male
8,T7,Person 150 164	pre-menarchial
9,T8,Person 165 171	female
10,T9,Scope 150 171	pre-menarchial female
11,*,OR T9 T6
12,T10,Person 200 214	pre-adolescent
13,T11,Condition 227 243	signs of puberty
14,T12,Negation 215 226	without any
15,R4,Has_negation Arg1:T11 Arg2:T12
16,T13,Measurement 245 257	Tanner Stage
17,T14,Value 258 259	1
18,R5,Has_value Arg1:T13 Arg2:T14
19,T15,Scope 215 243	without any signs of puberty
20,R6,Subsumes Arg1:T15 Arg2:T13
21,T16,Measurement 286 292	height
22,T17,Value 263 275	Normal range
23,T18,Measurement 297 303	weight
24,R7,Has_value Arg1:T16 Arg2:T17
25,R8,Has_value Arg1:T18 Arg2:T17
26,T19,Measurement 305 311	Weight
27,T21,Measurement 316 322	height
28,T22,Value 348 381	within the percentile range 3-97%
29,T5,Not_a_criteria 47 140	At least 15 (25%) children of the total study population must be aged 5 to less than 8 years.
30,T20,Condition 474 491	persistent asthma
31,T23,Qualifier 493 540	as defined by the National Institutes of Health
32,R9,Has_qualifier Arg1:T20 Arg2:T23
33,T24,Temporal 545 591	at least 3 months prior to the Screening Visit
34,T25,Reference_point 576 591	Screening Visit
35,R10,Has_index Arg1:T24 Arg2:T25
36,T26,Qualifier 596 615	pre-bronchodilatory
37,T27,Measurement 616 657	forced expiratory flow in 1 second (FEV1)
38,T28,Temporal 658 680	at Visit 1 (Screening)
39,T29,Reference_point 661 680	Visit 1 (Screening)
40,T30,Value 681 696	>=80% predicted
41,R11,Has_value Arg1:T27 Arg2:T30
42,R12,Has_temporal Arg1:T27 Arg2:T28
43,R13,Has_qualifier Arg1:T27 Arg2:T26
44,T31,Drug 717 749	Short acting beta-agonist (SABA)
45,T32,Temporal 754 788	within 4 hours of this measurement
46,T33,Reference_point 772 788	this measurement
47,R14,Has_index Arg1:T32 Arg2:T33
48,R15,Has_temporal Arg1:T31 Arg2:T32
49,T34,Negation 714 716	no
50,R16,Has_negation Arg1:T31 Arg2:T34
51,T35,Procedure 818 834	asthma therapies
52,T36,Temporal 835 864	prior to entry into the study
53,T37,Reference_point 844 864	entry into the study
54,R17,Has_index Arg1:T36 Arg2:T37
55,R18,Has_temporal Arg1:T35 Arg2:T36
56,T38,Drug 866 878	SABA inhaler
57,T39,Drug 891 901	salbutamol
58,R19,Subsumes Arg1:T38 Arg2:T39
59,T40,Drug 1027 1059	leukotriene receptor antagonists
60,T41,Drug 1015 1023	cromones
61,*,OR T41 T40 T42
62,T42,Drug 1092 1095	ICS
63,T43,Drug 1119 1129	budesonide
64,T44,Value 1130 1152	<=400 micrograms (mcg)
65,R20,Has_value Arg1:T43 Arg2:T44
66,R21,Subsumes Arg1:T42 Arg2:T43
67,T45,Scope 866 1170	SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <=400 micrograms (mcg) total daily dose)
68,R22,Subsumes Arg1:T35 Arg2:T45
69,T46,Procedure 1189 1192	ICS
70,T47,Negation 1186 1188	no
71,R23,Has_negation Arg1:T46 Arg2:T47
72,T48,Temporal 1197 1234	within 2 weeks of Visit 1 (Screening)
73,T49,Reference_point 1215 1234	Visit 1 (Screening)
74,R24,Has_index Arg1:T48 Arg2:T49
75,R25,Has_temporal Arg1:T46 Arg2:T48
76,T50,Drug 1267 1271	SABA
77,T51,Drug 1302 1313	rescue SABA
78,T52,Subjective_judgement 1237 1382	Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.
79,T53,Non-query-able 1237 1382	Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.
80,T54,"Non-query-able 1384 1719	Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement."
81,T55,"Post-eligibility 1384 1719	Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement."
82,T56,"Subjective_judgement 1720 1939	The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC)."
83,T57,"Non-query-able 1720 1939	The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC)."
84,T58,"Post-eligibility 1720 1939	The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC)."
85,T59,Not_a_criteria 1940 2057	(2) Subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis.
86,T60,"Non-query-able 2058 2315	(3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call."
87,T61,"Subjective_judgement 2058 2315	(3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call."
0,T1,Person 21 24	age
1,T2,Value 25 33;9 17	or older 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Multiplier 39 41	>3
4,T4,Observation 42 57	unformed stools
5,T5,Temporal 58 66	24 hours
6,R2,Has_multiplier Arg1:T4 Arg2:T3
7,R3,Has_temporal Arg1:T4 Arg2:T5
8,T6,Measurement 81 91	stool test
9,T7,Value 72 80	positive
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Qualifier 96 108	C. difficile
12,R5,Has_qualifier Arg1:T6 Arg2:T8
13,T9,"Non-query-able 111 279	Patients receiving = 1 high or medium risk antibiotic for treatment of an infection other than CDI, for an anticipated duration of = 5 days from the time of enrollment."
0,T1,Person 0 5	Adult
1,T2,Person 6 11	women
2,T3,Value 12 29	at least 18 years
3,T4,Person 33 36	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Qualifier 38 46	Elective
6,T6,Qualifier 47 60	Female Pelvic
7,T7,Procedure 74 96	Reconstructive Surgery
8,T8,Drug 61 69	Medicine
9,*,OR T7 T8
10,T9,Scope 61 96	Medicine and Reconstructive Surgery
11,R2,Has_qualifier Arg1:T9 Arg2:T6
12,R3,Has_qualifier Arg1:T9 Arg2:T5
13,T10,Qualifier 100 111	Gynecologic
14,T11,Qualifier 112 130	Minimally Invasive
15,T12,Procedure 131 140	surgeries
16,R4,Has_qualifier Arg1:T12 Arg2:T11
17,R5,Has_qualifier Arg1:T12 Arg2:T10
18,T13,Scope 100 140	Gynecologic Minimally Invasive surgeries
19,T14,Procedure 151 163	hysterectomy
20,T15,Procedure 165 182	suburethral sling
21,T16,Procedure 188 216	pelvic organ prolapse repair
22,*,OR T15 T14 T16 T13
23,T17,Procedure 230 240	cystoscopy
24,T18,Mood 222 229	require
25,R6,Has_mood Arg1:T17 Arg2:T18
26,T19,"Scope 100 216	Gynecologic Minimally Invasive surgeries including hysterectomy, suburethral sling, and pelvic organ prolapse repair"
27,R7,AND Arg1:T19 Arg2:T17
28,*,OR T19 T9
0,T1,Condition 0 15	type 1 diabetes
1,T2,Condition 34 42	diabetes
2,T3,Qualifier 16 30	specific types
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 43 63	gestational diabetes
5,T5,Condition 67 90	pregestational diabetes
6,*,OR T4 T5 T2 T1
7,T6,Condition 133 142;99 113	accidents cardiovascular
8,T7,Condition 117 142	cerebrovascular accidents
9,T8,Qualifier 93 98	acute
10,*,OR T7 T6
11,T9,Scope 99 142	cardiovascular or cerebrovascular accidents
12,T10,Temporal 143 163	within past 3 months
13,R2,Has_qualifier Arg1:T9 Arg2:T8
14,R3,Has_temporal Arg1:T9 Arg2:T10
15,T11,Condition 184 201	renal dysfunction
16,T12,Condition 173 180;190 201	hepatic dysfunction
17,*,OR T11 T12
18,T13,Scope 173 201	hepatic or renal dysfunction
19,T14,Qualifier 166 172	severe
20,R4,Has_qualifier Arg1:T13 Arg2:T14
21,T15,Condition 204 219	malignant tumor
22,T16,Condition 222 230	allergic
23,T17,Temporal 231 238	history
24,T18,Condition 242 258	contraindication
25,T19,Drug 267 282	drugs in trials
26,T20,Qualifier 263 266	any
27,R5,Has_qualifier Arg1:T19 Arg2:T20
28,R6,AND Arg1:T18 Arg2:T19
29,R7,Has_temporal Arg1:T16 Arg2:T17
30,*,OR T16 T18
31,T21,Competing_trial 285 321	taking part in other clinical trials
32,T22,Qualifier 324 333	obviously
33,T23,Observation 334 349	poor compliance
34,R8,Has_qualifier Arg1:T23 Arg2:T22
0,T1,Procedure 12 32	regular hemodialysis
1,T2,Multiplier 33 45	3sessions/wk
2,R1,Has_multiplier Arg1:T1 Arg2:T2
3,T3,Procedure 55 73	catheter insertion
4,T4,Temporal 74 99	at beginning of the study
5,T5,Temporal 48 54	Recent
6,R2,Has_temporal Arg1:T3 Arg2:T4
7,R3,Has_temporal Arg1:T3 Arg2:T5
8,T6,Reference_point 77 99	beginning of the study
9,R4,Has_index Arg1:T4 Arg2:T6
10,T7,Person 107 112	males
11,T8,Person 117 124	females
12,*,OR T7 T8
13,T9,Person 127 136	Age group
14,T10,Value 137 144	= 18 ys
15,R5,Has_value Arg1:T9 Arg2:T10
0,T1,Condition 30 36	asthma
1,T2,Qualifier 13 29	life-threatening
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Observation 2 9	history
4,T4,Procedure 98 108	intubation
5,T5,Condition 69 83	asthma episode
6,R2,AND Arg1:T5 Arg2:T4
7,T6,Condition 110 121	hypercapnea
8,T7,Device 132 164	non-invasive ventilatory support
9,T8,Condition 166 184	respiratory arrest
10,T9,Condition 186 202	hypoxic seizures
11,T10,Condition 206 237	asthma-related syncopal episode
12,*,OR T6 T5 T9 T10 T8
13,T11,"Scope 69 237	asthma episode that required intubation, hypercapnea requiring non-invasive ventilatory support, respiratory arrest, hypoxic seizures or asthma-related syncopal episode"
14,R3,Subsumes Arg1:T2 Arg2:T11
15,R4,Has_temporal Arg1:T1 Arg2:T3
16,T12,Observation 259 266	history
17,T13,Condition 270 289	asthma exacerbation
18,T14,Drug 311 335	systemic corticosteroids
19,T15,Temporal 372 391	for at least 3 days
20,T16,Drug 397 427	depot corticosteroid injection
21,T17,Temporal 458 473	within 3 months
22,T18,Procedure 431 456	emergency room attendance
23,R5,Has_temporal Arg1:T18 Arg2:T17
24,T19,Procedure 488 503	hospitalization
25,T20,Condition 508 514	asthma
26,R6,AND Arg1:T19 Arg2:T20
27,T21,Temporal 516 531	within 6 months
28,R7,Has_temporal Arg1:T19 Arg2:T21
29,R8,Has_temporal Arg1:T14 Arg2:T15
30,*,OR T14 T16 T18 T19
31,R9,Has_temporal Arg1:T13 Arg2:T12
32,T22,Condition 589 606	pulmonary disease
33,T23,Undefined_semantics 589 606	pulmonary disease
34,T24,Qualifier 554 565	Significant
35,T25,Subjective_judgement 554 565	Significant
36,T26,Qualifier 567 581	non-reversible
37,T27,Temporal 582 588	active
38,R10,Has_qualifier Arg1:T22 Arg2:T26
39,R11,Has_qualifier Arg1:T22 Arg2:T24
40,R12,Has_temporal Arg1:T22 Arg2:T27
41,T28,Condition 613 628	cystic fibrosis
42,T29,Condition 630 644	bronchiectasis
43,T30,Condition 646 658	tuberculosis
44,*,OR T28 T29 T30
45,T31,"Scope 613 658	cystic fibrosis, bronchiectasis, tuberculosis"
46,R13,Subsumes Arg1:T22 Arg2:T31
47,T32,Condition 707 735;745 762	viral infection of the upper respiratory tract
48,T33,Condition 694 703;713 735;745 762	bacterial infection of the upper respiratory tract
49,T34,Condition 707 729;739 762	viral infection of the lower respiratory tract
50,T35,Condition 694 703;713 729;739 762	bacterial infection of the lower respiratory tract
51,T36,Condition 707 729;764 769	viral infection of the sinus
52,T37,Condition 694 703;713 729;764 769	bacterial infection of the sinus
53,T38,Condition 707 729;773 783	viral infection of the middle ear
54,T39,Condition 694 703;713 729;773 783	bacterial infection of the middle ear
55,*,OR T37 T36 T39 T38 T34 T32 T35 T33
56,T40,Procedure 662 669	Culture
57,T41,Observation 684 693	suspected
58,T42,Scope 662 693	Culture-documented or suspected
59,*,OR T41 T40
60,T43,"Scope 694 783	bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear"
61,R14,Has_scope Arg1:T43 Arg2:T42
62,T44,Qualifier 796 804	resolved
63,T45,Negation 792 795	not
64,R15,Has_negation Arg1:T44 Arg2:T45
65,R16,Has_qualifier Arg1:T43 Arg2:T44
66,T46,Temporal 805 830	within 4 weeks of Visit 1
67,T47,Reference_point 823 830	Visit 1
68,R17,Has_index Arg1:T46 Arg2:T47
69,T48,Observation 844 871	change in asthma management
70,T49,Subjective_judgement 876 910	in the opinion of the Investigator
71,T50,Non-query-able 912 933	is expected to affect
72,T51,Subjective_judgement 969 1014	subject's ability to participate in the study
73,T52,Non-query-able 969 1014	subject's ability to participate in the study
74,R18,Has_temporal Arg1:T43 Arg2:T46
75,R19,Has_context Arg1:T43 Arg2:T48
76,T53,Procedure 854 871	asthma management
77,R20,AND Arg1:T48 Arg2:T53
78,T54,Condition 1021 1040	fracture in the leg
79,T55,Temporal 1056 1100	within 6 months prior to the screening visit
80,T56,Reference_point 1081 1100	the screening visit
81,R21,Has_index Arg1:T55 Arg2:T56
82,R22,Has_temporal Arg1:T54 Arg2:T55
83,T57,Condition 1107 1126	metabolic disorders
84,T58,Qualifier 1150 1186	may impact on normal growth patterns
85,T59,Subjective_judgement 1150 1186	may impact on normal growth patterns
86,T60,Undefined_semantics 1150 1186	may impact on normal growth patterns
87,T61,Condition 1130 1144	other diseases
88,*,OR T61 T57
89,T62,Scope 1107 1144	metabolic disorders or other diseases
90,R23,Has_qualifier Arg1:T62 Arg2:T58
91,T63,Condition 1192 1205	major surgery
92,T64,Undefined_semantics 1192 1205	major surgery
93,T65,Procedure 1216 1235	general anaesthesia
94,R24,AND Arg1:T63 Arg2:T65
95,T66,Temporal 1236 1286	for at least 3 months prior to the screening visit
96,T67,Reference_point 1267 1286	the screening visit
97,R25,Has_index Arg1:T66 Arg2:T67
98,R26,Has_temporal Arg1:T65 Arg2:T66
99,T68,Condition 1292 1309	febrile illnesses
100,T69,Negation 1189 1191	No
101,R27,Has_negation Arg1:T63 Arg2:T69
102,T70,Grammar_Error 1189 1191	No
103,T71,Measurement 1315 1326	temperature
104,T72,Value 1327 1345	>39 degree celsius
105,R28,Has_value Arg1:T71 Arg2:T72
106,T73,Temporal 1346 1381	for more than five consecutive days
107,T74,Temporal 1382 1427	within the week preceding the Screening Visit
108,T75,Reference_point 1408 1427	the Screening Visit
109,R29,Has_index Arg1:T74 Arg2:T75
110,R30,AND Arg1:T68 Arg2:T71
111,R31,Has_temporal Arg1:T71 Arg2:T73
112,R32,Has_temporal Arg1:T71 Arg2:T74
113,T76,Negation 1289 1291	No
114,R33,Has_negation Arg1:T68 Arg2:T76
115,T77,Qualifier 1434 1445	significant
116,T78,Subjective_judgement 1434 1445	significant
117,T79,Undefined_semantics 1434 1445	significant
118,T80,Condition 1446 1457	abnormality
119,T81,Condition 1461 1478	medical condition
120,*,OR T81 T80
121,T82,Scope 1446 1478	abnormality or medical condition
122,R34,Has_qualifier Arg1:T82 Arg2:T77
123,T83,"Subjective_judgement 1430 1714	Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study."
124,T84,"Post-eligibility 1430 1714	Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study."
125,T85,"Context_Error 1430 1714	Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study."
126,T86,Condition 1725 1740	visual evidence
127,T87,Condition 1744 1755	candidiasis
128,T88,Temporal 1756 1778	at Visit 1 (Screening)
129,T89,Reference_point 1759 1778	Visit 1 (Screening)
130,R35,Has_index Arg1:T88 Arg2:T89
131,R36,AND Arg1:T86 Arg2:T87
132,T90,Context_Error 1781 1841	Use of any of the prohibited medications listed in protocol.
133,T91,Drug 1799 1840	prohibited medications listed in protocol
134,T92,Condition 1843 1870	Strenuous physical exercise
135,T93,Temporal 1871 1908	within 3 hours of Visit 1 (Screening)
136,T94,Reference_point 1889 1908	Visit 1 (Screening)
137,R37,Has_index Arg1:T93 Arg2:T94
138,R38,Has_temporal Arg1:T92 Arg2:T93
139,T95,Condition 1910 1924	Drug allergies
140,T96,Drug 2002 2012;2035 2049	intranasal corticosteroid
141,T97,Drug 2026 2049	systemic corticosteroid
142,T98,Drug 2014 2021;2035 2049	inhaled corticosteroid
143,*,OR T96 T98 T97
144,T99,"Scope 2002 2049	intranasal, inhaled, or systemic corticosteroid"
145,T100,Condition 1957 1966;1978 1994	immediate hypersensitivity
146,T101,Condition 1970 1994	delayed hypersensitivity
147,*,OR T100 T101
148,T102,Condition 1930 1946	adverse reaction
149,T103,Scope 1957 1994	immediate or delayed hypersensitivity
150,R39,Subsumes Arg1:T102 Arg2:T103
151,R40,Has_scope Arg1:T103 Arg2:T99
152,T104,"Scope 1930 2049	adverse reaction including immediate or delayed hypersensitivity to any intranasal, inhaled, or systemic corticosteroid"
153,R41,Subsumes Arg1:T95 Arg2:T104
154,T105,Condition 2078 2089	sensitivity
155,T106,Drug 2097 2132	constituents of the ELLIPTA Inhaler
156,T107,Drug 2140 2147	lactose
157,T108,Drug 2149 2151	FF
158,*,OR T108 T107
159,T109,"Scope 2140 2151	lactose, FF"
160,R42,Subsumes Arg1:T106 Arg2:T109
161,R43,AND Arg1:T105 Arg2:T106
162,T110,Condition 2155 2175	Milk Protein Allergy
163,T111,Condition 2195 2215	milk protein allergy
164,T112,Qualifier 2188 2194	severe
165,R44,Has_qualifier Arg1:T111 Arg2:T112
166,R45,Subsumes Arg1:T110 Arg2:T111
167,T113,"Non-query-able 2218 2518	The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)."
168,T114,"Post-eligibility 2218 2518	The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)."
169,T115,Multiplier 2532 2543	more than 4
170,T116,Drug 2544 2578	investigational medicinal products
171,T117,Temporal 2579 2625	within 12 months prior to the first dosing day
172,T118,Reference_point 2605 2625	the first dosing day
173,R46,Has_index Arg1:T117 Arg2:T118
174,R47,Has_temporal Arg1:T116 Arg2:T117
175,R48,Has_multiplier Arg1:T116 Arg2:T115
176,T119,Drug 2646 2661	ELLIPTA inhaler
177,T120,Device 2666 2681	peak flow meter
178,T121,Condition 2628 2692	Unable to use the ELLIPTA inhaler and peak flow meter correctly.
179,T122,Non-query-able 2628 2692	Unable to use the ELLIPTA inhaler and peak flow meter correctly.
180,T123,Subjective_judgement 2628 2692	Unable to use the ELLIPTA inhaler and peak flow meter correctly.
181,T124,"Non-query-able 2694 2915	An affiliation with the Investigator site: the parents/guardians or child is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator"
182,T125,"Non-query-able 2918 3370	The Parent or Guardian has a history of psychiatric disease, intellectual deficiency, substance abuse or other condition (e.g. inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (e.g. completion of daily diary, attending scheduled clinic visits); subject safety and well-being."
183,T126,"Post-eligibility 2918 3370	The Parent or Guardian has a history of psychiatric disease, intellectual deficiency, substance abuse or other condition (e.g. inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (e.g. completion of daily diary, attending scheduled clinic visits); subject safety and well-being."
184,T127,Context_Error 3372 3488	Children in care: Children who are wards of the government or state are not eligible for participation in this study
185,T128,Non-query-able 3372 3488	Children in care: Children who are wards of the government or state are not eligible for participation in this study
0,T1,Condition 77 89	hypotenstion
1,T2,Condition 93 98	shock
2,T3,Condition 100 105	ileus
3,T4,Condition 109 126	bowel obstruction
4,T5,Condition 128 137	megacolon
5,T6,Non-query-able 0 75	Patients with severe-complicated disease that would compromise oral therapy
6,*,OR T1 T2 T3 T4 T5
7,T7,Condition 158 165	allergy
8,T8,Drug 174 184	vancomycin
9,T9,Drug 188 199	fidaxomicin
10,T10,Qualifier 169 173	oral
11,R1,Has_qualifier Arg1:T8 Arg2:T10
12,*,OR T8 T9
13,T11,Scope 174 199	vancomycin or fidaxomicin
14,R2,Has_scope Arg1:T7 Arg2:T11
15,T12,Drug 234 247	metronidazole
16,T13,Mood 211 222	anticipated
17,R3,Has_mood Arg1:T12 Arg2:T13
18,T14,Drug 302 312	vancomycin
19,T15,Drug 316 329	metronidazole
20,T16,Qualifier 297 301	oral
21,R4,Has_qualifier Arg1:T14 Arg2:T16
22,*,OR T14 T15
23,T17,Multiplier 363 373	> 24 hours
24,T18,Temporal 385 430	preceding 72 hours at the time of enrollment.
25,T19,Reference_point 419 429	enrollment
26,R5,Has_index Arg1:T18 Arg2:T19
27,T20,Scope 297 329	oral vancomycin or metronidazole
28,R6,Has_multiplier Arg1:T20 Arg2:T17
29,T21,Mood 441 452	anticipated
30,T22,Procedure 475 495	C. difficile therapy
31,T23,Drug 497 506	rifaxamin
32,T24,Drug 508 520	nitazoxanide
33,T25,Drug 522 533	tigecycline
34,*,OR T23 T24 T25
35,T26,"Scope 497 534	rifaxamin, nitazoxanide, tigecycline)"
36,R7,Subsumes Arg1:T22 Arg2:T26
37,R8,Has_mood Arg1:T22 Arg2:T21
0,T1,Condition 14 37	intercurrent infections
1,T2,Condition 54 60	sepsis
2,T3,Drug 82 111	drugs affecting immune system
3,T4,Drug 117 140	immunosuppressive drugs
4,R1,Subsumes Arg1:T3 Arg2:T4
5,T5,Drug 155 166	antibiotics
0,T1,Value 0 15	35-75 years old
1,T2,Person 12 15	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 31 46	type 2 diabetes
4,T4,Qualifier 64 113	criteria of the World Health Organization in 1999
5,R2,Has_qualifier Arg1:T3 Arg2:T4
0,T1,Drug 38 43	Botox
1,T2,Qualifier 24 37	intradetrusor
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Procedure 45 66	vaginal mesh excision
4,T4,Device 45 57	vaginal mesh
5,R2,multi Arg1:T3 Arg2:T4
6,T5,Procedure 72 86	fistula repair
7,*,OR T5 T3 T1
8,T6,Condition 88 97	Pregnancy
9,T7,Condition 110 125	nephrolithiasis
10,T8,Observation 99 106	History
11,R3,Has_temporal Arg1:T7 Arg2:T8
12,T9,Condition 127 134	Allergy
13,T10,Drug 138 155	study medications
14,R4,AND Arg1:T9 Arg2:T10
15,T11,Qualifier 157 167	Congenital
16,T12,Condition 168 186	urogenital anomaly
17,R5,Has_qualifier Arg1:T12 Arg2:T11
18,T13,Condition 188 206	Neurogenic bladder
0,T1,Multiplier 0 7	Chronic
1,T2,Drug 8 14	opiate
2,R1,Has_multiplier Arg1:T2 Arg2:T1
3,T3,Condition 20 33	Liver disease
4,T4,Observation 41 48	history
5,T5,Condition 52 63	hepatitis B
6,T6,Condition 52 61;67 68	hepatitis C
7,*,OR T6 T5
8,T7,Condition 70 79	cirrhosis
9,T8,Condition 81 109	nonalcoholic steatohepatitis
10,T9,Observation 111 118	history
11,T10,Condition 122 132	alcoholism
12,R2,Has_temporal Arg1:T10 Arg2:T9
13,T11,Measurement 134 141	ALT/AST
14,T12,Value 142 184	greater than 3 times upper limit of normal
15,T13,Temporal 185 205	in the past 3 months
16,R3,Has_value Arg1:T11 Arg2:T12
17,R4,Has_temporal Arg1:T11 Arg2:T13
18,T14,Scope 52 68	hepatitis B or C
19,R5,Has_temporal Arg1:T14 Arg2:T4
20,*,OR T14 T7 T8 T10 T11
21,T15,"Scope 41 205	history of hepatitis B or C, cirrhosis, nonalcoholic steatohepatitis, history of alcoholism, ALT/AST greater than 3 times upper limit of normal in the past 3 months"
22,R6,Subsumes Arg1:T3 Arg2:T15
23,T16,Condition 208 215	Allergy
24,T17,Condition 216 232	hypersensitivity
25,T18,Drug 236 249	acetaminophen
26,*,OR T16 T17
27,T19,Scope 208 232	Allergy/hypersensitivity
28,R7,AND Arg1:T19 Arg2:T18
29,T20,Temporal 265 273	baseline
30,T21,Condition 274 282	dementia
31,R8,Has_temporal Arg1:T21 Arg2:T20
32,T22,Condition 292 301	diathesis
33,T23,Qualifier 284 291	Chronic
34,R9,Has_qualifier Arg1:T22 Arg2:T23
35,T24,Qualifier 303 310	Chronic
36,T25,Condition 311 325	kidney disease
37,R10,Has_qualifier Arg1:T25 Arg2:T24
0,T1,Value 15 42	between 6 month and 5 years
1,T2,Person 43 46	old
2,T3,Person 6 14	children
3,R1,Has_value Arg1:T2 Arg2:T1
4,T4,Measurement 48 67	Westley croup score
5,T5,Value 68 84	between 3 and 11
6,R2,Has_value Arg1:T4 Arg2:T5
0,T1,Procedure 21 63	obotic-assisted laparoscopic prostatectomy
1,T2,Value 65 78	=18 years old
2,T3,Person 79 84	males
3,T4,Person 69 74	years
4,R1,Has_value Arg1:T4 Arg2:T2
5,T5,Measurement 86 95	ASA class
6,T6,Value 96 99	1-4
7,R2,Has_value Arg1:T5 Arg2:T6
0,T1,Condition 19 31	heart disase
1,T2,Condition 11 15;25 31	lung disase
2,*,OR T2 T1
3,T3,Drug 54 67	dexamethasone
4,T4,Condition 33 50	contra indication
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 69 91	immune deficient state
7,T6,Condition 93 106	preterm birth
8,T7,Procedure 117 127	intubation
9,T8,Condition 131 136	apnea
10,T9,Observation 137 144	history
11,T10,Temporal 108 116	previous
12,*,OR T7 T8
13,T11,Scope 117 136	intubation or apnea
14,R2,Has_temporal Arg1:T11 Arg2:T10
15,R3,Has_temporal Arg1:T11 Arg2:T9
0,T1,Condition 13 15	CD
1,T2,Qualifier 16 26	first time
2,T3,Qualifier 30 40	first year
3,*,OR T3 T2
4,T4,Scope 16 40	first time or first year
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Negation 43 45	No
7,T6,Observation 46 53	history
8,T7,Drug 63 68	5-ASA
9,T8,Procedure 101 108;70 80	therapy biological
10,T9,Procedure 84 108	immunomodulatory therapy
11,*,OR T9 T8 T7
12,T10,"Scope 63 108	5-ASA, biological or immunomodulatory therapy"
13,R2,Has_temporal Arg1:T10 Arg2:T6
14,R3,Has_negation Arg1:T10 Arg2:T5
0,T1,Condition 15 33	psychotic disorder
1,T2,Condition 58 83	psychotic affective state
2,T3,Temporal 0 6	Active
3,T4,Temporal 10 14	past
4,*,OR T4 T3
5,T5,Scope 0 14	Active or past
6,R1,Has_scope Arg1:T1 Arg2:T5
7,R2,Subsumes Arg1:T1 Arg2:T2
8,T6,Condition 85 103	Mental Retardation
9,T7,Condition 107 133	Autistic Spectrum Disorder
10,*,OR T6 T7
11,T8,Condition 135 165	Prominent personality disorder
12,T9,Condition 178 213	neurologic active medical condition
13,T10,Condition 167 174;189 213	Cardiac active medical condition
14,*,OR T9 T10
15,T11,Condition 230 233	CVA
16,T12,Condition 234 237	TIA
17,T13,Temporal 225 229	past
18,*,OR T11 T12
19,T14,Condition 239 262	Cardiovascular Accident
20,T15,Condition 263 288	Transient Ischemic Attack
21,*,OR T14 T15
22,R3,Subsumes Arg1:T11 Arg2:T14
23,R4,Subsumes Arg1:T12 Arg2:T15
24,T16,Scope 230 289	CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack)
25,R5,Has_temporal Arg1:T16 Arg2:T13
26,T17,Qualifier 303 311	unstable
27,T18,Condition 312 329	medical condition
28,R6,Has_qualifier Arg1:T18 Arg2:T17
29,T19,Scope 167 213	Cardiac or neurologic active medical condition
30,*,OR T16 T18
31,T20,Scope 225 329	past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition
32,R7,Subsumes Arg1:T19 Arg2:T20
33,T21,Condition 340 356	nasal congestion
34,T22,Temporal 332 339	Chronic
35,R8,Has_temporal Arg1:T21 Arg2:T22
36,T23,Condition 383 396	alcohol abuse
37,T24,Temporal 368 374	recent
38,T25,Temporal 358 364	Active
39,*,OR T24 T25
40,T26,Condition 375 379;391 396	drug abuse
41,*,OR T23 T26
42,T27,Scope 375 396	drug or alcohol abuse
43,T28,Scope 358 374	Active or recent
44,R9,Has_scope Arg1:T27 Arg2:T28
45,T29,Condition 410 421	suicidality
46,T30,Qualifier 398 409	Substantial
47,R10,Has_qualifier Arg1:T29 Arg2:T30
48,T31,Procedure 445 454	admission
49,R11,AND Arg1:T29 Arg2:T31
50,T32,"Non-representable 481 615	signs an ""against medical advice"" release form as part of clinical evaluation, and does not answer the terms for involuntary admission"
0,T1,Observation 3 10	consent
1,T2,Negation 0 2	No
2,R1,Has_negation Arg1:T1 Arg2:T2
3,T3,Informed_consent 0 10	No consent
4,T4,Procedure 12 29	Spinal anesthesia
5,T5,Procedure 33 52	sciatic nerve block
6,T6,Condition 53 68	contraindicated
7,*,OR T5 T4
8,T7,Scope 12 52	Spinal anesthesia or sciatic nerve block
9,R2,Has_scope Arg1:T6 Arg2:T7
10,T8,Condition 76 87	intolerance
11,T9,Drug 91 99	tramadol
12,T10,Condition 109 126	contraindications
13,T11,Drug 131 139	the drug
14,R3,AND Arg1:T10 Arg2:T11
15,R4,AND Arg1:T8 Arg2:T9
16,R5,AND Arg1:T8 Arg2:T10
17,T12,Qualifier 103 108	other
18,R6,Has_qualifier Arg1:T10 Arg2:T12
0,T1,Condition 0 13	Sensitization
1,T2,Measurement 20 23	PRA
2,T3,Value 24 28	>20%
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Scope 20 28	PRA >20%
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Condition 35 48	liver disease
7,T6,Measurement 63 70	Albumin
8,T7,Value 71 78	< 3g/dl
9,T8,Measurement 82 96	platelet count
10,T9,Value 97 110	< 75 x 103/mL
11,R3,Has_value Arg1:T8 Arg2:T9
12,R4,Has_value Arg1:T6 Arg2:T7
13,T10,Measurement 121 142	dual organ transplant
14,T11,Mood 112 120	Need for
15,R5,Has_mood Arg1:T10 Arg2:T11
0,T1,Qualifier 0 8	Moderate
1,T2,Qualifier 12 18	severe
2,T3,Condition 19 21	CD
3,T4,Measurement 32 41	HBI score
4,T5,Value 42 45	> 4
5,R1,Has_value Arg1:T4 Arg2:T5
6,*,OR T2 T1
7,T6,Scope 0 18	Moderate to severe
8,R2,Has_scope Arg1:T3 Arg2:T6
9,T7,Scope 32 45	HBI score > 4
10,R3,Subsumes Arg1:T6 Arg2:T7
11,T8,"Non-representable 48 102	Montreal classification: no limitation, except age> 6."
0,T1,Person 0 3	Age
1,T2,Value 4 9	18-65
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 24 27	MDD
4,T4,Condition 29 54	Major Depressive Disorder
5,R2,Subsumes Arg1:T3 Arg2:T4
6,T5,Measurement 112 123	MADRS score
7,T6,Value 124 128	> 20
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Drug 143 171	conventional anti-depressant
10,T8,Procedure 130 137	Treated
11,R4,AND Arg1:T8 Arg2:T7
0,T1,Condition 14 27	foot fracture
1,T2,Mood 28 41	scheduled for
2,T3,Procedure 42 57	surgical repair
3,T4,Procedure 61 78	spinal anesthesia
4,R1,AND Arg1:T3 Arg2:T4
5,R2,Has_mood Arg1:T3 Arg2:T2
6,T5,Informed_consent 80 96	Informed consent
0,T1,Person 13 16	Age
1,T2,Value 17 27	= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 29 38	Serum ALT
4,T4,Value 39 59	within normal limits
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Negation 65 67	no
7,T6,Observation 68 75	history
8,T7,Condition 79 92	liver disease
9,R3,Has_negation Arg1:T7 Arg2:T5
10,R4,Has_temporal Arg1:T7 Arg2:T6
11,T8,Negation 94 101	Lack of
12,T9,Condition 102 115	sensitization
13,T10,Measurement 122 125	PRA
14,T11,Value 126 131	< 20%
15,R5,Has_value Arg1:T10 Arg2:T11
16,T12,Scope 122 131	PRA < 20%
17,R6,Has_scope Arg1:T9 Arg2:T12
18,T13,Scope 102 132	sensitization (i.e. PRA < 20%)
19,R7,Has_negation Arg1:T13 Arg2:T8
20,T14,Non-representable 133 245	that would be expected to result in a high likelihood of needing aggressive immunosuppression to treat rejection
0,T1,Person 0 3	Age
1,T2,Value 4 21	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 32 50	penetrating trauma
4,T4,Condition 23 28;44 50	Blunt trauma
5,*,OR T3 T4
6,T5,Condition 61 64	VTE
7,T6,Procedure 65 83	thromboprophylaxis
8,R2,AND Arg1:T6 Arg2:T5
9,T7,Mood 85 94	High-risk
10,T8,Condition 99 102	VTE
11,R3,Has_mood Arg1:T8 Arg2:T7
0,T1,Condition 7 29	consumption of alcohol
1,T2,Condition 37 42;7 21	drugs consumption of
2,*,OR T2 T1
3,T3,Condition 62 90	human immunodeficiency virus
4,T4,Condition 92 109	hepatitis C virus
5,T5,Condition 114 131	hepatitis D virus
6,*,OR T3 T4 T5
7,T6,Condition 144 164	autoimmune hepatitis
8,T7,Qualifier 0 6	Active
9,T8,Scope 7 42	consumption of alcohol and/or drugs
10,R1,Has_qualifier Arg1:T8 Arg2:T7
11,T9,Observation 133 140	History
12,R2,Has_temporal Arg1:T6 Arg2:T9
13,T10,Condition 166 185	Psychiatric disease
14,T11,Condition 199 218	neoplastic diseases
15,T12,Mood 187 198	Evidence of
16,R3,Has_mood Arg1:T11 Arg2:T12
17,T13,Qualifier 226 231	liver
18,R4,Has_qualifier Arg1:T11 Arg2:T13
0,T1,Condition 0 16	Contraindication
1,T2,Drug 20 40	antiplatelet therapy
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Multiplier 50 58	continue
4,T4,Drug 59 70	clopidogrel
5,T5,Condition 78 84	stroke
6,T6,Condition 86 104	peripheral disease
7,T7,Qualifier 106 117	significant
8,T8,Condition 118 133	carotid disease
9,T9,Temporal 137 143	recent
10,T10,Condition 144 167	acute coronary syndrome
11,R2,Has_temporal Arg1:T10 Arg2:T9
12,R3,Has_qualifier Arg1:T8 Arg2:T7
13,*,OR T8 T10 T6 T5
14,T11,Mood 42 49	Need to
15,R4,Has_mood Arg1:T3 Arg2:T11
16,R5,Has_multiplier Arg1:T4 Arg2:T3
17,T12,"Scope 78 167	stroke, peripheral disease, significant carotid disease or recent acute coronary syndrome"
18,T13,Scope 42 70	Need to continue clopidogrel
19,R6,Has_scope Arg1:T13 Arg2:T12
20,T14,Qualifier 169 174	Major
21,T15,Observation 184 191	history
22,T16,Condition 175 183	bleeding
23,R7,Has_qualifier Arg1:T16 Arg2:T14
24,R8,Has_temporal Arg1:T16 Arg2:T15
25,T17,Condition 195 213	bleeding diathesis
26,*,OR T16 T17
27,T18,Condition 215 224	Pregnancy
0,T1,Condition 35 65	facial skin/soft tissue defect
1,T2,Condition 26 31;42 65	nasal skin/soft tissue defect
2,*,OR T2 T1
3,T3,Procedure 76 90	reconstruction
4,T4,Mood 66 75	requiring
5,R1,Has_mood Arg1:T3 Arg2:T4
6,T5,Scope 26 65	nasal or facial skin/soft tissue defect
7,R2,AND Arg1:T5 Arg2:T3
8,T6,Device 117 142	full-thickness skin graft
0,T1,Condition 10 24	HBeAg positive
1,T2,Condition 0 5;16 24	HBsAg positive
2,T3,Temporal 25 47	for more than 6 months
3,*,OR T2 T1
4,T4,Scope 0 24	HBsAg and HBeAg positive
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Condition 49 67	HBV DNA detectable
7,T6,Measurement 73 82	ALT level
8,T7,Value 83 91	abnormal
9,T8,Temporal 92 115	lasted for three months
10,R2,Has_temporal Arg1:T7 Arg2:T8
11,T9,Temporal 120 133	at least time
12,T10,Value 133 141	190 IU/L
13,R3,Has_temporal Arg1:T10 Arg2:T9
14,R4,Has_value Arg1:T6 Arg2:T7
15,R5,Has_value Arg1:T6 Arg2:T10
16,T11,Procedure 145 166	liver puncture biopsy
17,T12,Condition 189 201	inflammation
18,T13,Negation 203 208	never
19,T14,Procedure 209 216	treated
20,T15,Temporal 217 232	before enrolled
21,R6,Has_temporal Arg1:T14 Arg2:T15
22,R7,Has_negation Arg1:T14 Arg2:T13
23,R8,AND Arg1:T11 Arg2:T12
24,R9,AND Arg1:T12 Arg2:T14
25,R10,AND Arg1:T5 Arg2:T6
26,*,OR T4 T5 T11
0,T1,Condition 12 15	VTE
1,T2,Temporal 16 30	upon admission
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 32 40	Pregnant
4,T4,Condition 44 51	nursing
5,T5,Observation 53 87	Inability to give informed consent
6,T6,Informed_consent 53 118	Inability to give informed consent by patient or healthcare proxy
7,T7,Condition 120 136	Contraindication
8,T8,Drug 140 150	enoxaparin
9,R2,AND Arg1:T7 Arg2:T8
10,T9,Condition 152 168	Contraindication
11,T10,Drug 172 179	aspirin
12,R3,AND Arg1:T9 Arg2:T10
13,T11,Condition 181 189;202 210	Epidural hematoma
14,T12,Condition 193 210	subdural hematoma
15,*,OR T12 T11
16,T13,Procedure 225 232;259 273	removal of an epidural
17,T14,Condition 212 220;259 273	Presence of an epidural
18,T15,Temporal 233 257	within the last 12 hours
19,T16,Condition 212 220;259 263;277 292	Presence of a spinal catheter
20,T17,Procedure 225 232;259 263;277 292	removal of a spinal catheter
21,*,OR T16 T17 T14 T13
22,T18,"Scope 212 232;259 292	Presence, or removal of an epidural or spinal catheter"
23,R4,Has_temporal Arg1:T18 Arg2:T15
24,T19,Temporal 297 303	recent
25,T20,Temporal 305 329	within the last 12 hours
26,R5,Subsumes Arg1:T19 Arg2:T20
27,T21,Procedure 343 360	spinal anesthesia
28,T22,Procedure 331 339;350 360	epidural anesthesia
29,*,OR T21 T22
30,T23,Scope 331 360	epidural or spinal anesthesia
31,R6,Has_temporal Arg1:T23 Arg2:T19
0,T1,Person 0 3	Age
1,T2,Value 4 15	19 and more
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 28 55	triple antiplatelet therapy
4,T4,Procedure 20 24;35 55	dual antiplatelet therapy
5,*,OR T4 T3
6,T5,Temporal 60 139	between 12months and 14months from Bioresorbable Vascular Scaffold implantation
7,T6,Device 95 126	Bioresorbable Vascular Scaffold
8,T7,Procedure 127 139	implantation
9,R2,AND Arg1:T7 Arg2:T6
10,T8,Reference_point 95 139	Bioresorbable Vascular Scaffold implantation
11,R3,multi Arg1:T8 Arg2:T7
12,R4,Has_index Arg1:T5 Arg2:T8
13,T9,Scope 20 55	dual or triple antiplatelet therapy
14,R5,Has_temporal Arg1:T9 Arg2:T5
15,T10,Negation 141 143	No
16,T11,Observation 144 151	history
17,T12,Condition 155 160	death
18,T13,Qualifier 162 169	serious
19,T14,Condition 170 191	myocardial infarction
20,T15,Condition 193 199	stroke
21,T16,Multiplier 201 207	repeat
22,T17,Procedure 208 225	revascularization
23,T18,Qualifier 230 235	major
24,T19,Condition 236 244	bleeding
25,R6,Has_qualifier Arg1:T19 Arg2:T18
26,R7,Has_multiplier Arg1:T17 Arg2:T16
27,*,OR T17 T19 T15 T14 T12
28,R8,Has_qualifier Arg1:T14 Arg2:T13
29,T20,"Scope 155 244	death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding"
30,R9,Has_negation Arg1:T20 Arg2:T10
31,R10,Has_temporal Arg1:T20 Arg2:T11
0,T1,Drug 56 66	antibiotic
1,T2,Condition 72 83	intolerance
2,T3,Drug 92 103	clindamycin
3,T4,Drug 108 118	cephalexin
4,R1,AND Arg1:T2 Arg2:T3
5,R2,AND Arg1:T2 Arg2:T4
6,T5,Condition 135 166	persistent cutaneous malignancy
7,T6,Qualifier 174 192	site of the defect
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Temporal 193 231	following the reconstructive procedure
10,T8,Reference_point 203 231	the reconstructive procedure
11,T9,Procedure 207 231	reconstructive procedure
12,R4,AND Arg1:T8 Arg2:T9
13,R5,multi Arg1:T7 Arg2:T8
14,R6,Has_temporal Arg1:T5 Arg2:T7
15,*,OR T1 T2 T5
16,T10,Temporal 19 45	within one week of surgery
17,T11,Temporal 11 17	recent
18,T12,Temporal 0 7	current
19,R7,Subsumes Arg1:T11 Arg2:T10
20,*,OR T12 T11
21,T13,Scope 0 46	current or recent (within one week of surgery)
22,T14,"Scope 56 231	antibiotic use, intolerance to both clindamycin and cephalexin, discovery of a persistent cutaneous malignancy at the site of the defect following the reconstructive procedure"
23,R8,Has_scope Arg1:T14 Arg2:T13
0,T1,"Post-eligibility 0 188	Patients who are unwilling to participate in the study. For the one under guardianship, the refusal of the patient will be the final decision even if the guardian is willing to participate"
1,T2,Post-eligibility 191 292	Subjects who are unlikely to adhere to the study an/or poor adherence anticipated by the investigator
2,T3,Non-query-able 295 330	Un-controlled progressive pathology
3,T4,Condition 333 354	Osteoarticular lesion
4,T5,Non-query-able 333 425	Osteoarticular lesion which contraindicates part of the rehabilitation involved in the study
5,T6,"Non-query-able 428 531	Patients with other interventions planned prior to the end of the study period (orthosis, surgery etc.)"
6,T7,Procedure 534 541	Surgery
7,T8,Qualifier 549 561	treated limb
8,R1,Has_qualifier Arg1:T7 Arg2:T8
9,T9,Temporal 562 580	less than 6 months
10,R2,Has_temporal Arg1:T7 Arg2:T9
11,T10,Pregnancy_considerations 594 608	Pregnant woman
0,T1,Condition 23 32	pregnancy
1,T2,Condition 48 65	contraindications
2,T3,Procedure 69 88	regional anesthesia
3,T4,Condition 90 97	allergy
4,T5,Drug 101 104	LAs
5,R1,AND Arg1:T4 Arg2:T5
6,T6,Drug 122 129	opioids
7,T7,Multiplier 130 139	regularly
8,T8,Condition 147 159	chronic pain
9,R2,AND Arg1:T6 Arg2:T8
10,R3,Has_multiplier Arg1:T6 Arg2:T7
11,T9,Drug 168 189	anticoagulation drugs
12,T10,Drug 201 221	acetylsalicylic acid
13,T11,Drug 225 237	dipyridamole
14,T12,Condition 239 261	atrioventricular block
15,T13,Condition 263 271	diabetes
16,*,OR T10 T11
17,T14,Negation 190 200	other than
18,T15,Scope 201 237	acetylsalicylic acid or dipyridamole
19,R4,Has_negation Arg1:T15 Arg2:T14
20,R5,Has_scope Arg1:T9 Arg2:T15
21,*,OR T12 T13 T9 T6 T4 T2 T1
22,R6,AND Arg1:T2 Arg2:T3
0,T1,Qualifier 8 30	clinically significant
1,T2,Condition 31 40	condition
2,T3,Observation 44 53	situation
3,T4,Qualifier 59 82	anatomical malformation
4,T5,Negation 112 122	other than
5,T6,Condition 123 150	the condition being studied
6,R1,Has_negation Arg1:T6 Arg2:T5
7,T7,Observation 199 235	interfere with the trial evaluations
8,T8,Observation 199 213;239 260	interfere with optimal participation
9,*,OR T2 T3
10,T9,"Scope 31 111	condition or situation (eg, anatomical malformation that complicates intubation)"
11,R2,Subsumes Arg1:T3 Arg2:T4
12,R3,Has_qualifier Arg1:T9 Arg2:T1
13,R4,AND Arg1:T9 Arg2:T6
14,*,OR T8 T7
15,T10,Scope 199 260	interfere with the trial evaluations or optimal participation
16,R5,Has_scope Arg1:T9 Arg2:T10
17,T11,Condition 282 304	neuromuscular disorder
18,T12,Observation 314 324	affect NMB
19,T13,Observation 314 320;332 349	affect trial assessments
20,*,OR T13 T12
21,T14,Scope 314 349	affect NMB and/or trial assessments
22,R6,Has_scope Arg1:T11 Arg2:T14
23,T15,Condition 355 373	dialysis-dependent
24,T16,Condition 409 435	severe renal insufficiency
25,T17,Measurement 448 491	estimated glomerular filtration rate (eGFR)
26,T18,Value 492 502	<30 ml/min
27,R7,Has_value Arg1:T17 Arg2:T18
28,R8,Subsumes Arg1:T16 Arg2:T17
29,T19,Scope 409 503	severe renal insufficiency (defined as estimated glomerular filtration rate (eGFR) <30 ml/min)
30,*,OR T15 T16
31,T20,Observation 548 564	personal history
32,T21,Observation 538 544	family
33,T22,Condition 568 590	malignant hyperthermia
34,*,OR T21 T20
35,T23,Scope 538 564	family or personal history
36,R9,Has_scope Arg1:T22 Arg2:T23
37,T24,Condition 626 633	allergy
38,T25,Procedure 637 653	study treatments
39,T27,Drug 682 689	opioids
40,T28,Drug 690 697	opiates
41,T29,Drug 699 715	muscle relaxants
42,T30,Drug 725 735	excipients
43,*,OR T29 T30 T27 T28 T31 T25 T26
44,T31,Drug 746 756	medication
45,T32,Qualifier 740 745	other
46,R10,Has_qualifier Arg1:T31 Arg2:T32
47,T33,Procedure 772 790	general anesthesia
48,T34,Temporal 765 790	during general anesthesia
49,R11,Has_temporal Arg1:T31 Arg2:T34
50,T26,Drug 667 677	excipients
51,T35,"Scope 637 790	study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia"
52,R12,Has_scope Arg1:T24 Arg2:T35
53,T36,Drug 831 841	toremifene
54,T37,Mood 812 822	planned to
55,A1,Optional T37
56,T38,Drug 849 861	fusidic acid
57,T39,Qualifier 866 883	IV administration
58,T40,Temporal 884 906;932 965	within 24 hours before administration of study treatment
59,T41,Temporal 910 965	within 24 hours after administration of study treatment
60,T42,Reference_point 932 965	administration of study treatment
61,T43,Reference_point 932 965	administration of study treatment
62,R13,Has_index Arg1:T40 Arg2:T43
63,R14,Has_index Arg1:T41 Arg2:T42
64,*,OR T40 T41
65,T44,Scope 884 965	within 24 hours before or within 24 hours after administration of study treatment
66,*,OR T38 T36
67,T45,Scope 831 861	toremifene and/or fusidic acid
68,R15,Has_qualifier Arg1:T45 Arg2:T39
69,R16,Has_scope Arg1:T45 Arg2:T44
70,R17,Has_mood Arg1:T45 Arg2:T37
71,T46,Drug 1001 1011	sugammadex
72,T47,Temporal 977 987	previously
73,T48,Observation 1019 1034;1048 1062	participated in clinical trial
74,T49,Drug 1037 1047	sugammadex
75,R18,AND Arg1:T48 Arg2:T49
76,*,OR T46 T48
77,T50,Scope 1001 1062	sugammadex or has participated in a sugammadex clinical trial
78,R19,Has_temporal Arg1:T50 Arg2:T47
79,T51,Observation 1098 1150	has participated in an interventional clinical trial
80,T52,Observation 1068 1091;1115 1150	currently participating in an interventional clinical trial
81,*,OR T51 T52
82,T53,Drug 1159 1183	investigational compound
83,T54,Device 1187 1193	device
84,T55,Temporal 1194 1240	within 30 days of signing the informed consent
85,T56,Reference_point 1212 1240	signing the informed consent
86,R20,Has_index Arg1:T55 Arg2:T56
87,T57,Temporal 1194 1232;1241 1247	within 30 days of signing the informed assent
88,T58,Reference_point 1212 1232;1241 1247	signing the informed assent
89,R21,Has_index Arg1:T57 Arg2:T58
90,*,OR T57 T55
91,*,OR T53 T54
92,T59,Scope 1159 1193	investigational compound or device
93,T60,Scope 1068 1150	currently participating in or has participated in an interventional clinical trial
94,R22,Has_scope Arg1:T60 Arg2:T59
95,T61,Scope 1194 1247	within 30 days of signing the informed consent/assent
96,R23,Has_scope Arg1:T60 Arg2:T61
0,T1,Qualifier 10 19	singleton
1,T2,Condition 20 28	pregnant
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Qualifier 0 9	full term
4,R2,Has_qualifier Arg1:T2 Arg2:T3
5,T4,Person 29 34	women
6,T5,Mood 36 49	Scheduled for
7,T6,Qualifier 50 58	elective
8,T7,Procedure 59 76	Cesarean Delivery
9,R3,Has_qualifier Arg1:T7 Arg2:T6
10,R4,Has_mood Arg1:T7 Arg2:T5
11,T8,Person 78 82	Aged
12,T9,Value 83 106	between 18 and 40 years
13,R5,Has_value Arg1:T8 Arg2:T9
0,T1,Condition 0 4	ADHD
0,T1,Condition 111 141	esophagogastric adenocarcinoma
1,T2,Condition 127 141;42 49	adenocarcinoma gastric
2,*,OR T1 T2
3,T3,Qualifier 25 41	locally advanced
4,T4,Scope 42 141	gastric (primary endpoint includes proximal and mid-body stomach) or esophagogastric adenocarcinoma
5,R1,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Qualifier 90 106	mid-body stomach
7,T6,Qualifier 77 85;99 106	proximal stomach
8,*,OR T5 T6
9,T7,Scope 77 106	proximal and mid-body stomach
10,R2,Has_scope Arg1:T2 Arg2:T7
11,T8,Condition 167 182	adenocarcinomas
12,T9,Qualifier 143 157	distal gastric
13,T10,Qualifier 159 165	antral
14,R3,Subsumes Arg1:T9 Arg2:T10
15,R4,Has_qualifier Arg1:T8 Arg2:T9
16,*,OR T4 T8
17,T11,Non-query-able 183 258	are eligible for enrolment but will not be included in the primary analysis
18,T12,Condition 277 284	disease
19,T13,Qualifier 260 276	Locally advanced
20,R5,Has_qualifier Arg1:T12 Arg2:T13
21,T14,Procedure 302 323	endoscopic ultrasound
22,T15,"Value 336 428	> primary tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)"
23,R6,Has_value Arg1:T14 Arg2:T15
24,R7,AND Arg1:T12 Arg2:T14
25,T16,Procedure 325 328	EUS
26,R8,Subsumes Arg1:T14 Arg2:T16
27,T17,Procedure 464 475	laparoscopy
28,T18,Qualifier 453 463	diagnostic
29,R9,Has_qualifier Arg1:T17 Arg2:T18
30,T19,Procedure 492 513	washings for cytology
31,T20,Measurement 520 528	cytology
32,T21,Value 529 537	positive
33,T22,Value 542 550	negative
34,*,OR T21 T22
35,T23,Scope 529 550	positive and negative
36,R10,Has_scope Arg1:T20 Arg2:T23
37,T24,Non-query-able 593 706	nly cytology negative patients will be included in the primary analyses; gross peritoneal disease is not eligible
38,T25,Measurement 708 742;750 768	Eastern Cooperative Oncology Group performance status
39,T26,Value 769 773	=< 1
40,T27,Measurement 744 748	ECOG
41,R11,Subsumes Arg1:T25 Arg2:T27
42,R12,Has_value Arg1:T25 Arg2:T26
43,T28,Procedure 788 795	surgery
44,T29,Qualifier 801 809	curative
45,R13,Has_qualifier Arg1:T28 Arg2:T29
46,T30,Measurement 818 843	Absolute neutrophil count
47,T31,Measurement 845 848	ANC
48,T32,Value 850 860	>= 1250/ul
49,R14,Subsumes Arg1:T30 Arg2:T31
50,R15,Has_value Arg1:T30 Arg2:T32
51,T33,Measurement 862 872	Hemoglobin
52,T34,Value 873 882	>= 9 g/dL
53,R16,Has_value Arg1:T33 Arg2:T34
54,T35,Measurement 884 893	Platelets
55,T36,"Value 894 907	>= 100,000/ul"
56,R17,Has_value Arg1:T35 Arg2:T36
57,T37,Measurement 909 924	Total bilirubin
58,T38,Value 925 954	< 1.5 x upper limit of normal
59,R18,Has_value Arg1:T37 Arg2:T38
60,T39,Measurement 956 995	Serum glutamic oxaloacetic transaminase
61,T40,Measurement 997 1001	SGOT
62,T41,Measurement 1007 1044	serum glutamate pyruvate transaminase
63,T42,Measurement 1046 1050	SGPT
64,T43,Value 1052 1081	< 2.5 x upper limit of normal
65,T44,Negation 1095 1102	without
66,T45,Condition 1103 1119	liver metastases
67,T46,Measurement 1123 1127	SGOT
68,T47,Measurement 1132 1136	SGPT
69,T48,Value 1137 1164	< 5 x upper limit of normal
70,T49,Condition 1183 1199	liver metastases
71,R19,Subsumes Arg1:T39 Arg2:T40
72,R20,Subsumes Arg1:T41 Arg2:T42
73,T50,Scope 956 1051	Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT)
74,R21,Has_value Arg1:T50 Arg2:T43
75,R22,Has_negation Arg1:T45 Arg2:T44
76,R23,Has_scope Arg1:T45 Arg2:T50
77,T51,Scope 1123 1136	SGOT and SGPT
78,R24,Has_value Arg1:T51 Arg2:T48
79,R25,Has_scope Arg1:T49 Arg2:T51
80,T52,Measurement 1201 1211	Creatinine
81,T53,Value 1212 1242	=< 1.5 x upper limit of normal
82,R26,Has_value Arg1:T52 Arg2:T53
83,T54,Measurement 1284 1327	Response Evaluation Criteria in Solid Tumor
84,T55,Measurement 1329 1335	RECIST
85,T56,Value 1337 1340	1.1
86,R27,Subsumes Arg1:T54 Arg2:T55
87,R28,Has_value Arg1:T54 Arg2:T56
88,T57,"Pregnancy_considerations 1359 1760	omen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately"
89,T58,"Non-query-able 1762 2013	Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan"
90,T59,Informed_consent 2015 2038	Signed informed consent
0,T1,Person 0 5	Males
1,T2,Person 10 17	females
2,*,OR T1 T2
3,T3,Person 18 22	aged
4,T4,Value 23 45	between 18 to 75 years
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Informed_consent 48 150	Adult patient under guardianship with consent obtained and the legal guardian's authorisation obtained
7,T6,Condition 160 166	stroke
8,T7,Multiplier 153 159	Single
9,R2,Has_multiplier Arg1:T6 Arg2:T7
10,T8,Temporal 183 201	more than 6 months
11,R3,Has_temporal Arg1:T6 Arg2:T8
12,T9,Condition 219 222	TIA
13,R4,Subsumes Arg1:T6 Arg2:T9
14,T10,Post-eligibility 238 333	Capable of understanding instructions and participating in the definition of a therapeutic goal
15,T11,Measurement 335 372	Boston Diagnostic Aphasia Examination
16,T12,Measurement 374 378	BDAE
17,R5,Subsumes Arg1:T11 Arg2:T12
18,T13,Value 380 383	< 3
19,R6,Has_value Arg1:T11 Arg2:T13
20,T14,Procedure 415 418	BTI
21,T15,Procedure 429 438	injection
22,T16,Temporal 464 500	at least 4 months prior to inclusion
23,T17,Reference_point 491 500	inclusion
24,R7,Has_temporal Arg1:T15 Arg2:T16
25,R8,Has_index Arg1:T16 Arg2:T17
26,T18,Non-query-able 503 571	Affiliation to the French social security regime or a similar regime
27,T19,Informed_consent 574 674	Patient (or the legal guardian if under guardian adult patient) has signed the informed consent form
0,T1,Measurement 25 62;69 84	American Society of Anesthesiologists physical status
1,T2,Measurement 64 67	ASA
2,T3,Value 85 90	I-III
3,R1,Subsumes Arg1:T1 Arg2:T2
4,R2,Has_value Arg1:T1 Arg2:T3
5,T4,Person 92 95	age
6,T5,Value 96 119	between 18 and 70 years
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Measurement 124 139	body mass index
9,T7,Measurement 141 144	BMI
10,R4,Subsumes Arg1:T6 Arg2:T7
11,T8,Value 146 169	between 20 and 35 kg/m2
12,R5,Has_value Arg1:T6 Arg2:T8
0,T1,Measurement 18 83	American Society of Anesthesiologists (ASA) Physical Status Class
1,T2,Value 84 85	1
2,T3,Value 87 88	2
3,T4,Value 93 94	3
4,*,OR T2 T3 T4
5,T5,"Scope 84 94	1, 2, or 3"
6,R1,Has_scope Arg1:T1 Arg2:T5
7,T6,Mood 104 111	planned
8,T7,Qualifier 112 124	non-emergent
9,T8,Procedure 125 143	surgical procedure
10,T9,Condition 147 165	clinical situation
11,T10,Procedure 173 183	intubation
12,R2,Subsumes Arg1:T9 Arg2:T10
13,T11,"Scope 147 184	clinical situation (e.g., intubation)"
14,*,OR T8 T11
15,R3,Has_qualifier Arg1:T8 Arg2:T7
16,R4,Has_mood Arg1:T8 Arg2:T6
17,T12,Procedure 216 219	NMB
18,T13,Qualifier 199 207	moderate
19,T14,Qualifier 211 215	deep
20,*,OR T13 T14
21,T15,Scope 199 215	moderate or deep
22,R5,Has_scope Arg1:T12 Arg2:T15
23,T16,Drug 232 242	rocuronium
24,T17,Drug 246 256	vecuronium
25,*,OR T16 T17
26,T18,Scope 232 256	rocuronium or vecuronium
27,R6,Has_scope Arg1:T12 Arg2:T18
28,R7,AND Arg1:T8 Arg2:T12
29,T19,Mood 266 273	planned
30,T20,Procedure 274 292	surgical procedure
31,T21,Condition 296 314	clinical situation
32,*,OR T20 T21
33,T22,Procedure 332 377	objective neuromuscular monitoring techniques
34,T23,Qualifier 315 391	that would allow objective neuromuscular monitoring techniques to be applied
35,R9,multi Arg1:T23 Arg2:T22
36,T24,Scope 266 292	planned surgical procedure
37,R8,Has_qualifier Arg1:T24 Arg2:T23
38,R10,Has_mood Arg1:T20 Arg2:T19
39,T25,Person 459 462	Age
40,T26,Value 463 485	between 2 to <17 years
41,T27,Temporal 486 496	at Visit 2
42,R11,Has_temporal Arg1:T25 Arg2:T27
43,R12,Has_value Arg1:T25 Arg2:T26
44,T28,Person 502 508	female
45,A1,Optional T28
46,T29,Negation 536 539	not
47,T30,Condition 540 548	pregnant
48,T31,Negation 550 553	not
49,T32,Observation 554 567	breastfeeding
50,R13,Has_negation Arg1:T30 Arg2:T29
51,R14,Has_negation Arg1:T32 Arg2:T31
52,T33,Multiplier 573 585	at least one
53,T34,Condition 613 652	woman of childbearing potential (WOCBP)
54,T35,Negation 607 610	Not
55,T36,Condition 662 667	WOCBP
56,T37,Procedure 699 721	contraceptive guidance
57,T38,Temporal 722 749	during the treatment period
58,T39,Temporal 754 812	for at least 7 days after the last dose of study treatment
59,T40,Reference_point 780 812	the last dose of study treatment
60,T41,Reference_point 729 749	the treatment period
61,R15,Has_index Arg1:T38 Arg2:T41
62,R16,Has_index Arg1:T39 Arg2:T40
63,*,OR T38 T39
64,T42,Scope 722 812	during the treatment period and for at least 7 days after the last dose of study treatment
65,R17,Has_scope Arg1:T37 Arg2:T42
66,T43,Scope 662 812	WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment
67,R18,Has_negation Arg1:T34 Arg2:T35
68,T44,Scope 607 652	Not a woman of childbearing potential (WOCBP)
69,*,OR T44 T43
70,T45,Scope 607 812	Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment
71,R19,Has_multiplier Arg1:T45 Arg2:T33
72,T46,"Scope 536 812	not pregnant, not breastfeeding, and at least one of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment"
73,R20,Has_scope Arg1:T28 Arg2:T46
0,T1,Condition 23 33	malignancy
1,T2,Qualifier 0 8	Previous
2,T3,Qualifier 12 22	concurrent
3,*,OR T3 T2
4,T4,Scope 0 22	Previous or concurrent
5,T5,Negation 35 41	except
6,T6,Condition 79 104	squamous cell skin cancer
7,T7,Condition 65 75;93 104	basal cell skin cancer
8,T8,Condition 114 129	cervical cancer
9,T9,Qualifier 106 113	in situ
10,T10,Qualifier 46 64	adequately treated
11,R1,Has_qualifier Arg1:T8 Arg2:T9
12,*,OR T6 T7
13,T11,Scope 65 104	basal cell or squamous cell skin cancer
14,R2,Has_qualifier Arg1:T11 Arg2:T10
15,T12,Non-query-able 134 250	any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30%
16,T13,"Scope 46 129	adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer"
17,R3,Has_negation Arg1:T13 Arg2:T5
18,R4,Has_scope Arg1:T1 Arg2:T4
19,T14,Condition 252 278	Inflammatory bowel disease
20,T15,Qualifier 287 299	uncontrolled
21,T16,Procedure 313 322	treatment
22,T18,Condition 324 339	Crohn's disease
23,T19,Condition 341 359	ulcerative colitis
24,*,OR T18 T19
25,T20,"Scope 324 359	Crohn's disease, ulcerative colitis"
26,T21,Scope 252 322	Inflammatory bowel disease that is uncontrolled or on active treatment
27,R7,Subsumes Arg1:T21 Arg2:T20
28,T22,Condition 362 370	Diarrhea
29,T23,Measurement 398 470	National Cancer Institute Common Terminology Criteria for Adverse Events
30,T24,Value 372 390	grade 1 or greater
31,R8,Has_value Arg1:T23 Arg2:T24
32,R9,AND Arg1:T22 Arg2:T23
33,T25,"Measurement 472 498	NCI-CTCAE, version [v] 4.0"
34,R10,Subsumes Arg1:T23 Arg2:T25
35,T26,Condition 501 511	Neuropathy
36,T27,"Measurement 535 551	NCI-CTCAE, v 4.0"
37,T28,Value 513 531	grade 2 or greater
38,R11,AND Arg1:T26 Arg2:T27
39,R12,Has_value Arg1:T27 Arg2:T28
40,T29,"Non-query-able 553 729	Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment"
41,T30,Condition 751 759	bleeding
42,T31,Qualifier 731 737	Active
43,T32,Qualifier 738 750	uncontrolled
44,R13,Has_qualifier Arg1:T30 Arg2:T32
45,R14,Has_qualifier Arg1:T30 Arg2:T31
46,T33,Pregnancy_considerations 761 787	Pregnancy or breastfeeding
47,T34,Procedure 789 802	Major surgery
48,T35,Temporal 803 817	within 4 weeks
49,R15,Has_temporal Arg1:T34 Arg2:T35
50,T36,"Non-query-able 819 949	Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be allowed and treated as in the *28/*28 dosing group"
51,T17,Scope 287 322	uncontrolled or on active treatment
52,*,OR T15 T16
53,R5,Has_scope Arg1:T14 Arg2:T17
0,T1,Condition 0 9	Psychosis
1,T2,Condition 11 28	Tourette syndrome
2,T3,Measurement 30 51	Intelligence quotient
3,T4,Measurement 53 55	IQ
4,T5,Value 57 61	< 70
5,R1,Subsumes Arg1:T3 Arg2:T4
6,R2,Has_value Arg1:T3 Arg2:T5
7,T6,Condition 63 95	Pervasive developmental disorder
8,T7,Condition 97 100	PDD
9,R3,Subsumes Arg1:T6 Arg2:T7
0,T1,Condition 0 19	Cardiac morbidities
1,T2,Condition 21 56	Hypertensive disorders of pregnancy
2,T3,Condition 59 78	Peripartum bleeding
3,T4,Temporal 80 88	Baseline
4,T5,Measurement 89 112	systolic blood pressure
5,T6,Measurement 114 117	SBP
6,R1,Subsumes Arg1:T5 Arg2:T6
7,T7,Value 119 129	< 100 mmHg
8,R2,Has_value Arg1:T5 Arg2:T7
9,R3,Has_temporal Arg1:T5 Arg2:T4
10,T8,Measurement 131 146	Body mass index
11,T9,Value 147 151	> 35
12,R4,Has_value Arg1:T8 Arg2:T9
0,T1,Condition 8 34	unstable medical condition
1,T2,Qualifier 8 16	unstable
2,R1,multi Arg1:T1 Arg2:T2
3,T3,Temporal 0 7	Current
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Condition 41 56	unstable angina
6,T5,Condition 58 79	myocardial infarction
7,T6,Procedure 83 109	coronary revascularization
8,T7,Temporal 110 136	in the preceding 12 months
9,*,OR T6 T5 T4 T8 T9 T10 T11 T12 T13 T16
10,R3,Has_temporal Arg1:T6 Arg2:T7
11,R4,Has_temporal Arg1:T5 Arg2:T7
12,T8,Condition 138 153	cardiac failure
13,T9,Condition 155 176	chronic renal failure
14,T10,Condition 178 201	chronic hepatic disease
15,T11,Condition 210 227	pulmonary disease
16,T12,Condition 229 244	blood disorders
17,T13,Condition 264 272	diabetes
18,T14,Qualifier 253 263	controlled
19,R5,Has_qualifier Arg1:T13 Arg2:T14
20,T15,Negation 246 252	poorly
21,R6,Has_negation Arg1:T14 Arg2:T15
22,T16,Condition 274 291	chronic infection
23,T17,Qualifier 274 281	chronic
24,R7,multi Arg1:T16 Arg2:T17
25,T18,Qualifier 203 209	severe
26,R8,Has_qualifier Arg1:T11 Arg2:T18
27,T19,Qualifier 178 185	chronic
28,R9,multi Arg1:T10 Arg2:T19
29,T20,Qualifier 155 162	chronic
30,R10,multi Arg1:T9 Arg2:T20
31,T21,"Scope 41 291	unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection"
32,R11,Subsumes Arg1:T1 Arg2:T21
0,T1,Person 0 3	Age
1,T2,Value 5 20	20-70 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 23 29	Gender
4,T4,Value 31 35	male
5,T5,Value 39 45	female
6,*,OR T4 T5
7,T6,Scope 31 45	male or female
8,R2,Has_scope Arg1:T3 Arg2:T6
9,T8,Condition 86 110	hepatocellular carcinoma
10,T9,Qualifier 48 82	clinical or pathological diagnosis
11,T10,Condition 112 115	HCC
12,R3,Subsumes Arg1:T8 Arg2:T10
13,T11,Qualifier 131 140	untreated
14,R4,Has_qualifier Arg1:T8 Arg2:T9
15,R5,Has_qualifier Arg1:T8 Arg2:T11
16,T7,Observation 156 173	expected survival
17,T12,Value 173 183	> 3 months
18,R6,Has_value Arg1:T7 Arg2:T12
19,T13,Measurement 186 202	Child-Pugh grade
20,T14,Value 206 207	A
21,R7,Has_value Arg1:T13 Arg2:T14
22,T15,Measurement 216 225	KPS score
23,T16,Value 231 244	50-100 points
24,R8,Has_value Arg1:T15 Arg2:T16
25,T17,Measurement 247 257	BCLC stage
26,T18,Value 261 264	0-B
27,R9,Has_value Arg1:T17 Arg2:T18
28,T19,Procedure 297 308	hepatectomy
29,T20,Observation 282 308	indications of hepatectomy
30,R10,multi Arg1:T20 Arg2:T19
31,T21,Subjective_judgement 311 384	Viable tumor resection confirmed by two highly qualified surgical doctors
32,T22,Negation 387 389	No
33,T23,Observation 390 422	other surgical contraindications
34,R11,Has_negation Arg1:T23 Arg2:T22
35,T24,Person 425 430	women
36,T25,Observation 438 457	reproductive period
37,T26,Procedure 477 490	contraception
38,T27,Temporal 491 518	in 28 days before treatment
39,T28,Reference_point 509 518	treatment
40,R12,Has_index Arg1:T27 Arg2:T28
41,T29,Temporal 520 548	during the treatment process
42,T30,Temporal 553 579	in 28 days after treatment
43,T31,Reference_point 531 540	treatment
44,T32,Reference_point 570 579	treatment
45,R13,Has_index Arg1:T29 Arg2:T31
46,R14,Has_index Arg1:T30 Arg2:T32
47,T33,"Scope 491 579	in 28 days before treatment, during the treatment process and in 28 days after treatment"
48,R15,Has_temporal Arg1:T26 Arg2:T29
49,T34,Person 582 585	Men
50,T35,Procedure 605 618	contraception
51,T36,Negation 623 633	prohibited
52,T37,Procedure 647 661	sperm donation
53,T38,Temporal 662 690	during the treatment process
54,T39,Temporal 695 721	in 28 days after treatment
55,T40,Reference_point 673 682	treatment
56,T41,Reference_point 712 721	treatment
57,R16,Has_index Arg1:T38 Arg2:T40
58,R17,Has_index Arg1:T39 Arg2:T41
59,T42,Scope 662 721	during the treatment process and in 28 days after treatment
60,R18,Has_negation Arg1:T37 Arg2:T36
61,R19,Has_scope Arg1:T35 Arg2:T42
62,R20,Has_scope Arg1:T37 Arg2:T42
63,T43,Procedure 634 642	donation
64,R21,Has_negation Arg1:T43 Arg2:T36
65,R22,Has_scope Arg1:T43 Arg2:T42
66,T44,Negation 745 755	prohibited
67,T45,Procedure 756 764	donation
68,T46,Temporal 765 793	during the treatment process
69,T47,Reference_point 776 785	treatment
70,T48,Temporal 798 823	in 28 days after treatmen
71,T49,Reference_point 815 824	treatment
72,R23,Has_index Arg1:T46 Arg2:T47
73,R24,Has_index Arg1:T48 Arg2:T49
74,T50,Scope 765 824	during the treatment process and in 28 days after treatment
75,R25,Has_negation Arg1:T45 Arg2:T44
76,R26,Has_scope Arg1:T45 Arg2:T50
77,T51,"Undefined_semantics 827 901	In addition to the subjects, prohibitting other people taking this product"
78,T52,Subjective_judgement 904 992	patients have a good understanding and could coordinate with investigators for the trial
79,T53,"Post-eligibility 995 1183	Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial"
0,T1,Non-query-able 0 59	Patients not capable or willing to provide informed consent
1,T2,Drug 79 89	Adalimumab
2,T3,Temporal 90 169	less than five half-lives after the interruption of a previous anti-TNF therapy
3,T4,Reference_point 122 169	the interruption of a previous anti-TNF therapy
4,T5,Procedure 153 169	anti-TNF therapy
5,T6,Temporal 144 152	previous
6,R1,Has_temporal Arg1:T5 Arg2:T6
7,R2,multi Arg1:T4 Arg2:T5
8,R3,Has_index Arg1:T3 Arg2:T4
9,R4,Has_temporal Arg1:T2 Arg2:T3
0,T1,Qualifier 15 26	stable dose
1,T2,Temporal 55 91	at least 3 months prior to screening
2,T3,Drug 109 136	immediate-release metformin
3,T4,Value 95 108	>=1000 mg/day
4,T5,Drug 141 150	metformin
5,R1,Has_temporal Arg1:T1 Arg2:T2
6,T6,Value 151 164	>=1000 mg/day
7,T7,Drug 169 181	sulfonylurea
8,T8,Drug 186 198	sulfonylurea
9,T9,Drug 199 208	metformin
10,T10,Procedure 209 228	combination therapy
11,R2,AND Arg1:T6 Arg2:T5
12,T11,Scope 141 181	metformin >=1000 mg/day and sulfonylurea
13,R3,AND Arg1:T10 Arg2:T9
14,R4,AND Arg1:T10 Arg2:T8
15,R5,AND Arg1:T4 Arg2:T3
16,*,OR T3 T11 T10
17,T12,Scope 95 228	>=1000 mg/day immediate-release metformin; or metformin >=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy
18,R6,Has_qualifier Arg1:T12 Arg2:T1
19,T13,Measurement 231 236	HbA1c
20,T14,"Value 237 270	between 7.1% and 11.0%, inclusive"
21,T15,Measurement 273 294	Body Mass Index (BMI)
22,T16,Value 295 320	>21 kg/m^2 and <35 kg/m^2
23,R7,Has_value Arg1:T15 Arg2:T16
24,R8,Has_value Arg1:T13 Arg2:T14
25,T17,Reference_point 82 91	screening
26,R9,Has_index Arg1:T2 Arg2:T17
27,T18,Multiplier 30 50	one of the following
28,R10,Has_multiplier Arg1:T12 Arg2:T18
0,T1,Condition 31 51	coagulation disorder
1,T2,Condition 22 30;43 51	clotting disorder
2,T3,Condition 64 70	cancer
3,T4,Temporal 83 92	last year
4,R1,Has_temporal Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T5,Drug 119 135	anti-coagulation
7,T6,Condition 148 164	hypersensitivity
8,T7,Drug 177 185	apixaban
9,R2,AND Arg1:T6 Arg2:T7
10,T8,Condition 217 225	bleeding
11,T9,Qualifier 205 216	significant
12,T10,Qualifier 187 193	Active
13,R3,Has_qualifier Arg1:T8 Arg2:T9
14,R4,Has_qualifier Arg1:T8 Arg2:T10
15,T11,Measurement 227 237	Creatinine
16,T12,Value 238 249	> 1.5 mg/dL
17,R5,Has_value Arg1:T11 Arg2:T12
18,T13,Drug 296 311	anticoagulation
19,T14,Drug 315 341	blood thinning medications
20,T15,Drug 353 360	heparin
21,T16,Drug 362 391	low molecular weight heparins
22,T17,Drug 393 399	Plavix
23,T18,Drug 401 408	aspirin
24,T19,Drug 410 416	NSAIDS
25,*,OR T13 T14
26,T20,Scope 296 341	anticoagulation or blood thinning medications
27,*,OR T15 T16 T17 T18 T19
28,T21,"Scope 353 416	heparin, low molecular weight heparins, Plavix, aspirin, NSAIDS"
29,R6,Subsumes Arg1:T20 Arg2:T21
30,T22,Drug 427 441;479 488	P-glycoprotein inhibitor
31,T23,Drug 453 468;475 488	cytochrome P450 3A4 inhibitor
32,T24,Qualifier 446 452	strong
33,R7,Has_qualifier Arg1:T23 Arg2:T24
34,T25,Drug 499 513;535 544	P-glycoprotein inhibitor
35,T26,Drug 527 544	CYP 3A4 inhibitor
36,T27,Qualifier 518 526	moderate
37,R8,Has_qualifier Arg1:T26 Arg2:T27
38,T28,Drug 555 577	P-glycoprotein inducer
39,T29,Drug 589 604	CYP 3A4 inducer
40,T30,Qualifier 582 588	strong
41,R9,Has_qualifier Arg1:T29 Arg2:T30
42,T31,Drug 606 632	Inducers of p-glycoprotein
43,T32,Drug 641 660	inducers of CYP 3A4
44,T33,Qualifier 634 640	Strong
45,R10,Has_qualifier Arg1:T32 Arg2:T33
0,T1,Procedure 9 25	vaginal delivery
1,T2,Temporal 0 8	Previous
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 28 43	Submucous myoma
4,T4,Condition 46 63	Uterine anomalies
5,T5,Condition 78 94	vaginal bleeding
6,T6,Qualifier 66 77	Undiagnosed
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Condition 97 124	Pelvic inflammatory disease
0,T1,Measurement 0 3	GCS
1,T2,Value 4 16	less than 15
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 18 41	Preoperative Heart Rate
4,T4,Value 42 63	less than 50 beat/min
5,T5,Negation 65 67	No
6,T6,Drug 68 81	Beta-Blockers
7,R2,Has_negation Arg1:T6 Arg2:T5
8,T7,Condition 83 91	Pregnant
9,T8,Drug 111 127	Alpha-Methyldopa
10,T9,Drug 129 138	Clonodine
11,T10,Qualifier 140 145	Other
12,T11,Drug 146 172	Alpha-2 Adrenergic Agonist
13,R3,Has_qualifier Arg1:T11 Arg2:T10
14,*,OR T9 T11 T8
15,T12,Condition 174 194	Hemodynamic unstable
16,T13,Measurement 196 207	Systolic BP
17,T14,Value 208 225	more than 160mmHg
18,R4,Has_value Arg1:T13 Arg2:T14
19,T15,Condition 227 230	CAD
20,T16,Condition 232 251	Renal insuffuciency
21,T17,Condition 253 260	Allergy
22,T18,Drug 264 280	dexmedethomidine
23,T19,Drug 285 291	opioid
24,*,OR T18 T19
25,T20,Scope 264 291	dexmedethomidine and opioid
26,R5,Has_scope Arg1:T17 Arg2:T20
27,T21,Measurement 293 296	BMI
28,T22,Value 297 309	more than 30
29,R6,Has_value Arg1:T21 Arg2:T22
30,T23,Informed_consent 311 325	Denied consent
0,T1,Person 9 13	aged
1,T2,Value 17 28	18 and over
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 46 98	1987 American College of Rheumatology (ACR) criteria
4,T4,Condition 103 105	RA
5,R2,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Drug 135 145	Adalimumab
7,T6,Multiplier 146 151;165 180	40 mg every two weeks
8,R3,Has_multiplier Arg1:T5 Arg2:T6
9,T7,Qualifier 152 164	subcutaneous
10,R4,Has_qualifier Arg1:T5 Arg2:T7
0,T1,Not_a_criteria 0 2	NA
0,T1,Post-eligibility 0 46	Able to give fully informed consent in writing
1,T2,Person 48 53	Males
2,T3,Person 57 64	females
3,T4,Person 65 69	aged
4,T5,Value 70 82	>/= 50 years
5,R1,Has_value Arg1:T4 Arg2:T5
6,*,OR T3 T2
7,T6,Condition 110 118	drug use
8,T7,Condition 99 106	disease
9,T8,Qualifier 87 98	significant
10,R2,Has_qualifier Arg1:T7 Arg2:T8
11,T9,Subjective_judgement 87 98	significant
12,T10,Negation 84 86	No
13,*,OR T6 T7
14,T11,Scope 87 118	significant disease or drug use
15,R3,Has_negation Arg1:T11 Arg2:T10
16,T12,Condition 143 151	dementia
17,T13,Condition 135 151	sign of dementia
18,R4,multi Arg1:T13 Arg2:T12
19,T14,Condition 135 142;152 172	sign of cognitive impairment
20,T15,Condition 152 172	cognitive impairment
21,R5,multi Arg1:T14 Arg2:T15
22,*,OR T14 T13
23,T16,Negation 120 130	Absence of
24,T17,Scope 135 172	sign of dementia/cognitive impairment
25,T18,Procedure 176 207	neuropsychological examinations
26,R6,causal Arg1:T17 Arg2:T18
27,R7,Has_negation Arg1:T17 Arg2:T16
28,T19,Parsing_Error 207 234	Patients for brain imaging:
29,T20,Post-eligibility 236 308	Patient and designee capable of giving fully informed consent in writing
30,T21,Measurement 326 332;349 357	DSM-IV criteria
31,T22,Measurement 337 357	NINCDS-ADRA criteria
32,T23,Condition 371 389	Alzheimers disease
33,T24,Mood 362 370	probable
34,R8,Has_mood Arg1:T23 Arg2:T24
35,T25,Value 318 325	fulfils
36,R9,Has_value Arg1:T21 Arg2:T25
37,R10,Has_value Arg1:T22 Arg2:T25
38,T26,Scope 318 357	fulfils DSM-IV and NINCDS-ADRA criteria
39,R11,causal Arg1:T26 Arg2:T23
0,T1,Person 0 5	Women
1,T2,Mood 11 19	expected
2,T3,Qualifier 20 29	difficult
3,T4,Procedure 30 43	IUD insertion
4,R1,Has_qualifier Arg1:T4 Arg2:T3
5,R2,Has_mood Arg1:T4 Arg2:T2
6,T5,Observation 49 60	nulliparous
7,T6,Person 61 66	women
8,T7,Person 71 76	women
9,T8,Temporal 82 90	previous
10,T9,Procedure 91 107	cesarean section
11,R3,Has_temporal Arg1:T9 Arg2:T8
12,T10,Scope 49 66	nulliparous women
13,T11,Scope 71 107	women with previous cesarean section
14,T12,Scope 49 107	nulliparous women and women with previous cesarean section
15,*,OR T10 T11
16,T13,Scope 11 43	expected difficult IUD insertion
17,R4,Subsumes Arg1:T13 Arg2:T12
0,T1,Person 0 3	Men
1,T2,Person 7 12	women
2,T3,Person 29 32	old
3,T4,Value 14 28	18 to 65 years
4,*,OR T1 T2
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 40 43	BMI
7,T6,Value 47 66	35 kg/m2 or greater
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Procedure 90 107	bariatric surgery
10,T8,Procedure 109 112	VSG
11,T9,Procedure 117 121	RYGB
12,T10,Scope 109 121	VSG and RYGB
13,R3,Has_scope Arg1:T7 Arg2:T10
14,T11,Informed_consent 124 155	Signed written informed consent
15,T12,Pregnancy_considerations 157 353	Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug
16,T13,Pregnancy_considerations 355 386	Women must not be breastfeeding
0,T1,Drug 82 95	GLP-1 analogs
1,T2,Observation 21 31	this study
2,T4,Observation 47 62	any other study
3,T3,Drug 69 78	exenatide
4,*,OR T2 T4
5,T6,"Scope 21 62	this study previously, or any other study"
6,T7,Observation 122 136;175 180	interventional study
7,T8,Observation 138 145;175 180	medical study
8,T9,Observation 147 155;175 180	surgical study
9,T10,Observation 160 180	pharmaceutical study
10,T11,Temporal 181 208	within 30 days of screening
11,T12,"Scope 122 180	interventional, medical, surgical, or pharmaceutical study"
12,R4,Has_temporal Arg1:T12 Arg2:T11
13,T14,Drug 249 258	metformin
14,T15,Drug 262 274	sulfonylurea
15,T16,Condition 216 248	characteristics contraindicating
16,T17,Scope 249 274	metformin or sulfonylurea
17,R6,Has_scope Arg1:T16 Arg2:T17
18,T18,Drug 304 321	exogenous insulin
19,T19,Multiplier 322 342	for more than 1 week
20,T20,Temporal 343 381	within the 3 months prior to screening
21,R7,Has_multiplier Arg1:T18 Arg2:T19
22,R8,Has_temporal Arg1:T18 Arg2:T20
23,T22,Drug 394 415	drugs for weight loss
24,T23,Temporal 416 443	within 1 month of screening
25,R10,Has_temporal Arg1:T22 Arg2:T23
26,*,OR T14 T15
27,*,OR T3 T1
28,T5,Scope 69 95	exenatide or GLP-1 analogs
29,R1,Has_scope Arg1:T6 Arg2:T5
30,*,OR T7 T8 T9 T10
31,T13,Reference_point 199 208	screening
32,R2,Has_index Arg1:T11 Arg2:T13
33,T21,Reference_point 372 381	screening
34,R3,Has_index Arg1:T20 Arg2:T21
0,T1,Person 0 3	Age
1,T2,Value 3 8	18-65
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 10 13	ASA
4,T4,Value 14 17	1-2
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Procedure 28 42	TNTS resection
7,T6,Condition 46 61	Pituitary Tumor
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Qualifier 19 27	Elective
10,R4,Has_qualifier Arg1:T5 Arg2:T7
11,T8,Negation 63 65	No
12,T9,Drug 66 74	narcotic
13,T10,Temporal 75 89	before surgery
14,R5,Has_temporal Arg1:T9 Arg2:T10
15,T11,Reference_point 82 89	surgery
16,R6,Has_index Arg1:T10 Arg2:T11
17,T12,Procedure 82 89	surgery
18,R7,multi Arg1:T11 Arg2:T12
19,R8,Has_negation Arg1:T9 Arg2:T8
20,T13,Mood 108 115	Able to
21,T14,Procedure 116 124	Extubate
22,R9,Has_mood Arg1:T14 Arg2:T13
0,T1,Parsing_Error 0 2	NA
0,T1,Condition 27 43	multiple myeloma
1,T2,Measurement 57 108	criteria of the International Myeloma Working Group
2,R1,AND Arg1:T1 Arg2:T2
3,T6,Drug 133 136	DEX
4,T7,Drug 129 132	LEN
5,T8,Qualifier 129 142	LEN-DEX-based
6,R2,AND Arg1:T8 Arg2:T7
7,R3,AND Arg1:T8 Arg2:T6
8,T9,Procedure 143 160	treatment regimen
9,R4,Has_qualifier Arg1:T9 Arg2:T8
10,T10,Mood 161 173	is indicated
11,R5,Has_mood Arg1:T9 Arg2:T10
12,T11,Person 175 180	Adult
13,T12,Value 190 200	≥ 19 years
14,T13,Person 204 207	age
15,R6,Has_value Arg1:T13 Arg2:T12
16,T14,Observation 216 255	able to freely provide informed consent
0,T1,Post-eligibility 0 63	Patient's written informed consent. Adequate cognitive capacity
1,T2,Subjective_judgement 66 89	Adequate family support
2,T3,Condition 100 114	diverticulitis
3,T4,Qualifier 94 99	acute
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Temporal 123 143	in the last 3 months
6,R2,Has_temporal Arg1:T3 Arg2:T5
7,T6,Measurement 145 150	mNeff
8,T7,Value 151 152	0
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Condition 159 173	diverticulitis
11,T9,Qualifier 153 158	acute
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Procedure 175 209	abdominal computed tomography scan
14,T11,Drug 215 235	antibiotic treatment
15,T12,Temporal 236 255	in the last 2 weeks
16,T13,Negation 212 214	No
17,R5,Has_negation Arg1:T11 Arg2:T13
18,R6,Has_temporal Arg1:T11 Arg2:T12
19,T14,Condition 257 273	Immunocompetence
20,T15,Condition 291 304	comorbidities
21,T16,Negation 276 278	No
22,T17,Qualifier 279 290	significant
23,R7,Has_qualifier Arg1:T15 Arg2:T17
24,R8,Has_negation Arg1:T15 Arg2:T16
25,T18,Condition 313 327	oral tolerance
26,T19,Qualifier 308 312	Good
27,R9,Has_qualifier Arg1:T18 Arg2:T19
28,T20,Condition 334 349	symptom control
29,T21,Qualifier 329 333	Good
30,R10,Has_qualifier Arg1:T20 Arg2:T21
31,T22,Measurement 380 393	SIRS criteria
32,T23,Measurement 397 398	T
33,T24,Value 398 404	>38 ºC
34,T25,Value 408 413	<36ºC
35,T26,Measurement 415 416	L
36,T27,"Value 416 423;432 435	>12,000 /uL"
37,T28,Value 427 435	<4000/uL
38,T29,Measurement 437 439	HR
39,T30,Value 439 446	>90 bpm
40,T31,Measurement 448 450	RR
41,T32,Value 450 457	<20 rpm
42,T33,Measurement 462 465	CRP
43,T34,Value 465 474	>15 mg/dL
44,T35,Scope 398 413	>38 ºC or <36ºC
45,R11,Has_scope Arg1:T23 Arg2:T35
46,T36,"Scope 416 435	>12,000 or <4000/uL"
47,R12,Has_scope Arg1:T26 Arg2:T36
48,R13,Has_value Arg1:T29 Arg2:T30
49,R14,Has_value Arg1:T31 Arg2:T32
50,R15,Has_value Arg1:T33 Arg2:T34
51,T37,Scope 0 65;66 90;91 144;145 211;212 256;257 275;276 307;308 328;329 350;351 458	Patient's written informed consent. Adequate cognitive capacity.
52,Adequate,family support
53,No,acute diverticulitis episode in the last 3 months
54,mNeff,0 acute diverticulitis (abdominal computed tomography scan)
55,No,antibiotic treatment in the last 2 weeks
56,,
57,No,significant comorbidities**
58,Good,oral tolerance
59,Good,symptom control
60,Maximum,"one of the following SIRS criteria (* T>38 ºC or <36ºC, L>12,000 or <4000/uL, HR>90 bpm, RR<20 rpm)"
61,T38,"Scope 394 458	(* T>38 ºC or <36ºC, L>12,000 or <4000/uL, HR>90 bpm, RR<20 rpm)"
62,*,OR T22 T33
63,*,OR T23 T26 T29 T31
64,R16,Subsumes Arg1:T22 Arg2:T38
0,T1,Drug 12 24	antiplatelet
1,T2,Drug 28 41	anticoagulant
2,*,OR T2 T1
3,T3,Temporal 0 11	Concomitant
4,R1,Has_temporal Arg1:T1 Arg2:T3
5,R2,Has_temporal Arg1:T2 Arg2:T3
6,T4,Measurement 47 78	Calculated creatinine clearance
7,T5,Value 79 90	< 30 mL/min
8,T6,Measurement 94 117	Cockcroft-Gault formula
9,R3,AND Arg1:T4 Arg2:T6
10,R4,Has_value Arg1:T4 Arg2:T5
11,T7,Measurement 119 149	Alanine aminotransferase (ALT)
12,T8,Measurement 153 185	aspartate aminotransferase (AST)
13,*,OR T8 T7
14,T9,Value 186 223	> 3 times upper limit of normal (ULN)
15,R5,Has_value Arg1:T8 Arg2:T9
16,R6,Has_value Arg1:T7 Arg2:T9
17,T10,Measurement 225 240	Total bilirubin
18,T11,Value 241 250	> 2 x ULN
19,R7,Has_value Arg1:T10 Arg2:T11
20,T12,Measurement 252 268	Thrombocytopenia
21,T13,Value 269 294	< 50 x 10 gigalitres (Gl)
22,R8,Has_value Arg1:T12 Arg2:T13
23,T14,Condition 296 314	High bleeding risk
24,T15,Condition 332 358	prolonged prothrombin time
25,T16,Qualifier 318 331	spontaneously
26,R9,Has_qualifier Arg1:T15 Arg2:T16
27,T17,Measurement 362 399	activated partial thromboplastin time
28,T18,Value 400 411	> 1.5 x ULN
29,R10,Has_value Arg1:T17 Arg2:T18
30,*,OR T14 T15 T17
31,T19,Condition 413 424	Body weight
32,T20,Value 425 428;437 439	<50 kg
33,T21,Value 432 439	>120 kg
34,*,OR T21 T20
35,T22,Scope 425 439	<50 or >120 kg
36,R11,Has_scope Arg1:T19 Arg2:T22
37,T23,Drug 460 466	CYP3A4
38,T24,Drug 470 493	p-glycoprotein inducers
39,T25,Drug 470 484;497 507	p-glycoprotein inhibitors
40,*,OR T25 T24 T23
41,T26,Temporal 441 452	Concomitant
42,R12,Has_temporal Arg1:T23 Arg2:T26
43,R13,Has_temporal Arg1:T25 Arg2:T26
44,R14,Has_temporal Arg1:T24 Arg2:T26
45,T27,Drug 516 529	Ginkgo biloba
46,T30,Drug 597 610	Dexamethasone
47,T31,Temporal 615 635	within last 3 months
48,R15,Has_temporal Arg1:T30 Arg2:T31
49,T32,Person 637 642	Women
50,T33,Condition 646 668	Childbearing potential
51,T34,Procedure 684 706	contraceptive measures
52,T35,Negation 669 676	without
53,R16,Has_negation Arg1:T34 Arg2:T35
54,T36,Condition 708 717	pregnancy
55,T37,Observation 721 735	breast feeding
56,R17,AND Arg1:T33 Arg2:T34
57,*,OR T33 T36 T37
58,T38,Observation 737 752	Life expectancy
59,T39,Value 753 771	less than 3 months
60,R18,Has_value Arg1:T38 Arg2:T39
61,T40,Condition 773 793	Inability to swallow
62,T41,Condition 797 822	issues with malabsorption
63,T42,Undefined_semantics 797 822	issues with malabsorption
64,*,OR T40 T41
65,T43,"Subjective_judgement 824 1001	Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion"
66,T45,"Context_Error 824 1001	Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion"
67,T28,Drug 533 548	St. John's Wort
68,*,OR T27 T28
69,T29,Temporal 549 595	within 14 days before first dose of study drug
70,T44,Reference_point 571 595	first dose of study drug
71,T46,Multiplier 571 581	first dose
72,T47,Drug 585 595	study drug
73,R19,Has_multiplier Arg1:T47 Arg2:T46
74,R20,multi Arg1:T44 Arg2:T47
75,R21,Has_index Arg1:T29 Arg2:T44
76,T48,Scope 516 548	Ginkgo biloba or St. John's Wort
77,R22,Has_temporal Arg1:T48 Arg2:T29
0,T1,Informed_consent 0 34	Inability to give informed consent
1,T2,Condition 36 45	Pregnancy
2,T3,Drug 58 72	antibiotherapy
3,T4,Temporal 47 57	Concurrent
4,R1,Has_temporal Arg1:T3 Arg2:T4
5,T5,Condition 82 105	infectious endocarditis
6,T6,Qualifier 74 81	Certain
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Temporal 107 117	Concurrent
9,T8,Procedure 118 143	anti-inflammatory therapy
10,T9,Drug 118 135	anti-inflammatory
11,R3,multi Arg1:T8 Arg2:T9
12,T10,Procedure 155 177	corticosteroid therapy
13,T11,Drug 155 169	corticosteroid
14,R4,multi Arg1:T10 Arg2:T11
15,R5,Subsumes Arg1:T8 Arg2:T10
16,R6,Has_temporal Arg1:T8 Arg2:T7
0,T1,Observation 0 20	Inability to consent
1,T2,Observation 21 28	refusal
2,*,OR T2 T1
3,T3,Line 0 28	Inability to consent/refusal
4,T4,Line 29 68	Allergy to any of the study medications
5,T5,Line 69 96	Multiple traumatic injuries
6,T6,Line 97 148	Contraindication to neuraxial or general anesthesia
7,T7,Line 149 158	Pregnancy
8,T8,Condition 29 36	Allergy
9,T9,Drug 51 68	study medications
10,T10,Condition 69 96	Multiple traumatic injuries
11,R1,AND Arg1:T8 Arg2:T9
12,T11,Condition 97 113	Contraindication
13,T12,Procedure 117 126;138 148	neuraxial anesthesia
14,T13,Procedure 130 148	general anesthesia
15,*,OR T12 T13
16,T14,Condition 149 158	Pregnancy
0,T1,Condition 0 8	Pregnant
1,T2,Qualifier 32 41	scheduled
2,T3,Qualifier 45 55	non-urgent
3,T4,Procedure 56 70	cesarean birth
4,*,OR T3 T2
5,T5,Scope 32 55	scheduled or non-urgent
6,R1,Has_scope Arg1:T4 Arg2:T5
7,T6,Procedure 96 115	neuraxial analgesia
8,T7,Mood 80 95	able to receive
9,R2,Has_mood Arg1:T6 Arg2:T7
10,T8,Informed_consent 117 198	Patient able to give verbal and written consent for both cesarean birth and study
0,T1,Temporal 0 12	Preoperative
1,T2,Condition 13 26	renal failure
2,T3,Mood 27 36	requiring
3,T4,Procedure 37 45	dialysis
4,R1,Has_mood Arg1:T4 Arg2:T3
5,R2,AND Arg1:T2 Arg2:T4
6,R3,Has_temporal Arg1:T2 Arg2:T1
7,T5,Qualifier 47 64	Poorly controlled
8,T6,Condition 65 82	pulmonary disease
9,T7,Qualifier 84 90	severe
10,T8,Condition 91 97	asthma
11,T9,Condition 101 105	COPD
12,*,OR T8 T9
13,T10,Scope 91 105	asthma or COPD
14,R4,Has_qualifier Arg1:T10 Arg2:T7
15,R5,Has_qualifier Arg1:T6 Arg2:T5
16,T11,Scope 84 105	severe asthma or COPD
17,R6,Subsumes Arg1:T6 Arg2:T11
18,T12,Condition 108 124	Contraindication
19,T13,Procedure 128 147	regional anesthesia
20,R7,AND Arg1:T12 Arg2:T13
21,T14,Temporal 149 155	recent
22,T15,Drug 156 169	anticoagulant
23,R8,Has_temporal Arg1:T15 Arg2:T14
24,T16,Scope 108 147	Contraindication to regional anesthesia
25,T17,Scope 149 169	recent anticoagulant
26,R9,Subsumes Arg1:T16 Arg2:T17
27,T18,Condition 176 187	Sleep apnea
28,T19,Condition 191 205	morbid obesity
29,T20,Mood 211 219	possible
30,T21,Condition 220 231	sleep apnea
31,R10,Has_mood Arg1:T21 Arg2:T20
32,R11,AND Arg1:T19 Arg2:T21
33,*,OR T18 T19
34,T22,Condition 233 240	Allergy
35,T23,Drug 244 253	methadone
36,R12,AND Arg1:T22 Arg2:T23
37,T24,Condition 267 284	preoperative pain
38,T25,Qualifier 255 266	Significant
39,R13,Has_qualifier Arg1:T24 Arg2:T25
40,T26,Mood 285 294	requiring
41,T27,Multiplier 310 320	high doses
42,T28,Drug 324 331	opioids
43,R14,Has_multiplier Arg1:T28 Arg2:T27
44,R15,Has_mood Arg1:T28 Arg2:T26
45,R16,AND Arg1:T24 Arg2:T28
46,T29,Multiplier 333 346;376 383	more than 6-8 per day
47,T30,Drug 347 360	Norco tablets
48,T31,Drug 364 375	equivalence
49,R17,Subsumes Arg1:T30 Arg2:T31
50,R18,Has_multiplier Arg1:T30 Arg2:T29
51,T32,Temporal 388 394	recent
52,T33,Observation 395 402	history
53,T34,Condition 406 418	opioid abuse
54,R19,Has_temporal Arg1:T34 Arg2:T33
55,R20,Has_temporal Arg1:T34 Arg2:T32
56,T35,Scope 333 383	more than 6-8 Norco tablets or equivalence per day
57,R21,Subsumes Arg1:T27 Arg2:T35
58,*,OR T24 T34
0,T1,Person 0 3	age
1,T2,Value 4 8	> 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Informed_consent 10 34	written informed consent
4,T4,Condition 36 39	SVD
5,T5,Procedure 51 67	echocardiography
6,T6,Condition 74 119	alteration of bioprosthesis leaflets function
7,T7,Measurement 127 154	mean transvalvular gradient
8,T8,Value 155 164	> 20 mmHg
9,T9,Measurement 169 185	maximal velocity
10,T10,Value 186 193	= 3 m/s
11,T11,Measurement 198 220	effective orifice area
12,T12,Value 221 229	=1.2 cm²
13,T13,Condition 241 261	aortic regurgitation
14,T14,Value 262 278;285 291	more or equal to 2 on 4
15,T15,Measurement 279 284	grade
16,R2,Has_value Arg1:T15 Arg2:T14
17,R3,Has_value Arg1:T7 Arg2:T8
18,R4,Has_value Arg1:T9 Arg2:T10
19,R5,Has_value Arg1:T11 Arg2:T12
20,R6,AND Arg1:T13 Arg2:T15
21,T16,Scope 127 229	mean transvalvular gradient > 20 mmHg and maximal velocity = 3 m/s and effective orifice area =1.2 cm²
22,R7,Has_scope Arg1:T6 Arg2:T16
23,*,OR T6 T13
24,R8,AND Arg1:T4 Arg2:T5
25,T17,"Scope 74 291	alteration of bioprosthesis leaflets function with a mean transvalvular gradient > 20 mmHg and maximal velocity = 3 m/s and effective orifice area =1.2 cm², and/or an aortic regurgitation more or equal to grade 2 on 4"
26,R9,Has_scope Arg1:T5 Arg2:T17
0,T1,Procedure 19 42	emergent cesarean birth
1,T2,Condition 53 61	allergic
2,T3,Drug 65 74	lidocaine
3,T4,Drug 78 86	adhesive
4,*,OR T3 T4
5,T5,Scope 65 86	lidocaine or adhesive
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Procedure 126 134	epidural
8,T7,Temporal 135 156	during this admission
9,R2,Has_temporal Arg1:T6 Arg2:T7
10,T8,Mood 160 169	requiring
11,T9,Procedure 170 188	general anesthesia
12,R3,Has_mood Arg1:T9 Arg2:T8
13,T10,Procedure 193 207	cesarean birth
14,R4,AND Arg1:T9 Arg2:T10
15,*,OR T6 T9
16,T11,Drug 224 252	chronic oral neuromodulators
17,T12,Drug 293 315	anti-arrhythmic agents
18,T13,Condition 268 283	cardiac disease
19,*,OR T13 T12
20,T14,Condition 331 343	fibromyalgia
21,T15,Condition 347 369	chronic pain syndromes
22,T16,Condition 378 398	rheumatoid arthritis
23,T17,Condition 400 414	osteoarthritis
24,T18,Condition 419 424	lupus
25,*,OR T18 T17 T16
26,T19,"Scope 378 424	rheumatoid arthritis, osteoarthritis, or lupus"
27,R5,Subsumes Arg1:T15 Arg2:T19
28,*,OR T14 T15
29,T20,Drug 433 441	narcotic
30,T21,Multiplier 427 432	Daily
31,T22,Drug 445 451	opiate
32,T23,Temporal 456 518	for greater than the 2 months prior to enrollment in the study
33,T24,Reference_point 495 518	enrollment in the study
34,R6,Has_index Arg1:T23 Arg2:T24
35,*,OR T20 T22
36,T25,Scope 433 451	narcotic or opiate
37,R7,Has_multiplier Arg1:T25 Arg2:T21
38,R8,Has_temporal Arg1:T25 Arg2:T23
0,T1,Measurement 0 3	ASA
1,T2,Value 4 8	I-IV
2,T3,Person 9 12	Age
3,T4,Value 13 24	55 or older
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Mood 25 38	Scheduled for
6,T6,Procedure 39 55	operative repair
7,T7,Qualifier 59 67	isolated
8,T8,Condition 68 98	intertrochanteric hip fracture
9,R2,Has_qualifier Arg1:T8 Arg2:T7
10,R3,AND Arg1:T6 Arg2:T8
11,T9,Multiplier 59 67	isolated
12,R4,multi Arg1:T7 Arg2:T9
13,R5,Has_mood Arg1:T6 Arg2:T5
14,T10,Line 25 98	Scheduled for operative repair of isolated intertrochanteric hip fracture
15,T11,Line 9 24	Age 55 or older
16,T12,Line 0 8	ASA I-IV
17,R6,Has_value Arg1:T1 Arg2:T2
0,T1,Qualifier 28 36	elective
1,T2,Procedure 37 69	shoulder arthroscopic procedures
2,R1,Has_qualifier Arg1:T2 Arg2:T1
0,T1,Condition 0 24	Congestive heart failure
1,T2,Condition 37 60	ventricular tachycardia
2,T3,Observation 26 36	history of
3,T4,Condition 62 86	ventricular fibrillation
4,T5,Condition 90 126	multifocal ventricular extrasystoles
5,T6,Condition 130 146	QTc prolongation
6,*,OR T5 T6 T4 T2 T1
7,R1,Has_temporal Arg1:T2 Arg2:T3
8,T7,Condition 163 182	atrial fibrillation
9,T8,Procedure 194 215	anticoagulant therapy
10,T9,Observation 235 245	history of
11,T10,Condition 260 275	ischemic stroke
12,T11,Qualifier 246 259	cardioembolic
13,R2,Has_qualifier Arg1:T10 Arg2:T11
14,T12,Condition 279 297	hemorrhagic stroke
15,*,OR T12 T10
16,T13,Scope 246 297	cardioembolic ischemic stroke or hemorrhagic stroke
17,R3,Has_temporal Arg1:T13 Arg2:T9
18,T14,Scope 163 215	atrial fibrillation taking any anticoagulant therapy
19,*,OR T14 T13
20,T15,Observation 316 323	history
21,T16,Temporal 325 336	= 12 months
22,R4,Subsumes Arg1:T15 Arg2:T16
23,T17,Condition 341 364	acute coronary syndrome
24,T18,Procedure 375 400	dual antiplatelet therapy
25,T19,Procedure 424 435	monotherapy
26,T20,Drug 441 448	aspirin
27,R5,AND Arg1:T19 Arg2:T20
28,T21,Scope 341 400	acute coronary syndrome receiving dual antiplatelet therapy
29,*,OR T19 T21
30,T22,"Scope 341 448	acute coronary syndrome receiving dual antiplatelet therapy, or patients receiving monotherapy with aspirin"
31,R6,Has_temporal Arg1:T22 Arg2:T15
32,T23,Condition 465 483	hepatic impairment
33,T24,Measurement 485 503	child-Pugh staging
34,T25,Value 505 520	calibration = 5
35,R7,Has_value Arg1:T24 Arg2:T25
36,R8,Subsumes Arg1:T23 Arg2:T24
37,T26,Condition 525 541	renal impairment
38,T27,Measurement 543 563	creatinine clearance
39,T28,Value 564 576	= 30ml / min
40,R9,Has_value Arg1:T27 Arg2:T28
41,R10,Subsumes Arg1:T26 Arg2:T27
42,T29,Temporal 579 585	recent
43,T30,Condition 586 598	peptic ulcer
44,R11,Has_temporal Arg1:T30 Arg2:T29
45,T31,Observation 602 612	history of
46,T32,Condition 613 629	hypersensitivity
47,T33,Drug 633 643	cilostazol
48,T34,Condition 645 651	cancer
49,T35,Procedure 672 681	treatment
50,R12,AND Arg1:T34 Arg2:T35
51,R13,AND Arg1:T32 Arg2:T33
52,R14,Has_temporal Arg1:T32 Arg2:T31
53,*,OR T23 T26 T32 T34 T30
0,T1,Person 0 3	Age
1,T2,Value 7 18	18 and over
2,T3,Person 20 24	male
3,T4,Person 28 34	female
4,*,OR T3 T4
5,R1,Has_value Arg1:T1 Arg2:T2
6,T5,Qualifier 51 75	histologically confirmed
7,T6,Procedure 51 65	histologically
8,T7,Qualifier 76 84	advanced
9,T8,Qualifier 86 94	stage IV
10,R2,Subsumes Arg1:T7 Arg2:T8
11,T9,Condition 96 110	gastric cancer
12,R3,multi Arg1:T5 Arg2:T6
13,T10,Condition 112 117	NSCLC
14,T11,Condition 119 132	breast cancer
15,T12,Condition 136 150	ovarian cancer
16,T13,Procedure 163 174	monotherapy
17,T14,Drug 178 206	oral vascular targeting drug
18,T15,Drug 208 216	apatinib
19,R4,Subsumes Arg1:T14 Arg2:T15
20,R5,AND Arg1:T13 Arg2:T14
21,T16,Non-representable 218 279	due to intolerability or inappropriateness of other therapies
22,*,OR T9 T10 T11 T12
23,T17,"Scope 96 150	gastric cancer, NSCLC, breast cancer or ovarian cancer"
24,R6,Has_qualifier Arg1:T17 Arg2:T7
25,R7,Has_qualifier Arg1:T17 Arg2:T5
26,T18,Condition 294 312	measurable lesions
27,T19,Value 314 319	=10mm
28,T20,Procedure 323 337	spiral CT scan
29,R8,Has_value Arg1:T20 Arg2:T19
30,R9,AND Arg1:T18 Arg2:T20
31,T21,Qualifier 350 360	RECIST 1.1
32,R10,Has_qualifier Arg1:T18 Arg2:T21
33,T22,Measurement 363 378	Blood pressured
34,T23,Qualifier 379 389	controlled
35,T24,Value 393 404	150/100 mHg
36,R11,Has_value Arg1:T22 Arg2:T24
37,R12,Has_qualifier Arg1:T22 Arg2:T23
38,T25,Measurement 440 447	ECOG PS
39,T26,Value 457 472	between 0 and 1
40,R13,Has_value Arg1:T25 Arg2:T26
41,T27,Observation 477 492	life expectancy
42,T28,Value 496 513	at least 3 months
43,R14,Has_value Arg1:T27 Arg2:T28
44,T29,"Informed_consent 516 667	Subjects who volunteer to participate in this study and have signed the Informed Consent Form (ICF), with good compliance with treatment and follow-up."
0,T1,Person 9 13	aged
1,T2,Value 14 23	=50 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 29 32	DM2
4,T4,Condition 49 52	PAD
5,T5,Qualifier 37 48	symptomatic
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Measurement 88 105	Fontaine criteria
8,T7,Value 107 131	stage IIa or IIb and III
9,R3,Has_value Arg1:T6 Arg2:T7
10,R4,AND Arg1:T4 Arg2:T6
11,T8,Non-representable 137 178	by measuring the <U+0391><U+0392><U+0399>
0,T1,Condition 10 17	allergy
1,T2,Drug 21 29	apatinin
2,T3,Drug 41 51	excipients
3,*,OR T2 T3
4,T4,Scope 21 51	apatinin and or its excipients
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 54 66	Hypertension
7,T6,Condition 68 87	high blood pressure
8,R2,Subsumes Arg1:T5 Arg2:T6
9,T7,Qualifier 105 124	controlled by drugs
10,T8,Drug 119 124	drugs
11,R3,multi Arg1:T7 Arg2:T8
12,R4,Has_qualifier Arg1:T5 Arg2:T7
13,T9,Negation 98 101	not
14,R5,Has_negation Arg1:T7 Arg2:T9
15,T10,Qualifier 140 146	active
16,T11,Condition 147 157	hemorragge
17,T12,Condition 159 164	ulcer
18,T13,Condition 166 188	intestinal perforation
19,T14,Condition 190 212	intestinal obstruction
20,T15,Condition 217 230	major surgery
21,T16,Temporal 231 252	no older than 30 days
22,*,OR T15 T14 T13 T12 T11
23,R6,Has_qualifier Arg1:T11 Arg2:T10
24,T17,"Scope 140 230	active hemorragge, ulcer, intestinal perforation, intestinal obstruction, or major surgery"
25,R7,Has_temporal Arg1:T17 Arg2:T16
26,T18,Measurement 255 259	NYHA
27,T19,Value 260 266	III-IV
28,R8,Has_value Arg1:T18 Arg2:T19
29,T20,Condition 267 281	heart function
30,T21,Qualifier 286 292	severe
31,T22,Condition 293 300;310 323	hepatic insufficiency
32,T23,Condition 304 323	renal insufficiency
33,T24,Qualifier 325 332	Grade 4
34,R9,Subsumes Arg1:T21 Arg2:T24
35,T25,Scope 293 323	hepatic or renal insufficiency
36,R10,Has_qualifier Arg1:T25 Arg2:T21
37,*,OR T20 T25
38,R11,AND Arg1:T20 Arg2:T18
39,T26,Observation 357 393	factors that affect oral medications
40,T27,Condition 403 424	difficulty swallowing
41,T28,Condition 426 432	nausea
42,T29,Condition 434 442	vomiting
43,T30,Condition 444 460	chronic diarrhea
44,T31,Condition 465 487	intestinal obstruction
45,*,OR T30 T31 T29 T28 T27
46,T32,"Scope 403 487	difficulty swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction"
47,R12,Has_context Arg1:T32 Arg2:T26
48,T33,"Pregnancy_considerations 490 683	Pregnant or lactating women, or women of child-bearing potential who have planned a pregnancy, or male and female patients who do not agree to practice adequate contraception during this study;"
49,T34,Observation 705 712	history
50,T35,Condition 730 735	abuse
51,T36,Drug 716 729	psychotropics
52,R13,AND Arg1:T35 Arg2:T36
53,R14,Has_temporal Arg1:T35 Arg2:T34
54,T37,Condition 766 782	mental disorders
55,T38,Non-representable 736 752	and can not quit
56,*,OR T35 T37
57,T39,Competing_trial 785 852	Participation in other drug clinical trial within the last 4 weeks;
58,T40,Drug 873 889	VEGFR inhibitors
59,T41,Drug 898 907	sorafenib
60,T42,Drug 912 921	sunitinib
61,*,OR T41 T42
62,T43,Scope 898 921	sorafenib and sunitinib
63,R15,Has_scope Arg1:T40 Arg2:T43
64,T44,"Non-query-able 924 1058	Presence of comorbidities that seriously affect the patient's safety or ability to complete the study, in the investigator's judgment;"
65,T45,Condition 1081 1089	tolerate
66,T46,Negation 1077 1080	not
67,T47,Drug 1090 1098	apatinib
68,R16,Has_negation Arg1:T45 Arg2:T46
69,R17,AND Arg1:T45 Arg2:T47
70,T48,Non-query-able 1180 1255	Patients that are considered ineligible for this study by the investigator.
0,T1,Condition 18 36	systemic infection
1,T2,Condition 56 90	human Immunodeficiency virus (HIV)
2,T3,Condition 92 115	hepatitis B virus (HBV)
3,T4,Condition 121 144	hepatitis C virus (HCV)
4,T5,Grammar_Error 117 120	and
5,*,OR T3 T4 T2
6,T6,Context_Error 172 222	the medicine which is prohibited during this study
7,T7,Non-query-able 159 171	need to take
8,T8,Condition 242 248	asthma
9,T9,Non-query-able 263 275	can not stop
10,T10,Drug 291 307	topical steroids
11,T11,Context_Error 309 318	group 1~5
12,T12,Drug 321 337	oral antibiotics
13,T13,Procedure 339 367	whole body photochemotherapy
14,T14,Drug 369 391	immunosuppressive drug
15,T15,Temporal 392 413	within 4 weeks before
16,T16,Reference_point 418 433	treatment visit
17,R1,Has_index Arg1:T15 Arg2:T16
18,T17,"Scope 291 391	topical steroids (group 1~5), oral antibiotics, whole body photochemotherapy, immunosuppressive drug"
19,*,OR T10 T12 T13 T14
20,R2,AND Arg1:T17 Arg2:T9
21,R3,Has_temporal Arg1:T9 Arg2:T15
22,T18,Condition 435 443	Pregnant
23,T19,Condition 445 459	breast-feeding
24,T20,Person 460 465	women
25,T21,Person 469 474	women
26,T22,Non-query-able 479 493	plan to become
27,T23,Condition 494 502	pregnant
28,R4,AND Arg1:T23 Arg2:T22
29,T24,Temporal 503 520	during this study
30,R5,Has_temporal Arg1:T22 Arg2:T24
31,T25,Condition 533 555	childbearing potential
32,T26,Person 522 529	Females
33,T27,Measurement 577 597	urine pregnancy test
34,T28,Value 568 576	negative
35,R6,Has_value Arg1:T27 Arg2:T28
36,A1,Optional T20
37,A2,Optional T21
38,A3,Optional T26
39,A4,Optional T25
40,R7,AND Arg1:T25 Arg2:T27
41,R8,AND Arg1:T26 Arg2:T25
42,T29,"Scope 435 459	Pregnant, breast-feeding"
43,R9,Has_scope Arg1:T20 Arg2:T29
44,R10,AND Arg1:T21 Arg2:T23
45,*,OR T20 T21 T26
46,T30,Non-query-able 600 713	Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days
47,T31,Context_Error 600 713	Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days
48,T32,Undefined_semantics 734 756	serious adverse events
49,T33,Condition 734 756	serious adverse events
50,T34,Temporal 757 763	during
51,T35,Reference_point 764 781	stem cell therapy
52,T36,Procedure 764 781	stem cell therapy
53,R11,Has_index Arg1:T34 Arg2:T35
54,R12,Has_temporal Arg1:T33 Arg2:T34
55,T37,Condition 802 818	hypersensitivity
56,T38,Drug 822 833	antibiotics
57,T39,Drug 837 849	antimycotics
58,*,OR T38 T39
59,T40,Scope 822 849	antibiotics or antimycotics
60,R13,Has_scope Arg1:T37 Arg2:T40
61,T41,Measurement 864 874	creatinine
62,T42,Value 884 942	more than two times of the upper limit of the normal range
63,T43,Temporal 943 960	at screening test
64,T44,Reference_point 946 960	screening test
65,R14,Has_index Arg1:T43 Arg2:T44
66,R15,Has_value Arg1:T41 Arg2:T42
67,R16,Has_temporal Arg1:T41 Arg2:T43
68,T45,Measurement 975 1029	aspartate transaminase/alkaline transaminase (AST/ALT)
69,T46,Value 1039 1099	more than three times of the upper limit of the normal range
70,T47,Temporal 1100 1117	at screening test
71,T48,Reference_point 1103 1117	screening test
72,R17,Has_temporal Arg1:T45 Arg2:T47
73,R18,Has_value Arg1:T45 Arg2:T46
74,R19,Has_index Arg1:T47 Arg2:T48
75,T49,Condition 1137 1156	any other condition
76,T50,Qualifier 1163 1241	the investigator judges would make patients unsuitable for study participation
77,T51,Subjective_judgement 1163 1241	the investigator judges would make patients unsuitable for study participation
78,T52,Undefined_semantics 1163 1241	the investigator judges would make patients unsuitable for study participation
79,T53,Context_Error 1163 1241	the investigator judges would make patients unsuitable for study participation
80,R20,Has_qualifier Arg1:T49 Arg2:T50
0,T1,Condition 0 20	Complex kidney stone
1,T2,Condition 22 38	staghorn calculi
2,T3,Measurement 39 43	GUYS
3,T4,Value 44 54	III and IV
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,AND Arg1:T2 Arg2:T3
6,T5,Scope 22 54	staghorn calculi GUYS III and IV
7,R3,Has_scope Arg1:T1 Arg2:T5
0,T1,Visit 0 48	School districts that are too difficult to reach
1,T2,Measurement 69 137	walk from the farthest place reachable by a four-wheel drive vehicle
2,T3,Value 50 68	more than a 3-hour
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Visit 140 197	School districts in the 2 urban regions of the study area
5,T5,Non-query-able 199 223	Refusal of village chief
6,T6,Observation 239 247	residing
7,T7,Visit 248 270	near to the well sites
8,R2,AND Arg1:T6 Arg2:T7
9,T8,Informed_consent 315 358	Refusal of participant [or parent/guardian]
0,T1,Person 18 22	aged
1,T2,Value 23 40	≥19 and ≤70 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 42 59	Atopic dermatitis
4,T4,Measurement 93 129	Hanifin and Rajka diagnosis criteria
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Condition 184 203	dermatitis symptoms
7,T6,Temporal 204 233	continually at least 6 months
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Grammar_Error 140 143	and
10,T8,Qualifier 144 151	chronic
11,T9,Qualifier 131 139	Subacute
12,*,OR T9 T8
13,T10,Scope 131 151	Subacute and chronic
14,R4,Has_scope Arg1:T5 Arg2:T10
15,T11,Condition 263 280	atopic dermatitis
16,T12,Measurement 282 294	SCORAD score
17,T13,Value 295 299	> 20
18,R5,Has_value Arg1:T12 Arg2:T13
19,R6,AND Arg1:T11 Arg2:T12
20,T14,Qualifier 249 262	over moderate
21,R7,Has_qualifier Arg1:T11 Arg2:T14
22,T15,Post-eligibility 302 371	Subjects who understand and voluntarily sign an informed consent form
23,T16,Non-query-able 302 371	Subjects who understand and voluntarily sign an informed consent form
0,T1,Condition 0 23	Coronary artery disease
1,T2,Device 26 31	stent
2,*,OR T1 T2
3,T3,Qualifier 33 39	Severe
4,T4,Qualifier 40 47	chronic
5,T5,Condition 48 61	renal failure
6,R1,Has_qualifier Arg1:T5 Arg2:T4
7,R2,Has_qualifier Arg1:T5 Arg2:T3
8,T6,Qualifier 63 73	Congenital
9,T7,Qualifier 77 85	acquired
10,T8,Condition 86 99	thrombophilia
11,T9,Condition 100 116	thrombosis event
12,*,OR T7 T6
13,*,OR T8 T9
14,T10,Scope 86 116	thrombophilia/thrombosis event
15,T11,Scope 63 85	Congenital or acquired
16,R3,Has_scope Arg1:T10 Arg2:T11
17,T12,Condition 137 144	allergy
18,T13,Mood 118 123	Known
19,T14,Mood 127 136	suspected
20,*,OR T14 T13
21,T15,Scope 118 136	Known or suspected
22,R4,Has_scope Arg1:T12 Arg2:T15
0,T1,Visit 15 60	school district that is within the study area
1,T2,Visit 79 120	school district that is in need of a well
0,T1,Qualifier 0 7	Primary
1,T2,Condition 8 27	periampullary tumor
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Procedure 33 45	R1 resection
4,T4,Procedure 29 31;36 45	R0 resection
5,*,OR T3 T4
6,T5,Condition 47 67	Chronic pancreatitis
7,T6,Observation 68 77	requiring
8,T7,Procedure 78 99	pancreatoduodenectomy
9,R2,AND Arg1:T6 Arg2:T7
10,R3,Has_context Arg1:T5 Arg2:T6
0,T1,Person 3 6	age
1,T2,Value 7 12	50-70
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 17 23	stroke
4,T4,Temporal 24 54	within the past 6 to 60 months
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Condition 60 85	major depressive disorder
7,T6,Measurement 87 92	PHQ-9
8,T7,Value 93 97	> 10
9,R3,Has_value Arg1:T6 Arg2:T7
10,R4,AND Arg1:T5 Arg2:T6
11,T8,"Procedure 123 270	Structured Clinical Interview for Depression (SCID) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)"
12,R5,AND Arg1:T5 Arg2:T8
13,T9,Condition 276 292	residual paresis
14,T10,Qualifier 300 315	lower extremity
15,R6,Has_qualifier Arg1:T9 Arg2:T10
16,T11,Measurement 317 342	Fugl-Meyer LE motor score
17,T12,Value 343 346	<34
18,R7,Has_value Arg1:T11 Arg2:T12
19,R8,AND Arg1:T9 Arg2:T11
20,T13,Condition 353 387	ability to walk without assistance
21,T14,Measurement 403 423	AFO on the treadmill
22,T15,Value 424 436	≥ 30 seconds
23,R9,Has_value Arg1:T14 Arg2:T15
24,T16,Negation 392 399	without
25,R10,Has_negation Arg1:T14 Arg2:T16
26,T17,Qualifier 440 446	speeds
27,T18,Value 455 471	from 0.2-0.8 m/s
28,R11,Has_value Arg1:T17 Arg2:T18
29,R12,Has_qualifier Arg1:T14 Arg2:T17
30,T19,Drug 480 494	antidepressant
31,T20,Negation 477 479	no
32,R13,Has_negation Arg1:T19 Arg2:T20
33,T21,Condition 510 552	clinically able to discontinue medications
34,T22,Undefined_semantics 510 552	clinically able to discontinue medications
35,T23,Subjective_judgement 510 552	clinically able to discontinue medications
36,*,OR T19 T21
37,T24,Measurement 558 574	HRSD question #9
38,T25,Value 593 595	<2
39,R14,Has_value Arg1:T24 Arg2:T25
40,T26,Non-query-able 601 631	provision of informed consent.
41,T27,"Post-eligibility 632 801	In addition, all subjects who meet criteria for the training portion must complete an exercise tolerance test and be cleared for participation by the study cardiologist."
42,T28,Parsing_Error 0 2	1)
43,T29,Parsing_Error 14 16	2)
44,T30,Parsing_Error 57 59	3)
45,T31,Parsing_Error 273 275	4)
46,T32,Parsing_Error 350 352	5)
47,T33,Parsing_Error 474 476	6)
48,T34,Parsing_Error 555 557	7)
49,T35,Parsing_Error 598 600	8)
0,T1,Measurement 0 19	Response assessment
1,T2,Value 23 45	complete response (CR)
2,T3,Value 47 68	partial response (PR)
3,T4,Value 70 94	long stable disease (SD)
4,T5,Temporal 95 108	for >3 months
5,*,OR T3 T4 T2
6,T6,"Scope 23 94	complete response (CR), partial response (PR), long stable disease (SD)"
7,R1,Has_scope Arg1:T1 Arg2:T6
8,R2,Has_temporal Arg1:T6 Arg2:T5
9,T7,Qualifier 116 122	cancer
10,T8,Procedure 123 146	immunotherapy treatment
11,R3,Has_qualifier Arg1:T8 Arg2:T7
12,T9,Condition 151 168	metastatic cancer
13,T10,Condition 172 196	hematologic malignancies
14,T11,Procedure 214 226	marketed CPI
15,T12,Observation 238 291	participation in a Roche/Genentech CPI clinical trial
16,*,OR T11 T12
17,*,OR T9 T10
18,T13,Scope 151 196	metastatic cancer or hematologic malignancies
19,R4,Has_scope Arg1:T8 Arg2:T13
20,T14,Non-representable 294 381	Availability of tumor biopsy material extracted and preserved by the investigating site
0,T1,Condition 11 16	tumor
1,T2,Qualifier 18 38	Locally unresectable
2,T3,Condition 39 44	tumor
3,T4,Qualifier 0 10	Metastatic
4,R1,Has_qualifier Arg1:T1 Arg2:T4
5,T5,Temporal 46 54	Previous
6,T6,Procedure 55 72	gastric resection
7,R2,Has_temporal Arg1:T6 Arg2:T5
8,T7,Measurement 74 77	ASA
9,T8,Value 78 82	IV-V
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Person 84 87	Age
12,T10,Value 88 102	under 18 years
13,R4,Has_value Arg1:T9 Arg2:T10
14,T11,Temporal 104 116	Preoperative
15,T12,Condition 117 136;148 155	complete parenteral feeding
16,T13,Condition 117 125;140 155	complete enteral feeding
17,*,OR T12 T13
18,T14,Scope 117 155	complete parenteral or enteral feeding
19,R5,Has_temporal Arg1:T14 Arg2:T11
20,T15,Procedure 157 182	Immunosuppressive therapy
21,T16,Temporal 183 199	before operation
22,T17,Procedure 190 199	operation
23,T18,Reference_point 190 199	operation
24,R6,Has_index Arg1:T16 Arg2:T18
25,R7,multi Arg1:T18 Arg2:T17
26,R8,Has_temporal Arg1:T15 Arg2:T16
27,T19,Qualifier 201 207	Severe
28,T20,Condition 208 220	malnutrition
29,R9,Has_qualifier Arg1:T20 Arg2:T19
30,T21,"Informed_consent 222 325	Lack of the patient's consent for the trial participation, feeding tube insertion or epidural analgesia"
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 281 283	3.
2,T3,Parsing_Error 114 116	2.
3,T4,Parsing_Error 315 317	4.
4,T5,Parsing_Error 384 386	5.
5,T6,Parsing_Error 418 420	6.
6,T7,Parsing_Error 534 536	8.
7,T8,Parsing_Error 467 469	7.
8,T9,Parsing_Error 562 564	9.
9,T10,Parsing_Error 637 640	10.
10,T11,Parsing_Error 696 699	11.
11,T12,Parsing_Error 794 797	12.
12,T13,Parsing_Error 876 879	13.
13,T14,Parsing_Error 968 971	14.
14,T15,Parsing_Error 1110 1113	16)
15,T16,Condition 3 39	Unable to ambulate at least 150 feet
16,T17,Temporal 40 45	prior
17,T18,Condition 49 55	stroke
18,T19,Reference_point 49 55	stroke
19,R1,Has_index Arg1:T17 Arg2:T19
20,R2,Has_temporal Arg1:T16 Arg2:T17
21,T20,Condition 72 97	intermittent claudication
22,T21,Qualifier 98 111	while walking
23,R3,Has_qualifier Arg1:T20 Arg2:T21
24,*,OR T16 T20
25,T22,Observation 117 124	history
26,T23,Condition 128 152	congestive heart failure
27,T24,Condition 154 182	unstable cardiac arrhythmias
28,T25,Condition 184 211	hypertrophic cardiomyopathy
29,T26,Condition 213 235	severe aortic stenosis
30,T27,Condition 237 243	angina
31,T28,Condition 247 262	dyspnea at rest
32,T29,Condition 247 254;266 278	dyspnea during ADL's
33,*,OR T23 T24 T25 T26 T27 T29 T28
34,T30,"Scope 128 278	congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's"
35,R4,Has_scope Arg1:T22 Arg2:T30
36,T31,Condition 295 312	oxygen dependence
37,T32,Observation 284 291	History
38,R5,Has_temporal Arg1:T31 Arg2:T32
39,T33,Condition 330 352	neurological disorders
40,T34,Condition 354 362	dementia
41,T35,Condition 375 381	stroke
42,T36,Temporal 366 374	previous
43,*,OR T34 T33 T35
44,T37,Temporal 318 329	Preexisting
45,R6,Has_temporal Arg1:T35 Arg2:T36
46,R7,Has_temporal Arg1:T33 Arg2:T37
47,R8,Has_temporal Arg1:T34 Arg2:T37
48,T38,Condition 398 415	major head trauma
49,T39,Observation 387 394	History
50,R9,Has_temporal Arg1:T38 Arg2:T39
51,T40,Condition 440 464	severe visual impairment
52,T41,Condition 421 436	Legal blindness
53,*,OR T40 T41
54,T42,Condition 481 490	psychosis
55,T43,Condition 500 515	Axis I disorder
56,T44,Qualifier 524 531	primary
57,R10,Has_qualifier Arg1:T43 Arg2:T44
58,*,OR T43 T42
59,T45,Observation 470 477	history
60,R11,Has_temporal Arg1:T42 Arg2:T45
61,R12,Has_temporal Arg1:T43 Arg2:T45
62,T46,Observation 537 552	Life expectancy
63,T47,Value 553 558	<1 yr
64,R13,Has_value Arg1:T46 Arg2:T47
65,T48,Condition 565 581	Severe arthritis
66,T49,Condition 591 634	problems that limit passive range of motion
67,T50,Undefined_semantics 591 634	problems that limit passive range of motion
68,*,OR T48 T49
69,T51,Condition 652 655	DVT
70,T52,Condition 659 677	pulmonary embolism
71,T53,Temporal 678 693	within 6 months
72,R14,Has_temporal Arg1:T52 Arg2:T53
73,*,OR T51 T52
74,T54,Observation 641 648	History
75,T55,Scope 652 693	DVT or pulmonary embolism within 6 months
76,R15,Has_temporal Arg1:T55 Arg2:T54
77,T56,Condition 713 721	diabetes
78,T57,Qualifier 700 712	Uncontrolled
79,R16,Has_qualifier Arg1:T56 Arg2:T57
80,T58,Condition 734 745	weight loss
81,T59,Condition 747 760	diabetic coma
82,T60,Condition 774 791	insulin reactions
83,T61,Multiplier 765 773	frequent
84,R17,Has_multiplier Arg1:T60 Arg2:T61
85,*,OR T59 T60 T58 T56
86,T62,Condition 798 817	Severe hypertension
87,T63,Measurement 823 831	systolic
88,T64,Value 832 841	>200 mmHg
89,T65,Measurement 846 855	diastolic
90,T66,Value 856 865	>110 mmHg
91,R18,Has_value Arg1:T63 Arg2:T64
92,R19,Has_value Arg1:T65 Arg2:T66
93,R20,AND Arg1:T62 Arg2:T63
94,R21,AND Arg1:T62 Arg2:T65
95,T67,Condition 880 898	attempt of suicide
96,T68,Temporal 899 918	in the last 2 years
97,T69,Condition 922 938	at suicidal risk
98,T70,Procedure 951 965	SCID interview
99,R22,AND Arg1:T69 Arg2:T70
100,R23,Has_temporal Arg1:T67 Arg2:T68
101,*,OR T67 T69
102,T71,Non-query-able 972 1107	Previous or current enrollment in a clinical trial to enhance motor recovery; 15) currently exercising ≥ 2 times per week (≥20 minutes)
103,T72,Context_Error 972 1107	Previous or current enrollment in a clinical trial to enhance motor recovery; 15) currently exercising ≥ 2 times per week (≥20 minutes)
104,T73,Device 1126 1152	non-MR compatible implants
105,T74,Condition 1154 1163	pregnancy
106,T75,Condition 1174 1188	claustrophobia
107,T76,Qualifier 1167 1173	severe
108,R24,Has_qualifier Arg1:T75 Arg2:T76
109,*,OR T74 T75 T73
0,T1,Procedure 20 45	CPI combination therapies
1,T2,Procedure 51 63	chemotherapy
2,T3,Condition 84 92	Pregnant
3,T4,Condition 94 103	lactating
4,T5,Mood 108 127	intending to become
5,T6,Condition 128 136	pregnant
6,R1,Has_mood Arg1:T6 Arg2:T5
7,*,OR T3 T4 T6
8,T7,Temporal 137 153	during the study
9,R2,Has_temporal Arg1:T6 Arg2:T7
0,T1,Person 0 5	women
1,T2,Procedure 17 20	IVF
2,T3,Procedure 21 25	ICSI
3,T4,Procedure 29 58	frozen embryo transfers (FET)
4,T5,Value 64 82	less than 40 years
5,T6,Person 83 86	old
6,R1,Has_value Arg1:T6 Arg2:T5
7,*,OR T2 T3 T4
0,T1,Person 0 3	age
1,T2,Value 4 21	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 43 62	invasive procedures
4,T4,Temporal 32 42	undergoing
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Qualifier 71 77;89 97	radial arteries
7,T6,Qualifier 81 97	femoral arteries
8,*,OR T6 T5
9,T7,Scope 71 97	radial or femoral arteries
10,R3,Has_scope Arg1:T3 Arg2:T7
0,T1,"Pregnancy_considerations 0 221	Is not of reproductive potential, or is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication"
1,T2,Condition 227 244	chronic back pain
2,T3,Qualifier 248 266	=3 months duration
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Observation 270 277	history
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,T5,Condition 310 318	nr-axSpA
7,T6,Qualifier 303 309	active
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Measurement 324 340	disease duration
10,T8,Measurement 258 266	duration
11,T9,Value 248 257	=3 months
12,R4,Has_value Arg1:T8 Arg2:T9
13,R5,multi Arg1:T3 Arg2:T8
14,T10,Value 341 351	<= 5 years
15,R6,Has_value Arg1:T7 Arg2:T10
16,T11,Qualifier 324 351	disease duration <= 5 years
17,R7,Has_qualifier Arg1:T5 Arg2:T11
18,T12,Condition 355 377	Inflammatory back pain
19,T13,Condition 381 390	Arthritis
20,T14,Condition 416 426	Enthesitis
21,T15,Qualifier 428 432	heel
22,R8,Has_qualifier Arg1:T14 Arg2:T15
23,T16,Condition 467 471	pain
24,T17,Condition 475 485	tenderness
25,*,OR T16 T17
26,T18,Qualifier 508 552	site of the insertion of the Achilles tendon
27,T19,Qualifier 556 570	plantar fascia
28,*,OR T18 T19
29,T20,Scope 508 570	site of the insertion of the Achilles tendon or plantar fascia
30,T21,Scope 467 485	pain or tenderness
31,R9,Has_scope Arg1:T21 Arg2:T20
32,T22,Condition 575 585	Dactylitis
33,T23,Condition 611 620	Psoriasis
34,T24,Condition 677 709	inflammatory bowel disease (IBD)
35,T25,Condition 724 731	uveitis
36,T26,Non-representable 732 763	confirmed by an ophthalmologist
37,T27,Observation 646 653	History
38,R10,Has_temporal Arg1:T24 Arg2:T27
39,T28,Observation 713 720	History
40,R11,Has_temporal Arg1:T25 Arg2:T28
41,T29,Drug 784 828	nonsteroidal anti-inflammatory drugs (NSAID)
42,T30,Observation 767 780	Good response
43,R12,AND Arg1:T30 Arg2:T29
44,T31,Observation 832 846	Family history
45,T32,Condition 850 853	SpA
46,T33,Condition 867 889	ankylosing spondylitis
47,T34,Condition 891 900	psoriasis
48,T35,Condition 902 915	acute uveitis
49,T36,Condition 917 935	reactive arthritis
50,T37,Condition 940 943	IBD
51,*,OR T37 T36 T35 T34 T33
52,T38,"Scope 867 943	ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD"
53,R13,Subsumes Arg1:T32 Arg2:T38
54,R14,Has_context Arg1:T32 Arg2:T31
55,T39,Measurement 957 960	CRP
56,T40,Value 948 956	Elevated
57,R15,Has_value Arg1:T39 Arg2:T40
58,T41,Condition 1003 1007;964 991	gene Human leukocyte antigen B27
59,T42,Condition 992 1002	(HLA-B27)+
60,R16,Subsumes Arg1:T41 Arg2:T42
61,T43,Condition 1015 1023	HLA-B27+
62,T44,Condition 1050 1053	SpA
63,T45,Multiplier 1033 1042	2 or more
64,R17,Has_multiplier Arg1:T44 Arg2:T45
65,T46,Measurement 1097 1100	CRP
66,T47,Value 1088 1096	elevated
67,T48,Temporal 1101 1113	at Screening
68,R18,Has_value Arg1:T46 Arg2:T47
69,R19,Has_temporal Arg1:T46 Arg2:T48
70,T49,Qualifier 1129 1135	active
71,T50,Condition 1136 1148	inflammation
72,T51,Qualifier 1156 1173	sacroiliac joints
73,T52,Procedure 1177 1180	MRI
74,R20,Has_qualifier Arg1:T50 Arg2:T51
75,R21,AND Arg1:T50 Arg2:T52
76,R22,Has_qualifier Arg1:T50 Arg2:T49
77,*,OR T46 T50
78,T53,Measurement 1189 1194	ASDAS
79,T54,Value 1195 1201	>= 2.1
80,T55,Temporal 1202 1214	at Screening
81,R23,Has_value Arg1:T53 Arg2:T54
82,R24,Has_temporal Arg1:T53 Arg2:T55
83,T56,Measurement 1280 1301	Total Back Pain score
84,T57,Value 1305 1307	=4
85,R25,Has_value Arg1:T56 Arg2:T57
86,T58,Measurement 1314 1379	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score
87,T59,Value 1383 1387	>= 4
88,R26,Has_value Arg1:T58 Arg2:T59
89,T60,Condition 1222 1243	high disease activity
90,T61,Temporal 1244 1269	at Screening and Baseline
91,R27,Has_temporal Arg1:T60 Arg2:T61
92,R28,AND Arg1:T60 Arg2:T56
93,R29,AND Arg1:T60 Arg2:T58
94,T62,Observation 1407 1414	history
95,T63,Qualifier 1396 1406	acceptable
96,T64,Drug 1418 1423	NSAID
97,R30,Has_temporal Arg1:T64 Arg2:T62
98,R31,Has_qualifier Arg1:T64 Arg2:T63
99,T65,Qualifier 1467 1473	active
100,T66,Qualifier 1447 1456	untreated
101,T67,Qualifier 1457 1463	latent
102,*,OR T67 T65
103,T68,Condition 1474 1491	tuberculosis (TB)
104,T69,Scope 1457 1473	latent or active
105,R32,Has_scope Arg1:T68 Arg2:T69
106,R33,Has_qualifier Arg1:T68 Arg2:T66
107,T70,Negation 1433 1435	no
108,T71,Observation 1436 1443	history
109,R34,Has_temporal Arg1:T68 Arg2:T71
110,T72,Scope 1436 1491	history of untreated latent or active tuberculosis (TB)
111,R35,Has_negation Arg1:T72 Arg2:T70
112,T73,Temporal 1492 1510	prior to Screening
113,T74,Reference_point 1501 1510	Screening
114,R36,Has_index Arg1:T73 Arg2:T74
115,R37,Has_temporal Arg1:T72 Arg2:T73
116,T75,Observation 1530 1543	close contact
117,T76,Temporal 1523 1529	recent
118,R38,Has_temporal Arg1:T75 Arg2:T76
119,T77,Observation 1551 1572	person with active TB
120,T78,"Non-representable 1512 1692	Has had no recent close contact with a person with active TB or, if there has been such contact, will undergo additional evaluations and receive appropriate treatment for latent TB"
0,T1,Procedure 23 55	gynecologic laparoscopic surgery
1,T2,Observation 157 191	able to complete the questionnaire
2,T3,Observation 69 104	agrees to participate in this study
3,T4,Informed_consent 57 104	Patient who agrees to participate in this study
4,T5,Observation 114 147	able to speak and understand Thai
5,T6,Post-eligibility 106 147	Patient able to speak and understand Thai
0,T1,Condition 23 32	active TB
1,T2,Condition 48 57	allergies
2,T3,Non-query-able 42 116	Known allergies to any of the study medications by participant self-report
3,T4,Pregnancy_considerations 118 161	have a positive pregnancy test at screening
4,T5,Pregnancy_considerations 167 249	are not willing to use a reliable method of barrier contraception during the study
5,T6,Pregnancy_considerations 255 272	are breastfeeding
6,T7,Procedure 274 296	hormonal contraception
7,T8,Condition 298 310	HIV infected
8,T9,Drug 335 356	anti-retroviral drugs
9,R1,AND Arg1:T8 Arg2:T9
10,T10,Non-query-able 358 406	other drugs that interact with 3HP (see Table 1)
11,T11,Condition 446 455	resistant
12,T12,Drug 437 445	rifampin
13,T13,Drug 430 433	INH
14,*,OR T12 T13
15,T14,Scope 430 445	INH or rifampin
16,R2,Has_scope Arg1:T11 Arg2:T14
17,T15,Measurement 462 468	Weight
18,T16,Value 469 476	< 10 kg
19,R3,Has_value Arg1:T15 Arg2:T16
20,T17,Condition 499 511	liver damage
21,T18,Measurement 526 548	aspartate transaminase
22,T19,Measurement 550 553	AST
23,T20,Value 569 607	more than 3x the upper limit of normal
24,R4,Subsumes Arg1:T18 Arg2:T19
25,R5,AND Arg1:T17 Arg2:T18
26,R6,Has_value Arg1:T18 Arg2:T20
27,T21,Condition 636 645	Porphyria
28,T22,Post-eligibility 667 698	Inability to adhere to protocol
29,T23,"Non-query-able 701 819	Patients may be excluded from the study for other reasons, at the investigator's discretion with detailed documentatio"
0,T1,Measurement 0 15	gestational age
1,T2,Value 16 56	between 20 weeks and 23 weeks and 6 days
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 58 79	singleton pregnancies
0,T1,Condition 6 22	spinal pathology
1,T2,Condition 32 60	associated medical condition
2,*,OR T1 T2
3,T3,Condition 62 98	Major neurologic developmental delay
4,T4,Procedure 109 125	anterior surgery
5,T5,Mood 100 108	Need for
6,R1,Has_mood Arg1:T4 Arg2:T5
7,T6,Procedure 133 159	vertebral column resection
8,*,OR T4 T6
9,T7,Temporal 162 174	Preoperative
10,T8,Drug 175 181	opioid
11,R2,Has_temporal Arg1:T8 Arg2:T7
12,T9,Condition 187 203	Inability to use
13,T10,Procedure 204 207	PCA
14,R3,AND Arg1:T9 Arg2:T10
0,T1,Non-query-able 0 15	day 3 transfers
0,T1,Condition 24 31	allergy
1,T2,Drug 44 59	anesthetic drug
2,T3,Qualifier 35 43	any kind
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Observation 13 20	history
6,R3,Has_temporal Arg1:T1 Arg2:T4
7,T5,Condition 73 81	pregnant
8,T6,Qualifier 104 115	single port
9,T7,Procedure 116 148	gynecologic laparoscopic surgery
10,R4,Has_qualifier Arg1:T7 Arg2:T6
11,T8,Procedure 152 164	NOTE surgery
12,*,OR T7 T8
13,T9,Procedure 183 190	surgery
14,T10,Observation 194 202	withhold
15,T11,Observation 206 214	canceled
16,*,OR T10 T11
17,T12,Scope 194 214	withhold or canceled
18,R5,Has_scope Arg1:T9 Arg2:T12
19,T13,Procedure 233 240	surgery
20,T14,Observation 244 256	converted to
21,T15,Procedure 257 267	laparotomy
22,R6,AND Arg1:T14 Arg2:T15
23,R7,Has_context Arg1:T13 Arg2:T14
0,T1,Qualifier 4 13	bilateral
1,T2,Condition 14 26	sacroiliitis
2,T3,Qualifier 27 34	Grade 2
3,T4,Qualifier 38 48	unilateral
4,T5,Condition 49 61	sacroiliitis
5,T6,Qualifier 62 69	Grade 3
6,T7,Qualifier 73 80	Grade 4
7,*,OR T6 T7
8,T8,Scope 62 80	Grade 3 or Grade 4
9,R1,Has_scope Arg1:T5 Arg2:T8
10,R2,Has_qualifier Arg1:T5 Arg2:T4
11,R3,Has_qualifier Arg1:T2 Arg2:T3
12,*,OR T2 T5
13,R4,Has_qualifier Arg1:T2 Arg2:T1
14,T9,Condition 87 94	nursing
15,T10,Condition 98 106	pregnant
16,T11,Person 107 113	female
17,*,OR T10 T9
18,T12,Condition 136 144	pregnant
19,T13,Temporal 145 193	within 6 months after receiving trial medication
20,R5,Has_temporal Arg1:T12 Arg2:T13
21,T14,Mood 118 135	intends to become
22,R6,Has_mood Arg1:T12 Arg2:T14
23,T15,Procedure 206 217	donate eggs
24,T16,Procedure 206 212;243 248	donate sperm
25,T17,Person 219 225	female
26,T18,Person 250 254	male
27,T19,Temporal 269 301	while receiving trial medication
28,T20,Temporal 305 343	within 6 months after trial medication
29,T21,Reference_point 327 343	trial medication
30,T22,Reference_point 285 301	trial medication
31,R7,Has_index Arg1:T19 Arg2:T22
32,R8,Has_index Arg1:T20 Arg2:T21
33,*,OR T19 T20
34,A1,Optional T17
35,A2,Optional T18
36,R9,AND Arg1:T17 Arg2:T15
37,R10,AND Arg1:T18 Arg2:T16
38,*,OR T17 T18
39,T23,Scope 206 268	donate eggs (female participants) or sperm (male participants)
40,T24,Scope 269 343	while receiving trial medication or within 6 months after trial medication
41,R11,Has_scope Arg1:T23 Arg2:T24
42,T25,Post-eligibility 345 476	Has any clinically significant condition or situation that would interfere with the trial evaluations or participation in the trial
43,T26,Drug 500 515	cytotoxic drugs
44,T27,Drug 527 539	chlorambucil
45,T28,Drug 541 557	cyclophosphamide
46,T29,Drug 559 575	nitrogen mustard
47,T30,Drug 586 603	alkylating agents
48,*,OR T29 T30 T28 T27
49,T31,"Scope 527 603	chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents"
50,R12,Subsumes Arg1:T26 Arg2:T31
51,T32,Drug 607 645	Disease-modifying anti-rheumatic drugs
52,T33,Temporal 647 663	30 days off drug
53,R13,Has_temporal Arg1:T32 Arg2:T33
54,T34,Drug 668 685	Live vaccinations
55,T35,Temporal 687 704	3 months off drug
56,R14,Has_temporal Arg1:T34 Arg2:T35
57,T36,Drug 709 736	Investigational medications
58,T37,Temporal 738 745;762 770	30 days off drug
59,T38,Temporal 749 770	5 half-lives off drug
60,*,OR T38 T37
61,T39,Scope 738 770	30 days or 5 half-lives off drug
62,R15,Has_scope Arg1:T36 Arg2:T39
63,T40,Drug 796 837	Bacille Calmette-Guerin (BCG) vaccination
64,T41,Temporal 839 857	12 months off drug
65,R16,Has_temporal Arg1:T40 Arg2:T41
66,T42,Condition 877 899	inflammatory condition
67,T43,Condition 911 930	psoriatic arthritis
68,T44,Condition 939 951	Lyme disease
69,T45,Qualifier 932 938	active
70,R17,Has_qualifier Arg1:T44 Arg2:T45
71,T46,Condition 953 981	systemic lupus erythematosus
72,T47,Condition 983 1003	infectious arthritis
73,T48,Condition 1005 1015	vasculitis
74,T49,Condition 1017 1037	parvovirus infection
75,T50,Condition 1039 1059	rheumatoid arthritis
76,T51,Condition 1061 1075	active uveitis
77,T52,Condition 1080 1090	active IBD
78,*,OR T51 T52 T50 T49 T48 T47 T46 T44 T43
79,T53,"Scope 911 1090	psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD"
80,R18,Subsumes Arg1:T42 Arg2:T53
81,T54,Qualifier 1119 1125	active
82,T55,Qualifier 1109 1115	latent
83,*,OR T55 T54
84,T56,Condition 1126 1149	granulomatous infection
85,T57,Temporal 1150 1168	prior to Screening
86,T58,Reference_point 1159 1168	Screening
87,R19,Has_index Arg1:T57 Arg2:T58
88,T59,Scope 1109 1125	latent or active
89,R20,Has_scope Arg1:T56 Arg2:T59
90,R21,Has_temporal Arg1:T56 Arg2:T57
91,T60,Condition 1176 1214	nontuberculous mycobacterial infection
92,T61,Condition 1218 1241	opportunistic infection
93,T62,Temporal 1242 1276	within 6 months prior to Screening
94,*,OR T61 T60
95,T63,Scope 1176 1241	nontuberculous mycobacterial infection or opportunistic infection
96,R22,Has_temporal Arg1:T63 Arg2:T62
97,T64,Condition 1298 1306	infected
98,T65,Device 1307 1323	joint prosthesis
99,R23,AND Arg1:T64 Arg2:T65
100,T66,Observation 1284 1291	history
101,R24,Has_temporal Arg1:T64 Arg2:T66
102,T67,Drug 1341 1352	antibiotics
103,T68,Mood 1359 1368	suspected
104,T69,Condition 1369 1378	infection
105,T70,Device 1384 1400	joint prosthesis
106,R25,AND Arg1:T69 Arg2:T70
107,R26,Has_mood Arg1:T69 Arg2:T68
108,R27,AND Arg1:T67 Arg2:T69
109,*,OR T64 T69
110,T71,Condition 1461 1478	serious infection
111,T72,Procedure 1489 1501	hospitalized
112,T73,Condition 1509 1518	infection
113,R28,AND Arg1:T72 Arg2:T73
114,T74,Drug 1545 1559	IV antibiotics
115,T75,Condition 1567 1576	infection
116,T76,Temporal 1577 1610	within 2 months prior to Baseline
117,R29,Has_temporal Arg1:T74 Arg2:T76
118,R30,AND Arg1:T74 Arg2:T75
119,*,OR T72 T74 T71
120,T77,Qualifier 1653 1662	recurrent
121,T78,Qualifier 1642 1649	chronic
122,T79,Temporal 1633 1640	ongoing
123,T80,Observation 1618 1625	history
124,*,OR T77 T78
125,*,OR T79 T80
126,T81,"Scope 1618 1640	history of, or ongoing"
127,T82,Scope 1642 1662	chronic or recurrent
128,T83,Condition 1663 1681	infectious disease
129,R31,Has_scope Arg1:T83 Arg2:T82
130,R32,Has_scope Arg1:T83 Arg2:T81
131,T84,Condition 1712 1746	human immunodeficiency virus (HIV)
132,T85,Condition 1750 1790	seropositive for hepatitis C virus (HCV)
133,*,OR T84 T85
134,T86,Procedure 1802 1813	chest x-ray
135,T87,Temporal 1814 1848	within 2 months prior to Screening
136,T88,Condition 1863 1874	abnormality
137,T89,Mood 1875 1885	suggestive
138,T90,Temporal 1891 1898	current
139,T91,Qualifier 1899 1905	active
140,T92,Condition 1906 1915	infection
141,T93,Condition 1919 1929	malignancy
142,*,OR T92 T93
143,T94,Scope 1906 1929	infection or malignancy
144,R33,Has_qualifier Arg1:T94 Arg2:T91
145,R34,Has_temporal Arg1:T94 Arg2:T90
146,R35,Has_mood Arg1:T94 Arg2:T89
147,R36,Has_scope Arg1:T88 Arg2:T94
148,R37,Has_temporal Arg1:T86 Arg2:T87
149,R38,AND Arg1:T86 Arg2:T88
150,T95,Condition 1948 1975	lymphoproliferative disease
151,T96,Condition 1987 1997	malignancy
152,T97,Temporal 1998 2029	within 5 years before screening
153,R39,Has_temporal Arg1:T96 Arg2:T97
154,T98,Reference_point 2020 2029	screening
155,R40,Has_index Arg1:T97 Arg2:T98
156,T99,Reference_point 1839 1848	Screening
157,R41,Has_index Arg1:T87 Arg2:T99
158,T100,Condition 2046 2054;2070 2092	squamous carcinomas of the skin
159,T101,Condition 2059 2092	basal cell carcinomas of the skin
160,*,OR T100 T101 T102
161,T102,Condition 2097 2114	carcinoma in situ
162,T103,Qualifier 2118 2124	cervix
163,R42,Has_qualifier Arg1:T102 Arg2:T103
164,T104,Qualifier 2139 2155	surgically cured
165,T105,Procedure 2139 2149	surgically
166,R43,multi Arg1:T104 Arg2:T105
167,R44,Has_qualifier Arg1:T102 Arg2:T104
168,T106,Negation 2031 2041	exceptions
169,T107,Scope 2046 2155	squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured
170,R45,Has_negation Arg1:T107 Arg2:T106
171,R46,Has_scope Arg1:T96 Arg2:T107
172,T108,Condition 2181 2203	demyelinating diseases
173,T109,Observation 2164 2171	history
174,R47,Has_temporal Arg1:T108 Arg2:T109
175,T110,Condition 2212 2230	multiple sclerosis
176,T111,Condition 2234 2248	optic neuritis
177,*,OR T110 T111
178,T112,Scope 2212 2248	multiple sclerosis or optic neuritis
179,R48,Subsumes Arg1:T108 Arg2:T112
180,T113,Condition 2281 2305	congestive heart failure
181,T114,Temporal 2270 2280	concurrent
182,T115,Observation 2256 2263	history
183,*,OR T114 T115
184,T116,Scope 2256 2280	history of or concurrent
185,R49,Has_scope Arg1:T113 Arg2:T116
186,T117,Procedure 2326 2344	transplanted organ
187,T118,Procedure 2370 2388	corneal transplant
188,T119,Temporal 2399 2428	>= 3 months prior to baseline
189,R50,Has_temporal Arg1:T118 Arg2:T119
190,T120,Negation 2355 2367	exception of
191,R51,Has_negation Arg1:T118 Arg2:T120
192,R52,AND Arg1:T117 Arg2:T118
193,T121,Condition 2476 2491	medical illness
194,T122,Qualifier 2464 2475	significant
195,R53,Has_qualifier Arg1:T121 Arg2:T122
196,T123,Observation 2504 2528	interfere with the trial
197,T124,Mood 2533 2540	require
198,T125,Procedure 2541 2550	treatment
199,T126,Observation 2562 2586	interfere with the trial
200,R54,Has_mood Arg1:T125 Arg2:T124
201,R55,Has_context Arg1:T125 Arg2:T126
202,*,OR T123 T125
203,T127,"Scope 2504 2586	interfere with the trial, or require treatment that might interfere with the trial"
204,R56,Has_scope Arg1:T121 Arg2:T127
205,T128,Intoxication_considerations 2588 2716	Is a user of recreational or illicit drugs or has or had a substance abuse (drug or alcohol) problem within the previous 2 years
0,T1,Qualifier 14 22	acquired
1,T2,Qualifier 0 10	congenital
2,T3,Condition 23 40	bleeding tendency
3,*,OR T1 T2
4,T4,Scope 0 22	congenital or acquired
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Measurement 42 56	platelet count
7,T6,"Value 57 68	<50,000/ µL"
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 70 86	hypersensitivity
10,T8,Qualifier 90 97	shrimps
11,T9,Qualifier 99 107	lobsters
12,T10,Qualifier 111 118	beetles
13,*,OR T9 T10 T8
14,T11,"Scope 90 118	shrimps, lobsters or beetles"
15,R3,Has_scope Arg1:T7 Arg2:T11
0,T1,Negation 0 2	no
1,T2,Measurement 23 38	gestational age
2,R1,Has_negation Arg1:T2 Arg2:T1
3,T3,Condition 40 58	ruptured membranes
4,T4,Condition 60 96	painful regular uterine contractions
5,T5,Qualifier 98 103	major
6,T6,Condition 104 123	fetal abnormalities
7,R2,Has_qualifier Arg1:T6 Arg2:T5
0,T1,Person 0 5	Males
1,T2,"Pregnancy_considerations 9 34	non-pregnant, non-nursing"
2,T3,Person 35 42	females
3,*,OR T1 T3
4,T4,Person 55 59	ages
5,T5,Value 63 73	2-65 years
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 75 79	LTBI
8,T7,Measurement 136 156	Tuberculin Skin Test
9,T8,Measurement 158 161	TST
10,T9,Measurement 170 200	Interferon Gamma Release Assay
11,T10,Measurement 202 206	IGRA
12,R2,Subsumes Arg1:T7 Arg2:T8
13,R3,Subsumes Arg1:T9 Arg2:T10
14,*,OR T7 T9
15,T11,Scope 136 207	Tuberculin Skin Test (TST) or the Interferon Gamma Release Assay (IGRA)
16,R4,AND Arg1:T11 Arg2:T6
17,T12,Person 209 217	Children
18,T13,Person 222 227	years
19,T14,Value 218 221	2-5
20,R5,Has_value Arg1:T13 Arg2:T14
21,T15,Measurement 242 246	TSTs
22,T16,Value 233 241	negative
23,R6,Has_value Arg1:T15 Arg2:T16
24,T17,Non-query-able 247 319	who have been in close contact with a case of active TB disease recently
25,T18,Informed_consent 321 414	Able and willing to provide fully informed consent or parent/guardian able to provide consent
0,T1,Person 0 10	Adolescent
1,T2,Value 12 23	10-21 years
2,T3,Person 18 23	years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Scope 12 23	10-21 years
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Procedure 36 49	spinal fusion
7,T6,Condition 54 74	idiopathic scoliosis
8,T7,Condition 76 93	spondylolisthesis
9,T8,Condition 97 117	Scheuermann kyphosis
10,*,OR T6 T7 T8
11,T9,"Scope 54 117	idiopathic scoliosis, spondylolisthesis or Scheuermann kyphosis"
12,R3,Has_scope Arg1:T5 Arg2:T9
13,T10,Procedure 120 143	Posterior spinal fusion
14,T11,Condition 148 164	contraindication
15,T12,Negation 145 147	No
16,T13,Drug 169 179	Pregabalin
17,R4,AND Arg1:T11 Arg2:T13
18,R5,Has_negation Arg1:T11 Arg2:T12
19,T14,Measurement 185 188	ASA
20,T15,Value 189 194	I-III
21,R6,Has_value Arg1:T14 Arg2:T15
22,T16,Informed_consent 196 220	Written informed consent
0,T1,Condition 0 9	Infection
1,T2,Qualifier 15 36	Plasmodium falciparum
2,T3,Qualifier 40 48	P. vivax
3,*,OR T2 T3
4,T4,Scope 15 48	Plasmodium falciparum or P. vivax
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Person 72 75	Age
7,T6,Value 76 86	>12 months
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Person 88 94	Weight
10,T8,Value 95 99	>5kg
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Non-query-able 101 129	Living in the study clusters
0,T1,Person 0 3	age
1,T2,Value 3 12	=65 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 29 49	mantle cell lymphoma
4,T4,Measurement 51 66	Ann Arbor stage
5,T5,Value 67 69	II
6,T6,Value 70 73	III
7,T7,Value 77 79	IV
8,*,OR T5 T6 T7
9,T8,"Scope 67 79	II,III or IV"
10,R2,Has_scope Arg1:T4 Arg2:T8
11,T9,Measurement 81 85	ECOG
12,T10,Value 85 87	=1
13,R3,Has_value Arg1:T9 Arg2:T10
14,T11,Measurement 94 98	ECOG
15,T12,Value 98 100	=2
16,T14,Temporal 113 131	after pretreatment
17,T15,Reference_point 119 131	pretreatment
18,R4,Has_index Arg1:T14 Arg2:T15
19,R5,Has_value Arg1:T11 Arg2:T12
20,T16,Condition 105 112	recover
21,R7,AND Arg1:T11 Arg2:T16
22,*,OR T9 T11
23,R6,Has_temporal Arg1:T16 Arg2:T14
24,T13,Procedure 119 131	pretreatment
25,R8,multi Arg1:T15 Arg2:T13
0,T1,Measurement 111 117;25 100	status American Society of Anesthesiologists Physical Status Classification System
1,T2,Value 104 110	1 or 2
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Mood 119 126	planned
4,T4,Procedure 127 138	eye surgery
5,T5,Qualifier 139 153	under sedation
6,T6,Procedure 145 153	sedation
7,R2,multi Arg1:T5 Arg2:T6
8,R3,Has_mood Arg1:T4 Arg2:T3
9,R4,Has_qualifier Arg1:T4 Arg2:T5
0,T1,Condition 43 50	malaria
1,T2,Qualifier 36 42	severe
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 52 59	Anaemia
4,T4,Measurement 72 74	Hb
5,T5,Value 75 81	<9g/dl
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,AND Arg1:T3 Arg2:T4
8,T6,Condition 83 98	G6PD deficiency
9,T7,Pregnancy_considerations 123 181	Pregnant women as determined by Urine ß-HCG pregnancy test
10,T8,Condition 189 205	hypersensitivity
11,T9,Drug 220 225	drugs
12,R4,AND Arg1:T8 Arg2:T9
0,T1,Condition 5 37	centre neural system involvement
1,T2,Condition 82 90	diabetes
2,T3,Qualifier 69 81	uncontrolled
3,T4,Condition 47 60	complications
4,T5,Qualifier 39 46	serious
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,T6,Condition 92 105	gastric ulcer
7,T7,Condition 123 139	angiocardiopathy
8,T8,Qualifier 115 122	serious
9,T9,Subjective_judgement 140 167	determined by the physician
10,R2,Has_qualifier Arg1:T7 Arg2:T8
11,R3,Has_qualifier Arg1:T2 Arg2:T3
12,*,OR T2 T6 T7
13,T10,"Scope 69 139	uncontrolled diabetes, gastric ulcer or other serious angiocardiopathy"
14,R4,Subsumes Arg1:T4 Arg2:T10
15,T11,Condition 169 181	HIV positive
16,T12,Condition 185 205	active HBV infection
17,T13,Condition 228 248	systematic infection
18,T14,Qualifier 215 227	uncontrolled
19,R5,Has_qualifier Arg1:T13 Arg2:T14
20,*,OR T11 T12 T13
21,T15,Condition 259 286	central nervous dysfunction
22,T16,Procedure 296 303	surgery
23,T17,Qualifier 288 295	serious
24,R6,Has_qualifier Arg1:T16 Arg2:T17
25,T18,Temporal 304 318	within 30 days
26,R7,Has_temporal Arg1:T16 Arg2:T18
27,T19,Observation 320 329	pregnancy
28,T20,Observation 333 352	baby nursing period
29,T21,Negation 356 359	un-
30,T22,Procedure 359 371	contracepted
31,R8,Has_negation Arg1:T22 Arg2:T21
32,T23,Observation 372 392	child bearing period
33,T24,Person 393 398	woman
34,R9,AND Arg1:T23 Arg2:T22
35,*,OR T19 T20 T23
0,T1,Informed_consent 0 17	patient's refusal
1,T2,Condition 19 36	contraindications
2,T3,Drug 40 55	dexmedetomidine
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 57 65	diseases
5,T5,Drug 66 71	drugs
6,T6,Qualifier 77 123	influence on autonomic nervous system activity
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,R3,Has_qualifier Arg1:T4 Arg2:T6
9,*,OR T4 T5
0,T1,Drug 50 74	Systemic corticosteroids
1,T2,Temporal 96 123	within 7 days of first dose
2,T3,Drug 127 131	852A
3,T4,Drug 133 140;152 160	topical steroids
4,T5,Drug 144 160	inhaled steroids
5,*,OR T4 T5
6,R1,Has_temporal Arg1:T1 Arg2:T2
7,R2,AND Arg1:T2 Arg2:T3
8,T6,Scope 133 172	topical or inhaled steroids are allowed
9,T7,Drug 175 203	Investigational drugs/agents
10,T8,Temporal 204 232	within 14 days of first dose
11,T9,Drug 236 240	852A
12,R4,AND Arg1:T8 Arg2:T9
13,R5,Has_temporal Arg1:T7 Arg2:T8
14,T10,Procedure 242 267	Immunosuppressive therapy
15,T11,Drug 279 295	cytotoxic agents
16,R6,Subsumes Arg1:T10 Arg2:T11
17,T12,Temporal 296 324	within 14 days of first dose
18,T13,Drug 328 332	852A
19,R7,AND Arg1:T12 Arg2:T13
20,R8,Has_temporal Arg1:T10 Arg2:T12
21,T14,Drug 334 346	nitrosoureas
22,T15,Temporal 347 375	within 30 days of first dose
23,R9,Has_temporal Arg1:T14 Arg2:T15
24,*,OR T10 T14
25,T16,Drug 378 424	Drugs known to induce QT interval prolongation
26,T17,Drug 378 392;432 458	Drugs known to induce Torsades de pointes
27,T19,Scope 378 458	Drugs known to induce QT interval prolongation and/or induce Torsades de pointes
28,T20,Procedure 533 545	Radiotherapy
29,T21,Temporal 546 578	within 3 weeks of the first dose
30,T22,Drug 582 586	852A
31,R11,AND Arg1:T21 Arg2:T22
32,R12,Has_temporal Arg1:T20 Arg2:T21
33,T23,Procedure 588 622	Hematopoietic cell transplantation
34,T24,Temporal 623 651	within 4 weeks of first dose
35,T25,Drug 655 659	852A
36,R13,AND Arg1:T24 Arg2:T25
37,R14,Has_temporal Arg1:T23 Arg2:T24
38,T26,Condition 673 689	active infection
39,T27,Observation 661 669	Evidence
40,R15,AND Arg1:T27 Arg2:T26
41,T28,Temporal 690 717	within 3 days of first dose
42,T29,Drug 721 725	852A
43,R16,AND Arg1:T28 Arg2:T29
44,R17,Has_temporal Arg1:T27 Arg2:T28
45,T30,Condition 734 750	fungal infection
46,T31,Condition 754 775	pulmonary infiltrates
47,*,OR T30 T31
48,T32,Condition 777 798	prior treated disease
49,T33,Qualifier 799 805	stable
50,R18,Has_qualifier Arg1:T32 Arg2:T33
51,T34,Temporal 806 817	for 2 weeks
52,R19,Has_temporal Arg1:T33 Arg2:T34
53,T35,Scope 734 775	fungal infection or pulmonary infiltrates
54,T36,Condition 833 849	Cardiac ischemia
55,T37,Condition 851 870	cardiac arrhythmias
56,T38,Condition 874 898	congestive heart failure
57,*,OR T37 T36 T38
58,T39,Qualifier 899 925	uncontrolled by medication
59,R21,Has_qualifier Arg1:T38 Arg2:T39
60,T40,Observation 927 934	History
61,T41,Observation 942 959	clinical evidence
62,T42,Condition 1019 1091;964 981	could confound the results of the study or put the subject at undue risk a condition which
63,*,OR T40 T41
64,T43,"Scope 927 962	History of, or clinical evidence of"
65,R22,AND Arg1:T43 Arg2:T42
66,T44,Condition 1106 1118;1130 1137	intercurrent illness
67,T45,Condition 1122 1137	chronic illness
68,*,OR T44 T45
69,T46,Qualifier 1093 1105	Uncontrolled
70,T47,Condition 1146 1164	autoimmune disease
71,T48,Qualifier 1165 1174	requiring
72,T49,Procedure 1175 1200	immunosuppressive therapy
73,T50,Temporal 1201 1215	within 30 days
74,R23,AND Arg1:T48 Arg2:T49
75,R24,Has_temporal Arg1:T48 Arg2:T50
76,*,OR T47 T48
77,T51,Condition 1224 1244	coagulation disorder
78,T52,Temporal 1139 1145	Active
79,R25,Has_temporal Arg1:T47 Arg2:T52
80,T53,Temporal 1217 1223	Active
81,R26,Has_temporal Arg1:T51 Arg2:T53
82,T54,Qualifier 1249 1275	controlled with medication
83,T55,Negation 1245 1248	not
84,R27,Has_negation Arg1:T54 Arg2:T55
85,R28,Has_qualifier Arg1:T51 Arg2:T54
86,T56,Condition 1277 1285	Pregnant
87,T57,Condition 1289 1298	lactating
88,*,OR T56 T57
89,T58,Condition 1311 1321	malignancy
90,T59,Temporal 1300 1310	Concurrent
91,R29,Has_temporal Arg1:T58 Arg2:T59
92,T60,Value 1340 1356	at least 5 years
93,T61,Qualifier 1357 1369	disease free
94,R30,Has_value Arg1:T61 Arg2:T60
95,T62,Qualifier 1326 1338	in remission
96,A1,Optional T62
97,R31,Has_qualifier Arg1:T62 Arg2:T61
98,R32,Has_qualifier Arg1:T58 Arg2:T62
99,T63,Condition 1382 1409	localized (in-situ) disease
100,T64,Condition 1411 1427	basal carcinomas
101,T65,Condition 1432 1466	cutaneous squamous cell carcinomas
102,T66,Qualifier 1482 1500	adequately treated
103,*,OR T63 T64 T65
104,T67,"Scope 1382 1466	localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas"
105,R33,Has_qualifier Arg1:T67 Arg2:T66
106,T68,Condition 1517 1533	brain metastases
107,T69,Observation 1506 1516	history of
108,T70,Condition 1537 1546;1554 1590	any other central nervous system (CNS) disease
109,T71,Temporal 1547 1553	active
110,R35,Has_temporal Arg1:T70 Arg2:T71
111,*,OR T68 T70
112,T72,Scope 1517 1590	brain metastases or any other active central nervous system (CNS) disease
113,R36,Has_scope Arg1:T69 Arg2:T72
114,T73,Negation 818 830	is allowable
115,R20,Has_negation Arg1:T32 Arg2:T73
116,T74,Scope 777 830	prior treated disease stable for 2 weeks is allowable
117,R37,Has_scope Arg1:T35 Arg2:T74
118,T75,Negation 1371 1381	except for
119,T76,"Scope 1382 1500	localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated"
120,R34,Has_negation Arg1:T76 Arg2:T75
121,R38,Has_scope Arg1:T58 Arg2:T76
122,T77,Negation 161 172	are allowed
123,T78,Scope 133 160	topical or inhaled steroids
124,R3,Has_negation Arg1:T78 Arg2:T77
125,R39,Has_scope Arg1:T1 Arg2:T6
126,T18,Non-representable 459 531	unless best available drug required to treat life-threatening conditions
127,T83,Qualifier 84 94	injectable
128,T84,Qualifier 76 80	oral
129,*,OR T83 T84
130,T85,Scope 76 94	oral or injectable
131,R40,Has_scope Arg1:T1 Arg2:T85
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 26 28	2.
2,T3,Parsing_Error 310 312	3.
3,T4,Parsing_Error 545 547	1.
4,T5,Parsing_Error 578 580	2.
5,T6,Parsing_Error 610 612	3.
6,T7,Parsing_Error 666 668	4.
7,T8,Parsing_Error 722 724	4.
8,T9,Parsing_Error 860 862	5.
9,T10,Parsing_Error 1156 1158	6.
10,T11,Value 7 24	18 years or older
11,T12,Person 3 6	Age
12,R1,Has_value Arg1:T12 Arg2:T11
13,T13,Condition 42 61	venous leg ulcer(s)
14,T14,Measurement 122 140	venous reflux test
15,T15,Value 113 121	positive
16,R2,Has_value Arg1:T14 Arg2:T15
17,T16,Measurement 142 158	venous refilling
18,T17,Value 159 170	<20 seconds
19,R3,Has_value Arg1:T16 Arg2:T17
20,R4,Subsumes Arg1:T15 Arg2:T16
21,T18,Procedure 178 196	Doppler ultrasound
22,T19,Temporal 201 240	at least 4 weeks prior to screening day
23,T20,Reference_point 227 240	screening day
24,R5,Has_index Arg1:T19 Arg2:T20
25,R6,Has_temporal Arg1:T18 Arg2:T19
26,T21,Observation 268 277	responded
27,T22,Negation 253 256	not
28,R7,Has_negation Arg1:T21 Arg2:T22
29,T23,Qualifier 257 267	adequately
30,R8,Has_qualifier Arg1:T21 Arg2:T23
31,T24,Procedure 281 307	conventional ulcer therapy
32,R9,Has_context Arg1:T24 Arg2:T21
33,R10,AND Arg1:T13 Arg2:T14
34,R11,AND Arg1:T14 Arg2:T18
35,T25,Condition 324 340	venous leg ulcer
36,T26,Parsing_Error 313 412	Designated venous leg ulcer meets the following criteria at both the screening and baseline visits.
37,T27,Condition 441 447	ulcers
38,T28,Multiplier 432 440	multiple
39,R12,Has_multiplier Arg1:T27 Arg2:T28
40,T29,Multiplier 449 461	at least one
41,T30,Condition 462 467	ulcer
42,R13,Has_multiplier Arg1:T30 Arg2:T29
43,T31,"Parsing_Error 413 543	If the patient has multiple ulcers, at least one ulcer must meet the following criteria at both the screening and baseline visits:"
44,T32,Temporal 560 576	at least 4 weeks
45,T33,Qualifier 548 555	Present
46,R14,Has_temporal Arg1:T33 Arg2:T32
47,T34,Measurement 581 600	CEAP Classification
48,T35,Value 601 608	Stage 6
49,R15,Has_value Arg1:T34 Arg2:T35
50,T36,Condition 613 626	Surface ulcer
51,T37,Value 640 647	> 15cm2
52,T38,Measurement 635 639;648 664	area post debridement
53,R16,AND Arg1:T36 Arg2:T38
54,R17,Has_value Arg1:T38 Arg2:T37
55,T39,Qualifier 669 675	Viable
56,T40,Qualifier 677 688	granulating
57,T41,Condition 689 694	wound
58,R18,Has_qualifier Arg1:T41 Arg2:T40
59,R19,Has_qualifier Arg1:T41 Arg2:T39
60,T42,Subjective_judgement 696 719	investigator discretion
61,R20,AND Arg1:T41 Arg2:T42
62,T43,Condition 725 731	Ulcers
63,T44,Qualifier 737 765	extend through the epidermis
64,T45,Qualifier 737 743;774 792	extend through the muscle
65,T46,Negation 770 773	not
66,R21,Has_negation Arg1:T45 Arg2:T46
67,T47,Value 811 826	Stage II or III
68,T48,Measurement 852 856	IAET
69,T49,Condition 827 833	ulcers
70,R22,AND Arg1:T49 Arg2:T48
71,R23,Has_value Arg1:T48 Arg2:T47
72,T50,Qualifier 737 743;774 785;794 800	extend through the tendon
73,R24,Has_negation Arg1:T50 Arg2:T46
74,T51,Qualifier 737 743;774 785;805 809	extend through the bone
75,R25,Has_negation Arg1:T51 Arg2:T46
76,*,OR T51 T50 T44 T45
77,T52,"Scope 725 809	Ulcers that extend through the epidermis but not through the muscle, tendon, or bone"
78,R26,Subsumes Arg1:T52 Arg2:T49
79,T53,"Scope 737 809	extend through the epidermis but not through the muscle, tendon, or bone"
80,R27,Has_scope Arg1:T43 Arg2:T53
81,T54,Condition 882 904	childbearing potential
82,T55,Measurement 926 940	pregnancy test
83,T56,Value 917 925	negative
84,R28,Has_value Arg1:T55 Arg2:T56
85,T57,Temporal 941 953	at screening
86,T58,Reference_point 944 953	screening
87,R29,Has_index Arg1:T57 Arg2:T58
88,R30,Has_temporal Arg1:T55 Arg2:T57
89,T59,Drug 976 998	hormonal contraceptive
90,T60,Device 1000 1019	intrauterine device
91,T61,Device 1021 1046	diaphragm with spermicide
92,T62,Device 1048 1070	condom with spermicide
93,T63,Observation 1075 1085	abstinence
94,T64,Temporal 1086 1154	throughout until 2 weeks after the last administration of study drug
95,T65,Reference_point 1121 1154	last administration of study drug
96,R31,Has_index Arg1:T64 Arg2:T65
97,T66,Person 863 869	Female
98,T67,Scope 863 904	Female patients of childbearing potential
99,A1,Optional T67
100,T68,"Scope 917 1085	negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence"
101,*,OR T59 T60 T61 T62 T55 T63
102,R32,Has_temporal Arg1:T68 Arg2:T64
103,R33,Has_scope Arg1:T67 Arg2:T68
104,T69,Post-eligibility 1159 1182	Signed informed consent
105,T70,Non-query-able 1159 1182	Signed informed consent
0,T1,Qualifier 9 21	Laparoscopic
1,T2,Procedure 22 32	myomectomy
2,T3,Qualifier 0 8	elective
3,R1,Has_qualifier Arg1:T2 Arg2:T1
4,R2,Has_qualifier Arg1:T2 Arg2:T3
5,T4,Line 0 41	elective Laparoscopic myomectomy patients
6,T5,Line 42 61	24hr post-operative
7,T6,Line 62 100	patient controlled analgesia analgesia
8,T7,Line 101 145	no mild or severe liver or renal disfunction
9,T8,Temporal 42 61	24hr post-operative
10,T9,Procedure 62 90	patient controlled analgesia
11,T10,Non-representable 91 100	analgesia
12,T11,Negation 101 103	no
13,T12,Qualifier 104 108	mild
14,T13,Qualifier 112 118	severe
15,T14,Condition 128 145	renal disfunction
16,T15,Condition 119 124;134 145	liver disfunction
17,*,OR T15 T14
18,*,OR T12 T13
19,T16,Scope 119 145	liver or renal disfunction
20,T17,Scope 104 118	mild or severe
21,R3,Has_scope Arg1:T16 Arg2:T17
22,R4,Has_negation Arg1:T16 Arg2:T11
0,T1,Procedure 8 11	DVT
1,T2,Temporal 0 7	Current
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 23 37	varicose veins
4,T4,Multiplier 13 22	Recurrent
5,R2,Has_multiplier Arg1:T3 Arg2:T4
6,T5,Condition 39 55	Arterial disease
7,T6,Measurement 57 61	ABPI
8,T7,Value 61 65	<0.8
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Scope 57 65	ABPI<0.8
11,R4,Subsumes Arg1:T5 Arg2:T8
12,T9,Measurement 68 81	Vein diameter
13,T10,Value 82 87	< 3mm
14,R5,Has_value Arg1:T9 Arg2:T10
15,T11,Non-representable 89 132	Preference for one of the treatment options
16,T12,Observation 150 174	unwilling to participate
17,T13,Observation 189 229	unwillingness to complete questionnaires
18,T14,Observation 176 185;203 229	Inability to complete questionnaires
19,*,OR T13 T14
20,T15,Observation 231 273	Inability to attend follow-up appointments
21,T16,Competing_trial 275 339	Patient currently included in a study of varicose vein treatment
0,T1,Non-query-able 0 65	Nonfluency or inability to communicate in English spoken language
1,T2,Non-query-able 67 142	Inability to participate or attend biweekly 30 minute session over 14 weeks
2,T3,Condition 150 159	psychosis
3,T4,Qualifier 144 149	Frank
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Condition 168 183	self harm urges
6,T6,Temporal 161 167	Active
7,*,OR T5 T6
8,T7,Condition 193 208	medical illness
9,T8,Qualifier 185 192	Serious
10,T9,Undefined_semantics 193 208	medical illness
11,T10,Subjective_judgement 185 192	Serious
12,T11,Undefined_semantics 185 192	Serious
13,R2,Has_qualifier Arg1:T7 Arg2:T8
14,T12,Condition 217 226;238 255	substance use or dependence
15,T13,Condition 230 255	alcohol use or dependence
16,*,OR T12 T13
17,T14,Subjective_judgement 256 295	that could interfere with participation
18,T15,Non-query-able 256 295	that could interfere with participation
19,R3,AND Arg1:T12 Arg2:T15
20,R4,AND Arg1:T13 Arg2:T15
21,T16,Condition 310 328	mental retardation
22,T17,Condition 330 338	dementia
23,T18,Condition 342 350	delirium
24,*,OR T18 T17 T16
25,T19,Condition 352 360	Pregnant
26,T20,Person 361 366	women
27,A1,Optional T20
28,R5,AND Arg1:T20 Arg2:T19
0,T1,Condition 14 30	renal impairment
1,T2,Measurement 32 48	serum creatinine
2,T3,Value 49 90	more than twice the upper limit of normal
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Condition 108 121	heart failure
6,T5,Condition 138 144	sepsis
7,T6,Condition 148 164	active infection
8,*,OR T5 T6
9,T7,Condition 181 198	diabetes mellitus
10,T8,Qualifier 207 214	primary
11,T9,Qualifier 218 242	secondary to thalassemia
12,*,OR T8 T9
13,T10,Scope 207 242	primary or secondary to thalassemia
14,R3,Has_scope Arg1:T7 Arg2:T10
15,T11,Condition 295 309	hepatotoxicity
16,T12,Drug 269 279	medication
17,R4,AND Arg1:T11 Arg2:T12
18,T13,Drug 339 366	antioxidant supplementation
19,T14,Procedure 320 335	herbal medicine
20,*,OR T13 T14
21,T15,Non-query-able 369 452	patients with gastrointestinal conditions preventing adsorption of oral medication.
0,T1,Condition 10 29	pulmonary contusion
1,T2,Condition 33 43	laceration
2,*,OR T1 T2
3,T3,Qualifier 0 9	Traumatic
4,T4,Scope 10 43	pulmonary contusion or laceration
5,R1,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Procedure 45 67	Lung reduction surgery
7,T6,Multiplier 88 100	more than 10
8,T7,Condition 101 113	lung lesions
9,T8,Mood 69 76	Planned
10,T9,Procedure 77 84	removal
11,R2,Has_multiplier Arg1:T7 Arg2:T6
12,T10,Procedure 115 128	Pneumonectomy
13,T11,Condition 136 152	hypersensitivity
14,T12,Drug 156 170	bovine protein
15,R3,AND Arg1:T11 Arg2:T12
16,T13,Condition 178 194	hypersensitivity
17,T14,Drug 198 224	Brilliant Blue FCF (E133)
18,R4,AND Arg1:T13 Arg2:T14
19,T15,Drug 198 223	Brilliant Blue FCF (E133)
20,R5,AND Arg1:T13 Arg2:T15
21,T16,Condition 237 253	active infection
0,T1,Observation 0 10	MDD Cohort
1,T2,Qualifier 17 31	DSM-5 criteria
2,T3,Condition 36 61	Major Depressive Disorder
3,T4,Procedure 65 85	structured interview
4,T5,Procedure 87 95	MINI-KID
5,R2,Has_qualifier Arg1:T3 Arg2:T2
6,R3,AND Arg1:T3 Arg2:T4
7,T6,Measurement 98 110	CDRS-R score
8,T7,Value 111 114	>40
9,R4,Has_value Arg1:T6 Arg2:T7
10,T8,Negation 116 123	Failure
11,T9,Condition 135 144	remission
12,T10,Multiplier 150 160	at least 1
13,T11,Qualifier 161 169	adequate
14,T12,Procedure 176 196	antidepressant trial
15,T13,Drug 203 207	SSRI
16,T14,Temporal 170 175	prior
17,T15,Drug 209 213	SNRI
18,T16,Drug 218 221	TCA
19,*,OR T16 T15 T13
20,T17,"Scope 203 221	SSRI, SNRI, or TCA"
21,R5,Has_temporal Arg1:T12 Arg2:T14
22,R6,Has_qualifier Arg1:T12 Arg2:T11
23,R7,Subsumes Arg1:T12 Arg2:T17
24,R8,Has_multiplier Arg1:T12 Arg2:T10
25,R9,Has_negation Arg1:T9 Arg2:T8
26,T18,Multiplier 232 248	at least 8 weeks
27,T19,Procedure 252 270	therapeutic dosing
28,R11,Has_multiplier Arg1:T19 Arg2:T18
29,T20,Multiplier 282 298	at least 4 weeks
30,T21,Procedure 302 315	stable dosing
31,R10,Has_multiplier Arg1:T21 Arg2:T20
32,T22,"Scope 232 315	at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing"
33,T23,"Scope 150 222	at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA)"
34,R12,Has_scope Arg1:T23 Arg2:T22
35,R13,Has_scope Arg1:T9 Arg2:T23
36,T24,Observation 318 332	Anxiety Cohort
37,T25,Qualifier 339 353	DSM-5 criteria
38,T26,Condition 379 396	anxiety disorders
39,T27,Condition 398 422	Social Anxiety Disorders
40,T28,Condition 424 452	Generalized Anxiety Disorder
41,T29,Condition 454 481	Separation Anxiety Disorder
42,T30,Condition 489 503	Panic Disorder
43,T31,Procedure 507 527	structured interview
44,R1,Subsumes Arg1:T4 Arg2:T5
45,T32,Procedure 529 537	MINI-KID
46,R14,Subsumes Arg1:T31 Arg2:T32
47,*,OR T28 T29 T30 T27
48,T33,"Scope 398 503	Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder"
49,R15,AND Arg1:T33 Arg2:T31
50,R16,Subsumes Arg1:T26 Arg2:T33
51,T34,Measurement 540 569	ADIS Clinical Severity Rating
52,T35,Value 570 572	≥4
53,T36,Qualifier 574 591	moderately severe
54,R17,Has_value Arg1:T34 Arg2:T35
55,T37,Scope 540 572	ADIS Clinical Severity Rating ≥4
56,R18,Subsumes Arg1:T37 Arg2:T36
57,T38,Condition 619 636	anxiety disorders
58,T39,Condition 657 666	remission
59,T40,Negation 638 645	Failure
60,T41,Multiplier 672 682	at least 1
61,T42,Qualifier 683 691	adequate
62,T43,Temporal 692 697	prior
63,T44,Procedure 698 725	anxiolytic medication trial
64,T45,Drug 698 719	anxiolytic medication
65,R19,multi Arg1:T44 Arg2:T45
66,T46,Drug 176 190	antidepressant
67,R20,multi Arg1:T12 Arg2:T46
68,T47,Drug 732 736	SSRI
69,T48,Drug 738 742	SNRI
70,T49,Drug 747 750	TCA
71,*,OR T48 T49 T47
72,T50,"Scope 732 750	SSRI, SNRI, or TCA"
73,R21,Has_temporal Arg1:T44 Arg2:T43
74,R22,Subsumes Arg1:T44 Arg2:T50
75,R23,Has_qualifier Arg1:T44 Arg2:T42
76,R24,Has_multiplier Arg1:T44 Arg2:T41
77,R25,Has_negation Arg1:T39 Arg2:T40
78,T51,Multiplier 761 777	at least 8 weeks
79,T52,Procedure 781 799	therapeutic dosing
80,T53,Multiplier 811 827	at least 4 weeks
81,T54,Procedure 831 844	stable dosing
82,R26,Has_multiplier Arg1:T54 Arg2:T53
83,R27,Has_multiplier Arg1:T52 Arg2:T51
84,T55,Temporal 880 888	previous
85,T56,Procedure 889 892;925 932	CBT therapy
86,T57,Observation 896 912	subject declines
87,T58,Temporal 913 920	current
88,T59,Procedure 921 932	CBT therapy
89,R28,Has_temporal Arg1:T56 Arg2:T55
90,T60,Condition 865 874	remission
91,T61,Negation 846 853	Failure
92,R29,Has_negation Arg1:T60 Arg2:T61
93,R30,Has_temporal Arg1:T59 Arg2:T58
94,R31,AND Arg1:T57 Arg2:T59
95,*,OR T56 T57
96,T62,Scope 880 932	previous CBT or subject declines current CBT therapy
97,R32,Has_scope Arg1:T60 Arg2:T62
98,T63,"Scope 761 844	at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing"
99,T64,"Scope 672 751	at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA)"
100,R33,Has_scope Arg1:T64 Arg2:T63
101,R34,Has_scope Arg1:T39 Arg2:T64
102,R35,Has_qualifier Arg1:T26 Arg2:T25
103,R36,Has_scope Arg1:T38 Arg2:T37
104,T65,"Scope 339 932	DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy"
105,R37,Has_scope Arg1:T24 Arg2:T65
106,A1,Optional T24
107,T66,"Scope 12 315	Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID); CDRS-R score >40; Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing"
108,R38,Has_scope Arg1:T1 Arg2:T66
109,A2,Optional T1
110,T67,Qualifier 934 940	Stable
111,T68,Drug 941 964	psychiatric medications
112,T69,Multiplier 934 940;969 974	Stable doses
113,T70,Temporal 975 1008	for the month prior to enrollment
114,T71,Reference_point 998 1008	enrollment
115,R39,Has_index Arg1:T70 Arg2:T71
116,R40,Has_temporal Arg1:T68 Arg2:T70
117,R41,Has_multiplier Arg1:T68 Arg2:T69
118,R42,Has_qualifier Arg1:T68 Arg2:T67
119,T72,Non-representable 1010 1071	Subjects may continue to engage in any ongoing psychotherapy.
120,T73,Condition 1087 1109	neurologically healthy
121,T74,Condition 1073 1082;1102 1109	Medically healthy
122,T75,Procedure 1126 1146	physical examination
123,T76,Observation 1151 1166	medical history
124,T77,Scope 1126 1166	physical examination and medical history
125,T78,Scope 1073 1109	Medically and neurologically healthy
126,R43,Has_scope Arg1:T78 Arg2:T77
127,T79,Person 1169 1176	Parents
128,T80,Observation 1185 1217	provide written informed consent
129,T81,Person 1222 1233	adolescents
130,T82,Observation 1252 1266	provide assent
131,R44,Has_context Arg1:T79 Arg2:T80
132,A3,Optional T81
133,R45,Has_context Arg1:T81 Arg2:T82
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 98 100	2.
2,T3,Parsing_Error 154 156	3.
3,T4,Parsing_Error 257 259	4.
4,T5,Parsing_Error 321 323	5.
5,T6,Parsing_Error 440 442	6.
6,T7,Parsing_Error 503 505	7.
7,T8,Parsing_Error 543 545	8.
8,T9,Parsing_Error 588 590	9.
9,T10,Parsing_Error 792 794	1.
10,T11,Parsing_Error 863 865	2.
11,T12,Parsing_Error 959 961	3.
12,T13,Parsing_Error 1048 1050	4.
13,T14,Parsing_Error 1063 1065	5.
14,T15,Parsing_Error 1088 1090	6.
15,T16,Parsing_Error 1110 1112	7.
16,T17,Parsing_Error 1139 1142	10.
17,T18,Parsing_Error 1261 1264	11.
18,T19,Parsing_Error 1541 1544	12.
19,T20,Parsing_Error 1593 1596	13.
20,T21,Parsing_Error 1688 1691	14.
21,T22,Parsing_Error 1796 1799	15.
22,T23,Parsing_Error 1830 1833	16.
23,T24,Parsing_Error 1936 1939	17.
24,T25,Parsing_Error 2003 2006	18.
25,T26,Parsing_Error 2230 2233	19.
26,T27,Parsing_Error 2307 2310	20.
27,T28,Parsing_Error 2387 2390	21.
28,T29,Condition 38 50	target ulcer
29,T30,Qualifier 3 19	Decrease in size
30,T31,Value 57 62	≥ 30%
31,T32,Temporal 63 96	during the 7-day screening period
32,R1,Has_temporal Arg1:T31 Arg2:T32
33,R2,Has_qualifier Arg1:T29 Arg2:T30
34,R3,Has_value Arg1:T30 Arg2:T31
35,T33,Procedure 132 151	compression therapy
36,T34,Non-query-able 101 131	Cannot tolerate or comply with
37,T35,Post-eligibility 101 131	Cannot tolerate or comply with
38,T36,Condition 225 228	pus
39,T37,Condition 160 165	ulcer
40,T38,Qualifier 172 212	shows signs of severe clinical infection
41,T39,Subjective_judgement 172 212	shows signs of severe clinical infection
42,T40,Condition 187 212	severe clinical infection
43,R4,Has_qualifier Arg1:T37 Arg2:T38
44,R5,Subsumes Arg1:T38 Arg2:T36
45,T41,Condition 263 268	ulcer
46,T42,Qualifier 269 306	positive for β-hemolytic streptococci
47,R6,Has_qualifier Arg1:T41 Arg2:T42
48,T43,Measurement 344 350	slough
49,T44,Value 338 343	> 50%
50,T45,Condition 328 333	ulcer
51,R7,AND Arg1:T45 Arg2:T43
52,R8,Has_value Arg1:T43 Arg2:T44
53,T46,Observation 364 379	necrotic tissue
54,T47,Observation 381 385;406 414	bone exposure
55,T48,Observation 398 414	capsule exposure
56,T49,Observation 387 393;406 414	tendon exposure
57,*,OR T49 T47 T48 T46 T50
58,T50,Observation 418 438	avascular ulcer beds
59,T51,Qualifier 446 460	highly exuding
60,T52,Subjective_judgement 446 460	highly exuding
61,T53,Multiplier 476 481	daily
62,T54,Procedure 482 500	change of dressing
63,R9,Subsumes Arg1:T51 Arg2:T54
64,R10,Has_multiplier Arg1:T54 Arg2:T53
65,T55,Measurement 506 535	Ankle brachial pressure index
66,T56,Value 536 541	<0.65
67,R11,Has_value Arg1:T55 Arg2:T56
68,T57,Condition 567 586	systemic infections
69,T58,Temporal 560 566	active
70,R12,Has_temporal Arg1:T57 Arg2:T58
71,T59,Condition 628 646	medical conditions
72,T60,Qualifier 605 627	clinically significant
73,R13,Has_qualifier Arg1:T59 Arg2:T60
74,T61,Observation 647 680	as determined by the investigator
75,T62,Subjective_judgement 647 680	as determined by the investigator
76,T63,Condition 691 696;741 748	renal disease
77,T64,Condition 734 748	immune disease
78,T65,Condition 698 705;741 748	hepatic disease
79,T66,Condition 707 718;741 748	hematologic disease
80,T67,Condition 720 730;741 748	neurologic disease
81,*,OR T64 T66 T65 T63 T67
82,R14,AND Arg1:T60 Arg2:T62
83,T68,"Scope 691 748	renal, hepatic, hematologic, neurologic or immune disease"
84,R15,Subsumes Arg1:T60 Arg2:T68
85,T69,Parsing_Error 750 790	Examples include but are not limited to:
86,T70,Condition 795 814	Renal insufficiency
87,T71,Measurement 821 834	estimated GFR
88,T72,Value 844 861	< 30 mL/min/1.7m2
89,R16,Has_value Arg1:T71 Arg2:T72
90,R17,AND Arg1:T70 Arg2:T71
91,T73,Measurement 875 893	blood biochemistry
92,T74,Value 905 956	3 times that of the upper limit of the normal range
93,T75,Value 866 874	Abnormal
94,R18,Subsumes Arg1:T75 Arg2:T74
95,R19,Has_value Arg1:T73 Arg2:T75
96,T76,Condition 962 983	Hepatic insufficiency
97,T77,Measurement 995 1010	total bilirubin
98,T78,Value 1011 1020	> 2 mg/dL
99,T79,Measurement 1024 1037	serum albumin
100,T80,Value 1038 1046	< 25 g/L
101,R20,Has_value Arg1:T79 Arg2:T80
102,R21,Has_value Arg1:T77 Arg2:T78
103,*,OR T77 T79
104,T81,Scope 995 1046	total bilirubin > 2 mg/dL or serum albumin < 25 g/L
105,R22,Subsumes Arg1:T76 Arg2:T81
106,T82,Measurement 1051 1056	HbA1c
107,T83,Value 1057 1061	> 9%
108,R23,Has_value Arg1:T82 Arg2:T83
109,T84,Measurement 1066 1076	Hemoglobin
110,T85,Value 1077 1086	< 10 g/dL
111,R24,Has_value Arg1:T84 Arg2:T85
112,T86,Measurement 1091 1101	Hematocrit
113,T87,Value 1102 1108	< 0.30
114,R25,Has_value Arg1:T86 Arg2:T87
115,T88,Measurement 1113 1127	Platelet count
116,T89,"Value 1128 1137	< 100,000"
117,R26,Has_value Arg1:T88 Arg2:T89
118,T90,Condition 1177 1189	local cancer
119,T91,Condition 1165 1173;1183 1189	systemic cancer
120,T92,Temporal 1158 1164	active
121,*,OR T91 T90 T93
122,T93,Condition 1193 1210	tumor of any kind
123,T94,Condition 1234 1258	non-melanoma skin cancer
124,T95,Negation 1212 1233	with the exception of
125,R27,Has_negation Arg1:T94 Arg2:T95
126,T96,Scope 1165 1210	systemic or local cancer or tumor of any kind
127,R28,AND Arg1:T96 Arg2:T94
128,R29,Has_temporal Arg1:T96 Arg2:T92
129,T97,Condition 1286 1306	rheumatoid arthritis
130,T98,Qualifier 1279 1285	severe
131,R30,Has_qualifier Arg1:T97 Arg2:T98
132,T99,Multiplier 1313 1325	more than 20
133,T101,Condition 1339 1354	inflamed joints
134,T102,Temporal 1326 1338	persistently
135,R31,Has_temporal Arg1:T101 Arg2:T102
136,R32,Has_multiplier Arg1:T101 Arg2:T99
137,T100,Measurement 1384 1403	blood albumin level
138,T103,Value 1359 1383	below lower normal limit
139,R33,Has_value Arg1:T100 Arg2:T103
140,T104,Condition 1420 1445	bone and cartilage damage
141,T105,Procedure 1449 1454	x-ray
142,T106,Condition 1459 1500	inflammation in tissues other than joints
143,T107,Condition 1512 1538	collagen vascular diseases
144,T108,"Scope 1313 1500	more than 20 persistently inflamed joints, or below lower normal limit blood albumin level, or evidence of bone and cartilage damage on x-ray, or inflammation in tissues other than joints"
145,R34,Subsumes Arg1:T98 Arg2:T108
146,*,OR T107 T97
147,T109,Condition 1566 1591	connective tissue disease
148,T110,Temporal 1559 1565	active
149,R35,Has_temporal Arg1:T109 Arg2:T110
150,T111,Drug 1612 1636	systemic corticosteroids
151,T112,Value 1638 1648	>15 mg/day
152,R36,Has_value Arg1:T111 Arg2:T112
153,T113,Procedure 1597 1606	Treatment
154,R37,AND Arg1:T113 Arg2:T111
155,T114,Drug 1662 1686	immunosuppressive agents
156,T115,Temporal 1654 1661	current
157,R38,Has_temporal Arg1:T114 Arg2:T115
158,*,OR T113 T114
159,T116,Procedure 1712 1729	radiation therapy
160,T117,Non-query-able 1733 1746	likelihood to
161,T118,Subjective_judgement 1733 1746	likelihood to
162,T119,Temporal 1692 1700	Previous
163,T120,Temporal 1704 1711	current
164,*,OR T120 T119
165,T121,Scope 1692 1711	Previous or current
166,R39,Has_scope Arg1:T116 Arg2:T121
167,T122,Condition 1800 1808	Pregnant
168,T123,Condition 1812 1819	nursing
169,*,OR T123 T122
170,T124,Non-query-able 1834 1934	Known prior inability or unavailability to complete required study visits during study participation
171,T125,Context_Error 1886 1907	required study visits
172,T126,Condition 1952 1968	peripheral edema
173,T127,Qualifier 1940 1951	Significant
174,T128,Subjective_judgement 1940 1951	Significant
175,R40,Has_qualifier Arg1:T126 Arg2:T127
176,T129,Subjective_judgement 1969 2001	as per investigator's discretion
177,T130,Condition 2009 2030	psychiatric condition
178,T131,Condition 2038 2055	suicidal ideation
179,R41,Subsumes Arg1:T130 Arg2:T131
180,T132,Condition 2068 2075;2084 2097	alcohol abuse problem
181,T133,Condition 2079 2097	drug abuse problem
182,*,OR T133 T132 T130
183,T134,Subjective_judgement 2153 2187	in the opinion of the investigator
184,T135,Subjective_judgement 2193 2206	pose a threat
185,T136,Qualifier 2189 2228	may pose a threat to patient compliance
186,T137,"Scope 2009 2097	psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem"
187,R42,Has_qualifier Arg1:T137 Arg2:T136
188,T138,Drug 2243 2273	platelet-derived growth factor
189,T139,Temporal 2274 2305	within 28 days before screening
190,T140,Reference_point 2296 2305	screening
191,R43,Has_index Arg1:T139 Arg2:T140
192,R44,Has_temporal Arg1:T138 Arg2:T139
193,T141,Drug 2322 2342	investigational drug
194,T142,Procedure 2322 2337;2346 2353	investigational therapy
195,*,OR T142 T141
196,T143,Temporal 2354 2385	within 28 days before screening
197,T144,Reference_point 2376 2385	screening
198,R45,Has_index Arg1:T143 Arg2:T144
199,T145,"Subjective_judgement 2391 2513	Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study"
200,T146,"Context_Error 2391 2513	Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study"
201,T147,"Non-query-able 2391 2513	Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study"
0,T1,Measurement 30 54	Breast - Karnofsky score
1,T2,Value 55 59	> 50
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 97 147	Gynecologic Oncology Group (GOG) performance score
4,T4,Value 148 150	≤2
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Person 155 161	female
7,T6,Condition 169 191	childbearing potential
8,T7,Scope 155 191	female and of childbearing potential
9,A1,Optional T7
10,T8,Observation 197 207	willing to
11,T9,Procedure 221 234	contraception
12,T10,Drug 236 244	hormonal
13,T11,Procedure 246 260	barrier method
14,T12,Procedure 262 272	abstinence
15,*,OR T10 T11 T12
16,T13,"Scope 236 272	hormonal, barrier method, abstinence"
17,R3,Subsumes Arg1:T9 Arg2:T13
18,R4,AND Arg1:T8 Arg2:T9
19,R5,Has_context Arg1:T7 Arg2:T8
20,T14,Temporal 299 338	for the duration of study participation
21,T15,Temporal 274 294	prior to study entry
22,R6,Has_temporal Arg1:T9 Arg2:T15
23,T16,Condition 341 362	Normal organ function
24,T17,Temporal 363 392	within 14 days of study entry
25,R7,Has_temporal Arg1:T16 Arg2:T17
26,T18,Condition 443 467	Metastatic breast cancer
27,T19,Condition 474 499	Metastatic ovarian cancer
28,T20,Condition 506 535	Metastatic endometrial cancer
29,T21,Condition 542 568	Metastatic cervical cancer
30,T22,Condition 586 604	metastatic disease
31,T23,Qualifier 575 585	Measurable
32,R8,Has_qualifier Arg1:T22 Arg2:T23
33,T24,Value 606 610	>1cm
34,*,OR T23 T24
35,T25,Value 615 627	at least one
36,T26,Qualifier 628 653	site other than bone-only
37,R9,Has_qualifier Arg1:T25 Arg2:T26
38,R10,AND Arg1:T25 Arg2:T22
39,T27,Observation 673 691	failure to respond
40,T28,Observation 655 669	Progression on
41,*,OR T27 T28
42,T30,Temporal 708 716	previous
43,T31,Procedure 717 737	chemotherapy regimen
44,T32,Condition 742 760	metastatic disease
45,R11,AND Arg1:T31 Arg2:T32
46,R13,Has_temporal Arg1:T31 Arg2:T30
47,T33,Scope 655 691	Progression on or failure to respond
48,R12,AND Arg1:T33 Arg2:T31
49,T29,Observation 762 776	Progression on
50,T34,Temporal 777 782	prior
51,T35,Procedure 783 812	therapy with a hormonal agent
52,T36,Condition 816 833;859 867	estrogen receptor positive
53,T37,Condition 837 867	progesterone receptor positive
54,*,OR T36 T37
55,T38,Scope 816 867	estrogen receptor or progesterone receptor positive
56,R16,AND Arg1:T38 Arg2:T35
57,T39,Condition 896 913	HER2-neu positive
58,T40,Procedure 783 795;881 892	therapy with trastuzumab
59,R17,AND Arg1:T39 Arg2:T40
60,T41,"Scope 777 913	prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive"
61,*,OR T39 T38
62,R14,Has_temporal Arg1:T35 Arg2:T34
63,R15,Has_temporal Arg1:T40 Arg2:T34
64,A4,Optional T41
65,R18,Has_context Arg1:T41 Arg2:T29
66,T42,Observation 930 948	progressed through
67,T43,Procedure 949 956;972 979	hormone therapy
68,T44,Procedure 960 979	trastuzumab therapy
69,*,OR T43 T44
70,T45,Scope 930 979	progressed through hormone or trastuzumab therapy
71,R19,Has_context Arg1:T45 Arg2:T42
72,A2,Optional T45
73,R20,Has_context Arg1:T43 Arg2:T42
74,R21,Has_context Arg1:T44 Arg2:T42
75,T46,Procedure 1009 1029	chemotherapy regimen
76,R22,AND Arg1:T45 Arg2:T46
77,T47,Measurement 1076 1129	Response Evaluation Criteria in Solid Tumors (RECIST)
78,T48,Condition 1043 1061	metastatic disease
79,R23,AND Arg1:T48 Arg2:T47
80,T49,Condition 1195 1220	epithelial ovarian cancer
81,T50,Procedure 1170 1184	histologically
82,T51,Qualifier 1131 1144	Primary tumor
83,R24,Has_qualifier Arg1:T50 Arg2:T51
84,T52,Condition 1222 1243	fallopian tube cancer
85,T53,Condition 1248 1273	primary peritoneal cancer
86,T54,Qualifier 1279 1289	borderline
87,T55,Condition 1317 1337	epithelial carcinoma
88,*,OR T52 T53 T49
89,T57,Scope 1275 1337	not borderline or low malignant potential epithelial carcinoma
90,T56,"Scope 1195 1273	epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer"
91,R26,Has_scope Arg1:T50 Arg2:T56
92,T58,Multiplier 1367 1379	at least two
93,T59,Temporal 1380 1388	previous
94,T60,Procedure 1389 1410	chemotherapy regimens
95,R27,Has_temporal Arg1:T60 Arg2:T59
96,R28,AND Arg1:T58 Arg2:T60
97,T61,Observation 1360 1366	failed
98,R29,Has_context Arg1:T60 Arg2:T61
99,T62,Drug 1412 1422	Paclitaxel
100,T63,Drug 1478 1487	cisplatin
101,T64,Drug 1491 1502	carboplatin
102,T65,Condition 1567 1585	metastatic disease
103,T66,Qualifier 1556 1566	Measurable
104,R30,Has_qualifier Arg1:T65 Arg2:T66
105,T67,Measurement 1587 1601	Histologically
106,T68,Value 1602 1608	proven
107,R31,Has_value Arg1:T67 Arg2:T68
108,T71,Scope 1609 1651	recurrent or persistent endometrial cancer
109,R32,AND Arg1:T71 Arg2:T67
110,T72,Qualifier 1664 1694	amenable to curative treatment
111,T73,Negation 1660 1663	not
112,R33,Has_qualifier Arg1:T71 Arg2:T72
113,R34,Has_negation Arg1:T72 Arg2:T73
114,T74,Procedure 1700 1707	surgery
115,T75,Procedure 1715 1732	radiation therapy
116,*,OR T74 T75
117,T76,Scope 1700 1732	surgery and/or radiation therapy
118,R35,Has_scope Arg1:T72 Arg2:T76
119,T77,Value 1748 1749	2
120,T78,Temporal 1750 1758	previous
121,T79,Procedure 1759 1777	treatment regimens
122,R36,AND Arg1:T77 Arg2:T79
123,R37,Has_temporal Arg1:T79 Arg2:T78
124,T80,Observation 1741 1747	failed
125,R38,Has_context Arg1:T79 Arg2:T80
126,R39,Has_scope Arg1:T79 Arg2:T71
127,T81,Condition 1790 1808	metastatic disease
128,T82,Qualifier 1779 1789	Measurable
129,R40,Has_qualifier Arg1:T81 Arg2:T82
130,T83,Measurement 1810 1824	Histologically
131,T84,Value 1825 1831	proven
132,R41,Has_value Arg1:T83 Arg2:T84
133,T85,Condition 1856 1879	squamous cell carcinoma
134,T86,Qualifier 1845 1855	persistent
135,T87,Qualifier 1832 1841	recurrent
136,*,OR T87 T86
137,T88,Scope 1832 1855	recurrent or persistent
138,T89,Condition 1881 1904	adenosquamous carcinoma
139,T90,Condition 1909 1937	adenocarcinoma of the cervix
140,T91,Qualifier 1950 1980	amenable to curative treatment
141,T92,Negation 1946 1949	not
142,R44,Has_negation Arg1:T91 Arg2:T92
143,T93,Procedure 1986 1993	surgery
144,T94,Procedure 2001 2018	radiation therapy
145,T95,Value 2034 2035	2
146,T96,Procedure 2045 2063	treatment regimens
147,T97,Temporal 2036 2044	previous
148,R45,AND Arg1:T95 Arg2:T96
149,R46,Has_temporal Arg1:T96 Arg2:T97
150,*,OR T94 T93
151,T69,Condition 1633 1651	endometrial cancer
152,T70,Qualifier 1622 1632	persistent
153,T98,Qualifier 1609 1618	recurrent
154,*,OR T98 T70
155,T99,Scope 1609 1632	recurrent or persistent
156,R47,Has_scope Arg1:T69 Arg2:T99
157,T100,"Scope 1856 1937	squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix"
158,R42,Has_scope Arg1:T100 Arg2:T88
159,R43,AND Arg1:T100 Arg2:T83
160,R48,Has_qualifier Arg1:T100 Arg2:T91
161,R49,AND Arg1:T91 Arg2:T93
162,R50,Has_scope Arg1:T96 Arg2:T100
163,T101,Negation 1275 1278	not
164,T102,Qualifier 1293 1316	low malignant potential
165,T103,Scope 1279 1316	borderline or low malignant potential
166,*,OR T102 T54
167,R25,Has_scope Arg1:T55 Arg2:T103
168,R51,Has_negation Arg1:T55 Arg2:T101
169,R52,Has_scope Arg1:T56 Arg2:T57
170,*,OR T63 T64
171,T104,Scope 1412 1553	Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens
172,R53,Has_scope Arg1:T60 Arg2:T104
173,R54,Has_temporal Arg1:T9 Arg2:T14
174,T105,Reference_point 283 294	study entry
175,R55,Has_index Arg1:T15 Arg2:T105
176,T106,Reference_point 319 338	study participation
177,R56,Has_index Arg1:T14 Arg2:T106
178,T107,Reference_point 381 392	study entry
179,R57,Has_index Arg1:T17 Arg2:T107
180,T108,Qualifier 62 69	Ovarian
181,T109,Qualifier 71 82	endometrial
182,T110,Qualifier 86 94	cervical
183,*,OR T109 T110 T108
184,T111,"Scope 62 94	Ovarian, endometrial or cervical"
185,R58,Has_scope Arg1:T3 Arg2:T111
186,T112,Measurement 9 27	performance status
187,T113,Value 0 8	Adequate
188,R59,Has_value Arg1:T112 Arg2:T113
189,T114,Non-representable 0 27	Adequate performance status
0,T1,Person 0 6	Adults
1,T2,Value 7 27	over 18 years of age
2,T3,Person 24 27	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Condition 41 44;52 63	GSV vein reflux
5,T5,Condition 48 63	SSV vein reflux
6,T6,Qualifier 64 77	> 0.5 seconds
7,T7,Procedure 81 94	colour Duplex
8,*,OR T5 T4
9,T8,Scope 41 63	GSV or SSV vein reflux
10,R2,Has_qualifier Arg1:T8 Arg2:T6
11,R3,Has_scope Arg1:T7 Arg2:T8
12,T9,Qualifier 96 119	Varicose vein tributary
13,T10,Mood 120 129	requiring
14,T11,Procedure 130 139	treatment
15,R4,Has_mood Arg1:T11 Arg2:T10
16,R5,Has_qualifier Arg1:T11 Arg2:T9
0,T1,Post-eligibility 0 65	can't understand patient controlled analgesia device refuse trial
0,T1,Condition 15 37	Beta-Thalassemia Major
1,T2,Procedure 60 77	blood transfusion
2,T3,Qualifier 52 59	regular
3,T4,Procedure 85 107	iron chelating therapy
4,T5,Scope 60 107	blood transfusion and on iron chelating therapy
5,R1,Has_qualifier Arg1:T5 Arg2:T3
6,R2,Has_scope Arg1:T1 Arg2:T5
7,T6,Person 110 116	Weight
8,T7,Value 118 140	equal to or over 35 kg
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Condition 150 164	renal function
11,T9,Qualifier 143 149	Normal
12,R4,Has_qualifier Arg1:T8 Arg2:T9
0,T1,Value 7 18	18-65 years
1,T2,Person 0 6	Adults
2,T3,Person 7 18	18-65 years
3,R1,Has_value Arg1:T3 Arg2:T1
4,T4,Condition 43 72	functional neurologic symptom
5,T5,Condition 76 95	conversion disorder
6,*,OR T4 T5
7,T6,Condition 113 125	seizure type
8,T7,Procedure 131 140	video EEG
9,A1,Optional T6
10,T8,Measurement 275 337	criteria of the International Classification of the Epilepsies
11,R2,AND Arg1:T7 Arg2:T8
12,R3,AND Arg1:T6 Arg2:T7
13,T9,Condition 367 377	motor type
14,A2,Optional T9
15,T10,"Non-query-able 379 504	documented and clinically established levels of diagnostic certainty (Williams,1995) confirmed by 2 neurologists is required."
16,T11,Condition 542 549	symptom
17,T12,Multiplier 529 541;550 559	at least one per month
18,R4,Has_multiplier Arg1:T11 Arg2:T12
19,T13,Temporal 560 592	in the month prior to enrollment
20,T14,Reference_point 579 592	to enrollment
21,R5,Has_index Arg1:T13 Arg2:T14
22,T15,Non-query-able 594 628	Fluency in English spoken language
0,T1,Temporal 0 7	Current
1,T2,Visit 8 17	inpatient
2,T4,Temporal 37 43	active
3,T5,Condition 44 61	suicidal ideation
4,T6,Procedure 72 80	referral
5,T7,Visit 85 110	inpatient hospitalization
6,T3,Procedure 18 33	hospitalization
7,R1,AND Arg1:T3 Arg2:T2
8,R2,Has_temporal Arg1:T3 Arg2:T1
9,R3,Has_temporal Arg1:T5 Arg2:T4
10,T8,Mood 62 71	requiring
11,R4,AND Arg1:T6 Arg2:T7
12,R5,Has_mood Arg1:T6 Arg2:T8
13,R6,AND Arg1:T5 Arg2:T6
14,*,OR T3 T5
15,T9,Observation 124 131	History
16,T10,Condition 135 153	psychotic disorder
17,T11,Condition 157 170	manic episode
18,T12,Procedure 184 192	MINI-KID
19,*,OR T11 T10
20,T13,Scope 135 170	psychotic disorder or manic episode
21,R7,Has_temporal Arg1:T13 Arg2:T9
22,R8,AND Arg1:T13 Arg2:T12
23,T14,Observation 194 201	History
24,T15,Condition 205 225	substance dependence
25,T16,Procedure 239 247	MINI-KID
26,T17,Drug 259 266	tobacco
27,T18,Negation 249 258	excluding
28,R9,Has_negation Arg1:T17 Arg2:T18
29,R10,AND Arg1:T15 Arg2:T17
30,T19,Value 271 279	positive
31,T20,Measurement 280 296	urine toxicology
32,R11,Has_value Arg1:T20 Arg2:T19
33,*,OR T15 T20
34,T21,Scope 205 296	substance dependence diagnosis by MINI-KID (excluding tobacco) or positive urine toxicology
35,R12,Has_temporal Arg1:T21 Arg2:T14
36,R13,AND Arg1:T15 Arg2:T16
37,T22,Condition 299 308	Pregnancy
38,T23,Procedure 310 331	urine pregnancy tests
39,T24,Temporal 332 351	on the day of scans
40,T25,Person 356 374	menstruating girls
41,A1,Optional T25
42,R14,Has_temporal Arg1:T23 Arg2:T24
43,R15,AND Arg1:T25 Arg2:T23
44,T26,Negation 378 398	Inability to provide
45,T27,Observation 399 423	written informed consent
46,R16,Has_negation Arg1:T27 Arg2:T26
47,T28,Qualifier 441 492	Yale Human Investigation Committee (HIC) guidelines
48,T29,Qualifier 493 503	in English
49,R17,Has_qualifier Arg1:T28 Arg2:T29
50,R18,Has_qualifier Arg1:T27 Arg2:T28
0,T1,Person 9 33	over the age of 18 years
1,T2,Observation 42 77	able to give their informed consent
2,T3,Procedure 89 108	sublobar resections
3,T4,Procedure 79 84;98 108	Lobar resections
4,*,OR T3 T4
5,T5,Procedure 148 165	robotic surgeries
6,T6,Qualifier 116 130	video-assisted
7,T7,Procedure 131 144;156 165	thoracoscopic surgeries
8,*,OR T5 T7
9,T8,Scope 131 165	thoracoscopic or robotic surgeries
10,R1,Has_qualifier Arg1:T8 Arg2:T6
11,T9,Procedure 181 203	therapeutic procedures
12,T10,Procedure 167 177;193 203	Diagnostic procedures
13,*,OR T9 T10
0,T1,Condition 6 22	hypersensitivity
1,T2,Drug 26 29	egg
2,T3,Drug 31 47	soybean proteins
3,T4,Drug 49 64	peanut proteins
4,T5,Drug 66 70	corn
5,T6,Drug 74 87	corn products
6,T7,Drug 106 123	active substances
7,T8,Drug 127 137	excipients
8,*,OR T5 T6 T7 T8 T4 T3 T2
9,T9,"Scope 26 137	egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients"
10,R1,Has_scope Arg1:T1 Arg2:T9
11,T10,Condition 146 160	hyperlipidemia
12,T11,Qualifier 139 145	Severe
13,R2,Has_qualifier Arg1:T10 Arg2:T11
14,T12,Qualifier 164 170	severe
15,T13,Condition 171 200	disorders of lipid metabolism
16,R3,Has_qualifier Arg1:T13 Arg2:T12
17,T14,Condition 218 238	hypertriglyceridemia
18,T15,Measurement 240 272	serum triglyceride concentration
19,T16,"Value 273 284	>1,000 g/dL"
20,R4,Has_value Arg1:T15 Arg2:T16
21,R5,Subsumes Arg1:T14 Arg2:T15
22,*,OR T10 T13 T14
23,T17,Condition 288 326	Inborn errors of amino acid metabolism
24,T18,Condition 328 355	Cardiopulmonary instability
25,T19,Condition 367 382	pulmonary edema
26,T20,Condition 384 405	cardiac insufficiency
27,T21,Condition 407 428	myocardial infarction
28,T22,Condition 430 438	acidosis
29,T23,Condition 443 466	hemodynamic instability
30,T24,Qualifier 489 508	vasopressor support
31,T25,Qualifier 477 488	significant
32,R6,Has_qualifier Arg1:T24 Arg2:T25
33,R7,Has_qualifier Arg1:T23 Arg2:T24
34,T26,Drug 489 500	vasopressor
35,*,OR T22 T23 T21 T20 T19
36,T27,"Scope 367 508	pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support"
37,R8,Subsumes Arg1:T18 Arg2:T27
38,T28,Condition 511 534	Hemophagocytic syndrome
39,T29,Procedure 537 539	PN
40,T30,Temporal 540 584	in the last 7 days prior to study enrollment
41,T31,Reference_point 568 584	study enrollment
42,R9,Has_index Arg1:T30 Arg2:T31
43,R10,Has_temporal Arg1:T29 Arg2:T30
44,T32,Procedure 596 606	chronic PN
45,T33,Temporal 607 625	before study start
46,T34,Reference_point 614 625	study start
47,R11,Has_index Arg1:T33 Arg2:T34
48,R12,Has_temporal Arg1:T32 Arg2:T33
49,T35,Measurement 627 640	Liver enzymes
50,T36,Measurement 649 652	AST
51,T37,Measurement 654 657	ALT
52,T38,Measurement 659 663	GGPT
53,T39,Measurement 669 685	direct bilirubin
54,T40,Value 686 727	exceeding 2 x upper limit of normal range
55,*,OR T36 T37 T38
56,T41,"Scope 649 663	AST, ALT, GGPT"
57,R13,Subsumes Arg1:T35 Arg2:T41
58,*,OR T35 T39
59,T42,"Scope 627 685	Liver enzymes (either AST, ALT, GGPT), or direct bilirubin"
60,R14,Has_value Arg1:T42 Arg2:T40
61,T43,Value 729 751	Pathologically altered
62,T44,Measurement 752 782	level of any serum electrolyte
63,T45,Measurement 784 790	sodium
64,T46,Measurement 792 801	potassium
65,T47,Measurement 803 812	magnesium
66,T48,Measurement 814 821	calcium
67,T49,Measurement 823 831	chloride
68,T50,Measurement 833 842	phosphate
69,*,OR T45 T46 T47 T48 T49 T50
70,T51,"Scope 784 842	sodium, potassium, magnesium, calcium, chloride, phosphate"
71,R15,Subsumes Arg1:T44 Arg2:T51
72,R16,Has_value Arg1:T44 Arg2:T43
73,T52,Non-representable 844 898	unless corrected prior to the start of study treatment
74,T53,Value 900 922	Pathologically altered
75,T54,Measurement 923 931	blood pH
76,T55,Measurement 936 953	oxygen saturation
77,T56,Measurement 958 972	carbon dioxide
78,*,OR T55 T56 T54
79,T57,"Scope 923 972	blood pH, or oxygen saturation, or carbon dioxide"
80,R17,Has_value Arg1:T57 Arg2:T53
81,T58,Condition 1042 1051	lactation
82,T59,Condition 1029 1038	Pregnancy
83,*,OR T59 T58
84,T60,Competing_trial 1053 1092	Participation in another clinical study
0,T1,Post-eligibility 0 62	Informed consent must be obtained prior to any study procedure
1,T2,Person 65 68	Age
2,T3,Value 68 78	>18 years.
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 92 97	STEMI
5,T5,Procedure 112 123	primary PCI
6,T6,Temporal 124 150	within the first 12 hours.
7,R2,AND Arg1:T4 Arg2:T5
8,R3,Has_temporal Arg1:T5 Arg2:T6
0,T1,Non-query-able 0 2	NA
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,T3,Value 24 37	2 to 16 years
3,T4,Person 41 44	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,*,OR T1 T2
6,T5,Value 67 82;89 103	at least 80% of caloric intake
7,T6,Procedure 107 109	PN
8,R2,Has_value Arg1:T6 Arg2:T5
9,T7,Temporal 110 124	at study start
10,R3,Has_temporal Arg1:T6 Arg2:T7
11,T8,Condition 141 151	indication
12,T9,Procedure 156 158	PN
13,R4,AND Arg1:T8 Arg2:T9
14,T10,Multiplier 171 190	for at least 5 days
15,T11,Mood 162 170	expected
16,R6,Has_mood Arg1:T10 Arg2:T11
17,R5,Has_multiplier Arg1:T8 Arg2:T10
18,T12,Device 215 234	central venous line
19,T13,Procedure 246 248	PN
20,R7,AND Arg1:T12 Arg2:T13
21,T14,Device 267 286	central venous line
22,T15,Observation 300 313	other reasons
23,R8,Has_context Arg1:T14 Arg2:T15
24,*,OR T12 T14
25,T16,Informed_consent 315 368	Written informed consent from legal representative(s)
0,T1,Measurement 10 34	gestational age at birth
1,T2,Value 0 9	=32 weeks
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 45 58	postnatal age
4,T4,Temporal 59 75	at randomization
5,T5,Value 36 44	=6 weeks
6,R2,Has_value Arg1:T3 Arg2:T5
7,R3,Has_temporal Arg1:T3 Arg2:T4
8,T6,Observation 85 97	hospitalized
9,T7,Temporal 98 109	after birth
10,T8,Reference_point 104 109	birth
11,R4,Has_index Arg1:T7 Arg2:T8
12,R5,Has_temporal Arg1:T6 Arg2:T7
13,T9,Mood 176 184	eligible
14,T10,Drug 196 212	2-month vaccines
15,R6,Has_mood Arg1:T10 Arg2:T9
16,T11,Non-query-able 214 298	English- or Spanish-speaking parent(s)/legally authorized representative(s) (LAR(s))
17,T12,Mood 304 311	planned
18,T13,Procedure 316 325	discharge
19,T14,Temporal 326 356	within 60 hours of study entry
20,T15,Reference_point 345 356	study entry
21,T16,Measurement 300 303	Not
22,R8,Has_mood Arg1:T13 Arg2:T12
23,R9,Has_temporal Arg1:T13 Arg2:T14
24,R7,AND Arg1:T13 Arg2:T16
25,T17,Informed_consent 358 505	The parent/guardian must be willing and capable of providing permission for their child to participate through the written informed consent process
0,T1,Drug 11 15	DTaP
1,T2,Drug 17 20	IPV
2,T3,Drug 22 27	PCV13
3,T4,Drug 32 35	Hib
4,*,OR T3 T4 T2 T1
5,T5,Temporal 36 55	prior to enrollment
6,T6,Reference_point 45 55	enrollment
7,T7,"Scope 11 35	DTaP, IPV, PCV13, or Hib"
8,R1,Has_temporal Arg1:T7 Arg2:T5
9,T8,Drug 166 170	DTaP
10,T9,Drug 172 175	IPV
11,T10,Drug 177 180	HBV
12,T11,Drug 182 187	PCV13
13,T12,Drug 192 195	Hib
14,T13,Mood 120 139	Anticipated receipt
15,T14,Temporal 196 241	during the first 60 hours after randomization
16,T15,Reference_point 228 241	randomization
17,R2,Has_index Arg1:T14 Arg2:T15
18,*,OR T11 T12 T10 T9 T8
19,T16,"Scope 166 195	DTaP, IPV, HBV, PCV13, or Hib"
20,R3,Has_temporal Arg1:T16 Arg2:T14
21,R4,Has_mood Arg1:T16 Arg2:T13
22,T17,Qualifier 256 262	severe
23,T18,Condition 263 280	allergic reaction
24,T19,Condition 287 298	anaphylaxis
25,T20,Drug 326 345	hepatitis B vaccine
26,T21,Temporal 305 313	previous
27,R5,Has_temporal Arg1:T20 Arg2:T21
28,R6,Has_qualifier Arg1:T18 Arg2:T17
29,T22,Scope 256 280	severe allergic reaction
30,R7,Subsumes Arg1:T22 Arg2:T19
31,R8,AND Arg1:T22 Arg2:T20
32,T23,Qualifier 360 366	severe
33,T24,Condition 367 384	allergic reaction
34,R9,Has_qualifier Arg1:T24 Arg2:T23
35,T25,Condition 391 402	anaphylaxis
36,T26,Drug 411 454	component of the vaccines used in the study
37,T27,Drug 465 473	neomycin
38,T28,Drug 485 496	polymyxin B
39,T29,Drug 475 480	yeast
40,*,OR T28 T29 T27
41,T30,"Scope 465 496	neomycin, yeast and polymyxin B"
42,R10,Subsumes Arg1:T26 Arg2:T30
43,T31,Scope 360 384	severe allergic reaction
44,R11,Subsumes Arg1:T31 Arg2:T25
45,R12,AND Arg1:T31 Arg2:T26
46,T32,Condition 515 522	allergy
47,T33,Drug 509 514	latex
48,R13,AND Arg1:T32 Arg2:T33
49,T34,Observation 498 505	History
50,R14,Has_temporal Arg1:T32 Arg2:T34
51,T35,Condition 544 575	progressive neurologic disorder
52,T36,Qualifier 579 592	unknown cause
53,R15,Has_qualifier Arg1:T35 Arg2:T36
54,T37,Qualifier 535 543	unstable
55,R16,Has_qualifier Arg1:T35 Arg2:T37
56,T38,Observation 524 531	History
57,R17,Has_temporal Arg1:T35 Arg2:T38
58,T39,Condition 594 614	Known cause of apnea
59,T40,Condition 626 646	apnea of prematurity
60,T41,Negation 615 625	other than
61,R18,Has_negation Arg1:T40 Arg2:T41
62,R19,AND Arg1:T39 Arg2:T40
63,T42,Condition 648 670	Cyanotic heart disease
64,T43,Qualifier 672 682	congenital
65,T44,Qualifier 686 694	acquired
66,*,OR T43 T44
67,T45,Scope 672 694	congenital or acquired
68,R20,Has_scope Arg1:T42 Arg2:T45
69,T46,Non-query-able 697 805	Child or parent/LAR is an immediate relative of study staff or an employee who is supervised by study staff.
70,T47,"Non-query-able 807 1003	Any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol"
0,T1,Measurement 0 3	ASA
1,T2,Value 4 12	I and II
2,T3,Person 13 18	women
3,R1,Has_value Arg1:T1 Arg2:T2
4,T4,Person 30 33	old
5,T5,Value 20 29	18-45 yrs
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 35 54	Singleton pregnancy
8,T7,Procedure 56 73	Cervical cerclage
9,T8,Qualifier 74 77;85 94	1st trimester
10,T9,Qualifier 81 94	2nd trimester
11,T10,Condition 98 107	pregnancy
12,T11,Procedure 124 141	spinal anesthesia
13,R3,AND Arg1:T7 Arg2:T11
14,*,OR T8 T9
15,T12,Scope 74 94	1st or 2nd trimester
16,R4,Has_scope Arg1:T10 Arg2:T12
17,R5,AND Arg1:T7 Arg2:T10
18,T13,Measurement 143 149	Height
19,T14,Value 150 162	150 - 180 cm
20,R6,Has_value Arg1:T13 Arg2:T14
21,T15,Measurement 164 167	BMI
22,T16,Value 168 178	= 40 kg/m2
23,R7,Has_value Arg1:T15 Arg2:T16
0,T1,Condition 33 36	OSA
1,T2,Qualifier 14 22	moderate
2,T3,Qualifier 26 32	severe
3,*,OR T2 T3
4,T4,Scope 14 32	moderate-to-severe
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 103 106	OSA
7,T6,Measurement 111 114	AHI
8,T7,Value 108 110;114 117	20 =65
9,R2,Has_value Arg1:T6 Arg2:T7
10,R3,AND Arg1:T5 Arg2:T6
11,*,OR T1 T5
12,T8,Negation 186 189	not
13,T9,Procedure 215 227	CPAP therapy
14,R4,Has_negation Arg1:T9 Arg2:T8
15,T10,Person 423 426	Age
16,T11,Value 427 438	22 or above
17,R5,Has_value Arg1:T10 Arg2:T11
18,T12,"Post-eligibility 440 569	Willing and capable to have stimulation hardware permanently implanted, and to use the patient remote to activate the stimulation"
19,T13,"Post-eligibility 571 727	Willing and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires"
20,T14,Informed_consent 729 778	Willing and capable of providing informed consent
0,T1,Condition 15 18	VTE
1,T2,Visit 22 39	outpatient clinic
2,T3,Qualifier 46 65	discharge diagnosis
3,T4,Temporal 66 87	after hospitalization
4,R1,Has_temporal Arg1:T3 Arg2:T4
5,T5,Reference_point 72 87	hospitalization
6,T6,Procedure 72 87	hospitalization
7,R2,multi Arg1:T5 Arg2:T6
8,R3,Has_index Arg1:T4 Arg2:T5
9,*,OR T2 T3
10,T7,Scope 22 87	outpatient clinic or as discharge diagnosis after hospitalization
11,R4,Has_scope Arg1:T1 Arg2:T7
12,T8,Procedure 100 112	prescription
13,T9,Drug 118 122	NOAC
14,T10,Qualifier 130 145	Danish pharmacy
15,T11,Temporal 146 200	within 14 days of discharge or outpatient clinic visit
16,T12,Reference_point 164 200	discharge or outpatient clinic visit
17,T13,Procedure 164 173	discharge
18,T14,Procedure 177 200	outpatient clinic visit
19,T15,Visit 177 194	outpatient clinic
20,R5,multi Arg1:T14 Arg2:T15
21,R6,Has_index Arg1:T11 Arg2:T12
22,*,OR T13 T14
23,T16,Scope 164 200	discharge or outpatient clinic visit
24,R7,multi Arg1:T12 Arg2:T16
25,R8,Has_qualifier Arg1:T9 Arg2:T10
26,R9,Has_temporal Arg1:T9 Arg2:T11
27,R10,AND Arg1:T8 Arg2:T9
28,T17,Qualifier 92 99	claimed
29,R11,Has_qualifier Arg1:T8 Arg2:T17
0,T1,Multiplier 0 12	At least two
1,T2,Non-representable 0 49	At least two of the following additional criteria
2,T3,Value 51 66	At least 70 yrs
3,T4,Person 67 70	old
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Person 72 78	Female
6,T6,Condition 87 95	Diabetes
7,T7,Measurement 97 117	Creatinine clearance
8,T8,Value 118 127	<60mL/min
9,R2,Has_value Arg1:T7 Arg2:T8
10,T9,Condition 167 181	organ bleeding
11,T10,Condition 140 157;173 181	gastro-intestinal bleeding
12,*,OR T10 T9
13,T11,Qualifier 161 166	other
14,T12,Observation 129 136	History
15,R3,Has_qualifier Arg1:T9 Arg2:T11
16,T13,Scope 140 181	gastro-intestinal or other organ bleeding
17,R4,Has_temporal Arg1:T13 Arg2:T12
18,T14,Condition 192 198	anemia
19,T15,Temporal 183 191	Baseline
20,R5,Has_temporal Arg1:T14 Arg2:T15
21,T16,Procedure 208 217	treatment
22,T17,Drug 223 256	glycoproteins IIb-IIIa inhibitors
23,T18,Temporal 200 207	Current
24,R6,Has_temporal Arg1:T16 Arg2:T18
25,R7,AND Arg1:T16 Arg2:T17
0,T1,Condition 0 25	Major depressive disorder
1,T2,Scope 31 49	psychotic features
2,R1,Has_scope Arg1:T1 Arg2:T2
3,T3,Condition 51 79	Traumatic Brain Injury (TBI)
4,T4,Condition 93 129	impact on activities of daily living
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Condition 131 150	Developmental delay
7,T6,Condition 152 172	intellectual deficit
8,T7,Condition 182 210	evere educational disability
9,T8,Condition 229 270	dependence for activities of daily living
10,*,OR T7 T6 T5
11,T9,"Scope 131 210	Developmental delay, intellectual deficit, and/or severe educational disability"
12,R3,AND Arg1:T9 Arg2:T8
13,T10,Condition 280 302	substance use disorder
14,T11,Temporal 272 279	Ongoing
15,R4,Has_temporal Arg1:T10 Arg2:T11
16,T12,Condition 320 356	impact on activities of daily living
17,R5,AND Arg1:T10 Arg2:T12
18,T13,"Non-query-able 358 474	Difficult or impossible to determine whether cognitive or functional decline is due to substance use or HIV, or both"
19,T14,Condition 488 500	intoxication
20,T15,Condition 504 514	withdrawal
21,*,OR T15 T14
22,T16,Condition 548 587	Central nervous system (CNS) infections
23,T17,Condition 548 576;591 615	Central nervous system (CNS) opportunistic conditions
24,*,OR T17 T16
25,T18,Condition 617 630	brain abscess
26,T19,Condition 681 691	meningitis
27,T20,Condition 708 729	neurologic impairment
28,T21,Multiplier 697 707	persistent
29,R6,Has_multiplier Arg1:T20 Arg2:T21
30,R7,AND Arg1:T19 Arg2:T20
31,T22,Qualifier 632 641	bacterial
32,T23,Qualifier 643 656	mycobacterial
33,T24,Qualifier 658 664	fungal
34,T25,Qualifier 668 678	Toxoplasma
35,*,OR T25 T24 T23 T22
36,T26,"Scope 632 678	bacterial, mycobacterial, fungal or Toxoplasma"
37,R8,Has_scope Arg1:T18 Arg2:T26
38,T27,Condition 739 751	CNS lymphoma
39,T28,Condition 753 801	progressive multifocal leukoencephalopathy (PML)
40,T29,Qualifier 806 813	another
41,T30,Condition 814 837	structural brain lesion
42,T31,Condition 843 864	neurological sequelae
43,R9,AND Arg1:T30 Arg2:T31
44,R10,Has_qualifier Arg1:T30 Arg2:T29
45,*,OR T30 T28 T27 T18 T19
46,T32,"Scope 617 864	brain abscess (bacterial, mycobacterial, fungal or Toxoplasma), meningitis with persistent neurologic impairment, primary CNS lymphoma, progressive multifocal leukoencephalopathy (PML), or another structural brain lesion with neurological sequelae"
47,T33,Scope 548 615	Central nervous system (CNS) infections or opportunistic conditions
48,R11,Subsumes Arg1:T33 Arg2:T32
49,T34,Qualifier 866 871	Other
50,T35,Condition 872 886	CNS conditions
51,R12,Has_qualifier Arg1:T35 Arg2:T34
52,T36,Qualifier 888 905	non-opportunistic
53,T37,Qualifier 906 913	primary
54,T38,Qualifier 731 738	primary
55,R13,Has_qualifier Arg1:T27 Arg2:T38
56,T39,Qualifier 917 927	metastatic
57,T40,Condition 928 940	brain tumors
58,*,OR T39 T37
59,T41,Scope 906 927	primary or metastatic
60,R14,Has_scope Arg1:T40 Arg2:T41
61,R15,Has_qualifier Arg1:T40 Arg2:T36
62,T42,Qualifier 942 954	uncontrolled
63,T43,Condition 955 971	seizure disorder
64,R16,Has_qualifier Arg1:T43 Arg2:T42
65,T44,Condition 973 1003	progressive multiple sclerosis
66,T45,Condition 1005 1011	stroke
67,T46,Condition 1017 1038	neurological sequelae
68,T47,Condition 1043 1051	dementia
69,T48,Negation 1066 1076	other than
70,T49,Condition 1077 1080	HIV
71,R17,Has_negation Arg1:T49 Arg2:T48
72,T50,Condition 1086 1105	Alzheimer's disease
73,T51,Scope 1066 1080	other than HIV
74,R18,Subsumes Arg1:T51 Arg2:T50
75,R19,Has_scope Arg1:T47 Arg2:T51
76,R20,AND Arg1:T45 Arg2:T46
77,*,OR T47 T45 T44 T43 T40
78,T52,"Scope 888 1106	non-opportunistic primary or metastatic brain tumors, uncontrolled seizure disorder, progressive multiple sclerosis, stroke with neurological sequelae, or dementia due to causes other than HIV (eg, Alzheimer's disease)"
79,T53,Scope 866 886	Other CNS conditions
80,R21,Subsumes Arg1:T53 Arg2:T52
81,T54,Condition 1108 1130	Constitutional illness
82,T55,Condition 1147 1164	unexplained fever
83,T56,Multiplier 1136 1146	persistent
84,R22,Has_multiplier Arg1:T55 Arg2:T56
85,T57,Condition 1166 1174	diarrhea
86,T58,Qualifier 1176 1187	significant
87,T59,Condition 1188 1199	weight loss
88,R23,Has_qualifier Arg1:T59 Arg2:T58
89,T60,Condition 1201 1219	disabling weakness
90,*,OR T60 T59 T57 T55
91,T61,"Scope 1136 1219	persistent unexplained fever, diarrhea, significant weight loss, disabling weakness"
92,R24,Subsumes Arg1:T54 Arg2:T61
93,T62,Temporal 1221 1248	within 30 days of screening
94,R25,Has_temporal Arg1:T54 Arg2:T62
95,T63,Qualifier 1256 1265	untreated
96,T64,Condition 1266 1280	B12 deficiency
97,T65,Condition 1284 1296	malnutrition
98,*,OR T65 T64
99,T66,Measurement 1298 1319	body mass index [BMI]
100,T67,Value 1320 1332	less than 18
101,R26,Has_value Arg1:T66 Arg2:T67
102,T68,Temporal 1334 1346	at screening
103,R27,Subsumes Arg1:T65 Arg2:T66
104,T69,Scope 1266 1333	B12 deficiency or malnutrition (body mass index [BMI] less than 18)
105,R28,Has_qualifier Arg1:T69 Arg2:T63
106,R29,Has_temporal Arg1:T69 Arg2:T68
107,T70,Temporal 1360 1367	current
108,T71,Condition 1368 1401	hepatitis C virus infection (HCV)
109,T72,Measurement 1407 1424	HCV antibody [Ab]
110,T73,Value 1425 1433	positive
111,T74,Mood 1348 1356	Evidence
112,T75,Temporal 1434 1469	within 90 days prior to study entry
113,T76,Measurement 1494 1508	plasma HCV RNA
114,T77,Value 1509 1517	negative
115,R30,Has_value Arg1:T76 Arg2:T77
116,R31,Has_value Arg1:T72 Arg2:T73
117,R32,Has_temporal Arg1:T72 Arg2:T75
118,T78,Temporal 1518 1545	within the same time period
119,R33,Has_temporal Arg1:T76 Arg2:T78
120,*,OR T72 T76
121,T79,Scope 1407 1545	HCV antibody [Ab] positive within 90 days prior to study entry unless also shown to be plasma HCV RNA negative within the same time period
122,R34,Has_temporal Arg1:T71 Arg2:T70
123,R35,Has_mood Arg1:T71 Arg2:T74
124,R36,Subsumes Arg1:T71 Arg2:T79
125,T80,Qualifier 1548 1556	Unstable
126,T81,Qualifier 1561 1569	advanced
127,T82,Condition 1570 1583	liver disease
128,R37,Has_qualifier Arg1:T82 Arg2:T81
129,R38,Has_qualifier Arg1:T82 Arg2:T80
130,T83,Multiplier 1615 1627	at least one
131,T84,Condition 1646 1653	ascites
132,T85,Condition 1655 1669	encephalopathy
133,T86,Condition 1671 1683	coagulopathy
134,T87,Condition 1685 1700	hypoalbuminemia
135,T88,Condition 1702 1712;1724 1731	esophageal varices
136,T89,Condition 1716 1731	gastric varices
137,T90,Qualifier 1736 1746	persistent
138,T91,Condition 1747 1755	jaundice
139,R39,Has_qualifier Arg1:T91 Arg2:T90
140,*,OR T91 T88 T89 T87 T86 T85 T84
141,T92,"Scope 1646 1755	ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice"
142,R40,Has_multiplier Arg1:T92 Arg2:T83
143,T93,"Scope 1615 1755	at least one of the following: ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice"
144,R41,Subsumes Arg1:T82 Arg2:T93
145,T94,Temporal 1758 1763	Prior
146,T95,Temporal 1767 1774	current
147,*,OR T95 T94
148,T96,Drug 1786 1801	CCR5 antagonist
149,T97,Drug 1811 1814	MVC
150,T98,Drug 1819 1837	cenicriviroc [CVC]
151,*,OR T98 T97
152,T99,Scope 1811 1837	MVC and cenicriviroc [CVC]
153,R42,Subsumes Arg1:T96 Arg2:T99
154,T100,Drug 1843 1862	integrase inhibitor
155,T101,Drug 1872 1875	RAL
156,T102,Drug 1877 1880	DTG
157,T103,Drug 1886 1904	elvitegravir [EVG]
158,*,OR T102 T101 T103
159,T104,"Scope 1872 1904	RAL, DTG, and elvitegravir [EVG]"
160,R43,Subsumes Arg1:T100 Arg2:T104
161,*,OR T100 T96
162,T105,"Scope 1786 1905	CCR5 antagonist (such as MVC and cenicriviroc [CVC]) and integrase inhibitor (such as RAL, DTG, and elvitegravir [EVG])"
163,T106,Scope 1758 1774	Prior or current
164,R44,Has_scope Arg1:T105 Arg2:T106
165,T108,Observation 2076 2089	Breastfeeding
166,T109,Condition 2106 2143	AIDS-defining opportunistic infection
167,T110,Temporal 2144 2174	within 6 months prior to entry
168,R45,Has_temporal Arg1:T109 Arg2:T110
169,T111,Temporal 2286 2292	Active
170,T112,Condition 2293 2301	syphilis
171,T113,Procedure 2305 2314	treatment
172,T114,Condition 2319 2327	syphilis
173,R46,AND Arg1:T113 Arg2:T114
174,*,OR T113 T112
175,R47,Has_temporal Arg1:T112 Arg2:T111
176,T115,Temporal 2328 2363	within 90 days prior to study entry
177,R48,Has_temporal Arg1:T113 Arg2:T115
178,T116,Reference_point 2352 2363	study entry
179,R49,Has_index Arg1:T115 Arg2:T116
180,T117,Temporal 2371 2377	Active
181,T118,Condition 2378 2386	syphilis
182,R50,Has_temporal Arg1:T118 Arg2:T117
183,T119,Value 2401 2419	four-fold increase
184,T120,Measurement 2423 2454	serum rapid plasma reagin (RPR)
185,T121,Measurement 2458 2501	venereal disease research laboratory (VDRL)
186,T122,Condition 2535 2543	syphilis
187,T123,Temporal 2530 2534	past
188,R51,Has_temporal Arg1:T122 Arg2:T123
189,T124,Value 2554 2562	reactive
190,T125,Temporal 2548 2553	newly
191,T126,Measurement 2563 2572	serum RPR
192,T127,Measurement 2576 2580	VDRL
193,T128,Procedure 2588 2614	reactive confirmatory test
194,T129,Procedure 2616 2641	enzyme immunoassays [EIA]
195,T130,Procedure 2645 2673	chemiluminescent assay [CIA]
196,T131,Procedure 2675 2717	T. pallidum particle agglutination [TP-PA]
197,T132,Procedure 2722 2772	fluorescent treponemal antibody absorbed [FTA-ABS]
198,*,OR T132 T131 T130 T129
199,T133,"Scope 2616 2772	enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS]"
200,R52,Subsumes Arg1:T128 Arg2:T133
201,*,OR T127 T126
202,R53,Has_temporal Arg1:T124 Arg2:T125
203,T134,Scope 2563 2580	serum RPR or VDRL
204,R54,Has_value Arg1:T134 Arg2:T124
205,*,OR T121 T120
206,T135,Scope 2423 2501	serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL)
207,R55,Has_value Arg1:T135 Arg2:T119
208,T136,Scope 2401 2543	four-fold increase in serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) tests in an individual with past syphilis
209,T137,"Scope 2548 2773	newly reactive serum RPR or VDRL with a reactive confirmatory test (enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS])"
210,*,OR T136 T137
211,T138,"Scope 2401 2773	four-fold increase in serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) tests in an individual with past syphilis, or newly reactive serum RPR or VDRL with a reactive confirmatory test (enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS])"
212,R56,Subsumes Arg1:T118 Arg2:T138
213,T139,Condition 2782 2789	allergy
214,T140,Condition 2790 2801	sensitivity
215,*,OR T140 T139 T141
216,T141,Condition 2809 2825	hypersensitivity
217,T142,Drug 2829 2854	components of study drugs
218,T143,Scope 2782 2825	allergy/sensitivity or any hypersensitivity
219,R57,AND Arg1:T143 Arg2:T142
220,T107,Drug 1926 1936	medication
221,T144,Drug 1948 1963	antiretrovirals
222,T145,Qualifier 1965 1988	prohibited in the study
223,R58,Subsumes Arg1:T107 Arg2:T144
224,R59,Has_qualifier Arg1:T107 Arg2:T145
225,T146,Temporal 1907 1914	Current
226,R60,Has_temporal Arg1:T107 Arg2:T146
0,T1,Condition 4 20	contraindication
1,T2,Drug 24 44	neuraxial anesthesia
2,T3,Observation 46 53	history
3,T4,Condition 57 75	neurologic disease
4,T5,Condition 83 101	multiple sclerosis
5,T6,Condition 103 118	spinal stenosis
6,T7,Condition 120 127;142 152	central neuropathy
7,T8,Condition 131 152	peripheral neuropathy
8,*,OR T8 T7 T6 T5
9,T9,"Scope 83 152	multiple sclerosis, spinal stenosis, central or peripheral neuropathy"
10,R1,Subsumes Arg1:T4 Arg2:T9
11,R2,Has_temporal Arg1:T4 Arg2:T3
12,T10,"Scope 46 152	history of neurologic disease (e.g., multiple sclerosis, spinal stenosis, central or peripheral neuropathy"
13,R3,AND Arg1:T1 Arg2:T2
14,T11,Scope 4 44	contraindication to neuraxial anesthesia
15,R4,Subsumes Arg1:T11 Arg2:T10
16,T12,Qualifier 168 175	chronic
17,T13,Temporal 155 167	Pre-existing
18,T14,Condition 176 185	back pain
19,*,OR T12 T13
20,T15,Scope 155 175	Pre-existing/chronic
21,R5,Has_scope Arg1:T14 Arg2:T15
22,T16,Drug 187 209	Ester local anesthetic
23,T17,Condition 210 217	allergy
24,T18,Drug 219 223	PABA
25,T19,Condition 224 231	allergy
26,R6,AND Arg1:T19 Arg2:T18
27,R7,AND Arg1:T17 Arg2:T16
28,*,OR T17 T19
29,T20,Observation 233 240	History
30,T21,Drug 244 267	atypical cholinesterase
31,T22,Non-representable 269 304	CP is metabolized by cholinesterase
32,R8,Has_temporal Arg1:T21 Arg2:T20
0,T1,Condition 10 22	mixed apneas
1,T2,Condition 0 7;16 22	Central apneas
2,T3,Value 23 28	> 25%
3,T4,Measurement 36 62	total apnea-hypopnea index
4,T5,Measurement 64 67	AHI
5,R1,Subsumes Arg1:T4 Arg2:T5
6,T6,Scope 0 22	Central + mixed apneas
7,R2,Has_value Arg1:T4 Arg2:T3
8,R3,AND Arg1:T6 Arg2:T4
9,*,OR T1 T2
10,T7,"Non-query-able 70 231	Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate"
11,T8,Non-query-able 233 321	Any condition or procedure that has compromised neurological control of the upper airway
12,T9,Non-query-able 323 416	Patients who are unable or do not have the necessary assistance to operate the patient remote
13,T10,Pregnancy_considerations 418 470	Patients who are pregnant or plan to become pregnant
14,T11,Procedure 498 524	magnetic resonance imaging
15,T12,Procedure 526 529	MRI
16,R4,Subsumes Arg1:T11 Arg2:T12
17,T13,Non-query-able 532 641	Patients with an implantable device that may be susceptible to unintended interaction with the Inspire system
18,T14,Measurement 644 659	Body Mass Index
19,T15,Measurement 661 664	BMI
20,R5,Subsumes Arg1:T14 Arg2:T15
21,T16,Value 669 673	> 32
22,R6,Subsumes Arg1:T14 Arg2:T16
23,T17,Condition 721 736	contraindicates
24,T18,Procedure 739 757	surgical procedure
25,T19,Procedure 764 782	general anesthesia
26,R7,AND Arg1:T17 Arg2:T18
27,R8,AND Arg1:T18 Arg2:T19
28,T20,Observation 858 873	life expectancy
29,T21,Value 874 885	< 12 months
30,R9,Has_value Arg1:T20 Arg2:T21
31,T22,Condition 894 913	psychiatric disease
32,T23,Condition 915 932	psychotic illness
33,T24,Condition 934 950	major depression
34,T25,Condition 955 976	acute anxiety attacks
35,*,OR T23 T24 T25
36,T26,"Scope 915 976	psychotic illness, major depression, or acute anxiety attacks"
37,R10,Has_scope Arg1:T22 Arg2:T26
38,T27,Non-query-able 1072 1159	Any other reason the investigator deems subject is unfit for participation in the study
0,T1,Drug 20 24	NOAC
1,T2,Temporal 25 99	within 90 days prior to hospitalization or outpatient clinic visit for VTE
2,T5,Condition 96 99	VTE
3,T3,Reference_point 49 99	hospitalization or outpatient clinic visit for VTE
4,T4,Procedure 49 64	hospitalization
5,T6,Procedure 68 91	outpatient clinic visit
6,T7,Visit 68 85	outpatient clinic
7,R1,AND Arg1:T6 Arg2:T5
8,R2,multi Arg1:T6 Arg2:T7
9,T8,Visit 49 64	hospitalization
10,R3,multi Arg1:T4 Arg2:T8
11,R4,Has_index Arg1:T2 Arg2:T3
12,*,OR T6 T4
13,T9,Scope 49 99	hospitalization or outpatient clinic visit for VTE
14,R5,multi Arg1:T3 Arg2:T9
15,R6,Has_temporal Arg1:T1 Arg2:T2
16,T10,Drug 116 120	NOAC
17,T11,Observation 116 131	NOAC preference
18,R7,multi Arg1:T11 Arg2:T10
19,T12,Non-representable 132 202	apart from preference consistent with current cluster randomized NOAC.
20,T13,Condition 210 227	contraindications
21,T14,Qualifier 204 209	Other
22,R8,Has_qualifier Arg1:T13 Arg2:T14
23,T15,Qualifier 246 280	Summary of Product Characteristics
24,R9,Has_qualifier Arg1:T13 Arg2:T15
25,T16,Drug 301 305	NOAC
26,R10,AND Arg1:T13 Arg2:T16
0,T1,"Non-representable 0 1178	a licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. NOTE: The term ""licensed"" refers to a United States Food and Drug Administration (FDA)-approved kit, which is required for all IND studies, or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally. Non-US sites are encouraged to use US FDA-approved methods for IND studies. WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (eg, indirect versus competitive), or a Western blot or a plasma HIV-1 RNA. OR"
1,T2,Condition 1197 1210	HIV diagnosis
2,T3,Drug 1260 1295	Tenofovir disoproxil fumarate (TDF)
3,T4,Drug 1299 1335	tenofovir alafenamide fumarate (TAF)
4,T5,Procedure 1336 1382	TAF-containing fixed-dose combination regimens
5,R1,AND Arg1:T5 Arg2:T4
6,R2,AND Arg1:T5 Arg2:T3
7,T6,Drug 1384 1399	Ritonavir (RTV)
8,T7,Drug 1403 1420	cobicistat (COBI)
9,T8,Procedure 1421 1468	COBI-containing fixed-dose combination regimens
10,R3,AND Arg1:T8 Arg2:T7
11,R4,AND Arg1:T8 Arg2:T6
12,T9,Drug 1477 1480	TAF
13,T10,Drug 1470 1473	TDF
14,T11,Procedure 1481 1527	TAF-containing fixed-dose combination regimens
15,R5,AND Arg1:T11 Arg2:T9
16,R6,AND Arg1:T11 Arg2:T10
17,T12,Drug 1529 1532	RTV
18,T13,Drug 1536 1540	COBI
19,T14,Procedure 1541 1588	COBI-containing fixed-dose combination regimens
20,R7,AND Arg1:T14 Arg2:T13
21,R8,AND Arg1:T14 Arg2:T12
22,T15,Measurement 1590 1606	HIV-1 plasma RNA
23,T16,Value 1607 1629	less than 50 copies/mL
24,R9,Has_value Arg1:T15 Arg2:T16
25,T17,Temporal 1639 1674	within 90 days prior to study entry
26,R10,Has_temporal Arg1:T15 Arg2:T17
27,T18,Reference_point 1663 1674	study entry
28,R11,Has_index Arg1:T17 Arg2:T18
29,T19,"Non-representable 1675 2015	by any FDA-approved assay at any United States laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs."
30,T20,Multiplier 2017 2033	No more than one
31,T21,Measurement 2034 2050	HIV-1 plasma RNA
32,T22,Value 2051 2106	greater than or equal to 50 and less than 200 copies/mL
33,R12,Has_value Arg1:T21 Arg2:T22
34,R13,Has_multiplier Arg1:T21 Arg2:T20
35,T23,Temporal 2125 2145	in the past 6 months
36,T24,Measurement 2164 2180	HIV-1 plasma RNA
37,T25,Value 2181 2203	less than 50 copies/mL
38,R14,Has_value Arg1:T24 Arg2:T25
39,T26,Temporal 2153 2163	subsequent
40,R15,Has_temporal Arg1:T24 Arg2:T26
41,R16,Has_temporal Arg1:T21 Arg2:T23
42,R17,AND Arg1:T21 Arg2:T24
43,T27,Negation 2227 2229	no
44,T28,Measurement 2230 2246	plasma HIV-1 RNA
45,T29,Value 2247 2273	greater than 200 copies/mL
46,R18,Has_value Arg1:T28 Arg2:T29
47,R19,Has_negation Arg1:T28 Arg2:T27
48,T30,Temporal 2274 2314	within the 6 months prior to study entry
49,T31,Condition 2317 2321	HAND
50,T32,Condition 2333 2336	ANI
51,T33,Condition 2338 2341	MND
52,T34,Condition 2346 2349	HAD
53,*,OR T33 T34 T32
54,T35,"Scope 2333 2349	ANI, MND, or HAD"
55,R20,Subsumes Arg1:T31 Arg2:T35
56,T36,Temporal 2351 2386	within 60 days prior to study entry
57,R21,Has_temporal Arg1:T31 Arg2:T36
58,T39,Value 2459 2524	more than one standard deviation below appropriate normative data
59,T37,Measurement 2435 2457	neurocognitive testing
60,T38,Multiplier 2525 2554	in two domains of functioning
61,R23,Has_multiplier Arg1:T37 Arg2:T38
62,T40,Qualifier 2407 2420	at least mild
63,T41,Value 2421 2431	impairment
64,R22,Subsumes Arg1:T41 Arg2:T39
65,R24,Has_qualifier Arg1:T41 Arg2:T40
66,T42,Condition 2563 2591	severely confounding factors
67,T43,Negation 2560 2562	no
68,R25,Has_negation Arg1:T42 Arg2:T43
69,T44,Scope 2407 2591	at least mild impairment on neurocognitive testing (more than one standard deviation below appropriate normative data in two domains of functioning) and no severely confounding factors
70,R26,Subsumes Arg1:T31 Arg2:T44
71,T45,Measurement 2594 2625	Absolute neutrophil count (ANC)
72,T46,Value 2626 2659	greater than or equal to 500/mm^3
73,R27,Has_value Arg1:T45 Arg2:T46
74,T47,Measurement 2661 2671	Hemoglobin
75,T48,Value 2672 2705	greater than or equal to 7.5 g/dL
76,R28,Has_value Arg1:T47 Arg2:T48
77,T49,Measurement 2707 2721	Platelet count
78,T50,"Value 2722 2758	greater than or equal to 40,000/mm^3"
79,R29,Has_value Arg1:T49 Arg2:T50
80,T51,Measurement 2760 2770	Creatinine
81,T52,Value 2771 2826	less than or equal to 2.0 x upper limit of normal (ULN)
82,R30,Has_value Arg1:T51 Arg2:T52
83,T53,Measurement 2828 2856	Aspartate transaminase (AST)
84,T54,Value 2857 2886	less than or equal to 5 x ULN
85,R31,Has_value Arg1:T53 Arg2:T54
86,T55,Measurement 2888 2914	Alanine transaminase (ALT)
87,T56,Value 2915 2932	less than 3 x ULN
88,R32,Has_value Arg1:T55 Arg2:T56
89,T57,Measurement 2934 2954	Alkaline phosphatase
90,T58,Value 2955 2984	less than or equal to 5 x ULN
91,R33,Has_value Arg1:T57 Arg2:T58
92,T59,Measurement 2986 3001	Total bilirubin
93,T60,Value 3002 3021	less than 1.5 x ULN
94,R34,Has_value Arg1:T59 Arg2:T60
95,T61,Drug 3071 3086	indinavir (IDV)
96,T62,Drug 3091 3107	atazanavir (ATV)
97,T63,Procedure 3119 3126	regimen
98,*,OR T62 T61
99,T64,Scope 3071 3107	indinavir (IDV)- or atazanavir (ATV)
100,R35,Has_scope Arg1:T63 Arg2:T64
101,T65,Temporal 3127 3151	at the time of screening
102,T66,Measurement 3153 3168	total bilirubin
103,T67,Value 3169 3198	less than or equal to 5 x ULN
104,R36,Has_value Arg1:T66 Arg2:T67
105,R37,Has_temporal Arg1:T63 Arg2:T65
106,T68,"Scope 3071 3198	indinavir (IDV)- or atazanavir (ATV)-containing regimen at the time of screening, total bilirubin less than or equal to 5 x ULN"
107,T69,Scope 2986 3021	Total bilirubin less than 1.5 x ULN
108,*,OR T69 T68
109,T70,Measurement 3215 3242	Creatinine clearance (CrCl)
110,T71,Value 3243 3277	greater than or equal to 60 mL/min
111,R38,Has_value Arg1:T70 Arg2:T71
112,T72,Procedure 3311 3335	Cockcroft-Gault equation
113,R39,AND Arg1:T70 Arg2:T72
114,T73,"Pregnancy_considerations 3425 4115	Females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, ie, who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, hysterectomy or bilateral salpingectomy or bilateral oophorectomy or tubal ligation) must have a negative serum or urine pregnancy test by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC) / CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs within 48 hours prior to study entry"
115,T74,"Pregnancy_considerations 4117 4584	Females of reproductive potential must agree not to participate in the conception process (ie, active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must use at least one reliable form of contraception. Female participants must use contraceptives while receiving study treatment and for 6 weeks after stopping study treatment. More information on this criterion is available in the protocol."
116,T75,Person 4594 4599	women
117,T76,Person 4586 4589	Men
118,*,OR T75 T76
119,T77,Value 4600 4608;4616 4625	18 years and older
120,T78,Person 4612 4615	age
121,R40,Has_value Arg1:T78 Arg2:T77
122,T79,Observation 4634 4650	able to complete
123,T80,Procedure 4655 4679	neuropsychological tests
124,R41,Has_context Arg1:T80 Arg2:T79
125,T81,Post-eligibility 4681 4822	Ability and willingness of participant or a legally authorized representative (see protocol for more information) to provide informed consent
126,T82,Post-eligibility 4824 4878	Ability and willingness to take oral study medications
0,T1,Condition 0 11	Intolerance
1,T2,Condition 15 22	allergy
2,T3,Drug 26 29	ASA
3,*,OR T1 T2
4,T4,Scope 0 22	Intolerance or allergy
5,T5,Drug 31 42	clopidogrel
6,T6,Drug 46 57	ticlopidine
7,T7,Temporal 79 92	for 12 months
8,T8,Negation 58 68	precluding
9,T9,Procedure 69 78	treatment
10,R1,Has_temporal Arg1:T9 Arg2:T7
11,R2,Has_negation Arg1:T9 Arg2:T8
12,T10,Scope 58 92	precluding treatment for 12 months
13,*,OR T3 T5 T6
14,T11,"Scope 26 57	ASA, clopidogrel or ticlopidine"
15,R3,Has_scope Arg1:T11 Arg2:T10
16,R4,Has_scope Arg1:T4 Arg2:T11
17,T12,Competing_trial 94 149	Concurrent participation in other investigational study
18,T13,Condition 151 174	Femoral sheath (artery)
0,T1,Procedure 8 25	kidney transplant
1,T2,Qualifier 0 7	Primary
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Person 38 44	adults
0,T1,Measurement 0 3	PRA
1,T2,Value 4 9	> 50%
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 11 14	DSA
4,T4,Value 15 25	> 1500 MFI
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 27 44	Retransplantation
7,T6,Mood 63 74	planning to
8,T7,Drug 83 96	mycophenolate
9,T8,Negation 97 107	instead of
10,T9,Drug 108 118	everolimus
11,R3,Has_negation Arg1:T9 Arg2:T8
12,R4,AND Arg1:T7 Arg2:T9
13,R5,Has_mood Arg1:T7 Arg2:T6
14,T10,Mood 138 150	planning for
15,T11,Procedure 151 160	follow-up
16,T12,Visit 164 178	another center
17,R6,AND Arg1:T11 Arg2:T12
18,R7,Has_mood Arg1:T11 Arg2:T10
0,T1,Person 0 6	Female
1,T2,Temporal 7 15	at birth
2,T3,Reference_point 10 15	birth
3,R1,Has_index Arg1:T2 Arg2:T3
4,T4,Person 41 47	gender
5,T5,Value 34 40	female
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,Has_temporal Arg1:T1 Arg2:T2
8,T6,Post-eligibility 72 132	Able to understand and provide consent in English or Spanish
9,T7,Measurement 134 137;150 169	HIV 4th generation test
10,T8,Value 138 146	negative
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Measurement 171 181	Ag/Ab test
13,R5,Subsumes Arg1:T7 Arg2:T9
14,T10,Measurement 201 218	enzymeimmunoassay
15,T11,Measurement 229 236	HIV RNA
16,T12,Measurement 220 223	EIA
17,R6,Subsumes Arg1:T10 Arg2:T12
18,T13,Scope 201 235	enzymeimmunoassay (EIA) and HIV RN
19,*,OR T7 T13
20,R7,Has_value Arg1:T13 Arg2:T8
21,T14,Measurement 238 258	Creatinine clearance
22,T15,Value 259 270	= 60 ml/min
23,T16,Measurement 276 299	Cockcroft-Gault formula
24,R8,Subsumes Arg1:T14 Arg2:T16
25,R9,Has_value Arg1:T14 Arg2:T15
26,T17,Observation 302 316	Condomless sex
27,T18,Temporal 317 337	in the last 3 months
28,R10,Has_temporal Arg1:T17 Arg2:T18
29,T19,Multiplier 343 354	one or more
30,T20,Person 355 368	male partners
31,T21,Condition 372 390	unknown HIV status
32,T22,Observation 406 439	substantial risk of HIV infection
33,T23,Condition 426 439	HIV infection
34,R11,multi Arg1:T22 Arg2:T23
35,R12,Has_context Arg1:T21 Arg2:T22
36,R13,Has_multiplier Arg1:T20 Arg2:T19
37,R14,AND Arg1:T20 Arg2:T21
38,R15,AND Arg1:T17 Arg2:T20
39,T24,Observation 441 444	IDU
40,T25,Observation 446 454	bisexual
41,T26,Observation 456 469	sex for goods
42,T27,Observation 471 492	recently incarcerated
43,T28,Observation 494 532	from a country with HIV prevalence >1%
44,T29,Observation 534 564	interpersonal Partner Violence
45,T30,Condition 568 571	STI
46,T31,Condition 604 612	syphilis
47,T32,Condition 583 600	vaginal gonorrhea
48,T33,Condition 573 579;591 600	rectal gonorrhea
49,*,OR T32 T33 T31
50,T34,Scope 573 612	rectal or vaginal gonorrhea or syphilis
51,R16,Subsumes Arg1:T30 Arg2:T34
52,T35,Temporal 624 648	during the last 6 months
53,T36,Procedure 660 685;692 695	post-exposure prophylaxis use
54,T37,Procedure 687 690	PEP
55,R17,Subsumes Arg1:T36 Arg2:T37
56,T38,Temporal 696 721	during the last 12 months
57,T39,Multiplier 728 740	at least one
58,T40,Observation 754 768	sexual partner
59,T41,Condition 741 753	HIV-infected
60,R18,AND Arg1:T40 Arg2:T41
61,R19,Has_multiplier Arg1:T40 Arg2:T39
62,T42,Value 773 781	=4 weeks
63,R20,Has_value Arg1:T40 Arg2:T42
64,T43,"Observation 784 828	Sex for exchange of money, goods or services"
65,T44,Person 49 52	Age
66,T45,Value 53 70	18 years or older
67,R21,Has_value Arg1:T44 Arg2:T45
0,T1,Non-query-able 0 27	Not available for follow-up
1,T2,Condition 29 37	Pregnant
2,T3,Condition 41 55	breast-feeding
3,*,OR T2 T3
4,T4,Condition 57 78	Chronic pain syndrome
5,T5,Drug 101 121	analgesic medication
6,T6,Qualifier 97 100	any
7,R1,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Multiplier 122 132;147 152	on a daily basis
9,T8,Multiplier 122 126;136 152	on a near-daily basis
10,*,OR T7 T8
11,T9,Scope 122 152	on a daily or near-daily basis
12,R2,Has_scope Arg1:T5 Arg2:T9
13,T10,Scope 97 152	any analgesic medication on a daily or near-daily basis
14,R3,Subsumes Arg1:T4 Arg2:T10
15,T11,Condition 154 162	Allergic
16,T12,Condition 169 179	intolerant
17,T13,Drug 183 210	investigational medications
18,*,OR T12 T11
19,T14,Scope 154 179	Allergic to or intolerant
20,R4,AND Arg1:T14 Arg2:T13
21,T15,Condition 212 230	Contra-indications
22,T16,Drug 234 271	non-steroidal anti-inflammatory drugs
23,T17,Condition 287 303	hypersensitivity
24,T18,Drug 307 313	NSAIDs
25,T19,Drug 317 324	aspirin
26,*,OR T18 T19
27,T20,Scope 307 324	NSAIDs or aspirin
28,T21,Observation 276 283	history
29,R5,Has_temporal Arg1:T17 Arg2:T21
30,R6,Has_scope Arg1:T17 Arg2:T20
31,T22,Temporal 328 334	active
32,T23,Observation 338 345	history
33,*,OR T23 T22
34,T24,Condition 349 369	peptic ulcer disease
35,T25,Condition 371 388	chronic dyspepsia
36,T26,Temporal 393 399	active
37,T27,Observation 403 410	history
38,T28,Condition 414 436	gastrointestinal bleed
39,*,OR T27 T26
40,T29,Scope 328 345	active or history
41,*,OR T24 T25
42,T30,"Scope 349 388	peptic ulcer disease, chronic dyspepsia"
43,R7,Has_scope Arg1:T30 Arg2:T29
44,T31,Scope 393 410	active or history
45,R8,Has_scope Arg1:T28 Arg2:T31
46,T32,Qualifier 440 446	Severe
47,T33,Condition 447 460	heart failure
48,T34,Measurement 462 466	NYHA
49,T35,Value 467 477	2 or worse
50,R9,Has_value Arg1:T34 Arg2:T35
51,T36,Scope 462 477	NYHA 2 or worse
52,R10,Subsumes Arg1:T32 Arg2:T36
53,R11,Has_qualifier Arg1:T33 Arg2:T32
54,T37,Condition 482 494	hypertension
55,T38,Measurement 496 506	JNC7 stage
56,T39,Value 507 517	2 or worse
57,R12,Has_value Arg1:T38 Arg2:T39
58,T40,Condition 522 544	Chronic kidney disease
59,T41,Temporal 559 566	Current
60,T42,Drug 574 589	anti-coagulants
61,R13,Has_temporal Arg1:T42 Arg2:T41
62,T43,Condition 593 602	Hepatitis
63,T44,Condition 606 616	Alcoholism
64,R14,AND Arg1:T15 Arg2:T16
65,T45,Scope 212 271	Contra-indications to non-steroidal anti-inflammatory drugs
66,*,OR T17 T30 T28 T33 T37 T40 T42 T43 T44
67,T46,Scope 496 517	JNC7 stage 2 or worse
68,R15,Has_scope Arg1:T37 Arg2:T46
69,T47,"Scope 276 616	history of hypersensitivity to NSAIDs or aspirin 2) active or history of peptic ulcer disease, chronic dyspepsia, or active or history of gastrointestinal bleed 3) Severe heart failure (NYHA 2 or worse) 4) hypertension (JNC7 stage 2 or worse) 5) Chronic kidney disease 3 or worse 6) Current use of anti-coagulants 7) Hepatitis 8) Alcoholism"
70,R16,Subsumes Arg1:T45 Arg2:T47
71,T48,Condition 618 636	Contra-indications
72,T49,Drug 640 656	muscle relaxants
73,T50,Temporal 661 671	Concurrent
74,T51,Drug 679 703	centrally acting opioids
75,T52,Condition 708 724	Renal impairment
76,R17,Has_temporal Arg1:T51 Arg2:T50
77,T53,Condition 729 746	Liver abnormality
78,T54,Condition 757 766	cirrhosis
79,T55,Condition 770 786	elevated enzymes
80,*,OR T54 T55
81,T56,Scope 757 786	cirrhosis or elevated enzymes
82,R18,Subsumes Arg1:T53 Arg2:T56
83,*,OR T52 T53 T51 T68
84,T57,Drug 831 842	fluvoxamine
85,T58,Drug 844 860	fluoroquinolones
86,T59,Drug 862 872	amiodarone
87,T60,Drug 874 884	mexiletine
88,T61,Drug 886 897	propafenone
89,T62,Drug 899 908	verapamil
90,T63,Drug 910 920	cimetidine
91,T64,Drug 922 932	famotidine
92,T65,Drug 934 943	acyclovir
93,T66,Drug 945 956	ticlopidine
94,T67,Drug 958 982	oral contraceptive pills
95,*,OR T67 T66 T65 T64 T63 T62 T61 T60 T59 T58 T57
96,T68,"Scope 831 982	fluvoxamine, fluoroquinolones, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine, oral contraceptive pills"
97,R19,AND Arg1:T48 Arg2:T49
98,T69,Scope 618 656	Contra-indications to muscle relaxants
99,T70,"Scope 661 982	Concurrent use of centrally acting opioids; 2) Renal impairment; 3) Liver abnormality including cirrhosis or elevated enzymes 4) Use of any of the following medications: fluvoxamine, fluoroquinolones, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine, oral contraceptive pills"
100,R20,Subsumes Arg1:T69 Arg2:T70
0,T1,Measurement 0 22	end diastolic diameter
1,T2,Value 23 29	>60 mm
2,T3,Measurement 40 57	ejection fraction
3,T4,Value 58 62	<50%
4,R1,Has_value Arg1:T1 Arg2:T2
5,R2,Has_value Arg1:T3 Arg2:T4
6,*,OR T1 T3
7,T5,Informed_consent 64 88	written informed consent
8,T6,Person 90 93	age
9,T7,Value 94 103	>18 years
10,R3,Has_value Arg1:T6 Arg2:T7
0,T1,Person 0 5	Males
1,T2,Person 10 17	females
2,T3,Value 21 29;37 45	18 years or older
3,T4,Person 33 36	age
4,T5,Temporal 46 76	at the time of the vaccination
5,T6,Reference_point 65 76	vaccination
6,T7,Procedure 65 76	vaccination
7,R1,multi Arg1:T6 Arg2:T7
8,R2,Has_index Arg1:T5 Arg2:T6
9,R3,Has_value Arg1:T4 Arg2:T3
10,*,OR T1 T2
11,T8,Grammar_Error 6 9	and
12,R4,Has_temporal Arg1:T4 Arg2:T5
13,T9,Condition 85 107	chronic kidney disease
14,T10,Qualifier 78 84	Severe
15,R5,Has_qualifier Arg1:T9 Arg2:T10
16,T11,Condition 109 116;85 107	Stage 4 chronic kidney disease
17,T12,Condition 109 114;121 122;85 107	Stage 5 chronic kidney disease
18,T13,Grammar_Error 117 120	and
19,*,OR T11 T12
20,R6,Subsumes Arg1:T9 Arg2:T11
21,R7,Subsumes Arg1:T9 Arg2:T12
0,T1,Competing_trial 0 179	Patient has participated in a combination trial where ruxolitinib was dispensed in combination with another study medication and the patient is still receiving combination therapy
1,T2,"Pregnancy_considerations 182 374	Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test."
2,T3,"Pregnancy_considerations 376 611	Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study duration inclusive of the 30-day safety follow up"
0,T1,Person 20 25	years
1,T2,Value 17 19;26 34	19 or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Temporal 35 47	on screening
4,T4,Reference_point 38 47	screening
5,R2,Has_index Arg1:T3 Arg2:T4
6,R3,Has_temporal Arg1:T1 Arg2:T3
7,T5,Condition 63 87	type 2 diabetes mellitus
8,T6,Measurement 110 115	HbA1c
9,T7,Value 103 107;118 123	7.0% 11.0%
10,T8,Temporal 124 146	at the screening visit
11,T9,Reference_point 131 140	screening
12,R4,Has_index Arg1:T8 Arg2:T9
13,R5,Has_value Arg1:T6 Arg2:T7
14,R6,Has_temporal Arg1:T6 Arg2:T8
15,T10,Measurement 162 184	Fasting Plasma Glucose
16,T11,Value 185 194	<15mmol/L
17,T12,Value 195 203	270mg/dL
18,R7,Subsumes Arg1:T11 Arg2:T12
19,T13,Temporal 205 217	on screening
20,T14,Reference_point 208 217	screening
21,R8,Has_index Arg1:T13 Arg2:T14
22,R9,Has_value Arg1:T10 Arg2:T11
0,T1,Condition 0 9	Pregnancy
1,T2,Temporal 10 23	at enrollment
2,T3,Reference_point 13 23	enrollment
3,R1,Has_index Arg1:T2 Arg2:T3
4,T4,"Subjective_judgement 26 301	Any condition, which in the opinion of the provider, will seriously compromise the participant's ability to comply with the protocol, including adherence to PrEP medication dosing, such as active, untreated or unstable major mental illness (i.e. untreated psychotic disorder)"
5,T5,Qualifier 369 380	nephrotoxic
6,T6,Procedure 350 356	agents
7,R2,Has_qualifier Arg1:T6 Arg2:T5
8,T7,Procedure 384 389	drugs
9,T8,Qualifier 390 413	slow in renal excretion
10,R3,Has_qualifier Arg1:T7 Arg2:T8
11,T9,Undefined_semantics 304 333	Use of prohibited medications
12,*,OR T6 T7
13,T10,Observation 445 462	HIV vaccine trial
14,T11,Person 425 438	participation
15,T12,Temporal 416 424	Previous
16,R4,Has_context Arg1:T11 Arg2:T10
17,R5,Has_temporal Arg1:T11 Arg2:T12
18,T13,Person 464 476	Participants
19,R6,Has_temporal Arg1:T13 Arg2:T12
20,R7,Has_context Arg1:T13 Arg2:T10
21,T14,Procedure 520 527	placebo
22,R8,AND Arg1:T13 Arg2:T14
23,T15,Mood 532 535	not
24,R9,Has_mood Arg1:T13 Arg2:T15
25,T16,Condition 580 601	Primary HIV Infection
26,T17,Condition 603 606	PHI
27,R10,Subsumes Arg1:T16 Arg2:T17
28,T18,Condition 556 564	symptoms
29,T19,Condition 547 552	Signs
30,*,OR T19 T18
31,T20,Scope 547 564	Signs or symptoms
32,R11,AND Arg1:T20 Arg2:T16
0,T1,Condition 9 25	unusual response
1,T2,Drug 29 36	esmolol
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Competing_trial 38 75	inclusion in other randomized studies
4,T4,Drug 77 84	esmolol
5,T5,Temporal 100 123	in the previous 30 days
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Procedure 135 144	operation
8,T7,Qualifier 125 134	emergency
9,R3,Has_qualifier Arg1:T6 Arg2:T7
0,T1,Visit 11 13	ED
1,T2,Condition 40 43	LBP
2,T3,Observation 0 7	Present
3,R1,AND Arg1:T3 Arg2:T1
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Condition 56 60	pain
6,T5,Qualifier 73 141	between the lower border of the scapulae and the upper gluteal folds
7,R3,Has_qualifier Arg1:T4 Arg2:T5
8,T6,Scope 0 43	Present to ED primary for management of LBP
9,T7,Scope 56 141	pain originating between the lower border of the scapulae and the upper gluteal folds
10,R4,Subsumes Arg1:T6 Arg2:T7
11,T8,Condition 143 153	Flank pain
12,T9,Condition 163 167	pain
13,T10,Qualifier 185 226	tissues lateral to the paraspinal muscles
14,T11,Negation 233 236	not
15,R5,Has_qualifier Arg1:T9 Arg2:T10
16,R6,Subsumes Arg1:T8 Arg2:T9
17,R7,Has_negation Arg1:T8 Arg2:T11
18,T12,Condition 342 365	urinary tract infection
19,T13,Condition 267 275	etiology
20,T14,Negation 303 306	non
21,T15,Condition 323 333	etiologies
22,T16,Qualifier 279 287	low back
23,R8,Has_qualifier Arg1:T13 Arg2:T16
24,T17,Condition 367 380	ovarian cysts
25,T18,Condition 385 407	influenza like illness
26,T19,Negation 416 424	excluded
27,*,OR T18 T17 T12
28,T20,Scope 303 333	non-musculoskeletal etiologies
29,T21,"Scope 342 407	urinary tract infection, ovarian cysts, or influenza like illness"
30,R10,Subsumes Arg1:T20 Arg2:T21
31,R11,Has_negation Arg1:T20 Arg2:T19
32,T22,Condition 575 578	LBP
33,T23,Qualifier 544 557	non-radicular
34,T24,Qualifier 529 542	non-traumatic
35,T25,Qualifier 559 574	musculoskeletal
36,R12,Has_qualifier Arg1:T22 Arg2:T25
37,R13,Has_qualifier Arg1:T22 Arg2:T23
38,R14,Has_qualifier Arg1:T22 Arg2:T24
39,T26,Scope 251 287	Musculoskeletal etiology of low back
40,T27,"Scope 529 578	non-traumatic, non-radicular, musculoskeletal LBP"
41,R15,Subsumes Arg1:T26 Arg2:T27
42,T28,Non-representable 581 755	Patient is to be discharged home. Patients admitted to the hospital are more likely to be treated with parenteral medication and therefore are not appropriate for this study.
43,T29,Person 757 760	Age
44,T30,Value 761 766	18-64
45,R16,Has_value Arg1:T29 Arg2:T30
46,T31,Person 797 803	adults
47,T32,Value 804 825	younger than 65 years
48,R17,Has_value Arg1:T31 Arg2:T32
49,T33,Condition 859 866;878 885	adverse effects
50,T34,Drug 867 877	medication
51,R18,AND Arg1:T33 Arg2:T34
52,T35,Person 893 900	elderly
53,T36,Mood 841 855	increased risk
54,R19,Has_mood Arg1:T33 Arg2:T36
55,T37,Negation 903 906	Non
56,T38,Qualifier 907 916	radicular
57,T39,Condition 917 921	pain
58,T40,Qualifier 307 322	musculoskeletal
59,R9,Has_negation Arg1:T40 Arg2:T14
60,R20,Has_qualifier Arg1:T15 Arg2:T40
61,T41,Qualifier 251 266	Musculoskeletal
62,R21,Has_qualifier Arg1:T13 Arg2:T41
63,R22,Has_qualifier Arg1:T39 Arg2:T38
64,R23,Has_negation Arg1:T38 Arg2:T37
65,T42,Negation 940 948	excluded
66,T43,Condition 956 960	pain
67,T44,Qualifier 970 1016	below the gluteal folds in a radicular pattern
68,R24,Has_qualifier Arg1:T43 Arg2:T44
69,R25,Has_negation Arg1:T43 Arg2:T42
70,T45,Condition 1019 1023	Pain
71,T46,Temporal 1024 1041	duration <2 weeks
72,T47,Temporal 1024 1032;1043 1052	duration 336 hours
73,*,OR T46 T47
74,T48,Scope 1024 1053	duration <2 weeks (336 hours)
75,R26,Has_scope Arg1:T45 Arg2:T48
76,T49,Temporal 1174 1179	acute
77,T50,Condition 1180 1193	attack of LBP
78,T52,Negation 1205 1211	cannot
79,T53,Condition 1195 1204	back pain
80,R27,Has_temporal Arg1:T50 Arg2:T49
81,T54,Temporal 1161 1193	Prior to the acute attack of LBP
82,T55,Reference_point 1174 1193	acute attack of LBP
83,R28,Has_index Arg1:T54 Arg2:T55
84,R29,multi Arg1:T55 Arg2:T50
85,T51,Multiplier 1218 1253	more frequently than once per month
86,R30,Has_negation Arg1:T51 Arg2:T52
87,R31,Has_multiplier Arg1:T53 Arg2:T51
88,R32,Has_temporal Arg1:T53 Arg2:T54
89,T56,Condition 1371 1374	LBP
90,T57,Qualifier 1357 1370	Non-traumatic
91,R33,Has_qualifier Arg1:T56 Arg2:T57
92,T58,Qualifier 1395 1401	direct
93,T59,Qualifier 1379 1390	substantial
94,T60,Condition 1402 1408	trauma
95,*,OR T59 T58
96,T61,Scope 1379 1401	substantial and direct
97,R34,Has_scope Arg1:T60 Arg2:T61
98,T62,Negation 1376 1378	no
99,T63,Qualifier 1416 1420	back
100,R35,Has_qualifier Arg1:T60 Arg2:T63
101,T64,Temporal 1421 1446	within the previous month
102,R36,Has_temporal Arg1:T60 Arg2:T64
103,T65,Scope 1376 1446	no substantial and direct trauma to the back within the previous month
104,T66,Scope 1357 1374	Non-traumatic LBP
105,R37,Subsumes Arg1:T66 Arg2:T65
106,T67,Qualifier 1448 1470	Functionally impairing
107,T68,Condition 1471 1480	back pain
108,T69,Measurement 1513 1551	Roland-Morris Disability Questionnaire
109,T70,Temporal 1484 1492	baseline
110,T71,Value 1493 1505	score of > 5
111,R38,Has_value Arg1:T69 Arg2:T71
112,R39,Has_temporal Arg1:T69 Arg2:T70
113,R40,Has_qualifier Arg1:T68 Arg2:T67
114,T72,Scope 1448 1480	Functionally impairing back pain
115,T73,Scope 1484 1551	baseline score of > 5 on the Roland-Morris Disability Questionnaire
116,R41,Subsumes Arg1:T72 Arg2:T73
0,T1,Qualifier 0 6	Severe
1,T2,Qualifier 10 22	uncontrolled
2,T3,Condition 23 32	infection
3,*,OR T2 T1
4,T4,Scope 0 22	Severe or uncontrolled
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Condition 35 44	Sensitive
7,T6,Drug 48 59	the product
8,T7,Qualifier 63 68	other
9,T8,Drug 69 111	genetically engineered biological products
10,T9,Qualifier 117 141	Escherichia coli strains
11,R2,Has_qualifier Arg1:T8 Arg2:T9
12,T10,Condition 144 150;169 178	Mental disorders
13,T11,Condition 154 178	nervous system disorders
14,*,OR T11 T10
15,T12,Qualifier 181 187	Severe
16,T13,Condition 188 193;227 236	heart disorders
17,T14,Condition 195 199;227 236	lung disorders
18,T15,Condition 205 236	entral nervous system disorders
19,*,OR T13 T14 T15
20,T16,"Scope 188 236	heart, lung and central nervous system disorders"
21,R3,Has_qualifier Arg1:T16 Arg2:T12
22,T17,Condition 239 247	Pregnant
23,T18,Condition 251 260	lactating
24,T19,Person 261 266	women
25,*,OR T18 T17
26,T20,Measurement 274 289	total bilirubin
27,T21,Measurement 269 273	TBIL
28,T22,Measurement 293 296	ALT
29,T23,Measurement 297 321	alanine aminotransferase
30,T24,Measurement 323 326	AST
31,T25,Measurement 327 359	glutamic-oxalacetic transaminase
32,T26,Value 361 370	> 2.5×ULN
33,T27,Condition 416 432	liver metastases
34,T28,Measurement 434 438	TBIL
35,T29,Measurement 440 443	ALT
36,T30,Measurement 444 447	AST
37,T31,Value 448 454	>5×ULN
38,R4,Subsumes Arg1:T24 Arg2:T25
39,R5,Subsumes Arg1:T22 Arg2:T23
40,R6,Subsumes Arg1:T21 Arg2:T20
41,R7,Has_value Arg1:T24 Arg2:T26
42,R8,Has_value Arg1:T22 Arg2:T26
43,R9,Has_value Arg1:T21 Arg2:T26
44,R10,Has_value Arg1:T30 Arg2:T31
45,*,OR T21 T22 T24
46,R11,Has_value Arg1:T29 Arg2:T31
47,R12,Has_value Arg1:T28 Arg2:T31
48,T32,Measurement 457 459	Cr
49,T33,Measurement 460 470	creatinine
50,R13,Subsumes Arg1:T32 Arg2:T33
51,T34,Value 472 480	>1.5×ULN
52,R14,Has_value Arg1:T32 Arg2:T34
53,*,OR T30 T29 T28
54,T35,"Scope 269 370	TBIL(total bilirubin ), ALT(alanine aminotransferase),AST(glutamic-oxalacetic transaminase) > 2.5×ULN"
55,T36,"Scope 416 454	liver metastases, TBIL, ALT,AST >5×ULN"
56,*,OR T36 T35
0,T1,Procedure 0 12	immunization
1,T2,Drug 18 23	PPV23
2,T3,Temporal 24 44	within the last year
3,R1,AND Arg1:T1 Arg2:T2
4,T4,Condition 73 99	immunodeficiency condition
5,T5,Qualifier 63 72	suspected
6,T6,Qualifier 50 59	confirmed
7,T7,Condition 111 139;146 155	human immunodeficiency virus infection
8,T8,Condition 141 144	HIV
9,R2,Subsumes Arg1:T7 Arg2:T8
10,T9,Condition 157 182	haematological malignancy
11,T10,Condition 189 216	congenital immunodeficiency
12,*,OR T9 T10 T7
13,T11,"Scope 111 216	human immunodeficiency virus (HIV) infection, haematological malignancy, or a congenital immunodeficiency"
14,R3,Subsumes Arg1:T4 Arg2:T11
15,T12,Scope 50 72	confirmed or suspected
16,R4,Has_scope Arg1:T4 Arg2:T12
17,T13,Condition 229 245	allergic disease
18,T14,Condition 229 237;249 258	allergic reactions
19,*,OR T13 T14
20,T15,Scope 229 258	allergic disease or reactions
21,T16,Qualifier 272 315	exacerbated by any component of the vaccine
22,T17,Procedure 308 315	vaccine
23,R5,multi Arg1:T16 Arg2:T17
24,R6,Has_qualifier Arg1:T15 Arg2:T16
25,T18,Condition 328 344	allergic disease
26,T19,Qualifier 358 387	stimulated by the vaccination
27,T20,Procedure 376 387	vaccination
28,R7,multi Arg1:T19 Arg2:T20
29,R8,Has_qualifier Arg1:T18 Arg2:T19
30,T21,Procedure 411 436	immunosuppressive therapy
31,T22,Procedure 460 483	topical corticosteroids
32,T23,Negation 447 456	exception
33,R9,Has_negation Arg1:T22 Arg2:T23
34,T24,Temporal 485 506;527 541	for more than 14 days of vaccination
35,T25,Temporal 511 541	within 6 months of vaccination
36,T26,Scope 485 541	for more than 14 days and within 6 months of vaccination
37,R10,Has_scope Arg1:T21 Arg2:T26
38,T27,Reference_point 530 541	vaccination
39,R11,Has_index Arg1:T25 Arg2:T27
40,R12,Has_index Arg1:T24 Arg2:T27
41,R13,Has_scope Arg1:T22 Arg2:T26
42,T28,Procedure 584 599	immunoglobulins
43,T29,Procedure 611 625	blood products
44,T30,Temporal 626 649	during the study period
45,T31,Temporal 653 704	within the three months preceding the study vaccine
46,T32,Reference_point 637 649	study period
47,T33,Reference_point 691 704	study vaccine
48,R14,Has_index Arg1:T30 Arg2:T32
49,R15,Has_index Arg1:T31 Arg2:T33
50,*,OR T30 T31
51,*,OR T28 T29
52,T34,Grammar_Error 600 606	and/or
53,T35,Scope 584 625	immunoglobulins and/or any blood products
54,T36,Scope 626 704	during the study period or within the three months preceding the study vaccine
55,R16,Has_scope Arg1:T35 Arg2:T36
56,T37,Procedure 765 772	vaccine
57,T38,Procedure 757 761	drug
58,T39,Qualifier 723 738	investigational
59,T40,Qualifier 742 756	non-registered
60,*,OR T39 T40
61,*,OR T38 T37
62,T41,Scope 757 772	drug or vaccine
63,T42,Scope 723 756	investigational or non-registered
64,R17,Has_scope Arg1:T41 Arg2:T42
65,T43,Temporal 773 796	during the study period
66,T44,Temporal 800 842	within 30 days preceding the study vaccine
67,T45,Reference_point 784 796	study period
68,T46,Reference_point 829 842	study vaccine
69,R18,Has_index Arg1:T43 Arg2:T45
70,R19,Has_index Arg1:T44 Arg2:T46
71,*,OR T43 T44
72,T47,Scope 773 842	during the study period or within 30 days preceding the study vaccine
73,R20,Has_scope Arg1:T41 Arg2:T47
74,T48,Procedure 864 871	vaccine
75,T49,Temporal 872 962	during the period starting one month before the dose of vaccine and ending one month after
76,T51,Reference_point 916 935	the dose of vaccine
77,T52,Procedure 928 935	vaccine
78,R21,Has_index Arg1:T49 Arg2:T51
79,R22,multi Arg1:T51 Arg2:T52
80,T50,Condition 964 973	pregnancy
0,T1,Non-query-able 0 2	NA
0,T1,"Competing_trial 0 321	Patient is currently enrolled in a Novartis OGD or GMA-sponsored or Incyte-sponsored clinical study (where Incyte can delegate the sponsorship to a preferred CRO, if applicable) that is approved to enroll into this rollover study, is receiving ruxolitinib and has fulfilled all of the requirements of the parent protocol."
1,T2,Drug 379 390	ruxolitinib
2,T3,"Non-query-able 323 425	Patient is currently benefiting from the treatment with ruxolitinib, as determined by the investigator"
3,T4,"Post-eligibility 427 644	Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures"
4,T5,Condition 683 702	progressive disease
5,T6,Drug 773 784	ruxolitinib
6,T7,"Informed_consent 786 1021	Written informed consent obtained prior to enrolling in roll-over study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness"
0,T1,Condition 0 10	vulnerable
1,T2,Qualifier 47 86	Finnish law concerning clinical studies
2,T3,Condition 88 96	disabled
3,T4,Person 98 106	children
4,T5,Condition 108 116	pregnant
5,T6,Condition 120 134	breast-feeding
6,T7,Person 135 140	women
7,T8,Observation 142 151	prisoners
8,*,OR T3 T4 T5 T6 T7 T8
9,R1,Has_qualifier Arg1:T1 Arg2:T2
10,T9,Scope 0 86	vulnerable study subjects such as described in Finnish law concerning clinical studies
11,T10,"Scope 88 151	disabled, children, pregnant or breast-feeding women, prisoners"
12,R2,Subsumes Arg1:T9 Arg2:T10
0,T1,Condition 13 32	nonfunctional P-NET
1,T2,Mood 0 9	suspicion
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Procedure 36 46	primary CT
4,T4,Condition 52 68	hypervascularity
5,T5,Procedure 73 76	MRI
6,*,OR T5 T3
7,R2,AND Arg1:T1 Arg2:T3
8,R3,Subsumes Arg1:T3 Arg2:T4
9,T6,Informed_consent 78 101	signed informed consent
0,T1,Mood 0 8	Symptoms
1,T2,Condition 12 21	ischaemia
2,R1,Has_mood Arg1:T2 Arg2:T1
3,T3,Qualifier 44 55	significant
4,T4,Multiplier 24 27	New
5,T5,Multiplier 31 43	presumed new
6,*,OR T4 T5
7,T6,Condition 56 73	ST-T wave changes
8,R2,Has_qualifier Arg1:T6 Arg2:T3
9,T7,Scope 44 74	significant ST-T wave changes
10,T8,Scope 24 43	New or presumed new
11,T9,Scope 44 73	significant ST-T wave changes
12,R3,Has_scope Arg1:T9 Arg2:T8
13,T10,Condition 90 110	pathological Q waves
14,T11,Procedure 114 117	ECG
15,R4,AND Arg1:T11 Arg2:T10
16,T12,Procedure 120 127	Imaging
17,T13,Condition 128 136	evidence
18,R5,AND Arg1:T12 Arg2:T13
19,T14,Multiplier 147 159	presumed new
20,T15,Multiplier 140 143	new
21,*,OR T15 T14
22,T16,Condition 160 185	loss of viable myocardium
23,T17,Scope 140 159	new or presumed new
24,R7,Has_scope Arg1:T13 Arg2:T17
25,T18,Condition 189 221	regional wall motion abnormality
26,*,OR T16 T18
27,T19,Scope 160 221	loss of viable myocardium or regional wall motion abnormality
28,R6,Has_scope Arg1:T13 Arg2:T19
0,T1,Person 0 3	Age
1,T2,Value 4 27	from 40 to 80 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 69 80	age related
4,T4,Condition 81 90	cataracts
5,T5,Qualifier 59 68	bilateral
6,R2,Has_qualifier Arg1:T4 Arg2:T3
7,R3,Has_qualifier Arg1:T4 Arg2:T5
8,T6,Procedure 110 138	cataract phacoemulsification
9,T7,Qualifier 100 109	bilateral
10,T8,Procedure 148 177	Intraocular Lens implantation
11,T9,Scope 110 177	cataract phacoemulsification combined Intraocular Lens implantation
12,R4,Has_qualifier Arg1:T9 Arg2:T7
13,T10,Non-query-able 180 256	Willing to undergo second eye surgery within 7 days after first eye surgery;
14,T11,Non-query-able 258 332	The potential postoperative visual acuity of 20/40 or better in both eyes;
15,T12,Measurement 347 381	measurement of corneal astigmatism
16,T13,Procedure 421 463	multifocal intraocular lenses implantation
17,T14,Value 408 416	suitable
18,R5,AND Arg1:T14 Arg2:T13
19,R6,Has_value Arg1:T12 Arg2:T14
20,T15,Temporal 334 346	Preoperative
21,R7,Has_temporal Arg1:T12 Arg2:T15
22,T16,Post-eligibility 466 548	Capability to understand the informed consent and willing and able to attend study
0,T1,Condition 0 11	Sensitivity
1,T2,Drug 15 26	pilocarpine
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 38 56	Sjögren's syndrome
4,T4,Qualifier 28 37	Secondary
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 59 84	Type II diabetes mellitus
7,T6,Condition 87 91	AIDS
8,T7,Pregnancy_considerations 94 121	pregnant or lactating women
9,T8,Condition 124 132	Glaucoma
10,T9,Condition 148 154	asthma
11,T10,Qualifier 135 147	Uncontrolled
12,R3,Has_qualifier Arg1:T9 Arg2:T10
13,T11,Condition 157 194	Chronic obstructive pulmonary disease
14,T12,Condition 197 211	Renal diseases
15,T13,Condition 221 244	cardiovascular diseases
16,T14,Qualifier 214 220	Severe
17,R4,Has_qualifier Arg1:T13 Arg2:T14
18,T15,Condition 247 273	Gastrointestinal disorders
19,T16,Condition 276 297	Hepatic insufficiency
0,T1,Visit 17 27	outpatient
1,T2,Post-eligibility 30 130	Informed consent: Subjects must give their signed and dated written informed consent to participate.
2,T3,Person 140 144	Male
3,T4,Person 148 154	female
4,*,OR T4 T3
5,T5,Pregnancy_considerations 156 448	Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception.
6,T6,Person 450 453	Age
7,T7,Value 455 474	>=40 and <=80 years
8,T8,Person 478 481	age
9,R1,Has_value Arg1:T8 Arg2:T7
10,R2,Has_value Arg1:T6 Arg2:T7
11,*,OR T6 T8
12,T9,Temporal 482 494	at Screening
13,T10,Reference_point 485 494	Screening
14,R3,Has_index Arg1:T9 Arg2:T10
15,R4,Has_temporal Arg1:T8 Arg2:T9
16,R5,Has_temporal Arg1:T6 Arg2:T9
17,T11,Multiplier 564 579	>=10 pack-years
18,T12,Observation 583 600	cigarette smoking
19,R6,Has_multiplier Arg1:T12 Arg2:T11
20,T13,Temporal 601 613	at screening
21,R7,Has_temporal Arg1:T12 Arg2:T13
22,T14,Observation 553 560	history
23,T15,Temporal 547 552	prior
24,T16,Temporal 536 543	current
25,*,OR T15 T16
26,T17,Scope 536 552	current or prior
27,R8,Has_temporal Arg1:T12 Arg2:T14
28,R9,Has_scope Arg1:T12 Arg2:T17
29,T18,Condition 625 641	Previous smokers
30,T19,Observation 672 687	stopped smoking
31,T20,Temporal 688 726	for at least 6 months prior to Visit 1
32,T21,Reference_point 719 726	Visit 1
33,R10,Has_index Arg1:T20 Arg2:T21
34,R11,Has_temporal Arg1:T19 Arg2:T20
35,T22,Scope 672 726	stopped smoking for at least 6 months prior to Visit 1
36,R12,Subsumes Arg1:T18 Arg2:T22
37,T23,Parsing_Error 729 749	Airflow Obstruction:
38,T24,Drug 781 790	albuterol
39,T25,Drug 791 801	salbutamol
40,T26,Temporal 776 801	post-albuterol/salbutamol
41,T27,Measurement 802 878	forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio
42,T28,Value 882 888	<=0.70
43,R13,Has_value Arg1:T27 Arg2:T28
44,T29,Temporal 889 901	at Screening
45,R14,Has_temporal Arg1:T27 Arg2:T29
46,T30,Qualifier 776 801	post-albuterol/salbutamol
47,R15,Has_temporal Arg1:T30 Arg2:T26
48,T31,Reference_point 781 801	albuterol/salbutamol
49,R16,Has_index Arg1:T26 Arg2:T31
50,R17,Has_qualifier Arg1:T27 Arg2:T30
51,T32,Qualifier 939 964	post-albuterol/salbutamol
52,T33,Temporal 939 964	post-albuterol/salbutamol
53,T34,Drug 944 953	albuterol
54,T35,Drug 954 964	salbutamol
55,T36,Reference_point 944 964	albuterol/salbutamol
56,R18,Has_temporal Arg1:T32 Arg2:T33
57,R19,Has_index Arg1:T33 Arg2:T36
58,T37,Measurement 965 969	FEV1
59,R20,Has_qualifier Arg1:T37 Arg2:T32
60,T38,Value 970 1011	>=50 and <=70% of predicted normal values
61,T39,Qualifier 1023 1059	using NHANES III reference equations
62,R21,Has_value Arg1:T37 Arg2:T38
63,R22,Has_qualifier Arg1:T38 Arg2:T39
64,T40,Temporal 1095 1107	at Screening
65,T41,Reference_point 1098 1107	Screening
66,R23,Has_index Arg1:T40 Arg2:T41
67,R24,Has_temporal Arg1:T37 Arg2:T40
68,T42,Qualifier 1120 1139	Post-bronchodilator
69,T43,Temporal 1120 1139	Post-bronchodilator
70,T44,Drug 1125 1139	bronchodilator
71,T45,Reference_point 1125 1139	bronchodilator
72,R25,Has_index Arg1:T43 Arg2:T45
73,R26,Has_temporal Arg1:T42 Arg2:T43
74,T46,Procedure 1140 1150	spirometry
75,R27,Has_qualifier Arg1:T46 Arg2:T42
76,T47,Temporal 1169 1199	approximately 15 minutes after
77,R28,Has_temporal Arg1:T46 Arg2:T47
78,T48,Multiplier 1234 1235	4
79,T49,Procedure 1236 1247	inhalations
80,T50,Qualifier 1216 1233	self-administered
81,R29,Has_multiplier Arg1:T49 Arg2:T48
82,R30,Has_qualifier Arg1:T49 Arg2:T50
83,T51,Multiplier 1261 1267	400mcg
84,R31,Subsumes Arg1:T48 Arg2:T51
85,T52,Drug 1272 1281	albuterol
86,T53,Drug 1282 1292	salbutamol
87,T54,Scope 1272 1292	albuterol/salbutamol
88,R32,Has_scope Arg1:T49 Arg2:T54
89,T55,Procedure 1299 1326	metered dose inhaler (MDI )
90,T56,Qualifier 1326 1355	with a valved-holding chamber
91,R33,Has_qualifier Arg1:T55 Arg2:T56
92,R34,AND Arg1:T49 Arg2:T55
93,T57,Condition 1431 1447	Symptoms of COPD
94,T58,Value 1463 1480	score 2 or higher
95,T59,Measurement 1488 1535	modified Medical Research Council Dyspnea scale
96,R35,Has_value Arg1:T59 Arg2:T58
97,R36,Subsumes Arg1:T57 Arg2:T59
98,T60,Parsing_Error 1547 1570	Cardiovascular disease:
99,T61,Value 1585 1596	>= 40 years
100,T62,Person 1600 1603	age
101,R37,Has_value Arg1:T62 Arg2:T61
102,T63,Condition 1688 1717	coronary artery disease (CAD)
103,T64,Condition 1774 1807	peripheral vascular disease (PVD)
104,T65,Condition 1817 1823	stroke
105,T66,Temporal 1808 1816	Previous
106,T67,Observation 1718 1729	Established
107,T68,Observation 1739 1753	clinical signs
108,T69,Procedure 1757 1772	imaging studies
109,T70,Condition 1833 1835	MI
110,T71,Condition 1836 1853	Diabetes mellitus
111,T72,Condition 1859 1879	target organ disease
112,T73,Parsing_Error 1880 1882	OR
113,R38,AND Arg1:T71 Arg2:T72
114,*,OR T71 T70 T65 T64 T63
115,T74,Temporal 1824 1832	Previous
116,R39,Has_temporal Arg1:T70 Arg2:T74
117,R40,Has_temporal Arg1:T65 Arg2:T66
118,T75,Scope 1739 1772	clinical signs or imaging studies
119,R41,Subsumes Arg1:T67 Arg2:T75
120,R42,Has_context Arg1:T64 Arg2:T67
121,T76,Observation 1632 1643	Established
122,T77,Observation 1653 1667	clinical signs
123,T78,Procedure 1671 1686	imaging studies
124,*,OR T77 T78
125,*,OR T69 T68
126,T79,Scope 1653 1686	clinical signs or imaging studies
127,R43,Subsumes Arg1:T76 Arg2:T79
128,R44,Has_context Arg1:T63 Arg2:T76
129,T80,Value 1897 1907	>=60 years
130,T81,Person 1911 1914	age
131,R45,Has_value Arg1:T81 Arg2:T80
132,T82,Condition 1959 1979	hypercholesterolemia
133,T83,Procedure 1947 1979	treated for hypercholesterolemia
134,R46,AND Arg1:T83 Arg2:T82
135,T84,Procedure 1986 2010	treated for hypertension
136,T85,Condition 1998 2010	hypertension
137,R47,AND Arg1:T84 Arg2:T85
138,T86,Condition 2029 2046	diabetes mellitus
139,T87,Procedure 2017 2046	treated for diabetes mellitus
140,R48,AND Arg1:T87 Arg2:T86
141,T88,Procedure 2053 2092	treated for peripheral vascular disease
142,T89,Condition 2065 2092	peripheral vascular disease
143,R49,AND Arg1:T88 Arg2:T89
144,*,OR T83 T84 T87 T88
0,T1,Person 0 5	Women
1,T2,Person 9 16	any age
2,T3,Value 22 27	early
3,T4,Measurement 28 33	stage
4,T5,Condition 34 47	breast cancer
5,T6,Measurement 49 54	stage
6,T7,Value 55 59	I-II
7,T9,Scope 49 59	stage I-II
8,R3,Has_value Arg1:T4 Arg2:T3
9,T10,Measurement 65 114	American Society of Anesthesiologists (ASA) score
10,T11,Value 118 122	I-II
11,R4,Has_value Arg1:T6 Arg2:T7
12,R5,Has_value Arg1:T10 Arg2:T11
13,T8,Scope 22 33	early stage
14,R1,Subsumes Arg1:T8 Arg2:T9
15,R2,Has_scope Arg1:T5 Arg2:T8
16,R6,AND Arg1:T5 Arg2:T10
0,T1,Informed_consent 0 47	Unable or unwilling to provide informed consent
1,T2,Condition 57 65	ischemia
2,T3,Qualifier 50 56	Active
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 67 81	acute thrombus
5,T5,Procedure 95 115	coronary angiography
6,T6,Condition 128 146	ST segment changes
7,T7,Procedure 163 166	ECG
8,T8,Condition 199 201	VT
9,T9,Qualifier 179 189	reversible
10,T10,Condition 208 231	drug-induced arrhythmia
11,T11,Condition 245 268	acute coronary syndrome
12,T12,"Temporal 269 284	within 30 days,"
13,T13,Procedure 285 311	coronary revascularization
14,T14,Temporal 313 321	<90 days
15,T15,Procedure 322 336	bypass surgery
16,T16,Temporal 338 346	<30 days
17,T17,Procedure 347 381	percutaneous coronary intervention
18,T18,Condition 416 422	angina
19,T19,Measurement 392 412	CCS functional class
20,T20,Value 413 415	IV
21,T21,Non-query-able 424 554	Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia
22,R2,AND Arg1:T5 Arg2:T4
23,R3,AND Arg1:T7 Arg2:T6
24,R4,Has_qualifier Arg1:T8 Arg2:T9
25,R5,Subsumes Arg1:T8 Arg2:T10
26,R6,Has_temporal Arg1:T11 Arg2:T12
27,R7,Has_temporal Arg1:T15 Arg2:T14
28,R8,Has_temporal Arg1:T17 Arg2:T16
29,T22,"Scope 313 381	<90 days bypass surgery, <30 days percutaneous coronary intervention"
30,R9,Subsumes Arg1:T13 Arg2:T22
31,R10,Has_value Arg1:T19 Arg2:T20
32,R11,AND Arg1:T18 Arg2:T19
33,T23,"Scope 67 381	acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention"
34,R12,Subsumes Arg1:T2 Arg2:T23
35,*,OR T2 T18
36,T24,Condition 643 650	allergy
37,T25,Condition 652 663	intolerance
38,T26,Condition 667 683	contraindication
39,*,OR T26 T25 T24
40,T27,"Scope 643 683	allergy, intolerance or contraindication"
41,T28,Drug 584 603	antiarrhythmic drug
42,R13,AND Arg1:T27 Arg2:T28
43,T29,Condition 714 739	left ventricular thrombus
44,T30,Device 743 760;772 778	mechanical aortic valves
45,T31,Device 743 753;765 778	mechanical mitral valves
46,*,OR T31 T30 T29
47,T32,Procedure 797 824	catheter ablation procedure
48,T33,Condition 829 831	VT
49,R14,AND Arg1:T32 Arg2:T33
50,T34,Condition 840 853	renal failure
51,T35,Measurement 855 875	Creatinine clearance
52,T36,Value 876 886	<15 mL/min
53,T37,Measurement 894 915	NYHA Functional class
54,T38,Value 916 918	IV
55,T39,Condition 919 932	heart failure
56,T40,Condition 939 955	systemic illness
57,T41,Observation 972 980	survival
58,T42,Value 984 991	<1 year
59,R15,AND Arg1:T34 Arg2:T35
60,R16,Has_value Arg1:T35 Arg2:T36
61,R17,AND Arg1:T39 Arg2:T37
62,R18,Has_value Arg1:T37 Arg2:T38
63,*,OR T34 T39 T40
64,R19,Has_context Arg1:T40 Arg2:T41
65,R20,Has_value Arg1:T41 Arg2:T42
66,T43,Condition 1009 1043	ST elevation myocardial infarction
67,T44,Condition 1047 1066	non-ST elevation MI
68,T45,Temporal 1068 1077	< 30 days
69,T46,Non-query-able 1081 1164	ote that biomarker elevation alone after ventricular arrhythmias does not denote MI
70,T47,Condition 1171 1179	pregnant
71,*,OR T43 T44
72,T48,Scope 1009 1066	ST elevation myocardial infarction or non-ST elevation MI
73,R21,Has_temporal Arg1:T48 Arg2:T45
0,T1,Condition 0 27	acute myocardial infarction
1,T2,Condition 29 42	heart failure
2,T3,Condition 44 62	neoplastic disease
3,T4,Condition 64 80	chronic diseases
4,T5,Qualifier 86 121	may affect the inflammatory profile
5,T6,Qualifier 127 135	systemic
6,T7,Qualifier 140 150	epicardial
7,*,OR T6 T7
8,T8,Scope 127 150	systemic and epicardial
9,R1,Has_qualifier Arg1:T4 Arg2:T5
10,R2,Has_scope Arg1:T4 Arg2:T8
11,T9,Condition 152 158	cancer
12,T10,Condition 160 191	chronic intestinal inflammation
13,T11,Condition 193 202	hepatitis
14,T12,Condition 204 208	AIDS
15,*,OR T12 T11 T10 T9
16,T13,"Scope 152 208	cancer, chronic intestinal inflammation, hepatitis, AIDS"
17,T14,Scope 64 150	chronic diseases that may affect the inflammatory profile both systemic and epicardial
18,R3,Subsumes Arg1:T14 Arg2:T13
19,T15,Observation 211 226	life expectancy
20,T16,Value 227 237	< 6 months
21,R4,Has_value Arg1:T15 Arg2:T16
22,T17,Procedure 248 252	CABG
23,T18,Temporal 239 247	previous
24,R5,Has_temporal Arg1:T17 Arg2:T18
25,T19,Procedure 266 297	open heart surgery intervention
26,T20,Condition 299 322	acute coronary syndrome
27,T21,Qualifier 260 265	other
28,R6,Has_qualifier Arg1:T19 Arg2:T21
29,*,OR T17 T19 T20 T15 T14 T3 T2 T1
0,T1,Non-query-able 0 56	The informed consent has been obtained from the patient.
1,T2,Post-eligibility 0 56	The informed consent has been obtained from the patient.
2,T3,Condition 95 107	colon cancer
3,T4,Qualifier 86 94	stage II
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Measurement 129 152	ECOG health rating (PS)
6,T6,Value 154 163	0-1 score
7,T7,Value 115 128	moderate/good
8,R2,Subsumes Arg1:T7 Arg2:T6
9,R3,Has_value Arg1:T5 Arg2:T7
10,T8,Drug 189 210	anti-cancer treatment
11,T9,Negation 186 188	no
12,T10,Temporal 211 233	before primary surgery
13,T11,Procedure 218 233	primary surgery
14,T12,Reference_point 218 233	primary surgery
15,R4,Has_index Arg1:T10 Arg2:T12
16,R5,Has_temporal Arg1:T8 Arg2:T10
17,R6,Has_negation Arg1:T8 Arg2:T9
18,T13,Procedure 256 273;296 311	radical operation negative margin
19,T14,Condition 278 290	colon cancer
20,R7,AND Arg1:T13 Arg2:T14
0,T1,Condition 12 27	ocular diseases
1,T2,Temporal 0 11	Preexisting
2,T3,Condition 31 41	conditions
3,T4,Negation 42 52	other than
4,T5,Condition 65 74	cataracts
5,T6,Qualifier 53 64	age related
6,R1,Has_qualifier Arg1:T5 Arg2:T6
7,T7,Condition 81 98	contraindications
8,T8,Procedure 103 119	cataract surgery
9,R2,AND Arg1:T7 Arg2:T8
10,R3,Has_negation Arg1:T5 Arg2:T4
11,R4,AND Arg1:T3 Arg2:T5
12,*,OR T3 T1 T7
13,R5,Has_temporal Arg1:T1 Arg2:T2
14,T9,Temporal 122 133	Preexisting
15,T10,Condition 134 151	systemic diseases
16,R6,Has_temporal Arg1:T10 Arg2:T9
17,T11,Condition 155 165	conditions
18,T12,Qualifier 171 208	may confound the results of the study
19,R7,Has_qualifier Arg1:T11 Arg2:T12
20,*,OR T10 T11
21,T13,Procedure 220 234	ocular surgery
22,T14,Temporal 211 219	Previous
23,R8,Has_temporal Arg1:T13 Arg2:T14
24,T15,Condition 246 259	ocular trauma
25,T16,Qualifier 265 302	may confound the results of the study
26,*,OR T15 T13
27,T17,Scope 211 259	Previous ocular surgery history or ocular trauma
28,R9,Has_qualifier Arg1:T17 Arg2:T16
29,T18,Procedure 313 329	combined surgery
30,T19,Mood 305 312	Require
31,R10,Has_mood Arg1:T18 Arg2:T19
32,T20,Qualifier 335 372	may confound the results of the study
33,R11,Has_qualifier Arg1:T18 Arg2:T20
34,T21,Non-query-able 375 457	Previous participation in other clinical trial within 30 days of this study start;
35,T22,Drug 471 489	ocular medications
36,T23,Drug 459 467;478 489	Systemic medications
37,T24,Qualifier 495 539	may confound the outcome of the intervention
38,*,OR T23 T22
39,T25,Scope 459 489	Systemic or ocular medications
40,R12,Has_qualifier Arg1:T25 Arg2:T24
41,T26,Condition 541 549	Pregnant
42,T27,Condition 551 560	lactating
43,T28,Mood 565 583	planning to become
44,T29,Condition 584 592	pregnant
45,R13,Has_mood Arg1:T29 Arg2:T28
46,T30,Temporal 593 623	during the course of the trial
47,*,OR T26 T27 T29
48,T31,"Scope 541 592	Pregnant, lactating, or planning to become pregnant"
49,R14,Has_temporal Arg1:T31 Arg2:T30
0,T1,Pregnancy_considerations 0 47	Pregnancy: Women who are pregnant or lactating.
1,T2,Condition 49 55	Asthma
2,T3,Condition 94 100	asthma
3,T4,Temporal 73 80	current
4,R1,Has_temporal Arg1:T3 Arg2:T4
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,T5,Temporal 119 124	prior
7,T6,Observation 125 132	history
8,T7,Condition 136 142	asthma
9,R3,Has_temporal Arg1:T7 Arg2:T6
10,R4,Has_temporal Arg1:T7 Arg2:T5
11,T8,Condition 197 201	COPD
12,T9,Condition 205 235	alpha 1-antitrypsin deficiency
13,T10,Condition 315 319	COPD
14,T11,Condition 257 287	alpha-1 antitrypsin deficiency
15,R5,AND Arg1:T10 Arg2:T11
16,R6,Subsumes Arg1:T9 Arg2:T10
17,T12,Condition 372 384	tuberculosis
18,T13,Condition 322 349	Other respiratory disorders
19,T14,Undefined_semantics 322 349	Other respiratory disorders
20,T15,Condition 386 397	lung cancer
21,T16,Condition 399 413	bronchiectasis
22,T17,Condition 415 426	sarcoidosis
23,T18,Condition 428 446	pulmonary fibrosis
24,T19,Condition 448 470	pulmonary hypertension
25,T20,Condition 472 498	interstitial lung diseases
26,T21,Condition 508 533	active pulmonary diseases
27,*,OR T12 T15 T16 T17 T18 T19 T20 T21
28,T22,"Scope 372 533	tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases"
29,R7,Subsumes Arg1:T13 Arg2:T22
30,T23,Procedure 536 550	Lung resection
31,T24,Procedure 554 569	transplantation
32,*,OR T24 T23
33,T25,Procedure 585 614	lung volume reduction surgery
34,T26,Temporal 615 654	within the 12 months prior to Screening
35,T27,Reference_point 645 654	Screening
36,R8,Has_index Arg1:T26 Arg2:T27
37,T28,Procedure 671 686	lung transplant
38,T29,Condition 658 686	having had a lung transplant
39,R9,AND Arg1:T29 Arg2:T28
40,T30,Condition 580 614	with lung volume reduction surgery
41,R10,AND Arg1:T30 Arg2:T25
42,*,OR T30 T29
43,T31,Scope 580 686	with lung volume reduction surgery within the 12 months prior to Screening or having had a lung transplant
44,T32,Scope 536 569	Lung resection or transplantation
45,R11,Subsumes Arg1:T32 Arg2:T31
46,T33,Condition 707 724	COPD exacerbation
47,T34,Qualifier 691 699	moderate
48,T35,Qualifier 700 706	severe
49,*,OR T35 T34
50,T36,Scope 691 706	moderate/severe
51,T38,Temporal 747 780	at least 14 days prior to Visit 1
52,T37,Observation 738 746	resolved
53,T39,Negation 734 737	not
54,R12,Has_negation Arg1:T37 Arg2:T39
55,R13,Has_temporal Arg1:T37 Arg2:T38
56,R14,Has_context Arg1:T33 Arg2:T37
57,R15,Has_scope Arg1:T33 Arg2:T36
58,T40,Temporal 785 849	at least 30 days following the last dose of oral corticosteroids
59,T41,Reference_point 812 849	the last dose of oral corticosteroids
60,R16,Has_index Arg1:T40 Arg2:T41
61,R17,Has_temporal Arg1:T37 Arg2:T40
62,T42,Condition 883 896	heart failure
63,T43,Qualifier 876 882	severe
64,R18,Has_qualifier Arg1:T42 Arg2:T43
65,T44,Measurement 898 924	New York Heart Association
66,T45,Value 925 933	class IV
67,R19,Has_value Arg1:T44 Arg2:T45
68,R20,Subsumes Arg1:T43 Arg2:T44
69,T46,Measurement 988 1005	ejection fraction
70,T47,Value 1009 1013	<30%
71,R21,Has_value Arg1:T46 Arg2:T47
72,T48,Device 1033 1077	implantable cardioverter defibrillator (ICD)
73,*,OR T46 T48
74,T49,Observation 1146 1161	life expectancy
75,T50,Value 1162 1170	<3 years
76,R22,Has_value Arg1:T49 Arg2:T50
77,T51,Condition 1114 1140	life-threatening condition
78,T52,Condition 1183 1199	vascular disease
79,T53,Condition 1203 1207	COPD
80,*,OR T52 T53
81,T54,Subjective_judgement 1209 1265	that might prevent the subject from completing the study
82,R23,Has_context Arg1:T51 Arg2:T49
83,T55,Negation 1172 1182	other than
84,T56,Scope 1183 1207	vascular disease or COPD
85,R24,Has_negation Arg1:T56 Arg2:T55
86,R25,Has_scope Arg1:T51 Arg2:T56
87,T57,Condition 1268 1299	End stage chronic renal disease
88,T58,Procedure 1333 1358	renal replacement therapy
89,T59,Procedure 1360 1372	hemodialysis
90,T60,Qualifier 1376 1386	peritoneal
91,*,OR T59 T60
92,T61,Scope 1360 1386	hemodialysis or peritoneal
93,R26,Has_scope Arg1:T58 Arg2:T61
94,R27,Subsumes Arg1:T57 Arg2:T58
95,T62,Condition 1390 1394;1400 1407	Drug allergy
96,T63,Condition 1395 1407	food allergy
97,*,OR T62 T63
98,T64,Condition 1436 1452	hypersensitivity
99,T65,Drug 1491 1504	beta-agonists
100,T66,Drug 1506 1520	corticosteroid
101,T67,Drug 1467 1484	study medications
102,T68,Undefined_semantics 1467 1484	study medications
103,*,OR T65 T66
104,T69,"Scope 1491 1520	beta-agonists, corticosteroid"
105,R28,Subsumes Arg1:T67 Arg2:T69
106,T70,Drug 1525 1560	components of the inhalation powder
107,T71,Drug 1567 1574	lactose
108,T72,Drug 1576 1594	magnesium stearate
109,*,OR T71 T72
110,T73,"Scope 1567 1594	lactose, magnesium stearate"
111,R29,Subsumes Arg1:T70 Arg2:T73
112,*,OR T67 T70
113,T74,"Scope 1467 1595	study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate)"
114,R30,Has_scope Arg1:T64 Arg2:T74
115,T75,Condition 1644 1664	milk protein allergy
116,T76,Qualifier 1637 1643	severe
117,R31,Has_qualifier Arg1:T75 Arg2:T76
118,T77,Observation 1626 1633	history
119,T78,"Subjective_judgement 1671 1775	in the opinion of the study physician, contraindicates the subject's participation will also be excluded"
120,R32,Has_temporal Arg1:T75 Arg2:T77
121,T79,Drug 1783 1796	alcohol abuse
122,T80,Drug 1778 1782;1791 1796	Drug abuse
123,*,OR T79 T80
124,T81,Observation 1833 1840	history
125,T82,Drug 1855 1865	drug abuse
126,T83,Drug 1844 1851;1860 1865	alcohol abuse
127,*,OR T82 T83
128,T84,Temporal 1866 1889	within the last 2 years
129,T85,Scope 1844 1865	alcohol or drug abuse
130,R33,Has_temporal Arg1:T85 Arg2:T81
131,R34,Has_temporal Arg1:T85 Arg2:T84
132,T86,Procedure 1942 1973	long-term oxygen therapy (LTOT)
133,T87,Procedure 1977 2001	nocturnal oxygen therapy
134,T88,Multiplier 2015 2042	greater than 12 hours a day
135,*,OR T87 T86
136,T89,Scope 1942 2001	long-term oxygen therapy (LTOT) or nocturnal oxygen therapy
137,R35,Has_multiplier Arg1:T89 Arg2:T88
138,T90,Grammar_Error 2044 2105	Oxygen prn use (i.e. <=12 hours per day) is not exclusionary.
139,T91,"Post-eligibility 2107 2375	Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study or the potential compliance to study procedures."
140,T92,"Post-eligibility 2377 2611	Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study."
141,T93,Parsing_Error 2613 2771	Additional medication: Use of the following medications within the following time intervals prior to Visit 1 or during the study (unless otherwise specified):
142,T94,Drug 2918 2958	Inhaled Long acting beta-agonists (LABA)
143,T95,Temporal 2959 2967	48 hours
144,T96,Reference_point 2836 2845	Screening
145,T97,Drug 2968 2997	ICS/LABA combination products
146,T98,Temporal 2998 3006	48 hours
147,R36,Has_temporal Arg1:T94 Arg2:T95
148,R37,Has_temporal Arg1:T97 Arg2:T98
149,T99,Drug 3007 3030	Inhaled corticosteroids
150,T100,Temporal 3031 3039	48 hours
151,R38,Has_temporal Arg1:T99 Arg2:T100
152,T101,Drug 3040 3050	Tiotropium
153,T102,Temporal 3051 3057	1 week
154,T103,Drug 3102 3117	corticosteroids
155,T104,Qualifier 3058 3066	Systemic
156,T105,Qualifier 3068 3072	Oral
157,T106,Qualifier 3074 3084	parenteral
158,T107,Qualifier 3086 3101	intra-articular
159,*,OR T104 T105 T106 T107
160,T108,"Scope 3058 3101	Systemic, Oral, parenteral, intra-articular"
161,R39,Has_scope Arg1:T103 Arg2:T108
162,T109,Temporal 3118 3125	30 days
163,R40,Has_temporal Arg1:T103 Arg2:T109
164,T110,Drug 3145 3160	corticosteroids
165,T111,Qualifier 3127 3131	oral
166,T112,Qualifier 3136 3144	systemic
167,*,OR T112 T111
168,T113,Scope 3127 3144	oral and systemic
169,R41,Has_scope Arg1:T110 Arg2:T113
170,T114,Condition 3182 3200	COPD exacerbations
171,T115,Procedure 3176 3200	treat COPD exacerbations
172,R42,AND Arg1:T115 Arg2:T114
173,T116,Temporal 3201 3217	during the study
174,T117,Reference_point 3208 3217	the study
175,R43,Has_index Arg1:T116 Arg2:T117
176,R44,Has_temporal Arg1:T115 Arg2:T116
177,T118,Not_a_criteria 3127 3217	oral and systemic corticosteroids may be used to treat COPD exacerbations during the study
178,T119,Drug 3219 3256	Cytochrome P450 3A4 strong inhibitors
179,T120,Drug 3432 3444	Itraconazole
180,T121,Drug 3447 3461	Clarithromycin
181,T122,Drug 3463 3476	Telithromycin
182,T123,Drug 3478 3488	Amiodarone
183,T124,Drug 3494 3504	Nefazodone
184,T125,Temporal 3505 3512	6 weeks
185,T126,Drug 3513 3523	Grapefruit
186,T127,Grammar_Error 3513 3548	Grapefruit is allowed up to Visit 1
187,T128,Drug 3664 3684	investigational drug
188,T129,Undefined_semantics 3664 3684	investigational drug
189,T130,Temporal 3685 3692	30 days
190,T131,Temporal 3696 3708	5 half lives
191,*,OR T131 T130
192,T132,Scope 3685 3708	30 days or 5 half lives
193,R45,Has_scope Arg1:T128 Arg2:T132
194,*,OR T121 T122 T123 T124 T143 T133
195,T133,Drug 3286 3301	antiretrovirals
196,T134,Drug 3303 3322	protease inhibitors
197,T135,Drug 3329 3338	Indinavir
198,T136,Drug 3340 3350	Nelfinavir
199,T137,Drug 3352 3361	Ritonavir
200,T138,Drug 3363 3373	Saquinavir
201,*,OR T138 T137 T136 T135
202,T139,"Scope 3329 3373	Indinavir, Nelfinavir, Ritonavir, Saquinavir"
203,R46,Subsumes Arg1:T134 Arg2:T139
204,R47,Subsumes Arg1:T133 Arg2:T134
205,T140,Drug 3376 3385;3399 3411	Imidazole anti-fungals
206,T141,Drug 3390 3411	Triazole anti-fungals
207,T142,Drug 3418 3430	Ketaconazole
208,T143,Scope 3376 3411	Imidazole and Triazole anti-fungals
209,T144,"Scope 3418 3444	Ketaconazole, Itraconazole"
210,*,OR T142 T120
211,R48,Subsumes Arg1:T143 Arg2:T144
212,T145,"Scope 3286 3504	antiretrovirals (protease inhibitors) (e.g.Indinavir, Nelfinavir, Ritonavir, Saquinavir); Imidazole and Triazole anti-fungals (e.g. Ketaconazole, Itraconazole); Clarithromycin, Telithromycin, Amiodarone, and Nefazodone"
213,R49,Subsumes Arg1:T119 Arg2:T145
214,R50,Has_temporal Arg1:T119 Arg2:T125
215,T146,Negation 2784 2786	No
216,T147,Reference_point 2863 2888	any time during the study
217,*,OR T147 T96
218,*,OR T94 T97 T99 T101 T103 T110 T119
0,T1,Condition 0 24	Ductal carcinoma in situ
1,T2,Condition 26 30	DCIS
2,T3,Measurement 32 37	stage
3,T4,Condition 40 46	cancer
4,T5,Value 38 39	0
5,R1,AND Arg1:T4 Arg2:T3
6,R2,Has_value Arg1:T3 Arg2:T5
7,T6,Scope 26 46	DCIS; stage 0 cancer
8,*,OR T2 T4
9,R3,Subsumes Arg1:T1 Arg2:T6
10,T7,Value 62 80	distant metastatic
11,T8,Measurement 81 86	stage
12,T9,Value 50 58;70 80	Advanced metastatic
13,*,OR T9 T7
14,T10,Scope 50 80	Advanced or distant metastatic
15,R4,Has_scope Arg1:T8 Arg2:T10
16,T11,Procedure 103 122	neoadjuvant therapy
17,T12,Drug 150 161	antibiotics
18,T13,Temporal 162 183	within prior 3 months
19,T14,Observation 125 132	History
20,R6,Has_temporal Arg1:T12 Arg2:T13
21,R7,AND Arg1:T14 Arg2:T12
22,T16,Condition 197 213	immunodeficiency
23,T17,Observation 186 193	History
24,R8,AND Arg1:T17 Arg2:T16
25,T18,Condition 225 241	remote infection
26,T15,Condition 255 263	reaction
27,T19,Observation 244 251	History
28,R5,AND Arg1:T19 Arg2:T15
29,T20,Drug 267 284	study antibiotics
30,R9,AND Arg1:T15 Arg2:T20
31,T21,Negation 287 296	Denial of
32,T22,Informed_consent 297 321	signing the consent form
33,R10,Has_negation Arg1:T22 Arg2:T21
0,T1,Person 0 3	Age
1,T2,Value 4 33	equal or superior to 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 41 48	genders
4,T4,Condition 86 106	psychiatric disorder
5,T5,Negation 61 68	without
6,R2,Has_negation Arg1:T4 Arg2:T5
7,T6,Condition 51 56	Lucid
8,T7,Condition 124 144	head and neck cancer
9,T8,Temporal 179 186	5 years
10,R3,Has_temporal Arg1:T7 Arg2:T8
11,T9,Procedure 192 204	radiotherapy
12,T10,Qualifier 215 236	major salivary glands
13,T11,Qualifier 238 245	parotid
14,T12,Qualifier 247 260	submandibular
15,T13,Qualifier 265 275	sublingual
16,T14,"Scope 238 275	parotid, submandibular and sublingual"
17,R4,Subsumes Arg1:T10 Arg2:T14
18,R5,Has_qualifier Arg1:T9 Arg2:T10
19,R6,AND Arg1:T7 Arg2:T9
20,T15,Condition 316 342	Primary Sjögren's syndrome
21,T16,Qualifier 374 400	American-European criteria
22,R7,Has_qualifier Arg1:T15 Arg2:T16
0,T1,Condition 6 27	Myocardial Infarction
1,T2,Condition 43 57	monomorphic VT
2,T3,Qualifier 33 42	Sustained
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Procedure 72 83	12-lead ECG
5,T5,Procedure 87 99	rhythm strip
6,*,OR T4 T5
7,T6,Procedure 114 133	pharmacologic means
8,T7,Procedure 137 153	DC cardioversion
9,*,OR T6 T7
10,T8,Scope 72 99	12-lead ECG or rhythm strip
11,R2,AND Arg1:T8 Arg2:T2
12,T9,Scope 114 153	pharmacologic means or DC cardioversion
13,R3,AND Arg1:T9 Arg2:T2
14,T10,Multiplier 156 166	3 episodes
15,T11,Condition 170 172	VT
16,T12,Procedure 186 208	antitachycardia pacing
17,T13,Procedure 210 213	ATP
18,R4,Subsumes Arg1:T12 Arg2:T13
19,R5,Has_multiplier Arg1:T11 Arg2:T10
20,R6,AND Arg1:T11 Arg2:T12
21,T14,Multiplier 257 267	5 episodes
22,T15,Condition 271 273	VT
23,T16,Procedure 287 309	antitachycardia pacing
24,T17,Procedure 311 314	ATP
25,R7,Subsumes Arg1:T16 Arg2:T17
26,R8,Has_multiplier Arg1:T15 Arg2:T14
27,R9,AND Arg1:T15 Arg2:T16
28,T18,Multiplier 216 228	at least one
29,T19,Qualifier 242 253	symptomatic
30,R10,Has_multiplier Arg1:T19 Arg2:T18
31,R11,Has_qualifier Arg1:T11 Arg2:T19
32,T20,Multiplier 340 342	=1
33,T21,Procedure 355 365	ICD shocks
34,R12,Has_multiplier Arg1:T21 Arg2:T20
35,T22,Multiplier 369 370;374 382	3 episodes
36,T23,Condition 371 373	VT
37,T24,Temporal 383 398	within 24 hours
38,R13,Has_multiplier Arg1:T23 Arg2:T22
39,R14,Has_temporal Arg1:T23 Arg2:T24
0,T1,Person 9 13	aged
1,T2,"Value 14 22	>18, <75"
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 24 56	left ventricle ejection fraction
4,T4,Measurement 58 62	LVEF
5,R2,Subsumes Arg1:T3 Arg2:T4
6,T5,Value 64 68	>50%
7,R3,Has_value Arg1:T3 Arg2:T5
8,T6,Condition 70 98	multivessel coronary disease
9,T7,Procedure 111 125	coronarography
10,T8,Procedure 151 155	CABG
11,T9,Mood 127 148	indication to receive
12,R4,Has_mood Arg1:T8 Arg2:T9
13,R5,AND Arg1:T7 Arg2:T6
14,T10,Qualifier 157 163	stable
15,T11,Condition 164 167	CAD
16,R6,Has_qualifier Arg1:T11 Arg2:T10
17,T12,Condition 173 182	diabetics
18,T13,Condition 187 200	non diabetics
19,*,OR T1 T3 T7 T8 T11 T12 T13
0,T1,Condition 12 25	comorbidities
1,T2,Qualifier 5 11	severe
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 35 57	cardiovascular disease
4,T4,Undefined_semantics 12 25	comorbidities
5,T5,Condition 59 96	chronic obstructive pulmonary disease
6,T6,Condition 98 115	diabetes mellitus
7,T7,Condition 121 146	chronic renal dysfunction
8,T8,Grammar_Error 117 120	and
9,*,OR T7 T6 T5 T3
10,T9,"Scope 35 146	cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction"
11,T10,Scope 5 25	severe comorbidities
12,R2,Subsumes Arg1:T10 Arg2:T9
13,T11,Condition 154 168	bad compliance
14,T12,Subjective_judgement 154 168	bad compliance
15,T13,Condition 172 202	contraindication to enrollment
16,T14,Subjective_judgement 172 202	contraindication to enrollment
17,T15,Undefined_semantics 172 202	contraindication to enrollment
18,*,OR T13 T11
19,T16,Condition 205 213	Pregnant
20,T17,Person 214 219	woman
21,T18,Condition 223 232	lactating
22,T19,Person 233 238	woman
23,T20,Scope 223 238	lactating woman
24,T21,Scope 205 219	Pregnant woman
25,*,OR T21 T20
26,T22,Condition 246 262	contraindication
27,T23,Procedure 274 295	adjuvant chemotherapy
28,R3,AND Arg1:T22 Arg2:T23
29,T24,Subjective_judgement 246 262	contraindication
30,T25,Undefined_semantics 246 262	contraindication
0,T1,Value 13 30	18 years or older
1,T2,Person 8 12	aged
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 73 89	active proctitis
4,T4,Condition 93 117	distal proctosigmoiditis
5,*,OR T4 T3
6,T5,Qualifier 56 72	mild to moderate
7,T6,Scope 73 117	active proctitis or distal proctosigmoiditis
8,R2,Has_qualifier Arg1:T6 Arg2:T5
9,T7,Measurement 119 129	MAYO score
10,T8,Value 130 142	≥ 3 and ≤ 10
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Temporal 199 237	within 6 months before study inclusion
13,T10,Reference_point 222 237	study inclusion
14,R4,Has_index Arg1:T9 Arg2:T10
15,T11,Temporal 144 156	at inclusion
16,T12,Reference_point 147 156	inclusion
17,R5,Has_index Arg1:T11 Arg2:T12
18,R6,Has_temporal Arg1:T6 Arg2:T11
19,R7,Has_temporal Arg1:T6 Arg2:T9
20,T13,Condition 276 292	active proctitis
21,T14,Condition 296 320	distal proctosigmoiditis
22,*,OR T14 T13
23,T15,Procedure 265 275	endoscopic
24,T16,Scope 276 320	active proctitis or distal proctosigmoiditis
25,T17,Measurement 322 345	Montreal classification
26,T18,Value 346 354	E1 or E2
27,T19,Qualifier 369 421	involvement not exceeding 25 cm from the anal margin
28,R8,Subsumes Arg1:T18 Arg2:T19
29,R9,Has_value Arg1:T17 Arg2:T18
30,R10,AND Arg1:T16 Arg2:T17
31,R11,AND Arg1:T16 Arg2:T15
32,T20,Temporal 423 461	within 6 months before study inclusion
33,T21,Reference_point 446 461	study inclusion
34,R12,Has_index Arg1:T20 Arg2:T21
35,T22,Drug 500 507	Pentasa
36,T23,Procedure 464 473	Treatment
37,R13,AND Arg1:T23 Arg2:T22
38,T24,Condition 489 494	flare
39,R14,AND Arg1:T24 Arg2:T23
40,T25,Temporal 609 635	during the inclusion visit
41,T26,Reference_point 620 635	inclusion visit
42,R15,Has_index Arg1:T25 Arg2:T26
43,T27,Temporal 639 681	during the week before the inclusion visit
44,T28,Reference_point 646 681	the week before the inclusion visit
45,R16,Has_index Arg1:T27 Arg2:T28
46,*,OR T27 T25
47,T29,Scope 609 681	during the inclusion visit or during the week before the inclusion visit
48,R17,Has_scope Arg1:T23 Arg2:T29
49,T30,"Non-query-able 684 861	Patient having received oral and written information on the study, without any objections for the use of his/her personal data, and having signed a written Informed Consent Form"
0,T1,Condition 0 15	Post menopausal
1,T2,Person 16 21	women
2,T3,Observation 29 36	history
3,T4,Qualifier 40 57	estrogen positive
4,T5,Condition 58 71	breast cancer
5,T6,Drug 90 110	aromatase inhibitors
6,T7,Temporal 111 133	for at least one month
7,R1,Has_temporal Arg1:T6 Arg2:T7
8,R2,Has_qualifier Arg1:T5 Arg2:T4
9,R3,Has_temporal Arg1:T5 Arg2:T3
10,T8,Condition 179 189	arthralgia
11,T9,Qualifier 170 178	moderate
12,T10,Qualifier 162 166	mild
13,*,OR T9 T10
14,T11,Scope 162 178	mild to moderate
15,R4,Has_scope Arg1:T8 Arg2:T11
16,T12,Post-eligibility 192 240	Ability to understand and sign informed consent.
17,T13,Value 269 272	low
18,T14,Value 276 284	moderate
19,T15,Measurement 285 311	risk for moderate exercise
20,*,OR T14 T13
21,T16,Scope 269 284	low to moderate
22,R5,Has_scope Arg1:T15 Arg2:T16
23,T17,Measurement 326 341	ACSM guidelines
24,R6,Subsumes Arg1:T15 Arg2:T17
0,T1,Qualifier 0 13	Uncomplicated
1,T2,Procedure 14 18	RYGB
2,T3,Temporal 29 64	minimum 3 months prior to the study
3,T4,Reference_point 55 64	the study
4,R1,Has_index Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T2 Arg2:T1
6,R3,Has_temporal Arg1:T2 Arg2:T3
7,T5,Measurement 67 82	Fasting glucose
8,T6,"Value 83 91	< 7,0 mM"
9,T7,Measurement 93 98	HbA1c
10,T8,Value 99 112	< 48 mmol/mol
11,T9,Temporal 113 132	3 months after RYGB
12,T10,Reference_point 128 132	RYGB
13,T11,Procedure 128 132	RYGB
14,R4,multi Arg1:T10 Arg2:T11
15,R5,Has_index Arg1:T9 Arg2:T10
16,R6,Has_value Arg1:T7 Arg2:T8
17,R7,Has_value Arg1:T5 Arg2:T6
18,*,OR T5 T7
19,T12,"Scope 67 112	Fasting glucose < 7,0 mM, HbA1c < 48 mmol/mol"
20,R8,Has_temporal Arg1:T12 Arg2:T9
0,T1,Value 14 31	at least 18 years
1,T2,Person 32 35	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 82 122	percutaneous coronary intervention (PCI)
4,T4,Qualifier 58 65;75 81	single- vessel
5,T5,Qualifier 69 81	multi-vessel
6,*,OR T4 T5
7,T6,Scope 58 81	single- or multi-vessel
8,R2,Has_scope Arg1:T3 Arg2:T6
9,T8,Condition 148 161	target lesion
10,T9,Condition 173 200	in-stent restenotic lesions
11,T10,Qualifier 126 133	de novo
12,T11,Qualifier 137 147	restenotic
13,T12,Qualifier 173 181	in-stent
14,T13,Qualifier 182 192	restenotic
15,R5,Has_qualifier Arg1:T9 Arg2:T13
16,R6,Has_qualifier Arg1:T9 Arg2:T12
17,T14,Scope 126 161	de novo or restenotic target lesion
18,T15,Scope 126 201	de novo or restenotic target lesion (including in-stent restenotic lesions)
19,R8,Has_scope Arg1:T3 Arg2:T15
20,T16,Device 316 335	drug eluting stents
21,T17,Condition 236 263	amenable to stent treatment
22,T18,Device 302 312;329 335	bare metal stents
23,*,OR T16 T18
24,T19,Scope 302 335	bare metal or drug eluting stents
25,R9,Has_scope Arg1:T17 Arg2:T19
26,T20,Condition 410 445	coronary artery bypass graft (CABG)
27,T21,Qualifier 400 409	emergency
28,T22,Qualifier 390 396	urgent
29,T23,Qualifier 380 388	elective
30,*,OR T22 T23 T21
31,T24,"Scope 380 409	elective, urgent or emergency"
32,R10,Has_scope Arg1:T20 Arg2:T24
33,T25,Condition 484 506	ischemic heart disease
34,T26,Observation 463 480	clinical evidence
35,R11,Has_context Arg1:T25 Arg2:T26
36,T27,Procedure 530 546	functional study
37,T28,Value 521 529	positive
38,R12,Has_value Arg1:T27 Arg2:T28
39,R13,AND Arg1:T25 Arg2:T27
40,T29,Condition 587 609	stable angina pectoris
41,T30,Measurement 611 663	Canadian Cardiovascular Society Classification (CCS)
42,T31,"Value 664 677	1, 2, 3, or 4"
43,R14,Has_value Arg1:T30 Arg2:T31
44,T32,Qualifier 587 593	stable
45,R15,Has_qualifier Arg1:T29 Arg2:T32
46,R16,Subsumes Arg1:T32 Arg2:T30
47,T33,Qualifier 680 688	unstable
48,T34,Condition 680 704	unstable angina pectoris
49,R17,Has_qualifier Arg1:T34 Arg2:T33
50,T35,Condition 721 729	ischemia
51,T36,Observation 710 720	documented
52,T37,Measurement 731 746	Braunwald Class
53,T38,"Value 747 769	IB-C, IIB-C, or IIIB-C"
54,R18,Has_value Arg1:T37 Arg2:T38
55,T39,Condition 772 818	non-ST segment elevation myocardial infarction
56,T40,Condition 834 849	silent ischemia
57,T41,Qualifier 834 840	silent
58,R19,Has_qualifier Arg1:T40 Arg2:T41
59,T42,Observation 823 833	documented
60,R20,Has_context Arg1:T40 Arg2:T42
61,R21,Has_context Arg1:T35 Arg2:T36
62,R22,Subsumes Arg1:T35 Arg2:T37
63,R23,AND Arg1:T34 Arg2:T35
64,*,OR T34 T39 T40 T29
65,T43,Procedure 894 919	percutaneous intervention
66,T44,Observation 866 873	willing
67,T45,Observation 878 882	able
68,R24,Has_context Arg1:T43 Arg2:T45
69,R25,Has_context Arg1:T43 Arg2:T44
70,T46,Visit 923 935	SOS hospital
71,R26,AND Arg1:T43 Arg2:T46
72,T47,"Post-eligibility 855 968	Subject is willing and able to undergo percutaneous intervention at SOS hospital, if randomized to SOS study arm."
73,T48,Post-eligibility 973 1074	Subject and the treating physician agree that the subject will comply with all follow-up evaluations.
74,T49,Post-eligibility 1079 1298	Subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site.
75,T50,Qualifier 1334 1341	de novo
76,T51,Condition 1308 1321	target lesion
77,*,OR T11 T10
78,T7,Scope 126 147	de novo or restenotic
79,R3,Has_scope Arg1:T8 Arg2:T7
80,R4,Subsumes Arg1:T14 Arg2:T9
81,T52,Qualifier 1345 1355	restenotic
82,T53,Qualifier 1367 1386	in-stent restenotic
83,*,OR T50 T52
84,T54,Scope 1334 1355	de novo or restenotic
85,R7,Subsumes Arg1:T54 Arg2:T53
86,T55,Scope 1334 1387	de novo or restenotic (including in-stent restenotic)
87,R27,Has_scope Arg1:T51 Arg2:T55
88,T56,Condition 1395 1417	coronary artery lesion
89,R28,Subsumes Arg1:T51 Arg2:T56
90,T57,Value 1426 1460	greater than 50 and less than 100%
91,T58,Measurement 1461 1469	stenosis
92,T59,Condition 1461 1469	stenosis
93,R29,Has_value Arg1:T58 Arg2:T57
94,T60,Condition 1496 1509	target lesion
95,T61,Temporal 1516 1521	acute
96,T62,Temporal 1523 1540	less than 1 month
97,R30,Subsumes Arg1:T61 Arg2:T62
98,R31,Has_temporal Arg1:T60 Arg2:T61
99,T63,Condition 1542 1557	total occlusion
100,T64,Observation 1574 1591	clinical symptoms
101,R32,Has_context Arg1:T63 Arg2:T64
102,R33,Subsumes Arg1:T60 Arg2:T63
103,R34,AND Arg1:T56 Arg2:T59
104,*,OR T51 T60
105,T65,Condition 1598 1612	Target lesions
106,T66,Condition 1639 1646	infarct
107,T67,Qualifier 1633 1646;1695 1710	in an infarct -related artery
108,R35,AND Arg1:T67 Arg2:T66
109,T68,Procedure 1668 1679	primary PCI
110,T69,Negation 1651 1654	not
111,R36,Has_negation Arg1:T68 Arg2:T69
112,T70,Qualifier 1684 1710	non-infarct-related artery
113,*,OR T67 T70
114,T71,Value 1718 1732	70% or greater
115,T72,Measurement 1733 1741	stenosis
116,T73,Condition 1733 1741	stenosis
117,R37,Has_value Arg1:T72 Arg2:T71
118,R38,AND Arg1:T65 Arg2:T73
119,T74,Scope 1633 1710	in an infarct (if not treated with primary PCI) or non-infarct-related artery
120,R39,Has_scope Arg1:T65 Arg2:T74
121,T75,Temporal 1763 1846	more than 72 hours following the ST segment elevation myocardial infarction (STEMI)
122,T76,Reference_point 1792 1846	the ST segment elevation myocardial infarction (STEMI)
123,R40,Has_index Arg1:T75 Arg2:T76
124,T77,Condition 1796 1846	ST segment elevation myocardial infarction (STEMI)
125,R41,AND Arg1:T76 Arg2:T77
126,R42,Has_temporal Arg1:T73 Arg2:T75
127,T78,Not_a_criteria 1849 2130	Lesions treated with PCI more than 72 hours following STEMI would be subject to the same protocol inclusion/exclusion criteria listed above and below with the exception that a target lesion of 70% or greater stenosis may be treated with or without symptoms or abnormal stress test)
0,T1,Post-eligibility 0 44	Inability to comply with study requirements.
1,T2,Condition 57 70	breast cancer
2,T3,Qualifier 46 56	Metastatic
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 101 124	neuromuscular disorders
5,T5,Condition 115 124;87 97	disorders orthopedic
6,*,OR T4 T5
7,T6,Condition 167 187	Rheumatoid arthritis
8,T7,Condition 201 203	MI
9,T8,Condition 205 211	angina
10,T9,Condition 215 239	congestive heart failure
11,*,OR T9 T8 T7
12,T10,Observation 190 197	History
13,T11,"Scope 201 239	MI, angina or congestive heart failure"
14,R2,Has_temporal Arg1:T11 Arg2:T10
15,T12,Condition 242 250	Pregnant
16,T13,Condition 254 263	lactating
17,T14,Person 264 271	females
18,T15,Pregnancy_considerations 242 272	Pregnant or lactating females.
19,*,OR T13 T12
20,T16,Measurement 297 323	risk for moderate exercise
21,T17,Value 292 296	high
22,T18,Measurement 333 357	ACSM risk classification
23,R3,Subsumes Arg1:T16 Arg2:T18
24,R4,Has_value Arg1:T16 Arg2:T17
25,T19,Observation 373 421	exceed minimal physical activity recommendations
26,T20,Non-query-able 360 550	Patients who exceed minimal physical activity recommendations from the US Surgeon General's Report: Accumulation of 30 minutes or more of moderate physical activity on most days of the week.
27,T21,Condition 552 566	Morbidly obese
28,T22,Measurement 572 575	BMI
29,T23,Value 576 580	≥ 40
30,R5,Has_value Arg1:T22 Arg2:T23
31,R6,Subsumes Arg1:T21 Arg2:T22
0,T1,Condition 68 84	active proctitis
1,T2,Condition 88 112	distal proctosigmoiditis
2,*,OR T2 T1
3,T3,Procedure 54 63	treatment
4,T4,Undefined_semantics 54 63	treatment
5,T5,Scope 68 112	active proctitis or distal proctosigmoiditis
6,R1,Has_scope Arg1:T3 Arg2:T5
7,T6,Condition 140 147	colitis
8,T7,Condition 151 161	pancolitis
9,*,OR T6 T7
10,T8,Qualifier 128 138	left sided
11,T9,Scope 140 161	colitis or pancolitis
12,R2,Has_qualifier Arg1:T9 Arg2:T8
13,T10,Condition 184 193	proctitis
14,T11,Qualifier 177 183	severe
15,R3,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Measurement 195 205	MAYO score
17,T13,Value 206 210	≥ 11
18,T14,Temporal 211 223	at inclusion
19,R4,Has_value Arg1:T12 Arg2:T13
20,R5,Has_temporal Arg1:T12 Arg2:T14
21,R6,Subsumes Arg1:T11 Arg2:T12
22,T15,Drug 259 268	biologics
23,T16,Undefined_semantics 259 268	biologics
24,T17,Temporal 235 245	previously
25,T18,Procedure 246 253	treated
26,R7,Has_temporal Arg1:T18 Arg2:T17
27,R8,AND Arg1:T18 Arg2:T15
28,T19,Drug 292 309	immunosuppressive
29,T20,Temporal 310 347	within 1 month before study inclusion
30,T21,Reference_point 332 347	study inclusion
31,R9,Has_index Arg1:T20 Arg2:T21
32,R10,Has_temporal Arg1:T19 Arg2:T20
33,T22,Drug 371 386	corticosteroids
34,T23,Temporal 387 424	within 2 weeks before study inclusion
35,T24,Reference_point 409 424	study inclusion
36,R11,Has_index Arg1:T23 Arg2:T24
37,R12,Has_temporal Arg1:T22 Arg2:T23
0,T1,Condition 18 26	pregnant
1,T2,Observation 30 43	breastfeeding
2,*,OR T1 T2
3,T3,Condition 61 66	STEMI
4,T4,Temporal 67 82	within 72 hours
5,T5,Qualifier 112 127;151 157	infarct related artery
6,T6,Qualifier 131 157	non-infarct related artery
7,*,OR T6 T5
8,T7,Procedure 99 108	treatment
9,T8,Scope 112 157	infarct related or non-infarct related artery
10,R1,Has_scope Arg1:T7 Arg2:T8
11,R2,Has_temporal Arg1:T3 Arg2:T4
12,R3,AND Arg1:T3 Arg2:T7
13,T9,Condition 163 180	Cardiogenic shock
14,T10,Procedure 215 230	hospitalization
15,T11,Temporal 207 214	current
16,T12,Measurement 236 270	Left ventricular ejection fraction
17,T13,Value 271 284	less than 20%
18,R4,Has_value Arg1:T12 Arg2:T13
19,T14,Drug 310 317	aspirin
20,T15,Drug 319 330	clopidogrel
21,T16,Drug 332 338	Plavix
22,T17,Drug 344 355	ticlopidine
23,T18,Drug 357 363	Ticlid
24,T19,Drug 366 373	heparin
25,T20,Drug 375 386	bivalirudin
26,T21,Observation 388 403	stainless steel
27,T22,Drug 408 422	contrast agent
28,T23,Condition 296 305	allergies
29,*,OR T14 T15 T16 T17 T18 T19 T20 T21 T22
30,T24,"Scope 310 422	aspirin, clopidogrel (Plavix) and ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent"
31,R5,Has_scope Arg1:T23 Arg2:T24
32,T25,Measurement 472 486	platelet count
33,T26,"Value 487 513	less than 75,000 cells/mm3"
34,T27,"Value 517 547	greater than 700,000 cells/mm3"
35,*,OR T26 T27
36,T28,Measurement 553 556	WBC
37,T29,"Value 557 582	less than 3,000 cells/mm3"
38,R6,Has_value Arg1:T28 Arg2:T29
39,T30,"Scope 487 547	less than 75,000 cells/mm3 or greater than 700,000 cells/mm3"
40,R7,Has_scope Arg1:T25 Arg2:T30
41,*,OR T25 T28
42,T31,Condition 597 622	chronic renal dysfunction
43,T32,Condition 588 593;605 622	Acute renal dysfunction
44,*,OR T31 T32
45,T33,Measurement 624 634	creatinine
46,T34,Value 635 657	greater than 2.5 mg/dl
47,T35,Value 661 680	less than 150µmol/L
48,*,OR T34 T35
49,T36,Scope 635 680	greater than 2.5 mg/dl or less than 150µmol/L
50,R8,Has_scope Arg1:T33 Arg2:T36
51,T37,"Context_Error 687 1045	Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials)."
52,T38,"Post-eligibility 687 1045	Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials)."
53,T39,Context_Error 1050 1084	Prior participation in this study.
54,T40,Temporal 1090 1139	Within 30 days prior to the index study procedure
55,T41,Reference_point 1114 1139	the index study procedure
56,T42,Procedure 1178 1211	coronary interventional procedure
57,T43,Temporal 1169 1177	previous
58,R9,Has_temporal Arg1:T42 Arg2:T43
59,T45,Condition 1279 1284	STEMI
60,T44,Condition 1300 1306	Stroke
61,T46,Condition 1310 1335	transient ischemic attack
62,R10,multi Arg1:T40 Arg2:T41
63,R11,Has_temporal Arg1:T42 Arg2:T40
64,T47,Negation 1261 1264	not
65,R12,Has_negation Arg1:T45 Arg2:T47
66,T48,Temporal 1336 1361	within the prior 3 months
67,*,OR T46 T44
68,T49,Scope 1300 1335	Stroke or transient ischemic attack
69,R13,Has_temporal Arg1:T49 Arg2:T48
70,T50,Condition 1375 1387	peptic ulcer
71,T51,Temporal 1368 1374	Active
72,T52,Condition 1391 1422	upper gastrointestinal bleeding
73,T53,Temporal 1423 1448	within the prior 3 months
74,T54,Scope 1375 1422	peptic ulcer or upper gastrointestinal bleeding
75,*,OR T52 T50
76,R14,Has_temporal Arg1:T54 Arg2:T51
77,R15,Has_temporal Arg1:T54 Arg2:T53
78,T55,Condition 1474 1480	sepsis
79,T56,Temporal 1467 1473	active
80,R16,Has_temporal Arg1:T55 Arg2:T56
81,T57,Condition 1499 1532	left main coronary artery disease
82,T58,Qualifier 1487 1498	Unprotected
83,R17,Has_qualifier Arg1:T57 Arg2:T58
84,T59,Measurement 1534 1542	stenosis
85,T60,Condition 1534 1542	stenosis
86,T61,Value 1543 1559	greater than 50%
87,R18,multi Arg1:T60 Arg2:T59
88,R19,Has_value Arg1:T59 Arg2:T61
89,R20,AND Arg1:T57 Arg2:T60
90,T62,Subjective_judgement 1567 1596	In the investigator's opinion
91,T63,Measurement 1656 1671	life expectancy
92,T64,Observation 1656 1671	life expectancy
93,R21,multi Arg1:T64 Arg2:T63
94,T65,Value 1675 1693	less than one year
95,R22,Has_value Arg1:T63 Arg2:T65
96,T66,"Post-eligibility 1567 1840	In the investigator's opinion, subject has a co-morbid condition(s) that could limit the life expectancy to less than one year, or limit the subject's ability to participate in the study or comply with follow-up requirements or impact the scientific integrity of the study."
97,T67,Condition 1899 1914	coronary lesion
98,T68,Measurement 1899 1914	coronary lesion
99,T69,Value 1918 1940	less than 50% stenosis
100,T70,Condition 1932 1940	stenosis
101,R23,multi Arg1:T69 Arg2:T70
102,R24,multi Arg1:T67 Arg2:T68
103,R25,Has_value Arg1:T68 Arg2:T69
104,T71,Condition 1994 2002	thrombus
105,T72,Procedure 2018 2044	target vessel thrombectomy
106,T73,Condition 2047 2058	tortuousity
107,T74,Value 2060 2082	greater than 60 degree
108,T75,Measurement 2083 2088	angle
109,R26,Has_value Arg1:T75 Arg2:T74
110,R27,Subsumes Arg1:T73 Arg2:T75
111,T76,Procedure 2126 2155	stent delivery and deployment
112,T77,Qualifier 2104 2125	unsuitable for proper
113,T78,Subjective_judgement 2104 2125	unsuitable for proper
114,R28,Has_qualifier Arg1:T76 Arg2:T77
115,R29,causal Arg1:T73 Arg2:T76
116,T79,Condition 2164 2177	calcification
117,T80,Qualifier 2158 2163	heavy
118,R30,Has_qualifier Arg1:T79 Arg2:T80
119,T81,Device 2228 2299	device other than percutaneous transluminal coronary angioplasty (PTCA)
120,T82,Procedure 2246 2299	percutaneous transluminal coronary angioplasty (PTCA)
121,R31,multi Arg1:T81 Arg2:T82
122,T83,Negation 2235 2245	other than
123,R32,Has_negation Arg1:T82 Arg2:T83
124,T84,Procedure 2309 2324	stent placement
125,T85,Temporal 2300 2324	prior to stent placement
126,T86,Reference_point 2309 2324	stent placement
127,R33,multi Arg1:T85 Arg2:T86
128,R34,multi Arg1:T86 Arg2:T84
129,T87,Procedure 2351 2383	directional coronary atherectomy
130,T88,Procedure 2385 2398	excimer laser
131,T89,Procedure 2400 2422	rotational atherectomy
132,*,OR T88 T89 T87
133,T90,"Scope 2351 2422	directional coronary atherectomy, excimer laser, rotational atherectomy"
134,R35,Subsumes Arg1:T84 Arg2:T90
135,T91,Mood 2202 2210	requires
136,T92,Procedure 2211 2220	treatment
137,R36,AND Arg1:T92 Arg2:T81
138,R37,Has_temporal Arg1:T92 Arg2:T85
139,R38,Has_mood Arg1:T92 Arg2:T91
140,T93,Condition 2188 2201	target lesion
141,R39,AND Arg1:T93 Arg2:T92
142,T94,Device 2468 2488	saphenous vein graft
143,T95,Condition 2440 2446	lesion
144,T96,Qualifier 2455 2488	located in a saphenous vein graft
145,R40,multi Arg1:T96 Arg2:T94
146,R41,Has_qualifier Arg1:T95 Arg2:T96
147,T97,Qualifier 2515 2539	within the native vessel
148,T98,Grammar_Error 2571 2583	are eligible
149,T99,Qualifier 2544 2570	accessed through the graft
150,*,OR T97 T99
151,T100,Scope 2515 2570	within the native vessel but accessed through the graft
152,*,OR T96 T100
153,T101,"Non-representable 2590 2780	The target vessel is in a ""last remaining"" epicardial vessel (e.g. greater than 2 non-target epicardial vessels and the bypass grafts to these territories [if present] are totally occluded)."
0,T1,Measurement 0 22	Fasting plasma glucose
1,T2,"Value 23 31	> 7,0 mM"
2,T3,Measurement 33 38	HbA1c
3,T4,Value 39 52	> 48 mmol/mol
4,T5,Temporal 53 72	3 months after RYGB
5,R1,Has_value Arg1:T1 Arg2:T2
6,R2,Has_value Arg1:T3 Arg2:T4
7,*,OR T1 T3
8,T6,"Scope 0 52	Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol"
9,R3,Has_temporal Arg1:T6 Arg2:T5
10,T7,Qualifier 74 86	Dysregulated
11,T8,Condition 87 103	thyroid diseases
12,T9,Procedure 112 133	antithyroid treatment
13,R4,Has_qualifier Arg1:T8 Arg2:T7
14,*,OR T8 T9
15,T10,Condition 136 163	Late diabetic complications
16,T11,Condition 167 178	retinopathy
17,T12,Condition 180 199	renal insufficiency
18,T13,Condition 201 211	neuropathy
19,T14,Temporal 215 223	previous
20,T15,Condition 224 236	pancreatitis
21,R5,Has_temporal Arg1:T15 Arg2:T14
22,*,OR T13 T15 T12 T11
23,T16,"Scope 167 236	retinopathy, renal insufficiency, neuropathy or previous pancreatitis"
24,R6,Subsumes Arg1:T10 Arg2:T16
25,T17,Condition 239 252	Complications
26,T18,Procedure 256 260	RYGB
27,R7,AND Arg1:T17 Arg2:T18
28,T19,Condition 273 295	reactive hypoglycaemia
29,T20,Qualifier 297 303	severe
30,T21,Condition 304 311	dumping
31,T22,Condition 313 321	vomiting
32,T23,Condition 323 331	diarrhea
33,T24,Qualifier 333 339	severe
34,T25,Condition 340 354	abdominal pain
35,T26,Temporal 355 372	after food intake
36,T27,Reference_point 361 372	food intake
37,R8,Has_index Arg1:T26 Arg2:T27
38,R9,Has_temporal Arg1:T25 Arg2:T26
39,R10,Has_qualifier Arg1:T25 Arg2:T24
40,*,OR T23 T22 T25
41,T28,"Scope 313 372	vomiting, diarrhea, severe abdominal pain after food intake"
42,R11,Has_qualifier Arg1:T21 Arg2:T20
43,T29,Scope 297 311	severe dumping
44,R12,Subsumes Arg1:T29 Arg2:T28
45,*,OR T19 T29
46,T30,"Scope 273 373	reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake)"
47,T31,Scope 239 260	Complications to RYGB
48,R13,Subsumes Arg1:T31 Arg2:T30
49,T32,Procedure 375 390	Cholecystectomy
0,T1,Measurement 6 59;79 87	Diagnostic and Statistical Manual of Mental Disorders criteria
1,T2,Qualifier 61 71	Versions 4
2,T3,Qualifier 61 69;76 77	Versions 5
3,T4,Parsing_Error 72 75	and
4,*,OR T2 T3
5,T5,Scope 61 77	Versions 4 and 5
6,R1,Has_scope Arg1:T1 Arg2:T5
7,T6,Condition 96 121	Major Depressive Disorder
8,T7,Parsing_Error 92 95	and
9,R2,AND Arg1:T1 Arg2:T6
10,T8,Measurement 124 156	Hamilton Depression Rating Scale
11,T9,Value 166 181	greater than 18
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Person 184 187	Men
14,T11,Person 192 197	women
15,T12,Parsing_Error 188 191	and
16,*,OR T10 T11
17,T13,Person 206 210	ages
18,T14,Value 198 205;213 222	between 18 and 65
19,T15,Parsing_Error 211 213	>=
20,R4,Has_value Arg1:T13 Arg2:T14
0,T1,Condition 18 52	non muscle invasive bladder cancer
1,T2,Person 96 99	old
2,T3,Value 76 95	between 40-80 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Person 53 57	male
0,T1,Person 0 5	Males
1,T2,Person 10 17	females
2,T3,Person 18 22	aged
3,T4,Value 23 34	18-40 years
4,T5,Person 38 41	age
5,R1,Has_value Arg1:T5 Arg2:T4
6,R2,Has_value Arg1:T3 Arg2:T4
7,T6,Temporal 42 68	at the time of vaccination
8,T7,Reference_point 49 68	time of vaccination
9,R3,Has_index Arg1:T6 Arg2:T7
10,R4,Has_temporal Arg1:T4 Arg2:T6
11,T8,Condition 72 83	good health
12,T9,Undefined_semantics 72 83	good health
13,T10,Observation 101 116	medical history
14,T11,Procedure 118 131	physical exam
15,T12,Procedure 133 155	laboratory assessments
16,T13,Subjective_judgement 160 211	the clinical judgment of the Principal Investigator
17,T14,"Scope 101 211	medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator"
18,R5,Subsumes Arg1:T8 Arg2:T14
19,T15,Non-query-able 213 374	Able to provide informed consent indicating that they understand the purpose of this study and are willing to adhere to the procedures described in this protocol
20,T16,"Post-eligibility 376 916	If the subject is a female of childbearing potential, she must use adequate contraceptive precautions (e.g., intrauterine contraceptive device, oral contraceptives or other equivalent hormonal contraception) for 2 months prior to vaccination and continue to use such precautions for a minimum of three months after vaccination. She must also have a negative urine pregnancy test within 24 hours prior to receiving study vaccine. Women at least one year post-menopausal or surgically sterile will not be considered of childbearing potential."
21,T17,Non-query-able 918 984	Willing to receive the unlicensed vaccine given as an IM injection
22,T18,Drug 952 959	vaccine
23,T19,Procedure 972 984	IM injection
24,T20,Non-query-able 986 1055	Willing to provide multiple blood specimens collected by venipuncture
0,T1,Qualifier 18 24	DSM-IV
1,T2,Qualifier 10 17	primary
2,T3,Condition 25 34	diagnosis
3,R1,Has_qualifier Arg1:T3 Arg2:T1
4,R2,Has_qualifier Arg1:T3 Arg2:T2
5,T4,Measurement 36 51	DSM-IV criteria
6,T5,Condition 56 80	body dysmorphic disorder
7,T6,Condition 82 108	bipolar affective disorder
8,T7,Condition 110 123	schizophrenia
9,T8,"Condition 125 144	psychotic disorder,"
10,T9,Condition 161 176	substance abuse
11,T10,Condition 153 160;171 176	alcohol abuse
12,*,OR T9 T10 T8 T7 T6 T5
13,T11,"Scope 56 176	body dysmorphic disorder, bipolar affective disorder, schizophrenia, psychotic disorder, current alcohol/substance abuse"
14,R3,Has_scope Arg1:T4 Arg2:T11
15,T13,Condition 229 254	major depressive disorder
16,T14,Qualifier 220 228	Comorbid
17,R5,Has_qualifier Arg1:T13 Arg2:T14
18,T15,Temporal 271 293	predates OCD diagnosis
19,T16,Reference_point 280 293	OCD diagnosis
20,R6,Has_index Arg1:T15 Arg2:T16
21,R7,Has_temporal Arg1:T13 Arg2:T15
22,T17,Procedure 295 324	Cognitive behavioural therapy
23,T18,Procedure 339 352	psychotherapy
24,T19,Qualifier 328 338	additional
25,T20,Temporal 353 372	in past four months
26,R8,Has_qualifier Arg1:T18 Arg2:T19
27,*,OR T17 T18
28,T21,Condition 374 381	Allergy
29,T22,Condition 385 401	hypersensitivity
30,T23,Drug 405 415	topiramate
31,*,OR T21 T22
32,T24,Scope 374 401	Allergy or hypersensitivity
33,R9,AND Arg1:T24 Arg2:T23
34,T25,Measurement 417 420	BMI
35,T26,Value 421 425	< 20
36,R10,Has_value Arg1:T25 Arg2:T26
37,T27,Condition 438 451	kidney stones
38,T12,Drug 208 218	topiramate
39,T28,Temporal 181 189	previous
40,R4,Has_temporal Arg1:T12 Arg2:T28
41,T29,Observation 427 437	History of
42,R11,Has_temporal Arg1:T27 Arg2:T29
0,T1,Value 0 11	20-40 years
1,T2,Person 12 15	old
2,T3,Person 16 21	women
3,R1,Has_value Arg1:T2 Arg2:T1
4,T4,Condition 23 46	Spontaneously ovulating
5,T5,Person 47 52	women
6,T6,Visit 65 77	our IVF unit
7,T7,Procedure 82 111	frozen-thawed embryo transfer
8,T8,Value 113 125	At least one
9,T9,Measurement 126 144	top quality embryo
10,R2,Has_value Arg1:T9 Arg2:T8
0,T1,Condition 17 20	HCV
1,T2,Temporal 0 11	Co-infected
2,T3,Condition 22 25	HIV
3,T4,Qualifier 29 34	other
4,T5,Condition 35 50	viral hepatitis
5,R1,Has_qualifier Arg1:T5 Arg2:T4
6,*,OR T1 T3 T5
7,T6,"Scope 17 50	HCV, HIV or other viral hepatitis"
8,R2,Has_temporal Arg1:T6 Arg2:T2
9,T7,Condition 66 69	HCC
0,T1,Drug 45 49	drug
1,T2,Drug 53 68	vaccine product
2,T3,Qualifier 11 26	investigational
3,T4,Qualifier 30 44	non-registered
4,*,OR T4 T3
5,T5,Scope 11 44	investigational or non-registered
6,*,OR T2 T1
7,T6,Temporal 69 133	within 30 days preceding the administration of the study vaccine
8,T7,Reference_point 94 133	the administration of the study vaccine
9,R1,Has_index Arg1:T6 Arg2:T7
10,T8,Non-query-able 137 148	planned use
11,T9,Temporal 149 195	within the first six weeks of the study period
12,T10,Observation 137 148	planned use
13,R2,Has_mood Arg1:T9 Arg2:T10
14,T11,Reference_point 179 195	the study period
15,R3,Has_index Arg1:T9 Arg2:T11
16,*,OR T9 T6
17,T12,Scope 69 195	within 30 days preceding the administration of the study vaccine or planned use within the first six weeks of the study period
18,T13,Scope 45 68	drug or vaccine product
19,R4,Has_scope Arg1:T13 Arg2:T5
20,R5,Has_scope Arg1:T13 Arg2:T12
21,T14,Context_Error 0 195	Use of any investigational or non-registered drug or vaccine product within 30 days preceding the administration of the study vaccine or planned use within the first six weeks of the study period
22,T15,Drug 248 265	influenza vaccine
23,T16,Qualifier 214 222	licensed
24,T17,Qualifier 226 247	other investigational
25,*,OR T17 T16
26,T18,Scope 214 247	licensed or other investigational
27,R6,Has_scope Arg1:T15 Arg2:T18
28,T19,Temporal 266 315	within 3 months prior to enrollment in this study
29,T20,Reference_point 291 315	enrollment in this study
30,R7,Has_index Arg1:T19 Arg2:T20
31,T21,Observation 319 335	expected receipt
32,T22,Non-query-able 319 335	expected receipt
33,T23,Drug 339 364	any influenza vaccination
34,T24,Temporal 365 382	before the Day 21
35,T25,Reference_point 376 382	Day 21
36,R8,Has_index Arg1:T24 Arg2:T25
37,R9,Has_temporal Arg1:T15 Arg2:T19
38,R10,Has_context Arg1:T23 Arg2:T21
39,R11,Has_temporal Arg1:T23 Arg2:T24
40,*,OR T23 T15
41,T26,Observation 401 408	History
42,T27,Condition 412 433	excessive alcohol use
43,T28,Condition 435 445	drug abuse
44,T29,Condition 461 480	psychiatric illness
45,T30,Undefined_semantics 461 480	psychiatric illness
46,T31,Qualifier 449 460	significant
47,R12,Has_qualifier Arg1:T29 Arg2:T31
48,*,OR T29 T28 T27
49,T32,"Scope 412 480	excessive alcohol use, drug abuse or significant psychiatric illness"
50,R13,Has_temporal Arg1:T32 Arg2:T26
51,T33,Condition 482 493	Tobacco use
52,T34,Temporal 494 523	within 3 months of enrollment
53,T35,Reference_point 513 523	enrollment
54,R14,Has_index Arg1:T34 Arg2:T35
55,R15,Has_temporal Arg1:T33 Arg2:T34
56,T36,Temporal 528 566	throughout first 6 months of the study
57,T37,Reference_point 557 566	the study
58,R16,Has_index Arg1:T36 Arg2:T37
59,R17,Has_temporal Arg1:T33 Arg2:T36
60,T38,Condition 574 589	chronic illness
61,T39,Undefined_semantics 574 589	chronic illness
62,T40,Condition 597 602;613 620	liver disease
63,T41,Condition 606 620	kidney disease
64,*,OR T41 T40
65,T42,Scope 597 620	liver or kidney disease
66,R18,Subsumes Arg1:T38 Arg2:T42
67,T43,Procedure 647 654	therapy
68,T44,Temporal 635 646	concomitant
69,R19,Has_temporal Arg1:T43 Arg2:T44
70,T45,Undefined_semantics 647 654	therapy
71,T46,Condition 663 682	any other condition
72,T47,Qualifier 688 749	could interfere with the subject's participation in the study
73,R20,Has_qualifier Arg1:T46 Arg2:T47
74,T48,Measurement 829 849	liver function tests
75,T49,Value 820 828	abnormal
76,T50,Qualifier 797 819	Clinically significant
77,R21,Has_value Arg1:T48 Arg2:T49
78,R22,Has_qualifier Arg1:T48 Arg2:T50
79,T51,Subjective_judgement 797 819	Clinically significant
80,T52,Temporal 850 862	at screening
81,T53,Reference_point 853 862	screening
82,R23,Has_index Arg1:T52 Arg2:T53
83,R24,Has_temporal Arg1:T48 Arg2:T52
84,T54,Measurement 886 891;904 914	HBsAg antibodies
85,T55,Measurement 893 896;904 914	HCV antibodies
86,T56,Measurement 900 914	HIV antibodies
87,*,OR T54 T55 T56
88,T57,"Scope 886 914	HBsAg, HCV or HIV antibodies"
89,T58,Value 864 872	Positive
90,R25,Has_value Arg1:T57 Arg2:T58
91,T59,Condition 916 924	Pregnant
92,T60,Condition 928 937	lactating
93,T61,Person 938 944	female
94,*,OR T60 T59
95,T62,Condition 953 959	cancer
96,T63,Condition 991 997	cancer
97,T64,Procedure 977 997	treatment for cancer
98,R26,AND Arg1:T64 Arg2:T63
99,T65,Temporal 998 1016	within three years
100,*,OR T62 T64
101,T66,Scope 953 997	cancer or have received treatment for cancer
102,R27,Has_temporal Arg1:T66 Arg2:T65
103,T67,Condition 1044 1050	cancer
104,T68,Observation 1033 1040	history
105,T69,Condition 1059 1071	disease-free
106,T70,Procedure 1080 1089	treatment
107,T71,Negation 1072 1079	without
108,R28,Has_negation Arg1:T70 Arg2:T71
109,R29,AND Arg1:T67 Arg2:T70
110,T72,Temporal 1090 1113	for three years or more
111,R30,Has_temporal Arg1:T67 Arg2:T68
112,R31,AND Arg1:T67 Arg2:T69
113,T73,Grammar_Error 1114 1126	are eligible
114,T74,Scope 1033 1126	history of cancer who are disease-free without treatment for three years or more are eligible
115,*,OR T74 T66
116,T75,Condition 1230 1260	impaired immune responsiveness
117,T76,Condition 1287 1304	diabetes mellitus
118,T77,Condition 1309 1329	autoimmune disorders
119,*,OR T77 T76
120,T78,Scope 1287 1329	diabetes mellitus and autoimmune disorders
121,R32,Subsumes Arg1:T75 Arg2:T78
122,T79,Temporal 1400 1426	within the past six months
123,T80,Drug 1428 1442	any medication
124,T81,Procedure 1446 1466	therapeutic modality
125,*,OR T81 T80
126,T82,Qualifier 1472 1497	affects the immune system
127,T83,Drug 1506 1519	allergy shots
128,T84,Drug 1521 1536	immune globulin
129,T85,Drug 1538 1548	interferon
130,T86,Drug 1550 1566	immunomodulators
131,T87,Procedure 1568 1585	radiation therapy
132,T88,Drug 1587 1602	cytotoxic drugs
133,T89,Drug 1606 1683	drugs known to be frequently associated with significant major organ toxicity
134,T90,Qualifier 1612 1683	known to be frequently associated with significant major organ toxicity
135,R33,Has_qualifier Arg1:T89 Arg2:T90
136,T91,Drug 1688 1712	systemic corticosteroids
137,T92,Qualifier 1714 1718	oral
138,T93,Qualifier 1722 1732	injectable
139,*,OR T93 T92
140,T94,Scope 1714 1732	oral or injectable
141,R34,Has_scope Arg1:T91 Arg2:T94
142,T95,Grammar_Error 1735 1783	Inhaled and topical corticosteroids are allowed.
143,T96,Scope 1428 1497	any medication or therapeutic modality that affects the immune system
144,R35,Has_qualifier Arg1:T96 Arg2:T82
145,*,OR T83 T84 T85 T86 T87 T88 T89 T91
146,T97,"Scope 1506 1733	allergy shots, immune globulin, interferon, immunomodulators, radiation therapy, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable)"
147,R36,Subsumes Arg1:T96 Arg2:T97
148,R37,Has_temporal Arg1:T96 Arg2:T79
149,T98,Condition 1818 1835	allergic reaction
150,T99,Qualifier 1811 1817	severe
151,R38,Has_qualifier Arg1:T98 Arg2:T99
152,T100,Observation 1800 1807	history
153,R39,Has_temporal Arg1:T98 Arg2:T100
154,T101,Temporal 1836 1863	after previous vaccinations
155,T102,Reference_point 1842 1863	previous vaccinations
156,R40,Has_index Arg1:T101 Arg2:T102
157,R41,Has_temporal Arg1:T98 Arg2:T101
158,T103,Condition 1867 1927	hypersensitivity to any seasonal influenza vaccine component
159,*,OR T98 T103
160,T104,Drug 1891 1927	seasonal influenza vaccine component
161,T105,Condition 1955 1978	Guillain-Barré Syndrome
162,T106,Procedure 1980 1996	Receipt of blood
163,T107,Procedure 1980 1990;2000 2014	Receipt of blood products
164,*,OR T106 T107
165,T108,Temporal 2015 2043	8 weeks prior to vaccination
166,T109,Reference_point 2032 2043	vaccination
167,R42,Has_index Arg1:T108 Arg2:T109
168,T110,Temporal 2070 2126	during the three week study period following vaccination
169,T111,Reference_point 2081 2126	three week study period following vaccination
170,R43,Has_index Arg1:T110 Arg2:T111
171,T112,Observation 2047 2069	planned administration
172,T113,Scope 1980 2014	Receipt of blood or blood products
173,*,OR T108 T112
174,R44,Has_temporal Arg1:T112 Arg2:T110
175,T114,Scope 2015 2126	8 weeks prior to vaccination or planned administration during the three week study period following vaccination
176,R45,Has_scope Arg1:T113 Arg2:T114
177,T115,Procedure 2128 2145	Donation of blood
178,T116,Procedure 2128 2139;2149 2163	Donation of blood products
179,*,OR T116 T115
180,T117,Temporal 2164 2199	within 8 weeks prior to vaccination
181,T118,Reference_point 2188 2199	vaccination
182,R46,Has_index Arg1:T117 Arg2:T118
183,T119,Temporal 2203 2237	during the three week study period
184,T120,Reference_point 2210 2237	the three week study period
185,R47,Has_index Arg1:T119 Arg2:T120
186,*,OR T117 T119
187,T121,Scope 2164 2237	within 8 weeks prior to vaccination or during the three week study period
188,T122,Scope 2128 2163	Donation of blood or blood products
189,R48,Has_scope Arg1:T122 Arg2:T121
190,T123,Measurement 2252 2268	oral temperature
191,T124,Value 2269 2276	>100.4°
192,R49,Has_value Arg1:T123 Arg2:T124
193,T125,Condition 2280 2293	acute disease
194,T126,Temporal 2294 2330	within 72 hours prior to vaccination
195,T127,Reference_point 2319 2330	vaccination
196,R50,Has_index Arg1:T126 Arg2:T127
197,*,OR T125 T123
198,T128,Scope 2252 2293	oral temperature >100.4° or acute disease
199,R51,Has_temporal Arg1:T128 Arg2:T126
200,T129,Condition 2361 2369;2380 2387	moderate illness
201,T130,Condition 2373 2387	severe illness
202,*,OR T130 T129
203,T131,Measurement 2548 2563	Body Mass Index
204,T132,Value 2564 2569	>29.9
205,R52,Has_value Arg1:T131 Arg2:T132
206,T133,Condition 2575 2598	disorder of coagulation
207,T134,Condition 2624 2633	influenza
208,T135,Temporal 2634 2663	within the previous 12 months
209,R53,Has_temporal Arg1:T134 Arg2:T135
210,T136,"Subjective_judgement 2665 2811	Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study"
211,T137,"Context_Error 2665 2811	Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study"
212,T138,"Post-eligibility 2665 2811	Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study"
0,T1,Condition 32 35	OCD
1,T2,Qualifier 16 23	primary
2,T3,Qualifier 24 31	DSM- IV
3,R1,Has_qualifier Arg1:T1 Arg2:T3
4,R2,Has_qualifier Arg1:T1 Arg2:T2
5,T4,Drug 411 422	medications
6,T5,Qualifier 400 410	concurrent
7,T6,Qualifier 375 381	Stable
8,T7,Temporal 383 398	8 wks or longer
9,R3,Has_qualifier Arg1:T4 Arg2:T5
10,R4,Has_qualifier Arg1:T4 Arg2:T6
11,R5,Has_temporal Arg1:T4 Arg2:T7
12,T8,Drug 433 448	benzodiazepines
13,T9,Drug 450 468	sedative hypnotics
14,T10,Drug 470 484	antipsychotics
15,T11,Drug 490 505	antidepressants
16,*,OR T11 T10 T9 T8
17,T12,"Scope 433 505	benzodiazepines, sedative hypnotics, antipsychotics, and antidepressants"
18,R6,Subsumes Arg1:T4 Arg2:T12
19,T13,Multiplier 53 60	14-week
20,T14,Drug 106 116	fluoxetine
21,T15,Multiplier 117 126	80 mg/day
22,T16,Drug 128 138	paroxetine
23,T17,Multiplier 139 148	60 mg/day
24,T18,Drug 150 161	fluvoxamine
25,T19,Multiplier 162 172	300 mg/day
26,T20,Drug 174 186	clomipramine
27,T21,Multiplier 187 197	250 mg/day
28,T22,Drug 199 209	sertraline
29,T23,Multiplier 210 220	200 mg/day
30,T24,Drug 222 232	citalopram
31,T25,Multiplier 233 242	60 mg/day
32,T26,Drug 244 256	escitalopram
33,T27,Multiplier 257 266	30 mg/day
34,T28,Condition 302 314	responses to
35,T29,Measurement 330 335	CGI-I
36,T30,Value 339 340	3
37,T31,Value 344 345	4
38,*,OR T30 T31
39,T32,Scope 339 345	3 or 4
40,R7,Has_scope Arg1:T29 Arg2:T32
41,T33,Measurement 347 353	Y-BOCS
42,T34,Value 354 372	reduction of < 35%
43,R8,Has_value Arg1:T33 Arg2:T34
44,*,OR T33 T29
45,T35,"Scope 330 372	CGI-I of 3 or 4, Y-BOCS reduction of < 35%"
46,R10,Has_multiplier Arg1:T14 Arg2:T15
47,R11,Has_multiplier Arg1:T16 Arg2:T17
48,R12,Has_multiplier Arg1:T18 Arg2:T19
49,R13,Has_multiplier Arg1:T20 Arg2:T21
50,R14,Has_multiplier Arg1:T22 Arg2:T23
51,R15,Has_multiplier Arg1:T24 Arg2:T25
52,R16,Has_multiplier Arg1:T26 Arg2:T27
53,*,OR T14 T16 T18 T20 T22 T24 T26
54,T36,Multiplier 81 98	one the following
55,T37,"Scope 106 266	fluoxetine 80 mg/day, paroxetine 60 mg/day, fluvoxamine 300 mg/day, clomipramine 250 mg/day, sertraline 200 mg/day, citalopram 60 mg/day, escitalopram 30 mg/day"
56,R17,Has_multiplier Arg1:T37 Arg2:T36
57,R18,Has_multiplier Arg1:T37 Arg2:T13
58,T38,Procedure 315 328	SRI treatment
59,R19,AND Arg1:T28 Arg2:T38
60,T39,Scope 302 328	responses to SRI treatment
61,R9,Subsumes Arg1:T39 Arg2:T35
62,T40,Visit 0 10	Outpatient
63,R20,AND Arg1:T1 Arg2:T40
0,T1,Temporal 18 26	previous
1,T2,Condition 27 43	prostate surgery
2,T3,Line 44 92	Patients who have muscle invasive bladder cancer
3,T4,Line 0 43	Patients who have previous prostate surgery
4,T5,Condition 78 92	bladder cancer
5,T6,Qualifier 62 77	muscle invasive
6,R1,Has_qualifier Arg1:T5 Arg2:T6
7,R2,Has_temporal Arg1:T2 Arg2:T1
0,T1,Parsing_Error 0 2	NA
0,T1,Procedure 0 3	PGD
1,T2,Multiplier 14 25	More than 4
2,T3,Temporal 26 34	previous
3,T4,Procedure 35 51	embryo transfers
4,R1,Has_temporal Arg1:T4 Arg2:T3
5,R2,Has_multiplier Arg1:T4 Arg2:T2
0,T1,Condition 0 19	Chronic hepatitis B
1,T2,Drug 22 31	Antiviral
2,T3,Mood 32 43	experienced
3,R1,Has_mood Arg1:T2 Arg2:T3
4,T4,Observation 32 43	experienced
5,R2,multi Arg1:T3 Arg2:T4
6,T5,Drug 69 72	TDF
7,T6,Procedure 69 91	TDF anti-HBV treatment
8,T7,Multiplier 59 68	long term
9,R3,Has_multiplier Arg1:T5 Arg2:T7
10,T8,Condition 78 81	HBV
11,R4,multi Arg1:T6 Arg2:T5
12,R5,multi Arg1:T6 Arg2:T8
13,T9,Measurement 94 101	HBV DNA
14,T10,Value 102 115	< 6 log IU/ml
15,T11,Qualifier 117 121	LLOD
16,R6,Has_value Arg1:T9 Arg2:T10
17,R7,Has_qualifier Arg1:T9 Arg2:T11
18,T12,Informed_consent 124 182	Able to sign the consent form of anticipating in the study
0,T1,Condition 8 27	acute kidney injury
1,T2,Measurement 28 33	Stage
2,T3,Value 34 37	2/3
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Procedure 50 67	kidney transplant
6,T5,Observation 39 46	History
7,R3,Has_temporal Arg1:T4 Arg2:T5
0,T1,Condition 25 32	Healthy
1,T2,Condition 4 11	healthy
2,T3,Person 96 104	patients
3,A1,Optional T2
4,A2,Optional T3
5,T4,Negation 34 41	without
6,T5,Condition 42 51	allergies
7,T6,Value 72 89	18 years or above
8,T7,Person 65 68	age
9,R1,Has_value Arg1:T7 Arg2:T6
10,R2,Has_negation Arg1:T5 Arg2:T4
11,T8,"Scope 25 89	Healthy, without allergies and with the age of 18 years or above"
12,R3,Has_scope Arg1:T2 Arg2:T8
13,T9,Condition 106 117	Burn injury
14,T10,Value 118 131;158 159	exceeding 6-8 %
15,T11,Measurement 132 157	Total Burned Surface Area
16,R4,Has_value Arg1:T11 Arg2:T10
17,T12,Scope 106 159	Burn injury exceeding 6-8 Total Burned Surface Area %
18,R5,Has_scope Arg1:T3 Arg2:T12
0,T1,Drug 0 26	Cholesterol-lowering drugs
1,T2,Condition 28 45	Diabetes Mellitus
2,T3,Condition 47 69	Cardiovascular disease
3,T4,Condition 78 87	arrythmia
4,T5,Condition 89 112	ischaemic heart disease
5,*,OR T4 T5
6,T6,"Scope 78 112	arrythmia, ischaemic heart disease"
7,R1,Subsumes Arg1:T3 Arg2:T6
8,T7,Condition 115 140	Musculoskeletal disorders
9,T8,Qualifier 141 192	preventing the subject to perform physical training
10,R2,Has_qualifier Arg1:T7 Arg2:T8
11,T9,Condition 194 210	Mental disorders
12,T10,Qualifier 211 271	preventing the subject to understand the project description
13,R3,Has_qualifier Arg1:T9 Arg2:T10
0,T1,Condition 0 21	Cervical spine injury
1,T2,Observation 27 42	functional loss
2,T3,Qualifier 50 65	upper extremity
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,R2,Has_context Arg1:T1 Arg2:T2
5,T4,Condition 98 112	C-spine injury
6,T5,Temporal 67 87	Greater than 4 month
7,R3,Has_temporal Arg1:T4 Arg2:T5
8,T6,Observation 121 135	motor recovery
9,T7,Qualifier 114 120	Stable
10,R4,Has_qualifier Arg1:T6 Arg2:T7
11,T8,Condition 147 153	stable
12,T9,Qualifier 137 146	Medically
13,R5,Has_qualifier Arg1:T8 Arg2:T9
14,T10,Measurement 155 222	International Classification for Surgery of the Hand in Tetraplegia
15,T11,Value 226 229	0-5
16,T12,Temporal 230 241	at 6 months
17,R6,Has_value Arg1:T10 Arg2:T11
18,R7,Has_temporal Arg1:T10 Arg2:T12
19,T13,Measurement 264 273	extension
20,T14,Qualifier 258 263	thumb
21,T15,Qualifier 251 257	finger
22,T16,Value 243 250	Grade 0
23,*,OR T15 T14
24,T17,Scope 251 263	finger/thumb
25,R8,Has_scope Arg1:T13 Arg2:T17
26,R9,Has_value Arg1:T13 Arg2:T16
27,T18,Temporal 274 285	at 6 months
28,R10,Has_temporal Arg1:T13 Arg2:T18
29,T19,"Post-eligibility 287 370	Subjects fluent in English or when not fluent, an appropriate translator is present"
0,T1,Measurement 9 26	blood-cholesterol
1,T2,Value 0 8	Elevated
2,R1,Has_value Arg1:T1 Arg2:T2
0,T1,Condition 0 13	Heart failure
1,T2,Condition 24 37	kidney injury
2,T3,Condition 24 30;38 45	kidney failure
3,*,OR T3 T2
4,T4,Mood 15 23	Signs of
5,T5,Scope 24 45	kidney injury/failure
6,R1,Has_mood Arg1:T5 Arg2:T4
7,T6,Qualifier 47 53	Severe
8,T7,Condition 54 63	allergies
9,R2,Has_qualifier Arg1:T7 Arg2:T6
0,T1,Person 0 10	= 18 years
1,T2,Value 0 10	= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 12 21	High risk
4,T4,Measurement 32 62	General Surgery AKI Risk Index
5,T5,"Value 63 81	Class III, IV or V"
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,Subsumes Arg1:T3 Arg2:T4
8,T6,Procedure 83 106	Major abdominal surgery
0,T1,Person 9 16	patient
1,T2,Qualifier 0 8	Unstable
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 18 35	Joint contracture
4,T4,Condition 37 47	Spasticity
5,T5,Observation 49 65	Loss of function
6,T6,Mood 84 95	improved by
7,T7,Procedure 105 120	tendon transfer
8,T8,Procedure 122 131	tenodesis
9,T9,Procedure 135 146	arthrodesis
10,*,OR T7 T8 T9
11,T10,"Scope 105 146	tendon transfer, tenodesis or arthrodesis"
12,R2,Has_mood Arg1:T10 Arg2:T6
13,R3,Has_scope Arg1:T5 Arg2:T10
14,T11,Observation 178 188;202 211	recovering extension
15,T12,Qualifier 189 195	finger
16,T13,Qualifier 196 201	thumb
17,*,OR T12 T13
18,T14,Scope 189 201	finger/thumb
19,R4,Has_scope Arg1:T11 Arg2:T14
20,T15,Temporal 212 225	at 4-6 months
21,R5,Has_temporal Arg1:T11 Arg2:T15
22,T16,Condition 255 273	spinal cord injury
23,T17,Temporal 227 249	Greater than 12 months
24,R6,Has_temporal Arg1:T16 Arg2:T17
25,T18,Post-eligibility 275 347	Subject not fluent in English or an appropriate translator not available
0,T1,Mood 0 9	Scheduled
1,T2,Procedure 10 22	back surgery
2,R1,Has_mood Arg1:T2 Arg2:T1
0,T1,Condition 0 32	Contraindication for hepatectomy
1,T2,Condition 44 71	gastrointestinal hemorrhage
2,T3,Condition 80 101	hemorrhagic disorders
3,T4,Qualifier 73 79	severe
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Condition 130 147	infectious lesion
6,T6,Qualifier 118 129	nonspecific
7,T7,Temporal 112 117	acute
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,R3,Has_temporal Arg1:T5 Arg2:T7
10,T8,Condition 155 162	ascites
11,T9,Qualifier 149 154	overt
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Measurement 164 180	Child-Pugh Score
14,T11,Value 181 182	C
15,R5,Has_value Arg1:T10 Arg2:T11
16,T12,Measurement 184 234	indocyanine green retention rate at 15min (ICGR15)
17,T13,Value 234 238	＞30%
18,R6,Has_value Arg1:T12 Arg2:T13
19,T14,Measurement 244 277	serum hepatitis B virus (HBV)-DNA
20,T15,Value 277 291	＞126 copies/ml
21,T16,Measurement 296 332	serum alanine aminotransferase (ALT)
22,T17,Value 333 340	＞ 2×ULN
23,R7,Has_value Arg1:T16 Arg2:T17
24,T18,Measurement 342 361	serum triglycerides
25,T19,Value 361 372	＞2.0 mmol/L
26,R8,Has_value Arg1:T18 Arg2:T19
27,T20,Condition 374 391	circulatory shock
28,T21,Condition 393 399	stroke
29,T22,Condition 401 428	acute myocardial infarction
30,T23,Condition 430 443	renal failure
31,T24,Condition 445 449	coma
32,T25,Qualifier 453 466	unknown cause
33,R9,Has_qualifier Arg1:T24 Arg2:T25
34,*,OR T2 T3 T5 T8 T10 T12 T14 T16 T18 T20 T21 T22 T23 T24
35,R10,Has_value Arg1:T14 Arg2:T15
36,T26,"Scope 44 466	gastrointestinal hemorrhage, severe hemorrhagic disorders, explicit acute nonspecific infectious lesion, overt ascites, Child-Pugh Score C, indocyanine green retention rate at 15min (ICGR15)＞30%(12), serum hepatitis B virus (HBV)-DNA＞126 copies/ml and serum alanine aminotransferase (ALT) ＞ 2×ULN, serum triglycerides＞2.0 mmol/L, circulatory shock, stroke, acute myocardial infarction, renal failure, coma of unknown cause"
37,R11,Subsumes Arg1:T1 Arg2:T26
38,T27,Procedure 21 32	hepatectomy
39,R12,AND Arg1:T1 Arg2:T27
40,T28,Condition 468 477	Pregnancy
41,T29,Person 479 482	Age
42,T30,Value 485 496	＜18y or＞75y
43,R13,Has_value Arg1:T29 Arg2:T30
44,T31,Procedure 508 531	intraoperative ablation
45,T32,Condition 533 551	Unresectable tumor
46,T33,Drug 597 601;609 617	fish proteins
47,T34,Drug 605 617	egg proteins
48,*,OR T34 T33
49,T35,Condition 570 588	Allergic reactions
50,T36,Scope 597 617	fish or egg proteins
51,R14,Has_scope Arg1:T35 Arg2:T36
0,T1,Measurement 0 44	American Association of Anesthesiology class
1,T2,Value 45 48	1-3
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 50 82	American Heart Association class
4,T4,Value 83 85	>3
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 87 90	BMI
7,T6,Value 91 94	>37
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Qualifier 96 111	Insulin treated
10,T8,Condition 112 120	diabetes
11,T9,Drug 96 103	Insulin
12,R4,multi Arg1:T7 Arg2:T9
13,R5,Has_qualifier Arg1:T8 Arg2:T7
14,T10,Condition 122 131	Pregnancy
15,T11,Observation 135 149	breast feeding
16,*,OR T11 T10
17,T12,Condition 151 163	Sensistivity
18,T13,Condition 164 171	allergy
19,T14,Drug 180 197	anesthetic agents
20,*,OR T12 T13
21,T15,Scope 151 171	Sensistivity/allergy
22,R6,AND Arg1:T15 Arg2:T14
23,T16,Observation 199 239	Inadequate understanding about the study
24,T17,Value 241 250	Depressed
25,T18,Measurement 251 266	kidney function
26,T19,Condition 274 277	AKI
27,R7,Has_value Arg1:T18 Arg2:T17
28,T20,Condition 241 266	Depressed kidney function
29,R8,multi Arg1:T20 Arg2:T18
30,*,OR T20 T19
31,T21,Value 279 288	Depressed
32,T22,Measurement 289 303	liver function
33,R9,Has_value Arg1:T22 Arg2:T21
34,T23,Condition 279 303	Depressed liver function
35,R10,multi Arg1:T23 Arg2:T22
36,T24,Qualifier 305 312	Genetic
37,T25,Condition 313 335	malignant hyperthermia
38,R11,Has_qualifier Arg1:T25 Arg2:T24
0,T1,Condition 4 13	cirrhotic
1,T2,Condition 14 26	malnourished
2,T3,Condition 58 70	liver cancer
3,T4,Temporal 71 85	preoperatively
4,T5,Procedure 100 111	hepatectomy
5,R1,Has_temporal Arg1:T3 Arg2:T4
0,T1,Multiplier 0 14	30 min or more
1,T2,Condition 42 49	seizure
2,T3,Condition 78 85	seizure
3,T4,Temporal 22 32	continuous
4,R1,Has_temporal Arg1:T2 Arg2:T4
5,T5,Temporal 68 77	recurrent
6,R2,Has_temporal Arg1:T3 Arg2:T5
7,T6,Qualifier 97 113	without recovery
8,T7,Scope 68 85	recurrent seizure
9,*,OR T7 T6 T2
10,T8,Non-query-able 155 181	clinical data is complete.
0,T1,Condition 0 9	treatment
1,T2,Condition 30 45	B-cell lymphoma
2,T3,Negation 10 15	naive
3,R1,Has_negation Arg1:T1 Arg2:T3
4,T4,Condition 47 61	HBsAg positive
5,T5,Temporal 62 73	at baseline
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Qualifier 88 103	rituximab-based
8,T7,Drug 88 97	rituximab
9,R3,multi Arg1:T6 Arg2:T7
10,T8,Procedure 104 122	immunochemotherapy
11,R4,Has_qualifier Arg1:T8 Arg2:T6
12,T9,Observation 124 139	life expectancy
13,T10,Value 143 161	more than 3 months
14,R5,Has_value Arg1:T9 Arg2:T10
0,T1,Person 13 16	Age
1,T2,Value 17 27	= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 33 63	MGH transplant center criteria
4,T4,Procedure 76 92	liver transplant
5,R2,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Measurement 94 97	HCV
7,T6,Value 98 103	naive
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 94 103	HCV naive
10,R4,multi Arg1:T7 Arg2:T5
11,T8,Observation 105 134	Able to sign informed consent
0,T1,Condition 19 41	pulmonary hypertension
1,T3,Condition 175 205	chronic disease involved liver
2,T4,Temporal 166 171	acute
3,T5,Qualifier 158 165	serious
4,T6,Condition 175 199;207 213	chronic disease involved kidney
5,T7,Condition 175 199;219 224	chronic disease involved brain
6,*,OR T6 T7 T3
7,T8,"Scope 175 224	chronic disease involved liver, kidney, and brain"
8,R1,Has_temporal Arg1:T8 Arg2:T4
9,R2,Has_qualifier Arg1:T8 Arg2:T5
10,T9,Drug 247 263	CYP3A4-inhibitor
11,T10,Drug 267 274	nitrate
12,T11,Qualifier 240 246	potent
13,T12,Drug 350 360	sildenafil
14,T13,Condition 365 368	PAH
15,T14,Drug 379 389	sildenafil
16,T15,Drug 393 402	tadalafil
17,*,OR T14 T15 T12
18,T16,Observation 411 446	contraindications in package insert
19,T2,Observation 57 102	refuse to subscribe written informed consents
20,T17,Observation 106 136	can't cooperate with the trial
21,*,OR T2 T17
22,T18,Condition 288 307	underlying diseases
23,T19,Scope 247 274	CYP3A4-inhibitor or nitrate
24,*,OR T9 T10
25,R3,Has_qualifier Arg1:T19 Arg2:T11
26,R4,AND Arg1:T19 Arg2:T18
27,T20,Qualifier 4 15	other types
28,R6,Has_qualifier Arg1:T1 Arg2:T20
29,T21,Temporal 327 336	currently
30,T22,Scope 350 402	sildenafil for PAH or taking sildenafil or tadalafil
31,R7,Has_temporal Arg1:T22 Arg2:T21
0,T1,Condition 0 15	hypoglycemia SE
1,T2,Condition 16 30	psychogenic SE
2,T3,Condition 41 50	pseudo-SE
3,*,OR T3 T2 T1
0,T1,Value 0 21	younger than 18 years
1,T2,Person 22 25	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 27 41	HBsAg negative
4,T4,Temporal 42 53	at baseline
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Condition 55 63	pregnant
7,T6,Condition 67 76	lactating
8,T7,Person 77 82	women
9,*,OR T5 T6
10,T8,Scope 55 76	pregnant or lactating
11,R3,Has_scope Arg1:T7 Arg2:T8
0,T1,Condition 0 8	Pregnant
1,T2,Observation 12 19	nursing
2,T3,Observation 21 30	lactating
3,R1,Subsumes Arg1:T2 Arg2:T3
4,T4,Person 32 37	women
5,*,OR T1 T2
6,T5,Condition 39 53	HIV positivity
7,T6,Measurement 39 42	HIV
8,T7,Value 43 53	positivity
9,R2,Has_value Arg1:T6 Arg2:T7
10,R3,multi Arg1:T5 Arg2:T6
11,T8,Procedure 64 85	dual organ transplant
12,T9,Mood 55 63	Need for
13,R4,Has_mood Arg1:T8 Arg2:T9
14,T10,Condition 91 108	contra-indication
15,T11,Procedure 112 133	liver transplantation
16,R5,AND Arg1:T10 Arg2:T11
0,T1,Person 9 13	aged
1,T2,Value 14 19	12-65
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 32 65	idiopathic pulmonary hypertension
4,T4,Qualifier 67 103	connective tissue disease associated
5,T5,Condition 104 126	pulmonary hypertension
6,T6,Qualifier 128 152	congenital heart disease
7,T7,Condition 158 178	Eisenmenger syndrome
8,T10,Condition 191 213	pulmonary hypertension
9,R2,AND Arg1:T6 Arg2:T7
10,R3,causal Arg1:T10 Arg2:T6
11,T8,Measurement 225 251	6-minutes walking distance
12,T9,Value 252 261	150m-550m
13,R4,Has_value Arg1:T8 Arg2:T9
14,T11,Temporal 216 224	Baseline
15,R5,Has_temporal Arg1:T8 Arg2:T11
16,T12,Measurement 264 299	WHO pulmonary hypertension function
17,T13,Value 300 306	II-III
18,R6,Has_value Arg1:T12 Arg2:T13
19,T14,Condition 312 353	non-responder to calcium channel blockers
20,T15,Drug 329 353	calcium channel blockers
21,R7,multi Arg1:T14 Arg2:T15
22,R8,AND Arg1:T12 Arg2:T14
23,R9,Has_qualifier Arg1:T5 Arg2:T4
24,*,OR T3 T5 T10
25,T16,Observation 367 391	written informed consent
0,T1,Person 0 5	Males
1,T2,Person 10 17	females
2,*,OR T1 T2
3,T3,Grammar_Error 6 9	and
4,T4,Qualifier 42 47;84 89	Fabry naïve
5,T5,Procedure 97 100	ERT
6,T6,Procedure 52 63	GLA enzymes
7,T7,Procedure 71 82	DNA testing
8,*,OR T6 T7
9,T8,Scope 52 82	GLA enzymes and/or DNA testing
10,R1,Has_scope Arg1:T4 Arg2:T8
11,T9,Condition 23 40	confirmed disease
12,T10,Context_Error 23 40	confirmed disease
13,T11,Condition 102 124	Mitochondrial diseases
14,T12,Procedure 126 150	electron transport chain
15,T13,Procedure 158 169	DNA testing
16,*,OR T12 T13
17,T14,Scope 126 169	electron transport chain and/or DNA testing
18,R2,Has_scope Arg1:T11 Arg2:T14
19,T15,Condition 174 200	connective tissue diseases
20,T16,Procedure 227 238	DNA testing
21,A1,Optional T16
22,T17,Observation 202 219	clinical criteria
23,*,OR T17 T16
24,T18,Scope 202 238	clinical criteria and/or DNA testing
25,R3,Has_scope Arg1:T15 Arg2:T18
26,T19,Context_Error 42 47;84 89	Fabry naïve
27,*,OR T15 T11 T20
28,T20,Scope 42 100	Fabry (by GLA enzymes and/or DNA testing) naïve and on ERT
29,T21,"Scope 42 254	Fabry (by GLA enzymes and/or DNA testing) naïve and on ERT, Mitochondrial diseases (electron transport chain and/or DNA testing) or connective tissue diseases (clinical criteria and/or DNA testing when available)"
30,R4,Subsumes Arg1:T9 Arg2:T21
31,T22,Post-eligibility 256 353	Consenting adults (18 years and older) who agrees and consents to skin biopsy and QSART procedure
32,T23,Non-query-able 256 353	Consenting adults (18 years and older) who agrees and consents to skin biopsy and QSART procedure
0,T1,Observation 0 15	treatment-naive
1,T2,Condition 30 38	lymphoma
2,T3,Measurement 40 45	HBsAg
3,T4,Value 46 54	negative
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Measurement 55 60	HBcAb
6,T6,Value 61 69	positive
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Measurement 70 91	hepatitis B virus DNA
9,T8,Value 92 100	negative
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Temporal 101 112	at baseline
12,T10,Scope 40 100	HBsAg negative/HBcAb positive/hepatitis B virus DNA negative
13,R4,Has_temporal Arg1:T10 Arg2:T9
14,T11,Procedure 127 139	chemotherapy
15,T12,Procedure 147 172	immunosuppressive therapy
16,T13,Observation 174 189	life expectancy
17,T14,Temporal 193 211	more than 3 months
18,R5,Has_temporal Arg1:T13 Arg2:T14
0,T1,Intoxication_considerations 0 97	Active alcohol or drug use or dependence which may interfere with adherence to study requirements
1,T2,Condition 99 111	HIV-infected
2,T3,Temporal 112 124	at screening
3,T4,Temporal 112 114;128 138	at enrollment
4,*,OR T4 T3
5,T5,Scope 112 138	at screening or enrollment
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Measurement 140 154	Estimated CrCl
8,T7,Value 155 166	< 60 mL/min
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Non-query-able 168 210	Past participation in an HIV vaccine study
11,T9,Value 212 220	Positive
12,T10,Measurement 221 253	Hepatitis B surface antigen test
13,R3,Has_value Arg1:T10 Arg2:T9
14,T11,Condition 266 283	medical condition
15,T12,Condition 289 306	survival unlikely
16,R4,AND Arg1:T11 Arg2:T12
17,T14,Condition 472 480	Pregnant
18,T15,Observation 484 498	breast feeding
19,*,OR T15 T14
20,T16,Pregnancy_considerations 500 535	Actively trying to achieve pregnanc
21,T13,Condition 336 345	condition
22,T17,Qualifier 387 425	make participation in the study unsafe
23,T18,Qualifier 429 470	interfere with achieving study objectives
24,*,OR T17 T18
25,T19,Scope 387 470	make participation in the study unsafe or interfere with achieving study objectives
26,R5,Has_scope Arg1:T13 Arg2:T19
0,T1,Condition 13 24	infertility
1,T2,Value 26 45	older than 20 years
2,T3,Person 49 52	age
3,T4,Value 57 80	not older than 40 years
4,R1,Has_value Arg1:T3 Arg2:T2
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 87 102	Body mass index
7,T6,Measurement 104 107	BMI
8,T7,Value 109 114	20-29
9,R3,Subsumes Arg1:T5 Arg2:T6
10,R4,Has_value Arg1:T5 Arg2:T7
11,T8,Person 121 126	women
12,T9,Multiplier 144 155	two or more
13,T10,Procedure 156 168	implantation
14,T11,Qualifier 169 176	failure
15,R5,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Condition 191 225	inadequate endometrial development
17,T13,Mood 177 190	attributed to
18,R6,Has_mood Arg1:T12 Arg2:T13
19,R7,Has_multiplier Arg1:T10 Arg2:T9
20,R8,AND Arg1:T10 Arg2:T12
0,T1,Condition 14 23;47 55	cognitive problems
1,T2,Condition 25 36;47 55	psychiatric problems
2,*,OR T2 T1 T3
3,T3,Condition 41 86	other problems that preclude informed consent
4,T4,"Undefined_semantics 0 86	Subjects with cognitive, psychiatric, or other problems that preclude informed consent"
5,T5,Subjective_judgement 41 86	other problems that preclude informed consent
6,T6,Condition 114 133	glucose intolerance
7,T7,Condition 137 145	diabetes
8,*,OR T6 T7
9,T8,Observation 103 110	history
10,R1,Has_temporal Arg1:T6 Arg2:T8
11,R2,Has_temporal Arg1:T7 Arg2:T8
12,T9,Procedure 159 171	chemotherapy
13,T10,Condition 197 212	bleeding wounds
14,T11,Condition 189 193;206 212	open wounds
15,*,OR T10 T11
16,T12,Qualifier 213 257	at any sensor plate contact surface location
17,R3,Has_qualifier Arg1:T11 Arg2:T12
18,R4,Has_qualifier Arg1:T10 Arg2:T12
19,T13,Device 283 301	implantable device
20,T14,Condition 315 327	missing hand
21,T15,Condition 315 322;338 341	missing leg
22,*,OR T15 T14
23,T16,Condition 346 354	Pregnant
24,T17,Observation 396 414	possible pregnancy
25,*,OR T17 T16
26,T18,Non-query-able 378 414	uncertain about a possible pregnancy
27,T19,Condition 425 471	sensitive to chemicals used to induce sweating
28,T20,Undefined_semantics 425 471	sensitive to chemicals used to induce sweating
29,T21,Condition 487 503	heat intolerance
30,T22,Condition 519 537	bleeding disorders
31,T23,Procedure 559 580	anticoagulant therapy
32,T24,Temporal 551 558	current
33,R5,Has_temporal Arg1:T23 Arg2:T24
34,T25,Condition 596 603	keloids
35,T26,Qualifier 604 631	on the intended biopsy site
36,R6,Has_qualifier Arg1:T25 Arg2:T26
37,T27,Condition 645 661	hypersensitivity
38,T28,Drug 665 693	local amide-type anesthetics
39,R7,AND Arg1:T27 Arg2:T28
0,T1,Value 0 21	younger than 18 years
1,T2,Person 22 25	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 27 41	HBsAg positive
4,T4,Condition 45 59	HBcAb negative
5,T5,Condition 63 93	hepatitis B virus DNA positive
6,T6,Temporal 94 105	at baseline
7,*,OR T4 T5 T3
8,T7,Scope 27 93	HBsAg positive or HBcAb negative or hepatitis B virus DNA positive
9,R2,Has_temporal Arg1:T7 Arg2:T6
10,T8,Condition 107 115	pregnant
11,T9,Condition 119 128	lactating
12,*,OR T8 T9
13,T10,Person 129 134	women
0,T1,Condition 4 25	Uterine abnormalities
1,T2,Condition 32 39;64 70	septate uterus
2,T3,Condition 41 51;64 70	bicornuate uterus
3,T4,Condition 56 70	fibroid uterus
4,T5,Condition 72 89	Asherman Syndrome
5,*,OR T5 T2 T3 T4
6,T6,"Scope 32 89	septate, bicornuate and fibroid uterus, Asherman Syndrome"
7,R1,Has_scope Arg1:T1 Arg2:T6
8,T7,Temporal 93 103	Concurrent
9,T8,Drug 111 127	organic nitrites
10,T9,Drug 132 140	nitrates
11,R2,Has_temporal Arg1:T8 Arg2:T7
12,R3,Has_temporal Arg1:T9 Arg2:T7
13,T10,Qualifier 143 149	Severe
14,T11,Condition 150 168	hepatic impairment
15,R4,Has_qualifier Arg1:T11 Arg2:T10
16,T12,Qualifier 171 177	Severe
17,T13,Condition 178 194	renal impairment
18,T14,Condition 197 208	Hypotension
19,R5,Has_qualifier Arg1:T13 Arg2:T12
20,T15,Condition 218 224	stroke
21,T16,Condition 228 240	heart attack
22,*,OR T15 T16
23,T17,Temporal 211 217	Recent
24,T18,Scope 218 240	stroke or heart attack
25,R6,Has_temporal Arg1:T18 Arg2:T17
0,T1,Value 0 13	18 - 64 years
1,T2,Person 14 17	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Non-query-able 19 39	Able to give consent
4,T4,Observation 41 56	unprotected sex
5,T5,Temporal 58 74	in past 6 months
6,T6,Multiplier 81 90	1 or more
7,T7,Person 91 116	men of unknown HIV status
8,R2,Has_multiplier Arg1:T7 Arg2:T6
9,R3,Has_temporal Arg1:T4 Arg2:T5
10,R4,AND Arg1:T4 Arg2:T7
11,T8,Procedure 118 138	evaluated for an STI
12,T9,Temporal 139 173	within 6 months prior to screening
13,T10,Reference_point 164 173	screening
14,R5,Has_index Arg1:T9 Arg2:T10
15,R6,Has_temporal Arg1:T8 Arg2:T9
16,T11,Observation 175 178	sex
17,T12,Person 204 224	HIV-infected partner
18,R7,AND Arg1:T11 Arg2:T12
19,T13,Temporal 179 195	in last 6 months
20,R8,Has_temporal Arg1:T11 Arg2:T13
21,T15,Observation 245 284	using previously used or shared needles
22,T16,Temporal 285 301	in past 6 months
23,T17,Drug 319 328	methadone
24,T18,Drug 330 343	buprenorphine
25,T19,Drug 348 356	suboxone
26,T20,Procedure 357 374	treatment program
27,T21,Temporal 375 391	in past 6 months
28,T22,Observation 395 433	engaging in high-risk sexual behaviors
29,R10,Has_temporal Arg1:T15 Arg2:T16
30,T14,Person 226 229	IDU
31,*,OR T17 T18 T19
32,T23,"Scope 319 356	methadone, buprenorphine, or suboxone"
33,R9,Has_scope Arg1:T20 Arg2:T23
34,R11,Has_temporal Arg1:T20 Arg2:T21
35,*,OR T15 T20 T22
36,T24,Observation 459 476	transactional sex
37,T25,Observation 482 495	sex for money
38,T26,Observation 482 489;497 502	sex for drugs
39,T27,Observation 482 489;507 514	sex for housing
40,*,OR T25 T26 T27
41,T28,"Scope 482 514	sex for money, drugs, or housing"
42,R12,Subsumes Arg1:T24 Arg2:T28
43,T29,Observation 517 553	Infrequently uses condoms during sex
44,T30,Multiplier 559 568	1 or more
45,T31,Person 569 599	partners of unknown HIV status
46,T32,Observation 620 656	at substantial risk of HIV infection
47,R13,Has_context Arg1:T31 Arg2:T32
48,T33,Person 658 661	IDU
49,T34,Person 665 686	bisexual male partner
50,*,OR T33 T34
51,R14,Has_multiplier Arg1:T31 Arg2:T30
52,R15,AND Arg1:T29 Arg2:T31
53,T35,Measurement 689 693	CrCl
54,T36,Value 694 705	= 60 ml/min
55,R16,Has_value Arg1:T35 Arg2:T36
56,T37,Condition 707 722	HIV- uninfected
57,T38,Person 723 728	women
58,T39,Procedure 738 742	PrEP
59,T40,Mood 729 737	desiring
60,R17,Has_mood Arg1:T39 Arg2:T40
0,T1,Condition 6 36	intolerance to the doxycycline
1,T2,Drug 25 36	doxycycline
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Measurement 37 48	Body weight
4,T4,Value 49 55	<40 kg
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 56 65	Pregnancy
7,T6,Observation 69 82	breastfeeding
8,*,OR T6 T5 T13 T3 T1
9,T7,Condition 101 118	allergic reaction
10,T8,Qualifier 94 100	severe
11,R3,Has_qualifier Arg1:T7 Arg2:T8
12,T9,Condition 122 133	anaphylaxis
13,T10,Condition 134 141;150 155	Alcohol abuse
14,T11,Condition 145 155	drug abuse
15,*,OR T9 T7
16,*,OR T10 T11
17,T12,Observation 83 93	History of
18,T13,Scope 94 155	severe allergic reaction or anaphylaxis Alcohol or drug abuse
19,R4,Has_temporal Arg1:T13 Arg2:T12
0,T1,Person 0 3	Age
1,T2,Value 4 19	35-70 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 21 42	Fasting blood glucose
4,T4,Value 43 56	100-125 mg/dL
5,R2,Has_value Arg1:T3 Arg2:T4
0,T1,Observation 21 35	close to death
1,T2,Temporal 11 20	have been
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Person 0 6	Babies
4,T4,Condition 37 44	Seizure
5,T5,Qualifier 57 74	metabolic factors
6,T6,Condition 76 88	hypoglycemia
7,T7,Condition 90 102	hypocalcemia
8,T8,Condition 104 124	electrolyte disorder
9,*,OR T6 T7 T8
10,T9,"Scope 76 124	hypoglycemia, hypocalcemia, electrolyte disorder"
11,R2,Subsumes Arg1:T5 Arg2:T9
12,R3,Has_qualifier Arg1:T4 Arg2:T5
13,T10,Person 127 133	Babies
14,T11,Drug 152 166	phenobarbitone
15,T12,Qualifier 170 179	any other
16,T13,Drug 180 205	anticonvulsive medication
17,T14,Temporal 206 228	before hospitalization
18,T15,Procedure 213 228	hospitalization
19,T16,Reference_point 213 228	hospitalization
20,R4,multi Arg1:T16 Arg2:T15
21,R5,Has_index Arg1:T14 Arg2:T16
22,R6,Has_qualifier Arg1:T13 Arg2:T12
23,*,OR T11 T13
24,T17,Scope 152 205	phenobarbitone or any other anticonvulsive medication
25,R7,Has_temporal Arg1:T17 Arg2:T14
26,T18,Value 230 238	Abnormal
27,T19,Measurement 239 253	renal function
28,R8,Has_value Arg1:T19 Arg2:T18
29,T20,Condition 230 253	Abnormal renal function
30,R9,multi Arg1:T20 Arg2:T19
0,T1,Qualifier 0 8	Elective
1,T2,Procedure 9 36	open abdominal hysterectomy
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Qualifier 42 58	midline incision
4,R2,Has_qualifier Arg1:T2 Arg2:T3
5,T4,Person 60 63	age
6,T5,Value 64 74	> 18 years
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Measurement 76 133	American Society of Anesthesiologist classification score
9,T7,Measurement 135 153	ASA classification
10,T8,Value 155 158	1-3
11,R4,Subsumes Arg1:T6 Arg2:T7
12,R5,Has_value Arg1:T6 Arg2:T8
0,T1,Person 0 3	Age
1,T2,Value 4 15	18 or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-query-able 17 134	Willing and able to comply with the study procedures and provide written informed consent to participate in the study
4,T4,Condition 158 175	pancreatic cancer
5,T5,Mood 149 157	probable
6,T6,Condition 177 225	distal common bile duct (CBD) cholangiocarcinoma
7,T7,Condition 236 257	periampullary cancers
8,T8,Qualifier 230 235	other
9,R2,Has_qualifier Arg1:T7 Arg2:T8
10,*,OR T7 T6 T4
11,T9,"Scope 158 257	pancreatic cancer, distal common bile duct (CBD) cholangiocarcinoma and other periampullary cancers"
12,R3,Has_mood Arg1:T9 Arg2:T5
13,T10,Condition 284 312	Biliary obstructive symptoms
14,T11,Condition 284 303;316 321	Biliary obstructive signs
15,*,OR T11 T10
16,T12,Measurement 323 338	Bilirubin level
17,T13,Value 339 366	at/above 100 umol per liter
18,T14,Value 339 347;368 377	at/above 5.8 mg/dL
19,R4,Subsumes Arg1:T13 Arg2:T14
20,R5,Has_value Arg1:T12 Arg2:T13
21,T15,Condition 380 406	Distal biliary obstruction
22,T16,Condition 423 440	pancreatic cancer
23,T17,Condition 442 471	distal CBD cholangiocarcinoma
24,T18,Condition 481 505	periampullary malignancy
25,T19,Qualifier 475 480	other
26,R6,Has_qualifier Arg1:T18 Arg2:T19
27,*,OR T18 T17 T16
28,T20,Condition 519 545	distal biliary obstruction
29,T21,Procedure 596 601	stent
30,T22,Mood 562 573	would allow
31,T23,Qualifier 619 646	at least 2cm from the hilum
32,R7,Has_qualifier Arg1:T21 Arg2:T23
33,R8,Has_mood Arg1:T21 Arg2:T22
34,T24,Condition 657 677	deemed as resectable
35,T25,Procedure 681 703	pancreatic protocol CT
36,T26,Procedure 681 700;707 710	pancreatic protocol MRI
37,*,OR T26 T25
38,T27,Scope 681 710	pancreatic protocol CT or MRI
39,R9,AND Arg1:T27 Arg2:T24
40,T28,Condition 712 730	Surgical candidate
41,T29,Qualifier 731 759	per pancreatobiliary surgeon
42,R10,Has_qualifier Arg1:T28 Arg2:T29
43,T30,Procedure 797 804	Surgery
44,T31,Mood 805 811	intent
45,R11,Has_mood Arg1:T30 Arg2:T31
46,T32,Temporal 812 826	within 4 weeks
47,R12,Has_temporal Arg1:T30 Arg2:T32
48,T33,Procedure 843 861	surgical treatment
49,T34,Procedure 828 838;852 861	Endoscopic treatment
50,*,OR T34 T33
0,T1,Condition 18 35	esophageal cancer
1,T2,Observation 51 61	candidates
2,T3,Qualifier 66 84	minimally invasive
3,T4,Qualifier 85 99	robot assisted
4,T5,Qualifier 100 110	Ivor Lewis
5,T6,Procedure 111 130	esophagogastrectomy
6,R1,Has_qualifier Arg1:T6 Arg2:T5
7,R2,Has_qualifier Arg1:T6 Arg2:T4
8,R3,Has_qualifier Arg1:T6 Arg2:T3
9,R4,AND Arg1:T2 Arg2:T6
10,T7,Informed_consent 133 193	Patients who provide written informed consent for the study.
0,T1,Measurement 0 3	A1C
1,T2,Value 4 9	>7.0%
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 11 34	2hr glucose during OGTT
4,T4,Value 35 45	>200 mg/dL
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 47 64	Total cholesterol
7,T6,Value 65 75	>280 mg/dL
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 86 94	diabetic
10,T8,Observation 95 102	history
11,R4,Has_temporal Arg1:T7 Arg2:T8
12,T9,Temporal 77 85	Previous
13,R5,Has_temporal Arg1:T7 Arg2:T9
14,T10,Condition 104 127	coronary artery disease
15,*,OR T7 T10
16,T11,Condition 129 136	Allergy
17,T12,Drug 140 152	rosuvastatin
18,T13,Drug 156 167	parvastatin
19,*,OR T12 T13
20,T14,Scope 140 167	rosuvastatin or parvastatin
21,R6,Has_scope Arg1:T11 Arg2:T14
22,T15,Temporal 169 177	Baseline
23,T16,Measurement 178 181	ALT
24,T17,Value 182 203	more than 3 times UNL
25,R7,Has_value Arg1:T16 Arg2:T17
26,R8,Has_temporal Arg1:T16 Arg2:T15
27,T18,Measurement 205 213	Serum Cr
28,T19,Value 214 225	> 2.0 mg/dL
29,R9,Has_value Arg1:T18 Arg2:T19
30,T20,Condition 227 236	Pregnancy
31,T21,Observation 238 252	breast feeding
32,T22,Mood 256 266	plan to be
33,T23,Condition 267 275	pregnant
34,T24,Person 276 281	woman
35,R10,Has_mood Arg1:T23 Arg2:T22
36,*,OR T20 T21 T23
0,T1,Measurement 132 158	hepatic laboratory profile
1,T2,Value 115 121	Normal
2,T3,Measurement 122 127;140 158	renal laboratory profile
3,R1,Has_value Arg1:T3 Arg2:T2
4,R2,Has_value Arg1:T1 Arg2:T2
5,T4,Measurement 0 14	M. perstans mg
6,T5,Value 15 23	positive
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Condition 31 50	Good general health
9,T7,Condition 63 112	clinical condition requiring long-term medication
10,T8,Drug 92 112	long-term medication
11,T9,Qualifier 82 112	requiring long-term medication
12,R4,Has_qualifier Arg1:T7 Arg2:T9
13,R5,AND Arg1:T9 Arg2:T8
14,T10,Undefined_semantics 63 112	clinical condition requiring long-term medication
15,T11,Negation 51 58	without
16,R6,Has_negation Arg1:T7 Arg2:T11
17,T12,Parsing_Error 0 113	M. perstans mg-positive status Good general health without any clinical condition requiring long-term medication.
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,T3,Condition 15 19	term
3,T4,Person 20 24	baby
4,*,OR T1 T2
5,T5,Measurement 30 41	gestational
6,T6,Value 42 51	>37 weeks
7,T7,Measurement 56 69	postnatal age
8,R1,Has_value Arg1:T5 Arg2:T6
9,T8,Value 70 83	< or= 28 days
10,R2,Has_value Arg1:T7 Arg2:T8
11,T9,Measurement 85 96	Birthweight
12,T10,Value 97 103	>2500g
13,R3,Has_value Arg1:T9 Arg2:T10
14,T11,Informed_consent 105 151	Written informed consent of parent or guardian
0,T1,Condition 0 18	Biliary strictures
1,T2,Condition 39 52	benign tumors
2,T3,Qualifier 29 38	confirmed
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Condition 54 72	Biliary strictures
6,T5,Condition 83 95	malignancies
7,T6,Negation 96 106	other than
8,T7,Condition 107 124	pancreatic cancer
9,T8,Condition 126 155	distal CBD cholangiocarcinoma
10,T9,Condition 160 187	other periampullary cancers
11,*,OR T9 T8 T7
12,T10,"Scope 107 187	pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers"
13,R3,Has_negation Arg1:T10 Arg2:T6
14,R4,Has_scope Arg1:T5 Arg2:T10
15,R5,AND Arg1:T4 Arg2:T5
16,T11,Condition 189 229	Surgically altered biliary tract anatomy
17,T12,Procedure 251 266	cholecystectomy
18,T13,Temporal 245 250	prior
19,R6,Has_temporal Arg1:T12 Arg2:T13
20,T14,Negation 231 234	not
21,R7,Has_negation Arg1:T12 Arg2:T14
22,R8,AND Arg1:T11 Arg2:T12
23,T15,Procedure 268 292	Neoadjuvant chemotherapy
24,T16,Condition 305 315	malignancy
25,R9,AND Arg1:T15 Arg2:T16
26,T17,Non-query-able 317 390	Palliative indication due to reasons other than surgical candidate status
27,T18,Procedure 401 429	biliary drainage by ERCP/PTC
28,T19,Temporal 392 400	Previous
29,R10,Has_temporal Arg1:T18 Arg2:T19
30,T20,Condition 475 490	contraindicated
31,T21,Procedure 449 470	endoscopic techniques
32,R11,AND Arg1:T20 Arg2:T21
33,T22,Non-query-able 492 553	Participation in another investigational trial within 90 days
34,T23,Condition 555 564	Pregnancy
0,T1,Condition 15 37	chronic pain condition
1,T2,Qualifier 39 44	major
2,T3,Condition 45 77	unexpected surgical complication
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,T4,Multiplier 90 99	prolonged
5,T5,Procedure 100 110	intubation
6,T6,Qualifier 79 89	unexpected
7,R2,Has_multiplier Arg1:T5 Arg2:T4
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Observation 112 127	patient refusal
10,T8,Drug 129 145	local anesthetic
11,T9,Condition 146 153	allergy
12,R4,AND Arg1:T9 Arg2:T8
13,T10,Condition 159 175	contraindication
14,T11,Drug 179 198	regional anesthesia
15,R5,AND Arg1:T10 Arg2:T11
16,T12,Multiplier 200 214	greater than 2
17,T13,Multiplier 240 254	greater than 1
18,T14,Procedure 293 302	TAP block
19,T15,Person 227 235	resident
20,T16,Person 272 288	anesthesiologist
21,A1,Optional T15
22,A2,Optional T16
23,R6,Has_multiplier Arg1:T15 Arg2:T12
24,R7,Has_multiplier Arg1:T16 Arg2:T13
25,T17,Scope 200 288	greater than 2 attempts by resident and greater than 1 attempt by staff anesthesiologist
26,R8,Has_scope Arg1:T14 Arg2:T17
27,*,OR T1 T3 T5 T7 T9 T10 T14
0,T1,Condition 17 34	esophageal cancer
1,T2,Negation 42 45	not
2,T3,Observation 64 73	candidate
3,T4,Negation 84 87	not
4,T5,Observation 97 106	candidate
5,R1,Has_negation Arg1:T3 Arg2:T2
6,T6,Procedure 55 63	surgical
7,R2,AND Arg1:T3 Arg2:T6
8,T7,Qualifier 115 135	Ivor Lewis technique
9,T8,Procedure 139 152	esophagectomy
10,R3,Has_qualifier Arg1:T8 Arg2:T7
11,R4,AND Arg1:T5 Arg2:T8
12,R5,Has_negation Arg1:T5 Arg2:T4
13,*,OR T3 T5
14,T9,Condition 159 184	intrathoracic anastomosis
15,T10,Qualifier 154 184	with intrathoracic anastomosis
16,R6,multi Arg1:T10 Arg2:T9
17,R7,Has_qualifier Arg1:T8 Arg2:T10
18,T11,Value 200 218	less than 18 years
19,T12,Person 222 225	age
20,R8,Has_value Arg1:T12 Arg2:T11
0,T1,Person 0 4	aged
1,T2,Value 5 26	between 3 - 36 months
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 35 42	primary
4,T4,Procedure 43 67	corrective heart surgery
5,R2,Has_qualifier Arg1:T4 Arg2:T3
0,T1,Value 5 22	at least 18 years
1,T2,Person 0 4	Aged
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,"Condition 42 65	solid, malignant tumour"
4,T4,Condition 77 85	lymphoma
5,T5,Negation 67 76	excluding
6,R2,Has_negation Arg1:T4 Arg2:T5
7,T6,Qualifier 95 127	resistance to standard therapies
8,T7,Qualifier 131 168	for which no standard therapies exist
9,*,OR T7 T6
10,T8,Scope 95 168	resistance to standard therapies or for which no standard therapies exist
11,R3,Has_scope Arg1:T3 Arg2:T8
12,R4,AND Arg1:T3 Arg2:T4
13,T9,Multiplier 186 198	at least one
14,T10,Condition 199 205	lesion
15,T11,Qualifier 218 249	accurately assessed at baseline
16,T12,Procedure 253 281	Computerised Tomography (CT)
17,T13,Procedure 283 315	Magnetic Resonance Imaging (MRI)
18,T14,Procedure 319 330	plain X-ray
19,T15,Qualifier 338 370	suitable for repeated assessment
20,*,OR T14 T13 T12
21,R5,Has_qualifier Arg1:T10 Arg2:T11
22,T16,"Scope 253 330	Computerised Tomography (CT), Magnetic Resonance Imaging (MRI) or plain X-ray"
23,R6,Has_scope Arg1:T11 Arg2:T16
24,R7,Has_qualifier Arg1:T10 Arg2:T15
25,R8,Has_multiplier Arg1:T10 Arg2:T9
26,T17,Value 401 419	more than 12 weeks
27,T18,Observation 372 397	Estimated life expectancy
28,R9,Has_value Arg1:T18 Arg2:T17
0,T1,Condition 0 33	Idiopathic Granulomatous Mastitis
0,T1,Person 0 6	Adults
1,T2,Person 16 20	aged
2,T3,Value 21 35	18 to 85 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 52 77	Major Depressive Disorder
5,T5,Condition 79 87;99 109	unipolar depression
6,T6,Condition 91 109	bipolar depression
7,*,OR T6 T5 T4
8,T7,Procedure 122 125	ECT
9,T8,Temporal 111 121	Undergoing
10,R2,Has_temporal Arg1:T7 Arg2:T8
11,T9,Visit 181 189	Manitoba
12,T10,Observation 159 177	Currently residing
13,R3,AND Arg1:T10 Arg2:T9
0,T1,Procedure 7 14	surgery
1,T2,Temporal 0 6	recent
2,T3,Temporal 16 26	< 3 months
3,R1,Subsumes Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T1 Arg2:T2
5,T4,Temporal 29 37	previous
6,T5,Procedure 38 50	chemotherapy
7,R3,Has_temporal Arg1:T5 Arg2:T4
8,T6,Temporal 52 60	previous
9,T7,Procedure 61 90	transfusion of blood products
10,R4,Has_temporal Arg1:T7 Arg2:T6
11,T8,Condition 92 120	neurodevelopmental disorders
12,T9,Condition 132 142	Trisomy 21
13,R5,Subsumes Arg1:T8 Arg2:T9
14,T10,Procedure 145 164	supplemental oxygen
15,T11,Mood 165 176	requirement
16,T12,Temporal 178 188	< 3 months
17,R6,Has_mood Arg1:T10 Arg2:T11
18,R7,Has_temporal Arg1:T10 Arg2:T12
19,T13,Condition 191 197	asthma
20,T14,Procedure 208 223	regular therapy
21,R8,AND Arg1:T13 Arg2:T14
22,T15,Condition 225 248	obstructive sleep apnea
23,T16,Temporal 266 276	concurrent
24,T17,Condition 277 286	infection
25,T18,Condition 290 302	inflammation
26,*,OR T18 T17
27,T19,Scope 277 302	infection or inflammation
28,R9,Has_temporal Arg1:T19 Arg2:T16
29,T20,Condition 312 319	allergy
30,T21,Drug 323 352	dexmedetomidine hydrochloride
31,R10,AND Arg1:T20 Arg2:T21
0,T1,Qualifier 0 22	Clinically significant
1,T2,Condition 23 58	abnormalities of glucose metabolism
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 60 83	Spinal cord compression
4,T4,Condition 87 103	brain metastases
5,T5,Condition 111 123	asymptomatic
6,T6,Negation 104 110	unless
7,T7,Qualifier 125 132	treated
8,T8,Qualifier 137 143	stable
9,T9,"Scope 111 168	asymptomatic, treated and stable (not requiring steroids)"
10,T10,Drug 159 167	steroids
11,T11,Negation 145 148	not
12,R2,Has_negation Arg1:T10 Arg2:T11
13,*,OR T3 T4
14,T12,Scope 60 103	Spinal cord compression or brain metastases
15,R3,Has_negation Arg1:T9 Arg2:T6
16,R4,Has_scope Arg1:T12 Arg2:T9
17,R5,AND Arg1:T8 Arg2:T10
18,T13,Qualifier 192 204	uncontrolled
19,T14,Condition 205 222	systemic diseases
20,T15,Qualifier 182 188	severe
21,*,OR T13 T15
22,T16,Scope 182 204	severe or uncontrolled
23,R6,Has_scope Arg1:T14 Arg2:T16
24,T17,Condition 234 259	active bleeding diatheses
25,T18,Condition 263 280	active infections
26,T19,Condition 291 302	hepatitis B
27,T20,Condition 310 344	Human Immunodeficiency Virus (HIV)
28,T21,Condition 291 300;304 305	hepatitis C
29,*,OR T21 T20 T19
30,T22,"Scope 291 344	hepatitis B, C and Human Immunodeficiency Virus (HIV)"
31,R7,Subsumes Arg1:T18 Arg2:T22
32,*,OR T17 T18
33,T23,"Scope 234 344	active bleeding diatheses or active infections including hepatitis B, C and Human Immunodeficiency Virus (HIV)"
34,R8,Subsumes Arg1:T14 Arg2:T23
35,T24,Qualifier 358 380	clinically significant
36,T25,Undefined_semantics 358 380	clinically significant
37,T26,Condition 381 402	cardiac abnormalities
38,T27,Condition 404 428	uncontrolled hypotension
39,T28,Measurement 430 464	left ventricular ejection fraction
40,T29,Value 465 496	below the lower limit of normal
41,R10,Has_value Arg1:T28 Arg2:T29
42,T30,Procedure 539 572	cardiac interventional procedures
43,T31,Qualifier 527 538	significant
44,T32,Subjective_judgement 527 538	significant
45,R11,Has_qualifier Arg1:T30 Arg2:T31
46,R9,Has_qualifier Arg1:T26 Arg2:T24
47,*,OR T26 T27 T28 T30
48,T33,Condition 576 599	bad reaction to AZD5363
49,T34,Drug 592 599	AZD5363
50,T35,Context_Error 574 648	A bad reaction to AZD5363 or any drugs similar to it in structure or class
51,T36,Non-query-able 574 648	A bad reaction to AZD5363 or any drugs similar to it in structure or class
0,T1,Condition 0 16	Breast Carcinoma
0,T1,Condition 0 26	Relative contraindications
1,T2,Procedure 30 41	ECT therapy
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Temporal 43 49	recent
4,T4,Condition 50 52	MI
5,T5,Condition 56 59	CVA
6,*,OR T4 T5
7,T6,Scope 50 59	MI or CVA
8,R2,Has_temporal Arg1:T6 Arg2:T3
9,T7,Value 61 70	increased
10,T8,Measurement 71 92	intracranial pressure
11,R3,Has_value Arg1:T8 Arg2:T7
12,T9,Condition 94 118	intracranial mass lesion
13,T10,Condition 120 141	intracranial aneurysm
14,T11,Condition 143 151	epilepsy
15,T12,Condition 159 177	cardiac arrhythmia
16,T13,Condition 179 195	pheochromocytoma
17,T14,Condition 197 206	pregnancy
18,*,OR T14 T13 T12 T11 T10 T9 T8 T6
19,T15,"Scope 43 206	recent MI or CVA, increased intracranial pressure, intracranial mass lesion, intracranial aneurysm, epilepsy, known cardiac arrhythmia, pheochromocytoma, pregnancy"
20,T16,Scope 0 41	Relative contraindications to ECT therapy
21,R4,Subsumes Arg1:T16 Arg2:T15
22,T17,Condition 209 226	Contraindications
23,T18,Drug 230 239	etomidate
24,R5,AND Arg1:T17 Arg2:T18
25,T19,Condition 241 247	sepsis
26,T20,Qualifier 249 256	primary
27,T21,Qualifier 260 269	secondary
28,T22,Condition 270 291	adrenal insufficiency
29,T23,Condition 293 302	porphyria
30,*,OR T21 T20
31,T24,Qualifier 305 310	DSM-V
32,T25,Observation 326 342	lifetime history
33,T26,Condition 346 373	psychotic spectrum disorder
34,R6,Has_temporal Arg1:T26 Arg2:T25
35,R7,Has_qualifier Arg1:T26 Arg2:T24
36,T27,Condition 375 379;391 401	Drug dependence
37,T28,Condition 383 401	alcohol dependence
38,T29,Temporal 412 436	within the past 3 months
39,T30,Condition 375 379;406 411	Drug abuse
40,T31,Condition 383 390;406 411	alcohol abuse
41,*,OR T30 T31 T28 T27
42,T32,"Scope 375 411	Drug or alcohol dependence, or abuse"
43,R8,Has_temporal Arg1:T32 Arg2:T29
44,T33,Condition 438 458	soy-bean oil allergy
45,*,OR T33 T32
0,T1,Condition 0 8	Pregnant
1,T2,Person 9 14	women
2,T3,Condition 16 30	Claustrophobic
3,T4,Negation 39 45	unable
4,T5,Procedure 61 72	examination
5,R1,Has_negation Arg1:T5 Arg2:T4
6,R2,AND Arg1:T3 Arg2:T5
7,T6,Non-representable 74 137	Breastfeeding women unwilling to temporarily stop breastfeeding
8,T7,Condition 152 169	contra-indication
9,T8,Drug 174 186	dipyridamole
10,T9,Drug 188 201	aminophylline
11,T10,Drug 203 213	dobutamine
12,T11,Procedure 217 237	exercise stress test
13,*,OR T8 T9 T10 T11
14,T13,"Scope 174 237	dipyridamole, aminophylline, dobutamine or exercise stress test"
15,R3,Subsumes Arg1:T7 Arg2:T13
0,T1,Procedure 10 23	blood culture
1,T2,Value 0 6	E.coli
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Value 29 46	identical isolate
4,T4,Procedure 50 62	urine sample
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Measurement 73 76	CFU
7,T6,Value 64 72	>= 1.000
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Mood 90 104	clinical signs
10,T8,Condition 108 111	UTI
11,R4,Has_mood Arg1:T8 Arg2:T7
12,T9,Scope 64 76	>= 1.000 CFU
13,R5,Subsumes Arg1:T3 Arg2:T9
14,*,OR T4 T8
0,T1,Measurement 37 96	American Society of Anesthesiologists (ASA) physical status
1,T2,Value 9 29	Level III or greater
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 174 192	chronic conditions
4,T4,Condition 276 305	neurodevelopmental conditions
5,T5,Observation 331 360	understanding the Oucher tool
6,T6,Condition 306 316	preventing
7,R2,Has_context Arg1:T6 Arg2:T5
8,R3,AND Arg1:T4 Arg2:T6
9,T7,Observation 204 266	limit our ability to develop the study according to objectives
10,R4,Has_context Arg1:T3 Arg2:T7
11,T8,Scope 276 360	neurodevelopmental conditions preventing patients from understanding the Oucher tool
12,R5,Subsumes Arg1:T3 Arg2:T8
13,T9,Condition 373 386	renal disease
14,T10,Condition 362 369;379 386	Hepatic disease
15,*,OR T9 T10
16,T11,Condition 388 403	cardiac disease
17,T12,Condition 412 421	infection
18,T13,Qualifier 405 411	active
19,R6,Has_qualifier Arg1:T12 Arg2:T13
20,T14,Condition 423 440	diabetes mellitus
21,T15,Condition 442 461	sickle cell disease
22,T16,Condition 469 490	coagulation disorders
23,T17,Drug 549 559	analgesics
24,T18,Drug 536 544	steroids
25,T19,Drug 522 534	anti-emetics
26,T20,Temporal 492 506	pre- operative
27,T21,Procedure 507 516	treatment
28,*,OR T19 T18 T17
29,T22,"Scope 522 559	anti-emetics, steroids, or analgesics"
30,R7,Has_scope Arg1:T21 Arg2:T22
31,R8,Has_temporal Arg1:T21 Arg2:T20
32,T23,Drug 561 574	Acetaminophen
33,T24,Condition 575 582	allergy
34,T25,Drug 604 617	acetaminophen
35,T26,Temporal 618 640	within 24 h of surgery
36,R9,AND Arg1:T24 Arg2:T23
37,*,OR T24 T25
38,R10,Has_temporal Arg1:T25 Arg2:T26
39,T27,Condition 670 680	precluding
40,T28,Drug 692 699	opioids
41,T29,Drug 703 716	acetaminophen
42,T30,Condition 642 669	Complicating health factors
43,R11,AND Arg1:T30 Arg2:T27
44,*,OR T28 T29
45,T31,Scope 692 716	opioids or acetaminophen
46,R12,Has_scope Arg1:T27 Arg2:T31
47,T32,Condition 748 757	interfere
48,T33,Procedure 763 778	pain assessment
49,T34,Procedure 783 793	management
50,T35,Condition 722 735	other factors
51,R13,AND Arg1:T35 Arg2:T32
52,*,OR T33 T34
53,T37,Scope 763 793	pain assessment and management
54,R15,Has_scope Arg1:T32 Arg2:T37
55,T38,Measurement 804 812	weighing
56,T39,Value 813 828	more than 30 kg
57,R16,Has_value Arg1:T38 Arg2:T39
58,T40,Non-representable 875 917	Patients who live without a home telephone
59,T41,Non-representable 919 963	patient living without parental supervision.
60,T36,Non-representable 829 873	that would exceed maximum dexamethasone dose
0,T1,Condition 0 7	Healthy
1,T2,Person 18 22	aged
2,T3,Value 23 33	3-13 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 62 121	American Society of Anesthesiologists (ASA) physical status
5,T5,Value 35 54	Level I or level II
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 185 208	obstructive sleep apnea
8,T7,Multiplier 212 221	recurrent
9,T8,Condition 222 239	throat infections
10,R3,Has_multiplier Arg1:T8 Arg2:T7
11,*,OR T6 T8
12,T9,Qualifier 252 260	elective
13,T10,Condition 261 274	tonsillectomy
14,T11,Condition 291 304	adenoidectomy
15,A1,Optional T11
16,R4,Has_qualifier Arg1:T10 Arg2:T9
17,R5,AND Arg1:T10 Arg2:T11
18,T12,Informed_consent 306 390	Parents who agree to complete documentation and follow up at 14 days post-operation.
0,T1,Condition 14 51	pulmonary arterial hypertension (PAH)
1,T2,Condition 67 120	chronic thromboembolic pulmonary hypertension (CTEPH)
2,T3,Temporal 156 169	>12 month ago
3,T4,Condition 176 179	PAH
4,T5,Condition 190 195	CTEPH
5,T6,Qualifier 183 189	distal
6,R1,Has_qualifier Arg1:T5 Arg2:T6
7,T7,Non-query-able 206 235	consultation at the PH centre
8,T8,Visit 239 245	Zurich
9,R2,AND Arg1:T7 Arg2:T8
10,T9,Temporal 246 285	between November 2015 and November 2016
11,R3,Has_temporal Arg1:T7 Arg2:T9
12,T10,Visit 206 235	consultation at the PH centre
13,*,OR T4 T5
14,T11,Context_Error 126 135	prevalent
15,R4,Has_temporal Arg1:T11 Arg2:T3
0,T1,Condition 0 19	Bacterial infection
1,T2,Qualifier 32 45	another organ
2,T3,Condition 52 61	pneumonia
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,R2,Subsumes Arg1:T1 Arg2:T3
5,T4,Condition 64 77	Severe sepsis
6,T5,Condition 83 101	multiorgan failure
7,T6,Condition 103 124	Perinephritic abscess
8,T7,Condition 126 138	Pyonephrosis
9,T8,Mood 139 148	requiring
10,T9,Procedure 149 157	drainage
11,R3,Has_mood Arg1:T9 Arg2:T8
12,R4,AND Arg1:T7 Arg2:T9
13,T10,Condition 159 166	Allergy
14,T11,Drug 170 183	pivmecillinam
15,R5,AND Arg1:T10 Arg2:T11
16,T12,Drug 213 226	pivmecillinam
17,T13,Condition 185 199	E.coli isolate
18,T14,Qualifier 200 226	resistant to pivmecillinam
19,R6,multi Arg1:T14 Arg2:T12
20,R7,Has_qualifier Arg1:T13 Arg2:T14
21,T15,Condition 228 237	Pregnancy
22,T16,Observation 238 251	breastfeeding
23,*,OR T15 T16
24,T17,Condition 260 271	neutropenia
25,T18,Qualifier 253 259	Severe
26,R8,Has_qualifier Arg1:T17 Arg2:T18
27,T19,Condition 273 284	Prostatitis
28,T20,Qualifier 286 292	Severe
29,T21,Condition 293 307	kidney failure
30,R9,Has_qualifier Arg1:T21 Arg2:T20
31,T22,Measurement 309 313	eGFR
32,T23,Value 313 323	<15 ml/min
33,R10,Has_value Arg1:T22 Arg2:T23
34,T24,Scope 309 323	eGFR<15 ml/min
35,T25,Scope 286 307	Severe kidney failure
36,R11,Subsumes Arg1:T25 Arg2:T24
37,T26,Drug 332 341	valproate
0,T1,Person 0 5	Adult
1,T2,Qualifier 33 53	clinically indicated
2,T3,Procedure 54 111	positron emission tomography myocardial perfusion imaging
3,T4,Visit 119 165	Centre hospitalier de l'Université de Montréal
4,R1,AND Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T3 Arg2:T2
0,T1,Post-eligibility 0 34	anyone not excluded and consenting
0,T1,Person 3 8	Women
1,T2,Condition 17 25	pregnant
2,T3,Observation 33 42	lactating
3,*,OR T2 T3
4,T4,Person 47 52	women
5,T5,Observation 57 75	intend to conceive
6,T6,Temporal 76 89	within a year
7,R1,Has_temporal Arg1:T5 Arg2:T6
8,T7,Scope 47 89	women who intend to conceive within a year
9,T8,Scope 3 42	Women who are pregnant and/or lactating
10,*,OR T8 T7
11,T9,Observation 95 102	History
12,T10,Condition 106 115	allergies
13,T11,Drug 119 128	enalapril
14,T12,Drug 130 140	folic acid
15,T13,Drug 150 181	components of the compound drug
16,*,OR T12 T13 T11
17,T14,"Scope 119 181	enalapril, folic acid or other components of the compound drug"
18,R2,Has_scope Arg1:T10 Arg2:T14
19,R3,Has_temporal Arg1:T10 Arg2:T9
20,T15,Observation 187 194	History
21,T16,Condition 198 215	adverse reactions
22,T17,Condition 219 230	intolerance
23,T18,Drug 234 243	enalapril
24,T19,Qualifier 247 252	other
25,T20,Drug 253 267	ACE inhibitors
26,T21,Drug 304 314	folic acid
27,R4,Has_qualifier Arg1:T20 Arg2:T19
28,*,OR T18 T20 T21
29,*,OR T17 T16
30,T22,Scope 198 230	adverse reactions or intolerance
31,T23,"Scope 234 314	enalapril or other ACE inhibitors, or drugs or supplements containing folic acid"
32,R5,Has_scope Arg1:T22 Arg2:T23
33,R6,Has_temporal Arg1:T22 Arg2:T15
34,T24,Condition 346 368	secondary hypertension
35,T25,Mood 333 342	suspicion
36,T26,Mood 320 329	Diagnosis
37,*,OR T26 T25
38,T27,Scope 320 342	Diagnosis or suspicion
39,R7,Has_scope Arg1:T24 Arg2:T27
40,T28,Qualifier 380 387	serious
41,T29,Condition 388 406	medical conditions
42,R8,Has_qualifier Arg1:T29 Arg2:T28
43,T31,Condition 470 489	cardiac dysfunction
44,T32,Qualifier 449 469	clinically diagnosed
45,T33,Measurement 491 501	NYHA class
46,T34,Value 502 515	III and above
47,R9,Has_value Arg1:T33 Arg2:T34
48,R10,Has_qualifier Arg1:T31 Arg2:T32
49,T35,Scope 491 515	NYHA class III and above
50,R11,Subsumes Arg1:T31 Arg2:T35
51,T36,Condition 518 557	hypertrophic obstructive cardiomyopathy
52,T30,Qualifier 559 581	clinically significant
53,T37,Condition 582 604	valvular heart disease
54,T38,Condition 606 629	acute coronary syndrome
55,T39,Temporal 630 654	within the last 3 months
56,R12,Has_temporal Arg1:T38 Arg2:T39
57,T40,Procedure 659 699	percutaneous coronary intervention (PCI)
58,T41,Procedure 704 739	coronary artery bypass graft (CABG)
59,T42,Value 744 752	abnormal
60,T43,Temporal 753 767	pre-enrollment
61,T44,Measurement 768 776	ECG test
62,R13,Has_value Arg1:T44 Arg2:T42
63,R14,Has_temporal Arg1:T44 Arg2:T43
64,T45,Qualifier 790 812	clinically significant
65,T46,Condition 813 824	arrhythmias
66,T47,Condition 826 840	atrial flutter
67,T48,Condition 842 861	atrial fibrillation
68,T49,Condition 876 898	atrioventricular block
69,T50,Qualifier 863 871	grade II
70,T51,Qualifier 863 868;872 875	grade III
71,*,OR T51 T50
72,T52,Scope 863 875	grade II-III
73,R15,Has_scope Arg1:T49 Arg2:T52
74,*,OR T47 T48 T49
75,T53,"Scope 826 898	atrial flutter, atrial fibrillation, grade II-III atrioventricular block"
76,R16,Has_qualifier Arg1:T46 Arg2:T45
77,T54,Scope 790 824	clinically significant arrhythmias
78,R17,Subsumes Arg1:T54 Arg2:T53
79,T55,Temporal 920 928	previous
80,T56,Condition 959 974	viral hepatitis
81,T57,Qualifier 997 1009	active phase
82,R18,Has_qualifier Arg1:T56 Arg2:T57
83,T58,Value 1011 1019	abnormal
84,T59,Measurement 1035 1054	liver function test
85,R19,Has_value Arg1:T59 Arg2:T58
86,T60,Temporal 1020 1034	pre-enrollment
87,T61,Measurement 1064 1067	ALT
88,T62,Measurement 1069 1072	AST
89,T63,Measurement 1074 1077	GGT
90,T64,Measurement 1079 1083	TBIL
91,T65,Measurement 1088 1092	DBIL
92,T66,Value 1093 1119	3 times higher than normal
93,*,OR T61 T62 T63 T64 T65
94,T67,"Scope 1064 1092	ALT, AST, GGT, TBIL, or DBIL"
95,R20,Has_value Arg1:T67 Arg2:T66
96,T68,Measurement 1121 1124	ALB
97,T69,Value 1125 1132	= 30g/L
98,R21,Has_value Arg1:T68 Arg2:T69
99,R22,Has_temporal Arg1:T59 Arg2:T60
100,T70,Procedure 1135 1146	gastrectomy
101,T71,Procedure 1154 1171	gastrojejunostomy
102,T72,Condition 1173 1201	gastrointestinal dysfunction
103,T73,Temporal 1212 1226	pre-enrollment
104,T74,Measurement 1227 1243	serum creatinine
105,T75,Value 1244 1266	greater than 200umol/L
106,R23,Has_value Arg1:T74 Arg2:T75
107,R24,Has_temporal Arg1:T74 Arg2:T73
108,T76,Qualifier 1268 1286	clinical diagnosis
109,T77,Condition 1290 1311	renal artery stenosis
110,R25,Has_qualifier Arg1:T77 Arg2:T76
111,T78,Procedure 1330 1352	kidney transplantation
112,T79,Condition 1313 1328	isolated kidney
113,T80,Condition 1387 1402	type 1 diabetes
114,T81,Qualifier 1406 1418	uncontrolled
115,T82,Condition 1419 1434	type 2 diabetes
116,T83,Measurement 1436 1457	fasting blood glucose
117,T84,Value 1458 1475	above 11.1 mmol/L
118,T85,Temporal 1476 1493	at pre-enrollment
119,R26,Has_value Arg1:T83 Arg2:T84
120,R27,Has_temporal Arg1:T83 Arg2:T85
121,T86,Reference_point 1479 1493	pre-enrollment
122,R28,Has_index Arg1:T85 Arg2:T86
123,R29,Has_qualifier Arg1:T82 Arg2:T81
124,T87,Scope 1436 1493	fasting blood glucose above 11.1 mmol/L at pre-enrollment
125,T88,Scope 1406 1434	uncontrolled type 2 diabetes
126,R30,Subsumes Arg1:T88 Arg2:T87
127,T89,Temporal 1496 1504	previous
128,T90,Condition 1518 1533	hyperthyroidism
129,T91,Observation 1538 1556	failure to correct
130,R31,Has_context Arg1:T90 Arg2:T91
131,R32,Has_temporal Arg1:T90 Arg2:T89
132,T92,Condition 1571 1594	pulmonary heart disease
133,T93,Condition 1596 1633	chronic obstructive pulmonary disease
134,T94,Temporal 1653 1659	recent
135,T95,Condition 1660 1685	transient ischemic attack
136,T96,Condition 1689 1695	stroke
137,*,OR T96 T95
138,T97,Temporal 1697 1721	within the last 3 months
139,T98,Scope 1660 1695	transient ischemic attack or stroke
140,R33,Has_temporal Arg1:T98 Arg2:T97
141,T99,Qualifier 1724 1734	peripheral
142,T100,Qualifier 1738 1744	severe
143,T101,Condition 1745 1766	autonomic dysfunction
144,*,OR T100 T99
145,T102,Scope 1724 1744	peripheral or severe
146,R34,Has_scope Arg1:T101 Arg2:T102
147,T103,Condition 1768 1774;1786 1804	mental system dysfunction
148,T104,Condition 1778 1804	nervous system dysfunction
149,R35,Subsumes Arg1:T97 Arg2:T94
150,T105,"Scope 1064 1132	ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L"
151,R36,Subsumes Arg1:T59 Arg2:T105
152,R37,Has_temporal Arg1:T56 Arg2:T55
153,*,OR T31 T36 T37 T38 T40 T41 T44
154,R38,Has_qualifier Arg1:T37 Arg2:T30
155,R39,Has_scope Arg1:T44 Arg2:T54
156,T106,Observation 1806 1833	inability to express desire
157,T107,Condition 1841 1845;1857 1867	drug dependence
158,T108,Condition 1849 1867	alcohol dependence
159,*,OR T108 T107 T109 T110 T111 T56 T59 T92 T93 T98 T103 T104 T101 T90 T80 T88 T79 T78 T77 T74 T72 T71 T70 T54 T106
160,T109,Condition 1869 1879	Malignancy
161,T110,Condition 1881 1893	malnutrition
162,T111,Condition 1895 1918	hematopoietic disorders
163,T112,"Scope 449 1918	clinically diagnosed cardiac dysfunction (NYHA class III and above), hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, acute coronary syndrome within the last 3 months, or percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG); or abnormal pre-enrollment ECG test results with clinically significant arrhythmias (atrial flutter, atrial fibrillation, grade II-III atrioventricular block, etc.); Digestive: a previous diagnosis of various types of viral hepatitis that are still in the active phase; abnormal pre-enrollment liver function test results (ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L); gastrectomy and/or gastrojejunostomy; gastrointestinal dysfunction; Urinary: pre-enrollment serum creatinine greater than 200umol/L; clinical diagnosis of renal artery stenosis, isolated kidney, kidney transplantation and/or other diseases; Endocrine: type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose above 11.1 mmol/L at pre-enrollment); previous diagnosis of hyperthyroidism and failure to correct; Respiratory: pulmonary heart disease; chronic obstructive pulmonary disease; Neuropsychiatric: recent transient ischemic attack or stroke (within the last 3 months); peripheral or severe autonomic dysfunction; mental or nervous system dysfunction, inability to express desire; known drug or alcohol dependence; Malignancy, malnutrition, hematopoietic disorders"
164,R40,Subsumes Arg1:T29 Arg2:T112
165,T113,Qualifier 1951 1962	Significant
166,T114,Condition 1963 1985	signs of abnormalities
167,T115,Measurement 1997 2013	laboratory tests
168,R41,AND Arg1:T115 Arg2:T114
169,R42,Has_qualifier Arg1:T114 Arg2:T113
170,T116,"Non-representable 2014 2305	or physical characteristics, which, at the discretion of the investigators, indicates that the patient is experiencing a serious illness or, may affect the observation and evaluation of the drug's efficacy or adverse events, or renders the patient unsuitable for participating in this study;"
171,T117,Drug 2336 2342	folate
172,T118,Drug 2344 2347	B12
173,T119,Drug 2352 2354	B6
174,*,OR T117 T118 T119
175,T120,Observation 2420 2441	refusal to stop usage
176,T121,Observation 2405 2414	inability
177,*,OR T121 T120
178,T122,Temporal 2319 2328	currently
179,T123,"Scope 2336 2354	folate, B12, or B6"
180,R43,Has_temporal Arg1:T123 Arg2:T122
181,T124,Drug 2464 2486	folic acid supplements
182,T125,Multiplier 2447 2460	Regular usage
183,T126,Drug 2490 2521	compounds containing folic acid
184,T127,Temporal 2522 2542	in the past 3 months
185,*,OR T124 T126
186,T128,Scope 2464 2521	folic acid supplements or compounds containing folic acid
187,T129,Scope 2447 2460;2522 2542	Regular usage in the past 3 months
188,*,OR T125 T127
189,R44,Has_scope Arg1:T128 Arg2:T129
190,T130,Observation 2548 2581	Participation in a clinical trial
191,T131,Drug 2588 2648	drug that has not yet been officially approved for marketing
192,T132,Temporal 2649 2690	within one month prior to the first visit
193,R45,AND Arg1:T130 Arg2:T131
194,R46,Has_temporal Arg1:T130 Arg2:T132
195,T133,Reference_point 2675 2690	the first visit
196,R47,Has_index Arg1:T132 Arg2:T133
0,T1,Condition 0 9	pregnancy
1,T2,Procedure 39 56	bariatric surgery
2,T3,Procedure 28 35;49 56	gastric surgery
3,T4,Procedure 16 26;49 56	esophageal surgery
4,*,OR T2 T4 T3
5,T5,Condition 58 73	irritable bowel
6,T6,Condition 100 108	vomiting
7,T7,Condition 117 131	abdominal pain
8,T8,Qualifier 87 99	intermittent
9,T9,Condition 141 149	diarrhea
10,T10,Condition 153 165	constipation
11,*,OR T9 T10
12,T11,Scope 141 165	diarrhea or constipation
13,T12,Qualifier 133 140	chronic
14,R1,Has_qualifier Arg1:T11 Arg2:T12
15,T13,Qualifier 110 116	severe
16,R2,Has_qualifier Arg1:T7 Arg2:T13
17,R3,Has_qualifier Arg1:T6 Arg2:T8
18,*,OR T5 T6 T7 T11
19,T14,Condition 189 204	duodenal ulcers
20,T15,Condition 178 185;198 204	gastric ulcers
21,*,OR T14 T15
22,T16,Condition 220 234	hypoalbuminemy
23,T17,Qualifier 206 219	pre-operatory
24,R4,Has_qualifier Arg1:T16 Arg2:T17
25,T18,Condition 274 283;291 298	pulmonary disease
26,T19,Condition 263 270;291 298	cardiac disease
27,T20,Condition 254 261;291 298	hepatic disease
28,T21,Condition 247 252;291 298	renal disease
29,T22,Qualifier 284 290	severe
30,*,OR T21 T20 T19 T18
31,R5,Has_qualifier Arg1:T18 Arg2:T22
32,R6,Has_qualifier Arg1:T20 Arg2:T22
33,R7,Has_qualifier Arg1:T20 Arg2:T22
34,R8,Has_qualifier Arg1:T20 Arg2:T22
35,T23,Drug 309 323	corticosteroid
36,T24,Temporal 331 341	last month
37,R9,Has_temporal Arg1:T23 Arg2:T24
38,T25,Non-query-able 343 477	evidence of psycological problem that may affect the capacity to understand the project and to comply with the medical recommandations
39,T26,Condition 502 514	alcool abuse
40,T27,Condition 490 498	drug use
41,*,OR T27 T26
42,T28,Temporal 522 536	last 12 months
43,T29,Scope 490 514	drug use or alcool abuse
44,R10,Has_temporal Arg1:T29 Arg2:T28
45,T30,Condition 549 588	gastro-intestinal inflammatory diseases
0,T1,Post-eligibility 0 28	Signed Informed Consent Form
1,T2,Post-eligibility 30 101	Patients having physical and mental ability to participate in the study
2,T3,Person 120 125	sexes
3,T4,Value 115 119	both
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Person 126 130	aged
6,T6,Value 131 145	35 to 65 years
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Condition 170 204	ST-elevation myocardial infarction
9,T8,Procedure 218 221	ECG
10,T9,Measurement 234 244	troponin I
11,T10,Measurement 249 254	CK-MB
12,T11,"Scope 218 254	ECG, as well as troponin I and CK-MB"
13,R3,AND Arg1:T11 Arg2:T7
14,T12,Condition 301 312;317 323	stenosis of artery
15,T13,Multiplier 313 316	one
16,R4,Has_multiplier Arg1:T12 Arg2:T13
17,T14,Condition 335 357	infarct-related artery
18,R5,Subsumes Arg1:T12 Arg2:T14
19,T15,Qualifier 276 300	hemodynamically relevant
20,R6,Has_qualifier Arg1:T12 Arg2:T15
21,T16,Procedure 372 392	coronary angiography
22,T17,Procedure 394 397	CAG
23,R7,Subsumes Arg1:T16 Arg2:T17
24,R8,AND Arg1:T16 Arg2:T12
25,T18,Condition 409 436	occlusion of other arteries
26,T19,Multiplier 437 454	not exceeding 30%
27,R9,Has_multiplier Arg1:T18 Arg2:T19
0,T1,"Non-query-able 0 180	Use of investigational drugs either within 5 half-lives of enrollment, or within 30 days, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer"
1,T2,Procedure 183 196	Major surgery
2,T3,Temporal 204 301	last 3 months prior to baseline or planned major surgery or cardiac intervention during the study
3,T4,Reference_point 227 300	baseline or planned major surgery or cardiac intervention during the stud
4,R1,Has_index Arg1:T3 Arg2:T4
5,R2,Has_temporal Arg1:T2 Arg2:T3
6,T5,Condition 304 310	Cancer
7,T6,Condition 332 346	co-morbidities
8,*,OR T5 T6
9,T7,Condition 399 412	Comorbidities
10,T8,Measurement 450 469;475 481	natriuretic peptide levels
11,T9,Measurement 471 473	NP
12,R3,Subsumes Arg1:T8 Arg2:T9
13,T10,Value 441 449	elevated
14,R4,Has_value Arg1:T8 Arg2:T10
15,R5,AND Arg1:T7 Arg2:T8
16,T11,Condition 483 502	renal insufficiency
17,T12,Measurement 505 509	eGFR
18,T13,Value 510 529	< 25 ml/min/1.73 m²
19,R6,Has_value Arg1:T12 Arg2:T13
20,R7,AND Arg1:T11 Arg2:T12
21,T14,Condition 597 612	cerebral trauma
22,T15,Temporal 577 595	less than 3 months
23,R8,Has_temporal Arg1:T14 Arg2:T15
24,T16,Condition 644 668	cerebrovascular incident
25,T17,Temporal 624 642	less than 3 months
26,R9,Has_temporal Arg1:T16 Arg2:T17
27,T18,Condition 689 715	acute exacerbation of COPD
28,T19,Temporal 727 740	last 3 months
29,R10,Has_temporal Arg1:T18 Arg2:T19
30,*,OR T11 T14 T16 T18
31,T20,"Scope 483 740	renal insufficiency, (eGFR < 25 ml/min/1.73 m² calculated according to MDRD formula), recent (less than 3 months) cerebral trauma or recent (less than 3 months) cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the last 3 months"
32,R11,Subsumes Arg1:T7 Arg2:T14
33,T21,Non-query-able 743 834	Patients who are primarily managed and regularly followed-up by a cardiologist for their HF
34,T22,Observation 874 882	lifespan
35,T23,Temporal 944 962	less than 6 months
36,R12,Has_temporal Arg1:T22 Arg2:T23
0,T1,Person 0 5	Adult
1,T2,Person 21 26	years
2,T3,Value 16 20	= 18
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Procedure 40 52	hemodialysis
5,T5,Temporal 67 83	at least 1 month
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Condition 143 162	atrial fibrillation
8,T7,Qualifier 128 139	new episode
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Measurement 213 229	CHADS2VASC score
11,T9,Value 230 232	=2
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Observation 252 268	risk of bleeding
14,T11,Qualifier 247 251	high
15,R5,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Measurement 287 300	HASBLED score
17,T13,Value 301 303	=3
18,R6,Has_value Arg1:T12 Arg2:T13
19,T14,Measurement 321 337	CHADS2VASC score
20,T15,Condition 364 379	severe bleeding
21,T16,"Qualifier 381 396	type 3a, 3b, 3c"
22,R7,Has_qualifier Arg1:T15 Arg2:T16
23,T17,Qualifier 412 420	cerebral
24,T18,Qualifier 424 440	gastrointestinal
25,*,OR T17 T18
26,T19,Scope 412 440	cerebral or gastrointestinal
27,R8,Has_scope Arg1:T15 Arg2:T19
28,A1,Optional T17
29,A2,Optional T18
30,T20,Observation 481 486	falls
31,T21,Multiplier 466 468	>2
32,R9,Has_multiplier Arg1:T20 Arg2:T21
33,T22,Qualifier 455 464	recurrent
34,R10,Has_qualifier Arg1:T20 Arg2:T22
35,T23,Post-eligibility 489 579	Patient capable of understanding information about the study and of giving his/her consent
36,T24,Post-eligibility 581 637	Patient informed of the preliminary medical exam results
37,T25,Non-query-able 639 672	Patient with healthcare insurance
38,T26,Informed_consent 674 696	Written consent signed
0,T1,Condition 0 17	contraindications
1,T2,Drug 79 90	haloperidol
2,T3,Drug 100 109	Phenergan
3,T4,Drug 111 123	Promethazine
4,T5,Drug 92 98	artane
5,T6,Drug 126 140	chlorpromazine
6,T7,Drug 142 154	erythromycin
7,T8,Drug 156 168	Azithromycin
8,T9,Drug 170 184	clarithromycin
9,T10,Drug 186 198	Ketoconazole
10,T11,Drug 200 211	fluconazole
11,T12,Drug 213 223	mefloquine
12,T13,Drug 242 254	lumefantrine
13,T14,Drug 259 266	Coartem
14,T15,Drug 269 276	quinine
15,T16,Drug 278 285	Septrin
16,R1,AND Arg1:T13 Arg2:T14
17,R2,Subsumes Arg1:T3 Arg2:T4
18,*,OR T2 T5 T3 T6 T7 T8 T9 T10 T11 T12 T16 T15 T13
19,T17,"Scope 79 285	haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin"
20,R3,Has_scope Arg1:T1 Arg2:T17
21,T18,Condition 294 307	seriously ill
22,T19,Drug 326 348	antimalarial medicines
23,T20,Drug 361 378	artemisinin drugs
24,T21,Condition 350 357	allergy
25,R4,AND Arg1:T21 Arg2:T20
26,T22,Condition 380 388	pregnant
27,T23,Person 389 394	women
28,T24,Condition 398 414	first trimester
29,T26,Qualifier 398 413	first trimester
30,R5,Has_qualifier Arg1:T22 Arg2:T26
31,T25,Person 415 423	children
32,T27,Value 424 438	under 3 months
33,T28,Person 442 445	age
34,R6,Has_value Arg1:T28 Arg2:T27
35,T29,Condition 456 471	heart condition
0,T1,Measurement 0 3	BMI
1,T2,Value 4 8	= 35
2,T3,Condition 10 25	type 2 diabetes
3,T4,Measurement 27 32	HbA1c
4,T5,"Value 33 40	= 6,5 %"
5,T6,Measurement 44 60	fasting glycemia
6,T7,Value 61 69	=7mmol/l
7,T8,Measurement 73 93	non-fasting glycemia
8,T9,Value 94 103	=11mmol/l
9,R1,Has_value Arg1:T4 Arg2:T5
10,R2,Has_value Arg1:T6 Arg2:T7
11,R3,Has_value Arg1:T8 Arg2:T9
12,*,OR T4 T6 T8
13,T10,Informed_consent 105 120	able to consent
0,T1,Value 3 13	= 45 years
1,T2,Person 14 17	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Temporal 38 46	previous
4,T4,Mood 25 34	diagnosis
5,*,OR T4 T3
6,T5,Condition 60 82	essential hypertension
7,T6,Scope 25 46	diagnosis or previous
8,R2,Has_scope Arg1:T5 Arg2:T6
9,T7,Drug 118 140	antihypertensive drugs
10,T8,Drug 174 196	antihypertensive drugs
11,T9,Negation 164 167	not
12,T10,Temporal 197 220	within the last 2 weeks
13,R3,Has_negation Arg1:T8 Arg2:T9
14,R4,Has_temporal Arg1:T8 Arg2:T10
15,T11,Multiplier 222 237;266 288	two consecutive at least one day apart
16,T12,Procedure 299 321	sitting blood pressure
17,T13,Measurement 381 411	diastolic blood pressure (DBP)
18,T14,Value 412 420	=90 mmHg
19,T15,Measurement 424 453	systolic blood pressure (SBP)
20,T16,Value 454 463	=140 mmHg
21,R5,Has_value Arg1:T13 Arg2:T14
22,R6,Has_value Arg1:T15 Arg2:T16
23,*,OR T13 T15
24,T17,Scope 381 463	diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg
25,R7,Has_scope Arg1:T12 Arg2:T17
26,R8,Has_multiplier Arg1:T12 Arg2:T11
27,T18,Temporal 101 110	currently
28,R9,Has_temporal Arg1:T7 Arg2:T18
29,T19,Scope 164 220	not taken antihypertensive drugs within the last 2 weeks
30,A1,Optional T19
31,T20,Scope 101 140	currently taking antihypertensive drugs
32,R10,Subsumes Arg1:T5 Arg2:T20
33,T21,"Scope 222 463	two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg"
34,T22,Non-representable 464 510	(the second blood pressure was measured at V1)
35,R12,Has_scope Arg1:T19 Arg2:T21
36,*,OR T5 T19
37,T23,Person 544 549	woman
38,T24,Observation 553 569	childbearing age
39,T25,Scope 544 569	woman of childbearing age
40,A2,Optional T25
41,T26,Qualifier 591 599	reliable
42,T27,Observation 600 620	contraceptive method
43,R11,Has_qualifier Arg1:T27 Arg2:T26
44,T28,Temporal 621 637	during the trial
45,R13,Has_temporal Arg1:T27 Arg2:T28
46,T29,Reference_point 628 637	the trial
47,R14,Has_index Arg1:T28 Arg2:T29
48,R15,Has_context Arg1:T25 Arg2:T27
49,T30,Mood 575 588	agrees to use
50,R16,Has_mood Arg1:T27 Arg2:T30
51,T31,Observation 676 702	signed an informed consent
52,T32,Observation 643 667	Voluntarily participates
53,T33,Procedure 735 762	gene polymorphism detection
54,T34,Observation 795 817	genotype already known
55,*,OR T33 T34
56,T35,Qualifier 783 794	MTHFR C677T
57,R17,Has_qualifier Arg1:T34 Arg2:T35
58,T36,Qualifier 723 734	MTHFR C677T
59,R18,Has_qualifier Arg1:T33 Arg2:T36
60,T37,Condition 844 871	good tolerance to enalapril
61,T38,Drug 862 871	enalapril
62,R19,multi Arg1:T37 Arg2:T38
63,T39,Measurement 881 910	overall medication compliance
64,T40,Value 876 880	good
65,R20,Has_value Arg1:T39 Arg2:T40
66,T41,Value 912 916	>80%
67,R21,Subsumes Arg1:T40 Arg2:T41
68,T42,Temporal 938 948	previously
69,T43,Condition 959 973;988 1001	good tolerance to ACEI drugs
70,T44,Drug 991 1001	ACEI drugs
71,R22,multi Arg1:T43 Arg2:T44
72,T45,Observation 959 963;978 1001	good adherence to ACEI drugs
73,R23,multi Arg1:T45 Arg2:T44
74,T46,Observation 1014 1032	medication history
75,T47,Scope 959 1001	good tolerance and adherence to ACEI drugs
76,R24,Has_temporal Arg1:T47 Arg2:T42
77,R25,Has_temporal Arg1:T47 Arg2:T46
78,T48,Scope 844 934	good tolerance to enalapril and good overall medication compliance (>80%) in run-in period
79,*,OR T48 T47
80,T49,Observation 1050 1088	continues to participate in this study
81,T50,Qualifier 1038 1049	Voluntarily
82,R26,Has_qualifier Arg1:T49 Arg2:T50
0,T1,Parsing_Error 0 2	NA
0,T1,Informed_consent 0 99	Willing and able to provide written informed consent and accept study procedures and time schedule.
1,T2,Person 101 104	Age
2,T3,Value 105 115	= 18 years
3,T4,Condition 142 163	chronic heart failure
4,T5,Measurement 340 357	ejection fraction
5,T6,Value 359 364	= 40%
6,R1,Has_value Arg1:T5 Arg2:T6
0,T1,Condition 7 17	indication
1,T2,Drug 21 41	oral anticoagulation
2,T3,Condition 49 68	atrial fibrillation
3,R1,AND Arg1:T1 Arg2:T2
4,T4,Device 70 91	mechanic heart valves
5,T5,Condition 93 119	recurrent thrombophlebitis
6,T6,Condition 121 146	antiphospholipid syndrome
7,*,OR T4 T5 T6
8,T7,"Scope 70 146	mechanic heart valves, recurrent thrombophlebitis, antiphospholipid syndrome"
9,R2,Subsumes Arg1:T3 Arg2:T7
10,T8,Observation 149 164	Life expectancy
11,T9,Value 165 175	< 6 months
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Condition 183 198	terminal cancer
14,R4,Subsumes Arg1:T8 Arg2:T10
15,T11,Procedure 201 227	Live donor transplantation
16,T12,Temporal 238 253	within 6 months
17,T13,Mood 228 237	scheduled
18,R5,Has_mood Arg1:T11 Arg2:T13
19,R6,Has_temporal Arg1:T11 Arg2:T12
20,T14,Pregnancy_considerations 255 318	Pregnancy (ß-HCG blood-based assay)or nursing (lactating) women
21,T15,"Pregnancy_considerations 320 412	Women of child bearing potential, unless they are using an effective method of birth control"
22,T16,Non-query-able 414 446	Patient under legal guardianship
23,T17,Non-query-able 448 477	Patients under law protection
24,T18,Condition 485 501	hypersensibility
25,T19,Drug 505 513	coumadin
26,T20,Drug 517 524	indoine
27,*,OR T19 T20
28,T21,Scope 505 524	coumadin or indoine
29,R7,Has_scope Arg1:T18 Arg2:T21
30,T22,Condition 583 596	liver failure
31,T23,Qualifier 576 582	Severe
32,R8,Has_qualifier Arg1:T22 Arg2:T23
0,T1,Measurement 0 36	Estimated glomerular filtration rate
1,T2,Value 37 62	=20 mL/min and <60 mL/min
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 64 67	Hgb
4,T4,Value 68 92	=8.5 g/dL and =11.5 g/dL
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 94 108	Serum ferritin
7,T6,Value 109 119	=500 ng/mL
8,T7,Measurement 124 146	transferrin saturation
9,T8,Measurement 148 152	TSAT
10,R3,Subsumes Arg1:T7 Arg2:T8
11,T9,Value 154 158	=25%
12,R4,Has_value Arg1:T7 Arg2:T9
13,R5,Has_value Arg1:T5 Arg2:T6
14,*,OR T5 T7
15,T10,Measurement 160 192	Serum intact parathyroid hormone
16,T11,Value 193 203	=600 pg/mL
17,R6,Has_value Arg1:T10 Arg2:T11
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 70 72	2.
2,T3,Parsing_Error 139 141	3.
3,T4,Parsing_Error 196 198	4.
4,T5,Non-query-able 3 68	Patient or relatives unable or unwilling to give informed consent
5,T6,Post-eligibility 3 68	Patient or relatives unable or unwilling to give informed consent
6,T7,Condition 73 89	Contraindication
7,T8,Condition 93 100	allergy
8,T9,Drug 104 115	paracetamol
9,T10,Drug 119 129	artesunate
10,T11,Scope 73 100	Contraindication or allergy
11,T12,Scope 104 129	paracetamol or artesunate
12,R1,Has_scope Arg1:T11 Arg2:T12
13,*,OR T9 T10
14,*,OR T7 T8
15,T13,Condition 148 157	cirrhosis
16,T14,Condition 162 194	>6 standard alcoholic drinks/day
17,*,OR T13 T14
18,T15,Condition 199 208	Pregnancy
0,T1,Person 15 22	infants
1,T2,Value 28 59	between 28 0/7 and 34 0/7 weeks
2,T3,Measurement 60 69	gestation
3,T4,Condition 0 6	Inborn
4,T5,Condition 7 14	preterm
5,R1,AND Arg1:T1 Arg2:T5
6,R2,AND Arg1:T1 Arg2:T4
7,R3,Has_value Arg1:T3 Arg2:T2
8,T6,Observation 74 77;85 102	fed mother's own milk
9,T7,Observation 106 122;74 77	donor human milk fed
10,*,OR T7 T6
0,T1,Condition 0 19	Acute heart failure
1,T2,Condition 29 41	exacerbation
2,T3,Qualifier 23 28	acute
3,T4,Condition 45 66	chronic heart failure
4,R1,AND Arg1:T4 Arg2:T2
5,R2,Has_qualifier Arg1:T2 Arg2:T3
6,T5,Temporal 67 90	within the past 2 weeks
7,*,OR T1 T4
8,T6,Scope 0 66	Acute heart failure or acute exacerbation of chronic heart failure
9,R3,Has_temporal Arg1:T6 Arg2:T5
10,T7,Procedure 103 136	cardiac resynchronization therapy
11,T8,Procedure 140 161	heart transplantation
12,*,OR T7 T8
13,T9,Condition 175 190	malignant tumor
14,T10,Person 194 209	life expectancy
15,T11,Value 210 225	under 12 months
16,R4,Has_value Arg1:T10 Arg2:T11
17,*,OR T9 T10
18,T12,Drug 239 250	medications
19,T13,Measurement 267 283	thyroid function
20,T14,Value 260 266	affect
21,R5,Has_value Arg1:T13 Arg2:T14
22,T15,Drug 285 289	L-T4
23,T16,Drug 291 302	carbimazole
24,T17,Drug 304 320	propylthiouracil
25,T18,Drug 322 332	amiodarone
26,T19,Drug 334 341	lithium
27,*,OR T19 T18 T17 T16 T15
28,T20,"Scope 285 341	L-T4, carbimazole, propylthiouracil, amiodarone, lithium"
29,R6,Subsumes Arg1:T12 Arg2:T20
30,R7,AND Arg1:T12 Arg2:T13
31,T21,Condition 345 354	Pregnancy
32,T22,Condition 359 375	lactation period
33,R8,AND Arg1:T21 Arg2:T22
34,T23,Non-query-able 378 442	Participation in another clinical trial within the past 30 days.
35,T24,Condition 444 460	Contraindication
36,T25,Condition 464 475	intolerance
37,T26,Procedure 479 501	evidence-based therapy
38,T27,Condition 506 509	CHF
39,T28,Drug 519 531	beta-blocker
40,T29,Drug 533 572	angiotensin-converting enzyme inhibitor
41,T30,Drug 576 604	angiotensin receptor blocker
42,*,OR T28 T29 T30
43,T31,"Scope 519 604	beta-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker"
44,*,OR T24 T25
45,R9,AND Arg1:T26 Arg2:T27
46,T32,Scope 444 475	Contraindication or intolerance
47,R10,AND Arg1:T32 Arg2:T26
48,T33,Scope 444 509	Contraindication or intolerance to evidence-based therapy for CHF
49,R11,Subsumes Arg1:T33 Arg2:T31
50,T34,Procedure 637 655	trial treatment(s)
51,T35,Drug 637 642;659 667	trial diluents
52,*,OR T35 T34
53,T36,Scope 637 667	trial treatment(s) or diluents
54,T37,Condition 613 629	hypersensitivity
55,R12,Has_scope Arg1:T37 Arg2:T36
56,T38,Drug 697 704	placebo
57,T39,Qualifier 708 713	other
58,T40,Drug 714 732	comparator drug(s)
59,R13,Has_qualifier Arg1:T40 Arg2:T39
60,*,OR T38 T40
61,T41,Scope 697 732	placebo or other comparator drug(s)
62,T42,Scope 613 667	hypersensitivity to the trial treatment(s) or diluents
63,R14,Subsumes Arg1:T42 Arg2:T41
64,T43,Condition 745 766	adrenal insufficiency
65,T44,Qualifier 735 744	Untreated
66,R15,Has_qualifier Arg1:T43 Arg2:T44
67,T45,Condition 779 802	pituitary insufficiency
68,T46,Qualifier 769 778	Untreated
69,R16,Has_qualifier Arg1:T45 Arg2:T46
70,T47,Condition 815 829	thyrotoxicosis
71,T48,Qualifier 805 814	Untreated
72,R17,Has_qualifier Arg1:T47 Arg2:T48
73,T49,Drug 847 860	levothyroxine
74,T50,Condition 900 927	acute myocardial infarction
75,T51,Negation 866 882	not be initiated
76,T52,Procedure 832 841	Treatment
77,R18,AND Arg1:T52 Arg2:T49
78,R19,Has_negation Arg1:T52 Arg2:T51
79,T53,Condition 929 946	acute myocarditis
80,T54,Condition 951 968	acute pancarditis
81,*,OR T54 T53 T50
82,T55,"Scope 900 968	acute myocardial infarction, acute myocarditis, or acute pancarditis"
83,A1,Optional T55
84,R20,AND Arg1:T55 Arg2:T52
85,T56,Condition 978 995	renal dysfunction
86,T57,Qualifier 971 977	Severe
87,R21,Has_qualifier Arg1:T56 Arg2:T57
88,T58,Measurement 997 1001	eGFR
89,T59,Value 1001 1018	=30 ml/min/1.73m2
90,R22,Has_value Arg1:T58 Arg2:T59
91,T60,Scope 997 1018	eGFR=30 ml/min/1.73m2
92,T61,Scope 971 995	Severe renal dysfunction
93,R23,Subsumes Arg1:T61 Arg2:T60
94,T62,Condition 1034 1052	hepatic impairment
95,T63,Qualifier 1022 1033	Significant
96,R24,Has_qualifier Arg1:T62 Arg2:T63
97,T64,Measurement 1054 1063	Serum GPT
98,T65,Value 1064 1073	> 120 U/L
99,T66,"Post-eligibility 1077 1199	Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol."
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 239 241	2.
2,T3,Parsing_Error 338 340	3.
3,T4,Parsing_Error 361 363	4.
4,T5,Parsing_Error 422 424	5.
5,T6,Parsing_Error 737 739	6.
6,T7,Parsing_Error 977 979	7.
7,T8,Parsing_Error 1173 1175	8.
8,T9,Parsing_Error 1306 1308	9.
9,T10,Condition 26 53	microvascular complications
10,T11,Measurement 68 104	estimated glomerular filtration rate
11,T12,Value 105 120	below 40 ml/min
12,R1,Has_value Arg1:T11 Arg2:T12
13,T13,Condition 55 66	nephropathy
14,R2,Subsumes Arg1:T13 Arg2:T11
15,T14,Condition 123 133	neuropathy
16,T15,Condition 156 169	gastroparesis
17,R3,Subsumes Arg1:T14 Arg2:T15
18,T16,Condition 174 206	severe proliferative retinopathy
19,T17,Subjective_judgement 207 236	as judged by the investigator
20,T18,Qualifier 207 236	as judged by the investigator
21,R4,Has_qualifier Arg1:T10 Arg2:T18
22,*,OR T13 T14 T16
23,T19,"Scope 55 206	nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy"
24,R5,Subsumes Arg1:T10 Arg2:T19
25,T20,Temporal 250 260	< 3 months
26,T21,Temporal 242 248	Recent
27,R6,Subsumes Arg1:T21 Arg2:T20
28,T22,Condition 262 287	acute macrovascular event
29,T23,Condition 293 316	acute coronary syndrome
30,T24,Condition 320 335	cardiac surgery
31,*,OR T23 T24
32,T25,Scope 293 335	acute coronary syndrome or cardiac surgery
33,R7,Subsumes Arg1:T22 Arg2:T25
34,R8,Has_temporal Arg1:T22 Arg2:T21
35,T26,Condition 349 358	pregnancy
36,T27,Temporal 341 348	Ongoing
37,R9,Has_temporal Arg1:T26 Arg2:T27
38,T28,Condition 371 391	hypoglycemic episode
39,T29,Qualifier 364 370	Severe
40,R10,Has_qualifier Arg1:T28 Arg2:T29
41,T30,Temporal 392 419	within 1 month of screening
42,R11,Has_temporal Arg1:T28 Arg2:T30
43,T31,Drug 425 458	Agents affecting gastric emptying
44,T32,Undefined_semantics 425 458	Agents affecting gastric emptying
45,T33,Drug 460 468	Motilium
46,T34,Drug 471 479	Prandase
47,T35,Drug 482 489	Victoza
48,T36,Drug 492 498	Byetta
49,T37,Drug 504 510	Symlin
50,T38,Grammar_Error 500 503	and
51,*,OR T33 T34 T35 T36 T37
52,T39,"Scope 460 511	Motilium®, Prandase®, Victoza®, Byetta® and Symlin®"
53,R12,Subsumes Arg1:T31 Arg2:T39
54,T40,Drug 524 549	oral anti-diabetic agents
55,T41,Drug 551 560	Metformin
56,T42,Drug 562 579	SGLT-2 inhibitors
57,T43,Drug 584 600	DPP-4 inhibitors
58,T44,Grammar_Error 580 583	and
59,*,OR T42 T43 T41
60,T45,"Scope 551 600	Metformin, SGLT-2 inhibitors and DPP-4 inhibitors"
61,R13,Subsumes Arg1:T40 Arg2:T45
62,T46,Qualifier 614 625	stable dose
63,T47,Temporal 626 638	for 3 months
64,R14,Has_temporal Arg1:T46 Arg2:T47
65,T48,Scope 614 638	stable dose for 3 months
66,T49,Negation 605 608	not
67,R15,Has_negation Arg1:T48 Arg2:T49
68,R16,Has_scope Arg1:T40 Arg2:T48
69,*,OR T31 T40
70,T50,"Parsing_Error 640 735	Otherwise, these medications are acceptable and will be kept stable during the entire protocol."
71,T51,Drug 740 753	Oral steroids
72,T52,Negation 754 760	unless
73,T53,Qualifier 784 795	stable dose
74,T54,Qualifier 780 783;791 795	low dose
75,T55,Multiplier 802 815;830 837	10 mg or less per day
76,T56,Drug 819 829	prednisone
77,T57,Multiplier 841 860	physiological doses
78,T58,Multiplier 862 881	less than 35 mg/day
79,T59,Drug 886 900	hydrocortisone
80,T60,Drug 901 907	Cortef
81,R17,Subsumes Arg1:T59 Arg2:T60
82,R18,Subsumes Arg1:T57 Arg2:T58
83,R19,Has_multiplier Arg1:T59 Arg2:T57
84,R20,Has_multiplier Arg1:T56 Arg2:T55
85,*,OR T59 T56
86,T61,"Scope 802 907	10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef"
87,R21,Subsumes Arg1:T54 Arg2:T61
88,R22,Has_negation Arg1:T54 Arg2:T52
89,R23,Has_negation Arg1:T53 Arg2:T52
90,R24,Has_qualifier Arg1:T51 Arg2:T53
91,R25,Has_qualifier Arg1:T51 Arg2:T54
92,T62,Grammar_Error 911 974	Inhale steroids at stable dose in the last month are acceptable
93,T63,Drug 911 926	Inhale steroids
94,T64,Qualifier 930 941	stable dose
95,T65,Temporal 942 959	in the last month
96,R26,Has_qualifier Arg1:T63 Arg2:T64
97,R27,Has_temporal Arg1:T63 Arg2:T65
98,T66,Condition 980 985;994 1009	Other medical illness
99,T67,Qualifier 986 993	serious
100,T68,Subjective_judgement 986 993	serious
101,T69,Context_Error 1010 1054	likely to interfere with study participation
102,T70,Context_Error 1010 1029;1058 1096	likely to interfere with the ability to complete the trial
103,T71,Subjective_judgement 1097 1132	by the judgment of the investigator
104,T72,Condition 1148 1169	psychiatric condition
105,T73,Qualifier 1139 1147	unstable
106,R28,Has_qualifier Arg1:T72 Arg2:T73
107,T74,Scope 980 1132	Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator
108,R29,Subsumes Arg1:T74 Arg2:T72
109,T75,"Non-query-able 1176 1304	Failure to comply with team's recommendations (e.g. not willing to change pump parameters, follow algorithm's suggestions, etc)."
110,T76,Non-query-able 1309 1404	Living or planned travel outside Montreal (> 1h of driving) area during closed-loop procedures.
111,T77,Procedure 1381 1403	closed-loop procedures
112,T78,Temporal 1374 1403	during closed-loop procedures
113,T79,Reference_point 1381 1403	closed-loop procedures
114,R30,Has_index Arg1:T78 Arg2:T79
0,T1,Measurement 0 15	Serum phosphate
1,T2,Value 16 26	<3.0 mg/dL
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Drug 45 49	iron
4,T4,Qualifier 41 43	IV
5,T5,Qualifier 28 39	Intravenous
6,R2,Subsumes Arg1:T5 Arg2:T4
7,R3,Has_qualifier Arg1:T3 Arg2:T5
8,T6,Temporal 63 96	within 4 weeks prior to Screening
9,T7,Reference_point 87 96	Screening
10,R4,Has_index Arg1:T6 Arg2:T7
11,R5,Has_temporal Arg1:T3 Arg2:T6
12,T8,Drug 98 131	Erythropoiesis-stimulating agents
13,T9,Drug 133 136	ESA
14,R6,Subsumes Arg1:T8 Arg2:T9
15,T10,Temporal 151 184	within 4 weeks prior to Screening
16,T11,Reference_point 175 184	Screening
17,R7,Has_index Arg1:T10 Arg2:T11
18,T12,Procedure 186 203	Blood transfusion
19,T13,Temporal 204 237	within 4 weeks prior to Screening
20,T14,Reference_point 228 237	Screening
21,R8,Has_index Arg1:T13 Arg2:T14
22,R9,Has_temporal Arg1:T12 Arg2:T13
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 27 29	2.
2,T3,Parsing_Error 133 135	3.
3,T4,Parsing_Error 206 208	4.
4,T5,Parsing_Error 272 274	5.
5,T6,Person 11 14	age
6,T7,Value 15 25	≥ 12 years
7,R1,Has_value Arg1:T6 Arg2:T7
8,T8,Condition 42 61	P. knowlesi malaria
9,T9,Measurement 85 96	blood smear
10,T10,Value 76 84	positive
11,R2,Has_value Arg1:T9 Arg2:T10
12,T11,Qualifier 97 130	with asexual forms of P. knowlesi
13,R3,Has_qualifier Arg1:T10 Arg2:T11
14,R4,AND Arg1:T8 Arg2:T9
15,T12,Measurement 136 147	Temperature
16,T13,Value 148 152	>38C
17,R5,Has_value Arg1:T12 Arg2:T13
18,T14,Temporal 218 233	within 18 hours
19,T15,Observation 209 217	Enrolled
20,T16,Reference_point 237 270	commencing antimalarial treatment
21,T17,Procedure 248 270	antimalarial treatment
22,R6,Has_index Arg1:T14 Arg2:T16
23,T18,Non-query-able 275 380	Written informed consent from patient or attending relative able to and willing to give informed consent.
24,T19,Non-query-able 381 481	Consent form and information sheets will be translated into Malay and copies provided to the patient
25,T20,Not_a_criteria 381 482	Consent form and information sheets will be translated into Malay and copies provided to the patient.
26,T21,Post-eligibility 275 380	Written informed consent from patient or attending relative able to and willing to give informed consent.
0,T1,Person 0 15	Newborn infants
1,T2,Measurement 40 49	gestation
2,T3,Value 16 39	<28 weeks and >34 weeks
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 62 86	life threatening illness
5,T5,Condition 103 124	chromosomal anomalies
6,T6,Condition 115 124;88 98	anomalies congenital
7,T7,Condition 126 152	gastrointestinal anomalies
8,T8,Condition 156 181	necrotizing enterocolitis
9,T9,Observation 186 207	fed premature formula
10,*,OR T6 T5 T4 T7 T8
0,T1,Value 5 22	18 years or older
1,T2,Person 0 4	Aged
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Person 24 28	male
4,T4,Person 32 38	female
5,*,OR T4 T3
6,T5,Condition 41 63	Systolic heart failure
7,T6,Measurement 69 102	New York Heart Association (NYHA)
8,T7,Value 103 115	class II-III
9,R2,Has_value Arg1:T6 Arg2:T7
10,R3,AND Arg1:T5 Arg2:T6
11,T8,Measurement 118 159	Left ventricular ejection fraction (LVEF)
12,T9,Value 160 173	less than 40%
13,T10,Procedure 177 193	echocardiography
14,T11,Temporal 194 228	during screening and randomization
15,R4,Has_temporal Arg1:T10 Arg2:T11
16,R5,AND Arg1:T10 Arg2:T8
17,R6,Has_value Arg1:T8 Arg2:T9
18,T12,Condition 231 234	SCH
19,T13,Measurement 236 239	TSH
20,T14,Value 241 278	upper limits of normal (ULN) -10mIU/L
21,T15,Measurement 284 293	FT4 level
22,T16,Value 294 316	within reference range
23,R7,Has_value Arg1:T15 Arg2:T16
24,R8,Has_value Arg1:T13 Arg2:T14
25,T17,"Scope 236 316	TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range"
26,R9,Subsumes Arg1:T12 Arg2:T17
27,T18,Procedure 336 355	standard HF therapy
28,T19,Temporal 356 376	for at least 2 weeks
29,R10,Has_temporal Arg1:T18 Arg2:T19
30,T20,Multiplier 393 404	target dose
31,T21,Multiplier 408 426	max tolerable dose
32,*,OR T20 T21
33,T22,Scope 393 426	target dose or max tolerable dose
34,R11,Has_scope Arg1:T18 Arg2:T22
35,T23,Non-query-able 429 455	Provided informed consent.
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 38 40	2.
2,T3,Parsing_Error 103 105	3.
3,T4,Parsing_Error 259 261	4.
4,T5,Parsing_Error 302 304	5.
5,T6,Person 3 8	Males
6,T7,Grammar_Error 9 12	and
7,T8,Person 13 20	females
8,T9,Person 32 35	old
9,T10,Value 21 35	≥ 18 years old
10,R1,Has_value Arg1:T9 Arg2:T10
11,*,OR T6 T8
12,T11,Condition 63 78	type 1 diabetes
13,T12,Temporal 79 100	for at least one year
14,R2,Has_temporal Arg1:T11 Arg2:T12
15,T13,Procedure 136 156	insulin pump therapy
16,T14,Temporal 157 178	for at least 3 months
17,R3,Has_temporal Arg1:T13 Arg2:T14
18,T15,Temporal 183 192	currently
19,T16,Drug 201 226	fast actin insulin analog
20,T17,Drug 228 234	Lispro
21,T18,Drug 236 242	Aspart
22,T19,Drug 246 255	Guilisine
23,*,OR T19 T18 T17
24,T20,"Scope 228 255	Lispro, Aspart or Guilisine"
25,R4,Subsumes Arg1:T16 Arg2:T20
26,R5,Has_temporal Arg1:T16 Arg2:T15
27,T21,Measurement 288 293	HbA1c
28,T22,Value 294 299	≤ 10%
29,R6,Has_value Arg1:T21 Arg2:T22
30,T23,Temporal 262 287	Last (less than 3 months)
31,R7,Has_temporal Arg1:T21 Arg2:T23
32,T24,Procedure 321 342	carbohydrate counting
33,T25,Procedure 350 376	meal insulin dose strategy
34,R8,AND Arg1:T25 Arg2:T24
35,T26,Temporal 305 314	Currently
36,R9,Has_temporal Arg1:T24 Arg2:T26
0,T1,Procedure 8 30	allergen immunotherapy
1,T2,Condition 32 65	upper respiratory tract infection
2,T3,Condition 67 76	Pregnancy
3,T4,Condition 98 117	lactose-intolerance
4,T5,Condition 121 142	allergies to cow-milk
5,R1,OR Arg1:T4 Arg2:T5
0,T1,Condition 0 13	Corneal ulcer
1,T2,Measurement 22 27	smear
2,T4,Qualifier 48 56	bacteria
3,T5,Qualifier 60 78	filamentous fungus
4,*,OR T4 T5
5,T3,Scope 48 78	bacteria or filamentous fungus
6,R1,Has_scope Arg1:T2 Arg2:T3
7,T6,Value 28 36	positive
8,R2,Has_value Arg1:T2 Arg2:T6
9,R3,AND Arg1:T1 Arg2:T2
10,T7,Measurement 80 101	Pinhole visual acuity
11,T8,Value 102 118	worse than 20/70
12,R4,Has_value Arg1:T7 Arg2:T8
13,T9,Drug 165 190	antimicrobial medications
14,T10,Person 208 211	Age
15,T11,Value 212 225	over 18 years
16,R5,Has_value Arg1:T10 Arg2:T11
17,T12,Non-query-able 227 290	Basic understanding of the study as determined by the physician
18,T13,Post-eligibility 292 333	Commitment to return for follow up visits
0,T1,Condition 0 15	Type 1 diabetes
1,T2,Measurement 17 29	autoantibody
2,T3,Value 30 38	positive
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,Subsumes Arg1:T1 Arg2:T2
5,T4,Drug 67 82	GLP-1 analogues
6,T5,Drug 86 117	dipeptidyl peptidase inhibitors
7,*,OR T4 T5
8,T6,Scope 67 117	GLP-1 analogues or dipeptidyl peptidase inhibitors
9,T7,Temporal 118 133	within 6 months
10,R3,Has_temporal Arg1:T6 Arg2:T7
11,T8,Condition 148 161	heart failure
12,T9,Qualifier 141 147	severe
13,R4,Has_qualifier Arg1:T8 Arg2:T9
14,T10,Measurement 177 181	NYHA
15,T11,Value 182 183	4
16,R5,Has_value Arg1:T10 Arg2:T11
17,R6,Subsumes Arg1:T8 Arg2:T10
18,T12,Condition 186 204	Active myocarditis
19,T13,Device 221 243	artificial heart valve
20,T14,Qualifier 206 220	malfunctioning
21,R7,Has_qualifier Arg1:T13 Arg2:T14
22,*,OR T12 T13
23,T15,Condition 257 280	ventricular tachycardia
24,T16,Temporal 281 296	within 3 months
25,R8,Has_temporal Arg1:T15 Arg2:T16
26,T17,Condition 328 363	third-degree atrioventricular block
27,T18,Condition 317 324;334 363	second- degree atrioventricular block
28,*,OR T17 T18 T15
29,T19,Measurement 373 396	systolic blood pressure
30,T20,Qualifier 366 372	Supine
31,R9,Has_qualifier Arg1:T19 Arg2:T20
32,T21,Value 397 406	<85 mm Hg
33,T22,Value 410 420	>200 mm Hg
34,*,OR T21 T22
35,T23,Scope 397 420	<85 mm Hg or >200 mm Hg
36,R10,Has_scope Arg1:T19 Arg2:T23
37,T24,Condition 436 460	Primary renal impairment
38,T25,Measurement 462 482	creatinine clearance
39,T26,Value 483 494	< 45 ml/min
40,T27,Drug 511 520	metformin
41,R11,AND Arg1:T24 Arg2:T27
42,R12,AND Arg1:T24 Arg2:T25
43,R13,Has_value Arg1:T25 Arg2:T26
44,T28,Condition 535 546	hypokalemia
45,T29,Condition 550 562	hyperkalemia
46,*,OR T28 T29
47,T30,Measurement 564 573	potassium
48,T31,Value 574 585	<3.5 mmol/l
49,T32,Value 589 600	>5.5 mmol/l
50,*,OR T31 T32
51,T33,Scope 574 600	<3.5 mmol/l or >5.5 mmol/l
52,R14,Has_scope Arg1:T30 Arg2:T33
53,T34,Scope 535 562	hypokalemia or hyperkalemia
54,R15,Subsumes Arg1:T34 Arg2:T33
55,T35,Condition 616 622	anemia
56,T36,Qualifier 604 615	Significant
57,R16,Has_qualifier Arg1:T35 Arg2:T36
58,T37,Measurement 624 626	Hb
59,T38,Value 627 635	< 90 g/l
60,R17,Has_value Arg1:T37 Arg2:T38
61,R18,Subsumes Arg1:T35 Arg2:T37
62,T39,Condition 645 669	gastrointestinal disease
63,T40,Qualifier 638 644	Severe
64,R19,Has_qualifier Arg1:T39 Arg2:T40
65,T41,Condition 681 694	gastroparesis
66,R20,Subsumes Arg1:T39 Arg2:T41
67,T42,Measurement 728 743	Body mass index
68,T43,Measurement 745 748	BMI
69,T44,Value 750 760	> 45 kg/m2
70,R21,Subsumes Arg1:T42 Arg2:T43
71,R22,Has_value Arg1:T42 Arg2:T44
72,T45,Condition 763 781	Malignant neoplasm
73,T46,Procedure 792 804	chemotherapy
74,T47,Procedure 806 813	surgery
75,T48,Procedure 815 824	radiation
76,T49,Procedure 828 846	palliative therapy
77,T50,Temporal 854 871	previous 5 years.
78,*,OR T46 T47 T48 T49
79,T51,"Scope 792 846	chemotherapy, surgery, radiation or palliative therapy"
80,R23,Has_scope Arg1:T45 Arg2:T51
81,R24,Has_temporal Arg1:T45 Arg2:T50
82,T52,Negation 1008 1015	allowed
83,T53,Condition 886 925	intraepithelial squamous cell carcinoma
84,T54,Qualifier 933 937	skin
85,R25,Has_qualifier Arg1:T53 Arg2:T54
86,T55,Drug 951 962	topical 5FU
87,R26,AND Arg1:T53 Arg2:T55
88,T56,Condition 981 1003	basal cell skin cancer
89,*,OR T53 T56
90,T57,Scope 886 1003	intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer
91,R27,Has_negation Arg1:T57 Arg2:T52
92,T58,"Pregnancy_considerations 1037 1133	Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant"
93,T59,Condition 1153 1166	alcohol abuse
94,T60,Condition 1144 1148;1161 1166	drug abuse
95,*,OR T59 T60
96,T61,Condition 1180 1185;1197 1209	acute pancreatitis
97,T62,Condition 1189 1209	chronic pancreatitis
98,*,OR T62 T61
99,T63,Non-query-able 1211 1281	Subjects considered by the Investigator to be unsuitable for the study
0,T1,"Line 0 121	1) pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;"
1,T2,"Line 121 237	2) existing severe acute infection and is not controlled; or purulent and chronic infection, delayed healing wounds;"
2,T3,"Line 238 442	3) the original severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension;"
3,T4,"Line 443 756	4) suffering from neurological and psychiatric diseases or mental disorders is not easy to control, poor compliance, and can not be described with treatment responders; primary brain or central nervous metastasis disease has not been controlled, with significant cranial hypertension or neuropsychiatric symptoms;"
4,T5,Line 757 785	5) have bleeding tendencies;
5,T6,Line 786 873	6) other researchers believe that patients should not participate in the present trial.
6,T7,"Pregnancy_considerations 3 121	pregnancy, breast-feeding women, or female patients of childbearing potential but did not take contraceptive measures;"
7,T8,Qualifier 133 139	severe
8,T9,Qualifier 140 145	acute
9,T10,Condition 146 155	infection
10,R1,Has_qualifier Arg1:T10 Arg2:T9
11,R2,Has_qualifier Arg1:T10 Arg2:T8
12,T11,Qualifier 163 177	not controlled
13,R3,Has_qualifier Arg1:T10 Arg2:T11
14,T12,Qualifier 195 202	chronic
15,T13,Qualifier 182 190	purulent
16,T14,Condition 203 212	infection
17,T15,Condition 214 236	delayed healing wounds
18,R4,Has_qualifier Arg1:T14 Arg2:T12
19,R5,Has_qualifier Arg1:T14 Arg2:T13
20,T16,"Scope 182 236	purulent and chronic infection, delayed healing wounds"
21,*,OR T10 T16
22,T17,Qualifier 254 260	severe
23,T18,Condition 261 274	heart disease
24,R6,Has_qualifier Arg1:T18 Arg2:T17
25,T19,Condition 286 310	congestive heart failure
26,T20,Qualifier 312 324	uncontrolled
27,T21,Qualifier 325 334	high-risk
28,T22,Condition 335 346	arrhythmias
29,R7,Has_qualifier Arg1:T22 Arg2:T21
30,R8,Has_qualifier Arg1:T22 Arg2:T20
31,T23,Condition 348 363	unstable angina
32,T24,Condition 365 386	myocardial infarction
33,T25,Qualifier 388 394	severe
34,T26,Condition 395 414	heart valve disease
35,T27,Qualifier 419 428	resistant
36,T28,Condition 429 441	hypertension
37,R9,Has_qualifier Arg1:T28 Arg2:T27
38,R10,Has_qualifier Arg1:T26 Arg2:T25
39,*,OR T28 T26 T24 T23 T22 T19
40,T29,"Scope 286 441	congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension"
41,R11,Subsumes Arg1:T18 Arg2:T29
42,T30,Condition 478 498	psychiatric diseases
43,T31,Condition 461 473;490 498	neurological diseases
44,T32,Condition 502 518	mental disorders
45,T33,Condition 543 558	poor compliance
46,T34,Condition 629 663	central nervous metastasis disease
47,T35,Condition 612 625;656 663	primary brain disease
48,T36,Negation 668 671	not
49,T37,Qualifier 677 687	controlled
50,R12,Has_negation Arg1:T37 Arg2:T36
51,*,OR T35 T34
52,T38,Scope 612 663	primary brain or central nervous metastasis disease
53,R13,Has_qualifier Arg1:T38 Arg2:T37
54,T39,Qualifier 694 705	significant
55,T40,Condition 706 726	cranial hypertension
56,T41,Condition 730 755	neuropsychiatric symptoms
57,T42,Condition 765 784	bleeding tendencies
58,*,OR T41 T40
59,T43,Scope 706 755	cranial hypertension or neuropsychiatric symptoms
60,R14,Has_qualifier Arg1:T43 Arg2:T39
61,*,OR T38 T33 T31 T32 T30 T43
62,T44,Non-query-able 789 873	other researchers believe that patients should not participate in the present trial.
0,T1,Procedure 6 18	chemotherapy
1,T2,Temporal 0 5	Prior
2,T3,Line 0 18	Prior chemotherapy
3,T4,Procedure 25 34	treatment
4,T5,Drug 40 49	gefitinib
5,T6,Temporal 19 24	Prior
6,R2,Has_temporal Arg1:T4 Arg2:T6
7,R3,Has_temporal Arg1:T1 Arg2:T2
8,T8,Drug 51 60	erlotinib
9,T7,Drug 71 93	drugs that target EGFR
10,*,OR T5 T8 T7
11,T9,"Scope 40 93	gefitinib, erlotinib, or other drugs that target EGFR"
12,R1,Has_scope Arg1:T4 Arg2:T9
13,T10,"Line 19 93	Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR"
14,T11,Post-eligibility 94 157	Patients must not be receiving any other investigational agents
15,T12,Condition 174 199	interstitial lung disease
0,T1,Condition 22 39	allergic rhinitis
1,T2,Condition 49 63	sneeze attacks
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Condition 65 70;85 89	runny nose
4,T4,Condition 71 78;85 89	blocked nose
5,T5,Condition 79 89	itchy nose
6,T6,Condition 110 121	common cold
7,T7,Negation 97 104	absence
8,R2,Has_negation Arg1:T6 Arg2:T7
9,T8,Temporal 122 151	during the previous 12 months
10,R3,Has_temporal Arg1:T6 Arg2:T8
11,R4,OR Arg1:T1 Arg2:T3
12,R5,OR Arg1:T4 Arg2:T3
13,R6,OR Arg1:T5 Arg2:T3
14,*,OR T4 T6
15,T9,Measurement 174 189	skin prick test
16,T10,Value 165 173	positive
17,R7,Has_value Arg1:T9 Arg2:T10
18,T11,Measurement 193 231	blood radio-allergosorbent test (RAST)
19,T12,Qualifier 235 240	grass
20,T13,Qualifier 248 262	ragweed pollen
21,*,OR T12 T13
22,R8,Has_value Arg1:T11 Arg2:T10
23,R9,Has_qualifier Arg1:T11 Arg2:T12
0,T1,Qualifier 3 27	histologically confirmed
1,T2,Condition 88 114	non-small cell lung cancer
2,T3,Qualifier 129 143	wild-type EGFR
3,T4,Qualifier 148 160	ALK-negative
4,R1,Has_qualifier Arg1:T2 Arg2:T3
5,R2,Has_qualifier Arg1:T2 Arg2:T4
6,R3,Has_qualifier Arg1:T2 Arg2:T1
7,T5,Measurement 178 203	IASLC2009 new TNM staging
8,T6,Condition 207 218	lung cancer
9,T7,Value 219 246	stage <U+2162>B or <U+2163>
10,R4,Has_value Arg1:T5 Arg2:T7
11,R5,AND Arg1:T6 Arg2:T5
12,T8,Qualifier 259 268	untreated
13,T9,Qualifier 272 280	relapsed
14,T10,Temporal 281 318	after 1 year of lung cancer resection
15,T11,Reference_point 297 318	lung cancer resection
16,R6,Has_index Arg1:T10 Arg2:T11
17,*,OR T8 T9
18,T12,Scope 259 280	untreated or relapsed
19,R7,Has_scope Arg1:T6 Arg2:T12
20,R8,Has_temporal Arg1:T6 Arg2:T10
21,T13,Multiplier 328 340	at least one
22,T14,Condition 341 358	evaluable lesions
23,R9,Has_multiplier Arg1:T14 Arg2:T13
24,T15,Measurement 437 453	longest diameter
25,T16,Procedure 459 468	spiral CT
26,T17,Value 469 482	at least 10mm
27,R10,Has_value Arg1:T15 Arg2:T17
28,R11,AND Arg1:T16 Arg2:T15
29,T18,Procedure 488 498	regular CT
30,T19,Measurement 499 515	longest diameter
31,T20,Value 516 529	at least 20mm
32,R12,AND Arg1:T18 Arg2:T19
33,R13,Has_value Arg1:T19 Arg2:T20
34,T21,Person 535 539	Male
35,T22,Person 543 549	female
36,*,OR T21 T22
37,T23,Person 551 555	aged
38,T24,Value 556 570	18 to 75 years
39,R14,Has_value Arg1:T23 Arg2:T24
40,T25,Measurement 575 582	ECOG PS
41,T26,Value 583 589	0 or 1
42,R15,Has_value Arg1:T25 Arg2:T26
43,T27,Observation 594 611	expected survival
44,T28,Temporal 612 629	at least 3 months
45,R16,Has_temporal Arg1:T27 Arg2:T28
46,T29,Condition 634 665	adequate hematological function
47,T30,Measurement 667 698	absolute neutrophil count (ANC)
48,T31,Value 699 716	at least 2×10^9/L
49,T32,Measurement 721 735	platelet count
50,T33,Value 736 755	at least 100×10^9/L
51,R17,Has_value Arg1:T32 Arg2:T33
52,T34,Measurement 760 770	hemoglobin
53,T35,Value 771 786	at least 9 g/dL
54,R18,Has_value Arg1:T34 Arg2:T35
55,R19,Has_value Arg1:T30 Arg2:T31
56,T36,Scope 667 786	absolute neutrophil count (ANC) at least 2×10^9/L and platelet count at least 100×10^9/L and hemoglobin at least 9 g/dL
57,R20,Subsumes Arg1:T29 Arg2:T36
58,T37,Condition 791 814	adequate liver function
59,T38,Measurement 816 831	total bilirubin
60,T39,Value 832 869	less than upper limit of normal (ULN)
61,R21,Has_value Arg1:T38 Arg2:T39
62,T40,Measurement 871 874	AST
63,T41,Measurement 879 882	ALT
64,T42,Value 883 930	less than 2.5 times upper limit of normal (ULN)
65,R22,Has_value Arg1:T41 Arg2:T42
66,R23,Has_value Arg1:T40 Arg2:T42
67,T43,Measurement 932 952	alkaline phosphatase
68,T44,Value 953 1002	less than 5 times the upper limit of normal (ULN)
69,R24,Has_value Arg1:T43 Arg2:T44
70,T45,Condition 1007 1030	adequate renal function
71,T46,Measurement 1032 1048	serum creatinine
72,T47,Value 1049 1086	less than upper limit of normal (ULN)
73,R25,Has_value Arg1:T46 Arg2:T47
74,T48,Measurement 1090 1121	calculated creatinine clearance
75,T49,Value 1122 1140	at least 60 mL/min
76,R26,Has_value Arg1:T48 Arg2:T49
77,*,OR T46 T48
78,T50,Measurement 1146 1149	ECG
79,T51,Value 1153 1159	normal
80,R27,Has_value Arg1:T50 Arg2:T51
81,T52,Negation 1170 1172	no
82,T53,Condition 1173 1203	non-healing wounds on the body
83,R28,Has_negation Arg1:T53 Arg2:T52
84,T54,Scope 1032 1140	serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min
85,R29,Subsumes Arg1:T45 Arg2:T54
86,T55,Scope 816 1002	total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN)
87,R30,Subsumes Arg1:T37 Arg2:T55
88,T56,Drug 1245 1261	anticancer drugs
89,T57,Negation 1213 1225	not received
90,R31,Has_negation Arg1:T56 Arg2:T57
91,T58,Condition 1297 1318	non-metastatic tumors
92,T59,Qualifier 1331 1342	neoadjuvant
93,T60,Qualifier 1319 1327	adjuvant
94,*,OR T60 T59
95,T61,Procedure 1343 1355	chemotherapy
96,T62,Scope 1319 1342	adjuvant or neoadjuvant
97,R32,Has_scope Arg1:T61 Arg2:T62
98,R33,AND Arg1:T61 Arg2:T58
99,*,OR T56 T61
100,T63,Temporal 1399 1423	ended more than 6 months
101,R34,Has_temporal Arg1:T61 Arg2:T63
102,T64,Temporal 1288 1296	previous
103,R35,Has_temporal Arg1:T58 Arg2:T64
104,T65,"Non-representable 1429 1561	have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered"
105,T66,"Pregnancy_considerations 1567 1904	have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days. If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose);"
106,T67,Non-query-able 2032 2056	signed informed consent.
107,T68,"Non-representable 1909 2027	previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions;"
108,T69,Line 2028 2056	15) signed informed consent.
109,T70,"Line 1905 2027	14) previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions;"
110,T71,"Line 1567 1904	have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days. If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose);"
111,T72,"Line 1425 1562	12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered;"
112,T73,"Line 1205 1423	11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months"
113,T74,"Line 1146 1204	ECG is normal, there is no non-healing wounds on the body;"
114,T75,Line 1007 1141	adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min;
115,T76,Line 791 1002	adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN)
116,T77,Line 634 786	adequate hematological function: absolute neutrophil count (ANC) at least 2×10^9/L and platelet count at least 100×10^9/L and hemoglobin at least 9 g/dL
117,T78,Line 594 630	expected survival at least 3 months;
118,T79,"Line 535 589	Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1"
119,T80,"Line 323 530	have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm)"
120,T81,"Line 165 318	According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection"
121,T82,"Line 3 161	histologically confirmed (patients not receiving a single sputum cytology diagnosis) non-small cell lung cancer patients,with wild-type EGFR and ALK-negative;"
0,T1,Procedure 22 25	PCI
1,T2,Procedure 46 49	DES
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 58 61	ACS
4,R2,AND Arg1:T1 Arg2:T3
5,T4,Condition 103 106	T2D
6,T5,Person 210 214	Male
7,T6,Person 219 225	female
8,*,OR T5 T6
9,T7,Person 241 246	years
10,T8,Value 235 240	18-80
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Measurement 249 254	HbA1c
13,T10,Value 277 303	47 mmol/mol - 110 mmol/mol
14,R4,Has_value Arg1:T9 Arg2:T10
15,T11,Informed_consent 306 334	Signed informed consent form
0,T1,Condition 12 33	concomitant infection
1,T2,Condition 136 147	perforation
2,T3,Condition 164 185	Involvement of sclera
3,T4,Condition 221 241	autoimmune keratitis
4,T5,Condition 203 217;232 241	Non-infectious keratitis
5,*,OR T4 T5
6,T6,Procedure 254 277	corneal transplantation
7,T7,Procedure 288 307	intraocular surgery
8,*,OR T6 T7
9,T8,Negation 309 311	No
10,T9,Condition 312 328	light perception
11,R1,Has_negation Arg1:T9 Arg2:T8
12,T10,Measurement 350 371	Pinhole visual acuity
13,T11,Value 372 389	worse than 20/200
14,R2,Has_value Arg1:T10 Arg2:T11
15,T12,Condition 454 474	cognitively impaired
0,T1,Condition 27 46	lung adenocarcinoma
1,T2,Procedure 0 10	Pathologic
2,T3,Value 11 23	confirmation
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Qualifier 47 70	with measurable disease
5,R3,Has_qualifier Arg1:T1 Arg2:T4
6,T5,Multiplier 83 95	at least one
7,T6,Condition 96 102	lesion
8,T7,Qualifier 108 160	can be accurately measured in at least one dimension
9,R4,Has_multiplier Arg1:T6 Arg2:T5
10,R5,Has_qualifier Arg1:T6 Arg2:T7
11,T8,Qualifier 232 241	untreated
12,T9,Qualifier 242 258	locally advanced
13,T10,Qualifier 262 272	metastatic
14,T11,Condition 273 278	NSCLC
15,*,OR T10 T9
16,T12,Scope 242 272	locally advanced or metastatic
17,R6,Has_scope Arg1:T11 Arg2:T12
18,R7,Has_qualifier Arg1:T11 Arg2:T8
19,T13,Condition 299 310	lung cancer
20,T14,Qualifier 311 315;329 353	with EGFR activating mutation
21,R8,Has_qualifier Arg1:T13 Arg2:T14
22,T15,Condition 355 371	exon 19 deletion
23,T16,Condition 373 378	L858R
24,*,OR T15 T16
25,T17,"Scope 355 378	exon 19 deletion, L858R"
26,R9,Subsumes Arg1:T14 Arg2:T17
27,T18,Scope 27 70	lung adenocarcinoma with measurable disease
28,R2,AND Arg1:T18 Arg2:T2
29,R10,Subsumes Arg1:T18 Arg2:T6
30,T19,"Line 0 200	Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT)"
31,T20,Line 202 278	Patients must have previously untreated locally advanced or metastatic NSCLC
32,T21,"Line 280 380	Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R)."
0,T1,Multiplier 0 21	More than three doses
1,T2,Drug 29 35	opioid
2,T3,Temporal 36 62	within one week of surgery
3,T4,Reference_point 55 62	surgery
4,R1,Has_multiplier Arg1:T2 Arg2:T1
5,R2,Has_temporal Arg1:T2 Arg2:T3
6,R3,Has_index Arg1:T3 Arg2:T4
7,T5,Condition 64 73	Pregnancy
8,T6,Person 75 84	Prisoners
9,T7,Informed_consent 86 111	Unable to provide consent
10,T8,Procedure 113 130	Emergency surgery
11,T9,Condition 132 154	Chronic kidney disease
12,T10,Qualifier 155 162	stage 5
13,T11,Measurement 164 167	GFR
14,T12,Value 168 180	< 15 ml/min)
15,R4,Has_value Arg1:T11 Arg2:T12
16,R5,Has_qualifier Arg1:T9 Arg2:T10
17,R6,Subsumes Arg1:T9 Arg2:T11
18,T13,Condition 189 207	hepatic impairment
19,T14,Qualifier 182 188	Severe
20,R7,Has_qualifier Arg1:T13 Arg2:T14
21,T15,Condition 216 237	myocardial infarction
22,T16,Temporal 246 263	the last 3 months
23,R8,Has_temporal Arg1:T15 Arg2:T16
0,T1,Condition 0 16	Organic diseases
1,T2,Qualifier 24 40	digestive system
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 42 82	gastro-oesophageal reflux disease (GERD)
4,T4,Condition 84 89	ulcer
5,T5,Condition 91 111	chronic pancreatitis
6,T6,Condition 113 127	cholelithiasis
7,T7,Condition 129 148	fatty liver disease
8,T8,Condition 150 159	hepatitis
9,T9,Condition 161 179	cirrhosis of liver
10,*,OR T3 T4 T5 T6 T7 T8 T9
11,T10,"Scope 42 179	gastro-oesophageal reflux disease (GERD), ulcer, chronic pancreatitis, cholelithiasis, fatty liver disease, hepatitis, cirrhosis of liver"
12,T11,Scope 0 40	Organic diseases of the digestive system
13,R2,Subsumes Arg1:T11 Arg2:T10
14,T12,Condition 209 228	functional diseases
15,T13,Qualifier 236 252	digestive system
16,R3,Has_qualifier Arg1:T12 Arg2:T13
17,T14,Scope 209 252	functional diseases of the digestive system
18,T15,Condition 262 287	dyskinesia of cystic duct
19,T16,Condition 262 275;291 302	dyskinesia of gallbladder
20,*,OR T16 T15 T17
21,T17,Condition 304 328	irritable bowel syndrome
22,T18,"Scope 262 328	dyskinesia of cystic duct or gallbladder, irritable bowel syndrome"
23,R4,Subsumes Arg1:T14 Arg2:T18
24,T19,Drug 355 377	proton pump inhibitors
25,T20,Drug 379 390	propulsives
26,T21,Drug 392 406	antispasmodics
27,T22,Drug 408 416	antacids
28,T23,Drug 421 441	bismuth preparations
29,T24,Observation 336 351	Discontinuation
30,T25,Temporal 442 481	less than 7 days prior to randomization
31,*,OR T22 T23 T21 T20 T19
32,T26,"Scope 355 441	proton pump inhibitors, propulsives, antispasmodics, antacids, or bismuth preparations"
33,R5,Has_scope Arg1:T24 Arg2:T26
34,R6,Has_temporal Arg1:T24 Arg2:T25
35,T27,Procedure 484 505	H. Pylori eradication
36,T28,Temporal 506 540	within 2 months before study entry
37,R7,Has_temporal Arg1:T27 Arg2:T28
38,T29,Reference_point 529 540	study entry
39,R8,Has_index Arg1:T28 Arg2:T29
40,T30,Reference_point 468 481	randomization
41,R9,Has_index Arg1:T25 Arg2:T30
42,T31,Condition 543 563	Intestinal infection
43,T32,Temporal 564 598	within 2 months before study entry
44,T33,Reference_point 587 598	study entry
45,R10,Has_index Arg1:T32 Arg2:T33
46,R11,Has_temporal Arg1:T31 Arg2:T32
47,T34,Observation 607 617	history of
48,T35,Mood 618 627	suspected
49,*,OR T34 T35
50,T36,Condition 628 646	malignant neoplasm
51,T37,Qualifier 650 663	various sites
52,R12,Has_qualifier Arg1:T36 Arg2:T37
53,T38,Scope 607 627	history of/suspected
54,R13,Has_scope Arg1:T36 Arg2:T38
55,T39,Condition 696 718	cardiovascular disease
56,T40,Measurement 737 763	New York Heart Association
57,T41,Value 687 695	class IV
58,R14,Has_value Arg1:T40 Arg2:T41
59,R15,AND Arg1:T39 Arg2:T40
60,T42,Condition 772 786	hypothyroidism
61,T43,Condition 788 805	diabetes mellitus
62,T44,Condition 807 829	chronic kidney disease
63,T45,Measurement 831 832	С
64,T46,Value 832 835	3-5
65,R16,Has_value Arg1:T45 Arg2:T46
66,R17,AND Arg1:T44 Arg2:T45
67,T47,Condition 841 857	disease of liver
68,T48,Condition 863 882	portal hypertension
69,T49,Condition 890 911	severe decompensation
70,T50,Scope 841 882	disease of liver with portal hypertension
71,T51,Measurement 913 929	Child-Pugh score
72,T52,Value 930 933	> 6
73,R18,Has_value Arg1:T51 Arg2:T52
74,T53,Scope 913 933	Child-Pugh score > 6
75,R19,Has_scope Arg1:T49 Arg2:T53
76,*,OR T50 T49 T42 T43 T44 T39
77,T54,Temporal 950 960	coexisting
78,T55,Condition 961 970	morbidity
79,T56,"Non-query-able 978 1064	in the investigator's opinion, can prevent the patient from participating in the study"
80,R20,Has_temporal Arg1:T55 Arg2:T54
81,R21,AND Arg1:T55 Arg2:T56
82,T57,Condition 1067 1074	Allergy
83,T58,Condition 1075 1086	intolerance
84,T59,Drug 1101 1148	components of medications used in the treatment
85,*,OR T58 T57
86,T60,Scope 1067 1086	Allergy/intolerance
87,R22,AND Arg1:T60 Arg2:T59
88,T61,Condition 1151 1160	Pregnancy
89,T62,Observation 1162 1176	breast-feeding
90,*,OR T61 T62
91,T63,"Non-representable 1179 1351	Patients who, from investigator's point of view, will fail to comply with the observation requirements of the trial or with the dosing regimen of the investigational drugs."
92,T64,Mood 1353 1360	Planned
93,T65,Procedure 1361 1376	hospitalization
94,T66,Temporal 1377 1400	during the study period
95,R23,Has_temporal Arg1:T65 Arg2:T66
96,R24,Has_mood Arg1:T65 Arg2:T64
97,T67,Procedure 1424 1444	treatment procedures
98,T68,Procedure 1410 1420;1434 1444	diagnostic procedures
99,*,OR T67 T68
100,T69,Scope 1410 1444	diagnostic or treatment procedures
101,R25,Has_scope Arg1:T65 Arg2:T69
102,T70,Condition 1447 1461	Drug addiction
103,T71,Measurement 1463 1474	alcohol use
104,T72,Value 1489 1518	over 2 units of alcohol a day
105,R26,Has_value Arg1:T71 Arg2:T72
106,T73,Condition 1520 1535	mental diseases
107,*,OR T70 T71 T73
108,T74,Drug 1548 1557	medicines
109,T75,Qualifier 1558 1614	listed in the section 'Prohibited concomitant treatment'
110,R27,Has_qualifier Arg1:T74 Arg2:T75
111,T76,Temporal 1619 1663	1 month prior to the enrollment in the trial
112,T77,Reference_point 1636 1663	the enrollment in the trial
113,R28,Has_index Arg1:T76 Arg2:T77
114,R29,Has_temporal Arg1:T74 Arg2:T76
115,T78,Competing_trial 1666 1753	Participation in other clinical trials within 3 months to the enrollment in this study.
116,T79,"Non-representable 1755 2070	Patient is related to the research staff of the clinical investigative site who are directly involved in the trial or is the immediate family member of the investigator. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted."
117,T80,"Person 2080 2123	works for OOO ""NPF ""MATERIA MEDICA HOLDING"""
118,T81,Person 2138 2156	company's employee
119,T82,Person 2158 2183	temporary contract worker
120,T83,Person 2187 2205	appointed official
121,*,OR T82 T83 T81
122,T84,Observation 2206 2273	responsible for carrying out the research or their immediate family
123,R30,Has_context Arg1:T83 Arg2:T84
124,T85,"Scope 2138 2273	company's employee, temporary contract worker or appointed official responsible for carrying out the research or their immediate family"
125,R31,Subsumes Arg1:T80 Arg2:T85
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 109 111	2.
2,T3,Parsing_Error 144 146	3.
3,T4,Parsing_Error 522 524	4.
4,T5,Parsing_Error 594 596	5.
5,T6,Parsing_Error 614 616	6.
6,T7,Post-eligibility 3 107	Must have given written informed consent (signed and dated) and any authorizations required by local law
7,T8,Value 112 142	18 to 75 years old (inclusive)
8,T9,Person 121 130	years old
9,T10,Person 147 151	Male
10,T11,Person 155 161	female
11,*,OR T11 T10
12,T12,Condition 182 185	PBC
13,T13,Multiplier 190 202	at least two
14,T14,Parsing_Error 210 228	following criteria
15,T15,Measurement 210 228	following criteria
16,R1,Has_multiplier Arg1:T15 Arg2:T13
17,T16,Measurement 280 331	Positive Anti-Mitochondrial Antibodies (AMA) titers
18,T17,Value 333 338	>1/40
19,T18,Measurement 342 360	immunofluorescence
20,T19,Value 364 375	M2 positive
21,T20,Measurement 379 420	enzyme linked immunosorbent assay (ELISA)
22,T21,Measurement 433 468	PBC-specific antinuclear antibodies
23,T22,Value 424 432	positive
24,R2,Has_value Arg1:T20 Arg2:T19
25,R3,Has_value Arg1:T18 Arg2:T17
26,R4,Has_value Arg1:T21 Arg2:T22
27,T23,Scope 333 468	>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies
28,R5,Subsumes Arg1:T16 Arg2:T23
29,T24,Measurement 242 244	AP
30,T25,Value 245 254	above ULN
31,R6,Has_value Arg1:T24 Arg2:T25
32,T26,Temporal 255 278	for at least six months
33,R7,Has_temporal Arg1:T24 Arg2:T26
34,T27,Procedure 481 493	liver biopsy
35,T28,Condition 517 520	PBC
36,R8,AND Arg1:T27 Arg2:T28
37,T29,Qualifier 530 536;553 557	stable dose
38,T30,Qualifier 541 557	recommended dose
39,T31,Drug 561 565	UDCA
40,T32,Temporal 566 592	for the past twelve months
41,R9,Has_temporal Arg1:T31 Arg2:T32
42,R10,Has_qualifier Arg1:T31 Arg2:T29
43,R11,Has_qualifier Arg1:T31 Arg2:T30
44,T33,Measurement 597 599	AP
45,T34,Value 600 612	≥ 1.67 × ULN
46,R12,Has_value Arg1:T33 Arg2:T34
47,T35,Condition 632 654	reproductive potential
48,T36,Person 621 628	females
49,T37,Multiplier 663 675	at least one
50,T38,Device 676 697	barrier contraceptive
51,R13,Has_multiplier Arg1:T38 Arg2:T37
52,T39,Qualifier 704 710	second
53,T40,Device 721 741	birth control method
54,T41,Qualifier 711 720	effective
55,T42,Subjective_judgement 711 720	effective
56,R14,Has_qualifier Arg1:T40 Arg2:T39
57,R15,Has_qualifier Arg1:T40 Arg2:T41
58,T43,Temporal 742 758	during the study
59,T44,Temporal 763 805	for at least two weeks after the last dose
60,T45,Reference_point 792 805	the last dose
61,R16,Has_index Arg1:T44 Arg2:T45
62,R17,Has_temporal Arg1:T40 Arg2:T43
63,R18,Has_temporal Arg1:T40 Arg2:T44
64,T46,Scope 621 654	females of reproductive potential
65,T47,Scope 663 805	at least one barrier contraceptive and a second effective birth control method during the study and for at least two weeks after the last dose
66,R19,Has_scope Arg1:T46 Arg2:T47
67,A2,Optional T46
68,T48,Person 811 815	male
69,T49,Device 845 858	contraception
70,T50,Device 866 873	condoms
71,R20,Subsumes Arg1:T49 Arg2:T50
72,T51,Qualifier 833 844	appropriate
73,T52,Subjective_judgement 833 844	appropriate
74,R21,Has_qualifier Arg1:T49 Arg2:T51
75,T53,Person 885 891	female
76,T54,Condition 904 926	reproductive potential
77,T55,Condition 941 949	pregnant
78,T56,Negation 930 940	not become
79,R22,Has_negation Arg1:T55 Arg2:T56
80,T57,Temporal 950 966	during the study
81,T58,Temporal 971 1013	for at least two weeks after the last dose
82,T59,Reference_point 1000 1013	the last dose
83,R23,Has_index Arg1:T58 Arg2:T59
84,R24,Has_temporal Arg1:T55 Arg2:T57
85,R25,Has_temporal Arg1:T55 Arg2:T58
86,R26,AND Arg1:T53 Arg2:T54
87,R27,AND Arg1:T53 Arg2:T55
88,T60,"Post-eligibility 807 1013	For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose"
89,T61,"Non-query-able 807 1013	For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose"
0,T1,Condition 0 7	Healthy
1,T2,Condition 8 16	pregnant
2,T3,Person 17 22	women
3,T4,Person 23 26	age
4,T5,Value 27 35	18 to 50
5,R1,Has_value Arg1:T4 Arg2:T5
6,T6,Condition 37 56	Singleton pregnancy
7,T7,Measurement 60 75	gestational age
8,T8,Value 76 92	36 weeks or more
9,R2,Has_value Arg1:T7 Arg2:T8
10,T9,Observation 94 131	Able to read and understand Norwegian
0,T1,Temporal 0 7	Current
1,T2,Measurement 8 14	height
2,T3,Value 15 39	less than 5th percentile
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T2 Arg2:T1
5,T4,Non-representable 40 46	AND/OR
6,T5,Measurement 48 70	Predicted adult height
7,T6,Qualifier 81 89	bone age
8,T7,Value 91 126	more than 10 cm below target height
9,R3,Has_qualifier Arg1:T5 Arg2:T6
10,R4,Has_value Arg1:T5 Arg2:T7
11,T8,Qualifier 128 147	mid parental height
12,R5,Has_qualifier Arg1:T7 Arg2:T8
13,T9,Observation 150 169	Evidence of puberty
14,T10,Measurement 190 215	serum luteinizing hormone
15,T11,Condition 171 185	physical signs
16,T12,Value 216 226	> 0.3 IU/L
17,T13,Measurement 231 243	testosterone
18,T14,Value 244 254	> 15 ng/dl
19,R6,Has_value Arg1:T13 Arg2:T14
20,R7,Has_value Arg1:T10 Arg2:T12
21,T15,Scope 171 254	physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl
22,*,OR T10 T13
23,R8,Has_scope Arg1:T9 Arg2:T15
0,T1,Qualifier 12 18	severe
1,T2,Condition 19 35	systemic disease
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 49 70	coagulation disorders
4,T4,Temporal 72 79	Current
5,T5,Temporal 83 91	previous
6,T6,Observation 92 99	history
7,*,OR T5 T4
8,T7,Scope 72 91	Current or previous
9,R2,Has_scope Arg1:T6 Arg2:T7
10,T8,Condition 103 123	analgesic dependence
11,T9,Drug 103 112	analgesic
12,R3,multi Arg1:T8 Arg2:T9
13,R4,Has_temporal Arg1:T8 Arg2:T6
14,T10,Condition 125 132	Allergy
15,T11,Drug 147 170	drugs used in the study
16,R5,AND Arg1:T10 Arg2:T11
17,T12,Person 172 177	Women
18,T13,Condition 178 186	pregnant
19,T14,Condition 190 199	lactating
20,*,OR T13 T14 T17
21,T15,Person 204 209	women
22,T16,Mood 210 228	planning to become
23,T17,Condition 229 237	pregnant
24,R6,Has_mood Arg1:T17 Arg2:T16
25,T18,Condition 251 263	hearing loss
26,T19,Condition 277 305	cardiovascular comorbidities
27,T20,Condition 388 410	cognitive disabilities
28,T21,Condition 354 374	kidney comorbidities
29,T22,Condition 319 340	hepatic comorbidities
0,T1,Person 0 3	Men
1,T2,Person 8 13	women
2,T3,Person 14 18	aged
3,T4,Value 19 30	18-45 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T5,Condition 46 66	functional dyspepsia
7,T6,Measurement 81 104	Rome IV criteria (2016)
8,R2,AND Arg1:T6 Arg2:T5
9,T7,Measurement 107 116	GIS score
10,T8,Value 120 130	at least 6
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Measurement 142 156	H. pylori test
13,T10,Value 133 141	Negative
14,R4,Has_value Arg1:T9 Arg2:T10
15,T11,Post-eligibility 160 274	Availability of a signed patient information sheet (Informed Consent form) for participation in the clinical trial
16,T12,Pregnancy_considerations 277 370	Patients who agree to use an effective method of contraception throughout the clinical trial.
0,T1,Procedure 0 19	Major spine surgery
1,T2,Person 62 67	years
2,T3,Value 56 61	18-80
3,R1,Has_value Arg1:T2 Arg2:T3
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 182 184	2.
2,T3,Parsing_Error 207 209	3.
3,T4,Parsing_Error 237 239	4.
4,T5,Parsing_Error 263 265	5.
5,T6,Parsing_Error 298 300	6.
6,T7,Parsing_Error 350 352	7.
7,T8,Parsing_Error 395 397	8.
8,T9,Parsing_Error 425 427	9.
9,T10,Parsing_Error 456 459	10.
10,T11,Parsing_Error 502 505	11.
11,T12,Parsing_Error 613 616	12.
12,T13,Parsing_Error 682 685	13.
13,T14,Parsing_Error 728 731	14.
14,T15,Parsing_Error 785 788	15.
15,T16,Condition 5 22	medical condition
16,T17,Condition 35 38	PBC
17,T18,Negation 24 34	other than
18,*,OR T17 T18
19,R1,AND Arg1:T16 Arg2:T17
20,T19,Subjective_judgement 45 74	in the investigator's opinion
21,T20,"Non-query-able 3 180	A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)"
22,T21,"Post-eligibility 3 180	A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)"
23,T22,Measurement 185 188	AST
24,T23,Measurement 192 195	ALT
25,T24,Value 196 205	> 3 × ULN
26,R2,Has_value Arg1:T23 Arg2:T24
27,R3,Has_value Arg1:T22 Arg2:T24
28,*,OR T23 T22
29,T25,Measurement 210 225	Total bilirubin
30,T26,Value 226 235	> 2 × ULN
31,R4,Has_value Arg1:T25 Arg2:T26
32,T27,Condition 240 261	Auto-immune hepatitis
33,T28,Condition 266 296	Primary sclerosing cholangitis
34,T29,Condition 318 348	alpha-1-Antitrypsin deficiency
35,T30,Observation 307 314	history
36,R5,Has_temporal Arg1:T29 Arg2:T30
37,T31,Condition 378 393	viral hepatitis
38,T32,Temporal 370 377	chronic
39,R6,Has_temporal Arg1:T31 Arg2:T32
40,T33,Observation 359 366	history
41,R7,Has_temporal Arg1:T31 Arg2:T33
42,T34,Measurement 398 413	Creatine kinase
43,T35,Value 414 423	above ULN
44,R8,Has_value Arg1:T34 Arg2:T35
45,T36,Measurement 428 444	Serum creatinine
46,T37,Value 445 454	above ULN
47,R9,Has_value Arg1:T36 Arg2:T37
48,T38,Person 464 471	females
49,T39,Condition 473 482	pregnancy
50,T40,Condition 486 500	breast-feeding
51,*,OR T39 T40
52,T41,Scope 473 500	pregnancy or breast-feeding
53,A1,Optional T38
54,R10,Has_scope Arg1:T38 Arg2:T41
55,T42,Drug 513 523	colchicine
56,T43,Drug 525 537	methotrexate
57,T44,Drug 539 551	azathioprine
58,T45,Drug 556 573	systemic steroids
59,T46,Temporal 574 611	in the two months preceding screening
60,T47,Reference_point 602 611	screening
61,R11,Has_index Arg1:T46 Arg2:T47
62,*,OR T42 T43 T44 T45
63,T48,"Scope 513 573	colchicine, methotrexate, azathioprine, or systemic steroids"
64,R12,Has_temporal Arg1:T48 Arg2:T46
65,T49,Drug 632 640	fibrates
66,T50,Temporal 617 624	Current
67,T51,Drug 652 664	fenofibrates
68,T52,Drug 669 680	simvastatin
69,*,OR T52 T51 T49
70,T53,"Scope 632 680	fibrates, including fenofibrates, or simvastatin"
71,R13,Has_temporal Arg1:T53 Arg2:T50
72,T55,Procedure 696 726	experimental treatment for PBC
73,T56,Undefined_semantics 696 726	experimental treatment for PBC
74,T54,Context_Error 696 726	experimental treatment for PBC
75,T57,Drug 766 783	immunosuppressant
76,T58,Qualifier 755 765	unapproved
77,T59,Qualifier 739 751	experimental
78,*,OR T58 T59
79,T60,Scope 739 765	experimental or unapproved
80,R14,Has_scope Arg1:T57 Arg2:T60
81,T61,Undefined_semantics 739 765	experimental or unapproved
82,T62,Context_Error 739 765	experimental or unapproved
83,T63,"Non-query-able 789 938	Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator"
84,T64,"Context_Error 789 938	Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator"
85,T65,"Post-eligibility 789 938	Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator"
86,T66,"Subjective_judgement 789 938	Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator"
0,T1,Measurement 0 8	Bone age
1,T2,Value 17 37	more than 14.0 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 39 67	Follicle stimulating hormone
4,T4,Value 68 77	> 20 IU/L
5,R2,Has_value Arg1:T3 Arg2:T4
0,T1,Condition 14 32	placenta pathology
1,T2,Condition 41 48	praevia
2,T3,Condition 50 56	acreta
3,T4,Condition 58 71	pre-eclampsia
4,*,OR T3 T4 T2
5,T5,"Scope 41 71	praevia, acreta, pre-eclampsia"
6,R1,Subsumes Arg1:T1 Arg2:T5
7,T6,Condition 87 105	bleeding disorders
8,T7,Condition 116 144	vonWillebrand disease type I
9,R2,Subsumes Arg1:T6 Arg2:T7
10,T8,Condition 153 164	intolerance
11,T9,Multiplier 168 182	one of the two
12,T10,Drug 183 188	drugs
13,R3,Has_multiplier Arg1:T10 Arg2:T9
14,R4,AND Arg1:T8 Arg2:T10
15,T11,Condition 205 222	prolonged QT-time
16,T12,Qualifier 226 231	other
17,T13,Condition 232 256	serious cardiac diseases
18,R5,Has_qualifier Arg1:T13 Arg2:T12
19,*,OR T11 T13
20,T14,Condition 259 264;275 282	Liver failure
21,T15,Condition 268 282	kidney failure
22,*,OR T14 T15
23,T16,Condition 285 293	Epilepsy
24,T17,"Post-eligibility 296 390	Any medical reason why, in the opinion of the investigator, the patient should not participate"
0,T1,Mood 0 20	Scheduled to undergo
1,T2,Qualifier 21 30	bilateral
2,T3,Procedure 31 53	palatine tonsillectomy
3,T4,Multiplier 61 75	only procedure
4,R1,Has_multiplier Arg1:T3 Arg2:T4
5,T5,Procedure 66 75	procedure
6,R2,multi Arg1:T4 Arg2:T5
7,R3,Has_qualifier Arg1:T3 Arg2:T2
8,R4,Has_mood Arg1:T3 Arg2:T1
0,T1,Measurement 0 3	ASA
1,T2,Value 4 10	4 or 5
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 12 37	revision hip arthroplasty
4,T4,Condition 52 64	chronic pain
5,T5,Drug 80 86	opioid
6,T6,Qualifier 72 79	chronic
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Temporal 92 105	over 3 months
9,R3,Has_temporal Arg1:T5 Arg2:T7
10,T8,Post-eligibility 133 191	inability to communicate pain scores or need for analgesia
11,T9,Condition 199 211	hip fracture
12,T10,Qualifier 193 198	acute
13,R4,Has_qualifier Arg1:T9 Arg2:T10
14,T11,Condition 213 222	Infection
15,T12,Qualifier 230 253	site of block placement
16,R5,Has_qualifier Arg1:T11 Arg2:T12
17,T13,Person 255 258	Age
18,T14,Value 259 306	under 18 years old or greater than 75 years old
19,R6,Has_value Arg1:T13 Arg2:T14
20,T15,Pregnancy_considerations 308 322	Pregnant women
21,T16,Condition 324 335	Intolerance
22,T17,Condition 336 343	allergy
23,T18,Drug 347 364	local anesthetics
24,*,OR T16 T17
25,T19,Scope 324 343	Intolerance/allergy
26,R7,AND Arg1:T19 Arg2:T18
27,T20,Person 366 372	Weight
28,T21,Value 373 379	<50 kg
29,R8,Has_value Arg1:T20 Arg2:T21
30,T22,Condition 417 422	abuse
31,T23,Condition 401 410	addiction
32,T24,Qualifier 443 464	prescription medicine
33,T25,Qualifier 472 479	alcohol
34,*,OR T23 T22
35,T26,Qualifier 426 438	illicit drug
36,*,OR T26 T24 T25
37,T27,"Scope 426 479	illicit drug(s), prescription medicine(s), or alcohol"
38,T28,Scope 401 422	addiction to or abuse
39,T29,Temporal 491 503	past 2 years
40,R9,Has_temporal Arg1:T28 Arg2:T29
41,R10,Has_scope Arg1:T28 Arg2:T27
42,T30,Condition 519 526	anxiety
43,T31,Condition 528 541	schizophrenia
44,T32,Condition 552 572	psychiatric disorder
45,*,OR T30 T31 T32
46,T33,"Non-query-able 667 872	Current or historical evidence of any clinically significant disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course"
0,T1,Person 0 3	Age
1,T2,Value 4 23	= 19 and = 70 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 38 53	liver cirrhosis
4,T4,Measurement 55 68	Serum albumin
5,T5,Value 75 84	= 3.5g/dl
6,T6,Procedure 86 96	ultrasound
7,T7,Procedure 100 107	CT scan
8,T8,Condition 118 125	ascites
9,T9,Qualifier 128 135	Grade 1
10,R2,Has_qualifier Arg1:T8 Arg2:T9
11,*,OR T7 T6
12,T10,Scope 86 107	ultrasound or CT scan
13,R3,AND Arg1:T10 Arg2:T8
14,R4,Has_value Arg1:T4 Arg2:T5
15,T11,Negation 138 140	No
16,T12,Drug 159 168	diuretics
17,T13,Drug 173 177	BCAA
18,*,OR T12 T13
19,T14,Scope 159 177	diuretics and BCAA
20,R5,Has_negation Arg1:T14 Arg2:T11
21,T15,Temporal 189 200	past 1 week
22,R6,Has_temporal Arg1:T14 Arg2:T15
23,T16,Informed_consent 202 246	Voluntary consent to take part in this trial
0,T1,Person 0 5	Males
1,T2,Person 6 10	aged
2,T3,Value 11 29	18 years and above
3,T4,Condition 60 79	prostatic carcinoma
4,T5,Procedure 90 106	prostate surgery
5,R1,AND Arg1:T4 Arg2:T5
6,R2,Has_value Arg1:T2 Arg2:T3
0,T1,Non-query-able 0 16	English speaking
1,T2,Person 42 45	old
2,T3,Value 18 41	between 18 and 75 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 47 84	American Society of Anesthesiologists
5,T5,Measurement 86 89	ASA
6,T6,Value 91 94	1-3
7,R2,Subsumes Arg1:T4 Arg2:T5
8,R3,Has_value Arg1:T4 Arg2:T6
9,T7,Procedure 115 145	primary total hip arthroplasty
0,T1,Procedure 23 52	ophthalmic surgical procedure
1,T2,Temporal 53 98	within 6 months of the beginning of the study
2,T3,Reference_point 93 98	study
3,R1,Has_temporal Arg1:T1 Arg2:T2
4,R2,Has_index Arg1:T2 Arg2:T3
5,T4,Condition 130 138	glaucoma
6,T5,Condition 144 155	abnormality
7,T6,Qualifier 163 169	cornea
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Condition 226 233	allergy
10,T8,Condition 235 251	hypersensitivity
11,T9,Drug 264 275	Brimonidine
12,*,OR T7 T8
13,T10,Scope 226 251	allergy/ hypersensitivity
14,R4,AND Arg1:T10 Arg2:T9
15,T11,Condition 277 294	Contra-indication
16,T12,Drug 298 309	Brimonidine
17,T13,Drug 332 360	monoamine oxidase inhibitors
18,T14,Drug 362 365	MOA
19,R5,Subsumes Arg1:T13 Arg2:T14
20,R6,AND Arg1:T11 Arg2:T12
21,R7,Subsumes Arg1:T11 Arg2:T13
22,T15,Informed_consent 368 423	Patients unwilling or unable to provide informed consen
23,T16,Observation 452 479	difficult airway management
0,T1,Measurement 0 16	Child-Pugh score
1,T2,Value 17 21	> 12
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 48 51	HCC
4,T4,Temporal 63 75	past 5 years
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Measurement 77 93	Serum creatinine
7,T6,Value 94 104	> 1.5mg/dl
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 106 121	Serum bilirubin
10,T8,Value 122 131	> 5.0mg/d
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Condition 151 164	complications
13,T10,Condition 168 171	SBP
14,T11,Condition 176 198	hepatic encephalopathy
15,T12,Measurement 199 215	West Haven grade
16,T13,Value 216 219	= 3
17,R5,Has_value Arg1:T12 Arg2:T13
18,R6,AND Arg1:T11 Arg2:T12
19,*,OR T10 T11
20,T14,"Scope 168 220	SBP, or hepatic encephalopathy(West Haven grade = 3)"
21,R7,Subsumes Arg1:T9 Arg2:T14
22,T15,Condition 247 260	organ failure
23,T16,Condition 264 301	acute exacerbation of liver cirrhosis
24,T17,Temporal 313 325	past 1 month
25,R8,AND Arg1:T15 Arg2:T16
26,R9,Has_temporal Arg1:T16 Arg2:T17
27,T18,Condition 358 377	respiratory disease
28,T19,Condition 347 354;370 377	cardiac disease
29,*,OR T18 T19
30,T20,Scope 347 377	cardiac or respiratory disease
31,T21,Qualifier 339 346	serious
32,R10,Has_qualifier Arg1:T20 Arg2:T21
33,T22,Condition 379 394	Contraindicated
34,T23,Drug 405 414	diuretics
35,T24,Drug 418 422	BCAA
36,*,OR T23 T24
37,T25,Scope 405 422	diuretics or BCAA
38,R11,Has_scope Arg1:T22 Arg2:T25
39,T26,Procedure 441 461	anti-viral treatment
40,T27,Condition 470 481	hepatitis C
41,T28,Condition 470 479;483 484	hepatitis B
42,*,OR T27 T28
43,T29,"Scope 470 484	hepatitis C, B"
44,T30,Temporal 496 508	past 1 month
45,R12,Has_scope Arg1:T26 Arg2:T29
46,R13,Has_temporal Arg1:T26 Arg2:T30
47,T31,Pregnancy_considerations 510 537	Pregnant or lactating women
48,T32,Qualifier 539 546	Chronic
49,T33,Person 547 560	alcohol taker
50,R14,Has_qualifier Arg1:T33 Arg2:T32
51,T34,Pregnancy_considerations 562 640	Woman patients who do not agree to the contraception from baseline to 12 month
52,T35,Non-query-able 642 684	Unsuitable patients judged by investigator
53,T36,Competing_trial 686 749	Patients participating in another clinical trial within 1 month
0,T1,Procedure 6 29	endobronchial treatment
1,T2,Condition 34 43	emphysema
2,T3,Temporal 0 5	Prior
3,R1,causal Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Condition 45 52;69 76	Pleural disease
6,T5,Condition 56 76	interstitial disease
7,T6,Procedure 92 99	surgery
8,*,OR T4 T5
9,T7,Scope 45 76	Pleural or interstitial disease
10,T8,Negation 82 91	precludes
11,R3,Has_negation Arg1:T6 Arg2:T8
12,T9,Qualifier 82 99	precludes surgery
13,R4,Has_qualifier Arg1:T7 Arg2:T9
14,T10,Procedure 108 123	lung transplant
15,T11,Temporal 102 107	Prior
16,T12,Procedure 125 129	LVRS
17,T13,Procedure 131 148	median sternotomy
18,T14,Procedure 150 160	bullectomy
19,T15,Procedure 164 173	lobectomy
20,*,OR T15 T14 T13 T12 T10
21,T16,"Scope 108 174	lung transplant, LVRS, median sternotomy, bullectomy or lobectomy."
22,R5,Has_temporal Arg1:T16 Arg2:T11
23,T17,Condition 199 213	bronchiectasis
24,T18,Qualifier 176 198	Clinically significant
25,R6,Has_qualifier Arg1:T17 Arg2:T18
26,T19,Procedure 242 249	surgery
27,T20,Condition 215 231	Pulmonary nodule
28,R7,causal Arg1:T19 Arg2:T20
29,T21,Condition 272 294	respiratory infections
30,T22,Multiplier 262 271	recurrent
31,T23,Observation 251 258	History
32,R8,Has_multiplier Arg1:T21 Arg2:T22
33,T24,Multiplier 296 299;316 332	> 3 in the last year
34,T25,Procedure 300 315	hospitalization
35,R9,Has_multiplier Arg1:T25 Arg2:T24
36,R10,Has_temporal Arg1:T21 Arg2:T23
37,T26,Scope 296 332	> 3 hospitalization in the last year
38,R11,Subsumes Arg1:T21 Arg2:T26
39,T27,Qualifier 335 357	Clinically significant
40,T28,Multiplier 359 382	> 4 Tablespoons per day
41,T29,Observation 384 401	sputum production
42,R13,Subsumes Arg1:T27 Arg2:T28
43,R12,Has_qualifier Arg1:T29 Arg2:T27
44,T30,Condition 403 408	Fever
45,T31,Measurement 419 435	white cell count
46,T32,Value 410 418	elevated
47,R14,Has_value Arg1:T31 Arg2:T32
48,T33,Condition 458 474	active infection
49,T34,Mood 446 454	evidence
50,R15,Has_mood Arg1:T33 Arg2:T34
51,*,OR T33 T31 T30
52,T35,Condition 476 487	Dysrhythmia
53,T36,Condition 499 510	pose a risk
54,T37,Temporal 511 526	during exercise
55,T38,Reference_point 518 526	exercise
56,R16,multi Arg1:T37 Arg2:T38
57,T39,Temporal 511 517;530 538	during training
58,T40,Reference_point 530 538	training
59,R17,multi Arg1:T39 Arg2:T40
60,*,OR T39 T37
61,T41,Scope 511 538	during exercise or training
62,R18,Has_scope Arg1:T36 Arg2:T41
63,R19,AND Arg1:T35 Arg2:T36
64,T42,Condition 540 564	Congestive heart failure
65,T43,Temporal 565 576	within 6 mo
66,T44,Measurement 581 585	LVEF
67,T45,Value 586 591	< 45%
68,R20,Has_value Arg1:T44 Arg2:T45
69,R21,Has_temporal Arg1:T42 Arg2:T43
70,T46,Condition 616 629	Cor Pulmonale
71,T47,Mood 593 601	Evidence
72,T48,Observation 605 612	history
73,*,OR T48 T47
74,T49,Scope 593 612	Evidence or history
75,R22,Has_scope Arg1:T46 Arg2:T49
76,T50,Condition 631 650	Resting bradycardia
77,T51,Value 652 666	< 50 beats/min
78,R23,Has_value Arg1:T50 Arg2:T51
79,T52,Condition 678 693	multifocal PVCs
80,T53,Multiplier 669 677	frequent
81,R24,Has_multiplier Arg1:T52 Arg2:T53
82,T54,Condition 695 725	complex ventricular arrhythmia
83,T55,Condition 727 740	sustained SVT
84,*,OR T50 T52 T54 T55
85,T56,Condition 770 777	syncope
86,T57,Qualifier 753 769	exercise-related
87,R25,Has_qualifier Arg1:T56 Arg2:T57
88,T58,Observation 742 749	History
89,R26,Has_temporal Arg1:T56 Arg2:T58
90,T59,Condition 779 781	MI
91,T60,Temporal 782 793	within 6 mo
92,T61,Measurement 798 802	LVEF
93,T62,Value 803 808	< 45%
94,R27,Has_temporal Arg1:T59 Arg2:T60
95,R28,Has_value Arg1:T61 Arg2:T62
96,T67,Condition 1136 1166	Alpha-1-Antitrypsin Deficiency
97,T63,Condition 822 838	systemic disease
98,T68,Condition 842 851	neoplasia
99,*,OR T63 T68
100,T69,Qualifier 852 883	expected to compromise survival
101,T70,Scope 822 851	systemic disease or neoplasia
102,R29,Has_qualifier Arg1:T70 Arg2:T69
103,T71,Temporal 884 902	during 5-yr period
104,R30,Has_temporal Arg1:T69 Arg2:T71
105,T65,Observation 1019 1053	enrolled in another clinical trial
106,T66,Observation 1066 1084	unable to complete
107,T72,Qualifier 1085 1134	3 minutes of unloaded peddling on cycle ergometer
108,R31,Has_qualifier Arg1:T66 Arg2:T72
109,T64,Condition 908 915	disease
110,T73,Condition 919 928	condition
111,*,OR T64 T73
112,T74,Qualifier 934 996	interferes with completion of initial or follow-up assessments
113,T75,Scope 908 928	disease or condition
114,R32,Has_qualifier Arg1:T75 Arg2:T74
115,T76,Temporal 1009 1018	currently
116,R33,Has_temporal Arg1:T65 Arg2:T76
0,T1,Condition 0 37	chronic obstructive pulmonary disease
1,T2,Condition 39 43	COPD
2,T3,Measurement 46 56	GOLD grade
3,T4,Value 57 60	2-3
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Subsumes Arg1:T1 Arg2:T2
6,R3,AND Arg1:T1 Arg2:T3
7,T5,Non-query-able 62 96	residents at low altitude (<800 m)
0,T1,Condition 13 32	sickle cell disease
1,T2,Mood 0 9	Diagnosis
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Qualifier 34 56	Clinically significant
4,T4,Condition 34 64	Clinically significant disease
5,R2,multi Arg1:T4 Arg2:T3
6,T5,Multiplier 103 146;76 86	per year averaged over the previous 3 years at least 1
7,T6,Condition 87 102	painful episode
8,T7,Temporal 126 146	the previous 3 years
9,T8,Qualifier 112 146	averaged over the previous 3 years
10,R3,multi Arg1:T8 Arg2:T7
11,R4,multi Arg1:T5 Arg2:T8
12,T9,Observation 152 159	history
13,T10,Condition 163 171	priapism
14,T11,Condition 173 179	stroke
15,T12,Condition 181 201	acute chest syndrome
16,T13,Condition 203 221	avascular necrosis
17,T14,Condition 223 242	multi-organ failure
18,T15,Mood 250 258	need for
19,T16,Multiplier 259 266	chronic
20,T17,Qualifier 259 266	chronic
21,R5,multi Arg1:T17 Arg2:T16
22,T18,Drug 267 287	narcotic medications
23,T19,Condition 292 296	pain
24,T20,Condition 302 321	sickle cell disease
25,R6,causal Arg1:T19 Arg2:T20
26,R7,causal Arg1:T18 Arg2:T19
27,R8,Has_qualifier Arg1:T18 Arg2:T17
28,*,OR T18 T14 T13 T12 T11 T10 T6
29,R9,Has_temporal Arg1:T10 Arg2:T9
30,R10,Has_multiplier Arg1:T6 Arg2:T5
31,T21,"Scope 76 321	at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease"
32,R11,Subsumes Arg1:T4 Arg2:T21
33,T22,"Non-representable 323 704	Must have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea"
34,T23,Value 706 714;722 730	18 years or older
35,T24,Person 718 721	age
36,R12,Has_value Arg1:T24 Arg2:T23
37,T25,Non-representable 732 789	Hematologic laboratory values as outlined in the protocol
38,T26,Context_Error 732 789	Hematologic laboratory values as outlined in the protocol
39,T27,Context_Error 791 852	Non-hematologic laboratory values as outlined in the protocol
40,T28,Non-representable 791 852	Non-hematologic laboratory values as outlined in the protocol
41,T29,Procedure 872 884	donate blood
42,T30,Negation 865 868	not
43,T31,Mood 854 864;869 871	Must agree to
44,R13,Has_negation Arg1:T31 Arg2:T30
45,R14,Has_mood Arg1:T29 Arg2:T31
46,T32,Procedure 872 878;894 906	donate bodily fluid
47,R15,Has_mood Arg1:T32 Arg2:T31
48,T33,Temporal 907 934	while taking the study drug
49,T34,Reference_point 913 934	taking the study drug
50,T35,Drug 924 934	study drug
51,R16,multi Arg1:T34 Arg2:T35
52,R17,multi Arg1:T33 Arg2:T34
53,T36,Temporal 939 961	for 28 days thereafter
54,T37,Scope 907 961	while taking the study drug and for 28 days thereafter
55,T38,Scope 872 906	donate blood or other bodily fluid
56,R18,Subsumes Arg1:T38 Arg2:T37
57,T39,Condition 972 995	child-bearing potential
58,T40,Person 963 968	Women
59,T41,Scope 963 995	Women of child-bearing potential
60,T42,Person 997 1001	WCBP
61,R19,Subsumes Arg1:T41 Arg2:T42
62,T43,Measurement 1024 1044	serum pregnancy test
63,T44,Value 1015 1023	negative
64,T45,Temporal 1045 1089	72 hours or less prior to starting treatment
65,T46,Reference_point 1071 1089	starting treatment
66,T47,Procedure 1080 1089	treatment
67,R20,multi Arg1:T46 Arg2:T47
68,R21,multi Arg1:T45 Arg2:T46
69,R22,Has_temporal Arg1:T43 Arg2:T45
70,R23,Has_value Arg1:T43 Arg2:T44
71,T48,Scope 963 1002	Women of child-bearing potential (WCBP)
72,A1,Optional T48
73,R24,AND Arg1:T48 Arg2:T43
74,T49,Pregnancy_considerations 963 1089	Women of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment
75,T50,Condition 1100 1123	child-bearing potential
76,T51,Person 1091 1096	Women
77,T52,Person 1128 1131	men
78,T53,Mood 1132 1145	must agree to
79,T54,Multiplier 1150 1157	2 forms
80,T55,Procedure 1170 1183	contraception
81,T56,Qualifier 1161 1169	adequate
82,R25,Has_qualifier Arg1:T55 Arg2:T56
83,R26,Has_multiplier Arg1:T55 Arg2:T54
84,R27,Has_mood Arg1:T55 Arg2:T53
85,*,OR T51 T52
86,R28,AND Arg1:T51 Arg2:T50
87,T57,Scope 1091 1131	Women of child-bearing potential and men
88,A2,Optional T57
89,R29,AND Arg1:T57 Arg2:T55
90,T58,Temporal 1184 1204	prior to study entry
91,T59,Temporal 1209 1248	for the duration of study participation
92,T60,Reference_point 1229 1248	study participation
93,R30,multi Arg1:T59 Arg2:T60
94,T61,Reference_point 1193 1204	study entry
95,R31,multi Arg1:T58 Arg2:T61
96,R32,Has_temporal Arg1:T55 Arg2:T58
97,R33,Has_temporal Arg1:T55 Arg2:T59
0,T1,Non-query-able 0 2	NA
0,T1,Qualifier 0 8	unstable
1,T2,Condition 9 18	condition
2,T3,Condition 20 37	COPD exacerbation
3,R1,Has_qualifier Arg1:T2 Arg2:T1
4,*,OR T2 T3
5,T4,Condition 68 72	COPD
6,T5,Qualifier 39 43	mild
7,T6,Measurement 45 49	GOLD
8,T7,Value 50 52	1)
9,T8,Measurement 74 78	GOLD
10,T9,Value 79 80	4
11,T10,Qualifier 56 67	very severe
12,T11,Condition 68 72	COPD
13,R2,Has_qualifier Arg1:T11 Arg2:T5
14,R3,Has_value Arg1:T6 Arg2:T7
15,R4,AND Arg1:T11 Arg2:T6
16,R5,Has_qualifier Arg1:T4 Arg2:T10
17,R6,AND Arg1:T4 Arg2:T8
18,R7,Has_value Arg1:T8 Arg2:T9
19,*,OR T11 T4
20,T12,Procedure 99 113	oxygen therapy
21,T13,Condition 141 156	hypoventilation
22,T14,Condition 158 180	pulmonary hypertension
23,T15,Condition 209 231	cardiovascular disease
24,T16,Qualifier 200 208	unstable
25,T17,Qualifier 182 196	more than mild
26,T18,Scope 182 208	more than mild or unstable
27,*,OR T17 T16
28,R8,Has_scope Arg1:T15 Arg2:T18
29,T19,Non-query-able 233 282	use of drugs that affect respiratory center drive
30,T20,Condition 308 327	psychiatric disease
31,T21,Condition 294 304;320 327	neurologic disease
32,T22,Condition 284 292;320 327	internal disease
33,*,OR T20 T22 T21
34,T23,Observation 392 399	smoking
35,T24,Qualifier 386 391	heavy
36,R9,Has_qualifier Arg1:T23 Arg2:T24
37,T25,Multiplier 401 423	>20 cigarettes per day
38,R10,Has_multiplier Arg1:T23 Arg2:T25
39,T26,Negation 426 435	inability
40,T27,Procedure 447 462	6 min walk test
41,R11,Has_negation Arg1:T27 Arg2:T26
42,T28,Condition 474 485	intolerance
43,T29,Observation 498 506	altitude
44,T30,Qualifier 489 497	moderate
45,T31,Value 508 514	<2600m
46,R12,Has_qualifier Arg1:T29 Arg2:T30
47,R13,Has_value Arg1:T29 Arg2:T31
48,R14,Has_context Arg1:T28 Arg2:T29
49,T32,Non-query-able 518 600	exposure to altitudes >1500m for >2 days within the last 4 weeks before the study.
50,T33,Pregnancy_considerations 602 630	pregnant or nursing patients
0,T1,Procedure 21 34	HRCT Core Lab
1,T2,Condition 49 83	heterogeneous disease distribution
2,T3,Multiplier 88 100	at least one
3,T4,Condition 101 125	complete oblique fissure
4,R1,Has_multiplier Arg1:T4 Arg2:T3
5,T5,Person 128 131	Age
6,T6,Value 132 151	from 40 to 75 years
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Measurement 153 156	BMI
9,T8,Value 157 167	< 32 kg/m2
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Measurement 169 173	FEV1
12,T10,Value 174 198	< 40% of predicted value
13,T11,Measurement 200 208	FEV1/FVC
14,T12,Value 209 214	< 70%
15,R4,Has_value Arg1:T9 Arg2:T10
16,R5,Has_value Arg1:T11 Arg2:T12
17,T13,Measurement 216 219	TLC
18,T14,Value 220 236	> 120% predicted
19,T15,Measurement 238 240	RV
20,T16,Value 241 257	> 150% predicted
21,R6,Has_value Arg1:T15 Arg2:T16
22,R7,Has_value Arg1:T13 Arg2:T14
23,T17,Multiplier 272 279;307 309	< 20 mg qd
24,T18,Drug 280 290	prednisone
25,R8,Has_multiplier Arg1:T18 Arg2:T17
26,T19,Measurement 311 316	PaCO2
27,T20,Value 317 326	< 50mm Hg
28,R9,Has_value Arg1:T19 Arg2:T20
29,T21,Measurement 328 332	PaO2
30,T22,Value 333 343	> 45 mm Hg
31,T23,Qualifier 344 355	on room air
32,R10,Has_qualifier Arg1:T22 Arg2:T23
33,R11,Has_value Arg1:T21 Arg2:T22
34,T24,Measurement 357 367	6-min walk
35,T25,Value 371 376	> 50m
36,T26,Value 405 411	> 100m
37,T27,Negation 378 385	without
38,T28,Qualifier 386 400	rehabilitation
39,T29,Qualifier 418 432	rehabilitation
40,R12,Has_qualifier Arg1:T26 Arg2:T29
41,R13,Has_negation Arg1:T28 Arg2:T27
42,R14,Has_qualifier Arg1:T25 Arg2:T28
43,T30,Scope 371 433	> 50m (without rehabilitation) or > 100m (with rehabilitation)
44,*,OR T26 T25
45,R15,Has_scope Arg1:T24 Arg2:T30
46,T31,Condition 435 445	Nonsmoking
47,T32,Temporal 446 485	for 4 months prior to initial interview
48,T33,Reference_point 468 485	initial interview
49,T34,Temporal 490 510	throughout screening
50,T35,Reference_point 501 510	screening
51,R16,Has_index Arg1:T34 Arg2:T35
52,R17,Has_temporal Arg1:T31 Arg2:T32
53,R18,Has_temporal Arg1:T31 Arg2:T34
54,T37,Condition 597 620	child bearing potential
55,T38,Negation 594 596	no
56,T39,Observation 637 674	willing and able to complete protocol
57,R19,Has_negation Arg1:T37 Arg2:T38
58,T36,Observation 524 575	agrees to all protocol required follow-up intervals
59,T40,Visit 556 575	follow-up intervals
60,R20,multi Arg1:T36 Arg2:T40
61,T41,Procedure 684 704	baseline assessments
62,T42,Procedure 684 692;709 719	baseline procedures
63,T43,Scope 684 719	baseline assessments and procedures
64,R21,Has_scope Arg1:T39 Arg2:T43
65,T44,Condition 260 266	Stable
66,R22,AND Arg1:T1 Arg2:T2
67,R23,AND Arg1:T1 Arg2:T4
0,T1,Condition 14 27	hemoglobin SC
1,T2,Condition 31 46	SB+ thalassemia
2,*,OR T1 T2
3,T3,Procedure 68 87	transfusion program
4,T4,Qualifier 60 67	chronic
5,T5,Multiplier 60 67	chronic
6,R1,Has_qualifier Arg1:T3 Arg2:T4
7,R2,multi Arg1:T4 Arg2:T5
8,T6,Procedure 116 132	RBC transfusions
9,T7,Negation 133 144	cannot have
10,T8,Value 145 166	>15% adult hemoglobin
11,R3,Has_value Arg1:T6 Arg2:T8
12,R4,Has_negation Arg1:T6 Arg2:T7
13,T9,Condition 194 197	HIV
14,T10,Condition 206 217	hepatitis B
15,T11,Condition 221 232	hepatitis C
16,T12,Temporal 199 205	active
17,R5,Has_temporal Arg1:T10 Arg2:T12
18,R6,Has_temporal Arg1:T11 Arg2:T12
19,*,OR T9 T10 T11
20,T13,Condition 234 242	Pregnant
21,T14,Observation 246 260	breast feeding
22,T15,Person 261 266	women
23,*,OR T14 T13
24,T16,Condition 298 308	malignancy
25,T17,Observation 287 294	history
26,R7,Has_temporal Arg1:T16 Arg2:T17
27,T18,Condition 436 448	disease-free
28,T19,Temporal 449 469	for at least 5 years
29,T20,Mood 514 522	low risk
30,T21,Condition 527 556	recurrence of that malignancy
31,T22,Condition 541 556	that malignancy
32,R8,multi Arg1:T21 Arg2:T22
33,R9,Has_mood Arg1:T21 Arg2:T20
34,T23,Subjective_judgement 478 504	deemed by the investigator
35,T24,Condition 682 703	breast cancer in situ
36,T25,Condition 670 678;689 703	cervical cancer in situ
37,T26,Temporal 645 668	within the past 5 years
38,T27,Condition 723 758	squamous cell carcinoma of the skin
39,T28,Condition 709 719;737 758	basal cell carcinoma of the skin
40,*,OR T28 T27 T25 T24
41,T29,Grammar_Error 596 608	are eligible
42,T30,Negation 596 608	are eligible
43,T31,Mood 612 621	diagnosed
44,T32,Mood 626 644	adequately treated
45,T33,Procedure 637 644	treated
46,T34,Qualifier 626 636	adequately
47,R10,Has_qualifier Arg1:T33 Arg2:T34
48,R11,Has_temporal Arg1:T33 Arg2:T26
49,T35,Condition 787 797	thrombosis
50,T36,Condition 826 845	sickle cell disease
51,T37,Condition 860 875	thrombotic risk
52,T38,Mood 851 859;871 875	enhanced risk
53,R12,Has_mood Arg1:T37 Arg2:T38
54,T39,Observation 776 783	history
55,R13,Has_temporal Arg1:T35 Arg2:T39
56,T40,Negation 815 825	other than
57,R14,Has_negation Arg1:T36 Arg2:T40
58,*,OR T35 T37
59,T41,Condition 860 870	thrombotic
60,R15,multi Arg1:T37 Arg2:T41
61,R16,AND Arg1:T35 Arg2:T36
62,T42,Condition 902 912	infections
63,T43,Qualifier 891 901	unresolved
64,R17,Has_qualifier Arg1:T42 Arg2:T43
65,T44,Condition 937 955	medical conditions
66,T45,Qualifier 967 997	compromise study participation
67,T46,Post-eligibility 914 997	Severe or uncontrolled medical conditions that could compromise study participation
68,T47,Drug 1011 1043	fetal hemoglobin inducing agents
69,T48,Qualifier 1011 1016	fetal
70,R18,multi Arg1:T47 Arg2:T48
71,T49,Post-eligibility 1045 1200	Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy
72,T50,Context_Error 1045 1200	Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy
73,T51,Condition 1208 1225	allergic reaction
74,T52,Drug 1231 1260	histone deacetylase inhibitor
75,R19,causal Arg1:T51 Arg2:T52
76,T53,Drug 1289 1302	valproic acid
77,T54,Procedure 1307 1316	treatment
78,T55,Condition 1320 1328	epilepsy
79,R20,causal Arg1:T54 Arg2:T55
80,T56,Temporal 1329 1357	within 30 days of enrollment
81,T57,Reference_point 1347 1357	enrollment
82,R21,Has_index Arg1:T56 Arg2:T57
83,R22,Has_temporal Arg1:T55 Arg2:T56
84,R23,causal Arg1:T53 Arg2:T55
85,T58,Drug 1390 1405	HDAC inhibitors
86,T59,Negation 1406 1416	other than
87,T60,Drug 1417 1430	valproic acid
88,R24,Has_negation Arg1:T60 Arg2:T59
89,R25,AND Arg1:T58 Arg2:T60
0,T1,Procedure 14 31	SOF/VEL treatment
1,T2,Qualifier 53 60	chronic
2,T3,Measurement 61 73	HCV genotype
3,T4,Value 74 85	1 through 6
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T3 Arg2:T2
6,R3,AND Arg1:T1 Arg2:T3
7,T5,Temporal 99 134	at least 18 at the day of screening
8,T6,Reference_point 125 134	screening
9,R4,Has_index Arg1:T5 Arg2:T6
10,T7,Post-eligibility 137 198	Patient is able and willing to sign the Informed Consent Form
11,T8,Post-eligibility 201 260	Patient is able and willing to follow protocol requirements
0,T1,Procedure 8 15	surgery
1,T2,Procedure 22 41	regional anesthesia
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Mood 0 7	Planned
4,R2,Has_mood Arg1:T1 Arg2:T3
5,T4,Condition 43 59	contraindication
6,T5,Drug 67 77	study drug
7,R3,AND Arg1:T4 Arg2:T5
8,T6,Condition 79 95	contraindication
9,T7,Procedure 103 118	lumbar puncture
10,R4,AND Arg1:T6 Arg2:T7
11,T8,Condition 120 136	Contraindication
12,T9,Drug 140 149	oxycodone
13,R5,AND Arg1:T8 Arg2:T9
14,T10,Condition 151 160	Pregnancy
15,T11,Condition 164 173	lactation
16,*,OR T11 T10
17,T12,Non-query-able 175 194	no informed consent
0,T1,Procedure 8 43	gynecological lower abdomen surgery
1,T2,Mood 0 7	Planned
2,T3,Procedure 49 72	epidural pain treatment
3,R1,AND Arg1:T1 Arg2:T3
4,R2,Has_mood Arg1:T1 Arg2:T2
5,T4,Non-query-able 74 99	Informed consent obtained
0,T1,Measurement 3 18	Fasting glucose
1,T2,Value 19 24	> 7.0
2,T3,Drug 33 52	diabetes medication
3,T4,Condition 33 41	diabetes
4,T5,Undefined_semantics 33 52	diabetes medication
5,R1,Has_value Arg1:T1 Arg2:T2
6,*,OR T3 T1
7,T6,Person 58 62	Male
8,T7,Person 64 75	35-80 years
9,T8,Value 64 75	35-80 years
10,R2,Has_value Arg1:T7 Arg2:T8
11,T9,Person 77 83	female
12,T10,Condition 85 99	postmenopausal
13,T11,Person 100 111	to 80 years
14,T12,Value 100 111	to 80 years
15,A1,Optional T6
16,T13,"Scope 77 99	female, postmenopausal"
17,A2,Optional T13
18,R3,Has_value Arg1:T13 Arg2:T12
19,R4,Has_value Arg1:T6 Arg2:T8
20,*,OR T6 T13
21,T14,Post-eligibility 117 151	Agree to participant in the trial.
22,T15,Non-query-able 117 151	Agree to participant in the trial.
0,T1,Post-eligibility 3 37	Deny to sign the informed consent;
1,T2,Non-query-able 3 37	Deny to sign the informed consent;
2,T3,Condition 42 57	type 1 diabetes
3,T4,Condition 81 101	hypertriglyceridemia
4,T5,Measurement 105 125	fasting triglyceride
5,T6,Value 125 137	>4.56 mmol/L
6,R1,Has_value Arg1:T5 Arg2:T6
7,T7,Observation 63 77	Family history
8,*,OR T5 T4
9,T8,Scope 81 137	hypertriglyceridemia or fasting triglyceride>4.56 mmol/L
10,R2,Has_context Arg1:T8 Arg2:T7
11,T9,Qualifier 148 154	severe
12,T10,Condition 155 168	liver disease
13,T11,Condition 170 184	kidney disease
14,T12,Condition 188 194	cancer
15,*,OR T12 T11 T10
16,R3,Has_qualifier Arg1:T10 Arg2:T9
17,T13,Context_Error 200 257	Participating in the other clinical trial within 30 days;
18,T14,Condition 262 276	Other diseases
19,T15,Condition 262 267;280 290	Other conditions
20,*,OR T15 T14
21,T16,Undefined_semantics 262 290	Other diseases or conditions
22,T17,Subjective_judgement 292 367	for which the doctor of the patients do not agree his or her participating.
23,T18,Qualifier 292 366	for which the doctor of the patients do not agree his or her participating
24,T19,Scope 262 290	Other diseases or conditions
25,R4,Has_qualifier Arg1:T19 Arg2:T18
26,T20,"Non-query-able 262 367	Other diseases or conditions, for which the doctor of the patients do not agree his or her participating."
0,T1,Procedure 18 26	suturing
1,T2,Condition 31 41	laceration
2,T3,Procedure 48 69	procedural anesthesia
3,T4,Drug 76 84	ketamine
4,R1,AND Arg1:T3 Arg2:T4
5,R2,AND Arg1:T1 Arg2:T3
6,R3,AND Arg1:T1 Arg2:T2
0,T1,Person 0 3	Age
1,T2,Value 4 21	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 38 50	asymptomatic
4,T4,Condition 51 74	coronary artery disease
5,T5,Qualifier 23 34	Symptomatic
6,*,OR T3 T5
7,T6,Scope 23 50	Symptomatic or asymptomatic
8,R2,Has_scope Arg1:T4 Arg2:T6
9,T7,Measurement 85 88	MLA
10,T8,Measurement 89 109	minimal luminal area
11,R3,Subsumes Arg1:T7 Arg2:T8
12,T9,Value 110 115	<4mm2
13,R4,Has_value Arg1:T7 Arg2:T9
14,T10,Measurement 117 130	plaque burden
15,T11,Value 130 134	>70%
16,T12,Condition 136 153	Lipid-rich plaque
17,T13,Procedure 157 161	NIRS
18,T14,Procedure 162 202	Intracoronary Near-Infrared Spectroscopy
19,R5,Subsumes Arg1:T13 Arg2:T14
20,R6,AND Arg1:T13 Arg2:T12
21,T15,Measurement 216 226	maxLCBI4mm
22,T16,Value 226 230	>315
23,R7,Has_value Arg1:T15 Arg2:T16
24,R8,Subsumes Arg1:T12 Arg2:T15
25,T17,Multiplier 233 234	2
26,T18,Condition 235 260	target vulnerable lesions
27,R9,Has_multiplier Arg1:T18 Arg2:T17
28,T19,Mood 262 274	Eligible for
29,T20,Procedure 275 309	percutaneous coronary intervention
30,T21,Device 315 353	Absorb Bioresorbable Vascular Scaffold
31,T22,Device 357 381	Everolimus Eluting Stent
32,*,OR T21 T22
33,T23,Scope 315 381	Absorb Bioresorbable Vascular Scaffold or Everolimus Eluting Stent
34,R10,Has_mood Arg1:T20 Arg2:T19
35,R11,Has_scope Arg1:T20 Arg2:T23
36,T24,Post-eligibility 383 435	Willing and able to provide informed written consent
37,T25,Measurement 437 462	Reference vessel diameter
38,T26,Value 463 471	2.75-4.0
39,R12,Has_value Arg1:T25 Arg2:T26
40,T27,Measurement 473 486	Lesion length
41,T28,Value 487 491	= 40
42,R13,Has_value Arg1:T27 Arg2:T28
0,T1,Person 0 5	males
1,T2,Person 10 17	females
2,T3,Person 55 58	age
3,T4,Value 18 51	greater than or equal to 18 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T5,Person 76 80	user
7,T6,Qualifier 68 75	regular
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Qualifier 84 96	e-cigarettes
10,R3,Has_qualifier Arg1:T5 Arg2:T7
11,T8,Multiplier 102 121	at least once daily
12,R4,Has_multiplier Arg1:T7 Arg2:T8
13,T9,Temporal 122 142	for the past 30 days
14,R5,Has_temporal Arg1:T7 Arg2:T9
15,T10,Measurement 149 166	nicotine strength
16,T11,Value 167 175	> 6mg/ml
17,R6,Has_value Arg1:T10 Arg2:T11
18,R7,AND Arg1:T5 Arg2:T10
19,T12,Observation 184 199	medical history
20,T13,Qualifier 177 183	health
21,R8,Has_qualifier Arg1:T12 Arg2:T13
22,T14,Condition 201 210	abstinent
23,T15,Drug 220 227	tobacco
24,T16,Drug 228 236	nicotine
25,*,OR T15 T16
26,T17,Scope 220 236	tobacco/nicotine
27,R9,Has_scope Arg1:T14 Arg2:T17
28,T18,Temporal 241 269	for 4 hours prior to imaging
29,T19,Reference_point 262 269	imaging
30,R10,Has_index Arg1:T18 Arg2:T19
31,R11,Has_temporal Arg1:T14 Arg2:T18
0,T1,Qualifier 19 25	severe
1,T2,Condition 26 35	allergies
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 37 43	trauma
4,T4,Observation 44 51	history
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Procedure 59 68	operation
7,T6,Observation 69 76	history
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Temporal 77 92	within 3 months
10,*,OR T3 T5 T2
11,T8,"Scope 19 76	severe allergies, trauma history and/or operation history"
12,R4,Has_temporal Arg1:T8 Arg2:T7
13,T9,Condition 113 127	mental illness
14,T10,Observation 102 109	history
15,R5,Has_temporal Arg1:T9 Arg2:T10
16,T11,Observation 135 149	family history
17,T12,Condition 153 167	mental illness
18,R6,Has_context Arg1:T12 Arg2:T11
19,*,OR T9 T12
20,T13,Qualifier 168 181	limb disabled
21,R7,Has_qualifier Arg1:T12 Arg2:T13
22,R8,Has_qualifier Arg1:T9 Arg2:T13
23,T14,Drug 191 199	medicine
24,T15,Qualifier 200 216	within one month
25,R9,Has_qualifier Arg1:T14 Arg2:T15
26,T16,Condition 229 241	major events
27,T17,Condition 252 263	mood swings
28,*,OR T16 T17
29,T18,Condition 286 302	surgical disease
30,T19,Procedure 286 294	surgical
31,R10,multi Arg1:T18 Arg2:T19
32,T20,Condition 273 281;295 302	internal disease
33,T21,Procedure 327 347	physical examination
34,T22,Procedure 356 373	electrocardiogram
35,T23,Procedure 374 381;392 400	hepatic function
36,T24,Procedure 386 400	renal function
37,T25,Procedure 401 414	blood routine
38,T26,Procedure 419 432	urine routine
39,T27,Temporal 303 432	after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine
40,T28,Reference_point 309 432	having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine
41,T29,Scope 327 432	physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine
42,R11,multi Arg1:T28 Arg2:T29
43,R12,Has_index Arg1:T27 Arg2:T28
44,*,OR T18 T20
45,T30,Scope 273 302	internal and surgical disease
46,R13,Has_temporal Arg1:T30 Arg2:T27
47,T31,Condition 435 457	chromosome aberrations
48,T32,Observation 461 481	anyone of the couple
49,R14,Has_context Arg1:T31 Arg2:T32
50,T33,Qualifier 461 481	anyone of the couple
51,R15,multi Arg1:T32 Arg2:T33
52,T34,Drug 502 507	drugs
53,T35,Condition 508 525	contraindications
54,R16,AND Arg1:T35 Arg2:T34
0,T1,Device 83 90	Stented
1,T2,Condition 91 97	lesion
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Procedure 44 48	CABG
4,T4,Procedure 49 80	Coronary artery bypass grafting
5,R2,Subsumes Arg1:T3 Arg2:T4
6,T5,Device 99 111	Bypass graft
7,T6,Condition 112 118	lesion
8,R3,AND Arg1:T6 Arg2:T5
9,T7,Multiplier 142 165	more than or equal to 3
10,T8,Condition 166 180	target lesions
11,R4,Has_multiplier Arg1:T8 Arg2:T7
12,T9,Multiplier 182 183	2
13,T10,Condition 184 198	target lesions
14,T11,Qualifier 199 229	in the same coronary territory
15,R5,Has_qualifier Arg1:T10 Arg2:T11
16,R6,Has_multiplier Arg1:T10 Arg2:T9
17,T12,Qualifier 231 248	Heavily calcified
18,T13,Qualifier 252 261	angulated
19,T14,Condition 262 268	lesion
20,*,OR T13 T12
21,T15,Scope 231 261	Heavily calcified or angulated
22,R7,Has_scope Arg1:T14 Arg2:T15
23,T16,Condition 270 288	Bifurcation lesion
24,T17,Multiplier 299 300	2
25,T18,Procedure 301 319	stenting technique
26,R8,Has_multiplier Arg1:T18 Arg2:T17
27,R9,AND Arg1:T16 Arg2:T18
28,T19,Condition 321 337	Contraindication
29,T20,Mood 344 367	planned discontinuation
30,T21,Procedure 371 396	dual antiplatelet therapy
31,T22,Temporal 397 410	within 1 year
32,*,OR T20 T19
33,T23,Scope 321 367	Contraindication to or planned discontinuation
34,R10,Has_scope Arg1:T21 Arg2:T23
35,R11,Has_temporal Arg1:T21 Arg2:T22
36,T24,Observation 412 427	Life expectancy
37,T25,Value 428 445	less than 2 years
38,R12,Has_value Arg1:T24 Arg2:T25
39,T26,Procedure 455 470	cardiac surgery
40,T27,Mood 474 481	planned
41,T28,Mood 447 454	Planned
42,T29,Qualifier 482 487	major
43,T30,Procedure 488 507	non cardiac surgery
44,R13,Has_mood Arg1:T26 Arg2:T28
45,R14,Has_qualifier Arg1:T30 Arg2:T29
46,R15,Has_mood Arg1:T30 Arg2:T27
47,*,OR T30 T26
48,T31,Person 509 514	Woman
49,T32,Observation 523 536	breastfeeding
50,T33,Condition 538 546	pregnant
51,T34,Mood 550 568	planning to become
52,T35,Condition 569 577	pregnant
53,R16,Has_mood Arg1:T35 Arg2:T34
54,*,OR T32 T33 T35
55,T36,Temporal 578 608	during the course of the study
56,T37,"Scope 523 577	breastfeeding, pregnant or planning to become pregnant"
57,R17,Has_temporal Arg1:T37 Arg2:T36
0,T1,Person 6 18	regular user
1,T2,Procedure 22 34	e-cigarettes
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Negation 0 3	not
4,R2,Has_negation Arg1:T1 Arg2:T3
5,T4,Pregnancy_considerations 36 92	pregnant or lactating (only excluded from imaging study)
6,T5,Person 94 102	prisoner
7,T6,Post-eligibility 104 140	incapable of giving informed consent
8,T7,Post-eligibility 142 204	unable to lie flat on the scanner for extended periods of time
9,T8,Qualifier 206 214	unstable
10,T9,Condition 215 232	medical condition
11,R3,Has_qualifier Arg1:T9 Arg2:T8
12,T10,Condition 238 251	heart disease
13,T11,Condition 266 278	hypertension
14,T12,Qualifier 253 265	uncontrolled
15,T13,Condition 280 295	thyroid disease
16,T14,Condition 297 305	diabetes
17,T15,Condition 316 332	liver impairment
18,T16,Condition 307 312;322 332	renal impairment
19,T17,Condition 337 345	glaucoma
20,R4,Has_qualifier Arg1:T11 Arg2:T12
21,*,OR T10 T11 T13 T14 T16 T15 T17
22,T18,"Scope 238 344	heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, or glaucom"
23,R5,Subsumes Arg1:T9 Arg2:T18
24,T19,Condition 347 368	prostatic hypertrophy
25,T20,Condition 370 376	stroke
26,T21,Condition 381 386	ulcer
27,*,OR T19 T20 T21
28,T22,Condition 401 423	psychiatric conditions
29,T23,Condition 432 445	schizophrenia
30,T24,Condition 447 457	adult ADHD
31,T25,Condition 462 478	bipolar disorder
32,*,OR T23 T24 T25
33,T26,"Scope 432 478	schizophrenia, adult ADHD, or bipolar disorder"
34,R6,Subsumes Arg1:T22 Arg2:T26
35,T27,Drug 506 529	psychiatric medications
36,T28,Drug 538 551	tranquilizers
37,T29,Drug 553 567	antipsychotics
38,T30,Drug 576 591	antidepressants
39,*,OR T28 T29 T30
40,T31,"Scope 538 591	tranquilizers, antipsychotics, and/or antidepressants"
41,R7,Subsumes Arg1:T27 Arg2:T31
42,T32,Drug 600 611	medications
43,T33,Qualifier 621 639	inducers of CYP2A6
44,R8,Has_qualifier Arg1:T32 Arg2:T33
45,T34,Drug 643 671	nicotine metabolizing enzyme
46,T35,Drug 681 691	rifampicin
47,T36,Drug 693 706	dexamethasone
48,T37,Drug 708 721	phenobarbital
49,T38,Drug 733 754	anti-convulsant drugs
50,*,OR T35 T36 T37 T38
51,T39,"Scope 681 754	rifampicin, dexamethasone, phenobarbital, and other anti-convulsant drugs"
52,R9,Subsumes Arg1:T32 Arg2:T39
53,R10,Subsumes Arg1:T32 Arg2:T34
54,T40,Non-query-able 756 788	unable to communicate in English
55,T41,Procedure 805 822	smokeless tobacco
56,T42,Procedure 824 842	tobacco cigarettes
57,T43,Multiplier 844 861	5 and fewer a day
58,*,OR T41 T42
59,T44,"Scope 805 842	smokeless tobacco, tobacco cigarettes"
60,R11,Has_multiplier Arg1:T44 Arg2:T43
61,T45,Non-query-able 865 952	ccasional use of pipes is permitted if subject abstains for the week prior to the study
62,T46,Person 968 973	years
63,T47,Value 954 967	older than 80
64,R12,Has_value Arg1:T46 Arg2:T47
0,T1,Drug 20 28	ketamine
1,T2,Drug 33 42	lidocaine
2,T3,Condition 0 16	contraindication
3,*,OR T1 T2
4,T4,Scope 20 42	ketamine and lidocaine
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Competing_trial 44 78	patients involved to other studies
7,T6,Measurement 97 145	American Society of Anesthesiologist (ASA) class
8,T7,Value 146 149;80 96	III more or equal to
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Observation 151 160	not alert
0,T1,Person 0 5	Woman
1,T2,Multiplier 14 15	2
2,T3,Condition 16 27	miscarriage
3,T4,Qualifier 28 59	before 12(th) week of gestation
4,T5,Temporal 28 59	before 12(th) week of gestation
5,T6,Reference_point 35 59	12(th) week of gestation
6,R1,Has_index Arg1:T5 Arg2:T6
7,R2,multi Arg1:T4 Arg2:T5
8,R3,Has_qualifier Arg1:T3 Arg2:T4
9,R4,Has_multiplier Arg1:T3 Arg2:T2
10,T7,Condition 92 105	thrombophilia
11,T8,Multiplier 111 120	recurrent
12,T9,Condition 121 135	pregnancy loss
13,R5,Has_multiplier Arg1:T9 Arg2:T8
14,R6,AND Arg1:T7 Arg2:T9
15,T10,Informed_consent 137 157	Signed consent form.
0,T1,Condition 59 70	intolerance
1,T2,Condition 41 55	adverse events
2,T3,Qualifier 19 40	medically significant
3,T4,Drug 76 88	aripiprazole
4,T5,Temporal 89 112	during screening period
5,T6,Temporal 116 136	as prior experiences
6,*,OR T5 T6
7,*,OR T1 T2
8,T7,Scope 41 70	adverse events or intolerance
9,R1,Has_qualifier Arg1:T7 Arg2:T3
10,R2,AND Arg1:T7 Arg2:T4
11,T8,Scope 89 136	during screening period or as prior experiences
12,R3,Has_scope Arg1:T7 Arg2:T8
13,T9,Qualifier 163 178	DSM-<U+2163>-TR
14,T10,Condition 205 218	schizophrenia
15,T11,Negation 194 204	other than
16,R4,Has_negation Arg1:T10 Arg2:T11
17,T12,Qualifier 163 167;182 183	DSM- 5
18,*,OR T12 T9
19,T13,Scope 163 183	DSM-<U+2163>-TR or 5
20,T14,Condition 230 254	schizoaffective disorder
21,T15,Condition 256 281	major depressive disorder
22,T16,Condition 283 299	bipolar disorder
23,T17,Condition 301 309	delirium
24,T18,Condition 311 319	dementia
25,T19,Condition 321 328	amnesia
26,T20,Condition 330 340;432 441	Borderline disorders
27,T21,Condition 342 350;432 441	Paranoid disorders
28,T22,Condition 352 362;432 441	Histrionic disorders
29,T23,Condition 364 375;432 441	Schizotypal disorders
30,T24,Condition 377 385;432 441	Schizoid disorders
31,T25,Condition 387 397;432 441	Antisocial disorders
32,T26,Qualifier 401 406	other
33,T27,Condition 407 416;432 441	cognitive disorders
34,T28,Condition 420 441	personality disorders
35,T29,Scope 407 441	cognitive or personality disorders
36,R5,Has_qualifier Arg1:T29 Arg2:T26
37,*,OR T20 T21 T22 T23 T24 T25 T27 T28 T19 T18 T17 T16 T15 T14
38,R6,Has_scope Arg1:T10 Arg2:T13
39,T30,"Scope 230 441	schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnesia, Borderline, Paranoid, Histrionic, Schizotypal, Schizoid, Antisocial or other cognitive or personality disorders"
40,T31,Scope 163 218	DSM-<U+2163>-TR or 5 diagnosis other than schizophrenia
41,R7,Subsumes Arg1:T31 Arg2:T30
42,T32,Post-eligibility 444 584	Subjects with diseases of the central nervous system that may impact the assessment of the psychotic symptoms as per investigator's opinion.
43,T33,Drug 622 631	clozapine
44,T34,Drug 635 677	long-acting injectable antipsychotic drugs
45,T35,Temporal 678 716	within 3 months prior to the screening
46,T36,Reference_point 703 716	the screening
47,R8,Has_index Arg1:T35 Arg2:T36
48,*,OR T33 T34
49,T37,Scope 622 677	clozapine or long-acting injectable antipsychotic drugs
50,R9,Has_temporal Arg1:T37 Arg2:T35
51,T38,Multiplier 755 779	maximum maintenance dose
52,T39,Drug 812 831	oral antipsychotics
53,T40,Temporal 832 844	at screening
54,R10,Has_multiplier Arg1:T39 Arg2:T38
55,T41,Drug 852 864	Aripiprazole
56,T42,Drug 875 885	Olanzapine
57,T43,Drug 896 907	Risperidone
58,T44,Drug 919 929	Quetiapine
59,T45,Value 930 941	> 750mg/day
60,T46,Value 908 917	> 6mg/day
61,T47,Value 885 894	>20mg/day
62,T48,Value 864 873	>30mg/day
63,R12,Has_value Arg1:T41 Arg2:T48
64,R13,Has_value Arg1:T42 Arg2:T47
65,R14,Has_value Arg1:T43 Arg2:T46
66,R15,Has_value Arg1:T44 Arg2:T45
67,*,OR T44 T43 T42 T41
68,T49,"Scope 852 941	Aripiprazole>30mg/day, Olanzapine>20mg/day, Risperidone > 6mg/day, Quetiapine > 750mg/day"
69,T50,Scope 755 831	maximum maintenance dose (as specified in each label) of oral antipsychotics
70,R11,Subsumes Arg1:T50 Arg2:T49
71,R16,Has_temporal Arg1:T50 Arg2:T40
72,T51,Observation 980 997	violent behaviour
73,T52,Condition 1023 1041	committing suicide
74,T53,Mood 1003 1019	significant risk
75,T54,Mood 960 976	significant risk
76,R17,Has_mood Arg1:T51 Arg2:T54
77,R18,Has_mood Arg1:T52 Arg2:T53
78,*,OR T51 T52
79,T55,Condition 1114 1122	seizures
80,T56,Condition 1124 1154	neuroleptic malignant syndrome
81,T57,Qualifier 1156 1178	clinically significant
82,T58,Condition 1179 1197	tardive dyskinesia
83,T59,Non-representable 1199 1298	or other medical condition that would expose them to undue risk or interfere with study assessments
84,R19,Has_qualifier Arg1:T58 Arg2:T57
85,T60,Observation 1103 1110	history
86,*,OR T55 T56 T58
87,T61,"Scope 1114 1197	seizures, neuroleptic malignant syndrome, clinically significant tardive dyskinesia"
88,R20,Has_temporal Arg1:T61 Arg2:T60
89,T62,"Intoxication_considerations 1301 1490	Significant history of drug abuse disorder (including alcohol, as defined in DSM-5 substance use disorder or in the opinion of the investigator) within the last 6 months prior to screening."
90,T63,Competing_trial 1492 1587	Subjects participating another interventional clinical trial within 30 days prior to screening.
91,T64,"Pregnancy_considerations 1589 1672	Women who are pregnant, nursing, or who plan to become pregnant while in the trial."
92,T65,Post-eligibility 1674 1871	Subjects having any other clinically significant finding of the physical examination or laboratory value that make investigator consider that it would be inappropriate to participate in this study.
0,T1,Procedure 0 17	Emergency surgery
1,T2,Mood 18 24	needed
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Condition 26 43	Bowel obstruction
4,T4,Procedure 45 56	Colonoscopy
5,T5,Temporal 84 98	peroperatively
6,T6,Mood 57 66	scheduled
7,T7,Procedure 73 83	undertaken
8,R2,Has_temporal Arg1:T7 Arg2:T5
9,R3,Has_mood Arg1:T7 Arg2:T6
10,R4,AND Arg1:T4 Arg2:T7
11,T8,Procedure 124 146	mechanical preparation
12,T9,Condition 150 163	contradicting
13,R5,AND Arg1:T9 Arg2:T8
14,T10,Drug 184 189	drugs
15,T11,Condition 168 175	Allergy
16,T12,Drug 191 194	PEG
17,T13,Drug 196 204	neomycin
18,T14,Drug 206 219	metronidazole
19,*,OR T13 T14 T12
20,T15,"Scope 191 219	PEG, neomycin, metronidazole"
21,R6,Subsumes Arg1:T10 Arg2:T15
22,R7,AND Arg1:T11 Arg2:T10
0,T1,Drug 12 27	dexmedetomidine
1,T2,Condition 0 8	allergic
2,T3,Drug 29 55	similar active ingredients
3,T4,Drug 59 69	excipients
4,*,OR T3 T4 T1
5,T5,"Scope 12 69	dexmedetomidine, similar active ingredients or excipients"
6,R1,AND Arg1:T5 Arg2:T2
7,T6,Condition 71 88	G-6-PD deficiency
8,T7,Condition 103 113	arrhythmia
9,T8,Observation 92 99	history
10,T9,Condition 115 124;144 152	bronchial diseases
11,T10,Condition 129 152	cardiovascular diseases
12,T11,Condition 154 177	abnormal liver function
13,*,OR T11 T9 T10 T7
14,T12,"Scope 103 177	arrhythmia, bronchial and cardiovascular diseases, abnormal liver function"
15,R2,Has_temporal Arg1:T12 Arg2:T8
16,T13,Observation 191 198	history
17,T14,Drug 209 234	alpha 2 receptor agonists
18,T15,Drug 209 225;238 249	alpha 2 receptor antagonists
19,*,OR T15 T14
20,T16,Scope 209 249	alpha 2 receptor agonists or antagonists
21,R3,Has_temporal Arg1:T16 Arg2:T13
0,T1,Informed_consent 0 109	Subjects must be capable of providing signed and dated written informed consent by date of Visit 0 (-2 week).
1,T2,Person 111 115	Male
2,T3,Person 120 126	female
3,T4,Person 127 131	aged
4,T5,Value 132 150	=19 and < 65 years
5,R1,Has_value Arg1:T4 Arg2:T5
6,*,OR T2 T3
7,T6,Condition 175 188	schizophrenia
8,T7,"Qualifier 203 330	Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision or 5th edition (DSM-<U+2163>-TR or 5) criteria"
9,R2,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Observation 338 356	history of illness
11,T9,Multiplier 357 381	for at least for 3 years
12,T10,Temporal 382 400	prior to screening
13,R3,Has_multiplier Arg1:T8 Arg2:T9
14,R4,Has_temporal Arg1:T8 Arg2:T10
15,R5,Has_temporal Arg1:T6 Arg2:T8
16,T11,Drug 421 449	atypical antipsychotic drugs
17,T12,Non-representable 451 600	and should be maintained on current antipsychotic drugs (including atypical antipsychotic drugs) and dose for at least 4 weeks prior to the screening
18,T13,"Non-representable 603 775	Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching to long-acting injectable aripiprazole in the investigator's judgement."
19,T14,"Post-eligibility 777 911	Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to comply with all protocol procedures."
0,T1,Condition 20 35	colon resection
1,T2,Temporal 9 19	undergoing
2,R1,Has_temporal Arg1:T1 Arg2:T2
0,T1,Procedure 23 45	inguinal hernia repair
1,T2,Procedure 53 74	orthopedics operation
2,T3,Procedure 78 103	general surgery operation
3,T4,Person 107 115	children
4,*,OR T1 T2 T3
5,T5,Person 117 121	aged
6,T6,Value 122 131	3-9 years
7,R1,Has_value Arg1:T5 Arg2:T6
8,T7,Measurement 133 136	ASA
9,T8,Value 137 143	I - II
10,R2,Has_value Arg1:T7 Arg2:T8
11,T9,Non-query-able 145 196	enter the operating room by himself without parents
12,T10,Condition 198 204;215 230	normal kidney function
13,T11,Condition 198 210;222 230	normal liver function
14,T12,Negation 232 234	no
15,T13,Observation 235 242	history
16,T14,Drug 246 267	anesthesia medication
17,T15,Condition 268 275	allergy
18,R3,AND Arg1:T15 Arg2:T14
19,R4,Has_temporal Arg1:T15 Arg2:T13
20,R5,Has_negation Arg1:T15 Arg2:T12
0,T1,Person 0 5	White
1,T2,Person 6 15	Brazilian
2,T3,Person 19 35	European descent
3,T4,"Qualifier 56 155	Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria"
4,T5,Condition 160 164	ADHD
5,R1,Has_qualifier Arg1:T5 Arg2:T4
6,T6,Mood 166 177	Eligibility
7,T7,Drug 181 211	immediate-release MPH (IR-MPH)
8,R2,Has_mood Arg1:T7 Arg2:T6
0,T1,Condition 0 8	Diabetic
1,T2,Condition 37 52	macular changes
2,T3,Qualifier 33 36	any
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Temporal 53 73	prior to the surgery
5,T5,Reference_point 62 73	the surgery
6,T6,Procedure 66 73	surgery
7,R2,Has_index Arg1:T4 Arg2:T5
8,R3,multi Arg1:T5 Arg2:T6
9,T7,Condition 75 95	epiretinal membranes
10,T8,Condition 97 116	age macular disease
11,T9,Condition 118 131	macular edema
12,*,OR T9 T8 T7
13,T10,"Scope 75 131	epiretinal membranes, age macular disease, macular edema"
14,R4,Has_temporal Arg1:T2 Arg2:T4
15,R5,Subsumes Arg1:T2 Arg2:T10
16,T11,Qualifier 154 157	any
17,T12,Condition 158 170	complication
18,T13,Procedure 178 205	phacoemulsification surgery
19,T14,Temporal 171 205	during phacoemulsification surgery
20,T15,Reference_point 178 205	phacoemulsification surgery
21,R6,Has_index Arg1:T14 Arg2:T15
22,R7,multi Arg1:T15 Arg2:T13
23,R8,Has_temporal Arg1:T12 Arg2:T14
24,R9,Has_qualifier Arg1:T12 Arg2:T11
0,T1,Condition 0 8	Suicidal
1,T2,Condition 32 55	automutilation behavior
2,T3,Qualifier 25 31	severe
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 63 81	psychotic symptoms
5,T5,Condition 89 109	lack of event memory
6,*,OR T4 T5 T2 T1
0,T1,Value 0 11	3 -15 years
1,T2,Person 12 15	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Measurement 115 119	RADT
4,T4,Condition 49 60	pharyngitis
5,T5,Mood 17 48	Clinical symptoms suggestive of
6,T6,Measurement 66 80	MC Isaac score
7,T7,Value 81 83	=3
8,R2,Has_value Arg1:T6 Arg2:T7
9,R3,Has_mood Arg1:T4 Arg2:T5
10,R4,AND Arg1:T4 Arg2:T6
11,T8,Measurement 85 113	Rapid-antigen detection test
12,T9,Value 121 129	positive
13,R5,Subsumes Arg1:T8 Arg2:T3
14,R6,Has_value Arg1:T8 Arg2:T9
15,T10,Qualifier 134 138	GAS-
16,R7,Has_qualifier Arg1:T9 Arg2:T10
17,T11,Informed_consent 140 185	Signed informed parental/patient consent form
0,T1,Procedure 39 66	phacoemulsification surgery
1,T2,Mood 18 38	will be submitted to
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Visit 74 135	Hospital de Clinicas of State University of Campinas (BRAZIL)
4,R2,AND Arg1:T1 Arg2:T3
5,T4,Value 146 159	over 18 years
6,T5,Person 160 163	old
7,R3,Has_value Arg1:T5 Arg2:T4
8,T6,Mood 182 197	able to perform
9,T7,Procedure 198 204	SD-OCT
10,R4,Has_mood Arg1:T7 Arg2:T6
11,T8,Informed_consent 206 240	Patients who sign the consent form
0,T1,Condition 0 16	Contraindication
1,T2,Drug 21 27	IR-MPH
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Temporal 33 40	Current
4,T4,Procedure 41 60	stimulant treatment
5,R2,Has_temporal Arg1:T4 Arg2:T3
6,T5,Mood 62 70	Evidence
7,T6,Qualifier 76 98	clinically significant
8,T7,Condition 99 119	neurological disease
9,T8,Qualifier 125 147	might affect cognition
10,T9,Condition 155 163	delirium
11,T10,Condition 165 173	dementia
12,T11,Condition 175 183	epilepsy
13,T12,Condition 185 196	head trauma
14,T13,Condition 202 220	multiple sclerosis
15,*,OR T12 T13 T11 T10 T9
16,T14,"Scope 155 220	delirium, dementia, epilepsy, head trauma, and multiple sclerosis"
17,R3,Has_qualifier Arg1:T7 Arg2:T8
18,R4,Has_qualifier Arg1:T7 Arg2:T6
19,T15,Scope 76 147	clinically significant neurological disease that might affect cognition
20,R5,Has_scope Arg1:T15 Arg2:T14
21,R6,Has_mood Arg1:T15 Arg2:T5
22,T16,Temporal 223 230	Current
23,T17,Temporal 234 238	past
24,T18,Observation 239 246	history
25,T19,Condition 250 259	psychosis
26,*,OR T17 T16
27,R7,Has_temporal Arg1:T19 Arg2:T18
28,T20,Scope 223 238	Current or past
29,R8,Has_scope Arg1:T19 Arg2:T20
30,T21,Measurement 261 298	Estimated intelligence quotient score
31,T22,Value 299 312	lower than 70
32,R9,Has_value Arg1:T21 Arg2:T22
0,T1,Measurement 0 32	Clinical Administered PTSD Scale
1,T2,Value 66 76	>30 points
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Value 51 61	Criteria A
4,R2,Has_value Arg1:T1 Arg2:T3
0,T1,Drug 20 29	B-lactams
1,T2,Condition 0 16	Hypersensitivity
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Temporal 31 42	concomitant
4,T4,Condition 43 50	disease
5,R2,Has_temporal Arg1:T4 Arg2:T3
6,T5,Drug 78 89	antibiotics
7,T6,Procedure 65 72	treated
8,R3,AND Arg1:T6 Arg2:T5
9,R4,AND Arg1:T4 Arg2:T6
10,T7,Condition 107 124	Immunocompromised
11,T8,Drug 126 137	Antibiotics
12,T9,Temporal 138 149	within 72 h
13,R5,Has_temporal Arg1:T8 Arg2:T9
14,T10,Condition 162 165	ARF
15,T11,Observation 151 158	history
16,T12,Condition 166 179	scarlet fever
17,T13,Condition 180 188	impetigo
18,T14,Condition 189 213	acute glomerulonephritis
19,*,OR T13 T14 T12 T10
20,T15,"Scope 162 213	ARF,scarlet fever,impetigo,acute glomerulonephritis"
21,R6,Has_temporal Arg1:T15 Arg2:T11
22,T16,Condition 233 236	ARF
23,T17,Observation 215 229	Family history
24,R7,Has_context Arg1:T16 Arg2:T17
25,T18,Condition 250 261	pharyngitis
26,T19,Qualifier 238 249	Complicated
27,R8,Has_qualifier Arg1:T18 Arg2:T19
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 184 186	2.
2,T3,Parsing_Error 229 231	3.
3,T4,Parsing_Error 290 292	4.
4,T5,Parsing_Error 338 340	5.
5,T6,Parsing_Error 631 633	6.
6,T7,Parsing_Error 818 820	7.
7,T8,Parsing_Error 932 934	8.
8,T9,Parsing_Error 1023 1025	9.
9,T10,"Non-query-able 3 182	Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;"
10,T11,Condition 187 194	Healthy
11,T12,Condition 196 209	premenopausal
12,T13,Person 210 216	female
13,T14,Person 217 220	age
14,T15,Value 221 226	18-47
15,R1,Has_value Arg1:T14 Arg2:T15
16,T16,Condition 243 288	menstrual events that occur in regular cycles
17,T17,Observation 232 239	History
18,T18,Non-query-able 293 336	Agreement not to attempt to become pregnant
19,T19,Post-eligibility 293 336	Agreement not to attempt to become pregnant
20,T20,Non-query-able 341 459	Agrees to use double-barrier contraception during the study and for 30 days after discontinuation of study medication.
21,T21,Post-eligibility 341 459	Agrees to use double-barrier contraception during the study and for 30 days after discontinuation of study medication.
22,T22,Parsing_Error 460 629	Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide;
23,T23,Post-eligibility 460 629	Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide;
24,T24,Measurement 649 663	pregnancy test
25,T25,Value 640 648	negative
26,T26,Temporal 664 686	at the Screening visit
27,T27,Reference_point 671 686	Screening visit
28,R2,Has_index Arg1:T26 Arg2:T27
29,R3,Has_temporal Arg1:T24 Arg2:T26
30,R4,Has_value Arg1:T24 Arg2:T25
31,T28,Parsing_Error 688 816	An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history
32,T29,Not_a_criteria 688 816	An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history
33,T30,Condition 821 845	Normal laboratory values
34,T31,Value 821 827	Normal
35,T32,Procedure 828 838	laboratory
36,T33,Measurement 828 838	laboratory
37,R5,Has_value Arg1:T33 Arg2:T31
38,T34,Qualifier 849 873	clinically insignificant
39,T35,Subjective_judgement 849 873	clinically insignificant
40,T36,Condition 874 882	findings
41,R6,Has_qualifier Arg1:T36 Arg2:T34
42,T37,Temporal 883 895	at screening
43,T38,Reference_point 886 895	screening
44,T39,Subjective_judgement 896 929	as determined by the Investigator
45,T40,Non-query-able 935 1021	Subject is willing to remain in the clinic overnight for PK assessment on Days 0 and 8
46,T41,Post-eligibility 1026 1099	Ability to complete the study procedures in compliance with the protocol.
47,T42,Subjective_judgement 1026 1099	Ability to complete the study procedures in compliance with the protocol.
0,T1,Procedure 0 16	Systemic therapy
1,T2,Procedure 20 32	radiotherapy
2,*,OR T1 T2
3,T3,Temporal 33 62	within 4 weeks prior to Day 1
4,T4,Reference_point 57 62	Day 1
5,*,OR T3 T4
6,T5,Scope 0 32	Systemic therapy or radiotherapy
7,R1,Has_temporal Arg1:T5 Arg2:T3
8,T6,Temporal 64 69	Prior
9,T7,Procedure 70 77	therapy
10,T8,Drug 83 125	agents targeting the DR5 apoptosis pathway
11,*,OR T7 T8 T6
12,T9,Qualifier 127 132	Major
13,T10,Procedure 133 151	surgical procedure
14,T11,Procedure 153 164	open biopsy
15,T12,Qualifier 169 180	significant
16,T13,Condition 181 197	traumatic injury
17,T14,Temporal 198 227	within 4 weeks prior to Day 1
18,T15,Reference_point 222 227	Day 1
19,*,OR T14 T15
20,R2,Has_qualifier Arg1:T13 Arg2:T12
21,*,OR T13 T11 T10
22,R3,Has_qualifier Arg1:T10 Arg2:T9
23,T16,"Scope 127 197	Major surgical procedure, open biopsy, or significant traumatic injury"
24,R4,Has_temporal Arg1:T16 Arg2:T14
25,T17,Mood 232 252	anticipation of need
26,T18,Qualifier 257 262	major
27,T19,Procedure 263 281	surgical procedure
28,R5,Has_qualifier Arg1:T19 Arg2:T18
29,T20,Temporal 282 312	during the course of the study
30,T21,Reference_point 303 312	the study
31,*,OR T20 T21
32,R6,Has_mood Arg1:T19 Arg2:T17
33,*,OR T16 T19
34,R7,Has_temporal Arg1:T19 Arg2:T20
35,T22,Qualifier 314 319	Other
36,T23,Condition 320 341	invasive malignancies
37,T24,Temporal 342 371	within 5 years prior to Day 1
38,T25,Reference_point 366 371	Day 1
39,R8,Has_index Arg1:T24 Arg2:T25
40,R9,Has_qualifier Arg1:T23 Arg2:T22
41,R10,Has_temporal Arg1:T23 Arg2:T24
42,T26,Qualifier 379 385	active
43,T27,Condition 386 402	brain metastases
44,R11,Has_qualifier Arg1:T27 Arg2:T26
45,T28,Temporal 379 385	active
46,R12,multi Arg1:T26 Arg2:T28
47,T29,Qualifier 404 416	Uncontrolled
48,T30,Condition 417 437	intercurrent illness
49,T31,Temporal 468 475	ongoing
50,T32,Qualifier 479 485	active
51,T33,Condition 486 495	infection
52,T34,Drug 506 528	parenteral antibiotics
53,T35,Temporal 529 542	at enrollment
54,R13,Has_temporal Arg1:T34 Arg2:T35
55,*,OR T31 T32
56,T36,Scope 468 485	ongoing or active
57,R14,Has_scope Arg1:T33 Arg2:T36
58,R15,AND Arg1:T33 Arg2:T34
59,R16,Has_qualifier Arg1:T30 Arg2:T29
60,T37,Scope 404 437	Uncontrolled intercurrent illness
61,T38,Scope 468 542	ongoing or active infection requiring parenteral antibiotics at enrollment
62,T39,Reference_point 532 542	enrollment
63,R17,Has_index Arg1:T35 Arg2:T39
64,R18,Subsumes Arg1:T37 Arg2:T38
65,T40,Qualifier 544 566	Clinically significant
66,T41,Qualifier 568 579	symptomatic
67,T42,Condition 580 602	cardiovascular disease
68,T43,Measurement 604 637	New York Heart Association (NYHA)
69,T44,Value 638 657	Grade II or greater
70,R20,Has_qualifier Arg1:T42 Arg2:T41
71,R21,Has_qualifier Arg1:T42 Arg2:T40
72,R19,Has_value Arg1:T43 Arg2:T44
73,T45,Condition 658 682	congestive heart failure
74,R22,AND Arg1:T45 Arg2:T43
75,T46,Qualifier 684 691	serious
76,T47,Condition 692 710	cardiac arrhythmia
77,R23,Has_qualifier Arg1:T47 Arg2:T46
78,T48,Value 712 731	Grade II or greater
79,T49,Condition 732 759	peripheral vascular disease
80,T50,Observation 764 774	history of
81,T51,Qualifier 775 780	major
82,T52,Procedure 781 794	heart surgery
83,R24,Has_qualifier Arg1:T52 Arg2:T51
84,R25,Has_temporal Arg1:T52 Arg2:T50
85,*,OR T49 T52
86,T53,Temporal 795 819	within 6 months of Day 1
87,T54,Reference_point 814 819	Day 1
88,R26,Has_index Arg1:T53 Arg2:T54
89,T55,"Scope 732 794;856 872	peripheral vascular disease, or history of major heart surgery limit compliance"
90,T56,Observation 856 872	limit compliance
91,R27,Has_temporal Arg1:T55 Arg2:T53
92,T57,Value 910 918	positive
93,T58,Measurement 923 934	hepatitis C
94,T59,Measurement 938 965	hepatitis B surface antigen
95,*,OR T59 T58
96,T60,Scope 923 965	hepatitis C or hepatitis B surface antigen
97,R28,Has_value Arg1:T60 Arg2:T57
98,T61,Observation 967 974	History
99,T62,Qualifier 978 983	other
100,T63,Condition 984 991	disease
101,R29,Has_qualifier Arg1:T63 Arg2:T62
102,R30,Has_temporal Arg1:T63 Arg2:T61
103,T64,Condition 993 1014	metabolic dysfunction
104,T65,Procedure 1016 1036	physical examination
105,T66,Condition 1016 1044	physical examination finding
106,R31,multi Arg1:T66 Arg2:T65
107,T67,Condition 1049 1076	clinical laboratory finding
108,T68,Procedure 1049 1068	clinical laboratory
109,R32,multi Arg1:T67 Arg2:T68
110,T69,Mood 1095 1107	suspicion of
111,T70,Condition 1110 1117	disease
112,T71,Condition 1121 1130	condition
113,T72,Condition 1136 1151	contraindicates
114,*,OR T71 T70
115,T73,Scope 1110 1130	disease or condition
116,*,OR T73 T69
117,T74,Scope 1095 1130	suspicion of a disease or condition
118,T75,Drug 1162 1182	investigational drug
119,T76,Observation 1197 1233	affect interpretation of the results
120,T77,Observation 1250 1281	render the patient at high risk
121,T78,Condition 1286 1309	treatment complications
122,*,OR T76 T77
123,R34,AND Arg1:T77 Arg2:T78
124,T79,Scope 1136 1309	contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications
125,R33,AND Arg1:T72 Arg2:T75
126,R35,Subsumes Arg1:T74 Arg2:T79
127,T80,Procedure 1318 1341	anticoagulation therapy
128,T81,Drug 1318 1333	anticoagulation
129,R36,Subsumes Arg1:T80 Arg2:T81
130,T82,Observation 1343 1375	Participation in clinical trials
131,T83,Observation 1379 1422	undergoing other investigational procedures
132,T84,Temporal 1423 1452	within 30 days prior to Day 1
133,T85,Reference_point 1438 1452	prior to Day 1
134,R37,multi Arg1:T84 Arg2:T85
135,*,OR T82 T83
136,T86,Scope 1343 1422	Participation in clinical trials or undergoing other investigational procedures
137,R38,Has_temporal Arg1:T86 Arg2:T84
138,T87,Condition 1454 1463	Pregnancy
139,T88,Observation 1467 1481	breast feeding
140,*,OR T87 T88
141,T89,Condition 1489 1500	sensitivity
142,T90,Drug 1504 1553	any of the products administered during the study
143,T91,Condition 1559 1567	disorder
144,T92,Negation 1573 1599	compromises the ability of
145,T93,Measurement 1615 1644	give written informed consent
146,T94,Procedure 1652 1680	comply with study procedures
147,*,OR T93 T94
148,T95,Scope 1615 1680	give written informed consent and/or comply with study procedures
149,R39,Has_negation Arg1:T95 Arg2:T92
150,R40,Has_negation Arg1:T91 Arg2:T92
0,T1,Value 0 21	between 7 to 70 years
1,T2,Person 25 28	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Observation 30 47	fluent in English
4,T4,Observation 30 39;51 58	fluent in Spanish
5,T5,Mood 60 68	plans to
6,T6,Procedure 69 81	receive care
7,T7,Visit 89 112	Community Health Center
8,T8,Temporal 113 133	during the next year
9,R2,AND Arg1:T6 Arg2:T7
10,R3,Has_mood Arg1:T6 Arg2:T5
11,R4,Has_temporal Arg1:T6 Arg2:T8
12,T9,Condition 149 154	signs
13,T10,Condition 159 167	symptoms
14,T11,Condition 173 177	SSTI
15,*,OR T10 T9
16,T12,Scope 149 167	signs and symptoms
17,R5,AND Arg1:T12 Arg2:T11
18,T13,Informed_consent 179 219	willing/able to provide informed consent
0,T1,Person 0 3	Age
1,T2,Value 4 14	= 75 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 17 23	Severe
4,T4,Qualifier 25 36	symptomatic
5,T5,Condition 37 52	aortic stenosis
6,R2,Has_qualifier Arg1:T5 Arg2:T4
7,R3,Has_qualifier Arg1:T5 Arg2:T3
8,T6,Qualifier 55 64	High risk
9,T7,Procedure 69 84	cardiac surgery
10,R4,Has_qualifier Arg1:T7 Arg2:T6
11,T8,Qualifier 86 89	STS
12,T9,Qualifier 94 112	logistic Euroscore
13,*,OR T8 T9
14,T10,Scope 86 112	STS and logistic Euroscore
15,R5,Has_scope Arg1:T7 Arg2:T10
16,T11,"Non-representable 117 186	According multidisciplinary (heart) team decision TAVI is preferable,"
17,T12,Competing_trial 188 210	Willing to participate
0,T1,Qualifier 8 14	severe
1,T2,Condition 15 33	alcohol withdrawal
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Mood 0 7	Risk of
4,R2,Has_mood Arg1:T2 Arg2:T3
5,T4,Condition 51 59	seizures
6,T5,Observation 40 47	history
7,T6,Condition 63 79	delirium tremens
8,*,OR T6 T4
9,T7,Scope 51 79	seizures or delirium tremens
10,R3,Has_temporal Arg1:T7 Arg2:T5
11,T8,Condition 109 131	Substance Use Disorder
12,T9,Qualifier 90 98	Moderate
13,T10,Qualifier 102 108	Severe
14,*,OR T10 T9
15,T11,Temporal 82 89	Current
16,T12,Scope 90 108	Moderate or Severe
17,R4,Has_scope Arg1:T8 Arg2:T12
18,R5,Has_temporal Arg1:T8 Arg2:T11
19,T13,Negation 133 143	other than
20,T14,Condition 144 151;174 187	Alcohol Use Disorders
21,T15,Condition 153 161;174 187	Nicotine Use Disorders
22,T16,Condition 165 187	Caffeine Use Disorders
23,*,OR T14 T15 T16
24,T17,"Scope 144 187	Alcohol, Nicotine or Caffeine Use Disorders"
25,R6,Has_negation Arg1:T17 Arg2:T13
26,R7,Has_scope Arg1:T8 Arg2:T17
27,T18,Condition 209 225	Bipolar Disorder
28,T19,Observation 189 205	Lifetime history
29,T20,Condition 227 240	Schizophrenia
30,T21,Condition 244 268	Schizoaffective Disorder
31,*,OR T20 T21 T18
32,T22,"Scope 209 268	Bipolar Disorder, Schizophrenia or Schizoaffective Disorder"
33,R8,Has_temporal Arg1:T22 Arg2:T19
34,T23,Condition 282 302	psychiatric disorder
35,T24,Temporal 274 281	current
36,T25,Condition 315 335	Alcohol Use Disorder
37,T26,"Non-representable 337 448	that, in the judgment of the investigator, will require treatment that will interfere with study participation."
38,T27,Negation 304 314	other than
39,R9,Has_negation Arg1:T25 Arg2:T27
40,R10,AND Arg1:T23 Arg2:T25
41,R11,Has_temporal Arg1:T23 Arg2:T24
42,T28,Temporal 450 457	Current
43,T29,Qualifier 458 464	severe
44,T30,Condition 465 475	depression
45,T31,Measurement 477 482	HAM-D
46,T32,Value 483 486	>24
47,R12,Has_value Arg1:T31 Arg2:T32
48,R13,Subsumes Arg1:T29 Arg2:T31
49,R14,Has_qualifier Arg1:T30 Arg2:T29
50,T33,Condition 491 498	anxiety
51,T34,Measurement 500 505	HAM-A
52,T35,Value 506 509	>24
53,T36,Qualifier 458 464	severe
54,R15,Subsumes Arg1:T36 Arg2:T34
55,R16,Has_value Arg1:T34 Arg2:T35
56,*,OR T30 T33
57,T37,Scope 458 510	severe depression (HAM-D >24) or anxiety (HAM-A >24)
58,R17,Has_temporal Arg1:T37 Arg2:T28
59,T38,Condition 524 531;544 548	suicide risk
60,T39,Condition 535 548	violence risk
61,*,OR T39 T38
62,T40,Qualifier 512 523	Significant
63,T41,Scope 524 548	suicide or violence risk
64,R18,Has_qualifier Arg1:T41 Arg2:T40
65,T42,Drug 571 595	psychotropic medications
66,T43,Temporal 550 559	Currently
67,R19,Has_temporal Arg1:T42 Arg2:T43
68,T44,Non-query-able 597 641	Legally mandated to participate in treatment
69,T45,Drug 675 685	disulfiram
70,T46,Observation 643 669	History of prior treatment
71,R20,Has_temporal Arg1:T45 Arg2:T46
72,T47,Condition 700 717	socially unstable
73,T48,Qualifier 687 699	Sufficiently
74,R21,Has_qualifier Arg1:T47 Arg2:T48
75,T49,Condition 764 781	Contraindications
76,T50,Drug 785 795	disulfiram
77,T51,Condition 807 820	liver disease
78,T52,Condition 822 836	kidney disease
79,T53,Condition 838 853	cardiac disease
80,T54,Condition 855 871	seizure disorder
81,T55,Condition 873 887	hypothyroidism
82,T56,Condition 889 906	diabetes mellitus
83,T57,Condition 908 917	pregnancy
84,T58,Condition 921 930	lactation
85,T59,Condition 932 939	allergy
86,T60,Drug 943 953	disulfiram
87,T61,Drug 957 976	thiuran derivatives
88,*,OR T60 T61
89,T62,Scope 943 976	disulfiram or thiuran derivatives
90,R22,Has_scope Arg1:T59 Arg2:T62
91,*,OR T59 T58 T57 T56 T55 T54 T53 T52 T51
92,T63,"Scope 807 976	liver disease, kidney disease, cardiac disease, seizure disorder, hypothyroidism, diabetes mellitus, pregnancy or lactation, allergy to disulfiram or thiuran derivatives"
93,R23,AND Arg1:T49 Arg2:T50
94,T64,Scope 764 795	Contraindications to disulfiram
95,R24,Subsumes Arg1:T64 Arg2:T63
96,T65,Condition 995 1013	medical conditions
97,T66,Condition 1003 1013;979 991	conditions Neurological
98,T67,Condition 1025 1034	interfere
99,T68,Procedure 1040 1052	MRI scanning
100,*,OR T65 T66
101,T69,Scope 979 1013	Neurological or medical conditions
102,R25,AND Arg1:T69 Arg2:T67
103,R26,AND Arg1:T67 Arg2:T68
104,T70,Condition 1070 1076	stroke
105,T71,Condition 1078 1085	seizure
106,T72,Condition 1087 1098	brain tumor
107,T73,Condition 1100 1115	brain infection
108,T74,Condition 1117 1139	traumatic brain injury
109,T75,Condition 1141 1159	multiple sclerosis
110,T76,Condition 1161 1169	dementia
111,T77,Device 1171 1191	metal device in body
112,T78,Condition 1193 1202	pregnancy
113,T79,Condition 1204 1218	claustrophobia
114,T80,Condition 1220 1235	color blindness
115,T81,Condition 1244 1262	hearing impairment
116,T82,Qualifier 1237 1243	severe
117,R27,Has_qualifier Arg1:T81 Arg2:T82
118,T83,Measurement 1264 1270	weight
119,T84,Value 1270 1279	>300 lbs.
120,R28,Has_value Arg1:T83 Arg2:T84
121,T85,Condition 1281 1297	wheelchair-bound
122,T86,Drug 1340 1347	alcohol
123,T87,Drug 1349 1362	metronidazole
124,T88,Drug 1364 1373	isoniazid
125,T89,Drug 1375 1386	paraldehyde
126,T90,Drug 1388 1397	phenytoin
127,T91,Drug 1399 1407	warfarin
128,T92,Drug 1412 1424	theophylline
129,*,OR T91 T92 T90 T89 T88 T87 T86
130,T93,Temporal 1300 1309	Currently
131,T94,"Scope 1340 1424	alcohol, metronidazole, isoniazid, paraldehyde, phenytoin, warfarin, or theophylline"
132,R29,Has_temporal Arg1:T94 Arg2:T93
133,T95,Qualifier 1427 1438	Significant
134,T96,Condition 1439 1457	alcohol withdrawal
135,T97,Measurement 1459 1463	CIWA
136,T98,Value 1463 1465	>8
137,R30,Has_value Arg1:T97 Arg2:T98
138,R31,Subsumes Arg1:T95 Arg2:T97
139,R32,Has_qualifier Arg1:T96 Arg2:T95
140,T99,Temporal 1467 1479	at screening
141,T100,Measurement 1500 1519	blood alcohol level
142,T101,Value 1523 1527	zero
143,R33,Has_value Arg1:T100 Arg2:T101
144,R34,Has_temporal Arg1:T96 Arg2:T99
0,T1,Negation 11 18	without
1,T2,Procedure 19 21	PN
2,R1,Has_negation Arg1:T2 Arg2:T1
3,T3,Temporal 22 50	during their hospitalization
4,T4,Procedure 35 50	hospitalization
5,T5,Reference_point 29 50	their hospitalization
6,R2,Has_index Arg1:T3 Arg2:T5
7,R3,multi Arg1:T5 Arg2:T4
8,R4,Has_temporal Arg1:T2 Arg2:T3
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 191 193	2.
2,T3,Parsing_Error 294 296	3.
3,T4,Parsing_Error 468 470	4.
4,T5,Parsing_Error 558 560	5.
5,T6,Parsing_Error 591 593	6.
6,T7,Parsing_Error 769 771	7.
7,T8,Parsing_Error 875 877	8.
8,T9,Parsing_Error 899 901	9.
9,T10,Parsing_Error 935 938	10.
10,T11,Parsing_Error 978 981	11.
11,T12,Parsing_Error 1053 1056	12.
12,T13,Condition 16 31	post-menopausal
13,T14,Person 32 37	woman
14,T15,Temporal 58 80	six (6) months or more
15,T16,Temporal 82 118	immediately prior to screening visit
16,T17,Condition 130 146	menstrual period
17,T18,Negation 120 127	without
18,R1,Has_negation Arg1:T17 Arg2:T18
19,R2,AND Arg1:T15 Arg2:T17
20,R3,Has_temporal Arg1:T15 Arg2:T16
21,T19,Procedure 157 169	hysterectomy
22,T20,Temporal 151 156	prior
23,R4,Has_temporal Arg1:T19 Arg2:T20
24,T21,Procedure 177 189	oophorectomy
25,*,OR T19 T17 T21
26,T22,Condition 205 213	pregnant
27,T23,Condition 217 226	lactating
28,*,OR T23 T22
29,T24,Non-query-able 230 292	is attempting or expecting to become pregnant during the study
30,T25,Post-eligibility 230 292	is attempting or expecting to become pregnant during the study
31,T26,Person 297 302	Women
32,T27,Measurement 324 337	liver enzymes
33,T28,Condition 341 354	liver disease
34,T29,Value 319 323	high
35,R5,Has_value Arg1:T27 Arg2:T29
36,*,OR T27 T28
37,T30,Measurement 357 360	ALT
38,T31,Measurement 364 367	AST
39,T32,Value 368 387	exceeding 2.0 x ULN
40,*,OR T31 T30
41,T33,Scope 357 367	ALT or AST
42,R6,Has_value Arg1:T33 Arg2:T32
43,T34,Measurement 392 407	total bilirubin
44,T35,Value 408 427	exceeding 1.5 x ULN
45,R7,Has_value Arg1:T34 Arg2:T35
46,T36,Temporal 428 440	at screening
47,T37,Reference_point 431 440	screening
48,R8,Has_index Arg1:T36 Arg2:T37
49,R9,Has_temporal Arg1:T34 Arg2:T36
50,R10,Has_temporal Arg1:T33 Arg2:T36
51,T38,Temporal 504 541	in the 30 days prior to the screening
52,T39,Reference_point 528 541	the screening
53,R11,Has_index Arg1:T38 Arg2:T39
54,T40,Drug 483 503	investigational drug
55,R12,Has_temporal Arg1:T40 Arg2:T38
56,T41,Person 561 566	Women
57,T42,Condition 585 589	PCOS
58,T43,Observation 574 581	history
59,R13,Has_temporal Arg1:T42 Arg2:T43
60,T44,Drug 616 628	testosterone
61,T45,Drug 630 639	progestin
62,T46,Drug 641 649	androgen
63,T47,Drug 651 659	estrogen
64,T48,Drug 661 678	anabolic steroids
65,T49,Drug 680 684	DHEA
66,T50,Temporal 706 745	for at least 2 weeks prior to screening
67,T51,Temporal 750 766	during the study
68,T52,Reference_point 736 745	screening
69,R14,Has_index Arg1:T50 Arg2:T52
70,T53,Drug 688 705	hormonal products
71,T54,Undefined_semantics 688 705	hormonal products
72,*,OR T53 T49 T48 T47 T46 T45 T44
73,T55,"Scope 616 705	testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products"
74,R15,Has_temporal Arg1:T55 Arg2:T50
75,R16,Has_temporal Arg1:T55 Arg2:T51
76,T56,Drug 779 798	oral contraceptives
77,T57,Temporal 799 823	in the preceding 2 weeks
78,R17,Has_temporal Arg1:T56 Arg2:T57
79,T58,Drug 832 845	Depo-Provera®
80,T59,Temporal 846 872	in the preceding 10 months
81,R18,Has_temporal Arg1:T58 Arg2:T59
82,T60,Device 885 888	IUD
83,T61,Person 902 907	Women
84,T62,Drug 924 933	narcotics
85,T63,Person 939 944	Women
86,T64,Drug 962 976	spironolactone
87,T65,Condition 1024 1027	HIV
88,T66,Condition 1031 1042	Hepatitis A
89,T67,Condition 1031 1040;1044 1045	Hepatitis B
90,T68,Condition 1031 1040;1049 1050	Hepatitis C
91,*,OR T68 T67 T66 T65
92,T69,Non-query-able 1057 1323	Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study
0,T1,Person 83 86	Age
1,T2,Value 87 97	≥ 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 123 137	chondrosarcoma
4,T4,Measurement 99 109	Histologic
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Context_Error 168 186	Measurable disease
7,T6,Non-query-able 0 81	Ability to understand and willingness to sign a written informed consent document
8,T7,Context_Error 188 272	Previously treated or incurable disease without options for standard of care therapy
9,T8,Measurement 274 297	ECOG performance status
10,T9,Value 301 304	0-2
11,R3,Has_value Arg1:T8 Arg2:T9
12,T10,Observation 306 321	Life expectancy
13,T11,Value 325 335	> 3 months
14,R4,Has_value Arg1:T10 Arg2:T11
15,T12,Condition 353 375	reproductive potential
16,A1,Optional T12
17,T13,Procedure 423 436	contraception
18,T14,Drug 444 462	contraceptive pill
19,T15,Device 464 489	intrauterine device [IUD]
20,T16,Device 491 507	physical barrier
21,*,OR T15 T16 T14
22,T17,"Scope 444 507	contraceptive pill, intrauterine device [IUD], physical barrier"
23,R5,Subsumes Arg1:T13 Arg2:T17
24,T18,Temporal 509 529	throughout the trial
25,T19,Temporal 534 575	for 1 year following their final exposure
26,R6,Has_temporal Arg1:T13 Arg2:T18
27,R7,Has_temporal Arg1:T13 Arg2:T19
28,R8,AND Arg1:T12 Arg2:T13
0,T1,Observation 0 4	Died
1,T2,Temporal 5 16	before TAVI
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Informed_consent 18 44	Not willing to participate
0,T1,Informed_consent 0 52	The patient is unwilling to provide informed consent
1,T2,Condition 54 66	acutely sick
2,T3,Condition 81 87	crying
3,T4,Condition 89 97	wheezing
4,T5,Condition 99 107	bleeding
5,T6,Condition 109 118	screaming
6,T7,Condition 122 128	shaken
7,*,OR T7 T6 T5 T4 T3
8,T8,"Scope 81 128	crying, wheezing, bleeding, screaming or shaken"
9,R1,Subsumes Arg1:T2 Arg2:T8
10,T9,Non-query-able 131 184	unable to participate in a discussion about the study
0,T1,Procedure 14 16	PN
1,T2,Temporal 17 45	during their hospitalization
2,T3,Reference_point 24 45	their hospitalization
3,T4,Procedure 30 45	hospitalization
4,R1,multi Arg1:T3 Arg2:T4
5,R2,Has_index Arg1:T2 Arg2:T3
6,R3,Has_temporal Arg1:T1 Arg2:T2
7,T5,Procedure 56 68	hospitalized
8,T6,Visit 93 102	ICU wards
9,T7,Visit 81 89;97 102	surgical wards
10,T8,Visit 72 79;97 102	medical wards
11,*,OR T6 T8 T7
12,T9,"Scope 72 102	medical, surgical or ICU wards"
13,R4,Has_scope Arg1:T5 Arg2:T9
14,T10,"Informed_consent 104 218	Signed informed consent either from the patient, their legally authorized representative or a direct family member"
0,T1,Person 12 16	ages
1,T2,Value 0 7;20 25	Between 21-60
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 27 39	Right-handed
4,T4,Non-query-able 41 111	Capable of giving informed consent and complying with study procedures
5,T5,Value 132 160;200 227	minimum of 5 standard drinks on at least 4 days per week
6,T6,Measurement 121 129	drinking
7,T7,Person 165 168	men
8,T8,Value 172 189;200 227	4 standard drinks on at least 4 days per week
9,T9,Person 194 199	women
10,T11,Temporal 239 260	over the past 28 days
11,R2,Has_value Arg1:T7 Arg2:T5
12,R3,Has_value Arg1:T9 Arg2:T8
13,*,OR T7 T9
14,T10,Scope 132 227	minimum of 5 standard drinks for men or 4 standard drinks for women on at least 4 days per week
15,R4,Has_scope Arg1:T6 Arg2:T10
16,R5,Has_temporal Arg1:T6 Arg2:T11
17,T12,Measurement 268 282	DSM-V criteria
18,T13,Value 262 267	Meets
19,R6,Has_value Arg1:T12 Arg2:T13
20,T14,Condition 295 315	Alcohol Use Disorder
21,R7,AND Arg1:T14 Arg2:T12
22,T15,Condition 339 359	Alcohol Use Disorder
23,T16,Procedure 325 334	treatment
24,T17,Mood 317 324	Seeking
25,R8,Has_mood Arg1:T16 Arg2:T17
26,R9,AND Arg1:T16 Arg2:T15
27,T18,"Non-representable 361 432	Agree to not seek additional treatment, apart from Alcoholics Anonymous"
28,T19,Mood 434 441	Willing
29,T20,Condition 456 476	abstain from alcohol
30,T21,Qualifier 477 487	completely
31,R10,Has_qualifier Arg1:T20 Arg2:T21
32,R11,Has_mood Arg1:T20 Arg2:T19
33,T22,"Post-eligibility 519 613	Willing to be hospitalized on a research unit for 24 hours, longer if detoxification is needed"
0,T1,Person 0 6	Female
1,T2,Value 16 35	older than 18 years
2,T3,Person 30 35	years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Informed_consent 38 85	Patients who agree to participate in the study.
5,T5,Qualifier 107 115	ACR 1990
6,T6,Qualifier 107 110;120 124	ACR 2010
7,T7,Condition 138 150	Fibromyalgia
8,T8,Scope 107 124	ACR 1990 and 2010
9,R2,Has_scope Arg1:T7 Arg2:T8
10,T9,Negation 153 155	No
11,T10,Temporal 156 164	previous
12,T11,Value 172 181	vitamin D
13,R3,Has_temporal Arg1:T11 Arg2:T10
14,T12,Scope 156 181	previous use of vitamin D
15,R4,Has_negation Arg1:T12 Arg2:T9
16,T13,Condition 229 241	fibromyalgia
17,T14,Qualifier 219 228	secondary
18,T15,Qualifier 208 215	primary
19,*,OR T15 T14
20,T16,Scope 208 228	primary or secondary
21,R5,Has_scope Arg1:T13 Arg2:T16
0,T1,Observation 3 10	smoking
1,T2,Condition 24 38	drug addiction
2,*,OR T1 T2
3,T3,Drug 54 70	local anesthetic
4,T4,Condition 71 78	allergy
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Procedure 124 136	radiotherapy
7,T6,Procedure 112 120	chemical
8,*,OR T6 T5
9,T7,Condition 141 156	Hepatic disease
10,T8,Condition 172 188	immunodepression
11,T9,Condition 204 213	Pregnancy
12,T10,Condition 229 237	Diabetes
13,T11,Condition 253 266	Heart disease
0,T1,Person 0 5	Women
1,T2,Person 6 9	age
2,T3,Value 10 15	18-45
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Non-representable 17 234	Within 6 months of expiration or beyond the end of the FDA-approved duration of use of the levonorgestrel intrauterine device (LNG-IUD = 5 years) OR the etonogestrel-releasing subdermal implant (ENG implant = 3 years)
5,T5,Informed_consent 236 273	Able to consent in English or Spanish
6,T6,Negation 276 279	Not
7,T7,Condition 280 288	pregnant
8,T8,Temporal 289 314	at the time of enrollment
9,R2,Has_negation Arg1:T7 Arg2:T6
10,R3,Has_temporal Arg1:T7 Arg2:T8
0,T1,Condition 3 27	Congestive heart failure
1,T2,Procedure 33 37	CABG
2,T3,Procedure 41 81	Percutaneous Coronary Intervention (PCI)
3,*,OR T2 T3
4,T4,Procedure 114 127	major surgery
5,T5,Procedure 134 147	valve surgery
6,T8,Procedure 201 224	carotid end-arterectomy
7,T9,Procedure 226 259	abdominal aortic aneurysm surgery
8,T6,Procedure 151 163;174 199	resection of left ventricular aneurysm
9,T7,Procedure 151 170;191 199	resection of aortic aneurysm
10,*,OR T6 T8 T7 T9 T5 T4
11,T10,Procedure 271 295	Congenital heart disease
12,T11,Procedure 301 333	Transmural myocardial infarction
13,T12,Temporal 334 364	within the previous seven days
14,T13,Measurement 369 371	CK
15,T14,Negation 372 388	has not returned
16,T15,Value 392 398	normal
17,R1,Has_negation Arg1:T15 Arg2:T14
18,R2,Has_value Arg1:T13 Arg2:T15
19,R3,Has_temporal Arg1:T11 Arg2:T12
20,R4,AND Arg1:T11 Arg2:T13
21,T16,Condition 404 414	Chest pain
22,T17,Qualifier 415 445	lasting longer than 30 minutes
23,R5,Has_qualifier Arg1:T16 Arg2:T17
24,T18,Temporal 446 475	within 12 hours pre-procedure
25,R6,Has_temporal Arg1:T16 Arg2:T18
26,T19,Measurement 480 490	CK enzymes
27,T20,Value 491 499	positive
28,T21,Value 501 528	≥ 2x the normal upper limit
29,R7,Subsumes Arg1:T20 Arg2:T21
30,R8,Has_value Arg1:T19 Arg2:T20
31,T22,Scope 480 529	CK enzymes positive (≥ 2x the normal upper limit)
32,R9,AND Arg1:T22 Arg2:T16
33,A1,Optional T22
34,T23,Condition 546 574	any cerebrovascular accident
35,T24,Observation 535 545	History of
36,R10,AND Arg1:T24 Arg2:T23
37,T25,Condition 580 598	Left main stenosis
38,T26,Value 602 613	50% or more
39,R11,Has_value Arg1:T25 Arg2:T26
40,T27,Condition 697 710;730 737	Single vessel disease
41,T28,Condition 712 728;730 737	single territory disease
42,R12,Subsumes Arg1:T27 Arg2:T28
43,T29,Mood 619 631	Intention to
44,T30,Multiplier 638 649	more than 1
45,T31,Qualifier 650 690	totally occluded major epicardial vessel
46,R13,Has_multiplier Arg1:T31 Arg2:T30
47,T32,Procedure 632 637	treat
48,R15,Has_qualifier Arg1:T32 Arg2:T31
49,R14,Has_mood Arg1:T32 Arg2:T29
0,T1,Procedure 16 46	female sterilization procedure
1,T2,Mood 48 54	Desire
2,T3,Observation 59 69	conception
3,T4,Temporal 70 91	in the next 12 months
4,R1,Has_temporal Arg1:T3 Arg2:T4
5,R2,Has_mood Arg1:T3 Arg2:T2
6,T5,Negation 93 96	Not
7,T6,Observation 97 112	sexually active
8,T7,Qualifier 120 132	male partner
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,R4,Has_negation Arg1:T6 Arg2:T5
0,T1,Temporal 20 32	previous use
1,T2,Drug 36 45	vitamin D
2,R1,Has_temporal Arg1:T2 Arg2:T1
3,T3,Condition 101 110;68 73	disorders renal
4,T4,Condition 101 110;75 80	disorders liver
5,T5,Condition 82 110	calcium metabolism disorders
6,T6,Condition 112 135	malabsorption disorders
7,T7,Condition 143 152	neoplasms
8,*,OR T7 T6 T3 T4 T5
9,T8,Measurement 169 189	serum calcium levels
10,T9,Value 190 227	equal to or greater than 10.2 mg / dl
11,R2,Has_value Arg1:T8 Arg2:T9
0,T1,Procedure 0 34	Single unit implant rehabilitation
1,T2,Qualifier 36 43	Maxilla
2,T3,Qualifier 48 56	mandible
3,*,OR T2 T3
4,T4,Informed_consent 58 84	Must accept treatment plan
5,T5,Informed_consent 86 112	Must sign informed consent
6,T6,Procedure 114 131	dental extraction
7,T7,Temporal 142 164	at least 3 month prior
8,R1,Has_temporal Arg1:T6 Arg2:T7
9,T8,Value 176 189	at least 6 mm
10,T9,Measurement 193 206	residual bone
11,R2,Has_value Arg1:T9 Arg2:T8
12,T10,Negation 208 215	Absence
13,T11,Condition 219 231	oral lesions
14,R3,Has_negation Arg1:T11 Arg2:T10
15,T12,Condition 233 267	keratinized tissue must be present
0,T1,Measurement 25 56	Canadian Cardiovascular Society
1,T2,"Value 57 69	1, 2, 3 or 4"
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 17 23	stable
4,R2,Subsumes Arg1:T3 Arg2:T1
5,T4,Qualifier 74 82	unstable
6,T5,Measurement 84 99	Braunwald class
7,T6,Value 100 102	IB
8,R4,Subsumes Arg1:T4 Arg2:T5
9,T7,Condition 130 145	angina pectoris
10,*,OR T3 T4
11,R5,Has_qualifier Arg1:T7 Arg2:T3
12,T8,Condition 150 158	ischemia
13,T9,Condition 177 196	atypical chest pain
14,T10,"Scope 17 158	stable (Canadian Cardiovascular Society 1, 2, 3 or 4) or unstable (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) angina pectoris and ischemia"
15,*,OR T9 T10
16,T11,Condition 219 231	asymptomatic
17,T12,Condition 262 282	myocardial ischaemia
18,T13,Observation 251 261	documented
19,R6,AND Arg1:T13 Arg2:T12
20,R7,Has_context Arg1:T11 Arg2:T13
21,T14,Procedure 289 312	treadmill exercise test
22,T15,Procedure 314 339	radionuclide scintigraphy
23,T16,Procedure 341 364	stress echocardiography
24,T17,Procedure 366 377	Holter tape
25,*,OR T16 T17 T15 T14
26,T18,"Scope 289 377	treadmill exercise test, radionuclide scintigraphy, stress echocardiography, Holter tape"
27,R8,Subsumes Arg1:T13 Arg2:T18
28,T19,Procedure 414 440	coronary revascularization
29,T20,Mood 401 413	eligible for
30,R9,Has_mood Arg1:T19 Arg2:T20
31,T21,Procedure 442 453	angioplasty
32,T22,Procedure 457 461	CABG
33,*,OR T21 T22
34,T23,Scope 442 461	angioplasty or CABG
35,R10,Subsumes Arg1:T19 Arg2:T23
36,T24,Value 468 478	At least 2
37,T25,Condition 479 486	lesions
38,R11,Has_value Arg1:T25 Arg2:T24
39,T26,Qualifier 488 516	located in different vessels
40,T27,Qualifier 488 498;524 545	located in different territories
41,T28,Scope 488 545	located in different vessels and in different territories
42,R12,Has_scope Arg1:T25 Arg2:T28
43,T29,Procedure 571 589	stent implantation
44,T30,Observation 547 567	potentially amenable
45,R13,AND Arg1:T30 Arg2:T29
46,R14,Has_context Arg1:T25 Arg2:T30
47,T31,Condition 623 642	Multivessel disease
48,T32,Value 648 660	at least one
49,T33,Condition 661 688	significant stenosis in LAD
50,T34,Procedure 698 721	treatment of the lesion
51,R15,AND Arg1:T32 Arg2:T33
52,T35,Qualifier 722 765	in another major epicardial coronary artery
53,R16,Has_qualifier Arg1:T34 Arg2:T35
54,T36,Condition 1364 1386	total occluded vessels
55,T37,Temporal 1390 1406	unknown duration
56,R17,Has_temporal Arg1:T36 Arg2:T37
57,T38,Temporal 1419 1440	longer than one month
58,T39,Value 1457 1469	over 1.50 mm
59,T40,Measurement 1447 1456	reference
60,T41,Scope 1419 1469	longer than one month and a reference over 1.50 mm
61,*,OR T37 T41
62,T42,Measurement 1593 1601	stenosis
63,T43,Value 1605 1638	more than 50% in luminal diameter
64,R18,Has_value Arg1:T42 Arg2:T43
65,T44,Condition 1550 1570	Significant stenosis
66,R19,Subsumes Arg1:T44 Arg2:T42
67,T45,Measurement 1714 1748	Left ventricular ejection fraction
68,T46,Value 1759 1771	at least 30%
69,R20,Has_value Arg1:T45 Arg2:T46
70,T47,Value 104 106	IC
71,T48,Value 108 111	IIB
72,T49,Value 113 116	IIC
73,T50,Value 118 122	IIIB
74,T51,Value 124 128	IIIC
75,*,OR T51 T50 T49 T48 T47 T6
76,T52,"Scope 100 128	IB, IC, IIB, IIC, IIIB, IIIC"
77,R3,Has_scope Arg1:T5 Arg2:T52
78,T53,Qualifier 595 602	de novo
79,T54,Condition 603 617	native vessels
80,R21,Has_qualifier Arg1:T54 Arg2:T53
81,T55,"Non-representable 767 1004	A two-vessel disease or a three-vessel disease may be viewed as a combination of a side branch and a main epicardial vessel provided they supply different territories; left anterior descending, left circumflex and right coronary artery);"
82,T56,Condition 1009 1031	Total occluded vessels
83,T57,Multiplier 1033 1036	One
84,T58,Condition 1037 1075	total occluded major epicardial vessel
85,T59,Condition 1037 1051;1079 1090	total occluded side branch
86,*,OR T59 T58
87,T60,Scope 1037 1090	total occluded major epicardial vessel or side branch
88,R22,Has_multiplier Arg1:T60 Arg2:T57
89,R23,Subsumes Arg1:T56 Arg2:T60
0,T1,Temporal 0 5	Prior
1,T2,Procedure 6 15	treatment
2,T3,Drug 21 27	Acthar
3,T4,Temporal 28 44	in the past 2mos
4,R1,Subsumes Arg1:T1 Arg2:T4
5,R2,AND Arg1:T2 Arg2:T3
6,R3,Has_temporal Arg1:T2 Arg2:T1
7,T5,Condition 68 89	RA flare requirements
8,T6,Multiplier 51 57	one of
9,R4,Has_multiplier Arg1:T5 Arg2:T6
10,T7,Drug 126 150	live attenuated vaccines
11,T8,Temporal 151 203	within 6 weeks prior to the first dose of study drug
12,T9,Reference_point 175 203	the first dose of study drug
13,T10,Multiplier 179 189	first dose
14,T11,Drug 193 203	study drug
15,R5,Has_multiplier Arg1:T11 Arg2:T10
16,R6,multi Arg1:T9 Arg2:T11
17,R7,Has_index Arg1:T8 Arg2:T9
18,T12,Drug 212 226	zoster vaccine
19,T13,Drug 118 122;142 150	live vaccines
20,*,OR T13 T7
21,T14,Scope 118 150	live or live attenuated vaccines
22,R8,Has_temporal Arg1:T14 Arg2:T8
23,*,OR T14 T12
0,T1,Condition 18 35	1987 ACR criteria
1,T2,Person 37 40	Age
2,T3,Value 41 58	> 18 years of age
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Temporal 60 68	Baseline
5,T5,Measurement 69 111	DAS28/Erythrocyte Sedimentation Rate (ESR)
6,T6,Value 112 117	>=3.2
7,R2,Has_value Arg1:T5 Arg2:T6
8,R3,Has_temporal Arg1:T5 Arg2:T4
9,T7,Multiplier 119 125	Stable
10,T8,Temporal 126 137	concomitant
11,T9,Drug 138 185	Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12,R4,Has_temporal Arg1:T9 Arg2:T8
13,R5,Has_multiplier Arg1:T9 Arg2:T7
14,T10,Multiplier 187 193	Stable
15,T11,Drug 194 204	prednisone
16,T12,Value 205 210	<10mg
17,R6,Has_value Arg1:T11 Arg2:T12
18,R7,Has_multiplier Arg1:T11 Arg2:T10
19,T13,Measurement 226 245	Power Doppler score
20,T14,Value 249 253	>=10
21,R8,Has_value Arg1:T13 Arg2:T14
0,T1,Condition 34 57	glioblastoma multiforme
1,T2,Procedure 0 17	Histopathological
2,T3,Observation 0 30	Histopathological verification
3,R1,AND Arg1:T3 Arg2:T2
4,R2,AND Arg1:T3 Arg2:T1
5,T4,Measurement 64 67	WHO
6,T5,Value 68 76	grade IV
7,R3,Has_value Arg1:T4 Arg2:T5
8,R4,AND Arg1:T1 Arg2:T4
9,T6,Qualifier 78 90	in remission
10,T7,Qualifier 92 99	Group A
11,T8,Qualifier 125 132	Group B
12,T9,Temporal 109 115	active
13,T10,Qualifier 104 123	with active disease
14,A1,Optional T8
15,A2,Optional T7
16,R5,Has_qualifier Arg1:T7 Arg2:T6
17,R6,Has_qualifier Arg1:T8 Arg2:T10
18,*,OR T7 T8
19,T11,Scope 78 133	in remission (Group A) or with active disease (Group B)
20,R7,Has_scope Arg1:T1 Arg2:T11
21,T12,Qualifier 136 148	CMV-positive
22,T13,Condition 149 152	GBM
23,T14,Condition 59 62	GBM
24,R8,Subsumes Arg1:T1 Arg2:T14
25,R9,Has_qualifier Arg1:T13 Arg2:T12
26,T15,Condition 136 139	CMV
27,R10,AND Arg1:T12 Arg2:T15
28,T16,Condition 154 170	CMV seropositive
29,T17,Observation 172 187	Life expectancy
30,T18,Value 188 206	6 weeks or greater
31,R11,Has_value Arg1:T17 Arg2:T18
32,T19,Measurement 208 224	Karnofsky/Lansky
33,T20,Value 225 244	score 50 or greater
34,R12,Has_value Arg1:T19 Arg2:T20
35,T21,Post-eligibility 246 310	Patient or parent/guardian capable of providing informed consent
36,T22,Measurement 312 321	Bilirubin
37,T23,Value 322 358	less than 1.5x upper limit of normal
38,R13,Has_value Arg1:T22 Arg2:T23
39,T24,Measurement 360 363	AST
40,T25,Value 364 398	less than 3x upper limit of normal
41,R14,Has_value Arg1:T24 Arg2:T25
42,T26,Measurement 468 482	Pulse oximetry
43,T27,Value 486 500	90% or greater
44,R15,Has_value Arg1:T26 Arg2:T27
45,T28,Qualifier 501 512	on room air
46,R16,Has_qualifier Arg1:T26 Arg2:T28
47,T29,Pregnancy_considerations 514 688	Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom.
48,T30,Post-eligibility 690 808	Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.
49,T31,Procedure 742 764	antineoplastic therapy
50,T32,Negation 711 719	been off
51,R17,Has_negation Arg1:T31 Arg2:T32
52,T33,Temporal 765 807	for one month prior to entry in this study
53,T34,Reference_point 788 807	entry in this study
54,R18,Has_index Arg1:T33 Arg2:T34
55,R19,Has_temporal Arg1:T31 Arg2:T33
56,T35,"Post-eligibility 810 935	Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent."
0,T1,Condition 0 12	coagulopathy
1,T2,Condition 14 21	allergy
2,T3,Drug 28 45	local anesthetics
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 47 57	depression
5,T5,Drug 59 79	antidepressant drugs
6,T6,Condition 91 99	epilepsy
7,T7,Drug 110 120	painkiller
8,T8,Temporal 121 135	before surgery
9,R2,Has_temporal Arg1:T7 Arg2:T8
10,R3,AND Arg1:T4 Arg2:T5
11,T9,Condition 137 157	addiction to alcohol
12,T10,Condition 137 149;161 179	addiction to recreational drugs
13,*,OR T9 T10
0,T1,Condition 0 28	choroidal neovascularization
1,T2,Qualifier 39 50	age-related
2,T3,Condition 51 70	macula degeneration
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,R2,causal Arg1:T1 Arg2:T3
5,T4,Negation 72 74	no
6,T5,Temporal 75 83	previous
7,T6,Procedure 84 93	treatment
8,T7,Context_Error 72 93	no previous treatment
9,R3,Has_temporal Arg1:T6 Arg2:T5
10,R4,Has_negation Arg1:T6 Arg2:T4
11,T8,Observation 97 106	follow-up
12,T9,Temporal 107 125	at least 12 months
13,R5,Has_temporal Arg1:T8 Arg2:T9
14,T10,Measurement 138 151	visual acuity
15,T11,Temporal 129 137	baseline
16,R6,Has_temporal Arg1:T10 Arg2:T11
17,T12,Value 167 190	letter score of 0 to 70
18,T13,Procedure 198 246	Early Treatment Diabetic Retinopathy Study chart
19,R7,Has_value Arg1:T10 Arg2:T12
20,R8,causal Arg1:T10 Arg2:T13
0,T1,Non-query-able 0 16	obtained consent
1,T2,Condition 28 37	pregnancy
2,T3,Qualifier 18 27	singleton
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Procedure 39 63	subarachnoid anaesthesia
0,T1,Condition 20 29	infection
1,T2,Temporal 7 19	intercurrent
2,T3,Qualifier 0 6	Severe
3,R1,Has_qualifier Arg1:T1 Arg2:T3
4,R2,Has_temporal Arg1:T1 Arg2:T2
5,T4,Condition 37 51	HIV positivity
6,T5,Condition 53 61	Pregnant
7,T6,Condition 65 74	lactating
8,*,OR T6 T5
9,T7,Condition 87 113	hypersensitivity reactions
10,T8,Drug 117 151	murine protein-containing products
11,R3,AND Arg1:T7 Arg2:T8
12,T9,Drug 117 123	murine
13,R4,AND Arg1:T8 Arg2:T9
0,T1,Condition 0 28	choroidal neovascularization
1,T2,Condition 39 57	other eye diseases
2,R1,causal Arg1:T1 Arg2:T2
3,T3,Qualifier 39 44	other
4,R2,multi Arg1:T2 Arg2:T3
5,T4,Procedure 59 73	ocular surgery
6,T5,Temporal 74 98	within the past 3 mouths
7,R3,Has_temporal Arg1:T4 Arg2:T5
8,T6,Condition 111 118	uveitis
9,T7,Observation 100 107	history
10,R4,Has_temporal Arg1:T6 Arg2:T7
11,T8,Measurement 120 140	intraocular pressure
12,T9,Value 141 160	higher than 25 mmHg
13,T10,Condition 165 173	glaucoma
14,R5,Has_value Arg1:T8 Arg2:T9
15,*,OR T10 T8
16,T11,Condition 205 226	thromboembolic events
17,T13,Qualifier 198 204	ocular
18,T14,Qualifier 186 194	systemic
19,*,OR T13 T14
20,T12,Scope 186 204	systemic or ocular
21,R6,Has_scope Arg1:T11 Arg2:T12
0,T1,Condition 0 15	fetal anomalies
1,T2,Condition 17 35	contra-indications
2,T3,Procedure 40 66	medical induction of labor
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 68 89	placental pathologies
5,T5,Condition 91 96	St.p.
6,T6,Procedure 97 136	surgery with opening the uterine cavity
7,T7,Procedure 144 161	caesarean section
8,R2,AND Arg1:T5 Arg2:T6
9,R3,Subsumes Arg1:T6 Arg2:T7
10,T8,Condition 164 168	PROM
11,T9,Condition 170 189	multiple gestations
12,T10,Value 191 203	< 37-0 weeks
13,T11,Measurement 207 216	gestation
14,R4,Has_value Arg1:T11 Arg2:T10
15,T12,Condition 218 223	St.p.
16,T13,Procedure 224 237	cervical tear
17,R5,AND Arg1:T12 Arg2:T13
0,T1,Condition 13 48	spontaneous intracranial hemorrhage
1,T2,Condition 52 85	traumatic intracranial hemorrhage
2,T3,Mood 97 106	requiring
3,T4,Procedure 107 127	neurological surgery
4,R1,Has_mood Arg1:T4 Arg2:T3
5,*,OR T1 T2 T4
6,T5,Condition 129 149	Coagulation disorder
7,T6,Measurement 161 163	PT
8,T7,Value 164 177	less than 60%
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Scope 161 177	PT less than 60%
11,R3,Subsumes Arg1:T5 Arg2:T8
0,T1,Condition 0 8	pregnant
1,T2,Observation 12 25	breastfeeding
2,*,OR T1 T2
3,T3,Observation 51 61	history of
4,T4,Condition 62 78	hypersensitivity
5,T5,Drug 82 90	colistin
6,R1,AND Arg1:T4 Arg2:T5
7,R2,Has_temporal Arg1:T4 Arg2:T3
0,T1,Condition 0 18	medical indication
1,T2,Procedure 23 41	induction of labor
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Value 43 51	18 years
4,T4,Person 55 58	age
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Informed_consent 60 83	signed informed consent
7,T6,Condition 85 106	cephalic presentation
8,T7,Condition 111 115	PROM
9,T8,Negation 108 110	no
10,R3,Has_negation Arg1:T7 Arg2:T8
11,T9,Value 117 121	37+0
12,T10,Value 124 128	42+0
13,T11,Measurement 129 147	weeks of gestation
14,*,OR T10 T9
15,T12,Scope 117 128	37+0 - 42+0
16,R4,Has_scope Arg1:T11 Arg2:T12
17,T13,Measurement 149 161	Bishop-Score
18,T14,Value 162 165	= 6
19,R5,Has_value Arg1:T13 Arg2:T14
20,T15,Condition 170 187	contra-indication
21,T16,Negation 167 169	no
22,R6,Has_negation Arg1:T15 Arg2:T16
23,T17,Procedure 192 218	medical induction of labor
24,R7,AND Arg1:T15 Arg2:T17
25,T18,Negation 220 222	no
26,T19,Mood 223 240	clinical signs of
27,T20,Condition 241 250	infection
28,R8,Has_negation Arg1:T20 Arg2:T18
29,R9,Has_mood Arg1:T20 Arg2:T19
0,T1,Temporal 0 11	Concomitant
1,T2,Drug 21 45	oral anticoagulant drugs
2,R1,Has_temporal Arg1:T2 Arg2:T1
3,T3,Condition 47 89	Acquired deficiency of coagulation factors
4,T4,Qualifier 90 120	whose treatment is established
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 122 138	Hypersensitivity
7,T6,Drug 144 147	PCC
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Condition 160 176	thrombocytopenia
10,T8,Drug 188 195	heparin
11,R4,AND Arg1:T7 Arg2:T8
12,T9,Condition 197 235	Disseminated intravascular coagulation
13,T10,Condition 237 249;257 265	Extracranial bleeding
14,T11,Qualifier 250 256	active
15,R5,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Condition 267 283	Hypersensitivity
17,T13,Drug 287 296	vitamin K
18,R6,AND Arg1:T12 Arg2:T13
0,T1,Procedure 8 20	hospitalized
1,T2,Visit 24 43	critical care units
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Qualifier 65 85	multi drug resistant
4,T4,Condition 86 108	Gram negative bacteria
5,T5,Observation 109 120	susceptibly
6,T6,Multiplier 121 125	only
7,T7,Drug 129 137	colistin
8,R2,Has_multiplier Arg1:T7 Arg2:T6
9,R3,AND Arg1:T5 Arg2:T7
10,R4,Has_qualifier Arg1:T4 Arg2:T3
11,R5,Has_context Arg1:T4 Arg2:T5
12,T8,"Non-representable 139 206	source of infection: blood, respiratory, intra abdominal or urinary"
0,T1,Condition 13 22	emphysema
1,T2,Procedure 36 43	CT scan
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Procedure 65 72	CT scan
4,T4,Temporal 60 64	past
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T6,Negation 76 89	not available
7,T7,Observation 50 72	report of past CT scan
8,R5,AND Arg1:T7 Arg2:T3
9,T8,Procedure 117 124	CT scan
10,T9,Scope 50 89	report of past CT scan is not available
11,A1,Optional T9
12,R3,Has_negation Arg1:T3 Arg2:T6
13,R4,AND Arg1:T9 Arg2:T8
14,T5,Scope 50 156	report of past CT scan is not available at site documenting then a CT scan is to be performed at screening
15,T10,Temporal 144 156	at screening
16,R6,Has_temporal Arg1:T8 Arg2:T10
17,T11,Reference_point 147 156	screening
18,R7,Subsumes Arg1:T2 Arg2:T5
19,T12,Person 158 162	Male
20,T13,Person 166 172	female
21,T14,Value 182 199	at least 18 years
22,T15,Person 203 206	age
23,R8,Has_value Arg1:T15 Arg2:T14
24,*,OR T13 T12
25,T16,Post-eligibility 209 254	Able and willing to sign an informed consent.
26,T17,Condition 279 335	congenital AAT deficiency of phenotype PiZZ (homozygote)
27,T18,Condition 345 386	rare phenotypes related to AAT deficiency
28,T19,Measurement 396 411	AAT serum level
29,T20,Value 412 426	≤ 11 micromole
30,R9,Has_value Arg1:T19 Arg2:T20
31,*,OR T18 T17
32,T21,Procedure 451 478	IV AAT augmentation therapy
33,A2,Optional T21
34,T22,Context_Error 428 524	For patients receiving IV AAT augmentation therapy the serum AAT level threshold does not apply.
35,T23,Measurement 526 534	FEV1/SVC
36,T24,Value 535 558	<70% of predicted value
37,R10,Has_value Arg1:T23 Arg2:T24
38,T25,Qualifier 559 578	post bronchodilator
39,R11,Has_qualifier Arg1:T23 Arg2:T25
40,T26,Temporal 559 578	post bronchodilator
41,T27,Drug 564 578	bronchodilator
42,R12,Has_temporal Arg1:T25 Arg2:T26
43,T28,Measurement 600 604	FEV1
44,T29,Value 605 629	< 80% of predicted value
45,T30,Qualifier 630 649	post-bronchodilator
46,T31,Temporal 630 649	post-bronchodilator
47,T32,Drug 635 649	bronchodilator
48,T33,Reference_point 564 578	bronchodilator
49,R13,Has_index Arg1:T26 Arg2:T33
50,R14,AND Arg1:T33 Arg2:T27
51,T34,Reference_point 635 649	bronchodilator
52,R15,AND Arg1:T34 Arg2:T32
53,R16,Has_index Arg1:T31 Arg2:T34
54,R17,Has_temporal Arg1:T30 Arg2:T31
55,R19,Has_value Arg1:T28 Arg2:T29
56,R18,Has_qualifier Arg1:T28 Arg2:T30
57,T35,Multiplier 662 674	at least two
58,T36,Qualifier 675 683	moderate
59,T37,Qualifier 687 693	severe
60,*,OR T37 T36
61,T38,Condition 694 707	exacerbations
62,T39,Scope 675 693	moderate or severe
63,R20,Has_scope Arg1:T38 Arg2:T39
64,T40,Observation 722 741	change in treatment
65,T41,Qualifier 713 741	required change in treatment
66,R21,Has_context Arg1:T41 Arg2:T40
67,R22,Has_multiplier Arg1:T38 Arg2:T35
68,T42,Drug 743 754	antibiotics
69,T43,Drug 756 773	systemic steroids
70,T44,Procedure 775 790	hospitalization
71,T45,Qualifier 756 764	systemic
72,R23,Has_qualifier Arg1:T43 Arg2:T45
73,T46,Temporal 792 840	in the last 18 months prior to date of screening
74,T47,Reference_point 823 840	date of screening
75,R24,Has_index Arg1:T46 Arg2:T47
76,T48,Multiplier 848 860	at least one
77,T49,Temporal 880 924	within the last 12 months prior to screening
78,T50,Reference_point 915 924	screening
79,R25,Has_index Arg1:T49 Arg2:T50
80,R26,Has_temporal Arg1:T48 Arg2:T49
81,*,OR T44 T43 T42
82,T51,"Scope 743 790	antibiotics, systemic steroids, hospitalization"
83,T52,Procedure 732 741	treatment
84,R27,AND Arg1:T40 Arg2:T52
85,R28,Subsumes Arg1:T52 Arg2:T51
86,R29,Has_qualifier Arg1:T38 Arg2:T41
87,R30,Has_temporal Arg1:T40 Arg2:T46
88,R31,Has_multiplier Arg1:T41 Arg2:T48
89,T53,Observation 994 1021	self-administer inhaled AAT
90,T54,Observation 938 980	comply with completion of electronic diary
91,T55,Post-eligibility 927 981	Ability to comply with completion of electronic diary.
92,T56,Post-eligibility 983 1022	Ability to self-administer inhaled AAT.
93,T57,"Post-eligibility 1024 1258	No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency."
94,T58,"Subjective_judgement 1024 1258	No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency."
95,T59,"Post-eligibility 1260 1426	No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency."
96,T60,"Subjective_judgement 1260 1426	No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency."
97,T61,Procedure 1460 1463	ECG
98,T62,Condition 1443 1463	abnormalities in ECG
99,T63,Qualifier 1431 1442	significant
100,T64,Negation 1428 1430	No
101,R33,Has_qualifier Arg1:T62 Arg2:T63
102,R32,Has_negation Arg1:T62 Arg2:T64
103,R34,AND Arg1:T61 Arg2:T62
104,T65,Subjective_judgement 1428 1490	No significant abnormalities in ECG per investigator judgment.
105,T66,Measurement 1505 1510	HBsAg
106,T67,Value 1492 1500	Negative
107,R35,Has_value Arg1:T66 Arg2:T67
108,T68,Measurement 1519 1536	antibodies to HCV
109,T69,Measurement 1538 1543	HIV-1
110,R36,Has_value Arg1:T68 Arg2:T67
111,R37,Has_value Arg1:T69 Arg2:T67
112,T70,Condition 1546 1559	AAT deficient
113,T71,Condition 1584 1589	naïve
114,T72,Procedure 1605 1628	IV augmentation therapy
115,T73,Negation 1591 1604	not receiving
116,R38,Has_negation Arg1:T72 Arg2:T73
117,R39,Subsumes Arg1:T71 Arg2:T72
118,T75,Procedure 1667 1690	IV augmentation therapy
119,*,OR T71 T75
120,R40,AND Arg1:T70 Arg2:T71
121,T74,Procedure 1729 1736	therapy
122,T76,Temporal 1737 1781	for at least 3 months prior to the screening
123,T77,Reference_point 1768 1781	the screening
124,R41,Has_index Arg1:T76 Arg2:T77
125,T78,Observation 1796 1815	willing to continue
126,T79,Temporal 1832 1853	throughout this trial
127,T80,Reference_point 1843 1853	this trial
128,R42,Has_index Arg1:T79 Arg2:T80
129,R43,Has_temporal Arg1:T78 Arg2:T79
130,R44,Has_temporal Arg1:T74 Arg2:T76
131,T81,Qualifier 1711 1717	stable
132,R45,Has_qualifier Arg1:T74 Arg2:T81
133,T82,Condition 2128 2136	pregnant
134,T83,Negation 2124 2127	Non
135,T84,Condition 2142 2151	lactating
136,T85,Negation 2138 2141	non
137,T86,Person 2152 2158	female
138,T87,Measurement 2185 2199	pregnancy test
139,T88,Value 2203 2211	negative
140,R46,Has_value Arg1:T87 Arg2:T88
141,R47,Has_negation Arg1:T82 Arg2:T83
142,R48,Has_negation Arg1:T84 Arg2:T85
143,T89,Device 2230 2251	contraceptive methods
144,T90,Subjective_judgement 2252 2287	deemed reliable by the investigator
145,T91,Temporal 2300 2316	at least 2 years
146,T92,Condition 2317 2332	post-menopausal
147,T93,Condition 2336 2357	surgically sterilized
148,T94,Procedure 2336 2346	surgically
149,R49,AND Arg1:T93 Arg2:T94
150,*,OR T93 T92
151,T95,Qualifier 2252 2287	deemed reliable by the investigator
152,R50,Has_qualifier Arg1:T89 Arg2:T95
153,R51,AND Arg1:T95 Arg2:T90
154,T96,Scope 2317 2357	post-menopausal or surgically sterilized
155,R52,Has_temporal Arg1:T96 Arg2:T91
156,*,OR T89 T96 T87
157,T97,"Scope 2124 2158	Non-pregnant, non-lactating female"
158,A3,Optional T97
159,T98,"Scope 2185 2357	pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are at least 2 years post-menopausal or surgically sterilized"
160,R53,Has_scope Arg1:T97 Arg2:T98
0,T1,Drug 10 20	antibiotic
1,T2,Drug 28 37	probiotic
2,*,OR T1 T2
3,T3,Temporal 39 63	8 weeks before the study
4,T4,Reference_point 54 63	the study
5,R1,Has_index Arg1:T3 Arg2:T4
6,T5,Scope 10 37	antibiotic and/or probiotic
7,R2,Has_temporal Arg1:T5 Arg2:T3
8,T6,Condition 65 106	Chronic gastrointestinal system disorders
9,T7,Condition 108 128	Congenital anomalies
10,T8,Condition 130 146	Chronic diseases
11,T9,Procedure 148 160	Chemotherapy
12,T10,Procedure 165 177	radiotherapy
13,*,OR T9 T10
14,T11,Condition 179 188	Pregnancy
0,T1,Measurement 0 4	FEV1
1,T2,Value 5 11	>= 80%
2,T3,Measurement 15 19	FEV1
3,T4,Value 20 44	< 20% of predicted value
4,T5,Qualifier 45 64	post-bronchodilator
5,T6,Temporal 45 64	post-bronchodilator
6,T7,Drug 50 64	bronchodilator
7,T8,Reference_point 50 64	bronchodilator
8,R1,Has_index Arg1:T6 Arg2:T8
9,R2,Has_temporal Arg1:T5 Arg2:T6
10,R3,AND Arg1:T8 Arg2:T7
11,R4,Has_qualifier Arg1:T3 Arg2:T5
12,R5,Has_value Arg1:T3 Arg2:T4
13,R6,Has_value Arg1:T1 Arg2:T2
14,*,OR T1 T3
15,T9,Measurement 67 75	FEV1/SVC
16,T10,Value 75 80	>=70%
17,R7,Has_value Arg1:T9 Arg2:T10
18,T11,Procedure 93 108	lung transplant
19,T12,Observation 82 89	History
20,R8,Has_temporal Arg1:T11 Arg2:T12
21,T13,Procedure 115 127	lung surgery
22,T14,Temporal 128 153	within the past two years
23,R9,Has_temporal Arg1:T13 Arg2:T14
24,T15,Procedure 163 179	thoracic surgery
25,T16,Observation 163 192	thoracic surgery waiting list
26,R10,AND Arg1:T16 Arg2:T15
27,T17,Condition 207 219	exacerbation
28,T18,Temporal 220 275	less than 6 weeks prior to screening/re-screening visit
29,T19,Reference_point 247 275	screening/re-screening visit
30,R11,Has_index Arg1:T18 Arg2:T19
31,R12,Has_temporal Arg1:T17 Arg2:T18
32,T20,Condition 301 323	intercurrent illnesses
33,T21,Qualifier 278 300	Clinically significant
34,T22,Subjective_judgement 278 300	Clinically significant
35,T23,Undefined_semantics 278 300	Clinically significant
36,R13,Has_qualifier Arg1:T20 Arg2:T21
37,T24,Negation 325 335	except for
38,T25,Condition 336 347;357 364	respiratory disease
39,T26,Condition 351 364	liver disease
40,T27,Qualifier 365 392	secondary to AAT deficiency
41,T28,Condition 378 392	AAT deficiency
42,R14,AND Arg1:T27 Arg2:T28
43,*,OR T25 T26
44,T29,Scope 336 364	respiratory or liver disease
45,R15,Has_negation Arg1:T29 Arg2:T24
46,R16,Has_qualifier Arg1:T29 Arg2:T27
47,R17,Has_scope Arg1:T20 Arg2:T29
48,T30,Condition 406 413	cardiac
49,T31,Condition 415 422	hepatic
50,T32,Condition 424 429	renal
51,T33,Condition 431 440	endocrine
52,T34,Condition 442 454	neurological
53,T35,Condition 456 469	hematological
54,T36,Condition 471 481	neoplastic
55,T37,Condition 483 496	immunological
56,T38,Condition 498 506	skeletal
57,T39,Condition 510 515	other
58,T40,Undefined_semantics 510 515	other
59,T41,"Scope 406 515	cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other"
60,R18,Subsumes Arg1:T20 Arg2:T41
61,T42,Subjective_judgement 522 556	in the opinion of the investigator
62,T43,"Post-eligibility 278 772	Clinically significant intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor."
63,T44,Condition 774 788	Active smoking
64,T45,Temporal 774 780	Active
65,R19,Has_temporal Arg1:T44 Arg2:T45
66,T46,Temporal 789 834	during the last 12 months from screening date
67,T47,Reference_point 820 834	screening date
68,R20,Has_index Arg1:T46 Arg2:T47
69,R21,Has_temporal Arg1:T44 Arg2:T46
70,T48,Condition 837 846	Pregnancy
71,T49,Condition 850 859	lactation
72,*,OR T49 T48
73,T50,Person 862 867	Woman
74,T51,Condition 871 894	child-bearing potential
75,T52,Procedure 915 928	contraception
76,T53,Qualifier 906 914	adequate
77,T54,Subjective_judgement 906 914	adequate
78,T55,Subjective_judgement 929 964	deemed reliable by the investigator
79,R22,Has_qualifier Arg1:T52 Arg2:T53
80,T56,Negation 895 898	not
81,R23,Has_negation Arg1:T52 Arg2:T56
82,T57,Scope 862 893	Woman of child-bearing potentia
83,A1,Optional T57
84,R24,AND Arg1:T57 Arg2:T52
85,T58,Qualifier 929 964	deemed reliable by the investigator
86,R25,Has_qualifier Arg1:T52 Arg2:T58
87,T59,Pregnancy_considerations 862 965	Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator.
88,T60,Condition 979 990;999 1007	psychiatric disorder
89,T61,Condition 992 1007	mental disorder
90,T62,Condition 1015 1037	other medical disorder
91,T63,Undefined_semantics 1015 1037	other medical disorder
92,T64,Observation 1050 1103	impair the patient's ability to give informed consent
93,T65,Post-eligibility 967 1161	Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol.
94,*,OR T60 T61 T62
95,T66,Scope 979 1037	psychiatric/ mental disorder or any other medical disorder
96,R26,Has_context Arg1:T66 Arg2:T64
97,T67,Condition 1183 1198	viral infection
98,T68,Condition 1204 1207	HCV
99,T69,Condition 1209 1212	HBV
100,T70,Condition 1220 1223	HIV
101,*,OR T70 T69 T68
102,T71,"Scope 1204 1223	HCV, HBV and/or HIV"
103,R27,Subsumes Arg1:T67 Arg2:T71
104,T72,Temporal 1175 1182	ongoing
105,R28,Has_temporal Arg1:T67 Arg2:T72
106,T73,Condition 1238 1251	alcohol abuse
107,T74,Condition 1266 1279	alcohol abuse
108,T75,Observation 1255 1262	history
109,T76,Condition 1274 1279;1283 1290;1317 1322	abuse illegal drugs
110,T77,Condition 1274 1279;1298 1322	abuse legally prescribed drugs
111,T78,Scope 1266 1322	alcohol abuse or illegal and/or legally prescribed drugs
112,R29,Has_temporal Arg1:T78 Arg2:T75
113,*,OR T78 T73
114,*,OR T74 T77 T76
115,T79,Condition 1325 1339	IgA Deficiency
116,T80,Condition 1352 1376	life threatening allergy
117,T81,Qualifier 1352 1368	life threatening
118,R30,Has_qualifier Arg1:T80 Arg2:T81
119,T82,Condition 1378 1399	anaphylactic reaction
120,T83,Condition 1404 1454	systemic response to human plasma derived products
121,T84,Qualifier 1425 1445	human plasma derived
122,T85,Drug 1446 1454	products
123,R31,Has_qualifier Arg1:T85 Arg2:T84
124,R32,AND Arg1:T83 Arg2:T85
125,*,OR T82 T80 T83
126,T86,Observation 1341 1348	History
127,T87,"Scope 1352 1454	life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products"
128,R33,Has_temporal Arg1:T87 Arg2:T86
129,T88,Non-query-able 1457 1536	Participation in another clinical trial within 30 days prior to baseline visit.
130,T89,Context_Error 1457 1536	Participation in another clinical trial within 30 days prior to baseline visit.
131,T90,Post-eligibility 1538 1620	Inability to attend scheduled clinic visits and/or comply with the study protocol.
132,T91,"Post-eligibility 1622 1760	Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol."
0,T1,Drug 19 47	amoxicilline-clavulanic acid
1,T2,Person 0 8	Children
2,T3,Value 49 64	50-90 mg/kg/day
3,T4,Multiplier 66 77	twice daily
4,R1,Has_value Arg1:T1 Arg2:T3
5,R2,Has_multiplier Arg1:T1 Arg2:T4
6,T5,Condition 86 104	acute otitis media
7,T6,Condition 108 123	acute sinusitis
8,*,OR T5 T6
0,T1,Condition 0 8	pregnant
1,T2,Person 9 14	women
2,T3,Value 18 32	30 to 32 weeks
3,T4,Measurement 36 45	gestation
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Measurement 61 66	HBsAg
6,T6,Measurement 71 76	HBeAg
7,T7,Value 52 60	positive
8,T8,Scope 61 76	HBsAg and HBeAg
9,R2,Has_value Arg1:T8 Arg2:T7
10,T9,Measurement 77 93	serum viral load
11,T10,Value 94 120	above 8log10 copies per mL
12,R3,Has_value Arg1:T9 Arg2:T10
0,T1,Condition 13 25	dyslipidemia
1,T2,Procedure 107 129	lipid-lowering therapy
2,T3,Measurement 223 240	total cholesterol
3,T4,Value 241 254	= 200 mg / dl
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Measurement 256 269	triglycerides
6,T6,Value 270 283	= 180 mg / dl
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Measurement 285 300	HDL-cholesterol
9,T8,Value 301 313	= 40 mg / dl
10,T9,Measurement 317 332	LDL-cholesterol
11,T10,Value 333 346	= 150 mg / dl
12,R3,Has_value Arg1:T9 Arg2:T10
13,R4,Has_value Arg1:T7 Arg2:T8
14,*,OR T5 T7 T3 T9
15,T11,Procedure 348 372	Lipid-lowering treatment
16,T12,Procedure 348 362;377 381	Lipid-lowering diet
17,T13,Qualifier 383 389	stable
18,T14,Temporal 390 407	in the last month
19,R5,Has_temporal Arg1:T13 Arg2:T14
20,T15,Condition 174 192	altered analytical
21,T16,"Scope 223 346	total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40 mg / dl or LDL-cholesterol = 150 mg / dl"
22,R6,Subsumes Arg1:T15 Arg2:T16
23,T17,Condition 78 90	dyslipidemia
24,T18,Scope 78 129	dyslipidemia associated with lipid-lowering therapy
25,*,OR T18 T15
26,T19,"Scope 78 346	dyslipidemia associated with lipid-lowering therapy. It is also considered patients who have an altered analytical, using the following cutoffs: total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40 mg / dl or LDL-cholesterol = 150 mg / dl"
27,R7,Subsumes Arg1:T1 Arg2:T19
28,T20,Measurement 429 444	LDL-cholesterol
29,T21,Value 445 462	above 100 mg / dl
30,R8,Has_value Arg1:T20 Arg2:T21
31,T22,Temporal 464 495	in the month prior to inclusion
32,T23,Reference_point 486 495	inclusion
33,R9,Has_index Arg1:T22 Arg2:T23
34,R10,Has_temporal Arg1:T20 Arg2:T22
35,T24,Measurement 501 521	apnea-hypopnea index
36,T25,Value 522 538	between 5-30 h-1
37,R11,Has_value Arg1:T24 Arg2:T25
0,T1,Condition 0 20	submucosal leiomyoma
1,T2,Condition 23 46	endometrial hyperplasia
2,T3,Qualifier 47 58	with atypia
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Observation 61 68	history
5,T5,Procedure 72 87	uterine surgery
6,R2,Has_temporal Arg1:T5 Arg2:T4
0,T1,Condition 25 42	metastatic cancer
1,T2,Measurement 0 14	histologically
2,T3,Value 15 24	confirmed
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T5,Procedure 78 95	radiation therapy
6,T4,Procedure 67 74	surgery
7,T6,Qualifier 51 63	not amenable
8,R3,Has_qualifier Arg1:T4 Arg2:T6
9,R4,Has_qualifier Arg1:T5 Arg2:T6
10,*,OR T4 T5
11,T7,Scope 67 95	surgery or radiation therapy
12,R5,Has_scope Arg1:T1 Arg2:T7
13,T8,Procedure 139 141	CT
14,T9,Condition 118 135	measurable lesion
15,R6,AND Arg1:T9 Arg2:T8
0,T1,Qualifier 39 53	preoperatively
1,T2,Observation 22 38	wheelchair bound
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Negation 72 78	cannot
4,T4,Procedure 108 124	physical therapy
5,T5,Visit 97 107	outpatient
6,T6,Temporal 133 166	for 3 days per week after surgery
7,T7,Reference_point 159 166	surgery
8,R2,Has_index Arg1:T6 Arg2:T7
9,R3,AND Arg1:T4 Arg2:T5
10,R4,Has_negation Arg1:T4 Arg2:T3
11,R5,Has_temporal Arg1:T4 Arg2:T6
0,T1,Condition 0 22	major systemic disease
1,T2,Condition 24 32	Pregnant
2,T3,Condition 108 116	Pregnant
3,T4,Condition 220 228	Pregnant
4,T5,Condition 311 319	Pregnant
5,T6,Person 33 38	woman
6,T7,Person 117 122	woman
7,T8,Person 229 234	woman
8,T9,Person 320 325	woman
9,T10,Condition 57 85	human immunodeficiency virus
10,T11,Condition 89 106	hepatitis C virus
11,*,OR T11 T10
12,T12,Drug 140 168	drug with antiviral activity
13,T13,Procedure 184 196	drug therapy
14,T14,Condition 201 218	hepatitis B virus
15,R1,AND Arg1:T13 Arg2:T14
16,*,OR T12 T13
17,T15,Procedure 241 269	ultrasonographic examination
18,T16,Value 278 309	congenital anomaly of the fetus
19,R2,Has_value Arg1:T15 Arg2:T16
20,T17,Procedure 332 345	amniocentesis
21,T18,Value 358 377	genetic abnormality
22,R3,Has_value Arg1:T17 Arg2:T18
0,T1,Measurement 0 20	Apnea-hypopnea index
1,T2,Value 24 62	less than 5 h-1 or greater than 30 h-1
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 81 109	central apneas and hypopneas
4,T4,Value 122 135	more than 25%
5,T5,Measurement 139 161	all respiratory events
6,R2,Has_value Arg1:T5 Arg2:T4
7,T6,Condition 65 77	Predominance
8,R3,AND Arg1:T6 Arg2:T3
9,T7,Scope 65 109	Predominance of central apneas and hypopneas
10,R4,Subsumes Arg1:T7 Arg2:T5
11,T8,Person 164 184	Professional drivers
12,T9,Person 186 201	risk profession
13,T10,Condition 205 224	respiratory failure
14,*,OR T9 T8 T10
15,T11,Procedure 239 329	criteria of the clinical pathway for diagnosis and treatment of sleep-disordered breathing
16,R5,AND Arg1:T10 Arg2:T11
17,T12,Qualifier 333 347	Very excessive
18,T13,Condition 348 366	daytime sleepiness
19,T14,Measurement 368 392	Epworth Sleepiness Scale
20,T15,Value 392 396	> 18
21,R6,Has_value Arg1:T14 Arg2:T15
22,R7,Has_qualifier Arg1:T13 Arg2:T12
23,T16,Scope 333 366	Very excessive daytime sleepiness
24,T17,Scope 368 396	Epworth Sleepiness Scale> 18
25,R8,Subsumes Arg1:T16 Arg2:T17
26,T18,Condition 400 414	Morbid obesity
27,T19,Measurement 416 419	BMI
28,T20,Value 419 431	> 40 kg / m2
29,R9,Has_value Arg1:T19 Arg2:T20
30,R10,Subsumes Arg1:T18 Arg2:T19
31,T21,Procedure 456 460	CPAP
32,T22,Temporal 435 440	Prior
33,R11,Has_temporal Arg1:T21 Arg2:T22
0,T1,Condition 0 30	Inadequate bone marrow reserve
1,T2,Condition 43 73	poorly controlled hypertension
2,T3,Observation 32 39	history
3,R1,AND Arg1:T3 Arg2:T2
0,T1,Condition 11 28	uterine leiomyoma
1,T2,Qualifier 0 10	hypoechoic
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Measurement 30 42	echogenicity
4,T4,Value 43 45	<3
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Scope 30 45	echogenicity <3
7,R3,Subsumes Arg1:T2 Arg2:T5
8,T6,Condition 49 70	intramural leiomyomas
9,T7,Measurement 79 100	ultrasonographic size
10,T8,Value 101 116	<20 cm but >4cm
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Mood 119 132	indication to
13,T10,Procedure 133 140	surgery
14,R5,Has_mood Arg1:T10 Arg2:T9
15,T11,Condition 154 170	menometrorrhagia
16,T12,Condition 173 191	menstrual disorder
17,T13,Condition 194 205	infertility
18,T14,Condition 208 219	pelvic pain
19,T15,Condition 223 238	pelvic pressure
20,T16,Scope 119 140	indication to surgery
21,R6,Subsumes Arg1:T16 Arg2:T11
0,T1,Condition 96 110	osteoarthritis
1,T2,Procedure 42 76	unilateral total knee arthroplasty
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Qualifier 34 41	primary
4,R2,Has_qualifier Arg1:T2 Arg2:T3
0,T1,Condition 0 12	Chronic pain
1,T2,Temporal 13 31	more than 3 months
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 33 43	Drug abuse
4,T4,Temporal 45 52	Chronic
5,T5,Drug 60 75	analgesic drugs
6,T6,Temporal 77 95	more than 3 months
7,R2,Subsumes Arg1:T4 Arg2:T6
8,R3,Has_temporal Arg1:T5 Arg2:T4
9,T7,Condition 98 117	Psychiatric illness
10,T8,Condition 119 140	Peripheral neuropathy
11,T9,Condition 147 154	allergy
12,T10,Drug 142 146	Drug
13,R4,AND Arg1:T9 Arg2:T10
14,T11,Condition 163 194	gastroesophageal reflux disease
15,T12,Qualifier 156 162	Severe
16,R5,Has_qualifier Arg1:T11 Arg2:T12
0,T1,Condition 0 19	Singleton pregnancy
1,T2,Value 20 30	= 37 weeks
2,T3,Measurement 31 40	gestation
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Procedure 64 82	induction of labor
5,T5,Mood 50 63	presented for
6,R2,Has_mood Arg1:T4 Arg2:T5
7,T6,Condition 109 131	candidate for oxytocin
8,T7,Drug 123 131	oxytocin
9,R3,multi Arg1:T6 Arg2:T7
10,T8,Observation 133 154	Cephalic presentation
11,T9,Value 156 166	Reassuring
12,T10,Measurement 167 190	fetal health assessment
13,R4,Has_value Arg1:T10 Arg2:T9
14,T11,Negation 192 194	no
15,T12,Condition 195 212	abnormal findings
16,T13,Procedure 216 232	fetal assessment
17,R5,Has_negation Arg1:T12 Arg2:T11
18,R6,AND Arg1:T13 Arg2:T12
19,T14,Scope 192 232	no abnormal findings in fetal assessment
20,T15,Scope 156 190	Reassuring fetal health assessment
21,R7,Subsumes Arg1:T15 Arg2:T14
0,T1,Condition 12 33	respiratory disorders
1,T2,Condition 37 46;53 74	signs for respiratory disorders
2,T3,Condition 81 87	asthma
3,T4,Condition 89 100	lung cancer
4,T5,Condition 102 113	sarcoidosis
5,T6,Condition 115 127	tuberculosis
6,T7,Condition 129 142	lung fibrosis
7,T8,Condition 144 159	cystic fibrosis
8,T9,Condition 161 175	bronchoectasis
9,*,OR T3 T4 T5 T6 T7 T8 T9
10,T10,"Scope 81 175	asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis"
11,*,OR T1 T2
12,T11,Scope 12 74	respiratory disorders or signs for other respiratory disorders
13,R1,Subsumes Arg1:T11 Arg2:T10
14,T12,Condition 208 228	inflammatory disease
15,T13,Condition 241 245	COPD
16,T14,Condition 252 272	rheumatoid arthritis
17,T15,Condition 277 305	systemic lupus erythematosus
18,*,OR T14 T15
19,T16,Negation 230 240	other than
20,R2,Has_negation Arg1:T13 Arg2:T16
21,T17,Condition 330 359	alpha-1-antitrypsin deficient
22,T18,Procedure 392 404	lung surgery
23,T19,Procedure 411 425	lung resection
24,T20,Procedure 436 465	lung volume reduction surgery
25,T21,Procedure 467 482	lung transplant
26,*,OR T20 T21
27,R4,Subsumes Arg1:T18 Arg2:T19
28,T22,Procedure 510 517	surgery
29,T23,Observation 496 505	scheduled
30,R5,AND Arg1:T23 Arg2:T22
31,T24,Drug 531 554	medication from Visit 1
32,T25,Drug 629 657	monoamine oxidase inhibitors
33,T26,Drug 662 687	tricyclic antidepressants
34,T27,Drug 693 702	ritonavir
35,T28,Drug 720 749	cytochrome P450 3A4 inhibitor
36,*,OR T25 T26 T27
37,R6,Subsumes Arg1:T27 Arg2:T28
38,T29,"Scope 629 750	monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor)"
39,R7,Subsumes Arg1:T24 Arg2:T29
40,T30,Procedure 783 814	prophylactic antibiotic therapy
41,T31,Procedure 772 779;796 814	chronic antibiotic therapy
42,*,OR T31 T30
43,T32,Condition 826 846	uncontrolled disease
44,T33,Condition 866 889	psychological disorders
45,R8,Subsumes Arg1:T32 Arg2:T33
46,T34,Condition 1010 1017;1035 1040	alcohol abuse
47,T35,Condition 1019 1023;1035 1040	drug abuse
48,T36,Condition 1027 1040	solvent abuse
49,*,OR T34 T35 T36
50,T37,Condition 1113 1129	drug sensitivity
51,T38,Condition 1156 1173	allergic reaction
52,T39,Drug 1177 1192	corticosteroids
53,T40,Drug 1196 1206	salmeterol
54,T41,Scope 1177 1206	corticosteroids or salmeterol
55,*,OR T39 T40
56,*,OR T37 T38
57,T42,Scope 1113 1173	drug sensitivity or clinically significant allergic reaction
58,R9,Has_scope Arg1:T42 Arg2:T41
59,T43,Condition 1228 1245	COPD exacerbation
60,T44,Qualifier 1221 1227	severe
61,T45,Qualifier 1209 1217	Moderate
62,*,OR T45 T44
63,T46,Scope 1209 1227	Moderate or severe
64,R10,Has_scope Arg1:T43 Arg2:T46
65,T47,Drug 1257 1272	corticosteroids
66,T48,Drug 1296 1311	corticosteroids
67,T49,Qualifier 1276 1292	increased dosage
68,R11,Has_qualifier Arg1:T48 Arg2:T49
69,R12,AND Arg1:T48 Arg2:T47
70,T50,Drug 1319 1330	antibiotics
71,T51,Visit 1334 1349	hospitalization
72,*,OR T48 T50 T51
73,T52,Scope 1257 1349	corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization
74,R13,Has_scope Arg1:T43 Arg2:T52
75,T53,Temporal 1351 1386	within the 4 weeks prior to Visit 1
76,T54,Condition 1388 1421	Lower respiratory tract infection
77,T55,Temporal 1422 1457	within the 4 weeks prior to Visit 1
78,T56,Condition 1461 1469	Pregnant
79,T57,Condition 1473 1482	lactating
80,*,OR T56 T57 T59
81,T58,Person 1483 1489	female
82,T59,Condition 1504 1526	childbearing potential
83,T60,Person 1494 1500	female
84,R14,AND Arg1:T12 Arg2:T13
85,T61,Scope 252 305	rheumatoid arthritis and systemic lupus erythematosus
86,T62,"Scope 208 245	inflammatory disease, other than COPD"
87,R15,Subsumes Arg1:T62 Arg2:T61
88,T63,"Scope 436 482	lung volume reduction surgery, lung transplant"
89,R3,Subsumes Arg1:T19 Arg2:T63
90,*,OR T18 T22
91,R16,Has_temporal Arg1:T43 Arg2:T53
92,T64,Reference_point 1379 1386	Visit 1
93,R17,Has_index Arg1:T53 Arg2:T64
94,T65,Reference_point 1450 1457	Visit 1
95,R18,Has_index Arg1:T55 Arg2:T65
96,R19,Has_temporal Arg1:T54 Arg2:T55
97,T66,"Non-representable 1529 1764	Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK)."
98,T67,Observation 1774 1819	participated in an investigational drug study
99,T68,Temporal 1820 1851	within 30 days prior to Visit 1
100,T69,Reference_point 1844 1851	Visit 1
101,R20,Has_index Arg1:T68 Arg2:T69
102,R21,Has_temporal Arg1:T67 Arg2:T68
103,T70,Qualifier 196 207	significant
104,R22,Has_qualifier Arg1:T62 Arg2:T70
105,T71,Qualifier 321 329	severely
106,R23,Has_qualifier Arg1:T17 Arg2:T71
107,T72,Observation 1043 1053	History of
108,T73,Condition 1054 1064	depression
109,R24,Has_temporal Arg1:T73 Arg2:T72
110,T74,Non-representable 962 996	in the opinion of the investigator
111,T75,"Scope 1010 1040	alcohol, drug or solvent abuse"
112,R25,AND Arg1:T75 Arg2:T74
0,T1,Person 0 14	Perimenopausal
1,T2,Person 15 20	women
2,T3,Condition 36 61	abnormal uterine bleeding
3,T4,Condition 63 74	menorrhagia
4,T5,Condition 76 88	metrorrhagia
5,T6,Condition 90 104	polymenorrhoea
6,T7,Condition 108 123	polymenorrhagia
7,*,OR T6 T7 T5 T4
8,T8,"Scope 63 123	menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia"
9,T9,Negation 125 132	without
10,T10,Condition 133 158	local gynecological cause
11,R1,Has_negation Arg1:T10 Arg2:T9
12,R2,Subsumes Arg1:T3 Arg2:T8
13,R3,AND Arg1:T3 Arg2:T10
14,T11,Procedure 172 189	medical treatment
15,T12,Observation 161 168	Failure
16,R4,Has_context Arg1:T11 Arg2:T12
17,T13,Multiplier 190 211	for at least 3 months
18,R5,Has_multiplier Arg1:T12 Arg2:T13
0,T1,Drug 6 54	adenosine diphosphate (ADP) receptor antagonists
1,T2,Temporal 55 69	within 2 weeks
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Measurement 71 85	Platelet count
4,T4,Value 86 93	<100g/L
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 109 126	bleeding tendency
7,T6,Observation 98 105	history
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Drug 129 136	Aspirin
10,T8,Drug 138 148	ticagrelor
11,T9,Drug 152 163	clopidogrel
12,T10,Condition 164 173	allergies
13,*,OR T8 T9 T7
14,T11,"Scope 129 163	Aspirin, ticagrelor or clopidogrel"
15,R4,Has_scope Arg1:T10 Arg2:T11
16,T12,Condition 183 195	liver injury
17,T13,Qualifier 176 182	Severe
18,R5,Has_qualifier Arg1:T12 Arg2:T13
0,T1,Condition 0 21	Chronic HCV Infection
1,T2,Qualifier 27 37	Genotype 2
2,T3,Qualifier 27 35;41 42	Genotype 3
3,*,OR T2 T3
4,T4,Scope 27 42	Genotype 2 or 3
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Drug 44 54	Amiodarone
7,T6,Temporal 133 179	at least 60 days prior to day 1 of SOF/LDV FDC
8,T7,Reference_point 159 179	day 1 of SOF/LDV FDC
9,R2,Has_index Arg1:T6 Arg2:T7
10,T8,Non-query-able 56 132	Subjects previously treated with amiodarone must have stopped the amiodarone
11,R3,Has_temporal Arg1:T5 Arg2:T6
12,T9,Drug 181 194	Carbamazepine
13,T10,Drug 196 205	phenytoin
14,T11,Drug 207 220	phenobarbital
15,T12,Drug 222 235	oxcarbazepine
16,*,OR T9 T10 T11 T12
17,T13,Drug 237 246	Rifabutin
18,T14,Drug 248 256	rifampin
19,T15,Drug 260 271	rifapentine
20,*,OR T13 T14 T15
21,T16,Non-query-able 273 285	HIV regimens
22,T17,Drug 297 306	tenofovir
23,T18,Drug 310 330	tipranavir/ritonavir
24,*,OR T17 T18
25,T19,Condition 332 347	St. John's wort
26,T20,Drug 349 361	Rosuvastatin
27,T21,"Subjective_judgement 363 529	Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance"
28,T22,Condition 542 564	hepatic encephalopathy
29,T23,Condition 568 587	variceal hemorrhage
30,*,OR T22 T23
31,T24,Measurement 589 616	Hepatitis B surface antigen
32,T25,Value 617 625	positive
33,R4,Has_value Arg1:T24 Arg2:T25
34,T26,Measurement 627 637	Hemoglobin
35,T27,Measurement 639 641	Hb
36,T28,Value 643 651	< 8 g/dL
37,R5,Subsumes Arg1:T26 Arg2:T27
38,R6,Has_value Arg1:T26 Arg2:T28
39,T29,Measurement 653 662	Platelets
40,T30,"Value 663 675	= 50,000/mm3"
41,R7,Has_value Arg1:T29 Arg2:T30
42,T31,Measurement 677 701	alanine aminotransferase
43,T32,Measurement 703 706	ALT
44,T33,Measurement 709 735	aspartase aminotransferase
45,T34,Measurement 737 740	AST
46,T35,Measurement 746 766	alkaline phosphatase
47,T36,Value 767 799	= 10 times upper limit of normal
48,T37,"Scope 677 766	alanine aminotransferase (ALT), aspartase aminotransferase (AST), or alkaline phosphatase"
49,R8,Subsumes Arg1:T31 Arg2:T32
50,R9,Subsumes Arg1:T33 Arg2:T34
51,*,OR T31 T33 T35
52,R10,Has_value Arg1:T37 Arg2:T36
53,T38,Measurement 806 821	Total bilirubin
54,T39,Value 822 831	> 3 mg/dl
55,R11,Has_value Arg1:T38 Arg2:T39
56,T40,Condition 840 856	renal impairment
57,T41,Qualifier 833 839	Severe
58,R12,Has_qualifier Arg1:T40 Arg2:T41
59,T42,Measurement 857 877	creatinine clearance
60,T43,Measurement 879 883	CrCl
61,R13,AND Arg1:T42 Arg2:T43
62,T44,Value 891 902	< 30 mL/min
63,R14,Has_value Arg1:T42 Arg2:T44
64,T45,Condition 916 943	major organ transplantation
65,T46,Qualifier 952 977	existing functional graft
66,R15,Has_qualifier Arg1:T45 Arg2:T46
67,T47,Condition 1014 1026	drug allergy
68,T48,Qualifier 991 1013	clinically-significant
69,R16,Has_qualifier Arg1:T47 Arg2:T48
70,T49,Drug 1030 1040	nucleoside
71,T50,Drug 1041 1059	nucleotide analogs
72,*,OR T49 T50
73,T51,Scope 1030 1059	nucleoside/nucleotide analogs
74,R17,Has_scope Arg1:T47 Arg2:T51
75,T52,Pregnancy_considerations 1062 1113	Pregnant women or women planning to become pregnant
76,T53,Pregnancy_considerations 1115 1142	Women who are breastfeeding
77,T54,Observation 1191 1204	alcohol abuse
78,T55,Observation 1183 1187;1199 1204	drug abuse
79,*,OR T54 T55
80,T56,Temporal 1170 1178	= 1 year
81,T57,Scope 1183 1204	drug or alcohol abuse
82,R18,Has_temporal Arg1:T57 Arg2:T56
0,T1,Value 0 14	Non-reassuring
1,T2,Measurement 15 31	fetal assessment
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Temporal 32 58	at the time of recruitment
4,R2,Has_temporal Arg1:T2 Arg2:T3
5,T4,Temporal 60 68	Previous
6,T5,Drug 69 93	cervical ripening agents
7,R3,Has_temporal Arg1:T5 Arg2:T4
8,T6,Drug 95 102	cytotec
9,T7,Drug 104 112	cervidil
10,T8,Device 114 136	cervical Foley Balloon
11,*,OR T6 T7 T8
12,T9,"Scope 95 136	cytotec, cervidil, cervical Foley Balloon"
13,R4,Subsumes Arg1:T5 Arg2:T9
14,T10,Person 152 155	age
15,T11,Value 139 148	<18 years
16,R5,Has_value Arg1:T10 Arg2:T11
17,T12,Person 157 166	Prisoners
18,T13,Condition 181 196	contraindicated
19,T14,Procedure 201 217	vaginal delivery
20,R6,AND Arg1:T13 Arg2:T14
21,T15,Observation 219 238	Multiple gestations
22,T16,Observation 240 247	History
23,T17,Temporal 251 259	previous
24,T18,Procedure 260 277	cesarean delivery
25,R7,Has_temporal Arg1:T18 Arg2:T17
26,R8,Has_temporal Arg1:T18 Arg2:T16
27,T19,Observation 293 300	history
28,T20,Qualifier 304 315	significant
29,T21,Condition 316 331	cardiac disease
30,R9,Has_qualifier Arg1:T21 Arg2:T20
31,R10,Has_temporal Arg1:T21 Arg2:T19
32,T22,Condition 333 345	Fetal demise
33,T23,Measurement 347 369	Estimated fetal weight
34,T24,Value 370 393	greater than 4500 grams
35,T25,Condition 397 405	diabetic
36,T26,Value 410 420	5000 grams
37,T27,Negation 424 428	non-
38,T28,Condition 428 436	diabetic
39,R11,Has_negation Arg1:T28 Arg2:T27
40,T29,Scope 424 436	non-diabetic
41,A1,Optional T29
42,A2,Optional T25
43,R12,Has_value Arg1:T25 Arg2:T24
44,R13,Has_value Arg1:T28 Arg2:T26
45,T30,Scope 370 436	greater than 4500 grams in diabetic and 5000 grams in non-diabetic
46,R14,Has_scope Arg1:T23 Arg2:T30
47,T31,Condition 445 463	Ruptured membranes
48,T32,Condition 465 482	Spontaneous labor
49,T33,Qualifier 484 490;501 506	latent phase
50,T34,Qualifier 494 506	active phase
51,*,OR T34 T33
52,T35,Scope 484 506	latent or active phase
53,R15,Has_scope Arg1:T32 Arg2:T35
54,T36,Condition 509 530	Augmentation of labor
55,T37,Qualifier 532 538;549 554	latent phase
56,T38,Qualifier 542 554	active phase
57,*,OR T38 T37
58,T39,Scope 532 554	latent or active phase
59,R16,Has_scope Arg1:T36 Arg2:T39
0,T1,Person 0 4	Male
1,T2,Measurement 10 20	ASA status
2,T3,Value 21 28	I or II
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 30 33	BMI
5,T5,Value 34 57	between 20 and 34 kg/m2
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Procedure 89 111	reconstructive surgery
8,T7,Qualifier 59 88	Cruciate ligament of the knee
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Condition 116 133	contraindications
11,T9,Procedure 149 168	regional anesthesia
12,T10,Procedure 137 144;158 168	general anesthesia
13,T11,Negation 113 115	No
14,T12,Scope 137 168	general and regional anesthesia
15,R4,Has_scope Arg1:T8 Arg2:T12
16,R5,Has_negation Arg1:T8 Arg2:T11
0,T1,Condition 33 37	COPD
1,T2,Measurement 51 127	American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Value 160 170	>=40 years
4,T4,Person 155 159	aged
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Person 130 134	Male
7,T6,Person 138 144	female
8,*,OR T5 T6
9,T7,Person 172 179	Females
10,A1,Optional T7
11,T8,Condition 195 218	Child Bearing Potential
12,T9,Negation 191 194	Non
13,R3,Has_negation Arg1:T8 Arg2:T9
14,R4,AND Arg1:T7 Arg2:T8
15,T10,Condition 242 265	Child Bearing Potential
16,T11,Negation 238 241	Non
17,R5,Has_negation Arg1:T10 Arg2:T11
18,T12,Person 283 290	Females
19,T13,Condition 322 341	functioning ovaries
20,T14,Condition 376 390	tubal ligation
21,T15,Condition 394 406	hysterectomy
22,T17,Condition 427 442	post-menopausal
23,T16,Person 411 418	females
24,*,OR T14 T15
25,T18,"Scope 283 406	Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy"
26,T19,Scope 411 442	females who are post-menopausal
27,*,OR T18 T19
28,T20,"Scope 283 442	Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy, or females who are post-menopausal"
29,T21,Scope 238 265	Non Child Bearing Potential
30,R6,Subsumes Arg1:T21 Arg2:T20
31,T22,Condition 460 464	COPD
32,T23,Value 465 480	stage III or IV
33,T24,Measurement 494 507	GOLD criteria
34,R7,Has_value Arg1:T24 Arg2:T23
35,R8,AND Arg1:T22 Arg2:T24
36,T25,"Measurement 540 593	Forced Expiratory Volume, measured at 1 second (FEV1)"
37,T26,Value 594 618	<50% of predicted normal
38,R9,Has_value Arg1:T25 Arg2:T26
39,T27,Temporal 520 539	post-bronchodilator
40,R10,Has_temporal Arg1:T25 Arg2:T27
41,T28,Temporal 634 654	post- bronchodilator
42,T29,Measurement 655 698	FEV1/Inspiratory Vital Capacity (IVC) ratio
43,T30,Value 699 703	<70%
44,R11,Has_value Arg1:T29 Arg2:T30
45,R12,Has_temporal Arg1:T29 Arg2:T28
46,T31,Multiplier 723 733	at least 2
47,T32,Qualifier 746 752	severe
48,T33,Qualifier 734 742	moderate
49,*,OR T33 T32
50,T34,Condition 753 771	COPD exacerbations
51,T35,Scope 734 752	moderate or severe
52,R13,Has_scope Arg1:T34 Arg2:T35
53,R14,Has_multiplier Arg1:T34 Arg2:T31
54,T36,Drug 815 835	oral corticosteroids
55,T37,Drug 860 880	oral corticosteroids
56,T38,Qualifier 839 856	increasing dosage
57,R15,Has_qualifier Arg1:T37 Arg2:T38
58,T39,Drug 888 899	antibiotics
59,T40,Visit 903 918	hospitalization
60,*,OR T39 T40 T37 T36
61,T41,Temporal 920 958	within the 12 months preceding Visit 1
62,T42,Scope 815 918	oral corticosteroids or increasing dosage of oral corticosteroids and/or antibiotics or hospitalization
63,R16,Has_scope Arg1:T34 Arg2:T42
64,R17,Has_temporal Arg1:T34 Arg2:T41
65,T43,Drug 973 988	COPD medication
66,T44,Temporal 989 1020	within 4 weeks prior to Visit 1
67,R18,Has_temporal Arg1:T43 Arg2:T44
68,T45,Qualifier 966 972	stable
69,R19,Has_qualifier Arg1:T43 Arg2:T45
70,T46,Condition 1099 1106	smokers
71,T47,Measurement 1114 1129	smoking history
72,T48,Value 1142 1155	10 pack years
73,R20,Has_value Arg1:T47 Arg2:T48
74,T49,"Scope 1157 1321	number of pack years = [number of cigarettes per day / 20] x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years"
75,R21,Subsumes Arg1:T48 Arg2:T49
76,T52,Temporal 1085 1092	Current
77,T53,Negation 1096 1098	ex
78,*,OR T52 T53
79,T54,Scope 1085 1098	Current or ex
80,R22,Has_scope Arg1:T46 Arg2:T54
81,T55,Observation 1339 1354	managed at home
82,T56,Visit 1347 1354	at home
83,T57,Procedure 1339 1346	managed
84,R23,AND Arg1:T57 Arg2:T56
85,R24,multi Arg1:T55 Arg2:T57
86,T58,Observation 1356 1367	outpatients
87,T59,Visit 1356 1367	outpatients
88,R25,multi Arg1:T58 Arg2:T59
89,R26,Subsumes Arg1:T55 Arg2:T58
90,T51,Condition 1374 1384	ambulatory
91,T60,Observation 1389 1417	able to travel to the clinic
92,T61,Observation 1823 1847	written informed consent
93,T62,Temporal 1860 1882	prior to participation
94,R27,Has_temporal Arg1:T61 Arg2:T62
95,T50,Observation 1885 1937	Able to comply with the requirements of the protocol
96,T63,Observation 1945 1971	available for study visits
97,T64,Visit 1959 1971	study visits
98,R28,multi Arg1:T63 Arg2:T64
99,T65,Temporal 1972 1985	over 52 weeks
100,R29,Has_temporal Arg1:T63 Arg2:T65
101,T66,Drug 1461 1476	COPD medication
102,T67,Drug 1492 1500	vaccines
103,T68,Drug 1502 1538	inhaled short-acting beta-2-agonists
104,T69,Drug 1550 1562	short-acting
105,T70,Drug 1566 1594	long-acting anticholinergics
106,T71,Drug 1596 1606	tiotropium
107,R30,Subsumes Arg1:T70 Arg2:T71
108,T72,Drug 1609 1633	systemic beta-2-agonists
109,T73,Drug 1635 1647	theophylline
110,T74,Drug 1649 1659	mucolytics
111,T75,Drug 1661 1673	antioxidants
112,T76,Drug 1675 1690	beta-1-agonists
113,T78,Condition 1696 1721	cardiovascular indication
114,T77,Condition 1724 1748	non-invasive ventilation
115,R31,AND Arg1:T76 Arg2:T78
116,R32,Subsumes Arg1:T77 Arg2:T76
117,T79,Multiplier 1750 1759	long term
118,T80,Procedure 1760 1774	oxygen therapy
119,T81,Drug 1760 1766	oxygen
120,R33,multi Arg1:T80 Arg2:T81
121,T82,Condition 1788 1801	Cor Pulmonale
122,A3,Optional T82
123,*,OR T66 T67 T68 T69 T70 T72 T73 T74 T75
124,T83,"Scope 1461 1673	COPD medication. This includes vaccines, inhaled short-acting beta-2-agonists as needed, short-acting or long-acting anticholinergics (tiotropium), systemic beta-2-agonists, theophylline, mucolytics, antioxidants"
125,A2,Optional T83
126,A4,Optional T77
127,A5,Optional T76
128,A6,Optional T78
129,R34,Has_multiplier Arg1:T80 Arg2:T79
130,A7,Optional T80
131,*,OR T80 T82 T77
0,T1,Multiplier 6 15	half-dose
1,T2,Drug 16 26	ticagrelor
2,T3,Measurement 28 40	loading dose
3,T4,Value 41 45	90mg
4,T5,Multiplier 56 67	45mg bidpo.
5,R1,Has_value Arg1:T3 Arg2:T4
6,T6,"Scope 28 67	loading dose 90mg, and then 45mg bidpo."
7,R2,Subsumes Arg1:T1 Arg2:T6
8,R3,Has_multiplier Arg1:T2 Arg2:T1
9,T7,Temporal 69 89	treatment for 3 days
10,R4,Has_temporal Arg1:T2 Arg2:T7
11,T8,Measurement 95 115	platelet aggregation
12,T9,Value 131 140	inhibited
13,R5,Has_value Arg1:T8 Arg2:T9
14,T10,Qualifier 119 130	effectively
15,R6,Has_qualifier Arg1:T9 Arg2:T10
16,T11,Procedure 144 175	light transmission aggregometry
17,T12,Procedure 187 205	thromboela-stogram
18,T13,Scope 144 205	light transmission aggregometry method and thromboela-stogram
19,R7,Has_scope Arg1:T8 Arg2:T13
20,T14,Mood 208 226	planned to undergo
21,T15,Procedure 227 230	PCI
22,T16,Temporal 231 239	recently
23,R8,Has_mood Arg1:T15 Arg2:T14
24,T17,Scope 208 230	planned to undergo PCI
25,R9,Has_temporal Arg1:T17 Arg2:T16
26,T18,Mood 241 251	planned to
27,T19,Procedure 252 256	DAPT
28,T20,Multiplier 257 267	for 1 year
29,T21,Temporal 268 277	after PCI
30,T22,Procedure 274 277	PCI
31,T23,Reference_point 274 277	PCI
32,R10,Has_index Arg1:T21 Arg2:T23
33,R11,multi Arg1:T23 Arg2:T22
34,R12,Has_multiplier Arg1:T19 Arg2:T20
35,R13,Has_temporal Arg1:T19 Arg2:T21
36,R14,Has_mood Arg1:T19 Arg2:T18
0,T1,Person 0 3	Age
1,T2,Value 4 22	< 45 or > 55 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 25 40	Blood disorders
4,T4,Condition 44 56	coagulopathy
5,*,OR T3 T4
6,T5,Condition 82 106	local gynecologic lesion
7,T6,Mood 59 68	Diagnosed
8,T7,Mood 72 81	suspected
9,*,OR T6 T7
10,T8,Scope 59 81	Diagnosed or suspected
11,R2,Has_scope Arg1:T5 Arg2:T8
12,T9,Condition 108 113	polyp
13,T10,Condition 115 126	adenomyosis
14,T11,Condition 128 133	myoma
15,T12,Condition 135 145	malignancy
16,T13,Condition 149 167	cervical pathology
17,*,OR T13 T12 T11 T10 T9
18,T14,"Scope 108 167	polyp, adenomyosis, myoma, malignancy or cervical pathology"
19,R3,Subsumes Arg1:T5 Arg2:T14
20,T15,Device 175 208	intrauterine contraceptive device
21,T16,Condition 211 220	Pregnancy
22,T17,Condition 229 239	conditions
23,T18,Qualifier 211 228	Pregnancy related
24,R4,multi Arg1:T18 Arg2:T16
25,R5,Has_qualifier Arg1:T17 Arg2:T18
0,T1,Condition 0 21	Chronic HCV Infection
1,T2,Qualifier 25 33;34 35	Genotype 1
2,T3,Qualifier 25 33;37 38	Genotype 4
3,T4,Qualifier 25 33;40 41	Genotype 5
4,T5,Qualifier 25 33;46 47	Genotype 6
5,*,OR T5 T4 T3 T2
6,T6,"Scope 25 47	Genotype 1, 4, 5, or 6"
7,R1,Has_scope Arg1:T1 Arg2:T6
8,T7,Measurement 49 56	HCV RNA
9,T8,Value 57 68	> 103 IU/mL
10,T9,Temporal 69 81	at screening
11,R2,Has_value Arg1:T7 Arg2:T8
12,R3,Has_temporal Arg1:T7 Arg2:T9
13,T10,Reference_point 72 81	screening
14,R4,Has_index Arg1:T9 Arg2:T10
15,T11,Person 95 98	age
16,T12,Value 102 107;83 91	older 18 years
17,R5,Has_value Arg1:T11 Arg2:T12
18,T13,Condition 122 143	chronic HCV infection
19,T14,Measurement 165 177	HCV antibody
20,T15,Value 156 164	positive
21,T16,Measurement 181 188	HCV RNA
22,T17,Temporal 189 226	more than 6 months prior to screening
23,T18,Reference_point 217 226	screening
24,T19,Measurement 233 255	assessment of fibrosis
25,T20,Value 256 269	F2 or greater
26,T21,Temporal 270 288	prior to screening
27,T22,Reference_point 279 288	screening
28,R6,Has_index Arg1:T21 Arg2:T22
29,R7,Has_value Arg1:T19 Arg2:T20
30,R8,Has_temporal Arg1:T19 Arg2:T21
31,R9,Has_index Arg1:T17 Arg2:T18
32,R10,Has_temporal Arg1:T16 Arg2:T17
33,R11,Has_value Arg1:T14 Arg2:T15
34,R12,Has_temporal Arg1:T14 Arg2:T17
35,*,OR T14 T16
36,T23,Scope 156 226	positive HCV antibody or HCV RNA more than 6 months prior to screening
37,*,OR T23 T19
38,T24,Measurement 291 295	NYHA
39,T25,Value 296 305	Class III
40,R13,Has_value Arg1:T24 Arg2:T25
41,T26,"Non-query-able 307 511	Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain."
42,T27,"Non-query-able 528 788	Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased."
43,T28,Measurement 513 517	NYHA
44,T29,Value 518 526	Class IV
45,R14,Has_value Arg1:T28 Arg2:T29
46,T30,Measurement 790 807	ejection fraction
47,T31,Value 808 813	= 30%
48,R15,Has_value Arg1:T30 Arg2:T31
49,T32,Observation 815 827	hospitalized
50,T33,Condition 832 845	heart failure
51,T34,Temporal 846 863	in last 12 months
52,R16,AND Arg1:T32 Arg2:T33
53,R17,Has_temporal Arg1:T32 Arg2:T34
54,T35,Measurement 865 877	ILD criteria
55,T36,Condition 892 917	interstitial lung disease
56,T37,Observation 923 962	chronic supplemental oxygen requirement
57,T38,Qualifier 963 970	at rest
58,T39,Qualifier 978 991	with exertion
59,*,OR T38 T39
60,T40,Parsing_Error 971 977	and/or
61,T41,Scope 963 991	at rest and/or with exertion
62,R18,Has_scope Arg1:T37 Arg2:T41
63,T42,Measurement 994 1018	Forced expiratory volume
64,T43,Measurement 1020 1024	FEV1
65,R19,Subsumes Arg1:T42 Arg2:T43
66,T44,Value 1025 1040	< 30% predicted
67,R20,Has_value Arg1:T42 Arg2:T44
68,T45,Non-query-able 1042 1053	OR any FEV1
69,T46,Observation 1059 1098	chronic supplemental oxygen requirement
70,T47,Qualifier 1099 1106	at rest
71,T48,Qualifier 1114 1127	with exertion
72,T49,Parsing_Error 1107 1113	and/or
73,*,OR T47 T48
74,T50,Scope 1099 1127	at rest and/or with exertion
75,R21,Has_scope Arg1:T46 Arg2:T50
76,T51,Non-query-able 1129 1140	OR any FEV1
77,T52,Condition 1146 1165	chronic hypercapnia
78,T53,Measurement 1176 1219	partial pressure of arterial carbon dioxide
79,T54,Measurement 1221 1226	PaCO2
80,R22,Subsumes Arg1:T53 Arg2:T54
81,T55,Value 1228 1232	> 45
82,R23,Has_value Arg1:T53 Arg2:T55
0,T1,Value 8 26	18 years and older
1,T2,Person 3 6	Age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Person 37 41	Male
4,T4,Condition 50 58	pregnant
5,T5,Negation 46 49	non
6,T6,Negation 60 63	non
7,T7,Condition 64 73	lactating
8,T8,Person 74 80	female
9,R2,Has_negation Arg1:T7 Arg2:T6
10,R3,Has_negation Arg1:T4 Arg2:T5
11,T9,"Scope 46 73	non-pregnant, non-lactating"
12,A1,Optional T8
13,R4,Has_scope Arg1:T8 Arg2:T9
14,*,OR T8 T3
15,T14,Measurement 1417 1423	Weight
16,T15,Value 1425 1439	At least 60 kg
17,T16,Value 1425 1433;1441 1448	At least 132 lbs
18,R5,Subsumes Arg1:T15 Arg2:T16
19,T17,Person 1454 1457	man
20,T18,Value 1425 1433;1462 1467	At least 48 kg
21,T19,Value 1425 1433;1469 1476	At least 106 lbs
22,R6,Subsumes Arg1:T18 Arg2:T19
23,T20,Person 1482 1487	women
24,A2,Optional T20
25,A3,Optional T17
26,R7,Has_value Arg1:T17 Arg2:T15
27,R8,Has_value Arg1:T20 Arg2:T18
28,*,OR T20 T17
29,T21,Scope 1425 1487	At least 60 kg (132 lbs) for man and 48 kg (106 lbs) for women
30,R9,Has_scope Arg1:T14 Arg2:T21
31,T22,Value 1492 1529	within 15% of Ideal Body Weight (IBW)
32,R10,Has_value Arg1:T14 Arg2:T22
33,T10,Person 85 90	Women
34,T11,Condition 94 116	childbearing potential
35,T12,Value 127 135	negative
36,T13,Procedure 136 141;153 168	serum pregnancy tests
37,T23,Procedure 143 151	Beta HCG
38,R11,Subsumes Arg1:T13 Arg2:T23
39,R12,Has_value Arg1:T13 Arg2:T12
40,T24,Temporal 179 225	within 14 days prior to the start of the study
41,T25,Reference_point 203 225	the start of the study
42,R13,Has_index Arg1:T24 Arg2:T25
43,R14,Has_temporal Arg1:T13 Arg2:T24
44,T26,Temporal 230 278	on the evening prior to each dose administration
45,T27,Reference_point 254 278	each dose administration
46,R15,Has_index Arg1:T26 Arg2:T27
47,R16,Has_temporal Arg1:T13 Arg2:T26
48,T28,Scope 85 116	Women of childbearing potential
49,A4,Optional T28
50,T29,Scope 127 278	negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration
51,R17,Has_scope Arg1:T28 Arg2:T29
52,T30,Person 515 520	Women
53,T31,Condition 524 546	childbearing potential
54,T32,Procedure 561 571	abstinence
55,T33,Qualifier 587 602	acceptable form
56,T34,Procedure 606 619	contraception
57,T35,Temporal 620 656	throughout the duration of the study
58,R18,Has_qualifier Arg1:T34 Arg2:T33
59,*,OR T34 T32
60,T36,Scope 561 619	abstinence or be using an acceptable form of contraception
61,R19,Has_temporal Arg1:T36 Arg2:T35
62,T37,Scope 515 546	Women of childbearing potential
63,A5,Optional T37
64,R20,Has_scope Arg1:T37 Arg2:T36
65,T38,Device 720 739	intrauterine device
66,T39,Temporal 749 802	for at least 3 months prior to the start of the study
67,T40,Reference_point 780 802	the start of the study
68,R21,Has_index Arg1:T39 Arg2:T40
69,T41,Temporal 817 849	in place during the study period
70,T42,Reference_point 833 849	the study period
71,R22,Has_index Arg1:T41 Arg2:T42
72,R23,Has_temporal Arg1:T38 Arg2:T39
73,R24,Has_temporal Arg1:T38 Arg2:T41
74,T43,Procedure 858 873	barrier methods
75,T44,Drug 915 932	spermicidal agent
76,T45,Scope 858 932	barrier methods containing or used in conjunction with a spermicidal agent
77,T46,Condition 941 955	postmenopausal
78,T47,Temporal 1011 1028	at least one year
79,T48,Condition 1032 1050	surgical sterility
80,R25,Has_temporal Arg1:T46 Arg2:T47
81,T49,Procedure 1052 1066	tubal ligation
82,T50,Procedure 1068 1080	oophorectomy
83,T51,Procedure 1084 1096	hysterectomy
84,*,OR T50 T51 T49
85,T52,"Scope 1052 1096	tubal ligation, oophorectomy or hysterectomy"
86,R26,Subsumes Arg1:T48 Arg2:T52
87,T53,"Scope 1032 1097	surgical sterility (tubal ligation, oophorectomy or hysterectomy)"
88,*,OR T46 T53 T45 T38
89,T54,Person 1202 1207	women
90,T55,Condition 1211 1233	childbearing potential
91,T56,Procedure 1245 1298	spermicide containing barrier method of contraception
92,T57,Multiplier 1299 1313	in addition to
93,T58,Temporal 1320 1327	current
94,T59,Device 1328 1348	contraceptive device
95,R27,Has_temporal Arg1:T59 Arg2:T58
96,R28,Has_multiplier Arg1:T56 Arg2:T57
97,T60,Scope 1202 1233	women of childbearing potential
98,A6,Optional T60
99,T61,Scope 1245 1348	spermicide containing barrier method of contraception in addition to their current contraceptive device
100,R29,Has_scope Arg1:T60 Arg2:T61
101,T62,Temporal 1103 1133	During the course of the study
102,R30,Has_temporal Arg1:T61 Arg2:T62
103,T63,Condition 1735 1741	normal
104,T64,Condition 1746 1753	healthy
105,T65,Procedure 1763 1791	pre-study medical evaluation
106,T66,Scope 1735 1753	normal and healthy
107,R31,Has_scope Arg1:T65 Arg2:T66
108,T67,Procedure 1793 1813	physical examination
109,T68,Procedure 1815 1836	laboratory evaluation
110,T69,Procedure 1838 1849	12-lead ECG
111,T70,Procedure 1851 1862;1879 1884	hepatitis B tests
112,T71,Procedure 1867 1884	hepatitis C tests
113,T72,Procedure 1886 1894	HIV test
114,T73,Procedure 1900 1917	urine drug screen
115,T74,Qualifier 1928 1939	amphetamine
116,T75,Qualifier 1941 1953	barbiturates
117,T76,Qualifier 1955 1969	benzodiazepine
118,T77,Qualifier 1971 1982	cannabinoid
119,T78,Qualifier 1984 1991	cocaine
120,T79,Qualifier 1993 2000	opiates
121,T80,Qualifier 2002 2015	phencyclidine
122,T81,Qualifier 2021 2030	methadone
123,T82,"Scope 1928 2030	amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone"
124,R32,Has_scope Arg1:T73 Arg2:T82
125,T83,"Scope 1793 2030	physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C tests, HIV test, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone"
126,T84,Temporal 2042 2096	within 14 days of the initial dose of study medication
127,T85,Reference_point 2060 2096	the initial dose of study medication
128,R33,Has_index Arg1:T84 Arg2:T85
129,R34,Subsumes Arg1:T65 Arg2:T83
130,R35,Has_temporal Arg1:T65 Arg2:T84
0,T1,Condition 138 141	HIV
1,T2,Condition 143 147	AIDS
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Condition 108 116	Pregnant
4,T4,Condition 121 130	lactating
5,T5,Person 131 136	women
6,*,OR T3 T4
7,T6,Condition 0 17	Systemic diseases
8,T7,Procedure 149 170	periodontal treatment
9,T8,Temporal 171 187	in the last year
10,T9,Temporal 189 216	before baseline appointment
11,T10,Procedure 196 216	baseline appointment
12,T11,Reference_point 196 216	baseline appointment
13,R2,multi Arg1:T11 Arg2:T10
14,R3,Has_index Arg1:T9 Arg2:T11
15,R4,Has_temporal Arg1:T7 Arg2:T8
16,R5,Has_temporal Arg1:T7 Arg2:T9
17,T12,Drug 231 254	Immunosuppressive drugs
18,T13,Drug 256 267	antibiotics
19,T14,Temporal 268 292	in the past three months
20,*,OR T12 T13
21,T15,"Scope 231 267	Immunosuppressive drugs, antibiotics"
22,R6,Has_temporal Arg1:T15 Arg2:T14
23,T16,Temporal 294 321	before baseline appointment
24,T17,Procedure 301 321	baseline appointment
25,T18,Reference_point 301 321	baseline appointment
26,R7,Has_index Arg1:T16 Arg2:T18
27,R8,multi Arg1:T18 Arg2:T17
28,R9,Has_temporal Arg1:T15 Arg2:T16
29,T19,Device 326 347	orthodontic appliance
0,T1,Observation 0 17	Optune compliance
1,T2,Multiplier 18 23	< 75%
2,R1,Has_multiplier Arg1:T1 Arg2:T2
3,T3,Non-query-able 25 71	they would be excluded from the final analyses
4,T4,Procedure 85 96	craniectomy
5,T5,Condition 112 124	skull defect
6,T6,Qualifier 100 111	significant
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,*,OR T4 T5
9,T7,Device 146 152	Optune
10,T8,Condition 126 142	contraindication
11,R3,AND Arg1:T8 Arg2:T7
12,T9,Device 163 189	implantable medical device
13,T10,Device 196 199	DBS
14,T11,Device 201 223	spinal cord stimulator
15,T12,Device 225 234	pacemaker
16,T13,Device 236 249	defibrillator
17,T14,Device 251 273	vagus nerve stimulator
18,T15,Device 275 293	programmable shunt
19,*,OR T10 T11 T12 T13 T14 T15
20,T16,"Scope 196 293	DBS, spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt"
21,R4,Subsumes Arg1:T9 Arg2:T16
22,T17,Qualifier 156 162	Active
23,R5,Has_qualifier Arg1:T9 Arg2:T17
24,T18,Measurement 297 325	Karnofsky Performance Status
25,T19,Measurement 327 330	KPS
26,T20,Value 332 336	< 60
27,R6,Subsumes Arg1:T18 Arg2:T19
28,R7,Has_value Arg1:T18 Arg2:T20
0,T1,Measurement 0 18	ASA classification
1,T2,Value 19 28	II or III
2,T3,Person 29 36	females
3,R1,Has_value Arg1:T1 Arg2:T2
4,T4,Person 38 41	Age
5,T5,Value 43 58	18-45 years old
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 60 63	BMI
8,T7,Value 64 74	= 50 kg/m2
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Condition 76 95	Singleton pregnancy
11,T9,Qualifier 104 116	prophylactic
12,T10,Qualifier 97 103	Simple
13,T11,Procedure 117 134	cervical cerclage
14,R4,Has_qualifier Arg1:T11 Arg2:T9
15,R5,Has_qualifier Arg1:T11 Arg2:T10
16,T12,Procedure 145 165	neuraxial anesthesia
17,T13,Mood 136 144	Planning
18,R6,Has_mood Arg1:T12 Arg2:T13
0,T1,Qualifier 0 20	Moderate to advanced
1,T2,Condition 21 54	generalized chronic periodontitis
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Measurement 56 71	Body mass index
4,T4,Value 73 85	> 18.5 kg/m2
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Multiplier 87 100	Minimum of 12
7,T6,Observation 101 114	natural teeth
8,R3,Has_multiplier Arg1:T6 Arg2:T5
9,T7,Condition 116 123	Smokers
10,T8,Condition 125 136	non-smokers
11,T9,Condition 140 154	former-smokers
12,*,OR T8 T9 T7
0,T1,Parsing_Error 0 2	1.
1,T2,Non-query-able 3 47	Institutionalized subjects will not be used.
2,T3,Parsing_Error 66 68	1.
3,T4,Parsing_Error 48 64	2 Social Habits:
4,T5,Drug 80 96	tobacco products
5,T6,"Not_a_criteria 102 246	Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication."
6,T7,Parsing_Error 99 101	2.
7,T8,Not_a_criteria 251 366	Ingestion of any vitamins or herbal products within the 48 hours prior to the initial dose of the study medication.
8,T9,"Non-query-able 371 432	Any recent, significant change in dietary or exercise habits."
9,T10,Context_Error 437 498	Positive test for any drug included in the urine drug screen.
10,T11,Parsing_Error 248 250	3.
11,T12,Parsing_Error 368 370	4.
12,T13,Parsing_Error 434 436	5.
13,T14,Parsing_Error 500 502	3.
14,T15,Parsing_Error 517 519	1.
15,T16,Parsing_Error 609 611	2.
16,T17,Drug 531 541	medication
17,T18,Temporal 542 566	within the 14 days prior
18,T19,Reference_point 570 606	the initial dose of study medication
19,R1,Has_index Arg1:T18 Arg2:T19
20,R2,Has_temporal Arg1:T17 Arg2:T18
21,T20,Drug 623 672	medication known to alter hepatic enzyme activity
22,T21,Temporal 673 693	within 28 days prior
23,T22,Reference_point 697 733	the initial dose of study medication
24,R3,Has_index Arg1:T21 Arg2:T22
25,R4,Has_temporal Arg1:T20 Arg2:T21
26,T23,Parsing_Error 736 738	3.
27,T24,Drug 746 769	hormonal contraceptives
28,T25,Drug 774 802	hormonal replacement therapy
29,T26,Temporal 803 828	within three months prior
30,T27,Reference_point 832 868	the initial dose of study medication
31,R5,Has_index Arg1:T26 Arg2:T27
32,R6,Has_temporal Arg1:T25 Arg2:T26
33,R7,Has_temporal Arg1:T24 Arg2:T26
34,T28,Parsing_Error 871 873	4.
35,T29,Parsing_Error 874 883	Diseases:
36,T30,Parsing_Error 885 887	a.
37,T31,Observation 888 895	History
38,T32,Condition 915 930	chronic disease
39,T33,Condition 938 947	hepatitis
40,T34,Qualifier 903 914	significant
41,T35,Subjective_judgement 903 914	significant
42,R8,Has_qualifier Arg1:T32 Arg2:T34
43,R9,Has_qualifier Arg1:T33 Arg2:T34
44,*,OR T32 T33
45,T36,Scope 903 947	significant chronic disease and/or hepatitis
46,R10,Has_temporal Arg1:T36 Arg2:T31
47,T37,Condition 963 967;983 988	drug abuse
48,T38,Condition 975 988	alcohol abuse
49,*,OR T38 T37
50,T39,Observation 952 959	History
51,R11,Has_temporal Arg1:T38 Arg2:T39
52,R12,Has_temporal Arg1:T37 Arg2:T39
53,T40,Undefined_semantics 993 1071	Acute illness at the time of either the prestudy medical evaluation or dosing.
54,T41,Measurement 1085 1088;1118 1122	HIV test
55,T42,Measurement 1090 1101;1118 1122	Hepatitis B test
56,T43,Measurement 1106 1122	Hepatitis C test
57,T44,"Scope 1085 1122	HIV, Hepatitis B, or Hepatitis C test"
58,T45,Value 1076 1084	Positive
59,R13,Has_value Arg1:T44 Arg2:T45
60,*,OR T41 T42 T43
61,T46,Parsing_Error 949 951	b.
62,T47,Parsing_Error 990 992	c.
63,T48,Parsing_Error 1073 1075	d.
64,T49,Parsing_Error 1124 1126	e.
65,T50,Condition 1127 1140	Renal disease
66,T51,Condition 1144 1161	renal dysfunction
67,T52,Measurement 1179 1202	serum creatinine levels
68,T53,Value 1203 1237	greater than or equal to 1.5 mg/dL
69,T54,Person 1243 1248	males
70,A1,Optional T54
71,T55,Person 1294 1301	females
72,A2,Optional T55
73,T56,Value 1254 1288	greater than or equal to 1.4 mg/dL
74,R14,Has_value Arg1:T55 Arg2:T56
75,R15,Has_value Arg1:T54 Arg2:T53
76,*,OR T54 T55
77,T57,Condition 1306 1335	abnormal creatinine clearance
78,T58,Scope 1203 1302	greater than or equal to 1.5 mg/dL (for males) and greater than or equal to 1.4 mg/dL (for females)
79,R16,Has_scope Arg1:T52 Arg2:T58
80,*,OR T52 T57
81,T59,Scope 1179 1335	serum creatinine levels greater than or equal to 1.5 mg/dL (for males) and greater than or equal to 1.4 mg/dL (for females) or abnormal creatinine clearance
82,*,OR T50 T51
83,T60,Scope 1127 1161	Renal disease or renal dysfunction
84,R17,Subsumes Arg1:T60 Arg2:T59
85,T61,Parsing_Error 1339 1341	5.
86,T62,Parsing_Error 1342 1402	Abnormal and clinically significant laboratory test results:
87,T63,Parsing_Error 1404 1406	1.
88,T64,Subjective_judgement 1342 1402	Abnormal and clinically significant laboratory test results:
89,T65,Subjective_judgement 1407 1429	Clinically significant
90,T66,Context_Error 1449 1492	Guide for Clinically Relevant Abnormalities
91,T67,Non-query-able 1407 1557	Clinically significant deviation from the Guide for Clinically Relevant Abnormalities (see Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS)
92,T68,Parsing_Error 1560 1562	2.
93,T69,Condition 1563 1571;1596 1607	Abnormal ECG tracing
94,T70,Subjective_judgement 1576 1595	clinically relevant
95,T71,Parsing_Error 1609 1611	6.
96,T72,Non-query-able 1612 1744	Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.
97,T73,Parsing_Error 1746 1748	7.
98,T74,Non-query-able 1749 1861	Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
99,T75,Parsing_Error 1863 1865	8.
100,T76,Drug 1897 1920	metformin hydrochloride
101,T77,Condition 1877 1893	hypersensitivity
102,T78,Condition 1866 1873	Allergy
103,R18,AND Arg1:T77 Arg2:T76
104,R19,AND Arg1:T78 Arg2:T76
105,*,OR T77 T78
106,T80,Parsing_Error 1922 1924	9.
107,T79,Condition 1936 1971	difficulty in swallowing medication
108,T81,Observation 1925 1932	History
109,R20,Has_temporal Arg1:T79 Arg2:T81
110,T82,Condition 1980 2005	gastrointestinal disorder
111,T83,Qualifier 2018 2044	affect the drug absorption
112,T84,Subjective_judgement 2018 2044	affect the drug absorption
113,*,OR T79 T82
114,R21,Has_qualifier Arg1:T82 Arg2:T83
0,T1,Condition 16 28	glioblastoma
1,T2,Condition 30 33	GBM
2,T3,Measurement 36 39	WHO
3,T4,Value 40 48	grade IV
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Subsumes Arg1:T1 Arg2:T2
6,R3,AND Arg1:T1 Arg2:T3
7,T5,Qualifier 0 15	Newly diagnosed
8,R4,Has_qualifier Arg1:T1 Arg2:T5
0,T1,Procedure 22 39	cervical cerclage
1,T2,Qualifier 14 21	complex
2,T3,Qualifier 0 9	Abdominal
3,T4,Scope 0 21	Abdominal and complex
4,T5,Qualifier 46 57	bulging bag
5,R1,Has_scope Arg1:T1 Arg2:T4
6,R2,Subsumes Arg1:T4 Arg2:T5
7,T6,Condition 60 76	Contraindication
8,T7,Procedure 80 100	neuraxial anesthesia
9,R3,AND Arg1:T6 Arg2:T7
10,T8,Condition 108 124	hypersensitivity
11,T9,Drug 128 142	chloroprocaine
12,T11,Condition 151 164	Ester allergy
13,T12,Drug 167 188	paraaminobenzoic acid
14,T13,Drug 190 194	PABA
15,T14,Drug 199 210	bupivacaine
16,T15,Condition 219 232	Amide allergy
17,R6,Subsumes Arg1:T12 Arg2:T13
18,*,OR T9 T12 T14
19,T10,Scope 128 142;167 210	chloroprocaine paraaminobenzoic acid (PABA) or bupivacaine
20,R4,Has_scope Arg1:T8 Arg2:T10
21,R5,Subsumes Arg1:T8 Arg2:T11
22,R7,Subsumes Arg1:T8 Arg2:T15
23,T16,Condition 235 266	Pseudocholinesterase deficiency
24,T17,Temporal 268 279	Concomitant
25,T18,Drug 289 314	ergot-type oxytocic drugs
26,R8,Has_temporal Arg1:T18 Arg2:T17
0,T1,Condition 9 30	sacral pressure ulcer
1,T2,Procedure 45 62	cardiac procedure
2,T3,Undefined_semantics 45 62	cardiac procedure
3,T4,Condition 67 104	inability to provide informed consent
4,T5,Undefined_semantics 67 104	inability to provide informed consent
5,T6,Non-query-able 67 104	inability to provide informed consent
6,T7,Subjective_judgement 67 104	inability to provide informed consent
7,*,OR T2 T4 T1
0,T1,Condition 6 13	allergy
1,T2,Condition 17 33	hypersensitivity
2,*,OR T1 T2
3,T3,Drug 46 61	dexmedetomidine
4,T4,Scope 6 33	allergy or hypersensitivity
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 63 80	Organ dysfunction
7,T6,Condition 88 103	hepatic failure
8,T7,Condition 107 115	leukemia
9,T8,Condition 82 87;96 103	renal failure
10,*,OR T6 T8 T7
11,T9,Scope 82 115	renal/hepatic failure or leukemia
12,R2,Subsumes Arg1:T5 Arg2:T9
13,T10,Condition 118 133	Cardiac disease
14,T11,Qualifier 135 145	congenital
15,T12,Qualifier 149 157	acquired
16,*,OR T11 T12
17,T13,Scope 135 157	congenital or acquired
18,R3,Subsumes Arg1:T10 Arg2:T13
19,T14,Condition 170 191	thoracic malformation
20,T15,Condition 160 166;179 191	Airway malformation
21,*,OR T14 T15
22,T16,Condition 193 207	Cerebral palsy
23,T17,Condition 209 218	Hypotonia
24,T18,Drug 229 242	premedication
25,T19,Mood 220 228	Need for
26,R4,Has_mood Arg1:T18 Arg2:T19
27,T20,Temporal 244 251	Current
28,T21,Temporal 252 258	recent
29,T22,Condition 259 286	upper respiratory infection
30,T23,Temporal 288 326	within four weeks prior to the surgery
31,T24,Reference_point 315 326	the surgery
32,T25,Procedure 319 326	surgery
33,R5,multi Arg1:T24 Arg2:T25
34,R6,Has_index Arg1:T23 Arg2:T24
35,*,OR T21 T20
36,T26,Scope 244 258	Current/recent
37,R7,Has_scope Arg1:T22 Arg2:T26
38,R8,Subsumes Arg1:T26 Arg2:T23
39,T27,Condition 329 335	Asthma
40,T28,Condition 337 344	Allergy
41,T29,Condition 348 359	intolerance
42,T30,Drug 363 372	clonidine
43,*,OR T28 T29
44,T31,Observation 374 402	Non-English speaking parents
45,T32,Observation 374 394;403 411	Non-English speaking patients
46,*,OR T32 T31
0,T1,Procedure 0 14	histologically
1,T2,Qualifier 25 32	primary
2,T3,Condition 33 55	classical osteosarcoma
3,T4,Qualifier 56 70	in extremities
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T3 Arg2:T2
6,R3,AND Arg1:T1 Arg2:T3
7,T5,Qualifier 72 83	staging IIB
8,T6,Procedure 85 88	MRI
9,T7,Negation 97 99	no
10,T8,Observation 100 111	skip lesion
11,R4,Has_negation Arg1:T8 Arg2:T7
12,R5,Has_context Arg1:T6 Arg2:T8
13,T9,Procedure 121 155	standard neo-adjuvant chemotherapy
14,T10,Procedure 157 178	adjuvant chemotherapy
15,T11,Procedure 183 210	standard surgical treatment
16,*,OR T9 T10 T11
0,T1,Procedure 23 32	operation
1,T2,Qualifier 41 76	scheduled to last more than 2 hours
2,T3,Temporal 54 76	last more than 2 hours
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,T4,Undefined_semantics 41 76	scheduled to last more than 2 hours
5,T5,Non-query-able 41 76	scheduled to last more than 2 hours
0,T1,Procedure 13 35	non-standard treatment
1,T2,Procedure 36 48	chemotherapy
2,T3,Procedure 52 59	surgery
3,*,OR T2 T3
4,T4,Scope 36 59	chemotherapy or surgery
5,R1,Subsumes Arg1:T1 Arg2:T4
6,T5,Observation 2 9	history
7,T6,Condition 62 84	secondary osteosarcoma
8,T7,Condition 108 130	parosteal osteosarcoma
9,T8,Qualifier 88 107	well-differentiated
10,R2,Has_qualifier Arg1:T7 Arg2:T8
11,*,OR T6 T7
12,T9,Condition 140 161	dysfunction of cardia
13,T10,Condition 140 154;172 178	dysfunction of kidney
14,T11,Condition 140 154;162 167	dysfunction of liver
15,*,OR T10 T11 T9 T12 T13
16,T12,Condition 183 191	pregnant
17,T13,Condition 214 223	lactation
0,T1,Value 9 30	between 3 to 16 years
1,T2,Person 34 37	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 49 67	adenotonsillectomy
4,T4,Temporal 38 48	undergoing
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Procedure 85 96	myringotomy
7,T6,Procedure 100 113	myringoplasty
8,*,OR T5 T6
9,T7,Scope 85 112	myringotomy or myringoplast
10,A1,Optional T7
11,R3,Has_scope Arg1:T3 Arg2:T7
12,T8,Measurement 115 118	ASA
13,T9,Value 119 124	1 & 2
14,R4,Has_value Arg1:T8 Arg2:T9
0,T1,Person 9 12	old
1,T2,Value 0 8;13 21	18 years or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 24 28	ADHD
4,T4,Qualifier 125 130	DSM-5
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 143 165	Substance Use Disorder
7,T6,Qualifier 192 197	DSM-5
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Measurement 209 217	Qb-score
10,T8,Value 218 231	1.3 or higher
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Informed_consent 342 423	Participants are given their written informed consent to participate in the study
0,T1,Condition 4 11	smoking
1,T2,Negation 0 3	Non
2,R1,Has_negation Arg1:T1 Arg2:T2
3,T3,Condition 16 23	smoking
4,T4,Multiplier 24 39;76 83	no more than 10 per day
5,T5,Observation 40 50	cigarettes
6,*,OR T3 T1
7,T6,Observation 57 63	cigars
8,T7,Multiplier 24 36;55 56;76 83	no more than 2 per day
9,T8,Multiplier 24 36;68 69;76 83	no more than 2 per day
10,T9,Observation 70 75	pipes
11,R2,Has_multiplier Arg1:T5 Arg2:T4
12,R3,Has_multiplier Arg1:T6 Arg2:T7
13,R4,Has_multiplier Arg1:T9 Arg2:T8
14,*,OR T9 T6 T5
15,T10,"Scope 24 83	no more than 10 cigarettes, or 2 cigars, or 2 pipes per day"
16,R5,Has_scope Arg1:T3 Arg2:T10
17,T11,Temporal 84 124	for at least 3 months prior to selection
18,T12,Reference_point 115 124	selection
19,R6,multi Arg1:T11 Arg2:T12
20,R7,Has_temporal Arg1:T3 Arg2:T11
21,T13,Measurement 156 171	Body Mass Index
22,T14,Measurement 173 176	BMI
23,T15,Measurement 178 232	weight in kg divided by the square of height in meters
24,*,OR T14 T15
25,T16,"Scope 173 232	BMI, weight in kg divided by the square of height in meters"
26,R8,Subsumes Arg1:T13 Arg2:T16
27,T17,"Value 237 274	18.0 to 30.0 kg/m2, extremes included"
28,R9,Has_value Arg1:T13 Arg2:T17
29,T18,Condition 126 139	Normal weight
30,R10,AND Arg1:T18 Arg2:T13
31,T19,Observation 276 317	Able to comply with protocol requirements
32,T20,Condition 319 326	Healthy
33,T21,Procedure 345 363	medical evaluation
34,T22,Negation 381 388	absence
35,T23,Qualifier 396 415	clinically relevant
36,T24,Condition 416 427	abnormality
37,T25,Procedure 443 463	physical examination
38,T26,Procedure 465 480	medical history
39,T27,Procedure 482 499	electrocardiogram
40,T28,Procedure 507 518	vital signs
41,T29,Procedure 501 504	ECG
42,R11,Subsumes Arg1:T27 Arg2:T29
43,T30,Procedure 539 557;593 598	blood biochemistry tests
44,T31,Procedure 559 576;593 598	blood coagulation tests
45,T32,Procedure 582 598	hematology tests
46,T33,Procedure 605 615	urinalysis
47,T34,Temporal 628 640	at screening
48,T35,Reference_point 631 640	screening
49,R12,Has_index Arg1:T34 Arg2:T35
50,R13,Has_qualifier Arg1:T24 Arg2:T23
51,R14,Has_negation Arg1:T24 Arg2:T22
52,T36,"Scope 443 615	physical examination, medical history, electrocardiogram (ECG), vital signs, and the results of blood biochemistry, blood coagulation, and hematology tests and a urinalysis"
53,R15,Has_scope Arg1:T21 Arg2:T36
54,R16,AND Arg1:T21 Arg2:T24
55,R17,Has_temporal Arg1:T21 Arg2:T34
56,R18,AND Arg1:T21 Arg2:T20
0,T1,Value 3 11	positive
1,T2,Measurement 12 17;27 31	HIV 1 test
2,T3,Measurement 21 31	HIV 2 test
3,T4,Temporal 32 44	at screening
4,T5,Reference_point 35 44	screening
5,R1,multi Arg1:T4 Arg2:T5
6,*,OR T2 T3
7,T6,Scope 12 31	HIV 1 or HIV 2 test
8,R2,Has_value Arg1:T6 Arg2:T1
9,R3,Has_temporal Arg1:T6 Arg2:T4
10,T8,Condition 72 84	skin disease
11,T10,Observation 49 56	history
12,T11,Qualifier 60 71	significant
13,T12,Undefined_semantics 60 71	significant
14,R5,Has_qualifier Arg1:T8 Arg2:T11
15,R6,Has_temporal Arg1:T8 Arg2:T10
16,T13,Condition 113 117	rash
17,T14,Condition 121 130	eruptions
18,T15,Condition 132 146	drug allergies
19,T16,Condition 148 160	food allergy
20,T17,Condition 162 172	dermatitis
21,T18,Condition 174 180	eczema
22,T19,Condition 182 191	psoriasis
23,T20,Condition 196 205	urticaria
24,*,OR T20 T19 T18 T17 T16 T15 T14 T13
25,T21,"Scope 113 205	rash or eruptions, drug allergies, food allergy, dermatitis, eczema, psoriasis, or urticaria"
26,R8,Subsumes Arg1:T8 Arg2:T21
27,T22,Observation 210 217	history
28,T24,Condition 221 228	allergy
29,T25,Drug 267 280	sulphonamides
30,T26,Drug 285 296	penicillins
31,*,OR T25 T26
32,T27,Scope 267 296	sulphonamides and penicillins
33,R9,Has_scope Arg1:T24 Arg2:T27
34,R10,Has_temporal Arg1:T24 Arg2:T22
35,T30,Procedure 705 719	pregnancy test
36,T31,Value 696 704	positive
37,R12,Has_value Arg1:T30 Arg2:T31
38,T33,Observation 723 737	breast feeding
39,T34,Temporal 738 750	at screening
40,*,OR T30 T33
41,T35,Scope 696 737	positive pregnancy test or breast feeding
42,R14,Has_temporal Arg1:T35 Arg2:T34
43,T29,Temporal 301 311	previously
44,T36,Qualifier 325 347	clinically significant
45,T37,Condition 348 355	allergy
46,T38,Condition 359 375	hypersensitivity
47,*,OR T37 T38
48,T39,Drug 390 434	excipients of the investigational medication
49,T40,Scope 348 375	allergy or hypersensitivity
50,R15,Has_qualifier Arg1:T40 Arg2:T36
51,R16,AND Arg1:T40 Arg2:T39
52,R18,Has_temporal Arg1:T40 Arg2:T29
53,T7,Person 466 472	female
54,T9,Condition 484 506	childbearing potential
55,T23,Negation 507 514	without
56,T28,Qualifier 522 531	effective
57,T32,Procedure 532 557	nonhormonal birth control
58,R4,Has_qualifier Arg1:T32 Arg2:T28
59,T41,Negation 570 573	not
60,T42,Mood 574 604	willing to continue practicing
61,T43,Procedure 611 632	birth control methods
62,T44,Temporal 633 691	for at least 30 days after the end of the treatment period
63,T45,Reference_point 660 691	the end of the treatment period
64,R7,Has_index Arg1:T44 Arg2:T45
65,R11,Has_temporal Arg1:T43 Arg2:T44
66,R13,Has_mood Arg1:T43 Arg2:T42
67,R17,Has_negation Arg1:T42 Arg2:T41
68,R19,Has_negation Arg1:T32 Arg2:T23
69,*,OR T32 T43
0,T1,Observation 12 19	alcohol
1,T2,Observation 23 28	drugs
2,*,OR T1 T2
3,T3,Temporal 40 50	last month
4,T4,Scope 12 28	alcohol or drugs
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Condition 102 109;79 90	illness psychiatric
7,T6,Condition 94 109	somatic illness
8,*,OR T6 T5
9,T7,Qualifier 53 62	Untreated
10,T8,Qualifier 63 69	severe
11,T9,Qualifier 70 78	comorbid
12,T10,Scope 53 78	Untreated severe comorbid
13,T11,Scope 79 109	psychiatric or somatic illness
14,R2,Has_scope Arg1:T11 Arg2:T10
15,T12,Measurement 112 125	Bloodpressure
16,T13,Value 126 142	150/95 or higher
17,R3,Has_value Arg1:T12 Arg2:T13
18,T14,Measurement 155 160	pulse
19,T15,Value 145 154	Irregular
20,R4,Has_value Arg1:T14 Arg2:T15
21,T16,Measurement 165 170	pulse
22,T17,Value 171 184	100 or higher
23,R5,Has_value Arg1:T16 Arg2:T17
24,*,OR T14 T16
25,T18,Non-query-able 187 241	No counter indications according to the Medikinet pill
26,T19,Non-query-able 244 322	Concurrent clinical diagnosis that significantly could affect test performance
27,T20,Drug 352 361	medicines
28,T21,Condition 366 370	ADHD
29,R6,AND Arg1:T20 Arg2:T21
0,T1,Value 9 22	older than 18
1,T2,Person 23 28	years
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Measurement 30 89	Classification of the American Society of Anesthesiologists
4,T4,Measurement 91 94	ASA
5,T5,Value 95 100	I-III
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,Subsumes Arg1:T3 Arg2:T4
8,T6,Negation 103 105	No
9,T7,Condition 106 124	cognitive deficits
10,R4,Has_negation Arg1:T7 Arg2:T6
11,T8,Informed_consent 126 166	Signed informed consent prior to surgery
0,T1,Condition 0 24	Congestive heart failure
1,T2,Condition 28 51	coronary artery disease
2,T3,Measurement 53 67	Blood pressure
3,T4,Value 78 91	> 159/99 mmHg
4,*,OR T1 T2
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 93 109	Serum creatinine
7,T6,Value 110 121	> 1.5 mg/dL
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 123 140	Diabetes mellitus
10,T8,Condition 150 166	systemic illness
11,*,OR T7 T8
12,T9,Condition 168 196	Left ventricular hypertrophy
13,T10,Procedure 200 216	echocardiography
14,T11,Procedure 220 223	ECG
15,R3,Subsumes Arg1:T10 Arg2:T11
16,T12,Scope 200 223	echocardiography or ECG
17,R4,AND Arg1:T12 Arg2:T9
18,T13,Condition 225 234	Pregnancy
19,T14,Condition 236 252	Hypersensitivity
20,T15,Drug 256 270	spironolactone
21,T16,Drug 272 286	chlorthalidone
22,T17,Drug 288 298	amlodipine
23,T18,Drug 300 325	human recombinant insulin
24,*,OR T15 T16 T17 T18
25,T19,"Scope 256 325	spironolactone, chlorthalidone, amlodipine, human recombinant insulin"
26,R5,Has_scope Arg1:T14 Arg2:T19
27,T20,Condition 354 369	substance abuse
28,T21,Observation 382 389	tobacco
29,T22,Negation 371 376	other
30,R6,Has_negation Arg1:T21 Arg2:T22
31,T23,Condition 403 418	gouty arthritis
32,T24,"Qualifier 434 448	right-to-left,"
33,T25,Qualifier 449 463	bi-directional
34,T26,Qualifier 468 477	transient
35,T27,Qualifier 478 491	right-to-left
36,T28,Condition 492 506	cardiac shunts
37,*,OR T24 T25 T29
38,T29,Scope 468 491	transient right-to-left
39,T30,"Scope 434 491	right-to-left, bi-directional, or transient right-to-left"
40,R7,Has_scope Arg1:T28 Arg2:T30
41,T31,Condition 508 524	Hypersensitivity
42,T32,Drug 528 538	perflutren
43,T33,Procedure 540 545	blood
44,T34,Procedure 547 561	blood products
45,T35,Drug 565 572	albumin
46,*,OR T32 T33 T34 T35
47,T36,"Scope 528 572	perflutren, blood, blood products or albumin"
48,R8,Has_scope Arg1:T31 Arg2:T36
0,T1,Procedure 0 17	Emergency surgery
1,T2,Condition 19 28	Pregnancy
2,T3,Condition 32 41	lactation
3,*,OR T2 T3
4,T4,Condition 43 59	Immune disorders
5,T5,Condition 71 84	liver disease
6,T6,Condition 61 67;77 84	Kidney disease
7,T7,Condition 88 118	advanced-stage cardiopulmonary
8,*,OR T6 T7 T5
9,T8,Informed_consent 120 163	Patient refusal to participate in the study
10,T9,Person 183 188	years
11,T10,Value 174 182	under 18
12,R1,Has_value Arg1:T9 Arg2:T10
13,T11,Condition 192 212	inability to consent
14,*,OR T9 T11
15,T12,Informed_consent 192 212	inability to consent
16,R2,multi Arg1:T11 Arg2:T12
17,T13,Condition 225 248	neuromuscular disorders
18,T14,Condition 250 266	contraindication
19,T15,Drug 282 292	rocuronium
20,T16,Drug 294 304	sugammadex
21,*,OR T15 T16
22,T17,Scope 282 304	rocuronium/ sugammadex
23,R3,Has_scope Arg1:T14 Arg2:T17
24,T18,Condition 306 313	allergy
25,T19,Condition 317 333	hypersensitivity
26,T20,Drug 337 347	rocuronium
27,T21,Drug 350 360	sugammadex
28,*,OR T20 T21
29,T22,Scope 337 360	rocuronium / sugammadex
30,*,OR T18 T19
31,T23,Scope 306 333	allergy or hypersensitivity
32,R4,Has_scope Arg1:T23 Arg2:T22
0,T1,Procedure 13 21	controls
1,T2,Qualifier 0 12	Normotensive
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 76 98	essential hypertension
4,T4,Qualifier 23 30	Stage I
5,T5,Qualifier 52 61	untreated
6,R2,Has_qualifier Arg1:T3 Arg2:T5
7,R3,Has_qualifier Arg1:T3 Arg2:T4
8,T6,Condition 114 116	PA
9,T7,Condition 150 162	hypertension
10,T8,Qualifier 121 128	stage I
11,R4,Has_qualifier Arg1:T7 Arg2:T8
0,T1,Condition 9 31	retinal vein occlusion
1,T2,Temporal 0 8	previous
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Procedure 38 57	intraocular surgery
4,T4,Temporal 58 87	within the previous 12 months
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Condition 90 96	myopia
7,T6,Value 100 120	> or = to 8 diopters
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 140 160	periocular infection
10,T8,Condition 130 136;151 160	ocular infection
11,*,OR T8 T7
12,T9,Scope 130 160	ocular or periocular infection
13,T10,Qualifier 123 129	active
14,R4,Has_qualifier Arg1:T9 Arg2:T10
15,T11,Competing_trial 162 247	treatment with an investigational agent for any condition 60 days prior to enrollment
16,T12,Qualifier 262 268	severe
17,T13,Condition 269 284	cardiac disease
18,T14,Mood 250 261	evidence of
19,R5,Has_qualifier Arg1:T13 Arg2:T12
20,R6,Has_mood Arg1:T13 Arg2:T14
21,T15,Qualifier 287 309	clinically significant
22,T16,Condition 310 337	peripheral vascular disease
23,R7,Has_qualifier Arg1:T16 Arg2:T15
24,T17,Procedure 339 355	previous surgery
25,T18,Procedure 357 367	amputation
26,T19,Condition 372 396	symptoms of claudication
27,*,OR T17 T18 T19
28,T20,"Scope 339 396	previous surgery, amputation, or symptoms of claudication"
29,T21,Scope 287 337	clinically significant peripheral vascular disease
30,R8,Subsumes Arg1:T21 Arg2:T20
31,T22,Condition 412 424	hypertension
32,T23,Qualifier 399 411	uncontrolled
33,R9,Has_qualifier Arg1:T22 Arg2:T23
34,T24,Measurement 434 457	systolic blood pressure
35,T25,Qualifier 426 433	treated
36,T26,Value 458 468	> 155 mmHg
37,T27,Measurement 472 496	diastolic blood pressure
38,T28,Value 497 506	> 95 mmHg
39,R10,Has_value Arg1:T24 Arg2:T26
40,R11,Has_value Arg1:T27 Arg2:T28
41,*,OR T24 T27
42,T29,Scope 434 506	systolic blood pressure > 155 mmHg or diastolic blood pressure > 95 mmHg
43,R12,Has_qualifier Arg1:T29 Arg2:T25
44,T30,Scope 399 424	uncontrolled hypertension
45,R13,Subsumes Arg1:T30 Arg2:T29
46,T31,Condition 509 515	stroke
47,T32,Temporal 516 546	within the preceding 12 months
48,R14,Has_temporal Arg1:T31 Arg2:T32
0,T1,Measurement 18 28	Tacrolimus
1,T2,Value 54 61	2 ng/mg
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Drug 100 107	steroid
4,T4,Measurement 142 162	acute rejection test
5,T5,Value 123 131	positive
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Procedure 214 224	transplant
8,T7,Qualifier 233 238	liver
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Condition 258 266	allergic
11,T10,Drug 270 272	IP
12,T11,Scope 270 295	IP or macrolide compounds
13,T9,Drug 276 285	macrolide
14,*,OR T10 T9
15,R4,Has_scope Arg1:T8 Arg2:T11
16,T12,Drug 318 330	cyclosporine
17,T13,Drug 332 340	bosentan
18,T14,Drug 345 371	potassium sparing diuretic
19,*,OR T13 T12 T14
20,T15,Condition 388 404	genetic diseases
21,T16,Condition 413 434	galactose intolerance
22,T17,Condition 436 459	Lapp lactase deficiency
23,T18,Condition 464 495	glucose-galactose malabsorption
24,*,OR T18 T17 T16
25,T19,"Scope 413 495	galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption"
26,R5,Subsumes Arg1:T15 Arg2:T19
27,T20,Pregnancy_considerations 498 525	Pregnant or lactating women
28,T21,Post-eligibility 528 589	Patients not willing to adhere to study procedures/treatments
0,T1,Person 0 3	Age
1,T2,Value 4 46	younger than 18 yrs. or older than 75 yrs.
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 48 57	Pregnancy
4,T4,Condition 61 68	nursing
5,*,OR T3 T4
6,T5,Value 70 78	negative
7,T6,Measurement 79 99	pregnancy blood test
8,R2,Has_value Arg1:T6 Arg2:T5
9,T7,Scope 48 68	Pregnancy or nursing
10,T8,Scope 70 99	negative pregnancy blood test
11,R3,Subsumes Arg1:T7 Arg2:T8
12,T9,Observation 102 109	History
13,T10,Condition 113 131	allergic reactions
14,T11,Drug 135 148	phenylephrine
15,T12,Drug 152 161	ephedrine
16,*,OR T11 T12
17,T13,Scope 135 161	phenylephrine or ephedrine
18,R4,Has_temporal Arg1:T10 Arg2:T9
19,R5,Has_scope Arg1:T10 Arg2:T13
20,T14,Measurement 163 167	eGFR
21,T15,Value 168 185	< 60ml/min/1.73m2
22,R6,Has_value Arg1:T14 Arg2:T15
0,T1,Condition 0 16	hypersensitivity
1,T2,Drug 20 31	perindopril
2,T3,Drug 44 58	ACE inhibitors
3,T4,Drug 60 70	amlodipine
4,T5,Drug 72 84	atorvastatin
5,T6,Drug 86 102	dihydropyridines
6,T7,Drug 112 119	statins
7,T8,Qualifier 38 43	other
8,R1,Has_qualifier Arg1:T3 Arg2:T8
9,*,OR T3 T4 T5 T6 T7 T2
10,T9,"Scope 20 119	perindopril or to other ACE inhibitors, amlodipine, atorvastatin, dihydropyridines or to or statins"
11,R2,Has_scope Arg1:T1 Arg2:T9
12,T10,Condition 121 140	angioneurotic edema
13,T11,Qualifier 174 184	idiopathic
14,T12,Qualifier 161 171	hereditary
15,T13,Qualifier 188 198	associated
16,T14,Procedure 210 219	treatment
17,T15,Temporal 204 209	prior
18,R3,Has_temporal Arg1:T14 Arg2:T15
19,T16,Drug 225 239	ACE inhibitors
20,R4,AND Arg1:T14 Arg2:T16
21,R5,AND Arg1:T13 Arg2:T14
22,*,OR T11 T13 T12
23,T17,Scope 161 239	hereditary / idiopathic or associated with prior treatment with ACE inhibitors
24,R6,Has_scope Arg1:T10 Arg2:T17
25,T18,Condition 249 260	hypotension
26,T19,Condition 262 267	shock
27,T20,Condition 279 296	cardiogenic shock
28,T21,Qualifier 242 248	severe
29,*,OR T19 T20 T18
30,T22,"Scope 249 296	hypotension, shock, including cardiogenic shock"
31,R7,Has_qualifier Arg1:T22 Arg2:T21
32,T23,Qualifier 298 322	hemodynamically unstable
33,T24,Condition 323 336	heart failure
34,R8,Has_qualifier Arg1:T24 Arg2:T23
35,T25,Condition 345 358	liver disease
36,T26,Measurement 399 418	serum transaminases
37,T27,Value 419 447	more than three times normal
38,T28,Value 385 395	elevations
39,R9,Subsumes Arg1:T28 Arg2:T27
40,R10,Has_value Arg1:T26 Arg2:T28
41,T29,Qualifier 362 373	unexplained
42,T30,Qualifier 374 384	persistent
43,R11,Has_qualifier Arg1:T26 Arg2:T30
44,R12,Has_qualifier Arg1:T26 Arg2:T29
45,*,OR T25 T26
46,T31,Person 449 454	Women
47,T32,Person 458 474	childbearing age
48,T33,Qualifier 483 491	reliable
49,T34,Procedure 492 505	contraception
50,T35,Negation 475 482	without
51,R13,Has_negation Arg1:T34 Arg2:T35
52,*,OR T34 T33
53,T36,Condition 507 516	pregnancy
54,T37,Observation 518 531	breastfeeding
55,T38,Condition 547 564	contraindications
56,T39,Qualifier 565 597	listed in the currently valid SP
57,R14,Has_qualifier Arg1:T38 Arg2:T39
0,T1,Drug 29 39	ticagrelor
1,T2,Condition 0 11	intolerance
2,T3,Condition 18 25	allergy
3,T4,Drug 43 52	prasugrel
4,*,OR T1 T4
5,*,OR T3 T2
6,T5,Scope 29 52	ticagrelor or prasugrel
7,T6,Scope 0 25	intolerance of or allergy
8,R1,Has_scope Arg1:T6 Arg2:T5
9,T7,Condition 69 75	stroke
10,T8,Condition 77 102	transient ischemic attack
11,T9,Condition 106 127	intracranial bleeding
12,*,OR T9 T8 T7
13,T10,Condition 135 156	intracranial neoplasm
14,T11,Condition 158 197	intracranial arteriovenous malformation
15,T12,Condition 201 222	intracranial aneurysm
16,T13,Condition 231 239	bleeding
17,T14,Temporal 224 230	active
18,T15,"Condition 241 351	clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding"
19,*,OR T13 T15
20,T16,"Scope 231 351	bleeding, clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding"
21,R2,Has_temporal Arg1:T16 Arg2:T14
22,T17,Procedure 369 389	fibrinolytic therapy
23,T18,Qualifier 353 368	fibrin-specific
24,T19,Temporal 390 425	less than 24 h before randomization
25,T20,Procedure 447 467	fibrinolytic therapy
26,T21,Qualifier 427 446	non-fibrin-specific
27,R3,Has_qualifier Arg1:T17 Arg2:T18
28,R4,Has_qualifier Arg1:T20 Arg2:T21
29,T22,Temporal 468 503	less than 48 h before randomization
30,R5,Has_temporal Arg1:T20 Arg2:T22
31,R6,Has_temporal Arg1:T17 Arg2:T19
32,*,OR T17 T20
33,T23,Measurement 511 525	platelet count
34,T24,Value 526 538	< 100.000/µL
35,T25,Temporal 539 563	at the time of screening
36,T26,Reference_point 412 425	randomization
37,R7,Has_index Arg1:T19 Arg2:T26
38,T27,Reference_point 490 503	randomization
39,R8,Has_index Arg1:T22 Arg2:T27
40,T28,Reference_point 542 563	the time of screening
41,R9,Has_index Arg1:T25 Arg2:T28
42,R10,Has_value Arg1:T23 Arg2:T24
43,R11,Has_temporal Arg1:T23 Arg2:T25
44,T29,Condition 571 577	anemia
45,T30,Measurement 579 589	hemoglobin
46,T31,Value 590 598	<10 g/dL
47,R12,Has_value Arg1:T30 Arg2:T31
48,R13,Subsumes Arg1:T29 Arg2:T30
49,T32,Temporal 600 624	at the time of screening
50,T33,Reference_point 603 624	the time of screening
51,R14,Has_index Arg1:T32 Arg2:T33
52,T34,Procedure 626 646	oral anticoagulation
53,T35,Qualifier 652 681	cannot be safely discontinued
54,T36,Temporal 682 711	for the duration of the study
55,T37,Reference_point 702 711	the study
56,R15,Has_index Arg1:T36 Arg2:T37
57,R16,Has_qualifier Arg1:T34 Arg2:T35
58,R17,Has_temporal Arg1:T29 Arg2:T32
59,R18,Has_temporal Arg1:T34 Arg2:T36
60,T38,Measurement 713 716	INR
61,T39,Value 729 745	greater than 1.5
62,T40,Temporal 746 770	at the time of screening
63,T41,Reference_point 749 770	the time of screening
64,R19,Has_index Arg1:T40 Arg2:T41
65,R20,Has_value Arg1:T38 Arg2:T39
66,R21,Has_temporal Arg1:T38 Arg2:T40
67,T42,Condition 772 799	chronic renal insufficiency
68,T43,Procedure 810 818	dialysis
69,R22,AND Arg1:T42 Arg2:T43
70,T44,Condition 839 858	hepatic dysfunction
71,T45,Qualifier 832 838	severe
72,T46,Qualifier 820 828	moderate
73,*,OR T45 T46
74,T47,Scope 820 838	moderate or severe
75,R23,Has_scope Arg1:T44 Arg2:T47
76,T48,Measurement 860 870	Child Pugh
77,T49,Value 871 877	B or C
78,R24,Has_value Arg1:T48 Arg2:T49
79,R25,Subsumes Arg1:T47 Arg2:T48
80,T50,Condition 898 916	bradycardia events
81,T51,Mood 880 894	increased risk
82,T52,Condition 918 928	Sick Sinus
83,T53,Condition 930 938	AV block
84,T54,Measurement 939 944	grade
85,T55,Value 945 954	II or III
86,R26,Has_value Arg1:T54 Arg2:T55
87,R27,AND Arg1:T53 Arg2:T54
88,T56,Condition 956 983	bradycardia-induced syncope
89,*,OR T52 T53 T56
90,T57,"Scope 918 983	Sick Sinus, AV block grade II or III, bradycardia-induced syncope"
91,R28,Subsumes Arg1:T50 Arg2:T57
92,R29,Has_mood Arg1:T50 Arg2:T51
93,T58,Condition 1010 1022;1035 1041	complication of PCI
94,T59,Value 1024 1033	< 30 days
95,T60,Qualifier 1004 1009	acute
96,R30,Has_qualifier Arg1:T58 Arg2:T60
97,R31,Subsumes Arg1:T60 Arg2:T59
98,T61,Condition 1043 1070	concomitant medical illness
99,T62,Qualifier 1111 1156	is associated with a life expectancy < 1 year
100,R32,Has_qualifier Arg1:T61 Arg2:T62
101,T63,Procedure 1170 1174;1183 1190	oral therapy
102,T64,Procedure 1178 1190	i.v. therapy
103,T65,Drug 1196 1219	strong CYP3A Inhibitors
104,T66,Drug 1226 1238	ketoconazole
105,T67,Drug 1240 1252	itraconazole
106,T68,Drug 1254 1266	voriconazole
107,T69,Drug 1268 1281	telithromycin
108,T70,Drug 1283 1297	clarithromycin
109,T71,Drug 1299 1309	nefazodone
110,T72,Drug 1311 1320	ritonavir
111,T73,Drug 1322 1332	saquinavir
112,T74,Drug 1334 1344	nelfinavir
113,T75,Drug 1346 1355	indinavir
114,T76,Drug 1357 1367	atazanavir
115,T77,Drug 1369 1385	grapefruit juice
116,T78,Multiplier 1386 1393	> 1 L/d
117,R33,Has_multiplier Arg1:T77 Arg2:T78
118,*,OR T66 T67 T68 T69 T70 T71 T72 T73 T74 T75 T76 T77
119,T79,"Scope 1226 1393	ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice > 1 L/d"
120,R34,Subsumes Arg1:T65 Arg2:T79
121,*,OR T64 T63
122,T80,Scope 1170 1190	oral or i.v. therapy
123,R35,AND Arg1:T80 Arg2:T65
124,T81,Multiplier 1621 1629	=1 doses
125,T82,Drug 1633 1643	ticagrelor
126,T83,Drug 1647 1656	prasugrel
127,T84,Temporal 1657 1691	within 5 days before randomisation
128,T85,Reference_point 1678 1691	randomisation
129,R36,Has_index Arg1:T84 Arg2:T85
130,*,OR T82 T83
131,T86,Scope 1633 1656	ticagrelor or prasugrel
132,R37,Has_multiplier Arg1:T86 Arg2:T81
133,T87,Non-query-able 1693 1720	no written informed consent
134,T88,Post-eligibility 1722 1773	participation in another investigational drug study
135,T89,Non-query-able 1775 1807	previous enrolment in this study
136,T90,Pregnancy_considerations 1809 1941	for women of childbearing potential no negative pregnancy test and no agree to use reliable method of birth control during the study
137,T91,"Pregnancy_considerations 1943 2004	Pregnancy, giving birth within the last 90 days, or lactation"
138,T92,Non-query-able 2006 2055	inability to cooperate with protocol requirements
139,T93,Drug 1396 1444	CYP3A substrates with narrow therapeutic indices
140,T94,Drug 1451 1463	cyclosporine
141,T95,Drug 1465 1474	quinidine
142,T96,Drug 1480 1501	strong CYP3A inducers
143,T97,Drug 1508 1516	rifampin
144,T98,Drug 1517 1527	rifampicin
145,T99,Drug 1529 1538	phenytoin
146,T100,Drug 1540 1553	carbamazepine
147,T101,Drug 1555 1567	dexamethason
148,T102,Drug 1569 1582	phenobarbital
149,*,OR T98 T97 T99 T100 T101 T102
150,T103,"Scope 1508 1582	rifampin/rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital"
151,R38,Subsumes Arg1:T96 Arg2:T103
152,*,OR T94 T95
153,T104,"Scope 1451 1474	cyclosporine, quinidine"
154,R39,Subsumes Arg1:T93 Arg2:T104
0,T1,Person 9 12	old
1,T2,Value 0 8;13 22	19 years and above
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 65 81	liver transplant
4,T4,Temporal 91 134	last six months and within last three years
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Drug 157 167	Tacrolimus
7,T6,Multiplier 194 205	twice a day
8,T7,Temporal 210 228	at least two weeks
9,R3,Has_multiplier Arg1:T5 Arg2:T6
10,R4,Has_temporal Arg1:T5 Arg2:T7
11,T8,Qualifier 249 255	normal
12,T9,Condition 256 270	liver function
13,T10,Condition 275 289	renal function
14,R5,Has_qualifier Arg1:T9 Arg2:T8
15,R6,Has_qualifier Arg1:T10 Arg2:T8
16,T11,Negation 325 332	without
17,T12,Condition 333 345	complication
18,R7,Has_negation Arg1:T12 Arg2:T11
19,T13,Condition 354 369	acute rejection
20,R8,Subsumes Arg1:T12 Arg2:T13
21,T14,Informed_consent 372 412	Patients willing to sign his/her consent
0,T1,Value 0 17	18 years or older
1,T2,Person 12 17	older
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 19 25;31 39	Type 1 diabetes
4,T4,Condition 19 23;29 39	Type 2 diabetes
5,*,OR T3 T4
6,T5,Condition 41 44	PDR
7,T6,Procedure 64 85	surgical intervention
8,T7,Mood 54 63	requiring
9,R2,Has_mood Arg1:T6 Arg2:T7
10,T8,Condition 107 126	vitreous hemorrhage
11,T9,Condition 130 157	traction retinal detachment
12,T10,Qualifier 162 175	pre-operative
13,T11,Procedure 176 189	IVC treatment
14,R3,Has_qualifier Arg1:T11 Arg2:T10
15,*,OR T8 T9 T11
16,T12,Scope 107 189	vitreous hemorrhage or traction retinal detachment and pre-operative IVC treatment
17,R4,Has_scope Arg1:T6 Arg2:T12
18,T13,"Pregnancy_considerations 192 312	women postmenopausal for 12 months before the study, surgically sterile, or not pregnant and on effective contraception."
0,T1,Mood 9 18	scheduled
1,T2,Procedure 23 60	supine-positioned elective craniotomy
2,T3,Qualifier 65 79	supratentorial
3,T4,Qualifier 80 89	malignant
4,T5,Negation 94 97	non
5,T6,Qualifier 98 107	malignant
6,R1,Has_negation Arg1:T6 Arg2:T5
7,*,OR T4 T6
8,T7,Condition 108 120	brain tumors
9,T8,Qualifier 121 135	3 cm or larger
10,R2,Has_qualifier Arg1:T7 Arg2:T8
11,T9,Scope 80 107	malignant and non-malignant
12,R3,Has_scope Arg1:T7 Arg2:T9
13,R4,Has_qualifier Arg1:T7 Arg2:T3
14,T10,Qualifier 153 182	largest diameter in any plane
15,T11,Procedure 186 188	MR
16,T12,Scope 153 188	largest diameter in any plane on MR
17,R5,Has_scope Arg1:T8 Arg2:T12
18,R6,Has_mood Arg1:T2 Arg2:T1
19,T13,Scope 65 196	supratentorial malignant and non-malignant brain tumors 3 cm or larger (measured as the largest diameter in any plane on MR images)
20,R7,Has_scope Arg1:T2 Arg2:T13
21,T14,Measurement 198 201;241 247	ASA status
22,T15,Measurement 203 239;241 247	American Society of Anesthesiologist status
23,R8,Subsumes Arg1:T14 Arg2:T15
24,T16,Scope 198 240	ASA (American Society of Anesthesiologist)
25,T17,Value 248 251	1-3
26,T18,Value 253 255	27
27,R9,Subsumes Arg1:T17 Arg2:T18
28,R10,Has_value Arg1:T14 Arg2:T17
29,T19,Informed_consent 258 310	Written informed consent from participating patients
0,T1,Condition 12 31	cardiovascular risk
1,T2,Qualifier 2 11	very high
2,T3,Measurement 36 51	LDL-cholesterol
3,T4,Value 51 65	> 1.8 mmol / l
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T1 Arg2:T2
6,R3,AND Arg1:T1 Arg2:T3
7,T5,Condition 74 93	cardiovascular risk
8,T6,Qualifier 69 73	high
9,T7,Measurement 98 113	LDL-cholesterol
10,T8,Value 113 127	> 2.5 mmol / l
11,R4,Has_value Arg1:T7 Arg2:T8
12,R5,Has_qualifier Arg1:T5 Arg2:T6
13,R6,AND Arg1:T5 Arg2:T7
14,T9,Qualifier 152 161	very high
15,T10,Qualifier 144 148	high
16,T11,Condition 162 181	cardiovascular risk
17,T12,Procedure 193 214	lipidlowering therapy
18,T13,Drug 220 225	stati
19,R7,AND Arg1:T12 Arg2:T13
20,*,OR T9 T10
21,T14,Scope 144 161	high or very high
22,R8,Has_scope Arg1:T11 Arg2:T14
23,R9,AND Arg1:T11 Arg2:T12
0,T1,Condition 32 54	generalized vulvodynia
1,T2,Condition 88 112	localized vestibulodynia
2,T3,Person 0 5	women
3,T4,Person 56 61	women
0,T1,Person 0 5	Adult
1,T2,Person 6 31	men who have sex with men
2,T3,Person 37 54	transgender women
3,*,OR T2 T3
4,T4,Measurement 67 77	HIV status
5,T5,Value 56 63	Unaware
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Observation 56 77	Unaware of HIV status
8,R2,multi Arg1:T6 Arg2:T4
9,T7,Temporal 78 111	at enrollment in follow-up cohort
10,T8,Reference_point 81 111	enrollment in follow-up cohort
11,R3,Has_index Arg1:T7 Arg2:T8
12,R4,Has_temporal Arg1:T4 Arg2:T7
13,T9,Condition 127 140	HIV infection
14,T10,Mood 113 126	High risk for
15,R5,Has_mood Arg1:T9 Arg2:T10
16,T11,Mood 142 152	Willing to
17,T12,Condition 153 165	test for HIV
18,R6,Has_mood Arg1:T12 Arg2:T11
19,T13,Negation 167 169	No
20,T14,Temporal 170 175	prior
21,T15,Procedure 176 179	ART
22,R7,Has_temporal Arg1:T15 Arg2:T14
23,T16,Temporal 191 196	prior
24,T17,Procedure 197 211	administration
25,T18,Drug 224 249	post-exposure prophylaxis
26,T19,Drug 215 219;229 249	pre- exposure prophylaxis
27,T20,Temporal 250 269	in the last 30 days
28,*,OR T19 T18
29,T21,Scope 215 249	pre- and post-exposure prophylaxis
30,R9,Has_temporal Arg1:T17 Arg2:T16
31,R10,Has_temporal Arg1:T17 Arg2:T20
32,*,OR T17 T15
33,T22,"Scope 170 269	prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days"
34,R8,Has_negation Arg1:T22 Arg2:T13
35,T23,Observation 290 306	informed consent
36,T24,Mood 271 289	Willing to provide
37,R11,Has_mood Arg1:T23 Arg2:T24
0,T1,Value 4 21	at least 18 years
1,T2,Person 25 28	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Measurement 53 70	cough stress test
4,T4,Value 44 52	positive
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Procedure 78 118	complex multi-channel urodynamic testing
7,R3,causal Arg1:T3 Arg2:T5
8,T6,Condition 142 169	stress urinary incontinence
9,T7,Procedure 173 202	quality of life questionnaire
10,T8,Observation 208 226;236 262	able to comprehend a written informed consent
11,T13,Observation 208 215;231 262	able to sign a written informed consent
12,T9,Observation 283 328	willing to comply with the study requirements
13,T14,Observation 264 274;306 328	Understand the study requirements
14,T10,Condition 400 422	psychologically stable
15,T11,Condition 427 453	suitable for interventions
16,T12,Qualifier 454 484	determined by the investigator
17,T15,Scope 400 453	psychologically stable and suitable for interventions
18,R4,Has_qualifier Arg1:T15 Arg2:T12
19,T16,Condition 490 500	ambulatory
20,T17,Condition 505 539	able to use a toilet independently
0,T1,Condition 0 9	pregnancy
1,T2,Condition 11 20	menopause
2,T3,Condition 22 43	interstitial cystitis
3,T4,Condition 45 69	irritable bowel syndrome
4,T5,Condition 71 90	untreated vaginitis
5,T6,Condition 92 102	cervicitis
6,T7,Condition 104 131	pelvic inflammatory disease
7,T8,Condition 143 159	pelvic pathology
8,T9,Qualifier 160 172	causing pain
9,R1,Has_qualifier Arg1:T8 Arg2:T9
10,T10,Undefined_semantics 137 172	other pelvic pathology causing pain
11,T11,Procedure 186 202	physical therapy
12,T12,Temporal 174 185	concomitant
13,T13,Temporal 204 215	concomitant
14,T14,Procedure 216 227	biofeedback
15,T15,Procedure 241 248	massage
16,T16,Temporal 229 240	concomitant
17,R2,Has_temporal Arg1:T11 Arg2:T12
18,R3,Has_temporal Arg1:T14 Arg2:T13
19,R4,Has_temporal Arg1:T15 Arg2:T16
20,T17,Procedure 261 272	acupuncture
0,T1,Temporal 0 5	Prior
1,T2,Qualifier 17 32	investigational
2,T3,Drug 33 49	anti-HIV vaccine
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,R2,Has_temporal Arg1:T3 Arg2:T1
5,T4,Temporal 51 58	Ongoing
6,T5,Procedure 59 66	therapy
7,R3,Has_temporal Arg1:T5 Arg2:T4
8,T6,Drug 94 118	Systemic corticosteroids
9,T7,Multiplier 120 132	Short course
10,T8,Multiplier 133 162	less than or equal to 21 days
11,T9,Condition 166 181	corticosteroids
12,T10,Negation 182 192	is allowed
13,R4,Subsumes Arg1:T7 Arg2:T8
14,R5,Has_multiplier Arg1:T9 Arg2:T7
15,R6,Has_negation Arg1:T9 Arg2:T10
16,T11,Scope 120 192	Short course less than or equal to 21 days of corticosteroids is allowed
17,T12,Drug 194 226	Systemic chemotherapeutic agents
18,T13,Drug 228 255	Nephrotoxic systemic agents
19,T14,Drug 267 282	aminoglycosides
20,T15,Drug 284 298	amphotericin B
21,T16,Drug 300 309	cidofovir
22,T17,Drug 311 320	cisplatin
23,T18,Drug 322 331	foscarnet
24,T19,Drug 333 344	pentamidine
25,T20,Procedure 346 373	Immunomodulatory treatments
26,T21,Drug 384 397	Interleukin-2
27,T22,Drug 399 421	Investigational agents
28,R7,Subsumes Arg1:T20 Arg2:T21
29,*,OR T14 T15 T16 T17 T18 T19 T20 T22 T13 T12 T6
30,R8,Has_scope Arg1:T6 Arg2:T11
31,T23,"Scope 94 421	Systemic corticosteroids. Short course less than or equal to 21 days of corticosteroids is allowed; Systemic chemotherapeutic agents; Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine; Immunomodulatory treatments including Interleukin-2; Investigational agents"
32,R9,Has_scope Arg1:T5 Arg2:T23
33,T24,Condition 429 436	allergy
34,T25,Condition 437 448	sensitivity
35,T26,Condition 456 472	hypersensitivity
36,T27,Drug 476 501	components of study drugs
37,T28,Drug 503 506	ART
38,R10,Subsumes Arg1:T27 Arg2:T28
39,T29,Drug 508 529	or their formulations
40,*,OR T27 T29
41,T30,Scope 476 529	components of study drugs (ART) or their formulations
42,R11,Has_scope Arg1:T26 Arg2:T30
43,*,OR T25 T24 T26
44,T31,Condition 546 557	alcohol use
45,T32,Condition 554 557	use
46,T33,Condition 538 542;561 571	drug dependence
47,T34,Condition 546 553;561 571	alcohol dependence
48,*,OR T33 T34 T31 T32
49,T35,Qualifier 577 629	would interfere with adherence to study requirements
50,T36,Scope 538 571	drug or alcohol use or dependence
51,T37,Temporal 531 537	Active
52,R12,Has_temporal Arg1:T36 Arg2:T37
53,R13,Has_qualifier Arg1:T36 Arg2:T35
54,T38,Condition 650 669	psychiatric illness
55,T39,Condition 639 646;662 669	medical illness
56,*,OR T38 T39
57,T40,Qualifier 631 638	Serious
58,T41,Scope 639 669	medical or psychiatric illness
59,R14,Has_qualifier Arg1:T41 Arg2:T40
60,T42,Qualifier 675 739	would interfere with the ability to adhere to study requirements
61,R15,Has_qualifier Arg1:T41 Arg2:T42
62,T43,Condition 741 748;758 779	Chronic hepatitis B infection
63,T44,Condition 752 779	acute hepatitis B infection
64,T45,Drug 788 812	female hormonal products
65,T46,Qualifier 822 830;834 845	estrogen derivatives
66,T47,Qualifier 822 830	estrogen
67,*,OR T46 T47
68,T48,Scope 822 845	estrogen or derivatives
69,R16,Has_scope Arg1:T45 Arg2:T48
0,T1,Parsing_Error 0 9	Patients:
1,T3,Measurement 110 128	post-void residual
2,T4,Measurement 141 144	PVR
3,T5,Value 145 152	> 100cc
4,R1,Has_value Arg1:T4 Arg2:T5
5,R2,Subsumes Arg1:T3 Arg2:T4
6,T6,Value 101 109	elevated
7,R3,Has_value Arg1:T3 Arg2:T6
8,T7,Condition 162 180	bleeding condition
9,T8,Procedure 187 209	anti-coagulant therapy
10,T9,Condition 240 243	HIV
11,T10,Condition 245 253	lymphoma
12,T11,Observation 216 233	immunosuppression
13,*,OR T9 T10
14,T12,"Scope 240 253	HIV, lymphoma"
15,R4,Subsumes Arg1:T11 Arg2:T12
16,T13,Condition 261 279	multiple sclerosis
17,T14,Condition 289 321	progressive neurological disease
18,R5,Subsumes Arg1:T14 Arg2:T13
19,T15,Condition 351 369	systemic infection
20,T16,Condition 381 404	urinary tract infection
21,T17,Condition 342 347;360 369	local infection
22,*,OR T15 T17
23,T18,Scope 342 369	local or systemic infection
24,R6,Subsumes Arg1:T18 Arg2:T16
25,T19,Condition 423 453	intrinsic sphincter deficiency
26,T20,Measurement 470 503	maximal urethral closure pressure
27,T21,Value 507 517	<20 cm H2O
28,R7,Has_value Arg1:T20 Arg2:T21
29,R8,AND Arg1:T19 Arg2:T20
30,T22,Procedure 528 546	sub-urethral sling
31,T23,Temporal 519 527	Previous
32,R9,Has_temporal Arg1:T22 Arg2:T23
33,T24,Condition 560 587	overactive bladder symptoms
34,T26,Qualifier 548 559	Predominant
35,R11,Has_qualifier Arg1:T24 Arg2:T26
36,T2,Condition 19 27	pregnant
37,T27,Mood 31 49	planning to become
38,T28,Condition 50 58	pregnant
39,T29,Temporal 59 75	during the study
40,T30,Temporal 79 92	in the future
41,R12,Has_mood Arg1:T28 Arg2:T27
42,*,OR T2 T28
43,*,OR T30 T29
44,T31,Scope 59 92	during the study or in the future
45,T32,Scope 19 58	pregnant or planning to become pregnant
46,R13,Has_scope Arg1:T32 Arg2:T31
47,T25,Condition 560 578	overactive bladder
48,R10,multi Arg1:T24 Arg2:T25
0,T1,Condition 12 29	systemic diseases
1,T2,Condition 44 62	local inflammation
2,T3,Condition 44 49;70 79	local infection
3,*,OR T3 T2
4,T4,Observation 86 93	history
5,T5,Condition 97 114	allergic reaction
6,T6,Drug 118 135	local anesthetics
7,T7,Condition 137 162	gastrointestinal bleeding
8,T8,Condition 137 153;166 176	gastrointestinal ulceration
9,R1,AND Arg1:T5 Arg2:T6
10,*,OR T5 T8 T7
11,T9,"Scope 97 176	allergic reaction to local anesthetics, gastrointestinal bleeding or ulceration"
12,R2,Has_temporal Arg1:T9 Arg2:T4
13,T10,Condition 179 193;213 221	Cardiovascular diseases
14,T11,Condition 195 201;213 221	kidney diseases
15,T12,Condition 205 221	hepatic diseases
16,*,OR T10 T11 T12
17,T13,Drug 255 270	antidepressants
18,T14,Drug 272 281	diuretics
19,T15,Drug 285 299	anticoagulants
20,*,OR T13 T14 T15
21,T16,Condition 302 308	Asthma
22,T17,Condition 313 320	allergy
23,T18,Drug 324 331	aspirin
24,T19,Drug 333 342	ibuprofen
25,T20,Drug 356 390	nonsteroidal antiinflammatory drug
26,T21,Qualifier 346 355	any other
27,R3,Has_qualifier Arg1:T20 Arg2:T21
28,*,OR T19 T20 T18
29,T22,"Scope 324 390	aspirin, ibuprofen or any other nonsteroidal antiinflammatory drug"
30,R4,Has_scope Arg1:T17 Arg2:T22
31,*,OR T16 T17
32,T23,Multiplier 393 404	Regular use
33,T24,Condition 412 446	nonsteroidal antiinflammatory drug
34,R5,Has_multiplier Arg1:T24 Arg2:T23
35,T25,Condition 449 458	Pregnancy
36,T26,Observation 462 476	breast feeding
37,*,OR T26 T25
0,T1,Qualifier 8 14	DSM-IV
1,T2,Condition 28 47	cannabis dependence
2,T3,Multiplier 49 56	>1 week
3,T4,Condition 57 67	detoxified
4,T5,Condition 72 81	abstinent
5,T6,Scope 57 81	detoxified and abstinent
6,R1,Has_multiplier Arg1:T6 Arg2:T3
7,R2,Has_qualifier Arg1:T2 Arg2:T1
8,T7,Non-query-able 84 161	Able to provide written informed consent and to comply with study procedures.
9,T8,Non-query-able 163 206	Dutch speaking (Dutch as primary language).
0,T1,Procedure 14 24	craniotomy
1,T2,Condition 29 50	supratentorial tumors
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Procedure 57 75	general anesthesia
4,R2,AND Arg1:T1 Arg2:T3
5,T4,Measurement 77 115	American Society of Anaesthesiologists
6,T5,Measurement 117 120	ASA
7,R3,Subsumes Arg1:T4 Arg2:T5
8,T6,Value 122 123	2
9,T7,Measurement 135 138	ASA
10,T8,Value 139 140	3
11,T9,Qualifier 128 134	stable
12,R4,Has_qualifier Arg1:T7 Arg2:T9
13,R5,Has_value Arg1:T7 Arg2:T8
14,R6,Has_value Arg1:T4 Arg2:T6
15,*,OR T4 T7
16,T10,Procedure 151 167	Elective surgery
17,T11,Measurement 183 201	Glasgow Coma Scale
18,T12,Measurement 203 206	GCS
19,T13,Value 208 213	15/15
20,R7,Subsumes Arg1:T11 Arg2:T12
21,R8,Has_value Arg1:T11 Arg2:T13
0,T1,Procedure 0 21	small bowel resection
1,T2,Procedure 23 48	right sided hemicolectomy
2,T3,Condition 56 81	chronic diarrheal disease
3,T4,Condition 83 97	celiac disease
4,T5,Condition 99 120	lactose malabsorption
5,T6,Condition 122 149	Inflammatory bowel diseases
6,T7,Condition 156 175	microscopic colitis
7,*,OR T6 T7 T5 T4
8,T8,"Scope 83 175	celiac disease, lactose malabsorption, Inflammatory bowel diseases, incl microscopic colitis"
9,R1,Subsumes Arg1:T3 Arg2:T8
10,T9,Condition 178 187	pregnancy
11,T10,Temporal 208 232	within next three months
12,T11,Condition 198 207	pregnancy
13,T12,Mood 189 197	wish for
14,R2,Has_mood Arg1:T11 Arg2:T12
15,R3,Has_temporal Arg1:T11 Arg2:T10
16,T13,Condition 234 241	allergy
17,T14,Drug 245 249	eggs
18,R4,AND Arg1:T13 Arg2:T14
19,T15,Condition 251 258	allergy
20,T16,Drug 262 286	constituents in Xenbilox
21,T17,Drug 302 323	chenodeoxycholic acid
22,R5,Subsumes Arg1:T16 Arg2:T17
23,R6,AND Arg1:T15 Arg2:T16
24,T18,Condition 326 345	acute cholecystitis
25,T19,Temporal 346 363	within two months
26,R7,Has_temporal Arg1:T18 Arg2:T19
27,T20,Condition 365 386	chronic cholecystitis
28,T21,Condition 388 410	cirrhosis of the liver
29,T22,Mood 412 421	suspected
30,T23,Condition 422 453	obstructive choledocholithiasis
31,R8,Has_mood Arg1:T23 Arg2:T22
32,T24,Condition 455 462	icterus
0,T1,Drug 31 39	morphine
1,T2,Multiplier 45 71	daily dose more than 120mg
2,R1,Has_multiplier Arg1:T1 Arg2:T2
3,T3,Drug 75 83	Fentanyl
4,T4,Multiplier 89 117	daily dose more than 50ug/hr
5,R2,Has_multiplier Arg1:T3 Arg2:T4
6,*,OR T1 T3
7,T5,Condition 145 169;179 187	abnormalities in hepatic function
8,T6,Condition 145 161;173 187	abnormalities in renal function
9,*,OR T5 T6
10,T7,Condition 319 339	abnormalities in CNS
11,T8,Condition 319 335;356 379	abnormalities in cardiovascular function
12,T9,Condition 319 335;341 352;371 379	abnormalities in respiratory function
13,*,OR T9 T8 T7
14,T10,Drug 479 494	antidepressants
15,T11,Drug 498 518	anti-epileptic drugs
16,*,OR T10 T11 T12 T13 T14 T15 T16 T17
17,T12,Drug 520 538	sedative hypnotics
18,T13,Drug 540 578	selective serotonin reuptake inhibitor
19,T14,Drug 580 603	short-acting analgesics
20,T15,Drug 605 624	topical medications
21,T16,Drug 629 640	anesthetics
22,T17,Drug 648 664	muscle relaxants
23,T18,Drug 677 685	Tramadol
24,T19,Drug 686 699	Acetaminophen
25,*,OR T18 T19
26,T20,Scope 677 699	Tramadol/Acetaminophen
27,T21,"Scope 479 664	antidepressants or anti-epileptic drugs, sedative hypnotics, selective serotonin reuptake inhibitor, short-acting analgesics, topical medications and anesthetics and/or muscle relaxants"
28,T22,Temporal 665 699	when taking Tramadol/Acetaminophen
29,T23,Reference_point 670 699	taking Tramadol/Acetaminophen
30,R3,Has_index Arg1:T22 Arg2:T23
31,R4,Has_temporal Arg1:T21 Arg2:T22
0,T1,Person 0 3	age
1,T2,Value 4 21	=18 and <75 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 38 44	stable
4,T4,Condition 45 68	coronary artery disease
5,T5,Procedure 81 84	PCI
6,T6,Mood 69 80	referred to
7,R2,Has_mood Arg1:T5 Arg2:T6
8,T7,Qualifier 91 124	artery suitable for IVUS pullback
9,R3,Has_qualifier Arg1:T5 Arg2:T7
10,R4,Has_qualifier Arg1:T4 Arg2:T3
11,T8,Informed_consent 127 161	signed informed consent before PCI
0,T1,Informed_consent 0 33	Written informed consent obtained
1,T2,Person 35 39	Male
2,T3,Person 44 50	female
3,T4,Person 60 64	aged
4,T5,Value 65 82	20 years or older
5,R1,Has_value Arg1:T4 Arg2:T5
6,T6,Temporal 83 102	at informed consent
7,T7,Reference_point 86 102	informed consent
8,R2,Has_index Arg1:T6 Arg2:T7
9,*,OR T2 T3
10,T8,Condition 104 126	Essential hypertension
11,T9,Drug 150 185	angiotensin II receptor antagonists
12,T10,Drug 190 214	calcium channel blockers
13,T11,Negation 135 140	never
14,*,OR T9 T10
15,T12,Scope 150 214	angiotensin II receptor antagonists and calcium channel blockers
16,R3,Has_negation Arg1:T12 Arg2:T11
0,T1,Person 0 3	Men
1,T2,Value 4 21	18 years or older
2,T3,Person 4 21	18 years or older
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Condition 23 26	ONB
5,T5,Temporal 27 53	within 1 year post-surgery
6,T6,Procedure 46 53	surgery
7,T7,Reference_point 46 53	surgery
8,R2,Has_index Arg1:T5 Arg2:T7
9,R3,AND Arg1:T7 Arg2:T6
0,T1,Condition 27 34	allergy
1,T2,Condition 38 54	hypersensitivity
2,*,OR T1 T2
3,T3,Drug 58 66	tramadol
4,T4,Scope 27 54	allergy or hypersensitivity
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 80 88	epilepsy
7,T6,Condition 92 103	convulsions
8,*,OR T5 T6
9,T7,Drug 141 156	analgesic drugs
10,T8,Drug 174 202	monoamine oxidase inhibitors
11,T9,Measurement 244 247	ICP
12,T10,Value 237 243	raised
13,R2,Has_value Arg1:T9 Arg2:T10
14,T11,Condition 250 257	Obesity
15,T12,Person 259 264	women
16,T13,Measurement 272 287	body mass index
17,T14,Value 288 297	>35 kg/m2
18,T15,Person 301 304	men
19,T16,Measurement 312 327	body mass index
20,T17,Value 328 337	>42 kg/m2
21,R3,AND Arg1:T13 Arg2:T12
22,R4,Has_value Arg1:T13 Arg2:T14
23,R5,AND Arg1:T16 Arg2:T15
24,R6,Has_value Arg1:T16 Arg2:T17
25,*,OR T13 T16
26,T18,Scope 259 337	women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2
27,R7,Has_scope Arg1:T11 Arg2:T18
28,T19,Post-eligibility 340 356	Language barrier
29,T20,Drug 389 408	Ca channel blockers
30,T21,Drug 375 385	B-blockers
31,*,OR T21 T20
32,T22,Person 438 441	age
33,T23,Value 420 434	above 65 years
34,R8,Has_value Arg1:T22 Arg2:T23
0,T1,Procedure 26 35	surgeries
1,T2,Qualifier 8 25	lower third molar
2,R1,Has_qualifier Arg1:T1 Arg2:T2
0,T1,Condition 10 19	dependent
1,T2,Drug 27 36	substance
2,T3,Negation 37 47	other than
3,T4,Drug 48 56	cannabis
4,T5,Drug 58 65	alcohol
5,T6,Drug 69 77	nicotine
6,*,OR T6 T5 T4
7,T7,"Scope 48 77	cannabis, alcohol or nicotine"
8,R1,Has_negation Arg1:T7 Arg2:T3
9,R2,Has_scope Arg1:T2 Arg2:T7
10,R3,AND Arg1:T1 Arg2:T2
11,T8,Condition 95 117	major internal disease
12,T9,Condition 129 137	diabetes
13,T10,Condition 139 161	cardiovascular disease
14,T11,Condition 163 175	lung disease
15,T12,Condition 186 200	kidney disease
16,T13,Condition 177 182;193 200	liver disease
17,*,OR T9 T10 T11 T12 T13
18,T14,"Scope 129 200	diabetes, cardiovascular disease, lung disease, liver or kidney disease"
19,R4,Subsumes Arg1:T8 Arg2:T14
20,T15,Condition 232 253	neurological disorder
21,T16,Observation 221 228	history
22,T17,Qualifier 207 213	active
23,*,OR T16 T17
24,T18,Scope 207 228	active or any history
25,R5,Has_scope Arg1:T15 Arg2:T18
26,T19,Condition 284 300	seizure disorder
27,T20,Condition 302 310	epilepsy
28,T21,Condition 312 318	stroke
29,T22,Condition 320 340	neurological disease
30,T23,Condition 342 362	cognitive impairment
31,T24,Condition 364 375	head trauma
32,*,OR T19 T20 T21 T22 T23 T24 T27
33,T25,Condition 381 412	prolonged loss of consciousness
34,T26,Qualifier 414 425	>10 minutes
35,T27,Condition 431 449	migraine headaches
36,R6,Has_qualifier Arg1:T25 Arg2:T26
37,R7,AND Arg1:T24 Arg2:T25
38,T28,"Scope 284 449	seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches"
39,R8,Subsumes Arg1:T15 Arg2:T28
40,T29,Qualifier 455 461	active
41,T30,Observation 467 474	history
42,*,OR T29 T30
43,T31,Condition 480 500	psychiatric disorder
44,T32,Condition 532 542	depression
45,T33,Condition 544 557	schizophrenia
46,T34,Condition 559 575	bipolar disorder
47,T35,Condition 577 584	anxiety
48,T36,Condition 595 616	psychiatric disorders
49,*,OR T32 T33 T34 T35 T36
50,T37,Qualifier 589 594	other
51,R9,Has_qualifier Arg1:T36 Arg2:T37
52,T38,"Scope 532 616	depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders"
53,R10,Subsumes Arg1:T31 Arg2:T38
54,T39,Scope 455 474	active or a history
55,R11,Has_scope Arg1:T31 Arg2:T39
56,T40,Condition 619 625	Asthma
57,T41,Condition 634 650	hypersensitivity
58,T42,Condition 654 661	allergy
59,*,OR T42 T41
60,T43,Drug 665 681	n-acetylcysteine
61,T44,Scope 634 661	hypersensitivity or allergy
62,T45,Procedure 696 711	chronic therapy
63,T46,Drug 763 779	n-acetylcysteine
64,T47,Temporal 780 817	within 30 days prior to randomization
65,T48,Drug 825 838	nitroglycerin
66,T49,Drug 840 854	ACE inhibitors
67,T50,Drug 858 880	antihypertensive drugs
68,T51,Drug 882 897	anti-coagulants
69,*,OR T50 T51 T49 T48
70,T52,"Scope 825 897	nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants"
71,R12,AND Arg1:T44 Arg2:T43
72,R13,AND Arg1:T45 Arg2:T46
73,R14,Has_temporal Arg1:T45 Arg2:T47
74,R15,Subsumes Arg1:T45 Arg2:T52
75,T53,Condition 901 927	Exclusion criteria for MRI
76,T54,Device 936 953	metal in the body
77,T55,Condition 968 982	claustrophobia
78,*,OR T54 T55
79,T56,Scope 936 982	metal in the body and/or having claustrophobia
80,R16,Subsumes Arg1:T53 Arg2:T56
0,T1,Procedure 16 30	histologically
1,T2,Procedure 32 46	radiologically
2,T3,Procedure 50 66	haematologically
3,*,OR T1 T2 T3
4,T4,Value 67 76	confirmed
5,T5,Condition 77 87	malignancy
6,T6,Condition 94 98	pain
7,R1,AND Arg1:T5 Arg2:T6
8,T7,"Scope 16 66	histologically, radiologically or haematologically"
9,R2,Has_value Arg1:T7 Arg2:T4
10,T8,Drug 211 223	weak opioids
11,T9,Drug 227 241	strong opioids
12,*,OR T8 T9
13,T10,Temporal 246 292	at least 72 hours prior to the start the study
14,T11,Scope 211 241	weak opioids or strong opioids
15,R3,Has_temporal Arg1:T11 Arg2:T10
16,T12,Measurement 380 405	VAS (Visual analog scale)
17,T13,Value 406 412	>=40mm
18,R4,Has_value Arg1:T12 Arg2:T13
0,T1,Mood 0 7	planned
1,T2,Qualifier 8 16	elective
2,T3,Condition 17 32	cholecystectomy
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,R2,Has_mood Arg1:T3 Arg2:T1
0,T1,Condition 11 30	non-cardiac illness
1,T2,Condition 0 7;23 30	cardiac illness
2,*,OR T1 T2
3,T3,Observation 36 51	life expectancy
4,T4,Value 55 74	less than two years
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Device 100 113	IVUS catheter
7,T6,Procedure 88 113	advance the IVUS catheter
8,T7,Qualifier 77 84	failure
9,R2,Has_qualifier Arg1:T6 Arg2:T7
10,R3,multi Arg1:T6 Arg2:T5
11,T8,Qualifier 126 140	culprit lesion
12,R4,Has_qualifier Arg1:T6 Arg2:T8
13,T9,Condition 143 166	acute coronary syndrome
14,T10,Condition 168 192	congestive heart failure
15,T11,Measurement 193 197	NYHA
16,T12,Value 198 204	III-IV
17,R5,Has_value Arg1:T11 Arg2:T12
18,R6,AND Arg1:T10 Arg2:T11
19,T13,Condition 206 223	diabetes mellitus
20,T14,Condition 225 247	chronic kidney disease
21,T15,Procedure 258 261	PCI
22,T16,Temporal 249 257	previous
23,R7,Has_temporal Arg1:T15 Arg2:T16
24,T17,Qualifier 269 283	target vessel
25,R8,Has_qualifier Arg1:T15 Arg2:T17
26,T18,Qualifier 269 282	target vessel
27,R9,Has_qualifier Arg1:T15 Arg2:T18
28,T19,Condition 284 309	heavily calcified vessels
29,T20,Condition 311 318	allergy
30,T21,Drug 322 331	metformin
31,R10,AND Arg1:T20 Arg2:T21
0,T1,Condition 0 33	Upper urinary tract deterioration
1,T2,Condition 48 65	diabetes mellitus
2,T3,Qualifier 35 47	Uncontrolled
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 84 101	pelvic recurrence
5,T5,Condition 75 80;91 101	local recurrence
6,*,OR T5 T4
7,T6,Procedure 103 124	Adjuvant chemotherapy
8,T7,Condition 126 143	Chronic retention
9,T8,Condition 145 157	Pouch stones
10,T9,Condition 159 177	Urethral stricture
11,T10,Condition 181 207	urethro-ileal maldirection
12,T11,Drug 224 234	Mebeverine
13,T12,Condition 209 220	Sensitivity
14,R2,AND Arg1:T12 Arg2:T11
15,T13,Qualifier 236 245	Untreated
16,T14,Condition 246 266	chronic constipation
17,R3,Has_qualifier Arg1:T14 Arg2:T13
18,T15,Qualifier 275 286	symptomatic
19,T16,Qualifier 268 274	Active
20,T17,Condition 287 304	urinary infection
21,R4,Has_qualifier Arg1:T17 Arg2:T15
0,T1,Condition 0 22	Secondary hypertension
1,T2,Condition 26 48	malignant hypertension
2,*,OR T1 T2
3,T3,Condition 50 67	Diabetes mellitus
4,T4,Observation 69 76	History
5,T5,Mood 80 88	evidence
6,T6,Condition 94 100	stroke
7,*,OR T5 T4
8,T7,Scope 69 88	History or evidence
9,R1,Has_scope Arg1:T6 Arg2:T7
10,T8,Condition 102 109;125 136	Hepatic abnormality
11,T9,Condition 113 136	hematologic abnormality
12,T10,Condition 138 163	Mild Cognitive Impairment
13,T11,Condition 167 175	Dementia
14,*,OR T8 T9
15,*,OR T10 T11
16,T12,Measurement 177 198	Serum potassium level
17,T13,Value 199 210	= 5.5 mEq/L
18,T14,Measurement 212 234	Serum creatinine level
19,T15,Value 235 246	= 3.0 mg/dL
20,R2,Has_value Arg1:T12 Arg2:T13
21,R3,Has_value Arg1:T14 Arg2:T15
22,T16,Condition 257 272	chronic disease
23,T17,Condition 248 253;265 272	Acute disease
24,*,OR T16 T17
25,T18,Condition 274 281	Allergy
26,T19,Drug 285 294	any drugs
27,R4,AND Arg1:T18 Arg2:T19
28,T20,Condition 296 305	Pregnancy
0,T1,"Value 7 29	18-65 years, inclusive"
1,T2,Person 3 6	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Qualifier 47 65	moderate to severe
4,T4,Condition 66 68	AT
5,R2,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Non-query-able 70 93	confirmed by Dr. Wilson
7,T6,Condition 152 162	chronic AT
8,T7,Temporal 164 181	>6 month duration
9,R3,Has_temporal Arg1:T6 Arg2:T7
10,T8,Condition 200 276	pain while palpating the intratendinous swelling part of the Achilles tendon
11,T9,Condition 281 328	relief of pain when tendon placed under tension
12,T10,Condition 370 385	AT-related pain
13,T11,Observation 356 369	self-reported
14,T12,Temporal 386 407	for at least 6 months
15,T13,Measurement 412 442	VAS (Visual Analog Scale) pain
16,T14,Value 443 445	>5
17,R4,Has_value Arg1:T13 Arg2:T14
18,T15,Qualifier 447 457	0-10 scale
19,R5,Has_qualifier Arg1:T13 Arg2:T15
20,R6,Has_temporal Arg1:T10 Arg2:T12
21,T16,Scope 371 458	T-related pain for at least 6 months and VAS (Visual Analog Scale) pain >5 (0-10 scale)
22,R7,Has_context Arg1:T16 Arg2:T11
23,T17,Condition 477 515	failure of eccentric exercise protocol
24,T18,Value 517 529	at least 75%
25,R8,Has_value Arg1:T17 Arg2:T18
26,T19,Observation 463 476	self-reported
27,R9,Has_context Arg1:T17 Arg2:T19
28,T20,Observation 546 559	self-reported
29,T21,Condition 560 620	failure of at least 2 of the 3 most common treatments for AT
30,T22,Drug 622 628	NSAIDS
31,T23,Procedure 630 634	rest
32,T24,Drug 635 638	ice
33,T25,Procedure 642 648	taping
34,*,OR T25 T24 T23 T22
35,T26,"Scope 622 648	NSAIDS, rest/ice or taping"
36,R10,Subsumes Arg1:T21 Arg2:T26
37,T27,Procedure 673 680	surgery
38,T28,Parsing_Error 654 725	patient considered surgery but decided to wait and/or refused surgery -
0,T1,Condition 26 39	adverse event
1,T2,Procedure 108 128	smallpox vaccination
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Undefined_semantics 48 97	previous participation in VA-001 or VA-006 trials
4,T4,Condition 131 137	Eczema
5,T5,Observation 139 156	history of eczema
6,T6,Condition 158 185	exfoliative skin conditions
7,T7,Condition 187 193	wounds
8,T8,Condition 195 200	burns
9,T9,Condition 205 226	other skin conditions
10,T10,Subjective_judgement 227 259	at the investigator's discretion
11,*,OR T4 T5 T6 T7 T8 T9
12,T11,Condition 264 291	history of immunodeficiency
13,T12,Procedure 329 341	radiotherapy
14,T13,Procedure 345 357	chemotherapy
15,T14,Temporal 311 319	recently
16,*,OR T12 T13 T15 T17 T18
17,T15,Drug 359 386	adrenocorticotropic hormone
18,T16,Drug 388 392	ACTH
19,T17,Drug 395 410	corticosteroids
20,T18,Procedure 415 438	immunosuppressive drugs
21,R2,Subsumes Arg1:T15 Arg2:T16
22,T19,"Scope 329 438	radiotherapy or chemotherapy, adrenocorticotropic hormone (ACTH), corticosteroids, or immunosuppressive drugs"
23,R3,Has_temporal Arg1:T19 Arg2:T14
24,T20,Condition 441 452	Eye disease
25,T21,Procedure 466 482	topical steroids
26,R4,AND Arg1:T20 Arg2:T21
27,T22,Condition 504 541	disorders of immunoglobulin synthesis
28,T23,Qualifier 485 490	Known
29,T24,Qualifier 494 503	suspected
30,*,OR T24 T23
31,T25,Scope 485 503	Known or suspected
32,R5,Has_scope Arg1:T22 Arg2:T25
33,T26,Condition 544 552	Leukemia
34,T27,Condition 554 563	lymphomas
35,T28,Condition 577 585	melanoma
36,T29,Condition 596 615	malignant neoplasms
37,T30,Qualifier 616 641	affecting the bone marrow
38,T31,Condition 630 641	bone marrow
39,T32,Condition 645 662	lymphatic systems
40,T33,Qualifier 616 625;645 662	affecting lymphatic systems
41,R6,multi Arg1:T30 Arg2:T31
42,R7,multi Arg1:T33 Arg2:T32
43,*,OR T33 T30
44,T34,Scope 616 662	affecting the bone marrow or lymphatic systems
45,R8,Has_scope Arg1:T29 Arg2:T34
46,*,OR T26 T27 T28 T29
47,T35,Condition 674 695	diagnosed with cancer
48,T36,Procedure 723 735	chemotherapy
49,T37,Procedure 739 756	radiation therapy
50,T38,Temporal 757 792	during the vaccination healing time
51,T39,Reference_point 768 792	vaccination healing time
52,R9,Has_index Arg1:T38 Arg2:T39
53,*,OR T36 T37
54,T40,Scope 723 756	chemotherapy or radiation therapy
55,R10,Has_temporal Arg1:T40 Arg2:T38
56,T41,Person 800 820	transplant recipient
57,T42,Negation 822 828	except
58,T43,Condition 833 851	corneal transplant
59,R11,Has_negation Arg1:T43 Arg2:T42
60,T44,Condition 858 866	pregnant
61,T45,Observation 868 886	planning pregnancy
62,T46,Observation 890 904	breast feeding
63,*,OR T44 T45 T46
64,T48,Person 1025 1050	close/intimate contact(s)
65,T49,Person 1061 1064	age
66,T50,Value 1051 1056;1068 1077	under 12 months
67,R12,Has_value Arg1:T49 Arg2:T50
68,T51,Person 1006 1015	Household
69,*,OR T51 T48
70,T52,Condition 1091 1100	allergies
71,T53,Drug 1104 1110	phenol
72,T54,Procedure 1123 1134	antibiotics
73,T55,Qualifier 1135 1164	listed in the vaccine content
74,T56,Procedure 1149 1156	vaccine
75,R14,multi Arg1:T55 Arg2:T56
76,R15,Has_qualifier Arg1:T54 Arg2:T55
77,T57,Drug 1192 1200	ACAM2000
78,T58,Drug 1192 1200;1208 1216	ACAM2000 diluents
79,T59,"Scope 1104 1217	phenol, any of the antibiotics listed in the vaccine content, or any other component of ACAM2000 or its diluents."
80,R13,Has_scope Arg1:T52 Arg2:T59
81,*,OR T53 T54 T58 T57
82,T60,Condition 1233 1247	kidney disease
83,T61,Negation 1249 1255	except
84,T62,Condition 1256 1269	kidney stones
85,R16,Has_negation Arg1:T62 Arg2:T61
86,T63,Procedure 1296 1299	EKG
87,T64,Value 1287 1295	abnormal
88,T65,Temporal 1300 1312	at screening
89,T66,Reference_point 1303 1312	screening
90,R17,Has_index Arg1:T65 Arg2:T66
91,R18,Has_value Arg1:T63 Arg2:T64
92,R19,Has_temporal Arg1:T63 Arg2:T65
93,T67,Non-query-able 1330 1891	To mitigate the risk of enrolling at risk subjects and potentially jeopardizing subject safety an EKG will be performed prior to vaccination with ACAM2000 smallpox vaccine in all potential subjects =50 years old and for all potential subjects <50 with two cardiac risk factors as listed immediately below including; severely or morbidly obese or higher obesity classification (BMI =36); high blood pressure; high blood cholesterol; diabetes or high blood sugar; a first degree relative who had a heart condition before the age of 50; and current tobacco smokers
94,T68,Condition 1915 1920	obese
95,T69,Qualifier 1906 1914	morbidly
96,T70,Qualifier 1894 1902	Severely
97,T71,Observation 1924 1953	higher obesity classification
98,*,OR T68 T71 T72
99,R20,Has_qualifier Arg1:T68 Arg2:T69
100,R21,Has_qualifier Arg1:T68 Arg2:T70
101,T72,Measurement 1955 1958	BMI
102,T73,Value 1959 1962	=36
103,R22,Has_value Arg1:T72 Arg2:T73
104,T74,Condition 1965 1984	High blood pressure
105,T75,Condition 2008 2030	High blood cholesterol
106,T76,Condition 2054 2062	Diabetes
107,T77,Condition 2066 2082	high blood sugar
108,*,OR T76 T77
109,T78,Person 2106 2129	A first degree relative
110,T79,Condition 2187 2202	heart condition
111,T80,Temporal 2203 2223	before the age of 50
112,T81,Reference_point 2214 2223	age of 50
113,T82,Person 2214 2217	age
114,T83,Value 2221 2223	50
115,R23,Has_value Arg1:T82 Arg2:T83
116,R24,multi Arg1:T81 Arg2:T82
117,R25,Has_index Arg1:T80 Arg2:T81
118,R26,Has_temporal Arg1:T79 Arg2:T80
119,R27,AND Arg1:T78 Arg2:T79
120,T84,Person 2144 2150	mother
121,T85,Person 2152 2158	father
122,T86,Person 2160 2167	brother
123,T87,Person 2169 2175	sister
124,*,OR T84 T85 T86 T87
125,T88,"Scope 2144 2175	mother, father, brother, sister"
126,R28,Subsumes Arg1:T78 Arg2:T88
127,T89,Observation 2235 2249	smokes tobacco
128,T90,Observation 2235 2241;2251 2261	smokes cigarettes
129,R29,Subsumes Arg1:T89 Arg2:T90
130,T91,Condition 2264 2274	Arrhythmia
131,T92,Condition 2276 2283	Syncope
132,T93,Condition 2295 2310	cardiac disease
133,R30,AND Arg1:T92 Arg2:T93
134,T94,Condition 2312 2342	Previous myocardial infarction
135,T95,Condition 2344 2350	Angina
136,T96,Condition 2352 2375	Coronary artery disease
137,T97,Condition 2377 2401	Congestive heart failure
138,T98,Condition 2403 2417	Cardiomyopathy
139,T99,Condition 2429 2454	transient ischemic attack
140,T100,Condition 2419 2425	Stroke
141,*,OR T100 T99
142,T101,Condition 2456 2467	Myocarditis
143,T102,Condition 2469 2481	Pericarditis
144,T103,Condition 2483 2493	Chest pain
145,T104,Condition 2497 2530	shortness of breath with activity
146,T105,Condition 2558 2574	peripheral edema
147,T106,Condition 2576 2594	heart palpitations
148,T107,Condition 2596 2605	dry cough
149,T108,Condition 2607 2626	irregular heartbeat
150,T109,Condition 2628 2645	excessive fatigue
151,T110,Condition 2659 2666	syncope
152,*,OR T103 T104 T105 T106 T107 T108 T109 T110
153,T111,Condition 2668 2690	Other heart conditions
154,T47,Person 906 912	female
155,T112,Observation 925 947	childbearing potential
156,T113,Value 958 966	negative
157,T114,Measurement 967 981	pregnancy test
158,T115,Temporal 982 1002	prior to vaccination
159,T116,Procedure 991 1002	vaccination
160,T117,Reference_point 991 1002	vaccination
161,R31,multi Arg1:T117 Arg2:T116
162,R32,AND Arg1:T115 Arg2:T116
163,R33,Has_temporal Arg1:T114 Arg2:T115
164,R34,Has_value Arg1:T114 Arg2:T113
165,T118,Scope 906 947	female subjects of childbearing potential
166,A1,Optional T118
167,R35,AND Arg1:T118 Arg2:T114
0,T1,Procedure 59 69;9 29	transplant second single kidney
1,T2,Procedure 0 5;16 29;59 69	First single kidney transplant
2,*,OR T2 T1
3,T3,Qualifier 31 40;51 57	cadaveric donors
4,T4,Qualifier 44 57	living donors
5,*,OR T3 T4
6,T5,Scope 31 57	cadaveric or living donors
7,R1,Has_scope Arg1:T2 Arg2:T5
8,R2,Has_scope Arg1:T1 Arg2:T5
9,T6,Mood 83 97	Considered for
10,T7,Procedure 100 135	standard immunosuppressive protocol
11,R3,Has_mood Arg1:T7 Arg2:T6
12,T8,Post-eligibility 138 234	Must be capable of giving written informed connect for participation in the study for 24 months.
0,T1,Condition 24 42	fetal malformation
1,T2,Mood 11 20	certainty
2,T3,Mood 0 7	Suspect
3,*,OR T2 T3
4,T4,Scope 0 20	Suspect or certainty
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 76 88	preeclampsia
7,T6,Condition 90 101	multiparity
8,T7,Condition 103 116	preterm labor
9,*,OR T6 T7 T5
10,T8,Condition 129 145	adverse reaction
11,T9,Drug 149 172	a-2 adrenergic agonists
12,R2,AND Arg1:T8 Arg2:T9
13,T10,Condition 174 192	Nicotine addiction
14,T11,Multiplier 194 205	Chronic use
15,T12,Drug 209 214	opioi
16,R3,Has_multiplier Arg1:T12 Arg2:T11
0,T1,Post-eligibility 0 31	Signed written informed consent
1,T2,Person 34 37	Age
2,T3,Value 38 46	18 to 65
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Qualifier 49 55	Normal
5,T5,Qualifier 60 67	healthy
6,T6,Temporal 178 205	during the screening period
7,T7,Reference_point 189 205	screening period
8,R2,Has_index Arg1:T6 Arg2:T7
9,T8,Observation 104 119	medical history
10,T9,Procedure 121 134	physical exam
11,T10,Measurement 136 147	vital signs
12,T11,Measurement 152 177	clinical laboratory tests
13,T12,"Scope 104 177	medical history, physical exam, vital signs and clinical laboratory tests"
14,R3,Has_qualifier Arg1:T12 Arg2:T5
15,R4,Has_qualifier Arg1:T12 Arg2:T4
16,R5,Has_temporal Arg1:T12 Arg2:T6
17,T13,Measurement 231 268	quantitative IgA immunoglobulin level
18,T14,Value 273 306	lower than 15% below normal range
19,R6,Has_value Arg1:T13 Arg2:T14
20,T15,"Context_Error 208 368	If all lab results for quantitative IgA immunoglobulin level are lower than 15% below normal range, the subject may not proceed further in the screening process"
21,T16,Undefined_semantics 371 475	Subject must meet all required subject suitability criteria that pertain to normal source plasma donors.
22,T17,Measurement 486 498	HIV serology
23,T18,Value 477 485	Negative
24,T19,Temporal 499 522	during screening period
25,T20,Reference_point 506 522	screening period
26,R7,Has_index Arg1:T19 Arg2:T20
27,R8,Has_value Arg1:T17 Arg2:T18
28,R9,Has_temporal Arg1:T17 Arg2:T19
29,T21,Condition 573 581	smallpox
30,T22,Procedure 559 568	immunized
31,R10,AND Arg1:T22 Arg2:T21
32,T23,Temporal 587 641	3 years prior to commencement of screening assessments
33,R11,Has_temporal Arg1:T22 Arg2:T23
34,T24,Reference_point 604 641	commencement of screening assessments
35,R12,Has_index Arg1:T23 Arg2:T24
36,T25,Non-query-able 643 776	and vaccination history must be confirmed by oral or written history and the presence of a visible pathognomonic smallpox vaccination
37,T26,Person 784 790	Female
38,T27,Condition 803 825	childbearing potential
39,T28,Procedure 861 882	birth control methods
40,R13,AND Arg1:T26 Arg2:T27
41,R14,AND Arg1:T26 Arg2:T28
0,T1,Condition 3 15	bilateral AT
1,T2,Condition 20 34	insertional AT
2,T3,Procedure 39 62	local steroid injection
3,T4,Temporal 63 77	within 6 weeks
4,T5,Procedure 81 97	physical therapy
5,T6,Temporal 98 112	within 4 weeks
6,R1,Has_temporal Arg1:T5 Arg2:T6
7,R2,Has_temporal Arg1:T3 Arg2:T4
8,*,OR T5 T3
9,T7,Post-eligibility 117 160	inability to comply with follow-up criteria
10,T8,Subjective_judgement 117 160	inability to comply with follow-up criteria
11,T9,Non-query-able 117 160	inability to comply with follow-up criteria
12,T10,Observation 165 172	history
13,T11,Procedure 176 206	surgery on the Achilles tendon
14,R3,Has_temporal Arg1:T11 Arg2:T10
15,T12,Condition 210 227	systemic diseases
16,T13,Condition 229 258	general inflammatory diseases
17,T14,Condition 267 290	rheumatologic disorders
18,T15,Condition 295 303	diabetes
19,*,OR T15 T14
20,T16,Scope 267 303	rheumatologic disorders and diabetes
21,R4,Subsumes Arg1:T13 Arg2:T16
22,R5,Subsumes Arg1:T12 Arg2:T13
23,T17,Drug 322 329	opioids
24,T18,Condition 334 338	pain
25,R6,AND Arg1:T17 Arg2:T18
26,T19,Multiplier 309 314	daily
27,R7,Has_multiplier Arg1:T17 Arg2:T19
28,T20,Procedure 343 358;380 387	anticoagulation therapy
29,T21,Procedure 362 387	immunosuppressive therapy
30,*,OR T21 T20
31,T22,Drug 406 412	NSAIDs
32,T23,Drug 416 424	steroids
33,*,OR T22 T23
34,T24,Condition 443 452	pregnancy
0,T1,Post-eligibility 0 33	Written maternal informed consent
1,T2,Condition 35 54	Singleton pregnancy
2,T3,Measurement 56 71	Gestational age
3,T4,Value 72 82	= 37 weeks
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Measurement 85 88	ASA
6,T6,Value 89 90	I
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Measurement 92 95	BMI
9,T8,Value 96 100	< 30
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Condition 111 131	cephalic presentatio
0,T1,Condition 0 17	Diabetes mellitus
1,T2,Measurement 21 35	plasma glucose
2,T3,"Value 36 41	>11,1"
3,R1,Has_value Arg1:T2 Arg2:T3
4,*,OR T1 T2
5,T4,Temporal 42 54	at admission
6,R2,Has_temporal Arg1:T2 Arg2:T4
7,T5,Drug 67 75	steroids
8,T6,Procedure 57 66	Receiving
9,R3,AND Arg1:T6 Arg2:T5
10,T7,Temporal 76 106	at the time of transplantation
11,T8,Reference_point 91 106	transplantation
12,R4,Has_index Arg1:T7 Arg2:T8
13,T9,Mood 110 124	likely to need
14,T10,Drug 125 133	steroids
15,T11,Temporal 134 155	after transplantation
16,T12,Reference_point 140 155	transplantation
17,R5,Has_index Arg1:T11 Arg2:T12
18,R6,Has_temporal Arg1:T10 Arg2:T11
19,R7,Has_mood Arg1:T10 Arg2:T9
20,R8,Has_temporal Arg1:T6 Arg2:T7
21,*,OR T10 T6
22,T13,Procedure 158 180	Multiorgan transplants
23,T14,Temporal 188 198	previously
24,T15,Procedure 199 244	transplanted with any other organ than kidney
25,*,OR T13 T15
26,R9,Has_temporal Arg1:T15 Arg2:T14
27,T16,Measurement 247 277	Panel reacting antibodies(PRA)
28,T17,Value 278 282	>25%
29,T18,Temporal 286 302	most recent test
30,R10,Has_temporal Arg1:T16 Arg2:T18
31,R11,Has_value Arg1:T16 Arg2:T17
32,T19,Mood 306 335	considered to be of high risk
33,T20,Condition 340 349	rejection
34,T21,Procedure 368 394	enhanced immunosuppression
35,R12,AND Arg1:T20 Arg2:T21
36,R13,Has_mood Arg1:T20 Arg2:T19
37,*,OR T16 T20
38,T22,Procedure 397 414	Renal transplants
39,T23,Qualifier 420 441	HLA-identical sibling
40,R14,Has_qualifier Arg1:T22 Arg2:T23
41,T24,Condition 444 460	Hypersensitivity
42,T25,Condition 468 478	disability
43,T26,Drug 487 510	immunosuppressive drugs
44,R15,AND Arg1:T25 Arg2:T26
45,R16,AND Arg1:T24 Arg2:T26
46,*,OR T24 T25
47,T27,Qualifier 513 542	Blood group(ABO)-incompatible
48,T28,Procedure 543 554	transplants
49,R17,Has_qualifier Arg1:T28 Arg2:T27
50,T29,Non-query-able 557 604	Unlikely to comply with the study requirements.
51,T30,Condition 628 644	positive for HIV
52,T31,Condition 628 640;646 651	positive for HBsAg
53,T32,Condition 628 640;653 664	positive for Hepatitis C
54,*,OR T32 T31 T30
55,T33,Procedure 606 616	Transplant
56,T34,Qualifier 622 627	donor
57,T35,"Scope 628 664	positive for HIV, HBsAg, Hepatitis C"
58,R18,Has_scope Arg1:T34 Arg2:T35
59,R19,Has_qualifier Arg1:T33 Arg2:T34
60,T36,Pregnancy_considerations 667 757	Female of childbearing potential planing/being pregnant or unwilling to use contraception.
0,T2,Person 0 3	Age
1,T3,Value 4 22	less than 14 years
2,R1,Has_value Arg1:T2 Arg2:T3
3,T1,Condition 24 33	Pregnancy
4,T4,Person 35 60	Estimated life expectancy
5,T5,Value 84 101	less than 90 days
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 115 123;136 153	relative contraindications
8,T7,Condition 127 153	absolute contraindications
9,*,OR T7 T6
10,T8,Procedure 157 161	CPFA
11,T9,Scope 115 153	relative or absolute contraindications
12,R3,AND Arg1:T9 Arg2:T8
13,T10,Procedure 163 172	Admission
14,T11,Visit 178 190	an other ICU
15,T12,Observation 201 217	patient remained
16,T13,Multiplier 218 240	for more than 24 hours
17,R4,Has_multiplier Arg1:T12 Arg2:T13
18,R5,AND Arg1:T10 Arg2:T11
19,R6,Has_context Arg1:T11 Arg2:T12
20,T14,Informed_consent 242 269	Absence of informed consent
0,T1,Non-query-able 0 2	NA
0,T1,Condition 10 32	Iron deficiency anemia
1,T2,Condition 35 52	H-pylori positive
2,T3,Qualifier 61 77	Second trimester
3,T4,Condition 78 87	pregnancy
4,R1,Has_qualifier Arg1:T4 Arg2:T3
5,T5,Temporal 61 77	Second trimester
6,R2,multi Arg1:T3 Arg2:T5
0,T1,Condition 37 58	psychiatric condition
1,T2,Condition 26 33;49 58	medical condition
2,*,OR T1 T2
3,T3,Qualifier 14 25	significant
4,T4,Scope 26 58	medical or psychiatric condition
5,R1,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Condition 105 122	tuberculosis (TB)
7,T6,Condition 126 129	HIV
8,T7,Procedure 92 101	treatment
9,R2,AND Arg1:T7 Arg2:T5
10,*,OR T5 T7 T6 T8 T9 T13
11,T8,Condition 131 150	renal insufficiency
12,T9,Condition 152 167	hepatic disease
13,T10,Drug 177 198	parenteral medication
14,T11,Drug 169 173;188 198	oral medication
15,*,OR T10 T11
16,T12,Qualifier 199 234	known to affect the immune function
17,T13,Scope 169 198	oral or parenteral medication
18,R3,Has_qualifier Arg1:T13 Arg2:T12
19,T14,Drug 244 259	corticosteroids
20,T15,Drug 267 290	immunosuppressant drugs
21,T16,Qualifier 261 266	other
22,R4,Has_qualifier Arg1:T15 Arg2:T16
23,T17,Condition 295 306;317 323	behavioural issues
24,T18,Condition 310 323	memory issues
25,*,OR T18 T17
26,T19,Scope 295 323	behavioural or memory issues
27,*,OR T15 T19 T14
28,T20,"Scope 244 323	corticosteroids, other immunosuppressant drugs; or behavioural or memory issues"
29,T21,Scope 169 234	oral or parenteral medication known to affect the immune function
30,R5,Subsumes Arg1:T21 Arg2:T20
31,T22,"Scope 92 323	treatment of tuberculosis (TB) or HIV; renal insufficiency; hepatic disease; oral or parenteral medication known to affect the immune function, such as corticosteroids, other immunosuppressant drugs; or behavioural or memory issues"
32,R6,Subsumes Arg1:T4 Arg2:T22
33,T23,Drug 347 367	oral cholera vaccine
34,T24,Competing_trial 370 444	Receipt of an investigational product (within 30 days before vaccination).
35,T25,Condition 457 466	diarrhoea
36,T26,Temporal 467 507	in 7 days prior to first dose of vaccine
37,T27,Reference_point 486 507	first dose of vaccine
38,R7,Has_index Arg1:T26 Arg2:T27
39,T28,Value 520 522	=3
40,T29,Measurement 523 556	unformed loose stools in 24 hours
41,R8,Has_value Arg1:T29 Arg2:T28
42,R9,Subsumes Arg1:T25 Arg2:T29
43,R10,Has_temporal Arg1:T25 Arg2:T26
44,T30,Condition 571 587	chronic diarrhea
45,T31,Observation 560 567	History
46,T32,Observation 446 453	History
47,R11,Has_temporal Arg1:T25 Arg2:T32
48,R12,Has_temporal Arg1:T30 Arg2:T31
49,T33,Multiplier 589 618	lasting for more than 2 weeks
50,T34,Temporal 619 639	in the past 6 months
51,R13,Has_multiplier Arg1:T30 Arg2:T33
52,R14,Has_temporal Arg1:T30 Arg2:T34
53,T35,Drug 657 666	laxatives
54,T36,Drug 668 676	antacids
55,T37,Drug 687 718	agents to lower stomach acidity
56,T38,Qualifier 681 686	other
57,R15,Has_qualifier Arg1:T37 Arg2:T38
58,*,OR T35 T36 T37
59,T39,Pregnancy_considerations 721 769	Planning to become pregnant in the next 2 years.
0,T1,Drug 11 22	ceftriaxone
1,T2,Drug 26 36	macrolides
2,T3,Condition 0 7	Allergy
3,T4,Scope 11 36	ceftriaxone or macrolides
4,R1,Has_scope Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T5,Qualifier 44 68	typhoid fever-associated
7,T6,Condition 44 57	typhoid fever
8,T7,Condition 69 82	complications
9,R2,Has_qualifier Arg1:T7 Arg2:T5
10,R3,AND Arg1:T5 Arg2:T6
11,T8,Qualifier 38 43	Major
12,T9,Subjective_judgement 38 43	Major
13,T10,Drug 105 120	oral medication
14,T11,Condition 84 120	Inability to swallow oral medication
15,R4,AND Arg1:T11 Arg2:T10
16,T12,Condition 122 140	Underlying illness
17,T13,Undefined_semantics 122 140	Underlying illness
18,T14,Condition 142 151	Pregnancy
19,T15,Condition 153 162	Lactation
20,T16,Temporal 174 196	within the past 4 days
21,T17,Drug 205 215	antibiotic
22,T18,Qualifier 228 259	effective against typhoid fever
23,T19,Condition 246 259	typhoid fever
24,R5,Has_temporal Arg1:T17 Arg2:T16
25,R6,Has_qualifier Arg1:T17 Arg2:T18
26,R7,AND Arg1:T18 Arg2:T19
0,T1,Non-query-able 0 2	NA
0,T1,Procedure 13 21	admitted
1,T2,Visit 29 32	ICU
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 36 48	septic shock
4,T4,Condition 76 88	septic shock
5,T5,Temporal 89 105	while in the ICU
6,T6,Reference_point 95 105	in the ICU
7,R2,Has_index Arg1:T5 Arg2:T6
8,R3,Has_temporal Arg1:T4 Arg2:T5
0,T1,Qualifier 0 6	Severe
1,T2,Condition 7 29	Iron deficiency anemia
2,T3,Measurement 31 41	hemoglobin
3,T4,Value 42 52	< 8.0 g/dL
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T2 Arg2:T1
6,T5,Scope 31 52	hemoglobin < 8.0 g/dL
7,T6,Scope 0 29	Severe Iron deficiency anemia
8,R3,Subsumes Arg1:T6 Arg2:T5
9,T7,Condition 56 80	Parasitic worm infection
10,T8,Condition 86 101	schistosomiasis
11,T9,Condition 107 116	hook worm
12,T10,Procedure 120 134	stool analysis
13,*,OR T8 T9
14,T11,"Scope 86 116	schistosomiasis, and hook worm"
15,R4,Subsumes Arg1:T7 Arg2:T11
16,R5,AND Arg1:T10 Arg2:T7
17,T12,Mood 154 171	clinical symptoms
18,T13,Condition 175 184	gastritis
19,T14,Condition 190 196	nausea
20,T15,Condition 198 206	vomiting
21,T16,Condition 208 224	dull aching pain
22,T17,Condition 228 255	soreness in the epigastrium
23,*,OR T17 T16 T15 T14
24,T18,"Scope 190 255	nausea, vomiting, dull aching pain or soreness in the epigastrium"
25,R6,Has_mood Arg1:T13 Arg2:T12
26,T19,Scope 154 184	clinical symptoms of gastritis
27,R7,Subsumes Arg1:T19 Arg2:T18
28,T20,Condition 280 293	gastric ulcer
29,T21,Observation 269 276	history
30,T22,Procedure 307 322	upper endoscopy
31,R8,Has_temporal Arg1:T20 Arg2:T21
32,R9,AND Arg1:T20 Arg2:T22
33,T23,Condition 346 357	hematemesis
0,T1,Person 0 3	Age
1,T2,Value 4 11	=1 year
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-representable 13 49	stratified into different age groups
4,T4,Visit 65 91	Waya Clinic Catchment Area
5,T5,Person 51 57	Living
6,R2,AND Arg1:T5 Arg2:T4
7,T6,Condition 93 114	Good health condition
8,T7,Negation 116 123	without
9,T8,Qualifier 124 146	clinically significant
10,T9,Observation 147 162	medical history
11,R3,Has_negation Arg1:T9 Arg2:T7
12,R4,Has_qualifier Arg1:T9 Arg2:T8
13,T10,Negation 211 214	Not
14,T11,Condition 215 223	pregnant
15,T12,Person 228 234	female
16,A1,Optional T12
17,R5,AND Arg1:T12 Arg2:T11
18,R6,Has_negation Arg1:T11 Arg2:T10
19,T13,"Post-eligibility 246 368	Available to participate for the study duration, including all planned follow-up visits for up to 9 months from screening."
20,T14,Informed_consent 370 393	Signed informed consent
0,T1,Measurement 0 13	Blood culture
1,T2,Value 14 20	proven
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 21 34	typhoid fever
4,R2,AND Arg1:T3 Arg2:T1
5,T4,Condition 36 44	S. typhi
6,T5,Condition 48 60	S. paratyphi
7,*,OR T4 T5
8,T6,Scope 36 60	S. typhi or S. paratyphi
9,R3,Subsumes Arg1:T3 Arg2:T6
10,T7,Post-eligibility 63 115	Signed informed consent to participate in the study.
11,T8,Non-query-able 63 115	Signed informed consent to participate in the study.
0,T1,Measurement 16 53;60 75	American Society of Anesthesiologists physical status
1,T2,Measurement 55 58	ASA
2,T3,Value 76 84	I and II
3,R1,Has_value Arg1:T1 Arg2:T3
4,T4,Person 86 90	aged
5,T5,Value 91 105	8-14 years old
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Person 110 121	both gender
8,T7,Mood 128 137	suspected
9,T8,Condition 138 156	acute appendicitis
10,T9,Mood 157 170	scheduled for
11,T10,Procedure 171 198	laparoscopic appendicectomy
12,R3,Has_mood Arg1:T10 Arg2:T9
13,R4,Has_mood Arg1:T8 Arg2:T7
14,R5,AND Arg1:T8 Arg2:T10
0,T1,Qualifier 0 24	Histologically confirmed
1,T2,Procedure 0 14	Histologically
2,T3,Condition 25 50	colorectal adenocarcinoma
3,R1,Has_qualifier Arg1:T3 Arg2:T1
4,R2,multi Arg1:T1 Arg2:T2
5,T4,Observation 52 80	Disease limited to the liver
6,T5,Condition 81 101	Unresectable disease
7,T6,Procedure 105 112	surgery
8,T7,Procedure 122 137	local therapies
9,T8,Qualifier 116 121	other
10,R3,Has_qualifier Arg1:T7 Arg2:T8
11,*,OR T6 T7
12,T9,Scope 105 137	surgery or other local therapies
13,R4,Has_scope Arg1:T5 Arg2:T9
14,*,OR T5 T4
15,T10,Person 139 142	Age
16,T11,Value 143 152	>18 years
17,R5,Has_value Arg1:T10 Arg2:T11
18,T12,Measurement 154 177	ECOG performance status
19,T13,Value 178 181	0-2
20,T14,Measurement 182 192	Child pugh
21,T15,Value 193 194	A
22,T16,Value 198 199	B
23,*,OR T15 T16
24,T17,Scope 193 199	A or B
25,R6,Has_scope Arg1:T14 Arg2:T17
26,R7,Has_value Arg1:T12 Arg2:T13
27,T18,Observation 201 218	Expected survival
28,T19,Value 219 229	= 3 months
29,R8,Has_value Arg1:T18 Arg2:T19
30,T20,Qualifier 231 239	Adequate
31,T21,Measurement 268 282	renal function
32,T22,Measurement 255 262;274 282	hepatic function
33,T23,Measurement 240 253;274 282	hematological function
34,*,OR T22 T23 T21
35,T24,"Scope 240 282	hematological, hepatic, and renal function"
36,R9,Has_qualifier Arg1:T24 Arg2:T20
0,T1,Qualifier 0 9	Secondary
1,T2,Condition 10 29	knee osteoarthritis
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Qualifier 31 36	Other
4,T4,Condition 37 69	inflammatory Knee Osteoarthritis
5,R2,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Condition 76 80	gout
7,T6,Condition 82 102	rheumatoid arthritis
8,*,OR T5 T6
9,T7,"Scope 76 102	gout, rheumatoid arthritis"
10,T8,Scope 31 69	Other inflammatory Knee Osteoarthritis
11,R3,Subsumes Arg1:T8 Arg2:T7
12,T9,Condition 136 167	gastroesophageal reflux disease
13,T10,Condition 169 181	peptic ulcer
14,*,OR T9 T10
15,T11,Condition 184 205	Helicobacter infected
16,T12,Negation 224 227	not
17,T13,Procedure 233 256	treated for eradication
18,R4,Has_negation Arg1:T13 Arg2:T12
19,R5,AND Arg1:T11 Arg2:T13
20,T14,Condition 319 339	Short bowel syndrome
21,T15,Condition 355 381	inflammatory bowel disease
22,T16,Mood 345 354	can cause
23,R6,Has_mood Arg1:T15 Arg2:T16
24,T17,Qualifier 340 381	that can cause inflammatory bowel disease
25,R7,multi Arg1:T17 Arg2:T15
26,R8,Has_qualifier Arg1:T14 Arg2:T17
27,T18,Condition 383 401	ulcerative colitis
28,T19,Condition 403 418	Crohn's disease
29,T20,Condition 424 448	drug absorption disorder
30,*,OR T18 T19
31,T21,"Scope 383 418	ulcerative colitis, Crohn's disease"
32,T22,Scope 319 381	Short bowel syndrome that can cause inflammatory bowel disease
33,R9,Subsumes Arg1:T22 Arg2:T21
34,T23,Condition 451 482	Intestinal obstruction syndrome
35,T24,Qualifier 484 495	Unexplained
36,T25,Condition 496 510	abdominal pain
37,R10,Has_qualifier Arg1:T25 Arg2:T24
38,T26,Measurement 512 547	ALT(Alanine aminotransferase) level
39,T27,Procedure 551 570	liver function test
40,T28,Value 571 606	exceeded 5 times of reference range
41,R11,AND Arg1:T27 Arg2:T26
42,R12,Has_value Arg1:T26 Arg2:T28
43,T29,Measurement 608 629	Total bilirubin level
44,T30,Value 630 648	exceeded 2 mg / dL
45,R13,Has_value Arg1:T29 Arg2:T30
46,T31,Measurement 650 669	Serum albumin level
47,T32,Value 671 688	ess than 2 g / dL
48,R14,Has_value Arg1:T31 Arg2:T32
49,T33,Condition 690 697	Ascites
50,T34,Condition 699 721	Hepatic encephalopathy
51,T35,Condition 723 734	Hepatitis B
52,T36,Condition 736 747	hepatitis C
53,T37,Condition 780 792	HIV positive
54,T38,Negation 749 758	excluding
55,T39,Condition 759 775	healthy carriers
56,R15,Has_negation Arg1:T39 Arg2:T38
57,R16,AND Arg1:T36 Arg2:T39
58,*,OR T35 T36 T37
59,T40,Qualifier 794 837	MDRD(Modification of Diet in Renal Disease)
60,T41,Measurement 838 874	Estimated Glomerular filtration rate
61,T42,Value 875 895	less than 60 mL / m2
62,R17,Has_value Arg1:T41 Arg2:T42
63,R18,Has_qualifier Arg1:T41 Arg2:T40
64,T43,Condition 911 923	hyperkalemia
65,T44,Value 925 941	over 5.5 meq / L
66,R19,Has_value Arg1:T43 Arg2:T44
67,T45,Condition 955 961	asthma
68,T46,Condition 963 977	acute rhinitis
69,T47,Condition 979 991	nasal polyps
70,T48,Condition 993 1003	angioedema
71,T49,Condition 1005 1014	urticaria
72,T50,Condition 1018 1036	allergic reactions
73,T51,Drug 1040 1047	aspirin
74,T52,Qualifier 1051 1056	other
75,T53,Drug 1057 1094	non-steroidal anti-inflammatory drugs
76,T54,Drug 1105 1121	COX-2 inhibitors
77,R20,Subsumes Arg1:T53 Arg2:T54
78,R21,Has_qualifier Arg1:T53 Arg2:T52
79,T55,Scope 1040 1122	aspirin or other non-steroidal anti-inflammatory drugs(including COX-2 inhibitors)
80,*,OR T51 T53
81,R22,Has_scope Arg1:T50 Arg2:T55
82,*,OR T49 T50 T48 T47 T46 T45
83,T56,Condition 1125 1141	Malignant tumors
84,T57,Negation 1142 1152	other than
85,T58,Condition 1153 1163;1181 1202	basal cell carcinoma of the skin
86,T59,Condition 1167 1202	squamous cell carcinoma of the skin
87,*,OR T59 T58
88,T60,Scope 1153 1202	basal cell or squamous cell carcinoma of the skin
89,R23,Has_negation Arg1:T60 Arg2:T57
90,R24,Has_scope Arg1:T56 Arg2:T60
91,T61,Condition 1204 1243	CIN(Cervical Intraepitherial Neoplasia)
92,T62,Condition 1248 1284	CIS(Carcinoma in situ) of the cervix
93,*,OR T61 T62 T56 T63
94,T63,Condition 1290 1315	intraepithelial carcinoma
95,T64,Temporal 1331 1361	Within 5 years of consent date
96,T65,Reference_point 1349 1361	consent date
97,R25,Has_index Arg1:T64 Arg2:T65
98,T66,"Scope 1125 1315	Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma"
99,R26,Has_temporal Arg1:T66 Arg2:T64
100,T67,Condition 1383 1399	hypersensitivity
101,T68,Drug 1407 1449	components of the investigational products
102,R27,AND Arg1:T67 Arg2:T68
103,T69,Drug 1456 1481	components of test drug 1
104,T70,Drug 1456 1479;1486 1487	components of test drug 2
105,T71,Drug 1503 1519	Rhein-based drug
106,*,OR T70 T71 T69
107,T72,"Scope 1456 1519	components of test drug 1 and 2, including the Rhein-based drug"
108,R28,Subsumes Arg1:T68 Arg2:T72
109,T73,Condition 1539 1556	allergic reaction
110,T74,Drug 1560 1571	sulfonamide
111,R29,AND Arg1:T73 Arg2:T74
112,T75,Condition 1588 1609	galactose intolerance
113,T76,Condition 1611 1634	lapp lactase deficiency
114,T77,Condition 1638 1669	glucose-galactose malabsorption
115,*,OR T75 T76 T77
116,T78,Non-representable 1672 1824	Subjects who have not reached the prescribed period after receiving contraindicated medication or treatment before participation in this clinical trial.
117,T79,Drug 1845 1871	contraindicated medication
118,T80,Condition 1874 1881;1897 1902	Alcohol abuse
119,T81,Condition 1892 1902	drug abuse
120,T82,Temporal 1918 1943	6 months before screening
121,*,OR T80 T81
122,T83,Scope 1874 1902	Alcohol and other drug abuse
123,T84,Pregnancy_considerations 1946 2021	Pregnant women or nursing mothers who are not willing to stop breastfeeding
124,T85,Condition 2028 2037	Menopause
125,T86,Qualifier 2039 2058	non-therapy-induced
126,T87,Condition 2059 2069	amenorrhea
127,T88,Multiplier 2073 2092	more than 12 months
128,R30,Has_multiplier Arg1:T87 Arg2:T88
129,R31,Has_qualifier Arg1:T87 Arg2:T86
130,T89,Scope 2039 2092	non-therapy-induced amenorrhea of more than 12 months
131,R32,Subsumes Arg1:T85 Arg2:T89
132,T90,Person 2094 2100	Female
133,T91,Person 2106 2112	Female
134,T92,Condition 2113 2124	infertility
135,T93,Qualifier 2125 2139	due to surgery
136,R33,Has_qualifier Arg1:T92 Arg2:T93
137,T94,Condition 2141 2151	no ovaries
138,T95,Condition 2141 2143;2161 2167	no uterus
139,*,OR T95 T94
140,T96,Scope 2113 2139	infertility due to surgery
141,T97,Scope 2141 2167	no ovaries and / or uterus
142,R34,Subsumes Arg1:T96 Arg2:T97
143,T98,Pregnancy_considerations 2174 2292	If you have sexual intercourse with only one male partner who has been confirmed to have no semen after fertilization.
144,T99,Pregnancy_considerations 2298 2371	Female subjects who agreed to abstinence during the clinical trial period
145,T100,Pregnancy_considerations 2374 2458	If the subject is assured of an abstinence throughout the trial period.(e.g. clergy)
146,T101,"Pregnancy_considerations 2460 2611	However, intermittent abstinence (eg, contraception using ovulation period, symptothermal) or coitus interrupts is not a case of consent for abstinence"
147,T104,Competing_trial 2989 3126	If 30 days have not elapsed after the date of signing of the previous clinical trial or currently participating in other clinical trials.
148,T105,Non-query-able 3128 3300	Patients who are scheduled for surgery during the clinical trial period or who have difficulties in completing the protocol during this clinical trial due to other reasons.
149,T106,"Non-query-able 3302 3391	In addition to the above, other diseases that the investigator judges to be inappropriate"
150,T102,"Pregnancy_considerations 2614 2793	(5) For women of childbearing age, the following methods or methods of contraception use the effective method of contraception to be used during the period of this clinical trial:"
151,T103,Drug 2795 2813	Oral contraceptive
152,T107,Device 2819 2838	contraceptive patch
153,T108,Device 2840 2866	Intra uterine device (IUD)
154,T109,Device 2868 2889	contraceptive implant
155,T110,Device 2891 2914	contraceptive injection
156,T111,Device 2916 2947	intrauterine hormonal apparatus
157,T112,Procedure 2949 2963	Tubal ligation
158,T113,Procedure 2968 2987	infertility surgery
159,*,OR T112 T113
0,T1,Condition 0 9	Pregnancy
1,T2,Condition 13 22	lactating
2,*,OR T1 T2
3,T3,Condition 24 31	Allergy
4,T4,Drug 35 38	NAC
5,R1,AND Arg1:T3 Arg2:T4
6,T5,Condition 51 63	chronic pain
7,T6,Observation 40 47	History
8,R2,Has_temporal Arg1:T5 Arg2:T6
9,T7,Drug 72 79	opioids
10,T8,Drug 83 105	neuropathic analgesics
11,*,OR T7 T8
12,T9,Drug 114 117	NAC
13,T10,Temporal 118 132	prior to trial
14,T11,Reference_point 127 132	trial
15,R3,Has_index Arg1:T10 Arg2:T11
16,T12,Temporal 134 143	< 1 month
17,T13,Mood 147 154	planned
18,T14,Procedure 155 162	surgery
19,R4,Has_mood Arg1:T14 Arg2:T13
20,R5,Has_temporal Arg1:T14 Arg2:T12
21,T15,Scope 134 162	< 1 month of planned surgery
22,R6,Has_temporal Arg1:T9 Arg2:T10
23,R7,Subsumes Arg1:T10 Arg2:T15
24,T16,Condition 165 175	Alcoholism
25,T17,Condition 177 194	Diabetes Mellitus
26,T18,Drug 196 203	insulin
27,R8,AND Arg1:T17 Arg2:T18
28,T19,Condition 214 220	Asthma
29,T20,Condition 224 261	Chronic Obstructive pulmonary Disease
30,*,OR T20 T19
31,T21,Condition 269 293	renal function disorders
32,T22,Measurement 295 299	MDRD
33,T23,Value 300 303	<ô0
34,R9,Has_value Arg1:T22 Arg2:T23
35,T24,Scope 295 303	MDRD <ô0
36,R10,Subsumes Arg1:T21 Arg2:T24
37,T25,Condition 312 325	liver failure
38,T26,Measurement 327 336	bilirubin
39,T27,Value 337 364	>1.Sx upper limit of normal
40,R11,Has_value Arg1:T26 Arg2:T27
41,T28,Scope 327 364	bilirubin >1.Sx upper limit of normal
42,R12,Subsumes Arg1:T25 Arg2:T28
43,T29,Informed_consent 367 391	No written lC by patient
0,T1,Non-query-able 3 53	Are unable to understand and sign the consent form
1,T2,Post-eligibility 3 53	Are unable to understand and sign the consent form
2,T3,Condition 62 70	pregnant
3,T4,Condition 74 83	lactating
4,*,OR T4 T3
5,T5,Condition 92 134	physically unable to sit upright and still
6,T6,Multiplier 135 149	for 40 minutes
7,R1,Has_multiplier Arg1:T5 Arg2:T6
8,T7,Procedure 169 189	bilateral mastectomy
9,T8,Negation 198 201	not
10,T9,Observation 202 211	scheduled
11,T10,Procedure 223 246	conventional ultrasound
12,R2,Has_negation Arg1:T10 Arg2:T8
13,R3,Has_mood Arg1:T10 Arg2:T9
0,T1,Visit 29 38	Duke CICU
1,T2,Procedure 13 21	admitted
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Procedure 52 62	intubation
4,T4,Procedure 67 75	sedation
5,T5,Procedure 80 102	mechanical ventilation
6,T6,Multiplier 126 147	>24 hours in duration
7,T7,Mood 111 125	expected to be
8,R2,Has_mood Arg1:T6 Arg2:T7
9,R3,Has_multiplier Arg1:T5 Arg2:T6
10,T8,Scope 52 75	intubation and sedation
11,R4,AND Arg1:T8 Arg2:T5
12,T9,Procedure 227 236	intubated
13,T10,Temporal 237 277	within one hour prior to care transition
14,T11,Procedure 262 277	care transition
15,T12,Reference_point 262 277	care transition
16,R5,multi Arg1:T12 Arg2:T11
17,R6,Has_index Arg1:T10 Arg2:T12
18,R7,Has_temporal Arg1:T9 Arg2:T10
0,T1,Drug 0 10	Amiodarone
1,T2,Drug 12 42	P-glycoprotein (P-gp) inducers
2,T3,Drug 50 58	rifampin
3,T4,Drug 60 75	St. John's wort
4,*,OR T3 T4
5,T5,"Scope 50 75	rifampin, St. John's wort"
6,R1,Subsumes Arg1:T2 Arg2:T5
7,T6,Procedure 78 90	Liver biopsy
8,T7,Measurement 111 121	mHAI stage
9,T8,Value 122 133	4 or higher
10,R2,Has_value Arg1:T7 Arg2:T8
11,R3,AND Arg1:T6 Arg2:T7
12,T9,Temporal 94 102	any time
13,R4,Has_temporal Arg1:T6 Arg2:T9
14,T10,Procedure 147 156	FibroScan
15,T11,Temporal 157 173	within 12 months
16,R5,Has_temporal Arg1:T10 Arg2:T11
17,T12,Measurement 188 203	liver stiffness
18,T13,Value 207 223	=9.5 kilo Pascal
19,R6,Has_value Arg1:T12 Arg2:T13
20,R7,AND Arg1:T10 Arg2:T12
21,T14,Measurement 228 262	AST to platelet ratio index (APRI)
22,T15,Value 263 267	=2.0
23,R8,Has_value Arg1:T14 Arg2:T15
24,T16,Measurement 272 290	Fibrosis-4 (FIB-4)
25,T17,Value 291 296	=3.25
26,R9,Has_value Arg1:T16 Arg2:T17
27,*,OR T14 T16
28,T18,Non-representable 298 393	NOTE: If APRI and FIB-4 are discordant one of the other forms of fibrosis staging must be used.
29,T19,Condition 401 408	allergy
30,T20,Condition 409 420	sensitivity
31,*,OR T20 T19 T21
32,T21,Condition 428 444	hypersensitivity
33,T22,Drug 448 473	components of study drugs
34,T23,Scope 401 444	allergy/sensitivity or any hypersensitivity
35,R10,AND Arg1:T23 Arg2:T22
36,T24,Condition 497 512	Hemochromatosis
37,T25,Condition 514 544	Alpha-1 antitrypsin deficiency
38,T26,Condition 546 562	Wilson's disease
39,T27,Condition 564 584	Autoimmune hepatitis
40,T28,Condition 586 609	Alcoholic liver disease
41,T29,Condition 611 637	Drug-related liver disease
42,T30,Condition 673 679	stroke
43,T31,Condition 681 692	head injury
44,T32,Condition 697 730	developmental learning disability
45,*,OR T31 T32 T30
46,T33,Condition 646 671	NC confounding conditions
47,T34,"Scope 673 730	stroke, head injury, or developmental learning disability"
48,R11,Subsumes Arg1:T33 Arg2:T34
49,T35,Drug 749 772	anti-inflammatory drugs
50,T36,Drug 808 828	pegylated interferon
51,T37,Drug 830 837	PEG-IFN
52,R12,Subsumes Arg1:T36 Arg2:T37
53,T38,Procedure 793 802	treatment
54,T39,Temporal 786 792	recent
55,T40,Temporal 775 782	Current
56,*,OR T39 T40
57,R13,AND Arg1:T38 Arg2:T36
58,T41,Scope 775 792	Current or recent
59,R14,Has_scope Arg1:T38 Arg2:T41
60,T42,Condition 847 874	active inflammatory process
61,T43,Qualifier 841 846	Other
62,R15,Has_qualifier Arg1:T42 Arg2:T43
63,T44,Condition 876 891	major infection
64,T45,Condition 893 903	malignancy
65,T46,Condition 905 925	rheumatoid arthritis
66,T47,Condition 926 945	autoimmune disorder
67,*,OR T47 T46 T45 T44
68,T48,"Scope 876 945	major infection, malignancy, rheumatoid arthritis/autoimmune disorder"
69,R16,Subsumes Arg1:T42 Arg2:T48
70,T49,Temporal 947 971	within the prior 28 days
71,R17,Has_temporal Arg1:T42 Arg2:T49
72,T50,Procedure 995 1027	magnetic resonance imaging (MRI)
73,T51,Condition 974 991	Contraindications
74,R18,AND Arg1:T51 Arg2:T50
75,T52,Condition 1030 1048	Bleeding diathesis
76,T53,Condition 1050 1066	thrombocytopenia
77,T54,Drug 1078 1092	anticoagulants
78,T55,Condition 1104 1118	contraindicate
79,T56,Procedure 1119 1134	lumbar puncture
80,R19,AND Arg1:T55 Arg2:T56
81,R20,AND Arg1:T54 Arg2:T55
82,*,OR T53 T52 T54
83,T57,Temporal 1153 1159	active
84,T58,Qualifier 1137 1149	Uncontrolled
85,T59,Condition 1160 1170	depression
86,*,OR T57 T58
87,T60,Scope 1137 1159	Uncontrolled or active
88,T61,Condition 1180 1200	psychiatric disorder
89,T62,Qualifier 1174 1179	other
90,R21,Has_qualifier Arg1:T61 Arg2:T62
91,*,OR T59 T61
92,T63,Scope 1160 1200	depression or other psychiatric disorder
93,R22,Has_scope Arg1:T63 Arg2:T60
94,T64,Condition 1351 1376	alcohol use or dependence
95,T65,Condition 1343 1347;1359 1376	drug use or dependence
96,*,OR T64 T65
97,T66,Temporal 1336 1342	Active
98,T67,Scope 1343 1376	drug or alcohol use or dependence
99,R23,Has_temporal Arg1:T67 Arg2:T66
100,T68,Temporal 1501 1506	acute
101,T69,Temporal 1491 1497	active
102,T70,Condition 1507 1545	AIDS-defining opportunistic infections
103,T71,Temporal 1546 1582	within 12 weeks prior to study entry
104,*,OR T68 T69
105,T72,Scope 1491 1506	active or acute
106,R24,Has_temporal Arg1:T70 Arg2:T71
107,R25,Has_scope Arg1:T70 Arg2:T72
0,T1,Procedure 6 15	treatment
1,T2,Temporal 0 5	Prior
2,T3,Procedure 78 99	chemotherapy regimens
3,T4,Qualifier 55 77	alkylating agent-based
4,R2,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Value 21 39	more than 6 cycles
6,T6,Qualifier 144 162	carboplating-based
7,T7,Value 122 140	more than 2 cycles
8,T8,Procedure 107 116	treatment
9,T9,Temporal 101 106	Prior
10,T10,Procedure 163 184	chemotherapy regimens
11,R4,Has_qualifier Arg1:T10 Arg2:T6
12,R3,AND Arg1:T5 Arg2:T3
13,R5,AND Arg1:T7 Arg2:T10
14,R1,Subsumes Arg1:T10 Arg2:T8
15,R6,Subsumes Arg1:T3 Arg2:T1
16,R7,Has_temporal Arg1:T3 Arg2:T2
17,R8,Has_temporal Arg1:T10 Arg2:T9
18,T11,Condition 190 207	colorectal cancer
19,T12,Procedure 248 257	treatment
20,T13,Temporal 242 247	prior
21,T14,Value 263 274	more than 2
22,T15,Procedure 275 305	systemic chemotherapy regimens
23,T16,Qualifier 313 323	metastatic
24,R9,AND Arg1:T14 Arg2:T15
25,R10,Subsumes Arg1:T15 Arg2:T12
26,R11,Has_temporal Arg1:T15 Arg2:T13
27,R12,Has_qualifier Arg1:T15 Arg2:T16
28,A1,Optional T11
29,R13,AND Arg1:T11 Arg2:T15
0,T1,Condition 0 8	Pregnant
1,T2,Condition 12 21	lactating
2,T3,Person 22 27	women
3,*,OR T2 T1
4,T4,Qualifier 43 49	severe
5,T5,Condition 50 67	organ dysfunction
6,T6,Condition 50 55;71 78	organ failure
7,*,OR T6 T5
8,T7,Scope 50 78	organ dysfunction or failure
9,R1,Has_qualifier Arg1:T7 Arg2:T4
10,T8,Condition 92 114	cardiovascular disease
11,T9,Condition 107 114;119 125	disease mental
12,*,OR T8 T9
13,T10,Qualifier 85 91	severe
14,T11,"Scope 92 126	cardiovascular disease, or mental"
15,R2,Has_qualifier Arg1:T11 Arg2:T10
16,T12,Condition 127 148	Extraliver metastases
17,T13,Qualifier 127 137	Extraliver
18,T14,Condition 138 148	metastases
19,R3,Has_qualifier Arg1:T14 Arg2:T13
20,R4,multi Arg1:T12 Arg2:T14
0,T1,Condition 17 36	developmental delay
1,T2,Condition 38 64	attention deficit disorder
2,T3,Condition 66 78	chronic pain
3,T4,Condition 80 99	psychiatric illness
4,T5,Temporal 101 109	previous
5,T6,Procedure 110 132	open abdominal surgery
6,T7,Device 152 163	gastrostomy
7,T8,Device 165 193	ventricular-peritoneal shunt
8,T9,Device 203 223	abdominal prosthesis
9,T10,Condition 225 242	immunosuppression
10,T11,Condition 254 262	allergic
11,T12,Drug 266 288	any of the medications
12,R1,AND Arg1:T11 Arg2:T12
13,R2,Has_temporal Arg1:T6 Arg2:T5
14,*,OR T6 T7 T1 T2 T3 T4 T8 T9 T10 T11
0,T1,"Informed_consent 0 114	Subjects who voluntarily consented, after listening enough explanation for this study and investigational product."
1,T2,Person 116 121	Adult
2,T3,Value 122 135	over 50 years
3,T4,Person 139 142	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Multiplier 145 157	At least one
6,T6,Condition 165 174	knee pain
7,T7,Measurement 175 184	VAS score
8,T8,Value 188 200	40mm or more
9,R2,Has_value Arg1:T7 Arg2:T8
10,R3,Has_multiplier Arg1:T6 Arg2:T5
11,R4,AND Arg1:T6 Arg2:T7
12,T9,Drug 224 234	medication
13,T10,Multiplier 239 257	more than 12 weeks
14,T11,Condition 265 288	osteoarthritis symptoms
15,R5,Has_multiplier Arg1:T9 Arg2:T10
16,R6,AND Arg1:T11 Arg2:T9
17,T12,"Non-query-able 291 466	Those who are able to follow the requirements of this clinical trial, such as being able to trace during the clinical trial period and to read and write the VAS questionnaire."
18,T13,Measurement 478 483	weigh
19,T14,Value 484 498	more than 40kg
20,R7,Has_value Arg1:T13 Arg2:T14
0,T1,Mood 9 18	scheduled
1,T2,Qualifier 23 35	laparoscopic
2,T3,Procedure 47 69	inguinal hernia repair
3,T4,Qualifier 36 46	unilateral
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T3 Arg2:T2
6,T5,Measurement 71 74	ASA
7,T6,Value 75 80	1 or2
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Person 83 86	Age
10,T8,Value 87 96	>18 years
11,R4,Has_value Arg1:T7 Arg2:T8
12,R5,Has_mood Arg1:T3 Arg2:T1
0,T1,Condition 23 34	mass lesion
1,T2,Procedure 38 49	mammography
2,T3,Procedure 53 63	breast MRI
3,T4,Measurement 65 71	BIRADS
4,T5,"Value 72 81	0, 4 or 5"
5,R1,Has_value Arg1:T4 Arg2:T5
6,T6,Condition 210 221	mass lesion
7,T7,Value 91 109	>0.5 cm and < 2 cm
8,T8,Measurement 113 117	size
9,R2,Has_value Arg1:T8 Arg2:T7
10,R3,AND Arg1:T1 Arg2:T8
11,*,OR T2 T3
12,R4,AND Arg1:T3 Arg2:T4
13,T9,"Scope 38 82	mammography or breast MRI (BIRADS 0, 4 or 5)"
14,R5,Has_scope Arg1:T1 Arg2:T9
15,T10,Non-query-able 122 184	has had or will have additional workup with focused ultrasound
16,T11,Procedure 225 235	ultrasound
17,T12,Measurement 237 243	BIRADS
18,T13,"Value 244 253	0, 4 or 5"
19,R6,Has_value Arg1:T12 Arg2:T13
20,T14,Value 263 282	> 0.5 cm and < 2 cm
21,T15,Measurement 286 290	size
22,R7,Has_value Arg1:T15 Arg2:T14
23,R8,AND Arg1:T6 Arg2:T15
24,R9,AND Arg1:T6 Arg2:T11
25,R10,AND Arg1:T11 Arg2:T12
26,T16,Grammar_Error 323 326	MBI
27,T17,Procedure 323 326	MBI
28,T18,Condition 303 319	positive finding
29,T19,Undefined_semantics 303 319	positive finding
30,T20,Value 335 341	< 2 cm
31,T21,Measurement 345 349	size
32,R11,Has_value Arg1:T21 Arg2:T20
33,T22,Undefined_semantics 354 415	requires additional diagnostic workup with focused ultrasound
34,T23,Subjective_judgement 354 415	requires additional diagnostic workup with focused ultrasound
35,R12,AND Arg1:T18 Arg2:T17
36,R13,AND Arg1:T17 Arg2:T21
0,T1,Condition 0 31	Advanced solid tumor malignancy
1,T2,"Parsing_Error 33 157	during expansion at the maximum tolerated dose, entry will be limited to patients wtih adenocarcinoma of the colon or rectum"
2,T3,Measurement 160 201	Eastern Cooperative Oncology Group (ECOG)
3,T4,Value 202 208	0 or 1
4,R1,Has_value Arg1:T3 Arg2:T4
0,T1,Person 0 5	Adult
1,T2,Value 7 21	= 18 years old
2,T3,Person 18 21	old
3,R1,Has_value Arg1:T3 Arg2:T2
4,R2,Subsumes Arg1:T1 Arg2:T3
5,T4,Qualifier 45 55	genotype 1
6,T5,Temporal 37 44	chronic
7,T6,Condition 56 59	HCV
8,T7,Condition 64 67	NCI
9,*,OR T6 T7
10,T8,Measurement 75 78	GDS
11,T9,Value 79 107	greater than or equal to 0.5
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Scope 56 67	HCV and NCI
14,R4,Has_qualifier Arg1:T10 Arg2:T4
15,R5,Has_temporal Arg1:T10 Arg2:T5
16,R6,AND Arg1:T10 Arg2:T8
17,T11,Temporal 129 136	chronic
18,T12,Condition 137 150	HCV infection
19,R7,Has_temporal Arg1:T12 Arg2:T11
20,T13,Measurement 205 222	anti-HCV antibody
21,T14,Value 192 200	positive
22,T15,Measurement 226 233	HCV RNA
23,T16,Scope 205 233	anti-HCV antibody or HCV RNA
24,*,OR T13 T15
25,R8,Has_value Arg1:T16 Arg2:T14
26,T17,Temporal 234 268	at least 6 months before screening
27,R9,Has_temporal Arg1:T16 Arg2:T17
28,R10,Has_scope Arg1:T12 Arg2:T16
29,T18,"Non-representable 271 617	For the HIV/HCV co-infected group only, subjects must have HIV. HIV status will be obtained through self report. Self report will be confirmed at screening using a HIV-1 point of care test. In the event that point of care test and self-report are discordant, then HIV status will be confirmed by a licensed Western blot or a second antibody test."
30,T19,Condition 619 622	HIV
31,T20,Condition 623 626	HCV
32,T21,Condition 627 638	co-infected
33,R11,AND Arg1:T21 Arg2:T20
34,R12,AND Arg1:T21 Arg2:T19
35,T22,Measurement 672 691	HIV RNA measurement
36,T23,Value 692 705	<50 copies/mL
37,R13,Has_value Arg1:T22 Arg2:T23
38,T24,Temporal 706 732	at the pre-treatment visit
39,R14,Has_temporal Arg1:T22 Arg2:T24
40,T25,Measurement 735 744	Platelets
41,T26,Scope 619 638	HIV/HCV co-infected
42,A1,Optional T26
43,R15,AND Arg1:T26 Arg2:T22
44,T27,"Value 745 753	>150,000"
45,R16,Has_value Arg1:T25 Arg2:T27
46,T28,Measurement 755 787	Aspartate aminotransferase (AST)
47,T29,Measurement 788 818	Alanine aminotransferase (ALT)
48,T30,Value 819 845	<10x upper limit of normal
49,R17,Has_value Arg1:T29 Arg2:T30
50,R18,Has_value Arg1:T28 Arg2:T30
51,T31,Measurement 847 867	Creatinine clearance
52,T32,Value 868 914	>30 milliliters/minute/1.73 centimeter squared
53,R19,Has_value Arg1:T31 Arg2:T32
0,T1,Procedure 46 79	resuscitation from cardiac arrest
1,T2,Qualifier 103 119	cooling protocol
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 150 166	neurologic event
4,T4,Condition 168 175	seizure
5,T5,Condition 177 183	stroke
6,*,OR T4 T5
7,T6,"Scope 168 183	seizure, stroke"
8,R2,Subsumes Arg1:T3 Arg2:T6
9,T7,Condition 197 214	baseline dementia
10,T8,Non-representable 216 261	both of which could limit delirium assessment
11,*,OR T3 T7
12,T9,Measurement 277 288	child class
13,T10,Condition 297 310	liver disease
14,T11,Value 289 290	B
15,T12,Value 295 296	C
16,*,OR T11 T12
17,T13,Scope 289 296	B and C
18,R3,Has_scope Arg1:T9 Arg2:T13
19,R4,AND Arg1:T10 Arg2:T9
20,T14,Condition 332 339	allergy
21,T15,Drug 343 360	study medications
22,R5,AND Arg1:T14 Arg2:T15
0,T1,Temporal 0 9	currently
1,T2,Procedure 13 25	hemodialysis
2,T3,Visit 31 48	CDC dialysis unit
3,R1,AND Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T2 Arg2:T1
5,T4,Observation 50 66	English speaking
6,T5,Informed_consent 68 100	able to provide informed consent
0,T1,Non-query-able 0 2	NA
0,T1,Observation 0 27	Limited English proficiency
1,T2,Observation 29 32	LEP
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Condition 35 43	Pregnant
4,T4,Person 45 54	Prisoners
5,T5,Condition 56 86	Wolff Parkinson White syndrome
6,T6,Procedure 120 142	chemical cardioversion
7,T7,Procedure 106 116;129 142	electrical cardioversion
8,T8,Temporal 143 159	before screening
9,T9,Reference_point 150 159	screening
10,R2,Has_index Arg1:T8 Arg2:T9
11,*,OR T7 T6
12,T10,Scope 106 142	electrical or chemical cardioversion
13,R3,Has_temporal Arg1:T10 Arg2:T8
14,T11,Drug 185 200	antiarrhythmics
15,T12,Qualifier 205 210	acute
16,T13,Procedure 211 229	heart rate control
17,R4,Has_qualifier Arg1:T13 Arg2:T12
18,R5,AND Arg1:T11 Arg2:T13
19,T14,Negation 231 240	excluding
20,T15,Drug 241 250	adenosine
21,R6,Has_negation Arg1:T15 Arg2:T14
22,R7,AND Arg1:T11 Arg2:T15
23,T16,Condition 264 271	allergy
24,T17,Condition 275 297	idiosyncratic reaction
25,T18,Drug 301 310	diltiazem
26,*,OR T17 T16
27,T19,Scope 264 297	allergy or idiosyncratic reaction
28,R8,AND Arg1:T19 Arg2:T18
29,T20,Condition 312 326	Unable to take
30,T21,Drug 327 343	oral medications
31,R9,AND Arg1:T21 Arg2:T20
32,T22,Measurement 345 355	Heart rate
33,T23,Value 356 369	<60 beats/min
34,R10,Has_value Arg1:T22 Arg2:T23
0,T1,Procedure 3 15	hemodialysis
1,T2,Temporal 16 38	for less than 3 months
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 49 58	psychotic
4,T4,Condition 60 67	bipolar
5,T5,Condition 69 93	substance use dependence
6,T6,Condition 95 106	Alzheimer's
7,T7,Condition 110 118	dementia
8,*,OR T7 T6 T5 T4 T3
9,T8,Temporal 40 48	comorbid
10,T9,"Scope 49 118	psychotic, bipolar, substance use dependence, Alzheimer's or dementia"
11,R2,Has_temporal Arg1:T9 Arg2:T8
0,T1,Non-query-able 0 2	NA
0,T1,Value 0 16	>/= 18 years old
1,T2,Person 13 16	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 18 37	Atrial fibrillation
4,T4,Condition 18 24;41 48	Atrial flutter
5,*,OR T4 T3
6,T5,Procedure 52 69	electrocardiogram
7,T6,Scope 18 48	Atrial fibrillation or flutter
8,R2,Has_scope Arg1:T5 Arg2:T6
9,T7,Measurement 71 81	Heart rate
10,T8,Value 82 96	>110 beats/min
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Measurement 98 121	Systolic blood pressure
13,T10,Value 122 133	>/= 90 mmHg
14,R4,Has_value Arg1:T9 Arg2:T10
0,T1,Person 0 3	Age
1,T2,Value 6 11	18-65
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 27 52	major depressive disorder
4,T4,Measurement 66 81	DSM-IV criteria
5,T5,Temporal 92 107	lasted >8 weeks
6,R2,AND Arg1:T4 Arg2:T3
7,R3,Has_temporal Arg1:T3 Arg2:T5
8,T6,Measurement 109 114	MADRS
9,T7,Value 121 142	score of 18 or higher
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Measurement 203 208	MADRS
12,T9,Value 183 195	score of >18
13,T10,Qualifier 213 223	first-line
14,T11,Drug 224 238	antidepressant
15,T12,Temporal 249 258	of 4 week
16,T13,Observation 157 179	responded inadequately
17,R5,Has_qualifier Arg1:T11 Arg2:T10
18,R6,Has_value Arg1:T8 Arg2:T9
19,R7,AND Arg1:T13 Arg2:T8
20,R8,AND Arg1:T13 Arg2:T11
21,R9,Has_temporal Arg1:T11 Arg2:T12
22,T14,Qualifier 284 292	standard
23,T15,Drug 293 307	antidepressant
24,T16,Qualifier 321 332	monotherapy
25,T17,Multiplier 351 352	2
26,T18,Drug 353 368	antidepressants
27,T19,Drug 371 383	escitalopram
28,T20,Drug 399 409	fluoxetine
29,T21,Drug 424 437	paroxetine CR
30,T22,Drug 452 462	sertraline
31,T23,Drug 479 490	mirtazapine
32,T24,Drug 506 516	duloxetine
33,T25,Multiplier 385 396	10 - 20mg/d
34,T26,Multiplier 410 421	20 - 40mg/d
35,T27,Multiplier 438 449	25 - 50mg/d
36,T28,Multiplier 463 476	100 - 150mg/d
37,T29,Multiplier 492 503	15 - 45mg/d
38,T30,Multiplier 518 529	30 - 60mg/d
39,R10,Has_qualifier Arg1:T15 Arg2:T14
40,R11,Has_qualifier Arg1:T15 Arg2:T16
41,R12,Has_multiplier Arg1:T18 Arg2:T17
42,*,OR T15 T18
43,T31,Drug 534 548	venlafaxine ER
44,T32,Multiplier 549 560	150-225mg/d
45,T33,"Scope 371 561	escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine ER(150-225mg/d)"
46,R13,Has_multiplier Arg1:T19 Arg2:T25
47,R14,Has_multiplier Arg1:T20 Arg2:T26
48,R15,Has_multiplier Arg1:T21 Arg2:T27
49,R16,Has_multiplier Arg1:T22 Arg2:T28
50,R17,Has_multiplier Arg1:T23 Arg2:T29
51,R18,Has_multiplier Arg1:T24 Arg2:T30
52,R19,Has_multiplier Arg1:T31 Arg2:T32
53,T34,Scope 284 368	standard antidepressant treatment in monotherapy or combination of 2 antidepressants
54,R20,Subsumes Arg1:T34 Arg2:T33
0,T1,Measurement 0 21	Body mass index (BMI)
1,T2,Value 25 41	35 kg/m2 or more
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 56 65;80 88	metabolic diseases
4,T4,Condition 70 88	endocrine diseases
5,*,OR T3 T4
6,T5,Condition 104 110	cancer
7,T6,Drug 120 128	steroids
8,T7,Drug 132 184	drugs that interfere with the metabolism of estrogen
9,*,OR T6 T7
10,T8,Drug 198 215	systemic estrogen
11,T9,Drug 198 206;217 226	systemic progestin
12,T10,Drug 231 235	DHEA
13,T11,Temporal 236 277	in the eight weeks prior to randomization
14,T12,"Scope 198 235	systemic estrogen, progestin, or DHEA"
15,*,OR T9 T8 T10
16,R2,Has_temporal Arg1:T12 Arg2:T11
17,T13,Procedure 287 308	alternative therapies
18,T14,Drug 312 328	natural products
19,T15,Condition 338 361	postmenopausal symptoms
20,T16,Temporal 362 402	in the four weeks prior to randomization
21,T17,Scope 287 328	alternative therapies or natural products
22,*,OR T13 T14
23,R3,AND Arg1:T17 Arg2:T15
24,R4,Has_temporal Arg1:T17 Arg2:T16
25,T18,Condition 405 422	Palpable fibroids
26,T19,Condition 426 442	uterine prolapse
27,*,OR T18 T19
28,T20,Measurement 444 449	Grade
29,T21,Value 450 456	2 or 3
30,R5,Has_value Arg1:T20 Arg2:T21
31,T22,Scope 405 442	Palpable fibroids or uterine prolapse
32,R6,AND Arg1:T22 Arg2:T20
33,T23,Condition 459 476	Cigarette smoking
0,T1,Value 0 13	over 18 years
1,T2,Person 0 13	over 18 years
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 190 226;26 37	on the venous-prosthesis anastomosis angioplasty
4,T4,Qualifier 15 25	successful
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Measurement 39 56	residual stenosis
7,T6,Value 57 62	< 30%
8,R3,Has_value Arg1:T5 Arg2:T6
9,R4,Subsumes Arg1:T4 Arg2:T5
10,T7,Condition 81 89	stenosis
11,T8,Qualifier 69 80	significant
12,R5,Has_qualifier Arg1:T7 Arg2:T8
13,R6,AND Arg1:T3 Arg2:T7
14,T9,Measurement 91 113	maximal systolic speed
15,T10,Value 114 134	3 times > from basal
16,R7,Has_value Arg1:T9 Arg2:T10
17,T11,Measurement 159 167	stenosis
18,T12,Value 168 173	> 70%
19,R8,Has_value Arg1:T11 Arg2:T12
20,T13,Procedure 177 188	angiography
21,R9,AND Arg1:T13 Arg2:T11
22,R10,AND Arg1:T13 Arg2:T9
23,T14,"Scope 91 188	maximal systolic speed 3 times > from basal maximal systolic speed, stenosis > 70% on angiography"
24,R11,Subsumes Arg1:T4 Arg2:T14
25,T15,Procedure 230 278;26 37	on the venous segment 5 cm after the anastomosis angioplasty
26,T16,Observation 349 376	social security affiliation
27,T17,Observation 378 401	signed informed consent
0,T1,Condition 0 24	Type 2 Diabetes Mellitus
1,T2,Measurement 101 106	HbA1c
2,T3,Value 117 126	8.0-12.0%
3,T4,Temporal 77 95	previous 12 months
4,R1,Has_value Arg1:T2 Arg2:T3
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,T5,Negation 188 191	not
7,T6,Condition 200 225	proliferative retinopathy
8,R3,Has_negation Arg1:T6 Arg2:T5
9,T7,Negation 132 135	not
10,T8,Observation 143 178	medical history related to diabetes
11,R4,Has_negation Arg1:T8 Arg2:T7
0,T1,Condition 13 29	medical problems
1,T2,Qualifier 0 12	Uncontrolled
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 40 49;80 87	pulmonary disease
4,T4,Condition 69 87	orthopedic disease
5,T5,Condition 51 65;80 87	cardiovascular disease
6,*,OR T3 T5 T4
7,T6,"Scope 40 87	pulmonary, cardiovascular or orthopedic disease"
8,R2,Subsumes Arg1:T1 Arg2:T6
9,T7,Condition 94 114	debilitating disease
10,T8,Temporal 115 131	prior to the SCI
11,T9,Condition 144 164	exercise intolerance
12,R3,AND Arg1:T7 Arg2:T9
13,R4,Has_temporal Arg1:T7 Arg2:T8
14,T10,Condition 185 201	major depression
15,T11,Condition 205 214	psychosis
16,T12,Condition 216 240	altered cognitive status
17,T13,Temporal 177 184	ongoing
18,T14,Qualifier 166 175	Premorbid
19,*,OR T10 T11
20,T15,Scope 185 214	major depression or psychosis
21,R5,Has_temporal Arg1:T15 Arg2:T13
22,R6,Has_qualifier Arg1:T15 Arg2:T14
23,*,OR T15 T12
24,T16,Condition 253 264	head injury
25,T17,Condition 268 274	stroke
26,*,OR T17 T16
27,T18,Observation 242 252	History of
28,R7,Has_temporal Arg1:T16 Arg2:T18
29,R8,Has_temporal Arg1:T17 Arg2:T18
30,T19,Device 277 297	Metal plate in skull
31,T20,Condition 310 318	seizures
32,T21,Drug 330 382	drugs acting primarily on the central nervous system
33,T22,Drug 426 445	antipsychotic drugs
34,T23,Qualifier 390 417	lower the seizure threshold
35,R9,Has_qualifier Arg1:T21 Arg2:T23
36,T24,Drug 447 461	chlorpromazine
37,T25,Drug 463 472	clozapine
38,*,OR T24 T25
39,T26,Drug 477 502	tricyclic antidepressants
40,T27,"Scope 447 472	chlorpromazine, clozapine"
41,R10,Subsumes Arg1:T22 Arg2:T27
42,*,OR T22 T26
43,T28,"Scope 426 502	antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants"
44,T29,"Scope 330 417	drugs acting primarily on the central nervous system, which lower the seizure threshold"
45,R11,Subsumes Arg1:T29 Arg2:T27
46,T30,Condition 505 513	Pregnant
47,T31,Person 514 521	females
48,T32,Condition 536 552	cord compression
49,T33,Condition 558 564	syrinx
50,T34,Qualifier 572 583	spinal cord
51,R12,Has_qualifier Arg1:T33 Arg2:T34
52,*,OR T33 T32 T35
53,T35,Condition 605 624	spinal cord disease
54,T36,Condition 633 648	spinal stenosis
55,T37,Condition 650 662	spina bifida
56,T38,Condition 666 689	herniated cervical disk
57,*,OR T36 T37 T38
58,T39,"Scope 633 689	spinal stenosis, spina bifida or herniated cervical disk"
59,R13,Subsumes Arg1:T35 Arg2:T39
60,T40,Condition 761 779	orthopedic disease
61,T41,Condition 743 757;772 779	cardiovascular disease
62,T42,Condition 732 741;772 779	pulmonary disease
63,*,OR T41 T42 T40
64,T43,Condition 705 721	medical problems
65,T44,Qualifier 692 704	Uncontrolled
66,R14,Has_qualifier Arg1:T43 Arg2:T44
67,T45,"Scope 732 779	pulmonary, cardiovascular or orthopedic disease"
68,T46,Scope 692 721	Uncontrolled medical problems
69,R15,Subsumes Arg1:T46 Arg2:T45
70,T47,Condition 786 806	debilitating disease
71,T48,Condition 819 839	exercise intolerance
72,R16,AND Arg1:T47 Arg2:T48
73,T49,Qualifier 841 850	Premorbid
74,T50,Temporal 852 859	ongoing
75,T51,Condition 860 876	major depression
76,T52,Condition 880 889	psychosis
77,*,OR T51 T52
78,T53,Condition 891 915	altered cognitive status
79,T54,Scope 860 889	major depression or psychosis
80,R17,Has_temporal Arg1:T54 Arg2:T50
81,R18,Has_qualifier Arg1:T54 Arg2:T49
82,*,OR T54 T53
83,T55,Condition 928 939	head injury
84,T56,Condition 943 949	stroke
85,*,OR T56 T55
86,T57,Observation 917 924	History
87,R19,Has_temporal Arg1:T55 Arg2:T57
88,R20,Has_temporal Arg1:T56 Arg2:T57
89,T58,Device 952 972	Metal plate in skull
90,T59,Condition 985 993	seizures
91,T60,Observation 974 984	History of
92,R21,Has_temporal Arg1:T59 Arg2:T60
93,T61,Drug 1005 1057	drugs acting primarily on the central nervous system
94,T62,Qualifier 1065 1092	lower the seizure threshold
95,T63,Drug 1101 1120	antipsychotic drugs
96,T64,Drug 1122 1136	chlorpromazine
97,T65,Drug 1138 1147	clozapine
98,T66,Drug 1152 1177	tricyclic antidepressants
99,*,OR T64 T65
100,T67,"Scope 1122 1147	chlorpromazine, clozapine"
101,R22,Subsumes Arg1:T63 Arg2:T67
102,*,OR T63 T66
103,R23,Has_qualifier Arg1:T61 Arg2:T62
104,T68,"Scope 1101 1177	antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants"
105,T69,"Scope 1005 1092	drugs acting primarily on the central nervous system, which lower the seizure threshold"
106,R24,Subsumes Arg1:T69 Arg2:T68
107,T70,Condition 1180 1188	Pregnant
108,T71,Person 1189 1196	females
109,T72,Condition 1211 1227	cord compression
110,T73,Condition 1233 1239	syrinx
111,T74,Qualifier 1247 1258	spinal cord
112,R25,Has_qualifier Arg1:T73 Arg2:T74
113,*,OR T73 T72 T75
114,T75,Condition 1280 1299	spinal cord disease
115,T76,Condition 1308 1323	spinal stenosis
116,T77,Condition 1325 1337	spina bifida
117,T78,Condition 1341 1364	herniated cervical disk
118,*,OR T76 T77 T78
119,T79,"Scope 1308 1364	spinal stenosis, spina bifida or herniated cervical disk"
120,R26,Subsumes Arg1:T75 Arg2:T79
0,T1,Condition 16 32	hypersensitivity
1,T2,Drug 36 48	aripiprazole
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 71 74	MDD
4,T4,Condition 80 97	psychotic feature
5,T5,Condition 99 115	bipolar disorder
6,T6,Condition 117 130	schizophrenia
7,T7,Condition 132 156	schizoaffective disorder
8,T8,Condition 164 182	psychotic disorder
9,T9,Qualifier 158 163	other
10,T10,"Condition 186 203	anxiety disorder,"
11,T11,Condition 226 236	drug abuse
12,T12,Condition 217 224;231 236	alcohol abuse
13,T13,Temporal 237 262	within the past 12 months
14,T14,Condition 282 290	dementia
15,*,OR T4 T5 T3 T6 T7 T8 T10 T15 T14
16,R2,Has_qualifier Arg1:T8 Arg2:T9
17,*,OR T11 T12
18,T15,Scope 217 236	alcohol/ drug abuse
19,R3,Has_temporal Arg1:T15 Arg2:T13
20,T16,"Scope 80 202	psychotic feature, bipolar disorder, schizophrenia, schizoaffective disorder, other psychotic disorder or anxiety disorder"
21,R4,Has_scope Arg1:T3 Arg2:T16
22,T17,Qualifier 323 330	Axis II
23,T18,Condition 343 352	diagnosis
24,R5,Has_qualifier Arg1:T18 Arg2:T17
25,T19,Qualifier 332 341	DSM-IV-TR
26,R6,Has_qualifier Arg1:T18 Arg2:T19
27,T20,Observation 368 383	risk of suicide
28,T21,Qualifier 356 367	significant
29,R7,Has_qualifier Arg1:T20 Arg2:T21
30,T22,Measurement 451 462	MADRS scale
31,T23,Value 402 424	score of =5 on item 10
32,R8,Has_value Arg1:T22 Arg2:T23
33,R9,AND Arg1:T20 Arg2:T22
34,T24,Non-query-able 466 506	by clinical judgment of the investigator
35,T25,Pregnancy_considerations 508 538	Pregnancy or in breast-feeding
36,T26,Qualifier 554 561	serious
37,T28,Condition 562 577	medical illness
38,R10,Has_qualifier Arg1:T28 Arg2:T26
39,T27,Condition 588 595	cardiac
40,T29,Condition 597 604	hepatic
41,T30,Condition 606 611	renal
42,T31,Condition 613 624	respiratory
43,T32,Condition 626 640	endocrinologic
44,T33,Condition 642 652	neurologic
45,T34,Condition 657 676	hematologic disease
46,T35,Condition 680 697	physical disorder
47,T36,"Non-query-able 540 760	Presence of a serious medical illness including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease or physical disorder judged to significantly affect central nervous system function"
48,T37,Drug 778 792	antipsychotics
49,T38,Drug 794 809	mood stabilizer
50,T39,Drug 817 841	psychotropic medications
51,T40,Negation 842 849	besides
52,T41,Drug 850 865	antidepressants
53,T42,Negation 867 873	except
54,T43,Drug 874 889	benzodiazepines
55,T44,Drug 893 906	beta blockers
56,T45,Drug 910 919	hypnotics
57,*,OR T43 T44 T45
58,T46,Scope 874 919	benzodiazepines or beta blockers or hypnotics
59,R11,Has_negation Arg1:T46 Arg2:T42
60,R12,Has_negation Arg1:T41 Arg2:T40
61,T47,Scope 817 865	psychotropic medications besides antidepressants
62,*,OR T37 T38 T47
63,T48,Drug 962 974	aripiprazole
64,T49,Observation 940 958	treatment failures
65,R13,Has_context Arg1:T48 Arg2:T49
0,T1,Procedure 22 34	radiotherapy
1,T2,Condition 0 18	contra-indications
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Procedure 36 61	angioplasty with stenting
0,T1,Qualifier 11 26	weight-lowering
1,T2,Drug 27 32	drugs
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Qualifier 38 53	investigational
4,T4,Qualifier 71 85	lipid-lowering
5,T5,Qualifier 54 67	blood-glucose
6,T6,Drug 86 91	agent
7,*,OR T4 T5
8,T7,Scope 54 85	blood-glucose or lipid-lowering
9,R2,Has_scope Arg1:T6 Arg2:T7
10,R3,Has_qualifier Arg1:T6 Arg2:T3
11,*,OR T2 T6
12,T8,Temporal 137 150	past 3 months
13,T9,Negation 93 98	other
14,T10,Drug 104 111	statins
15,T11,Drug 115 124	ezetimibe
16,*,OR T10 T11
17,T12,Scope 104 124	statins or ezetimibe
18,R4,Has_negation Arg1:T12 Arg2:T9
19,T13,"Scope 11 91	weight-lowering drugs, any investigational blood-glucose or lipid-lowering agent"
20,R5,Has_temporal Arg1:T13 Arg2:T8
21,T14,Drug 176 200	systemic corticosteroids
22,T15,Drug 226 242	thyroid hormones
23,T16,Qualifier 206 222	change in dosage
24,R6,Has_qualifier Arg1:T15 Arg2:T16
25,T17,Temporal 250 266	previous 6 weeks
26,*,OR T14 T15
27,T18,Scope 176 242	systemic corticosteroids or a change in dosage of thyroid hormones
28,R7,Has_temporal Arg1:T18 Arg2:T17
29,T19,Drug 279 286	insulin
30,T20,Temporal 287 325	within the 3 months prior to screening
31,T21,Reference_point 316 325	screening
32,R8,Has_temporal Arg1:T19 Arg2:T20
33,R9,Has_index Arg1:T20 Arg2:T21
34,T22,Non-query-able 327 333	Others
0,T1,Condition 8 22	postmenopausal
1,T2,Condition 0 7	Healthy
2,T3,Person 23 28	women
3,T4,Value 34 44	50 or more
4,T5,Condition 45 75	moderate to severe hot flushes
5,R1,AND Arg1:T4 Arg2:T5
6,T6,Person 78 83	Women
7,T7,Value 84 106	between 40 to 70 years
8,T8,Person 110 113	age
9,R2,Has_value Arg1:T8 Arg2:T7
0,T1,Person 0 4	Male
1,T2,Person 9 16	females
2,T3,Value 17 24;30 48	between 18-85 years of age
3,T4,Person 25 29	ages
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Condition 50 53	SCI
6,T6,Temporal 56 74	=1 month of injury
7,R2,Has_temporal Arg1:T5 Arg2:T6
8,T7,Measurement 77 81	ASIA
9,T8,"Value 82 94	A, B,C and D"
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Measurement 96 99	SCI
12,T10,Value 100 108	above L5
13,R4,Has_value Arg1:T9 Arg2:T10
14,T11,Non-representable 110 235	Able to perform a visible contraction with dorsiflexor and hip flexor muscles (allowing testing of largely impaired patients)
15,T13,Person 312 319	females
16,T14,Person 305 306	l
17,T15,Value 320 327;333 351	between 18-85 years of age
18,T16,Person 328 332	ages
19,R5,Has_value Arg1:T16 Arg2:T15
20,*,OR T13 T14
21,*,OR T2 T1
22,T17,Condition 353 365	Able to walk
23,T18,Condition 237 265	Able to ambulate a few steps
24,T12,Qualifier 274 301	without an assistive device
25,T19,Qualifier 266 270;285 301	with assistive device
26,*,OR T12 T19
27,T20,Scope 266 301	with or without an assistive device
28,R6,Has_scope Arg1:T18 Arg2:T20
29,T21,Condition 353 360;370 395	Able to complete lower-limb tests
30,T22,Qualifier 396 410	with both legs
31,R7,Has_qualifier Arg1:T21 Arg2:T22
32,*,OR T21 T17
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 79 81	2.
2,T3,Parsing_Error 133 135	3.
3,T4,Parsing_Error 242 244	4.
4,T5,Parsing_Error 362 364	5.
5,T6,Parsing_Error 522 524	6.
6,T7,Person 3 7	Male
7,T8,Person 11 17	female
8,*,OR T8 T7
9,T9,Value 31 48	at least 18 years
10,T10,Person 52 55	age
11,R1,Has_value Arg1:T10 Arg2:T9
12,T11,Temporal 56 76	at Visit 1 Screening
13,T12,Reference_point 59 76	Visit 1 Screening
14,R2,Has_index Arg1:T11 Arg2:T12
15,R3,Has_temporal Arg1:T10 Arg2:T11
16,T13,Post-eligibility 82 131	Has provided verbal and written informed consent.
17,T14,Non-query-able 82 131	Has provided verbal and written informed consent.
18,T15,"Post-eligibility 136 240	Be able and willing to follow instructions, including participation in all study assessments and visits."
19,T16,"Non-query-able 136 240	Be able and willing to follow instructions, including participation in all study assessments and visits."
20,T17,Condition 273 281	glaucoma
21,T18,Procedure 261 268	treated
22,T19,Temporal 245 254	Currently
23,R4,Has_temporal Arg1:T18 Arg2:T19
24,R5,AND Arg1:T18 Arg2:T17
25,T20,Multiplier 288 300	at least two
26,T21,Drug 301 312	medications
27,T22,Undefined_semantics 301 312	medications
28,R6,Has_multiplier Arg1:T21 Arg2:T20
29,R7,AND Arg1:T18 Arg2:T21
30,T23,Non-query-able 321 340	willing to continue
31,T24,Multiplier 378 390	at least two
32,T25,Condition 398 406	symptoms
33,T26,Measurement 414 481	GLIA™ Glaucoma Medication Ocular Side Effect Symptoms Questionnaire
34,T27,Value 487 500;512 519	severity of 2 or more
35,T28,Value 502 510	moderate
36,R8,Subsumes Arg1:T27 Arg2:T28
37,R9,Has_value Arg1:T26 Arg2:T27
38,R10,Has_multiplier Arg1:T25 Arg2:T24
39,R11,AND Arg1:T25 Arg2:T26
40,T29,Person 530 535	woman
41,A1,Optional T29
42,T30,Condition 539 561	childbearing potential
43,R12,AND Arg1:T29 Arg2:T30
44,T31,Measurement 579 599	urine pregnancy test
45,T32,Value 570 578	negative
46,R13,Has_value Arg1:T31 Arg2:T32
47,T33,Temporal 600 610	at Visit 1
48,T34,Reference_point 603 610	Visit 1
49,R14,Has_index Arg1:T33 Arg2:T34
50,R15,Has_temporal Arg1:T31 Arg2:T33
51,T35,Device 636 659	method of birth control
52,T36,Qualifier 627 635	adequate
53,T37,Subjective_judgement 627 635	adequate
54,R16,Has_qualifier Arg1:T35 Arg2:T36
55,T38,Temporal 660 687	throughout the study period
56,T39,Reference_point 675 687	study period
57,R17,Has_index Arg1:T38 Arg2:T39
58,R18,Has_temporal Arg1:T35 Arg2:T38
0,T1,Condition 12 19	illness
1,T2,Condition 21 27	trauma
2,T3,Procedure 31 50	surgical procedures
3,*,OR T2 T3 T1
4,T4,Qualifier 0 11	Significant
5,T5,Subjective_judgement 0 11	Significant
6,T6,"Scope 12 50	illness, trauma or surgical procedures"
7,R1,Has_qualifier Arg1:T6 Arg2:T4
8,T7,Condition 76 100	laboratory abnormalities
9,T8,Procedure 76 86	laboratory
10,R2,multi Arg1:T7 Arg2:T8
11,T9,Qualifier 53 75	Clinically significant
12,T10,Subjective_judgement 53 75	Clinically significant
13,R3,Has_qualifier Arg1:T7 Arg2:T9
14,T11,Observation 126 141	medical history
15,T12,Qualifier 103 125	Clinically significant
16,R4,Has_qualifier Arg1:T11 Arg2:T12
0,T1,Person 0 3	men
1,T2,Person 8 13	women
2,*,OR T1 T2
3,T3,Value 14 25	30-55 years
4,T4,Measurement 31 34	BMI
5,T5,Value 35 40	30-40
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 45 50	waist
8,T7,Value 51 64	95 cm or more
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Person 14 25	30-55 years
11,R3,Has_value Arg1:T8 Arg2:T3
12,R4,multi Arg1:T8 Arg2:T3
13,T9,Measurement 73 77	OGTT
14,T10,Value 66 72	normal
15,R5,Has_value Arg1:T9 Arg2:T10
16,T11,Measurement 86 107	treadmill stress test
17,T12,Value 79 85	normal
18,R6,Has_value Arg1:T11 Arg2:T12
19,T13,Multiplier 114 120	2 of 4
20,T14,Non-representable 109 121	plus 2 of 4:
21,T15,Parsing_Error 109 121	plus 2 of 4:
22,T16,Measurement 130 161	serum levels of HDL cholesterol
23,T17,Value 126 129	low
24,R7,Has_value Arg1:T16 Arg2:T17
25,T18,Value 163 172	<40 mg⁄dL
26,T19,Value 184 195	< 50 mg ⁄dL
27,T20,Person 177 180	men
28,T21,Person 200 205	women
29,A1,Optional T21
30,A2,Optional T20
31,R8,Has_value Arg1:T20 Arg2:T18
32,R9,Has_value Arg1:T21 Arg2:T19
33,T22,Scope 163 205	<40 mg⁄dL for men or < 50 mg ⁄dL for women
34,R10,Subsumes Arg1:T17 Arg2:T22
35,T23,Condition 212 232	hypertriglyceridemia
36,T24,Measurement 234 253	triglyceride levels
37,T25,Value 257 277	150 mg⁄dL or greater
38,R11,Has_value Arg1:T24 Arg2:T25
39,T26,Scope 234 277	triglyceride levels of 150 mg⁄dL or greater
40,R12,Subsumes Arg1:T23 Arg2:T26
41,T27,Condition 284 312	impaired glucose homeostasis
42,T28,Measurement 314 350	fasting plasma glucose concentration
43,T29,Value 354 374	110 mg⁄dL or greater
44,R13,Has_value Arg1:T28 Arg2:T29
45,T30,Measurement 378 385	glucose
46,T31,Value 389 409	140 mg⁄dL or greater
47,T32,Procedure 416 420	OGTT
48,T33,Temporal 410 420	after OGTT
49,T34,Reference_point 416 420	OGTT
50,R14,multi Arg1:T33 Arg2:T34
51,R15,multi Arg1:T34 Arg2:T32
52,R16,Has_value Arg1:T30 Arg2:T31
53,*,OR T28 T30
54,T35,Scope 314 420	fasting plasma glucose concentration of 110 mg⁄dL or greater or glucose of 140 mg⁄dL or greater after OGTT
55,T36,Qualifier 410 420	after OGTT
56,R17,multi Arg1:T36 Arg2:T33
57,R18,Has_qualifier Arg1:T30 Arg2:T36
58,R19,Subsumes Arg1:T27 Arg2:T35
59,T37,Condition 428 440	hypertension
60,T38,Measurement 442 465	systolic blood pressure
61,T39,Value 466 471	≥ 140
62,T40,Measurement 475 499	diastolic blood pressure
63,T41,Value 500 508	≥90 mmHg
64,T42,Procedure 512 521	treatment
65,T43,Drug 527 549	antihypertensive drugs
66,R20,AND Arg1:T42 Arg2:T43
67,R21,Has_value Arg1:T40 Arg2:T41
68,R22,Has_value Arg1:T38 Arg2:T39
69,*,OR T38 T40 T42
70,T44,Scope 442 549	systolic blood pressure ≥ 140 or diastolic blood pressure ≥90 mmHg or treatment with antihypertensive drugs
71,R23,Subsumes Arg1:T37 Arg2:T44
0,T1,Measurement 0 21	body mass index (BMI)
1,T2,Value 22 44	between 19 to 30 kg/m2
2,T3,Measurement 49 60	body weight
3,T4,Value 69 91	50 to 100 kg inclusive
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Has_value Arg1:T1 Arg2:T2
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 241 243	2.
2,T3,Parsing_Error 302 304	3.
3,T4,Parsing_Error 450 452	4.
4,T5,Parsing_Error 523 525	5.
5,T6,Parsing_Error 612 614	6.
6,T7,Parsing_Error 685 687	7.
7,T8,Parsing_Error 867 869	8.
8,T9,Subjective_judgement 64 99	in the judgment of the investigator
9,T10,Non-query-able 100 137	will interfere with study assessments
10,T11,Context_Error 100 137	will interfere with study assessments
11,T12,Condition 147 164	corneal opacities
12,T13,Condition 147 154;169 174	corneal scars
13,T14,Condition 176 187	dystrophies
14,T15,Condition 189 208	epithelial scarring
15,T16,Condition 210 220	infections
16,T17,Condition 222 233	blood clots
17,T18,Condition 44 58	eye conditions
18,T19,Qualifier 100 137	will interfere with study assessments
19,R1,Has_qualifier Arg1:T18 Arg2:T19
20,T20,"Scope 147 233	corneal opacities and scars, dystrophies, epithelial scarring, infections, blood clots"
21,*,OR T13 T12 T14 T15 T16 T17
22,R2,Has_scope Arg1:T18 Arg2:T20
23,T21,Measurement 244 279	Best corrected visual acuity (BCVA)
24,T22,Value 292 299	<20/200
25,T23,Temporal 280 291	at baseline
26,T24,Reference_point 283 291	baseline
27,R3,Has_index Arg1:T23 Arg2:T24
28,R4,Has_temporal Arg1:T21 Arg2:T23
29,R5,Has_value Arg1:T21 Arg2:T22
30,T27,Subjective_judgement 338 372	in the opinion of the investigator
31,T28,Subjective_judgement 374 401	may interfere significantly
32,T29,Non-query-able 374 401	may interfere significantly
33,T25,Person 455 460	woman
34,T26,Condition 468 476	pregnant
35,T30,Condition 478 485	nursing
36,T31,Non-query-able 500 508	planning
37,T32,Condition 511 520	pregnancy
38,*,OR T32 T30 T26
39,T33,Condition 538 554;574 609	adverse reaction to the study drug or its components
40,T34,Condition 562 609	sensitivity to the study drug or its components
41,*,OR T34 T33
42,T35,Multiplier 628 650	more than twice a week
43,T36,Multiplier 615 626	Routine use
44,R6,Subsumes Arg1:T36 Arg2:T35
45,T37,Observation 657 682	chlorinated swimming pool
46,T38,Non-query-able 657 682	chlorinated swimming pool
47,R7,Has_multiplier Arg1:T37 Arg2:T36
48,T39,Post-eligibility 688 707	Unwilling or unable
49,T40,Non-query-able 688 707	Unwilling or unable
50,T41,Drug 774 801	Topical ocular cyclosporine
51,T42,Drug 808 817	Restasis®
52,R8,Subsumes Arg1:T41 Arg2:T42
53,T43,Drug 820 835	anti-histamines
54,T44,Drug 837 851	antipsychotics
55,T45,Drug 856 864	eye gels
56,*,OR T45 T44 T43 T41
57,T46,Temporal 749 772	during the study period
58,T47,Reference_point 760 772	study period
59,R9,Has_index Arg1:T46 Arg2:T47
60,T48,"Scope 774 864	Topical ocular cyclosporine (e.g. Restasis®), anti-histamines, antipsychotics, or eye gels"
61,R10,Has_temporal Arg1:T48 Arg2:T46
62,T49,Drug 895 915	investigational drug
63,T50,Context_Error 895 915	investigational drug
64,T51,Device 895 910;919 925	investigational device
65,T52,Context_Error 895 910;919 925	investigational device
66,T53,Drug 948 968	investigational drug
67,T54,Context_Error 948 968	investigational drug
68,T55,Temporal 979 1010	within 30 days prior to Visit 1
69,T56,Reference_point 1003 1010	Visit 1
70,R11,Has_index Arg1:T55 Arg2:T56
71,*,OR T49 T51 T53 T57
72,T57,Device 948 963;972 978	investigational device
73,T58,Scope 895 978	investigational drug or device study or have used an investigational drug or device
74,R12,Has_temporal Arg1:T58 Arg2:T55
0,T1,Condition 0 8	diabetes
1,T2,Condition 10 32	ischemic heart disease
2,T3,Measurement 55 76	treadmill stress test
3,T4,Value 40 51	abnormality
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T2 T3
6,T5,Condition 102 110;78 90	disorder inflammatory
7,T6,Condition 94 110	chronic disorder
8,*,OR T5 T6
9,T7,Condition 112 121	pregnancy
10,T8,Condition 123 132	lactation
11,T9,Measurement 134 150	creatinine level
12,T10,"Value 154 171	1,5 mg/dL or more"
13,R2,Has_value Arg1:T9 Arg2:T10
14,T11,Condition 173 198	gastrointestinal problems
15,T12,Condition 202 227	musculoskeletal disorders
16,T13,Mood 239 246	prevent
17,T14,Negation 239 246	prevent
18,T15,Procedure 266 276	test diets
19,T16,Procedure 280 302	exercise interventions
20,*,OR T15 T16
21,T17,Scope 266 302	test diets or exercise interventions
22,R3,Has_negation Arg1:T17 Arg2:T14
23,R4,multi Arg1:T14 Arg2:T13
24,*,OR T12 T11
25,T18,Scope 173 227	gastrointestinal problems or musculoskeletal disorders
26,R5,Has_scope Arg1:T18 Arg2:T17
27,T19,Condition 304 321	liver dysfunction
28,T20,Value 329 381	factor of at least 3 above the upper limit of normal
29,T21,Measurement 385 388;397 403	AST levels
30,T22,Measurement 393 403	ALT levels
31,T23,Scope 385 403	AST and ALT levels
32,R6,Has_scope Arg1:T19 Arg2:T23
33,R7,Has_value Arg1:T23 Arg2:T20
34,T24,Condition 405 424	thyroid dysfunction
35,T25,Measurement 431 440	serum TSH
36,T26,Value 441 461	out of normal limits
37,R8,Has_value Arg1:T25 Arg2:T26
38,R9,AND Arg1:T24 Arg2:T25
39,T27,Drug 470 493	immunosuppressive drugs
40,T28,Drug 495 510	corticosteroids
41,T29,Drug 514 524	anorexigen
42,*,OR T29 T28 T27
0,T1,Condition 0 20	pathological obesity
1,T2,Condition 22 38	chronic diseases
2,T3,Condition 44 58	cerebral palsy
3,T4,Condition 60 77	metabolic disease
4,*,OR T3 T4
5,T5,"Scope 44 77	cerebral palsy, metabolic disease"
6,R1,Subsumes Arg1:T2 Arg2:T5
7,T6,Condition 85 112	diseases of red blood cells
8,T7,Drug 133 140	steroid
9,T8,Drug 142 155	multivitamins
10,T9,Drug 157 185	thiamine-containing vitamins
11,T10,Drug 187 201	diuretic drugs
12,*,OR T9 T10 T8 T7
13,T11,Procedure 203 215	hemodialysis
14,T12,Procedure 219 238	peritoneal dialysis
15,*,OR T11 T12
16,T13,Procedure 240 257	bariatric surgery
0,T1,Condition 14 30	hypersensitivity
1,T2,Drug 43 49	Statin
2,T3,Drug 54 63	Ezetimibe
3,*,OR T2 T3
4,T4,Scope 43 63	Statin and Ezetimibe
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Qualifier 79 85	severe
7,T6,Condition 86 100	kidney disease
8,R2,Has_qualifier Arg1:T6 Arg2:T5
9,T7,Condition 116 128	HIV positive
10,T8,Temporal 136 152	at the screening
11,R3,Has_temporal Arg1:T7 Arg2:T8
12,T9,Condition 154 162	Pregnant
13,T10,Condition 166 180	breast-feeding
14,*,OR T10 T9
15,T11,Procedure 246 249	LDL
16,T12,Drug 251 262	Fenofibrate
17,T13,Drug 216 226	medication
18,T14,Condition 227 236	affecting
19,R4,AND Arg1:T14 Arg2:T11
20,R5,AND Arg1:T13 Arg2:T14
21,T15,Drug 264 282	Omega 3 fatty aicd
22,*,OR T12 T15
23,T16,"Scope 251 282	Fenofibrate, Omega 3 fatty aicd"
24,R6,Subsumes Arg1:T13 Arg2:T16
25,T17,Drug 290 297	Insulin
26,T18,Non-representable 316 340	Other exclusions applied
0,T1,Condition 0 5	obese
1,T2,Measurement 8 25	weight for height
2,T3,Value 26 58	> median + 3 standard deviations
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Scope 8 58	weight for height > median + 3 standard deviations
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Condition 60 74	simple obesity
0,T1,Value 9 27	= 19 or = 75 years
1,T2,Person 31 34	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 70 85	type 2 diabetes
4,T4,Procedure 56 65	treatment
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Procedure 107 116	treatment
7,T6,Condition 131 151	hypercholesterolemia
8,T7,Drug 120 126	statin
9,R3,AND Arg1:T5 Arg2:T7
10,T8,Scope 107 126	treatment of statin
11,R4,AND Arg1:T8 Arg2:T6
12,T9,Measurement 153 166	Fasting LDL-C
13,T10,Measurement 202 215	Fasting LDL-C
14,T11,Value 167 177	= 250mg/dL
15,R5,Has_value Arg1:T9 Arg2:T11
16,T12,Temporal 178 200	at the screening visit
17,R6,Has_temporal Arg1:T9 Arg2:T12
18,T13,Value 216 224	=70mg/dL
19,T14,Value 228 238	= 160mg/dL
20,*,OR T13 T14
21,T15,Scope 216 237	=70mg/dL or = 160mg/d
22,R7,Has_scope Arg1:T10 Arg2:T15
23,T16,Temporal 239 266	at the randomization visit
24,R8,Has_temporal Arg1:T10 Arg2:T16
25,T17,Measurement 267 277	Fasting TG
26,T18,Value 277 286	<500mg/dL
27,R9,Has_value Arg1:T17 Arg2:T18
28,T19,Temporal 239 265	at the randomization visit
29,R10,Has_temporal Arg1:T10 Arg2:T19
0,T1,Non-representable 0 46	Therapy area located outside of head and neck;
1,T2,Condition 54 67	skin diseases
2,T3,Qualifier 79 117	interfere with the efficacy evaluation
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Drug 157 164	isotope
5,T5,Drug 168 171	PDT
6,T6,Procedure 181 190	treatment
7,T7,Qualifier 197 241	might interfere with the efficacy evaluation
8,R2,Has_qualifier Arg1:T6 Arg2:T7
9,*,OR T5 T4
10,T8,Scope 157 171	isotope or PDT
11,R3,Has_scope Arg1:T6 Arg2:T8
12,T9,Condition 244 251	Allergy
13,T10,Drug 255 265	porphyrins
14,T11,Condition 281 297	Photosensitivity
15,T12,Drug 270 279	analogues
16,T13,Condition 299 308	Porphyria
17,T14,Condition 310 331	Allergic constitution
18,*,OR T13 T14 T11
19,*,OR T10 T12
20,T15,Scope 255 279	porphyrins and analogues
21,R4,Has_scope Arg1:T9 Arg2:T15
22,T16,Condition 334 348	Scar diathesis
23,T17,Condition 351 379	Immunocompromised conditions
24,T18,Condition 382 416	Electrocardiographic abnormalities
25,T19,Qualifier 420 427	organic
26,T20,Condition 428 442	heart diseases
27,R5,Has_qualifier Arg1:T20 Arg2:T19
28,T21,Procedure 382 402	Electrocardiographic
29,R6,multi Arg1:T18 Arg2:T21
30,*,OR T18 T20
31,T22,Condition 445 466	Coagulation disorders
32,T23,Measurement 469 476;486 495	Hepatic functions
33,T24,Measurement 480 495	renal functions
34,T25,Value 496 504	abnormal
35,R7,Has_value Arg1:T23 Arg2:T25
36,R8,Has_value Arg1:T24 Arg2:T25
37,*,OR T23 T24
38,T26,Measurement 506 530	alanine aminotransferase
39,T27,Measurement 534 556	aspartate transaminase
40,T28,Measurement 560 575	total bilirubin
41,*,OR T26 T27 T28
42,T29,Value 576 609	> 1.5 upper limit of normal [ULN]
43,T30,Scope 506 575	alanine aminotransferase or aspartate transaminase or total bilirubin
44,R9,Has_value Arg1:T30 Arg2:T29
45,T31,Measurement 614 630	serum creatinine
46,T32,Measurement 634 653	blood urea nitrogen
47,T33,Value 654 663	> 1.5 ULN
48,*,OR T31 T32
49,T34,Scope 614 653	serum creatinine or blood urea nitrogen
50,R10,Has_value Arg1:T34 Arg2:T33
51,*,OR T30 T34
52,T35,"Scope 506 663	alanine aminotransferase or aspartate transaminase or total bilirubin > 1.5 upper limit of normal [ULN], or serum creatinine or blood urea nitrogen > 1.5 ULN"
53,T36,Scope 469 504	Hepatic or renal functions abnormal
54,R11,Subsumes Arg1:T36 Arg2:T35
55,T37,Condition 667 687	Psychiatric diseases
56,T38,Qualifier 689 695	Severe
57,T39,Condition 696 712	endocrinopathies
58,R12,Has_qualifier Arg1:T39 Arg2:T38
59,T40,Temporal 715 723	Previous
60,T41,Procedure 724 731	therapy
61,T42,Temporal 739 762	within the last 4 weeks
62,R13,Has_temporal Arg1:T41 Arg2:T40
63,R14,Has_temporal Arg1:T41 Arg2:T42
64,T43,Observation 765 802	Participation in any clinical studies
65,T44,Temporal 803 826	within the last 4 weeks
66,R15,Has_temporal Arg1:T43 Arg2:T44
67,T45,Non-query-able 829 897	Be judged not suitable to participate the study by the investigators
68,T46,Condition 735 738	PWS
69,R16,AND Arg1:T41 Arg2:T46
0,T1,Qualifier 25 37	uncontrolled
1,T2,Qualifier 13 21	unstable
2,T3,Qualifier 0 11	Progressive
3,T4,Condition 38 57	clinical conditions
4,*,OR T1 T2 T3
5,T5,"Scope 0 37	Progressive, unstable or uncontrolled"
6,R1,Has_scope Arg1:T4 Arg2:T5
7,T6,Condition 60 76	Hypersensitivity
8,T7,Condition 88 95	allergy
9,T8,Drug 104 125	component of vaccines
10,*,OR T6 T7
11,T9,Drug 127 145	medicinal products
12,T10,Device 149 166	medical equipment
13,T11,Qualifier 167 202	whose use is foreseen in this study
14,*,OR T9 T10 T8
15,T12,"Scope 104 166	component of vaccines, medicinal products or medical equipment"
16,R2,Has_qualifier Arg1:T12 Arg2:T11
17,T13,"Scope 60 95	Hypersensitivity, including allergy"
18,R3,Has_scope Arg1:T13 Arg2:T12
19,T14,Condition 240 256	contraindication
20,T15,Procedure 260 285	intramuscular vaccination
21,T16,Procedure 290 301	blood draws
22,*,OR T15 T16
23,T17,Scope 260 301	intramuscular vaccination and blood draws
24,R4,Has_scope Arg1:T14 Arg2:T17
25,T18,Non-representable 304 324	Clinical conditions.
26,T19,Qualifier 326 349	Systemic administration
27,T20,Drug 353 368	corticosteroids
28,T21,Qualifier 370 372	PO
29,T22,Qualifier 373 375	IV
30,T23,Qualifier 376 378	IM
31,*,OR T21 T22 T23
32,T24,Scope 370 378	PO/IV/IM
33,R5,Subsumes Arg1:T19 Arg2:T24
34,R6,Has_qualifier Arg1:T20 Arg2:T19
35,T25,Temporal 380 420	within 90 days prior to informed consent
36,T26,Reference_point 404 420	informed consent
37,R7,Has_index Arg1:T25 Arg2:T26
38,R8,Has_temporal Arg1:T19 Arg2:T25
39,T27,Drug 460 483	immunomodulating agents
40,T28,Drug 441 455;477 483	antineoplastic agents
41,*,OR T27 T28 T29
42,T29,Procedure 487 499	radiotherapy
43,T30,Temporal 500 540	within 90 days prior to informed consent
44,T31,Reference_point 524 540	informed consent
45,R9,Has_index Arg1:T30 Arg2:T31
46,T32,Scope 441 499	antineoplastic and immunomodulating agents or radiotherapy
47,R10,Has_temporal Arg1:T32 Arg2:T30
48,T33,Drug 552 567	immunoglobulins
49,T34,Drug 575 589	blood products
50,T35,Temporal 590 631	within 180 days prior to informed consent
51,T36,Reference_point 615 631	informed consent
52,R11,Has_index Arg1:T35 Arg2:T36
53,*,OR T34 T33
54,T37,Scope 552 589	immunoglobulins or any blood products
55,R12,Has_temporal Arg1:T37 Arg2:T35
56,T38,Qualifier 646 661	investigational
57,T39,Qualifier 665 679	non-registered
58,T40,Drug 680 697	medicinal product
59,T41,Temporal 698 738	within 30 days prior to informed consent
60,T42,Reference_point 722 738	informed consent
61,R13,Has_index Arg1:T41 Arg2:T42
62,*,OR T39 T38
63,T43,Scope 646 679	investigational or non-registered
64,R14,Has_scope Arg1:T40 Arg2:T43
65,R15,Has_temporal Arg1:T40 Arg2:T41
66,T44,"Non-representable 741 888	Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study."
67,T45,Drug 905 930	meningococcal vaccination
68,T46,Observation 894 901	history
69,T47,Condition 934 947;963 971	meningococcal diseases
70,T48,Condition 952 971	gonorrhoea diseases
71,*,OR T48 T47 T45
72,T49,Scope 905 971	meningococcal vaccination or meningococcal and gonorrhoea diseases
73,R16,Has_temporal Arg1:T49 Arg2:T46
74,T50,Procedure 1012 1026	blood donation
75,T51,Non-representable 974 1011	Enrolment in any activity requiring a
76,T52,Multiplier 1027 1045	greater than 50 mL
77,R17,Has_multiplier Arg1:T50 Arg2:T52
78,T53,Temporal 1046 1109	during the period starting 30 days before the first study visit
79,T54,Reference_point 1073 1109	30 days before the first study visit
80,R18,Has_index Arg1:T53 Arg2:T54
81,T55,Temporal 1143 1179	for the duration of the study period
82,T56,Reference_point 1163 1179	the study period
83,R20,Has_index Arg1:T55 Arg2:T56
84,*,OR T53 T55
85,T57,"Scope 1046 1179	during the period starting 30 days before the first study visit (Day -83, Day -60 or Day -30) or for the duration of the study period"
86,R19,Has_scope Arg1:T50 Arg2:T57
87,T58,Drug 1212 1234	immune-modifying drugs
88,T59,Temporal 1235 1270	at any time during the study period
89,T60,Reference_point 1254 1270	the study period
90,R21,Has_index Arg1:T59 Arg2:T60
91,R22,Has_temporal Arg1:T58 Arg2:T59
92,T61,Qualifier 1200 1211	long-acting
93,R23,Has_qualifier Arg1:T58 Arg2:T61
94,T62,Condition 1286 1301	blood disorders
95,T63,Observation 1320 1327	history
96,T64,Observation 1331 1368	difficulty in providing blood samples
97,R24,Has_temporal Arg1:T64 Arg2:T63
98,T65,Drug 1374 1384	antibiotic
99,T66,Temporal 1392 1424	7 days prior to blood collection
100,T67,Reference_point 1408 1424	blood collection
101,R25,Has_index Arg1:T66 Arg2:T67
102,R26,Has_temporal Arg1:T65 Arg2:T66
103,T68,Procedure 1440 1447;1459 1464	donated blood
104,T69,Value 1448 1455	>450 mL
105,T70,Temporal 1465 1516	within 60 days prior to any blood collection visits
106,T71,Reference_point 1489 1516	any blood collection visits
107,R27,Has_index Arg1:T70 Arg2:T71
108,R28,Has_value Arg1:T68 Arg2:T69
109,R29,Has_temporal Arg1:T68 Arg2:T70
110,T72,Measurement 1578 1598	lost red blood cells
111,T73,Value 1537 1544	>200 mL
112,R30,Has_value Arg1:T72 Arg2:T73
113,T74,Multiplier 1554 1560	single
114,T75,Procedure 1561 1570	apheresis
115,R31,Has_multiplier Arg1:T75 Arg2:T74
116,R32,AND Arg1:T75 Arg2:T72
117,T76,Procedure 1632 1641	apheresis
118,T77,Multiplier 1602 1624	more than one occasion
119,T78,Temporal 1642 1669	within the previous 60 days
120,T79,Reference_point 1649 1669	the previous 60 days
121,R33,Has_index Arg1:T78 Arg2:T79
122,R34,Has_multiplier Arg1:T76 Arg2:T77
123,R35,Has_temporal Arg1:T76 Arg2:T78
124,*,OR T75 T76
125,T80,Temporal 1672 1684	Concurrently
126,T81,Observation 1685 1701;1710 1724	participating in clinical study
127,R36,Has_temporal Arg1:T81 Arg2:T80
128,T82,Temporal 1726 1761	at any time during the study period
129,R37,Has_temporal Arg1:T81 Arg2:T82
130,T83,Reference_point 1745 1761	the study period
131,R38,Has_index Arg1:T82 Arg2:T83
132,T84,Drug 1859 1866	vaccine
133,T85,Drug 1867 1874	product
134,*,OR T84 T85
135,T86,Scope 1859 1874	vaccine/product
136,T87,Qualifier 1818 1833	investigational
137,T88,Qualifier 1839 1858	non-investigational
138,*,OR T87 T88
139,T89,Scope 1818 1858	investigational or a non-investigational
140,R39,Has_scope Arg1:T86 Arg2:T89
141,R40,Has_scope Arg1:T81 Arg2:T86
142,T90,Temporal 1876 1883	Ongoing
143,T91,Condition 1884 1891	anaemia
144,R41,Has_temporal Arg1:T91 Arg2:T90
145,T92,Measurement 1908 1919	haemoglobin
146,T93,Value 1927 1992	below the lower limit of the laboratory-specified reference range
147,R42,Has_value Arg1:T92 Arg2:T93
148,R43,AND Arg1:T91 Arg2:T92
149,T94,Procedure 2001 2020	finger prick method
150,T95,Condition 2037 2044	anaemia
151,R44,AND Arg1:T94 Arg2:T95
152,*,OR T91 T94
153,T96,Non-representable 2096 2273	and the subject will be referred for appropriate medical management. The subject may participate in this study following therapy and evidence that the anaemia has been resolved.
154,T97,Condition 2290 2298	reaction
155,T98,Condition 2302 2318	hypersensitivity
156,T99,Qualifier 2319 2376	likely to be exacerbated by any component of the vaccines
157,T100,Drug 2351 2376	component of the vaccines
158,R45,multi Arg1:T99 Arg2:T100
159,*,OR T97 T98
160,T101,Scope 2290 2318	reaction or hypersensitivity
161,R46,Has_qualifier Arg1:T101 Arg2:T99
162,T102,Condition 2379 2387	Pregnant
163,T103,Observation 2391 2400	lactating
164,T104,Person 2401 2407	female
165,*,OR T102 T103
166,T105,Person 2410 2416	Female
167,T106,Observation 2417 2444	planning to become pregnant
168,T107,Mood 2448 2471	planning to discontinue
169,T108,Observation 2472 2497	contraceptive precautions
170,R47,Has_mood Arg1:T108 Arg2:T107
171,*,OR T106 T108
172,T109,Mood 2417 2428	planning to
173,T110,Observation 2429 2444	become pregnant
174,R48,multi Arg1:T106 Arg2:T110
175,R49,Has_mood Arg1:T110 Arg2:T109
176,T111,Qualifier 2504 2513	confirmed
177,T112,Mood 2517 2526	suspected
178,T113,Condition 2527 2544;2565 2574	immunosuppressive condition
179,T114,Condition 2548 2574	immunodeficiency condition
180,*,OR T114 T113
181,T115,Observation 2584 2599	medical history
182,T116,Procedure 2604 2624	physical examination
183,*,OR T115 T116
184,T117,Scope 2584 2624	medical history and physical examination
185,T118,Scope 2527 2574	immunosuppressive or immunodeficiency condition
186,*,OR T111 T112
187,T119,Scope 2504 2526	confirmed or suspected
188,R50,Has_scope Arg1:T118 Arg2:T119
189,R51,Has_scope Arg1:T118 Arg2:T117
190,T120,Observation 2626 2640	Family history
191,T121,Condition 2658 2685	hereditary immunodeficiency
192,T122,Condition 2644 2654;2669 2685	congenital immunodeficiency
193,*,OR T121 T122
194,T123,Scope 2644 2685	congenital or hereditary immunodeficiency
195,R52,Has_context Arg1:T123 Arg2:T120
196,T124,Qualifier 2688 2695	Serious
197,T125,Condition 2696 2711	chronic illness
198,R53,Has_qualifier Arg1:T125 Arg2:T124
199,T126,Condition 2725 2752	chronic alcohol consumption
200,T127,Condition 2760 2770	drug abuse
201,*,OR T126 T127
202,T128,Observation 2714 2721	History
203,T129,Scope 2725 2770	chronic alcohol consumption and/or drug abuse
204,R54,Has_temporal Arg1:T129 Arg2:T128
0,T1,Condition 0 14	Cardiac arrest
1,T2,Condition 16 27	Head trauma
2,T3,Condition 29 37	Drowning
3,T4,Condition 39 63	Congenital heart disease
4,T5,Condition 65 92	Inborn errors of metabolism
5,T6,Condition 94 115	Electrolyte imbalance
6,T7,Condition 117 130	hypocalcaemia
7,T8,Condition 132 144	hyponatremia
8,T9,Condition 149 161	hypoglycemia
9,*,OR T8 T7 T9
10,T10,"Scope 117 161	hypocalcaemia, hyponatremia and hypoglycemia"
11,R1,Subsumes Arg1:T6 Arg2:T10
12,T11,Condition 164 187	Hemodynamic instability
13,T12,Condition 189 196	Allergy
14,T13,Drug 200 215	benzodiazepines
15,R2,AND Arg1:T12 Arg2:T13
16,T14,Condition 217 231	Focal seizures
17,T15,Condition 237 269	preserved level of consciousness
18,R3,AND Arg1:T14 Arg2:T15
0,T1,Temporal 0 7	Current
1,T2,Mood 11 18	planned
2,T3,Condition 19 28	pregnancy
3,*,OR T2 T1
4,T4,Scope 0 18	Current or planned
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Condition 41 57	neuropathic pain
7,T6,Observation 30 37	History
8,T7,Condition 59 80	chronic pain syndrome
9,T8,Temporal 85 97	preoperative
10,T9,Drug 105 113;134 142	narcotic medicine
11,T10,Drug 117 142	neuropathic pain medicine
12,*,OR T10 T9
13,T11,Scope 105 142	narcotic or neuropathic pain medicine
14,R2,Has_temporal Arg1:T11 Arg2:T8
15,*,OR T7 T5 T11
16,T12,"Scope 41 142	neuropathic pain, chronic pain syndrome, or preoperative use of narcotic or neuropathic pain medicine"
17,R3,Has_temporal Arg1:T12 Arg2:T6
18,T13,Mood 144 162	Radiographic signs
19,T14,Procedure 144 156	Radiographic
20,T15,Condition 166 180	osteoarthritis
21,R4,Has_mood Arg1:T15 Arg2:T13
22,R5,multi Arg1:T13 Arg2:T14
23,T16,Measurement 184 195	Tonis grade
24,T17,Value 182 183;196 197	> 1
25,R6,Has_value Arg1:T16 Arg2:T17
26,R7,AND Arg1:T15 Arg2:T16
27,T18,Condition 200 209	Inability
28,T19,Observation 213 236	attend follow up visits
29,R8,Has_context Arg1:T18 Arg2:T19
30,T20,Condition 249 256	allergy
31,T21,Drug 260 276	local anesthetic
32,R9,AND Arg1:T20 Arg2:T21
0,T1,Person 0 8	Children
1,T2,Qualifier 14 32	clinical diagnosis
2,T3,Condition 36 39	PWS
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,T4,Person 42 45	Age
5,T5,Value 53 70	7 to 14 years-old
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Observation 102 133	Written informed consent signed
8,T7,Observation 73 97	Voluntarily participated
0,T1,Non-query-able 14 48	in the opinion of the investigator
1,T2,Observation 63 107	comply with the requirements of the protocol
2,T3,Observation 110 134	Written informed consent
3,T4,Procedure 185 209	study specific procedure
4,T5,Temporal 161 209	prior to performing any study specific procedure
5,T6,Reference_point 170 209	performing any study specific procedure
6,R1,Has_index Arg1:T5 Arg2:T6
7,R2,multi Arg1:T6 Arg2:T4
8,R3,Has_temporal Arg1:T3 Arg2:T5
9,T7,Person 214 218	male
10,T8,Person 222 228	female
11,*,OR T7 T8
12,T9,Value 253 268	18 and 50 years
13,T10,Person 272 275	age
14,R4,Has_value Arg1:T10 Arg2:T9
15,T11,Temporal 276 312	at the time of the first study visit
16,T12,Reference_point 291 312	the first study visit
17,R5,Has_index Arg1:T11 Arg2:T12
18,R6,Has_temporal Arg1:T10 Arg2:T11
19,T13,Condition 315 322	Healthy
20,T14,Observation 350 365	medical history
21,T15,Procedure 370 390	clinical examination
22,T16,Temporal 391 421	before entering into the study
23,T17,Reference_point 398 421	entering into the study
24,R7,Has_index Arg1:T16 Arg2:T17
25,R8,Has_temporal Arg1:T13 Arg2:T16
26,R9,Has_temporal Arg1:T13 Arg2:T14
27,R10,AND Arg1:T13 Arg2:T15
28,T18,"Non-query-able 423 562	Healthy subjects with no medical conditions that, in the opinion of the investigator, prevents the subject from participating in the study."
29,T19,Measurement 578 583	weigh
30,T20,Value 584 603	at least 110 pounds
31,T21,Value 584 592;605 610	at least 50 kg
32,R11,Subsumes Arg1:T20 Arg2:T21
33,T22,Scope 584 611	at least 110 pounds (50 kg)
34,R12,Has_scope Arg1:T19 Arg2:T22
35,T23,Condition 632 639	obesity
36,T24,Measurement 641 644	BMI
37,T25,Negation 617 631	not to present
38,R13,Has_negation Arg1:T23 Arg2:T25
39,T26,Value 645 654	< 32kg/m2
40,R14,Has_value Arg1:T24 Arg2:T26
41,T27,Person 658 664	Female
42,T28,Negation 677 681	non-
43,T29,Observation 681 703	childbearing potential
44,R15,Has_negation Arg1:T29 Arg2:T28
45,T30,Observation 775 787	pre-menarche
46,T31,Scope 641 654	BMI < 32kg/m2
47,R16,Subsumes Arg1:T23 Arg2:T31
48,T32,Temporal 789 796	current
49,T33,Condition 797 821	bilateral tubal ligation
50,T34,Condition 797 812;825 834	bilateral tubal occlusion
51,*,OR T34 T33
52,T35,Scope 797 834	bilateral tubal ligation or occlusion
53,R17,Has_temporal Arg1:T35 Arg2:T32
54,*,OR T30 T35 T36 T39 T40
55,T36,Condition 836 848	hysterectomy
56,T37,Procedure 797 821	bilateral tubal ligation
57,T38,Procedure 797 812;825 834	bilateral tubal occlusion
58,R18,multi Arg1:T34 Arg2:T38
59,R19,multi Arg1:T33 Arg2:T37
60,T39,Condition 850 871	bilateral ovariectomy
61,T40,Observation 875 889	post-menopause
62,T42,Procedure 850 871	bilateral ovariectomy
63,R20,multi Arg1:T39 Arg2:T42
64,T41,"Scope 775 889	pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause"
65,T43,Scope 677 703	non-childbearing potential
66,T44,"Scope 775 889	pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause"
67,R21,Subsumes Arg1:T43 Arg2:T44
68,T45,Observation 915 928	contraception
69,T46,Qualifier 906 914	adequate
70,R22,Has_qualifier Arg1:T45 Arg2:T46
71,T47,Temporal 933 961	30 days prior to vaccination
72,R23,Has_temporal Arg1:T45 Arg2:T47
73,T48,Reference_point 950 961	vaccination
74,R24,Has_index Arg1:T47 Arg2:T48
75,T49,Value 974 982	negative
76,T50,Measurement 983 997	pregnancy test
77,R25,Has_value Arg1:T50 Arg2:T49
78,T51,Temporal 998 1023	on the day of vaccination
79,T52,Reference_point 1012 1023	vaccination
80,R26,Has_index Arg1:T51 Arg2:T52
81,R27,Has_temporal Arg1:T50 Arg2:T51
82,T53,Multiplier 1043 1051	continue
83,T54,Observation 1052 1074	adequate contraception
84,T55,Temporal 1075 1109	during the entire treatment period
85,T56,"Temporal 1114 1169	for 1 month, after completion of the vaccination series"
86,T57,Reference_point 1133 1169	completion of the vaccination series
87,R28,Has_index Arg1:T56 Arg2:T57
88,R29,Has_multiplier Arg1:T54 Arg2:T53
89,*,OR T55 T56
90,T58,"Scope 1075 1169	during the entire treatment period and for 1 month, after completion of the vaccination series"
91,R30,Has_scope Arg1:T54 Arg2:T58
0,T1,Person 0 8	Children
1,T2,Value 9 28	6 month to 14 years
2,T3,Person 23 28	years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Visit 58 77	pediatric emergency
5,T5,Observation 81 118	attended by emergency medical service
6,T6,Qualifier 128 134	active
7,T7,Condition 135 142	seizure
8,R2,Has_qualifier Arg1:T7 Arg2:T6
9,T8,Negation 151 153	no
10,T9,Device 154 172	intravenous access
11,R3,Has_negation Arg1:T9 Arg2:T8
12,*,OR T4 T5
0,T1,Procedure 14 40	arthroscopic labral repair
1,T2,Procedure 57 68	osteoplasty
2,T3,Qualifier 76 79	hip
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Scope 57 79	osteoplasty of the hip
5,A1,Optional T4
6,T5,Mood 0 9	Scheduled
7,R2,Has_mood Arg1:T1 Arg2:T5
8,R3,Has_scope Arg1:T1 Arg2:T4
9,T6,Person 97 100	old
10,T7,Value 82 96	18 to 50 years
11,R4,Has_value Arg1:T6 Arg2:T7
12,T8,Measurement 102 155;165 170	American Society of Anesthesiologists Physical Status score
13,T9,Measurement 157 163	ASA PS
14,R5,Subsumes Arg1:T8 Arg2:T9
15,T10,Value 174 181	I or II
16,R6,Has_value Arg1:T8 Arg2:T10
0,T1,Condition 15 41	sleep disordered breathing
1,T2,Procedure 44 68	Nocturnal oxygen therapy
0,T1,Measurement 0 22	Fasting plasma glucose
1,T2,"Value 23 31	> 7,0 mM"
2,T3,Measurement 33 38	HbA1c
3,T4,Value 39 52	> 48 mmol/mol
4,T5,Temporal 53 72	3 months after RYGB
5,T6,Procedure 68 72	RYGB
6,T7,Reference_point 68 72	RYGB
7,R1,multi Arg1:T7 Arg2:T6
8,R2,Has_index Arg1:T5 Arg2:T7
9,R3,Has_value Arg1:T3 Arg2:T4
10,R4,Has_value Arg1:T1 Arg2:T2
11,*,OR T1 T3
12,T8,"Scope 0 52	Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol"
13,R5,Has_temporal Arg1:T8 Arg2:T5
14,T9,Qualifier 75 87	Dysregulated
15,T10,Condition 88 104	thyroid diseases
16,T11,Procedure 113 134	antithyroid treatment
17,R6,Has_qualifier Arg1:T10 Arg2:T9
18,*,OR T10 T11
19,T12,Condition 137 164	Late diabetic complications
20,T13,Condition 168 179	retinopathy
21,T14,Condition 181 200	renal insufficiency
22,T15,Condition 202 212	neuropathy
23,T16,Condition 225 237	pancreatitis
24,T17,Temporal 216 224	previous
25,R7,Has_temporal Arg1:T16 Arg2:T17
26,*,OR T15 T14 T13
27,T18,"Scope 168 212	retinopathy, renal insufficiency, neuropathy"
28,R8,Subsumes Arg1:T12 Arg2:T18
29,*,OR T12 T16
30,T19,Condition 240 253	Complications
31,T20,Procedure 257 261	RYGB
32,R9,AND Arg1:T19 Arg2:T20
33,T21,Condition 274 296	reactive hypoglycaemia
34,T22,Qualifier 298 304	severe
35,T23,Condition 305 312	dumping
36,R10,Has_qualifier Arg1:T23 Arg2:T22
37,T24,Condition 314 322	vomiting
38,T25,Condition 324 332	diarrhea
39,T26,Qualifier 334 340	severe
40,T27,Condition 341 355	abdominal pain
41,T28,Temporal 356 373	after food intake
42,R11,Has_qualifier Arg1:T27 Arg2:T26
43,T29,Reference_point 362 373	food intake
44,R12,Has_index Arg1:T28 Arg2:T29
45,R13,Has_temporal Arg1:T27 Arg2:T28
46,*,OR T24 T25 T27
47,T30,"Scope 314 373	vomiting, diarrhea, severe abdominal pain after food intake"
48,T31,Scope 298 312	severe dumping
49,R14,Subsumes Arg1:T31 Arg2:T30
50,T32,"Scope 274 374	reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake)"
51,T33,Scope 240 261	Complications to RYGB
52,R15,Subsumes Arg1:T33 Arg2:T32
53,T34,Procedure 377 392	Cholecystectomy
0,T1,Procedure 14 18	RYGB
1,T2,Qualifier 0 13	Uncomplicated
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Temporal 29 64	minimum 3 months prior to the study
4,T4,Reference_point 55 64	the study
5,R2,Has_index Arg1:T3 Arg2:T4
6,R3,Has_temporal Arg1:T1 Arg2:T3
7,T5,Measurement 67 89	Fasting plasma glucose
8,T6,"Value 90 98	< 7,0 mM"
9,T7,Measurement 100 105	HbA1c
10,T8,Value 106 119	< 48 mmol/mol
11,T9,Temporal 120 139	3 months after RYGB
12,T10,Reference_point 135 139	RYGB
13,T11,Procedure 135 139	RYGB
14,R4,multi Arg1:T10 Arg2:T11
15,R5,Has_index Arg1:T9 Arg2:T10
16,R6,Has_value Arg1:T7 Arg2:T8
17,R7,Has_value Arg1:T5 Arg2:T6
18,*,OR T5 T7
19,R8,Has_temporal Arg1:T7 Arg2:T9
0,T1,Qualifier 0 18	Moderate to severe
1,T2,Condition 19 23	COPD
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Qualifier 25 44	post-bronchodilator
4,T4,Measurement 45 83	forced expiratory volume in 1 s (FEV1)
5,T5,Value 84 99	30-79%predicted
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,Has_qualifier Arg1:T4 Arg2:T3
8,T6,Measurement 103 145	Resting functional residual capacity (FRC)
9,T7,Value 146 161	>120% predicted
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Procedure 189 210	stable triple therapy
12,T9,Condition 164 181	Clinically stable
13,T10,Drug 219 227	ICS/LABA
14,T11,Drug 232 242	tiotropium
15,T12,Scope 219 242	ICS/LABA and tiotropium
16,R5,Has_scope Arg1:T8 Arg2:T12
17,T13,Measurement 258 280	Baseline Dyspnea Index
18,T14,Value 281 283	=8
19,R6,Has_value Arg1:T13 Arg2:T14
20,T15,Observation 329 375	what time of day their COPD symptoms are worst
21,T16,Value 296 310	in the morning
22,R7,Has_value Arg1:T15 Arg2:T16
0,T1,Condition 0 8	thrombus
1,T2,Qualifier 16 18	LA
2,T3,Qualifier 22 25	LAA
3,*,OR T3 T2
4,T4,Scope 16 25	LA or LAA
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Device 28 55	mechanical valve prosthesis
7,T6,Condition 58 73	mitral stenosis
8,T7,Procedure 85 97	LAA ligation
9,T8,Procedure 105 120	cardiac surgery
10,T9,Observation 123 138	life expectancy
11,T10,Value 139 156	less than 2 years
12,R2,Has_value Arg1:T9 Arg2:T10
13,T11,Condition 184 186	AF
14,T12,Negation 173 183	other than
15,T13,Condition 159 172	comorbidities
16,R3,AND Arg1:T13 Arg2:T11
17,T14,Condition 205 215	indication
18,T15,Procedure 220 235	anticoagulation
19,R4,AND Arg1:T14 Arg2:T15
20,R5,Has_negation Arg1:T11 Arg2:T12
21,T16,Scope 159 186	comorbidities other than AF
22,R6,AND Arg1:T16 Arg2:T14
23,T17,Condition 238 258	patent foramen ovale
24,T18,Condition 264 286	atrial septal aneurysm
25,T19,Condition 288 314	mobile plaque in the aorta
26,T20,Condition 329 344	atherosclerosis
27,T21,Qualifier 317 328	symptomatic
28,T22,Qualifier 345 366	of the carotid artery
29,R7,Has_qualifier Arg1:T20 Arg2:T22
30,R8,Has_qualifier Arg1:T20 Arg2:T21
31,T23,Condition 369 389	pericardial effusion
32,T24,Qualifier 390 408	greater than 10 mm
33,R9,Has_qualifier Arg1:T23 Arg2:T24
34,T25,Qualifier 411 433	clinically significant
35,T26,Condition 434 442	bleeding
36,T27,Temporal 443 494	within the 30 days prior to the scheduled procedure
37,R10,Has_temporal Arg1:T26 Arg2:T27
38,R11,Has_qualifier Arg1:T26 Arg2:T25
39,T28,Condition 497 503	stroke
40,T29,Qualifier 507 512	other
41,T30,Condition 513 532	cardioembolic event
42,R12,Has_qualifier Arg1:T30 Arg2:T29
43,*,OR T28 T30
44,T31,Temporal 533 584	within the 30 days prior to the scheduled procedure
45,T32,Reference_point 471 494	the scheduled procedure
46,R13,Has_index Arg1:T27 Arg2:T32
47,T33,Reference_point 561 584	the scheduled procedure
48,R14,Has_index Arg1:T31 Arg2:T33
49,T34,Scope 497 532	stroke or other cardioembolic event
50,R15,Has_temporal Arg1:T34 Arg2:T31
51,T35,Condition 587 610	acute coronary syndrome
52,T36,Temporal 611 662	within the 90 days prior to the scheduled procedure
53,T37,Reference_point 639 662	the scheduled procedure
54,R16,Has_index Arg1:T36 Arg2:T37
55,R17,Has_temporal Arg1:T35 Arg2:T36
56,T38,Condition 665 674	gravidity
57,T39,Condition 689 705	valvular disease
58,T40,Qualifier 677 688	significant
59,R18,Has_qualifier Arg1:T39 Arg2:T40
60,T41,Measurement 708 728	creatinine clearance
61,T42,Value 729 748	less than 30 ml/min
62,R19,Has_value Arg1:T41 Arg2:T42
0,T1,Procedure 11 20	curettage
1,T2,Observation 0 7	History
2,T3,Procedure 30 50	intrauterine surgery
3,R2,Subsumes Arg1:T3 Arg2:T1
4,T4,Scope 11 50	curettage or other intrauterine surgery
5,R1,Has_temporal Arg1:T4 Arg2:T2
6,T5,Condition 63 89	post-abortion complication
7,T6,Condition 63 76;93 102	post-abortion infection
8,*,OR T5 T6
9,T7,Scope 63 102	post-abortion complication or infection
10,T8,Observation 52 59	History
11,R3,Has_temporal Arg1:T7 Arg2:T8
0,T1,Informed_consent 0 34	Signed informed consent form (ICF)
1,T2,Person 36 39	Age
2,T3,Value 40 60	18 to 55 years old (
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 118 120	MS
5,T5,Measurement 138 160	McDonald criteria 2010
6,T6,Procedure 165 181	cranial MRI scan
7,T7,Temporal 236 268	within 10 years before Screening
8,T8,Scope 138 181	McDonald criteria 2010 and cranial MRI scan
9,R2,AND Arg1:T8 Arg2:T4
10,R3,Has_temporal Arg1:T4 Arg2:T7
11,T9,Condition 279 290	MS symptoms
12,T10,Temporal 362 377	within 10 years
13,R4,Has_temporal Arg1:T9 Arg2:T10
14,T11,Measurement 409 419	EDSS score
15,T12,Value 420 430	0.0 to 5.0
16,R5,Has_value Arg1:T11 Arg2:T12
17,T13,Condition 487 491	RRMS
18,T14,Qualifier 480 486	active
19,T15,Drug 528 539	alemtuzumab
20,R6,Has_qualifier Arg1:T13 Arg2:T14
21,R7,AND Arg1:T13 Arg2:T15
22,T16,Condition 638 649	MS relapses
23,T17,Multiplier 635 637	=2
24,T18,"Temporal 650 667	within 24 months,"
25,T19,Condition 684 691	relapse
26,T20,Multiplier 681 683	=1
27,T21,Procedure 696 699	MRI
28,T22,Condition 815 822	relapse
29,T23,Qualifier 808 814	severe
30,T24,Condition 870 877	Lesions
31,T25,Qualifier 854 869	T2 hyperintense
32,T26,Multiplier 851 853	=9
33,T27,Condition 906 912	lesion
34,T28,Qualifier 885 905	gadolinium enhancing
35,T29,Multiplier 882 884	=1
36,T30,Procedure 917 920	MRI
37,T31,Condition 726 733	lesions
38,T32,Qualifier 705 725	gadolinium enhancing
39,T33,Qualifier 701 704	new
40,R8,Has_multiplier Arg1:T16 Arg2:T17
41,R9,Has_temporal Arg1:T16 Arg2:T18
42,R10,Has_multiplier Arg1:T19 Arg2:T20
43,R11,Has_qualifier Arg1:T31 Arg2:T32
44,R12,Has_qualifier Arg1:T31 Arg2:T33
45,R13,AND Arg1:T21 Arg2:T31
46,*,OR T19 T21
47,T34,Scope 671 734	clinical (=1 relapse) or MRI (new gadolinium enhancing lesions)
48,R14,Has_qualifier Arg1:T22 Arg2:T23
49,R15,Has_qualifier Arg1:T24 Arg2:T25
50,R16,Has_multiplier Arg1:T24 Arg2:T26
51,R17,Has_qualifier Arg1:T27 Arg2:T28
52,R18,Has_multiplier Arg1:T27 Arg2:T29
53,T35,Scope 851 912	=9 T2 hyperintense Lesions and =1 gadolinium enhancing lesion
54,R19,Has_scope Arg1:T30 Arg2:T35
55,R20,AND Arg1:T22 Arg2:T30
56,T36,"Non-query-able 923 1051	Completion of all vaccinations required by the applicable immunization guidelines published by ""ständige Impfkommission"" (STIKO)"
57,T37,Condition 1064 1074	chickenpox
58,T38,Measurement 1087 1106	test for antibodies
59,T39,Value 1078 1086	positive
60,T40,Qualifier 1115 1137	varicella zoster virus
61,T41,Qualifier 1139 1142	VZV
62,R21,Subsumes Arg1:T40 Arg2:T41
63,R22,Has_qualifier Arg1:T38 Arg2:T40
64,R23,Has_value Arg1:T38 Arg2:T39
65,*,OR T37 T38
0,T1,Condition 0 17	Rotator cuff tear
1,T2,Procedure 38 68	arthroscopic rotator cuff tear
0,T1,Multiplier 0 4	dual
1,T2,Procedure 5 21	organ transplant
2,R1,Has_multiplier Arg1:T2 Arg2:T1
0,T1,Condition 0 7	Healthy
1,T2,Value 14 37	between 18 and 45 years
2,T3,Person 41 44	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Measurement 59 74	Body mass index
5,T5,Value 81 103	between 18 to 30 kg/m2
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Qualifier 182 204	clinically significant
8,T7,Undefined_semantics 182 204	clinically significant
9,T8,Condition 205 222	abnormal findings
10,T9,Procedure 226 246	physical examination
11,T10,Procedure 248 251	ECG
12,T11,Observation 253 268	medical history
13,T12,Procedure 273 292	clinical laboratory
14,T13,Temporal 301 317	during screening
15,T14,Negation 179 181	no
16,R3,Has_negation Arg1:T8 Arg2:T14
17,R4,Has_qualifier Arg1:T8 Arg2:T6
18,*,OR T11 T12 T10 T9
19,R5,Has_temporal Arg1:T8 Arg2:T13
20,T15,"Scope 226 292	physical examination, ECG, medical history, or clinical laboratory"
21,R6,Has_scope Arg1:T8 Arg2:T15
22,T16,Subjective_judgement 338 372	in the opinion of the investigator
23,T17,Measurement 470 486	serum creatinine
24,T18,Measurement 488 503	total bilirubin
25,T19,Measurement 509 528	transaminase levels
26,T20,Measurement 436 452	hepatic function
27,T21,Measurement 426 431;444 452	renal function
28,T22,Qualifier 382 404	clinically significant
29,T23,Condition 405 422	abnormal findings
30,T24,Scope 426 452	renal and hepatic function
31,T25,"Scope 470 528	serum creatinine, total bilirubin, and transaminase levels"
32,R7,Has_scope Arg1:T23 Arg2:T24
33,R8,Subsumes Arg1:T24 Arg2:T25
34,R9,Has_qualifier Arg1:T23 Arg2:T22
35,T26,Negation 379 381	no
36,R10,Has_negation Arg1:T23 Arg2:T26
37,T27,Condition 555 580	users of tobacco products
38,T28,Negation 551 554	non
39,R11,Has_negation Arg1:T27 Arg2:T28
40,T29,Temporal 582 633	minimum of 6 months prior to the start of the study
41,T30,Reference_point 611 633	the start of the study
42,R12,Has_temporal Arg1:T27 Arg2:T29
43,T31,Measurement 670 686	screen for HIV I
44,T32,Measurement 670 684;691 693	screen for HIV II
45,T33,Value 661 669	negative
46,R13,Has_value Arg1:T32 Arg2:T33
47,R14,Has_value Arg1:T31 Arg2:T33
48,T34,Measurement 695 700	HBsAg
49,T35,Measurement 706 735	antibody to Hepatitis C virus
50,R15,Has_value Arg1:T34 Arg2:T33
51,R16,Has_value Arg1:T35 Arg2:T33
52,T36,Measurement 771 795	urine screen for alcohol
53,T37,Measurement 771 787;797 811	urine screen for drugs of abuse
54,T38,Measurement 771 787;834 842	urine screen for cotinine
55,T39,Value 762 770	negative
56,R17,Has_value Arg1:T38 Arg2:T39
57,R18,Has_value Arg1:T37 Arg2:T39
58,R19,Has_value Arg1:T36 Arg2:T39
59,T40,Post-eligibility 845 1152	Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g.female condom or occlusive cap with spermicide) during the study and for 3 months following administration of the study drug.
60,T41,Post-eligibility 1154 1246	Subjects were able to comply with the protocol and the restrictions and assessments therein.
61,T42,Post-eligibility 1248 1332	Subjects were to give voluntary written informed consent to participate in the trial
0,T1,Procedure 25 57	therapeutic endoscopic procedure
1,T2,Procedure 63 79	variceal banding
2,T3,Procedure 81 96	stent insertion
3,T4,Procedure 98 116	balloon dilatation
4,*,OR T2 T3 T4
5,T5,"Scope 63 116	variceal banding, stent insertion, balloon dilatation"
6,R1,Subsumes Arg1:T1 Arg2:T5
7,T6,Condition 156 185	upper gastrointestinal cancer
8,T7,Condition 135 150	known diagnosis
9,R2,Subsumes Arg1:T7 Arg2:T6
10,T8,Procedure 220 242	HP eradication therapy
11,T9,Drug 267 270	PPI
12,T10,Drug 272 295	H2 receptor antagonists
13,T11,Drug 300 311	antibiotics
14,T12,Temporal 312 326	within 4 weeks
15,T13,Grammar_Error 296 299	and
16,*,OR T11 T10 T9
17,T14,"Scope 267 311	PPI, H2 receptor antagonists and antibiotics"
18,R3,Has_temporal Arg1:T14 Arg2:T12
19,T15,Condition 348 373	gastrointestinal bleeding
20,T16,Qualifier 342 347	acute
21,R4,Has_qualifier Arg1:T15 Arg2:T16
22,T17,Procedure 403 418	gastric surgery
23,T18,Temporal 394 402	previous
24,R5,Has_temporal Arg1:T17 Arg2:T18
25,T19,Procedure 442 455	liver disease
26,T20,Qualifier 434 441	chronic
27,R6,Has_qualifier Arg1:T19 Arg2:T20
28,T21,Condition 471 491	abnormal coagulation
29,T22,Condition 505 522	contra-indication
30,T23,Procedure 533 548	standard biopsy
31,T24,Procedure 560 592	diagnostic endoscopic procedures
32,*,OR T21 T22
33,R7,AND Arg1:T22 Arg2:T23
34,T25,Non-query-able 594 655	Patients who are unable or unwilling to give informed consent
35,T26,Person 676 679	age
36,T27,Value 666 671;683 691	under 18 years
37,R8,Has_value Arg1:T26 Arg2:T27
0,T1,Procedure 12 21	curettage
1,T2,Procedure 66 74	abortion
2,T3,Qualifier 49 65	second trimester
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 26 42	retained product
5,R2,AND Arg1:T1 Arg2:T4
6,R3,AND Arg1:T4 Arg2:T2
0,T1,Condition 23 31	bleeding
1,T2,Qualifier 11 22	significant
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 38 46	bleeding
4,T4,Procedure 62 74	intervention
5,T5,Procedure 78 93	hospitalization
6,*,OR T4 T5
7,T6,Scope 62 93	intervention or hospitalization
8,R2,Has_scope Arg1:T3 Arg2:T6
9,T7,Scope 38 93	bleeding which required intervention or hospitalization
10,T8,Scope 11 31	significant bleeding
11,R3,Subsumes Arg1:T8 Arg2:T7
12,T9,Condition 186 205	cardioembolic event
13,T10,Drug 225 240	anticoagulation
14,T11,Temporal 213 240	occurred on anticoagulation
15,R4,Has_temporal Arg1:T9 Arg2:T11
16,T12,Measurement 295 313	CHA2DS2-VASc score
17,T13,Value 314 317	= 3
18,R5,Has_value Arg1:T12 Arg2:T13
19,T14,Measurement 324 338	HAS-BLED score
20,T15,Value 339 342	= 2
21,R6,Has_value Arg1:T14 Arg2:T15
22,T16,Condition 248 265	high risk profile
23,T17,Scope 295 342	CHA2DS2-VASc score = 3 and a HAS-BLED score = 2
24,R7,Subsumes Arg1:T16 Arg2:T17
0,T1,Competing_trial 1 146	articipation in another clinical trial at present or within 4 weeks of study entry. There may be exceptions at the discretion of the Investigator
1,T2,Condition 177 179	MS
2,T3,Qualifier 157 168	progressive
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 181 197	Hypersensitivity
5,T5,Drug 254 262	Lemtrada
6,R2,AND Arg1:T4 Arg2:T5
7,T6,"Post-eligibility 265 512	Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study"
8,T7,Post-eligibility 514 629	Any disability acquired from trauma or another illness that could interfere with evaluation of disability due to MS
9,T8,"Post-eligibility 631 888	Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the interpretation of study results, e.g., current peptic ulcer disease or other conditions that may predispose to hemorrhage"
10,T9,Condition 896 913	bleeding disorder
11,T10,Condition 921 938	dysfibrinogenemia
12,T11,Condition 940 960	factor IX deficiency
13,T12,Condition 962 972	hemophilia
14,T13,Condition 974 998	Von Willebrand's disease
15,T14,Condition 1000 1038	disseminated intravascular coagulation
16,T15,Condition 1040 1043	DIC
17,T16,Condition 1046 1067	fibrinogen deficiency
18,T17,Condition 1072 1098	clotting factor deficiency
19,*,OR T10 T11 T12 T13 T14 T16 T17
20,R3,Subsumes Arg1:T14 Arg2:T15
21,T18,"Scope 921 1098	dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand's disease, disseminated intravascular coagulation (DIC), fibrinogen deficiency, or clotting factor deficiency"
22,R4,Subsumes Arg1:T9 Arg2:T18
23,T19,Condition 1113 1131	autoimmune disease
24,T20,"Condition 1161 1179	immune cytopenias,"
25,T21,"Condition 1180 1201	rheumatoid arthritis,"
26,T22,Condition 1202 1230	systemic lupus erythematosus
27,T23,Condition 1238 1265	connective tissue disorders
28,T24,Condition 1267 1277	vasculitis
29,T25,Condition 1279 1305	inflammatory bowel disease
30,T26,Condition 1314 1323	psoriasis
31,T27,Qualifier 1307 1313	severe
32,R5,Has_qualifier Arg1:T26 Arg2:T27
33,*,OR T26 T25 T24 T23 T22 T21 T20
34,T28,"Scope 1161 1323	immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis"
35,R6,Subsumes Arg1:T19 Arg2:T28
36,T29,Condition 1336 1346	malignancy
37,T30,Negation 1348 1354	except
38,T31,Condition 1355 1380	basal skin cell carcinoma
39,R7,Has_negation Arg1:T31 Arg2:T30
40,T32,Condition 1388 1408	psychiatric disorder
41,T33,Qualifier 1382 1387	Major
42,R8,Has_qualifier Arg1:T32 Arg2:T33
43,T34,Qualifier 1421 1442	adequately controlled
44,T35,Negation 1417 1420	not
45,R9,Has_negation Arg1:T34 Arg2:T35
46,R10,Has_qualifier Arg1:T32 Arg2:T34
47,T36,Condition 1457 1475	Epileptic seizures
48,T37,Qualifier 1489 1510	adequately controlled
49,T38,Negation 1485 1488	not
50,R11,Has_negation Arg1:T37 Arg2:T38
51,R12,Has_qualifier Arg1:T36 Arg2:T37
52,T39,Condition 1532 1541	infection
53,T40,Qualifier 1525 1531	Active
54,R13,Has_qualifier Arg1:T39 Arg2:T40
55,T41,Condition 1549 1570	deep-tissue infection
56,R14,Subsumes Arg1:T39 Arg2:T41
57,T42,Observation 1700 1718	risk for infection
58,T43,Qualifier 1695 1699	high
59,R15,Has_qualifier Arg1:T42 Arg2:T43
60,T44,Device 1726 1745	indwelling catheter
61,T45,Condition 1747 1756	dysphagia
62,T46,Condition 1762 1772	aspiration
63,T47,Condition 1774 1789	decubitus ulcer
64,T48,Condition 1808 1828	aspiration pneumonia
65,T49,Condition 1842 1865	urinary tract infection
66,T50,Qualifier 1832 1841	recurrent
67,*,OR T44 T45 T47 T48 T49
68,R16,AND Arg1:T45 Arg2:T46
69,R17,Has_qualifier Arg1:T49 Arg2:T50
70,T51,"Scope 1726 1865	indwelling catheter, dysphagia with aspiration, decubitus ulcer, history of prior aspiration pneumonia or recurrent urinary tract infection"
71,R18,Has_scope Arg1:T42 Arg2:T51
72,T52,Measurement 1887 1915	human immunodeficiency virus
73,T53,Measurement 1917 1920	HIV
74,R19,Subsumes Arg1:T52 Arg2:T53
75,T54,Value 1868 1882	Seropositivity
76,R20,Has_value Arg1:T52 Arg2:T54
77,T55,Qualifier 1938 1955	hepatitis C Virus
78,T56,Condition 1923 1932	Infection
79,R21,Has_qualifier Arg1:T56 Arg2:T55
80,T57,Condition 1973 1994	hepatitis B infection
81,T58,Measurement 2005 2025	hepatitis B serology
82,T59,Value 1996 2004	positive
83,R22,Has_value Arg1:T58 Arg2:T59
84,R23,AND Arg1:T57 Arg2:T58
85,T60,Qualifier 2050 2072	human cytomegaly virus
86,T61,Qualifier 2074 2078	HCMV
87,T62,Qualifier 2081 2099	Epstein-Barr virus
88,T63,Qualifier 2101 2104	EBV
89,T64,Qualifier 2107 2129	varicella-zoster virus
90,T65,Qualifier 2131 2134	VZV
91,T66,Condition 2035 2044	infection
92,T67,Qualifier 2028 2034	Active
93,R24,Has_qualifier Arg1:T66 Arg2:T67
94,T68,"Scope 2050 2135	human cytomegaly virus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV)"
95,R25,Subsumes Arg1:T60 Arg2:T61
96,R26,Subsumes Arg1:T62 Arg2:T63
97,R27,Subsumes Arg1:T64 Arg2:T65
98,*,OR T60 T62 T64
99,R28,Has_scope Arg1:T66 Arg2:T68
100,T69,Condition 2137 2156	Latent tuberculosis
101,T70,Negation 2157 2163	unless
102,T71,Procedure 2174 2199	anti-tuberculosis therapy
103,T72,Qualifier 2209 2218	completed
104,R29,Has_negation Arg1:T72 Arg2:T70
105,R30,Has_qualifier Arg1:T71 Arg2:T72
106,R31,AND Arg1:T69 Arg2:T71
107,T73,Condition 2223 2242	active tuberculosis
108,*,OR T69 T73
109,T74,Condition 2254 2271	fungal infections
110,T75,Qualifier 2245 2253	Invasive
111,R32,Has_qualifier Arg1:T74 Arg2:T75
112,T76,Measurement 2299 2316	Cervical cytology
113,T77,Negation 2317 2322	other
114,T78,Qualifier 2328 2333	PAP I
115,T79,Qualifier 2337 2343	PAP II
116,T80,Qualifier 2345 2357	Papanicolaou
117,*,OR T78 T79 T80
118,T82,Qualifier 2381 2401	human papillomavirus
119,T83,Qualifier 2362 2380	cervical high risk
120,T84,Qualifier 2403 2406	HPV
121,R35,Subsumes Arg1:T82 Arg2:T84
122,R36,Has_qualifier Arg1:T82 Arg2:T83
123,T85,Value 2408 2418	positivity
124,T86,Value 0 13	Participation
125,R37,Has_value Arg1:T76 Arg2:T85
126,T87,Scope 2317 2407	other than PAP I or PAP II (Papanicolaou) or cervical high risk human papillomavirus (HPV)
127,T88,Scope 2328 2358	PAP I or PAP II (Papanicolaou)
128,R38,Has_negation Arg1:T88 Arg2:T77
129,T89,Scope 2362 2407	cervical high risk human papillomavirus (HPV)
130,*,OR T88 T89
131,R39,Has_scope Arg1:T76 Arg2:T87
132,T81,Condition 2430 2437	illness
133,T90,Condition 2441 2450	infection
134,T91,Qualifier 2452 2458	latent
135,T92,Qualifier 2462 2468	active
136,*,OR T91 T92
137,T93,Temporal 2462 2468	active
138,R33,multi Arg1:T92 Arg2:T93
139,T94,Non-representable 2476 2505	in the Investigator's opinion
140,T95,Qualifier 2516 2547	exacerbated by study medication
141,T96,Drug 2531 2547	study medication
142,R34,multi Arg1:T95 Arg2:T96
143,R40,AND Arg1:T95 Arg2:T94
144,*,OR T90 T81
145,T97,Scope 2452 2468	latent or active
146,T98,Scope 2430 2450	illness or infection
147,R41,Has_scope Arg1:T98 Arg2:T97
148,R42,Has_qualifier Arg1:T98 Arg2:T95
149,T99,Measurement 2549 2573	Differential blood count
150,T100,Value 2574 2603	< lower limit of normal (LLN)
151,R43,Has_value Arg1:T99 Arg2:T100
152,T101,Temporal 2604 2616	at Screening
153,R44,Has_temporal Arg1:T99 Arg2:T101
154,T102,Measurement 2628 2642	platelet count
155,T103,Qualifier 2618 2627	Confirmed
156,R45,Has_qualifier Arg1:T102 Arg2:T103
157,T104,Value 2643 2681	< the LLN of the evaluating laboratory
158,T105,Temporal 2682 2694	at Screening
159,T106,"Value 2712 2723	<100,000/µL"
160,T107,Temporal 2724 2744	within the past year
161,R48,Has_temporal Arg1:T106 Arg2:T107
162,R46,Has_temporal Arg1:T104 Arg2:T105
163,*,OR T104 T106
164,T108,Qualifier 2750 2782	sample without platelet clumping
165,T109,"Scope 2643 2744	< the LLN of the evaluating laboratory at Screening or documented at <100,000/µL within the past year"
166,R47,Has_scope Arg1:T102 Arg2:T109
167,R49,Has_qualifier Arg1:T102 Arg2:T108
168,T110,Value 2800 2813	above the ULN
169,T111,Value 2784 2792	Presence
170,T112,Measurement 2818 2882	anti-thyroid stimulating hormone receptor antibodies (anti-TSHR)
171,R50,Subsumes Arg1:T111 Arg2:T110
172,T113,Measurement 2887 2930	anti-thyroid peroxidase antibody (anti-TPO)
173,T114,Scope 2818 2930	anti-thyroid stimulating hormone receptor antibodies (anti-TSHR) and anti-thyroid peroxidase antibody (anti-TPO)
174,R51,Has_value Arg1:T114 Arg2:T111
175,T115,Drug 2932 2943	Vaccination
176,T116,Temporal 2944 2994	less than 6 weeks prior to treatment with Lemtrada
177,T117,Reference_point 2971 2994	treatment with Lemtrada
178,T118,Procedure 2971 2980	treatment
179,T119,Drug 2986 2994	Lemtrada
180,R52,AND Arg1:T118 Arg2:T119
181,R53,multi Arg1:T117 Arg2:T118
182,R54,Has_index Arg1:T116 Arg2:T117
183,R55,AND Arg1:T116 Arg2:T115
184,T120,Procedure 2997 3006	Treatment
185,T121,Drug 3012 3026;3048 3053	antineoplastic drugs
186,T122,Drug 3030 3053	immunosuppressive drugs
187,*,OR T122 T121
188,T123,Temporal 3054 3093	within 8 weeks prior to study inclusion
189,T124,Reference_point 3078 3093	study inclusion
190,R56,Has_index Arg1:T123 Arg2:T124
191,T125,Scope 3012 3053	antineoplastic or immunosuppressive drugs
192,R57,Has_scope Arg1:T120 Arg2:T125
193,*,OR T120 T123
194,T126,Drug 3110 3132	pulsed corticosteroids
195,T127,Observation 3147 3157	history of
196,T128,Condition 3158 3175	steroid psychosis
197,T129,Condition 3095 3106	Intolerance
198,R59,Has_temporal Arg1:T128 Arg2:T127
199,R58,AND Arg1:T129 Arg2:T126
200,*,OR T129 T128
201,T130,Condition 3177 3201	Inability to undergo MRI
202,T131,Procedure 3198 3201	MRI
203,T132,Drug 3207 3217	gadolinium
204,R60,AND Arg1:T131 Arg2:T132
205,T133,Mood 3177 3189	Inability to
206,R61,Has_mood Arg1:T131 Arg2:T133
207,R62,multi Arg1:T130 Arg2:T131
208,T134,Person 3237 3259	childbearing potential
209,T135,Value 3267 3275	positive
210,T136,Measurement 3276 3296	serum pregnancy test
211,T137,Condition 3298 3306	pregnant
212,T138,Condition 3310 3319	lactating
213,*,OR T137 T138 T134
214,R63,Has_value Arg1:T136 Arg2:T135
215,R64,AND Arg1:T134 Arg2:T136
216,T139,Person 3321 3327	Female
217,T140,Person 3340 3362	childbearing potential
218,T141,Scope 3321 3362	Female patients of childbearing potential
219,A1,Optional T141
220,T142,"Pregnancy_considerations 3364 3728	Unwilling to agree to use a reliable and acceptable contraceptive method (Pearl index <1) throughout the study period. These methods include: hormone releasing intrauterine device (IUD), hormonal-based contraception, surgical sterilization, abstinence, or double-barrier contraception (condom and occlusive cap [diaphragm or cervical cap combined with spermicide])"
221,R65,AND Arg1:T141 Arg2:T142
0,T1,Person 0 3	age
1,T2,Value 4 14	<45 or >80
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 16 25	allergies
4,T4,Drug 29 40	medications
5,T5,Qualifier 41 58	used in the study
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,R3,AND Arg1:T3 Arg2:T4
8,T6,Observation 60 67	history
9,T7,Condition 71 85	renal diseases
10,T8,Condition 89 112	coagulation abnormality
11,T9,Condition 116 131	hepatic disease
12,T10,Condition 136 146	drug abuse
13,*,OR T9 T10 T8 T7
14,T11,"Scope 71 146	renal diseases, a coagulation abnormality, a hepatic disease, or drug abuse"
15,R4,Has_temporal Arg1:T11 Arg2:T6
16,T12,Mood 157 178	radiographic evidence
17,T13,Condition 182 196	osteoarthritis
18,T14,Qualifier 204 222	glenohumeral joint
19,R5,Has_qualifier Arg1:T13 Arg2:T14
20,T15,Procedure 157 169	radiographic
21,R6,multi Arg1:T12 Arg2:T15
22,R7,Has_mood Arg1:T13 Arg2:T12
23,T16,Qualifier 148 156	definite
24,R8,Has_qualifier Arg1:T12 Arg2:T16
25,T17,Condition 224 246	inflammatory arthritis
26,T18,Condition 257 277	rheumatoid arthritis
27,T19,Condition 292 304	acute trauma
28,T20,Observation 281 288	history
29,T21,Condition 306 325	systemic conditions
30,T22,Qualifier 326 354	associated with chronic pain
31,T23,Condition 342 354	chronic pain
32,R9,multi Arg1:T22 Arg2:T23
33,R10,Has_qualifier Arg1:T21 Arg2:T22
34,T24,Observation 358 365	history
35,T25,Condition 369 378	infection
36,R11,Has_temporal Arg1:T25 Arg2:T24
37,T26,Observation 383 425	inability to understand the questionnaires
0,T1,Procedure 0 16	liver transplant
0,T1,"Undefined_semantics 0 211	Subjects were not to have a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease."
1,T2,Condition 284 297	schizophrenia
2,T3,Condition 305 322	psychotic illness
3,T4,Condition 324 351	severe personality disorder
4,T5,Undefined_semantics 305 322	psychotic illness
5,T6,Condition 353 363	depression
6,T7,Condition 386 406	psychiatric disorder
7,T8,Qualifier 374 385	significant
8,T9,Undefined_semantics 374 406	significant psychiatric disorder
9,R1,Has_qualifier Arg1:T7 Arg2:T8
10,T10,Observation 266 280	family history
11,T11,Observation 243 250	history
12,T12,Observation 254 262	presence
13,*,OR T10 T12 T11
14,T13,Scope 243 280	history or presence or family history
15,T14,"Scope 284 406	schizophrenia, other psychotic illness, severe personality disorder, depression, or other significant psychiatric disorder"
16,R2,Has_scope Arg1:T14 Arg2:T13
17,T15,Measurement 473 496	systolic blood pressure
18,T16,Value 437 461	postural drop of 20 mmHg
19,T17,Temporal 497 509	at screening
20,R3,Has_temporal Arg1:T15 Arg2:T17
21,R4,Has_value Arg1:T15 Arg2:T16
22,T18,Temporal 587 620	90 days prior to study initiation
23,T19,Observation 538 579	participated in a previous clinical trial
24,T20,Context_Error 512 621	Subjects were not to have participated in a previous clinical trial within 90 days prior to study initiation.
25,R5,Has_temporal Arg1:T19 Arg2:T18
26,T21,Procedure 649 663	donated plasma
27,T22,Temporal 664 704	within 90 days prior to study initiation
28,T23,Reference_point 688 704	study initiation
29,R6,Has_index Arg1:T22 Arg2:T23
30,T24,Negation 637 640	not
31,R7,Has_negation Arg1:T21 Arg2:T24
32,R8,Has_temporal Arg1:T21 Arg2:T22
33,T25,Negation 423 426	not
34,R9,Has_negation Arg1:T16 Arg2:T25
35,T26,Procedure 733 746	donated blood
36,T27,Negation 721 724	not
37,T28,Temporal 747 787	within 90 days prior to study initiation
38,T29,Reference_point 771 787	study initiation
39,R10,Has_index Arg1:T28 Arg2:T29
40,R11,Has_temporal Arg1:T26 Arg2:T28
41,R12,Has_negation Arg1:T26 Arg2:T27
42,T30,Observation 823 836	abnormal diet
43,T31,Observation 852 876	changes in eating habits
44,T32,Qualifier 840 851	substantial
45,R13,Has_qualifier Arg1:T31 Arg2:T32
46,T33,Temporal 877 917	within 30 days prior to study initiation
47,T34,Reference_point 901 917	study initiation
48,R14,Has_index Arg1:T33 Arg2:T34
49,*,OR T30 T31
50,T35,Scope 823 876	abnormal diet or substantial changes in eating habits
51,T36,Negation 804 807	not
52,R15,Has_negation Arg1:T35 Arg2:T36
53,R16,Has_temporal Arg1:T35 Arg2:T33
54,T37,Drug 975 997	enzyme-altering agents
55,T38,Drug 999 1011	barbiturates
56,T39,Drug 1013 1027	phenothiazines
57,T40,Drug 1029 1039	cimetidine
58,*,OR T40 T39 T38
59,T41,Temporal 1046 1089	within 30 days prior to or during the study
60,T42,Condition 1134 1150	hypersensitivity
61,T43,Condition 1154 1176	idiosyncratic reaction
62,T44,Drug 1184 1194	study drug
63,R17,AND Arg1:T43 Arg2:T44
64,R18,AND Arg1:T42 Arg2:T44
65,T45,Negation 1114 1116	no
66,R19,Has_negation Arg1:T42 Arg2:T45
67,R20,Has_negation Arg1:T43 Arg2:T45
68,T46,Drug 1247 1270	prescription medication
69,T47,Temporal 1271 1294;1305 1314	within 14 days prior to the study
70,T48,Temporal 1298 1314	during the study
71,*,OR T47 T48
72,T49,Scope 1271 1314	within 14 days prior to or during the study
73,T50,Negation 1232 1235	not
74,R21,Has_negation Arg1:T46 Arg2:T50
75,R22,Has_scope Arg1:T46 Arg2:T49
76,T51,Temporal 1374 1396;1407 1416	within 7 days prior to the study
77,T52,Temporal 1400 1416	during the study
78,*,OR T52 T51
79,T53,Scope 1374 1416	within 7 days prior to or during the study
80,T54,Drug 1346 1373	over-the-counter medication
81,R23,Has_scope Arg1:T54 Arg2:T53
82,T55,Negation 1331 1334	not
83,R24,Has_negation Arg1:T54 Arg2:T55
84,T56,Condition 1469 1479	drug abuse
85,T57,Condition 1458 1465;1474 1479	alcohol abuse
86,T58,Temporal 1480 1513	within 2 years prior to the study
87,T59,Reference_point 1504 1513	the study
88,R25,Has_index Arg1:T58 Arg2:T59
89,T60,Reference_point 1407 1416	the study
90,*,OR T56 T57
91,T61,Scope 1458 1479	alcohol or drug abuse
92,T62,Observation 1447 1454	history
93,T63,Condition 1551 1566	use of cannabis
94,T64,Negation 1572 1584	not excluded
95,T65,Grammar_Error 1572 1584	not excluded
96,R26,Has_temporal Arg1:T61 Arg2:T58
97,R27,Has_temporal Arg1:T61 Arg2:T62
98,T66,Negation 1433 1436	not
99,R28,Has_negation Arg1:T61 Arg2:T66
100,T67,Not_a_criteria 1514 1754	(subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study)
0,T1,Condition 107 116	dyspepsia
1,T2,Condition 121 135	abdominal pain
2,T3,Procedure 39 70	diagnostic endoscopic procedure
3,T4,Visit 74 102	St Mary's Hospital NHS Trust
4,*,OR T2 T1
5,R1,AND Arg1:T3 Arg2:T4
6,T5,Scope 107 135	dyspepsia and abdominal pain
7,R2,Has_scope Arg1:T3 Arg2:T5
0,T1,Condition 0 24	major depressive episode
1,T2,Condition 28 50	type2 bipolar disorder
2,T3,Condition 54 70	bipolar disorder
3,T4,Qualifier 71 74	NOS
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Measurement 76 81	MADRS
6,T6,Value 82 100	more than 20 point
7,R2,Has_value Arg1:T5 Arg2:T6
8,*,OR T2 T3
9,T7,Scope 76 100	MADRS more than 20 point
10,R3,Subsumes Arg1:T1 Arg2:T7
11,T8,Scope 28 74	type2 bipolar disorder or bipolar disorder NOS
12,R4,Has_scope Arg1:T1 Arg2:T8
13,T9,Value 103 121	18years to 65years
14,T10,Person 116 121	years
15,R5,Has_value Arg1:T10 Arg2:T9
16,T11,Observation 136 161	sign the informed consent
0,T1,Person 0 5	adult
1,T2,Person 15 19	aged
2,T3,Value 20 30	= 55 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 66 78	hip fracture
5,T5,Procedure 39 55	radiographically
6,R2,AND Arg1:T5 Arg2:T4
0,T1,Negation 0 10	don't have
1,T2,Condition 11 19	Diabetes
2,T3,Condition 24 52	abnormal metabolism of sugar
3,*,OR T3 T2
4,T4,Scope 11 52	Diabetes and abnormal metabolism of sugar
5,R1,Has_negation Arg1:T4 Arg2:T1
6,T5,Negation 54 57	not
7,T6,Mood 58 65	noticed
8,T7,Condition 69 85	bipolar disorder
9,R2,Has_mood Arg1:T7 Arg2:T6
10,R3,Has_negation Arg1:T7 Arg2:T5
11,T8,Condition 95 116	organic brain disease
12,T9,Condition 118 126	pregnant
13,T10,Observation 130 143	breastfeeding
14,T11,Person 144 149	women
15,*,OR T10 T9
16,T12,Negation 151 161	don't have
17,T13,Condition 162 175	heart disease
18,R4,Has_negation Arg1:T13 Arg2:T12
19,T14,Condition 182 207	actively suicidal thought
20,T15,Measurement 208 240	Suicidal ideation score of MADRS
21,T16,Value 244 245	6
22,R5,Has_value Arg1:T15 Arg2:T16
23,T17,Scope 208 245	Suicidal ideation score of MADRS is 6
24,R6,Subsumes Arg1:T14 Arg2:T17
25,T18,Observation 256 319	judged by the investigator to should be excluded from the study
0,T1,Condition 0 17	multiple injuries
1,T2,Condition 19 29	polytrauma
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Condition 50 66	adverse reaction
4,T4,Condition 76 83	allergy
5,*,OR T3 T4
6,T5,Procedure 87 105	local anaesthetics
7,T6,Drug 109 116	opioids
8,T7,Drug 120 131	paracetamol
9,*,OR T5 T6 T7
10,T8,Scope 87 131	local anaesthetics or opioids or paracetamol
11,T9,Scope 50 83	adverse reaction or known allergy
12,R2,Has_scope Arg1:T9 Arg2:T8
13,T10,Condition 133 147	skin infection
14,T11,Qualifier 164 178	injection site
15,R3,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Condition 180 189	delirious
0,T1,Procedure 20 27	surgery
1,T2,Qualifier 31 39	shoulder
2,T3,Qualifier 41 48	humerus
3,T4,Qualifier 53 61	clavicle
4,*,OR T4 T3 T2
5,T5,"Scope 31 61	shoulder, humerus, or clavicle"
6,R1,Has_scope Arg1:T1 Arg2:T5
0,T1,Condition 37 47	malignancy
1,T2,Qualifier 27 36	any other
2,T3,Observation 16 23	history
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Temporal 50 61	Concomitant
6,T5,Procedure 62 71	treatment
7,T6,Qualifier 77 86	any other
8,T7,Procedure 87 105	anticancer therapy
9,R3,Has_qualifier Arg1:T7 Arg2:T6
10,R4,AND Arg1:T5 Arg2:T7
11,R5,Has_temporal Arg1:T5 Arg2:T4
12,T8,Condition 121 137	contraindication
13,T9,Procedure 141 153	chemotherapy
14,T10,Qualifier 157 169	uncontrolled
15,T11,Condition 170 180	coronarism
16,T12,Condition 185 198	heart failure
17,*,OR T11 T12
18,T13,Scope 170 198	coronarism and heart failure
19,R6,Has_qualifier Arg1:T13 Arg2:T10
20,R7,AND Arg1:T8 Arg2:T9
21,T14,Observation 200 207	History
22,T15,Condition 211 232	myocardial infarction
23,T16,Temporal 233 257	within the past 6 months
24,R8,Has_temporal Arg1:T15 Arg2:T16
25,R9,Has_temporal Arg1:T15 Arg2:T14
26,T17,Condition 259 288	Chronic obstructive pulmonary
27,T18,Qualifier 290 302	uncontrolled
28,T19,Condition 303 319	epileptic attack
29,T20,Qualifier 324 329	other
30,T21,Condition 330 337	disease
31,T22,Condition 368 399	unsuitable for the chemotherapy
32,T23,Procedure 387 399	chemotherapy
33,R10,AND Arg1:T22 Arg2:T23
34,R11,Has_qualifier Arg1:T21 Arg2:T20
35,R12,Has_qualifier Arg1:T19 Arg2:T18
36,*,OR T19 T21 T17 T15 T13
37,R13,AND Arg1:T21 Arg2:T22
38,T24,"Scope 157 399	uncontrolled coronarism and heart failure; History of myocardial infarction within the past 6 months, Chronic obstructive pulmonary, uncontrolled epileptic attack and other disease that investigator consider it unsuitable for the chemotherapy"
39,T25,Scope 121 153	contraindication to chemotherapy
40,R14,Subsumes Arg1:T25 Arg2:T24
0,T1,Condition 0 26	Obstructed outlet syndrome
1,T2,Procedure 43 56	defeacography
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Condition 59 83	Irritable bowel syndrome
4,T4,Measurement 85 101	Rome-IV criteria
5,T5,Condition 106 130	irritable bowel syndrome
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Condition 147 170	organic bowel pathology
8,T7,Condition 133 143;155 170	Congenital bowel pathology
9,*,OR T6 T7
10,T8,Condition 172 187	Rectal prolapse
11,T9,Observation 189 211	Anatomical limitations
12,T10,Procedure 223 248	placement of an electrode
13,T11,Negation 212 222	preventing
14,R3,Has_negation Arg1:T10 Arg2:T11
15,T12,Non-query-able 189 248	Anatomical limitations preventing placement of an electrode
16,T13,Condition 259 275	perineal disease
17,T14,Condition 250 254;268 275	Skin disease
18,T15,Observation 281 298	risk of infection
19,T16,Parsing_Error 255 258	and
20,*,OR T13 T14
21,T17,Procedure 321 335	rectal surgery
22,T18,Procedure 309 320;328 335	large bowel surgery
23,T19,Parsing_Error 320 321	/
24,*,OR T17 T18
25,T20,Condition 337 342	Stoma
26,T21,Condition 355 375	neurological disease
27,T22,Condition 389 415	psychological co-morbidity
28,T23,Qualifier 377 388	Significant
29,R4,Has_qualifier Arg1:T22 Arg2:T23
30,T24,Subjective_judgement 416 460	as assessed subjectively by the investigator
31,T25,Pregnancy_considerations 462 523	Being or attempting to become pregnant during study follow-up
0,T1,Measurement 0 4	eGFR
1,T2,Value 5 8	<60
2,T3,Condition 9 13	T2DM
3,R1,Has_value Arg1:T1 Arg2:T2
4,T4,Drug 26 33	insulin
5,T5,Drug 35 40	GLP-1
6,T6,Drug 41 43	RA
7,T7,Drug 47 52	SGLT2
8,*,OR T6 T7 T5 T4
9,T8,Condition 63 82	Major organ disease
10,T9,Condition 83 98	type 1 diabetes
11,T10,"Scope 26 52	insulin, GLP-1 RA or SGLT2"
12,T11,Line 0 8	eGFR <60
13,T12,"Line 9 62	T2DM patients on insulin, GLP-1 RA or SGLT2 treatment"
14,T13,Line 63 82	Major organ disease
15,T14,Line 83 98	type 1 diabetes
0,T1,"Non-query-able 0 164	No informed consent for participation in the study, mental illness, which don't allow to obtain informed consent and conduct the treatment according to the protocol"
1,T2,Condition 166 175	Pregnancy
2,T3,Condition 177 190	HIV infection
3,T4,Condition 199 205	cancer
4,T5,Temporal 192 198	Active
5,R1,Has_temporal Arg1:T4 Arg2:T5
6,T6,Condition 214 239	hepatitis virus infection
7,T7,Temporal 207 213	Active
8,R2,Has_temporal Arg1:T6 Arg2:T7
0,T1,Qualifier 27 37	outpatient
1,T2,Procedure 38 47	MRI scans
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Measurement 53 78	expected duration of scan
4,T4,Value 79 112	between 30 minutes and 75 minutes
5,R2,Has_value Arg1:T3 Arg2:T4
0,T1,"Post-eligibility 0 173	Before participate in the study, patients must understand the treatment plan and willing to participate in the study. Patients must have signed an approved informed consent."
1,T2,Procedure 175 190	Histopathologic
2,T3,Condition 201 224	squamous cell carcinoma
3,T4,Qualifier 175 200	Histopathologic confirmed
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Qualifier 228 241	head and neck
6,R2,Has_qualifier Arg1:T3 Arg2:T5
7,T6,Qualifier 253 264	oral cavity
8,T7,Qualifier 266 276	oropharynx
9,T8,Qualifier 278 284	larynx
10,T9,Qualifier 289 300	hypopharynx
11,T10,"Scope 253 300	oral cavity, oropharynx, larynx, or hypopharynx"
12,*,OR T6 T7 T8 T9
13,R3,Subsumes Arg1:T5 Arg2:T10
14,T11,Person 303 307	Ages
15,T12,Value 307 316	=65 years
16,R4,Has_value Arg1:T11 Arg2:T12
17,T13,Measurement 341 364	ECOG performance status
18,T14,Value 365 367	=2
19,R5,Has_value Arg1:T13 Arg2:T14
20,T15,Condition 393 409	contraindication
21,T16,Procedure 384 392	surgical
22,R6,AND Arg1:T15 Arg2:T16
23,T17,Observation 413 419	reject
24,T18,Procedure 423 430	surgery
25,R7,AND Arg1:T17 Arg2:T18
26,*,OR T15 T17
27,T19,Measurement 447 450;492 499	TNM staging
28,T20,Qualifier 433 446	Postoperative
29,R8,Has_qualifier Arg1:T19 Arg2:T20
30,T21,"Value 500 507	III~IV,"
31,T22,Value 508 516	positive
32,T23,Measurement 517 532	surgical margin
33,R9,Has_value Arg1:T23 Arg2:T22
34,R10,Has_value Arg1:T19 Arg2:T21
35,T24,Condition 555 573	distant metastases
36,T25,Negation 535 542	without
37,R11,Has_negation Arg1:T24 Arg2:T25
38,T26,Mood 543 551	evidence
39,R12,Has_mood Arg1:T24 Arg2:T26
40,T27,Condition 579 595	contraindication
41,T28,Procedure 599 616	chemoradiotherapy
42,T29,Negation 576 578	No
43,R13,Has_negation Arg1:T27 Arg2:T29
44,R14,AND Arg1:T27 Arg2:T28
45,T30,Observation 619 634	Life expectancy
46,T31,Value 635 645	> 3 months
47,R15,Has_value Arg1:T30 Arg2:T31
48,T32,Measurement 674 690	white blood cell
49,T33,Value 690 700	=3.5×109/L
50,T34,Measurement 702 713	Neutrophils
51,T35,Value 714 724	=1.5×109/L
52,T36,Measurement 726 736	Hemoglobin
53,T37,Value 737 743	=80g/L
54,T38,Measurement 745 759	Blood platelet
55,T39,Value 759 769	>100×109/L
56,R16,Has_value Arg1:T38 Arg2:T39
57,R17,Has_value Arg1:T36 Arg2:T37
58,R18,Has_value Arg1:T34 Arg2:T35
59,R19,Has_value Arg1:T32 Arg2:T33
60,T40,Measurement 771 801	Alanine aminotransferase (ALT)
61,T41,Measurement 806 838	Aspartate aminotransferase (AST)
62,T42,Value 838 870	= 2.5 upper limit of normal(ULN)
63,R20,Has_value Arg1:T41 Arg2:T42
64,R21,Has_value Arg1:T40 Arg2:T42
65,T43,Measurement 872 894	Total bilirubin (TBIL)
66,T44,Value 895 903	<1.5 ULN
67,R22,Has_value Arg1:T43 Arg2:T44
68,T45,Measurement 904 920	serum creatinine
69,T46,Value 920 928	=1.5 ULN
70,R23,Has_value Arg1:T45 Arg2:T46
71,T47,Measurement 930 950	creatinine clearance
72,T48,Value 954 964	= 50ml/min
73,R24,Has_value Arg1:T47 Arg2:T48
0,T1,Qualifier 47 53	Severe
1,T2,Condition 54 66	coagulopathy
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Informed_consent 0 15	Patient refusal
4,T4,Condition 17 24	Allergy
5,T5,Drug 28 45	local anaesthesia
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Qualifier 68 81	Contralateral
8,T7,Condition 82 101	phrenic nerve palsy
9,R3,Has_qualifier Arg1:T7 Arg2:T6
10,T8,Condition 103 118	Local infection
11,T9,Qualifier 120 128	Moderate
12,T10,Qualifier 132 138	severe
13,T11,Condition 139 160	pulmonary dysfunction
14,T12,Measurement 162 166	GOLD
15,T13,"Value 167 177	II, II, IV"
16,R4,Has_value Arg1:T12 Arg2:T13
17,*,OR T10 T9
18,T14,Scope 120 138	Moderate to severe
19,R5,Has_scope Arg1:T11 Arg2:T14
20,T15,"Scope 162 177	GOLD II, II, IV"
21,R6,Subsumes Arg1:T14 Arg2:T15
0,T1,Condition 0 28	Adult acute myeloid leukemia
1,T2,Person 30 33	Age
2,T3,Value 35 47	≥18 and ≤ 60
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 122 145	ECOG performance status
5,T5,Value 147 150	≤ 2
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 159 215	Hematopoietic Cell Transplant-Co-morbidity Index (HCT-I)
8,T7,Value 217 219	≤3
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Post-eligibility 221 278	Informed consent to participate in the study (ICF signed)
11,T9,Measurement 362 386	percentage of the blasts
12,T10,Value 400 404	>10%
13,T11,Temporal 405 415	on 7th day
14,R4,Has_value Arg1:T9 Arg2:T10
15,R5,Has_temporal Arg1:T9 Arg2:T11
0,T1,Measurement 3 31	average defecation frequency
1,T2,Measurement 33 35	DF
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Value 40 51	<3 per week
4,T4,Procedure 63 86	3-week defecation diary
5,R2,Has_value Arg1:T1 Arg2:T3
6,R3,AND Arg1:T1 Arg2:T4
7,T7,Multiplier 112 124	at least one
8,T8,Measurement 148 192	Rome-IV criteria for idiopathic constipation
9,T9,Condition 169 192	idiopathic constipation
10,T10,Procedure 206 229	3-week defecation diary
11,T13,Qualifier 125 130	other
12,T14,Procedure 249 271	conservative treatment
13,T15,Qualifier 235 245	Refractory
14,R12,Has_qualifier Arg1:T14 Arg2:T15
15,T16,Person 273 276	Age
16,T17,Value 278 289	14-80 years
17,R13,Has_value Arg1:T16 Arg2:T17
18,T18,Condition 291 300	Straining
19,T21,Multiplier 308 312	=25%
20,T22,Condition 316 327	defecations
21,T23,Observation 338 349	hard stools
22,T24,Observation 329 334;343 349	Lumpy stools
23,*,OR T23 T24
24,T25,Condition 361 372	defecations
25,T26,Multiplier 353 357	=25%
26,R19,Has_multiplier Arg1:T25 Arg2:T26
27,T29,Condition 374 408	Sensation of incomplete evacuation
28,T30,Multiplier 413 417	=25%
29,T31,Condition 421 432	defecations
30,R21,Has_multiplier Arg1:T31 Arg2:T30
31,T27,Condition 490 501	defecations
32,T28,Multiplier 482 486	=25%
33,R20,Has_multiplier Arg1:T27 Arg2:T28
34,T32,Condition 434 468	Sensation of anorectal obstruction
35,T33,Condition 434 456;469 477	Sensation of anorectal blockage
36,*,OR T32 T33
37,T35,Condition 543 554	defecations
38,T36,Multiplier 535 539	=25%
39,R22,Has_multiplier Arg1:T35 Arg2:T36
40,T37,Procedure 503 520	Manual manoeuvres
41,T11,Condition 131 140	criterion
42,R8,AND Arg1:T11 Arg2:T8
43,R10,Has_qualifier Arg1:T11 Arg2:T13
44,R9,Has_multiplier Arg1:T11 Arg2:T7
45,R6,AND Arg1:T8 Arg2:T10
46,R7,multi Arg1:T8 Arg2:T9
47,R4,AND Arg1:T29 Arg2:T31
48,T12,Scope 434 477	Sensation of anorectal obstruction/blockage
49,R11,AND Arg1:T12 Arg2:T27
50,R23,AND Arg1:T37 Arg2:T35
51,T34,Scope 329 349	Lumpy or hard stools
52,R24,AND Arg1:T34 Arg2:T25
53,T5,Qualifier 88 104	patient-reported
54,R5,Has_qualifier Arg1:T4 Arg2:T5
55,R14,AND Arg1:T18 Arg2:T22
56,R15,Has_multiplier Arg1:T22 Arg2:T21
0,T1,Measurement 0 4	eGFR
1,T2,Value 4 14	>60 ml/min
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 15 22	healthy
4,T4,Condition 34 49	type 2 diabetes
5,T5,Line 0 14	eGFR>60 ml/min
6,T6,Line 15 33	healthy volunteers
7,T7,Line 34 80	type 2 diabetes patients who otherwise healthy
0,T1,Observation 0 16	Inpatient status
1,T2,Condition 18 38	airway abnormalities
2,T3,Condition 40 47	allergy
3,T4,Drug 55 72	study medications
4,T5,Drug 74 78	eggs
5,T6,Drug 83 86	soy
6,T7,Condition 92 115	mitochondrial disorders
7,*,OR T4 T5 T6
8,T8,"Scope 55 86	study medications, eggs and soy"
9,R1,Has_scope Arg1:T3 Arg2:T8
10,*,OR T2 T3 T7 T1
11,T9,Condition 140 155	cardiac disease
12,T10,Condition 170 189	cardiac arrhythmias
13,T11,Observation 159 166	history
14,R2,Has_temporal Arg1:T10 Arg2:T11
15,*,OR T9 T10
0,T1,Condition 23 49	refractory medulloblastoma
1,T2,Condition 10 19;34 49	Recurrent medulloblastoma
2,T3,Procedure 67 85	standard treatment
3,T4,Qualifier 102 108	failed
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Scope 10 49	Recurrent or refractory medulloblastoma
6,R2,AND Arg1:T5 Arg2:T3
7,T6,Condition 183 200	high-grade glioma
8,T7,Measurement 202 239	World Health Organization [WHO] grade
9,T8,Value 240 246	3 or 4
10,R3,Has_value Arg1:T7 Arg2:T8
11,R4,AND Arg1:T6 Arg2:T7
12,T9,Measurement 249 264	Life expectancy
13,T10,Value 265 275	≥ 3 months
14,T11,Mood 120 132	not required
15,R5,Has_value Arg1:T9 Arg2:T10
0,T1,Condition 8 27	non-cardiac surgery
1,T2,Temporal 28 90	at least after 12 months of implantation of drug eluting stent
2,T3,Reference_point 56 90	implantation of drug eluting stent
3,T4,Procedure 56 68	implantation
4,T5,Device 72 90	drug eluting stent
5,R1,AND Arg1:T4 Arg2:T5
6,R2,multi Arg1:T3 Arg2:T4
7,R3,Has_index Arg1:T2 Arg2:T3
8,R4,Has_temporal Arg1:T1 Arg2:T2
9,T6,Mood 0 7	Planned
10,R5,Has_mood Arg1:T1 Arg2:T6
11,T8,Procedure 99 130	intermediate risk level surgery
12,T9,Procedure 112 130;92 95	risk level surgery Low
13,*,OR T9 T8
14,T10,Observation 132 156	Written informed consent
0,T1,Condition 0 24	Congestive heart failure
1,T2,Condition 26 48	Ischemic heart disease
2,T3,Condition 50 61	Hypotension
3,T4,Measurement 63 86	Systolic blood pressure
4,T5,Value 87 96	<100 mmHg
5,R1,Has_value Arg1:T4 Arg2:T5
6,T6,Scope 63 96	Systolic blood pressure <100 mmHg
7,R2,Subsumes Arg1:T3 Arg2:T6
8,T7,Qualifier 114 121	class I
9,T8,Qualifier 114 119;125 128	class III
10,*,OR T8 T7
11,T9,Drug 129 149	antiarrhythmic drugs
12,T10,Scope 114 128	class I or III
13,R3,Has_scope Arg1:T9 Arg2:T10
14,T11,Qualifier 151 157	Severe
15,T12,Condition 169 182	renal failure
16,T13,Condition 158 165;175 182	hepatic failure
17,*,OR T13 T12
18,T15,Scope 158 182	hepatic or renal failure
19,R5,Has_qualifier Arg1:T15 Arg2:T11
20,T16,Condition 184 193	Pregnancy
21,T17,Condition 197 206	lactation
22,*,OR T17 T16
23,T18,Condition 208 224	Hypersensitivity
24,T19,Condition 228 242	contradictions
25,T20,Drug 246 257	study drugs
26,*,OR T18 T19
27,T21,Scope 208 242	Hypersensitivity or contradictions
28,R6,AND Arg1:T21 Arg2:T20
29,T23,Condition 302 316	Thyrotoxicosis
30,T24,Condition 259 300	Atrio-ventricular conduction disturbances
31,T25,Condition 318 339	Life limiting disease
32,T26,Condition 343 358	substance abuse
33,T27,Qualifier 365 389	may affect participation
34,*,OR T25 T26
35,T28,Scope 318 358	Life limiting disease or substance abuse
36,R7,Has_qualifier Arg1:T28 Arg2:T27
0,T1,Condition 13 29	brainstem glioma
1,T2,Procedure 70 88	anti-tumor therapy
2,T3,Condition 103 124	uncontrolled diarrhea
3,T4,Temporal 31 41	Concurrent
4,R1,Has_temporal Arg1:T2 Arg2:T4
5,T5,Qualifier 60 69	any other
6,R2,Has_qualifier Arg1:T2 Arg2:T5
0,T1,Person 18 21	age
1,T2,Value 0 14	Above 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 23 34	Symptomatic
4,T4,Qualifier 36 45	permanent
5,T5,Condition 46 48	AF
6,T6,Multiplier 52 82	at least three months duration
7,R2,Has_multiplier Arg1:T5 Arg2:T6
8,T7,"Scope 23 45	Symptomatic, permanent"
9,R3,Has_scope Arg1:T5 Arg2:T7
10,T8,Measurement 84 102	Resting heart rate
11,T9,Value 103 110	=80 bpm
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Informed_consent 112 135	Signed informed consent
0,T1,Condition 0 23	Acute coronary syndrome
1,T2,Temporal 24 38	within 1 month
2,T3,Condition 40 53	Heart failure
3,T4,Measurement 54 58	NYHA
4,T5,Value 59 68	III to IV
5,T6,Condition 70 86	Contraindication
6,T7,Drug 90 97	Aspirin
7,R1,AND Arg1:T6 Arg2:T7
8,T8,Procedure 102 123	anticoagulant therapy
9,T9,Procedure 125 141	Emergent surgery
10,T10,Procedure 143 158	Cardiac surgery
11,T11,Condition 160 188	High bleeding risk surgeries
12,T12,Condition 196 217	Intra-cranial surgery
13,T13,Condition 219 239	Intra-spinal surgery
14,T14,Condition 241 256	Retinal surgery
15,*,OR T12 T13 T14
16,T15,"Scope 196 256	Intra-cranial surgery, Intra-spinal surgery, Retinal surgery"
17,R2,Subsumes Arg1:T11 Arg2:T15
18,T16,Condition 258 267	Pregnancy
19,T17,Condition 271 285	breast-feeding
20,T18,Observation 287 302	Life expectancy
21,T19,Value 303 318	less than 1year
22,R3,Has_value Arg1:T18 Arg2:T19
23,R4,Has_value Arg1:T4 Arg2:T5
24,R5,AND Arg1:T3 Arg2:T4
25,R6,Has_temporal Arg1:T1 Arg2:T2
26,*,OR T16 T17
0,T1,Measurement 0 38	Columbia-Suicide Severity Rating Scale
1,T2,Measurement 40 46	C-SSRS
2,T3,Condition 52 69	suicidal ideation
3,T4,Condition 52 60;74 82	suicidal behavior
4,T5,Temporal 83 95	in past year
5,R1,Subsumes Arg1:T1 Arg2:T2
6,*,OR T3 T4
7,T6,Scope 52 82	suicidal ideation and behavior
8,R2,Has_scope Arg1:T1 Arg2:T6
9,R3,Has_temporal Arg1:T6 Arg2:T5
10,T7,Condition 98 114	Hypersensitivity
11,T8,Drug 118 126	morphine
12,T9,Drug 128 138	naltrexone
13,T10,"Scope 118 138	morphine, naltrexone"
14,*,OR T8 T9
15,R4,Has_scope Arg1:T7 Arg2:T10
16,T11,Observation 143 158	life expectancy
17,T12,Value 189 207	less than 6 months
18,R5,Has_value Arg1:T11 Arg2:T12
19,T13,Non-query-able 211 259	is no longer capable of taking medication orally
20,T14,Procedure 272 279	surgery
21,T15,Temporal 280 326	within 3 days prior to the first day of dosing
22,T16,Reference_point 307 326	first day of dosing
23,R6,Has_index Arg1:T15 Arg2:T16
24,R7,Has_temporal Arg1:T14 Arg2:T15
0,T1,Condition 5 17	osteoporosis
1,T2,Measurement 26 59	10 yr probability of hip fracture
2,T3,Condition 47 59	hip fracture
3,T4,Value 60 63	>3%
4,R1,Has_value Arg1:T2 Arg2:T4
5,T5,Measurement 26 46;67 81	10 yr probability of major fracture
6,T6,Condition 67 81	major fracture
7,T7,Undefined_semantics 67 81	major fracture
8,T8,Value 82 86	>20%
9,R2,Has_value Arg1:T5 Arg2:T8
10,T9,Drug 137 152	bisphosphonates
11,T10,Procedure 154 182	estrogen replacement therapy
12,T11,Drug 184 204	glucocorticosteroids
13,T12,Drug 215 235	drugs affecting bone
14,T13,Undefined_semantics 215 235	drugs affecting bone
15,*,OR T9 T10 T11 T12
16,T14,Condition 247 283	participate in a resistance training
17,T15,Non-query-able 247 283	participate in a resistance training
18,T16,Condition 247 261;287 322	participate in high impact weight bearing exercise
19,T17,Non-query-able 247 261;287 322	participate in high impact weight bearing exercise
20,T18,Multiplier 331 355	two or more times weekly
21,R3,Has_multiplier Arg1:T16 Arg2:T18
22,*,OR T14 T16
23,R4,Has_multiplier Arg1:T14 Arg2:T18
24,T19,Measurement 357 362	Weigh
25,T20,Value 363 371	>300 lbs
26,R5,Has_value Arg1:T19 Arg2:T20
27,T21,Value 378 394	abnormal results
28,T22,Measurement 431 444	serum 25(OH)D
29,R6,Has_value Arg1:T22 Arg2:T21
30,T23,Measurement 446 462	serum creatinine
31,R7,Has_value Arg1:T23 Arg2:T21
32,T24,Measurement 464 477	serum calcium
33,R8,Has_value Arg1:T24 Arg2:T21
34,T25,Measurement 479 482	PTH
35,T26,Measurement 484 487	TSH
36,R9,Has_value Arg1:T25 Arg2:T21
37,R10,Has_value Arg1:T26 Arg2:T21
38,T27,Condition 494 509	Paget's disease
39,T28,Condition 511 524	heart disease
40,T29,Condition 526 551	uncontrolled hypertension
41,T30,Condition 553 566	renal disease
42,T31,Condition 571 640	other concomitant conditions that prohibit participation in exercises
43,T32,Undefined_semantics 571 640	other concomitant conditions that prohibit participation in exercises
44,T33,Procedure 642 661	risedronate therapy
45,T34,Drug 673 688	CaD supplements
46,*,OR T27 T28 T29 T30 T31 T33 T34
0,T1,Multiplier 14 29;63 70	2 or more doses per day
1,T2,Drug 33 51	methylprednisolone
2,T3,Drug 52 62	prednisone
3,*,OR T2 T3
4,T4,Scope 33 62	methylprednisolone/prednisone
5,R1,Has_multiplier Arg1:T4 Arg2:T1
6,T5,Drug 92 110	methylprednisolone
7,T6,Drug 114 124	prednisone
8,T7,Drug 72 80	Steroids
9,T8,Negation 81 91	other than
10,*,OR T6 T5
11,T9,Scope 92 124	methylprednisolone or prednisone
12,R2,Has_negation Arg1:T9 Arg2:T8
13,R3,Has_scope Arg1:T7 Arg2:T9
14,T10,Condition 126 135	Pregnancy
15,T11,Measurement 137 180	estimated glomerular filtration rate (eGFR)
16,T12,Value 181 199	< 45 ml/min/1.73m2
17,R4,Has_value Arg1:T11 Arg2:T12
0,T1,Non-query-able 0 34	Unable to speak Spanish or English
1,T2,Qualifier 36 42	Active
2,T3,Observation 43 50	smoking
3,R1,Has_qualifier Arg1:T3 Arg2:T2
4,T4,Value 52 72	within the past year
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 117 124;75 85	disease Autoimmune
7,T6,Condition 104 124	inflammatory disease
8,T7,Condition 117 124;87 100	disease rheumatologic
9,*,OR T5 T7 T6
10,T8,Negation 135 138	not
11,T9,Condition 139 148	psoriasis
12,T10,Condition 152 171	psoriatic arthritis
13,*,OR T10 T9
14,T11,Scope 139 171	psoriasis or psoriatic arthritis
15,R3,Has_negation Arg1:T11 Arg2:T8
16,T12,"Scope 75 124	Autoimmune, rheumatologic or inflammatory disease"
17,R4,Has_scope Arg1:T12 Arg2:T11
18,T13,Condition 186 192	cancer
19,T14,Qualifier 179 185	active
20,T15,Procedure 203 212	treatment
21,R5,Has_qualifier Arg1:T13 Arg2:T14
22,R6,AND Arg1:T13 Arg2:T15
23,T16,Condition 214 223	Pregnancy
24,T17,Condition 225 231	Anemia
25,T18,Measurement 233 243	hemoglobin
26,T19,Value 244 253	< 9 mg/dl
27,R7,Has_value Arg1:T18 Arg2:T19
28,T20,Condition 258 274	thrombocytopenia
29,T21,Measurement 276 290	Platelet count
30,T22,Value 291 294	<75
31,R8,Has_value Arg1:T21 Arg2:T22
32,T23,Condition 300 314	thrombocytosis
33,T24,Measurement 316 330	Platelet count
34,T25,Value 331 335	>600
35,R9,Has_value Arg1:T24 Arg2:T25
36,*,OR T23 T20 T17
37,R10,Subsumes Arg1:T23 Arg2:T24
38,R11,Subsumes Arg1:T20 Arg2:T21
39,R12,Subsumes Arg1:T17 Arg2:T18
40,T26,Observation 340 347	history
41,T27,Qualifier 351 357	severe
42,T28,Condition 358 366	bleeding
43,T29,Condition 370 388	bleeding disorders
44,R13,Has_qualifier Arg1:T28 Arg2:T27
45,T30,Scope 351 388	severe bleeding or bleeding disorders
46,R14,Has_temporal Arg1:T30 Arg2:T26
47,T31,Temporal 390 397	Current
48,T32,Drug 398 408	medication
49,T33,Drug 440 447	aspirin
50,T34,Drug 451 463	atorvastatin
51,T35,Condition 419 427	interact
52,*,OR T34 T33
53,T36,Scope 440 463	aspirin or atorvastatin
54,R15,Subsumes Arg1:T35 Arg2:T36
55,R16,AND Arg1:T32 Arg2:T35
56,R17,Has_temporal Arg1:T32 Arg2:T31
57,T37,Condition 465 487	Chronic kidney disease
58,T38,Measurement 489 493	CrCl
59,T39,Value 494 504	< 30ml/min
60,R18,Has_value Arg1:T38 Arg2:T39
61,R19,Subsumes Arg1:T37 Arg2:T38
62,T40,Condition 507 531	Congestive heart failure
63,T41,Drug 550 557	aspirin
64,T42,Drug 563 569	statin
65,T43,Drug 572 577	NSAID
66,T44,Temporal 582 606	within the past 48 hours
67,R20,Has_temporal Arg1:T43 Arg2:T44
0,T1,Person 0 8	Children
1,T2,Condition 38 42	pain
2,T3,Qualifier 19 27	moderate
3,T4,Qualifier 31 37	severe
4,T5,Drug 88 104	opioid analgesic
5,T6,Procedure 53 79	around the clock treatment
6,R1,AND Arg1:T6 Arg2:T5
7,*,OR T3 T4
8,T7,Scope 19 37	moderate to severe
9,R2,Has_scope Arg1:T2 Arg2:T7
10,R3,AND Arg1:T2 Arg2:T6
11,T8,Drug 174 188	opioid therapy
12,T9,Drug 231 239	morphine
13,T10,Multiplier 213 227	>20 mg per day
14,T11,Qualifier 190 200	equivalent
15,R5,Has_qualifier Arg1:T9 Arg2:T11
16,T12,Drug 231 239	morphine
17,R4,Has_multiplier Arg1:T9 Arg2:T10
18,R6,Has_multiplier Arg1:T12 Arg2:T10
19,T13,Temporal 257 316	3 consecutive days immediately prior to first day of dosing
20,T14,Reference_point 297 316	first day of dosing
21,R7,Has_index Arg1:T13 Arg2:T14
22,T15,Scope 190 239	equivalent or equal to >20 mg per day of morphine
23,R8,Has_scope Arg1:T8 Arg2:T15
24,R9,Has_temporal Arg1:T8 Arg2:T13
0,T1,Person 0 5	Women
1,T2,Temporal 15 49	n their first 5 years of menopause
2,T3,Reference_point 40 49	menopause
3,T4,Condition 40 49	menopause
4,T5,Measurement 58 65	T score
5,T6,Temporal 66 86	between -1 and -2.49
6,T7,Qualifier 94 106	femoral neck
7,R2,Has_temporal Arg1:T5 Arg2:T6
8,T8,Qualifier 108 117	total hip
9,T9,Qualifier 122 133	L1-L4 spine
10,R1,Has_qualifier Arg1:T5 Arg2:T7
11,R3,Has_qualifier Arg1:T5 Arg2:T8
12,R4,Has_qualifier Arg1:T5 Arg2:T9
13,T10,Value 138 162	19 years of age or older
14,T11,Person 150 153	age
15,R5,Has_value Arg1:T11 Arg2:T10
16,T12,Non-query-able 164 232	Have their health care provider's permission to enroll in the study.
0,T1,Qualifier 27 35	moderate
1,T2,Qualifier 39 45	severe
2,T3,Condition 46 63	psoriatic disease
3,*,OR T2 T1
4,T4,Scope 27 45	moderate to severe
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Observation 16 23	history
7,R2,Has_temporal Arg1:T3 Arg2:T5
8,T6,Condition 74 81	Healthy
9,T7,Condition 105 122	psoriatic disease
10,T8,Condition 126 148	cardiovascular disease
11,*,OR T8 T7
12,T9,Negation 91 98	without
13,T10,Scope 105 148	psoriatic disease or cardiovascular disease
14,R3,Has_negation Arg1:T10 Arg2:T9
0,T1,Multiplier 19 29	once daily
1,T2,Drug 40 58	methylprednisolone
2,T3,Drug 62 72	prednisone
3,T4,Multiplier 86 106	10 mg/day or greater
4,*,OR T2 T3
5,T5,Scope 40 72	methylprednisolone or prednisone
6,R1,Has_multiplier Arg1:T5 Arg2:T1
7,R2,Has_multiplier Arg1:T5 Arg2:T4
8,T6,Condition 108 121	Hyperglycemic
9,T7,Measurement 123 136	Glucose level
10,T8,Value 137 148	> 126 mg/dL
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Scope 123 148	Glucose level > 126 mg/dL
13,R4,Has_scope Arg1:T6 Arg2:T9
14,T10,Condition 164 175	nondiabetic
15,T11,Condition 151 159	Diabetic
16,*,OR T10 T11
17,T12,Measurement 186 220	Expected duration of hospital stay
18,T13,Measurement 225 241	time on steroids
19,T14,Value 242 251	>= 3 days
20,R5,Has_value Arg1:T13 Arg2:T14
21,R6,Has_value Arg1:T12 Arg2:T14
22,T15,Informed_consent 253 315	Patient of appropriate caregiver able to give Informed Consent
0,T1,Condition 14 25	head trauma
1,T2,Procedure 29 55	Neurosurgical intervention
2,*,OR T1 T2
3,T3,Value 66 75	<65 years
4,T4,Person 79 82	age
5,R1,Has_value Arg1:T4 Arg2:T3
6,T5,Observation 101 125	expected life expectancy
7,T6,Value 126 135	<48 hours
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 137 142	Blind
10,T8,Condition 169 176	seizure
11,T9,Observation 177 184	history
12,R3,Has_temporal Arg1:T8 Arg2:T9
13,T10,Condition 200 225	uncontrolled hypertension
14,T11,Value 243 258	supratheraputic
15,T12,Value 260 264	>3.0
16,T13,Measurement 266 269	INR
17,R4,Subsumes Arg1:T11 Arg2:T12
18,R5,Has_value Arg1:T13 Arg2:T11
19,T14,Drug 309 322	ciprofloxacin
20,T15,Drug 324 335	fluvoxamine
21,T16,Drug 337 348	methoxsalen
22,T17,Drug 350 359	ofloxacin
23,T18,Drug 361 371	primaquine
24,*,OR T14 T15 T16 T17 T18
25,T19,Drug 283 307	strong CYP1A2 inhibitors
26,T20,"Scope 309 371	ciprofloxacin, fluvoxamine, methoxsalen, ofloxacin, primaquine"
27,R6,Subsumes Arg1:T19 Arg2:T20
28,T21,Negation 389 392	not
29,T22,Observation 393 406	speak English
30,T23,Observation 393 398;410 417	speak Spanish
31,*,OR T23 T22
32,T24,Scope 393 417	speak English or Spanish
33,R7,Has_negation Arg1:T24 Arg2:T21
0,T1,Person 6 10	year
1,T2,Value 0 5	18-80
2,T3,Person 12 16	male
3,T4,Person 20 26	female
4,*,OR T3 T4
5,R1,Has_value Arg1:T1 Arg2:T2
6,T5,Condition 29 50	Chronic Heart failure
7,T6,Condition 84 99	cardiac disease
8,T7,Condition 117 139	cardiovascular disease
9,T8,Qualifier 109 116	related
10,R2,Has_qualifier Arg1:T7 Arg2:T8
11,*,OR T6 T7
12,T9,Scope 84 139	cardiac disease or other related cardiovascular disease
13,R3,Has_scope Arg1:T5 Arg2:T9
14,T10,Measurement 142 176	Left ventricular ejection fraction
15,T11,Measurement 178 182	LVEF
16,T12,Value 184 205;211 221	less than or equal to 40 percent
17,T13,Value 207 209;211 213;223 224	=< 40 %
18,R4,Has_value Arg1:T12 Arg2:T13
19,R5,Subsumes Arg1:T10 Arg2:T11
20,R6,Has_value Arg1:T10 Arg2:T12
21,T14,Measurement 228 254;262 267	New York Heart Association class
22,T15,Value 271 278	II - IV
23,T16,Measurement 256 260	NYHA
24,R7,Subsumes Arg1:T14 Arg2:T16
25,R8,Has_value Arg1:T14 Arg2:T15
26,T17,"Non-query-able 280 437	NYHA II : Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue or palpitation"
27,T18,"Non-query-able 440 593	NYHA III:Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitation"
28,T19,"Non-query-able 596 758	NYHA IV:Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort increased"
29,T20,Post-eligibility 761 795	Signed Informed Consent Form (ICF)
0,T1,Condition 15 33	psychotic disorder
1,T2,Condition 60 82	open head brain trauma
2,T3,Temporal 51 58	current
3,T4,Observation 36 43	History
4,*,OR T3 T4
5,T5,"Scope 36 58	History of, or current"
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Device 104 109	metal
8,T7,Device 111 119	shrapnel
9,T8,Device 137 156	objects in the head
10,T9,Procedure 179 183	QEEG
11,T10,Condition 168 174	affect
12,R2,AND Arg1:T10 Arg2:T9
13,*,OR T7 T8 T6
14,T11,"Scope 104 156	metal, shrapnel or other similar objects in the head"
15,R3,AND Arg1:T11 Arg2:T10
16,T12,Procedure 197 207	craniotomy
17,T13,Condition 209 228	cerebral metastases
18,T14,Condition 230 254	cerebrovascular accident
19,T15,Condition 277 293	seizure disorder
20,T16,Condition 295 308	schizophrenia
21,T17,Condition 310 335	schizo-affective disorder
22,T18,Condition 337 345	dementia
23,T19,Condition 347 365	mental retardation
24,T20,Condition 370 386	major depression
25,T21,Condition 392 410	psychotic features
26,T22,Drug 422 440	depot neuroleptics
27,T23,Temporal 441 458	in last 12 months
28,R4,Has_temporal Arg1:T22 Arg2:T23
29,R5,AND Arg1:T20 Arg2:T21
30,*,OR T14 T13 T12 T19 T20 T18 T17 T16 T15 T22
31,T24,Observation 185 192	History
32,T25,"Scope 197 458	craniotomy, cerebral metastases, cerebrovascular accident; current diagnosis of seizure disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features; or use of depot neuroleptics in last 12 months"
33,R6,Has_temporal Arg1:T25 Arg2:T24
34,T26,Condition 474 491	thyroid disorders
35,T27,Qualifier 461 473	Uncontrolled
36,R7,Has_qualifier Arg1:T26 Arg2:T27
37,T28,"Pregnancy_considerations 494 575	Known pregnancy and/or lactation, or intent to become pregnant during this study."
38,T29,Qualifier 588 593	acute
39,T30,Qualifier 577 584	Chronic
40,T31,Condition 594 598	pain
41,*,OR T29 T30
42,T32,Scope 577 593	Chronic or acute
43,R8,Has_scope Arg1:T31 Arg2:T32
44,T33,Drug 609 637	prescription pain medication
45,R9,AND Arg1:T31 Arg2:T33
46,T34,Drug 642 650	narcotic
47,T35,Drug 654 672	synthetic narcotic
48,*,OR T34 T35
49,T36,Scope 642 672	narcotic or synthetic narcotic
50,R10,Subsumes Arg1:T33 Arg2:T36
51,T37,Competing_trial 675 760	Participation in any other therapeutic drug study within 60 days preceding inclusion.
0,T1,Person 33 36	age
1,T2,Value 24 28;40 42	over 65
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 4 14	ventilated
4,T4,Negation 0 3	Non
5,R2,Has_negation Arg1:T3 Arg2:T4
0,T1,Condition 0 23	Acute coronary syndrome
1,T2,Condition 25 28	ACS
2,T3,Temporal 30 45	within 3 months
3,T4,Drug 54 66	beta-blocker
4,T5,Temporal 77 97	for the last 2 weeks
5,R1,Subsumes Arg1:T1 Arg2:T2
6,R2,Has_temporal Arg1:T1 Arg2:T3
7,R3,Has_temporal Arg1:T4 Arg2:T5
8,T6,Drug 165 209	Non-dihydropyridine calcium channel blockers
9,T7,Drug 211 220	NDHP-CCBs
10,R4,Subsumes Arg1:T6 Arg2:T7
11,T8,Drug 225 235	ivabradine
12,T9,Temporal 236 256	for the last 2 weeks
13,T10,Drug 264 271	Digoxin
14,T11,Multiplier 283 292;297 312	more than 0.125 milligram
15,T12,Value 294 295;297 302;314 316	> 0.125 mg
16,R5,Subsumes Arg1:T11 Arg2:T12
17,R6,Has_multiplier Arg1:T10 Arg2:T11
18,*,OR T6 T8
19,T13,Scope 165 235	Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine
20,R7,Has_temporal Arg1:T13 Arg2:T9
21,T14,Non-query-able 100 158	Under other medicine treatment which may affect heart rate
22,T15,Condition 334 342	Diabetes
23,T16,Qualifier 321 333	Uncontrolled
24,R8,Has_qualifier Arg1:T15 Arg2:T16
25,T17,Measurement 344 358	hemoglobin A1c
26,T18,Measurement 361 366	HbA1c
27,T19,Value 368 373	>7.5%
28,R9,Subsumes Arg1:T17 Arg2:T18
29,R10,Has_value Arg1:T17 Arg2:T19
30,R11,AND Arg1:T15 Arg2:T17
31,T20,Condition 400 412	hypertension
32,T21,Qualifier 387 399	uncontrolled
33,T22,Qualifier 377 383	Severe
34,*,OR T22 T21
35,T23,Scope 377 399	Severe or uncontrolled
36,R12,Has_scope Arg1:T20 Arg2:T23
37,T24,Measurement 422 445	Systolic Blood Pressure
38,T25,Measurement 447 450	SBP
39,T26,Value 452 479	>180 millimeters of mercury
40,T27,Value 452 456;481 485	>180 mmHg
41,R13,Subsumes Arg1:T26 Arg2:T27
42,T28,Measurement 499 523	Diastolic Blood Pressure
43,T29,Measurement 525 528	DBP
44,T30,Value 530 538	>110mmHg
45,T31,Temporal 539 558	at screening period
46,T32,Reference_point 542 551	screening
47,R14,Has_index Arg1:T31 Arg2:T32
48,R15,Subsumes Arg1:T28 Arg2:T29
49,R16,Has_value Arg1:T28 Arg2:T30
50,T33,Qualifier 491 498	resting
51,R17,Has_qualifier Arg1:T28 Arg2:T33
52,R18,Subsumes Arg1:T24 Arg2:T25
53,R19,Has_value Arg1:T24 Arg2:T26
54,T34,Qualifier 414 421	resting
55,R20,Has_qualifier Arg1:T24 Arg2:T34
56,T35,"Scope 414 558	resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg at screening period"
57,R21,Has_scope Arg1:T20 Arg2:T35
58,*,OR T24 T28
59,T36,"Scope 414 538	resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg"
60,R22,Has_temporal Arg1:T36 Arg2:T31
61,T37,Condition 569 580	hypotension
62,T38,Qualifier 562 568	Severe
63,T39,Measurement 590 593	SBP
64,T40,Value 594 603;608 614	less than 90mmHg
65,T41,Qualifier 582 589	resting
66,T42,Qualifier 619 626	resting
67,T43,Measurement 627 630	DBP
68,T44,Value 630 637	<50mmHg
69,R23,Has_value Arg1:T43 Arg2:T44
70,R24,Has_qualifier Arg1:T43 Arg2:T42
71,R25,Has_value Arg1:T39 Arg2:T40
72,R26,Has_qualifier Arg1:T39 Arg2:T41
73,*,OR T39 T43
74,R27,Has_qualifier Arg1:T37 Arg2:T38
75,T45,"Scope 582 637	resting SBP less than (<) 90mmHg, or resting DBP<50mmHg"
76,R28,Has_scope Arg1:T37 Arg2:T45
77,T46,Measurement 649 659	heart rate
78,T47,Qualifier 641 648	Resting
79,T48,Value 660 679	<60 beat per minute
80,T49,Value 660 663;681 684	<60 bpm
81,R29,Subsumes Arg1:T48 Arg2:T49
82,R30,Has_qualifier Arg1:T46 Arg2:T47
83,R31,Has_value Arg1:T46 Arg2:T48
84,T50,Drug 709 719	Bisoprolol
85,T51,Condition 692 705	contradiction
86,R32,AND Arg1:T51 Arg2:T50
87,T52,Condition 752 771	Acute heart failure
88,T53,Condition 794 822	heart failure decompensation
89,T54,Procedure 833 862	intravenous inotropic therapy
90,R33,AND Arg1:T53 Arg2:T54
91,*,OR T52 T53
92,T55,Condition 865 882	Cardiogenic shock
93,T56,Condition 885 917;927 933	Atrioventricular block of second degree
94,T57,Condition 885 910;921 933	Atrioventricular block of third degree
95,*,OR T57 T56
96,T58,Device 945 954	pacemaker
97,T59,Negation 935 942	without
98,R34,Has_negation Arg1:T58 Arg2:T59
99,T60,Condition 958 977	Sick sinus syndrome
100,T61,Condition 980 996	Sinoatrial block
101,T62,Condition 1006 1016	heart rate
102,T63,Qualifier 999 1005	Slowed
103,R35,Has_qualifier Arg1:T62 Arg2:T63
104,T64,Condition 1048 1059	bradycardia
105,T65,Qualifier 1036 1047	symptomatic
106,T66,Condition 1026 1034	symptoms
107,R36,AND Arg1:T62 Arg2:T66
108,R37,Subsumes Arg1:T62 Arg2:T64
109,R38,Has_qualifier Arg1:T64 Arg2:T65
110,T67,Condition 1073 1087	blood pressure
111,T68,Qualifier 1063 1072	Decreased
112,R39,Has_qualifier Arg1:T67 Arg2:T68
113,T69,Condition 1097 1105	symptoms
114,R40,AND Arg1:T67 Arg2:T69
115,T70,Condition 1119 1130	hypotension
116,T71,Qualifier 1107 1118	symptomatic
117,R41,Has_qualifier Arg1:T70 Arg2:T71
118,R42,Subsumes Arg1:T67 Arg2:T70
119,T72,Condition 1141 1157	bronchial asthma
120,T73,Qualifier 1134 1140	Severe
121,T74,Condition 1168 1205	chronic obstructive pulmonary disease
122,T75,Qualifier 1161 1167	severe
123,R43,Has_qualifier Arg1:T74 Arg2:T75
124,R44,Has_qualifier Arg1:T72 Arg2:T73
125,*,OR T72 T74
126,T76,Condition 1223 1260	peripheral arterial occlusive disease
127,T77,Condition 1265 1283	Raynaud's syndrome
128,T78,Qualifier 1208 1213	Sever
129,T79,Scope 1223 1283	peripheral arterial occlusive disease and Raynaud's syndrome
130,T80,Non-query-able 1261 1264	and
131,*,OR T76 T77
132,R45,Has_qualifier Arg1:T79 Arg2:T78
133,T81,Condition 1296 1313	phaeochromocytoma
134,T82,Qualifier 1286 1295	Untreated
135,R46,Has_qualifier Arg1:T81 Arg2:T82
136,T83,Condition 1316 1334	Metabolic acidosis
137,T84,Condition 1337 1353	Hypersensitivity
138,T85,Drug 1357 1367	bisoprolol
139,T86,Drug 1385 1395	excipients
140,T87,Qualifier 1374 1377	any
141,R47,Has_qualifier Arg1:T86 Arg2:T87
142,*,OR T85 T86
143,T88,Scope 1357 1395	bisoprolol or to any of the excipients
144,R48,Has_scope Arg1:T84 Arg2:T88
145,T89,Condition 1405 1415	Arrhythmia
146,T90,Qualifier 1398 1404	Severe
147,T91,Condition 1426 1445	atrial fibrillation
148,T92,Condition 1447 1461	atrial flutter
149,T93,Condition 1463 1487	ventricular fibrillation
150,T94,Condition 1489 1508	ventricular flutter
151,T95,Condition 1512 1535	ventricular tachycardia
152,*,OR T91 T92 T93 T94 T95
153,R49,Has_qualifier Arg1:T89 Arg2:T90
154,T96,"Scope 1426 1535	atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter or ventricular tachycardia"
155,R50,Subsumes Arg1:T89 Arg2:T96
156,T97,Condition 1550 1572	valvular heart disease
157,T98,Qualifier 1538 1549	Significant
158,T99,Condition 1574 1598	congenital heart disease
159,T100,Condition 1600 1623	pulmonary heart disease
160,T101,Condition 1627 1650	perinatal heart disease
161,*,OR T97 T99 T100 T101
162,T102,"Scope 1550 1650	valvular heart disease, congenital heart disease, pulmonary heart disease or perinatal heart disease"
163,R51,Has_qualifier Arg1:T102 Arg2:T98
164,T103,Condition 1653 1674	Acute pulmonary edema
165,T104,Condition 1684 1703	hepatic dysfunction
166,T105,Qualifier 1677 1683	Severe
167,R52,Has_qualifier Arg1:T104 Arg2:T105
168,T106,Measurement 1718 1748	Serum Alanine Aminotransferase
169,T107,Measurement 1750 1753	ALT
170,R53,Subsumes Arg1:T106 Arg2:T107
171,T108,Value 1755 1799	> triple the upper limit of the normal range
172,R54,Has_value Arg1:T106 Arg2:T108
173,T109,Non-query-able 1801 1807	and/or
174,T110,Measurement 1809 1841	Serum Aspartate Aminotransferase
175,T111,Measurement 1843 1846	AST
176,R55,Subsumes Arg1:T110 Arg2:T111
177,T112,Value 1848 1898	> triple the upper limit of the normal value range
178,R56,Has_value Arg1:T110 Arg2:T112
179,T113,Non-query-able 1899 1905	and/or
180,*,OR T106 T110
181,T114,Condition 1914 1931	renal dysfunction
182,T115,Qualifier 1907 1913	Severe
183,R57,Has_qualifier Arg1:T114 Arg2:T115
184,T116,Measurement 1946 1962	Serum creatinine
185,T117,Value 1963 2006	> twice the upper limit of the normal range
186,R58,Has_value Arg1:T116 Arg2:T117
187,T118,Condition 2008 2030	Chronic Kidney Disease
188,T119,Measurement 2032 2058	glomerular filtration rate
189,T120,Value 2059 2084	<45 Milliliter per minute
190,R59,Has_value Arg1:T119 Arg2:T120
191,R60,AND Arg1:T118 Arg2:T119
192,T121,Condition 2088 2103	Hyperthyroidism
193,T122,Condition 2107 2121	hypothyroidism
194,*,OR T121 T122
195,T123,Condition 2131 2149	infectious disease
196,T124,Qualifier 2124 2130	Severe
197,R61,Has_qualifier Arg1:T123 Arg2:T124
198,T125,Condition 2164 2201	Human Immunodeficiency Virus positive
199,T127,Condition 2212 2224	tuberculosis
200,T128,Qualifier 2205 2211	active
201,R63,Has_qualifier Arg1:T127 Arg2:T128
202,*,OR T125 T127
203,T126,Scope 2164 2224	Human Immunodeficiency Virus positive or active tuberculosis
204,R62,Subsumes Arg1:T123 Arg2:T126
205,T129,Condition 2234 2252	autoimmune disease
206,T130,Qualifier 2227 2233	Severe
207,T131,Condition 2259 2278	lupus erythematosus
208,T132,Condition 2280 2298	multiple sclerosis
209,*,OR T131 T132
210,T133,"Scope 2259 2298	lupus erythematosus, multiple sclerosis"
211,R64,Subsumes Arg1:T129 Arg2:T133
212,R65,Has_qualifier Arg1:T129 Arg2:T130
213,T134,Condition 2308 2319;2346 2353	respiratory disease
214,T135,Condition 2321 2330;2346 2353	digestive disease
215,T136,Condition 2332 2353	hematological disease
216,T137,Qualifier 2301 2307	Severe
217,T138,"Scope 2308 2353	respiratory, digestive, hematological disease"
218,*,OR T136 T135 T134
219,R66,Has_qualifier Arg1:T138 Arg2:T137
220,T139,Condition 2365 2371	Anemia
221,T140,Measurement 2375 2377	Hb
222,T141,Value 2378 2398	< 100 gram per litre
223,R67,Has_value Arg1:T140 Arg2:T141
224,R68,AND Arg1:T139 Arg2:T140
225,R69,Subsumes Arg1:T138 Arg2:T139
226,T142,Condition 2403 2408	tumor
227,*,OR T138 T142
228,T143,Condition 2423 2439	hypersensitivity
229,T144,Drug 2443 2453	Bisoprolol
230,T145,Drug 2469 2478	excipient
231,T146,Qualifier 2458 2461	any
232,*,OR T144 T145
233,R70,Has_qualifier Arg1:T145 Arg2:T146
234,T147,"Scope 2443 2478	Bisoprolol, or any of the excipient"
235,R71,Has_scope Arg1:T143 Arg2:T147
236,T148,Condition 2494 2507	alcohol abuse
237,T149,Condition 2481 2490;2502 2507	Substance abuse
238,*,OR T148 T149
239,T150,Procedure 2519 2540	heart transplantation
240,T151,Procedure 2544 2566	pacemaker implantation
241,T152,Procedure 2568 2585	revascularization
242,T153,Temporal 2596 2611	within 3 months
243,T154,Mood 2616 2623	plan to
244,T155,Temporal 2648 2659	in 6 months
245,*,OR T150 T151 T152 T159
246,T156,Scope 2519 2585	heart transplantation or pacemaker implantation; revascularization
247,R72,Has_temporal Arg1:T156 Arg2:T153
248,T157,Procedure 2519 2540	heart transplantation
249,T158,Procedure 2544 2566	pacemaker implantation
250,T159,Procedure 2568 2585	revascularization
251,*,OR T157 T158
252,T160,Scope 2519 2585	heart transplantation or pacemaker implantation; revascularization
253,R73,Has_mood Arg1:T160 Arg2:T154
254,R74,Has_temporal Arg1:T160 Arg2:T155
255,*,OR T160 T156
256,T161,Non-query-able 2662 2753	Currently undertaking other treatment that may affect the safety and/or efficacy evaluation
257,T162,Drug 2760 2783	beta receptors agonists
258,T163,Post-eligibility 2797 2841	No legal ability or legal ability is limited
259,T164,Post-eligibility 2845 2947	ubjects unlikely to cooperate in the study or with inability or unwillingness to give informed consent
260,T165,"Pregnancy_considerations 2950 3042	Child-bearing period women without effective contraceptive measures, pregnancy and lactation"
261,T166,Non-query-able 3045 3108	Participation in another clinical trial within the past 90 days
262,T167,Post-eligibility 3111 3214	Other significant condition that in the Investigator's opinion would exclude the subject from the trial
0,T1,Condition 38 48	depression
1,T2,Drug 97 107	medication
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Measurement 180 185	PHQ-9
4,T4,Value 153 172	score of 10 or more
5,R2,Has_value Arg1:T3 Arg2:T4
6,R3,AND Arg1:T3 Arg2:T1
7,T5,"Non-representable 231 706	Some practices utilize the PHQ-2 and PHQ-9 are part of routine screening for depression. If the tests are performed routinely, they do not need to be repeated for study eligibility, and may be performed prior to informed consent for this study. If, however, the PHQ-9 is not routinely performed, informed consent must be performed prior to administration. Patients with a score below 10 will be considered screen failures and will not be enrolled or offered the MYnd testing."
8,T6,Condition 722 735;745 755	non-psychotic conditions
9,T7,Drug 798 808	medication
10,T8,Condition 829 849	behavioral illnesses
11,T9,Negation 819 824	naïve
12,R4,Has_negation Arg1:T7 Arg2:T9
13,R5,AND Arg1:T8 Arg2:T7
14,T10,Negation 858 860	no
15,T11,Qualifier 861 867	active
16,T12,Drug 868 878	medication
17,T13,Temporal 890 930	for at least 1 month prior to enrollment
18,R6,Has_qualifier Arg1:T12 Arg2:T11
19,R7,Has_negation Arg1:T12 Arg2:T10
20,R8,Has_temporal Arg1:T12 Arg2:T13
21,T14,Drug 1006 1021	benzodiazepines
22,T15,Drug 1026 1029	THC
23,T16,Drug 994 1004	stimulants
24,*,OR T15 T14 T16
25,T17,"Non-representable 774 1103	Patients must be either medication treatment naïve for behavioral illnesses or have no active medication treatments for at least 1 month prior to enrollment. Prohibited medications at the time of enrollment will include stimulants, benzodiazepines and THC. Prior therapy with these agents is permitted with a washout of >30 days."
26,T18,"Non-query-able 1105 1371	Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield. This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs."
0,T1,Person 9 13	aged
1,T2,Value 14 41	between 40 and 60 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 49 60	Child score
4,T4,Value 61 62	B
5,T5,Value 66 67	C
6,*,OR T4 T5
7,T6,Scope 61 67	B or C
8,R2,Has_scope Arg1:T3 Arg2:T6
9,T7,Qualifier 83 91	elective
10,T8,Procedure 92 118	gastrointestinal endoscopy
11,R3,Has_qualifier Arg1:T8 Arg2:T7
0,T1,Condition 0 4;10 30	Type II diabetes mellitus
1,T2,Condition 0 6;13 30	Type I diabetes mellitus
2,*,OR T2 T1
3,T3,Measurement 33 50	Target ulcer area
4,T4,Value 51 73	between 0.5 and 5 sqcm
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Temporal 79 100	more than 4 weeks old
7,R2,Has_temporal Arg1:T3 Arg2:T5
8,T6,Measurement 103 132	Ankle-brachial pressure index
9,T7,Value 133 142	above 0.7
10,R3,Has_value Arg1:T6 Arg2:T7
0,T1,Measurement 0 3	BMI
1,T2,Value 4 15	> 30 kg.m-2
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 18 36	ASA physical state
4,T4,Value 37 40	>II
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 42 49	Allergy
7,T6,Drug 62 79	local anesthetics
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Condition 81 90	Infection
10,T8,Qualifier 98 112	injection site
11,R4,Has_qualifier Arg1:T7 Arg2:T8
12,T9,Person 114 117	age
13,T10,Value 118 122	<18y
14,R5,Has_value Arg1:T9 Arg2:T10
0,T1,Procedure 20 29	surgeries
1,T2,Qualifier 37 47	upper limb
2,T3,Qualifier 49 52	arm
3,T4,Qualifier 54 61	forearm
4,T5,Qualifier 65 69	hand
5,*,OR T5 T4 T3
6,T6,"Scope 49 69	arm, forearm or hand"
7,R1,Subsumes Arg1:T2 Arg2:T6
8,R2,Has_qualifier Arg1:T1 Arg2:T2
0,T1,Person 9 13	aged
1,T2,Value 14 31	7 years and older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Post-eligibility 32 135	must have provided written assent accompanied by written informed consent from patient's representative
4,T4,Condition 166 182	plaque psoriasis
5,T5,Qualifier 159 165	stable
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Measurement 209 226	body surface area
8,T7,Negation 228 237	excluding
9,T8,Condition 238 242	face
10,T9,Condition 247 252	scalp
11,T10,Value 203 208	= 10%
12,R3,Has_value Arg1:T6 Arg2:T10
13,R4,AND Arg1:T4 Arg2:T6
14,*,OR T8 T9
15,T11,Grammar_Error 243 246	and
16,T12,Scope 238 252	face and scalp
17,R5,Has_negation Arg1:T12 Arg2:T7
18,R6,Has_scope Arg1:T4 Arg2:T12
19,T13,Measurement 255 289	Physicians Global Assessment score
20,T14,Value 293 294	3
21,T15,Value 298 299	4
22,*,OR T14 T15
23,T16,Temporal 300 311	at baseline
24,T17,Scope 293 299	3 or 4
25,R7,Has_scope Arg1:T13 Arg2:T17
26,R8,Has_temporal Arg1:T13 Arg2:T16
0,T1,Condition 24 35	hematemesis
1,T2,Condition 0 18	Emergent condition
2,R1,Subsumes Arg1:T2 Arg2:T1
3,T3,Qualifier 64 70	severe
4,T4,Qualifier 52 60	moderate
5,*,OR T4 T3
6,T5,Condition 71 93	hepatic encephalopathy
7,T6,Scope 52 70	moderate to severe
8,R2,Has_scope Arg1:T5 Arg2:T6
9,T7,Condition 110 134	hepatopulmonary syndrome
10,T8,Condition 170 186	hypersensitivity
11,T9,Mood 160 169	suspected
12,T10,Mood 151 156	known
13,*,OR T9 T10
14,T11,Scope 151 169	known or suspected
15,R3,Has_scope Arg1:T8 Arg2:T11
16,T12,Drug 194 209	used medication
17,R4,AND Arg1:T8 Arg2:T12
0,T1,Condition 0 14	Coagulopathies
1,T2,Measurement 21 46	prothrombin concentration
2,T3,Value 47 60	less than 60%
3,T4,Value 68 81	more than 1.5
4,R1,Has_value Arg1:T2 Arg2:T3
5,T5,Measurement 64 67	INR
6,R2,Has_value Arg1:T5 Arg2:T4
7,*,OR T2 T5
8,T6,Scope 21 81	prothrombin concentration less than 60% or INR more than 1.5
9,R3,Has_scope Arg1:T1 Arg2:T6
10,T7,Drug 107 135	anti-coagulation medications
11,T8,Mood 84 106	In-ability to postpone
12,R4,Has_mood Arg1:T7 Arg2:T8
13,T9,Condition 138 147	Infection
14,T10,Condition 151 157	injury
15,T11,Condition 163 169	lesion
16,T12,Qualifier 170 187	at the block site
17,*,OR T11 T10 T9
18,T13,Scope 138 169	Infection or injury or a lesion
19,R5,Has_qualifier Arg1:T13 Arg2:T12
20,T14,Condition 200 232	cervical vertebral column injury
21,T15,Mood 190 199	Suspected
22,R6,Has_mood Arg1:T14 Arg2:T15
23,T16,Condition 271 287	compromised lung
24,T17,Qualifier 295 326	contralateral side of the block
25,R7,Has_qualifier Arg1:T16 Arg2:T17
26,T18,Condition 328 340	Pneumothorax
27,T19,Condition 342 352	hemothorax
28,T20,Condition 356 369	Pneumonectomy
29,*,OR T18 T19 T20
30,T21,"Scope 328 369	Pneumothorax, hemothorax or Pneumonectomy"
31,R8,Subsumes Arg1:T16 Arg2:T21
32,T22,Condition 373 400	Traumatic vascular injuries
33,T23,Procedure 404 427	operative interventions
34,*,OR T22 T23
35,T24,Procedure 429 448	Surgical harvesting
36,R9,Subsumes Arg1:T23 Arg2:T24
37,T25,Qualifier 460 508	arteries of the upper limb on the operative side
38,T26,Scope 373 449	Traumatic vascular injuries or operative interventions (Surgical harvesting)
39,R10,Has_qualifier Arg1:T26 Arg2:T25
40,T27,Condition 525 551	communication difficulties
41,T28,Condition 554 570	Hypersensitivity
42,T29,Drug 574 591	local anesthetics
43,T30,Drug 599 612	Dexamethasone
44,*,OR T29 T30
45,T31,Scope 574 612	local anesthetics and/or Dexamethasone
46,R11,Has_scope Arg1:T28 Arg2:T31
47,T32,Temporal 627 640	perioperative
48,T33,Drug 641 666	intravenous (IV) steroids
49,R12,Has_temporal Arg1:T33 Arg2:T32
0,T1,Person 0 5	Adult
1,T2,Mood 15 24	scheduled
2,T3,Procedure 29 70	arthroscopic knee ligament reconstruction
3,R1,Has_mood Arg1:T3 Arg2:T2
0,T1,Condition 0 6	Ulcers
1,T2,Qualifier 14 26	non-diabetic
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 38 59	Uncontrolled diabetes
4,T4,Measurement 71 76	HbA1c
5,T5,Value 77 94	above 70 mmol/mol
6,T6,Condition 99 130	insufficient nutritional status
7,R2,Has_value Arg1:T4 Arg2:T5
8,T7,Scope 71 130	HbA1c above 70 mmol/mol and insufficient nutritional status
9,R3,Subsumes Arg1:T3 Arg2:T7
10,T8,Condition 133 139	Ulcers
11,T9,Temporal 140 157	older than 1 year
12,R4,Has_temporal Arg1:T8 Arg2:T9
13,T10,Condition 167 175	gangrene
14,T11,Multiplier 160 166	Any of
15,T12,Condition 177 190	osteomyelitis
16,T13,Condition 192 202	cellulitis
17,T14,Condition 207 231	Charcot osteoarthropathy
18,*,OR T14 T13 T12 T10
19,T15,"Scope 167 231	gangrene, osteomyelitis, cellulitis, or Charcot osteoarthropathy"
20,R5,Has_multiplier Arg1:T15 Arg2:T11
0,T1,Subjective_judgement 0 80	Has other dermatological conditions that may interfere with clinical assessments
1,T2,Qualifier 108 123	corticosteroids
2,T3,Condition 131 152	drug hypersensitivity
3,T4,Condition 131 135;156 167	drug intolerance
4,T5,Condition 82 89	Allergy
5,T6,Condition 93 104	sensitivity
6,T7,Subjective_judgement 169 221	hat would compromise patient safety or study results
7,*,OR T3 T4
8,T8,Drug 108 123	corticosteroids
9,R1,multi Arg1:T2 Arg2:T8
10,T9,Scope 82 104	Allergy or sensitivity
11,R2,Has_qualifier Arg1:T9 Arg2:T2
12,T10,Scope 131 167	drug hypersensitivity or intolerance
13,*,OR T9 T10
14,T11,Condition 237 253	adverse reaction
15,T12,Qualifier 257 266	Cortrosyn
16,T13,Drug 257 266	Cortrosyn
17,T14,Procedure 279 292	test reagents
18,T15,Qualifier 271 278	similar
19,R3,Has_qualifier Arg1:T14 Arg2:T15
20,T16,Qualifier 271 292	similar test reagents
21,*,OR T12 T16
22,T17,Scope 257 292	Cortrosyn™ or similar test reagents
23,R4,Has_scope Arg1:T11 Arg2:T17
24,T18,"Subjective_judgement 294 435	Chronic infectious disease, system or organ disorder or other medical condition that would place patient at undue risk by study participation"
0,T1,Non-query-able 0 87	implanted hardware or other material that would prohibit treatment planning or delivery
1,T2,Procedure 89 101	chemotherapy
2,T3,Condition 108 118	malignancy
3,T4,Temporal 119 146	within the previous 5 years
4,R1,AND Arg1:T2 Arg2:T3
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,T5,Condition 162 181	invasive malignancy
7,T6,Negation 183 193	other than
8,T7,Condition 199 214	prostate cancer
9,T8,Condition 227 248	squamous skin cancers
10,T9,Condition 218 223;236 248	basal skin cancers
11,*,OR T8 T9 T7
12,T10,"Scope 199 248	prostate cancer,or basal or squamous skin cancers"
13,R3,Has_negation Arg1:T10 Arg2:T6
14,T11,Temporal 250 270	within prior 5 years
15,T12,"Scope 162 248	invasive malignancy (other than this prostate cancer,or basal or squamous skin cancers"
16,R4,Has_temporal Arg1:T12 Arg2:T11
17,T13,Procedure 272 288	hormone ablation
18,T14,Temporal 289 320	for 2 months prior to treatment
19,T15,Reference_point 311 320	treatment
20,R5,Has_index Arg1:T14 Arg2:T15
21,T16,Temporal 324 340	during treatment
22,T17,Reference_point 331 340	treatment
23,R6,Has_index Arg1:T16 Arg2:T17
24,*,OR T14 T16
25,T18,Scope 289 340	for 2 months prior to treatment or during treatment
26,R7,Has_scope Arg1:T13 Arg2:T18
0,T1,Condition 22 45	prostate adenocarcinoma
1,T2,Qualifier 0 21	histologically proven
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Temporal 46 73	within 1 year of enrollment
4,T4,Reference_point 63 73	enrollment
5,R2,Has_index Arg1:T3 Arg2:T4
6,R3,Has_temporal Arg1:T1 Arg2:T3
7,T5,Measurement 85 92	Gleason
8,T6,Observation 75 83	Low risk
9,T7,Value 93 98	<or=6
10,T8,Measurement 101 104	PSA
11,T9,Value 105 111	<or=10
12,T10,Measurement 114 128	Clinical Stage
13,T12,Value 129 136	T1b-T2a
14,T13,Value 147 149	Mx
15,T14,Value 153 155	M0
16,*,OR T13 T14
17,T11,Value 137 139	Nx
18,T15,Value 143 145	N0
19,*,OR T11 T15
20,T16,"Scope 129 155	T1b-T2a,Nx or N0, Mx or M0"
21,R4,Has_scope Arg1:T10 Arg2:T16
22,R5,Has_value Arg1:T8 Arg2:T9
23,R6,Has_value Arg1:T5 Arg2:T7
24,T17,"Scope 85 155	Gleason <or=6 & PSA <or=10 & Clinical Stage T1b-T2a,Nx or N0, Mx or M0"
25,R7,Subsumes Arg1:T6 Arg2:T17
26,T18,Observation 157 174	Intermediate risk
27,T19,Measurement 175 182	Gleason
28,T20,Value 183 188	<or=6
29,T21,Measurement 191 194	PSA
30,T22,Value 194 200	<or=10
31,T23,Measurement 203 217	Clinical Stage
32,T24,Value 218 221	T2b
33,T25,Measurement 225 232	Gleason
34,T26,Value 232 234	=7
35,T27,Measurement 237 240	PSA
36,T28,Value 240 246	<or=10
37,T29,Measurement 249 263	Clinical Stage
38,T30,Value 264 271	T1b-T2b
39,T31,Measurement 275 282	Gleason
40,T32,Value 283 288	<or=6
41,T33,Measurement 291 294	PSA
42,T34,Value 295 310	> 10 & < or =20
43,T35,Measurement 313 327	Clinical Stage
44,T36,Value 328 336	T1b- T2b
45,T37,Value 338 340	Nx
46,T38,Value 344 346	NO
47,T39,Value 348 350	Mx
48,T40,Value 354 356	M0
49,*,OR T37 T38
50,*,OR T39 T40
51,T41,"Scope 328 356	T1b- T2b, Nx or NO, Mx or M0"
52,R8,Has_scope Arg1:T35 Arg2:T41
53,R9,Has_value Arg1:T33 Arg2:T34
54,R10,Has_value Arg1:T31 Arg2:T32
55,T42,"Scope 275 356	Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0"
56,R11,Has_value Arg1:T29 Arg2:T30
57,R12,Has_value Arg1:T27 Arg2:T28
58,R13,Has_value Arg1:T25 Arg2:T26
59,R14,Has_value Arg1:T23 Arg2:T24
60,R15,Has_value Arg1:T21 Arg2:T22
61,R16,Has_value Arg1:T19 Arg2:T20
62,T43,Scope 175 221	Gleason <or=6 & PSA<or=10 & Clinical Stage T2b
63,T44,Scope 225 271	Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b
64,*,OR T43 T44 T42
65,T45,"Scope 175 356	Gleason <or=6 & PSA<or=10 & Clinical Stage T2b OR Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b OR Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0"
66,R17,Subsumes Arg1:T18 Arg2:T45
67,T46,Measurement 358 381	ECOG Performance Status
68,T47,Value 382 385	0-1
69,R18,Has_value Arg1:T46 Arg2:T47
70,T48,Procedure 396 414	prostate radiation
71,T49,Negation 387 389	No
72,T50,Procedure 424 442	definitive therapy
73,*,OR T48 T50
74,T51,Scope 396 442	prostate radiation or other definitive therapy
75,R19,Has_negation Arg1:T51 Arg2:T49
0,T1,Condition 15 35	cutaneous vasculitis
1,T2,Condition 37 46	urticaria
2,T3,Condition 48 57	psoriasis
3,T4,Condition 59 63	acne
4,T5,Condition 65 86	bullous skin diseases
5,T6,Condition 88 106	sterile pustulosis
6,T7,Condition 108 115	leprosy
7,T8,Condition 117 139	pneumocystis pneumonia
8,T9,Drug 172 179	dapsone
9,*,OR T1 T2 T3 T4 T5 T6 T7 T8 T9
10,T10,Drug 210 217	dapsone
11,T11,Negation 218 223	naive
12,R1,Has_negation Arg1:T10 Arg2:T11
13,T12,Non-query-able 226 346	All subjects must have a clinical need for treatment with dapsone that precedes the decision to participate in the study
14,T13,Post-eligibility 349 419	All subjects are willing to complete the 6-weeks period clinical trial
15,T14,Informed_consent 422 463	All subjects are written informed consent
0,T1,Observation 0 14;43 53	osteoarticular limitation
1,T2,Observation 16 29;43 53	neuromuscular limitation
2,T3,Observation 33 53	cognitive limitation
3,*,OR T3 T2 T1
4,T4,Negation 59 67	prevents
5,T5,Observation 68 78	ambulation
6,R1,Has_negation Arg1:T5 Arg2:T4
7,T6,Condition 109 127	neoplastic disease
8,T7,Person 129 146	institutionalized
9,T8,Observation 157 176	alcohol consumption
10,T9,Multiplier 177 186	>60 g/day
11,R2,Has_multiplier Arg1:T8 Arg2:T9
12,T10,Non-query-able 188 276	patient belonging to another health sector in the Community of Madrid or other community
13,T11,Competing_trial 278 331	participation in another study within 6 months prior.
0,T1,Condition 0 17	contra-indication
1,T2,Procedure 21 43	inhalational induction
2,T3,Qualifier 45 57	full stomach
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Condition 60 77	contra-indication
6,T5,Drug 92 102	rocuronium
7,R3,AND Arg1:T4 Arg2:T5
8,T6,Measurement 104 153	American Society of Anesthesiologists score (ASA)
9,T7,Value 154 157	III
10,T8,Value 161 163	IV
11,*,OR T7 T8
12,T9,Scope 154 163	III or IV
13,R4,Has_scope Arg1:T6 Arg2:T9
14,T10,Procedure 165 185	intracranial surgery
15,T11,Informed_consent 187 203	parental refusal
16,T12,Observation 216 246	affiliation to social security
17,T13,Negation 205 212	absence
18,R5,Has_negation Arg1:T12 Arg2:T13
0,T1,Condition 12 20	pregnant
1,T2,Post-eligibility 22 78	Subject is unable to perform tasks associated with study
0,T1,Drug 24 31	Dapsone
1,T2,Non-query-able 42 124	The subject or any of their healthcare providers is aware of the subjects HLA type
2,T3,Condition 151 195	Glucose-6-phosphate dehydrogenase deficiency
3,T4,Condition 199 233	methemoglobin reductase deficiency
4,*,OR T3 T4
5,T5,Condition 249 266	contraindications
6,T6,Drug 286 293	Dapsone
7,R1,AND Arg1:T5 Arg2:T6
8,T7,Condition 387 400	renal failure
9,T8,Condition 377 382;393 400	liver failure
10,T9,Condition 370 375;393 400	heart failure
11,*,OR T7 T9 T8 T10 T11
12,T10,Condition 402 423	major organ allograft
13,T11,Condition 425 435	malignancy
14,T12,Procedure 457 469	chemotherapy
15,R2,AND Arg1:T11 Arg2:T12
16,T13,"Non-query-able 647 866	Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject's participation in the study [alanine aminotransferase (ALT), glutamic oxaloacetic transaminase(ALT), et al)"
17,T14,Pregnancy_considerations 870 914	regnant women or women who are breastfeeding
18,T15,"Non-query-able 917 1049	Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required"
19,T16,Measurement 1074 1084	HLA-B*1301
20,T17,Value 1054 1062	positive
21,R3,Has_value Arg1:T16 Arg2:T17
0,T1,Person 23 28	years
1,T2,Value 9 22	older than 35
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 67 71	COPD
4,T4,Qualifier 43 51	moderate
5,T5,Qualifier 55 66	very severe
6,*,OR T4 T5
7,T6,Measurement 73 77	FEV1
8,T7,Value 78 92	<80% predicted
9,T8,"Measurement 112 129	GesEPOC criteria,"
10,T9,Temporal 142 159	at least 3 months
11,R2,Has_value Arg1:T6 Arg2:T7
12,R3,Has_temporal Arg1:T3 Arg2:T9
13,T10,Scope 43 66	moderate to very severe
14,R4,Has_scope Arg1:T3 Arg2:T10
15,R5,AND Arg1:T8 Arg2:T3
16,R6,AND Arg1:T3 Arg2:T6
17,T11,Person 179 185	smoker
18,T12,Observation 206 217	consumption
19,T13,Multiplier 218 234	>10 packs x year
20,R7,Has_multiplier Arg1:T12 Arg2:T13
21,T14,Visit 245 254	admission
22,T15,Condition 259 276	COPD exacerbation
23,R8,AND Arg1:T14 Arg2:T15
0,T1,Value 12 29	at least 18 years
1,T2,Person 33 36	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 60 82	Pulmonary Hypertension
4,T4,Condition 87 112	Interstitial Lung Disease
5,T5,Mood 50 59	confirmed
6,R2,Has_mood Arg1:T3 Arg2:T5
7,R3,Has_mood Arg1:T4 Arg2:T5
8,T6,Procedure 185 208	Pulmonary Exercise test
9,T7,Procedure 169 179	spirometry
10,T8,Procedure 143 159	study procedures
11,T9,Undefined_semantics 143 159	study procedures
12,T10,"Scope 169 208	spirometry, and Pulmonary Exercise test"
13,R4,Subsumes Arg1:T8 Arg2:T10
0,T1,Person 0 3	age
1,T2,Value 4 12	<2 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 28 46	general anesthesia
4,T4,Procedure 52 71	tracheal intubation
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Mood 14 24	indication
7,R3,Has_mood Arg1:T3 Arg2:T5
8,T6,Procedure 73 95	inhalational induction
9,T7,Mood 96 105	scheduled
10,R4,Has_mood Arg1:T6 Arg2:T7
11,T8,Informed_consent 107 147	written informed consent of both parents
0,T1,Qualifier 14 20	active
1,T2,Condition 21 33	GIT bleeding
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 61 78	bowel obstruction
4,T4,Condition 61 66;80 91	bowel perforation
5,T5,Observation 50 57	history
6,*,OR T4 T3
7,T6,"Scope 61 91	bowel obstruction, perforation"
8,R2,Has_temporal Arg1:T6 Arg2:T5
9,T7,Observation 108 115	history
10,T8,Condition 119 126	allergy
11,T9,Drug 130 133	PEG
12,R3,AND Arg1:T8 Arg2:T9
13,R4,Has_temporal Arg1:T8 Arg2:T7
14,T10,Drug 151 160	rifaximin
15,T11,Drug 164 172	neomycin
16,T12,Temporal 173 195	in the previous 7 days
17,*,OR T11 T10
18,T13,Scope 151 172	rifaximin or neomycin
19,R5,Has_temporal Arg1:T13 Arg2:T12
20,T14,Condition 212 237	major psychiatric illness
21,T15,Drug 259 274	benzodiazepines
22,T16,Drug 279 288	narcotics
23,*,OR T15 T16
24,T17,Condition 305 322	compromised renal
25,T18,Drug 344 387	medications highly bound to plasma proteins
26,T19,Drug 392 400	Warfarin
27,R6,Subsumes Arg1:T18 Arg2:T19
28,T20,Condition 403 411	Pregnant
29,T21,Condition 415 424	lactating
30,T22,Person 425 430	women
31,*,OR T21 T20
32,T23,Condition 443 458	hepatic failure
33,T24,Qualifier 433 442	Fulminant
34,R7,Has_qualifier Arg1:T23 Arg2:T24
0,T1,Person 0 5	Adult
1,T2,Condition 20 48	Overt Hepatic Encephalopathy
0,T1,Person 0 6	Female
1,T2,Condition 25 34	pregnancy
2,T3,Qualifier 38 54	unknown location
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 59 68	pregnancy
5,T5,Qualifier 72 88	unknown location
6,T6,Condition 105 114	pregnancy
7,T7,Person 120 125	woman
8,T8,Measurement 142 156	pregnancy test
9,T9,Value 133 141	positive
10,R2,Has_value Arg1:T8 Arg2:T9
11,R3,Has_qualifier Arg1:T4 Arg2:T5
12,T10,Not_a_criteria 57 240	A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging.
13,T11,Parsing_Error 241 402	A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa.
14,T12,Parsing_Error 54 55	:
15,T13,Procedure 403 413	Ultrasound
16,T14,Not_a_criteria 241 402	A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa.
17,T15,Temporal 432 468	within 7 days prior to randomization
18,T16,Reference_point 455 468	randomization
19,R4,Has_index Arg1:T15 Arg2:T16
20,R5,Has_temporal Arg1:T13 Arg2:T15
21,T17,Condition 471 489	Persistence of hCG
22,T18,Measurement 522 525	hCG
23,T19,Multiplier 504 514	at least 2
24,T20,Temporal 534 548	over 2-14 days
25,T21,Value 559 577	< 15% rise per day
26,R6,Has_value Arg1:T18 Arg2:T21
27,R7,Has_temporal Arg1:T18 Arg2:T20
28,T22,Value 582 626	< 50% fall between the first and last value.
29,*,OR T21 T22
30,T23,Condition 639 661	hemodynamically stable
31,T24,Measurement 663 673	hemoglobin
32,T25,Value 674 683	>10 mg/dL
33,R8,Has_value Arg1:T24 Arg2:T25
34,T26,Value 685 709	Greater than or 18 years
35,T27,Person 713 716	age
36,R9,Has_value Arg1:T27 Arg2:T26
0,T1,Measurement 0 4	AJCC
1,T2,Value 5 25	Stage III or greater
2,T3,Condition 59 83	Medullary Thyroid Cancer
3,T4,Condition 45 55;69 83	Anaplastic Thyroid Cancer
4,*,OR T3 T4 T5
5,T5,Condition 27 43;69 83	Undifferentiated Thyroid Cancer
6,T6,Measurement 107 110	TSH
7,T7,Qualifier 93 106	postoperative
8,R1,Has_qualifier Arg1:T6 Arg2:T7
9,T8,Value 127 139	0.1-0.5 mU/L
10,T9,Negation 116 126	other than
11,R2,Has_negation Arg1:T8 Arg2:T9
12,R3,Has_value Arg1:T6 Arg2:T8
13,T10,Condition 152 182	gastrointestinal malabsorption
14,T11,Procedure 186 208	gastric bypass surgery
15,*,OR T10 T11
16,T12,Pregnancy_considerations 210 219	Pregnancy
17,T13,Drug 228 239	medications
18,T14,Observation 269 296	metabolism of levothyroxine
19,T15,Drug 283 296	levothyroxine
20,T16,Drug 311 324	levothyroxine
21,T17,Temporal 298 303	Prior
22,R4,Has_temporal Arg1:T16 Arg2:T17
23,T18,Observation 255 265;280 296	absorption of levothyroxine
24,*,OR T14 T18
25,R5,multi Arg1:T14 Arg2:T15
26,R6,multi Arg1:T18 Arg2:T15
27,T19,Scope 255 296	absorption or metabolism of levothyroxine
28,T20,Negation 245 250	alter
29,R7,Has_negation Arg1:T19 Arg2:T20
30,R8,Has_scope Arg1:T13 Arg2:T19
0,T1,Person 0 5	Women
1,T2,Observation 14 22	pregnant
2,T3,Observation 26 39	breastfeeding
3,*,OR T2 T3
4,T4,Mood 41 46	Known
5,T5,Mood 50 59	suspected
6,*,OR T4 T5
7,T6,Condition 85 105	coagulation disorder
8,T7,Condition 73 81;97 105	bleeding disorder
9,T8,Condition 61 69;97 105	acquired disorder
10,T9,Person 106 120	in the subject
11,T10,Person 126 147	first degree relative
12,*,OR T9 T10
13,T11,Scope 106 147	in the subject or a first degree relative
14,*,OR T7 T8 T6
15,T12,Scope 61 105	acquired or bleeding or coagulation disorder
16,T13,Scope 41 59	Known or suspected
17,R1,Has_scope Arg1:T12 Arg2:T13
18,R2,Has_scope Arg1:T12 Arg2:T11
19,T14,Qualifier 149 155	Active
20,T15,Condition 156 164	bleeding
21,T16,Mood 168 184	at high risk for
22,T17,Condition 185 193	bleeding
23,R3,Has_mood Arg1:T17 Arg2:T16
24,*,OR T15 T17
25,R4,Has_qualifier Arg1:T15 Arg2:T14
26,T18,Procedure 236 243	surgery
27,T19,Condition 247 253	trauma
28,*,OR T18 T19
29,T20,Scope 236 253	surgery or trauma
30,T21,Qualifier 230 235	major
31,T22,Qualifier 211 225	ophthalmologic
32,T23,Qualifier 203 209	spinal
33,T24,Qualifier 196 201	Brain
34,*,OR T21 T22 T23 T24
35,T25,"Scope 196 235	Brain, spinal, ophthalmologic, or major"
36,T26,Temporal 254 277	within the past 90 days
37,T27,Procedure 293 306;311 318	elective knee surgery
38,T28,Procedure 293 301;307 318	elective hip surgery
39,*,OR T28 T27
40,T29,Negation 278 288	other than
41,T30,Scope 293 318	elective knee/hip surgery
42,R5,Has_negation Arg1:T30 Arg2:T29
43,R6,Has_temporal Arg1:T20 Arg2:T26
44,R7,Has_scope Arg1:T20 Arg2:T25
45,R8,Has_scope Arg1:T20 Arg2:T30
46,T31,Qualifier 320 326	Active
47,T32,Condition 327 348	hepatobiliary disease
48,R9,Has_qualifier Arg1:T32 Arg2:T31
49,T33,Measurement 350 360	Hemoglobin
50,T34,Value 361 368	<9 g/dL
51,R10,Has_value Arg1:T33 Arg2:T34
52,T35,Measurement 370 384	Platelet count
53,T36,"Value 385 397	<100,000/mm3"
54,R11,Has_value Arg1:T35 Arg2:T36
55,T37,Measurement 399 419	Creatinine clearance
56,T38,Value 420 430	<30 mL/min
57,R12,Has_value Arg1:T37 Arg2:T38
0,T1,Condition 9 32	hemodynamic instability
1,T2,Measurement 39 62	systolic blood pressure
2,T3,Value 63 77	<100 mm Hg.St.
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 92 120	systolic blood pressure fall
5,T5,Value 125 134	=40 mm Hg
6,R2,Has_value Arg1:T4 Arg2:T5
7,*,OR T2 T4 T6
8,T6,Measurement 141 151	heart rate
9,T7,Value 152 157	> 110
10,R3,Has_value Arg1:T6 Arg2:T7
11,T8,Multiplier 158 182	lasting more than 15 min
12,R4,Has_multiplier Arg1:T6 Arg2:T8
13,T9,Procedure 196 215	ventilatory support
14,T10,Mood 187 195	need for
15,R5,Has_mood Arg1:T9 Arg2:T10
16,T11,Temporal 216 254	within 12 hours prior to randomisation
17,R6,Has_temporal Arg1:T9 Arg2:T11
18,T12,Scope 39 182	systolic blood pressure <100 mm Hg.St. or episode of systolic blood pressure fall for =40 mm Hg. / or heart rate > 110 lasting more than 15 min
19,R7,Subsumes Arg1:T1 Arg2:T12
20,*,OR T1 T9
21,T13,Procedure 276 296	oral anticoagulation
22,T14,Mood 261 275	indication for
23,R8,Has_mood Arg1:T13 Arg2:T14
24,T15,Qualifier 331 340	malignant
25,T16,Condition 341 349	neoplasm
26,R9,Has_qualifier Arg1:T16 Arg2:T15
27,T17,Condition 367 384	Contraindications
28,T18,Drug 388 396	warfarin
29,T19,Drug 400 407	pradaxa
30,*,OR T19 T18
31,T20,Scope 388 407	warfarin or pradaxa
32,R10,Has_scope Arg1:T17 Arg2:T20
33,T21,Qualifier 421 457	Russian Instructions for medical use
34,R11,Has_qualifier Arg1:T17 Arg2:T21
35,T22,Drug 517 536	antiplatelet agents
36,T23,Temporal 490 501	concomitant
37,T24,Mood 474 485	Indications
38,R12,Has_mood Arg1:T22 Arg2:T24
39,R13,Has_temporal Arg1:T22 Arg2:T23
40,T25,Condition 542 548	stroke
41,T26,Temporal 549 585	within 6 months before randomization
42,R14,Has_temporal Arg1:T25 Arg2:T26
43,T27,Condition 587 610	Intracranial hemorrhage
44,T28,Procedure 614 623	anamnesis
45,R15,AND Arg1:T28 Arg2:T27
46,T29,Condition 632 640	bleeding
47,T30,Condition 642 660	bleeding diathesis
48,*,OR T30 T29
49,T31,Qualifier 663 685	Clinically significant
50,T32,Condition 686 694	bleeding
51,T33,Temporal 695 718	within the last 30 days
52,R16,Has_qualifier Arg1:T32 Arg2:T31
53,R17,Has_temporal Arg1:T32 Arg2:T33
54,T34,Condition 721 727	Trauma
55,T35,Procedure 731 748	extensive surgery
56,T36,Temporal 749 784	within 1 month before randomization
57,*,OR T34 T35
58,T37,Scope 721 748	Trauma or extensive surgery
59,R18,Has_temporal Arg1:T37 Arg2:T36
60,T38,Procedure 788 795	surgery
61,T39,Mood 796 803	planned
62,T40,Temporal 804 844	in the next 6 months after randomization
63,R19,Has_temporal Arg1:T38 Arg2:T40
64,R20,Has_mood Arg1:T38 Arg2:T39
65,*,OR T37 T38
66,T41,Condition 847 869	Intracranial pathology
67,T42,Condition 871 876	tumor
68,T43,Condition 878 899	arteriovenous fistula
69,T44,Condition 903 911	aneurysm
70,*,OR T43 T44 T42
71,T45,"Scope 871 911	tumor, arteriovenous fistula or aneurysm"
72,R21,Subsumes Arg1:T41 Arg2:T45
73,T46,Condition 914 939	Gastrointestinal bleeding
74,T47,Temporal 940 964	in the previous 3 months
75,R22,Has_temporal Arg1:T46 Arg2:T47
76,T48,Condition 967 980	Gastric ulcer
77,T49,Condition 984 998	duodenal ulcer
78,T50,Condition 1004 1027	clinical manifestations
79,R23,AND Arg1:T49 Arg2:T50
80,*,OR T48 T49 T53
81,T51,Qualifier 1031 1056	endoscopically identified
82,T52,Procedure 1031 1045	endoscopically
83,T53,Condition 1057 1068	acute ulcer
84,T54,Negation 1069 1076	without
85,T55,Condition 1077 1094	signs of scarring
86,T56,Temporal 1095 1118	during previous 30 days
87,R24,Has_negation Arg1:T55 Arg2:T54
88,R25,Has_qualifier Arg1:T53 Arg2:T51
89,R26,multi Arg1:T51 Arg2:T52
90,R27,AND Arg1:T53 Arg2:T55
91,R28,Has_temporal Arg1:T53 Arg2:T56
92,T57,Qualifier 1121 1133	Uncontrolled
93,T58,Condition 1134 1146	hypertension
94,T59,Measurement 1148 1171	systolic blood pressure
95,T60,Value 1171 1182	> 180 mm Hg
96,R29,Has_value Arg1:T59 Arg2:T60
97,T61,Measurement 1193 1217	diastolic blood pressure
98,T62,Value 1217 1228	> 100 mm.hg
99,R30,Has_value Arg1:T61 Arg2:T62
100,*,OR T59 T61
101,T63,Drug 1251 1273	antihypertensive drugs
102,T64,Scope 1148 1273	systolic blood pressure> 180 mm Hg. and / or diastolic blood pressure> 100 mm.hg in patients receiving antihypertensive drugs
103,R31,Has_qualifier Arg1:T58 Arg2:T57
104,R32,Subsumes Arg1:T58 Arg2:T64
105,T65,Condition 1277 1286	Pregnancy
106,T66,Condition 1288 1297	lactation
107,T67,Observation 1300 1315	Life expectancy
108,T68,Value 1316 1325	<6 months
109,R33,Has_value Arg1:T67 Arg2:T68
110,T69,Qualifier 1328 1350	Clinically significant
111,T70,Condition 1351 1364	liver disease
112,R34,Has_qualifier Arg1:T70 Arg2:T69
113,T71,Measurement 1367 1387	Creatinine clearance
114,T72,Qualifier 1402 1417	Cockcroft-Gault
115,R35,Has_qualifier Arg1:T71 Arg2:T72
116,T73,Value 1419 1431	<30 ml / min
117,R36,Has_value Arg1:T71 Arg2:T73
118,T74,Measurement 1434 1450	hemoglobin level
119,T75,Value 1451 1458	<90 g/l
120,R37,Has_value Arg1:T74 Arg2:T75
121,T76,Condition 1461 1477	thrombocytopenia
122,T77,Value 1478 1491	<100x10^9 / L
123,R38,Has_value Arg1:T76 Arg2:T77
124,T78,"Non-query-able 1494 1664	Patients who, in the opinion of the researcher, are not suitable for inclusion in the study, for example, due to the low likelihood of doctor's recommendations following."
125,T79,Drug 1683 1689	NSAIDs
126,T80,Multiplier 1666 1679	Long-term use
127,R39,Has_multiplier Arg1:T79 Arg2:T80
128,T81,Non-query-able 1691 1739	Current participation in another clinical study.
129,T82,Condition 1741 1749	Allergic
130,T83,Drug 1753 1771	contrast substance
131,T84,Drug 1775 1793	radioisotope drugs
132,*,OR T83 T84
133,T85,Scope 1753 1793	contrast substance or radioisotope drugs
134,R40,Has_scope Arg1:T82 Arg2:T85
135,T86,Qualifier 625 631	Active
136,R41,Has_qualifier Arg1:T29 Arg2:T86
0,T1,Post-eligibility 0 49	Willing and capable of providing informed consent
1,T2,Observation 58 68	indication
2,T3,Procedure 106 117;73 97	chamber ICD implantation of a single
3,T4,Procedure 101 117;73 90	dual chamber ICD implantation of a
4,T5,Procedure 121 133;73 90	CRT-D system implantation of a
5,*,OR T5 T3 T4
6,T6,Scope 73 133	implantation of a single or dual chamber ICD or CRT-D system
7,R1,Has_context Arg1:T6 Arg2:T2
8,T7,Observation 174 181	planned
9,T8,Procedure 188 245	implanted with the RELIANCE 4-FRONT Passive Fixation Lead
10,T9,Device 207 245	RELIANCE 4-FRONT Passive Fixation Lead
11,T10,Non-query-able 247 425	Willing and capable of participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol
12,T11,Person 427 430	Age
13,T12,Value 431 442	18 or above
14,T13,Value 447 459	of legal age
15,*,OR T13 T12
16,T14,"Scope 431 459	18 or above, or of legal age"
17,R2,Has_scope Arg1:T11 Arg2:T14
0,T1,Condition 0 24	Hemodynamically unstable
1,T2,Measurement 65 68	hCG
2,T3,Temporal 53 64	Most recent
3,T4,Value 69 82	> 5000 mIU/mL
4,R1,Has_value Arg1:T2 Arg2:T4
5,R2,Has_temporal Arg1:T2 Arg2:T3
6,T5,"Non-query-able 84 197	Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion)"
7,T6,Condition 212 245	gestational trophoblastic disease
8,T7,Non-query-able 247 306	Subject unwilling or unable to comply with study procedures
9,T8,Condition 314 337	hypersensitivity to MTX
10,T9,Drug 334 337	MTX
11,T10,Undefined_semantics 339 400	Presence of clinical contraindications for treatment with MTX
12,T11,Procedure 408 415;428 438	medical management
13,T12,Procedure 419 438	surgical management
14,*,OR T12 T11
15,T13,Condition 447 456	gestation
16,R3,AND Arg1:T11 Arg2:T13
17,R4,AND Arg1:T12 Arg2:T13
18,T14,Non-query-able 458 505	Subject unwilling to accept a blood transfusion
19,T15,Post-eligibility 458 505	Subject unwilling to accept a blood transfusion
0,T1,Person 0 3	Age
1,T2,Value 4 14	> 18 years
2,T3,Measurement 25 29;67 80	AJCC tumor Stage I
3,T4,Measurement 31 65	American Joint Committee on Cancer
4,R1,Subsumes Arg1:T3 Arg2:T4
5,T5,Value 79 80	I
6,T6,Value 84 86	II
7,*,OR T5 T6
8,T7,Scope 79 86	I or II
9,R2,Has_scope Arg1:T3 Arg2:T7
10,T8,Procedure 116 129	thyroidectomy
11,T9,Qualifier 96 101	total
12,T10,Qualifier 105 115	near-total
13,*,OR T9 T10
14,T11,Scope 96 115	total or near-total
15,R3,Has_scope Arg1:T8 Arg2:T11
16,T12,Temporal 177 210	at least 18 weeks postoperatively
17,T13,Reference_point 195 210	postoperatively
18,R4,Has_index Arg1:T12 Arg2:T13
19,T14,Condition 144 159	TSH suppression
20,T15,Value 160 172	0.1-0.5 mU/L
21,R5,Has_value Arg1:T14 Arg2:T15
22,R6,Has_temporal Arg1:T14 Arg2:T12
23,T16,Measurement 219 228	serum TSH
24,T17,Value 212 218	Normal
25,T18,Temporal 229 263	within 12 months preceding surgery
26,T19,Reference_point 256 263	surgery
27,R7,Has_index Arg1:T18 Arg2:T19
28,R8,Has_value Arg1:T16 Arg2:T17
29,R9,Has_temporal Arg1:T16 Arg2:T18
0,T1,Person 0 3	Men
1,T2,Person 8 13	women
2,*,OR T2 T1
3,T3,Person 14 18	aged
4,T4,Value 19 29	> 18 years
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Procedure 31 47	Angiographically
7,T6,Qualifier 31 57	Angiographically confirmed
8,R2,multi Arg1:T6 Arg2:T5
9,T7,Qualifier 58 63	acute
10,T8,Qualifier 64 71	massive
11,T9,Condition 72 90	pulmonary embolism
12,R3,Has_qualifier Arg1:T9 Arg2:T8
13,R4,Has_qualifier Arg1:T9 Arg2:T7
14,R5,Has_qualifier Arg1:T9 Arg2:T6
15,T10,Condition 96 137	involvement of Central pulmonary arteries
16,R6,AND Arg1:T9 Arg2:T10
17,T11,Condition 140 186	endovascular mechanical thrombus fragmentation
18,T12,Procedure 189 209	thrombolytic therapy
19,T13,Drug 217 260	recombinant tissue activator of plasminogen
20,T14,Temporal 329 371	in less than 48 hours before randomization
21,T15,Procedure 277 286	treatment
22,T16,Condition 310 328	pulmonary embolism
23,R7,AND Arg1:T15 Arg2:T16
24,R8,AND Arg1:T12 Arg2:T13
25,T17,Scope 140 261	endovascular mechanical thrombus fragmentation + thrombolytic therapy (using recombinant tissue activator of plasminogen)
26,R9,AND Arg1:T17 Arg2:T15
27,R10,Has_temporal Arg1:T15 Arg2:T14
28,T18,Post-eligibility 520 561	ritten informed consent signed by patient
29,T19,Non-representable 373 517	The patient should be randomized no earlier than 24 hours after procedures endovascular mechanical thrombus fragmentation + thrombolytic therapy
0,T1,Person 0 3	Age
1,T2,Value 4 13	=18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 35 43	elective
4,T4,Procedure 44 54;62 73	total knee replacement
5,T5,Procedure 44 49;58 73	total hip replacement
6,*,OR T4 T5
7,T6,Procedure 117 129;137 148;79 90	a total knee replacement revision of
8,T7,Qualifier 91 113	at least one component
9,T8,Procedure 117 118;133 148;79 90	a hip replacement revision of
10,*,OR T6 T8
11,T9,Scope 114 148;79 90	of a total knee or hip replacement revision of
12,R2,Has_qualifier Arg1:T9 Arg2:T7
13,T10,Scope 44 73	total knee or hip replacement
14,R3,Has_qualifier Arg1:T10 Arg2:T3
15,T11,Temporal 24 34	undergoing
16,R4,Has_temporal Arg1:T10 Arg2:T11
17,R5,Has_temporal Arg1:T9 Arg2:T11
0,T1,Condition 19 61	sensitivity to Dexamethasone Acetate (DXA)
1,T2,Drug 34 61	Dexamethasone Acetate (DXA)
2,T3,Observation 9 18	suspected
3,T4,Observation 0 5	Known
4,*,OR T3 T4
5,T5,Scope 0 18	Known or suspected
6,R1,Has_scope Arg1:T1 Arg2:T5
7,T6,Device 63 95	Mechanical tricuspid heart valve
8,T7,"Context_Error 97 364	Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following:"
9,T8,"Parsing_Error 97 364	Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following:"
10,T9,Context_Error 366 472	Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause additional or missed visits);
11,T10,Non-query-able 366 472	Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause additional or missed visits);
12,T11,Non-query-able 474 580	RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart rate of the subject);
13,T12,Context_Error 474 580	RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart rate of the subject);
14,T13,Non-query-able 582 748	Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations
15,T14,Context_Error 582 748	Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations
16,T15,Observation 767 795	active heart transplant list
17,T16,Observation 808 823	life expectancy
18,T17,Value 827 846	less than 12 months
19,R2,Has_value Arg1:T16 Arg2:T17
20,T18,Condition 857 879	childbearing potential
21,T19,Person 848 853	Women
22,T20,Observation 884 899	are or might be
23,T22,Condition 900 908	pregnant
24,T23,Temporal 909 940	at the time of study enrollment
25,R3,Has_temporal Arg1:T22 Arg2:T23
26,R4,Has_context Arg1:T22 Arg2:T20
27,T21,Scope 848 879	Women of childbearing potential
28,A1,Optional T21
29,R5,AND Arg1:T21 Arg2:T22
30,T24,Procedure 1011 1027	chronic dialysis
31,T25,Condition 1001 1027	requiring chronic dialysis
32,T26,Temporal 991 1000	Currently
33,R6,Has_temporal Arg1:T25 Arg2:T26
0,T1,Drug 22 46	anti-diabetic medication
1,T2,Temporal 0 8	Previous
2,T3,Procedure 9 16	treated
3,R1,AND Arg1:T3 Arg2:T1
4,R2,Has_temporal Arg1:T3 Arg2:T2
5,T4,Condition 48 56	Pregnant
6,T5,Condition 60 67	nursing
7,T6,Person 68 73	women
8,*,OR T5 T4
9,T7,Condition 76 99	Impaired liver function
10,T8,Measurement 101 104	ALT
11,T9,Value 105 114	> 120 U/L
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Scope 101 114	ALT > 120 U/L
14,R4,Subsumes Arg1:T7 Arg2:T10
15,T11,Condition 117 140	Impaired renal function
16,T12,Measurement 142 158	Serum creatinine
17,T13,Value 159 169	>1.5 mg/dL
18,T14,Person 173 177	male
19,T15,Person 193 199	female
20,T16,Value 179 189	>1.4 mg/dL
21,A1,Optional T14
22,A2,Optional T15
23,R5,Has_value Arg1:T14 Arg2:T13
24,R6,Has_value Arg1:T15 Arg2:T16
25,*,OR T14 T15
26,T17,"Scope 159 199	>1.5 mg/dL in male, >1.4 mg/dL in female"
27,R7,Has_scope Arg1:T12 Arg2:T17
28,R8,AND Arg1:T11 Arg2:T12
29,T18,Condition 226 228	MI
30,T19,Condition 232 235	CVA
31,T20,Temporal 203 211	Recently
32,*,OR T18 T19
33,T21,Scope 226 235	MI or CVA
34,R9,Has_temporal Arg1:T21 Arg2:T20
35,T22,Condition 251 277	acute intercurrent illness
36,T23,Measurement 280 302	2-hour C-peptide level
37,T24,Value 303 314	< 1.8 ng/mL
38,R10,Has_value Arg1:T23 Arg2:T24
0,T1,Visit 0 12	Hospitalised
1,T2,Person 13 21	children
2,T3,Person 22 26	aged
3,T4,Value 27 40	3-mo to 5-yrs
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Condition 110 119	pneumonia
6,T6,Qualifier 103 109	severe
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Measurement 134 145	temperature
9,T8,Value 146 159	>37.5 celsius
10,T9,Person 227 230	age
11,T10,Condition 240 250	tachypnoea
12,R3,Has_value Arg1:T7 Arg2:T8
13,T11,Measurement 252 268	respiratory rate
14,T12,Value 268 271	>50
15,T13,Value 275 285	<12-months
16,T14,Value 310 320	>12-months
17,T15,Measurement 287 303	respiratory rate
18,T16,Value 303 306	>40
19,R4,Has_value Arg1:T11 Arg2:T12
20,R5,Has_value Arg1:T15 Arg2:T16
21,T17,Person 227 230	age
22,R6,Has_value Arg1:T17 Arg2:T13
23,R7,Has_value Arg1:T9 Arg2:T14
24,*,OR T9 T17
25,R8,AND Arg1:T9 Arg2:T15
26,R9,AND Arg1:T17 Arg2:T11
27,R10,AND Arg1:T10 Arg2:T17
28,R11,AND Arg1:T10 Arg2:T9
29,T18,Condition 327 347	chest wall recession
30,T19,Measurement 355 372	oxygen saturation
31,T20,Value 373 384	<92% in air
32,R12,Has_value Arg1:T19 Arg2:T20
33,*,OR T18 T19
34,T21,Scope 327 384	chest wall recession and/or oxygen saturation <92% in air
35,R13,Has_scope Arg1:T10 Arg2:T21
36,T22,"Scope 134 384	temperature >37.5 celsius or a history of fever at home or observed at the referring clinic, age-adjusted tachypnoea [respiratory rate>50 if <12-months; respiratory rate>40 if >12-months] with chest wall recession and/or oxygen saturation <92% in air"
37,R14,Subsumes Arg1:T5 Arg2:T22
38,T23,Condition 391 404	consolidation
39,T24,Procedure 408 419	chest X-ray
40,R15,AND Arg1:T24 Arg2:T23
41,T25,"Non-query-able 456 644	After 1-3 days of IV antibiotics, are afebrile, with improved respiratory symptoms and signs, oxygen saturation>90% in air and are ready to be switched to oral amoxicillin-clavulanate, and"
42,T26,Condition 651 659	symptoms
43,T27,Temporal 663 712	no longer than 7 days at point of hospitalisation
44,T28,Reference_point 697 712	hospitalisation
45,R16,Has_index Arg1:T27 Arg2:T28
46,R17,Has_temporal Arg1:T26 Arg2:T27
0,T1,Condition 31 45	atrial flutter
1,T3,Condition 115 117	AF
2,T4,Drug 138 152	antiarrhythmic
3,T5,Drug 156 163	sotalol
4,T6,Qualifier 123 130	class I
5,T7,Qualifier 123 128;134 137	class III
6,*,OR T6 T7
7,T8,Scope 123 137	class I or III
8,T9,Non-query-able 164 322	with the intention to prevent an AF recurrence. Patients pretreated with above AAD at maximum 48 hours with the intention to convert an AF episode are allowed
9,*,OR T4 T5
10,T10,Scope 138 163	antiarrhythmic or sotalol
11,R1,Has_scope Arg1:T10 Arg2:T8
12,R2,Has_scope Arg1:T3 Arg2:T10
13,T2,Procedure 355 370	atrial ablation
14,T11,Qualifier 350 354	left
15,R3,Has_qualifier Arg1:T2 Arg2:T11
16,T12,Procedure 398 413	cardiac surgery
17,T13,Device 420 437	prosthetic valves
18,R4,Subsumes Arg1:T12 Arg2:T13
19,T14,Device 452 471	permanent pacemaker
20,T15,Device 475 496	defibrillator implant
21,*,OR T14 T15
22,T16,Condition 523 541	3° degree AV-block
23,T17,Condition 511 521;533 541	2° type II AV-block
24,T18,Condition 550 575	right bundle branch block
25,T19,Condition 545 549;556 575	left bundle branch block
26,*,OR T16 T17 T18 T19
27,T20,Condition 598 622	unstable angina pectoris
28,T21,Condition 657 678	myocardial infarction
29,T22,Procedure 682 707	percutaneous intervention
30,T23,Temporal 719 736	last three months
31,*,OR T21 T22
32,T24,Scope 657 707	myocardial infarction or percutaneous intervention
33,R5,Has_temporal Arg1:T24 Arg2:T23
34,T25,Condition 763 779	carotid stenosis
35,T26,Qualifier 751 762	symptomatic
36,R6,Has_qualifier Arg1:T25 Arg2:T26
37,T27,Condition 794 831	chronic obstructive pulmonary disease
38,T28,Condition 846 868	pulmonary hypertension
39,T29,Condition 906 918	lung disease
40,T30,Qualifier 894 905	significant
41,R7,Has_qualifier Arg1:T29 Arg2:T30
42,*,OR T28 T29
43,T31,Scope 846 918	pulmonary hypertension or any other evidence of significant lung disease
44,R8,Has_scope Arg1:T27 Arg2:T31
45,T32,Condition 937 953	contraindication
46,T33,Drug 958 978	oral anticoagulation
47,R9,AND Arg1:T32 Arg2:T33
48,T34,Condition 1017 1042	transient ischemic attack
49,T35,Condition 1046 1052	stroke
50,*,OR T34 T35
51,T36,Condition 1073 1095	intra-cardiac thrombus
52,T37,Condition 1136 1159	congenital heart defect
53,T38,Qualifier 1124 1135	significant
54,R10,Has_qualifier Arg1:T37 Arg2:T38
55,T39,Negation 1178 1184	except
56,T40,Condition 1189 1209	patent foramen ovale
57,R11,Has_negation Arg1:T40 Arg2:T39
58,T41,Condition 1253 1277	congestive heart failure
59,T42,Measurement 1279 1289	NYHA class
60,T43,Value 1290 1292	II
61,T44,Value 1294 1297	III
62,T45,Value 1301 1303	IV
63,*,OR T43 T44 T45
64,T46,Condition 1308 1320	sinus rhythm
65,T47,"Scope 1290 1303	II, III or IV"
66,R12,Has_scope Arg1:T42 Arg2:T47
67,R13,AND Arg1:T41 Arg2:T42
68,T48,Condition 1335 1362	hypertrophic cardiomyopathy
69,T49,Measurement 1400 1411	QT interval
70,T50,Qualifier 1377 1385	abnormal
71,T51,Value 1386 1390	long
72,T52,Value 1394 1399	short
73,T53,Condition 1422 1438	Brugada syndrome
74,T54,Condition 1446 1476	inheriting ion channel disease
75,T55,Observation 1446 1490	inheriting ion channel disease on the family
76,T56,Condition 1507 1534	right ventricular dysplasia
77,T57,Qualifier 1492 1506	arrhythmogenic
78,R14,Has_qualifier Arg1:T56 Arg2:T57
79,*,OR T51 T52
80,T58,Scope 1386 1399	long or short
81,R15,Has_qualifier Arg1:T58 Arg2:T50
82,R16,Has_scope Arg1:T49 Arg2:T58
83,*,OR T49 T53 T55 T56
84,T59,Condition 1549 1560	sarcoidosis
85,T60,Device 1575 1595	pulmonary vein stent
86,T61,Condition 1610 1616	myxoma
87,T62,Non-query-able 1618 1670	Exclusion criteria based on laboratory abnormalities
88,T63,Condition 1684 1698	thrombocytosis
89,T64,Measurement 1700 1714	platelet count
90,T65,"Value 1715 1729	> 600,000 / µl"
91,T66,Condition 1734 1750	thrombocytopenia
92,T67,Measurement 1752 1766	platelet count
93,T68,"Value 1767 1780	<100,000 / µl"
94,R17,Has_value Arg1:T64 Arg2:T65
95,R18,AND Arg1:T63 Arg2:T64
96,R19,AND Arg1:T66 Arg2:T67
97,R20,Has_value Arg1:T67 Arg2:T68
98,*,OR T63 T66
99,T69,Condition 1826 1841	hyperthyroidism
100,T70,Condition 1845 1859	hypothyroidism
101,T71,Qualifier 1800 1809	untreated
102,T72,Qualifier 1813 1825	uncontrolled
103,*,OR T71 T72
104,*,OR T69 T70
105,T73,Scope 1826 1859	hyperthyroidism or hypothyroidism
106,T74,Scope 1800 1825	untreated or uncontrolled
107,R21,Has_scope Arg1:T73 Arg2:T74
108,T75,Condition 1874 1891	renal dysfunction
109,T76,Measurement 1897 1923	glomerular filtration rate
110,T77,Value 1924 1937	< 60 ml / min
111,R22,AND Arg1:T75 Arg2:T76
112,R23,Has_value Arg1:T76 Arg2:T77
113,T78,Condition 1958 1975	cryoglobulinaemia
114,T79,Condition 2049 2064	hyperthyroidism
115,T80,Condition 2069 2079	alcoholism
116,*,OR T79 T80
117,T81,Pregnancy_considerations 2082 2396	Subject is a pregnant woman or woman of childbearing potential not on adequate birth control: only woman with a highly effective method of contraception [oral contraception or intra-uterine device] (who must have a negative pregnancy test within 1 week of the start of the therapy) or sterile woman can be enrolled
118,T82,Pregnancy_considerations 2399 2431	Subject is a breastfeeding woman
119,T83,Condition 2456 2474	systemic infection
120,T84,Qualifier 2449 2455	active
121,R24,Has_qualifier Arg1:T83 Arg2:T84
122,T85,Post-eligibility 2477 2609	Subject is employed by Medtronic or by the department of any of the investigators or is a close relative of any of the investigators
123,T86,"Post-eligibility 2612 2890	Subject is unwilling or unable to comply fully with study procedures and follow-up due to any disease condition, which can raise doubt about compliance and influencing the study outcome especially any kind of cancer, severe bleeding in history or a suspected pro-coagulant state"
124,T87,Post-eligibility 2894 3054	egal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up
125,T88,Observation 3071 3086	life expectancy
126,T89,Value 3090 3098	= 1 year
127,R25,Has_value Arg1:T88 Arg2:T89
128,T90,Competing_trial 3101 3365	Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager
0,T1,Procedure 0 16	Pacing threshold
1,T2,Qualifier 21 37	at 0.4 or 0.5 ms
2,T3,Condition 91 105	not measurable
3,T4,Procedure 46 63	sensing amplitude
4,T5,Procedure 74 83	impedance
5,R1,Has_qualifier Arg1:T1 Arg2:T2
6,*,OR T4 T5 T1
7,T6,Scope 0 83	Pacing threshold(s) (at 0.4 or 0.5 ms) and/or sensing amplitude(s) and/or impedance
8,R2,AND Arg1:T6 Arg2:T3
9,T7,Multiplier 112 123	one or more
10,T8,Condition 131 148	contraindications
11,T9,Procedure 153 156	MRI
12,T10,Condition 167 188	Psychiatric disorders
13,T11,Condition 190 197	anxiety
14,T12,Condition 199 213	claustrophobia
15,T13,Condition 214 231	Cardiac disorders
16,T14,Condition 249 265	contraindication
17,T15,Procedure 269 272	MRI
18,R3,AND Arg1:T14 Arg2:T15
19,R4,AND Arg1:T13 Arg2:T14
20,*,OR T13 T12 T11 T10
21,T16,"Scope 167 272	Psychiatric disorders, anxiety, claustrophobia Cardiac disorders that represent a contraindication to MRI"
22,R5,AND Arg1:T8 Arg2:T9
23,R6,Has_multiplier Arg1:T8 Arg2:T7
24,R7,Subsumes Arg1:T8 Arg2:T16
25,T17,Procedure 274 289	Cardiac surgery
26,T18,Mood 298 307	scheduled
27,T19,Temporal 308 332	in the next three months
28,R8,Has_mood Arg1:T17 Arg2:T18
29,R9,Has_temporal Arg1:T17 Arg2:T19
30,T20,Reference_point 320 332	three months
31,R10,Has_index Arg1:T19 Arg2:T20
32,T21,Device 345 361	medical implants
33,T22,Condition 371 388	interact with MRI
34,R11,AND Arg1:T21 Arg2:T22
35,T23,Device 395 455	abandoned implantable cardioverter defibrillator (ICD) leads
36,T24,Device 459 474	pacemaker leads
37,T25,Negation 475 485	other than
38,T26,Device 486 501	MRI conditional
39,T27,Device 503 518	lead extensions
40,T28,Device 526 548	active medical devices
41,T29,Qualifier 520 525	other
42,R12,Has_qualifier Arg1:T28 Arg2:T29
43,T30,Device 550 576	non-MRI compatible devices
44,T31,Device 578 594	mechanical valve
45,*,OR T24 T23 T27 T28 T30 T31
46,R13,Has_negation Arg1:T26 Arg2:T25
47,R14,AND Arg1:T24 Arg2:T26
48,T32,"Scope 395 594	abandoned implantable cardioverter defibrillator (ICD) leads or pacemaker leads other than MRI conditional, lead extensions, other active medical devices, non-MRI compatible devices, mechanical valve"
49,T33,Scope 345 388	medical implants that may interact with MRI
50,R15,Subsumes Arg1:T33 Arg2:T32
51,T34,Device 607 625	metallic artifacts
52,T35,Device 607 615;626 636	metallic components
53,T36,Condition 654 662	interact
54,T37,Procedure 668 671	MRI
55,R16,AND Arg1:T36 Arg2:T37
56,*,OR T35 T34
57,R17,AND Arg1:T35 Arg2:T36
58,R18,AND Arg1:T34 Arg2:T36
59,T38,Multiplier 693 699	single
60,T39,Multiplier 700 726	dose of 1.0 milligram (mg)
61,T40,Drug 727 748	dexamethasone acetate
62,T41,Condition 756 771	contraindicated
63,R19,AND Arg1:T41 Arg2:T40
64,R20,Has_multiplier Arg1:T40 Arg2:T39
65,R21,Has_multiplier Arg1:T40 Arg2:T38
66,T42,Non-query-able 773 847	Subjects who require a legally authorized representative to obtain consent
67,T43,Temporal 866 875	immediate
68,T44,Mood 876 890	candidates for
69,T45,Procedure 894 897	ICD
70,R22,Has_mood Arg1:T45 Arg2:T44
71,R23,Has_temporal Arg1:T45 Arg2:T43
72,T46,Condition 913 931	medical conditions
73,T47,Condition 937 945	preclude
74,T48,Procedure 950 981	testing required by the protoco
75,T49,Condition 986 1011	limit study participation
76,R24,AND Arg1:T47 Arg2:T48
77,*,OR T47 T49
78,T50,Scope 937 1011	preclude the testing required by the protocol or limit study participation
79,R25,Has_scope Arg1:T46 Arg2:T50
80,T51,"Non-query-able 1013 1274	Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study"
81,T52,Condition 1282 1290	pregnant
82,T53,Observation 1299 1314	life expectancy
83,T54,Value 1318 1340	less than three months
84,R26,Has_value Arg1:T53 Arg2:T54
85,T55,"Post-eligibility 1342 1422	Subjects with exclusion criteria required by local law (e.g. age, breastfeeding)"
0,T1,Measurement 0 21	Endometrial thickness
1,T2,Value 22 28	= 7 mm
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Temporal 29 46	after stimulation
4,T4,Procedure 35 46	stimulation
5,T5,Reference_point 35 46	stimulation
6,R2,multi Arg1:T5 Arg2:T4
7,R3,AND Arg1:T3 Arg2:T4
8,R4,Has_temporal Arg1:T1 Arg2:T3
9,T6,Value 48 53	18-45
10,T7,Person 54 59	years
11,R5,Has_value Arg1:T7 Arg2:T6
12,T8,Procedure 61 64;70 83	IVF fertilisation
13,T9,Procedure 65 83	ICSI fertilisation
14,*,OR T9 T8
15,T10,Measurement 85 88	BMI
16,T11,"Value 89 105	> 18,5 <30 kg/m2"
17,R6,Has_value Arg1:T10 Arg2:T11
18,T12,Measurement 107 119	cycle length
19,T13,Value 120 130	25-34 days
20,R7,Has_value Arg1:T12 Arg2:T13
0,T1,Value 2 10	18 years
1,T2,Person 11 14	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Temporal 16 21	Acute
4,T4,Qualifier 22 33	symptomatic
5,T5,Condition 34 36	BV
6,R2,Has_qualifier Arg1:T5 Arg2:T4
7,R3,Has_temporal Arg1:T5 Arg2:T3
8,T6,Informed_consent 38 61	Signed informed consent
9,T7,Observation 63 95	Insufficient knowledge of German
10,T8,Observation 97 107	Illiteracy
11,T9,Condition 109 118	Pregnancy
12,T10,Condition 120 133	Acute illness
13,T11,Condition 141 150	allergies
14,T12,Drug 159 202	ingredients of the investigational products
15,R4,AND Arg1:T11 Arg2:T12
0,T1,Condition 8 14	wheeze
1,T2,Condition 27 42	chronic illness
2,T3,Negation 43 48	other
3,T4,Condition 54 60	asthma
4,R1,Has_negation Arg1:T4 Arg2:T3
5,T5,Condition 67 81	bronchiectasis
6,T6,Condition 83 116	cyanotic congenital heart disease
7,T7,Condition 120 135	cardiac failure
8,T8,Condition 137 160	neuromuscular disorders
9,T9,Condition 162 178	immunodeficiency
10,T10,"Scope 67 178	bronchiectasis, cyanotic congenital heart disease or cardiac failure, neuromuscular disorders, immunodeficiency"
11,*,OR T9 T8 T7 T6 T5
12,R2,Subsumes Arg1:T2 Arg2:T10
13,T11,Condition 241 253	malnutrition
14,T12,Qualifier 234 240	Severe
15,R3,Has_qualifier Arg1:T11 Arg2:T12
16,T13,Measurement 255 280	weight-for-height Z-score
17,T14,Value 281 284	<-3
18,R4,Has_value Arg1:T13 Arg2:T14
19,R5,AND Arg1:T11 Arg2:T13
20,T15,Condition 287 298;330 339	Complicated pneumonia
21,T16,Condition 351 363	tuberculosis
22,R6,Subsumes Arg1:T15 Arg2:T16
23,T17,Condition 300 308	effusion
24,T18,Condition 310 317	empyema
25,T19,Condition 321 328	abscess
26,*,OR T17 T18 T19
27,T20,"Scope 301 328	ffusion, empyema or abscess"
28,R7,Subsumes Arg1:T15 Arg2:T20
29,T21,Qualifier 365 380	Extra-pulmonary
30,T22,Condition 381 390	infection
31,R8,Has_qualifier Arg1:T22 Arg2:T21
32,T23,Procedure 401 419	antibiotic therapy
33,T24,Condition 426 436	meningitis
34,R9,Subsumes Arg1:T22 Arg2:T24
35,R10,AND Arg1:T22 Arg2:T23
36,T25,Condition 451 458	allergy
37,T26,Drug 439 450	Beta-lactam
38,R11,AND Arg1:T25 Arg2:T26
39,T27,Competing_trial 460 479	Previously enrolled
40,T28,Post-eligibility 481 578	Lack a mobile phone and/or unable to return for follow-up clinic visits during the next 24 months
0,T1,Condition 19 34	type 2 diabetic
1,T2,Temporal 0 18	Recently diagnosed
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Measurement 46 68	Fasting plasma glucose
4,T4,Value 69 90	between 200-300 mg/dl
5,T5,Measurement 92 101	A1C level
6,T6,Value 102 120	between 7% and 10%
7,R2,Has_value Arg1:T5 Arg2:T6
8,R3,Has_value Arg1:T3 Arg2:T4
9,T7,Scope 92 120	A1C level between 7% and 10%
10,T8,Scope 46 90	Fasting plasma glucose between 200-300 mg/dl
11,R4,Subsumes Arg1:T8 Arg2:T7
12,T9,Value 138 165	between 30 and 80 years old
13,T10,Person 134 137	age
14,R5,Has_value Arg1:T10 Arg2:T9
15,T11,Observation 170 173	can
16,T12,Procedure 174 188	inject insulin
17,R6,Has_context Arg1:T12 Arg2:T11
0,T3,Condition 67 104	elective replacement indication (ERI)
1,T4,Condition 106 126	end of service (EOS)
2,*,OR T3 T4
3,T5,"Scope 67 126	elective replacement indication (ERI), end of service (EOS)"
4,T1,Condition 9 28	clinical indication
5,T2,Procedure 33 60	pectoral pacemaker exchange
6,R1,AND Arg1:T1 Arg2:T2
7,T6,Scope 9 60	clinical indication for pectoral pacemaker exchange
8,R2,Subsumes Arg1:T6 Arg2:T5
9,T7,Qualifier 131 137;146 153	single chamber
10,T8,Qualifier 141 153	dual chamber
11,*,OR T7 T8
12,T9,Scope 131 153	single or dual chamber
13,T10,Device 170 179	pacemaker
14,T11,Device 181 185	BSCI
15,R3,Has_scope Arg1:T10 Arg2:T9
16,T12,Scope 131 179	single or dual chamber MRI conditional pacemaker
17,R4,Subsumes Arg1:T12 Arg2:T11
18,T13,Device 221 243	MRI conditional system
19,T14,Device 245 249	BSCI
20,*,OR T13 T14
21,T15,Device 206 219	successor IPG
22,T16,Qualifier 195 205	comparable
23,R5,Has_qualifier Arg1:T15 Arg2:T16
24,T17,Scope 195 219	comparable successor IPG
25,T18,"Scope 221 249	MRI conditional system, BSCI"
26,R6,Subsumes Arg1:T17 Arg2:T18
27,T19,Device 268 295	Implanted Fineline-II-leads
28,T20,Device 297 301	BSCI
29,R7,Subsumes Arg1:T19 Arg2:T20
30,T21,Qualifier 304 319	MRI conditional
31,T22,Qualifier 154 169	MRI conditional
32,R8,Has_qualifier Arg1:T10 Arg2:T22
33,T23,Scope 268 302	Implanted Fineline-II-leads (BSCI)
34,R9,Has_qualifier Arg1:T23 Arg2:T21
35,T24,Measurement 325 351	ascertained lead impedance
36,T25,Value 355 379	between 200 and 1500 Ohm
37,R10,Has_value Arg1:T24 Arg2:T25
38,T26,Measurement 386 411	pacing capture thresholds
39,T27,Measurement 413 416	PCT
40,R11,Subsumes Arg1:T26 Arg2:T27
41,T28,Value 418 452	do not exceed 2.0 V @0.4 or 0.5 ms
42,T29,Condition 456 475	pacemaker dependent
43,A1,Optional T29
44,T30,Scope 386 417	pacing capture thresholds (PCT)
45,R12,Has_value Arg1:T30 Arg2:T28
46,R13,Has_scope Arg1:T29 Arg2:T30
47,T31,Person 486 490	Male
48,T32,Person 494 500	female
49,T33,Value 501 518	18 years or older
50,T34,Person 504 518	years or older
51,R14,Has_value Arg1:T34 Arg2:T33
52,*,OR T31 T32
53,T35,Non-query-able 520 558	Understand the nature of the procedure
54,T36,Post-eligibility 560 589	Give written informed consent
55,T37,Post-eligibility 591 653	Able to complete all testing required by the clinical protocol
56,T38,Post-eligibility 655 736	Ability to measure atrial and/or ventricular pacing threshold(s) at 0.4 or 0.5 ms
57,T39,Measurement 746 757	body height
58,T40,Value 758 784	greater or equal to 140 cm
59,R15,Has_value Arg1:T39 Arg2:T40
60,T41,Device 786 811	Pectoral implanted device
61,T42,Mood 839 857	willing to undergo
62,T43,Qualifier 858 866	elective
63,T44,Procedure 867 893;899 907	cardiac magnetic resonance scanning
64,T45,Procedure 895 897	MR
65,R16,Subsumes Arg1:T44 Arg2:T45
66,T46,Qualifier 908 924	without sedation
67,R17,Has_qualifier Arg1:T44 Arg2:T46
68,R18,Has_qualifier Arg1:T44 Arg2:T43
69,R19,Has_mood Arg1:T44 Arg2:T42
70,T47,Person 955 976	geographically stable
71,T48,Observation 981 1004	available for follow-up
72,T49,Visit 1005 1024	at the study center
73,T50,Temporal 1025 1052	for the length of the study
74,T51,Scope 955 1004	geographically stable and available for follow-up
75,T52,Scope 1005 1052	at the study center for the length of the study
76,R20,Has_scope Arg1:T51 Arg2:T52
0,T1,Condition 44 74	paroxysmal atrial fibrillation
1,T2,Qualifier 32 43	symptomatic
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Multiplier 96 108	at least two
4,T4,Condition 121 129	episodes
5,T5,Qualifier 109 120	symptomatic
6,T6,Temporal 137 171	last six months prior to inclusion
7,T7,Reference_point 162 171	inclusion
8,R2,Has_index Arg1:T6 Arg2:T7
9,R3,Has_qualifier Arg1:T4 Arg2:T5
10,R4,Has_multiplier Arg1:T4 Arg2:T3
11,R5,AND Arg1:T1 Arg2:T4
12,T8,Multiplier 174 186	At least one
13,T9,Condition 187 194	episode
14,T10,Condition 198 200	AF
15,R6,Has_multiplier Arg1:T9 Arg2:T8
16,R7,AND Arg1:T10 Arg2:T9
17,T11,Temporal 231 241	prior year
18,T12,Measurement 257 260	ECG
19,R8,AND Arg1:T12 Arg2:T9
20,R9,Has_temporal Arg1:T9 Arg2:T11
21,T13,Condition 303 308	heart
22,T14,Qualifier 296 302	normal
23,T15,Qualifier 285 295	structural
24,R10,Has_qualifier Arg1:T13 Arg2:T14
25,R11,Has_qualifier Arg1:T13 Arg2:T15
26,T16,Measurement 317 321	LVEF
27,T17,"Value 322 328	= 50%,"
28,T18,Measurement 329 370	thickness of the inter-ventricular septum
29,T19,Value 371 377	=12 mm
30,T20,Measurement 382 403	left atrium diameters
31,T21,Value 417 424	< 46 mm
32,T22,Measurement 405 415	short axis
33,T23,Procedure 437 467	transthoracic echocardiography
34,R12,Has_value Arg1:T16 Arg2:T17
35,R13,Has_value Arg1:T18 Arg2:T19
36,R14,Subsumes Arg1:T20 Arg2:T22
37,R15,Has_value Arg1:T20 Arg2:T21
38,T24,"Scope 317 424	LVEF = 50%, thickness of the inter-ventricular septum =12 mm and left atrium diameters (short axis) < 46 mm"
39,R16,Has_scope Arg1:T23 Arg2:T24
40,R17,AND Arg1:T13 Arg2:T23
41,T25,Procedure 489 492	ECG
42,T26,Value 482 488	normal
43,R18,Has_value Arg1:T25 Arg2:T26
44,T27,Measurement 505 514	QRS width
45,T28,Qualifier 522 544	12 channel surface ECG
46,T29,Value 545 552	=120 ms
47,T30,Measurement 554 568	QTc - interval
48,T31,Value 569 577	< 440 ms
49,T32,Measurement 579 592	PQ - interval
50,T33,Value 593 601	= 210 ms
51,T34,Condition 640 652	sinus rhythm
52,R19,Has_qualifier Arg1:T27 Arg2:T28
53,R20,Has_value Arg1:T27 Arg2:T29
54,R21,Has_value Arg1:T30 Arg2:T31
55,R22,Has_value Arg1:T32 Arg2:T33
56,T35,"Scope 505 652	QRS width in the 12 channel surface ECG =120 ms, QTc - interval < 440 ms, PQ - interval = 210 ms; all parameters should be measured at sinus rhythm"
57,R23,Subsumes Arg1:T25 Arg2:T35
58,T36,Person 706 709	old
59,T37,Value 667 705	at least 18 and not older than 75years
60,R24,Has_value Arg1:T36 Arg2:T37
61,T38,Informed_consent 712 764	Subject is able and willing to give informed consent
0,T1,Measurement 0 21	endometrial thickness
1,T2,Value 22 28	< 7 mm
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Negation 32 34	no
4,T4,Observation 35 59	triple layer endometrium
5,T5,Observation 67 87	functional follicles
6,*,OR T4 T5
7,T6,Scope 35 87	triple layer endometrium and/or functional follicles
8,R2,Has_negation Arg1:T6 Arg2:T3
9,T7,Condition 89 108	Uterine abnormality
10,T8,Condition 110 133	Chronic medical disease
11,T9,Procedure 135 157	oocyte donation cycles
0,T1,Observation 19 27	Cohort A
1,T2,Non-query-able 19 27	Cohort A
2,T3,Procedure 38 45	therapy
3,T4,Undefined_semantics 38 45	therapy
4,T5,Temporal 29 37	previous
5,R1,Has_temporal Arg1:T3 Arg2:T5
6,T6,Temporal 46 68	for more than 48 hours
7,R2,Has_temporal Arg1:T3 Arg2:T6
8,T7,Drug 78 131	parenteral antibiotic with activity against S. aureus
9,T8,Qualifier 100 131	with activity against S. aureus
10,T9,Observation 122 131	S. aureus
11,T10,Temporal 132 181	within 72 hours of positive blood culture results
12,T11,Reference_point 151 181	positive blood culture results
13,T12,Procedure 160 173	blood culture
14,T13,Value 151 159;174 181	positive results
15,R3,Has_value Arg1:T12 Arg2:T13
16,R4,Has_index Arg1:T10 Arg2:T11
17,T14,Observation 203 211	Cohort B
18,T15,Non-query-able 203 211	Cohort B
19,A1,Optional T1
20,T16,Scope 29 182	previous therapy for more than 48 hours with any parenteral antibiotic with activity against S. aureus within 72 hours of positive blood culture results.
21,R5,Has_scope Arg1:T1 Arg2:T16
22,T17,Temporal 213 221	previous
23,T18,Procedure 222 229	therapy
24,T19,Undefined_semantics 222 229	therapy
25,R6,Has_temporal Arg1:T18 Arg2:T17
26,T20,Temporal 230 252	for more than 48 hours
27,R7,Has_temporal Arg1:T18 Arg2:T20
28,T21,Drug 262 310	parenteral antibiotic with activity against MRSA
29,T22,Qualifier 78 88	parenteral
30,T23,Qualifier 262 272	parenteral
31,T24,Qualifier 284 310	with activity against MRSA
32,T25,Observation 306 310	MRSA
33,T26,Drug 319 329	vancomycin
34,T27,Negation 312 318	except
35,R8,Has_negation Arg1:T26 Arg2:T27
36,T28,Drug 337 347	daptomycin
37,R9,Has_negation Arg1:T28 Arg2:T27
38,T29,Temporal 349 398	within 72 hours of positive blood culture results
39,T30,Reference_point 368 398	positive blood culture results
40,T31,Value 368 376;391 398	positive results
41,T32,Procedure 377 390	blood culture
42,R10,Has_value Arg1:T32 Arg2:T31
43,T33,Scope 312 347	except vancomycin and/or daptomycin
44,R11,Has_temporal Arg1:T33 Arg2:T29
45,T34,Condition 447 467	S. aureus bacteremia
46,T35,Observation 447 456	S. aureus
47,T36,Qualifier 447 456	S. aureus
48,T37,Temporal 468 483	within 3 months
49,R12,Has_temporal Arg1:T34 Arg2:T37
50,T38,Condition 495 518	left-sided endocarditis
51,T39,Qualifier 495 505	left-sided
52,T40,Device 522 544	prosthetic heart valve
53,*,OR T38 T40
54,T41,Condition 550 563	Osteomyelitis
55,T42,Condition 567 593	prosthetic joint infection
56,T43,Temporal 601 610	new onset
57,T44,Qualifier 611 633	nonhardware-associated
58,T45,Condition 634 657	vertebral osteomyelitis
59,R13,Has_qualifier Arg1:T45 Arg2:T44
60,R14,Has_temporal Arg1:T45 Arg2:T43
61,*,OR T41 T42
62,T46,Negation 594 600	except
63,R15,Has_negation Arg1:T45 Arg2:T46
64,T47,Condition 678 694	hypersensitivity
65,T48,Condition 698 715	allergic reaction
66,T49,Drug 723 751	β-lactam antibacterial agent
67,*,OR T47 T48
68,T50,Scope 678 715	hypersensitivity or allergic reaction
69,R16,AND Arg1:T50 Arg2:T49
70,T51,Observation 663 670	History
71,R17,Has_temporal Arg1:T50 Arg2:T51
72,T52,Condition 781 788;818 828	hepatic impairment
73,T53,Condition 806 828	immunologic impairment
74,T54,Condition 790 801;818 828	hematologic impairment
75,*,OR T52 T54 T53
76,T55,Condition 834 842	Pregnant
77,T56,Condition 846 853	nursing
78,T57,Person 854 861	females
79,*,OR T56 T55
80,A2,Optional T14
81,T58,"Scope 213 421	previous therapy for more than 48 hours with any parenteral antibiotic with activity against MRSA, except vancomycin and/or daptomycin, within 72 hours of positive blood culture results confirming persistence"
82,R18,Has_scope Arg1:T14 Arg2:T58
0,T1,Value 0 13	Over 18 years
1,T2,Person 17 20	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Condition 22 42	Systemically healthy
4,T4,Condition 44 55	Non-smoking
5,T5,Observation 63 80	good oral hygiene
6,T6,Condition 90 120	irreversible pulpal alteration
7,T7,Negation 83 89	Absent
8,R2,Has_negation Arg1:T6 Arg2:T7
9,T8,Condition 146 181	non-carious cervical lesion (LCNCs)
10,T9,Procedure 199 207	restored
11,T10,Mood 187 198	needs to be
12,R3,Has_mood Arg1:T9 Arg2:T10
13,*,OR T8 T9
14,T11,Condition 214 220	lesion
15,T12,Qualifier 231 242	non-carious
16,T13,Qualifier 244 257	non-retentive
17,T14,Value 264 292	at least 1 mm and up to 3 mm
18,T15,Measurement 293 298	depth
19,R4,Has_value Arg1:T15 Arg2:T14
20,T16,Qualifier 307 337	involve both enamel and dentin
21,T17,Condition 383 399	hypersensitivity
22,R5,Has_qualifier Arg1:T11 Arg2:T12
23,R6,Has_qualifier Arg1:T11 Arg2:T13
24,R7,AND Arg1:T11 Arg2:T15
25,R8,Has_qualifier Arg1:T11 Arg2:T16
26,R9,AND Arg1:T11 Arg2:T17
27,T18,"Non-representable 402 554	Presence a natural tooth of the same position of the restored tooth, but in the opposite arch of the same jaw to be considered for the positive control;"
28,T19,Measurement 581 599	Depth Probing (PS)
29,T20,Measurement 601 627	Visible Plaque Index (IPV)
30,T21,Measurement 629 648	Gingival Index (GI)
31,T22,Measurement 653 677	Probing Bleed Index (SS)
32,T23,Measurement 705 707	PS
33,T24,Value 708 719	= 1 to 3 mm
34,T25,Value 724 727	= 0
35,T26,Value 735 742	score 0
36,T27,Value 750 757	score 0
37,T28,Measurement 745 747	SS
38,T29,Measurement 729 732	IPV
39,R10,Has_value Arg1:T23 Arg2:T24
40,T30,Measurement 721 723	GI
41,R11,Has_value Arg1:T30 Arg2:T25
42,R12,Has_value Arg1:T29 Arg2:T26
43,R13,Has_value Arg1:T28 Arg2:T27
44,*,OR T29 T28 T30
45,*,OR T21 T22 T20 T19
46,T31,"Scope 581 677	Depth Probing (PS), Visible Plaque Index (IPV), Gingival Index (GI) and Probing Bleed Index (SS)"
47,T32,"Scope 705 757	PS = 1 to 3 mm, GI = 0, IPV = score 0 e SS = score 0"
48,R14,Has_scope Arg1:T31 Arg2:T32
0,T1,Condition 77 80	CLL
1,T2,Condition 81 84	SLL
2,*,OR T2 T1 T3
3,T3,Condition 88 115	B-cell Non-Hodgkin lymphoma
4,T4,Condition 117 122	DLBCL
5,T5,Condition 124 126	FL
6,T6,Condition 128 131	MCL
7,T7,Condition 133 136	MZL
8,T8,Condition 138 164	lymphoplasmacytic lymphoma
9,T9,"Scope 117 164	DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma"
10,T10,Scope 77 115	CLL/SLL or B-cell Non-Hodgkin lymphoma
11,R1,Subsumes Arg1:T10 Arg2:T9
12,T11,Value 25 39	at least 18yrs
13,T12,Person 43 46	age
14,R2,Has_value Arg1:T12 Arg2:T11
15,T13,Procedure 52 66	histologically
16,T14,Value 67 76	confirmed
17,R3,Has_value Arg1:T13 Arg2:T14
18,R4,AND Arg1:T10 Arg2:T13
19,T15,Parsing_Error 168 186	Phase 2a Inclusion
20,T16,Procedure 188 200	Histological
21,T17,Condition 211 213	FL
22,T18,Measurement 214 219	Grade
23,T19,Value 220 224	1-3A
24,R5,Has_value Arg1:T18 Arg2:T19
25,R6,AND Arg1:T17 Arg2:T18
26,T20,Condition 225 229	iNHL
27,*,OR T20 T17
28,T21,Condition 248 266	refractory disease
29,T22,Condition 236 244;259 266	relapsed disease
30,*,OR T21 T22
31,T23,Condition 268 272	iNHL
32,T24,Condition 282 285	LPL
33,T25,Condition 286 288	WM
34,T26,Condition 290 293	MZL
35,*,OR T26 T25 T24
36,T27,"Scope 282 293	LPL/WM, MZL"
37,R7,Subsumes Arg1:T23 Arg2:T27
38,T28,Scope 236 266	relapsed or refractory disease
39,R8,Subsumes Arg1:T28 Arg2:T23
40,T29,Condition 296 300	aNHL
41,T30,Condition 313 318	DLBCL
42,T31,Condition 320 322	FL
43,T32,Measurement 323 328	Grade
44,T33,Value 329 331	3B
45,R9,Has_value Arg1:T32 Arg2:T33
46,T34,Condition 333 336	MCL
47,T35,Condition 342 357	transformed NHL
48,T36,Condition 363 379	relapsed disease
49,T37,Condition 381 384	CLL
50,T38,Condition 385 388	SLL
51,T39,Condition 390 394	PTCL
52,T40,Condition 399 403	CTCL
53,T41,Condition 410 412	MF
54,T42,Condition 413 415	SS
55,*,OR T41 T42
56,T43,Scope 410 415	MF/SS
57,R10,Has_scope Arg1:T40 Arg2:T43
58,R11,AND Arg1:T35 Arg2:T36
59,*,OR T34 T35 T32 T31 T30
60,T44,"Scope 313 379	DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease"
61,R12,Subsumes Arg1:T29 Arg2:T44
62,*,OR T29 T23 T37 T38 T39 T40
63,T45,Drug 467 482	BCL2 inhibitors
64,T46,Drug 456 459;472 482	BCR inhibitors
65,*,OR T46 T45
66,T47,Condition 488 498	intolerant
67,T48,Scope 456 482	BCR and/or BCL2 inhibitors
68,R13,Has_scope Arg1:T47 Arg2:T48
69,T49,Condition 506 514	relapsed
70,T50,Condition 515 533	refractory disease
71,*,OR T49 T50
72,T51,Temporal 534 544	afterwards
73,T52,Scope 506 533	relapsed/refractory disease
74,R14,Has_temporal Arg1:T52 Arg2:T51
75,*,OR T52 T47
76,T53,Temporal 547 552	Prior
77,T54,Procedure 553 562	treatment
78,*,OR T54 T53
79,T55,Condition 567 586	lymphoid malignancy
80,T56,Condition 604 622	refractory disease
81,T57,Condition 591 602;615 622	progressive disease
82,*,OR T56 T57
83,T58,Drug 662 680	antibody conjugate
84,T59,Procedure 682 704	cytotoxic chemotherapy
85,T60,Drug 709 712	TKI
86,*,OR T60 T59 T58
87,T61,Multiplier 624 641	≥ 1 prior regimen
88,T62,Multiplier 643 655	min 2 cycles
89,T63,"Scope 662 712	antibody conjugate, cytotoxic chemotherapy, or TKI"
90,R15,Has_multiplier Arg1:T63 Arg2:T61
91,R16,Has_multiplier Arg1:T61 Arg2:T62
92,T64,Condition 739 758	Measureable disease
93,T65,Multiplier 771 781	≥ 1 lesion
94,T66,Measurement 782 807	≥ 1.5 cm single dimension
95,T67,Value 782 790	≥ 1.5 cm
96,R17,Has_value Arg1:T66 Arg2:T67
97,T68,Procedure 812 814	CT
98,T69,Procedure 816 822	CT/PET
99,T70,Condition 837 849	mass lesions
100,T71,Condition 828 833;842 849	nodal lesions
101,*,OR T70 T71
102,*,OR T69 T68
103,T72,Condition 864 887	circulating tumor cells
104,T73,Condition 896 927	Waldenström's macroglobulinemia
105,T74,Measurement 940 945	IgM l
106,T75,Value 946 954	> 2X ULN
107,R18,Has_value Arg1:T74 Arg2:T75
108,T76,Condition 960 964	CTCL
109,T77,Measurement 966 971	mSWAT
110,T78,Value 972 975	> 0
111,R19,Has_value Arg1:T77 Arg2:T78
112,R20,AND Arg1:T76 Arg2:T77
113,A1,Optional T76
114,A2,Optional T73
115,R21,AND Arg1:T73 Arg2:T74
116,*,OR T76 T73 T72
117,T79,Scope 828 849	nodal or mass lesions
118,T80,"Scope 812 822	CT, CT/PET"
119,R22,Has_scope Arg1:T66 Arg2:T80
120,R23,Has_scope Arg1:T80 Arg2:T79
121,T81,"Scope 771 975	≥ 1 lesion ≥ 1.5 cm single dimension via CT, CT/PET with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenström's macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0"
122,R24,Subsumes Arg1:T64 Arg2:T81
123,T82,Non-query-able 977 1014	Ability to provide diagnostic reports
124,T83,Parsing_Error 1016 1033	General Inclusion
125,T84,Measurement 1035 1045	ECOG Score
126,T85,Value 1049 1055	0 or 1
127,R25,Has_value Arg1:T84 Arg2:T85
128,T86,Measurement 1058 1073	Hematologic ANC
129,T87,Value 1074 1083	> 1000/uL
130,R26,Has_value Arg1:T86 Arg2:T87
131,T88,Measurement 1088 1096	platelet
132,T89,"Value 1097 1108	> 75,000/uL"
133,R27,Has_value Arg1:T88 Arg2:T89
134,T90,Measurement 1111 1127	Serum creatinine
135,T91,Value 1131 1140	< 1.5 ULN
136,R28,Has_value Arg1:T90 Arg2:T91
137,T92,Measurement 1144 1159	calculated CrCl
138,T93,Value 1163 1174	> 50 mL/min
139,R29,Has_value Arg1:T92 Arg2:T93
140,*,OR T90 T92
141,T94,Measurement 1176 1185	Bilirubin
142,T95,Value 1186 1197	< 20.0mg/dL
143,T96,Condition 1202 1210	Gilberts
144,A3,Optional T96
145,T97,Value 1216 1227	< 2.5 mg/dL
146,*,OR T95 T96
147,R30,Has_value Arg1:T96 Arg2:T97
148,T98,Scope 1186 1228	< 20.0mg/dL (if Gilberts then < 2.5 mg/dL)
149,R31,Has_scope Arg1:T94 Arg2:T98
150,T99,Measurement 1233 1240	AST/AST
151,T100,Value 1241 1250	< 2.5 ULN
152,R32,Has_value Arg1:T99 Arg2:T100
0,T1,Condition 15 25	bacteremia
1,T2,Parsing_Error 26 40	due solely to:
2,T3,Procedure 66 79	blood culture
3,T4,Multiplier 55 65	at least 1
4,T5,Observation 42 51	S. aureus
5,R1,Has_context Arg1:T3 Arg2:T5
6,R2,Has_multiplier Arg1:T3 Arg2:T4
7,T6,Temporal 80 119	within 72 hours of beginning study drug
8,T7,Reference_point 99 119	beginning study drug
9,R3,Has_index Arg1:T6 Arg2:T7
10,T8,Observation 135 139	MRSA
11,T9,Procedure 154 167	blood culture
12,T10,Temporal 145 153	baseline
13,R4,Has_temporal Arg1:T9 Arg2:T10
14,R5,Has_temporal Arg1:T3 Arg2:T6
15,T11,Multiplier 175 196	at least 1 additional
16,T12,Procedure 197 210	blood culture
17,T13,Temporal 211 276	after at least 72 hours of vancomycin and/or daptomycin treatment
18,T14,Reference_point 238 276	vancomycin and/or daptomycin treatment
19,T15,Drug 238 248	vancomycin
20,T16,Drug 256 266	daptomycin
21,T17,Procedure 256 276	daptomycin treatment
22,T18,Procedure 238 248;267 276	vancomycin treatment
23,*,OR T18 T17
24,R6,Has_temporal Arg1:T12 Arg2:T13
25,R7,Has_multiplier Arg1:T12 Arg2:T11
26,R8,Has_context Arg1:T9 Arg2:T8
27,T19,Person 293 297	Male
28,T20,Person 301 307	female
29,*,OR T20 T19
30,T21,Value 308 318	≥ 18 years
31,T22,Person 322 325	age
32,R9,Has_value Arg1:T22 Arg2:T21
33,T23,Person 334 340	female
34,T24,Condition 344 366	childbearing potential
35,T25,Observation 375 382	willing
36,T26,Procedure 386 412	practice sexual abstinence
37,T27,Multiplier 416 420	dual
38,T28,Procedure 421 445	methods of contraception
39,R11,Has_multiplier Arg1:T28 Arg2:T27
40,*,OR T28 T26
41,T29,Temporal 446 462	during treatment
42,T30,Temporal 467 521	for at least 30 days after the last dose of study drug
43,T31,Reference_point 494 521	the last dose of study drug
44,T32,Scope 386 445	practice sexual abstinence or dual methods of contraception
45,R10,Has_context Arg1:T32 Arg2:T25
46,R12,Has_temporal Arg1:T32 Arg2:T29
47,R13,Has_temporal Arg1:T32 Arg2:T30
48,T33,Scope 334 366	female of childbearing potential
49,A1,Optional T33
50,R14,Has_scope Arg1:T33 Arg2:T32
51,T34,Observation 527 538	Expectation
52,T35,Condition 542 550	survival
53,T36,Temporal 551 572	for at least 2 months
54,R15,Has_temporal Arg1:T35 Arg2:T36
55,R16,Has_context Arg1:T35 Arg2:T34
0,T1,Condition 12 31	systemic alteration
1,T2,Qualifier 5 11	severe
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Drug 48 59	antibiotics
4,T4,Drug 64 83	anti-inflammatories
5,T5,Temporal 84 108	in the last three months
6,*,OR T4 T3
7,T6,Scope 48 83	antibiotics and anti-inflammatories
8,R2,Has_temporal Arg1:T6 Arg2:T5
9,T7,Non-representable 111 216	With periodontium with periodontal parameters different from those established in the inclusion criteria.
10,T8,Condition 235 274	clinical signs of parafunctional habits
11,T9,Observation 277 284	Smoking
12,T10,Procedure 318 336	other restorations
13,T11,Temporal 337 358	in the last 12 months
14,R3,Has_temporal Arg1:T10 Arg2:T11
15,T12,Condition 361 369	Pregnant
16,T13,Person 370 375	women
17,T14,Person 380 387	infants
18,T15,Scope 361 375	Pregnant women
19,*,OR T15 T14
20,T16,Non-representable 390 530	Periodontal sites that presented bleeding during crevicular fluid collection or sites that prevent proper collection of clinical parameters.
0,T1,Condition 0 18	Richter's syndrome
1,T2,Condition 20 38	Burkitt's lymphoma
2,T3,Condition 43 64	Burkitt-like Lymphoma
3,T4,Condition 78 83	DLBCL
4,T5,Condition 89 103	Follicular NHL
5,*,OR T5 T4 T3 T2 T1
6,T6,Procedure 126 136	transplant
7,T7,Procedure 142 160	stem cell infusion
8,T8,Temporal 161 168;222 230	90 days of Day 1
9,T9,Temporal 172 178	active
10,T10,Procedure 179 206	graft-versus-host treatment
11,T11,Temporal 207 230	within 8 weeks of Day 1
12,R1,Has_temporal Arg1:T10 Arg2:T11
13,T12,Drug 252 266	SYK inhibitors
14,T13,Procedure 239 246	therapy
15,R2,AND Arg1:T13 Arg2:T12
16,T14,Temporal 233 238	Prior
17,T15,Temporal 120 125	Prior
18,R3,Has_temporal Arg1:T6 Arg2:T15
19,R4,Has_temporal Arg1:T13 Arg2:T14
20,R5,AND Arg1:T6 Arg2:T7
21,R6,Has_temporal Arg1:T6 Arg2:T8
22,R7,Has_temporal Arg1:T10 Arg2:T9
23,*,OR T10 T6
24,T16,Drug 292 315	strong CYP3A4 inhibitor
25,T17,Drug 292 305;317 324	strong CYP3A4 inducer
26,T18,Drug 326 345	acid reducing agent
27,T19,Drug 347 369	Proton pump inhibitors
28,*,OR T19 T18 T17 T16
29,T20,Condition 377 412	lymphomatous involvement of the CNS
30,T21,Undefined_semantics 377 412	lymphomatous involvement of the CNS
31,T22,Measurement 438 452	NCI CTCAE v4.0
32,T23,Value 453 462	≥ Grade 2
33,R8,Has_value Arg1:T22 Arg2:T23
34,T24,Condition 473 494	drug-related toxicity
35,T25,Temporal 464 472	previous
36,T26,Condition 503 511	alopecia
37,T27,Negation 496 502	except
38,T28,Condition 513 531	erectile impotence
39,T29,Condition 533 544	hot flashes
40,T30,Condition 546 552	libido
41,T31,Condition 554 564	neuropathy
42,*,OR T31 T30 T29 T28 T26
43,T32,"Scope 503 564	alopecia, erectile impotence, hot flashes, libido, neuropathy"
44,R9,Has_negation Arg1:T32 Arg2:T27
45,R10,Has_temporal Arg1:T24 Arg2:T25
46,T33,Drug 574 593	monoclonal antibody
47,T34,Drug 595 615	radioimmunoconjugate
48,T35,Drug 617 640	antibody drug conjugate
49,T36,Procedure 642 654	phototherapy
50,T37,Procedure 656 668	radiotherapy
51,T38,Procedure 670 682	chemotherapy
52,T39,Procedure 684 697	immunotherapy
53,T40,Procedure 699 724	immunosuppressive therapy
54,T41,Temporal 744 758;786 794	within 3 weeks of Day 1
55,T42,Drug 766 777	alemtuzumab
56,A1,Optional T42
57,T43,Temporal 778 794	8 weeks of Day 1
58,T44,"Scope 574 724	monoclonal antibody, radioimmunoconjugate, antibody drug conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy"
59,T45,Scope 744 794	within 3 weeks or for alemtuzumab 8 weeks of Day 1
60,*,OR T41 T42
61,T46,Reference_point 789 794	Day 1
62,R11,Has_index Arg1:T41 Arg2:T46
63,R12,Has_index Arg1:T43 Arg2:T46
64,R13,Has_scope Arg1:T44 Arg2:T45
65,T47,Condition 801 805	CTCL
66,T48,Procedure 808 813	TSEBT
67,T49,Temporal 815 830	within 12 weeks
68,R14,Has_temporal Arg1:T48 Arg2:T49
69,T50,Drug 849 864	topical steroid
70,T51,Observation 835 845	initiation
71,R15,Has_context Arg1:T50 Arg2:T51
72,T52,Drug 866 882	nitrogen mustard
73,T53,Drug 887 903	topical retinoid
74,T54,Temporal 904 918	within 2 weeks
75,*,OR T50 T52 T53
76,T55,"Scope 849 903	topical steroid, nitrogen mustard, or topical retinoid"
77,R16,Has_temporal Arg1:T55 Arg2:T54
78,T56,Temporal 936 960	≥ 4 weeks prior to Day 1
79,T57,Reference_point 955 960	Day 1
80,R17,Has_index Arg1:T56 Arg2:T57
81,T58,Grammar_Error 961 968	allowed
82,T59,Condition 989 1006	infection for HIV
83,T60,Condition 1007 1012;989 1002	Hep B infection for
84,T61,Condition 1007 1010;1016 1017;989 1002	Hep C infection for
85,*,OR T61 T60 T59
86,T62,Condition 1019 1026	HCV ab+
87,T63,Qualifier 1035 1039	PCR-
88,R18,Has_qualifier Arg1:T62 Arg2:T63
89,T64,Condition 1041 1048	HBV ab+
90,T65,Qualifier 1057 1063	HBsAg-
91,R19,Has_qualifier Arg1:T64 Arg2:T65
92,T66,Condition 1067 1083	undetectable DNA
93,A2,Optional T62
94,A3,Optional T64
95,T67,Scope 989 1017	infection for HIV/Hep B or C
96,*,OR T67 T62 T64
97,T68,Condition 1092 1101	infection
98,T69,Procedure 1112 1130	systemic treatment
99,T70,Qualifier 1102 1130	requiring systemic treatment
100,R20,AND Arg1:T70 Arg2:T69
101,R21,Has_qualifier Arg1:T68 Arg2:T70
102,T71,Condition 1145 1155	GI disease
103,T72,Qualifier 1133 1144	Significant
104,T73,Subjective_judgement 1133 1144	Significant
105,R22,Has_qualifier Arg1:T71 Arg2:T72
106,T74,Procedure 1180 1193	bowel surgery
107,T75,Procedure 1172 1179;1186 1193	gastric surgery
108,T76,Qualifier 1166 1171	major
109,T77,Subjective_judgement 1166 1171	major
110,*,OR T75 T74
111,T78,Condition 1195 1216	difficulty swallowing
112,T79,Condition 1220 1242	malabsorption syndrome
113,*,OR T79 T78
114,T80,Scope 1172 1193	gastric/bowel surgery
115,R23,Has_qualifier Arg1:T80 Arg2:T76
116,R24,AND Arg1:T80 Arg2:T78
117,T81,Procedure 1251 1258	surgery
118,T82,Qualifier 1245 1250	Major
119,T83,Undefined_semantics 1245 1250	Major
120,T84,Subjective_judgement 1245 1250	Major
121,R25,Has_qualifier Arg1:T81 Arg2:T82
122,T85,Temporal 1259 1273	within 4 weeks
123,R26,Has_temporal Arg1:T81 Arg2:T85
124,T86,Condition 1284 1296	malignancies
125,T87,Temporal 1297 1310	within 2 yrs.
126,T88,Non-query-able 1311 1346	unless relapse risk is small (< 5%)
127,T89,Subjective_judgement 1311 1346	unless relapse risk is small (< 5%)
128,T90,Undefined_semantics 1311 1346	unless relapse risk is small (< 5%)
129,R27,Has_temporal Arg1:T86 Arg2:T87
130,T91,Drug 1364 1381	systemic steroids
131,T92,Multiplier 1382 1391	>20 mg QD
132,T93,Drug 1392 1402	prednisone
133,R28,Subsumes Arg1:T91 Arg2:T93
134,R29,Has_multiplier Arg1:T93 Arg2:T92
135,T94,Observation 1420 1433	Breastfeeding
136,T95,Condition 1437 1445	pregnant
137,T96,Person 1468 1475	females
138,*,OR T95 T94
0,T1,Condition 7 21	uterine cavity
1,T2,Qualifier 0 6	Normal
2,T3,Qualifier 23 29	Normal
3,T4,Measurement 30 52	Hormonal investigation
4,T5,Measurement 54 57	TSH
5,T6,Measurement 58 61	PRL
6,T7,Measurement 62 65	FBS
7,R1,Has_qualifier Arg1:T4 Arg2:T3
8,T8,"Scope 54 65	TSH,PRL,FBS"
9,R2,Subsumes Arg1:T4 Arg2:T8
10,T9,Procedure 67 96	Frozen embryo transfer cycles
11,T10,Multiplier 98 108	at least 2
12,T11,Condition 109 116	embryos
13,R3,Has_multiplier Arg1:T11 Arg2:T10
14,R4,AND Arg1:T9 Arg2:T11
15,T12,Condition 118 125;139 150	Primary infertility
16,T13,Condition 129 138;139 150	secondary infertility
17,*,OR T13 T12
18,T14,Condition 152 167	tubal occlusion
19,T15,Observation 169 180	male factor
20,T16,Observation 182 193;218 225	unexplained factors
21,T17,Condition 195 208	endometriosis
22,T18,Observation 210 225	ovarian factors
23,T19,"Scope 152 225	tubal occlusion, male factor, unexplained, endometriosis, ovarian factors"
24,*,OR T14 T15 T16 T17 T18
25,T20,Scope 118 150	Primary or secondary infertility
26,R5,Subsumes Arg1:T20 Arg2:T19
27,T21,Measurement 228 243	Body mass index
28,T22,Measurement 245 248	BMI
29,T23,Value 250 266	=18 to =30 kg/m2
30,R6,Subsumes Arg1:T21 Arg2:T22
31,R7,Has_value Arg1:T21 Arg2:T23
0,T1,Informed_consent 0 81	Has given written informed consent before any study-related activity is performed
1,T2,Qualifier 92 109	hormone-dependent
2,T3,Qualifier 83 91	Advanced
3,T4,Condition 110 125	prostate cancer
4,T5,Procedure 136 164	androgen deprivation therapy
5,R1,AND Arg1:T4 Arg2:T5
6,R2,Has_qualifier Arg1:T4 Arg2:T2
7,R3,Has_qualifier Arg1:T4 Arg2:T3
8,T6,Drug 214 222	Firmagon
9,T7,Mood 227 235	intended
10,R4,Has_mood Arg1:T6 Arg2:T7
11,R5,AND Arg1:T4 Arg2:T6
12,T8,Person 262 265	Age
13,T9,Value 266 322	greater than or equal to 18 years and less than 80 years
14,R6,Has_value Arg1:T8 Arg2:T9
15,T10,Qualifier 324 332	Advanced
16,T11,Qualifier 333 350	hormone-dependent
17,T12,Condition 351 366	prostate cancer
18,R7,Has_qualifier Arg1:T12 Arg2:T11
19,R8,Has_qualifier Arg1:T12 Arg2:T10
20,T13,Non-query-able 367 416	without any other clinically significant disorder
21,T14,Measurement 418 457	Easten Cooperative Oncology Group score
22,T15,Value 458 461	= 2
23,R9,Has_value Arg1:T14 Arg2:T15
24,T16,Measurement 463 466	PSA
25,T17,Value 467 476	= 2 ng/mL
26,R10,Has_value Arg1:T16 Arg2:T17
27,T18,Observation 491 506	Life expectancy
28,T19,Value 510 528	at least 12 months
29,R11,Has_value Arg1:T18 Arg2:T19
0,T1,Condition 22 39	medical condition
1,T3,Qualifier 12 21	untreated
2,T2,Condition 41 56	thyroid disease
3,T4,Condition 58 75	diabetes mellitus
4,T5,Condition 77 89	hypertension
5,T6,Condition 91 111	pulmonary conditions
6,T7,Condition 113 130	cardiac condition
7,*,OR T2 T4 T5 T6 T7
8,T8,"Scope 41 130	thyroid disease, diabetes mellitus, hypertension, pulmonary conditions, cardiac condition"
9,R1,Has_qualifier Arg1:T1 Arg2:T3
10,R2,Has_scope Arg1:T1 Arg2:T8
11,T9,Qualifier 0 11	Preexisting
12,R3,Has_qualifier Arg1:T1 Arg2:T9
13,T10,Multiplier 145 158	three or more
14,T11,Procedure 180 202	In Vitro Fertilization
15,T12,Procedure 204 207	IVF
16,T13,Qualifier 159 179	consecutively failed
17,R4,Subsumes Arg1:T11 Arg2:T12
18,T14,Temporal 216 237	after embryo transfer
19,T15,Reference_point 222 237	embryo transfer
20,T16,Procedure 222 237	embryo transfer
21,R5,AND Arg1:T15 Arg2:T16
22,R6,Has_index Arg1:T14 Arg2:T15
23,R7,Has_qualifier Arg1:T11 Arg2:T13
24,R8,Has_multiplier Arg1:T11 Arg2:T10
25,R9,Has_temporal Arg1:T11 Arg2:T14
26,T17,Multiplier 250 263	three or more
27,T18,Condition 264 276	miscarriages
28,R10,Has_multiplier Arg1:T18 Arg2:T17
29,T19,Condition 287 294	allergy
30,T20,Drug 308 329	progesterone products
31,R11,AND Arg1:T19 Arg2:T20
0,T1,Procedure 23 42	hormonal management
1,T2,Condition 46 61	prostate cancer
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 63 79	Contraindication
4,T4,Drug 100 108	Firmagon
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Drug 139 162	5-a-reductase inhibitor
7,T6,Procedure 194 210	curative therapy
8,T7,Condition 240 246	asthma
9,T8,Qualifier 230 239	untreated
10,T9,Qualifier 223 229	severe
11,T10,Condition 248 270	anaphylactic reactions
12,T11,Condition 281 290	urticaria
13,T12,Qualifier 274 280	severe
14,R3,Has_qualifier Arg1:T11 Arg2:T12
15,T13,Condition 298 308	angioedema
16,R4,Has_qualifier Arg1:T7 Arg2:T8
17,R5,Has_qualifier Arg1:T7 Arg2:T9
18,*,OR T7 T10 T11 T13
19,T14,Measurement 310 322	QTc interval
20,T15,Value 323 336	over 450 msec
21,R6,Has_value Arg1:T14 Arg2:T15
22,T16,Observation 340 376	risk factors for torsades de pointes
23,T17,Drug 396 433	Class III anti arrhythmic medications
24,T18,Drug 383 391;406 433	Class IA anti arrhythmic medications
25,*,OR T17 T18 T16 T14
26,T19,Condition 435 441	Cancer
27,T20,Temporal 453 465	last 5 years
28,R7,Has_temporal Arg1:T19 Arg2:T20
29,T21,Negation 466 472	except
30,T22,Condition 473 488	prostate cancer
31,T23,Condition 521 556	squamous cell carcinoma of the skin
32,T24,Condition 512 517;530 556	basal cell carcinoma of the skin
33,*,OR T23 T24
34,T25,Procedure 493 503	surgically
35,T26,Scope 512 556	basal or squamous cell carcinoma of the skin
36,R8,AND Arg1:T26 Arg2:T25
37,*,OR T22 T26
38,T27,Scope 473 556	prostate cancer and surgically removed basal or squamous cell carcinoma of the skin
39,R9,Has_negation Arg1:T27 Arg2:T21
40,T28,Condition 598 613	biliary disease
41,T29,Condition 577 584;606 613	hepatic disease
42,*,OR T28 T29
43,T30,Qualifier 629 637	moderate
44,T31,Qualifier 641 647	severe
45,T32,Condition 648 674	chronic hepatic impairment
46,*,OR T30 T31
47,T33,Scope 629 647	moderate to severe
48,R10,Has_scope Arg1:T32 Arg2:T33
49,R11,Subsumes Arg1:T29 Arg2:T32
50,T34,Non-query-able 677 777	Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer
51,T35,Condition 792 809;880 890	Hepatitis B Virus infections
52,T36,Condition 817 834;880 890	Hepatitis C Virus infections
53,T37,Condition 811 814	HBV
54,T38,Condition 836 839	HCV
55,T39,Condition 845 873;880 890	Human Immunodeficiency Virus infections
56,T40,Condition 875 878	HIV
57,*,OR T39 T36 T35
58,R12,Subsumes Arg1:T35 Arg2:T37
59,R13,Subsumes Arg1:T36 Arg2:T38
60,R14,Subsumes Arg1:T39 Arg2:T40
0,T1,Condition 0 12	Septic shock
1,T2,Procedure 30 57	early goal directed therapy
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Post-eligibility 59 90	Agree to participate this study
0,T1,Person 0 16	Mexican-american
1,T2,Person 18 24	Female
2,T3,Measurement 26 29	BMI
3,T4,Value 30 35	30-42
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Informed_consent 37 69	willingness to complete protocol
6,T6,Condition 71 83	pre-diabetic
7,T7,Non-query-able 85 112	English or Spanish literate
0,T1,Measurement 20 31;38 53	hepatitis B surface antigen
1,T2,Value 11 19	positive
2,T3,Measurement 62 69	HBV DNA
3,*,OR T1 T3
4,T4,Temporal 70 89	prior to enrollment
5,T5,Reference_point 79 89	enrollment
6,R3,Has_index Arg1:T4 Arg2:T5
7,T6,"Scope 20 69	hepatitis B (HBV) surface antigen, and/or HBV DNA"
8,R1,Has_value Arg1:T6 Arg2:T2
9,R2,Has_temporal Arg1:T6 Arg2:T4
10,T7,Procedure 113 143	HCV protease inhibitor therapy
11,T8,Condition 145 161	HIV co-infection
12,T9,Drug 170 188	protease inhibitor
13,R4,AND Arg1:T8 Arg2:T9
14,T10,Measurement 216 226	creatinine
15,T11,Value 204 212;227 244	Increase of 15% or greater
16,R5,Has_value Arg1:T10 Arg2:T11
17,T12,Temporal 245 261	within one month
18,T13,Temporal 263 270	30 days
19,R6,Subsumes Arg1:T12 Arg2:T13
20,R7,Has_temporal Arg1:T10 Arg2:T12
21,T14,Condition 308 332	hepatocellular carcinoma
22,T15,Condition 360 373	Liver disease
23,T16,Negation 396 401	other
24,T17,Observation 407 410	HCV
25,R8,Has_negation Arg1:T17 Arg2:T16
26,T18,Condition 418 441	decompensated cirrhotic
27,T19,Observation 412 414	F4
28,*,OR T18 T19
29,T20,Measurement 477 480	AST
30,T21,Measurement 484 487	ALT
31,T22,Value 488 492	>350
32,T23,Temporal 493 528	within 6 months prior to enrollment
33,T24,Reference_point 518 528	enrollment
34,R9,Has_index Arg1:T23 Arg2:T24
35,*,OR T20 T21
36,T25,Scope 477 487	AST or ALT
37,R10,Has_value Arg1:T25 Arg2:T22
38,R11,Has_temporal Arg1:T25 Arg2:T23
39,T26,Measurement 452 468	Child Pugh class
40,T27,Value 469 475	B or C
41,R12,Has_value Arg1:T26 Arg2:T27
42,T28,Measurement 530 537	Albumin
43,T29,Value 538 545	< 3g/dL
44,R13,Has_value Arg1:T28 Arg2:T29
45,T30,Measurement 573 587	Platelet count
46,T31,Value 588 592	< 75
47,R14,Has_value Arg1:T30 Arg2:T31
48,T32,Condition 654 661	allergy
49,T33,Condition 665 678	adverse event
50,T34,Drug 684 703	protease inhibitors
51,*,OR T33 T32
52,T35,Scope 654 678	allergy or adverse event
53,R15,AND Arg1:T35 Arg2:T34
54,T36,Condition 721 739	acquisition of HCV
55,T37,Temporal 740 779	at the time of or after transplantation
56,T38,Reference_point 764 779	transplantation
57,R16,Has_index Arg1:T37 Arg2:T38
58,R17,Has_temporal Arg1:T36 Arg2:T37
59,T39,Pregnancy_considerations 781 812	Pregnant or breastfeeding women
60,T40,Drug 814 826	Cyclosporine
61,T41,Drug 828 843	St. John's Wort
62,T42,Drug 845 854	Efavirenz
63,T43,Drug 856 865	Phenytoin
64,T44,Drug 867 880	Carbamazepine
65,T45,Drug 882 890	Bosentan
66,T46,Drug 892 915	HIV protease inhibitors
67,T47,Drug 917 926	modafinil
68,T48,Drug 928 940	ketoconazole
69,T49,Drug 945 953	rifampin
70,T50,Temporal 958 985	within 7 days of enrollment
71,T51,Reference_point 975 985	enrollment
72,R18,Has_index Arg1:T50 Arg2:T51
73,*,OR T40 T41 T42 T43 T44 T45 T46 T47 T48 T49
74,T52,Scope 814 953	Cyclosporine; St. John's Wort; Efavirenz; Phenytoin; Carbamazepine; Bosentan; HIV protease inhibitors; modafinil; ketoconazole; or rifampin
75,R19,Has_temporal Arg1:T52 Arg2:T50
76,T53,Multiplier 1007 1022	more than 20 mg
77,T54,Drug 1023 1035	atorvastatin
78,T55,Multiplier 1007 1016;1037 1042	more than 10 mg
79,T56,Multiplier 1007 1016;1057 1062	more than 20 mg
80,R20,Has_multiplier Arg1:T54 Arg2:T53
81,T57,Drug 1043 1055	rosuvastatin
82,T58,Drug 1066 1077	fluvastatin
83,T59,Drug 1079 1089	lovastatin
84,T60,Drug 1093 1104	simvastatin
85,*,OR T60 T59 T58
86,T61,"Scope 1066 1104	fluvastatin, lovastatin or simvastatin"
87,R21,Has_multiplier Arg1:T61 Arg2:T56
88,R22,Has_multiplier Arg1:T57 Arg2:T55
89,*,OR T54 T57 T61
0,T1,Person 0 3	Age
1,T2,Value 4 22	less than 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 24 66	American Society of Anesthesiologist Class
4,T4,Value 67 68	5
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Observation 70 95	Projected life expectancy
7,T6,Value 96 113	less than 30 days
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Mood 115 120	Known
10,T8,Mood 124 133	suspected
11,T9,Condition 134 150	hypersensitivity
12,T10,Drug 161 169	propofol
13,T11,Drug 176 179	egg
14,T12,Drug 183 186	soy
15,T13,Condition 187 194	allergy
16,T14,Drug 199 233	volatile general anesthetic agents
17,*,OR T12 T11
18,T15,Scope 176 186	egg or soy
19,R4,Has_scope Arg1:T13 Arg2:T15
20,*,OR T10 T14
21,T16,Scope 161 169;199 233	propofol volatile general anesthetic agents
22,R5,Has_scope Arg1:T9 Arg2:T16
23,*,OR T9 T13
24,*,OR T8 T7
25,T17,Scope 115 133	Known or suspected
26,R6,Has_scope Arg1:T9 Arg2:T17
27,T19,Condition 265 287	malignant hyperthermia
28,T18,Mood 235 240	Known
29,T20,Mood 244 253	suspected
30,T21,Observation 254 261	history
31,*,OR T20 T18
32,R7,Has_temporal Arg1:T19 Arg2:T21
33,T22,Scope 235 253	Known or suspected
34,R8,Has_scope Arg1:T19 Arg2:T22
0,T1,Person 0 3	Age
1,T2,Value 3 7	< 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 9 18	Pregnancy
4,T4,Condition 20 31	Bradycardia
5,T5,Measurement 33 35	HR
6,T6,Value 35 41	<55bpm
7,R2,Has_value Arg1:T5 Arg2:T6
8,R3,Subsumes Arg1:T4 Arg2:T5
9,T7,Measurement 44 67	Systolic Blood Pressure
10,T8,Value 68 77	< 80 mmHg
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Measurement 80 102	Mean arterial pressure
13,T10,Value 103 112	< 50 mmHg
14,R5,Has_value Arg1:T9 Arg2:T10
15,T11,Qualifier 113 131	on maximal support
16,*,OR T7 T9
17,T12,Scope 44 112	Systolic Blood Pressure < 80 mmHg / Mean arterial pressure < 50 mmHg
18,R6,Has_qualifier Arg1:T12 Arg2:T11
19,T13,Procedure 124 131	support
20,R7,multi Arg1:T11 Arg2:T13
21,T14,Condition 133 138	Death
22,T15,Temporal 139 147	imminent
23,R8,Has_temporal Arg1:T14 Arg2:T15
24,T16,Non-representable 149 176	Unlikely to survive 90 days
25,T17,Condition 178 197	Acute liver failure
26,T18,Condition 199 207	Dementia
27,T19,Condition 209 225	High-grade block
28,T20,Negation 226 243	in the absence of
29,T21,Device 258 267	pacemaker
30,T22,Qualifier 246 257	functioning
31,R9,Has_qualifier Arg1:T21 Arg2:T22
32,R10,Has_negation Arg1:T21 Arg2:T20
33,R11,AND Arg1:T19 Arg2:T21
0,T1,Condition 0 8	pregnant
1,T2,Observation 28 57	moderate to vigorous activity
2,T3,Multiplier 58 84	more than 3 times per week
3,T4,Multiplier 10 24	30 min or more
4,R1,Has_multiplier Arg1:T2 Arg2:T4
5,R2,Has_multiplier Arg1:T2 Arg2:T3
6,T5,Condition 86 108	cardiovascular disease
7,T6,Condition 110 130	physical limitations
8,T7,Qualifier 145 158;168 185	aggravated by physical activity
9,T8,Qualifier 159 167	moderate
10,R3,Has_qualifier Arg1:T7 Arg2:T8
11,R4,Has_qualifier Arg1:T6 Arg2:T7
12,T9,Observation 187 203	planning to move
13,T10,Temporal 204 224	in next 12-24 months
14,R5,Has_temporal Arg1:T9 Arg2:T10
15,T11,Condition 226 234	diabetic
0,T1,Person 21 24	age
1,T2,Value 0 17	At least 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 63 77	renal function
4,T4,Value 56 62	stable
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Temporal 82 121	one month (30 days) prior to enrollment
7,T6,Reference_point 111 121	enrollment
8,R3,Has_index Arg1:T5 Arg2:T6
9,R4,Has_temporal Arg1:T3 Arg2:T5
10,T7,Condition 128 149	Chronic HCV infection
11,T8,Temporal 150 174	prior to transplantation
12,T9,Reference_point 159 174	transplantation
13,R5,Has_temporal Arg1:T7 Arg2:T8
14,R6,Has_index Arg1:T8 Arg2:T9
15,T10,Measurement 191 202	HCV viremia
16,T11,"Value 203 216	= 1,000 IU/ml"
17,T12,Measurement 252 258	HCV Ab
18,T13,Value 259 269	positivity
19,T14,Measurement 273 284	HCV viremia
20,T15,"Value 285 298	= 1,000 IU/ml"
21,T16,Temporal 299 337	at least 6 months prior to enrollment.
22,T17,Reference_point 326 336	enrollment
23,R7,Has_value Arg1:T10 Arg2:T11
24,R8,Has_value Arg1:T12 Arg2:T13
25,R9,Has_value Arg1:T14 Arg2:T15
26,*,OR T12 T14
27,T18,"Scope 252 298	HCV Ab positivity or HCV viremia = 1,000 IU/ml"
28,R10,Has_temporal Arg1:T18 Arg2:T16
29,R11,Has_index Arg1:T16 Arg2:T17
30,R12,AND Arg1:T7 Arg2:T10
31,R13,Has_scope Arg1:T7 Arg2:T18
32,T19,Qualifier 350 360	genotype 1
33,T20,Condition 361 374	HCV infection
34,T21,Temporal 375 394	prior to enrollment
35,T22,Temporal 399 423	after their transplant i
36,T23,Reference_point 384 394	enrollment
37,T24,Reference_point 411 421	transplant
38,R14,Has_index Arg1:T21 Arg2:T23
39,R15,Has_index Arg1:T22 Arg2:T24
40,R16,Has_qualifier Arg1:T20 Arg2:T19
41,R17,Has_temporal Arg1:T20 Arg2:T21
42,R18,Has_temporal Arg1:T20 Arg2:T22
43,T25,Procedure 462 477	disease staging
44,T26,Qualifier 458 461	HCV
45,R19,Has_qualifier Arg1:T25 Arg2:T26
46,T27,Temporal 478 514	within 12 months prior to enrollment
47,T28,Reference_point 504 514	enrollment
48,R20,Has_index Arg1:T27 Arg2:T28
49,R21,Has_temporal Arg1:T25 Arg2:T27
50,T29,Procedure 518 530	liver biopsy
51,T30,Procedure 532 554	transient elastography
52,T31,Procedure 559 578	biochemical testing
53,*,OR T29 T30 T31
54,T32,"Scope 518 578	liver biopsy, transient elastography, or biochemical testing"
55,R22,Subsumes Arg1:T25 Arg2:T32
56,T33,Informed_consent 580 645	Be able to give informed consent and comply with study guidelines
57,T34,Pregnancy_considerations 647 797	Women of childbearing age will be required to have a negative pregnancy test at enrollment and use birth control throughout the duration of treatment.
58,T35,Non-query-able 799 928	On the transplant waiting list followed by the University of Maryland's nephrology clinic or the Baltimore VA's nephrology clinic
59,T36,Procedure 941 953	hemodialysis
60,T37,Qualifier 933 940	chronic
61,R23,Has_qualifier Arg1:T36 Arg2:T37
62,T38,Non-query-able 954 1078	not yet on the transplant list and followed in the University's hemodialysis center or in the University's nephrology clinic
63,T39,Condition 1085 1107	chronic kidney disease
64,T40,Measurement 1113 1116	GFR
65,T41,Value 1117 1120	<50
66,R24,Has_value Arg1:T40 Arg2:T41
67,R25,AND Arg1:T39 Arg2:T40
0,T1,Procedure 0 9	Lobectomy
1,T2,Procedure 13 26	pneumonectomy
2,*,OR T1 T2
3,T3,Procedure 28 41	Esophagectomy
4,T4,Procedure 43 50;59 69	Radical cystectomy
5,T5,Procedure 71 85	Pancreatectomy
6,T6,Procedure 52 57;59 69	total cystectomy
7,R1,Subsumes Arg1:T4 Arg2:T6
8,T7,Procedure 87 106	Partial hepatectomy
9,T8,Procedure 108 149	Hyperthermic intraperitoneal chemotherapy
10,T9,Procedure 151 156	HIPEC
11,R2,Subsumes Arg1:T8 Arg2:T9
12,T10,Procedure 159 170	Gastrectomy
13,T11,Qualifier 172 180	subtotal
14,T12,Qualifier 184 189	total
15,*,OR T11 T12
16,T13,Scope 172 189	subtotal or total
17,R3,Has_scope Arg1:T10 Arg2:T13
18,T14,Procedure 192 207	Cholecystectomy
19,T15,Procedure 211 230	bile duct resection
20,*,OR T14 T15
0,T1,Person 10 18	Homeless
1,T2,Observation 20 26	Smoked
2,T3,Multiplier 27 50	at least 100 cigarettes
3,R1,Has_multiplier Arg1:T2 Arg2:T3
4,T4,Measurement 64 69	AUDIT
5,T5,"Value 70 112	score of > or equal to 5, < or equal to 26"
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Person 114 118	Aged
8,T7,Value 119 136	18 years or older
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Post-eligibility 138 202	Willing to attend study sessions and follow other study protocol
0,T1,Parsing_Error 5509 5511	2.
1,T2,Parsing_Error 5380 5382	1.
2,T3,Parsing_Error 5317 5320	12.
3,T4,Parsing_Error 5206 5208	2.
4,T5,Parsing_Error 4961 4963	1.
5,T6,Parsing_Error 4909 4912	11.
6,T7,Parsing_Error 4789 4791	2.
7,T8,Parsing_Error 4719 4721	1.
8,T9,Parsing_Error 4587 4590	10.
9,T10,Parsing_Error 4523 4525	2.
10,T11,Parsing_Error 4436 4438	1.
11,T12,Parsing_Error 4258 4260	9.
12,T13,Parsing_Error 4082 4084	2.
13,T14,Parsing_Error 3951 3953	1.
14,T15,Parsing_Error 3703 3705	8.
15,T16,Parsing_Error 3343 3345	2.
16,T17,Parsing_Error 3117 3119	1.
17,T18,Parsing_Error 2916 2918	7.
18,T19,Parsing_Error 2797 2799	2.
19,T20,Parsing_Error 2549 2551	1.
20,T21,Parsing_Error 2444 2446	6.
21,T22,Parsing_Error 2250 2252	2.
22,T23,Parsing_Error 2120 2122	1.
23,T24,Parsing_Error 1936 1938	5.
24,T25,Parsing_Error 1887 1889	2.
25,T26,Parsing_Error 1731 1733	1.
26,T27,Parsing_Error 1687 1689	4.
27,T28,Parsing_Error 1600 1602	2.
28,T29,Parsing_Error 1439 1441	1.
29,T30,Parsing_Error 1101 1103	3.
30,T31,Parsing_Error 1036 1038	2.
31,T32,Parsing_Error 708 710	1.
32,T33,Parsing_Error 556 558	2.
33,T34,Parsing_Error 0 2	1.
34,T35,Procedure 5528 5562	TMS safety screening questionnaire
35,T36,Not_a_criteria 5512 5563	Screening tool: TMS safety screening questionnaire.
36,T37,"Not_a_criteria 5383 5507	Justification: in order to limit exposure to TMS, we will not enroll subjects who have received TMS less than two weeks ago."
37,T38,Procedure 5341 5353	rTMS session
38,T39,Temporal 5354 5377	less than two weeks ago
39,R1,Has_temporal Arg1:T38 Arg2:T39
40,T40,Procedure 5225 5267	Wechsler Abbreviated Scale of Intelligence
41,T41,Observation 5269 5284	Medical history
42,T42,Procedure 5286 5314	Adult ADHD Self-Report Scale
43,T43,"Not_a_criteria 5209 5315	Screening tool: Wechsler Abbreviated Scale of Intelligence, Medical history, Adult ADHD Self-Report Scale."
44,T44,"Not_a_criteria 4964 5108	Justification: Subjects should be able to perform cognitive tasks to a high degree of accuracy, both in the MRI scanner and outside the scanner."
45,T45,Condition 5123 5127	ADHD
46,T46,Condition 5128 5130	LD
47,T47,Parsing_Error 5109 5204	Subjects with ADHD/LD may engage different neural circuitry even if they can perform the tasks.
48,T48,Not_a_criteria 5109 5204	Subjects with ADHD/LD may engage different neural circuitry even if they can perform the tasks.
49,T49,"Parsing_Error 4964 5108	Justification: Subjects should be able to perform cognitive tasks to a high degree of accuracy, both in the MRI scanner and outside the scanner."
50,T50,"Parsing_Error 5383 5507	Justification: in order to limit exposure to TMS, we will not enroll subjects who have received TMS less than two weeks ago."
51,T51,Parsing_Error 5512 5563	Screening tool: TMS safety screening questionnaire.
52,T52,Condition 4924 4943	learning disability
53,T53,Temporal 4947 4954	current
54,T54,Observation 4913 4920	History
55,T55,Condition 4955 4959	ADHD
56,R2,Has_temporal Arg1:T55 Arg2:T53
57,R3,Has_temporal Arg1:T52 Arg2:T54
58,*,OR T52 T55
59,T56,Measurement 4829 4849	urine pregnancy test
60,T57,Procedure 4808 4827	Medical assessments
61,R4,Subsumes Arg1:T57 Arg2:T56
62,T58,Temporal 4851 4881	at the beginning of each visit
63,T59,Reference_point 4854 4881	the beginning of each visit
64,R5,Has_index Arg1:T58 Arg2:T59
65,R6,Has_temporal Arg1:T57 Arg2:T58
66,T60,Procedure 4896 4899	TMS
67,T61,Procedure 4903 4906	MRI
68,*,OR T60 T61
69,T62,Scope 4896 4906	TMS or MRI
70,R7,Has_scope Arg1:T57 Arg2:T62
71,T63,Parsing_Error 4722 4787	Justification: it is unknown whether TMS poses a risk to fetuses.
72,T64,Not_a_criteria 4722 4787	Justification: it is unknown whether TMS poses a risk to fetuses.
73,T65,Condition 4591 4599	Pregnant
74,T66,Person 4600 4605	women
75,T67,Person 4609 4614	women
76,T68,Condition 4620 4642	reproductive potential
77,T69,Condition 4651 4666	sexually active
78,T70,Condition 4703 4716	contraception
79,T71,Qualifier 4684 4702	acceptable form of
80,R8,Has_qualifier Arg1:T70 Arg2:T71
81,T72,Subjective_judgement 4684 4702	acceptable form of
82,T73,Negation 4671 4674	not
83,R9,Has_negation Arg1:T70 Arg2:T73
84,T74,Scope 4591 4605	Pregnant women
85,T75,Scope 4609 4716	women with reproductive potential who are sexually active and not using an acceptable form of contraception
86,*,OR T75 T74
87,T76,"Parsing_Error 4526 4585	Screening tool: physical assessment (EKG), medical history."
88,T77,"Not_a_criteria 4526 4585	Screening tool: physical assessment (EKG), medical history."
89,T78,Parsing_Error 4439 4521	Justifications: the risk of TMS for individuals with a heart condition is unknown.
90,T79,Not_a_criteria 4439 4521	Justifications: the risk of TMS for individuals with a heart condition is unknown.
91,T80,Condition 4272 4293	myocardial infarction
92,T81,Condition 4295 4301	angina
93,T82,Condition 4303 4327	congestive heart failure
94,T83,Condition 4329 4343	cardiomyopathy
95,T84,Condition 4345 4351	stroke
96,T85,Condition 4355 4380	transient ischemic attack
97,T86,Condition 4389 4404	heart condition
98,T87,Qualifier 4415 4433	under medical care
99,T88,Temporal 4405 4414	currently
100,R10,Has_temporal Arg1:T87 Arg2:T88
101,R11,Has_qualifier Arg1:T86 Arg2:T87
102,T89,Undefined_semantics 4389 4433	heart condition currently under medical care
103,*,OR T84 T83 T82 T81 T80
104,T90,Observation 4261 4268	History
105,T91,"Scope 4272 4380	myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack"
106,R12,Has_temporal Arg1:T91 Arg2:T90
107,*,OR T91 T86
108,T92,Not_a_criteria 2800 2851	Screening tools: SCID Screen Patient Questionnaire.
109,T93,Parsing_Error 2800 2851	Screening tools: SCID Screen Patient Questionnaire.
110,T94,Not_a_criteria 2852 2914	Potential diagnoses will be further evaluated by a counsellor.
111,T95,Not_a_criteria 3120 3230	Justification: The population of interest here is a healthy control population with no substance use disorder.
112,T96,Parsing_Error 3120 3230	Justification: The population of interest here is a healthy control population with no substance use disorder.
113,T97,Measurement 2932 2946	DSM V criteria
114,T98,Qualifier 2951 2969	moderate to severe
115,T99,Condition 2970 2992	substance use disorder
116,T100,Drug 3004 3012	nicotine
117,T101,Negation 2994 3003	excluding
118,R13,Has_negation Arg1:T100 Arg2:T101
119,T102,Observation 3015 3026	smoke daily
120,T103,Measurement 3031 3047	urine toxicology
121,T104,Value 3048 3056	positive
122,T105,Drug 3065 3082	illicit substance
123,T106,Qualifier 3083 3108	inconsistent with history
124,T107,Subjective_judgement 3083 3108	inconsistent with history
125,R14,Has_qualifier Arg1:T105 Arg2:T106
126,R15,Has_value Arg1:T103 Arg2:T104
127,T108,Undefined_semantics 3031 3047	urine toxicology
128,T109,Undefined_semantics 3065 3082	illicit substance
129,*,OR T103 T102
130,T110,Parsing_Error 3231 3341	Current use of illicit substances could impact on seizure threshold and is therefore contra-indicated for TMS.
131,T111,Not_a_criteria 3231 3341	Current use of illicit substances could impact on seizure threshold and is therefore contra-indicated for TMS.
132,R16,AND Arg1:T103 Arg2:T105
133,R17,AND Arg1:T99 Arg2:T100
134,R18,Has_qualifier Arg1:T99 Arg2:T98
135,R19,AND Arg1:T97 Arg2:T99
136,T112,Value 2919 2923	Meet
137,R20,Has_value Arg1:T97 Arg2:T112
138,T113,Not_a_criteria 4137 4198	Potential diagnoses will be further evaluated by a counselor.
139,T114,Subjective_judgement 4137 4198	Potential diagnoses will be further evaluated by a counselor.
140,T115,Procedure 4199 4220	Drug Use Survey (DUS)
141,T116,Procedure 4222 4255	Substance Use Disorder Evaluation
142,T117,"Not_a_criteria 4199 4256	Drug Use Survey (DUS), Substance Use Disorder Evaluation."
143,T118,"Parsing_Error 4199 4256	Drug Use Survey (DUS), Substance Use Disorder Evaluation."
144,T119,Parsing_Error 4137 4198	Potential diagnoses will be further evaluated by a counselor.
145,T120,Procedure 4102 4135	SCID Screen Patient Questionnaire
146,T121,Parsing_Error 4085 4136	Screening tools: SCID Screen Patient Questionnaire.
147,T122,Not_a_criteria 4085 4136	Screening tools: SCID Screen Patient Questionnaire.
148,T123,Parsing_Error 3954 4080	Justification: the population of interest here is a healthy control population with no present or past substance use disorder.
149,T124,Not_a_criteria 3954 4080	Justification: the population of interest here is a healthy control population with no present or past substance use disorder.
150,T125,Measurement 3715 3729	DSM V criteria
151,T126,Value 3711 3714	met
152,R21,Has_value Arg1:T125 Arg2:T126
153,T127,Qualifier 3734 3752	moderate to severe
154,T128,Condition 3753 3775	substance use disorder
155,T129,Drug 3787 3795	nicotine
156,T130,Drug 3797 3804	alcohol
157,T131,Drug 3809 3817	cannabis
158,T132,Negation 3777 3786	excluding
159,R22,Has_negation Arg1:T129 Arg2:T132
160,R23,Has_negation Arg1:T130 Arg2:T132
161,R24,Has_negation Arg1:T131 Arg2:T132
162,T133,Temporal 3819 3830	in the past
163,T134,Measurement 3844 3858	DSM V criteria
164,T135,Value 3840 3843	met
165,R25,Has_value Arg1:T134 Arg2:T135
166,T136,"Scope 3777 3817	excluding nicotine, alcohol and cannabis"
167,R26,Has_scope Arg1:T128 Arg2:T136
168,R27,Has_qualifier Arg1:T128 Arg2:T127
169,R28,AND Arg1:T125 Arg2:T128
170,R29,Has_temporal Arg1:T128 Arg2:T133
171,*,OR T128 T134
172,T137,Qualifier 3863 3881	moderate to severe
173,T138,Condition 3882 3904	substance use disorder
174,T139,Drug 3909 3917	cannabis
175,T140,Drug 3921 3928	alcohol
176,T141,Temporal 3929 3948	in the past 5 years
177,*,OR T140 T139
178,T142,Scope 3909 3928	cannabis or alcohol
179,R30,Has_scope Arg1:T138 Arg2:T142
180,R31,Has_temporal Arg1:T138 Arg2:T141
181,R32,Has_qualifier Arg1:T138 Arg2:T137
182,R33,AND Arg1:T134 Arg2:T138
183,T143,"Not_a_criteria 3398 3701	Potential diagnoses will be further evaluated by a counsellor, Drug Use Survey (DUS), Substance Use Disorder Evaluation, Medical Assessments: urine qualitative drug screen is performed for methadone, benzodiazepines, cocaine, amphetamine/methamphetamine, opiates, barbiturates, and tetrahydrocannabinol."
184,T144,"Parsing_Error 3398 3701	Potential diagnoses will be further evaluated by a counsellor, Drug Use Survey (DUS), Substance Use Disorder Evaluation, Medical Assessments: urine qualitative drug screen is performed for methadone, benzodiazepines, cocaine, amphetamine/methamphetamine, opiates, barbiturates, and tetrahydrocannabinol."
185,T145,Parsing_Error 3346 3397	Screening tools: SCID Screen Patient Questionnaire.
186,T146,Not_a_criteria 3346 3397	Screening tools: SCID Screen Patient Questionnaire.
187,T147,Procedure 3363 3396	SCID Screen Patient Questionnaire
188,T148,Observation 12 22	history of
189,T149,Condition 23 29	stroke
190,T150,Condition 31 44	brain lesions
191,T151,Condition 55 67	neurosurgery
192,T152,Temporal 46 54	previous
193,R34,Has_temporal Arg1:T151 Arg2:T152
194,T153,Observation 73 92	personal history of
195,T154,Condition 93 100	seizure
196,T155,Condition 104 120	fainting episode
197,T156,Qualifier 124 137	unknown cause
198,T157,Condition 142 188	head trauma resulting in loss of consciousness
199,T158,Qualifier 190 213	lasting over 30 minutes
200,T159,Condition 222 229	sequela
201,T160,Measurement 230 237	lasting
202,T161,Value 238 258	longer than two days
203,R35,Has_value Arg1:T160 Arg2:T161
204,R36,AND Arg1:T159 Arg2:T160
205,*,OR T158 T159
206,T162,Scope 190 258	lasting over 30 minutes or with sequela lasting longer than two days
207,R37,Has_scope Arg1:T157 Arg2:T162
208,R38,Has_qualifier Arg1:T155 Arg2:T156
209,*,OR T155 T157 T154
210,T163,"Scope 93 258	seizure or fainting episode of unknown cause, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than two days"
211,R39,Has_temporal Arg1:T163 Arg2:T153
212,*,OR T149 T150 T151
213,T164,"Scope 23 67	stroke, brain lesions, previous neurosurgery"
214,R40,Has_temporal Arg1:T164 Arg2:T148
215,*,OR T164 T163
216,T165,"Non-representable 261 487	Justification: Stroke or head trauma can lower the seizure threshold, and are therefore contra-indications for TMS. Fainting episodes or syncope of unknown cause could indicate an undiagnosed condition associated with seizures"
217,T166,Procedure 506 536	TMS adult safety questionnaire
218,T167,Observation 538 553	Medical History
219,T168,Procedure 490 499	Screening
220,T169,"Scope 506 553	TMS adult safety questionnaire, Medical History"
221,R41,Has_scope Arg1:T168 Arg2:T169
222,T170,Qualifier 559 571	First-degree
223,T171,Observation 572 589	family history of
224,T172,Condition 594 615	neurological disorder
225,T173,Qualifier 623 651	potentially hereditary basis
226,T174,Condition 663 672	migraines
227,T175,Condition 674 682	epilepsy
228,T176,Condition 687 705	multiple sclerosis
229,*,OR T175 T176 T174
230,T177,"Scope 663 705	migraines, epilepsy, or multiple sclerosis"
231,R42,Has_qualifier Arg1:T172 Arg2:T173
232,T178,Scope 594 651	neurological disorder with a potentially hereditary basis
233,R43,Subsumes Arg1:T178 Arg2:T177
234,R44,Has_context Arg1:T178 Arg2:T171
235,R45,Has_qualifier Arg1:T171 Arg2:T170
236,T179,"Non-representable 711 1034	Justification: Neurological disorders can lower the seizure threshold, and are therefore contra-indications for TMS. First-degree family history of certain neurological disorders with a hereditary component increases the risk of the subject having an undiagnosed condition that is associated with lowered seizure threshold."
237,T180,Procedure 1039 1048	Screening
238,T181,Procedure 1055 1081	TMS adult safety screening
239,T182,Observation 1083 1098	Medical History
240,T183,"Scope 1055 1098	TMS adult safety screening, Medical History"
241,R46,Has_scope Arg1:T180 Arg2:T183
242,T184,Device 1104 1122	Cardiac pacemakers
243,T185,Device 1124 1142	neural stimulators
244,T186,Device 1144 1169	implantable defibrillator
245,T187,Device 1171 1197	implanted medication pumps
246,T188,Device 1199 1217	intracardiac lines
247,T189,Qualifier 1222 1227	acute
248,T190,Qualifier 1229 1237	unstable
249,T191,Condition 1238 1253	cardiac disease
250,R47,Has_qualifier Arg1:T191 Arg2:T190
251,R48,Has_qualifier Arg1:T191 Arg2:T189
252,T192,Device 1260 1281	intracranial implants
253,T193,Device 1288 1302	aneurysm clips
254,T194,Device 1304 1310	shunts
255,T195,Device 1312 1323	stimulators
256,T196,Device 1325 1342	cochlear implants
257,T197,Device 1347 1357	electrodes
258,T198,Device 1372 1408	metal object within or near the head
259,T199,Qualifier 1414 1436	precludes MRI scanning
260,T200,Negation 1414 1423	precludes
261,T201,Procedure 1424 1436	MRI scanning
262,R49,Has_negation Arg1:T201 Arg2:T200
263,R50,multi Arg1:T199 Arg2:T201
264,R51,Has_qualifier Arg1:T198 Arg2:T199
265,*,OR T197 T196 T195 T194 T193
266,T202,"Scope 1288 1357	aneurysm clips, shunts, stimulators, cochlear implants, or electrodes"
267,R52,Subsumes Arg1:T192 Arg2:T202
268,R53,AND Arg1:T191 Arg2:T192
269,*,OR T188 T187 T186 T185 T184 T191 T198
270,T203,"Non-representable 1442 1598	Justification: Any metal around the head is a contraindication for both MRI and TMS, as both methods involve exposure to a relatively strong magnetic field."
271,T204,Non-representable 1734 1885	Justification: individuals with noise-induced hearing problems may be particularly vulnerable to the acoustic noise generated by TMS and MRI equipment.
272,T205,Non-representable 2123 2248	Justification: The use of certain medications or drugs can lower seizure threshold and is therefore contra-indicated for TMS.
273,T206,"Non-representable 2552 2795	Justification: The population of interest here is a healthy control population with no psychiatric disorders. In subjects with depression, bipolar disorder, mania or hypomania, there is a small chance that TMS can trigger (hypo)manic symptoms."
274,T207,Procedure 1603 1612	Screening
275,T208,Procedure 1619 1645	TMS adult safety screening
276,T209,Procedure 1647 1667	MRI safety screening
277,T210,Observation 1669 1684	Medical History
278,T211,"Scope 1619 1684	TMS adult safety screening, MRI safety screening, Medical History"
279,R54,Subsumes Arg1:T207 Arg2:T211
280,T212,Condition 1690 1716	Noise-induced hearing loss
281,T213,Condition 1720 1728	tinnitus
282,*,OR T212 T213
283,T214,Procedure 1890 1899	Screening
284,T215,Procedure 1907 1933	TMS adult safety screening
285,R55,Subsumes Arg1:T214 Arg2:T215
286,T216,Qualifier 1939 1950	Current use
287,T217,Temporal 1960 1979	in the past 4 weeks
288,T218,Qualifier 1952 1959	any use
289,T219,Qualifier 1981 1992	chronic use
290,T220,Temporal 1993 2017	within 6 past six months
291,A1,Optional T218
292,A2,Optional T219
293,R56,Has_temporal Arg1:T218 Arg2:T217
294,R57,Has_temporal Arg1:T219 Arg2:T220
295,*,OR T218 T219
296,T221,"Scope 1952 2017	any use in the past 4 weeks, chronic use within 6 past six months"
297,T222,Temporal 1939 1950	Current use
298,R58,multi Arg1:T216 Arg2:T222
299,R59,Subsumes Arg1:T216 Arg2:T221
300,T223,Drug 2026 2046	investigational drug
301,T224,Drug 2057 2068	medications
302,T225,Qualifier 2074 2086;2111 2117	psychotropic action
303,T226,Qualifier 2096 2117	pro-convulsive action
304,*,OR T225 T226
305,T227,"Scope 2074 2117	psychotropic, anti or pro-convulsive action"
306,R60,Has_scope Arg1:T224 Arg2:T227
307,*,OR T223 T224
308,T228,"Scope 2026 2117	investigational drug or of any medications with psychotropic, anti or pro-convulsive action"
309,R61,Has_qualifier Arg1:T228 Arg2:T216
310,T229,Procedure 2253 2262	Screening
311,T230,Procedure 2270 2304	MRI safety screening questionnaire
312,T231,Procedure 2270 2273	MRI
313,T232,Procedure 2274 2304	safety screening questionnaire
314,R62,AND Arg1:T232 Arg2:T231
315,R63,multi Arg1:T230 Arg2:T232
316,T233,Procedure 2306 2321	Medical history
317,T234,Procedure 2344 2369	Urine toxicology analyzes
318,T235,Qualifier 2403 2415	prescription
319,T236,Qualifier 2420 2435	nonprescription
320,T237,Drug 2436 2441	drugs
321,*,OR T236 T235
322,T238,Scope 2403 2435	prescription and nonprescription
323,R64,Has_scope Arg1:T237 Arg2:T238
324,R65,AND Arg1:T234 Arg2:T237
325,T239,"Scope 2270 2441	MRI safety screening questionnaire, Medical history, Medical Assessments: Urine toxicology analyzes for presence of a broad range of prescription and nonprescription drugs"
326,R66,Subsumes Arg1:T229 Arg2:T239
327,T240,Observation 2447 2466	Lifetime history of
328,T241,Condition 2467 2492	major depressive disorder
329,T242,Condition 2494 2507	schizophrenia
330,T243,Condition 2509 2525	bipolar disorder
331,T244,Condition 2527 2532	mania
332,T245,Condition 2537 2546	hypomania
333,*,OR T245 T244 T243 T242 T241
334,T246,"Scope 2467 2546	major depressive disorder, schizophrenia, bipolar disorder, mania, or hypomania"
335,R67,Has_temporal Arg1:T246 Arg2:T240
0,T1,Condition 14 29	hepatocirrhosis
0,T1,Condition 35 54	Parkinson's disease
1,T2,Measurement 99 140	UK Parkinson's Disease Society Brain Bank
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Drug 174 194	levodopa combination
4,T4,Temporal 204 214	>= 1 month
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Parsing_Error 219 247	has either of the following.
7,T6,Condition 249 271	Wearing off phenomenon
8,T7,Condition 273 291	Decreased response
9,T8,Drug 296 321	evodopa combination drugs
10,R3,AND Arg1:T7 Arg2:T8
11,T9,Drug 354 379	levodopa combination drug
12,T10,Qualifier 380 414	without change in the dose regimen
13,R4,Has_qualifier Arg1:T9 Arg2:T10
14,T11,Person 464 468	aged
15,T12,Value 469 489	>= 30 and < 80 years
16,R5,Has_value Arg1:T11 Arg2:T12
0,T1,Measurement 20 41	Modified Hoehn & Yahr
1,T2,Value 42 49	stage 5
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 117 139	wearing off phenomenon
4,A1,Optional T3
5,T4,Temporal 62 64;72 79	at on-time
6,T5,Temporal 62 64;83 91	at off-time
7,*,OR T4 T5
8,T6,Value 54 61	stage 5
9,R2,Has_value Arg1:T3 Arg2:T6
10,T7,Scope 62 91	at eather on-time or off-time
11,R3,Has_scope Arg1:T6 Arg2:T7
12,T8,Scope 54 139	stage 5 at eather on-time or off-time for the participant with wearing off phenomenon
13,*,OR T2 T8
14,T9,Condition 170 180	dyskinesia
15,T10,Qualifier 163 169	severe
16,R4,Has_qualifier Arg1:T9 Arg2:T10
17,T11,Condition 212 228	systemic disease
18,T12,Undefined_semantics 212 228	systemic disease
19,T13,Qualifier 203 211	unstable
20,T14,Subjective_judgement 203 211	unstable
21,R5,Has_qualifier Arg1:T11 Arg2:T13
22,T15,Measurement 253 290	Mini-Mental State Examinations (MMSE)
23,T16,Value 300 305	<= 24
24,R6,Has_value Arg1:T15 Arg2:T16
25,T17,Condition 307 326	psychiatric disease
26,T18,Parsing_Error 231 327	The participant has a Mini-Mental State Examinations (MMSE) score of <= 24. psychiatric disease.
27,T19,Condition 385 397	hypertension
28,T20,Qualifier 362 384	clinically significant
29,T21,Subjective_judgement 362 384	clinically significant
30,R7,Has_qualifier Arg1:T19 Arg2:T20
31,T22,Condition 407 464	reactions associated with ingestion of tyramine-rich food
32,T23,Undefined_semantics 407 464	reactions associated with ingestion of tyramine-rich food
33,*,OR T19 T22
34,T24,Procedure 496 522	neurosurgical intervention
35,T25,Condition 527 546	Parkinson's disease
36,R8,AND Arg1:T24 Arg2:T25
37,T26,Condition 554 565	pallidotomy
38,T27,Condition 567 578	thalamotomy
39,T28,Condition 580 602	deep brain stimulation
40,*,OR T27 T28 T26
41,T29,"Scope 554 602	pallidotomy, thalamotomy, deep brain stimulation"
42,T30,Scope 496 546	neurosurgical intervention for Parkinson's disease
43,R9,Subsumes Arg1:T30 Arg2:T29
44,T31,Procedure 635 668	transcranial magnetic stimulation
45,T32,Temporal 669 684	within 6 months
46,R10,Has_temporal Arg1:T31 Arg2:T32
47,T33,Drug 714 724	selegiline
48,T34,Drug 726 735	pethidine
49,T35,Drug 737 745	tramadol
50,T36,Drug 747 756	reserpine
51,T37,Drug 760 770	methyldopa
52,T38,Temporal 771 785	within 90 days
53,*,OR T37 T36 T35 T34 T33
54,T39,"Scope 714 770	selegiline, pethidine, tramadol, reserpine or methyldopa"
55,R11,Has_temporal Arg1:T39 Arg2:T38
56,T40,"Parsing_Error 606 786	The participant has received transcranial magnetic stimulation within 6 months.The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days."
57,T41,Procedure 817 837	levodopa monotherapy
58,T42,Drug 817 825	levodopa
59,R12,AND Arg1:T41 Arg2:T42
60,T43,Drug 843 863	psychoneurotic agent
61,T44,Drug 867 908	antiemetic medication of dopamine agonist
62,T45,Temporal 909 923	within 14 days
63,T46,Undefined_semantics 867 908	antiemetic medication of dopamine agonist
64,T47,Undefined_semantics 843 863	psychoneurotic agent
65,*,OR T44 T43 T42
66,T48,"Scope 817 908	levodopa monotherapy, any psychoneurotic agent or antiemetic medication of dopamine agonist"
67,R13,Has_temporal Arg1:T48 Arg2:T45
68,T49,Drug 969 979	quetiapine
69,T50,Drug 983 994	domperidone
70,T51,Qualifier 1002 1013	stable dose
71,T52,Temporal 1026 1036	>= 14 days
72,R14,Has_temporal Arg1:T51 Arg2:T52
73,*,OR T50 T49
74,T53,Scope 969 994	quetiapine or domperidone
75,R15,Has_qualifier Arg1:T53 Arg2:T51
76,T54,Post-eligibility 1068 1150	The participant is required to take any of the excluded medications or treatments.
77,T55,Context_Error 1068 1150	The participant is required to take any of the excluded medications or treatments.
78,T56,Parsing_Error 1152 1218	The participant with laboratory data meeting any of the following:
79,T57,Measurement 1220 1230	Creatinine
80,T58,Value 1231 1265	>= 2 x upper limit of normal (ULN)
81,R16,Has_value Arg1:T57 Arg2:T58
82,T59,Measurement 1267 1282	Total bilirubin
83,T60,Value 1283 1293	>= 2 x ULN
84,R17,Has_value Arg1:T59 Arg2:T60
85,T61,Value 1306 1318	>= 1.5 x ULN
86,T62,Measurement 1302 1305	AST
87,T63,Measurement 1295 1298	ALT
88,*,OR T62 T63
89,T64,Scope 1295 1305	ALT or AST
90,R18,Has_value Arg1:T64 Arg2:T61
91,T65,Measurement 1320 1323	ALP
92,T66,Value 1324 1334	>= 3 x ULN
93,R19,Has_value Arg1:T65 Arg2:T66
94,T67,Post-eligibility 1336 1418	The participant has received any of the excluded medications or treatments during.
95,T68,Context_Error 1336 1418	The participant has received any of the excluded medications or treatments during.
0,T1,Measurement 28 44	child-pugh score
1,T2,Value 17 24	C class
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 80 96	severe hepatitis
4,T4,Qualifier 65 76	acute phase
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 135 154	cancer of the liver
7,T6,Condition 180 212	cardiopulmonary cerebral disease
8,T7,Qualifier 173 179	severe
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Condition 255 283	Highly allergic constitution
11,T9,Condition 320 334	mental disease
12,T10,Qualifier 302 319	moderately severe
13,T11,Undefined_semantics 320 334	mental disease
14,R4,Has_qualifier Arg1:T9 Arg2:T10
0,T1,Parsing_Error 1936 1938	2.
1,T2,Parsing_Error 1833 1835	1.
2,T3,Parsing_Error 1788 1790	5.
3,T4,Parsing_Error 1736 1738	2.
4,T5,Parsing_Error 1644 1646	1.
5,T6,Parsing_Error 1626 1628	4.
6,T7,Parsing_Error 646 648	2.
7,T8,Parsing_Error 558 560	1.
8,T9,Parsing_Error 535 537	3.
9,T10,Parsing_Error 355 357	2.
10,T11,Parsing_Error 86 88	1.
11,T12,Parsing_Error 59 61	2.
12,T13,Parsing_Error 16 18	1.
13,T14,Parsing_Error 0 14	Subjects must:
14,T15,Not_a_criteria 561 644	Justification: Many illnesses may alter neural functioning as well as fMRI signals.
15,T16,Non-query-able 19 57	Be able to give valid informed consent
16,T17,Post-eligibility 19 57	Be able to give valid informed consent
17,T18,Person 80 83	age
18,T19,Value 65 76	18 55 years
19,R1,Has_value Arg1:T18 Arg2:T19
20,T20,"Parsing_Error 89 233	Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals."
21,T21,"Not_a_criteria 89 233	Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals."
22,T22,"Not_a_criteria 234 353	In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age."
23,T23,"Parsing_Error 234 353	In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age."
24,T24,Observation 374 381	History
25,T25,"Not_a_criteria 383 533	Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range."
26,T26,Condition 544 555	good health
27,T27,Undefined_semantics 544 555	good health
28,T28,Subjective_judgement 544 555	good health
29,T29,Procedure 666 684	Medical Assessment
30,T30,Observation 686 701	Medical History
31,T31,Procedure 706 726	Physical Examination
32,T32,Measurement 757 768	Vital Signs
33,T33,Procedure 770 773	EKG
34,T34,Procedure 775 788	oral HIV test
35,T35,Measurement 790 796;804 815	height measurement
36,T36,Measurement 797 815	weight measurement
37,T37,Procedure 818 828	urinalysis
38,T38,Procedure 833 845	blood sample
39,T39,Procedure 881 884	CBC
40,T40,Procedure 886 912	complete metabolic profile
41,T41,Procedure 914 917	TSH
42,T42,Procedure 919 922	ESR
43,T43,Procedure 924 927	STS
44,T44,Procedure 932 935	HIV
45,T45,Measurement 969 990	salivary test for HIV
46,T46,Value 960 968	positive
47,R2,Has_value Arg1:T45 Arg2:T46
48,T47,Grammar_Error 1056 1066	disqualify
49,T48,Measurement 1080 1091	Cholesterol
50,T49,Value 1092 1102	>250 mg/dl
51,R3,Has_value Arg1:T48 Arg2:T49
52,T50,Measurement 1104 1114	Hemoglobin
53,T51,Value 1115 1126	< 10.5 g/dl
54,R4,Has_value Arg1:T50 Arg2:T51
55,T52,Measurement 1128 1131	WBC
56,T53,Value 1132 1145	< 2400/microl
57,R5,Has_value Arg1:T52 Arg2:T53
58,T54,Measurement 1147 1151	LFTs
59,T55,Value 1152 1162	> 3Xnormal
60,R6,Has_value Arg1:T54 Arg2:T55
61,T56,Measurement 1164 1167	HCG
62,T57,Value 1168 1176	positive
63,R7,Has_value Arg1:T56 Arg2:T57
64,T58,Measurement 1185 1198	serum glucose
65,T59,Value 1199 1210	> 200 mg/dl
66,R8,Has_value Arg1:T58 Arg2:T59
67,T60,Measurement 1212 1225	Urine protein
68,T61,Value 1226 1230	> 1+
69,R9,Has_value Arg1:T60 Arg2:T61
70,*,OR T60 T58 T56 T54 T52 T50 T48
71,T62,Negation 1056 1066	disqualify
72,T63,"Scope 1080 1230	Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+"
73,R10,Has_negation Arg1:T63 Arg2:T62
74,T64,"Not_a_criteria 1232 1337	The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation."
75,T65,"Subjective_judgement 1232 1337	The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation."
76,T66,Measurement 1339 1352	Serum glucose
77,T67,Value 1353 1367	over 140 mg/dl
78,R11,Has_value Arg1:T66 Arg2:T67
79,T68,Procedure 1395 1427	fasting serum glucose assessment
80,T69,Scope 1339 1367	Serum glucose over 140 mg/dl
81,A1,Optional T69
82,R12,AND Arg1:T69 Arg2:T68
83,T70,Condition 1629 1641	Right-handed
84,T71,Not_a_criteria 1647 1734	Justification: Using right-handed individuals will reduce variability in BOLD MRI data.
85,T72,Not_a_criteria 1739 1786	Screening tool: Edinburgh Handedness Inventory.
86,T73,Procedure 1755 1785	Edinburgh Handedness Inventory
87,T74,Measurement 1791 1803	Estimated IQ
88,T75,Value 1804 1831	greater than or equal to 85
89,R13,Has_value Arg1:T74 Arg2:T75
90,T76,Not_a_criteria 1836 1934	Justification: Subjects must be able to perform a cognitively challenging task to a high standard.
91,T77,Procedure 1955 1997	Wechsler Abbreviated Scale of Intelligence
0,T1,Procedure 7 24	smoking cessation
1,T2,Procedure 25 36	medications
2,T3,Procedure 40 53	interventions
3,*,OR T2 T3
4,T4,Temporal 54 69	in last 30 days
5,T5,Scope 25 53	medications or interventions
6,R1,AND Arg1:T5 Arg2:T1
7,R2,Has_temporal Arg1:T5 Arg2:T4
8,T6,Non-query-able 71 132	Unstable medical illness that requires immediate medical care
9,T7,Measurement 134 139	AUDIT
10,T8,Value 140 160	score of < 5 or > 26
11,R3,Has_value Arg1:T7 Arg2:T8
12,T9,Condition 162 171	Pregnancy
13,T10,Condition 216 233	contraindications
14,T11,Procedure 181 209	Nicotine Replacement Therapy
15,T12,Procedure 211 214	NRT
16,R4,Subsumes Arg1:T11 Arg2:T12
17,R5,AND Arg1:T10 Arg2:T11
18,*,OR T10 T9
19,T13,Condition 274 292	psychotic disorder
20,T14,Condition 296 322	major depressive disorders
21,T15,Qualifier 331 341	not stable
22,T16,Temporal 355 372	for past 3 months
23,R6,Has_qualifier Arg1:T14 Arg2:T15
24,R7,Has_temporal Arg1:T14 Arg2:T16
25,T17,Temporal 257 270	past 6 months
26,R8,Has_temporal Arg1:T13 Arg2:T17
27,*,OR T13 T14
28,T18,Condition 374 394	Cognitive impairment
0,T1,Condition 11 19	seizures
1,T2,Temporal 20 40	within last 10 years
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 53 61	epilepsy
4,T4,Condition 80 86	stroke
5,T5,Temporal 74 79	prior
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Drug 109 119	medication
8,T7,Qualifier 125 148	anti-epileptic activity
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Drug 150 156	keppra
11,T9,Drug 158 166	dilantin
12,T10,Drug 168 176	tegretol
13,T11,Drug 178 186	lamictal
14,T12,Drug 188 195	topamax
15,*,OR T11 T12 T10 T9 T8
16,T13,"Scope 150 195	keppra, dilantin, tegretol, lamictal, topamax"
17,T14,Scope 109 148	medication with anti-epileptic activity
18,R4,Subsumes Arg1:T14 Arg2:T13
19,T15,Condition 204 215	Brain tumor
20,T16,Condition 217 225	Pregnant
21,T17,Condition 229 236	nursing
22,*,OR T16 T17
23,T18,Person 237 242	woman
24,T19,Drug 250 263	levetiracetam
25,T20,Condition 264 271	allergy
26,R5,AND Arg1:T20 Arg2:T19
0,T1,Visit 28 32	ICUs
1,T2,Measurement 41 63	average length of stay
2,T3,Value 67 83	less than 2 days
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Non-query-able 86 253	HCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded.
0,T1,Procedure 19 26	surgery
1,T2,Condition 31 51	neoplastic processes
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Drug 64 77	acetaminophen
4,T4,Condition 53 60	Allergy
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Condition 79 96	Liver dysfunction
7,T6,Value 101 109	elevated
8,T7,Measurement 110 130	Liver Function Tests
9,T8,Measurement 132 136	LFTs
10,R3,Subsumes Arg1:T7 Arg2:T8
11,R4,Has_value Arg1:T7 Arg2:T6
12,T9,Condition 150 165	drug dependency
13,T10,Condition 139 146;155 165	Alcohol dependency
14,*,OR T9 T10
15,T11,Condition 167 185	Mental retardation
16,T12,Value 187 202	Less than 50 kg
17,T13,Measurement 206 212	weight
18,R5,Has_value Arg1:T13 Arg2:T12
19,T14,Condition 214 221	regnant
20,T15,Person 222 227	women
21,T16,Drug 248 266	long-acting opioid
22,T17,Mood 238 247	requiring
23,R6,Has_mood Arg1:T16 Arg2:T17
24,T18,Drug 294 308	fentanyl patch
25,T19,Drug 310 319	oxycontin
26,T20,Multiplier 326 342	for over 3 weeks
27,T21,Temporal 343 371	immediately prior to surgery
28,*,OR T19 T18
29,T22,"Scope 294 319	fentanyl patch, oxycontin"
30,R7,Subsumes Arg1:T16 Arg2:T22
31,R8,Has_multiplier Arg1:T16 Arg2:T20
32,R9,Has_temporal Arg1:T16 Arg2:T21
0,T1,Negation 8 11	not
1,T2,Temporal 12 22	previously
2,T3,Mood 23 36	scheduled for
3,T4,Procedure 37 60	radiofrequency ablation
4,T5,Qualifier 68 76;98 104	cervical facets
5,T6,Qualifier 78 86;98 104	thoracic facets
6,T7,Qualifier 91 104	lumbar facets
7,*,OR T7 T6 T5 T8
8,T8,Qualifier 109 126	sacroiliac joints
9,T9,"Scope 68 126	cervical, thoracic, or lumbar facets, or sacroiliac joints"
10,R1,Has_mood Arg1:T4 Arg2:T3
11,R2,Has_temporal Arg1:T4 Arg2:T2
12,R3,Has_negation Arg1:T4 Arg2:T1
13,R4,Has_scope Arg1:T4 Arg2:T9
14,T10,Procedure 131 146	anticoagulation
15,T11,Device 155 164	pacemaker
16,T12,Drug 131 146	anticoagulation
17,R5,multi Arg1:T10 Arg2:T12
18,T13,Person 166 169	age
19,T14,Value 170 192	less than 18 years old
20,R6,Has_value Arg1:T13 Arg2:T14
21,T15,Observation 198 214	English speaking
22,T16,Negation 194 197	non
23,R7,Has_negation Arg1:T15 Arg2:T16
0,T1,"Non-representable 0 67	none, all patients meeting the inclusion criteria will be eligible."
0,T1,Visit 32 36	U.S.
1,T2,Visit 37 50	HCA hospitals
2,T3,Person 59 64	adult
3,T4,Visit 59 68	adult ICU
4,R1,multi Arg1:T4 Arg2:T3
5,R2,AND Arg1:T2 Arg2:T1
6,R3,AND Arg1:T2 Arg2:T4
7,T5,"Non-representable 71 160	Note: Unit of randomization is the hospital, but the participants are hospital adult ICUs"
8,T6,Visit 182 192	adult ICUs
9,T7,Person 182 187	adult
10,R4,multi Arg1:T6 Arg2:T7
11,T8,Person 217 230	rare patients
12,T9,Value 231 255	<18 years and >=12 years
13,T10,Person 235 239	year
14,R5,Has_value Arg1:T10 Arg2:T9
0,T1,Person 0 5	Adult
1,T2,Value 7 16	=18 years
2,T3,Person 11 16	years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Scope 7 16	=18 years
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Condition 31 52	intracranial aneurysm
7,T6,Qualifier 62 77	without rupture
8,T7,Qualifier 54 58;70 77	with rupture
9,*,OR T6 T7
10,T8,Scope 54 77	with or without rupture
11,R3,Has_scope Arg1:T5 Arg2:T8
12,T9,Procedure 113 128	surgical repair
13,T10,Condition 136 144	aneurysm
14,R4,AND Arg1:T9 Arg2:T10
15,T11,Mood 101 112	recommended
16,R5,Has_mood Arg1:T9 Arg2:T11
17,T12,Qualifier 80 96	Treating surgeon
18,R6,Has_qualifier Arg1:T11 Arg2:T12
0,T1,Condition 36 44;86 96	cervical joint pain
1,T2,Condition 46 54;86 96	thoracic joint pain
2,T3,Condition 59 71;86 96	lumbar facet joint pain
3,T4,Condition 75 96	sacroiliac joint pain
4,T5,Procedure 119 139	medial branch blocks
5,T6,Observation 106 115	responded
6,R1,AND Arg1:T6 Arg2:T5
7,T7,Mood 156 169	scheduled for
8,T8,Procedure 170 204	bilateral radiofrequency ablations
9,R2,Has_mood Arg1:T8 Arg2:T7
10,T9,Person 206 209	age
11,T10,Value 210 235	greater than 18 years old
12,R3,Has_value Arg1:T9 Arg2:T10
13,T11,Observation 237 253	English speaking
14,T12,"Scope 36 96	cervical, thoracic, or lumbar facet or sacroiliac joint pain"
15,R4,Has_context Arg1:T12 Arg2:T6
16,*,OR T1 T2 T3 T4
0,T1,Measurement 0 3	ASA
1,T2,Value 4 9	I-III
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Mood 19 28	scheduled
4,T4,Qualifier 33 41	elective
5,T5,Qualifier 49 58	two level
6,T6,Qualifier 42 45;53 58	one level
7,T7,Procedure 59 92	minimally invasive lumbar fusions
8,*,OR T6 T5
9,T8,Scope 42 58	one or two level
10,R2,Has_scope Arg1:T7 Arg2:T8
11,R3,Has_qualifier Arg1:T7 Arg2:T4
12,R4,Has_mood Arg1:T7 Arg2:T3
0,T1,Condition 0 27	acute myocardial infarction
1,T2,Condition 32 55	ischemic cardiomyopathy
2,T3,Condition 81 102	myocardial infarction
3,T4,Temporal 72 80	previous
4,R1,Has_temporal Arg1:T3 Arg2:T4
5,T5,Scope 72 102	previous myocardial infarction
6,A1,Optional T5
7,T6,Condition 107 129	dilated cardiomyopathy
8,T7,Condition 137 159	valvular heart disease
9,R2,causal Arg1:T6 Arg2:T7
10,T8,Condition 161 187	hypertensive heart disease
11,T9,Condition 200 211	myocarditis
12,T10,Observation 189 196	history
13,R3,Has_temporal Arg1:T9 Arg2:T10
14,T11,Condition 223 243	myocardial infection
15,T12,Negation 213 215	no
16,T13,Temporal 216 222	active
17,R4,Has_temporal Arg1:T11 Arg2:T13
18,R5,Has_negation Arg1:T11 Arg2:T12
19,R6,AND Arg1:T9 Arg2:T11
20,*,OR T8 T6 T9
0,T1,Condition 13 35	primary sleep disorder
1,T2,Negation 36 41	other
2,T3,Condition 47 50	RLS
3,R1,Has_negation Arg1:T3 Arg2:T2
4,T4,Measurement 103 117	Serum ferritin
5,T5,Value 124 134	< 20 ng/mL
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 161 168	allergy
8,T7,Condition 170 186	hypersensitivity
9,T8,Condition 191 202	intolerance
10,T9,"Scope 161 202	allergy, hypersensitivity, or intolerance"
11,*,OR T6 T7 T8
12,T10,Drug 206 214	HORIZANT
13,T11,Drug 228 238	gabapentin
14,*,OR T10 T11
15,T12,Drug 253 262	Neurontin
16,T13,Drug 265 272	Gralise
17,T14,"Scope 253 273	Neurontin®, Gralise®"
18,R3,Subsumes Arg1:T11 Arg2:T14
19,*,OR T12 T13
20,T15,"Scope 206 273	HORIZANT or any other gabapentin products (eg, Neurontin®, Gralise®"
21,R4,Has_scope Arg1:T9 Arg2:T15
22,T16,Condition 294 311	movement disorder
23,T17,Condition 376 395	Tourette's syndrome
24,T18,Condition 397 409	tic disorder
25,T19,Condition 411 442	periodic limb movement disorder
26,T20,Condition 444 448	PLMD
27,T21,Condition 451 466	sleep disorders
28,*,OR T17 T18 T19 T21
29,R5,Subsumes Arg1:T19 Arg2:T20
30,T22,"Scope 376 466	Tourette's syndrome, tic disorder, periodic limb movement disorder [PLMD], sleep disorders"
31,R6,Subsumes Arg1:T16 Arg2:T22
32,T23,Condition 576 598	substance use disorder
33,T24,Temporal 620 636	within 12 months
34,R7,Has_temporal Arg1:T23 Arg2:T24
35,T25,Measurement 485 554	Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition
36,T26,Measurement 556 561	DSM-5
37,R8,Subsumes Arg1:T25 Arg2:T26
38,R9,AND Arg1:T25 Arg2:T23
39,T27,Condition 696 716	psychiatric disorder
40,T28,Qualifier 684 695	significant
41,R10,Has_qualifier Arg1:T27 Arg2:T28
42,T29,Condition 748 758	depression
43,T30,Drug 775 790	antidepressants
44,T31,Condition 793 809	bipolar disorder
45,T32,Condition 814 827	schizophrenia
46,R11,AND Arg1:T29 Arg2:T30
47,*,OR T29 T31 T32
48,T33,"Scope 748 827	depression (treatment with antidepressants), bipolar disorder, or schizophrenia"
49,R12,Subsumes Arg1:T27 Arg2:T33
50,T34,Condition 843 883	attention-deficit hyperactivity disorder
51,T35,Condition 885 889	ADHD
52,R13,Subsumes Arg1:T34 Arg2:T35
53,T36,Negation 894 901	allowed
54,R14,AND Arg1:T36 Arg2:T34
55,T37,Observation 1006 1023	suicidal behavior
56,T38,Condition 1027 1044	suicidal ideation
57,*,OR T37 T38
58,T39,Condition 1194 1210	seizure disorder
59,T40,Condition 1301 1328	complicated febrile seizure
60,T41,Condition 1356 1367	head injury
61,*,OR T40 T41
62,T42,Scope 1301 1367	complicated febrile seizure and history of significant head injury
63,R15,Subsumes Arg1:T39 Arg2:T42
64,T43,"Non-query-able 1370 1758	Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of gabapentin enacarbil, or, in the investigator's judgment is considered to be clinically significant and may pose a safety concern, or, could interfere with the accurate assessment of safety or efficacy, or could potentially affect a patient's safety or study outcome"
65,T44,Non-query-able 1761 1891	Clinically significant abnormal laboratory result or physical examination finding not resolved by the time of baseline assessments
0,T1,Person 0 3	Age
1,T2,Value 4 14	> 18 Years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-query-able 16 36	Physician discretion
4,T4,Condition 38 44;60 65	Septic shock
5,T5,Condition 48 65	hypovolemic shock
6,*,OR T5 T4
7,T6,Condition 93 107	cerebral edema
8,T7,Condition 111 130	multi-organ failure
9,T8,Mood 67 75	Signs of
10,T9,Qualifier 76 92	life-threatening
11,*,OR T7 T6
12,T10,Scope 93 130	cerebral edema or multi-organ failure
13,R2,Has_qualifier Arg1:T10 Arg2:T9
14,R3,Has_mood Arg1:T10 Arg2:T8
15,T11,Visit 156 170	emergency room
16,T12,Visit 174 203	pediatric intensive care unit
17,*,OR T11 T12
18,T13,Observation 205 215	Enrollment
19,T14,Temporal 221 275	more than 1 hr since arrival to emergency room or PICU
20,T15,Visit 253 267	emergency room
21,T16,Visit 271 275	PICU
22,*,OR T15 T16
23,T17,Temporal 131 203	upon presentation to the emergency room or pediatric intensive care unit
24,T18,Reference_point 136 203	presentation to the emergency room or pediatric intensive care unit
25,T19,Scope 156 203	emergency room or pediatric intensive care unit
26,R4,multi Arg1:T18 Arg2:T19
27,R5,Has_index Arg1:T17 Arg2:T18
28,R6,Has_temporal Arg1:T10 Arg2:T17
29,T20,Scope 253 275	emergency room or PICU
30,T21,Reference_point 242 275	arrival to emergency room or PICU
31,R7,Has_index Arg1:T14 Arg2:T21
32,R8,multi Arg1:T21 Arg2:T20
33,R9,Has_temporal Arg1:T13 Arg2:T14
34,T22,Condition 277 286	Pregnancy
0,T1,Person 0 5	Women
1,T2,Condition 9 32	child-bearing potential
2,T3,Condition 42 71	biologically able to conceive
3,T4,Multiplier 87 90	two
4,T5,Device 100 130	highly effective contraception
5,T6,Condition 142 150	pregnant
6,T7,Negation 73 76	not
7,R1,Has_negation Arg1:T5 Arg2:T7
8,R2,Has_multiplier Arg1:T5 Arg2:T4
9,T8,"Scope 0 71	Women of child-bearing potential, who are biologically able to conceive"
10,A1,Optional T8
11,*,OR T5 T6
12,T9,Scope 73 150	not employing two forms of highly effective contraception or who are pregnant
13,R3,Has_scope Arg1:T8 Arg2:T9
14,T10,Person 153 158	Women
15,T11,Condition 167 181	breast-feeding
16,T12,Person 191 196	males
17,T13,Condition 183 190	Fertile
18,T14,Observation 197 227	unwilling to use contraception
19,T15,Non-query-able 183 227	Fertile males unwilling to use contraception
20,T16,Post-eligibility 183 227	Fertile males unwilling to use contraception
21,T17,Condition 243 259	brain metastases
22,T18,Condition 278 294	brain metastases
23,T19,Observation 267 274	history
24,R4,Has_temporal Arg1:T18 Arg2:T19
25,*,OR T18 T17
26,T20,Procedure 324 337	major surgery
27,T21,Procedure 345 359	intra-thoracic
28,T22,Procedure 345 350;361 371	intra -abdominal
29,T23,Procedure 345 350;376 383	intra -pelvic
30,*,OR T23 T22 T21
31,T24,"Scope 345 383	intra-thoracic, -abdominal, or -pelvic"
32,R5,Subsumes Arg1:T20 Arg2:T24
33,T25,Subjective_judgement 324 337	major surgery
34,T26,Value 385 430	</= 4 weeks prior to starting study treatment
35,T27,Reference_point 406 430	starting study treatment
36,R6,Has_index Arg1:T26 Arg2:T27
37,T28,Undefined_semantics 447 474	recovered from such therapy
38,T29,Subjective_judgement 447 474	recovered from such therapy
39,R7,Has_value Arg1:T20 Arg2:T26
40,T30,Condition 503 521	pulmonary embolism
41,T31,Condition 536 556	deep vein thrombosis
42,T32,Qualifier 526 535	untreated
43,T33,Temporal 557 581	within the past 6 months
44,*,OR T31 T30
45,R8,Has_qualifier Arg1:T31 Arg2:T32
46,T34,Observation 492 499	history
47,T35,"Scope 503 556	pulmonary embolism, or untreated deep vein thrombosis"
48,R9,Has_temporal Arg1:T35 Arg2:T34
49,R10,Has_temporal Arg1:T35 Arg2:T33
50,T36,Condition 583 627	Impairment of gastrointestinal (GI) function
51,T37,Condition 631 641	GI disease
52,T38,Qualifier 647 698	may significantly alter the absorption of dovitinib
53,T39,Undefined_semantics 647 698	may significantly alter the absorption of dovitinib
54,*,OR T37 T36
55,T40,Scope 583 641	Impairment of gastrointestinal (GI) function or GI disease
56,R11,Has_qualifier Arg1:T40 Arg2:T38
57,T41,Condition 728 745	active malignancy
58,T42,Temporal 746 769	within the past 5 years
59,T43,Condition 781 804	cervical cancer in situ
60,T44,Negation 770 776	except
61,R13,Has_temporal Arg1:T41 Arg2:T42
62,T45,Condition 806 838	in situ carcinoma of the bladder
63,T46,Condition 842 876	non-melanoma carcinoma of the skin
64,*,OR T45 T46 T43
65,T47,"Scope 781 876	cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin"
66,R12,Has_negation Arg1:T47 Arg2:T44
67,R14,Has_scope Arg1:T41 Arg2:T47
68,T48,Procedure 936 954	anticancer therapy
69,T49,Procedure 965 977	chemotherapy
70,T50,Procedure 979 992	immunotherapy
71,T51,Procedure 994 1010	hormonal therapy
72,T52,Drug 1015 1036	monoclonal antibodies
73,T53,Temporal 1037 1081	</= 2 weeks prior to starting the study drug
74,T54,Reference_point 1058 1081	starting the study drug
75,R15,Has_index Arg1:T53 Arg2:T54
76,T55,Condition 1099 1146	recovered from the side effects of such therapy
77,T56,Negation 443 446	not
78,T57,Condition 447 474	recovered from such therapy
79,R16,Has_negation Arg1:T57 Arg2:T56
80,*,OR T57 T20
81,*,OR T49 T50 T51 T52
82,T58,"Scope 965 1036	chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies"
83,R17,Subsumes Arg1:T48 Arg2:T58
84,R18,Has_temporal Arg1:T48 Arg2:T53
85,*,OR T48 T55
86,T59,Condition 1148 1157	Cirrhosis
87,T60,Condition 1159 1183	chronic active hepatitis
88,T61,Condition 1187 1215	chronic persistent hepatitis
89,*,OR T61 T60 T59
90,T62,Drug 1254 1263	prasugrel
91,T63,Drug 1286 1295	isoniazid
92,T64,Drug 1297 1306	labetolol
93,T65,Drug 1308 1321	trovafloxacin
94,T66,Drug 1323 1332	tolcapone
95,T67,Drug 1338 1347	felbamate
96,*,OR T63 T64 T65 T66 T67
97,T68,Negation 1265 1267	No
98,T69,"Scope 1286 1347	isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate"
99,R19,Has_negation Arg1:T69 Arg2:T68
100,T70,Negation 1349 1351	No
101,T71,Drug 1370 1397	other investigational drugs
102,T72,Procedure 1401 1425	antineoplastic therapies
103,*,OR T72 T71
104,T73,Undefined_semantics 1370 1397	other investigational drugs
105,T74,Scope 1370 1425	other investigational drugs or antineoplastic therapies
106,R20,Has_negation Arg1:T74 Arg2:T70
107,T75,Condition 1442 1467	impaired cardiac function
108,T76,Qualifier 1471 1493	clinically significant
109,T77,Condition 1494 1510	cardiac diseases
110,T78,Subjective_judgement 1471 1493	clinically significant
111,R21,Has_qualifier Arg1:T77 Arg2:T76
112,*,OR T77 T75
113,T79,Undefined_semantics 1442 1467	impaired cardiac function
0,T1,Person 0 3	Age
1,T2,Value 4 26	between 0 and 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 28 37	Venous pH
4,T4,Value 38 52	less than 7.25
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 54 63	Ketonuria
7,T6,Measurement 80 107	urine point-of-care testing
8,T7,Measurement 111 121	urinalysis
9,*,OR T6 T7
10,T8,Scope 80 121	urine point-of-care testing or urinalysis
11,R3,Has_scope Arg1:T5 Arg2:T8
12,T9,Condition 123 136	Hyperglycemia
13,T10,Measurement 138 151	Serum glucose
14,T11,Value 152 163	> 200 mg/dl
15,R4,Has_value Arg1:T10 Arg2:T11
16,T12,Scope 138 163	Serum glucose > 200 mg/dl
17,R5,Subsumes Arg1:T9 Arg2:T12
18,T13,Measurement 166 183	Serum bicarbonate
19,T14,Value 184 194	<15 mmol/L
20,R6,Has_value Arg1:T13 Arg2:T14
21,T15,Visit 196 200	PICU
22,T16,Procedure 201 210	admission
23,R7,AND Arg1:T16 Arg2:T15
0,T1,Parsing_Error 1 39	atients with a confirmed diagnosis of:
1,T2,Condition 52 64	colon cancer
2,T3,Qualifier 44 51	Stage 4
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 72 90	s/p metastasectomy
5,T5,Procedure 76 90	metastasectomy
6,T6,Condition 94 119	post-initial chemotherapy
7,T7,Procedure 107 119	chemotherapy
8,T8,Drug 172 207	5-fluorouracil/leucovorin (5-FU/LV)
9,T9,Drug 227 238	bevacizumab
10,*,OR T8 T9
11,T10,Scope 172 238	5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab
12,T11,"Procedure 123 153	maintenance ""standard of care"""
13,T12,"Undefined_semantics 123 153	maintenance ""standard of care"""
14,*,OR T4 T6 T11
15,R2,Has_scope Arg1:T11 Arg2:T10
16,T13,Multiplier 291 292	2
17,T14,Procedure 305 313	CT scans
18,R3,Has_multiplier Arg1:T14 Arg2:T13
19,T15,Qualifier 322 328	stable
20,T16,Condition 329 336	disease
21,T17,Undefined_semantics 329 336	disease
22,T18,Condition 379 405	treatment-related toxicity
23,T19,Temporal 373 378	prior
24,T20,Negation 341 344	not
25,R4,Has_negation Arg1:T18 Arg2:T20
26,R5,Has_temporal Arg1:T18 Arg2:T19
27,R6,Has_qualifier Arg1:T16 Arg2:T15
28,T21,Condition 425 440	Pancreas cancer
29,T22,Condition 449 462	s/p resection
30,T23,Procedure 453 462	resection
31,T24,Condition 449 452;467 488	s/p adjuvant chemotherapy
32,T25,Procedure 467 488	adjuvant chemotherapy
33,T26,Condition 509 524	pancreas cancer
34,T27,Qualifier 492 508	locally advanced
35,R7,Has_qualifier Arg1:T26 Arg2:T27
36,T28,Condition 525 541	s/p chemotherapy
37,T29,Procedure 529 541	chemotherapy
38,T30,Condition 525 528;546 555	s/p radiation
39,T31,Procedure 546 555	radiation
40,T32,Procedure 565 577	chemotherapy
41,T33,Procedure 581 598	radiation therapy
42,T34,Temporal 621 670	between 2 weeks and 2 months prior to study start
43,T35,Reference_point 659 670	study start
44,R8,Has_index Arg1:T34 Arg2:T35
45,T36,Condition 695 725	recovered from prior treatment
46,T37,Procedure 716 725	treatment
47,T38,Temporal 710 715	prior
48,R9,Has_temporal Arg1:T37 Arg2:T38
49,T39,Scope 449 488	s/p resection and adjuvant chemotherapy
50,T40,Scope 492 555	locally advanced pancreas cancer s/p chemotherapy and radiation
51,*,OR T40 T39
52,*,OR T32 T33
53,T41,Observation 599 620	may have been stopped
54,T42,Scope 565 598	chemotherapy or radiation therapy
55,R10,Has_context Arg1:T42 Arg2:T41
56,R11,Has_temporal Arg1:T42 Arg2:T34
57,T43,Procedure 770 777	surgery
58,T44,Temporal 764 769	Prior
59,T45,Procedure 808 822	metastasectomy
60,T46,Procedure 789 804	tumor resection
61,T47,Temporal 848 890	at least 4 weeks prior to study enrollment
62,T48,Reference_point 874 890	study enrollment
63,R12,Has_index Arg1:T47 Arg2:T48
64,*,OR T45 T46
65,T49,Scope 789 822	tumor resection or metastasectomy
66,R13,Subsumes Arg1:T43 Arg2:T49
67,R14,Has_temporal Arg1:T43 Arg2:T44
68,R15,Has_temporal Arg1:T43 Arg2:T47
69,T50,Context_Error 893 940	No concomitant anti-cancer treatment is allowed
70,T51,Post-eligibility 893 940	No concomitant anti-cancer treatment is allowed
71,T52,Person 942 945	Age
72,T53,Value 946 958	>/= 18 years
73,R16,Has_value Arg1:T52 Arg2:T53
74,T54,Measurement 960 978	Performance status
75,T55,Value 982 985	0-1
76,R17,Has_value Arg1:T54 Arg2:T55
77,T56,Measurement 1022 1036	renal function
78,T57,Measurement 1005 1016;1028 1036	bone marrow function
79,T58,Measurement 1028 1036;996 1003	function hepatic
80,T59,Value 987 995	Adequate
81,R18,Has_value Arg1:T58 Arg2:T59
82,R19,Has_value Arg1:T57 Arg2:T59
83,R20,Has_value Arg1:T56 Arg2:T59
84,T60,Measurement 1038 1071	Partial thromboplastin time (PTT)
85,T61,Value 1080 1108	</= 1.5 x upper normal limit
86,T62,Measurement 1143 1179	INR (International Normalized Ratio)
87,T63,Value 1180 1185	< 1.5
88,R21,Has_value Arg1:T62 Arg2:T63
89,R22,Has_value Arg1:T60 Arg2:T61
90,T64,Observation 1188 1203	Life expectancy
91,T65,Value 1204 1216	>/= 4 months
92,T66,Context_Error 1221 1240	maintenance cohorts
93,T67,Observation 1221 1240	maintenance cohorts
94,A1,Optional T67
95,T68,Value 1245 1257	>/= 6 months
96,T69,Observation 1262 1278	adjuvant cohorts
97,A2,Optional T69
98,*,OR T67 T69
99,R23,Has_value Arg1:T69 Arg2:T68
100,R24,Has_value Arg1:T67 Arg2:T65
101,T70,Scope 1204 1278	>/= 4 months for maintenance cohorts and >/= 6 months for adjuvant cohorts
102,R25,Has_scope Arg1:T64 Arg2:T70
103,T71,Condition 1289 1311	childbearing potential
104,T72,Person 1280 1285	Women
105,T73,Measurement 1333 1353	serum pregnancy test
106,T74,Value 1324 1332	negative
107,R26,Has_value Arg1:T73 Arg2:T74
108,T75,Temporal 1354 1401	within 14 days prior to initiation of treatment
109,T76,Reference_point 1378 1401	initiation of treatment
110,R27,Has_index Arg1:T75 Arg2:T76
111,T77,Condition 1418 1427	lactating
112,T78,Negation 1411 1414	not
113,R28,Has_negation Arg1:T77 Arg2:T78
114,R29,Has_temporal Arg1:T73 Arg2:T75
115,T79,Scope 1280 1311	Women of childbearing potential
116,A3,Optional T79
117,R30,AND Arg1:T79 Arg2:T73
118,T80,Non-query-able 1430 1548	Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent
119,T81,Post-eligibility 1430 1548	Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent
0,T1,Person 0 4	Male
1,T2,Person 9 15	female
2,T3,Person 16 26	adolescent
3,*,OR T1 T2
4,T4,Person 37 41	aged
5,T5,Value 42 56	13 to 17 years
6,R1,Has_value Arg1:T4 Arg2:T5
7,R2,Subsumes Arg1:T3 Arg2:T4
8,T6,Condition 73 76	RLS
9,T7,Measurement 90 115	IRLSSG consensus criteria
10,R3,AND Arg1:T6 Arg2:T7
11,T8,Measurement 147 171	Total RLS severity score
12,T9,Value 175 188	15 or greater
13,R4,Has_value Arg1:T8 Arg2:T9
14,T10,Multiplier 295 338	at least 4 of 7 consecutive evenings/nights
15,T11,Condition 278 290	RLS symptoms
16,R5,Has_multiplier Arg1:T11 Arg2:T10
17,T12,Measurement 369 380	Body weight
18,T13,Value 381 401	greater than 33.4 kg
19,R6,Has_value Arg1:T12 Arg2:T13
20,T14,Measurement 439 454	body mass index
21,T15,Measurement 456 459	BMI
22,R7,Subsumes Arg1:T14 Arg2:T15
23,T16,Value 467 486	5th-85th percentile
24,R8,Has_value Arg1:T14 Arg2:T16
25,T17,Measurement 577 607	Estimated creatinine clearance
26,T18,Value 611 629	at least 60 mL/min
27,R9,Has_value Arg1:T17 Arg2:T18
28,T19,Informed_consent 687 849	Signed patient and parent Institutional Review Board (IRB)-approved informed consent/assent form (as applicable) before any study-related procedures are performed
0,T1,Condition 0 18	polycystic ovaries
1,T2,Condition 30 47	thyroid pathology
2,T3,Qualifier 20 29	untreated
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 49 78	hypogonadotropic hypogonadism
5,T5,Qualifier 80 88	untreaed
6,T6,Condition 89 107	hyperprolactinemia
7,R2,Has_qualifier Arg1:T6 Arg2:T5
8,T7,Condition 120 136	hypersensitivity
9,T8,Drug 109 119	study drug
10,R3,AND Arg1:T7 Arg2:T8
11,T9,Condition 147 151	OHSS
12,T10,Temporal 138 146	previous
13,R4,Has_temporal Arg1:T9 Arg2:T10
14,T11,Qualifier 153 163	unilateral
15,T12,Procedure 164 175	ovariectomy
16,R5,Has_qualifier Arg1:T12 Arg2:T11
17,T13,Condition 177 197	genital malformation
18,T14,Measurement 199 202	BMI
19,T15,Value 202 205	>40
20,R6,Has_value Arg1:T14 Arg2:T15
0,T1,Condition 21 40	Alzheimer's disease
1,T2,Measurement 42 195	National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Value 12 20	probable
4,T4,Value 0 8	Possible
5,*,OR T3 T4
6,T5,Scope 0 20	Possible or probable
7,R2,Has_scope Arg1:T2 Arg2:T5
8,T6,Measurement 203 232	Mini-Mental State Exam (MMSE)
9,T7,Value 233 257	score of 10-26 inclusive
10,T8,Measurement 259 263	MMSE
11,T9,Value 264 279	scores above 26
12,R3,Has_value Arg1:T8 Arg2:T9
13,R4,Has_value Arg1:T6 Arg2:T7
14,*,OR T6 T8
15,T10,Condition 324 326	AD
16,T11,Condition 423 429	apathy
17,T12,Person 434 453	at least four weeks
18,T13,Measurement 517 549	Neuropsychiatric Inventory (NPI)
19,T14,Value 554 569	Very frequently
20,R5,Has_value Arg1:T13 Arg2:T14
21,T15,Measurement 621 624	NPI
22,T16,Value 629 639	Frequently
23,T17,Value 645 650	Often
24,*,OR T17 T16
25,T18,Measurement 698 701	NPI
26,T19,Observation 660 678	severity of apathy
27,T20,Observation 582 601	frequency of apathy
28,R6,AND Arg1:T20 Arg2:T15
29,T21,Scope 628 651	'Frequently' or 'Often'
30,T22,Value 706 714	Moderate
31,T23,Value 720 726	Marked
32,*,OR T23 T22
33,T24,Scope 705 727	'Moderate' or 'Marked'
34,R7,Has_scope Arg1:T18 Arg2:T24
35,R8,Has_scope Arg1:T15 Arg2:T21
36,R9,AND Arg1:T19 Arg2:T18
37,T25,Scope 582 727	frequency of apathy as assessed by the NPI is 'Frequently' or 'Often' AND the severity of apathy as assessed by the NPI is 'Moderate' or 'Marked'
38,T26,Observation 478 497	frequency of apathy
39,R10,AND Arg1:T26 Arg2:T13
40,*,OR T26 T25
41,T27,Drug 731 752	medication for apathy
42,T28,Condition 746 752	apathy
43,R11,AND Arg1:T27 Arg2:T28
44,T29,"Post-eligibility 729 806	A medication for apathy is appropriate, in the opinion of the study physician"
45,T30,"Parsing_Error 729 806	A medication for apathy is appropriate, in the opinion of the study physician"
46,T31,Post-eligibility 808 961	Provision of informed consent for participation in the study by patient or surrogate (if the patient is unable to provide informed consent) and caregiver
47,T32,"Post-eligibility 963 1157	Availability of primary caregiver, who spends greater than ten hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study"
48,T33,"Post-eligibility 1159 1315	Sufficient fluency, of both the patient and caregiver, in written and spoken English to participate in study visits, physical exams, and outcome assessments"
49,T34,Drug 1330 1344	AD medications
50,T35,Temporal 1345 1385	within the month preceding randomization
51,T36,Reference_point 1372 1385	randomization
52,R12,Has_index Arg1:T35 Arg2:T36
53,T37,Observation 1320 1344	change to AD medications
54,T38,Negation 1317 1319	No
55,R13,Has_negation Arg1:T37 Arg2:T38
56,R14,AND Arg1:T37 Arg2:T34
57,R15,Has_temporal Arg1:T37 Arg2:T35
58,T39,Drug 1473 1534	selective serotonin reuptake inhibitor antidepressants(SSRIs)
59,T40,Qualifier 1457 1469	stable doses
60,T41,Procedure 1442 1451	Treatment
61,R16,AND Arg1:T41 Arg2:T39
62,R17,Has_qualifier Arg1:T39 Arg2:T40
63,T42,"Context_Error 1442 1757	Treatment with stable doses of selective serotonin reuptake inhibitor antidepressants(SSRIs) is appropriate if stable for 3 months prior to randomization. Other psychotropics(with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis."
0,T1,Drug 29 48	antiarrhythmic drug
1,T2,Condition 3 11	response
2,T3,Negation 0 2	No
3,R1,Has_negation Arg1:T2 Arg2:T3
4,T4,Multiplier 15 28	more than one
5,R2,Has_multiplier Arg1:T1 Arg2:T4
6,R3,AND Arg1:T2 Arg2:T1
7,T5,Non-query-able 50 99	or unwilling to receive long-term drug treatment.
8,T6,Post-eligibility 101 244	Can provide informed consent form expressing willingness to participate in the study and comply with follow-up tests and evaluation procedures.
9,T7,Person 246 250	Aged
10,T8,Value 251 262	18-80 years
11,R4,Has_value Arg1:T7 Arg2:T8
0,T1,Condition 0 7	Allergy
1,T2,Drug 17 21	fish
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 23 31	Pregnant
4,T4,Person 32 37	women
5,T5,Condition 42 53	breast-feed
6,T7,Measurement 57 61;71 84	test for pregnancy
7,T8,Value 62 70	positive
8,R2,Has_value Arg1:T7 Arg2:T8
9,*,OR T5 T7 T3
0,T1,Condition 13 26	schizophrenia
1,T2,Condition 30 54	schizoaffective disorder
2,*,OR T1 T2
3,T3,Drug 161 183	atypical antipsychotic
4,T4,Observation 305 335	living in a stable environment
5,T5,Visit 84 93	inpatient
6,T6,Visit 95 110	hospitalization
7,T7,Temporal 115 121	recent
8,R1,Has_temporal Arg1:T6 Arg2:T7
9,A1,Optional T5
10,R2,AND Arg1:T5 Arg2:T6
11,T8,Temporal 123 132	Currently
12,T9,Procedure 143 152	treatment
13,R3,AND Arg1:T9 Arg2:T3
14,R4,Has_temporal Arg1:T9 Arg2:T8
15,T10,Procedure 188 218	continuation on the medication
16,T11,Mood 228 239	recommended
17,R5,Has_mood Arg1:T10 Arg2:T11
18,R6,AND Arg1:T10 Arg2:T3
19,T12,Non-query-able 241 293	Assumes primary responsibility for taking medication
0,T1,Person 15 19	aged
1,T2,Value 21 24	>18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 27 32	males
4,T4,Person 37 44	females
5,*,OR T3 T4
6,T5,Qualifier 57 65	elective
7,T6,Procedure 102 109;66 94	surgery coronary artery bypass graft
8,T7,Procedure 96 100	CABG
9,R2,Subsumes Arg1:T6 Arg2:T7
10,R3,Has_qualifier Arg1:T6 Arg2:T5
11,T8,Procedure 115 137	cardiopulmonary bypass
12,T9,Procedure 139 142	CPB
13,R4,Subsumes Arg1:T8 Arg2:T9
14,R5,AND Arg1:T6 Arg2:T8
0,T1,Condition 19 43	Major Depressive Episode
1,T2,Measurement 48 115	Diagnostic Statistical Manual of Mental Disorder - IV (TR) criteria
2,T3,Value 0 5	Meets
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Condition 140 161	agitation /aggression
6,T5,Qualifier 117 139	Clinically significant
7,T6,Undefined_semantics 117 139	Clinically significant
8,R3,Has_qualifier Arg1:T4 Arg2:T5
9,T8,Multiplier 186 220	frequency of agitation /aggression
10,T7,Condition 199 220	agitation /aggression
11,R4,AND Arg1:T8 Arg2:T7
12,T9,Measurement 240 243	NPI
13,R5,AND Arg1:T8 Arg2:T9
14,T10,Value 248 263	Very frequently
15,R6,Has_value Arg1:T9 Arg2:T10
16,T11,Multiplier 276 310	frequency of agitation /aggression
17,T12,Condition 289 310	agitation /aggression
18,R7,AND Arg1:T11 Arg2:T12
19,T13,Measurement 330 333	NPI
20,T14,Value 338 348	Frequently
21,R8,Has_value Arg1:T13 Arg2:T14
22,T15,Measurement 403 406	NPI
23,T16,Value 411 419	Moderate
24,T17,Value 426 432	Marked
25,*,OR T16 T17
26,T18,"Scope 410 433	'Moderate', or 'Marked'"
27,R9,Has_scope Arg1:T15 Arg2:T18
28,T19,Qualifier 358 383	severity of the agitation
29,T20,Condition 374 383	agitation
30,R10,AND Arg1:T19 Arg2:T20
31,R11,AND Arg1:T19 Arg2:T15
32,T21,Condition 458 467	delusions
33,T22,Qualifier 435 457	Clinically significant
34,T23,Multiplier 492 514	frequency of delusions
35,T24,Condition 505 514	delusions
36,R12,AND Arg1:T23 Arg2:T24
37,T25,Measurement 534 537	NPI
38,T26,Value 542 557	Very frequently
39,R13,Has_value Arg1:T25 Arg2:T26
40,R14,AND Arg1:T23 Arg2:T25
41,R15,Has_qualifier Arg1:T21 Arg2:T22
42,T27,Multiplier 570 592	frequency of delusions
43,T28,Condition 583 592	delusions
44,T29,Measurement 612 615	NPI
45,T30,Value 620 630	Frequently
46,T31,Qualifier 640 665	severity of the delusions
47,T32,Condition 656 665	delusions
48,R16,AND Arg1:T31 Arg2:T32
49,T33,Measurement 685 688	NPI
50,T34,Value 693 701	Moderate
51,T35,Value 708 714	Marked
52,*,OR T34 T35
53,T36,"Scope 692 715	'Moderate', or 'Marked'"
54,R17,Has_scope Arg1:T33 Arg2:T36
55,R18,Has_value Arg1:T29 Arg2:T30
56,R19,AND Arg1:T27 Arg2:T29
57,R20,AND Arg1:T31 Arg2:T33
58,T37,Condition 740 754	hallucinations
59,T38,Qualifier 717 739	Clinically significant
60,R21,Has_qualifier Arg1:T37 Arg2:T38
61,T39,Multiplier 779 806	frequency of hallucinations
62,T40,Condition 792 806	hallucinations
63,R22,AND Arg1:T39 Arg2:T40
64,T41,Measurement 826 829	NPI
65,T42,Value 834 849	Very frequently
66,R23,Has_value Arg1:T41 Arg2:T42
67,T43,Multiplier 862 889	frequency of hallucinations
68,T44,Condition 875 889	hallucinations
69,R24,AND Arg1:T43 Arg2:T44
70,T45,Measurement 909 912	NPI
71,T46,Value 917 927	Frequently
72,T47,Qualifier 937 967	severity of the hallucinations
73,T48,Condition 953 967	hallucinations
74,R25,AND Arg1:T47 Arg2:T48
75,T49,Measurement 987 990	NPI
76,T50,Value 995 1003	Moderate
77,T51,Value 1010 1016	Marked
78,*,OR T50 T51
79,T52,"Scope 994 1017	'Moderate', or 'Marked'"
80,R26,Has_scope Arg1:T49 Arg2:T52
81,R27,AND Arg1:T47 Arg2:T49
82,R28,Has_value Arg1:T45 Arg2:T46
83,R29,AND Arg1:T43 Arg2:T45
84,R30,AND Arg1:T39 Arg2:T41
85,*,OR T8 T11 T19
86,R31,AND Arg1:T11 Arg2:T13
87,T53,"Scope 186 433	frequency of agitation /aggression as assessed by the NPI is 'Very frequently', or 2) the frequency of agitation /aggression as assessed by the NPI is 'Frequently' AND the severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked'"
88,R32,Has_scope Arg1:T4 Arg2:T53
89,T54,"Scope 492 715	frequency of delusions as assessed by the NPI is 'Very frequently', or 2) the frequency of delusions as assessed by the NPI is 'Frequently' AND the severity of the delusions as assessed by the NPI is 'Moderate', or 'Marked'"
90,R33,Has_scope Arg1:T21 Arg2:T54
91,*,OR T23 T27 T31
92,*,OR T47 T43
93,T55,"Scope 779 1017	frequency of hallucinations as assessed by the NPI is 'Very frequently', or 2) the frequency of hallucinations as assessed by the NPI is 'Frequently' AND the severity of the hallucinations as assessed by the NPI is 'Moderate', or 'Marked'"
94,R34,Has_scope Arg1:T37 Arg2:T55
95,T56,Drug 1034 1058	psychotropic medications
96,T57,Temporal 1059 1096	in the 2 weeks prior to randomization
97,T58,Reference_point 1083 1096	randomization
98,R35,Has_index Arg1:T57 Arg2:T58
99,T59,Condition 1143 1151	dementia
100,T60,Procedure 1128 1151	treatments for dementia
101,R36,AND Arg1:T60 Arg2:T59
102,T61,Drug 1153 1158	ChEIs
103,T62,Drug 1163 1172	memantine
104,T63,Scope 1153 1172	ChEIs and memantine
105,R37,Has_scope Arg1:T60 Arg2:T63
106,T64,Drug 1175 1229	selective serotonin reuptake inhibitor antidepressants
107,T65,Drug 1235 1244	trazodone
108,R38,Has_temporal Arg1:T56 Arg2:T57
109,T66,Negation 1097 1118	with the exception of
110,*,OR T65 T64 T60
111,T67,"Scope 1128 1244	treatments for dementia (ChEIs and memantine), selective serotonin reuptake inhibitor antidepressants, and trazodone"
112,R39,Has_negation Arg1:T67 Arg2:T66
113,R40,Has_scope Arg1:T56 Arg2:T67
114,T68,Context_Error 1245 1313	(if used as an aid to facilitate sleep and not as an antidepressant)
115,T69,Drug 1315 1334	other psychotropics
116,T70,Drug 1358 1372	antipsychotics
117,T71,Negation 1336 1357	with the exclusion of
118,R41,Has_negation Arg1:T70 Arg2:T71
119,R42,AND Arg1:T69 Arg2:T70
120,T72,Qualifier 1378 1384	stable
121,T73,Temporal 1385 1397	for 3 months
122,R43,Has_temporal Arg1:T72 Arg2:T73
123,R44,Has_qualifier Arg1:T69 Arg2:T72
124,*,OR T69 T56
125,T74,Drug 1544 1559	methylphenidate
126,T75,Drug 1644 1659	methylphenidate
127,T76,Subjective_judgement 1730 1758	as judged by study physician
128,T77,Drug 1777 1850	medication that would prohibit the safe concurrent use of methylphenidate
129,T78,Drug 1835 1850	methylphenidate
130,T79,Temporal 1817 1827	concurrent
131,T80,Observation 1799 1807	prohibit
132,R45,Has_temporal Arg1:T78 Arg2:T79
133,R46,Has_context Arg1:T78 Arg2:T80
134,T81,Drug 1859 1887	monoamine oxidase inhibitors
135,T82,Drug 1892 1917	tricyclic antidepressants
136,T83,Scope 1859 1917	monoamine oxidase inhibitors and tricyclic antidepressants
137,*,OR T82 T81
138,R47,Subsumes Arg1:T77 Arg2:T83
139,T84,Procedure 1934 1961	psychiatric hospitalization
140,T85,Observation 1919 1927	Need for
141,T86,Temporal 1928 1933	acute
142,R48,Has_temporal Arg1:T84 Arg2:T86
143,R49,Has_context Arg1:T84 Arg2:T85
144,T87,Condition 1968 1976	suicidal
145,*,OR T84 T87
146,T88,Condition 1978 2003	Uncontrolled hypertension
147,T89,Qualifier 1978 1990	Uncontrolled
148,R50,Has_qualifier Arg1:T88 Arg2:T89
149,T90,Condition 2005 2030	medication non-compliance
150,T91,Temporal 2034 2047	past 3 months
151,T92,Measurement 2055 2072	diastolic reading
152,T93,Value 2076 2079	105
153,R51,Has_value Arg1:T92 Arg2:T93
154,T94,Context_Error 2055 2072	diastolic reading
155,T95,Measurement 2095 2143	compartment pressure of the rectus sheath (CPRS)
156,T96,Qualifier 2080 2143	as verified by compartment pressure of the rectus sheath (CPRS)
157,R52,AND Arg1:T96 Arg2:T95
158,R53,Has_qualifier Arg1:T92 Arg2:T96
159,R54,Has_temporal Arg1:T90 Arg2:T91
160,T97,Scope 2005 2143	medication non-compliance or past 3 months with a diastolic reading of 105 as verified by compartment pressure of the rectus sheath (CPRS)
161,R55,Has_scope Arg1:T88 Arg2:T97
162,T98,Condition 2158 2181	coronary artery disease
163,T99,Qualifier 2146 2157	Symptomatic
164,R56,Has_qualifier Arg1:T98 Arg2:T99
165,T100,Temporal 2226 2250	at the time of screening
166,T101,Reference_point 2233 2250	time of screening
167,R57,Has_index Arg1:T100 Arg2:T101
168,T102,Condition 2297 2322	unintentional weight loss
169,T103,Qualifier 2285 2296	significant
170,T104,Undefined_semantics 2285 2296	significant
171,R58,Has_qualifier Arg1:T102 Arg2:T103
172,T105,Condition 2252 2268	Lack of appetite
173,R59,AND Arg1:T105 Arg2:T102
174,T106,Qualifier 2323 2359	as determined by the study physician
175,T107,Temporal 2360 2384	in the last three months
176,R60,Has_temporal Arg1:T105 Arg2:T107
177,R61,Has_qualifier Arg1:T102 Arg2:T106
178,T108,Qualifier 2386 2397	Significant
179,T109,Undefined_semantics 2386 2397	Significant
180,T110,Condition 2398 2423	communicative impairments
181,R62,Has_qualifier Arg1:T110 Arg2:T108
182,T111,Undefined_semantics 2398 2423	communicative impairments
183,T112,Post-eligibility 2425 2539	Current participation in a clinical trial or in any study that may add significant burden or affect study outcomes
184,T113,Condition 2541 2556	Hyperthyroidism
185,T114,Condition 2567 2583	arteriosclerosis
186,T115,Qualifier 2558 2566	advanced
187,R63,Has_qualifier Arg1:T114 Arg2:T115
188,T116,Condition 2597 2619	cardiovascular disease
189,T117,Qualifier 2585 2596	symptomatic
190,R64,Has_qualifier Arg1:T116 Arg2:T117
191,T118,Qualifier 2621 2628	serious
192,T119,Condition 2629 2661	structural cardiac abnormalities
193,R65,Has_qualifier Arg1:T119 Arg2:T118
194,T120,Condition 2663 2677	cardiomyopathy
195,T121,Condition 2687 2713	heart rhythm abnormalities
196,T122,Qualifier 2679 2686	serious
197,R66,Has_qualifier Arg1:T121 Arg2:T122
198,T123,Observation 2720 2734	family history
199,T124,Condition 2738 2750	sudden death
200,T125,Condition 2754 2785	death related to heart problems
201,T126,Qualifier 2760 2785	related to heart problems
202,R67,Has_qualifier Arg1:T125 Arg2:T126
203,*,OR T124 T125
204,T127,Scope 2738 2785	sudden death or death related to heart problems
205,R68,Has_context Arg1:T127 Arg2:T123
206,*,OR T121 T127 T120 T119 T116 T114 T113
207,T128,Condition 2787 2795	Glaucoma
208,T129,Condition 2797 2813	pheochromocytoma
209,T130,Condition 2837 2853	hypersensitivity
210,T131,Drug 2857 2890	methylphenidate or its excipients
211,R69,AND Arg1:T130 Arg2:T131
212,T132,Drug 2876 2890	its excipients
213,R70,AND Arg1:T131 Arg2:T132
214,*,OR T131 T132
215,T133,Observation 2827 2836	suspected
216,T134,Observation 2818 2823	known
217,*,OR T133 T134
218,T135,Scope 2818 2836	known or suspected
219,R71,Has_scope Arg1:T130 Arg2:T135
220,*,OR T130 T129 T128
221,T136,Condition 2892 2934	Central Nervous System (CNS) abnormalities
222,T137,Condition 2942 2959	cerebral aneurysm
223,R72,Subsumes Arg1:T136 Arg2:T137
224,T138,Condition 2974 2996	vascular abnormalities
225,T139,Condition 3005 3015	vasculitis
226,R73,Subsumes Arg1:T138 Arg2:T139
227,T140,Condition 3032 3038	stroke
228,T141,Temporal 3019 3031	pre-existing
229,R74,Has_temporal Arg1:T140 Arg2:T141
230,T142,Condition 3040 3050	motor tics
231,T143,Observation 3056 3070	family history
232,T144,Condition 3087 3106	Tourette's syndrome
233,T145,Condition 3108 3116	seizures
234,T146,Condition 3118 3129	convulsions
235,T147,Observation 3074 3083	diagnosis
236,*,OR T147 T143
237,T148,Scope 3056 3083	family history or diagnosis
238,R75,Has_scope Arg1:T144 Arg2:T148
239,T149,Condition 3131 3139	epilepsy
240,*,OR T149 T146
241,T150,"Scope 3118 3139	convulsions, epilepsy"
242,R76,Subsumes Arg1:T145 Arg2:T150
243,T151,Qualifier 3145 3153	abnormal
244,T152,Condition 3154 3158	EEGs
245,R77,Has_qualifier Arg1:T152 Arg2:T151
246,*,OR T136 T138 T140 T142 T144 T145 T152
247,T153,"Post-eligibility 3160 3299	Any condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the patient to enroll in the trial"
0,T1,Person 0 6	female
1,T2,Condition 7 16	infertile
2,T3,Mood 26 34	eligible
3,T4,Procedure 39 52	IVF treatment
4,R1,Has_mood Arg1:T4 Arg2:T3
0,T1,Condition 5 19	acute diseases
1,T2,Temporal 29 40	acute phase
2,T3,Condition 47 68	myocardial infarction
3,T4,Temporal 70 85	within 3 months
4,R1,Has_temporal Arg1:T3 Arg2:T2
5,R2,Subsumes Arg1:T2 Arg2:T4
6,T5,Temporal 88 103	within 3 months
7,T6,Condition 110 129	acute heart failure
8,T7,Condition 137 156	cerebral infarction
9,*,OR T7 T6
10,T8,Scope 110 156	acute heart failure or new cerebral infarction
11,R3,Has_temporal Arg1:T8 Arg2:T5
12,*,OR T3 T8
13,T9,"Scope 29 156	acute phase after myocardial infarction (within 3 months), within 3 months after acute heart failure or new cerebral infarction"
14,R4,Subsumes Arg1:T1 Arg2:T9
15,T10,Procedure 174 195	heart transplantation
16,T11,Mood 159 170	In the list
17,R5,Has_mood Arg1:T10 Arg2:T11
18,T12,Observation 198 215	Expected survival
19,T13,Value 216 232	less than 1 year
20,R6,Has_value Arg1:T12 Arg2:T13
21,T14,Condition 246 266	hemorrhagic diseases
22,T15,Qualifier 240 245	other
23,R7,Has_qualifier Arg1:T14 Arg2:T15
24,T16,Procedure 271 292	anticoagulant therapy
25,T17,Condition 296 307	not allowed
26,R8,AND Arg1:T16 Arg2:T17
27,R9,AND Arg1:T14 Arg2:T16
28,T18,Condition 310 320	Thrombosis
29,T19,Qualifier 324 335	left atrium
30,R10,Has_qualifier Arg1:T18 Arg2:T19
31,T20,Condition 338 351	Heart failure
32,T21,Measurement 353 385	New York Heart Association(NYHA)
33,T22,Value 386 392	III/IV
34,R11,Has_value Arg1:T21 Arg2:T22
35,T23,Measurement 396 414	eject fraction(EF)
36,T24,Value 414 418	<40%
37,R12,Has_value Arg1:T23 Arg2:T24
38,*,OR T20 T21 T23
39,T25,Qualifier 435 447	uncontrolled
40,T26,Condition 448 454	cancer
41,R13,Has_qualifier Arg1:T26 Arg2:T25
42,T27,Condition 480 496	renal impairment
43,T28,Condition 469 476;486 496	hepatic impairment
44,*,OR T27 T28
45,T29,Qualifier 457 468	Significant
46,T30,Scope 469 496	hepatic or renal impairment
47,R14,Has_qualifier Arg1:T30 Arg2:T29
48,T31,Measurement 505 530	alanine transaminase(ALT)
49,T32,Measurement 534 561	Aspartate transaminase(AST)
50,T33,Value 562 592	>2 times upper limit of normal
51,R15,Has_value Arg1:T32 Arg2:T33
52,T34,Measurement 594 624	creatinine clearance rate(CCr)
53,T35,Value 624 628	<50%
54,R16,Has_value Arg1:T34 Arg2:T35
55,*,OR T32 T31 T34
56,T36,"Scope 505 628	alanine transaminase(ALT) or Aspartate transaminase(AST) >2 times upper limit of normal, creatinine clearance rate(CCr)<50%"
57,R17,Subsumes Arg1:T30 Arg2:T36
58,T37,Procedure 641 673	catheter radiofrequency ablation
59,T38,Condition 678 680	AF
60,T39,Procedure 684 699	cardiac surgery
61,R18,AND Arg1:T37 Arg2:T38
62,*,OR T37 T39
63,T40,"Pregnancy_considerations 702 839	Pregnant and lactating women, women who plan to become pregnant, or women of child bearing age not using reliable contraceptive measures."
0,T1,Person 12 16	aged
1,T2,Value 17 27	19 or over
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Informed_consent 29 176	Available for the entire duration of the study and willing to participate on the basis of the information provided in the FIU duly read and signed.
0,T1,Condition 23 34	head trauma
1,T2,Condition 36 52	seizure disorder
2,T3,Condition 57 75	mental retardation
3,*,OR T1 T2 T3
4,T4,Observation 0 7	History
5,T5,"Scope 23 75	head trauma, seizure disorder, or mental retardation"
6,R1,Has_scope Arg1:T4 Arg2:T5
7,T6,Observation 77 84	History
8,T7,Condition 104 109;88 95	abuse alcohol
9,T8,Condition 99 109	drug abuse
10,T9,Condition 113 123;88 95	dependence alcohol
11,T10,Condition 113 123;99 103	dependence drug
12,*,OR T7 T8 T10 T9
13,T11,Temporal 124 144	within 1 month prior
14,T12,Scope 88 123	alcohol or drug abuse or dependence
15,R2,Has_scope Arg1:T6 Arg2:T12
16,R3,Has_temporal Arg1:T12 Arg2:T11
17,T13,Temporal 181 202	within 6 months prior
18,T14,Observation 172 180	violence
19,R4,Has_temporal Arg1:T14 Arg2:T13
20,T15,Observation 161 168	History
21,R5,Has_context Arg1:T15 Arg2:T14
0,T1,Post-eligibility 0 15	Patient refusal
1,T2,Procedure 18 37	Emergency surgeries
2,T3,Procedure 39 53	Redo surgeries
3,T4,Condition 55 64	Pregnancy
4,T5,Condition 66 76	Vasculitis
5,T6,Condition 78 90	Inflammation
6,T7,Condition 94 103	infection
7,T8,Qualifier 111 121	study site
8,*,OR T7 T6
9,T9,Scope 78 103	Inflammation or infection
10,R1,Has_qualifier Arg1:T9 Arg2:T8
11,T10,Condition 134 142	allergic
12,T11,Non-query-able 123 172	History of allergic reaction to study medications
0,T1,Drug 28 47	systemic antibiotic
1,T2,Temporal 54 80	over the previous 4 months
2,T3,Observation 17 24	history
3,R1,Has_temporal Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Condition 100 108	pregnant
6,T5,Procedure 136 170	non-surgical periodontal treatment
7,T6,Temporal 171 195	within the past 6 months
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,T7,Procedure 223 253	surgical periodontal treatment
10,T8,Temporal 254 279	within the past 12 months
11,R4,Has_temporal Arg1:T7 Arg2:T8
12,T9,Condition 299 306	smokers
13,T10,Condition 335 341	stroke
14,T11,Procedure 348 374	acute cardiovascular event
15,T12,Temporal 375 402	over the previous 12 months
16,R5,Has_temporal Arg1:T11 Arg2:T12
17,*,OR T10 T11
0,T1,Drug 31 55	MF59-containing vaccines
1,T2,Drug 62 67	Fluad
2,T3,Drug 72 80	Addigrip
3,T4,Drug 85 118	virosome-based influenza vaccines
4,T5,Drug 127 137	Inflexal V
5,T6,Drug 140 154	InfectoVac Flu
6,T7,Drug 159 166	Invivac
7,T8,Temporal 168 205	during the 2006-2007 influenza season
8,*,OR T6 T7 T5
9,T9,"Scope 127 167	Inflexal V™, InfectoVac Flu™ or Invivac™"
10,R1,Subsumes Arg1:T4 Arg2:T9
11,T10,Scope 62 81	Fluad™ or Addigrip™
12,*,OR T2 T3
13,R2,Subsumes Arg1:T1 Arg2:T10
14,*,OR T1 T4
15,T11,"Scope 31 167	MF59-containing vaccines, e.g. Fluad™ or Addigrip™ or virosome-based influenza vaccines such as Inflexal V™, InfectoVac Flu™ or Invivac™"
16,R3,Has_temporal Arg1:T11 Arg2:T8
17,T12,Temporal 244 258;317 349	within 2 weeks prior to enrolment in this study
18,T13,Temporal 244 250;289 296;317 349	within 4 weeks prior to enrolment in this study
19,T14,Drug 264 284	inactivated vaccines
20,A1,Optional T14
21,R4,Has_temporal Arg1:T14 Arg2:T12
22,T15,Drug 302 315	live vaccines
23,A2,Optional T15
24,R5,Has_temporal Arg1:T15 Arg2:T13
25,*,OR T14 T15
26,T16,Drug 226 243	licensed vaccines
27,T17,Scope 244 349	within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study
28,R6,Has_scope Arg1:T16 Arg2:T17
29,T18,Drug 380 387	vaccine
30,T19,Qualifier 392 422	foreseen by the study protocol
31,T20,Negation 388 391	not
32,*,OR T19 T20
33,R7,Has_qualifier Arg1:T18 Arg2:T19
34,T21,Temporal 423 436	up to 30 days
35,T22,Drug 454 465	vaccination
36,T23,Value 447 453	second
37,R8,AND Arg1:T23 Arg2:T22
38,T24,Drug 471 483	H5N1 vaccine
39,R9,AND Arg1:T22 Arg2:T24
40,R10,Has_value Arg1:T21 Arg2:T23
41,R11,Has_temporal Arg1:T18 Arg2:T21
42,T25,Temporal 521 538	more than 14 days
43,T26,Qualifier 486 493	Chronic
44,T27,Drug 543 561	immunosuppressants
45,R13,Subsumes Arg1:T26 Arg2:T25
46,T28,Drug 565 593	other immune-modifying drugs
47,T29,Temporal 594 617	within six months prior
48,T30,Scope 543 593	immunosuppressants or other immune-modifying drugs
49,R12,Has_qualifier Arg1:T30 Arg2:T26
50,R14,Has_temporal Arg1:T30 Arg2:T29
51,T31,Condition 696 713;733 742	immunosuppressive condition
52,T32,Condition 717 742	immunodeficient condition
53,*,OR T32 T31
54,T33,Qualifier 673 682	confirmed
55,T34,Qualifier 686 695	suspected
56,*,OR T33 T34
57,T35,Scope 673 695	confirmed or suspected
58,T36,Scope 696 742	immunosuppressive or immunodeficient condition
59,R15,Has_scope Arg1:T36 Arg2:T35
60,T37,Condition 840 867	chronic alcohol consumption
61,T38,Condition 875 885	drug abuse
62,*,OR T37 T38
63,T39,Observation 829 836	History
64,T40,Scope 840 885	chronic alcohol consumption and/or drug abuse
65,R16,Has_scope Arg1:T39 Arg2:T40
66,T41,Condition 899 927	hypersensitivity to vaccines
67,T42,Observation 888 895	History
68,R17,AND Arg1:T42 Arg2:T41
69,T43,Condition 941 957	allergic disease
70,T44,Condition 941 949;961 970	allergic reactions
71,*,OR T44 T43
72,T45,Observation 930 937	History
73,T46,Scope 1039 1065	egg and thiomersal allergy
74,T47,Condition 1039 1042;1058 1065	egg allergy
75,T48,Condition 1047 1065	thiomersal allergy
76,T49,Scope 941 970	allergic disease or reactions
77,R18,Subsumes Arg1:T49 Arg2:T46
78,R19,Has_scope Arg1:T45 Arg2:T49
79,T51,Condition 1109 1123;1142 1164	cardiovascular functional abnormality
80,T52,Condition 1125 1132;1142 1164	hepatic functional abnormality
81,T53,Condition 1136 1164	renal functional abnormality
82,T50,Condition 1098 1107;1142 1164	pulmonary functional abnormality
83,*,OR T50 T51 T52 T53
84,T54,Condition 1236 1249	Acute disease
85,T55,Temporal 1250 1274	at the time of enrolment
86,R20,Has_temporal Arg1:T54 Arg2:T55
87,T56,Condition 1337 1354;1418 1426	chronic pulmonary disorder
88,T57,Condition 1337 1344;1356 1370;1418 1426	chronic cardiovascular disorder
89,T58,Condition 1337 1344;1372 1377;1418 1426	chronic renal disorder
90,T59,Condition 1337 1344;1379 1391;1418 1426	chronic neurological disorder
91,T60,Condition 1337 1344;1393 1404;1418 1426	chronic psychiatric disorder
92,T61,Condition 1337 1344;1408 1426	chronic metabolic disorder
93,*,OR T56 T57 T58 T59 T60 T61
94,T62,Drug 1506 1521	immunoglobulins
95,T63,Drug 1529 1547	any blood products
96,*,OR T62 T63
97,T64,Temporal 1548 1603	within the three months preceding the first vaccination
98,T65,Scope 1506 1547	immunoglobulins and/or any blood products
99,T66,Condition 1821 1830	condition
100,T67,Qualifier 1831 1836;1874 1926	which prevents the subject from participation in the study
101,R22,Has_qualifier Arg1:T66 Arg2:T67
102,T68,Non-representable 1838 1872	in the opinion of the investigator
103,R23,AND Arg1:T67 Arg2:T68
104,T69,"Non-representable 1817 1927	Any condition which, in the opinion of the investigator, prevents the subject from participation in the study."
105,T70,Qualifier 1637 1652	investigational
106,T71,Qualifier 1656 1670	non-registered
107,*,OR T70 T71
108,T72,Drug 1671 1678	product
109,T73,Scope 1637 1670	investigational or non-registered
110,R24,Has_scope Arg1:T72 Arg2:T73
111,T74,Drug 1680 1684	drug
112,T75,Drug 1688 1695	vaccine
113,*,OR T74 T75
114,T76,Scope 1680 1695	drug or vaccine
115,R25,Subsumes Arg1:T72 Arg2:T76
116,T77,Negation 1697 1707	other than
117,T78,Drug 1712 1728	study vaccine(s)
118,R26,Has_negation Arg1:T78 Arg2:T77
119,T79,Qualifier 1697 1728	other than the study vaccine(s)
120,R27,Has_qualifier Arg1:T72 Arg2:T79
121,R28,multi Arg1:T79 Arg2:T78
122,T80,Temporal 1729 1774	within 30 days prior to the first vaccination
123,R29,Has_temporal Arg1:T72 Arg2:T80
124,T81,Reference_point 1753 1774	the first vaccination
125,T82,Procedure 1763 1774	vaccination
126,T83,Temporal 1757 1762	first
127,R30,Has_temporal Arg1:T82 Arg2:T83
128,R31,multi Arg1:T81 Arg2:T82
129,R32,Has_index Arg1:T80 Arg2:T81
130,T84,Mood 1779 1786	planned
131,T85,Temporal 1791 1814	during the study period
132,T86,Procedure 1787 1790	use
133,R33,Has_mood Arg1:T86 Arg2:T84
134,R34,Has_temporal Arg1:T86 Arg2:T85
135,R35,AND Arg1:T72 Arg2:T86
136,T87,Qualifier 1277 1284	Serious
137,T88,Condition 1285 1300	chronic disease
138,R36,Has_qualifier Arg1:T88 Arg2:T87
139,T89,"Scope 1337 1426	chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder"
140,R37,Subsumes Arg1:T88 Arg2:T89
141,T90,Temporal 1607 1623	during the study
142,T91,Reference_point 1582 1603	the first vaccination
143,T92,Procedure 1592 1603	vaccination
144,T93,Temporal 1586 1591	first
145,R38,Has_temporal Arg1:T92 Arg2:T93
146,R39,multi Arg1:T91 Arg2:T92
147,R40,Has_index Arg1:T64 Arg2:T91
148,T94,Scope 1548 1623	within the three months preceding the first vaccination or during the study
149,*,OR T64 T90
150,R21,Has_scope Arg1:T65 Arg2:T94
151,T95,Reference_point 1614 1623	the study
152,R41,Has_index Arg1:T90 Arg2:T95
0,T1,Observation 9 42	provided written informed consent
1,T2,Person 54 58	aged
2,T3,Value 59 82	between 18 and 75 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Qualifier 90 101	symptomatic
5,T5,Condition 102 104;85 89	OA Knee
6,R2,Has_qualifier Arg1:T5 Arg2:T4
7,T6,Measurement 106 129	Kellgren-Lawrence grade
8,T7,Value 130 133	1-4
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Scope 106 133	Kellgren-Lawrence grade 1-4
11,R4,Subsumes Arg1:T4 Arg2:T8
12,T9,Observation 136 143	Failure
13,T10,Procedure 147 169	conservative treatment
14,T11,Temporal 170 191	for at least 3 months
15,R5,Has_context Arg1:T10 Arg2:T9
16,R6,Has_temporal Arg1:T9 Arg2:T11
17,T12,Observation 203 264	agreed to actively participate in the rehabilitation protocol
18,T13,Observation 203 240;269 286	agreed to actively participate in the follow-up program
19,T14,Person 289 293	Male
20,T15,Person 297 303	female
21,*,OR T14 T15
22,T16,Observation 324 340	childbearing age
23,T17,Person 315 320	Women
24,T18,Observation 361 388	method to prevent pregnancy
25,T19,Temporal 390 419	before the surgical treatment
26,T20,Reference_point 397 419	the surgical treatment
27,R7,Has_index Arg1:T19 Arg2:T20
28,T21,Procedure 401 419	surgical treatment
29,R8,AND Arg1:T20 Arg2:T21
30,R9,Has_temporal Arg1:T18 Arg2:T19
31,T22,Scope 315 340	Women of childbearing age
32,A1,Optional T22
33,R10,Has_context Arg1:T22 Arg2:T18
0,T1,Procedure 32 57	ocular refractive surgery
1,T2,Condition 11 67	indicated to have an ocular refractive surgery performed
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Condition 69 75	myopia
4,T4,Condition 77 88	astigmatism
5,T5,Condition 90 102	hypermetropy
6,T6,Qualifier 111 123	Lasik method
7,R2,Has_qualifier Arg1:T1 Arg2:T6
8,*,OR T3 T4 T5
9,T7,"Scope 69 102	myopia, astigmatism, hypermetropy"
10,R3,Subsumes Arg1:T2 Arg2:T7
11,T8,Condition 145 162	normal eye fundus
12,T9,Measurement 152 162	eye fundus
13,T10,Value 145 151	normal
14,R4,Has_value Arg1:T9 Arg2:T10
15,R5,AND Arg1:T8 Arg2:T9
16,T11,Measurement 177 203	intraocular pressure (IOP)
17,T12,Value 204 213	≤ 20 mmHg
18,R6,Has_value Arg1:T11 Arg2:T12
0,T1,Qualifier 20 29	untreated
1,T2,Qualifier 0 15	Newly diagnosed
2,T3,Measurement 30 42	sputum smear
3,T4,Value 43 51	positive
4,T5,Condition 52 64	tuberculosis
5,R1,Has_value Arg1:T3 Arg2:T4
6,*,OR T1 T2
7,R2,AND Arg1:T5 Arg2:T3
8,T6,Scope 0 29	Newly diagnosed and untreated
9,R3,Has_scope Arg1:T5 Arg2:T6
10,T7,Condition 74 90	Pulmonary lesion
11,T8,Condition 107 109	TB
12,T9,Procedure 113 137	radiological examination
13,T10,Qualifier 91 109	consistent with TB
14,R4,multi Arg1:T10 Arg2:T8
15,R5,Has_qualifier Arg1:T7 Arg2:T10
16,R6,AND Arg1:T9 Arg2:T7
17,T11,Value 139 147	Positive
18,T12,Measurement 148 162	sputum culture
19,R7,Has_value Arg1:T12 Arg2:T11
20,T13,Condition 207 233	Mycobacterium tuberculosis
21,T14,Qualifier 182 196	bacterial type
22,R8,Has_qualifier Arg1:T13 Arg2:T14
23,T15,Measurement 235 267	MGIT drug sensitivity test (DST)
24,T16,"Value 280 366	sensitive of the first-line drugs (isoniazid, streptomycin, rifampicin and ethambutol)"
25,T17,Drug 297 313	first-line drugs
26,T18,Drug 315 324	isoniazid
27,T19,Drug 326 338	streptomycin
28,T20,Drug 340 350	rifampicin
29,T21,Drug 355 365	ethambutol
30,*,OR T21 T20 T19 T18
31,T22,"Scope 315 365	isoniazid, streptomycin, rifampicin and ethambutol"
32,R9,Subsumes Arg1:T17 Arg2:T22
33,R10,AND Arg1:T15 Arg2:T17
34,T23,Person 369 372	Age
35,T24,Value 373 394	18 years-65 years old
36,R11,Has_value Arg1:T23 Arg2:T24
37,T25,Person 396 401	Males
38,T26,Negation 405 409	non-
39,T27,Condition 409 417	pregnant
40,T28,Negation 419 423	non-
41,T29,Observation 423 430	nursing
42,T30,Person 431 438	females
43,T31,"Scope 405 438	non-pregnant, non-nursing females"
44,*,OR T31 T25
45,R12,Has_negation Arg1:T27 Arg2:T26
46,R13,Has_negation Arg1:T29 Arg2:T28
47,T32,Measurement 449 473	plasma aminotransferases
48,T33,Measurement 475 478	AST
49,T34,Measurement 480 483	ALT
50,T35,Measurement 440 445;456 473	Serum aminotransferases
51,*,OR T32 T35
52,*,OR T33 T34
53,T36,Scope 440 473	Serum or plasma aminotransferases
54,T37,"Scope 475 483	AST, ALT"
55,R14,Subsumes Arg1:T36 Arg2:T37
56,T38,Value 485 528	less than 3 times the upper limit of normal
57,R15,Has_value Arg1:T36 Arg2:T38
58,T39,Qualifier 539 545	plasma
59,T40,Qualifier 530 535	Serum
60,T41,Measurement 546 561	total bilirubin
61,*,OR T39 T40
62,T42,Value 562 619	less than or equal to 2.5 times the upper limit of normal
63,T43,Scope 530 545	Serum or plasma
64,R16,Has_scope Arg1:T41 Arg2:T43
65,R17,Has_value Arg1:T41 Arg2:T42
66,T44,Qualifier 630 636	plasma
67,T45,Qualifier 621 626	Serum
68,T46,Measurement 637 653	creatinine level
69,T47,Value 654 709	less than or equal to 2 times the upper limit of normal
70,*,OR T44 T45
71,T48,Scope 621 636	Serum or plasma
72,R18,Has_scope Arg1:T46 Arg2:T48
73,R19,Has_value Arg1:T46 Arg2:T47
74,T49,Qualifier 711 716	Serum
75,T50,Qualifier 720 726	plasma
76,T51,Measurement 727 742	potassium level
77,T52,Value 743 777	greater than or equal to 3.5 meq/L
78,*,OR T50 T49
79,T53,Scope 711 726	Serum or plasma
80,R20,Has_scope Arg1:T51 Arg2:T53
81,R21,Has_value Arg1:T51 Arg2:T52
82,T54,Measurement 779 795	Hemoglobin level
83,T55,Value 799 818	7.0 g/dL or greater
84,R22,Has_value Arg1:T54 Arg2:T55
85,T56,Measurement 820 834	Platelet count
86,T57,"Value 838 860	100,000/mm3 or greater"
87,R23,Has_value Arg1:T56 Arg2:T57
88,T58,Person 866 871	women
89,T59,Observation 875 897	childbearing potential
90,T60,Value 901 909	negative
91,T61,Measurement 910 924	pregnancy test
92,T62,Scope 866 897	women of childbearing potential
93,A1,Optional T62
94,R24,Has_value Arg1:T61 Arg2:T60
95,T63,Temporal 937 953	during screening
96,T64,Reference_point 944 953	screening
97,R25,Has_index Arg1:T63 Arg2:T64
98,R26,Has_temporal Arg1:T61 Arg2:T63
99,R27,AND Arg1:T62 Arg2:T61
100,T65,Observation 964 988	written informed consent
101,T66,Observation 1006 1050	ability to attend scheduled follow-up visits
102,T67,Observation 1006 1016;1055 1080	ability to undergo study assessments
103,T68,Observation 1014 1050;990 1001	to attend scheduled follow-up visits Willingness
104,T69,Observation 1014 1016;1055 1080;990 1001	to undergo study assessments Willingness
0,T1,Condition 0 8	Epilepsy
1,T2,Condition 10 23	Hydrocephalus
2,T3,Device 29 46	ventricular drain
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 48 69	Coagulation disorders
5,T5,Condition 71 78	Allergy
6,T6,Drug 82 99	anesthetic agents
7,R2,AND Arg1:T5 Arg2:T6
8,T7,Condition 101 125	Severe health conditions
9,T8,Undefined_semantics 101 125	Severe health conditions
10,T9,Subjective_judgement 101 125	Severe health conditions
11,T10,Condition 134 140	cancer
12,T11,Condition 142 158	failure of heart
13,T12,Condition 142 152;160 164	failure of lung
14,T13,Condition 142 152;166 171	failure of liver
15,T14,Condition 142 152;175 181	failure of kidney
16,*,OR T12 T11 T14 T13 T10
17,T15,"Scope 134 181	cancer, failure of heart, lung, liver or kidney"
18,R3,Has_scope Arg1:T7 Arg2:T15
19,T16,Condition 190 200	infections
20,T17,Undefined_semantics 190 200	infections
21,T18,Temporal 183 189	Active
22,R4,Has_temporal Arg1:T16 Arg2:T18
0,T1,Person 27 31	aged
1,T2,Value 32 55	from 18 to 65 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 92 98	Female
4,A1,Optional T3
5,T4,Procedure 123 143	contraceptive method
6,R2,AND Arg1:T3 Arg2:T4
7,T5,Condition 435 462	allergic contact dermatitis
8,T6,Drug 466 493	para-phenylenediamine (PPD)
9,R3,AND Arg1:T5 Arg2:T6
10,T7,Condition 520 538	contact dermatitis
11,T8,Drug 516 519	PPD
12,R4,AND Arg1:T7 Arg2:T8
13,T9,Measurement 552 567	PPD patch tests
14,T10,Value 543 551	positive
15,R5,Has_value Arg1:T9 Arg2:T10
16,T11,Scope 516 567	PPD contact dermatitis and positive PPD patch tests
17,R6,Subsumes Arg1:T5 Arg2:T11
18,T12,Condition 625 652	allergic contact dermatitis
19,T13,Drug 621 624	PPD
20,R7,AND Arg1:T12 Arg2:T13
21,T14,Negation 607 609	No
22,R8,Has_negation Arg1:T12 Arg2:T14
23,T15,Measurement 670 684	PPD patch test
24,T16,Value 661 669	negative
25,R9,Has_value Arg1:T15 Arg2:T16
26,T17,Scope 661 684	negative PPD patch test
27,R10,Subsumes Arg1:T17 Arg2:T12
28,T18,Condition 402 410	allergic
29,T19,Observation 587 594	healthy
30,T20,Mood 146 160	Feasibility of
31,T21,Post-eligibility 161 174	patch testing
32,R11,Has_mood Arg1:T21 Arg2:T20
33,T22,Person 58 70	Both genders
34,T23,Mood 195 205	be able to
35,T24,Informed_consent 206 246	understand and sign the Informed Consent
36,T25,Informed_consent 252 291	comply with all aspects of the protocol
37,T26,"Scope 206 291	understand and sign the Informed Consent, and comply with all aspects of the protocol"
38,R12,Has_mood Arg1:T26 Arg2:T23
39,T27,Observation 311 349	registered in a social security system
40,T28,Observation 360 385	health insurance coverage
41,T29,Non-query-able 360 385	health insurance coverage
42,T30,Non-query-able 311 349	registered in a social security system
43,R13,multi Arg1:T30 Arg2:T27
44,R14,multi Arg1:T29 Arg2:T28
0,T1,Measurement 14 25	temperature
1,T2,Value 26 34	> 39.0◦C
2,T3,Person 4 9	child
3,R1,Has_value Arg1:T1 Arg2:T2
4,T4,Qualifier 40 46	severe
5,T5,Condition 47 60	acute illness
6,T6,Qualifier 61 94	as defined by the examining nurse
7,R2,Has_qualifier Arg1:T5 Arg2:T4
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Person 100 105	child
10,T8,Measurement 115 142	mid upper arm circumference
11,T9,Value 143 151	< 110 mm
12,R4,Has_value Arg1:T8 Arg2:T9
13,T10,Value 156 178	is older than 6 months
14,T11,Person 159 162	old
15,R5,Has_value Arg1:T11 Arg2:T10
16,T12,Non-representable 179 256	(most feasible local indicator of AIDS and chronic immunosuppressive disease)
17,T13,Person 262 267	child
18,T14,Condition 286 310	severe allergic reaction
19,T15,"Temporal 311 351	after previous vaccination, drug or food"
20,T16,"Reference_point 317 351	previous vaccination, drug or food"
21,R6,Has_index Arg1:T15 Arg2:T16
22,T17,Procedure 326 337	vaccination
23,T18,Procedure 339 343	drug
24,T19,Procedure 347 351	food
25,*,OR T19 T18 T17
26,T20,"Scope 326 351	vaccination, drug or food"
27,T21,Temporal 317 325	previous
28,R7,Has_temporal Arg1:T20 Arg2:T21
29,R8,multi Arg1:T16 Arg2:T20
30,R9,Has_temporal Arg1:T14 Arg2:T15
31,T22,Competing_trial 354 453	the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old
32,T23,Observation 463 478	RECAMP-MV trial
33,A1,Optional T23
34,T24,Observation 493 515	enrolled in RECAMP-OPV
35,R10,Has_context Arg1:T23 Arg2:T24
0,T1,Condition 83 104	Chronic periodontitis
1,T2,Qualifier 74 82	Advanced
2,T3,Qualifier 62 70	Moderate
3,*,OR T3 T2
4,T4,Scope 62 82	Moderate to Advanced
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 33 46	teeth present
7,T6,Multiplier 21 32	at least 12
8,R2,Has_multiplier Arg1:T5 Arg2:T6
9,T7,Multiplier 120 129	2 or more
10,T8,Condition 130 149;170 211	interproximal sites with probing pocket depths of 5mm or more
11,T9,Value 200 211	5mm or more
12,T10,Multiplier 216 225	2 or more
13,T11,Condition 226 245;265 306	interproximal sites of probing attachment loss of 4mm or more
14,R3,Has_multiplier Arg1:T11 Arg2:T10
15,T12,Value 295 306	4mm or more
16,T13,Qualifier 313 328	bled on probing
17,T14,Procedure 321 328	probing
18,R4,Has_qualifier Arg1:T11 Arg2:T13
19,R5,Has_multiplier Arg1:T8 Arg2:T7
0,T1,Procedure 0 7	Surgery
1,T2,Condition 24 40	ocular pathology
2,T3,Temporal 15 23	previous
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,*,OR T1 T2
5,T4,Condition 54 58	scar
6,T5,Observation 59 79	change in the cornea
7,T6,Condition 81 89	glaucoma
8,T7,Condition 91 104	retinopathies
9,*,OR T4 T5 T6 T7
10,T8,"Scope 54 104	scar/change in the cornea, glaucoma, retinopathies"
11,R2,Subsumes Arg1:T2 Arg2:T8
12,T9,Condition 126 134	diabetes
13,T10,Condition 141 156	immunodepressed
14,*,OR T10 T9
15,T11,Condition 172 181	infection
16,T12,Qualifier 163 171	systemic
17,T13,Temporal 182 198	during the study
18,T14,Reference_point 189 198	the study
19,T15,Condition 226 245	ocular inflammation
20,T16,Condition 226 232;246 255	ocular infection
21,T17,Qualifier 257 266;350 358	bacterial etiology
22,T18,Qualifier 268 273;350 358	viral etiology
23,T19,Qualifier 275 281;350 358	fungal etiology
24,T20,Observation 293 302	Chlamydia
25,T21,Observation 307 320	Mycobacterium
26,T22,Observation 322 334	Acanthamoeba
27,T23,Condition 341 358	allergic etiology
28,T24,Qualifier 283 302	caused by Chlamydia
29,T25,Qualifier 283 289;304 320	caused by Mycobacterium
30,T26,Qualifier 283 292;322 334	caused by Acanthamoeba
31,*,OR T17 T18 T19 T24 T25 T26 T23
32,T27,"Scope 257 358	bacterial, viral, fungal, caused by Chlamydia, by Mycobacterium, Acanthamoeba or of allergic etiology"
33,*,OR T15 T16
34,T28,Scope 226 255	ocular inflammation/infection
35,R3,Subsumes Arg1:T28 Arg2:T27
36,T29,Drug 388 407	topical antibiotics
37,T30,Qualifier 388 395	topical
38,R4,Has_qualifier Arg1:T29 Arg2:T30
39,T31,Drug 376 384;396 407	systemic antibiotics
40,T32,Qualifier 376 384	systemic
41,T33,Condition 412 428	ocular infection
42,T34,Temporal 429 452	in the previous 14 days
43,*,OR T29 T31
44,T35,Scope 376 407	systemic or topical antibiotics
45,R5,AND Arg1:T35 Arg2:T33
46,R6,Has_temporal Arg1:T35 Arg2:T34
47,T36,Condition 473 489	hypersensitivity
48,T37,Qualifier 504 534	components of the formulations
49,R7,Has_qualifier Arg1:T36 Arg2:T37
50,R8,Has_temporal Arg1:T11 Arg2:T13
51,R9,Has_index Arg1:T13 Arg2:T14
52,R10,Has_qualifier Arg1:T11 Arg2:T12
0,T1,Observation 9 35	incapable to understanding
1,T2,Observation 40 44;9 21	will incapable to
2,*,OR T1 T2
3,T3,Temporal 73 81	previous
4,T4,Observation 102 108;56 72	trials participating in
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Qualifier 110 117	ongoing
7,T6,Qualifier 121 130	completed
8,T7,Temporal 131 150	within three months
9,*,OR T5 T6
10,R2,Has_temporal Arg1:T6 Arg2:T7
11,T8,Scope 110 150	ongoing or completed within three months
12,R3,Has_scope Arg1:T4 Arg2:T8
13,T9,Procedure 163 181	surgically treated
14,T10,Condition 186 201	the same defect
15,T11,Temporal 202 217	within one year
16,R4,AND Arg1:T9 Arg2:T10
17,R5,Has_temporal Arg1:T9 Arg2:T11
18,T12,Condition 241 251	malignancy
19,T13,Condition 275 284;296 305	metabolic disorders
20,T14,Condition 288 305	thyroid disorders
21,*,OR T14 T13
22,T15,Condition 325 332;354 359	alcohol abuse
23,T16,Condition 336 340;354 359	drug abuse
24,T17,Condition 342 352;354 359	medication abuse
25,R6,Subsumes Arg1:T16 Arg2:T17
26,*,OR T17 T15
27,T18,Condition 383 392	synovitis
28,T19,Condition 404 423	valgus misalignment
29,T20,Condition 395 400;411 423	Varus misalignment
30,T21,Measurement 404 423	valgus misalignment
31,T22,Measurement 395 400;411 423	Varus misalignment
32,R8,multi Arg1:T19 Arg2:T21
33,R7,multi Arg1:T20 Arg2:T22
34,T23,Value 424 437	exceeding 15°
35,R9,Has_value Arg1:T22 Arg2:T23
36,R10,Has_value Arg1:T21 Arg2:T23
37,*,OR T19 T20 T22 T21
38,T24,Measurement 440 455	Body Mass Index
39,T25,Value 456 460	> 40
40,R11,Has_value Arg1:T24 Arg2:T25
41,T26,Procedure 477 483	trauma
42,T27,Temporal 484 513	within 6 months pre-operative
43,T28,Reference_point 500 513	pre-operative
44,T29,Procedure 504 513	operative
45,R12,multi Arg1:T28 Arg2:T29
46,R13,Has_index Arg1:T27 Arg2:T28
47,R14,Has_temporal Arg1:T26 Arg2:T27
0,T1,Person 158 162	aged
1,T2,Value 163 180	61 years or above
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 273 280	Healthy
4,T4,Condition 323 341	underlying disease
5,T5,Qualifier 307 322	well controlled
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Person 151 157	female
8,T7,Person 143 147	male
9,*,OR T7 T6
10,*,OR T3 T4
11,T8,Observation 220 244	Written informed consent
12,T9,Observation 49 106	can and will comply with the requirements of the protocol
0,T1,Condition 38 55	Neonatal Jaundice
1,T2,Condition 0 14	Cerebral palsy
2,R1,AND Arg1:T2 Arg2:T1
0,T1,Condition 0 12	Tuberculosis
1,T2,Qualifier 13 25	resistant to
2,T3,Drug 37 48	study drugs
3,T4,Drug 50 59	isoniazid
4,T5,Drug 61 69	rifampin
5,T6,Drug 71 74	EMB
6,T7,Drug 76 79	PZA
7,T8,Drug 81 84	CFZ
8,T9,Drug 86 89	Pto
9,*,OR T9 T8 T7 T6 T5 T4
10,T10,"Scope 50 89	isoniazid, rifampin, EMB, PZA, CFZ, Pto"
11,R1,Subsumes Arg1:T3 Arg2:T10
12,R2,AND Arg1:T2 Arg2:T3
13,R3,Has_qualifier Arg1:T1 Arg2:T2
14,T11,Observation 92 123	Unable to take oral medications
15,T12,Condition 137 144	allergy
16,T13,Observation 126 133	History
17,T14,Condition 148 159	intolerance
18,*,OR T12 T14
19,T15,Drug 174 185	study drugs
20,T16,Scope 137 159	allergy or intolerance
21,R4,Has_temporal Arg1:T16 Arg2:T13
22,R5,AND Arg1:T16 Arg2:T15
23,T17,Measurement 187 209	Serum aminotransferase
24,T18,Measurement 211 214	AST
25,T19,Measurement 218 221	ALT
26,*,OR T18 T19
27,T20,Scope 211 221	AST or ALT
28,R6,Subsumes Arg1:T17 Arg2:T20
29,T21,Scope 187 222	Serum aminotransferase (AST or ALT)
30,T22,Value 223 257	3x upper limit of normal or higher
31,R7,Has_value Arg1:T21 Arg2:T22
32,T23,Condition 259 267	Pregnant
33,T24,Observation 271 278	nursing
34,T25,Person 279 286	females
35,*,OR T23 T24 T30
36,T26,Mood 291 298	plan to
37,T27,Observation 299 314	become pregnant
38,T28,Observation 318 323	nurse
39,T29,Temporal 324 347	during the study period
40,*,OR T27 T28
41,T30,Scope 299 323	become pregnant or nurse
42,R8,Has_mood Arg1:T30 Arg2:T26
43,R9,Has_temporal Arg1:T30 Arg2:T29
44,T31,Person 349 354	Males
45,T32,Mood 355 366	planning to
46,T33,Observation 367 383	conceive a child
47,R10,Has_mood Arg1:T33 Arg2:T32
48,T34,Temporal 384 400	during the study
49,T35,Temporal 404 445	within 6 months of cessation of treatment
50,T36,Reference_point 423 445	cessation of treatment
51,R11,Has_index Arg1:T35 Arg2:T36
52,T37,Reference_point 391 400	the study
53,R12,Has_index Arg1:T34 Arg2:T37
54,*,OR T34 T35
55,T38,Scope 384 445	during the study or within 6 months of cessation of treatment
56,R13,Has_scope Arg1:T33 Arg2:T38
57,T39,Qualifier 479 485	active
58,T40,Condition 486 498	tuberculosis
59,T41,Temporal 499 550	within 6 months preceding initiation of study drugs
60,R14,Has_qualifier Arg1:T40 Arg2:T39
61,R15,Has_temporal Arg1:T40 Arg2:T41
62,T42,Procedure 452 461	treatment
63,R16,AND Arg1:T42 Arg2:T40
64,T43,Condition 577 589	tuberculosis
65,T44,Qualifier 604 626	central nervous system
66,T45,Qualifier 634 639	bones
67,T46,Qualifier 647 653	joints
68,T47,Qualifier 662 682	miliary tuberculosis
69,T48,Qualifier 690 714	pericardial tuberculosis
70,*,OR T44 T45 T46 T47 T48
71,T49,"Scope 604 714	central nervous system and/or bones and/or joints, and/or miliary tuberculosis and/or pericardial tuberculosis"
72,R17,Has_scope Arg1:T43 Arg2:T49
73,T50,Mood 566 576	documented
74,T51,Mood 553 562	Suspected
75,*,OR T51 T50
76,T52,Scope 553 576	Suspected or documented
77,R18,Has_scope Arg1:T43 Arg2:T52
78,T53,Condition 717 729	HIV infected
79,T54,Condition 731 743	HBV infected
80,T55,Condition 747 759	HCV infected
81,*,OR T54 T55
82,T56,Non-representable 760 819	(these increase the risk of TB-drug induced hepatotoxicity)
83,T57,Measurement 821 827	Weight
84,T58,Value 828 845	less than 40.0 kg
85,R19,Has_value Arg1:T57 Arg2:T58
86,T59,Condition 854 861	allergy
87,T60,Condition 865 876	intolerance
88,T61,Drug 891 908	study medications
89,*,OR T59 T60
90,T62,Scope 854 876	allergy or intolerance
91,R20,AND Arg1:T62 Arg2:T61
92,T63,Condition 993 1016	M. tuberculosis isolate
93,T64,Qualifier 1040 1075	resistant to any of the study drugs
94,T65,Drug 1064 1075	study drugs
95,R21,multi Arg1:T64 Arg2:T65
96,R22,Has_qualifier Arg1:T63 Arg2:T64
97,T66,Measurement 1078 1082	QTcF
98,T67,Value 1083 1093	> 500 msec
99,R23,Has_value Arg1:T66 Arg2:T67
100,T68,"Non-query-able 1095 1222	Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest."
101,T69,Temporal 1224 1231	Current
102,T70,Mood 1235 1242	planned
103,*,OR T69 T70
104,T71,Observation 1243 1256	incarceration
105,T72,Observation 1266 1287	involuntary detention
106,*,OR T71 T72
107,T73,Scope 1243 1287	incarceration or other involuntary detention
108,T74,Scope 1224 1242	Current or planned
109,R24,Has_scope Arg1:T73 Arg2:T74
110,T75,Observation 1296 1334	participated in other clinical studies
111,T76,Drug 1350 1372	investigational agents
112,T77,Temporal 1373 1408	within 8 weeks prior to trial start
113,T78,Temporal 1412 1421	currently
114,T79,Observation 1422 1458	enrolled in an investigational study
115,T80,Reference_point 1397 1408	trial start
116,R25,Has_index Arg1:T77 Arg2:T80
117,R26,Has_temporal Arg1:T79 Arg2:T78
118,R27,Has_temporal Arg1:T75 Arg2:T77
119,R28,AND Arg1:T75 Arg2:T76
120,T81,Drug 1488 1504	medicinal agents
121,R29,AND Arg1:T79 Arg2:T81
122,T82,Non-representable 1506 1665	Subjects who are participating in observational studies or who are in a follow up period of a trial that included drug therapy may be considered for inclusion.
0,T1,Person 0 8	Children
1,T2,Person 9 13	aged
2,T3,Value 14 25	0-59 months
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Observation 26 99	living with families registered in the rural Bandim Health Project Health
5,T5,Visit 104 133	Person Surveillance Site
0,T1,Condition 0 8	Pregnant
1,T2,Condition 12 21	lactating
2,T3,Person 22 27	women
3,*,OR T1 T2
4,T4,Condition 30 52	Evolutive skin disease
5,T5,Qualifier 60 72	testing zone
6,T6,Qualifier 74 84	lower back
7,R1,Subsumes Arg1:T5 Arg2:T6
8,R2,Has_qualifier Arg1:T4 Arg2:T5
9,T7,Procedure 168 191	Systemic corticotherapy
10,T8,Procedure 195 222	immunosuppressive treatment
11,*,OR T7 T8
12,T9,Temporal 223 248	during the previous month
13,T10,Scope 168 222	Systemic corticotherapy or immunosuppressive treatment
14,R3,Has_temporal Arg1:T10 Arg2:T9
15,T11,Procedure 253 278	local corticoid treatment
16,T12,Temporal 279 294	the week before
17,T13,Condition 386 401	Exposure to sun
18,T14,Condition 386 397;405 418	Exposure to UV radiations
19,*,OR T14 T13
20,T15,Temporal 420 452	15 days before the patch testing
21,T16,Scope 386 418	Exposure to sun or UV radiations
22,R4,Has_temporal Arg1:T16 Arg2:T15
23,T17,Condition 464 494	deprived of their civic rights
24,T18,Condition 496 506	in custody
25,T19,Condition 511 532	subject to a tutorial
26,T20,Condition 511 523;534 543;562 570	subject to a judiciary decision
27,T21,Condition 511 521;547 570	subject to administrative decision
28,*,OR T17 T18 T19 T20 T21
29,T22,Condition 630 656	critical medical situation
30,T23,Condition 582 613	subject to a protection measure
31,T24,Qualifier 104 126	clinically significant
32,T25,Condition 127 134	disease
33,R5,Has_qualifier Arg1:T25 Arg2:T24
34,T26,Qualifier 136 143	chronic
35,T27,Qualifier 145 154	recurrent
36,T28,Qualifier 158 164	active
37,*,OR T27 T28 T26
38,T29,"Scope 136 164	chronic, recurrent or active"
39,R6,Subsumes Arg1:T24 Arg2:T29
40,T30,Qualifier 315 320	Local
41,T31,Qualifier 324 332	systemic
42,T32,Drug 333 337	drug
43,T33,Qualifier 348 383	interacts with the outcome measures
44,*,OR T31 T30
45,T34,Scope 315 332	Local or systemic
46,R7,Has_scope Arg1:T32 Arg2:T34
47,R8,Has_qualifier Arg1:T32 Arg2:T33
48,T35,Reference_point 435 452	the patch testing
49,R9,Has_index Arg1:T15 Arg2:T35
50,T36,Observation 675 693	personal situation
51,T37,Non-representable 694 789	judged by the investigator as unlikely to be compatible with optimal participation in the study
52,T38,Non-query-able 800 839	could constitute a risk for the patient
53,*,OR T37 T38
54,T39,"Scope 694 839	judged by the investigator as unlikely to be compatible with optimal participation in the study, or which could constitute a risk for the patient"
55,R10,Has_scope Arg1:T36 Arg2:T39
56,T40,Observation 842 860	Linguistic barrier
57,T41,Condition 864 885	psychological profile
58,T42,Negation 886 896	preventing
59,T43,Informed_consent 914 938	signing the consent form
60,R11,Has_negation Arg1:T43 Arg2:T42
61,*,OR T41 T40
62,T44,Scope 842 885	Linguistic barrier or psychological profile
63,R12,AND Arg1:T44 Arg2:T43
64,T45,Competing_trial 992 1031	participation in another clinical trial
65,T46,Temporal 949 987	still in an exclusion period following
66,R13,Has_temporal Arg1:T45 Arg2:T46
67,T47,Competing_trial 1092 1124	participation in clinical trials
68,T48,Temporal 1125 1154	during the previous 12 months
69,T49,Reference_point 1132 1154	the previous 12 months
70,R14,Has_index Arg1:T48 Arg2:T49
71,R15,Has_temporal Arg1:T47 Arg2:T48
72,T50,Observation 1050 1087	earned more than 4500€ in indemnities
73,T51,Non-query-able 1050 1087	earned more than 4500€ in indemnities
74,R16,AND Arg1:T50 Arg2:T51
75,R17,AND Arg1:T50 Arg2:T47
0,T1,Visit 0 13	Nursing homes
1,T2,Visit 84 105	Licensed nursing home
2,T3,Visit 109 122	Orange County
3,T4,Visit 126 153	Southern Los Angeles County
4,T5,Qualifier 154 168	serving adults
5,*,OR T3 T4 T2
6,T6,Scope 84 153	Licensed nursing home in Orange County or Southern Los Angeles County
7,R1,Has_qualifier Arg1:T6 Arg2:T5
8,T7,Procedure 185 206	chlorhexidine bathing
9,T8,Drug 185 198	chlorhexidine
10,R2,multi Arg1:T7 Arg2:T8
11,T9,Multiplier 170 181	Minimal use
12,R3,Has_multiplier Arg1:T7 Arg2:T9
13,T10,Multiplier 209 220	Minimal use
14,T11,Procedure 224 244	nasal decolonization
15,R4,Has_multiplier Arg1:T11 Arg2:T10
16,T12,Multiplier 247 258	Minimal use
17,T13,Value 270 274	<15%
18,T14,Measurement 278 329	residents receiving at least one chlorhexidine bath
19,T15,Multiplier 298 310	at least one
20,T16,Procedure 311 329	chlorhexidine bath
21,T17,Drug 311 324	chlorhexidine
22,R5,multi Arg1:T16 Arg2:T17
23,R6,Has_multiplier Arg1:T16 Arg2:T15
24,R7,multi Arg1:T15 Arg2:T16
25,R8,Has_value Arg1:T14 Arg2:T13
26,T18,Scope 270 329	<15% of residents receiving at least one chlorhexidine bath
27,R9,Has_multiplier Arg1:T10 Arg2:T12
28,T19,Procedure 333 363	nasal decolonization treatment
29,T20,Temporal 364 394	during their nursing home stay
30,R10,Has_temporal Arg1:T19 Arg2:T20
31,T21,Scope 333 394	nasal decolonization treatment during their nursing home stay
32,*,OR T18 T21
33,T22,Scope 270 394	<15% of residents receiving at least one chlorhexidine bath or nasal decolonization treatment during their nursing home stay
34,R11,Subsumes Arg1:T12 Arg2:T22
0,T1,Not_a_criteria 0 2	NA
0,T1,Condition 11 15	PCOS
1,T2,Person 0 5	Women
2,T3,Measurement 34 52	Rotterdam criteria
3,R1,AND Arg1:T3 Arg2:T1
4,T4,Multiplier 67 77	at least 2
5,T5,Observation 105 126	cleavage-stage embryo
6,T6,Qualifier 92 96	good
7,T7,Qualifier 78 91	cryopreserved
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,R3,Has_qualifier Arg1:T5 Arg2:T7
10,R4,Has_multiplier Arg1:T5 Arg2:T4
0,T1,Condition 14 34	functional dyspepsia
1,T2,Qualifier 48 65	Rome III criteria
2,T3,Qualifier 71 88	inadequate relief
3,T4,Condition 92 110	dyspeptic symptoms
4,R1,Has_qualifier Arg1:T4 Arg2:T3
5,R2,AND Arg1:T1 Arg2:T4
6,R3,Has_qualifier Arg1:T1 Arg2:T2
7,T5,Person 112 115	Age
8,T6,Value 116 119	>18
9,T7,Informed_consent 121 149	Provision of written consent
0,T1,Condition 14 20	angina
1,T2,Condition 31 39	ischemia
2,T3,Qualifier 24 30	silent
3,T4,Qualifier 44 54	documented
4,*,OR T1 T2 T5
5,R1,Has_qualifier Arg1:T2 Arg2:T3
6,T5,Condition 55 63	ischemia
7,R2,Has_qualifier Arg1:T5 Arg2:T4
8,T6,Grammar_Error 40 43	and
9,T7,Procedure 95 117	intracoronary stenting
10,T8,Person 119 122	Age
11,T9,Value 123 133	> 18 years
12,R3,Has_value Arg1:T8 Arg2:T9
13,T10,Condition 150 153	CTO
14,T11,Qualifier 135 149	De novo lesion
15,R4,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Value 177 183	2.5 mm
17,T13,Measurement 155 176;184 204	Reference vessel size by visual estimation
18,R5,Has_value Arg1:T13 Arg2:T12
19,T14,Multiplier 206 218	At least one
20,T15,Condition 219 230	CTO lesions
21,T16,Qualifier 239 250;269 284	in proximal coronary artery
22,R6,Has_multiplier Arg1:T15 Arg2:T14
23,T17,Qualifier 254 284	mid epicardial coronary artery
24,T18,Condition 269 284	coronary artery
25,R7,multi Arg1:T17 Arg2:T18
26,R8,multi Arg1:T16 Arg2:T18
27,*,OR T17 T16
28,T19,Scope 239 284	in proximal or mid epicardial coronary artery
29,R9,Has_scope Arg1:T15 Arg2:T19
30,T20,"Parsing_Error 287 401	If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery"
31,T21,Condition 429 444	total occlusion
32,T22,Qualifier 404 428	Angiographically defined
33,R10,Has_qualifier Arg1:T21 Arg2:T22
34,T23,Temporal 450 458	3 months
35,R11,Has_temporal Arg1:T21 Arg2:T23
36,T24,"Subjective_judgement 460 693	If no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals)"
0,T2,Visit 0 13	Nursing homes
1,T1,Non-representable 50 86	if they meet the following criteria:
2,T3,Multiplier 99 108	routinely
3,T4,Procedure 115 129	decolonization
4,R1,Has_multiplier Arg1:T4 Arg2:T3
5,T5,Visit 141 166	psychiatric nursing homes
6,T6,Measurement 186 205	resident population
7,T7,Value 211 216	>=20%
8,T8,Observation 217 235	combative patients
9,R2,AND Arg1:T8 Arg2:T6
10,R3,Has_value Arg1:T6 Arg2:T7
11,T9,Visit 237 257	Pediatric facilities
0,T1,Condition 19 32	endometriosis
1,T2,Qualifier 12 18	severe
2,T3,Qualifier 0 8	Moderate
3,*,OR T3 T2
4,T4,Scope 0 18	Moderate or severe
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 35 47	Hydrosalpinx
7,T6,Condition 50 71	Uterine abnormalities
8,T7,Condition 75 80	myoma
9,T8,Procedure 92 107	uterine surgery
10,*,OR T6 T7
0,T1,Procedure 44 59	upper endoscopy
1,T2,Condition 12 29	organic pathology
2,T3,Procedure 69 83	investigations
3,*,OR T1 T3
4,T4,Scope 44 83	upper endoscopy or other investigations
5,R1,AND Arg1:T4 Arg2:T2
6,T5,Condition 105 118	hiatus hernia
7,T6,Qualifier 97 104	sliding
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Measurement 133 143;153 177	flap valve disruption of morphology
10,T8,Value 144 152	grade IV
11,T9,Qualifier 178 207	at gastro-esophageal junction
12,R3,Has_value Arg1:T7 Arg2:T8
13,R4,Has_qualifier Arg1:T5 Arg2:T9
14,R5,AND Arg1:T7 Arg2:T5
15,T10,Drug 220 231	medications
16,T11,Condition 244 269	gastrointestinal motility
17,R6,AND Arg1:T10 Arg2:T11
18,T12,Condition 283 294	acid reflux
19,T13,Condition 298 316	heartburn symptoms
20,T14,Temporal 320 343	more than twice a month
21,*,OR T12 T13
22,T15,Scope 283 316	acid reflux or heartburn symptoms
23,R7,Has_temporal Arg1:T15 Arg2:T14
24,T16,Procedure 356 371	gastric surgery
25,T17,Condition 373 392	H. pylori infection
26,T18,Drug 401 404	PPI
27,T19,Drug 408 413	NSAID
28,T20,Temporal 414 433	in the past 4 weeks
29,*,OR T18 T19
30,T21,Scope 401 413	PPI or NSAID
31,R8,Has_temporal Arg1:T21 Arg2:T20
32,T22,Condition 435 444	Pregnancy
33,T23,Condition 452 468	hypersensitivity
34,T24,Drug 472 475	PPI
35,R9,AND Arg1:T23 Arg2:T24
0,T1,Qualifier 14 20	second
1,T2,"Condition 21 36	primary cancer,"
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Negation 37 43	except
4,T4,Condition 63 87	non-melanoma skin cancer
5,T5,Condition 108 136	in-situ cancer of the cervix
6,T6,Condition 147 158	solid tumor
7,T7,Non-query-able 147 221	solid tumor curatively treated with no evidence of disease for <= 5 years.
8,T8,Mood 55 62	treated
9,T9,Mood 100 107	treated
10,R2,Has_mood Arg1:T4 Arg2:T8
11,R3,Has_mood Arg1:T5 Arg2:T9
12,*,OR T4 T5
13,T10,"Scope 55 136	treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix"
14,R4,Has_negation Arg1:T10 Arg2:T3
15,T11,Condition 268 278	metastases
16,T12,Qualifier 240 262	central nervous system
17,T13,Qualifier 263 266	CNS
18,R5,Subsumes Arg1:T12 Arg2:T13
19,R6,Has_qualifier Arg1:T11 Arg2:T12
20,T14,Condition 287 303	active infection
21,T15,Pregnancy_considerations 332 359	Pregnancy or breast feeding
22,T16,Condition 375 390	cardiac problem
23,T17,Drug 420 429	sunitinib
0,T1,Post-eligibility 0 45	Inability to provide written informed consent
1,T2,Condition 70 91	intracranial bleeding
2,T3,Qualifier 64 69	prior
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Drug 113 138	P2Y12 receptor antagonist
5,T5,Drug 140 151	ticlopidine
6,T6,Drug 153 164	clopidogrel
7,T7,Drug 166 175	prasugrel
8,T8,Drug 177 187	ticagrelor
9,T9,"Scope 140 187	ticlopidine, clopidogrel, prasugrel, ticagrelor"
10,R2,Subsumes Arg1:T4 Arg2:T9
11,*,OR T5 T6 T7 T8
12,T10,Temporal 196 209	prior 10 days
13,R3,Has_temporal Arg1:T4 Arg2:T10
14,T11,Condition 217 226	allergies
15,T12,Drug 230 237	aspirin
16,T13,Drug 239 249	ticagrelor
17,T14,Drug 253 262	cangrelor
18,*,OR T12 T13 T14
19,T15,"Scope 230 262	aspirin, ticagrelor or cangrelor"
20,R4,Has_scope Arg1:T11 Arg2:T15
21,T16,Drug 287 300	anticoagulant
22,T17,Qualifier 282 286	oral
23,R5,Has_qualifier Arg1:T16 Arg2:T17
24,T18,Drug 317 349	glycoprotein IIb/IIIa inhibitors
25,T19,Procedure 351 364	Fibrinolytics
26,T20,Temporal 365 380	within 24 hours
27,R6,Has_temporal Arg1:T19 Arg2:T20
28,T21,Condition 382 397	Active bleeding
29,T22,Qualifier 399 408	High risk
30,T23,Condition 412 420	bleeding
31,R7,Has_qualifier Arg1:T23 Arg2:T22
32,T24,Measurement 428 442	platelet count
33,T25,Value 443 453	<80x106/mL
34,R8,Has_value Arg1:T24 Arg2:T25
35,T26,Measurement 461 471	hemoglobin
36,T27,Value 472 480	<10 g/dL
37,R9,Has_value Arg1:T26 Arg2:T27
38,T28,Condition 482 491	Intubated
39,T29,Temporal 502 524	prior to randomization
40,T30,Reference_point 511 524	randomization
41,R10,Has_index Arg1:T29 Arg2:T30
42,R11,Has_temporal Arg1:T28 Arg2:T29
43,T31,Measurement 533 553	creatinine clearance
44,T32,Value 554 567	<30 mL/minute
45,R12,Has_value Arg1:T31 Arg2:T32
46,T33,Procedure 574 586	hemodialysis
47,*,OR T31 T33
48,T34,Condition 602 621	hepatic dysfunction
49,T35,Qualifier 595 601	severe
50,R13,Has_qualifier Arg1:T34 Arg2:T35
51,T36,Condition 637 656	sick sinus syndrome
52,T37,Condition 658 661	SSS
53,T38,Condition 678 686	AV block
54,T39,Qualifier 666 677	high degree
55,R14,Has_qualifier Arg1:T38 Arg2:T39
56,T40,Procedure 695 704	pacemaker
57,T41,Negation 687 694	without
58,R15,Has_negation Arg1:T40 Arg2:T41
59,R16,AND Arg1:T38 Arg2:T40
60,R17,Subsumes Arg1:T36 Arg2:T37
61,*,OR T36 T38
62,T42,Drug 740 745	drugs
63,T43,Condition 763 780	CYP3A4 metabolism
64,T44,Drug 808 818	ticagrelor
65,R18,AND Arg1:T42 Arg2:T43
66,T45,Mood 746 762	interfering with
67,R19,Has_mood Arg1:T43 Arg2:T45
68,T46,Drug 821 833	Ketoconazole
69,T47,Non-query-able 782 818	to avoid interaction with ticagrelor
70,T48,Drug 835 847	itraconazole
71,T49,Drug 849 861	voriconazole
72,T50,Drug 863 877	clarithromycin
73,T51,Drug 879 889	nefazodone
74,T52,Drug 891 900	ritonavir
75,T53,Drug 902 912	saquinavir
76,T54,Drug 914 924	nelfinavir
77,T55,Drug 926 935	indinavir
78,T56,Drug 937 947	atazanavir
79,T57,Drug 953 968	telithromizycin
80,*,OR T46 T48 T49 T50 T51 T52 T53 T54 T55 T56 T57
81,T58,"Scope 821 968	Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin"
82,R20,Subsumes Arg1:T42 Arg2:T58
83,T59,Condition 971 979	Pregnant
84,T60,Condition 983 992	lactating
85,*,OR T59 T60
86,T61,Person 993 1000	females
87,A1,Optional T61
88,T62,Scope 971 992	Pregnant or lactating
89,R21,Has_scope Arg1:T61 Arg2:T62
0,T1,Informed_consent 0 70	Provision of fully informed consent prior to study specific procedures
1,T2,Person 105 108	age
2,T3,Value 90 101	>= 19 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 110 120	RET fusion
5,T5,Value 121 129	positive
6,T6,Qualifier 133 145	FGFR2 fusion
7,T7,Qualifier 152 165	FGFR mutation
8,T8,Qualifier 166 176	Refractory
9,T9,Condition 177 188	solid tumor
10,R2,Has_value Arg1:T4 Arg2:T5
11,*,OR T6 T7
12,T10,Scope 133 165	FGFR2 fusion/other FGFR mutation
13,R3,Has_qualifier Arg1:T9 Arg2:T8
14,R4,Has_scope Arg1:T9 Arg2:T10
15,T11,Qualifier 205 216	sensitivity
16,T12,Drug 220 229	Sunitinib
17,R5,Has_qualifier Arg1:T12 Arg2:T11
18,T13,Non-query-able 231 379	y Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy
19,*,OR T4 T9 T12
20,T14,Measurement 382 405	ECOG Performance status
21,T15,Value 405 408	0-2
22,R6,Has_value Arg1:T14 Arg2:T15
23,T16,Non-query-able 410 496	Have measurable or evaluated disease based on RECIST 1.1 as determined by investigator
24,T17,Measurement 499 524	Absolute neutrophil count
25,T18,Value 525 539	>= 1.5 x 109/L
26,T19,Measurement 541 551	Hemoglobin
27,T20,"Value 552 561	>= 9g/dL,"
28,T21,Measurement 562 571	Platelets
29,T22,Value 571 584	>=100 x 109/L
30,T23,Measurement 585 594	Bilirubin
31,T24,Value 595 625	<= 1.5 x upper limit of normal
32,T25,Measurement 626 629	AST
33,T26,Measurement 630 633	ALT
34,T27,Value 634 665	<= 2.5 X upper limit of normal(
35,T28,Condition 711 727	liver metastases
36,T29,Value 665 692	5.0 x upper limit of normal
37,T30,Measurement 729 739	Creatinine
38,T31,Value 739 751	<= 1.5 X UNL
39,R7,Has_value Arg1:T17 Arg2:T18
40,R8,Has_value Arg1:T19 Arg2:T20
41,R9,Has_value Arg1:T21 Arg2:T22
42,R10,Has_value Arg1:T23 Arg2:T24
43,R11,Has_value Arg1:T25 Arg2:T27
44,R12,Has_value Arg1:T26 Arg2:T27
45,T32,Measurement 626 629	AST
46,T33,Measurement 630 633	ALT
47,A1,Optional T28
48,R13,AND Arg1:T28 Arg2:T32
49,R14,AND Arg1:T28 Arg2:T33
50,R15,Has_value Arg1:T32 Arg2:T29
51,R16,Has_value Arg1:T33 Arg2:T29
52,R17,Has_value Arg1:T30 Arg2:T31
53,T34,Condition 932 955	Adequate heart function
54,T35,Measurement 941 955	heart function
55,T36,Value 932 940	Adequate
56,R18,Has_value Arg1:T35 Arg2:T36
57,R19,multi Arg1:T34 Arg2:T35
58,T37,Observation 765 788	child-bearing potential
59,A2,Optional T37
60,T38,Procedure 805 836	adequate contraceptive measures
61,T39,Negation 844 850	not be
62,T40,Condition 851 865	breast feeding
63,T41,Value 882 890	negative
64,T42,Measurement 891 905	pregnancy test
65,T43,Temporal 906 930	prior to start of dosing
66,T44,Reference_point 915 930	start of dosing
67,R20,Has_index Arg1:T43 Arg2:T44
68,R21,Has_temporal Arg1:T42 Arg2:T43
69,R22,Has_value Arg1:T42 Arg2:T41
70,R23,Has_negation Arg1:T40 Arg2:T39
71,T45,Scope 805 930	adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing
72,R24,Has_scope Arg1:T37 Arg2:T45
0,T1,Condition 14 19	STEMI
1,T2,Procedure 31 43	primary PPCI
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Person 45 48	Age
4,T4,Value 49 63	> 18 years old
5,R2,Has_value Arg1:T3 Arg2:T4
0,T1,Condition 0 9	Pregnancy
1,T2,Condition 11 23	coagulopathy
2,T3,Condition 25 32	allergy
3,T4,Drug 36 47	bupivacaine
4,T5,Condition 49 62	renal failure
5,T6,Condition 64 85	hepatic insufficiency
6,T7,Condition 94 117	inappropriate candidate
7,T8,Procedure 122 135	usual therapy
8,R1,AND Arg1:T3 Arg2:T4
9,R2,AND Arg1:T7 Arg2:T8
10,T9,Mood 154 171	unable to receive
11,T10,Procedure 182 219	preoperative interscalene nerve block
12,R3,Has_mood Arg1:T10 Arg2:T9
13,T12,Temporal 221 232	preexisting
14,T13,Condition 233 245	nerve injury
15,T14,Qualifier 249 264	side of surgery
16,T15,Condition 266 288	refusal of nerve block
17,T16,Condition 290 299	infection
18,T17,Qualifier 303 322	site of nerve block
19,R4,Has_qualifier Arg1:T16 Arg2:T17
20,R5,Has_qualifier Arg1:T13 Arg2:T14
21,R6,Has_temporal Arg1:T13 Arg2:T12
22,*,OR T15 T16
23,T18,"Scope 221 322	preexisting nerve injury on side of surgery, refusal of nerve block, infection at site of nerve block"
24,T11,Scope 154 219	unable to receive the usual preoperative interscalene nerve block
25,R7,Has_scope Arg1:T11 Arg2:T18
26,A1,Optional T11
27,*,OR T1 T2 T3 T5 T6 T7
28,T19,Scope 94 135	inappropriate candidate for usual therapy
29,T20,"Scope 154 322	unable to receive the usual preoperative interscalene nerve block: preexisting nerve injury on side of surgery, refusal of nerve block, infection at site of nerve block"
30,R8,Subsumes Arg1:T19 Arg2:T18
0,T1,Qualifier 20 34	thoracic aorta
1,T2,Procedure 35 42	surgery
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 48 78	hypothermic circulatory arrest
4,T4,Person 91 94	age
5,T5,Value 80 87	over 20
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,AND Arg1:T2 Arg2:T3
0,T1,Measurement 0 21	Fasting blood glucose
1,T2,Value 22 32	>126 mg/dL
2,T3,Temporal 33 45	at screening
3,R1,Has_value Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Condition 47 59	Heterozygous
6,T5,Measurement 92 113	fasting blood glucose
7,T6,Value 114 124	>140 mg/dL
8,R3,Has_value Arg1:T5 Arg2:T6
9,A1,Optional T4
10,R4,AND Arg1:T4 Arg2:T5
11,T7,Measurement 127 145	Resting heart rate
12,T8,Value 146 153	<45 bpm
13,T9,Value 157 164	>90 bpm
14,T10,Temporal 165 177	at screening
15,T11,Reference_point 168 177	screening
16,R5,Has_index Arg1:T10 Arg2:T11
17,*,OR T8 T9
18,T12,Scope 146 164	<45 bpm or >90 bpm
19,R6,Has_scope Arg1:T7 Arg2:T12
20,R7,Has_temporal Arg1:T7 Arg2:T10
21,T13,Measurement 189 222	thyroid stimulating hormone (TSH)
22,T14,Measurement 226 240	thyroxine (T4)
23,T15,Value 180 188	Abnormal
24,R8,Has_value Arg1:T13 Arg2:T15
25,R9,Has_value Arg1:T14 Arg2:T15
26,T16,Temporal 248 260	on screening
27,T17,Reference_point 251 260	screening
28,R10,Has_index Arg1:T16 Arg2:T17
29,*,OR T13 T14
30,R11,Has_temporal Arg1:T13 Arg2:T16
31,R12,Has_temporal Arg1:T14 Arg2:T16
32,T18,Measurement 272 275	ALT
33,T19,Value 263 271	Elevated
34,R13,Has_value Arg1:T18 Arg2:T19
35,T20,Measurement 279 295	serum creatinine
36,T21,Temporal 296 308	on screening
37,T22,Reference_point 299 308	screening
38,R14,Has_index Arg1:T21 Arg2:T22
39,T23,Measurement 366 382	laboratory tests
40,T24,Undefined_semantics 366 382	laboratory tests
41,T25,Subjective_judgement 383 416	as determined by the Investigator
42,T26,Non-query-able 312 416	any clinically significant abnormalities on screening laboratory tests as determined by the Investigator
43,T27,Value 339 352	abnormalities
44,R15,Has_value Arg1:T23 Arg2:T27
45,R16,AND Arg1:T27 Arg2:T25
46,*,OR T20 T18 T23
47,R17,Has_value Arg1:T20 Arg2:T19
48,R18,Has_temporal Arg1:T18 Arg2:T21
49,R19,Has_temporal Arg1:T20 Arg2:T21
50,T28,Condition 448 456	diabetes
51,T29,Qualifier 430 447	medically treated
52,T30,Drug 430 439	medically
53,T31,Procedure 430 447	medically treated
54,*,OR T31 T30
55,R20,AND Arg1:T29 Arg2:T31
56,R21,Has_qualifier Arg1:T28 Arg2:T29
57,T32,Condition 494 506	hypertension
58,T33,Qualifier 463 470	treated
59,T34,Drug 474 483	medically
60,*,OR T33 T34
61,T35,Scope 463 483	treated or medically
62,R22,Has_scope Arg1:T32 Arg2:T35
63,T36,Observation 419 426	History
64,R23,Has_temporal Arg1:T28 Arg2:T36
65,*,OR T28 T32
66,R24,Has_temporal Arg1:T32 Arg2:T36
67,T37,Condition 508 520	Heterozygous
68,T38,Context_Error 47 59	Heterozygous
69,T39,Condition 549 561	hypertension
70,T40,Procedure 589 598	treatment
71,T41,Qualifier 570 585	well controlled
72,T42,Grammar_Error 639 651	are eligible
73,R25,Has_qualifier Arg1:T39 Arg2:T41
74,A2,Optional T37
75,R26,AND Arg1:T37 Arg2:T39
76,R27,AND Arg1:T41 Arg2:T40
77,T43,Parsing_Error 653 654	.
78,T44,Condition 670 681	skin lesion
79,T45,Qualifier 682 707	suspicious for malignancy
80,T46,Condition 697 707	malignancy
81,R28,AND Arg1:T45 Arg2:T46
82,R29,Has_qualifier Arg1:T44 Arg2:T45
83,T47,Procedure 716 723	excised
84,T48,Temporal 724 738	prior to Day 1
85,T49,Reference_point 733 738	Day 1
86,R30,Has_index Arg1:T48 Arg2:T49
87,R31,Has_temporal Arg1:T47 Arg2:T48
88,R32,AND Arg1:T44 Arg2:T47
89,T50,Condition 752 762	malignancy
90,T51,Observation 741 748	History
91,T52,Condition 782 808	cervical carcinoma in situ
92,T53,Qualifier 774 781	treated
93,T54,Procedure 774 781	treated
94,R33,AND Arg1:T53 Arg2:T54
95,R34,AND Arg1:T50 Arg2:T52
96,T55,Negation 763 773	except for
97,R35,Has_negation Arg1:T52 Arg2:T55
98,R36,Has_qualifier Arg1:T52 Arg2:T53
99,R37,Has_temporal Arg1:T50 Arg2:T51
100,T56,Temporal 809 828	in the past 5 years
101,R38,Has_temporal Arg1:T50 Arg2:T56
102,T57,Condition 879 896	medical condition
103,T58,Qualifier 856 878	clinically significant
104,T59,Subjective_judgement 856 878	clinically significant
105,T60,Undefined_semantics 856 878	clinically significant
106,R39,Has_qualifier Arg1:T57 Arg2:T58
107,T61,Observation 841 848	history
108,T62,Temporal 831 837	Active
109,*,OR T61 T62
110,T63,Scope 831 848	Active or history
111,T64,Condition 1059 1066;907 912	disease renal
112,T65,Condition 1045 1066	hematological disease
113,T66,Condition 1030 1041;1059 1066	psychiatric disease
114,T67,Condition 1018 1028;1059 1066	neurologic disease
115,T68,Condition 1007 1016;1059 1066	metabolic disease
116,T69,Condition 1059 1066;994 1005	disease immunologic
117,T70,Condition 1059 1066;983 992	disease endocrine
118,T71,Condition 1059 1066;968 981	disease genitourinary
119,T72,Condition 1059 1066;952 966	disease cardiovascular
120,T73,Condition 1059 1066;934 950	disease gastrointestinal
121,T74,Condition 1059 1066;923 932	disease pulmonary
122,T75,Condition 1059 1066;914 921	disease hepatic
123,*,OR T75 T64 T74 T66 T69 T68 T72 T67 T73 T71 T70
124,T76,Qualifier 1068 1098	based on Investigator judgment
125,T77,Subjective_judgement 1068 1098	based on Investigator judgment
126,T78,Non-query-able 1068 1098	based on Investigator judgment
127,T79,"Scope 907 1066	renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic, psychiatric or hematological disease"
128,R40,Subsumes Arg1:T57 Arg2:T79
129,R41,Has_scope Arg1:T57 Arg2:T63
130,R42,Has_qualifier Arg1:T58 Arg2:T76
131,T80,"Non-query-able 1101 1308	Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data."
132,T81,"Context_Error 1101 1308	Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data."
133,T82,"Subjective_judgement 1101 1308	Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data."
134,T83,Measurement 1319 1346	hepatitis B surface antigen
135,T84,Value 1310 1318	Positive
136,R43,Has_value Arg1:T83 Arg2:T84
137,T85,Measurement 1357 1377	hepatitis C antibody
138,T86,Value 1348 1356	positive
139,T87,Measurement 1390 1398	HIV test
140,T88,Value 1381 1389	positive
141,R44,Has_value Arg1:T87 Arg2:T88
142,R45,Has_value Arg1:T85 Arg2:T86
143,*,OR T87 T85 T83
144,T89,Temporal 1399 1411	at screening
145,T90,Reference_point 1402 1411	screening
146,R46,Has_index Arg1:T89 Arg2:T90
147,T91,Observation 1417 1424	history
148,T92,"Scope 1310 1398	Positive hepatitis B surface antigen, positive hepatitis C antibody or positive HIV test"
149,T93,Procedure 1451 1463	liver biopsy
150,T94,Procedure 1465 1473	serology
151,T95,Procedure 1437 1444	testing
152,T96,Value 1428 1436	positive
153,R47,Has_value Arg1:T95 Arg2:T96
154,T97,"Scope 1451 1473	liver biopsy, serology"
155,R48,Subsumes Arg1:T95 Arg2:T97
156,T98,Undefined_semantics 1437 1444	testing
157,T99,Context_Error 1437 1444	testing
158,T100,Condition 1495 1512	chronic hepatitis
159,T101,Condition 1486 1491;1503 1512	acute hepatitis
160,*,OR T101 T100
161,T102,Scope 1486 1512	acute or chronic hepatitis
162,R49,Has_scope Arg1:T95 Arg2:T102
163,R50,Has_temporal Arg1:T95 Arg2:T91
164,*,OR T92 T95
165,T103,Procedure 1524 1555	12-lead electrocardiogram (ECG)
166,T104,Value 1515 1523	Abnormal
167,R51,Has_value Arg1:T103 Arg2:T104
168,T105,Temporal 1556 1568	at screening
169,T106,Temporal 1556 1558;1572 1580	at pre-dose
170,T107,Reference_point 1559 1568	screening
171,T108,Reference_point 1572 1580	pre-dose
172,R52,Has_index Arg1:T105 Arg2:T107
173,R53,Has_index Arg1:T106 Arg2:T108
174,T109,Temporal 1582 1588	Day -1
175,T110,Temporal 1592 1597	Day 1
176,*,OR T110 T109
177,T111,Drug 1700 1718	experimental drugs
178,T112,Device 1700 1712;1722 1729	experimental devices
179,T113,Temporal 1730 1744	within 30 days
180,T114,Temporal 1730 1736;1748 1760	within 5 half lives
181,*,OR T114 T113
182,*,OR T112 T111
183,T115,Scope 1700 1729	experimental drugs or devices
184,T116,Scope 1730 1760	within 30 days or 5 half lives
185,R54,Has_scope Arg1:T115 Arg2:T116
186,T117,Context_Error 1700 1760	experimental drugs or devices within 30 days or 5 half lives
187,T118,Non-query-able 1700 1760	experimental drugs or devices within 30 days or 5 half lives
188,T119,Context_Error 1801 1874	Ongoing participation in a prior clinical study at the time of screening.
189,T120,Non-query-able 1801 1874	Ongoing participation in a prior clinical study at the time of screening.
190,T121,Procedure 1876 1890	Blood donation
191,T122,Temporal 1891 1924	within 60 days prior to screening
192,T123,Reference_point 1915 1924	screening
193,R55,Has_index Arg1:T122 Arg2:T123
194,R56,Has_temporal Arg1:T121 Arg2:T122
195,T124,Observation 1928 1944	intent to donate
196,T125,Non-query-able 1928 1944	intent to donate
197,T126,Temporal 1945 1983	within 60 days after Final Study Visit
198,T127,Reference_point 1966 1983	Final Study Visit
199,R57,Has_index Arg1:T126 Arg2:T127
200,R58,Has_temporal Arg1:T124 Arg2:T126
201,T128,Procedure 1986 2001	Hospitalization
202,T129,Procedure 2012 2019	surgery
203,T130,Qualifier 2006 2011	major
204,T131,Subjective_judgement 2006 2011	major
205,T132,Undefined_semantics 2006 2011	major
206,R59,Has_qualifier Arg1:T129 Arg2:T130
207,T133,Procedure 2073 2095	cardiovascular surgery
208,T134,Procedure 2060 2068;2088 2095	thoracic surgery
209,T135,Procedure 2049 2058;2088 2095	abdominal surgery
210,*,OR T134 T135 T133
211,T136,Temporal 2096 2139	within the past 3 months prior to screening
212,T137,Reference_point 2130 2139	screening
213,R60,Has_index Arg1:T136 Arg2:T137
214,T138,Condition 2173 2193	non-surgical illness
215,T139,Qualifier 2150 2172	clinically significant
216,T140,Subjective_judgement 2150 2172	clinically significant
217,T141,Undefined_semantics 2150 2172	clinically significant
218,R61,Has_qualifier Arg1:T138 Arg2:T139
219,T142,Subjective_judgement 2195 2225	based on Investigator judgment
220,T143,Temporal 2227 2251	within the past 3 months
221,R62,AND Arg1:T128 Arg2:T129
222,T144,"Scope 2049 2095	abdominal, thoracic, or cardiovascular surgery"
223,R63,Subsumes Arg1:T129 Arg2:T144
224,R64,Has_temporal Arg1:T129 Arg2:T136
225,R65,Has_temporal Arg1:T138 Arg2:T143
226,T145,Procedure 2262 2278	elective surgery
227,T146,Observation 2254 2261	Planned
228,T147,Non-query-able 2254 2261	Planned
229,R66,Has_mood Arg1:T145 Arg2:T146
230,T148,Temporal 2279 2318	within 30 days of the Final Study Visit
231,T149,Reference_point 2301 2318	Final Study Visit
232,R67,Has_index Arg1:T148 Arg2:T149
233,R68,Has_temporal Arg1:T145 Arg2:T148
234,*,OR T138 T128
235,T150,Condition 2321 2339	Poor venous access
236,T151,Procedure 2365 2377	venipuncture
237,T152,Condition 2343 2377	inability to tolerate venipuncture
238,R69,AND Arg1:T152 Arg2:T151
239,*,OR T150 T152
240,T153,Condition 2403 2424	drug hypersensitivity
241,T154,Condition 2403 2407;2428 2439	drug anaphylaxis
242,T155,Qualifier 2391 2402	significant
243,*,OR T154 T153
244,R70,Has_qualifier Arg1:T154 Arg2:T155
245,R71,Has_qualifier Arg1:T153 Arg2:T155
246,T156,Subjective_judgement 2391 2402	significant
247,T157,Observation 2380 2387	History
248,R72,Has_temporal Arg1:T154 Arg2:T157
249,R73,Has_temporal Arg1:T153 Arg2:T157
250,T158,Condition 2453 2481	hypersensitivity to proteins
251,T159,Condition 2453 2472;2489 2502	hypersensitivity to allergy shots
252,R74,Subsumes Arg1:T158 Arg2:T159
253,T160,Drug 2513 2537	prescription medications
254,T161,Drug 2574 2601	any prescription medication
255,T162,Temporal 2562 2570;2617 2642	last use greater than 5 half-lives
256,T163,Temporal 2674 2709	at least 14 days prior to admission
257,T164,Reference_point 2700 2709	admission
258,R75,Has_index Arg1:T163 Arg2:T164
259,T166,Temporal 2543 2556	regular basis
260,R77,Has_temporal Arg1:T160 Arg2:T166
261,T167,Observation 2442 2449	History
262,R78,Has_temporal Arg1:T159 Arg2:T167
263,R79,Has_temporal Arg1:T158 Arg2:T167
264,R80,Has_temporal Arg1:T161 Arg2:T162
265,*,OR T162 T163
266,T168,Grammar_Error 2764 2774	is allowed
267,T169,Grammar_Error 2797 2915	Heterozygous cohorts: Use of prescription medications on a regular basis is not allowed with the following exceptions:
268,T170,Parsing_Error 2797 2915	Heterozygous cohorts: Use of prescription medications on a regular basis is not allowed with the following exceptions:
269,T171,Drug 2917 2934	Antihypertensives
270,T172,Multiplier 2936 2950	<3 medications
271,T173,Qualifier 2956 2967	stable dose
272,T174,Temporal 2968 2981	for ≥ 30 days
273,R81,Has_multiplier Arg1:T173 Arg2:T172
274,R82,Has_temporal Arg1:T173 Arg2:T174
275,R83,Has_qualifier Arg1:T171 Arg2:T173
276,T175,Drug 2985 2992	Statins
277,T176,Multiplier 3007 3030	≤ half the maximum dose
278,T177,Qualifier 3045 3056	stable dose
279,T178,Temporal 3057 3066	≥3 months
280,R84,Has_temporal Arg1:T177 Arg2:T178
281,R85,Has_multiplier Arg1:T175 Arg2:T176
282,R86,Has_qualifier Arg1:T175 Arg2:T177
283,T179,Drug 3070 3078	Fibrates
284,T180,Qualifier 3091 3102	stable dose
285,T181,Temporal 3107 3116	≥3 months
286,R87,Has_temporal Arg1:T180 Arg2:T181
287,R88,Has_qualifier Arg1:T179 Arg2:T180
288,T182,Drug 3120 3126	Niacin
289,T183,Qualifier 3139 3150	stable dose
290,T184,Temporal 3155 3164	≥3 months
291,R89,Has_temporal Arg1:T183 Arg2:T184
292,R90,Has_qualifier Arg1:T182 Arg2:T183
293,T185,Drug 3168 3176	Thyroxin
294,T186,Qualifier 3178 3189	stable dose
295,T187,Temporal 3194 3203	≥ 30 days
296,R91,Has_temporal Arg1:T186 Arg2:T187
297,R92,Has_qualifier Arg1:T185 Arg2:T186
298,T188,"Context_Error 3206 3327	The last use of any other prescription medication will need follow the criteria for all other cohorts, as outlined above."
299,T189,"Non-query-able 3206 3327	The last use of any other prescription medication will need follow the criteria for all other cohorts, as outlined above."
300,T190,Drug 3336 3360	prescription medications
301,T192,Subjective_judgement 3329 3461	Use of prescription medications not listed above may be allowed at the discretion of the Investigator upon consultation with Rhythm.
302,T191,Drug 3472 3493	non-prescription drug
303,T193,Drug 3498 3515	herbal substances
304,T194,Temporal 3516 3532	during the study
305,T195,Grammar_Error 3494 3497	and
306,*,OR T193 T191
307,R93,Has_temporal Arg1:T191 Arg2:T194
308,R94,Has_temporal Arg1:T193 Arg2:T194
309,T196,Drug 3583 3608	any non-prescription drug
310,T165,Temporal 3630 3655;3670 3697	greater than 5 half-lives before receiving study drug
311,R76,Has_temporal Arg1:T196 Arg2:T165
312,T197,Context_Error 3583 3608	any non-prescription drug
313,T198,"Non-query-able 3700 3877	Inability to attend all study visits or to comply with protocol requirements including fasting and restrictions on alcohol, caffeine, nicotine and concomitant medication intake."
314,T199,Condition 3904 3922	drug/solvent abuse
315,T200,Observation 3893 3900	history
316,T201,Temporal 3923 3950	within 5 years of screening
317,T202,Reference_point 3941 3950	screening
318,R95,Has_index Arg1:T201 Arg2:T202
319,R96,Has_temporal Arg1:T199 Arg2:T201
320,R97,Has_temporal Arg1:T199 Arg2:T200
321,T203,Measurement 3974 3993	drugs of abuse test
322,T204,Value 3956 3964	positive
323,R98,Has_value Arg1:T203 Arg2:T204
324,T205,Temporal 3994 4006	at screening
325,T206,Reference_point 3997 4006	screening
326,R99,Has_index Arg1:T205 Arg2:T206
327,R100,Has_temporal Arg1:T203 Arg2:T205
328,*,OR T199 T203
329,T207,Measurement 4040 4051	breath test
330,T208,Measurement 4031 4038;4047 4051	alcohol test
331,*,OR T207 T208
332,T209,Scope 4031 4052	alcohol (breath test)
333,T210,Value 4022 4030	Positive
334,R101,Has_value Arg1:T209 Arg2:T210
335,T211,Measurement 4056 4071	nicotine screen
336,R102,Has_value Arg1:T211 Arg2:T210
337,T212,Temporal 4072 4090	at Screening Visit
338,T213,Reference_point 4075 4090	Screening Visit
339,R103,Has_index Arg1:T212 Arg2:T213
340,T214,Scope 4022 4071	Positive alcohol (breath test) or nicotine screen
341,R104,Has_temporal Arg1:T214 Arg2:T212
342,T215,Condition 4178 4191	alcohol abuse
343,T216,Observation 4167 4174	History
344,R105,Has_temporal Arg1:T215 Arg2:T216
345,T217,Multiplier 4222 4241;4253 4260	three or more units per day
346,T218,Drug 4245 4252	alcohol
347,R106,Has_multiplier Arg1:T218 Arg2:T217
348,R107,Subsumes Arg1:T215 Arg2:T218
349,T219,Temporal 4262 4299	within 5 years of the Screening Visit
350,T220,Reference_point 4280 4299	the Screening Visit
351,R108,Has_index Arg1:T219 Arg2:T220
352,T221,Observation 4302 4309	History
353,T222,Condition 4313 4320;4340 4343	tobacco use
354,T223,Condition 4324 4343	tobacco product use
355,*,OR T223 T222
356,T224,Condition 4351 4360	abstinent
357,T225,Temporal 4361 4411	for at least one year prior to the Screening Visit
358,T226,Reference_point 4392 4411	the Screening Visit
359,R111,Has_index Arg1:T225 Arg2:T226
360,R112,Has_temporal Arg1:T224 Arg2:T225
361,T227,Negation 4344 4350	unless
362,R113,Has_negation Arg1:T224 Arg2:T227
363,T228,Scope 4313 4343	tobacco or tobacco product use
364,R109,Has_temporal Arg1:T228 Arg2:T221
365,R110,AND Arg1:T228 Arg2:T224
366,T229,Parsing_Error 4413 4468	This criterion does not apply to heterozygous subjects.
367,T230,Not_a_criteria 4470 4516	Previously randomized and dosed in this study.
368,T231,Parsing_Error 4517 4572	This criterion does not apply to heterozygous subjects.
369,T232,"Subjective_judgement 4574 4679	Any other reason, which in the opinion of the Investigator would confound proper evaluation of the study."
370,T233,"Non-query-able 4574 4679	Any other reason, which in the opinion of the Investigator would confound proper evaluation of the study."
371,T234,Procedure 2741 2763	Hormonal contraception
372,T235,Person 2779 2785	female
373,A3,Optional T235
374,R114,AND Arg1:T235 Arg2:T234
0,T1,Drug 24 39	anti-VEGF drugs
1,T2,Drug 43 57	corticosteroid
2,T3,Procedure 61 90	grid laser photocoagulation (
3,*,OR T1 T2 T3
4,T4,Procedure 113 131	vitrectomy surgery
5,T5,Procedure 133 151	submacular surgery
6,T6,Procedure 162 183	surgical intervention
7,T7,Condition 188 191	RVO
8,R1,AND Arg1:T6 Arg2:T7
9,*,OR T4 T5 T6
10,T8,Non-query-able 193 276	Ocular disorders in the study eye that may confound interpretation of study results
11,T9,Measurement 278 282	BCVA
12,T10,Value 283 298	over 77 letters
13,R2,Has_value Arg1:T9 Arg2:T10
14,T11,Pregnancy_considerations 328 359	The pregnant or lactating woman
0,T1,Parsing_Error 0 18	Healthy Volunteers
1,T2,Condition 33 50	contraindications
2,T3,Drug 20 32	Treprostinil
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 58 74	hypersensitivity
5,T5,Drug 78 90	treprostinil
6,R2,AND Arg1:T4 Arg2:T5
7,T6,Drug 94 115	any of the excipients
8,R3,Subsumes Arg1:T5 Arg2:T6
9,T7,Condition 117 148	Pulmonary arterial hypertension
10,T8,Condition 160 182	veno-occlusive disease
11,R4,AND Arg1:T7 Arg2:T8
12,T9,Condition 184 208	Congestive heart failure
13,T10,Condition 223 251	left ventricular dysfunction
14,T11,Condition 260 281	hepatic insufficiency
15,T12,Qualifier 216 222	severe
16,R5,Has_qualifier Arg1:T10 Arg2:T12
17,T13,Qualifier 253 259	Severe
18,R6,Has_qualifier Arg1:T11 Arg2:T13
19,T14,Measurement 283 293	Child-Pugh
20,T15,Value 294 301	stage C
21,R7,Has_value Arg1:T14 Arg2:T15
22,R8,Subsumes Arg1:T13 Arg2:T14
23,*,OR T10 T11
24,T16,Condition 313 335	gastrointestinal ulcer
25,T17,Qualifier 304 312	Evolving
26,R9,Has_qualifier Arg1:T16 Arg2:T17
27,T18,Condition 337 360	intracranial hemorrhage
28,T19,Condition 369 375	trauma
29,T20,Temporal 362 368	recent
30,R10,Has_temporal Arg1:T19 Arg2:T20
31,T21,Condition 385 429	clinical condition that may lead to bleeding
32,T22,Undefined_semantics 385 429	clinical condition that may lead to bleeding
33,T23,Condition 431 441;454 476	Congenital valvular abnormalities
34,T24,Condition 445 476	acquired valvular abnormalities
35,T25,Qualifier 477 503	with cardiac repercussions
36,R11,Has_qualifier Arg1:T23 Arg2:T25
37,R12,Has_qualifier Arg1:T24 Arg2:T25
38,T26,Condition 512 534	ischemic heart disease
39,T27,Qualifier 505 511	Severe
40,T28,Condition 538 553	unstable angina
41,R13,Has_qualifier Arg1:T26 Arg2:T27
42,*,OR T28 T26 T24 T23 T21 T29 T31 T35
43,T29,Condition 555 576	Myocardial infarction
44,T30,Temporal 577 599	in the last six months
45,R14,Has_temporal Arg1:T29 Arg2:T30
46,T31,Condition 601 636	Decompensated cardiac insufficiency
47,T32,Qualifier 637 661	not medically controlled
48,R15,Has_qualifier Arg1:T31 Arg2:T32
49,T33,Condition 670 681	arrhythmias
50,T34,Qualifier 663 669	Severe
51,R16,Has_qualifier Arg1:T33 Arg2:T34
52,R17,AND Arg1:T31 Arg2:T33
53,T35,Condition 683 706	Cerebrovascular lesions
54,T36,Condition 716 741	transient ischemic attack
55,T37,Condition 743 749	stroke
56,*,OR T37 T36
57,T38,"Scope 716 749	transient ischemic attack, stroke"
58,R18,Subsumes Arg1:T35 Arg2:T38
59,T39,Temporal 765 793	within the last three months
60,R19,Has_temporal Arg1:T35 Arg2:T39
61,T40,Context_Error 796 879	Persons referred to in Articles L1121-5 to L1121-8 of the French Public health Code
62,T41,Condition 881 889	pregnant
63,T42,Person 890 895	woman
64,A1,Optional T42
65,R20,AND Arg1:T42 Arg2:T41
66,T43,Condition 897 907	parturient
67,T44,Condition 909 916	nursing
68,T45,Observation 932 951	deprived of liberty
69,*,OR T45 T44 T43 T41
70,T46,"Scope 881 951	pregnant woman, parturient, nursing mother, person deprived of liberty"
71,R21,Subsumes Arg1:T40 Arg2:T46
72,T47,"Context_Error 1079 1129	Subject in an exclusion period from another study,"
73,T48,"Non-query-able 1079 1129	Subject in an exclusion period from another study,"
74,T49,Non-query-able 1131 1285	Subject who would receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study
75,T50,Context_Error 1131 1285	Subject who would receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study
76,T51,Condition 1287 1305	Systemic sclerosis
77,T52,Drug 1317 1325	Iloprost
78,T53,Temporal 1343 1364	in the previous month
79,T54,Temporal 1376 1398	in the following month
80,T55,Observation 1368 1375	planned
81,R22,Has_temporal Arg1:T52 Arg2:T53
82,T56,Drug 1317 1325	Iloprost
83,R23,Has_mood Arg1:T56 Arg2:T55
84,R24,Has_temporal Arg1:T56 Arg2:T54
85,*,OR T56 T52
86,T57,Non-query-able 1368 1398	planned in the following month
87,T58,Drug 1435 1443	bosentan
88,T59,Drug 1445 1455	sildenafil
89,T60,Drug 1459 1483	calcium channel blockers
90,T61,Temporal 1484 1505	in the previous month
91,T62,Temporal 1509 1531	in the following month
92,*,OR T62 T61
93,T63,Scope 1484 1531	in the previous month or in the following month
94,T64,"Scope 1435 1483	bosentan, sildenafil or calcium channel blockers"
95,R25,Has_scope Arg1:T64 Arg2:T63
96,T65,Procedure 1533 1554	Digital Sympathectomy
97,T66,Procedure 1558 1583	botulinum toxin injection
98,T67,Observation 1584 1591	planned
99,T68,Non-query-able 1584 1591	planned
100,T69,Temporal 1592 1614	in the following month
101,*,OR T66 T65
102,T70,Scope 1533 1583	Digital Sympathectomy or botulinum toxin injection
103,R26,Has_mood Arg1:T70 Arg2:T67
104,R27,Has_temporal Arg1:T70 Arg2:T69
105,T71,Condition 1642 1656	digital ulcers
106,T72,Observation 1628 1641	superinfected
107,R28,Has_context Arg1:T71 Arg2:T72
108,T73,Drug 1658 1670	Treprostinil
109,T74,Condition 1671 1688	contraindications
110,R29,AND Arg1:T74 Arg2:T73
111,T75,Condition 1696 1712	hypersensitivity
112,T76,Drug 1716 1728	treprostinil
113,T77,Drug 1732 1753	any of the excipients
114,*,OR T77 T76
115,T78,Scope 1716 1753	treprostinil or any of the excipients
116,R30,Has_scope Arg1:T75 Arg2:T78
117,T79,Condition 1755 1786	Pulmonary arterial hypertension
118,T80,Condition 1798 1820	veno-occlusive disease
119,R31,AND Arg1:T79 Arg2:T80
120,T81,Condition 1822 1846	Congestive heart failure
121,T82,Condition 1861 1889	left ventricular dysfunction
122,T83,Qualifier 1854 1860	severe
123,R32,Has_qualifier Arg1:T82 Arg2:T83
124,T84,Condition 1898 1919	hepatic insufficiency
125,T85,Qualifier 1891 1897	Severe
126,T86,Measurement 1921 1931	Child-Pugh
127,T87,Value 1932 1939	stage C
128,R33,Has_value Arg1:T86 Arg2:T87
129,R34,Subsumes Arg1:T85 Arg2:T86
130,R35,Has_qualifier Arg1:T84 Arg2:T85
131,T88,Condition 1951 1973	gastrointestinal ulcer
132,T89,Condition 1975 1998	intracranial hemorrhage
133,T90,Condition 2007 2013	trauma
134,T91,Temporal 2000 2006	recent
135,R36,Has_temporal Arg1:T90 Arg2:T91
136,T92,Condition 2023 2067	clinical condition that may lead to bleeding
137,T93,Undefined_semantics 2023 2067	clinical condition that may lead to bleeding
138,T94,Condition 2069 2079;2092 2114	Congenital valvular abnormalities
139,T95,Condition 2083 2114	acquired valvular abnormalities
140,T96,Qualifier 2115 2141	with cardiac repercussions
141,R37,Has_qualifier Arg1:T94 Arg2:T96
142,R38,Has_qualifier Arg1:T95 Arg2:T96
143,T97,Condition 2150 2172	ischemic heart disease
144,T98,Qualifier 2143 2149	Severe
145,R39,Has_qualifier Arg1:T97 Arg2:T98
146,T99,Condition 2176 2191	unstable angina
147,T100,Condition 2193 2214	Myocardial infarction
148,T101,Temporal 2215 2237	in the last six months
149,R40,Has_temporal Arg1:T100 Arg2:T101
150,T102,Condition 2239 2274	Decompensated cardiac insufficiency
151,T103,Condition 2308 2319	arrhythmias
152,T104,Qualifier 2301 2307	Severe
153,R41,Has_qualifier Arg1:T103 Arg2:T104
154,T105,Condition 2321 2344	Cerebrovascular lesions
155,T106,Condition 2354 2379	transient ischemic attack
156,T107,Condition 2381 2387	stroke
157,T108,Temporal 2403 2431	within the last three months
158,*,OR T107 T106
159,T109,"Scope 2354 2387	transient ischemic attack, stroke"
160,R42,Subsumes Arg1:T105 Arg2:T109
161,R43,Has_temporal Arg1:T105 Arg2:T108
162,*,OR T88 T79 T81 T82 T84 T89
163,T110,Scope 2000 2013	recent trauma
164,R44,Has_scope Arg1:T89 Arg2:T110
165,R45,Subsumes Arg1:T110 Arg2:T92
166,*,OR T97 T99 T92 T94 T95 T100 T102 T103 T105
167,T111,Context_Error 2434 2517	Persons referred to in Articles L1121-5 to L1121-8 of the French Public health Code
168,T112,Condition 2519 2527	pregnant
169,T113,Person 2528 2533	woman
170,A2,Optional T113
171,R46,AND Arg1:T113 Arg2:T112
172,T114,Condition 2535 2545	parturient
173,T115,Condition 2547 2554	nursing
174,T116,Observation 2570 2589	deprived of liberty
175,T117,Observation 2637 2666	subject to a legal protection
176,*,OR T115 T114 T113 T116 T117
177,T118,"Scope 2519 2666	pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection"
178,R47,Subsumes Arg1:T111 Arg2:T118
179,T119,Non-query-able 2717 2766	Subject in an exclusion period from another study
180,T120,Context_Error 2717 2766	Subject in an exclusion period from another study
181,T121,Non-query-able 2769 2923	Subject who would receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study
0,T1,Condition 0 19	hematology diseases
1,T2,Condition 21 47	clotting factor deficiency
0,T1,"Post-eligibility 0 133	Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures."
1,T2,"Non-query-able 0 133	Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures."
2,T3,Condition 143 148	obese
3,T4,Condition 135 142	Healthy
4,T5,Person 149 153	male
5,T6,Person 158 164	female
6,*,OR T6 T5
7,T7,Grammar_Error 154 157	and
8,T8,Person 176 180	aged
9,T9,"Value 181 206	18 to 55 years, inclusive"
10,R1,Has_value Arg1:T8 Arg2:T9
11,T10,Condition 208 220	Heterozygous
12,T11,Context_Error 208 220	Heterozygous
13,T12,Value 237 261	18 to 65 years inclusive
14,T13,Parsing_Error 208 262	Heterozygous subjects may be 18 to 65 years inclusive.
15,T14,Condition 267 286	good general health
16,T15,"Undefined_semantics 264 393	In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities."
17,T16,"Context_Error 264 393	In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities."
18,T17,"Subjective_judgement 264 393	In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities."
19,T18,Measurement 395 410	Body Mass Index
20,T19,"Value 414 436	30-40 kg/m2, inclusive"
21,R2,Has_value Arg1:T18 Arg2:T19
22,T20,Condition 438 450	Heterozygous
23,T21,Context_Error 438 450	Heterozygous
24,T22,Condition 505 517	heterozygous
25,T23,Measurement 538 541	BMI
26,T24,"Value 542 566	27 -55 kg/ m2, inclusive"
27,R3,Has_value Arg1:T23 Arg2:T24
28,T25,"Parsing_Error 438 567	Heterozygous subjects may have a broader BMI range; to be eligible heterozygous subjects may have a BMI 27 -55 kg/ m2, inclusive."
29,T26,Measurement 576 587	body weight
30,T27,Qualifier 569 575	Stable
31,R4,Has_qualifier Arg1:T26 Arg2:T27
32,T28,Temporal 588 616	during the previous 6 months
33,T29,Subjective_judgement 618 648	based on Investigator judgment
34,R5,Has_temporal Arg1:T26 Arg2:T28
35,T30,Measurement 651 665	Blood pressure
36,T31,Value 666 678	<140/90 mmHg
37,T32,Temporal 679 699	at Screening and D-1
38,T33,Reference_point 682 699	Screening and D-1
39,R6,Has_index Arg1:T32 Arg2:T33
40,R7,Has_value Arg1:T30 Arg2:T31
41,R8,Has_temporal Arg1:T30 Arg2:T32
42,T34,"Parsing_Error 701 777	Measurement may be repeated within 24 hours, based on Investigator judgment."
43,T35,"Subjective_judgement 701 777	Measurement may be repeated within 24 hours, based on Investigator judgment."
44,T36,"Non-query-able 701 777	Measurement may be repeated within 24 hours, based on Investigator judgment."
45,T37,Condition 799 807	pregnant
46,T38,Negation 792 795	not
47,R9,Has_negation Arg1:T37 Arg2:T38
48,T39,Person 779 786	Females
49,T40,Measurement 833 853	serum pregnancy test
50,T41,Value 824 832	negative
51,T42,Temporal 861 894	at the Screening Visit and Day -1
52,T43,Reference_point 864 894	the Screening Visit and Day -1
53,R10,Has_index Arg1:T42 Arg2:T43
54,R11,Has_value Arg1:T40 Arg2:T41
55,R12,Has_temporal Arg1:T40 Arg2:T42
56,T44,Post-eligibility 779 895	Females must not be pregnant and must have a negative serum pregnancy test result at the Screening Visit and Day -1.
57,T45,Condition 908 930	childbearing potential
58,T46,"Non-query-able 897 1194	Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through the Final Study Visit: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or IUD."
59,T47,"Post-eligibility 897 1194	Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through the Final Study Visit: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or IUD."
60,T48,Procedure 1195 1217	Hormonal contraception
61,T49,Temporal 1236 1272	at least 3 months prior to screening
62,T50,Reference_point 1263 1272	screening
63,R13,Has_index Arg1:T49 Arg2:T50
64,R14,Has_temporal Arg1:T48 Arg2:T49
65,T51,Post-eligibility 1274 1398	A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception.
66,T52,Post-eligibility 1399 1519	Subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.
67,T53,Non-query-able 1274 1398	A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception.
68,T54,Non-query-able 1399 1519	Subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.
69,T55,"Non-query-able 1521 1831	Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal range), do not require contraception during the study."
70,T56,"Post-eligibility 1521 1831	Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal range), do not require contraception during the study."
71,T57,"Non-query-able 1833 2084	Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the Final Study Visit."
72,T58,"Post-eligibility 1833 2084	Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the Final Study Visit."
73,T59,Non-query-able 2085 2271	Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time.
74,T60,Post-eligibility 2085 2271	Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time.
75,T61,Post-eligibility 2272 2397	Male subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.
76,T62,Non-query-able 2272 2397	Male subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.
0,T1,Qualifier 0 8	Unstable
1,T2,Condition 9 19	vital sign
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Temporal 20 34	before surgery
4,T4,Procedure 27 34	surgery
5,T5,Reference_point 27 34	surgery
6,R2,multi Arg1:T5 Arg2:T4
7,R3,Has_index Arg1:T3 Arg2:T5
8,R4,Has_temporal Arg1:T2 Arg2:T3
9,T6,Condition 43 60	pulmonary disease
10,T7,Procedure 71 91	consistent treatment
11,T8,Mood 61 70	requiring
12,R5,Has_mood Arg1:T7 Arg2:T8
13,T9,Qualifier 36 42	Severe
14,R6,Has_qualifier Arg1:T6 Arg2:T9
15,R7,AND Arg1:T6 Arg2:T7
16,T10,Observation 93 103	Illiterate
17,T11,Condition 105 114	Pregnancy
0,T1,Person 0 5	Adult
1,T2,Person 21 24	age
2,T3,Value 15 20;25 33	up to 75 years
3,T4,Qualifier 46 54	elective
4,T5,Visit 56 66	ambulatory
5,T6,Procedure 68 100	arthroscopic rotator cuff repair
6,R1,AND Arg1:T6 Arg2:T5
7,R2,Has_qualifier Arg1:T6 Arg2:T4
8,R3,Has_value Arg1:T2 Arg2:T3
0,T1,Parsing_Error 0 19	Healthy Volunteers:
1,T2,Value 28 45	at least 18 years
2,T3,Person 21 24	Age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Device 62 82	contraceptive method
5,T5,Person 87 92	women
6,T6,Value 96 109	child-bearing
7,T7,Person 110 113	age
8,R2,AND Arg1:T5 Arg2:T7
9,R3,Has_value Arg1:T7 Arg2:T6
10,T8,Scope 87 113	women of child-bearing age
11,A1,Optional T8
12,R4,AND Arg1:T8 Arg2:T4
13,T9,Non-query-able 115 183	Person affiliated to social security or beneficiary of such a scheme
14,T10,Non-query-able 185 204	Signed consent form
15,T11,Not_a_criteria 206 234	Systemic sclerosis patients:
16,T12,Condition 236 254	Systemic sclerosis
17,T13,Measurement 267 281	EULAR criteria
18,T14,Value 255 262	meeting
19,R5,Has_value Arg1:T13 Arg2:T14
20,R6,AND Arg1:T12 Arg2:T13
21,T15,Multiplier 296 306;346 370	at least 2 on two different fingers
22,T16,Condition 307 345	ischemic digital cutaneous ulcerations
23,R7,Has_multiplier Arg1:T16 Arg2:T15
24,T17,Condition 377 391	digital ulcers
25,T18,Qualifier 407 413	active
26,R8,Has_qualifier Arg1:T17 Arg2:T18
27,T19,Measurement 439 478	North American working group definition
28,T20,"Qualifier 480 689	epithelial denudation is clearly Visible at one place and the bed of de-epithelialized ulcer can be seen; Ulcerations distal to the proximal interphalangeal joint, not associated with calcinosis or bony relief"
29,R9,Subsumes Arg1:T19 Arg2:T20
30,R10,Subsumes Arg1:T18 Arg2:T19
31,R11,AND Arg1:T16 Arg2:T17
32,T21,Condition 692 698	Ulcers
33,T22,Measurement 705 715	major axis
34,T23,Value 756 762	≥ 2 mm
35,T24,Qualifier 716 752	measured with the electronic caliper
36,R12,Has_qualifier Arg1:T22 Arg2:T24
37,R13,Has_value Arg1:T22 Arg2:T23
38,R14,AND Arg1:T21 Arg2:T22
39,T25,Person 764 767	Age
40,T26,Value 768 801	greater than or equal to 18 years
41,R15,Has_value Arg1:T25 Arg2:T26
42,T27,Device 818 831	contraceptive
43,T28,Person 843 848	women
44,T29,Value 852 864	reproductive
45,T30,Person 865 868	age
46,R16,Has_value Arg1:T30 Arg2:T29
47,R17,AND Arg1:T28 Arg2:T30
48,T31,Scope 843 868	women of reproductive age
49,A2,Optional T31
50,R18,AND Arg1:T31 Arg2:T27
51,T32,Non-query-able 870 924	A person who is or is a beneficiary of social security
52,T33,Non-query-able 926 1009	Informed and signed consent signed by the patient or his / her legal representative
0,T1,Informed_consent 0 28	Signed informed consent form
1,T2,Condition 30 42	Macula edema
2,T3,Condition 56 60	BRVO
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Measurement 62 66	BCVA
5,T5,Value 70 86	77 to 20 letters
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 126 129	CRT
8,T7,Value 138 143	250µm
9,R3,Has_value Arg1:T6 Arg2:T7
0,T1,Condition 0 7	healthy
1,T2,Condition 12 19	allergy
2,T3,Drug 29 40	these drugs
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Negation 9 11	no
5,R2,Has_negation Arg1:T2 Arg2:T4
6,T5,Qualifier 42 58	second trimester
7,T6,Condition 59 67	abortion
8,R3,Has_qualifier Arg1:T6 Arg2:T5
0,T1,Condition 14 18	T2DM
1,T2,Condition 23 26	CAS
2,T6,Condition 68 72	T2DM
3,T7,Qualifier 101 113	WHO criteria
4,R1,Has_qualifier Arg1:T6 Arg2:T7
5,T8,Condition 121 124	CAD
6,T9,Condition 163 169	Angina
7,T10,Measurement 184 207	exercise tolerance test
8,T11,Value 175 183	positive
9,R2,Has_value Arg1:T10 Arg2:T11
10,T12,Qualifier 223 238	Q wave positive
11,T13,Condition 239 260	myocardial infarction
12,T14,Qualifier 209 215;230 238	enzyme positive
13,*,OR T14 T12
14,T15,Scope 209 238	enzyme and/or Q wave positive
15,R3,Has_scope Arg1:T13 Arg2:T15
16,T16,Condition 262 283	angiographic evidence
17,T17,Value 286 290	>50%
18,T18,Measurement 291 313	stenosis of one vessel
19,R4,Has_value Arg1:T18 Arg2:T17
20,T19,Person 370 374	Aged
21,T20,Value 375 392	between 18 and 75
22,R5,Has_value Arg1:T19 Arg2:T20
23,T21,Observation 403 449	written consent for participation in the trial
24,T22,Temporal 450 504	prior to any study-specific procedures or requirements
25,T23,Reference_point 459 504	any study-specific procedures or requirements
26,R6,Has_index Arg1:T22 Arg2:T23
27,R7,Has_temporal Arg1:T21 Arg2:T22
28,T24,Scope 286 313	>50% stenosis of one vessel
29,R8,Subsumes Arg1:T16 Arg2:T24
30,*,OR T16 T13 T25 T28
31,T25,Scope 163 207	Angina plus positive exercise tolerance test
32,T26,Qualifier 332 340	surgical
33,T27,Qualifier 316 328	percutaneous
34,*,OR T27 T26
35,T28,Procedure 341 367	coronary revascularisation
36,T29,Scope 316 340	percutaneous or surgical
37,R9,Has_scope Arg1:T28 Arg2:T29
38,T30,"Scope 163 367	Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( >50% stenosis of one vessel), percutaneous or surgical coronary revascularisation"
39,R10,Subsumes Arg1:T8 Arg2:T30
0,T1,Drug 21 30	cisplatin
1,T2,Temporal 31 51	before randomization
2,T3,Reference_point 38 51	randomization
3,R1,Has_index Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T1 Arg2:T2
5,T4,Condition 66 84	concurrent disease
6,T5,Qualifier 53 65	Uncontrolled
7,R3,Has_qualifier Arg1:T4 Arg2:T5
8,T6,Condition 86 95	Pregnancy
0,T1,Qualifier 14 31	protocol criteria
1,T2,Condition 49 54	IBS-C
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 56 70	abdominal pain
4,T4,Condition 72 90	abdominal bloating
5,T5,Condition 95 110	abdominal girth
0,T1,Condition 15 25	malignancy
1,T2,Condition 35 50	severe diseases
2,*,OR T1 T2
3,T3,Pregnancy_considerations 52 143	Female patients who are pregnant or breastfeeding before or during the three-year follow-up
4,T4,Observation 145 160	Poor compliance
5,T5,Observation 164 186	refusal to participate
6,*,OR T4 T5
0,T1,Drug 21 33	enzalutamide
1,T2,Drug 37 56	abiraterone acetate
2,T3,Multiplier 57 70	for > 14 days
3,T4,Temporal 71 90	prior to enrollment
4,T5,Reference_point 80 90	enrollment
5,R1,Has_index Arg1:T4 Arg2:T5
6,*,OR T1 T2
7,T6,Procedure 6 15	treatment
8,T7,Scope 21 56	enzalutamide or abiraterone acetate
9,R2,Has_scope Arg1:T6 Arg2:T7
10,R3,Has_multiplier Arg1:T6 Arg2:T3
11,R4,Has_temporal Arg1:T6 Arg2:T4
12,T8,Procedure 137 149	chemotherapy
13,T9,Condition 154 162;172 178	prostate cancer
14,T10,Qualifier 166 171	other
15,T11,Condition 172 178	cancer
16,R5,Has_qualifier Arg1:T11 Arg2:T10
17,*,OR T9 T11
18,T12,Scope 154 178	prostate or other cancer
19,R6,Has_scope Arg1:T8 Arg2:T12
20,T13,Temporal 179 204	within the past 12 months
21,R7,Has_temporal Arg1:T8 Arg2:T13
22,T14,Condition 210 237	residual cognitive deficits
23,R8,AND Arg1:T8 Arg2:T14
24,T15,Procedure 253 265	chemotherapy
25,T16,Condition 270 275	mCRPC
26,R9,AND Arg1:T15 Arg2:T16
27,*,OR T8 T15
28,T17,Non-representable 277 402	Patients/physicians planning treatment with chemotherapy during the 12 month period of the investigation are also ineligible.
29,T18,Condition 415 435	cognitive impairment
30,T19,Condition 415 424;439 450	cognitive dysfunction
31,T20,Condition 475 483	dementia
32,T21,Condition 485 504	Alzheimer's disease
33,T22,Condition 506 512	stroke
34,T23,Condition 518 545	residual cognitive deficits
35,T24,Condition 547 568	cognitive dysfunction
36,T25,Condition 591 606	substance abuse
37,T26,Condition 580 587;601 606	alcohol abuse
38,R10,AND Arg1:T22 Arg2:T23
39,*,OR T22 T24 T21 T20 T25 T26 T28
40,*,OR T19 T18
41,T27,Scope 415 450	cognitive impairment or dysfunction
42,T28,Condition 611 632	cognitive dysfunction
43,T29,Procedure 650 659	treatment
44,T30,Temporal 644 649	prior
45,T31,Condition 668 674	cancer
46,T32,Qualifier 664 667	any
47,R11,Has_qualifier Arg1:T31 Arg2:T32
48,R12,AND Arg1:T29 Arg2:T31
49,R13,Has_temporal Arg1:T29 Arg2:T30
50,R14,AND Arg1:T28 Arg2:T29
51,T33,"Scope 475 674	dementia, Alzheimer's disease, stroke with residual cognitive deficits, cognitive dysfunction related to alcohol or substance abuse, or cognitive dysfunction related to prior treatment for any cancer"
52,R15,Subsumes Arg1:T27 Arg2:T33
53,T34,Condition 693 700	seizure
54,T35,Condition 721 736	recurrent falls
55,T36,Condition 747 763	brain metastases
56,*,OR T35 T36 T34
57,T37,Observation 701 708	history
58,T38,Observation 710 720	history of
59,R16,Has_temporal Arg1:T35 Arg2:T38
60,R17,Has_temporal Arg1:T34 Arg2:T37
61,T39,Condition 987 1007	intercurrent illness
62,T40,Qualifier 974 986	Uncontrolled
63,R18,Has_qualifier Arg1:T39 Arg2:T40
64,T41,Qualifier 1039 1051	uncontrolled
65,T42,Condition 1052 1060	diabetes
66,R19,Has_qualifier Arg1:T42 Arg2:T41
67,T43,Temporal 1062 1069	ongoing
68,T44,Qualifier 1073 1079	active
69,*,OR T43 T44
70,T45,Condition 1080 1089	infection
71,T46,Scope 1062 1079	ongoing or active
72,R20,Has_scope Arg1:T45 Arg2:T46
73,T47,Qualifier 1091 1102	symptomatic
74,T48,Condition 1103 1127	congestive heart failure
75,T49,Measurement 1129 1155	New York Heart Association
76,T50,Value 1156 1172	Class III and IV
77,T51,Condition 1173 1186	heart failure
78,R21,AND Arg1:T51 Arg2:T49
79,R22,Has_value Arg1:T49 Arg2:T50
80,R23,Has_qualifier Arg1:T48 Arg2:T47
81,T52,Scope 1129 1186	New York Heart Association Class III and IV heart failure
82,T53,Scope 1091 1127	symptomatic congestive heart failure
83,R24,Subsumes Arg1:T53 Arg2:T52
84,T54,Condition 1189 1213	unstable angina pectoris
85,T55,Condition 1215 1233	cardiac arrhythmia
86,T56,Condition 1238 1257	psychiatric illness
87,T57,Condition 1258 1275	social situations
88,T58,Condition 1276 1291	substance abuse
89,*,OR T45 T42 T53 T55 T54 T57 T58 T56
90,T59,"Scope 1039 1291	uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations/substance abuse"
91,T60,Scope 974 1007	Uncontrolled intercurrent illness
92,R25,Subsumes Arg1:T60 Arg2:T59
93,T61,Multiplier 1381 1387	second
94,T62,Condition 1388 1398	malignancy
95,T63,Qualifier 1363 1379	currently active
96,T64,Condition 1410 1435	non-melanoma skin cancers
97,R26,Has_multiplier Arg1:T62 Arg2:T61
98,T65,Negation 1399 1409	other than
99,R27,Has_negation Arg1:T64 Arg2:T65
100,R28,AND Arg1:T62 Arg2:T64
101,R29,Has_qualifier Arg1:T62 Arg2:T63
102,T66,Condition 1634 1655	cognitive dysfunction
103,T67,Procedure 1667 1676	treatment
104,T68,Qualifier 1680 1687	another
105,T69,Condition 1688 1698	malignancy
106,R30,Has_qualifier Arg1:T69 Arg2:T68
107,R31,AND Arg1:T67 Arg2:T69
108,R32,AND Arg1:T66 Arg2:T67
109,*,OR T62 T66
110,T70,Drug 1771 1795	psychotropic medications
111,T71,Drug 1799 1812	illicit drugs
112,T72,Condition 1822 1837	alter cognition
113,T73,Condition 1822 1827;1839 1852	alter concentration
114,T74,Condition 1822 1827;1857 1865	alter behavior
115,*,OR T73 T74 T72
116,*,OR T71 T70
117,T75,Scope 1771 1812	psychotropic medications or illicit drugs
118,T76,"Scope 1822 1865	alter cognition, concentration, or behavior"
119,R33,Has_scope Arg1:T75 Arg2:T76
120,T77,"Non-representable 1867 2062	Appropriate treatment by a licensed provider with medications for depression or anxiety, including but not limited to SSRIs, SNRIs, and standard dose benzodiazepines at a stable dose, is permitte"
0,T1,Person 0 3	Age
1,T2,Value 4 14	> 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 16 50	Eastern Cooperative Oncology Group
4,T4,Value 51 60	score 0-2
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 78 98	Head and neck cancer
7,T6,Mood 103 107	plan
8,T7,Drug 127 136	cisplatin
9,R3,Has_mood Arg1:T7 Arg2:T6
10,R4,AND Arg1:T5 Arg2:T7
11,T8,Measurement 138 154	Serum creatinine
12,T9,Value 155 165	=1.5 mg/dl
13,T10,Measurement 169 173	eGFR
14,T11,Value 173 192	=60(ml/min/1.73 m2)
15,R5,Has_value Arg1:T10 Arg2:T11
16,R6,Has_value Arg1:T8 Arg2:T9
17,*,OR T8 T10
0,T1,Condition 32 45	watery stools
1,T2,Condition 23 28;39 45	loose stools
2,*,OR T2 T1
3,T3,Observation 12 22	history of
4,T4,Scope 23 45	loose or watery stools
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Condition 64 95	clinically significant findings
7,T6,Qualifier 100 111	unexplained
8,T7,Condition 112 149	clinically significant alarm symptoms
9,R2,Has_qualifier Arg1:T7 Arg2:T6
10,T8,Condition 200 217	medical condition
11,T9,Qualifier 223 255	may contribute to abdominal pain
12,T10,Condition 241 255	abdominal pain
13,R3,multi Arg1:T9 Arg2:T10
14,R4,Has_qualifier Arg1:T8 Arg2:T9
15,T11,Qualifier 273 290	protocol-excluded
16,T12,Qualifier 294 316	clinically significant
17,T13,Observation 328 344	surgical history
18,T14,Observation 317 324;337 344	medical history
19,*,OR T14 T13
20,T15,Scope 317 344	medical or surgical history
21,*,OR T12 T11
22,T16,Scope 273 316	protocol-excluded or clinically significant
23,R5,Has_scope Arg1:T15 Arg2:T16
24,T17,Qualifier 350 386	could confound the study assessments
25,R6,Has_qualifier Arg1:T15 Arg2:T17
26,T18,Post-eligibility 257 386	Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
0,T1,Drug 20 31	Clopidogrel
1,T2,Condition 0 16	Contraindication
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Condition 33 40	Smoking
4,T4,Condition 50 57	smokers
5,T5,Temporal 42 49	current
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Condition 75 87	quit smoking
8,T7,Temporal 88 108	less than six months
9,T8,Condition 111 121	Malignancy
10,T9,Mood 122 131	diagnosed
11,T10,Mood 135 154	under investigation
12,*,OR T9 T10
13,T11,Scope 122 154	diagnosed or under investigation
14,R3,AND Arg1:T11 Arg2:T8
15,T12,Condition 157 181	Haematological disorders
16,T13,Condition 183 190	Anaemia
17,T14,Condition 192 202	malignancy
18,T15,Condition 204 222	bleeding disorders
19,*,OR T15 T14 T13
20,T16,"Scope 183 222	Anaemia, malignancy, bleeding disorders"
21,R4,Subsumes Arg1:T12 Arg2:T16
22,T17,Person 225 230	Women
23,T18,Condition 234 257	child-bearing potential
24,R5,AND Arg1:T18 Arg2:T17
25,T19,Drug 266 281	corticosteroids
26,T20,Drug 288 309	antithrombotic agents
27,T21,Drug 310 318	warfarin
28,R6,Subsumes Arg1:T20 Arg2:T21
29,*,OR T19 T20
30,T22,Condition 321 342	Chronic liver disease
31,T23,Condition 344 353	Cirrhosis
32,T24,Condition 355 365	malignancy
33,T25,Value 384 415	more than twice the upper limit
34,T26,Measurement 419 439	liver function tests
35,R7,Has_value Arg1:T26 Arg2:T25
36,*,OR T23 T24 T26
37,T27,"Scope 344 439	Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests"
38,R8,Subsumes Arg1:T22 Arg2:T27
39,T28,Observation 442 460	Unable to consent.
40,T29,Drug 475 502	investigational study drugs
41,T31,Temporal 503 537	within 1 year prior to study entry
42,R9,Has_temporal Arg1:T29 Arg2:T31
43,T30,Temporal 539 547	Previous
44,T32,Observation 548 575	participation in this study
45,R10,Has_temporal Arg1:T32 Arg2:T30
0,T1,Condition 0 15	Type 1 diabetes
1,T2,Qualifier 29 42	ADA criterias
2,T3,Temporal 43 51	<5 years
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Person 54 57	Age
6,T5,Value 57 90	= 18 years and less than 70 years
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Negation 93 96	Non
9,T7,Condition 97 102	obese
10,R4,Has_negation Arg1:T7 Arg2:T6
11,T8,Measurement 115 118	BMI
12,T9,Value 119 137	less than 28 kg/m2
13,R5,Has_value Arg1:T8 Arg2:T9
14,T10,Multiplier 152 164	at least one
15,T11,Condition 172 197	anti-islet autoantibodies
16,T12,Condition 199 203	GADA
17,T13,Condition 205 209	IA2A
18,T14,Condition 211 216	ZnT8A
19,*,OR T12 T13 T14
20,T15,"Scope 199 216	GADA, IA2A, ZnT8A"
21,R6,Subsumes Arg1:T11 Arg2:T15
22,R7,Has_multiplier Arg1:T11 Arg2:T10
23,T16,Measurement 229 258	postprandial plasma C-peptide
24,T17,Measurement 218 225;242 258	Fasting plasma C-peptide
25,*,OR T17 T16
26,T18,Scope 218 258	Fasting or postprandial plasma C-peptide
27,T19,Value 259 279	more than 100 pmol/L
28,R8,Has_value Arg1:T18 Arg2:T19
29,T20,Informed_consent 281 348	Written informed consent from the patient or family representative.
0,T1,Condition 18 33	prostate cancer
1,T2,Drug 67 79	GnRH agonist
2,T3,Drug 67 71;83 93	GnRH antagonist
3,*,OR T2 T3
4,T4,Multiplier 102 122	for at least 1 month
5,T5,Temporal 123 142	prior to enrollment
6,T6,Procedure 52 61	treatment
7,T7,Scope 67 93	GnRH agonist or antagonist
8,R1,Has_scope Arg1:T6 Arg2:T7
9,R2,Has_multiplier Arg1:T6 Arg2:T4
10,R3,Has_temporal Arg1:T6 Arg2:T5
11,T8,Non-query-able 145 403	Willing and able to complete survey questionnaires in English without assistance through the duration of the study. This stipulation is in place because not all of the proposed quality of life or cognitive tests are available or validated in other languages.
12,T9,Person 405 408	Age
13,T10,Value 409 419	= 18 years
14,R4,Has_value Arg1:T9 Arg2:T10
15,T11,Non-query-able 422 577	Ability to understand and the willingness to sign a written informed consent document written in English that is approved by an institutional review board.
16,T12,Qualifier 607 617	metastatic
17,T13,Qualifier 618 635	hormone sensitive
18,T14,Condition 636 651	prostate cancer
19,T15,Condition 653 658	mHSPC
20,R5,Has_qualifier Arg1:T14 Arg2:T13
21,R6,Has_qualifier Arg1:T14 Arg2:T12
22,T16,Scope 607 651	metastatic hormone sensitive prostate cancer
23,R7,Subsumes Arg1:T15 Arg2:T16
24,T17,Qualifier 663 683	castration-resistant
25,T18,Qualifier 684 694	metastatic
26,T19,Condition 695 710	prostate cancer
27,T20,Condition 712 717	mCRPC
28,R8,Has_qualifier Arg1:T19 Arg2:T18
29,R9,Has_qualifier Arg1:T19 Arg2:T17
30,T21,Scope 663 710	castration-resistant metastatic prostate cancer
31,R10,Subsumes Arg1:T20 Arg2:T21
32,T22,Drug 758 777	abiraterone acetate
33,T23,Procedure 743 752	treatment
34,T24,Condition 779 784	mHSPC
35,T25,Condition 788 793	mCRPC
36,*,OR T24 T25
37,T26,Drug 798 810	enzalutamide
38,T27,Condition 812 817	mCRPC
39,T28,Scope 758 817	abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC
40,T29,Scope 798 818	enzalutamide (mCRPC)
41,T30,Scope 758 794	abiraterone acetate (mHSPC or mCRPC)
42,*,OR T30 T29
43,R11,Has_scope Arg1:T23 Arg2:T28
44,T31,Scope 663 818	castration-resistant metastatic prostate cancer (mCRPC) and eligible to undergo treatment with abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC)
45,*,OR T16 T31
46,T32,Procedure 1124 1136	chemotherapy
47,T33,Qualifier 1141 1158	hormone-sensitive
48,T34,Qualifier 1159 1169	metastatic
49,T35,Condition 1170 1185	prostate cancer
50,R12,Has_qualifier Arg1:T35 Arg2:T34
51,R13,Has_qualifier Arg1:T35 Arg2:T33
52,R14,AND Arg1:T32 Arg2:T35
53,T36,Multiplier 1213 1242	lasted for more than 6 months
54,T37,Negation 1204 1207	not
55,R15,Has_negation Arg1:T36 Arg2:T37
56,R16,Has_multiplier Arg1:T32 Arg2:T36
57,T38,Temporal 1244 1313	At least 12 months must have elapsed since completion of chemotherapy
58,T39,Reference_point 1287 1313	completion of chemotherapy
59,T40,Procedure 1301 1313	chemotherapy
60,R17,multi Arg1:T39 Arg2:T40
61,R18,Has_index Arg1:T38 Arg2:T39
62,R19,Has_temporal Arg1:T32 Arg2:T38
63,T41,Temporal 1343 1348	prior
64,T42,Qualifier 1349 1359	definitive
65,T43,Procedure 1360 1377	radiation therapy
66,T44,Procedure 1381 1388	surgery
67,*,OR T43 T44
68,T45,Scope 1360 1388	radiation therapy or surgery
69,R20,Has_qualifier Arg1:T45 Arg2:T42
70,R21,Has_temporal Arg1:T45 Arg2:T41
71,T46,Temporal 1390 1484	At least 60 days must have elapsed since completion of definitive radiation therapy or surgery
72,T47,Procedure 1456 1473	radiation therapy
73,T48,Procedure 1477 1484	surgery
74,*,OR T47 T48
75,T49,Qualifier 1445 1455	definitive
76,T50,Reference_point 1431 1484	completion of definitive radiation therapy or surgery
77,R22,Has_index Arg1:T46 Arg2:T50
78,T51,Qualifier 1512 1527	grade 2 or less
79,T52,Condition 1528 1543	adverse effects
80,R23,Has_qualifier Arg1:T52 Arg2:T51
81,T53,Temporal 1544 1571	at the time of registration
82,T54,"Non-representable 1573 1696	Enrollment during palliative radiation of = 10 days, or radiation of = 10 days during the duration of the study is allowed."
83,R24,Has_temporal Arg1:T52 Arg2:T53
84,R25,Has_temporal Arg1:T45 Arg2:T46
85,T55,Non-query-able 1698 1743	Patients must be able to take oral medication
0,T1,Measurement 0 3	BMI
1,T2,Value 4 22	<35 and > 60 kg/m2
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 24 41	Inability to walk
4,T4,Condition 56 77	wheelchair dependence
5,T5,Condition 43 52	bed-bound
6,*,OR T5 T4
7,T6,Scope 43 77	bed-bound or wheelchair dependence
8,R2,Subsumes Arg1:T3 Arg2:T6
9,T7,Procedure 80 104	open abdominal surgeries
10,T8,Procedure 112 131	simple appendectomy
11,T9,Procedure 136 160	common OB/GYN procedures
12,T10,Qualifier 168 174	pelvis
13,R3,Has_qualifier Arg1:T9 Arg2:T10
14,T11,Procedure 176 188	hysterectomy
15,T12,Procedure 190 199	C-section
16,T13,Procedure 205 217	oophorectomy
17,T14,Procedure 219 233	tubal ligation
18,*,OR T11 T12 T13 T14
19,T15,"Scope 176 233	hysterectomy, C-section, and oophorectomy, tubal ligation"
20,T16,Scope 136 174	common OB/GYN procedures in the pelvis
21,R4,Subsumes Arg1:T16 Arg2:T15
22,T17,Negation 105 111	except
23,*,OR T8 T16
24,T18,"Scope 112 234	simple appendectomy and common OB/GYN procedures in the pelvis (hysterectomy, C-section, and oophorectomy, tubal ligation)"
25,R5,Has_negation Arg1:T18 Arg2:T17
26,R6,Has_scope Arg1:T7 Arg2:T18
27,T19,Procedure 236 254;270 279	laparoscopic bowel resection
28,T20,Procedure 258 279	solid organ resection
29,T21,Procedure 287 315	laparoscopic cholecystectomy
30,*,OR T20 T19
31,T22,Negation 280 286	except
32,T23,Scope 236 279	laparoscopic bowel or solid organ resection
33,R7,Has_negation Arg1:T21 Arg2:T22
34,R8,AND Arg1:T23 Arg2:T21
35,T24,Condition 317 331	ventral hernia
36,T25,Procedure 332 348	repair with mesh
37,R9,AND Arg1:T25 Arg2:T24
38,T26,Temporal 350 362	Preoperative
39,T28,Condition 386 398	chronic pain
40,T29,Drug 371 377	opiate
41,T27,Multiplier 363 370	chronic
42,R10,Has_multiplier Arg1:T29 Arg2:T27
43,R11,AND Arg1:T29 Arg2:T28
44,R12,Has_temporal Arg1:T29 Arg2:T26
45,T30,Drug 410 416	opiate
46,T31,Multiplier 423 464	at least 60 mg/day of morphine equivalent
47,T32,Multiplier 465 479	for = 3 months
48,R13,Has_multiplier Arg1:T30 Arg2:T31
49,R14,Has_multiplier Arg1:T30 Arg2:T32
50,T33,Temporal 546 599	in the one year period prior to the bariatric surgery
51,T34,Reference_point 578 599	the bariatric surgery
52,T35,Procedure 582 599	bariatric surgery
53,R15,multi Arg1:T34 Arg2:T35
54,R16,AND Arg1:T33 Arg2:T35
55,R17,Has_temporal Arg1:T30 Arg2:T33
56,T36,Scope 410 479	opiate usage at least 60 mg/day of morphine equivalent for = 3 months
57,T37,Scope 363 398	chronic opiate use for chronic pain
58,R18,Subsumes Arg1:T37 Arg2:T36
59,T38,Measurement 605 654	American Society of Anesthesiologists (ASA) score
60,T39,Value 655 658	> 3
61,R19,Has_value Arg1:T38 Arg2:T39
62,T40,Condition 671 687	hypersensitivity
63,T41,Condition 691 707	adverse reaction
64,T42,Drug 711 722	bupivacaine
65,T43,Drug 726 735	narcotics
66,*,OR T42 T43
67,*,OR T40 T41
68,T44,Scope 671 707	hypersensitivity or adverse reaction
69,T45,Scope 711 735	bupivacaine or narcotics
70,R20,Has_scope Arg1:T44 Arg2:T45
71,T46,Non-query-able 737 763	Inability to speak English
72,T47,Condition 765 779	ventral hernia
73,T48,Procedure 780 786	repair
74,R21,AND Arg1:T48 Arg2:T47
75,T49,Procedure 788 803	Cholecystectomy
76,T50,Condition 805 818	hiatal hernia
77,T51,Procedure 819 825	repair
78,T52,Procedure 831 852	posterior cruroplasty
79,R22,AND Arg1:T51 Arg2:T50
80,R23,AND Arg1:T51 Arg2:T52
81,T53,Condition 864 882	lysis of adhesions
82,T54,Qualifier 854 863	extensive
83,R24,Has_qualifier Arg1:T53 Arg2:T54
84,T55,"Non-representable 884 955	other procedures that mandate addition of ""trocar(s)"" or ""feeding tube"""
85,T56,Drug 969 975	trocar
86,T57,Observation 982 1003	conversion of surgery
87,T58,Procedure 1007 1020	hand-assisted
88,T59,Procedure 1024 1028	open
89,*,OR T58 T59
90,T60,Procedure 996 1003	surgery
91,R25,multi Arg1:T57 Arg2:T60
92,T61,Mood 957 968	Addition of
93,R26,Has_mood Arg1:T56 Arg2:T61
94,*,OR T56 T57
95,R27,AND Arg1:T57 Arg2:T58
0,T1,Condition 18 35	contraindications
1,T2,Condition 39 55	hypersensitivity
2,T3,Procedure 67 87	antiplatelet therapy
3,*,OR T1 T2
4,T4,Scope 18 55	contraindications or hypersensitivity
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 103 130	Acute Myocardial Infarction
7,T6,Condition 132 166	ST elevation myocardial infarction
8,T7,Condition 168 206	Non ST elevation myocardial infarction
9,*,OR T6 T7
10,T8,"Scope 132 206	ST elevation myocardial infarction, Non ST elevation myocardial infarction"
11,R2,Subsumes Arg1:T5 Arg2:T8
12,T9,Mood 226 240	anticipated to
13,T10,Procedure 249 258	treatment
14,T11,Procedure 262 269	surgery
15,T12,Procedure 319 339	antiplatelet therapy
16,T13,Temporal 340 361	for 2 weeks or longer
17,*,OR T10 T11
18,T14,Scope 249 269	treatment or surgery
19,R3,Has_mood Arg1:T14 Arg2:T9
20,R4,AND Arg1:T14 Arg2:T12
21,R5,Has_temporal Arg1:T12 Arg2:T13
22,T15,Condition 403 426	Chronic total occlusion
23,T16,Condition 428 431	CTO
24,T17,Condition 442 461	in-stent restenosis
25,T18,Condition 463 466	ISR
26,R6,Subsumes Arg1:T15 Arg2:T16
27,R7,Subsumes Arg1:T17 Arg2:T18
28,*,OR T15 T17
29,T19,Condition 491 508	cardiogenic shock
30,T20,"Pregnancy_considerations 510 570	Women who are breastfeeding, pregnant, or desiring pregnancy"
31,T21,Condition 598 608	hemorrhage
32,T22,Observation 626 641	life expectancy
33,T23,Value 645 661	less than 1 year
34,R8,Has_value Arg1:T22 Arg2:T23
35,T24,Procedure 692 710;717 726	drug-eluting stent procedure
36,T25,Procedure 712 715	DES
37,R9,Subsumes Arg1:T24 Arg2:T25
38,T26,Temporal 738 751	past 6 months
39,R10,Has_temporal Arg1:T24 Arg2:T26
40,T27,Non-query-able 753 829	Any other patients judged by the investigator to be unsuitable for the trial
0,T1,Person 0 5	Adult
1,T2,Visit 6 17	outpatients
2,T3,Value 19 36	18 years or older
3,R1,Has_value Arg1:T1 Arg2:T3
4,T4,Multiplier 39 57	routinely referred
5,T5,Procedure 62 97	small bowel video capsule endoscopy
6,R2,Has_multiplier Arg1:T5 Arg2:T4
0,T1,Measurement 9 21	NIH criteria
1,T2,Condition 26 43	bariatric surgery
2,T3,Value 0 8	Fulfills
3,R1,Has_value Arg1:T1 Arg2:T3
4,R2,AND Arg1:T2 Arg2:T1
5,T4,Procedure 66 111	laparoscopic Roux-en Y gastric bypass (LRYGB)
6,T5,Procedure 115 152	laparoscopic sleeve gastrectomy (LSG)
7,*,OR T4 T5
8,T6,Qualifier 156 163	primary
9,T7,Scope 66 152	laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG)
10,R3,Has_qualifier Arg1:T7 Arg2:T6
0,T1,Condition 0 9	dysphagia
1,T2,Condition 18 31	gastroparesis
2,T3,Qualifier 11 17	severe
3,T4,Procedure 42 62	endoscopic placement
4,T5,Device 66 73	capsule
5,R1,AND Arg1:T4 Arg2:T5
6,T6,Mood 32 41	requiring
7,R2,Has_mood Arg1:T4 Arg2:T6
8,R3,Has_qualifier Arg1:T2 Arg2:T3
9,R4,AND Arg1:T2 Arg2:T4
10,T7,Condition 75 98	small bowel obstruction
11,T8,Condition 100 109	pregnancy
0,T1,Person 9 13	aged
1,T2,Value 14 25	19 or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Informed_consent 27 109	Patients who have submitted a written consent to participate in the clinical trial
4,T4,Condition 111 125	De novo lesion
5,T5,Post-eligibility 127 212	Patients scheduled for elective intervention to treat ischemic cardiovascular disease
0,T1,Condition 30 42	pancreatitis
1,T2,Condition 44 71	Medullary thyroid carcinoma
2,T3,Condition 73 76	MTC
3,T4,Condition 81 125	Multiple Endocrine Neoplasia Syndrome Type 2
4,T5,Condition 127 132	MEN 2
5,R1,Subsumes Arg1:T4 Arg2:T5
6,R2,Subsumes Arg1:T2 Arg2:T3
7,*,OR T2 T4
8,T6,Condition 135 148	Gastroparesis
9,T7,Condition 150 157	Allergy
10,T8,Drug 161 172	liraglutide
11,T9,Drug 230 244	GLP-1 analogue
12,*,OR T8 T9
13,T10,Scope 161 244	liraglutide or any of the active ingredients in liraglutide or other GLP-1 analogue
14,R3,Has_scope Arg1:T7 Arg2:T10
15,T11,Observation 246 257	Weight loss
16,T12,Negation 264 269	other
17,T13,Drug 275 284	metformin
18,R4,AND Arg1:T11 Arg2:T13
19,R5,Has_negation Arg1:T13 Arg2:T12
20,T14,Condition 286 310	Type 1 diabetes mellitus
21,T15,Condition 314 335	diabetic ketoacidosis
22,*,OR T14 T15
23,T16,Condition 367 375	dementia
24,T17,Condition 349 366	cognitive deficit
25,R6,AND Arg1:T16 Arg2:T17
26,T18,Condition 388 399	head trauma
27,T19,Condition 405 426	loss of consciousness
28,T20,Multiplier 427 434	>30 min
29,R7,Has_multiplier Arg1:T19 Arg2:T20
30,R8,AND Arg1:T18 Arg2:T19
31,T21,Condition 447 453	stroke
32,T22,Condition 463 485;492 500	central nervous system disorder
33,T23,Condition 509 517	seizures
34,T24,Condition 521 548	opportunistic CNS infection
35,*,OR T23 T24
36,T25,Scope 509 548	seizures or opportunistic CNS infection
37,R9,Subsumes Arg1:T22 Arg2:T25
38,*,OR T16 T18 T22 T21
39,T26,Condition 550 569	Renal insufficiency
40,T27,Measurement 581 601	creatinine clearance
41,T28,Value 602 613	< 60 mL/min
42,R10,AND Arg1:T26 Arg2:T27
43,R11,Has_value Arg1:T27 Arg2:T28
44,T29,Condition 622 646	opportunistic infections
45,T30,Qualifier 615 621	Active
46,R12,Has_qualifier Arg1:T29 Arg2:T30
47,T31,Pregnancy_considerations 648 674	Pregnancy or breastfeeding
48,T33,Visit 713 728	hospitalization
49,T34,Temporal 729 742	within 1 year
50,T35,Condition 747 770	acute coronary syndrome
51,R13,Has_temporal Arg1:T35 Arg2:T34
52,R14,AND Arg1:T35 Arg2:T33
53,T32,Condition 772 799	Decompensated heart failure
54,T36,Condition 801 816	Substance abuse
55,T37,Procedure 836 863	opioid substitution therapy
56,T38,Observation 825 832	alcohol
57,*,OR T37 T38
58,T39,Non-query-able 865 992	Serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation
0,T1,Non-representable 0 23	Stage IA or IIA disease
1,T2,Non-representable 25 38	Not specified
2,T3,Non-representable 40 56	No prior therapy
0,T1,Condition 0 3	HIV
1,T2,Qualifier 4 14	controlled
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Temporal 30 47	at least 12 weeks
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Measurement 49 59	Viral load
6,T5,Value 60 72	< 200 copies
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Person 74 77	BMI
9,T7,Value 78 87	>27 to 45
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Condition 102 111	DM type 2
12,T9,Measurement 117 121	A1-C
13,T10,Value 122 130	>7 to 15
14,R5,Has_value Arg1:T9 Arg2:T10
15,R6,AND Arg1:T8 Arg2:T9
16,T11,Post-eligibility 132 204	Participants must be willing to comply with all study related procedures
0,T1,Non-query-able 0 2	NA
0,T1,Qualifier 0 18	Moderate to severe
1,T2,Condition 19 39	rheumatoid arthritis
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Drug 48 60	methotrexate
4,T4,Negation 61 68	without
5,T5,Observation 69 97	adequate control of symptoms
6,R2,Has_negation Arg1:T5 Arg2:T4
7,T6,Multiplier 104 116	at least one
8,T7,Condition 117 143	cardiovascular risk factor
9,R3,Has_multiplier Arg1:T7 Arg2:T6
10,T8,Temporal 149 156	current
11,T9,Observation 157 163	smoker
12,T10,Condition 165 184	high blood pressure
13,T11,Condition 186 209	high cholesterol levels
14,T12,Condition 211 228	diabetes mellitus
15,T13,Observation 230 237	history
16,T14,Condition 241 253	heart attack
17,R4,Has_temporal Arg1:T14 Arg2:T13
18,T15,Observation 255 269	family history
19,T16,Condition 273 295	coronary heart disease
20,T17,Qualifier 297 312	extra-articular
21,T18,Condition 313 323	RA disease
22,R5,Has_qualifier Arg1:T18 Arg2:T17
23,R6,Has_temporal Arg1:T9 Arg2:T8
24,*,OR T9 T10 T11 T12 T14 T16 T18
25,R7,Has_context Arg1:T16 Arg2:T15
26,T19,"Scope 149 323	current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease"
27,R8,Subsumes Arg1:T7 Arg2:T19
0,T1,Condition 19 35	severe allergies
1,T2,Condition 37 43	trauma
2,T3,Procedure 59 68	operation
3,T4,Temporal 77 92	within 3 months
4,*,OR T2 T1 T3
5,R1,Has_temporal Arg1:T3 Arg2:T4
6,R2,Has_temporal Arg1:T2 Arg2:T4
7,R3,Has_temporal Arg1:T1 Arg2:T4
8,T5,Condition 113 127	mental illness
9,T6,Observation 135 149	family history
10,T7,Condition 153 167	mental illness
11,R4,Has_context Arg1:T7 Arg2:T6
12,*,OR T5 T7
13,T8,Observation 102 109	history
14,R5,Has_temporal Arg1:T5 Arg2:T8
15,T9,Condition 170 183	Limb disabled
16,T10,Drug 193 201	medicine
17,T11,Temporal 202 218	within one month
18,R6,Has_temporal Arg1:T10 Arg2:T11
19,T12,Non-query-able 186 218	Taking medicine within one month
20,T13,Condition 231 243	major events
21,T14,Undefined_semantics 231 243	major events
22,T15,Subjective_judgement 231 243	major events
23,T16,Condition 254 265	mood swings
24,*,OR T13 T16
0,T1,Condition 13 43	idiopathic Parkinson's disease
1,T2,Qualifier 62 69	treated
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Measurement 71 89	motor fluctuations
4,T4,Value 90 118	<20% of subject's awake time
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Observation 213 228	Sexually active
7,T6,Person 252 257	males
8,T7,Person 276 279	age
9,T8,Value 259 272	40 - 64 years
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Multiplier 235 250	=1 attempt/week
12,R4,Has_multiplier Arg1:T5 Arg2:T9
13,T10,Condition 336 356	erectile dysfunction
14,T11,Qualifier 327 335	moderate
15,R5,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Temporal 429 451	for more than 6 months
17,R6,Has_temporal Arg1:T10 Arg2:T12
18,T13,Drug 497 506	tadalafil
19,T14,Condition 485 493	response
20,T15,Qualifier 474 484	incomplete
21,R7,Has_qualifier Arg1:T14 Arg2:T15
22,R8,AND Arg1:T14 Arg2:T13
23,T16,Measurement 539 570	IIEF-5 drug-free baseline score
24,T17,Value 579 592	= 10 but = 16
25,R9,Has_value Arg1:T16 Arg2:T17
26,T18,Measurement 601 638	IIEF-5 tadalafil-alone baseline score
27,T19,Value 647 651	= 18
28,R10,Has_value Arg1:T18 Arg2:T19
29,T20,Observation 673 698	heterosexual relationship
30,T21,Qualifier 666 672	stable
31,R11,Has_qualifier Arg1:T20 Arg2:T21
32,T22,Temporal 703 720	at least 6 months
33,R12,Has_temporal Arg1:T20 Arg2:T22
34,T23,Condition 767 787	erectile dysfunction
35,T24,Procedure 753 762	treatment
36,T25,Post-eligibility 727 787	Subject motivated to seek treatment for erectile dysfunction
37,T26,Measurement 805 835	total serum testosterone level
38,T27,Value 836 847	= 300 ng/dL
39,R13,Has_value Arg1:T26 Arg2:T27
40,T28,Measurement 882 908	Hoehn and Yahr Scale score
41,T29,Value 912 917	1 - 3
42,R14,Has_value Arg1:T28 Arg2:T29
43,T30,Informed_consent 919 980	Patient able to consent and comply with protocol requirements
0,T1,Visit 0 31	Accident & Emergency Department
1,T2,Procedure 52 76	parenteral drug sedation
2,T3,Mood 42 51	requiring
3,R1,Has_mood Arg1:T2 Arg2:T3
0,T1,Condition 0 9	Pregnancy
1,T2,Observation 13 26	breastfeeding
2,*,OR T1 T2
3,T3,Condition 28 35	Allergy
4,T4,Drug 47 57	penicillin
5,T5,Drug 61 75	cephalosporins
6,*,OR T4 T5
7,T6,Scope 47 75	penicillin or cephalosporins
8,R1,Has_scope Arg1:T3 Arg2:T6
9,T7,Condition 77 93	Renal impairment
10,T8,Condition 102 117	hepatic disease
11,T9,Qualifier 95 101	Active
12,R2,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Drug 119 129	Antibiotic
14,T11,Negation 134 140	except
15,T12,Drug 141 152	study drugs
16,R3,Has_negation Arg1:T12 Arg2:T11
17,R4,AND Arg1:T10 Arg2:T12
18,T13,Procedure 154 179	Immunosuppressive therapy
19,T14,Temporal 180 215	before 6 months of study initiation
20,T15,Reference_point 199 215	study initiation
21,R5,Has_index Arg1:T14 Arg2:T15
22,T16,Drug 224 245	probenecid like drugs
23,R6,Has_temporal Arg1:T13 Arg2:T14
24,T17,Drug 224 234	probenecid
25,T18,Qualifier 224 239	probenecid like
26,R7,multi Arg1:T16 Arg2:T18
27,R8,multi Arg1:T18 Arg2:T17
0,T1,Temporal 11 17	recent
1,T2,Temporal 0 7	Current
2,*,OR T2 T1
3,T3,Condition 18 27	infection
4,T4,Scope 0 17	Current or recent
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Qualifier 29 51	Clinically significant
7,T6,Condition 52 76	laboratory abnormalities
8,R2,Has_qualifier Arg1:T6 Arg2:T5
9,T7,Procedure 52 62	laboratory
10,R3,multi Arg1:T6 Arg2:T7
11,T8,Condition 78 87	Pregnancy
0,T1,Person 0 5	Women
1,T2,Person 6 10	aged
2,T3,Value 11 16	20-49
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 28 51	regular menstrual cycle
5,T5,Measurement 65 81	menstrual period
6,T6,Value 85 100	between day 3-7
7,T7,Grammar_Error 102 105	and
8,T8,Value 117 134	between day 25-35
9,*,OR T8 T6
10,T9,"Scope 85 134	between day 3-7, and the period between day 25-35"
11,R2,Has_scope Arg1:T5 Arg2:T9
12,T10,Condition 147 155;169 176	internal disease
13,T11,Condition 160 176	surgical disease
14,T12,Context_Error 137 308	Excluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine)
15,T13,Undefined_semantics 137 309	Excluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine).
16,T14,Non-query-able 137 309	Excluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine).
0,T1,Procedure 38 47	treatment
1,T2,Condition 52 72	erectile dysfunction
2,T3,Temporal 73 89	during the study
3,R1,AND Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Procedure 101 116	oral medication
6,T5,Device 118 132	vacuum devices
7,T6,Device 134 154	constrictive devices
8,T7,Procedure 156 166	injections
9,T8,Device 168 190	urethral suppositories
10,T9,Procedure 192 196	gels
11,T10,Qualifier 202 218	over-the-counter
12,T11,Qualifier 222 237	nonprescription
13,T12,Procedure 238 249	medications
14,*,OR T10 T11
15,T13,Scope 202 237	over-the-counter or nonprescription
16,R3,Has_scope Arg1:T12 Arg2:T13
17,T14,"Scope 101 250	oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or nonprescription medications,"
18,*,OR T4 T5 T6 T7 T8 T9 T12
19,R4,Subsumes Arg1:T1 Arg2:T14
20,T15,Drug 310 327	dopamine agonists
21,T16,Drug 329 337	nitrates
22,T17,Drug 339 369	alpha-receptor blocking agents
23,T18,Drug 374 401	antihypertensive medication
24,*,OR T15 T16 T17 T18
25,T19,Condition 479 486	syncope
26,T20,Temporal 487 530	within the last 6 months prior to screening
27,T21,Reference_point 521 530	screening
28,R5,Has_temporal Arg1:T19 Arg2:T20
29,R6,Has_index Arg1:T20 Arg2:T21
30,T22,Condition 557 577	postural hypotension
31,T23,Qualifier 545 556	symptomatic
32,R7,Has_qualifier Arg1:T22 Arg2:T23
33,T24,Condition 586 595	dizziness
34,T25,Condition 599 607	fainting
35,T26,Qualifier 579 585	severe
36,*,OR T24 T25
37,T27,Scope 586 607	dizziness or fainting
38,R8,Has_qualifier Arg1:T27 Arg2:T26
39,R9,Subsumes Arg1:T22 Arg2:T27
40,T28,Condition 622 633	hypotension
41,T29,Measurement 648 671	systolic blood pressure
42,T30,Value 675 684	< 90 mmHG
43,T31,Condition 688 700	hypertension
44,T32,Measurement 716 739	systolic blood pressure
45,T33,Value 740 750	> 170 mmHG
46,T34,Measurement 764 788	diastolic blood pressure
47,T35,Value 789 799	> 110 mmHG
48,R10,Has_value Arg1:T29 Arg2:T30
49,R11,AND Arg1:T28 Arg2:T29
50,T36,Scope 716 799	systolic blood pressure > 170 mmHG or a resting diastolic blood pressure > 110 mmHG
51,R12,Has_value Arg1:T32 Arg2:T33
52,*,OR T32 T34
53,R13,Has_value Arg1:T34 Arg2:T35
54,R14,Has_scope Arg1:T31 Arg2:T36
55,T37,Condition 829 853	cardiovascular condition
56,T38,Condition 865 889	unstable angina pectoris
57,T39,Observation 906 921	sexual activity
58,T40,Negation 897 905	preclude
59,R15,Subsumes Arg1:T37 Arg2:T38
60,R16,Has_negation Arg1:T39 Arg2:T40
61,T41,Condition 949 970	myocardial infarction
62,T42,Condition 972 978	stroke
63,T43,Condition 999 1009	arrhythmia
64,T44,Qualifier 982 998	life-threatening
65,T45,Temporal 1010 1044	within 6 months prior to screening
66,T46,Reference_point 1035 1044	screening
67,R17,Has_index Arg1:T45 Arg2:T46
68,T47,"Scope 949 1009	myocardial infarction, stroke or life-threatening arrhythmia"
69,*,OR T41 T42 T43
70,R18,Has_qualifier Arg1:T43 Arg2:T44
71,R19,Has_temporal Arg1:T47 Arg2:T45
72,T48,Condition 1072 1091	atrial fibrillation
73,T49,Condition 1072 1078;1092 1099	atrial flutter
74,*,OR T48 T49
75,T50,Qualifier 1059 1071	uncontrolled
76,T51,Temporal 1100 1112	at screening
77,T52,Scope 1072 1099	atrial fibrillation/flutter
78,R20,Has_qualifier Arg1:T52 Arg2:T50
79,R21,Has_temporal Arg1:T52 Arg2:T51
80,T53,Condition 1178 1195	bleeding disorder
81,T54,Procedure 1223 1236	prostatectomy
82,T55,Condition 1248 1263	prostate cancer
83,R22,AND Arg1:T54 Arg2:T55
84,T56,Procedure 1275 1299	nerve sparing techniques
85,R23,Subsumes Arg1:T54 Arg2:T56
86,T57,Procedure 1328 1347	surgical procedures
87,T58,Condition 1369 1396	benign prostate hypertrophy
88,R24,AND Arg1:T57 Arg2:T58
89,T59,Negation 1401 1410	permitted
90,R25,Has_negation Arg1:T57 Arg2:T59
91,T60,Procedure 1434 1445	cryosurgery
92,T61,Procedure 1447 1458	cryotherapy
93,T62,Procedure 1462 1474	cryoablation
94,*,OR T60 T61 T62
95,T63,"Scope 1434 1474	cryosurgery, cryotherapy or cryoablation"
96,R26,AND Arg1:T63 Arg2:T58
97,T64,Condition 1489 1530	hereditary degenerative retinal disorders
98,T65,Condition 1539 1559	retinitis pigmentosa
99,R27,Subsumes Arg1:T64 Arg2:T65
100,T66,Condition 1613 1661	non-arteritic anterior ischemic optic neuropathy
101,T67,Condition 1663 1668	NAION
102,R28,Subsumes Arg1:T66 Arg2:T67
103,T68,Condition 1587 1601	loss of vision
104,R29,AND Arg1:T68 Arg2:T66
105,T69,Condition 1705 1719	loss of vision
106,T70,Qualifier 1682 1691	temporary
107,T71,Qualifier 1695 1704	permanent
108,*,OR T70 T71
109,T72,Scope 1682 1704	temporary or permanent
110,R30,Has_scope Arg1:T69 Arg2:T72
111,T73,Qualifier 1731 1741	unilateral
112,T74,Condition 1742 1756	loss of vision
113,R31,Has_qualifier Arg1:T74 Arg2:T73
114,R32,Subsumes Arg1:T69 Arg2:T74
115,*,OR T68 T69
116,T75,Condition 1784 1810	congenital QT prolongation
117,T76,Condition 1827 1856	penile anatomical abnormality
118,T77,Condition 1864 1879	penile fibrosis
119,T78,Condition 1864 1870;1881 1890	penile fractures
120,T79,Condition 1895 1914	Peyronie's disease)
121,*,OR T77 T78 T79
122,T81,"Scope 1864 1913	penile fibrosis, fractures, or Peyronie's disease"
123,R33,Subsumes Arg1:T76 Arg2:T81
124,T82,Observation 2098 2130	primary hypoactive sexual desire
125,T83,Condition 2148 2166	spinal cord injury
126,T84,Condition 2201 2206;2207 2220	acute liver disease
127,T85,Qualifier 2183 2189	severe
128,T86,Condition 2190 2197;2207 2220	chronic liver disease
129,*,OR T86 T84
130,T87,Condition 2283 2301	hepatic impairment
131,T88,Measurement 2243 2253	Child-Pugh
132,T89,Measurement 2269 2279	Child-Pugh
133,T90,Value 2254 2255	B
134,T91,Value 2280 2281	C
135,T92,Qualifier 2233 2241	moderate
136,T93,Qualifier 2261 2267	severe
137,T94,Scope 2190 2220	chronic or acute liver disease
138,R34,Has_qualifier Arg1:T94 Arg2:T85
139,T95,Condition 2283 2301	hepatic impairment
140,R35,Has_qualifier Arg1:T95 Arg2:T93
141,R36,Has_qualifier Arg1:T87 Arg2:T92
142,R37,AND Arg1:T87 Arg2:T88
143,R38,Has_value Arg1:T88 Arg2:T90
144,R39,AND Arg1:T95 Arg2:T89
145,R40,Has_value Arg1:T89 Arg2:T91
146,T96,Condition 2347 2368	hematological disease
147,T80,"Scope 829 889	cardiovascular condition, including unstable angina pectoris"
148,R41,Has_context Arg1:T80 Arg2:T39
149,T97,Measurement 1125 1150	ventricular response rate
150,T98,Value 1151 1160	= 100 bpm
151,R42,Has_value Arg1:T97 Arg2:T98
152,R43,Subsumes Arg1:T52 Arg2:T97
153,T99,Observation 1317 1327	history of
154,R44,Has_temporal Arg1:T57 Arg2:T99
155,T100,Negation 1412 1433	with the exception of
156,R45,Has_negation Arg1:T63 Arg2:T100
157,T101,Observation 1576 1586	history of
158,R46,Has_temporal Arg1:T68 Arg2:T101
159,T102,Observation 1773 1783	history of
160,R47,Has_temporal Arg1:T75 Arg2:T102
161,T103,Non-representable 1922 1951	in the investigator's opinion
162,T104,Qualifier 1953 1998	could significantly impair sexual performance
163,T106,Qualifier 2339 2346	chronic
164,R50,Has_qualifier Arg1:T96 Arg2:T106
165,T107,Qualifier 2375 2397	could lead to priapism
166,T108,Condition 2406 2424	sickle cell anemia
167,T109,Condition 2426 2442	multiple myeloma
168,T110,Condition 2448 2456	leukemia
169,*,OR T108 T109 T110
170,T111,"Scope 2406 2456	sickle cell anemia, multiple myeloma, and leukemia"
171,R48,AND Arg1:T104 Arg2:T103
172,R49,Has_qualifier Arg1:T76 Arg2:T104
173,T105,Procedure 2058 2069	penile exam
174,A1,Optional T105
175,T112,Qualifier 2316 2338	clinically significant
176,R51,Has_qualifier Arg1:T96 Arg2:T112
177,T113,Condition 1973 1998	impair sexual performance
178,R52,multi Arg1:T104 Arg2:T113
179,T114,Condition 2389 2397	priapism
180,R53,multi Arg1:T107 Arg2:T114
181,R54,Subsumes Arg1:T107 Arg2:T111
182,R55,Has_qualifier Arg1:T96 Arg2:T107
183,T115,Qualifier 2471 2477	active
184,T116,Condition 2478 2495	peptic ulceration
185,R56,Has_qualifier Arg1:T116 Arg2:T115
186,T117,Observation 2512 2522	history of
187,T118,Condition 2523 2533	malignancy
188,T119,Temporal 2534 2557	within the past 5 years
189,T120,Negation 2559 2569	other than
190,T121,Condition 2570 2578;2593 2604	squamous skin cancer
191,T122,Condition 2582 2604	basal cell skin cancer
192,*,OR T122 T121
193,T123,Scope 2570 2604	squamous or basal cell skin cancer
194,R57,Has_negation Arg1:T123 Arg2:T120
195,R58,Has_temporal Arg1:T118 Arg2:T119
196,R59,Has_temporal Arg1:T118 Arg2:T117
197,R60,Has_scope Arg1:T118 Arg2:T123
198,T124,Observation 2622 2632	history of
199,T125,Value 2635 2643	positive
200,T126,Measurement 2644 2688	test for Hepatitis B surface antigen (HbsAg)
201,T127,Measurement 2644 2652;2692 2703	test for Hepatitis C
202,*,OR T127 T126
203,T128,Scope 2644 2703	test for Hepatitis B surface antigen (HbsAg) or Hepatitis C
204,R61,Has_value Arg1:T128 Arg2:T125
205,R62,Has_temporal Arg1:T128 Arg2:T124
206,T129,Condition 2726 2742	hypersensitivity
207,T130,Qualifier 2767 2782	investigational
208,T131,Drug 2783 2794	medications
209,T132,Drug 2796 2824	monoamine oxidase inhibitors
210,T133,Drug 2826 2861	phosphodiesterase type 5 inhibitors
211,T134,Drug 2865 2882	phenylethylamines
212,*,OR T133 T134 T132 T131
213,R63,Has_qualifier Arg1:T131 Arg2:T130
214,T135,"Scope 2767 2882	investigational medications, monoamine oxidase inhibitors, phosphodiesterase type 5 inhibitors or phenylethylamines"
215,R64,AND Arg1:T135 Arg2:T129
216,T136,Observation 2900 2910	history of
217,T137,Condition 2911 2915;2927 2932	drug abuse
218,T138,Condition 2919 2932	alcohol abuse
219,T139,Temporal 2933 2957	within the past 6 months
220,T140,Reference_point 2940 2957	the past 6 months
221,R65,Has_index Arg1:T139 Arg2:T140
222,*,OR T137 T138
223,T141,Scope 2911 2932	drug or alcohol abuse
224,R66,Has_temporal Arg1:T141 Arg2:T136
225,R67,Has_temporal Arg1:T141 Arg2:T139
226,T142,Temporal 2968 2977	currently
227,T143,Observation 2978 2987;3000 3015	consuming alcohol per day
228,T144,Value 2988 2996	=5 units
229,R68,Has_value Arg1:T143 Arg2:T144
230,R69,Has_temporal Arg1:T143 Arg2:T142
231,T145,Observation 3032 3042	illiterate
232,T146,Negation 3046 3055	unable to
233,T147,Informed_consent 3056 3092	understand the Informed Consent Form
234,T148,Informed_consent 3056 3070;3112 3125	understand the subject diary
235,T149,Informed_consent 3056 3070;3094 3108	understand the questionnaires
236,*,OR T148 T149 T147
237,T150,"Scope 3056 3125	understand the Informed Consent Form, questionnaires or subject diary"
238,R70,Has_negation Arg1:T150 Arg2:T146
239,R71,Has_context Arg1:T150 Arg2:T145
240,T151,Non-representable 3140 3174	in the opinion of the investigator
241,T152,Informed_consent 3184 3239	noncompliant with the visit schedule or study procedure
242,R72,AND Arg1:T152 Arg2:T151
243,T153,Qualifier 3259 3267	unstable
244,T154,Condition 3268 3275;3309 3317	medical disorder
245,T155,Condition 3277 3288;3309 3317	psychiatric disorder
246,T156,Condition 3293 3317	substance abuse disorder
247,*,OR T154 T155 T156
248,T157,"Scope 3268 3317	medical, psychiatric, or substance abuse disorder"
249,R73,Has_qualifier Arg1:T157 Arg2:T153
250,T158,Non-representable 3323 3357	in the opinion of the investigator
251,T159,Qualifier 3361 3421	likely to affect the subject's ability to complete the study
252,T160,Qualifier 3425 3474	preclude the subject's participation in the study
253,*,OR T159 T160
254,T161,Scope 3361 3474	likely to affect the subject's ability to complete the study or preclude the subject's participation in the study
255,R74,AND Arg1:T161 Arg2:T158
256,R75,Has_scope Arg1:T157 Arg2:T161
257,T162,Condition 3499 3517	neurologic disease
258,T163,Qualifier 3489 3498	any other
259,R76,Has_qualifier Arg1:T162 Arg2:T163
260,T164,Qualifier 3519 3531	Uncontrolled
261,T165,Condition 3532 3540	Diabetes
262,T166,Measurement 3542 3556	Hemoglobin A1C
263,T167,Value 3557 3562	> 7.5
264,R77,Has_value Arg1:T166 Arg2:T167
265,T168,Scope 3542 3562	Hemoglobin A1C > 7.5
266,R78,Has_qualifier Arg1:T165 Arg2:T164
267,T169,Scope 3519 3540	Uncontrolled Diabetes
268,R79,Subsumes Arg1:T169 Arg2:T168
269,T170,Negation 8 17	unwilling
270,T171,Mood 21 33	cease use of
271,R80,Has_negation Arg1:T171 Arg2:T170
272,R81,Has_mood Arg1:T1 Arg2:T171
0,T1,Condition 6 22	hypersensitivity
1,T2,Condition 26 42	contraindication
2,*,OR T1 T2
3,T3,Drug 50 61	study drugs
4,T4,Scope 6 42	hypersensitivity or contraindication
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 63 83	reversible aetiology
7,T6,Condition 88 97	agitation
8,R2,AND Arg1:T5 Arg2:T6
9,T7,Condition 104 115	hypotension
10,T8,Condition 117 124	hypoxia
11,T9,Condition 126 139	hypoglycaemia
12,*,OR T7 T8 T9
13,T10,"Scope 104 139	hypotension, hypoxia, hypoglycaemia"
14,T11,Scope 63 97	reversible aetiology for agitation
15,R3,Subsumes Arg1:T11 Arg2:T10
16,T12,Condition 148 157	pregnancy
17,T13,Condition 159 183	acute alcohol withdrawal
18,T14,Person 194 198	aged
19,T15,Value 198 207	>75 years
20,R4,Has_value Arg1:T14 Arg2:T15
0,T1,Condition 17 35	chronic bronchitis
1,T2,Condition 54 83	community-acquired pneumoniae
2,T3,Measurement 85 95	FEV1 value
3,T4,Value 96 104	= 30-80%
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Qualifier 123 134	mild-severe
6,T6,Qualifier 135 140	acute
7,T7,Condition 141 175	exacerbation of chronic bronchitis
8,R2,Has_qualifier Arg1:T7 Arg2:T6
9,R3,Has_qualifier Arg1:T7 Arg2:T5
10,T8,Scope 123 175	mild-severe acute exacerbation of chronic bronchitis
11,T9,Condition 177 181	AECB
12,R4,Subsumes Arg1:T8 Arg2:T9
13,T10,Measurement 184 201	Oxygen saturation
14,T11,Value 202 207	< 90%
15,R5,Has_value Arg1:T10 Arg2:T11
0,T1,Condition 0 18	Operative findings
1,T2,Negation 19 22	not
2,T3,Mood 23 33	suggestive
3,R1,Has_negation Arg1:T3 Arg2:T2
4,T4,Condition 37 55	endometriotic cyst
5,R2,AND Arg1:T1 Arg2:T4
6,R3,Has_mood Arg1:T4 Arg2:T3
7,T5,Condition 57 74	Contraindications
8,T6,Drug 78 90	progestogens
9,T7,Drug 94 118	oral contraceptive pills
10,*,OR T6 T7
11,T8,Scope 78 118	progestogens or oral contraceptive pills
12,R4,Has_scope Arg1:T5 Arg2:T8
13,T9,Condition 146 168	menstrual irregularity
14,T10,Mood 120 145	Unwillingness to tolerate
15,R5,Has_mood Arg1:T9 Arg2:T10
16,T11,Mood 170 178	Planning
17,T12,Condition 179 188	pregnancy
18,T13,Temporal 189 212	within 2 years of study
19,R6,Has_temporal Arg1:T12 Arg2:T13
20,R7,Has_mood Arg1:T12 Arg2:T11
21,T14,"Non-query-able 214 263	Cannot understand English, Cantonese or Putonghua"
0,T1,Person 0 3	Age
1,T2,Value 4 21	less than 18 year
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 36 52	arterial disease
4,T4,Qualifier 24 35	Significant
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Measurement 54 83	Ankle Brachial Pressure Index
7,T6,Value 84 88	<0•9
8,T7,Procedure 104 119	Arterial Duplex
9,R3,AND Arg1:T7 Arg2:T3
10,R4,Has_value Arg1:T5 Arg2:T6
11,*,OR T7 T5
12,T8,Condition 122 148	Acute Deep Vein Thrombosis
13,T9,Post-eligibility 150 219	Patient unable or unwilling to have high compression (30mmHg minimum)
14,T10,Condition 235 267	dexterity insufficiency of hands
15,T11,Condition 283 304	peripheral neuropathy
16,T12,Condition 306 316	Leg ulcers
17,T13,Condition 328 344	underlying cause
18,T14,Qualifier 320 327	another
19,R5,Has_qualifier Arg1:T13 Arg2:T14
20,R6,AND Arg1:T12 Arg2:T13
21,T15,Condition 346 356	Leg ulcers
22,T16,Temporal 360 388	greater than 1 year duration
23,R7,Has_temporal Arg1:T15 Arg2:T16
24,T17,"Post-eligibility 390 455	Patients unable or unwilling to provide written, informed consent"
0,T1,Person 0 3	Age
1,T2,Value 4 17	>18 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 31 43	surface area
4,T4,Value 19 30	1cm squared
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 45 64	Venous incompetence
7,T6,Procedure 78 97	clinical assessment
8,T7,Procedure 102 124	duplex ultrasound scan
9,T8,Scope 78 124	clinical assessment and duplex ultrasound scan
10,R3,AND Arg1:T8 Arg2:T5
11,T9,Condition 141 157	arterial disease
12,T10,Negation 126 128	No
13,R4,Has_negation Arg1:T9 Arg2:T10
14,T11,Procedure 159 174	Arterial Duplex
15,T12,Measurement 178 207	Ankle Brachial Pressure Index
16,T13,Value 208 212	>0.9
17,R5,Has_value Arg1:T12 Arg2:T13
18,*,OR T11 T12
19,T14,Scope 159 212	Arterial Duplex or Ankle Brachial Pressure Index >0.9
20,R6,AND Arg1:T14 Arg2:T9
21,T15,Post-eligibility 215 257	Patients able to complete trial procedures
22,T16,Observation 275 290	life expectancy
23,T17,Value 294 313	greater than 1 year
24,R7,Has_value Arg1:T16 Arg2:T17
0,T1,Condition 0 19	Good general health
1,T2,Value 21 56	Older than the age of legal consent
2,T3,Person 36 39	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Value 63 75	18 years old
5,R2,Subsumes Arg1:T2 Arg2:T4
6,T5,Procedure 78 89	Sonographic
7,T6,Condition 103 123	ovarian endometrioma
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Qualifier 129 150	diameter at least 4cm
10,T8,Multiplier 154 170	2 separate scans
11,T9,Temporal 171 193	at least 6 weeks apart
12,R6,Has_qualifier Arg1:T6 Arg2:T7
13,T10,Scope 78 150	Sonographic diagnosis of ovarian endometrioma with diameter at least 4cm
14,R4,Has_multiplier Arg1:T5 Arg2:T8
15,R5,Has_temporal Arg1:T8 Arg2:T9
16,T11,Negation 195 197	No
17,T12,Condition 198 214	contraindication
18,T13,Drug 225 237	progesterone
19,T14,Drug 241 274	combined oral contraceptive pills
20,*,OR T13 T14
21,R7,Has_negation Arg1:T12 Arg2:T11
22,T15,Scope 225 274	progesterone or combined oral contraceptive pills
23,R8,Has_scope Arg1:T12 Arg2:T15
24,T16,Mood 280 290	attempting
25,T17,Procedure 294 302	conceive
26,R9,Has_mood Arg1:T17 Arg2:T16
27,T18,Temporal 310 336	at the time of study entry
28,T19,Temporal 340 374	for at least 2 years after surgery
29,*,OR T18 T19
30,T20,Scope 310 374	at the time of study entry or for at least 2 years after surgery
31,T21,Negation 276 279	Not
32,R10,Has_negation Arg1:T16 Arg2:T21
33,R11,Has_scope Arg1:T17 Arg2:T20
34,T22,Non-query-able 376 442	Willing and able to participate after the study has been explained
0,T1,Qualifier 366 371	acute
1,T2,Condition 372 398	non-specific low back pain
2,T3,Procedure 424 445	physical examinations
3,T4,Observation 412 419	history
4,T5,Scope 412 445	history and physical examinations
5,R1,Has_scope Arg1:T2 Arg2:T5
6,R2,Has_qualifier Arg1:T2 Arg2:T1
7,T6,Non-representable 0 129	All subjects underwent a detailed history and systemic physical examination including neurologic and musculoskeletal evaluations.
8,T7,Procedure 214 234	complete blood count
9,T8,Procedure 239 260	acute phase reactants
10,T9,Procedure 262 292	erythrocyte sedimentation rate
11,T10,Procedure 297 315	C-reactive protein
12,T11,Scope 262 315	erythrocyte sedimentation rate and C-reactive protein
13,R3,Subsumes Arg1:T8 Arg2:T11
14,T12,Procedure 176 203	diagnostic laboratory tests
15,T13,Condition 562 566	pain
16,T14,Qualifier 574 618	area between the 12th rib and buttock crease
17,T15,Condition 627 635	leg pain
18,T16,Negation 619 626	without
19,R4,Has_negation Arg1:T15 Arg2:T16
20,R5,Has_qualifier Arg1:T13 Arg2:T14
21,R6,AND Arg1:T13 Arg2:T15
22,T17,Person 637 643	Female
23,T18,Person 647 651	male
24,T19,Value 653 666	20 - 80 years
25,T20,Person 670 673	age
26,R7,Has_value Arg1:T20 Arg2:T19
27,T21,Condition 675 688	Low back pain
28,T22,Temporal 692 721	less than six weeks' duration
29,R8,Has_temporal Arg1:T21 Arg2:T22
30,T23,Value 727 744	at least moderate
31,T24,Measurement 745 759	pain intensity
32,T25,Measurement 761 764	NRS
33,T26,Value 772 773	4
34,R9,Has_value Arg1:T25 Arg2:T26
35,R10,Has_value Arg1:T24 Arg2:T23
36,T27,Scope 727 759	at least moderate pain intensity
37,T28,Scope 761 773	NRS<U+2267>4
38,R11,Subsumes Arg1:T27 Arg2:T28
0,T1,Condition 0 8	Pregnant
1,T2,"Post-eligibility 11 127	Not have informed consent for the present clinical trial, or do not fully understand the meaning of informed consent"
2,T3,Condition 135 162	acute myocardial infarction
3,T4,Condition 168 188	ST segment elevation
4,T5,Temporal 189 237	in the first 12 hours from the onset of symptoms
5,T6,Reference_point 216 237	the onset of symptoms
6,R1,Has_index Arg1:T5 Arg2:T6
7,R2,AND Arg1:T3 Arg2:T4
8,R3,Has_temporal Arg1:T3 Arg2:T5
9,T7,Condition 249 272	acute coronary syndrome
10,T8,Condition 290 311	acute pulmonary edema
11,T9,Condition 313 330	cardiogenic shock
12,T10,Condition 350 373	ventricular arrhythmias
13,T11,Qualifier 340 349	malignant
14,R4,Has_qualifier Arg1:T10 Arg2:T11
15,*,OR T8 T9 T10
16,T12,"Scope 290 374	acute pulmonary edema, cardiogenic shock and / or malignant ventricular arrhythmias."
17,R5,Has_scope Arg1:T7 Arg2:T12
18,T13,Procedure 387 410	cardiac catheterization
19,T14,Qualifier 451 458	femoral
20,T15,Qualifier 460 468	brachial
21,T16,Qualifier 472 477	ulnar
22,*,OR T14 T15 T16
23,T17,"Scope 451 477	femoral, brachial or ulnar"
24,R6,Has_scope Arg1:T13 Arg2:T17
25,T18,Non-query-able 480 615	Patients in whom first attempt of arterial puncture is performed by 2nd year interventional cardiology fellow or by physician in charge
26,T19,Non-query-able 618 657	Participating in another clinical trial
27,T20,Condition 663 671	allergic
28,T21,Drug 701 714	nitroglycerin
29,T22,Drug 724 732	nitrates
30,*,OR T21 T22
31,T23,Scope 701 732	nitroglycerin or other nitrates
32,T24,Condition 680 697	contraindications
33,*,OR T20 T24
34,T25,Scope 663 697	allergic or have contraindications
35,R7,Has_scope Arg1:T25 Arg2:T23
36,T26,Drug 739 768	phosphodiesterase 5 inhibitor
37,T27,Drug 770 780	sildenafil
38,T28,Drug 782 791	tadalafil
39,T29,Drug 793 801	avanafil
40,T30,Drug 803 813	vardenafil
41,*,OR T27 T28 T29 T30
42,T31,"Scope 770 814	sildenafil, tadalafil, avanafil, vardenafil)"
43,R8,Subsumes Arg1:T26 Arg2:T31
44,T32,Temporal 830 864	within 72 hours prior to the study
45,T33,Reference_point 859 864	study
46,R9,Has_index Arg1:T32 Arg2:T33
47,R10,Has_temporal Arg1:T26 Arg2:T32
0,T1,Condition 7 29	consumption of alcohol
1,T2,Condition 37 42;7 21	drugs consumption of
2,T3,Qualifier 0 6	Active
3,*,OR T2 T1
4,T4,Scope 7 42	consumption of alcohol and/or drugs
5,R1,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Condition 62 90	human immunodeficiency virus
7,T6,Condition 92 109	hepatitis C virus
8,T7,Condition 114 131	hepatitis D virus
9,*,OR T6 T7 T5
10,T8,Condition 144 164	autoimmune hepatitis
11,T9,Condition 166 185	Psychiatric disease
12,T10,Condition 199 218	neoplastic diseases
13,T11,Qualifier 226 231	liver
14,R2,Has_qualifier Arg1:T10 Arg2:T11
0,T1,Condition 0 27	Acute Myocardial Infarction
1,T2,Procedure 39 81	Primary percutaneous coronary intervention
0,T1,Condition 11 39	Non-proteinuric hypertension
1,T2,Person 0 5	Women
2,T3,Qualifier 41 47	severe
3,T4,Condition 48 64	renal impairment
4,R1,Has_qualifier Arg1:T4 Arg2:T3
5,T5,Condition 66 83	Myasthenia gravis
6,T6,Value 85 96	High amount
7,T7,Measurement 100 118	magnesium in blood
8,R2,Has_value Arg1:T7 Arg2:T6
9,T8,Value 120 123;132 138	Low amount
10,T9,Value 127 138	high amount
11,T10,Measurement 142 158	calcium in blood
12,T11,Scope 120 138	Low or high amount
13,*,OR T8 T9
14,R3,Has_scope Arg1:T10 Arg2:T11
15,T12,Condition 160 177	Myocardial damage
16,T13,Condition 179 192	diabetic coma
17,T14,Condition 194 205	heart block
18,*,OR T13 T14 T12
0,T1,Observation 9 33	admitted to the hospital
1,T2,Condition 56 73	medical illnesses
2,T3,Qualifier 48 55	chronic
3,T4,Qualifier 39 44	acute
4,T5,Scope 39 55	acute or chronic
5,R1,Has_scope Arg1:T2 Arg2:T5
6,T6,Condition 104 120	surgical illness
7,T7,Condition 124 130	trauma
8,T8,Qualifier 94 103	emergency
9,T9,Qualifier 81 89	elective
10,T10,Scope 81 103	elective and emergency
11,T11,Grammar_Error 90 93	and
12,*,OR T8 T9
13,*,OR T3 T4
14,T12,Scope 104 130	surgical illness or trauma
15,*,OR T7 T6
16,R2,Has_scope Arg1:T12 Arg2:T10
17,*,OR T2 T12
18,R3,AND Arg1:T1 Arg2:T2
19,R4,Has_scope Arg1:T1 Arg2:T12
20,T13,Condition 149 173	Type 2 diabetes mellitus
21,T14,Value 178 187	>3 months
22,R5,Has_value Arg1:T13 Arg2:T14
23,T15,Procedure 209 213	diet
24,T16,Drug 240 264	oral antidiabetic agents
25,T17,Drug 293 300	insulin
26,T18,Drug 266 289;301 308	non-insulin injectables therapy
27,*,OR T16 T18 T17 T15
28,T19,Measurement 310 330	Blood glucose levels
29,T20,Value 339 361	>140 mg and <400 mg/dL
30,T21,Negation 362 369	without
31,T22,Qualifier 370 389	laboratory evidence
32,T23,Condition 393 414	diabetic ketoacidosis
33,R6,Has_qualifier Arg1:T23 Arg2:T22
34,R7,Has_negation Arg1:T23 Arg2:T21
35,R8,Has_value Arg1:T19 Arg2:T20
0,T1,Condition 0 43	Human immunodeficiency virus (HIV)-infected
1,T2,Temporal 45 53	Baseline
2,T3,Procedure 54 62	serology
3,T4,Value 72 83	nonreactive
4,T5,Measurement 84 92	RPR test
5,R1,Has_value Arg1:T5 Arg2:T4
6,R2,AND Arg1:T3 Arg2:T5
7,R3,Has_temporal Arg1:T3 Arg2:T2
8,T6,Observation 94 117	follow-up is inadequate
9,T7,Condition 119 127	Allergic
10,T8,Drug 131 141	penicillin
11,R4,AND Arg1:T7 Arg2:T8
12,T9,Condition 143 151	Pregnant
13,T10,Person 152 157	woman
0,T1,Procedure 0 17	Emergency surgery
1,T2,Visit 0 9	Emergency
2,R1,multi Arg1:T1 Arg2:T2
3,T3,Procedure 19 44	Monitored Anesthesia Care
4,T4,Procedure 52 71	regional anesthesia
5,T5,Multiplier 72 77	alone
6,T6,Negation 78 85	without
7,T7,Mood 86 95	plans for
8,T8,Procedure 96 114	general anesthesia
9,R2,Has_mood Arg1:T8 Arg2:T7
10,R3,Has_negation Arg1:T8 Arg2:T6
11,R4,Has_multiplier Arg1:T4 Arg2:T5
12,R5,AND Arg1:T4 Arg2:T8
13,T9,Scope 52 114	regional anesthesia alone without plans for general anesthesia
14,R6,Subsumes Arg1:T3 Arg2:T9
15,T10,Procedure 117 124	Surgery
16,T11,Qualifier 139 142	eye
17,T12,Qualifier 144 151	eyebrow
18,T13,Qualifier 153 161	forehead
19,T14,Qualifier 166 179	frontal scalp
20,T15,Non-representable 180 205	near the sensor placement
21,*,OR T13 T14 T12 T11
22,T16,"Scope 139 179	eye, eyebrow, forehead, or frontal scalp"
23,R7,Has_scope Arg1:T10 Arg2:T16
24,T17,Observation 207 227	Poor health literacy
25,T18,Condition 229 236	Allergy
26,T19,Condition 262 275	drug reaction
27,T20,Drug 279 287	ketamine
28,*,OR T18 T19
29,T21,"Scope 229 275	Allergy, or have experienced any drug reaction"
30,R8,AND Arg1:T21 Arg2:T20
31,T22,Condition 289 297	Pregnant
32,T23,Condition 301 310	lactating
33,*,OR T22 T23
34,T24,Qualifier 325 331	active
35,T25,Condition 332 350	alcohol withdrawal
36,R9,Has_qualifier Arg1:T25 Arg2:T24
37,T26,Temporal 312 321	Currently
38,R10,Has_temporal Arg1:T25 Arg2:T26
0,T1,Condition 27 43	spinal pathology
1,T2,Device 48 63	spinal implants
2,T3,Qualifier 19 26	serious
3,T4,Mood 9 18	suspected
4,T5,Mood 0 5	Known
5,*,OR T4 T5
6,*,OR T1 T2
7,R1,Has_qualifier Arg1:T1 Arg2:T3
8,T6,Scope 19 63	serious spinal pathology and spinal implants
9,T7,Mood 0 18	Known or suspected
10,R2,Has_mood Arg1:T6 Arg2:T7
11,T8,Procedure 65 86	Lumbar spinal surgery
12,T9,Temporal 87 118	within the preceding six months
13,R3,Has_temporal Arg1:T8 Arg2:T9
14,T10,Qualifier 120 127	Serious
15,T11,Condition 128 141	comorbidities
16,T12,Condition 142 152	preventing
17,T13,Drug 169 180	paracetamol
18,R4,AND Arg1:T12 Arg2:T13
19,R5,Has_qualifier Arg1:T11 Arg2:T10
20,R6,AND Arg1:T11 Arg2:T12
21,T14,Qualifier 182 193	Alternative
22,T15,Procedure 194 203	treatment
23,T16,Condition 208 221	low back pain
24,T17,Temporal 222 243	in previous two weeks
25,R7,Has_temporal Arg1:T16 Arg2:T17
26,R8,Has_qualifier Arg1:T15 Arg2:T14
27,R9,AND Arg1:T15 Arg2:T16
28,T18,Condition 245 272	Chronic neurological lesion
29,T19,Condition 274 304	Chronic musculoskeletal lesion
30,T20,Condition 313 319	cancer
31,T21,Qualifier 306 312	Active
32,R10,Has_qualifier Arg1:T20 Arg2:T21
33,T22,Condition 321 330	Pregnancy
34,T23,Drug 339 354	pain medication
35,T24,Negation 356 362	except
36,T25,Drug 363 374	paracetamol
37,R11,Has_negation Arg1:T25 Arg2:T24
38,R12,AND Arg1:T23 Arg2:T25
39,T26,Temporal 376 389	within 3 days
40,R13,Has_temporal Arg1:T23 Arg2:T26
41,T27,Condition 417 428	skin lesion
42,T28,Condition 432 444	inflammation
43,T29,Qualifier 410 416	active
44,*,OR T27 T28
45,T30,Scope 417 444	skin lesion or inflammation
46,R14,Has_qualifier Arg1:T30 Arg2:T29
47,T31,Condition 452 459	allergy
48,T32,Device 463 473	skin patch
49,R15,AND Arg1:T31 Arg2:T32
0,T1,Person 0 3	Men
1,T2,Person 8 13	women
2,T3,Person 28 33	years
3,*,OR T1 T2
4,T4,Value 14 27	older than 18
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Mood 35 44	scheduled
7,T6,Procedure 72 90	coronary procedure
8,R2,Has_mood Arg1:T6 Arg2:T5
9,T7,"Visit 128 181	the National Institute of Cardiology ""Ignacio Chavez"""
10,R3,AND Arg1:T6 Arg2:T10
11,T8,Procedure 239 262	cardiac catheterization
12,T9,Condition 223 234	indications
13,R4,AND Arg1:T9 Arg2:T8
14,T10,Visit 98 124	department of hemodynamics
15,R5,AND Arg1:T10 Arg2:T7
16,T11,Condition 264 277	Thoracic pain
17,T12,Qualifier 291 297	Stable
18,T13,Condition 298 322	chronic coronary disease
19,R6,Has_qualifier Arg1:T13 Arg2:T12
20,T14,Condition 324 351	Acute myocardial infarction
21,T15,Condition 357 377	ST segment elevation
22,T16,Procedure 408 427	reperfusion therapy
23,T17,Qualifier 401 407	timely
24,T18,Negation 393 400	without
25,R7,Has_qualifier Arg1:T16 Arg2:T17
26,R8,Has_negation Arg1:T16 Arg2:T18
27,T19,Temporal 429 464	with less than 4 weeks of evolution
28,T20,Reference_point 455 464	evolution
29,R9,Has_index Arg1:T19 Arg2:T20
30,R10,Has_temporal Arg1:T16 Arg2:T19
31,T21,Condition 466 493	Acute myocardial infarction
32,T22,Condition 499 519	ST-segment elevation
33,R11,AND Arg1:T14 Arg2:T15
34,T23,Procedure 532 552	thrombolytic therapy
35,T24,Qualifier 521 531	successful
36,R12,Has_qualifier Arg1:T23 Arg2:T24
37,R13,AND Arg1:T14 Arg2:T16
38,R14,AND Arg1:T21 Arg2:T22
39,T25,Mood 560 572	will undergo
40,T26,Procedure 573 594	drug-invasive therapy
41,R15,AND Arg1:T21 Arg2:T23
42,R16,AND Arg1:T21 Arg2:T26
43,R17,Has_mood Arg1:T26 Arg2:T25
44,T27,Condition 596 623	Acute myocardial infarction
45,T28,Negation 624 631	without
46,T29,Condition 632 652	ST segment elevation
47,R18,AND Arg1:T27 Arg2:T29
48,R19,Has_negation Arg1:T29 Arg2:T28
49,T30,Condition 654 669	Unstable angina
50,T31,Condition 675 698	acute coronary syndrome
51,T32,Procedure 703 712	intervene
52,T33,Qualifier 733 739	artery
53,T34,Qualifier 713 732	non-infarct-related
54,R20,Has_qualifier Arg1:T33 Arg2:T34
55,R21,Has_qualifier Arg1:T32 Arg2:T33
56,R22,AND Arg1:T31 Arg2:T32
57,T35,Condition 741 748	Disease
58,T36,Qualifier 756 767	heart valve
59,R23,Has_qualifier Arg1:T35 Arg2:T36
60,T37,Condition 769 780	Myocarditis
61,T38,Condition 784 796	pericarditis
62,T39,Condition 806 820	cardiomyopathy
63,T40,Qualifier 798 805	Dilated
64,R24,Has_qualifier Arg1:T39 Arg2:T40
65,T41,Condition 843 866	cardiac transplantation
66,T42,Condition 834 839;851 866	renal transplantation
67,*,OR T41 T42 T37 T38 T35 T11 T13 T14 T21 T27 T30 T31 T39 T43
68,T43,Condition 894 918	Congenital heart disease
69,T44,Qualifier 933 961	knowing the coronary anatomy
70,T45,Temporal 962 991	prior to surgical correction.
71,R25,Has_qualifier Arg1:T43 Arg2:T44
72,R26,Has_temporal Arg1:T43 Arg2:T45
73,T46,Reference_point 971 990	surgical correction
74,R27,Has_index Arg1:T45 Arg2:T46
75,T47,Procedure 1005 1014	procedure
76,T48,Qualifier 1048 1058	diagnostic
77,T49,Procedure 1069 1089	coronary angiography
78,T50,Qualifier 1090 1094	only
79,T51,Procedure 1096 1116	left catheterization
80,T52,Procedure 1118 1122;1133 1148	left catheterization
81,T53,Procedure 1127 1148	right catheterization
82,T54,Scope 1118 1148	left and right catheterization
83,R28,Has_qualifier Arg1:T49 Arg2:T50
84,T55,Procedure 1069 1089	coronary angiography
85,T56,Procedure 1069 1089	coronary angiography
86,R29,AND Arg1:T56 Arg2:T51
87,R30,Has_scope Arg1:T55 Arg2:T54
88,*,OR T55 T56 T49
89,T57,"Scope 1069 1148	coronary angiography only, left catheterization, left and right catheterization"
90,R31,Has_qualifier Arg1:T57 Arg2:T48
91,T58,Qualifier 1155 1166	therapeutic
92,T59,"Scope 264 990	Thoracic pain under study. Stable chronic coronary disease. Acute myocardial infarction with ST segment elevation, not perfused (without timely reperfusion therapy) with less than 4 weeks of evolution. Acute myocardial infarction with ST-segment elevation, successful thrombolytic therapy, which will undergo drug-invasive therapy. Acute myocardial infarction without ST segment elevation. Unstable angina. Any acute coronary syndrome, to intervene non-infarct-related artery. Disease of any heart valve. Myocarditis or pericarditis. Dilated cardiomyopathy. Patients in renal or cardiac transplantation protocol for any etiology. Congenital heart disease that requires knowing the coronary anatomy prior to surgical correction"
93,R32,Subsumes Arg1:T9 Arg2:T59
94,T60,Procedure 1177 1211	percutaneous coronary intervention
95,T61,Procedure 1213 1216	PCI
96,T62,Procedure 1235 1250	stent placement
97,A1,Optional T62
98,R33,Subsumes Arg1:T60 Arg2:T61
99,R34,Has_qualifier Arg1:T60 Arg2:T58
100,R35,AND Arg1:T60 Arg2:T62
101,*,OR T57 T60
102,T63,"Scope 1048 1250	diagnostic purposes (coronary angiography only, left catheterization, left and right catheterization). For therapeutic purposes: percutaneous coronary intervention (PCI), with or without stent placement"
103,R36,Subsumes Arg1:T47 Arg2:T63
104,T64,Procedure 1262 1268	access
105,T65,Qualifier 1255 1261	priori
106,R37,Has_qualifier Arg1:T64 Arg2:T65
107,T66,Qualifier 1286 1304	left radial artery
108,T67,Qualifier 1277 1282;1291 1304	right radial artery
109,*,OR T66 T67
110,T68,Scope 1277 1304	right or left radial artery
111,R38,Has_scope Arg1:T64 Arg2:T68
112,T69,Condition 1323 1328	pulse
113,T70,Qualifier 1307 1322	Radial arterial
114,R39,Has_qualifier Arg1:T69 Arg2:T70
115,T71,Measurement 1357 1366	palpation
116,T72,Value 1347 1353	absent
117,T73,Value 1336 1343	present
118,*,OR T72 T73
119,T74,Scope 1336 1353	present or absent
120,R40,Has_scope Arg1:T71 Arg2:T74
121,R41,AND Arg1:T69 Arg2:T71
122,T75,Measurement 1369 1383;1395 1399	Modified Allen test
123,T76,Measurement 1387 1399	Barbeau test
124,*,OR T76 T75
125,T77,Value 1410 1418	positive
126,T78,Scope 1369 1399	Modified Allen or Barbeau test
127,R42,Has_value Arg1:T78 Arg2:T77
128,T79,Condition 1432 1454	collateral palmar flow
129,T80,Qualifier 1420 1428	presence
130,R43,Has_qualifier Arg1:T79 Arg2:T80
0,T1,Condition 10 24	HBeAg positive
1,T2,Condition 0 5;16 24	HBsAg positive
2,T3,Temporal 25 47	for more than 6 months
3,*,OR T2 T1 T5 T11
4,T4,Scope 0 24	HBsAg and HBeAg positive
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Condition 49 67	HBV DNA detectable
7,T6,Measurement 73 82	ALT level
8,T7,Value 83 91	abnormal
9,R2,Has_value Arg1:T6 Arg2:T7
10,T8,Temporal 92 115	lasted for three months
11,T9,Temporal 120 133	at least time
12,T10,Value 133 141	190 IU/L
13,R3,Has_temporal Arg1:T7 Arg2:T8
14,R4,Has_value Arg1:T6 Arg2:T10
15,R5,Has_temporal Arg1:T10 Arg2:T9
16,T11,Procedure 145 166	liver puncture biopsy
17,T12,Condition 189 201	inflammation
18,T13,Negation 203 208	never
19,T14,Procedure 209 216	treated
20,T15,Temporal 217 232	before enrolled
21,R6,Has_temporal Arg1:T14 Arg2:T15
22,T16,Reference_point 224 232	enrolled
23,T17,Procedure 224 232	enrolled
24,R7,multi Arg1:T16 Arg2:T17
25,R8,Has_index Arg1:T15 Arg2:T16
26,R9,Has_negation Arg1:T14 Arg2:T13
27,R10,AND Arg1:T11 Arg2:T12
28,R11,AND Arg1:T5 Arg2:T6
29,R12,AND Arg1:T12 Arg2:T14
0,T1,Condition 24 40	hypersensitivity
1,T2,Condition 44 60	contraindication
2,T4,Drug 98 105	Heparin
3,T3,Drug 107 114	Aspirin
4,T5,Drug 116 127	Clopidogrel
5,T6,Drug 129 139	Cilostazol
6,*,OR T4 T3 T5 T6
7,*,OR T1 T2
8,T7,Scope 24 60	hypersensitivity or contraindication
9,T8,"Scope 98 139	Heparin, Aspirin, Clopidogrel, Cilostazol"
10,R1,Has_scope Arg1:T7 Arg2:T8
11,T9,Qualifier 141 153	Uncontrolled
12,T10,Condition 154 166	hypertension
13,R2,Has_qualifier Arg1:T10 Arg2:T9
14,T11,Condition 179 197	bleeding diathesis
15,T12,Observation 168 175	History
16,R3,Has_temporal Arg1:T11 Arg2:T12
17,T13,Condition 207 219	coagulopathy
18,*,OR T11 T13 T15
19,T14,Condition 231 263	heparin-induced thrombocytopenia
20,R4,Subsumes Arg1:T13 Arg2:T14
21,T15,Observation 269 295	refuses blood transfusions
22,T16,Procedure 277 295	blood transfusions
23,R5,multi Arg1:T15 Arg2:T16
24,T17,Procedure 307 315	hemogram
25,T18,Temporal 298 306	Baseline
26,R6,Has_temporal Arg1:T17 Arg2:T18
27,T19,Measurement 321 323	Hb
28,T20,Value 323 330	<10g/dL
29,R7,Has_value Arg1:T19 Arg2:T20
30,T21,Measurement 334 343	PLT count
31,T22,"Value 343 354	<100,000/μL"
32,R8,Has_value Arg1:T21 Arg2:T22
33,*,OR T19 T21
34,T23,"Scope 321 354	Hb<10g/dL or PLT count<100,000/μL"
35,R9,Has_scope Arg1:T17 Arg2:T23
36,T24,Drug 380 388	warfarin
37,T25,Drug 390 400	cilostazol
38,*,OR T24 T25 T26
39,T26,Drug 422 442	anti-platelet agents
40,T27,Drug 450 457	aspirin
41,T28,Drug 462 473	clopidogrel
42,*,OR T27 T28
43,T29,Negation 443 449	except
44,T30,Scope 450 473	aspirin and clopidogrel
45,R10,Has_negation Arg1:T30 Arg2:T29
46,R11,Has_scope Arg1:T26 Arg2:T30
47,T31,Condition 495 517	genitourinary bleeding
48,T32,Condition 475 491;509 517	Gastrointestinal bleeding
49,*,OR T32 T31
50,T33,Temporal 518 543	within the prior 3 months
51,T34,Scope 475 517	Gastrointestinal or genitourinary bleeding
52,R12,Has_temporal Arg1:T34 Arg2:T33
53,T35,Procedure 548 561	major surgery
54,T36,Temporal 562 577	within 2 months
55,R13,Has_temporal Arg1:T35 Arg2:T36
56,*,OR T34 T35
57,T37,Condition 580 589	Pregnancy
0,T1,Condition 21 40	otolaryngeal cancer
1,T2,Temporal 45 55	undergoing
2,T3,Procedure 56 63	surgery
3,T4,Procedure 69 87	general anesthesia
4,R1,AND Arg1:T3 Arg2:T4
5,R2,Has_temporal Arg1:T3 Arg2:T2
6,*,OR T1 T3
7,T5,Informed_consent 89 126	Competent to provide informed consent
0,T1,Not_a_criteria 0 2	NA
0,T1,Condition 0 8	Pregnant
1,T2,Person 9 14	women
2,T3,Procedure 15 26	admitted to
3,T4,Visit 27 48	Women health hospital
4,T5,Qualifier 69 75	severe
5,T6,Condition 76 89	pre-eclampsia
6,R1,Has_qualifier Arg1:T6 Arg2:T5
7,R2,AND Arg1:T3 Arg2:T4
0,T1,Condition 0 14	Early Syphilis
1,T2,Qualifier 38 46	Serofast
2,T3,Temporal 50 82	6 Months after Initial Treatment
3,T4,Reference_point 65 82	Initial Treatment
4,T5,Procedure 73 82	Treatment
5,R1,Has_index Arg1:T3 Arg2:T4
6,R2,multi Arg1:T4 Arg2:T5
7,T6,Multiplier 65 72	Initial
8,R3,Has_multiplier Arg1:T5 Arg2:T6
9,R4,Has_temporal Arg1:T2 Arg2:T3
10,R5,Has_qualifier Arg1:T1 Arg2:T2
0,T1,Non-query-able 0 29	Non-English speaking patients
1,T2,Pregnancy_considerations 31 132	Pregnant women (women of childbearing potential will be advised to undergo regular pregnancy testing)
2,T3,Competing_trial 134 207	Patients who had previously undergone operative therapy for the condition
0,T1,Person 19 24	years
1,T2,Value 16 18;25 33	18 or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 74 93	adhesive capsulitis
4,T4,Measurement 112 151	American Academy of Orthopedic Surgeons
5,R2,AND Arg1:T4 Arg2:T3
6,T5,"Non-query-able 153 353	Self-limiting condition resulting from any inflammatory process about the shoulder in which capsular scar tissue is produced, resulting in pain and limited range of motion; also called frozen shoulder"
7,T6,Post-eligibility 355 407	Must be amenable to randomization into either cohort
0,T1,Condition 4 12	pregnant
1,T2,Condition 16 25	lactating
2,*,OR T1 T2
3,T3,Observation 28 101	Have participated in any other studies involving investigational products
4,T4,Temporal 102 147	within 30 days prior to entry into this study
5,T5,Reference_point 126 146	entry into this stud
6,R1,Has_index Arg1:T4 Arg2:T5
7,R2,Has_temporal Arg1:T3 Arg2:T4
8,T6,Condition 168 193	acute withdrawal syndrome
9,T7,Drug 199 204	drugs
10,T8,Drug 208 215	alcohol
11,*,OR T7 T8
12,T9,Scope 199 215	drugs or alcohol
13,R3,Has_scope Arg1:T6 Arg2:T9
14,T10,Condition 246 259	Schizophrenia
15,T11,Condition 261 285	Schizoaffective Disorder
16,T12,Condition 287 312	Schizophreniform Disorder
17,T13,Condition 316 334	Bipolar I Disorder
18,*,OR T10 T11 T12 T13
19,T14,Non-query-able 488 671	Have an unstable medical disorder as determined by physical examination or laboratory testing. The primary investigator will be responsible for making this judgment based on the above
20,T15,Non-query-able 674 781	Had an unsatisfactory response to a previous adequate trial of quetiapine as judged by a study investigator
21,T17,Non-representable 894 1023	Patients who are currently receiving quetiapine therapy may not undergo a washout period and then restart quetiapine in the study
22,T18,Procedure 355 421	Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
23,T19,"Scope 246 334	Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or Bipolar I Disorder"
24,R4,Has_scope Arg1:T18 Arg2:T19
25,T16,"Non-representable 784 891	Patients cannot begin psychotherapy during the study period, but may continue if started prior to the study"
0,T1,Condition 17 30	uncooperative
1,T2,Observation 35 54	difficult to manage
2,T3,Subjective_judgement 61 66	major
3,T4,Condition 67 84	systemic diseases
4,T5,Qualifier 61 66	major
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,T6,Temporal 96 105	long-term
7,T7,Drug 106 116	medication
8,T8,Scope 17 54	uncooperative and difficult to manage
9,*,OR T4 T8 T7
10,R2,Has_temporal Arg1:T7 Arg2:T6
0,T1,"Informed_consent 0 145	Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent"
1,T2,"Pregnancy_considerations 147 223	Male or non-pregnant, non-lactating female patients at least 18 years of age"
2,T3,Qualifier 238 246	moderate
3,T4,Qualifier 250 256	severe
4,*,OR T4 T3
5,T5,Condition 257 284	Ankylosing Spondylitis (AS)
6,T6,Scope 238 256	moderate to severe
7,R1,Has_scope Arg1:T5 Arg2:T6
8,T7,Condition 307 326	radiologic evidence
9,T8,Procedure 307 317	radiologic
10,T9,Temporal 290 295	prior
11,R2,Has_temporal Arg1:T7 Arg2:T9
12,R3,multi Arg1:T7 Arg2:T8
13,T10,Measurement 342 375	Modified New York criteria for AS
14,T11,Value 327 337	fulfilling
15,R4,Has_value Arg1:T10 Arg2:T11
16,R5,AND Arg1:T7 Arg2:T10
17,R6,AND Arg1:T5 Arg2:T7
18,T12,Condition 384 386	AS
19,T13,Qualifier 377 383	Active
20,T14,Measurement 399 464	total Bath Ankylosing Spondylitis Disease Activity index (BASDAI)
21,T15,Value 465 468	= 4
22,R7,Has_value Arg1:T14 Arg2:T15
23,T16,Temporal 476 487	at baseline
24,R8,Has_temporal Arg1:T14 Arg2:T16
25,R9,Has_qualifier Arg1:T12 Arg2:T13
26,R10,AND Arg1:T12 Arg2:T14
27,T17,Condition 489 500	Spinal pain
28,T18,Measurement 516 534	BASDAI question #2
29,T19,Value 535 541	= 4 cm
30,R11,Has_value Arg1:T18 Arg2:T19
31,T20,Temporal 552 563	at baseline
32,R12,Has_temporal Arg1:T18 Arg2:T20
33,R13,AND Arg1:T17 Arg2:T18
34,T21,Measurement 596 621	visual analog scale (VAS)
35,T22,Value 622 629	= 40 mm
36,T23,Temporal 641 652	at baseline
37,R14,Has_value Arg1:T21 Arg2:T22
38,R15,Has_temporal Arg1:T21 Arg2:T23
39,T24,Condition 565 580	Total back pain
40,R16,AND Arg1:T24 Arg2:T21
41,T25,Drug 683 729	non-steroidal anti-inflammatory drugs (NSAIDs)
42,T26,Multiplier 737 759	maximum tolerated dose
43,T27,Temporal 760 810	for at least 4 weeks prior to their Baseline Visit
44,T28,Reference_point 790 810	their Baseline Visit
45,R17,Has_index Arg1:T27 Arg2:T28
46,T29,Condition 820 839	inadequate response
47,T30,Temporal 843 864	for less than 4 weeks
48,T31,Condition 868 893	withdrawn for intolerance
49,T32,Condition 868 881;895 903	withdrawn for toxicity
50,T33,Condition 907 924	contraindications
51,R18,Has_multiplier Arg1:T25 Arg2:T26
52,R19,Has_temporal Arg1:T25 Arg2:T27
53,R20,Has_temporal Arg1:T29 Arg2:T30
54,*,OR T32 T33 T31
55,T34,"Scope 868 924	withdrawn for intolerance, toxicity or contraindications"
56,A1,Optional T34
57,R21,AND Arg1:T34 Arg2:T29
58,T35,Drug 1011 1021;958 982	inhibitors Cyclooxygenase-1 (COX-1)
59,T36,Drug 986 1021	Cyclooxygenase-2 (COX-2) inhibitors
60,T37,Drug 941 947	NSAIDs
61,T38,Temporal 1022 1070	for at least 2 weeks before their Baseline Visit
62,T39,Reference_point 1050 1070	their Baseline Visit
63,R22,Has_index Arg1:T38 Arg2:T39
64,*,OR T35 T36 T37
65,T40,Scope 941 1021	NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors
66,R23,Has_temporal Arg1:T40 Arg2:T38
67,T41,Drug 1100 1144	tumor necrosis factor alpha (TNFa) inhibitor
68,T42,Multiplier 1146 1163	not more than one
69,R24,Has_multiplier Arg1:T41 Arg2:T42
70,T43,Condition 1190 1209	inadequate response
71,T44,Multiplier 1255 1268	approved dose
72,T45,Temporal 1269 1308	for at least 3 months prior to baseline
73,R25,Has_temporal Arg1:T44 Arg2:T45
74,T46,Procedure 1233 1242	treatment
75,T47,Temporal 1225 1232	current
76,T48,Temporal 1213 1221	previous
77,*,OR T47 T48
78,T49,Scope 1213 1232	previous or current
79,R26,Has_scope Arg1:T46 Arg2:T49
80,R27,AND Arg1:T43 Arg2:T46
81,R28,Has_multiplier Arg1:T46 Arg2:T44
82,T50,Condition 1321 1331	intolerant
83,T51,Drug 1358 1373	anti-TNFa agent
84,T52,Scope 1100 1164	tumor necrosis factor alpha (TNFa) inhibitor (not more than one)
85,A2,Optional T52
86,*,OR T43 T50
87,R29,AND Arg1:T50 Arg2:T51
88,T53,Scope 1190 1373	inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent
89,R30,Has_scope Arg1:T52 Arg2:T53
90,T54,Condition 1375 1403	Total ankylosis of the spine
91,T55,"Competing_trial 1405 1540	Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer."
92,T56,Condition 1553 1569	hypersensitivity
93,T57,Drug 1584 1595	study drugs
94,T58,Drug 1603 1613	excipients
95,R31,AND Arg1:T57 Arg2:T58
96,T59,Drug 1620 1653	drugs of similar chemical classes
97,*,OR T57 T59
98,T60,Scope 1584 1653	study drugs or its excipients or to drugs of similar chemical classes
99,R32,Has_scope Arg1:T56 Arg2:T60
100,T61,Procedure 1656 1667	Chest x-ray
101,T62,Procedure 1669 1702	computerized tomography (CT) scan
102,T63,Procedure 1707 1745	chest magnetic resonance imaging (MRI)
103,T64,Temporal 1763 1770	ongoing
104,T65,Condition 1771 1781	infectious
105,T66,Condition 1785 1802	malignant process
106,*,OR T65 T66
107,T67,Temporal 1813 1847	within 3 months prior to screening
108,T68,Scope 1771 1802	infectious or malignant process
109,R33,Has_temporal Arg1:T68 Arg2:T64
110,*,OR T62 T63 T61
111,T69,"Scope 1656 1745	Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI)"
112,R34,Has_scope Arg1:T69 Arg2:T68
113,R35,Has_temporal Arg1:T69 Arg2:T67
114,T70,Drug 1910 1921	secukinumab
115,T71,Drug 1935 1948	biologic drug
116,T72,Qualifier 1929 1934	other
117,R36,Has_qualifier Arg1:T71 Arg2:T72
118,*,OR T70 T71
119,T73,Drug 1968 1990	Interleukin-17 (IL-17)
120,T74,Condition 1958 1967	targeting
121,T75,Drug 1992 2020	Interleukin-12/23 (IL-12/23)
122,T76,Drug 2029 2043	IL-17 receptor
123,*,OR T73 T75 T76 T77
124,T77,Drug 2058 2089	biologic immunomodulating agent
125,T78,Negation 2091 2097	except
126,T79,Drug 2114 2118	TNFa
127,R37,Has_negation Arg1:T79 Arg2:T78
128,T80,"Scope 1968 2089	Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent"
129,R38,AND Arg1:T80 Arg2:T79
130,R39,Has_scope Arg1:T74 Arg2:T80
131,T81,Scope 1910 1948	secukinumab or any other biologic drug
132,R40,AND Arg1:T81 Arg2:T74
133,T82,Multiplier 2144 2157	more than one
134,T83,Drug 2158 2173	anti-TNFa agent
135,R41,Has_multiplier Arg1:T83 Arg2:T82
136,T84,Procedure 2208 2232	corticosteroid injection
137,T85,Qualifier 2196 2207	intravenous
138,T86,Qualifier 2179 2192	intramuscular
139,*,OR T85 T86
140,T87,Scope 2179 2207	intramuscular or intravenous
141,R42,Has_scope Arg1:T84 Arg2:T87
142,T88,Temporal 2233 2263	within 2 weeks before baseline
143,T89,Reference_point 2255 2263	baseline
144,R43,Has_index Arg1:T88 Arg2:T89
145,R44,Has_temporal Arg1:T84 Arg2:T88
146,T90,Procedure 2280 2306	intra-articular injections
147,T91,Drug 2313 2327	corticosteroid
148,T92,Temporal 2329 2359	within 4 weeks before baseline
149,R45,AND Arg1:T90 Arg2:T91
150,R46,Has_temporal Arg1:T90 Arg2:T92
151,T93,Procedure 2389 2413	cell-depleting therapies
152,T94,Temporal 2361 2369	Previous
153,R47,Has_temporal Arg1:T93 Arg2:T94
154,T95,Drug 2431 2461	high potency opioid analgesics
155,T96,Drug 2469 2478	methadone
156,T97,Drug 2480 2493	hydromorphone
157,T98,Drug 2495 2503	morphine
158,*,OR T97 T98 T96
159,T99,"Scope 2469 2503	methadone, hydromorphone, morphine"
160,R48,Subsumes Arg1:T95 Arg2:T99
0,T1,Multiplier 12 19	chronic
1,T2,Drug 20 26	statin
2,T3,Procedure 27 36	treatment
3,R1,AND Arg1:T3 Arg2:T2
4,R2,Has_multiplier Arg1:T3 Arg2:T1
5,T4,Value 38 46	>30 days
6,R3,Has_value Arg1:T3 Arg2:T4
7,T5,Procedure 71 75	CABG
8,T6,Qualifier 62 70	isolated
9,R4,Has_qualifier Arg1:T5 Arg2:T6
10,T7,Mood 48 57	scheduled
11,R5,Has_mood Arg1:T5 Arg2:T7
12,T8,Procedure 122 150	revascularisation procedures
13,T9,Qualifier 87 112	on- or off-pump or repeat
14,T10,Qualifier 114 120	redo's
15,R6,Subsumes Arg1:T9 Arg2:T10
16,R7,Has_qualifier Arg1:T8 Arg2:T9
17,R8,Subsumes Arg1:T5 Arg2:T8
18,T11,Condition 152 158;171 177	Stable angina
19,T12,Condition 162 177	unstable angina
20,*,OR T12 T11
21,T13,Condition 189 237	non ST-segment-elevation acute coronary syndrome
22,T14,Condition 239 247	NSTE-ACS
23,R9,Subsumes Arg1:T13 Arg2:T14
24,R10,Subsumes Arg1:T12 Arg2:T13
25,T15,Person 250 253	Age
26,T16,Value 254 264	= 18 years
27,R11,Has_value Arg1:T15 Arg2:T16
28,T17,Non-query-able 266 290	Written informed consent
0,T1,Condition 0 20	Inability to perform
1,T2,Procedure 21 35	exercise tests
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 62 81	cognitive disorders
4,T4,Condition 47 58;72 81	psychiatric disorders
5,*,OR T3 T4
6,T5,Condition 125 134;83 107	disorders Progressive neurological
7,T6,Condition 111 134;83 94	neuromuscular disorders Progressive
8,T7,Condition 150 177	impact on exercise capacity
9,*,OR T5 T6
10,T8,Scope 83 134	Progressive neurological or neuromuscular disorders
11,R2,AND Arg1:T8 Arg2:T7
0,T1,Person 0 15	Kindergarteners
1,T2,Person 96 114	Preschool children
2,T3,Person 115 119	aged
3,T4,Value 120 129	3-4 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Condition 139 150	tooth decay
0,T2,Person 91 94	age
1,T3,Value 83 90;95 110	between 18 and 55 years
2,R1,Has_value Arg1:T2 Arg2:T3
3,T5,Condition 243 246	BPD
4,T6,Qualifier 218 238	Meet DSM-IV criteria
5,R2,Has_qualifier Arg1:T5 Arg2:T6
6,T4,"Observation 115 152	able to speak, read and write English"
7,T8,Observation 115 122;157 183	able to follow simple instructions
8,T1,Observation 8 32	written informed consent
9,T9,Temporal 33 78	before beginning any study related activities
10,T10,Reference_point 50 78	any study related activities
11,R3,Has_index Arg1:T9 Arg2:T10
12,R4,Has_temporal Arg1:T1 Arg2:T9
13,T7,Procedure 266 338	Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II)
14,R5,AND Arg1:T7 Arg2:T5
0,T1,Condition 22 26	COPD
1,T2,Condition 31 33	HF
2,*,OR T2 T1
3,T3,Procedure 50 68	clinical treatment
4,T4,Qualifier 40 49	optimized
5,R1,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Scope 22 33	COPD and HF
7,R2,AND Arg1:T5 Arg2:T3
8,T6,Value 110 117	Reduced
9,T7,Measurement 118 152	left ventricular ejection fraction
10,T8,Value 154 158	<50%
11,R3,Has_value Arg1:T7 Arg2:T6
12,R4,Subsumes Arg1:T6 Arg2:T8
13,T9,Condition 176 194	airway obstruction
14,T10,Qualifier 161 175	Non-reversible
15,R5,Has_qualifier Arg1:T9 Arg2:T10
16,T11,Measurement 216 224	FEV1/FVC
17,T12,Qualifier 196 215	post-bronchodilator
18,R6,Has_qualifier Arg1:T11 Arg2:T12
19,T13,Value 225 230	< 0.7
20,T14,Measurement 235 239	FEV1
21,T15,Value 240 246	< 80 %
22,R7,Has_qualifier Arg1:T14 Arg2:T12
23,R8,Has_value Arg1:T14 Arg2:T15
24,R9,Has_value Arg1:T11 Arg2:T13
25,T16,Scope 196 246	post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80 %
26,T17,Scope 161 194	Non-reversible airway obstruction
27,R10,Subsumes Arg1:T17 Arg2:T16
28,T18,Condition 249 276	Respiratory muscle weakness
29,T19,"Measurement 278 284	Pi,max"
30,T20,Value 285 294	< 70cmH2O
31,R11,Has_value Arg1:T19 Arg2:T20
32,T21,Condition 308 329	dyspnea on daily life
33,T22,Temporal 297 307	Persistent
34,R12,Has_temporal Arg1:T21 Arg2:T22
35,T23,Temporal 331 339	Baseline
36,T24,Measurement 340 365	Dyspnea Index focal score
37,T25,Value 366 372	<or= 8
38,R13,Has_value Arg1:T24 Arg2:T25
39,R14,Has_temporal Arg1:T24 Arg2:T23
40,T26,Scope 331 372	Baseline Dyspnea Index focal score <or= 8
41,T27,Scope 297 329	Persistent dyspnea on daily life
42,R15,Subsumes Arg1:T27 Arg2:T26
0,T1,Procedure 16 40	cardiovascular procedure
1,T2,Procedure 44 48	CABG
2,T3,Temporal 4 15	concomitant
3,R1,Has_temporal Arg1:T1 Arg2:T3
4,R2,Has_temporal Arg1:T2 Arg2:T3
5,T4,Procedure 72 87	carotid surgery
6,T5,Procedure 62 68;80 87	aortic surgery
7,T6,Procedure 55 60;80 87	valve surgery
8,*,OR T6 T5 T4
9,T7,"Scope 55 87	valve, aortic or carotid surgery"
10,R3,Subsumes Arg1:T1 Arg2:T7
11,T8,Condition 90 138	Acute ST-segment-elevation myocardial infarction
12,T9,Condition 140 145	STEMI
13,R4,Subsumes Arg1:T8 Arg2:T9
14,T10,Condition 148 156	NSTE-ACS
15,T11,Condition 162 179	cardiogenic shock
16,T12,Procedure 200 215	salvage surgery
17,T13,Mood 180 190	warranting
18,R5,Has_mood Arg1:T12 Arg2:T13
19,T14,Temporal 216 253	within 12 hrs from hospital admission
20,T15,Reference_point 235 253	hospital admission
21,R6,Has_index Arg1:T14 Arg2:T15
22,T16,Scope 148 179	NSTE-ACS with cardiogenic shock
23,R7,AND Arg1:T16 Arg2:T12
24,R8,Has_temporal Arg1:T16 Arg2:T14
25,T17,Condition 266 285	atrial fibrillation
26,T18,Condition 289 303	muscle disease
27,T19,Condition 305 313	myopathy
28,R9,Subsumes Arg1:T18 Arg2:T19
29,*,OR T17 T18
30,T20,Measurement 331 341	creatinine
31,T21,Value 341 372	>2x upper limit of normal (ULN)
32,R10,Has_value Arg1:T20 Arg2:T21
33,T22,Procedure 374 382	dialysis
34,T23,Procedure 384 401	kidney transplant
35,*,OR T22 T23 T20
36,T24,"Scope 331 401	creatinine>2x upper limit of normal (ULN), dialysis, kidney transplant"
37,T25,Condition 324 329;414 425	renal dysfunction
38,T26,Condition 406 425	hepatic dysfunction
39,*,OR T26 T25
40,T27,Measurement 427 430	AST
41,T28,Measurement 431 434	ALT
42,T29,Value 434 441	>2x ULN
43,*,OR T27 T28
44,R11,Has_value Arg1:T28 Arg2:T29
45,R12,Has_value Arg1:T27 Arg2:T29
46,T30,Procedure 443 459	liver transplant
47,T31,Condition 463 471	neoplasm
48,*,OR T30 T31 T32
49,T32,Scope 427 441	AST/ALT>2x ULN
50,T33,"Scope 427 471	AST/ALT>2x ULN, liver transplant or neoplasm"
51,R13,Subsumes Arg1:T26 Arg2:T33
52,R14,Subsumes Arg1:T25 Arg2:T24
53,T34,Mood 474 486	Inability of
54,T35,Drug 487 496	oral drug
55,T36,Observation 487 503	oral drug intake
56,R15,multi Arg1:T36 Arg2:T35
57,T37,Negation 474 483	Inability
58,R16,multi Arg1:T34 Arg2:T37
59,R17,Has_mood Arg1:T36 Arg2:T34
0,T1,Negation 0 7	Failure
1,T2,Condition 16 31	fully recovered
2,R1,Has_negation Arg1:T2 Arg2:T1
3,T3,Value 42 76	less than or equal to [<=] Grade 1
4,T4,Measurement 77 85	toxicity
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Procedure 124 136	chemotherapy
7,T6,Scope 0 31	Failure to have fully recovered
8,T7,Scope 42 85	less than or equal to [<=] Grade 1 toxicity
9,R3,Subsumes Arg1:T6 Arg2:T7
10,R4,Has_scope Arg1:T5 Arg2:T6
11,T8,Procedure 139 152	Major surgery
12,T9,Temporal 153 185	within 14 days before enrollment
13,R5,Has_temporal Arg1:T8 Arg2:T9
14,T10,Procedure 188 200	Radiotherapy
15,T11,Temporal 201 233	within 14 days before enrollment
16,T12,Observation 242 265	involved field is small
17,A1,Optional T12
18,T13,Temporal 267 273	7 days
19,R6,Has_temporal Arg1:T12 Arg2:T13
20,*,OR T12 T11
21,T14,"Scope 201 233;242 273	within 14 days before enrollment involved field is small, 7 days"
22,R7,Has_scope Arg1:T10 Arg2:T14
23,T15,Condition 371 405	Central nervous system involvement
24,T16,Condition 408 417	Infection
25,T17,Procedure 428 455	systemic antibiotic therapy
26,T18,Qualifier 459 464	other
27,T19,Qualifier 465 472	serious
28,T20,Condition 473 482	infection
29,T21,Temporal 483 521	within 14 days before study enrollment
30,R8,Has_temporal Arg1:T20 Arg2:T21
31,R9,Has_qualifier Arg1:T20 Arg2:T19
32,R10,Has_qualifier Arg1:T20 Arg2:T18
33,R11,AND Arg1:T16 Arg2:T17
34,*,OR T16 T20
35,T22,Condition 557 582	cardiovascular conditions
36,T23,Qualifier 594 606	uncontrolled
37,T24,Condition 607 619	hypertension
38,T25,Qualifier 621 633	uncontrolled
39,T26,Condition 634 653	cardiac arrhythmias
40,T27,Qualifier 655 666	symptomatic
41,T28,Condition 667 691	congestive heart failure
42,T29,Condition 693 708	unstable angina
43,T30,Condition 713 734	myocardial infarction
44,T31,Temporal 735 759	within the past 6 months
45,R12,Has_temporal Arg1:T30 Arg2:T31
46,R13,Has_qualifier Arg1:T24 Arg2:T23
47,R14,Has_qualifier Arg1:T26 Arg2:T25
48,R15,Has_qualifier Arg1:T28 Arg2:T27
49,*,OR T24 T26 T30 T29 T28
50,T32,Qualifier 544 556	uncontrolled
51,T33,Temporal 536 543	current
52,R16,Has_qualifier Arg1:T22 Arg2:T32
53,R17,Has_temporal Arg1:T22 Arg2:T33
54,T34,"Scope 594 759	uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months"
55,T35,Scope 536 582	current uncontrolled cardiovascular conditions
56,R18,Subsumes Arg1:T35 Arg2:T34
57,T36,Procedure 762 780	Systemic treatment
58,T37,Temporal 782 830	within 14 days before the first dose of ixazomib
59,T38,Reference_point 804 830	the first dose of ixazomib
60,T39,Drug 822 830	ixazomib
61,R19,Has_index Arg1:T37 Arg2:T38
62,R20,multi Arg1:T38 Arg2:T39
63,R21,Has_temporal Arg1:T36 Arg2:T37
64,T40,Drug 837 879	strong cytochrome P450 3A (CYP3A) inducers
65,T41,Drug 881 889	rifampin
66,T42,Drug 891 902	rifapentine
67,T43,Drug 904 913	rifabutin
68,T44,Drug 915 928	carbamazepine
69,T45,Drug 930 939	phenytoin
70,T46,Drug 941 954	phenobarbital
71,*,OR T41 T42 T43 T44 T45 T46
72,T47,"Scope 881 954	rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital"
73,R22,Subsumes Arg1:T40 Arg2:T47
74,T48,Drug 967 980	Ginkgo biloba
75,T49,Drug 984 999	St. John's wort
76,*,OR T48 T49 T40
77,T50,"Scope 837 999	strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort"
78,R23,Has_scope Arg1:T36 Arg2:T50
79,T51,Qualifier 1013 1019	active
80,T52,Temporal 1002 1009	Ongoing
81,T53,Condition 1020 1038	systemic infection
82,T54,Qualifier 1040 1046	active
83,T55,Condition 1047 1058;1064 1079	hepatitis B virus infection
84,T56,Condition 1062 1079	C virus infection
85,*,OR T55 T56
86,T57,Scope 1047 1079	hepatitis B or C virus infection
87,R24,Has_qualifier Arg1:T57 Arg2:T54
88,*,OR T51 T52
89,T58,Scope 1002 1019	Ongoing or active
90,R25,Has_scope Arg1:T53 Arg2:T58
91,*,OR T53 T57 T59
92,T59,Measurement 1090 1118	human immunodeficiency virus
93,T60,Value 1119 1127	positive
94,R26,Has_value Arg1:T59 Arg2:T60
95,T61,Condition 1163 1173	malignancy
96,T62,Temporal 1174 1212	within 2 years before study enrollment
97,T63,Temporal 1216 1226	previously
98,T64,Qualifier 1242 1249	another
99,T65,Condition 1250 1260	malignancy
100,R27,Has_qualifier Arg1:T65 Arg2:T64
101,R28,Has_temporal Arg1:T61 Arg2:T62
102,R29,Has_temporal Arg1:T65 Arg2:T63
103,*,OR T61 T65
104,T66,Condition 1286 1302	residual disease
105,T67,Mood 1270 1285	any evidence of
106,R30,Has_mood Arg1:T66 Arg2:T67
107,T68,Condition 1322 1346	non-melanoma skin cancer
108,T69,Condition 1350 1367	carcinoma in situ
109,T70,Qualifier 1371 1379	any type
110,R31,Has_qualifier Arg1:T69 Arg2:T70
111,*,OR T68 T69
112,T71,Negation 1384 1396	not excluded
113,T72,Procedure 1420 1438	complete resection
114,A2,Optional T72
115,R32,Has_negation Arg1:T72 Arg2:T71
116,T73,Scope 1322 1379	non-melanoma skin cancer or carcinoma in situ of any type
117,R33,AND Arg1:T73 Arg2:T72
118,T74,Qualifier 1445 1482	greater than or equal to (>=) Grade 2
119,T75,Condition 1483 1504	peripheral neuropathy
120,R34,Has_qualifier Arg1:T75 Arg2:T74
121,T76,Qualifier 1509 1516	Grade 1
122,T77,Condition 1522 1526	pain
123,T78,Scope 1509 1526	Grade 1 with pain
124,T79,Scope 1445 1504	greater than or equal to (>=) Grade 2 peripheral neuropathy
125,*,OR T79 T78
126,T80,Drug 1581 1583	PD
127,T81,Qualifier 1587 1605	first-line therapy
128,R35,Has_qualifier Arg1:T80 Arg2:T81
129,T82,Competing_trial 1608 1661	Participation in other interventional clinical trials
130,T83,Temporal 1741 1782	within 30 days of the start of this trial
131,T84,Temporal 1787 1824	throughout the duration of this trial
132,T85,Reference_point 1759 1782	the start of this trial
133,R36,Has_index Arg1:T83 Arg2:T85
134,T86,Reference_point 1798 1824	the duration of this trial
135,R37,Has_index Arg1:T84 Arg2:T86
136,*,OR T83 T84
137,T87,Scope 1741 1824	within 30 days of the start of this trial and throughout the duration of this trial
138,R38,AND Arg1:T82 Arg2:T87
0,T1,Person 19 22	age
1,T2,Value 26 28;9 14	18 under
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-representable 29 189	(Subjects under the age of 18 will not be included in this study due to the continued growth and development of their joints and unstudied effects on children.)
4,T4,Value 191 195;207 209	Over 80
5,T5,Person 200 203	age
6,R2,Has_value Arg1:T5 Arg2:T4
7,T6,Condition 211 232	Multiple pain sources
8,T7,Condition 237 264	multifactorial pain sources
9,*,OR T6 T7
10,T8,Non-representable 265 400	that complicated or confound diagnosing the SI joint as the primary and predominant pain generator that may contribute to low back pain
11,T9,Condition 432 448	lumbar diagnosis
12,T10,Condition 450 470	lumbar radiculopathy
13,T11,Condition 481 510	extra-articular hip pathology
14,T12,Condition 472 477;486 510	intra -articular hip pathology
15,*,OR T11 T12
16,T13,Condition 522 532;570 579	acetabulum pathology
17,T14,Condition 537 549;570 579	femoral head pathology
18,T16,Condition 551 579	lumbo-sacral joint pathology
19,T15,Condition 581 608	intervertebral disk disease
20,T17,Condition 610 627	spondylolisthesis
21,T18,Condition 628 639	spondylosis
22,T19,Condition 640 672	spondylolysis of lumbar vertebra
23,*,OR T19 T18 T17 T15 T13 T14
24,T20,Scope 472 510	intra or extra-articular hip pathology
25,T21,"Scope 522 672	acetabulum and femoral head, lumbo-sacral joint pathology, intervertebral disk disease, spondylolisthesis/spondylosis/spondylolysis of lumbar vertebra"
26,R3,Subsumes Arg1:T20 Arg2:T21
27,*,OR T9 T10 T20
28,T22,Scope 211 264	Multiple pain sources and multifactorial pain sources
29,T23,"Scope 432 672	lumbar diagnosis, lumbar radiculopathy, intra or extra-articular hip pathology to include acetabulum and femoral head, lumbo-sacral joint pathology, intervertebral disk disease, spondylolisthesis/spondylosis/spondylolysis of lumbar vertebra"
30,R4,Subsumes Arg1:T22 Arg2:T23
31,T24,Condition 675 691	Immunosuppressed
32,T25,Condition 692 710	immune compromised
33,*,OR T24 T25
34,T26,Condition 712 736	Underlying comorbidities
35,T27,Qualifier 742 770	contraindicate the procedure
36,T28,Condition 742 756	contraindicate
37,T29,Procedure 761 770	procedure
38,R5,AND Arg1:T28 Arg2:T29
39,R6,Has_qualifier Arg1:T26 Arg2:T27
40,T30,Condition 801 813	polycythemia
41,T31,Condition 815 835	coagulation disorder
42,T32,Condition 840 850	malignancy
43,*,OR T32 T31 T30
44,T33,"Scope 801 850	polycythemia, coagulation disorder, or malignancy"
45,T34,Scope 712 770	Underlying comorbidities that contraindicate the procedure
46,R7,Subsumes Arg1:T34 Arg2:T33
0,T1,Condition 4 27	neurological conditions
1,T2,Condition 39 41	PD
2,T3,Negation 28 38	other than
3,R1,Has_negation Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Condition 75 99	cardiopulmonary diseases
6,T5,Condition 56 71;91 99	musculoskeletal diseases
7,*,OR T4 T5
8,T6,Qualifier 44 55	significant
9,T7,Subjective_judgement 44 55	significant
10,T8,Undefined_semantics 44 55	significant
11,T9,Scope 56 99	musculoskeletal or cardiopulmonary diseases
12,R3,Has_qualifier Arg1:T9 Arg2:T6
13,T10,Condition 108 155	disorders that may affect balance or locomotion
14,T11,Undefined_semantics 108 155	disorders that may affect balance or locomotion
15,T12,Procedure 168 178;193 210	structured exercise programs
16,T13,Procedure 168 189;202 210	structured behavioral programs
17,T14,Temporal 211 231	in the past 3 months
18,*,OR T13 T12
19,T15,Scope 168 210	structured behavioral or exercise programs
20,R4,Has_temporal Arg1:T15 Arg2:T14
21,T16,Procedure 255 286	regular physical rehabilitation
22,T17,Temporal 287 297	at present
23,R5,Has_temporal Arg1:T16 Arg2:T17
24,T18,Condition 300 318	unstable condition
25,T19,Drug 322 351	anti-parkinsonian medications
26,R6,AND Arg1:T18 Arg2:T19
27,T20,Undefined_semantics 300 351	unstable condition on anti-parkinsonian medications
28,T21,Procedure 354 383	surgical interventions for PD
29,T22,Condition 381 383	PD
30,R7,AND Arg1:T21 Arg2:T22
31,T23,Condition 403 421	cognitive deficits
32,T24,"Measurement 427 464	mini-mental state examination, (MMSE)"
33,T25,Value 465 471	<24/30
34,R8,Has_value Arg1:T24 Arg2:T25
35,T26,Condition 386 399;413 421	communication deficits
36,*,OR T23 T26
37,T27,Scope 386 421	communication or cognitive deficits
38,R9,AND Arg1:T27 Arg2:T24
39,T28,Multiplier 511 524	more than two
40,T29,Condition 525 530	falls
41,T30,Temporal 531 556	in the previous 12 months
42,T31,Observation 500 507	history
43,R10,Has_multiplier Arg1:T29 Arg2:T28
44,R11,Has_temporal Arg1:T29 Arg2:T30
45,R12,Has_temporal Arg1:T29 Arg2:T31
0,T1,Observation 0 22	French Native language
1,T2,Value 24 32;37 45	18 years or older
2,T3,Person 33 36	old
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Informed_consent 47 61	Signed consent
5,T5,Observation 63 103	Covered by the French social care system
0,T1,Condition 0 17	Contraindications
1,T2,Procedure 22 48	magnetic resonance imaging
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 50 63	Hemosiderosis
4,T4,Condition 64 79	hemochromatosis
5,*,OR T4 T3
0,T1,Qualifier 0 12	Unresectable
1,T2,Condition 39 63	hepatocellular carcinoma
2,T3,Measurement 14 28	histologically
3,T4,Value 29 38	confirmed
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,AND Arg1:T2 Arg2:T3
6,R3,Has_qualifier Arg1:T2 Arg2:T1
7,T5,Qualifier 77 101	disease limited to liver
8,R4,Has_qualifier Arg1:T2 Arg2:T5
9,T6,Procedure 291 297	biopsy
10,T7,Measurement 315 332	alpha-fetoprotein
11,T8,Value 336 358	greater than 500 ng/mL
12,R5,Has_value Arg1:T7 Arg2:T8
13,R6,Subsumes Arg1:T6 Arg2:T7
14,T9,Qualifier 589 607	measurable disease
15,T10,Procedure 618 635	radiation therapy
16,T11,Qualifier 654 672	measurable disease
17,T12,Qualifier 681 708	outside the radiation field
18,R7,Has_qualifier Arg1:T11 Arg2:T12
19,A1,Optional T10
20,R8,Has_qualifier Arg1:T10 Arg2:T11
21,T13,Measurement 732 757	Zubrod performance status
22,T14,Value 761 764	0-2
23,R9,Has_value Arg1:T13 Arg2:T14
24,T15,Measurement 788 813	predicted life expectancy
25,T16,Value 817 834	at least 12 weeks
26,R10,Has_value Arg1:T15 Arg2:T16
27,T17,Measurement 872 889	granulocyte count
28,T18,Temporal 858 871	pre-treatment
29,T19,Measurement 897 926	segmented neutrophils + bands
30,R12,Subsumes Arg1:T17 Arg2:T19
31,T20,"Value 931 965	greater than or equal to 1,500/mm3"
32,T21,Measurement 969 985	hemoglobin level
33,T22,Value 989 1021	greater than or equal to 9 gm/dl
34,T23,Measurement 1027 1041	platelet count
35,T24,"Value 1042 1077	greater than or equal to 50,000/mm3"
36,R13,Has_value Arg1:T23 Arg2:T24
37,R14,Has_value Arg1:T21 Arg2:T22
38,R15,Has_value Arg1:T17 Arg2:T20
39,T25,"Scope 872 1077	granulocyte count (i.e., segmented neutrophils + bands) of greater than or equal to 1,500/mm3, a hemoglobin level of greater than or equal to 9 gm/dl, and platelet count greater than or equal to 50,000/mm3"
40,R11,Has_temporal Arg1:T25 Arg2:T18
41,T26,Measurement 1258 1272	renal function
42,T27,Value 1249 1257	adequate
43,R16,Has_value Arg1:T26 Arg2:T27
44,T28,Measurement 1292 1323	calculated creatinine clearance
45,T29,Value 1324 1328	≥ 60
46,R17,Has_value Arg1:T28 Arg2:T29
47,R18,AND Arg1:T26 Arg2:T28
48,T30,Measurement 1359 1375	hepatic function
49,T31,Value 1350 1358	adequate
50,R19,Has_value Arg1:T30 Arg2:T31
51,T32,Measurement 1395 1410	serum bilirubin
52,T33,Value 1411 1475	less than or equal to 2x the institutional upper limit of normal
53,R20,Has_value Arg1:T32 Arg2:T33
54,R21,AND Arg1:T30 Arg2:T32
55,T34,Condition 1573 1580	ascites
56,T35,Negation 1560 1572	may not have
57,R22,Has_negation Arg1:T34 Arg2:T35
58,T36,Condition 1588 1595	ascites
59,T37,Qualifier 1604 1627	responsive to diuretics
60,R23,Has_qualifier Arg1:T36 Arg2:T37
61,T38,Procedure 489 507	blood sample drawn
62,T39,Qualifier 483 488	20 cc
63,R24,Has_qualifier Arg1:T38 Arg2:T39
64,T40,Informed_consent 467 475	agree to
65,T41,Procedure 523 535	routine labs
66,T42,Multiplier 536 567	with each cycle of chemotherapy
67,T43,Scope 483 535	20 cc blood sample drawn in addition to routine labs
68,R25,Has_multiplier Arg1:T43 Arg2:T42
69,R26,AND Arg1:T43 Arg2:T40
0,T1,Drug 14 26	azathioprine
1,T2,Drug 30 39	biologics
2,T3,Procedure 40 47	therapy
3,*,OR T2 T1
4,T4,Scope 14 39	azathioprine or biologics
5,R1,Has_scope Arg1:T3 Arg2:T4
0,T1,Multiplier 33 41	3 cycles
1,T2,Drug 47 57	bortezomib
2,T3,Procedure 64 81	induction regimen
3,R1,AND Arg1:T3 Arg2:T2
4,R2,Has_multiplier Arg1:T3 Arg2:T1
5,T4,Qualifier 105 120	NCCN guidelines
6,R3,Has_qualifier Arg1:T3 Arg2:T4
7,T5,Value 131 165	no evidence of disease progression
8,T6,Measurement 180 193	IMWG criteria
9,R4,Has_value Arg1:T6 Arg2:T5
10,T7,Measurement 295 325	criteria for a diagnosis of MM
11,T8,Value 287 290	all
12,R5,Has_value Arg1:T7 Arg2:T8
13,T9,Condition 214 252	light chain and free light chain (FLC)
14,A1,Optional T9
15,R6,AND Arg1:T9 Arg2:T7
16,T10,Mood 379 390	eligible to
17,T11,Procedure 405 416	IRD regimen
18,R7,Has_mood Arg1:T11 Arg2:T10
19,T12,Measurement 419 479	Eastern Cooperative Oncology Group (ECOG) performance status
20,T13,"Value 512 522	0, 1, or 2"
21,R8,Has_value Arg1:T12 Arg2:T13
22,T14,Temporal 523 544	at time of enrollment
23,R9,Has_temporal Arg1:T12 Arg2:T14
0,T1,Condition 13 25	sacroiliitis
1,T2,Person 27 30	Age
2,T3,Value 31 45	18 to 80 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 51 72	Chronic low back pain
5,T5,Condition 74 92	SI joint pathology
6,T6,Non-representable 93 126	is the predominant source of pain
7,T7,Value 128 136	Positive
8,T8,Measurement 137 161	Fortin Finger Test (PMT)
9,R2,Has_value Arg1:T8 Arg2:T7
10,T9,Non-representable 163 214	Joint anatomy is identifiable using ultrasonography
11,T10,Negation 228 230	no
12,T11,Qualifier 231 236	other
13,T12,Condition 237 284	comorbidities that contraindicate the procedure
14,R3,Has_qualifier Arg1:T12 Arg2:T11
15,R4,Has_negation Arg1:T12 Arg2:T10
16,T13,Procedure 308 324	physical therapy
17,T15,Procedure 329 354	corticosteroid injections
18,T14,Drug 361 376	ocal anesthetic
19,T16,Non-representable 377 470	-Previous injections of lidocaine and corticosteroid provided at least minor immediate relief
20,T17,Negation 485 488	not
21,T18,Procedure 500 524	corticosteroid injection
22,T19,Qualifier 532 540	SI joint
23,R5,Has_qualifier Arg1:T18 Arg2:T19
24,R6,AND Arg1:T15 Arg2:T14
25,T20,Temporal 541 569	within the last three months
26,R7,Has_temporal Arg1:T18 Arg2:T20
27,R8,Has_negation Arg1:T18 Arg2:T17
28,T21,Observation 584 608	consent to the procedure
0,T1,Condition 0 13	Osteonecrosis
1,T2,Procedure 23 44	decompression surgery
2,T3,Mood 15 22	planned
3,T4,Procedure 50 81	autologous stem cell transplant
4,R1,AND Arg1:T2 Arg2:T4
5,R2,Has_mood Arg1:T2 Arg2:T3
0,T1,Observation 0 21	Unable to participate
1,T2,Qualifier 26 48	administrative reasons
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 50 70	Psychiatric troubles
4,T4,Condition 72 84	Pain at rest
5,T5,Condition 88 110	critical limb ischemia
6,*,OR T4 T5
7,T6,Condition 112 126	Unable to walk
8,T7,Observation 132 151	wheelchair subjects
9,R2,Subsumes Arg1:T6 Arg2:T7
0,T1,Condition 15 17	PD
1,T2,Qualifier 18 34	by a neurologist
2,T3,Non-query-able 18 34	by a neurologist
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,T4,Person 60 64	aged
5,T5,Value 65 79	30 to 85 years
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 85 114	modified Hoehn and Yahr (H&Y)
8,T7,Value 115 129	stage 1.5 to 3
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Non-query-able 175 247	able and willing to give written consent for participation in the study;
11,T9,Post-eligibility 175 247	able and willing to give written consent for participation in the study;
12,T10,Observation 249 280	living at home in the community
13,T11,Condition 283 309;324 359	able to walk independently with or without an assistive device
14,T12,Multiplier 310 323	for 30 metres
15,R4,Has_multiplier Arg1:T11 Arg2:T12
0,T1,Condition 0 18	Ulcerative colitis
1,T2,Qualifier 33 51	moderate to severe
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 76 94	clinical remission
4,T4,Temporal 95 133	by the first course of corticosteroids
5,T5,Reference_point 102 133	first course of corticosteroids
6,T6,Multiplier 102 114	first course
7,T7,Drug 118 133	corticosteroids
8,R2,Has_multiplier Arg1:T7 Arg2:T6
9,R3,Has_index Arg1:T4 Arg2:T5
10,R4,multi Arg1:T5 Arg2:T7
11,R5,Has_temporal Arg1:T3 Arg2:T4
12,R6,AND Arg1:T1 Arg2:T3
13,T8,Negation 154 161	without
14,T9,Drug 162 169	steroid
15,T10,Temporal 174 192	during last 1 year
16,R7,Has_temporal Arg1:T9 Arg2:T10
17,R8,Has_negation Arg1:T9 Arg2:T8
18,T11,Measurement 194 218	Endoscopic Mayo subscore
19,T12,Value 219 221	>0
20,R9,Has_value Arg1:T11 Arg2:T12
0,T1,Procedure 33 45	chemotherapy
1,T2,Condition 50 70	unresectable disease
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Qualifier 100 112	uncontrolled
4,T4,Qualifier 90 96	active
5,T5,Condition 113 122	infection
6,T6,Scope 90 112	active or uncontrolled
7,R2,Has_scope Arg1:T5 Arg2:T6
8,T7,Procedure 140 153	HIV infection
9,R3,Subsumes Arg1:T5 Arg2:T7
10,T8,Condition 177 188	hepatitis B
11,T9,Qualifier 170 176	active
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Scope 170 188	active hepatitis B
14,A1,Optional T10
15,T11,Drug 207 217	lamivudine
16,R5,AND Arg1:T10 Arg2:T11
17,T12,Condition 240 251	hepatitis C
18,T13,Qualifier 233 239	active
19,R6,Has_qualifier Arg1:T12 Arg2:T13
20,T14,Scope 233 251	active hepatitis C
21,A2,Optional T14
22,T15,Measurement 272 283	liver tests
23,T16,Value 284 291	qualify
24,R7,Has_value Arg1:T15 Arg2:T16
25,R8,AND Arg1:T14 Arg2:T15
26,T17,Condition 315 336	psychiatric disorders
27,T18,Qualifier 348 370	interfere with consent
28,T19,Qualifier 348 362;374 383	interfere with follow-up
29,*,OR T18 T19
30,R9,Has_qualifier Arg1:T17 Arg2:T19
31,T20,Condition 385 393	Pregnant
32,T21,Condition 397 406	lactating
33,T22,Person 407 412	women
34,*,OR T20 T21
35,T23,Condition 431 453	reproductive potential
36,A3,Optional T23
37,T24,Procedure 508 538	effective contraceptive method
38,R10,AND Arg1:T23 Arg2:T24
39,T25,Qualifier 565 571	severe
40,T26,Condition 572 590	concurrent disease
41,R11,Has_qualifier Arg1:T26 Arg2:T25
42,T27,"Non-query-able 592 634	which in the judgment of the investigator,"
43,T28,Observation 676 697	entry into this study
44,T29,Mood 658 675	inappropriate for
45,R12,Has_mood Arg1:T28 Arg2:T29
46,R13,Has_context Arg1:T26 Arg2:T28
0,T1,Non-query-able 0 2	NA
0,T1,Condition 0 22	Intracranial infection
1,T2,Condition 48 74	circulatory system disease
2,T3,Condition 32 43;60 74	respiratory system disease
3,*,OR T3 T2
4,T4,Qualifier 25 31	Severe
5,T5,Scope 32 75	respiratory and circulatory system diseases
6,R1,Has_qualifier Arg1:T5 Arg2:T4
7,T6,Condition 78 102	Hematologic malignancies
8,T7,Condition 140 144	AIDS
9,T8,Condition 146 163	hepatitis B virus
10,T9,Condition 165 182	hepatitis C virus
11,T10,Condition 187 195	syphilis
12,T11,Condition 220 226	Tumors
13,*,OR T10 T9 T8 T7
14,T12,Grammar_Error 183 186	and
15,T13,Condition 241 259	metabolic diseases
16,T14,Condition 229 236;251 259	Genetic diseases
17,*,OR T14 T13
0,T1,Temporal 0 8	previous
1,T2,Procedure 9 22	brain surgery
2,R1,Has_temporal Arg1:T2 Arg2:T1
3,T3,Condition 25 45	cognitive impairment
4,T4,Value 47 59	< 120 points
5,T5,Measurement 67 95	Mattis Dementia Rating Scale
6,R2,Has_value Arg1:T5 Arg2:T4
7,T6,Qualifier 98 116	moderate-to-severe
8,T7,Condition 117 127	depression
9,R3,Has_qualifier Arg1:T7 Arg2:T6
10,T8,Value 129 140	> 25 points
11,T9,Measurement 148 173	Beck Depression Inventory
12,R4,Has_value Arg1:T9 Arg2:T8
13,T10,Condition 183 196	brain atrophy
14,T11,Procedure 212 238	magnetic resonance imaging
15,R5,AND Arg1:T10 Arg2:T11
16,T12,Post-eligibility 240 369	other medical or psychiatric coexisting disorders that could increase the surgical risk or interfere with completion of the trial
0,T1,Person 0 13	Premenopausal
1,T2,Person 14 19	women
2,T3,Person 33 36	old
3,T4,Value 21 32	18-35 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Measurement 38 48	FSH levels
6,T6,Value 49 60	< 10 mIU/ml
7,T7,Measurement 62 65	AFC
8,T8,Value 65 69	> 10
9,R2,Has_value Arg1:T7 Arg2:T8
10,T9,Condition 71 85	Regular cycles
11,T10,Measurement 87 90	BMI
12,T11,Value 91 95	< 28
13,R3,Has_value Arg1:T10 Arg2:T11
14,T12,Informed_consent 97 120	Signed informed consent
0,T1,Non-query-able 0 2	NA
0,T1,Person 0 4	ages
1,T2,Value 8 22	7 and 75 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 31 41	disability
4,T4,Condition 84 92	dystonia
5,T5,Qualifier 74 83	segmental
6,T6,Qualifier 59 70	generalized
7,*,OR T6 T5
8,T7,Qualifier 51 58	primary
9,T8,Scope 59 83	generalized or segmental
10,R2,Has_scope Arg1:T4 Arg2:T8
11,R3,Has_qualifier Arg1:T4 Arg2:T7
12,R4,AND Arg1:T3 Arg2:T4
13,T9,Qualifier 102 109	optimal
14,T10,Procedure 110 133	pharmacologic treatment
15,R5,Has_qualifier Arg1:T10 Arg2:T9
16,R6,AND Arg1:T3 Arg2:T10
17,T11,Measurement 135 151	disease duration
18,T12,Value 155 171	at least 5 years
19,R7,Has_value Arg1:T11 Arg2:T12
0,T1,Condition 27 41	cerebral palsy
1,T2,Non-query-able 44 100	Patients' curator must be able to give voluntary consent
2,T3,Post-eligibility 44 100	Patients' curator must be able to give voluntary consent
0,T1,Condition 0 4	PCOS
1,T2,Drug 26 40	gonadotrophins
2,T3,Condition 15 22	Allergy
3,R1,AND Arg1:T3 Arg2:T2
4,T4,Competing_trial 42 82	Concomitant participation in other trial
0,T1,Condition 0 8	pregnant
1,T2,Condition 12 19	nursing
2,*,OR T1 T2
3,T3,Person 20 25	woman
4,T4,Scope 0 19	pregnant or nursing
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Condition 47 54	illness
7,T6,Temporal 35 46	concomitant
8,T7,Qualifier 27 34	serious
9,R2,Has_qualifier Arg1:T5 Arg2:T7
10,R3,Has_temporal Arg1:T5 Arg2:T6
11,T8,Condition 59 74	malignant tumor
12,T9,Qualifier 78 86	any kind
13,R4,Has_qualifier Arg1:T8 Arg2:T9
14,T10,Observation 88 98	history of
15,T11,Condition 99 115	hypersensitivity
16,T12,Drug 119 129	test drugs
17,R5,AND Arg1:T11 Arg2:T12
18,R6,Has_temporal Arg1:T11 Arg2:T10
19,T13,Qualifier 131 138	serious
20,T14,Condition 139 147	bleeding
21,T15,Temporal 148 178	during the course of the ulcer
22,R7,Has_qualifier Arg1:T14 Arg2:T13
23,R8,Has_temporal Arg1:T14 Arg2:T15
24,T16,Temporal 180 188	previous
25,T17,Procedure 189 204	gastric surgery
26,R9,Has_temporal Arg1:T17 Arg2:T16
27,T18,Drug 216 229	bismuth salts
28,T19,Drug 231 235	PPIs
29,T20,Drug 240 251	antibiotics
30,T21,Temporal 252 273	in the previous month
31,*,OR T19 T20 T18
32,T22,"Scope 216 251	bismuth salts, PPIs, or antibiotics"
33,R10,Has_temporal Arg1:T22 Arg2:T21
0,T1,Procedure 4 28	anti-coagulation therapy
1,T2,Drug 41 52	rivaroxaban
2,T3,Negation 30 40	apart from
3,R1,Has_negation Arg1:T2 Arg2:T3
4,T4,Condition 76 92	Hypersensitivity
5,T5,Condition 96 103	allergy
6,T6,Drug 107 127	factor Xa inhibitors
7,*,OR T5 T4
8,T7,Scope 76 103	Hypersensitivity or allergy
9,R2,AND Arg1:T7 Arg2:T6
10,T8,Condition 129 157	Acute bacterial endocarditis
11,T9,Condition 159 176	Bleeding disorder
12,T10,Condition 198 213	active bleeding
13,T11,Condition 215 237	Gastrointestinal ulcer
14,T12,Condition 215 231;241 246	Gastrointestinal tumor
15,*,OR T11 T12
16,T13,Condition 248 267	Hepatic dysfunction
17,T14,Observation 283 296	bleeding risk
18,T15,Qualifier 273 282	increased
19,R3,Has_qualifier Arg1:T14 Arg2:T15
20,R4,AND Arg1:T14 Arg2:T13
21,T16,Condition 298 311	Renal failure
22,T17,Procedure 334 342	dialysis
23,*,OR T16 T17
24,T18,Pregnancy_considerations 344 372	Pregnancy and breast feeding
25,T19,Procedure 374 385	Gastrectomy
26,T20,Procedure 387 412	biliopancreatic diversion
27,T21,Procedure 427 437	re-routing
28,T22,Procedure 414 423	resection
29,T23,Qualifier 441 457	small intestines
30,*,OR T21 T22
31,T24,Scope 414 437	resection or re-routing
32,R5,Has_qualifier Arg1:T24 Arg2:T23
33,*,OR T24 T20 T19
34,T25,Device 459 471	Feeding tube
35,T26,Observation 480 494	blood donation
36,T27,Measurement 532 556	alanine-aminotransferase
37,T28,Measurement 558 562	ALAT
38,T29,Measurement 565 591	aspartate-aminotransferase
39,T30,Measurement 593 597	ASAT
40,T31,Measurement 600 626	gamma-glutamyl transferase
41,T32,Measurement 628 635	gammaGT
42,T33,Measurement 638 657	alkalic phosphatase
43,T34,Measurement 659 661	AP
44,T35,Measurement 664 673	bilirubin
45,T36,Measurement 675 682	amylase
46,T37,Measurement 684 690	lipase
47,T38,Measurement 692 702	cystatin C
48,T39,Measurement 704 714	creatinine
49,T40,Measurement 716 738	white blood cell count
50,T41,Measurement 740 751	haemoglobin
51,T42,Measurement 753 767	platelet count
52,T43,"Measurement 769 786	prothrombin time,"
53,T44,Measurement 787 791	aPTT
54,T45,Measurement 793 803	fibrinogen
55,T46,Measurement 805 818	thrombin time
56,T47,Measurement 820 830	factors II
57,T48,Measurement 820 827;831 832	factors V
58,T49,Measurement 820 827;833 836	factors VII
59,T50,Measurement 820 827;841 842	factors X
60,R6,Subsumes Arg1:T27 Arg2:T28
61,R7,Subsumes Arg1:T29 Arg2:T30
62,R8,Subsumes Arg1:T31 Arg2:T32
63,R9,Subsumes Arg1:T33 Arg2:T34
64,*,OR T27 T29 T31 T47 T49 T50 T48 T46 T45 T44 T43 T42 T41 T33 T35 T36 T37 T38 T39
65,T51,"Scope 532 842	alanine-aminotransferase (ALAT), aspartate-aminotransferase (ASAT), gamma-glutamyl transferase (gammaGT), alkalic phosphatase (AP), bilirubin, amylase, lipase, cystatin C, creatinine, white blood cell count, haemoglobin, platelet count, prothrombin time, aPTT, fibrinogen, thrombin time, factors II,V,VII and X"
66,T52,Value 496 509	Abnormalities
67,R10,Has_value Arg1:T51 Arg2:T52
68,T53,Non-query-able 844 918	Use of therapeutic or recreational drugs influencing plasmatic coagulation
0,T1,Condition 27 49	vitamin B12 deficiency
1,T2,Mood 9 18	suspected
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Measurement 63 81	plasma vitamin B12
4,T4,Value 82 110	below the reference interval
5,T5,Value 112 123	<200 pmol/L
6,R2,Subsumes Arg1:T4 Arg2:T5
7,R3,Has_value Arg1:T3 Arg2:T4
8,R4,Subsumes Arg1:T1 Arg2:T3
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 54 56	2.
2,T3,Parsing_Error 80 82	3.
3,T4,Parsing_Error 105 107	4.
4,T5,Parsing_Error 133 135	5.
5,T6,Parsing_Error 219 221	6.
6,T7,Parsing_Error 362 364	7.
7,T8,Measurement 14 29	gestational age
8,T9,Value 30 52	between 27 to 34 weeks
9,R1,Has_value Arg1:T8 Arg2:T9
10,T10,Condition 3 8	PPROM
11,R2,AND Arg1:T10 Arg2:T8
12,T11,Condition 57 78	Cephalic presentation
13,T12,Observation 83 103	Clear amniotic fluid
14,T13,Measurement 108 124	Oral temperature
15,T14,Value 125 131	> 38 C
16,R3,Has_value Arg1:T13 Arg2:T14
17,T15,Post-eligibility 136 217	Near distance from the hospital (the patient can reach hospital within one hour )
18,T16,Non-query-able 136 217	Near distance from the hospital (the patient can reach hospital within one hour )
19,T17,"Non-query-able 222 360	Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at home ."
20,T18,"Subjective_judgement 222 360	Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at home ."
21,T19,Condition 378 393	fetal condition
22,T20,Condition 365 373;384 393	Maternal condition
23,T21,Qualifier 401 407	stable
24,T22,Temporal 408 442	after hospitalization for 72 hours
25,T23,Reference_point 414 429	hospitalization
26,R4,Has_index Arg1:T22 Arg2:T23
27,T24,Scope 365 393	Maternal and fetal condition
28,R5,Has_qualifier Arg1:T24 Arg2:T21
29,R6,Has_temporal Arg1:T24 Arg2:T22
0,T1,Qualifier 20 37	H. pylori related
1,T2,Condition 38 55	chronic gastritis
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 69 82	peptic ulcers
4,A1,Optional T3
5,T4,Person 91 95	aged
6,T5,Value 96 121	greater than 20 years old
7,R2,Has_value Arg1:T4 Arg2:T5
8,T6,Procedure 150 169	eradication therapy
9,T7,Mood 130 148	willing to receive
10,R3,Has_mood Arg1:T6 Arg2:T7
0,T1,Condition 15 26	tetraplegia
1,T2,Qualifier 6 14	complete
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Temporal 31 48	at least 3 months
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Person 50 53	Age
6,T5,Value 54 73	from 18 to 74 years
7,R3,Has_value Arg1:T4 Arg2:T5
8,T6,Measurement 75 90	Body mass index
9,T7,Measurement 92 95	BMI
10,R4,Subsumes Arg1:T6 Arg2:T7
11,T8,Value 97 115	from 18 to 35kg/m2
12,R5,Has_value Arg1:T6 Arg2:T8
13,T9,Informed_consent 118 160	nformed consent as documented by signature
0,T1,Condition 18 26	pregnant
1,T2,Condition 28 35	nursing
2,*,OR T1 T2
3,T3,Observation 43 80	able to give written informed consent
4,T4,Negation 39 42	not
5,R1,Has_negation Arg1:T3 Arg2:T4
6,R2,Has_context Arg1:T2 Arg2:T3
0,T1,Parsing_Error 0 2	1.
1,T2,Condition 39 59	rupture of membranes
2,T3,Negation 16 25	equivocal
3,R1,Has_negation Arg1:T2 Arg2:T3
4,T4,Condition 64 78	advanced labor
5,T5,Condition 83 105	intrauterine infection
6,T6,Condition 110 126	vaginal bleeding
7,T8,Parsing_Error 127 129	or
8,T7,Measurement 149 165	fetal heart rate
9,T9,Qualifier 134 148	non reassuring
10,T10,Subjective_judgement 134 148	non reassuring
11,T11,Context_Error 134 148	non reassuring
12,R2,Has_qualifier Arg1:T7 Arg2:T9
0,T1,Person 0 4	Aged
1,T2,Value 5 22	at least 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Observation 31 38;55 87	ability to give written informed consent
4,T4,Observation 43 54;55 87	willingness to give written informed consent
5,T5,Measurement 90 105	Body mass index
6,T6,Value 106 117	25-35 kg/m2
7,T7,Multiplier 128 143;166 173	at least 2 cups per day
8,T8,Drug 147 165	caffeinated coffee
9,R2,Has_multiplier Arg1:T8 Arg2:T7
10,T9,Observation 182 206	willing to be randomized
11,T10,Condition 237 248	Non-smoking
0,T1,Person 0 7	Veteran
1,T2,Visit 34 82	Veterans Health Administration healthcare system
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Person 84 87	Age
4,T4,Value 88 96	18 years
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 121 142	chronic heart failure
7,T6,Measurement 144 176	American Heart Association Stage
8,T7,Value 177 180	C-D
9,R3,AND Arg1:T5 Arg2:T6
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Measurement 182 186	LVEF
12,T9,Value 187 191	<45%
13,R5,Has_value Arg1:T8 Arg2:T9
14,T10,Negation 193 195	No
15,T11,Qualifier 196 202	change
16,T12,Drug 213 232	cardiac medications
17,R6,Has_qualifier Arg1:T12 Arg2:T11
18,R7,Has_negation Arg1:T11 Arg2:T10
19,T13,Temporal 233 267	for 4 weeks prior to randomization
20,T14,Reference_point 254 267	randomization
21,R8,Has_index Arg1:T13 Arg2:T14
22,R9,Has_temporal Arg1:T12 Arg2:T13
23,T15,Informed_consent 269 304	Ability to provide informed consent
24,T16,Condition 354 377	obstructive sleep apnea
25,T17,Condition 325 332;366 377	central sleep apnea
26,T18,Condition 336 349;366 377	mixed central sleep apnea
27,*,OR T16 T18 T17
28,T19,Qualifier 318 324	severe
29,T20,Qualifier 306 314	Moderate
30,*,OR T20 T19
31,T21,Measurement 393 413	apnea-hypopnea index
32,T22,Measurement 415 418	AHI
33,T23,"Value 420 439	15 events per hour,"
34,T24,Measurement 447 458	central AHI
35,T25,Value 459 473	>5 events/hour
36,R10,Subsumes Arg1:T21 Arg2:T22
37,R11,Has_value Arg1:T21 Arg2:T23
38,R12,Has_value Arg1:T24 Arg2:T25
39,T26,"Scope 393 473	apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hour"
40,T27,Scope 325 377	central or mixed central and obstructive sleep apnea
41,T28,Scope 306 324	Moderate to severe
42,R13,Has_scope Arg1:T27 Arg2:T28
43,R14,Has_scope Arg1:T27 Arg2:T26
0,T1,Condition 14 29	liver cirrhosis
1,T2,Condition 31 55	Hepatocellular Carcinoma
2,T3,Condition 65 77	malignancies
3,*,OR T1 T2 T3
4,T4,Non-representable 80 130	Patients with other factors causing liver diseases
5,T5,Pregnancy_considerations 133 161	Pregnant and lactating women
6,T6,Condition 190 203	HIV infection
7,T7,Qualifier 178 189	concomitant
8,R1,Has_qualifier Arg1:T6 Arg2:T7
9,T8,Condition 207 245	congenital immune deficiency diseases.
10,*,OR T6 T8
11,T9,Condition 261 269	diabetes
12,T10,Condition 271 290	autoimmune diseases
13,*,OR T9 T10
14,T11,Condition 317 335	organ dysfunctions
15,T12,Qualifier 352 359	serious
16,T13,Condition 360 373	complications
17,R2,Has_qualifier Arg1:T13 Arg2:T12
18,T14,Condition 381 390	infection
19,T15,Condition 392 414	hepatic encephalopathy
20,T16,Condition 416 436	hepatorenal syndrome
21,T17,Condition 438 463	gastrointestinal bleeding
22,*,OR T17 T16 T15 T14
23,T18,"Scope 381 463	infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding"
24,R3,Subsumes Arg1:T13 Arg2:T18
25,T19,Procedure 488 502;523 530	antineoplastic therapy
26,T20,Procedure 506 530	immunomodulatory therapy
27,T21,Temporal 538 552	past 12 months
28,T22,Scope 488 530	antineoplastic or immunomodulatory therapy
29,R4,Has_temporal Arg1:T22 Arg2:T21
30,T23,Post-eligibility 555 619	Patients who can't come back to clinic for follow-up on schedule
0,T1,Condition 23 48	non-Burkitt B-lineage ALL
1,T2,Qualifier 0 9	Confirmed
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Value 50 63	1 to 17 years
4,T4,Person 67 70	age
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Measurement 95 109	Renal function
7,T6,Value 110 137	within normal range for age
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 139 153	Liver function
10,T8,Value 154 181	within normal range for age
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Observation 183 202	Able to participate
13,T10,Procedure 226 235	treatment
14,T11,Multiplier 210 222	full 2 years
15,R5,Has_multiplier Arg1:T10 Arg2:T11
16,R6,AND Arg1:T9 Arg2:T10
0,T1,Condition 0 3	CHB
1,T2,Drug 30 33	NAs
2,T3,Temporal 38 58	more than 12 months.
3,R1,AND Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T2 Arg2:T3
5,T4,Measurement 60 81	Hepatitis B e antigen
6,T5,Value 90 98	negative
7,T6,Measurement 103 113	anti-HBeAg
8,T7,Value 114 122	positive
9,R3,Has_value Arg1:T4 Arg2:T5
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Measurement 83 88	HBeAg
12,R5,Subsumes Arg1:T4 Arg2:T8
13,T9,Measurement 125 152	Hepatitis B surface antigen
14,T10,Measurement 154 159	HBsAg
15,T11,Value 161 169	positive
16,T12,Value 174 185	<1500 IU/mL
17,R6,Subsumes Arg1:T9 Arg2:T10
18,R7,Has_value Arg1:T9 Arg2:T11
19,R8,Has_value Arg1:T9 Arg2:T12
20,T13,Measurement 188 209	Hepatitis B virus DNA
21,T14,Value 210 224	not detectable
22,R9,Has_value Arg1:T13 Arg2:T14
0,T1,Observation 0 15	Hospitalization
1,T2,Condition 20 42	acute decompensated HF
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Temporal 43 66	within previous 30 days
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Observation 68 83	Hospitalization
6,T5,Condition 88 109	myocardial infarction
7,T6,Procedure 113 128	cardiac surgery
8,T7,Temporal 129 152	within previous 90 days
9,*,OR T5 T6
10,T8,Scope 88 128	myocardial infarction or cardiac surgery
11,R3,Has_scope Arg1:T4 Arg2:T8
12,R4,Has_temporal Arg1:T8 Arg2:T7
13,T9,Device 168 198	left ventricular assist device
14,T10,Procedure 211 232	heart transplantation
15,T11,Condition 252 264	hypertension
16,T12,Qualifier 234 251	Poorly controlled
17,R5,Has_qualifier Arg1:T11 Arg2:T12
18,T13,Condition 296 304	diabetes
19,T14,Qualifier 278 295	Poorly controlled
20,R6,Has_qualifier Arg1:T13 Arg2:T14
21,T15,Measurement 306 311	HbA1c
22,T16,Value 312 317	> 9.0
23,R7,Has_value Arg1:T15 Arg2:T16
24,R8,AND Arg1:T13 Arg2:T15
25,T17,Condition 327 340	renal failure
26,T18,Qualifier 320 326	Severe
27,T19,Measurement 346 382	estimated glomerular filtration rate
28,T20,Value 383 393	<30 ml/min
29,R9,Has_value Arg1:T19 Arg2:T20
30,R10,Has_qualifier Arg1:T17 Arg2:T18
31,R11,AND Arg1:T17 Arg2:T19
32,T21,Condition 401 407	stroke
33,T22,Condition 413 434	functional impairment
34,T23,"Non-query-able 438 595	other severe, uncontrolled medical problems that may impair ability to participate in the study exams, based on medical history and review of medical records"
35,R12,AND Arg1:T21 Arg2:T22
36,T24,Condition 604 620	chronic insomnia
37,T25,Observation 642 656	sleep duration
38,T26,Value 657 665	<4 hours
39,R13,Has_value Arg1:T25 Arg2:T26
40,R14,Has_context Arg1:T24 Arg2:T25
41,T27,Condition 674 692	daytime sleepiness
42,T28,Measurement 705 729	Epworth Sleepiness Scale
43,T29,Value 730 748	score 18 or higher
44,R15,Has_value Arg1:T28 Arg2:T29
45,T30,"Non-query-able 752 856	a report of falling asleep driving during the previous year, and deemed a safety risk by study physician"
46,T31,Measurement 872 896	oxyhemoglobin saturation
47,T32,Qualifier 864 871	resting
48,T33,Qualifier 858 863	Awake
49,R16,Has_qualifier Arg1:T31 Arg2:T32
50,R17,Has_qualifier Arg1:T31 Arg2:T33
51,T34,Value 897 901	<89%
52,R18,Has_value Arg1:T31 Arg2:T34
53,T35,Condition 903 912	Pregnancy
54,T36,"Non-query-able 914 1005	Smoking by subject or other person in the subject's bedroom, or other open flame in bedroom"
55,T37,Device 1024 1055	positive airway pressure device
56,T38,Device 1081 1114	bi-level positive airway pressure
57,T39,Device 1067 1077;1099 1114	continuous airway pressure
58,T40,Device 1118 1144	adaptive servo-ventilation
59,*,OR T38 T39 T40
60,T41,Procedure 1149 1176	supplemental oxygen therapy
61,T42,Scope 1067 1144	continuous or bi-level positive airway pressure or adaptive servo-ventilation
62,R19,Subsumes Arg1:T37 Arg2:T42
63,*,OR T37 T41
0,T1,Condition 113 122	pregnancy
1,T2,Observation 126 139	breastfeeding
2,T3,Condition 141 158	diabetes mellitus
3,T4,Condition 160 173	heart disease
4,T5,Condition 175 181	stroke
5,T6,Condition 183 195	hypertension
6,T7,Condition 197 220	malabsorption syndromes
7,T8,Condition 222 226	GERD
8,T9,Observation 230 240	history of
9,T10,Condition 241 246	ulcer
10,R1,AND Arg1:T9 Arg2:T10
11,T11,Condition 14 56	illness that may affect the study outcomes
12,T12,Condition 14 26;60 104	illness that would make participation potentially harmful
13,*,OR T12 T11
14,T13,"Scope 113 246	pregnancy or breastfeeding, diabetes mellitus, heart disease, stroke, hypertension, malabsorption syndromes, GERD, a history of ulcer"
15,T14,Scope 14 104	illness that may affect the study outcomes or would make participation potentially harmful
16,R2,Subsumes Arg1:T14 Arg2:T13
17,T15,Measurement 299 315	hepatic function
18,T16,Value 290 298	Abnormal
19,R3,Has_value Arg1:T15 Arg2:T16
20,T17,Measurement 317 336	liver function test
21,T18,Value 337 361	> twice the normal range
22,R4,Has_value Arg1:T17 Arg2:T18
23,T19,Measurement 373 387	renal function
24,T20,Value 364 372	abnormal
25,R5,Has_value Arg1:T19 Arg2:T20
26,T21,Measurement 389 399	creatinine
27,T22,Value 400 411	> 1.1 mg/dl
28,R6,Has_value Arg1:T21 Arg2:T22
29,T23,Measurement 414 436	fasting plasma glucose
30,T24,Value 437 458	in the diabetic range
31,R8,Has_value Arg1:T23 Arg2:T24
32,R7,Subsumes Arg1:T20 Arg2:T21
33,T25,Value 460 473	>/= 126 mg/dl
34,R9,Subsumes Arg1:T24 Arg2:T25
35,T26,Measurement 479 493	blood pressure
36,T27,Value 494 507	> 140/90 mmHg
37,R10,Has_value Arg1:T26 Arg2:T27
38,*,OR T15 T19 T23 T26
39,T28,Condition 518 528	alcoholism
40,T29,Condition 532 542	drug abuse
41,T30,Drug 553 604	medications that could interfere with the treatment
42,T31,Drug 615 630	bronchodilators
43,T32,Drug 632 653	quinolone antibiotics
44,T33,Drug 655 683	monoamine oxidase inhibitors
45,T34,Drug 685 696	anxiolytics
46,T35,Drug 698 708	ranitidine
47,T36,Drug 710 725	corticosteroids
48,T37,Drug 727 741	growth hormone
49,T38,Drug 743 760	antihypertensives
50,*,OR T38 T37 T36 T35 T34 T33 T32
51,T39,"Scope 615 760	bronchodilators, quinolone antibiotics, monoamine oxidase inhibitors, anxiolytics, ranitidine, corticosteroids, growth hormone, antihypertensives"
52,R11,Subsumes Arg1:T30 Arg2:T39
53,*,OR T28 T29 T30
54,*,OR T1 T2 T3 T4 T5 T6 T7 T8 T10
55,T40,Observation 272 287	medical history
56,R12,Has_temporal Arg1:T13 Arg2:T40
0,T1,Person 0 3	Age
1,T2,Value 4 22	less than one year
2,T3,Value 30 61	greater than/equals to 18 years
3,T4,Person 26 29	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,R2,Has_value Arg1:T1 Arg2:T2
6,*,OR T1 T4
7,T5,Temporal 63 71	Previous
8,T6,Procedure 72 81	treatment
9,T7,Drug 87 103	cytotoxic agents
10,T8,Drug 107 125	high-dose steroids
11,*,OR T7 T8
12,T9,Scope 87 125	cytotoxic agents or high-dose steroids
13,R3,Has_scope Arg1:T6 Arg2:T9
14,R4,Has_temporal Arg1:T6 Arg2:T5
15,T10,Condition 127 157	Mixed phenotype acute leukemia
16,T11,Condition 159 163	MPAL
17,R5,Subsumes Arg1:T10 Arg2:T11
18,T12,Condition 166 169	ALL
19,T13,Qualifier 173 182	secondary
20,T14,Condition 183 193	malignancy
21,R6,Has_qualifier Arg1:T14 Arg2:T13
22,T15,Scope 173 193	secondary malignancy
23,R7,Subsumes Arg1:T12 Arg2:T15
24,T16,Condition 195 203;213 227	Abnormal liver function
25,T17,Condition 195 209;219 227	Abnormal renal function
26,*,OR T17 T16
27,T18,Observation 229 248	Doubtful compliance
28,T19,Observation 252 291	unable to afford full course of therapy
29,*,OR T18 T19
0,T1,Condition 35 60	adenocarcinoma of stomach
1,T2,Qualifier 22 34	unresectable
2,T3,Measurement 0 14	Pathologically
3,T4,Value 15 21	proven
4,R1,Has_qualifier Arg1:T1 Arg2:T2
5,R2,Has_value Arg1:T3 Arg2:T4
6,R3,AND Arg1:T2 Arg2:T3
7,T5,Condition 96 103	disease
8,T6,Qualifier 67 95	uni-dimensionally measurable
9,R4,Has_qualifier Arg1:T5 Arg2:T6
10,T7,Measurement 114 130	longest diameter
11,T8,Procedure 139 159	conventional CT scan
12,R5,AND Arg1:T8 Arg2:T7
13,T9,Value 105 113;131 135	at least 2 cm
14,R6,Has_value Arg1:T7 Arg2:T9
15,T10,Procedure 161 166	x-ray
16,T11,Procedure 170 190	physical examination
17,*,OR T10 T11 T8 T13
18,T13,Procedure 202 216	spiral CT scan
19,T14,Measurement 114 130	longest diameter
20,T15,Value 105 113;195 198	at least 1cm
21,R7,Has_value Arg1:T14 Arg2:T15
22,R8,AND Arg1:T13 Arg2:T14
23,T12,"Scope 105 216	at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan"
24,R9,Subsumes Arg1:T6 Arg2:T12
25,T16,Person 219 222	Age
26,T17,Value 223 241	18 to 70 years old
27,R10,Has_value Arg1:T16 Arg2:T17
28,T18,Measurement 243 268	Estimated life expectancy
29,T19,Value 272 290	more than 3 months
30,R11,Has_value Arg1:T18 Arg2:T19
31,T20,Measurement 292 315	ECOG performance status
32,T21,Value 319 329	2 or lower
33,R12,Has_value Arg1:T20 Arg2:T21
34,T22,Measurement 340 360	bone marrow function
35,T23,Value 331 339	Adequate
36,R13,Has_value Arg1:T22 Arg2:T23
37,T24,Measurement 361 392	absolute neutrophil count [ANC]
38,T25,"Value 393 402	≥1,500/µL"
39,R14,Has_value Arg1:T24 Arg2:T25
40,T26,Measurement 404 414	hemoglobin
41,T27,Value 415 424	≥9.0 g/dL
42,R15,Has_value Arg1:T26 Arg2:T27
43,T28,Measurement 429 438	platelets
44,T29,"Value 439 450	≥100,000/µL"
45,R16,Has_value Arg1:T28 Arg2:T29
46,*,OR T24 T26 T28
47,T30,"Scope 361 450	absolute neutrophil count [ANC] ≥1,500/µL, hemoglobin ≥9.0 g/dL,and platelets ≥100,000/µL"
48,R17,Subsumes Arg1:T23 Arg2:T30
49,T31,Measurement 462 477	kidney function
50,T32,Value 453 461	Adequate
51,R18,Has_value Arg1:T31 Arg2:T32
52,T33,Measurement 479 495	serum creatinine
53,T34,Value 496 507	< 1.5 mg/dL
54,R19,Has_value Arg1:T33 Arg2:T34
55,R20,Subsumes Arg1:T32 Arg2:T33
56,T35,Measurement 519 533	liver function
57,T36,Value 510 518	Adequate
58,R21,Has_value Arg1:T35 Arg2:T36
59,T37,Measurement 535 556	serum total bilirubin
60,T38,Value 557 595	< 2 times the upper normal limit (UNL)
61,R22,Has_value Arg1:T37 Arg2:T38
62,T39,Measurement 597 623	serum transaminases levels
63,T40,Value 624 632;679 682	<3 times UNL
64,T41,Condition 661 677	liver metastasis
65,T42,Value 634 642;679 682	<5 times UNL
66,T43,Scope 624 682	<3 times [<5 times for patients with liver metastasis] UNL
67,R24,Has_scope Arg1:T39 Arg2:T43
68,R25,AND Arg1:T37 Arg2:T39
69,T44,Scope 535 682	serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver metastasis] UNL
70,R26,Subsumes Arg1:T36 Arg2:T44
71,T45,Procedure 694 706	chemotherapy
72,T46,Temporal 688 693	prior
73,T47,Negation 685 687	No
74,R27,Has_negation Arg1:T45 Arg2:T47
75,R28,Has_temporal Arg1:T45 Arg2:T46
76,T48,Procedure 717 738	adjuvant chemotherapy
77,T49,Temporal 711 716	prior
78,R29,Has_temporal Arg1:T48 Arg2:T49
79,T50,Temporal 748 783	at least 6 months before enrollment
80,R30,Has_temporal Arg1:T48 Arg2:T50
81,T51,Procedure 809 830	adjuvant chemotherapy
82,T52,Temporal 803 808	prior
83,T53,Drug 836 848	capecitabine
84,T54,Drug 852 855	S-1
85,*,OR T53 T54 T55
86,R32,Has_temporal Arg1:T51 Arg2:T52
87,R33,AND Arg1:T51 Arg2:T53
88,T55,Drug 859 881	camptothecin analogues
89,T56,Negation 886 894	excluded
90,R34,Has_negation Arg1:T51 Arg2:T56
91,T57,Procedure 906 923	radiation therapy
92,T58,Temporal 928 962	at least 4 weeks before enrollment
93,R35,Has_temporal Arg1:T57 Arg2:T58
94,T59,Negation 897 899	No
95,T60,Temporal 900 905	prior
96,R36,Has_temporal Arg1:T57 Arg2:T60
97,R37,Has_negation Arg1:T57 Arg2:T59
98,T61,Reference_point 773 783	enrollment
99,R31,Has_index Arg1:T50 Arg2:T61
100,T62,Negation 784 795	was allowed
101,R38,Has_negation Arg1:T48 Arg2:T62
102,T63,Scope 711 795	prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed
103,R39,Has_scope Arg1:T45 Arg2:T63
104,T64,Reference_point 952 962	enrollment
105,R40,Has_index Arg1:T58 Arg2:T64
106,A1,Optional T41
107,R23,Has_value Arg1:T41 Arg2:T42
108,*,OR T40 T41
0,T1,Qualifier 0 6	Active
1,T2,Condition 7 24	opioid dependence
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Qualifier 26 31	Acute
4,T4,Qualifier 35 42	chronic
5,*,OR T3 T4
6,T5,Condition 43 47	pain
7,T6,Scope 26 42	Acute or chronic
8,R2,Has_scope Arg1:T5 Arg2:T6
9,T7,Procedure 58 74	opioid treatment
10,R3,AND Arg1:T5 Arg2:T7
11,T8,Condition 76 94	Acute liver injury
12,T9,Measurement 96 133	liver aminotransferase concentrations
13,T10,Value 134 168	>5 times the upper limit of normal
14,R4,Has_value Arg1:T9 Arg2:T10
15,T11,Scope 96 168	liver aminotransferase concentrations >5 times the upper limit of normal
16,R5,Subsumes Arg1:T8 Arg2:T11
17,T12,Condition 171 187	Health condition
18,T13,Qualifier 188 219	considered unsafe for inclusion
19,R6,Has_qualifier Arg1:T12 Arg2:T13
20,T14,Non-query-able 221 267	at discretion of PI and/or attending physician
21,T15,Observation 290 312	willingness to consent
22,T16,Negation 270 277	Lack of
23,T17,Observation 278 286;302 312	capacity to consent
24,*,OR T15 T17
25,T18,Scope 278 312	capacity or willingness to consent
26,R7,Has_negation Arg1:T18 Arg2:T16
27,T19,Condition 355 373	alcohol dependence
28,T20,Procedure 335 350	pharmacotherapy
29,T21,Temporal 314 323	Currently
30,R8,AND Arg1:T20 Arg2:T19
31,R9,Has_temporal Arg1:T20 Arg2:T21
32,T22,Negation 375 388	not including
33,T23,Procedure 389 398	treatment
34,T24,Condition 402 435	acute alcohol withdrawal syndrome
35,R10,AND Arg1:T23 Arg2:T24
36,R11,Has_negation Arg1:T23 Arg2:T22
37,R12,AND Arg1:T20 Arg2:T23
38,T25,Temporal 438 446	Previous
39,T26,Qualifier 447 458	significant
40,T27,Condition 459 475	adverse reaction
41,T28,Drug 479 489	naltrexone
42,T29,Drug 493 500	diluent
43,*,OR T28 T29
44,T30,Scope 479 500	naltrexone or diluent
45,R13,Has_qualifier Arg1:T27 Arg2:T26
46,R14,Has_temporal Arg1:T27 Arg2:T25
47,R15,Has_scope Arg1:T27 Arg2:T30
48,T31,Condition 502 510	Pregnant
49,T32,Condition 512 519	nursing
50,T33,Negation 524 527	not
51,T34,Procedure 555 568	birth control
52,T35,Qualifier 534 551	effective methods
53,R16,Has_qualifier Arg1:T34 Arg2:T35
54,R17,Has_negation Arg1:T34 Arg2:T33
55,*,OR T31 T32 T34
56,T36,Person 570 579	Prisoners
57,T37,Qualifier 595 630	Office of Human Research Protection
58,R18,Has_qualifier Arg1:T36 Arg2:T37
59,T38,Temporal 632 657	at the time of enrollment
60,T39,Reference_point 635 657	the time of enrollment
61,R19,Has_index Arg1:T38 Arg2:T39
62,R20,Has_temporal Arg1:T36 Arg2:T38
63,T40,"Non-representable 692 866	However, subjects who become prisoners after being enrolled will be included and not be withdrawn from the study. Patients on parole or probation are eligible for enrollment."
0,T1,Condition 25 34	allergies
1,T2,Drug 38 46	propofol
2,T3,Drug 48 63	dexmedetomidine
3,T4,Drug 65 73	fentanyl
4,T5,Observation 75 79	eggs
5,T6,Observation 83 95	egg products
6,T7,Observation 100 103	soy
7,T8,Observation 107 119	soy products
8,*,OR T2 T3 T4 T5 T6 T7 T8
9,T9,"Scope 38 119	propofol, dexmedetomidine, fentanyl, eggs or egg products, or soy or soy products"
10,R1,Has_scope Arg1:T1 Arg2:T9
11,T10,Measurement 124 134	heart rate
12,T11,Value 135 160	less than 50 beats/minute
13,T12,Condition 177 191	AV heart block
14,T13,Qualifier 164 171	grade 2
15,T14,Qualifier 164 169;175 176	grade 3
16,*,OR T13 T14
17,T15,Scope 164 176	grade 2 or 3
18,R2,Has_scope Arg1:T12 Arg2:T15
19,R3,Has_value Arg1:T10 Arg2:T11
20,*,OR T10 T12
21,T16,Measurement 193 215	Mean arterial pressure
22,T17,Value 216 233	less than 55 mmHg
23,R4,Has_value Arg1:T16 Arg2:T17
24,T18,Procedure 254 273	fluid resuscitation
25,T19,Procedure 278 289	vasopressor
26,T20,Measurement 308 326	triglyceride level
27,T21,Value 327 338	> 400 mg/dl
28,R5,Has_value Arg1:T20 Arg2:T21
0,T1,Condition 22 36	adenocarcinoma
1,T2,Condition 6 11	tumor
2,T3,Condition 38 77	Central nervous system (CNS) metastases
3,T4,Procedure 87 96	radiation
4,T5,Condition 101 115	CNS metastases
5,R2,AND Arg1:T4 Arg2:T5
6,*,OR T3 T4
7,T6,Condition 117 143	Gastric outlet obstruction
8,T7,Condition 147 169	intestinal obstruction
9,*,OR T6 T7
10,T8,Condition 183 208	gastrointestinal bleeding
11,T9,Observation 171 182	Evidence of
12,R3,AND Arg1:T9 Arg2:T8
13,T10,Condition 226 238	bony lesions
14,T11,Value 242 250	the sole
15,T12,Qualifier 251 268	evaluable disease
16,R4,Has_qualifier Arg1:T11 Arg2:T12
17,R5,Has_value Arg1:T10 Arg2:T11
18,T13,Observation 290 300	history of
19,T14,Condition 301 309	neoplasm
20,T15,Condition 321 335	stomach cancer
21,R7,AND Arg1:T13 Arg2:T14
22,T16,Condition 367 391	non-melanoma skin cancer
23,T17,Condition 395 432	in situ carcinoma of the cervix uteri
24,*,OR T16 T17
25,T18,Procedure 359 366	treated
26,T19,Qualifier 348 358	curatively
27,R8,Has_qualifier Arg1:T18 Arg2:T19
28,T20,Scope 367 432	non-melanoma skin cancer or in situ carcinoma of the cervix uteri
29,R9,Has_scope Arg1:T18 Arg2:T20
30,T21,Condition 434 442	Pregnant
31,T22,Condition 446 455	lactating
32,T23,Person 456 461	women
33,*,OR T21 T22 T66
34,T24,Condition 472 494	childbearing potential
35,T25,Person 463 468	women
36,T26,Procedure 518 531	contraception
37,T27,Negation 495 508	not employing
38,R10,Has_negation Arg1:T26 Arg2:T27
39,T28,Condition 539 554	serious illness
40,T29,Condition 558 576	medical conditions
41,*,OR T28 T29
42,T30,Condition 578 602	Unstable cardiac disease
43,T31,Procedure 611 620	treatment
44,T32,Condition 622 643	myocardial infarction
45,T33,Temporal 644 680	within 6 months prior to study entry
46,R11,Has_temporal Arg1:T32 Arg2:T33
47,*,OR T30 T32
48,T34,Condition 705 715;731 740	neurologic disorders
49,T35,Condition 719 740	psychiatric disorders
50,*,OR T34 T35
51,T36,Condition 751 759	dementia
52,T37,Condition 763 771	seizures
53,*,OR T36 T37
54,T38,Scope 751 771	dementia or seizures
55,T39,Scope 705 740	neurologic or psychiatric disorders
56,R12,Subsumes Arg1:T39 Arg2:T38
57,T40,Observation 682 689	History
58,T41,Condition 793 802	infection
59,T42,Qualifier 780 792	uncontrolled
60,R13,Has_qualifier Arg1:T41 Arg2:T42
61,T43,Temporal 773 779	Active
62,R14,Has_temporal Arg1:T41 Arg2:T43
63,T44,Condition 810 817;829 847	serious medical conditions
64,T45,Observation 871 908	ability of the patient to participate
65,R15,AND Arg1:T45 Arg2:T44
66,T46,Drug 963 980	experimental drug
67,T47,Temporal 923 934	Concomitant
68,R16,Has_temporal Arg1:T46 Arg2:T47
69,T48,Procedure 1017 1029	chemotherapy
70,T49,Procedure 1031 1047	hormonal therapy
71,T50,Procedure 1052 1065	immunotherapy
72,*,OR T50 T49 T48
73,T51,Temporal 1005 1016	concomitant
74,T52,"Scope 1017 1065	chemotherapy, hormonal therapy, or immunotherapy"
75,R17,Has_temporal Arg1:T52 Arg2:T51
76,*,OR T52 T46
77,T53,Drug 1084 1094	medication
78,T54,Drug 1079 1083	drug
79,*,OR T54 T53
80,T55,Temporal 1067 1078	concomitant
81,T56,Scope 1079 1094	drug medication
82,R18,Has_temporal Arg1:T56 Arg2:T55
83,T57,Drug 1153 1161	Warfarin
84,T58,Drug 1163 1176	phenprocoumon
85,T59,Measurement 1187 1204	bleeding tendency
86,T60,Measurement 1218 1250	blood concentration of phenytoin
87,T61,Value 1209 1217	Increase
88,R19,Has_value Arg1:T60 Arg2:T61
89,T62,Drug 1256 1266	sorivudine
90,T63,Drug 1335 1346	allopurinol
91,T64,Value 1178 1186	increase
92,R20,Has_value Arg1:T59 Arg2:T64
93,T65,Drug 1314 1330	fluoropyrimidine
94,T66,Scope 472 531	childbearing potential not employing adequate contraception
95,*,OR T57 T58
96,*,OR T65 T63 T62
97,T67,Non-representable 1178 1204	increase bleeding tendency
98,T68,Non-representable 1209 1250	Increase blood concentration of phenytoin
99,T69,Non-representable 1096 1148	The following drugs cause drug interaction with S-1.
100,T70,Negation 310 320	other than
101,R6,Has_negation Arg1:T15 Arg2:T70
102,R21,AND Arg1:T14 Arg2:T15
103,T71,Negation 337 347	except for
104,R22,AND Arg1:T14 Arg2:T18
105,T72,Negation 0 5	Other
106,R1,Has_negation Arg1:T1 Arg2:T72
107,R23,AND Arg1:T2 Arg2:T1
108,R24,Has_negation Arg1:T18 Arg2:T71
0,T1,Observation 0 7;19 27	English speaking
1,T2,Observation 11 27	Spanish speaking
2,*,OR T2 T1
3,T3,Visit 30 50	Emergency Department
4,T4,Person 60 64	Aged
5,T5,Value 65 70	18-80
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Multiplier 81 83	>4
8,T7,Visit 84 111	emergency department visits
9,T8,Temporal 112 128	within 12 months
10,T9,Temporal 147 163	12-month periods
11,T10,Multiplier 133 146	2 consecutive
12,R2,Has_multiplier Arg1:T9 Arg2:T10
13,R3,Has_temporal Arg1:T7 Arg2:T8
14,R4,Has_temporal Arg1:T7 Arg2:T9
15,R5,Has_multiplier Arg1:T7 Arg2:T6
16,T11,Person 217 229	incarcerated
17,T12,Person 233 250	institutionalized
18,*,OR T12 T11
19,T14,Scope 217 250	incarcerated or institutionalized
20,T13,Temporal 187 213	extended by up to 6 months
21,R6,Has_temporal Arg1:T14 Arg2:T13
22,A1,Optional T14
23,T15,Qualifier 273 335	Diagnostic and Statistical Manual version IV (DSM-IV) criteria
24,T16,Condition 340 358	alcohol dependence
25,T17,Qualifier 364 378	DSM-V criteria
26,T18,Condition 383 403	alcohol use disorder
27,T19,Qualifier 405 411	severe
28,R7,Has_qualifier Arg1:T18 Arg2:T19
29,R8,Has_qualifier Arg1:T18 Arg2:T17
30,R9,Has_qualifier Arg1:T16 Arg2:T15
31,T20,Multiplier 419 431	≥2 days/week
32,T21,Condition 435 449	heavy drinking
33,R10,Has_multiplier Arg1:T21 Arg2:T20
34,T22,Value 451 453	>4
35,T23,Measurement 454 464	drinks/day
36,R11,Has_value Arg1:T23 Arg2:T22
37,T24,Observation 485 501	informed consent
38,T25,Mood 467 484	Capable of giving
39,R12,Has_mood Arg1:T24 Arg2:T25
0,T1,Person 0 3	Men
1,T2,Person 8 13	women
2,T3,Person 26 29	old
3,T4,Value 14 25	18-89 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T5,Condition 53 59	sepsis
7,T6,Temporal 81 109	within the previous 24 hours
8,R2,Has_temporal Arg1:T5 Arg2:T6
9,T7,Procedure 123 145	mechanical ventilation
10,T8,Informed_consent 152 229	provide informed consent either personally or by an authorized representative
0,T1,Qualifier 0 12	uncontrolled
1,T2,Condition 13 25	hypertension
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Qualifier 27 39	uncontrolled
4,T4,Condition 40 48	diabetes
5,R2,Has_qualifier Arg1:T4 Arg2:T3
6,T5,Measurement 50 60	creatinine
7,T6,"Value 61 72	> 2,5 mg/dl"
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Measurement 74 83	potassium
10,T8,Value 84 93	> 6 mg/dl
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Condition 95 118	acute coronary syndrome
13,T10,Condition 120 147	hypertrophic cardiomyopathy
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 119 121	2.
2,T3,Parsing_Error 204 206	3.
3,T4,Parsing_Error 249 251	4.
4,T5,Parsing_Error 353 355	5.
5,T6,Parsing_Error 429 431	6.
6,T7,Parsing_Error 616 618	7.
7,T8,Parsing_Error 703 705	8.
8,T9,Condition 28 40	GTC seizures
9,T10,Condition 49 60	primary GTC
10,T11,Condition 64 86	partial onset seizures
11,T12,Condition 92 116	secondary generalization
12,R1,AND Arg1:T11 Arg2:T12
13,*,OR T11 T10
14,T13,Scope 49 116	primary GTC or partial onset seizures with secondary generalization
15,R2,Subsumes Arg1:T9 Arg2:T13
16,T14,Observation 17 24	history
17,R3,Has_temporal Arg1:T9 Arg2:T14
18,T15,Procedure 166 181	vEEG monitoring
19,T16,Condition 193 201	seizures
20,R4,AND Arg1:T15 Arg2:T16
21,T17,Procedure 131 153	admitted to a hospital
22,R5,AND Arg1:T17 Arg2:T15
23,T18,Person 215 221	female
24,T19,Person 207 211	Male
25,*,OR T18 T19
26,T21,Person 230 238	the ages
27,T20,Value 222 229;242 246	between 2-99
28,R6,Has_value Arg1:T21 Arg2:T20
29,T22,Measurement 259 282	upper arm circumference
30,T23,Qualifier 292 334	adequate for proper fit of the EMG monitor
31,T24,Undefined_semantics 292 334	adequate for proper fit of the EMG monitor
32,T25,Value 336 349	at least 14cm
33,R7,Subsumes Arg1:T23 Arg2:T25
34,R8,Has_qualifier Arg1:T22 Arg2:T23
35,T26,Condition 373 395	childbearing potential
36,T27,Person 359 365	female
37,T28,Scope 359 395	female and of childbearing potential
38,A1,Optional T28
39,T29,Measurement 412 426	pregnancy test
40,T30,Value 403 411	negative
41,R9,Has_value Arg1:T29 Arg2:T30
42,R10,AND Arg1:T28 Arg2:T29
43,T31,"Post-eligibility 432 614	Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments."
44,T32,"Non-query-able 432 614	Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments."
45,T33,Post-eligibility 619 701	Subject and/or Primary Caregiver must be competent to follow all study procedures.
46,T34,Non-query-able 619 700	Subject and/or Primary Caregiver must be competent to follow all study procedures
47,T35,"Non-query-able 706 753	Is able to read, speak, and understand English."
0,T1,Condition 14 21	anaemia
1,T2,Person 23 28	males
2,T3,Measurement 29 31	Hb
3,T4,Value 32 40	<130 g/L
4,T5,Person 42 49	females
5,T6,Value 50 58	<120 g/L
6,A1,Optional T2
7,A2,Optional T5
8,R1,Has_value Arg1:T2 Arg2:T4
9,R2,Has_value Arg1:T5 Arg2:T6
10,T7,"Scope 23 28;32 58	males <130 g/L, females <120 g/L"
11,R3,Has_scope Arg1:T3 Arg2:T7
12,*,OR T5 T2
13,T8,"Scope 23 58	males Hb <130 g/L, females <120 g/L"
14,R4,Subsumes Arg1:T1 Arg2:T8
15,T9,Qualifier 71 79	elective
16,T10,Procedure 80 95	cardiac surgery
17,R5,Has_qualifier Arg1:T10 Arg2:T9
18,T11,Mood 101 121	available to receive
19,T12,Drug 122 132	trial drug
20,T13,Temporal 133 161	1- 10 weeks prior to surgery
21,R6,Has_mood Arg1:T12 Arg2:T11
22,R7,Has_temporal Arg1:T12 Arg2:T13
23,T14,Reference_point 154 161	surgery
24,T15,Procedure 154 161	surgery
25,R8,Has_index Arg1:T13 Arg2:T14
26,R9,multi Arg1:T14 Arg2:T15
0,T1,Person 0 5	Adult
1,T2,Person 15 19	male
2,T3,Person 23 29	female
3,*,OR T2 T3
4,T4,Procedure 41 74	emergency endotracheal intubation
0,T1,Condition 0 18	Abnormal karyotype
1,T2,Procedure 29 35;49 61	pelvic radiotherapy
2,T3,Procedure 39 61	abdominal radiotherapy
3,*,OR T2 T3
4,T4,Temporal 20 28	Previous
5,T5,Scope 29 61	pelvic or abdominal radiotherapy
6,R1,Has_temporal Arg1:T5 Arg2:T4
7,T6,Procedure 72 91	surgical management
8,T7,Condition 95 112	ovarian pathology
9,R2,AND Arg1:T6 Arg2:T7
10,T8,Temporal 63 71	Previous
11,R3,Has_temporal Arg1:T6 Arg2:T8
12,T9,Condition 131 136;154 164	renal malignancy
13,T10,Condition 145 152;154 164	cardiac malignancy
14,T11,Condition 138 143;154 164	liver malignancy
15,T12,Condition 114 129	Chronic disease
16,T13,Undefined_semantics 114 129	Chronic disease
17,T14,"Scope 131 164	renal, liver, cardiac, malignancy"
18,*,OR T9 T11 T10
19,R4,Subsumes Arg1:T12 Arg2:T14
0,T1,Condition 10 27;46 64	symptomatic brain metastatic disease
1,T2,Condition 10 21;31 64	symptomatic leptomeningeal metastatic disease
2,*,OR T1 T2
3,T3,Qualifier 0 9	Untreated
4,R1,Has_qualifier Arg1:T2 Arg2:T3
5,R2,Has_qualifier Arg1:T2 Arg2:T3
6,T4,Condition 78 100	psychiatric conditions
7,T5,Undefined_semantics 78 100	psychiatric conditions
8,T6,Condition 67 74;90 100	Medical conditions
9,*,OR T6 T4
10,T8,Subjective_judgement 67 128	Medical or psychiatric conditions comprising informed consent
11,T7,Non-query-able 67 128	Medical or psychiatric conditions comprising informed consent
12,T9,Subjective_judgement 131 321	Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.
13,T10,Context_Error 131 321	Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.
14,T11,Procedure 323 335	Radiotherapy
15,T12,Temporal 336 365	within 4 weeks of trial entry
16,T13,Reference_point 354 365	trial entry
17,R3,Has_index Arg1:T12 Arg2:T13
18,R4,Has_temporal Arg1:T11 Arg2:T12
19,T14,Condition 375 393	autoimmune disease
20,T15,Temporal 368 374	Active
21,R5,Has_temporal Arg1:T14 Arg2:T15
22,T16,Procedure 412 430	systemic treatment
23,T17,Temporal 431 446	in past 2 years
24,R6,Has_temporal Arg1:T16 Arg2:T17
25,R7,AND Arg1:T14 Arg2:T16
26,T18,Drug 465 473	steroids
27,T19,Multiplier 448 461	Chronic usage
28,R8,Has_multiplier Arg1:T18 Arg2:T19
29,T20,Drug 483 511	immunosuppressant medication
30,T21,Undefined_semantics 483 511	immunosuppressant medication
31,*,OR T20 T18
32,R9,Has_multiplier Arg1:T20 Arg2:T19
33,T22,Condition 534 545	pneumonitis
34,T23,Observation 523 530	history
35,R10,Has_temporal Arg1:T22 Arg2:T23
36,T24,Condition 573 585	autoimmunity
37,T25,Condition 548 585	Any evidence of clinical autoimmunity
38,*,OR T25 T24
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 64 66	2.
2,T3,Parsing_Error 212 214	3.
3,T4,Parsing_Error 259 261	4.
4,T5,Parsing_Error 366 368	5.
5,T6,Parsing_Error 387 389	6.
6,T7,Condition 41 61	generalized seizures
7,T8,Observation 30 37	history
8,T9,Negation 8 11	not
9,R1,Has_negation Arg1:T7 Arg2:T9
10,R2,Has_temporal Arg1:T7 Arg2:T8
11,T10,Condition 81 92	GTC seizure
12,T11,Negation 71 74	not
13,T12,Temporal 93 113	within the last year
14,R3,Has_temporal Arg1:T10 Arg2:T12
15,R4,Has_negation Arg1:T10 Arg2:T11
16,T13,Drug 157 177	anti-epileptic drugs
17,T14,Procedure 144 177	reduction of anti-epileptic drugs
18,R5,AND Arg1:T14 Arg2:T13
19,T15,Temporal 178 209	during their hospital admission
20,T16,Reference_point 191 209	hospital admission
21,R6,Has_index Arg1:T15 Arg2:T16
22,R7,Has_temporal Arg1:T14 Arg2:T15
23,T17,Negation 121 124	not
24,R8,Has_negation Arg1:T14 Arg2:T17
25,T18,Device 215 242	Intracranial EEG electrodes
26,T19,Measurement 276 299	upper arm circumference
27,T20,Qualifier 304 346	adequate for proper fit of the EMG monitor
28,T21,Negation 300 303	not
29,T22,Non-query-able 304 346	adequate for proper fit of the EMG monitor
30,T23,Value 348 362	less than 14cm
31,R9,Subsumes Arg1:T20 Arg2:T23
32,R10,Has_negation Arg1:T20 Arg2:T21
33,R11,Has_qualifier Arg1:T19 Arg2:T20
34,T24,Person 378 384	female
35,T25,Condition 369 377	Pregnant
36,T26,Non-query-able 390 437	Subject/Caregiver is unable to provide consent.
37,T27,Post-eligibility 390 437	Subject/Caregiver is unable to provide consent.
0,T1,Condition 0 13	heart failure
1,T2,Measurement 14 18	NYHA
2,T3,Value 19 24	II-IV
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Procedure 35 44	treatment
6,T5,Temporal 26 34	previous
7,T6,Drug 50 59	diuretics
8,R3,AND Arg1:T4 Arg2:T6
9,R4,Has_temporal Arg1:T4 Arg2:T5
10,T7,Person 61 64	age
11,T8,Value 64 73	>18 years
12,R5,Has_value Arg1:T7 Arg2:T8
0,T1,Condition 0 9	Pregnancy
1,T2,Condition 17 33	hypersensitivity
2,T3,Drug 37 47	study drug
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Drug 49 70	ferric carboxymaltose
5,R2,Subsumes Arg1:T3 Arg2:T4
6,T5,Condition 124 141	haemoglobinopathy
7,T6,Condition 142 154	thalassaemia
8,T7,Mood 114 123	suspected
9,T8,Mood 105 110	Known
10,*,OR T8 T7
11,T9,Scope 105 123	Known or suspected
12,*,OR T5 T6
13,T10,Scope 124 154	haemoglobinopathy/thalassaemia
14,R3,Subsumes Arg1:T10 Arg2:T9
15,T11,Condition 156 175	Bone marrow disease
16,T12,Condition 177 193	Haemochromatosis
17,T13,Procedure 195 209	Renal dialysis
18,T14,Drug 211 225	Erythropoietin
19,T15,Drug 229 236	IV iron
20,T16,Temporal 237 260	in the previous 4 weeks
21,*,OR T14 T15
22,T17,Scope 211 236	Erythropoietin or IV iron
23,R4,Subsumes Arg1:T17 Arg2:T16
0,T1,Person 0 8	Children
1,T2,Value 10 19	<18 years
2,T3,Person 20 23	old
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Scope 10 23	<18 years old
5,R2,Subsumes Arg1:T1 Arg2:T4
6,T5,Person 27 32	Women
7,T6,Condition 53 61	pregnant
8,T7,Procedure 100 110	randomized
9,T8,Temporal 89 99	previously
10,R3,Has_temporal Arg1:T7 Arg2:T8
11,T9,Procedure 151 174	endotracheal intubation
12,T10,Observation 143 150	require
13,R4,Has_context Arg1:T9 Arg2:T10
14,T11,Drug 183 202	sedative medication
15,T12,Negation 175 182	without
16,R5,Has_negation Arg1:T11 Arg2:T12
17,R6,AND Arg1:T9 Arg2:T11
18,T13,Condition 229 248	full cardiac arrest
19,T14,Condition 273 280	allergy
20,T15,Drug 284 292	ketamine
21,T16,Drug 296 305	etomidate
22,*,OR T16 T15
23,T17,Scope 284 305	ketamine or etomidate
24,R7,Has_scope Arg1:T14 Arg2:T17
25,T18,Condition 308 413	Any individual wearing a MedAlert bracelet indicating that he/she has formally opted out of the EvK Trial
0,T1,Condition 46 51	NSCLC
1,T2,Qualifier 25 37	PD-L1 status
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Procedure 53 59	Biopsy
4,T4,Temporal 68 101	within 70 days of first treatment
5,T5,Reference_point 86 120	first treatment with pembrolizumab
6,T6,Drug 107 120	pembrolizumab
7,R2,Has_temporal Arg1:T3 Arg2:T4
8,R3,Has_index Arg1:T4 Arg2:T5
9,T7,Measurement 123 146	ECOG performance status
10,T8,Value 147 148	2
11,R4,Has_value Arg1:T7 Arg2:T8
12,T9,Observation 151 166	Life expectancy
13,T10,Measurement 230 289	Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
14,T11,Value 180 208	Uni-dimensionally measurable
15,T12,Condition 209 216	disease
16,T13,Context_Error 209 216	disease
17,R5,AND Arg1:T12 Arg2:T10
18,R6,Has_value Arg1:T10 Arg2:T11
19,T14,Procedure 291 345	Computerised Tomography (CT) scan of chest and abdomen
20,T15,Temporal 346 386	within 28 days of starting pembrolizumab
21,T16,Reference_point 364 386	starting pembrolizumab
22,T17,Drug 373 386	pembrolizumab
23,R7,Has_index Arg1:T15 Arg2:T16
24,R8,Has_temporal Arg1:T14 Arg2:T15
25,T18,Measurement 424 438	Platelet count
26,T19,Value 439 452	≥100 x 109 /L
27,R9,Has_value Arg1:T18 Arg2:T19
28,T20,Measurement 455 466	Neutrophils
29,T21,Value 467 479	≥1.5 x 109/L
30,R10,Has_value Arg1:T20 Arg2:T21
31,T22,Measurement 482 493	Haemoglobin
32,T23,Value 494 501	≥ 9g/dL
33,R11,Has_value Arg1:T22 Arg2:T23
34,T24,Parsing_Error 389 422	Adequate haematological function:
35,T25,Parsing_Error 504 530	Adequate hepatic function:
36,T26,Measurement 532 547	Serum bilirubin
37,T27,Value 548 582	≤1.5 x upper limit of normal (ULN)
38,R12,Has_value Arg1:T26 Arg2:T27
39,T28,Measurement 585 604	Serum transaminases
40,T29,Value 605 615	≤2.5 x ULN
41,R13,Has_value Arg1:T28 Arg2:T29
42,T30,Measurement 643 663	Creatinine clearance
43,T31,Value 664 678	<1.5 times ULN
44,R14,Has_value Arg1:T30 Arg2:T31
45,T32,Temporal 679 689	concurrent
46,T33,Measurement 695 715	creatinine clearance
47,T34,Value 716 726	>50 ml/min
48,R15,Has_value Arg1:T33 Arg2:T34
49,R16,Has_temporal Arg1:T30 Arg2:T32
50,R17,Has_temporal Arg1:T33 Arg2:T32
51,T35,Measurement 627 641	renal function
52,T36,Value 618 626	Adequate
53,R18,Has_value Arg1:T35 Arg2:T36
54,T37,Scope 643 726	Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min
55,R19,Subsumes Arg1:T36 Arg2:T37
56,T38,"Post-eligibility 729 847	Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses."
57,T39,"Non-query-able 729 847	Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses."
0,T1,Person 0 5	Women
1,T2,Condition 11 14	POI
2,A1,Optional T1
3,R1,AND Arg1:T1 Arg2:T2
4,T3,Person 90 94	aged
5,T4,Value 95 113	less than 40 years
6,R2,Has_value Arg1:T3 Arg2:T4
7,T5,Condition 122 132	amenorrhea
8,T6,Temporal 136 152	at least 4 month
9,T7,Measurement 158 167	FSH level
10,T8,Value 168 181	above 25 IU/L
11,T9,Multiplier 183 197	repeated twice
12,T10,Temporal 198 212	>4 weeks apart
13,R3,Has_temporal Arg1:T9 Arg2:T10
14,R4,Has_value Arg1:T7 Arg2:T8
15,R5,Has_multiplier Arg1:T7 Arg2:T9
16,R6,Has_temporal Arg1:T5 Arg2:T6
17,R7,AND Arg1:T5 Arg2:T7
18,T11,Scope 90 213	aged less than 40 years and has amenorrhea of at least 4 month with FSH level above 25 IU/L (repeated twice >4 weeks apart)
19,R8,Has_scope Arg1:T2 Arg2:T11
0,T1,Person 9 12	age
1,T2,Value 13 24	8- 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Line 25 109	2) Patients undergoing minimally invasive pectus excavatum repair via Nuss procedure
4,T4,Line 110 160	3) American Society of Anesthesiology Status I-III
5,T5,Procedure 48 90	minimally invasive pectus excavatum repair
6,T6,Qualifier 95 109	Nuss procedure
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Measurement 113 154	American Society of Anesthesiology Status
9,T8,Value 155 160	I-III
10,R3,Has_value Arg1:T7 Arg2:T8
0,T1,Condition 18 22	coma
1,T2,Condition 24 34	convulsion
2,T3,Condition 38 47	paralysis
3,T4,Condition 55 78	intracranial hemorrhage
4,T5,Qualifier 82 104	central nervous system
5,T6,Condition 105 113	leukemia
6,R1,Has_qualifier Arg1:T6 Arg2:T5
7,T7,Temporal 114 126	at diagnosis
8,*,OR T4 T6
9,T8,Scope 55 113	intracranial hemorrhage or central nervous system leukemia
10,R2,Has_temporal Arg1:T8 Arg2:T7
11,*,OR T2 T3 T1
12,T9,"Scope 18 47	coma, convulsion or paralysis"
13,R3,Has_scope Arg1:T9 Arg2:T8
0,T1,Measurement 14 26	Ph (BCR/ABL)
1,T2,Value 27 35	positive
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 36 43	de novo
4,R2,Has_qualifier Arg1:T1 Arg2:T3
5,T4,Value 44 54	< 55 years
6,T5,Person 55 58	old
7,R3,Has_value Arg1:T5 Arg2:T4
8,T6,Non-representable 59 128	(it is advisable to include patients over 55 years LAL07OPH protocol)
9,T7,Measurement 131 149	Performance status
10,T8,Value 150 153	0-2
11,R4,Has_value Arg1:T7 Arg2:T8
12,T10,Condition 255 286	functional impairment of organs
13,T9,Non-representable 154 235	(Appendix B) may include patients with performance status > 2 attributable to LAL
14,T11,Negation 247 254	without
15,T12,Measurement 304 319	total bilirubin
16,T13,Measurement 321 324	AST
17,T14,Measurement 326 329	ALT
18,T15,Measurement 331 338	alfa-GT
19,T16,Measurement 343 363	alkaline phosphatase
20,T17,Value 364 407	less than 3 times the upper limit of normal
21,R5,Has_negation Arg1:T10 Arg2:T11
22,T18,"Scope 304 363	total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase"
23,R6,Has_value Arg1:T18 Arg2:T17
24,T19,"Scope 304 407	total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal"
25,T20,Scope 247 286	without functional impairment of organs
26,T21,Measurement 435 451	serum creatinine
27,T22,Value 452 461	< 2 mg/dL
28,T23,Measurement 465 485	clearance creatinine
29,T24,Value 486 497	> 30 ml/min
30,T25,Non-representable 498 541	(except renal function attributable to LAL)
31,T26,Measurement 542 558	cardiac function
32,T27,Value 572 578	normal
33,R8,Has_value Arg1:T26 Arg2:T27
34,R9,Has_value Arg1:T23 Arg2:T24
35,R10,Has_value Arg1:T21 Arg2:T22
36,*,OR T21 T23
37,T28,Measurement 580 594	ventricular EF
38,T29,Value 595 600	> 50%
39,R7,Has_value Arg1:T28 Arg2:T29
40,T30,Negation 602 612	absence of
41,T31,Condition 613 647	severe chronic respiratory disease
42,R11,Has_negation Arg1:T31 Arg2:T30
43,T32,Scope 542 578	cardiac function (Appendix B) normal
44,T33,Scope 580 600	ventricular EF > 50%
45,R12,Subsumes Arg1:T32 Arg2:T33
46,T34,Non-representable 649 805	In the event that alterations are secondary to the disease is at the discretion of the investigator to determine if the patient can be included in the trial
47,T35,"Scope 304 648	total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease."
48,R13,Subsumes Arg1:T20 Arg2:T35
0,T1,Mood 3 10	Refusal
1,T2,Device 14 31	epidural catheter
2,R1,Has_mood Arg1:T2 Arg2:T1
3,T3,Condition 35 44	Pregnancy
4,T4,Condition 48 56	Bleeding
5,T5,Observation 57 64	History
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Non-query-able 68 117	Inability to understand how to use the PCA device
8,T7,Drug 121 131	Medication
9,T8,Qualifier 132 166	interfering with blood coagulation
10,R3,Has_qualifier Arg1:T7 Arg2:T8
11,T9,Condition 179 187	allergic
12,T10,Drug 191 208	local anesthetics
13,R4,AND Arg1:T9 Arg2:T10
14,T11,Line 0 31	1) Refusal of epidural catheter
15,T12,Line 32 44	2) Pregnancy
16,T13,Line 45 64	3) Bleeding History
17,T14,Line 65 117	4) Inability to understand how to use the PCA device
18,T15,Line 118 166	5) Medication interfering with blood coagulation
19,T16,Line 167 208	6) Patients allergic to local anesthetics
20,T17,Line 209 251	7) Patient refusal to participate in study
21,T18,Line 252 274	8) Developmental delay
22,T19,Non-query-able 212 251	Patient refusal to participate in study
23,T20,Condition 255 274	Developmental delay
0,T1,Value 9 27	less than 16 years
1,T2,Person 28 31	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Measurement 53 61	PML-RARa
4,T4,Value 62 70	positive
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 71 99	acute promyelocytic leukemia
7,R3,AND Arg1:T5 Arg2:T3
0,T1,Qualifier 4 17	other variety
1,T2,Condition 21 24	LAL
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Observation 42 49	history
4,T4,Condition 53 76	coronary artery disease
5,T5,Condition 90 116	hypertensive heart disease
6,T6,Condition 103 116;78 86	heart disease valvular
7,*,OR T5 T6 T4
8,T7,"Scope 53 116	coronary artery disease, valvular or hypertensive heart disease"
9,R2,Has_temporal Arg1:T7 Arg2:T3
10,T8,Condition 132 153	chronic liver disease
11,T9,Condition 169 196	chronic respiratory failure
12,T10,Condition 198 211	Renal failure
13,T11,Condition 223 226	LAL
14,T12,Negation 212 215	not
15,R3,Has_negation Arg1:T11 Arg2:T12
16,T13,Mood 216 222	due to
17,R4,Has_mood Arg1:T11 Arg2:T13
18,R5,AND Arg1:T11 Arg2:T10
19,T14,Value 242 250	positive
20,T15,Measurement 251 261	HIV status
21,R6,Has_value Arg1:T15 Arg2:T14
22,T16,Negation 263 265	No
23,T17,Qualifier 266 273	serious
24,T18,Condition 274 300	neurological abnormalities
25,T19,Mood 301 307	due to
26,T20,Condition 308 311	LAL
27,R7,Has_mood Arg1:T20 Arg2:T19
28,R8,AND Arg1:T18 Arg2:T20
29,R9,Has_qualifier Arg1:T18 Arg2:T17
30,R10,Has_negation Arg1:T18 Arg2:T16
31,T21,Non-representable 313 397	Impact on overall severe (grade 3 or 4 of the WHO scale) not attributable to the LAL
32,T22,Observation 399 407	Pregnant
33,T23,Observation 411 424	breastfeeding
34,*,OR T22 T23
35,T24,Qualifier 434 446	blast crisis
36,T25,Condition 447 450	CML
37,R11,Has_qualifier Arg1:T25 Arg2:T24
0,T1,Condition 0 24	Diabetes mellitus type 1
1,T2,Condition 26 45	renal insufficiency
2,T3,Qualifier 46 53	III-V °
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Condition 55 72	Cirrhosis hepatis
5,T5,Measurement 74 79	Child
6,T6,Value 80 91	B or higher
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Qualifier 74 91	Child B or higher
9,R3,multi Arg1:T7 Arg2:T5
10,R4,Has_qualifier Arg1:T4 Arg2:T7
11,T8,Multiplier 94 101	Chronic
12,T9,Condition 102 115	alcohol abuse
13,R5,Has_multiplier Arg1:T9 Arg2:T8
14,T10,Condition 117 134	rheumatic disease
15,T11,Condition 136 138	RA
16,T12,Condition 140 143	SpA
17,T13,Condition 145 148	SLE
18,*,OR T13 T12 T11
19,T14,"Scope 136 148	RA, SpA, SLE"
20,R6,Subsumes Arg1:T10 Arg2:T14
21,T15,Condition 151 163	Malignancies
22,T16,Temporal 165 173	<5 years
23,R7,Has_temporal Arg1:T15 Arg2:T16
24,T17,Condition 176 191	Eating Disorder
25,T18,Condition 193 209	anorexia nervosa
26,T19,Condition 211 218	bulimia
27,*,OR T18 T19
28,T20,"Scope 193 218	anorexia nervosa, bulimia"
29,R8,Subsumes Arg1:T17 Arg2:T20
30,T21,Procedure 221 247	bone-specific pretreatment
31,T22,Drug 249 253	DMAB
32,T23,Drug 255 259	TPTD
33,T24,Drug 281 286	SERMs
34,T25,Drug 261 279	strontium ranelate
35,*,OR T24 T25 T23 T22
36,T26,Non-representable 288 323	Bisphosphonate treatment is allowed
37,T27,"Scope 249 286	DMAB, TPTD, strontium ranelate, SERMs"
38,R9,Subsumes Arg1:T21 Arg2:T27
0,T1,Condition 0 17	Contraindications
1,T2,Drug 21 34	empagliflozin
2,T3,Drug 36 47	Sitagliptin
3,*,OR T2 T3
4,T4,"Scope 21 47	empagliflozin, Sitagliptin"
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Drug 49 64	DPP4 inhibitors
7,T6,Drug 68 116	Sodium-glucose cotransporter-2(SGLT2) inhibitors
8,T7,Temporal 117 144	within the previous 4 weeks
9,*,OR T5 T6
10,T8,Scope 49 116	DPP4 inhibitors or Sodium-glucose cotransporter-2(SGLT2) inhibitors
11,R2,Has_temporal Arg1:T8 Arg2:T7
12,T9,Drug 146 153	Insulin
13,T10,Procedure 164 172	diabetes
14,R3,AND Arg1:T10 Arg2:T9
15,T11,Condition 174 194	Poor glucose control
16,T12,Measurement 196 201	HbA1C
17,T13,Value 201 206	>10 %
18,R4,Has_value Arg1:T12 Arg2:T13
19,T14,Scope 196 206	HbA1C>10 %
20,R5,Subsumes Arg1:T11 Arg2:T14
21,T15,Condition 209 232	Acute coronary syndrome
22,T16,Device 234 239	Stent
23,T17,Procedure 240 249	placement
24,R6,AND Arg1:T17 Arg2:T16
25,T18,Temporal 250 278	within the previous 6 months
26,R7,Has_temporal Arg1:T17 Arg2:T18
27,T19,Temporal 326 354	within the previous 6 months
28,T20,Procedure 289 325	coronary artery bypass graft surgery
29,R8,Has_temporal Arg1:T20 Arg2:T19
30,T21,Temporal 280 288	Previous
31,R9,Has_temporal Arg1:T20 Arg2:T21
32,T22,Procedure 364 381	revascularization
33,T23,Temporal 382 397	within 6 months
34,R10,Has_temporal Arg1:T22 Arg2:T23
35,T24,Mood 356 363	Planned
36,R11,Has_mood Arg1:T22 Arg2:T24
37,T25,Condition 399 412	Heart failure
38,T26,Drug 423 437	loop diuretics
39,R12,AND Arg1:T25 Arg2:T26
40,T27,Condition 446 474	left ventricular hypertrophy
41,T28,Qualifier 439 445	Severe
42,R13,Has_qualifier Arg1:T27 Arg2:T28
43,T29,Measurement 476 514	left ventricular septal wall thickness
44,T30,Value 515 521	> 13mm
45,*,OR T29 T30
46,T31,Scope 439 474	Severe left ventricular hypertrophy
47,T32,Scope 476 521	left ventricular septal wall thickness > 13mm
48,R14,Subsumes Arg1:T31 Arg2:T32
49,T33,Qualifier 524 535	Significant
50,T34,Condition 536 549	renal disease
51,T35,Measurement 564 584	creatinine clearance
52,T36,Value 588 599	< 30 ml/min
53,R15,Has_value Arg1:T35 Arg2:T36
54,R16,Has_qualifier Arg1:T34 Arg2:T33
55,T37,Scope 524 549	Significant renal disease
56,T38,Scope 564 599	creatinine clearance of < 30 ml/min
57,R17,Subsumes Arg1:T37 Arg2:T38
58,T39,Condition 602 617	Hepatic disease
59,T40,Condition 621 646	biliary tract obstruction
60,T41,Condition 663 687	hepatic enzyme elevation
61,T42,Qualifier 651 662	significant
62,R18,Has_qualifier Arg1:T41 Arg2:T42
63,*,OR T39 T40 T41 T47
64,T43,Measurement 689 709	alanine transaminase
65,T44,Measurement 713 739	Aspartate Aminotransferase
66,T45,Value 740 771	> 3 times upper limit of normal
67,*,OR T43 T44
68,T46,Scope 689 739	alanine transaminase or Aspartate Aminotransferase
69,R19,Has_value Arg1:T46 Arg2:T45
70,T47,Scope 689 771	alanine transaminase or Aspartate Aminotransferase > 3 times upper limit of normal
71,T48,Device 774 793	Radiopaque material
72,T49,Qualifier 811 821	chest wall
73,R20,Has_qualifier Arg1:T48 Arg2:T49
74,T50,Procedure 867 888	adenosine stress test
75,T51,Condition 847 863	Contraindication
76,R21,AND Arg1:T51 Arg2:T50
77,T52,"Post-eligibility 890 1113	Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study."
78,T53,Condition 1125 1133	pregnant
79,T54,Condition 1137 1151	breast-feeding
80,T55,Condition 1155 1178	child-bearing potential
81,*,OR T55 T54 T53
82,T56,Observation 1180 1204	Expected life expectancy
83,T57,Value 1205 1213	< 1 year
84,R22,Has_value Arg1:T56 Arg2:T57
85,T58,Non-query-able 1215 1298	Unwillingness or inability to comply with the procedures described in this protocol
0,T1,Condition 0 14	Postmenopausal
1,T2,Person 15 20	women
2,T3,Person 22 25	Age
3,T4,Value 26 37	60-80 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Measurement 39 46	T-score
6,T6,Procedure 60 63	DXA
7,T7,Qualifier 47 63	according to DXA
8,R2,multi Arg1:T7 Arg2:T6
9,R3,Has_qualifier Arg1:T5 Arg2:T7
10,T8,Value 65 70	<-2.5
11,R4,Has_value Arg1:T5 Arg2:T8
12,T9,Mood 72 86	indication for
13,T10,Procedure 87 107	osteoporosis therapy
14,T11,Condition 87 99	osteoporosis
15,R5,multi Arg1:T10 Arg2:T11
16,T12,Qualifier 121 145	international guidelines
17,R6,Has_mood Arg1:T10 Arg2:T9
18,R7,Has_qualifier Arg1:T9 Arg2:T12
0,T1,Person 0 3	Men
1,T2,Person 7 12	women
2,T3,Value 13 30	at least 19 years
3,T4,Person 34 37	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,*,OR T1 T2
6,T5,Condition 39 63	Type 2 diabetes mellitus
7,T6,Condition 72 95	coronary artery disease
8,T7,Qualifier 65 71	Stable
9,R2,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Measurement 97 144	Global myocardial perfusion reserve (MPR) index
11,T10,Value 145 150	< 2.5
12,R3,Has_value Arg1:T8 Arg2:T10
13,T9,"Informed_consent 276 301	informed, written consent"
0,T1,Condition 18 31	other cancers
1,T2,Temporal 32 48	at the same time
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 72 85	other cancers
4,T4,Negation 86 92	except
5,T5,Condition 93 129	controlled skin basal cell carcinoma
6,T6,Condition 133 161	skin squamous cell carcinoma
7,T7,Condition 165 199	carcinoma in situ of cervix uterus
8,*,OR T5 T6 T7
9,T8,Scope 93 199	controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus
10,R2,Has_negation Arg1:T8 Arg2:T4
11,R3,Has_scope Arg1:T3 Arg2:T8
12,*,OR T1 T3
13,T9,Temporal 220 226	active
14,T10,Condition 227 237	infections
15,T11,Negation 248 251	not
16,T12,Qualifier 252 277	suitable for chemotherapy
17,R4,Has_negation Arg1:T12 Arg2:T11
18,R5,Has_qualifier Arg1:T10 Arg2:T12
19,R6,Has_temporal Arg1:T10 Arg2:T9
20,T13,Qualifier 298 304	severe
21,T14,Condition 305 327	non-cancerous diseases
22,R7,Has_qualifier Arg1:T14 Arg2:T13
23,T15,Procedure 359 386	neoadjuvant hormone therapy
24,T16,Condition 407 431	bilateral breast cancers
25,T17,Condition 435 439	DCIS
26,T18,Condition 443 468	metastatic breast cancers
27,*,OR T18 T17 T16
28,T19,Procedure 525 546	anti-cancer therapies
29,T20,Observation 555 586	attending other clinical trials
30,*,OR T19 T20
31,T21,Condition 606 614	pregnant
32,T22,Condition 618 629	lactational
33,*,OR T22 T21 T23
34,T23,Procedure 658 671	contraception
35,T24,Negation 639 657	refuse to practice
36,R8,Has_negation Arg1:T23 Arg2:T24
37,T25,Temporal 672 694	during the whole trial
38,R9,Has_temporal Arg1:T23 Arg2:T25
39,T26,"Post-eligibility 697 835	The patients are in some special conditions that they can't understand the written informed consent, such as they are demented or hawkish."
40,T27,Condition 855 863	allergic
41,T28,Drug 895 904	tamoxifen
42,T29,Condition 875 891	contraindication
43,*,OR T29 T27
44,T30,Scope 855 891	allergic history or contraindication
45,R10,AND Arg1:T30 Arg2:T28
0,T1,Condition 25 46	primary breast cancer
1,T2,Qualifier 0 24	Histologically confirmed
2,T3,Procedure 0 14	Histologically
3,R1,multi Arg1:T2 Arg2:T3
4,R2,Has_qualifier Arg1:T1 Arg2:T2
5,T4,Drug 65 74	docetaxel
6,T5,Mood 48 64	Planned to start
7,T6,Procedure 88 93	FEC-D
8,T7,Procedure 97 101	AC-D
9,*,OR T6 T7
10,T8,Multiplier 106 120	first cycle of
11,T9,Procedure 122 137	dose-dense AC-T
12,T10,Procedure 139 141	TC
13,T11,Procedure 143 148	FEC-D
14,T12,Procedure 152 168	TAC chemotherapy
15,*,OR T9 T10 T11 T12 T13
16,T13,Scope 88 101	FEC-D or AC-D
17,*,OR T4 T8
18,T14,Scope 106 120;65 74	first cycle of docetaxel
19,R3,Has_scope Arg1:T13 Arg2:T14
20,R4,Has_mood Arg1:T13 Arg2:T5
21,T15,Person 183 186	age
22,T16,Value 170 179	=19 years
23,R5,Has_value Arg1:T15 Arg2:T16
24,T17,Informed_consent 188 218	Able to provide verbal consent
0,T1,Condition 0 21	Thalassemia syndromes
1,T2,Condition 24 54	Myelodysplastic syndrome (MDS)
2,T3,Condition 58 71	myelofibrosis
3,*,OR T3 T2
4,T4,Condition 74 97	Diamond Blackfan anemia
5,T5,Condition 100 127	Primary bone marrow failure
6,T6,Measurement 139 142	LIC
7,T7,Value 143 151	>30 mg/g
8,R1,Has_value Arg1:T6 Arg2:T7
9,T8,Temporal 130 138	Baseline
10,R2,Has_temporal Arg1:T6 Arg2:T8
11,T9,Procedure 168 171	MRI
12,T10,Mood 156 167	measured by
13,R3,Has_mood Arg1:T9 Arg2:T10
14,R4,AND Arg1:T6 Arg2:T9
15,T11,Post-eligibility 175 303	Unable or unwilling to undergo a 7 day washout period if currently being treated with deferiprone or deferoxamine or deferasirox
16,T12,Procedure 315 343	discontinuation of treatment
17,T13,Condition 349 360	deferiprone
18,T14,Condition 364 376	deferoxamine
19,*,OR T13 T14
20,T15,Scope 349 376	deferiprone or deferoxamine
21,R5,Has_scope Arg1:T12 Arg2:T15
22,T16,Condition 424 440	hypersensitivity
23,T17,Condition 444 466	idiosyncratic reaction
24,T18,Drug 470 481	deferiprone
25,T19,Drug 485 497	deferoxamine
26,*,OR T19 T18
27,T20,Scope 470 497	deferiprone or deferoxamine
28,*,OR T16 T17
29,T21,Scope 424 466	hypersensitivity or idiosyncratic reaction
30,R6,Has_scope Arg1:T21 Arg2:T20
31,T22,Drug 513 524	hydroxyurea
32,T23,Temporal 525 539	within 30 days
33,R7,Has_temporal Arg1:T22 Arg2:T23
34,T24,Condition 553 563	malignancy
35,T25,Value 578 586	abnormal
36,T26,Measurement 587 601	liver function
37,T27,Measurement 603 621	serum ALT level(s)
38,T28,Value 622 653	> 5 times upper limit of normal
39,T29,Temporal 654 666	at screening
40,T30,Measurement 670 687	creatinine levels
41,T31,Value 688 718	>2 times upper limit of normal
42,T32,Temporal 719 731	at screening
43,R8,Has_value Arg1:T27 Arg2:T28
44,R9,Has_temporal Arg1:T27 Arg2:T29
45,R10,Has_value Arg1:T30 Arg2:T31
46,R11,Has_temporal Arg1:T30 Arg2:T32
47,*,OR T27 T30
48,T33,Scope 603 731	serum ALT level(s) > 5 times upper limit of normal at screening or creatinine levels >2 times upper limit of normal at screening
49,R12,Has_value Arg1:T26 Arg2:T25
50,T34,Scope 578 601	abnormal liver function
51,R13,Subsumes Arg1:T34 Arg2:T33
52,T35,Condition 746 762	unstable illness
53,T36,Qualifier 737 744	serious
54,R14,Has_qualifier Arg1:T35 Arg2:T36
55,T37,Qualifier 764 793	as judged by the Investigator
56,R15,Has_qualifier Arg1:T36 Arg2:T37
57,T38,Temporal 795 851	during the past 3 months before screening/baseline visit
58,R16,Has_temporal Arg1:T35 Arg2:T38
59,T39,Condition 977 996	immunologic disease
60,T40,Condition 963 973;989 996	neurologic disease
61,T41,Condition 947 961;989 996	endocrinologic disease
62,T42,Condition 931 945;989 996	cardiovascular disease
63,T43,Condition 918 929;989 996	respiratory disease
64,T44,Condition 898 916;989 996	gastro-enterologic disease
65,T45,Condition 891 896;989 996	renal disease
66,T46,Condition 882 889;989 996	hepatic disease
67,*,OR T43 T46 T40 T41 T45 T42 T44 T39
68,T47,"Scope 882 996	hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease"
69,R17,Subsumes Arg1:T35 Arg2:T47
70,T48,Qualifier 999 1021	Clinically significant
71,T49,Qualifier 1022 1030	abnormal
72,T50,Procedure 1031 1042	12-lead ECG
73,T51,Condition 1043 1051	findings
74,R18,Has_qualifier Arg1:T51 Arg2:T49
75,R19,Has_qualifier Arg1:T51 Arg2:T48
76,R20,AND Arg1:T50 Arg2:T51
77,T52,Measurement 1054 1069	Cardiac MRI T2*
78,T53,Value 1070 1075	<10ms
79,R21,Has_value Arg1:T52 Arg2:T53
80,T54,Condition 1078 1099	Myocardial infarction
81,T55,Condition 1101 1115	cardiac arrest
82,T56,Condition 1119 1134	cardiac failure
83,T57,Temporal 1135 1180	within 1 year before screening/baseline visit
84,*,OR T56 T55 T54
85,T58,"Scope 1078 1134	Myocardial infarction, cardiac arrest or cardiac failure"
86,R22,Has_temporal Arg1:T58 Arg2:T57
87,T59,Condition 1183 1200	Unable to undergo
88,T60,Procedure 1201 1204	MRI
89,R23,AND Arg1:T59 Arg2:T60
90,T61,"Post-eligibility 1206 1423	Presence of metallic objects such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas that would prevent use of MRI imaging"
0,T1,Condition 0 12	normotensive
1,T2,Measurement 14 74	forced expiratory volume in 1s : forced vital capacity ratio
2,T3,Value 75 81	> 0.75
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Negation 83 85	no
5,T5,Observation 86 101	medical history
6,T6,Condition 105 119;136 143	cardiovascular disease
7,T7,Condition 124 143	respiratory disease
8,*,OR T6 T7
9,T8,Scope 105 143	cardiovascular and respiratory disease
10,R2,Has_temporal Arg1:T8 Arg2:T5
11,R3,Has_negation Arg1:T8 Arg2:T4
12,T9,Negation 145 148	not
13,T10,Drug 156 167	medications
14,T11,Negation 168 178	other than
15,T12,Drug 179 198	oral contraceptives
16,R4,Has_negation Arg1:T12 Arg2:T11
17,R5,AND Arg1:T10 Arg2:T12
18,T13,Scope 156 198	medications other than oral contraceptives
19,R6,Has_negation Arg1:T13 Arg2:T9
20,T14,Negation 200 209	free from
21,T15,Condition 210 221	sleep apnea
22,R7,Has_negation Arg1:T15 Arg2:T14
23,T16,Measurement 223 238	body mass index
24,T17,Value 239 257	less than 30 kg/m2
25,R8,Has_value Arg1:T16 Arg2:T17
0,T1,Condition 18 33	medical disease
1,T2,Qualifier 0 5	acute
2,T3,Qualifier 9 17	unstable
3,*,OR T2 T3
4,T4,Scope 0 17	acute or unstable
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 63 82	psychiatric disease
7,T6,Condition 84 94	alcoholism
8,T7,Condition 98 108	drug abuse
9,T8,Condition 120 143	primary sleep disorders
10,*,OR T5 T6 T7 T8
0,T1,Condition 11 28	allergic rhinitis
1,T2,Condition 30 38	Wheezing
0,T1,Condition 6 22	hypersensitivity
1,T2,Drug 26 32	statin
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Drug 49 56	statins
4,T4,Temporal 57 93	during the past month prior to study
5,T5,Reference_point 64 93	the past month prior to study
6,R2,Has_index Arg1:T4 Arg2:T5
7,R3,Has_temporal Arg1:T3 Arg2:T4
8,T6,Measurement 96 112	Serum creatinine
9,T7,Value 113 122	> 3 mg/dl
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Condition 136 149	liver disease
12,T9,Measurement 151 164	liver enzymes
13,T10,Value 165 197	2.5 folds the upper normal limit
14,R5,Has_value Arg1:T9 Arg2:T10
15,T11,Qualifier 124 135	Significant
16,R6,Has_qualifier Arg1:T8 Arg2:T11
17,T12,Scope 151 197	liver enzymes 2.5 folds the upper normal limit
18,T13,Scope 124 149	Significant liver disease
19,R7,Subsumes Arg1:T13 Arg2:T12
20,T14,Condition 199 209	Malignancy
21,T15,Condition 211 220	Pregnancy
22,T16,Condition 224 233	lactation
23,*,OR T15 T16
0,T1,Condition 0 16	Contraindication
1,T2,Drug 20 30	Filgrastim
2,R1,AND Arg1:T1 Arg2:T2
0,T1,Non-query-able 0 48	The patients signed the written informed consent
1,T2,Qualifier 76 84	operable
2,T3,Qualifier 85 95	unilateral
3,T4,Qualifier 96 104	invasive
4,T5,Condition 105 119	breast cancers
5,T6,Condition 128 146	distant metastasis
6,T7,Negation 120 127	without
7,R1,Has_negation Arg1:T6 Arg2:T7
8,T8,Measurement 147 152	stage
9,T9,"Value 153 167	I, II, and III"
10,R2,Has_value Arg1:T8 Arg2:T9
11,T10,Scope 120 146	without distant metastasis
12,R3,Subsumes Arg1:T10 Arg2:T8
13,R4,Has_qualifier Arg1:T5 Arg2:T4
14,R5,Has_qualifier Arg1:T5 Arg2:T3
15,R6,Has_qualifier Arg1:T5 Arg2:T2
16,R7,Has_scope Arg1:T5 Arg2:T10
17,T11,Condition 174 186	breast tumor
18,T12,Measurement 189 208	positive ER/PR rate
19,T13,Value 212 215	<1%
20,R8,Has_value Arg1:T12 Arg2:T13
21,T14,Measurement 221 243	positive ER-beta1 rate
22,T15,Value 247 251	=10%
23,T16,Procedure 255 258	IHC
24,R10,Has_value Arg1:T14 Arg2:T15
25,T17,"Scope 189 251	positive ER/PR rate is <1%, and positive ER-beta1 rate is =10%"
26,R9,Has_scope Arg1:T11 Arg2:T17
27,R11,AND Arg1:T17 Arg2:T16
28,T18,Procedure 293 320	neoadjuvant hormone therapy
29,T19,Negation 279 289	no history
30,R12,Has_negation Arg1:T18 Arg2:T19
31,T21,Condition 341 365	normal cardiac functions
32,T20,Procedure 369 385	echocardiography
33,R13,AND Arg1:T21 Arg2:T20
34,T22,Measurement 402 413	ECOG scores
35,T23,Value 418 422	=0-2
36,R14,Has_value Arg1:T22 Arg2:T23
37,T24,Person 425 431	Female
38,T25,Value 447 454	= 18yrs
39,T26,Value 460 467	= 65yrs
40,T27,"Scope 447 467	= 18yrs, and = 65yrs"
41,R15,Has_scope Arg1:T24 Arg2:T27
42,T28,"Pregnancy_considerations 470 563	The patients are non-pregnant, and disposed to practice contraception during the whole trial."
43,T29,Procedure 588 612	neoadjuvant chemotherapy
44,T30,Procedure 618 625	surgery
45,T31,Procedure 647 665	radical mastectomy
46,T32,Qualifier 629 646	directly modified
47,R16,Has_qualifier Arg1:T31 Arg2:T32
48,T33,Scope 588 625	neoadjuvant chemotherapy plus surgery
49,*,OR T31 T33 T34
50,T34,Procedure 669 694	breast-conserving surgery
51,T35,Procedure 701 727	sentinel lymph node biopsy
52,T36,Procedure 731 761	axillary lymph node dissection
53,*,OR T36 T35
54,T37,Temporal 763 795	after diagnosis of breast cancer
55,T38,Reference_point 769 795	diagnosis of breast cancer
56,R17,Has_index Arg1:T37 Arg2:T38
57,T39,Scope 588 762	neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection)
58,R18,Has_temporal Arg1:T39 Arg2:T37
59,T40,Procedure 821 833	chemotherapy
60,T41,Procedure 835 852	radiation therapy
61,T42,Procedure 856 872	targeted therapy
62,T43,Drug 873 882	herceptin
63,R19,Subsumes Arg1:T42 Arg2:T43
64,T44,Reference_point 890 897	surgery
65,T45,Temporal 884 897	after surgery
66,R20,Has_index Arg1:T45 Arg2:T44
67,T46,Procedure 890 897	surgery
68,T47,Qualifier 915 934	2013 NCCN guideline
69,*,OR T40 T41 T42
70,T48,"Scope 821 883	chemotherapy, radiation therapy or targeted therapy(herceptin)"
71,R21,Has_temporal Arg1:T48 Arg2:T45
72,R22,Has_qualifier Arg1:T48 Arg2:T47
73,T49,Non-query-able 937 989	The results of patients' blood tests are as follows:
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,*,OR T2 T1
3,T3,Value 15 24	= 2 years
4,T4,Person 28 31	age
5,R1,Has_value Arg1:T4 Arg2:T3
6,T5,Condition 39 58	sickle cell disease
7,T6,Procedure 73 91	Hb electrophoresis
8,T7,Procedure 95 114	more specific tests
9,*,OR T6 T7
10,T8,Scope 73 114	Hb electrophoresis or more specific tests
11,R2,Has_scope Arg1:T5 Arg2:T8
12,T10,Condition 119 154	other conditions with iron overload
13,T9,Multiplier 160 168	repeated
14,T11,Procedure 169 187	blood transfusions
15,R3,Has_multiplier Arg1:T11 Arg2:T9
16,R4,AND Arg1:T10 Arg2:T11
17,*,OR T5 T10
18,T12,Measurement 230 242	Baseline LIC
19,T13,Value 243 250	>7 mg/g
20,R5,Has_value Arg1:T12 Arg2:T13
21,T14,Procedure 267 270	MRI
22,R6,AND Arg1:T12 Arg2:T14
23,T15,Multiplier 301 316	no less than 20
24,T16,Procedure 317 337	transfusions of RBCs
25,R7,Has_multiplier Arg1:T16 Arg2:T15
26,T17,Multiplier 367 377;390 398	at least 1 per year
27,T18,Temporal 399 418	in the last 2 years
28,T19,Procedure 378 389	transfusion
29,R8,Has_multiplier Arg1:T19 Arg2:T17
30,R9,Has_temporal Arg1:T19 Arg2:T18
31,T20,Condition 431 472	expected to have a continuing requirement
32,T21,Temporal 509 541	during the duration of the trial
33,R10,Has_temporal Arg1:T20 Arg2:T21
0,T1,Condition 19 27	insomnia
1,T2,Qualifier 0 5	DSM-5
2,R1,Has_qualifier Arg1:T1 Arg2:T2
0,T1,Condition 11 23	hypertension
1,T2,Observation 0 7	history
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 31 54	impaired renal function
4,T4,Condition 56 69	liver disease
5,T5,Condition 71 84	heart failure
6,T6,Condition 86 107	myocardial infarction
7,T7,Condition 109 132	coronary artery disease
8,T8,Observation 134 140	smoked
9,T9,Temporal 141 161	within the past year
10,R2,Has_temporal Arg1:T8 Arg2:T9
11,T10,Measurement 163 183	apnea hypopnea index
12,T11,Value 184 203	> 5 events per hour
13,R3,Has_value Arg1:T10 Arg2:T11
0,T1,Person 14 19	years
1,T2,Value 0 13	older than 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 24 34	both sexes
4,T4,Qualifier 52 58	stable
5,T5,Condition 59 80	chronic heart failure
6,T6,Measurement 81 91	NYHA class
7,T7,Value 92 98	II-III
8,R2,Has_value Arg1:T6 Arg2:T7
9,R3,Has_qualifier Arg1:T5 Arg2:T4
10,R4,AND Arg1:T5 Arg2:T6
11,T8,Measurement 100 117	ejection fraction
12,T9,Value 118 124	< 40 %
13,T10,Procedure 140 159	2D echocardiography
14,R5,Has_value Arg1:T8 Arg2:T9
15,R6,AND Arg1:T10 Arg2:T8
16,T11,Non-representable 161 275	who have been optimized on Guideline Directed treatment for heart failure for at least a month prior to enrolling.
0,T1,Drug 7 20	antihistamine
1,T2,Temporal 21 45	within the past 72 hours
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 47 74	Chronic Pulmonary Condition
4,T4,Condition 86 92	asthma
5,T5,Negation 75 80	other
6,R2,Has_negation Arg1:T4 Arg2:T5
7,T6,Condition 100 116	contraindication
8,T7,Drug 120 130	cetirizine
9,R3,AND Arg1:T6 Arg2:T7
10,T8,Condition 139 158	asthma exacerbation
11,T9,Procedure 169 182	resuscitation
12,R4,AND Arg1:T8 Arg2:T9
13,T10,Qualifier 132 138	Severe
14,R5,Has_qualifier Arg1:T8 Arg2:T10
0,T1,Condition 20 42	pneumococcal infection
1,T2,Procedure 0 11	Vaccination
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Drug 73 104	preparations of immune globulin
4,T4,Procedure 108 125	blood transfusion
5,T5,Temporal 126 176	within last three months prior to clinical studies
6,*,OR T3 T4
7,T6,Scope 73 125	preparations of immune globulin or blood transfusion
8,R2,Has_temporal Arg1:T6 Arg2:T5
9,T7,Temporal 194 211	more than 14 days
10,T8,Temporal 179 192	Prolonged use
11,R3,Subsumes Arg1:T8 Arg2:T7
12,T9,Drug 213 231	immunosuppressants
13,T10,Qualifier 235 240	other
14,T11,Drug 241 264	immunosuppressive drugs
15,R4,Has_qualifier Arg1:T11 Arg2:T10
16,*,OR T9 T11
17,T12,Temporal 265 312	within 6 months prior to the start of the study
18,T13,Scope 213 264	immunosuppressants or other immunosuppressive drugs
19,R5,Has_temporal Arg1:T13 Arg2:T8
20,R6,Has_temporal Arg1:T13 Arg2:T12
21,T14,Condition 342 359;379 388	immunosuppressive condition
22,T15,Condition 363 388	immunodeficient condition
23,*,OR T15 T14
24,T16,Condition 400 413	HIV infection
25,T17,Scope 342 388	immunosuppressive or immunodeficient condition
26,R7,Subsumes Arg1:T17 Arg2:T16
27,T18,Non-representable 416 469	A history or currently hematologic and other cancers;
28,T19,Measurement 482 508	reaction for HIV infection
29,T20,Value 473 481	positive
30,T21,Measurement 482 494;510 527	reaction for viral hepatitis B
31,T22,Measurement 482 494;532 543	reaction for hepatitis C
32,*,OR T21 T22 T19
33,T23,"Scope 482 543	reaction for HIV infection, viral hepatitis B and hepatitis C"
34,R8,Has_value Arg1:T23 Arg2:T20
35,T24,Condition 575 604	cardio-vascular insufficiency
36,T25,Condition 562 573;591 604	respiratory insufficiency
37,T26,Condition 606 620	impaired liver
38,T27,Condition 606 614;625 640	impaired kidney function
39,*,OR T27 T26 T25 T24
40,T28,Temporal 684 701	at visit number 1
41,T29,"Scope 562 640	respiratory, cardio-vascular insufficiency, impaired liver and kidney function"
42,R9,Has_temporal Arg1:T29 Arg2:T28
43,T30,Condition 715 733	congenital defects
44,T31,Condition 745 761	chronic diseases
45,T32,Qualifier 769 780	acute stage
46,R10,Has_qualifier Arg1:T31 Arg2:T32
47,*,OR T30 T31
48,T33,Qualifier 796 816	clinically important
49,T34,Qualifier 737 744	serious
50,R11,Has_qualifier Arg1:T31 Arg2:T34
51,T35,Condition 817 829	exacerbation
52,T36,Condition 841 862	diseases of the liver
53,T37,Qualifier 833 840	chronic
54,T38,Condition 841 856;864 870	diseases of the kidney
55,T39,Condition 841 856;872 886;896 902	diseases of the cardiovascular system
56,T40,Condition 841 856;888 902	diseases of the nervous system
57,T41,Condition 904 919	mental diseases
58,T42,Condition 923 942	metabolic disorders
59,T43,Condition 1006 1021	cystic fibrosis
60,T44,Condition 1023 1035	lung abscess
61,T45,Condition 1037 1044	empyema
62,T46,Qualifier 1046 1052	active
63,T47,Condition 1053 1065	tuberculosis
64,R12,Has_qualifier Arg1:T47 Arg2:T46
65,T48,Condition 1084 1108	congestive heart failure
66,T49,Condition 1110 1123	malabsorption
67,T50,Condition 1143 1158	hepatic failure
68,T51,Condition 1133 1138;1151 1158	renal failure
69,T52,Qualifier 1125 1132	chronic
70,T53,Scope 1133 1158	renal and hepatic failure
71,R13,Has_qualifier Arg1:T53 Arg2:T52
72,T54,Condition 1160 1169	cirrhosis
73,T55,Condition 1171 1181	malignancy
74,T56,Condition 1183 1199	immunodeficiency
75,T57,Condition 1201 1223	cirrhosis of the liver
76,*,OR T56 T57 T55 T54 T53 T49 T48 T47 T45 T44 T43
77,T58,"Scope 995 1223	pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver"
78,*,OR T42 T41 T59 T35
79,T59,"Scope 841 902	diseases of the liver, kidney, cardiovascular, nervous system"
80,R14,Has_qualifier Arg1:T59 Arg2:T37
81,T60,"Scope 817 942	exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders"
82,R15,Has_qualifier Arg1:T60 Arg2:T33
83,R16,Subsumes Arg1:T59 Arg2:T58
84,T61,Scope 715 780	congenital defects or serious chronic diseases in the acute stage
85,R17,Subsumes Arg1:T61 Arg2:T59
86,T62,Qualifier 1227 1233	Severe
87,T63,Condition 1234 1252	allergic reactions
88,R18,Has_qualifier Arg1:T63 Arg2:T62
89,T64,Qualifier 1306 1311	acute
90,T65,Condition 1312 1322;1343 1352	infectious illnesses
91,T66,Condition 1330 1352	communicable illnesses
92,T67,Temporal 1353 1382	within 1 month prior to study
93,T68,Scope 1312 1352	infectious and/or communicable illnesses
94,R19,Has_qualifier Arg1:T68 Arg2:T64
95,R20,Has_temporal Arg1:T68 Arg2:T67
96,T69,Condition 1404 1417	alcohol abuse
97,T70,Condition 1425 1433	drug use
98,T71,Qualifier 1396 1403	chronic
99,*,OR T69 T70
100,T72,Scope 1404 1433	alcohol abuse and/or drug use
101,R21,Has_qualifier Arg1:T72 Arg2:T71
102,T73,Condition 1436 1448	Exacerbation
103,T74,Condition 1452 1468	chronic diseases
104,R22,AND Arg1:T73 Arg2:T74
105,T75,Observation 1471 1484	Breastfeeding
106,T76,Condition 1487 1496	Pregnancy
107,T77,Observation 1499 1515;1526 1540	Participation in clinical study
108,T78,Qualifier 1516 1525	any other
109,T79,Temporal 1541 1565	within the last 3 months
110,R23,Has_qualifier Arg1:T77 Arg2:T78
111,R24,Has_temporal Arg1:T77 Arg2:T79
112,T80,Reference_point 1377 1382	study
113,R25,Has_index Arg1:T67 Arg2:T80
0,T3,Value 62 89	greater than or equal to 40
1,T4,Person 57 61	aged
2,T5,Value 94 124	less than or equal to 89 years
3,T7,Scope 62 124	greater than or equal to 40 and less than or equal to 89 years
4,R1,Has_scope Arg1:T4 Arg2:T7
5,T8,Value 161 181	between 90g and 200g
6,T9,Measurement 147 160	prostate size
7,T10,Procedure 200 203	MRI
8,R3,Has_value Arg1:T9 Arg2:T8
9,R4,AND Arg1:T9 Arg2:T10
10,T11,Condition 229 264	lower urinary tract symptoms (LUTS)
11,T12,Temporal 269 312	at least 6 months prior to study enrollment
12,T13,Reference_point 296 312	study enrollment
13,R5,Has_index Arg1:T12 Arg2:T13
14,R6,Has_temporal Arg1:T11 Arg2:T12
15,T14,Measurement 329 339	IPSS score
16,T15,Value 343 354	at least 13
17,T16,Temporal 355 366	at baseline
18,T17,Reference_point 358 366	baseline
19,R7,Has_index Arg1:T16 Arg2:T17
20,R8,Has_value Arg1:T14 Arg2:T15
21,R9,Has_temporal Arg1:T14 Arg2:T16
22,T18,Condition 387 418	refractory to medical treatment
23,T19,Condition 420 456	contraindicated to medical treatment
24,T20,Condition 461 486	refuses medical treatment
25,*,OR T18 T19 T20
26,T21,Condition 504 530	refuses surgical treatment
27,T22,Condition 537 575	contraindicated for surgical treatment
28,*,OR T21 T22
29,T23,Measurement 631 634	PSA
30,T24,Temporal 622 630	baseline
31,R10,Has_temporal Arg1:T23 Arg2:T24
32,T25,Value 635 645	< 4.0ng/mL
33,R11,Has_value Arg1:T23 Arg2:T25
34,T26,Measurement 688 691	PSA
35,T27,Temporal 679 687	baseline
36,R12,Has_temporal Arg1:T26 Arg2:T27
37,T28,Value 692 703	>/= 4 ng/mL
38,T29,Measurement 719 734	prostate biopsy
39,T30,Value 710 718	negative
40,R13,Has_value Arg1:T29 Arg2:T30
41,R14,Has_value Arg1:T26 Arg2:T28
42,T31,Multiplier 736 746	minimum 12
43,T32,Procedure 747 758	core biopsy
44,R15,Has_multiplier Arg1:T32 Arg2:T31
45,T33,Temporal 760 786	within the prior 12 months
46,T34,Scope 622 759	baseline PSA < 4.0ng/mL (no prostate biopsy required) OR baseline PSA >/= 4 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy)
47,R16,Has_temporal Arg1:T34 Arg2:T33
48,T35,Scope 679 733	baseline PSA >/= 4 ng/mL AND a negative prostate biops
49,*,OR T35 T23
50,T1,Observation 21 44	signed informed consent
0,T1,Procedure 35 55	lumbar decompression
1,T2,Procedure 35 41;60 66	lumbar fusion
2,T3,Qualifier 22 34	single level
3,R1,Has_qualifier Arg1:T1 Arg2:T3
4,R2,Has_qualifier Arg1:T2 Arg2:T3
5,T5,Person 104 107	age
6,T6,Value 68 78;86 100	> 18 years and < 70 years
7,R4,Has_value Arg1:T5 Arg2:T6
8,T4,"Post-eligibility 109 277	The subject is willing and able to understand, sign and date the study specific patient informed consent and HIPAA authorization to volunteer participation in the study"
0,T1,Condition 10 17	healthy
1,T2,Condition 19 33	postmenopausal
2,T3,Person 34 39	woman
3,T4,Condition 64 75	hot flushes
4,T5,Temporal 104 122	At least 12 months
5,T6,Condition 126 148	spontaneous amenorrhea
6,R1,Has_temporal Arg1:T6 Arg2:T5
7,T7,Temporal 150 167	At least 6 months
8,T8,Condition 171 193	spontaneous amenorrhea
9,R2,Has_temporal Arg1:T8 Arg2:T7
10,T9,Measurement 199 246	serum follicle-stimulating hormone (FSH) levels
11,T10,Value 247 258	> 40 mIU/mL
12,R3,Has_value Arg1:T9 Arg2:T10
13,T11,Temporal 260 289	At least 6 weeks postsurgical
14,T12,Procedure 290 312	bilateral oophorectomy
15,T13,Procedure 290 312;322 342	bilateral oophorectomy without hysterectomy
16,T14,Procedure 290 312;314 318;330 342	bilateral oophorectomy with hysterectomy
17,T15,Scope 314 342	with or without hysterectomy
18,*,OR T13 T14
19,R4,Subsumes Arg1:T12 Arg2:T15
20,T16,Scope 290 343	bilateral oophorectomy (with or without hysterectomy)
21,R5,Has_temporal Arg1:T16 Arg2:T11
22,T17,Condition 345 360	Hysterectomized
23,T18,Procedure 369 391	bilateral oophorectomy
24,T19,Negation 361 368	without
25,R6,Has_negation Arg1:T18 Arg2:T19
26,T20,Measurement 401 417	serum FSH levels
27,T21,Value 418 428	>40 mIU/mL
28,R7,Has_value Arg1:T20 Arg2:T21
29,T22,Scope 150 258	At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL
30,T23,Scope 260 343	At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy)
31,T24,Scope 345 428	Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/mL
32,*,OR T16 T24
33,T25,Line 104 148	At least 12 months of spontaneous amenorrhea
34,T26,Scope 150 258	At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL
35,T27,Multiplier 78 102	Meets 1 of the following
0,T1,Pregnancy_considerations 0 207	Pregnant women and nursing mothers are ineligible due to the possible risk of adverse effects in the newborn. Eligible patients of reproductive potential should use adequate contraception if sexually active.
1,T2,Post-eligibility 209 369	Serious concurrent medical illness which would jeopardize the ability of the subject to receive the therapy as outlined in this protocol with reasonable safety.
2,T3,Condition 371 381	Malignancy
3,T4,Temporal 403 417	within 5 years
4,R1,Has_temporal Arg1:T3 Arg2:T4
5,T5,Procedure 436 445	treatment
6,T6,Qualifier 426 435	localized
7,T7,Temporal 419 425	recent
8,T8,Condition 449 457;480 496	squamous cell skin cancer
9,T9,Condition 461 496	non-invasive basal cell skin cancer
10,*,OR T9 T8
11,T10,Negation 501 510	permitted
12,T11,Scope 449 496	squamous or non-invasive basal cell skin cancer
13,R2,Has_scope Arg1:T5 Arg2:T11
14,R3,Has_qualifier Arg1:T5 Arg2:T6
15,R4,Has_negation Arg1:T5 Arg2:T10
16,T12,Condition 512 538	cervical carcinoma in situ
17,T13,Negation 542 549	allowed
18,T14,Procedure 567 574	treated
19,T15,Qualifier 553 566	appropriately
20,R5,Has_qualifier Arg1:T14 Arg2:T15
21,T16,Temporal 575 593	prior to screening
22,R6,Has_temporal Arg1:T14 Arg2:T16
23,R7,AND Arg1:T12 Arg2:T14
24,R8,Has_negation Arg1:T12 Arg2:T13
25,T17,Non-representable 596 656	subjects under evaluation for a malignancy are not eligible.
26,T18,Condition 673 696	hepatitis B virus (HBV)
27,T19,Condition 700 734	human immunodeficiency virus (HIV)
28,*,OR T18 T19
29,T20,Post-eligibility 736 825	Use of any prohibited concomitant medications within 30 days of the Baseline/Day 1 visit.
30,T21,Condition 833 849	hypersensitivity
31,T22,Drug 853 856	LDV
32,T23,Drug 857 860	SOF
33,*,OR T22 T23
34,T24,Scope 853 860	LDV/SOF
35,R9,Has_scope Arg1:T21 Arg2:T24
0,T1,Value 0 15;32 49	15 weeks 0 days - 23 weeks 5 days
1,T2,Measurement 16 31	gestational age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Temporal 66 94	at time of dilator insertion
4,T4,Reference_point 77 94	dilator insertion
5,R2,Has_index Arg1:T3 Arg2:T4
6,R3,Has_temporal Arg1:T2 Arg2:T3
7,T5,Observation 96 129	Able to read and write in English
8,T6,Observation 131 179	Active cell phone with text messaging capability
9,T7,Observation 181 190	Ride home
10,T8,Procedure 196 213	dilator insertion
11,R4,AND Arg1:T7 Arg2:T8
0,T1,Person 15 25	both sexes
1,T2,Value 26 39	from 18 years
2,T3,Person 26 39	from 18 years
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Condition 60 88	community-acquired pneumonia
5,T5,Condition 90 94	COPD
6,T6,Condition 98 114	Bronchial Asthma
7,*,OR T6 T5 T4
8,T7,Non-query-able 117 202	The presence of signed and dated informed consent to participate in a clinical study;
9,T8,Post-eligibility 204 260	The ability to perform the requirements of the Protocol;
10,T9,Pregnancy_considerations 262 352	For women of childbearing age is a negative result of a pregnancy test before vaccination.
11,T10,Qualifier 400 424	radiologically confirmed
12,T11,Procedure 400 414	radiologically
13,R2,multi Arg1:T10 Arg2:T11
14,T12,Condition 425 456	infiltration of the lung tissue
15,R3,Has_qualifier Arg1:T12 Arg2:T10
16,T13,Multiplier 474 486	at least two
17,T14,Condition 520 531	acute fever
18,T15,Temporal 532 552	early in the disease
19,T16,Measurement 554 565	temperature
20,T17,Value 566 574	> 38.0°C
21,R4,Has_value Arg1:T16 Arg2:T17
22,R5,Subsumes Arg1:T14 Arg2:T16
23,R6,Has_temporal Arg1:T14 Arg2:T15
24,T18,Condition 577 594	cough with sputum
25,T19,Condition 618 627	pneumonia
26,T20,Condition 600 614	physical signs
27,R7,AND Arg1:T20 Arg2:T19
28,T21,Condition 638 647;667 672	crepitate rales
29,T22,Condition 655 672	fine bubble rales
30,T23,Condition 674 698	bronchial breathing hard
31,T24,Condition 700 731	shortening of percussion sounds
32,*,OR T24 T23 T21 T22
33,T25,"Scope 638 731	crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds"
34,T26,Scope 600 627	physical signs of pneumonia
35,R8,Subsumes Arg1:T26 Arg2:T25
36,T27,Measurement 734 746	leukocytosis
37,T28,Value 747 759	> 10*10 9 /l
38,T29,Measurement 767 777	stab shift
39,T30,Value 778 783	> 10%
40,R9,Has_value Arg1:T29 Arg2:T30
41,R10,Has_value Arg1:T27 Arg2:T28
42,*,OR T27 T29 T25
43,*,OR T26 T18 T14
44,T31,"Scope 520 783	acute fever early in the disease (temperature > 38.0°C), cough with sputum, the physical signs of pneumonia (focus of crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds), leukocytosis > 10*10 9 /l and/or stab shift > 10%"
45,R11,Has_multiplier Arg1:T31 Arg2:T13
46,*,OR T31 T12
47,T32,Condition 912 919	dyspnea
48,T33,Condition 354 382	community-acquired pneumonia
49,T34,"Scope 400 783	radiologically confirmed infiltration of the lung tissue; the presence of at least two of the following clinical signs: acute fever early in the disease (temperature > 38.0°C), cough with sputum, the physical signs of pneumonia (focus of crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds), leukocytosis > 10*10 9 /l and/or stab shift > 10%"
50,R12,Subsumes Arg1:T33 Arg2:T34
51,T35,Qualifier 921 932	progressive
52,T36,Qualifier 934 951	worsens over time
53,R13,Subsumes Arg1:T35 Arg2:T36
54,T37,Qualifier 954 977	increases with exertion
55,T38,Qualifier 979 989	persistent
56,T39,Condition 991 1004	chronic cough
57,T40,Condition 1056 1077	chronic expectoration
58,T41,Condition 1130 1137	Smoking
59,T42,Condition 1093 1105	risk factors
60,T43,Condition 1139 1181	occupational dust pollutants and chemicals
61,*,OR T41 T43
62,T44,Condition 1195 1230	wheeze on auscultation of the chest
63,T45,Condition 1238 1267	distant wheezing in the chest
64,T46,Qualifier 1184 1194	widespread
65,R14,Has_qualifier Arg1:T44 Arg2:T46
66,T47,Observation 1269 1283	family history
67,T48,Condition 1287 1291	COPD
68,R15,Has_context Arg1:T48 Arg2:T47
69,T49,Procedure 1293 1304	spirometric
70,T50,Condition 1337 1364	fixed bronchial obstruction
71,R16,AND Arg1:T49 Arg2:T50
72,*,OR T49 T48 T44 T45 T42 T40 T39 T32
73,T51,"Scope 1130 1181	Smoking, occupational dust pollutants and chemicals"
74,R17,Subsumes Arg1:T42 Arg2:T51
75,T52,"Scope 921 989	progressive (worsens over time), increases with exertion, persistent"
76,R18,Has_scope Arg1:T32 Arg2:T52
77,T53,Condition 906 910	COPD
78,T54,"Scope 912 1364	dyspnea: progressive (worsens over time), increases with exertion, persistent; chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the impact of risk factors in the medical history (Smoking, occupational dust pollutants and chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the chest; family history of COPD; spirometric data confirming the presence of fixed bronchial obstruction"
79,R19,Subsumes Arg1:T53 Arg2:T54
0,T1,Condition 13 29	seizure disorder
1,T2,Condition 50 75	childhood febrile seizure
2,T3,Multiplier 43 49	single
3,R1,Has_multiplier Arg1:T2 Arg2:T3
4,T4,Observation 0 7	History
5,R3,Has_temporal Arg1:T1 Arg2:T4
6,T5,Observation 78 85	History
7,T6,Condition 101 121;122 129;139 146	clinically important hepatic disease
8,T7,Condition 101 121;133 146	clinically important renal disease
9,T8,Condition 101 121;150 171	clinically important other medical disease
10,T9,Observation 193 200	history
11,T10,Condition 204 229	major depressive disorder
12,T11,Condition 231 247	bipolar disorder
13,T12,Condition 249 267	psychotic disorder
14,T13,Condition 272 300	generalized anxiety disorder
15,T14,Qualifier 301 318	requiring therapy
16,*,OR T10 T11 T12 T13
17,T15,"Scope 204 300	major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder"
18,R4,Has_temporal Arg1:T15 Arg2:T9
19,R5,Has_qualifier Arg1:T15 Arg2:T14
20,T16,Scope 101 171	clinically important hepatic or renal disease or other medical disease
21,R6,Has_temporal Arg1:T16 Arg2:T5
22,T17,Negation 30 40	other than
23,R2,Has_negation Arg1:T2 Arg2:T17
24,R7,AND Arg1:T1 Arg2:T2
25,*,OR T6 T7 T8
0,T1,Condition 14 27	liver disease
1,T2,Measurement 40 59	liver function test
2,T3,Value 60 71	abnormality
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Condition 88 101	renal disease
6,T5,Measurement 114 140	glomerular filtration rate
7,T6,Value 141 158	< 60mL/min/1.73m2
8,R3,AND Arg1:T4 Arg2:T5
9,R4,Has_value Arg1:T5 Arg2:T6
10,T7,Drug 202 208	opioid
11,T8,Qualifier 177 185	baseline
12,T9,Qualifier 187 200	pre-operative
13,T10,Multiplier 213 259	greater than 30 mg of morphine equivalents/day
14,R5,Has_multiplier Arg1:T7 Arg2:T10
15,R6,Has_qualifier Arg1:T7 Arg2:T8
16,R7,Subsumes Arg1:T8 Arg2:T9
17,T11,Condition 283 301	alcohol dependence
18,T12,Condition 324 347	illicit drug dependence
19,T13,Person 372 375	age
20,T14,Value 358 368	< 18 years
21,T15,Person 393 396	age
22,T16,Value 380 389	>70 years
23,R8,Has_value Arg1:T13 Arg2:T14
24,R9,Has_value Arg1:T15 Arg2:T16
25,*,OR T13 T15
26,T17,Condition 407 415	allergic
27,T18,Drug 423 433	medication
28,R10,AND Arg1:T17 Arg2:T18
29,T19,Condition 494 510	seizure disorder
0,T1,Condition 33 46	rectal cancer
1,T2,Condition 21 28;40 46	bladder cancer
2,T3,Condition 11 19;40 46	prostate cancer
3,*,OR T1 T2 T3
4,T4,Procedure 59 105	transurethral resection of the prostate (TURP)
5,T5,Procedure 107 128	open prostate surgery
6,T6,Procedure 133 147	radiofrequency
7,T7,Procedure 151 170	microwave therapies
8,*,OR T7 T6 T5 T4
9,T8,Procedure 183 195;233 240	open bladder surgery
10,T9,Procedure 226 240	pelvic surgery
11,T10,Procedure 197 215;233 240	rectosigmoid colon surgery
12,R1,Subsumes Arg1:T9 Arg2:T10
13,R2,Subsumes Arg1:T9 Arg2:T8
14,T11,Non-query-able 242 322	Patient is unwilling to discontinue alpha blockers 1 month after study treatment
15,T12,Drug 278 292	alpha blockers
16,T13,Drug 360 387	5-alph reductase inhibitors
17,T14,Temporal 293 322	1 month after study treatment
18,T15,Reference_point 307 322	study treatment
19,R3,Has_index Arg1:T14 Arg2:T15
20,T16,Temporal 388 417	1 month after study treatment
21,R4,Has_temporal Arg1:T13 Arg2:T16
22,T17,Non-query-able 324 417	Patient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study treatment
23,T18,Condition 419 437	Neurogenic bladder
24,T19,Condition 447 493	neurologic disorder impacting bladder function
25,T20,Condition 502 521	Parkinson's disease
26,T21,Condition 523 541	multiple sclerosis
27,T22,Condition 543 569	cerebral vascular accident
28,T23,Condition 573 581	diabetes
29,*,OR T23 T22 T21 T20 T18
30,T24,"Scope 419 437;502 581	Neurogenic bladder Parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes"
31,R5,Subsumes Arg1:T19 Arg2:T24
32,T25,Condition 616 634	urethral pathology
33,T26,Undefined_semantics 616 634	urethral pathology
34,T27,Condition 646 664	urethral stricture
35,T28,Condition 666 690	bladder neck contracture
36,T29,Condition 695 709	bladder atonia
37,*,OR T29 T28 T27
38,T30,Condition 605 612;625 634	bladder pathology
39,T31,Undefined_semantics 605 612;625 634	bladder pathology
40,*,OR T30 T25
41,T32,Scope 605 634	bladder or urethral pathology
42,T33,"Scope 646 709	urethral stricture, bladder neck contracture, or bladder atonia"
43,R6,Subsumes Arg1:T32 Arg2:T33
44,T34,Condition 718 729	prostatitis
45,T35,Condition 733 756	urinary tract infection
46,*,OR T34 T35
47,T36,Temporal 711 717	Active
48,R7,Has_temporal Arg1:T34 Arg2:T36
49,R8,Has_temporal Arg1:T35 Arg2:T36
50,T37,Condition 758 772	Cystolithiasis
51,T38,Temporal 773 797	within the past 3 months
52,T39,Measurement 799 815	Serum creatinine
53,T40,Value 816 826	> 1.7mg/dL
54,R9,Has_value Arg1:T39 Arg2:T40
55,T41,Drug 853 871	oral anticoagulant
56,T42,Temporal 872 905	2-5 days prior to study treatment
57,T43,Reference_point 890 905	study treatment
58,R10,Has_index Arg1:T42 Arg2:T43
59,T44,Non-query-able 828 905	Inability to discontinue oral anticoagulant 2-5 days prior to study treatment
60,T45,Condition 907 931	Coagulation disturbances
61,T46,Undefined_semantics 907 931	Coagulation disturbances
62,T47,Procedure 950 967	medical treatment
63,T48,Qualifier 936 946	normalized
64,T49,Negation 932 935	not
65,R11,Has_negation Arg1:T48 Arg2:T49
66,R12,AND Arg1:T48 Arg2:T47
67,R13,Has_qualifier Arg1:T45 Arg2:T48
68,T50,Condition 988 995	allergy
69,T51,Drug 969 987	Iodinated contrast
70,R14,AND Arg1:T50 Arg2:T51
71,T52,"Non-query-able 969 1071	Iodinated contrast allergy that, in the opinion of the Investigator, cannot be adequately premedicated"
72,T53,Condition 1081 1088	allergy
73,T54,Drug 1073 1080	Gelatin
74,R15,AND Arg1:T53 Arg2:T54
75,T55,Condition 1103 1130	peripheral vascular disease
76,T56,Qualifier 1096 1102	severe
77,R16,Has_qualifier Arg1:T55 Arg2:T56
78,T57,Condition 1140 1172	iliac arterial occlusive disease
79,T58,Qualifier 1134 1139	major
80,T59,Subjective_judgement 1134 1139	major
81,T60,Subjective_judgement 1096 1102	severe
82,R17,Has_qualifier Arg1:T57 Arg2:T58
83,*,OR T57 T55
84,T61,Post-eligibility 1174 1202	Interest in future fertility
85,T62,Non-query-able 1174 1202	Interest in future fertility
86,T63,Condition 1227 1245	cardiac arrhythmia
87,T64,Condition 1255 1270	cardiac disease
88,T65,Condition 1282 1306	congestive heart failure
89,T66,Condition 1322 1339	diabetes mellitus
90,T67,Qualifier 1309 1321	uncontrolled
91,R18,Has_qualifier Arg1:T66 Arg2:T67
92,T68,Condition 1364 1383	respiratory disease
93,T69,Qualifier 1341 1363	clinically significant
94,T70,Non-query-able 1341 1363	clinically significant
95,T71,Subjective_judgement 1341 1363	clinically significant
96,R19,Has_qualifier Arg1:T68 Arg2:T69
97,T72,Condition 1394 1411	immunosuppression
98,*,OR T72 T68 T66 T64 T63
99,R20,Subsumes Arg1:T64 Arg2:T65
100,T73,Non-query-able 1413 1524	Other condition that the Investigator believes puts the patient at risk for a complication during the procedure
101,T74,Post-eligibility 1413 1524	Other condition that the Investigator believes puts the patient at risk for a complication during the procedure
0,T1,Post-eligibility 0 74	The subject must be willingly and able to provide written informed consent
1,T2,Value 80 104	19 years of age or older
2,T3,Person 76 79	Age
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Non-representable 105 137	(The age of consent in Nebraska)
5,T5,Negation 153 158	naïve
6,T6,Procedure 143 152	treatment
7,T7,Condition 139 142	HCV
8,R2,Has_negation Arg1:T6 Arg2:T5
9,R3,AND Arg1:T6 Arg2:T7
10,T9,Drug 199 215	Interferon (IFN)
11,T8,Drug 217 220	RBV
12,T10,Non-representable 225 302	other FDA approved or experimental HCV-specific direct-acting antiviral agent
13,*,OR T9 T8
14,T11,Negation 174 176	no
15,T12,Temporal 177 182	prior
16,T13,"Scope 199 220	Interferon (IFN), RBV"
17,R4,Has_temporal Arg1:T13 Arg2:T12
18,R5,Has_negation Arg1:T13 Arg2:T11
19,T14,Scope 139 158	HCV treatment-naïve
20,T15,"Scope 174 302	no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent"
21,R6,Subsumes Arg1:T14 Arg2:T15
22,T16,Measurement 304 317	HCV RNA level
23,T17,Temporal 318 368	at most 6 months prior to the Baseline/Day 1 visit
24,R7,Has_temporal Arg1:T16 Arg2:T17
25,T18,Reference_point 344 368	the Baseline/Day 1 visit
26,R8,Has_index Arg1:T17 Arg2:T18
27,T19,Measurement 371 385	HCV genotyping
28,T20,"Value 386 408	1a, 1b, or mixed 1a/ab"
29,R9,Has_value Arg1:T19 Arg2:T20
30,T21,Non-representable 410 487	Any non-definitive results will exclude the subject from study participation.
31,T22,Condition 489 503	Alcohol misuse
32,T23,Measurement 522 577	Alcohol Use Disorders Identification Test (AUDIT) score
33,T24,Value 598 601	> 8
34,R10,Has_value Arg1:T23 Arg2:T24
35,R11,Subsumes Arg1:T22 Arg2:T23
36,T25,Procedure 664 676	liver biopsy
37,T26,Condition 685 694	cirrhosis
38,T27,Measurement 701 714	Metavir score
39,T28,Measurement 722 733	Ishak score
40,T29,Value 715 718	= 4
41,T30,Value 734 737	> 5
42,R12,Has_value Arg1:T27 Arg2:T29
43,R13,Has_value Arg1:T28 Arg2:T30
44,*,OR T27 T28
45,T31,Scope 701 737	Metavir score = 4 or Ishak score > 5
46,R14,Subsumes Arg1:T26 Arg2:T31
47,R15,AND Arg1:T25 Arg2:T26
48,T32,Procedure 740 749	Fibroscan
49,T33,Condition 758 767	cirrhosis
50,T34,Value 779 789	> 12.5 kPa
51,*,OR T33 T34
52,T35,Scope 758 789	cirrhosis or results > 12.5 kPa
53,R16,Has_scope Arg1:T32 Arg2:T35
54,T36,Measurement 791 811	FIBRO Spect II index
55,T37,Measurement 850 878	platelet ration index (APRI)
56,T38,Value 882 885	> 2
57,R17,Has_value Arg1:T37 Arg2:T38
58,T39,Temporal 886 902	during Screening
59,T40,Value 828 836	F3 or F4
60,T41,Value 844 847	AST
61,R18,Has_value Arg1:T36 Arg2:T40
62,R19,Has_value Arg1:T36 Arg2:T41
63,T42,Procedure 904 916	Liver biopsy
64,T43,Temporal 917 944	within 2 years of Screening
65,T44,Condition 964 973	cirrhosis
66,T45,Negation 953 960	absence
67,R20,Has_negation Arg1:T44 Arg2:T45
68,R21,Has_temporal Arg1:T42 Arg2:T43
69,R22,AND Arg1:T42 Arg2:T44
70,T46,Procedure 975 984	Fibroscan
71,T47,Temporal 985 1017	within 6 months of Baseline/Day1
72,T48,Value 1035 1045	= 12.5 kPa
73,R23,Has_value Arg1:T46 Arg2:T48
74,R24,Has_temporal Arg1:T46 Arg2:T47
75,T49,Measurement 1047 1067	FIBRO Spect II Index
76,T50,Value 1084 1090	F0- F2
77,T51,Measurement 1095 1099	APRI
78,T52,Value 1103 1106	= 1
79,R25,Has_value Arg1:T51 Arg2:T52
80,T53,Temporal 1107 1123	during Screening
81,R27,AND Arg1:T36 Arg2:T37
82,R28,Has_value Arg1:T49 Arg2:T50
83,R29,AND Arg1:T49 Arg2:T51
84,R30,Has_temporal Arg1:T49 Arg2:T53
85,R26,Has_temporal Arg1:T36 Arg2:T39
86,T54,Procedure 1125 1138	Liver imaging
87,T55,Temporal 1139 1172	within 6 months of Baseline/Day 1
88,T56,Condition 1184 1213	hepatocellular carcinoma HCC)
89,R31,Has_temporal Arg1:T54 Arg2:T55
90,T57,Negation 1176 1183	exclude
91,R32,Has_negation Arg1:T56 Arg2:T57
92,R33,AND Arg1:T54 Arg2:T56
93,T58,Measurement 1227 1230	ALT
94,T59,Measurement 1271 1274	AST
95,T60,Value 1231 1269	< 10 x the upper limit of normal (ULN)
96,T61,Value 1275 1285	< 10 x ULN
97,R34,Has_value Arg1:T58 Arg2:T60
98,R35,Has_value Arg1:T59 Arg2:T61
99,T62,Measurement 1287 1303	Direct bilirubin
100,T63,Value 1304 1315	< 2.0 x ULN
101,T64,Measurement 1317 1326	Platelets
102,T65,"Value 1327 1335	> 50,000"
103,R36,Has_value Arg1:T64 Arg2:T65
104,R37,Has_value Arg1:T62 Arg2:T63
105,T66,Measurement 1337 1342	HbA1c
106,T67,Value 1343 1349	< 8.5%
107,R38,Has_value Arg1:T66 Arg2:T67
108,T68,Measurement 1351 1378	Creatinine clearance (CLcr)
109,T69,Value 1379 1391	= 60 mL /min
110,R39,Has_value Arg1:T68 Arg2:T69
111,T70,Qualifier 1414 1438	Cockcroft-Gault equation
112,R40,Has_qualifier Arg1:T68 Arg2:T70
113,T71,Measurement 1440 1450	Hemoglobin
114,T72,Value 1451 1460	= 11 g/dL
115,T73,Person 1465 1471	female
116,T74,Value 1482 1491	= 12 g/dL
117,T75,Person 1496 1500	male
118,A1,Optional T73
119,A2,Optional T75
120,R41,Has_value Arg1:T75 Arg2:T74
121,R42,Has_value Arg1:T73 Arg2:T72
122,*,OR T75 T73
123,T76,Scope 1451 1500	= 11 g/dL for female subjects; = 12 g/dL for male
124,R43,Has_scope Arg1:T71 Arg2:T76
125,T77,Measurement 1512 1519	Albumin
126,T78,Value 1520 1530	= 2.5 g/dL
127,R44,Has_value Arg1:T77 Arg2:T78
128,T79,Measurement 1532 1535	INR
129,T80,Value 1536 1547	= 1.5 x ULN
130,R45,Has_value Arg1:T79 Arg2:T80
131,T81,Condition 1573 1583	hemophilia
132,T82,Condition 1590 1638	stable on an anticoagulant regimen affecting INR
133,*,OR T81 T82
134,T83,Negation 1548 1554	unless
135,T84,Scope 1573 1638	hemophilia or is stable on an anticoagulant regimen affecting INR
136,R46,Has_negation Arg1:T84 Arg2:T83
137,R47,Has_scope Arg1:T79 Arg2:T84
138,T85,Non-query-able 1641 1748	Subject has not been treated with any investigational drug or device within 30 days of the screening visit.
0,T1,Drug 15 25	gabapentin
1,T2,Temporal 0 7	Current
2,T3,Drug 29 39	pregabalin
3,*,OR T1 T3
4,T4,Scope 15 39	gabapentin or pregabalin
5,R1,Has_temporal Arg1:T4 Arg2:T2
6,T5,Condition 41 48	Allergy
7,T6,Drug 52 62	gabapentin
8,T7,Drug 64 77	acetaminophen
9,T8,Drug 79 86	codeine
10,T9,Drug 91 100	ibuprofen
11,*,OR T8 T9 T7 T6
12,T10,"Scope 52 100	gabapentin, acetaminophen, codeine, or ibuprofen"
13,R2,Has_scope Arg1:T5 Arg2:T10
14,T11,Qualifier 102 115	Self reported
15,T12,Condition 116 129	renal disease
16,R3,Has_qualifier Arg1:T12 Arg2:T11
17,T13,Qualifier 131 137	severe
18,T14,Condition 138 161	impaired renal function
19,R4,Has_qualifier Arg1:T14 Arg2:T13
20,T15,Scope 102 129	Self reported renal disease
21,T16,Scope 131 161	severe impaired renal function
22,R5,Subsumes Arg1:T15 Arg2:T16
23,T17,Qualifier 164 177	Self reported
24,T18,Temporal 178 185	current
25,T19,Qualifier 189 196	chronic
26,T20,Condition 197 209	narcotic use
27,*,OR T19 T18
28,T21,Scope 178 196	current or chronic
29,R6,Has_scope Arg1:T20 Arg2:T21
30,R7,Has_qualifier Arg1:T20 Arg2:T17
31,T22,Multiplier 219 228	daily use
32,R8,Has_multiplier Arg1:T20 Arg2:T22
33,T23,"Non-representable 231 368	Women with any issue that, in the opinion of the investigator, would interfere with study participation or generating accurate study data"
0,T1,Condition 0 17	Immunocompromised
1,T2,Condition 74 90	immunodeficiency
2,T3,Qualifier 65 73	acquired
3,T4,Qualifier 51 61	congenital
4,*,OR T4 T3
5,T5,Scope 51 73	congenital or acquired
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Procedure 115 127	chemotherapy
8,T7,Temporal 128 149	less than 6 weeks ago
9,R2,Has_temporal Arg1:T6 Arg2:T7
10,T8,Drug 174 189	corticosteroids
11,T9,Temporal 190 209	in the last 6 weeks
12,R3,Has_temporal Arg1:T8 Arg2:T9
13,T10,Procedure 234 262	immunosuppressive medication
14,T11,Temporal 263 282	in the last 6 weeks
15,T12,Drug 289 300	cyclosporin
16,T13,Drug 302 318	cyclophosphamide
17,T14,Drug 320 332	azathioprine
18,*,OR T12 T13 T14
19,R4,Has_temporal Arg1:T10 Arg2:T11
20,T15,"Scope 289 332	cyclosporin, cyclophosphamide, azathioprine"
21,R5,Has_scope Arg1:T10 Arg2:T15
22,T16,Condition 350 387	chronic obstructive pulmonary disease
23,T17,Drug 399 423	systemic corticosteroids
24,R6,AND Arg1:T16 Arg2:T17
25,T18,Visit 447 466	intensive care unit
26,T19,Condition 493 516	tropical worm infection
27,T20,Drug 533 546	dexamethasone
28,T21,Condition 547 558	intolerance
29,R7,AND Arg1:T21 Arg2:T20
30,T22,Pregnancy_considerations 561 593	Pregnant and breastfeeding women
0,T1,Condition 0 15	Type 1 diabetes
1,T2,Condition 30 54	diabetes mellitus type 2
2,T3,Qualifier 17 29	uncontrolled
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,T4,Measurement 60 75	fasting glucose
5,T5,Value 76 89	> 13.3 mmol/l
6,R2,Has_value Arg1:T4 Arg2:T5
7,R3,AND Arg1:T2 Arg2:T4
8,T6,Condition 136 152	hypersensitivity
9,T7,Drug 156 169	empagliflozin
10,T8,Drug 171 182	glimepiride
11,T9,Condition 231 247	hypersensitivity
12,T10,Drug 251 264	sulfonylureas
13,T11,Drug 266 278	sulfonamides
14,T12,Drug 282 298	SGLT2 inhibitors
15,*,OR T10 T11 T12
16,T13,"Scope 251 298	sulfonylureas, sulfonamides or SGLT2 inhibitors"
17,R4,Has_scope Arg1:T9 Arg2:T13
18,*,OR T7 T8
19,T14,"Scope 156 182	empagliflozin, glimepiride"
20,R5,Has_scope Arg1:T6 Arg2:T14
21,*,OR T6 T9
22,T15,Condition 338 359	hypoglycemic episodes
23,T16,Qualifier 331 337	severe
24,T17,Multiplier 322 330	multiple
25,R6,Has_qualifier Arg1:T15 Arg2:T16
26,R7,Has_multiplier Arg1:T15 Arg2:T17
27,T18,Temporal 371 385	last two years
28,R8,Has_temporal Arg1:T15 Arg2:T18
29,T19,Drug 394 401	Insulin
30,T20,Drug 403 418	SGLT2-inhibitor
31,T21,Drug 420 441	sulfonylurea derivate
32,T22,Drug 447 454	glinide
33,*,OR T19 T20 T21 T22
34,T23,"Scope 394 454	Insulin, SGLT2-inhibitor, sulfonylurea derivate or a glinide"
35,T24,Temporal 462 475	past 3 months
36,R9,Has_temporal Arg1:T23 Arg2:T24
37,T25,Condition 498 511	macular edema
38,T26,Qualifier 515 524	both eyes
39,R10,Has_qualifier Arg1:T25 Arg2:T26
40,T27,Procedure 544 576	intravitreal anti-VEGF treatment
41,T28,Qualifier 581 590	both eyes
42,R11,Has_qualifier Arg1:T27 Arg2:T28
43,T29,Non-query-able 623 977	Eyes with a small amount of intraretinal or subretinal fluid (seen in OCT) but no need for intravitreal treatment as judged by the investigator (according to current practice patterns) may be included. Eyes with a history of intravitreal treatment of macular edema which do not need ongoing intravitreal treatment at the time of screening may be included
44,T30,Negation 1013 1020	prevent
45,T31,Procedure 1027 1041	ophthalmoscopy
46,R12,Has_negation Arg1:T31 Arg2:T30
47,T32,Condition 1181 1200	vitreous hemorrhage
48,T33,Condition 1202 1217	mature cataract
49,T34,Condition 1219 1238	macular pathologies
50,T35,Negation 1239 1244	other
51,T36,Condition 1250 1270	diabetic maculopathy
52,*,OR T32 T33 T34
53,R13,Has_negation Arg1:T36 Arg2:T35
54,T37,Condition 1283 1295	ketoacidosis
55,T38,Condition 1299 1317	metabolic acidosis
56,*,OR T37 T38
57,T39,Drug 1326 1340	loop diuretics
58,T40,Condition 1357 1377	urogenital infection
59,T41,Multiplier 1353 1356;1377 1382	> 1 /year
60,R14,Has_multiplier Arg1:T40 Arg2:T41
61,T42,Condition 1399 1405	stroke
62,T43,Condition 1407 1432	transient ischemic attack
63,T44,Condition 1434 1437	TIA
64,T45,Condition 1449 1464	angina pectoris
65,T46,Qualifier 1440 1448	instable
66,T47,Condition 1468 1489	myocardial infarction
67,T48,Temporal 1497 1534	last 3 months prior to baseline visit
68,T49,Reference_point 1520 1534	baseline visit
69,R15,Has_index Arg1:T48 Arg2:T49
70,*,OR T42 T43 T45 T47
71,R16,Subsumes Arg1:T43 Arg2:T44
72,R17,Has_qualifier Arg1:T45 Arg2:T46
73,T50,"Scope 1399 1489	stroke, transient ischemic attack (TIA), instable angina pectoris or myocardial infarction"
74,R18,Has_temporal Arg1:T50 Arg2:T48
75,T51,Condition 1536 1560	congestive heart failure
76,T52,Measurement 1561 1587	New York Heart Association
77,T53,Measurement 1589 1593	NYHA
78,R19,Subsumes Arg1:T52 Arg2:T53
79,T54,Value 1595 1605	III and IV
80,R20,Has_value Arg1:T52 Arg2:T54
81,R21,AND Arg1:T51 Arg2:T52
82,T55,Condition 1626 1662	left ventricular outflow obstruction
83,T56,Condition 1614 1622;1663 1670	valvular disease
84,*,OR T55 T56
85,T57,Qualifier 1607 1613	severe
86,T58,Scope 1614 1670	valvular or left ventricular outflow obstruction disease
87,R22,Has_qualifier Arg1:T58 Arg2:T57
88,T59,Procedure 1679 1691	intervention
89,R23,AND Arg1:T58 Arg2:T59
90,T60,Condition 1694 1713	atrial fibrillation
91,T61,Condition 1694 1700;1714 1721	atrial flutter
92,*,OR T60 T61
93,T62,Measurement 1729 1759	mean ventricular response rate
94,T63,Qualifier 1760 1767	at rest
95,R24,Has_qualifier Arg1:T62 Arg2:T63
96,T64,Value 1768 1789	>100 beats per minute
97,R25,Has_value Arg1:T62 Arg2:T64
98,T65,Scope 1694 1721	atrial fibrillation/flutter
99,R26,AND Arg1:T65 Arg2:T62
100,T66,Condition 1799 1829	lower urinary tract infections
101,T67,Qualifier 1791 1798	chronic
102,R27,Has_qualifier Arg1:T66 Arg2:T67
103,T68,Negation 1835 1838	not
104,T69,Condition 1846 1870	asymptomatic bacteriuria
105,R28,Has_negation Arg1:T69 Arg2:T68
106,T70,Measurement 1873 1877	eGFR
107,T71,"Value 1878 1897	< 60 ml/min/1,73 m2"
108,R29,Has_value Arg1:T70 Arg2:T71
109,T72,Condition 1941 1957	chronic diarrhea
110,T73,Condition 1981 1997	volume depletion
111,T74,Measurement 2003 2013	hematocrit
112,T75,Value 2014 2020	> 48 %
113,T76,Person 2022 2027	women
114,T77,Value 2033 2039	> 53 %
115,T78,Person 2041 2044	men
116,T79,Measurement 2003 2013	hematocrit
117,R30,AND Arg1:T79 Arg2:T76
118,R31,Has_value Arg1:T79 Arg2:T75
119,R32,AND Arg1:T74 Arg2:T78
120,R33,Has_value Arg1:T74 Arg2:T77
121,*,OR T74 T79
122,T80,Scope 2003 2045	hematocrit > 48 % (women) and > 53 % (men)
123,*,OR T72 T73 T80
124,T81,"Observation 2056 2082	risk for volume depletion,"
125,T82,Qualifier 2047 2055	elevated
126,R34,Has_qualifier Arg1:T81 Arg2:T82
127,T83,Condition 2154 2175	chronic liver disease
128,T84,Condition 2193 2209	active hepatitis
129,R35,Subsumes Arg1:T83 Arg2:T84
130,T85,Measurement 2228 2248	alanine transaminase
131,T86,Measurement 2250 2253	ALT
132,T87,Measurement 2258 2280	aspartate transaminase
133,T88,Measurement 2282 2285	AST
134,T89,Value 2287 2314	> 3 x upper limit of normal
135,R36,Subsumes Arg1:T85 Arg2:T86
136,R37,Subsumes Arg1:T87 Arg2:T88
137,*,OR T87 T85
138,T90,Scope 2228 2286	alanine transaminase (ALT) or aspartate transaminase (AST)
139,R38,Has_value Arg1:T90 Arg2:T89
140,T91,Measurement 2388 2416	human immunodeficiency virus
141,T92,Value 2370 2384	seropositivity
142,R39,Has_value Arg1:T91 Arg2:T92
143,T93,Non-query-able 2419 2516	acute illness at screening or randomization according to judgement by the investigator or patient
144,T94,Condition 2526 2539	alcohol abuse
145,T95,Condition 2518 2522;2534 2539	drug abuse
146,*,OR T94 T95
147,T96,Condition 2558 2578	psychiatric diseases
148,T97,Condition 2541 2554;2570 2578	psychosomatic diseases
149,*,OR T96 T97
150,T98,Visit 2589 2604	hospitalization
151,T99,Temporal 2616 2630	last 12 months
152,T100,Scope 2541 2578	psychosomatic or psychiatric diseases
153,R40,Has_temporal Arg1:T98 Arg2:T99
154,T101,Condition 2661 2671	malignancy
155,T102,Negation 2677 2686	exception
156,T103,Condition 2690 2700;2718 2727;2728 2739	basal cell carcinoma of the skin
157,T104,Condition 2704 2739	squamous cell carcinoma of the skin
158,*,OR T104 T103 T105
159,T105,Condition 2745 2779	cervical intraepithelial neoplasia
160,T106,Temporal 2781 2811	5 years prior to randomization
161,T107,Reference_point 2798 2811	randomization
162,R41,Has_index Arg1:T106 Arg2:T107
163,R42,Has_temporal Arg1:T101 Arg2:T106
164,T108,"Scope 2690 2779	basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia"
165,R43,Has_negation Arg1:T108 Arg2:T102
166,T109,Non-query-able 2815 2975	ny medical or surgical intervention planned for the next 13 months after randomization not allowing study participation according to the investigator´s judgment
167,T110,Competing_trial 2977 3101	current participation in any other clinical trial or participation in another clinical trial within 30 days before screening
0,T1,Non-query-able 0 148	Subjects with any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study
1,T2,Pregnancy_considerations 151 173	Pregnancy or lactation
2,T3,Condition 181 189	allergic
3,T4,Drug 202 217	tranexamic acid
4,R1,AND Arg1:T3 Arg2:T4
0,T1,Temporal 21 48	4 weeks preceding inclusion
1,T2,Reference_point 39 48	inclusion
2,T3,Observation 52 73	planned participation
3,T4,"Context_Error 0 200	Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure."
4,T5,"Post-eligibility 0 200	Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure."
5,T6,Drug 217 224	vaccine
6,T7,Temporal 225 272	in the 4 weeks preceding each trial vaccination
7,T8,Reference_point 250 272	each trial vaccination
8,T9,Temporal 307 354	in the 4 weeks following each trial vaccination
9,T10,Reference_point 332 354	each trial vaccination
10,R1,Has_temporal Arg1:T6 Arg2:T7
11,R2,Has_index Arg1:T7 Arg2:T8
12,T11,Observation 276 291	planned receipt
13,T12,Drug 299 306	vaccine
14,R3,Has_mood Arg1:T12 Arg2:T11
15,R4,Has_temporal Arg1:T11 Arg2:T9
16,R5,Has_index Arg1:T9 Arg2:T10
17,T13,Parsing_Error 356 367	except for:
18,T14,Drug 373 394	influenza vaccination
19,T15,Temporal 418 456	at least 2 weeks before study vaccines
20,T16,Reference_point 442 456	study vaccines
21,R6,Has_index Arg1:T15 Arg2:T16
22,R7,Has_temporal Arg1:T14 Arg2:T15
23,T17,Negation 356 366	except for
24,T18,Procedure 464 475;517 528	measles (M) vaccination
25,T19,"Procedure 479 508;517 528	measles, mumps, rubella (MMR) vaccination"
26,*,OR T19 T18
27,T20,Temporal 556 606	concomitantly with the first dose of study vaccine
28,T21,Reference_point 575 606	the first dose of study vaccine
29,R8,Has_index Arg1:T20 Arg2:T21
30,T22,"Scope 464 528	measles (M) or measles, mumps, rubella (MMR) routine vaccination"
31,R9,Has_temporal Arg1:T22 Arg2:T20
32,T23,Visit 676 688	Indian sites
33,A1,Optional T23
34,T24,Drug 690 722	oral poliomyelitis vaccine (OPV)
35,T25,Temporal 732 772	during National Immunization Days (NIDs)
36,T26,Reference_point 739 772	National Immunization Days (NIDs)
37,R10,Has_index Arg1:T25 Arg2:T26
38,T27,Temporal 732 738;777 825	during supplementary immunization activity days (SIADs)
39,T28,Reference_point 777 825	supplementary immunization activity days (SIADs)
40,R11,Has_index Arg1:T27 Arg2:T28
41,T29,Scope 732 825	during National Immunization Days (NIDs) and supplementary immunization activity days (SIADs)
42,R12,Has_scope Arg1:T24 Arg2:T29
43,R13,AND Arg1:T23 Arg2:T24
44,T30,Procedure 836 877	vaccination against meningococcal disease
45,T31,Drug 894 907	study vaccine
46,T32,Drug 911 940	another meningococcal vaccine
47,R14,AND Arg1:T30 Arg2:T31
48,R15,AND Arg1:T30 Arg2:T32
49,T33,Drug 953 969	immune globulins
50,T34,Drug 971 976	blood
51,T35,Drug 980 1002	blood-derived products
52,*,OR T33 T34 T35
53,T36,Temporal 1003 1023	in the past 3 months
54,T37,"Scope 953 1002	immune globulins, blood or blood-derived products"
55,R16,Has_temporal Arg1:T37 Arg2:T36
56,T38,Condition 1058 1083	acquired immunodeficiency
57,T39,Condition 1044 1054;1067 1083	congenital immunodeficiency
58,T40,Procedure 1099 1124	immunosuppressive therapy
59,T41,Procedure 1134 1158	anti-cancer chemotherapy
60,T42,Procedure 1162 1179	radiation therapy
61,T43,Temporal 1181 1210	within the preceding 6 months
62,T44,Procedure 1225 1256	systemic corticosteroid therapy
63,T45,Multiplier 1215 1224	long-term
64,R17,Has_multiplier Arg1:T44 Arg2:T45
65,T46,Drug 1258 1268	prednisone
66,T47,Temporal 1283 1316	for more than 2 consecutive weeks
67,T48,Temporal 1317 1341	within the past 3 months
68,R18,Has_temporal Arg1:T46 Arg2:T47
69,R19,Has_temporal Arg1:T46 Arg2:T48
70,R20,Subsumes Arg1:T44 Arg2:T46
71,*,OR T42 T41
72,T49,Scope 1134 1179	anti-cancer chemotherapy or radiation therapy
73,R21,Subsumes Arg1:T40 Arg2:T49
74,R22,Has_temporal Arg1:T40 Arg2:T43
75,T50,Observation 1034 1043	suspected
76,T51,Observation 1025 1030	Known
77,*,OR T50 T51
78,T52,Scope 1025 1043	Known or suspected
79,*,OR T39 T38
80,T53,Scope 1044 1083	congenital or acquired immunodeficiency
81,R23,Has_scope Arg1:T53 Arg2:T52
82,*,OR T53 T40 T44
83,T54,Condition 1355 1377	meningococcal diseases
84,T55,Procedure 1408 1421	serologically
85,T56,Procedure 1426 1443	microbiologically
86,R24,AND Arg1:T54 Arg2:T55
87,R25,AND Arg1:T54 Arg2:T56
88,T57,Value 1379 1388	confirmed
89,R26,Has_value Arg1:T55 Arg2:T57
90,R27,Has_value Arg1:T56 Arg2:T57
91,T58,"Non-query-able 1445 1537	At high risk, in the opinion of the Investigator, for meningococcal disease during the trial"
92,T59,"Subjective_judgement 1445 1537	At high risk, in the opinion of the Investigator, for meningococcal disease during the trial"
93,T60,Condition 1558 1583	systemic hypersensitivity
94,T61,Drug 1598 1616	vaccine components
95,R28,AND Arg1:T60 Arg2:T61
96,T62,Observation 1621 1628	history
97,T63,Condition 1634 1659	life-threatening reaction
98,T64,Drug 1667 1674	vaccine
99,R29,AND Arg1:T63 Arg2:T64
100,T65,Drug 1701 1708	vaccine
101,T66,Qualifier 1675 1692	used in the trial
102,R30,Has_qualifier Arg1:T64 Arg2:T66
103,T67,Context_Error 1675 1692	used in the trial
104,T68,"Context_Error 1539 1746	Known or suspected systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances"
105,T69,Condition 1754 1770	thrombocytopenia
106,T70,Condition 1772 1788	contraindicating
107,T71,Procedure 1789 1814	intramuscular vaccination
108,R31,AND Arg1:T70 Arg2:T71
109,R32,Subsumes Arg1:T69 Arg2:T70
110,T72,Condition 1816 1833	Bleeding disorder
111,T73,Drug 1849 1863	anticoagulants
112,T74,Temporal 1864 1898	in the 3 weeks preceding inclusion
113,T75,Reference_point 1889 1898	inclusion
114,R33,Has_index Arg1:T74 Arg2:T75
115,T76,Condition 1900 1916	contraindicating
116,T77,Procedure 1917 1942	intramuscular vaccination
117,R35,Subsumes Arg1:T76 Arg2:T77
118,*,OR T72 T73
119,T78,"Scope 1816 1863	Bleeding disorder, or receipt of anticoagulants"
120,R34,Has_temporal Arg1:T78 Arg2:T74
121,T79,Visit 1950 1967	emergency setting
122,T80,Procedure 1972 1984	hospitalized
123,T81,Qualifier 1985 1998	involuntarily
124,R36,Has_qualifier Arg1:T80 Arg2:T81
125,T82,Condition 1972 1998	hospitalized involuntarily
126,*,OR T79 T82
127,T83,"Subjective_judgement 2000 2129	Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion"
128,T84,Visit 2156 2168	Indian sites
129,A2,Optional T84
130,T85,Qualifier 2170 2178	Moderate
131,T86,Qualifier 2182 2188	severe
132,T87,Condition 2189 2202	acute illness
133,T88,Condition 2189 2194;2203 2212	acute infection
134,T89,Subjective_judgement 2214 2248	according to investigator judgment
135,T90,Temporal 2250 2275	on the day of vaccination
136,T91,Reference_point 2253 2275	the day of vaccination
137,R37,Has_index Arg1:T90 Arg2:T91
138,T92,Condition 2279 2294	febrile illness
139,T93,Measurement 2296 2307	temperature
140,T94,Value 2308 2316	≥ 38.0°C
141,R38,Has_value Arg1:T93 Arg2:T94
142,R39,Subsumes Arg1:T92 Arg2:T93
143,*,OR T88 T87
144,T95,Scope 2189 2212	acute illness/infection
145,*,OR T86 T85
146,T96,Scope 2170 2188	Moderate or severe
147,R40,Has_scope Arg1:T95 Arg2:T96
148,R41,Has_temporal Arg1:T95 Arg2:T90
149,R42,Has_temporal Arg1:T92 Arg2:T90
150,T97,Scope 2170 2317	Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C)
151,R43,Has_scope Arg1:T84 Arg2:T97
152,T98,Visit 2345 2358	Russian sites
153,A3,Optional T98
154,T99,Condition 2360 2373	Acute disease
155,T100,Temporal 2390 2415	on the day of vaccination
156,T101,Reference_point 2393 2415	the day of vaccination
157,R44,Has_index Arg1:T100 Arg2:T101
158,T102,Condition 2419 2434	febrile illness
159,T103,Measurement 2436 2456	axillary temperature
160,T104,Value 2457 2465	≥ 37.0°C
161,R45,Has_value Arg1:T103 Arg2:T104
162,R46,Subsumes Arg1:T102 Arg2:T103
163,R47,Has_temporal Arg1:T99 Arg2:T100
164,T105,Scope 2360 2466	Acute disease of any severity on the day of vaccination or febrile illness (axillary temperature ≥ 37.0°C)
165,R48,Has_scope Arg1:T98 Arg2:T105
166,T106,Non-query-able 2469 2594	A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
167,T107,Not_a_criteria 2469 2594	A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
168,T108,Drug 2626 2644	antibiotic therapy
169,T109,Qualifier 2615 2625	injectable
170,T110,Qualifier 2607 2611	oral
171,*,OR T109 T110
172,T111,Scope 2607 2625	oral or injectable
173,T112,Temporal 2645 2690	within 72 hours prior to the first blood draw
174,T113,Reference_point 2670 2690	the first blood draw
175,R49,Has_index Arg1:T112 Arg2:T113
176,R50,Has_temporal Arg1:T108 Arg2:T112
177,R51,Has_scope Arg1:T108 Arg2:T111
178,T114,Non-query-able 2692 2810	Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study
179,T115,Condition 2832 2855	Guillain-Barré Syndrome
180,T116,Observation 2821 2828	history
181,R52,Has_temporal Arg1:T115 Arg2:T116
0,T1,Condition 12 34	Dupuytrens contracture
1,T2,Qualifier 0 11	symptomatic
2,T3,Condition 40 53	palpable cord
3,T4,Qualifier 55 68	involving MCP
4,T5,Measurement 70 92	total contracture size
5,T6,Value 93 108	over 30 degrees
6,R1,Has_value Arg1:T5 Arg2:T6
7,R2,Has_qualifier Arg1:T1 Arg2:T2
8,R3,AND Arg1:T1 Arg2:T3
9,R4,Has_qualifier Arg1:T1 Arg2:T4
10,R5,AND Arg1:T1 Arg2:T5
0,T1,Person 3 8	years
1,T2,Value 0 2;9 17	18 or older
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 19 35	Chest radiograph
4,T4,Condition 48 57	opacities
5,T5,Qualifier 44 47	new
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,R3,AND Arg1:T3 Arg2:T4
8,T6,Condition 60 65	Cough
9,T7,Condition 81 87	sputum
10,T8,Measurement 89 93	Temp
11,T9,"Value 94 102	>38,0 °C"
12,T10,"Value 106 114	<36,0 °C"
13,*,OR T9 T10
14,T11,"Scope 94 114	>38,0 °C or <36,0 °C"
15,R4,Has_scope Arg1:T8 Arg2:T11
16,T12,Observation 116 137	Audible abnormalities
17,T13,Procedure 141 158	chest examination
18,T14,Condition 175 184	pneumonia
19,R5,Has_context Arg1:T13 Arg2:T12
20,R6,AND Arg1:T14 Arg2:T13
21,T15,Condition 186 198	Leukocytosis
22,T16,Multiplier 200 217	>10.000 cells/mm3
23,T17,Condition 245 255	leucopenia
24,T18,Multiplier 257 272	<4000 cells/mm3
25,T19,Multiplier 220 234;236 240	leftward shift >10%
26,T20,"Scope 200 241	>10.000 cells/mm3), leftward shift (>10%)"
27,R7,Has_scope Arg1:T15 Arg2:T20
28,R8,Has_multiplier Arg1:T17 Arg2:T18
29,*,OR T15 T17
30,T21,Measurement 275 293	C-reactive protein
31,T22,Value 294 303	> 15 mg/l
32,T23,Value 305 353	three fold higher than the upper limit of normal
33,R9,Subsumes Arg1:T22 Arg2:T23
34,R10,Has_value Arg1:T21 Arg2:T22
0,T1,Person 0 5	women
1,T2,Person 10 13	men
2,*,OR T1 T2
3,T3,Person 39 42	age
4,T4,Value 14 35	between 18 - 80 years
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 44 68	type 2 diabetes mellitus
7,T6,Condition 94 114	diabetic retinopathy
8,T7,Qualifier 70 75	early
9,T8,Qualifier 79 93	moderate stage
10,*,OR T8 T7
11,T9,Scope 70 93	early to moderate stage
12,R2,Has_scope Arg1:T6 Arg2:T9
13,T10,Measurement 116 121	ETDRS
14,T11,Value 123 125	20
15,T12,Value 151 153	35
16,*,OR T11 T12
17,T13,Scope 123 153	20 (microaneurysms only) to 35
18,R3,Has_scope Arg1:T10 Arg2:T13
19,T14,Qualifier 222 226	eyes
20,T15,Measurement 235 240	HbA1c
21,T16,Value 242 248	± 0.5%
22,R4,Has_value Arg1:T15 Arg2:T16
23,T17,Temporal 254 271	at least 12 weeks
24,R5,Has_temporal Arg1:T16 Arg2:T17
25,T18,Procedure 273 295	antidiabetic treatment
26,T19,Observation 308 312	diet
27,T20,Drug 314 323	metformin
28,T21,Drug 325 329	DPP4
29,T22,Drug 331 335	GLP1
30,T23,Drug 337 349	pioglitazone
31,T24,Drug 351 359	acarbose
32,T25,"Scope 308 359	diet, metformin, DPP4, GLP1, pioglitazone, acarbose"
33,*,OR T19 T20 T21 T22 T23 T24
34,R6,Subsumes Arg1:T18 Arg2:T25
35,T26,Measurement 389 394	HbA1c
36,T27,Value 395 413	= 6.5 and = 10.0 %
37,R7,Has_value Arg1:T26 Arg2:T27
38,T28,Person 415 430	body mass index
39,T29,Value 431 441	< 46 kg/m2
40,R8,Has_value Arg1:T28 Arg2:T29
41,T30,Measurement 450 464	blood pressure
42,T31,Value 465 478	= 150/95 mmHg
43,R9,Has_value Arg1:T30 Arg2:T31
44,T32,Non-query-able 479 757	(confirmed on a second day; 24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure = 145/90 mm Hg is possible); patients with hypertension should be treated according to current treatment guidelines
45,T33,Procedure 782 804	surgical sterilization
46,T34,Procedure 808 832	bilateral tubal ligation
47,T35,Procedure 836 858	bilateral oophorectomy
48,*,OR T34 T35
49,T36,Scope 808 858	bilateral tubal ligation or bilateral oophorectomy
50,R10,Has_scope Arg1:T33 Arg2:T36
51,T37,Temporal 759 775	at least 6 weeks
52,R11,Has_temporal Arg1:T36 Arg2:T37
53,T38,Procedure 860 872	hysterectomy
54,T39,Person 879 884	years
55,T40,Value 874 878	= 50
56,T41,Observation 892 912	postmenopausal state
57,T42,Temporal 913 921	> 1 year
58,R12,Has_temporal Arg1:T41 Arg2:T42
59,R13,Has_value Arg1:T39 Arg2:T40
60,T43,"Pregnancy_considerations 923 1403	< 50 years and in postmenopausal state > 1 year with serum follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or women of childbearing potential with a negative serum beta human chorionic gonadotropin (ß-hCG) pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication"
61,T44,"Pregnancy_considerations 1406 1802	correct use of one of the following accepted contraception methods: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e.g. condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository)"
62,T45,Pregnancy_considerations 1804 1900	true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)
63,T46,Non-query-able 1902 1947	sexual relationship only with female partners
64,T47,Non-query-able 1949 1970	sterile male partners
65,T48,Informed_consent 1972 2069	signed written informed consent and willingness to comply with treatment and follow-up procedures
66,T49,"Post-eligibility 2071 2177	capability of understanding the investigational nature, potential risks and benefits of the clinical trial"
0,T1,Mood 9 22	scheduled for
1,T2,Procedure 23 40	dental extraction
2,T3,Drug 58 66	edoxaban
3,T4,Drug 68 76	apixaban
4,T5,Drug 78 89	rivaroxaban
5,T6,Drug 93 103	dabigatran
6,*,OR T3 T4 T5 T6
7,T7,"Scope 58 103	edoxaban, apixaban, rivaroxaban or dabigatran"
8,R1,Has_mood Arg1:T2 Arg2:T1
9,T8,Temporal 152 180	on the day of the extraction
10,T9,Reference_point 170 180	extraction
11,R2,Has_index Arg1:T8 Arg2:T9
12,T10,Negation 105 108	Not
13,T11,Drug 138 151	anticoagulant
14,T12,Qualifier 133 137	oral
15,R3,Has_qualifier Arg1:T11 Arg2:T12
16,R4,Has_negation Arg1:T11 Arg2:T10
17,R5,Has_temporal Arg1:T11 Arg2:T8
18,T13,Post-eligibility 182 233	Provision of signed and dated informed consent form
19,T14,Post-eligibility 235 336	Stated willingness to comply with all study procedures and availability for the duration of the study
0,T1,Person 0 4	Male
1,T2,Person 9 15	female
2,T3,Person 25 29	aged
3,T4,Value 30 44	9 to 17 months
4,T5,Temporal 45 68	on the day of inclusion
5,T6,Reference_point 48 68	the day of inclusion
6,R1,Has_index Arg1:T5 Arg2:T6
7,R2,Has_value Arg1:T3 Arg2:T4
8,*,OR T2 T1
9,T7,Grammar_Error 5 8	and
10,R3,Has_temporal Arg1:T3 Arg2:T5
11,T8,Non-query-able 70 196	Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative(s) (if applicable)
12,T9,Non-query-able 198 343	Subject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial procedures.
13,T10,Post-eligibility 198 343	Subject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial procedures.
0,T1,Temporal 0 8	previous
1,T2,Qualifier 9 16	treated
2,T3,Condition 17 39	dupuytrens contracture
3,T4,Qualifier 40 49	same hand
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T3 Arg2:T2
6,R3,Has_temporal Arg1:T3 Arg2:T1
7,T5,Multiplier 51 65	more than tree
8,T6,Condition 66 85	fingers involvement
9,R4,Has_multiplier Arg1:T6 Arg2:T5
10,T7,Non-representable 87 113	we will not include thumbs
11,T8,Condition 115 127	other things
12,T9,Qualifier 128 151	affecting hand function
13,R5,Has_qualifier Arg1:T8 Arg2:T9
14,T10,Measurement 153 156	ASA
15,T11,Value 156 158	>3
16,R6,Has_value Arg1:T10 Arg2:T11
17,T12,Observation 160 176	expected to live
18,T13,Value 177 193	under five years
19,R7,Has_value Arg1:T12 Arg2:T13
20,T14,Drug 195 207	Tetracycline
21,T15,Temporal 218 234	within two weeks
22,R8,Has_temporal Arg1:T14 Arg2:T15
23,T16,Condition 236 245	pregnancy
24,T17,Condition 247 254	nursing
25,T18,Condition 256 263	allergy
26,T19,Observation 267 291	clostridium histolyticum
27,R9,Has_context Arg1:T18 Arg2:T19
28,T20,Competing_trial 293 319	participant in other trial
0,T1,Competing_trial 0 87	The patient is participating in another clinical study using an investigational product
1,T2,"Non-query-able 90 191	The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study"
0,T1,Condition 14 26	coagulopathy
1,T2,Procedure 36 60	anti-coagulation therapy
2,*,OR T1 T2
3,T3,Condition 63 87	Gastrointestinal disease
4,T4,Condition 90 105	motion sickness
5,T5,Condition 108 125	diabetes mellitus
6,T6,Condition 142 154	preeclampsia
0,T1,Person 0 3	Age
1,T2,Value 4 17	<18 years old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Post-eligibility 19 75	Patient unable to communicate or to understand the study
4,T4,Post-eligibility 77 121	Patient refusing to participate to the study
5,T5,Condition 123 139	contraindication
6,T6,Procedure 143 154	laparoscopy
7,R2,AND Arg1:T5 Arg2:T6
0,T1,Person 0 3	Age
1,T2,Value 11 29	14 to 65 years-old
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 56 71	Port-wine Stain
4,T4,Drug 93 103	hemoporfin
5,T5,Post-eligibility 159 231	Written informed consent signed and agreed to receive periodic follow-up
0,T1,Procedure 8 26	kidney transplants
1,T2,Qualifier 0 7	De novo
2,T3,Person 42 45	old
3,T4,Value 28 41	20 - 65 years
4,T5,Measurement 74 98	alanine aminotransferase
5,T6,Measurement 47 73	aspartate aminotransferase
6,R1,Has_qualifier Arg1:T1 Arg2:T2
7,R2,Has_value Arg1:T3 Arg2:T4
8,T7,Value 99 145	within 2 times the upper limit of normal range
9,T8,Scope 47 98	aspartate aminotransferase/alanine aminotransferase
10,R3,Has_value Arg1:T8 Arg2:T7
0,T1,Post-eligibility 0 109	The patient and/or the patient's parent/legal guardian is willing and able to provide signed informed consent
1,T2,Condition 140 161	GAA enzyme deficiency
2,T3,Qualifier 167 171	skin
3,T4,Qualifier 173 178	blood
4,T5,Qualifier 183 196	muscle tissue
5,T6,Multiplier 204 205	2
6,T7,Observation 216 234	GAA gene mutations
7,R1,Has_multiplier Arg1:T7 Arg2:T6
8,*,OR T3 T4 T5
9,T8,"Scope 167 196	skin, blood, or muscle tissue"
10,R2,Has_scope Arg1:T2 Arg2:T8
11,T9,Condition 256 269	Pompe disease
12,T10,Person 237 243	Infant
13,T11,Person 248 255	toddler
14,*,OR T10 T11
15,T12,Non-query-able 237 552	Infant and toddler Pompe disease patients can be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) will not exceed 3 percent of the total blood volume during a period of 4 weeks and will not exceed 1 percent at any single time.
16,T13,"Pregnancy_considerations 554 861	The patient, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female patients of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study"
17,T14,Non-representable 864 919	For patients previously treated with alglucosidase alfa
18,T15,Drug 945 963	alglucosidase alfa
19,T16,Temporal 964 985	for at least 6 months
20,R3,Has_temporal Arg1:T15 Arg2:T16
0,T1,Person 0 5	women
1,T2,Condition 14 38	pelvic floor dysfunction
2,T3,Informed_consent 41 56	nformed consent
0,T1,Person 0 5	adult
1,T2,Person 6 12	female
2,T3,Observation 6 20	female partner
3,R1,multi Arg1:T3 Arg2:T2
4,T4,Person 22 26	aged
5,T5,Value 27 41	18 to 40 years
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Procedure 67 83	cesarean section
8,T7,Qualifier 58 66	elective
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Mood 44 57	scheduled for
11,R4,Has_mood Arg1:T6 Arg2:T8
0,T1,Condition 0 9	Pregnancy
1,T2,Condition 11 23	Tuberculosis
2,T3,Condition 25 36;42 49	Hepatitis B carrier
3,T4,Condition 25 34;40 49	Hepatitis C carrier
4,*,OR T4 T3
5,T5,Measurement 58 86	Human immunodeficiency virus
6,T6,Value 87 95	positive
7,R1,Has_value Arg1:T5 Arg2:T6
8,T7,Procedure 104 121	Retransplantation
9,T8,Procedure 136 151	transplantation
10,T9,Qualifier 125 135	multiorgan
11,R2,Has_qualifier Arg1:T8 Arg2:T9
12,*,OR T7 T8
13,T10,Condition 164 184	rheumatoid arthritis
14,T11,Non-query-able 186 260	Use of drugs that might have enhanced or inhibited CYP3A4 or P-gp activity
0,T1,Condition 0 7	Allergy
1,T2,Drug 11 21	porphyrins
2,T3,Drug 11 21;26 35	porphyrins analogues
3,T4,Condition 37 53	Photosensitivity
4,T5,Condition 55 64	Porphyria
5,T6,Condition 66 87	Allergic constitution
6,T7,Scope 11 35	porphyrins and analogues
7,*,OR T2 T3
8,R1,Has_scope Arg1:T1 Arg2:T7
9,*,OR T1 T4 T5 T6
10,T8,Condition 90 104	Scar diathesis
11,T9,Pregnancy_considerations 107 210	Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application
12,T10,Post-eligibility 213 281	Be judged not suitable to participate the study by the investigators
0,T1,Condition 27 37	drug abuse
1,T2,Observation 16 23	history
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Observation 53 60	history
4,T4,Condition 64 77	schizophrenia
5,T5,Temporal 40 52	preoperative
6,T6,Condition 79 87	epilepsy
7,T7,Condition 89 101	parkinsonism
8,T8,Drug 110 134	cholinesterase inhibitor
9,T9,Condition 136 160	inability to communicate
10,T10,Condition 189 193	coma
11,T11,Condition 195 212	profound dementia
12,T12,Condition 217 233	language barrier
13,*,OR T10 T11
0,T1,Visit 0 17	Ambulatory status
1,T2,Visit 19 29	outpatient
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Temporal 31 49	at time of consent
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Value 55 66	10-55 years
6,T5,Person 51 54	Age
7,R3,Has_value Arg1:T5 Arg2:T4
8,T6,Condition 90 114	Autism Spectrum Disorder
9,T7,Measurement 116 118	IQ
10,T8,Value 119 146	greater than or equal to 70
11,T9,Measurement 172 220	Children's Yale-Brown Obsessive Compulsive Scale
12,T10,Value 154 168	greater than 8
13,R4,Has_value Arg1:T9 Arg2:T10
14,T11,Drug 230 253	psychoactive medication
15,T12,Negation 222 229	Free of
16,R5,Has_negation Arg1:T11 Arg2:T12
17,T13,Temporal 258 266;268 277	at least one month
18,T14,Temporal 258 266;294 303	at least two weeks
19,T15,Temporal 258 266;342 351	at least five days
20,T16,Drug 282 292	fluoxetine
21,T17,Drug 314 319	SSRIs
22,T18,Drug 324 336	neuroleptics
23,*,OR T17 T18
24,T19,Scope 314 336	SSRIs and neuroleptics
25,T20,Drug 356 366	stimulants
26,T21,Temporal 367 388	prior to MRI scanning
27,T22,Drug 453 478	anticonvulsant medication
28,T23,Condition 483 499	seizure disorder
29,R7,AND Arg1:T22 Arg2:T23
30,R8,Has_temporal Arg1:T20 Arg2:T15
31,T24,Temporal 414 439	greater than three months
32,T25,Qualifier 400 412	stable doses
33,R9,Subsumes Arg1:T25 Arg2:T24
34,T26,Scope 258 366	at least: one month for fluoxetine; two weeks for other SSRIs and neuroleptics; and five days for stimulants
35,R10,Has_temporal Arg1:T26 Arg2:T21
36,R11,Has_scope Arg1:T11 Arg2:T26
37,R12,Has_qualifier Arg1:T22 Arg2:T25
38,R13,Has_value Arg1:T7 Arg2:T8
39,R6,Has_temporal Arg1:T16 Arg2:T13
40,R14,Has_temporal Arg1:T19 Arg2:T14
41,*,OR T20 T19 T16
42,T27,Negation 390 399	excepting
43,R15,Has_negation Arg1:T22 Arg2:T27
44,R16,AND Arg1:T11 Arg2:T22
45,T28,Qualifier 68 86	Clinical diagnosis
46,R17,Has_qualifier Arg1:T6 Arg2:T28
0,T1,Condition 37 64	primary knee osteoarthritis
1,T2,Measurement 66 85	Kellgren & Lawrence
2,T3,"Value 86 98	I, II or III"
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Qualifier 0 8;24 33	Clinical diagnosis
6,T5,Qualifier 13 33	radiologic diagnosis
7,R3,Has_qualifier Arg1:T1 Arg2:T5
8,R4,Has_qualifier Arg1:T1 Arg2:T4
9,T6,Non-query-able 102 153	Capability to understand the Informed Consent Form;
10,T7,Post-eligibility 102 153	Capability to understand the Informed Consent Form;
11,T8,Condition 155 167	Chronic pain
12,T9,Temporal 172 195	at least 3 months prior
13,T10,Reference_point 199 208	inclusion
14,R5,Has_index Arg1:T9 Arg2:T10
15,T11,Procedure 222 225	VAS
16,T12,Qualifier 210 225	measured by VAS
17,R6,Has_temporal Arg1:T8 Arg2:T9
18,R7,Has_qualifier Arg1:T8 Arg2:T12
19,T13,Measurement 228 231	VAS
20,T14,Value 232 242	4 or above
21,R8,Has_value Arg1:T13 Arg2:T14
22,T15,Parsing_Error 227 244	(VAS 4 or above);
23,T16,Condition 257 269	skin injures
24,T17,Negation 246 253	Absence
25,R9,Has_negation Arg1:T16 Arg2:T17
26,T18,Condition 271 281	infections
27,T19,Condition 285 290	tumor
28,T20,Reference_point 298 309	target knee
29,R10,Has_index Arg1:T19 Arg2:T20
30,R11,Has_index Arg1:T18 Arg2:T20
31,*,OR T19 T18 T16
32,T21,Non-query-able 312 350	Availability to comply with the visits
33,T22,Post-eligibility 312 350	Availability to comply with the visits
0,T1,Condition 0 13	breast cancer
1,T2,Measurement 26 47	unilateral mastectomy
2,T3,Temporal 15 25	undergoing
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,T4,Procedure 64 88	axillary node dissection
5,A1,Optional T4
6,R2,AND Arg1:T2 Arg2:T4
7,T5,Informed_consent 90 188	received adequate oral and written information about the study and signed an informed-consent form
0,T1,Person 0 3	Age
1,T2,Value 4 14	= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 19 69	NYHA (New York Heart Association) functional class
4,T4,"Value 70 84	II, III and IV"
5,R2,Has_value Arg1:T3 Arg2:T4
0,T1,Condition 0 23	endometrial hyperplasia
1,T2,Condition 29 35	atypia
2,T3,Procedure 38 64	estrogen-progestin therapy
3,T4,Temporal 65 98	in the 2 months before enrollment
4,T5,Condition 101 120	autoimmune diseases
5,T6,Condition 123 130;166 175	chronic disorders
6,T7,Condition 132 141;166 175	metabolic disorders
7,T8,Condition 143 151;166 175	systemic disorders
8,T9,Condition 156 175	endocrine disorders
9,T10,Condition 187 203	hyperandrogenism
10,T11,Condition 205 223	hyperprolactinemia
11,T12,Condition 225 242	diabetes mellitus
12,T13,Condition 247 262	thyroid disease
13,*,OR T12 T13 T11 T10
14,T14,"Scope 187 262	hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease"
15,T15,"Scope 123 175	chronic, metabolic, systemic and endocrine disorders"
16,R1,Subsumes Arg1:T15 Arg2:T14
17,T16,Condition 265 294	hypogonadotropic hypogonadism
18,T17,Condition 297 323	majors clinical conditions
0,T1,Condition 9 31	neurological condition
1,T2,Condition 70 84	pain diagnosis
2,T3,Negation 32 42	other than
3,T4,Qualifier 48 84	associated with their pain diagnosis
4,R1,multi Arg1:T4 Arg2:T2
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,R3,Has_qualifier Arg1:T1 Arg2:T4
7,T5,Undefined_semantics 92 126	in the opinion of the investigator
8,T6,Drug 209 237	lidocaine-containing product
9,T7,Qualifier 243 268	could not be discontinued
10,T8,Temporal 269 294	while receiving lidocaine
11,T9,Drug 285 294	lidocaine
12,T10,Reference_point 275 294	receiving lidocaine
13,R4,multi Arg1:T8 Arg2:T10
14,R5,AND Arg1:T10 Arg2:T9
15,R6,Has_qualifier Arg1:T6 Arg2:T7
16,T11,Drug 311 340	class 1 anti-arrhythmic drugs
17,T12,Drug 348 358	mexiletine
18,T13,Drug 360 369	tocainide
19,*,OR T12 T13
20,T14,"Scope 348 369	mexiletine, tocainide"
21,R7,Subsumes Arg1:T11 Arg2:T14
0,T1,Person 0 3	age
1,T2,Value 4 23	> 17 and < 60 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 26 66	American Society of Anesthesiology (ASA)
4,T4,Value 67 72	I-III
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Procedure 88 122	living donor renal transplantation
7,T6,Mood 75 87	admitted for
8,R3,Has_mood Arg1:T5 Arg2:T6
0,T1,Condition 11 31	spinal cord stenosis
1,T2,Observation 0 7	History
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 56 76	lumbar radiculopathy
4,T4,Condition 35 52	clinical symptoms
5,R2,AND Arg1:T4 Arg2:T3
6,*,OR T4 T1
7,T5,Condition 96 117	neurological diseases
8,T6,Observation 79 86	History
9,T7,Temporal 90 95	onset
10,*,OR T6 T7
11,T8,Scope 79 95	History or onset
12,R3,Has_scope Arg1:T5 Arg2:T8
13,T9,Condition 120 136	Generalized pain
14,T10,Condition 140 152	fibromyalgia
15,*,OR T10 T9
16,T11,Condition 155 172	Inability to walk
17,T12,Procedure 186 198	knee surgery
18,T13,Reference_point 206 217	target knee
19,R4,Has_index Arg1:T12 Arg2:T13
20,T14,Observation 175 182	History
21,R5,Has_temporal Arg1:T12 Arg2:T14
22,T15,Condition 240 254	osteoarthritis
23,T16,Condition 220 236	Secondary causes
24,R6,AND Arg1:T16 Arg2:T15
25,T17,Undefined_semantics 220 254	Secondary causes of osteoarthritis
26,T18,Drug 264 271	statins
27,T19,Drug 276 286	quinolones
28,T20,Temporal 287 307	in the previous year
29,R7,Has_temporal Arg1:T19 Arg2:T20
30,R8,Has_temporal Arg1:T18 Arg2:T20
31,T21,Condition 335 355	psychiatric diseases
32,T22,Temporal 327 334	ongoing
33,T23,Qualifier 310 322	Uncontrolled
34,R9,Has_temporal Arg1:T21 Arg2:T22
35,R10,Has_qualifier Arg1:T21 Arg2:T23
36,T24,Procedure 358 382	Invasive knee treatments
37,T25,Drug 388 403	hyaluronic acid
38,T26,Procedure 388 412	hyaluronic acid infusion
39,T27,Drug 414 429	corticosteroids
40,T28,Drug 434 446	anaesthetics
41,T29,Reference_point 455 466	target knee
42,T30,Temporal 468 491	up to 6 months previous
43,T31,Reference_point 495 510	study inclusion
44,R11,Has_index Arg1:T30 Arg2:T31
45,T32,"Scope 358 446	Invasive knee treatments with hyaluronic acid infusion, corticosteroids and anaesthetics"
46,R12,Has_index Arg1:T32 Arg2:T29
47,R13,Has_temporal Arg1:T32 Arg2:T30
0,T1,Person 0 3	Age
1,T2,Value 4 22	less than 10 years
2,T3,Value 26 47	greater than 55 years
3,*,OR T2 T3
4,T4,Scope 4 47	less than 10 years or greater than 55 years
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Temporal 49 67	at time of consent
7,R2,Has_temporal Arg1:T1 Arg2:T5
8,T6,Measurement 69 81	Estimated IQ
9,T7,Value 82 86	< 70
10,R3,Has_value Arg1:T6 Arg2:T7
11,T8,Condition 88 109	Uncontrolled epilepsy
12,T9,Value 119 151	within 6 months prior to consent
13,T10,Condition 111 118	seizure
14,R4,Has_value Arg1:T10 Arg2:T9
15,R5,Subsumes Arg1:T8 Arg2:T10
16,T11,"Context_Error 157 276	Presence of medical conditions that might interfere with participation, or where participation would be contraindicated"
17,T12,Condition 289 308	neurological injury
18,T13,Observation 278 285	History
19,R6,Has_temporal Arg1:T12 Arg2:T13
20,T14,Condition 310 321	head trauma
21,T15,Condition 341 357	seizure disorder
22,T16,Qualifier 323 340	poorly-controlled
23,T17,Condition 359 366	seizure
24,T18,Temporal 367 398	within the preceding six months
25,R7,Has_temporal Arg1:T17 Arg2:T18
26,R8,Has_qualifier Arg1:T15 Arg2:T16
27,R9,AND Arg1:T16 Arg2:T17
28,T19,Condition 401 407	stroke
29,T20,Condition 415 427	neurosurgery
30,T21,Temporal 409 414	prior
31,T22,Observation 432 463	under the care of a neurologist
32,T23,Observation 432 451;467 479	under the care of a neurosurgeon
33,R10,Has_temporal Arg1:T20 Arg2:T21
34,*,OR T19 T20 T15 T14 T23 T22
35,T24,"Scope 310 479	head trauma, poorly-controlled seizure disorder (seizure within the preceding six months), stroke, prior neurosurgery, or under the care of a neurologist or neurosurgeon"
36,R11,Subsumes Arg1:T12 Arg2:T24
37,T25,Condition 519 533	claustrophobia
38,T26,Observation 508 515	History
39,R12,Has_temporal Arg1:T25 Arg2:T26
40,T27,Device 535 544;560 577	Implanted metal in the body
41,T28,Device 548 577	irremovable metal in the body
42,*,OR T27 T28
43,T29,Condition 637 646	pregnancy
44,T30,Temporal 629 636	Current
45,R13,Has_temporal Arg1:T29 Arg2:T30
46,T31,Not_a_criteria 647 884	(as verified by testing prior to both initial dose administration of citalopram or placebo and prior to magnetic resonance imaging) due to the risk that may be associated with SSRI treatment and magnetic resonance imaging on fetal health
47,T32,Condition 894 927	contraindications to SSRI therapy
48,T33,Condition 977 982	mania
49,T34,Temporal 996 1015	during SSRI therapy
50,T35,Condition 986 995	hypomania
51,*,OR T33 T35
52,T36,Scope 977 995	mania or hypomania
53,R14,Has_temporal Arg1:T36 Arg2:T34
54,T37,Condition 1026 1038	drug allergy
55,*,OR T37 T36
56,T38,Observation 945 952	history
57,R15,Has_temporal Arg1:T32 Arg2:T38
58,T39,Context_Error 1041 1109	Concomitant medication that would interfere with study participation
59,T40,Drug 1128 1138	citalopram
60,T41,Observation 1117 1124	history
61,T42,Temporal 1111 1116	Prior
62,T43,Procedure 1139 1148	treatment
63,T44,Qualifier 1149 1156	failure
64,R16,Has_qualifier Arg1:T43 Arg2:T44
65,R17,AND Arg1:T43 Arg2:T40
66,R18,AND Arg1:T41 Arg2:T43
67,R19,Has_temporal Arg1:T43 Arg2:T42
68,T45,Context_Error 1111 1190	Prior history of citalopram treatment failure at appropriate doses and duration
69,T46,Non-query-able 1192 1288	Prior history of treatment failure to two previous SSRI trials at appropriate doses and duration
70,T47,Drug 1307 1330	psychoactive medication
71,T48,Drug 1342 1358	study medication
72,T50,Subjective_judgement 1370 1382	stable doses
73,T51,Temporal 1384 1409	greater than three months
74,T52,Drug 1423 1448	anticonvulsant medication
75,T53,Condition 1453 1469	seizure disorder
76,R20,AND Arg1:T52 Arg2:T53
77,T54,Drug 1474 1489	diphenhydramine
78,*,OR T54 T52
79,R21,Has_temporal Arg1:T50 Arg2:T51
80,R22,AND Arg1:T52 Arg2:T50
81,T55,"Scope 1360 1510	excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder, or diphenhydramine (Benadryl®)for sleep"
82,T56,Negation 1331 1341	other than
83,R24,Has_negation Arg1:T48 Arg2:T56
84,R25,AND Arg1:T47 Arg2:T48
85,T49,Negation 1360 1369	excepting
86,R23,Has_negation Arg1:T52 Arg2:T49
87,R26,AND Arg1:T47 Arg2:T52
88,T57,Observation 60 67	consent
89,T58,Reference_point 60 67	consent
90,R27,multi Arg1:T58 Arg2:T57
91,R28,Has_index Arg1:T5 Arg2:T58
92,T59,Procedure 915 927	SSRI therapy
93,R29,multi Arg1:T32 Arg2:T59
94,T60,"Scope 977 1038	mania or hypomania during SSRI therapy, or known drug allergy"
95,R30,Subsumes Arg1:T32 Arg2:T60
0,T1,Condition 22 25	PHN
1,T2,Condition 27 29	DN
2,T3,Condition 31 35	CRPS
3,T4,Condition 37 59	carpal tunnel syndrome
4,T5,Condition 61 75	HIV neuropathy
5,T6,Condition 65 75	neuropathy
6,T7,Condition 61 64	HIV
7,R1,causal Arg1:T6 Arg2:T7
8,R2,multi Arg1:T5 Arg2:T6
9,T8,Condition 88 106	sensory neuropathy
10,T9,Qualifier 77 87	idiopathic
11,T10,Condition 117 138	peripheral neuropathy
12,T11,Condition 213 216	PHN
13,A1,Optional T11
14,T12,Multiplier 236 245	>3 months
15,T13,Temporal 246 264	after rash healing
16,T14,Reference_point 252 264	rash healing
17,T15,Condition 252 264	rash healing
18,R3,multi Arg1:T13 Arg2:T14
19,R4,multi Arg1:T14 Arg2:T15
20,T16,Condition 231 235	pain
21,R5,Has_multiplier Arg1:T16 Arg2:T12
22,R6,Has_temporal Arg1:T16 Arg2:T13
23,R7,AND Arg1:T11 Arg2:T16
24,T17,Condition 283 285	DN
25,T18,Condition 300 306;313 321	Type I diabetes
26,T19,Condition 300 304;310 321	Type II diabetes
27,T20,Qualifier 326 333	painful
28,T21,Qualifier 334 340	distal
29,T22,Qualifier 341 350	symmetric
30,T23,Condition 351 378	sensorimotor polyneuropathy
31,R8,Has_qualifier Arg1:T23 Arg2:T20
32,R9,Has_qualifier Arg1:T23 Arg2:T21
33,R10,Has_qualifier Arg1:T23 Arg2:T22
34,T24,Condition 395 412	dynamic allodynia
35,A2,Optional T24
36,A3,Optional T17
37,T25,Scope 300 378	Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy
38,R11,Has_scope Arg1:T17 Arg2:T25
39,*,OR T1 T2 T3 T4 T5 T8 T10
40,R12,Has_qualifier Arg1:T8 Arg2:T9
41,T26,Subjective_judgement 140 193	upon mutual agreement of the sponsor and investigator
42,T27,Condition 456 460	CRPS
43,T28,Measurement 483 557	IASP (International Association for the Study of Pain) diagnostic criteria
44,T29,Value 471 474	met
45,R13,Has_value Arg1:T28 Arg2:T29
46,T30,Condition 576 598	carpal tunnel syndrome
47,T31,Procedure 640 673	clinical neurological examination
48,T32,Condition 681 689;702 707	Phalen's signs
49,T33,Condition 694 707	Tinel's signs
50,T34,Scope 681 707	Phalen's and Tinel's signs
51,R14,Subsumes Arg1:T31 Arg2:T34
52,T35,Procedure 710 727	electrodiagnostic
53,T36,Multiplier 741 746	daily
54,T37,Temporal 767 794	at least 3 months' duration
55,T38,Condition 747 763	painful symptoms
56,R15,Has_temporal Arg1:T38 Arg2:T37
57,R16,Has_multiplier Arg1:T38 Arg2:T36
58,R17,AND Arg1:T30 Arg2:T31
59,R18,AND Arg1:T30 Arg2:T35
60,R19,AND Arg1:T30 Arg2:T38
61,T39,Condition 813 827	HIV neuropathy
62,T40,Condition 842 845	HIV
63,T41,Condition 847 866	subjective symptoms
64,T42,Condition 878 899	peripheral neuropathy
65,T43,Qualifier 870 877	painful
66,R20,Has_qualifier Arg1:T42 Arg2:T43
67,T44,Multiplier 905 910	daily
68,T45,Condition 911 927	painful symptoms
69,T46,Temporal 931 958	at least 3 months' duration
70,R21,Has_temporal Arg1:T45 Arg2:T46
71,R22,Has_multiplier Arg1:T45 Arg2:T44
72,A4,Optional T39
73,T47,"Scope 842 958	HIV, subjective symptoms of painful peripheral neuropathy, and daily painful symptoms of at least 3 months' duration"
74,R23,Has_scope Arg1:T39 Arg2:T47
75,T48,Condition 977 1006	idiopathic sensory neuropathy
76,T49,Condition 1021 1025	pain
77,T50,Temporal 1029 1056	at least 3 months' duration
78,R24,Has_temporal Arg1:T49 Arg2:T50
79,A5,Optional T48
80,R25,AND Arg1:T48 Arg2:T49
81,T51,Measurement 1080 1097	daily pain rating
82,T52,Temporal 1098 1122	during the baseline week
83,T53,Reference_point 1109 1122	baseline week
84,R26,multi Arg1:T52 Arg2:T53
85,R27,Has_temporal Arg1:T51 Arg2:T52
86,T54,Qualifier 1072 1079	average
87,R28,Has_qualifier Arg1:T51 Arg2:T54
88,T55,Value 1139 1153	greater than 4
89,T56,Procedure 1161 1196	0-to-10 numerical pain rating scale
90,R29,AND Arg1:T51 Arg2:T56
91,R30,Has_value Arg1:T51 Arg2:T55
92,T57,Drug 1247 1264	analgesic regimen
93,T58,Drug 1280 1289	lidocaine
94,T59,Drug 1293 1303	gabapentin
95,T60,Scope 1280 1303	lidocaine or gabapentin
96,*,OR T59 T58
97,R31,Has_scope Arg1:T57 Arg2:T60
0,T1,Condition 0 10	submucosal
1,T2,Condition 27 48	subserosal leiomyomas
2,T3,Condition 13 23;38 48	intramural leiomyomas
3,T4,Mood 51 59	symptoms
4,T5,Condition 63 79	menometrorrhagia
5,R1,Has_mood Arg1:T5 Arg2:T4
6,T6,Condition 82 100	menstrual disorder
7,T7,Condition 103 114	infertility
8,T8,Condition 117 128	pelvic pain
0,T1,Condition 0 21	Anaphylactic reaction
1,T2,Drug 48 75	trivalent influenza vaccine
2,T3,Drug 44 47	TIV
3,R1,Subsumes Arg1:T3 Arg2:T2
4,R2,AND Arg1:T1 Arg2:T3
5,T4,Condition 84 132	IgE( Immunoglobulin E)-mediated hypersensitivity
6,T5,Drug 136 140	eggs
7,T6,Condition 155 160	hives
8,T7,Condition 162 194	swelling of the mouth and throat
9,T8,Condition 196 219	difficulty in breathing
10,T9,Condition 221 232	hypotension
11,T10,Condition 237 242	shock
12,*,OR T9 T10 T8 T7 T6
13,R3,AND Arg1:T4 Arg2:T5
14,T11,"Scope 155 242	hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock"
15,R4,Has_scope Arg1:T4 Arg2:T11
16,T12,Condition 244 267	Guillain-Barré syndrome
17,T13,Temporal 268 318	within eight weeks of a previous influenza vaccine
18,T14,Reference_point 290 318	a previous influenza vaccine
19,T15,Temporal 292 300	previous
20,T16,Drug 301 318	influenza vaccine
21,R5,Has_temporal Arg1:T16 Arg2:T15
22,R6,AND Arg1:T14 Arg2:T16
23,R7,Has_index Arg1:T13 Arg2:T14
24,R8,Has_temporal Arg1:T12 Arg2:T13
25,T17,Condition 320 341	Anaphylactic reaction
26,T18,Drug 345 353	neomycin
27,R9,AND Arg1:T17 Arg2:T18
28,T19,Drug 377 394	influenza vaccine
29,T20,Temporal 395 429	in two of the three previous years
30,R10,Has_temporal Arg1:T19 Arg2:T20
0,T1,Condition 0 8	pregnant
1,T2,Observation 12 25	breastfeeding
2,*,OR T1 T2
3,T3,Condition 33 55	thromboembolic disease
4,T4,Mood 64 76	high risk of
5,T5,Condition 77 92	thromboembolism
6,R1,Has_mood Arg1:T5 Arg2:T4
7,T6,Procedure 105 126	extra anticoagulation
8,R2,AND Arg1:T5 Arg2:T6
9,*,OR T3 T5
10,T7,Condition 167 174	allergy
11,T8,Drug 178 193	tranexamic acid
12,T9,Drug 194 205	Cyklokapron
13,R3,Subsumes Arg1:T8 Arg2:T9
14,T10,Scope 178 205	tranexamic acid/Cyklokapron
15,R4,Has_scope Arg1:T7 Arg2:T10
0,T1,Condition 0 15	Type 2 diabetic
1,T2,Person 26 29	Age
2,T3,Value 30 34	= 50
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 54 59	HbA1c
5,T5,Value 60 67	= 10.0%
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 74 105	Beck Depression Inventory (BDI)
8,T7,Value 106 116	<30 points
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Pregnancy_considerations 118 200	Participants who can undergo contraception in case of being in childbearing period
11,T9,"Post-eligibility 202 331	Understands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed concent"
0,T1,Person 0 5	Women
1,T2,Pregnancy_considerations 12 111	Cannot be pregnant or nursing at baseline or plan to become pregnant during the course of the study
2,A1,Optional T1
3,R1,AND Arg1:T1 Arg2:T2
4,T3,Measurement 113 134	Body Mass Index (BMI)
5,T4,Value 135 139	> 32
6,R2,Has_value Arg1:T3 Arg2:T4
7,T5,Measurement 141 147	Weight
8,T6,Value 148 160	> 220 pounds
9,R3,Has_value Arg1:T5 Arg2:T6
10,T7,Condition 162 171	Allergies
11,T8,Observation 175 185	shell fish
12,T9,Observation 187 194	seafood
13,T10,Observation 196 200	eggs
14,T11,Drug 204 210	iodine
15,*,OR T10 T11 T9 T8
16,T12,"Scope 175 210	shell fish, seafood, eggs or iodine"
17,R4,Has_scope Arg1:T7 Arg2:T12
18,T13,Condition 212 225	Heart disease
19,T14,Condition 227 241	kidney disease
20,T15,Condition 245 253	diabetes
21,*,OR T15 T14 T13
22,T16,Condition 268 274	asthma
23,T17,Device 280 288;295 303	metal in the body
24,T18,Device 280 285;292 303	metal on the body
25,*,OR T17 T18
26,T19,Qualifier 329 361	between the nose and the abdomen
27,T20,Scope 280 303	metal in or on the body
28,R5,Has_qualifier Arg1:T20 Arg2:T19
29,T21,Condition 367 393	major organ system disease
30,T22,Measurement 437 463	glomerular filtration rate
31,T23,Value 467 491	60 cc per minute or less
32,T24,Drug 494 507	Nitroglycerin
33,T25,Drug 517 525	nitrates
34,T26,Drug 537 574	phosphodiesterase 5 (PDE5) inhibitors
35,R6,Has_value Arg1:T22 Arg2:T23
36,T27,Scope 517 574	nitrates and use of phosphodiesterase 5 (PDE5) inhibitors
37,*,OR T27 T24
38,T28,Condition 593 609	hypersensitivity
39,T29,Drug 613 623	sildenafil
40,R7,AND Arg1:T28 Arg2:T29
41,T30,Observation 576 589	Prior history
42,R8,Has_temporal Arg1:T28 Arg2:T30
43,T31,Drug 648 682	phosphodiesterase (PDE) inhibitors
44,T32,Drug 699 705	Viagra
45,T33,Drug 707 713	Cialis
46,*,OR T32 T33
47,T34,"Scope 699 713	Viagra, Cialis"
48,R9,Subsumes Arg1:T31 Arg2:T34
49,T35,Condition 727 749	Pulmonary Hypertension
50,T36,Observation 755 772	used e-cigarettes
51,T37,Observation 755 759;777 786	used marijuana
52,T38,Temporal 787 795	<1 years
53,*,OR T37 T36
54,T39,Scope 755 786	used e-cigarettes and marijuana
55,R10,Has_temporal Arg1:T39 Arg2:T38
0,T1,Visit 16 45	cardiothoracic intensive care
1,T2,Temporal 46 95	after cardiac surgery with cardiopulmonary bypass
2,T3,Procedure 52 67	cardiac surgery
3,T4,Reference_point 52 95	cardiac surgery with cardiopulmonary bypass
4,R1,multi Arg1:T4 Arg2:T3
5,R2,Has_index Arg1:T2 Arg2:T4
6,T5,Procedure 73 95	cardiopulmonary bypass
7,R3,AND Arg1:T3 Arg2:T5
8,R4,Has_temporal Arg1:T1 Arg2:T2
9,T6,Condition 97 116	Acute kidney injury
10,T7,Measurement 129 153	increase in S-creatinine
11,T8,Value 154 169	50% or 27 mol/L
12,R5,Has_value Arg1:T7 Arg2:T8
13,T9,Value 171 177	Normal
14,T10,Measurement 178 190	S-creatinine
15,R6,Has_value Arg1:T10 Arg2:T9
16,T11,Temporal 191 205	before surgery
17,T12,Reference_point 198 205	surgery
18,T13,Procedure 198 205	surgery
19,R7,multi Arg1:T12 Arg2:T13
20,R8,Has_index Arg1:T11 Arg2:T12
21,R9,Has_temporal Arg1:T10 Arg2:T11
0,T1,Value 0 7;19 27	Between 25 to 65
1,T2,Person 12 15	age
2,T3,Temporal 28 39	at baseline
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,R2,Has_value Arg1:T2 Arg2:T1
5,T4,Mood 44 66	willing to participate
6,T5,Procedure 72 97	smoking cessation program
7,R3,Has_mood Arg1:T5 Arg2:T4
8,T6,Non-query-able 99 137	Be willing to attend all clinic visits
9,T7,Observation 157 164	smoking
10,T8,Value 165 175	at least ½
11,T9,Measurement 176 184	pack/day
12,R4,Has_value Arg1:T9 Arg2:T8
13,R5,AND Arg1:T7 Arg2:T9
14,T10,Temporal 185 196	at baseline
15,R6,Has_temporal Arg1:T7 Arg2:T10
16,T11,Procedure 213 227	cotinine level
17,T12,Procedure 232 246	CO Smokerlyzer
18,R7,AND Arg1:T7 Arg2:T11
19,R8,AND Arg1:T7 Arg2:T12
20,T13,Measurement 251 260	pack-year
21,T14,Value 248 250	>5
22,R9,Has_value Arg1:T13 Arg2:T14
23,T15,Observation 272 279	smoking
24,R10,AND Arg1:T15 Arg2:T13
25,T16,Measurement 281 342	Global Initiative for Chronic Obstructive Lung Disease (GOLD)
26,T17,Value 343 344	0
27,T18,Measurement 346 350	FEV1
28,T19,Value 350 355	=0.80
29,T20,Measurement 360 368	FEV1/FVC
30,T21,Value 368 373	>0.70
31,R11,Has_value Arg1:T20 Arg2:T21
32,T22,"Non-representable 374 446	Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC)"
33,R12,Has_value Arg1:T18 Arg2:T19
34,R13,Has_value Arg1:T16 Arg2:T17
35,T23,Scope 281 344	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 0
36,T24,Scope 346 373	FEV1=0.80 and FEV1/FVC>0.70
37,R14,Subsumes Arg1:T23 Arg2:T24
38,T25,Measurement 448 452	GOLD
39,T26,Value 453 454	1
40,R15,Has_value Arg1:T25 Arg2:T26
41,T27,Measurement 456 460	FEV1
42,T28,Value 460 465	=0.80
43,T29,Measurement 470 478	FEV1/FVC
44,T30,Value 479 485	< 0.70
45,R16,Has_value Arg1:T29 Arg2:T30
46,R17,Has_value Arg1:T27 Arg2:T28
47,T31,Scope 456 485	FEV1=0.80 and FEV1/FVC < 0.70
48,T32,Scope 448 454	GOLD 1
49,R18,Subsumes Arg1:T32 Arg2:T31
50,T33,Measurement 487 491	GOLD
51,T34,Value 492 493	2
52,R19,Has_value Arg1:T33 Arg2:T34
53,T35,Scope 487 493	GOLD 2
54,T36,Measurement 500 504	FEV1
55,T37,Value 495 500;504 509	0.50= <0.80
56,R20,Has_value Arg1:T36 Arg2:T37
57,T38,Measurement 514 522	FEV1/FVC
58,T39,Value 523 529	< 0.70
59,R21,Has_value Arg1:T38 Arg2:T39
60,T40,Scope 495 529	0.50=FEV1<0.80 and FEV1/FVC < 0.70
61,R22,Subsumes Arg1:T35 Arg2:T40
62,T41,"Non-query-able 531 643	Be willing to abstain from using any nicotine patches, e-cigarettes, or marijuana for the duration of the study."
0,T1,Condition 0 15	Type 1 diabetes
1,T2,Condition 17 35	Secondary diabetes
2,T3,Condition 37 57	gestational diabetes
3,*,OR T3 T2 T1
4,T4,Condition 67 75	dementia
5,T5,Procedure 76 85	treatment
6,T6,Drug 89 124	anti-depressive disorder medication
7,R1,AND Arg1:T5 Arg2:T4
8,T7,Temporal 59 66	Ongoing
9,R2,Has_temporal Arg1:T5 Arg2:T7
10,*,OR T5 T6
11,T8,Qualifier 126 138	Uncontrolled
12,T9,Measurement 161 164	BDI
13,T10,Value 165 176	= 30 points
14,R3,Has_value Arg1:T9 Arg2:T10
15,T11,Qualifier 178 183	Heavy
16,T12,Condition 184 194	alcoholics
17,R4,Has_qualifier Arg1:T12 Arg2:T11
18,T13,Condition 207 228	chronic liver disease
19,T14,Condition 230 245	hemochromatosis
20,T15,Condition 247 267	liver cell carcinoma
21,T16,Condition 269 293	autoimmune liver disease
22,T17,Condition 295 310	liver cirrhosis
23,T18,Condition 312 335	chronic viral hepatitis
24,*,OR T18 T17 T16 T15 T14
25,T19,"Scope 230 335	hemochromatosis, liver cell carcinoma, autoimmune liver disease, liver cirrhosis, chronic viral hepatitis"
26,R5,Subsumes Arg1:T13 Arg2:T19
27,T20,Condition 338 345	Allergy
28,T21,Condition 349 365	hypersensitivity
29,T22,Drug 369 386	target medication
30,*,OR T20 T21
31,T23,Scope 338 365	Allergy or hypersensitivity
32,R6,AND Arg1:T23 Arg2:T22
33,T24,Condition 413 426	Renal failure
34,T25,Qualifier 428 436	moderate
35,T26,Qualifier 440 446	severe
36,T27,Condition 447 463	renal impairment
37,*,OR T25 T26
38,T28,Scope 428 446	moderate or severe
39,R7,Has_scope Arg1:T27 Arg2:T28
40,T29,Measurement 465 501	estimated glomerular filtration rate
41,T30,Value 502 521	< 30 mL/min/1.73 m2
42,R8,Has_value Arg1:T29 Arg2:T30
43,T31,Temporal 527 534	ongoing
44,T32,Procedure 535 543	dialysis
45,R9,Has_temporal Arg1:T32 Arg2:T31
46,T33,Scope 428 463	moderate or severe renal impairment
47,T34,Scope 465 521	estimated glomerular filtration rate < 30 mL/min/1.73 m2
48,R10,Subsumes Arg1:T33 Arg2:T34
49,*,OR T24 T33 T32
50,T35,Measurement 554 568	liver function
51,T36,Value 545 553	Abnormal
52,T37,Measurement 570 577	AST/ALT
53,T38,Value 578 601	> x3 upper normal limit
54,R11,Has_value Arg1:T37 Arg2:T38
55,R12,Has_value Arg1:T35 Arg2:T36
56,T39,Scope 545 568	Abnormal liver function
57,T40,Scope 570 601	AST/ALT > x3 upper normal limit
58,R13,Subsumes Arg1:T39 Arg2:T40
59,T41,Condition 626 636	drug abuse
60,T42,Condition 615 622;631 636	alcohol abuse
61,T43,Temporal 637 661	in the previous 3 months
62,*,OR T42 T41
63,T44,Scope 615 636	alcohol or drug abuse
64,R14,Has_temporal Arg1:T44 Arg2:T43
65,T45,Condition 663 676	Premenopausal
66,T46,Person 677 682	women
67,T47,Condition 691 698	nursing
68,T48,Condition 702 710	pregnant
69,*,OR T47 T48
70,T49,Condition 712 746	Human immunodeficiency virus (HIV)
71,T50,Condition 750 785	human immunodeficiency virus (AIDS)
72,*,OR T49 T50
73,T51,Condition 787 807	chronic pancreatitis
74,T52,Condition 811 828	pancreatic cancer
75,*,OR T51 T52
0,T1,Temporal 0 7	Ongoing
1,T2,Procedure 8 17	treatment
2,T3,Drug 23 38	inotropic drugs
3,T4,Drug 44 58	norepinephrine
4,T5,Negation 40 43	not
5,R1,Has_negation Arg1:T4 Arg2:T5
6,R2,AND Arg1:T3 Arg2:T4
7,R3,AND Arg1:T2 Arg2:T3
8,R4,Has_temporal Arg1:T2 Arg2:T1
9,T6,Measurement 61 101	Central venous oxygen saturation (ScvO2)
10,T7,Value 102 107	< 60%
11,R5,Has_value Arg1:T6 Arg2:T7
12,T8,Procedure 116 142	optimization of hematocrit
13,T9,Observation 147 160	volume status
14,T10,Observation 108 115	despite
15,R6,AND Arg1:T10 Arg2:T8
16,R7,Has_context Arg1:T10 Arg2:T9
17,R8,Has_context Arg1:T6 Arg2:T10
18,T11,Procedure 170 195	renal replacement therapy
19,T12,Mood 162 166	Need
20,R9,Has_mood Arg1:T11 Arg2:T12
21,T13,Temporal 197 204	Ongoing
22,T14,Condition 205 213	bleeding
23,R10,Has_temporal Arg1:T14 Arg2:T13
24,T15,Informed_consent 215 279	Patient or next of kin does not consent with study participation
0,T1,Temporal 0 8	Previous
1,T2,Procedure 9 27	thoracic operation
2,T3,Qualifier 35 44	same side
3,R1,Has_qualifier Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T2 Arg2:T1
0,T1,Qualifier 7 12	other
1,T2,Drug 13 18	drugs
2,T3,Qualifier 25 56	can influence the lipid profile
3,T4,Measurement 43 56	lipid profile
4,R1,multi Arg1:T3 Arg2:T4
5,T5,Drug 62 68	Niacin
6,T6,Drug 70 78	Fibrates
7,R2,Has_qualifier Arg1:T2 Arg2:T3
8,R3,Has_qualifier Arg1:T2 Arg2:T1
9,*,OR T5 T6
10,T7,"Scope 62 78	Niacin, Fibrates"
11,R4,Has_scope Arg1:T2 Arg2:T7
12,T8,Measurement 81 103	Serum creatinine level
13,T9,Value 104 115	> 2.0 mg/dL
14,R5,Has_value Arg1:T8 Arg2:T9
15,T10,Measurement 117 145	Serum aspartate transaminase
16,T11,Value 146 177	> 3 times upper limit of normal
17,R6,Has_value Arg1:T10 Arg2:T11
18,T12,Measurement 179 205	Serum alanine transaminase
19,T13,Value 206 237	> 3 times upper limit of normal
20,R7,Has_value Arg1:T12 Arg2:T13
21,T14,Condition 246 267	anaphylactic reaction
22,T15,Drug 272 284	Rosuvastatin
23,R8,AND Arg1:T14 Arg2:T15
24,T16,Condition 304 321	contraindications
25,T17,Drug 326 338	Rosuvastatin
26,R9,AND Arg1:T16 Arg2:T17
27,T18,Mood 348 352	plan
28,T19,Condition 359 367	pregnant
29,R10,Has_mood Arg1:T19 Arg2:T18
30,T20,Observation 377 392	life expectancy
31,T21,Value 393 409	less than 1 year
32,R11,Has_value Arg1:T20 Arg2:T21
0,T1,Condition 13 26	Heart Failure
1,T2,Measurement 29 69	Lower left ventricular ejection fraction
2,T3,Value 70 73	45%
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 75 79	LVEF
5,T5,Value 80 84	<45%
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Scope 75 84	LVEF <45%
8,T7,Scope 29 73	Lower left ventricular ejection fraction 45%
9,R3,Subsumes Arg1:T7 Arg2:T6
10,T8,Procedure 116 130	echocardiogram
11,R4,Has_scope Arg1:T8 Arg2:T7
12,T9,Temporal 109 115	recent
13,R5,Has_temporal Arg1:T8 Arg2:T9
14,T10,Measurement 168 201	New York Heart Association (NYHA)
15,T11,Value 144 160	Class II and III
16,R6,Has_value Arg1:T10 Arg2:T11
17,T12,Condition 203 220	Clinically stable
18,T13,Condition 223 233	Ex-smokers
19,T14,Temporal 234 249	over five years
20,R7,Has_temporal Arg1:T13 Arg2:T14
21,T15,Measurement 252 286	Maximal inspiratory pressure (MIP)
22,T16,Value 287 304	<70% of predicted
23,R8,Has_value Arg1:T15 Arg2:T16
24,T17,Measurement 307 366	Forced expiratory volume/Forced vital capacity (FEV1 / FVC)
25,T18,Value 367 385	> 70% of predicted
26,R9,Has_value Arg1:T17 Arg2:T18
0,T1,Condition 0 4	UTIs
1,T2,Multiplier 7 23	12 within 1 year
2,R1,Has_multiplier Arg1:T1 Arg2:T2
3,T3,Temporal 10 23	within 1 year
4,R2,multi Arg1:T2 Arg2:T3
5,T4,Condition 25 34	Pregnancy
6,T5,Condition 38 47	Lactation
7,*,OR T4 T5
8,T6,Condition 49 63	Immune disease
9,T7,Condition 73 84	intolerance
10,T8,Drug 65 72	Lactose
11,T9,Condition 65 84	Lactose intolerance
12,R3,AND Arg1:T7 Arg2:T8
13,R4,multi Arg1:T9 Arg2:T7
14,T10,Condition 86 107	Urinary tract anomaly
15,T11,Condition 109 127	Systemic infection
16,T12,Multiplier 129 142	Newly started
17,T13,Procedure 143 158	hormone therapy
18,T14,Temporal 159 183	within the last 6 months
19,R5,Has_temporal Arg1:T13 Arg2:T14
20,R6,Has_multiplier Arg1:T13 Arg2:T12
21,T16,Procedure 185 207	Antibiotic prophylaxis
22,T17,Temporal 208 232	within the last 6 months
23,T15,Drug 185 195	Antibiotic
24,R7,multi Arg1:T16 Arg2:T15
25,R8,Has_temporal Arg1:T16 Arg2:T17
26,T18,Drug 234 245	a-D-mannose
27,T19,Temporal 253 274	within the last month
28,R9,Has_temporal Arg1:T18 Arg2:T19
29,T20,Device 283 292	catheters
30,T21,Condition 294 311	Diabetes mellitus
31,T22,Competing_trial 313 343	Participation to other studies
0,T1,Condition 0 15	Unstable angina
1,T2,Condition 18 39	Myocardial infarction
2,T3,Procedure 44 57	heart surgery
3,T4,Temporal 58 94	up to three months before the survey
4,T5,Scope 18 57	Myocardial infarction and heart surgery
5,R1,Has_temporal Arg1:T5 Arg2:T4
6,*,OR T3 T2
7,T6,Condition 97 125	Chronic respiratory diseases
8,T7,Condition 128 151	Hemodynamic instability
9,T8,Condition 154 160	Trauma
10,T9,Condition 174 180	nausea
11,T10,Condition 185 193	vomiting
12,*,OR T10 T9 T8
13,T11,Condition 211 232	neurological diseases
14,T12,Condition 196 206	Orthopedic
15,T13,Qualifier 242 331	preclude the achievement of the cardiopulmonary test and Cardiac Rehabilitation exercises
16,*,OR T12 T11
17,R2,Has_qualifier Arg1:T11 Arg2:T13
18,R3,Has_qualifier Arg1:T12 Arg2:T13
19,T14,Condition 357 378	cognitive impairments
20,T15,Qualifier 384 426	restrict them to respond to questionnaires
21,T16,Condition 334 347;367 378	Psychological impairments
22,*,OR T16 T14
23,R4,Has_qualifier Arg1:T16 Arg2:T15
24,R5,Has_qualifier Arg1:T14 Arg2:T15
0,T1,Person 0 5	Women
1,T2,Condition 11 15	UTIs
2,T3,Multiplier 7 10	= 3
3,R1,Has_multiplier Arg1:T2 Arg2:T3
4,T4,Temporal 16 41	within the last 12 months
5,T5,Multiplier 45 48	= 2
6,T6,Condition 49 53	UTIs
7,R2,Has_multiplier Arg1:T6 Arg2:T5
8,T7,Temporal 54 78	within the last 6 months
9,R3,Has_temporal Arg1:T6 Arg2:T7
10,R4,Has_temporal Arg1:T2 Arg2:T4
11,*,OR T2 T6
12,T8,Measurement 81 105	Laboratory urine culture
13,T9,Value 107 116	<103 CFUs
14,R5,Has_value Arg1:T8 Arg2:T9
15,T10,Person 118 121	Age
16,T11,Value 122 132	> 18 years
17,R6,Has_value Arg1:T10 Arg2:T11
0,T1,Procedure 19 53	percutaneous coronary intervention
1,T2,Device 59 77	drug-eluting stent
2,R1,AND Arg1:T1 Arg2:T2
0,T1,Procedure 0 21	Thoracoscopic surgery
1,T2,Mood 22 31	candidate
2,R1,Has_mood Arg1:T1 Arg2:T2
3,T3,Value 34 51	Over 18 years old
4,T4,Person 48 51	old
5,R2,Has_value Arg1:T4 Arg2:T3
6,T5,Condition 63 70	allergy
7,T6,Drug 74 85	Bupivacaine
8,R3,AND Arg1:T5 Arg2:T6
9,T7,Negation 54 56	No
10,R4,Has_negation Arg1:T5 Arg2:T7
11,T8,Observation 99 111	able to read
12,T9,Observation 112 122	understand
13,T10,Observation 127 132	singe
0,T1,Measurement 14 28	histologically
1,T2,Value 29 38	confirmed
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 52 67	prostate cancer
4,R2,AND Arg1:T3 Arg2:T1
5,T4,Condition 95 110	bone metastases
6,*,NOT T3 T4
7,T5,Condition 112 127	Prostate cancer
8,T6,Measurement 152 155	PSA
9,T7,Value 144 148	rise
10,R3,Has_value Arg1:T6 Arg2:T7
11,T8,Procedure 162 177	hormone therapy
12,R4,AND Arg1:T8 Arg2:T5
13,T9,Procedure 223 236	prostatectomy
14,T10,Measurement 250 253	PSA
15,T11,Value 242 246	rise
16,R5,Has_value Arg1:T10 Arg2:T11
17,A1,Optional T9
18,R6,AND Arg1:T9 Arg2:T10
19,T12,Procedure 275 288	prostatectomy
20,T13,Negation 267 274	without
21,T14,Measurement 313 323	PSA levels
22,T15,Value 304 309	rises
23,T16,Value 290 291	2
24,T17,Temporal 292 303	consecutive
25,R7,Has_temporal Arg1:T16 Arg2:T17
26,R8,Has_value Arg1:T16 Arg2:T15
27,R9,Has_value Arg1:T14 Arg2:T15
28,T18,Temporal 364 386	separated by one month
29,R10,Has_temporal Arg1:T16 Arg2:T18
30,T19,Temporal 421 456	one month after the reference value
31,T20,Value 469 494	above the reference value
32,T21,Value 392 397	first
33,T22,Procedure 398 409	measurement
34,R11,AND Arg1:T21 Arg2:T22
35,R12,Has_temporal Arg1:T22 Arg2:T19
36,R13,Has_value Arg1:T22 Arg2:T20
37,T23,Value 500 506	second
38,T24,Procedure 520 531	measurement
39,T25,Temporal 538 575	one month after the first measurement
40,T26,Value 584 618	greater than the first measurement
41,R14,AND Arg1:T23 Arg2:T24
42,R15,Has_temporal Arg1:T24 Arg2:T25
43,R16,Has_value Arg1:T24 Arg2:T26
44,T27,Procedure 630 642	chemotherapy
45,T28,Procedure 646 658	radiotherapy
46,T29,Temporal 621 629	Previous
47,T30,Temporal 684 714	≥ 8 weeks prior to study entry
48,*,OR T27 T28
49,T31,Scope 630 658	chemotherapy or radiotherapy
50,R17,Has_temporal Arg1:T31 Arg2:T29
51,R18,Has_temporal Arg1:T31 Arg2:T30
52,T32,Measurement 717 764	Eastern Cooperative Oncology Group (ECOG) score
53,T33,"Value 768 777	0, 1 or 2"
54,R19,Has_value Arg1:T32 Arg2:T33
55,T34,Measurement 793 798;816 842	spend time in bed during the day
56,T35,Value 799 812	less than 50%
57,R20,Has_value Arg1:T34 Arg2:T35
58,T36,"Scope 717 777	Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2"
59,T37,Scope 793 842	spend less than 50% of time in bed during the day
60,R21,Subsumes Arg1:T36 Arg2:T37
61,T38,Measurement 854 868	liver function
62,T39,Value 845 853	Adequate
63,T40,Measurement 871 906	serum total bilirubin concentration
64,T41,Value 907 950	less than 1.5 x upper limit of normal value
65,R22,Has_value Arg1:T40 Arg2:T41
66,R23,Has_value Arg1:T38 Arg2:T39
67,R24,Subsumes Arg1:T39 Arg2:T40
68,T42,Person 952 955	Age
69,T43,Value 957 967	≥ 18 years
70,R25,Has_value Arg1:T42 Arg2:T43
71,T44,Condition 1066 1077;1091 1100	psychiatric disorders
72,T45,Condition 1081 1100	addictive disorders
73,*,OR T44 T45
74,T46,Observation 1125 1131;1138 1154	giving informed consent
75,T47,Negation 1107 1114	prevent
76,R26,Has_negation Arg1:T46 Arg2:T47
77,T48,Scope 1066 1100	psychiatric or addictive disorders
78,R27,Has_context Arg1:T48 Arg2:T46
79,T49,Non-representable 180 192	PSA criteria
0,T1,Condition 0 7	Allergy
1,T2,Drug 11 31	narcotic medications
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Multiplier 47 54	chronic
4,T4,Drug 55 62	opioids
5,T5,Qualifier 43 46	any
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,R3,Has_multiplier Arg1:T4 Arg2:T3
8,T6,Drug 66 82	pain medications
9,T7,Temporal 83 97	preoperatively
10,R4,Has_temporal Arg1:T6 Arg2:T7
11,*,OR T6 T4
0,T1,Drug 23 37	bisphosphonate
1,T2,Temporal 0 5	Prior
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Measurement 48 62	renal function
4,T4,Value 39 47	Abnormal
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Measurement 81 112	calculated creatinine clearance
7,T6,Value 113 127	< 30 ml/minute
8,R3,Has_value Arg1:T5 Arg2:T6
9,R4,Subsumes Arg1:T4 Arg2:T5
10,T7,Measurement 130 139;169 196	Corrected serum calcium concentration
11,T8,Value 197 208	< 8.0 mg/dl
12,T9,Value 210 221	2.00 mmol/L
13,T10,Value 226 238	≥ 12.0 mg/dl
14,T11,Value 240 251	3.00 mmol/L
15,*,OR T10 T11 T8 T9
16,T12,Scope 197 251	< 8.0 mg/dl (2.00 mmol/L) or ≥ 12.0 mg/dl (3.00 mmol/L
17,R5,Has_scope Arg1:T7 Arg2:T12
18,T13,Observation 269 291	clinically symptomatic
19,T14,Condition 292 308	brain metastases
20,R6,Has_context Arg1:T14 Arg2:T13
21,T15,Observation 310 317	History
22,T16,Condition 321 363	diseases with influence on bone metabolism
23,T17,Condition 372 387	Paget's disease
24,T18,Condition 392 419	primary hyperparathyroidism
25,*,OR T17 T18 T16
26,T19,Scope 321 419	diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism
27,R7,Has_scope Arg1:T15 Arg2:T19
28,T20,Condition 428 436;466 474	physical diseases
29,T21,Condition 440 453;466 474	psychological diseases
30,*,OR T20 T21
31,T22,Condition 637 644	ascites
32,T23,Qualifier 614 636	clinically significant
33,T24,Condition 646 661	cardiac failure
34,T25,Measurement 663 667	NYHA
35,T26,Value 668 677	III or IV
36,R8,Has_value Arg1:T25 Arg2:T26
37,T27,Qualifier 679 698	clinically relevant
38,T28,Observation 699 718	pathologic findings
39,T29,Procedure 722 725	ECG
40,R9,Has_context Arg1:T29 Arg2:T28
41,R10,Has_qualifier Arg1:T29 Arg2:T27
42,R11,AND Arg1:T24 Arg2:T25
43,R12,Has_qualifier Arg1:T22 Arg2:T23
44,*,OR T22 T24 T29
45,T30,"Scope 614 725	clinically significant ascites, cardiac failure, NYHA III or IV, clinically relevant pathologic findings in ECG"
46,T31,Scope 428 474	physical or psychological concomitant diseases
47,R13,Subsumes Arg1:T31 Arg2:T30
48,T32,Condition 733 749	hypersensitivity
49,T33,Drug 753 768	zoledronic acid
50,T34,Drug 772 793	other bisphosphonates
51,*,OR T33 T34
52,T35,Scope 753 793	zoledronic acid or other bisphosphonates
53,R14,Has_scope Arg1:T32 Arg2:T35
54,T36,Drug 802 829	other investigational drugs
55,T37,Temporal 830 872	30 days prior to the date of randomization
56,R15,Has_temporal Arg1:T36 Arg2:T37
57,T38,Observation 880 887	history
58,T39,Temporal 891 898	present
59,*,OR T38 T39
60,T40,Scope 880 898	history or present
61,T41,Condition 899 915	abuse of alcohol
62,T42,Condition 899 907;919 924	abuse of drugs
63,*,OR T42 T41
64,T43,Scope 899 924	abuse of alcohol or drugs
65,R16,Has_scope Arg1:T40 Arg2:T43
66,T44,Condition 1041 1056	dental problems
67,T45,Temporal 1026 1033	Current
68,R17,Has_temporal Arg1:T44 Arg2:T45
69,T46,Condition 1067 1089	infection of the teeth
70,T47,Condition 1067 1083;1093 1100	infection of the jawbone
71,*,OR T47 T46
72,T48,Scope 1067 1100	infection of the teeth or jawbone
73,T49,Condition 1067 1083;1102 1109	infection of the maxilla
74,T50,Condition 1067 1083;1113 1123	infection of the mandibular
75,*,OR T49 T50
76,T51,Scope 1067 1083;1102 1123	infection of the maxilla or mandibular
77,R18,Subsumes Arg1:T48 Arg2:T51
78,T52,Condition 1126 1132;1144 1150	dental trauma
79,T53,Condition 1136 1150	fixture trauma
80,*,OR T53 T52 T48
81,T54,Temporal 1157 1164	current
82,T55,Temporal 1168 1173	prior
83,*,OR T54 T55
84,T56,Condition 1187 1217	osteonecrosis of the jaw (ONJ)
85,T57,Condition 1222 1247	exposed bone in the mouth
86,T58,Condition 1255 1291	slow healing after dental procedures
87,*,OR T57 T58 T56
88,T59,"Scope 1187 1291	osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures"
89,T60,Scope 1157 1173	current or prior
90,R19,Has_scope Arg1:T60 Arg2:T59
91,T61,"Scope 1067 1291	infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures"
92,R20,Subsumes Arg1:T44 Arg2:T61
93,T62,Temporal 1302 1316	within 6 weeks
94,T63,Temporal 1294 1300	Recent
95,R21,Subsumes Arg1:T63 Arg2:T62
96,T64,Observation 1321 1328	planned
97,T65,Procedure 1329 1335;1343 1350	dental surgery
98,T66,Procedure 1339 1350	jaw surgery
99,*,OR T65 T66
100,T67,Procedure 1357 1367	extraction
101,T68,Procedure 1369 1377	implants
102,*,OR T67 T68
103,T69,"Scope 1357 1377	extraction, implants"
104,T70,Scope 1329 1350	dental or jaw surgery
105,R22,Subsumes Arg1:T70 Arg2:T69
106,*,OR T63 T64
107,T71,Scope 1294 1328	Recent (within 6 weeks) or planned
108,R23,Has_scope Arg1:T70 Arg2:T71
109,T72,"Non-query-able 926 1024	Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study"
110,T73,Non-representable 1380 1442	Other protocol defined inclusion/exclusion criteria may apply.
0,T1,Person 17 23	female
1,T2,Value 42 59	18 years or older
2,T3,Person 54 59	older
3,R1,Has_value Arg1:T3 Arg2:T2
4,T4,Qualifier 89 99	unilateral
5,T5,Qualifier 103 112	bilateral
6,T6,Procedure 113 123	mastectomy
7,*,OR T4 T5
8,T7,Procedure 129 159	tissue expander reconstruction
9,R2,AND Arg1:T6 Arg2:T7
10,T8,Scope 89 112	unilateral or bilateral
11,R3,Has_scope Arg1:T6 Arg2:T8
12,T9,Temporal 78 88	undergoing
13,R4,Has_temporal Arg1:T6 Arg2:T9
0,T1,"Non-query-able 0 324	Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, willingness and ability to complete collection of data via wearable device and study mobile must be obtained and documented according to the local regulatory requirements"
1,T2,Person 327 333	Female
2,T3,Person 337 341	male
3,*,OR T2 T3
4,T4,Person 353 356	Age
5,T5,Value 357 371	= 18 years old
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 438 451	breast cancer
8,T7,Qualifier 385 393	invasive
9,T8,Qualifier 374 384	Metastatic
10,T9,Qualifier 394 419	hormone receptor positive
11,T10,Qualifier 424 437	HER2 negative
12,T11,Scope 374 437	Metastatic invasive hormone receptor positive and HER2 negative
13,R2,Has_scope Arg1:T6 Arg2:T11
14,T12,Non-query-able 453 477	histologically confirmed
15,T13,"Non-query-able 481 800	Patients who in the opinion of the treating physician are candidates suitable for randomization for mono-chemotherapy treatment, that has either an approved label in Europe and/or is supported by guidelines for the treatment of first-line advanced BC, which are based on evidence on safety and efficacy in this setting."
16,T14,Condition 830 854	metastatic breast cancer
17,T15,Qualifier 817 829	asymptomatic
18,T16,Qualifier 802 813	Symptomatic
19,*,OR T15 T16
20,T17,Scope 802 829	Symptomatic or asymptomatic
21,R3,Has_scope Arg1:T14 Arg2:T17
22,T18,Observation 1096 1111	Life-expectancy
23,T19,Value 1112 1122	> 6 months
24,R4,Has_value Arg1:T18 Arg2:T19
25,T20,Measurement 950 971	NCI CTCAE version 4.0
26,T21,Value 972 981	grade = 1
27,R5,Has_value Arg1:T20 Arg2:T21
28,T22,Observation 857 867	Resolution
29,T23,Condition 875 894	acute toxic effects
30,T24,Procedure 904 923	anti-cancer therapy
31,T25,Procedure 927 945	surgical procedure
32,*,OR T24 T25
33,T26,Scope 904 946	anti-cancer therapy or surgical procedures
34,T27,Qualifier 898 903	prior
35,R6,Has_qualifier Arg1:T26 Arg2:T27
36,R7,Has_context Arg1:T23 Arg2:T22
37,R8,Has_scope Arg1:T23 Arg2:T26
38,R9,AND Arg1:T23 Arg2:T20
39,T28,Negation 983 989	except
40,T29,Condition 990 998	alopecia
41,T30,Non-query-able 983 1093	except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion)
42,T31,Pregnancy_considerations 1126 1419	or female patients: The patients need to be either A) of non-childbearing potential (documented postmenopausal or post hysterectomy) B) childbearing potential with negative serum or urinary pregnancy test (in this case patients need to use highly effective non-hormonal contraceptive methods).
0,T1,Person 0 3	Age
1,T2,Value 4 11	65 - 79
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 24 47	coronary artery disease
4,T4,Observation 13 20	History
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Condition 52 64	heart attack
7,T6,Condition 49 51	MI
8,T7,Condition 66 72	stroke
9,T8,Condition 74 87	heart failure
10,T9,Condition 92 117	peripheral artery disease
11,*,OR T8 T9 T7 T5 T6
12,T10,"Scope 49 117	MI/heart attack, stroke, heart failure, or peripheral artery disease"
13,R3,Subsumes Arg1:T3 Arg2:T10
14,T11,Condition 120 126	Cancer
15,T12,Negation 133 135	no
16,T14,Procedure 136 152	active treatment
17,T13,Temporal 153 169	in the last year
18,R4,Has_temporal Arg1:T14 Arg2:T13
19,R5,Has_negation Arg1:T14 Arg2:T12
20,R6,AND Arg1:T11 Arg2:T14
21,T15,Condition 171 174	MCI
22,T16,Measurement 176 180	MoCA
23,T17,Value 181 187	>18<26
24,R7,Has_value Arg1:T16 Arg2:T17
25,T18,Non-representable 188 243	-inclusive of 1 point if <12 years of education Group 2
26,T19,Scope 176 187	MoCA >18<26
27,R8,Subsumes Arg1:T15 Arg2:T19
28,T20,Condition 245 270	Decline physical function
29,T21,Measurement 272 285	walking speed
30,T22,Value 286 293	< 1 m/s
31,R9,Has_value Arg1:T21 Arg2:T22
32,T23,Non-representable 295 319	Group 3 (Either or both)
33,T24,Scope 272 293	walking speed < 1 m/s
34,R10,Subsumes Arg1:T20 Arg2:T24
35,T25,Condition 321 338	Abdominal obesity
36,T26,Value 340 345	>88cm
37,T27,Value 353 359	>102cm
38,T28,Measurement 321 330	Abdominal
39,T29,Person 346 351	women
40,T30,Person 360 363	men
41,A1,Optional T29
42,A2,Optional T30
43,R11,Has_value Arg1:T29 Arg2:T26
44,R12,Has_value Arg1:T30 Arg2:T27
45,*,OR T29 T30
46,T31,"Scope 340 363	>88cm women, >102cm men"
47,R13,Has_scope Arg1:T28 Arg2:T31
48,T32,Condition 369 381	hypertension
49,T33,Procedure 383 390	treated
50,T34,Measurement 394 416	resting blood pressure
51,T35,Value 417 424	>140/90
52,R14,Has_value Arg1:T34 Arg2:T35
53,*,OR T33 T34
54,T36,Scope 383 424	treated or resting blood pressure >140/90
55,R15,Has_scope Arg1:T32 Arg2:T36
56,T37,Condition 426 443	Abdominal obesity
57,T38,Value 445 450	>88cm
58,T39,Value 458 464	>102cm
59,T40,Person 451 456	women
60,T41,Person 465 468	men
61,A3,Optional T40
62,A4,Optional T41
63,R16,Has_value Arg1:T40 Arg2:T38
64,R17,Has_value Arg1:T41 Arg2:T39
65,*,OR T40 T41
66,T42,"Scope 445 468	>88cm women, >102cm men"
67,R18,Has_scope Arg1:T37 Arg2:T42
68,T43,Condition 474 488	hyperlipidemia
69,T44,Procedure 490 497	treated
70,T45,Measurement 501 526	fasting total cholesterol
71,T46,Value 527 531	>240
72,R19,Has_value Arg1:T45 Arg2:T46
73,*,OR T44 T45
74,T47,Observation 532 548	English literacy
75,T48,Observation 560 584	provide informed consent
76,T49,Mood 549 559	Willing to
77,R20,Has_mood Arg1:T48 Arg2:T49
78,T50,Scope 490 531	treated or fasting total cholesterol >240
79,R21,Subsumes Arg1:T43 Arg2:T50
0,T1,Person 0 5	Women
1,T2,Person 13 18	years
2,T3,Value 7 12	18-75
3,T4,Condition 35 38	UTI
4,T5,Qualifier 25 34	suspected
5,R1,Has_qualifier Arg1:T4 Arg2:T5
6,R2,Has_value Arg1:T2 Arg2:T3
7,T6,Scope 0 19	Women (18-75 years)
8,R3,AND Arg1:T6 Arg2:T4
9,T7,Condition 53 68	symptoms of UTI
10,T8,Multiplier 40 52	at least two
11,R4,Has_multiplier Arg1:T7 Arg2:T8
12,T9,Condition 70 77	dysuria
13,T10,Condition 79 101	urgency of micturition
14,T11,Condition 103 112	frequency
15,T12,Condition 114 134	lower abdominal pain
16,*,OR T9 T10 T11 T12
17,T13,"Scope 70 134	dysuria, urgency of micturition, frequency, lower abdominal pain"
18,R5,Subsumes Arg1:T7 Arg2:T13
19,T14,Post-eligibility 137 161	Written informed consent
0,T1,Condition 9 24	complicated UTI
1,T2,Condition 52 67	loin tenderness
2,T3,Measurement 32 43	temperature
3,T4,Value 44 50	> 38°C
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T3 T2
6,T5,"Scope 32 67	temperature > 38°C, loin tenderness"
7,R2,Subsumes Arg1:T1 Arg2:T5
8,T6,Condition 70 80	conditions
9,T7,Condition 98 120	complicated infections
10,T8,Condition 127 141	renal diseases
11,T9,Device 157 173	urinary catheter
12,T10,Person 143 151	patients
13,R3,AND Arg1:T10 Arg2:T9
14,*,OR T8 T10
15,T11,"Scope 127 173	renal diseases, patients with urinary catheter"
16,R4,Subsumes Arg1:T6 Arg2:T11
17,R5,AND Arg1:T6 Arg2:T7
18,T12,Pregnancy_considerations 176 200	pregnancy/ breastfeeding
19,T13,Drug 231 246	UU preparations
20,T14,Drug 252 266	z.B. Cystinol®
21,T15,Drug 268 277	Uvalysat®
22,T16,Drug 279 288	Arctuvan®
23,*,OR T14 T15 T16
24,T17,"Scope 252 288	z.B. Cystinol®, Uvalysat®, Arctuvan®"
25,R6,Subsumes Arg1:T13 Arg2:T17
26,T18,Qualifier 210 225	self-medication
27,R7,Has_qualifier Arg1:T13 Arg2:T18
28,T19,Drug 290 300	antibiotic
29,T20,Temporal 312 323	last 7 days
30,R8,Has_temporal Arg1:T19 Arg2:T20
31,T21,Condition 334 337	UTI
32,T22,Temporal 345 357	past 2 weeks
33,R9,Has_temporal Arg1:T21 Arg2:T22
34,T23,Condition 370 384	pyelonephritis
35,T24,Mood 386 407	contraindications for
36,T25,Drug 414 419	drugs
37,T26,Qualifier 408 413	trial
38,R10,Has_qualifier Arg1:T25 Arg2:T26
39,R11,Has_mood Arg1:T25 Arg2:T24
40,T27,Condition 429 437	diseases
41,T28,Qualifier 421 428	serious
42,R12,Has_qualifier Arg1:T27 Arg2:T28
43,T29,Post-eligibility 439 480	inability to understand trial Information
44,T30,Non-query-able 482 596	current participation in another clinical trial or participation in another clinical trial within the last 4 weeks
0,T1,Measurement 0 4	eGFR
1,T2,Value 5 8	<45
2,T3,Condition 10 25	Type 2 diabetes
3,T4,Measurement 27 32	HbA1c
4,T5,Value 32 36	>6.5
5,R1,AND Arg1:T3 Arg2:T4
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 41 56	type 1 diabetes
8,*,OR T6 T3
9,R3,Has_value Arg1:T1 Arg2:T2
10,T7,Observation 73 93	nicotine product use
11,T8,Observation 62 69	tobacco
12,*,OR T8 T7
13,T9,Scope 62 93	tobacco or nicotine product use
14,T10,Temporal 101 110	past year
15,R4,Has_temporal Arg1:T9 Arg2:T10
16,T11,Measurement 116 134	vitamin B12 Levels
17,T12,Value 136 147	< 300 pg/mL
18,R5,Has_value Arg1:T11 Arg2:T12
19,T13,Non-query-able 150 252	Self-reported severe difficulty or inability to walk 400m or climb 10 steps (from Q 2 and 19 on PAT-D)
20,T14,"Non-query-able 254 355	Self-reported difficulty or inability to perform basic ADL functions (from Q 10, 13, 14, 16 on PAT-D)"
21,T15,Observation 367 378	alcohol use
22,T16,Multiplier 380 395	>14 drinks/week
23,R6,Has_multiplier Arg1:T15 Arg2:T16
24,T17,Condition 398 404	Cancer
25,T18,Procedure 415 424	treatment
26,T19,Temporal 428 437	past year
27,R7,AND Arg1:T17 Arg2:T18
28,R8,Has_temporal Arg1:T17 Arg2:T19
29,T20,Condition 453 461	Dementia
30,T21,Measurement 481 491	MoCA score
31,T22,Value 492 495	<18
32,R9,Has_value Arg1:T21 Arg2:T22
33,R10,AND Arg1:T20 Arg2:T21
34,T23,Condition 497 508	Parkinson's
35,T24,Condition 518 538	neurological disease
36,*,OR T23 T24
37,T25,Condition 540 561	Chronic liver disease
38,T26,Condition 565 574	cirrhosis
39,*,OR T25 T26
40,T27,Condition 576 599	End stage renal disease
41,T28,Procedure 606 614	dialysis
42,*,OR T27 T28
43,T29,Condition 616 636	Rheumatic conditions
44,T30,Condition 638 658	Rheumatoid arthritis
45,T31,Condition 660 665	lupus
46,T32,Condition 681 699	autoimmune disease
47,*,OR T30 T31 T32
48,T33,"Scope 638 699	Rheumatoid arthritis, lupus, and any other autoimmune disease"
49,R11,Subsumes Arg1:T29 Arg2:T33
50,T34,Condition 742 758	Thyroid problems
51,T35,Condition 799 803	Gout
52,T36,Competing_trial 805 845	Involved in another interventional study
53,T37,Measurement 847 857	Hemoglobin
54,T38,Value 858 860	<8
55,R12,Has_value Arg1:T37 Arg2:T38
56,T39,Condition 879 885	anemia
57,*,OR T37 T39
58,T40,Measurement 908 914	weight
59,T41,Value 923 934	+/- 10 lbs.
60,R13,Has_value Arg1:T40 Arg2:T41
61,T42,Temporal 942 956	last 12 months
62,R14,Has_temporal Arg1:T40 Arg2:T42
63,T43,Measurement 959 962	BMI
64,T44,Value 963 968	<18.5
65,R15,Has_value Arg1:T43 Arg2:T44
66,T45,Post-eligibility 970 1003	Likely to not follow the protocol
67,T46,Non-query-able 1005 1034	PI deems unfit to participate
68,T47,Drug 1051 1060	Metformin
69,T48,Drug 1074 1078	drug
70,*,OR T47 T48
71,T49,Qualifier 1097 1105	diabetes
72,R16,Has_qualifier Arg1:T48 Arg2:T49
0,T1,Non-query-able 0 2	NA
0,T1,Measurement 0 19	ASA physical status
1,T2,Value 20 23	1-3
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 34 45	thoracotomy
4,T4,Qualifier 25 33	elective
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Non-query-able 47 101	can operate patient-controlled analgesia (PCA) machine
0,T1,Condition 0 16	Healthy patients
1,T2,Measurement 18 21	ASA
2,T3,Value 22 23	I
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,Subsumes Arg1:T1 Arg2:T2
5,T4,Measurement 91 132	Pel-Gregory's and Winter's classification
6,T5,Value 26 77	Bilateral symmetrically impacted lower third molars
7,R3,Has_value Arg1:T4 Arg2:T5
0,T1,Person 0 3	Age
1,T2,Value 4 14	> 40 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 21 48	Primary knee osteoarthritis
4,T4,Qualifier 69 110	American College of Rheumatology criteria
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Procedure 161 184	total knee arthroplasty
7,T6,Qualifier 150 160	unilateral
8,T7,Qualifier 138 145	primary
9,T8,Qualifier 128 136	elective
10,R3,Has_qualifier Arg1:T5 Arg2:T6
11,R4,Has_qualifier Arg1:T5 Arg2:T7
12,R5,Has_qualifier Arg1:T5 Arg2:T8
13,T9,Measurement 186 220;227 248	American Society of Anesthesiology physical status class
14,T10,Value 249 252	1-3
15,T11,Measurement 222 225	ASA
16,R6,Subsumes Arg1:T9 Arg2:T11
17,R7,Has_value Arg1:T9 Arg2:T10
18,T12,Measurement 254 257	BMI
19,T13,Value 258 268	< 40 kg/m2
20,R8,Has_value Arg1:T12 Arg2:T13
0,T1,"Non-query-able 0 202	Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason"
1,T2,Competing_trial 204 457	Patient has participated in a Novartis sponsored combination trial where pasireotide was dispensed in combination with another study medication and is still receiving combination therapy. (only patients receiving pasireotide monotherapy can be included)
2,T3,"Pregnancy_considerations 463 650	nant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test"
3,T4,"Pregnancy_considerations 652 891	Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception"
4,T5,Procedure 893 913	Female sterilization
5,T6,Procedure 933 955	bilateral oophorectomy
6,T7,Procedure 972 984	hysterectomy
7,A1,Optional T7
8,T8,Procedure 989 1003	tubal ligation
9,T9,Temporal 1004 1052	at least six weeks before taking study treatment
10,T10,Reference_point 1030 1052	taking study treatment
11,R1,Has_index Arg1:T9 Arg2:T10
12,*,OR T5 T8
13,R2,Subsumes Arg1:T5 Arg2:T6
14,R3,Subsumes Arg1:T5 Arg2:T7
15,T11,Scope 893 1003	Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation
16,R4,Subsumes Arg1:T11 Arg2:T9
17,T12,"Non-query-able 1054 1188	In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment"
18,T13,Procedure 1190 1208	Male sterilization
19,T14,Temporal 1210 1246	at least 6 months prior to screening
20,T15,Reference_point 1237 1246	screening
21,R5,Has_index Arg1:T14 Arg2:T15
22,R6,Has_temporal Arg1:T13 Arg2:T14
23,T16,Non-query-able 1249 1355	For female subjects on the study the vasectomized male partner should be the sole partner for that subject
24,T17,"Non-query-able 1358 1516	Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%)"
25,T18,Procedure 1530 1550	hormone vaginal ring
26,T19,Procedure 1554 1587	transdermal hormone contraception
27,*,OR T18 T19
28,T20,Device 1605 1624	intrauterine device
29,T21,Device 1626 1629	IUD
30,T22,Device 1634 1653	intrauterine system
31,T23,Device 1655 1658	IUS
32,R7,Subsumes Arg1:T20 Arg2:T21
33,R8,Subsumes Arg1:T22 Arg2:T23
34,*,OR T20 T22
35,T24,Procedure 1680 1693	contraception
36,T25,Device 1695 1701	Condom
37,T26,Device 1705 1728	Occlusive cap diaphragm
38,T27,Device 1741 1751	vault caps
39,T28,Device 1732 1740;1747 1751	cervical caps
40,T29,Procedure 1758 1774	spermicidal foam
41,T30,Non-query-able 1661 1949	Barrier methods of contraception: Condom or Occlusive cap diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment
42,T31,"Non-query-able 1951 2702	Sexually active males unless they use a condom during intercourse while taking drug and for 1 months after pasireotide s.c. last dose and 3 months after pasireotide LAR last dose and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid If a study patient or partner becomes pregnant or suspects being pregnant during the study or within 1 month after the final dose of pasireotide s.c. or 3 months after the final dose of pasireotide LAR, the Study Doctor needs to be informed immediately and ongoing study treatment with pasireotide has to be stopped immediately For patients taking pasireotide LAR, the future dose injections will be cancelled."
0,T1,Condition 0 7	allergy
1,T2,Drug 11 19	morphine
2,T3,Drug 23 31	ketamine
3,*,OR T2 T3
4,T4,Scope 11 31	morphine or ketamine
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 33 47	contraindicate
7,T6,Drug 51 59	ketamine
8,R2,AND Arg1:T5 Arg2:T6
9,T7,Condition 68 77	intubated
10,T8,Temporal 78 105	in the postoperative period
11,T9,Reference_point 85 105	postoperative period
12,R3,Has_index Arg1:T8 Arg2:T9
13,R4,Has_temporal Arg1:T7 Arg2:T8
14,T10,Procedure 68 77	intubated
15,R5,multi Arg1:T7 Arg2:T10
0,T1,Condition 0 21	Heavy tobacco smokers
1,T2,Condition 37 52	alcohol abusers
2,T3,Condition 23 27;45 52	Drug abusers
3,*,OR T2 T3
0,T1,Competing_trial 0 295	Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives
1,T2,"Non-query-able 297 399	Patient is currently benefiting from the treatment with pasireotide, as determined by the investigator"
2,T3,"Non-query-able 401 505	Patient has demonstrated compliance, as assessed by the investigator, with the parent study requirements"
3,T4,"Post-eligibility 507 610	Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures"
4,T5,"Informed_consent 612 848	Written informed consent obtained prior to enrolling in roll-over study and receiving study medication • If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness"
0,T1,Condition 18 36	rheumatic diseases
1,T2,Qualifier 11 17	active
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 58 80	musculoskeletal injury
4,T4,Qualifier 93 97	knee
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 126 155	secondary knee osteoarthritis
7,*,OR T3 T5
8,T6,Procedure 177 184	surgery
9,T7,Qualifier 197 201	knee
10,R3,Has_qualifier Arg1:T6 Arg2:T7
11,T8,Non-representable 203 271	History of adverse effects from medications to be used in this study
12,T9,Condition 273 289	Contraindication
13,T10,Procedure 293 310	spinal anesthesia
14,R4,AND Arg1:T9 Arg2:T10
15,T11,Condition 323 344	psychiatric disorders
16,T12,Condition 348 368	cognitive impairment
17,*,OR T11 T12
18,T13,Condition 370 386	Contraindication
19,T14,Drug 390 404	corticosteroid
20,R5,AND Arg1:T13 Arg2:T14
21,T15,Condition 431 448	diabetes mellitus
22,T16,Qualifier 413 430	Poorly controlled
23,R6,Has_qualifier Arg1:T15 Arg2:T16
24,T17,Measurement 450 455	HbA1C
25,T18,Value 456 461	> 7.5
26,R7,Has_value Arg1:T17 Arg2:T18
27,R8,AND Arg1:T15 Arg2:T17
28,T19,Qualifier 464 481	Poorly controlled
29,T20,Condition 482 494	hypertension
30,R9,Has_qualifier Arg1:T20 Arg2:T19
31,T21,Condition 507 529	ischemic heart disease
32,T22,Condition 533 560	peripheral arterial disease
33,T23,Condition 564 587	cerebrovascular disease
34,*,OR T21 T22 T23
35,T24,Condition 589 610	Hepatic insufficiency
36,T25,Measurement 612 628	Child-Pugh score
37,T26,Value 629 632	> 5
38,R10,Has_value Arg1:T25 Arg2:T26
39,R11,AND Arg1:T24 Arg2:T25
40,T27,Condition 635 654	Renal insufficiency
41,T28,Measurement 656 676	Creatinine clearance
42,T29,Value 677 688	< 30 mL/min
43,R12,AND Arg1:T27 Arg2:T28
44,R13,Has_value Arg1:T28 Arg2:T29
45,T30,Condition 702 711	cataracts
46,T31,Condition 715 723	glaucoma
47,T32,Condition 727 746	ocular hypertension
48,*,OR T30 T31 T32
49,T33,Drug 759 766	steroid
50,T34,Drug 770 792	immunosuppressive drug
51,T35,Temporal 797 823	within 6 months of surgery
52,T36,Reference_point 816 823	surgery
53,R14,Has_index Arg1:T35 Arg2:T36
54,*,OR T33 T34
55,T37,Scope 759 792	steroid or immunosuppressive drug
56,R15,Has_temporal Arg1:T37 Arg2:T35
0,T1,Qualifier 0 18	moderate to severe
1,T2,Condition 19 34	Crohn's Disease
2,T3,Measurement 36 45	basic HBI
3,T4,Value 46 49	= 7
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T2 Arg2:T1
6,R3,Subsumes Arg1:T1 Arg2:T3
7,T5,Condition 56 64	stenosis
8,R4,AND Arg1:T2 Arg2:T5
0,T1,Condition 42 106	heart team considers the patient to be a good surgical candidate
1,T2,Procedure 0 36	Heart Team assessment of operability
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 125 152	acute myocardial infarction
4,T4,Temporal 153 202	= 1 month (30 days) before the intended treatment
5,T5,Condition 406 428	valvular heart disease
6,T6,Qualifier 395 405	left sided
7,T7,Qualifier 387 393	severe
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,R3,Has_qualifier Arg1:T5 Arg2:T7
10,T8,Qualifier 376 385	Untreated
11,R4,Has_qualifier Arg1:T5 Arg2:T8
12,T9,Condition 439 459	mitral regurgitation
13,T10,Condition 439 445;463 471	mitral stenosis
14,T11,Condition 477 497	aortic regurgitation
15,T12,Condition 477 483;501 509	aortic stenosis
16,*,OR T10 T9 T12 T11
17,T13,"Scope 439 509	mitral regurgitation or stenosis, and aortic regurgitation or stenosis"
18,R5,Subsumes Arg1:T5 Arg2:T13
19,T14,Measurement 512 543	Mean pulmonary artery pressures
20,T15,Value 544 551	=40mmHG
21,R6,Has_value Arg1:T14 Arg2:T15
22,T16,Measurement 556 559	PVR
23,T17,Value 560 574	>4 woods units
24,R7,Has_value Arg1:T16 Arg2:T17
25,T18,Condition 590 617	right heart catheterization
26,T19,Scope 512 574	Mean pulmonary artery pressures =40mmHG and PVR >4 woods units
27,R8,AND Arg1:T19 Arg2:T18
28,T20,Procedure 645 662	cardiac procedure
29,T21,Qualifier 636 644	invasive
30,T22,Qualifier 624 635	therapeutic
31,R9,Has_qualifier Arg1:T20 Arg2:T21
32,R10,Has_qualifier Arg1:T20 Arg2:T22
33,T23,Device 678 695	permanent implant
34,T24,Temporal 714 751	within 30 days of the index procedure
35,T25,Reference_point 732 751	the index procedure
36,R11,Has_index Arg1:T24 Arg2:T25
37,T26,Device 805 816	heart valve
38,R12,Subsumes Arg1:T23 Arg2:T26
39,R13,AND Arg1:T20 Arg2:T23
40,R14,Has_temporal Arg1:T20 Arg2:T24
41,T27,Device 836 855	permanent pacemaker
42,T28,Negation 859 867	excluded
43,R15,Has_negation Arg1:T27 Arg2:T28
44,R16,AND Arg1:T23 Arg2:T27
45,T29,Procedure 904 912;930 938	surgical ablation
46,T30,Procedure 916 938	transcatheter ablation
47,T31,Condition 943 962	Atrial Fibrillation
48,*,OR T29 T30
49,T32,Mood 884 891	planned
50,T33,Temporal 892 903	concomitant
51,T34,Scope 904 938	surgical or transcatheter ablation
52,R17,Has_temporal Arg1:T34 Arg2:T33
53,R18,Has_mood Arg1:T34 Arg2:T32
54,R19,AND Arg1:T34 Arg2:T31
55,T35,Condition 965 975	Leukopenia
56,T36,Measurement 977 980	WBC
57,T37,Value 981 995	< 3000 cell/mL
58,R20,Has_value Arg1:T36 Arg2:T37
59,T38,Condition 998 1010	acute anemia
60,T39,Measurement 1012 1015	Hgb
61,T40,Value 1016 1024	< 9 g/dL
62,R21,Has_value Arg1:T39 Arg2:T40
63,R22,Subsumes Arg1:T38 Arg2:T39
64,R23,Subsumes Arg1:T35 Arg2:T36
65,T41,Condition 1027 1043	Thrombocytopenia
66,T42,Measurement 1045 1048	Plt
67,T43,"Value 1049 1065	< 50,000 cell/mL"
68,R24,Has_value Arg1:T42 Arg2:T43
69,R25,Subsumes Arg1:T41 Arg2:T42
70,*,OR T35 T38 T41
71,T44,Condition 1084 1107	respiratory instability
72,T45,Procedure 1118 1135	inotropic support
73,T46,Condition 1069 1080;1096 1107	Hemodynamic instability
74,*,OR T44 T46
75,T47,Procedure 1137 1159	mechanical ventilation
76,T48,Procedure 1163 1190	mechanical heart assistance
77,*,OR T45 T47 T48
78,T49,Temporal 1191 1229	within 30 days of screening evaluation
79,T50,Reference_point 1209 1229	screening evaluation
80,R26,Has_index Arg1:T49 Arg2:T50
81,T51,"Scope 1118 1190	inotropic support, mechanical ventilation or mechanical heart assistance"
82,R27,Has_temporal Arg1:T51 Arg2:T49
83,T52,Scope 1069 1107	Hemodynamic or respiratory instability
84,R28,Has_scope Arg1:T52 Arg2:T51
85,T53,Procedure 1241 1258	emergency surgery
86,T54,Mood 1232 1240	Need for
87,R29,Has_mood Arg1:T53 Arg2:T54
88,T55,Measurement 1276 1310	Left ventricular ejection fraction
89,T56,Value 1311 1315	<40%
90,R30,Has_value Arg1:T55 Arg2:T56
91,T57,Procedure 1318 1335	Echocardiographic
92,T58,Condition 1348 1365	intracardiac mass
93,T59,Condition 1348 1360;1367 1375	intracardiac thrombus
94,T60,Condition 1348 1360;1379 1389	intracardiac vegetation
95,*,OR T60 T59 T58
96,T61,"Scope 1348 1389	intracardiac mass, thrombus or vegetation"
97,R31,Has_scope Arg1:T57 Arg2:T61
98,T62,Temporal 1392 1398	Active
99,T63,Condition 1399 1416	upper GI bleeding
100,R32,Has_temporal Arg1:T63 Arg2:T62
101,T64,Temporal 1417 1461	within 3 months (90 days) prior to procedure
102,T65,Reference_point 1452 1461	procedure
103,R33,Has_index Arg1:T64 Arg2:T65
104,T66,Condition 1472 1488	contraindication
105,T67,Condition 1492 1508	hypersensitivity
106,*,OR T67 T66
107,T68,Procedure 1516 1540	anticoagulation regimens
108,T69,Condition 1545 1554	inability
109,T70,Procedure 1561 1575	anticoagulated
110,T71,Temporal 1576 1599	for the study procedure
111,T72,Reference_point 1584 1599	study procedure
112,R34,Has_index Arg1:T71 Arg2:T72
113,R35,AND Arg1:T69 Arg2:T70
114,T73,Scope 1472 1508	contraindication or hypersensitivity
115,R36,AND Arg1:T73 Arg2:T68
116,*,OR T73 T69
117,R37,Has_temporal Arg1:T69 Arg2:T71
118,T74,Condition 1609 1612	CVA
119,T75,Procedure 1654 1666	neuroimaging
120,T76,Value 1667 1676	confirmed
121,T77,Condition 1677 1683	stroke
122,R38,Has_value Arg1:T75 Arg2:T76
123,T78,Condition 1687 1718	transient ischemic attack (TIA)
124,*,OR T77 T78
125,T79,Scope 1677 1718	stroke or transient ischemic attack (TIA)
126,R39,AND Arg1:T79 Arg2:T75
127,T80,Qualifier 1613 1650	clinically confirmed (by neurologist)
128,R40,Has_qualifier Arg1:T74 Arg2:T80
129,*,OR T79 T74
130,T81,Temporal 1719 1762	within 6 months (180 days) of the procedure
131,T82,Reference_point 1749 1762	the procedure
132,R41,Has_index Arg1:T81 Arg2:T82
133,T83,Observation 1765 1790	Estimated life expectancy
134,T84,Value 1791 1799	< 1 year
135,R42,Has_value Arg1:T83 Arg2:T84
136,T85,Non-query-able 1832 1918	Expectation that patient will not improve despite treatment of tricuspid regurgitation
137,T86,"Non-query-able 1920 2221	Currently participating in another investigational cardiac device study or any other clinical trial, including drugs or biologics. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials."
138,T87,Condition 2230 2252	bacterial endocarditis
139,T88,Temporal 2223 2229	Active
140,R43,Has_temporal Arg1:T87 Arg2:T88
141,T89,Temporal 2253 2292	within 6 months (180 days) of procedure
142,R44,Has_temporal Arg1:T87 Arg2:T89
143,T90,Reference_point 2280 2292	of procedure
144,R45,Has_index Arg1:T89 Arg2:T90
145,T91,Condition 2330 2342	SVC syndrome
146,T92,Condition 2347 2364	hepatic cirrhosis
147,T93,Condition 2381 2407	passive congestion from TR
148,R46,AND Arg1:T92 Arg2:T93
149,*,OR T91 T92
0,T1,Condition 0 7	Smokers
1,T2,Multiplier 24 35	chronic use
2,T3,Drug 39 50	medications
3,R1,Has_multiplier Arg1:T3 Arg2:T2
4,T4,Condition 52 73	Neurological diseases
5,T5,Condition 75 98	Coronary artery disease
6,T6,Condition 100 119	Acute heart failure
7,T7,Condition 129 142	renal failure
8,T8,Multiplier 121 128	Chronic
9,R2,Has_multiplier Arg1:T7 Arg2:T8
10,T9,Measurement 144 147	GFR
11,T10,Value 148 159	< 30 ml/min
12,R3,Has_value Arg1:T9 Arg2:T10
13,T11,Scope 121 142	Chronic renal failure
14,R4,Subsumes Arg1:T11 Arg2:T9
15,T12,Condition 170 199	obstructive pulmonary disease
16,T13,Multiplier 162 169	Chronic
17,R5,Has_multiplier Arg1:T12 Arg2:T13
18,T14,Condition 201 209	Mild OSA
19,T15,Measurement 228 231	BMI
20,T16,Value 232 245	over 40 kg/m2
21,R6,Has_value Arg1:T15 Arg2:T16
0,T1,Condition 20 31	intolerance
1,T2,Procedure 35 49	blood products
2,T3,Non-query-able 53 140	to one of the components of the study product or is unwilling to receive blood products
3,R1,AND Arg1:T1 Arg2:T2
4,T4,"Pregnancy_considerations 143 234	Female subjects, who are of childbearing age (i.e. adolescent), who are pregnant or nursing"
5,T5,Post-eligibility 237 379	Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor
6,T6,Person 429 441	drug abusers
7,T7,Person 414 421;434 441	alcohol abusers
8,*,OR T6 T7
9,T8,Procedure 465 479	trauma surgery
10,T9,Non-query-able 481 605	Subjects with any pre or intra-operative findings identified by the surgeon that may preclude conduct of the study procedure
11,T10,Condition 621 624	TBS
12,T11,Qualifier 656 678	Class III Contaminated
13,T12,Qualifier 682 708	Class IV Dirty or Infected
14,*,OR T11 T12
15,T13,Scope 656 708	Class III Contaminated or Class IV Dirty or Infected
16,R2,Has_scope Arg1:T10 Arg2:T13
17,T14,Non-query-able 711 987	TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the EVARREST™ or SURGICEL® to blood flow and pressure during healing and absorption of the produc
18,T15,Condition 991 994	TBS
19,T16,Condition 1000 1023	major arterial bleeding
20,T17,Procedure 1044 1063	mechanical ligation
21,T18,Procedure 1034 1040	suture
22,*,OR T18 T17
23,T19,Scope 1034 1063	suture or mechanical ligation
24,R3,AND Arg1:T15 Arg2:T16
25,R4,Has_scope Arg1:T16 Arg2:T19
26,T20,"Non-query-able 1066 1156	Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine"
0,T1,Procedure 20 59	laparoscopic assisted donor nephrectomy
1,T2,Procedure 98 109	nerve block
2,T3,Mood 80 95	elected to have
3,R1,Has_mood Arg1:T2 Arg2:T3
4,T4,Value 111 119;127 135	18 years or older
5,T5,Person 123 126	age
6,R2,Has_value Arg1:T5 Arg2:T4
7,T6,Measurement 149 159	ASA status
8,T7,Value 160 167	I - III
9,R3,Has_value Arg1:T6 Arg2:T7
0,T1,Condition 21 49	acute lymphoblastic leukemia
1,T2,Condition 51 54	ALL
2,T3,Qualifier 0 20	Cytologically proven
3,R1,Subsumes Arg1:T1 Arg2:T2
4,R2,Has_qualifier Arg1:T1 Arg2:T3
5,T4,Condition 97 100	ALL
6,T5,Qualifier 73 96	previously unrecognized
7,T6,Negation 57 59	No
8,T7,Condition 60 67	relapse
9,R3,Has_negation Arg1:T7 Arg2:T6
10,R4,Has_qualifier Arg1:T4 Arg2:T5
11,R5,AND Arg1:T7 Arg2:T4
12,T8,Line 158 220	Standard-risk (SR) group meeting all of the following criteria
13,T9,"Line 223 274	Blasts < 1,000/µL in peripheral blood (PB) on day 8"
14,T10,Line 276 295	Aged 1 to < 6 years
15,T11,"Line 297 320	Initial WBC < 20,000/µL"
16,T12,Line 322 383	M1 (5%) or M2 (= 5% to < 25%) blasts in bone marrow on day 15
17,T13,Line 386 406	M1 marrow on day 33.
18,T14,"Line 408 452	Aged < 1 or = 6 years and/or WBC = 20,000/µL"
19,T15,"Line 454 486	Blasts < 1,000/µL in PB on day 8"
20,T16,Line 488 513	M1 or M2 marrow on day 15
21,T17,Line 515 612	M3 (= 25%) marrow on day 15 OR meets SR criteria but M3 marrow on day 15 and *M1 marrow on day 33
22,T18,Line 615 682	Meets IR criteria and M3 marrow on day 15 (not SR and M3 on day 15)
23,T19,"Line 684 716	Blasts = 1,000/µL in PB on day 8"
24,T20,Line 718 743	M2 or M3 marrow on day 33
25,T21,Line 745 834	Translocation t(9;22) [BCR/ABL+] (Philadelphia chromosome-positive) or t(4;11) [MLL/AF4+]
26,T22,Measurement 158 171	Standard-risk
27,T23,Measurement 173 175	SR
28,R6,Subsumes Arg1:T22 Arg2:T23
29,T24,Multiplier 191 194	all
30,T25,Measurement 212 220	criteria
31,R7,Has_multiplier Arg1:T25 Arg2:T24
32,R8,AND Arg1:T22 Arg2:T25
33,T26,Measurement 223 229	Blasts
34,T27,"Value 230 240	< 1,000/µL"
35,T28,Qualifier 244 260	peripheral blood
36,T29,Qualifier 262 264	PB
37,R9,Subsumes Arg1:T28 Arg2:T29
38,R10,Has_qualifier Arg1:T26 Arg2:T28
39,T30,Temporal 266 274	on day 8
40,R11,Has_temporal Arg1:T26 Arg2:T30
41,T31,Person 276 280	Aged
42,T32,Value 281 295	1 to < 6 years
43,R12,Has_value Arg1:T31 Arg2:T32
44,T33,Measurement 305 308	WBC
45,T34,Qualifier 297 304	Initial
46,T35,"Value 309 320	< 20,000/µL"
47,R13,Has_value Arg1:T33 Arg2:T35
48,R14,Has_qualifier Arg1:T33 Arg2:T34
49,T36,Measurement 322 324;352 358	M1 blasts
50,T37,Measurement 333 335;352 358	M2 blasts
51,T38,Qualifier 362 373	bone marrow
52,T39,Value 325 328	(5%
53,T40,Value 337 350	= 5% to < 25%
54,R15,Has_value Arg1:T37 Arg2:T40
55,R16,Has_value Arg1:T36 Arg2:T39
56,*,OR T36 T37
57,T41,Temporal 374 383	on day 15
58,T42,Scope 322 358	M1 (5%) or M2 (= 5% to < 25%) blasts
59,R17,Has_qualifier Arg1:T42 Arg2:T38
60,R18,Has_temporal Arg1:T42 Arg2:T41
61,T43,Condition 386 395	M1 marrow
62,T44,Temporal 396 405	on day 33
63,R19,Has_temporal Arg1:T43 Arg2:T44
64,T45,Person 408 412	Aged
65,T46,Value 413 429	< 1 or = 6 years
66,T47,Measurement 437 440	WBC
67,T48,"Value 441 452	= 20,000/µL"
68,R20,Has_value Arg1:T47 Arg2:T48
69,R21,Has_value Arg1:T45 Arg2:T46
70,*,OR T45 T47
71,T49,Measurement 454 460	Blasts
72,T50,"Value 461 471	< 1,000/µL"
73,T51,Condition 475 477	PB
74,R22,AND Arg1:T49 Arg2:T51
75,R23,Has_value Arg1:T49 Arg2:T50
76,T52,Temporal 478 486	on day 8
77,R24,Has_temporal Arg1:T49 Arg2:T52
78,T53,Condition 494 503	M2 marrow
79,T54,Condition 488 490;497 503	M1 marrow
80,*,OR T53 T54
81,T55,Temporal 504 513	on day 15
82,T56,Scope 488 503	M1 or M2 marrow
83,R25,Has_temporal Arg1:T56 Arg2:T55
84,T57,Condition 515 517;526 532	M3 marrow
85,T58,Value 519 524	= 25%
86,R26,Has_value Arg1:T57 Arg2:T58
87,T59,Temporal 533 542	on day 15
88,T60,Measurement 552 563	SR criteria
89,T61,Value 546 551	meets
90,R27,Has_value Arg1:T60 Arg2:T61
91,T62,Condition 568 577	M3 marrow
92,T63,Temporal 578 587	on day 15
93,T64,Condition 593 602	M1 marrow
94,T65,Temporal 603 612	on day 33
95,R28,Has_temporal Arg1:T64 Arg2:T65
96,R29,Has_temporal Arg1:T62 Arg2:T63
97,T66,Scope 546 612	meets SR criteria but M3 marrow on day 15 and *M1 marrow on day 33
98,R30,Has_temporal Arg1:T57 Arg2:T59
99,*,OR T57 T66
100,T67,Measurement 621 632	IR criteria
101,T68,Value 615 620	Meets
102,R31,Has_value Arg1:T67 Arg2:T68
103,T69,Condition 637 646	M3 marrow
104,T70,Temporal 647 656	on day 15
105,R32,Has_temporal Arg1:T69 Arg2:T70
106,T71,Value 658 661	not
107,T72,Measurement 662 664	SR
108,R33,Has_value Arg1:T72 Arg2:T71
109,T73,Condition 669 671	M3
110,T74,Temporal 672 681	on day 15
111,R34,Has_temporal Arg1:T73 Arg2:T74
112,T75,Measurement 684 690	Blasts
113,T76,"Value 691 701	= 1,000/µL"
114,T77,Qualifier 705 707	PB
115,T78,Temporal 708 716	on day 8
116,R35,Has_value Arg1:T75 Arg2:T76
117,R36,Has_qualifier Arg1:T75 Arg2:T77
118,R37,Has_temporal Arg1:T75 Arg2:T78
119,T79,Condition 724 733	M3 marrow
120,T80,Condition 718 720;727 733	M2 marrow
121,T81,Temporal 734 743	on day 33
122,T82,Scope 718 733	M2 or M3 marrow
123,*,OR T79 T80
124,R38,Has_temporal Arg1:T82 Arg2:T81
125,T83,Measurement 745 766	Translocation t(9;22)
126,T84,Measurement 768 775	BCR/ABL
127,T85,Value 775 776	+
128,R39,Has_value Arg1:T84 Arg2:T85
129,R40,Subsumes Arg1:T84 Arg2:T83
130,T86,Measurement 779 802	Philadelphia chromosome
131,T87,Value 803 811	positive
132,R41,Has_value Arg1:T86 Arg2:T87
133,T88,Measurement 816 823	t(4;11)
134,T89,Measurement 825 832	MLL/AF4
135,T90,Value 832 833	+
136,R42,Subsumes Arg1:T89 Arg2:T88
137,R43,Has_value Arg1:T89 Arg2:T90
138,R44,Subsumes Arg1:T84 Arg2:T86
139,*,OR T84 T89
0,T1,Person 21 24	age
1,T2,Value 8 17	>18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 48 71	acute coronary syndrome
4,T4,Condition 73 76	ACS
5,R2,Subsumes Arg1:T3 Arg2:T4
6,T5,Condition 88 111	coronary artery disease
7,T6,Condition 113 116	CAD
8,T7,Qualifier 81 87	stable
9,R3,Subsumes Arg1:T5 Arg2:T6
10,R4,Has_qualifier Arg1:T5 Arg2:T7
11,*,OR T3 T5
12,T8,Procedure 143 146	PCI
13,T9,Mood 130 138	eligible
14,R5,Has_mood Arg1:T8 Arg2:T9
15,T10,Post-eligibility 148 211	Patient is willing and able to provide informed written consent
16,T11,Condition 225 240	able to receive
17,T12,Procedure 254 280	dual anti-platelet therapy
18,T13,Temporal 241 250	12 months
19,R6,Has_temporal Arg1:T12 Arg2:T13
20,T14,Procedure 299 302	PCI
21,T15,Temporal 293 298	index
22,R7,Has_temporal Arg1:T14 Arg2:T15
23,T16,Observation 282 289	Failure
24,R8,Has_context Arg1:T14 Arg2:T16
25,T17,Post-eligibility 304 355	Patient or physician refusal to enroll in the study
26,T18,Condition 376 392	CYP2C19 genotype
27,T19,Temporal 393 415	prior to randomization
28,T20,Reference_point 402 415	randomization
29,R9,Has_index Arg1:T19 Arg2:T20
30,R10,Has_temporal Arg1:T18 Arg2:T19
31,T21,Procedure 425 442	revascularization
32,T22,Mood 417 424	Planned
33,T23,Qualifier 446 456	any vessel
34,R12,Has_mood Arg1:T21 Arg2:T22
35,T24,Temporal 457 492	within 30 days post-index procedure
36,T25,Reference_point 477 492	index procedure
37,R13,Has_index Arg1:T24 Arg2:T25
38,T26,Temporal 524 555	within 12 months post-procedure
39,T27,Reference_point 546 555	procedure
40,R15,Has_index Arg1:T26 Arg2:T27
41,T28,Qualifier 500 523	of the target vessel(s)
42,R16,Has_temporal Arg1:T28 Arg2:T26
43,R14,Has_temporal Arg1:T23 Arg2:T24
44,*,OR T23 T28
45,T29,Scope 446 555	any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure
46,R11,Has_scope Arg1:T21 Arg2:T29
47,T30,Drug 588 599	clopidogrel
48,T31,Drug 603 613	ticagrelor
49,*,OR T30 T31
50,T32,Temporal 614 650	within the 12 month follow up period
51,T33,Procedure 664 680	elective surgery
52,T34,Mood 652 663	example for
53,R17,Has_mood Arg1:T33 Arg2:T34
54,T35,Scope 588 612	clopidogrel or ticagrelo
55,R18,Has_temporal Arg1:T35 Arg2:T32
56,*,OR T35 T33
57,T36,Measurement 682 698	Serum creatinine
58,T37,Value 699 709	>2.5 mg/dL
59,R19,Has_value Arg1:T36 Arg2:T37
60,T38,Temporal 710 742	within 7 days of index procedure
61,T39,Reference_point 727 742	index procedure
62,R20,Has_index Arg1:T38 Arg2:T39
63,R21,Has_temporal Arg1:T36 Arg2:T38
64,T40,Measurement 744 758	Platelet count
65,T42,"Value 759 788	<80,000 or >700,000 cells/mm3"
66,T41,Measurement 793 815	white blood cell count
67,T43,"Value 816 832	<3,000 cells/mm3"
68,R22,Has_value Arg1:T41 Arg2:T43
69,R23,Has_value Arg1:T40 Arg2:T42
70,*,OR T40 T41
71,T44,Temporal 876 914	within 7 days prior to index procedure
72,T45,Reference_point 899 914	index procedure
73,R24,Has_index Arg1:T44 Arg2:T45
74,T46,"Scope 744 832	Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3"
75,R25,Has_temporal Arg1:T46 Arg2:T44
76,T47,Condition 928 951	intracranial hemorrhage
77,T48,Condition 959 975	hypersensitivity
78,T49,Drug 979 990	clopidogrel
79,T50,Drug 994 1004	ticagrelor
80,T51,Drug 1008 1029	any of its components
81,*,OR T50 T49
82,T52,Scope 979 1004	clopidogrel or ticagrelor
83,R26,Subsumes Arg1:T52 Arg2:T51
84,R27,Has_scope Arg1:T48 Arg2:T52
85,T53,Non-query-able 1031 1149	Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint
86,T54,Non-query-able 1151 1192	Patient previously enrolled in this study
87,T55,Condition 1205 1213	pregnant
88,T56,Condition 1215 1224	lactating
89,T57,Mood 1229 1247	planning to become
90,T58,Condition 1248 1256	pregnant
91,T59,Temporal 1257 1273	within 12 months
92,R28,Has_temporal Arg1:T58 Arg2:T59
93,R29,Has_mood Arg1:T58 Arg2:T57
94,*,OR T55 T56 T58
95,T60,Procedure 1299 1315	organ transplant
96,T61,Mood 1319 1339	is on a waiting list
97,T62,Procedure 1347 1363	organ transplant
98,R30,Has_mood Arg1:T62 Arg2:T61
99,*,OR T60 T62
100,T63,Procedure 1410 1422	chemotherapy
101,T64,Mood 1373 1385	is receiving
102,T65,Mood 1389 1409	scheduled to receive
103,*,OR T64 T65
104,T66,Scope 1373 1409	is receiving or scheduled to receive
105,R31,Has_scope Arg1:T63 Arg2:T66
106,T67,Temporal 1423 1467	within 30 days before or after the procedure
107,T68,Reference_point 1454 1467	the procedure
108,R32,Has_index Arg1:T67 Arg2:T68
109,R33,Has_temporal Arg1:T66 Arg2:T67
110,T69,Procedure 1490 1515	immunosuppressive therapy
111,T70,Condition 1529 1546;1561 1568	immunosuppressive disease
112,T71,Condition 1550 1568	autoimmune disease
113,*,OR T70 T71 T69
114,T72,Condition 1576 1604	human immunodeficiency virus
115,T73,Condition 1606 1633	systemic lupus erythematous
116,*,OR T72 T73
117,T74,"Scope 1576 1633	human immunodeficiency virus, systemic lupus erythematous"
118,R34,Subsumes Arg1:T71 Arg2:T74
119,T75,Procedure 1671 1699	oral anticoagulation therapy
120,T76,Multiplier 1663 1670	chronic
121,R35,Has_multiplier Arg1:T75 Arg2:T76
122,T77,Drug 1707 1727	vitamin K antagonist
123,T78,Drug 1729 1754	direct thrombin inhibitor
124,T79,Drug 1756 1775	Factor Xa inhibitor
125,*,OR T79 T78 T77
126,T80,"Scope 1707 1775	vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor"
127,R36,Subsumes Arg1:T75 Arg2:T80
128,T81,Drug 1797 1808	simvastatin
129,T82,Drug 1809 1819	lovastatin
130,*,OR T82 T81
131,T83,Multiplier 1820 1830	> 40 mg qd
132,T84,Temporal 1778 1789	Concomitant
133,R37,Has_temporal Arg1:T81 Arg2:T84
134,R38,Has_temporal Arg1:T82 Arg2:T84
135,R39,Has_multiplier Arg1:T82 Arg2:T83
136,R40,Has_multiplier Arg1:T81 Arg2:T83
137,T85,Drug 1851 1875	potent CYP3A4 inhibitors
138,T86,Drug 1877 1887	atazanavir
139,T87,Drug 1889 1903	clarithromycin
140,T88,Drug 1905 1914	indinavir
141,T89,Drug 1916 1928	itraconazole
142,T90,Drug 1930 1942	ketoconazole
143,T91,Drug 1944 1954	nefazodone
144,T92,Drug 1956 1966	nelfinavir
145,T93,Drug 1968 1977	ritonavir
146,T94,Drug 1979 1989	saquinavir
147,T95,Drug 1991 2004	telithromycin
148,T96,Drug 2009 2021	voriconazole
149,T97,Drug 1851 1864;2026 2034	potent CYP3A4 inducers
150,T98,Drug 2036 2049	carbamazepine
151,T99,Drug 2051 2064	dexamethasone
152,T100,Drug 2066 2079	phenobarbital
153,T101,Drug 2081 2090	phenytoin
154,T102,Drug 2092 2100	rifampin
155,T103,Drug 2106 2117	rifapentine
156,*,OR T86 T87 T88 T89 T90 T91 T92 T93 T94 T95 T96
157,*,OR T98 T99 T100 T101 T102 T103
158,T104,"Scope 2036 2117	carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine"
159,R41,Subsumes Arg1:T97 Arg2:T104
160,T105,"Scope 1877 2021	atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole"
161,R42,Subsumes Arg1:T85 Arg2:T105
162,T106,Temporal 1832 1843	Concomitant
163,R43,Has_temporal Arg1:T97 Arg2:T106
164,R44,Has_temporal Arg1:T85 Arg2:T106
165,T107,Condition 2120 2141	Non-cardiac condition
166,T108,Observation 2151 2166	life expectancy
167,T109,Temporal 2170 2188	less than one year
168,R45,Has_temporal Arg1:T108 Arg2:T109
169,R46,Has_context Arg1:T107 Arg2:T108
170,T110,Condition 2252 2270	hepatic impairment
171,T111,Qualifier 2245 2251	severe
172,R47,Has_qualifier Arg1:T110 Arg2:T111
173,T112,Condition 2297 2315	bleeding diathesis
174,T113,Condition 2319 2331	coagulopathy
175,*,OR T113 T112 T114
176,T114,Procedure 2347 2365	blood transfusions
177,T115,Mood 2335 2346	will refuse
178,R48,Has_mood Arg1:T114 Arg2:T115
179,T116,Condition 2389 2410	pathological bleeding
180,T117,Qualifier 2382 2388	active
181,R49,Has_qualifier Arg1:T116 Arg2:T117
182,T118,Qualifier 2420 2426	active
183,T119,Condition 2427 2457	gastrointestinal (GI) bleeding
184,R50,Has_qualifier Arg1:T119 Arg2:T118
185,R51,Subsumes Arg1:T116 Arg2:T119
186,T120,Condition 2459 2476	Inability to take
187,T121,Drug 2477 2484	aspirin
188,T122,Multiplier 2500 2514	100 mg or less
189,R52,Has_multiplier Arg1:T121 Arg2:T122
190,R53,AND Arg1:T120 Arg2:T121
191,T123,Condition 2524 2539	substance abuse
0,T1,Person 35 38	old
1,T2,Value 17 34	at least 21 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 63 69	severe
4,T4,Qualifier 71 82	symptomatic
5,T5,Condition 110 133	tricuspid regurgitation
6,T6,Condition 135 137	TR
7,T7,Measurement 84 91	ACC/AHA
8,T8,Value 92 99	Stage D
9,R2,Has_value Arg1:T7 Arg2:T8
10,R3,Subsumes Arg1:T4 Arg2:T7
11,R4,Has_qualifier Arg1:T5 Arg2:T4
12,R5,Has_qualifier Arg1:T5 Arg2:T3
13,R6,Subsumes Arg1:T5 Arg2:T6
14,T9,Procedure 154 171	2D echocardiogram
15,R7,AND Arg1:T5 Arg2:T9
16,T10,Condition 189 199;212 229	peripheral venous congestion
17,T11,Condition 204 229	central venous congestion
18,T12,Condition 244 265	lower extremity edema
19,T13,Condition 270 287	abdominal ascites
20,T14,Drug 298 307	diuretics
21,R10,AND Arg1:T13 Arg2:T14
22,T15,Scope 189 229	peripheral and central venous congestion
23,R8,Has_scope Arg1:T9 Arg2:T15
24,T16,Scope 244 307	lower extremity edema and abdominal ascites requiring diuretics
25,R9,Subsumes Arg1:T15 Arg2:T16
26,T17,"Non-query-able 311 691	The patient must be evaluated by a ""heart team"" of physicians including an interventional cardiologist, cardiothoracic surgeon, heart failure specialist, and imaging specialist, and presented for review at a local multi-disciplinary conference. By consensus, the heart team must agree (and verify in the case review process) that valve implantation will likely benefit the patient"
27,T18,"Non-query-able 694 1506	The heart team must agree that medical factors preclude operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. Also, other factors which may increase the patients perceived surgical risk for inclusion in the trial will be clearly delineated if they are present. These include, but are not limited to the following as defined by VARC 2: Frailty, Hostile chest, porcelain aorta, IMA or other critical conduit crossing the midline or adherent to the posterior table of sternum, severe right ventricular (RV) dysfunction. The surgeons' consultation notes shall specify the medical or anatomic factors leading to that conclusion. At least one of the cardiac surgeon assessors must have interviewed and examined the patient."
28,T19,"Post-eligibility 1508 1662	The study patient provides informed consent and agrees to comply with all required post-procedure follow-up visits, including annual visits up to 5 years."
0,T1,Condition 0 8	Allergic
1,T2,Drug 12 21	sirolimus
2,T3,Qualifier 25 32	serious
3,T4,Condition 33 45	side effects
4,R1,Has_qualifier Arg1:T4 Arg2:T3
5,R2,AND Arg1:T1 Arg2:T2
6,*,OR T1 T4
7,T5,Mood 47 51	Need
8,T6,Temporal 147 163	less than 1 year
9,T7,Measurement 137 146	Follow-up
10,R3,Has_temporal Arg1:T7 Arg2:T6
11,T8,Procedure 52 69	emergency surgery
12,R4,Has_mood Arg1:T8 Arg2:T5
13,T9,Condition 94 108	severe disease
14,T10,Condition 118 134	C.diff infection
0,T1,Person 20 24	aged
1,T2,Value 25 58	=28 days (= 1 month) to <18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 158 177	surgical procedures
4,T4,Qualifier 135 143	thoracic
5,T5,Qualifier 125 131	pelvic
6,T6,Qualifier 108 123	retroperitoneal
7,T7,Qualifier 97 106	abdominal
8,T8,Qualifier 88 95	hepatic
9,T9,Qualifier 83 87	open
10,T10,Qualifier 70 82	non-emergent
11,*,OR T8 T7 T6 T5 T4 T11
12,T11,Qualifier 145 156	non-cardiac
13,T12,"Scope 88 157	hepatic, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac)"
14,R2,Has_scope Arg1:T3 Arg2:T12
15,R3,Has_qualifier Arg1:T3 Arg2:T9
16,R4,Has_qualifier Arg1:T3 Arg2:T10
17,T13,Non-query-able 182 344	The first 36 subjects to be enrolled will be subjects aged =1 years to <18 years. ii) The next 4 subjects to be enrolled will be subjects aged =28 days to <1 year
18,T14,"Informed_consent 347 966	The subject's parent/legal guardian must be willing to give permission for the subject to participate in the trial, and provide written informed consent for the subject. In addition, assent must be obtained from paediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the trial. If the paediatric subject is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the trial), the parent/legal guardian's written Informed Consent for the subject will be acceptable for the subject to be included in the study"
19,T15,Non-query-able 970 1126	resence of an appropriate mild or moderate bleeding soft tissue or hepatic parenchyma Target Bleeding Site (TBS) identified intra-operatively by the surgeon
20,T16,Post-eligibility 1129 1211	Ability to firmly press trial treatment at TBS until 4 minutes after randomisation
0,T1,Condition 0 12	Chronic pain
1,T2,Drug 16 24	narcotic
2,*,OR T1 T2
3,T3,Temporal 31 59	during the preceding 30 days
4,T4,Scope 0 24	Chronic pain or narcotic
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Condition 61 70	Infection
7,T6,Qualifier 86 116	intended needle insertion site
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Condition 129 159	altered abdominal wall anatomy
10,T8,Condition 118 125;137 159	Complex abdominal wall anatomy
11,T9,Measurement 161 167	Weight
12,*,OR T8 T7
13,T10,Value 168 173	<45kg
14,R3,Has_value Arg1:T9 Arg2:T10
0,T1,Condition 0 18	Metabolic Syndrome
1,T2,Measurement 20 23	ATP
2,T3,Value 24 27	III
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,Subsumes Arg1:T1 Arg2:T2
5,T4,Qualifier 30 48	Moderate to severe
6,T5,Condition 49 52	OSA
7,R3,Has_qualifier Arg1:T5 Arg2:T4
0,T1,Negation 0 2	No
1,T2,Negation 18 20	No
2,T3,Negation 113 116	Not
3,T4,Negation 209 211	No
4,T5,Negation 254 256	No
5,T6,Condition 3 16	Down syndrome
6,T7,Condition 27 40	major disease
7,T8,Qualifier 21 26	other
8,R1,Has_negation Arg1:T6 Arg2:T1
9,R2,Has_qualifier Arg1:T7 Arg2:T8
10,R3,Has_negation Arg1:T7 Arg2:T2
11,T9,Condition 86 110	congenital heart disease
12,T10,Qualifier 79 85	severe
13,R4,Has_qualifier Arg1:T9 Arg2:T10
14,R5,Subsumes Arg1:T7 Arg2:T9
15,T11,Non-query-able 41 71	that prohibits study treatment
16,T12,Procedure 169 182	study therapy
17,T13,Condition 194 207	complications
18,T14,Non-query-able 113 207	Not requiring significant therapy modification owing to study therapy associated complications
19,T15,"Non-query-able 255 369	o one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm"
20,T16,Procedure 239 252	interventions
21,T17,Qualifier 233 238	other
22,T18,Condition 212 225	complications
23,R6,Has_qualifier Arg1:T16 Arg2:T17
24,R7,AND Arg1:T18 Arg2:T16
25,R8,Has_negation Arg1:T18 Arg2:T4
0,T1,Condition 0 26	Toxic epidermal necrolysis
1,T2,Measurement 32 39	SCORTEN
2,T3,Value 40 46	1 to 5
3,T4,Temporal 47 59	at admission
4,T5,Reference_point 50 59	admission
5,R1,Has_index Arg1:T4 Arg2:T5
6,R2,Has_value Arg1:T2 Arg2:T3
7,R3,Has_temporal Arg1:T2 Arg2:T4
0,T1,Condition 0 26	Toxic epidermal necrolysis
1,T2,Measurement 32 39	SCORTEN
2,T3,Value 40 46	6 or 7
3,T4,Temporal 47 59	at admission
4,T5,Reference_point 50 59	admission
5,R1,Has_index Arg1:T4 Arg2:T5
6,T6,Condition 61 82	Hypercoagulable state
7,T7,Condition 95 122	peripheral arterial disease
8,Hypercoagulable,state
9,Car,disease
10,T8,Condition 115 122;84 91	disease Cardiac
11,*,OR T7 T8
12,T9,Condition 131 141	malignancy
13,T10,Qualifier 124 130	Active
14,R2,Has_qualifier Arg1:T9 Arg2:T10
15,T11,Condition 143 167	Myelodysplastic syndrome
16,T12,Condition 171 195	hematological malignancy
17,*,OR T11 T12
18,T13,Condition 197 217	Fructose intolerance
19,T14,Drug 197 205	Fructose
20,T15,Pregnancy_considerations 219 228	Pregnancy
21,T16,Post-eligibility 230 245	Patient refusal
22,R3,Has_temporal Arg1:T2 Arg2:T4
23,R4,Has_value Arg1:T2 Arg2:T3
0,T1,Condition 16 29	heart failure
1,T2,Condition 41 62	diastolic dysfunction
2,T3,Negation 30 40	other than
3,R1,Has_negation Arg1:T2 Arg2:T3
4,R2,AND Arg1:T1 Arg2:T2
5,T4,Condition 72 98	restrictive cardiomyopathy
6,T5,Condition 102 129	infiltrative cardiomyopathy
7,*,OR T4 T5
8,T6,Scope 72 129	restrictive cardiomyopathy or infiltrative cardiomyopathy
9,T7,Scope 16 62	heart failure other than diastolic dysfunction
10,R3,Subsumes Arg1:T7 Arg2:T6
11,T8,Person 131 136	Women
12,T9,Condition 145 153	pregnant
13,T10,Condition 157 164	nursing
14,*,OR T9 T10
15,T11,Condition 166 181	Liver cirrhosis
16,T12,Condition 184 208	Primary valvular disease
17,T13,Condition 210 233	Acute coronary syndrome
18,T14,Condition 235 247	Causes of PH
19,T15,Negation 248 258	other than
20,T16,Condition 267 280	heart failure
21,R4,Has_negation Arg1:T16 Arg2:T15
22,R5,AND Arg1:T14 Arg2:T16
23,T17,Condition 291 316	chronic thromboembolic PH
24,T18,Condition 318 337	sickle-cell disease
25,T19,Condition 342 353	sarcoidosis
26,*,OR T19 T18 T17
27,T20,"Scope 291 353	chronic thromboembolic PH, sickle-cell disease, or sarcoidosis"
28,R6,Has_scope Arg1:T16 Arg2:T20
29,T21,Condition 362 373	bradycardia
30,T22,Qualifier 355 361	Severe
31,R7,Has_qualifier Arg1:T21 Arg2:T22
32,T23,Qualifier 377 400	greater than 1st degree
33,T24,Condition 401 412	heart block
34,R8,Has_qualifier Arg1:T24 Arg2:T23
35,*,OR T21 T24
36,T25,Condition 428 441	heart failure
37,T26,Qualifier 414 427	Decompensated
38,R9,Has_qualifier Arg1:T25 Arg2:T26
39,T27,Drug 460 489	third generation beta-blocker
40,T28,Drug 491 500	nebivolol
41,T29,Drug 502 512	carvedilol
42,T30,Drug 517 526	labetalol
43,*,OR T30 T29 T28
44,T31,"Scope 491 526	nebivolol, carvedilol, or labetalol"
45,R10,Subsumes Arg1:T27 Arg2:T31
46,T32,Multiplier 531 540	high dose
47,T33,Drug 544 561	any beta-blockers
48,T34,Multiplier 563 588	greater than 100 mg daily
49,T35,Drug 592 602	metoprolol
50,R11,Has_multiplier Arg1:T35 Arg2:T34
51,R12,Has_multiplier Arg1:T33 Arg2:T32
52,T36,Scope 563 602	greater than 100 mg daily of metoprolol
53,T37,Scope 531 561	high dose of any beta-blockers
54,R13,Subsumes Arg1:T37 Arg2:T36
55,*,OR T37 T27
0,T1,Procedure 14 32	colorectal surgery
1,T2,Observation 3 10	History
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Condition 56 83	digestive tract obstruction
4,T4,Condition 56 71;85 94	digestive tract stricture
5,T5,Condition 56 71;99 110	digestive tract perforation
6,*,OR T4 T5 T3
7,T6,Parsing_Error 34 36	2.
8,T7,Parsing_Error 0 2	1.
9,T8,Parsing_Error 112 114	3.
10,T9,Condition 157 170	renal failure
11,T10,Measurement 177 197	creatinine clearance
12,T11,Value 197 207	<30 ml/min
13,R2,Has_value Arg1:T10 Arg2:T11
14,T12,Qualifier 150 156	severe
15,R3,Has_qualifier Arg1:T9 Arg2:T12
16,T13,Measurement 209 235	New York Heart Association
17,T14,Value 236 257	grade III or grade IV
18,T15,Condition 258 282	congestive heart failure
19,R4,Has_value Arg1:T13 Arg2:T14
20,R5,AND Arg1:T15 Arg2:T13
21,T16,Condition 287 310	hemodynamic instability
22,R6,Subsumes Arg1:T12 Arg2:T10
23,T17,Undefined_semantics 115 140	Serious status of illness
24,T18,Subjective_judgement 115 140	Serious status of illness
25,*,OR T9 T15 T16
26,T19,"Scope 150 310	severe renal failure whose creatinine clearance<30 ml/min, New York Heart Association grade III or grade IV congestive heart failure, or hemodynamic instability"
27,T20,Condition 115 140	Serious status of illness
28,R7,Subsumes Arg1:T20 Arg2:T19
29,T21,Parsing_Error 318 320	4.
30,T22,Condition 321 362	Incapable of completing bowel preparation
31,T23,Condition 371 380	dysphagia
32,T24,Condition 382 389	allergy
33,T25,Drug 393 403	purgatives
34,R8,AND Arg1:T24 Arg2:T25
35,T26,Condition 408 430	impaired mental status
36,*,OR T23 T24 T26
37,T27,"Scope 371 430	dysphagia, allergy to purgatives, or impaired mental status"
38,R9,Has_scope Arg1:T22 Arg2:T27
39,T28,Parsing_Error 438 440	5.
40,T29,Condition 441 450	Pregnancy
41,T30,Observation 454 467	breastfeeding
42,*,OR T29 T30
43,T31,Parsing_Error 469 471	6.
44,T32,Procedure 483 494	colonoscopy
45,T33,Condition 516 538	poor bowel preparation
46,T34,Negation 509 515	except
47,R10,Has_negation Arg1:T33 Arg2:T34
48,T35,Qualifier 472 482	Incomplete
49,R11,Has_qualifier Arg1:T32 Arg2:T35
50,R12,AND Arg1:T32 Arg2:T33
51,T36,Parsing_Error 540 542	7.
52,T38,Parsing_Error 576 578	8.
53,T40,Observation 558 574	informed consent
0,T1,Condition 0 19	Renal insufficiency
1,T2,Informed_consent 36 73	Incapability to give informed consent
2,T3,Condition 75 92	Cardiogenic shock
3,T4,Measurement 109 115	KILLIP
4,T5,Value 116 125	III or IV
5,R1,Has_value Arg1:T4 Arg2:T5
6,T6,Condition 127 135	pregnant
7,T7,Observation 139 153	breast feeding
8,T8,Person 154 161	females
9,*,OR T6 T7
10,T9,Qualifier 163 175	insufficient
11,T10,Procedure 176 189	contraception
12,R2,Has_qualifier Arg1:T10 Arg2:T9
13,T11,Non-representable 20 34	(> 265 µmol/l)
0,T1,Condition 10 21	contracture
1,T2,Qualifier 29 49	finger to be treated
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Qualifier 0 9	recurrent
4,R2,Has_qualifier Arg1:T1 Arg2:T3
5,T4,Condition 51 71	neurologic condition
6,T5,Condition 84 100	loss of function
7,T6,Qualifier 108 128	finger to be treated
8,R3,Has_qualifier Arg1:T5 Arg2:T6
9,R4,AND Arg1:T4 Arg2:T5
10,T7,Condition 130 146	contraindication
11,T8,Drug 151 187	collagenase clostridium histolyticym
12,T9,Drug 189 195	Xiapex
13,T10,Drug 196 203	Xiaflex
14,*,OR T9 T10
15,T11,Scope 189 203	Xiapex/Xiaflex
16,R5,Subsumes Arg1:T8 Arg2:T11
17,R6,AND Arg1:T7 Arg2:T8
18,T12,Condition 208 216	pregnant
19,T13,Observation 220 234	breast feeding
20,*,OR T13 T12
21,T14,Measurement 236 240	TPED
22,T15,Value 241 247	> 135°
23,R7,Has_value Arg1:T14 Arg2:T15
24,T16,Measurement 249 256	Tubiana
25,T17,Value 257 264	stage 4
26,R8,Has_value Arg1:T16 Arg2:T17
27,T18,Scope 236 247	TPED > 135°
28,T19,Scope 249 264	Tubiana stage 4
29,R9,Subsumes Arg1:T18 Arg2:T19
30,T20,Qualifier 269 289	finger to be treated
31,R10,Has_qualifier Arg1:T18 Arg2:T20
32,T21,Condition 291 311	rheumatoid arthritis
33,T22,Qualifier 334 354	finger to be treated
34,T23,Condition 322 330	fracture
35,T24,Temporal 313 321	previous
36,R11,Has_temporal Arg1:T23 Arg2:T24
37,R12,Has_qualifier Arg1:T23 Arg2:T22
38,T25,Condition 362 385	affects range of motion
39,T26,Qualifier 389 391;399 404	MP joint
40,T27,Qualifier 395 404	PIP joint
41,*,OR T26 T27
42,T28,Scope 389 404	MP or PIP joint
43,R13,Has_scope Arg1:T25 Arg2:T28
44,R14,AND Arg1:T23 Arg2:T25
45,T29,Person 406 409	age
46,T30,Value 410 420	> 80 years
47,R15,Has_value Arg1:T29 Arg2:T30
0,T1,Condition 0 16	Renal impairment
1,T2,Condition 64 72	allergic
2,T3,Drug 86 97	varenicline
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Condition 101 121	cardiovascular event
5,T5,Temporal 122 139	in the past month
6,R2,Has_temporal Arg1:T4 Arg2:T5
7,T6,Condition 163 178	drug dependence
8,T7,Condition 152 159;168 178	alcohol dependence
9,*,OR T6 T7
10,T8,Scope 152 178	alcohol or drug dependence
11,T9,Temporal 182 195	the past year
12,R3,Has_temporal Arg1:T8 Arg2:T9
13,T10,Condition 197 222	Major depressive disorder
14,T11,Temporal 230 239	last year
15,R4,Has_temporal Arg1:T10 Arg2:T11
16,T12,Procedure 250 259	treatment
17,R5,AND Arg1:T10 Arg2:T12
18,T13,Condition 272 286	panic disorder
19,T14,Condition 288 297	psychosis
20,T15,Condition 299 315	bipolar disorder
21,T16,Condition 320 336	eating disorders
22,*,OR T13 T14 T15 T16
23,T17,Observation 338 352	Use of tobacco
24,T18,Negation 362 372	other than
25,T19,Observation 373 383	cigarettes
26,R6,Has_context Arg1:T18 Arg2:T19
27,T20,Temporal 387 399	past 30 days
28,R7,Has_temporal Arg1:T17 Arg2:T20
29,T21,Procedure 408 423	pharmacotherapy
30,T22,Temporal 431 456	month prior to enrollment
31,T23,Reference_point 446 456	enrollment
32,R8,Has_index Arg1:T22 Arg2:T23
33,R9,Has_temporal Arg1:T21 Arg2:T22
34,T24,"Pregnancy_considerations 494 552	Pregnant, contemplating getting pregnant, or breastfeeding"
35,T25,Non-query-able 554 625	Plans to move from Kansas City during the treatment and follow-up phase
36,T26,Non-query-able 627 673	Another household member enrolled in the study
37,T27,Condition 702 727	major depressive disorder
38,T28,Qualifier 695 701	severe
39,T29,Condition 731 748	suicidal ideation
40,R10,Has_qualifier Arg1:T27 Arg2:T28
41,*,OR T27 T29
0,T1,Person 0 6	Adults
1,T2,Value 8 18	= 18 years
2,T3,Person 22 25	age
3,R1,Has_value Arg1:T3 Arg2:T2
4,R2,Subsumes Arg1:T1 Arg2:T3
5,T4,Condition 66 88	Pulmonary Hypertension
6,T5,Qualifier 32 65	World Health Organization Group 2
7,R3,Has_qualifier Arg1:T4 Arg2:T5
8,T6,Measurement 89 120	(Mean pulmonary artery pressure
9,T7,Value 121 130	= 25 mmHg
10,R4,Has_value Arg1:T6 Arg2:T7
11,T8,Measurement 135 169	pulmonary capillary wedge pressure
12,T9,Value 170 179	= 15 mmHg
13,R5,Has_value Arg1:T8 Arg2:T9
14,T10,Measurement 182 208	New York Heart Association
15,T11,Value 209 220	class II-IV
16,T12,Condition 221 229	symptoms
17,R6,Has_value Arg1:T10 Arg2:T11
18,R7,AND Arg1:T12 Arg2:T10
19,T13,Measurement 231 272	Left ventricular ejection fraction (LVEF)
20,T14,Value 273 278	= 45%
21,R8,Has_value Arg1:T13 Arg2:T14
0,T1,Visit 59 110	Endoscopy Center of Wuxi people's Hospital in China
1,T2,Procedure 40 51	colonoscopy
2,T3,Non-query-able 15 39	scheduled for undergoing
3,R1,AND Arg1:T2 Arg2:T3
4,R2,AND Arg1:T2 Arg2:T1
5,T4,Parsing_Error 0 2	1.
6,T5,Parsing_Error 112 114	2.
7,T6,Value 115 127;139 141	Greater than 18
8,T7,Person 132 135	age
9,R3,Has_value Arg1:T7 Arg2:T6
10,T8,Parsing_Error 143 145	3.
11,T9,Non-query-able 146 190	Individuals living with other family members
12,T10,Parsing_Error 192 194	4.
13,T11,Visit 195 206	Outpatients
0,T1,Condition 19 50	passive extension deficit (PED)
1,T2,Qualifier 14 18	=20°
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Qualifier 113 118;54 78	joint metacarpophalangeal (MP)
4,T4,Qualifier 82 118	proximal interphalangeal (PIP) joint
5,*,OR T3 T4
6,T5,Scope 54 118	metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint
7,R2,Has_scope Arg1:T1 Arg2:T5
8,T6,Condition 123 127	TPED
9,T7,Qualifier 131 135	=30°
10,T8,Qualifier 139 141	MP
11,T9,Qualifier 146 156	PIP joints
12,T10,Qualifier 160 179	finger/fingers II-V
13,R3,Has_qualifier Arg1:T6 Arg2:T7
14,R4,Has_qualifier Arg1:T6 Arg2:T8
15,R5,Has_qualifier Arg1:T6 Arg2:T9
16,R6,Has_qualifier Arg1:T6 Arg2:T10
17,T11,Person 181 184	age
18,T12,Value 185 195	> 18 years
19,R7,Has_value Arg1:T11 Arg2:T12
20,T13,Condition 197 210	palpable cord
21,T14,Informed_consent 212 241	provision of informed consent
22,T15,Non-query-able 243 298	ability to fill the Finnish versions of questionnaires.
0,T1,Procedure 14 35	heart transplantation
1,T2,Condition 50 73	coronary artery disease
2,T3,Person 75 78	Age
3,T4,Value 79 102	between 18 and 80 years
4,R1,Has_value Arg1:T3 Arg2:T4
0,T1,Person 16 32	African American
1,T2,Observation 34 40	Smokes
2,T3,Multiplier 41 62	= 1 cigarette per day
3,R1,Has_multiplier Arg1:T2 Arg2:T3
4,T4,Observation 70 75	Smoke
5,T5,Multiplier 79 108	= 25 days of the past 30 days
6,R2,Has_multiplier Arg1:T4 Arg2:T5
7,T6,Non-query-able 110 131	Functioning telephone
8,T7,Mood 133 143	Interested
9,T8,Observation 147 163	quitting smoking
10,R3,Has_mood Arg1:T8 Arg2:T7
11,T9,Post-eligibility 133 163	Interested in quitting smoking
12,T10,Post-eligibility 165 209	Interested in taking 3 months of varenicline
13,T11,Post-eligibility 211 247	Willing to complete all study visits
0,T1,Temporal 0 7	Current
1,T2,Temporal 11 18	chronic
2,*,OR T2 T1
3,T3,Observation 19 26	history
4,T4,Condition 30 43	liver disease
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Scope 0 18	Current or chronic
7,R2,Has_scope Arg1:T4 Arg2:T5
8,T6,Condition 65 86	biliary abnormalities
9,T7,Condition 54 61;73 86	hepatic abnormalities
10,*,OR T7 T6 T4
11,T8,Condition 110 128	Gilbert's syndrome
12,T9,Negation 97 106	exception
13,T10,Condition 145 155	gallstones
14,T11,Qualifier 132 144	asymptomatic
15,R3,Has_qualifier Arg1:T10 Arg2:T11
16,*,OR T10 T8
17,R4,Has_negation Arg1:T8 Arg2:T9
18,R5,Has_negation Arg1:T10 Arg2:T9
19,T12,Scope 88 156	with the exception of Gilbert's syndrome or asymptomatic gallstones)
20,T13,"Scope 30 86	liver disease, or known hepatic or biliary abnormalities"
21,R6,Has_scope Arg1:T13 Arg2:T12
22,T14,Condition 170 197	regular alcohol consumption
23,T15,Observation 159 166	History
24,R7,Has_temporal Arg1:T14 Arg2:T15
25,T16,Temporal 198 226	within 6 months of the study
26,T17,Reference_point 217 226	the study
27,R8,Has_index Arg1:T16 Arg2:T17
28,T18,Measurement 242 263	average weekly intake
29,T19,Value 267 276	>21 units
30,T20,Person 281 286	males
31,T21,Value 290 299	>14 units
32,T22,Person 304 311	females
33,R9,Has_value Arg1:T22 Arg2:T21
34,R10,Has_value Arg1:T20 Arg2:T19
35,A1,Optional T20
36,A2,Optional T22
37,*,OR T22 T20
38,T23,Scope 267 311	>21 units for males or >14 units for females
39,R11,Has_scope Arg1:T18 Arg2:T23
40,R12,AND Arg1:T14 Arg2:T18
41,R13,Has_temporal Arg1:T14 Arg2:T16
42,T24,"Parsing_Error 313 472	One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 milliliter [mL]) of beer, 1 glass (100 mL) of wine or 1 (25 mL) measure of spirits."
43,T25,Condition 485 507	sensitivity to heparin
44,T26,Drug 500 507	heparin
45,T27,Condition 511 543	heparin-induced thrombocytopenia
46,T28,Qualifier 511 526	heparin-induced
47,T29,Drug 511 518	heparin
48,*,OR T27 T25
49,T30,Drug 583 600	study medications
50,T31,Context_Error 583 600	study medications
51,T32,Condition 557 600	sensitivity to any of the study medications
52,T33,Context_Error 557 600	sensitivity to any of the study medications
53,T34,Observation 546 553	History
54,T35,Condition 640 644;654 661	drug allergy
55,T36,Condition 654 661	allergy
56,*,OR T35 T36 T32
57,T37,Subjective_judgement 668 725	in the opinion of the investigator or GSK Medical Monitor
58,T38,Undefined_semantics 727 762	contraindicates their participation
59,T39,Subjective_judgement 727 762	contraindicates their participation
60,T40,Condition 765 789	Gastrointestinal disease
61,T41,Observation 798 831	gastrointestinal surgical history
62,T42,Procedure 798 823	gastrointestinal surgical
63,T43,Qualifier 842 894	affect the absorption of the investigational product
64,T44,Context_Error 842 894	affect the absorption of the investigational product
65,T45,Undefined_semantics 842 894	affect the absorption of the investigational product
66,*,OR T41 T40
67,T46,Measurement 918 945	Hepatitis B surface antigen
68,T47,Value 899 907	positive
69,R14,Has_value Arg1:T46 Arg2:T47
70,T48,Temporal 908 917	pre-study
71,R15,Has_temporal Arg1:T46 Arg2:T48
72,T49,Measurement 958 978	Hepatitis C antibody
73,T50,Value 949 957	positive
74,R16,Has_value Arg1:T49 Arg2:T50
75,T51,Temporal 986 1014	within 3 months of screening
76,T52,Reference_point 1005 1014	screening
77,R17,Has_index Arg1:T51 Arg2:T52
78,*,OR T49 T46
79,T53,Scope 899 978	positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
80,R18,Has_temporal Arg1:T53 Arg2:T51
81,T54,Grammar_Error 1024 1032	cotinine
82,T55,Measurement 1016 1039	Urinary cotinine levels
83,T56,Condition 1054 1061	smoking
84,T57,Condition 1076 1098	regular use of tobacco
85,T58,Observation 1065 1072	history
86,R19,Has_temporal Arg1:T57 Arg2:T58
87,R20,AND Arg1:T56 Arg2:T55
88,T59,Condition 1076 1090;1103 1131	regular use of nicotine-containing products
89,T60,Temporal 1132 1166	within 6 months prior to screening
90,T61,Reference_point 1157 1166	screening
91,R22,Has_index Arg1:T60 Arg2:T61
92,*,OR T59 T57 T56
93,R21,Has_temporal Arg1:T59 Arg2:T58
94,T62,Scope 1016 1131	Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products
95,R23,Has_temporal Arg1:T62 Arg2:T60
96,T63,Temporal 1180 1189	pre-study
97,T64,Measurement 1190 1194;1203 1209	drug screen
98,T65,Measurement 1195 1209	alcohol screen
99,*,OR T65 T64
100,T66,Scope 1190 1209	drug/alcohol screen
101,R24,Has_temporal Arg1:T66 Arg2:T63
102,T67,Value 1171 1179	positive
103,R25,Has_value Arg1:T66 Arg2:T67
104,T68,Measurement 1232 1275	Human Immunodeficiency Virus (HIV) antibody
105,T69,Value 1214 1222	positive
106,R26,Has_value Arg1:T68 Arg2:T69
107,T70,Condition 1278 1286	Pregnant
108,T71,Person 1287 1294	females
109,T72,Measurement 1321 1335	serum hCG test
110,T73,Value 1312 1320	positive
111,R27,Has_value Arg1:T72 Arg2:T73
112,R28,Subsumes Arg1:T70 Arg2:T72
113,T74,Temporal 1336 1348	at screening
114,T75,Temporal 1352 1367	prior to dosing
115,T76,Reference_point 1339 1348	screening
116,T77,Reference_point 1361 1367	dosing
117,R29,Has_index Arg1:T75 Arg2:T77
118,*,OR T74 T75
119,R30,Has_index Arg1:T74 Arg2:T76
120,T78,Scope 1336 1367	at screening or prior to dosing
121,R31,Has_scope Arg1:T72 Arg2:T78
122,T79,Non-query-able 1370 1498	Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.
123,T80,Undefined_semantics 1370 1498	Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.
124,T81,Context_Error 1370 1498	Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.
125,T82,Person 1510 1517	females
126,T83,Condition 1500 1509	Lactating
127,T84,"Undefined_semantics 1520 1820	The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)."
128,T85,"Post-eligibility 1520 1820	The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)."
129,T86,Multiplier 1834 1848	more than four
130,T87,Drug 1849 1870	new chemical entities
131,T88,Undefined_semantics 1849 1870	new chemical entities
132,R32,Has_multiplier Arg1:T87 Arg2:T86
133,T89,Temporal 1871 1917	within 12 months prior to the first dosing day
134,T90,Reference_point 1897 1917	the first dosing day
135,R33,Has_index Arg1:T89 Arg2:T90
136,R34,Has_temporal Arg1:T87 Arg2:T89
0,T1,Post-eligibility 0 71	Informed consent as documented by signature (see informed consent form)
1,T2,Condition 73 84	Primary ITP
2,T3,Measurement 102 126	definition of Rodeghiero
3,T4,Measurement 145 159	platelet count
4,T5,Value 163 172	<30x109/l
5,R1,Has_value Arg1:T4 Arg2:T5
6,T6,Scope 102 172	definition of Rodeghiero et al. (52) and a platelet count of <30x109/l
7,R2,AND Arg1:T6 Arg2:T2
8,T7,Person 174 177	Age
9,T8,Value 185 196	18-45 years
10,R3,Has_value Arg1:T7 Arg2:T8
11,T9,Observation 198 216	Previously treated
12,T10,Procedure 258 276	first-line therapy
13,T11,Qualifier 232 239	failure
14,T12,Qualifier 243 254	intolerance
15,R4,Has_qualifier Arg1:T10 Arg2:T12
16,R5,Has_qualifier Arg1:T10 Arg2:T11
17,T13,Condition 281 288	relapse
18,T14,Temporal 289 313	after first-line therapy
19,T15,Reference_point 295 313	first-line therapy
20,T16,Procedure 295 313	first-line therapy
21,R6,multi Arg1:T15 Arg2:T16
22,R7,Has_index Arg1:T14 Arg2:T15
23,R8,Has_temporal Arg1:T13 Arg2:T14
24,*,OR T10 T13
25,T17,Drug 320 335	corticosteroids
26,T18,Drug 337 363	intravenous immunoglobulin
27,T19,Drug 375 397	anti-D immunoglobulins
28,*,OR T17 T18 T19
29,T20,Drug 365 369	IVIG
30,R9,Subsumes Arg1:T18 Arg2:T20
0,T1,Person 0 3	Age
1,T2,Value 3 12	>18 years
2,T3,Qualifier 29 36	2-level
3,T4,Qualifier 24 25;30 36	1 -level
4,T5,Procedure 37 55	ACDF spine surgery
5,*,OR T4 T3
6,T6,Scope 24 36	1 or 2-level
7,R1,Has_scope Arg1:T5 Arg2:T6
8,T7,Non-query-able 57 98	The capacity to provide informed consent.
9,T8,Condition 100 125	Degenerative Disc Disease
10,T9,Condition 141 150	neck pain
11,T10,Qualifier 154 171	discogenic origin
12,R2,Has_qualifier Arg1:T9 Arg2:T10
13,T11,Condition 177 201	degeneration of the disc
14,T12,Observation 215 230	patient history
15,T13,Procedure 235 255	radiographic studies
16,R3,Has_temporal Arg1:T11 Arg2:T12
17,R4,AND Arg1:T11 Arg2:T13
18,R5,AND Arg1:T9 Arg2:T11
19,T14,Condition 258 264	Trauma
20,T15,Condition 276 285	fractures
21,R6,Subsumes Arg1:T14 Arg2:T15
22,T16,Condition 288 294	Tumors
23,T17,Condition 296 307	Deformities
24,T18,Condition 311 321	curvatures
25,T19,Condition 333 341	kyphosis
26,T20,Condition 343 351	lordosis
27,T21,Condition 356 365	scoliosis
28,*,OR T21 T20 T19
29,T22,"Scope 333 365	kyphosis, lordosis, or scoliosis"
30,*,OR T17 T18
31,T23,Scope 296 321	Deformities or curvatures
32,R7,Subsumes Arg1:T23 Arg2:T22
33,T24,Condition 368 383	Pseudoarthrosis
34,T25,Procedure 401 407	fusion
35,T26,Qualifier 385 391	Failed
36,T27,Temporal 392 400	previous
37,R8,Has_temporal Arg1:T25 Arg2:T27
38,R9,Has_qualifier Arg1:T25 Arg2:T26
39,T28,Procedure 409 441	Decompression of the spinal cord
40,T29,Procedure 461 491	partial cervical vertebrectomy
41,T30,Procedure 452 457;469 491	total cervical vertebrectomy
42,*,OR T30 T29
43,T31,Scope 452 491	total or partial cervical vertebrectomy
44,R10,AND Arg1:T31 Arg2:T28
45,T32,Condition 493 510	Spondylolisthesis
46,T34,Temporal 554 560	recent
47,T35,Temporal 543 550	current
48,T36,Observation 561 568	history
49,T37,Condition 572 582	malignancy
50,T38,Condition 586 604	infectious disease
51,T33,Condition 512 527	Spinal stenosis
52,T39,Non-query-able 607 649	The inability to provide informed consent.
53,T40,Condition 670 688	local inflammation
54,T41,Qualifier 663 669	marked
55,R11,Has_qualifier Arg1:T40 Arg2:T41
56,T42,Condition 706 712;730 738	mental disorder
57,T43,Condition 716 738	neuromuscular disorder
58,*,OR T43 T42
59,T44,Condition 782 798	fixation failure
60,T45,Qualifier 761 773	unacceptable
61,T46,Condition 802 815	complications
62,T47,Mood 774 781	risk of
63,*,OR T46 T44
64,T48,Scope 782 815	fixation failure or complications
65,R12,Has_mood Arg1:T48 Arg2:T47
66,R13,Has_qualifier Arg1:T48 Arg2:T45
67,T49,Scope 706 738	mental or neuromuscular disorder
68,R14,Has_scope Arg1:T49 Arg2:T48
69,T50,Condition 854 876	bone stock compromised
70,T51,Condition 880 887	disease
71,T52,Condition 889 898	infection
72,T53,Procedure 908 920	implantation
73,T54,Temporal 902 907	prior
74,T55,Observation 942 958	adequate support
75,T56,Procedure 966 989	fixation to the devices
76,*,OR T55 T56
77,T57,Measurement 927 933	cannot
78,T58,Scope 942 989	adequate support and/or fixation to the devices
79,R15,AND Arg1:T58 Arg2:T57
80,R16,Has_temporal Arg1:T53 Arg2:T54
81,R17,Has_scope Arg1:T53 Arg2:T58
82,*,OR T52 T51 T53
83,T59,"Scope 880 989	disease, infection or prior implantation which cannot provide adequate support and/or fixation to the devices"
84,R18,Has_scope Arg1:T50 Arg2:T59
85,T60,Condition 1004 1022	bone abnormalities
86,T61,Procedure 1039 1053	screw fixation
87,T62,Negation 1023 1033	preventing
88,T63,Qualifier 1034 1038	safe
89,R19,Has_qualifier Arg1:T61 Arg2:T63
90,R20,Has_negation Arg1:T61 Arg2:T62
91,T64,Scope 1023 1053	preventing safe screw fixation
92,R21,Has_scope Arg1:T60 Arg2:T64
93,T65,Condition 1098 1117	rapid joint disease
94,T66,Condition 1119 1134	bone absorption
95,T67,Condition 1136 1146	osteopenia
96,T68,Condition 1148 1160	osteomalacia
97,T69,Condition 1169 1181	osteoporosis
98,*,OR T68 T69 T67 T66 T65
99,T70,Condition 1183 1195	Osteoporosis
100,T71,Condition 1199 1209	osteopenia
101,T72,Condition 1223 1240	contraindications
102,T73,Qualifier 1214 1222	relative
103,R22,Has_qualifier Arg1:T72 Arg2:T73
104,*,OR T70 T71
105,R23,Subsumes Arg1:T67 Arg2:T71
106,R24,Subsumes Arg1:T69 Arg2:T70
107,R25,AND Arg1:T71 Arg2:T72
108,R26,AND Arg1:T70 Arg2:T72
109,T74,Condition 1396 1407	sensitivity
110,T75,Device 1390 1395	metal
111,T76,Mood 1366 1376	documented
112,T77,Mood 1380 1389	suspected
113,*,OR T77 T76
114,T78,Scope 1366 1389	documented or suspected
115,R27,AND Arg1:T74 Arg2:T75
116,R28,Has_scope Arg1:T74 Arg2:T78
117,T79,Condition 1421 1429	pregnant
118,T80,Observation 1444 1465	anatomical structures
119,T81,Observation 1469 1494	physiological performance
120,T82,Observation 1506 1520;1529 1540	interfere with utilization
121,T83,Device 1521 1528	implant
122,R29,AND Arg1:T82 Arg2:T83
123,*,OR T80 T81
124,T84,Scope 1444 1494	anatomical structures or physiological performance
125,R30,Has_context Arg1:T84 Arg2:T82
126,T85,Condition 1555 1581	inadequate tissue coverage
127,T86,Qualifier 1591 1605	operative site
128,R31,Has_qualifier Arg1:T85 Arg2:T86
129,T87,Condition 1637 1656	surgical conditions
130,T88,Condition 1626 1633;1646 1656	medical conditions
131,T89,Negation 1669 1677	preclude
132,T90,Procedure 1703 1710	surgery
133,T91,Condition 1720 1744	congenital abnormalities
134,T92,Condition 1746 1771	immunosuppressive disease
135,T93,Value 1773 1782	elevation
136,T94,Measurement 1786 1804	sedimentation rate
137,R32,Has_value Arg1:T94 Arg2:T93
138,T95,Qualifier 1805 1834	unexplained by other diseases
139,T96,Value 1836 1845	elevation
140,T97,Measurement 1849 1872	white blood count (WBC)
141,R33,Has_value Arg1:T97 Arg2:T96
142,T98,Value 1884 1894	left shift
143,T99,Measurement 1902 1924	WBC differential count
144,R34,Has_value Arg1:T99 Arg2:T98
145,R35,Has_qualifier Arg1:T94 Arg2:T95
146,*,OR T92 T94 T97 T99
147,T100,"Non-representable 1927 2281	Note: The Aviator Anterior Cervical Plating System is not approved or intended for screw attachment to the posterior elements (pedicles) of the cervical, thoracic, or lumbar spine. The surgeon must consider the levels of implantation, patient weight, patient activity level, and other patient conditions which may impact on the performance of the system."
148,T101,Condition 1072 1083	open wounds
0,T1,Visit 0 10	Inpatients
1,T2,Procedure 18 46	major foot and ankle surgery
2,T3,Device 119 138	indwelling catheter
3,R1,AND Arg1:T2 Arg2:T3
4,T4,Procedure 81 110	popliteal sciatic nerve block
5,T5,Qualifier 70 80	continuous
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Measurement 140 174;181 196	American Society Anesthesiologists physical status
8,T7,Measurement 176 179	ASA
9,R3,Subsumes Arg1:T6 Arg2:T7
10,T8,Value 197 202	I-III
11,R4,Has_value Arg1:T6 Arg2:T8
12,T9,Person 219 222	age
13,T10,Value 204 215	18-85 years
14,R5,Has_value Arg1:T9 Arg2:T10
15,T11,Person 242 244	kg
16,T12,Value 235 241	40-120
17,R6,Has_value Arg1:T11 Arg2:T12
18,T13,Person 267 273	height
19,T14,Value 257 263;274 284	150 cm or greater
20,R7,Has_value Arg1:T13 Arg2:T14
0,T1,Informed_consent 0 40	Patients unable to give informed consent
1,T2,Condition 61 70	condition
2,T3,Negation 76 79	not
3,T4,Mood 80 85	allow
4,T5,Procedure 90 99	placement
5,T6,Device 107 123	electrode PadSet
6,R1,AND Arg1:T5 Arg2:T6
7,R2,Has_mood Arg1:T5 Arg2:T4
8,R3,Has_negation Arg1:T4 Arg2:T3
9,R4,AND Arg1:T2 Arg2:T5
10,T7,Procedure 159 168	extubated
11,T8,Qualifier 141 149	tracheas
12,T9,Negation 155 158	not
13,R5,Has_negation Arg1:T7 Arg2:T9
14,R6,Has_qualifier Arg1:T7 Arg2:T8
15,T10,Visit 172 174	OR
16,T11,Visit 178 182	PACU
17,*,OR T10 T11
18,T12,Scope 172 182	OR or PACU
19,R7,Has_scope Arg1:T7 Arg2:T12
20,T13,Condition 199 222	Impaired Renal Function
21,T14,Measurement 243 257	estimated CrCl
22,T15,Value 257 267	<30 ml/min
23,R8,Has_value Arg1:T14 Arg2:T15
24,T16,Procedure 284 302	oral contraception
25,T17,Drug 284 302	oral contraception
26,R9,multi Arg1:T16 Arg2:T17
0,T1,Person 0 4	Male
1,T2,Person 9 16	females
2,T3,Grammar_Error 5 8	and
3,*,OR T2 T1
4,T4,Person 17 21	aged
5,T5,Value 22 45	between 18 and 65 years
6,R1,Has_value Arg1:T4 Arg2:T5
7,T6,Person 49 52	age
8,R2,Has_value Arg1:T6 Arg2:T5
9,*,OR T6 T4
10,T7,Temporal 64 107	at the time of signing the informed consent
11,T8,Reference_point 79 107	signing the informed consent
12,R3,Has_index Arg1:T7 Arg2:T8
13,R4,Has_temporal Arg1:T5 Arg2:T7
14,T9,Condition 110 117	Healthy
15,T10,Qualifier 118 174	as determined by a responsible and experienced physician
16,T11,Subjective_judgement 118 174	as determined by a responsible and experienced physician
17,T12,Undefined_semantics 118 174	as determined by a responsible and experienced physician
18,T13,Procedure 187 205	medical evaluation
19,T14,Observation 216 231	medical history
20,T15,Procedure 233 253	physical examination
21,T16,Procedure 255 271	laboratory tests
22,T17,Procedure 276 294	cardiac monitoring
23,R5,AND Arg1:T9 Arg2:T13
24,R6,Has_temporal Arg1:T9 Arg2:T14
25,R7,AND Arg1:T9 Arg2:T15
26,R8,AND Arg1:T9 Arg2:T16
27,R9,AND Arg1:T9 Arg2:T17
28,T18,Condition 313 333	clinical abnormality
29,T19,Context_Error 370 436	are not specifically listed in the inclusion or exclusion criteria
30,T20,Value 438 465	outside the reference range
31,T21,Measurement 337 357	laboratory parameter
32,T22,Undefined_semantics 337 357	laboratory parameter
33,R10,Has_value Arg1:T21 Arg2:T20
34,T23,Context_Error 499 514	may be included
35,T24,"Non-query-able 296 731	A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures."
36,T25,"Post-eligibility 296 728	A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedur"
37,T26,Measurement 733 744	Body weight
38,T27,Value 745 764	>= 50 kilogram (kg)
39,T28,Measurement 769 784	body mass index
40,T29,Value 785 818	within the range 19 - 24.9 kg/m^2
41,R11,Has_value Arg1:T28 Arg2:T29
42,R12,Has_value Arg1:T26 Arg2:T27
43,T30,Condition 895 917	childbearing potential
44,T31,Negation 891 894	Non
45,R13,Has_negation Arg1:T30 Arg2:T31
46,T32,Condition 929 943	pre-menopausal
47,T33,Person 944 951	females
48,T34,Person 835 841	female
49,T35,Procedure 970 984	tubal ligation
50,T36,Procedure 988 1000	hysterectomy
51,*,OR T35 T36
52,T37,Condition 1247 1261	postmenopausal
53,T38,Temporal 1273 1282	12 months
54,T39,Condition 1286 1308	spontaneous amenorrhea
55,R14,Has_temporal Arg1:T39 Arg2:T38
56,T40,Measurement 1365 1399	follicle stimulating hormone (FSH)
57,T41,Value 1400 1454	> 40 milli-international units per milliliter (MlU/mL)
58,R15,Has_value Arg1:T40 Arg2:T41
59,T42,Measurement 1459 1468	estradiol
60,T43,Value 1469 1505	< 40 picograms per mililiter (pg/mL)
61,T44,Value 1507 1530	<147 picomole per liter
62,R16,Subsumes Arg1:T43 Arg2:T44
63,R17,Has_value Arg1:T42 Arg2:T43
64,T45,Scope 1365 1530	follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter
65,R18,Subsumes Arg1:T39 Arg2:T45
66,R19,Subsumes Arg1:T37 Arg2:T39
67,T46,Scope 929 1000	pre-menopausal females with a documented tubal ligation or hysterectomy
68,*,OR T46 T39
69,T47,"Scope 929 1548	pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, ""documented"" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter] is confirmatory]"
70,R20,Subsumes Arg1:T30 Arg2:T47
71,T48,Procedure 1561 1594	hormone replacement therapy (HRT)
72,T49,Person 1550 1557	Females
73,T50,Measurement 1605 1622	menopausal status
74,T51,Value 1626 1634	in doubt
75,R21,Has_value Arg1:T50 Arg2:T51
76,T52,Not_a_criteria 1550 1744	Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study.
77,T53,"Parsing_Error 1745 1856	Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment."
78,T54,"Not_a_criteria 1745 1856	Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment."
79,T55,Parsing_Error 1550 1744	Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study.
80,T56,"Parsing_Error 1857 2016	For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT."
81,T57,"Not_a_criteria 1857 2016	For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT."
82,T58,"Parsing_Error 2017 2553	Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing AND; Agrees to use one of the contraception methods listed in protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point."
83,T59,"Post-eligibility 2017 2553	Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing AND; Agrees to use one of the contraception methods listed in protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point."
84,T60,"Not_a_criteria 2554 2715	Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle."
85,T61,"Non-query-able 2554 2715	Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle."
86,T62,"Post-eligibility 2554 2715	Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle."
87,T63,Context_Error 2717 2849	Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Protocol.
88,T64,Post-eligibility 2717 2849	Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Protocol.
89,T65,Parsing_Error 2850 2968	This criterion must be followed from the time of the first dose of study medication until the follow-up contact visit.
90,T66,Post-eligibility 2850 2968	This criterion must be followed from the time of the first dose of study medication until the follow-up contact visit.
91,T67,"Non-query-able 2970 3105	Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form"
92,T68,Measurement 3107 3131	Alanine aminotransferase
93,T69,Measurement 3133 3153	alkaline phosphatase
94,T70,Measurement 3158 3167	bilirubin
95,T71,"Scope 3107 3167	Alanine aminotransferase, alkaline phosphatase and bilirubin"
96,T72,Value 3168 3202	<=1.5x upper limit of normal (ULN)
97,R22,Has_value Arg1:T71 Arg2:T72
98,T73,Measurement 3213 3222	bilirubin
99,T74,Value 3223 3231	>1.5xULN
100,R23,Has_value Arg1:T73 Arg2:T74
101,T75,Measurement 3279 3295	direct bilirubin
102,T76,Grammar_Error 3203 3301	(isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
103,T77,Measurement 3440 3444	QTcF
104,T78,Value 3445 3455	< 450 msec
105,R24,Has_value Arg1:T77 Arg2:T78
106,T79,Qualifier 3313 3319	single
107,T80,Qualifier 3323 3331	averaged
108,*,OR T80 T79
109,T81,Scope 3313 3331	single or averaged
110,T82,Measurement 3332 3359	corrected QT interval (QTc)
111,T83,Procedure 3381 3399	electrocardiograms
112,T84,Temporal 3409 3438	over a brief recording period
113,R25,Has_temporal Arg1:T83 Arg2:T84
114,R26,Subsumes Arg1:T82 Arg2:T77
115,R27,Has_value Arg1:T82 Arg2:T78
116,R28,Has_scope Arg1:T82 Arg2:T81
117,R29,Has_scope Arg1:T77 Arg2:T81
118,R30,AND Arg1:T82 Arg2:T83
119,R31,AND Arg1:T77 Arg2:T83
0,T1,Person 0 6	Adults
1,T2,Value 7 20	older than 45
2,T3,Person 25 33	children
3,T4,Value 34 55	younger than 18 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,R2,Has_value Arg1:T1 Arg2:T2
6,T5,Measurement 57 71	Platelet count
7,T6,Value 72 92	higher than 30x109/l
8,T7,Temporal 93 113	at time of screening
9,T8,Reference_point 104 113	screening
10,R3,Has_index Arg1:T7 Arg2:T8
11,R4,Has_value Arg1:T5 Arg2:T6
12,R5,Has_temporal Arg1:T5 Arg2:T7
13,T9,Condition 128 141	secondary ITP
14,T10,Observation 152 174	family history for ITP
15,T11,Parsing_Error 143 151	Positive
16,T12,Condition 199 217	autoimmune disease
17,T13,Parsing_Error 176 195	Presence or history
18,T14,Subjective_judgement 218 247	as judged by the investigator
19,T15,Subjective_judgement 317 346	as judged by the investigator
20,T16,Subjective_judgement 394 423	as judged by the investigator
21,T17,Condition 301 316	hepatic disease
22,T18,Qualifier 292 300	relevant
23,R6,Has_qualifier Arg1:T17 Arg2:T18
24,T19,Parsing_Error 269 288	Presence or history
25,T20,Parsing_Error 348 367	Presence or history
26,T21,Condition 371 393	thromboembolic disease
27,T22,Procedure 439 450	splenectomy
28,T23,Pregnancy_considerations 452 492	Women who are pregnant or breast feeding
29,T24,Pregnancy_considerations 494 553	Intention to become pregnant during the course of the study
30,T25,Pregnancy_considerations 555 598	Lack of safe double contraception (see 7.1)
31,T26,Procedure 604 615	vaccination
32,T27,Temporal 616 648	2 weeks prior start of the study
33,T28,Reference_point 630 648	start of the study
34,R7,Has_index Arg1:T27 Arg2:T28
35,R8,Has_temporal Arg1:T26 Arg2:T27
36,T29,Subjective_judgement 650 809	Drugs with a known impact on the immune system or on platelet function must be recorded and an exclusion of the study should be discussed with the study center
37,T30,Condition 854 867	alcohol abuse
38,T31,Condition 846 850;862 867	drug abuse
39,*,OR T30 T31
40,T32,Qualifier 830 844	non-compliance
41,T33,Scope 846 867	drug or alcohol abuse
42,R9,Has_qualifier Arg1:T33 Arg2:T32
43,T34,"Post-eligibility 869 1003	Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia of the study subject"
44,T35,Non-query-able 1005 1119	Participation in another study with investigational drug within the 30 days preceding and during the present study
45,T36,Non-query-able 1121 1162	Previous enrolment into the current study
46,T37,Drug 1188 1199	romiplostim
47,T38,Drug 1203 1214	eltrombopag
48,*,OR T37 T38
49,T39,Condition 1216 1232	Hypersensitivity
50,T40,"Non-query-able 1317 1409	Enrolment of the investigator, his/her family members, employees and other dependent persons"
51,T41,Non-query-able 1233 1315	to the active substance or to any of the excipients or to E. coli derived proteins
52,T42,Condition 249 267	Hepatosplenomegaly
0,T1,Procedure 20 27	surgery
1,T2,Temporal 9 19	undergoing
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Qualifier 33 51	general anesthesia
4,R2,Has_qualifier Arg1:T1 Arg2:T3
5,T4,Procedure 33 51	general anesthesia
6,R3,multi Arg1:T3 Arg2:T4
7,T5,Measurement 63 71	weighing
8,T6,Value 72 83	= 80 pounds
9,T7,Negation 92 95	not
10,T8,Procedure 97 106	intubated
11,T9,Temporal 107 123	prior to surgery
12,T10,Reference_point 116 123	surgery
13,T11,Procedure 116 123	surgery
14,R4,multi Arg1:T10 Arg2:T11
15,R5,Has_index Arg1:T9 Arg2:T10
16,R6,Has_temporal Arg1:T8 Arg2:T9
17,R7,Has_negation Arg1:T8 Arg2:T7
18,R8,Has_value Arg1:T5 Arg2:T6
19,T12,Informed_consent 126 172	Patients who are able to give informed consent
0,T1,Procedure 21 54	iliac crest bone graft harvesting
1,T2,Condition 93 114	neurological deficits
2,T3,Condition 118 139	peripheral neuropathy
3,T4,Qualifier 167 180	sciatic nerve
4,*,OR T2 T3
5,T5,Scope 93 139	neurological deficits or peripheral neuropathy
6,R1,Has_qualifier Arg1:T5 Arg2:T4
7,T6,Condition 182 197	Local infection
8,T7,Condition 199 215	Contraindication
9,T8,Procedure 219 238	regional anesthesia
10,T9,Condition 244 262	bleeding diathesis
11,T10,Condition 264 276	coagulopathy
12,*,OR T9 T10
13,T11,"Scope 244 276	bleeding diathesis, coagulopathy"
14,R2,Subsumes Arg1:T7 Arg2:T11
15,R3,AND Arg1:T7 Arg2:T8
16,T12,Condition 278 290	Chronic pain
17,T13,Multiplier 320 329;354 361	over 30mg per day
18,T14,Drug 330 339	oxycodone
19,T15,Drug 330 339;343 353	oxycodone equivalent
20,*,OR T14 T15
21,T16,Scope 330 353	oxycodone or equivalent
22,R4,Has_multiplier Arg1:T16 Arg2:T13
23,T17,Procedure 374 391	local anesthetics
24,T18,Condition 363 370	Allergy
25,R5,AND Arg1:T18 Arg2:T17
26,T19,Non-query-able 393 473	History of significant psychiatric conditions that may affect patient assessment
27,T20,Condition 475 484	Pregnancy
28,T21,Informed_consent 486 523	Inability to provide informed consent
0,T1,Condition 0 4	T2DM
1,T2,Qualifier 19 63	American Diabetes Association (ADA) criteria
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Person 65 70	Adult
4,T4,Condition 85 89	T2DM
5,T5,Drug 119 130	liraglutide
6,T6,Mood 98 118	indicated to receive
7,T7,Qualifier 139 157	first-line therapy
8,T8,Negation 132 135	not
9,R2,Has_negation Arg1:T7 Arg2:T8
10,R3,Has_qualifier Arg1:T5 Arg2:T7
11,T9,Non-representable 159 219	in addition to diet and exercise to improve glycemic control
12,R4,Has_mood Arg1:T5 Arg2:T6
13,T10,Measurement 221 243	Hemoglobin A1c (HbA1c)
14,T11,Value 244 248	= 9%
15,R5,Has_value Arg1:T10 Arg2:T11
16,T12,Person 250 253	Age
17,T13,Value 254 268	= 18 years old
18,R6,Has_value Arg1:T12 Arg2:T13
19,T14,Measurement 270 291	Body mass index (BMI)
20,T15,Value 292 302	= 27 Kg/m2
21,T16,Measurement 310 329	waist circumference
22,T17,Value 330 338	= 102 cm
23,T18,Value 340 349	40 inches
24,R7,Subsumes Arg1:T17 Arg2:T18
25,T19,Person 354 357	men
26,T20,Value 362 367	88 cm
27,T21,Value 369 378	35 inches
28,R8,Subsumes Arg1:T20 Arg2:T21
29,T22,Person 383 388	women
30,A1,Optional T19
31,A2,Optional T22
32,R9,Has_value Arg1:T22 Arg2:T20
33,R10,Has_value Arg1:T19 Arg2:T17
34,*,OR T19 T22
35,T23,Scope 330 388	= 102 cm (40 inches) in men and 88 cm (35 inches) in women
36,R11,Has_scope Arg1:T16 Arg2:T23
37,R12,Has_value Arg1:T14 Arg2:T15
38,*,OR T14 T16
39,T24,Qualifier 420 443	angiographically stable
40,T25,Condition 444 447	CAD
41,T26,Procedure 461 465	CABG
42,T27,Mood 452 460	requires
43,R13,Has_mood Arg1:T26 Arg2:T27
44,R14,Has_qualifier Arg1:T25 Arg2:T24
45,T28,Qualifier 405 415;437 443	Clinically stable
46,R15,Has_qualifier Arg1:T25 Arg2:T28
47,T29,Non-representable 504 691	as CAD does not represent a contraindication for using liraglutide. The stability of the CAD further warranties that study patients will not be exposed to higher risk by using liraglutide
0,T1,Condition 17 23;31 39	lumbar diseases
1,T2,Condition 46 57	Lumbar disc
2,T3,Condition 59 81	Lumbar spinal stenosis
3,T4,Condition 83 98	Lumbar slippage
4,*,OR T2 T3 T4
5,T5,"Scope 46 99	Lumbar disc, Lumbar spinal stenosis, Lumbar slippage,"
6,R1,Subsumes Arg1:T1 Arg2:T5
7,T6,Condition 188 204	Spinal deformity
8,T7,"Condition 206 221	spine fracture,"
9,T8,Condition 222 244	ankylosing spondylitis
10,T9,Condition 246 265	spinal tuberculosis
11,T10,Condition 270 286	spinal infection
12,T11,Condition 288 300	spinal tumor
13,T12,Condition 302 329	pelvic inflammatory disease
14,*,OR T6 T7 T8 T9 T10 T11 T12
15,T13,Condition 407 430	nervous system diseases
16,T14,Condition 437 451	cerebral tumor
17,T15,Condition 453 462	neurinoma
18,T16,Condition 464 484	trigeminal neuralgia
19,*,OR T14 T15 T16
20,T17,"Scope 437 484	cerebral tumor, neurinoma, trigeminal neuralgia"
21,R2,Subsumes Arg1:T13 Arg2:T17
22,T18,Procedure 508 534	Magnetic resonance imaging
23,T19,Condition 535 551	contraindication
24,R3,AND Arg1:T19 Arg2:T18
25,T20,Condition 563 586	claustrophobic syndrome
26,R4,Subsumes Arg1:T19 Arg2:T20
27,T21,Non-query-able 601 698	atients with recent (less than 3 years) use chemical drugs or have obvious psychological problems
28,T22,Competing_trial 703 774	In the past 2 months involved in other drugs or devices clinical trials
0,T1,Observation 16 24;35 42	personal history
1,T2,Observation 28 42	family history
2,*,OR T2 T1
3,T3,Condition 46 73	medullary thyroid carcinoma
4,T4,Condition 91 135	Multiple Endocrine Neoplasia syndrome type 2
5,*,OR T3 T4
6,T5,Scope 16 42	personal or family history
7,T6,Scope 46 135	medullary thyroid carcinoma or patients with Multiple Endocrine Neoplasia syndrome type 2
8,R1,Has_scope Arg1:T6 Arg2:T5
9,T7,Condition 167 192	hypersensitivity reaction
10,T8,Drug 196 207	liraglutide
11,R2,AND Arg1:T7 Arg2:T8
12,T9,Temporal 153 158	prior
13,T10,Qualifier 159 166	serious
14,R3,Has_qualifier Arg1:T7 Arg2:T10
15,R4,Has_temporal Arg1:T7 Arg2:T9
16,T11,Drug 237 248	liraglutide
17,T12,Condition 215 233	contra-indications
18,R5,AND Arg1:T12 Arg2:T11
19,T13,Qualifier 209 214	Other
20,R6,Has_qualifier Arg1:T12 Arg2:T13
21,T14,Condition 353 368	Type 1 diabetes
22,T15,Qualifier 384 396	ADA criteria
23,R7,Has_qualifier Arg1:T14 Arg2:T15
24,T16,Drug 419 425	GLP-1A
25,T17,Qualifier 413 418	other
26,T18,Drug 427 456;498 508	dipeptidyl peptidase 4 (DPP4) inhibitors
27,T19,Drug 460 508	Sodium Glucose transporters 2 (SGLT2) inhibitors
28,T20,Drug 510 535	thiazolidinediones (TZDs)
29,T21,Drug 537 548	pramlintide
30,T22,Drug 559 575	prandial insulin
31,*,OR T21 T22 T20 T18 T19 T16
32,R8,Has_qualifier Arg1:T16 Arg2:T17
33,T23,Condition 592 604	unstable CAD
34,T24,Condition 653 669	new onset angina
35,T25,Condition 671 682	rest angina
36,T26,Condition 684 702;716 722	rapidly increasing angina
37,T27,Condition 706 722	crescendo angina
38,*,OR T26 T27 T25 T24
39,T28,"Scope 653 722	new onset angina, rest angina, rapidly increasing or crescendo angina"
40,R9,Subsumes Arg1:T23 Arg2:T28
41,T29,Condition 735 756	diabetic ketoacidosis
42,T30,Procedure 758 766;780 795	pancreas transplantation
43,T31,Procedure 770 795	beta-cell transplantation
44,T32,Condition 800 808	diabetes
45,T33,Procedure 822 834	pancreatitis
46,T34,Procedure 838 852	pancreatectomy
47,*,OR T33 T34
48,T35,Scope 822 852	pancreatitis or pancreatectomy
49,T36,Qualifier 809 821	secondary to
50,R10,Has_scope Arg1:T36 Arg2:T35
51,R11,Has_qualifier Arg1:T32 Arg2:T36
52,T37,Qualifier 854 859	acute
53,T38,Qualifier 863 870	chronic
54,T39,Condition 871 889	infective diseases
55,T40,Condition 891 897	cancer
56,T41,Procedure 901 913	chemotherapy
57,T42,Condition 946 960	liver diseases
58,T43,Condition 937 942;952 960	renal diseases
59,T44,Condition 926 935;952 960	pulmonary diseases
60,T45,Condition 966 976	drug abuse
61,*,OR T40 T41 T45 T43 T44 T42 T39 T32 T30 T31 T29
62,*,OR T37 T38
63,T46,Scope 854 870	acute or chronic
64,R12,Has_scope Arg1:T39 Arg2:T46
65,T47,Observation 724 731	History
66,T48,"Scope 735 976	diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy; acute or chronic infective diseases, cancer or chemotherapy, history of pulmonary, renal or liver diseases, and drug abuse"
67,R13,Has_temporal Arg1:T48 Arg2:T47
68,T49,Qualifier 992 999	chronic
69,T50,Qualifier 1004 1009	acute
70,*,OR T50 T49
71,T51,Condition 1010 1033	inflammatory conditions
72,T52,Condition 1042 1048	sepsis
73,T53,Condition 1050 1070	rheumatoid arthritis
74,T54,Condition 1072 1090	ectopic dermatitis
75,T55,Condition 1092 1098	asthma
76,T56,Condition 1100 1118	ulcerative colitis
77,*,OR T55 T56 T54 T53 T52
78,T57,"Scope 1042 1118	sepsis, rheumatoid arthritis, ectopic dermatitis, asthma, ulcerative colitis"
79,R14,Subsumes Arg1:T51 Arg2:T57
80,T58,Scope 992 1009	chronic and acute
81,R15,Has_scope Arg1:T51 Arg2:T58
82,T59,Temporal 1121 1128	Current
83,T60,Drug 1136 1160	systemic corticosteroids
84,T61,Temporal 1161 1193	in the 3 months prior this study
85,R16,Has_temporal Arg1:T60 Arg2:T59
86,R17,Has_temporal Arg1:T60 Arg2:T61
87,T62,Condition 1196 1204	Pregnant
88,T63,Condition 1208 1228	breast-feeding women
89,*,OR T63 T62
90,T64,Pregnancy_considerations 1230 1351	Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice)
0,T1,Condition 30 55	sacral perineurial cysts(
1,T2,Qualifier 18 29	symptomatic
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 76 89	perineal pain
4,T4,Condition 61 72;85 89	lumbosacral pain
5,T5,Condition 100 124	urinary functions change
6,T6,"Condition 108 125;91 96	functions change, fecal"
7,T7,Condition 126 148	sexual function change
8,T8,Condition 150 175	lower limb radiation pain
9,T9,Condition 177 189	muscle abate
10,T10,Condition 191 202	paresthesia
11,T11,"Scope 61 202	lumbosacral or perineal pain, fecal or urinary functions change, sexual function change, lower limb radiation pain, muscle abate, paresthesia"
12,*,OR T3 T4 T6 T5 T7 T8 T9 T10
13,R2,Subsumes Arg1:T1 Arg2:T11
14,T12,Measurement 213 232	Visual analog scale
15,T13,Value 233 256	more than or equal to 4
16,R3,Has_value Arg1:T12 Arg2:T13
17,T14,Informed_consent 261 288	Signed the informed consent
18,T15,Person 293 298	Years
19,T16,Value 306 311	18-60
20,R4,Has_value Arg1:T15 Arg2:T16
21,T17,Measurement 316 341	Self-rating anxiety scale
22,T18,Measurement 343 346	SAS
23,R5,Subsumes Arg1:T17 Arg2:T18
24,T19,Measurement 352 380	self-rating depression scale
25,T20,Measurement 382 385	SDS
26,R6,AND Arg1:T19 Arg2:T20
27,T21,Value 387 398	scores < 50
28,T22,Scope 316 385	Self-rating anxiety scale (SAS) and self-rating depression scale (SDS
29,R7,Has_value Arg1:T22 Arg2:T21
30,T23,Condition 434 457	Nervous system diseases
31,T24,Negation 403 405	No
32,T25,Condition 406 416;449 457	Congenital diseases
33,T26,Condition 417 423;449 456	Mental disease
34,T27,"Scope 406 456	Congenital,Mental and other Nervous system disease"
35,R8,Has_negation Arg1:T27 Arg2:T24
36,T28,Condition 503 520	Nephritic disease
37,T29,Condition 491 498	Hepatic
38,T30,Condition 481 490	Pulmonary
39,T31,Condition 473 480	Cardiac
40,*,OR T29 T28 T31 T30
41,T32,Condition 544 551	allergy
42,T33,Drug 539 543	drug
43,R9,AND Arg1:T32 Arg2:T33
44,T34,Negation 556 558	No
45,T35,Negation 462 464	No
46,T36,Negation 525 527	No
47,T37,"Condition 473 498	Cardiac,Pulmonary,Hepatic"
48,R10,Has_negation Arg1:T37 Arg2:T35
49,R11,Has_negation Arg1:T33 Arg2:T36
50,T38,Condition 559 563	pain
51,T39,Temporal 647 657	last month
52,T40,Condition 574 586	dysmenorrhea
53,T41,Drug 591 595	drug
54,R12,AND Arg1:T40 Arg2:T38
55,R13,Has_negation Arg1:T38 Arg2:T34
56,*,OR T38 T41
57,R14,Has_temporal Arg1:T41 Arg2:T39
58,T42,Non-query-able 607 619	antipyretics
59,T43,"Post-eligibility 783 908	MRI finding healthy volunteers don't have sacral perineurial cysts, included in the negative control groupblank control group"
60,T44,"Non-query-able 663 777	MRI finding of sacral perineurial cysts, but without any clinical symptoms, included in the negative control group"
0,T1,Qualifier 14 22	valvular
1,T2,Qualifier 0 10	congenital
2,*,OR T2 T1
3,T3,Scope 0 22	congenital or valvular
4,T4,Condition 23 37	cardiomyopathy
5,R1,Has_scope Arg1:T4 Arg2:T3
6,T5,Condition 40 62	ischemic heart disease
7,T6,Condition 65 83	endocrine diseases
8,T7,Condition 85 102	male hypogonadism
9,T8,Condition 104 119	hyperthyroidism
10,T9,Condition 121 137	adrenal diseases
11,T10,Condition 139 157	pituitary diseases
12,*,OR T10 T9 T8 T7
13,T11,"Scope 85 157	male hypogonadism, hyperthyroidism, adrenal diseases, pituitary diseases"
14,R2,Subsumes Arg1:T6 Arg2:T11
15,T12,Condition 159 184	proliferative retinopathy
16,T13,Condition 188 208	autonomic neuropathy
17,*,OR T12 T13
18,T14,Condition 211 228	contraindications
19,T15,Drug 232 242	sildenafil
20,T16,Procedure 250 261	CMR imaging
21,*,OR T15 T16
22,T17,Scope 232 261	sildenafil use or CMR imaging
23,R3,Has_scope Arg1:T14 Arg2:T17
0,T1,Person 0 3	age
1,T2,Value 4 15	35-75 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 31 46	Type 2 Diabetes
4,T4,Temporal 52 68	at least 3 years
5,R2,Has_temporal Arg1:T3 Arg2:T4
6,T5,Measurement 71 76	HbA1c
7,T6,Value 77 82	< 10%
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 85 106	normal blood pressure
10,T8,Condition 110 133	controlled hypertension
11,*,OR T7 T8
12,T9,Measurement 136 139	BMI
13,T10,Value 140 144	< 40
14,R4,Has_value Arg1:T9 Arg2:T10
0,T1,Condition 0 8	diabetic
1,T2,Drug 32 39	aspirin
2,T3,Drug 44 51	insulin
3,*,OR T2 T3
4,T4,Condition 62 77	well responders
0,T1,Condition 13 32	atrial fibrillation
1,T2,Qualifier 0 12	non-valvular
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 37 45	diabetic
4,T4,Negation 34 37	non
5,R2,Has_negation Arg1:T3 Arg2:T4
6,T5,Condition 69 77	diabetic
7,T6,Qualifier 56 62	type 1
8,T7,Qualifier 56 60;67 68	type 2
9,*,OR T7 T6
10,T8,Scope 56 68	type 1 and 2
11,R3,Has_scope Arg1:T5 Arg2:T8
0,T1,Condition 0 15	type 2 diabetic
1,T2,Person 17 20	age
2,T3,Value 21 32	18 and over
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Informed_consent 34 50	informed consent
0,T1,Condition 14 20	cancer
1,T2,Condition 36 65	chronic inflammation diseases
0,T1,Condition 4 12	diabetic
1,T2,Negation 0 3	not
2,R1,Has_negation Arg1:T1 Arg2:T2
3,T3,Procedure 35 60	dual antiplatelet therapy
4,T4,Condition 83 96	renal failure
5,T5,Qualifier 76 82	severe
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Condition 107 122	poor responders
0,T1,Condition 0 15	type 1 diabetic
1,T2,Condition 19 31	non-diabetic
2,*,OR T1 T2
0,T1,Condition 0 6	ASA 3+
1,T2,Observation 19 33	treatment plan
2,T3,Negation 8 10	No
3,R1,Has_negation Arg1:T2 Arg2:T3
4,T4,Temporal 11 18	current
5,R2,Has_temporal Arg1:T2 Arg2:T4
6,T5,Visit 37 41	OHSU
7,R3,AND Arg1:T2 Arg2:T5
8,T6,Condition 52 65	carious teeth
9,T7,Qualifier 43 51	Severely
10,R4,Has_qualifier Arg1:T6 Arg2:T7
11,T8,Condition 79 113	inability to isolate for procedure
12,R5,causal Arg1:T8 Arg2:T6
13,T9,Post-eligibility 115 156	Unable to understand or sign consent form
0,T1,Person 0 8	Children
1,T2,Person 10 14	aged
2,T3,Value 15 40	between one and 24 months
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 57 94	American Society of Anesthesiologists
5,T5,Measurement 96 115	ASA physical status
6,T6,Value 116 123	I or II
7,R2,Subsumes Arg1:T5 Arg2:T4
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Procedure 136 139	TEE
0,T1,Non-query-able 0 36	Previous randomization in this study
1,T2,Drug 53 67	IV antibiotics
2,T3,Temporal 68 99	in the 6 weeks prior to Visit 1
3,T4,Reference_point 92 99	Visit 1
4,R1,Has_index Arg1:T3 Arg2:T4
5,R2,Has_temporal Arg1:T2 Arg2:T3
6,T5,Observation 101 137	Admission to the intensive care unit
7,T6,Visit 118 137	intensive care unit
8,R3,multi Arg1:T5 Arg2:T6
9,T7,Condition 150 172	pulmonary exacerbation
10,R4,AND Arg1:T5 Arg2:T7
11,T8,Temporal 173 206	in the two weeks prior to Visit 2
12,T9,Reference_point 199 206	Visit 2
13,R5,Has_index Arg1:T8 Arg2:T9
14,R6,Subsumes Arg1:T7 Arg2:T8
15,T11,Procedure 238 262	desensitization protocol
16,T10,Negation 208 214	unless
17,R7,Has_negation Arg1:T11 Arg2:T10
18,T12,Condition 264 276	Pneumothorax
19,T13,Temporal 277 310	in the two weeks prior to Visit 2
20,T14,Reference_point 303 310	Visit 2
21,R8,Has_index Arg1:T13 Arg2:T14
22,T15,Condition 312 329	Primary diagnosis
23,T16,Observation 334 357	current hospitalization
24,R9,Has_context Arg1:T15 Arg2:T16
25,T17,Negation 361 370	unrelated
26,T18,Condition 384 410	lower respiratory symptoms
27,T19,Qualifier 374 383	worsening
28,R10,Has_qualifier Arg1:T18 Arg2:T19
29,*,NOT T18 T17
30,T20,Condition 418 437	pulmonary clean out
31,T21,Condition 439 477	distal intestinal obstruction syndrome
32,T22,Condition 479 483	DIOS
33,T23,Condition 486 495	sinusitis
34,*,OR T20 T21 T23
35,R11,Subsumes Arg1:T21 Arg2:T22
36,T24,"Scope 411 496	(e.g., pulmonary clean out, distal intestinal obstruction syndrome (DIOS), sinusitis)"
37,R12,Subsumes Arg1:T18 Arg2:T24
38,T25,Condition 506 516	hemoptysis
39,T26,Qualifier 498 505	Massive
40,T27,Multiplier 528 536	> 250 cc
41,T28,Temporal 537 556	in a 24 hour period
42,T29,Multiplier 560 570	100 cc/day
43,T30,Temporal 571 594	over 4 consecutive days
44,T31,Temporal 605 638	in the two weeks prior to Visit 2
45,T32,Reference_point 631 638	Visit 2
46,R13,Has_index Arg1:T31 Arg2:T32
47,R14,Has_qualifier Arg1:T25 Arg2:T26
48,T33,Scope 528 594	> 250 cc in a 24 hour period or 100 cc/day over 4 consecutive days
49,*,OR T27 T29
50,R15,Has_scope Arg1:T25 Arg2:T33
51,R16,Has_temporal Arg1:T25 Arg2:T31
52,T34,Condition 648 670	pulmonary exacerbation
53,T35,Condition 692 731	allergic bronchopulmonary aspergillosis
54,T36,Condition 733 737	ABPA
55,R17,Subsumes Arg1:T35 Arg2:T36
56,R18,AND Arg1:T34 Arg2:T35
57,T38,Temporal 740 750;799 816	At Visit 1 more than 2 weeks
58,T37,Drug 822 832	prednisone
59,T39,Multiplier 847 856	>10mg/day
60,R19,Has_multiplier Arg1:T37 Arg2:T39
61,R20,Has_temporal Arg1:T37 Arg2:T38
62,T40,Reference_point 743 750	Visit 1
63,R21,Has_index Arg1:T38 Arg2:T40
64,T41,Condition 869 896	solid organ transplantation
65,T42,Drug 908 929	antimicrobial therapy
66,T43,Qualifier 939 968	non-tuberculous mycobacterium
67,R22,Has_qualifier Arg1:T42 Arg2:T43
68,T44,Qualifier 976 988	M. abscessus
69,T45,Qualifier 990 1006	M. avium complex
70,R23,Subsumes Arg1:T43 Arg2:T44
71,R24,Subsumes Arg1:T43 Arg2:T45
72,T46,Temporal 1008 1041	in the two weeks prior to Visit 2
73,T47,Reference_point 1034 1041	Visit 2
74,R25,Has_index Arg1:T46 Arg2:T47
75,R26,Has_temporal Arg1:T42 Arg2:T46
0,T1,Parsing_Error 0 30	Cases (with a history of TBI):
1,T2,Person 35 39	Ages
2,T3,Value 40 51	50-95 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 67 89	traumatic brain injury
5,T5,Observation 56 63	History
6,T6,Qualifier 93 112	sufficient severity
7,T7,Subjective_judgement 93 112	sufficient severity
8,T8,Measurement 172 237	Ohio State University TBI Identification Questionnaire—OSU TBI-ID
9,T9,Value 93 112	sufficient severity
10,R2,Has_value Arg1:T8 Arg2:T9
11,R3,Has_qualifier Arg1:T4 Arg2:T6
12,R4,AND Arg1:T4 Arg2:T8
13,R5,Has_temporal Arg1:T4 Arg2:T5
14,T10,Visit 286 306	AFRH-Washington D.C.
15,T11,Visit 314 352	Veterans Home of California-Yountville
16,*,OR T10 T11
17,T12,Measurement 357 361	MMSE
18,T13,Value 362 372	score ≥ 20
19,R6,Has_value Arg1:T12 Arg2:T13
20,T14,Non-query-able 377 468	Capacity to provide consent to participate in research (assessment made by study physician)
21,T15,Post-eligibility 377 468	Capacity to provide consent to participate in research (assessment made by study physician)
22,T16,Non-query-able 473 506	Ability to read and write English
23,T17,Post-eligibility 473 506	Ability to read and write English
24,T18,Parsing_Error 508 544	Controls (without a history of TBI):
25,T19,Person 549 553	Ages
26,T20,Value 554 565	50-95 years
27,R7,Has_value Arg1:T19 Arg2:T20
28,T21,Condition 584 606	traumatic brain injury
29,T22,Qualifier 610 629	sufficient severity
30,T23,Measurement 689 754	Ohio State University TBI Identification Questionnaire—OSU TBI-ID
31,T24,Negation 570 572	No
32,T25,Observation 573 580	history
33,R8,Has_negation Arg1:T21 Arg2:T24
34,R9,Has_temporal Arg1:T21 Arg2:T25
35,R10,Has_qualifier Arg1:T21 Arg2:T22
36,T26,Subjective_judgement 610 629	sufficient severity
37,T27,Value 610 629	sufficient severity
38,R11,Has_value Arg1:T23 Arg2:T27
39,T28,Visit 773 788	AFRH-Washington
40,T29,Visit 796 834	Veterans Home of California-Yountville
41,*,OR T29 T28
42,T30,Observation 760 769	Residence
43,T31,Observation 273 282	Residence
44,T32,Scope 286 352	AFRH-Washington D.C. or the Veterans Home of California-Yountville
45,R12,Has_context Arg1:T32 Arg2:T31
46,T33,Scope 773 834	AFRH-Washington or the Veterans Home of California-Yountville
47,R13,Has_context Arg1:T33 Arg2:T30
48,T34,Measurement 839 843	MMSE
49,T35,Value 844 854	score ≥ 20
50,R14,Has_value Arg1:T34 Arg2:T35
51,T36,Non-query-able 859 923	Capacity to provide consent or assent to participate in research
52,T37,Post-eligibility 859 923	Capacity to provide consent or assent to participate in research
53,T38,Post-eligibility 928 963	Ability to read and write English -
54,T39,Non-query-able 928 963	Ability to read and write English -
0,T1,Condition 0 5	ASA 1
1,T2,Condition 7 12	ASA 2
2,T3,Observation 31 53	treatment plan at OHSU
3,T4,Mood 107 120	scheduled for
4,T5,Non-representable 14 170	Pts have current treatment plan at OHSU for extraction of some or all of remaining teeth and scheduled for delivery of a removable appliance post extraction
5,T6,Non-representable 172 222	Teeth used are able to be isolated with rubber dam
6,T7,Post-eligibility 224 256	Understand and sign consent form
0,T1,Condition 6 13	allergy
1,T2,Condition 17 31	hypersensitive
2,T3,Drug 44 59	dexmedetomidine
3,*,OR T1 T2
4,T4,Scope 6 31	allergy or hypersensitive
5,R1,AND Arg1:T4 Arg2:T3
6,T5,Condition 61 78	Organ dysfunction
7,T6,Condition 96 116	developmental delays
8,T7,Qualifier 84 95	significant
9,R2,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Condition 120 137	behavior problems
11,*,OR T6 T8 T5
12,T9,Condition 139 157	Cardiac arrhythmia
13,T10,Condition 166 200	acyanotic congenital heart disease
14,T11,Person 204 212	children
15,T12,Temporal 213 252	after cardiac interventional procedures
16,T13,Reference_point 219 252	cardiac interventional procedures
17,T14,Procedure 219 252	cardiac interventional procedures
18,R3,multi Arg1:T13 Arg2:T14
19,R4,AND Arg1:T12 Arg2:T14
20,T15,Procedure 257 278	follow-up examination
21,T16,Qualifier 253 278	for follow-up examination
22,R5,Has_qualifier Arg1:T14 Arg2:T16
23,R6,multi Arg1:T16 Arg2:T15
24,*,OR T10 T14
0,T1,Parsing_Error 0 30	Cases (with a history of TBI):
1,T2,Observation 35 42	History
2,T3,Condition 46 70	penetrating brain injury
3,R1,Has_temporal Arg1:T3 Arg2:T2
4,T4,Observation 75 82	History
5,T5,Condition 124 133;86 108	condition disabling neurological
6,T6,Condition 112 133;86 95	psychiatric condition disabling
7,T7,Condition 142 150	epilepsy
8,T8,Condition 160 182	posttraumatic epilepsy
9,T9,Negation 152 159	besides
10,R2,Has_negation Arg1:T8 Arg2:T9
11,R3,AND Arg1:T7 Arg2:T8
12,T10,Condition 185 203	multiple sclerosis
13,T11,Condition 205 220	cortical stroke
14,T12,Condition 222 253	hypoxic-ischemic encephalopathy
15,T13,Condition 255 267	encephalitis
16,T14,Condition 272 285	schizophrenia
17,*,OR T14 T13 T12 T11 T10 T7
18,T15,"Scope 86 285	disabling neurological or psychiatric condition such as epilepsy (besides posttraumatic epilepsy), multiple sclerosis, cortical stroke, hypoxic-ischemic encephalopathy, encephalitis, or schizophrenia"
19,R4,Has_temporal Arg1:T15 Arg2:T4
20,T16,Parsing_Error 287 323	Controls (without a history of TBI):
21,T17,Observation 325 332	History
22,T18,Condition 336 358;374 383	disabling neurological condition
23,T19,Undefined_semantics 86 133	disabling neurological or psychiatric condition
24,T21,Condition 336 345;362 383	disabling psychiatric condition
25,T22,Condition 392 400	epilepsy
26,T23,Condition 402 420	multiple sclerosis
27,T24,Condition 422 437	cortical stroke
28,T25,Condition 439 470	hypoxic-ischemic encephalopathy
29,T26,Condition 472 484	encephalitis
30,T27,Condition 489 502	schizophrenia
31,*,OR T27 T26 T25 T24 T23 T22
32,T28,"Scope 142 285	epilepsy (besides posttraumatic epilepsy), multiple sclerosis, cortical stroke, hypoxic-ischemic encephalopathy, encephalitis, or schizophrenia"
33,T29,Scope 86 133	disabling neurological or psychiatric condition
34,R5,Subsumes Arg1:T29 Arg2:T28
35,*,OR T5 T6
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,T3,Person 28 31	age
3,T4,Value 15 24	=18 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Temporal 32 42	at Visit 1
6,T6,Reference_point 35 42	Visit 1
7,R2,Has_index Arg1:T5 Arg2:T6
8,R3,Has_temporal Arg1:T3 Arg2:T5
9,*,OR T1 T2
10,T7,Condition 63 65	CF
11,T10,Drug 241 255	IV antibiotics
12,T11,Condition 262 284	pulmonary exacerbation
13,R4,AND Arg1:T10 Arg2:T11
14,T12,Temporal 189 211	At the time of Visit 1
15,T13,Reference_point 204 211	Visit 1
16,R5,Has_index Arg1:T12 Arg2:T13
17,R6,Has_temporal Arg1:T10 Arg2:T12
18,T14,Procedure 296 306	spirometry
19,T15,Temporal 307 317	at Visit 1
20,T16,Temporal 307 309;322 329	at Visit 2
21,T17,Temporal 364 374	at Visit 3
22,T18,Scope 307 329	at Visit 1 and Visit 2
23,R7,Has_scope Arg1:T14 Arg2:T18
24,T8,Mood 334 352	willing to perform
25,T9,Procedure 353 363	spirometry
26,R8,Has_temporal Arg1:T9 Arg2:T17
27,R9,Has_mood Arg1:T9 Arg2:T8
28,T23,Reference_point 310 317	Visit 1
29,R10,Has_index Arg1:T15 Arg2:T23
30,T24,Reference_point 322 329	Visit 2
31,R11,Has_index Arg1:T16 Arg2:T24
32,T25,Reference_point 367 374	Visit 3
33,R12,Has_index Arg1:T17 Arg2:T25
34,T19,Procedure 390 409	CRISS questionnaire
35,T26,Temporal 410 420	at Visit 1
36,T27,Temporal 410 412;425 432	at Visit 2
37,T28,Reference_point 413 420	Visit 1
38,T29,Reference_point 425 432	Visit 2
39,R13,Has_index Arg1:T26 Arg2:T28
40,*,OR T27 T29
41,T30,Scope 410 432	at Visit 1 and Visit 2
42,R14,Has_scope Arg1:T19 Arg2:T30
43,T31,Mood 437 456	willing to complete
44,T32,Procedure 461 525	Cystic Fibrosis Respiratory Symptoms Diary (CFRSD) questionnaire
45,R15,Has_mood Arg1:T32 Arg2:T31
46,T33,Temporal 526 536	at Visit 3
47,T34,Reference_point 529 536	Visit 3
48,R16,Has_index Arg1:T33 Arg2:T34
49,R17,Has_temporal Arg1:T32 Arg2:T33
50,T35,Observation 77 154	Enrolled in the Cystic Fibrosis Foundation National Patient Registry (CFFNPR)
51,T36,Temporal 155 171	prior to Visit 1
52,T37,Reference_point 164 171	Visit 1
53,R18,Has_index Arg1:T36 Arg2:T37
54,T38,Visit 173 181	US sites
55,A1,Optional T38
56,R19,Has_temporal Arg1:T35 Arg2:T36
57,R20,Has_context Arg1:T38 Arg2:T35
58,T20,Mood 538 548	Willing to
59,T39,Non-representable 549 661	adhere to a specific treatment duration determined by initial response to treatment and subsequent randomization
60,T21,Mood 663 673	Willing to
61,T41,Procedure 685 702	follow up Visit 3
62,R21,Has_mood Arg1:T41 Arg2:T21
63,T22,Observation 704 728	Written informed consent
64,T40,Qualifier 738 754	from the subject
65,T42,Qualifier 738 746;758 788	from the subject's legal representative
66,*,OR T40 T42
67,T43,Scope 738 788	from the subject or subject's legal representative
68,R22,Has_scope Arg1:T22 Arg2:T43
0,T1,Parsing_Error 0 2	NA
0,T1,Measurement 0 3	ASA
1,T2,Value 4 10	I & II
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 12 23	Nulliparous
4,T4,Condition 28 39	Multiparous
5,T5,Procedure 61 76	Augmented Labor
6,T6,Procedure 53 60;71 76	Induced Labor
7,T7,Condition 41 52;71 76	Spontaneous Labor
8,*,OR T6 T5 T7
9,T8,Condition 78 96	Early active labor
10,T9,Measurement 98 104	cervix
11,T10,Value 105 110	<5 cm
12,R2,Has_value Arg1:T9 Arg2:T10
13,A1,Optional T9
14,T11,Measurement 124 134	Pain (VPS)
15,T12,Value 135 138	> 3
16,R3,Has_value Arg1:T11 Arg2:T12
17,T13,Value 140 151	18-45 years
18,T14,Person 155 158	age
19,R4,Has_value Arg1:T14 Arg2:T13
20,T15,Scope 98 121	cervix <5 cm (if known)
21,R5,Subsumes Arg1:T8 Arg2:T15
0,T1,Measurement 10 19	gestation
1,T2,Value 0 9	<37 weeks
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 25 41	Cesarean Section
4,T4,Condition 43 61	Multiple Gestation
5,T5,Observation 21 24	H/o
6,T6,Condition 63 76	Pre-eclampsia
7,T7,Drug 78 87	Narcotics
8,T8,Temporal 88 136	within 3 hours prior to labor epidural placement
9,T9,Procedure 112 136	labor epidural placement
10,T10,Reference_point 112 136	labor epidural placement
11,R2,multi Arg1:T10 Arg2:T9
12,R3,Has_index Arg1:T8 Arg2:T10
13,R4,Has_temporal Arg1:T7 Arg2:T8
14,T11,Condition 138 150	Chronic Pain
15,T12,Multiplier 166 173	chronic
16,T13,Drug 174 180	opiate
17,R5,Has_multiplier Arg1:T13 Arg2:T12
18,T14,Scope 166 180	chronic opiate
19,R6,Subsumes Arg1:T11 Arg2:T14
20,*,OR T6 T7 T4 T3 T11
21,T15,"Scope 25 193	Cesarean Section, Multiple Gestation, Pre-eclampsia, Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined by chronic opiate consumption)"
22,R7,Has_context Arg1:T15 Arg2:T5
23,T16,Competing_trial 195 265	Women who are participating in another study that will impact protocol
0,T1,Procedure 24 33;67 80	ascending aorta surgery
1,T2,Procedure 35 39;67 80	arch aorta surgery
2,T3,Procedure 47 80	proximal descending aorta surgery
3,*,OR T3 T2 T1
4,T4,Procedure 86 108	cardiopulmonary bypass
5,T5,Person 123 126	old
6,T6,Value 110 122	20 - 100 yrs
7,R1,Has_value Arg1:T5 Arg2:T6
0,T1,Person 8 13	women
1,T2,Person 0 3	Men
2,*,OR T1 T2
3,T3,Person 29 32	age
4,T4,Value 33 46	ranging 40-80
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 59 82	coronary artery disease
7,T6,Mood 49 58	Suspected
8,R2,Has_mood Arg1:T5 Arg2:T6
9,T7,Procedure 111 140	invasive coronary angiography
10,T8,Mood 91 110	supposed to undergo
11,R3,Has_mood Arg1:T7 Arg2:T8
12,T9,Post-eligibility 180 238	Patients who are willing to sign the informed consent form
0,T1,Qualifier 0 8	Advanced
1,T2,Condition 9 32	male factor infertility
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 35 67	Polycystic ovary syndrome (PCOS)
4,T4,Qualifier 86 104	Rotterdam criteria
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 107 120	Endometriosis
7,T6,Condition 123 136	Tubal disease
8,T7,Condition 139 160	Uterine abnormalities
9,T8,Condition 164 169	myoma
10,*,OR T7 T8
11,T9,Procedure 181 196	uterine surgery
12,T10,Temporal 172 180	Previous
13,R3,Has_temporal Arg1:T9 Arg2:T10
14,T11,Condition 199 208;221 234	Metabolic abnormalities
15,T12,Condition 212 234	hormonal abnormalities
16,*,OR T12 T11
0,T1,Condition 8 21	alcohol abuse
1,T2,Condition 25 40	drug dependence
2,*,OR T1 T2
3,T3,Temporal 0 7	current
4,T4,Scope 8 40	alcohol abuse or drug dependence
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Condition 42 51	pregnancy
7,T6,Condition 60 83	opportunistic infection
8,T7,Condition 99 113	co-morbidities
9,T8,Qualifier 87 98	significant
10,T9,Undefined_semantics 87 98	significant
11,T10,Drug 146 156	medication
12,T11,Temporal 134 145	concomitant
13,T12,Temporal 115 122	current
14,T13,Qualifier 123 133	prohibited
15,R2,Has_temporal Arg1:T10 Arg2:T11
16,R3,Has_temporal Arg1:T10 Arg2:T12
17,R4,Has_qualifier Arg1:T10 Arg2:T13
18,T14,"Post-eligibility 158 307	a likelihood of diminished response to any of the study treatment arms, in the opinion of the investigator, based on HIV genotypic resistance testing"
0,T1,Condition 0 22	Contraindication of CT
1,T2,Condition 23 36	Known allergy
2,T3,Drug 40 64	iodinated contrast media
3,T4,Condition 79 107	contrast-induced nephropathy
4,R1,AND Arg1:T2 Arg2:T3
5,*,OR T2 T4
6,T5,Measurement 118 132	renal function
7,T6,Value 108 117	Decreased
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Value 134 142	elevated
10,T8,Measurement 143 159	serum creatinine
11,T9,Value 160 169	>1.5mg/dl
12,R3,Subsumes Arg1:T7 Arg2:T9
13,R4,Has_value Arg1:T8 Arg2:T7
14,T10,Drug 191 204	beta-blockers
15,T11,Condition 171 187	Contraindication
16,R5,AND Arg1:T11 Arg2:T10
17,T12,Condition 212 222	arrhythmia
18,T13,Qualifier 205 211	Severe
19,R6,Has_qualifier Arg1:T12 Arg2:T13
20,T14,Condition 224 245	arterial fibrillation
21,T15,Condition 249 277	uncontrolled tachyarrhythmia
22,*,OR T14 T15 T16
23,T16,Condition 282 313	advanced atrioventricular block
24,T17,Condition 325 349	third degree heart block
25,T18,Condition 315 321;331 349	second degree heart block
26,*,OR T17 T18
27,T19,Scope 315 349	second or third degree heart block
28,R7,Subsumes Arg1:T16 Arg2:T19
29,T20,Line 0 22	Contraindication of CT
30,T21,Line 23 107	Known allergy to iodinated contrast media or history of contrast-induced nephropathy
31,T22,Line 108 170	Decreased renal function: elevated serum creatinine(>1.5mg/dl)
32,T23,Line 171 204	Contraindication to beta-blockers
33,T24,"Line 205 350	Severe arrhythmia: arterial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block)"
34,T25,Condition 352 368	Contraindication
35,T26,Procedure 372 375	MRI
36,R8,AND Arg1:T25 Arg2:T26
37,T27,Condition 376 390	Claustrophobia
38,T28,Condition 391 407	Metallic hazards
39,T29,Device 408 425	Pacemaker implant
40,R9,Subsumes Arg1:T23 Arg2:T24
41,R10,Subsumes Arg1:T20 Arg2:T21
42,T30,Measurement 426 430	eGFR
43,T31,Value 430 440	<30 ml/min
44,R11,Has_value Arg1:T30 Arg2:T31
45,*,OR T27 T28 T29 T30
46,T32,Scope 376 440	Claustrophobia Metallic hazards Pacemaker implant eGFR<30 ml/min
47,R12,Subsumes Arg1:T25 Arg2:T32
48,T33,Condition 454 476	uncooperative patients
49,T34,Condition 442 450;468 476	Unstable patients
50,T35,Person 486 501	life expectancy
51,T36,Value 478 485	Limited
52,T37,Condition 509 515	cancer
53,T38,Condition 519 534;544 551	end-stage renal disease
54,T39,Condition 538 551	liver disease
55,*,OR T38 T39 T37
56,T40,Scope 509 551	cancer or end-stage renal or liver disease
57,R13,Has_value Arg1:T35 Arg2:T36
58,R14,Has_scope Arg1:T35 Arg2:T40
59,T41,Qualifier 565 571	severe
60,T42,Qualifier 572 583	symptomatic
61,T43,Condition 584 597	heart failure
62,R15,Has_qualifier Arg1:T43 Arg2:T42
63,R16,Has_qualifier Arg1:T43 Arg2:T41
64,T44,Measurement 599 603	NYHA
65,T45,Value 604 619	Class III or IV
66,R17,Has_value Arg1:T44 Arg2:T45
67,T46,Condition 631 652	myocardial infarction
68,T47,Temporal 622 630	Previous
69,T48,Procedure 654 682	coronary artery intervention
70,T49,Procedure 684 714	coronary artery bypass surgery
71,T50,Procedure 719 740	other cardiac surgery
72,*,OR T48 T49 T50 T46
73,T51,"Scope 631 740	myocardial infarction, coronary artery intervention, coronary artery bypass surgery, or other cardiac surgery"
74,R18,Has_temporal Arg1:T51 Arg2:T47
0,T1,Qualifier 0 4	Mild
1,T2,Condition 5 28	male factor infertility
2,T3,Condition 32 55	unexplained infertility
3,R1,Has_qualifier Arg1:T2 Arg2:T1
4,*,OR T2 T3
0,T1,Condition 0 14	HIV-1 infected
1,T2,Person 15 20	males
2,T3,Person 24 31	females
3,*,OR T2 T3
4,T4,Value 33 46	over 18 years
5,T5,Person 50 53	age
6,R1,Has_value Arg1:T5 Arg2:T4
7,T6,Post-eligibility 55 78	signed informed consent
8,T7,Procedure 109 131	antiretroviral regimen
9,T8,Multiplier 148 159	two or more
10,T9,Drug 169 173	NRTI
11,T10,Qualifier 160 168	licensed
12,R2,Has_qualifier Arg1:T9 Arg2:T10
13,R3,Has_multiplier Arg1:T9 Arg2:T8
14,T11,Multiplier 176 179	one
15,T12,Qualifier 180 188	licensed
16,T13,Drug 189 194	NNRTI
17,T14,Drug 198 224	boosted protease inhibitor
18,*,OR T14 T13
19,T15,Scope 189 224	NNRTI or boosted protease inhibitor
20,R4,Has_qualifier Arg1:T15 Arg2:T12
21,R5,Has_multiplier Arg1:T15 Arg2:T11
22,T16,Drug 238 256	protease inhibitor
23,T17,Condition 238 267	protease inhibitor resistance
24,R6,AND Arg1:T17 Arg2:T16
25,T18,Procedure 282 316	HIV-1 genotypic resistance testing
26,T19,Condition 282 287	HIV-1
27,T20,Condition 282 308	HIV-1 genotypic resistance
28,R7,AND Arg1:T20 Arg2:T19
29,R8,AND Arg1:T18 Arg2:T20
30,R9,AND Arg1:T17 Arg2:T20
31,T21,Procedure 337 359	antiretroviral regimen
32,T22,Condition 318 359	failure of current antiretroviral regimen
33,T23,Temporal 329 336	current
34,R10,Has_temporal Arg1:T21 Arg2:T23
35,R11,AND Arg1:T22 Arg2:T21
36,T24,Condition 369 377	toxicity
37,T25,Condition 379 390	intolerance
38,T26,Condition 394 413	virological failure
39,T27,Drug 430 435	NNRTI
40,T28,Procedure 430 454	NNRTI containing regimen
41,T29,Temporal 455 467	at screening
42,R12,AND Arg1:T28 Arg2:T27
43,*,OR T26 T25 T24
44,T30,Scope 430 467	NNRTI containing regimen at screening
45,A1,Optional T30
46,T31,"Scope 369 413	toxicity, intolerance or virological failure"
47,R13,Has_scope Arg1:T30 Arg2:T31
48,T32,Condition 469 477	toxicity
49,T33,Condition 481 492	intolerance
50,T34,Procedure 508 542	boosted-protease inhibitor regimen
51,T35,Drug 516 534	protease inhibitor
52,R14,AND Arg1:T34 Arg2:T35
53,T36,Temporal 543 555	at screening
54,T37,Measurement 562 576	plasma HIV RNA
55,T38,Value 577 592	< 400 copies/mL
56,T39,Temporal 593 605	at screening
57,R15,Has_value Arg1:T37 Arg2:T38
58,R16,Has_temporal Arg1:T37 Arg2:T39
59,R17,Has_temporal Arg1:T34 Arg2:T36
60,*,OR T33 T32
61,T40,Scope 508 606	boosted-protease inhibitor regimen at screening (with plasma HIV RNA < 400 copies/mL at screening)
62,A2,Optional T40
63,T41,Scope 469 492	toxicity or intolerance
64,R18,Has_scope Arg1:T40 Arg2:T41
65,T42,Procedure 626 648	antiretroviral therapy
66,T43,Observation 608 615	willing
67,R19,Has_context Arg1:T42 Arg2:T43
68,T44,Drug 723 733	etravirine
69,T45,Negation 699 701	no
70,T46,Temporal 702 710	previous
71,R20,Has_temporal Arg1:T44 Arg2:T46
72,R21,Has_negation Arg1:T44 Arg2:T45
73,T47,Condition 747 758	good health
74,T48,Observation 764 779	medical history
75,T49,Procedure 781 794	physical exam
76,T50,Procedure 800 818	laboratory testing
77,T51,"Scope 764 818	medical history, physical exam, and laboratory testing"
78,R22,Has_scope Arg1:T47 Arg2:T51
79,T52,Condition 863 905	serologic evidence of active HBV infection
80,T53,Condition 892 905	HBV infection
81,T54,Measurement 928 955	hepatitis B surface antigen
82,T55,Value 919 927	negative
83,R23,Has_value Arg1:T54 Arg2:T55
84,R24,AND Arg1:T52 Arg2:T53
85,R25,AND Arg1:T52 Arg2:T54
86,T56,Person 957 963	female
87,T57,Condition 981 1002	heterosexually active
88,T58,Condition 1010 1032	childbearing potential
89,T59,Condition 1044 1062	surgically sterile
90,T60,Procedure 1044 1054	surgically
91,R26,AND Arg1:T59 Arg2:T60
92,T61,Negation 1040 1043	not
93,R27,Has_negation Arg1:T59 Arg2:T61
94,T62,Temporal 1066 1084	at least two years
95,T63,Condition 1085 1100	post menopausal
96,R28,Has_temporal Arg1:T63 Arg2:T62
97,*,OR T63 T59
98,R29,Has_negation Arg1:T63 Arg2:T61
99,T64,Scope 1040 1100	not surgically sterile or at least two years post menopausal
100,R30,Subsumes Arg1:T58 Arg2:T64
101,T65,Procedure 1116 1129	contraception
102,T66,"Pregnancy_considerations 957 1188	female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study:"
103,T67,"Parsing_Error 957 1188	female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study:"
104,T68,Device 1190 1212	barrier contraceptives
105,T69,Device 1214 1220	condom
106,T70,Device 1222 1231	diaphragm
107,*,OR T69 T70
108,T71,Qualifier 1232 1247	with spermicide
109,R31,Has_qualifier Arg1:T70 Arg2:T71
110,T72,"Scope 1214 1247	condom, diaphragm with spermicide"
111,R32,Subsumes Arg1:T68 Arg2:T72
112,T73,Device 1250 1253	IUD
113,T74,Device 1257 1261	Depo
114,T75,Device 1269 1290	barrier contraceptive
115,*,OR T73 T74
116,T76,Measurement 1355 1369	pregnancy test
117,T77,Value 1346 1354	negative
118,R33,Has_value Arg1:T76 Arg2:T77
119,T78,Condition 1311 1333	childbearing potential
120,T79,Person 1292 1298	female
121,T80,Scope 1292 1333	female subjects of childbearing potential
122,A3,Optional T80
123,R34,AND Arg1:T80 Arg2:T76
0,T1,Qualifier 6 12	proved
1,T2,Condition 13 28	BKV nephropathy
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Condition 30 46	Hypersensitivity
4,T4,Drug 50 60	everolimus
5,T5,Drug 62 71	sirolimus
6,T6,Drug 75 84	excipient
7,*,OR T5 T6 T4
8,T7,"Scope 50 84	everolimus, sirolimus or excipient"
9,R2,Has_scope Arg1:T3 Arg2:T7
10,T8,Temporal 86 97	Concomitant
11,T10,Drug 111 122	leflunomide
12,T11,Drug 124 133	cidofovir
13,T12,Drug 135 144	sirolimus
14,T13,Drug 146 158	Millepertuis
15,T9,Drug 160 180	Hypericum Perforatum
16,R3,Subsumes Arg1:T13 Arg2:T9
17,*,OR T12 T13 T11 T10
18,T14,"Scope 111 181	leflunomide, cidofovir, sirolimus, Millepertuis (Hypericum Perforatum)"
19,R4,Has_temporal Arg1:T14 Arg2:T8
20,T15,Condition 183 191	Pregnant
21,T16,Condition 195 204	lactating
22,T17,Person 205 210	women
23,*,OR T16 T15
24,T18,Person 212 217	Women
25,T19,Condition 221 244	child bearing potential
26,T20,Negation 245 251	unless
27,T21,Procedure 269 289	birth control method
28,R5,Has_negation Arg1:T21 Arg2:T20
0,T1,Condition 0 24	Unstable medical disease
1,T2,Condition 28 56	comorbid psychiatric disease
2,T3,Condition 58 66	Dementia
3,T4,Multiplier 82 109	less than one year duration
4,T5,Condition 113 124	Parkinson's
5,R1,Has_multiplier Arg1:T5 Arg2:T4
6,T6,Drug 151 167	dopamine agonist
7,T7,Temporal 126 133	Current
8,R2,Has_temporal Arg1:T6 Arg2:T7
0,T1,Observation 0 14	Primary groups
1,A1,Optional T1
2,T2,Procedure 16 49	Vaccination against typhoid fever
3,T3,Condition 36 49	typhoid fever
4,R1,multi Arg1:T2 Arg2:T3
5,T4,Temporal 50 78	within 5 years before dosing
6,T5,Reference_point 72 78	dosing
7,R2,Has_index Arg1:T4 Arg2:T5
8,R3,Has_temporal Arg1:T2 Arg2:T4
9,R4,AND Arg1:T1 Arg2:T2
10,T6,Observation 81 88	History
11,T7,Condition 92 114	clinical typhoid fever
12,T8,Condition 116 138;144 149	clinical paratyphoid A fever
13,T9,Condition 116 136;142 149	clinical paratyphoid B fever
14,*,OR T8 T9 T7
15,T10,"Scope 92 149	clinical typhoid fever, clinical paratyphoid A or B fever"
16,R5,Has_temporal Arg1:T10 Arg2:T6
17,T12,Procedure 152 169;180 187	Immunization with vaccine
18,T13,Qualifier 170 179	any other
19,R6,Has_qualifier Arg1:T12 Arg2:T13
20,T11,Qualifier 189 193	oral
21,T14,Qualifier 197 207	parenteral
22,*,OR T11 T14
23,T15,Scope 189 207	oral or parenteral
24,R7,Has_scope Arg1:T12 Arg2:T15
25,T16,Temporal 209 244	within 4 weeks prior to study start
26,T17,Reference_point 233 244	study start
27,R8,Has_index Arg1:T16 Arg2:T17
28,R9,Has_temporal Arg1:T12 Arg2:T16
29,T18,Mood 248 255	planned
30,T19,Procedure 256 267	vaccination
31,T20,Temporal 268 284	during the study
32,R10,Has_mood Arg1:T19 Arg2:T18
33,R11,Has_temporal Arg1:T19 Arg2:T20
34,T21,Reference_point 275 284	the study
35,R12,Has_index Arg1:T20 Arg2:T21
36,*,OR T12 T19
37,T22,Drug 304 315	antibiotics
38,T23,Temporal 286 293	Current
39,T24,Multiplier 319 325	end of
40,T25,Procedure 326 344	antibiotic therapy
41,T26,Temporal 345 384	<8 days before first IMP administration
42,T27,Reference_point 360 384	first IMP administration
43,R13,Has_index Arg1:T26 Arg2:T27
44,R14,Has_temporal Arg1:T25 Arg2:T26
45,R15,Has_multiplier Arg1:T25 Arg2:T24
46,R16,Has_temporal Arg1:T22 Arg2:T23
47,*,OR T22 T25
48,T28,Multiplier 386 393;416 430	Chronic administration
49,T29,Multiplier 395 414	longer than 14 days
50,R17,Subsumes Arg1:T28 Arg2:T29
51,T30,Drug 434 452	immunosuppressants
52,T31,Drug 462 484	immune-modifying drugs
53,T32,Qualifier 456 461	other
54,R18,Has_qualifier Arg1:T31 Arg2:T32
55,*,OR T30 T31
56,T33,Scope 434 484	immunosuppressants or other immune-modifying drugs
57,R19,Has_multiplier Arg1:T33 Arg2:T28
58,T34,Temporal 485 549	within 6 months before the first dose of investigational vaccine
59,T35,Reference_point 508 549	the first dose of investigational vaccine
60,T36,Drug 526 549	investigational vaccine
61,R20,multi Arg1:T35 Arg2:T36
62,R21,Has_index Arg1:T34 Arg2:T35
63,T37,Drug 551 571	oral corticosteroids
64,T38,Multiplier 575 582	dosages
65,T39,Value 586 598	=0.5 mg/kg/d
66,T40,Negation 630 638	excluded
67,T41,Qualifier 599 625	prednisolone or equivalent
68,R22,Has_value Arg1:T38 Arg2:T39
69,R23,Has_qualifier Arg1:T39 Arg2:T41
70,R24,Has_multiplier Arg1:T37 Arg2:T38
71,R25,Has_negation Arg1:T37 Arg2:T40
72,R26,Has_temporal Arg1:T33 Arg2:T34
73,R27,AND Arg1:T33 Arg2:T37
74,T42,Non-representable 640 679	inhaled or topical steroids are allowed
75,T43,Qualifier 698 720	clinically significant
76,T44,Condition 721 745	gastrointestinal disease
77,T45,Qualifier 681 686	Acute
78,T46,Qualifier 690 697	chronic
79,*,OR T45 T46
80,T47,Scope 681 697	Acute or chronic
81,R28,Has_qualifier Arg1:T44 Arg2:T43
82,R29,Has_scope Arg1:T44 Arg2:T47
0,T1,Person 0 5	Adult
1,T2,Procedure 16 33	Kidney transplant
2,T3,Drug 68 89	calcineurin inhibitor
3,T4,Drug 94 111	mycophenolic acid
4,T5,Measurement 113 120	Viremia
5,T6,Value 121 135	>= 3 log UI/ml
6,R1,Has_value Arg1:T5 Arg2:T6
7,T7,Informed_consent 137 185	Patients who have given written informed consent
8,T8,Measurement 196 210	pregnancy test
9,T9,Value 187 195	Negative
10,R2,Has_value Arg1:T8 Arg2:T9
11,T10,Measurement 212 230	blood ß-HCG dosage
12,R3,Subsumes Arg1:T8 Arg2:T10
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,*,OR T1 T2
3,T3,Person 24 28	aged
4,T4,Value 29 45	=18 to =65 years
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 47 66	General good health
7,T6,Qualifier 70 100	established by medical history
8,T7,Procedure 105 125	physical examination
9,R2,Has_qualifier Arg1:T5 Arg2:T6
10,R3,AND Arg1:T5 Arg2:T7
11,T8,Observation 127 151	Written informed consent
12,T9,Person 153 160	Females
13,T10,Observation 164 186	childbearing potential
14,T11,Mood 192 204	agree to use
15,T12,Qualifier 208 219	efficacious
16,T13,Qualifier 220 228;240 246	hormonal method
17,T14,Qualifier 232 246	barrier method
18,*,OR T13 T14
19,T15,Procedure 250 263	birth control
20,T16,Temporal 264 280	during the study
21,T17,Scope 220 246	hormonal or barrier method
22,R4,Has_scope Arg1:T15 Arg2:T17
23,R5,Has_qualifier Arg1:T15 Arg2:T12
24,R6,Has_temporal Arg1:T15 Arg2:T16
25,T18,Observation 282 292	Abstinence
26,*,OR T15 T18
27,R7,Has_mood Arg1:T15 Arg2:T11
28,T19,Scope 153 186	Females of childbearing potential
29,A1,Optional T19
30,T20,Scope 192 292	agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence
31,R8,Has_scope Arg1:T19 Arg2:T20
32,T21,Observation 309 333	Available for all visits
33,T22,Qualifier 334 357	scheduled in this study
34,R9,Has_qualifier Arg1:T21 Arg2:T22
0,T1,Condition 13 35	DSM 5 Anxiety Disorder
1,T2,Observation 37 59	Stable medical history
2,T3,Condition 37 43;64 78	Stable general health
3,T4,Qualifier 83 89	stable
4,T5,Procedure 90 115	anti-parkinsonian therapy
5,T6,Multiplier 116 127	for 2 weeks
6,T7,Temporal 128 145	before enrollment
7,R1,Has_multiplier Arg1:T5 Arg2:T6
8,R2,Has_qualifier Arg1:T5 Arg2:T4
9,R3,Has_temporal Arg1:T5 Arg2:T7
0,T1,Condition 0 13	premenopausal
1,T2,Person 14 19	women
2,T3,Condition 21 34	BRCA1 carrier
0,T1,Measurement 0 4	eGFR
1,T2,Measurement 5 37	Epidermal growth factor receptor
2,T3,Value 39 49	< 50mL/min
3,R1,Subsumes Arg1:T1 Arg2:T2
4,R2,Has_value Arg1:T1 Arg2:T3
5,T4,Measurement 51 54	AST
6,T5,Measurement 55 81	aspartate aminotransferase
7,T6,Measurement 83 86	ALT
8,T7,Measurement 87 112	alanine aminotransaminase
9,T8,Value 114 140	>2.5 upper limit of normal
10,R3,Subsumes Arg1:T4 Arg2:T5
11,R4,Subsumes Arg1:T6 Arg2:T7
12,T9,Scope 51 112	AST(aspartate aminotransferase)/ALT(alanine aminotransaminase
13,R5,Has_value Arg1:T9 Arg2:T8
14,T10,Pregnancy_considerations 142 169	Pregnant or lactating women
15,T11,Non-query-able 171 248	Subject who the investigator deems inappropriate to participate in this study
16,T12,Condition 277 291	bladder cancer
17,T13,Qualifier 309 315	active
18,T14,Condition 316 330	bladder cancer
19,R6,Has_qualifier Arg1:T14 Arg2:T13
20,*,OR T12 T14
21,T15,Condition 361 382	macroscopic hematuria
22,T16,Qualifier 346 360	uninvestigated
23,R7,Has_qualifier Arg1:T15 Arg2:T16
24,T17,Condition 398 413	cardiac failure
25,T18,Observation 419 445	history of cardiac failure
26,T19,Measurement 447 473;481 487	New York Heart Association Stages
27,T20,Value 488 494	3 to 4
28,T21,Measurement 475 479	NYHA
29,R8,Subsumes Arg1:T19 Arg2:T21
30,R9,Has_value Arg1:T19 Arg2:T20
31,*,OR T17 T18
32,T22,Scope 398 445	cardiac failure or a history of cardiac failure
33,R10,AND Arg1:T22 Arg2:T19
34,T23,Condition 511 527	genetic problems
35,T24,Condition 536 557	galactose intolerance
36,T25,Condition 559 582	Lapp lactase deficiency
37,T26,Condition 586 617	glucose-galactose malabsorption
38,*,OR T24 T25 T26
39,T27,"Scope 536 617	galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption"
40,R11,Subsumes Arg1:T23 Arg2:T27
0,T1,Condition 92 100	diabetes
1,T2,Condition 102 114	hypertension
2,T3,Condition 116 131	cardiac disease
3,T4,Condition 133 139	asthma
4,T5,Condition 141 173	chronic obstructive lung disease
5,*,OR T5 T4 T3 T2 T1
6,T6,"Scope 92 173	diabetes, hypertension, cardiac disease, asthma, chronic obstructive lung disease"
7,T7,Condition 33 48	medical illness
8,R1,Subsumes Arg1:T7 Arg2:T6
9,T8,Qualifier 16 21	acute
10,T9,Qualifier 25 32	chronic
11,*,OR T9 T8
12,T10,Scope 16 32	acute or chronic
13,R2,Has_scope Arg1:T7 Arg2:T10
14,T11,Observation 208 215;228 231	tobacco use
15,T12,Observation 219 231	nicotine use
16,*,OR T12 T11
17,T13,Scope 208 231	tobacco or nicotine use
18,T14,Temporal 194 206	last 60 days
19,R3,Has_temporal Arg1:T13 Arg2:T14
20,T15,Condition 244 261	sickle cell trait
21,T16,Condition 244 255;265 272	sickle cell disease
22,T17,Condition 298 334	hereditary hematological abnormality
23,T18,Condition 286 294;309 334	acquired hematological abnormality
24,*,OR T17 T18 T15 T16
25,T19,Condition 347 355	fainting
26,T20,Procedure 401 411	phlebotomy
27,T21,Condition 377 393	adverse reaction
28,T22,Observation 415 432	donation of blood
29,*,OR T20 T22
30,T23,Scope 401 432	phlebotomy or donation of blood
31,R4,Has_scope Arg1:T21 Arg2:T23
32,*,OR T19 T21
33,T24,Measurement 450 453	QTc
34,T25,Procedure 492 509	electrocardiogram
35,T26,Value 521 528	>470 ms
36,R5,Has_value Arg1:T24 Arg2:T26
37,R6,AND Arg1:T25 Arg2:T24
38,T27,Condition 549 561;573 578	illicit drug abuse
39,T28,Condition 565 578	alcohol abuse
40,T29,Condition 599 602;632 641	HIV infection
41,T30,Condition 604 615;632 641	Hepatitis B infection
42,T31,Condition 620 641	Hepatitis C infection
43,*,OR T31 T30 T29
44,*,OR T28 T27
45,T32,Condition 654 667	thrombophilia
46,T33,Drug 671 692	anticoagulant therapy
47,*,OR T32 T33
48,T34,Condition 694 703	Pregnancy
49,T35,Measurement 724 727	BMI
50,T36,Condition 705 712	Obesity
51,T37,Value 727 730	>30
52,R7,AND Arg1:T36 Arg2:T35
53,R8,Has_value Arg1:T35 Arg2:T37
54,T38,Observation 750 764	blood donation
55,T39,Non-query-able 767 947	) Single whole blood unit donation within the past 8 weeks; b) Double RBC donation by apheresis within the past 16 weeks; or c) Plasma donation by apheresis within the past 4 weeks
56,T40,Observation 960 968	RBC mass
57,T41,Qualifier 949 959	Inadequate
58,R9,Has_qualifier Arg1:T40 Arg2:T41
59,T42,Measurement 978 981	TBV
60,T43,Value 982 990	<4500 ml
61,T44,Measurement 1012 1014	Hb
62,T45,Value 1015 1023	<14 g/dL
63,R10,Has_value Arg1:T42 Arg2:T43
64,R11,Has_value Arg1:T44 Arg2:T45
65,*,OR T42 T44
66,T46,Scope 978 1023	TBV <4500 ml (above) or screening Hb <14 g/dL
67,R12,Has_scope Arg1:T40 Arg2:T46
0,T1,Person 0 4	Aged
1,T2,Value 5 14	=18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 38 61	acute coronary syndrome
4,T4,Procedure 114 140	dual anti-platelet therapy
5,T5,Drug 146 153	aspirin
6,T6,Drug 160 185	P2Y12 receptor antagonist
7,T7,Mood 105 113	requires
8,R2,AND Arg1:T4 Arg2:T5
9,R3,AND Arg1:T4 Arg2:T6
10,R4,Has_mood Arg1:T4 Arg2:T7
11,T8,Person 187 195	Resident
12,T9,Visit 199 207	Scotland
13,R5,AND Arg1:T8 Arg2:T9
14,T10,Non-representable 215 250	Community Health Index (CHI) number
15,T11,Non-representable 252 323	The attending clinician has equipoise regarding the duration of therapy
16,T12,Informed_consent 325 354	Provision of informed consent
0,T1,Person 23 26	age
1,T2,Value 9 19	= 70 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 41 70	noncardiac surgical procedure
4,T4,Procedure 77 95	general anesthesia
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Mood 105 116	anticipated
7,T6,Measurement 117 152	duration of postoperative admission
8,T7,Value 156 171	at least 2 days
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Procedure 143 152	admission
11,T9,Temporal 129 142	postoperative
12,R4,multi Arg1:T6 Arg2:T8
13,R5,Has_temporal Arg1:T8 Arg2:T9
14,R6,Has_mood Arg1:T6 Arg2:T5
0,T1,Observation 0 7	History
1,T2,Condition 11 28	allergic reaction
2,T3,Drug 32 92	compounds of similar chemical or biologic composition to hCG
3,T4,Drug 89 92	hCG
4,R1,multi Arg1:T3 Arg2:T4
5,R2,AND Arg1:T2 Arg2:T3
6,R3,Has_temporal Arg1:T2 Arg2:T1
7,T5,Drug 104 114	medication
8,T6,Qualifier 120 170	could interfere with the study protocol objectives
9,T7,Drug 172 195	hormonal contraceptives
10,T8,Drug 197 206	androgens
11,T9,Drug 208 218	prednisone
12,T10,Drug 220 236	thyroid hormones
13,T11,Drug 238 245	insulin
14,*,OR T11 T10 T9 T8 T7
15,T12,"Scope 172 245	hormonal contraceptives, androgens, prednisone, thyroid hormones, insulin"
16,R4,Has_qualifier Arg1:T5 Arg2:T6
17,R5,Subsumes Arg1:T5 Arg2:T12
18,T13,Temporal 248 256	previous
19,T14,Temporal 94 103	receiving
20,R6,Has_temporal Arg1:T5 Arg2:T14
21,T15,Procedure 257 266	treatment
22,T16,Drug 272 300	follicle stimulating hormone
23,R7,AND Arg1:T15 Arg2:T16
24,T17,Procedure 305 326	assisted reproduction
25,R8,AND Arg1:T15 Arg2:T17
26,R9,Has_temporal Arg1:T15 Arg2:T13
27,T18,Qualifier 328 340	uncontrolled
28,T19,Condition 341 361	intercurrent illness
29,R10,Has_qualifier Arg1:T19 Arg2:T18
30,T20,Condition 363 376	Heart disease
31,T21,Qualifier 378 384	Severe
32,T22,Condition 385 402	cognitive decline
33,R11,Has_qualifier Arg1:T22 Arg2:T21
34,T23,Condition 404 423	Psychiatric desease
35,T24,Condition 425 437	HIV positive
36,T25,Condition 439 450;456 465	Hepatitis B infection
37,T26,Condition 439 448;454 465	Hepatitis C infection
38,*,OR T25 T26
0,T1,Procedure 42 68	dual anti-platelet therapy
1,T2,Condition 0 38	Clear indication for specific duration
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Condition 70 98	Type 2 myocardial infarction
4,T4,Condition 100 116	Contraindication
5,T5,Condition 120 127	aspirin
6,T6,Condition 131 156	P2Y12 receptor antagonist
7,*,OR T6 T5
8,T7,Scope 120 156	aspirin or P2Y12 receptor antagonist
9,R2,Has_scope Arg1:T4 Arg2:T7
10,T8,Person 158 170	Non-resident
11,T9,Visit 174 182	Scotland
12,R3,AND Arg1:T8 Arg2:T9
13,T10,Competing_trial 184 219	Previous recruitment into the trial
14,T11,Informed_consent 221 268	Inability or unwilling to give informed consent
0,T1,Line 0 50	1) preoperative diagnosis of delirium or dementia;
1,T2,Line 51 185	2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing;
2,T3,Line 186 235	3) language barriers that would preclude testing;
3,T4,Line 236 289	4) preoperative steroid use within 3 days of surgery;
4,T5,Line 293 337	5) anticipation of postoperative intubation.
5,T6,Condition 29 37	delirium
6,T7,Condition 41 49	dementia
7,*,OR T6 T7
8,T8,Temporal 3 15	preoperative
9,T9,Scope 29 49	delirium or dementia
10,R1,Has_temporal Arg1:T9 Arg2:T8
11,T10,Measurement 54 64	MMSE score
12,T11,Value 68 82	= 20 out of 30
13,T12,Temporal 86 98	preoperative
14,R3,Has_value Arg1:T10 Arg2:T11
15,T13,Qualifier 108 122	more than mild
16,T14,Condition 123 143	cognitive impairment
17,R4,Has_qualifier Arg1:T14 Arg2:T13
18,T15,Scope 54 82	MMSE score of = 20 out of 30
19,T16,Scope 108 143	more than mild cognitive impairment
20,R2,Subsumes Arg1:T15 Arg2:T16
21,R5,Has_temporal Arg1:T15 Arg2:T12
22,T17,Condition 148 156	delirium
23,T18,Temporal 160 172	preoperative
24,T19,Procedure 173 184	CAM testing
25,R6,Has_temporal Arg1:T19 Arg2:T18
26,R7,AND Arg1:T19 Arg2:T17
27,*,OR T15 T19
28,T20,Observation 189 206	language barriers
29,T21,Temporal 239 251	preoperative
30,T22,Drug 252 259	steroid
31,T23,Temporal 264 288	within 3 days of surgery
32,T24,Reference_point 281 288	surgery
33,T25,Procedure 281 288	surgery
34,R8,multi Arg1:T24 Arg2:T25
35,R9,Has_index Arg1:T23 Arg2:T24
36,R10,Has_temporal Arg1:T22 Arg2:T21
37,R11,Subsumes Arg1:T21 Arg2:T23
38,T26,Temporal 312 325	postoperative
39,T27,Procedure 326 336	intubation
40,T28,Mood 296 308	anticipation
41,R12,Has_mood Arg1:T27 Arg2:T28
42,R13,Has_temporal Arg1:T27 Arg2:T26
0,T1,"Non-query-able 0 383	Habitual exerciser defined as = 30 minutes of at least moderate or high intensity exercise = 3 times per week. After consent, and at the subsequent screening visit, a VO2 max test will be performed, and subjects with a low value (< 35 mL/kg/min) will be excluded (screen failure). Based on our previous experience, we anticipate that <10% of the subjects will fall into this category"
1,T2,Person 385 388	Men
2,T3,Measurement 427 430	TBV
3,T4,Value 390 426	(0.006012 x H3) + (14.6 x W) + 604 =
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Person 432 437	Women
6,T6,Measurement 474 477	TBV
7,T7,Value 439 471	(0.005835 x H3) + (15 x W) + 183
8,R2,Has_value Arg1:T6 Arg2:T7
9,T8,Non-query-able 520 638	Has access to transportation to visit the blood collection facility and to return to Stony Brook for all study visits.
0,T1,"Post-eligibility 0 70	Completed ""ALO-IIT-012(PEAK study)"", without major protocol deviations"
1,T2,Person 73 77	Male
2,T3,Person 82 88	female
3,T4,Person 105 110	years
4,T5,Value 90 104	19 years to 75
5,R1,Has_value Arg1:T4 Arg2:T5
6,*,OR T2 T3
7,T6,Pregnancy_considerations 113 304	Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study
8,T7,Post-eligibility 306 383	Subjects completed PEAK can be included within 30 days after End Of the Study
9,T8,Post-eligibility 385 508	Subjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study
0,T1,Condition 7 24	behavioral issues
1,T2,Qualifier 0 6	severe
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 38 45	fistula
4,T4,Condition 49 56	abscess
5,T5,Qualifier 57 80	near the selected tooth
6,*,OR T3 T4
7,T6,Scope 38 56	fistula or abscess
8,R2,Has_qualifier Arg1:T6 Arg2:T5
9,T7,Condition 94 107	pulp exposure
10,T8,Qualifier 115 129	selected tooth
11,R3,Has_qualifier Arg1:T7 Arg2:T8
12,T9,Condition 143 151	mobility
13,T10,Qualifier 159 173	selected tooth
14,R4,Has_qualifier Arg1:T9 Arg2:T10
0,T1,Person 0 8	Children
1,T2,Person 9 14	aging
2,T3,Value 15 36	between 3 and 6 years
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Condition 49 71	good health conditions
5,T5,Informed_consent 73 138	whose parents or legal guardians accept and sign the consent form
6,T6,Multiplier 145 157	at least one
7,T7,Qualifier 170 187	occlusal proximal
8,T8,Qualifier 158 166	occlusal
9,T9,Condition 188 201	caries lesion
10,T10,Qualifier 205 219	primary molars
11,*,OR T7 T8
12,T11,Scope 158 187	occlusal or occlusal proximal
13,R2,Has_scope Arg1:T9 Arg2:T11
14,R3,Has_qualifier Arg1:T9 Arg2:T10
15,R4,Has_multiplier Arg1:T9 Arg2:T6
16,T12,Condition 274 288	caries lesions
17,T13,Condition 294 312	dentin involvement
18,T14,Qualifier 242 268	occlusal-proximal surfaces
19,T15,Qualifier 226 234;260 268	occlusal surfaces
20,*,OR T15 T14
21,T16,Scope 226 268	occlusal and/or occlusal-proximal surfaces
22,T17,Scope 274 312	caries lesions with dentin involvement
23,R5,Has_scope Arg1:T17 Arg2:T16
0,T1,Person 16 21	years
1,T2,Value 8 15	over 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Measurement 22 30	weighing
4,T4,Value 31 51	between 65 and 85 Kg
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 66 71	STEMI
7,T7,Multiplier 162 174	loading dose
8,T8,Drug 178 187	Prasugrel
9,T9,Drug 191 201	Ticagrelor
10,*,OR T8 T9
11,T10,Scope 178 201	Prasugrel or Ticagrelor
12,R3,Has_multiplier Arg1:T10 Arg2:T7
13,T11,Temporal 72 115	within 6 hours from beginning of chest pain
14,T12,Reference_point 92 115	beginning of chest pain
15,R4,Has_temporal Arg1:T5 Arg2:T11
16,R5,Has_index Arg1:T11 Arg2:T12
17,T13,Condition 126 149	coronary artery disease
18,T14,Qualifier 119 125	stable
19,R6,Has_qualifier Arg1:T13 Arg2:T14
20,*,OR T5 T13
21,R7,Has_scope Arg1:T13 Arg2:T10
22,T15,Negation 251 253	No
23,T16,Drug 278 289	Clopidogrel
24,T17,Drug 291 300	Prasugrel
25,T18,Drug 304 314	Ticagrelor
26,*,OR T16 T17 T18
27,T19,"Scope 278 314	Clopidogrel, Prasugrel or Ticagrelor"
28,T20,Observation 325 332	fasting
29,T21,Temporal 333 354	for at least 6 hours.
30,R9,Has_temporal Arg1:T20 Arg2:T21
31,T22,Non-query-able 356 403	Affiliate or receiving a social security system
32,T6,Condition 105 115	chest pain
33,R10,multi Arg1:T12 Arg2:T6
34,T24,Temporal 254 262	previous
35,T25,Procedure 263 272	treatment
36,R8,Has_scope Arg1:T25 Arg2:T19
37,R11,Has_temporal Arg1:T25 Arg2:T24
38,R12,Has_negation Arg1:T25 Arg2:T15
39,T23,Observation 406 430	Written informed consent
0,T1,Condition 0 7	Allergy
1,T2,Condition 11 27	contraindication
2,T3,Drug 31 42	paracetamol
3,T4,Drug 44 53	Prasugrel
4,T5,Drug 57 67	Ticagrelor
5,*,OR T4 T5 T3
6,T6,"Scope 31 67	paracetamol, Prasugrel or Ticagrelor"
7,*,OR T1 T2
8,T7,Scope 0 27	Allergy or contraindication
9,R1,Has_scope Arg1:T7 Arg2:T6
10,T8,Drug 69 80	Paracetamol
11,T9,Temporal 91 115	in the previous 48 hours
12,R2,Has_temporal Arg1:T8 Arg2:T9
13,T10,Drug 186 205	calcium antagonists
14,T11,Procedure 207 234	Alimentary tract treatments
15,T12,Drug 236 253	opioid analgesics
16,T13,Drug 255 280	tricyclic antidepressants
17,T14,Drug 282 293	antibiotics
18,*,OR T10 T11 T12 T13 T14
19,T15,Condition 365 384	Thyroid dysfunction
20,T16,Condition 386 407	chronic renal failure
21,T17,Condition 409 428	Parkinson's disease
22,T18,Condition 430 441	scleroderma
23,T19,Condition 443 454	amyloidosis
24,T20,Condition 460 484	gastrointestinal disease
25,T21,Condition 500 510	malignancy
26,T22,Condition 529 540;557 564	psychiatric disease
27,T23,Condition 544 564	neurological disease
28,T24,Qualifier 520 528	advanced
29,*,OR T23 T22
30,T25,Scope 529 564	psychiatric or neurological disease
31,R3,Has_qualifier Arg1:T25 Arg2:T24
32,*,OR T25 T21 T20 T19 T18 T17 T16 T15
33,T26,Condition 580 588	vomiting
34,T27,Condition 590 607	Cardiogenic shock
35,T28,Condition 609 631	ventricular arrhythmia
36,T29,Condition 648 662	cardiac arrest
37,T30,Qualifier 635 647	resuscitated
38,R4,Has_qualifier Arg1:T29 Arg2:T30
39,*,OR T29 T28 T27
40,T31,Condition 664 685	Hepatic insufficiency
41,T32,Condition 694 713	respiratory disease
42,T33,Qualifier 687 693	Severe
43,R5,Has_qualifier Arg1:T32 Arg2:T33
44,T35,Drug 138 184	drugs supposed to alter gastric emptying times
45,T36,"Scope 186 293	calcium antagonists, Alimentary tract treatments, opioid analgesics, tricyclic antidepressants, antibiotics"
46,R6,Subsumes Arg1:T35 Arg2:T36
47,T37,Condition 311 363	pathologies supposed to alter gastric emptying times
48,T38,Condition 297 307;323 363	Conditions supposed to alter gastric emptying times
49,*,OR T37 T38
50,T39,Scope 297 363	Conditions or pathologies supposed to alter gastric emptying times
51,T40,"Scope 365 564	Thyroid dysfunction, chronic renal failure, Parkinson's disease, scleroderma, amyloidosis, any gastrointestinal disease, any not cured malignancy, and any advanced psychiatric or neurological disease"
52,R7,Subsumes Arg1:T39 Arg2:T40
53,T34,Condition 715 723	Pregnant
54,T41,Observation 727 740	breastfeeding
55,*,OR T34 T41
56,T42,Person 741 746	women
0,T1,Condition 0 15	Type I diabetic
1,T2,Condition 26 37	Parturients
2,T3,Measurement 52 68	Cesarean section
0,T1,Condition 16 36	bacterial infections
1,T2,Qualifier 8 15	serious
2,T3,Temporal 37 61	at the time of screening
3,T4,Reference_point 52 61	screening
4,R1,Has_index Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T1 Arg2:T2
6,R3,Has_temporal Arg1:T1 Arg2:T3
7,T5,Non-query-able 64 144	Other significant medical conditions that could increase the risk to the subject
8,T6,"Pregnancy_considerations 147 237	Females who are pregnant, breast feeding, or planning a pregnancy during the course study."
9,T7,Non-query-able 239 371	Participation in a study with an Investigational Medicinal Product (IMP) other than IgPro20 within three months prior to enrollment.
0,T1,Value 14 34	18 years old or more
1,T2,Person 23 26	old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 46 59	HCV treatment
4,T4,Negation 37 42	naive
5,R2,Has_negation Arg1:T3 Arg2:T4
6,T5,Measurement 62 74	HCV genotype
7,T6,Value 75 76	4
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Qualifier 79 90	compensated
10,T8,Condition 91 104	liver disease
11,R4,Has_qualifier Arg1:T8 Arg2:T7
0,T1,Qualifier 14 21	de novo
1,T2,Condition 23 36	heart Failure
2,T3,Measurement 41 45	LVEF
3,T4,Value 46 52	<= 40%
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Procedure 53 61	admitted
6,T6,Visit 65 73	hospital
7,R2,AND Arg1:T5 Arg2:T6
8,R3,Has_qualifier Arg1:T2 Arg2:T1
9,T7,Negation 75 82	without
10,T8,Condition 83 100	contraindications
11,T9,Drug 105 107	BB
12,R4,Has_negation Arg1:T8 Arg2:T7
13,R5,AND Arg1:T8 Arg2:T9
0,T1,Person 0 4	Male
1,T2,Person 8 14	female
2,*,OR T1 T2
3,T3,Drug 33 40	IgPro20
4,T4,Drug 42 50	Hizentra
5,R1,Subsumes Arg1:T3 Arg2:T4
6,T5,Qualifier 18 29	stable dose
7,R2,Has_qualifier Arg1:T3 Arg2:T5
8,T6,Pregnancy_considerations 62 269	Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening
9,T7,Condition 286 289	PID
10,T8,Condition 315 347	common variable immunodeficiency
11,T9,Condition 351 378	X-linked agammaglobulinemia
12,T10,Measurement 398 438	Pan American Group for Immune Deficiency
13,T11,Measurement 447 486	European Society of Immune Deficiencies
14,T12,Non-query-able 439 442	and
15,*,OR T10 T11
16,T13,Scope 398 486	Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies
17,*,OR T8 T9
18,T14,Scope 315 378	common variable immunodeficiency or X-linked agammaglobulinemia
19,R3,Has_scope Arg1:T13 Arg2:T14
20,T15,Qualifier 551 574	pump-assisted infusions
21,T16,Drug 578 585	IgPro20
22,R4,Has_qualifier Arg1:T16 Arg2:T15
23,T17,Multiplier 603 642	flow rate of 25 mL/h per injection site
24,T18,Qualifier 593 602	tolerated
25,R5,Has_qualifier Arg1:T17 Arg2:T18
26,R6,Has_multiplier Arg1:T16 Arg2:T17
27,T19,Temporal 643 678	for at least 1 month prior to Day 1
28,T20,Reference_point 673 678	Day 1
29,R7,Has_index Arg1:T19 Arg2:T20
30,R8,Has_temporal Arg1:T16 Arg2:T19
31,T21,Qualifier 687 693	weekly
32,T22,Drug 694 701	IgPro20
33,T23,Multiplier 710 717	= 50 mL
34,T24,Multiplier 719 725	= 10 g
35,R9,Subsumes Arg1:T23 Arg2:T24
36,R10,Has_qualifier Arg1:T22 Arg2:T21
37,R11,Has_multiplier Arg1:T22 Arg2:T23
38,T25,Qualifier 745 768	pump-assisted infusions
39,T26,Drug 772 779	IgPro20
40,T27,Multiplier 793 824	volumes of 25 mL/injection site
41,T28,Qualifier 783 792	tolerated
42,T29,Temporal 825 860	for at least 1 month prior to Day 1
43,T30,Reference_point 855 860	Day 1
44,R12,Has_index Arg1:T29 Arg2:T30
45,R13,Has_qualifier Arg1:T27 Arg2:T28
46,R14,Has_multiplier Arg1:T26 Arg2:T27
47,R15,Has_temporal Arg1:T26 Arg2:T29
48,R16,Has_qualifier Arg1:T26 Arg2:T25
49,T31,Qualifier 879 887	frequent
50,T32,Drug 922 929	IgPro20
51,T33,Multiplier 1012 1030;947 984	per injection site flow rate of approximately 0.5 mL/min
52,T34,Multiplier 1000 1010	25-30 mL/h
53,T35,Temporal 1031 1066	for at least 1 month prior to Day 1
54,T36,Reference_point 1061 1066	Day 1
55,R17,Has_qualifier Arg1:T32 Arg2:T31
56,T37,Multiplier 889 907	2-7 times per week
57,R18,Has_multiplier Arg1:T32 Arg2:T37
58,R19,Has_multiplier Arg1:T32 Arg2:T33
59,R20,Subsumes Arg1:T33 Arg2:T34
60,R21,Has_temporal Arg1:T32 Arg2:T35
61,R22,Has_index Arg1:T35 Arg2:T36
62,T38,Negation 1112 1115	not
63,T39,Multiplier 1116 1129	exceed 25 mL.
64,R23,Has_negation Arg1:T39 Arg2:T38
65,R24,Has_multiplier Arg1:T32 Arg2:T39
0,T1,Condition 0 17	Contraindications
1,T2,Procedure 22 39	spinal anesthesia
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 46 64	bleeding diathesis
4,T4,Condition 68 86	regional infection
5,T5,Qualifier 90 114	site of neuroaxial block
6,*,OR T3 T4
7,T6,Scope 46 86	bleeding diathesis or regional infection
8,R2,Has_qualifier Arg1:T6 Arg2:T5
9,T7,Condition 123 130	allergy
10,T8,Drug 134 145	Granisetron
11,T9,Drug 149 166	local anaesthetic
12,T10,Drug 168 185	heavy bupivacaine
13,T11,Drug 187 213	Marcaine Spinal 0.5% Heavy
14,T12,Qualifier 215 221	5mg/ml
15,T13,Qualifier 223 241	AstraZeneca ampule
16,R3,Subsumes Arg1:T10 Arg2:T11
17,R4,Has_qualifier Arg1:T11 Arg2:T12
18,R5,Has_qualifier Arg1:T11 Arg2:T13
19,T14,"Scope 168 241	heavy bupivacaine, Marcaine Spinal 0.5% Heavy, 5mg/ml, AstraZeneca ampule"
20,*,OR T8 T9
21,R6,Subsumes Arg1:T9 Arg2:T14
22,T15,"Scope 134 242	Granisetron or local anaesthetic (heavy bupivacaine, Marcaine Spinal 0.5% Heavy, 5mg/ml, AstraZeneca ampule)"
23,R7,Has_scope Arg1:T7 Arg2:T15
24,T16,Condition 244 253	Pregnancy
25,T17,Condition 262 274	hypertension
26,T18,Qualifier 244 261	Pregnancy induced
27,R8,multi Arg1:T18 Arg2:T16
28,R9,Has_qualifier Arg1:T17 Arg2:T18
29,T19,Qualifier 276 286	Congenital
30,T20,Qualifier 290 299	rheumatic
31,T21,Condition 300 314	heart diseases
32,*,OR T20 T19
33,T22,Scope 276 299	Congenital or rheumatic
34,R10,Has_scope Arg1:T21 Arg2:T22
35,T23,Condition 316 338	Antepartum haemorrhage
36,T24,Condition 340 354	Fetal destress
37,T25,Measurement 358 373	gestational age
38,T26,Value 374 383	< 36 week
39,R11,Has_value Arg1:T25 Arg2:T26
40,*,OR T24 T25
0,T1,Condition 23 26;34 43	HCV infection
1,T2,Condition 27 30;34 43	HBV infection
2,*,OR T1 T2
3,T3,Condition 45 75	hepatocellular carcinoma (HCC)
4,T4,Condition 91 106	liver cirrhosis
5,T5,Qualifier 77 90	decompensated
6,R1,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Measurement 108 124	Child-Pugh score
8,T7,Value 125 132	above 6
9,R2,Has_value Arg1:T6 Arg2:T7
10,R3,Subsumes Arg1:T5 Arg2:T6
11,T8,Condition 139 149	genotype 4
12,T9,Negation 135 138	non
13,R4,Has_negation Arg1:T8 Arg2:T9
0,T1,Condition 0 17	Contraindications
1,T2,Drug 22 24	BB
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Visit 39 51	nursing home
4,T4,Observation 27 33	Living
5,R2,AND Arg1:T4 Arg2:T3
6,T5,Observation 54 69	Life expectancy
7,T6,Value 70 80	< 6 months
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 83 102	Unable to self-care
10,T8,Condition 106 120	mental disease
11,T9,Qualifier 121 138	without caregiver
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,*,OR T7 T8
14,T10,Procedure 151 157	weight
15,T11,Condition 141 147	Unable
16,R5,AND Arg1:T11 Arg2:T10
17,T12,Observation 167 172	phone
18,T13,Negation 159 166	Without
19,R6,Has_negation Arg1:T12 Arg2:T13
20,T14,Observation 174 180	Unable
21,T15,Observation 184 202	go to clinic visit
22,R7,Has_context Arg1:T15 Arg2:T14
0,T1,Condition 14 26	renal cancer
1,T2,Qualifier 41 53	laparoscopic
2,T3,Procedure 54 73	radical nephrectomy
3,R1,Has_qualifier Arg1:T3 Arg2:T2
0,T1,Condition 0 6	asthma
1,T2,Condition 11 15	COPD
2,*,OR T1 T2
0,T1,Condition 45 63	middle ear disease
1,T2,Condition 65 85	chronic lung disease
2,T3,Condition 89 103	claustrophobia
3,*,OR T2 T3 T1
0,T1,Person 0 3	age
1,T2,Value 4 25	under 18y or over 85y
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 27 42	diabetes type 1
4,T4,Condition 48 61	complications
5,R2,AND Arg1:T3 Arg2:T4
6,T5,Observation 66 78	co-operation
7,T6,Negation 63 65	no
8,R3,Has_negation Arg1:T5 Arg2:T6
9,T7,Observation 82 116	inadequate finnish language skills
10,*,OR T7 T5
11,T8,Condition 118 133	persistent pain
12,T9,Qualifier 138 150	other reason
13,R4,Has_qualifier Arg1:T8 Arg2:T9
14,T10,Qualifier 152 158	severe
15,T11,Condition 159 180	hepatic insufficiency
16,T12,Drug 184 195	paracetamol
17,T13,Drug 197 210	acetaminophen
18,T14,Condition 215 230	contraindicated
19,R5,Subsumes Arg1:T12 Arg2:T13
20,R6,AND Arg1:T14 Arg2:T12
21,R7,Has_qualifier Arg1:T11 Arg2:T10
22,*,OR T11 T14
23,T15,Drug 261 268	steroid
24,T16,Multiplier 272 283	regular use
25,R8,Has_multiplier Arg1:T15 Arg2:T16
26,T17,Drug 285 294	oxycodone
27,T18,Condition 295 310	contraindicated
28,R9,AND Arg1:T18 Arg2:T17
29,T19,Drug 341 352	paracetamol
30,T20,Drug 354 367	acetaminophen
31,R10,Subsumes Arg1:T19 Arg2:T20
32,T21,Drug 376 387	ropivacaine
33,T23,Multiplier 402 413	regular use
34,*,OR T19 T21
35,T22,Scope 341 387	paracetamol (acetaminophen) and/or ropivacaine
36,R11,Has_multiplier Arg1:T22 Arg2:T23
0,T1,Condition 0 6	asthma
1,T2,Condition 10 14	COPD
2,*,OR T1 T2
0,T1,Condition 31 40	deep peel
1,T2,Person 41 46	women
2,T3,Condition 48 55	exoderm
3,R1,Subsumes Arg1:T1 Arg2:T3
4,T4,Value 58 77	older than 18 years
5,T5,Person 78 81	old
6,R2,Has_value Arg1:T5 Arg2:T4
7,T6,"Non-representable 132 265	The treatment group will receive 5 consecutive daily hyperbaric treatments, 1 hours long each, at 2 ATF, starting from day 7 to peel."
8,T7,Observation 384 397	control group
9,T8,Person 443 446	age
10,T9,Person 448 458	skin color
11,T10,Person 463 467	type
12,T11,"Scope 443 467	age, skin color and type"
13,R3,Has_context Arg1:T11 Arg2:T7
0,T1,Measurement 0 52	American Society of Anesthesiologist physical status
1,T2,Value 53 56	1-3
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Qualifier 72 80	elective
4,T4,Mood 58 71	Scheduled for
5,T5,Procedure 81 112	video-assisted thoracic surgery
6,R2,Has_qualifier Arg1:T5 Arg2:T3
7,R3,Has_mood Arg1:T5 Arg2:T4
8,T6,Device 132 167	patient-controlled analgesia device
9,T7,Device 169 172	PCA
10,R4,Subsumes Arg1:T6 Arg2:T7
0,T1,Person 0 3	Age
1,T2,Value 7 17	= 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Observation 29 66	able to give written informed consent
4,T4,Qualifier 69 75	Active
5,T5,Qualifier 76 83	chronic
6,T6,Condition 84 123	central serous chorioretinopathy (cCSC)
7,R2,Has_qualifier Arg1:T6 Arg2:T5
8,R3,Has_qualifier Arg1:T6 Arg2:T4
9,T7,Condition 126 148	Subjective visual loss
10,T8,Temporal 149 158	> 6 weeks
11,R4,Has_temporal Arg1:T7 Arg2:T8
12,T9,Non-representable 160 199	interpreted as onset of active disease;
13,T10,Condition 201 230	Foveal subretinal fluid (SRF)
14,T11,Procedure 235 269	optical coherence tomography (OCT)
15,R5,AND Arg1:T11 Arg2:T10
16,T12,Temporal 271 294	at Baseline Examination
17,R6,Has_temporal Arg1:T11 Arg2:T12
18,T13,Reference_point 274 294	Baseline Examination
19,R7,Has_index Arg1:T12 Arg2:T13
20,T14,Multiplier 297 299	=1
21,T15,Qualifier 300 311	ill-defined
22,T16,Condition 312 342	hyperfluorescent leakage areas
23,R8,Has_qualifier Arg1:T16 Arg2:T15
24,R9,Has_multiplier Arg1:T16 Arg2:T14
25,T17,Procedure 346 374	fluorescein angiography (FA)
26,R10,AND Arg1:T17 Arg2:T16
27,T18,Condition 380 423	retinal pigment epithelial window defect(s)
28,R11,AND Arg1:T17 Arg2:T18
29,T19,Non-representable 424 453	that are compatible with cCSC
30,T20,Condition 456 478	Hyperfluorescent areas
31,T21,Procedure 482 518	indocyanine green angiography (ICGA)
32,R12,AND Arg1:T21 Arg2:T20
0,T1,Context_Error 0 155	Prior treatment toxicities have not resolved to < Grade 2 according to NCI CTCAE Version 4.0 (except clinically insignificant toxicities such as alopecia).
1,T2,Context_Error 157 209	Subjects receiving any other investigational agents.
2,T3,Condition 232 258	tumor lysis syndrome (TLS)
3,T4,Condition 325 361	central nervous system (CNS) disease
4,T5,Condition 385 403	meningeal lymphoma
5,T6,Qualifier 373 384	symptomatic
6,R1,Has_qualifier Arg1:T5 Arg2:T6
7,T7,Condition 413 437	CNS parenchymal lymphoma
8,*,OR T7 T5
9,T8,Scope 373 437	symptomatic meningeal lymphoma or known CNS parenchymal lymphoma
10,R2,Has_scope Arg1:T4 Arg2:T8
11,T9,Condition 458 476	allergic reactions
12,T10,Qualifier 451 457	severe
13,R3,Has_qualifier Arg1:T9 Arg2:T10
14,T12,Drug 491 557	compounds of similar chemical or biologic composition to rituximab
15,T11,Drug 491 547;561 592	compounds of similar chemical or biologic composition to other agents used in this study
16,*,OR T12 T11
17,T13,Undefined_semantics 491 592	compounds of similar chemical or biologic composition to rituximab or other agents used in this study
18,T14,Scope 491 592	compounds of similar chemical or biologic composition to rituximab or other agents used in this study
19,R4,Has_scope Arg1:T9 Arg2:T14
20,T15,Undefined_semantics 595 642	Subjects with uncontrolled intercurrent illness
21,T16,Condition 646 658	HIV-positive
22,T17,Procedure 671 705	combination antiretroviral therapy
23,T20,Parsing_Error 913 1024	Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.
24,T21,Not_a_criteria 913 1024	Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.
25,T22,Not_a_criteria 1025 1164	HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV assessment.
26,T23,Measurement 1204 1227	hepatitis B virus (HBV)
27,T24,Measurement 1229 1264	hepatitis B surface antigen (HBsAg)
28,T25,Measurement 1269 1295	hepatitis C (HCV) antibody
29,T26,Value 1178 1186	positive
30,R5,Has_value Arg1:T23 Arg2:T26
31,R6,Has_value Arg1:T24 Arg2:T26
32,R7,Has_value Arg1:T25 Arg2:T26
33,T27,Measurement 1328 1340	HCV antibody
34,T28,Value 1315 1323	positive
35,R8,Has_value Arg1:T27 Arg2:T28
36,T29,Measurement 1362 1365	HCV
37,T30,Value 1349 1357	negative
38,R9,Has_value Arg1:T29 Arg2:T30
39,T31,Scope 1315 1340	positive for HCV antibody
40,A1,Optional T31
41,R10,AND Arg1:T31 Arg2:T29
42,T32,Procedure 1369 1400	polymerase chain reaction (PCR)
43,R11,AND Arg1:T29 Arg2:T32
44,T33,Condition 1471 1484	HBV infection
45,T34,Measurement 1506 1545	total hepatitis B core antibody [HBcAb]
46,T35,Value 1497 1505	positive
47,T36,Measurement 1559 1564	HBsAg
48,T37,Value 1550 1558	negative
49,R12,Has_value Arg1:T36 Arg2:T37
50,R13,Has_value Arg1:T34 Arg2:T35
51,T38,Measurement 1585 1592	HBV DNA
52,T39,Value 1596 1608	undetectable
53,R14,Has_value Arg1:T38 Arg2:T39
54,T40,Scope 1497 1564	positive total hepatitis B core antibody [HBcAb] and negative HBsAg
55,R15,Has_scope Arg1:T33 Arg2:T40
56,A2,Optional T33
57,R16,AND Arg1:T33 Arg2:T38
58,T41,Grammar_Error 1566 1581	may be included
59,T42,Non-query-able 1610 1672	These patients must be willing to undergo monthly DNA testing.
60,T43,Person 1674 1679	Women
61,T44,Condition 1688 1696	pregnant
62,T45,Condition 1700 1709	lactating
63,*,OR T44 T45
64,A3,Optional T43
65,R17,AND Arg1:T43 Arg2:T44
66,T46,Condition 1711 1733	Malabsorption syndrome
67,T47,Condition 1743 1799	condition that precludes enteral route of administration
68,T48,Undefined_semantics 1743 1799	condition that precludes enteral route of administration
69,*,OR T46 T47
70,T49,Drug 1801 1813	Chemotherapy
71,T50,Procedure 1817 1826	radiation
72,T51,Temporal 1827 1880	within 3 weeks of the first scheduled study treatment
73,T52,Reference_point 1845 1880	the first scheduled study treatment
74,R18,Has_index Arg1:T51 Arg2:T52
75,R19,Has_temporal Arg1:T50 Arg2:T51
76,R20,Has_temporal Arg1:T49 Arg2:T51
77,*,OR T50 T49
78,T53,Temporal 1883 1899	Less than 2-year
79,T54,Condition 1900 1912	disease free
80,T55,Condition 1926 1944	primary malignancy
81,T56,Qualifier 1918 1925	another
82,R21,Has_qualifier Arg1:T55 Arg2:T56
83,R22,Has_temporal Arg1:T54 Arg2:T53
84,R23,AND Arg1:T54 Arg2:T55
85,T57,Condition 1957 2001	squamous or basal cell carcinoma of the skin
86,T58,"Condition 2003 2036	""in-situ"" carcinoma of the cervix"
87,T59,"Condition 2003 2036;2040 2046	""in-situ"" carcinoma of the cervix breast"
88,T60,Condition 2048 2077	superficial bladder carcinoma
89,T61,Condition 2101 2126	localized prostate cancer
90,T62,Measurement 2139 2177	prostate specific antigen (PSA) levels
91,T63,Value 2132 2138	normal
92,R24,Has_value Arg1:T62 Arg2:T63
93,R25,AND Arg1:T61 Arg2:T62
94,*,OR T57 T59 T58 T60 T61
95,T64,"Scope 1957 2177	squamous or basal cell carcinoma of the skin, ""in-situ"" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels"
96,T65,Procedure 2216 2237	anti-cancer treatment
97,T66,Condition 2250 2268	primary malignancy
98,T67,Qualifier 2242 2249	another
99,R27,Has_qualifier Arg1:T66 Arg2:T67
100,T68,Temporal 2269 2292	more than 2 years prior
101,T69,Reference_point 2296 2305	screening
102,R28,Has_index Arg1:T68 Arg2:T69
103,R29,AND Arg1:T65 Arg2:T66
104,R30,Has_temporal Arg1:T65 Arg2:T68
105,T70,Negation 2306 2318	are eligible
106,T71,Procedure 2436 2449	Major surgery
107,T72,Procedure 2462 2480	diagnostic surgery
108,T73,Temporal 2482 2496	within 2 weeks
109,R32,Has_temporal Arg1:T71 Arg2:T73
110,T74,Drug 2552 2576	systemic corticosteroids
111,T75,Drug 2593 2603	prednisone
112,T76,Multiplier 2604 2625	higher than 10 mg/day
113,T77,Multiplier 2542 2551	high dose
114,R33,Has_multiplier Arg1:T74 Arg2:T77
115,R34,Has_multiplier Arg1:T75 Arg2:T76
116,T78,Condition 2499 2516	Medical condition
117,T79,Undefined_semantics 2499 2516	Medical condition
118,T80,Temporal 2527 2534	chronic
119,R35,Has_temporal Arg1:T74 Arg2:T80
120,R36,AND Arg1:T78 Arg2:T74
121,T81,Scope 2584 2625	doses of prednisone higher than 10 mg/day
122,R37,Subsumes Arg1:T77 Arg2:T81
123,T82,Temporal 2649 2657	<15 days
124,T83,Drug 2674 2689	glucocorticoids
125,T84,Drug 2691 2701	prednisone
126,T85,Multiplier 2702 2708;2718 2723	100 mg daily
127,T86,Grammar_Error 2740 2753	is acceptable
128,R38,Has_multiplier Arg1:T84 Arg2:T85
129,R39,Has_temporal Arg1:T83 Arg2:T82
130,R40,Subsumes Arg1:T83 Arg2:T84
131,T87,Drug 2778 2805	xanthine oxidase inhibitors
132,T88,Drug 2810 2821	rasburicase
133,T89,Condition 2762 2769	allergy
134,R41,AND Arg1:T89 Arg2:T87
135,T90,Condition 2762 2769	allergy
136,R42,AND Arg1:T90 Arg2:T88
137,T91,Drug 2831 2839	warfarin
138,T92,Procedure 2855 2870	Anticoagulation
139,T93,Drug 2876 2904	low-molecular weight heparin
140,T94,Drug 2911 2921	enoxaparin
141,R43,Subsumes Arg1:T93 Arg2:T94
142,T95,Drug 2926 2952	direct thrombin inhibitors
143,*,OR T95 T93
144,T96,Grammar_Error 2953 2966	is permitted.
145,R44,AND Arg1:T92 Arg2:T93
146,T97,Temporal 3027 3039	7 days prior
147,T98,Reference_point 3047 3071	first dose of study drug
148,T99,Drug 3083 3093	venetoclax
149,T100,Procedure 3083 3108	venetoclax administration
150,T101,Drug 3110 3134	Strong CYP3A4 inhibitors
151,T102,Drug 3164 3175	fluconazole
152,T103,Drug 3177 3189	ketoconazole
153,T104,Drug 3195 3209	clarithromycin
154,T105,Drug 3213 3235	strong CYP3A4 inducers
155,T106,Drug 3264 3272	rifampin
156,T107,Drug 3274 3287	carbamazepine
157,T108,"Scope 3264 3287	rifampin, carbamazepine"
158,R45,Subsumes Arg1:T105 Arg2:T108
159,T109,"Scope 3164 3209	fluconazole, ketoconazole, and clarithromycin"
160,R46,Subsumes Arg1:T101 Arg2:T109
161,*,OR T101 T105
162,*,OR T100 T97
163,R47,Has_index Arg1:T97 Arg2:T98
164,T110,Scope 3027 3108	7 days prior to the first dose of study drug and during venetoclax administration
165,A4,Optional T110
166,T111,"Scope 3110 3287	Strong CYP3A4 inhibitors including but not limited to fluconazole, ketoconazole, and clarithromycin or strong CYP3A4 inducers included but not limited to rifampin, carbamazepine"
167,R48,Has_scope Arg1:T110 Arg2:T111
168,T112,Drug 3301 3320	live-virus vaccines
169,T113,Temporal 3321 3341	within 28 days prior
170,T114,Reference_point 3345 3378	the initiation of study treatment
171,T115,Non-query-able 3382 3390	need for
172,T116,Drug 3391 3410	live-virus vaccines
173,T117,Temporal 3414 3429	any time during
174,T118,Reference_point 3430 3445	study treatment
175,R49,Has_index Arg1:T117 Arg2:T118
176,R50,Has_temporal Arg1:T116 Arg2:T117
177,R51,AND Arg1:T116 Arg2:T115
178,T119,Observation 3382 3390	need for
179,R52,Has_temporal Arg1:T112 Arg2:T113
180,R53,Has_index Arg1:T113 Arg2:T114
181,*,OR T112 T116
182,T120,Undefined_semantics 3448 3588	Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be considered cautionary.
183,T121,Context_Error 3448 3588	Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be considered cautionary.
184,T122,Drug 3599 3618	Weak CYP3A inducers
185,T123,Drug 3590 3598;3604 3618	Moderate CYP3A inducers
186,T124,Drug 3627 3636	efavirenz
187,T125,Drug 3641 3654	oxcarbazepine
188,*,OR T124 T125
189,T126,Scope 3590 3618	Moderate/Weak CYP3A inducers
190,*,OR T123 T122
191,T127,Scope 3627 3654	efavirenz and oxcarbazepine
192,R54,Subsumes Arg1:T126 Arg2:T127
193,T128,Drug 3656 3673	CYP2C8 substrates
194,T129,Undefined_semantics 3656 3673	CYP2C8 substrates
195,T130,Drug 3682 3700	thiazolidinediones
196,T131,Drug 3702 3712	glitazones
197,R55,Subsumes Arg1:T130 Arg2:T131
198,T132,Drug 3725 3732	statins
199,T133,Qualifier 3718 3724	select
200,R56,Has_qualifier Arg1:T132 Arg2:T133
201,R57,Subsumes Arg1:T128 Arg2:T130
202,T134,Drug 3820 3837	CYP2C9 substrates
203,T135,Drug 3846 3857	tolbutamide
204,R58,Subsumes Arg1:T134 Arg2:T135
205,T136,Drug 3973 3990	CYP2C9 substrates
206,T137,Drug 4031 4040	phenytoin
207,T138,Qualifier 3998 4022	narrow therapeutic index
208,R59,Has_qualifier Arg1:T136 Arg2:T138
209,R60,Subsumes Arg1:T136 Arg2:T137
210,T139,Subjective_judgement 3944 4040	It is recommended to exclude CYP2C9 substrates with a narrow therapeutic index such as phenytoin
211,T18,"Non-representable 796 912	In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy."
212,R61,AND Arg1:T16 Arg2:T17
213,*,OR T128 T132
214,T19,Negation 2451 2461	other than
215,R31,AND Arg1:T71 Arg2:T72
216,R62,Has_negation Arg1:T72 Arg2:T19
217,T140,Negation 1946 1956	other than
218,R26,Has_negation Arg1:T64 Arg2:T140
219,R63,Has_scope Arg1:T54 Arg2:T64
220,R64,Has_negation Arg1:T65 Arg2:T70
0,T1,Drug 21 35	anti-TNF agent
1,T2,Drug 39 44	DMARD
2,T3,Multiplier 4 17	dose increase
3,*,OR T1 T2
4,T4,Scope 21 44	anti-TNF agent or DMARD
5,R1,Has_multiplier Arg1:T4 Arg2:T3
6,T5,Drug 81 95	anti-TNF agent
7,T6,Drug 99 104	DMARD
8,T7,Procedure 71 77	change
9,*,OR T5 T6
10,T8,Scope 81 104	anti-TNF agent or DMARD
11,T9,Temporal 45 65	in the last 6 months
12,R2,Has_temporal Arg1:T4 Arg2:T9
13,T10,Temporal 105 125	in the last 6 months
14,R3,Has_scope Arg1:T7 Arg2:T8
15,R4,Has_temporal Arg1:T7 Arg2:T10
16,T11,Drug 150 159	golimumab
17,T12,Drug 163 175	certolizumab
18,*,OR T11 T12
19,T13,Multiplier 190 208	greater than 10 mg
20,T14,Drug 212 222	prednisone
21,T15,Multiplier 239 244	daily
22,T16,Temporal 245 265	in the last 6 months
23,R5,Has_multiplier Arg1:T14 Arg2:T13
24,R6,Has_multiplier Arg1:T14 Arg2:T15
25,R7,Has_temporal Arg1:T14 Arg2:T16
26,T17,Multiplier 280 297	greater than 5 mg
27,T18,Drug 301 311	prednisone
28,T19,Multiplier 328 333	daily
29,T20,Temporal 334 354	in the last 3 months
30,R8,Has_multiplier Arg1:T18 Arg2:T17
31,R9,Has_multiplier Arg1:T18 Arg2:T19
32,R10,Has_temporal Arg1:T18 Arg2:T20
33,T21,Qualifier 369 382	intramuscular
34,T22,Qualifier 386 397	intravenous
35,*,OR T21 T22
36,T23,Drug 398 413	corticosteroids
37,T24,Temporal 414 434	in the last 6 months
38,T25,Condition 439 441	RA
39,T26,Scope 369 397	intramuscular or intravenous
40,R11,Has_scope Arg1:T23 Arg2:T26
41,R12,Has_temporal Arg1:T23 Arg2:T24
42,T27,Drug 465 473	anakinra
43,T28,Drug 475 484	abatacept
44,T29,Drug 489 500	tocilizumab
45,T30,Temporal 501 521	in the last 6 months
46,*,OR T28 T29 T27
47,T31,"Scope 465 500	anakinra, abatacept, or tocilizumab"
48,R13,Has_temporal Arg1:T31 Arg2:T30
49,T32,Drug 536 545	rituximab
50,T33,Temporal 546 567	in the last 12 months
51,R14,Has_temporal Arg1:T32 Arg2:T33
52,T34,Qualifier 585 600	investigational
53,T35,Drug 601 608	RA drug
54,T36,Temporal 609 629	in the last 6 months
55,R15,Has_temporal Arg1:T35 Arg2:T36
56,R16,Has_qualifier Arg1:T35 Arg2:T34
57,T37,Condition 631 639	Pregnant
58,T38,Condition 693 702	lactating
59,T39,Person 703 708	women
60,*,OR T37 T38
61,T40,Mood 644 654;665 688	anticipate during the study period
62,T41,Condition 655 664	pregnancy
63,R17,Has_mood Arg1:T41 Arg2:T40
64,R18,Subsumes Arg1:T37 Arg2:T41
65,T42,Negation 710 720	Absence of
66,T43,Condition 760 778	clinical remission
67,T44,Temporal 779 800	for the last 6 months
68,R19,Has_temporal Arg1:T43 Arg2:T44
69,R20,Has_negation Arg1:T43 Arg2:T42
70,T45,Mood 802 811	Unwilling
71,T46,Procedure 815 826	discontinue
72,T47,Drug 827 841	anti-TNF agent
73,R21,AND Arg1:T46 Arg2:T47
74,R22,Has_mood Arg1:T46 Arg2:T45
75,T48,Negation 843 853	Absence of
76,T49,Value 871 879	negative
77,T50,Procedure 880 900	tuberculin skin test
78,R23,Has_value Arg1:T50 Arg2:T49
79,R24,Has_negation Arg1:T50 Arg2:T48
80,T51,Value 902 910	negative
81,T52,Measurement 911 935	QuantiFERON-TB Gold test
82,R25,Has_value Arg1:T52 Arg2:T51
83,T53,Qualifier 954 960	latent
84,T54,Condition 961 973	tuberculosis
85,R26,Has_qualifier Arg1:T54 Arg2:T53
86,T55,Procedure 940 949	treatment
87,R27,AND Arg1:T55 Arg2:T54
88,T56,Temporal 974 1025	prior to starting treatment with the anti-TNF agent
89,T57,Reference_point 983 1025	starting treatment with the anti-TNF agent
90,T58,Procedure 992 1025	treatment with the anti-TNF agent
91,T59,Drug 1011 1025	anti-TNF agent
92,R28,multi Arg1:T58 Arg2:T59
93,R29,multi Arg1:T57 Arg2:T58
94,R30,Has_index Arg1:T56 Arg2:T57
95,R31,Has_temporal Arg1:T55 Arg2:T56
96,T60,Condition 1040 1056	solid malignancy
97,T61,Condition 1060 1084	non-melanoma skin cancer
98,*,OR T60 T61
99,T62,Temporal 1085 1108	within the past 5 years
100,T63,Condition 1128 1136	melanoma
101,T64,Condition 1140 1151	hematologic
102,T65,Condition 1155 1185	lymphoproliferative malignancy
103,*,OR T63 T64 T65 T67
104,T67,Scope 1040 1084	solid malignancy or non-melanoma skin cancer
105,R32,Has_temporal Arg1:T67 Arg2:T62
106,T66,Procedure 1231 1247	cancer screening
107,T68,Qualifier 1215 1230	age-appropriate
108,R33,Has_qualifier Arg1:T66 Arg2:T68
109,T69,Temporal 1248 1276	at the time of randomization
110,T70,Reference_point 1251 1276	the time of randomization
111,R34,Has_index Arg1:T69 Arg2:T70
112,R35,Has_temporal Arg1:T66 Arg2:T69
113,T71,Measurement 1315 1337	hepatitis B serologies
114,T72,Value 1306 1314	negative
115,R36,Has_value Arg1:T71 Arg2:T72
116,T73,Negation 1278 1288	Absence of
117,R37,Has_negation Arg1:T71 Arg2:T73
118,T74,Procedure 1364 1373	treatment
119,T75,Condition 1378 1397	chronic hepatitis B
120,R38,AND Arg1:T74 Arg2:T75
121,T76,Negation 1339 1349	absence of
122,T77,Non-representable 1350 1363	completion of
123,T78,Procedure 1413 1444	suppressive antiviral treatment
124,T79,Negation 1402 1409	absence
125,R39,Has_negation Arg1:T78 Arg2:T79
126,*,OR T75 T78 T71
127,R40,Has_negation Arg1:T75 Arg2:T76
128,T80,Informed_consent 1446 1480	Unable to provide informed consent
129,T81,Post-eligibility 1482 1564	Anticipate not being available or able to comply with the schedule of study visits
0,T1,Drug 11 19	morphine
1,T2,Condition 20 27	allergy
2,R1,AND Arg1:T2 Arg2:T1
3,T3,Observation 0 7	History
4,T4,Drug 40 51	bupivacaine
5,T5,Condition 52 59	allergy
6,R2,AND Arg1:T5 Arg2:T4
7,T6,Observation 29 36	History
8,R3,Has_temporal Arg1:T5 Arg2:T6
9,R4,Has_temporal Arg1:T2 Arg2:T3
10,T7,Condition 61 77	Contraindication
11,T8,Drug 82 90	ketamine
12,T9,Procedure 82 99	ketamine infusion
13,R5,multi Arg1:T9 Arg2:T8
14,R6,AND Arg1:T7 Arg2:T9
15,T10,Condition 101 117	Contraindication
16,T11,Qualifier 122 130	thoracic
17,T12,Procedure 131 150	paravertebral block
18,R7,Has_qualifier Arg1:T12 Arg2:T11
19,R8,AND Arg1:T10 Arg2:T12
20,T13,Temporal 164 177	postoperative
21,T14,Procedure 178 207	positive pressure ventilation
22,R9,Has_temporal Arg1:T14 Arg2:T13
23,T15,Mood 152 163	Anticipated
24,T16,Scope 164 207	postoperative positive pressure ventilation
25,R10,Has_mood Arg1:T16 Arg2:T15
26,T17,Measurement 209 224	Body mass index
27,T18,Value 225 237	more than 35
28,R11,Has_value Arg1:T17 Arg2:T18
29,T19,Condition 249 269	psychiatric disorder
0,T1,Qualifier 28 34	active
1,T2,Condition 35 38	CSC
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Procedure 13 23	treatments
4,R2,AND Arg1:T3 Arg2:T2
5,T4,Temporal 4 12	previous
6,R3,Has_temporal Arg1:T3 Arg2:T4
7,T5,Temporal 41 49	Previous
8,T6,Drug 66 104	mineralocorticoid receptor antagonists
9,T7,Condition 110 114	cCSC
10,T8,Condition 122 136	other diseases
11,*,OR T7 T8
12,T9,Scope 110 136	cCSC or for other diseases
13,R4,Has_scope Arg1:T6 Arg2:T9
14,R5,Has_temporal Arg1:T6 Arg2:T5
15,T10,Drug 162 177	corticosteroids
16,T11,Temporal 139 146	Current
17,R6,Has_temporal Arg1:T10 Arg2:T11
18,T12,Qualifier 179 186	topical
19,T13,Qualifier 190 198	systemic
20,T14,Scope 179 198	topical or systemic
21,R7,Has_scope Arg1:T10 Arg2:T14
22,T15,Procedure 201 219	corticosteroid use
23,T16,Temporal 220 276	within 3 months before possible start of trial treatment
24,T17,Reference_point 243 276	possible start of trial treatment
25,R8,Has_index Arg1:T16 Arg2:T17
26,T18,Procedure 302 326	corticosteroid treatment
27,T19,Temporal 327 386	within the first 2 years from the start of the trial period
28,T20,Reference_point 334 386	the first 2 years from the start of the trial period
29,R9,Has_index Arg1:T19 Arg2:T20
30,T21,Mood 281 292	anticipated
31,R10,Has_mood Arg1:T18 Arg2:T21
32,R11,Has_temporal Arg1:T18 Arg2:T19
33,R12,Has_temporal Arg1:T15 Arg2:T16
34,*,OR T10 T15 T18
35,T22,Non-representable 389 462	Evidence of another diagnosis that can explain serous SRF or visual loss;
36,T23,Measurement 464 492	Best-corrected visual acuity
37,T24,Value 493 501	< 20/200
38,R13,Has_value Arg1:T23 Arg2:T24
39,T25,Qualifier 525 533	Profound
40,T26,Condition 534 555	chorioretinal atrophy
41,R14,Has_qualifier Arg1:T26 Arg2:T25
42,T27,Qualifier 559 579	central macular area
43,R15,Has_qualifier Arg1:T26 Arg2:T27
44,T28,Procedure 583 597	ophthalmoscopy
45,T29,Procedure 602 605	OCT
46,T30,Scope 583 605	ophthalmoscopy and OCT
47,R16,AND Arg1:T30 Arg2:T26
48,T31,Measurement 608 614	Myopia
49,T32,Value 615 619	> 6D
50,R17,Has_value Arg1:T31 Arg2:T32
51,T33,Condition 622 633	Visual loss
52,T34,Condition 641 658	serous detachment
53,T35,Procedure 662 665	OCT
54,T36,Temporal 666 675	< 6 weeks
55,*,OR T34 T33
56,T37,Scope 622 658	Visual loss and/or serous detachment
57,R18,Has_scope Arg1:T35 Arg2:T37
58,R19,Has_temporal Arg1:T35 Arg2:T36
59,T38,Qualifier 678 688	Continuous
60,T39,Qualifier 696 707	progressive
61,T40,Condition 708 719	visual loss
62,*,OR T39 T38
63,T41,Scope 678 707	Continuous and/or progressive
64,R20,Has_scope Arg1:T40 Arg2:T41
65,T42,Temporal 720 731	> 18 months
66,T43,Condition 735 752	serous detachment
67,T44,Procedure 756 759	OCT
68,T45,Temporal 760 771	> 18 months
69,R21,Has_temporal Arg1:T44 Arg2:T45
70,R22,Has_temporal Arg1:T40 Arg2:T42
71,R23,AND Arg1:T44 Arg2:T43
72,*,OR T44 T40
73,T46,Measurement 798 802	ICGA
74,T47,Value 777 794	hyperfluorescence
75,T48,Negation 774 776	No
76,R24,Has_negation Arg1:T47 Arg2:T48
77,R25,Has_value Arg1:T46 Arg2:T47
78,T49,Condition 805 823	Intraretinal edema
79,T50,Procedure 827 830	OCT
80,R26,AND Arg1:T50 Arg2:T49
81,T51,Condition 844 861	Contraindications
82,T52,Procedure 866 868	FA
83,T53,Procedure 872 876	ICGA
84,*,OR T52 T53
85,T54,Scope 866 876	FA or ICGA
86,R27,Has_scope Arg1:T51 Arg2:T54
87,T55,Condition 890 907	Contraindications
88,T56,Procedure 912 934	photodynamic treatment
89,T57,Condition 936 945	pregnancy
90,T58,Condition 947 956	porphyria
91,T59,Qualifier 958 966	severely
92,T60,Condition 967 991	disturbed liver function
93,R28,Has_qualifier Arg1:T60 Arg2:T59
94,*,OR T57 T58 T60
95,T61,"Scope 936 991	pregnancy, porphyria, severely disturbed liver function"
96,R29,AND Arg1:T55 Arg2:T56
97,T62,Scope 890 934	Contraindications for photodynamic treatment
98,R30,Subsumes Arg1:T62 Arg2:T61
99,T63,"Non-representable 994 1120	Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening"
100,T64,Condition 1139 1156	contraindications
101,T65,Drug 1175 1185	eplerenone
102,T66,Condition 1197 1209	hyperkalemia
103,T67,Condition 1211 1235	abnormal renal clearance
104,T68,Measurement 1220 1235	renal clearance
105,T69,Value 1211 1219	abnormal
106,R31,Has_value Arg1:T68 Arg2:T69
107,T70,Condition 1237 1265	severe hepatic insufficiency
108,T71,Measurement 1267 1277	Child-Pugh
109,T72,Value 1278 1279	C
110,R32,Has_value Arg1:T71 Arg2:T72
111,R33,AND Arg1:T64 Arg2:T65
112,*,OR T66 T68 T70 T75 T83
113,R34,multi Arg1:T68 Arg2:T67
114,R35,Subsumes Arg1:T70 Arg2:T71
115,T73,Condition 1282 1306	type 2 diabetes mellitus
116,T74,Condition 1312 1328	microalbuminuria
117,T75,Scope 1282 1328	type 2 diabetes mellitus with microalbuminuria
118,T76,Temporal 1330 1341	concomitant
119,T77,Drug 1349 1370	potassium supplements
120,T78,Drug 1372 1399	potassium-sparing diuretics
121,T79,Drug 1401 1425	strong CYP3A4 inhibitors
122,T80,Drug 1452 1465	ACE-inhibitor
123,T81,Drug 1473 1508	angiotensin receptor blocking agent
124,T82,Scope 1452 1508	ACE-inhibitor and an angiotensin receptor blocking agent
125,*,OR T77 T78 T79 T82
126,T83,"Scope 1349 1508	potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent"
127,R36,Has_temporal Arg1:T83 Arg2:T76
128,T84,"Non-representable 1511 1638	Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening;"
129,T85,Condition 1640 1651	Soft drusen
130,T86,Qualifier 1655 1666	treated eye
131,T87,Qualifier 1670 1680	fellow eye
132,*,OR T86 T87
133,T88,Scope 1655 1680	treated eye or fellow eye
134,T89,Condition 1691 1719	choroidal neovascularization
135,T90,Procedure 1723 1737	ophthalmoscopy
136,R38,Has_scope Arg1:T85 Arg2:T88
137,T91,Procedure 1745 1747	FA
138,T92,Procedure 1748 1752	ICGA
139,T93,Qualifier 1760 1769	study eye
140,T94,Scope 1723 1752	ophthalmoscopy and/or FA/ICGA
141,*,OR T90 T91 T92
142,R37,AND Arg1:T94 Arg2:T89
143,R39,Has_qualifier Arg1:T94 Arg2:T93
144,*,OR T85 T94
0,T1,Person 0 3	Age
1,T2,Value 4 37	greater than or equal to 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 44 46	RA
4,T4,Qualifier 66 120	1987 revised American College of Rheumatology criteria
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 125 153	sustained clinical remission
7,T6,Multiplier 154 175	for the last 6 months
8,R3,Has_multiplier Arg1:T5 Arg2:T6
9,T7,Drug 214 224	etanercept
10,T8,Drug 226 236	infliximab
11,T9,Drug 241 251	adalimumab
12,T10,Multiplier 257 283	greater than or equal to 1
13,T11,Drug 284 289	DMARD
14,R4,Has_multiplier Arg1:T11 Arg2:T10
15,*,OR T7 T8 T9
16,T12,Drug 291 303	methotrexate
17,T13,Drug 305 323	hydroxychloroquine
18,T14,Drug 325 338	sulfasalazine
19,T15,Drug 340 351	leflunomide
20,T16,Drug 353 364	minocycline
21,T17,Drug 366 378	cyclosporine
22,T18,Drug 380 392	azathioprine
23,T19,Drug 394 398	gold
24,T20,Drug 400 413	penicillamine
25,*,OR T20 T19 T18 T17 T16 T15 T14 T13 T12
26,T21,"Scope 291 413	methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine"
27,R5,Subsumes Arg1:T11 Arg2:T21
28,T22,Measurement 416 421	DAS28
29,T23,Value 432 445	less than 2.6
30,R6,Has_value Arg1:T22 Arg2:T23
31,T24,Multiplier 460 487	over the preceding 6 months
32,T25,Multiplier 494 506	at least one
33,T26,Procedure 507 512	visit
34,T27,Procedure 454 459	visit
35,T28,Multiplier 446 459	on each visit
36,R7,multi Arg1:T28 Arg2:T27
37,R10,Has_multiplier Arg1:T26 Arg2:T25
38,T29,Temporal 513 541	2-4 months before enrollment
39,T30,"Non-representable 543 705	If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6."
40,R11,Has_temporal Arg1:T26 Arg2:T29
41,R8,Has_multiplier Arg1:T22 Arg2:T28
42,R9,Has_multiplier Arg1:T22 Arg2:T24
0,T1,Procedure 0 12	Histological
1,T2,Value 13 25	confirmation
2,T3,Condition 63 78	B-cell lymphoma
3,T4,Qualifier 57 62	large
4,T5,Qualifier 49 56	diffuse
5,R1,Has_qualifier Arg1:T3 Arg2:T4
6,R2,Has_qualifier Arg1:T3 Arg2:T5
7,T7,Procedure 91 156	rituximab and anthracycline-containing systemic treatment regimen
8,T8,Drug 165 171	R-CHOP
9,T9,Drug 173 182	rituximab
10,T10,Drug 184 200	cyclophosphamide
11,T11,Drug 202 213	doxorubicin
12,T12,Drug 215 226	vincristine
13,T13,Drug 232 242	prednisone
14,T14,"Scope 173 242	rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone"
15,R3,Subsumes Arg1:T8 Arg2:T14
16,T15,Drug 245 252	R-EPOCH
17,T16,Drug 254 263	rituximab
18,T17,Drug 265 284	etoposide phosphate
19,T18,Drug 286 296	prednisone
20,T19,Drug 298 317	vincristine sulfate
21,T20,Drug 319 335	cyclophosphamide
22,T21,Drug 337 362	doxorubicin hydrochloride
23,T22,"Scope 254 362	rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride"
24,R4,Subsumes Arg1:T15 Arg2:T22
25,T23,Drug 365 376	R-HyperCVAD
26,T24,Drug 378 387	rituximab
27,T25,Drug 389 405	cyclophosphamide
28,T26,Drug 407 426	vincristine sulfate
29,T27,Drug 428 453	doxorubicin hydrochloride
30,T28,Drug 455 468	dexamethasone
31,T29,"Scope 378 468	rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone"
32,R5,Has_scope Arg1:T23 Arg2:T29
33,R6,Has_value Arg1:T1 Arg2:T2
34,T6,Drug 91 100	rituximab
35,T30,Drug 105 118	anthracycline
36,T31,"Scope 165 473	R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc"
37,R7,Subsumes Arg1:T7 Arg2:T31
38,T32,Temporal 79 84	after
39,T33,Reference_point 85 156	prior rituximab and anthracycline-containing systemic treatment regimen
40,R8,Has_index Arg1:T32 Arg2:T33
41,R9,Has_temporal Arg1:T1 Arg2:T32
42,R10,AND Arg1:T1 Arg2:T3
43,T34,Multiplier 504 518	no more than 2
44,T35,Temporal 519 524	prior
45,T36,Procedure 525 556	systemic therapies for lymphoma
46,R11,Has_temporal Arg1:T36 Arg2:T35
47,R12,Has_multiplier Arg1:T36 Arg2:T34
48,T37,Drug 586 595	rituximab
49,T38,Procedure 577 585;596 607	systemic monotherapy
50,R13,AND Arg1:T38 Arg2:T37
51,T39,Temporal 558 563	Prior
52,T40,Procedure 611 636	conventional chemotherapy
53,T41,Drug 643 655	bendamustine
54,T42,Drug 657 660	CVP
55,T43,Drug 662 678	Cyclophosphamide
56,T44,Drug 680 699	Vincristine Sulfate
57,T45,Drug 701 711	Prednisone
58,T46,"Scope 662 711	Cyclophosphamide, Vincristine Sulfate, Prednisone"
59,R14,Subsumes Arg1:T42 Arg2:T46
60,*,OR T41 T42
61,T47,Drug 725 734	rituximab
62,A1,Optional T47
63,T48,Condition 748 776	non-Hodgkin's lymphoma (NHL)
64,T49,Qualifier 739 747	indolent
65,R15,Has_qualifier Arg1:T48 Arg2:T49
66,T50,Drug 804 813	rituximab
67,*,OR T38 T40
68,T51,"Scope 643 721	bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or other"
69,R16,Subsumes Arg1:T40 Arg2:T51
70,R17,AND Arg1:T47 Arg2:T48
71,A2,Optional T50
72,T52,Qualifier 779 790	maintenance
73,T53,Qualifier 791 803	extended-use
74,*,OR T53 T52
75,T54,Scope 779 803	maintenance/extended-use
76,R18,Has_scope Arg1:T50 Arg2:T54
77,T55,Measurement 857 917	Eastern Cooperative Oncology Group (ECOG) Performance status
78,T56,Value 918 921	≤ 2
79,R19,Has_value Arg1:T55 Arg2:T56
80,T57,Condition 942 954;966 974	normal organ function
81,T58,Condition 942 948;959 974	normal marrow function
82,*,OR T58 T57
83,T59,Scope 923 992	Subjects must have normal organ and marrow function as defined below:
84,T60,Measurement 994 1004	Hemoglobin
85,T61,Value 1005 1015	≥ 8.0 g/dl
86,R20,Has_value Arg1:T60 Arg2:T61
87,T62,Measurement 1017 1042	Absolute neutrophil count
88,T63,"Value 1043 1054	≥ 1,000/mcL"
89,R21,Has_value Arg1:T62 Arg2:T63
90,T64,Measurement 1056 1070	Platelet count
91,T65,"Value 1071 1083	≥ 75,000/mcL"
92,R22,Has_value Arg1:T64 Arg2:T65
93,T66,Measurement 1085 1100	Total bilirubin
94,T67,Value 1101 1140	≤ 1.5 X the upper limit of normal (ULN)
95,T68,Condition 1167 1197	impaired bilirubin conjugation
96,T69,Condition 1206 1215	Gilbert's
97,R24,Subsumes Arg1:T68 Arg2:T69
98,T70,Value 1230 1237;1246 1253	maximum 2.5 ULN
99,*,OR T67 T70
100,R23,AND Arg1:T70 Arg2:T68
101,T71,"Scope 1101 1253	≤ 1.5 X the upper limit of normal (ULN) unless a known history of impaired bilirubin conjugation such as Gilbert's, for whom the maximum will be 2.5 ULN"
102,R25,Has_scope Arg1:T66 Arg2:T71
103,T72,Measurement 1256 1291	Aspartate transaminase (AST) (SGOT)
104,T73,Value 1292 1317	≤ 2.5 X institutional ULN
105,R26,Has_value Arg1:T72 Arg2:T73
106,T74,Measurement 1319 1352	Alanine transaminase (ALT) (SGPT)
107,T75,Value 1353 1378	≤ 2.5 X institutional ULN
108,R27,Has_value Arg1:T74 Arg2:T75
109,T76,Measurement 1380 1416	International normalized ratio (INR)
110,T77,Value 1417 1427	> 1.5 ×ULN
111,R28,Has_value Arg1:T76 Arg2:T77
112,T78,Measurement 1461 1487	serum creatinine clearance
113,T79,Value 1488 1499	> 50 mL/min
114,R29,Has_value Arg1:T78 Arg2:T79
115,T80,Qualifier 1506 1533	Cockcroft-Gault calculation
116,T81,Qualifier 1546 1570	24-hour urine collection
117,T82,Temporal 1581 1600	within 7 days prior
118,T83,Reference_point 1604 1613	treatment
119,R30,Has_index Arg1:T82 Arg2:T83
120,*,OR T80 T81
121,T84,Scope 1506 1570	Cockcroft-Gault calculation or based on 24-hour urine collection
122,R31,Has_scope Arg1:T78 Arg2:T84
123,R32,Has_temporal Arg1:T78 Arg2:T82
124,T85,Parsing_Error 1616 1753	Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on Hepatitis B serological testing as follow:
125,T86,Measurement 1755 1760	HBsAg
126,T87,Value 1761 1769	negative
127,T88,Measurement 1771 1776	HBcAb
128,T89,Value 1777 1785	negative
129,R33,Has_value Arg1:T86 Arg2:T87
130,R34,Has_value Arg1:T88 Arg2:T89
131,T90,Measurement 1787 1792	HBsAb
132,T91,Value 1793 1801	positive
133,R35,Has_value Arg1:T90 Arg2:T91
134,T92,Measurement 1857 1862	HBsAg
135,T93,Value 1844 1852	positive
136,R36,Has_value Arg1:T92 Arg2:T93
137,T94,Grammar_Error 1863 1877	are ineligible
138,T95,Measurement 1893 1898	HBsAg
139,T96,Value 1899 1907	negative
140,R37,Has_value Arg1:T95 Arg2:T96
141,T97,Measurement 1913 1918	HBcAb
142,T98,Value 1919 1927	positive
143,R38,Has_value Arg1:T97 Arg2:T98
144,T99,Procedure 1971 1986	HBV DNA testing
145,T100,"Parsing_Error 1879 2042	Patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a HBV DNA testing performed and protocol eligibility determined as follow"
146,T101,Measurement 2048 2055	HBV DNA
147,T102,Value 2059 2067	positive
148,R39,Has_value Arg1:T101 Arg2:T102
149,T103,"Grammar_Error 2045 2094	If HBV DNA is positive, the subject is ineligible"
150,T104,Measurement 2100 2107	HBV DNA
151,T105,Value 2111 2119	negative
152,R40,Has_value Arg1:T104 Arg2:T105
153,T106,Non-query-able 2153 2242	must undergo HBV DNA PCR testing monthly x 3 months beginning from the start of treatment
154,T107,Non-query-able 2244 2352	Subjects must have the ability to understand and the willingness to sign a written informed consent document
155,T108,"Post-eligibility 2355 2683	For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of rituximab, whichever is longer."
156,T109,"Not_a_criteria 2685 2969	A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus)"
157,T110,"Parsing_Error 2972 3145	For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:"
158,T111,"Non-query-able 2972 3145	For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:"
159,T112,"Post-eligibility 2972 3144	For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below"
160,T113,"Post-eligibility 3147 3420	With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab."
161,T115,Non-query-able 3421 3482	Men must refrain from donating sperm during this same period.
162,T116,"Non-query-able 3484 3673	With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo."
0,T1,Condition 6 13	allergy
1,T2,Drug 24 34	drugs used
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 36 48	coagulopathy
4,T4,Condition 54 59	wound
5,T5,Condition 63 72	infection
6,T6,Qualifier 84 97	puncture site
7,*,OR T5 T4
8,T7,Scope 54 72	wound or infection
9,R2,Has_qualifier Arg1:T7 Arg2:T6
10,T8,Observation 130 148	consent of parents
11,T9,Negation 114 129	failure to gain
12,R3,Has_negation Arg1:T8 Arg2:T9
13,T10,Informed_consent 114 148	failure to gain consent of parents
14,T11,Qualifier 99 104	major
15,T12,Condition 105 112	illness
16,R4,Has_qualifier Arg1:T12 Arg2:T11
0,T1,Person 0 5	Women
1,T2,Condition 11 30	singleton pregnancy
2,T3,Condition 44 57	preterm labor
3,T4,Condition 65 89	midtrimester miscarriage
4,T5,Temporal 95 103	previous
5,T6,Condition 104 113	pregnancy
6,R1,Has_temporal Arg1:T6 Arg2:T5
7,T7,Scope 95 113	previous pregnancy
8,*,OR T4 T3
9,T8,Scope 44 89	preterm labor and/or midtrimester miscarriage
10,R2,Has_scope Arg1:T8 Arg2:T7
11,T9,Measurement 116 131	Cervical length
12,T10,Value 135 143	15-25 mm
13,T11,Procedure 147 176	transvaginal sonography (TVS)
14,T12,Value 180 191	16-24 weeks
15,T13,Measurement 195 204	gestation
16,R3,Has_value Arg1:T13 Arg2:T12
17,T14,Temporal 177 204	at 16-24 weeks of gestation
18,T15,Reference_point 180 204	16-24 weeks of gestation
19,R4,multi Arg1:T15 Arg2:T13
20,R5,Has_index Arg1:T14 Arg2:T15
21,R6,Has_temporal Arg1:T11 Arg2:T14
22,R7,Has_value Arg1:T9 Arg2:T10
23,R8,AND Arg1:T9 Arg2:T11
0,T1,Measurement 0 36;43 58	American society of anesthesiologist physical status
1,T2,Measurement 38 41	ASA
2,R1,Subsumes Arg1:T1 Arg2:T2
3,T3,Value 59 66	I or II
4,R2,Has_value Arg1:T1 Arg2:T3
0,T1,Person 0 3	Age
1,T2,Value 4 8	< 20
2,T3,Value 12 22	> 35 years
3,*,OR T2 T3
4,T4,Scope 4 22	< 20 or > 35 years
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 25 56	Congenital uterine malformation
7,T6,Condition 59 79	Multifetal pregnancy
8,T7,Condition 114 137	chromosomal abnormality
9,T8,Condition 94 110	fetal structural
10,T9,Qualifier 88 93	major
11,*,OR T8 T7
12,T10,Scope 94 137	fetal structural or chromosomal abnormality
13,R2,Has_qualifier Arg1:T10 Arg2:T9
14,T11,Condition 146 153	allergy
15,T12,Condition 157 173	contraindication
16,T13,Qualifier 175 183	relative
17,T14,Qualifier 187 195	absolute
18,*,OR T13 T14
19,T15,Procedure 200 220	progesterone therapy
20,*,OR T12 T11
21,T16,Scope 175 195	relative or absolute
22,T17,Scope 146 173	allergy or contraindication
23,R3,Has_scope Arg1:T17 Arg2:T16
24,R4,AND Arg1:T17 Arg2:T15
25,T18,Condition 235 251	contraindication
26,T19,Procedure 255 272	cervical cerclage
27,T20,Condition 275 293	Medical conditions
28,T21,Qualifier 294 316	complicating pregnancy
29,T22,Condition 319 335	Vaginal bleeding
0,T1,Parsing_Error 0 56	-Patients residing in the following clinical states wit!
1,T2,Parsing_Error 57 74	be considered: A.
2,T3,Measurement 82 85	PSA
3,T4,Value 75 81	Rising
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Observation 103 113	history of
6,T6,Condition 114 131	localized disease
7,T7,Procedure 162 171	radiation
8,T8,Procedure 175 182	surgery
9,*,OR T7 T8
10,T9,Qualifier 151 161	definitive
11,T10,Scope 162 182	radiation or surgery
12,R2,Has_qualifier Arg1:T10 Arg2:T9
13,T11,Observation 216 238	progression of disease
14,T12,Qualifier 239 252	biochemically
15,R3,Has_qualifier Arg1:T11 Arg2:T12
16,R4,Has_temporal Arg1:T6 Arg2:T5
17,R5,Has_scope Arg1:T6 Arg2:T10
18,T13,Qualifier 308 332	radiographically evident
19,T14,Condition 333 340	disease
20,R6,Has_qualifier Arg1:T14 Arg2:T13
21,T15,Qualifier 346 358	Non-castrate
22,T16,Qualifier 359 369	metastatic
23,T17,Observation 398 419	radiographic evidence
24,T18,Procedure 398 410	radiographic
25,R7,Has_context Arg1:T18 Arg2:T17
26,T19,Condition 423 441	metastatic disease
27,R8,AND Arg1:T18 Arg2:T19
28,T20,Temporal 442 466	at the time of diagnosis
29,T21,Temporal 470 507	after treatment for localized disease
30,T22,Procedure 476 485	treatment
31,T23,Condition 490 507	localized disease
32,T24,Reference_point 476 507	treatment for localized disease
33,*,OR T20 T21
34,T25,Reference_point 445 466	the time of diagnosis
35,R9,Has_index Arg1:T20 Arg2:T25
36,T26,Scope 442 507	at the time of diagnosis or after treatment for localized disease
37,R10,Has_scope Arg1:T19 Arg2:T26
38,T27,Scope 346 369	Non-castrate metastatic
39,R11,Has_scope Arg1:T19 Arg2:T27
40,T28,Temporal 534 548	newly detected
41,T29,Condition 549 556;580 587	disease in bone
42,T30,Condition 560 579;591 605	progressing disease in soft tissue
43,*,OR T29 T30 T31 T32
44,T31,Condition 549 556;591 605	disease in soft tissue
45,T32,Condition 560 587	progressing disease in bone
46,T33,Observation 607 630	Biochemical progression
47,T34,Measurement 736 773	Minimal % increase in range of values
48,T35,Value 775 778	50%
49,R12,Has_value Arg1:T34 Arg2:T35
50,T36,Measurement 698 724	Minimal Baseline PSA value
51,T37,Value 725 735	(ng/ml): 2
52,R13,Has_value Arg1:T36 Arg2:T37
53,T38,Measurement 646 675	minimum no. of determinations
54,T39,Value 677 678	3
55,R14,Has_value Arg1:T38 Arg2:T39
56,T40,Measurement 679 687	Interval
57,T41,Value 689 697	>2 weeks
58,R15,Has_value Arg1:T40 Arg2:T41
59,T42,Scope 646 778	minimum no. of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50%
60,R16,Has_scope Arg1:T33 Arg2:T42
61,T43,Scope 549 605	disease or progressing disease in bone or in soft tissue
62,R17,Has_temporal Arg1:T43 Arg2:T28
63,R18,Has_context Arg1:T30 Arg2:T33
64,R19,Has_context Arg1:T32 Arg2:T33
65,T44,Condition 793 816	prostate adenocarcinoma
66,T45,Procedure 817 831	histologically
67,T46,Value 832 841	confirmed
68,T47,Qualifier 817 841	histologically confirmed
69,R20,Has_value Arg1:T45 Arg2:T46
70,R21,multi Arg1:T47 Arg2:T45
71,R22,Has_qualifier Arg1:T44 Arg2:T47
72,T48,Measurement 871 898	level of serum testosterone
73,T49,Value 899 930	above the lower limit of normal
74,R23,Has_value Arg1:T48 Arg2:T49
75,T50,Measurement 933 968	Karnofskcy performance status (KPS)
76,T51,Value 969 974	>_70%
77,R24,Has_value Arg1:T50 Arg2:T51
78,T52,Value 996 1004	adequate
79,T53,Measurement 1005 1019	organ function
80,R25,Has_value Arg1:T53 Arg2:T52
81,T54,Observation 996 1019	adequate organ function
82,R26,multi Arg1:T54 Arg2:T53
83,T55,Measurement 1070 1073	WBC
84,T56,Value 1074 1084	>_3500/mm3
85,T57,Measurement 1086 1100	platelet count
86,T58,"Value 1101 1114	>_100,000/mm3"
87,R27,Has_value Arg1:T57 Arg2:T58
88,R28,Has_value Arg1:T55 Arg2:T56
89,T59,Measurement 1117 1126	Bilirubin
90,T60,Value 1127 1137	<2.0 mg/dl
91,T61,Measurement 1141 1145	SGOT
92,T62,Value 1146 1178	<3.0 X the upper limit of normal
93,R29,Has_value Arg1:T61 Arg2:T62
94,R30,Has_value Arg1:T59 Arg2:T60
95,*,OR T59 T61
96,T63,Measurement 1181 1191	Creatinine
97,T64,Value 1192 1203	<_1.6 mg/dl
98,T65,Measurement 1207 1227	creatinine clearance
99,T66,Value 1228 1239	>_60 cc/min
100,R31,Has_value Arg1:T65 Arg2:T66
101,R32,Has_value Arg1:T63 Arg2:T64
102,*,OR T63 T65
103,T67,Temporal 1242 1247	Prior
104,T68,Procedure 1248 1264	hormonal therapy
105,R33,Has_temporal Arg1:T68 Arg2:T67
106,T69,Mood 1265 1275	is allowed
107,R34,Has_mood Arg1:T68 Arg2:T69
108,T70,Procedure 1284 1305	Neoadjuvant treatment
109,T71,Temporal 1306 1357	prior to radiation therapy or radical prostatectomy
110,T72,Procedure 1315 1332	radiation therapy
111,T73,Procedure 1336 1357	radical prostatectomy
112,T74,Reference_point 1315 1357	radiation therapy or radical prostatectomy
113,*,OR T72 T73
114,R35,Has_index Arg1:T71 Arg2:T74
115,R36,Has_temporal Arg1:T70 Arg2:T71
116,T75,Measurement 1377 1403	total duration of exposure
117,T76,Value 1404 1429	does not exceed 10 months
118,R37,Has_value Arg1:T75 Arg2:T76
119,R38,AND Arg1:T70 Arg2:T75
120,T77,Multiplier 1435 1444	One cycle
121,T78,Procedure 1448 1468	intermittent therapy
122,R39,Has_multiplier Arg1:T78 Arg2:T77
123,T79,Measurement 1477 1493	maximum exposure
124,T80,Value 1497 1506	10 months
125,R40,Has_value Arg1:T79 Arg2:T80
126,R41,AND Arg1:T78 Arg2:T79
127,T81,Value 1526 1543	at least 18 years
128,T82,Person 1547 1550	age
129,R42,Has_value Arg1:T82 Arg2:T81
130,T83,Informed_consent 1572 1607	signed an informed consent document
0,T1,Person 0 3	Age
1,T2,Value 4 19	greater than 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 29 41	thoracoscopy
4,T5,Subjective_judgement 47 115	low probability(by surgeon estimate) of conversion to open procedure
5,T6,Undefined_semantics 47 115	low probability(by surgeon estimate) of conversion to open procedure
6,T8,Non-query-able 21 115	Planned thoracoscopy with low probability(by surgeon estimate) of conversion to open procedure
7,T4,Qualifier 47 115	low probability(by surgeon estimate) of conversion to open procedure
8,R2,Has_qualifier Arg1:T3 Arg2:T4
0,T1,Condition 0 7	Healthy
1,T2,Person 9 13	Male
2,T3,Value 15 17	>7
3,T4,Measurement 18 39	Metabolic Equivalents
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Informed_consent 41 65	Written informed consent
6,T6,Condition 67 88	Chronic pain syndrome
7,T7,Condition 90 100	Drug abuse
8,T8,Condition 102 115	Alcohol abuse
9,T9,Mood 117 126	Suspicion
10,T10,Condition 130 152	neurologic dysfunction
11,T11,Qualifier 156 168	tested sites
12,R2,Has_qualifier Arg1:T10 Arg2:T11
13,R3,Has_mood Arg1:T10 Arg2:T9
14,T12,Temporal 170 177	Ongoing
15,T13,Procedure 178 187	treatment
16,T14,Drug 193 208	antidepressants
17,R4,AND Arg1:T13 Arg2:T14
18,R5,Has_temporal Arg1:T13 Arg2:T12
19,T15,Temporal 210 217	Ongoing
20,T16,Procedure 218 227	treatment
21,T17,Drug 233 243	analgesics
22,R6,AND Arg1:T16 Arg2:T17
23,R7,Has_temporal Arg1:T16 Arg2:T15
24,T18,Procedure 245 257	Pretreatment
25,T19,Drug 267 281	CYP3A inducers
26,T20,Drug 267 272;285 295	CYP3A inhibitors
27,*,OR T20 T19
28,T21,Scope 267 295	CYP3A inducers or inhibitors
29,R8,Has_scope Arg1:T18 Arg2:T21
30,T22,Condition 303 310	allergy
31,T23,Drug 314 326	tested drugs
32,R9,AND Arg1:T22 Arg2:T23
33,T24,Condition 328 349	Elevated eye pressure
34,T25,Condition 351 371	Obstructive uropathy
35,T26,Condition 373 386	Heart disease
36,T27,Condition 388 405	Pulmonary disease
37,T28,Condition 407 427	Neurological disease
38,T29,Condition 429 448	Psychiatric illness
0,T1,Condition 30 45	substance abuse
1,T2,Condition 19 26;40 45	alcohol abuse
2,*,OR T1 T2
3,T3,Temporal 53 72	preceding 12 months
4,T4,Scope 19 45	alcohol or substance abuse
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Pregnancy_considerations 75 114	Women who are pregnant or breastfeeding
7,T6,Pregnancy_considerations 117 210	Women of childbearing potential (WOCP) who are not using at least one method of contraception
8,T7,Condition 234 250	renal impairment
9,T8,Qualifier 227 233	severe
10,T9,Measurement 252 256	CLcr
11,T10,Value 257 268	= 29 mL/min
12,T11,Measurement 273 277	eGFR
13,T12,Value 278 297	= 29 mL/min/1.73 m2
14,R2,Has_qualifier Arg1:T7 Arg2:T8
15,R3,Has_value Arg1:T9 Arg2:T10
16,R4,Has_value Arg1:T11 Arg2:T12
17,*,OR T9 T11
18,T13,"Scope 252 297	CLcr = 29 mL/min, or eGFR = 29 mL/min/1.73 m2"
19,R5,Subsumes Arg1:T7 Arg2:T13
20,T14,Condition 322 340	hepatic impairment
21,T15,Qualifier 315 321	severe
22,T16,Qualifier 303 311	moderate
23,*,OR T16 T15
24,T17,Scope 303 321	moderate or severe
25,R6,Has_scope Arg1:T14 Arg2:T17
26,T18,Measurement 342 360	Child-Pugh classes
27,T19,Value 361 362	B
28,T20,Value 366 367	C
29,*,OR T19 T20
30,T21,Scope 361 367	B or C
31,R7,Has_scope Arg1:T18 Arg2:T21
32,R8,Subsumes Arg1:T14 Arg2:T18
33,*,OR T7 T14
34,T22,Condition 385 411	bladder outlet obstruction
35,T23,Condition 413 416	BOO
36,R9,Subsumes Arg1:T22 Arg2:T23
37,T24,Drug 532 542	mirabegron
38,T25,Observation 484 509	risk of urinary retention
39,R10,Has_context Arg1:T22 Arg2:T25
40,T26,Non-query-able 545 606	Patients treated with drugs metabolized by the CYP2D6 pathway
41,T27,Measurement 630 653	systolic blood pressure
42,T28,Qualifier 623 629	supine
43,R11,Has_qualifier Arg1:T27 Arg2:T28
44,T29,Measurement 655 658	SBP
45,R12,Subsumes Arg1:T27 Arg2:T29
46,T30,Value 660 671	= 180 mm Hg
47,R13,Has_value Arg1:T27 Arg2:T30
48,T31,Measurement 676 700	diastolic blood pressure
49,T32,Measurement 702 705	DBP
50,R14,Subsumes Arg1:T31 Arg2:T32
51,T33,Value 707 718	= 110 mm Hg
52,R15,Has_value Arg1:T31 Arg2:T33
53,*,OR T27 T31
54,T34,Condition 758 776	cardiac arrhythmia
55,T35,Qualifier 745 757	uncontrolled
56,R16,Has_qualifier Arg1:T34 Arg2:T35
57,T36,Condition 778 793	unstable angina
58,T37,Condition 795 819	congestive heart failure
59,T38,Measurement 821 831	NYHA Class
60,T39,Value 832 833	3
61,T40,Value 837 838	4
62,*,OR T39 T40
63,T41,Scope 832 838	3 or 4
64,R17,Has_scope Arg1:T38 Arg2:T41
65,T42,Condition 855 876	myocardial infarction
66,T43,Temporal 884 901	preceding 2 years
67,R18,Has_temporal Arg1:T42 Arg2:T43
68,R19,Subsumes Arg1:T37 Arg2:T38
69,*,OR T34 T36 T37 T42
70,T44,Condition 915 921	cancer
71,T45,Temporal 929 946	preceding 2 years
72,R20,Has_temporal Arg1:T44 Arg2:T45
73,T46,Negation 947 952	other
74,T47,Condition 1038 1061	cervical cancer in situ
75,T48,Condition 1013 1033	basal cell carcinoma
76,T49,Condition 1024 1033;996 1009	carcinoma squamous cell
77,T50,Qualifier 980 994	non-metastatic
78,T51,"Scope 996 1061	squamous cell or basal cell carcinoma, or cervical cancer in situ"
79,T52,Qualifier 958 978	successfully treated
80,R21,Has_qualifier Arg1:T51 Arg2:T50
81,R22,Has_qualifier Arg1:T51 Arg2:T52
82,*,OR T48 T49 T47
83,R23,Has_negation Arg1:T51 Arg2:T46
84,T53,Procedure 1068 1094	major urological procedure
85,T54,Temporal 1102 1119	preceding 90 days
86,R24,Has_temporal Arg1:T53 Arg2:T54
87,T55,Procedure 1126 1150	major surgical procedure
88,T56,Temporal 1158 1175	preceding 30 days
89,R25,Has_temporal Arg1:T55 Arg2:T56
90,T57,Drug 1202 1212	mirabegron
91,T58,Temporal 1213 1255	within 60 days prior to the baseline visit
92,T59,Reference_point 1241 1255	baseline visit
93,R26,Has_index Arg1:T58 Arg2:T59
94,R27,Has_temporal Arg1:T57 Arg2:T58
95,T60,Drug 1465 1486	antimuscarinic agents
96,T61,Condition 1491 1503	OAB symptoms
97,R28,AND Arg1:T60 Arg2:T61
98,T62,Temporal 1391 1438	within the 60 days preceding the baseline visit
99,T63,Reference_point 1424 1438	baseline visit
100,R29,Has_index Arg1:T62 Arg2:T63
101,R30,Has_temporal Arg1:T60 Arg2:T62
102,T64,Post-eligibility 1510 1584	willingness to not use antimuscarinic agents for the duration of the study
103,T65,Competing_trial 1587 1738	Currently receiving any other investigational drug or having received an investigational drug within the 60 days preceding the baseline visit (Visit 2)
104,T66,"Non-query-able 1741 1946	Any condition or laboratory test result, which, in the opinion of the Investigator or the Study Urologist, might result in an increased risk to the patient, or would affect their participation in the study"
105,T67,"Non-query-able 1949 2086	Any patient who, in the opinion of the Investigator, is not a good candidate for the study or will not be able to follow study procedures"
0,T1,Qualifier 12 25	decompensated
1,T2,Condition 26 39	liver disease
2,R1,Has_qualifier Arg1:T2 Arg2:T1
3,T3,Measurement 41 47	Childs
4,T4,Value 48 51	B-C
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Scope 12 39	decompensated liver disease
7,T6,Scope 41 51	Childs B-C
8,R3,Subsumes Arg1:T5 Arg2:T6
9,T7,Condition 54 79	hepato-cellular carcinoma
10,T8,Temporal 81 93	pre-existing
11,T9,Qualifier 94 100	severe
12,T10,Condition 101 111	depression
13,T11,Condition 121 140	psychiatric disease
14,T12,Qualifier 115 120	other
15,T13,Condition 154 169	cardiac disease
16,T14,Qualifier 142 153	significant
17,R4,Has_qualifier Arg1:T13 Arg2:T14
18,T15,Qualifier 171 182	significant
19,T16,Condition 183 196	renal disease
20,R5,Has_qualifier Arg1:T16 Arg2:T15
21,T17,Condition 198 215	seizure disorders
22,T18,Qualifier 219 225	severe
23,T19,Condition 226 237	retinopathy
24,R6,Has_qualifier Arg1:T11 Arg2:T12
25,R7,Has_qualifier Arg1:T10 Arg2:T9
26,*,OR T10 T11
27,T20,Scope 94 140	severe depression or other psychiatric disease
28,R8,Has_temporal Arg1:T20 Arg2:T8
29,*,OR T7 T20 T5 T19 T18 T17 T16 T13
30,T21,Drug 249 260	telbivudine
31,T22,Procedure 268 285	antiviral therapy
32,R9,Subsumes Arg1:T22 Arg2:T21
33,T23,Multiplier 303 316	more than one
34,T24,Condition 317 319	NA
35,*,OR T24 T23 T22
36,T25,Temporal 320 331	in the past
37,R10,Has_temporal Arg1:T24 Arg2:T25
38,T26,Drug 343 353	interferon
39,T27,Drug 357 370	peginterferon
40,T28,Procedure 371 380	treatment
41,T29,Temporal 381 392	in the past
42,*,OR T27 T26
43,T30,Scope 343 370	interferon or peginterferon
44,R11,Has_scope Arg1:T28 Arg2:T30
45,R12,Has_temporal Arg1:T28 Arg2:T29
46,T31,Procedure 404 421	antiviral therapy
47,T32,Drug 430 449	systemic anti-viral
48,R13,AND Arg1:T31 Arg2:T32
49,T33,Procedure 451 466;488 497	anti-neoplastic treatment
50,T34,Procedure 470 497	immuno-modulatory treatment
51,T35,Multiplier 509 531	supraphysiologic doses
52,T36,Drug 535 543	steroids
53,T37,Procedure 548 557	radiation
54,R14,Has_multiplier Arg1:T36 Arg2:T35
55,R15,Has_multiplier Arg1:T37 Arg2:T35
56,*,OR T36 T37
57,T38,Scope 509 557	supraphysiologic doses of steroids and radiation
58,*,OR T33 T34 T31
59,T39,"Scope 404 497	antiviral therapy for any systemic anti-viral, anti-neoplastic or immuno-modulatory treatment"
60,R16,Subsumes Arg1:T39 Arg2:T38
61,T40,Temporal 559 583	within the past 6 months
62,R17,Has_temporal Arg1:T39 Arg2:T40
63,T41,Value 586 594	Positive
64,T42,Measurement 595 599;613 625	test for anti-HIV
65,T43,Measurement 595 599;613 616;627 635	test for anti-HCV
66,*,OR T43 T42
67,T44,Temporal 600 612	at screening
68,T45,"Scope 595 599;613 635	test for anti-HIV, anti-HCV"
69,R18,Has_value Arg1:T45 Arg2:T41
70,R19,Has_temporal Arg1:T45 Arg2:T44
71,T46,Mood 655 671	expected to need
72,T47,Procedure 672 698	systemic antiviral therapy
73,R20,Has_mood Arg1:T47 Arg2:T46
74,T48,Temporal 737 788	at any time during their participation in the study
75,R21,Has_temporal Arg1:T47 Arg2:T48
76,T49,Reference_point 756 788	their participation in the study
77,R22,Has_index Arg1:T48 Arg2:T49
78,T50,Drug 872 881	acyclovir
79,T51,Multiplier 843 850;862 868	limited course
80,T52,Multiplier 852 860	<=7 days
81,R23,Subsumes Arg1:T51 Arg2:T52
82,R24,Has_multiplier Arg1:T50 Arg2:T51
83,T53,Condition 886 902	herpetic lesions
84,T54,Temporal 903 967	more than 1 month prior to the first administration of test drug
85,T55,Reference_point 930 967	the first administration of test drug
86,R25,Has_index Arg1:T54 Arg2:T55
87,T56,Mood 972 984	not excluded
88,R26,AND Arg1:T50 Arg2:T53
89,R27,Has_temporal Arg1:T50 Arg2:T54
90,R28,Has_mood Arg1:T50 Arg2:T56
91,T57,Negation 808 817	Exception
92,R29,Has_negation Arg1:T50 Arg2:T57
93,T58,Measurement 987 1008	Serum total bilirubin
94,T59,Value 1009 1044	> 3 times the upper limit of normal
95,R30,Has_value Arg1:T58 Arg2:T59
96,T60,Temporal 1045 1057	at screening
97,R31,Has_temporal Arg1:T58 Arg2:T60
98,T61,Condition 1089 1097	bleeding
99,T62,Condition 1103 1121	esophageal varices
100,R32,AND Arg1:T61 Arg2:T62
101,T63,Qualifier 1125 1130	other
102,T64,Condition 1131 1185	conditions consistent with decompensated liver disease
103,R33,Has_qualifier Arg1:T64 Arg2:T63
104,*,OR T61 T64
105,T65,Condition 1219 1236	medical condition
106,T66,Condition 1253 1274	chronic liver disease
107,R34,AND Arg1:T65 Arg2:T66
108,T67,Negation 1275 1285	other than
109,T68,Condition 1286 1289	HBV
110,R35,Has_negation Arg1:T68 Arg2:T67
111,T69,Scope 1275 1289	other than HBV
112,T70,Condition 1297 1312	hemochromatosis
113,T71,Condition 1314 1334	autoimmune hepatitis
114,*,OR T71 T70 T72
115,T72,Condition 1336 1360	metabolic liver diseases
116,T73,Condition 1371 1379	Wilson's
117,T74,Condition 1384 1413	alpha1-antitrypsin deficiency
118,T75,Condition 1415 1438	alcoholic liver disease
119,T76,Condition 1440 1455	toxin exposures
120,T77,Condition 1457 1468	thalassemia
121,*,OR T77 T76 T75 T73 T74
122,T78,"Scope 1371 1468	Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia"
123,R36,Subsumes Arg1:T72 Arg2:T78
124,T79,"Scope 1297 1468	hemochromatosis, autoimmune hepatitis, metabolic liver diseases including Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia"
125,R37,Subsumes Arg1:T69 Arg2:T78
126,R38,AND Arg1:T65 Arg2:T68
127,T80,Person 1472 1477	Women
128,T81,Condition 1491 1500	pregnancy
129,T82,Temporal 1483 1490	ongoing
130,R39,Has_temporal Arg1:T81 Arg2:T82
131,T83,Observation 1512 1526	breast feeding
132,*,OR T83 T81
133,T84,Measurement 1529 1545	Neutrophil count
134,T85,Value 1546 1561	<1500 cells/mm3
135,R40,Has_value Arg1:T84 Arg2:T85
136,T86,Measurement 1565 1579	platelet count
137,T87,"Value 1580 1597	<90,000 cells/mm3"
138,R41,Has_value Arg1:T86 Arg2:T87
139,T88,Temporal 1598 1610	at screening
140,*,OR T84 T86
141,T89,"Scope 1529 1597	Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3"
142,R42,Has_temporal Arg1:T89 Arg2:T88
143,T90,Measurement 1613 1623	Hemoglobin
144,T91,Value 1624 1635	< 11.5 g/dL
145,T92,Person 1640 1647	females
146,T93,Value 1652 1663	< 12.5 g/dL
147,T94,Person 1668 1671	men
148,T95,Temporal 1672 1684	at screening
149,A1,Optional T92
150,A2,Optional T94
151,R43,Has_value Arg1:T92 Arg2:T91
152,R44,Has_value Arg1:T94 Arg2:T93
153,*,OR T92 T94
154,T96,Scope 1624 1671	< 11.5 g/dL for females and < 12.5 g/dL for men
155,R45,Has_scope Arg1:T90 Arg2:T96
156,R46,Has_temporal Arg1:T90 Arg2:T95
157,T97,Measurement 1687 1709	Serum creatinine level
158,T98,Value 1710 1722	>120 umol/ml
159,T99,Person 1727 1730	men
160,T100,Value 1735 1747	>105 umol/ml
161,T101,Person 1752 1757	women
162,A3,Optional T101
163,A4,Optional T99
164,R47,Has_value Arg1:T101 Arg2:T100
165,R48,Has_value Arg1:T99 Arg2:T98
166,T102,Temporal 1758 1770	at screening
167,T103,Scope 1710 1757	>120 umol/ml for men and >105 umol/ml for women
168,R49,Has_scope Arg1:T97 Arg2:T103
169,R50,Has_temporal Arg1:T97 Arg2:T102
170,T104,Condition 1791 1810	psychiatric disease
171,T105,Qualifier 1784 1790	severe
172,R51,Has_qualifier Arg1:T104 Arg2:T105
173,T106,Condition 1823 1833	depression
174,R52,Subsumes Arg1:T104 Arg2:T106
175,T107,Qualifier 1835 1841	Severe
176,T108,Condition 1842 1861	psychiatric disease
177,T109,Condition 1876 1892	major depression
178,T110,Condition 1896 1905	psychosis
179,T111,Procedure 1919 1928	treatment
180,T112,Drug 1937 1962	antidepressant medication
181,T113,Drug 1966 1984	major tranquilizer
182,T114,Multiplier 1988 2005	therapeutic doses
183,T115,Condition 2010 2020	depression
184,T116,Condition 2024 2033	psychosis
185,T117,Temporal 2034 2055	for at least 3 months
186,T118,Condition 2059 2075	suicidal attempt
187,T119,Procedure 2077 2092	hospitalization
188,T120,Condition 2097 2116	psychiatric disease
189,R53,AND Arg1:T119 Arg2:T120
190,T121,Condition 2133 2143	disability
191,T122,Condition 2153 2172	psychiatric disease
192,R54,AND Arg1:T121 Arg2:T122
193,*,OR T113 T112
194,T123,Scope 1937 1984	antidepressant medication or major tranquilizer
195,R56,Has_multiplier Arg1:T123 Arg2:T114
196,R57,Has_temporal Arg1:T116 Arg2:T117
197,R58,Has_scope Arg1:T111 Arg2:T123
198,R55,AND Arg1:T111 Arg2:T115
199,*,OR T110 T109 T121 T119 T118 T116 T111
200,T124,"Scope 1876 2172	major depression or psychosis, a period of treatment with an antidepressant medication or major tranquilizer at therapeutic doses for depression or psychosis for at least 3 months, a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease"
201,*,OR T108 T107
202,T125,Scope 1835 1861	Severe psychiatric disease
203,R59,Subsumes Arg1:T125 Arg2:T124
204,T126,"Scope 1784 1833	severe psychiatric disease, especially depression"
205,R60,Subsumes Arg1:T126 Arg2:T125
206,T127,Condition 2226 2252	inflammatory bowel disease
207,T128,Condition 2186 2218	immunologically mediated disease
208,T129,Condition 2254 2289	idiopathic thrombocytopenic purpura
209,T130,Condition 2291 2310	lupus erythematosus
210,T131,Condition 2312 2339	autoimmune hemolytic anemia
211,T132,Condition 2341 2352	scleroderma
212,T133,Qualifier 2354 2360	severe
213,T134,Condition 2361 2370	psoriasis
214,R61,Has_qualifier Arg1:T134 Arg2:T133
215,T135,Condition 2372 2392	rheumatoid arthritis
216,*,OR T130 T129 T127 T135 T134 T132 T131
217,T136,"Scope 2226 2392	inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis"
218,R62,Subsumes Arg1:T128 Arg2:T136
219,T137,Condition 2425 2450	chronic pulmonary disease
220,T138,Condition 2467 2488	functional limitation
221,R63,AND Arg1:T137 Arg2:T138
222,T139,Qualifier 2490 2496	Severe
223,T140,Condition 2497 2512	cardiac disease
224,R64,Has_qualifier Arg1:T140 Arg2:T139
225,T141,Measurement 2520 2524	NYHA
226,T142,Value 2525 2551	Functional Class III or IV
227,T143,Condition 2553 2574	myocardial infarction
228,T144,Temporal 2575 2590	within 6 months
229,R65,Has_temporal Arg1:T143 Arg2:T144
230,T145,Condition 2592 2620	ventricular tachyarrhythmias
231,T146,Temporal 2631 2638	ongoing
232,T147,Procedure 2639 2648	treatment
233,R66,Has_temporal Arg1:T147 Arg2:T146
234,R67,AND Arg1:T145 Arg2:T147
235,T148,Condition 2650 2665	unstable angina
236,T149,Qualifier 2669 2674	other
237,T150,Qualifier 2675 2686	significant
238,T151,Condition 2687 2710	cardiovascular diseases
239,R68,Has_qualifier Arg1:T151 Arg2:T150
240,R69,Has_qualifier Arg1:T151 Arg2:T149
241,*,OR T148 T151 T145 T143 T141
242,R70,Has_value Arg1:T141 Arg2:T142
243,T152,Scope 2490 2512	Severe cardiac disease
244,T153,"Scope 2520 2710	NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases"
245,R71,Subsumes Arg1:T152 Arg2:T153
246,T154,Qualifier 2727 2733	severe
247,T155,Condition 2734 2750	seizure disorder
248,T156,Drug 2762 2776	anticonvulsant
249,T157,Temporal 2754 2761	current
250,R72,Has_temporal Arg1:T156 Arg2:T157
251,R73,Has_qualifier Arg1:T155 Arg2:T154
252,*,OR T156 T155
253,T158,Temporal 2798 2804	active
254,T159,Mood 2808 2817	suspected
255,T160,Condition 2818 2824	cancer
256,*,OR T159 T158
257,T161,Scope 2798 2817	active or suspected
258,R74,Has_scope Arg1:T160 Arg2:T161
259,T162,Condition 2841 2851	malignancy
260,T163,Measurement 2862 2880	risk of recurrence
261,T164,Value 2884 2904	>=20% within 2 years
262,R75,Has_value Arg1:T163 Arg2:T164
263,R76,AND Arg1:T162 Arg2:T163
264,T165,Condition 2922 2928	lesion
265,T166,Mood 2929 2939	suspicious
266,T167,Condition 2943 2961	hepatic malignancy
267,R77,Has_mood Arg1:T167 Arg2:T166
268,R78,AND Arg1:T165 Arg2:T167
269,T168,Procedure 2967 2990	screening imaging study
270,T169,Measurement 3020 3043	likelihood of carcinoma
271,T170,Value 3047 3052	<=10%
272,R79,Has_value Arg1:T169 Arg2:T170
273,R80,AND Arg1:T165 Arg2:T168
274,T171,Scope 2922 2990	lesion suspicious of hepatic malignancy on a screening imaging study
275,A5,Optional T171
276,R81,AND Arg1:T171 Arg2:T169
277,*,OR T160 T162
278,T172,Qualifier 3122 3130	systemic
279,T173,Procedure 3131 3146;3189 3198	anti-neoplastic treatment
280,T174,Procedure 3172 3198	immunomodulatory treatment
281,T175,Procedure 3158 3167	radiation
282,R82,Subsumes Arg1:T173 Arg2:T175
283,T176,Qualifier 3210 3218	systemic
284,T177,Drug 3219 3234	corticosteroids
285,R83,Has_qualifier Arg1:T177 Arg2:T176
286,*,OR T173 T174
287,T178,Scope 3131 3235	anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic corticosteroids)
288,R84,Has_qualifier Arg1:T178 Arg2:T172
289,R85,Subsumes Arg1:T174 Arg2:T177
290,T179,Temporal 3236 3284	<=6 months prior to the first dose of study drug
291,T180,Reference_point 3256 3284	the first dose of study drug
292,R86,Has_index Arg1:T179 Arg2:T180
293,R87,Has_temporal Arg1:T178 Arg2:T179
294,T181,Mood 3292 3303	expectation
295,T182,Procedure 3314 3323	treatment
296,T183,Mood 3324 3338	will be needed
297,R88,Has_mood Arg1:T182 Arg2:T181
298,R89,Has_mood Arg1:T182 Arg2:T183
299,T184,Temporal 3339 3367	at any time during the study
300,R90,Has_temporal Arg1:T182 Arg2:T184
301,*,OR T178 T182
302,T185,Procedure 3370 3397	Major organ transplantation
303,T186,Condition 3400 3415	Thyroid disease
304,T187,Measurement 3421 3437	thyroid function
305,T188,Value 3438 3455	poorly controlled
306,R91,Has_value Arg1:T187 Arg2:T188
307,R92,AND Arg1:T186 Arg2:T187
308,T189,Qualifier 3456 3481	on prescribed medications
309,R93,Has_qualifier Arg1:T187 Arg2:T189
310,T190,Value 3497 3505	abnormal
311,T191,Measurement 3506 3533	thyroid stimulating hormone
312,T192,Measurement 3537 3554	T4 concentrations
313,*,OR T191 T192
314,T193,Scope 3497 3554	abnormal thyroid stimulating hormone or T4 concentrations
315,R94,Has_value Arg1:T193 Arg2:T190
316,T194,Scope 3497 3554	abnormal thyroid stimulating hormone or T4 concentrations
317,T195,Measurement 3574 3606	antibodies to thyroid peroxidase
318,T196,Value 3561 3570	elevation
319,R95,Has_value Arg1:T195 Arg2:T196
320,T197,Condition 3615 3657	clinical manifestations of thyroid disease
321,*,OR T195 T197 T193
322,T198,Qualifier 3702 3708	severe
323,T199,Condition 3709 3720	retinopathy
324,R96,Has_qualifier Arg1:T199 Arg2:T198
325,T200,Condition 3727 3740	CMV retinitis
326,T201,Condition 3742 3761	macula degeneration
327,*,OR T200 T201
328,T202,"Scope 3727 3761	CMV retinitis, macula degeneration"
329,T203,Scope 3702 3720	severe retinopathy
330,R97,Subsumes Arg1:T203 Arg2:T202
331,T204,Qualifier 3766 3785	clinically relevant
332,T205,Condition 3786 3811	ophthalmological disorder
333,T206,Condition 3819 3836	diabetes mellitus
334,T207,Condition 3840 3852	hypertension
335,*,OR T206 T207
336,T208,Scope 3819 3852	diabetes mellitus or hypertension
337,R98,Has_scope Arg1:T205 Arg2:T208
338,*,OR T205 T204 T203
339,T209,Post-eligibility 3854 3951	Inability or unwillingness to provide informed consent or abide by the requirements of the study.
340,T210,"Post-eligibility 3953 4112	History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study."
341,T211,Measurement 4139 4156	alpha-fetoprotein
342,T212,Value 4157 4167	>100 ng/mL
343,R99,Has_value Arg1:T211 Arg2:T212
344,T213,Temporal 4249 4279	at least the previous 3 months
345,T214,Reference_point 4258 4279	the previous 3 months
346,R100,Has_index Arg1:T213 Arg2:T214
347,T215,Condition 4189 4198	stability
348,T216,Value 4200 4213	less than 10%
349,T217,Measurement 4214 4222	increase
350,R101,Has_value Arg1:T217 Arg2:T216
351,T218,Scope 4200 4222	less than 10% increase
352,R102,Subsumes Arg1:T215 Arg2:T218
353,R103,Has_temporal Arg1:T215 Arg2:T213
354,T219,Negation 4182 4188	unless
355,R104,Has_negation Arg1:T215 Arg2:T219
356,T220,Condition 4306 4319	alcohol abuse
357,T221,Condition 4294 4298;4314 4319	drug abuse
358,*,OR T220 T221
359,T222,Multiplier 4321 4328	20g/day
360,T223,Multiplier 4341 4348	30g/day
361,T224,Person 4353 4356	men
362,T225,Person 4333 4338	women
363,*,OR T222 T223
364,R105,AND Arg1:T222 Arg2:T225
365,R106,AND Arg1:T223 Arg2:T224
366,T226,Scope 4321 4356	20g/day for women & 30g/day for men
367,R107,Subsumes Arg1:T220 Arg2:T226
368,T227,Post-eligibility 4360 4472	Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening
369,T228,Condition 4495 4511	hypersensitivity
370,T229,Drug 4515 4525	interferon
371,R108,AND Arg1:T228 Arg2:T229
0,T1,Condition 22 28	Autism
1,T2,Condition 32 88	Pervasive Developmental Disorder not otherwise specified
2,T3,Condition 90 97	PDD-NOS
3,R1,Subsumes Arg1:T2 Arg2:T3
4,T4,Non-query-able 100 128	given by a child neurologist
5,*,OR T1 T2
6,T5,Person 131 134	Age
7,T6,Value 136 147	10-18 years
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Informed_consent 150 180	A signed parental consent form
0,T1,Condition 9 18	gestation
1,T2,Value 0 8;22 29	37 weeks greater
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 39 54	singleton fetus
4,T4,Qualifier 31 37	Living
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 59 84	major fetal malformations
7,T6,Negation 56 58	No
8,R3,Has_negation Arg1:T5 Arg2:T6
9,T7,Condition 86 107	Cephalic presentation
10,T8,Negation 109 111	No
11,T9,Condition 118 130	uterine scar
12,R4,Has_negation Arg1:T9 Arg2:T8
13,T10,Condition 139 154	fetal membranes
14,T11,Qualifier 132 138	Intact
15,R5,Has_qualifier Arg1:T10 Arg2:T11
16,T12,Procedure 170 198	prostaglandin administration
17,T13,Procedure 220 237	Parkland protocol
18,R6,AND Arg1:T13 Arg2:T12
19,T14,Condition 246 263	cervical dilation
20,T15,Multiplier 267 288	2 centimeters or less
21,R7,Has_multiplier Arg1:T14 Arg2:T15
22,T16,Qualifier 319 330	internal os
23,R8,Has_qualifier Arg1:T14 Arg2:T16
24,T17,Condition 340 350	indication
25,T18,Procedure 355 364;388 396	induction of labor
26,T19,Qualifier 368 377	attempted
27,T20,Procedure 410 427	Parkland protocol
28,R9,AND Arg1:T20 Arg2:T17
29,T21,Procedure 378 387	induction
30,R11,Has_qualifier Arg1:T21 Arg2:T19
31,*,OR T18 T21
32,T22,Scope 355 396	induction or attempted induction of labor
33,R10,Has_scope Arg1:T17 Arg2:T22
0,T1,Condition 11 22	sensitivity
1,T2,Drug 26 43	study medications
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 72 74	RA
4,A1,Optional T3
5,T4,Condition 92 103	intolerance
6,T5,Drug 107 110	MTX
7,R2,AND Arg1:T4 Arg2:T5
8,R3,AND Arg1:T3 Arg2:T4
9,T6,Procedure 135 155	antiplatelet therapy
10,T7,Temporal 112 119	Current
11,R4,Has_temporal Arg1:T6 Arg2:T7
12,T8,Procedure 181 202	anti-platelet therapy
13,T9,Mood 157 180	Absolute indication for
14,R5,Has_mood Arg1:T8 Arg2:T9
15,T10,Mood 204 212	Need for
16,T11,Procedure 213 247	chronic oral anticoagulant therapy
17,T12,Condition 249 274	Severe hepatic impairment
18,T13,Condition 280 287	ascites
19,T14,Condition 313 325	coagulopathy
20,T15,Mood 295 312	clinical signs of
21,R6,Has_mood Arg1:T14 Arg2:T15
22,*,OR T13 T14
23,T16,Scope 280 325	ascites and/or clinical signs of coagulopathy
24,R7,Subsumes Arg1:T12 Arg2:T16
25,T17,Condition 328 341	Renal failure
26,T18,Measurement 343 347	eGFR
27,T19,Value 348 351	<30
28,T20,Mood 355 364	requiring
29,T21,Procedure 365 373	dialysis
30,R8,Has_mood Arg1:T21 Arg2:T20
31,R9,Has_value Arg1:T18 Arg2:T19
32,*,OR T18 T21
33,T22,Scope 343 373	eGFR <30 or requiring dialysis
34,R10,Subsumes Arg1:T17 Arg2:T22
35,T23,Condition 384 402	bleeding diathesis
36,T24,Condition 418 438	coagulation disorder
37,T25,Condition 404 414;430 438	hemostatic disorder
38,*,OR T25 T24 T23 T26
39,T26,Condition 449 463	major bleeding
40,T27,Condition 471 477	stroke
41,T28,Temporal 479 485	Active
42,T29,Temporal 465 470	Prior
43,T30,Temporal 443 448	prior
44,R11,Has_temporal Arg1:T26 Arg2:T30
45,R12,Has_temporal Arg1:T27 Arg2:T29
46,T31,Condition 486 507	pathological bleeding
47,R13,Has_temporal Arg1:T31 Arg2:T28
48,T32,Condition 520 544	intracranial haemorrhage
49,T33,Observation 509 516	History
50,R14,Has_temporal Arg1:T32 Arg2:T33
51,T34,Measurement 546 561	Life expectancy
52,T35,Value 562 572	<12 months
53,R15,Has_value Arg1:T34 Arg2:T35
54,T36,Non-representable 573 606	based on investigator's judgement
55,T37,Condition 645 663	bradycardic events
56,T38,Mood 634 644	at risk of
57,R16,Has_mood Arg1:T37 Arg2:T38
58,T39,Condition 677 696	sick sinus syndrome
59,T40,Condition 710 751	third degree atrioventricular [AV)] block
60,T41,Condition 700 706;716 751	second degree atrioventricular [AV)] block
61,*,OR T41 T40 T39
62,T42,Device 783 802	permanent pacemaker
63,T43,Negation 753 759	unless
64,R17,Has_negation Arg1:T42 Arg2:T43
65,T44,Scope 677 751	sick sinus syndrome or second or third degree atrioventricular [AV)] block
66,R18,Subsumes Arg1:T37 Arg2:T44
67,R19,AND Arg1:T37 Arg2:T42
68,T45,Condition 804 810	Anemia
69,T46,Measurement 812 822	hematocrit
70,T47,Value 823 828	< 27%
71,R20,Has_value Arg1:T46 Arg2:T47
72,T48,Scope 812 828	hematocrit < 27%
73,R21,Has_scope Arg1:T45 Arg2:T48
74,T49,Measurement 831 845	Platelet count
75,T50,"Value 846 858	< 100,000/ml"
76,R22,Has_value Arg1:T49 Arg2:T50
77,T51,Drug 879 903	strong CYP 3A inhibitors
78,T52,Drug 879 892;907 915	strong CYP 3A inducers
79,*,OR T51 T52
80,T53,Condition 928 944	thrombocytopenia
81,T54,Condition 948 959	neutropenia
82,*,OR T53 T54
83,T55,Observation 917 924	History
84,T56,Scope 928 959	thrombocytopenia or neutropenia
85,R23,Has_temporal Arg1:T56 Arg2:T55
86,T57,Condition 961 969	Pregnant
87,T58,Condition 973 980	nursing
88,T59,Person 981 986	women
89,*,OR T57 T58
90,T60,Person 991 998	females
91,T61,Value 1006 1014	positive
92,T62,Measurement 1015 1029	pregnancy test
93,T63,Temporal 1030 1042	at screening
94,R24,Has_temporal Arg1:T62 Arg2:T63
95,R25,Has_value Arg1:T62 Arg2:T61
96,T64,Scope 961 986	Pregnant or nursing women
97,T65,Scope 991 1042	females with a positive pregnancy test at screening
98,*,OR T64 T65
99,T66,Reference_point 1033 1042	screening
100,R26,Has_index Arg1:T63 Arg2:T66
101,T67,Person 1044 1051	Females
102,T68,Condition 1055 1078	child bearing potential
103,T69,Qualifier 1089 1099	acceptable
104,T70,Observation 1100 1123	method of birth control
105,R27,Has_qualifier Arg1:T70 Arg2:T69
106,T71,Temporal 1124 1132;1143 1148	prior to study
107,T72,Temporal 1136 1148	during study
108,*,OR T71 T72
109,T73,Scope 1124 1148	prior to or during study
110,R28,Has_scope Arg1:T70 Arg2:T73
111,T74,Negation 1079 1082	not
112,R29,Has_negation Arg1:T70 Arg2:T74
113,T76,Observation 1162 1171;1187 1218	inability to comply with study procedures
114,T75,Observation 1162 1171;1187 1201;1226 1235	inability to comply with follow up
115,*,OR T75 T76
116,T77,Condition 1241 1248;1257 1262	alcohol abuse
117,T78,Condition 1252 1262	drug abuse
118,*,OR T77 T78
119,T79,Scope 1241 1262	alcohol or drug abuse
120,T80,Scope 1162 1235	inability of the patient to comply with study procedures and/or follow up
121,T81,Mood 1150 1161	Concern for
122,R30,Has_mood Arg1:T80 Arg2:T81
123,R31,Has_scope Arg1:T80 Arg2:T79
0,T1,Person 0 3	Age
1,T2,Value 4 16	less than 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Undefined_semantics 18 71	Clinical or laboratory evidence of systemic infection
4,T4,Temporal 106 118	preoperative
5,T5,Measurement 119 133	urine HCG test
6,T6,Value 81 90	pregnancy
7,R2,Has_value Arg1:T5 Arg2:T6
8,T7,Condition 81 90	pregnancy
9,T8,Condition 158 179	non-malignant illness
10,T9,Qualifier 144 156	uncontrolled
11,T10,Qualifier 135 142	Serious
12,R3,Has_qualifier Arg1:T8 Arg2:T9
13,R4,Has_qualifier Arg1:T8 Arg2:T10
14,T11,Condition 181 198	Malignant illness
15,T12,Procedure 209 230	systemic chemotherapy
16,T13,Temporal 231 251	in the last 6 months
17,R5,Has_temporal Arg1:T12 Arg2:T13
18,R6,AND Arg1:T11 Arg2:T12
19,T14,Drug 275 284	oxycodone
20,T15,Drug 286 302	morphine sulfate
21,T16,Drug 306 319	acetaminophen
22,*,OR T15 T16 T14
23,T17,Condition 264 271	allergy
24,T18,"Scope 275 319	oxycodone, morphine sulfate or acetaminophen"
25,R7,Has_scope Arg1:T17 Arg2:T18
26,T19,Condition 321 366	Contraindication to peripheral nerve blockade
27,T20,Condition 321 340;370 388	Contraindication to general anesthesia
28,*,OR T20 T19
29,T21,Non-query-able 401 419	1. patient refusal
30,T22,Non-query-able 421 465	2. active infection at site of planned block
31,T23,Undefined_semantics 467 535	3. documented allergy to any local or general anesthetic medications
32,T24,Condition 552 564	coagulopathy
33,T25,Qualifier 540 551	significant
34,T26,Measurement 566 582	prothrombin time
35,T27,Value 583 594	>15 seconds
36,R8,Has_value Arg1:T26 Arg2:T27
37,T28,Measurement 596 599	INR
38,T29,Value 599 603	>1.5
39,R9,Has_value Arg1:T28 Arg2:T29
40,T30,"Scope 566 603	prothrombin time >15 seconds, INR>1.5"
41,R10,Subsumes Arg1:T25 Arg2:T30
42,R11,Has_qualifier Arg1:T24 Arg2:T25
43,T31,Condition 621 631	neuropathy
44,T32,Temporal 608 620	pre-existing
45,R12,Has_temporal Arg1:T31 Arg2:T32
46,T33,Undefined_semantics 636 719	medical conditions or deformities which would compromise block or anesthetic safety
47,T34,Condition 729 740	pleurodesis
48,T35,Non-query-able 721 740	Planned pleurodesis
49,T36,Drug 787 795	steroids
50,T37,Qualifier 767 774	inhaled
51,T38,Qualifier 778 786	systemic
52,*,OR T37 T38
53,T39,Scope 767 786	inhaled or systemic
54,R13,Has_scope Arg1:T36 Arg2:T39
55,T40,Qualifier 757 766	high dose
56,R14,Has_qualifier Arg1:T36 Arg2:T40
57,T41,Temporal 742 749	Current
58,R15,Has_temporal Arg1:T36 Arg2:T41
59,T42,Drug 812 822	Amiodarone
60,T43,Drug 824 833	Cordarone
61,R16,Subsumes Arg1:T42 Arg2:T43
62,T44,Temporal 797 804	Current
63,R17,Has_temporal Arg1:T42 Arg2:T44
64,T45,Condition 836 850	Morbid obesity
65,T46,Measurement 852 855	BMI
66,T47,Value 856 863	40kg/m2
67,R18,Has_value Arg1:T46 Arg2:T47
68,R19,AND Arg1:T45 Arg2:T46
69,T48,Condition 903 923	mental health issues
70,T49,Condition 932 941	psychosis
71,T50,Drug 967 992	antipsychotic medications
72,T51,Procedure 952 961	treatment
73,R20,AND Arg1:T51 Arg2:T50
74,T52,Qualifier 880 902	clinically significant
75,R21,Has_qualifier Arg1:T48 Arg2:T52
76,R22,Subsumes Arg1:T48 Arg2:T49
77,T53,Scope 880 941	clinically significant mental health issues such as psychosis
78,R23,AND Arg1:T53 Arg2:T51
79,T54,Non-query-able 995 1021	Patients unable to consent
80,T55,Condition 1044 1054	infections
81,T56,Temporal 1037 1043	active
82,R24,Has_temporal Arg1:T55 Arg2:T56
83,T57,Drug 1065 1076	antibiotics
84,R25,AND Arg1:T55 Arg2:T57
85,T58,Temporal 1077 1109	within one month of registration
86,R26,Has_temporal Arg1:T55 Arg2:T58
87,T59,Non-query-able 1111 1184	Participation in other clinical trials that may interfere with this study
0,T1,Condition 23 38	cardiac disease
1,T2,Measurement 40 66	New York Heart Association
2,T3,Value 67 79	Class III/IV
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Qualifier 11 22	significant
5,R2,Subsumes Arg1:T4 Arg2:T2
6,R3,Has_qualifier Arg1:T1 Arg2:T4
7,T5,Condition 91 121	debilitating puhnonary disease
8,T6,Qualifier 84 90	severe
9,R4,Has_qualifier Arg1:T5 Arg2:T6
10,T7,Condition 152 161	infection
11,T8,Qualifier 124 144	Uncontrolled serious
12,R5,Has_qualifier Arg1:T7 Arg2:T8
13,T9,Observation 164 184	Anticipated survival
14,T10,Value 188 206	less than 3 months
15,R6,Has_value Arg1:T9 Arg2:T10
16,T11,Condition 216 219;231 236	CNS tumor
17,T12,Condition 223 236	epiduraltumor
18,*,OR T11 T12
19,T13,Condition 238 247	Inability
20,T14,Observation 251 264	unwillingness
21,T15,Informed_consent 268 302	comply with the treatment protocol
22,T16,Procedure 304 313	follow-up
23,T17,Post-eligibility 318 332	research tests
24,*,OR T16 T15 T17
25,*,OR T14 T13
26,T18,"Scope 268 332	comply with the treatment protocol, follow-up, or research tests"
27,T19,Scope 238 264	Inability or unwillingness
28,R7,Has_scope Arg1:T18 Arg2:T19
0,T1,Condition 14 32	infectious disease
1,T2,Qualifier 3 13	underlying
2,R1,Has_qualifier Arg1:T1 Arg2:T2
3,T3,Condition 34 57	chromosomal abnormality
4,T4,Condition 59 77	metabolic disorder
5,T5,Condition 102 110	disorder
6,T6,Qualifier 88 93	brain
7,R2,Has_qualifier Arg1:T5 Arg2:T6
8,T7,Condition 120 138	tuberous sclerosis
9,R3,Subsumes Arg1:T5 Arg2:T7
10,T8,Condition 158 183	cytomegalovirus infection
11,T9,Qualifier 152 157	fetal
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Condition 185 199	birth asphyxia
14,T11,Condition 214 231	major head injury
15,T12,Condition 235 246	chronic use
16,T13,Drug 250 287	non-steroidal anti-inflammatory drugs
17,T14,Drug 290 295	NSAID
18,R5,Subsumes Arg1:T13 Arg2:T14
19,R6,AND Arg1:T12 Arg2:T13
20,T15,Condition 304 316	brain damage
21,T16,Condition 318 326	Epilepsy
22,T17,Measurement 337 355	Electro-cardiogram
23,T18,Measurement 357 360	ECG
24,T19,Value 328 336	Abnormal
25,R7,Subsumes Arg1:T17 Arg2:T18
26,R8,Has_value Arg1:T17 Arg2:T19
27,T20,Measurement 376 379	EEG
28,T21,Value 363 375	Epileptiform
29,R9,Has_value Arg1:T20 Arg2:T21
30,T22,Drug 388 404	psychostimulants
31,T23,Drug 406 422	anti-depressants
32,T24,Drug 424 436	neuroleptics
33,T25,Drug 440 462	anti-convulsive agents
34,T26,Temporal 463 484	within the past month
35,*,OR T22 T23 T24 T25
36,T27,"Scope 388 462	psychostimulants, anti-depressants, neuroleptics or anti-convulsive agents"
37,R10,Has_temporal Arg1:T27 Arg2:T26
38,T28,Post-eligibility 487 529	Lack of cooperation in the screening phase
0,T1,Person 0 4	Male
1,T2,Person 7 13	female
2,T3,Value 23 43	>= 18 and < 70 years
3,T4,Person 47 50	age
4,*,OR T2 T1
5,R1,Has_value Arg1:T4 Arg2:T3
6,T5,Measurement 61 66	HBeAg
7,T6,Value 52 60	Positive
8,R2,Has_value Arg1:T5 Arg2:T6
9,T7,Temporal 67 95	before starting NA treatment
10,T8,Reference_point 74 95	starting NA treatment
11,R3,Has_index Arg1:T7 Arg2:T8
12,R4,Has_temporal Arg1:T5 Arg2:T7
13,T9,Drug 121 131	lamivudine
14,T10,Drug 133 141	adefovir
15,T11,Drug 143 152	entecavir
16,T12,Drug 156 165	tenofovir
17,*,OR T12 T11 T10 T9
18,T13,Multiplier 110 116	single
19,T14,Drug 117 119	NA
20,R5,Has_multiplier Arg1:T14 Arg2:T13
21,T15,Procedure 97 104	Treated
22,R6,AND Arg1:T15 Arg2:T14
23,T16,"Scope 121 165	lamivudine, adefovir, entecavir or tenofovir"
24,R7,Subsumes Arg1:T14 Arg2:T16
25,T17,Temporal 167 190	for 6 months to 5 years
26,R8,Has_temporal Arg1:T15 Arg2:T17
27,T18,Measurement 202 207	HBeAg
28,T19,Value 208 222	seroconversion
29,T20,Measurement 224 229	HBeAg
30,T21,Measurement 243 250	ant-HBe
31,T22,Value 230 238	negative
32,T23,Value 251 259	negative
33,*,OR T21 T23
34,*,OR T20 T22
35,*,OR T18 T19
36,T24,Scope 224 259	HBeAg negative and ant-HBe negative
37,R9,Subsumes Arg1:T19 Arg2:T24
38,T25,Value 266 278	undetectable
39,T26,Measurement 279 286	HBV DNA
40,T27,Procedure 290 305	PCR based assay
41,T28,Drug 309 311	NA
42,T29,Procedure 312 321	treatment
43,R10,AND Arg1:T29 Arg2:T28
44,R11,Has_value Arg1:T26 Arg2:T25
45,R12,AND Arg1:T27 Arg2:T26
46,R13,AND Arg1:T27 Arg2:T29
47,T30,Value 324 332	Negative
48,T31,Measurement 342 362	serum pregnancy test
49,T32,Measurement 333 338;348 362	urine pregnancy test
50,*,OR T31 T32
51,T33,Scope 333 362	urine or serum pregnancy test
52,R14,Has_value Arg1:T33 Arg2:T30
53,T34,Person 368 373	women
54,T35,Condition 377 399	childbearing potential
55,T36,Scope 368 399	women of childbearing potential
56,A1,Optional T36
57,R15,Has_scope Arg1:T36 Arg2:T33
58,T37,Temporal 412 474	within the 24-hour period prior to the first dose of test drug
59,T38,Reference_point 447 474	the first dose of test drug
60,R16,Has_index Arg1:T37 Arg2:T38
61,R17,Has_temporal Arg1:T33 Arg2:T37
62,T39,"Pregnancy_considerations 476 599	Additionally, all females must be using reliable contraception during the study and for 3 months after treatment completion"
0,T1,Person 0 4	Aged
1,T2,Value 5 10	25-80
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-query-able 25 91	Subjects older than 80 will be allowed at the discretion of the PI
4,T4,Person 94 104	Ambulatory
5,T5,"Non-query-able 106 180	defined as able to ambulate at least 10 meters, with or without assistance"
6,T6,Condition 206 208	PD
7,T7,Measurement 222 267	United Kingdom Brain Bank diagnostic criteria
8,T8,Condition 288 300	micturitions
9,T9,Multiplier 277 287;301 313	At least 8 per 24 hours
10,R2,Has_multiplier Arg1:T8 Arg2:T9
11,T10,Condition 330 346	urgency episodes
12,T11,Multiplier 319 329;347 363	At least 3 per 3-day diary.
13,R3,Has_multiplier Arg1:T10 Arg2:T11
14,T12,Measurement 367 377	MoCA score
15,T13,Value 378 395	between 19 and 28
16,R4,Has_value Arg1:T12 Arg2:T13
17,T14,Procedure 435 454	cognitive enhancers
18,T15,Drug 456 465	donepezil
19,T16,Drug 467 479	rivastigmine
20,T17,Drug 481 490	memantine
21,T18,Drug 492 503	galantamine
22,T19,Measurement 507 517	MoCA score
23,T20,Value 518 535	between 19 and 29
24,R5,Has_value Arg1:T19 Arg2:T20
25,*,OR T15 T16 T17 T18
26,T21,"Scope 456 503	donepezil, rivastigmine, memantine, galantamine"
27,R6,Subsumes Arg1:T14 Arg2:T21
28,T22,"Scope 435 535	cognitive enhancers (donepezil, rivastigmine, memantine, galantamine) a MoCA score between 19 and 29"
29,*,OR T12 T22
30,T23,Informed_consent 563 726	Provide informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care
31,T24,"Informed_consent 729 832	Be cognitively capable, in the opinion of investigator, to understand and provide such informed consent"
32,T25,"Post-eligibility 835 1012	Be cognitively capable to complete the required questionnaires and assessments, OR have a care partner who is willing and capable to assist them in the completion of these tasks"
33,T26,Drug 1041 1068	antiparkinson's medications
34,T27,Temporal 1069 1104	at least 30 days prior to screening
35,T28,Reference_point 1095 1104	screening
36,R7,Has_index Arg1:T27 Arg2:T28
37,R8,Has_temporal Arg1:T26 Arg2:T27
38,T29,Procedure 1191 1210	cognitive enhancers
39,T30,Drug 1212 1221	donepezil
40,T31,Drug 1223 1235	rivastigmine
41,T32,Drug 1237 1246	memantine
42,T33,Drug 1248 1259	galantamine
43,*,OR T30 T31 T32 T33
44,T34,"Scope 1212 1259	donepezil, rivastigmine, memantine, galantamine"
45,R9,Subsumes Arg1:T29 Arg2:T34
46,T35,Qualifier 1273 1284	stable dose
47,R10,Has_qualifier Arg1:T29 Arg2:T35
48,T36,Temporal 1285 1320	at least 30 days prior to screening
49,T37,Reference_point 1311 1320	screening
50,R11,Has_temporal Arg1:T29 Arg2:T36
51,R12,Has_index Arg1:T36 Arg2:T37
0,T1,Condition 0 2	RA
1,A1,Optional T1
2,T2,Drug 21 24	MTX
3,T3,Multiplier 28 40	stable doses
4,T4,Multiplier 44 62	10 to 25 mg weekly
5,T5,Temporal 63 84	for at least 12 weeks
6,R1,Has_multiplier Arg1:T2 Arg2:T3
7,R2,Has_multiplier Arg1:T2 Arg2:T4
8,R3,Has_temporal Arg1:T2 Arg2:T5
9,T6,Measurement 93 98	DAS28
10,T7,Value 102 115	3.2 or higher
11,R4,Has_value Arg1:T6 Arg2:T7
12,T8,"Non-representable 116 221	(The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995)"
13,T9,Condition 223 225	OA
14,A2,Optional T9
15,T10,Condition 247 261	osteoarthritis
16,T11,Observation 262 279	made by physician
17,R5,Has_context Arg1:T10 Arg2:T11
18,T12,"Scope 21 221	MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks, Have a DAS28 of 3.2 or higher (The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995)"
19,R6,Has_scope Arg1:T1 Arg2:T12
20,T13,Scope 247 279	osteoarthritis made by physician
21,R7,Has_scope Arg1:T9 Arg2:T13
0,T1,Condition 6 13	allergy
1,T2,Drug 0 5	latex
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 30 42	fetal status
4,T4,Qualifier 15 29	non-reassuring
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 44 47	HIV
7,T6,Condition 56 62	herpes
8,T7,Qualifier 49 55	active
9,R3,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Condition 79 91	uterine scar
11,T9,Condition 93 109	Contraindication
12,T10,Drug 113 127	prostaglandins
13,T11,Procedure 149 166	Parkland protocol
14,R4,AND Arg1:T9 Arg2:T10
15,R5,AND Arg1:T9 Arg2:T11
16,T12,Condition 168 184	Contraindication
17,T13,Procedure 188 204	vaginal delivery
18,R6,AND Arg1:T12 Arg2:T13
0,T1,Person 0 9	Inpatient
1,T2,Person 13 23	outpatient
2,*,OR T1 T2
3,T3,Person 24 27	age
4,T4,Value 28 38	8-19 years
5,T5,Non-query-able 113 131	Fluent in English;
6,T6,"Non-query-able 50 110	participants must live with a parent, guardian, or caregiver"
7,T7,Condition 202 228	bipolar spectrum disorders
8,T8,Condition 230 233	BSD
9,T9,Condition 236 245	bipolar I
10,T10,Condition 247 257	bipolar II
11,T11,Condition 259 300	unspecified bipolar and related disorders
12,T12,Condition 302 340	Disruptive Mood Dysregulation Disorder
13,T13,Condition 342 346	DMDD
14,T14,Condition 349 369	cyclothymic disorder
15,T15,Condition 371 416	other specified bipolar and related disorders
16,T16,Condition 429 466	mood disorder not otherwise specified
17,R1,Subsumes Arg1:T7 Arg2:T8
18,*,OR T9 T10 T11 T12 T14 T15 T16
19,R2,Subsumes Arg1:T12 Arg2:T13
20,T17,"Scope 236 466	bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified"
21,R3,Subsumes Arg1:T7 Arg2:T17
22,T18,Measurement 510 525	Body mass index
23,T19,Value 526 533	>85%ile
24,R4,Has_value Arg1:T18 Arg2:T19
25,T20,Multiplier 621 633	at least one
26,T21,Drug 634 637	SGA
27,R5,Has_multiplier Arg1:T21 Arg2:T20
28,T22,Drug 645 655	olanzapine
29,T23,Drug 657 666	clozapine
30,T24,Drug 668 679	risperidone
31,T25,Drug 681 691	quetiapine
32,T26,Drug 693 705	aripiprazole
33,T27,Drug 707 718	ziprasidone
34,T28,Drug 720 731	iloperidone
35,T29,Drug 733 743	lurasidone
36,T30,Drug 745 757	paliperidone
37,T31,Drug 759 772	brexpiprazole
38,T32,Drug 776 787	cariprazine
39,*,OR T22 T23 T24 T25 T26 T27 T28 T29 T30 T31 T32
40,T33,"Scope 645 787	olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, iloperidone, lurasidone, paliperidone, brexpiprazole or cariprazine"
41,R6,Subsumes Arg1:T21 Arg2:T33
0,T1,Person 0 4	Male
1,T2,Person 9 15	female
2,T3,Person 37 41	ages
3,T4,Value 45 56	18-65 years
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T5,Informed_consent 69 161	Patients (or legal representative) willing and able to provide written Informed Consent Form
7,T6,Condition 206 219	schizophrenia
8,T7,Condition 223 239	bipolar disorder
9,*,OR T6 T7
10,T8,Measurement 258 315	Diagnostic and Statistical Manual of Mental Disorders- IV
11,T9,Measurement 317 373	Diagnostic and Statistical Manual of Mental Disorders- V
12,T10,Measurement 377 415	International Code of Disease criteria
13,*,OR T8 T9 T10
14,T11,"Scope 206 240	schizophrenia or bipolar disorder,"
15,T12,"Scope 258 415	Diagnostic and Statistical Manual of Mental Disorders- IV, Diagnostic and Statistical Manual of Mental Disorders- V or International Code of Disease criteria"
16,R2,Subsumes Arg1:T11 Arg2:T12
17,T13,Condition 444 461	agitation episode
18,T14,Temporal 486 524	within the 6 months prior to screening
19,T15,Reference_point 515 524	screening
20,R3,Has_index Arg1:T14 Arg2:T15
21,R4,Has_temporal Arg1:T13 Arg2:T14
22,T16,Drug 597 604	ADASUVE
23,T17,Measurement 691 702	CGI-I score
24,T18,Value 706 712	1 or 2
25,T19,Temporal 716 763	2 hours after administration of the inhalation)
26,T20,Reference_point 730 763	administration of the inhalation)
27,R5,Has_value Arg1:T17 Arg2:T18
28,R6,Has_temporal Arg1:T17 Arg2:T19
29,R7,Has_index Arg1:T19 Arg2:T20
30,T21,Negation 774 778	free
31,T22,Condition 789 808	respiratory disease
32,T23,Qualifier 782 788	active
33,R8,Has_qualifier Arg1:T22 Arg2:T23
34,R9,Has_negation Arg1:T22 Arg2:T21
35,T24,Condition 817 840	acute respiratory signs
36,T25,Condition 817 834;841 849	acute respiratory symptoms
37,T26,Condition 857 865	wheezing
38,T27,Condition 882 897	airways disease
39,T28,Qualifier 875 881	active
40,R10,Has_qualifier Arg1:T27 Arg2:T28
41,R11,Has_negation Arg1:T27 Arg2:T21
42,T29,Condition 899 905	asthma
43,T30,Condition 907 944	chronic obstructive pulmonary disease
44,T31,Condition 948 957	emphysema
45,*,OR T29 T30 T31
46,T32,"Scope 899 957	asthma, chronic obstructive pulmonary disease or emphysema"
47,R12,Subsumes Arg1:T27 Arg2:T32
48,T33,"Scope 817 866	acute respiratory signs/symptoms (e.g., wheezing)"
49,*,OR T24 T25
50,R13,Subsumes Arg1:T25 Arg2:T26
51,R14,Subsumes Arg1:T22 Arg2:T33
52,T34,"Non-query-able 961 1342	Requirement of family or other caregiver support at study investigator criteria (defined as a patient's relative or caregiver (male or female) = 80 year old, who spend = 3 consecutive hours with patient, with good physical and psychological health status and without physical limitations, reading and writing educational level and able to understand and follow the study procedures"
53,T35,Non-query-able 1346 1455	Availability of patient's medical records data about the previous treatment with ADASUVE® at hospital setting
54,T36,"Pregnancy_considerations 1458 1885	If a female is of childbearing potential and sexually active (except if female is surgically sterile or post-menopausal with history of no menses for at least 24 months), patient must be non-lactating and non-pregnant (with a negative pregnancy test result at baseline visit) and have to agree to use a medically acceptable and effective birth control method throughout the study and for one week following the end of the study"
0,T1,Condition 3 16	HIV infection
1,T2,Measurement 22 28;45 58	plasma concentration
2,T3,Measurement 33 58	CSF HIV RNA concentration
3,T4,Procedure 67 87	Roche Amplicor assay
4,R1,AND Arg1:T3 Arg2:T4
5,R2,AND Arg1:T2 Arg2:T4
6,T5,"Value 89 107	> 1,000 copies/ mL"
7,R3,Has_value Arg1:T2 Arg2:T5
8,R4,Has_value Arg1:T3 Arg2:T5
9,T6,Procedure 147 175	antiretroviral therapy (ART)
10,T7,Condition 143 175	Off antiretroviral therapy (ART)
11,R5,multi Arg1:T7 Arg2:T6
12,T8,Temporal 180 206	> 6 weeks before the study
13,T9,Reference_point 197 206	the study
14,R6,Has_index Arg1:T8 Arg2:T9
15,T10,Mood 214 228	plans to begin
16,T11,Procedure 229 238	treatment
17,T12,Temporal 239 261	for the study duration
18,T13,Reference_point 247 252	study
19,R7,multi Arg1:T12 Arg2:T13
20,R8,Has_temporal Arg1:T11 Arg2:T12
21,R9,Has_mood Arg1:T11 Arg2:T10
22,T14,Negation 211 213	no
23,R10,Has_negation Arg1:T10 Arg2:T14
24,R11,Has_temporal Arg1:T7 Arg2:T8
25,T15,Context_Error 229 238	treatment
26,T16,Non-representable 453 491	Predicted adherence to the medication.
27,T17,Post-eligibility 496 534	Capable of providing informed consent.
28,T18,Value 541 549	18 years
29,T19,Person 550 553	old
30,R12,Has_value Arg1:T19 Arg2:T18
31,T20,Measurement 558 573	CD4 cell counts
32,T21,Value 574 587	>150 cells/μL
33,R13,Has_value Arg1:T20 Arg2:T21
34,T22,Value 629 642	>250 cells/μL
35,R14,Subsumes Arg1:T21 Arg2:T22
36,T23,"Not_a_criteria 649 737	When available, subjects will be screened for stability of blood CD4 and HIV RNA levels."
0,T1,Condition 23 39	systemic disease
1,T2,Qualifier 0 22	Clinically significant
2,T3,Condition 49 57	diabetes
3,T4,Condition 59 77	metabolic syndrome
4,T5,Condition 79 101	immunological diseases
5,T6,Condition 103 126	diagnosed thrombophilia
6,T7,Condition 128 137	porphyria
7,T8,Condition 152 169	medical condition
8,T9,Drug 191 219	low-molecular weight heparin
9,R1,AND Arg1:T8 Arg2:T9
10,*,OR T7 T6 T5 T4 T3 T8
11,T10,"Scope 49 227	diabetes, metabolic syndrome, immunological diseases, diagnosed thrombophilia, porphyria, or any other medical condition requiring the use of low-molecular weight heparin therapy"
12,R2,Has_qualifier Arg1:T1 Arg2:T2
13,T11,Scope 0 39	Clinically significant systemic disease
14,R3,Subsumes Arg1:T11 Arg2:T10
15,T12,Condition 230 262	Polycystic ovary syndrome (PCOS)
16,T13,Qualifier 276 304	Rotterdam Consensus Criteria
17,T14,"Qualifier 306 423	European Society of Human Reproduction and Embryology [ESHRE]/American Society for Reproductive Medicine [ASRM], 2003"
18,R4,Subsumes Arg1:T13 Arg2:T14
19,R5,Has_qualifier Arg1:T12 Arg2:T13
20,T15,Condition 426 453	Poor ovarian response (POR)
21,T16,Qualifier 471 541	European Society of Human Reproduction and Embryology (ESHRE) Criteria
22,R6,Has_qualifier Arg1:T15 Arg2:T16
23,T17,Condition 543 578	RIF (repeated implantation failure)
24,T18,Value 591 623	greater than or equals to (>=) 2
25,T19,Measurement 624 656	previous failed embryo transfers
26,R7,Has_value Arg1:T19 Arg2:T18
27,R8,AND Arg1:T17 Arg2:T19
28,T20,Condition 658 671	Endometriosis
29,T21,Qualifier 672 684	III-IV stage
30,R9,AND Arg1:T21 Arg2:T20
31,T22,Condition 688 699	adenomyosis
32,*,OR T20 T22
33,T23,Qualifier 701 723	Clinically significant
34,T24,Procedure 736 740	exam
35,T25,Procedure 744 754	ultrasound
36,T26,Condition 764 775	salpingitis
37,T27,Condition 777 789	hydrosalpynx
38,T28,Condition 805 818	ovarian cysts
39,T29,Mood 793 801	evidence
40,R10,Has_mood Arg1:T28 Arg2:T29
41,*,OR T26 T27 T28
42,*,OR T24 T25
43,T30,Scope 736 754	exam or ultrasound
44,T31,Observation 724 732	findings
45,R11,Has_qualifier Arg1:T31 Arg2:T23
46,R12,Has_context Arg1:T30 Arg2:T31
47,T32,Scope 701 754	Clinically significant findings on exam or ultrasound
48,T33,"Scope 764 818	salpingitis, hydrosalpynx or evidence of ovarian cysts"
49,R13,Subsumes Arg1:T32 Arg2:T33
50,T34,Condition 826 842	hypersensitivity
51,T36,Non-representable 820 884	Known hypersensitivity to any of the components of the solution
52,T37,Condition 891 907	hypersensitivity
53,T35,Drug 911 931	vaginal progesterone
54,R14,AND Arg1:T37 Arg2:T35
55,T38,Drug 939 949	excipients
56,*,OR T35 T38
57,T39,Drug 857 883	components of the solution
58,R15,AND Arg1:T34 Arg2:T39
59,T40,Non-representable 951 1004	Other protocol defined exclusion criteria could apply
0,T1,Drug 12 24	tetracycline
1,T2,Temporal 25 40	within 6 months
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Observation 44 51	history
4,T4,Condition 55 71	adverse reaction
5,T5,Drug 75 86	minocycline
6,T6,Drug 98 110	tetracycline
7,*,OR T6 T5
8,T7,Scope 75 110	minocycline or another tetracycline
9,R2,Has_scope Arg1:T4 Arg2:T7
10,R3,Has_temporal Arg1:T4 Arg2:T3
11,T8,Procedure 135 150	lumbar puncture
12,T9,Mood 116 129	Enhanced risk
13,R4,Has_mood Arg1:T8 Arg2:T9
14,T10,Condition 186 206	cerebral mass lesion
15,T11,Qualifier 207 261	predisposing to brain herniation or bleeding diathesis
16,T12,Mood 207 222	predisposing to
17,T13,Condition 223 239	brain herniation
18,T14,Condition 243 261	bleeding diathesis
19,*,OR T14 T13
20,T15,Scope 223 261	brain herniation or bleeding diathesis
21,R5,Has_mood Arg1:T15 Arg2:T12
22,R6,multi Arg1:T11 Arg2:T15
23,R7,Has_qualifier Arg1:T10 Arg2:T11
24,T16,Mood 162 172	documented
25,T17,Mood 176 185	suspected
26,*,OR T17 T16
27,T18,Scope 162 185	documented or suspected
28,R8,Has_scope Arg1:T10 Arg2:T18
29,T19,Scope 162 261	documented or suspected cerebral mass lesion predisposing to brain herniation or bleeding diathesis
30,T20,Scope 116 150	Enhanced risk from lumbar puncture
31,R9,Subsumes Arg1:T20 Arg2:T19
32,T21,Condition 267 276	Pregnancy
33,T22,Mood 280 291	expectation
34,T23,Condition 295 304	pregnancy
35,T24,Temporal 305 321	during the study
36,R10,Has_mood Arg1:T23 Arg2:T22
37,*,OR T23 T21
38,T25,Scope 267 304	Pregnancy or expectation of pregnancy
39,R11,Has_temporal Arg1:T25 Arg2:T24
40,T26,Condition 334 357	opportunistic infection
41,T27,Qualifier 334 347	opportunistic
42,R12,multi Arg1:T26 Arg2:T27
43,T28,Temporal 327 333	Active
44,R13,Has_temporal Arg1:T26 Arg2:T28
45,T29,Condition 368 388	neurological disease
46,T30,Temporal 361 367	active
47,R14,Has_temporal Arg1:T29 Arg2:T30
48,*,OR T29 T26
49,T31,Measurement 425 434	ADC Stage
50,T32,Value 435 438	> 1
51,R15,Has_value Arg1:T31 Arg2:T32
52,T33,Measurement 444 454	Hemoglobin
53,T34,Value 455 466	< 10 Gms/dL
54,R16,Has_value Arg1:T33 Arg2:T34
55,T35,Measurement 472 475	BUN
56,T36,Measurement 479 487	creatine
57,T37,Value 488 511	above the normal limits
58,*,OR T35 T36
59,T38,Scope 472 487	BUN or creatine
60,R17,Has_value Arg1:T38 Arg2:T37
61,T39,Drug 570 581	minocycline
62,T40,Non-representable 545 581	reduce the metabolism of minocycline
63,T41,Non-representable 517 628	Taking other drugs known to reduce the metabolism of minocycline and thus increase the probability of toxicity.
0,T1,Condition 23 31	dementia
1,T2,Qualifier 48 55	serious
2,T3,Qualifier 60 68	unstable
3,T4,Scope 48 68	serious and unstable
4,T5,Condition 97 104	hepatic
5,T6,Condition 106 111	renal
6,T7,Condition 113 130	gastroenterologic
7,T8,Condition 132 143	respiratory
8,T9,Condition 145 159	cardiovascular
9,T10,Condition 241 251	neurologic
10,T11,Condition 225 239	endocrinologic
11,*,OR T5 T6 T7 T8 T9 T11 T10
12,T12,Condition 171 193	ischemic heart disease
13,T13,Condition 198 222	congestive heart failure
14,*,OR T12 T13
15,T14,Condition 263 269	stroke
16,T15,Condition 271 296	transient ischemic attack
17,T16,Condition 298 321	subarachnoidal bleeding
18,T17,Condition 323 334	brain tumor
19,T18,Condition 336 350	encephalopathy
20,T19,Condition 356 366	meningitis
21,*,OR T14 T15 T16 T17 T18 T19
22,T20,"Scope 263 366	stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis"
23,R1,Subsumes Arg1:T10 Arg2:T20
24,T21,Scope 171 223	ischemic heart disease and congestive heart failure)
25,R2,Subsumes Arg1:T9 Arg2:T21
26,T22,"Scope 97 366	hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and congestive heart failure), endocrinologic, neurologic (including stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis"
27,R3,Has_scope Arg1:T22 Arg2:T4
28,T23,Condition 397 415	allergic reactions
29,T24,Drug 419 427	loxapine
30,T25,Drug 431 440	amoxapine
31,*,OR T24 T25
32,T26,Scope 419 440	loxapine or amoxapine
33,R4,Has_scope Arg1:T23 Arg2:T26
34,T27,Competing_trial 442 563	Patients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded
35,T28,"Post-eligibility 566 684	Patients who are considered by the investigator, for any reason, to be unable to self-administer the inhalation device"
0,T1,Drug 77 80	MET
1,T2,Multiplier 81 92	1000 mg bid
2,T3,Temporal 97 134	at least 2 weeks in the past 3 months
3,R1,Has_multiplier Arg1:T1 Arg2:T2
4,R2,Has_temporal Arg1:T1 Arg2:T3
5,T4,Condition 177 189	not tolerate
6,T5,Drug 190 193	MET
7,R3,AND Arg1:T4 Arg2:T5
8,T6,Condition 343 358	thyroid disease
9,T7,Qualifier 334 342	unstable
10,R4,Has_qualifier Arg1:T6 Arg2:T7
11,T8,Condition 447 464	diabetes mellitus
12,T9,Drug 466 473	insulin
13,T10,Condition 476 497	chronic renal failure
14,T11,Drug 499 507	steroids
15,*,OR T6 T8 T10 T9 T11
16,T12,Measurement 512 527	Fasting glucose
17,T13,Value 528 539	= 126 mg/dL
18,T14,Multiplier 543 546	2 o
19,R5,Has_value Arg1:T12 Arg2:T13
20,R6,Has_multiplier Arg1:T12 Arg2:T14
21,T15,Measurement 669 685	serum creatinine
22,T16,Value 686 696	=1.3 mg/dL
23,T17,Multiplier 700 701	2
24,R7,Has_value Arg1:T15 Arg2:T16
25,R8,Has_multiplier Arg1:T15 Arg2:T17
26,T18,Pregnancy_considerations 802 828	Pregnant or breast feeding
27,T19,Informed_consent 831 908	Children and caregivers who are unable to complete assessments for any reason
0,T1,Condition 4 13	infertile
1,T2,Person 14 19	women
2,T3,Procedure 33 72	intracytoplasmic sperm injection (ICSI)
3,T4,Procedure 73 123	Fertilization in Vitro and Embryo Transfer (FIVET)
4,*,OR T3 T4
5,T5,Value 125 153	Less than or equal to (<=) 1
6,T6,Measurement 154 185	previous failed embryo transfer
7,R1,Has_value Arg1:T6 Arg2:T5
8,T7,Condition 187 199	Eumenorrheic
9,T8,Condition 200 218	normo-gonadotropic
10,T9,Person 219 224	women
11,T10,Measurement 226 266	Basal follicle-stimulating hormone (FSH)
12,T11,Value 267 307	<=12 International unit per liter (IU/L)
13,T12,Measurement 309 337	Anti-mullerian hormone (AMH)
14,T13,Value 338 390	greater than (>) 1.1 nanogram per milliliter (ng/mL)
15,R2,Has_value Arg1:T12 Arg2:T13
16,R3,Has_value Arg1:T10 Arg2:T11
17,T14,Measurement 409 453	number of antral follicles 2 millimeter (mm)
18,T15,Value 454 500	between 6 <= antral follicle count (AFC) <= 16
19,R4,Has_value Arg1:T14 Arg2:T15
20,T16,Measurement 502 519	Follicles > 16 mm
21,T17,Value 542 554	between 5-14
22,R5,Has_value Arg1:T16 Arg2:T17
23,T18,Temporal 520 541	at the triggering day
24,R6,Has_temporal Arg1:T16 Arg2:T18
25,T19,Measurement 556 577	Body Mass Index (BMI)
26,T20,Value 578 636	between 18 <= BMI <= 27 kilogram per meter square (kg/m^2)
27,R7,Has_value Arg1:T19 Arg2:T20
28,T21,Mood 638 652	Indication for
29,T22,Procedure 653 674	Fresh Embryo transfer
30,R8,Has_mood Arg1:T22 Arg2:T21
31,T23,Procedure 701 716	ultrasound exam
32,T24,Observation 676 697	Normal uterine cavity
33,R9,Has_context Arg1:T23 Arg2:T24
34,T25,Negation 724 738	no presence of
35,T26,Condition 739 751	hydrosalpinx
36,R10,Has_negation Arg1:T26 Arg2:T25
37,T27,Scope 724 751	no presence of hydrosalpinx
38,R11,Subsumes Arg1:T24 Arg2:T27
39,T28,Procedure 765 802	Assisted Reproductive Technique (ART)
40,T29,Procedure 807 824	oocyte maturation
41,T30,Procedure 828 873	human chorionic gonadotropin (HCG) triggering
42,T31,Temporal 754 764	Undergoing
43,T32,Scope 765 873	Assisted Reproductive Technique (ART) and oocyte maturation by human chorionic gonadotropin (HCG) triggering
44,R12,AND Arg1:T29 Arg2:T30
45,R13,Has_temporal Arg1:T32 Arg2:T31
46,T33,Measurement 875 904	Progesterone (P4) serum level
47,T34,Temporal 905 930	at the HCG triggering day
48,T35,Reference_point 908 930	the HCG triggering day
49,R14,Has_index Arg1:T34 Arg2:T35
50,T36,Value 931 943	<= 1.5 ng/mL
51,T37,Reference_point 945 964	Day O/Randomization
52,R15,Subsumes Arg1:T35 Arg2:T37
53,R16,Has_value Arg1:T34 Arg2:T36
54,R17,Has_temporal Arg1:T33 Arg2:T34
55,T38,Measurement 967 981	Estradiol (E2)
56,T39,Value 982 1017	<= 3000 picogram/milliliter (pg/mL)
57,T40,Reference_point 1021 1074	the human chorionic gonadotropin (HCG) triggering day
58,T41,Temporal 1018 1074	at the human chorionic gonadotropin (HCG) triggering day
59,T42,Reference_point 1076 1095	Day 0/Randomization
60,R18,Subsumes Arg1:T40 Arg2:T42
61,R19,Has_index Arg1:T41 Arg2:T40
62,R20,Has_value Arg1:T38 Arg2:T39
63,R21,Has_temporal Arg1:T38 Arg2:T41
64,T43,Informed_consent 1098 1222	Subjects must have read and signed the Informed Consent Form prior to study-specific-procedures not part of standard of care
65,T44,Non-representable 1224 1277	Other protocol defined inclusion criteria could apply
0,T1,Condition 31 39;52 56	thoracic pain
1,T2,Qualifier 40 51	homolateral
2,T3,Condition 22 29;52 56	axillar pain
3,T4,Condition 12 20;52 56	pectoral pain
4,T5,"Scope 12 39;52 56	pectoral, axillar, thoracic pain"
5,R1,Has_qualifier Arg1:T5 Arg2:T2
6,*,OR T4 T3 T1
7,T6,Observation 67 85	opioid consumption
8,T7,Qualifier 58 66	habitual
9,R2,Has_qualifier Arg1:T6 Arg2:T7
10,T8,Condition 93 113	alcoholics addiction
11,T9,Condition 104 113;88 92	addiction drug
12,*,OR T9 T8
13,T10,Observation 117 143	ICU postoperative recovery
14,T11,Condition 146 160	kidney failure
15,T12,Measurement 162 171	creatinin
16,T13,Measurement 182 202	creatinin <clearance
17,T14,Value 203 210	30 ml/h
18,T15,Value 172 180	> 2 g/dl
19,R3,Has_value Arg1:T12 Arg2:T15
20,R4,Has_value Arg1:T13 Arg2:T14
21,T16,Condition 219 234	hepatic failure
22,T17,Measurement 236 250	cholinesterase
23,T18,Value 251 260	< 2000 UI
24,R5,Has_value Arg1:T17 Arg2:T18
25,R6,Subsumes Arg1:T16 Arg2:T17
26,*,OR T12 T13
27,T19,"Scope 162 210	creatinin > 2 g/dl, creatinin <clearance 30 ml/h"
28,R7,Subsumes Arg1:T11 Arg2:T19
29,*,OR T16 T11
30,T20,Condition 264 283	cardiac arrhythmias
31,T21,Condition 288 296	Epilepsy
32,T22,"Condition 299 331	Psychiatric, cognitive disorders"
33,T23,Condition 333 351	mental retardation
34,*,OR T23 T22
35,T24,Condition 354 368	Coagulopathies
36,T25,Measurement 370 373	INR
37,T26,Value 374 377	> 2
38,R8,Has_value Arg1:T25 Arg2:T26
39,T27,Measurement 379 423	activated partial thromboplastin time - aPTT
40,T28,Value 423 430	>44 sec
41,R9,Has_value Arg1:T27 Arg2:T28
42,*,OR T25 T27
43,T29,"Scope 370 430	INR > 2, activated partial thromboplastin time - aPTT>44 sec"
44,R10,Subsumes Arg1:T24 Arg2:T29
45,T30,Measurement 434 448	platelet count
46,T31,Value 449 470	less than 100.000/mm3
47,R11,Has_value Arg1:T30 Arg2:T31
48,T32,Measurement 473 476	BMI
49,T33,Value 477 481	> 30
50,R12,Has_value Arg1:T32 Arg2:T33
51,T34,Condition 484 493	Allergies
52,T35,Drug 497 508	study drugs
53,R13,AND Arg1:T34 Arg2:T35
0,T1,Condition 116 128	hip fracture
1,T2,"Non-query-able 0 88	At the cluster level, ED physicians practicing at a participating site will be eligible."
2,T3,Non-query-able 130 183	seen by a participating ED physician will be eligible
3,T4,Context_Error 0 20	At the cluster level
4,T5,Context_Error 90 110	At the patient level
5,T6,Parsing_Error 90 110	At the patient level
6,T7,Parsing_Error 0 20	At the cluster level
0,T1,Informed_consent 0 16	Informed consent
1,T2,Condition 31 46	type 2 diabetes
2,T3,Measurement 48 53	HbA1c
3,T4,Value 54 67	> 48 mmol/mol
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Person 70 73	Age
6,T6,Value 74 93	older than 30 years
7,R2,Has_value Arg1:T5 Arg2:T6
0,T1,Condition 18 35	allergy to nickel
1,T2,Drug 29 35	nickel
2,R1,multi Arg1:T1 Arg2:T2
3,T3,Condition 68 85	bowel obstruction
4,T4,Condition 87 106	bowel strangulation
5,T5,Condition 108 119	peritonitis
6,T6,Condition 121 138	bowel perforation
7,T7,Condition 149 167	systemic infection
8,T8,Condition 140 145;158 167	local infection
9,T9,Condition 169 183	ischemic bowel
10,T10,Condition 185 199	carcinomatosis
11,T11,Condition 222 248	inflammatory bowel disease
12,T12,Qualifier 203 221	extensively spread
13,R2,Has_qualifier Arg1:T11 Arg2:T12
14,*,OR T3 T4 T5 T6 T8 T7 T9 T10 T11
15,T13,Post-eligibility 254 344	Patient is participating in another clinical trial which may affect this study's outcomes.
16,T14,Context_Error 254 344	Patient is participating in another clinical trial which may affect this study's outcomes.
17,T15,Drug 381 399	steroid medication
18,T16,Multiplier 373 380	regular
19,R3,Has_multiplier Arg1:T15 Arg2:T16
20,T17,Condition 417 456	contraindications to general anesthesia
21,T18,Procedure 438 456	general anesthesia
22,R4,multi Arg1:T17 Arg2:T18
23,T19,Condition 486 504	sphincter problems
24,T20,Condition 530 557	local disease in the pelvis
25,T21,Qualifier 520 529	extensive
26,R5,Has_qualifier Arg1:T20 Arg2:T21
27,T22,Mood 508 519	evidence of
28,R6,Has_mood Arg1:T20 Arg2:T22
29,*,OR T19 T20
0,T1,Condition 14 28	osteoarthritis
1,T2,Qualifier 36 39	hip
2,T3,Qualifier 40 65	secondary to degeneration
3,T4,Condition 53 65	degeneration
4,R1,multi Arg1:T3 Arg2:T4
5,R2,Has_qualifier Arg1:T1 Arg2:T2
6,R3,Has_qualifier Arg1:T1 Arg2:T3
7,T5,Condition 67 89	inflammatory arthritis
8,T6,Condition 91 106	gouty arthritis
9,T7,Condition 108 128	acetabular dysplasia
10,T8,Condition 132 145	osteonecrosis
11,T9,Qualifier 153 165	femoral head
12,T10,Temporal 171 181	undergoing
13,T11,Qualifier 182 189	primary
14,T12,Qualifier 190 200	unilateral
15,T13,Procedure 201 223	minimally invasive THA
16,R5,Has_qualifier Arg1:T13 Arg2:T12
17,R6,Has_qualifier Arg1:T13 Arg2:T11
18,R7,Has_temporal Arg1:T13 Arg2:T10
19,*,OR T8 T7
20,T14,Scope 108 145	acetabular dysplasia or osteonecrosis
21,R4,Has_qualifier Arg1:T14 Arg2:T9
22,*,OR T14 T13 T6 T5 T1
23,T15,Person 225 228	Age
24,T16,Value 229 239	> 18 years
25,T17,Value 244 254	< 90 years
26,R8,Has_value Arg1:T15 Arg2:T16
27,R9,Has_value Arg1:T15 Arg2:T17
28,T18,Qualifier 256 263	Failure
29,T19,Procedure 267 284	medical treatment
30,T20,Procedure 288 302	rehabilitation
31,*,OR T19 T20
32,T21,Scope 267 302	medical treatment or rehabilitation
33,R10,Has_qualifier Arg1:T21 Arg2:T18
34,T22,Measurement 305 315	Hemoglobin
35,T23,Value 316 324	> 11g/dl
36,R11,Has_value Arg1:T22 Arg2:T23
37,T24,Drug 337 372	non-steroid anti-inflammatory agent
38,T25,Temporal 373 398	one week before operation
39,T26,Reference_point 389 398	operation
40,R12,Has_index Arg1:T25 Arg2:T26
41,R13,Has_temporal Arg1:T24 Arg2:T25
42,T27,Negation 327 329	No
43,R14,Has_negation Arg1:T24 Arg2:T27
0,T1,Person 0 1	F
1,T2,Person 3 6	age
2,T3,Value 7 15	18 to 70
3,R1,Has_value Arg1:T2 Arg2:T3
4,T4,Measurement 17 60	American Society of Anesthesiologists (ASA)
5,T5,Value 61 67	I e II
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Condition 70 83	breast cancer
8,T7,Measurement 86 89	DIN
9,T8,Value 90 95	2 e 3
10,T9,Measurement 99 102	LIN
11,T10,Value 103 112	2 e 3 sec
12,R3,Has_value Arg1:T7 Arg2:T8
13,R4,Has_value Arg1:T9 Arg2:T10
14,*,OR T7 T9
15,T11,Condition 139 164	nipple-sparing mastectomy
16,T12,Mood 125 138	scheduled for
17,R5,Has_mood Arg1:T11 Arg2:T12
18,T13,Condition 166 183	simple mastectomy
19,T14,Condition 185 208	skin-sparing mastectomy
20,T15,Condition 210 234	skin-reducing mastectomy
21,T16,Condition 238 254	lymphnode biopsy
22,T17,Condition 259 278	axillary dissection
23,*,OR T11 T13 T16 T17 T15 T14 T6
24,T18,"Scope 86 123	DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli"
25,R6,Subsumes Arg1:T6 Arg2:T18
26,T19,Procedure 291 329	sub-pectoral prosthetic reconstruction
27,T20,Qualifier 281 290	immediate
28,R7,Has_qualifier Arg1:T19 Arg2:T20
29,T21,Non-query-able 332 355	signed informed consent
0,T1,Non-query-able 0 69	ED physicians who work casually (less than 0.25 Full Time Equivalent)
1,T2,"Non-query-able 71 188	ED Physicians who are routinely using U/S guided RA for hip fracture patients, or decline participation in the trial."
2,T3,Value 204 222	less than 65 years
3,T4,Person 200 203	age
4,R1,Has_value Arg1:T4 Arg2:T3
5,T5,Condition 242 251	delirious
6,T6,Temporal 252 273	on initial assessment
7,T7,Reference_point 255 273	initial assessment
8,R2,Has_index Arg1:T6 Arg2:T7
9,R3,Has_temporal Arg1:T5 Arg2:T6
10,T8,Condition 300 308	dementia
11,T9,Qualifier 293 299	severe
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,*,OR T5 T8
14,T10,Condition 324 346	communication problems
15,T11,Undefined_semantics 324 346	communication problems
16,T12,Condition 348 362	critically ill
17,T13,Condition 364 375	unconscious
18,T14,Condition 377 393	language barrier
19,*,OR T14 T13 T12
20,T15,"Scope 348 393	critically ill, unconscious, language barrier"
21,R5,Subsumes Arg1:T10 Arg2:T15
22,T16,Condition 468 477	allergies
23,T17,Drug 481 490	narcotics
24,T18,Drug 494 510	local anesthetic
25,T19,Scope 481 510	narcotics or local anesthetic
26,R6,Has_scope Arg1:T16 Arg2:T19
27,T20,Drug 515 528	anticoagulant
28,T21,Drug 539 547	warfarin
29,T22,Drug 549 559	dabigatran
30,T23,Drug 561 572	rivaroxaban
31,*,OR T21 T22 T23
32,T24,"Scope 539 572	warfarin, dabigatran, rivaroxaban"
33,R7,Subsumes Arg1:T20 Arg2:T24
34,*,OR T20 T16
35,T25,Condition 590 603	hip fractures
36,T26,Procedure 618 625	surgery
37,T27,Qualifier 608 625	requiring surgery
38,T28,Negation 604 607	not
39,R8,Has_negation Arg1:T27 Arg2:T28
40,R9,Has_qualifier Arg1:T25 Arg2:T27
41,T29,Condition 632 659	greater trochanter avulsion
42,T30,Undefined_semantics 590 625	hip fractures not requiring surgery
43,T31,Scope 590 625	hip fractures not requiring surgery
44,R10,Subsumes Arg1:T31 Arg2:T29
0,T1,Value 14 31	over 18 years old
1,T2,Person 22 31	years old
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Procedure 64 87	non-emergency procedure
4,T4,Qualifier 64 77	non-emergency
5,R2,multi Arg1:T3 Arg2:T4
6,T5,Mood 48 57	scheduled
7,R3,Has_mood Arg1:T3 Arg2:T5
8,T6,Post-eligibility 90 210	3. Subject signs and dates a written informed consent form (ICF) and indicates an understanding of the study procedures.
0,T1,Condition 0 15	Type 1 diabetes
1,T2,Drug 32 39	insulin
2,T3,Procedure 17 26	Treatment
3,R1,AND Arg1:T3 Arg2:T2
4,T4,Measurement 41 52	Body weight
5,T5,Value 53 61	> 140 kg
6,R2,Has_value Arg1:T4 Arg2:T5
7,T6,Measurement 63 68	HbA1c
8,T7,Value 69 82	> 75 mmol/mol
9,R3,Has_value Arg1:T6 Arg2:T7
10,T8,Drug 99 114	GLP-1 analogues
11,T9,Drug 116 149	Dipeptidyl peptidase-4 inhibitors
12,T10,Drug 154 164	glitazones
13,*,OR T10 T9 T8
14,T11,Condition 207 219	Pancreatitis
15,T12,Condition 166 188	Chronic kidney disease
16,T13,Condition 190 205	Hepatic disease
17,T14,Condition 221 247	Inflammatory bowel disease
18,T15,Condition 249 261	Osteoporosis
19,T16,Condition 293 320	medullary thyroid carcinoma
20,T17,Observation 273 289	personal history
21,T18,Observation 263 269	Family
22,*,OR T18 T17
23,T19,Scope 263 289	Family or personal history
24,T20,Drug 337 352	glucocorticoids
25,T21,Procedure 322 331	Treatment
26,R4,AND Arg1:T21 Arg2:T20
27,R5,Has_scope Arg1:T16 Arg2:T19
28,T22,Procedure 354 381	Hormone replacement therapy
29,T23,Condition 383 405	Diabetic gastroparesis
30,T24,Condition 407 416	Pregnancy
31,T25,Condition 420 429	lactation
32,*,OR T25 T24
0,T1,Temporal 0 12	Preoperative
1,T2,Measurement 13 23	Hemoglobin
2,T3,Value 24 39	<U+2266>11 g/dl
3,R1,Has_value Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T2 Arg2:T1
5,T4,Condition 52 61	infection
6,T5,Condition 65 88	intraarticular fracture
7,T6,Qualifier 96 109	affective hip
8,*,OR T5 T4
9,T7,Scope 52 88	infection or intraarticular fracture
10,R3,Has_qualifier Arg1:T7 Arg2:T6
11,T8,Observation 41 48	History
12,R4,Has_temporal Arg1:T7 Arg2:T8
13,T9,Condition 111 136	Renal function deficiency
14,T10,Measurement 138 141	GFR
15,T11,Value 142 159	<30 ml/min/1.73m2
16,R5,Has_value Arg1:T10 Arg2:T11
17,T12,Scope 138 159	GFR <30 ml/min/1.73m2
18,R6,Subsumes Arg1:T9 Arg2:T12
19,T13,Measurement 171 183	liver enzyme
20,T14,Value 162 170	Elevated
21,R7,Has_value Arg1:T13 Arg2:T14
22,T15,Measurement 185 246	aspartate transaminase (AST)/ alanine transaminase(ALT) level
23,T16,Value 251 279	more than twice normal range
24,R8,Has_value Arg1:T15 Arg2:T16
25,T17,Observation 283 290	history
26,T18,Condition 294 309	liver cirrhosis
27,T19,Condition 311 334	impaired liver function
28,T20,Value 335 343	elevated
29,T21,Measurement 344 365	total bilirubin level
30,R9,Has_value Arg1:T21 Arg2:T20
31,T22,Condition 371 383	coagulopathy
32,T23,Multiplier 395 408	long-term use
33,T24,Drug 409 422	anticoagulant
34,R10,Has_multiplier Arg1:T24 Arg2:T23
35,T25,Scope 395 422	long-term use anticoagulant
36,T26,Condition 436 456	deep vein thrombosis
37,T27,Condition 458 480	ischemic heart disease
38,T28,Condition 484 490	stroke
39,*,OR T27 T28 T26
40,T29,Condition 492 509	Contraindications
41,T30,Drug 513 528	tranexamic acid
42,T31,Drug 530 537	floseal
43,T32,Drug 542 553	rivaroxaban
44,*,OR T31 T32 T30
45,T33,"Scope 513 553	tranexamic acid, floseal, or rivaroxaban"
46,R11,Has_scope Arg1:T29 Arg2:T33
47,T34,Condition 555 562	Allergy
48,T35,Drug 566 581	tranexamic acid
49,T36,Drug 583 590	floseal
50,T37,Drug 592 603	rivaroxaban
51,T38,Drug 612 622	excipients
52,*,OR T38 T37 T36 T35
53,T39,"Scope 566 622	tranexamic acid, floseal, rivaroxaban, or the excipients"
54,R12,Subsumes Arg1:T34 Arg2:T39
55,T40,Condition 635 673	heparin-induced thrombocytopenia (HIT)
56,T41,Observation 624 631	History
57,R13,Has_temporal Arg1:T40 Arg2:T41
58,T42,Condition 675 687	Coagulopathy
59,T43,Condition 691 708	bleeding tendency
60,T44,Condition 719 736	organ dysfunction
61,T45,Condition 746 755	cirrhosis
62,T46,Condition 757 780	bone marrow suppression
63,*,OR T45 T46
64,T47,"Scope 746 780	cirrhosis, bone marrow suppression"
65,R14,Subsumes Arg1:T44 Arg2:T47
66,*,OR T43 T42
67,T48,Scope 675 708	Coagulopathy or bleeding tendency
68,R15,AND Arg1:T48 Arg2:T44
69,T49,Qualifier 804 810	active
70,T50,Condition 811 828	bleeding disorder
71,T51,Condition 838 861	intracranial hemorrhage
72,T52,Condition 863 894	upper gastrointestinal bleeding
73,T53,Condition 896 905	hematuria
74,*,OR T52 T53 T51
75,T54,"Scope 838 905	intracranial hemorrhage, upper gastrointestinal bleeding, hematuria"
76,R16,Has_qualifier Arg1:T50 Arg2:T49
77,R17,Subsumes Arg1:T50 Arg2:T54
78,T55,Condition 928 937	allergies
79,T56,Drug 941 967	materials of bovine origin
80,R18,AND Arg1:T55 Arg2:T56
0,T1,Observation 21 31	diagnostic
1,T2,Observation 35 46	therapeutic
2,T3,Procedure 47 58	colonoscopy
3,*,OR T2 T1
4,T4,Scope 21 46	diagnostic or therapeutic
5,R1,Has_scope Arg1:T3 Arg2:T4
0,T1,Observation 27 43	new relationship
1,T2,Temporal 57 101	no more than six months prior to study entry
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Observation 125 146	remaining in Montreal
4,T4,Multiplier 147 166	for at least 1 year
5,R2,Has_multiplier Arg1:T3 Arg2:T4
6,T5,Mood 168 175	Plan on
7,T6,Mood 117 124	plan on
8,R3,Has_mood Arg1:T3 Arg2:T6
9,T7,Observation 176 220	having continued sexual contact with partner
10,R4,Has_mood Arg1:T7 Arg2:T5
11,T8,Informed_consent 222 264	Be willing to comply with study procedures
0,T1,Value 0 11	19-65 years
1,T2,Person 15 18	age
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Measurement 20 54	ASA physical status classification
4,T4,Value 55 62	I or II
5,T5,Procedure 78 106	total hip replacement surger
6,T6,Mood 64 77	Scheduled for
7,R2,Has_mood Arg1:T5 Arg2:T6
0,T1,Qualifier 0 12	cauda equina
1,T2,Qualifier 16 21	conus
2,T3,Condition 22 28	lesion
3,*,OR T2 T1
4,T4,Scope 0 21	cauda equina or conus
5,R1,Has_scope Arg1:T3 Arg2:T4
6,T5,Temporal 30 39	currently
7,T6,Procedure 44 54	ventilator
8,R2,Has_temporal Arg1:T6 Arg2:T5
9,T7,Procedure 56 65	colostomy
10,T8,Procedure 85 103	regular bowel care
11,T9,Negation 70 84	do not perform
12,R3,Has_negation Arg1:T8 Arg2:T9
13,*,OR T7 T8
14,T10,Condition 124 138	skin breakdown
15,T11,Condition 140 154	pressure sores
16,R4,Subsumes Arg1:T10 Arg2:T11
17,T12,Negation 160 163	not
18,T13,Observation 164 177	speak English
19,R5,Has_negation Arg1:T13 Arg2:T12
20,T14,Value 183 197	under 19 years
21,T15,Person 198 201	old
22,R6,Has_value Arg1:T15 Arg2:T14
23,T16,Condition 207 215	pregnant
24,T17,Mood 219 237	think you might be
25,T18,Condition 238 246	pregnant
26,R7,Has_mood Arg1:T18 Arg2:T17
27,*,OR T16 T18
28,T19,Condition 248 255;268 277	medical condition
29,T20,Condition 256 277	psychiatric condition
30,T21,Condition 281 296	substance abuse
31,*,OR T20 T19 T21
32,T22,Temporal 359 368	currently
33,T24,Drug 375 407	medications containing lidocaine
34,T23,Drug 420 429	lidocaine
35,T25,Condition 409 416	allergy
36,R8,AND Arg1:T25 Arg2:T23
0,T1,Negation 16 19	not
1,T2,Temporal 20 29	have been
2,T3,Procedure 30 40	vaccinated
3,T4,Condition 49 63	HPV-Gardasil-9
4,R1,AND Arg1:T3 Arg2:T4
5,R2,Has_negation Arg1:T3 Arg2:T1
6,R3,Has_temporal Arg1:T3 Arg2:T2
7,T5,Observation 81 92	Any history
8,T6,Condition 127 134;96 104	cancers cervical
9,T7,Condition 106 112;127 134	penile cancers
10,T8,Condition 114 118;127 134	oral cancers
11,T9,Condition 122 134	anal cancers
12,*,OR T6 T7 T8 T9
13,T10,Condition 142 150	pregnant
14,T11,Mood 154 182	plan on immediately becoming
15,T12,Condition 183 191	pregnant
16,R4,Has_mood Arg1:T12 Arg2:T11
17,*,OR T10 T12
0,T1,Condition 0 5	ileus
1,T2,Mood 7 12	known
2,T3,Mood 16 25	suspected
3,*,OR T2 T3
4,T4,Condition 26 43	bowel obstruction
5,T5,Scope 7 25	known or suspected
6,R1,Has_scope Arg1:T4 Arg2:T5
7,T6,Temporal 45 51	active
8,T7,Condition 52 70	bowel inflammation
9,R2,Has_temporal Arg1:T7 Arg2:T6
10,T8,Condition 72 81	pregnancy
11,T9,Condition 99 125	serious medical conditions
12,T10,Condition 133 140;155 163	cardiac diseases
13,T11,Condition 149 163	liver diseases
14,T12,Condition 142 147;155 163	renal diseases
15,*,OR T10 T12 T11
16,T13,"Scope 133 163	cardiac, renal, liver diseases"
17,R3,Subsumes Arg1:T9 Arg2:T13
18,T14,Observation 166 176	history of
19,T15,Temporal 177 182	prior
20,T16,Procedure 183 190;201 208	colonic surgery
21,T17,Procedure 194 208	rectal surgery
22,*,OR T17 T16
23,T18,Scope 183 208	colonic or rectal surgery
24,R4,Has_temporal Arg1:T18 Arg2:T15
25,R5,Has_temporal Arg1:T18 Arg2:T14
26,T19,Non-query-able 210 245	inability to obtain valid data from
0,T1,Condition 0 28	traumatic spinal cord injury
1,T2,Temporal 29 50	at least one year ago
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T3,Observation 52 78	regular bowel care routine
4,T4,Temporal 80 99	at least four weeks
5,R2,Has_temporal Arg1:T3 Arg2:T4
0,T1,Condition 0 8	Allergic
1,T2,Drug 12 23	study drugs
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 38 44	asthma
4,T4,Condition 48 52	COPD
5,*,OR T3 T4 T6
6,T5,Qualifier 69 77	severely
7,T6,Condition 78 99	respiratory depressed
8,R2,Has_qualifier Arg1:T6 Arg2:T5
9,T7,Condition 110 131	hepatic insufficiency
10,T8,Condition 101 106;118 131	Renal insufficiency
11,T9,Condition 133 149	Epileptic status
12,T10,Condition 151 170	Intracranial lesion
13,T11,Measurement 197 218	intracranial pressure
14,T12,Value 187 196	increased
15,R3,Has_value Arg1:T11 Arg2:T12
16,R4,AND Arg1:T10 Arg2:T11
17,T13,Condition 220 233	Acute abdomen
18,T14,Condition 261 276	paralytic ileus
19,T15,Condition 280 296	suspicious ileus
20,*,OR T14 T15 T13
21,T16,Condition 298 306	Pregnant
22,T17,Condition 310 319	lactating
23,T18,Person 320 324	wome
24,*,OR T17 T16
0,T1,Procedure 36 43	surgery
1,T2,Mood 17 35	being prepared for
2,T3,Temporal 48 54;64 71	during surgery
3,T4,Temporal 58 71	after surgery
4,R1,Has_mood Arg1:T1 Arg2:T2
5,*,OR T3 T1 T4
6,T5,Condition 88 108	congenital anomalies
7,T6,Condition 110 131	chromosomal anomalies
8,T7,Condition 136 149	heart defects
9,*,OR T7 T6 T5
10,T8,Non-query-able 152 193	Patients whose parents refuse to consent.
0,T1,Person 12 20	neonates
1,T2,Condition 0 11	Nonsurgical
2,T3,Person 25 31	babies
3,T4,Value 32 50	up to age 6 months
4,T5,Person 38 41	age
5,R1,Has_value Arg1:T5 Arg2:T4
6,T6,Measurement 56 59	INR
7,T7,Value 60 71	1.5 or more
8,R2,Has_value Arg1:T6 Arg2:T7
9,T8,Procedure 106 121	plasma infusion
10,T9,Condition 101 105	need
11,R3,AND Arg1:T9 Arg2:T8
12,*,OR T3 T1
13,R4,AND Arg1:T1 Arg2:T2
14,R5,AND Arg1:T3 Arg2:T5
0,T1,Condition 41 53	osteoporosis
1,T2,Procedure 63 66	DXA
2,T3,Measurement 86 106	bone mineral density
3,T4,Qualifier 114 124	femur neck
4,T5,Qualifier 132 141	total hip
5,T6,Qualifier 149 161	lumbar spine
6,*,OR T4 T5 T6
7,T7,Scope 114 161	femur neck and/or total hip and/or lumbar spine
8,R1,AND Arg1:T2 Arg2:T3
9,R2,Has_scope Arg1:T3 Arg2:T7
10,R3,AND Arg1:T1 Arg2:T2
11,T8,Temporal 232 246	past 24 months
12,R4,Has_temporal Arg1:T1 Arg2:T8
13,T9,Measurement 163 170	T value
14,T10,Value 171 219	2.5 SD or more below the young female adult mean
15,R5,Has_value Arg1:T9 Arg2:T10
16,R6,AND Arg1:T3 Arg2:T9
17,T11,Negation 249 252	Not
18,T12,Drug 271 293	anti-resorptive agents
19,T13,Drug 300 315	bisphosphonates
20,T14,Drug 320 329	denosumab
21,*,OR T13 T14
22,T15,Scope 300 329	bisphosphonates and denosumab
23,R7,Subsumes Arg1:T12 Arg2:T15
24,T16,"Temporal 335 365	more than 4 consecutive years,"
25,R8,Has_temporal Arg1:T12 Arg2:T16
26,R9,Has_negation Arg1:T12 Arg2:T11
27,T17,Person 473 476	old
28,T18,Value 462 472	= 50 years
29,R10,Has_value Arg1:T17 Arg2:T18
30,T19,Condition 496 505	menopause
31,T20,Condition 532 554	cessation of ovulation
32,T21,Qualifier 522 531	permanent
33,R11,Has_qualifier Arg1:T20 Arg2:T21
34,T22,Temporal 560 577	at least one year
35,R12,Has_temporal Arg1:T19 Arg2:T22
36,R13,Subsumes Arg1:T19 Arg2:T20
37,T23,"Non-query-able 602 833	Edentulous area involving a maximum of two teeth (wisdom teeth and second molars are excluded) and presenting at least one neighbouring tooth (e.g. gap in the area of a second premolar and first molar, with first premolar in place)"
38,T24,Measurement 836 859	Residual alveolar width
39,T25,Value 860 866	= 4 mm
40,R14,Has_value Arg1:T24 Arg2:T25
41,T26,Measurement 899 923	residual alveolar height
42,T27,Value 924 929	>8 mm
43,R15,Has_value Arg1:T26 Arg2:T27
44,T28,"Non-query-able 931 1133	enough inter-arch space for a crown (at least 5 mm) and a minimum distance of 7 mm from the adjacent teeth (Shah and Lum, 2008). The width and height will be confirmed after x-ray examination in Visit 2"
45,T29,Post-eligibility 1136 1261	Possibility to restore a functional occlusion with a minimum of four occlusal units (i.e. pairs of occluding posterior teeth)
46,T30,Post-eligibility 1264 1331	Willingness to replace the missing tooth/teeth with dental implants
47,T31,Non-query-able 1333 1356	Registration with a GDP
0,T1,Procedure 22 44	loop ileostomy closure
0,T1,Drug 37 40	NAs
1,T2,Qualifier 30 36	single
2,T3,Condition 0 3	CHB
3,R1,Has_qualifier Arg1:T1 Arg2:T2
4,R2,AND Arg1:T3 Arg2:T1
5,T4,Temporal 45 64	more than 12 months
6,R3,Has_temporal Arg1:T1 Arg2:T4
7,T5,Measurement 67 88	Hepatitis B e antigen
8,T6,Measurement 90 95	HBeAg
9,T7,Value 97 105	negative
10,R4,Subsumes Arg1:T5 Arg2:T6
11,R5,Has_value Arg1:T5 Arg2:T7
12,T8,Measurement 108 135	Hepatitis B surface antigen
13,T9,Measurement 137 142	HBsAg
14,T10,Value 144 152	positive
15,T11,Value 157 168	<1000 IU/mL
16,R6,Subsumes Arg1:T8 Arg2:T9
17,R7,Has_value Arg1:T8 Arg2:T10
18,R8,Has_value Arg1:T8 Arg2:T11
19,T12,Measurement 171 192	Hepatitis B virus DNA
20,T13,Value 193 203	<100 IU/mL
21,R9,Has_value Arg1:T12 Arg2:T13
0,T1,Post-eligibility 0 29	Able to give informed consent
1,T2,Condition 31 43	Right-handed
2,T3,Person 45 48	Age
3,T4,Value 49 72	between 18-50 years old
4,R1,Has_value Arg1:T3 Arg2:T4
5,T5,Condition 90 112	neurologically healthy
6,T6,Condition 105 112;75 85	healthy Physically
7,T7,Procedure 129 158	comprehensive medical history
8,R2,AND Arg1:T6 Arg2:T7
9,R3,AND Arg1:T5 Arg2:T7
10,T8,Condition 169 173	PTSD
11,T9,Temporal 161 168	Current
12,R4,Has_temporal Arg1:T8 Arg2:T9
0,T1,Person 0 5	Women
1,T2,Condition 11 45	systemic lupus erythematosus (SLE)
2,T3,Person 47 52	Women
3,T4,Person 91 96	Women
4,T5,Qualifier 58 64	active
5,T6,Condition 65 89	thromboembolic disorders
6,R1,Has_qualifier Arg1:T6 Arg2:T5
7,T7,Observation 102 109	history
8,T8,Temporal 113 121	previous
9,T9,Condition 122 146	thromboembolic disorders
10,R2,Has_temporal Arg1:T9 Arg2:T8
11,R3,Has_temporal Arg1:T9 Arg2:T7
0,T1,Measurement 9 30	dietary sodium intake
1,T2,Value 31 47	> 3400mg per day
2,R1,Has_value Arg1:T1 Arg2:T2
0,T1,Procedure 11 20	treatment
1,T2,Temporal 28 45	two weeks or more
2,R1,Has_temporal Arg1:T1 Arg2:T2
3,T4,Condition 511 529	Cushing's syndrome
4,T5,Condition 531 548	Addison's disease
5,T6,Condition 550 574	diabetes mellitus type 1
6,T7,Condition 576 585	leukaemia
7,T8,Condition 587 605	pernicious anaemia
8,T9,Condition 607 630	malabsorption syndromes
9,T10,Condition 632 653	chronic liver disease
10,T11,Condition 655 675	rheumatoid arthritis
11,*,OR T11 T10 T9 T8 T7 T6 T5 T4
12,T3,Drug 214 231	immunosuppressive
13,T12,Drug 191 203	cyclosporine
14,T13,Drug 170 189	calcium antagonists
15,T14,Drug 153 168	anti-epileptics
16,T15,Condition 122 142	gingival hypertrophy
17,*,OR T14 T13 T12 T3
18,T16,"Scope 153 231	anti-epileptics, calcium antagonists, cyclosporine and other immunosuppressive"
19,R2,Has_scope Arg1:T15 Arg2:T16
20,T17,Observation 236 251	bone metabolism
21,T18,Drug 258 271	anticoagulant
22,T19,Drug 299 306	steroid
23,T20,Multiplier 325 344;361 366	equal or more 2.5mg a day
24,T21,Drug 348 360	prednisolone
25,R3,Has_multiplier Arg1:T21 Arg2:T20
26,T22,Temporal 377 386	>3 months
27,R4,Has_temporal Arg1:T21 Arg2:T22
28,T23,Drug 390 405	anticonvulsants
29,T24,Drug 407 425	immunosuppressants
30,*,OR T15 T17
31,*,OR T18 T19 T21 T23 T24
32,T25,"Scope 258 426	anticoagulant medications, long-standing steroid medications -i.e. equal or more 2.5mg of prednisolone a day taken for >3 months -, anticonvulsants, immunosuppressants)"
33,R5,Subsumes Arg1:T17 Arg2:T25
34,T26,Condition 708 717	Hepatitis
35,T27,Condition 701 704	HIV
36,*,OR T26 T27
37,T28,Procedure 731 754	local radiation therapy
38,T29,Temporal 762 777	last five years
39,R6,Has_temporal Arg1:T28 Arg2:T29
40,T30,"Post-eligibility 781 963	ffected by limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained, or simple instructions cannot be followed"
41,T31,Condition 997 1015	periodontal lesion
42,T32,Condition 1009 1015;986 996	lesion endodontic
43,*,OR T31 T32
44,T33,Condition 1074 1084	edentulous
45,T34,Qualifier 1063 1073	Completely
46,R7,Has_qualifier Arg1:T33 Arg2:T34
47,T35,Non-query-able 1086 1206	With evident severe atrophy of the alveolar ridge that could preclude an implant placement (e.g. sharp knife edge ridge)
48,T36,Observation 1226 1242	clenching habits
49,T37,Observation 1215 1222	bruxism
50,*,OR T36 T37
51,T38,Person 1244 1251	Smokers
52,T39,Observation 1259 1269	cigarettes
53,T40,Multiplier 1255 1258;1270 1275	> 5 a day
54,R8,Has_multiplier Arg1:T39 Arg2:T40
55,T41,Observation 1286 1293	alcohol
56,T42,Multiplier 1301 1313	>2 units/day
57,R9,Has_multiplier Arg1:T41 Arg2:T42
58,T43,"Non-query-able 1316 1677	Other severe acute or chronic medical or psychiatric condition or laboratory abnormality which may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial"
59,T44,Post-eligibility 1680 1735	Patients unable or not willing to return for follow-ups
0,T1,Person 9 17	under 18
1,T2,Value 9 17	under 18
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 19 28	Pregnancy
4,T4,Condition 33 42	Lactation
5,*,OR T4 T3
6,T5,Condition 53 61	allergic
7,T6,Drug 65 77;93 102	polyglycolic carbonate
8,T7,Drug 80 102	trimethylene carbonate
9,T8,Scope 65 102	polyglycolic / trimethylene carbonate
10,R2,Has_scope Arg1:T5 Arg2:T8
11,T9,Device 115 130	prosthetic mesh
12,T10,Procedure 138 144	ostomy
13,R3,AND Arg1:T10 Arg2:T9
14,T11,Condition 166 180	midline hernia
15,T12,Condition 204 230	inflammatory bowel disease
0,T1,Qualifier 0 22	clinically significant
1,T2,Condition 34 54	neurologic condition
2,T3,Condition 23 30;45 54	medical condition
3,T4,Condition 58 84	neurocognitive dysfunction
4,*,OR T3 T2 T4
5,T5,Scope 23 84	medical or neurologic condition or neurocognitive dysfunction
6,R1,Has_qualifier Arg1:T5 Arg2:T1
7,T6,Temporal 182 189	current
8,T7,Temporal 194 214	within past 2 months
9,R2,Subsumes Arg1:T6 Arg2:T7
10,T8,Condition 216 233	medical condition
11,T9,Drug 244 254	medication
12,T10,Mood 260 279	would interact with
13,T11,Drug 280 290	dronabinol
14,T12,Mood 294 327	interfere with the study protocol
15,R3,Has_mood Arg1:T11 Arg2:T10
16,*,OR T11 T12
17,T13,Scope 260 327	would interact with dronabinol or interfere with the study protocol
18,R4,Has_scope Arg1:T9 Arg2:T13
19,R5,AND Arg1:T8 Arg2:T9
20,R6,Has_temporal Arg1:T8 Arg2:T6
21,T14,Non-query-able 329 396	risk of harm to self or others that requires immediate intervention
22,T15,Condition 410 427	contraindications
23,T16,Temporal 429 436	current
24,T17,Temporal 440 444	past
25,*,OR T17 T16
26,T18,Condition 445 453;465 473	allergic reaction
27,T19,Condition 457 473	adverse reaction
28,T20,Condition 484 495	sensitivity
29,T21,Drug 499 526	cannabinoid-like substances
30,T22,Drug 528 538	dronabinol
31,T23,Drug 539 548	marijuana
32,T24,Drug 549 557	cannabis
33,T25,Drug 558 561	THC
34,T26,Drug 563 578	cannabinoid oil
35,T27,Drug 580 590	sesame oil
36,T28,Drug 592 599	gelatin
37,T29,Drug 601 609	glycerin
38,T30,Drug 615 631	titanium dioxide
39,*,OR T30 T29 T28 T27 T26 T25 T24 T23 T22
40,T31,"Scope 528 631	dronabinol/marijuana/cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide"
41,R7,Subsumes Arg1:T21 Arg2:T31
42,T32,Scope 445 473	allergic or adverse reaction
43,T33,Scope 429 444	current or past
44,R9,Has_scope Arg1:T32 Arg2:T33
45,*,OR T15 T32 T20
46,T34,Non-query-able 634 660	lack of fluency in English
47,T35,Measurement 671 682	drug screen
48,T36,Value 662 670	positive
49,T37,Measurement 686 706	alcohol breathalyzer
50,*,OR T35 T37
51,T38,Scope 671 706	drug screen or alcohol breathalyzer
52,R10,Has_value Arg1:T38 Arg2:T36
53,T39,Post-eligibility 708 758	unwilling/unable to sign informed consent document
54,T40,Temporal 760 769	currently
55,T41,Condition 770 778	pregnant
56,R11,Has_temporal Arg1:T41 Arg2:T40
57,T42,Measurement 789 803	pregnancy test
58,T43,Value 780 788	positive
59,R12,Has_value Arg1:T42 Arg2:T43
60,T44,Mood 806 814	planning
61,T45,Condition 815 824	pregnancy
62,T46,Condition 829 838	lactating
63,*,OR T46 T45 T47
64,R13,Has_mood Arg1:T45 Arg2:T44
65,T47,Scope 760 778	currently pregnant
66,R14,Subsumes Arg1:T47 Arg2:T42
67,T48,Value 848 873	under 18 or over 50 years
68,T49,Person 877 880	age
69,R15,Has_value Arg1:T49 Arg2:T48
70,T50,Condition 882 904	traumatic brain injury
71,T51,"Non-representable 906 1507	as defined by The American Congress of Rehabilitation as a person who has had a traumatically induced physiological disruption of brain function (i.e., the head being struck, the head striking an object, and/or the brain undergoing an acceleration/deceleration movement (i.e., whiplash) without direct external trauma to the head), as manifested by at least one of the following: any loss of consciousness; any loss of memory for events immediately before or after the injury; any alteration in mental status at the time of the incident; or focal neurological deficits that may or may not be transient"
72,T52,Condition 1577 1591	claustrophobia
73,T53,"Condition 1523 1570	tolerate small, enclosed spaces without anxiety"
74,T54,Mood 1510 1519	inability
75,T55,Negation 1510 1519	inability
76,R16,Has_negation Arg1:T53 Arg2:T55
77,R17,multi Arg1:T55 Arg2:T54
78,T56,Procedure 1611 1622	self-report
79,R18,Subsumes Arg1:T53 Arg2:T52
80,R19,AND Arg1:T53 Arg2:T56
81,T57,Condition 1671 1682	left-handed
82,T58,Device 1697 1722	ferrous-containing metals
83,T59,Device 1746 1760	aneurysm clips
84,T60,Device 1762 1770	shrapnel
85,T61,Device 1771 1789	retained particles
86,*,OR T61 T60 T59
87,T62,"Scope 1746 1789	aneurysm clips, shrapnel/retained particles"
88,R20,Subsumes Arg1:T58 Arg2:T62
89,T63,Temporal 1829 1863	in the 4 weeks following the study
90,T64,Procedure 1819 1828	drug test
91,R21,Has_temporal Arg1:T64 Arg2:T63
92,T65,Mood 1792 1807	anticipation of
93,R22,Has_mood Arg1:T64 Arg2:T65
94,T66,Condition 1889 1893;1913 1921	mood disorder
95,T67,Condition 1895 1902;1913 1921	anxiety disorder
96,T68,Condition 1913 1921	disorder
97,T69,Qualifier 1907 1912	other
98,R23,Has_qualifier Arg1:T68 Arg2:T69
99,*,OR T66 T68 T67
100,T70,Condition 1959 1963	PTSD
101,T71,Qualifier 1930 1963	more clinically salient than PTSD
102,R24,multi Arg1:T71 Arg2:T70
103,T72,"Scope 1889 1921	mood, anxiety, or other disorder"
104,R25,Has_qualifier Arg1:T72 Arg2:T71
105,T73,Qualifier 1973 1981	moderate
106,T74,Qualifier 1985 1991	severe
107,T75,Condition 1992 1999;2005 2017	alcohol use disorder
108,T76,Condition 2000 2017	drug use disorder
109,*,OR T75 T76
110,T77,Scope 1992 2017	alcohol/drug use disorder
111,*,OR T74 T73
112,T78,Scope 1973 1991	moderate or severe
113,R26,Has_scope Arg1:T77 Arg2:T78
114,T79,Temporal 2021 2040	in the past 8 weeks
115,R27,Has_temporal Arg1:T77 Arg2:T79
116,T80,Condition 2071 2078	bipolar
117,T81,Qualifier 2083 2088	other
118,T82,Condition 2089 2106	related disorders
119,R28,Has_qualifier Arg1:T82 Arg2:T81
120,T83,Condition 2108 2130	schizophrenia spectrum
121,T84,Condition 2141 2160	psychotic disorders
122,*,OR T84 T83 T80 T82
123,T85,Procedure 2174 2184	treatments
124,T86,Drug 2190 2200	medication
125,T87,Condition 2215 2232	drug interactions
126,T88,Drug 2238 2248	dronabinol
127,T89,Drug 2259 2293	central nervous system depressants
128,T90,Drug 2295 2307	barbiturates
129,T91,Drug 2309 2324	benzodiazepines
130,T92,Drug 2326 2335	buspirone
131,T93,Drug 2337 2344	lithium
132,*,OR T93 T92 T91 T90
133,T94,"Scope 2295 2344	barbiturates, benzodiazepines, buspirone, lithium"
134,R29,Subsumes Arg1:T89 Arg2:T94
135,T95,Drug 2355 2377	anticholinergic agents
136,T96,Drug 2379 2387	atropine
137,T97,Drug 2389 2400	scopolamine
138,T98,Drug 2402 2416	antihistamines
139,*,OR T96 T97 T98
140,T99,"Scope 2379 2416	atropine, scopolamine, antihistamines"
141,R30,Subsumes Arg1:T95 Arg2:T99
142,*,OR T95 T89
143,R31,AND Arg1:T87 Arg2:T88
144,R33,AND Arg1:T86 Arg2:T87
145,R32,AND Arg1:T85 Arg2:T86
146,T100,"Scope 2259 2422	central nervous system depressants (barbiturates, benzodiazepines, buspirone, lithium, etc) and anticholinergic agents (atropine, scopolamine, antihistamines, etc)"
147,R34,Subsumes Arg1:T86 Arg2:T100
148,T101,"Scope 410 495	contraindications, current or past allergic or adverse reaction, or known sensitivity"
149,R8,AND Arg1:T101 Arg2:T21
0,T1,Condition 14 29	liver cirrhosis
1,T2,Condition 31 55	Hepatocellular Carcinoma
2,T3,Measurement 59 62	AFP
3,T4,Value 63 69	>2 ULN
4,T5,Condition 79 91	malignancies
5,*,OR T1 T2 T3 T5
6,R1,Has_value Arg1:T3 Arg2:T4
7,T6,Condition 130 144	liver diseases
8,T7,Non-query-able 94 144	Patients with other factors causing liver diseases
9,T8,Pregnancy_considerations 147 175	Pregnant and lactating women
10,T9,Condition 204 217	HIV infection
11,T10,Qualifier 192 203	concomitant
12,R2,Has_qualifier Arg1:T9 Arg2:T10
13,T11,Condition 221 258	congenital immune deficiency diseases
14,T12,Condition 275 283	diabetes
15,T13,Condition 285 304	autoimmune diseases
16,*,OR T9 T11
17,*,OR T13 T12
18,T14,Condition 331 349	organ dysfunctions
19,T15,Qualifier 321 330	important
20,R3,Has_qualifier Arg1:T14 Arg2:T15
21,T16,Qualifier 366 373	serious
22,T17,Condition 374 387	complications
23,T18,Condition 395 404	infection
24,T19,Condition 406 428	hepatic encephalopathy
25,T20,Condition 430 450	hepatorenal syndrome
26,T21,Condition 452 477	gastrointestinal bleeding
27,*,OR T21 T20 T19 T18
28,T22,"Scope 395 477	infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding"
29,R4,Has_qualifier Arg1:T17 Arg2:T16
30,R5,Subsumes Arg1:T17 Arg2:T22
31,T23,Procedure 502 516;537 544	antineoplastic therapy
32,T24,Procedure 520 544	immunomodulatory therapy
33,*,OR T24 T23
34,T25,Scope 502 544	antineoplastic or immunomodulatory therapy
35,T26,Temporal 552 566	past 12 months
36,R6,Has_temporal Arg1:T25 Arg2:T26
37,T27,Drug 601 604	IFN
38,T28,Qualifier 605 627	anti hepatitis B virus
39,R7,Has_qualifier Arg1:T27 Arg2:T28
40,T29,Condition 655 665	resistance
41,T30,Drug 646 654	NAs drug
42,R8,AND Arg1:T29 Arg2:T30
43,*,OR T27 T29
44,T31,Post-eligibility 668 732	Patients who can't come back to clinic for follow-up on schedule
0,T1,Value 0 8	Abnormal
1,T2,Procedure 9 20	resting ECG
2,R1,Has_value Arg1:T2 Arg2:T1
3,T3,Temporal 22 29	Current
4,T4,Value 30 38	abnormal
5,T5,Procedure 39 50	blood panel
6,R2,Has_value Arg1:T5 Arg2:T4
7,R3,Has_temporal Arg1:T5 Arg2:T3
8,T6,Procedure 78 93	metabolic panel
9,T7,Procedure 95 106	lipid panel
10,T8,Procedure 111 131	complete blood count
11,T9,"Scope 78 131	metabolic panel, lipid panel and complete blood count"
12,R4,Subsumes Arg1:T5 Arg2:T9
13,T10,Condition 135 147	Hypertension
14,T11,Drug 166 195	anti-hypertensive medications
15,T12,Measurement 199 221	resting blood pressure
16,T13,Value 222 234	>140/90 mmHg
17,R5,Has_value Arg1:T12 Arg2:T13
18,*,OR T11 T12
19,T14,Scope 166 234	anti-hypertensive medications or resting blood pressure >140/90 mmHg
20,R6,Subsumes Arg1:T10 Arg2:T14
21,T15,Condition 256 278	cardiovascular disease
22,T16,Condition 280 296	malignant cancer
23,T17,Condition 298 306	diabetes
24,T18,Condition 310 324	kidney disease
25,*,OR T17 T18 T16 T15
26,T19,Condition 326 333	Obesity
27,T20,Measurement 335 350	Body Mass Index
28,T21,Value 351 355	> 30
29,R7,Has_value Arg1:T20 Arg2:T21
30,T22,Condition 366 375	pregnancy
31,T23,Temporal 358 365	Current
32,R8,Has_temporal Arg1:T22 Arg2:T23
33,T24,Scope 335 355	Body Mass Index > 30
34,R9,Subsumes Arg1:T19 Arg2:T24
35,T25,Informed_consent 377 402	Unable to provide consent
0,T1,Condition 0 8	Pregnant
1,T2,Person 9 14	women
2,T3,Condition 20 23	APS
3,T4,"Qualifier 51 119	revised classification criteria for APS in 2006 in Sydney, Australia"
4,R1,Has_qualifier Arg1:T3 Arg2:T4
5,T5,Temporal 121 136	Early pregnancy
6,T6,Measurement 137 148	body weight
7,T7,Value 152 160	50-90 Kg
8,R2,Has_value Arg1:T6 Arg2:T7
9,R3,Has_temporal Arg1:T6 Arg2:T5
0,T1,Person 0 3	Age
1,T2,Value 4 22	less than one year
2,T3,Value 26 39	over 18 years
3,*,OR T2 T3
4,T4,Scope 4 39	less than one year or over 18 years
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Condition 55 71	renal impairment
7,T6,Drug 73 81	Colistin
8,T7,Temporal 86 104	less than 72 hours
9,R2,Has_temporal Arg1:T6 Arg2:T7
0,T1,Condition 19 46	allergy to trial product(s)
1,T2,Condition 19 26;50 66	allergy related products
2,T3,Drug 30 46	trial product(s)
3,T4,Drug 50 66	related products
4,T5,"Non-query-able 68 200	Subjects who are unlikely to comply with protocol requirements, e.g. uncooperative attitude, inability to return for the final visit"
5,T6,"Post-eligibility 68 200	Subjects who are unlikely to comply with protocol requirements, e.g. uncooperative attitude, inability to return for the final visit"
6,T7,Context_Error 202 248	Subjects who previously enrolled in this study
7,T8,Post-eligibility 202 248	Subjects who previously enrolled in this study
8,T9,Condition 261 283	childbearing potential
9,T10,Person 250 257	Females
10,T11,Condition 292 300	pregnant
11,T12,Condition 302 316	breast-feeding
12,T13,Condition 337 345	pregnant
13,T14,Mood 320 336	intend to become
14,*,OR T13 T14 T15 T12 T11 T9
15,T15,Procedure 372 393	contraceptive methods
16,T16,Qualifier 363 371	adequate
17,R1,Has_qualifier Arg1:T15 Arg2:T16
18,T17,Negation 353 356	not
19,R2,Has_negation Arg1:T16 Arg2:T17
20,T18,"Pregnancy_considerations 250 393	Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods"
21,T19,Drug 414 437	investigational product
22,T20,Temporal 438 473	within 3 months prior to this trial
23,R3,Has_temporal Arg1:T19 Arg2:T20
24,T21,Reference_point 463 473	this trial
25,R4,multi Arg1:T20 Arg2:T21
26,R5,AND Arg1:T1 Arg2:T3
27,R6,AND Arg1:T2 Arg2:T4
28,*,OR T1 T2
0,T1,Person 20 23	old
1,T2,Value 10 19	>18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Non-query-able 26 123	Person is a unilateral transfemoral or knee-disarticulation amputee with stabilized residual limb
4,T4,Measurement 170 210	Medicare Functional Classification Level
5,T5,Measurement 212 216	MFCL
6,R2,Subsumes Arg1:T4 Arg2:T5
7,T6,"Value 138 150	K2, K3 or K4"
8,R3,Has_value Arg1:T4 Arg2:T6
9,T7,Device 254 264	prosthesis
10,T8,Device 303 318	prosthetic knee
11,T9,Qualifier 273 302	non-microprocessor controlled
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,R5,AND Arg1:T7 Arg2:T8
14,T10,Temporal 323 340	at least 6 months
15,R6,Has_temporal Arg1:T8 Arg2:T10
16,T11,Negation 354 359	never
17,T12,Device 398 419	prosthetic knee joint
18,T13,Qualifier 372 397	microprocessor controlled
19,R7,Has_qualifier Arg1:T12 Arg2:T13
20,R8,Has_negation Arg1:T12 Arg2:T11
21,T14,Informed_consent 422 490	Person is willing and able to independently provide informed consent
22,T15,Post-eligibility 493 542	Person is willing to comply with study procedures
23,T16,Device 558 568	prosthesis
24,T17,Multiplier 569 592	daily and = 8 hours/day
25,R9,Has_multiplier Arg1:T16 Arg2:T17
26,T18,Observation 605 612	walking
27,T19,Multiplier 624 631	1km/day
28,R10,Has_multiplier Arg1:T18 Arg2:T19
29,T20,Observation 644 651	walking
30,T21,Multiplier 652 673	not slower than 3km/h
31,T22,Observation 749 756	walking
32,T23,Non-query-able 739 799	Person is walking on level ground in a step over step manner
33,R11,Has_multiplier Arg1:T20 Arg2:T21
0,T1,Measurement 0 3	HPN
1,T2,Value 4 15	< 12 months
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 17 39	metabolically unstable
4,T4,Condition 41 47	cancer
5,T5,Condition 66 84	intestinal failure
6,R2,AND Arg1:T4 Arg2:T5
0,T1,Person 0 3	age
1,T2,Value 4 11	over 40
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Procedure 13 52	composite head and neck tumor resection
4,T4,Condition 62 74	hypertension
5,T5,Qualifier 54 61	treated
6,R2,Has_qualifier Arg1:T4 Arg2:T5
7,T6,Drug 76 100	hypertension medications
8,T7,Temporal 107 128	on morning of surgery
9,T8,Drug 137 146	diuretics
10,T9,Negation 130 136	except
11,R3,Has_negation Arg1:T8 Arg2:T9
12,R4,Has_temporal Arg1:T6 Arg2:T7
13,R5,AND Arg1:T6 Arg2:T8
0,T1,Person 0 4	Male
1,T2,Person 9 16	females
2,*,OR T1 T2
3,T3,Person 17 21	aged
4,T4,Value 22 36	18 to 70 years
5,R1,Has_value Arg1:T3 Arg2:T4
6,T5,Condition 38 49	Brain death
7,T6,Person 51 55	Male
8,T7,Person 60 67	females
9,T8,Person 68 72	aged
10,T9,Value 73 87	18 to 70 years
11,R2,Has_value Arg1:T8 Arg2:T9
12,T10,Procedure 103 125	kidney transplantation
13,T11,Mood 89 99	Indication
14,R3,Has_mood Arg1:T10 Arg2:T11
15,T12,Informed_consent 127 143	Informed consent
0,T1,Person 28 31	age
1,T2,Value 10 24	under 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Person 45 51	weighs
4,T4,Value 52 67	more than 136kg
5,R2,Has_value Arg1:T3 Arg2:T4
6,T5,Person 81 87	weighs
7,T6,Value 88 102	less than 50kg
8,R3,Has_value Arg1:T5 Arg2:T6
9,T7,Condition 119 127	pregnant
10,T8,Condition 162 176	skin breakdown
11,T9,Qualifier 154 161	chronic
12,R4,Has_qualifier Arg1:T8 Arg2:T9
13,T10,Qualifier 184 197	residual limb
14,R5,Has_qualifier Arg1:T8 Arg2:T10
15,T11,Non-query-able 200 369	Person has conditions that would prevent participation and pose increased risk (e.g. unstable cardiovascular conditions that preclude physical activity such as walking).
16,T12,Observation 378 383	falls
17,T13,Multiplier 386 397	once a week
18,R6,Has_multiplier Arg1:T12 Arg2:T13
19,T14,Non-query-able 371 508	Person falls = once a week due to the reasons that could not be corrected by the new prosthesis (for ex. problems with vestibular system)
20,T15,Device 527 554	under arm axillary crutches
21,T16,Device 558 564	walker
22,*,OR T15 T16
23,T17,Observation 591 617	life threatening situation
24,T18,Observation 580 589;608 617	emergency situation
25,*,OR T17 T18
26,T19,Post-eligibility 620 668	Person is unwilling/unable to follow instruction
27,T20,Post-eligibility 672 735	Person who is not available to follow the entire study protocol
28,T21,Competing_trial 738 853	Person who is participating in another study or intends to participate in another study during this study duration.
29,T22,Informed_consent 855 905	Person who cannot personally provide their consent
30,T23,Negation 922 925	not
31,T24,Device 934 944	prosthesis
32,T25,Multiplier 945 955	8hours/day
33,R7,Has_negation Arg1:T24 Arg2:T23
34,R8,Has_multiplier Arg1:T24 Arg2:T25
35,T26,Measurement 995 1008	10m walk test
36,T27,Value 1009 1024	less than 3km/h
37,T28,Value 1027 1034	0.8m/s)
38,R9,Subsumes Arg1:T27 Arg2:T28
39,R10,Has_value Arg1:T26 Arg2:T27
40,T29,Observation 1101 1106	walks
41,T30,Multiplier 1119 1139	ess than 1km per day
42,R11,Has_multiplier Arg1:T29 Arg2:T30
43,T31,Non-query-able 1142 1215	Person who is not able to walk on level ground in a step over step manner
0,T1,Person 0 3	Age
1,T2,Value 4 33	between one year and 18 years
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 35 41	Sepsis
4,T4,Qualifier 49 52	MDR
5,R2,Has_qualifier Arg1:T3 Arg2:T4
6,T5,Condition 56 100	minimally susceptible gram-negative bacteria
7,R3,AND Arg1:T5 Arg2:T3
8,T6,Qualifier 113 116	MDR
9,T7,Condition 117 140	gram-negative infection
10,T8,Condition 144 150	sepsis
11,*,OR T8 T7
12,T9,Scope 117 150	gram-negative infection or sepsis
13,R4,Has_qualifier Arg1:T9 Arg2:T6
14,T10,Qualifier 168 189	sensitive to colistin
15,T11,Observation 158 167	organisms
16,R5,Has_qualifier Arg1:T11 Arg2:T10
17,T12,Qualifier 223 226	MDR
18,T13,Condition 227 240	gram negative
19,R6,Has_qualifier Arg1:T13 Arg2:T12
20,T14,Condition 291 297	sepsis
21,T15,Drug 302 310	colistin
22,T16,Procedure 315 339	administered empirically
23,R7,AND Arg1:T16 Arg2:T15
0,T1,Condition 114 129	type 2 diabetic
1,T2,Qualifier 141 164	inadequately controlled
2,T3,Temporal 130 140	previously
3,R1,Has_temporal Arg1:T2 Arg2:T3
4,R2,Has_qualifier Arg1:T1 Arg2:T2
5,T4,Multiplier 170 181	two or more
6,T5,Condition 182 186	OADs
7,R3,Has_multiplier Arg1:T5 Arg2:T4
8,T6,Non-representable 214 300	The selection of the subjects will be at the discretion of the individual investigator
9,T7,Non-representable 0 108	After the investigator has taken the decision to use human insulin or insulin analogues to treat the subject
0,T1,Condition 0 17	Contra-indication
1,T2,Procedure 22 44	multiorgan procurement
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 46 56	infections
4,T4,Condition 58 64	cancer
5,*,OR T3 T4
6,T5,"Scope 46 64	infections, cancer"
7,T6,Scope 0 44	Contra-indication for multiorgan procurement
8,R2,Subsumes Arg1:T6 Arg2:T5
9,T7,Condition 84 105	chronic renal failure
10,T8,Temporal 72 83	Preexistent
11,R3,Has_temporal Arg1:T7 Arg2:T8
12,T9,Procedure 120 137	organ procurement
13,T10,Observation 108 115;138 150	Refusal by the donor
14,R4,AND Arg1:T10 Arg2:T9
15,T11,Qualifier 169 193	French national register
16,T12,Qualifier 197 224	reported by the next-of-kin
17,*,OR T11 T12
18,T13,Scope 169 224	French national register or reported by the next-of-kin
19,R5,Has_scope Arg1:T10 Arg2:T13
20,T14,Mood 228 236	Need for
21,T15,Procedure 239 268	double kidney transplantation
22,T16,Mood 271 279	Need for
23,T17,Procedure 282 308	multiorgan transplantation
24,R6,Has_mood Arg1:T15 Arg2:T14
25,R7,Has_mood Arg1:T17 Arg2:T16
0,T1,Measurement 19 50	home parenteral nutrition (HPN)
1,T2,Condition 62 82	short bowel syndrome
2,T3,Temporal 83 105	for at least 12 months
3,*,OR T1 T2
4,T4,Scope 19 82	home parenteral nutrition (HPN) because of short bowel syndrome
5,R1,Has_temporal Arg1:T4 Arg2:T3
6,T5,Measurement 114 130	metabolic status
7,T6,Qualifier 107 113	stable
8,R2,Has_qualifier Arg1:T5 Arg2:T6
9,T7,Condition 132 146	benign disease
0,T1,Observation 0 15	patient refusal
1,T2,Person 17 20	age
2,T3,Value 21 33	less than 40
3,T4,Value 37 50	over 80 years
4,*,OR T3 T4
5,T5,Scope 21 50	less than 40 or over 80 years
6,R1,Has_scope Arg1:T2 Arg2:T5
7,T6,Procedure 52 80	combined surgical procedures
8,T7,Procedure 82 99	emergency surgery
9,T8,Measurement 101 135	Left ventricular ejection fraction
10,T9,Value 136 157	less than 50 per cent
11,R2,Has_value Arg1:T8 Arg2:T9
12,T10,Measurement 159 190	calculated creatinine clearance
13,T11,Value 191 217	less than 60 mL per minute
14,R3,Has_value Arg1:T10 Arg2:T11
0,T1,Condition 0 7	Allergy
1,T2,Drug 18 38	proposed medications
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Condition 58 74	active infection
4,T4,Condition 85 88	HBV
5,T5,Condition 90 93	HCV
6,T6,Condition 98 101	HIV
7,*,OR T6 T5 T4
8,T7,"Scope 85 101	HBV, HCV and HIV"
9,R2,Subsumes Arg1:T3 Arg2:T7
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 76 78	2.
2,T3,Parsing_Error 192 194	3.
3,T4,Parsing_Error 247 249	4.
4,T5,Parsing_Error 307 309	5.
5,T6,Parsing_Error 346 348	6.
6,T7,Parsing_Error 372 374	7.
7,T8,Parsing_Error 430 432	8.
8,T9,Condition 17 46	other uncontrolled infections
9,T10,Context_Error 17 46	other uncontrolled infections
10,T11,Undefined_semantics 17 46	other uncontrolled infections
11,T12,Drug 101 104	ATG
12,T13,Drug 106 113	Campath
13,T14,Drug 124 170	T cell immunosuppressive monoclonal antibodies
14,T15,Temporal 171 190	in the last 28 days
15,T16,"Scope 101 170	ATG, Campath, or other T cell immunosuppressive monoclonal antibodies"
16,*,OR T12 T13 T14
17,R1,Has_temporal Arg1:T16 Arg2:T15
18,T17,Procedure 204 229	donor lymphocyte infusion
19,T18,Temporal 230 245	in last 28 days
20,R2,Has_temporal Arg1:T17 Arg2:T18
21,T19,Condition 263 279	Omenn's syndrome
22,T20,Condition 283 305	MHC class I deficiency
23,*,OR T20 T19
24,T21,Condition 334 344	malignancy
25,T22,Qualifier 321 333	uncontrolled
26,T23,Temporal 310 316	Active
27,R3,Has_temporal Arg1:T21 Arg2:T23
28,R4,Has_qualifier Arg1:T21 Arg2:T22
29,T24,Condition 349 357	Pregnant
30,T25,Condition 361 370	lactating
31,*,OR T25 T24
32,T26,Drug 390 398	steroids
33,T27,Value 402 416	≤0.5 mg/kg/day
34,T28,Procedure 385 389	wean
35,R5,AND Arg1:T28 Arg2:T26
36,T29,Drug 417 427	prednisone
37,R7,Has_value Arg1:T29 Arg2:T27
38,R6,Subsumes Arg1:T26 Arg2:T29
39,T30,Negation 375 381	Unable
40,R8,Has_negation Arg1:T28 Arg2:T30
41,T31,Condition 455 473	hyperbilirubinemia
42,T32,Qualifier 447 454	Grade 3
43,R9,Has_qualifier Arg1:T31 Arg2:T32
0,T1,Qualifier 0 12	Uncontrolled
1,T2,Condition 13 29	medical problems
2,T3,Condition 40 49;80 87	pulmonary disease
3,T4,Condition 51 65;80 87	cardiovascular disease
4,T5,Condition 69 87	orthopedic disease
5,*,OR T3 T4 T5
6,T6,"Scope 40 87	pulmonary, cardiovascular or orthopedic disease"
7,R1,Subsumes Arg1:T2 Arg2:T6
8,R2,Has_qualifier Arg1:T2 Arg2:T1
9,T7,Condition 143 163	exercise intolerance
10,T8,Condition 93 113	debilitating disease
11,T9,Temporal 114 130	prior to the SCI
12,T10,Reference_point 123 130	the SCI
13,R3,Has_index Arg1:T9 Arg2:T10
14,R4,Has_temporal Arg1:T8 Arg2:T9
15,R5,AND Arg1:T8 Arg2:T7
16,T11,Qualifier 165 174	Premorbid
17,T12,Temporal 176 183	ongoing
18,T13,Condition 184 200	major depression
19,T14,Condition 204 213	psychosis
20,T15,Condition 215 239	altered cognitive status
21,*,OR T13 T14
22,T16,Scope 184 213	major depression or psychosis
23,R6,Has_temporal Arg1:T16 Arg2:T12
24,R7,Has_qualifier Arg1:T16 Arg2:T11
25,*,OR T16 T15
26,T17,Condition 252 263	head injury
27,T18,Condition 267 273	stroke
28,*,OR T18 T17
29,T19,Device 275 295	Metal plate in skull
30,T20,Condition 308 316	seizures
31,T21,Observation 241 248	History
32,T22,Scope 252 273	head injury or stroke
33,R8,Has_temporal Arg1:T22 Arg2:T21
34,T23,Observation 297 304	History
35,R9,Has_temporal Arg1:T20 Arg2:T23
36,T24,Drug 328 380	drugs acting primarily on the central nervous system
37,T25,Qualifier 388 415	lower the seizure threshold
38,R10,Has_qualifier Arg1:T24 Arg2:T25
39,T26,Condition 434 442	Pregnant
40,T27,Person 443 450	females
41,T28,Condition 460 476	cord compression
42,T29,Condition 482 488	syrinx
43,T30,Qualifier 496 507	spinal cord
44,R11,Has_qualifier Arg1:T29 Arg2:T30
45,T31,Condition 557 572	spinal stenosis
46,T32,Condition 529 548	spinal cord disease
47,T33,Condition 574 586	spina bifida
48,T34,Condition 588 590	MS
49,T35,Condition 595 609	herniated disk
50,*,OR T35 T34 T33 T31
51,T36,"Scope 557 609	spinal stenosis, spina bifida, MS, or herniated disk"
52,R12,Subsumes Arg1:T32 Arg2:T36
53,*,OR T29 T32 T28
54,T37,Device 628 642	scalp shrapnel
55,T38,Device 644 661	cochlear implants
56,T39,Device 666 680	aneurysm clips
57,*,OR T37 T38 T39
0,T2,Qualifier 20 30	ambulatory
1,T1,Procedure 31 43	hand surgery
2,T3,Condition 48 61	carpal tunnel
3,T4,Condition 66 80	trigger finger
4,T5,Scope 48 80	carpal tunnel and trigger finger
5,R1,Has_scope Arg1:T1 Arg2:T5
6,R2,Has_qualifier Arg1:T1 Arg2:T2
7,T6,Procedure 88 104	local anesthesia
8,R3,AND Arg1:T1 Arg2:T6
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 297 299	2.
2,T3,Parsing_Error 412 414	3.
3,T4,Parsing_Error 460 462	4.
4,T5,Parsing_Error 495 497	5.
5,T6,Parsing_Error 524 526	6.
6,T7,Parsing_Error 605 607	7.
7,T8,Parsing_Error 645 647	8.
8,T9,Parsing_Error 711 713	9.
9,T10,Condition 16 40	primary immunodeficiency
10,T11,Procedure 109 154;74 87	allogeneic hematopoietic stem cell transplant myeloablative
11,T12,Procedure 91 154	non-myeloablative allogeneic hematopoietic stem cell transplant
12,*,OR T12 T11
13,T13,Condition 203 227	primary immunodeficiency
14,T14,Procedure 238 277	hematopoietic stem cell transplantation
15,T15,Negation 281 294	not indicated
16,R1,Has_negation Arg1:T14 Arg2:T15
17,R2,AND Arg1:T13 Arg2:T14
18,T16,Scope 74 154	myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant
19,R3,Has_scope Arg1:T10 Arg2:T16
20,*,OR T10 T13
21,T17,Condition 322 325	EBV
22,T18,Condition 327 330	CMV
23,T19,Condition 339 349	Adenovirus
24,T20,Qualifier 351 363;377 387	unable to be controlled
25,T21,Procedure 393 409	standard therapy
26,R4,Has_qualifier Arg1:T21 Arg2:T20
27,T22,"Scope 322 349	EBV, CMV, and/or Adenovirus"
28,*,OR T19 T18 T17
29,R5,AND Arg1:T22 Arg2:T21
30,T23,Drug 415 423	Steroids
31,T24,Multiplier 424 447	less than 0.5 mg/kg/day
32,T25,Drug 448 458	prednisone
33,R6,Subsumes Arg1:T23 Arg2:T25
34,R7,Has_multiplier Arg1:T25 Arg2:T24
35,T26,Measurement 463 485	Karnofsky/Lansky score
36,T27,Value 489 493	≥ 50
37,R8,Has_value Arg1:T26 Arg2:T27
38,T28,Measurement 498 501	ANC
39,T29,Value 502 521	greater than 500/µL
40,R9,Has_value Arg1:T28 Arg2:T29
41,T30,Measurement 527 536	Bilirubin
42,T31,Value 537 540	<2x
43,T32,Measurement 542 545	AST
44,T33,Value 546 549	<3x
45,T34,Measurement 551 567	Serum creatinine
46,T35,Value 568 593	<2x upper limit of normal
47,T36,Measurement 595 598	Hgb
48,T37,Value 599 603	>8.0
49,R10,Has_value Arg1:T30 Arg2:T31
50,R11,Has_value Arg1:T32 Arg2:T33
51,R12,Has_value Arg1:T34 Arg2:T35
52,R13,Has_value Arg1:T36 Arg2:T37
53,T38,Measurement 608 622;632 643	Pulse oximetry on room air
54,T39,Value 626 631	> 90%
55,R14,Has_value Arg1:T38 Arg2:T39
56,T40,Measurement 657 671	pregnancy test
57,T41,Value 648 656	Negative
58,R15,Has_value Arg1:T40 Arg2:T41
59,T42,Condition 686 708	childbearing potential
60,T43,Person 676 682	female
61,T44,Scope 676 708	female of childbearing potential
62,A1,Optional T44
63,R16,AND Arg1:T44 Arg2:T40
64,T45,Post-eligibility 714 778	Patient or parent/guardian capable of providing informed consent
65,T46,Non-query-able 714 779	Patient or parent/guardian capable of providing informed consent.
0,T1,Person 9 16	females
1,T2,Person 0 4	Male
2,T3,Value 17 24;30 41	between 18-85 years
3,T4,Person 25 29	ages
4,R1,Has_value Arg1:T4 Arg2:T3
5,*,OR T1 T2
6,T5,Condition 43 55	Right handed
7,T6,Procedure 65 105	complete precision grips with both hands
8,T7,Procedure 115 164	complete full wrist flexion-extension bilaterally
9,T8,Procedure 174 189	walk unassisted
10,T9,Mood 57 64	Able to
11,T10,Mood 107 114	Able to
12,R2,Has_mood Arg1:T6 Arg2:T9
13,R3,Has_mood Arg1:T7 Arg2:T10
14,T11,Mood 166 173	Able to
15,T12,Mood 191 198	Able to
16,T13,Procedure 199 248	complete full ankle flexion-extension bilaterally
17,R4,Has_mood Arg1:T13 Arg2:T12
18,T14,Person 250 254	Male
19,T15,Person 259 266	females
20,T16,Value 267 274;280 291	between 18-85 years
21,T17,Person 275 279	ages
22,R5,Has_value Arg1:T17 Arg2:T16
23,*,OR T14 T15
24,T18,Condition 293 296	SCI
25,T19,Temporal 299 317	2 months of injury
26,R6,Has_temporal Arg1:T18 Arg2:T19
27,T20,Condition 320 338	Spinal Cord injury
28,T21,Qualifier 339 353	at or above L5
29,R7,Has_qualifier Arg1:T20 Arg2:T21
30,T22,Procedure 370 422	produce a visible precision grip force with one hand
31,T23,Mood 355 369	The ability to
32,R8,Has_mood Arg1:T22 Arg2:T23
33,T24,Mood 424 431	Able to
34,T25,Procedure 445 478	small wrist flexion and extension
35,R9,Has_mood Arg1:T25 Arg2:T24
36,T26,Mood 480 494	The ability to
37,T27,Procedure 505 571	small visible contraction with dorsiflexion and hip flexor muscles
38,R10,Has_mood Arg1:T27 Arg2:T26
39,T28,"Non-representable 573 665	No subjects will be excluded based on their race, religion, ethnicity, gender or HIV status."
40,T29,Measurement 667 671	ASIA
41,T30,"Value 672 683	A,B,C, or D"
42,R11,Has_value Arg1:T29 Arg2:T30
0,T1,Person 17 21	male
1,T2,Person 26 32	female
2,T3,Measurement 44 48	aged
3,T4,Value 49 53	= 60
4,R1,Has_value Arg1:T3 Arg2:T4
5,*,OR T1 T2
6,T5,Condition 33 43;4 9	recipients renal
7,T6,Procedure 72 94	kidney transplantation
8,T7,Qualifier 102 108;121 126	living donor
9,T8,Qualifier 112 126	deceased donor
10,*,OR T7 T8
11,T9,Qualifier 138 168	Expanded Criteria Donors (ECD)
12,T10,"Scope 102 127	living or deceased donor,"
13,R2,Subsumes Arg1:T10 Arg2:T9
14,T11,Measurement 171 200	Panel Reactive Antibody (PRA)
15,T12,Value 201 206	< 30%
16,R3,Has_value Arg1:T11 Arg2:T12
17,T13,Informed_consent 209 357	Patients who consented to participate in the study by signing the informed consent form before the transplant surgery to the 1st post-operative day)
0,T1,Measurement 0 3	ASA
1,T2,Value 3 6	> 3
2,R1,Has_value Arg1:T1 Arg2:T2
3,T3,Condition 9 21	Coagulopathy
4,T4,Condition 24 37	Renal disease
5,T5,Condition 40 53	Liver disease
6,T6,Condition 74 100	gastro-intestinal bleeding
7,T7,Temporal 67 73	recent
8,R2,Has_temporal Arg1:T6 Arg2:T7
9,T8,Condition 102 111	Pregnancy
10,T9,Condition 127 139	chronic pain
11,T10,Drug 157 179	opioid pain medication
12,T11,Observation 190 200	history of
13,T12,Condition 201 211	drug abuse
14,R3,Has_temporal Arg1:T12 Arg2:T11
15,R4,AND Arg1:T9 Arg2:T10
16,*,OR T9 T12
17,T13,Condition 245 252	allergy
18,T14,Drug 256 259	ASA
19,T15,Drug 261 274	acetaminophen
20,T16,Drug 276 282	NSAIDS
21,T17,Drug 287 294	codeine
22,*,OR T16 T17 T15 T14
23,T18,"Scope 256 294	ASA, acetaminophen, NSAIDS and codeine"
24,R5,Has_scope Arg1:T13 Arg2:T18
25,T19,Procedure 322 343	brachial plexus block
0,T1,Informed_consent 0 55	Written consent for participation in the clinical trial
1,T2,Person 57 60	Age
2,T3,Value 61 75	18 to 45 years
3,T4,Condition 76 98	Irregular menstruation
4,T5,Line 57 75	Age 18 to 45 years
5,T6,Line 76 144	Irregular menstruation (> 35 days) or secondary amenorrhea> 3 months
6,T7,Value 100 109	> 35 days
7,R1,Subsumes Arg1:T4 Arg2:T7
8,T8,Condition 114 134	secondary amenorrhea
9,T9,Temporal 134 144	> 3 months
10,R2,Has_temporal Arg1:T8 Arg2:T9
11,*,OR T4 T8
0,T1,Procedure 15 24	IVF cycle
1,T2,Device 46 67	frozen-thawed embryos
2,T3,Condition 69 95	Regular menstruation cycle
3,T4,Informed_consent 97 146	Patient's willingness to participate in the study
0,T1,Person 12 15	age
1,T2,Value 16 26	4-16 years
2,T3,Condition 32 51	sickle cell disease
3,T4,Visit 69 81	Pediatric ER
4,T5,Condition 87 116	acute sickle cell pain crisis
5,T6,Measurement 124 128	pain
6,T7,Value 132 146	6/10 or higher
7,R1,Has_value Arg1:T6 Arg2:T7
8,R2,Has_value Arg1:T1 Arg2:T2
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 191 193	2.
2,T3,Parsing_Error 320 322	3.
3,T4,Parsing_Error 413 415	4.
4,T5,Parsing_Error 764 766	5.
5,T6,Parsing_Error 844 846	1.
6,T7,Parsing_Error 870 872	2.
7,T8,Parsing_Error 960 962	3.
8,T9,Parsing_Error 1216 1218	4.
9,T10,Parsing_Error 1292 1294	5.
10,T11,Parsing_Error 1375 1377	6.
11,T12,Parsing_Error 1521 1523	6.
12,T13,Parsing_Error 1578 1580	7.
13,T14,Parsing_Error 2107 2109	8.
14,T15,Parsing_Error 3503 3506	20.
15,T16,Parsing_Error 3388 3391	19.
16,T17,Parsing_Error 3181 3184	18.
17,T18,Parsing_Error 3037 3040	17.
18,T19,Parsing_Error 2946 2949	16.
19,T20,Parsing_Error 2867 2870	15.
20,T21,Parsing_Error 2777 2780	14.
21,T22,Parsing_Error 2669 2672	13.
22,T23,Parsing_Error 2570 2573	12.
23,T24,Parsing_Error 2469 2472	11.
24,T25,Parsing_Error 2394 2397	10.
25,T26,Parsing_Error 2230 2232	9.
26,T27,Drug 21 32	doxorubicin
27,T28,Drug 34 37	PLD
28,T29,Drug 51 64	anthracycline
29,T30,Drug 66 75	motolimod
30,T31,Drug 86 98	TLR agonists
31,T32,Drug 100 108	MEDI4736
32,T33,Drug 112 133	checkpoint inhibitors
33,T34,Drug 143 153	anti-CTLA4
34,T35,Drug 158 166;178 188	anti-PD1 antibodies
35,T36,Drug 167 188	anti-PD-L1 antibodies
36,T37,Scope 143 188	anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies
37,*,OR T34 T35 T36
38,T38,Grammar_Error 154 157	and
39,R1,Subsumes Arg1:T33 Arg2:T37
40,*,OR T33 T32 T31 T30 T29 T28 T27
41,T39,Temporal 3 8	Prior
42,T40,"Scope 21 188	doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736 or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies"
43,R2,Has_temporal Arg1:T40 Arg2:T39
44,T41,Condition 208 235	platinum-refractory disease
45,T42,Undefined_semantics 208 235	platinum-refractory disease
46,T43,Condition 248 267	disease progression
47,T44,Temporal 268 317	while receiving first line platinum-based therapy
48,T45,Reference_point 284 317	first line platinum-based therapy
49,R3,Has_index Arg1:T44 Arg2:T45
50,R4,Has_temporal Arg1:T43 Arg2:T44
51,R5,Subsumes Arg1:T41 Arg2:T43
52,T46,Condition 357 386	immune-related adverse events
53,T47,Temporal 387 410	following prior therapy
54,T48,Reference_point 397 410	prior therapy
55,R6,Has_index Arg1:T47 Arg2:T48
56,R7,Has_temporal Arg1:T46 Arg2:T47
57,T49,Qualifier 323 345	Clinically significant
58,T50,Qualifier 346 356	persistent
59,R8,Has_qualifier Arg1:T46 Arg2:T50
60,R9,Has_qualifier Arg1:T46 Arg2:T49
61,T51,Subjective_judgement 323 345	Clinically significant
62,T52,Undefined_semantics 323 345	Clinically significant
63,T53,Condition 479 490	CNS disease
64,T54,Condition 502 521	primary brain tumor
65,T55,Condition 523 531	seizures
66,T56,Qualifier 536 546	controlled
67,T57,Negation 532 535	not
68,T58,Drug 552 576	standard medical therapy
69,R10,AND Arg1:T56 Arg2:T58
70,R11,Has_negation Arg1:T56 Arg2:T57
71,R12,Has_qualifier Arg1:T55 Arg2:T56
72,*,OR T54 T55 T59 T68
73,T59,Condition 582 598	brain metastases
74,T60,Temporal 604 650	within six months prior to Day 1 of this study
75,T61,Reference_point 631 650	Day 1 of this study
76,R13,Has_index Arg1:T60 Arg2:T61
77,T62,Condition 663 687	cerebrovascular accident
78,T63,Condition 689 692	CVA
79,T64,Condition 694 700	stroke
80,*,OR T63 T64
81,T65,"Scope 689 700	CVA, stroke"
82,R14,Subsumes Arg1:T62 Arg2:T65
83,T66,Condition 703 734	transient ischemic attack (TIA)
84,T67,Condition 738 761	subarachnoid hemorrhage
85,*,OR T66 T67 T62
86,T68,"Scope 663 761	cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage"
87,R15,Has_temporal Arg1:T68 Arg2:T60
88,T69,Condition 804 826	cardiovascular disease
89,T70,Qualifier 781 803	clinically significant
90,T71,Subjective_judgement 781 803	clinically significant
91,T72,Undefined_semantics 781 803	clinically significant
92,R16,Has_qualifier Arg1:T69 Arg2:T70
93,T73,Parsing_Error 828 842	This includes:
94,T74,Condition 847 868	Resisted hypertension
95,T75,Condition 873 894	Myocardial infarction
96,T76,Condition 898 913	unstable angina
97,T77,Temporal 914 957	within 6 months prior to Day 1 of the study
98,T78,Reference_point 939 957	Day 1 of the study
99,R17,Has_index Arg1:T77 Arg2:T78
100,T79,Condition 982 1004	ventricular arrhythmia
101,*,OR T76 T75
102,T80,Scope 873 913	Myocardial infarction or unstable angina
103,R18,Has_temporal Arg1:T80 Arg2:T77
104,T81,Condition 1012 1035	ventricular tachycardia
105,T82,Condition 1039 1063	ventricular fibrillation
106,*,OR T82 T81
107,T83,Scope 1012 1063	ventricular tachycardia or ventricular fibrillation
108,R19,Subsumes Arg1:T79 Arg2:T83
109,T84,Qualifier 974 981	serious
110,T85,Observation 963 970	History
111,T86,Condition 1068 1087	cardiac arrhythmias
112,T87,Drug 1098 1125	anti-arrhythmic medications
113,T88,Qualifier 1088 1125	requiring anti-arrhythmic medications
114,R20,AND Arg1:T88 Arg2:T87
115,R21,Has_qualifier Arg1:T86 Arg2:T88
116,T89,Condition 1138 1157	atrial fibrillation
117,T90,Negation 1127 1133	except
118,T91,Qualifier 1166 1213	well controlled with anti-arrhythmic medication
119,T92,Drug 1187 1213	anti-arrhythmic medication
120,R22,AND Arg1:T91 Arg2:T92
121,R23,Has_qualifier Arg1:T89 Arg2:T91
122,R24,Has_negation Arg1:T89 Arg2:T90
123,R25,AND Arg1:T86 Arg2:T89
124,R26,Has_qualifier Arg1:T79 Arg2:T84
125,*,OR T86 T79
126,R27,Has_temporal Arg1:T79 Arg2:T85
127,R28,Has_temporal Arg1:T86 Arg2:T85
128,T93,Measurement 1228 1245	ejection fraction
129,T94,Temporal 1219 1227	Baseline
130,T95,Value 1246 1251	≤ 50%
131,R29,Has_value Arg1:T93 Arg2:T95
132,R30,Has_temporal Arg1:T93 Arg2:T94
133,T96,Procedure 1267 1281	echocardiogram
134,T97,Procedure 1285 1289	MUGA
135,*,OR T97 T96
136,T98,Scope 1267 1289	echocardiogram or MUGA
137,R31,Has_scope Arg1:T93 Arg2:T98
138,T99,Measurement 1295 1328	New York Heart Association (NYHA)
139,T100,Value 1329 1347	Class II or higher
140,R32,Has_value Arg1:T99 Arg2:T100
141,T101,Condition 1348 1372	congestive heart failure
142,R33,AND Arg1:T101 Arg2:T99
143,T102,Condition 1396 1415	peripheral ischemia
144,T103,Qualifier 1378 1395	Grade 2 or higher
145,T104,Value 1384 1395	2 or higher
146,R34,Has_value Arg1:T103 Arg2:T104
147,R35,Has_qualifier Arg1:T102 Arg2:T103
148,T105,Temporal 1428 1433	brief
149,T106,Value 1435 1443	< 24 hrs
150,R36,Subsumes Arg1:T105 Arg2:T106
151,T107,Condition 1457 1465	ischemia
152,T108,Procedure 1478 1488	surgically
153,T109,Negation 1474 1477	non
154,R37,Has_negation Arg1:T108 Arg2:T109
155,R38,AND Arg1:T107 Arg2:T108
156,T110,Condition 1501 1518	permanent deficit
157,T111,Negation 1493 1500	without
158,R39,Has_negation Arg1:T110 Arg2:T111
159,R40,AND Arg1:T107 Arg2:T110
160,R41,Has_temporal Arg1:T107 Arg2:T105
161,T112,Negation 1417 1423	except
162,T113,Scope 1428 1518	brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit
163,R42,Has_negation Arg1:T113 Arg2:T112
164,R43,Has_scope Arg1:T102 Arg2:T113
165,T114,Condition 1535 1546	pneumonitis
166,T115,Condition 1550 1575	interstitial lung disease
167,*,OR T115 T114
168,T116,Observation 1524 1531	History
169,R44,Has_temporal Arg1:T114 Arg2:T116
170,R45,Has_temporal Arg1:T115 Arg2:T116
171,T117,Condition 1619 1637	autoimmune disease
172,T118,Condition 1649 1675	inflammatory bowel disease
173,T119,Condition 1677 1691	celiac disease
174,T120,Condition 1693 1716	Wegner's granulomatosis
175,T121,Condition 1725 1748	Hashimoto's thyroiditis
176,T122,Condition 1750 1770	rheumatoid arthritis
177,T123,Condition 1772 1777	lupus
178,T124,Condition 1779 1790	scleroderma
179,T125,Condition 1779 1790;1799 1807	scleroderma variants
180,T126,Condition 1809 1827	multiple sclerosis
181,T127,Condition 1829 1846	myasthenia gravis
182,*,OR T127 T126 T125 T124 T123 T122 T121 T120 T119 T118
183,T128,"Scope 1649 1846	inflammatory bowel disease, celiac disease, Wegner's granulomatosis, active Hashimoto's thyroiditis, rheumatoid arthritis, lupus, scleroderma and its variants, multiple sclerosis, myasthenia gravis"
184,R46,Subsumes Arg1:T117 Arg2:T128
185,T129,Condition 1849 1857	Vitiligo
186,T130,Condition 1859 1883	type I diabetes mellitus
187,T131,Condition 1885 1908	residual hypothyroidism
188,T132,Condition 1916 1936	autoimmune condition
189,T133,Qualifier 1909 1936	due to autoimmune condition
190,R47,AND Arg1:T133 Arg2:T132
191,R48,Has_qualifier Arg1:T131 Arg2:T133
192,*,OR T130 T131 T129
193,T134,Drug 1952 1971	hormone replacement
194,T135,Qualifier 1942 1971	requiring hormone replacement
195,R49,AND Arg1:T135 Arg2:T134
196,R50,Has_qualifier Arg1:T132 Arg2:T135
197,T136,Qualifier 1987 2015	requiring systemic treatment
198,T137,Procedure 1997 2015	systemic treatment
199,T138,Negation 1983 1986	not
200,R51,Has_negation Arg1:T136 Arg2:T138
201,R52,AND Arg1:T136 Arg2:T137
202,T139,Condition 1973 1982	psoriasis
203,R53,Has_qualifier Arg1:T139 Arg2:T136
204,T140,Qualifier 2031 2052	not expected to recur
205,T141,Subjective_judgement 2031 2052	not expected to recur
206,T142,Condition 2020 2030	conditions
207,T143,Undefined_semantics 2020 2030	conditions
208,R54,Has_qualifier Arg1:T142 Arg2:T140
209,*,OR T139 T142 T132
210,T144,Temporal 2127 2169	within 2 years prior to Day 1 of the study
211,T145,Reference_point 2151 2169	Day 1 of the study
212,R55,Has_index Arg1:T144 Arg2:T145
213,T146,Condition 2116 2126	malignancy
214,R56,Has_temporal Arg1:T146 Arg2:T144
215,T147,Procedure 2201 2222	surgical intervention
216,T148,Negation 2171 2181	except for
217,R57,Has_negation Arg1:T147 Arg2:T148
218,T149,Condition 2182 2187	those
219,R58,AND Arg1:T149 Arg2:T147
220,T150,Undefined_semantics 2182 2187	those
221,R59,AND Arg1:T146 Arg2:T149
222,T151,Condition 2247 2264;2274 2305	clinical symptoms of gastrointestinal obstruction
223,T152,Condition 2268 2305	signs of gastrointestinal obstruction
224,T153,Device 2325 2350	drainage gastrostomy tube
225,T154,Procedure 2358 2378	parenteral hydration
226,T155,Procedure 2358 2368;2382 2391	parenteral nutrition
227,*,OR T153 T155 T154 T151 T152
228,T156,Condition 2404 2420	immunodeficiency
229,T157,Condition 2424 2427	HIV
230,T158,Condition 2429 2440	Hepatitis B
231,T159,Condition 2444 2455	Hepatitis C
232,*,OR T159 T158 T157 T156
233,T160,Condition 2491 2509	allergic reactions
234,T161,Qualifier 2484 2490	severe
235,R60,Has_qualifier Arg1:T160 Arg2:T161
236,T162,Observation 2473 2480	History
237,T164,Drug 2510 2567	to any unknown allergens or components of the study drugs
238,T165,Context_Error 2510 2567	to any unknown allergens or components of the study drugs
239,R61,AND Arg1:T160 Arg2:T164
240,R62,Has_temporal Arg1:T160 Arg2:T162
241,T163,Condition 2588 2597	illnesses
242,T166,Qualifier 2580 2587	serious
243,T167,Subjective_judgement 2580 2587	serious
244,T168,Undefined_semantics 2580 2587	serious
245,T169,Condition 2613 2645	infections requiring antibiotics
246,T170,Undefined_semantics 2613 2645	infections requiring antibiotics
247,T171,Qualifier 2605 2612	serious
248,R63,Has_qualifier Arg1:T169 Arg2:T171
249,T172,Condition 2647 2665	bleeding disorders
250,*,OR T169 T172
251,T173,"Scope 2605 2665	serious infections requiring antibiotics, bleeding disorders"
252,R64,Has_qualifier Arg1:T163 Arg2:T166
253,R65,Has_scope Arg1:T163 Arg2:T173
254,T174,Procedure 2679 2688	treatment
255,T175,Context_Error 2673 2775	Prior treatment in any other interventional clinical trial within 4 weeks prior to Day 1 of the study.
256,T177,Condition 2781 2798	Mental impairment
257,T178,Observation 2808 2829	compromise compliance
258,R66,Has_context Arg1:T177 Arg2:T178
259,T179,Context_Error 2781 2865	Mental impairment that may compromise compliance with the requirements of the study.
260,T182,Observation 2964 2977	breastfeeding
261,T183,Condition 2981 2989	pregnant
262,T184,Person 2950 2955	Women
263,T185,Measurement 3015 3035	serum pregnancy test
264,T186,Value 3006 3014	positive
265,R67,Has_value Arg1:T185 Arg2:T186
266,*,OR T183 T182
267,T187,Scope 2964 2989	breastfeeding or pregnant
268,R68,AND Arg1:T187 Arg2:T185
269,T190,Person 3106 3112	Female
270,T191,Observation 3142 3155	breastfeeding
271,T193,Temporal 3156 3179	throughout this period.
272,T194,Reference_point 3167 3178	this period
273,R69,Has_index Arg1:T193 Arg2:T194
274,T198,"Non-query-able 3185 3386	Any condition that, in the clinical judgment of the treating physician, is likely to prevent the subject from complying with any aspect of the protocol or that may put the subject at unacceptable risk."
275,T199,Procedure 3410 3422	donate blood
276,T200,Negation 3406 3409	not
277,R70,Has_negation Arg1:T199 Arg2:T200
278,T201,Temporal 3423 3437	while on study
279,T202,Reference_point 3429 3437	on study
280,R71,Has_index Arg1:T201 Arg2:T202
281,T203,Temporal 3442 3500	for at least 90 days following the last MEDI4736 treatment
282,T204,Reference_point 3473 3500	the last MEDI4736 treatment
283,R72,Has_index Arg1:T203 Arg2:T204
284,T205,Scope 3423 3500	while on study and for at least 90 days following the last MEDI4736 treatment
285,R73,Has_scope Arg1:T199 Arg2:T205
286,T206,Procedure 3518 3545	allogeneic organ transplant
287,T207,Observation 3507 3514	History
288,R74,Has_temporal Arg1:T206 Arg2:T207
289,T176,Temporal 2673 2678	Prior
290,R75,Has_temporal Arg1:T174 Arg2:T176
291,A1,Optional T190
292,T188,Negation 3129 3141	refrain from
293,R76,Has_temporal Arg1:T191 Arg2:T193
294,R77,Has_negation Arg1:T191 Arg2:T188
295,R78,Has_context Arg1:T190 Arg2:T191
296,T180,Negation 2871 2878	Lack of
297,T181,Procedure 2896 2909;2923 2943	immunological follow-up assessment
298,T189,Procedure 2914 2943	clinical follow-up assessment
299,*,OR T181 T189
300,T192,Scope 2896 2943	immunological and clinical follow-up assessment
301,R79,Has_negation Arg1:T192 Arg2:T180
302,T195,Mood 2879 2895	availability for
303,R80,Has_mood Arg1:T192 Arg2:T195
304,T196,Condition 3050 3059	unwilling
305,T208,Qualifier 3067 3077	acceptable
306,T209,Procedure 3089 3102	contraception
307,R81,Has_qualifier Arg1:T209 Arg2:T208
308,R82,AND Arg1:T196 Arg2:T209
0,T1,Drug 298 312	immunoglobulin
1,T2,Temporal 313 363	in the past 12 months before the study vaccination
2,T3,Reference_point 342 363	the study vaccination
3,R1,Has_index Arg1:T2 Arg2:T3
4,R2,Has_temporal Arg1:T1 Arg2:T2
5,T4,Condition 8 24	adverse reaction
6,T5,Condition 48 70	respiratory difficulty
7,T6,Procedure 32 43	vaccination
8,R3,AND Arg1:T4 Arg2:T6
9,T7,Condition 72 82	angioedema
10,T8,Condition 87 98	anaphylaxis
11,T9,"Scope 48 98	respiratory difficulty, angioedema and anaphylaxis"
12,R4,Subsumes Arg1:T4 Arg2:T9
13,T10,Condition 110 125	chronic disease
14,T11,Condition 130 138	diabetes
15,T12,Condition 101 106;118 125	Acute disease
16,T13,Condition 140 153	heart disease
17,T14,Condition 155 185	systemic arterial hypertension
18,*,OR T13 T14 T11
19,T15,"Scope 130 185	diabetes, heart disease, systemic arterial hypertension"
20,T16,Scope 101 125	Acute or chronic disease
21,*,OR T12 T10
22,R5,Subsumes Arg1:T16 Arg2:T15
23,T17,Procedure 214 232	antigen injections
24,T18,Drug 195 208	anti-allergic
25,T19,Temporal 238 288	maximum timeline of 14 days before the vaccination
26,T20,Reference_point 273 288	the vaccination
27,R6,Has_index Arg1:T19 Arg2:T20
28,R7,AND Arg1:T18 Arg2:T17
29,R8,Has_temporal Arg1:T18 Arg2:T19
30,T21,Drug 373 387	blood products
31,T22,Temporal 388 427	within 12 months before the vaccination
32,T23,Reference_point 412 427	the vaccination
33,R9,Has_index Arg1:T22 Arg2:T23
34,R10,Has_temporal Arg1:T21 Arg2:T22
35,T24,Drug 437 453	any vaccine type
36,T25,Temporal 454 504	within 30 days before the vaccination of the study
37,T26,Reference_point 476 504	the vaccination of the study
38,R11,Has_index Arg1:T25 Arg2:T26
39,R12,Has_temporal Arg1:T24 Arg2:T25
40,T27,Multiplier 507 518	Chronic use
41,T28,Drug 522 536	any medication
42,T29,Undefined_semantics 437 453	any vaccine type
43,T30,Undefined_semantics 522 536	any medication
44,R13,Has_multiplier Arg1:T28 Arg2:T27
45,T31,Procedure 545 555	homeopathy
46,T32,Drug 578 604	nasal physiologic solution
47,T33,Drug 609 617	vitamins
48,T34,Grammar_Error 605 608	and
49,T35,Drug 561 573	trivial ones
50,T36,Undefined_semantics 561 573	trivial ones
51,T37,Subjective_judgement 561 573	trivial ones
52,*,OR T33 T32
53,T38,Scope 578 617	nasal physiologic solution and vitamins
54,R14,Subsumes Arg1:T35 Arg2:T38
55,T39,Negation 538 544	except
56,T40,"Scope 545 617	homeopathy, and trivial ones, as nasal physiologic solution and vitamins"
57,R15,Has_negation Arg1:T40 Arg2:T39
58,R16,Has_scope Arg1:T28 Arg2:T40
59,T41,Drug 629 646;660 670	immunosuppressive medication
60,T42,Drug 650 670	cytotoxic medication
61,T43,Undefined_semantics 650 670	cytotoxic medication
62,T44,Undefined_semantics 629 646;660 670	immunosuppressive medication
63,*,OR T41 T42
64,T45,Temporal 672 692	in the last 6 months
65,T46,Scope 629 670	immunosuppressive or cytotoxic medication
66,R17,Has_temporal Arg1:T46 Arg2:T45
67,T47,"Parsing_Error 694 948	Individuals who have made use of this kind of medication in non-immunosuppressant doses, as nasal corticosteroid for allergic rhinitis of topic corticosteroid for non-complicated dermatitis, for more than 14 days, are allowed to be included in the study."
68,T48,"Not_a_criteria 694 948	Individuals who have made use of this kind of medication in non-immunosuppressant doses, as nasal corticosteroid for allergic rhinitis of topic corticosteroid for non-complicated dermatitis, for more than 14 days, are allowed to be included in the study."
69,T49,Drug 969 999	medication under investigation
70,T50,Undefined_semantics 969 999	medication under investigation
71,T51,Temporal 1000 1038	within one year before the vaccination
72,T52,Reference_point 1023 1038	the vaccination
73,R18,Has_index Arg1:T51 Arg2:T52
74,R19,Has_temporal Arg1:T49 Arg2:T51
75,T53,Condition 1041 1056	Unstable asthma
76,T54,Qualifier 1075 1095	required urgent care
77,T55,Procedure 1097 1112	hospitalization
78,T56,Procedure 1084 1095	urgent care
79,T57,Procedure 1116 1126	intubation
80,T58,Qualifier 1075 1083;1097 1112	required hospitalization
81,T59,Qualifier 1075 1083;1116 1126	required intubation
82,*,OR T59 T58 T54
83,T60,Temporal 1127 1150	within the last 2 years
84,T61,Drug 1177 1181;1197 1211	oral corticosteroid
85,T62,Drug 1185 1211	intravenous corticosteroid
86,T63,"Scope 1075 1126	required urgent care, hospitalization or intubation"
87,T64,Qualifier 1161 1181;1197 1211	requires use of oral corticosteroid
88,T65,Qualifier 1161 1176;1185 1211	requires use of intravenous corticosteroid
89,*,OR T65 T64
90,T66,Scope 1161 1211	requires use of oral or intravenous corticosteroid
91,R21,Has_temporal Arg1:T63 Arg2:T60
92,T67,"Scope 1075 1150	required urgent care, hospitalization or intubation within the last 2 years"
93,*,OR T67 T66
94,T68,"Scope 1075 1211	required urgent care, hospitalization or intubation within the last 2 years, or which requires use of oral or intravenous corticosteroid"
95,R20,Has_scope Arg1:T53 Arg2:T68
96,T69,Condition 1214 1228	Coagulopathies
97,T70,Condition 1267 1286	capillary fragility
98,T71,Condition 1292 1299	bruises
99,T72,Condition 1303 1312	bleedings
100,T73,Qualifier 1313 1338	without justifiable cause
101,T74,Non-query-able 1313 1338	without justifiable cause
102,R22,Has_qualifier Arg1:T72 Arg2:T73
103,R23,Has_qualifier Arg1:T71 Arg2:T73
104,*,OR T72 T71
105,T75,Scope 1292 1338	bruises or bleedings without justifiable cause
106,R24,Has_scope Arg1:T70 Arg2:T75
107,R25,AND Arg1:T69 Arg2:T70
108,T76,Condition 1341 1352	Convulsions
109,T77,Temporal 1387 1405	before 2 years old
110,T78,Qualifier 1370 1385	caused by fever
111,T79,Negation 1354 1360	except
112,R26,Has_negation Arg1:T78 Arg2:T79
113,T80,Condition 1380 1385	fever
114,R27,Has_temporal Arg1:T76 Arg2:T77
115,T81,Reference_point 1394 1405	2 years old
116,R28,Has_qualifier Arg1:T76 Arg2:T78
117,T82,Condition 1408 1427	Psychiatric disease
118,T83,Qualifier 1434 1474	difficults the adherence to the protocol
119,T84,Subjective_judgement 1434 1474	difficults the adherence to the protocol
120,T85,Undefined_semantics 1434 1474	difficults the adherence to the protocol
121,R29,Has_qualifier Arg1:T82 Arg2:T83
122,T86,Condition 1484 1493	psychosis
123,T87,Condition 1495 1525	obsessive-compulsive disorders
124,T88,Condition 1527 1542	bipolar disease
125,T89,Qualifier 1543 1558	under treatment
126,T90,Procedure 1549 1558	treatment
127,T91,Undefined_semantics 1543 1558	under treatment
128,T92,Drug 1598 1605	lithium
129,T93,Procedure 1583 1605	treatment with lithium
130,T94,Condition 1610 1624	suicidal ideas
131,T95,Temporal 1625 1663	in the last 5 years from the inclusion
132,T96,Reference_point 1650 1663	the inclusion
133,R30,Has_qualifier Arg1:T88 Arg2:T89
134,T97,Condition 1560 1605	diseases which require treatment with lithium
135,T98,"Scope 1484 1663	psychosis, obsessive-compulsive disorders, bipolar disease under treatment, diseases which require treatment with lithium and suicidal ideas in the last 5 years from the inclusion"
136,R31,Subsumes Arg1:T82 Arg2:T98
137,R32,Has_temporal Arg1:T94 Arg2:T95
138,T99,Condition 1673 1682;1720 1727	malignant disease
139,T100,Temporal 1666 1672	Active
140,T101,Condition 1701 1707	cancer
141,T102,Qualifier 1689 1697	any kind
142,R33,Has_qualifier Arg1:T101 Arg2:T102
143,T103,Condition 1712 1727	treated disease
144,T104,Procedure 1712 1719	treated
145,T105,Qualifier 1712 1719	treated
146,T106,Qualifier 1673 1682	malignant
147,R34,Subsumes Arg1:T99 Arg2:T101
148,R35,Has_temporal Arg1:T99 Arg2:T100
149,*,OR T99 T103
150,T107,Subjective_judgement 1729 1781	to which the individual may relapse during the study
151,T108,Undefined_semantics 1729 1781	to which the individual may relapse during the study
152,T109,Non-query-able 1729 1781	to which the individual may relapse during the study
153,T110,Qualifier 1729 1764	to which the individual may relapse
154,T111,Temporal 1765 1781	during the study
155,R36,Has_temporal Arg1:T110 Arg2:T111
156,T112,Reference_point 1772 1781	the study
157,T113,Scope 1666 1727	Active malignant (p.e. any kind of cancer) or treated disease
158,R37,Has_qualifier Arg1:T113 Arg2:T110
159,T114,Condition 1784 1792	Asplenia
160,T115,Negation 1794 1804	absence of
161,T116,Condition 1805 1811	spleen
162,T117,Procedure 1805 1811;1819 1826	spleen removal
163,R38,Has_negation Arg1:T116 Arg2:T115
164,*,OR T117 T116
165,T118,Scope 1794 1826	absence of spleen or its removal
166,R39,Subsumes Arg1:T114 Arg2:T116
167,T119,Measurement 1839 1842	HIV
168,T120,Value 1830 1838	Positive
169,R40,Has_value Arg1:T119 Arg2:T120
170,T121,Temporal 1843 1871	in the screening examination
171,T122,Reference_point 1850 1871	screening examination
172,T123,Condition 1890 1915	immunosuppressant disease
173,T124,Undefined_semantics 1890 1915	immunosuppressant disease
174,R41,Has_temporal Arg1:T119 Arg2:T121
175,*,OR T119 T123
176,T125,Measurement 1927 1951	serology for C hepatitis
177,T126,Value 1918 1926	Positive
178,R42,Has_value Arg1:T125 Arg2:T126
179,T127,Temporal 1952 1979	in the screening evaluation
180,T128,Reference_point 1959 1979	screening evaluation
181,R43,Has_temporal Arg1:T125 Arg2:T127
182,T129,Measurement 1991 2002	Antigen HBs
183,T130,Value 1982 1990	Positive
184,R44,Has_value Arg1:T129 Arg2:T130
185,T131,Temporal 2003 2030	in the screening evaluation
186,T132,Reference_point 2010 2030	screening evaluation
187,R45,Has_temporal Arg1:T129 Arg2:T131
188,T133,Condition 2033 2043	Alcoholism
189,T134,Measurement 2045 2058	CAGE criteria
190,T135,Value 2033 2043	Alcoholism
191,R46,Has_value Arg1:T134 Arg2:T135
192,R47,Subsumes Arg1:T133 Arg2:T134
193,T136,"Not_a_criteria 2061 2321	used for detection of abusive drinkers or alcoholic, validated in the Brazilian population with sensibility of 88% and specificity of 83%, if two or more answers, among four possible, are afirmative(Mansur and Monteiro, 1983), or according to medical decision;"
194,T137,Condition 2323 2345	Abuse of illicit drugs
195,T138,Subjective_judgement 2347 2376	according to medical decision
196,T139,Condition 2379 2387;2402 2418	Acquired immunodeficiency
197,T140,Condition 2391 2418	congenital immunodeficiency
198,*,OR T140 T139
199,T141,Condition 2421 2453	Allergy to the vaccine compounds
200,T142,Drug 2436 2453	vaccine compounds
201,T143,Drug 2458 2461	egg
202,T144,Drug 2463 2471	neomycin
203,T145,Drug 2476 2483	gelatin
204,*,OR T143 T144 T145
205,T146,"Scope 2458 2483	egg, neomycin and gelatin"
206,R48,Subsumes Arg1:T142 Arg2:T146
0,T1,Condition 2 27	Irregular menstrual cycle
1,T2,Procedure 38 98	preparing endometrium with hormones for frozen-thawed embryo
2,R1,AND Arg1:T1 Arg2:T2
3,T3,Procedure 124 133	IVF cycle
4,T5,Negation 100 102	No
5,T6,Observation 103 117	frozen embryos
6,R2,Has_negation Arg1:T6 Arg2:T5
7,R3,Has_context Arg1:T3 Arg2:T6
8,T4,Condition 135 142	Allergy
9,T7,Drug 146 153	Pregnyl
10,T8,Drug 158 181	some of its ingredients
11,*,OR T7 T8
12,T9,Scope 146 181	Pregnyl® or some of its ingredients
13,R4,AND Arg1:T9 Arg2:T4
14,T10,Condition 209 226	contraindications
15,T11,Drug 234 241	Pregnyl
16,R5,AND Arg1:T10 Arg2:T11
17,*,OR T4 T10
0,T1,Condition 0 14	Ovarian cancer
1,T2,Condition 16 35	adrenal gland tumor
2,T3,Condition 37 55	endometrial cancer
3,T4,Condition 57 72	cervical cancer
4,T5,Condition 74 87	breast cancer
5,*,OR T4 T5 T3 T2 T1
6,T6,Condition 89 119	Congenital adrenal hyperplasia
7,T7,Measurement 121 139	17-OH-progesterone
8,T8,Value 139 152	> 2.5 ng / mL
9,R1,Has_value Arg1:T7 Arg2:T8
10,T9,Scope 121 152	17-OH-progesterone> 2.5 ng / mL
11,R2,Subsumes Arg1:T6 Arg2:T9
12,T10,Qualifier 155 175	Clinically diagnosed
13,T11,Condition 176 193	Cushing's disease
14,T12,Condition 195 205	acromegaly
15,T13,Condition 207 216	gigantism
16,*,OR T12 T13 T11
17,T14,"Scope 176 216	Cushing's disease, acromegaly, gigantism"
18,R3,Has_qualifier Arg1:T14 Arg2:T10
19,T15,Condition 218 224;231 239	Type I diabetes
20,T16,Condition 218 222;228 239	Type II diabetes
21,*,OR T15 T16
22,T17,Condition 241 261	Unexplained bleeding
23,T18,Qualifier 271 284	genital tract
24,R4,Has_qualifier Arg1:T17 Arg2:T18
25,T19,Procedure 286 303	Hormone treatment
26,T20,Drug 286 293	Hormone
27,R5,multi Arg1:T19 Arg2:T20
28,T21,Temporal 304 328	within the last 2 months
29,R6,Has_temporal Arg1:T19 Arg2:T21
0,T1,Parsing_Error 0 2	1.
1,T2,Parsing_Error 972 974	2.
2,T3,Parsing_Error 1032 1034	3.
3,T4,Parsing_Error 1166 1168	4.
4,T5,Parsing_Error 1503 1505	5.
5,T6,Parsing_Error 1542 1544	6.
6,T7,Measurement 1833 1843	Hemoglobin
7,T8,Value 1845 1853	≥ 9 g/dL
8,R1,Has_value Arg1:T7 Arg2:T8
9,T9,Value 1873 1886	≥ 1.5 x 109/L
10,T10,Measurement 1855 1871	Neutrophil count
11,R2,Has_value Arg1:T10 Arg2:T9
12,T11,"Value 1904 1917	≥ 100,000/mm3"
13,T12,Measurement 1888 1902	Platelet count
14,R3,Has_value Arg1:T12 Arg2:T11
15,T13,Measurement 1919 1935	Serum creatinine
16,T14,Value 1937 1985	≤ 1.5x Institutional Upper Limit of Normal (ULN)
17,R4,Has_value Arg1:T13 Arg2:T14
18,T15,Measurement 1990 2010	Creatinine Clearance
19,T16,Value 2011 2022	≥ 50 mL/min
20,R5,Has_value Arg1:T15 Arg2:T16
21,T17,Qualifier 2027 2050	Cockcroft-Gault formula
22,R6,Has_qualifier Arg1:T15 Arg2:T17
23,T18,Measurement 2053 2068	Serum bilirubin
24,T19,Value 2070 2081	≤ 1.2 mg/dL
25,R7,Has_value Arg1:T18 Arg2:T19
26,T20,Condition 104 132	primary peritoneal carcinoma
27,T21,Condition 123 132;85 99	carcinoma fallopian tube
28,T22,Condition 123 132;65 83	carcinoma epithelial ovarian
29,T23,Qualifier 22 31	recurrent
30,T24,Qualifier 35 45	persistent
31,T25,Qualifier 46 64	platinum-resistant
32,*,OR T24 T23
33,*,OR T22 T21 T20
34,T27,"Scope 65 132	epithelial ovarian, fallopian tube, or primary peritoneal carcinoma"
35,T26,Scope 22 45	recurrent or persistent
36,R8,Has_scope Arg1:T27 Arg2:T26
37,R9,Has_qualifier Arg1:T27 Arg2:T25
38,T28,Condition 138 157	measureable disease
39,T29,Temporal 186 197;208 240	after first line platinum-based chemotherapy
40,T30,Reference_point 192 197;208 240	first line platinum-based chemotherapy
41,T31,Temporal 186 191;201 240	after second line platinum-based chemotherapy
42,T32,Reference_point 201 240	second line platinum-based chemotherapy
43,R10,Has_index Arg1:T29 Arg2:T30
44,R11,Has_index Arg1:T31 Arg2:T32
45,*,OR T29 T31
46,T33,Scope 186 240	after first or second line platinum-based chemotherapy
47,R12,Has_scope Arg1:T28 Arg2:T33
48,R13,AND Arg1:T27 Arg2:T28
49,T34,Procedure 252 270	treatment with PLD
50,T35,Drug 267 270	PLD
51,T36,Qualifier 274 283	indicated
52,R14,Has_qualifier Arg1:T34 Arg2:T36
53,T37,Undefined_semantics 274 283	indicated
54,T38,Subjective_judgement 274 283	indicated
55,R15,AND Arg1:T27 Arg2:T34
56,T39,Procedure 285 307	Platinum-based therapy
57,T40,Drug 337 348	carboplatin
58,T41,Drug 350 359	cisplatin
59,T42,Drug 363 394	another organoplatinum compound
60,T43,"Not_a_criteria 285 395	Platinum-based therapy is defined as treatment with carboplatin, cisplatin or another organoplatinum compound."
61,*,OR T40 T41 T42
62,T44,"Scope 337 394	carboplatin, cisplatin or another organoplatinum compound"
63,R16,Subsumes Arg1:T39 Arg2:T44
64,T45,Measurement 438 466	platinum-free interval (PFI)
65,T46,Temporal 470 537	< 12 months after first- or second-line platinum-based chemotherapy
66,T47,Reference_point 488 537	first- or second-line platinum-based chemotherapy
67,R17,Has_index Arg1:T46 Arg2:T47
68,R18,Has_temporal Arg1:T45 Arg2:T46
69,T48,Condition 396 414	Platinum-resistant
70,T49,Condition 549 568	disease progression
71,T50,Procedure 585 624	second-line platinum-based chemotherapy
72,T51,Scope 549 624	disease progression while receiving second-line platinum-based chemotherapy
73,*,OR T45 T51
74,T52,"Scope 438 624	platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy"
75,R19,Subsumes Arg1:T48 Arg2:T52
76,T53,"Parsing_Error 627 704	Subjects are allowed to have received, but are not required to have received:"
77,T54,Drug 721 738	cytotoxic regimen
78,T55,Drug 746 760	PARP inhibitor
79,T56,Multiplier 706 720	one additional
80,*,OR T54 T55
81,T57,Scope 721 760	cytotoxic regimen and/or PARP inhibitor
82,R20,Has_multiplier Arg1:T57 Arg2:T56
83,T58,Condition 803 810	disease
84,T59,Temporal 792 802	persistent
85,T60,Temporal 779 788	recurrent
86,*,OR T59 T60
87,T61,Scope 779 802	recurrent or persistent
88,R21,Has_scope Arg1:T58 Arg2:T61
89,R22,AND Arg1:T57 Arg2:T58
90,T62,Drug 837 848	bevacizumab
91,T63,Undefined_semantics 803 810	disease
92,T64,Procedure 813 829	biologic therapy
93,R23,Subsumes Arg1:T64 Arg2:T62
94,T65,Procedure 867 892	primary treatment regimen
95,T66,Temporal 951 961	persistent
96,T67,Temporal 938 947	recurrent
97,*,OR T66 T67
98,T68,Scope 938 961	recurrent or persistent
99,T69,Condition 962 969	disease
100,R24,Has_scope Arg1:T69 Arg2:T68
101,T70,Procedure 910 919	treatment
102,R25,AND Arg1:T70 Arg2:T69
103,R26,Subsumes Arg1:T65 Arg2:T64
104,R27,Subsumes Arg1:T65 Arg2:T70
105,T71,Context_Error 938 969	recurrent or persistent disease
106,T72,Undefined_semantics 938 969	recurrent or persistent disease
107,T73,Procedure 975 985	Histologic
108,T74,Condition 1007 1029	original primary tumor
109,T75,Value 986 999	documentation
110,R28,Has_value Arg1:T73 Arg2:T75
111,R29,AND Arg1:T74 Arg2:T73
112,T76,Procedure 1046 1058	radiographic
113,T77,Condition 1059 1078	disease progression
114,R30,AND Arg1:T76 Arg2:T77
115,T78,Temporal 1079 1163	< 12 months after the last dose of first- or second-line platinum-based chemotherapy
116,T79,Reference_point 1097 1163	the last dose of first- or second-line platinum-based chemotherapy
117,R31,Has_index Arg1:T78 Arg2:T79
118,R32,Has_temporal Arg1:T77 Arg2:T78
119,T80,Condition 1199 1225	disease amenable to biopsy
120,T81,Subjective_judgement 1199 1225	disease amenable to biopsy
121,T82,Undefined_semantics 1199 1225	disease amenable to biopsy
122,T83,Non-query-able 1238 1295	willing to undergo pre- and post-treatment tumor biopsies
123,T84,Post-eligibility 1238 1295	willing to undergo pre- and post-treatment tumor biopsies
124,T85,Parsing_Error 1297 1318	Optional for Phase 1.
125,T86,"Not_a_criteria 1320 1501	Note: archival tissue will be requested for all subjects preferably from primary tumor site prior to cancer treatment; however, archival tissue is not a requirement for study entry."
126,T87,Measurement 1506 1529	ECOG performance status
127,T88,Value 1533 1539	0 or 1
128,R33,Has_value Arg1:T87 Arg2:T88
129,T89,Measurement 1545 1586	Laboratory parameters for vital functions
130,T90,Undefined_semantics 1545 1586	Laboratory parameters for vital functions
131,T91,Value 1604 1616	normal range
132,R34,Has_value Arg1:T89 Arg2:T91
133,T92,Measurement 2083 2090	AST/ALT
134,T93,Value 2092 2103	≤ 2.5 x ULN
135,R35,Has_value Arg1:T92 Arg2:T93
136,T94,Measurement 2105 2125	Alkaline phosphatase
137,T95,Value 2127 2138	≤ 2.5 x ULN
138,R36,Has_value Arg1:T94 Arg2:T95
139,T96,Parsing_Error 2140 2142	7.
140,T97,Person 2143 2146	Age
141,T98,Value 2147 2156	≥18 years
142,R37,Has_value Arg1:T97 Arg2:T98
143,T99,Parsing_Error 2159 2161	8.
144,T100,Non-query-able 2162 2218	Able and willing to give valid written informed consent.
145,T101,Post-eligibility 2162 2218	Able and willing to give valid written informed consent.
146,T102,Parsing_Error 2220 2222	9.
147,T103,Measurement 2223 2234	Body weight
148,T104,Value 2235 2242	> 30 kg
149,R38,Has_value Arg1:T103 Arg2:T104
0,T1,Condition 13 18	fever
1,T2,Value 20 23	38C
2,T3,Value 27 33	100.4F
3,*,OR T2 T3
4,T4,Scope 20 33	38C or 100.4F
5,R1,Has_scope Arg1:T1 Arg2:T4
6,T5,Value 44 53;58 65	less than 4 years
7,T6,Person 54 57	age
8,R2,Has_value Arg1:T6 Arg2:T5
9,T7,Value 75 87;92 100	greater than 16 years
10,T8,Person 88 91	age
11,R3,Has_value Arg1:T8 Arg2:T7
12,T9,Condition 115 131	hypersensitivity
13,T10,Condition 132 139	allergy
14,T11,Drug 150 158	morphine
15,T12,Drug 160 166	NSAIDs
16,T13,Drug 171 184	acetaminophen
17,*,OR T12 T13 T11
18,T14,"Scope 150 184	morphine, NSAIDs, or acetaminophen"
19,*,OR T9 T10
20,T15,Scope 115 139	hypersensitivity/allergy
21,R4,Subsumes Arg1:T15 Arg2:T14
22,T16,Drug 203 216	acetaminophen
23,T17,Temporal 217 240	within the past 4 hours
24,R5,Has_temporal Arg1:T16 Arg2:T17
25,T18,Condition 261 274	liver disease
26,T19,Condition 278 291	renal disease
27,*,OR T18 T19
28,T20,Negation 301 304	not
29,T21,Mood 305 314	requiring
30,T22,Drug 315 326	IV morphine
31,T23,Measurement 328 338	pain score
32,T24,Value 339 351	5/10 or less
33,R6,Has_value Arg1:T23 Arg2:T24
34,R7,Has_mood Arg1:T22 Arg2:T21
35,R8,Has_negation Arg1:T21 Arg2:T20
36,T25,Scope 301 326	not requiring IV morphine
37,T26,Scope 328 351	pain score 5/10 or less
38,R9,Subsumes Arg1:T25 Arg2:T26
39,T27,Observation 362 383	enrolled in the study
40,T28,Temporal 384 408	within the past 72 hours
41,R10,Has_temporal Arg1:T27 Arg2:T28
0,T1,Person 0 4	Male
1,T2,Person 6 9	Age
2,T3,Value 10 37	between 18 and 49 years old
3,T4,"Non-query-able 40 283	Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);"
4,T5,Non-query-able 285 331	Willing to strictly follow the study protocol;
5,T6,"Post-eligibility 40 283	Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);"
6,T7,Post-eligibility 285 331	Willing to strictly follow the study protocol;
7,T8,Post-eligibility 333 401	Capacity for understanding and signing in the Informed Consent Form;
8,T9,Non-query-able 333 401	Capacity for understanding and signing in the Informed Consent Form;
9,T10,"Non-query-able 403 561	To understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion;"
10,T11,"Post-eligibility 403 561	To understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion;"
11,T12,Undefined_semantics 563 657	Intellectual level which allows to filling in the diaries for registering of symptoms at home;
12,T13,Post-eligibility 563 657	Intellectual level which allows to filling in the diaries for registering of symptoms at home;
13,T14,Non-query-able 563 657	Intellectual level which allows to filling in the diaries for registering of symptoms at home;
14,T15,Procedure 681 707	serological testing to HIV
15,T16,Procedure 681 703;709 712	serological testing to HBV
16,T17,Procedure 681 703;717 720	serological testing to HCV
17,T18,"Non-query-able 659 721	Willing to undergo to serological testing to HIV, HBV and HCV;"
18,T19,"Post-eligibility 659 721	Willing to undergo to serological testing to HIV, HBV and HCV;"
19,T20,Condition 732 743	good health
20,T21,Undefined_semantics 732 743	good health
21,T22,"Subjective_judgement 723 781	Being in good health, with no significant medical history;"
22,T23,Procedure 783 803	Physical examination
23,T24,Temporal 804 823	at screening period
24,T25,Reference_point 807 823	screening period
25,T26,Undefined_semantics 783 863	Physical examination at screening period without clinically significant changes;
26,T27,Subjective_judgement 783 863	Physical examination at screening period without clinically significant changes;
27,T28,"Subjective_judgement 865 1028	Lab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision."
28,T29,"Post-eligibility 865 1028	Lab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision."
